[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "The generation of reactive oxygen species (ROS) is required for proper cell signaling, but must be tightly regulated to minimize deleterious oxidizing effects. Activation of the NADPH oxidases (Nox) triggers ROS production and, thus, regulatory mechanisms exist to properly control Nox activity. In this study, we report a novel mechanism in which Nox1 activity is regulated through the proteasomal degradation of Nox organizer 1 (NoxO1). We found that through the interaction between NoxO1 and growth receptor-bound protein 2 (Grb2), the Casitas B-lineage lymphoma (Cbl) E3 ligase was recruited, leading to decreased NoxO1 stability and a subsequent reduction in ROS generation upon epidermal growth factor (EGF) stimulation. Additionally, we show that EGF-mediated phosphorylation of NoxO1 induced its release from Grb2 and facilitated its association with Nox activator 1 (NoxA1) to stimulate ROS production. Consistently, overexpression of Grb2 resulted in decreased Nox1 activity, whereas knockdown of Grb2 led to increased Nox1 activity in response to EGF. CRISPR/Cas9-mediated NoxO1 knockout in human colon cancer cells abrogated anchorage-independent growth on soft agar and tumor-forming ability in athymic nude mice. Moreover, the expression and stability of NoxO1 were significantly increased in human colon cancer tissues compared with normal colon. Taken together, these results support a model whereby Nox1 activity and ROS generation are regulated by Grb2/Cbl-mediated proteolysis of NoxO1 in response to EGF, providing new insight into the processes by which excessive ROS production may promote oncogenic signaling to drive colorectal tumorigenesis.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "9017897d71c2434d90f474f17544eebd", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[172, 172], [247, 247], [182, 182], [62, 62]], "char_spans": [[971, 974], [1416, 1419], [1029, 1032], [348, 351]]}]}], "context_tokens": [["The", 0], ["generation", 4], ["of", 15], ["reactive", 18], ["oxygen", 27], ["species", 34], ["(", 42], ["ROS", 43], [")", 46], ["is", 48], ["required", 51], ["for", 60], ["proper", 64], ["cell", 71], ["signaling", 76], [",", 85], ["but", 87], ["must", 91], ["be", 96], ["tightly", 99], ["regulated", 107], ["to", 117], ["minimize", 120], ["deleterious", 129], ["oxidizing", 141], ["effects", 151], [".", 158], ["Activation", 160], ["of", 171], ["the", 174], ["NADPH", 178], ["oxidases", 184], ["(", 193], ["Nox", 194], [")", 197], ["triggers", 199], ["ROS", 208], ["production", 212], ["and", 223], [",", 226], ["thus", 228], [",", 232], ["regulatory", 234], ["mechanisms", 245], ["exist", 256], ["to", 262], ["properly", 265], ["control", 274], ["Nox", 282], ["activity", 286], [".", 294], ["In", 296], ["this", 299], ["study", 304], [",", 309], ["we", 311], ["report", 314], ["a", 321], ["novel", 323], ["mechanism", 329], ["in", 339], ["which", 342], ["Nox1", 348], ["activity", 353], ["is", 362], ["regulated", 365], ["through", 375], ["the", 383], ["proteasomal", 387], ["degradation", 399], ["of", 411], ["Nox", 414], ["organizer", 418], ["1", 428], ["(", 430], ["NoxO1", 431], [")", 436], [".", 437], ["We", 439], ["found", 442], ["that", 448], ["through", 453], ["the", 461], ["interaction", 465], ["between", 477], ["NoxO1", 485], ["and", 491], ["growth", 495], ["receptor", 502], ["-", 510], ["bound", 511], ["protein", 517], ["2", 525], ["(", 527], ["Grb2", 528], [")", 532], [",", 533], ["the", 535], ["Casitas", 539], ["B", 547], ["-", 548], ["lineage", 549], ["lymphoma", 557], ["(", 566], ["Cbl", 567], [")", 570], ["E3", 572], ["ligase", 575], ["was", 582], ["recruited", 586], [",", 595], ["leading", 597], ["to", 605], ["decreased", 608], ["NoxO1", 618], ["stability", 624], ["and", 634], ["a", 638], ["subsequent", 640], ["reduction", 651], ["in", 661], ["ROS", 664], ["generation", 668], ["upon", 679], ["epidermal", 684], ["growth", 694], ["factor", 701], ["(", 708], ["EGF", 709], [")", 712], ["stimulation", 714], [".", 725], ["Additionally", 727], [",", 739], ["we", 741], ["show", 744], ["that", 749], ["EGF", 754], ["-", 757], ["mediated", 758], ["phosphorylation", 767], ["of", 783], ["NoxO1", 786], ["induced", 792], ["its", 800], ["release", 804], ["from", 812], ["Grb2", 817], ["and", 822], ["facilitated", 826], ["its", 838], ["association", 842], ["with", 854], ["Nox", 859], ["activator", 863], ["1", 873], ["(", 875], ["NoxA1", 876], [")", 881], ["to", 883], ["stimulate", 886], ["ROS", 896], ["production", 900], [".", 910], ["Consistently", 912], [",", 924], ["overexpression", 926], ["of", 941], ["Grb2", 944], ["resulted", 949], ["in", 958], ["decreased", 961], ["Nox1", 971], ["activity", 976], [",", 984], ["whereas", 986], ["knockdown", 994], ["of", 1004], ["Grb2", 1007], ["led", 1012], ["to", 1016], ["increased", 1019], ["Nox1", 1029], ["activity", 1034], ["in", 1043], ["response", 1046], ["to", 1055], ["EGF", 1058], [".", 1061], ["CRISPR", 1063], ["/", 1069], ["Cas9-mediated", 1070], ["NoxO1", 1084], ["knockout", 1090], ["in", 1099], ["human", 1102], ["colon", 1108], ["cancer", 1114], ["cells", 1121], ["abrogated", 1127], ["anchorage", 1137], ["-", 1146], ["independent", 1147], ["growth", 1159], ["on", 1166], ["soft", 1169], ["agar", 1174], ["and", 1179], ["tumor", 1183], ["-", 1188], ["forming", 1189], ["ability", 1197], ["in", 1205], ["athymic", 1208], ["nude", 1216], ["mice", 1221], [".", 1225], ["Moreover", 1227], [",", 1235], ["the", 1237], ["expression", 1241], ["and", 1252], ["stability", 1256], ["of", 1266], ["NoxO1", 1269], ["were", 1275], ["significantly", 1280], ["increased", 1294], ["in", 1304], ["human", 1307], ["colon", 1313], ["cancer", 1319], ["tissues", 1326], ["compared", 1334], ["with", 1343], ["normal", 1348], ["colon", 1355], [".", 1360], ["Taken", 1362], ["together", 1368], [",", 1376], ["these", 1378], ["results", 1384], ["support", 1392], ["a", 1400], ["model", 1402], ["whereby", 1408], ["Nox1", 1416], ["activity", 1421], ["and", 1430], ["ROS", 1434], ["generation", 1438], ["are", 1449], ["regulated", 1453], ["by", 1463], ["Grb2/Cbl", 1466], ["-", 1474], ["mediated", 1475], ["proteolysis", 1484], ["of", 1496], ["NoxO1", 1499], ["in", 1505], ["response", 1508], ["to", 1517], ["EGF", 1520], [",", 1523], ["providing", 1525], ["new", 1535], ["insight", 1539], ["into", 1547], ["the", 1552], ["processes", 1556], ["by", 1566], ["which", 1569], ["excessive", 1575], ["ROS", 1585], ["production", 1589], ["may", 1600], ["promote", 1604], ["oncogenic", 1612], ["signaling", 1622], ["to", 1632], ["drive", 1635], ["colorectal", 1641], ["tumorigenesis", 1652], [".", 1665]]}
{"context": "Nusinersen is a 2'-O-methoxyethyl phosphorothioate-modified antisense drug being developed to treat spinal muscular atrophy. Nusinersen is specifically designed to alter splicing of SMN2 pre-mRNA and thus increase the amount of functional survival motor neuron (SMN) protein that is deficient in patients with spinal muscular atrophy. This open-label, phase 2, escalating dose clinical study assessed the safety and tolerability, pharmacokinetics, and clinical efficacy of multiple intrathecal doses of nusinersen (6 mg and 12 mg dose equivalents) in patients with infantile-onset spinal muscular atrophy. Eligible participants were of either gender aged between 3 weeks and 7 months old with onset of spinal muscular atrophy symptoms between 3 weeks and 6 months, who had SMN1 homozygous gene deletion or mutation. Safety assessments included adverse events, physical and neurological examinations, vital signs, clinical laboratory tests, cerebrospinal fluid laboratory tests, and electrocardiographs. Clinical efficacy assessments included event free survival, and change from baseline of two assessments of motor function: the motor milestones portion of the Hammersmith Infant Neurological Exam-Part 2 (HINE-2) and the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) motor function test, and compound motor action potentials. Autopsy tissue was analysed for target engagement, drug concentrations, and pharmacological activity. HINE-2, CHOP-INTEND, and compound motor action potential were compared between baseline and last visit using the Wilcoxon signed-rank test. Age at death or permanent ventilation was compared with natural history using the log-rank test. The study is registered at ClinicalTrials.gov, number NCT01839656. 20 participants were enrolled between May 3, 2013, and July 9, 2014, and assessed through to an interim analysis done on Jan 26, 2016. All participants experienced adverse events, with 77 serious adverse events reported in 16 participants, all considered by study investigators not related or unlikely related to the study drug. In the 12 mg dose group, incremental achievements of motor milestones (p<0\u00b70001), improvements in CHOP-INTEND motor function scores (p=0\u00b70013), and increased compound muscle action potential amplitude of the ulnar nerve (p=0\u00b70103) and peroneal nerve (p<0\u00b70001), compared with baseline, were observed. Median age at death or permanent ventilation was not reached and the Kaplan-Meier survival curve diverged from a published natural history case series (p=0\u00b70014). Analysis of autopsy tissue from patients exposed to nusinersen showed drug uptake into motor neurons throughout the spinal cord and neurons and other cell types in the brainstem and other brain regions, exposure at therapeutic concentrations, and increased SMN2 mRNA exon 7 inclusion and SMN protein concentrations in the spinal cord. Administration of multiple intrathecal doses of nusinersen showed acceptable safety and tolerability, pharmacology consistent with its intended mechanism of action, and encouraging clinical efficacy. Results informed the design of an ongoing, sham-controlled, phase 3 clinical study of nusinersen in infantile-onset spinal muscular atrophy. Ionis Pharmaceuticals, Inc and Biogen.", "qas": [{"question": "Which disease is treated with Nusinersen?", "answers": ["Spinal Muscular Atrophy", "SMA"], "qid": "0ddc50b6e2eb4c54b88303df7172ac37", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["treated", 17], ["with", 25], ["Nusinersen", 30], ["?", 40]], "detected_answers": [{"text": "Spinal Muscular Atrophy", "token_spans": [[120, 122], [99, 101], [15, 17], [546, 548], [51, 53]], "char_spans": [[702, 724], [581, 603], [100, 122], [3221, 3243], [310, 332]]}]}], "context_tokens": [["Nusinersen", 0], ["is", 11], ["a", 14], ["2'-O", 16], ["-", 20], ["methoxyethyl", 21], ["phosphorothioate", 34], ["-", 50], ["modified", 51], ["antisense", 60], ["drug", 70], ["being", 75], ["developed", 81], ["to", 91], ["treat", 94], ["spinal", 100], ["muscular", 107], ["atrophy", 116], [".", 123], ["Nusinersen", 125], ["is", 136], ["specifically", 139], ["designed", 152], ["to", 161], ["alter", 164], ["splicing", 170], ["of", 179], ["SMN2", 182], ["pre", 187], ["-", 190], ["mRNA", 191], ["and", 196], ["thus", 200], ["increase", 205], ["the", 214], ["amount", 218], ["of", 225], ["functional", 228], ["survival", 239], ["motor", 248], ["neuron", 254], ["(", 261], ["SMN", 262], [")", 265], ["protein", 267], ["that", 275], ["is", 280], ["deficient", 283], ["in", 293], ["patients", 296], ["with", 305], ["spinal", 310], ["muscular", 317], ["atrophy", 326], [".", 333], ["This", 335], ["open", 340], ["-", 344], ["label", 345], [",", 350], ["phase", 352], ["2", 358], [",", 359], ["escalating", 361], ["dose", 372], ["clinical", 377], ["study", 386], ["assessed", 392], ["the", 401], ["safety", 405], ["and", 412], ["tolerability", 416], [",", 428], ["pharmacokinetics", 430], [",", 446], ["and", 448], ["clinical", 452], ["efficacy", 461], ["of", 470], ["multiple", 473], ["intrathecal", 482], ["doses", 494], ["of", 500], ["nusinersen", 503], ["(", 514], ["6", 515], ["mg", 517], ["and", 520], ["12", 524], ["mg", 527], ["dose", 530], ["equivalents", 535], [")", 546], ["in", 548], ["patients", 551], ["with", 560], ["infantile", 565], ["-", 574], ["onset", 575], ["spinal", 581], ["muscular", 588], ["atrophy", 597], [".", 604], ["Eligible", 606], ["participants", 615], ["were", 628], ["of", 633], ["either", 636], ["gender", 643], ["aged", 650], ["between", 655], ["3", 663], ["weeks", 665], ["and", 671], ["7", 675], ["months", 677], ["old", 684], ["with", 688], ["onset", 693], ["of", 699], ["spinal", 702], ["muscular", 709], ["atrophy", 718], ["symptoms", 726], ["between", 735], ["3", 743], ["weeks", 745], ["and", 751], ["6", 755], ["months", 757], [",", 763], ["who", 765], ["had", 769], ["SMN1", 773], ["homozygous", 778], ["gene", 789], ["deletion", 794], ["or", 803], ["mutation", 806], [".", 814], ["Safety", 816], ["assessments", 823], ["included", 835], ["adverse", 844], ["events", 852], [",", 858], ["physical", 860], ["and", 869], ["neurological", 873], ["examinations", 886], [",", 898], ["vital", 900], ["signs", 906], [",", 911], ["clinical", 913], ["laboratory", 922], ["tests", 933], [",", 938], ["cerebrospinal", 940], ["fluid", 954], ["laboratory", 960], ["tests", 971], [",", 976], ["and", 978], ["electrocardiographs", 982], [".", 1001], ["Clinical", 1003], ["efficacy", 1012], ["assessments", 1021], ["included", 1033], ["event", 1042], ["free", 1048], ["survival", 1053], [",", 1061], ["and", 1063], ["change", 1067], ["from", 1074], ["baseline", 1079], ["of", 1088], ["two", 1091], ["assessments", 1095], ["of", 1107], ["motor", 1110], ["function", 1116], [":", 1124], ["the", 1126], ["motor", 1130], ["milestones", 1136], ["portion", 1147], ["of", 1155], ["the", 1158], ["Hammersmith", 1162], ["Infant", 1174], ["Neurological", 1181], ["Exam", 1194], ["-", 1198], ["Part", 1199], ["2", 1204], ["(", 1206], ["HINE-2", 1207], [")", 1213], ["and", 1215], ["the", 1219], ["Children", 1223], ["'s", 1231], ["Hospital", 1234], ["of", 1243], ["Philadelphia", 1246], ["Infant", 1259], ["Test", 1266], ["of", 1271], ["Neuromuscular", 1274], ["Disorders", 1288], ["(", 1298], ["CHOP", 1299], ["-", 1303], ["INTEND", 1304], [")", 1310], ["motor", 1312], ["function", 1318], ["test", 1327], [",", 1331], ["and", 1333], ["compound", 1337], ["motor", 1346], ["action", 1352], ["potentials", 1359], [".", 1369], ["Autopsy", 1371], ["tissue", 1379], ["was", 1386], ["analysed", 1390], ["for", 1399], ["target", 1403], ["engagement", 1410], [",", 1420], ["drug", 1422], ["concentrations", 1427], [",", 1441], ["and", 1443], ["pharmacological", 1447], ["activity", 1463], [".", 1471], ["HINE-2", 1473], [",", 1479], ["CHOP", 1481], ["-", 1485], ["INTEND", 1486], [",", 1492], ["and", 1494], ["compound", 1498], ["motor", 1507], ["action", 1513], ["potential", 1520], ["were", 1530], ["compared", 1535], ["between", 1544], ["baseline", 1552], ["and", 1561], ["last", 1565], ["visit", 1570], ["using", 1576], ["the", 1582], ["Wilcoxon", 1586], ["signed", 1595], ["-", 1601], ["rank", 1602], ["test", 1607], [".", 1611], ["Age", 1613], ["at", 1617], ["death", 1620], ["or", 1626], ["permanent", 1629], ["ventilation", 1639], ["was", 1651], ["compared", 1655], ["with", 1664], ["natural", 1669], ["history", 1677], ["using", 1685], ["the", 1691], ["log", 1695], ["-", 1698], ["rank", 1699], ["test", 1704], [".", 1708], ["The", 1710], ["study", 1714], ["is", 1720], ["registered", 1723], ["at", 1734], ["ClinicalTrials.gov", 1737], [",", 1755], ["number", 1757], ["NCT01839656", 1764], [".", 1775], ["20", 1777], ["participants", 1780], ["were", 1793], ["enrolled", 1798], ["between", 1807], ["May", 1815], ["3", 1819], [",", 1820], ["2013", 1822], [",", 1826], ["and", 1828], ["July", 1832], ["9", 1837], [",", 1838], ["2014", 1840], [",", 1844], ["and", 1846], ["assessed", 1850], ["through", 1859], ["to", 1867], ["an", 1870], ["interim", 1873], ["analysis", 1881], ["done", 1890], ["on", 1895], ["Jan", 1898], ["26", 1902], [",", 1904], ["2016", 1906], [".", 1910], ["All", 1912], ["participants", 1916], ["experienced", 1929], ["adverse", 1941], ["events", 1949], [",", 1955], ["with", 1957], ["77", 1962], ["serious", 1965], ["adverse", 1973], ["events", 1981], ["reported", 1988], ["in", 1997], ["16", 2000], ["participants", 2003], [",", 2015], ["all", 2017], ["considered", 2021], ["by", 2032], ["study", 2035], ["investigators", 2041], ["not", 2055], ["related", 2059], ["or", 2067], ["unlikely", 2070], ["related", 2079], ["to", 2087], ["the", 2090], ["study", 2094], ["drug", 2100], [".", 2104], ["In", 2106], ["the", 2109], ["12", 2113], ["mg", 2116], ["dose", 2119], ["group", 2124], [",", 2129], ["incremental", 2131], ["achievements", 2143], ["of", 2156], ["motor", 2159], ["milestones", 2165], ["(", 2176], ["p<0\u00b70001", 2177], [")", 2185], [",", 2186], ["improvements", 2188], ["in", 2201], ["CHOP", 2204], ["-", 2208], ["INTEND", 2209], ["motor", 2216], ["function", 2222], ["scores", 2231], ["(", 2238], ["p=0\u00b70013", 2239], [")", 2247], [",", 2248], ["and", 2250], ["increased", 2254], ["compound", 2264], ["muscle", 2273], ["action", 2280], ["potential", 2287], ["amplitude", 2297], ["of", 2307], ["the", 2310], ["ulnar", 2314], ["nerve", 2320], ["(", 2326], ["p=0\u00b70103", 2327], [")", 2335], ["and", 2337], ["peroneal", 2341], ["nerve", 2350], ["(", 2356], ["p<0\u00b70001", 2357], [")", 2365], [",", 2366], ["compared", 2368], ["with", 2377], ["baseline", 2382], [",", 2390], ["were", 2392], ["observed", 2397], [".", 2405], ["Median", 2407], ["age", 2414], ["at", 2418], ["death", 2421], ["or", 2427], ["permanent", 2430], ["ventilation", 2440], ["was", 2452], ["not", 2456], ["reached", 2460], ["and", 2468], ["the", 2472], ["Kaplan", 2476], ["-", 2482], ["Meier", 2483], ["survival", 2489], ["curve", 2498], ["diverged", 2504], ["from", 2513], ["a", 2518], ["published", 2520], ["natural", 2530], ["history", 2538], ["case", 2546], ["series", 2551], ["(", 2558], ["p=0\u00b70014", 2559], [")", 2567], [".", 2568], ["Analysis", 2570], ["of", 2579], ["autopsy", 2582], ["tissue", 2590], ["from", 2597], ["patients", 2602], ["exposed", 2611], ["to", 2619], ["nusinersen", 2622], ["showed", 2633], ["drug", 2640], ["uptake", 2645], ["into", 2652], ["motor", 2657], ["neurons", 2663], ["throughout", 2671], ["the", 2682], ["spinal", 2686], ["cord", 2693], ["and", 2698], ["neurons", 2702], ["and", 2710], ["other", 2714], ["cell", 2720], ["types", 2725], ["in", 2731], ["the", 2734], ["brainstem", 2738], ["and", 2748], ["other", 2752], ["brain", 2758], ["regions", 2764], [",", 2771], ["exposure", 2773], ["at", 2782], ["therapeutic", 2785], ["concentrations", 2797], [",", 2811], ["and", 2813], ["increased", 2817], ["SMN2", 2827], ["mRNA", 2832], ["exon", 2837], ["7", 2842], ["inclusion", 2844], ["and", 2854], ["SMN", 2858], ["protein", 2862], ["concentrations", 2870], ["in", 2885], ["the", 2888], ["spinal", 2892], ["cord", 2899], [".", 2903], ["Administration", 2905], ["of", 2920], ["multiple", 2923], ["intrathecal", 2932], ["doses", 2944], ["of", 2950], ["nusinersen", 2953], ["showed", 2964], ["acceptable", 2971], ["safety", 2982], ["and", 2989], ["tolerability", 2993], [",", 3005], ["pharmacology", 3007], ["consistent", 3020], ["with", 3031], ["its", 3036], ["intended", 3040], ["mechanism", 3049], ["of", 3059], ["action", 3062], [",", 3068], ["and", 3070], ["encouraging", 3074], ["clinical", 3086], ["efficacy", 3095], [".", 3103], ["Results", 3105], ["informed", 3113], ["the", 3122], ["design", 3126], ["of", 3133], ["an", 3136], ["ongoing", 3139], [",", 3146], ["sham", 3148], ["-", 3152], ["controlled", 3153], [",", 3163], ["phase", 3165], ["3", 3171], ["clinical", 3173], ["study", 3182], ["of", 3188], ["nusinersen", 3191], ["in", 3202], ["infantile", 3205], ["-", 3214], ["onset", 3215], ["spinal", 3221], ["muscular", 3228], ["atrophy", 3237], [".", 3244], ["Ionis", 3246], ["Pharmaceuticals", 3252], [",", 3267], ["Inc", 3269], ["and", 3273], ["Biogen", 3277], [".", 3283]]}
{"context": "Ca2+ is a ubiquitous intracellular messenger responsible for controlling numerous cellular processes including fertilization, mitosis, neuronal transmission, contraction and relaxation of muscles, gene transcription, and cell death. At rest, the cytoplasmic Ca2+ concentration [Ca2+]i is approximately 100 nM, but this level rises to 500-1,000 nM upon activation. In osteoblasts, the elevation of [Ca2+]i is a result of an increase in the release of Ca2+ from endoplasmic reticulum and/or extracellular Ca2+ influx through voltage gated Ca2+ channels. Many of the cellular effects of Ca2+ are mediated by the Ca2+ binding protein, calmodulin (CaM). Upon binding up to four calcium ions, CaM undergoes a conformational change, which enables it to bind to specific proteins eliciting a specific response. Calmodulin kinase II (CaMKII) is a major target of the Ca(2+)/CaM second messenger system. Once bound to Ca(2+)/CaM, the multimeric CaMKII is released from its autoinhibitory status and maximally activated, which then leads to an intraholoenzyme autophosphorylation reaction. Calcineurin (Cn) is another major target protein that is activated by Ca(2+)/CaM. Cn is a serine-threonine phosphatase that consists of a heterodimeric protein complex composed of a catalytic subunit (CnA) and a regulatory subunit (CnB). Upon activation, Cn directly binds to, and dephosphorylates nuclear factor of activated T cells (NFAT) transcription factors within the cytoplasm allowing them to translocate to the nucleus and participate in the regulation of gene expression. This review will examine the potential mechanisms by which calcium, CaM, CaMKII, and Cn/NFAT control osteoblast proliferation and differentiation.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "4739d60b47ce43b3a2834c15aa922cab", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[189, 189]], "char_spans": [[1079, 1089]]}]}], "context_tokens": [["Ca2", 0], ["+", 3], ["is", 5], ["a", 8], ["ubiquitous", 10], ["intracellular", 21], ["messenger", 35], ["responsible", 45], ["for", 57], ["controlling", 61], ["numerous", 73], ["cellular", 82], ["processes", 91], ["including", 101], ["fertilization", 111], [",", 124], ["mitosis", 126], [",", 133], ["neuronal", 135], ["transmission", 144], [",", 156], ["contraction", 158], ["and", 170], ["relaxation", 174], ["of", 185], ["muscles", 188], [",", 195], ["gene", 197], ["transcription", 202], [",", 215], ["and", 217], ["cell", 221], ["death", 226], [".", 231], ["At", 233], ["rest", 236], [",", 240], ["the", 242], ["cytoplasmic", 246], ["Ca2", 258], ["+", 261], ["concentration", 263], ["[", 277], ["Ca2+]i", 278], ["is", 285], ["approximately", 288], ["100", 302], ["nM", 306], [",", 308], ["but", 310], ["this", 314], ["level", 319], ["rises", 325], ["to", 331], ["500", 334], ["-", 337], ["1,000", 338], ["nM", 344], ["upon", 347], ["activation", 352], [".", 362], ["In", 364], ["osteoblasts", 367], [",", 378], ["the", 380], ["elevation", 384], ["of", 394], ["[", 397], ["Ca2+]i", 398], ["is", 405], ["a", 408], ["result", 410], ["of", 417], ["an", 420], ["increase", 423], ["in", 432], ["the", 435], ["release", 439], ["of", 447], ["Ca2", 450], ["+", 453], ["from", 455], ["endoplasmic", 460], ["reticulum", 472], ["and/or", 482], ["extracellular", 489], ["Ca2", 503], ["+", 506], ["influx", 508], ["through", 515], ["voltage", 523], ["gated", 531], ["Ca2", 537], ["+", 540], ["channels", 542], [".", 550], ["Many", 552], ["of", 557], ["the", 560], ["cellular", 564], ["effects", 573], ["of", 581], ["Ca2", 584], ["+", 587], ["are", 589], ["mediated", 593], ["by", 602], ["the", 605], ["Ca2", 609], ["+", 612], ["binding", 614], ["protein", 622], [",", 629], ["calmodulin", 631], ["(", 642], ["CaM", 643], [")", 646], [".", 647], ["Upon", 649], ["binding", 654], ["up", 662], ["to", 665], ["four", 668], ["calcium", 673], ["ions", 681], [",", 685], ["CaM", 687], ["undergoes", 691], ["a", 701], ["conformational", 703], ["change", 718], [",", 724], ["which", 726], ["enables", 732], ["it", 740], ["to", 743], ["bind", 746], ["to", 751], ["specific", 754], ["proteins", 763], ["eliciting", 772], ["a", 782], ["specific", 784], ["response", 793], [".", 801], ["Calmodulin", 803], ["kinase", 814], ["II", 821], ["(", 824], ["CaMKII", 825], [")", 831], ["is", 833], ["a", 836], ["major", 838], ["target", 844], ["of", 851], ["the", 854], ["Ca(2+)/CaM", 858], ["second", 869], ["messenger", 876], ["system", 886], [".", 892], ["Once", 894], ["bound", 899], ["to", 905], ["Ca(2+)/CaM", 908], [",", 918], ["the", 920], ["multimeric", 924], ["CaMKII", 935], ["is", 942], ["released", 945], ["from", 954], ["its", 959], ["autoinhibitory", 963], ["status", 978], ["and", 985], ["maximally", 989], ["activated", 999], [",", 1008], ["which", 1010], ["then", 1016], ["leads", 1021], ["to", 1027], ["an", 1030], ["intraholoenzyme", 1033], ["autophosphorylation", 1049], ["reaction", 1069], [".", 1077], ["Calcineurin", 1079], ["(", 1091], ["Cn", 1092], [")", 1094], ["is", 1096], ["another", 1099], ["major", 1107], ["target", 1113], ["protein", 1120], ["that", 1128], ["is", 1133], ["activated", 1136], ["by", 1146], ["Ca(2+)/CaM.", 1149], ["Cn", 1161], ["is", 1164], ["a", 1167], ["serine", 1169], ["-", 1175], ["threonine", 1176], ["phosphatase", 1186], ["that", 1198], ["consists", 1203], ["of", 1212], ["a", 1215], ["heterodimeric", 1217], ["protein", 1231], ["complex", 1239], ["composed", 1247], ["of", 1256], ["a", 1259], ["catalytic", 1261], ["subunit", 1271], ["(", 1279], ["CnA", 1280], [")", 1283], ["and", 1285], ["a", 1289], ["regulatory", 1291], ["subunit", 1302], ["(", 1310], ["CnB", 1311], [")", 1314], [".", 1315], ["Upon", 1317], ["activation", 1322], [",", 1332], ["Cn", 1334], ["directly", 1337], ["binds", 1346], ["to", 1352], [",", 1354], ["and", 1356], ["dephosphorylates", 1360], ["nuclear", 1377], ["factor", 1385], ["of", 1392], ["activated", 1395], ["T", 1405], ["cells", 1407], ["(", 1413], ["NFAT", 1414], [")", 1418], ["transcription", 1420], ["factors", 1434], ["within", 1442], ["the", 1449], ["cytoplasm", 1453], ["allowing", 1463], ["them", 1472], ["to", 1477], ["translocate", 1480], ["to", 1492], ["the", 1495], ["nucleus", 1499], ["and", 1507], ["participate", 1511], ["in", 1523], ["the", 1526], ["regulation", 1530], ["of", 1541], ["gene", 1544], ["expression", 1549], [".", 1559], ["This", 1561], ["review", 1566], ["will", 1573], ["examine", 1578], ["the", 1586], ["potential", 1590], ["mechanisms", 1600], ["by", 1611], ["which", 1614], ["calcium", 1620], [",", 1627], ["CaM", 1629], [",", 1632], ["CaMKII", 1634], [",", 1640], ["and", 1642], ["Cn", 1646], ["/", 1648], ["NFAT", 1649], ["control", 1654], ["osteoblast", 1662], ["proliferation", 1673], ["and", 1687], ["differentiation", 1691], [".", 1706]]}
{"context": "Viroids are plant subviral pathogens whose genomes are constituted by a single-stranded and covalently closed small RNA molecule that does not encode for any protein. Despite this genomic simplicity, they are able of inducing devastating symptoms in susceptible plants. Most of the 29 described viroid species fold into a rodlike or quasi-rodlike structure, whereas a few of them fold as branched structures. The shape of these RNA structures is perhaps one of the most characteristic properties of viroids and sometimes is considered their only phenotype. Here we use RNA thermodynamic secondary structure prediction algorithms to compare the mutational robustness of all viroid species. After characterizing the statistical properties of the distribution of mutational effects on structure stability and the wideness of neutral neighborhood for each viroid species, we show an evolutionary trend toward increased structural robustness during viroid radiation, giving support to the adaptive value of robustness. Differences in robustness among the 2 viroid families can be explained by the larger fragility of branched structures compared with the rodlike ones. We also show that genomic redundancy can contribute to the robustness of these simple RNA genomes.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "8eceba755842479382ec48217193b107", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[0, 0], [86, 86]], "char_spans": [[0, 6], [499, 505]]}]}], "context_tokens": [["Viroids", 0], ["are", 8], ["plant", 12], ["subviral", 18], ["pathogens", 27], ["whose", 37], ["genomes", 43], ["are", 51], ["constituted", 55], ["by", 67], ["a", 70], ["single", 72], ["-", 78], ["stranded", 79], ["and", 88], ["covalently", 92], ["closed", 103], ["small", 110], ["RNA", 116], ["molecule", 120], ["that", 129], ["does", 134], ["not", 139], ["encode", 143], ["for", 150], ["any", 154], ["protein", 158], [".", 165], ["Despite", 167], ["this", 175], ["genomic", 180], ["simplicity", 188], [",", 198], ["they", 200], ["are", 205], ["able", 209], ["of", 214], ["inducing", 217], ["devastating", 226], ["symptoms", 238], ["in", 247], ["susceptible", 250], ["plants", 262], [".", 268], ["Most", 270], ["of", 275], ["the", 278], ["29", 282], ["described", 285], ["viroid", 295], ["species", 302], ["fold", 310], ["into", 315], ["a", 320], ["rodlike", 322], ["or", 330], ["quasi", 333], ["-", 338], ["rodlike", 339], ["structure", 347], [",", 356], ["whereas", 358], ["a", 366], ["few", 368], ["of", 372], ["them", 375], ["fold", 380], ["as", 385], ["branched", 388], ["structures", 397], [".", 407], ["The", 409], ["shape", 413], ["of", 419], ["these", 422], ["RNA", 428], ["structures", 432], ["is", 443], ["perhaps", 446], ["one", 454], ["of", 458], ["the", 461], ["most", 465], ["characteristic", 470], ["properties", 485], ["of", 496], ["viroids", 499], ["and", 507], ["sometimes", 511], ["is", 521], ["considered", 524], ["their", 535], ["only", 541], ["phenotype", 546], [".", 555], ["Here", 557], ["we", 562], ["use", 565], ["RNA", 569], ["thermodynamic", 573], ["secondary", 587], ["structure", 597], ["prediction", 607], ["algorithms", 618], ["to", 629], ["compare", 632], ["the", 640], ["mutational", 644], ["robustness", 655], ["of", 666], ["all", 669], ["viroid", 673], ["species", 680], [".", 687], ["After", 689], ["characterizing", 695], ["the", 710], ["statistical", 714], ["properties", 726], ["of", 737], ["the", 740], ["distribution", 744], ["of", 757], ["mutational", 760], ["effects", 771], ["on", 779], ["structure", 782], ["stability", 792], ["and", 802], ["the", 806], ["wideness", 810], ["of", 819], ["neutral", 822], ["neighborhood", 830], ["for", 843], ["each", 847], ["viroid", 852], ["species", 859], [",", 866], ["we", 868], ["show", 871], ["an", 876], ["evolutionary", 879], ["trend", 892], ["toward", 898], ["increased", 905], ["structural", 915], ["robustness", 926], ["during", 937], ["viroid", 944], ["radiation", 951], [",", 960], ["giving", 962], ["support", 969], ["to", 977], ["the", 980], ["adaptive", 984], ["value", 993], ["of", 999], ["robustness", 1002], [".", 1012], ["Differences", 1014], ["in", 1026], ["robustness", 1029], ["among", 1040], ["the", 1046], ["2", 1050], ["viroid", 1052], ["families", 1059], ["can", 1068], ["be", 1072], ["explained", 1075], ["by", 1085], ["the", 1088], ["larger", 1092], ["fragility", 1099], ["of", 1109], ["branched", 1112], ["structures", 1121], ["compared", 1132], ["with", 1141], ["the", 1146], ["rodlike", 1150], ["ones", 1158], [".", 1162], ["We", 1164], ["also", 1167], ["show", 1172], ["that", 1177], ["genomic", 1182], ["redundancy", 1190], ["can", 1201], ["contribute", 1205], ["to", 1216], ["the", 1219], ["robustness", 1223], ["of", 1234], ["these", 1237], ["simple", 1243], ["RNA", 1250], ["genomes", 1254], [".", 1261]]}
{"context": "CADASIL is a cerebrovascular disease caused by mutations in the NOTCH3 gene. Most mutations result in a gain or loss of cysteine residue in one of the 34 epidermal growth factor-like repeats in the extracellular domain of the Notch3 protein, thus sparing the number of cysteine residues. To date, more than 130 different mutations in the NOTCH3 gene have been reported in CADASIL patients, of which 95% are missense point mutations. Many polymorphisms have also been identified in the NOTCH3 coding sequence, some of them leading to amino acid substitutions. The aim of the present study was to analyze the NOTCH3 gene in a large group of patients affected by leukoencephalopathy and to investigate the presence of genetic variants. The molecular analysis revealed several nucleotide alterations. In particular, we identified 20 different mutations, 22 polymorphisms, and 8 genetic variants of unknown pathological significance never reported previously. We hope that this NOTCH3 gene mutational analysis, performed in such a significant number of unrelated and related patients affected by leukoencephalopathy, will help in molecular screening for the NOTCH3 gene, thus contributing to enlargement of the NOTCH3 gene variation database.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "3aa0a515baa742df87b15ccd76e1ea2d", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[49, 49], [22, 22]], "char_spans": [[269, 276], [120, 127]]}]}], "context_tokens": [["CADASIL", 0], ["is", 8], ["a", 11], ["cerebrovascular", 13], ["disease", 29], ["caused", 37], ["by", 44], ["mutations", 47], ["in", 57], ["the", 60], ["NOTCH3", 64], ["gene", 71], [".", 75], ["Most", 77], ["mutations", 82], ["result", 92], ["in", 99], ["a", 102], ["gain", 104], ["or", 109], ["loss", 112], ["of", 117], ["cysteine", 120], ["residue", 129], ["in", 137], ["one", 140], ["of", 144], ["the", 147], ["34", 151], ["epidermal", 154], ["growth", 164], ["factor", 171], ["-", 177], ["like", 178], ["repeats", 183], ["in", 191], ["the", 194], ["extracellular", 198], ["domain", 212], ["of", 219], ["the", 222], ["Notch3", 226], ["protein", 233], [",", 240], ["thus", 242], ["sparing", 247], ["the", 255], ["number", 259], ["of", 266], ["cysteine", 269], ["residues", 278], [".", 286], ["To", 288], ["date", 291], [",", 295], ["more", 297], ["than", 302], ["130", 307], ["different", 311], ["mutations", 321], ["in", 331], ["the", 334], ["NOTCH3", 338], ["gene", 345], ["have", 350], ["been", 355], ["reported", 360], ["in", 369], ["CADASIL", 372], ["patients", 380], [",", 388], ["of", 390], ["which", 393], ["95", 399], ["%", 401], ["are", 403], ["missense", 407], ["point", 416], ["mutations", 422], [".", 431], ["Many", 433], ["polymorphisms", 438], ["have", 452], ["also", 457], ["been", 462], ["identified", 467], ["in", 478], ["the", 481], ["NOTCH3", 485], ["coding", 492], ["sequence", 499], [",", 507], ["some", 509], ["of", 514], ["them", 517], ["leading", 522], ["to", 530], ["amino", 533], ["acid", 539], ["substitutions", 544], [".", 557], ["The", 559], ["aim", 563], ["of", 567], ["the", 570], ["present", 574], ["study", 582], ["was", 588], ["to", 592], ["analyze", 595], ["the", 603], ["NOTCH3", 607], ["gene", 614], ["in", 619], ["a", 622], ["large", 624], ["group", 630], ["of", 636], ["patients", 639], ["affected", 648], ["by", 657], ["leukoencephalopathy", 660], ["and", 680], ["to", 684], ["investigate", 687], ["the", 699], ["presence", 703], ["of", 712], ["genetic", 715], ["variants", 723], [".", 731], ["The", 733], ["molecular", 737], ["analysis", 747], ["revealed", 756], ["several", 765], ["nucleotide", 773], ["alterations", 784], [".", 795], ["In", 797], ["particular", 800], [",", 810], ["we", 812], ["identified", 815], ["20", 826], ["different", 829], ["mutations", 839], [",", 848], ["22", 850], ["polymorphisms", 853], [",", 866], ["and", 868], ["8", 872], ["genetic", 874], ["variants", 882], ["of", 891], ["unknown", 894], ["pathological", 902], ["significance", 915], ["never", 928], ["reported", 934], ["previously", 943], [".", 953], ["We", 955], ["hope", 958], ["that", 963], ["this", 968], ["NOTCH3", 973], ["gene", 980], ["mutational", 985], ["analysis", 996], [",", 1004], ["performed", 1006], ["in", 1016], ["such", 1019], ["a", 1024], ["significant", 1026], ["number", 1038], ["of", 1045], ["unrelated", 1048], ["and", 1058], ["related", 1062], ["patients", 1070], ["affected", 1079], ["by", 1088], ["leukoencephalopathy", 1091], [",", 1110], ["will", 1112], ["help", 1117], ["in", 1122], ["molecular", 1125], ["screening", 1135], ["for", 1145], ["the", 1149], ["NOTCH3", 1153], ["gene", 1160], [",", 1164], ["thus", 1166], ["contributing", 1171], ["to", 1184], ["enlargement", 1187], ["of", 1199], ["the", 1202], ["NOTCH3", 1206], ["gene", 1213], ["variation", 1218], ["database", 1228], [".", 1236]]}
{"context": "Restless legs syndrome/Willis Ekbom disease (RLS/WED) has been recognized as a significant medical disorder since the 17th century. It was studied mostly in the last 50 years in relation to increasing interest in sleep medicine and health-related quality of life. This led to recognition that the disease is not well characterized as restless feelings in the legs. These symptoms are reported in many situations, but the subjective experience of RLS/WED patients differs from that experienced by others. Thus a new name has been introduced that avoids problems of symptom definition of a disease by naming it after those who first characterized it, i.e. 'Willis Ekbom disease'. This article emphasizes the importance of RLS/WED for psychiatry. The disease carries significant increased risk for depression and anxiety disorders. Treatment requires consideration of these co-morbid disorders. RLS/WED can exacerbate or even engender psychiatric disease, so treatment of psychiatric disease should also include consideration of RLS/WED. The need for attention to RLS/WED is particularly significant for depression. Most anti-depressants exacerbate or can even engender RLS/WED. Thus this article seeks to introduce RLS/WED in relation to psychiatric practice. It presents the RLS/WED disease, its overlap with psychiatry and the current treatment options.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "289d6353e4064a62a58db9f9192b3eff", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["/", 22], ["Willis", 23], ["Ekbom", 30], ["disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["has", 54], ["been", 58], ["recognized", 63], ["as", 74], ["a", 77], ["significant", 79], ["medical", 91], ["disorder", 99], ["since", 108], ["the", 114], ["17th", 118], ["century", 123], [".", 130], ["It", 132], ["was", 135], ["studied", 139], ["mostly", 147], ["in", 154], ["the", 157], ["last", 161], ["50", 166], ["years", 169], ["in", 175], ["relation", 178], ["to", 187], ["increasing", 190], ["interest", 201], ["in", 210], ["sleep", 213], ["medicine", 219], ["and", 228], ["health", 232], ["-", 238], ["related", 239], ["quality", 247], ["of", 255], ["life", 258], [".", 262], ["This", 264], ["led", 269], ["to", 273], ["recognition", 276], ["that", 288], ["the", 293], ["disease", 297], ["is", 305], ["not", 308], ["well", 312], ["characterized", 317], ["as", 331], ["restless", 334], ["feelings", 343], ["in", 352], ["the", 355], ["legs", 359], [".", 363], ["These", 365], ["symptoms", 371], ["are", 380], ["reported", 384], ["in", 393], ["many", 396], ["situations", 401], [",", 411], ["but", 413], ["the", 417], ["subjective", 421], ["experience", 432], ["of", 443], ["RLS", 446], ["/", 449], ["WED", 450], ["patients", 454], ["differs", 463], ["from", 471], ["that", 476], ["experienced", 481], ["by", 493], ["others", 496], [".", 502], ["Thus", 504], ["a", 509], ["new", 511], ["name", 515], ["has", 520], ["been", 524], ["introduced", 529], ["that", 540], ["avoids", 545], ["problems", 552], ["of", 561], ["symptom", 564], ["definition", 572], ["of", 583], ["a", 586], ["disease", 588], ["by", 596], ["naming", 599], ["it", 606], ["after", 609], ["those", 615], ["who", 621], ["first", 625], ["characterized", 631], ["it", 645], [",", 647], ["i.e.", 649], ["'", 654], ["Willis", 655], ["Ekbom", 662], ["disease", 668], ["'", 675], [".", 676], ["This", 678], ["article", 683], ["emphasizes", 691], ["the", 702], ["importance", 706], ["of", 717], ["RLS", 720], ["/", 723], ["WED", 724], ["for", 728], ["psychiatry", 732], [".", 742], ["The", 744], ["disease", 748], ["carries", 756], ["significant", 764], ["increased", 776], ["risk", 786], ["for", 791], ["depression", 795], ["and", 806], ["anxiety", 810], ["disorders", 818], [".", 827], ["Treatment", 829], ["requires", 839], ["consideration", 848], ["of", 862], ["these", 865], ["co", 871], ["-", 873], ["morbid", 874], ["disorders", 881], [".", 890], ["RLS", 892], ["/", 895], ["WED", 896], ["can", 900], ["exacerbate", 904], ["or", 915], ["even", 918], ["engender", 923], ["psychiatric", 932], ["disease", 944], [",", 951], ["so", 953], ["treatment", 956], ["of", 966], ["psychiatric", 969], ["disease", 981], ["should", 989], ["also", 996], ["include", 1001], ["consideration", 1009], ["of", 1023], ["RLS", 1026], ["/", 1029], ["WED", 1030], [".", 1033], ["The", 1035], ["need", 1039], ["for", 1044], ["attention", 1048], ["to", 1058], ["RLS", 1061], ["/", 1064], ["WED", 1065], ["is", 1069], ["particularly", 1072], ["significant", 1085], ["for", 1097], ["depression", 1101], [".", 1111], ["Most", 1113], ["anti", 1118], ["-", 1122], ["depressants", 1123], ["exacerbate", 1135], ["or", 1146], ["can", 1149], ["even", 1153], ["engender", 1158], ["RLS", 1167], ["/", 1170], ["WED", 1171], [".", 1174], ["Thus", 1176], ["this", 1181], ["article", 1186], ["seeks", 1194], ["to", 1200], ["introduce", 1203], ["RLS", 1213], ["/", 1216], ["WED", 1217], ["in", 1221], ["relation", 1224], ["to", 1233], ["psychiatric", 1236], ["practice", 1248], [".", 1256], ["It", 1258], ["presents", 1261], ["the", 1270], ["RLS", 1274], ["/", 1277], ["WED", 1278], ["disease", 1282], [",", 1289], ["its", 1291], ["overlap", 1295], ["with", 1303], ["psychiatry", 1308], ["and", 1319], ["the", 1323], ["current", 1327], ["treatment", 1335], ["options", 1345], [".", 1352]]}
{"context": "Many Prader-Willi syndrome (PWS) and Angelman syndrome (AS) patients have a cytogenetic deletion of 15q11q13. While AS and PWS share a similar cytogenetic anomaly, they have very different clinical phenotypes. DNAs from 4 AS patients were examined using 5 chromosome 15q11q13-specific cloned DNA segments. With the present level of resolution, the molecular deletions between AS and those previously reported for PWS did not appear to differ. However, in contrast to the paternal inheritance of the deleted chromosome 15 observed in the majority of PWS patients, maternal inheritance of the deleted chromosome 15 was demonstrated in the AS patients by restriction fragment length polymorphisms (RFLPs).", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "0886b5bfb37f4842a63d965014d3b9fa", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[1, 4]], "char_spans": [[5, 25]]}]}], "context_tokens": [["Many", 0], ["Prader", 5], ["-", 11], ["Willi", 12], ["syndrome", 18], ["(", 27], ["PWS", 28], [")", 31], ["and", 33], ["Angelman", 37], ["syndrome", 46], ["(", 55], ["AS", 56], [")", 58], ["patients", 60], ["have", 69], ["a", 74], ["cytogenetic", 76], ["deletion", 88], ["of", 97], ["15q11q13", 100], [".", 108], ["While", 110], ["AS", 116], ["and", 119], ["PWS", 123], ["share", 127], ["a", 133], ["similar", 135], ["cytogenetic", 143], ["anomaly", 155], [",", 162], ["they", 164], ["have", 169], ["very", 174], ["different", 179], ["clinical", 189], ["phenotypes", 198], [".", 208], ["DNAs", 210], ["from", 215], ["4", 220], ["AS", 222], ["patients", 225], ["were", 234], ["examined", 239], ["using", 248], ["5", 254], ["chromosome", 256], ["15q11q13-specific", 267], ["cloned", 285], ["DNA", 292], ["segments", 296], [".", 304], ["With", 306], ["the", 311], ["present", 315], ["level", 323], ["of", 329], ["resolution", 332], [",", 342], ["the", 344], ["molecular", 348], ["deletions", 358], ["between", 368], ["AS", 376], ["and", 379], ["those", 383], ["previously", 389], ["reported", 400], ["for", 409], ["PWS", 413], ["did", 417], ["not", 421], ["appear", 425], ["to", 432], ["differ", 435], [".", 441], ["However", 443], [",", 450], ["in", 452], ["contrast", 455], ["to", 464], ["the", 467], ["paternal", 471], ["inheritance", 480], ["of", 492], ["the", 495], ["deleted", 499], ["chromosome", 507], ["15", 518], ["observed", 521], ["in", 530], ["the", 533], ["majority", 537], ["of", 546], ["PWS", 549], ["patients", 553], [",", 561], ["maternal", 563], ["inheritance", 572], ["of", 584], ["the", 587], ["deleted", 591], ["chromosome", 599], ["15", 610], ["was", 613], ["demonstrated", 617], ["in", 630], ["the", 633], ["AS", 637], ["patients", 640], ["by", 649], ["restriction", 652], ["fragment", 664], ["length", 673], ["polymorphisms", 680], ["(", 694], ["RFLPs", 695], [")", 700], [".", 701]]}
{"context": "The literature is divided as to the necessity of an intact posterior cruciate ligament for functional stability. Presented here is a prospective study of isolated posterior cruciate injuries seen in the acute stage in 13 patients, 6 males and 7 females. The diagnosis of posterior cruciate ligament tear was made clinically and confirmed by arthroscopy. The average age at injury was 22 years. The athletic activity at injury was varied. Hyperflexion was the most common mechanism of injury, followed by pretibial trauma in the hyperflexed knee or in the \"dashboard\" injury. There were seven complete midsubstance tears and five partial tears. Direct visualization of the posterior cruciate ligament was not attained in one patient. All patients were treated nonoperatively on a physiotherapy routine. Average followup was 2.6 years. Patients were clinically examined and subjected to KT-1000 and Cybex testing. All patients were able to return to their previous activity and experienced no limitations with their injured knees. Using Hughston's criteria, subjective and functional ratings were all good. However, only 3 rated good and 10 fair when assessed objectively. We conclude that acceptable functional stability in these patients does not necessarily require absolute static stability. Nonoperative treatment of the isolated posterior cruciate ligament midsubstance injury may be a viable alternative to the difficult repair/reconstruction procedure.", "qas": [{"question": "Which ligament is most commonly injured in dashboard injury?", "answers": ["Posterior cruciate ligament"], "qid": "227ac45c39224b96946662810578c154", "question_tokens": [["Which", 0], ["ligament", 6], ["is", 15], ["most", 18], ["commonly", 23], ["injured", 32], ["in", 40], ["dashboard", 43], ["injury", 53], ["?", 59]], "detected_answers": [{"text": "Posterior cruciate ligament", "token_spans": [[47, 49], [221, 223], [116, 118], [11, 13]], "char_spans": [[271, 297], [1333, 1359], [672, 698], [59, 85]]}]}], "context_tokens": [["The", 0], ["literature", 4], ["is", 15], ["divided", 18], ["as", 26], ["to", 29], ["the", 32], ["necessity", 36], ["of", 46], ["an", 49], ["intact", 52], ["posterior", 59], ["cruciate", 69], ["ligament", 78], ["for", 87], ["functional", 91], ["stability", 102], [".", 111], ["Presented", 113], ["here", 123], ["is", 128], ["a", 131], ["prospective", 133], ["study", 145], ["of", 151], ["isolated", 154], ["posterior", 163], ["cruciate", 173], ["injuries", 182], ["seen", 191], ["in", 196], ["the", 199], ["acute", 203], ["stage", 209], ["in", 215], ["13", 218], ["patients", 221], [",", 229], ["6", 231], ["males", 233], ["and", 239], ["7", 243], ["females", 245], [".", 252], ["The", 254], ["diagnosis", 258], ["of", 268], ["posterior", 271], ["cruciate", 281], ["ligament", 290], ["tear", 299], ["was", 304], ["made", 308], ["clinically", 313], ["and", 324], ["confirmed", 328], ["by", 338], ["arthroscopy", 341], [".", 352], ["The", 354], ["average", 358], ["age", 366], ["at", 370], ["injury", 373], ["was", 380], ["22", 384], ["years", 387], [".", 392], ["The", 394], ["athletic", 398], ["activity", 407], ["at", 416], ["injury", 419], ["was", 426], ["varied", 430], [".", 436], ["Hyperflexion", 438], ["was", 451], ["the", 455], ["most", 459], ["common", 464], ["mechanism", 471], ["of", 481], ["injury", 484], [",", 490], ["followed", 492], ["by", 501], ["pretibial", 504], ["trauma", 514], ["in", 521], ["the", 524], ["hyperflexed", 528], ["knee", 540], ["or", 545], ["in", 548], ["the", 551], ["\"", 555], ["dashboard", 556], ["\"", 565], ["injury", 567], [".", 573], ["There", 575], ["were", 581], ["seven", 586], ["complete", 592], ["midsubstance", 601], ["tears", 614], ["and", 620], ["five", 624], ["partial", 629], ["tears", 637], [".", 642], ["Direct", 644], ["visualization", 651], ["of", 665], ["the", 668], ["posterior", 672], ["cruciate", 682], ["ligament", 691], ["was", 700], ["not", 704], ["attained", 708], ["in", 717], ["one", 720], ["patient", 724], [".", 731], ["All", 733], ["patients", 737], ["were", 746], ["treated", 751], ["nonoperatively", 759], ["on", 774], ["a", 777], ["physiotherapy", 779], ["routine", 793], [".", 800], ["Average", 802], ["followup", 810], ["was", 819], ["2.6", 823], ["years", 827], [".", 832], ["Patients", 834], ["were", 843], ["clinically", 848], ["examined", 859], ["and", 868], ["subjected", 872], ["to", 882], ["KT-1000", 885], ["and", 893], ["Cybex", 897], ["testing", 903], [".", 910], ["All", 912], ["patients", 916], ["were", 925], ["able", 930], ["to", 935], ["return", 938], ["to", 945], ["their", 948], ["previous", 954], ["activity", 963], ["and", 972], ["experienced", 976], ["no", 988], ["limitations", 991], ["with", 1003], ["their", 1008], ["injured", 1014], ["knees", 1022], [".", 1027], ["Using", 1029], ["Hughston", 1035], ["'s", 1043], ["criteria", 1046], [",", 1054], ["subjective", 1056], ["and", 1067], ["functional", 1071], ["ratings", 1082], ["were", 1090], ["all", 1095], ["good", 1099], [".", 1103], ["However", 1105], [",", 1112], ["only", 1114], ["3", 1119], ["rated", 1121], ["good", 1127], ["and", 1132], ["10", 1136], ["fair", 1139], ["when", 1144], ["assessed", 1149], ["objectively", 1158], [".", 1169], ["We", 1171], ["conclude", 1174], ["that", 1183], ["acceptable", 1188], ["functional", 1199], ["stability", 1210], ["in", 1220], ["these", 1223], ["patients", 1229], ["does", 1238], ["not", 1243], ["necessarily", 1247], ["require", 1259], ["absolute", 1267], ["static", 1276], ["stability", 1283], [".", 1292], ["Nonoperative", 1294], ["treatment", 1307], ["of", 1317], ["the", 1320], ["isolated", 1324], ["posterior", 1333], ["cruciate", 1343], ["ligament", 1352], ["midsubstance", 1361], ["injury", 1374], ["may", 1381], ["be", 1385], ["a", 1388], ["viable", 1390], ["alternative", 1397], ["to", 1409], ["the", 1412], ["difficult", 1416], ["repair", 1426], ["/", 1432], ["reconstruction", 1433], ["procedure", 1448], [".", 1457]]}
{"context": "The CRISPR-Cas (clustered regularly interspaced short palindromic repeats, CRISPR-associated genes) is an adaptive immunity system in bacteria and archaea that functions via a distinct self-non-self recognition mechanism that is partially analogous to the mechanism of eukaryotic RNA interference (RNAi). The CRISPR-Cas system incorporates fragments of virus or plasmid DNA into the CRISPR repeat cassettes and employs the processed transcripts of these spacers as guide RNAs to cleave the cognate foreign DNA or RNA. The Cas proteins, however, are not homologous to the proteins involved in RNAi and comprise numerous, highly diverged families. The majority of the Cas proteins contain diverse variants of the RNA recognition motif (RRM), a widespread RNA-binding domain. Despite the fast evolution that is typical of the cas genes, the presence of diverse versions of the RRM in most Cas proteins provides for a simple scenario for the evolution of the three distinct types of CRISPR-cas systems. In addition to several proteins that are directly implicated in the immune response, the cas genes encode a variety of proteins that are homologous to prokaryotic toxins that typically possess nuclease activity. The predicted toxins associated with CRISPR-Cas systems include the essential Cas2 protein, proteins of COG1517 that, in addition to a ligand-binding domain and a helix-turn-helix domain, typically contain different nuclease domains and several other predicted nucleases. The tight association of the CRISPR-Cas immunity systems with predicted toxins that, upon activation, would induce dormancy or cell death suggests that adaptive immunity and dormancy/suicide response are functionally coupled. Such coupling could manifest in the persistence state being induced and potentially providing conditions for more effective action of the immune system or in cell death being triggered when immunity fails.", "qas": [{"question": "Gene silencing can be achieved by RNA interference (RNAi) in eukaryotic organisms. What is the name of the analogous process in prokaryotic organisms?", "answers": ["CRISPR-Cas"], "qid": "c40581ee9c7a4286b6e7d0e14ece96df", "question_tokens": [["Gene", 0], ["silencing", 5], ["can", 15], ["be", 19], ["achieved", 22], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["in", 58], ["eukaryotic", 61], ["organisms", 72], [".", 81], ["What", 83], ["is", 88], ["the", 91], ["name", 95], ["of", 100], ["the", 103], ["analogous", 107], ["process", 117], ["in", 125], ["prokaryotic", 128], ["organisms", 140], ["?", 149]], "detected_answers": [{"text": "CRISPR-Cas", "token_spans": [[1, 3], [268, 270], [54, 56], [220, 222], [176, 178]], "char_spans": [[4, 13], [1512, 1521], [309, 318], [1248, 1257], [979, 988]]}]}], "context_tokens": [["The", 0], ["CRISPR", 4], ["-", 10], ["Cas", 11], ["(", 15], ["clustered", 16], ["regularly", 26], ["interspaced", 36], ["short", 48], ["palindromic", 54], ["repeats", 66], [",", 73], ["CRISPR", 75], ["-", 81], ["associated", 82], ["genes", 93], [")", 98], ["is", 100], ["an", 103], ["adaptive", 106], ["immunity", 115], ["system", 124], ["in", 131], ["bacteria", 134], ["and", 143], ["archaea", 147], ["that", 155], ["functions", 160], ["via", 170], ["a", 174], ["distinct", 176], ["self", 185], ["-", 189], ["non", 190], ["-", 193], ["self", 194], ["recognition", 199], ["mechanism", 211], ["that", 221], ["is", 226], ["partially", 229], ["analogous", 239], ["to", 249], ["the", 252], ["mechanism", 256], ["of", 266], ["eukaryotic", 269], ["RNA", 280], ["interference", 284], ["(", 297], ["RNAi", 298], [")", 302], [".", 303], ["The", 305], ["CRISPR", 309], ["-", 315], ["Cas", 316], ["system", 320], ["incorporates", 327], ["fragments", 340], ["of", 350], ["virus", 353], ["or", 359], ["plasmid", 362], ["DNA", 370], ["into", 374], ["the", 379], ["CRISPR", 383], ["repeat", 390], ["cassettes", 397], ["and", 407], ["employs", 411], ["the", 419], ["processed", 423], ["transcripts", 433], ["of", 445], ["these", 448], ["spacers", 454], ["as", 462], ["guide", 465], ["RNAs", 471], ["to", 476], ["cleave", 479], ["the", 486], ["cognate", 490], ["foreign", 498], ["DNA", 506], ["or", 510], ["RNA", 513], [".", 516], ["The", 518], ["Cas", 522], ["proteins", 526], [",", 534], ["however", 536], [",", 543], ["are", 545], ["not", 549], ["homologous", 553], ["to", 564], ["the", 567], ["proteins", 571], ["involved", 580], ["in", 589], ["RNAi", 592], ["and", 597], ["comprise", 601], ["numerous", 610], [",", 618], ["highly", 620], ["diverged", 627], ["families", 636], [".", 644], ["The", 646], ["majority", 650], ["of", 659], ["the", 662], ["Cas", 666], ["proteins", 670], ["contain", 679], ["diverse", 687], ["variants", 695], ["of", 704], ["the", 707], ["RNA", 711], ["recognition", 715], ["motif", 727], ["(", 733], ["RRM", 734], [")", 737], [",", 738], ["a", 740], ["widespread", 742], ["RNA", 753], ["-", 756], ["binding", 757], ["domain", 765], [".", 771], ["Despite", 773], ["the", 781], ["fast", 785], ["evolution", 790], ["that", 800], ["is", 805], ["typical", 808], ["of", 816], ["the", 819], ["cas", 823], ["genes", 827], [",", 832], ["the", 834], ["presence", 838], ["of", 847], ["diverse", 850], ["versions", 858], ["of", 867], ["the", 870], ["RRM", 874], ["in", 878], ["most", 881], ["Cas", 886], ["proteins", 890], ["provides", 899], ["for", 908], ["a", 912], ["simple", 914], ["scenario", 921], ["for", 930], ["the", 934], ["evolution", 938], ["of", 948], ["the", 951], ["three", 955], ["distinct", 961], ["types", 970], ["of", 976], ["CRISPR", 979], ["-", 985], ["cas", 986], ["systems", 990], [".", 997], ["In", 999], ["addition", 1002], ["to", 1011], ["several", 1014], ["proteins", 1022], ["that", 1031], ["are", 1036], ["directly", 1040], ["implicated", 1049], ["in", 1060], ["the", 1063], ["immune", 1067], ["response", 1074], [",", 1082], ["the", 1084], ["cas", 1088], ["genes", 1092], ["encode", 1098], ["a", 1105], ["variety", 1107], ["of", 1115], ["proteins", 1118], ["that", 1127], ["are", 1132], ["homologous", 1136], ["to", 1147], ["prokaryotic", 1150], ["toxins", 1162], ["that", 1169], ["typically", 1174], ["possess", 1184], ["nuclease", 1192], ["activity", 1201], [".", 1209], ["The", 1211], ["predicted", 1215], ["toxins", 1225], ["associated", 1232], ["with", 1243], ["CRISPR", 1248], ["-", 1254], ["Cas", 1255], ["systems", 1259], ["include", 1267], ["the", 1275], ["essential", 1279], ["Cas2", 1289], ["protein", 1294], [",", 1301], ["proteins", 1303], ["of", 1312], ["COG1517", 1315], ["that", 1323], [",", 1327], ["in", 1329], ["addition", 1332], ["to", 1341], ["a", 1344], ["ligand", 1346], ["-", 1352], ["binding", 1353], ["domain", 1361], ["and", 1368], ["a", 1372], ["helix", 1374], ["-", 1379], ["turn", 1380], ["-", 1384], ["helix", 1385], ["domain", 1391], [",", 1397], ["typically", 1399], ["contain", 1409], ["different", 1417], ["nuclease", 1427], ["domains", 1436], ["and", 1444], ["several", 1448], ["other", 1456], ["predicted", 1462], ["nucleases", 1472], [".", 1481], ["The", 1483], ["tight", 1487], ["association", 1493], ["of", 1505], ["the", 1508], ["CRISPR", 1512], ["-", 1518], ["Cas", 1519], ["immunity", 1523], ["systems", 1532], ["with", 1540], ["predicted", 1545], ["toxins", 1555], ["that", 1562], [",", 1566], ["upon", 1568], ["activation", 1573], [",", 1583], ["would", 1585], ["induce", 1591], ["dormancy", 1598], ["or", 1607], ["cell", 1610], ["death", 1615], ["suggests", 1621], ["that", 1630], ["adaptive", 1635], ["immunity", 1644], ["and", 1653], ["dormancy", 1657], ["/", 1665], ["suicide", 1666], ["response", 1674], ["are", 1683], ["functionally", 1687], ["coupled", 1700], [".", 1707], ["Such", 1709], ["coupling", 1714], ["could", 1723], ["manifest", 1729], ["in", 1738], ["the", 1741], ["persistence", 1745], ["state", 1757], ["being", 1763], ["induced", 1769], ["and", 1777], ["potentially", 1781], ["providing", 1793], ["conditions", 1803], ["for", 1814], ["more", 1818], ["effective", 1823], ["action", 1833], ["of", 1840], ["the", 1843], ["immune", 1847], ["system", 1854], ["or", 1861], ["in", 1864], ["cell", 1867], ["death", 1872], ["being", 1878], ["triggered", 1884], ["when", 1894], ["immunity", 1899], ["fails", 1908], [".", 1913]]}
{"context": "Extrapolating the figures from a previous study on FSHD in a province of The Netherlands to the entire Dutch population suggests that at present a nearly complete overview is obtained of all symptomatic kindred. In 139 families, dominant inheritance was observed in 97, a pattern compatible with germline mosaicism in 6, while sporadic cases were found in 36 families. A mutation frequency of 9.6% was calculated. Mental retardation and severe retinal vasculopathy were reported in low frequencies (1%). Early onset was seen more frequently in sporadic cases. Chromosome 4 linkage appeared excluded in 3 of 22 autosomal-dominant families. The clinical pictures in the linked and nonlinked families were identical.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "4aa2254c611946849f987fbc7af289e2", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[108, 110]], "char_spans": [[610, 627]]}]}], "context_tokens": [["Extrapolating", 0], ["the", 14], ["figures", 18], ["from", 26], ["a", 31], ["previous", 33], ["study", 42], ["on", 48], ["FSHD", 51], ["in", 56], ["a", 59], ["province", 61], ["of", 70], ["The", 73], ["Netherlands", 77], ["to", 89], ["the", 92], ["entire", 96], ["Dutch", 103], ["population", 109], ["suggests", 120], ["that", 129], ["at", 134], ["present", 137], ["a", 145], ["nearly", 147], ["complete", 154], ["overview", 163], ["is", 172], ["obtained", 175], ["of", 184], ["all", 187], ["symptomatic", 191], ["kindred", 203], [".", 210], ["In", 212], ["139", 215], ["families", 219], [",", 227], ["dominant", 229], ["inheritance", 238], ["was", 250], ["observed", 254], ["in", 263], ["97", 266], [",", 268], ["a", 270], ["pattern", 272], ["compatible", 280], ["with", 291], ["germline", 296], ["mosaicism", 305], ["in", 315], ["6", 318], [",", 319], ["while", 321], ["sporadic", 327], ["cases", 336], ["were", 342], ["found", 347], ["in", 353], ["36", 356], ["families", 359], [".", 367], ["A", 369], ["mutation", 371], ["frequency", 380], ["of", 390], ["9.6", 393], ["%", 396], ["was", 398], ["calculated", 402], [".", 412], ["Mental", 414], ["retardation", 421], ["and", 433], ["severe", 437], ["retinal", 444], ["vasculopathy", 452], ["were", 465], ["reported", 470], ["in", 479], ["low", 482], ["frequencies", 486], ["(", 498], ["1", 499], ["%", 500], [")", 501], [".", 502], ["Early", 504], ["onset", 510], ["was", 516], ["seen", 520], ["more", 525], ["frequently", 530], ["in", 541], ["sporadic", 544], ["cases", 553], [".", 558], ["Chromosome", 560], ["4", 571], ["linkage", 573], ["appeared", 581], ["excluded", 590], ["in", 599], ["3", 602], ["of", 604], ["22", 607], ["autosomal", 610], ["-", 619], ["dominant", 620], ["families", 629], [".", 637], ["The", 639], ["clinical", 643], ["pictures", 652], ["in", 661], ["the", 664], ["linked", 668], ["and", 675], ["nonlinked", 679], ["families", 689], ["were", 698], ["identical", 703], [".", 712]]}
{"context": "Previously, autosomal dominant catecholaminergic polymorphic ventricular tachycardia (CPVT [1]) was mapped to chromosome 1q42-43 with identification of pathogenic mutations in RYR2. Autosomal recessive CPVT (2) was mapped to chromosome 1p13-21, leading to the identification of mutations in CASQ2. In this study, we aimed to elucidate clinical phenotypes of a new variant of CPVT (3) in an inbred Arab family and also delineate the chromosomal location of the gene causing CPVT (3). In a highly inbred family, clinical symptoms of CPVT appeared early in childhood (7-12 years) and in three of the four cases, the first appearance of symptoms turned into a fatal outcome. Parents of the affected children were first-degree cousins and without any symptoms. Segregation analysis suggested an autosomal recessive inheritance. A genome-wide search using polymorphic DNA markers mapped the disease locus to a 25-Mb interval on chromosome 7p14-p22. A maximal multipoint LOD score of 3.17 was obtained at marker D7S493. Sequencing of putative candidate genes, SP4, NPY, FKBP9, FKBP14, PDE1C, and TBX20, in and around this locus, did not reveal any mutation. We have identified a novel highly malignant autosomal recessive form of CPVT and mapped this disorder to a 25-Mb interval on chromosome 7p14-p22.", "qas": [{"question": "What is the inheritance pattern of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) caused by RYR2 mutations?", "answers": ["autosomal dominant"], "qid": "67b5647fc6814b5d880a3bc12a5c419c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["inheritance", 12], ["pattern", 24], ["of", 32], ["Catecholaminergic", 35], ["Polymorphic", 53], ["Ventricular", 65], ["Tachycardia", 77], ["(", 89], ["CPVT", 90], [")", 94], ["caused", 96], ["by", 103], ["RYR2", 106], ["mutations", 111], ["?", 120]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[2, 3]], "char_spans": [[12, 29]]}]}], "context_tokens": [["Previously", 0], [",", 10], ["autosomal", 12], ["dominant", 22], ["catecholaminergic", 31], ["polymorphic", 49], ["ventricular", 61], ["tachycardia", 73], ["(", 85], ["CPVT", 86], ["[", 91], ["1", 92], ["]", 93], [")", 94], ["was", 96], ["mapped", 100], ["to", 107], ["chromosome", 110], ["1q42", 121], ["-", 125], ["43", 126], ["with", 129], ["identification", 134], ["of", 149], ["pathogenic", 152], ["mutations", 163], ["in", 173], ["RYR2", 176], [".", 180], ["Autosomal", 182], ["recessive", 192], ["CPVT", 202], ["(", 207], ["2", 208], [")", 209], ["was", 211], ["mapped", 215], ["to", 222], ["chromosome", 225], ["1p13", 236], ["-", 240], ["21", 241], [",", 243], ["leading", 245], ["to", 253], ["the", 256], ["identification", 260], ["of", 275], ["mutations", 278], ["in", 288], ["CASQ2", 291], [".", 296], ["In", 298], ["this", 301], ["study", 306], [",", 311], ["we", 313], ["aimed", 316], ["to", 322], ["elucidate", 325], ["clinical", 335], ["phenotypes", 344], ["of", 355], ["a", 358], ["new", 360], ["variant", 364], ["of", 372], ["CPVT", 375], ["(", 380], ["3", 381], [")", 382], ["in", 384], ["an", 387], ["inbred", 390], ["Arab", 397], ["family", 402], ["and", 409], ["also", 413], ["delineate", 418], ["the", 428], ["chromosomal", 432], ["location", 444], ["of", 453], ["the", 456], ["gene", 460], ["causing", 465], ["CPVT", 473], ["(", 478], ["3", 479], [")", 480], [".", 481], ["In", 483], ["a", 486], ["highly", 488], ["inbred", 495], ["family", 502], [",", 508], ["clinical", 510], ["symptoms", 519], ["of", 528], ["CPVT", 531], ["appeared", 536], ["early", 545], ["in", 551], ["childhood", 554], ["(", 564], ["7", 565], ["-", 566], ["12", 567], ["years", 570], [")", 575], ["and", 577], ["in", 581], ["three", 584], ["of", 590], ["the", 593], ["four", 597], ["cases", 602], [",", 607], ["the", 609], ["first", 613], ["appearance", 619], ["of", 630], ["symptoms", 633], ["turned", 642], ["into", 649], ["a", 654], ["fatal", 656], ["outcome", 662], [".", 669], ["Parents", 671], ["of", 679], ["the", 682], ["affected", 686], ["children", 695], ["were", 704], ["first", 709], ["-", 714], ["degree", 715], ["cousins", 722], ["and", 730], ["without", 734], ["any", 742], ["symptoms", 746], [".", 754], ["Segregation", 756], ["analysis", 768], ["suggested", 777], ["an", 787], ["autosomal", 790], ["recessive", 800], ["inheritance", 810], [".", 821], ["A", 823], ["genome", 825], ["-", 831], ["wide", 832], ["search", 837], ["using", 844], ["polymorphic", 850], ["DNA", 862], ["markers", 866], ["mapped", 874], ["the", 881], ["disease", 885], ["locus", 893], ["to", 899], ["a", 902], ["25-Mb", 904], ["interval", 910], ["on", 919], ["chromosome", 922], ["7p14-p22", 933], [".", 941], ["A", 943], ["maximal", 945], ["multipoint", 953], ["LOD", 964], ["score", 968], ["of", 974], ["3.17", 977], ["was", 982], ["obtained", 986], ["at", 995], ["marker", 998], ["D7S493", 1005], [".", 1011], ["Sequencing", 1013], ["of", 1024], ["putative", 1027], ["candidate", 1036], ["genes", 1046], [",", 1051], ["SP4", 1053], [",", 1056], ["NPY", 1058], [",", 1061], ["FKBP9", 1063], [",", 1068], ["FKBP14", 1070], [",", 1076], ["PDE1C", 1078], [",", 1083], ["and", 1085], ["TBX20", 1089], [",", 1094], ["in", 1096], ["and", 1099], ["around", 1103], ["this", 1110], ["locus", 1115], [",", 1120], ["did", 1122], ["not", 1126], ["reveal", 1130], ["any", 1137], ["mutation", 1141], [".", 1149], ["We", 1151], ["have", 1154], ["identified", 1159], ["a", 1170], ["novel", 1172], ["highly", 1178], ["malignant", 1185], ["autosomal", 1195], ["recessive", 1205], ["form", 1215], ["of", 1220], ["CPVT", 1223], ["and", 1228], ["mapped", 1232], ["this", 1239], ["disorder", 1244], ["to", 1253], ["a", 1256], ["25-Mb", 1258], ["interval", 1264], ["on", 1273], ["chromosome", 1276], ["7p14-p22", 1287], [".", 1295]]}
{"context": "Growth differentiation factor 15 (GDF15), a distant member of the transforming growth factor (TGF)-\u03b2 family, is a secreted protein that circulates as a 25-kDa dimer. In humans, elevated GDF15 correlates with weight loss, and the administration of GDF15 to mice with obesity reduces body weight, at least in part, by decreasing food intake. The mechanisms through which GDF15 reduces body weight remain poorly understood, because the cognate receptor for GDF15 is unknown. Here we show that recombinant GDF15 induces weight loss in mice fed a high-fat diet and in nonhuman primates with spontaneous obesity. Furthermore, we find that GDF15 binds with high affinity to GDNF family receptor \u03b1-like (GFRAL), a distant relative of receptors for a distinct class of the TGF-\u03b2 superfamily ligands. Gfral is expressed in neurons of the area postrema and nucleus of the solitary tract in mice and humans, and genetic deletion of the receptor abrogates the ability of GDF15 to decrease food intake and body weight in mice. In addition, diet-induced obesity and insulin resistance are exacerbated in GFRAL-deficient mice, suggesting a homeostatic role for this receptor in metabolism. Finally, we demonstrate that GDF15-induced cell signaling requires the interaction of GFRAL with the coreceptor RET. Our data identify GFRAL as a new regulator of body weight and as the bona fide receptor mediating the metabolic effects of GDF15, enabling a more comprehensive assessment of GDF15 as a potential pharmacotherapy for the treatment of obesity.", "qas": [{"question": "How does increased GDF15 affect body weight?", "answers": ["Reduces body weight"], "qid": "de1a17e690e849e3a857822511b54678", "question_tokens": [["How", 0], ["does", 4], ["increased", 9], ["GDF15", 19], ["affect", 25], ["body", 32], ["weight", 37], ["?", 43]], "detected_answers": [{"text": "Reduces body weight", "token_spans": [[69, 71], [50, 52]], "char_spans": [[375, 393], [274, 292]]}]}], "context_tokens": [["Growth", 0], ["differentiation", 7], ["factor", 23], ["15", 30], ["(", 33], ["GDF15", 34], [")", 39], [",", 40], ["a", 42], ["distant", 44], ["member", 52], ["of", 59], ["the", 62], ["transforming", 66], ["growth", 79], ["factor", 86], ["(", 93], ["TGF)-\u03b2", 94], ["family", 101], [",", 107], ["is", 109], ["a", 112], ["secreted", 114], ["protein", 123], ["that", 131], ["circulates", 136], ["as", 147], ["a", 150], ["25-kDa", 152], ["dimer", 159], [".", 164], ["In", 166], ["humans", 169], [",", 175], ["elevated", 177], ["GDF15", 186], ["correlates", 192], ["with", 203], ["weight", 208], ["loss", 215], [",", 219], ["and", 221], ["the", 225], ["administration", 229], ["of", 244], ["GDF15", 247], ["to", 253], ["mice", 256], ["with", 261], ["obesity", 266], ["reduces", 274], ["body", 282], ["weight", 287], [",", 293], ["at", 295], ["least", 298], ["in", 304], ["part", 307], [",", 311], ["by", 313], ["decreasing", 316], ["food", 327], ["intake", 332], [".", 338], ["The", 340], ["mechanisms", 344], ["through", 355], ["which", 363], ["GDF15", 369], ["reduces", 375], ["body", 383], ["weight", 388], ["remain", 395], ["poorly", 402], ["understood", 409], [",", 419], ["because", 421], ["the", 429], ["cognate", 433], ["receptor", 441], ["for", 450], ["GDF15", 454], ["is", 460], ["unknown", 463], [".", 470], ["Here", 472], ["we", 477], ["show", 480], ["that", 485], ["recombinant", 490], ["GDF15", 502], ["induces", 508], ["weight", 516], ["loss", 523], ["in", 528], ["mice", 531], ["fed", 536], ["a", 540], ["high", 542], ["-", 546], ["fat", 547], ["diet", 551], ["and", 556], ["in", 560], ["nonhuman", 563], ["primates", 572], ["with", 581], ["spontaneous", 586], ["obesity", 598], [".", 605], ["Furthermore", 607], [",", 618], ["we", 620], ["find", 623], ["that", 628], ["GDF15", 633], ["binds", 639], ["with", 645], ["high", 650], ["affinity", 655], ["to", 664], ["GDNF", 667], ["family", 672], ["receptor", 679], ["\u03b1", 688], ["-", 689], ["like", 690], ["(", 695], ["GFRAL", 696], [")", 701], [",", 702], ["a", 704], ["distant", 706], ["relative", 714], ["of", 723], ["receptors", 726], ["for", 736], ["a", 740], ["distinct", 742], ["class", 751], ["of", 757], ["the", 760], ["TGF", 764], ["-", 767], ["\u03b2", 768], ["superfamily", 770], ["ligands", 782], [".", 789], ["Gfral", 791], ["is", 797], ["expressed", 800], ["in", 810], ["neurons", 813], ["of", 821], ["the", 824], ["area", 828], ["postrema", 833], ["and", 842], ["nucleus", 846], ["of", 854], ["the", 857], ["solitary", 861], ["tract", 870], ["in", 876], ["mice", 879], ["and", 884], ["humans", 888], [",", 894], ["and", 896], ["genetic", 900], ["deletion", 908], ["of", 917], ["the", 920], ["receptor", 924], ["abrogates", 933], ["the", 943], ["ability", 947], ["of", 955], ["GDF15", 958], ["to", 964], ["decrease", 967], ["food", 976], ["intake", 981], ["and", 988], ["body", 992], ["weight", 997], ["in", 1004], ["mice", 1007], [".", 1011], ["In", 1013], ["addition", 1016], [",", 1024], ["diet", 1026], ["-", 1030], ["induced", 1031], ["obesity", 1039], ["and", 1047], ["insulin", 1051], ["resistance", 1059], ["are", 1070], ["exacerbated", 1074], ["in", 1086], ["GFRAL", 1089], ["-", 1094], ["deficient", 1095], ["mice", 1105], [",", 1109], ["suggesting", 1111], ["a", 1122], ["homeostatic", 1124], ["role", 1136], ["for", 1141], ["this", 1145], ["receptor", 1150], ["in", 1159], ["metabolism", 1162], [".", 1172], ["Finally", 1174], [",", 1181], ["we", 1183], ["demonstrate", 1186], ["that", 1198], ["GDF15-induced", 1203], ["cell", 1217], ["signaling", 1222], ["requires", 1232], ["the", 1241], ["interaction", 1245], ["of", 1257], ["GFRAL", 1260], ["with", 1266], ["the", 1271], ["coreceptor", 1275], ["RET", 1286], [".", 1289], ["Our", 1291], ["data", 1295], ["identify", 1300], ["GFRAL", 1309], ["as", 1315], ["a", 1318], ["new", 1320], ["regulator", 1324], ["of", 1334], ["body", 1337], ["weight", 1342], ["and", 1349], ["as", 1353], ["the", 1356], ["bona", 1360], ["fide", 1365], ["receptor", 1370], ["mediating", 1379], ["the", 1389], ["metabolic", 1393], ["effects", 1403], ["of", 1411], ["GDF15", 1414], [",", 1419], ["enabling", 1421], ["a", 1430], ["more", 1432], ["comprehensive", 1437], ["assessment", 1451], ["of", 1462], ["GDF15", 1465], ["as", 1471], ["a", 1474], ["potential", 1476], ["pharmacotherapy", 1486], ["for", 1502], ["the", 1506], ["treatment", 1510], ["of", 1520], ["obesity", 1523], [".", 1530]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a small vessel disease of the brain caused by mutations in the NOTCH3 gene. CADASIL progresses, in some cases, to subcortical dementia with a particular cognitive impairment. Different diseases in the dementia spectrum share a central cholinergic and sensorimotor plasticity alteration. We aimed to study different intracortical circuits and sensorimotor plasticity in CADASIL patients using transcranial magnetic stimulation protocols, and to determine whether these characteristics correlated with the results of clinical neuropsychological evaluation. Ten CADASIL patients and 10 healthy subjects were included in the study. All subjects underwent a transcranial magnetic stimulation study examining different intracortical circuits. Sensorimotor plasticity was also assessed using a paired associative stimulation and extensive neuropsychological tests. CADASIL patients showed a lack of intracortical facilitation, short latency afferent inhibition and sensorimotor plasticity when compared with control subjects. CADASIL patients also showed an altered neuropsychological profile. Correlation between sensorimotor plasticity and neuropsychological alterations was observed in CADASIL patients. These results suggest that acetylcholine and glutamate could be involved in the dementia process in CADASIL and that abnormal sensorimotor plasticity correlates with the neuropsychological profile in CADASIL patients.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "27c99f3d44a94401b785406bd2f20967", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[25, 26]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["a", 104], ["small", 106], ["vessel", 112], ["disease", 119], ["of", 127], ["the", 130], ["brain", 134], ["caused", 140], ["by", 147], ["mutations", 150], ["in", 160], ["the", 163], ["NOTCH3", 167], ["gene", 174], [".", 178], ["CADASIL", 180], ["progresses", 188], [",", 198], ["in", 200], ["some", 203], ["cases", 208], [",", 213], ["to", 215], ["subcortical", 218], ["dementia", 230], ["with", 239], ["a", 244], ["particular", 246], ["cognitive", 257], ["impairment", 267], [".", 277], ["Different", 279], ["diseases", 289], ["in", 298], ["the", 301], ["dementia", 305], ["spectrum", 314], ["share", 323], ["a", 329], ["central", 331], ["cholinergic", 339], ["and", 351], ["sensorimotor", 355], ["plasticity", 368], ["alteration", 379], [".", 389], ["We", 391], ["aimed", 394], ["to", 400], ["study", 403], ["different", 409], ["intracortical", 419], ["circuits", 433], ["and", 442], ["sensorimotor", 446], ["plasticity", 459], ["in", 470], ["CADASIL", 473], ["patients", 481], ["using", 490], ["transcranial", 496], ["magnetic", 509], ["stimulation", 518], ["protocols", 530], [",", 539], ["and", 541], ["to", 545], ["determine", 548], ["whether", 558], ["these", 566], ["characteristics", 572], ["correlated", 588], ["with", 599], ["the", 604], ["results", 608], ["of", 616], ["clinical", 619], ["neuropsychological", 628], ["evaluation", 647], [".", 657], ["Ten", 659], ["CADASIL", 663], ["patients", 671], ["and", 680], ["10", 684], ["healthy", 687], ["subjects", 695], ["were", 704], ["included", 709], ["in", 718], ["the", 721], ["study", 725], [".", 730], ["All", 732], ["subjects", 736], ["underwent", 745], ["a", 755], ["transcranial", 757], ["magnetic", 770], ["stimulation", 779], ["study", 791], ["examining", 797], ["different", 807], ["intracortical", 817], ["circuits", 831], [".", 839], ["Sensorimotor", 841], ["plasticity", 854], ["was", 865], ["also", 869], ["assessed", 874], ["using", 883], ["a", 889], ["paired", 891], ["associative", 898], ["stimulation", 910], ["and", 922], ["extensive", 926], ["neuropsychological", 936], ["tests", 955], [".", 960], ["CADASIL", 962], ["patients", 970], ["showed", 979], ["a", 986], ["lack", 988], ["of", 993], ["intracortical", 996], ["facilitation", 1010], [",", 1022], ["short", 1024], ["latency", 1030], ["afferent", 1038], ["inhibition", 1047], ["and", 1058], ["sensorimotor", 1062], ["plasticity", 1075], ["when", 1086], ["compared", 1091], ["with", 1100], ["control", 1105], ["subjects", 1113], [".", 1121], ["CADASIL", 1123], ["patients", 1131], ["also", 1140], ["showed", 1145], ["an", 1152], ["altered", 1155], ["neuropsychological", 1163], ["profile", 1182], [".", 1189], ["Correlation", 1191], ["between", 1203], ["sensorimotor", 1211], ["plasticity", 1224], ["and", 1235], ["neuropsychological", 1239], ["alterations", 1258], ["was", 1270], ["observed", 1274], ["in", 1283], ["CADASIL", 1286], ["patients", 1294], [".", 1302], ["These", 1304], ["results", 1310], ["suggest", 1318], ["that", 1326], ["acetylcholine", 1331], ["and", 1345], ["glutamate", 1349], ["could", 1359], ["be", 1365], ["involved", 1368], ["in", 1377], ["the", 1380], ["dementia", 1384], ["process", 1393], ["in", 1401], ["CADASIL", 1404], ["and", 1412], ["that", 1416], ["abnormal", 1421], ["sensorimotor", 1430], ["plasticity", 1443], ["correlates", 1454], ["with", 1465], ["the", 1470], ["neuropsychological", 1474], ["profile", 1493], ["in", 1501], ["CADASIL", 1504], ["patients", 1512], [".", 1520]]}
{"context": "The serotonergic system is implicated in the pathophysiology of posttraumatic stress disorder (PTSD) and depression. The present study focused on platelet serotonin (5-HT) concentration and symptoms of comorbid depression in war veterans with or without PTSD. PTSD and depression were evaluated using Clinician Administered PTSD Scale, Davidson Trauma Scale, Montgomery-Asberg Depression Rating Scale and Hamilton Anxiety Scale. Sixty-five male drug-free war veterans (48 with PTSD and 17 without PTSD) and 65 age- and sex-matched healthy controls were studied. Comorbid depression occurred in 54 and 31% of war veterans with PTSD and without PTSD, respectively. Platelet 5-HT concentration was similar in the groups of depressed and nondepressed war veterans with or without PTSD and healthy controls. Platelet 5-HT concentration was found to differ between war veterans with various degrees of appetite loss. A positive correlation was observed between platelet 5-HT concentration and severity of appetite loss in veterans with PTSD. There was no relationship between platelet 5-HT concentration and severity of other symptoms of PTSD or depression. War veterans included in the study were outpatients. War veterans with PTSD had a high incidence of comorbid depression, that was not related to platelet 5-HT concentration. The marked relationship between platelet 5-HT concentration and severity of appetite loss, suggested that 5-HT system is involved in the regulation of appetite, at least in depressed war veterans with PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "3a4f863ee8e149ab960b2f0eccb04cdd", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[80, 80], [13, 13], [173, 173], [42, 42], [134, 134], [189, 189], [205, 205], [84, 84], [40, 40], [255, 255], [50, 50], [113, 113], [110, 110]], "char_spans": [[477, 480], [95, 98], [1030, 1033], [260, 263], [776, 779], [1132, 1135], [1223, 1226], [497, 500], [254, 257], [1527, 1530], [324, 327], [643, 646], [626, 629]]}]}], "context_tokens": [["The", 0], ["serotonergic", 4], ["system", 17], ["is", 24], ["implicated", 27], ["in", 38], ["the", 41], ["pathophysiology", 45], ["of", 61], ["posttraumatic", 64], ["stress", 78], ["disorder", 85], ["(", 94], ["PTSD", 95], [")", 99], ["and", 101], ["depression", 105], [".", 115], ["The", 117], ["present", 121], ["study", 129], ["focused", 135], ["on", 143], ["platelet", 146], ["serotonin", 155], ["(", 165], ["5-HT", 166], [")", 170], ["concentration", 172], ["and", 186], ["symptoms", 190], ["of", 199], ["comorbid", 202], ["depression", 211], ["in", 222], ["war", 225], ["veterans", 229], ["with", 238], ["or", 243], ["without", 246], ["PTSD", 254], [".", 258], ["PTSD", 260], ["and", 265], ["depression", 269], ["were", 280], ["evaluated", 285], ["using", 295], ["Clinician", 301], ["Administered", 311], ["PTSD", 324], ["Scale", 329], [",", 334], ["Davidson", 336], ["Trauma", 345], ["Scale", 352], [",", 357], ["Montgomery", 359], ["-", 369], ["Asberg", 370], ["Depression", 377], ["Rating", 388], ["Scale", 395], ["and", 401], ["Hamilton", 405], ["Anxiety", 414], ["Scale", 422], [".", 427], ["Sixty", 429], ["-", 434], ["five", 435], ["male", 440], ["drug", 445], ["-", 449], ["free", 450], ["war", 455], ["veterans", 459], ["(", 468], ["48", 469], ["with", 472], ["PTSD", 477], ["and", 482], ["17", 486], ["without", 489], ["PTSD", 497], [")", 501], ["and", 503], ["65", 507], ["age-", 510], ["and", 515], ["sex", 519], ["-", 522], ["matched", 523], ["healthy", 531], ["controls", 539], ["were", 548], ["studied", 553], [".", 560], ["Comorbid", 562], ["depression", 571], ["occurred", 582], ["in", 591], ["54", 594], ["and", 597], ["31", 601], ["%", 603], ["of", 605], ["war", 608], ["veterans", 612], ["with", 621], ["PTSD", 626], ["and", 631], ["without", 635], ["PTSD", 643], [",", 647], ["respectively", 649], [".", 661], ["Platelet", 663], ["5-HT", 672], ["concentration", 677], ["was", 691], ["similar", 695], ["in", 703], ["the", 706], ["groups", 710], ["of", 717], ["depressed", 720], ["and", 730], ["nondepressed", 734], ["war", 747], ["veterans", 751], ["with", 760], ["or", 765], ["without", 768], ["PTSD", 776], ["and", 781], ["healthy", 785], ["controls", 793], [".", 801], ["Platelet", 803], ["5-HT", 812], ["concentration", 817], ["was", 831], ["found", 835], ["to", 841], ["differ", 844], ["between", 851], ["war", 859], ["veterans", 863], ["with", 872], ["various", 877], ["degrees", 885], ["of", 893], ["appetite", 896], ["loss", 905], [".", 909], ["A", 911], ["positive", 913], ["correlation", 922], ["was", 934], ["observed", 938], ["between", 947], ["platelet", 955], ["5-HT", 964], ["concentration", 969], ["and", 983], ["severity", 987], ["of", 996], ["appetite", 999], ["loss", 1008], ["in", 1013], ["veterans", 1016], ["with", 1025], ["PTSD", 1030], [".", 1034], ["There", 1036], ["was", 1042], ["no", 1046], ["relationship", 1049], ["between", 1062], ["platelet", 1070], ["5-HT", 1079], ["concentration", 1084], ["and", 1098], ["severity", 1102], ["of", 1111], ["other", 1114], ["symptoms", 1120], ["of", 1129], ["PTSD", 1132], ["or", 1137], ["depression", 1140], [".", 1150], ["War", 1152], ["veterans", 1156], ["included", 1165], ["in", 1174], ["the", 1177], ["study", 1181], ["were", 1187], ["outpatients", 1192], [".", 1203], ["War", 1205], ["veterans", 1209], ["with", 1218], ["PTSD", 1223], ["had", 1228], ["a", 1232], ["high", 1234], ["incidence", 1239], ["of", 1249], ["comorbid", 1252], ["depression", 1261], [",", 1271], ["that", 1273], ["was", 1278], ["not", 1282], ["related", 1286], ["to", 1294], ["platelet", 1297], ["5-HT", 1306], ["concentration", 1311], [".", 1324], ["The", 1326], ["marked", 1330], ["relationship", 1337], ["between", 1350], ["platelet", 1358], ["5-HT", 1367], ["concentration", 1372], ["and", 1386], ["severity", 1390], ["of", 1399], ["appetite", 1402], ["loss", 1411], [",", 1415], ["suggested", 1417], ["that", 1427], ["5-HT", 1432], ["system", 1437], ["is", 1444], ["involved", 1447], ["in", 1456], ["the", 1459], ["regulation", 1463], ["of", 1474], ["appetite", 1477], [",", 1485], ["at", 1487], ["least", 1490], ["in", 1496], ["depressed", 1499], ["war", 1509], ["veterans", 1513], ["with", 1522], ["PTSD", 1527], [".", 1531]]}
{"context": "Shprintzen-Goldberg syndrome (SGS) is a rare disorder characterized by a Marfan-like habitus, mental retardation and craniosynostosis. Cardiac abnormalities, such as aortic root dilation have also been noted as well as several skeletal abnormalities. Its nosological status is unclear as it is hard to delineate SGS from similar disorders, such as Furlong, Marfan type II, Camurati-Engelmann and Loeys-Dietz syndromes. It has been suggested that these conditions represent a phenotypical spectrum associated with aberrant TGF-beta signalling. In support of this notion, we found a novel TGFBR2 missense mutation in a patient with features of SGS.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "9038f03f7233434d94806443d485149a", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[22, 22]], "char_spans": [[117, 132]]}]}], "context_tokens": [["Shprintzen", 0], ["-", 10], ["Goldberg", 11], ["syndrome", 20], ["(", 29], ["SGS", 30], [")", 33], ["is", 35], ["a", 38], ["rare", 40], ["disorder", 45], ["characterized", 54], ["by", 68], ["a", 71], ["Marfan", 73], ["-", 79], ["like", 80], ["habitus", 85], [",", 92], ["mental", 94], ["retardation", 101], ["and", 113], ["craniosynostosis", 117], [".", 133], ["Cardiac", 135], ["abnormalities", 143], [",", 156], ["such", 158], ["as", 163], ["aortic", 166], ["root", 173], ["dilation", 178], ["have", 187], ["also", 192], ["been", 197], ["noted", 202], ["as", 208], ["well", 211], ["as", 216], ["several", 219], ["skeletal", 227], ["abnormalities", 236], [".", 249], ["Its", 251], ["nosological", 255], ["status", 267], ["is", 274], ["unclear", 277], ["as", 285], ["it", 288], ["is", 291], ["hard", 294], ["to", 299], ["delineate", 302], ["SGS", 312], ["from", 316], ["similar", 321], ["disorders", 329], [",", 338], ["such", 340], ["as", 345], ["Furlong", 348], [",", 355], ["Marfan", 357], ["type", 364], ["II", 369], [",", 371], ["Camurati", 373], ["-", 381], ["Engelmann", 382], ["and", 392], ["Loeys", 396], ["-", 401], ["Dietz", 402], ["syndromes", 408], [".", 417], ["It", 419], ["has", 422], ["been", 426], ["suggested", 431], ["that", 441], ["these", 446], ["conditions", 452], ["represent", 463], ["a", 473], ["phenotypical", 475], ["spectrum", 488], ["associated", 497], ["with", 508], ["aberrant", 513], ["TGF", 522], ["-", 525], ["beta", 526], ["signalling", 531], [".", 541], ["In", 543], ["support", 546], ["of", 554], ["this", 557], ["notion", 562], [",", 568], ["we", 570], ["found", 573], ["a", 579], ["novel", 581], ["TGFBR2", 587], ["missense", 594], ["mutation", 603], ["in", 612], ["a", 615], ["patient", 617], ["with", 625], ["features", 630], ["of", 639], ["SGS", 642], [".", 645]]}
{"context": "The inflammatory cytokine IL-1\u03b2 has an essential role in the innate immune response. High levels of IL-1\u03b2 have been implicated in the development of many diseases, including type 1 and 2 diabetes (T1D and T2D), rheumatoid arthritis (RA) and cardiovascular disease. XOMA is developing gevokizumab (XOMA-052), an IgG2 humanized mAb against human IL-1\u03b2, for the potential treatment of these diseases. Gevokizumab has a high affinity for IL-1\u03b2 and a long t1/2, which would allow for once-monthly dosing and offer a considerable advantage for patients over agents requiring more frequent dosing. Data from preclinical studies and clinical trials suggest that gevokizumab is a potentially effective and well-tolerated treatment for the indicated diseases. At the time of publication, phase II clinical trials were ongoing in patients with T1D, T2D and RA, with the T2D trials assessing key cardiovascular markers. Following promising data from a recent pilot trial, XOMA was also planning a phase I/II trial of gevokizumab for the potential treatment of uveitis in patients with the vasculitic inflammatory disorder Beh\u00e7et's disease and the autoinflammatory conditions familial cold autoinflammatory syndrome and Muckle-Wells syndrome.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "e156bae24ed442c581112e4b34e212a5", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[17, 17], [63, 63], [3, 3], [79, 79]], "char_spans": [[100, 104], [344, 348], [26, 30], [434, 438]]}]}], "context_tokens": [["The", 0], ["inflammatory", 4], ["cytokine", 17], ["IL-1\u03b2", 26], ["has", 32], ["an", 36], ["essential", 39], ["role", 49], ["in", 54], ["the", 57], ["innate", 61], ["immune", 68], ["response", 75], [".", 83], ["High", 85], ["levels", 90], ["of", 97], ["IL-1\u03b2", 100], ["have", 106], ["been", 111], ["implicated", 116], ["in", 127], ["the", 130], ["development", 134], ["of", 146], ["many", 149], ["diseases", 154], [",", 162], ["including", 164], ["type", 174], ["1", 179], ["and", 181], ["2", 185], ["diabetes", 187], ["(", 196], ["T1D", 197], ["and", 201], ["T2D", 205], [")", 208], [",", 209], ["rheumatoid", 211], ["arthritis", 222], ["(", 232], ["RA", 233], [")", 235], ["and", 237], ["cardiovascular", 241], ["disease", 256], [".", 263], ["XOMA", 265], ["is", 270], ["developing", 273], ["gevokizumab", 284], ["(", 296], ["XOMA-052", 297], [")", 305], [",", 306], ["an", 308], ["IgG2", 311], ["humanized", 316], ["mAb", 326], ["against", 330], ["human", 338], ["IL-1\u03b2", 344], [",", 349], ["for", 351], ["the", 355], ["potential", 359], ["treatment", 369], ["of", 379], ["these", 382], ["diseases", 388], [".", 396], ["Gevokizumab", 398], ["has", 410], ["a", 414], ["high", 416], ["affinity", 421], ["for", 430], ["IL-1\u03b2", 434], ["and", 440], ["a", 444], ["long", 446], ["t1/2", 451], [",", 455], ["which", 457], ["would", 463], ["allow", 469], ["for", 475], ["once", 479], ["-", 483], ["monthly", 484], ["dosing", 492], ["and", 499], ["offer", 503], ["a", 509], ["considerable", 511], ["advantage", 524], ["for", 534], ["patients", 538], ["over", 547], ["agents", 552], ["requiring", 559], ["more", 569], ["frequent", 574], ["dosing", 583], [".", 589], ["Data", 591], ["from", 596], ["preclinical", 601], ["studies", 613], ["and", 621], ["clinical", 625], ["trials", 634], ["suggest", 641], ["that", 649], ["gevokizumab", 654], ["is", 666], ["a", 669], ["potentially", 671], ["effective", 683], ["and", 693], ["well", 697], ["-", 701], ["tolerated", 702], ["treatment", 712], ["for", 722], ["the", 726], ["indicated", 730], ["diseases", 740], [".", 748], ["At", 750], ["the", 753], ["time", 757], ["of", 762], ["publication", 765], [",", 776], ["phase", 778], ["II", 784], ["clinical", 787], ["trials", 796], ["were", 803], ["ongoing", 808], ["in", 816], ["patients", 819], ["with", 828], ["T1D", 833], [",", 836], ["T2D", 838], ["and", 842], ["RA", 846], [",", 848], ["with", 850], ["the", 855], ["T2D", 859], ["trials", 863], ["assessing", 870], ["key", 880], ["cardiovascular", 884], ["markers", 899], [".", 906], ["Following", 908], ["promising", 918], ["data", 928], ["from", 933], ["a", 938], ["recent", 940], ["pilot", 947], ["trial", 953], [",", 958], ["XOMA", 960], ["was", 965], ["also", 969], ["planning", 974], ["a", 983], ["phase", 985], ["I", 991], ["/", 992], ["II", 993], ["trial", 996], ["of", 1002], ["gevokizumab", 1005], ["for", 1017], ["the", 1021], ["potential", 1025], ["treatment", 1035], ["of", 1045], ["uveitis", 1048], ["in", 1056], ["patients", 1059], ["with", 1068], ["the", 1073], ["vasculitic", 1077], ["inflammatory", 1088], ["disorder", 1101], ["Beh\u00e7et", 1110], ["'s", 1116], ["disease", 1119], ["and", 1127], ["the", 1131], ["autoinflammatory", 1135], ["conditions", 1152], ["familial", 1163], ["cold", 1172], ["autoinflammatory", 1177], ["syndrome", 1194], ["and", 1203], ["Muckle", 1207], ["-", 1213], ["Wells", 1214], ["syndrome", 1220], [".", 1228]]}
{"context": "Chronic myelogenous leukemia (CML) accounts for 15-20% of adult leukemias but is very rare in children (2%). Fewer than 10% of CML patients are younger than 20 years. CML is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome or the BCR-ABL fusion oncogene. The objective of this paper is to present the monitoring of imatinib therapy in two children with CML by the BCR-ABL fusion gene expression assessment from peripheral blood with quantitative real-time polymerase chain reaction (PCR) method. The 18 and six months follow-up of the patients included clinical examination, routine laboratory tests, bone marrow aspirate investigation including cytogenetic tests and the major BCR-ABL fusion gene expression measurement with qRT-PCR method from the peripheral blood. Patient No. 1 diagnosed with chronic phase CML showed excellent adherence to daily 400 mg imatinib treatment and achieved complete hematologic (CHR) and cytogenetic response (CCR) by three months and major molecular response (MMR) by 12 months, with lack of side effects due to imatinib. Patient No. 2 experienced severe hematologic toxicity, which necessitated temporary withdrawal of the drug. Transient non-compliance together with imatinib dose reduction has driven to treatment failure. In this case, mutational analysis is warranted. BCR-ABL fusion gene expression level measurement from peripheral blood with qRT-PCR method is an excellent tool in the follow-up of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee2bb6f12fef47d0a3ddeb7d9f328f4d", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[132, 134], [244, 246], [54, 56], [80, 82]], "char_spans": [[720, 726], [1350, 1356], [272, 278], [406, 412]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["accounts", 35], ["for", 44], ["15", 48], ["-", 50], ["20", 51], ["%", 53], ["of", 55], ["adult", 58], ["leukemias", 64], ["but", 74], ["is", 78], ["very", 81], ["rare", 86], ["in", 91], ["children", 94], ["(", 103], ["2", 104], ["%", 105], [")", 106], [".", 107], ["Fewer", 109], ["than", 115], ["10", 120], ["%", 122], ["of", 124], ["CML", 127], ["patients", 131], ["are", 140], ["younger", 144], ["than", 152], ["20", 157], ["years", 160], [".", 165], ["CML", 167], ["is", 171], ["a", 174], ["myeloproliferative", 176], ["disorder", 195], ["characterized", 204], ["by", 218], ["the", 221], ["presence", 225], ["of", 234], ["the", 237], ["Philadelphia", 241], ["chromosome", 254], ["or", 265], ["the", 268], ["BCR", 272], ["-", 275], ["ABL", 276], ["fusion", 280], ["oncogene", 287], [".", 295], ["The", 297], ["objective", 301], ["of", 311], ["this", 314], ["paper", 319], ["is", 325], ["to", 328], ["present", 331], ["the", 339], ["monitoring", 343], ["of", 354], ["imatinib", 357], ["therapy", 366], ["in", 374], ["two", 377], ["children", 381], ["with", 390], ["CML", 395], ["by", 399], ["the", 402], ["BCR", 406], ["-", 409], ["ABL", 410], ["fusion", 414], ["gene", 421], ["expression", 426], ["assessment", 437], ["from", 448], ["peripheral", 453], ["blood", 464], ["with", 470], ["quantitative", 475], ["real", 488], ["-", 492], ["time", 493], ["polymerase", 498], ["chain", 509], ["reaction", 515], ["(", 524], ["PCR", 525], [")", 528], ["method", 530], [".", 536], ["The", 538], ["18", 542], ["and", 545], ["six", 549], ["months", 553], ["follow", 560], ["-", 566], ["up", 567], ["of", 570], ["the", 573], ["patients", 577], ["included", 586], ["clinical", 595], ["examination", 604], [",", 615], ["routine", 617], ["laboratory", 625], ["tests", 636], [",", 641], ["bone", 643], ["marrow", 648], ["aspirate", 655], ["investigation", 664], ["including", 678], ["cytogenetic", 688], ["tests", 700], ["and", 706], ["the", 710], ["major", 714], ["BCR", 720], ["-", 723], ["ABL", 724], ["fusion", 728], ["gene", 735], ["expression", 740], ["measurement", 751], ["with", 763], ["qRT", 768], ["-", 771], ["PCR", 772], ["method", 776], ["from", 783], ["the", 788], ["peripheral", 792], ["blood", 803], [".", 808], ["Patient", 810], ["No", 818], [".", 820], ["1", 822], ["diagnosed", 824], ["with", 834], ["chronic", 839], ["phase", 847], ["CML", 853], ["showed", 857], ["excellent", 864], ["adherence", 874], ["to", 884], ["daily", 887], ["400", 893], ["mg", 897], ["imatinib", 900], ["treatment", 909], ["and", 919], ["achieved", 923], ["complete", 932], ["hematologic", 941], ["(", 953], ["CHR", 954], [")", 957], ["and", 959], ["cytogenetic", 963], ["response", 975], ["(", 984], ["CCR", 985], [")", 988], ["by", 990], ["three", 993], ["months", 999], ["and", 1006], ["major", 1010], ["molecular", 1016], ["response", 1026], ["(", 1035], ["MMR", 1036], [")", 1039], ["by", 1041], ["12", 1044], ["months", 1047], [",", 1053], ["with", 1055], ["lack", 1060], ["of", 1065], ["side", 1068], ["effects", 1073], ["due", 1081], ["to", 1085], ["imatinib", 1088], [".", 1096], ["Patient", 1098], ["No", 1106], [".", 1108], ["2", 1110], ["experienced", 1112], ["severe", 1124], ["hematologic", 1131], ["toxicity", 1143], [",", 1151], ["which", 1153], ["necessitated", 1159], ["temporary", 1172], ["withdrawal", 1182], ["of", 1193], ["the", 1196], ["drug", 1200], [".", 1204], ["Transient", 1206], ["non", 1216], ["-", 1219], ["compliance", 1220], ["together", 1231], ["with", 1240], ["imatinib", 1245], ["dose", 1254], ["reduction", 1259], ["has", 1269], ["driven", 1273], ["to", 1280], ["treatment", 1283], ["failure", 1293], [".", 1300], ["In", 1302], ["this", 1305], ["case", 1310], [",", 1314], ["mutational", 1316], ["analysis", 1327], ["is", 1336], ["warranted", 1339], [".", 1348], ["BCR", 1350], ["-", 1353], ["ABL", 1354], ["fusion", 1358], ["gene", 1365], ["expression", 1370], ["level", 1381], ["measurement", 1387], ["from", 1399], ["peripheral", 1404], ["blood", 1415], ["with", 1421], ["qRT", 1426], ["-", 1429], ["PCR", 1430], ["method", 1434], ["is", 1441], ["an", 1444], ["excellent", 1447], ["tool", 1457], ["in", 1462], ["the", 1465], ["follow", 1469], ["-", 1475], ["up", 1476], ["of", 1479], ["CML", 1482], ["patients", 1486], [".", 1494]]}
{"context": "Inhibitors of sodium-glucose co-transporter type 2 (SGLT2) are proposed as a novel approach for the management of type 2 diabetes mellitus (T2DM). Several compounds are already available in many countries (dapagliflozin, canagliflozin, empagliflozin and ipragliflozin) and some others are in a late phase of development. The available SGLT2 inhibitors share similar pharmacokinetic characteristics, with a rapid oral absorption, a long elimination half-life allowing once-daily administration, an extensive hepatic metabolism mainly via glucuronidation to inactive metabolites, the absence of clinically relevant drug-drug interactions and a low renal elimination as parent drug. SGLT2 co-transporters are responsible for reabsorption of most (90\u00a0%) of the glucose filtered by the kidneys. The pharmacological inhibition of SGLT2 co-transporters reduces hyperglycaemia by decreasing renal glucose threshold and thereby increasing urinary glucose excretion. The amount of glucose excreted in the urine depends on both the level of hyperglycaemia and the glomerular filtration rate. Results of numerous placebo-controlled randomised clinical trials of 12-104\u00a0weeks duration have shown significant reductions in glycated haemoglobin (HbA1c), resulting in a significant increase in the proportion of patients reaching HbA1c targets, and a significant lowering of fasting plasma glucose when SGLT2 inhibitors were administered as monotherapy or in addition to other glucose-lowering therapies including insulin in patients with T2DM. In head-to-head trials of up to 2\u00a0years, SGLT2 inhibitors exerted similar glucose-lowering activity to metformin, sulphonylureas or sitagliptin. The durability of the glucose-lowering effect of SGLT2 inhibitors appears to be better; however, this remains to be more extensively investigated. The risk of hypoglycaemia was much lower with SGLT2 inhibitors than with sulphonylureas and was similarly low as that reported with metformin, pioglitazone or sitagliptin. Increased renal glucose elimination also assists weight loss and could help to reduce blood pressure. Both effects were very consistent across the trials and they represent some advantages for SGLT2 inhibitors when compared with other oral glucose-lowering agents. The pharmacodynamic response to SGLT2 inhibitors declines with increasing severity of renal impairment, and prescribing information for each SGLT2 inhibitor should be consulted regarding dosage adjustments or restrictions in moderate to severe renal dysfunction. Caution is also recommended in the elderly population because of a higher risk of renal impairment, orthostatic hypotension and dehydration, even if the absence of hypoglycaemia represents an obvious advantage in this population. The overall effect of SGLT2 inhibitors on the risk of cardiovascular disease is unknown and will be evaluated in several ongoing prospective placebo-controlled trials with cardiovascular outcomes. The impact of SGLT2 inhibitors on renal function and their potential to influence the course of diabetic nephropathy also deserve more attention. SGLT2 inhibitors are generally well-tolerated. The most frequently reported adverse events are female genital mycotic infections, while urinary tract infections are less commonly observed and generally benign. In conclusion, with their unique mechanism of action that is independent of insulin secretion and action, SGLT2 inhibitors are a useful addition to the therapeutic options available for the management of T2DM at any stage in the natural history of the disease. Although SGLT2 inhibitors have already been extensively investigated, further studies should even better delineate the best place of these new glucose-lowering agents in the already rich armamentarium for the management of T2DM.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "32d5c9e48b75450989842a6e97cc6f21", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[288, 288], [229, 229], [141, 141], [11, 11], [115, 115], [61, 61], [362, 362], [378, 378], [499, 499], [313, 313], [393, 393], [577, 577], [549, 549], [264, 264], [450, 450], [479, 479]], "char_spans": [[1723, 1727], [1387, 1391], [824, 828], [52, 56], [680, 684], [335, 339], [2186, 2190], [2290, 2294], [3094, 3098], [1867, 1871], [2399, 2403], [3574, 3578], [3410, 3414], [1570, 1574], [2773, 2777], [2962, 2966]]}]}], "context_tokens": [["Inhibitors", 0], ["of", 11], ["sodium", 14], ["-", 20], ["glucose", 21], ["co", 29], ["-", 31], ["transporter", 32], ["type", 44], ["2", 49], ["(", 51], ["SGLT2", 52], [")", 57], ["are", 59], ["proposed", 63], ["as", 72], ["a", 75], ["novel", 77], ["approach", 83], ["for", 92], ["the", 96], ["management", 100], ["of", 111], ["type", 114], ["2", 119], ["diabetes", 121], ["mellitus", 130], ["(", 139], ["T2DM", 140], [")", 144], [".", 145], ["Several", 147], ["compounds", 155], ["are", 165], ["already", 169], ["available", 177], ["in", 187], ["many", 190], ["countries", 195], ["(", 205], ["dapagliflozin", 206], [",", 219], ["canagliflozin", 221], [",", 234], ["empagliflozin", 236], ["and", 250], ["ipragliflozin", 254], [")", 267], ["and", 269], ["some", 273], ["others", 278], ["are", 285], ["in", 289], ["a", 292], ["late", 294], ["phase", 299], ["of", 305], ["development", 308], [".", 319], ["The", 321], ["available", 325], ["SGLT2", 335], ["inhibitors", 341], ["share", 352], ["similar", 358], ["pharmacokinetic", 366], ["characteristics", 382], [",", 397], ["with", 399], ["a", 404], ["rapid", 406], ["oral", 412], ["absorption", 417], [",", 427], ["a", 429], ["long", 431], ["elimination", 436], ["half", 448], ["-", 452], ["life", 453], ["allowing", 458], ["once", 467], ["-", 471], ["daily", 472], ["administration", 478], [",", 492], ["an", 494], ["extensive", 497], ["hepatic", 507], ["metabolism", 515], ["mainly", 526], ["via", 533], ["glucuronidation", 537], ["to", 553], ["inactive", 556], ["metabolites", 565], [",", 576], ["the", 578], ["absence", 582], ["of", 590], ["clinically", 593], ["relevant", 604], ["drug", 613], ["-", 617], ["drug", 618], ["interactions", 623], ["and", 636], ["a", 640], ["low", 642], ["renal", 646], ["elimination", 652], ["as", 664], ["parent", 667], ["drug", 674], [".", 678], ["SGLT2", 680], ["co", 686], ["-", 688], ["transporters", 689], ["are", 702], ["responsible", 706], ["for", 718], ["reabsorption", 722], ["of", 735], ["most", 738], ["(", 743], ["90", 744], ["%", 747], [")", 748], ["of", 750], ["the", 753], ["glucose", 757], ["filtered", 765], ["by", 774], ["the", 777], ["kidneys", 781], [".", 788], ["The", 790], ["pharmacological", 794], ["inhibition", 810], ["of", 821], ["SGLT2", 824], ["co", 830], ["-", 832], ["transporters", 833], ["reduces", 846], ["hyperglycaemia", 854], ["by", 869], ["decreasing", 872], ["renal", 883], ["glucose", 889], ["threshold", 897], ["and", 907], ["thereby", 911], ["increasing", 919], ["urinary", 930], ["glucose", 938], ["excretion", 946], [".", 955], ["The", 957], ["amount", 961], ["of", 968], ["glucose", 971], ["excreted", 979], ["in", 988], ["the", 991], ["urine", 995], ["depends", 1001], ["on", 1009], ["both", 1012], ["the", 1017], ["level", 1021], ["of", 1027], ["hyperglycaemia", 1030], ["and", 1045], ["the", 1049], ["glomerular", 1053], ["filtration", 1064], ["rate", 1075], [".", 1079], ["Results", 1081], ["of", 1089], ["numerous", 1092], ["placebo", 1101], ["-", 1108], ["controlled", 1109], ["randomised", 1120], ["clinical", 1131], ["trials", 1140], ["of", 1147], ["12", 1150], ["-", 1152], ["104", 1153], ["weeks", 1157], ["duration", 1163], ["have", 1172], ["shown", 1177], ["significant", 1183], ["reductions", 1195], ["in", 1206], ["glycated", 1209], ["haemoglobin", 1218], ["(", 1230], ["HbA1c", 1231], [")", 1236], [",", 1237], ["resulting", 1239], ["in", 1249], ["a", 1252], ["significant", 1254], ["increase", 1266], ["in", 1275], ["the", 1278], ["proportion", 1282], ["of", 1293], ["patients", 1296], ["reaching", 1305], ["HbA1c", 1314], ["targets", 1320], [",", 1327], ["and", 1329], ["a", 1333], ["significant", 1335], ["lowering", 1347], ["of", 1356], ["fasting", 1359], ["plasma", 1367], ["glucose", 1374], ["when", 1382], ["SGLT2", 1387], ["inhibitors", 1393], ["were", 1404], ["administered", 1409], ["as", 1422], ["monotherapy", 1425], ["or", 1437], ["in", 1440], ["addition", 1443], ["to", 1452], ["other", 1455], ["glucose", 1461], ["-", 1468], ["lowering", 1469], ["therapies", 1478], ["including", 1488], ["insulin", 1498], ["in", 1506], ["patients", 1509], ["with", 1518], ["T2DM", 1523], [".", 1527], ["In", 1529], ["head", 1532], ["-", 1536], ["to", 1537], ["-", 1539], ["head", 1540], ["trials", 1545], ["of", 1552], ["up", 1555], ["to", 1558], ["2", 1561], ["years", 1563], [",", 1568], ["SGLT2", 1570], ["inhibitors", 1576], ["exerted", 1587], ["similar", 1595], ["glucose", 1603], ["-", 1610], ["lowering", 1611], ["activity", 1620], ["to", 1629], ["metformin", 1632], [",", 1641], ["sulphonylureas", 1643], ["or", 1658], ["sitagliptin", 1661], [".", 1672], ["The", 1674], ["durability", 1678], ["of", 1689], ["the", 1692], ["glucose", 1696], ["-", 1703], ["lowering", 1704], ["effect", 1713], ["of", 1720], ["SGLT2", 1723], ["inhibitors", 1729], ["appears", 1740], ["to", 1748], ["be", 1751], ["better", 1754], [";", 1760], ["however", 1762], [",", 1769], ["this", 1771], ["remains", 1776], ["to", 1784], ["be", 1787], ["more", 1790], ["extensively", 1795], ["investigated", 1807], [".", 1819], ["The", 1821], ["risk", 1825], ["of", 1830], ["hypoglycaemia", 1833], ["was", 1847], ["much", 1851], ["lower", 1856], ["with", 1862], ["SGLT2", 1867], ["inhibitors", 1873], ["than", 1884], ["with", 1889], ["sulphonylureas", 1894], ["and", 1909], ["was", 1913], ["similarly", 1917], ["low", 1927], ["as", 1931], ["that", 1934], ["reported", 1939], ["with", 1948], ["metformin", 1953], [",", 1962], ["pioglitazone", 1964], ["or", 1977], ["sitagliptin", 1980], [".", 1991], ["Increased", 1993], ["renal", 2003], ["glucose", 2009], ["elimination", 2017], ["also", 2029], ["assists", 2034], ["weight", 2042], ["loss", 2049], ["and", 2054], ["could", 2058], ["help", 2064], ["to", 2069], ["reduce", 2072], ["blood", 2079], ["pressure", 2085], [".", 2093], ["Both", 2095], ["effects", 2100], ["were", 2108], ["very", 2113], ["consistent", 2118], ["across", 2129], ["the", 2136], ["trials", 2140], ["and", 2147], ["they", 2151], ["represent", 2156], ["some", 2166], ["advantages", 2171], ["for", 2182], ["SGLT2", 2186], ["inhibitors", 2192], ["when", 2203], ["compared", 2208], ["with", 2217], ["other", 2222], ["oral", 2228], ["glucose", 2233], ["-", 2240], ["lowering", 2241], ["agents", 2250], [".", 2256], ["The", 2258], ["pharmacodynamic", 2262], ["response", 2278], ["to", 2287], ["SGLT2", 2290], ["inhibitors", 2296], ["declines", 2307], ["with", 2316], ["increasing", 2321], ["severity", 2332], ["of", 2341], ["renal", 2344], ["impairment", 2350], [",", 2360], ["and", 2362], ["prescribing", 2366], ["information", 2378], ["for", 2390], ["each", 2394], ["SGLT2", 2399], ["inhibitor", 2405], ["should", 2415], ["be", 2422], ["consulted", 2425], ["regarding", 2435], ["dosage", 2445], ["adjustments", 2452], ["or", 2464], ["restrictions", 2467], ["in", 2480], ["moderate", 2483], ["to", 2492], ["severe", 2495], ["renal", 2502], ["dysfunction", 2508], [".", 2519], ["Caution", 2521], ["is", 2529], ["also", 2532], ["recommended", 2537], ["in", 2549], ["the", 2552], ["elderly", 2556], ["population", 2564], ["because", 2575], ["of", 2583], ["a", 2586], ["higher", 2588], ["risk", 2595], ["of", 2600], ["renal", 2603], ["impairment", 2609], [",", 2619], ["orthostatic", 2621], ["hypotension", 2633], ["and", 2645], ["dehydration", 2649], [",", 2660], ["even", 2662], ["if", 2667], ["the", 2670], ["absence", 2674], ["of", 2682], ["hypoglycaemia", 2685], ["represents", 2699], ["an", 2710], ["obvious", 2713], ["advantage", 2721], ["in", 2731], ["this", 2734], ["population", 2739], [".", 2749], ["The", 2751], ["overall", 2755], ["effect", 2763], ["of", 2770], ["SGLT2", 2773], ["inhibitors", 2779], ["on", 2790], ["the", 2793], ["risk", 2797], ["of", 2802], ["cardiovascular", 2805], ["disease", 2820], ["is", 2828], ["unknown", 2831], ["and", 2839], ["will", 2843], ["be", 2848], ["evaluated", 2851], ["in", 2861], ["several", 2864], ["ongoing", 2872], ["prospective", 2880], ["placebo", 2892], ["-", 2899], ["controlled", 2900], ["trials", 2911], ["with", 2918], ["cardiovascular", 2923], ["outcomes", 2938], [".", 2946], ["The", 2948], ["impact", 2952], ["of", 2959], ["SGLT2", 2962], ["inhibitors", 2968], ["on", 2979], ["renal", 2982], ["function", 2988], ["and", 2997], ["their", 3001], ["potential", 3007], ["to", 3017], ["influence", 3020], ["the", 3030], ["course", 3034], ["of", 3041], ["diabetic", 3044], ["nephropathy", 3053], ["also", 3065], ["deserve", 3070], ["more", 3078], ["attention", 3083], [".", 3092], ["SGLT2", 3094], ["inhibitors", 3100], ["are", 3111], ["generally", 3115], ["well", 3125], ["-", 3129], ["tolerated", 3130], [".", 3139], ["The", 3141], ["most", 3145], ["frequently", 3150], ["reported", 3161], ["adverse", 3170], ["events", 3178], ["are", 3185], ["female", 3189], ["genital", 3196], ["mycotic", 3204], ["infections", 3212], [",", 3222], ["while", 3224], ["urinary", 3230], ["tract", 3238], ["infections", 3244], ["are", 3255], ["less", 3259], ["commonly", 3264], ["observed", 3273], ["and", 3282], ["generally", 3286], ["benign", 3296], [".", 3302], ["In", 3304], ["conclusion", 3307], [",", 3317], ["with", 3319], ["their", 3324], ["unique", 3330], ["mechanism", 3337], ["of", 3347], ["action", 3350], ["that", 3357], ["is", 3362], ["independent", 3365], ["of", 3377], ["insulin", 3380], ["secretion", 3388], ["and", 3398], ["action", 3402], [",", 3408], ["SGLT2", 3410], ["inhibitors", 3416], ["are", 3427], ["a", 3431], ["useful", 3433], ["addition", 3440], ["to", 3449], ["the", 3452], ["therapeutic", 3456], ["options", 3468], ["available", 3476], ["for", 3486], ["the", 3490], ["management", 3494], ["of", 3505], ["T2DM", 3508], ["at", 3513], ["any", 3516], ["stage", 3520], ["in", 3526], ["the", 3529], ["natural", 3533], ["history", 3541], ["of", 3549], ["the", 3552], ["disease", 3556], [".", 3563], ["Although", 3565], ["SGLT2", 3574], ["inhibitors", 3580], ["have", 3591], ["already", 3596], ["been", 3604], ["extensively", 3609], ["investigated", 3621], [",", 3633], ["further", 3635], ["studies", 3643], ["should", 3651], ["even", 3658], ["better", 3663], ["delineate", 3670], ["the", 3680], ["best", 3684], ["place", 3689], ["of", 3695], ["these", 3698], ["new", 3704], ["glucose", 3708], ["-", 3715], ["lowering", 3716], ["agents", 3725], ["in", 3732], ["the", 3735], ["already", 3739], ["rich", 3747], ["armamentarium", 3752], ["for", 3766], ["the", 3770], ["management", 3774], ["of", 3785], ["T2DM", 3788], [".", 3792]]}
{"context": "MicroRNAs (miRNAs) constitute a large family of noncoding RNAs that function as guide molecules in diverse gene silencing pathways. Current efforts are focused on the regulatory function of miRNAs, while little is known about how these unusual genes themselves are regulated. Here we present the first direct evidence that miRNA genes are transcribed by RNA polymerase II (pol II). The primary miRNA transcripts (pri-miRNAs) contain cap structures as well as poly(A) tails, which are the unique properties of class II gene transcripts. The treatment of human cells with alpha-amanitin decreased the level of pri-miRNAs at a concentration that selectively inhibits pol II activity. Furthermore, chromatin immunoprecipitation analyses show that pol II is physically associated with a miRNA promoter. We also describe, for the first time, the detailed structure of a miRNA gene by determining the promoter and the terminator of mir-23a approximately 27a approximately 24-2. These data indicate that pol II is the main, if not the only, RNA polymerase for miRNA gene transcription. Our study offers a basis for understanding the structure and regulation of miRNA genes.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "bfbcb1b432584aff8df5bc3c70e56f62", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[59, 61]], "char_spans": [[354, 370]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["constitute", 19], ["a", 30], ["large", 32], ["family", 38], ["of", 45], ["noncoding", 48], ["RNAs", 58], ["that", 63], ["function", 68], ["as", 77], ["guide", 80], ["molecules", 86], ["in", 96], ["diverse", 99], ["gene", 107], ["silencing", 112], ["pathways", 122], [".", 130], ["Current", 132], ["efforts", 140], ["are", 148], ["focused", 152], ["on", 160], ["the", 163], ["regulatory", 167], ["function", 178], ["of", 187], ["miRNAs", 190], [",", 196], ["while", 198], ["little", 204], ["is", 211], ["known", 214], ["about", 220], ["how", 226], ["these", 230], ["unusual", 236], ["genes", 244], ["themselves", 250], ["are", 261], ["regulated", 265], [".", 274], ["Here", 276], ["we", 281], ["present", 284], ["the", 292], ["first", 296], ["direct", 302], ["evidence", 309], ["that", 318], ["miRNA", 323], ["genes", 329], ["are", 335], ["transcribed", 339], ["by", 351], ["RNA", 354], ["polymerase", 358], ["II", 369], ["(", 372], ["pol", 373], ["II", 377], [")", 379], [".", 380], ["The", 382], ["primary", 386], ["miRNA", 394], ["transcripts", 400], ["(", 412], ["pri", 413], ["-", 416], ["miRNAs", 417], [")", 423], ["contain", 425], ["cap", 433], ["structures", 437], ["as", 448], ["well", 451], ["as", 456], ["poly(A", 459], [")", 465], ["tails", 467], [",", 472], ["which", 474], ["are", 480], ["the", 484], ["unique", 488], ["properties", 495], ["of", 506], ["class", 509], ["II", 515], ["gene", 518], ["transcripts", 523], [".", 534], ["The", 536], ["treatment", 540], ["of", 550], ["human", 553], ["cells", 559], ["with", 565], ["alpha", 570], ["-", 575], ["amanitin", 576], ["decreased", 585], ["the", 595], ["level", 599], ["of", 605], ["pri", 608], ["-", 611], ["miRNAs", 612], ["at", 619], ["a", 622], ["concentration", 624], ["that", 638], ["selectively", 643], ["inhibits", 655], ["pol", 664], ["II", 668], ["activity", 671], [".", 679], ["Furthermore", 681], [",", 692], ["chromatin", 694], ["immunoprecipitation", 704], ["analyses", 724], ["show", 733], ["that", 738], ["pol", 743], ["II", 747], ["is", 750], ["physically", 753], ["associated", 764], ["with", 775], ["a", 780], ["miRNA", 782], ["promoter", 788], [".", 796], ["We", 798], ["also", 801], ["describe", 806], [",", 814], ["for", 816], ["the", 820], ["first", 824], ["time", 830], [",", 834], ["the", 836], ["detailed", 840], ["structure", 849], ["of", 859], ["a", 862], ["miRNA", 864], ["gene", 870], ["by", 875], ["determining", 878], ["the", 890], ["promoter", 894], ["and", 903], ["the", 907], ["terminator", 911], ["of", 922], ["mir-23a", 925], ["approximately", 933], ["27a", 947], ["approximately", 951], ["24", 965], ["-", 967], ["2", 968], [".", 969], ["These", 971], ["data", 977], ["indicate", 982], ["that", 991], ["pol", 996], ["II", 1000], ["is", 1003], ["the", 1006], ["main", 1010], [",", 1014], ["if", 1016], ["not", 1019], ["the", 1023], ["only", 1027], [",", 1031], ["RNA", 1033], ["polymerase", 1037], ["for", 1048], ["miRNA", 1052], ["gene", 1058], ["transcription", 1063], [".", 1076], ["Our", 1078], ["study", 1082], ["offers", 1088], ["a", 1095], ["basis", 1097], ["for", 1103], ["understanding", 1107], ["the", 1121], ["structure", 1125], ["and", 1135], ["regulation", 1139], ["of", 1150], ["miRNA", 1153], ["genes", 1159], [".", 1164]]}
{"context": "Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Despite significant progresses in the last decades, the origin of this cancer remains unclear and no efficient therapy exists. PDAC does not arise de novo: three remarkable different types of pancreatic lesions can evolve towards pancreatic cancer. These precursor lesions include: Pancreatic intraepithelial neoplasia (PanIN) that are microscopic lesions of the pancreas, Intraductal Papillary Mucinous Neoplasms (IPMN) and Mucinous Cystic Neoplasms (MCN) that are both macroscopic lesions. However, the cellular origin of these lesions is still a matter of debate. Classically, neoplasm initiation or progression is driven by several genetic and epigenetic alterations. The aim of this review is to assemble the current information on genetic mutations and epigenetic disorders that affect genes during pancreatic carcinogenesis. We will further discuss the interest of the genetic and epigenetic alterations for the diagnosis and prognosis of PDAC. Large genetic alterations (chromosomal deletion/amplification) and single point mutations are well described for carcinogenesis inducers. Mutations classically occur within key regions of the genome. Consequences are various and include activation of mitogenic pathways or silencing of apoptotic processes. Alterations of K-RAS, P16 and DPC4 genes are frequently observed in PDAC samples and have been described to arise gradually during carcinogenesis. DNA methylation is an epigenetic process involved in imprinting and X chromosome inactivation. Alteration of DNA methylation patterns leads to deregulation of gene expression, in the absence of mutation. Both genetic and epigenetic events influence genes and non-coding RNA expression, with dramatic effects on proliferation, survival and invasion. Besides improvement in our fundamental understanding of PDAC development, highlighting the molecular alterations that occur in pancreatic carcinogenesis could provide new clinical tools for early diagnosis of PDAC and the molecular basis for the development of new effective therapies.", "qas": [{"question": "Which is the molecular mechanism underlying K-ras alterations in carcinomas?", "answers": ["Point mutations"], "qid": "2729af5d87194532a74ffb452dcb9886", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["molecular", 13], ["mechanism", 23], ["underlying", 33], ["K", 44], ["-", 45], ["ras", 46], ["alterations", 50], ["in", 62], ["carcinomas", 65], ["?", 75]], "detected_answers": [{"text": "Point mutations", "token_spans": [[180, 181]], "char_spans": [[1111, 1125]]}]}], "context_tokens": [["Pancreatic", 0], ["ductal", 11], ["adenocarcinoma", 18], ["(", 33], ["PDAC", 34], [")", 38], ["is", 40], ["one", 43], ["of", 47], ["the", 50], ["most", 54], ["lethal", 59], ["cancers", 66], ["worldwide", 74], [".", 83], ["Despite", 85], ["significant", 93], ["progresses", 105], ["in", 116], ["the", 119], ["last", 123], ["decades", 128], [",", 135], ["the", 137], ["origin", 141], ["of", 148], ["this", 151], ["cancer", 156], ["remains", 163], ["unclear", 171], ["and", 179], ["no", 183], ["efficient", 186], ["therapy", 196], ["exists", 204], [".", 210], ["PDAC", 212], ["does", 217], ["not", 222], ["arise", 226], ["de", 232], ["novo", 235], [":", 239], ["three", 241], ["remarkable", 247], ["different", 258], ["types", 268], ["of", 274], ["pancreatic", 277], ["lesions", 288], ["can", 296], ["evolve", 300], ["towards", 307], ["pancreatic", 315], ["cancer", 326], [".", 332], ["These", 334], ["precursor", 340], ["lesions", 350], ["include", 358], [":", 365], ["Pancreatic", 367], ["intraepithelial", 378], ["neoplasia", 394], ["(", 404], ["PanIN", 405], [")", 410], ["that", 412], ["are", 417], ["microscopic", 421], ["lesions", 433], ["of", 441], ["the", 444], ["pancreas", 448], [",", 456], ["Intraductal", 458], ["Papillary", 470], ["Mucinous", 480], ["Neoplasms", 489], ["(", 499], ["IPMN", 500], [")", 504], ["and", 506], ["Mucinous", 510], ["Cystic", 519], ["Neoplasms", 526], ["(", 536], ["MCN", 537], [")", 540], ["that", 542], ["are", 547], ["both", 551], ["macroscopic", 556], ["lesions", 568], [".", 575], ["However", 577], [",", 584], ["the", 586], ["cellular", 590], ["origin", 599], ["of", 606], ["these", 609], ["lesions", 615], ["is", 623], ["still", 626], ["a", 632], ["matter", 634], ["of", 641], ["debate", 644], [".", 650], ["Classically", 652], [",", 663], ["neoplasm", 665], ["initiation", 674], ["or", 685], ["progression", 688], ["is", 700], ["driven", 703], ["by", 710], ["several", 713], ["genetic", 721], ["and", 729], ["epigenetic", 733], ["alterations", 744], [".", 755], ["The", 757], ["aim", 761], ["of", 765], ["this", 768], ["review", 773], ["is", 780], ["to", 783], ["assemble", 786], ["the", 795], ["current", 799], ["information", 807], ["on", 819], ["genetic", 822], ["mutations", 830], ["and", 840], ["epigenetic", 844], ["disorders", 855], ["that", 865], ["affect", 870], ["genes", 877], ["during", 883], ["pancreatic", 890], ["carcinogenesis", 901], [".", 915], ["We", 917], ["will", 920], ["further", 925], ["discuss", 933], ["the", 941], ["interest", 945], ["of", 954], ["the", 957], ["genetic", 961], ["and", 969], ["epigenetic", 973], ["alterations", 984], ["for", 996], ["the", 1000], ["diagnosis", 1004], ["and", 1014], ["prognosis", 1018], ["of", 1028], ["PDAC", 1031], [".", 1035], ["Large", 1037], ["genetic", 1043], ["alterations", 1051], ["(", 1063], ["chromosomal", 1064], ["deletion", 1076], ["/", 1084], ["amplification", 1085], [")", 1098], ["and", 1100], ["single", 1104], ["point", 1111], ["mutations", 1117], ["are", 1127], ["well", 1131], ["described", 1136], ["for", 1146], ["carcinogenesis", 1150], ["inducers", 1165], [".", 1173], ["Mutations", 1175], ["classically", 1185], ["occur", 1197], ["within", 1203], ["key", 1210], ["regions", 1214], ["of", 1222], ["the", 1225], ["genome", 1229], [".", 1235], ["Consequences", 1237], ["are", 1250], ["various", 1254], ["and", 1262], ["include", 1266], ["activation", 1274], ["of", 1285], ["mitogenic", 1288], ["pathways", 1298], ["or", 1307], ["silencing", 1310], ["of", 1320], ["apoptotic", 1323], ["processes", 1333], [".", 1342], ["Alterations", 1344], ["of", 1356], ["K", 1359], ["-", 1360], ["RAS", 1361], [",", 1364], ["P16", 1366], ["and", 1370], ["DPC4", 1374], ["genes", 1379], ["are", 1385], ["frequently", 1389], ["observed", 1400], ["in", 1409], ["PDAC", 1412], ["samples", 1417], ["and", 1425], ["have", 1429], ["been", 1434], ["described", 1439], ["to", 1449], ["arise", 1452], ["gradually", 1458], ["during", 1468], ["carcinogenesis", 1475], [".", 1489], ["DNA", 1491], ["methylation", 1495], ["is", 1507], ["an", 1510], ["epigenetic", 1513], ["process", 1524], ["involved", 1532], ["in", 1541], ["imprinting", 1544], ["and", 1555], ["X", 1559], ["chromosome", 1561], ["inactivation", 1572], [".", 1584], ["Alteration", 1586], ["of", 1597], ["DNA", 1600], ["methylation", 1604], ["patterns", 1616], ["leads", 1625], ["to", 1631], ["deregulation", 1634], ["of", 1647], ["gene", 1650], ["expression", 1655], [",", 1665], ["in", 1667], ["the", 1670], ["absence", 1674], ["of", 1682], ["mutation", 1685], [".", 1693], ["Both", 1695], ["genetic", 1700], ["and", 1708], ["epigenetic", 1712], ["events", 1723], ["influence", 1730], ["genes", 1740], ["and", 1746], ["non", 1750], ["-", 1753], ["coding", 1754], ["RNA", 1761], ["expression", 1765], [",", 1775], ["with", 1777], ["dramatic", 1782], ["effects", 1791], ["on", 1799], ["proliferation", 1802], [",", 1815], ["survival", 1817], ["and", 1826], ["invasion", 1830], [".", 1838], ["Besides", 1840], ["improvement", 1848], ["in", 1860], ["our", 1863], ["fundamental", 1867], ["understanding", 1879], ["of", 1893], ["PDAC", 1896], ["development", 1901], [",", 1912], ["highlighting", 1914], ["the", 1927], ["molecular", 1931], ["alterations", 1941], ["that", 1953], ["occur", 1958], ["in", 1964], ["pancreatic", 1967], ["carcinogenesis", 1978], ["could", 1993], ["provide", 1999], ["new", 2007], ["clinical", 2011], ["tools", 2020], ["for", 2026], ["early", 2030], ["diagnosis", 2036], ["of", 2046], ["PDAC", 2049], ["and", 2054], ["the", 2058], ["molecular", 2062], ["basis", 2072], ["for", 2078], ["the", 2082], ["development", 2086], ["of", 2098], ["new", 2101], ["effective", 2105], ["therapies", 2115], [".", 2124]]}
{"context": "Ehlers-Danlos syndrome is an inherited connective tissue disorder. Clinical manifestations of this syndrome are due to fragile connective tissue. Though many cardiovascular disorders in association with it have been reported, myocardial infarction is quite rare. In this report, two cases with type 4 Ehlers-Danlos syndrome and myocardial infarction are described. Patient 1 was a 30-year-old woman. She was diagnosed as having myocardial infarction on the basis of typical changes in electrocardiograms and serum enzymes (CPK, SGOT and LDH). The diagnosis of type 4 Ehlers-Danlos syndrome was made by the microscopic examination of her connective tissue. Patient 2 was a 32-year-old man. He was also diagnosed as having acute myocardial infarction. His fibroblasts were cultured and they could not synthesize type 3 collagen. Type 4 Ehlers-Danlos syndrome was diagnosed. It was likely that myocardial infarction might have resulted from the fragility of their coronary arteries in type 4 Ehlers-Danlos syndrome.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "2400eadb605d444e87f69ff530a1856c", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[20, 21], [7, 8], [112, 113]], "char_spans": [[127, 143], [39, 55], [637, 653]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["an", 26], ["inherited", 29], ["connective", 39], ["tissue", 50], ["disorder", 57], [".", 65], ["Clinical", 67], ["manifestations", 76], ["of", 91], ["this", 94], ["syndrome", 99], ["are", 108], ["due", 112], ["to", 116], ["fragile", 119], ["connective", 127], ["tissue", 138], [".", 144], ["Though", 146], ["many", 153], ["cardiovascular", 158], ["disorders", 173], ["in", 183], ["association", 186], ["with", 198], ["it", 203], ["have", 206], ["been", 211], ["reported", 216], [",", 224], ["myocardial", 226], ["infarction", 237], ["is", 248], ["quite", 251], ["rare", 257], [".", 261], ["In", 263], ["this", 266], ["report", 271], [",", 277], ["two", 279], ["cases", 283], ["with", 289], ["type", 294], ["4", 299], ["Ehlers", 301], ["-", 307], ["Danlos", 308], ["syndrome", 315], ["and", 324], ["myocardial", 328], ["infarction", 339], ["are", 350], ["described", 354], [".", 363], ["Patient", 365], ["1", 373], ["was", 375], ["a", 379], ["30-year", 381], ["-", 388], ["old", 389], ["woman", 393], [".", 398], ["She", 400], ["was", 404], ["diagnosed", 408], ["as", 418], ["having", 421], ["myocardial", 428], ["infarction", 439], ["on", 450], ["the", 453], ["basis", 457], ["of", 463], ["typical", 466], ["changes", 474], ["in", 482], ["electrocardiograms", 485], ["and", 504], ["serum", 508], ["enzymes", 514], ["(", 522], ["CPK", 523], [",", 526], ["SGOT", 528], ["and", 533], ["LDH", 537], [")", 540], [".", 541], ["The", 543], ["diagnosis", 547], ["of", 557], ["type", 560], ["4", 565], ["Ehlers", 567], ["-", 573], ["Danlos", 574], ["syndrome", 581], ["was", 590], ["made", 594], ["by", 599], ["the", 602], ["microscopic", 606], ["examination", 618], ["of", 630], ["her", 633], ["connective", 637], ["tissue", 648], [".", 654], ["Patient", 656], ["2", 664], ["was", 666], ["a", 670], ["32-year", 672], ["-", 679], ["old", 680], ["man", 684], [".", 687], ["He", 689], ["was", 692], ["also", 696], ["diagnosed", 701], ["as", 711], ["having", 714], ["acute", 721], ["myocardial", 727], ["infarction", 738], [".", 748], ["His", 750], ["fibroblasts", 754], ["were", 766], ["cultured", 771], ["and", 780], ["they", 784], ["could", 789], ["not", 795], ["synthesize", 799], ["type", 810], ["3", 815], ["collagen", 817], [".", 825], ["Type", 827], ["4", 832], ["Ehlers", 834], ["-", 840], ["Danlos", 841], ["syndrome", 848], ["was", 857], ["diagnosed", 861], [".", 870], ["It", 872], ["was", 875], ["likely", 879], ["that", 886], ["myocardial", 891], ["infarction", 902], ["might", 913], ["have", 919], ["resulted", 924], ["from", 933], ["the", 938], ["fragility", 942], ["of", 952], ["their", 955], ["coronary", 961], ["arteries", 970], ["in", 979], ["type", 982], ["4", 987], ["Ehlers", 989], ["-", 995], ["Danlos", 996], ["syndrome", 1003], [".", 1011]]}
{"context": "The actin-cross-linking protein spectrin is a prominent component of the membrane cytoskeleton. Spectrin is a tetramer of two antiparallel alphabeta-dimers which share a unique and ancient gene structure. The alpha-spectrin and beta-spectrin genes are composed primarily of tandemly repeated 106-amino-acid segments, each of which forms a triple alpha-helical coiled coil. Both the genes and the repeats themselves are homologous. The two genes are thought to be the result of a gene duplication event, and each gene is the product of duplications of the 106-amino-acid repeats. In this work we compare the process of molecular evolution across the repeated segments of the alpha- and beta-spectrin genes. We find that the alpha-spectrin segments have, for the most part, evolved in a homogeneous fashion, while considerable heterogeneity is found among beta-spectrin segments. Several segments with unique known functions are found to have evolved differently than the others. On the basis of heterogeneity of the evolutionary process, we suggest that at least one repeat has a unique function that has yet to be documented. We also present new statistical methods for comparing the evolutionary process between different regions of DNA sequences.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "b37db289ef2948e9b5e75fbc0cbd66bf", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[23, 23]], "char_spans": [[126, 137]]}]}], "context_tokens": [["The", 0], ["actin", 4], ["-", 9], ["cross", 10], ["-", 15], ["linking", 16], ["protein", 24], ["spectrin", 32], ["is", 41], ["a", 44], ["prominent", 46], ["component", 56], ["of", 66], ["the", 69], ["membrane", 73], ["cytoskeleton", 82], [".", 94], ["Spectrin", 96], ["is", 105], ["a", 108], ["tetramer", 110], ["of", 119], ["two", 122], ["antiparallel", 126], ["alphabeta", 139], ["-", 148], ["dimers", 149], ["which", 156], ["share", 162], ["a", 168], ["unique", 170], ["and", 177], ["ancient", 181], ["gene", 189], ["structure", 194], [".", 203], ["The", 205], ["alpha", 209], ["-", 214], ["spectrin", 215], ["and", 224], ["beta", 228], ["-", 232], ["spectrin", 233], ["genes", 242], ["are", 248], ["composed", 252], ["primarily", 261], ["of", 271], ["tandemly", 274], ["repeated", 283], ["106-amino", 292], ["-", 301], ["acid", 302], ["segments", 307], [",", 315], ["each", 317], ["of", 322], ["which", 325], ["forms", 331], ["a", 337], ["triple", 339], ["alpha", 346], ["-", 351], ["helical", 352], ["coiled", 360], ["coil", 367], [".", 371], ["Both", 373], ["the", 378], ["genes", 382], ["and", 388], ["the", 392], ["repeats", 396], ["themselves", 404], ["are", 415], ["homologous", 419], [".", 429], ["The", 431], ["two", 435], ["genes", 439], ["are", 445], ["thought", 449], ["to", 457], ["be", 460], ["the", 463], ["result", 467], ["of", 474], ["a", 477], ["gene", 479], ["duplication", 484], ["event", 496], [",", 501], ["and", 503], ["each", 507], ["gene", 512], ["is", 517], ["the", 520], ["product", 524], ["of", 532], ["duplications", 535], ["of", 548], ["the", 551], ["106-amino", 555], ["-", 564], ["acid", 565], ["repeats", 570], [".", 577], ["In", 579], ["this", 582], ["work", 587], ["we", 592], ["compare", 595], ["the", 603], ["process", 607], ["of", 615], ["molecular", 618], ["evolution", 628], ["across", 638], ["the", 645], ["repeated", 649], ["segments", 658], ["of", 667], ["the", 670], ["alpha-", 674], ["and", 681], ["beta", 685], ["-", 689], ["spectrin", 690], ["genes", 699], [".", 704], ["We", 706], ["find", 709], ["that", 714], ["the", 719], ["alpha", 723], ["-", 728], ["spectrin", 729], ["segments", 738], ["have", 747], [",", 751], ["for", 753], ["the", 757], ["most", 761], ["part", 766], [",", 770], ["evolved", 772], ["in", 780], ["a", 783], ["homogeneous", 785], ["fashion", 797], [",", 804], ["while", 806], ["considerable", 812], ["heterogeneity", 825], ["is", 839], ["found", 842], ["among", 848], ["beta", 854], ["-", 858], ["spectrin", 859], ["segments", 868], [".", 876], ["Several", 878], ["segments", 886], ["with", 895], ["unique", 900], ["known", 907], ["functions", 913], ["are", 923], ["found", 927], ["to", 933], ["have", 936], ["evolved", 941], ["differently", 949], ["than", 961], ["the", 966], ["others", 970], [".", 976], ["On", 978], ["the", 981], ["basis", 985], ["of", 991], ["heterogeneity", 994], ["of", 1008], ["the", 1011], ["evolutionary", 1015], ["process", 1028], [",", 1035], ["we", 1037], ["suggest", 1040], ["that", 1048], ["at", 1053], ["least", 1056], ["one", 1062], ["repeat", 1066], ["has", 1073], ["a", 1077], ["unique", 1079], ["function", 1086], ["that", 1095], ["has", 1100], ["yet", 1104], ["to", 1108], ["be", 1111], ["documented", 1114], [".", 1124], ["We", 1126], ["also", 1129], ["present", 1134], ["new", 1142], ["statistical", 1146], ["methods", 1158], ["for", 1166], ["comparing", 1170], ["the", 1180], ["evolutionary", 1184], ["process", 1197], ["between", 1205], ["different", 1213], ["regions", 1223], ["of", 1231], ["DNA", 1234], ["sequences", 1238], [".", 1247]]}
{"context": "Many mutations of the NF1 gene have been reported in patients with neurofibromatosis type 1 (NF1); however, there have been no documented NF1 gene mutations in Japanese NF1 patients. In the present study, we used the polymerase chain reaction (PCR) and DNA sequencing analysis to characterize the NF1 gene in a 53-year-old Japanese patient with NF1 who suffered from neurofibroma, pheochromocytoma, and gastrointestinal stromal tumor (GIST). Direct sequence analyses revealed a single base substitution in the splicing donor site of intron 6 (IVS6 888+1, G --> A) in one NF1 allele, resulting in an altered splice site (ss) in the mutated allele. Splicing at the cryptic 5' ss in the mutated allele generated mRNA with an insertion of 60 nucleotides. In addition, we screened for mutations in exons 9, 11, 13, and 17 of the c-kit gene in GIST and the succinate dehydrogenase subunit D (SDHD) gene in the pheochromocytoma, but we did not detect any somatic mutations. We report here the first case of an NF1 patient with four neoplasms: neurofibroma, pheochromocytoma, astrocytoma and GIST. Our results suggest that the molecular pathogenesis of GISTs in NF1 patients is different from that in non-NF1 patients.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "5976ad62650747a3bc3be03c0e430c7d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[16, 16], [203, 203], [227, 227], [26, 26], [4, 4], [65, 65], [55, 55], [236, 236], [110, 110], [31, 31]], "char_spans": [[93, 95], [1003, 1005], [1154, 1156], [138, 140], [22, 24], [345, 347], [297, 299], [1197, 1199], [571, 573], [169, 171]]}]}], "context_tokens": [["Many", 0], ["mutations", 5], ["of", 15], ["the", 18], ["NF1", 22], ["gene", 26], ["have", 31], ["been", 36], ["reported", 41], ["in", 50], ["patients", 53], ["with", 62], ["neurofibromatosis", 67], ["type", 85], ["1", 90], ["(", 92], ["NF1", 93], [")", 96], [";", 97], ["however", 99], [",", 106], ["there", 108], ["have", 114], ["been", 119], ["no", 124], ["documented", 127], ["NF1", 138], ["gene", 142], ["mutations", 147], ["in", 157], ["Japanese", 160], ["NF1", 169], ["patients", 173], [".", 181], ["In", 183], ["the", 186], ["present", 190], ["study", 198], [",", 203], ["we", 205], ["used", 208], ["the", 213], ["polymerase", 217], ["chain", 228], ["reaction", 234], ["(", 243], ["PCR", 244], [")", 247], ["and", 249], ["DNA", 253], ["sequencing", 257], ["analysis", 268], ["to", 277], ["characterize", 280], ["the", 293], ["NF1", 297], ["gene", 301], ["in", 306], ["a", 309], ["53-year", 311], ["-", 318], ["old", 319], ["Japanese", 323], ["patient", 332], ["with", 340], ["NF1", 345], ["who", 349], ["suffered", 353], ["from", 362], ["neurofibroma", 367], [",", 379], ["pheochromocytoma", 381], [",", 397], ["and", 399], ["gastrointestinal", 403], ["stromal", 420], ["tumor", 428], ["(", 434], ["GIST", 435], [")", 439], [".", 440], ["Direct", 442], ["sequence", 449], ["analyses", 458], ["revealed", 467], ["a", 476], ["single", 478], ["base", 485], ["substitution", 490], ["in", 503], ["the", 506], ["splicing", 510], ["donor", 519], ["site", 525], ["of", 530], ["intron", 533], ["6", 540], ["(", 542], ["IVS6", 543], ["888", 548], ["+", 551], ["1", 552], [",", 553], ["G", 555], ["--", 557], [">", 559], ["A", 561], [")", 562], ["in", 564], ["one", 567], ["NF1", 571], ["allele", 575], [",", 581], ["resulting", 583], ["in", 593], ["an", 596], ["altered", 599], ["splice", 607], ["site", 614], ["(", 619], ["ss", 620], [")", 622], ["in", 624], ["the", 627], ["mutated", 631], ["allele", 639], [".", 645], ["Splicing", 647], ["at", 656], ["the", 659], ["cryptic", 663], ["5", 671], ["'", 672], ["ss", 674], ["in", 677], ["the", 680], ["mutated", 684], ["allele", 692], ["generated", 699], ["mRNA", 709], ["with", 714], ["an", 719], ["insertion", 722], ["of", 732], ["60", 735], ["nucleotides", 738], [".", 749], ["In", 751], ["addition", 754], [",", 762], ["we", 764], ["screened", 767], ["for", 776], ["mutations", 780], ["in", 790], ["exons", 793], ["9", 799], [",", 800], ["11", 802], [",", 804], ["13", 806], [",", 808], ["and", 810], ["17", 814], ["of", 817], ["the", 820], ["c", 824], ["-", 825], ["kit", 826], ["gene", 830], ["in", 835], ["GIST", 838], ["and", 843], ["the", 847], ["succinate", 851], ["dehydrogenase", 861], ["subunit", 875], ["D", 883], ["(", 885], ["SDHD", 886], [")", 890], ["gene", 892], ["in", 897], ["the", 900], ["pheochromocytoma", 904], [",", 920], ["but", 922], ["we", 926], ["did", 929], ["not", 933], ["detect", 937], ["any", 944], ["somatic", 948], ["mutations", 956], [".", 965], ["We", 967], ["report", 970], ["here", 977], ["the", 982], ["first", 986], ["case", 992], ["of", 997], ["an", 1000], ["NF1", 1003], ["patient", 1007], ["with", 1015], ["four", 1020], ["neoplasms", 1025], [":", 1034], ["neurofibroma", 1036], [",", 1048], ["pheochromocytoma", 1050], [",", 1066], ["astrocytoma", 1068], ["and", 1080], ["GIST", 1084], [".", 1088], ["Our", 1090], ["results", 1094], ["suggest", 1102], ["that", 1110], ["the", 1115], ["molecular", 1119], ["pathogenesis", 1129], ["of", 1142], ["GISTs", 1145], ["in", 1151], ["NF1", 1154], ["patients", 1158], ["is", 1167], ["different", 1170], ["from", 1180], ["that", 1185], ["in", 1190], ["non", 1193], ["-", 1196], ["NF1", 1197], ["patients", 1201], [".", 1209]]}
{"context": "The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, we report the final results from the same trial, including the efficacy of a booster dose. From March 27, 2009, until Jan 31, 2011, children (age 5-17 months) and young infants (age 6-12 weeks) were enrolled at 11 centres in seven countries in sub-Saharan Africa. Participants were randomly assigned (1:1:1) at first vaccination by block randomisation with minimisation by centre to receive three doses of RTS,S/AS01 at months 0, 1, and 2 and a booster dose at month 20 (R3R group); three doses of RTS,S/AS01 and a dose of comparator vaccine at month 20 (R3C group); or a comparator vaccine at months 0, 1, 2, and 20 (C3C [control group]). Participants were followed up until Jan 31, 2014. Cases of clinical and severe malaria were captured through passive case detection. Serious adverse events (SAEs) were recorded. Analyses were by modified intention to treat and per protocol. The coprimary endpoints were the occurrence of malaria over 12 months after dose 3 in each age category. In this final analysis, we present data for the efficacy of the booster on the occurrence of malaria. Vaccine efficacy (VE) against clinical malaria was analysed by negative binomial regression and against severe malaria by relative risk reduction. This trial is registered with ClinicalTrials.gov, number NCT00866619. 8922 children and 6537 young infants were included in the modified intention-to-treat analyses. Children were followed up for a median of 48 months (IQR 39-50) and young infants for 38 months (34-41) after dose 1. From month 0 until study end, compared with 9585 episodes of clinical malaria that met the primary case definition in children in the C3C group, 6616 episodes occurred in the R3R group (VE 36\u00b73%, 95% CI 31\u00b78-40\u00b75) and 7396 occurred in the R3C group (28\u00b73%, 23\u00b73-32\u00b79); compared with 171 children who experienced at least one episode of severe malaria in the C3C group, 116 children experienced at least one episode of severe malaria in the R3R group (32\u00b72%, 13\u00b77 to 46\u00b79) and 169 in the R3C group (1\u00b71%, -23\u00b70 to 20\u00b75). In young infants, compared with 6170 episodes of clinical malaria that met the primary case definition in the C3C group, 4993 episodes occurred in the R3R group (VE 25\u00b79%, 95% CI 19\u00b79-31\u00b75) and 5444 occurred in the R3C group (18\u00b73%, 11\u00b77-24\u00b74); and compared with 116 infants who experienced at least one episode of severe malaria in the C3C group, 96 infants experienced at least one episode of severe malaria in the R3R group (17\u00b73%, 95% CI -9\u00b74 to 37\u00b75) and 104 in the R3C group (10\u00b73%, -17\u00b79 to 31\u00b78). In children, 1774 cases of clinical malaria were averted per 1000 children (95% CI 1387-2186) in the R3R group and 1363 per 1000 children (995-1797) in the R3C group. The numbers of cases averted per 1000 young infants were 983 (95% CI 592-1337) in the R3R group and 558 (158-926) in the R3C group. The frequency of SAEs overall was balanced between groups. However, meningitis was reported as a SAE in 22 children: 11 in the R3R group, ten in the R3C group, and one in the C3C group. The incidence of generalised convulsive seizures within 7 days of RTS,S/AS01 booster was 2\u00b72 per 1000 doses in young infants and 2\u00b75 per 1000 doses in children. RTS,S/AS01 prevented a substantial number of cases of clinical malaria over a 3-4 year period in young infants and children when administered with or without a booster dose. Efficacy was enhanced by the administration of a booster dose in both age categories. Thus, the vaccine has the potential to make a substantial contribution to malaria control when used in combination with other effective control measures", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "e339e78113964de2b3b0f21b5a8d959d", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[261, 261], [419, 419], [358, 358], [547, 547], [739, 739], [789, 789], [196, 196], [12, 12], [231, 231], [434, 434], [532, 532], [585, 585], [280, 280], [472, 472], [270, 270]], "char_spans": [[1217, 1223], [2000, 2006], [1727, 1733], [2579, 2585], [3391, 3397], [3662, 3668], [857, 863], [52, 58], [1066, 1072], [2082, 2088], [2499, 2505], [2718, 2724], [1337, 1343], [2235, 2241], [1265, 1271]]}]}], "context_tokens": [["The", 0], ["efficacy", 4], ["and", 13], ["safety", 17], ["of", 24], ["the", 27], ["RTS", 31], [",", 34], ["S", 35], ["/", 36], ["AS01", 37], ["candidate", 42], ["malaria", 52], ["vaccine", 60], ["during", 68], ["18", 75], ["months", 78], ["of", 85], ["follow", 88], ["-", 94], ["up", 95], ["have", 98], ["been", 103], ["published", 108], ["previously", 118], [".", 128], ["Herein", 130], [",", 136], ["we", 138], ["report", 141], ["the", 148], ["final", 152], ["results", 158], ["from", 166], ["the", 171], ["same", 175], ["trial", 180], [",", 185], ["including", 187], ["the", 197], ["efficacy", 201], ["of", 210], ["a", 213], ["booster", 215], ["dose", 223], [".", 227], ["From", 229], ["March", 234], ["27", 240], [",", 242], ["2009", 244], [",", 248], ["until", 250], ["Jan", 256], ["31", 260], [",", 262], ["2011", 264], [",", 268], ["children", 270], ["(", 279], ["age", 280], ["5", 284], ["-", 285], ["17", 286], ["months", 289], [")", 295], ["and", 297], ["young", 301], ["infants", 307], ["(", 315], ["age", 316], ["6", 320], ["-", 321], ["12", 322], ["weeks", 325], [")", 330], ["were", 332], ["enrolled", 337], ["at", 346], ["11", 349], ["centres", 352], ["in", 360], ["seven", 363], ["countries", 369], ["in", 379], ["sub", 382], ["-", 385], ["Saharan", 386], ["Africa", 394], [".", 400], ["Participants", 402], ["were", 415], ["randomly", 420], ["assigned", 429], ["(", 438], ["1:1:1", 439], [")", 444], ["at", 446], ["first", 449], ["vaccination", 455], ["by", 467], ["block", 470], ["randomisation", 476], ["with", 490], ["minimisation", 495], ["by", 508], ["centre", 511], ["to", 518], ["receive", 521], ["three", 529], ["doses", 535], ["of", 541], ["RTS", 544], [",", 547], ["S", 548], ["/", 549], ["AS01", 550], ["at", 555], ["months", 558], ["0", 565], [",", 566], ["1", 568], [",", 569], ["and", 571], ["2", 575], ["and", 577], ["a", 581], ["booster", 583], ["dose", 591], ["at", 596], ["month", 599], ["20", 605], ["(", 608], ["R3R", 609], ["group", 613], [")", 618], [";", 619], ["three", 621], ["doses", 627], ["of", 633], ["RTS", 636], [",", 639], ["S", 640], ["/", 641], ["AS01", 642], ["and", 647], ["a", 651], ["dose", 653], ["of", 658], ["comparator", 661], ["vaccine", 672], ["at", 680], ["month", 683], ["20", 689], ["(", 692], ["R3C", 693], ["group", 697], [")", 702], [";", 703], ["or", 705], ["a", 708], ["comparator", 710], ["vaccine", 721], ["at", 729], ["months", 732], ["0", 739], [",", 740], ["1", 742], [",", 743], ["2", 745], [",", 746], ["and", 748], ["20", 752], ["(", 755], ["C3C", 756], ["[", 760], ["control", 761], ["group", 769], ["]", 774], [")", 775], [".", 776], ["Participants", 778], ["were", 791], ["followed", 796], ["up", 805], ["until", 808], ["Jan", 814], ["31", 818], [",", 820], ["2014", 822], [".", 826], ["Cases", 828], ["of", 834], ["clinical", 837], ["and", 846], ["severe", 850], ["malaria", 857], ["were", 865], ["captured", 870], ["through", 879], ["passive", 887], ["case", 895], ["detection", 900], [".", 909], ["Serious", 911], ["adverse", 919], ["events", 927], ["(", 934], ["SAEs", 935], [")", 939], ["were", 941], ["recorded", 946], [".", 954], ["Analyses", 956], ["were", 965], ["by", 970], ["modified", 973], ["intention", 982], ["to", 992], ["treat", 995], ["and", 1001], ["per", 1005], ["protocol", 1009], [".", 1017], ["The", 1019], ["coprimary", 1023], ["endpoints", 1033], ["were", 1043], ["the", 1048], ["occurrence", 1052], ["of", 1063], ["malaria", 1066], ["over", 1074], ["12", 1079], ["months", 1082], ["after", 1089], ["dose", 1095], ["3", 1100], ["in", 1102], ["each", 1105], ["age", 1110], ["category", 1114], [".", 1122], ["In", 1124], ["this", 1127], ["final", 1132], ["analysis", 1138], [",", 1146], ["we", 1148], ["present", 1151], ["data", 1159], ["for", 1164], ["the", 1168], ["efficacy", 1172], ["of", 1181], ["the", 1184], ["booster", 1188], ["on", 1196], ["the", 1199], ["occurrence", 1203], ["of", 1214], ["malaria", 1217], [".", 1224], ["Vaccine", 1226], ["efficacy", 1234], ["(", 1243], ["VE", 1244], [")", 1246], ["against", 1248], ["clinical", 1256], ["malaria", 1265], ["was", 1273], ["analysed", 1277], ["by", 1286], ["negative", 1289], ["binomial", 1298], ["regression", 1307], ["and", 1318], ["against", 1322], ["severe", 1330], ["malaria", 1337], ["by", 1345], ["relative", 1348], ["risk", 1357], ["reduction", 1362], [".", 1371], ["This", 1373], ["trial", 1378], ["is", 1384], ["registered", 1387], ["with", 1398], ["ClinicalTrials.gov", 1403], [",", 1421], ["number", 1423], ["NCT00866619", 1430], [".", 1441], ["8922", 1443], ["children", 1448], ["and", 1457], ["6537", 1461], ["young", 1466], ["infants", 1472], ["were", 1480], ["included", 1485], ["in", 1494], ["the", 1497], ["modified", 1501], ["intention", 1510], ["-", 1519], ["to", 1520], ["-", 1522], ["treat", 1523], ["analyses", 1529], [".", 1537], ["Children", 1539], ["were", 1548], ["followed", 1553], ["up", 1562], ["for", 1565], ["a", 1569], ["median", 1571], ["of", 1578], ["48", 1581], ["months", 1584], ["(", 1591], ["IQR", 1592], ["39", 1596], ["-", 1598], ["50", 1599], [")", 1601], ["and", 1603], ["young", 1607], ["infants", 1613], ["for", 1621], ["38", 1625], ["months", 1628], ["(", 1635], ["34", 1636], ["-", 1638], ["41", 1639], [")", 1641], ["after", 1643], ["dose", 1649], ["1", 1654], [".", 1655], ["From", 1657], ["month", 1662], ["0", 1668], ["until", 1670], ["study", 1676], ["end", 1682], [",", 1685], ["compared", 1687], ["with", 1696], ["9585", 1701], ["episodes", 1706], ["of", 1715], ["clinical", 1718], ["malaria", 1727], ["that", 1735], ["met", 1740], ["the", 1744], ["primary", 1748], ["case", 1756], ["definition", 1761], ["in", 1772], ["children", 1775], ["in", 1784], ["the", 1787], ["C3C", 1791], ["group", 1795], [",", 1800], ["6616", 1802], ["episodes", 1807], ["occurred", 1816], ["in", 1825], ["the", 1828], ["R3R", 1832], ["group", 1836], ["(", 1842], ["VE", 1843], ["36\u00b73", 1846], ["%", 1850], [",", 1851], ["95", 1853], ["%", 1855], ["CI", 1857], ["31\u00b78", 1860], ["-", 1864], ["40\u00b75", 1865], [")", 1869], ["and", 1871], ["7396", 1875], ["occurred", 1880], ["in", 1889], ["the", 1892], ["R3C", 1896], ["group", 1900], ["(", 1906], ["28\u00b73", 1907], ["%", 1911], [",", 1912], ["23\u00b73", 1914], ["-", 1918], ["32\u00b79", 1919], [")", 1923], [";", 1924], ["compared", 1926], ["with", 1935], ["171", 1940], ["children", 1944], ["who", 1953], ["experienced", 1957], ["at", 1969], ["least", 1972], ["one", 1978], ["episode", 1982], ["of", 1990], ["severe", 1993], ["malaria", 2000], ["in", 2008], ["the", 2011], ["C3C", 2015], ["group", 2019], [",", 2024], ["116", 2026], ["children", 2030], ["experienced", 2039], ["at", 2051], ["least", 2054], ["one", 2060], ["episode", 2064], ["of", 2072], ["severe", 2075], ["malaria", 2082], ["in", 2090], ["the", 2093], ["R3R", 2097], ["group", 2101], ["(", 2107], ["32\u00b72", 2108], ["%", 2112], [",", 2113], ["13\u00b77", 2115], ["to", 2120], ["46\u00b79", 2123], [")", 2127], ["and", 2129], ["169", 2133], ["in", 2137], ["the", 2140], ["R3C", 2144], ["group", 2148], ["(", 2154], ["1\u00b71", 2155], ["%", 2158], [",", 2159], ["-23\u00b70", 2161], ["to", 2167], ["20\u00b75", 2170], [")", 2174], [".", 2175], ["In", 2177], ["young", 2180], ["infants", 2186], [",", 2193], ["compared", 2195], ["with", 2204], ["6170", 2209], ["episodes", 2214], ["of", 2223], ["clinical", 2226], ["malaria", 2235], ["that", 2243], ["met", 2248], ["the", 2252], ["primary", 2256], ["case", 2264], ["definition", 2269], ["in", 2280], ["the", 2283], ["C3C", 2287], ["group", 2291], [",", 2296], ["4993", 2298], ["episodes", 2303], ["occurred", 2312], ["in", 2321], ["the", 2324], ["R3R", 2328], ["group", 2332], ["(", 2338], ["VE", 2339], ["25\u00b79", 2342], ["%", 2346], [",", 2347], ["95", 2349], ["%", 2351], ["CI", 2353], ["19\u00b79", 2356], ["-", 2360], ["31\u00b75", 2361], [")", 2365], ["and", 2367], ["5444", 2371], ["occurred", 2376], ["in", 2385], ["the", 2388], ["R3C", 2392], ["group", 2396], ["(", 2402], ["18\u00b73", 2403], ["%", 2407], [",", 2408], ["11\u00b77", 2410], ["-", 2414], ["24\u00b74", 2415], [")", 2419], [";", 2420], ["and", 2422], ["compared", 2426], ["with", 2435], ["116", 2440], ["infants", 2444], ["who", 2452], ["experienced", 2456], ["at", 2468], ["least", 2471], ["one", 2477], ["episode", 2481], ["of", 2489], ["severe", 2492], ["malaria", 2499], ["in", 2507], ["the", 2510], ["C3C", 2514], ["group", 2518], [",", 2523], ["96", 2525], ["infants", 2528], ["experienced", 2536], ["at", 2548], ["least", 2551], ["one", 2557], ["episode", 2561], ["of", 2569], ["severe", 2572], ["malaria", 2579], ["in", 2587], ["the", 2590], ["R3R", 2594], ["group", 2598], ["(", 2604], ["17\u00b73", 2605], ["%", 2609], [",", 2610], ["95", 2612], ["%", 2614], ["CI", 2616], ["-9\u00b74", 2619], ["to", 2624], ["37\u00b75", 2627], [")", 2631], ["and", 2633], ["104", 2637], ["in", 2641], ["the", 2644], ["R3C", 2648], ["group", 2652], ["(", 2658], ["10\u00b73", 2659], ["%", 2663], [",", 2664], ["-17\u00b79", 2666], ["to", 2672], ["31\u00b78", 2675], [")", 2679], [".", 2680], ["In", 2682], ["children", 2685], [",", 2693], ["1774", 2695], ["cases", 2700], ["of", 2706], ["clinical", 2709], ["malaria", 2718], ["were", 2726], ["averted", 2731], ["per", 2739], ["1000", 2743], ["children", 2748], ["(", 2757], ["95", 2758], ["%", 2760], ["CI", 2762], ["1387", 2765], ["-", 2769], ["2186", 2770], [")", 2774], ["in", 2776], ["the", 2779], ["R3R", 2783], ["group", 2787], ["and", 2793], ["1363", 2797], ["per", 2802], ["1000", 2806], ["children", 2811], ["(", 2820], ["995", 2821], ["-", 2824], ["1797", 2825], [")", 2829], ["in", 2831], ["the", 2834], ["R3C", 2838], ["group", 2842], [".", 2847], ["The", 2849], ["numbers", 2853], ["of", 2861], ["cases", 2864], ["averted", 2870], ["per", 2878], ["1000", 2882], ["young", 2887], ["infants", 2893], ["were", 2901], ["983", 2906], ["(", 2910], ["95", 2911], ["%", 2913], ["CI", 2915], ["592", 2918], ["-", 2921], ["1337", 2922], [")", 2926], ["in", 2928], ["the", 2931], ["R3R", 2935], ["group", 2939], ["and", 2945], ["558", 2949], ["(", 2953], ["158", 2954], ["-", 2957], ["926", 2958], [")", 2961], ["in", 2963], ["the", 2966], ["R3C", 2970], ["group", 2974], [".", 2979], ["The", 2981], ["frequency", 2985], ["of", 2995], ["SAEs", 2998], ["overall", 3003], ["was", 3011], ["balanced", 3015], ["between", 3024], ["groups", 3032], [".", 3038], ["However", 3040], [",", 3047], ["meningitis", 3049], ["was", 3060], ["reported", 3064], ["as", 3073], ["a", 3076], ["SAE", 3078], ["in", 3082], ["22", 3085], ["children", 3088], [":", 3096], ["11", 3098], ["in", 3101], ["the", 3104], ["R3R", 3108], ["group", 3112], [",", 3117], ["ten", 3119], ["in", 3123], ["the", 3126], ["R3C", 3130], ["group", 3134], [",", 3139], ["and", 3141], ["one", 3145], ["in", 3149], ["the", 3152], ["C3C", 3156], ["group", 3160], [".", 3165], ["The", 3167], ["incidence", 3171], ["of", 3181], ["generalised", 3184], ["convulsive", 3196], ["seizures", 3207], ["within", 3216], ["7", 3223], ["days", 3225], ["of", 3230], ["RTS", 3233], [",", 3236], ["S", 3237], ["/", 3238], ["AS01", 3239], ["booster", 3244], ["was", 3252], ["2\u00b72", 3256], ["per", 3260], ["1000", 3264], ["doses", 3269], ["in", 3275], ["young", 3278], ["infants", 3284], ["and", 3292], ["2\u00b75", 3296], ["per", 3300], ["1000", 3304], ["doses", 3309], ["in", 3315], ["children", 3318], [".", 3326], ["RTS", 3328], [",", 3331], ["S", 3332], ["/", 3333], ["AS01", 3334], ["prevented", 3339], ["a", 3349], ["substantial", 3351], ["number", 3363], ["of", 3370], ["cases", 3373], ["of", 3379], ["clinical", 3382], ["malaria", 3391], ["over", 3399], ["a", 3404], ["3", 3406], ["-", 3407], ["4", 3408], ["year", 3410], ["period", 3415], ["in", 3422], ["young", 3425], ["infants", 3431], ["and", 3439], ["children", 3443], ["when", 3452], ["administered", 3457], ["with", 3470], ["or", 3475], ["without", 3478], ["a", 3486], ["booster", 3488], ["dose", 3496], [".", 3500], ["Efficacy", 3502], ["was", 3511], ["enhanced", 3515], ["by", 3524], ["the", 3527], ["administration", 3531], ["of", 3546], ["a", 3549], ["booster", 3551], ["dose", 3559], ["in", 3564], ["both", 3567], ["age", 3572], ["categories", 3576], [".", 3586], ["Thus", 3588], [",", 3592], ["the", 3594], ["vaccine", 3598], ["has", 3606], ["the", 3610], ["potential", 3614], ["to", 3624], ["make", 3627], ["a", 3632], ["substantial", 3634], ["contribution", 3646], ["to", 3659], ["malaria", 3662], ["control", 3670], ["when", 3678], ["used", 3683], ["in", 3688], ["combination", 3691], ["with", 3703], ["other", 3708], ["effective", 3714], ["control", 3724], ["measures", 3732]]}
{"context": "Six persons with the classical Angelman syndrome (AS) phenotype and de novo deletions of chromosome 15q11-q13 were studied to determine the parental origin of the chromosome deletion. Four of the 6 patients had informative cytogenetic studies and all demonstrated maternal inheritance of the deletion. These findings, together with other reported cases of the origin of the chromosome 15 deletion in AS, suggest that deletion of the maternally contributed chromosome leads to the AS phenotype. This contrasts with the Prader-Willi syndrome (PWS) in which a similar deletion of the paternally contributed chromosome 15 is observed. In deletion cases, a parental gamete effect such as genomic imprinting may be the best model to explain why apparently identical 15q11-q13 deletions may develop the different phenotypes of AS or PWS.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "03aa34b985ac43f7b28e110d51d52e44", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[85, 88]], "char_spans": [[518, 538]]}]}], "context_tokens": [["Six", 0], ["persons", 4], ["with", 12], ["the", 17], ["classical", 21], ["Angelman", 31], ["syndrome", 40], ["(", 49], ["AS", 50], [")", 52], ["phenotype", 54], ["and", 64], ["de", 68], ["novo", 71], ["deletions", 76], ["of", 86], ["chromosome", 89], ["15q11-q13", 100], ["were", 110], ["studied", 115], ["to", 123], ["determine", 126], ["the", 136], ["parental", 140], ["origin", 149], ["of", 156], ["the", 159], ["chromosome", 163], ["deletion", 174], [".", 182], ["Four", 184], ["of", 189], ["the", 192], ["6", 196], ["patients", 198], ["had", 207], ["informative", 211], ["cytogenetic", 223], ["studies", 235], ["and", 243], ["all", 247], ["demonstrated", 251], ["maternal", 264], ["inheritance", 273], ["of", 285], ["the", 288], ["deletion", 292], [".", 300], ["These", 302], ["findings", 308], [",", 316], ["together", 318], ["with", 327], ["other", 332], ["reported", 338], ["cases", 347], ["of", 353], ["the", 356], ["origin", 360], ["of", 367], ["the", 370], ["chromosome", 374], ["15", 385], ["deletion", 388], ["in", 397], ["AS", 400], [",", 402], ["suggest", 404], ["that", 412], ["deletion", 417], ["of", 426], ["the", 429], ["maternally", 433], ["contributed", 444], ["chromosome", 456], ["leads", 467], ["to", 473], ["the", 476], ["AS", 480], ["phenotype", 483], [".", 492], ["This", 494], ["contrasts", 499], ["with", 509], ["the", 514], ["Prader", 518], ["-", 524], ["Willi", 525], ["syndrome", 531], ["(", 540], ["PWS", 541], [")", 544], ["in", 546], ["which", 549], ["a", 555], ["similar", 557], ["deletion", 565], ["of", 574], ["the", 577], ["paternally", 581], ["contributed", 592], ["chromosome", 604], ["15", 615], ["is", 618], ["observed", 621], [".", 629], ["In", 631], ["deletion", 634], ["cases", 643], [",", 648], ["a", 650], ["parental", 652], ["gamete", 661], ["effect", 668], ["such", 675], ["as", 680], ["genomic", 683], ["imprinting", 691], ["may", 702], ["be", 706], ["the", 709], ["best", 713], ["model", 718], ["to", 724], ["explain", 727], ["why", 735], ["apparently", 739], ["identical", 750], ["15q11-q13", 760], ["deletions", 770], ["may", 780], ["develop", 784], ["the", 792], ["different", 796], ["phenotypes", 806], ["of", 817], ["AS", 820], ["or", 823], ["PWS", 826], [".", 829]]}
{"context": "Erythrasma is a superficial cutaneous infection caused by Corynebacterium minutissimum and is characterized by fluorescence under Wood's light (UV) because of the presence of porphyrins. These molecules are photosensitizing and we propose to assess efficacy of red light that activates porphyrins (photodynamic reaction) in treatment of this pathology. Assessment of effects of photodynamic action of red light for treatment of erythrasma without exogenous photosensitizing molecules. Thirteen patients with erythrasma were treated by one illumination (80 J/cm2) by red light (broad band, peak at 635 nm) without exogenous photosensitizing molecules. Disappearance or reduction of extent of lesions were observed 2 weeks later. If lesions were still present, a second irradiation was conducted with the same method. Preliminary results are presented. As a result of red light irradiation, we noticed a complete recovery for three patients and, in most other cases, reduction of extent of lesions (mean: -29% after one session). The treatment was well tolerated. We report first cases of photodynamic treatment of erythrasma. There are other reports of clinical applications of antimicrobial action of photodynamic therapy in dermatology (acne vulgaris, leishmaniasis, warts, etc.). But there are few applications without addition of exogenous photosensitizing agent. The originality and interest of our study is to use spontaneous presence of porphyrins in the lesions. This technique seems to be an interesting alternative, inexpensive and easy, for the treatment of this localized infection. But an optimal method is still to be determined to improve efficacy.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "6216a4e8801a4b69bc9d147d4f205120", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[8, 9]], "char_spans": [[58, 85]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["cutaneous", 28], ["infection", 38], ["caused", 48], ["by", 55], ["Corynebacterium", 58], ["minutissimum", 74], ["and", 87], ["is", 91], ["characterized", 94], ["by", 108], ["fluorescence", 111], ["under", 124], ["Wood", 130], ["'s", 134], ["light", 137], ["(", 143], ["UV", 144], [")", 146], ["because", 148], ["of", 156], ["the", 159], ["presence", 163], ["of", 172], ["porphyrins", 175], [".", 185], ["These", 187], ["molecules", 193], ["are", 203], ["photosensitizing", 207], ["and", 224], ["we", 228], ["propose", 231], ["to", 239], ["assess", 242], ["efficacy", 249], ["of", 258], ["red", 261], ["light", 265], ["that", 271], ["activates", 276], ["porphyrins", 286], ["(", 297], ["photodynamic", 298], ["reaction", 311], [")", 319], ["in", 321], ["treatment", 324], ["of", 334], ["this", 337], ["pathology", 342], [".", 351], ["Assessment", 353], ["of", 364], ["effects", 367], ["of", 375], ["photodynamic", 378], ["action", 391], ["of", 398], ["red", 401], ["light", 405], ["for", 411], ["treatment", 415], ["of", 425], ["erythrasma", 428], ["without", 439], ["exogenous", 447], ["photosensitizing", 457], ["molecules", 474], [".", 483], ["Thirteen", 485], ["patients", 494], ["with", 503], ["erythrasma", 508], ["were", 519], ["treated", 524], ["by", 532], ["one", 535], ["illumination", 539], ["(", 552], ["80", 553], ["J", 556], ["/", 557], ["cm2", 558], [")", 561], ["by", 563], ["red", 566], ["light", 570], ["(", 576], ["broad", 577], ["band", 583], [",", 587], ["peak", 589], ["at", 594], ["635", 597], ["nm", 601], [")", 603], ["without", 605], ["exogenous", 613], ["photosensitizing", 623], ["molecules", 640], [".", 649], ["Disappearance", 651], ["or", 665], ["reduction", 668], ["of", 678], ["extent", 681], ["of", 688], ["lesions", 691], ["were", 699], ["observed", 704], ["2", 713], ["weeks", 715], ["later", 721], [".", 726], ["If", 728], ["lesions", 731], ["were", 739], ["still", 744], ["present", 750], [",", 757], ["a", 759], ["second", 761], ["irradiation", 768], ["was", 780], ["conducted", 784], ["with", 794], ["the", 799], ["same", 803], ["method", 808], [".", 814], ["Preliminary", 816], ["results", 828], ["are", 836], ["presented", 840], [".", 849], ["As", 851], ["a", 854], ["result", 856], ["of", 863], ["red", 866], ["light", 870], ["irradiation", 876], [",", 887], ["we", 889], ["noticed", 892], ["a", 900], ["complete", 902], ["recovery", 911], ["for", 920], ["three", 924], ["patients", 930], ["and", 939], [",", 942], ["in", 944], ["most", 947], ["other", 952], ["cases", 958], [",", 963], ["reduction", 965], ["of", 975], ["extent", 978], ["of", 985], ["lesions", 988], ["(", 996], ["mean", 997], [":", 1001], ["-29", 1003], ["%", 1006], ["after", 1008], ["one", 1014], ["session", 1018], [")", 1025], [".", 1026], ["The", 1028], ["treatment", 1032], ["was", 1042], ["well", 1046], ["tolerated", 1051], [".", 1060], ["We", 1062], ["report", 1065], ["first", 1072], ["cases", 1078], ["of", 1084], ["photodynamic", 1087], ["treatment", 1100], ["of", 1110], ["erythrasma", 1113], [".", 1123], ["There", 1125], ["are", 1131], ["other", 1135], ["reports", 1141], ["of", 1149], ["clinical", 1152], ["applications", 1161], ["of", 1174], ["antimicrobial", 1177], ["action", 1191], ["of", 1198], ["photodynamic", 1201], ["therapy", 1214], ["in", 1222], ["dermatology", 1225], ["(", 1237], ["acne", 1238], ["vulgaris", 1243], [",", 1251], ["leishmaniasis", 1253], [",", 1266], ["warts", 1268], [",", 1273], ["etc", 1275], [".", 1278], [")", 1279], [".", 1280], ["But", 1282], ["there", 1286], ["are", 1292], ["few", 1296], ["applications", 1300], ["without", 1313], ["addition", 1321], ["of", 1330], ["exogenous", 1333], ["photosensitizing", 1343], ["agent", 1360], [".", 1365], ["The", 1367], ["originality", 1371], ["and", 1383], ["interest", 1387], ["of", 1396], ["our", 1399], ["study", 1403], ["is", 1409], ["to", 1412], ["use", 1415], ["spontaneous", 1419], ["presence", 1431], ["of", 1440], ["porphyrins", 1443], ["in", 1454], ["the", 1457], ["lesions", 1461], [".", 1468], ["This", 1470], ["technique", 1475], ["seems", 1485], ["to", 1491], ["be", 1494], ["an", 1497], ["interesting", 1500], ["alternative", 1512], [",", 1523], ["inexpensive", 1525], ["and", 1537], ["easy", 1541], [",", 1545], ["for", 1547], ["the", 1551], ["treatment", 1555], ["of", 1565], ["this", 1568], ["localized", 1573], ["infection", 1583], [".", 1592], ["But", 1594], ["an", 1598], ["optimal", 1601], ["method", 1609], ["is", 1616], ["still", 1619], ["to", 1625], ["be", 1628], ["determined", 1631], ["to", 1642], ["improve", 1645], ["efficacy", 1653], [".", 1661]]}
{"context": "LHCII, the most abundant membrane protein on earth, is the major light-harvesting complex of plants. It is generally accepted that LHCII is associated with Photosystem II and only as a short-term response to overexcitation of PSII a subset moves to Photosystem I, triggered by its phosphorylation (state1 to state2 transition). However, here we show that in most natural light conditions LHCII serves as an antenna of both Photosystem I and Photosystem II and it is quantitatively demonstrated that this is required to achieve excitation balance between the two photosystems. This allows for acclimation to different light intensities simply by regulating the expression of LHCII genes only. It is demonstrated that indeed the amount of LHCII that is bound to both photosystems decreases when growth light intensity increases and vice versa. Finally, time-resolved fluorescence measurements on the photosynthetic thylakoid membranes show that LHCII is even a more efficient light harvester when associated with Photosystem I than with Photosystem II.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "60b7c837674146058fe26d85952d6ef1", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[0, 0], [128, 128], [116, 116], [25, 25], [72, 72], [159, 159]], "char_spans": [[0, 4], [737, 741], [674, 678], [131, 135], [388, 392], [943, 947]]}]}], "context_tokens": [["LHCII", 0], [",", 5], ["the", 7], ["most", 11], ["abundant", 16], ["membrane", 25], ["protein", 34], ["on", 42], ["earth", 45], [",", 50], ["is", 52], ["the", 55], ["major", 59], ["light", 65], ["-", 70], ["harvesting", 71], ["complex", 82], ["of", 90], ["plants", 93], [".", 99], ["It", 101], ["is", 104], ["generally", 107], ["accepted", 117], ["that", 126], ["LHCII", 131], ["is", 137], ["associated", 140], ["with", 151], ["Photosystem", 156], ["II", 168], ["and", 171], ["only", 175], ["as", 180], ["a", 183], ["short", 185], ["-", 190], ["term", 191], ["response", 196], ["to", 205], ["overexcitation", 208], ["of", 223], ["PSII", 226], ["a", 231], ["subset", 233], ["moves", 240], ["to", 246], ["Photosystem", 249], ["I", 261], [",", 262], ["triggered", 264], ["by", 274], ["its", 277], ["phosphorylation", 281], ["(", 297], ["state1", 298], ["to", 305], ["state2", 308], ["transition", 315], [")", 325], [".", 326], ["However", 328], [",", 335], ["here", 337], ["we", 342], ["show", 345], ["that", 350], ["in", 355], ["most", 358], ["natural", 363], ["light", 371], ["conditions", 377], ["LHCII", 388], ["serves", 394], ["as", 401], ["an", 404], ["antenna", 407], ["of", 415], ["both", 418], ["Photosystem", 423], ["I", 435], ["and", 437], ["Photosystem", 441], ["II", 453], ["and", 456], ["it", 460], ["is", 463], ["quantitatively", 466], ["demonstrated", 481], ["that", 494], ["this", 499], ["is", 504], ["required", 507], ["to", 516], ["achieve", 519], ["excitation", 527], ["balance", 538], ["between", 546], ["the", 554], ["two", 558], ["photosystems", 562], [".", 574], ["This", 576], ["allows", 581], ["for", 588], ["acclimation", 592], ["to", 604], ["different", 607], ["light", 617], ["intensities", 623], ["simply", 635], ["by", 642], ["regulating", 645], ["the", 656], ["expression", 660], ["of", 671], ["LHCII", 674], ["genes", 680], ["only", 686], [".", 690], ["It", 692], ["is", 695], ["demonstrated", 698], ["that", 711], ["indeed", 716], ["the", 723], ["amount", 727], ["of", 734], ["LHCII", 737], ["that", 743], ["is", 748], ["bound", 751], ["to", 757], ["both", 760], ["photosystems", 765], ["decreases", 778], ["when", 788], ["growth", 793], ["light", 800], ["intensity", 806], ["increases", 816], ["and", 826], ["vice", 830], ["versa", 835], [".", 840], ["Finally", 842], [",", 849], ["time", 851], ["-", 855], ["resolved", 856], ["fluorescence", 865], ["measurements", 878], ["on", 891], ["the", 894], ["photosynthetic", 898], ["thylakoid", 913], ["membranes", 923], ["show", 933], ["that", 938], ["LHCII", 943], ["is", 949], ["even", 952], ["a", 957], ["more", 959], ["efficient", 964], ["light", 974], ["harvester", 980], ["when", 990], ["associated", 995], ["with", 1006], ["Photosystem", 1011], ["I", 1023], ["than", 1025], ["with", 1030], ["Photosystem", 1035], ["II", 1047], [".", 1049]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome, which is associated with a balanced translocation involving chromosomes 9 and 22 to produce a fusion gene (bcr-abl) that gives rise to a constitutively activated Abl tyrosine kinase. This kinase led to the discovery of several small-molecule inhibitors, imatinib being the first and most successful of these. Resistance to imatinib results in some patients from Abl kinase point mutations. Overcoming imatinib resistance represents one of the biggest challenges facing clinicians in the modern management of CML. In this review, we discuss the current understanding of CML pathophysiology and mechanisms of imatinib resistance and how advancing this knowledge has led to the design of novel therapies in the area of blastic phase CML and Philadelphia chromosome-positive acute lymphoblastic leukemia with previous imatinib failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "0c2e363266584674a6c79cd1c7d3e1eb", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[34, 36]], "char_spans": [[203, 209]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["the", 51], ["presence", 55], ["of", 64], ["the", 67], ["Philadelphia", 71], ["chromosome", 84], [",", 94], ["which", 96], ["is", 102], ["associated", 105], ["with", 116], ["a", 121], ["balanced", 123], ["translocation", 132], ["involving", 146], ["chromosomes", 156], ["9", 168], ["and", 170], ["22", 174], ["to", 177], ["produce", 180], ["a", 188], ["fusion", 190], ["gene", 197], ["(", 202], ["bcr", 203], ["-", 206], ["abl", 207], [")", 210], ["that", 212], ["gives", 217], ["rise", 223], ["to", 228], ["a", 231], ["constitutively", 233], ["activated", 248], ["Abl", 258], ["tyrosine", 262], ["kinase", 271], [".", 277], ["This", 279], ["kinase", 284], ["led", 291], ["to", 295], ["the", 298], ["discovery", 302], ["of", 312], ["several", 315], ["small", 323], ["-", 328], ["molecule", 329], ["inhibitors", 338], [",", 348], ["imatinib", 350], ["being", 359], ["the", 365], ["first", 369], ["and", 375], ["most", 379], ["successful", 384], ["of", 395], ["these", 398], [".", 403], ["Resistance", 405], ["to", 416], ["imatinib", 419], ["results", 428], ["in", 436], ["some", 439], ["patients", 444], ["from", 453], ["Abl", 458], ["kinase", 462], ["point", 469], ["mutations", 475], [".", 484], ["Overcoming", 486], ["imatinib", 497], ["resistance", 506], ["represents", 517], ["one", 528], ["of", 532], ["the", 535], ["biggest", 539], ["challenges", 547], ["facing", 558], ["clinicians", 565], ["in", 576], ["the", 579], ["modern", 583], ["management", 590], ["of", 601], ["CML", 604], [".", 607], ["In", 609], ["this", 612], ["review", 617], [",", 623], ["we", 625], ["discuss", 628], ["the", 636], ["current", 640], ["understanding", 648], ["of", 662], ["CML", 665], ["pathophysiology", 669], ["and", 685], ["mechanisms", 689], ["of", 700], ["imatinib", 703], ["resistance", 712], ["and", 723], ["how", 727], ["advancing", 731], ["this", 741], ["knowledge", 746], ["has", 756], ["led", 760], ["to", 764], ["the", 767], ["design", 771], ["of", 778], ["novel", 781], ["therapies", 787], ["in", 797], ["the", 800], ["area", 804], ["of", 809], ["blastic", 812], ["phase", 820], ["CML", 826], ["and", 830], ["Philadelphia", 834], ["chromosome", 847], ["-", 857], ["positive", 858], ["acute", 867], ["lymphoblastic", 873], ["leukemia", 887], ["with", 896], ["previous", 901], ["imatinib", 910], ["failure", 919], [".", 926]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensorimotor disorder that can result in considerable sleep disruption. This narrative review provides an overview of RLS diagnosis and reports epidemiologic evidence for an association between RLS and mood disorders. Possible links between RLS, sleep disturbances, and mood disorders are considered, and theoretical pathophysiologic pathways are discussed. Finally, pharmacologic therapies for RLS are summarized. A PubMed search was performed using the search term restless legs syndrome in combination with affective/anxiety, antidepressants, anxiety/anxiety disorder, attention deficit hyperactivity disorder, depression/depressive disorder, mood/mood disorder, neuropsychiatric, panic/panic disorder, psychiatric disorder, and psychosis. English-language articles published between January 1993 and May 2013 were retrieved. Additional studies were identified from the reference lists of relevant publications. 173 publications were retrieved. Articles related to the association between idiopathic RLS and depression, anxiety, and mood disorders were reviewed. In total, 32 epidemiologic studies were identified. These studies were reviewed in detail and ranked according to quality. Data were extracted on the basis of relevance to the topic. Epidemiologic studies were assessed using 3 parameters: methodology, data quality, and generalizability of the results. Each factor was scored from 1 (high quality) to 4 (low quality), giving a total score of between 3 and 12 for each study. RLS and mood disorders are frequently comorbid. Recognition and appropriate treatment of comorbid RLS are particularly important in patients with psychiatric disorders, as RLS is a common medical reason for insomnia, and antidepressant use may exacerbate sensory symptoms.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "f69aed865e4f4461b59e86ff393595b6", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2], [88, 90]], "char_spans": [[0, 21], [538, 559]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], [",", 64], ["is", 66], ["a", 69], ["sensorimotor", 71], ["disorder", 84], ["that", 93], ["can", 98], ["result", 102], ["in", 109], ["considerable", 112], ["sleep", 125], ["disruption", 131], [".", 141], ["This", 143], ["narrative", 148], ["review", 158], ["provides", 165], ["an", 174], ["overview", 177], ["of", 186], ["RLS", 189], ["diagnosis", 193], ["and", 203], ["reports", 207], ["epidemiologic", 215], ["evidence", 229], ["for", 238], ["an", 242], ["association", 245], ["between", 257], ["RLS", 265], ["and", 269], ["mood", 273], ["disorders", 278], [".", 287], ["Possible", 289], ["links", 298], ["between", 304], ["RLS", 312], [",", 315], ["sleep", 317], ["disturbances", 323], [",", 335], ["and", 337], ["mood", 341], ["disorders", 346], ["are", 356], ["considered", 360], [",", 370], ["and", 372], ["theoretical", 376], ["pathophysiologic", 388], ["pathways", 405], ["are", 414], ["discussed", 418], [".", 427], ["Finally", 429], [",", 436], ["pharmacologic", 438], ["therapies", 452], ["for", 462], ["RLS", 466], ["are", 470], ["summarized", 474], [".", 484], ["A", 486], ["PubMed", 488], ["search", 495], ["was", 502], ["performed", 506], ["using", 516], ["the", 522], ["search", 526], ["term", 533], ["restless", 538], ["legs", 547], ["syndrome", 552], ["in", 561], ["combination", 564], ["with", 576], ["affective", 581], ["/", 590], ["anxiety", 591], [",", 598], ["antidepressants", 600], [",", 615], ["anxiety", 617], ["/", 624], ["anxiety", 625], ["disorder", 633], [",", 641], ["attention", 643], ["deficit", 653], ["hyperactivity", 661], ["disorder", 675], [",", 683], ["depression", 685], ["/", 695], ["depressive", 696], ["disorder", 707], [",", 715], ["mood", 717], ["/", 721], ["mood", 722], ["disorder", 727], [",", 735], ["neuropsychiatric", 737], [",", 753], ["panic", 755], ["/", 760], ["panic", 761], ["disorder", 767], [",", 775], ["psychiatric", 777], ["disorder", 789], [",", 797], ["and", 799], ["psychosis", 803], [".", 812], ["English", 814], ["-", 821], ["language", 822], ["articles", 831], ["published", 840], ["between", 850], ["January", 858], ["1993", 866], ["and", 871], ["May", 875], ["2013", 879], ["were", 884], ["retrieved", 889], [".", 898], ["Additional", 900], ["studies", 911], ["were", 919], ["identified", 924], ["from", 935], ["the", 940], ["reference", 944], ["lists", 954], ["of", 960], ["relevant", 963], ["publications", 972], [".", 984], ["173", 986], ["publications", 990], ["were", 1003], ["retrieved", 1008], [".", 1017], ["Articles", 1019], ["related", 1028], ["to", 1036], ["the", 1039], ["association", 1043], ["between", 1055], ["idiopathic", 1063], ["RLS", 1074], ["and", 1078], ["depression", 1082], [",", 1092], ["anxiety", 1094], [",", 1101], ["and", 1103], ["mood", 1107], ["disorders", 1112], ["were", 1122], ["reviewed", 1127], [".", 1135], ["In", 1137], ["total", 1140], [",", 1145], ["32", 1147], ["epidemiologic", 1150], ["studies", 1164], ["were", 1172], ["identified", 1177], [".", 1187], ["These", 1189], ["studies", 1195], ["were", 1203], ["reviewed", 1208], ["in", 1217], ["detail", 1220], ["and", 1227], ["ranked", 1231], ["according", 1238], ["to", 1248], ["quality", 1251], [".", 1258], ["Data", 1260], ["were", 1265], ["extracted", 1270], ["on", 1280], ["the", 1283], ["basis", 1287], ["of", 1293], ["relevance", 1296], ["to", 1306], ["the", 1309], ["topic", 1313], [".", 1318], ["Epidemiologic", 1320], ["studies", 1334], ["were", 1342], ["assessed", 1347], ["using", 1356], ["3", 1362], ["parameters", 1364], [":", 1374], ["methodology", 1376], [",", 1387], ["data", 1389], ["quality", 1394], [",", 1401], ["and", 1403], ["generalizability", 1407], ["of", 1424], ["the", 1427], ["results", 1431], [".", 1438], ["Each", 1440], ["factor", 1445], ["was", 1452], ["scored", 1456], ["from", 1463], ["1", 1468], ["(", 1470], ["high", 1471], ["quality", 1476], [")", 1483], ["to", 1485], ["4", 1488], ["(", 1490], ["low", 1491], ["quality", 1495], [")", 1502], [",", 1503], ["giving", 1505], ["a", 1512], ["total", 1514], ["score", 1520], ["of", 1526], ["between", 1529], ["3", 1537], ["and", 1539], ["12", 1543], ["for", 1546], ["each", 1550], ["study", 1555], [".", 1560], ["RLS", 1562], ["and", 1566], ["mood", 1570], ["disorders", 1575], ["are", 1585], ["frequently", 1589], ["comorbid", 1600], [".", 1608], ["Recognition", 1610], ["and", 1622], ["appropriate", 1626], ["treatment", 1638], ["of", 1648], ["comorbid", 1651], ["RLS", 1660], ["are", 1664], ["particularly", 1668], ["important", 1681], ["in", 1691], ["patients", 1694], ["with", 1703], ["psychiatric", 1708], ["disorders", 1720], [",", 1729], ["as", 1731], ["RLS", 1734], ["is", 1738], ["a", 1741], ["common", 1743], ["medical", 1750], ["reason", 1758], ["for", 1765], ["insomnia", 1769], [",", 1777], ["and", 1779], ["antidepressant", 1783], ["use", 1798], ["may", 1802], ["exacerbate", 1806], ["sensory", 1817], ["symptoms", 1825], [".", 1833]]}
{"context": "NADPH oxidase (Nox) family enzymes are one of the main sources of cellular reactive oxygen species (ROS), which have been shown to function as second messenger molecules. To date, seven members of this family have been reported, including Nox1-5 and Duox1 and -2. With the exception of Nox2, the regulation of the Nox enzymes is still poorly understood. Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase, for its activity. In this study, we investigate the role of the tyrosine kinase c-Src in the regulation of ROS formation by Nox1. We show that c-Src induces Nox1-mediated ROS generation in the HT29 human colon carcinoma cell line through a Rac-dependent mechanism. Treatment of HT29 cells with the Src inhibitor PP2, expression of a kinase-inactive form of c-Src, and c-Src depletion by small interfering RNA (siRNA) reduce both ROS generation and the levels of active Rac1. This is associated with decreased Src-mediated phosphorylation and activation of the Rac1-guanine nucleotide exchange factor Vav2. Consistent with this, Vav2 siRNA that specifically reduces endogenous Vav2 protein is able to dramatically decrease Nox1-dependent ROS generation and abolish c-Src-induced Nox1 activity. Together, these results establish c-Src as an important regulator of Nox1 activity, and they may provide insight into the mechanisms of tumor formation in colon cancers.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "fdc8771a13204b6eb28d48a0e3f1d6c5", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[259, 259], [125, 125], [243, 243], [71, 71], [46, 46]], "char_spans": [[1353, 1356], [615, 618], [1269, 1272], [354, 357], [239, 242]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["(", 14], ["Nox", 15], [")", 18], ["family", 20], ["enzymes", 27], ["are", 35], ["one", 39], ["of", 43], ["the", 46], ["main", 50], ["sources", 55], ["of", 63], ["cellular", 66], ["reactive", 75], ["oxygen", 84], ["species", 91], ["(", 99], ["ROS", 100], [")", 103], [",", 104], ["which", 106], ["have", 112], ["been", 117], ["shown", 122], ["to", 128], ["function", 131], ["as", 140], ["second", 143], ["messenger", 150], ["molecules", 160], [".", 169], ["To", 171], ["date", 174], [",", 178], ["seven", 180], ["members", 186], ["of", 194], ["this", 197], ["family", 202], ["have", 209], ["been", 214], ["reported", 219], [",", 227], ["including", 229], ["Nox1", 239], ["-", 243], ["5", 244], ["and", 246], ["Duox1", 250], ["and", 256], ["-2", 260], [".", 262], ["With", 264], ["the", 269], ["exception", 273], ["of", 283], ["Nox2", 286], [",", 290], ["the", 292], ["regulation", 296], ["of", 307], ["the", 310], ["Nox", 314], ["enzymes", 318], ["is", 326], ["still", 329], ["poorly", 335], ["understood", 342], [".", 352], ["Nox1", 354], ["is", 359], ["highly", 362], ["expressed", 369], ["in", 379], ["the", 382], ["colon", 386], [",", 391], ["and", 393], ["it", 397], ["requires", 400], ["two", 409], ["cytosolic", 413], ["regulators", 423], [",", 433], ["NoxO1", 435], ["and", 441], ["NoxA1", 445], [",", 450], ["as", 452], ["well", 455], ["as", 460], ["the", 463], ["binding", 467], ["of", 475], ["Rac1", 478], ["GTPase", 483], [",", 489], ["for", 491], ["its", 495], ["activity", 499], [".", 507], ["In", 509], ["this", 512], ["study", 517], [",", 522], ["we", 524], ["investigate", 527], ["the", 539], ["role", 543], ["of", 548], ["the", 551], ["tyrosine", 555], ["kinase", 564], ["c", 571], ["-", 572], ["Src", 573], ["in", 577], ["the", 580], ["regulation", 584], ["of", 595], ["ROS", 598], ["formation", 602], ["by", 612], ["Nox1", 615], [".", 619], ["We", 621], ["show", 624], ["that", 629], ["c", 634], ["-", 635], ["Src", 636], ["induces", 640], ["Nox1-mediated", 648], ["ROS", 662], ["generation", 666], ["in", 677], ["the", 680], ["HT29", 684], ["human", 689], ["colon", 695], ["carcinoma", 701], ["cell", 711], ["line", 716], ["through", 721], ["a", 729], ["Rac", 731], ["-", 734], ["dependent", 735], ["mechanism", 745], [".", 754], ["Treatment", 756], ["of", 766], ["HT29", 769], ["cells", 774], ["with", 780], ["the", 785], ["Src", 789], ["inhibitor", 793], ["PP2", 803], [",", 806], ["expression", 808], ["of", 819], ["a", 822], ["kinase", 824], ["-", 830], ["inactive", 831], ["form", 840], ["of", 845], ["c", 848], ["-", 849], ["Src", 850], [",", 853], ["and", 855], ["c", 859], ["-", 860], ["Src", 861], ["depletion", 865], ["by", 875], ["small", 878], ["interfering", 884], ["RNA", 896], ["(", 900], ["siRNA", 901], [")", 906], ["reduce", 908], ["both", 915], ["ROS", 920], ["generation", 924], ["and", 935], ["the", 939], ["levels", 943], ["of", 950], ["active", 953], ["Rac1", 960], [".", 964], ["This", 966], ["is", 971], ["associated", 974], ["with", 985], ["decreased", 990], ["Src", 1000], ["-", 1003], ["mediated", 1004], ["phosphorylation", 1013], ["and", 1029], ["activation", 1033], ["of", 1044], ["the", 1047], ["Rac1-guanine", 1051], ["nucleotide", 1064], ["exchange", 1075], ["factor", 1084], ["Vav2", 1091], [".", 1095], ["Consistent", 1097], ["with", 1108], ["this", 1113], [",", 1117], ["Vav2", 1119], ["siRNA", 1124], ["that", 1130], ["specifically", 1135], ["reduces", 1148], ["endogenous", 1156], ["Vav2", 1167], ["protein", 1172], ["is", 1180], ["able", 1183], ["to", 1188], ["dramatically", 1191], ["decrease", 1204], ["Nox1-dependent", 1213], ["ROS", 1228], ["generation", 1232], ["and", 1243], ["abolish", 1247], ["c", 1255], ["-", 1256], ["Src", 1257], ["-", 1260], ["induced", 1261], ["Nox1", 1269], ["activity", 1274], [".", 1282], ["Together", 1284], [",", 1292], ["these", 1294], ["results", 1300], ["establish", 1308], ["c", 1318], ["-", 1319], ["Src", 1320], ["as", 1324], ["an", 1327], ["important", 1330], ["regulator", 1340], ["of", 1350], ["Nox1", 1353], ["activity", 1358], [",", 1366], ["and", 1368], ["they", 1372], ["may", 1377], ["provide", 1381], ["insight", 1389], ["into", 1397], ["the", 1402], ["mechanisms", 1406], ["of", 1417], ["tumor", 1420], ["formation", 1426], ["in", 1436], ["colon", 1439], ["cancers", 1445], [".", 1452]]}
{"context": "Siltuximab, a chimeric monoclonal antibody with high affinity and specificity for interleukin-6, has been shown to enhance anti-multiple myeloma activity of bortezomib and corticosteroid in vitro. We evaluated the safety, pharmacokinetics, immunogenicity, and antitumor effect of siltuximab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. This open-label, phase 1, dose-escalating study used two doses of siltuximab: 5.5 and 11.0 mg/kg (administered on day 1 of each 21-day cycle). In total, nine patients were treated. The most common grade 3/4 adverse events, lymphopenia (89 %) and thrombocytopenia (44 %), occurred in patients receiving both doses of siltuximab; however, no dose-limiting toxicities (DLTs) were observed. Following intravenous administration of siltuximab at 5.5 and 11.0 mg/kg, the maximum serum concentration and the area under the curve from 0 to 21 days and from 0 to infinity increased in an approximately dose-proportional manner. Mean half-life, total systemic clearance, and volume of distribution were similar at doses of 5.5 and 11.0 mg/kg. Across both doses, six of the nine patients had complete or partial response (22 and 44 %, respectively). In conclusion, as no DLT was observed, the recommended dose for this combination is 11.0 mg/kg once every 3 weeks. The study is registered at http://www.clinicaltrials.gov as NCT01309412.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "5cd7ff3ebd7f4aeea91e08b630ebba14", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[12, 12]], "char_spans": [[82, 94]]}]}], "context_tokens": [["Siltuximab", 0], [",", 10], ["a", 12], ["chimeric", 14], ["monoclonal", 23], ["antibody", 34], ["with", 43], ["high", 48], ["affinity", 53], ["and", 62], ["specificity", 66], ["for", 78], ["interleukin-6", 82], [",", 95], ["has", 97], ["been", 101], ["shown", 106], ["to", 112], ["enhance", 115], ["anti", 123], ["-", 127], ["multiple", 128], ["myeloma", 137], ["activity", 145], ["of", 154], ["bortezomib", 157], ["and", 168], ["corticosteroid", 172], ["in", 187], ["vitro", 190], [".", 195], ["We", 197], ["evaluated", 200], ["the", 210], ["safety", 214], [",", 220], ["pharmacokinetics", 222], [",", 238], ["immunogenicity", 240], [",", 254], ["and", 256], ["antitumor", 260], ["effect", 270], ["of", 277], ["siltuximab", 280], ["in", 291], ["combination", 294], ["with", 306], ["bortezomib", 311], ["and", 322], ["dexamethasone", 326], ["in", 340], ["Japanese", 343], ["patients", 352], ["with", 361], ["relapsed", 366], ["or", 375], ["refractory", 378], ["multiple", 389], ["myeloma", 398], [".", 405], ["This", 407], ["open", 412], ["-", 416], ["label", 417], [",", 422], ["phase", 424], ["1", 430], [",", 431], ["dose", 433], ["-", 437], ["escalating", 438], ["study", 449], ["used", 455], ["two", 460], ["doses", 464], ["of", 470], ["siltuximab", 473], [":", 483], ["5.5", 485], ["and", 489], ["11.0", 493], ["mg", 498], ["/", 500], ["kg", 501], ["(", 504], ["administered", 505], ["on", 518], ["day", 521], ["1", 525], ["of", 527], ["each", 530], ["21-day", 535], ["cycle", 542], [")", 547], [".", 548], ["In", 550], ["total", 553], [",", 558], ["nine", 560], ["patients", 565], ["were", 574], ["treated", 579], [".", 586], ["The", 588], ["most", 592], ["common", 597], ["grade", 604], ["3/4", 610], ["adverse", 614], ["events", 622], [",", 628], ["lymphopenia", 630], ["(", 642], ["89", 643], ["%", 646], [")", 647], ["and", 649], ["thrombocytopenia", 653], ["(", 670], ["44", 671], ["%", 674], [")", 675], [",", 676], ["occurred", 678], ["in", 687], ["patients", 690], ["receiving", 699], ["both", 709], ["doses", 714], ["of", 720], ["siltuximab", 723], [";", 733], ["however", 735], [",", 742], ["no", 744], ["dose", 747], ["-", 751], ["limiting", 752], ["toxicities", 761], ["(", 772], ["DLTs", 773], [")", 777], ["were", 779], ["observed", 784], [".", 792], ["Following", 794], ["intravenous", 804], ["administration", 816], ["of", 831], ["siltuximab", 834], ["at", 845], ["5.5", 848], ["and", 852], ["11.0", 856], ["mg", 861], ["/", 863], ["kg", 864], [",", 866], ["the", 868], ["maximum", 872], ["serum", 880], ["concentration", 886], ["and", 900], ["the", 904], ["area", 908], ["under", 913], ["the", 919], ["curve", 923], ["from", 929], ["0", 934], ["to", 936], ["21", 939], ["days", 942], ["and", 947], ["from", 951], ["0", 956], ["to", 958], ["infinity", 961], ["increased", 970], ["in", 980], ["an", 983], ["approximately", 986], ["dose", 1000], ["-", 1004], ["proportional", 1005], ["manner", 1018], [".", 1024], ["Mean", 1026], ["half", 1031], ["-", 1035], ["life", 1036], [",", 1040], ["total", 1042], ["systemic", 1048], ["clearance", 1057], [",", 1066], ["and", 1068], ["volume", 1072], ["of", 1079], ["distribution", 1082], ["were", 1095], ["similar", 1100], ["at", 1108], ["doses", 1111], ["of", 1117], ["5.5", 1120], ["and", 1124], ["11.0", 1128], ["mg", 1133], ["/", 1135], ["kg", 1136], [".", 1138], ["Across", 1140], ["both", 1147], ["doses", 1152], [",", 1157], ["six", 1159], ["of", 1163], ["the", 1166], ["nine", 1170], ["patients", 1175], ["had", 1184], ["complete", 1188], ["or", 1197], ["partial", 1200], ["response", 1208], ["(", 1217], ["22", 1218], ["and", 1221], ["44", 1225], ["%", 1228], [",", 1229], ["respectively", 1231], [")", 1243], [".", 1244], ["In", 1246], ["conclusion", 1249], [",", 1259], ["as", 1261], ["no", 1264], ["DLT", 1267], ["was", 1271], ["observed", 1275], [",", 1283], ["the", 1285], ["recommended", 1289], ["dose", 1301], ["for", 1306], ["this", 1310], ["combination", 1315], ["is", 1327], ["11.0", 1330], ["mg", 1335], ["/", 1337], ["kg", 1338], ["once", 1341], ["every", 1346], ["3", 1352], ["weeks", 1354], [".", 1359], ["The", 1361], ["study", 1365], ["is", 1371], ["registered", 1374], ["at", 1385], ["http://www.clinicaltrials.gov", 1388], ["as", 1418], ["NCT01309412", 1421], [".", 1432]]}
{"context": "There has been much debate about the appropriate statistical methodology for the evaluation of malaria field studies and the challenges in interpreting data arising from these trials. The present paper describes, for a pivotal phase III efficacy of the RTS, S/AS01 malaria vaccine, the methods of the statistical analysis and the rationale for their selection. The methods used to estimate efficacy of the primary course of vaccination, and of a booster dose, in preventing clinical episodes of uncomplicated and severe malaria, and to determine the duration of protection, are described. The interpretation of various measures of efficacy in terms of the potential public health impact of the vaccine is discussed. The methodology selected to analyse the clinical trial must be scientifically sound, acceptable to regulatory authorities and meaningful to those responsible for malaria control and public health policy.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "565e79886a2d468ab49544a0c8e4d2c9", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[146, 146], [89, 89], [46, 46], [14, 14]], "char_spans": [[878, 884], [520, 526], [265, 271], [95, 101]]}]}], "context_tokens": [["There", 0], ["has", 6], ["been", 10], ["much", 15], ["debate", 20], ["about", 27], ["the", 33], ["appropriate", 37], ["statistical", 49], ["methodology", 61], ["for", 73], ["the", 77], ["evaluation", 81], ["of", 92], ["malaria", 95], ["field", 103], ["studies", 109], ["and", 117], ["the", 121], ["challenges", 125], ["in", 136], ["interpreting", 139], ["data", 152], ["arising", 157], ["from", 165], ["these", 170], ["trials", 176], [".", 182], ["The", 184], ["present", 188], ["paper", 196], ["describes", 202], [",", 211], ["for", 213], ["a", 217], ["pivotal", 219], ["phase", 227], ["III", 233], ["efficacy", 237], ["of", 246], ["the", 249], ["RTS", 253], [",", 256], ["S", 258], ["/", 259], ["AS01", 260], ["malaria", 265], ["vaccine", 273], [",", 280], ["the", 282], ["methods", 286], ["of", 294], ["the", 297], ["statistical", 301], ["analysis", 313], ["and", 322], ["the", 326], ["rationale", 330], ["for", 340], ["their", 344], ["selection", 350], [".", 359], ["The", 361], ["methods", 365], ["used", 373], ["to", 378], ["estimate", 381], ["efficacy", 390], ["of", 399], ["the", 402], ["primary", 406], ["course", 414], ["of", 421], ["vaccination", 424], [",", 435], ["and", 437], ["of", 441], ["a", 444], ["booster", 446], ["dose", 454], [",", 458], ["in", 460], ["preventing", 463], ["clinical", 474], ["episodes", 483], ["of", 492], ["uncomplicated", 495], ["and", 509], ["severe", 513], ["malaria", 520], [",", 527], ["and", 529], ["to", 533], ["determine", 536], ["the", 546], ["duration", 550], ["of", 559], ["protection", 562], [",", 572], ["are", 574], ["described", 578], [".", 587], ["The", 589], ["interpretation", 593], ["of", 608], ["various", 611], ["measures", 619], ["of", 628], ["efficacy", 631], ["in", 640], ["terms", 643], ["of", 649], ["the", 652], ["potential", 656], ["public", 666], ["health", 673], ["impact", 680], ["of", 687], ["the", 690], ["vaccine", 694], ["is", 702], ["discussed", 705], [".", 714], ["The", 716], ["methodology", 720], ["selected", 732], ["to", 741], ["analyse", 744], ["the", 752], ["clinical", 756], ["trial", 765], ["must", 771], ["be", 776], ["scientifically", 779], ["sound", 794], [",", 799], ["acceptable", 801], ["to", 812], ["regulatory", 815], ["authorities", 826], ["and", 838], ["meaningful", 842], ["to", 853], ["those", 856], ["responsible", 862], ["for", 874], ["malaria", 878], ["control", 886], ["and", 894], ["public", 898], ["health", 905], ["policy", 912], [".", 918]]}
{"context": "The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Data were obtained from the Psocare Registry on those patients (n\u00a0=\u00a04946) with age >\u00a018\u00a0years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Latent tuberculosis infection was diagnosed in 8\u00b73% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4\u00b73% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen-ultraviolet A (P\u00a0<\u00a00\u00b705). Independent factors associated with LTBI were male sex [odds ratio (OR) 1\u00b730, 95% confidence interval (CI) 1\u00b704-1\u00b762; P\u00a0=\u00a00\u00b702], age over 55\u00a0years (OR 2\u00b793, 95% CI 2\u00b718-3\u00b793; P\u00a0<\u00a00\u00b7001) and being entered into a conventional treatment (OR 3\u00b783, 95% CI 3\u00b710-4\u00b774; P\u00a0<\u00a00\u00b7001). Positive history of tuberculosis was seen in 1% of patients (n\u00a0=\u00a049). The nationwide prevalence of LTBI in Italian patients with psoriasis candidate to systemic treatment is high, and screening is recommended prior to biological treatment.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "4edb95a363144efdb21977cc7f1912a8", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[104, 104], [5, 5], [101, 101], [250, 250]], "char_spans": [[615, 626], [36, 47], [594, 605], [1229, 1240]]}]}], "context_tokens": [["The", 0], ["nationwide", 4], ["prevalence", 15], ["of", 26], ["latent", 29], ["tuberculosis", 36], ["infection", 49], ["(", 59], ["LTBI", 60], [")", 64], ["in", 66], ["Italian", 69], ["patients", 77], ["with", 86], ["psoriasis", 91], ["has", 101], ["never", 105], ["been", 111], ["investigated", 116], [".", 128], ["To", 130], ["estimate", 133], ["the", 142], ["nationwide", 146], ["prevalence", 157], ["of", 168], ["LTBI", 171], ["in", 176], ["Italian", 179], ["patients", 187], ["with", 196], ["psoriasis", 201], ["who", 211], ["are", 215], ["candidates", 219], ["for", 230], ["systemic", 234], ["treatment", 243], [".", 252], ["Data", 254], ["were", 259], ["obtained", 264], ["from", 273], ["the", 278], ["Psocare", 282], ["Registry", 290], ["on", 299], ["those", 302], ["patients", 308], ["(", 317], ["n", 318], ["=", 320], ["4946", 322], [")", 326], ["with", 328], ["age", 333], [">", 337], ["18", 339], ["years", 342], [",", 347], ["systemic", 349], ["treatment", 358], ["at", 368], ["entry", 371], ["specified", 377], ["and", 387], ["tuberculin", 391], ["skin", 402], ["test", 407], ["(", 412], ["TST", 413], [")", 416], ["performed", 418], ["according", 428], ["to", 438], ["the", 441], ["Mantoux", 445], ["method", 453], [".", 459], ["LTBI", 461], ["diagnosis", 466], ["was", 476], ["based", 480], ["on", 486], ["a", 489], ["positive", 491], ["TST", 500], ["result", 504], ["in", 511], ["the", 514], ["absence", 518], ["of", 526], ["any", 529], ["clinical", 533], [",", 541], ["radiological", 543], ["or", 556], ["microbiological", 559], ["evidence", 575], ["of", 584], ["active", 587], ["tuberculosis", 594], [".", 606], ["Latent", 608], ["tuberculosis", 615], ["infection", 628], ["was", 638], ["diagnosed", 642], ["in", 652], ["8\u00b73", 655], ["%", 658], ["of", 660], ["patients", 663], ["with", 672], ["psoriasis", 677], ["(", 687], ["409", 688], ["of", 692], ["4946", 695], [")", 699], [".", 700], ["The", 702], ["prevalence", 706], ["of", 717], ["LTBI", 720], ["was", 725], ["lower", 729], ["in", 735], ["patients", 738], ["on", 747], ["biologics", 750], ["than", 760], ["in", 765], ["those", 768], ["on", 774], ["conventional", 777], ["systemic", 790], ["treatments", 799], [",", 809], ["ranging", 811], ["from", 819], ["4\u00b73", 824], ["%", 827], ["(", 829], ["19", 830], ["of", 833], ["444", 836], [")", 839], ["of", 841], ["patients", 844], ["on", 853], ["adalimumab", 856], ["to", 867], ["31", 870], ["%", 872], ["(", 874], ["eight", 875], ["of", 881], ["26", 884], [")", 886], ["of", 888], ["those", 891], ["on", 897], ["psoralen", 900], ["-", 908], ["ultraviolet", 909], ["A", 921], ["(", 923], ["P", 924], ["<", 926], ["0\u00b705", 928], [")", 932], [".", 933], ["Independent", 935], ["factors", 947], ["associated", 955], ["with", 966], ["LTBI", 971], ["were", 976], ["male", 981], ["sex", 986], ["[", 990], ["odds", 991], ["ratio", 996], ["(", 1002], ["OR", 1003], [")", 1005], ["1\u00b730", 1007], [",", 1011], ["95", 1013], ["%", 1015], ["confidence", 1017], ["interval", 1028], ["(", 1037], ["CI", 1038], [")", 1040], ["1\u00b704", 1042], ["-", 1046], ["1\u00b762", 1047], [";", 1051], ["P", 1053], ["=", 1055], ["0\u00b702", 1057], ["]", 1061], [",", 1062], ["age", 1064], ["over", 1068], ["55", 1073], ["years", 1076], ["(", 1082], ["OR", 1083], ["2\u00b793", 1086], [",", 1090], ["95", 1092], ["%", 1094], ["CI", 1096], ["2\u00b718", 1099], ["-", 1103], ["3\u00b793", 1104], [";", 1108], ["P", 1110], ["<", 1112], ["0\u00b7001", 1114], [")", 1119], ["and", 1121], ["being", 1125], ["entered", 1131], ["into", 1139], ["a", 1144], ["conventional", 1146], ["treatment", 1159], ["(", 1169], ["OR", 1170], ["3\u00b783", 1173], [",", 1177], ["95", 1179], ["%", 1181], ["CI", 1183], ["3\u00b710", 1186], ["-", 1190], ["4\u00b774", 1191], [";", 1195], ["P", 1197], ["<", 1199], ["0\u00b7001", 1201], [")", 1206], [".", 1207], ["Positive", 1209], ["history", 1218], ["of", 1226], ["tuberculosis", 1229], ["was", 1242], ["seen", 1246], ["in", 1251], ["1", 1254], ["%", 1255], ["of", 1257], ["patients", 1260], ["(", 1269], ["n", 1270], ["=", 1272], ["49", 1274], [")", 1276], [".", 1277], ["The", 1279], ["nationwide", 1283], ["prevalence", 1294], ["of", 1305], ["LTBI", 1308], ["in", 1313], ["Italian", 1316], ["patients", 1324], ["with", 1333], ["psoriasis", 1338], ["candidate", 1348], ["to", 1358], ["systemic", 1361], ["treatment", 1370], ["is", 1380], ["high", 1383], [",", 1387], ["and", 1389], ["screening", 1393], ["is", 1403], ["recommended", 1406], ["prior", 1418], ["to", 1424], ["biological", 1427], ["treatment", 1438], [".", 1447]]}
{"context": "The sodium-calcium exchanger (NCX) is one of the transporters contributing to the control of intracellular calcium (Ca(2+)) concentration by normally mediating net Ca(2+) efflux. However, the reverse mode of the NCX can cause intracellular Ca(2+) concentration overload, which exacerbates the myocardial tissue injury resulting from ischemia. Although the NCX inhibitor SEA0400 has been shown to therapeutically reduce myocardial injury, no in vivo technique exists to monitor intracellular Ca(2+) fluctuations produced by this drug. Cardiac manganese-enhanced MRI (MEMRI) may indirectly assess Ca(2+) efflux by estimating changes in manganese (Mn(2+)) content in vivo, since Mn(2+) has been suggested as a surrogate marker for Ca(2+). This study used the MEMRI technique to examine the temporal features of cardiac Mn(2+) efflux by implementing a T(1)-mapping method and inhibiting the NCX with SEA0400. The change in (1)H(2)O longitudinal relaxation rate, Delta R(1), in the left ventricular free wall, was calculated at different time points following infusion of 190 nmol/g manganese chloride (MnCl(2)) in healthy adult male mice. The results showed 50% MEMRI signal attenuation at 3.4 +/- 0.6 h post-MnCl(2) infusion without drug intervention. Furthermore, treatment with 50 +/- 0.2 mg/kg of SEA0400 significantly reduced the rate of decrease in Delta R(1). At 4.9-5.9 h post-MnCl(2) infusion, the average Delta R(1) values for the two groups treated with SEA0400 were 2.46 +/- 0.29 and 1.72 +/- 0.24 s(-1) for 50 and 20 mg/kg doses, respectively, as compared to the value of 1.27 +/- 0.28 s(-1) for the control group. When this in vivo data were compared to ex vivo absolute manganese content data, the MEMRI T(1)-mapping technique was shown to effectively quantify Mn(2+) efflux rates in the myocardium. Therefore, combining an NCX inhibitor with MEMRI may be a useful technique for assessing Mn(2+) transport mechanisms and rates in vivo, which may reflect changes in Ca(2+) transport.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "f0923f0865c044f8998e18a6c175e105", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[64, 64], [163, 163], [42, 42], [6, 6], [360, 360]], "char_spans": [[356, 358], [887, 889], [212, 214], [30, 32], [1835, 1837]]}]}], "context_tokens": [["The", 0], ["sodium", 4], ["-", 10], ["calcium", 11], ["exchanger", 19], ["(", 29], ["NCX", 30], [")", 33], ["is", 35], ["one", 38], ["of", 42], ["the", 45], ["transporters", 49], ["contributing", 62], ["to", 75], ["the", 78], ["control", 82], ["of", 90], ["intracellular", 93], ["calcium", 107], ["(", 115], ["Ca(2", 116], ["+", 120], [")", 121], [")", 122], ["concentration", 124], ["by", 138], ["normally", 141], ["mediating", 150], ["net", 160], ["Ca(2", 164], ["+", 168], [")", 169], ["efflux", 171], [".", 177], ["However", 179], [",", 186], ["the", 188], ["reverse", 192], ["mode", 200], ["of", 205], ["the", 208], ["NCX", 212], ["can", 216], ["cause", 220], ["intracellular", 226], ["Ca(2", 240], ["+", 244], [")", 245], ["concentration", 247], ["overload", 261], [",", 269], ["which", 271], ["exacerbates", 277], ["the", 289], ["myocardial", 293], ["tissue", 304], ["injury", 311], ["resulting", 318], ["from", 328], ["ischemia", 333], [".", 341], ["Although", 343], ["the", 352], ["NCX", 356], ["inhibitor", 360], ["SEA0400", 370], ["has", 378], ["been", 382], ["shown", 387], ["to", 393], ["therapeutically", 396], ["reduce", 412], ["myocardial", 419], ["injury", 430], [",", 436], ["no", 438], ["in", 441], ["vivo", 444], ["technique", 449], ["exists", 459], ["to", 466], ["monitor", 469], ["intracellular", 477], ["Ca(2", 491], ["+", 495], [")", 496], ["fluctuations", 498], ["produced", 511], ["by", 520], ["this", 523], ["drug", 528], [".", 532], ["Cardiac", 534], ["manganese", 542], ["-", 551], ["enhanced", 552], ["MRI", 561], ["(", 565], ["MEMRI", 566], [")", 571], ["may", 573], ["indirectly", 577], ["assess", 588], ["Ca(2", 595], ["+", 599], [")", 600], ["efflux", 602], ["by", 609], ["estimating", 612], ["changes", 623], ["in", 631], ["manganese", 634], ["(", 644], ["Mn(2", 645], ["+", 649], [")", 650], [")", 651], ["content", 653], ["in", 661], ["vivo", 664], [",", 668], ["since", 670], ["Mn(2", 676], ["+", 680], [")", 681], ["has", 683], ["been", 687], ["suggested", 692], ["as", 702], ["a", 705], ["surrogate", 707], ["marker", 717], ["for", 724], ["Ca(2", 728], ["+", 732], [")", 733], [".", 734], ["This", 736], ["study", 741], ["used", 747], ["the", 752], ["MEMRI", 756], ["technique", 762], ["to", 772], ["examine", 775], ["the", 783], ["temporal", 787], ["features", 796], ["of", 805], ["cardiac", 808], ["Mn(2", 816], ["+", 820], [")", 821], ["efflux", 823], ["by", 830], ["implementing", 833], ["a", 846], ["T(1)-mapping", 848], ["method", 861], ["and", 868], ["inhibiting", 872], ["the", 883], ["NCX", 887], ["with", 891], ["SEA0400", 896], [".", 903], ["The", 905], ["change", 909], ["in", 916], ["(", 919], ["1)H(2)O", 920], ["longitudinal", 928], ["relaxation", 941], ["rate", 952], [",", 956], ["Delta", 958], ["R(1", 964], [")", 967], [",", 968], ["in", 970], ["the", 973], ["left", 977], ["ventricular", 982], ["free", 994], ["wall", 999], [",", 1003], ["was", 1005], ["calculated", 1009], ["at", 1020], ["different", 1023], ["time", 1033], ["points", 1038], ["following", 1045], ["infusion", 1055], ["of", 1064], ["190", 1067], ["nmol", 1071], ["/", 1075], ["g", 1076], ["manganese", 1078], ["chloride", 1088], ["(", 1097], ["MnCl(2", 1098], [")", 1104], [")", 1105], ["in", 1107], ["healthy", 1110], ["adult", 1118], ["male", 1124], ["mice", 1129], [".", 1133], ["The", 1135], ["results", 1139], ["showed", 1147], ["50", 1154], ["%", 1156], ["MEMRI", 1158], ["signal", 1164], ["attenuation", 1171], ["at", 1183], ["3.4", 1186], ["+", 1190], ["/-", 1191], ["0.6", 1194], ["h", 1198], ["post", 1200], ["-", 1204], ["MnCl(2", 1205], [")", 1211], ["infusion", 1213], ["without", 1222], ["drug", 1230], ["intervention", 1235], [".", 1247], ["Furthermore", 1249], [",", 1260], ["treatment", 1262], ["with", 1272], ["50", 1277], ["+", 1280], ["/-", 1281], ["0.2", 1284], ["mg", 1288], ["/", 1290], ["kg", 1291], ["of", 1294], ["SEA0400", 1297], ["significantly", 1305], ["reduced", 1319], ["the", 1327], ["rate", 1331], ["of", 1336], ["decrease", 1339], ["in", 1348], ["Delta", 1351], ["R(1", 1357], [")", 1360], [".", 1361], ["At", 1363], ["4.9", 1366], ["-", 1369], ["5.9", 1370], ["h", 1374], ["post", 1376], ["-", 1380], ["MnCl(2", 1381], [")", 1387], ["infusion", 1389], [",", 1397], ["the", 1399], ["average", 1403], ["Delta", 1411], ["R(1", 1417], [")", 1420], ["values", 1422], ["for", 1429], ["the", 1433], ["two", 1437], ["groups", 1441], ["treated", 1448], ["with", 1456], ["SEA0400", 1461], ["were", 1469], ["2.46", 1474], ["+", 1479], ["/-", 1480], ["0.29", 1483], ["and", 1488], ["1.72", 1492], ["+", 1497], ["/-", 1498], ["0.24", 1501], ["s(-1", 1506], [")", 1510], ["for", 1512], ["50", 1516], ["and", 1519], ["20", 1523], ["mg", 1526], ["/", 1528], ["kg", 1529], ["doses", 1532], [",", 1537], ["respectively", 1539], [",", 1551], ["as", 1553], ["compared", 1556], ["to", 1565], ["the", 1568], ["value", 1572], ["of", 1578], ["1.27", 1581], ["+", 1586], ["/-", 1587], ["0.28", 1590], ["s(-1", 1595], [")", 1599], ["for", 1601], ["the", 1605], ["control", 1609], ["group", 1617], [".", 1622], ["When", 1624], ["this", 1629], ["in", 1634], ["vivo", 1637], ["data", 1642], ["were", 1647], ["compared", 1652], ["to", 1661], ["ex", 1664], ["vivo", 1667], ["absolute", 1672], ["manganese", 1681], ["content", 1691], ["data", 1699], [",", 1703], ["the", 1705], ["MEMRI", 1709], ["T(1)-mapping", 1715], ["technique", 1728], ["was", 1738], ["shown", 1742], ["to", 1748], ["effectively", 1751], ["quantify", 1763], ["Mn(2", 1772], ["+", 1776], [")", 1777], ["efflux", 1779], ["rates", 1786], ["in", 1792], ["the", 1795], ["myocardium", 1799], [".", 1809], ["Therefore", 1811], [",", 1820], ["combining", 1822], ["an", 1832], ["NCX", 1835], ["inhibitor", 1839], ["with", 1849], ["MEMRI", 1854], ["may", 1860], ["be", 1864], ["a", 1867], ["useful", 1869], ["technique", 1876], ["for", 1886], ["assessing", 1890], ["Mn(2", 1900], ["+", 1904], [")", 1905], ["transport", 1907], ["mechanisms", 1917], ["and", 1928], ["rates", 1932], ["in", 1938], ["vivo", 1941], [",", 1945], ["which", 1947], ["may", 1953], ["reflect", 1957], ["changes", 1965], ["in", 1973], ["Ca(2", 1976], ["+", 1980], [")", 1981], ["transport", 1983], [".", 1992]]}
{"context": "Protein kinases (PKs) and lipid kinases (LKs) are good choices for targets of signal transduction therapy as these enzymes are involved in signaling pathways, and are often related to the pathogenesis of lymphoid malignancies. The attractiveness of PKs and LKs as drug able targets is enhanced by the fact that they are enzymes whose biological activity can be turned off by drugs that block their catalytic site. In the last few years small molecular kinase inhibitors (KIs) have been synthesized and become available for preclinical studies and clinical trials. The first KI, introduced into clinical practice in 1998, was imatinib mesylate, which became the first choice drug in chronic myeloid leukemia. More recently, several KIs have been developed to target the proximal B-cell receptor (BCR) signaling pathway including spleen tyrosine kinase inhibitor (Fostamatinib) and Bruton's tyrosine kinase inhibitors (Ibrutinib, AVL-263). These agents are currently evaluated in early clinical trials in chronic lymphocytic leukemia (CLL) and other diseases. Cyclin-dependent kinase (Cdk) inhibitors, flavopiridol (alvocidib), BMS-387032 (SNS-032), sunitinib and sorafenib are currently under evaluation in clinical trials for relapsed/refractory CLL. Multi-tyrosine kinase inhibitors including vandetanib (ZD6474) bosutinib (SKI-606), TKI258 (CHIR-258), pazopanib (GW786034) and axitinib (AG013736) have been also developed for the treatment of lymphoid malignancies. Phosphatidylinositol 3-kinases (PI3K ) are a family of lipid kinases that mediate signals from cell surface receptors. CAL-101 (GS-1101) is an oral PI3K\u03b4-specific inhibitor which has shown preclinical and clinical activity against CLL. This article summarizes recent achievements in the mechanism of action, pharmacological properties and clinical activity and toxicity of PK and LK inhibitors in CLL.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "1eb2d0fe88414c37812859c1e4d6e1b5", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[161, 161]], "char_spans": [[917, 925]]}]}], "context_tokens": [["Protein", 0], ["kinases", 8], ["(", 16], ["PKs", 17], [")", 20], ["and", 22], ["lipid", 26], ["kinases", 32], ["(", 40], ["LKs", 41], [")", 44], ["are", 46], ["good", 50], ["choices", 55], ["for", 63], ["targets", 67], ["of", 75], ["signal", 78], ["transduction", 85], ["therapy", 98], ["as", 106], ["these", 109], ["enzymes", 115], ["are", 123], ["involved", 127], ["in", 136], ["signaling", 139], ["pathways", 149], [",", 157], ["and", 159], ["are", 163], ["often", 167], ["related", 173], ["to", 181], ["the", 184], ["pathogenesis", 188], ["of", 201], ["lymphoid", 204], ["malignancies", 213], [".", 225], ["The", 227], ["attractiveness", 231], ["of", 246], ["PKs", 249], ["and", 253], ["LKs", 257], ["as", 261], ["drug", 264], ["able", 269], ["targets", 274], ["is", 282], ["enhanced", 285], ["by", 294], ["the", 297], ["fact", 301], ["that", 306], ["they", 311], ["are", 316], ["enzymes", 320], ["whose", 328], ["biological", 334], ["activity", 345], ["can", 354], ["be", 358], ["turned", 361], ["off", 368], ["by", 372], ["drugs", 375], ["that", 381], ["block", 386], ["their", 392], ["catalytic", 398], ["site", 408], [".", 412], ["In", 414], ["the", 417], ["last", 421], ["few", 426], ["years", 430], ["small", 436], ["molecular", 442], ["kinase", 452], ["inhibitors", 459], ["(", 470], ["KIs", 471], [")", 474], ["have", 476], ["been", 481], ["synthesized", 486], ["and", 498], ["become", 502], ["available", 509], ["for", 519], ["preclinical", 523], ["studies", 535], ["and", 543], ["clinical", 547], ["trials", 556], [".", 562], ["The", 564], ["first", 568], ["KI", 574], [",", 576], ["introduced", 578], ["into", 589], ["clinical", 594], ["practice", 603], ["in", 612], ["1998", 615], [",", 619], ["was", 621], ["imatinib", 625], ["mesylate", 634], [",", 642], ["which", 644], ["became", 650], ["the", 657], ["first", 661], ["choice", 667], ["drug", 674], ["in", 679], ["chronic", 682], ["myeloid", 690], ["leukemia", 698], [".", 706], ["More", 708], ["recently", 713], [",", 721], ["several", 723], ["KIs", 731], ["have", 735], ["been", 740], ["developed", 745], ["to", 755], ["target", 758], ["the", 765], ["proximal", 769], ["B", 778], ["-", 779], ["cell", 780], ["receptor", 785], ["(", 794], ["BCR", 795], [")", 798], ["signaling", 800], ["pathway", 810], ["including", 818], ["spleen", 828], ["tyrosine", 835], ["kinase", 844], ["inhibitor", 851], ["(", 861], ["Fostamatinib", 862], [")", 874], ["and", 876], ["Bruton", 880], ["'s", 886], ["tyrosine", 889], ["kinase", 898], ["inhibitors", 905], ["(", 916], ["Ibrutinib", 917], [",", 926], ["AVL-263", 928], [")", 935], [".", 936], ["These", 938], ["agents", 944], ["are", 951], ["currently", 955], ["evaluated", 965], ["in", 975], ["early", 978], ["clinical", 984], ["trials", 993], ["in", 1000], ["chronic", 1003], ["lymphocytic", 1011], ["leukemia", 1023], ["(", 1032], ["CLL", 1033], [")", 1036], ["and", 1038], ["other", 1042], ["diseases", 1048], [".", 1056], ["Cyclin", 1058], ["-", 1064], ["dependent", 1065], ["kinase", 1075], ["(", 1082], ["Cdk", 1083], [")", 1086], ["inhibitors", 1088], [",", 1098], ["flavopiridol", 1100], ["(", 1113], ["alvocidib", 1114], [")", 1123], [",", 1124], ["BMS-387032", 1126], ["(", 1137], ["SNS-032", 1138], [")", 1145], [",", 1146], ["sunitinib", 1148], ["and", 1158], ["sorafenib", 1162], ["are", 1172], ["currently", 1176], ["under", 1186], ["evaluation", 1192], ["in", 1203], ["clinical", 1206], ["trials", 1215], ["for", 1222], ["relapsed", 1226], ["/", 1234], ["refractory", 1235], ["CLL", 1246], [".", 1249], ["Multi", 1251], ["-", 1256], ["tyrosine", 1257], ["kinase", 1266], ["inhibitors", 1273], ["including", 1284], ["vandetanib", 1294], ["(", 1305], ["ZD6474", 1306], [")", 1312], ["bosutinib", 1314], ["(", 1324], ["SKI-606", 1325], [")", 1332], [",", 1333], ["TKI258", 1335], ["(", 1342], ["CHIR-258", 1343], [")", 1351], [",", 1352], ["pazopanib", 1354], ["(", 1364], ["GW786034", 1365], [")", 1373], ["and", 1375], ["axitinib", 1379], ["(", 1388], ["AG013736", 1389], [")", 1397], ["have", 1399], ["been", 1404], ["also", 1409], ["developed", 1414], ["for", 1424], ["the", 1428], ["treatment", 1432], ["of", 1442], ["lymphoid", 1445], ["malignancies", 1454], [".", 1466], ["Phosphatidylinositol", 1468], ["3-kinases", 1489], ["(", 1499], ["PI3", 1500], ["K", 1503], [")", 1505], ["are", 1507], ["a", 1511], ["family", 1513], ["of", 1520], ["lipid", 1523], ["kinases", 1529], ["that", 1537], ["mediate", 1542], ["signals", 1550], ["from", 1558], ["cell", 1563], ["surface", 1568], ["receptors", 1576], [".", 1585], ["CAL-101", 1587], ["(", 1595], ["GS-1101", 1596], [")", 1603], ["is", 1605], ["an", 1608], ["oral", 1611], ["PI3K\u03b4", 1616], ["-", 1621], ["specific", 1622], ["inhibitor", 1631], ["which", 1641], ["has", 1647], ["shown", 1651], ["preclinical", 1657], ["and", 1669], ["clinical", 1673], ["activity", 1682], ["against", 1691], ["CLL", 1699], [".", 1702], ["This", 1704], ["article", 1709], ["summarizes", 1717], ["recent", 1728], ["achievements", 1735], ["in", 1748], ["the", 1751], ["mechanism", 1755], ["of", 1765], ["action", 1768], [",", 1774], ["pharmacological", 1776], ["properties", 1792], ["and", 1803], ["clinical", 1807], ["activity", 1816], ["and", 1825], ["toxicity", 1829], ["of", 1838], ["PK", 1841], ["and", 1844], ["LK", 1848], ["inhibitors", 1851], ["in", 1862], ["CLL", 1865], [".", 1868]]}
{"context": "Lewy body disease is a heterogeneous group of neurodegenerative disorders characterized by alpha-synuclein accumulation that includes dementia with Lewy bodies (DLB) and Parkinson's Disease (PD). Recent evidence suggests that impairment of lysosomal pathways (i.e. autophagy) involved in alpha-synuclein clearance might play an important role. For this reason, we sought to examine the expression levels of members of the autophagy pathway in brains of patients with DLB and Alzheimer's Disease (AD) and in alpha-synuclein transgenic mice. By immunoblot analysis, compared to controls and AD, in DLB cases levels of mTor were elevated and Atg7 were reduced. Levels of other components of the autophagy pathway such as Atg5, Atg10, Atg12 and Beclin-1 were not different in DLB compared to controls. In DLB brains, mTor was more abundant in neurons displaying alpha-synuclein accumulation. These neurons also showed abnormal expression of lysosomal markers such as LC3, and ultrastructural analysis revealed the presence of abundant and abnormal autophagosomes. Similar alterations were observed in the brains of alpha-synuclein transgenic mice. Intra-cerebral infusion of rapamycin, an inhibitor of mTor, or injection of a lentiviral vector expressing Atg7 resulted in reduced accumulation of alpha-synuclein in transgenic mice and amelioration of associated neurodegenerative alterations. This study supports the notion that defects in the autophagy pathway and more specifically in mTor and Atg7 are associated with neurodegeneration in DLB cases and alpha-synuclein transgenic models and supports the possibility that modulators of the autophagy pathway might have potential therapeutic effects.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "2fa17a29be5d4cdb8b61ce90ede60e4a", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[26, 30]], "char_spans": [[170, 192]]}]}], "context_tokens": [["Lewy", 0], ["body", 5], ["disease", 10], ["is", 18], ["a", 21], ["heterogeneous", 23], ["group", 37], ["of", 43], ["neurodegenerative", 46], ["disorders", 64], ["characterized", 74], ["by", 88], ["alpha", 91], ["-", 96], ["synuclein", 97], ["accumulation", 107], ["that", 120], ["includes", 125], ["dementia", 134], ["with", 143], ["Lewy", 148], ["bodies", 153], ["(", 160], ["DLB", 161], [")", 164], ["and", 166], ["Parkinson", 170], ["'s", 179], ["Disease", 182], ["(", 190], ["PD", 191], [")", 193], [".", 194], ["Recent", 196], ["evidence", 203], ["suggests", 212], ["that", 221], ["impairment", 226], ["of", 237], ["lysosomal", 240], ["pathways", 250], ["(", 259], ["i.e.", 260], ["autophagy", 265], [")", 274], ["involved", 276], ["in", 285], ["alpha", 288], ["-", 293], ["synuclein", 294], ["clearance", 304], ["might", 314], ["play", 320], ["an", 325], ["important", 328], ["role", 338], [".", 342], ["For", 344], ["this", 348], ["reason", 353], [",", 359], ["we", 361], ["sought", 364], ["to", 371], ["examine", 374], ["the", 382], ["expression", 386], ["levels", 397], ["of", 404], ["members", 407], ["of", 415], ["the", 418], ["autophagy", 422], ["pathway", 432], ["in", 440], ["brains", 443], ["of", 450], ["patients", 453], ["with", 462], ["DLB", 467], ["and", 471], ["Alzheimer", 475], ["'s", 484], ["Disease", 487], ["(", 495], ["AD", 496], [")", 498], ["and", 500], ["in", 504], ["alpha", 507], ["-", 512], ["synuclein", 513], ["transgenic", 523], ["mice", 534], [".", 538], ["By", 540], ["immunoblot", 543], ["analysis", 554], [",", 562], ["compared", 564], ["to", 573], ["controls", 576], ["and", 585], ["AD", 589], [",", 591], ["in", 593], ["DLB", 596], ["cases", 600], ["levels", 606], ["of", 613], ["mTor", 616], ["were", 621], ["elevated", 626], ["and", 635], ["Atg7", 639], ["were", 644], ["reduced", 649], [".", 656], ["Levels", 658], ["of", 665], ["other", 668], ["components", 674], ["of", 685], ["the", 688], ["autophagy", 692], ["pathway", 702], ["such", 710], ["as", 715], ["Atg5", 718], [",", 722], ["Atg10", 724], [",", 729], ["Atg12", 731], ["and", 737], ["Beclin-1", 741], ["were", 750], ["not", 755], ["different", 759], ["in", 769], ["DLB", 772], ["compared", 776], ["to", 785], ["controls", 788], [".", 796], ["In", 798], ["DLB", 801], ["brains", 805], [",", 811], ["mTor", 813], ["was", 818], ["more", 822], ["abundant", 827], ["in", 836], ["neurons", 839], ["displaying", 847], ["alpha", 858], ["-", 863], ["synuclein", 864], ["accumulation", 874], [".", 886], ["These", 888], ["neurons", 894], ["also", 902], ["showed", 907], ["abnormal", 914], ["expression", 923], ["of", 934], ["lysosomal", 937], ["markers", 947], ["such", 955], ["as", 960], ["LC3", 963], [",", 966], ["and", 968], ["ultrastructural", 972], ["analysis", 988], ["revealed", 997], ["the", 1006], ["presence", 1010], ["of", 1019], ["abundant", 1022], ["and", 1031], ["abnormal", 1035], ["autophagosomes", 1044], [".", 1058], ["Similar", 1060], ["alterations", 1068], ["were", 1080], ["observed", 1085], ["in", 1094], ["the", 1097], ["brains", 1101], ["of", 1108], ["alpha", 1111], ["-", 1116], ["synuclein", 1117], ["transgenic", 1127], ["mice", 1138], [".", 1142], ["Intra", 1144], ["-", 1149], ["cerebral", 1150], ["infusion", 1159], ["of", 1168], ["rapamycin", 1171], [",", 1180], ["an", 1182], ["inhibitor", 1185], ["of", 1195], ["mTor", 1198], [",", 1202], ["or", 1204], ["injection", 1207], ["of", 1217], ["a", 1220], ["lentiviral", 1222], ["vector", 1233], ["expressing", 1240], ["Atg7", 1251], ["resulted", 1256], ["in", 1265], ["reduced", 1268], ["accumulation", 1276], ["of", 1289], ["alpha", 1292], ["-", 1297], ["synuclein", 1298], ["in", 1308], ["transgenic", 1311], ["mice", 1322], ["and", 1327], ["amelioration", 1331], ["of", 1344], ["associated", 1347], ["neurodegenerative", 1358], ["alterations", 1376], [".", 1387], ["This", 1389], ["study", 1394], ["supports", 1400], ["the", 1409], ["notion", 1413], ["that", 1420], ["defects", 1425], ["in", 1433], ["the", 1436], ["autophagy", 1440], ["pathway", 1450], ["and", 1458], ["more", 1462], ["specifically", 1467], ["in", 1480], ["mTor", 1483], ["and", 1488], ["Atg7", 1492], ["are", 1497], ["associated", 1501], ["with", 1512], ["neurodegeneration", 1517], ["in", 1535], ["DLB", 1538], ["cases", 1542], ["and", 1548], ["alpha", 1552], ["-", 1557], ["synuclein", 1558], ["transgenic", 1568], ["models", 1579], ["and", 1586], ["supports", 1590], ["the", 1599], ["possibility", 1603], ["that", 1615], ["modulators", 1620], ["of", 1631], ["the", 1634], ["autophagy", 1638], ["pathway", 1648], ["might", 1656], ["have", 1662], ["potential", 1667], ["therapeutic", 1677], ["effects", 1689], [".", 1696]]}
{"context": "Chediak-Higashi syndrome (CHS) is an inherited immunodeficiency disease characterized by giant lysosomes and impaired leukocyte degranulation. CHS results from mutations in the lysosomal trafficking regulator (LYST) gene, which encodes a 425-kD cytoplasmic protein of unknown function. The goal of this study was to identify proteins that interact with LYST as a first step in understanding how LYST modulates lysosomal exocytosis. Fourteen cDNA fragments, covering the entire coding domain of LYST, were used as baits to screen five human cDNA libraries by a yeast two-hybrid method, modified to allow screening in the activation and the binding domain, three selectable markers, and more stringent confirmation procedures. Five of the interactions were confirmed by an in vitro binding assay. Twenty-one proteins that interact with LYST were identified in yeast two-hybrid screens. Four interactions, confirmed directly, were with proteins important in vesicular transport and signal transduction (the SNARE-complex protein HRS, 14-3-3, and casein kinase II). On the basis of protein interactions, LYST appears to function as an adapter protein that may juxtapose proteins that mediate intracellular membrane fusion reactions. The pathologic manifestations observed in CHS patients and in mice with the homologous mutation beige suggest that understanding the role of LYST may be relevant to the treatment of not only CHS but also of diseases such as asthma, urticaria, and lupus, as well as to the molecular dissection of the CHS-associated cancer predisposition.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "6a6c0c5ae87d4079ad03b0e1d5ecdd40", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["an", 34], ["inherited", 37], ["immunodeficiency", 47], ["disease", 64], ["characterized", 72], ["by", 86], ["giant", 89], ["lysosomes", 95], ["and", 105], ["impaired", 109], ["leukocyte", 118], ["degranulation", 128], [".", 141], ["CHS", 143], ["results", 147], ["from", 155], ["mutations", 160], ["in", 170], ["the", 173], ["lysosomal", 177], ["trafficking", 187], ["regulator", 199], ["(", 209], ["LYST", 210], [")", 214], ["gene", 216], [",", 220], ["which", 222], ["encodes", 228], ["a", 236], ["425-kD", 238], ["cytoplasmic", 245], ["protein", 257], ["of", 265], ["unknown", 268], ["function", 276], [".", 284], ["The", 286], ["goal", 290], ["of", 295], ["this", 298], ["study", 303], ["was", 309], ["to", 313], ["identify", 316], ["proteins", 325], ["that", 334], ["interact", 339], ["with", 348], ["LYST", 353], ["as", 358], ["a", 361], ["first", 363], ["step", 369], ["in", 374], ["understanding", 377], ["how", 391], ["LYST", 395], ["modulates", 400], ["lysosomal", 410], ["exocytosis", 420], [".", 430], ["Fourteen", 432], ["cDNA", 441], ["fragments", 446], [",", 455], ["covering", 457], ["the", 466], ["entire", 470], ["coding", 477], ["domain", 484], ["of", 491], ["LYST", 494], [",", 498], ["were", 500], ["used", 505], ["as", 510], ["baits", 513], ["to", 519], ["screen", 522], ["five", 529], ["human", 534], ["cDNA", 540], ["libraries", 545], ["by", 555], ["a", 558], ["yeast", 560], ["two", 566], ["-", 569], ["hybrid", 570], ["method", 577], [",", 583], ["modified", 585], ["to", 594], ["allow", 597], ["screening", 603], ["in", 613], ["the", 616], ["activation", 620], ["and", 631], ["the", 635], ["binding", 639], ["domain", 647], [",", 653], ["three", 655], ["selectable", 661], ["markers", 672], [",", 679], ["and", 681], ["more", 685], ["stringent", 690], ["confirmation", 700], ["procedures", 713], [".", 723], ["Five", 725], ["of", 730], ["the", 733], ["interactions", 737], ["were", 750], ["confirmed", 755], ["by", 765], ["an", 768], ["in", 771], ["vitro", 774], ["binding", 780], ["assay", 788], [".", 793], ["Twenty", 795], ["-", 801], ["one", 802], ["proteins", 806], ["that", 815], ["interact", 820], ["with", 829], ["LYST", 834], ["were", 839], ["identified", 844], ["in", 855], ["yeast", 858], ["two", 864], ["-", 867], ["hybrid", 868], ["screens", 875], [".", 882], ["Four", 884], ["interactions", 889], [",", 901], ["confirmed", 903], ["directly", 913], [",", 921], ["were", 923], ["with", 928], ["proteins", 933], ["important", 942], ["in", 952], ["vesicular", 955], ["transport", 965], ["and", 975], ["signal", 979], ["transduction", 986], ["(", 999], ["the", 1000], ["SNARE", 1004], ["-", 1009], ["complex", 1010], ["protein", 1018], ["HRS", 1026], [",", 1029], ["14", 1031], ["-", 1033], ["3", 1034], ["-", 1035], ["3", 1036], [",", 1037], ["and", 1039], ["casein", 1043], ["kinase", 1050], ["II", 1057], [")", 1059], [".", 1060], ["On", 1062], ["the", 1065], ["basis", 1069], ["of", 1075], ["protein", 1078], ["interactions", 1086], [",", 1098], ["LYST", 1100], ["appears", 1105], ["to", 1113], ["function", 1116], ["as", 1125], ["an", 1128], ["adapter", 1131], ["protein", 1139], ["that", 1147], ["may", 1152], ["juxtapose", 1156], ["proteins", 1166], ["that", 1175], ["mediate", 1180], ["intracellular", 1188], ["membrane", 1202], ["fusion", 1211], ["reactions", 1218], [".", 1227], ["The", 1229], ["pathologic", 1233], ["manifestations", 1244], ["observed", 1259], ["in", 1268], ["CHS", 1271], ["patients", 1275], ["and", 1284], ["in", 1288], ["mice", 1291], ["with", 1296], ["the", 1301], ["homologous", 1305], ["mutation", 1316], ["beige", 1325], ["suggest", 1331], ["that", 1339], ["understanding", 1344], ["the", 1358], ["role", 1362], ["of", 1367], ["LYST", 1370], ["may", 1375], ["be", 1379], ["relevant", 1382], ["to", 1391], ["the", 1394], ["treatment", 1398], ["of", 1408], ["not", 1411], ["only", 1415], ["CHS", 1420], ["but", 1424], ["also", 1428], ["of", 1433], ["diseases", 1436], ["such", 1445], ["as", 1450], ["asthma", 1453], [",", 1459], ["urticaria", 1461], [",", 1470], ["and", 1472], ["lupus", 1476], [",", 1481], ["as", 1483], ["well", 1486], ["as", 1491], ["to", 1494], ["the", 1497], ["molecular", 1501], ["dissection", 1511], ["of", 1522], ["the", 1525], ["CHS", 1529], ["-", 1532], ["associated", 1533], ["cancer", 1544], ["predisposition", 1551], [".", 1565]]}
{"context": "Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by extracellular plaques containing amyloid \u03b2 (A\u03b2)-protein and intracellular tangles containing hyperphosphorylated Tau protein. Here, we describe the generation of inducible pluripotent stem cell lines from patients harboring the London familial AD (fAD) amyloid precursor protein (APP) mutation (V717I). We examine AD-relevant phenotypes following directed differentiation to forebrain neuronal fates vulnerable in AD. We observe that over differentiation time to mature neuronal fates, APP expression and levels of A\u03b2 increase dramatically. In both immature and mature neuronal fates, the APPV717I mutation affects both \u03b2- and \u03b3-secretase cleavage of APP. Although the mutation lies near the \u03b3-secretase cleavage site in the transmembrane domain of APP, we find that \u03b2-secretase cleavage of APP is elevated leading to generation of increased levels of both APPs\u03b2 and A\u03b2. Furthermore, we find that this mutation alters the initial cleavage site of \u03b3-secretase, resulting in an increased generation of both A\u03b242 and A\u03b238. In addition to altered APP processing, an increase in levels of total and phosphorylated Tau is observed in neurons with the APPV717I mutation. We show that treatment with A\u03b2-specific antibodies early in culture reverses the phenotype of increased total Tau levels, implicating altered A\u03b2 production in fAD neurons in this phenotype. These studies use human neurons to reveal previously unrecognized effects of the most common fAD APP mutation and provide a model system for testing therapeutic strategies in the cell types most relevant to disease processes.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "cded98aedc6a494e8a1a1d00dd9f85aa", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "AD", "token_spans": [[4, 4], [76, 76], [63, 63], [46, 46]], "char_spans": [[21, 22], [496, 497], [396, 397], [326, 327]]}]}], "context_tokens": [["Alzheimer", 0], ["'s", 9], ["disease", 12], ["(", 20], ["AD", 21], [")", 23], ["is", 25], ["a", 28], ["complex", 30], ["neurodegenerative", 38], ["disorder", 56], ["characterized", 65], ["by", 79], ["extracellular", 82], ["plaques", 96], ["containing", 104], ["amyloid", 115], ["\u03b2", 123], ["(", 125], ["A\u03b2)-protein", 126], ["and", 138], ["intracellular", 142], ["tangles", 156], ["containing", 164], ["hyperphosphorylated", 175], ["Tau", 195], ["protein", 199], [".", 206], ["Here", 208], [",", 212], ["we", 214], ["describe", 217], ["the", 226], ["generation", 230], ["of", 241], ["inducible", 244], ["pluripotent", 254], ["stem", 266], ["cell", 271], ["lines", 276], ["from", 282], ["patients", 287], ["harboring", 296], ["the", 306], ["London", 310], ["familial", 317], ["AD", 326], ["(", 329], ["fAD", 330], [")", 333], ["amyloid", 335], ["precursor", 343], ["protein", 353], ["(", 361], ["APP", 362], [")", 365], ["mutation", 367], ["(", 376], ["V717I", 377], [")", 382], [".", 383], ["We", 385], ["examine", 388], ["AD", 396], ["-", 398], ["relevant", 399], ["phenotypes", 408], ["following", 419], ["directed", 429], ["differentiation", 438], ["to", 454], ["forebrain", 457], ["neuronal", 467], ["fates", 476], ["vulnerable", 482], ["in", 493], ["AD", 496], [".", 498], ["We", 500], ["observe", 503], ["that", 511], ["over", 516], ["differentiation", 521], ["time", 537], ["to", 542], ["mature", 545], ["neuronal", 552], ["fates", 561], [",", 566], ["APP", 568], ["expression", 572], ["and", 583], ["levels", 587], ["of", 594], ["A\u03b2", 597], ["increase", 600], ["dramatically", 609], [".", 621], ["In", 623], ["both", 626], ["immature", 631], ["and", 640], ["mature", 644], ["neuronal", 651], ["fates", 660], [",", 665], ["the", 667], ["APPV717I", 671], ["mutation", 680], ["affects", 689], ["both", 697], ["\u03b2-", 702], ["and", 705], ["\u03b3", 709], ["-", 710], ["secretase", 711], ["cleavage", 721], ["of", 730], ["APP", 733], [".", 736], ["Although", 738], ["the", 747], ["mutation", 751], ["lies", 760], ["near", 765], ["the", 770], ["\u03b3", 774], ["-", 775], ["secretase", 776], ["cleavage", 786], ["site", 795], ["in", 800], ["the", 803], ["transmembrane", 807], ["domain", 821], ["of", 828], ["APP", 831], [",", 834], ["we", 836], ["find", 839], ["that", 844], ["\u03b2", 849], ["-", 850], ["secretase", 851], ["cleavage", 861], ["of", 870], ["APP", 873], ["is", 877], ["elevated", 880], ["leading", 889], ["to", 897], ["generation", 900], ["of", 911], ["increased", 914], ["levels", 924], ["of", 931], ["both", 934], ["APPs\u03b2", 939], ["and", 945], ["A\u03b2", 949], [".", 951], ["Furthermore", 953], [",", 964], ["we", 966], ["find", 969], ["that", 974], ["this", 979], ["mutation", 984], ["alters", 993], ["the", 1000], ["initial", 1004], ["cleavage", 1012], ["site", 1021], ["of", 1026], ["\u03b3", 1029], ["-", 1030], ["secretase", 1031], [",", 1040], ["resulting", 1042], ["in", 1052], ["an", 1055], ["increased", 1058], ["generation", 1068], ["of", 1079], ["both", 1082], ["A\u03b242", 1087], ["and", 1092], ["A\u03b238", 1096], [".", 1100], ["In", 1102], ["addition", 1105], ["to", 1114], ["altered", 1117], ["APP", 1125], ["processing", 1129], [",", 1139], ["an", 1141], ["increase", 1144], ["in", 1153], ["levels", 1156], ["of", 1163], ["total", 1166], ["and", 1172], ["phosphorylated", 1176], ["Tau", 1191], ["is", 1195], ["observed", 1198], ["in", 1207], ["neurons", 1210], ["with", 1218], ["the", 1223], ["APPV717I", 1227], ["mutation", 1236], [".", 1244], ["We", 1246], ["show", 1249], ["that", 1254], ["treatment", 1259], ["with", 1269], ["A\u03b2", 1274], ["-", 1276], ["specific", 1277], ["antibodies", 1286], ["early", 1297], ["in", 1303], ["culture", 1306], ["reverses", 1314], ["the", 1323], ["phenotype", 1327], ["of", 1337], ["increased", 1340], ["total", 1350], ["Tau", 1356], ["levels", 1360], [",", 1366], ["implicating", 1368], ["altered", 1380], ["A\u03b2", 1388], ["production", 1391], ["in", 1402], ["fAD", 1405], ["neurons", 1409], ["in", 1417], ["this", 1420], ["phenotype", 1425], [".", 1434], ["These", 1436], ["studies", 1442], ["use", 1450], ["human", 1454], ["neurons", 1460], ["to", 1468], ["reveal", 1471], ["previously", 1478], ["unrecognized", 1489], ["effects", 1502], ["of", 1510], ["the", 1513], ["most", 1517], ["common", 1522], ["fAD", 1529], ["APP", 1533], ["mutation", 1537], ["and", 1546], ["provide", 1550], ["a", 1558], ["model", 1560], ["system", 1566], ["for", 1573], ["testing", 1577], ["therapeutic", 1585], ["strategies", 1597], ["in", 1608], ["the", 1611], ["cell", 1615], ["types", 1620], ["most", 1626], ["relevant", 1631], ["to", 1640], ["disease", 1643], ["processes", 1651], [".", 1660]]}
{"context": "Epigenetic modifications of histones regulate gene expression and chromatin structure. Here we show that Meisetz (meiosis-induced factor containing a PR/SET domain and zinc-finger motif) is a histone methyltransferase that is important for the progression of early meiotic prophase. Meisetz transcripts are detected only in germ cells entering meiotic prophase in female fetal gonads and in postnatal testis. Notably, Meisetz has catalytic activity for trimethylation, but not mono- or dimethylation, of lysine 4 of histone H3, and a transactivation activity that depends on its methylation activity. Mice in which the Meisetz gene is disrupted show sterility in both sexes due to severe impairment of the double-stranded break repair pathway, deficient pairing of homologous chromosomes and impaired sex body formation. In Meisetz-deficient testis, trimethylation of lysine 4 of histone H3 is attenuated and meiotic gene transcription is altered. These findings indicate that meiosis-specific epigenetic events in mammals are crucial for proper meiotic progression.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "549167c35b584704bfc6c93fb4bb55e9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[25, 26]], "char_spans": [[153, 162]]}]}], "context_tokens": [["Epigenetic", 0], ["modifications", 11], ["of", 25], ["histones", 28], ["regulate", 37], ["gene", 46], ["expression", 51], ["and", 62], ["chromatin", 66], ["structure", 76], [".", 85], ["Here", 87], ["we", 92], ["show", 95], ["that", 100], ["Meisetz", 105], ["(", 113], ["meiosis", 114], ["-", 121], ["induced", 122], ["factor", 130], ["containing", 137], ["a", 148], ["PR", 150], ["/", 152], ["SET", 153], ["domain", 157], ["and", 164], ["zinc", 168], ["-", 172], ["finger", 173], ["motif", 180], [")", 185], ["is", 187], ["a", 190], ["histone", 192], ["methyltransferase", 200], ["that", 218], ["is", 223], ["important", 226], ["for", 236], ["the", 240], ["progression", 244], ["of", 256], ["early", 259], ["meiotic", 265], ["prophase", 273], [".", 281], ["Meisetz", 283], ["transcripts", 291], ["are", 303], ["detected", 307], ["only", 316], ["in", 321], ["germ", 324], ["cells", 329], ["entering", 335], ["meiotic", 344], ["prophase", 352], ["in", 361], ["female", 364], ["fetal", 371], ["gonads", 377], ["and", 384], ["in", 388], ["postnatal", 391], ["testis", 401], [".", 407], ["Notably", 409], [",", 416], ["Meisetz", 418], ["has", 426], ["catalytic", 430], ["activity", 440], ["for", 449], ["trimethylation", 453], [",", 467], ["but", 469], ["not", 473], ["mono-", 477], ["or", 483], ["dimethylation", 486], [",", 499], ["of", 501], ["lysine", 504], ["4", 511], ["of", 513], ["histone", 516], ["H3", 524], [",", 526], ["and", 528], ["a", 532], ["transactivation", 534], ["activity", 550], ["that", 559], ["depends", 564], ["on", 572], ["its", 575], ["methylation", 579], ["activity", 591], [".", 599], ["Mice", 601], ["in", 606], ["which", 609], ["the", 615], ["Meisetz", 619], ["gene", 627], ["is", 632], ["disrupted", 635], ["show", 645], ["sterility", 650], ["in", 660], ["both", 663], ["sexes", 668], ["due", 674], ["to", 678], ["severe", 681], ["impairment", 688], ["of", 699], ["the", 702], ["double", 706], ["-", 712], ["stranded", 713], ["break", 722], ["repair", 728], ["pathway", 735], [",", 742], ["deficient", 744], ["pairing", 754], ["of", 762], ["homologous", 765], ["chromosomes", 776], ["and", 788], ["impaired", 792], ["sex", 801], ["body", 805], ["formation", 810], [".", 819], ["In", 821], ["Meisetz", 824], ["-", 831], ["deficient", 832], ["testis", 842], [",", 848], ["trimethylation", 850], ["of", 865], ["lysine", 868], ["4", 875], ["of", 877], ["histone", 880], ["H3", 888], ["is", 891], ["attenuated", 894], ["and", 905], ["meiotic", 909], ["gene", 917], ["transcription", 922], ["is", 936], ["altered", 939], [".", 946], ["These", 948], ["findings", 954], ["indicate", 963], ["that", 972], ["meiosis", 977], ["-", 984], ["specific", 985], ["epigenetic", 994], ["events", 1005], ["in", 1012], ["mammals", 1015], ["are", 1023], ["crucial", 1027], ["for", 1035], ["proper", 1039], ["meiotic", 1046], ["progression", 1054], [".", 1065]]}
{"context": "Anterograde amnesia, possibly accompanied by acute brain syndrome, is a potential side-effect of certain benzodiazepines, particularly triazolam. Flumazenil is a benzodiazepine antagonist that is highly effective in reversing the central nervous system effects of benzodiazepine overdose. We report a case of triazolam overdose resulting in anterograde amnesia after flumazenil administration had restored clear consciousness. The defect in memory may have been due to too little flumazenil being given or failure of memory consolidation affected by the character of triazolam during the induced lucent period. We feel that physicians should be aware of the potential occurrence of acute brain syndrome in patients with benzodiazepine overdose despite treatment with flumazenil.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "6d6de0afbd534ae696a092a6416d4001", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[116, 116], [55, 55], [23, 23], [73, 73]], "char_spans": [[767, 776], [367, 376], [146, 155], [480, 489]]}]}], "context_tokens": [["Anterograde", 0], ["amnesia", 12], [",", 19], ["possibly", 21], ["accompanied", 30], ["by", 42], ["acute", 45], ["brain", 51], ["syndrome", 57], [",", 65], ["is", 67], ["a", 70], ["potential", 72], ["side", 82], ["-", 86], ["effect", 87], ["of", 94], ["certain", 97], ["benzodiazepines", 105], [",", 120], ["particularly", 122], ["triazolam", 135], [".", 144], ["Flumazenil", 146], ["is", 157], ["a", 160], ["benzodiazepine", 162], ["antagonist", 177], ["that", 188], ["is", 193], ["highly", 196], ["effective", 203], ["in", 213], ["reversing", 216], ["the", 226], ["central", 230], ["nervous", 238], ["system", 246], ["effects", 253], ["of", 261], ["benzodiazepine", 264], ["overdose", 279], [".", 287], ["We", 289], ["report", 292], ["a", 299], ["case", 301], ["of", 306], ["triazolam", 309], ["overdose", 319], ["resulting", 328], ["in", 338], ["anterograde", 341], ["amnesia", 353], ["after", 361], ["flumazenil", 367], ["administration", 378], ["had", 393], ["restored", 397], ["clear", 406], ["consciousness", 412], [".", 425], ["The", 427], ["defect", 431], ["in", 438], ["memory", 441], ["may", 448], ["have", 452], ["been", 457], ["due", 462], ["to", 466], ["too", 469], ["little", 473], ["flumazenil", 480], ["being", 491], ["given", 497], ["or", 503], ["failure", 506], ["of", 514], ["memory", 517], ["consolidation", 524], ["affected", 538], ["by", 547], ["the", 550], ["character", 554], ["of", 564], ["triazolam", 567], ["during", 577], ["the", 584], ["induced", 588], ["lucent", 596], ["period", 603], [".", 609], ["We", 611], ["feel", 614], ["that", 619], ["physicians", 624], ["should", 635], ["be", 642], ["aware", 645], ["of", 651], ["the", 654], ["potential", 658], ["occurrence", 668], ["of", 679], ["acute", 682], ["brain", 688], ["syndrome", 694], ["in", 703], ["patients", 706], ["with", 715], ["benzodiazepine", 720], ["overdose", 735], ["despite", 744], ["treatment", 752], ["with", 762], ["flumazenil", 767], [".", 777]]}
{"context": "To elucidate the phenotype, genotype, and MRI findings of Korean patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and mutation carriers. The authors studied 40 members of nine unrelated Korean CADASIL families. After genetic analysis of Notch3, clinical and MRI findings were correlated in 27 mutation carriers. Notch3 mutation sites were C174R (one family, n = 3), R133C (one family, n = 3), R587C (one family, n = 1), R544C (two families, n = 5), and R75P (four families, n = 15). The clinical features were typical of CADASIL, but the frequency of migraine in the Korean population appears low. MRI abnormalities were found in 54% of the mutant carriers, the most common being white matter hyperintensities. The prevalence of lacunes and microbleeds increased with patient age. Anterior temporal areas were less often involved in subjects with R75P mutations than in those where mutations occurred in other sites (p = 0.02). Gradient echo imaging identified microbleedings in 33% of mutation carriers (64% of those with abnormal MRI), whereas diffusion-weighted MRI showed abnormal findings in only one patient. Neurologic disability was related to the number of lacunar infarcts and the lesion volume of white matter hyperintensities (p < 0.001) whereas MMSE score was related to the number of lacunar infarcts (p < 0.005). Although Korean cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) mutation carriers show similar clinical and MRI findings, these abnormalities appear less frequently than in other populations. Relatively frequent microbleedings on gradient echo imaging suggest that treatment should be individualized according to MRI findings. The novel mutation of R75P, not involving a cysteine residue, is related to less frequent involvement of the anterior temporal area, thus broadening the spectrum of CADASIL.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "ea472668bef643f08d9793d914e6370d", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[326, 326]], "char_spans": [[1818, 1825]]}]}], "context_tokens": [["To", 0], ["elucidate", 3], ["the", 13], ["phenotype", 17], [",", 26], ["genotype", 28], [",", 36], ["and", 38], ["MRI", 42], ["findings", 46], ["of", 55], ["Korean", 58], ["patients", 65], ["with", 74], ["cerebral", 79], ["autosomal", 88], ["dominant", 98], ["arteriopathy", 107], ["with", 120], ["subcortical", 125], ["infarcts", 137], ["and", 146], ["leukoencephalopathy", 150], ["(", 170], ["CADASIL", 171], [")", 178], ["and", 180], ["mutation", 184], ["carriers", 193], [".", 201], ["The", 203], ["authors", 207], ["studied", 215], ["40", 223], ["members", 226], ["of", 234], ["nine", 237], ["unrelated", 242], ["Korean", 252], ["CADASIL", 259], ["families", 267], [".", 275], ["After", 277], ["genetic", 283], ["analysis", 291], ["of", 300], ["Notch3", 303], [",", 309], ["clinical", 311], ["and", 320], ["MRI", 324], ["findings", 328], ["were", 337], ["correlated", 342], ["in", 353], ["27", 356], ["mutation", 359], ["carriers", 368], [".", 376], ["Notch3", 378], ["mutation", 385], ["sites", 394], ["were", 400], ["C174R", 405], ["(", 411], ["one", 412], ["family", 416], [",", 422], ["n", 424], ["=", 426], ["3", 428], [")", 429], [",", 430], ["R133C", 432], ["(", 438], ["one", 439], ["family", 443], [",", 449], ["n", 451], ["=", 453], ["3", 455], [")", 456], [",", 457], ["R587C", 459], ["(", 465], ["one", 466], ["family", 470], [",", 476], ["n", 478], ["=", 480], ["1", 482], [")", 483], [",", 484], ["R544C", 486], ["(", 492], ["two", 493], ["families", 497], [",", 505], ["n", 507], ["=", 509], ["5", 511], [")", 512], [",", 513], ["and", 515], ["R75P", 519], ["(", 524], ["four", 525], ["families", 530], [",", 538], ["n", 540], ["=", 542], ["15", 544], [")", 546], [".", 547], ["The", 549], ["clinical", 553], ["features", 562], ["were", 571], ["typical", 576], ["of", 584], ["CADASIL", 587], [",", 594], ["but", 596], ["the", 600], ["frequency", 604], ["of", 614], ["migraine", 617], ["in", 626], ["the", 629], ["Korean", 633], ["population", 640], ["appears", 651], ["low", 659], [".", 662], ["MRI", 664], ["abnormalities", 668], ["were", 682], ["found", 687], ["in", 693], ["54", 696], ["%", 698], ["of", 700], ["the", 703], ["mutant", 707], ["carriers", 714], [",", 722], ["the", 724], ["most", 728], ["common", 733], ["being", 740], ["white", 746], ["matter", 752], ["hyperintensities", 759], [".", 775], ["The", 777], ["prevalence", 781], ["of", 792], ["lacunes", 795], ["and", 803], ["microbleeds", 807], ["increased", 819], ["with", 829], ["patient", 834], ["age", 842], [".", 845], ["Anterior", 847], ["temporal", 856], ["areas", 865], ["were", 871], ["less", 876], ["often", 881], ["involved", 887], ["in", 896], ["subjects", 899], ["with", 908], ["R75P", 913], ["mutations", 918], ["than", 928], ["in", 933], ["those", 936], ["where", 942], ["mutations", 948], ["occurred", 958], ["in", 967], ["other", 970], ["sites", 976], ["(", 982], ["p", 983], ["=", 985], ["0.02", 987], [")", 991], [".", 992], ["Gradient", 994], ["echo", 1003], ["imaging", 1008], ["identified", 1016], ["microbleedings", 1027], ["in", 1042], ["33", 1045], ["%", 1047], ["of", 1049], ["mutation", 1052], ["carriers", 1061], ["(", 1070], ["64", 1071], ["%", 1073], ["of", 1075], ["those", 1078], ["with", 1084], ["abnormal", 1089], ["MRI", 1098], [")", 1101], [",", 1102], ["whereas", 1104], ["diffusion", 1112], ["-", 1121], ["weighted", 1122], ["MRI", 1131], ["showed", 1135], ["abnormal", 1142], ["findings", 1151], ["in", 1160], ["only", 1163], ["one", 1168], ["patient", 1172], [".", 1179], ["Neurologic", 1181], ["disability", 1192], ["was", 1203], ["related", 1207], ["to", 1215], ["the", 1218], ["number", 1222], ["of", 1229], ["lacunar", 1232], ["infarcts", 1240], ["and", 1249], ["the", 1253], ["lesion", 1257], ["volume", 1264], ["of", 1271], ["white", 1274], ["matter", 1280], ["hyperintensities", 1287], ["(", 1304], ["p", 1305], ["<", 1307], ["0.001", 1309], [")", 1314], ["whereas", 1316], ["MMSE", 1324], ["score", 1329], ["was", 1335], ["related", 1339], ["to", 1347], ["the", 1350], ["number", 1354], ["of", 1361], ["lacunar", 1364], ["infarcts", 1372], ["(", 1381], ["p", 1382], ["<", 1384], ["0.005", 1386], [")", 1391], [".", 1392], ["Although", 1394], ["Korean", 1403], ["cerebral", 1410], ["autosomal", 1419], ["dominant", 1429], ["arteriopathy", 1438], ["with", 1451], ["subcortical", 1456], ["infarcts", 1468], ["and", 1477], ["leukoencephalopathy", 1481], ["(", 1501], ["CADASIL", 1502], [")", 1509], ["mutation", 1511], ["carriers", 1520], ["show", 1529], ["similar", 1534], ["clinical", 1542], ["and", 1551], ["MRI", 1555], ["findings", 1559], [",", 1567], ["these", 1569], ["abnormalities", 1575], ["appear", 1589], ["less", 1596], ["frequently", 1601], ["than", 1612], ["in", 1617], ["other", 1620], ["populations", 1626], [".", 1637], ["Relatively", 1639], ["frequent", 1650], ["microbleedings", 1659], ["on", 1674], ["gradient", 1677], ["echo", 1686], ["imaging", 1691], ["suggest", 1699], ["that", 1707], ["treatment", 1712], ["should", 1722], ["be", 1729], ["individualized", 1732], ["according", 1747], ["to", 1757], ["MRI", 1760], ["findings", 1764], [".", 1772], ["The", 1774], ["novel", 1778], ["mutation", 1784], ["of", 1793], ["R75P", 1796], [",", 1800], ["not", 1802], ["involving", 1806], ["a", 1816], ["cysteine", 1818], ["residue", 1827], [",", 1834], ["is", 1836], ["related", 1839], ["to", 1847], ["less", 1850], ["frequent", 1855], ["involvement", 1864], ["of", 1876], ["the", 1879], ["anterior", 1883], ["temporal", 1892], ["area", 1901], [",", 1905], ["thus", 1907], ["broadening", 1912], ["the", 1923], ["spectrum", 1927], ["of", 1936], ["CADASIL", 1939], [".", 1946]]}
{"context": "MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression that act by direct base pairing to target sites within untranslated regions of messenger RNAs. Recently, miRNA activity has been shown to be affected by the presence of miRNA sponge transcripts, the so-called competing endogenous RNA in humans and target mimicry in plants. We previously identified a highly expressed circular RNA (circRNA) in human and mouse brain. Here we show that this circRNA acts as a miR-7 sponge; we term this circular transcript ciRS-7 (circular RNA sponge for miR-7). ciRS-7 contains more than 70 selectively conserved miRNA target sites, and it is highly and widely associated with Argonaute (AGO) proteins in a miR-7-dependent manner. Although the circRNA is completely resistant to miRNA-mediated target destabilization, it strongly suppresses miR-7 activity, resulting in increased levels of miR-7 targets. In the mouse brain, we observe overlapping co-expression of ciRS-7 and miR-7, particularly in neocortical and hippocampal neurons, suggesting a high degree of endogenous interaction. We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon. This study serves as the first, to our knowledge, functional analysis of a naturally expressed circRNA.", "qas": [{"question": "Which miRNA is targeted by SRY/Sox9?", "answers": ["mir-138"], "qid": "aac69dde3c754b6ab56366207d37f1f7", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["targeted", 15], ["by", 24], ["SRY", 27], ["/", 30], ["Sox9", 31], ["?", 35]], "detected_answers": [{"text": "mir-138", "token_spans": [[214, 214]], "char_spans": [[1199, 1205]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["important", 23], ["post", 33], ["-", 37], ["transcriptional", 38], ["regulators", 54], ["of", 65], ["gene", 68], ["expression", 73], ["that", 84], ["act", 89], ["by", 93], ["direct", 96], ["base", 103], ["pairing", 108], ["to", 116], ["target", 119], ["sites", 126], ["within", 132], ["untranslated", 139], ["regions", 152], ["of", 160], ["messenger", 163], ["RNAs", 173], [".", 177], ["Recently", 179], [",", 187], ["miRNA", 189], ["activity", 195], ["has", 204], ["been", 208], ["shown", 213], ["to", 219], ["be", 222], ["affected", 225], ["by", 234], ["the", 237], ["presence", 241], ["of", 250], ["miRNA", 253], ["sponge", 259], ["transcripts", 266], [",", 277], ["the", 279], ["so", 283], ["-", 285], ["called", 286], ["competing", 293], ["endogenous", 303], ["RNA", 314], ["in", 318], ["humans", 321], ["and", 328], ["target", 332], ["mimicry", 339], ["in", 347], ["plants", 350], [".", 356], ["We", 358], ["previously", 361], ["identified", 372], ["a", 383], ["highly", 385], ["expressed", 392], ["circular", 402], ["RNA", 411], ["(", 415], ["circRNA", 416], [")", 423], ["in", 425], ["human", 428], ["and", 434], ["mouse", 438], ["brain", 444], [".", 449], ["Here", 451], ["we", 456], ["show", 459], ["that", 464], ["this", 469], ["circRNA", 474], ["acts", 482], ["as", 487], ["a", 490], ["miR-7", 492], ["sponge", 498], [";", 504], ["we", 506], ["term", 509], ["this", 514], ["circular", 519], ["transcript", 528], ["ciRS-7", 539], ["(", 546], ["circular", 547], ["RNA", 556], ["sponge", 560], ["for", 567], ["miR-7", 571], [")", 576], [".", 577], ["ciRS-7", 579], ["contains", 586], ["more", 595], ["than", 600], ["70", 605], ["selectively", 608], ["conserved", 620], ["miRNA", 630], ["target", 636], ["sites", 643], [",", 648], ["and", 650], ["it", 654], ["is", 657], ["highly", 660], ["and", 667], ["widely", 671], ["associated", 678], ["with", 689], ["Argonaute", 694], ["(", 704], ["AGO", 705], [")", 708], ["proteins", 710], ["in", 719], ["a", 722], ["miR-7-dependent", 724], ["manner", 740], [".", 746], ["Although", 748], ["the", 757], ["circRNA", 761], ["is", 769], ["completely", 772], ["resistant", 783], ["to", 793], ["miRNA", 796], ["-", 801], ["mediated", 802], ["target", 811], ["destabilization", 818], [",", 833], ["it", 835], ["strongly", 838], ["suppresses", 847], ["miR-7", 858], ["activity", 864], [",", 872], ["resulting", 874], ["in", 884], ["increased", 887], ["levels", 897], ["of", 904], ["miR-7", 907], ["targets", 913], [".", 920], ["In", 922], ["the", 925], ["mouse", 929], ["brain", 935], [",", 940], ["we", 942], ["observe", 945], ["overlapping", 953], ["co", 965], ["-", 967], ["expression", 968], ["of", 979], ["ciRS-7", 982], ["and", 989], ["miR-7", 993], [",", 998], ["particularly", 1000], ["in", 1013], ["neocortical", 1016], ["and", 1028], ["hippocampal", 1032], ["neurons", 1044], [",", 1051], ["suggesting", 1053], ["a", 1064], ["high", 1066], ["degree", 1071], ["of", 1078], ["endogenous", 1081], ["interaction", 1092], [".", 1103], ["We", 1105], ["further", 1108], ["show", 1116], ["that", 1121], ["the", 1126], ["testis", 1130], ["-", 1136], ["specific", 1137], ["circRNA", 1146], [",", 1153], ["sex", 1155], ["-", 1158], ["determining", 1159], ["region", 1171], ["Y", 1178], ["(", 1180], ["Sry", 1181], [")", 1184], [",", 1185], ["serves", 1187], ["as", 1194], ["a", 1197], ["miR-138", 1199], ["sponge", 1207], [",", 1213], ["suggesting", 1215], ["that", 1226], ["miRNA", 1231], ["sponge", 1237], ["effects", 1244], ["achieved", 1252], ["by", 1261], ["circRNA", 1264], ["formation", 1272], ["are", 1282], ["a", 1286], ["general", 1288], ["phenomenon", 1296], [".", 1306], ["This", 1308], ["study", 1313], ["serves", 1319], ["as", 1326], ["the", 1329], ["first", 1333], [",", 1338], ["to", 1340], ["our", 1343], ["knowledge", 1347], [",", 1356], ["functional", 1358], ["analysis", 1369], ["of", 1378], ["a", 1381], ["naturally", 1383], ["expressed", 1393], ["circRNA", 1403], [".", 1410]]}
{"context": "The Davidson Trauma Scale (DTS) was developed as a self-rating for use in diagnosing and measuring symptom severity and treatment outcome in post-traumatic stress disorder (PTSD); 630 subjects were identified by random digit dialing and evaluated for a history of trauma. Prevalence rates of PTSD and subthreshold PTSD with impairment were 2.2 and 4.1%, respectively. In this general population sample, 438 subjects endorsed at least one trauma, and four groups were generated: A) threshold PTSD (n = 13), B) subthreshold PTSD with impairment (n = 26), C) subthreshold PTSD without impairment (n = 78), and D) no PTSD (n = 321). Mean (SD) DTS score in the entire population was 11.0 +/- 18.1. Differences were found in four of the five pairwise between-group contrasts. In a second sample of 447 clinical trial participants from three SSRI vs. placebo studies, we assessed treatment effect size according to different measures. In all three clinical trials, effect size with the DTS was equal to, or better than, those found for the Impact of Event Scale (IES), Clinician Administered PTSD Scale (CAPS), and Structured Interview for PTSD (SIP). These results further affirm the utility of the DTS as a self-rating measure of PTSD symptom severity and in evaluating treatment response.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "73a1af5a2b084b75a3a2d56d9cdceaf4", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[26, 30]], "char_spans": [[141, 170]]}, {"text": "PTSD", "token_spans": [[32, 32], [91, 91], [101, 101], [54, 54], [253, 253], [57, 57], [222, 222], [232, 232], [126, 126], [113, 113]], "char_spans": [[173, 176], [491, 494], [522, 525], [292, 295], [1225, 1228], [314, 317], [1085, 1088], [1133, 1136], [613, 616], [569, 572]]}]}], "context_tokens": [["The", 0], ["Davidson", 4], ["Trauma", 13], ["Scale", 20], ["(", 26], ["DTS", 27], [")", 30], ["was", 32], ["developed", 36], ["as", 46], ["a", 49], ["self", 51], ["-", 55], ["rating", 56], ["for", 63], ["use", 67], ["in", 71], ["diagnosing", 74], ["and", 85], ["measuring", 89], ["symptom", 99], ["severity", 107], ["and", 116], ["treatment", 120], ["outcome", 130], ["in", 138], ["post", 141], ["-", 145], ["traumatic", 146], ["stress", 156], ["disorder", 163], ["(", 172], ["PTSD", 173], [")", 177], [";", 178], ["630", 180], ["subjects", 184], ["were", 193], ["identified", 198], ["by", 209], ["random", 212], ["digit", 219], ["dialing", 225], ["and", 233], ["evaluated", 237], ["for", 247], ["a", 251], ["history", 253], ["of", 261], ["trauma", 264], [".", 270], ["Prevalence", 272], ["rates", 283], ["of", 289], ["PTSD", 292], ["and", 297], ["subthreshold", 301], ["PTSD", 314], ["with", 319], ["impairment", 324], ["were", 335], ["2.2", 340], ["and", 344], ["4.1", 348], ["%", 351], [",", 352], ["respectively", 354], [".", 366], ["In", 368], ["this", 371], ["general", 376], ["population", 384], ["sample", 395], [",", 401], ["438", 403], ["subjects", 407], ["endorsed", 416], ["at", 425], ["least", 428], ["one", 434], ["trauma", 438], [",", 444], ["and", 446], ["four", 450], ["groups", 455], ["were", 462], ["generated", 467], [":", 476], ["A", 478], [")", 479], ["threshold", 481], ["PTSD", 491], ["(", 496], ["n", 497], ["=", 499], ["13", 501], [")", 503], [",", 504], ["B", 506], [")", 507], ["subthreshold", 509], ["PTSD", 522], ["with", 527], ["impairment", 532], ["(", 543], ["n", 544], ["=", 546], ["26", 548], [")", 550], [",", 551], ["C", 553], [")", 554], ["subthreshold", 556], ["PTSD", 569], ["without", 574], ["impairment", 582], ["(", 593], ["n", 594], ["=", 596], ["78", 598], [")", 600], [",", 601], ["and", 603], ["D", 607], [")", 608], ["no", 610], ["PTSD", 613], ["(", 618], ["n", 619], ["=", 621], ["321", 623], [")", 626], [".", 627], ["Mean", 629], ["(", 634], ["SD", 635], [")", 637], ["DTS", 639], ["score", 643], ["in", 649], ["the", 652], ["entire", 656], ["population", 663], ["was", 674], ["11.0", 678], ["+", 683], ["/-", 684], ["18.1", 687], [".", 691], ["Differences", 693], ["were", 705], ["found", 710], ["in", 716], ["four", 719], ["of", 724], ["the", 727], ["five", 731], ["pairwise", 736], ["between", 745], ["-", 752], ["group", 753], ["contrasts", 759], [".", 768], ["In", 770], ["a", 773], ["second", 775], ["sample", 782], ["of", 789], ["447", 792], ["clinical", 796], ["trial", 805], ["participants", 811], ["from", 824], ["three", 829], ["SSRI", 835], ["vs.", 840], ["placebo", 844], ["studies", 852], [",", 859], ["we", 861], ["assessed", 864], ["treatment", 873], ["effect", 883], ["size", 890], ["according", 895], ["to", 905], ["different", 908], ["measures", 918], [".", 926], ["In", 928], ["all", 931], ["three", 935], ["clinical", 941], ["trials", 950], [",", 956], ["effect", 958], ["size", 965], ["with", 970], ["the", 975], ["DTS", 979], ["was", 983], ["equal", 987], ["to", 993], [",", 995], ["or", 997], ["better", 1000], ["than", 1007], [",", 1011], ["those", 1013], ["found", 1019], ["for", 1025], ["the", 1029], ["Impact", 1033], ["of", 1040], ["Event", 1043], ["Scale", 1049], ["(", 1055], ["IES", 1056], [")", 1059], [",", 1060], ["Clinician", 1062], ["Administered", 1072], ["PTSD", 1085], ["Scale", 1090], ["(", 1096], ["CAPS", 1097], [")", 1101], [",", 1102], ["and", 1104], ["Structured", 1108], ["Interview", 1119], ["for", 1129], ["PTSD", 1133], ["(", 1138], ["SIP", 1139], [")", 1142], [".", 1143], ["These", 1145], ["results", 1151], ["further", 1159], ["affirm", 1167], ["the", 1174], ["utility", 1178], ["of", 1186], ["the", 1189], ["DTS", 1193], ["as", 1197], ["a", 1200], ["self", 1202], ["-", 1206], ["rating", 1207], ["measure", 1214], ["of", 1222], ["PTSD", 1225], ["symptom", 1230], ["severity", 1238], ["and", 1247], ["in", 1251], ["evaluating", 1254], ["treatment", 1265], ["response", 1275], [".", 1283]]}
{"context": "Delamanid (Deltyba(\u00ae)), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB) drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. It is approved in several countries, including Japan and those of the EU, for use as part of an appropriate combination regimen in adults with multidrug-resistant tuberculosis (MDR-TB) when an effective treatment regimen cannot otherwise be composed due to resistance or tolerability. In a robust phase\u00a0II trial in adult patients with MDR-TB, oral delamanid 100\u00a0mg twice daily for 2\u00a0months plus an optimized background regimen improved sputum culture conversion rates to a significantly greater extent than placebo. In a 6-month extension study, long-term (\u22648\u00a0months) treatment with delamanid was associated with a higher incidence of favourable outcomes (i.e. cured or completed all treatment) than short-term (\u22642\u00a0months) treatment, with an accompanying reduction inunfavourable outcomes as defined by the WHO (i.e. pre-specified proportion of TB-positive sputum cultures, death or treatment discontinuation for \u22652\u00a0months without medical approval). Delamanid was not associated with clinically relevant drug-drug interactions, including with antiretroviral drugs and those commonly used in treating TB. Delamanid was generally well tolerated in patients with MDR-TB, with gastrointestinal adverse events and insomnia reported most commonly. Although the incidence of QT interval prolongation was higher with delamanid-based therapy, it was not associated with clinical symptoms such as syncope and arrhythmia. In conclusion, delamanid is a useful addition to the treatment options currently available for patients with MDR-TB.", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "cffa38bb217641c08713c8debdecf88f", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[75, 75], [19, 19], [43, 43]], "char_spans": [[405, 416], [73, 84], [228, 239]]}]}], "context_tokens": [["Delamanid", 0], ["(", 10], ["Deltyba", 11], ["(", 18], ["\u00ae", 19], [")", 20], [")", 21], [",", 22], ["a", 24], ["nitroimidazo", 26], ["-", 38], ["oxazole", 39], ["derivative", 47], [",", 57], ["is", 59], ["a", 62], ["new", 64], ["anti", 68], ["-", 72], ["tuberculosis", 73], ["(", 86], ["TB", 87], [")", 89], ["drug", 91], ["which", 96], ["exhibits", 102], ["potent", 111], ["in", 118], ["vitro", 121], ["and", 127], ["in", 131], ["vivo", 134], ["antitubercular", 139], ["activity", 154], ["against", 163], ["drug", 171], ["-", 175], ["susceptible", 176], ["and", 188], ["-resistant", 192], ["strains", 203], ["of", 211], ["Mycobacterium", 214], ["tuberculosis", 228], [".", 240], ["It", 242], ["is", 245], ["approved", 248], ["in", 257], ["several", 260], ["countries", 268], [",", 277], ["including", 279], ["Japan", 289], ["and", 295], ["those", 299], ["of", 305], ["the", 308], ["EU", 312], [",", 314], ["for", 316], ["use", 320], ["as", 324], ["part", 327], ["of", 332], ["an", 335], ["appropriate", 338], ["combination", 350], ["regimen", 362], ["in", 370], ["adults", 373], ["with", 380], ["multidrug", 385], ["-", 394], ["resistant", 395], ["tuberculosis", 405], ["(", 418], ["MDR", 419], ["-", 422], ["TB", 423], [")", 425], ["when", 427], ["an", 432], ["effective", 435], ["treatment", 445], ["regimen", 455], ["can", 463], ["not", 466], ["otherwise", 470], ["be", 480], ["composed", 483], ["due", 492], ["to", 496], ["resistance", 499], ["or", 510], ["tolerability", 513], [".", 525], ["In", 527], ["a", 530], ["robust", 532], ["phase", 539], ["II", 545], ["trial", 548], ["in", 554], ["adult", 557], ["patients", 563], ["with", 572], ["MDR", 577], ["-", 580], ["TB", 581], [",", 583], ["oral", 585], ["delamanid", 590], ["100", 600], ["mg", 604], ["twice", 607], ["daily", 613], ["for", 619], ["2", 623], ["months", 625], ["plus", 632], ["an", 637], ["optimized", 640], ["background", 650], ["regimen", 661], ["improved", 669], ["sputum", 678], ["culture", 685], ["conversion", 693], ["rates", 704], ["to", 710], ["a", 713], ["significantly", 715], ["greater", 729], ["extent", 737], ["than", 744], ["placebo", 749], [".", 756], ["In", 758], ["a", 761], ["6-month", 763], ["extension", 771], ["study", 781], [",", 786], ["long", 788], ["-", 792], ["term", 793], ["(", 798], ["\u22648", 799], ["months", 802], [")", 808], ["treatment", 810], ["with", 820], ["delamanid", 825], ["was", 835], ["associated", 839], ["with", 850], ["a", 855], ["higher", 857], ["incidence", 864], ["of", 874], ["favourable", 877], ["outcomes", 888], ["(", 897], ["i.e.", 898], ["cured", 903], ["or", 909], ["completed", 912], ["all", 922], ["treatment", 926], [")", 935], ["than", 937], ["short", 942], ["-", 947], ["term", 948], ["(", 953], ["\u22642", 954], ["months", 957], [")", 963], ["treatment", 965], [",", 974], ["with", 976], ["an", 981], ["accompanying", 984], ["reduction", 997], ["inunfavourable", 1007], ["outcomes", 1022], ["as", 1031], ["defined", 1034], ["by", 1042], ["the", 1045], ["WHO", 1049], ["(", 1053], ["i.e.", 1054], ["pre", 1059], ["-", 1062], ["specified", 1063], ["proportion", 1073], ["of", 1084], ["TB", 1087], ["-", 1089], ["positive", 1090], ["sputum", 1099], ["cultures", 1106], [",", 1114], ["death", 1116], ["or", 1122], ["treatment", 1125], ["discontinuation", 1135], ["for", 1151], ["\u22652", 1155], ["months", 1158], ["without", 1165], ["medical", 1173], ["approval", 1181], [")", 1189], [".", 1190], ["Delamanid", 1192], ["was", 1202], ["not", 1206], ["associated", 1210], ["with", 1221], ["clinically", 1226], ["relevant", 1237], ["drug", 1246], ["-", 1250], ["drug", 1251], ["interactions", 1256], [",", 1268], ["including", 1270], ["with", 1280], ["antiretroviral", 1285], ["drugs", 1300], ["and", 1306], ["those", 1310], ["commonly", 1316], ["used", 1325], ["in", 1330], ["treating", 1333], ["TB", 1342], [".", 1344], ["Delamanid", 1346], ["was", 1356], ["generally", 1360], ["well", 1370], ["tolerated", 1375], ["in", 1385], ["patients", 1388], ["with", 1397], ["MDR", 1402], ["-", 1405], ["TB", 1406], [",", 1408], ["with", 1410], ["gastrointestinal", 1415], ["adverse", 1432], ["events", 1440], ["and", 1447], ["insomnia", 1451], ["reported", 1460], ["most", 1469], ["commonly", 1474], [".", 1482], ["Although", 1484], ["the", 1493], ["incidence", 1497], ["of", 1507], ["QT", 1510], ["interval", 1513], ["prolongation", 1522], ["was", 1535], ["higher", 1539], ["with", 1546], ["delamanid", 1551], ["-", 1560], ["based", 1561], ["therapy", 1567], [",", 1574], ["it", 1576], ["was", 1579], ["not", 1583], ["associated", 1587], ["with", 1598], ["clinical", 1603], ["symptoms", 1612], ["such", 1621], ["as", 1626], ["syncope", 1629], ["and", 1637], ["arrhythmia", 1641], [".", 1651], ["In", 1653], ["conclusion", 1656], [",", 1666], ["delamanid", 1668], ["is", 1678], ["a", 1681], ["useful", 1683], ["addition", 1690], ["to", 1699], ["the", 1702], ["treatment", 1706], ["options", 1716], ["currently", 1724], ["available", 1734], ["for", 1744], ["patients", 1748], ["with", 1757], ["MDR", 1762], ["-", 1765], ["TB", 1766], [".", 1768]]}
{"context": "Muenke syndrome, defined by heterozygosity for a Pro250Arg substitution in fibroblast growth factor receptor 3 (FGFR3), is the most common genetic cause of craniosynostosis in humans. We have used gene targeting to introduce the Muenke syndrome mutation (equivalent to P244R) into the murine Fgfr3 gene. A rounded skull and shortened snout (often skewed) with dental malocclusion was observed in a minority of heterozygotes and many homozygotes. Development of this incompletely penetrant skull phenotype was dependent on genetic background and sex, with males more often affected. However, these cranial abnormalities were rarely attributable to craniosynostosis, which was only present in 2/364 mutants; more commonly, we found fusion of the premaxillary and/or zygomatic sutures. We also found decreased cortical thickness and bone mineral densities in long bones. We conclude that although both cranial and long bone development is variably affected by the murine Fgfr3(P244R) mutation, coronal craniosynostosis is not reliably reproduced.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "0e24607baaa74369a7171110551ca197", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[11, 17]], "char_spans": [[75, 116]]}]}], "context_tokens": [["Muenke", 0], ["syndrome", 7], [",", 15], ["defined", 17], ["by", 25], ["heterozygosity", 28], ["for", 43], ["a", 47], ["Pro250Arg", 49], ["substitution", 59], ["in", 72], ["fibroblast", 75], ["growth", 86], ["factor", 93], ["receptor", 100], ["3", 109], ["(", 111], ["FGFR3", 112], [")", 117], [",", 118], ["is", 120], ["the", 123], ["most", 127], ["common", 132], ["genetic", 139], ["cause", 147], ["of", 153], ["craniosynostosis", 156], ["in", 173], ["humans", 176], [".", 182], ["We", 184], ["have", 187], ["used", 192], ["gene", 197], ["targeting", 202], ["to", 212], ["introduce", 215], ["the", 225], ["Muenke", 229], ["syndrome", 236], ["mutation", 245], ["(", 254], ["equivalent", 255], ["to", 266], ["P244R", 269], [")", 274], ["into", 276], ["the", 281], ["murine", 285], ["Fgfr3", 292], ["gene", 298], [".", 302], ["A", 304], ["rounded", 306], ["skull", 314], ["and", 320], ["shortened", 324], ["snout", 334], ["(", 340], ["often", 341], ["skewed", 347], [")", 353], ["with", 355], ["dental", 360], ["malocclusion", 367], ["was", 380], ["observed", 384], ["in", 393], ["a", 396], ["minority", 398], ["of", 407], ["heterozygotes", 410], ["and", 424], ["many", 428], ["homozygotes", 433], [".", 444], ["Development", 446], ["of", 458], ["this", 461], ["incompletely", 466], ["penetrant", 479], ["skull", 489], ["phenotype", 495], ["was", 505], ["dependent", 509], ["on", 519], ["genetic", 522], ["background", 530], ["and", 541], ["sex", 545], [",", 548], ["with", 550], ["males", 555], ["more", 561], ["often", 566], ["affected", 572], [".", 580], ["However", 582], [",", 589], ["these", 591], ["cranial", 597], ["abnormalities", 605], ["were", 619], ["rarely", 624], ["attributable", 631], ["to", 644], ["craniosynostosis", 647], [",", 663], ["which", 665], ["was", 671], ["only", 675], ["present", 680], ["in", 688], ["2/364", 691], ["mutants", 697], [";", 704], ["more", 706], ["commonly", 711], [",", 719], ["we", 721], ["found", 724], ["fusion", 730], ["of", 737], ["the", 740], ["premaxillary", 744], ["and/or", 757], ["zygomatic", 764], ["sutures", 774], [".", 781], ["We", 783], ["also", 786], ["found", 791], ["decreased", 797], ["cortical", 807], ["thickness", 816], ["and", 826], ["bone", 830], ["mineral", 835], ["densities", 843], ["in", 853], ["long", 856], ["bones", 861], [".", 866], ["We", 868], ["conclude", 871], ["that", 880], ["although", 885], ["both", 894], ["cranial", 899], ["and", 907], ["long", 911], ["bone", 916], ["development", 921], ["is", 933], ["variably", 936], ["affected", 945], ["by", 954], ["the", 957], ["murine", 961], ["Fgfr3(P244R", 968], [")", 979], ["mutation", 981], [",", 989], ["coronal", 991], ["craniosynostosis", 999], ["is", 1016], ["not", 1019], ["reliably", 1023], ["reproduced", 1032], [".", 1042]]}
{"context": "Insulin is the cornerstone of type 1 diabetes mellitus (T1DM) therapy. However, it cannot achieve a delay in the onset or evolution of this condition, while cardiovascular morbidity remains an unquestionable threat. In this review, the authors discuss gevokizumab (XOMA 052), a recombinant monoclonal antibody that can neutralize human IL-1\u03b2 by binding to it. This is relevant, because this IL has been associated with \u03b2-cell toxicity in both diabetes types. Moreover, gevokizumab presents two major advantages: it spares IL-1\u03b1 and it exhibits favorable pharmacokinetic properties. Gevokizumab has already proven its safety and efficacy in improving glycemic control, \u03b2 cell function and inflammation markers in clinical trials in diabetic patients. Despite the very promising characteristics of gevokizumab, important questions remain to be answered. One important question is what to expect from a combination of this agent with insulin and if there is a subset of patients that might respond more favorably to treatment. We also need to know at what stage in the natural history of T1DM could gevokizumab be most efficacious, as well as its potential effects on cardiovascular outcomes.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "c44c66126f324ce3acbc22cbc8a73352", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[60, 60]], "char_spans": [[336, 340]]}]}], "context_tokens": [["Insulin", 0], ["is", 8], ["the", 11], ["cornerstone", 15], ["of", 27], ["type", 30], ["1", 35], ["diabetes", 37], ["mellitus", 46], ["(", 55], ["T1DM", 56], [")", 60], ["therapy", 62], [".", 69], ["However", 71], [",", 78], ["it", 80], ["can", 83], ["not", 86], ["achieve", 90], ["a", 98], ["delay", 100], ["in", 106], ["the", 109], ["onset", 113], ["or", 119], ["evolution", 122], ["of", 132], ["this", 135], ["condition", 140], [",", 149], ["while", 151], ["cardiovascular", 157], ["morbidity", 172], ["remains", 182], ["an", 190], ["unquestionable", 193], ["threat", 208], [".", 214], ["In", 216], ["this", 219], ["review", 224], [",", 230], ["the", 232], ["authors", 236], ["discuss", 244], ["gevokizumab", 252], ["(", 264], ["XOMA", 265], ["052", 270], [")", 273], [",", 274], ["a", 276], ["recombinant", 278], ["monoclonal", 290], ["antibody", 301], ["that", 310], ["can", 315], ["neutralize", 319], ["human", 330], ["IL-1\u03b2", 336], ["by", 342], ["binding", 345], ["to", 353], ["it", 356], [".", 358], ["This", 360], ["is", 365], ["relevant", 368], [",", 376], ["because", 378], ["this", 386], ["IL", 391], ["has", 394], ["been", 398], ["associated", 403], ["with", 414], ["\u03b2", 419], ["-", 420], ["cell", 421], ["toxicity", 426], ["in", 435], ["both", 438], ["diabetes", 443], ["types", 452], [".", 457], ["Moreover", 459], [",", 467], ["gevokizumab", 469], ["presents", 481], ["two", 490], ["major", 494], ["advantages", 500], [":", 510], ["it", 512], ["spares", 515], ["IL-1\u03b1", 522], ["and", 528], ["it", 532], ["exhibits", 535], ["favorable", 544], ["pharmacokinetic", 554], ["properties", 570], [".", 580], ["Gevokizumab", 582], ["has", 594], ["already", 598], ["proven", 606], ["its", 613], ["safety", 617], ["and", 624], ["efficacy", 628], ["in", 637], ["improving", 640], ["glycemic", 650], ["control", 659], [",", 666], ["\u03b2", 668], ["cell", 670], ["function", 675], ["and", 684], ["inflammation", 688], ["markers", 701], ["in", 709], ["clinical", 712], ["trials", 721], ["in", 728], ["diabetic", 731], ["patients", 740], [".", 748], ["Despite", 750], ["the", 758], ["very", 762], ["promising", 767], ["characteristics", 777], ["of", 793], ["gevokizumab", 796], [",", 807], ["important", 809], ["questions", 819], ["remain", 829], ["to", 836], ["be", 839], ["answered", 842], [".", 850], ["One", 852], ["important", 856], ["question", 866], ["is", 875], ["what", 878], ["to", 883], ["expect", 886], ["from", 893], ["a", 898], ["combination", 900], ["of", 912], ["this", 915], ["agent", 920], ["with", 926], ["insulin", 931], ["and", 939], ["if", 943], ["there", 946], ["is", 952], ["a", 955], ["subset", 957], ["of", 964], ["patients", 967], ["that", 976], ["might", 981], ["respond", 987], ["more", 995], ["favorably", 1000], ["to", 1010], ["treatment", 1013], [".", 1022], ["We", 1024], ["also", 1027], ["need", 1032], ["to", 1037], ["know", 1040], ["at", 1045], ["what", 1048], ["stage", 1053], ["in", 1059], ["the", 1062], ["natural", 1066], ["history", 1074], ["of", 1082], ["T1DM", 1085], ["could", 1090], ["gevokizumab", 1096], ["be", 1108], ["most", 1111], ["efficacious", 1116], [",", 1127], ["as", 1129], ["well", 1132], ["as", 1137], ["its", 1140], ["potential", 1144], ["effects", 1154], ["on", 1162], ["cardiovascular", 1165], ["outcomes", 1180], [".", 1188]]}
{"context": "U.K ambulance services assess patients with suspected stroke using the Face Arm Speech Test (FAST). The Recognition Of Stroke In the Emergency Room (ROSIER) tool has been shown superior to the FAST in identifying strokes in emergency departments but has not previously been tested in the ambulance setting. We investigated whether ROSIER use by ambulance clinicians can improve stroke recognition. Ambulance clinicians used the ROSIER in place of the FAST to assess patients with suspected stroke. As the ROSIER includes all FAST elements, we calculated a FAST score from the ROSIER to enable comparisons between the two tools. Ambulance clinicians' provisional stroke diagnoses using the ROSIER and calculated FAST were compared with stroke consultants' diagnosis. We used stepwise logistic regression to compare the contribution of individual ROSIER and FAST items and patient demographics to the prediction of consultants' diagnoses. Sixty-four percent of strokes and 78% of nonstrokes identified by ambulance clinicians using the ROSIER were subsequently confirmed by a stroke consultant. There was no difference in the proportion of strokes correctly detected by the ROSIER or FAST with both displaying excellent levels of sensitivity. The ROSIER detected marginally more nonstroke cases than the FAST, but both demonstrated poor specificity. Facial weakness, arm weakness, seizure activity, age, and sex predicted consultants' diagnosis of stroke. The ROSIER was not better than the FAST for prehospital recognition of stroke. A revised version of the FAST incorporating assessment of seizure activity may improve stroke identification and decision making by ambulance clinicians.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "14137672ed6a4876bd365f25ca43ab63", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[112, 112], [64, 64], [21, 21], [123, 123], [253, 253], [268, 268], [7, 7], [82, 82], [239, 239], [177, 177]], "char_spans": [[662, 667], [378, 383], [119, 124], [735, 740], [1525, 1530], [1620, 1625], [54, 59], [490, 495], [1446, 1451], [1074, 1079]]}]}], "context_tokens": [["U.K", 0], ["ambulance", 4], ["services", 14], ["assess", 23], ["patients", 30], ["with", 39], ["suspected", 44], ["stroke", 54], ["using", 61], ["the", 67], ["Face", 71], ["Arm", 76], ["Speech", 80], ["Test", 87], ["(", 92], ["FAST", 93], [")", 97], [".", 98], ["The", 100], ["Recognition", 104], ["Of", 116], ["Stroke", 119], ["In", 126], ["the", 129], ["Emergency", 133], ["Room", 143], ["(", 148], ["ROSIER", 149], [")", 155], ["tool", 157], ["has", 162], ["been", 166], ["shown", 171], ["superior", 177], ["to", 186], ["the", 189], ["FAST", 193], ["in", 198], ["identifying", 201], ["strokes", 213], ["in", 221], ["emergency", 224], ["departments", 234], ["but", 246], ["has", 250], ["not", 254], ["previously", 258], ["been", 269], ["tested", 274], ["in", 281], ["the", 284], ["ambulance", 288], ["setting", 298], [".", 305], ["We", 307], ["investigated", 310], ["whether", 323], ["ROSIER", 331], ["use", 338], ["by", 342], ["ambulance", 345], ["clinicians", 355], ["can", 366], ["improve", 370], ["stroke", 378], ["recognition", 385], [".", 396], ["Ambulance", 398], ["clinicians", 408], ["used", 419], ["the", 424], ["ROSIER", 428], ["in", 435], ["place", 438], ["of", 444], ["the", 447], ["FAST", 451], ["to", 456], ["assess", 459], ["patients", 466], ["with", 475], ["suspected", 480], ["stroke", 490], [".", 496], ["As", 498], ["the", 501], ["ROSIER", 505], ["includes", 512], ["all", 521], ["FAST", 525], ["elements", 530], [",", 538], ["we", 540], ["calculated", 543], ["a", 554], ["FAST", 556], ["score", 561], ["from", 567], ["the", 572], ["ROSIER", 576], ["to", 583], ["enable", 586], ["comparisons", 593], ["between", 605], ["the", 613], ["two", 617], ["tools", 621], [".", 626], ["Ambulance", 628], ["clinicians", 638], ["'", 648], ["provisional", 650], ["stroke", 662], ["diagnoses", 669], ["using", 679], ["the", 685], ["ROSIER", 689], ["and", 696], ["calculated", 700], ["FAST", 711], ["were", 716], ["compared", 721], ["with", 730], ["stroke", 735], ["consultants", 742], ["'", 753], ["diagnosis", 755], [".", 764], ["We", 766], ["used", 769], ["stepwise", 774], ["logistic", 783], ["regression", 792], ["to", 803], ["compare", 806], ["the", 814], ["contribution", 818], ["of", 831], ["individual", 834], ["ROSIER", 845], ["and", 852], ["FAST", 856], ["items", 861], ["and", 867], ["patient", 871], ["demographics", 879], ["to", 892], ["the", 895], ["prediction", 899], ["of", 910], ["consultants", 913], ["'", 924], ["diagnoses", 926], [".", 935], ["Sixty", 937], ["-", 942], ["four", 943], ["percent", 948], ["of", 956], ["strokes", 959], ["and", 967], ["78", 971], ["%", 973], ["of", 975], ["nonstrokes", 978], ["identified", 989], ["by", 1000], ["ambulance", 1003], ["clinicians", 1013], ["using", 1024], ["the", 1030], ["ROSIER", 1034], ["were", 1041], ["subsequently", 1046], ["confirmed", 1059], ["by", 1069], ["a", 1072], ["stroke", 1074], ["consultant", 1081], [".", 1091], ["There", 1093], ["was", 1099], ["no", 1103], ["difference", 1106], ["in", 1117], ["the", 1120], ["proportion", 1124], ["of", 1135], ["strokes", 1138], ["correctly", 1146], ["detected", 1156], ["by", 1165], ["the", 1168], ["ROSIER", 1172], ["or", 1179], ["FAST", 1182], ["with", 1187], ["both", 1192], ["displaying", 1197], ["excellent", 1208], ["levels", 1218], ["of", 1225], ["sensitivity", 1228], [".", 1239], ["The", 1241], ["ROSIER", 1245], ["detected", 1252], ["marginally", 1261], ["more", 1272], ["nonstroke", 1277], ["cases", 1287], ["than", 1293], ["the", 1298], ["FAST", 1302], [",", 1306], ["but", 1308], ["both", 1312], ["demonstrated", 1317], ["poor", 1330], ["specificity", 1335], [".", 1346], ["Facial", 1348], ["weakness", 1355], [",", 1363], ["arm", 1365], ["weakness", 1369], [",", 1377], ["seizure", 1379], ["activity", 1387], [",", 1395], ["age", 1397], [",", 1400], ["and", 1402], ["sex", 1406], ["predicted", 1410], ["consultants", 1420], ["'", 1431], ["diagnosis", 1433], ["of", 1443], ["stroke", 1446], [".", 1452], ["The", 1454], ["ROSIER", 1458], ["was", 1465], ["not", 1469], ["better", 1473], ["than", 1480], ["the", 1485], ["FAST", 1489], ["for", 1494], ["prehospital", 1498], ["recognition", 1510], ["of", 1522], ["stroke", 1525], [".", 1531], ["A", 1533], ["revised", 1535], ["version", 1543], ["of", 1551], ["the", 1554], ["FAST", 1558], ["incorporating", 1563], ["assessment", 1577], ["of", 1588], ["seizure", 1591], ["activity", 1599], ["may", 1608], ["improve", 1612], ["stroke", 1620], ["identification", 1627], ["and", 1642], ["decision", 1646], ["making", 1655], ["by", 1662], ["ambulance", 1665], ["clinicians", 1675], [".", 1685]]}
{"context": "To evaluate the usefulness of the periportal free air (PPFA) sign on computed tomography (CT) to distinguish upper from lower gastrointestinal (GI) tract perforation. During a 30-month period, we retrospectively analyzed abdominal CT images of 53 consecutive patients with surgically proven GI tract perforation. We divided the patients into two groups, i.e. upper and lower GI tract perforation groups. According to the distribution of free air, we divided the peritoneal cavity into supramesocolic compartment and inframesocolic compartment. We observed the presence or absence of free air in each compartment in each group. When there was free air in the periportal area, it was defined as periportal free air (PPFA) and the sign was positive. To evaluate the usefulness of the PPFA sign, we compared the PPFA sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known CT signs of pneumoperitoneum. Statistical analyses were performed with univariate and multivariate analyses using SPSS version 11.5 for significant findings among the CT signs. Free air was seen in supramesocolic compartment in 29 of 30 (97%) patients in the upper GI perforation group and in 17 of 23 (74%) in the lower GI perforation group. Free air in inframesocolic compartment did not show significant difference in either group (p=.16). The PPFA sign was seen in 28 of 30 (93%) patients with upper GI tract perforation, but in only 8 of 23 (35%) patients with lower GI tract perforation (p<.0001). The falciform ligament sign was seen in 24 of 30 (80%) patients with upper GI tract perforation and in 10 of 23 (43%) patients with lower GI tract perforation (p=.020). The ligamentum teres sign was seen in 16 of 30 (53%) patients with upper GI tract perforation and in 2 of 23 (8%) patients with lower GI tract perforation (p=.008). Multivariate logistic regression analysis showed that the PPFA sign was the only variable, which adjusted odds ratio of 15.5 (p=.002). The PPFA sign is a useful finding which can help to distinguish upper from lower GI tract perforation. When this sign is present, upper GI tract perforation is strongly suggested.", "qas": [{"question": "Falciform ligament sign is characteristic to which disease?", "answers": ["pneumoperitoneum"], "qid": "7b02cb46d87c4b849e37b82396d1c3b0", "question_tokens": [["Falciform", 0], ["ligament", 10], ["sign", 19], ["is", 24], ["characteristic", 27], ["to", 42], ["which", 45], ["disease", 51], ["?", 58]], "detected_answers": [{"text": "pneumoperitoneum", "token_spans": [[167, 167]], "char_spans": [[923, 938]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["usefulness", 16], ["of", 27], ["the", 30], ["periportal", 34], ["free", 45], ["air", 50], ["(", 54], ["PPFA", 55], [")", 59], ["sign", 61], ["on", 66], ["computed", 69], ["tomography", 78], ["(", 89], ["CT", 90], [")", 92], ["to", 94], ["distinguish", 97], ["upper", 109], ["from", 115], ["lower", 120], ["gastrointestinal", 126], ["(", 143], ["GI", 144], [")", 146], ["tract", 148], ["perforation", 154], [".", 165], ["During", 167], ["a", 174], ["30-month", 176], ["period", 185], [",", 191], ["we", 193], ["retrospectively", 196], ["analyzed", 212], ["abdominal", 221], ["CT", 231], ["images", 234], ["of", 241], ["53", 244], ["consecutive", 247], ["patients", 259], ["with", 268], ["surgically", 273], ["proven", 284], ["GI", 291], ["tract", 294], ["perforation", 300], [".", 311], ["We", 313], ["divided", 316], ["the", 324], ["patients", 328], ["into", 337], ["two", 342], ["groups", 346], [",", 352], ["i.e.", 354], ["upper", 359], ["and", 365], ["lower", 369], ["GI", 375], ["tract", 378], ["perforation", 384], ["groups", 396], [".", 402], ["According", 404], ["to", 414], ["the", 417], ["distribution", 421], ["of", 434], ["free", 437], ["air", 442], [",", 445], ["we", 447], ["divided", 450], ["the", 458], ["peritoneal", 462], ["cavity", 473], ["into", 480], ["supramesocolic", 485], ["compartment", 500], ["and", 512], ["inframesocolic", 516], ["compartment", 531], [".", 542], ["We", 544], ["observed", 547], ["the", 556], ["presence", 560], ["or", 569], ["absence", 572], ["of", 580], ["free", 583], ["air", 588], ["in", 592], ["each", 595], ["compartment", 600], ["in", 612], ["each", 615], ["group", 620], [".", 625], ["When", 627], ["there", 632], ["was", 638], ["free", 642], ["air", 647], ["in", 651], ["the", 654], ["periportal", 658], ["area", 669], [",", 673], ["it", 675], ["was", 678], ["defined", 682], ["as", 690], ["periportal", 693], ["free", 704], ["air", 709], ["(", 713], ["PPFA", 714], [")", 718], ["and", 720], ["the", 724], ["sign", 728], ["was", 733], ["positive", 737], [".", 745], ["To", 747], ["evaluate", 750], ["the", 759], ["usefulness", 763], ["of", 774], ["the", 777], ["PPFA", 781], ["sign", 786], [",", 790], ["we", 792], ["compared", 795], ["the", 804], ["PPFA", 808], ["sign", 813], ["with", 818], ["the", 823], ["falciform", 827], ["ligament", 837], ["sign", 846], ["and", 851], ["the", 855], ["ligamentum", 859], ["teres", 870], ["sign", 876], [",", 880], ["both", 882], ["of", 887], ["which", 890], ["are", 896], ["well", 900], ["-", 904], ["known", 905], ["CT", 911], ["signs", 914], ["of", 920], ["pneumoperitoneum", 923], [".", 939], ["Statistical", 941], ["analyses", 953], ["were", 962], ["performed", 967], ["with", 977], ["univariate", 982], ["and", 993], ["multivariate", 997], ["analyses", 1010], ["using", 1019], ["SPSS", 1025], ["version", 1030], ["11.5", 1038], ["for", 1043], ["significant", 1047], ["findings", 1059], ["among", 1068], ["the", 1074], ["CT", 1078], ["signs", 1081], [".", 1086], ["Free", 1088], ["air", 1093], ["was", 1097], ["seen", 1101], ["in", 1106], ["supramesocolic", 1109], ["compartment", 1124], ["in", 1136], ["29", 1139], ["of", 1142], ["30", 1145], ["(", 1148], ["97", 1149], ["%", 1151], [")", 1152], ["patients", 1154], ["in", 1163], ["the", 1166], ["upper", 1170], ["GI", 1176], ["perforation", 1179], ["group", 1191], ["and", 1197], ["in", 1201], ["17", 1204], ["of", 1207], ["23", 1210], ["(", 1213], ["74", 1214], ["%", 1216], [")", 1217], ["in", 1219], ["the", 1222], ["lower", 1226], ["GI", 1232], ["perforation", 1235], ["group", 1247], [".", 1252], ["Free", 1254], ["air", 1259], ["in", 1263], ["inframesocolic", 1266], ["compartment", 1281], ["did", 1293], ["not", 1297], ["show", 1301], ["significant", 1306], ["difference", 1318], ["in", 1329], ["either", 1332], ["group", 1339], ["(", 1345], ["p=.16", 1346], [")", 1351], [".", 1352], ["The", 1354], ["PPFA", 1358], ["sign", 1363], ["was", 1368], ["seen", 1372], ["in", 1377], ["28", 1380], ["of", 1383], ["30", 1386], ["(", 1389], ["93", 1390], ["%", 1392], [")", 1393], ["patients", 1395], ["with", 1404], ["upper", 1409], ["GI", 1415], ["tract", 1418], ["perforation", 1424], [",", 1435], ["but", 1437], ["in", 1441], ["only", 1444], ["8", 1449], ["of", 1451], ["23", 1454], ["(", 1457], ["35", 1458], ["%", 1460], [")", 1461], ["patients", 1463], ["with", 1472], ["lower", 1477], ["GI", 1483], ["tract", 1486], ["perforation", 1492], ["(", 1504], ["p<.0001", 1505], [")", 1512], [".", 1513], ["The", 1515], ["falciform", 1519], ["ligament", 1529], ["sign", 1538], ["was", 1543], ["seen", 1547], ["in", 1552], ["24", 1555], ["of", 1558], ["30", 1561], ["(", 1564], ["80", 1565], ["%", 1567], [")", 1568], ["patients", 1570], ["with", 1579], ["upper", 1584], ["GI", 1590], ["tract", 1593], ["perforation", 1599], ["and", 1611], ["in", 1615], ["10", 1618], ["of", 1621], ["23", 1624], ["(", 1627], ["43", 1628], ["%", 1630], [")", 1631], ["patients", 1633], ["with", 1642], ["lower", 1647], ["GI", 1653], ["tract", 1656], ["perforation", 1662], ["(", 1674], ["p=.020", 1675], [")", 1681], [".", 1682], ["The", 1684], ["ligamentum", 1688], ["teres", 1699], ["sign", 1705], ["was", 1710], ["seen", 1714], ["in", 1719], ["16", 1722], ["of", 1725], ["30", 1728], ["(", 1731], ["53", 1732], ["%", 1734], [")", 1735], ["patients", 1737], ["with", 1746], ["upper", 1751], ["GI", 1757], ["tract", 1760], ["perforation", 1766], ["and", 1778], ["in", 1782], ["2", 1785], ["of", 1787], ["23", 1790], ["(", 1793], ["8", 1794], ["%", 1795], [")", 1796], ["patients", 1798], ["with", 1807], ["lower", 1812], ["GI", 1818], ["tract", 1821], ["perforation", 1827], ["(", 1839], ["p=.008", 1840], [")", 1846], [".", 1847], ["Multivariate", 1849], ["logistic", 1862], ["regression", 1871], ["analysis", 1882], ["showed", 1891], ["that", 1898], ["the", 1903], ["PPFA", 1907], ["sign", 1912], ["was", 1917], ["the", 1921], ["only", 1925], ["variable", 1930], [",", 1938], ["which", 1940], ["adjusted", 1946], ["odds", 1955], ["ratio", 1960], ["of", 1966], ["15.5", 1969], ["(", 1974], ["p=.002", 1975], [")", 1981], [".", 1982], ["The", 1984], ["PPFA", 1988], ["sign", 1993], ["is", 1998], ["a", 2001], ["useful", 2003], ["finding", 2010], ["which", 2018], ["can", 2024], ["help", 2028], ["to", 2033], ["distinguish", 2036], ["upper", 2048], ["from", 2054], ["lower", 2059], ["GI", 2065], ["tract", 2068], ["perforation", 2074], [".", 2085], ["When", 2087], ["this", 2092], ["sign", 2097], ["is", 2102], ["present", 2105], [",", 2112], ["upper", 2114], ["GI", 2120], ["tract", 2123], ["perforation", 2129], ["is", 2141], ["strongly", 2144], ["suggested", 2153], [".", 2162]]}
{"context": "Transcription factors belonging to the nuclear factor of activated T cells (NFAT) family regulate the expression of cytokine genes and other inducible genes during the immune response. The functions of NFAT proteins are directly controlled by the calcium- and calmodulin-dependent phosphatase calcineurin. Here we show that the binding of calcineurin to NFAT is substantially increased when calcineurin is activated with calmodulin and calcium. FK506.FKBP12 drug-immunophilin complexes inhibited the interaction of NFAT with activated calcineurin much more effectively than they inhibited the interaction with inactive calcineurin, suggesting that part of the interaction with activated calcineurin involved the enzyme active site. We have previously shown that NFAT is targeted to inactive calcineurin at a region distinct from the calcineurin active site (Aramburu, J., Garcia-Cozar, F. J., Raghavan, A., Okamura, H., Rao, A., and Hogan, P. G. (1998) Mol. Cell 1, 627-637); this region is also involved in NFAT binding to activated calcineurin, since binding is inhibited by an NFAT peptide spanning the calcineurin docking site on NFAT. The interacting surfaces are located on the catalytic domain of the calcineurin A chain and on an 86-amino acid fragment of the NFAT regulatory domain. NFAT binding to the calcineurin catalytic domain was inhibited by the calcineurin autoinhibitory domain and the RII substrate peptide, which bind in the calcineurin active site, as well as by the NFAT docking site peptide, which binds to a region of calcineurin distinct from the active site. We propose that, in resting cells, NFAT is targeted to a region of the calcineurin catalytic domain that does not overlap the calcineurin active site. Upon cell activation, displacement of the autoinhibitory domain by calmodulin binding allows NFAT to bind additionally to the calcineurin active site, thus positioning NFAT for immediate dephosphorylation at functional phosphoserine residues.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "95cd880240a7419293999192f422b60e", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[194, 194], [293, 293], [93, 93], [211, 211], [82, 82], [46, 46], [182, 182], [230, 230], [237, 237], [250, 250], [55, 55], [103, 103], [324, 324], [270, 270], [120, 120], [62, 62], [301, 301], [127, 127]], "char_spans": [[1106, 1116], [1656, 1666], [619, 629], [1208, 1218], [535, 545], [293, 303], [1034, 1044], [1312, 1322], [1362, 1372], [1445, 1455], [339, 349], [687, 697], [1862, 1872], [1542, 1552], [791, 801], [391, 401], [1711, 1721], [833, 843]]}]}], "context_tokens": [["Transcription", 0], ["factors", 14], ["belonging", 22], ["to", 32], ["the", 35], ["nuclear", 39], ["factor", 47], ["of", 54], ["activated", 57], ["T", 67], ["cells", 69], ["(", 75], ["NFAT", 76], [")", 80], ["family", 82], ["regulate", 89], ["the", 98], ["expression", 102], ["of", 113], ["cytokine", 116], ["genes", 125], ["and", 131], ["other", 135], ["inducible", 141], ["genes", 151], ["during", 157], ["the", 164], ["immune", 168], ["response", 175], [".", 183], ["The", 185], ["functions", 189], ["of", 199], ["NFAT", 202], ["proteins", 207], ["are", 216], ["directly", 220], ["controlled", 229], ["by", 240], ["the", 243], ["calcium-", 247], ["and", 256], ["calmodulin", 260], ["-", 270], ["dependent", 271], ["phosphatase", 281], ["calcineurin", 293], [".", 304], ["Here", 306], ["we", 311], ["show", 314], ["that", 319], ["the", 324], ["binding", 328], ["of", 336], ["calcineurin", 339], ["to", 351], ["NFAT", 354], ["is", 359], ["substantially", 362], ["increased", 376], ["when", 386], ["calcineurin", 391], ["is", 403], ["activated", 406], ["with", 416], ["calmodulin", 421], ["and", 432], ["calcium", 436], [".", 443], ["FK506.FKBP12", 445], ["drug", 458], ["-", 462], ["immunophilin", 463], ["complexes", 476], ["inhibited", 486], ["the", 496], ["interaction", 500], ["of", 512], ["NFAT", 515], ["with", 520], ["activated", 525], ["calcineurin", 535], ["much", 547], ["more", 552], ["effectively", 557], ["than", 569], ["they", 574], ["inhibited", 579], ["the", 589], ["interaction", 593], ["with", 605], ["inactive", 610], ["calcineurin", 619], [",", 630], ["suggesting", 632], ["that", 643], ["part", 648], ["of", 653], ["the", 656], ["interaction", 660], ["with", 672], ["activated", 677], ["calcineurin", 687], ["involved", 699], ["the", 708], ["enzyme", 712], ["active", 719], ["site", 726], [".", 730], ["We", 732], ["have", 735], ["previously", 740], ["shown", 751], ["that", 757], ["NFAT", 762], ["is", 767], ["targeted", 770], ["to", 779], ["inactive", 782], ["calcineurin", 791], ["at", 803], ["a", 806], ["region", 808], ["distinct", 815], ["from", 824], ["the", 829], ["calcineurin", 833], ["active", 845], ["site", 852], ["(", 857], ["Aramburu", 858], [",", 866], ["J.", 868], [",", 870], ["Garcia", 872], ["-", 878], ["Cozar", 879], [",", 884], ["F.", 886], ["J.", 889], [",", 891], ["Raghavan", 893], [",", 901], ["A.", 903], [",", 905], ["Okamura", 907], [",", 914], ["H.", 916], [",", 918], ["Rao", 920], [",", 923], ["A.", 925], [",", 927], ["and", 929], ["Hogan", 933], [",", 938], ["P.", 940], ["G.", 943], ["(", 946], ["1998", 947], [")", 951], ["Mol", 953], [".", 956], ["Cell", 958], ["1", 963], [",", 964], ["627", 966], ["-", 969], ["637", 970], [")", 973], [";", 974], ["this", 976], ["region", 981], ["is", 988], ["also", 991], ["involved", 996], ["in", 1005], ["NFAT", 1008], ["binding", 1013], ["to", 1021], ["activated", 1024], ["calcineurin", 1034], [",", 1045], ["since", 1047], ["binding", 1053], ["is", 1061], ["inhibited", 1064], ["by", 1074], ["an", 1077], ["NFAT", 1080], ["peptide", 1085], ["spanning", 1093], ["the", 1102], ["calcineurin", 1106], ["docking", 1118], ["site", 1126], ["on", 1131], ["NFAT", 1134], [".", 1138], ["The", 1140], ["interacting", 1144], ["surfaces", 1156], ["are", 1165], ["located", 1169], ["on", 1177], ["the", 1180], ["catalytic", 1184], ["domain", 1194], ["of", 1201], ["the", 1204], ["calcineurin", 1208], ["A", 1220], ["chain", 1222], ["and", 1228], ["on", 1232], ["an", 1235], ["86-amino", 1238], ["acid", 1247], ["fragment", 1252], ["of", 1261], ["the", 1264], ["NFAT", 1268], ["regulatory", 1273], ["domain", 1284], [".", 1290], ["NFAT", 1292], ["binding", 1297], ["to", 1305], ["the", 1308], ["calcineurin", 1312], ["catalytic", 1324], ["domain", 1334], ["was", 1341], ["inhibited", 1345], ["by", 1355], ["the", 1358], ["calcineurin", 1362], ["autoinhibitory", 1374], ["domain", 1389], ["and", 1396], ["the", 1400], ["RII", 1404], ["substrate", 1408], ["peptide", 1418], [",", 1425], ["which", 1427], ["bind", 1433], ["in", 1438], ["the", 1441], ["calcineurin", 1445], ["active", 1457], ["site", 1464], [",", 1468], ["as", 1470], ["well", 1473], ["as", 1478], ["by", 1481], ["the", 1484], ["NFAT", 1488], ["docking", 1493], ["site", 1501], ["peptide", 1506], [",", 1513], ["which", 1515], ["binds", 1521], ["to", 1527], ["a", 1530], ["region", 1532], ["of", 1539], ["calcineurin", 1542], ["distinct", 1554], ["from", 1563], ["the", 1568], ["active", 1572], ["site", 1579], [".", 1583], ["We", 1585], ["propose", 1588], ["that", 1596], [",", 1600], ["in", 1602], ["resting", 1605], ["cells", 1613], [",", 1618], ["NFAT", 1620], ["is", 1625], ["targeted", 1628], ["to", 1637], ["a", 1640], ["region", 1642], ["of", 1649], ["the", 1652], ["calcineurin", 1656], ["catalytic", 1668], ["domain", 1678], ["that", 1685], ["does", 1690], ["not", 1695], ["overlap", 1699], ["the", 1707], ["calcineurin", 1711], ["active", 1723], ["site", 1730], [".", 1734], ["Upon", 1736], ["cell", 1741], ["activation", 1746], [",", 1756], ["displacement", 1758], ["of", 1771], ["the", 1774], ["autoinhibitory", 1778], ["domain", 1793], ["by", 1800], ["calmodulin", 1803], ["binding", 1814], ["allows", 1822], ["NFAT", 1829], ["to", 1834], ["bind", 1837], ["additionally", 1842], ["to", 1855], ["the", 1858], ["calcineurin", 1862], ["active", 1874], ["site", 1881], [",", 1885], ["thus", 1887], ["positioning", 1892], ["NFAT", 1904], ["for", 1909], ["immediate", 1913], ["dephosphorylation", 1923], ["at", 1941], ["functional", 1944], ["phosphoserine", 1955], ["residues", 1969], [".", 1977]]}
{"context": "We report the development of OikoBase (http://oikoarrays.biology.uiowa.edu/Oiko/), a tiling array-based genome browser resource for Oikopleura dioica, a metazoan belonging to the urochordates, the closest extant group to vertebrates. OikoBase facilitates retrieval and mining of a variety of useful genomics information. First, it includes a genome browser which interrogates 1260 genomic sequence scaffolds and features gene, transcript and CDS annotation tracks. Second, we annotated gene models with gene ontology (GO) terms and InterPro domains which are directly accessible in the browser with links to their entries in the GO (http://www.geneontology.org/) and InterPro (http://www.ebi.ac.uk/interpro/) databases, and we provide transcript and peptide links for sequence downloads. Third, we introduce the transcriptomics of a comprehensive set of developmental stages of O. dioica at high resolution and provide downloadable gene expression data for all developmental stages. Fourth, we incorporate a BLAST tool to identify homologs of genes and proteins. Finally, we include a tutorial that describes how to use OikoBase as well as a link to detailed methods, explaining the data generation and analysis pipeline. OikoBase will provide a valuable resource for research in chordate development, genome evolution and plasticity and the molecular ecology of this important marine planktonic organism.", "qas": [{"question": "Mention the only available genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica", "answers": ["OikoBase"], "qid": "6fc08188d45a419184053b7f1897cddc", "question_tokens": [["Mention", 0], ["the", 8], ["only", 12], ["available", 17], ["genomics", 27], ["and", 36], ["developmental", 40], ["transcriptomics", 54], ["resource", 70], ["for", 79], ["the", 83], ["urochordate", 87], ["Oikopleura", 99], ["dioica", 110]], "detected_answers": [{"text": "OikoBase", "token_spans": [[36, 36], [180, 180], [5, 5], [198, 198]], "char_spans": [[234, 241], [1120, 1127], [29, 36], [1222, 1229]]}]}], "context_tokens": [["We", 0], ["report", 3], ["the", 10], ["development", 14], ["of", 26], ["OikoBase", 29], ["(", 38], ["http://oikoarrays.biology.uiowa.edu/Oiko/", 39], [")", 80], [",", 81], ["a", 83], ["tiling", 85], ["array", 92], ["-", 97], ["based", 98], ["genome", 104], ["browser", 111], ["resource", 119], ["for", 128], ["Oikopleura", 132], ["dioica", 143], [",", 149], ["a", 151], ["metazoan", 153], ["belonging", 162], ["to", 172], ["the", 175], ["urochordates", 179], [",", 191], ["the", 193], ["closest", 197], ["extant", 205], ["group", 212], ["to", 218], ["vertebrates", 221], [".", 232], ["OikoBase", 234], ["facilitates", 243], ["retrieval", 255], ["and", 265], ["mining", 269], ["of", 276], ["a", 279], ["variety", 281], ["of", 289], ["useful", 292], ["genomics", 299], ["information", 308], [".", 319], ["First", 321], [",", 326], ["it", 328], ["includes", 331], ["a", 340], ["genome", 342], ["browser", 349], ["which", 357], ["interrogates", 363], ["1260", 376], ["genomic", 381], ["sequence", 389], ["scaffolds", 398], ["and", 408], ["features", 412], ["gene", 421], [",", 425], ["transcript", 427], ["and", 438], ["CDS", 442], ["annotation", 446], ["tracks", 457], [".", 463], ["Second", 465], [",", 471], ["we", 473], ["annotated", 476], ["gene", 486], ["models", 491], ["with", 498], ["gene", 503], ["ontology", 508], ["(", 517], ["GO", 518], [")", 520], ["terms", 522], ["and", 528], ["InterPro", 532], ["domains", 541], ["which", 549], ["are", 555], ["directly", 559], ["accessible", 568], ["in", 579], ["the", 582], ["browser", 586], ["with", 594], ["links", 599], ["to", 605], ["their", 608], ["entries", 614], ["in", 622], ["the", 625], ["GO", 629], ["(", 632], ["http://www.geneontology.org/", 633], [")", 661], ["and", 663], ["InterPro", 667], ["(", 676], ["http://www.ebi.ac.uk/interpro/", 677], [")", 707], ["databases", 709], [",", 718], ["and", 720], ["we", 724], ["provide", 727], ["transcript", 735], ["and", 746], ["peptide", 750], ["links", 758], ["for", 764], ["sequence", 768], ["downloads", 777], [".", 786], ["Third", 788], [",", 793], ["we", 795], ["introduce", 798], ["the", 808], ["transcriptomics", 812], ["of", 828], ["a", 831], ["comprehensive", 833], ["set", 847], ["of", 851], ["developmental", 854], ["stages", 868], ["of", 875], ["O.", 878], ["dioica", 881], ["at", 888], ["high", 891], ["resolution", 896], ["and", 907], ["provide", 911], ["downloadable", 919], ["gene", 932], ["expression", 937], ["data", 948], ["for", 953], ["all", 957], ["developmental", 961], ["stages", 975], [".", 981], ["Fourth", 983], [",", 989], ["we", 991], ["incorporate", 994], ["a", 1006], ["BLAST", 1008], ["tool", 1014], ["to", 1019], ["identify", 1022], ["homologs", 1031], ["of", 1040], ["genes", 1043], ["and", 1049], ["proteins", 1053], [".", 1061], ["Finally", 1063], [",", 1070], ["we", 1072], ["include", 1075], ["a", 1083], ["tutorial", 1085], ["that", 1094], ["describes", 1099], ["how", 1109], ["to", 1113], ["use", 1116], ["OikoBase", 1120], ["as", 1129], ["well", 1132], ["as", 1137], ["a", 1140], ["link", 1142], ["to", 1147], ["detailed", 1150], ["methods", 1159], [",", 1166], ["explaining", 1168], ["the", 1179], ["data", 1183], ["generation", 1188], ["and", 1199], ["analysis", 1203], ["pipeline", 1212], [".", 1220], ["OikoBase", 1222], ["will", 1231], ["provide", 1236], ["a", 1244], ["valuable", 1246], ["resource", 1255], ["for", 1264], ["research", 1268], ["in", 1277], ["chordate", 1280], ["development", 1289], [",", 1300], ["genome", 1302], ["evolution", 1309], ["and", 1319], ["plasticity", 1323], ["and", 1334], ["the", 1338], ["molecular", 1342], ["ecology", 1352], ["of", 1360], ["this", 1363], ["important", 1368], ["marine", 1378], ["planktonic", 1385], ["organism", 1396], [".", 1404]]}
{"context": "Past studies have documented a crosstalk between H2B ubiquitylation (H2Bub) and H3K4 methylation, but little (if any) direct evidence exists explaining the mechanism underlying H2Bub-dependent H3K4 methylation on chromatin templates. Here, we took advantage of an in vitro histone methyltransferase assay employing a reconstituted yeast Set1 complex (ySet1C) and a recombinant chromatin template containing fully ubiquitylated H2B to gain valuable insights. Combined with genetic analyses, we demonstrate that the n-SET domain within Set1, but not Swd2, is essential for H2Bub-dependent H3K4 methylation. Spp1, a homolog of human CFP1, is conditionally involved in this crosstalk. Our findings extend to the human Set1 complex, underscoring the conserved nature of this disease-relevant crosstalk pathway. As not all members of the H3K4 methyltransferase family contain n-SET domains, our studies draw attention to the n-SET domain as a predictor of an H2B ubiquitylation-sensing mechanism that leads to downstream H3K4 methylation.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "0e9ad5ae9db7422d92338cea8e52e210", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[84, 85], [161, 162]], "char_spans": [[516, 525], [921, 930]]}]}], "context_tokens": [["Past", 0], ["studies", 5], ["have", 13], ["documented", 18], ["a", 29], ["crosstalk", 31], ["between", 41], ["H2B", 49], ["ubiquitylation", 53], ["(", 68], ["H2Bub", 69], [")", 74], ["and", 76], ["H3K4", 80], ["methylation", 85], [",", 96], ["but", 98], ["little", 102], ["(", 109], ["if", 110], ["any", 113], [")", 116], ["direct", 118], ["evidence", 125], ["exists", 134], ["explaining", 141], ["the", 152], ["mechanism", 156], ["underlying", 166], ["H2Bub", 177], ["-", 182], ["dependent", 183], ["H3K4", 193], ["methylation", 198], ["on", 210], ["chromatin", 213], ["templates", 223], [".", 232], ["Here", 234], [",", 238], ["we", 240], ["took", 243], ["advantage", 248], ["of", 258], ["an", 261], ["in", 264], ["vitro", 267], ["histone", 273], ["methyltransferase", 281], ["assay", 299], ["employing", 305], ["a", 315], ["reconstituted", 317], ["yeast", 331], ["Set1", 337], ["complex", 342], ["(", 350], ["ySet1C", 351], [")", 357], ["and", 359], ["a", 363], ["recombinant", 365], ["chromatin", 377], ["template", 387], ["containing", 396], ["fully", 407], ["ubiquitylated", 413], ["H2B", 427], ["to", 431], ["gain", 434], ["valuable", 439], ["insights", 448], [".", 456], ["Combined", 458], ["with", 467], ["genetic", 472], ["analyses", 480], [",", 488], ["we", 490], ["demonstrate", 493], ["that", 505], ["the", 510], ["n", 514], ["-", 515], ["SET", 516], ["domain", 520], ["within", 527], ["Set1", 534], [",", 538], ["but", 540], ["not", 544], ["Swd2", 548], [",", 552], ["is", 554], ["essential", 557], ["for", 567], ["H2Bub", 571], ["-", 576], ["dependent", 577], ["H3K4", 587], ["methylation", 592], [".", 603], ["Spp1", 605], [",", 609], ["a", 611], ["homolog", 613], ["of", 621], ["human", 624], ["CFP1", 630], [",", 634], ["is", 636], ["conditionally", 639], ["involved", 653], ["in", 662], ["this", 665], ["crosstalk", 670], [".", 679], ["Our", 681], ["findings", 685], ["extend", 694], ["to", 701], ["the", 704], ["human", 708], ["Set1", 714], ["complex", 719], [",", 726], ["underscoring", 728], ["the", 741], ["conserved", 745], ["nature", 755], ["of", 762], ["this", 765], ["disease", 770], ["-", 777], ["relevant", 778], ["crosstalk", 787], ["pathway", 797], [".", 804], ["As", 806], ["not", 809], ["all", 813], ["members", 817], ["of", 825], ["the", 828], ["H3K4", 832], ["methyltransferase", 837], ["family", 855], ["contain", 862], ["n", 870], ["-", 871], ["SET", 872], ["domains", 876], [",", 883], ["our", 885], ["studies", 889], ["draw", 897], ["attention", 902], ["to", 912], ["the", 915], ["n", 919], ["-", 920], ["SET", 921], ["domain", 925], ["as", 932], ["a", 935], ["predictor", 937], ["of", 947], ["an", 950], ["H2B", 953], ["ubiquitylation", 957], ["-", 971], ["sensing", 972], ["mechanism", 980], ["that", 990], ["leads", 995], ["to", 1001], ["downstream", 1004], ["H3K4", 1015], ["methylation", 1020], [".", 1031]]}
{"context": "To investigate the clinical feature of Parkinson's disease (PD) with restless leg syndrome (RLS) and the pathogenesis of RLS. We conducted a cross-sectional and control study. The case group concluded 31 PD with RLS patients, meanwhile 39 PD patients were selected as the control group. Clinical history, clinical manifestations, complications and laboratory examinations were compared respectively between the two groups. All the RLS symptoms did not appear in RLS patients until the PD symptoms came out. Significant differences were found in complications such as swallow disturbance, constipation and illusion, when we compared the two PD groups (P < 0.05). Compared with the PD or healthy group, the level of serum ferritin and the H-reflex latency of tibial nerve were significantly decreased in PD with RLS group (P < 0.05). Secondary RLS is a complication of PD. Deficiency of iron and decreased inhibition function of spinal cord may lead to the occurrence of RLS in PD patients. When their motor symptoms are serious and complications are more common, PD patients are more possible to have RLS symptoms.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "174f261677d84e0880d30296aca0dc8a", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[165, 165]], "char_spans": [[885, 888]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["clinical", 19], ["feature", 28], ["of", 36], ["Parkinson", 39], ["'s", 48], ["disease", 51], ["(", 59], ["PD", 60], [")", 62], ["with", 64], ["restless", 69], ["leg", 78], ["syndrome", 82], ["(", 91], ["RLS", 92], [")", 95], ["and", 97], ["the", 101], ["pathogenesis", 105], ["of", 118], ["RLS", 121], [".", 124], ["We", 126], ["conducted", 129], ["a", 139], ["cross", 141], ["-", 146], ["sectional", 147], ["and", 157], ["control", 161], ["study", 169], [".", 174], ["The", 176], ["case", 180], ["group", 185], ["concluded", 191], ["31", 201], ["PD", 204], ["with", 207], ["RLS", 212], ["patients", 216], [",", 224], ["meanwhile", 226], ["39", 236], ["PD", 239], ["patients", 242], ["were", 251], ["selected", 256], ["as", 265], ["the", 268], ["control", 272], ["group", 280], [".", 285], ["Clinical", 287], ["history", 296], [",", 303], ["clinical", 305], ["manifestations", 314], [",", 328], ["complications", 330], ["and", 344], ["laboratory", 348], ["examinations", 359], ["were", 372], ["compared", 377], ["respectively", 386], ["between", 399], ["the", 407], ["two", 411], ["groups", 415], [".", 421], ["All", 423], ["the", 427], ["RLS", 431], ["symptoms", 435], ["did", 444], ["not", 448], ["appear", 452], ["in", 459], ["RLS", 462], ["patients", 466], ["until", 475], ["the", 481], ["PD", 485], ["symptoms", 488], ["came", 497], ["out", 502], [".", 505], ["Significant", 507], ["differences", 519], ["were", 531], ["found", 536], ["in", 542], ["complications", 545], ["such", 559], ["as", 564], ["swallow", 567], ["disturbance", 575], [",", 586], ["constipation", 588], ["and", 601], ["illusion", 605], [",", 613], ["when", 615], ["we", 620], ["compared", 623], ["the", 632], ["two", 636], ["PD", 640], ["groups", 643], ["(", 650], ["P", 651], ["<", 653], ["0.05", 655], [")", 659], [".", 660], ["Compared", 662], ["with", 671], ["the", 676], ["PD", 680], ["or", 683], ["healthy", 686], ["group", 694], [",", 699], ["the", 701], ["level", 705], ["of", 711], ["serum", 714], ["ferritin", 720], ["and", 729], ["the", 733], ["H", 737], ["-", 738], ["reflex", 739], ["latency", 746], ["of", 754], ["tibial", 757], ["nerve", 764], ["were", 770], ["significantly", 775], ["decreased", 789], ["in", 799], ["PD", 802], ["with", 805], ["RLS", 810], ["group", 814], ["(", 820], ["P", 821], ["<", 823], ["0.05", 825], [")", 829], [".", 830], ["Secondary", 832], ["RLS", 842], ["is", 846], ["a", 849], ["complication", 851], ["of", 864], ["PD", 867], [".", 869], ["Deficiency", 871], ["of", 882], ["iron", 885], ["and", 890], ["decreased", 894], ["inhibition", 904], ["function", 915], ["of", 924], ["spinal", 927], ["cord", 934], ["may", 939], ["lead", 943], ["to", 948], ["the", 951], ["occurrence", 955], ["of", 966], ["RLS", 969], ["in", 973], ["PD", 976], ["patients", 979], [".", 987], ["When", 989], ["their", 994], ["motor", 1000], ["symptoms", 1006], ["are", 1015], ["serious", 1019], ["and", 1027], ["complications", 1031], ["are", 1045], ["more", 1049], ["common", 1054], [",", 1060], ["PD", 1062], ["patients", 1065], ["are", 1074], ["more", 1078], ["possible", 1083], ["to", 1092], ["have", 1095], ["RLS", 1100], ["symptoms", 1104], [".", 1112]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a common movement disorder characterised by an uncontrollable urge to move because of uncomfortable, sometimes painful sensations in the legs with a diurnal variation and a release with movement. The pathophysiology is only partially known and a genetic component together with dopaminergic and brain iron dysregulation plays an important role. Secondary causes for RLS need to be excluded. Treatment depends on the severity and frequency of RLS symptoms, comprises non-pharmacological (eg lifestyle changes) and pharmacological interventions (eg dopaminergic medication, alpha-2-delta calcium channel ligands, opioids) and relieves symptoms only. Augmentation is the main complication of long-term dopaminergic treatment of RLS. This article will provide a clinically useful overview of RLS with provision of diagnostic criteria, differential diagnoses, possible investigations and different treatment strategies with their associated complications.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "ee27b6a18fa848d0a07f50eae299fa52", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], ["(", 65], ["WED", 66], [")", 69], [",", 70], ["is", 72], ["a", 75], ["common", 77], ["movement", 84], ["disorder", 93], ["characterised", 102], ["by", 116], ["an", 119], ["uncontrollable", 122], ["urge", 137], ["to", 142], ["move", 145], ["because", 150], ["of", 158], ["uncomfortable", 161], [",", 174], ["sometimes", 176], ["painful", 186], ["sensations", 194], ["in", 205], ["the", 208], ["legs", 212], ["with", 217], ["a", 222], ["diurnal", 224], ["variation", 232], ["and", 242], ["a", 246], ["release", 248], ["with", 256], ["movement", 261], [".", 269], ["The", 271], ["pathophysiology", 275], ["is", 291], ["only", 294], ["partially", 299], ["known", 309], ["and", 315], ["a", 319], ["genetic", 321], ["component", 329], ["together", 339], ["with", 348], ["dopaminergic", 353], ["and", 366], ["brain", 370], ["iron", 376], ["dysregulation", 381], ["plays", 395], ["an", 401], ["important", 404], ["role", 414], [".", 418], ["Secondary", 420], ["causes", 430], ["for", 437], ["RLS", 441], ["need", 445], ["to", 450], ["be", 453], ["excluded", 456], [".", 464], ["Treatment", 466], ["depends", 476], ["on", 484], ["the", 487], ["severity", 491], ["and", 500], ["frequency", 504], ["of", 514], ["RLS", 517], ["symptoms", 521], [",", 529], ["comprises", 531], ["non", 541], ["-", 544], ["pharmacological", 545], ["(", 561], ["eg", 562], ["lifestyle", 565], ["changes", 575], [")", 582], ["and", 584], ["pharmacological", 588], ["interventions", 604], ["(", 618], ["eg", 619], ["dopaminergic", 622], ["medication", 635], [",", 645], ["alpha-2-delta", 647], ["calcium", 661], ["channel", 669], ["ligands", 677], [",", 684], ["opioids", 686], [")", 693], ["and", 695], ["relieves", 699], ["symptoms", 708], ["only", 717], [".", 721], ["Augmentation", 723], ["is", 736], ["the", 739], ["main", 743], ["complication", 748], ["of", 761], ["long", 764], ["-", 768], ["term", 769], ["dopaminergic", 774], ["treatment", 787], ["of", 797], ["RLS", 800], [".", 803], ["This", 805], ["article", 810], ["will", 818], ["provide", 823], ["a", 831], ["clinically", 833], ["useful", 844], ["overview", 851], ["of", 860], ["RLS", 863], ["with", 867], ["provision", 872], ["of", 882], ["diagnostic", 885], ["criteria", 896], [",", 904], ["differential", 906], ["diagnoses", 919], [",", 928], ["possible", 930], ["investigations", 939], ["and", 954], ["different", 958], ["treatment", 968], ["strategies", 978], ["with", 989], ["their", 994], ["associated", 1000], ["complications", 1011], [".", 1024]]}
{"context": "The Ehlers-Danlos Syndrome (EDS) is a rare connective tissue disorder characterised by fragility of the soft connective tissues and widespread manifestations in skin, ligaments, joints, blood vessels and internal organs. We report a case of a 12-year-old boy, previously diagnosed with kyphoscoliosis-type EDS (type VI), presenting with a left brachial artery pseudo-aneursym with history of multiple spontaneous and post-traumatic arterial ruptures. Surgical management of this patient was performed successfully by primary repair of brachial artery lesion.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "151aa629d0054dd180576c092fb49055", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[11, 12]], "char_spans": [[43, 59]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["Syndrome", 18], ["(", 27], ["EDS", 28], [")", 31], ["is", 33], ["a", 36], ["rare", 38], ["connective", 43], ["tissue", 54], ["disorder", 61], ["characterised", 70], ["by", 84], ["fragility", 87], ["of", 97], ["the", 100], ["soft", 104], ["connective", 109], ["tissues", 120], ["and", 128], ["widespread", 132], ["manifestations", 143], ["in", 158], ["skin", 161], [",", 165], ["ligaments", 167], [",", 176], ["joints", 178], [",", 184], ["blood", 186], ["vessels", 192], ["and", 200], ["internal", 204], ["organs", 213], [".", 219], ["We", 221], ["report", 224], ["a", 231], ["case", 233], ["of", 238], ["a", 241], ["12-year", 243], ["-", 250], ["old", 251], ["boy", 255], [",", 258], ["previously", 260], ["diagnosed", 271], ["with", 281], ["kyphoscoliosis", 286], ["-", 300], ["type", 301], ["EDS", 306], ["(", 310], ["type", 311], ["VI", 316], [")", 318], [",", 319], ["presenting", 321], ["with", 332], ["a", 337], ["left", 339], ["brachial", 344], ["artery", 353], ["pseudo", 360], ["-", 366], ["aneursym", 367], ["with", 376], ["history", 381], ["of", 389], ["multiple", 392], ["spontaneous", 401], ["and", 413], ["post", 417], ["-", 421], ["traumatic", 422], ["arterial", 432], ["ruptures", 441], [".", 449], ["Surgical", 451], ["management", 460], ["of", 471], ["this", 474], ["patient", 479], ["was", 487], ["performed", 491], ["successfully", 501], ["by", 514], ["primary", 517], ["repair", 525], ["of", 532], ["brachial", 535], ["artery", 544], ["lesion", 551], [".", 557]]}
{"context": "Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) has an unusual pathogenic mechanism. FSHD is caused by deletion of a subset of D4Z4 macrosatellite repeat units in the subtelomere of chromosome 4q. Recent studies provide compelling evidence that a retrotransposed gene in the D4Z4 repeat, DUX4, is expressed in the human germline and then epigenetically silenced in somatic tissues. In FSHD, the combination of inefficient chromatin silencing of the D4Z4 repeat and polymorphisms on the FSHD-permissive alleles that stabilize the DUX4 mRNAs emanating from the repeat result in inappropriate DUX4 protein expression in muscle cells. FSHD is thereby the first example of a human disease caused by the inefficient repression of a retrogene in a macrosatellite repeat array.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "fb6050311b794585986ab4a8b17b564e", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[6, 6], [65, 65], [104, 104], [14, 14], [81, 81]], "char_spans": [[59, 62], [402, 405], [648, 651], [102, 105], [503, 506]]}]}], "context_tokens": [["Autosomal", 0], ["dominant", 10], ["facioscapulohumeral", 19], ["muscular", 39], ["dystrophy", 48], ["(", 58], ["FSHD", 59], [")", 63], ["has", 65], ["an", 69], ["unusual", 72], ["pathogenic", 80], ["mechanism", 91], [".", 100], ["FSHD", 102], ["is", 107], ["caused", 110], ["by", 117], ["deletion", 120], ["of", 129], ["a", 132], ["subset", 134], ["of", 141], ["D4Z4", 144], ["macrosatellite", 149], ["repeat", 164], ["units", 171], ["in", 177], ["the", 180], ["subtelomere", 184], ["of", 196], ["chromosome", 199], ["4q", 210], [".", 212], ["Recent", 214], ["studies", 221], ["provide", 229], ["compelling", 237], ["evidence", 248], ["that", 257], ["a", 262], ["retrotransposed", 264], ["gene", 280], ["in", 285], ["the", 288], ["D4Z4", 292], ["repeat", 297], [",", 303], ["DUX4", 305], [",", 309], ["is", 311], ["expressed", 314], ["in", 324], ["the", 327], ["human", 331], ["germline", 337], ["and", 346], ["then", 350], ["epigenetically", 355], ["silenced", 370], ["in", 379], ["somatic", 382], ["tissues", 390], [".", 397], ["In", 399], ["FSHD", 402], [",", 406], ["the", 408], ["combination", 412], ["of", 424], ["inefficient", 427], ["chromatin", 439], ["silencing", 449], ["of", 459], ["the", 462], ["D4Z4", 466], ["repeat", 471], ["and", 478], ["polymorphisms", 482], ["on", 496], ["the", 499], ["FSHD", 503], ["-", 507], ["permissive", 508], ["alleles", 519], ["that", 527], ["stabilize", 532], ["the", 542], ["DUX4", 546], ["mRNAs", 551], ["emanating", 557], ["from", 567], ["the", 572], ["repeat", 576], ["result", 583], ["in", 590], ["inappropriate", 593], ["DUX4", 607], ["protein", 612], ["expression", 620], ["in", 631], ["muscle", 634], ["cells", 641], [".", 646], ["FSHD", 648], ["is", 653], ["thereby", 656], ["the", 664], ["first", 668], ["example", 674], ["of", 682], ["a", 685], ["human", 687], ["disease", 693], ["caused", 701], ["by", 708], ["the", 711], ["inefficient", 715], ["repression", 727], ["of", 738], ["a", 741], ["retrogene", 743], ["in", 753], ["a", 756], ["macrosatellite", 758], ["repeat", 773], ["array", 780], [".", 785]]}
{"context": "Among the movement disorders associated with acanthocytosis, McLeod syndrome (McKusick 314850) is the one that is best characterized on the molecular level. Its defining feature is low reactivity of Kell erythrocyte antigens. This is due to absence of membrane protein KX that forms a complex with the Kell protein. KX is coded for by the XK gene on the X-chromosome. We present six males (aged 29 to 60 years), with proven XK mutations, to discuss the chorea associated with McLeod syndrome. The movement disorder commonly develops in the fifth decade and is progressive. It affects the limbs, the trunk and the face. In addition to facial grimacing, involuntary vocalization can be present. In early stages there may only be some restlessness or slight involuntary distal movements of ankles and fingers. Lip-biting and facial tics seem more common in autosomal recessive choreoacanthocytosis linked to chromosome 9. This, together with the absence of dysphagia in McLeod syndrome, may help in differential diagnosis. Recent findings suggest a role for the endothelin system of the striatum in the pathogenesis of McLeod syndrome.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "7188c1bd11be428bab87e000b19fdf3b", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[83, 83], [61, 61]], "char_spans": [[424, 425], [339, 340]]}]}], "context_tokens": [["Among", 0], ["the", 6], ["movement", 10], ["disorders", 19], ["associated", 29], ["with", 40], ["acanthocytosis", 45], [",", 59], ["McLeod", 61], ["syndrome", 68], ["(", 77], ["McKusick", 78], ["314850", 87], [")", 93], ["is", 95], ["the", 98], ["one", 102], ["that", 106], ["is", 111], ["best", 114], ["characterized", 119], ["on", 133], ["the", 136], ["molecular", 140], ["level", 150], [".", 155], ["Its", 157], ["defining", 161], ["feature", 170], ["is", 178], ["low", 181], ["reactivity", 185], ["of", 196], ["Kell", 199], ["erythrocyte", 204], ["antigens", 216], [".", 224], ["This", 226], ["is", 231], ["due", 234], ["to", 238], ["absence", 241], ["of", 249], ["membrane", 252], ["protein", 261], ["KX", 269], ["that", 272], ["forms", 277], ["a", 283], ["complex", 285], ["with", 293], ["the", 298], ["Kell", 302], ["protein", 307], [".", 314], ["KX", 316], ["is", 319], ["coded", 322], ["for", 328], ["by", 332], ["the", 335], ["XK", 339], ["gene", 342], ["on", 347], ["the", 350], ["X", 354], ["-", 355], ["chromosome", 356], [".", 366], ["We", 368], ["present", 371], ["six", 379], ["males", 383], ["(", 389], ["aged", 390], ["29", 395], ["to", 398], ["60", 401], ["years", 404], [")", 409], [",", 410], ["with", 412], ["proven", 417], ["XK", 424], ["mutations", 427], [",", 436], ["to", 438], ["discuss", 441], ["the", 449], ["chorea", 453], ["associated", 460], ["with", 471], ["McLeod", 476], ["syndrome", 483], [".", 491], ["The", 493], ["movement", 497], ["disorder", 506], ["commonly", 515], ["develops", 524], ["in", 533], ["the", 536], ["fifth", 540], ["decade", 546], ["and", 553], ["is", 557], ["progressive", 560], [".", 571], ["It", 573], ["affects", 576], ["the", 584], ["limbs", 588], [",", 593], ["the", 595], ["trunk", 599], ["and", 605], ["the", 609], ["face", 613], [".", 617], ["In", 619], ["addition", 622], ["to", 631], ["facial", 634], ["grimacing", 641], [",", 650], ["involuntary", 652], ["vocalization", 664], ["can", 677], ["be", 681], ["present", 684], [".", 691], ["In", 693], ["early", 696], ["stages", 702], ["there", 709], ["may", 715], ["only", 719], ["be", 724], ["some", 727], ["restlessness", 732], ["or", 745], ["slight", 748], ["involuntary", 755], ["distal", 767], ["movements", 774], ["of", 784], ["ankles", 787], ["and", 794], ["fingers", 798], [".", 805], ["Lip", 807], ["-", 810], ["biting", 811], ["and", 818], ["facial", 822], ["tics", 829], ["seem", 834], ["more", 839], ["common", 844], ["in", 851], ["autosomal", 854], ["recessive", 864], ["choreoacanthocytosis", 874], ["linked", 895], ["to", 902], ["chromosome", 905], ["9", 916], [".", 917], ["This", 919], [",", 923], ["together", 925], ["with", 934], ["the", 939], ["absence", 943], ["of", 951], ["dysphagia", 954], ["in", 964], ["McLeod", 967], ["syndrome", 974], [",", 982], ["may", 984], ["help", 988], ["in", 993], ["differential", 996], ["diagnosis", 1009], [".", 1018], ["Recent", 1020], ["findings", 1027], ["suggest", 1036], ["a", 1044], ["role", 1046], ["for", 1051], ["the", 1055], ["endothelin", 1059], ["system", 1070], ["of", 1077], ["the", 1080], ["striatum", 1084], ["in", 1093], ["the", 1096], ["pathogenesis", 1100], ["of", 1113], ["McLeod", 1116], ["syndrome", 1123], [".", 1131]]}
{"context": "Nox activator 1 (NoxA1) is a homologue of p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1. The phosphorylation of cytosolic regulatory components by multiple kinases plays important roles in assembly and activity of the phagocyte NADPH oxidase (Nox2) system, but little is known about regulation by phosphorylation in the Nox1 system. Here we identify Ser(172) and Ser(461) of NoxA1 as phosphorylation sites for protein kinase A (PKA). A consequence of this phosphorylation was the enhancement of NoxA1 complex formation with 14-3-3 proteins. Using both a transfected human embryonic kidney 293 cell Nox1 model system and endogenous Nox1 in colon cell lines, we showed that the elevation of cAMP inhibits, whereas the inhibition of PKA enhances, Nox1-dependent ROS production through effects on NoxA1. Inhibition of Nox1 activity was intensified by the availability of 14-3-3zeta protein, and this regulatory interaction was dependent on PKA-phosphorylatable sites at Ser(172) and Ser(461) in NoxA1. We showed that phosphorylation and 14-3-3 binding induce the dissociation of NoxA1 from the Nox1 complex at the plasma membrane, suggesting a mechanism for the inhibitory effect on Nox1 activity. Our data establish that PKA-phosphorylated NoxA1 is a new binding partner of 14-3-3 protein(s) and that this forms the basis of a novel mechanism regulating the formation of ROS by Nox1 and, potentially, other NoxA1-regulated Nox family members.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "1d136608f31e4ac89782b0aa4082ddf6", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[272, 272], [74, 74], [164, 164], [36, 36], [132, 132], [217, 217], [232, 232], [127, 127]], "char_spans": [[1472, 1475], [417, 420], [911, 914], [180, 183], [728, 731], [1187, 1190], [1276, 1279], [695, 698]]}]}], "context_tokens": [["Nox", 0], ["activator", 4], ["1", 14], ["(", 16], ["NoxA1", 17], [")", 22], ["is", 24], ["a", 27], ["homologue", 29], ["of", 39], ["p67(phox", 42], [")", 50], ["that", 52], ["acts", 57], ["in", 62], ["conjunction", 65], ["with", 77], ["Nox", 82], ["organizer", 86], ["1", 96], ["(", 98], ["NoxO1", 99], [")", 104], ["to", 106], ["regulate", 109], ["reactive", 118], ["oxygen", 127], ["species", 134], ["(", 142], ["ROS", 143], [")", 146], ["production", 148], ["by", 159], ["the", 162], ["NADPH", 166], ["oxidase", 172], ["Nox1", 180], [".", 184], ["The", 186], ["phosphorylation", 190], ["of", 206], ["cytosolic", 209], ["regulatory", 219], ["components", 230], ["by", 241], ["multiple", 244], ["kinases", 253], ["plays", 261], ["important", 267], ["roles", 277], ["in", 283], ["assembly", 286], ["and", 295], ["activity", 299], ["of", 308], ["the", 311], ["phagocyte", 315], ["NADPH", 325], ["oxidase", 331], ["(", 339], ["Nox2", 340], [")", 344], ["system", 346], [",", 352], ["but", 354], ["little", 358], ["is", 365], ["known", 368], ["about", 374], ["regulation", 380], ["by", 391], ["phosphorylation", 394], ["in", 410], ["the", 413], ["Nox1", 417], ["system", 422], [".", 428], ["Here", 430], ["we", 435], ["identify", 438], ["Ser(172", 447], [")", 454], ["and", 456], ["Ser(461", 460], [")", 467], ["of", 469], ["NoxA1", 472], ["as", 478], ["phosphorylation", 481], ["sites", 497], ["for", 503], ["protein", 507], ["kinase", 515], ["A", 522], ["(", 524], ["PKA", 525], [")", 528], [".", 529], ["A", 531], ["consequence", 533], ["of", 545], ["this", 548], ["phosphorylation", 553], ["was", 569], ["the", 573], ["enhancement", 577], ["of", 589], ["NoxA1", 592], ["complex", 598], ["formation", 606], ["with", 616], ["14", 621], ["-", 623], ["3", 624], ["-", 625], ["3", 626], ["proteins", 628], [".", 636], ["Using", 638], ["both", 644], ["a", 649], ["transfected", 651], ["human", 663], ["embryonic", 669], ["kidney", 679], ["293", 686], ["cell", 690], ["Nox1", 695], ["model", 700], ["system", 706], ["and", 713], ["endogenous", 717], ["Nox1", 728], ["in", 733], ["colon", 736], ["cell", 742], ["lines", 747], [",", 752], ["we", 754], ["showed", 757], ["that", 764], ["the", 769], ["elevation", 773], ["of", 783], ["cAMP", 786], ["inhibits", 791], [",", 799], ["whereas", 801], ["the", 809], ["inhibition", 813], ["of", 824], ["PKA", 827], ["enhances", 831], [",", 839], ["Nox1-dependent", 841], ["ROS", 856], ["production", 860], ["through", 871], ["effects", 879], ["on", 887], ["NoxA1", 890], [".", 895], ["Inhibition", 897], ["of", 908], ["Nox1", 911], ["activity", 916], ["was", 925], ["intensified", 929], ["by", 941], ["the", 944], ["availability", 948], ["of", 961], ["14", 964], ["-", 966], ["3", 967], ["-", 968], ["3zeta", 969], ["protein", 975], [",", 982], ["and", 984], ["this", 988], ["regulatory", 993], ["interaction", 1004], ["was", 1016], ["dependent", 1020], ["on", 1030], ["PKA", 1033], ["-", 1036], ["phosphorylatable", 1037], ["sites", 1054], ["at", 1060], ["Ser(172", 1063], [")", 1070], ["and", 1072], ["Ser(461", 1076], [")", 1083], ["in", 1085], ["NoxA1", 1088], [".", 1093], ["We", 1095], ["showed", 1098], ["that", 1105], ["phosphorylation", 1110], ["and", 1126], ["14", 1130], ["-", 1132], ["3", 1133], ["-", 1134], ["3", 1135], ["binding", 1137], ["induce", 1145], ["the", 1152], ["dissociation", 1156], ["of", 1169], ["NoxA1", 1172], ["from", 1178], ["the", 1183], ["Nox1", 1187], ["complex", 1192], ["at", 1200], ["the", 1203], ["plasma", 1207], ["membrane", 1214], [",", 1222], ["suggesting", 1224], ["a", 1235], ["mechanism", 1237], ["for", 1247], ["the", 1251], ["inhibitory", 1255], ["effect", 1266], ["on", 1273], ["Nox1", 1276], ["activity", 1281], [".", 1289], ["Our", 1291], ["data", 1295], ["establish", 1300], ["that", 1310], ["PKA", 1315], ["-", 1318], ["phosphorylated", 1319], ["NoxA1", 1334], ["is", 1340], ["a", 1343], ["new", 1345], ["binding", 1349], ["partner", 1357], ["of", 1365], ["14", 1368], ["-", 1370], ["3", 1371], ["-", 1372], ["3", 1373], ["protein(s", 1375], [")", 1384], ["and", 1386], ["that", 1390], ["this", 1395], ["forms", 1400], ["the", 1406], ["basis", 1410], ["of", 1416], ["a", 1419], ["novel", 1421], ["mechanism", 1427], ["regulating", 1437], ["the", 1448], ["formation", 1452], ["of", 1462], ["ROS", 1465], ["by", 1469], ["Nox1", 1472], ["and", 1477], [",", 1480], ["potentially", 1482], [",", 1493], ["other", 1495], ["NoxA1-regulated", 1501], ["Nox", 1517], ["family", 1521], ["members", 1528], [".", 1535]]}
{"context": "Primary sinonasal intestinal-type adenocarcinomas (ITAC) are defined on the basis of their morphological similarities to colorectal adenocarcinomas (CRA). Thus, differential diagnosis with sinonasal metastasis of CRA could be a real challenge. Neuroendocrine differentiation has been variably described in several types of adenocarcinomas and notably in ITACs and CRAs. In a series of 25 ITACs and 25 lymph node metastasis of CRAs (nmCRA), we analysed neuroendocrine differentiation by immunohistochemistry with anti-chromogranin A and synaptophysin antibodies. Neuroendocrine differentiation (chromogranin A and/or synaptophysin positivity) was significantly different (p=0.0002) in ITACs (72%) and in nmCRAs (20%). In conclusion, presence of neuroendocrine cells seems more in favour of a sinonasal intestinal-type adenocarcinoma, than metastatic CRA. This immunohistochemical study could be useful in difficult cases and should be an interesting complement in a clinical discussion.", "qas": [{"question": "Which cell type has the protein Chromogranin A as marker?", "answers": ["neuroendocrine cells"], "qid": "ec272621cd3149a5b39e759406ab8844", "question_tokens": [["Which", 0], ["cell", 6], ["type", 11], ["has", 16], ["the", 20], ["protein", 24], ["Chromogranin", 32], ["A", 45], ["as", 47], ["marker", 50], ["?", 56]], "detected_answers": [{"text": "neuroendocrine cells", "token_spans": [[124, 125]], "char_spans": [[744, 763]]}]}], "context_tokens": [["Primary", 0], ["sinonasal", 8], ["intestinal", 18], ["-", 28], ["type", 29], ["adenocarcinomas", 34], ["(", 50], ["ITAC", 51], [")", 55], ["are", 57], ["defined", 61], ["on", 69], ["the", 72], ["basis", 76], ["of", 82], ["their", 85], ["morphological", 91], ["similarities", 105], ["to", 118], ["colorectal", 121], ["adenocarcinomas", 132], ["(", 148], ["CRA", 149], [")", 152], [".", 153], ["Thus", 155], [",", 159], ["differential", 161], ["diagnosis", 174], ["with", 184], ["sinonasal", 189], ["metastasis", 199], ["of", 210], ["CRA", 213], ["could", 217], ["be", 223], ["a", 226], ["real", 228], ["challenge", 233], [".", 242], ["Neuroendocrine", 244], ["differentiation", 259], ["has", 275], ["been", 279], ["variably", 284], ["described", 293], ["in", 303], ["several", 306], ["types", 314], ["of", 320], ["adenocarcinomas", 323], ["and", 339], ["notably", 343], ["in", 351], ["ITACs", 354], ["and", 360], ["CRAs", 364], [".", 368], ["In", 370], ["a", 373], ["series", 375], ["of", 382], ["25", 385], ["ITACs", 388], ["and", 394], ["25", 398], ["lymph", 401], ["node", 407], ["metastasis", 412], ["of", 423], ["CRAs", 426], ["(", 431], ["nmCRA", 432], [")", 437], [",", 438], ["we", 440], ["analysed", 443], ["neuroendocrine", 452], ["differentiation", 467], ["by", 483], ["immunohistochemistry", 486], ["with", 507], ["anti", 512], ["-", 516], ["chromogranin", 517], ["A", 530], ["and", 532], ["synaptophysin", 536], ["antibodies", 550], [".", 560], ["Neuroendocrine", 562], ["differentiation", 577], ["(", 593], ["chromogranin", 594], ["A", 607], ["and/or", 609], ["synaptophysin", 616], ["positivity", 630], [")", 640], ["was", 642], ["significantly", 646], ["different", 660], ["(", 670], ["p=0.0002", 671], [")", 679], ["in", 681], ["ITACs", 684], ["(", 690], ["72", 691], ["%", 693], [")", 694], ["and", 696], ["in", 700], ["nmCRAs", 703], ["(", 710], ["20", 711], ["%", 713], [")", 714], [".", 715], ["In", 717], ["conclusion", 720], [",", 730], ["presence", 732], ["of", 741], ["neuroendocrine", 744], ["cells", 759], ["seems", 765], ["more", 771], ["in", 776], ["favour", 779], ["of", 786], ["a", 789], ["sinonasal", 791], ["intestinal", 801], ["-", 811], ["type", 812], ["adenocarcinoma", 817], [",", 831], ["than", 833], ["metastatic", 838], ["CRA", 849], [".", 852], ["This", 854], ["immunohistochemical", 859], ["study", 879], ["could", 885], ["be", 891], ["useful", 894], ["in", 901], ["difficult", 904], ["cases", 914], ["and", 920], ["should", 924], ["be", 931], ["an", 934], ["interesting", 937], ["complement", 949], ["in", 960], ["a", 963], ["clinical", 965], ["discussion", 974], [".", 984]]}
{"context": "To study the impact of genetic and lifestyle factors on protein biomarkers and develop personally normalized plasma protein profiles (PNPPP) controlling for non-disease-related variance. Proximity extension assays were used to measure 145 proteins in 632 controls and 344 cases with non-communicable diseases. Genetic and lifestyle factors explained 20-88% of the variation in healthy controls. Adjusting for these factors reduced the number of candidate biomarkers by 63%. PNPPP efficiently controls for non-disease-related variance, allowing both for efficient discovery of novel biomarkers and for covariate-independent linear cut-offs suitable for clinical use.", "qas": [{"question": "What is PNPPP?", "answers": ["personally normalized plasma protein profiles"], "qid": "fd51aa90ceb147e78cd27c4328ac7962", "question_tokens": [["What", 0], ["is", 5], ["PNPPP", 8], ["?", 13]], "detected_answers": [{"text": "personally normalized plasma protein profiles", "token_spans": [[14, 18]], "char_spans": [[87, 131]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["impact", 13], ["of", 20], ["genetic", 23], ["and", 31], ["lifestyle", 35], ["factors", 45], ["on", 53], ["protein", 56], ["biomarkers", 64], ["and", 75], ["develop", 79], ["personally", 87], ["normalized", 98], ["plasma", 109], ["protein", 116], ["profiles", 124], ["(", 133], ["PNPPP", 134], [")", 139], ["controlling", 141], ["for", 153], ["non", 157], ["-", 160], ["disease", 161], ["-", 168], ["related", 169], ["variance", 177], [".", 185], ["Proximity", 187], ["extension", 197], ["assays", 207], ["were", 214], ["used", 219], ["to", 224], ["measure", 227], ["145", 235], ["proteins", 239], ["in", 248], ["632", 251], ["controls", 255], ["and", 264], ["344", 268], ["cases", 272], ["with", 278], ["non", 283], ["-", 286], ["communicable", 287], ["diseases", 300], [".", 308], ["Genetic", 310], ["and", 318], ["lifestyle", 322], ["factors", 332], ["explained", 340], ["20", 350], ["-", 352], ["88", 353], ["%", 355], ["of", 357], ["the", 360], ["variation", 364], ["in", 374], ["healthy", 377], ["controls", 385], [".", 393], ["Adjusting", 395], ["for", 405], ["these", 409], ["factors", 415], ["reduced", 423], ["the", 431], ["number", 435], ["of", 442], ["candidate", 445], ["biomarkers", 455], ["by", 466], ["63", 469], ["%", 471], [".", 472], ["PNPPP", 474], ["efficiently", 480], ["controls", 492], ["for", 501], ["non", 505], ["-", 508], ["disease", 509], ["-", 516], ["related", 517], ["variance", 525], [",", 533], ["allowing", 535], ["both", 544], ["for", 549], ["efficient", 553], ["discovery", 563], ["of", 573], ["novel", 576], ["biomarkers", 582], ["and", 593], ["for", 597], ["covariate", 601], ["-", 610], ["independent", 611], ["linear", 623], ["cut", 630], ["-", 633], ["offs", 634], ["suitable", 639], ["for", 648], ["clinical", 652], ["use", 661], [".", 664]]}
{"context": "The ubiquitously expressed iron storage protein ferritin plays a central role in maintaining cellular iron homeostasis. Cytosolic ferritins are composed of heavy (H) and light (L) subunits that co-assemble into a hollow spherical shell with an internal cavity where iron is stored. The ferroxidase activity of the ferritin H chain is critical to store iron in its Fe3+ oxidation state, while the L chain shows iron nucleation properties. We describe a unique case of a 23-yr-old female patient affected by a homozygous loss of function mutation in the L-ferritin gene, idiopathic generalized seizures, and atypical restless leg syndrome (RLS). We show that L chain ferritin is undetectable in primary fibroblasts from the patient, and thus ferritin consists only of H chains. Increased iron incorporation into the FtH homopolymer leads to reduced cellular iron availability, diminished levels of cytosolic catalase, SOD1 protein levels, enhanced ROS production and higher levels of oxidized proteins. Importantly, key phenotypic features observed in fibroblasts are also mirrored in reprogrammed neurons from the patient's fibroblasts. Our results demonstrate for the first time the pathophysiological consequences of L-ferritin deficiency in a human and help to define the concept for a new disease entity hallmarked by idiopathic generalized seizure and atypical RLS.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "f7f92b936c074e0eb3a943162c19c19b", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[14, 14], [144, 144], [75, 75], [3, 3], [46, 46], [154, 154], [62, 62]], "char_spans": [[102, 105], [786, 789], [410, 413], [27, 30], [266, 269], [856, 859], [352, 355]]}]}], "context_tokens": [["The", 0], ["ubiquitously", 4], ["expressed", 17], ["iron", 27], ["storage", 32], ["protein", 40], ["ferritin", 48], ["plays", 57], ["a", 63], ["central", 65], ["role", 73], ["in", 78], ["maintaining", 81], ["cellular", 93], ["iron", 102], ["homeostasis", 107], [".", 118], ["Cytosolic", 120], ["ferritins", 130], ["are", 140], ["composed", 144], ["of", 153], ["heavy", 156], ["(", 162], ["H", 163], [")", 164], ["and", 166], ["light", 170], ["(", 176], ["L", 177], [")", 178], ["subunits", 180], ["that", 189], ["co", 194], ["-", 196], ["assemble", 197], ["into", 206], ["a", 211], ["hollow", 213], ["spherical", 220], ["shell", 230], ["with", 236], ["an", 241], ["internal", 244], ["cavity", 253], ["where", 260], ["iron", 266], ["is", 271], ["stored", 274], [".", 280], ["The", 282], ["ferroxidase", 286], ["activity", 298], ["of", 307], ["the", 310], ["ferritin", 314], ["H", 323], ["chain", 325], ["is", 331], ["critical", 334], ["to", 343], ["store", 346], ["iron", 352], ["in", 357], ["its", 360], ["Fe3", 364], ["+", 367], ["oxidation", 369], ["state", 379], [",", 384], ["while", 386], ["the", 392], ["L", 396], ["chain", 398], ["shows", 404], ["iron", 410], ["nucleation", 415], ["properties", 426], [".", 436], ["We", 438], ["describe", 441], ["a", 450], ["unique", 452], ["case", 459], ["of", 464], ["a", 467], ["23-yr", 469], ["-", 474], ["old", 475], ["female", 479], ["patient", 486], ["affected", 494], ["by", 503], ["a", 506], ["homozygous", 508], ["loss", 519], ["of", 524], ["function", 527], ["mutation", 536], ["in", 545], ["the", 548], ["L", 552], ["-", 553], ["ferritin", 554], ["gene", 563], [",", 567], ["idiopathic", 569], ["generalized", 580], ["seizures", 592], [",", 600], ["and", 602], ["atypical", 606], ["restless", 615], ["leg", 624], ["syndrome", 628], ["(", 637], ["RLS", 638], [")", 641], [".", 642], ["We", 644], ["show", 647], ["that", 652], ["L", 657], ["chain", 659], ["ferritin", 665], ["is", 674], ["undetectable", 677], ["in", 690], ["primary", 693], ["fibroblasts", 701], ["from", 713], ["the", 718], ["patient", 722], [",", 729], ["and", 731], ["thus", 735], ["ferritin", 740], ["consists", 749], ["only", 758], ["of", 763], ["H", 766], ["chains", 768], [".", 774], ["Increased", 776], ["iron", 786], ["incorporation", 791], ["into", 805], ["the", 810], ["FtH", 814], ["homopolymer", 818], ["leads", 830], ["to", 836], ["reduced", 839], ["cellular", 847], ["iron", 856], ["availability", 861], [",", 873], ["diminished", 875], ["levels", 886], ["of", 893], ["cytosolic", 896], ["catalase", 906], [",", 914], ["SOD1", 916], ["protein", 921], ["levels", 929], [",", 935], ["enhanced", 937], ["ROS", 946], ["production", 950], ["and", 961], ["higher", 965], ["levels", 972], ["of", 979], ["oxidized", 982], ["proteins", 991], [".", 999], ["Importantly", 1001], [",", 1012], ["key", 1014], ["phenotypic", 1018], ["features", 1029], ["observed", 1038], ["in", 1047], ["fibroblasts", 1050], ["are", 1062], ["also", 1066], ["mirrored", 1071], ["in", 1080], ["reprogrammed", 1083], ["neurons", 1096], ["from", 1104], ["the", 1109], ["patient", 1113], ["'s", 1120], ["fibroblasts", 1123], [".", 1134], ["Our", 1136], ["results", 1140], ["demonstrate", 1148], ["for", 1160], ["the", 1164], ["first", 1168], ["time", 1174], ["the", 1179], ["pathophysiological", 1183], ["consequences", 1202], ["of", 1215], ["L", 1218], ["-", 1219], ["ferritin", 1220], ["deficiency", 1229], ["in", 1240], ["a", 1243], ["human", 1245], ["and", 1251], ["help", 1255], ["to", 1260], ["define", 1263], ["the", 1270], ["concept", 1274], ["for", 1282], ["a", 1286], ["new", 1288], ["disease", 1292], ["entity", 1300], ["hallmarked", 1307], ["by", 1318], ["idiopathic", 1321], ["generalized", 1332], ["seizure", 1344], ["and", 1352], ["atypical", 1356], ["RLS", 1365], [".", 1368]]}
{"context": "Although peak finding in next-generation sequencing (NGS) datasets has been addressed extensively, there is no consensus on how to analyze and process biological replicates. Furthermore, most peak finders do not focus on accurate determination of enrichment site widths and are not widely applicable to different types of datasets. We developed JAMM (Joint Analysis of NGS replicates via Mixture Model clustering): a peak finder that can integrate information from biological replicates, determine enrichment site widths accurately and resolve neighboring narrow peaks. JAMM is a universal peak finder that is applicable to different types of datasets. We show that JAMM is among the best performing peak finders in terms of site detection accuracy and in terms of accurate determination of enrichment sites widths. In addition, JAMM's replicate integration improves peak spatial resolution, sorting and peak finding accuracy. JAMM is available for free and can run on Linux machines through the command line: http://code.google.com/p/jamm-peak-finder.", "qas": [{"question": "Which peak calling algorithm employs mixture model clustering under the hood?", "answers": ["JAMM"], "qid": "34f812a7bd0645b481c7269f56ee725d", "question_tokens": [["Which", 0], ["peak", 6], ["calling", 11], ["algorithm", 19], ["employs", 29], ["mixture", 37], ["model", 45], ["clustering", 51], ["under", 62], ["the", 68], ["hood", 72], ["?", 76]], "detected_answers": [{"text": "JAMM", "token_spans": [[139, 139], [93, 93], [154, 154], [58, 58], [111, 111]], "char_spans": [[829, 832], [570, 573], [927, 930], [345, 348], [666, 669]]}]}], "context_tokens": [["Although", 0], ["peak", 9], ["finding", 14], ["in", 22], ["next", 25], ["-", 29], ["generation", 30], ["sequencing", 41], ["(", 52], ["NGS", 53], [")", 56], ["datasets", 58], ["has", 67], ["been", 71], ["addressed", 76], ["extensively", 86], [",", 97], ["there", 99], ["is", 105], ["no", 108], ["consensus", 111], ["on", 121], ["how", 124], ["to", 128], ["analyze", 131], ["and", 139], ["process", 143], ["biological", 151], ["replicates", 162], [".", 172], ["Furthermore", 174], [",", 185], ["most", 187], ["peak", 192], ["finders", 197], ["do", 205], ["not", 208], ["focus", 212], ["on", 218], ["accurate", 221], ["determination", 230], ["of", 244], ["enrichment", 247], ["site", 258], ["widths", 263], ["and", 270], ["are", 274], ["not", 278], ["widely", 282], ["applicable", 289], ["to", 300], ["different", 303], ["types", 313], ["of", 319], ["datasets", 322], [".", 330], ["We", 332], ["developed", 335], ["JAMM", 345], ["(", 350], ["Joint", 351], ["Analysis", 357], ["of", 366], ["NGS", 369], ["replicates", 373], ["via", 384], ["Mixture", 388], ["Model", 396], ["clustering", 402], [")", 412], [":", 413], ["a", 415], ["peak", 417], ["finder", 422], ["that", 429], ["can", 434], ["integrate", 438], ["information", 448], ["from", 460], ["biological", 465], ["replicates", 476], [",", 486], ["determine", 488], ["enrichment", 498], ["site", 509], ["widths", 514], ["accurately", 521], ["and", 532], ["resolve", 536], ["neighboring", 544], ["narrow", 556], ["peaks", 563], [".", 568], ["JAMM", 570], ["is", 575], ["a", 578], ["universal", 580], ["peak", 590], ["finder", 595], ["that", 602], ["is", 607], ["applicable", 610], ["to", 621], ["different", 624], ["types", 634], ["of", 640], ["datasets", 643], [".", 651], ["We", 653], ["show", 656], ["that", 661], ["JAMM", 666], ["is", 671], ["among", 674], ["the", 680], ["best", 684], ["performing", 689], ["peak", 700], ["finders", 705], ["in", 713], ["terms", 716], ["of", 722], ["site", 725], ["detection", 730], ["accuracy", 740], ["and", 749], ["in", 753], ["terms", 756], ["of", 762], ["accurate", 765], ["determination", 774], ["of", 788], ["enrichment", 791], ["sites", 802], ["widths", 808], [".", 814], ["In", 816], ["addition", 819], [",", 827], ["JAMM", 829], ["'s", 833], ["replicate", 836], ["integration", 846], ["improves", 858], ["peak", 867], ["spatial", 872], ["resolution", 880], [",", 890], ["sorting", 892], ["and", 900], ["peak", 904], ["finding", 909], ["accuracy", 917], [".", 925], ["JAMM", 927], ["is", 932], ["available", 935], ["for", 945], ["free", 949], ["and", 954], ["can", 958], ["run", 962], ["on", 966], ["Linux", 969], ["machines", 975], ["through", 984], ["the", 992], ["command", 996], ["line", 1004], [":", 1008], ["http://code.google.com/p/jamm-peak-finder", 1010], [".", 1051]]}
{"context": "The rash in infectious mononucleosis is usually diffusely macular. A 15-year-old boy presented to us with high grade fever, sore throat, malaise, body aches, and polyarthralgia. He developed annular, erythematous, and non-scaly eruptions on chest and right arm. Blanching erythema was noted on his trunk. He had bilateral tender cervical lymph nodes, severe pharyngeal congestion, petechiae on soft palate, uvular edema, infraorbital edema, and marginal tender hepatomegaly. Investigations revealed lymphocytosis and activated atypical lymphocytes in the peripheral smear, and positive monospot test. The boy subsequently recovered in one week with total disappearance of his rash. Epstein-Barr virus-related infectious mononucleosis was considered the most likely diagnosis for our patient. To our knowledge, this atypical case is the third reported case of annular lesions in infectious mononucleosis. Dermatologists and other clinicians should be alerted to this special presentation of primary EBV infection.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "2fa6c155febe4bc2bb8a93675adab78c", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[118, 121]], "char_spans": [[682, 699]]}]}], "context_tokens": [["The", 0], ["rash", 4], ["in", 9], ["infectious", 12], ["mononucleosis", 23], ["is", 37], ["usually", 40], ["diffusely", 48], ["macular", 58], [".", 65], ["A", 67], ["15-year", 69], ["-", 76], ["old", 77], ["boy", 81], ["presented", 85], ["to", 95], ["us", 98], ["with", 101], ["high", 106], ["grade", 111], ["fever", 117], [",", 122], ["sore", 124], ["throat", 129], [",", 135], ["malaise", 137], [",", 144], ["body", 146], ["aches", 151], [",", 156], ["and", 158], ["polyarthralgia", 162], [".", 176], ["He", 178], ["developed", 181], ["annular", 191], [",", 198], ["erythematous", 200], [",", 212], ["and", 214], ["non", 218], ["-", 221], ["scaly", 222], ["eruptions", 228], ["on", 238], ["chest", 241], ["and", 247], ["right", 251], ["arm", 257], [".", 260], ["Blanching", 262], ["erythema", 272], ["was", 281], ["noted", 285], ["on", 291], ["his", 294], ["trunk", 298], [".", 303], ["He", 305], ["had", 308], ["bilateral", 312], ["tender", 322], ["cervical", 329], ["lymph", 338], ["nodes", 344], [",", 349], ["severe", 351], ["pharyngeal", 358], ["congestion", 369], [",", 379], ["petechiae", 381], ["on", 391], ["soft", 394], ["palate", 399], [",", 405], ["uvular", 407], ["edema", 414], [",", 419], ["infraorbital", 421], ["edema", 434], [",", 439], ["and", 441], ["marginal", 445], ["tender", 454], ["hepatomegaly", 461], [".", 473], ["Investigations", 475], ["revealed", 490], ["lymphocytosis", 499], ["and", 513], ["activated", 517], ["atypical", 527], ["lymphocytes", 536], ["in", 548], ["the", 551], ["peripheral", 555], ["smear", 566], [",", 571], ["and", 573], ["positive", 577], ["monospot", 586], ["test", 595], [".", 599], ["The", 601], ["boy", 605], ["subsequently", 609], ["recovered", 622], ["in", 632], ["one", 635], ["week", 639], ["with", 644], ["total", 649], ["disappearance", 655], ["of", 669], ["his", 672], ["rash", 676], [".", 680], ["Epstein", 682], ["-", 689], ["Barr", 690], ["virus", 695], ["-", 700], ["related", 701], ["infectious", 709], ["mononucleosis", 720], ["was", 734], ["considered", 738], ["the", 749], ["most", 753], ["likely", 758], ["diagnosis", 765], ["for", 775], ["our", 779], ["patient", 783], [".", 790], ["To", 792], ["our", 795], ["knowledge", 799], [",", 808], ["this", 810], ["atypical", 815], ["case", 824], ["is", 829], ["the", 832], ["third", 836], ["reported", 842], ["case", 851], ["of", 856], ["annular", 859], ["lesions", 867], ["in", 875], ["infectious", 878], ["mononucleosis", 889], [".", 902], ["Dermatologists", 904], ["and", 919], ["other", 923], ["clinicians", 929], ["should", 940], ["be", 947], ["alerted", 950], ["to", 958], ["this", 961], ["special", 966], ["presentation", 974], ["of", 987], ["primary", 990], ["EBV", 998], ["infection", 1002], [".", 1011]]}
{"context": "Imatinib mesylate (Glivec) is a selective inhibitor of bcr-abl tyrosine kinase, the product of the Philadelphia chromosome, which is the hallmark of chronic myeloid leukaemia (CML). With imatinib, complete cytogenetic response (CCR) can be achieved in over 70% of newly diagnosed patients with CML. However, the optimal long-term management of patients who achieve CCR after imatinib is unknown. With longer follow-up, it is anticipated that some patients are likely to progress and become candidates for autologous transplantation. We studied filgrastim (r-metHuG-CSF) mobilisation of peripheral blood stem cells (PBSC) in 32 patients who have achieved CCR with imatinib. Our data demonstrate that (1) the target CD34(+) cell yields of >/=2.0 x 10(6)/kg were attained with filgrastim 10 microg/kg/day, in 9/18 (50%) of patients during uninterrupted imatinib therapy, and in 10/14 (70%) when imatinib was temporarily withheld. The median CD34(+) cell yield per aphaeresis was 0.70 x 10(6)/kg (range 0.14-2.18) and 2.90 x 10(6)/kg (range 0.15-8.71) in the two groups, respectively (P&<0.005). (2) The cell yields did not correlate with the duration of imatinib administration. (3) There was no impact of the mobilisation procedure on the level of leukaemia as measured by serial blood bcr-abl levels using real-time quantitative PCR with either protocol. (4) bcr-abl remained detectable at low levels in the harvests in most but not all patients. In conclusion, filgrastim can safely be used to mobilise PBSC in patients who have achieved CCR with imatinib, but CD34(+) cell yields are significantly improved when imatinib is temporarily withheld.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "5900db93e2d94cedaf489326063c2ede", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[258, 260], [10, 12], [275, 277]], "char_spans": [[1284, 1290], [55, 61], [1358, 1364]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["Glivec", 19], [")", 25], ["is", 27], ["a", 30], ["selective", 32], ["inhibitor", 42], ["of", 52], ["bcr", 55], ["-", 58], ["abl", 59], ["tyrosine", 63], ["kinase", 72], [",", 78], ["the", 80], ["product", 84], ["of", 92], ["the", 95], ["Philadelphia", 99], ["chromosome", 112], [",", 122], ["which", 124], ["is", 130], ["the", 133], ["hallmark", 137], ["of", 146], ["chronic", 149], ["myeloid", 157], ["leukaemia", 165], ["(", 175], ["CML", 176], [")", 179], [".", 180], ["With", 182], ["imatinib", 187], [",", 195], ["complete", 197], ["cytogenetic", 206], ["response", 218], ["(", 227], ["CCR", 228], [")", 231], ["can", 233], ["be", 237], ["achieved", 240], ["in", 249], ["over", 252], ["70", 257], ["%", 259], ["of", 261], ["newly", 264], ["diagnosed", 270], ["patients", 280], ["with", 289], ["CML", 294], [".", 297], ["However", 299], [",", 306], ["the", 308], ["optimal", 312], ["long", 320], ["-", 324], ["term", 325], ["management", 330], ["of", 341], ["patients", 344], ["who", 353], ["achieve", 357], ["CCR", 365], ["after", 369], ["imatinib", 375], ["is", 384], ["unknown", 387], [".", 394], ["With", 396], ["longer", 401], ["follow", 408], ["-", 414], ["up", 415], [",", 417], ["it", 419], ["is", 422], ["anticipated", 425], ["that", 437], ["some", 442], ["patients", 447], ["are", 456], ["likely", 460], ["to", 467], ["progress", 470], ["and", 479], ["become", 483], ["candidates", 490], ["for", 501], ["autologous", 505], ["transplantation", 516], [".", 531], ["We", 533], ["studied", 536], ["filgrastim", 544], ["(", 555], ["r", 556], ["-", 557], ["metHuG", 558], ["-", 564], ["CSF", 565], [")", 568], ["mobilisation", 570], ["of", 583], ["peripheral", 586], ["blood", 597], ["stem", 603], ["cells", 608], ["(", 614], ["PBSC", 615], [")", 619], ["in", 621], ["32", 624], ["patients", 627], ["who", 636], ["have", 640], ["achieved", 645], ["CCR", 654], ["with", 658], ["imatinib", 663], [".", 671], ["Our", 673], ["data", 677], ["demonstrate", 682], ["that", 694], ["(", 699], ["1", 700], [")", 701], ["the", 703], ["target", 707], ["CD34(+", 714], [")", 720], ["cell", 722], ["yields", 727], ["of", 734], [">", 737], ["/=2.0", 738], ["x", 744], ["10(6)/kg", 746], ["were", 755], ["attained", 760], ["with", 769], ["filgrastim", 774], ["10", 785], ["microg", 788], ["/", 794], ["kg", 795], ["/", 797], ["day", 798], [",", 801], ["in", 803], ["9/18", 806], ["(", 811], ["50", 812], ["%", 814], [")", 815], ["of", 817], ["patients", 820], ["during", 829], ["uninterrupted", 836], ["imatinib", 850], ["therapy", 859], [",", 866], ["and", 868], ["in", 872], ["10/14", 875], ["(", 881], ["70", 882], ["%", 884], [")", 885], ["when", 887], ["imatinib", 892], ["was", 901], ["temporarily", 905], ["withheld", 917], [".", 925], ["The", 927], ["median", 931], ["CD34(+", 938], [")", 944], ["cell", 946], ["yield", 951], ["per", 957], ["aphaeresis", 961], ["was", 972], ["0.70", 976], ["x", 981], ["10(6)/kg", 983], ["(", 992], ["range", 993], ["0.14", 999], ["-", 1003], ["2.18", 1004], [")", 1008], ["and", 1010], ["2.90", 1014], ["x", 1019], ["10(6)/kg", 1021], ["(", 1030], ["range", 1031], ["0.15", 1037], ["-", 1041], ["8.71", 1042], [")", 1046], ["in", 1048], ["the", 1051], ["two", 1055], ["groups", 1059], [",", 1065], ["respectively", 1067], ["(", 1080], ["P&<0.005", 1081], [")", 1089], [".", 1090], ["(", 1092], ["2", 1093], [")", 1094], ["The", 1096], ["cell", 1100], ["yields", 1105], ["did", 1112], ["not", 1116], ["correlate", 1120], ["with", 1130], ["the", 1135], ["duration", 1139], ["of", 1148], ["imatinib", 1151], ["administration", 1160], [".", 1174], ["(", 1176], ["3", 1177], [")", 1178], ["There", 1180], ["was", 1186], ["no", 1190], ["impact", 1193], ["of", 1200], ["the", 1203], ["mobilisation", 1207], ["procedure", 1220], ["on", 1230], ["the", 1233], ["level", 1237], ["of", 1243], ["leukaemia", 1246], ["as", 1256], ["measured", 1259], ["by", 1268], ["serial", 1271], ["blood", 1278], ["bcr", 1284], ["-", 1287], ["abl", 1288], ["levels", 1292], ["using", 1299], ["real", 1305], ["-", 1309], ["time", 1310], ["quantitative", 1315], ["PCR", 1328], ["with", 1332], ["either", 1337], ["protocol", 1344], [".", 1352], ["(", 1354], ["4", 1355], [")", 1356], ["bcr", 1358], ["-", 1361], ["abl", 1362], ["remained", 1366], ["detectable", 1375], ["at", 1386], ["low", 1389], ["levels", 1393], ["in", 1400], ["the", 1403], ["harvests", 1407], ["in", 1416], ["most", 1419], ["but", 1424], ["not", 1428], ["all", 1432], ["patients", 1436], [".", 1444], ["In", 1446], ["conclusion", 1449], [",", 1459], ["filgrastim", 1461], ["can", 1472], ["safely", 1476], ["be", 1483], ["used", 1486], ["to", 1491], ["mobilise", 1494], ["PBSC", 1503], ["in", 1508], ["patients", 1511], ["who", 1520], ["have", 1524], ["achieved", 1529], ["CCR", 1538], ["with", 1542], ["imatinib", 1547], [",", 1555], ["but", 1557], ["CD34(+", 1561], [")", 1567], ["cell", 1569], ["yields", 1574], ["are", 1581], ["significantly", 1585], ["improved", 1599], ["when", 1608], ["imatinib", 1613], ["is", 1622], ["temporarily", 1625], ["withheld", 1637], [".", 1645]]}
{"context": "The proliferation and migration of vascular smooth muscle cells (VSMCs) in the intima of an artery, known as intimal hyperplasia, is an important component of cardiovascular diseases. This is seen most clearly in the case of in-stent restenosis, where drug eluting stents are used to deliver agents that prevent VSMC proliferation and migration. One class of agents that are highly effective in the prevention of in-stent restenosis is the mammalian Target of Rapamycin (mTOR) inhibitors. Inhibition of mTOR blocks protein synthesis, cell cycle progression, and cell migration. Key to the effects on cell cycle progression and cell migration is the inhibition of mTOR-mediated degradation of p27Kip1 protein. p27Kip1 is a cyclin dependent kinase inhibitor that is elevated in quiescent VSMCs and inhibits the G1 to S phase transition and cell migration. Under normal conditions, vascular injury promotes degradation of p27Kip1 protein in an mTOR dependent manner. Recent reports from our lab suggest that in the presence of diabetes mellitus, elevation of extracellular signal response kinase activity may promote decreased p27Kip1 mRNA and produce a relative resistance to mTOR inhibition. Here we review these findings and their relevance to designing treatments for cardiovascular disease in the presence of diabetes mellitus.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "4512014da03b487ba5925f69cc357394", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[80, 83]], "char_spans": [[440, 468]]}]}], "context_tokens": [["The", 0], ["proliferation", 4], ["and", 18], ["migration", 22], ["of", 32], ["vascular", 35], ["smooth", 44], ["muscle", 51], ["cells", 58], ["(", 64], ["VSMCs", 65], [")", 70], ["in", 72], ["the", 75], ["intima", 79], ["of", 86], ["an", 89], ["artery", 92], [",", 98], ["known", 100], ["as", 106], ["intimal", 109], ["hyperplasia", 117], [",", 128], ["is", 130], ["an", 133], ["important", 136], ["component", 146], ["of", 156], ["cardiovascular", 159], ["diseases", 174], [".", 182], ["This", 184], ["is", 189], ["seen", 192], ["most", 197], ["clearly", 202], ["in", 210], ["the", 213], ["case", 217], ["of", 222], ["in", 225], ["-", 227], ["stent", 228], ["restenosis", 234], [",", 244], ["where", 246], ["drug", 252], ["eluting", 257], ["stents", 265], ["are", 272], ["used", 276], ["to", 281], ["deliver", 284], ["agents", 292], ["that", 299], ["prevent", 304], ["VSMC", 312], ["proliferation", 317], ["and", 331], ["migration", 335], [".", 344], ["One", 346], ["class", 350], ["of", 356], ["agents", 359], ["that", 366], ["are", 371], ["highly", 375], ["effective", 382], ["in", 392], ["the", 395], ["prevention", 399], ["of", 410], ["in", 413], ["-", 415], ["stent", 416], ["restenosis", 422], ["is", 433], ["the", 436], ["mammalian", 440], ["Target", 450], ["of", 457], ["Rapamycin", 460], ["(", 470], ["mTOR", 471], [")", 475], ["inhibitors", 477], [".", 487], ["Inhibition", 489], ["of", 500], ["mTOR", 503], ["blocks", 508], ["protein", 515], ["synthesis", 523], [",", 532], ["cell", 534], ["cycle", 539], ["progression", 545], [",", 556], ["and", 558], ["cell", 562], ["migration", 567], [".", 576], ["Key", 578], ["to", 582], ["the", 585], ["effects", 589], ["on", 597], ["cell", 600], ["cycle", 605], ["progression", 611], ["and", 623], ["cell", 627], ["migration", 632], ["is", 642], ["the", 645], ["inhibition", 649], ["of", 660], ["mTOR", 663], ["-", 667], ["mediated", 668], ["degradation", 677], ["of", 689], ["p27Kip1", 692], ["protein", 700], [".", 707], ["p27Kip1", 709], ["is", 717], ["a", 720], ["cyclin", 722], ["dependent", 729], ["kinase", 739], ["inhibitor", 746], ["that", 756], ["is", 761], ["elevated", 764], ["in", 773], ["quiescent", 776], ["VSMCs", 786], ["and", 792], ["inhibits", 796], ["the", 805], ["G1", 809], ["to", 812], ["S", 815], ["phase", 817], ["transition", 823], ["and", 834], ["cell", 838], ["migration", 843], [".", 852], ["Under", 854], ["normal", 860], ["conditions", 867], [",", 877], ["vascular", 879], ["injury", 888], ["promotes", 895], ["degradation", 904], ["of", 916], ["p27Kip1", 919], ["protein", 927], ["in", 935], ["an", 938], ["mTOR", 941], ["dependent", 946], ["manner", 956], [".", 962], ["Recent", 964], ["reports", 971], ["from", 979], ["our", 984], ["lab", 988], ["suggest", 992], ["that", 1000], ["in", 1005], ["the", 1008], ["presence", 1012], ["of", 1021], ["diabetes", 1024], ["mellitus", 1033], [",", 1041], ["elevation", 1043], ["of", 1053], ["extracellular", 1056], ["signal", 1070], ["response", 1077], ["kinase", 1086], ["activity", 1093], ["may", 1102], ["promote", 1106], ["decreased", 1114], ["p27Kip1", 1124], ["mRNA", 1132], ["and", 1137], ["produce", 1141], ["a", 1149], ["relative", 1151], ["resistance", 1160], ["to", 1171], ["mTOR", 1174], ["inhibition", 1179], [".", 1189], ["Here", 1191], ["we", 1196], ["review", 1199], ["these", 1206], ["findings", 1212], ["and", 1221], ["their", 1225], ["relevance", 1231], ["to", 1241], ["designing", 1244], ["treatments", 1254], ["for", 1265], ["cardiovascular", 1269], ["disease", 1284], ["in", 1292], ["the", 1295], ["presence", 1299], ["of", 1308], ["diabetes", 1311], ["mellitus", 1320], [".", 1328]]}
{"context": "Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to evaluate the tolerability, pharmacokinetics (including the effect of food) and pharmacodynamics (effect on COMT activity) following single oral doses of opicapone in young healthy male volunteers. Single rising oral doses of opicapone (10, 25, 50, 100, 200, 400, 800 and 1,200 mg) were administered to eight groups of eight subjects per group (two subjects randomized to placebo and six subjects to opicapone), under a double-blind, randomized, placebo-controlled design. In an additional group of 12 subjects, a 50 mg single dose of opicapone was administered on two occasions, once having fasted overnight and once with a high-fat high-calorie meal. Opicapone was well tolerated at all doses tested. The extent of systemic exposure (area under the plasma concentration-time curve and maximum plasma concentration) to opicapone and metabolites increased in an approximately dose-proportional manner and showed a decrease following concomitant ingestion of a high-fat high-calorie meal. The apparent terminal elimination half-life of opicapone was 0.8-3.2 h. Sulphation appeared to be the main metabolic pathway for opicapone, and both opicapone and the main sulphated metabolite are likely excreted by the biliary route. Maximum COMT inhibition by opicapone was dose dependent, ranged from 36.1% (10 mg) to 100% (200 mg and above), and reached statistical significance at all doses tested. The long duration of COMT inhibition by opicapone, however, tended to be independent from the dose taken. The observed half-life of opicapone-induced COMT inhibition in human erythrocytes was 61.6 h (standard deviation [SD] = 37.6 h), which reflects an underlying dissociative process with a kinetic rate constant of 3.1 \u00d7 10(-6) s(-1) (SD = 1.9 \u00d7 10(-6) s(-1)). Such a process compares well to the estimated dissociation rate constant (k(off)) of the COMT-opicapone molecular complex (k(off) = 1.9 \u00d7 10(-6) s(-1)). Opicapone was well-tolerated and presented dose-proportional kinetics. Opicapone demonstrated marked and sustained inhibition of erythrocyte soluble COMT activity. Based on the observation that the half-life of COMT inhibition is independent of the dose and that it reflects an underlying kinetic process that is consistent with the k(off) value of the COMT-opicapone complex, we propose that the sustained COMT inhibition, far beyond the observable point of clearance of circulating drug, is due to the long residence time of the reversible complex formed between COMT and opicapone. Globally, these promising results provide a basis for further clinical development of opicapone.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "27c5cce16a694b1292f9a384c43beab6", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[4, 8]], "char_spans": [[21, 48]]}]}], "context_tokens": [["Opicapone", 0], ["is", 10], ["a", 13], ["novel", 15], ["catechol", 21], ["-", 29], ["O", 30], ["-", 31], ["methyltransferase", 32], ["(", 50], ["COMT", 51], [")", 55], ["inhibitor", 57], [".", 66], ["The", 68], ["purpose", 72], ["of", 80], ["this", 83], ["study", 88], ["was", 94], ["to", 98], ["evaluate", 101], ["the", 110], ["tolerability", 114], [",", 126], ["pharmacokinetics", 128], ["(", 145], ["including", 146], ["the", 156], ["effect", 160], ["of", 167], ["food", 170], [")", 174], ["and", 176], ["pharmacodynamics", 180], ["(", 197], ["effect", 198], ["on", 205], ["COMT", 208], ["activity", 213], [")", 221], ["following", 223], ["single", 233], ["oral", 240], ["doses", 245], ["of", 251], ["opicapone", 254], ["in", 264], ["young", 267], ["healthy", 273], ["male", 281], ["volunteers", 286], [".", 296], ["Single", 298], ["rising", 305], ["oral", 312], ["doses", 317], ["of", 323], ["opicapone", 326], ["(", 336], ["10", 337], [",", 339], ["25", 341], [",", 343], ["50", 345], [",", 347], ["100", 349], [",", 352], ["200", 354], [",", 357], ["400", 359], [",", 362], ["800", 364], ["and", 368], ["1,200", 372], ["mg", 378], [")", 380], ["were", 382], ["administered", 387], ["to", 400], ["eight", 403], ["groups", 409], ["of", 416], ["eight", 419], ["subjects", 425], ["per", 434], ["group", 438], ["(", 444], ["two", 445], ["subjects", 449], ["randomized", 458], ["to", 469], ["placebo", 472], ["and", 480], ["six", 484], ["subjects", 488], ["to", 497], ["opicapone", 500], [")", 509], [",", 510], ["under", 512], ["a", 518], ["double", 520], ["-", 526], ["blind", 527], [",", 532], ["randomized", 534], [",", 544], ["placebo", 546], ["-", 553], ["controlled", 554], ["design", 565], [".", 571], ["In", 573], ["an", 576], ["additional", 579], ["group", 590], ["of", 596], ["12", 599], ["subjects", 602], [",", 610], ["a", 612], ["50", 614], ["mg", 617], ["single", 620], ["dose", 627], ["of", 632], ["opicapone", 635], ["was", 645], ["administered", 649], ["on", 662], ["two", 665], ["occasions", 669], [",", 678], ["once", 680], ["having", 685], ["fasted", 692], ["overnight", 699], ["and", 709], ["once", 713], ["with", 718], ["a", 723], ["high", 725], ["-", 729], ["fat", 730], ["high", 734], ["-", 738], ["calorie", 739], ["meal", 747], [".", 751], ["Opicapone", 753], ["was", 763], ["well", 767], ["tolerated", 772], ["at", 782], ["all", 785], ["doses", 789], ["tested", 795], [".", 801], ["The", 803], ["extent", 807], ["of", 814], ["systemic", 817], ["exposure", 826], ["(", 835], ["area", 836], ["under", 841], ["the", 847], ["plasma", 851], ["concentration", 858], ["-", 871], ["time", 872], ["curve", 877], ["and", 883], ["maximum", 887], ["plasma", 895], ["concentration", 902], [")", 915], ["to", 917], ["opicapone", 920], ["and", 930], ["metabolites", 934], ["increased", 946], ["in", 956], ["an", 959], ["approximately", 962], ["dose", 976], ["-", 980], ["proportional", 981], ["manner", 994], ["and", 1001], ["showed", 1005], ["a", 1012], ["decrease", 1014], ["following", 1023], ["concomitant", 1033], ["ingestion", 1045], ["of", 1055], ["a", 1058], ["high", 1060], ["-", 1064], ["fat", 1065], ["high", 1069], ["-", 1073], ["calorie", 1074], ["meal", 1082], [".", 1086], ["The", 1088], ["apparent", 1092], ["terminal", 1101], ["elimination", 1110], ["half", 1122], ["-", 1126], ["life", 1127], ["of", 1132], ["opicapone", 1135], ["was", 1145], ["0.8", 1149], ["-", 1152], ["3.2", 1153], ["h.", 1157], ["Sulphation", 1160], ["appeared", 1171], ["to", 1180], ["be", 1183], ["the", 1186], ["main", 1190], ["metabolic", 1195], ["pathway", 1205], ["for", 1213], ["opicapone", 1217], [",", 1226], ["and", 1228], ["both", 1232], ["opicapone", 1237], ["and", 1247], ["the", 1251], ["main", 1255], ["sulphated", 1260], ["metabolite", 1270], ["are", 1281], ["likely", 1285], ["excreted", 1292], ["by", 1301], ["the", 1304], ["biliary", 1308], ["route", 1316], [".", 1321], ["Maximum", 1323], ["COMT", 1331], ["inhibition", 1336], ["by", 1347], ["opicapone", 1350], ["was", 1360], ["dose", 1364], ["dependent", 1369], [",", 1378], ["ranged", 1380], ["from", 1387], ["36.1", 1392], ["%", 1396], ["(", 1398], ["10", 1399], ["mg", 1402], [")", 1404], ["to", 1406], ["100", 1409], ["%", 1412], ["(", 1414], ["200", 1415], ["mg", 1419], ["and", 1422], ["above", 1426], [")", 1431], [",", 1432], ["and", 1434], ["reached", 1438], ["statistical", 1446], ["significance", 1458], ["at", 1471], ["all", 1474], ["doses", 1478], ["tested", 1484], [".", 1490], ["The", 1492], ["long", 1496], ["duration", 1501], ["of", 1510], ["COMT", 1513], ["inhibition", 1518], ["by", 1529], ["opicapone", 1532], [",", 1541], ["however", 1543], [",", 1550], ["tended", 1552], ["to", 1559], ["be", 1562], ["independent", 1565], ["from", 1577], ["the", 1582], ["dose", 1586], ["taken", 1591], [".", 1596], ["The", 1598], ["observed", 1602], ["half", 1611], ["-", 1615], ["life", 1616], ["of", 1621], ["opicapone", 1624], ["-", 1633], ["induced", 1634], ["COMT", 1642], ["inhibition", 1647], ["in", 1658], ["human", 1661], ["erythrocytes", 1667], ["was", 1680], ["61.6", 1684], ["h", 1689], ["(", 1691], ["standard", 1692], ["deviation", 1701], ["[", 1711], ["SD", 1712], ["]", 1714], ["=", 1716], ["37.6", 1718], ["h", 1723], [")", 1724], [",", 1725], ["which", 1727], ["reflects", 1733], ["an", 1742], ["underlying", 1745], ["dissociative", 1756], ["process", 1769], ["with", 1777], ["a", 1782], ["kinetic", 1784], ["rate", 1792], ["constant", 1797], ["of", 1806], ["3.1", 1809], ["\u00d7", 1813], ["10(-6", 1815], [")", 1820], ["s(-1", 1822], [")", 1826], ["(", 1828], ["SD", 1829], ["=", 1832], ["1.9", 1834], ["\u00d7", 1838], ["10(-6", 1840], [")", 1845], ["s(-1", 1847], [")", 1851], [")", 1852], [".", 1853], ["Such", 1855], ["a", 1860], ["process", 1862], ["compares", 1870], ["well", 1879], ["to", 1884], ["the", 1887], ["estimated", 1891], ["dissociation", 1901], ["rate", 1914], ["constant", 1919], ["(", 1928], ["k(off", 1929], [")", 1934], [")", 1935], ["of", 1937], ["the", 1940], ["COMT", 1944], ["-", 1948], ["opicapone", 1949], ["molecular", 1959], ["complex", 1969], ["(", 1977], ["k(off", 1978], [")", 1983], ["=", 1985], ["1.9", 1987], ["\u00d7", 1991], ["10(-6", 1993], [")", 1998], ["s(-1", 2000], [")", 2004], [")", 2005], [".", 2006], ["Opicapone", 2008], ["was", 2018], ["well", 2022], ["-", 2026], ["tolerated", 2027], ["and", 2037], ["presented", 2041], ["dose", 2051], ["-", 2055], ["proportional", 2056], ["kinetics", 2069], [".", 2077], ["Opicapone", 2079], ["demonstrated", 2089], ["marked", 2102], ["and", 2109], ["sustained", 2113], ["inhibition", 2123], ["of", 2134], ["erythrocyte", 2137], ["soluble", 2149], ["COMT", 2157], ["activity", 2162], [".", 2170], ["Based", 2172], ["on", 2178], ["the", 2181], ["observation", 2185], ["that", 2197], ["the", 2202], ["half", 2206], ["-", 2210], ["life", 2211], ["of", 2216], ["COMT", 2219], ["inhibition", 2224], ["is", 2235], ["independent", 2238], ["of", 2250], ["the", 2253], ["dose", 2257], ["and", 2262], ["that", 2266], ["it", 2271], ["reflects", 2274], ["an", 2283], ["underlying", 2286], ["kinetic", 2297], ["process", 2305], ["that", 2313], ["is", 2318], ["consistent", 2321], ["with", 2332], ["the", 2337], ["k(off", 2341], [")", 2346], ["value", 2348], ["of", 2354], ["the", 2357], ["COMT", 2361], ["-", 2365], ["opicapone", 2366], ["complex", 2376], [",", 2383], ["we", 2385], ["propose", 2388], ["that", 2396], ["the", 2401], ["sustained", 2405], ["COMT", 2415], ["inhibition", 2420], [",", 2430], ["far", 2432], ["beyond", 2436], ["the", 2443], ["observable", 2447], ["point", 2458], ["of", 2464], ["clearance", 2467], ["of", 2477], ["circulating", 2480], ["drug", 2492], [",", 2496], ["is", 2498], ["due", 2501], ["to", 2505], ["the", 2508], ["long", 2512], ["residence", 2517], ["time", 2527], ["of", 2532], ["the", 2535], ["reversible", 2539], ["complex", 2550], ["formed", 2558], ["between", 2565], ["COMT", 2573], ["and", 2578], ["opicapone", 2582], [".", 2591], ["Globally", 2593], [",", 2601], ["these", 2603], ["promising", 2609], ["results", 2619], ["provide", 2627], ["a", 2635], ["basis", 2637], ["for", 2643], ["further", 2647], ["clinical", 2655], ["development", 2664], ["of", 2676], ["opicapone", 2679], [".", 2688]]}
{"context": "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. A special feature of the Sry gene is its ability to generate linear and circular transcripts, both transcribed in the sense orientation. Here we remark that both sense (e.g. Sry RNA) and antisense (e.g. CDR1as) transcripts could circularize and behave as miRNAs sponges, and importantly, that also protein-coding segments of mRNAs could also assume this role. Thus, it is reasonable to think that the linear Sry sense transcript could additionally act as a miRNA sponge, or as an endogenous competing RNA for miR-138.", "qas": [{"question": "Which miRNA is targeted by SRY/Sox9?", "answers": ["mir-138"], "qid": "71b0e329f10047c39ece3b5149f7ae9c", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["targeted", 15], ["by", 24], ["SRY", 27], ["/", 30], ["Sox9", 31], ["?", 35]], "detected_answers": [{"text": "mir-138", "token_spans": [[52, 52], [153, 153]], "char_spans": [[284, 290], [826, 832]]}]}], "context_tokens": [["Recently", 0], [",", 8], ["the", 10], ["sex", 14], ["determining", 18], ["region", 30], ["Y", 37], ["(", 39], ["Sry", 41], [")", 44], ["and", 46], ["the", 50], ["cerebellar", 54], ["degeneration", 65], ["-", 77], ["related", 78], ["protein", 86], ["1", 94], ["(", 96], ["CDR1as", 98], [")", 104], ["RNA", 106], ["transcripts", 110], ["have", 122], ["been", 127], ["described", 132], ["to", 142], ["function", 145], ["as", 154], ["a", 157], ["new", 159], ["class", 163], ["of", 169], ["post", 172], ["-", 176], ["transcriptional", 177], ["regulatory", 193], ["RNAs", 204], ["that", 209], ["behave", 214], ["as", 221], ["circular", 224], ["endogenous", 233], ["RNA", 244], ["sponges", 248], ["for", 256], ["the", 260], ["micro", 264], ["RNAs", 270], ["(", 275], ["miRNAs", 276], [")", 282], ["miR-138", 284], ["and", 292], ["miR-7", 296], [",", 301], ["respectively", 303], [".", 315], ["A", 317], ["special", 319], ["feature", 327], ["of", 335], ["the", 338], ["Sry", 342], ["gene", 346], ["is", 351], ["its", 354], ["ability", 358], ["to", 366], ["generate", 369], ["linear", 378], ["and", 385], ["circular", 389], ["transcripts", 398], [",", 409], ["both", 411], ["transcribed", 416], ["in", 428], ["the", 431], ["sense", 435], ["orientation", 441], [".", 452], ["Here", 454], ["we", 459], ["remark", 462], ["that", 469], ["both", 474], ["sense", 479], ["(", 485], ["e.g.", 486], ["Sry", 491], ["RNA", 495], [")", 498], ["and", 500], ["antisense", 504], ["(", 514], ["e.g.", 515], ["CDR1as", 520], [")", 526], ["transcripts", 528], ["could", 540], ["circularize", 546], ["and", 558], ["behave", 562], ["as", 569], ["miRNAs", 572], ["sponges", 579], [",", 586], ["and", 588], ["importantly", 592], [",", 603], ["that", 605], ["also", 610], ["protein", 615], ["-", 622], ["coding", 623], ["segments", 630], ["of", 639], ["mRNAs", 642], ["could", 648], ["also", 654], ["assume", 659], ["this", 666], ["role", 671], [".", 675], ["Thus", 677], [",", 681], ["it", 683], ["is", 686], ["reasonable", 689], ["to", 700], ["think", 703], ["that", 709], ["the", 714], ["linear", 718], ["Sry", 725], ["sense", 729], ["transcript", 735], ["could", 746], ["additionally", 752], ["act", 765], ["as", 769], ["a", 772], ["miRNA", 774], ["sponge", 780], [",", 786], ["or", 788], ["as", 791], ["an", 794], ["endogenous", 797], ["competing", 808], ["RNA", 818], ["for", 822], ["miR-138", 826], [".", 833]]}
{"context": "Spectrin, the major component of the erythroid membrane skeleton, is a long, asymmetrical rodlike protein that interacts with several other proteins to form a two-dimensional membrane skeleton. Progress in several laboratories over the past few years including substantial partial peptide and nucleotide sequence determination has greatly enhanced our knowledge of the structural properties of this large molecule (heterodimer = 465,000 daltons). The alpha and beta subunits are homologous with approximately 30% identity. They are aligned in an antiparallel side-to-side orientation with the amino- and carboxy-termini near opposite physical ends of the molecule. The predominant structural feature elucidated from sequencing this large molecule is the nearly universal occurrence in both subunits of a single type of repetitive structure. The periodicity of this homologous structure is exactly 106 amino acid residues. As many as 36 homologous, but nonidentical, repeats exist and comprise more than 90% of the mass of the heterodimer. Each of these repetitive units is folded into a triple-stranded structure that is highly helical. Peptide maps, antibody crossreactivity, peptide sequence analysis, and more recently nucleic acid sequences have defined several major properties of the erythroid molecule and related proteins in other tissues. Tissue-specific spectrins have the same 106-residue repetitive structure and show sequence homology to erythroid spectrin.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "98eb6a6cc03a4c00a5f1dbda3e4cead5", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[88, 88]], "char_spans": [[546, 557]]}]}], "context_tokens": [["Spectrin", 0], [",", 8], ["the", 10], ["major", 14], ["component", 20], ["of", 30], ["the", 33], ["erythroid", 37], ["membrane", 47], ["skeleton", 56], [",", 64], ["is", 66], ["a", 69], ["long", 71], [",", 75], ["asymmetrical", 77], ["rodlike", 90], ["protein", 98], ["that", 106], ["interacts", 111], ["with", 121], ["several", 126], ["other", 134], ["proteins", 140], ["to", 149], ["form", 152], ["a", 157], ["two", 159], ["-", 162], ["dimensional", 163], ["membrane", 175], ["skeleton", 184], [".", 192], ["Progress", 194], ["in", 203], ["several", 206], ["laboratories", 214], ["over", 227], ["the", 232], ["past", 236], ["few", 241], ["years", 245], ["including", 251], ["substantial", 261], ["partial", 273], ["peptide", 281], ["and", 289], ["nucleotide", 293], ["sequence", 304], ["determination", 313], ["has", 327], ["greatly", 331], ["enhanced", 339], ["our", 348], ["knowledge", 352], ["of", 362], ["the", 365], ["structural", 369], ["properties", 380], ["of", 391], ["this", 394], ["large", 399], ["molecule", 405], ["(", 414], ["heterodimer", 415], ["=", 427], ["465,000", 429], ["daltons", 437], [")", 444], [".", 445], ["The", 447], ["alpha", 451], ["and", 457], ["beta", 461], ["subunits", 466], ["are", 475], ["homologous", 479], ["with", 490], ["approximately", 495], ["30", 509], ["%", 511], ["identity", 513], [".", 521], ["They", 523], ["are", 528], ["aligned", 532], ["in", 540], ["an", 543], ["antiparallel", 546], ["side", 559], ["-", 563], ["to", 564], ["-", 566], ["side", 567], ["orientation", 572], ["with", 584], ["the", 589], ["amino-", 593], ["and", 600], ["carboxy", 604], ["-", 611], ["termini", 612], ["near", 620], ["opposite", 625], ["physical", 634], ["ends", 643], ["of", 648], ["the", 651], ["molecule", 655], [".", 663], ["The", 665], ["predominant", 669], ["structural", 681], ["feature", 692], ["elucidated", 700], ["from", 711], ["sequencing", 716], ["this", 727], ["large", 732], ["molecule", 738], ["is", 747], ["the", 750], ["nearly", 754], ["universal", 761], ["occurrence", 771], ["in", 782], ["both", 785], ["subunits", 790], ["of", 799], ["a", 802], ["single", 804], ["type", 811], ["of", 816], ["repetitive", 819], ["structure", 830], [".", 839], ["The", 841], ["periodicity", 845], ["of", 857], ["this", 860], ["homologous", 865], ["structure", 876], ["is", 886], ["exactly", 889], ["106", 897], ["amino", 901], ["acid", 907], ["residues", 912], [".", 920], ["As", 922], ["many", 925], ["as", 930], ["36", 933], ["homologous", 936], [",", 946], ["but", 948], ["nonidentical", 952], [",", 964], ["repeats", 966], ["exist", 974], ["and", 980], ["comprise", 984], ["more", 993], ["than", 998], ["90", 1003], ["%", 1005], ["of", 1007], ["the", 1010], ["mass", 1014], ["of", 1019], ["the", 1022], ["heterodimer", 1026], [".", 1037], ["Each", 1039], ["of", 1044], ["these", 1047], ["repetitive", 1053], ["units", 1064], ["is", 1070], ["folded", 1073], ["into", 1080], ["a", 1085], ["triple", 1087], ["-", 1093], ["stranded", 1094], ["structure", 1103], ["that", 1113], ["is", 1118], ["highly", 1121], ["helical", 1128], [".", 1135], ["Peptide", 1137], ["maps", 1145], [",", 1149], ["antibody", 1151], ["crossreactivity", 1160], [",", 1175], ["peptide", 1177], ["sequence", 1185], ["analysis", 1194], [",", 1202], ["and", 1204], ["more", 1208], ["recently", 1213], ["nucleic", 1222], ["acid", 1230], ["sequences", 1235], ["have", 1245], ["defined", 1250], ["several", 1258], ["major", 1266], ["properties", 1272], ["of", 1283], ["the", 1286], ["erythroid", 1290], ["molecule", 1300], ["and", 1309], ["related", 1313], ["proteins", 1321], ["in", 1330], ["other", 1333], ["tissues", 1339], [".", 1346], ["Tissue", 1348], ["-", 1354], ["specific", 1355], ["spectrins", 1364], ["have", 1374], ["the", 1379], ["same", 1383], ["106-residue", 1388], ["repetitive", 1400], ["structure", 1411], ["and", 1421], ["show", 1425], ["sequence", 1430], ["homology", 1439], ["to", 1448], ["erythroid", 1451], ["spectrin", 1461], [".", 1469]]}
{"context": "In order to determine the prevalence of latent infection due to Mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the Monotest and, for reference purposes, to the Mantoux test. The overall prevalence of subjects with a tuberculin skin reaction size > or = 5 mm in the Mantoux test was 25.7%; utilizing a cut-off of > or = 10 mm, the prevalence was 11.4%. Irrespective of cut-off, the Monotest showed a sensitivity of > 90% and a specificity of > 80%. At a prevalence of 25.7%, and with cut-offs of > or = 5 or > or = 10 mm, the positive predictive value was 83% or 62.2%, respectively. Irrespective of cut-off, the negative predictive value was > 97%. In conclusion, the Monotest proved satisfactory as a tool for epidemiological screening in a population with a high prevalence for latent tuberculosis, namely drug users.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "36caa3ccb74340beb0182b812e4fbc13", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[12, 12], [189, 189], [28, 28]], "char_spans": [[78, 89], [902, 913], [169, 180]]}]}], "context_tokens": [["In", 0], ["order", 3], ["to", 9], ["determine", 12], ["the", 22], ["prevalence", 26], ["of", 37], ["latent", 40], ["infection", 47], ["due", 57], ["to", 61], ["Mycobacterium", 64], ["tuberculosis", 78], ["in", 91], ["drug", 94], ["users", 99], ["and", 105], ["to", 109], ["provide", 112], ["centres", 120], ["for", 128], ["drug", 132], ["users", 137], ["with", 143], ["a", 148], ["practical", 150], ["tool", 160], ["for", 165], ["tuberculosis", 169], ["screening", 182], [",", 191], ["237", 193], ["drug", 197], ["users", 202], ["were", 208], ["subjected", 213], ["to", 223], ["the", 226], ["Monotest", 230], ["and", 239], [",", 242], ["for", 244], ["reference", 248], ["purposes", 258], [",", 266], ["to", 268], ["the", 271], ["Mantoux", 275], ["test", 283], [".", 287], ["The", 289], ["overall", 293], ["prevalence", 301], ["of", 312], ["subjects", 315], ["with", 324], ["a", 329], ["tuberculin", 331], ["skin", 342], ["reaction", 347], ["size", 356], [">", 361], ["or", 363], ["=", 366], ["5", 368], ["mm", 370], ["in", 373], ["the", 376], ["Mantoux", 380], ["test", 388], ["was", 393], ["25.7", 397], ["%", 401], [";", 402], ["utilizing", 404], ["a", 414], ["cut", 416], ["-", 419], ["off", 420], ["of", 424], [">", 427], ["or", 429], ["=", 432], ["10", 434], ["mm", 437], [",", 439], ["the", 441], ["prevalence", 445], ["was", 456], ["11.4", 460], ["%", 464], [".", 465], ["Irrespective", 467], ["of", 480], ["cut", 483], ["-", 486], ["off", 487], [",", 490], ["the", 492], ["Monotest", 496], ["showed", 505], ["a", 512], ["sensitivity", 514], ["of", 526], [">", 529], ["90", 531], ["%", 533], ["and", 535], ["a", 539], ["specificity", 541], ["of", 553], [">", 556], ["80", 558], ["%", 560], [".", 561], ["At", 563], ["a", 566], ["prevalence", 568], ["of", 579], ["25.7", 582], ["%", 586], [",", 587], ["and", 589], ["with", 593], ["cut", 598], ["-", 601], ["offs", 602], ["of", 607], [">", 610], ["or", 612], ["=", 615], ["5", 617], ["or", 619], [">", 622], ["or", 624], ["=", 627], ["10", 629], ["mm", 632], [",", 634], ["the", 636], ["positive", 640], ["predictive", 649], ["value", 660], ["was", 666], ["83", 670], ["%", 672], ["or", 674], ["62.2", 677], ["%", 681], [",", 682], ["respectively", 684], [".", 696], ["Irrespective", 698], ["of", 711], ["cut", 714], ["-", 717], ["off", 718], [",", 721], ["the", 723], ["negative", 727], ["predictive", 736], ["value", 747], ["was", 753], [">", 757], ["97", 759], ["%", 761], [".", 762], ["In", 764], ["conclusion", 767], [",", 777], ["the", 779], ["Monotest", 783], ["proved", 792], ["satisfactory", 799], ["as", 812], ["a", 815], ["tool", 817], ["for", 822], ["epidemiological", 826], ["screening", 842], ["in", 852], ["a", 855], ["population", 857], ["with", 868], ["a", 873], ["high", 875], ["prevalence", 880], ["for", 891], ["latent", 895], ["tuberculosis", 902], [",", 914], ["namely", 916], ["drug", 923], ["users", 928], [".", 933]]}
{"context": "Nox3, a member of the superoxide-producing NADPH oxidase (Nox) family, participates in otoconia formation in mouse inner ears, which is required for perception of balance and gravity. The activity of other Nox enzymes such as gp91(phox)/Nox2 and Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivatorprotein (p67(phox) or Noxa1); for the p47(phox)-dependent activation of these oxidases, treatment of cells with stimulants such as phorbol 12-myristate 13-acetate is also indispensable. Here we show that ectopic expression of Nox3 in various types of cells leads to phorbol 12-myristate 13-acetate-independent constitutive production of a substantial amount of superoxide under the conditions where gp91(phox) and Nox1 fail to generate superoxide, i.e. in the absence of the oxidase organizers and activators. Nox3 likely forms a functional complex with p22(phox); Nox3 physically interacts with and stabilizes p22(phox), and the Nox3-dependent superoxide production is totally dependent on p22(phox). The organizers p47(phox) and Noxo1 are capable of enhancing the superoxide production by Nox3 in the absence of the activators, and the enhancement requires the interaction of the organizers with p22(phox), further indicating a link between Nox3 and p22(phox). The p47(phox)-enhanced Nox3 activity is further facilitated by p67(phox) or Noxa1, whereas the activators cancel the Noxo1-induced enhancement. On the other hand, the small GTPase Rac, essential for the gp91(phox) activity, is likely dispensable to the Nox3 system. Thus Nox3 functions together with p22(phox) as an enzyme constitutively producing superoxide, which can be distinctly regulated by combinatorial use of the organizers and activators.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "e662d0daac3047e6bbb879f08d0a56eb", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[45, 45], [126, 126]], "char_spans": [[246, 249], [757, 760]]}]}], "context_tokens": [["Nox3", 0], [",", 4], ["a", 6], ["member", 8], ["of", 15], ["the", 18], ["superoxide", 22], ["-", 32], ["producing", 33], ["NADPH", 43], ["oxidase", 49], ["(", 57], ["Nox", 58], [")", 61], ["family", 63], [",", 69], ["participates", 71], ["in", 84], ["otoconia", 87], ["formation", 96], ["in", 106], ["mouse", 109], ["inner", 115], ["ears", 121], [",", 125], ["which", 127], ["is", 133], ["required", 136], ["for", 145], ["perception", 149], ["of", 160], ["balance", 163], ["and", 171], ["gravity", 175], [".", 182], ["The", 184], ["activity", 188], ["of", 197], ["other", 200], ["Nox", 206], ["enzymes", 210], ["such", 218], ["as", 223], ["gp91(phox)/Nox2", 226], ["and", 242], ["Nox1", 246], ["is", 251], ["known", 254], ["to", 260], ["absolutely", 263], ["require", 274], ["both", 282], ["an", 287], ["organizer", 290], ["protein", 300], ["(", 308], ["p47(phox", 309], [")", 317], ["or", 319], ["Noxo1", 322], [")", 327], ["andanactivatorprotein", 329], ["(", 351], ["p67(phox", 352], [")", 360], ["or", 362], ["Noxa1", 365], [")", 370], [";", 371], ["for", 373], ["the", 377], ["p47(phox)-dependent", 381], ["activation", 401], ["of", 412], ["these", 415], ["oxidases", 421], [",", 429], ["treatment", 431], ["of", 441], ["cells", 444], ["with", 450], ["stimulants", 455], ["such", 466], ["as", 471], ["phorbol", 474], ["12-myristate", 482], ["13-acetate", 495], ["is", 506], ["also", 509], ["indispensable", 514], [".", 527], ["Here", 529], ["we", 534], ["show", 537], ["that", 542], ["ectopic", 547], ["expression", 555], ["of", 566], ["Nox3", 569], ["in", 574], ["various", 577], ["types", 585], ["of", 591], ["cells", 594], ["leads", 600], ["to", 606], ["phorbol", 609], ["12-myristate", 617], ["13-acetate", 630], ["-", 640], ["independent", 641], ["constitutive", 653], ["production", 666], ["of", 677], ["a", 680], ["substantial", 682], ["amount", 694], ["of", 701], ["superoxide", 704], ["under", 715], ["the", 721], ["conditions", 725], ["where", 736], ["gp91(phox", 742], [")", 751], ["and", 753], ["Nox1", 757], ["fail", 762], ["to", 767], ["generate", 770], ["superoxide", 779], [",", 789], ["i.e.", 791], ["in", 796], ["the", 799], ["absence", 803], ["of", 811], ["the", 814], ["oxidase", 818], ["organizers", 826], ["and", 837], ["activators", 841], [".", 851], ["Nox3", 853], ["likely", 858], ["forms", 865], ["a", 871], ["functional", 873], ["complex", 884], ["with", 892], ["p22(phox", 897], [")", 905], [";", 906], ["Nox3", 908], ["physically", 913], ["interacts", 924], ["with", 934], ["and", 939], ["stabilizes", 943], ["p22(phox", 954], [")", 962], [",", 963], ["and", 965], ["the", 969], ["Nox3-dependent", 973], ["superoxide", 988], ["production", 999], ["is", 1010], ["totally", 1013], ["dependent", 1021], ["on", 1031], ["p22(phox", 1034], [")", 1042], [".", 1043], ["The", 1045], ["organizers", 1049], ["p47(phox", 1060], [")", 1068], ["and", 1070], ["Noxo1", 1074], ["are", 1080], ["capable", 1084], ["of", 1092], ["enhancing", 1095], ["the", 1105], ["superoxide", 1109], ["production", 1120], ["by", 1131], ["Nox3", 1134], ["in", 1139], ["the", 1142], ["absence", 1146], ["of", 1154], ["the", 1157], ["activators", 1161], [",", 1171], ["and", 1173], ["the", 1177], ["enhancement", 1181], ["requires", 1193], ["the", 1202], ["interaction", 1206], ["of", 1218], ["the", 1221], ["organizers", 1225], ["with", 1236], ["p22(phox", 1241], [")", 1249], [",", 1250], ["further", 1252], ["indicating", 1260], ["a", 1271], ["link", 1273], ["between", 1278], ["Nox3", 1286], ["and", 1291], ["p22(phox", 1295], [")", 1303], [".", 1304], ["The", 1306], ["p47(phox)-enhanced", 1310], ["Nox3", 1329], ["activity", 1334], ["is", 1343], ["further", 1346], ["facilitated", 1354], ["by", 1366], ["p67(phox", 1369], [")", 1377], ["or", 1379], ["Noxa1", 1382], [",", 1387], ["whereas", 1389], ["the", 1397], ["activators", 1401], ["cancel", 1412], ["the", 1419], ["Noxo1-induced", 1423], ["enhancement", 1437], [".", 1448], ["On", 1450], ["the", 1453], ["other", 1457], ["hand", 1463], [",", 1467], ["the", 1469], ["small", 1473], ["GTPase", 1479], ["Rac", 1486], [",", 1489], ["essential", 1491], ["for", 1501], ["the", 1505], ["gp91(phox", 1509], [")", 1518], ["activity", 1520], [",", 1528], ["is", 1530], ["likely", 1533], ["dispensable", 1540], ["to", 1552], ["the", 1555], ["Nox3", 1559], ["system", 1564], [".", 1570], ["Thus", 1572], ["Nox3", 1577], ["functions", 1582], ["together", 1592], ["with", 1601], ["p22(phox", 1606], [")", 1614], ["as", 1616], ["an", 1619], ["enzyme", 1622], ["constitutively", 1629], ["producing", 1644], ["superoxide", 1654], [",", 1664], ["which", 1666], ["can", 1672], ["be", 1676], ["distinctly", 1679], ["regulated", 1690], ["by", 1700], ["combinatorial", 1703], ["use", 1717], ["of", 1721], ["the", 1724], ["organizers", 1728], ["and", 1739], ["activators", 1743], [".", 1753]]}
{"context": "McLeod syndrome and chorea-acanthocytosis are classified with the so-called neuroacanthocytosis group of syndromes. Both lead to progressive basal ganglia degeneration and were not easily distinguished in the past. With the discovery of their molecular bases, mutations of the X-linked gene XK and autosomal recessive mutations of the gene coding for chorein, respectively, the two phenotypes can now be differentiated and extend the diagnostic spectrum in patients presenting with chorea. The present review compares the two conditions and proposes a practical approach to diagnosis and treatment. Better-defined disease concepts should eventually replace the umbrella term of \"neuroacanthocytosis.\" Animal models are needed to understand the underlying mechanisms. A final common pathway is likely for the pathogenesis of these conditions and is most probably shared with Huntington's disease.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "4678fd2baf4f4fc2a3d6a5f6d70178ed", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[49, 49]], "char_spans": [[291, 292]]}]}], "context_tokens": [["McLeod", 0], ["syndrome", 7], ["and", 16], ["chorea", 20], ["-", 26], ["acanthocytosis", 27], ["are", 42], ["classified", 46], ["with", 57], ["the", 62], ["so", 66], ["-", 68], ["called", 69], ["neuroacanthocytosis", 76], ["group", 96], ["of", 102], ["syndromes", 105], [".", 114], ["Both", 116], ["lead", 121], ["to", 126], ["progressive", 129], ["basal", 141], ["ganglia", 147], ["degeneration", 155], ["and", 168], ["were", 172], ["not", 177], ["easily", 181], ["distinguished", 188], ["in", 202], ["the", 205], ["past", 209], [".", 213], ["With", 215], ["the", 220], ["discovery", 224], ["of", 234], ["their", 237], ["molecular", 243], ["bases", 253], [",", 258], ["mutations", 260], ["of", 270], ["the", 273], ["X", 277], ["-", 278], ["linked", 279], ["gene", 286], ["XK", 291], ["and", 294], ["autosomal", 298], ["recessive", 308], ["mutations", 318], ["of", 328], ["the", 331], ["gene", 335], ["coding", 340], ["for", 347], ["chorein", 351], [",", 358], ["respectively", 360], [",", 372], ["the", 374], ["two", 378], ["phenotypes", 382], ["can", 393], ["now", 397], ["be", 401], ["differentiated", 404], ["and", 419], ["extend", 423], ["the", 430], ["diagnostic", 434], ["spectrum", 445], ["in", 454], ["patients", 457], ["presenting", 466], ["with", 477], ["chorea", 482], [".", 488], ["The", 490], ["present", 494], ["review", 502], ["compares", 509], ["the", 518], ["two", 522], ["conditions", 526], ["and", 537], ["proposes", 541], ["a", 550], ["practical", 552], ["approach", 562], ["to", 571], ["diagnosis", 574], ["and", 584], ["treatment", 588], [".", 597], ["Better", 599], ["-", 605], ["defined", 606], ["disease", 614], ["concepts", 622], ["should", 631], ["eventually", 638], ["replace", 649], ["the", 657], ["umbrella", 661], ["term", 670], ["of", 675], ["\"", 678], ["neuroacanthocytosis", 679], [".", 698], ["\"", 699], ["Animal", 701], ["models", 708], ["are", 715], ["needed", 719], ["to", 726], ["understand", 729], ["the", 740], ["underlying", 744], ["mechanisms", 755], [".", 765], ["A", 767], ["final", 769], ["common", 775], ["pathway", 782], ["is", 790], ["likely", 793], ["for", 800], ["the", 804], ["pathogenesis", 808], ["of", 821], ["these", 824], ["conditions", 830], ["and", 841], ["is", 845], ["most", 848], ["probably", 853], ["shared", 862], ["with", 869], ["Huntington", 874], ["'s", 884], ["disease", 887], [".", 894]]}
{"context": "The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations. The usual clinical dose of gefitinib (250 mg/d) is only one third of its maximum tolerated dose, whereas the dose of erlotinib (150 mg/d) is at its maximum tolerated dose. In NSCLC cell lines, both TKIs have similar micromolar inhibitory concentrations. We explored whether erlotinib at 25 mg/d (trough serum concentration similar to gefitinib 250 mg/d) would be efficacious in EGFR-mutated NSCLC. To study the inhibitory concentrations of gefitinib and erlotinib, we exposed EGFR-mutated cell lines (HCC827, H3255, PC-9, and H1975) to increasing concentrations of these TKIs. Further on, we performed a retrospective evaluation of seven patients with advanced EGFR-mutated (exon 19 deletions and L858R) NSCLC that were given erlotinib at 25 mg/d as their first EGFR TKI. Gefitinib and erlotinib generated similar inhibitory curves across our panel of EGFR-mutated NSCLC cell lines with overlapping mean 50% inhibitory concentration 95% confidence intervals for HCC827, PC-9, and H1975. Both drugs also displayed a high degree of correlation in mean 50% inhibitory concentration (Pearson's r = 0.99, p = 0.0417). Of the seven patients, five patients (71.5%) had partial responses to erlotinib 25 mg/d. Median progression-free survival was 17 months (95% confidence interval, 6-35 months). Toxicities were minimal, with only two (28.5%) patients having a rash and none experiencing (0%) diarrhea. In NSCLC cell lines, gefitinib and erlotinib have similar inhibitory profiles. In patients with NSCLC and EGFR-activating mutations, a dose of erlotinib 25 mg/d (equivalent to gefitinib 250 mg/d) leads to impressive response rates and progression-free survival similar to the growing experience with the approved doses of gefitinib (250 mg/d) and erlotinib (150 mg/d). Identifying prospectively the lowest and clinically active dose ranges of erlotinib and gefitinib will help further to personalize care for patients with tumors harboring EGFR mutations.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "2e559521de4543c0bcd36ddc1c47fc44", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[23, 30]], "char_spans": [[121, 164]]}]}], "context_tokens": [["The", 0], ["tyrosine", 4], ["kinase", 13], ["inhibitors", 20], ["(", 31], ["TKIs", 32], [")", 36], ["gefitinib", 38], ["and", 48], ["erlotinib", 52], ["are", 62], ["effective", 66], ["in", 76], ["non", 79], ["-", 82], ["small", 83], ["cell", 89], ["lung", 94], ["cancers", 99], ["(", 107], ["NSCLCs", 108], [")", 114], ["with", 116], ["epidermal", 121], ["growth", 131], ["factor", 138], ["receptor", 145], ["(", 154], ["EGFR", 155], [")", 159], ["gene", 161], ["mutations", 166], [".", 175], ["The", 177], ["usual", 181], ["clinical", 187], ["dose", 196], ["of", 201], ["gefitinib", 204], ["(", 214], ["250", 215], ["mg", 219], ["/", 221], ["d", 222], [")", 223], ["is", 225], ["only", 228], ["one", 233], ["third", 237], ["of", 243], ["its", 246], ["maximum", 250], ["tolerated", 258], ["dose", 268], [",", 272], ["whereas", 274], ["the", 282], ["dose", 286], ["of", 291], ["erlotinib", 294], ["(", 304], ["150", 305], ["mg", 309], ["/", 311], ["d", 312], [")", 313], ["is", 315], ["at", 318], ["its", 321], ["maximum", 325], ["tolerated", 333], ["dose", 343], [".", 347], ["In", 349], ["NSCLC", 352], ["cell", 358], ["lines", 363], [",", 368], ["both", 370], ["TKIs", 375], ["have", 380], ["similar", 385], ["micromolar", 393], ["inhibitory", 404], ["concentrations", 415], [".", 429], ["We", 431], ["explored", 434], ["whether", 443], ["erlotinib", 451], ["at", 461], ["25", 464], ["mg", 467], ["/", 469], ["d", 470], ["(", 472], ["trough", 473], ["serum", 480], ["concentration", 486], ["similar", 500], ["to", 508], ["gefitinib", 511], ["250", 521], ["mg", 525], ["/", 527], ["d", 528], [")", 529], ["would", 531], ["be", 537], ["efficacious", 540], ["in", 552], ["EGFR", 555], ["-", 559], ["mutated", 560], ["NSCLC", 568], [".", 573], ["To", 575], ["study", 578], ["the", 584], ["inhibitory", 588], ["concentrations", 599], ["of", 614], ["gefitinib", 617], ["and", 627], ["erlotinib", 631], [",", 640], ["we", 642], ["exposed", 645], ["EGFR", 653], ["-", 657], ["mutated", 658], ["cell", 666], ["lines", 671], ["(", 677], ["HCC827", 678], [",", 684], ["H3255", 686], [",", 691], ["PC-9", 693], [",", 697], ["and", 699], ["H1975", 703], [")", 708], ["to", 710], ["increasing", 713], ["concentrations", 724], ["of", 739], ["these", 742], ["TKIs", 748], [".", 752], ["Further", 754], ["on", 762], [",", 764], ["we", 766], ["performed", 769], ["a", 779], ["retrospective", 781], ["evaluation", 795], ["of", 806], ["seven", 809], ["patients", 815], ["with", 824], ["advanced", 829], ["EGFR", 838], ["-", 842], ["mutated", 843], ["(", 851], ["exon", 852], ["19", 857], ["deletions", 860], ["and", 870], ["L858R", 874], [")", 879], ["NSCLC", 881], ["that", 887], ["were", 892], ["given", 897], ["erlotinib", 903], ["at", 913], ["25", 916], ["mg", 919], ["/", 921], ["d", 922], ["as", 924], ["their", 927], ["first", 933], ["EGFR", 939], ["TKI", 944], [".", 947], ["Gefitinib", 949], ["and", 959], ["erlotinib", 963], ["generated", 973], ["similar", 983], ["inhibitory", 991], ["curves", 1002], ["across", 1009], ["our", 1016], ["panel", 1020], ["of", 1026], ["EGFR", 1029], ["-", 1033], ["mutated", 1034], ["NSCLC", 1042], ["cell", 1048], ["lines", 1053], ["with", 1059], ["overlapping", 1064], ["mean", 1076], ["50", 1081], ["%", 1083], ["inhibitory", 1085], ["concentration", 1096], ["95", 1110], ["%", 1112], ["confidence", 1114], ["intervals", 1125], ["for", 1135], ["HCC827", 1139], [",", 1145], ["PC-9", 1147], [",", 1151], ["and", 1153], ["H1975", 1157], [".", 1162], ["Both", 1164], ["drugs", 1169], ["also", 1175], ["displayed", 1180], ["a", 1190], ["high", 1192], ["degree", 1197], ["of", 1204], ["correlation", 1207], ["in", 1219], ["mean", 1222], ["50", 1227], ["%", 1229], ["inhibitory", 1231], ["concentration", 1242], ["(", 1256], ["Pearson", 1257], ["'s", 1264], ["r", 1267], ["=", 1269], ["0.99", 1271], [",", 1275], ["p", 1277], ["=", 1279], ["0.0417", 1281], [")", 1287], [".", 1288], ["Of", 1290], ["the", 1293], ["seven", 1297], ["patients", 1303], [",", 1311], ["five", 1313], ["patients", 1318], ["(", 1327], ["71.5", 1328], ["%", 1332], [")", 1333], ["had", 1335], ["partial", 1339], ["responses", 1347], ["to", 1357], ["erlotinib", 1360], ["25", 1370], ["mg", 1373], ["/", 1375], ["d", 1376], [".", 1377], ["Median", 1379], ["progression", 1386], ["-", 1397], ["free", 1398], ["survival", 1403], ["was", 1412], ["17", 1416], ["months", 1419], ["(", 1426], ["95", 1427], ["%", 1429], ["confidence", 1431], ["interval", 1442], [",", 1450], ["6", 1452], ["-", 1453], ["35", 1454], ["months", 1457], [")", 1463], [".", 1464], ["Toxicities", 1466], ["were", 1477], ["minimal", 1482], [",", 1489], ["with", 1491], ["only", 1496], ["two", 1501], ["(", 1505], ["28.5", 1506], ["%", 1510], [")", 1511], ["patients", 1513], ["having", 1522], ["a", 1529], ["rash", 1531], ["and", 1536], ["none", 1540], ["experiencing", 1545], ["(", 1558], ["0", 1559], ["%", 1560], [")", 1561], ["diarrhea", 1563], [".", 1571], ["In", 1573], ["NSCLC", 1576], ["cell", 1582], ["lines", 1587], [",", 1592], ["gefitinib", 1594], ["and", 1604], ["erlotinib", 1608], ["have", 1618], ["similar", 1623], ["inhibitory", 1631], ["profiles", 1642], [".", 1650], ["In", 1652], ["patients", 1655], ["with", 1664], ["NSCLC", 1669], ["and", 1675], ["EGFR", 1679], ["-", 1683], ["activating", 1684], ["mutations", 1695], [",", 1704], ["a", 1706], ["dose", 1708], ["of", 1713], ["erlotinib", 1716], ["25", 1726], ["mg", 1729], ["/", 1731], ["d", 1732], ["(", 1734], ["equivalent", 1735], ["to", 1746], ["gefitinib", 1749], ["250", 1759], ["mg", 1763], ["/", 1765], ["d", 1766], [")", 1767], ["leads", 1769], ["to", 1775], ["impressive", 1778], ["response", 1789], ["rates", 1798], ["and", 1804], ["progression", 1808], ["-", 1819], ["free", 1820], ["survival", 1825], ["similar", 1834], ["to", 1842], ["the", 1845], ["growing", 1849], ["experience", 1857], ["with", 1868], ["the", 1873], ["approved", 1877], ["doses", 1886], ["of", 1892], ["gefitinib", 1895], ["(", 1905], ["250", 1906], ["mg", 1910], ["/", 1912], ["d", 1913], [")", 1914], ["and", 1916], ["erlotinib", 1920], ["(", 1930], ["150", 1931], ["mg", 1935], ["/", 1937], ["d", 1938], [")", 1939], [".", 1940], ["Identifying", 1942], ["prospectively", 1954], ["the", 1968], ["lowest", 1972], ["and", 1979], ["clinically", 1983], ["active", 1994], ["dose", 2001], ["ranges", 2006], ["of", 2013], ["erlotinib", 2016], ["and", 2026], ["gefitinib", 2030], ["will", 2040], ["help", 2045], ["further", 2050], ["to", 2058], ["personalize", 2061], ["care", 2073], ["for", 2078], ["patients", 2082], ["with", 2091], ["tumors", 2096], ["harboring", 2103], ["EGFR", 2113], ["mutations", 2118], [".", 2127]]}
{"context": "Coexpression of PU.1 and GATA-1 is required for proper specification of the mast cell lineage; however, in the myeloid and erythroid lineages, PU.1 and GATA-1 are functionally antagonistic. In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development. We isolated a variant mRNA isoform of GATA-1 in murine mast cells that is significantly upregulated during mast cell differentiation. This isoform contains an alternatively spliced first exon (IB) that is distinct from the first exon (IE) incorporated in the major erythroid mRNA transcript. In contrast to erythroid and megakaryocyte cells, in mast cells we show that PU.1 and GATA-2 predominantly occupy potential cis-regulatory elements in the IB exon region in vivo. Using reporter assays, we identify an enhancer flanking the IB exon that is activated by PU.1. Furthermore, we observe that in PU.1(-/-) fetal liver cells, low levels of the IE GATA-1 isoform is expressed, but the variant IB isoform is absent. Reintroduction of PU.1 restores variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation. Our results are consistent with a transcriptional hierarchy in which PU.1, possibly in concert with GATA-2, activates GATA-1 expression in mast cells in a pathway distinct from that seen in the erythroid and megakaryocytic lineages.", "qas": [{"question": "Which gene controls the expression of GATA-1 isoforms?", "answers": ["PU.1"], "qid": "f6516640f1d44d11963b1679aae29f07", "question_tokens": [["Which", 0], ["gene", 6], ["controls", 11], ["the", 20], ["expression", 24], ["of", 35], ["GATA-1", 38], ["isoforms", 45], ["?", 53]], "detected_answers": [{"text": "PU.1", "token_spans": [[117, 117], [43, 43], [151, 151], [25, 25], [185, 185], [215, 215], [2, 2], [159, 159]], "char_spans": [[689, 692], [250, 253], [880, 883], [143, 146], [1053, 1056], [1256, 1259], [16, 19], [918, 925]]}]}], "context_tokens": [["Coexpression", 0], ["of", 13], ["PU.1", 16], ["and", 21], ["GATA-1", 25], ["is", 32], ["required", 35], ["for", 44], ["proper", 48], ["specification", 55], ["of", 69], ["the", 72], ["mast", 76], ["cell", 81], ["lineage", 86], [";", 93], ["however", 95], [",", 102], ["in", 104], ["the", 107], ["myeloid", 111], ["and", 119], ["erythroid", 123], ["lineages", 133], [",", 141], ["PU.1", 143], ["and", 148], ["GATA-1", 152], ["are", 159], ["functionally", 163], ["antagonistic", 176], [".", 188], ["In", 190], ["this", 193], ["study", 198], [",", 203], ["we", 205], ["report", 208], ["a", 215], ["transcriptional", 217], ["network", 233], ["in", 241], ["which", 244], ["PU.1", 250], ["positively", 255], ["regulates", 266], ["GATA-1", 276], ["expression", 283], ["in", 294], ["mast", 297], ["cell", 302], ["development", 307], [".", 318], ["We", 320], ["isolated", 323], ["a", 332], ["variant", 334], ["mRNA", 342], ["isoform", 347], ["of", 355], ["GATA-1", 358], ["in", 365], ["murine", 368], ["mast", 375], ["cells", 380], ["that", 386], ["is", 391], ["significantly", 394], ["upregulated", 408], ["during", 420], ["mast", 427], ["cell", 432], ["differentiation", 437], [".", 452], ["This", 454], ["isoform", 459], ["contains", 467], ["an", 476], ["alternatively", 479], ["spliced", 493], ["first", 501], ["exon", 507], ["(", 512], ["IB", 513], [")", 515], ["that", 517], ["is", 522], ["distinct", 525], ["from", 534], ["the", 539], ["first", 543], ["exon", 549], ["(", 554], ["IE", 555], [")", 557], ["incorporated", 559], ["in", 572], ["the", 575], ["major", 579], ["erythroid", 585], ["mRNA", 595], ["transcript", 600], [".", 610], ["In", 612], ["contrast", 615], ["to", 624], ["erythroid", 627], ["and", 637], ["megakaryocyte", 641], ["cells", 655], [",", 660], ["in", 662], ["mast", 665], ["cells", 670], ["we", 676], ["show", 679], ["that", 684], ["PU.1", 689], ["and", 694], ["GATA-2", 698], ["predominantly", 705], ["occupy", 719], ["potential", 726], ["cis", 736], ["-", 739], ["regulatory", 740], ["elements", 751], ["in", 760], ["the", 763], ["IB", 767], ["exon", 770], ["region", 775], ["in", 782], ["vivo", 785], [".", 789], ["Using", 791], ["reporter", 797], ["assays", 806], [",", 812], ["we", 814], ["identify", 817], ["an", 826], ["enhancer", 829], ["flanking", 838], ["the", 847], ["IB", 851], ["exon", 854], ["that", 859], ["is", 864], ["activated", 867], ["by", 877], ["PU.1", 880], [".", 884], ["Furthermore", 886], [",", 897], ["we", 899], ["observe", 902], ["that", 910], ["in", 915], ["PU.1(-/-", 918], [")", 926], ["fetal", 928], ["liver", 934], ["cells", 940], [",", 945], ["low", 947], ["levels", 951], ["of", 958], ["the", 961], ["IE", 965], ["GATA-1", 968], ["isoform", 975], ["is", 983], ["expressed", 986], [",", 995], ["but", 997], ["the", 1001], ["variant", 1005], ["IB", 1013], ["isoform", 1016], ["is", 1024], ["absent", 1027], [".", 1033], ["Reintroduction", 1035], ["of", 1050], ["PU.1", 1053], ["restores", 1058], ["variant", 1067], ["IB", 1075], ["isoform", 1078], ["and", 1086], ["upregulates", 1090], ["total", 1102], ["GATA-1", 1108], ["protein", 1115], ["expression", 1123], [",", 1133], ["which", 1135], ["is", 1141], ["concurrent", 1144], ["with", 1155], ["mast", 1160], ["cell", 1165], ["differentiation", 1170], [".", 1185], ["Our", 1187], ["results", 1191], ["are", 1199], ["consistent", 1203], ["with", 1214], ["a", 1219], ["transcriptional", 1221], ["hierarchy", 1237], ["in", 1247], ["which", 1250], ["PU.1", 1256], [",", 1260], ["possibly", 1262], ["in", 1271], ["concert", 1274], ["with", 1282], ["GATA-2", 1287], [",", 1293], ["activates", 1295], ["GATA-1", 1305], ["expression", 1312], ["in", 1323], ["mast", 1326], ["cells", 1331], ["in", 1337], ["a", 1340], ["pathway", 1342], ["distinct", 1350], ["from", 1359], ["that", 1364], ["seen", 1369], ["in", 1374], ["the", 1377], ["erythroid", 1381], ["and", 1391], ["megakaryocytic", 1395], ["lineages", 1410], [".", 1418]]}
{"context": "The Shprintzen-Goldberg syndrome (SGS) is a disorder of unknown cause comprising craniosynostosis, a marfanoid habitus and skeletal, neurological, cardiovascular, and connective-tissue anomalies. There are no pathognomonic signs of SGS and diagnosis depends on recognition of a characteristic combination of anomalies. Here, we describe 14 persons with SGS and compare their clinical findings with those of 23 previously reported individuals, including two families with more than one affected individual. Our analysis suggests that there is a characteristic facial appearance, with more than two thirds of all individuals having hypertelorism, down-slanting palpebral fissures, a high-arched palate, micrognathia, and apparently low-set and posteriorly rotated ears. Other commonly reported manifestations include hypotonia in at least the neonatal period, developmental delay, and inguinal or umbilical hernia. The degree of reported intellectual impairment ranges from mild to severe. The most common skeletal manifestations in SGS were arachnodactyly, pectus deformity, camptodactyly, scoliosis, and joint hypermobility. None of the skeletal signs alone is specific for SGS. Our study includes 14 mainly German individuals with SGS evaluated over a period of 10 years. Given that only 23 other persons with SGS have been reported to date worldwide, we suggest that SGS may be more common than previously assumed.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "2406a794568840628014804927e40975", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[15, 15]], "char_spans": [[81, 96]]}]}], "context_tokens": [["The", 0], ["Shprintzen", 4], ["-", 14], ["Goldberg", 15], ["syndrome", 24], ["(", 33], ["SGS", 34], [")", 37], ["is", 39], ["a", 42], ["disorder", 44], ["of", 53], ["unknown", 56], ["cause", 64], ["comprising", 70], ["craniosynostosis", 81], [",", 97], ["a", 99], ["marfanoid", 101], ["habitus", 111], ["and", 119], ["skeletal", 123], [",", 131], ["neurological", 133], [",", 145], ["cardiovascular", 147], [",", 161], ["and", 163], ["connective", 167], ["-", 177], ["tissue", 178], ["anomalies", 185], [".", 194], ["There", 196], ["are", 202], ["no", 206], ["pathognomonic", 209], ["signs", 223], ["of", 229], ["SGS", 232], ["and", 236], ["diagnosis", 240], ["depends", 250], ["on", 258], ["recognition", 261], ["of", 273], ["a", 276], ["characteristic", 278], ["combination", 293], ["of", 305], ["anomalies", 308], [".", 317], ["Here", 319], [",", 323], ["we", 325], ["describe", 328], ["14", 337], ["persons", 340], ["with", 348], ["SGS", 353], ["and", 357], ["compare", 361], ["their", 369], ["clinical", 375], ["findings", 384], ["with", 393], ["those", 398], ["of", 404], ["23", 407], ["previously", 410], ["reported", 421], ["individuals", 430], [",", 441], ["including", 443], ["two", 453], ["families", 457], ["with", 466], ["more", 471], ["than", 476], ["one", 481], ["affected", 485], ["individual", 494], [".", 504], ["Our", 506], ["analysis", 510], ["suggests", 519], ["that", 528], ["there", 533], ["is", 539], ["a", 542], ["characteristic", 544], ["facial", 559], ["appearance", 566], [",", 576], ["with", 578], ["more", 583], ["than", 588], ["two", 593], ["thirds", 597], ["of", 604], ["all", 607], ["individuals", 611], ["having", 623], ["hypertelorism", 630], [",", 643], ["down", 645], ["-", 649], ["slanting", 650], ["palpebral", 659], ["fissures", 669], [",", 677], ["a", 679], ["high", 681], ["-", 685], ["arched", 686], ["palate", 693], [",", 699], ["micrognathia", 701], [",", 713], ["and", 715], ["apparently", 719], ["low", 730], ["-", 733], ["set", 734], ["and", 738], ["posteriorly", 742], ["rotated", 754], ["ears", 762], [".", 766], ["Other", 768], ["commonly", 774], ["reported", 783], ["manifestations", 792], ["include", 807], ["hypotonia", 815], ["in", 825], ["at", 828], ["least", 831], ["the", 837], ["neonatal", 841], ["period", 850], [",", 856], ["developmental", 858], ["delay", 872], [",", 877], ["and", 879], ["inguinal", 883], ["or", 892], ["umbilical", 895], ["hernia", 905], [".", 911], ["The", 913], ["degree", 917], ["of", 924], ["reported", 927], ["intellectual", 936], ["impairment", 949], ["ranges", 960], ["from", 967], ["mild", 972], ["to", 977], ["severe", 980], [".", 986], ["The", 988], ["most", 992], ["common", 997], ["skeletal", 1004], ["manifestations", 1013], ["in", 1028], ["SGS", 1031], ["were", 1035], ["arachnodactyly", 1040], [",", 1054], ["pectus", 1056], ["deformity", 1063], [",", 1072], ["camptodactyly", 1074], [",", 1087], ["scoliosis", 1089], [",", 1098], ["and", 1100], ["joint", 1104], ["hypermobility", 1110], [".", 1123], ["None", 1125], ["of", 1130], ["the", 1133], ["skeletal", 1137], ["signs", 1146], ["alone", 1152], ["is", 1158], ["specific", 1161], ["for", 1170], ["SGS", 1174], [".", 1177], ["Our", 1179], ["study", 1183], ["includes", 1189], ["14", 1198], ["mainly", 1201], ["German", 1208], ["individuals", 1215], ["with", 1227], ["SGS", 1232], ["evaluated", 1236], ["over", 1246], ["a", 1251], ["period", 1253], ["of", 1260], ["10", 1263], ["years", 1266], [".", 1271], ["Given", 1273], ["that", 1279], ["only", 1284], ["23", 1289], ["other", 1292], ["persons", 1298], ["with", 1306], ["SGS", 1311], ["have", 1315], ["been", 1320], ["reported", 1325], ["to", 1334], ["date", 1337], ["worldwide", 1342], [",", 1351], ["we", 1353], ["suggest", 1356], ["that", 1364], ["SGS", 1369], ["may", 1373], ["be", 1377], ["more", 1380], ["common", 1385], ["than", 1392], ["previously", 1397], ["assumed", 1408], [".", 1415]]}
{"context": "Prominin-1 (CD133) is commonly used to isolate stem and progenitor cells from the developing and adult nervous system and to identify cancer stem cells in brain tumors. However, despite extensive characterization of Prominin-1(+) precursor cells from the adult subventricular zone, no information about the expression of Prominin-1 by precursor cells in the subgranular zone (SGZ) of the adult hippocampus has been available. We show here that Prominin-1 is expressed by a significant number of cells in the SGZ of adult mice in vivo and ex vivo, including postmitotic astrocytes. A small subset of Prominin-1(+) cells coexpressed the nonspecific precursor cell marker Nestin as well as GFAP and Sox2. Upon fluorescence-activated cell sorting, only Prominin-1/Nestin double-positive cells fulfilled the defining stem cell criteria of proliferation, self-renewal, and multipotentiality as assessed by a neurosphere assay. In addition, isolated primary Prominin-1(+) cells preferentially migrated to the neurogenic niche in the SGZ upon transplantation in vivo. Finally, despite its expression by various stem and progenitor cells, Prominin-1 turned out to be dispensable for precursor cell proliferation in vitro and in vivo. Nevertheless, a net decrease in hippocampal neurogenesis, by \u223c30% was found in Prominin-1 knock-out mice, suggesting other roles in controlling adult hippocampal neurogenesis. Remarkably, an upregulation of Prominin-2 was detected in Prominin-1-deficient mice highlighting a potential compensatory mechanism, which might explain the lack of severe symptoms in individuals carrying mutations in the Prom1 gene.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "6cc9877ac4fc485b8865be0daa1ae5a3", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[113, 113]], "char_spans": [[669, 674]]}]}], "context_tokens": [["Prominin-1", 0], ["(", 11], ["CD133", 12], [")", 17], ["is", 19], ["commonly", 22], ["used", 31], ["to", 36], ["isolate", 39], ["stem", 47], ["and", 52], ["progenitor", 56], ["cells", 67], ["from", 73], ["the", 78], ["developing", 82], ["and", 93], ["adult", 97], ["nervous", 103], ["system", 111], ["and", 118], ["to", 122], ["identify", 125], ["cancer", 134], ["stem", 141], ["cells", 146], ["in", 152], ["brain", 155], ["tumors", 161], [".", 167], ["However", 169], [",", 176], ["despite", 178], ["extensive", 186], ["characterization", 196], ["of", 213], ["Prominin-1(+", 216], [")", 228], ["precursor", 230], ["cells", 240], ["from", 246], ["the", 251], ["adult", 255], ["subventricular", 261], ["zone", 276], [",", 280], ["no", 282], ["information", 285], ["about", 297], ["the", 303], ["expression", 307], ["of", 318], ["Prominin-1", 321], ["by", 332], ["precursor", 335], ["cells", 345], ["in", 351], ["the", 354], ["subgranular", 358], ["zone", 370], ["(", 375], ["SGZ", 376], [")", 379], ["of", 381], ["the", 384], ["adult", 388], ["hippocampus", 394], ["has", 406], ["been", 410], ["available", 415], [".", 424], ["We", 426], ["show", 429], ["here", 434], ["that", 439], ["Prominin-1", 444], ["is", 455], ["expressed", 458], ["by", 468], ["a", 471], ["significant", 473], ["number", 485], ["of", 492], ["cells", 495], ["in", 501], ["the", 504], ["SGZ", 508], ["of", 512], ["adult", 515], ["mice", 521], ["in", 526], ["vivo", 529], ["and", 534], ["ex", 538], ["vivo", 541], [",", 545], ["including", 547], ["postmitotic", 557], ["astrocytes", 569], [".", 579], ["A", 581], ["small", 583], ["subset", 589], ["of", 596], ["Prominin-1(+", 599], [")", 611], ["cells", 613], ["coexpressed", 619], ["the", 631], ["nonspecific", 635], ["precursor", 647], ["cell", 657], ["marker", 662], ["Nestin", 669], ["as", 676], ["well", 679], ["as", 684], ["GFAP", 687], ["and", 692], ["Sox2", 696], [".", 700], ["Upon", 702], ["fluorescence", 707], ["-", 719], ["activated", 720], ["cell", 730], ["sorting", 735], [",", 742], ["only", 744], ["Prominin-1/Nestin", 749], ["double", 767], ["-", 773], ["positive", 774], ["cells", 783], ["fulfilled", 789], ["the", 799], ["defining", 803], ["stem", 812], ["cell", 817], ["criteria", 822], ["of", 831], ["proliferation", 834], [",", 847], ["self", 849], ["-", 853], ["renewal", 854], [",", 861], ["and", 863], ["multipotentiality", 867], ["as", 885], ["assessed", 888], ["by", 897], ["a", 900], ["neurosphere", 902], ["assay", 914], [".", 919], ["In", 921], ["addition", 924], [",", 932], ["isolated", 934], ["primary", 943], ["Prominin-1(+", 951], [")", 963], ["cells", 965], ["preferentially", 971], ["migrated", 986], ["to", 995], ["the", 998], ["neurogenic", 1002], ["niche", 1013], ["in", 1019], ["the", 1022], ["SGZ", 1026], ["upon", 1030], ["transplantation", 1035], ["in", 1051], ["vivo", 1054], [".", 1058], ["Finally", 1060], [",", 1067], ["despite", 1069], ["its", 1077], ["expression", 1081], ["by", 1092], ["various", 1095], ["stem", 1103], ["and", 1108], ["progenitor", 1112], ["cells", 1123], [",", 1128], ["Prominin-1", 1130], ["turned", 1141], ["out", 1148], ["to", 1152], ["be", 1155], ["dispensable", 1158], ["for", 1170], ["precursor", 1174], ["cell", 1184], ["proliferation", 1189], ["in", 1203], ["vitro", 1206], ["and", 1212], ["in", 1216], ["vivo", 1219], [".", 1223], ["Nevertheless", 1225], [",", 1237], ["a", 1239], ["net", 1241], ["decrease", 1245], ["in", 1254], ["hippocampal", 1257], ["neurogenesis", 1269], [",", 1281], ["by", 1283], ["\u223c30", 1286], ["%", 1289], ["was", 1291], ["found", 1295], ["in", 1301], ["Prominin-1", 1304], ["knock", 1315], ["-", 1320], ["out", 1321], ["mice", 1325], [",", 1329], ["suggesting", 1331], ["other", 1342], ["roles", 1348], ["in", 1354], ["controlling", 1357], ["adult", 1369], ["hippocampal", 1375], ["neurogenesis", 1387], [".", 1399], ["Remarkably", 1401], [",", 1411], ["an", 1413], ["upregulation", 1416], ["of", 1429], ["Prominin-2", 1432], ["was", 1443], ["detected", 1447], ["in", 1456], ["Prominin-1-deficient", 1459], ["mice", 1480], ["highlighting", 1485], ["a", 1498], ["potential", 1500], ["compensatory", 1510], ["mechanism", 1523], [",", 1532], ["which", 1534], ["might", 1540], ["explain", 1546], ["the", 1554], ["lack", 1558], ["of", 1563], ["severe", 1566], ["symptoms", 1573], ["in", 1582], ["individuals", 1585], ["carrying", 1597], ["mutations", 1606], ["in", 1616], ["the", 1619], ["Prom1", 1623], ["gene", 1629], [".", 1633]]}
{"context": "Natively disordered proteins are a growing class of anomalies to the structure-function paradigm. The natively disordered protein alpha-synuclein is the primary component of Lewy bodies, the cellular hallmark of Parkinson's disease. We noticed a dramatic difference in dilute solution 1H-15N Heteronuclear Single Quantum Coherence (HSQC) spectra of wild-type alpha-synuclein and two disease-related mutants (A30P and A53T), with spectra collected at 35 degrees C showing fewer cross-peaks than spectra acquired at 10 degrees C. Here, we show the change to be the result of a reversible conformational exchange linked to an increase in hydrodynamic radius and secondary structure as the temperature is raised. Combined with analytical ultracentrifugation data showing alpha-synuclein to be monomeric at both temperatures, we conclude that the poor quality of the 1H-15N HSQC spectra obtained at 35 degrees C is due to conformational fluctuations that occur on the proton chemical shift time scale. Using a truncated variant of alpha-synuclein, we show the conformational exchange occurs in the first 100 amino acids of the protein. Our data illustrate a key difference between globular and natively disordered proteins. The properties of globular proteins change little with solution conditions until they denature cooperatively, but the properties of natively disordered proteins can vary dramatically with solution conditions.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "8af93cd51edd4155854b8bc805023cf9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[132, 134], [60, 62], [20, 22], [178, 180]], "char_spans": [[767, 781], [359, 373], [130, 144], [1026, 1040]]}]}], "context_tokens": [["Natively", 0], ["disordered", 9], ["proteins", 20], ["are", 29], ["a", 33], ["growing", 35], ["class", 43], ["of", 49], ["anomalies", 52], ["to", 62], ["the", 65], ["structure", 69], ["-", 78], ["function", 79], ["paradigm", 88], [".", 96], ["The", 98], ["natively", 102], ["disordered", 111], ["protein", 122], ["alpha", 130], ["-", 135], ["synuclein", 136], ["is", 146], ["the", 149], ["primary", 153], ["component", 161], ["of", 171], ["Lewy", 174], ["bodies", 179], [",", 185], ["the", 187], ["cellular", 191], ["hallmark", 200], ["of", 209], ["Parkinson", 212], ["'s", 221], ["disease", 224], [".", 231], ["We", 233], ["noticed", 236], ["a", 244], ["dramatic", 246], ["difference", 255], ["in", 266], ["dilute", 269], ["solution", 276], ["1H-15N", 285], ["Heteronuclear", 292], ["Single", 306], ["Quantum", 313], ["Coherence", 321], ["(", 331], ["HSQC", 332], [")", 336], ["spectra", 338], ["of", 346], ["wild", 349], ["-", 353], ["type", 354], ["alpha", 359], ["-", 364], ["synuclein", 365], ["and", 375], ["two", 379], ["disease", 383], ["-", 390], ["related", 391], ["mutants", 399], ["(", 407], ["A30P", 408], ["and", 413], ["A53", 417], ["T", 420], [")", 421], [",", 422], ["with", 424], ["spectra", 429], ["collected", 437], ["at", 447], ["35", 450], ["degrees", 453], ["C", 461], ["showing", 463], ["fewer", 471], ["cross", 477], ["-", 482], ["peaks", 483], ["than", 489], ["spectra", 494], ["acquired", 502], ["at", 511], ["10", 514], ["degrees", 517], ["C.", 525], ["Here", 528], [",", 532], ["we", 534], ["show", 537], ["the", 542], ["change", 546], ["to", 553], ["be", 556], ["the", 559], ["result", 563], ["of", 570], ["a", 573], ["reversible", 575], ["conformational", 586], ["exchange", 601], ["linked", 610], ["to", 617], ["an", 620], ["increase", 623], ["in", 632], ["hydrodynamic", 635], ["radius", 648], ["and", 655], ["secondary", 659], ["structure", 669], ["as", 679], ["the", 682], ["temperature", 686], ["is", 698], ["raised", 701], [".", 707], ["Combined", 709], ["with", 718], ["analytical", 723], ["ultracentrifugation", 734], ["data", 754], ["showing", 759], ["alpha", 767], ["-", 772], ["synuclein", 773], ["to", 783], ["be", 786], ["monomeric", 789], ["at", 799], ["both", 802], ["temperatures", 807], [",", 819], ["we", 821], ["conclude", 824], ["that", 833], ["the", 838], ["poor", 842], ["quality", 847], ["of", 855], ["the", 858], ["1H-15N", 862], ["HSQC", 869], ["spectra", 874], ["obtained", 882], ["at", 891], ["35", 894], ["degrees", 897], ["C", 905], ["is", 907], ["due", 910], ["to", 914], ["conformational", 917], ["fluctuations", 932], ["that", 945], ["occur", 950], ["on", 956], ["the", 959], ["proton", 963], ["chemical", 970], ["shift", 979], ["time", 985], ["scale", 990], [".", 995], ["Using", 997], ["a", 1003], ["truncated", 1005], ["variant", 1015], ["of", 1023], ["alpha", 1026], ["-", 1031], ["synuclein", 1032], [",", 1041], ["we", 1043], ["show", 1046], ["the", 1051], ["conformational", 1055], ["exchange", 1070], ["occurs", 1079], ["in", 1086], ["the", 1089], ["first", 1093], ["100", 1099], ["amino", 1103], ["acids", 1109], ["of", 1115], ["the", 1118], ["protein", 1122], [".", 1129], ["Our", 1131], ["data", 1135], ["illustrate", 1140], ["a", 1151], ["key", 1153], ["difference", 1157], ["between", 1168], ["globular", 1176], ["and", 1185], ["natively", 1189], ["disordered", 1198], ["proteins", 1209], [".", 1217], ["The", 1219], ["properties", 1223], ["of", 1234], ["globular", 1237], ["proteins", 1246], ["change", 1255], ["little", 1262], ["with", 1269], ["solution", 1274], ["conditions", 1283], ["until", 1294], ["they", 1300], ["denature", 1305], ["cooperatively", 1314], [",", 1327], ["but", 1329], ["the", 1333], ["properties", 1337], ["of", 1348], ["natively", 1351], ["disordered", 1360], ["proteins", 1371], ["can", 1380], ["vary", 1384], ["dramatically", 1389], ["with", 1402], ["solution", 1407], ["conditions", 1416], [".", 1426]]}
{"context": "Mowat-Wilson syndrome (MWS) is a severe intellectual disability (ID)-distinctive facial gestalt-multiple congenital anomaly syndrome, commonly associating microcephaly, epilepsy, corpus callosum agenesis, conotruncal heart defects, urogenital malformations and Hirschsprung disease (HSCR). MWS is caused by de novo heterozygous mutations in the ZEB2 gene. The majority of mutations lead to haplo-insufficiency through premature stop codons or large gene deletions. Only three missense mutations have been reported so far; none of which resides in a known functional domain of ZEB2. In this study, we report and analyze the functional consequences of three novel missense mutations, p.Tyr1055Cys, p.Ser1071Pro and p.His1045Arg, identified in the highly conserved C-zinc-finger (C-ZF) domain of ZEB2. Patients' phenotype included the facial gestalt of MWS and moderate ID, but no microcephaly, heart defects or HSCR. In vitro studies showed that all the three mutations prevented binding and repression of the E-cadherin promoter, a characterized ZEB2 target gene. Taking advantage of the zebrafish morphant technology, we performed rescue experiments using wild-type (WT) and mutant human ZEB2 mRNAs. Variable, mutation-dependent, embryo rescue, correlating with the severity of patients' phenotype, was observed. Our data provide evidence that these missense mutations cause a partial loss of function of ZEB2, suggesting that its role is not restricted to repression of E-cadherin. Functional domains other than C-ZF may play a role in early embryonic development. Finally, these findings broaden the clinical spectrum of ZEB2 mutations, indicating that MWS ought to be considered in patients with lesser degrees of ID and a suggestive facial gestalt, even in the absence of congenital malformation.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "66de6d84167b4ec996cf97c56aab9b0c", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[96, 96], [144, 144], [55, 55], [216, 216], [296, 296], [190, 190], [255, 255]], "char_spans": [[576, 579], [793, 796], [345, 348], [1188, 1191], [1623, 1626], [1045, 1048], [1405, 1408]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["severe", 33], ["intellectual", 40], ["disability", 53], ["(", 64], ["ID)-distinctive", 65], ["facial", 81], ["gestalt", 88], ["-", 95], ["multiple", 96], ["congenital", 105], ["anomaly", 116], ["syndrome", 124], [",", 132], ["commonly", 134], ["associating", 143], ["microcephaly", 155], [",", 167], ["epilepsy", 169], [",", 177], ["corpus", 179], ["callosum", 186], ["agenesis", 195], [",", 203], ["conotruncal", 205], ["heart", 217], ["defects", 223], [",", 230], ["urogenital", 232], ["malformations", 243], ["and", 257], ["Hirschsprung", 261], ["disease", 274], ["(", 282], ["HSCR", 283], [")", 287], [".", 288], ["MWS", 290], ["is", 294], ["caused", 297], ["by", 304], ["de", 307], ["novo", 310], ["heterozygous", 315], ["mutations", 328], ["in", 338], ["the", 341], ["ZEB2", 345], ["gene", 350], [".", 354], ["The", 356], ["majority", 360], ["of", 369], ["mutations", 372], ["lead", 382], ["to", 387], ["haplo", 390], ["-", 395], ["insufficiency", 396], ["through", 410], ["premature", 418], ["stop", 428], ["codons", 433], ["or", 440], ["large", 443], ["gene", 449], ["deletions", 454], [".", 463], ["Only", 465], ["three", 470], ["missense", 476], ["mutations", 485], ["have", 495], ["been", 500], ["reported", 505], ["so", 514], ["far", 517], [";", 520], ["none", 522], ["of", 527], ["which", 530], ["resides", 536], ["in", 544], ["a", 547], ["known", 549], ["functional", 555], ["domain", 566], ["of", 573], ["ZEB2", 576], [".", 580], ["In", 582], ["this", 585], ["study", 590], [",", 595], ["we", 597], ["report", 600], ["and", 607], ["analyze", 611], ["the", 619], ["functional", 623], ["consequences", 634], ["of", 647], ["three", 650], ["novel", 656], ["missense", 662], ["mutations", 671], [",", 680], ["p", 682], [".", 683], ["Tyr1055Cys", 684], [",", 694], ["p", 696], [".", 697], ["Ser1071Pro", 698], ["and", 709], ["p", 713], [".", 714], ["His1045Arg", 715], [",", 725], ["identified", 727], ["in", 738], ["the", 741], ["highly", 745], ["conserved", 752], ["C", 762], ["-", 763], ["zinc", 764], ["-", 768], ["finger", 769], ["(", 776], ["C", 777], ["-", 778], ["ZF", 779], [")", 781], ["domain", 783], ["of", 790], ["ZEB2", 793], [".", 797], ["Patients", 799], ["'", 807], ["phenotype", 809], ["included", 819], ["the", 828], ["facial", 832], ["gestalt", 839], ["of", 847], ["MWS", 850], ["and", 854], ["moderate", 858], ["ID", 867], [",", 869], ["but", 871], ["no", 875], ["microcephaly", 878], [",", 890], ["heart", 892], ["defects", 898], ["or", 906], ["HSCR", 909], [".", 913], ["In", 915], ["vitro", 918], ["studies", 924], ["showed", 932], ["that", 939], ["all", 944], ["the", 948], ["three", 952], ["mutations", 958], ["prevented", 968], ["binding", 978], ["and", 986], ["repression", 990], ["of", 1001], ["the", 1004], ["E", 1008], ["-", 1009], ["cadherin", 1010], ["promoter", 1019], [",", 1027], ["a", 1029], ["characterized", 1031], ["ZEB2", 1045], ["target", 1050], ["gene", 1057], [".", 1061], ["Taking", 1063], ["advantage", 1070], ["of", 1080], ["the", 1083], ["zebrafish", 1087], ["morphant", 1097], ["technology", 1106], [",", 1116], ["we", 1118], ["performed", 1121], ["rescue", 1131], ["experiments", 1138], ["using", 1150], ["wild", 1156], ["-", 1160], ["type", 1161], ["(", 1166], ["WT", 1167], [")", 1169], ["and", 1171], ["mutant", 1175], ["human", 1182], ["ZEB2", 1188], ["mRNAs", 1193], [".", 1198], ["Variable", 1200], [",", 1208], ["mutation", 1210], ["-", 1218], ["dependent", 1219], [",", 1228], ["embryo", 1230], ["rescue", 1237], [",", 1243], ["correlating", 1245], ["with", 1257], ["the", 1262], ["severity", 1266], ["of", 1275], ["patients", 1278], ["'", 1286], ["phenotype", 1288], [",", 1297], ["was", 1299], ["observed", 1303], [".", 1311], ["Our", 1313], ["data", 1317], ["provide", 1322], ["evidence", 1330], ["that", 1339], ["these", 1344], ["missense", 1350], ["mutations", 1359], ["cause", 1369], ["a", 1375], ["partial", 1377], ["loss", 1385], ["of", 1390], ["function", 1393], ["of", 1402], ["ZEB2", 1405], [",", 1409], ["suggesting", 1411], ["that", 1422], ["its", 1427], ["role", 1431], ["is", 1436], ["not", 1439], ["restricted", 1443], ["to", 1454], ["repression", 1457], ["of", 1468], ["E", 1471], ["-", 1472], ["cadherin", 1473], [".", 1481], ["Functional", 1483], ["domains", 1494], ["other", 1502], ["than", 1508], ["C", 1513], ["-", 1514], ["ZF", 1515], ["may", 1518], ["play", 1522], ["a", 1527], ["role", 1529], ["in", 1534], ["early", 1537], ["embryonic", 1543], ["development", 1553], [".", 1564], ["Finally", 1566], [",", 1573], ["these", 1575], ["findings", 1581], ["broaden", 1590], ["the", 1598], ["clinical", 1602], ["spectrum", 1611], ["of", 1620], ["ZEB2", 1623], ["mutations", 1628], [",", 1637], ["indicating", 1639], ["that", 1650], ["MWS", 1655], ["ought", 1659], ["to", 1665], ["be", 1668], ["considered", 1671], ["in", 1682], ["patients", 1685], ["with", 1694], ["lesser", 1699], ["degrees", 1706], ["of", 1714], ["ID", 1717], ["and", 1720], ["a", 1724], ["suggestive", 1726], ["facial", 1737], ["gestalt", 1744], [",", 1751], ["even", 1753], ["in", 1758], ["the", 1761], ["absence", 1765], ["of", 1773], ["congenital", 1776], ["malformation", 1787], [".", 1799]]}
{"context": "Opioid overdose is rarely the primary cause of altered mental status in cancer patients receiving opioid therapy. The inappropriate administration of naloxone to reverse an abnormal mental status can cause severe withdrawal symptoms and pain. To illustrate this problem, we report the case of a patient inappropriately treated with naloxone and the results of a retrospective review of the medical records of 15 consecutive patients with cancer treated with naloxone in the emergency department over a 5-month period. We offer guidelines for a more thoughtful approach to the management of patients with cancer who present with encephalopathy.", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "bbac40c6eb3c41cd806dbc42ad8f54dc", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[52, 52], [72, 72], [22, 22]], "char_spans": [[332, 339], [458, 465], [150, 157]]}]}], "context_tokens": [["Opioid", 0], ["overdose", 7], ["is", 16], ["rarely", 19], ["the", 26], ["primary", 30], ["cause", 38], ["of", 44], ["altered", 47], ["mental", 55], ["status", 62], ["in", 69], ["cancer", 72], ["patients", 79], ["receiving", 88], ["opioid", 98], ["therapy", 105], [".", 112], ["The", 114], ["inappropriate", 118], ["administration", 132], ["of", 147], ["naloxone", 150], ["to", 159], ["reverse", 162], ["an", 170], ["abnormal", 173], ["mental", 182], ["status", 189], ["can", 196], ["cause", 200], ["severe", 206], ["withdrawal", 213], ["symptoms", 224], ["and", 233], ["pain", 237], [".", 241], ["To", 243], ["illustrate", 246], ["this", 257], ["problem", 262], [",", 269], ["we", 271], ["report", 274], ["the", 281], ["case", 285], ["of", 290], ["a", 293], ["patient", 295], ["inappropriately", 303], ["treated", 319], ["with", 327], ["naloxone", 332], ["and", 341], ["the", 345], ["results", 349], ["of", 357], ["a", 360], ["retrospective", 362], ["review", 376], ["of", 383], ["the", 386], ["medical", 390], ["records", 398], ["of", 406], ["15", 409], ["consecutive", 412], ["patients", 424], ["with", 433], ["cancer", 438], ["treated", 445], ["with", 453], ["naloxone", 458], ["in", 467], ["the", 470], ["emergency", 474], ["department", 484], ["over", 495], ["a", 500], ["5-month", 502], ["period", 510], [".", 516], ["We", 518], ["offer", 521], ["guidelines", 527], ["for", 538], ["a", 542], ["more", 544], ["thoughtful", 549], ["approach", 560], ["to", 569], ["the", 572], ["management", 576], ["of", 587], ["patients", 590], ["with", 599], ["cancer", 604], ["who", 611], ["present", 615], ["with", 623], ["encephalopathy", 628], [".", 642]]}
{"context": "Nucleotide excision repair (NER) is a multistep process capable to remove a variety of DNA distorting lesions from prokaryotic and eukaryotic genomes. In eukaryotic cells, the process requires more than 30 proteins to perform the different steps, i.e. recognition of DNA damage, single strand incisions and excision of the lesion-containing DNA fragment and DNA repair synthesis/ligation. NER can operate via two subpathways: global genome repair (GGR) and a specialized pathway coupled to active transcription (transcription-coupled repair, TCR) and directed to DNA lesions in the transcribed strand of active genes. Both in vivo as well as in cultured cells the fast removal of transcription blocking lesions by TCR is crucial to escape from lethal effects of inhibited transcription inhibition The most delicate step in NER is the recognition of the DNA lesions in their different chromatin context and the mechanism of damage recognition in GGR and TCR is principally different and requires specific proteins. In GGR, the XPC-HR23B is essential for the formation of the incision complex. In TCR the Cockayne syndrome (CS) gene products are key players in the recognition of a stalled RNA polymerase the presumed signaling structure for repair of transcribed strands. In this study, we show that the extent of recovery of UV-inhibited transcription and TCR strictly depends on the amount of CSB protein as well as the amount of DNA damage present in the cell. This indicates that the ratio between DNA damage frequency and CSB protein concentration in the cell is rather critical for acute cellular response, i.e. recovery of inhibited transcription upon DNA damage infliction, and hence cellular survival.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "dfc374abfd1246c8bd30686662c51d05", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[103, 104]], "char_spans": [[582, 599]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], ["is", 33], ["a", 36], ["multistep", 38], ["process", 48], ["capable", 56], ["to", 64], ["remove", 67], ["a", 74], ["variety", 76], ["of", 84], ["DNA", 87], ["distorting", 91], ["lesions", 102], ["from", 110], ["prokaryotic", 115], ["and", 127], ["eukaryotic", 131], ["genomes", 142], [".", 149], ["In", 151], ["eukaryotic", 154], ["cells", 165], [",", 170], ["the", 172], ["process", 176], ["requires", 184], ["more", 193], ["than", 198], ["30", 203], ["proteins", 206], ["to", 215], ["perform", 218], ["the", 226], ["different", 230], ["steps", 240], [",", 245], ["i.e.", 247], ["recognition", 252], ["of", 264], ["DNA", 267], ["damage", 271], [",", 277], ["single", 279], ["strand", 286], ["incisions", 293], ["and", 303], ["excision", 307], ["of", 316], ["the", 319], ["lesion", 323], ["-", 329], ["containing", 330], ["DNA", 341], ["fragment", 345], ["and", 354], ["DNA", 358], ["repair", 362], ["synthesis", 369], ["/", 378], ["ligation", 379], [".", 387], ["NER", 389], ["can", 393], ["operate", 397], ["via", 405], ["two", 409], ["subpathways", 413], [":", 424], ["global", 426], ["genome", 433], ["repair", 440], ["(", 447], ["GGR", 448], [")", 451], ["and", 453], ["a", 457], ["specialized", 459], ["pathway", 471], ["coupled", 479], ["to", 487], ["active", 490], ["transcription", 497], ["(", 511], ["transcription", 512], ["-", 525], ["coupled", 526], ["repair", 534], [",", 540], ["TCR", 542], [")", 545], ["and", 547], ["directed", 551], ["to", 560], ["DNA", 563], ["lesions", 567], ["in", 575], ["the", 578], ["transcribed", 582], ["strand", 594], ["of", 601], ["active", 604], ["genes", 611], [".", 616], ["Both", 618], ["in", 623], ["vivo", 626], ["as", 631], ["well", 634], ["as", 639], ["in", 642], ["cultured", 645], ["cells", 654], ["the", 660], ["fast", 664], ["removal", 669], ["of", 677], ["transcription", 680], ["blocking", 694], ["lesions", 703], ["by", 711], ["TCR", 714], ["is", 718], ["crucial", 721], ["to", 729], ["escape", 732], ["from", 739], ["lethal", 744], ["effects", 751], ["of", 759], ["inhibited", 762], ["transcription", 772], ["inhibition", 786], ["The", 797], ["most", 801], ["delicate", 806], ["step", 815], ["in", 820], ["NER", 823], ["is", 827], ["the", 830], ["recognition", 834], ["of", 846], ["the", 849], ["DNA", 853], ["lesions", 857], ["in", 865], ["their", 868], ["different", 874], ["chromatin", 884], ["context", 894], ["and", 902], ["the", 906], ["mechanism", 910], ["of", 920], ["damage", 923], ["recognition", 930], ["in", 942], ["GGR", 945], ["and", 949], ["TCR", 953], ["is", 957], ["principally", 960], ["different", 972], ["and", 982], ["requires", 986], ["specific", 995], ["proteins", 1004], [".", 1012], ["In", 1014], ["GGR", 1017], [",", 1020], ["the", 1022], ["XPC", 1026], ["-", 1029], ["HR23B", 1030], ["is", 1036], ["essential", 1039], ["for", 1049], ["the", 1053], ["formation", 1057], ["of", 1067], ["the", 1070], ["incision", 1074], ["complex", 1083], [".", 1090], ["In", 1092], ["TCR", 1095], ["the", 1099], ["Cockayne", 1103], ["syndrome", 1112], ["(", 1121], ["CS", 1122], [")", 1124], ["gene", 1126], ["products", 1131], ["are", 1140], ["key", 1144], ["players", 1148], ["in", 1156], ["the", 1159], ["recognition", 1163], ["of", 1175], ["a", 1178], ["stalled", 1180], ["RNA", 1188], ["polymerase", 1192], ["the", 1203], ["presumed", 1207], ["signaling", 1216], ["structure", 1226], ["for", 1236], ["repair", 1240], ["of", 1247], ["transcribed", 1250], ["strands", 1262], [".", 1269], ["In", 1271], ["this", 1274], ["study", 1279], [",", 1284], ["we", 1286], ["show", 1289], ["that", 1294], ["the", 1299], ["extent", 1303], ["of", 1310], ["recovery", 1313], ["of", 1322], ["UV", 1325], ["-", 1327], ["inhibited", 1328], ["transcription", 1338], ["and", 1352], ["TCR", 1356], ["strictly", 1360], ["depends", 1369], ["on", 1377], ["the", 1380], ["amount", 1384], ["of", 1391], ["CSB", 1394], ["protein", 1398], ["as", 1406], ["well", 1409], ["as", 1414], ["the", 1417], ["amount", 1421], ["of", 1428], ["DNA", 1431], ["damage", 1435], ["present", 1442], ["in", 1450], ["the", 1453], ["cell", 1457], [".", 1461], ["This", 1463], ["indicates", 1468], ["that", 1478], ["the", 1483], ["ratio", 1487], ["between", 1493], ["DNA", 1501], ["damage", 1505], ["frequency", 1512], ["and", 1522], ["CSB", 1526], ["protein", 1530], ["concentration", 1538], ["in", 1552], ["the", 1555], ["cell", 1559], ["is", 1564], ["rather", 1567], ["critical", 1574], ["for", 1583], ["acute", 1587], ["cellular", 1593], ["response", 1602], [",", 1610], ["i.e.", 1612], ["recovery", 1617], ["of", 1626], ["inhibited", 1629], ["transcription", 1639], ["upon", 1653], ["DNA", 1658], ["damage", 1662], ["infliction", 1669], [",", 1679], ["and", 1681], ["hence", 1685], ["cellular", 1691], ["survival", 1700], [".", 1708]]}
{"context": "Chronic myeloid leukemia (CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by imatinib is effective to control the tyrosyl phosphorylation of the protein related to the cell signaling. BCR-ABL mRNA is overexpressed in the minimal residual disease (MRD), known as an early sign of relapse. Between December 2005 and June 2008, we measured BCR-ABL mRNA levels in the bone marrow (BM) from patients by quantitative real-time polymerase chain reaction (RQ-PCR) in Aomori Prefectural Central Hospital. Eighty-six samples from 26 patients were collected. Among the 26 CML patients, 11 patients (42%) were in the pretreatment group. Seven (64%) of the 11 patients achieved complete molecular response (CMR). In the post-treatment group consisting of the remaining 15 patients, 9 (60%) patients achieved CMR. The patients receiving imatinib at a dose over 300 mg per day required 13 (6-77) months [median (range)] to achieve CMR. On the other hand, the patients receiving a dose below 300 mg per day required 29.5 (11-84) months [median (range)]. When BCR-ABL mRNA was detected during the treatment course of patients with CMR, careful observation of BCR-ABL mRNA was useful for tracking the clinical course of patients. In conclusion, the BCR-ABL mRNA level was useful for monitoring the clinical course in 26 patients with CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "412a49803a00424099cd84a75d92bd63", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[295, 297], [36, 38], [101, 103], [69, 71], [10, 12], [277, 279], [259, 261]], "char_spans": [[1409, 1415], [172, 178], [515, 521], [362, 368], [48, 54], [1320, 1326], [1221, 1227]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["caused", 34], ["by", 41], ["the", 44], ["BCR", 48], ["-", 51], ["ABL", 52], ["oncogene", 56], [".", 64], ["The", 66], ["Philadelphia", 70], ["chromosome", 83], ["(", 94], ["Ph", 95], [")", 97], ["from", 99], ["a", 104], ["reciprocal", 106], ["translocation", 117], [",", 130], ["t(9;22", 132], [")", 138], ["(", 140], ["q34;q11", 141], [")", 148], ["causes", 150], ["a", 157], ["fusion", 159], ["gene", 166], [",", 170], ["BCR", 172], ["-", 175], ["ABL", 176], [",", 179], ["that", 181], ["encodes", 186], ["a", 194], ["constitutively", 196], ["active", 211], ["tyrosine", 218], ["kinase", 227], [".", 233], ["Treatment", 235], ["of", 245], ["CML", 248], ["by", 252], ["imatinib", 255], ["is", 264], ["effective", 267], ["to", 277], ["control", 280], ["the", 288], ["tyrosyl", 292], ["phosphorylation", 300], ["of", 316], ["the", 319], ["protein", 323], ["related", 331], ["to", 339], ["the", 342], ["cell", 346], ["signaling", 351], [".", 360], ["BCR", 362], ["-", 365], ["ABL", 366], ["mRNA", 370], ["is", 375], ["overexpressed", 378], ["in", 392], ["the", 395], ["minimal", 399], ["residual", 407], ["disease", 416], ["(", 424], ["MRD", 425], [")", 428], [",", 429], ["known", 431], ["as", 437], ["an", 440], ["early", 443], ["sign", 449], ["of", 454], ["relapse", 457], [".", 464], ["Between", 466], ["December", 474], ["2005", 483], ["and", 488], ["June", 492], ["2008", 497], [",", 501], ["we", 503], ["measured", 506], ["BCR", 515], ["-", 518], ["ABL", 519], ["mRNA", 523], ["levels", 528], ["in", 535], ["the", 538], ["bone", 542], ["marrow", 547], ["(", 554], ["BM", 555], [")", 557], ["from", 559], ["patients", 564], ["by", 573], ["quantitative", 576], ["real", 589], ["-", 593], ["time", 594], ["polymerase", 599], ["chain", 610], ["reaction", 616], ["(", 625], ["RQ", 626], ["-", 628], ["PCR", 629], [")", 632], ["in", 634], ["Aomori", 637], ["Prefectural", 644], ["Central", 656], ["Hospital", 664], [".", 672], ["Eighty", 674], ["-", 680], ["six", 681], ["samples", 685], ["from", 693], ["26", 698], ["patients", 701], ["were", 710], ["collected", 715], [".", 724], ["Among", 726], ["the", 732], ["26", 736], ["CML", 739], ["patients", 743], [",", 751], ["11", 753], ["patients", 756], ["(", 765], ["42", 766], ["%", 768], [")", 769], ["were", 771], ["in", 776], ["the", 779], ["pretreatment", 783], ["group", 796], [".", 801], ["Seven", 803], ["(", 809], ["64", 810], ["%", 812], [")", 813], ["of", 815], ["the", 818], ["11", 822], ["patients", 825], ["achieved", 834], ["complete", 843], ["molecular", 852], ["response", 862], ["(", 871], ["CMR", 872], [")", 875], [".", 876], ["In", 878], ["the", 881], ["post", 885], ["-", 889], ["treatment", 890], ["group", 900], ["consisting", 906], ["of", 917], ["the", 920], ["remaining", 924], ["15", 934], ["patients", 937], [",", 945], ["9", 947], ["(", 949], ["60", 950], ["%", 952], [")", 953], ["patients", 955], ["achieved", 964], ["CMR", 973], [".", 976], ["The", 978], ["patients", 982], ["receiving", 991], ["imatinib", 1001], ["at", 1010], ["a", 1013], ["dose", 1015], ["over", 1020], ["300", 1025], ["mg", 1029], ["per", 1032], ["day", 1036], ["required", 1040], ["13", 1049], ["(", 1052], ["6", 1053], ["-", 1054], ["77", 1055], [")", 1057], ["months", 1059], ["[", 1066], ["median", 1067], ["(", 1074], ["range", 1075], [")", 1080], ["]", 1081], ["to", 1083], ["achieve", 1086], ["CMR", 1094], [".", 1097], ["On", 1099], ["the", 1102], ["other", 1106], ["hand", 1112], [",", 1116], ["the", 1118], ["patients", 1122], ["receiving", 1131], ["a", 1141], ["dose", 1143], ["below", 1148], ["300", 1154], ["mg", 1158], ["per", 1161], ["day", 1165], ["required", 1169], ["29.5", 1178], ["(", 1183], ["11", 1184], ["-", 1186], ["84", 1187], [")", 1189], ["months", 1191], ["[", 1198], ["median", 1199], ["(", 1206], ["range)].", 1207], ["When", 1216], ["BCR", 1221], ["-", 1224], ["ABL", 1225], ["mRNA", 1229], ["was", 1234], ["detected", 1238], ["during", 1247], ["the", 1254], ["treatment", 1258], ["course", 1268], ["of", 1275], ["patients", 1278], ["with", 1287], ["CMR", 1292], [",", 1295], ["careful", 1297], ["observation", 1305], ["of", 1317], ["BCR", 1320], ["-", 1323], ["ABL", 1324], ["mRNA", 1328], ["was", 1333], ["useful", 1337], ["for", 1344], ["tracking", 1348], ["the", 1357], ["clinical", 1361], ["course", 1370], ["of", 1377], ["patients", 1380], [".", 1388], ["In", 1390], ["conclusion", 1393], [",", 1403], ["the", 1405], ["BCR", 1409], ["-", 1412], ["ABL", 1413], ["mRNA", 1417], ["level", 1422], ["was", 1428], ["useful", 1432], ["for", 1439], ["monitoring", 1443], ["the", 1454], ["clinical", 1458], ["course", 1467], ["in", 1474], ["26", 1477], ["patients", 1480], ["with", 1489], ["CML", 1494], [".", 1497]]}
{"context": "Spleen tyrosine kinase (Syk) is a cytoplasmic tyrosine kinase involved in signalling in many of the cells that drive immune inflammation. The development of small molecules that inhibit Syk kinase may change the way we treat disorders such as rheumatoid arthritis (RA), as well as a range of other inflammatory diseases. Fostamatinib (R-788) is an orally bioavailable small molecule. It is the prodrug of R406, which is a potent Syk inhibitor. Fostamatinib was developed because it has more favourable physiochemical properties. It is rapidly converted to R406 by intestinal enterocytes. It has been evaluated in experimental models of RA, such as collagen-induced arthritis. In these models, fostamatinib suppressed clinical arthritis, bone erosions, pannus formation and synovitis. A phase II programme with fostamatinib has largely been completed. Three key trials have been published, lasting 12-26 weeks and each enrolling 189-457 patients (875 in total). All these trials involved placebo therapy and patients continued to receive methotrexate in addition to active treatment with fostamatinib. The first dose-ranging trial evaluated three treatment doses in RA patients who had not fully responded to methotrexate therapy. The second trial compared two treatment doses in patients who had not responded to methotrexate therapy. The third trial compared a single treatment dose with placebo in patients who had not responded to biological therapy. The primary outcome measure was the number of patients achieving American College of Rheumatology (ACR) 20% (ACR20) responses. Placebo ACR20 response rates in all three trials were similar (35-38%). All three trials involved one treatment arm receiving fostamatinib 100 mg twice daily; ACR20 responses with this active treatment ranged from 38% to 67%. A meta-analysis of ACR responses in these trials, using responses to the highest dose in each trial for comparisons with placebo therapy in a random effects model, showed a borderline benefit with ACR20 responses. There were more significant differences with ACR50 and ACR70 responses. The reason that this meta-analysis was not more strongly positive is that the third trial, which evaluated patients who had failed to respond to biological treatments, gave negative results. Individual ACR response components, such as changes in swollen joint counts, showed significant differences in the first two trials, but there were no definite treatment benefits in the third trial. Overall, the differences were significant in a meta-analysis of all three trials. The most important adverse reactions were diarrhoea, neutropenia and raised ALT levels, which all showed significant excesses with active treatment compared with placebo. Too few patients have been studied for a definitive safety profile to be known. Overall, the results of the phase II trials were sufficiently encouraging for a phase III programme to be initiated. It will be some years before their definitive results are available.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "cdffae7e17c6461b9d318dade835ff28", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["Syk", 24], [")", 27], ["is", 29], ["a", 32], ["cytoplasmic", 34], ["tyrosine", 46], ["kinase", 55], ["involved", 62], ["in", 71], ["signalling", 74], ["in", 85], ["many", 88], ["of", 93], ["the", 96], ["cells", 100], ["that", 106], ["drive", 111], ["immune", 117], ["inflammation", 124], [".", 136], ["The", 138], ["development", 142], ["of", 154], ["small", 157], ["molecules", 163], ["that", 173], ["inhibit", 178], ["Syk", 186], ["kinase", 190], ["may", 197], ["change", 201], ["the", 208], ["way", 212], ["we", 216], ["treat", 219], ["disorders", 225], ["such", 235], ["as", 240], ["rheumatoid", 243], ["arthritis", 254], ["(", 264], ["RA", 265], [")", 267], [",", 268], ["as", 270], ["well", 273], ["as", 278], ["a", 281], ["range", 283], ["of", 289], ["other", 292], ["inflammatory", 298], ["diseases", 311], [".", 319], ["Fostamatinib", 321], ["(", 334], ["R-788", 335], [")", 340], ["is", 342], ["an", 345], ["orally", 348], ["bioavailable", 355], ["small", 368], ["molecule", 374], [".", 382], ["It", 384], ["is", 387], ["the", 390], ["prodrug", 394], ["of", 402], ["R406", 405], [",", 409], ["which", 411], ["is", 417], ["a", 420], ["potent", 422], ["Syk", 429], ["inhibitor", 433], [".", 442], ["Fostamatinib", 444], ["was", 457], ["developed", 461], ["because", 471], ["it", 479], ["has", 482], ["more", 486], ["favourable", 491], ["physiochemical", 502], ["properties", 517], [".", 527], ["It", 529], ["is", 532], ["rapidly", 535], ["converted", 543], ["to", 553], ["R406", 556], ["by", 561], ["intestinal", 564], ["enterocytes", 575], [".", 586], ["It", 588], ["has", 591], ["been", 595], ["evaluated", 600], ["in", 610], ["experimental", 613], ["models", 626], ["of", 633], ["RA", 636], [",", 638], ["such", 640], ["as", 645], ["collagen", 648], ["-", 656], ["induced", 657], ["arthritis", 665], [".", 674], ["In", 676], ["these", 679], ["models", 685], [",", 691], ["fostamatinib", 693], ["suppressed", 706], ["clinical", 717], ["arthritis", 726], [",", 735], ["bone", 737], ["erosions", 742], [",", 750], ["pannus", 752], ["formation", 759], ["and", 769], ["synovitis", 773], [".", 782], ["A", 784], ["phase", 786], ["II", 792], ["programme", 795], ["with", 805], ["fostamatinib", 810], ["has", 823], ["largely", 827], ["been", 835], ["completed", 840], [".", 849], ["Three", 851], ["key", 857], ["trials", 861], ["have", 868], ["been", 873], ["published", 878], [",", 887], ["lasting", 889], ["12", 897], ["-", 899], ["26", 900], ["weeks", 903], ["and", 909], ["each", 913], ["enrolling", 918], ["189", 928], ["-", 931], ["457", 932], ["patients", 936], ["(", 945], ["875", 946], ["in", 950], ["total", 953], [")", 958], [".", 959], ["All", 961], ["these", 965], ["trials", 971], ["involved", 978], ["placebo", 987], ["therapy", 995], ["and", 1003], ["patients", 1007], ["continued", 1016], ["to", 1026], ["receive", 1029], ["methotrexate", 1037], ["in", 1050], ["addition", 1053], ["to", 1062], ["active", 1065], ["treatment", 1072], ["with", 1082], ["fostamatinib", 1087], [".", 1099], ["The", 1101], ["first", 1105], ["dose", 1111], ["-", 1115], ["ranging", 1116], ["trial", 1124], ["evaluated", 1130], ["three", 1140], ["treatment", 1146], ["doses", 1156], ["in", 1162], ["RA", 1165], ["patients", 1168], ["who", 1177], ["had", 1181], ["not", 1185], ["fully", 1189], ["responded", 1195], ["to", 1205], ["methotrexate", 1208], ["therapy", 1221], [".", 1228], ["The", 1230], ["second", 1234], ["trial", 1241], ["compared", 1247], ["two", 1256], ["treatment", 1260], ["doses", 1270], ["in", 1276], ["patients", 1279], ["who", 1288], ["had", 1292], ["not", 1296], ["responded", 1300], ["to", 1310], ["methotrexate", 1313], ["therapy", 1326], [".", 1333], ["The", 1335], ["third", 1339], ["trial", 1345], ["compared", 1351], ["a", 1360], ["single", 1362], ["treatment", 1369], ["dose", 1379], ["with", 1384], ["placebo", 1389], ["in", 1397], ["patients", 1400], ["who", 1409], ["had", 1413], ["not", 1417], ["responded", 1421], ["to", 1431], ["biological", 1434], ["therapy", 1445], [".", 1452], ["The", 1454], ["primary", 1458], ["outcome", 1466], ["measure", 1474], ["was", 1482], ["the", 1486], ["number", 1490], ["of", 1497], ["patients", 1500], ["achieving", 1509], ["American", 1519], ["College", 1528], ["of", 1536], ["Rheumatology", 1539], ["(", 1552], ["ACR", 1553], [")", 1556], ["20", 1558], ["%", 1560], ["(", 1562], ["ACR20", 1563], [")", 1568], ["responses", 1570], [".", 1579], ["Placebo", 1581], ["ACR20", 1589], ["response", 1595], ["rates", 1604], ["in", 1610], ["all", 1613], ["three", 1617], ["trials", 1623], ["were", 1630], ["similar", 1635], ["(", 1643], ["35", 1644], ["-", 1646], ["38", 1647], ["%", 1649], [")", 1650], [".", 1651], ["All", 1653], ["three", 1657], ["trials", 1663], ["involved", 1670], ["one", 1679], ["treatment", 1683], ["arm", 1693], ["receiving", 1697], ["fostamatinib", 1707], ["100", 1720], ["mg", 1724], ["twice", 1727], ["daily", 1733], [";", 1738], ["ACR20", 1740], ["responses", 1746], ["with", 1756], ["this", 1761], ["active", 1766], ["treatment", 1773], ["ranged", 1783], ["from", 1790], ["38", 1795], ["%", 1797], ["to", 1799], ["67", 1802], ["%", 1804], [".", 1805], ["A", 1807], ["meta", 1809], ["-", 1813], ["analysis", 1814], ["of", 1823], ["ACR", 1826], ["responses", 1830], ["in", 1840], ["these", 1843], ["trials", 1849], [",", 1855], ["using", 1857], ["responses", 1863], ["to", 1873], ["the", 1876], ["highest", 1880], ["dose", 1888], ["in", 1893], ["each", 1896], ["trial", 1901], ["for", 1907], ["comparisons", 1911], ["with", 1923], ["placebo", 1928], ["therapy", 1936], ["in", 1944], ["a", 1947], ["random", 1949], ["effects", 1956], ["model", 1964], [",", 1969], ["showed", 1971], ["a", 1978], ["borderline", 1980], ["benefit", 1991], ["with", 1999], ["ACR20", 2004], ["responses", 2010], [".", 2019], ["There", 2021], ["were", 2027], ["more", 2032], ["significant", 2037], ["differences", 2049], ["with", 2061], ["ACR50", 2066], ["and", 2072], ["ACR70", 2076], ["responses", 2082], [".", 2091], ["The", 2093], ["reason", 2097], ["that", 2104], ["this", 2109], ["meta", 2114], ["-", 2118], ["analysis", 2119], ["was", 2128], ["not", 2132], ["more", 2136], ["strongly", 2141], ["positive", 2150], ["is", 2159], ["that", 2162], ["the", 2167], ["third", 2171], ["trial", 2177], [",", 2182], ["which", 2184], ["evaluated", 2190], ["patients", 2200], ["who", 2209], ["had", 2213], ["failed", 2217], ["to", 2224], ["respond", 2227], ["to", 2235], ["biological", 2238], ["treatments", 2249], [",", 2259], ["gave", 2261], ["negative", 2266], ["results", 2275], [".", 2282], ["Individual", 2284], ["ACR", 2295], ["response", 2299], ["components", 2308], [",", 2318], ["such", 2320], ["as", 2325], ["changes", 2328], ["in", 2336], ["swollen", 2339], ["joint", 2347], ["counts", 2353], [",", 2359], ["showed", 2361], ["significant", 2368], ["differences", 2380], ["in", 2392], ["the", 2395], ["first", 2399], ["two", 2405], ["trials", 2409], [",", 2415], ["but", 2417], ["there", 2421], ["were", 2427], ["no", 2432], ["definite", 2435], ["treatment", 2444], ["benefits", 2454], ["in", 2463], ["the", 2466], ["third", 2470], ["trial", 2476], [".", 2481], ["Overall", 2483], [",", 2490], ["the", 2492], ["differences", 2496], ["were", 2508], ["significant", 2513], ["in", 2525], ["a", 2528], ["meta", 2530], ["-", 2534], ["analysis", 2535], ["of", 2544], ["all", 2547], ["three", 2551], ["trials", 2557], [".", 2563], ["The", 2565], ["most", 2569], ["important", 2574], ["adverse", 2584], ["reactions", 2592], ["were", 2602], ["diarrhoea", 2607], [",", 2616], ["neutropenia", 2618], ["and", 2630], ["raised", 2634], ["ALT", 2641], ["levels", 2645], [",", 2651], ["which", 2653], ["all", 2659], ["showed", 2663], ["significant", 2670], ["excesses", 2682], ["with", 2691], ["active", 2696], ["treatment", 2703], ["compared", 2713], ["with", 2722], ["placebo", 2727], [".", 2734], ["Too", 2736], ["few", 2740], ["patients", 2744], ["have", 2753], ["been", 2758], ["studied", 2763], ["for", 2771], ["a", 2775], ["definitive", 2777], ["safety", 2788], ["profile", 2795], ["to", 2803], ["be", 2806], ["known", 2809], [".", 2814], ["Overall", 2816], [",", 2823], ["the", 2825], ["results", 2829], ["of", 2837], ["the", 2840], ["phase", 2844], ["II", 2850], ["trials", 2853], ["were", 2860], ["sufficiently", 2865], ["encouraging", 2878], ["for", 2890], ["a", 2894], ["phase", 2896], ["III", 2902], ["programme", 2906], ["to", 2916], ["be", 2919], ["initiated", 2922], [".", 2931], ["It", 2933], ["will", 2936], ["be", 2941], ["some", 2944], ["years", 2949], ["before", 2955], ["their", 2962], ["definitive", 2968], ["results", 2979], ["are", 2987], ["available", 2991], [".", 3000]]}
{"context": "Neurological abnormalities associated with spiculated, \"acanthocytic\" red cells in blood have been described as neuroacanthocytosis. This is a heterogeneous group of conditions that can be clearly subdivided on the basis of recent genetic findings. The McLeod Syndrome, one of the core neuroacanthocytosis syndromes, is a rare X-linked disorder caused by mutations of the XK gene, an X-chromosomal gene of unknown function characterized by haemopoietic abnormalities and late-onset neurological and muscular defects. We report two Chilean brothers with the McLeod phenotype who showed important psychiatric features. The diagnosis may be elusive if the presence of acanthocytosis is not properly studied. We describe a method which allowed the diagnosis that unmasked acanthocytosis. Otherwise the condition could have remained undiagnosed as it had been for decades in this family. This syndrome must be considered when assessing a familial movement disorder, specially affecting males with relevant psychiatric features. A reliable test for acanthocytosis assessment is available.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c79bc1f8f85548358708cf9eb729f140", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[62, 62]], "char_spans": [[372, 373]]}]}], "context_tokens": [["Neurological", 0], ["abnormalities", 13], ["associated", 27], ["with", 38], ["spiculated", 43], [",", 53], ["\"", 55], ["acanthocytic", 56], ["\"", 68], ["red", 70], ["cells", 74], ["in", 80], ["blood", 83], ["have", 89], ["been", 94], ["described", 99], ["as", 109], ["neuroacanthocytosis", 112], [".", 131], ["This", 133], ["is", 138], ["a", 141], ["heterogeneous", 143], ["group", 157], ["of", 163], ["conditions", 166], ["that", 177], ["can", 182], ["be", 186], ["clearly", 189], ["subdivided", 197], ["on", 208], ["the", 211], ["basis", 215], ["of", 221], ["recent", 224], ["genetic", 231], ["findings", 239], [".", 247], ["The", 249], ["McLeod", 253], ["Syndrome", 260], [",", 268], ["one", 270], ["of", 274], ["the", 277], ["core", 281], ["neuroacanthocytosis", 286], ["syndromes", 306], [",", 315], ["is", 317], ["a", 320], ["rare", 322], ["X", 327], ["-", 328], ["linked", 329], ["disorder", 336], ["caused", 345], ["by", 352], ["mutations", 355], ["of", 365], ["the", 368], ["XK", 372], ["gene", 375], [",", 379], ["an", 381], ["X", 384], ["-", 385], ["chromosomal", 386], ["gene", 398], ["of", 403], ["unknown", 406], ["function", 414], ["characterized", 423], ["by", 437], ["haemopoietic", 440], ["abnormalities", 453], ["and", 467], ["late", 471], ["-", 475], ["onset", 476], ["neurological", 482], ["and", 495], ["muscular", 499], ["defects", 508], [".", 515], ["We", 517], ["report", 520], ["two", 527], ["Chilean", 531], ["brothers", 539], ["with", 548], ["the", 553], ["McLeod", 557], ["phenotype", 564], ["who", 574], ["showed", 578], ["important", 585], ["psychiatric", 595], ["features", 607], [".", 615], ["The", 617], ["diagnosis", 621], ["may", 631], ["be", 635], ["elusive", 638], ["if", 646], ["the", 649], ["presence", 653], ["of", 662], ["acanthocytosis", 665], ["is", 680], ["not", 683], ["properly", 687], ["studied", 696], [".", 703], ["We", 705], ["describe", 708], ["a", 717], ["method", 719], ["which", 726], ["allowed", 732], ["the", 740], ["diagnosis", 744], ["that", 754], ["unmasked", 759], ["acanthocytosis", 768], [".", 782], ["Otherwise", 784], ["the", 794], ["condition", 798], ["could", 808], ["have", 814], ["remained", 819], ["undiagnosed", 828], ["as", 840], ["it", 843], ["had", 846], ["been", 850], ["for", 855], ["decades", 859], ["in", 867], ["this", 870], ["family", 875], [".", 881], ["This", 883], ["syndrome", 888], ["must", 897], ["be", 902], ["considered", 905], ["when", 916], ["assessing", 921], ["a", 931], ["familial", 933], ["movement", 942], ["disorder", 951], [",", 959], ["specially", 961], ["affecting", 971], ["males", 981], ["with", 987], ["relevant", 992], ["psychiatric", 1001], ["features", 1013], [".", 1021], ["A", 1023], ["reliable", 1025], ["test", 1034], ["for", 1039], ["acanthocytosis", 1043], ["assessment", 1058], ["is", 1069], ["available", 1072], [".", 1081]]}
{"context": "Restless legs syndrome (RLS) is a clinically important, common disease and should be diagnosed and treated early and adequately. At present, there have been no clinical biomarkers or methodologies that can contribute to the correct diagnosis of RLS, RLS should be diagnosed on the basis of 4 essential criteria: urge to move the legs, improvement after movement, and worsening or occurrence of symptoms in the evening and at rest. When applying the criteria, RLS mimics should be ruled out and comorbid diseases should be taken into account. The origin and pathogenesis of RLS are still under investigation; however, iron deficiency in the brain has been observed on imaging and cerebrospinal fluid analyses of patients with RLS. In contrast, the results of neuroimaging studies evaluating brain dopaminergic functions in patients with RLS have yielded inconclusive results, although involvement of the hypothalamus (A11) is thought to cause impaired dopaminergic modulation in the dorsal horn and intermediolateral nucleus, resulting in the restlessness of legs.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "f86ef5e1ac664cb0a799f69a2e54f94d", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[112, 112]], "char_spans": [[617, 620]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["is", 29], ["a", 32], ["clinically", 34], ["important", 45], [",", 54], ["common", 56], ["disease", 63], ["and", 71], ["should", 75], ["be", 82], ["diagnosed", 85], ["and", 95], ["treated", 99], ["early", 107], ["and", 113], ["adequately", 117], [".", 127], ["At", 129], ["present", 132], [",", 139], ["there", 141], ["have", 147], ["been", 152], ["no", 157], ["clinical", 160], ["biomarkers", 169], ["or", 180], ["methodologies", 183], ["that", 197], ["can", 202], ["contribute", 206], ["to", 217], ["the", 220], ["correct", 224], ["diagnosis", 232], ["of", 242], ["RLS", 245], [",", 248], ["RLS", 250], ["should", 254], ["be", 261], ["diagnosed", 264], ["on", 274], ["the", 277], ["basis", 281], ["of", 287], ["4", 290], ["essential", 292], ["criteria", 302], [":", 310], ["urge", 312], ["to", 317], ["move", 320], ["the", 325], ["legs", 329], [",", 333], ["improvement", 335], ["after", 347], ["movement", 353], [",", 361], ["and", 363], ["worsening", 367], ["or", 377], ["occurrence", 380], ["of", 391], ["symptoms", 394], ["in", 403], ["the", 406], ["evening", 410], ["and", 418], ["at", 422], ["rest", 425], [".", 429], ["When", 431], ["applying", 436], ["the", 445], ["criteria", 449], [",", 457], ["RLS", 459], ["mimics", 463], ["should", 470], ["be", 477], ["ruled", 480], ["out", 486], ["and", 490], ["comorbid", 494], ["diseases", 503], ["should", 512], ["be", 519], ["taken", 522], ["into", 528], ["account", 533], [".", 540], ["The", 542], ["origin", 546], ["and", 553], ["pathogenesis", 557], ["of", 570], ["RLS", 573], ["are", 577], ["still", 581], ["under", 587], ["investigation", 593], [";", 606], ["however", 608], [",", 615], ["iron", 617], ["deficiency", 622], ["in", 633], ["the", 636], ["brain", 640], ["has", 646], ["been", 650], ["observed", 655], ["on", 664], ["imaging", 667], ["and", 675], ["cerebrospinal", 679], ["fluid", 693], ["analyses", 699], ["of", 708], ["patients", 711], ["with", 720], ["RLS", 725], [".", 728], ["In", 730], ["contrast", 733], [",", 741], ["the", 743], ["results", 747], ["of", 755], ["neuroimaging", 758], ["studies", 771], ["evaluating", 779], ["brain", 790], ["dopaminergic", 796], ["functions", 809], ["in", 819], ["patients", 822], ["with", 831], ["RLS", 836], ["have", 840], ["yielded", 845], ["inconclusive", 853], ["results", 866], [",", 873], ["although", 875], ["involvement", 884], ["of", 896], ["the", 899], ["hypothalamus", 903], ["(", 916], ["A11", 917], [")", 920], ["is", 922], ["thought", 925], ["to", 933], ["cause", 936], ["impaired", 942], ["dopaminergic", 951], ["modulation", 964], ["in", 975], ["the", 978], ["dorsal", 982], ["horn", 989], ["and", 994], ["intermediolateral", 998], ["nucleus", 1016], [",", 1023], ["resulting", 1025], ["in", 1035], ["the", 1038], ["restlessness", 1042], ["of", 1055], ["legs", 1058], [".", 1062]]}
{"context": "Although Gaucher disease is a rare disorder, recent developments in novel means for therapeutic intervention have invigorated both academic research and pharmaceutical industry discovery programmes. The common mutations found in the lysosomal enzyme deficient in Gaucher disease, beta-glucocerebrosidase, earmark these proteins for destruction by the endoplasmic reticulum-localised protein folding machinery, resulting in enzyme insufficiency, lysosomal glycolipid storage and subsequent pathology. However, many of these mutants can be rescued from global misfolding to preserve glycolipid substrate binding and eventual catalysis in the lysosome, by the addition of subinhibitory concentrations of pharmacologically active small molecules. This novel, chaperon-mediated approach has benefited from insights into the molecular understanding of beta-glucocerebrosidase structure, drug design and development in cellular models for disease.", "qas": [{"question": "Which enzyme is deficient in Gaucher's disease?", "answers": ["beta-glucocerebrosidase", "Beta glucocerebrosidase"], "qid": "60b2647e211743f5a7666d2124d1686a", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["deficient", 16], ["in", 26], ["Gaucher", 29], ["'s", 36], ["disease", 39], ["?", 46]], "detected_answers": [{"text": "Beta glucocerebrosidase", "token_spans": [[40, 42], [123, 125]], "char_spans": [[280, 302], [846, 868]]}]}], "context_tokens": [["Although", 0], ["Gaucher", 9], ["disease", 17], ["is", 25], ["a", 28], ["rare", 30], ["disorder", 35], [",", 43], ["recent", 45], ["developments", 52], ["in", 65], ["novel", 68], ["means", 74], ["for", 80], ["therapeutic", 84], ["intervention", 96], ["have", 109], ["invigorated", 114], ["both", 126], ["academic", 131], ["research", 140], ["and", 149], ["pharmaceutical", 153], ["industry", 168], ["discovery", 177], ["programmes", 187], [".", 197], ["The", 199], ["common", 203], ["mutations", 210], ["found", 220], ["in", 226], ["the", 229], ["lysosomal", 233], ["enzyme", 243], ["deficient", 250], ["in", 260], ["Gaucher", 263], ["disease", 271], [",", 278], ["beta", 280], ["-", 284], ["glucocerebrosidase", 285], [",", 303], ["earmark", 305], ["these", 313], ["proteins", 319], ["for", 328], ["destruction", 332], ["by", 344], ["the", 347], ["endoplasmic", 351], ["reticulum", 363], ["-", 372], ["localised", 373], ["protein", 383], ["folding", 391], ["machinery", 399], [",", 408], ["resulting", 410], ["in", 420], ["enzyme", 423], ["insufficiency", 430], [",", 443], ["lysosomal", 445], ["glycolipid", 455], ["storage", 466], ["and", 474], ["subsequent", 478], ["pathology", 489], [".", 498], ["However", 500], [",", 507], ["many", 509], ["of", 514], ["these", 517], ["mutants", 523], ["can", 531], ["be", 535], ["rescued", 538], ["from", 546], ["global", 551], ["misfolding", 558], ["to", 569], ["preserve", 572], ["glycolipid", 581], ["substrate", 592], ["binding", 602], ["and", 610], ["eventual", 614], ["catalysis", 623], ["in", 633], ["the", 636], ["lysosome", 640], [",", 648], ["by", 650], ["the", 653], ["addition", 657], ["of", 666], ["subinhibitory", 669], ["concentrations", 683], ["of", 698], ["pharmacologically", 701], ["active", 719], ["small", 726], ["molecules", 732], [".", 741], ["This", 743], ["novel", 748], [",", 753], ["chaperon", 755], ["-", 763], ["mediated", 764], ["approach", 773], ["has", 782], ["benefited", 786], ["from", 796], ["insights", 801], ["into", 810], ["the", 815], ["molecular", 819], ["understanding", 829], ["of", 843], ["beta", 846], ["-", 850], ["glucocerebrosidase", 851], ["structure", 870], [",", 879], ["drug", 881], ["design", 886], ["and", 893], ["development", 897], ["in", 909], ["cellular", 912], ["models", 921], ["for", 928], ["disease", 932], [".", 939]]}
{"context": "Centrosomes are composed of a centriole pair surrounded by an intricate proteinaceous matrix referred to as pericentriolar material. Although the mechanisms underpinning the control of centriole duplication are now well understood, we know relatively little about the control of centrosome size and shape. Here we used interaction proteomics to identify the E3 ligase HERC2 and the neuralized homologue NEURL4 as novel interaction partners of the centrosomal protein CP110. Using high resolution imaging, we find that HERC2 and NEURL4 localize to the centrosome and that interfering with their function alters centrosome morphology through the appearance of aberrant filamentous structures that stain for a subset of pericentriolar material proteins including pericentrin and CEP135. Using an RNA interference-resistant transgene approach in combination with structure-function analyses, we show that the association between CP110 and HERC2 depends on nonoverlapping regions of NEURL4. Whereas CP110 binding to NEURL4 is dispensable for the regulation of pericentriolar material architecture, its association with HERC2 is required to maintain normal centrosome integrity. NEURL4 is a substrate of HERC2, and together these results indicate that the NEURL4-HERC2 complex participates in the ubiquitin-dependent regulation of centrosome architecture.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "edb15e5cd3594668933fa0a9f6c83206", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[173, 173], [86, 86], [41, 41], [200, 200], [94, 94]], "char_spans": [[1151, 1160], [551, 560], [279, 288], [1325, 1334], [610, 619]]}]}], "context_tokens": [["Centrosomes", 0], ["are", 12], ["composed", 16], ["of", 25], ["a", 28], ["centriole", 30], ["pair", 40], ["surrounded", 45], ["by", 56], ["an", 59], ["intricate", 62], ["proteinaceous", 72], ["matrix", 86], ["referred", 93], ["to", 102], ["as", 105], ["pericentriolar", 108], ["material", 123], [".", 131], ["Although", 133], ["the", 142], ["mechanisms", 146], ["underpinning", 157], ["the", 170], ["control", 174], ["of", 182], ["centriole", 185], ["duplication", 195], ["are", 207], ["now", 211], ["well", 215], ["understood", 220], [",", 230], ["we", 232], ["know", 235], ["relatively", 240], ["little", 251], ["about", 258], ["the", 264], ["control", 268], ["of", 276], ["centrosome", 279], ["size", 290], ["and", 295], ["shape", 299], [".", 304], ["Here", 306], ["we", 311], ["used", 314], ["interaction", 319], ["proteomics", 331], ["to", 342], ["identify", 345], ["the", 354], ["E3", 358], ["ligase", 361], ["HERC2", 368], ["and", 374], ["the", 378], ["neuralized", 382], ["homologue", 393], ["NEURL4", 403], ["as", 410], ["novel", 413], ["interaction", 419], ["partners", 431], ["of", 440], ["the", 443], ["centrosomal", 447], ["protein", 459], ["CP110", 467], [".", 472], ["Using", 474], ["high", 480], ["resolution", 485], ["imaging", 496], [",", 503], ["we", 505], ["find", 508], ["that", 513], ["HERC2", 518], ["and", 524], ["NEURL4", 528], ["localize", 535], ["to", 544], ["the", 547], ["centrosome", 551], ["and", 562], ["that", 566], ["interfering", 571], ["with", 583], ["their", 588], ["function", 594], ["alters", 603], ["centrosome", 610], ["morphology", 621], ["through", 632], ["the", 640], ["appearance", 644], ["of", 655], ["aberrant", 658], ["filamentous", 667], ["structures", 679], ["that", 690], ["stain", 695], ["for", 701], ["a", 705], ["subset", 707], ["of", 714], ["pericentriolar", 717], ["material", 732], ["proteins", 741], ["including", 750], ["pericentrin", 760], ["and", 772], ["CEP135", 776], [".", 782], ["Using", 784], ["an", 790], ["RNA", 793], ["interference", 797], ["-", 809], ["resistant", 810], ["transgene", 820], ["approach", 830], ["in", 839], ["combination", 842], ["with", 854], ["structure", 859], ["-", 868], ["function", 869], ["analyses", 878], [",", 886], ["we", 888], ["show", 891], ["that", 896], ["the", 901], ["association", 905], ["between", 917], ["CP110", 925], ["and", 931], ["HERC2", 935], ["depends", 941], ["on", 949], ["nonoverlapping", 952], ["regions", 967], ["of", 975], ["NEURL4", 978], [".", 984], ["Whereas", 986], ["CP110", 994], ["binding", 1000], ["to", 1008], ["NEURL4", 1011], ["is", 1018], ["dispensable", 1021], ["for", 1033], ["the", 1037], ["regulation", 1041], ["of", 1052], ["pericentriolar", 1055], ["material", 1070], ["architecture", 1079], [",", 1091], ["its", 1093], ["association", 1097], ["with", 1109], ["HERC2", 1114], ["is", 1120], ["required", 1123], ["to", 1132], ["maintain", 1135], ["normal", 1144], ["centrosome", 1151], ["integrity", 1162], [".", 1171], ["NEURL4", 1173], ["is", 1180], ["a", 1183], ["substrate", 1185], ["of", 1195], ["HERC2", 1198], [",", 1203], ["and", 1205], ["together", 1209], ["these", 1218], ["results", 1224], ["indicate", 1232], ["that", 1241], ["the", 1246], ["NEURL4-HERC2", 1250], ["complex", 1263], ["participates", 1271], ["in", 1284], ["the", 1287], ["ubiquitin", 1291], ["-", 1300], ["dependent", 1301], ["regulation", 1311], ["of", 1322], ["centrosome", 1325], ["architecture", 1336], [".", 1348]]}
{"context": "Tanezumab, a monoclonal antibody, inhibits nerve growth factor and reduces chronic pain. This randomised, double-blind, controlled multicentre study was conducted to evaluate the efficacy and safety of tanezumab added to oral diclofenac sustained release (DSR) in patients with hip or knee osteoarthritis (OA) pain. Patients (N=604) with moderate to severe knee or hip OA tolerating stable DSR were randomised and treated with DSR 75\u2005mg twice daily combined with intravenous tanezumab 10, 5 or 2.5\u2005mg or placebo at weeks 0, 8 and 16. Co-primary efficacy endpoints (Western Ontario and McMaster Universities OA Index (WOMAC) Pain and Physical Function subscales and patient's global assessment of OA) were assessed at week 16. All co-primary endpoints were significantly improved for all tanezumab+DSR groups versus placebo+DSR (p\u22640.039). The incidence of adverse events of abnormal peripheral sensation was lower than in previous tanezumab trials. No new safety signals emerged. Overall incidence of adverse events was higher with tanezumab+DSR (45.2%-49.7%) than with placebo+DSR (34.9%); serious adverse event rates were similar across treatments (5.3%-7.6%). Osteonecrosis was reported in six of 452 patients with tanezumab+DSR (1.3%), but an external adjudication committee did not confirm osteonecrosis in any patient. Addition of tanezumab to DSR resulted in significant improvements in pain, function and global assessments in patients with OA. Although no new safety signals were observed, the higher incidence of adverse events in the tanezumab+diclofenac group suggests that combination therapy is unfavourable. Further investigations of tanezumab monotherapy for OA pain treatment are required. NCT00864097.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "24a13e3726da44deb5ad15627d9c04f8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[7, 9]], "char_spans": [[43, 61]]}]}], "context_tokens": [["Tanezumab", 0], [",", 9], ["a", 11], ["monoclonal", 13], ["antibody", 24], [",", 32], ["inhibits", 34], ["nerve", 43], ["growth", 49], ["factor", 56], ["and", 63], ["reduces", 67], ["chronic", 75], ["pain", 83], [".", 87], ["This", 89], ["randomised", 94], [",", 104], ["double", 106], ["-", 112], ["blind", 113], [",", 118], ["controlled", 120], ["multicentre", 131], ["study", 143], ["was", 149], ["conducted", 153], ["to", 163], ["evaluate", 166], ["the", 175], ["efficacy", 179], ["and", 188], ["safety", 192], ["of", 199], ["tanezumab", 202], ["added", 212], ["to", 218], ["oral", 221], ["diclofenac", 226], ["sustained", 237], ["release", 247], ["(", 255], ["DSR", 256], [")", 259], ["in", 261], ["patients", 264], ["with", 273], ["hip", 278], ["or", 282], ["knee", 285], ["osteoarthritis", 290], ["(", 305], ["OA", 306], [")", 308], ["pain", 310], [".", 314], ["Patients", 316], ["(", 325], ["N=604", 326], [")", 331], ["with", 333], ["moderate", 338], ["to", 347], ["severe", 350], ["knee", 357], ["or", 362], ["hip", 365], ["OA", 369], ["tolerating", 372], ["stable", 383], ["DSR", 390], ["were", 394], ["randomised", 399], ["and", 410], ["treated", 414], ["with", 422], ["DSR", 427], ["75", 431], ["mg", 434], ["twice", 437], ["daily", 443], ["combined", 449], ["with", 458], ["intravenous", 463], ["tanezumab", 475], ["10", 485], [",", 487], ["5", 489], ["or", 491], ["2.5", 494], ["mg", 498], ["or", 501], ["placebo", 504], ["at", 512], ["weeks", 515], ["0", 521], [",", 522], ["8", 524], ["and", 526], ["16", 530], [".", 532], ["Co", 534], ["-", 536], ["primary", 537], ["efficacy", 545], ["endpoints", 554], ["(", 564], ["Western", 565], ["Ontario", 573], ["and", 581], ["McMaster", 585], ["Universities", 594], ["OA", 607], ["Index", 610], ["(", 616], ["WOMAC", 617], [")", 622], ["Pain", 624], ["and", 629], ["Physical", 633], ["Function", 642], ["subscales", 651], ["and", 661], ["patient", 665], ["'s", 672], ["global", 675], ["assessment", 682], ["of", 693], ["OA", 696], [")", 698], ["were", 700], ["assessed", 705], ["at", 714], ["week", 717], ["16", 722], [".", 724], ["All", 726], ["co", 730], ["-", 732], ["primary", 733], ["endpoints", 741], ["were", 751], ["significantly", 756], ["improved", 770], ["for", 779], ["all", 783], ["tanezumab+DSR", 787], ["groups", 801], ["versus", 808], ["placebo+DSR", 815], ["(", 827], ["p\u22640.039", 828], [")", 835], [".", 836], ["The", 838], ["incidence", 842], ["of", 852], ["adverse", 855], ["events", 863], ["of", 870], ["abnormal", 873], ["peripheral", 882], ["sensation", 893], ["was", 903], ["lower", 907], ["than", 913], ["in", 918], ["previous", 921], ["tanezumab", 930], ["trials", 940], [".", 946], ["No", 948], ["new", 951], ["safety", 955], ["signals", 962], ["emerged", 970], [".", 977], ["Overall", 979], ["incidence", 987], ["of", 997], ["adverse", 1000], ["events", 1008], ["was", 1015], ["higher", 1019], ["with", 1026], ["tanezumab+DSR", 1031], ["(", 1045], ["45.2%-49.7", 1046], ["%", 1056], [")", 1057], ["than", 1059], ["with", 1064], ["placebo+DSR", 1069], ["(", 1081], ["34.9", 1082], ["%", 1086], [")", 1087], [";", 1088], ["serious", 1090], ["adverse", 1098], ["event", 1106], ["rates", 1112], ["were", 1118], ["similar", 1123], ["across", 1131], ["treatments", 1138], ["(", 1149], ["5.3%-7.6", 1150], ["%", 1158], [")", 1159], [".", 1160], ["Osteonecrosis", 1162], ["was", 1176], ["reported", 1180], ["in", 1189], ["six", 1192], ["of", 1196], ["452", 1199], ["patients", 1203], ["with", 1212], ["tanezumab+DSR", 1217], ["(", 1231], ["1.3", 1232], ["%", 1235], [")", 1236], [",", 1237], ["but", 1239], ["an", 1243], ["external", 1246], ["adjudication", 1255], ["committee", 1268], ["did", 1278], ["not", 1282], ["confirm", 1286], ["osteonecrosis", 1294], ["in", 1308], ["any", 1311], ["patient", 1315], [".", 1322], ["Addition", 1324], ["of", 1333], ["tanezumab", 1336], ["to", 1346], ["DSR", 1349], ["resulted", 1353], ["in", 1362], ["significant", 1365], ["improvements", 1377], ["in", 1390], ["pain", 1393], [",", 1397], ["function", 1399], ["and", 1408], ["global", 1412], ["assessments", 1419], ["in", 1431], ["patients", 1434], ["with", 1443], ["OA", 1448], [".", 1450], ["Although", 1452], ["no", 1461], ["new", 1464], ["safety", 1468], ["signals", 1475], ["were", 1483], ["observed", 1488], [",", 1496], ["the", 1498], ["higher", 1502], ["incidence", 1509], ["of", 1519], ["adverse", 1522], ["events", 1530], ["in", 1537], ["the", 1540], ["tanezumab+diclofenac", 1544], ["group", 1565], ["suggests", 1571], ["that", 1580], ["combination", 1585], ["therapy", 1597], ["is", 1605], ["unfavourable", 1608], [".", 1620], ["Further", 1622], ["investigations", 1630], ["of", 1645], ["tanezumab", 1648], ["monotherapy", 1658], ["for", 1670], ["OA", 1674], ["pain", 1677], ["treatment", 1682], ["are", 1692], ["required", 1696], [".", 1704], ["NCT00864097", 1706], [".", 1717]]}
{"context": "Osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL) are dominant regulators of bone resorption. Many hormones, cytokines and growth factors mediate bone resorption by altering the ratio of RANKL to OPG. RANKL and OPG expression is also altered in numerous bone diseases, and these changes can reflect disease etiology or compensatory responses to disease. RANKL stimulates osteoclast formation, function and survival, and each of these effects is inhibited by OPG. OPG suppresses bone resorption and increases the density, area and strength of both cancellous and cortical bone. Denosumab (AMG 162), a fully human monoclonal antibody to RANKL, shares the pharmacologic attributes of OPG but has a significantly longer half-life that allows less frequent administration.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "bd9c8ec49b8446ba9d107c61a8280a06", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[117, 117], [67, 67], [42, 42], [38, 38], [14, 14]], "char_spans": [[670, 674], [389, 393], [236, 240], [222, 226], [78, 82]]}]}], "context_tokens": [["Osteoprotegerin", 0], ["(", 16], ["OPG", 17], [")", 20], ["and", 22], ["receptor", 26], ["activator", 35], ["of", 45], ["nuclear", 48], ["factor", 56], ["-", 62], ["kappaB", 63], ["ligand", 70], ["(", 77], ["RANKL", 78], [")", 83], ["are", 85], ["dominant", 89], ["regulators", 98], ["of", 109], ["bone", 112], ["resorption", 117], [".", 127], ["Many", 129], ["hormones", 134], [",", 142], ["cytokines", 144], ["and", 154], ["growth", 158], ["factors", 165], ["mediate", 173], ["bone", 181], ["resorption", 186], ["by", 197], ["altering", 200], ["the", 209], ["ratio", 213], ["of", 219], ["RANKL", 222], ["to", 228], ["OPG", 231], [".", 234], ["RANKL", 236], ["and", 242], ["OPG", 246], ["expression", 250], ["is", 261], ["also", 264], ["altered", 269], ["in", 277], ["numerous", 280], ["bone", 289], ["diseases", 294], [",", 302], ["and", 304], ["these", 308], ["changes", 314], ["can", 322], ["reflect", 326], ["disease", 334], ["etiology", 342], ["or", 351], ["compensatory", 354], ["responses", 367], ["to", 377], ["disease", 380], [".", 387], ["RANKL", 389], ["stimulates", 395], ["osteoclast", 406], ["formation", 417], [",", 426], ["function", 428], ["and", 437], ["survival", 441], [",", 449], ["and", 451], ["each", 455], ["of", 460], ["these", 463], ["effects", 469], ["is", 477], ["inhibited", 480], ["by", 490], ["OPG", 493], [".", 496], ["OPG", 498], ["suppresses", 502], ["bone", 513], ["resorption", 518], ["and", 529], ["increases", 533], ["the", 543], ["density", 547], [",", 554], ["area", 556], ["and", 561], ["strength", 565], ["of", 574], ["both", 577], ["cancellous", 582], ["and", 593], ["cortical", 597], ["bone", 606], [".", 610], ["Denosumab", 612], ["(", 622], ["AMG", 623], ["162", 627], [")", 630], [",", 631], ["a", 633], ["fully", 635], ["human", 641], ["monoclonal", 647], ["antibody", 658], ["to", 667], ["RANKL", 670], [",", 675], ["shares", 677], ["the", 684], ["pharmacologic", 688], ["attributes", 702], ["of", 713], ["OPG", 716], ["but", 720], ["has", 724], ["a", 728], ["significantly", 730], ["longer", 744], ["half", 751], ["-", 755], ["life", 756], ["that", 761], ["allows", 766], ["less", 773], ["frequent", 778], ["administration", 787], [".", 801]]}
{"context": "The two major virulence factors of Bacillus anthracis are the tripartite toxin and the polyglutamate capsule, which are encoded by genes on the large plasmids, pXO1 and pXO2, respectively. The genes atxA, located on pXO1, and acpA, located on pXO2, encode positive trans-acting proteins that are involved in bicarbonate-mediated regulation of toxin and capsule production, respectively. A derivative strain cured of pXO1 produced less capsular substance than the parent strain harbouring both pXO1 and pXO2, and electroporation of the strain cured of pXO1 with a plasmid containing the cloned atxA gene resulted in an increased level of capsule production. An acpA-null mutant was complemented by not only acpA but also the atxA gene. The cap region, which is essential for encapsulation, contains three genes capB, capC, and capA, arranged in that order. The atxA gene stimulated capsule synthesis from the cloned cap region. Transcriptional analysis of cap by RNA slot-blot hybridization and primer-extension analysis revealed that atxA activated expression of cap in trans at the transcriptional level. These results indicate that cross-talk occurs, in which the pXO1-located gene, atxA, activates transcription of the cap region genes located on pXO2. We identified two major apparent transcriptional start sites, designated P1 and P2, located at positions 731 bp and 625 bp, respectively, upstream of the translation-initiation codon of capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment of 70 bp extending upstream of the P1 site. These results suggest that cross-talk by atxA to the genes encoding capsule synthesis is caused by the interaction of the atxA gene product with a regulatory sequence upstream of cap.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "cf65aa1d62524b4690d8d12f1565be18", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "bicarbonate", "token_spans": [[281, 281], [58, 58]], "char_spans": [[1568, 1578], [308, 318]]}]}], "context_tokens": [["The", 0], ["two", 4], ["major", 8], ["virulence", 14], ["factors", 24], ["of", 32], ["Bacillus", 35], ["anthracis", 44], ["are", 54], ["the", 58], ["tripartite", 62], ["toxin", 73], ["and", 79], ["the", 83], ["polyglutamate", 87], ["capsule", 101], [",", 108], ["which", 110], ["are", 116], ["encoded", 120], ["by", 128], ["genes", 131], ["on", 137], ["the", 140], ["large", 144], ["plasmids", 150], [",", 158], ["pXO1", 160], ["and", 165], ["pXO2", 169], [",", 173], ["respectively", 175], [".", 187], ["The", 189], ["genes", 193], ["atxA", 199], [",", 203], ["located", 205], ["on", 213], ["pXO1", 216], [",", 220], ["and", 222], ["acpA", 226], [",", 230], ["located", 232], ["on", 240], ["pXO2", 243], [",", 247], ["encode", 249], ["positive", 256], ["trans", 265], ["-", 270], ["acting", 271], ["proteins", 278], ["that", 287], ["are", 292], ["involved", 296], ["in", 305], ["bicarbonate", 308], ["-", 319], ["mediated", 320], ["regulation", 329], ["of", 340], ["toxin", 343], ["and", 349], ["capsule", 353], ["production", 361], [",", 371], ["respectively", 373], [".", 385], ["A", 387], ["derivative", 389], ["strain", 400], ["cured", 407], ["of", 413], ["pXO1", 416], ["produced", 421], ["less", 430], ["capsular", 435], ["substance", 444], ["than", 454], ["the", 459], ["parent", 463], ["strain", 470], ["harbouring", 477], ["both", 488], ["pXO1", 493], ["and", 498], ["pXO2", 502], [",", 506], ["and", 508], ["electroporation", 512], ["of", 528], ["the", 531], ["strain", 535], ["cured", 542], ["of", 548], ["pXO1", 551], ["with", 556], ["a", 561], ["plasmid", 563], ["containing", 571], ["the", 582], ["cloned", 586], ["atxA", 593], ["gene", 598], ["resulted", 603], ["in", 612], ["an", 615], ["increased", 618], ["level", 628], ["of", 634], ["capsule", 637], ["production", 645], [".", 655], ["An", 657], ["acpA", 660], ["-", 664], ["null", 665], ["mutant", 670], ["was", 677], ["complemented", 681], ["by", 694], ["not", 697], ["only", 701], ["acpA", 706], ["but", 711], ["also", 715], ["the", 720], ["atxA", 724], ["gene", 729], [".", 733], ["The", 735], ["cap", 739], ["region", 743], [",", 749], ["which", 751], ["is", 757], ["essential", 760], ["for", 770], ["encapsulation", 774], [",", 787], ["contains", 789], ["three", 798], ["genes", 804], ["capB", 810], [",", 814], ["capC", 816], [",", 820], ["and", 822], ["capA", 826], [",", 830], ["arranged", 832], ["in", 841], ["that", 844], ["order", 849], [".", 854], ["The", 856], ["atxA", 860], ["gene", 865], ["stimulated", 870], ["capsule", 881], ["synthesis", 889], ["from", 899], ["the", 904], ["cloned", 908], ["cap", 915], ["region", 919], [".", 925], ["Transcriptional", 927], ["analysis", 943], ["of", 952], ["cap", 955], ["by", 959], ["RNA", 962], ["slot", 966], ["-", 970], ["blot", 971], ["hybridization", 976], ["and", 990], ["primer", 994], ["-", 1000], ["extension", 1001], ["analysis", 1011], ["revealed", 1020], ["that", 1029], ["atxA", 1034], ["activated", 1039], ["expression", 1049], ["of", 1060], ["cap", 1063], ["in", 1067], ["trans", 1070], ["at", 1076], ["the", 1079], ["transcriptional", 1083], ["level", 1099], [".", 1104], ["These", 1106], ["results", 1112], ["indicate", 1120], ["that", 1129], ["cross", 1134], ["-", 1139], ["talk", 1140], ["occurs", 1145], [",", 1151], ["in", 1153], ["which", 1156], ["the", 1162], ["pXO1-located", 1166], ["gene", 1179], [",", 1183], ["atxA", 1185], [",", 1189], ["activates", 1191], ["transcription", 1201], ["of", 1215], ["the", 1218], ["cap", 1222], ["region", 1226], ["genes", 1233], ["located", 1239], ["on", 1247], ["pXO2", 1250], [".", 1254], ["We", 1256], ["identified", 1259], ["two", 1270], ["major", 1274], ["apparent", 1280], ["transcriptional", 1289], ["start", 1305], ["sites", 1311], [",", 1316], ["designated", 1318], ["P1", 1329], ["and", 1332], ["P2", 1336], [",", 1338], ["located", 1340], ["at", 1348], ["positions", 1351], ["731", 1361], ["bp", 1365], ["and", 1368], ["625", 1372], ["bp", 1376], [",", 1378], ["respectively", 1380], [",", 1392], ["upstream", 1394], ["of", 1403], ["the", 1406], ["translation", 1410], ["-", 1421], ["initiation", 1422], ["codon", 1433], ["of", 1439], ["capB.", 1442], ["Transcription", 1448], ["initiated", 1462], ["from", 1472], ["P1", 1477], ["and", 1480], ["P2", 1484], ["was", 1487], ["activated", 1491], ["by", 1501], ["both", 1504], ["atxA", 1509], ["and", 1514], ["acpA", 1518], [",", 1522], ["and", 1524], ["activation", 1528], ["appeared", 1539], ["to", 1548], ["be", 1551], ["stimulated", 1554], ["by", 1565], ["bicarbonate", 1568], [".", 1579], ["Deletion", 1581], ["analysis", 1590], ["of", 1599], ["the", 1602], ["upstream", 1606], ["region", 1615], ["of", 1622], ["the", 1625], ["cap", 1629], ["promoter", 1633], ["revealed", 1642], ["that", 1651], ["activation", 1656], ["by", 1667], ["both", 1670], ["atxA", 1675], ["and", 1680], ["acpA", 1684], ["required", 1689], ["a", 1698], ["DNA", 1700], ["segment", 1704], ["of", 1712], ["70", 1715], ["bp", 1718], ["extending", 1721], ["upstream", 1731], ["of", 1740], ["the", 1743], ["P1", 1747], ["site", 1750], [".", 1754], ["These", 1756], ["results", 1762], ["suggest", 1770], ["that", 1778], ["cross", 1783], ["-", 1788], ["talk", 1789], ["by", 1794], ["atxA", 1797], ["to", 1802], ["the", 1805], ["genes", 1809], ["encoding", 1815], ["capsule", 1824], ["synthesis", 1832], ["is", 1842], ["caused", 1845], ["by", 1852], ["the", 1855], ["interaction", 1859], ["of", 1871], ["the", 1874], ["atxA", 1878], ["gene", 1883], ["product", 1888], ["with", 1896], ["a", 1901], ["regulatory", 1903], ["sequence", 1914], ["upstream", 1923], ["of", 1932], ["cap", 1935], [".", 1938]]}
{"context": "The McLeod phenotype is derived from various forms of XK gene defects that result in the absence of XK protein, and is defined hematologically by the absence of Kx antigen, weakening of Kell system antigens, and red cell acanthocytosis. Individuals with the McLeod phenotype usually develop late-onset neuromuscular abnormalities known as the McLeod syndrome (MLS). MLS is an X-linked multi-system disorder caused by absence of XK alone, or when the disorder is caused by large deletions, it may be accompanied with Duchenne muscular dystrophy (DMD), chronic granulomatous disease (CYBB), retinitis pigmentosa (RPGR), and ornithine transcarbamylase deficiency (OTC). XK defects derived from a large deletion at the XK locus (Xp21.1) have not been characterized at the molecular level. In this study, the deletion breakpoints of two novel cases of McLeod phenotype with extensive deletions are reported. Case 1 has greater than 1.12 million base-pairs (mb) deletion around the XK locus with 7 genes affected. Case 2 has greater than 5.65 mb deletion from TCTE1L to DMD encompassing 20 genes. Phylogenetic analyses demonstrated that DMD, XK and CYBB have close paralogs, some of which may partially substitute for the functions of their counterparts. The loci around XK are highly conserved from fish to human; however, the disorders are probably specific to mammals, and may coincide with the translocation of the loci to the X chromosome after the speciation in birds. The non-synonymous to synonymous nucleotide substitution rate ratio (omega=dN/dS) in these genes was examined. CYBB and RPGR show evidence of positive selection, whereas DMD, XK and OTC are subject to selective constraint.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "22c0308943bd43cc8df2cab2658af54e", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[133, 133], [235, 235], [124, 124], [212, 212], [9, 9], [183, 183], [18, 18], [308, 308], [78, 78]], "char_spans": [[715, 716], [1265, 1266], [667, 668], [1136, 1137], [54, 55], [976, 977], [100, 101], [1644, 1645], [428, 429]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["phenotype", 11], ["is", 21], ["derived", 24], ["from", 32], ["various", 37], ["forms", 45], ["of", 51], ["XK", 54], ["gene", 57], ["defects", 62], ["that", 70], ["result", 75], ["in", 82], ["the", 85], ["absence", 89], ["of", 97], ["XK", 100], ["protein", 103], [",", 110], ["and", 112], ["is", 116], ["defined", 119], ["hematologically", 127], ["by", 143], ["the", 146], ["absence", 150], ["of", 158], ["Kx", 161], ["antigen", 164], [",", 171], ["weakening", 173], ["of", 183], ["Kell", 186], ["system", 191], ["antigens", 198], [",", 206], ["and", 208], ["red", 212], ["cell", 216], ["acanthocytosis", 221], [".", 235], ["Individuals", 237], ["with", 249], ["the", 254], ["McLeod", 258], ["phenotype", 265], ["usually", 275], ["develop", 283], ["late", 291], ["-", 295], ["onset", 296], ["neuromuscular", 302], ["abnormalities", 316], ["known", 330], ["as", 336], ["the", 339], ["McLeod", 343], ["syndrome", 350], ["(", 359], ["MLS", 360], [")", 363], [".", 364], ["MLS", 366], ["is", 370], ["an", 373], ["X", 376], ["-", 377], ["linked", 378], ["multi", 385], ["-", 390], ["system", 391], ["disorder", 398], ["caused", 407], ["by", 414], ["absence", 417], ["of", 425], ["XK", 428], ["alone", 431], [",", 436], ["or", 438], ["when", 441], ["the", 446], ["disorder", 450], ["is", 459], ["caused", 462], ["by", 469], ["large", 472], ["deletions", 478], [",", 487], ["it", 489], ["may", 492], ["be", 496], ["accompanied", 499], ["with", 511], ["Duchenne", 516], ["muscular", 525], ["dystrophy", 534], ["(", 544], ["DMD", 545], [")", 548], [",", 549], ["chronic", 551], ["granulomatous", 559], ["disease", 573], ["(", 581], ["CYBB", 582], [")", 586], [",", 587], ["retinitis", 589], ["pigmentosa", 599], ["(", 610], ["RPGR", 611], [")", 615], [",", 616], ["and", 618], ["ornithine", 622], ["transcarbamylase", 632], ["deficiency", 649], ["(", 660], ["OTC", 661], [")", 664], [".", 665], ["XK", 667], ["defects", 670], ["derived", 678], ["from", 686], ["a", 691], ["large", 693], ["deletion", 699], ["at", 708], ["the", 711], ["XK", 715], ["locus", 718], ["(", 724], ["Xp21.1", 725], [")", 731], ["have", 733], ["not", 738], ["been", 742], ["characterized", 747], ["at", 761], ["the", 764], ["molecular", 768], ["level", 778], [".", 783], ["In", 785], ["this", 788], ["study", 793], [",", 798], ["the", 800], ["deletion", 804], ["breakpoints", 813], ["of", 825], ["two", 828], ["novel", 832], ["cases", 838], ["of", 844], ["McLeod", 847], ["phenotype", 854], ["with", 864], ["extensive", 869], ["deletions", 879], ["are", 889], ["reported", 893], [".", 901], ["Case", 903], ["1", 908], ["has", 910], ["greater", 914], ["than", 922], ["1.12", 927], ["million", 932], ["base", 940], ["-", 944], ["pairs", 945], ["(", 951], ["mb", 952], [")", 954], ["deletion", 956], ["around", 965], ["the", 972], ["XK", 976], ["locus", 979], ["with", 985], ["7", 990], ["genes", 992], ["affected", 998], [".", 1006], ["Case", 1008], ["2", 1013], ["has", 1015], ["greater", 1019], ["than", 1027], ["5.65", 1032], ["mb", 1037], ["deletion", 1040], ["from", 1049], ["TCTE1L", 1054], ["to", 1061], ["DMD", 1064], ["encompassing", 1068], ["20", 1081], ["genes", 1084], [".", 1089], ["Phylogenetic", 1091], ["analyses", 1104], ["demonstrated", 1113], ["that", 1126], ["DMD", 1131], [",", 1134], ["XK", 1136], ["and", 1139], ["CYBB", 1143], ["have", 1148], ["close", 1153], ["paralogs", 1159], [",", 1167], ["some", 1169], ["of", 1174], ["which", 1177], ["may", 1183], ["partially", 1187], ["substitute", 1197], ["for", 1208], ["the", 1212], ["functions", 1216], ["of", 1226], ["their", 1229], ["counterparts", 1235], [".", 1247], ["The", 1249], ["loci", 1253], ["around", 1258], ["XK", 1265], ["are", 1268], ["highly", 1272], ["conserved", 1279], ["from", 1289], ["fish", 1294], ["to", 1299], ["human", 1302], [";", 1307], ["however", 1309], [",", 1316], ["the", 1318], ["disorders", 1322], ["are", 1332], ["probably", 1336], ["specific", 1345], ["to", 1354], ["mammals", 1357], [",", 1364], ["and", 1366], ["may", 1370], ["coincide", 1374], ["with", 1383], ["the", 1388], ["translocation", 1392], ["of", 1406], ["the", 1409], ["loci", 1413], ["to", 1418], ["the", 1421], ["X", 1425], ["chromosome", 1427], ["after", 1438], ["the", 1444], ["speciation", 1448], ["in", 1459], ["birds", 1462], [".", 1467], ["The", 1469], ["non", 1473], ["-", 1476], ["synonymous", 1477], ["to", 1488], ["synonymous", 1491], ["nucleotide", 1502], ["substitution", 1513], ["rate", 1526], ["ratio", 1531], ["(", 1537], ["omega", 1538], ["=", 1543], ["dN", 1544], ["/", 1546], ["dS", 1547], [")", 1549], ["in", 1551], ["these", 1554], ["genes", 1560], ["was", 1566], ["examined", 1570], [".", 1578], ["CYBB", 1580], ["and", 1585], ["RPGR", 1589], ["show", 1594], ["evidence", 1599], ["of", 1608], ["positive", 1611], ["selection", 1620], [",", 1629], ["whereas", 1631], ["DMD", 1639], [",", 1642], ["XK", 1644], ["and", 1647], ["OTC", 1651], ["are", 1655], ["subject", 1659], ["to", 1667], ["selective", 1670], ["constraint", 1680], [".", 1690]]}
{"context": "The objective was to determine the composition of the Cystic Fibrosis (CF) Population attending specialist UK CF centres in terms of age, gender, age at diagnosis, genotype and ethnicity. With the planned introduction of the national CF screening programme in the UK, cystic fibrosis transmembrane regulator (CFTR) mutations were compared between different ethnic groups enabling a UK-specific frequency of mutations to be defined. Data were analysed from the patient biographies held in the UK CF Database (see www.cystic-fibrosis.org.uk). The currently registered population of 5,274 CF patients is 96.3% Caucasian with a male preponderance that significantly increases with age. The majority of the 196 non-Caucasian CF patients are from the Indian Subcontinent (ISC), of which one in 84 UK CF patients are of Pakistani origin. The commonest CFTR mutation, deltaF508, is found in 74.1% of all CF chromosomes. In the Caucasian CF population, 57.5% are deltaF508 homozygotes but the UK ISC CF population with only 24.7%, has significantly fewer deltaF508 homozygotes patients (95% confidence interval (CI) 0.2-0.4). The distribution of Caucasian patients with deltaF508/deltaF508, deltaF508/Other and Other/Other does not fit the expected distribution with a Hardy-Weinberg model unless those patients without a detected mutation are excluded (P<0.001). The UK CF Database has shown the UK CF population to have distinct characteristics separate from the North American and European CF Registries. The ISC group contains many mutations not recognised by current genetic analysis, and one in four ISC patients have no CFTR mutations identified. The CFTR analysis proposed for the screening programme would detect 96% of patients registered in the database, but is unlikely to achieve the desired >80% detection rates in the ethnic minority groups. Screen-positive, non-Caucasian infants without an identifiable CFTR mutation should be referred for a sweat test and genetic counselling when serum trypsinogen concentrations remain elevated after birth.", "qas": [{"question": "Which is the most common CFTR mutation in Caucasians?", "answers": ["deltaF508"], "qid": "7d3f2b1fca4442a8ae60dafaeaa4cb04", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["CFTR", 25], ["mutation", 30], ["in", 39], ["Caucasians", 42], ["?", 52]], "detected_answers": [{"text": "deltaF508", "token_spans": [[152, 152], [173, 173], [189, 189]], "char_spans": [[860, 868], [954, 962], [1046, 1054]]}]}], "context_tokens": [["The", 0], ["objective", 4], ["was", 14], ["to", 18], ["determine", 21], ["the", 31], ["composition", 35], ["of", 47], ["the", 50], ["Cystic", 54], ["Fibrosis", 61], ["(", 70], ["CF", 71], [")", 73], ["Population", 75], ["attending", 86], ["specialist", 96], ["UK", 107], ["CF", 110], ["centres", 113], ["in", 121], ["terms", 124], ["of", 130], ["age", 133], [",", 136], ["gender", 138], [",", 144], ["age", 146], ["at", 150], ["diagnosis", 153], [",", 162], ["genotype", 164], ["and", 173], ["ethnicity", 177], [".", 186], ["With", 188], ["the", 193], ["planned", 197], ["introduction", 205], ["of", 218], ["the", 221], ["national", 225], ["CF", 234], ["screening", 237], ["programme", 247], ["in", 257], ["the", 260], ["UK", 264], [",", 266], ["cystic", 268], ["fibrosis", 275], ["transmembrane", 284], ["regulator", 298], ["(", 308], ["CFTR", 309], [")", 313], ["mutations", 315], ["were", 325], ["compared", 330], ["between", 339], ["different", 347], ["ethnic", 357], ["groups", 364], ["enabling", 371], ["a", 380], ["UK", 382], ["-", 384], ["specific", 385], ["frequency", 394], ["of", 404], ["mutations", 407], ["to", 417], ["be", 420], ["defined", 423], [".", 430], ["Data", 432], ["were", 437], ["analysed", 442], ["from", 451], ["the", 456], ["patient", 460], ["biographies", 468], ["held", 480], ["in", 485], ["the", 488], ["UK", 492], ["CF", 495], ["Database", 498], ["(", 507], ["see", 508], ["www.cystic-fibrosis.org.uk", 512], [")", 538], [".", 539], ["The", 541], ["currently", 545], ["registered", 555], ["population", 566], ["of", 577], ["5,274", 580], ["CF", 586], ["patients", 589], ["is", 598], ["96.3", 601], ["%", 605], ["Caucasian", 607], ["with", 617], ["a", 622], ["male", 624], ["preponderance", 629], ["that", 643], ["significantly", 648], ["increases", 662], ["with", 672], ["age", 677], [".", 680], ["The", 682], ["majority", 686], ["of", 695], ["the", 698], ["196", 702], ["non", 706], ["-", 709], ["Caucasian", 710], ["CF", 720], ["patients", 723], ["are", 732], ["from", 736], ["the", 741], ["Indian", 745], ["Subcontinent", 752], ["(", 765], ["ISC", 766], [")", 769], [",", 770], ["of", 772], ["which", 775], ["one", 781], ["in", 785], ["84", 788], ["UK", 791], ["CF", 794], ["patients", 797], ["are", 806], ["of", 810], ["Pakistani", 813], ["origin", 823], [".", 829], ["The", 831], ["commonest", 835], ["CFTR", 845], ["mutation", 850], [",", 858], ["deltaF508", 860], [",", 869], ["is", 871], ["found", 874], ["in", 880], ["74.1", 883], ["%", 887], ["of", 889], ["all", 892], ["CF", 896], ["chromosomes", 899], [".", 910], ["In", 912], ["the", 915], ["Caucasian", 919], ["CF", 929], ["population", 932], [",", 942], ["57.5", 944], ["%", 948], ["are", 950], ["deltaF508", 954], ["homozygotes", 964], ["but", 976], ["the", 980], ["UK", 984], ["ISC", 987], ["CF", 991], ["population", 994], ["with", 1005], ["only", 1010], ["24.7", 1015], ["%", 1019], [",", 1020], ["has", 1022], ["significantly", 1026], ["fewer", 1040], ["deltaF508", 1046], ["homozygotes", 1056], ["patients", 1068], ["(", 1077], ["95", 1078], ["%", 1080], ["confidence", 1082], ["interval", 1093], ["(", 1102], ["CI", 1103], [")", 1105], ["0.2", 1107], ["-", 1110], ["0.4", 1111], [")", 1114], [".", 1115], ["The", 1117], ["distribution", 1121], ["of", 1134], ["Caucasian", 1137], ["patients", 1147], ["with", 1156], ["deltaF508/deltaF508", 1161], [",", 1180], ["deltaF508/Other", 1182], ["and", 1198], ["Other", 1202], ["/", 1207], ["Other", 1208], ["does", 1214], ["not", 1219], ["fit", 1223], ["the", 1227], ["expected", 1231], ["distribution", 1240], ["with", 1253], ["a", 1258], ["Hardy", 1260], ["-", 1265], ["Weinberg", 1266], ["model", 1275], ["unless", 1281], ["those", 1288], ["patients", 1294], ["without", 1303], ["a", 1311], ["detected", 1313], ["mutation", 1322], ["are", 1331], ["excluded", 1335], ["(", 1344], ["P<0.001", 1345], [")", 1352], [".", 1353], ["The", 1355], ["UK", 1359], ["CF", 1362], ["Database", 1365], ["has", 1374], ["shown", 1378], ["the", 1384], ["UK", 1388], ["CF", 1391], ["population", 1394], ["to", 1405], ["have", 1408], ["distinct", 1413], ["characteristics", 1422], ["separate", 1438], ["from", 1447], ["the", 1452], ["North", 1456], ["American", 1462], ["and", 1471], ["European", 1475], ["CF", 1484], ["Registries", 1487], [".", 1497], ["The", 1499], ["ISC", 1503], ["group", 1507], ["contains", 1513], ["many", 1522], ["mutations", 1527], ["not", 1537], ["recognised", 1541], ["by", 1552], ["current", 1555], ["genetic", 1563], ["analysis", 1571], [",", 1579], ["and", 1581], ["one", 1585], ["in", 1589], ["four", 1592], ["ISC", 1597], ["patients", 1601], ["have", 1610], ["no", 1615], ["CFTR", 1618], ["mutations", 1623], ["identified", 1633], [".", 1643], ["The", 1645], ["CFTR", 1649], ["analysis", 1654], ["proposed", 1663], ["for", 1672], ["the", 1676], ["screening", 1680], ["programme", 1690], ["would", 1700], ["detect", 1706], ["96", 1713], ["%", 1715], ["of", 1717], ["patients", 1720], ["registered", 1729], ["in", 1740], ["the", 1743], ["database", 1747], [",", 1755], ["but", 1757], ["is", 1761], ["unlikely", 1764], ["to", 1773], ["achieve", 1776], ["the", 1784], ["desired", 1788], [">", 1796], ["80", 1797], ["%", 1799], ["detection", 1801], ["rates", 1811], ["in", 1817], ["the", 1820], ["ethnic", 1824], ["minority", 1831], ["groups", 1840], [".", 1846], ["Screen", 1848], ["-", 1854], ["positive", 1855], [",", 1863], ["non", 1865], ["-", 1868], ["Caucasian", 1869], ["infants", 1879], ["without", 1887], ["an", 1895], ["identifiable", 1898], ["CFTR", 1911], ["mutation", 1916], ["should", 1925], ["be", 1932], ["referred", 1935], ["for", 1944], ["a", 1948], ["sweat", 1950], ["test", 1956], ["and", 1961], ["genetic", 1965], ["counselling", 1973], ["when", 1985], ["serum", 1990], ["trypsinogen", 1996], ["concentrations", 2008], ["remain", 2023], ["elevated", 2030], ["after", 2039], ["birth", 2045], [".", 2050]]}
{"context": "While Clostridium difficile epidemiology is well documented in many European countries, data are largely missing for South Eastern European region. Here we report the PCR ribotype distribution of 249 C.\u00a0difficile isolates received for typing from six hospital settings from Croatia, Bosnia and Herzegovina, Republic of Macedonia and Serbia in time period from 2008 to 2015. Twenty-four PCR ribotypes were detected. The majority of strains from Bosnia and Herzegovina and Serbia belonged to PCR ribotype 027 (65.8%). Other three dominating PCR ribotypes were 176 (18 strains; Croatia), 001/072 (15 strains; all countries) and 014/020 (15 strains; all countries).", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "7bfea0506db945dca07567f46a77be7c", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[82, 83]], "char_spans": [[494, 505]]}]}], "context_tokens": [["While", 0], ["Clostridium", 6], ["difficile", 18], ["epidemiology", 28], ["is", 41], ["well", 44], ["documented", 49], ["in", 60], ["many", 63], ["European", 68], ["countries", 77], [",", 86], ["data", 88], ["are", 93], ["largely", 97], ["missing", 105], ["for", 113], ["South", 117], ["Eastern", 123], ["European", 131], ["region", 140], [".", 146], ["Here", 148], ["we", 153], ["report", 156], ["the", 163], ["PCR", 167], ["ribotype", 171], ["distribution", 180], ["of", 193], ["249", 196], ["C.", 200], ["difficile", 203], ["isolates", 213], ["received", 222], ["for", 231], ["typing", 235], ["from", 242], ["six", 247], ["hospital", 251], ["settings", 260], ["from", 269], ["Croatia", 274], [",", 281], ["Bosnia", 283], ["and", 290], ["Herzegovina", 294], [",", 305], ["Republic", 307], ["of", 316], ["Macedonia", 319], ["and", 329], ["Serbia", 333], ["in", 340], ["time", 343], ["period", 348], ["from", 355], ["2008", 360], ["to", 365], ["2015", 368], [".", 372], ["Twenty", 374], ["-", 380], ["four", 381], ["PCR", 386], ["ribotypes", 390], ["were", 400], ["detected", 405], [".", 413], ["The", 415], ["majority", 419], ["of", 428], ["strains", 431], ["from", 439], ["Bosnia", 444], ["and", 451], ["Herzegovina", 455], ["and", 467], ["Serbia", 471], ["belonged", 478], ["to", 487], ["PCR", 490], ["ribotype", 494], ["027", 503], ["(", 507], ["65.8", 508], ["%", 512], [")", 513], [".", 514], ["Other", 516], ["three", 522], ["dominating", 528], ["PCR", 539], ["ribotypes", 543], ["were", 553], ["176", 558], ["(", 562], ["18", 563], ["strains", 566], [";", 573], ["Croatia", 575], [")", 582], [",", 583], ["001/072", 585], ["(", 593], ["15", 594], ["strains", 597], [";", 604], ["all", 606], ["countries", 610], [")", 619], ["and", 621], ["014/020", 625], ["(", 633], ["15", 634], ["strains", 637], [";", 644], ["all", 646], ["countries", 650], [")", 659], [".", 660]]}
{"context": "Abnormal accumulation of Abeta and tau in senile plaques (SP) and neurofibrillary tangles (NFTs) is a key event in Alzheimer's disease (AD). Here, we show that T668-phosphorylated cytoplasmic domain of APP (pT668-ACD) accumulates Abeta and tau in AD and its transgenic models. Anti-pT668 immunostaining of AD brain sections with hydrated autoclave enhancement identified SP neurites and NFTs in which pT668-ACD colocalizes with tau. We produced and examined transgenic (Tg) mice that overexpress human APP695, harboring the double Swedish/London mutation, and develop age-dependently Abeta plaques in the brain. All Abeta plaques contain co-accumulations of pT668-ACD, but co-accumulation of tau appears in only a fraction of Abeta plaques in older animals. We also examined the established tau Tg mice that overexpress the smallest human brain tau isoform and develop neuronal accumulations of tau in older animals. Examination of the old tau Tg mice showed that neuronal cells affected by tau accumulation induce co-accumulation of pT668-ACD. We speculate that in AD brains, extracellular Abeta deposition is accompanied by intracellular accumulation of pT668-ACD, followed by tau accumulation in the SP with dystrophic neurites and that neuronal cells affected by tau accumulation induce co-accumulation of pT668-ACD in NFTs. Thus, pT668-ACD is likely to mediate pathological interaction between Abeta and tau.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "359b351dab714a9eb679ec9eef3d8227", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[23, 25]], "char_spans": [[115, 133]]}, {"text": "AD", "token_spans": [[191, 191], [59, 59], [48, 48], [27, 27]], "char_spans": [[1066, 1067], [306, 307], [247, 248], [136, 137]]}]}], "context_tokens": [["Abnormal", 0], ["accumulation", 9], ["of", 22], ["Abeta", 25], ["and", 31], ["tau", 35], ["in", 39], ["senile", 42], ["plaques", 49], ["(", 57], ["SP", 58], [")", 60], ["and", 62], ["neurofibrillary", 66], ["tangles", 82], ["(", 90], ["NFTs", 91], [")", 95], ["is", 97], ["a", 100], ["key", 102], ["event", 106], ["in", 112], ["Alzheimer", 115], ["'s", 124], ["disease", 127], ["(", 135], ["AD", 136], [")", 138], [".", 139], ["Here", 141], [",", 145], ["we", 147], ["show", 150], ["that", 155], ["T668-phosphorylated", 160], ["cytoplasmic", 180], ["domain", 192], ["of", 199], ["APP", 202], ["(", 206], ["pT668-ACD", 207], [")", 216], ["accumulates", 218], ["Abeta", 230], ["and", 236], ["tau", 240], ["in", 244], ["AD", 247], ["and", 250], ["its", 254], ["transgenic", 258], ["models", 269], [".", 275], ["Anti", 277], ["-", 281], ["pT668", 282], ["immunostaining", 288], ["of", 303], ["AD", 306], ["brain", 309], ["sections", 315], ["with", 324], ["hydrated", 329], ["autoclave", 338], ["enhancement", 348], ["identified", 360], ["SP", 371], ["neurites", 374], ["and", 383], ["NFTs", 387], ["in", 392], ["which", 395], ["pT668-ACD", 401], ["colocalizes", 411], ["with", 423], ["tau", 428], [".", 431], ["We", 433], ["produced", 436], ["and", 445], ["examined", 449], ["transgenic", 458], ["(", 469], ["Tg", 470], [")", 472], ["mice", 474], ["that", 479], ["overexpress", 484], ["human", 496], ["APP695", 502], [",", 508], ["harboring", 510], ["the", 520], ["double", 524], ["Swedish", 531], ["/", 538], ["London", 539], ["mutation", 546], [",", 554], ["and", 556], ["develop", 560], ["age", 568], ["-", 571], ["dependently", 572], ["Abeta", 584], ["plaques", 590], ["in", 598], ["the", 601], ["brain", 605], [".", 610], ["All", 612], ["Abeta", 616], ["plaques", 622], ["contain", 630], ["co", 638], ["-", 640], ["accumulations", 641], ["of", 655], ["pT668-ACD", 658], [",", 667], ["but", 669], ["co", 673], ["-", 675], ["accumulation", 676], ["of", 689], ["tau", 692], ["appears", 696], ["in", 704], ["only", 707], ["a", 712], ["fraction", 714], ["of", 723], ["Abeta", 726], ["plaques", 732], ["in", 740], ["older", 743], ["animals", 749], [".", 756], ["We", 758], ["also", 761], ["examined", 766], ["the", 775], ["established", 779], ["tau", 791], ["Tg", 795], ["mice", 798], ["that", 803], ["overexpress", 808], ["the", 820], ["smallest", 824], ["human", 833], ["brain", 839], ["tau", 845], ["isoform", 849], ["and", 857], ["develop", 861], ["neuronal", 869], ["accumulations", 878], ["of", 892], ["tau", 895], ["in", 899], ["older", 902], ["animals", 908], [".", 915], ["Examination", 917], ["of", 929], ["the", 932], ["old", 936], ["tau", 940], ["Tg", 944], ["mice", 947], ["showed", 952], ["that", 959], ["neuronal", 964], ["cells", 973], ["affected", 979], ["by", 988], ["tau", 991], ["accumulation", 995], ["induce", 1008], ["co", 1015], ["-", 1017], ["accumulation", 1018], ["of", 1031], ["pT668-ACD", 1034], [".", 1043], ["We", 1045], ["speculate", 1048], ["that", 1058], ["in", 1063], ["AD", 1066], ["brains", 1069], [",", 1075], ["extracellular", 1077], ["Abeta", 1091], ["deposition", 1097], ["is", 1108], ["accompanied", 1111], ["by", 1123], ["intracellular", 1126], ["accumulation", 1140], ["of", 1153], ["pT668-ACD", 1156], [",", 1165], ["followed", 1167], ["by", 1176], ["tau", 1179], ["accumulation", 1183], ["in", 1196], ["the", 1199], ["SP", 1203], ["with", 1206], ["dystrophic", 1211], ["neurites", 1222], ["and", 1231], ["that", 1235], ["neuronal", 1240], ["cells", 1249], ["affected", 1255], ["by", 1264], ["tau", 1267], ["accumulation", 1271], ["induce", 1284], ["co", 1291], ["-", 1293], ["accumulation", 1294], ["of", 1307], ["pT668-ACD", 1310], ["in", 1320], ["NFTs", 1323], [".", 1327], ["Thus", 1329], [",", 1333], ["pT668-ACD", 1335], ["is", 1345], ["likely", 1348], ["to", 1355], ["mediate", 1358], ["pathological", 1366], ["interaction", 1379], ["between", 1391], ["Abeta", 1399], ["and", 1405], ["tau", 1409], [".", 1412]]}
{"context": "It has been reported that the R497K polymorphism of the epidermal growth factor receptor (EGFR) gene has attenuated functions in ligand binding, tyrosine kinase activation, and growth stimulation. On other hand, EGFR gene mutations at kinase domain in non-small cell lung cancer (NSCLC) have been examined for their ability to predict sensitivity to gefitinib or erlotinib. We investigated the EGFR mutations and/or R497K polymorphism statuses in 225 surgically treated NSCLC cases. 192 adenocarcinoma cases were included. The presence or absence of EGFR polymorphism of exon 13 was analyzed by PCR-RFLP method. EGFR mutations at kinase domain were found from 95 of 225 lung cancer patients. In 86.2% of patients, homo- or heterozygous Lys497 allele was present. No correlation existed between R497K EGFR genotype and clinico-pathological features, such as gender, smoking status, and pathological subtypes. EGFR mutation status was not correlated with R497KEGFR genotype of lung cancers. In node-negative patients, R497KEGFR genotype was not correlated with disease outcome. In node-positive patients, however, R497K EGFR was significantly associated with better overall survival. This association was attributable to neo-adjuvant or adjuvant chemotherapy. In 46 total gefitinib treated NSCLC patients, the prognosis was not different between the EGFR wild type (GG) patients and AG+AA patients. R497KEGFR polymorphism might be associated with favorable prognosis of advanced lung cancers and correlated with chemosensitivity.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "98bf14cf3f54411fb46b808b1029b76d", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[11, 18]], "char_spans": [[56, 99]]}]}], "context_tokens": [["It", 0], ["has", 3], ["been", 7], ["reported", 12], ["that", 21], ["the", 26], ["R497", 30], ["K", 34], ["polymorphism", 36], ["of", 49], ["the", 52], ["epidermal", 56], ["growth", 66], ["factor", 73], ["receptor", 80], ["(", 89], ["EGFR", 90], [")", 94], ["gene", 96], ["has", 101], ["attenuated", 105], ["functions", 116], ["in", 126], ["ligand", 129], ["binding", 136], [",", 143], ["tyrosine", 145], ["kinase", 154], ["activation", 161], [",", 171], ["and", 173], ["growth", 177], ["stimulation", 184], [".", 195], ["On", 197], ["other", 200], ["hand", 206], [",", 210], ["EGFR", 212], ["gene", 217], ["mutations", 222], ["at", 232], ["kinase", 235], ["domain", 242], ["in", 249], ["non", 252], ["-", 255], ["small", 256], ["cell", 262], ["lung", 267], ["cancer", 272], ["(", 279], ["NSCLC", 280], [")", 285], ["have", 287], ["been", 292], ["examined", 297], ["for", 306], ["their", 310], ["ability", 316], ["to", 324], ["predict", 327], ["sensitivity", 335], ["to", 347], ["gefitinib", 350], ["or", 360], ["erlotinib", 363], [".", 372], ["We", 374], ["investigated", 377], ["the", 390], ["EGFR", 394], ["mutations", 399], ["and/or", 409], ["R497", 416], ["K", 420], ["polymorphism", 422], ["statuses", 435], ["in", 444], ["225", 447], ["surgically", 451], ["treated", 462], ["NSCLC", 470], ["cases", 476], [".", 481], ["192", 483], ["adenocarcinoma", 487], ["cases", 502], ["were", 508], ["included", 513], [".", 521], ["The", 523], ["presence", 527], ["or", 536], ["absence", 539], ["of", 547], ["EGFR", 550], ["polymorphism", 555], ["of", 568], ["exon", 571], ["13", 576], ["was", 579], ["analyzed", 583], ["by", 592], ["PCR", 595], ["-", 598], ["RFLP", 599], ["method", 604], [".", 610], ["EGFR", 612], ["mutations", 617], ["at", 627], ["kinase", 630], ["domain", 637], ["were", 644], ["found", 649], ["from", 655], ["95", 660], ["of", 663], ["225", 666], ["lung", 670], ["cancer", 675], ["patients", 682], [".", 690], ["In", 692], ["86.2", 695], ["%", 699], ["of", 701], ["patients", 704], [",", 712], ["homo-", 714], ["or", 720], ["heterozygous", 723], ["Lys497", 736], ["allele", 743], ["was", 750], ["present", 754], [".", 761], ["No", 763], ["correlation", 766], ["existed", 778], ["between", 786], ["R497", 794], ["K", 798], ["EGFR", 800], ["genotype", 805], ["and", 814], ["clinico", 818], ["-", 825], ["pathological", 826], ["features", 839], [",", 847], ["such", 849], ["as", 854], ["gender", 857], [",", 863], ["smoking", 865], ["status", 873], [",", 879], ["and", 881], ["pathological", 885], ["subtypes", 898], [".", 906], ["EGFR", 908], ["mutation", 913], ["status", 922], ["was", 929], ["not", 933], ["correlated", 937], ["with", 948], ["R497KEGFR", 953], ["genotype", 963], ["of", 972], ["lung", 975], ["cancers", 980], [".", 987], ["In", 989], ["node", 992], ["-", 996], ["negative", 997], ["patients", 1006], [",", 1014], ["R497KEGFR", 1016], ["genotype", 1026], ["was", 1035], ["not", 1039], ["correlated", 1043], ["with", 1054], ["disease", 1059], ["outcome", 1067], [".", 1074], ["In", 1076], ["node", 1079], ["-", 1083], ["positive", 1084], ["patients", 1093], [",", 1101], ["however", 1103], [",", 1110], ["R497", 1112], ["K", 1116], ["EGFR", 1118], ["was", 1123], ["significantly", 1127], ["associated", 1141], ["with", 1152], ["better", 1157], ["overall", 1164], ["survival", 1172], [".", 1180], ["This", 1182], ["association", 1187], ["was", 1199], ["attributable", 1203], ["to", 1216], ["neo", 1219], ["-", 1222], ["adjuvant", 1223], ["or", 1232], ["adjuvant", 1235], ["chemotherapy", 1244], [".", 1256], ["In", 1258], ["46", 1261], ["total", 1264], ["gefitinib", 1270], ["treated", 1280], ["NSCLC", 1288], ["patients", 1294], [",", 1302], ["the", 1304], ["prognosis", 1308], ["was", 1318], ["not", 1322], ["different", 1326], ["between", 1336], ["the", 1344], ["EGFR", 1348], ["wild", 1353], ["type", 1358], ["(", 1363], ["GG", 1364], [")", 1366], ["patients", 1368], ["and", 1377], ["AG+AA", 1381], ["patients", 1387], [".", 1395], ["R497KEGFR", 1397], ["polymorphism", 1407], ["might", 1420], ["be", 1426], ["associated", 1429], ["with", 1440], ["favorable", 1445], ["prognosis", 1455], ["of", 1465], ["advanced", 1468], ["lung", 1477], ["cancers", 1482], ["and", 1490], ["correlated", 1494], ["with", 1505], ["chemosensitivity", 1510], [".", 1526]]}
{"context": "In breast cancer the development of metastasis is a major turning point in the treatment and outcome of the disease. Throughout tumour development, and especially in the development of metastasis, epithelial mesenchymal transition takes place. During this transformation into a mesenchymal phenotype, the tumour cells undergo a series of structural changes. The loss of structural integrity and adoption of mesenchymal filaments enables cells to detach from the epithelial cell layer and metastasise. Keratins form the intermediate filaments of the cytoskeleton and provide scaffold structures within cells. During cancer progression the intermediate filaments are reorganised, and dramatic changes are seen in their protein components. Keratins K8, K18, K19 and vimentin are intermediate filament proteins with altered expression profiles during tumour development. We have used in vivo and in vitro models to analyse changes in intermediate filament proteins. Antibody-based methods were used to study K8 levels and proteomic analysis to profile the protein content of metastatic breast cancer cell variants. K8 expression declines as human breast tumours progress into an invasive phenotype. Analysis of IF proteins indicated altered expression profiles of K8, K18, K19 and vimentin, with K8, K18, K19 expressed in high levels in the T47D and MCF-7 cell lines, whereas the highly metastatic cell lines expressed lower levels of K8 and K18 and no detectable K19. Vimentin showed reverse expression profile with T47D and MCF-7 cells having no detectable vimentin expression whereas the highly metastatic MDA-MB-231 and MDA-MB-436 showed high levels. Analysis of acetylation status using specific antibodies suggested acetylation occurred within the central coiled domain in the MCF-7 and T47D cells. Inhibition of tumour growth by tissue factor (TF) shRNA resulted in a dramatic re-elevation of expression of K8 in xenographs of the highly metastatic MDA-MB-436 line. Intermediate filament expression alters during epithelial mesenchymal transition. Identified post translational modifications may play a role in alterations seen in the organisation, solubility and stability of these filaments. Epithelial mesenchymal transition can be reversed and an epithelial phenotype re-established.", "qas": [{"question": "What are the structures formed when keratin molecules come together?", "answers": ["Intermediate filaments"], "qid": "0b44e46a198e44a3a793781a09543148", "question_tokens": [["What", 0], ["are", 5], ["the", 9], ["structures", 13], ["formed", 24], ["when", 31], ["keratin", 36], ["molecules", 44], ["come", 54], ["together", 59], ["?", 67]], "detected_answers": [{"text": "Intermediate filaments", "token_spans": [[82, 83], [98, 99]], "char_spans": [[519, 540], [638, 659]]}]}], "context_tokens": [["In", 0], ["breast", 3], ["cancer", 10], ["the", 17], ["development", 21], ["of", 33], ["metastasis", 36], ["is", 47], ["a", 50], ["major", 52], ["turning", 58], ["point", 66], ["in", 72], ["the", 75], ["treatment", 79], ["and", 89], ["outcome", 93], ["of", 101], ["the", 104], ["disease", 108], [".", 115], ["Throughout", 117], ["tumour", 128], ["development", 135], [",", 146], ["and", 148], ["especially", 152], ["in", 163], ["the", 166], ["development", 170], ["of", 182], ["metastasis", 185], [",", 195], ["epithelial", 197], ["mesenchymal", 208], ["transition", 220], ["takes", 231], ["place", 237], [".", 242], ["During", 244], ["this", 251], ["transformation", 256], ["into", 271], ["a", 276], ["mesenchymal", 278], ["phenotype", 290], [",", 299], ["the", 301], ["tumour", 305], ["cells", 312], ["undergo", 318], ["a", 326], ["series", 328], ["of", 335], ["structural", 338], ["changes", 349], [".", 356], ["The", 358], ["loss", 362], ["of", 367], ["structural", 370], ["integrity", 381], ["and", 391], ["adoption", 395], ["of", 404], ["mesenchymal", 407], ["filaments", 419], ["enables", 429], ["cells", 437], ["to", 443], ["detach", 446], ["from", 453], ["the", 458], ["epithelial", 462], ["cell", 473], ["layer", 478], ["and", 484], ["metastasise", 488], [".", 499], ["Keratins", 501], ["form", 510], ["the", 515], ["intermediate", 519], ["filaments", 532], ["of", 542], ["the", 545], ["cytoskeleton", 549], ["and", 562], ["provide", 566], ["scaffold", 574], ["structures", 583], ["within", 594], ["cells", 601], [".", 606], ["During", 608], ["cancer", 615], ["progression", 622], ["the", 634], ["intermediate", 638], ["filaments", 651], ["are", 661], ["reorganised", 665], [",", 676], ["and", 678], ["dramatic", 682], ["changes", 691], ["are", 699], ["seen", 703], ["in", 708], ["their", 711], ["protein", 717], ["components", 725], [".", 735], ["Keratins", 737], ["K8", 746], [",", 748], ["K18", 750], [",", 753], ["K19", 755], ["and", 759], ["vimentin", 763], ["are", 772], ["intermediate", 776], ["filament", 789], ["proteins", 798], ["with", 807], ["altered", 812], ["expression", 820], ["profiles", 831], ["during", 840], ["tumour", 847], ["development", 854], [".", 865], ["We", 867], ["have", 870], ["used", 875], ["in", 880], ["vivo", 883], ["and", 888], ["in", 892], ["vitro", 895], ["models", 901], ["to", 908], ["analyse", 911], ["changes", 919], ["in", 927], ["intermediate", 930], ["filament", 943], ["proteins", 952], [".", 960], ["Antibody", 962], ["-", 970], ["based", 971], ["methods", 977], ["were", 985], ["used", 990], ["to", 995], ["study", 998], ["K8", 1004], ["levels", 1007], ["and", 1014], ["proteomic", 1018], ["analysis", 1028], ["to", 1037], ["profile", 1040], ["the", 1048], ["protein", 1052], ["content", 1060], ["of", 1068], ["metastatic", 1071], ["breast", 1082], ["cancer", 1089], ["cell", 1096], ["variants", 1101], [".", 1109], ["K8", 1111], ["expression", 1114], ["declines", 1125], ["as", 1134], ["human", 1137], ["breast", 1143], ["tumours", 1150], ["progress", 1158], ["into", 1167], ["an", 1172], ["invasive", 1175], ["phenotype", 1184], [".", 1193], ["Analysis", 1195], ["of", 1204], ["IF", 1207], ["proteins", 1210], ["indicated", 1219], ["altered", 1229], ["expression", 1237], ["profiles", 1248], ["of", 1257], ["K8", 1260], [",", 1262], ["K18", 1264], [",", 1267], ["K19", 1269], ["and", 1273], ["vimentin", 1277], [",", 1285], ["with", 1287], ["K8", 1292], [",", 1294], ["K18", 1296], [",", 1299], ["K19", 1301], ["expressed", 1305], ["in", 1315], ["high", 1318], ["levels", 1323], ["in", 1330], ["the", 1333], ["T47D", 1337], ["and", 1342], ["MCF-7", 1346], ["cell", 1352], ["lines", 1357], [",", 1362], ["whereas", 1364], ["the", 1372], ["highly", 1376], ["metastatic", 1383], ["cell", 1394], ["lines", 1399], ["expressed", 1405], ["lower", 1415], ["levels", 1421], ["of", 1428], ["K8", 1431], ["and", 1434], ["K18", 1438], ["and", 1442], ["no", 1446], ["detectable", 1449], ["K19", 1460], [".", 1463], ["Vimentin", 1465], ["showed", 1474], ["reverse", 1481], ["expression", 1489], ["profile", 1500], ["with", 1508], ["T47D", 1513], ["and", 1518], ["MCF-7", 1522], ["cells", 1528], ["having", 1534], ["no", 1541], ["detectable", 1544], ["vimentin", 1555], ["expression", 1564], ["whereas", 1575], ["the", 1583], ["highly", 1587], ["metastatic", 1594], ["MDA", 1605], ["-", 1608], ["MB-231", 1609], ["and", 1616], ["MDA", 1620], ["-", 1623], ["MB-436", 1624], ["showed", 1631], ["high", 1638], ["levels", 1643], [".", 1649], ["Analysis", 1651], ["of", 1660], ["acetylation", 1663], ["status", 1675], ["using", 1682], ["specific", 1688], ["antibodies", 1697], ["suggested", 1708], ["acetylation", 1718], ["occurred", 1730], ["within", 1739], ["the", 1746], ["central", 1750], ["coiled", 1758], ["domain", 1765], ["in", 1772], ["the", 1775], ["MCF-7", 1779], ["and", 1785], ["T47D", 1789], ["cells", 1794], [".", 1799], ["Inhibition", 1801], ["of", 1812], ["tumour", 1815], ["growth", 1822], ["by", 1829], ["tissue", 1832], ["factor", 1839], ["(", 1846], ["TF", 1847], [")", 1849], ["shRNA", 1851], ["resulted", 1857], ["in", 1866], ["a", 1869], ["dramatic", 1871], ["re", 1880], ["-", 1882], ["elevation", 1883], ["of", 1893], ["expression", 1896], ["of", 1907], ["K8", 1910], ["in", 1913], ["xenographs", 1916], ["of", 1927], ["the", 1930], ["highly", 1934], ["metastatic", 1941], ["MDA", 1952], ["-", 1955], ["MB-436", 1956], ["line", 1963], [".", 1967], ["Intermediate", 1969], ["filament", 1982], ["expression", 1991], ["alters", 2002], ["during", 2009], ["epithelial", 2016], ["mesenchymal", 2027], ["transition", 2039], [".", 2049], ["Identified", 2051], ["post", 2062], ["translational", 2067], ["modifications", 2081], ["may", 2095], ["play", 2099], ["a", 2104], ["role", 2106], ["in", 2111], ["alterations", 2114], ["seen", 2126], ["in", 2131], ["the", 2134], ["organisation", 2138], [",", 2150], ["solubility", 2152], ["and", 2163], ["stability", 2167], ["of", 2177], ["these", 2180], ["filaments", 2186], [".", 2195], ["Epithelial", 2197], ["mesenchymal", 2208], ["transition", 2220], ["can", 2231], ["be", 2235], ["reversed", 2238], ["and", 2247], ["an", 2251], ["epithelial", 2254], ["phenotype", 2265], ["re", 2275], ["-", 2277], ["established", 2278], [".", 2289]]}
{"context": "The tumorigenesis of sporadic endocrine tumors is still not fully understood. It is well known that patients with von Recklinghausen syndrome (NF-1) (OMIM 162200) carrying NF1 germline mutations are predisposed to endocrine tumors including pheochromocytomas and duodenal somatostatinomas. It is unclear, however, whether the rarely reported occurrence of pancreatic insulinomas in NF-1 patients represents a coincidental finding or whether insulinomas are a rare manifestation of the NF-1 syndrome. To determine the potential association between the NF-1 syndrome and pancreatic endocrine tumors, we analyzed a NF-1 patient with a well-differentiated pancreatic endocrine carcinoma for NF1 mutation, allelic loss of the NF1 gene and its expression in peripheral blood and tumor cells. The germline mutation c. 499 del TGTT known in the family was confirmed by polymerase chain reaction (PCR) and direct sequencing of exon 4 in DNA extracted from peripheral blood. Loss of heterozygosity (LOH) analysis of the NF1 gene was carried out using 3 intragenic microsatellite markers on 17q11.2. RNA expression was examined by reverse transcription and a consecutive PCR spanning intron 3 of the NF1 gene including the mutated site in exon 4. Immunohistochemistry was used to analyze NF-1 protein expression. Mutation analysis of peripheral blood leukocytes confirmed the 4 base pair deletion in exon 4 starting at codon 167 (499 del TGTT). LOH analysis of tumor tissue revealed retention of both NF1 alleles. While reverse transcriptase-PCR of peripheral blood showed bi-allelic expression of both the wild-type NF1 and the mutated form, reverse transcriptase-PCR of tumor extracts demonstrated expression of the mutated but not the wild-type NF1 allele. Additionally, neurofibromin, the NF1 gene product, was absent in the tumor tissue of the NF-1 patient. These results show that the wild-type NF1 transcrips and protein are reduced, in the reported insulinoma, supposedly by epigenetic mechanisms. This provides strong evidence that there is a relationship between von Recklinghausen disease and the patient's insulinoma. In this line, insulinomas may be viewed as a rare manifestation of the NF-1 syndrome. Furthermore, the NF1 gene must be considered as a candidate tumor suppressor gene for sporadic insulinomas and probably other pancreatic endocrine tumors.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "c0d1452ed8b34c4d932f62aae61d37a4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[112, 112], [195, 195], [302, 302], [166, 166], [294, 294], [325, 325], [381, 381], [105, 105], [270, 270], [248, 248], [30, 30]], "char_spans": [[721, 723], [1189, 1191], [1782, 1784], [1010, 1012], [1737, 1739], [1890, 1892], [2222, 2224], [687, 689], [1606, 1608], [1490, 1492], [172, 174]]}]}], "context_tokens": [["The", 0], ["tumorigenesis", 4], ["of", 18], ["sporadic", 21], ["endocrine", 30], ["tumors", 40], ["is", 47], ["still", 50], ["not", 56], ["fully", 60], ["understood", 66], [".", 76], ["It", 78], ["is", 81], ["well", 84], ["known", 89], ["that", 95], ["patients", 100], ["with", 109], ["von", 114], ["Recklinghausen", 118], ["syndrome", 133], ["(", 142], ["NF-1", 143], [")", 147], ["(", 149], ["OMIM", 150], ["162200", 155], [")", 161], ["carrying", 163], ["NF1", 172], ["germline", 176], ["mutations", 185], ["are", 195], ["predisposed", 199], ["to", 211], ["endocrine", 214], ["tumors", 224], ["including", 231], ["pheochromocytomas", 241], ["and", 259], ["duodenal", 263], ["somatostatinomas", 272], [".", 288], ["It", 290], ["is", 293], ["unclear", 296], [",", 303], ["however", 305], [",", 312], ["whether", 314], ["the", 322], ["rarely", 326], ["reported", 333], ["occurrence", 342], ["of", 353], ["pancreatic", 356], ["insulinomas", 367], ["in", 379], ["NF-1", 382], ["patients", 387], ["represents", 396], ["a", 407], ["coincidental", 409], ["finding", 422], ["or", 430], ["whether", 433], ["insulinomas", 441], ["are", 453], ["a", 457], ["rare", 459], ["manifestation", 464], ["of", 478], ["the", 481], ["NF-1", 485], ["syndrome", 490], [".", 498], ["To", 500], ["determine", 503], ["the", 513], ["potential", 517], ["association", 527], ["between", 539], ["the", 547], ["NF-1", 551], ["syndrome", 556], ["and", 565], ["pancreatic", 569], ["endocrine", 580], ["tumors", 590], [",", 596], ["we", 598], ["analyzed", 601], ["a", 610], ["NF-1", 612], ["patient", 617], ["with", 625], ["a", 630], ["well", 632], ["-", 636], ["differentiated", 637], ["pancreatic", 652], ["endocrine", 663], ["carcinoma", 673], ["for", 683], ["NF1", 687], ["mutation", 691], [",", 699], ["allelic", 701], ["loss", 709], ["of", 714], ["the", 717], ["NF1", 721], ["gene", 725], ["and", 730], ["its", 734], ["expression", 738], ["in", 749], ["peripheral", 752], ["blood", 763], ["and", 769], ["tumor", 773], ["cells", 779], [".", 784], ["The", 786], ["germline", 790], ["mutation", 799], ["c.", 808], ["499", 811], ["del", 815], ["TGTT", 819], ["known", 824], ["in", 830], ["the", 833], ["family", 837], ["was", 844], ["confirmed", 848], ["by", 858], ["polymerase", 861], ["chain", 872], ["reaction", 878], ["(", 887], ["PCR", 888], [")", 891], ["and", 893], ["direct", 897], ["sequencing", 904], ["of", 915], ["exon", 918], ["4", 923], ["in", 925], ["DNA", 928], ["extracted", 932], ["from", 942], ["peripheral", 947], ["blood", 958], [".", 963], ["Loss", 965], ["of", 970], ["heterozygosity", 973], ["(", 988], ["LOH", 989], [")", 992], ["analysis", 994], ["of", 1003], ["the", 1006], ["NF1", 1010], ["gene", 1014], ["was", 1019], ["carried", 1023], ["out", 1031], ["using", 1035], ["3", 1041], ["intragenic", 1043], ["microsatellite", 1054], ["markers", 1069], ["on", 1077], ["17q11.2", 1080], [".", 1087], ["RNA", 1089], ["expression", 1093], ["was", 1104], ["examined", 1108], ["by", 1117], ["reverse", 1120], ["transcription", 1128], ["and", 1142], ["a", 1146], ["consecutive", 1148], ["PCR", 1160], ["spanning", 1164], ["intron", 1173], ["3", 1180], ["of", 1182], ["the", 1185], ["NF1", 1189], ["gene", 1193], ["including", 1198], ["the", 1208], ["mutated", 1212], ["site", 1220], ["in", 1225], ["exon", 1228], ["4", 1233], [".", 1234], ["Immunohistochemistry", 1236], ["was", 1257], ["used", 1261], ["to", 1266], ["analyze", 1269], ["NF-1", 1277], ["protein", 1282], ["expression", 1290], [".", 1300], ["Mutation", 1302], ["analysis", 1311], ["of", 1320], ["peripheral", 1323], ["blood", 1334], ["leukocytes", 1340], ["confirmed", 1351], ["the", 1361], ["4", 1365], ["base", 1367], ["pair", 1372], ["deletion", 1377], ["in", 1386], ["exon", 1389], ["4", 1394], ["starting", 1396], ["at", 1405], ["codon", 1408], ["167", 1414], ["(", 1418], ["499", 1419], ["del", 1423], ["TGTT", 1427], [")", 1431], [".", 1432], ["LOH", 1434], ["analysis", 1438], ["of", 1447], ["tumor", 1450], ["tissue", 1456], ["revealed", 1463], ["retention", 1472], ["of", 1482], ["both", 1485], ["NF1", 1490], ["alleles", 1494], [".", 1501], ["While", 1503], ["reverse", 1509], ["transcriptase", 1517], ["-", 1530], ["PCR", 1531], ["of", 1535], ["peripheral", 1538], ["blood", 1549], ["showed", 1555], ["bi", 1562], ["-", 1564], ["allelic", 1565], ["expression", 1573], ["of", 1584], ["both", 1587], ["the", 1592], ["wild", 1596], ["-", 1600], ["type", 1601], ["NF1", 1606], ["and", 1610], ["the", 1614], ["mutated", 1618], ["form", 1626], [",", 1630], ["reverse", 1632], ["transcriptase", 1640], ["-", 1653], ["PCR", 1654], ["of", 1658], ["tumor", 1661], ["extracts", 1667], ["demonstrated", 1676], ["expression", 1689], ["of", 1700], ["the", 1703], ["mutated", 1707], ["but", 1715], ["not", 1719], ["the", 1723], ["wild", 1727], ["-", 1731], ["type", 1732], ["NF1", 1737], ["allele", 1741], [".", 1747], ["Additionally", 1749], [",", 1761], ["neurofibromin", 1763], [",", 1776], ["the", 1778], ["NF1", 1782], ["gene", 1786], ["product", 1791], [",", 1798], ["was", 1800], ["absent", 1804], ["in", 1811], ["the", 1814], ["tumor", 1818], ["tissue", 1824], ["of", 1831], ["the", 1834], ["NF-1", 1838], ["patient", 1843], [".", 1850], ["These", 1852], ["results", 1858], ["show", 1866], ["that", 1871], ["the", 1876], ["wild", 1880], ["-", 1884], ["type", 1885], ["NF1", 1890], ["transcrips", 1894], ["and", 1905], ["protein", 1909], ["are", 1917], ["reduced", 1921], [",", 1928], ["in", 1930], ["the", 1933], ["reported", 1937], ["insulinoma", 1946], [",", 1956], ["supposedly", 1958], ["by", 1969], ["epigenetic", 1972], ["mechanisms", 1983], [".", 1993], ["This", 1995], ["provides", 2000], ["strong", 2009], ["evidence", 2016], ["that", 2025], ["there", 2030], ["is", 2036], ["a", 2039], ["relationship", 2041], ["between", 2054], ["von", 2062], ["Recklinghausen", 2066], ["disease", 2081], ["and", 2089], ["the", 2093], ["patient", 2097], ["'s", 2104], ["insulinoma", 2107], [".", 2117], ["In", 2119], ["this", 2122], ["line", 2127], [",", 2131], ["insulinomas", 2133], ["may", 2145], ["be", 2149], ["viewed", 2152], ["as", 2159], ["a", 2162], ["rare", 2164], ["manifestation", 2169], ["of", 2183], ["the", 2186], ["NF-1", 2190], ["syndrome", 2195], [".", 2203], ["Furthermore", 2205], [",", 2216], ["the", 2218], ["NF1", 2222], ["gene", 2226], ["must", 2231], ["be", 2236], ["considered", 2239], ["as", 2250], ["a", 2253], ["candidate", 2255], ["tumor", 2265], ["suppressor", 2271], ["gene", 2282], ["for", 2287], ["sporadic", 2291], ["insulinomas", 2300], ["and", 2312], ["probably", 2316], ["other", 2325], ["pancreatic", 2331], ["endocrine", 2342], ["tumors", 2352], [".", 2358]]}
{"context": "During mitosis, Promyelocytic leukemia nuclear bodies (PML NBs) change dramatically in morphology and composition, but little is known about function of PML in mitosis. Here, we show that PML is phosphorylated at T409 (PML p409) in a mitosis-specific manner. More importantly, PML p409 contributes to maintain the duration of pro-metaphase and regulates spindle checkpoint. Deficient PML p409 caused a shortening of pro-metaphase and challenged the nocodazole-triggered mitotic arrest. T409A mutation led to a higher frequency of misaligned chromosomes on metaphase plate, and subsequently death in late mitosis. In addition, inhibition of PML p409 repressed growth of tumor cells, suggesting that PML p409 is a potential target for cancer therapy. Collectively, our study demonstrated an important phosphorylated site of PML, which contributed to explore the role of PML in mitosis.", "qas": [{"question": "What is the effect of nocodazole cell treatment?", "answers": ["Mitotic arrest"], "qid": "fb1932c2568743f8a7e02da6141a50f9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["nocodazole", 22], ["cell", 33], ["treatment", 38], ["?", 47]], "detected_answers": [{"text": "Mitotic arrest", "token_spans": [[85, 86]], "char_spans": [[470, 483]]}]}], "context_tokens": [["During", 0], ["mitosis", 7], [",", 14], ["Promyelocytic", 16], ["leukemia", 30], ["nuclear", 39], ["bodies", 47], ["(", 54], ["PML", 55], ["NBs", 59], [")", 62], ["change", 64], ["dramatically", 71], ["in", 84], ["morphology", 87], ["and", 98], ["composition", 102], [",", 113], ["but", 115], ["little", 119], ["is", 126], ["known", 129], ["about", 135], ["function", 141], ["of", 150], ["PML", 153], ["in", 157], ["mitosis", 160], [".", 167], ["Here", 169], [",", 173], ["we", 175], ["show", 178], ["that", 183], ["PML", 188], ["is", 192], ["phosphorylated", 195], ["at", 210], ["T409", 213], ["(", 218], ["PML", 219], ["p409", 223], [")", 227], ["in", 229], ["a", 232], ["mitosis", 234], ["-", 241], ["specific", 242], ["manner", 251], [".", 257], ["More", 259], ["importantly", 264], [",", 275], ["PML", 277], ["p409", 281], ["contributes", 286], ["to", 298], ["maintain", 301], ["the", 310], ["duration", 314], ["of", 323], ["pro", 326], ["-", 329], ["metaphase", 330], ["and", 340], ["regulates", 344], ["spindle", 354], ["checkpoint", 362], [".", 372], ["Deficient", 374], ["PML", 384], ["p409", 388], ["caused", 393], ["a", 400], ["shortening", 402], ["of", 413], ["pro", 416], ["-", 419], ["metaphase", 420], ["and", 430], ["challenged", 434], ["the", 445], ["nocodazole", 449], ["-", 459], ["triggered", 460], ["mitotic", 470], ["arrest", 478], [".", 484], ["T409A", 486], ["mutation", 492], ["led", 501], ["to", 505], ["a", 508], ["higher", 510], ["frequency", 517], ["of", 527], ["misaligned", 530], ["chromosomes", 541], ["on", 553], ["metaphase", 556], ["plate", 566], [",", 571], ["and", 573], ["subsequently", 577], ["death", 590], ["in", 596], ["late", 599], ["mitosis", 604], [".", 611], ["In", 613], ["addition", 616], [",", 624], ["inhibition", 626], ["of", 637], ["PML", 640], ["p409", 644], ["repressed", 649], ["growth", 659], ["of", 666], ["tumor", 669], ["cells", 675], [",", 680], ["suggesting", 682], ["that", 693], ["PML", 698], ["p409", 702], ["is", 707], ["a", 710], ["potential", 712], ["target", 722], ["for", 729], ["cancer", 733], ["therapy", 740], [".", 747], ["Collectively", 749], [",", 761], ["our", 763], ["study", 767], ["demonstrated", 773], ["an", 786], ["important", 789], ["phosphorylated", 799], ["site", 814], ["of", 819], ["PML", 822], [",", 825], ["which", 827], ["contributed", 833], ["to", 845], ["explore", 848], ["the", 856], ["role", 860], ["of", 865], ["PML", 868], ["in", 872], ["mitosis", 875], [".", 882]]}
{"context": "To develop polymeric films containing dual combinations of anti-HIV drug candidate tenofovir, maraviroc and dapivirine for vaginal application as topical microbicides. A solvent casting method was used to manufacture the films. Solid phase solubility was used to identify potential polymers for use in the film formulation. Physical and chemical properties (such as water content, puncture strength and in vitro release) and product stability were determined. The bioactivity of the film products against HIV was assessed using the TZM-bl assay and a cervical explant model. Polymers identified from the solid phase solubility study maintained tenofovir and maraviroc in an amorphous state and prevented drug crystallization. Three combination film products were developed using cellulose polymers and polyvinyl alcohol. The residual water content in all films was <10% (w/w). All films delivered the active agents with release of >50% of film drug content within 30 min. Stability testing confirmed that the combination film products were stable for 12 months at ambient temperature and 6 months under stressed conditions. Antiviral activity was confirmed in TZM-bl and cervical explant models. Polymeric films can be used as a stable dosage form for the delivery of antiretroviral combinations as microbicides.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "387330c38e704509996ffc03774c1391", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[82, 82], [10, 10]], "char_spans": [[505, 507], [64, 66]]}]}], "context_tokens": [["To", 0], ["develop", 3], ["polymeric", 11], ["films", 21], ["containing", 27], ["dual", 38], ["combinations", 43], ["of", 56], ["anti", 59], ["-", 63], ["HIV", 64], ["drug", 68], ["candidate", 73], ["tenofovir", 83], [",", 92], ["maraviroc", 94], ["and", 104], ["dapivirine", 108], ["for", 119], ["vaginal", 123], ["application", 131], ["as", 143], ["topical", 146], ["microbicides", 154], [".", 166], ["A", 168], ["solvent", 170], ["casting", 178], ["method", 186], ["was", 193], ["used", 197], ["to", 202], ["manufacture", 205], ["the", 217], ["films", 221], [".", 226], ["Solid", 228], ["phase", 234], ["solubility", 240], ["was", 251], ["used", 255], ["to", 260], ["identify", 263], ["potential", 272], ["polymers", 282], ["for", 291], ["use", 295], ["in", 299], ["the", 302], ["film", 306], ["formulation", 311], [".", 322], ["Physical", 324], ["and", 333], ["chemical", 337], ["properties", 346], ["(", 357], ["such", 358], ["as", 363], ["water", 366], ["content", 372], [",", 379], ["puncture", 381], ["strength", 390], ["and", 399], ["in", 403], ["vitro", 406], ["release", 412], [")", 419], ["and", 421], ["product", 425], ["stability", 433], ["were", 443], ["determined", 448], [".", 458], ["The", 460], ["bioactivity", 464], ["of", 476], ["the", 479], ["film", 483], ["products", 488], ["against", 497], ["HIV", 505], ["was", 509], ["assessed", 513], ["using", 522], ["the", 528], ["TZM", 532], ["-", 535], ["bl", 536], ["assay", 539], ["and", 545], ["a", 549], ["cervical", 551], ["explant", 560], ["model", 568], [".", 573], ["Polymers", 575], ["identified", 584], ["from", 595], ["the", 600], ["solid", 604], ["phase", 610], ["solubility", 616], ["study", 627], ["maintained", 633], ["tenofovir", 644], ["and", 654], ["maraviroc", 658], ["in", 668], ["an", 671], ["amorphous", 674], ["state", 684], ["and", 690], ["prevented", 694], ["drug", 704], ["crystallization", 709], [".", 724], ["Three", 726], ["combination", 732], ["film", 744], ["products", 749], ["were", 758], ["developed", 763], ["using", 773], ["cellulose", 779], ["polymers", 789], ["and", 798], ["polyvinyl", 802], ["alcohol", 812], [".", 819], ["The", 821], ["residual", 825], ["water", 834], ["content", 840], ["in", 848], ["all", 851], ["films", 855], ["was", 861], ["<", 865], ["10", 866], ["%", 868], ["(", 870], ["w", 871], ["/", 872], ["w", 873], [")", 874], [".", 875], ["All", 877], ["films", 881], ["delivered", 887], ["the", 897], ["active", 901], ["agents", 908], ["with", 915], ["release", 920], ["of", 928], [">", 931], ["50", 932], ["%", 934], ["of", 936], ["film", 939], ["drug", 944], ["content", 949], ["within", 957], ["30", 964], ["min", 967], [".", 970], ["Stability", 972], ["testing", 982], ["confirmed", 990], ["that", 1000], ["the", 1005], ["combination", 1009], ["film", 1021], ["products", 1026], ["were", 1035], ["stable", 1040], ["for", 1047], ["12", 1051], ["months", 1054], ["at", 1061], ["ambient", 1064], ["temperature", 1072], ["and", 1084], ["6", 1088], ["months", 1090], ["under", 1097], ["stressed", 1103], ["conditions", 1112], [".", 1122], ["Antiviral", 1124], ["activity", 1134], ["was", 1143], ["confirmed", 1147], ["in", 1157], ["TZM", 1160], ["-", 1163], ["bl", 1164], ["and", 1167], ["cervical", 1171], ["explant", 1180], ["models", 1188], [".", 1194], ["Polymeric", 1196], ["films", 1206], ["can", 1212], ["be", 1216], ["used", 1219], ["as", 1224], ["a", 1227], ["stable", 1229], ["dosage", 1236], ["form", 1243], ["for", 1248], ["the", 1252], ["delivery", 1256], ["of", 1265], ["antiretroviral", 1268], ["combinations", 1283], ["as", 1296], ["microbicides", 1299], [".", 1311]]}
{"context": "The efficacy of RTS,S/AS01 as a vaccine for malaria is being tested in a phase 3 clinical trial. Early results show significant, albeit partial, protection against clinical malaria and severe malaria. To ascertain variations in vaccine efficacy according to covariates such as transmission intensity, choice of adjuvant, age at vaccination, and bednet use, we did an individual-participant pooled analysis of phase 2 clinical data. We analysed data from 11 different sites in Africa, including 4453 participants. We measured heterogeneity in vaccine efficacy by estimating the interactions between covariates and vaccination in pooled multivariable Cox regression and Poisson regression analyses. Endpoints for measurement of vaccine efficacy were infection, clinical malaria, severe malaria, and death. We defined transmission intensity levels according to the estimated local parasite prevalence in children aged 2-10 years (PrP\u2082\u208b\u2081\u2080), ranging from 5% to 80%. Choice of adjuvant was either AS01 or AS02. Vaccine efficacy against all episodes of clinical malaria varied by transmission intensity (p=0\u00b7001). At low transmission (PrP\u2082\u208b\u2081\u2080 10%) vaccine efficacy was 60% (95% CI 54 to 67), at moderate transmission (PrP\u2082\u208b\u2081\u2080 20%) it was 41% (21 to 57), and at high transmission (PrP\u2082\u208b\u2081\u2080 70%) the efficacy was 4% (-10 to 22). Vaccine efficacy also varied by adjuvant choice (p<0\u00b70001)--eg, at low transmission (PrP\u2082\u208b\u2081\u2080 10%), efficacy varied from 60% (95% CI 54 to 67) for AS01 to 47% (14 to 75) for AS02. Variations in efficacy by age at vaccination were of borderline significance (p=0\u00b7038), and bednet use and sex were not significant covariates. Vaccine efficacy (pooled across adjuvant choice and transmission intensity) varied significantly (p<0\u00b70001) according to time since vaccination, from 36% efficacy (95% CI 24 to 45) at time of vaccination to 0% (-38 to 38) after 3 years. Vaccine efficacy against clinical disease was of limited duration and was not detectable 3 years after vaccination. Furthermore, efficacy fell with increasing transmission intensity. Outcomes after vaccination cannot be gauged accurately on the basis of one pooled efficacy figure. However, predictions of public-health outcomes of vaccination will need to take account of variations in efficacy by transmission intensity and by time since vaccination. Medical Research Council (UK); Bill & Melinda Gates Foundation Vaccine Modelling Initiative; Wellcome Trust.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "fe31178b0e794792bab8b7ad3722944f", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[37, 37], [182, 182], [12, 12], [34, 34], [130, 130], [127, 127]], "char_spans": [[192, 198], [1055, 1061], [44, 50], [173, 179], [784, 790], [768, 774]]}]}], "context_tokens": [["The", 0], ["efficacy", 4], ["of", 13], ["RTS", 16], [",", 19], ["S", 20], ["/", 21], ["AS01", 22], ["as", 27], ["a", 30], ["vaccine", 32], ["for", 40], ["malaria", 44], ["is", 52], ["being", 55], ["tested", 61], ["in", 68], ["a", 71], ["phase", 73], ["3", 79], ["clinical", 81], ["trial", 90], [".", 95], ["Early", 97], ["results", 103], ["show", 111], ["significant", 116], [",", 127], ["albeit", 129], ["partial", 136], [",", 143], ["protection", 145], ["against", 156], ["clinical", 164], ["malaria", 173], ["and", 181], ["severe", 185], ["malaria", 192], [".", 199], ["To", 201], ["ascertain", 204], ["variations", 214], ["in", 225], ["vaccine", 228], ["efficacy", 236], ["according", 245], ["to", 255], ["covariates", 258], ["such", 269], ["as", 274], ["transmission", 277], ["intensity", 290], [",", 299], ["choice", 301], ["of", 308], ["adjuvant", 311], [",", 319], ["age", 321], ["at", 325], ["vaccination", 328], [",", 339], ["and", 341], ["bednet", 345], ["use", 352], [",", 355], ["we", 357], ["did", 360], ["an", 364], ["individual", 367], ["-", 377], ["participant", 378], ["pooled", 390], ["analysis", 397], ["of", 406], ["phase", 409], ["2", 415], ["clinical", 417], ["data", 426], [".", 430], ["We", 432], ["analysed", 435], ["data", 444], ["from", 449], ["11", 454], ["different", 457], ["sites", 467], ["in", 473], ["Africa", 476], [",", 482], ["including", 484], ["4453", 494], ["participants", 499], [".", 511], ["We", 513], ["measured", 516], ["heterogeneity", 525], ["in", 539], ["vaccine", 542], ["efficacy", 550], ["by", 559], ["estimating", 562], ["the", 573], ["interactions", 577], ["between", 590], ["covariates", 598], ["and", 609], ["vaccination", 613], ["in", 625], ["pooled", 628], ["multivariable", 635], ["Cox", 649], ["regression", 653], ["and", 664], ["Poisson", 668], ["regression", 676], ["analyses", 687], [".", 695], ["Endpoints", 697], ["for", 707], ["measurement", 711], ["of", 723], ["vaccine", 726], ["efficacy", 734], ["were", 743], ["infection", 748], [",", 757], ["clinical", 759], ["malaria", 768], [",", 775], ["severe", 777], ["malaria", 784], [",", 791], ["and", 793], ["death", 797], [".", 802], ["We", 804], ["defined", 807], ["transmission", 815], ["intensity", 828], ["levels", 838], ["according", 845], ["to", 855], ["the", 858], ["estimated", 862], ["local", 872], ["parasite", 878], ["prevalence", 887], ["in", 898], ["children", 901], ["aged", 910], ["2", 915], ["-", 916], ["10", 917], ["years", 920], ["(", 926], ["PrP\u2082\u208b\u2081\u2080", 927], [")", 934], [",", 935], ["ranging", 937], ["from", 945], ["5", 950], ["%", 951], ["to", 953], ["80", 956], ["%", 958], [".", 959], ["Choice", 961], ["of", 968], ["adjuvant", 971], ["was", 980], ["either", 984], ["AS01", 991], ["or", 996], ["AS02", 999], [".", 1003], ["Vaccine", 1005], ["efficacy", 1013], ["against", 1022], ["all", 1030], ["episodes", 1034], ["of", 1043], ["clinical", 1046], ["malaria", 1055], ["varied", 1063], ["by", 1070], ["transmission", 1073], ["intensity", 1086], ["(", 1096], ["p=0\u00b7001", 1097], [")", 1104], [".", 1105], ["At", 1107], ["low", 1110], ["transmission", 1114], ["(", 1127], ["PrP\u2082\u208b\u2081\u2080", 1128], ["10", 1136], ["%", 1138], [")", 1139], ["vaccine", 1141], ["efficacy", 1149], ["was", 1158], ["60", 1162], ["%", 1164], ["(", 1166], ["95", 1167], ["%", 1169], ["CI", 1171], ["54", 1174], ["to", 1177], ["67", 1180], [")", 1182], [",", 1183], ["at", 1185], ["moderate", 1188], ["transmission", 1197], ["(", 1210], ["PrP\u2082\u208b\u2081\u2080", 1211], ["20", 1219], ["%", 1221], [")", 1222], ["it", 1224], ["was", 1227], ["41", 1231], ["%", 1233], ["(", 1235], ["21", 1236], ["to", 1239], ["57", 1242], [")", 1244], [",", 1245], ["and", 1247], ["at", 1251], ["high", 1254], ["transmission", 1259], ["(", 1272], ["PrP\u2082\u208b\u2081\u2080", 1273], ["70", 1281], ["%", 1283], [")", 1284], ["the", 1286], ["efficacy", 1290], ["was", 1299], ["4", 1303], ["%", 1304], ["(", 1306], ["-10", 1307], ["to", 1311], ["22", 1314], [")", 1316], [".", 1317], ["Vaccine", 1319], ["efficacy", 1327], ["also", 1336], ["varied", 1341], ["by", 1348], ["adjuvant", 1351], ["choice", 1360], ["(", 1367], ["p<0\u00b70001)--eg", 1368], [",", 1381], ["at", 1383], ["low", 1386], ["transmission", 1390], ["(", 1403], ["PrP\u2082\u208b\u2081\u2080", 1404], ["10", 1412], ["%", 1414], [")", 1415], [",", 1416], ["efficacy", 1418], ["varied", 1427], ["from", 1434], ["60", 1439], ["%", 1441], ["(", 1443], ["95", 1444], ["%", 1446], ["CI", 1448], ["54", 1451], ["to", 1454], ["67", 1457], [")", 1459], ["for", 1461], ["AS01", 1465], ["to", 1470], ["47", 1473], ["%", 1475], ["(", 1477], ["14", 1478], ["to", 1481], ["75", 1484], [")", 1486], ["for", 1488], ["AS02", 1492], [".", 1496], ["Variations", 1498], ["in", 1509], ["efficacy", 1512], ["by", 1521], ["age", 1524], ["at", 1528], ["vaccination", 1531], ["were", 1543], ["of", 1548], ["borderline", 1551], ["significance", 1562], ["(", 1575], ["p=0\u00b7038", 1576], [")", 1583], [",", 1584], ["and", 1586], ["bednet", 1590], ["use", 1597], ["and", 1601], ["sex", 1605], ["were", 1609], ["not", 1614], ["significant", 1618], ["covariates", 1630], [".", 1640], ["Vaccine", 1642], ["efficacy", 1650], ["(", 1659], ["pooled", 1660], ["across", 1667], ["adjuvant", 1674], ["choice", 1683], ["and", 1690], ["transmission", 1694], ["intensity", 1707], [")", 1716], ["varied", 1718], ["significantly", 1725], ["(", 1739], ["p<0\u00b70001", 1740], [")", 1748], ["according", 1750], ["to", 1760], ["time", 1763], ["since", 1768], ["vaccination", 1774], [",", 1785], ["from", 1787], ["36", 1792], ["%", 1794], ["efficacy", 1796], ["(", 1805], ["95", 1806], ["%", 1808], ["CI", 1810], ["24", 1813], ["to", 1816], ["45", 1819], [")", 1821], ["at", 1823], ["time", 1826], ["of", 1831], ["vaccination", 1834], ["to", 1846], ["0", 1849], ["%", 1850], ["(", 1852], ["-38", 1853], ["to", 1857], ["38", 1860], [")", 1862], ["after", 1864], ["3", 1870], ["years", 1872], [".", 1877], ["Vaccine", 1879], ["efficacy", 1887], ["against", 1896], ["clinical", 1904], ["disease", 1913], ["was", 1921], ["of", 1925], ["limited", 1928], ["duration", 1936], ["and", 1945], ["was", 1949], ["not", 1953], ["detectable", 1957], ["3", 1968], ["years", 1970], ["after", 1976], ["vaccination", 1982], [".", 1993], ["Furthermore", 1995], [",", 2006], ["efficacy", 2008], ["fell", 2017], ["with", 2022], ["increasing", 2027], ["transmission", 2038], ["intensity", 2051], [".", 2060], ["Outcomes", 2062], ["after", 2071], ["vaccination", 2077], ["can", 2089], ["not", 2092], ["be", 2096], ["gauged", 2099], ["accurately", 2106], ["on", 2117], ["the", 2120], ["basis", 2124], ["of", 2130], ["one", 2133], ["pooled", 2137], ["efficacy", 2144], ["figure", 2153], [".", 2159], ["However", 2161], [",", 2168], ["predictions", 2170], ["of", 2182], ["public", 2185], ["-", 2191], ["health", 2192], ["outcomes", 2199], ["of", 2208], ["vaccination", 2211], ["will", 2223], ["need", 2228], ["to", 2233], ["take", 2236], ["account", 2241], ["of", 2249], ["variations", 2252], ["in", 2263], ["efficacy", 2266], ["by", 2275], ["transmission", 2278], ["intensity", 2291], ["and", 2301], ["by", 2305], ["time", 2308], ["since", 2313], ["vaccination", 2319], [".", 2330], ["Medical", 2332], ["Research", 2340], ["Council", 2349], ["(", 2357], ["UK", 2358], [")", 2360], [";", 2361], ["Bill", 2363], ["&", 2368], ["Melinda", 2370], ["Gates", 2378], ["Foundation", 2384], ["Vaccine", 2395], ["Modelling", 2403], ["Initiative", 2413], [";", 2423], ["Wellcome", 2425], ["Trust", 2434], [".", 2439]]}
{"context": "Histone methyltransferase (HMT)(1) class enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain, which shares sequence homology with an independently described sequence motif, the PR domain. Intact PR or SET sequence is required for tumor suppression functions, but it remains unclear whether it is histone methyltransferase activity that underlies tumor suppression. We now show that tumor suppressor RIZ1 (PRDM2) methylates histone H3 on lysine 9, and this activity is reduced by mutations in the PR domain found in human cancers. Also, S-adenosylhomocysteine or methyl donor deficiency inhibits RIZ1 and other H3 lysine 9 methylation activities. These results support the hypothesis that H3 lysine 9 methylation activities of a PR/SET domain have tumor suppression functions and may underlie carcinogenesis associated with dietary methyl donor deficiency.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "bf7e56357754453da53cec3c83cb7ef2", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[22, 23], [134, 135]], "char_spans": [[150, 159], [799, 808]]}]}], "context_tokens": [["Histone", 0], ["methyltransferase", 8], ["(", 26], ["HMT)(1", 27], [")", 33], ["class", 35], ["enzymes", 41], ["that", 49], ["methylate", 54], ["lysine", 64], ["residues", 71], ["of", 80], ["histones", 83], ["or", 92], ["proteins", 95], ["contain", 104], ["a", 112], ["conserved", 114], ["catalytic", 124], ["core", 134], ["termed", 139], ["the", 146], ["SET", 150], ["domain", 154], [",", 160], ["which", 162], ["shares", 168], ["sequence", 175], ["homology", 184], ["with", 193], ["an", 198], ["independently", 201], ["described", 215], ["sequence", 225], ["motif", 234], [",", 239], ["the", 241], ["PR", 245], ["domain", 248], [".", 254], ["Intact", 256], ["PR", 263], ["or", 266], ["SET", 269], ["sequence", 273], ["is", 282], ["required", 285], ["for", 294], ["tumor", 298], ["suppression", 304], ["functions", 316], [",", 325], ["but", 327], ["it", 331], ["remains", 334], ["unclear", 342], ["whether", 350], ["it", 358], ["is", 361], ["histone", 364], ["methyltransferase", 372], ["activity", 390], ["that", 399], ["underlies", 404], ["tumor", 414], ["suppression", 420], [".", 431], ["We", 433], ["now", 436], ["show", 440], ["that", 445], ["tumor", 450], ["suppressor", 456], ["RIZ1", 467], ["(", 472], ["PRDM2", 473], [")", 478], ["methylates", 480], ["histone", 491], ["H3", 499], ["on", 502], ["lysine", 505], ["9", 512], [",", 513], ["and", 515], ["this", 519], ["activity", 524], ["is", 533], ["reduced", 536], ["by", 544], ["mutations", 547], ["in", 557], ["the", 560], ["PR", 564], ["domain", 567], ["found", 574], ["in", 580], ["human", 583], ["cancers", 589], [".", 596], ["Also", 598], [",", 602], ["S", 604], ["-", 605], ["adenosylhomocysteine", 606], ["or", 627], ["methyl", 630], ["donor", 637], ["deficiency", 643], ["inhibits", 654], ["RIZ1", 663], ["and", 668], ["other", 672], ["H3", 678], ["lysine", 681], ["9", 688], ["methylation", 690], ["activities", 702], [".", 712], ["These", 714], ["results", 720], ["support", 728], ["the", 736], ["hypothesis", 740], ["that", 751], ["H3", 756], ["lysine", 759], ["9", 766], ["methylation", 768], ["activities", 780], ["of", 791], ["a", 794], ["PR", 796], ["/", 798], ["SET", 799], ["domain", 803], ["have", 810], ["tumor", 815], ["suppression", 821], ["functions", 833], ["and", 843], ["may", 847], ["underlie", 851], ["carcinogenesis", 860], ["associated", 875], ["with", 886], ["dietary", 891], ["methyl", 899], ["donor", 906], ["deficiency", 912], [".", 922]]}
{"context": "Parkinson's disease (PD) and dementia with Lewy bodies are common disorders of the aging population and characterized by the progressive accumulation of \u03b1-synuclein (\u03b1-syn) in the central nervous system. Aggregation of \u03b1-syn into oligomers with a ring-like appearance has been proposed to play a role in toxicity. However, the molecular mechanisms and the potential sequence of events involved in the formation of pore-like structures are unclear. We utilized computer modeling and cell-based studies to investigate the process of oligomerization of wild-type and A53T mutant \u03b1-syn in membranes. The studies suggest that \u03b1-syn penetrates the membrane rapidly, changing its conformation from \u03b1-helical towards a coiled structure. This penetration facilitates the incorporation of additional \u03b1-syn monomers in the complex, and the subsequent displacement of phospholipids and the formation of oligomers in the membrane. This process occurred more rapidly, and with a more favorable energy of interaction, for mutant A53T compared with wild-type \u03b1-syn. After 4 ns of simulation of the protein-membrane model, \u03b1-syn had penetrated through two-thirds of the membrane. By 9 ns, the penetration of the annular \u03b1-syn oligomers can result in the formation of pore-like structures that fully perforate the lipid bilayer. Experimental incubation of recombinant \u03b1-syn in synthetic membranes resulted in the formation of similar pore-like complexes. Moreover, mutant (A53T) \u03b1-syn had a greater tendency to accumulate in neuronal membrane fractions in cell cultures, resulting in greater neuronal permeability, as demonstrated with the calcein efflux assay. These studies provide a sequential molecular explanation for the process of \u03b1-syn oligomerization in the membrane, and support the role of formation of pore-like structures in the pathogenesis of the neurodegenerative process in PD.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "c042537f3aac4a97a4633fcf4c88fc5b", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["and", 25], ["dementia", 29], ["with", 38], ["Lewy", 43], ["bodies", 48], ["are", 55], ["common", 59], ["disorders", 66], ["of", 76], ["the", 79], ["aging", 83], ["population", 89], ["and", 100], ["characterized", 104], ["by", 118], ["the", 121], ["progressive", 125], ["accumulation", 137], ["of", 150], ["\u03b1", 153], ["-", 154], ["synuclein", 155], ["(", 165], ["\u03b1", 166], ["-", 167], ["syn", 168], [")", 171], ["in", 173], ["the", 176], ["central", 180], ["nervous", 188], ["system", 196], [".", 202], ["Aggregation", 204], ["of", 216], ["\u03b1", 219], ["-", 220], ["syn", 221], ["into", 225], ["oligomers", 230], ["with", 240], ["a", 245], ["ring", 247], ["-", 251], ["like", 252], ["appearance", 257], ["has", 268], ["been", 272], ["proposed", 277], ["to", 286], ["play", 289], ["a", 294], ["role", 296], ["in", 301], ["toxicity", 304], [".", 312], ["However", 314], [",", 321], ["the", 323], ["molecular", 327], ["mechanisms", 337], ["and", 348], ["the", 352], ["potential", 356], ["sequence", 366], ["of", 375], ["events", 378], ["involved", 385], ["in", 394], ["the", 397], ["formation", 401], ["of", 411], ["pore", 414], ["-", 418], ["like", 419], ["structures", 424], ["are", 435], ["unclear", 439], [".", 446], ["We", 448], ["utilized", 451], ["computer", 460], ["modeling", 469], ["and", 478], ["cell", 482], ["-", 486], ["based", 487], ["studies", 493], ["to", 501], ["investigate", 504], ["the", 516], ["process", 520], ["of", 528], ["oligomerization", 531], ["of", 547], ["wild", 550], ["-", 554], ["type", 555], ["and", 560], ["A53", 564], ["T", 567], ["mutant", 569], ["\u03b1", 576], ["-", 577], ["syn", 578], ["in", 582], ["membranes", 585], [".", 594], ["The", 596], ["studies", 600], ["suggest", 608], ["that", 616], ["\u03b1", 621], ["-", 622], ["syn", 623], ["penetrates", 627], ["the", 638], ["membrane", 642], ["rapidly", 651], [",", 658], ["changing", 660], ["its", 669], ["conformation", 673], ["from", 686], ["\u03b1", 691], ["-", 692], ["helical", 693], ["towards", 701], ["a", 709], ["coiled", 711], ["structure", 718], [".", 727], ["This", 729], ["penetration", 734], ["facilitates", 746], ["the", 758], ["incorporation", 762], ["of", 776], ["additional", 779], ["\u03b1", 790], ["-", 791], ["syn", 792], ["monomers", 796], ["in", 805], ["the", 808], ["complex", 812], [",", 819], ["and", 821], ["the", 825], ["subsequent", 829], ["displacement", 840], ["of", 853], ["phospholipids", 856], ["and", 870], ["the", 874], ["formation", 878], ["of", 888], ["oligomers", 891], ["in", 901], ["the", 904], ["membrane", 908], [".", 916], ["This", 918], ["process", 923], ["occurred", 931], ["more", 940], ["rapidly", 945], [",", 952], ["and", 954], ["with", 958], ["a", 963], ["more", 965], ["favorable", 970], ["energy", 980], ["of", 987], ["interaction", 990], [",", 1001], ["for", 1003], ["mutant", 1007], ["A53", 1014], ["T", 1017], ["compared", 1019], ["with", 1028], ["wild", 1033], ["-", 1037], ["type", 1038], ["\u03b1", 1043], ["-", 1044], ["syn", 1045], [".", 1048], ["After", 1050], ["4", 1056], ["ns", 1058], ["of", 1061], ["simulation", 1064], ["of", 1075], ["the", 1078], ["protein", 1082], ["-", 1089], ["membrane", 1090], ["model", 1099], [",", 1104], ["\u03b1", 1106], ["-", 1107], ["syn", 1108], ["had", 1112], ["penetrated", 1116], ["through", 1127], ["two", 1135], ["-", 1138], ["thirds", 1139], ["of", 1146], ["the", 1149], ["membrane", 1153], [".", 1161], ["By", 1163], ["9", 1166], ["ns", 1168], [",", 1170], ["the", 1172], ["penetration", 1176], ["of", 1188], ["the", 1191], ["annular", 1195], ["\u03b1", 1203], ["-", 1204], ["syn", 1205], ["oligomers", 1209], ["can", 1219], ["result", 1223], ["in", 1230], ["the", 1233], ["formation", 1237], ["of", 1247], ["pore", 1250], ["-", 1254], ["like", 1255], ["structures", 1260], ["that", 1271], ["fully", 1276], ["perforate", 1282], ["the", 1292], ["lipid", 1296], ["bilayer", 1302], [".", 1309], ["Experimental", 1311], ["incubation", 1324], ["of", 1335], ["recombinant", 1338], ["\u03b1", 1350], ["-", 1351], ["syn", 1352], ["in", 1356], ["synthetic", 1359], ["membranes", 1369], ["resulted", 1379], ["in", 1388], ["the", 1391], ["formation", 1395], ["of", 1405], ["similar", 1408], ["pore", 1416], ["-", 1420], ["like", 1421], ["complexes", 1426], [".", 1435], ["Moreover", 1437], [",", 1445], ["mutant", 1447], ["(", 1454], ["A53", 1455], ["T", 1458], [")", 1459], ["\u03b1", 1461], ["-", 1462], ["syn", 1463], ["had", 1467], ["a", 1471], ["greater", 1473], ["tendency", 1481], ["to", 1490], ["accumulate", 1493], ["in", 1504], ["neuronal", 1507], ["membrane", 1516], ["fractions", 1525], ["in", 1535], ["cell", 1538], ["cultures", 1543], [",", 1551], ["resulting", 1553], ["in", 1563], ["greater", 1566], ["neuronal", 1574], ["permeability", 1583], [",", 1595], ["as", 1597], ["demonstrated", 1600], ["with", 1613], ["the", 1618], ["calcein", 1622], ["efflux", 1630], ["assay", 1637], [".", 1642], ["These", 1644], ["studies", 1650], ["provide", 1658], ["a", 1666], ["sequential", 1668], ["molecular", 1679], ["explanation", 1689], ["for", 1701], ["the", 1705], ["process", 1709], ["of", 1717], ["\u03b1", 1720], ["-", 1721], ["syn", 1722], ["oligomerization", 1726], ["in", 1742], ["the", 1745], ["membrane", 1749], [",", 1757], ["and", 1759], ["support", 1763], ["the", 1771], ["role", 1775], ["of", 1780], ["formation", 1783], ["of", 1793], ["pore", 1796], ["-", 1800], ["like", 1801], ["structures", 1806], ["in", 1817], ["the", 1820], ["pathogenesis", 1824], ["of", 1837], ["the", 1840], ["neurodegenerative", 1844], ["process", 1862], ["in", 1870], ["PD", 1873], [".", 1875]]}
{"context": "Selenoprotein P (SeP) is an extracellular glycoprotein with 8-10 selenocysteines per molecule, containing approximately 50% of total selenium in human serum. An antioxidant function of SeP has been postulated. In the present study, we show that SeP protects low-density lipoproteins (LDL) against oxidation in a cell-free in-vitro system. LDL were isolated from human blood plasma and oxidized with CuCl2, 2,2'-azobis(2-amidinopropane) (AAPH) or peroxynitrite in the presence or absence of SeP, using the formation of conjugated dienes as parameter for lipid peroxidation. SeP delayed the CuCl2- and AAPH-induced LDL oxidation significantly and more efficiently than bovine serum albumin used as control. In contrast, SeP was not capable of inhibiting peroxynitrite-induced LDL oxidation. The protection of LDL against CuCl2- and AAPH-induced oxidation provides evidence for the antioxidant capacity of SeP. Because SeP associates with endothelial membranes, it may act in vivo as a protective factor inhibiting the oxidation of LDL by reactive oxygen species.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "bc72c59b993848e78839cf94591aaa7c", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[0, 1]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Selenoprotein", 0], ["P", 14], ["(", 16], ["SeP", 17], [")", 20], ["is", 22], ["an", 25], ["extracellular", 28], ["glycoprotein", 42], ["with", 55], ["8", 60], ["-", 61], ["10", 62], ["selenocysteines", 65], ["per", 81], ["molecule", 85], [",", 93], ["containing", 95], ["approximately", 106], ["50", 120], ["%", 122], ["of", 124], ["total", 127], ["selenium", 133], ["in", 142], ["human", 145], ["serum", 151], [".", 156], ["An", 158], ["antioxidant", 161], ["function", 173], ["of", 182], ["SeP", 185], ["has", 189], ["been", 193], ["postulated", 198], [".", 208], ["In", 210], ["the", 213], ["present", 217], ["study", 225], [",", 230], ["we", 232], ["show", 235], ["that", 240], ["SeP", 245], ["protects", 249], ["low", 258], ["-", 261], ["density", 262], ["lipoproteins", 270], ["(", 283], ["LDL", 284], [")", 287], ["against", 289], ["oxidation", 297], ["in", 307], ["a", 310], ["cell", 312], ["-", 316], ["free", 317], ["in", 322], ["-", 324], ["vitro", 325], ["system", 331], [".", 337], ["LDL", 339], ["were", 343], ["isolated", 348], ["from", 357], ["human", 362], ["blood", 368], ["plasma", 374], ["and", 381], ["oxidized", 385], ["with", 394], ["CuCl2", 399], [",", 404], ["2,2'-azobis(2-amidinopropane", 406], [")", 434], ["(", 436], ["AAPH", 437], [")", 441], ["or", 443], ["peroxynitrite", 446], ["in", 460], ["the", 463], ["presence", 467], ["or", 476], ["absence", 479], ["of", 487], ["SeP", 490], [",", 493], ["using", 495], ["the", 501], ["formation", 505], ["of", 515], ["conjugated", 518], ["dienes", 529], ["as", 536], ["parameter", 539], ["for", 549], ["lipid", 553], ["peroxidation", 559], [".", 571], ["SeP", 573], ["delayed", 577], ["the", 585], ["CuCl2-", 589], ["and", 596], ["AAPH", 600], ["-", 604], ["induced", 605], ["LDL", 613], ["oxidation", 617], ["significantly", 627], ["and", 641], ["more", 645], ["efficiently", 650], ["than", 662], ["bovine", 667], ["serum", 674], ["albumin", 680], ["used", 688], ["as", 693], ["control", 696], [".", 703], ["In", 705], ["contrast", 708], [",", 716], ["SeP", 718], ["was", 722], ["not", 726], ["capable", 730], ["of", 738], ["inhibiting", 741], ["peroxynitrite", 752], ["-", 765], ["induced", 766], ["LDL", 774], ["oxidation", 778], [".", 787], ["The", 789], ["protection", 793], ["of", 804], ["LDL", 807], ["against", 811], ["CuCl2-", 819], ["and", 826], ["AAPH", 830], ["-", 834], ["induced", 835], ["oxidation", 843], ["provides", 853], ["evidence", 862], ["for", 871], ["the", 875], ["antioxidant", 879], ["capacity", 891], ["of", 900], ["SeP.", 903], ["Because", 908], ["SeP", 916], ["associates", 920], ["with", 931], ["endothelial", 936], ["membranes", 948], [",", 957], ["it", 959], ["may", 962], ["act", 966], ["in", 970], ["vivo", 973], ["as", 978], ["a", 981], ["protective", 983], ["factor", 994], ["inhibiting", 1001], ["the", 1012], ["oxidation", 1016], ["of", 1026], ["LDL", 1029], ["by", 1033], ["reactive", 1036], ["oxygen", 1045], ["species", 1052], [".", 1059]]}
{"context": "The TNF family member receptor activator for NF-\u03baB ligand (RANKL) and its receptors RANK and osteoprotegerin are key regulators of bone remodeling but also influence cellular functions of tumor and immune effector cells. In this work, we studied the involvement of RANK-RANKL interaction in NK cell-mediated immunosurveillance of acute myeloid leukemia (AML). Substantial levels of RANKL were found to be expressed on leukemia cells in 53 of 78 (68%) investigated patients. Signaling via RANKL into the leukemia cells stimulated their metabolic activity and induced the release of cytokines involved in AML pathophysiology. In addition, the immunomodulatory factors released by AML cells upon RANKL signaling impaired the anti-leukemia reactivity of NK cells and induced RANK expression, and NK cells of AML patients displayed significantly upregulated RANK expression compared with healthy controls. Treatment of AML cells with the clinically available RANKL Ab Denosumab resulted in enhanced NK cell anti-leukemia reactivity. This was due to both blockade of the release of NK-inhibitory factors by AML cells and prevention of RANK signaling into NK cells. The latter was found to directly impair NK anti-leukemia reactivity with a more pronounced effect on IFN-\u03b3 production compared with cytotoxicity. Together, our data unravel a previously unknown function of the RANK-RANKL molecule system in AML pathophysiology as well as NK cell function and suggest that neutralization of RANKL with therapeutic Abs may serve to reinforce NK cell reactivity in leukemia patients.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "d8c9be80bd4a48e8898ad993a1531d7f", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[161, 161], [256, 256], [90, 90], [68, 68], [12, 12], [121, 121], [239, 239], [49, 49]], "char_spans": [[954, 958], [1482, 1486], [488, 492], [382, 386], [59, 63], [693, 697], [1374, 1378], [270, 274]]}]}], "context_tokens": [["The", 0], ["TNF", 4], ["family", 8], ["member", 15], ["receptor", 22], ["activator", 31], ["for", 41], ["NF", 45], ["-", 47], ["\u03baB", 48], ["ligand", 51], ["(", 58], ["RANKL", 59], [")", 64], ["and", 66], ["its", 70], ["receptors", 74], ["RANK", 84], ["and", 89], ["osteoprotegerin", 93], ["are", 109], ["key", 113], ["regulators", 117], ["of", 128], ["bone", 131], ["remodeling", 136], ["but", 147], ["also", 151], ["influence", 156], ["cellular", 166], ["functions", 175], ["of", 185], ["tumor", 188], ["and", 194], ["immune", 198], ["effector", 205], ["cells", 214], [".", 219], ["In", 221], ["this", 224], ["work", 229], [",", 233], ["we", 235], ["studied", 238], ["the", 246], ["involvement", 250], ["of", 262], ["RANK", 265], ["-", 269], ["RANKL", 270], ["interaction", 276], ["in", 288], ["NK", 291], ["cell", 294], ["-", 298], ["mediated", 299], ["immunosurveillance", 308], ["of", 327], ["acute", 330], ["myeloid", 336], ["leukemia", 344], ["(", 353], ["AML", 354], [")", 357], [".", 358], ["Substantial", 360], ["levels", 372], ["of", 379], ["RANKL", 382], ["were", 388], ["found", 393], ["to", 399], ["be", 402], ["expressed", 405], ["on", 415], ["leukemia", 418], ["cells", 427], ["in", 433], ["53", 436], ["of", 439], ["78", 442], ["(", 445], ["68", 446], ["%", 448], [")", 449], ["investigated", 451], ["patients", 464], [".", 472], ["Signaling", 474], ["via", 484], ["RANKL", 488], ["into", 494], ["the", 499], ["leukemia", 503], ["cells", 512], ["stimulated", 518], ["their", 529], ["metabolic", 535], ["activity", 545], ["and", 554], ["induced", 558], ["the", 566], ["release", 570], ["of", 578], ["cytokines", 581], ["involved", 591], ["in", 600], ["AML", 603], ["pathophysiology", 607], [".", 622], ["In", 624], ["addition", 627], [",", 635], ["the", 637], ["immunomodulatory", 641], ["factors", 658], ["released", 666], ["by", 675], ["AML", 678], ["cells", 682], ["upon", 688], ["RANKL", 693], ["signaling", 699], ["impaired", 709], ["the", 718], ["anti", 722], ["-", 726], ["leukemia", 727], ["reactivity", 736], ["of", 747], ["NK", 750], ["cells", 753], ["and", 759], ["induced", 763], ["RANK", 771], ["expression", 776], [",", 786], ["and", 788], ["NK", 792], ["cells", 795], ["of", 801], ["AML", 804], ["patients", 808], ["displayed", 817], ["significantly", 827], ["upregulated", 841], ["RANK", 853], ["expression", 858], ["compared", 869], ["with", 878], ["healthy", 883], ["controls", 891], [".", 899], ["Treatment", 901], ["of", 911], ["AML", 914], ["cells", 918], ["with", 924], ["the", 929], ["clinically", 933], ["available", 944], ["RANKL", 954], ["Ab", 960], ["Denosumab", 963], ["resulted", 973], ["in", 982], ["enhanced", 985], ["NK", 994], ["cell", 997], ["anti", 1002], ["-", 1006], ["leukemia", 1007], ["reactivity", 1016], [".", 1026], ["This", 1028], ["was", 1033], ["due", 1037], ["to", 1041], ["both", 1044], ["blockade", 1049], ["of", 1058], ["the", 1061], ["release", 1065], ["of", 1073], ["NK", 1076], ["-", 1078], ["inhibitory", 1079], ["factors", 1090], ["by", 1098], ["AML", 1101], ["cells", 1105], ["and", 1111], ["prevention", 1115], ["of", 1126], ["RANK", 1129], ["signaling", 1134], ["into", 1144], ["NK", 1149], ["cells", 1152], [".", 1157], ["The", 1159], ["latter", 1163], ["was", 1170], ["found", 1174], ["to", 1180], ["directly", 1183], ["impair", 1192], ["NK", 1199], ["anti", 1202], ["-", 1206], ["leukemia", 1207], ["reactivity", 1216], ["with", 1227], ["a", 1232], ["more", 1234], ["pronounced", 1239], ["effect", 1250], ["on", 1257], ["IFN", 1260], ["-", 1263], ["\u03b3", 1264], ["production", 1266], ["compared", 1277], ["with", 1286], ["cytotoxicity", 1291], [".", 1303], ["Together", 1305], [",", 1313], ["our", 1315], ["data", 1319], ["unravel", 1324], ["a", 1332], ["previously", 1334], ["unknown", 1345], ["function", 1353], ["of", 1362], ["the", 1365], ["RANK", 1369], ["-", 1373], ["RANKL", 1374], ["molecule", 1380], ["system", 1389], ["in", 1396], ["AML", 1399], ["pathophysiology", 1403], ["as", 1419], ["well", 1422], ["as", 1427], ["NK", 1430], ["cell", 1433], ["function", 1438], ["and", 1447], ["suggest", 1451], ["that", 1459], ["neutralization", 1464], ["of", 1479], ["RANKL", 1482], ["with", 1488], ["therapeutic", 1493], ["Abs", 1505], ["may", 1509], ["serve", 1513], ["to", 1519], ["reinforce", 1522], ["NK", 1532], ["cell", 1535], ["reactivity", 1540], ["in", 1551], ["leukemia", 1554], ["patients", 1563], [".", 1571]]}
{"context": "To validate the presence and demonstrate the clinical value of the type I interferon (IFN)-signature during arthritis development. In 115 seropositive arthralgia patients who were followed for the development of arthritis (Amsterdam Reade cohort), and 25 presymptomatic individuals who developed rheumatoid arthritis (RA) later, and 45 population-based controls (Northern Sweden cohort), the expression levels of 7 type I IFN response genes were determined with multiplex qPCR and an IFN-score was calculated. The diagnostic performance of the IFN-score was evaluated using Cox regression and Receiver Operating Characteristics (ROC)-curve analysis. In 44 of the 115 at-risk individuals (38%) from the Amsterdam Reade cohort, arthritis developed after a median period of 8 months (IQR 5-13). Stratification of these individuals based on the IFN-score revealed that 15 out of 25 IFN(high) individuals converted to arthritis, compared with 29 out of 90 IFN(low) individuals (p=0.011). In the Northern Sweden cohort, the level of the IFN-score was also significantly increased in presymptomatic individuals who developed RA compared with population-based controls (p=0.002). Cox regression analysis of the Amsterdam Reade cohort showed that the hazard ratio (HR) for development of arthritis was 2.38 (p=0.008) for IFN(high) at-risk individuals after correction for anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF). The ROC-curve area under the curve (AUC) for the IFN-score combined with ACPA and RF in the prediction of arthritis was 78.5% (p=0.0001, 95% CI 0.70 to 0.87). The results demonstrated clinical utility for the IFN-signature as a biomarker in the prediction of arthritis development.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["IFN-signature", "Interferon signature", "IFN signature"], "qid": "78f9bca0ee664b74b0be699e63138b9b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[307, 309]], "char_spans": [[1644, 1656]]}]}], "context_tokens": [["To", 0], ["validate", 3], ["the", 12], ["presence", 16], ["and", 25], ["demonstrate", 29], ["the", 41], ["clinical", 45], ["value", 54], ["of", 60], ["the", 63], ["type", 67], ["I", 72], ["interferon", 74], ["(", 85], ["IFN)-signature", 86], ["during", 101], ["arthritis", 108], ["development", 118], [".", 129], ["In", 131], ["115", 134], ["seropositive", 138], ["arthralgia", 151], ["patients", 162], ["who", 171], ["were", 175], ["followed", 180], ["for", 189], ["the", 193], ["development", 197], ["of", 209], ["arthritis", 212], ["(", 222], ["Amsterdam", 223], ["Reade", 233], ["cohort", 239], [")", 245], [",", 246], ["and", 248], ["25", 252], ["presymptomatic", 255], ["individuals", 270], ["who", 282], ["developed", 286], ["rheumatoid", 296], ["arthritis", 307], ["(", 317], ["RA", 318], [")", 320], ["later", 322], [",", 327], ["and", 329], ["45", 333], ["population", 336], ["-", 346], ["based", 347], ["controls", 353], ["(", 362], ["Northern", 363], ["Sweden", 372], ["cohort", 379], [")", 385], [",", 386], ["the", 388], ["expression", 392], ["levels", 403], ["of", 410], ["7", 413], ["type", 415], ["I", 420], ["IFN", 422], ["response", 426], ["genes", 435], ["were", 441], ["determined", 446], ["with", 457], ["multiplex", 462], ["qPCR", 472], ["and", 477], ["an", 481], ["IFN", 484], ["-", 487], ["score", 488], ["was", 494], ["calculated", 498], [".", 508], ["The", 510], ["diagnostic", 514], ["performance", 525], ["of", 537], ["the", 540], ["IFN", 544], ["-", 547], ["score", 548], ["was", 554], ["evaluated", 558], ["using", 568], ["Cox", 574], ["regression", 578], ["and", 589], ["Receiver", 593], ["Operating", 602], ["Characteristics", 612], ["(", 628], ["ROC)-curve", 629], ["analysis", 640], [".", 648], ["In", 650], ["44", 653], ["of", 656], ["the", 659], ["115", 663], ["at", 667], ["-", 669], ["risk", 670], ["individuals", 675], ["(", 687], ["38", 688], ["%", 690], [")", 691], ["from", 693], ["the", 698], ["Amsterdam", 702], ["Reade", 712], ["cohort", 718], [",", 724], ["arthritis", 726], ["developed", 736], ["after", 746], ["a", 752], ["median", 754], ["period", 761], ["of", 768], ["8", 771], ["months", 773], ["(", 780], ["IQR", 781], ["5", 785], ["-", 786], ["13", 787], [")", 789], [".", 790], ["Stratification", 792], ["of", 807], ["these", 810], ["individuals", 816], ["based", 828], ["on", 834], ["the", 837], ["IFN", 841], ["-", 844], ["score", 845], ["revealed", 851], ["that", 860], ["15", 865], ["out", 868], ["of", 872], ["25", 875], ["IFN(high", 878], [")", 886], ["individuals", 888], ["converted", 900], ["to", 910], ["arthritis", 913], [",", 922], ["compared", 924], ["with", 933], ["29", 938], ["out", 941], ["of", 945], ["90", 948], ["IFN(low", 951], [")", 958], ["individuals", 960], ["(", 972], ["p=0.011", 973], [")", 980], [".", 981], ["In", 983], ["the", 986], ["Northern", 990], ["Sweden", 999], ["cohort", 1006], [",", 1012], ["the", 1014], ["level", 1018], ["of", 1024], ["the", 1027], ["IFN", 1031], ["-", 1034], ["score", 1035], ["was", 1041], ["also", 1045], ["significantly", 1050], ["increased", 1064], ["in", 1074], ["presymptomatic", 1077], ["individuals", 1092], ["who", 1104], ["developed", 1108], ["RA", 1118], ["compared", 1121], ["with", 1130], ["population", 1135], ["-", 1145], ["based", 1146], ["controls", 1152], ["(", 1161], ["p=0.002", 1162], [")", 1169], [".", 1170], ["Cox", 1172], ["regression", 1176], ["analysis", 1187], ["of", 1196], ["the", 1199], ["Amsterdam", 1203], ["Reade", 1213], ["cohort", 1219], ["showed", 1226], ["that", 1233], ["the", 1238], ["hazard", 1242], ["ratio", 1249], ["(", 1255], ["HR", 1256], [")", 1258], ["for", 1260], ["development", 1264], ["of", 1276], ["arthritis", 1279], ["was", 1289], ["2.38", 1293], ["(", 1298], ["p=0.008", 1299], [")", 1306], ["for", 1308], ["IFN(high", 1312], [")", 1320], ["at", 1322], ["-", 1324], ["risk", 1325], ["individuals", 1330], ["after", 1342], ["correction", 1348], ["for", 1359], ["anticitrullinated", 1363], ["protein", 1381], ["antibodies", 1389], ["(", 1400], ["ACPA", 1401], [")", 1405], ["and", 1407], ["rheumatoid", 1411], ["factor", 1422], ["(", 1429], ["RF", 1430], [")", 1432], [".", 1433], ["The", 1435], ["ROC", 1439], ["-", 1442], ["curve", 1443], ["area", 1449], ["under", 1454], ["the", 1460], ["curve", 1464], ["(", 1470], ["AUC", 1471], [")", 1474], ["for", 1476], ["the", 1480], ["IFN", 1484], ["-", 1487], ["score", 1488], ["combined", 1494], ["with", 1503], ["ACPA", 1508], ["and", 1513], ["RF", 1517], ["in", 1520], ["the", 1523], ["prediction", 1527], ["of", 1538], ["arthritis", 1541], ["was", 1551], ["78.5", 1555], ["%", 1559], ["(", 1561], ["p=0.0001", 1562], [",", 1570], ["95", 1572], ["%", 1574], ["CI", 1576], ["0.70", 1579], ["to", 1584], ["0.87", 1587], [")", 1591], [".", 1592], ["The", 1594], ["results", 1598], ["demonstrated", 1606], ["clinical", 1619], ["utility", 1628], ["for", 1636], ["the", 1640], ["IFN", 1644], ["-", 1647], ["signature", 1648], ["as", 1658], ["a", 1661], ["biomarker", 1663], ["in", 1673], ["the", 1676], ["prediction", 1680], ["of", 1691], ["arthritis", 1694], ["development", 1704], [".", 1715]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent adult muscular dystrophies. The common clinical signs usually appear during the second decade of life but when the first molecular dysregulations occur is still unknown. Our aim was to determine whether molecular dysregulations can be identified during FSHD fetal muscle development. We compared muscle biopsies derived from FSHD1 fetuses and the cells derived from some of these biopsies with biopsies and cells derived from control fetuses. We mainly focus on DUX4 isoform expression because the expression of DUX4 has been confirmed in both FSHD cells and biopsies by several laboratories. We measured DUX4 isoform expression by using qRT-PCR in fetal FSHD1 myotubes treated or not with an shRNA directed against DUX4 mRNA. We also analyzed DUX4 downstream target gene expression in myotubes and fetal or adult FSHD1 and control quadriceps biopsies. We show that both DUX4-FL isoforms are already expressed in FSHD1 myotubes. Interestingly, DUX4-FL expression level is much lower in trapezius than in quadriceps myotubes, which is confirmed by the level of expression of DUX4 downstream genes. We observed that TRIM43 and MBD3L2 are already overexpressed in FSHD1 fetal quadriceps biopsies, at similar levels to those observed in adult FSHD1 quadriceps biopsies. These results indicate that molecular markers of the disease are already expressed during fetal life, thus opening a new field of investigation for mechanisms leading to FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "ecab61b49d944c2daff330eafcf4f174", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[99, 99], [4, 4], [51, 51], [247, 247]], "char_spans": [[619, 622], [40, 43], [328, 331], [1511, 1514]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["one", 49], ["of", 53], ["the", 56], ["most", 60], ["prevalent", 65], ["adult", 75], ["muscular", 81], ["dystrophies", 90], [".", 101], ["The", 103], ["common", 107], ["clinical", 114], ["signs", 123], ["usually", 129], ["appear", 137], ["during", 144], ["the", 151], ["second", 155], ["decade", 162], ["of", 169], ["life", 172], ["but", 177], ["when", 181], ["the", 186], ["first", 190], ["molecular", 196], ["dysregulations", 206], ["occur", 221], ["is", 227], ["still", 230], ["unknown", 236], [".", 243], ["Our", 245], ["aim", 249], ["was", 253], ["to", 257], ["determine", 260], ["whether", 270], ["molecular", 278], ["dysregulations", 288], ["can", 303], ["be", 307], ["identified", 310], ["during", 321], ["FSHD", 328], ["fetal", 333], ["muscle", 339], ["development", 346], [".", 357], ["We", 359], ["compared", 362], ["muscle", 371], ["biopsies", 378], ["derived", 387], ["from", 395], ["FSHD1", 400], ["fetuses", 406], ["and", 414], ["the", 418], ["cells", 422], ["derived", 428], ["from", 436], ["some", 441], ["of", 446], ["these", 449], ["biopsies", 455], ["with", 464], ["biopsies", 469], ["and", 478], ["cells", 482], ["derived", 488], ["from", 496], ["control", 501], ["fetuses", 509], [".", 516], ["We", 518], ["mainly", 521], ["focus", 528], ["on", 534], ["DUX4", 537], ["isoform", 542], ["expression", 550], ["because", 561], ["the", 569], ["expression", 573], ["of", 584], ["DUX4", 587], ["has", 592], ["been", 596], ["confirmed", 601], ["in", 611], ["both", 614], ["FSHD", 619], ["cells", 624], ["and", 630], ["biopsies", 634], ["by", 643], ["several", 646], ["laboratories", 654], [".", 666], ["We", 668], ["measured", 671], ["DUX4", 680], ["isoform", 685], ["expression", 693], ["by", 704], ["using", 707], ["qRT", 713], ["-", 716], ["PCR", 717], ["in", 721], ["fetal", 724], ["FSHD1", 730], ["myotubes", 736], ["treated", 745], ["or", 753], ["not", 756], ["with", 760], ["an", 765], ["shRNA", 768], ["directed", 774], ["against", 783], ["DUX4", 791], ["mRNA", 796], [".", 800], ["We", 802], ["also", 805], ["analyzed", 810], ["DUX4", 819], ["downstream", 824], ["target", 835], ["gene", 842], ["expression", 847], ["in", 858], ["myotubes", 861], ["and", 870], ["fetal", 874], ["or", 880], ["adult", 883], ["FSHD1", 889], ["and", 895], ["control", 899], ["quadriceps", 907], ["biopsies", 918], [".", 926], ["We", 928], ["show", 931], ["that", 936], ["both", 941], ["DUX4-FL", 946], ["isoforms", 954], ["are", 963], ["already", 967], ["expressed", 975], ["in", 985], ["FSHD1", 988], ["myotubes", 994], [".", 1002], ["Interestingly", 1004], [",", 1017], ["DUX4-FL", 1019], ["expression", 1027], ["level", 1038], ["is", 1044], ["much", 1047], ["lower", 1052], ["in", 1058], ["trapezius", 1061], ["than", 1071], ["in", 1076], ["quadriceps", 1079], ["myotubes", 1090], [",", 1098], ["which", 1100], ["is", 1106], ["confirmed", 1109], ["by", 1119], ["the", 1122], ["level", 1126], ["of", 1132], ["expression", 1135], ["of", 1146], ["DUX4", 1149], ["downstream", 1154], ["genes", 1165], [".", 1170], ["We", 1172], ["observed", 1175], ["that", 1184], ["TRIM43", 1189], ["and", 1196], ["MBD3L2", 1200], ["are", 1207], ["already", 1211], ["overexpressed", 1219], ["in", 1233], ["FSHD1", 1236], ["fetal", 1242], ["quadriceps", 1248], ["biopsies", 1259], [",", 1267], ["at", 1269], ["similar", 1272], ["levels", 1280], ["to", 1287], ["those", 1290], ["observed", 1296], ["in", 1305], ["adult", 1308], ["FSHD1", 1314], ["quadriceps", 1320], ["biopsies", 1331], [".", 1339], ["These", 1341], ["results", 1347], ["indicate", 1355], ["that", 1364], ["molecular", 1369], ["markers", 1379], ["of", 1387], ["the", 1390], ["disease", 1394], ["are", 1402], ["already", 1406], ["expressed", 1414], ["during", 1424], ["fetal", 1431], ["life", 1437], [",", 1441], ["thus", 1443], ["opening", 1448], ["a", 1456], ["new", 1458], ["field", 1462], ["of", 1468], ["investigation", 1471], ["for", 1485], ["mechanisms", 1489], ["leading", 1500], ["to", 1508], ["FSHD", 1511], [".", 1515]]}
{"context": "To compare the sensitivity and specificity of bedside diagnostic stroke scales in patients with suspected stroke. A cross-sectional observational study of patients with suspected acute stroke in an emergency department in a UK hospital. DIAGNOSTIC SCALES: The results of an assessment with the Recognition of Stroke in the Emergency Room (ROSIER) scale, the Face Arm Speech Test (FAST) scale and the diagnosis of definite or probable stroke by an emergency department. Reference standard A consensus diagnosis of stroke or transient ischaemic attack (TIA) made after discussion by an expert panel (members included stroke physicians, neurologists and neuroradiologists), who had access to the clinical findings, imaging and subsequent clinical course, but were blinded to the results of the assessments by emergency-department staff. In 356 patients with complete data, the expert panel assigned a diagnosis of acute stroke or TIA in 246 and a diagnosis of mimic in 110. The ROSIER had a sensitivity of 83% (95% CI 78 to 87) and specificity of 44% (95% CI 34 to 53), and the FAST had a sensitivity of 81% (95% CI 76 to 86) and a specificity of 39% (95% CI 30 to 48). There was no detectable difference between the scales in sensitivity (p = 0.39) or specificity (p = 0.30). The simpler FAST scale could replace the more complex ROSIER for the initial assessment of patients with suspected acute stroke in the emergency department.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "87e2ed1c3da9432d8d2e5c5818f3483b", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[158, 158], [275, 275], [106, 106], [76, 76], [28, 28], [9, 9], [88, 88], [50, 50], [15, 15]], "char_spans": [[917, 922], [1395, 1400], [615, 620], [434, 439], [185, 190], [65, 70], [513, 518], [309, 314], [106, 111]]}]}], "context_tokens": [["To", 0], ["compare", 3], ["the", 11], ["sensitivity", 15], ["and", 27], ["specificity", 31], ["of", 43], ["bedside", 46], ["diagnostic", 54], ["stroke", 65], ["scales", 72], ["in", 79], ["patients", 82], ["with", 91], ["suspected", 96], ["stroke", 106], [".", 112], ["A", 114], ["cross", 116], ["-", 121], ["sectional", 122], ["observational", 132], ["study", 146], ["of", 152], ["patients", 155], ["with", 164], ["suspected", 169], ["acute", 179], ["stroke", 185], ["in", 192], ["an", 195], ["emergency", 198], ["department", 208], ["in", 219], ["a", 222], ["UK", 224], ["hospital", 227], [".", 235], ["DIAGNOSTIC", 237], ["SCALES", 248], [":", 254], ["The", 256], ["results", 260], ["of", 268], ["an", 271], ["assessment", 274], ["with", 285], ["the", 290], ["Recognition", 294], ["of", 306], ["Stroke", 309], ["in", 316], ["the", 319], ["Emergency", 323], ["Room", 333], ["(", 338], ["ROSIER", 339], [")", 345], ["scale", 347], [",", 352], ["the", 354], ["Face", 358], ["Arm", 363], ["Speech", 367], ["Test", 374], ["(", 379], ["FAST", 380], [")", 384], ["scale", 386], ["and", 392], ["the", 396], ["diagnosis", 400], ["of", 410], ["definite", 413], ["or", 422], ["probable", 425], ["stroke", 434], ["by", 441], ["an", 444], ["emergency", 447], ["department", 457], [".", 467], ["Reference", 469], ["standard", 479], ["A", 488], ["consensus", 490], ["diagnosis", 500], ["of", 510], ["stroke", 513], ["or", 520], ["transient", 523], ["ischaemic", 533], ["attack", 543], ["(", 550], ["TIA", 551], [")", 554], ["made", 556], ["after", 561], ["discussion", 567], ["by", 578], ["an", 581], ["expert", 584], ["panel", 591], ["(", 597], ["members", 598], ["included", 606], ["stroke", 615], ["physicians", 622], [",", 632], ["neurologists", 634], ["and", 647], ["neuroradiologists", 651], [")", 668], [",", 669], ["who", 671], ["had", 675], ["access", 679], ["to", 686], ["the", 689], ["clinical", 693], ["findings", 702], [",", 710], ["imaging", 712], ["and", 720], ["subsequent", 724], ["clinical", 735], ["course", 744], [",", 750], ["but", 752], ["were", 756], ["blinded", 761], ["to", 769], ["the", 772], ["results", 776], ["of", 784], ["the", 787], ["assessments", 791], ["by", 803], ["emergency", 806], ["-", 815], ["department", 816], ["staff", 827], [".", 832], ["In", 834], ["356", 837], ["patients", 841], ["with", 850], ["complete", 855], ["data", 864], [",", 868], ["the", 870], ["expert", 874], ["panel", 881], ["assigned", 887], ["a", 896], ["diagnosis", 898], ["of", 908], ["acute", 911], ["stroke", 917], ["or", 924], ["TIA", 927], ["in", 931], ["246", 934], ["and", 938], ["a", 942], ["diagnosis", 944], ["of", 954], ["mimic", 957], ["in", 963], ["110", 966], [".", 969], ["The", 971], ["ROSIER", 975], ["had", 982], ["a", 986], ["sensitivity", 988], ["of", 1000], ["83", 1003], ["%", 1005], ["(", 1007], ["95", 1008], ["%", 1010], ["CI", 1012], ["78", 1015], ["to", 1018], ["87", 1021], [")", 1023], ["and", 1025], ["specificity", 1029], ["of", 1041], ["44", 1044], ["%", 1046], ["(", 1048], ["95", 1049], ["%", 1051], ["CI", 1053], ["34", 1056], ["to", 1059], ["53", 1062], [")", 1064], [",", 1065], ["and", 1067], ["the", 1071], ["FAST", 1075], ["had", 1080], ["a", 1084], ["sensitivity", 1086], ["of", 1098], ["81", 1101], ["%", 1103], ["(", 1105], ["95", 1106], ["%", 1108], ["CI", 1110], ["76", 1113], ["to", 1116], ["86", 1119], [")", 1121], ["and", 1123], ["a", 1127], ["specificity", 1129], ["of", 1141], ["39", 1144], ["%", 1146], ["(", 1148], ["95", 1149], ["%", 1151], ["CI", 1153], ["30", 1156], ["to", 1159], ["48", 1162], [")", 1164], [".", 1165], ["There", 1167], ["was", 1173], ["no", 1177], ["detectable", 1180], ["difference", 1191], ["between", 1202], ["the", 1210], ["scales", 1214], ["in", 1221], ["sensitivity", 1224], ["(", 1236], ["p", 1237], ["=", 1239], ["0.39", 1241], [")", 1245], ["or", 1247], ["specificity", 1250], ["(", 1262], ["p", 1263], ["=", 1265], ["0.30", 1267], [")", 1271], [".", 1272], ["The", 1274], ["simpler", 1278], ["FAST", 1286], ["scale", 1291], ["could", 1297], ["replace", 1303], ["the", 1311], ["more", 1315], ["complex", 1320], ["ROSIER", 1328], ["for", 1335], ["the", 1339], ["initial", 1343], ["assessment", 1351], ["of", 1362], ["patients", 1365], ["with", 1374], ["suspected", 1379], ["acute", 1389], ["stroke", 1395], ["in", 1402], ["the", 1405], ["emergency", 1409], ["department", 1419], [".", 1429]]}
{"context": "MicroRNAs (miRNAs) play a major part in the post-transcriptional regulation of gene expression. Mammalian miRNA biogenesis begins with cotranscriptional cleavage of RNA polymerase II (Pol II) transcripts by the Microprocessor complex. Although most miRNAs are located within introns of protein-coding transcripts, a substantial minority of miRNAs originate from long noncoding (lnc) RNAs, for which transcript processing is largely uncharacterized. We show, by detailed characterization of liver-specific lnc-pri-miR-122 and genome-wide analysis in human cell lines, that most lncRNA transcripts containing miRNAs (lnc-pri-miRNAs) do not use the canonical cleavage-and-polyadenylation pathway but instead use Microprocessor cleavage to terminate transcription. Microprocessor inactivation leads to extensive transcriptional readthrough of lnc-pri-miRNA and transcriptional interference with downstream genes. Consequently we define a new RNase III-mediated, polyadenylation-independent mechanism of Pol II transcription termination in mammalian cells.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "cc8c050eacbc476399b7a6d1ccc9c404", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[26, 28]], "char_spans": [[165, 181]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["play", 19], ["a", 24], ["major", 26], ["part", 32], ["in", 37], ["the", 40], ["post", 44], ["-", 48], ["transcriptional", 49], ["regulation", 65], ["of", 76], ["gene", 79], ["expression", 84], [".", 94], ["Mammalian", 96], ["miRNA", 106], ["biogenesis", 112], ["begins", 123], ["with", 130], ["cotranscriptional", 135], ["cleavage", 153], ["of", 162], ["RNA", 165], ["polymerase", 169], ["II", 180], ["(", 183], ["Pol", 184], ["II", 188], [")", 190], ["transcripts", 192], ["by", 204], ["the", 207], ["Microprocessor", 211], ["complex", 226], [".", 233], ["Although", 235], ["most", 244], ["miRNAs", 249], ["are", 256], ["located", 260], ["within", 268], ["introns", 275], ["of", 283], ["protein", 286], ["-", 293], ["coding", 294], ["transcripts", 301], [",", 312], ["a", 314], ["substantial", 316], ["minority", 328], ["of", 337], ["miRNAs", 340], ["originate", 347], ["from", 357], ["long", 362], ["noncoding", 367], ["(", 377], ["lnc", 378], [")", 381], ["RNAs", 383], [",", 387], ["for", 389], ["which", 393], ["transcript", 399], ["processing", 410], ["is", 421], ["largely", 424], ["uncharacterized", 432], [".", 447], ["We", 449], ["show", 452], [",", 456], ["by", 458], ["detailed", 461], ["characterization", 470], ["of", 487], ["liver", 490], ["-", 495], ["specific", 496], ["lnc", 505], ["-", 508], ["pri", 509], ["-", 512], ["miR-122", 513], ["and", 521], ["genome", 525], ["-", 531], ["wide", 532], ["analysis", 537], ["in", 546], ["human", 549], ["cell", 555], ["lines", 560], [",", 565], ["that", 567], ["most", 572], ["lncRNA", 577], ["transcripts", 584], ["containing", 596], ["miRNAs", 607], ["(", 614], ["lnc", 615], ["-", 618], ["pri", 619], ["-", 622], ["miRNAs", 623], [")", 629], ["do", 631], ["not", 634], ["use", 638], ["the", 642], ["canonical", 646], ["cleavage", 656], ["-", 664], ["and", 665], ["-", 668], ["polyadenylation", 669], ["pathway", 685], ["but", 693], ["instead", 697], ["use", 705], ["Microprocessor", 709], ["cleavage", 724], ["to", 733], ["terminate", 736], ["transcription", 746], [".", 759], ["Microprocessor", 761], ["inactivation", 776], ["leads", 789], ["to", 795], ["extensive", 798], ["transcriptional", 808], ["readthrough", 824], ["of", 836], ["lnc", 839], ["-", 842], ["pri", 843], ["-", 846], ["miRNA", 847], ["and", 853], ["transcriptional", 857], ["interference", 873], ["with", 886], ["downstream", 891], ["genes", 902], [".", 907], ["Consequently", 909], ["we", 922], ["define", 925], ["a", 932], ["new", 934], ["RNase", 938], ["III", 944], ["-", 947], ["mediated", 948], [",", 956], ["polyadenylation", 958], ["-", 973], ["independent", 974], ["mechanism", 986], ["of", 996], ["Pol", 999], ["II", 1003], ["transcription", 1006], ["termination", 1020], ["in", 1032], ["mammalian", 1035], ["cells", 1045], [".", 1050]]}
{"context": "The apolipoprotein E (ApoE) \u03b54 allele is the strongest risk factor of sporadic Alzheimer's disease (AD), however, the fluid concentrations of ApoE and its different isoforms (ApoE2, ApoE3 and ApoE4) in AD patients and among APOE genotypes (APOE \u03b52, \u03b53, \u03b54) remain controversial. Using a novel mass spectrometry-based method, we quantified total ApoE and specific ApoE isoform concentrations and potential associations with age, cognitive status, cholesterol levels and established AD biomarkers in cerebrospinal fluid (CSF) from AD patients versus non-AD individuals with different APOE genotypes. We also investigated plasma total ApoE and ApoE isoform composition in a subset of these individuals. In total n = 43 AD and n = 43 non-AD subjects were included. We found that CSF and plasma total ApoE levels did not correlate with age or cognitive status and did not differ between AD and non-AD subjects deeming ApoE as an unfit diagnostic marker for AD. Also, whereas CSF ApoE levels did not vary between APOE genotypes APOE \u03b54 carriers exhibited significantly decreased plasma ApoE levels attributed to a specific decrease in the ApoE4 isoform concentrations. CSF total ApoE concentrations were positively associated with CSF, total tau, tau phosphorylated at Thr181 and A\u03b21-42 of which the latter association was weaker and only present in APOE \u03b54 carriers indicating a differential involvement of ApoE in tau versus A\u03b2-linked neuropathological processes. Future studies need to elucidate whether the observed plasma ApoE4 deficiency is a life-long condition in APOE \u025b4 carriers and whether this decrease in plasma ApoE predisposes APOE \u025b4 carriers to AD.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "19f812e350824082b6b21522a0ba9fa9", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[210, 211]], "char_spans": [[1133, 1145]]}]}], "context_tokens": [["The", 0], ["apolipoprotein", 4], ["E", 19], ["(", 21], ["ApoE", 22], [")", 26], ["\u03b54", 28], ["allele", 31], ["is", 38], ["the", 41], ["strongest", 45], ["risk", 55], ["factor", 60], ["of", 67], ["sporadic", 70], ["Alzheimer", 79], ["'s", 88], ["disease", 91], ["(", 99], ["AD", 100], [")", 102], [",", 103], ["however", 105], [",", 112], ["the", 114], ["fluid", 118], ["concentrations", 124], ["of", 139], ["ApoE", 142], ["and", 147], ["its", 151], ["different", 155], ["isoforms", 165], ["(", 174], ["ApoE2", 175], [",", 180], ["ApoE3", 182], ["and", 188], ["ApoE4", 192], [")", 197], ["in", 199], ["AD", 202], ["patients", 205], ["and", 214], ["among", 218], ["APOE", 224], ["genotypes", 229], ["(", 239], ["APOE", 240], ["\u03b52", 245], [",", 247], ["\u03b53", 249], [",", 251], ["\u03b54", 253], [")", 255], ["remain", 257], ["controversial", 264], [".", 277], ["Using", 279], ["a", 285], ["novel", 287], ["mass", 293], ["spectrometry", 298], ["-", 310], ["based", 311], ["method", 317], [",", 323], ["we", 325], ["quantified", 328], ["total", 339], ["ApoE", 345], ["and", 350], ["specific", 354], ["ApoE", 363], ["isoform", 368], ["concentrations", 376], ["and", 391], ["potential", 395], ["associations", 405], ["with", 418], ["age", 423], [",", 426], ["cognitive", 428], ["status", 438], [",", 444], ["cholesterol", 446], ["levels", 458], ["and", 465], ["established", 469], ["AD", 481], ["biomarkers", 484], ["in", 495], ["cerebrospinal", 498], ["fluid", 512], ["(", 518], ["CSF", 519], [")", 522], ["from", 524], ["AD", 529], ["patients", 532], ["versus", 541], ["non", 548], ["-", 551], ["AD", 552], ["individuals", 555], ["with", 567], ["different", 572], ["APOE", 582], ["genotypes", 587], [".", 596], ["We", 598], ["also", 601], ["investigated", 606], ["plasma", 619], ["total", 626], ["ApoE", 632], ["and", 637], ["ApoE", 641], ["isoform", 646], ["composition", 654], ["in", 666], ["a", 669], ["subset", 671], ["of", 678], ["these", 681], ["individuals", 687], [".", 698], ["In", 700], ["total", 703], ["n", 709], ["=", 711], ["43", 713], ["AD", 716], ["and", 719], ["n", 723], ["=", 725], ["43", 727], ["non", 730], ["-", 733], ["AD", 734], ["subjects", 737], ["were", 746], ["included", 751], [".", 759], ["We", 761], ["found", 764], ["that", 770], ["CSF", 775], ["and", 779], ["plasma", 783], ["total", 790], ["ApoE", 796], ["levels", 801], ["did", 808], ["not", 812], ["correlate", 816], ["with", 826], ["age", 831], ["or", 835], ["cognitive", 838], ["status", 848], ["and", 855], ["did", 859], ["not", 863], ["differ", 867], ["between", 874], ["AD", 882], ["and", 885], ["non", 889], ["-", 892], ["AD", 893], ["subjects", 896], ["deeming", 905], ["ApoE", 913], ["as", 918], ["an", 921], ["unfit", 924], ["diagnostic", 930], ["marker", 941], ["for", 948], ["AD", 952], [".", 954], ["Also", 956], [",", 960], ["whereas", 962], ["CSF", 970], ["ApoE", 974], ["levels", 979], ["did", 986], ["not", 990], ["vary", 994], ["between", 999], ["APOE", 1007], ["genotypes", 1012], ["APOE", 1022], ["\u03b54", 1027], ["carriers", 1030], ["exhibited", 1039], ["significantly", 1049], ["decreased", 1063], ["plasma", 1073], ["ApoE", 1080], ["levels", 1085], ["attributed", 1092], ["to", 1103], ["a", 1106], ["specific", 1108], ["decrease", 1117], ["in", 1126], ["the", 1129], ["ApoE4", 1133], ["isoform", 1139], ["concentrations", 1147], [".", 1161], ["CSF", 1163], ["total", 1167], ["ApoE", 1173], ["concentrations", 1178], ["were", 1193], ["positively", 1198], ["associated", 1209], ["with", 1220], ["CSF", 1225], [",", 1228], ["total", 1230], ["tau", 1236], [",", 1239], ["tau", 1241], ["phosphorylated", 1245], ["at", 1260], ["Thr181", 1263], ["and", 1270], ["A\u03b21", 1274], ["-", 1277], ["42", 1278], ["of", 1281], ["which", 1284], ["the", 1290], ["latter", 1294], ["association", 1301], ["was", 1313], ["weaker", 1317], ["and", 1324], ["only", 1328], ["present", 1333], ["in", 1341], ["APOE", 1344], ["\u03b54", 1349], ["carriers", 1352], ["indicating", 1361], ["a", 1372], ["differential", 1374], ["involvement", 1387], ["of", 1399], ["ApoE", 1402], ["in", 1407], ["tau", 1410], ["versus", 1414], ["A\u03b2", 1421], ["-", 1423], ["linked", 1424], ["neuropathological", 1431], ["processes", 1449], [".", 1458], ["Future", 1460], ["studies", 1467], ["need", 1475], ["to", 1480], ["elucidate", 1483], ["whether", 1493], ["the", 1501], ["observed", 1505], ["plasma", 1514], ["ApoE4", 1521], ["deficiency", 1527], ["is", 1538], ["a", 1541], ["life", 1543], ["-", 1547], ["long", 1548], ["condition", 1553], ["in", 1563], ["APOE", 1566], ["\u025b4", 1571], ["carriers", 1574], ["and", 1583], ["whether", 1587], ["this", 1595], ["decrease", 1600], ["in", 1609], ["plasma", 1612], ["ApoE", 1619], ["predisposes", 1624], ["APOE", 1636], ["\u025b4", 1641], ["carriers", 1644], ["to", 1653], ["AD", 1656], [".", 1658]]}
{"context": "Epidemiology of Clostridium difficile is characterized by worldwide increase of C. difficile infections (CDI) and the emergence of new epidemic outbreak strains with the capacity for global spreading. Long-term local surveillance at the University of Saarland Medical Center between 2000 and 2013 shows that the incidence rate of laboratory-confirmed CDI was influenced by local epidemiology as well as by testing strategies. Since 2008, molecular typing of C. difficile was regularly performed for symptomatic hospitalized patients by surface-layer protein A sequence typing (slpAST), which is an established highly standardized technique for genotyping of C. difficile. The results were assigned to known ribotypes for better comparison to international data. It could be demonstrated that distribution of genotypes was different between age groups. Older patients were predominantly infected with ribotype 001 and 027, whereas ribotype 027 was not detected in the pediatric population. Molecular typing of German isolates sent to the advisory laboratory between 2011 and 2013 revealed that ribotype 027 is present with high percentages in most German regions except for the very North. In conclusion, optimized testing of all hospitalized patients with diarrhea should be generally implemented to avoid under-diagnosis of C. difficile infection. Ribotype 027 is highly prevalent in Germany, but its infections are restricted to older patients, while absent in children. Molecular typing of suspected hospital outbreaks and of patients with severe or recurrent disease may help to better understand virulence and epidemic spreading of C. difficile.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "e08396e636f94ad19455f09fad2df0c8", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[149, 150], [175, 176], [217, 218]], "char_spans": [[930, 941], [1093, 1104], [1349, 1360]]}]}], "context_tokens": [["Epidemiology", 0], ["of", 13], ["Clostridium", 16], ["difficile", 28], ["is", 38], ["characterized", 41], ["by", 55], ["worldwide", 58], ["increase", 68], ["of", 77], ["C.", 80], ["difficile", 83], ["infections", 93], ["(", 104], ["CDI", 105], [")", 108], ["and", 110], ["the", 114], ["emergence", 118], ["of", 128], ["new", 131], ["epidemic", 135], ["outbreak", 144], ["strains", 153], ["with", 161], ["the", 166], ["capacity", 170], ["for", 179], ["global", 183], ["spreading", 190], [".", 199], ["Long", 201], ["-", 205], ["term", 206], ["local", 211], ["surveillance", 217], ["at", 230], ["the", 233], ["University", 237], ["of", 248], ["Saarland", 251], ["Medical", 260], ["Center", 268], ["between", 275], ["2000", 283], ["and", 288], ["2013", 292], ["shows", 297], ["that", 303], ["the", 308], ["incidence", 312], ["rate", 322], ["of", 327], ["laboratory", 330], ["-", 340], ["confirmed", 341], ["CDI", 351], ["was", 355], ["influenced", 359], ["by", 370], ["local", 373], ["epidemiology", 379], ["as", 392], ["well", 395], ["as", 400], ["by", 403], ["testing", 406], ["strategies", 414], [".", 424], ["Since", 426], ["2008", 432], [",", 436], ["molecular", 438], ["typing", 448], ["of", 455], ["C.", 458], ["difficile", 461], ["was", 471], ["regularly", 475], ["performed", 485], ["for", 495], ["symptomatic", 499], ["hospitalized", 511], ["patients", 524], ["by", 533], ["surface", 536], ["-", 543], ["layer", 544], ["protein", 550], ["A", 558], ["sequence", 560], ["typing", 569], ["(", 576], ["slpAST", 577], [")", 583], [",", 584], ["which", 586], ["is", 592], ["an", 595], ["established", 598], ["highly", 610], ["standardized", 617], ["technique", 630], ["for", 640], ["genotyping", 644], ["of", 655], ["C.", 658], ["difficile", 661], [".", 670], ["The", 672], ["results", 676], ["were", 684], ["assigned", 689], ["to", 698], ["known", 701], ["ribotypes", 707], ["for", 717], ["better", 721], ["comparison", 728], ["to", 739], ["international", 742], ["data", 756], [".", 760], ["It", 762], ["could", 765], ["be", 771], ["demonstrated", 774], ["that", 787], ["distribution", 792], ["of", 805], ["genotypes", 808], ["was", 818], ["different", 822], ["between", 832], ["age", 840], ["groups", 844], [".", 850], ["Older", 852], ["patients", 858], ["were", 867], ["predominantly", 872], ["infected", 886], ["with", 895], ["ribotype", 900], ["001", 909], ["and", 913], ["027", 917], [",", 920], ["whereas", 922], ["ribotype", 930], ["027", 939], ["was", 943], ["not", 947], ["detected", 951], ["in", 960], ["the", 963], ["pediatric", 967], ["population", 977], [".", 987], ["Molecular", 989], ["typing", 999], ["of", 1006], ["German", 1009], ["isolates", 1016], ["sent", 1025], ["to", 1030], ["the", 1033], ["advisory", 1037], ["laboratory", 1046], ["between", 1057], ["2011", 1065], ["and", 1070], ["2013", 1074], ["revealed", 1079], ["that", 1088], ["ribotype", 1093], ["027", 1102], ["is", 1106], ["present", 1109], ["with", 1117], ["high", 1122], ["percentages", 1127], ["in", 1139], ["most", 1142], ["German", 1147], ["regions", 1154], ["except", 1162], ["for", 1169], ["the", 1173], ["very", 1177], ["North", 1182], [".", 1187], ["In", 1189], ["conclusion", 1192], [",", 1202], ["optimized", 1204], ["testing", 1214], ["of", 1222], ["all", 1225], ["hospitalized", 1229], ["patients", 1242], ["with", 1251], ["diarrhea", 1256], ["should", 1265], ["be", 1272], ["generally", 1275], ["implemented", 1285], ["to", 1297], ["avoid", 1300], ["under", 1306], ["-", 1311], ["diagnosis", 1312], ["of", 1322], ["C.", 1325], ["difficile", 1328], ["infection", 1338], [".", 1347], ["Ribotype", 1349], ["027", 1358], ["is", 1362], ["highly", 1365], ["prevalent", 1372], ["in", 1382], ["Germany", 1385], [",", 1392], ["but", 1394], ["its", 1398], ["infections", 1402], ["are", 1413], ["restricted", 1417], ["to", 1428], ["older", 1431], ["patients", 1437], [",", 1445], ["while", 1447], ["absent", 1453], ["in", 1460], ["children", 1463], [".", 1471], ["Molecular", 1473], ["typing", 1483], ["of", 1490], ["suspected", 1493], ["hospital", 1503], ["outbreaks", 1512], ["and", 1522], ["of", 1526], ["patients", 1529], ["with", 1538], ["severe", 1543], ["or", 1550], ["recurrent", 1553], ["disease", 1563], ["may", 1571], ["help", 1575], ["to", 1580], ["better", 1583], ["understand", 1590], ["virulence", 1601], ["and", 1611], ["epidemic", 1615], ["spreading", 1624], ["of", 1634], ["C.", 1637], ["difficile", 1640], [".", 1649]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a common form of muscular dystrophy characterized by an asymmetric progressive weakness and wasting of the facial, shoulder and upper arm muscles, frequently accompanied by hearing loss and retinal vasculopathy. FSHD is an autosomal dominant disease linked to chromosome 4q35, but the causative gene remains controversial. DUX4 is a leading candidate gene as causative of FSHD. However, DUX4 expression is extremely low in FSHD muscle, and there is no DUX4 animal model that mirrors the pathology in human FSHD. Here, we show that the misexpression of very low levels of human DUX4 in zebrafish development recapitulates the phenotypes seen in human FSHD patients. Microinjection of small amounts of human full-length DUX4 (DUX4-fl) mRNA into fertilized zebrafish eggs caused asymmetric abnormalities such as less pigmentation of the eyes, altered morphology of ears, developmental abnormality of fin muscle, disorganization of facial musculature and/or degeneration of trunk muscle later in development. Moreover, DUX4-fl expression caused aberrant localization of myogenic cells marked with \u03b1-actin promoter-driven enhanced green fluorescent protein outside somite boundary, especially in head region. These abnormalities were rescued by coinjection of the short form of DUX4 (DUX4-s). Our results suggest that the misexpression of DUX4-fl, even at extremely low level, can recapitulate the phenotype observed in FSHD patients in a vertebrate model. These results strongly support the current hypothesis for a role of DUX4 in FSHD pathogenesis. We also propose that DUX4 expression during development is important for the pathogenesis of FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "69c2179d41c04582949a39853d960dbb", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[93, 93], [67, 67], [77, 77], [118, 118], [262, 262], [4, 4], [279, 279], [40, 40], [242, 242]], "char_spans": [[555, 558], [421, 424], [472, 475], [699, 702], [1577, 1580], [40, 43], [1689, 1692], [261, 264], [1464, 1467]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["common", 51], ["form", 58], ["of", 63], ["muscular", 66], ["dystrophy", 75], ["characterized", 85], ["by", 99], ["an", 102], ["asymmetric", 105], ["progressive", 116], ["weakness", 128], ["and", 137], ["wasting", 141], ["of", 149], ["the", 152], ["facial", 156], [",", 162], ["shoulder", 164], ["and", 173], ["upper", 177], ["arm", 183], ["muscles", 187], [",", 194], ["frequently", 196], ["accompanied", 207], ["by", 219], ["hearing", 222], ["loss", 230], ["and", 235], ["retinal", 239], ["vasculopathy", 247], [".", 259], ["FSHD", 261], ["is", 266], ["an", 269], ["autosomal", 272], ["dominant", 282], ["disease", 291], ["linked", 299], ["to", 306], ["chromosome", 309], ["4q35", 320], [",", 324], ["but", 326], ["the", 330], ["causative", 334], ["gene", 344], ["remains", 349], ["controversial", 357], [".", 370], ["DUX4", 372], ["is", 377], ["a", 380], ["leading", 382], ["candidate", 390], ["gene", 400], ["as", 405], ["causative", 408], ["of", 418], ["FSHD", 421], [".", 425], ["However", 427], [",", 434], ["DUX4", 436], ["expression", 441], ["is", 452], ["extremely", 455], ["low", 465], ["in", 469], ["FSHD", 472], ["muscle", 477], [",", 483], ["and", 485], ["there", 489], ["is", 495], ["no", 498], ["DUX4", 501], ["animal", 506], ["model", 513], ["that", 519], ["mirrors", 524], ["the", 532], ["pathology", 536], ["in", 546], ["human", 549], ["FSHD", 555], [".", 559], ["Here", 561], [",", 565], ["we", 567], ["show", 570], ["that", 575], ["the", 580], ["misexpression", 584], ["of", 598], ["very", 601], ["low", 606], ["levels", 610], ["of", 617], ["human", 620], ["DUX4", 626], ["in", 631], ["zebrafish", 634], ["development", 644], ["recapitulates", 656], ["the", 670], ["phenotypes", 674], ["seen", 685], ["in", 690], ["human", 693], ["FSHD", 699], ["patients", 704], [".", 712], ["Microinjection", 714], ["of", 729], ["small", 732], ["amounts", 738], ["of", 746], ["human", 749], ["full", 755], ["-", 759], ["length", 760], ["DUX4", 767], ["(", 772], ["DUX4-fl", 773], [")", 780], ["mRNA", 782], ["into", 787], ["fertilized", 792], ["zebrafish", 803], ["eggs", 813], ["caused", 818], ["asymmetric", 825], ["abnormalities", 836], ["such", 850], ["as", 855], ["less", 858], ["pigmentation", 863], ["of", 876], ["the", 879], ["eyes", 883], [",", 887], ["altered", 889], ["morphology", 897], ["of", 908], ["ears", 911], [",", 915], ["developmental", 917], ["abnormality", 931], ["of", 943], ["fin", 946], ["muscle", 950], [",", 956], ["disorganization", 958], ["of", 974], ["facial", 977], ["musculature", 984], ["and/or", 996], ["degeneration", 1003], ["of", 1016], ["trunk", 1019], ["muscle", 1025], ["later", 1032], ["in", 1038], ["development", 1041], [".", 1052], ["Moreover", 1054], [",", 1062], ["DUX4-fl", 1064], ["expression", 1072], ["caused", 1083], ["aberrant", 1090], ["localization", 1099], ["of", 1112], ["myogenic", 1115], ["cells", 1124], ["marked", 1130], ["with", 1137], ["\u03b1", 1142], ["-", 1143], ["actin", 1144], ["promoter", 1150], ["-", 1158], ["driven", 1159], ["enhanced", 1166], ["green", 1175], ["fluorescent", 1181], ["protein", 1193], ["outside", 1201], ["somite", 1209], ["boundary", 1216], [",", 1224], ["especially", 1226], ["in", 1237], ["head", 1240], ["region", 1245], [".", 1251], ["These", 1253], ["abnormalities", 1259], ["were", 1273], ["rescued", 1278], ["by", 1286], ["coinjection", 1289], ["of", 1301], ["the", 1304], ["short", 1308], ["form", 1314], ["of", 1319], ["DUX4", 1322], ["(", 1327], ["DUX4-s", 1328], [")", 1334], [".", 1335], ["Our", 1337], ["results", 1341], ["suggest", 1349], ["that", 1357], ["the", 1362], ["misexpression", 1366], ["of", 1380], ["DUX4-fl", 1383], [",", 1390], ["even", 1392], ["at", 1397], ["extremely", 1400], ["low", 1410], ["level", 1414], [",", 1419], ["can", 1421], ["recapitulate", 1425], ["the", 1438], ["phenotype", 1442], ["observed", 1452], ["in", 1461], ["FSHD", 1464], ["patients", 1469], ["in", 1478], ["a", 1481], ["vertebrate", 1483], ["model", 1494], [".", 1499], ["These", 1501], ["results", 1507], ["strongly", 1515], ["support", 1524], ["the", 1532], ["current", 1536], ["hypothesis", 1544], ["for", 1555], ["a", 1559], ["role", 1561], ["of", 1566], ["DUX4", 1569], ["in", 1574], ["FSHD", 1577], ["pathogenesis", 1582], [".", 1594], ["We", 1596], ["also", 1599], ["propose", 1604], ["that", 1612], ["DUX4", 1617], ["expression", 1622], ["during", 1633], ["development", 1640], ["is", 1652], ["important", 1655], ["for", 1665], ["the", 1669], ["pathogenesis", 1673], ["of", 1686], ["FSHD", 1689], [".", 1693]]}
{"context": "Nucleotide excision repair (NER) mechanism is the major pathway responsible for the removal of a large variety of bulky lesions from the genome. Two different NER subpathways have been identified, i.e. the transcription-coupled and the global genome repair pathways. For DNA-damage induced by ultraviolet light both transcription-coupled repair and global genome repair are essential to confer resistance to cytotoxic effects. To gain further insight into the contribution of NER subpathways in the repair of bulky lesions and in their prevention of biological effects we measured the rate of repair of dG-C8-AF in active and inactive genes in normal human cells, XP-C cells (only transcription-coupled repair) and XP-A cells (completely NER-deficient) exposed to NA-AAF. XP-C cells are only slightly more sensitive to NA-AAF than normal cells and, like normal cells, they are able to recover RNA synthesis repressed by the treatment. In contrast, XP-A cells are sensitive to NA-AAF and unable to recover from RNA synthesis inhibition. Repair of dG-C8-AF in the active ADA gene proceeds in a biphasic way and without strand specificity, with a subclass of lesions quickly repaired during the first 8 h after treatment. Repair in the inactive 754 gene occurs more slowly than in the ADA gene. In XP-C cells, repair of dG-C8-AF in the ADA gene is confined to the transcribed strand and occurs at about half the rate of repair seen in normal cells. Repair in the inactive 754 gene in XP-C cells is virtually absent. Consistent with these results we found that repair replication in XP-C is drastically reduced when compared with normal cells and abolished by alpha-amanitin indicating that the repair in XP-C cells is mediated by transcription-coupled repair only. Our data suggest that dG-C8-AF is a target for transcription-coupled repair and that this repair pathway is the main pathway or recovery of RNA synthesis inhibition conferring resistance to cytotoxic effects of NA-AAF. In spite of this, repair of dG-C8-AF in active genes in normal cells by transcription-coupled repair and global genome repair is not additive, but dominated by global genome repair. This indicates that the subset of lesions which are capable of stalling RNA polymerase II, and are, therefore, a substrate for TCR, are also the lesions which are very efficiently recognized by the global genome repair system.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "bcb2d242686c440fb698f05cac959004", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[268, 269]], "char_spans": [[1361, 1378]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], ["mechanism", 33], ["is", 43], ["the", 46], ["major", 50], ["pathway", 56], ["responsible", 64], ["for", 76], ["the", 80], ["removal", 84], ["of", 92], ["a", 95], ["large", 97], ["variety", 103], ["of", 111], ["bulky", 114], ["lesions", 120], ["from", 128], ["the", 133], ["genome", 137], [".", 143], ["Two", 145], ["different", 149], ["NER", 159], ["subpathways", 163], ["have", 175], ["been", 180], ["identified", 185], [",", 195], ["i.e.", 197], ["the", 202], ["transcription", 206], ["-", 219], ["coupled", 220], ["and", 228], ["the", 232], ["global", 236], ["genome", 243], ["repair", 250], ["pathways", 257], [".", 265], ["For", 267], ["DNA", 271], ["-", 274], ["damage", 275], ["induced", 282], ["by", 290], ["ultraviolet", 293], ["light", 305], ["both", 311], ["transcription", 316], ["-", 329], ["coupled", 330], ["repair", 338], ["and", 345], ["global", 349], ["genome", 356], ["repair", 363], ["are", 370], ["essential", 374], ["to", 384], ["confer", 387], ["resistance", 394], ["to", 405], ["cytotoxic", 408], ["effects", 418], [".", 425], ["To", 427], ["gain", 430], ["further", 435], ["insight", 443], ["into", 451], ["the", 456], ["contribution", 460], ["of", 473], ["NER", 476], ["subpathways", 480], ["in", 492], ["the", 495], ["repair", 499], ["of", 506], ["bulky", 509], ["lesions", 515], ["and", 523], ["in", 527], ["their", 530], ["prevention", 536], ["of", 547], ["biological", 550], ["effects", 561], ["we", 569], ["measured", 572], ["the", 581], ["rate", 585], ["of", 590], ["repair", 593], ["of", 600], ["dG", 603], ["-", 605], ["C8-AF", 606], ["in", 612], ["active", 615], ["and", 622], ["inactive", 626], ["genes", 635], ["in", 641], ["normal", 644], ["human", 651], ["cells", 657], [",", 662], ["XP", 664], ["-", 666], ["C", 667], ["cells", 669], ["(", 675], ["only", 676], ["transcription", 681], ["-", 694], ["coupled", 695], ["repair", 703], [")", 709], ["and", 711], ["XP", 715], ["-", 717], ["A", 718], ["cells", 720], ["(", 726], ["completely", 727], ["NER", 738], ["-", 741], ["deficient", 742], [")", 751], ["exposed", 753], ["to", 761], ["NA", 764], ["-", 766], ["AAF", 767], [".", 770], ["XP", 772], ["-", 774], ["C", 775], ["cells", 777], ["are", 783], ["only", 787], ["slightly", 792], ["more", 801], ["sensitive", 806], ["to", 816], ["NA", 819], ["-", 821], ["AAF", 822], ["than", 826], ["normal", 831], ["cells", 838], ["and", 844], [",", 847], ["like", 849], ["normal", 854], ["cells", 861], [",", 866], ["they", 868], ["are", 873], ["able", 877], ["to", 882], ["recover", 885], ["RNA", 893], ["synthesis", 897], ["repressed", 907], ["by", 917], ["the", 920], ["treatment", 924], [".", 933], ["In", 935], ["contrast", 938], [",", 946], ["XP", 948], ["-", 950], ["A", 951], ["cells", 953], ["are", 959], ["sensitive", 963], ["to", 973], ["NA", 976], ["-", 978], ["AAF", 979], ["and", 983], ["unable", 987], ["to", 994], ["recover", 997], ["from", 1005], ["RNA", 1010], ["synthesis", 1014], ["inhibition", 1024], [".", 1034], ["Repair", 1036], ["of", 1043], ["dG", 1046], ["-", 1048], ["C8-AF", 1049], ["in", 1055], ["the", 1058], ["active", 1062], ["ADA", 1069], ["gene", 1073], ["proceeds", 1078], ["in", 1087], ["a", 1090], ["biphasic", 1092], ["way", 1101], ["and", 1105], ["without", 1109], ["strand", 1117], ["specificity", 1124], [",", 1135], ["with", 1137], ["a", 1142], ["subclass", 1144], ["of", 1153], ["lesions", 1156], ["quickly", 1164], ["repaired", 1172], ["during", 1181], ["the", 1188], ["first", 1192], ["8", 1198], ["h", 1200], ["after", 1202], ["treatment", 1208], [".", 1217], ["Repair", 1219], ["in", 1226], ["the", 1229], ["inactive", 1233], ["754", 1242], ["gene", 1246], ["occurs", 1251], ["more", 1258], ["slowly", 1263], ["than", 1270], ["in", 1275], ["the", 1278], ["ADA", 1282], ["gene", 1286], [".", 1290], ["In", 1292], ["XP", 1295], ["-", 1297], ["C", 1298], ["cells", 1300], [",", 1305], ["repair", 1307], ["of", 1314], ["dG", 1317], ["-", 1319], ["C8-AF", 1320], ["in", 1326], ["the", 1329], ["ADA", 1333], ["gene", 1337], ["is", 1342], ["confined", 1345], ["to", 1354], ["the", 1357], ["transcribed", 1361], ["strand", 1373], ["and", 1380], ["occurs", 1384], ["at", 1391], ["about", 1394], ["half", 1400], ["the", 1405], ["rate", 1409], ["of", 1414], ["repair", 1417], ["seen", 1424], ["in", 1429], ["normal", 1432], ["cells", 1439], [".", 1444], ["Repair", 1446], ["in", 1453], ["the", 1456], ["inactive", 1460], ["754", 1469], ["gene", 1473], ["in", 1478], ["XP", 1481], ["-", 1483], ["C", 1484], ["cells", 1486], ["is", 1492], ["virtually", 1495], ["absent", 1505], [".", 1511], ["Consistent", 1513], ["with", 1524], ["these", 1529], ["results", 1535], ["we", 1543], ["found", 1546], ["that", 1552], ["repair", 1557], ["replication", 1564], ["in", 1576], ["XP", 1579], ["-", 1581], ["C", 1582], ["is", 1584], ["drastically", 1587], ["reduced", 1599], ["when", 1607], ["compared", 1612], ["with", 1621], ["normal", 1626], ["cells", 1633], ["and", 1639], ["abolished", 1643], ["by", 1653], ["alpha", 1656], ["-", 1661], ["amanitin", 1662], ["indicating", 1671], ["that", 1682], ["the", 1687], ["repair", 1691], ["in", 1698], ["XP", 1701], ["-", 1703], ["C", 1704], ["cells", 1706], ["is", 1712], ["mediated", 1715], ["by", 1724], ["transcription", 1727], ["-", 1740], ["coupled", 1741], ["repair", 1749], ["only", 1756], [".", 1760], ["Our", 1762], ["data", 1766], ["suggest", 1771], ["that", 1779], ["dG", 1784], ["-", 1786], ["C8-AF", 1787], ["is", 1793], ["a", 1796], ["target", 1798], ["for", 1805], ["transcription", 1809], ["-", 1822], ["coupled", 1823], ["repair", 1831], ["and", 1838], ["that", 1842], ["this", 1847], ["repair", 1852], ["pathway", 1859], ["is", 1867], ["the", 1870], ["main", 1874], ["pathway", 1879], ["or", 1887], ["recovery", 1890], ["of", 1899], ["RNA", 1902], ["synthesis", 1906], ["inhibition", 1916], ["conferring", 1927], ["resistance", 1938], ["to", 1949], ["cytotoxic", 1952], ["effects", 1962], ["of", 1970], ["NA", 1973], ["-", 1975], ["AAF", 1976], [".", 1979], ["In", 1981], ["spite", 1984], ["of", 1990], ["this", 1993], [",", 1997], ["repair", 1999], ["of", 2006], ["dG", 2009], ["-", 2011], ["C8-AF", 2012], ["in", 2018], ["active", 2021], ["genes", 2028], ["in", 2034], ["normal", 2037], ["cells", 2044], ["by", 2050], ["transcription", 2053], ["-", 2066], ["coupled", 2067], ["repair", 2075], ["and", 2082], ["global", 2086], ["genome", 2093], ["repair", 2100], ["is", 2107], ["not", 2110], ["additive", 2114], [",", 2122], ["but", 2124], ["dominated", 2128], ["by", 2138], ["global", 2141], ["genome", 2148], ["repair", 2155], [".", 2161], ["This", 2163], ["indicates", 2168], ["that", 2178], ["the", 2183], ["subset", 2187], ["of", 2194], ["lesions", 2197], ["which", 2205], ["are", 2211], ["capable", 2215], ["of", 2223], ["stalling", 2226], ["RNA", 2235], ["polymerase", 2239], ["II", 2250], [",", 2252], ["and", 2254], ["are", 2258], [",", 2261], ["therefore", 2263], [",", 2272], ["a", 2274], ["substrate", 2276], ["for", 2286], ["TCR", 2290], [",", 2293], ["are", 2295], ["also", 2299], ["the", 2304], ["lesions", 2308], ["which", 2316], ["are", 2322], ["very", 2326], ["efficiently", 2331], ["recognized", 2343], ["by", 2354], ["the", 2357], ["global", 2361], ["genome", 2368], ["repair", 2375], ["system", 2382], [".", 2388]]}
{"context": "Osteoporosis and several other bone disorders occur when there is an imbalance between the resorption and formation components of bone remodeling activity. Therapies available for some of these conditions modulate the activity of osteoclasts and/or osteoblasts. The recent discoveries of receptor activator of NF-kappaB ligand (RANKL), an endogenous activator of osteoclastogenenesis and osteoclast activity and its inhibitor, osteoprotegerin (OPG) as pivotal regulatory factors in the pathogenesis of bone diseases like osteoporosis provide unique targets for therapeutic agents. In laboratory animals and now in humans, administering forms of OPG markedly inhibits osteoclast activity and improves bone strength, documenting that the strategy of inhibiting RANKL activity has therapeutic promise. A highly specific, fully human antibody against RANKL has been produced (denosumab) that in early studies in humans reduces bone turnover and improves bone density. Attributes of denosumab in these clinical studies include a very rapid onset of action, sustained effects for several months after a single injection, and good tolerability. These results provide the basis for studies evaluating the effectiveness of denosumab in several clinical conditions characterized by increased osteoclastic activity.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "93cde7c0b055488588b25d93e9cddb8a", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[129, 129], [115, 115], [50, 50]], "char_spans": [[847, 851], [759, 763], [328, 332]]}]}], "context_tokens": [["Osteoporosis", 0], ["and", 13], ["several", 17], ["other", 25], ["bone", 31], ["disorders", 36], ["occur", 46], ["when", 52], ["there", 57], ["is", 63], ["an", 66], ["imbalance", 69], ["between", 79], ["the", 87], ["resorption", 91], ["and", 102], ["formation", 106], ["components", 116], ["of", 127], ["bone", 130], ["remodeling", 135], ["activity", 146], [".", 154], ["Therapies", 156], ["available", 166], ["for", 176], ["some", 180], ["of", 185], ["these", 188], ["conditions", 194], ["modulate", 205], ["the", 214], ["activity", 218], ["of", 227], ["osteoclasts", 230], ["and/or", 242], ["osteoblasts", 249], [".", 260], ["The", 262], ["recent", 266], ["discoveries", 273], ["of", 285], ["receptor", 288], ["activator", 297], ["of", 307], ["NF", 310], ["-", 312], ["kappaB", 313], ["ligand", 320], ["(", 327], ["RANKL", 328], [")", 333], [",", 334], ["an", 336], ["endogenous", 339], ["activator", 350], ["of", 360], ["osteoclastogenenesis", 363], ["and", 384], ["osteoclast", 388], ["activity", 399], ["and", 408], ["its", 412], ["inhibitor", 416], [",", 425], ["osteoprotegerin", 427], ["(", 443], ["OPG", 444], [")", 447], ["as", 449], ["pivotal", 452], ["regulatory", 460], ["factors", 471], ["in", 479], ["the", 482], ["pathogenesis", 486], ["of", 499], ["bone", 502], ["diseases", 507], ["like", 516], ["osteoporosis", 521], ["provide", 534], ["unique", 542], ["targets", 549], ["for", 557], ["therapeutic", 561], ["agents", 573], [".", 579], ["In", 581], ["laboratory", 584], ["animals", 595], ["and", 603], ["now", 607], ["in", 611], ["humans", 614], [",", 620], ["administering", 622], ["forms", 636], ["of", 642], ["OPG", 645], ["markedly", 649], ["inhibits", 658], ["osteoclast", 667], ["activity", 678], ["and", 687], ["improves", 691], ["bone", 700], ["strength", 705], [",", 713], ["documenting", 715], ["that", 727], ["the", 732], ["strategy", 736], ["of", 745], ["inhibiting", 748], ["RANKL", 759], ["activity", 765], ["has", 774], ["therapeutic", 778], ["promise", 790], [".", 797], ["A", 799], ["highly", 801], ["specific", 808], [",", 816], ["fully", 818], ["human", 824], ["antibody", 830], ["against", 839], ["RANKL", 847], ["has", 853], ["been", 857], ["produced", 862], ["(", 871], ["denosumab", 872], [")", 881], ["that", 883], ["in", 888], ["early", 891], ["studies", 897], ["in", 905], ["humans", 908], ["reduces", 915], ["bone", 923], ["turnover", 928], ["and", 937], ["improves", 941], ["bone", 950], ["density", 955], [".", 962], ["Attributes", 964], ["of", 975], ["denosumab", 978], ["in", 988], ["these", 991], ["clinical", 997], ["studies", 1006], ["include", 1014], ["a", 1022], ["very", 1024], ["rapid", 1029], ["onset", 1035], ["of", 1041], ["action", 1044], [",", 1050], ["sustained", 1052], ["effects", 1062], ["for", 1070], ["several", 1074], ["months", 1082], ["after", 1089], ["a", 1095], ["single", 1097], ["injection", 1104], [",", 1113], ["and", 1115], ["good", 1119], ["tolerability", 1124], [".", 1136], ["These", 1138], ["results", 1144], ["provide", 1152], ["the", 1160], ["basis", 1164], ["for", 1170], ["studies", 1174], ["evaluating", 1182], ["the", 1193], ["effectiveness", 1197], ["of", 1211], ["denosumab", 1214], ["in", 1224], ["several", 1227], ["clinical", 1235], ["conditions", 1244], ["characterized", 1255], ["by", 1269], ["increased", 1272], ["osteoclastic", 1282], ["activity", 1295], [".", 1303]]}
{"context": "With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in oncology, distinct cutaneous and oral adverse events have been identified. In fact, stomatitis and rash are documented as the most frequent and potentially dose-limiting side effects. Clinically, mTOR inhibitor-associated stomatitis (mIAS) more closely resembles aphthous stomatitis than oral mucositis due to conventional anticancer therapies. While most cases of mIAS are mild to moderate and self-limiting, more severe and persistent mIAS can become a dose-limiting toxicity. Small ulcerations may cause significant pain and mucosal sensitivity may occur in the absence of clinical changes. Use of clinical assessment tools that are primarily driven by ulceration size may underestimate mIAS, and assessment should include patient-reported outcomes. This article provides an up-to-date review of the clinical presentation, terminology, pathogenesis, assessment and management of mIAS and other mTOR inhibitor-associated oral adverse events. In addition, areas of future research are considered.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "51c0f6328c564f34adfee63c41eda084", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[7, 10]], "char_spans": [[46, 74]]}]}], "context_tokens": [["With", 0], ["the", 5], ["recent", 9], ["introduction", 16], ["of", 29], ["inhibitors", 32], ["of", 43], ["mammalian", 46], ["target", 56], ["of", 63], ["rapamycin", 66], ["(", 76], ["mTOR", 77], [")", 81], ["in", 83], ["oncology", 86], [",", 94], ["distinct", 96], ["cutaneous", 105], ["and", 115], ["oral", 119], ["adverse", 124], ["events", 132], ["have", 139], ["been", 144], ["identified", 149], [".", 159], ["In", 161], ["fact", 164], [",", 168], ["stomatitis", 170], ["and", 181], ["rash", 185], ["are", 190], ["documented", 194], ["as", 205], ["the", 208], ["most", 212], ["frequent", 217], ["and", 226], ["potentially", 230], ["dose", 242], ["-", 246], ["limiting", 247], ["side", 256], ["effects", 261], [".", 268], ["Clinically", 270], [",", 280], ["mTOR", 282], ["inhibitor", 287], ["-", 296], ["associated", 297], ["stomatitis", 308], ["(", 319], ["mIAS", 320], [")", 324], ["more", 326], ["closely", 331], ["resembles", 339], ["aphthous", 349], ["stomatitis", 358], ["than", 369], ["oral", 374], ["mucositis", 379], ["due", 389], ["to", 393], ["conventional", 396], ["anticancer", 409], ["therapies", 420], [".", 429], ["While", 431], ["most", 437], ["cases", 442], ["of", 448], ["mIAS", 451], ["are", 456], ["mild", 460], ["to", 465], ["moderate", 468], ["and", 477], ["self", 481], ["-", 485], ["limiting", 486], [",", 494], ["more", 496], ["severe", 501], ["and", 508], ["persistent", 512], ["mIAS", 523], ["can", 528], ["become", 532], ["a", 539], ["dose", 541], ["-", 545], ["limiting", 546], ["toxicity", 555], [".", 563], ["Small", 565], ["ulcerations", 571], ["may", 583], ["cause", 587], ["significant", 593], ["pain", 605], ["and", 610], ["mucosal", 614], ["sensitivity", 622], ["may", 634], ["occur", 638], ["in", 644], ["the", 647], ["absence", 651], ["of", 659], ["clinical", 662], ["changes", 671], [".", 678], ["Use", 680], ["of", 684], ["clinical", 687], ["assessment", 696], ["tools", 707], ["that", 713], ["are", 718], ["primarily", 722], ["driven", 732], ["by", 739], ["ulceration", 742], ["size", 753], ["may", 758], ["underestimate", 762], ["mIAS", 776], [",", 780], ["and", 782], ["assessment", 786], ["should", 797], ["include", 804], ["patient", 812], ["-", 819], ["reported", 820], ["outcomes", 829], [".", 837], ["This", 839], ["article", 844], ["provides", 852], ["an", 861], ["up", 864], ["-", 866], ["to", 867], ["-", 869], ["date", 870], ["review", 875], ["of", 882], ["the", 885], ["clinical", 889], ["presentation", 898], [",", 910], ["terminology", 912], [",", 923], ["pathogenesis", 925], [",", 937], ["assessment", 939], ["and", 950], ["management", 954], ["of", 965], ["mIAS", 968], ["and", 973], ["other", 977], ["mTOR", 983], ["inhibitor", 988], ["-", 997], ["associated", 998], ["oral", 1009], ["adverse", 1014], ["events", 1022], [".", 1028], ["In", 1030], ["addition", 1033], [",", 1041], ["areas", 1043], ["of", 1049], ["future", 1052], ["research", 1059], ["are", 1068], ["considered", 1072], [".", 1082]]}
{"context": "Embryonic neuroepithelia and adult subventricular zone (SVZ) stem and progenitor cells express nestin. We characterized a transgenic line that expresses enhanced green fluorescent protein (eGFP) specified to neural tissue by the second intronic enhancer of the nestin promoter that had several novel features. During embryogenesis, the dorsal telencephalon contained many and the ventral telencephalon few eGFP+ cells. eGFP+ cells were found in postnatal and adult neurogenic regions. eGFP+ cells in the SVZ expressed multiple phenotype markers, glial fibrillary acidic protein, Dlx, and neuroblast-specific molecules suggesting the transgene is expressed through the lineage. eGFP+ cell numbers increased in the SVZ after cortical injury, suggesting this line will be useful in probing postinjury neurogenesis. In non-neurogenic regions, eGFP was strongly expressed in oligodendrocyte progenitors, but not in astrocytes, even when they were reactive. This eGFP+ mouse will facilitate studies of proliferative neuroepithelia and adult neurogenesis, as well as of parenchymal oligodendrocytes.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "1f13212b55544ebc9031055963334233", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[41, 41], [14, 14]], "char_spans": [[261, 266], [95, 100]]}]}], "context_tokens": [["Embryonic", 0], ["neuroepithelia", 10], ["and", 25], ["adult", 29], ["subventricular", 35], ["zone", 50], ["(", 55], ["SVZ", 56], [")", 59], ["stem", 61], ["and", 66], ["progenitor", 70], ["cells", 81], ["express", 87], ["nestin", 95], [".", 101], ["We", 103], ["characterized", 106], ["a", 120], ["transgenic", 122], ["line", 133], ["that", 138], ["expresses", 143], ["enhanced", 153], ["green", 162], ["fluorescent", 168], ["protein", 180], ["(", 188], ["eGFP", 189], [")", 193], ["specified", 195], ["to", 205], ["neural", 208], ["tissue", 215], ["by", 222], ["the", 225], ["second", 229], ["intronic", 236], ["enhancer", 245], ["of", 254], ["the", 257], ["nestin", 261], ["promoter", 268], ["that", 277], ["had", 282], ["several", 286], ["novel", 294], ["features", 300], [".", 308], ["During", 310], ["embryogenesis", 317], [",", 330], ["the", 332], ["dorsal", 336], ["telencephalon", 343], ["contained", 357], ["many", 367], ["and", 372], ["the", 376], ["ventral", 380], ["telencephalon", 388], ["few", 402], ["eGFP+", 406], ["cells", 412], [".", 417], ["eGFP+", 419], ["cells", 425], ["were", 431], ["found", 436], ["in", 442], ["postnatal", 445], ["and", 455], ["adult", 459], ["neurogenic", 465], ["regions", 476], [".", 483], ["eGFP+", 485], ["cells", 491], ["in", 497], ["the", 500], ["SVZ", 504], ["expressed", 508], ["multiple", 518], ["phenotype", 527], ["markers", 537], [",", 544], ["glial", 546], ["fibrillary", 552], ["acidic", 563], ["protein", 570], [",", 577], ["Dlx", 579], [",", 582], ["and", 584], ["neuroblast", 588], ["-", 598], ["specific", 599], ["molecules", 608], ["suggesting", 618], ["the", 629], ["transgene", 633], ["is", 643], ["expressed", 646], ["through", 656], ["the", 664], ["lineage", 668], [".", 675], ["eGFP+", 677], ["cell", 683], ["numbers", 688], ["increased", 696], ["in", 706], ["the", 709], ["SVZ", 713], ["after", 717], ["cortical", 723], ["injury", 732], [",", 738], ["suggesting", 740], ["this", 751], ["line", 756], ["will", 761], ["be", 766], ["useful", 769], ["in", 776], ["probing", 779], ["postinjury", 787], ["neurogenesis", 798], [".", 810], ["In", 812], ["non", 815], ["-", 818], ["neurogenic", 819], ["regions", 830], [",", 837], ["eGFP", 839], ["was", 844], ["strongly", 848], ["expressed", 857], ["in", 867], ["oligodendrocyte", 870], ["progenitors", 886], [",", 897], ["but", 899], ["not", 903], ["in", 907], ["astrocytes", 910], [",", 920], ["even", 922], ["when", 927], ["they", 932], ["were", 937], ["reactive", 942], [".", 950], ["This", 952], ["eGFP+", 957], ["mouse", 963], ["will", 969], ["facilitate", 974], ["studies", 985], ["of", 993], ["proliferative", 996], ["neuroepithelia", 1010], ["and", 1025], ["adult", 1029], ["neurogenesis", 1035], [",", 1047], ["as", 1049], ["well", 1052], ["as", 1057], ["of", 1060], ["parenchymal", 1063], ["oligodendrocytes", 1075], [".", 1091]]}
{"context": "We evaluated the adherence and acceptability of a vaginal ring containing dapivirine, maraviroc, or both drugs for 28\u00a0days during a Phase I placebo-controlled trial in 48 HIV-negative sexually abstinent U.S. women aged 18-40. Adherence was assessed weekly by clinical interview and computer-assisted self-interviewing; acceptability assessment occurred at the last product-use visit. Study retention was 98\u00a0% (47/48); 94\u00a0% (45/48) reported being fully adherent with ring use during the 28-day period. Two participants experienced the ring partially coming out. Analysis was blinded and behavioral data were combined across study groups. Most women reported being very comfortable having the ring in their vagina; 44\u00a0% preferred continuous use, whereas 51\u00a0% had no preference compared to episodic use. Although a range of minor ring concerns were expressed, few were actually experienced. High adherence to and acceptability of this vaginal ring in this Phase I trial contributes to its promise as a sustained mechanism for multidrug vaginal microbicide delivery.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "c1f471c321514f0caf736b5b44d25ecb", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[31, 31]], "char_spans": [[171, 173]]}]}], "context_tokens": [["We", 0], ["evaluated", 3], ["the", 13], ["adherence", 17], ["and", 27], ["acceptability", 31], ["of", 45], ["a", 48], ["vaginal", 50], ["ring", 58], ["containing", 63], ["dapivirine", 74], [",", 84], ["maraviroc", 86], [",", 95], ["or", 97], ["both", 100], ["drugs", 105], ["for", 111], ["28", 115], ["days", 118], ["during", 123], ["a", 130], ["Phase", 132], ["I", 138], ["placebo", 140], ["-", 147], ["controlled", 148], ["trial", 159], ["in", 165], ["48", 168], ["HIV", 171], ["-", 174], ["negative", 175], ["sexually", 184], ["abstinent", 193], ["U.S.", 203], ["women", 208], ["aged", 214], ["18", 219], ["-", 221], ["40", 222], [".", 224], ["Adherence", 226], ["was", 236], ["assessed", 240], ["weekly", 249], ["by", 256], ["clinical", 259], ["interview", 268], ["and", 278], ["computer", 282], ["-", 290], ["assisted", 291], ["self", 300], ["-", 304], ["interviewing", 305], [";", 317], ["acceptability", 319], ["assessment", 333], ["occurred", 344], ["at", 353], ["the", 356], ["last", 360], ["product", 365], ["-", 372], ["use", 373], ["visit", 377], [".", 382], ["Study", 384], ["retention", 390], ["was", 400], ["98", 404], ["%", 407], ["(", 409], ["47/48", 410], [")", 415], [";", 416], ["94", 418], ["%", 421], ["(", 423], ["45/48", 424], [")", 429], ["reported", 431], ["being", 440], ["fully", 446], ["adherent", 452], ["with", 461], ["ring", 466], ["use", 471], ["during", 475], ["the", 482], ["28-day", 486], ["period", 493], [".", 499], ["Two", 501], ["participants", 505], ["experienced", 518], ["the", 530], ["ring", 534], ["partially", 539], ["coming", 549], ["out", 556], [".", 559], ["Analysis", 561], ["was", 570], ["blinded", 574], ["and", 582], ["behavioral", 586], ["data", 597], ["were", 602], ["combined", 607], ["across", 616], ["study", 623], ["groups", 629], [".", 635], ["Most", 637], ["women", 642], ["reported", 648], ["being", 657], ["very", 663], ["comfortable", 668], ["having", 680], ["the", 687], ["ring", 691], ["in", 696], ["their", 699], ["vagina", 705], [";", 711], ["44", 713], ["%", 716], ["preferred", 718], ["continuous", 728], ["use", 739], [",", 742], ["whereas", 744], ["51", 752], ["%", 755], ["had", 757], ["no", 761], ["preference", 764], ["compared", 775], ["to", 784], ["episodic", 787], ["use", 796], [".", 799], ["Although", 801], ["a", 810], ["range", 812], ["of", 818], ["minor", 821], ["ring", 827], ["concerns", 832], ["were", 841], ["expressed", 846], [",", 855], ["few", 857], ["were", 861], ["actually", 866], ["experienced", 875], [".", 886], ["High", 888], ["adherence", 893], ["to", 903], ["and", 906], ["acceptability", 910], ["of", 924], ["this", 927], ["vaginal", 932], ["ring", 940], ["in", 945], ["this", 948], ["Phase", 953], ["I", 959], ["trial", 961], ["contributes", 967], ["to", 979], ["its", 982], ["promise", 986], ["as", 994], ["a", 997], ["sustained", 999], ["mechanism", 1009], ["for", 1019], ["multidrug", 1023], ["vaginal", 1033], ["microbicide", 1041], ["delivery", 1053], [".", 1061]]}
{"context": "The reactive oxygen-generating NADPH oxidases (Noxes) function in a variety of biological roles, and can be broadly classified into those that are regulated by subunit interactions and those that are regulated by calcium. The prototypical subunit-regulated Nox, Nox2, is the membrane-associated catalytic subunit of the phagocyte NADPH-oxidase. Nox2 forms a heterodimer with the integral membrane protein, p22phox, and this heterodimer binds to the regulatory subunits p47phox, p67phox, p40phox and the small GTPase Rac, triggering superoxide generation. Nox-organizer protein 1 (NOXO1) and Nox-activator 1 (NOXA1), respective homologs of p47phox and p67phox, together with p22phox and Rac, activate Nox1, a non-phagocytic homolog of Nox2. NOXO1 and p22phox also regulate Nox3, whereas Nox4 requires only p22phox. In this study, we have assembled and analyzed amino acid sequences of Nox regulatory subunit orthologs from vertebrates, a urochordate, an echinoderm, a mollusc, a cnidarian, a choanoflagellate, fungi and a slime mold amoeba to investigate the evolutionary history of these subunits. Ancestral p47phox, p67phox, and p22phox genes are broadly seen in the metazoa, except for the ecdysozoans. The choanoflagellate Monosiga brevicollis, the unicellular organism that is the closest relatives of multicellular animals, encodes early prototypes of p22phox, p47phox as well as the earliest known Nox2-like ancestor of the Nox1-3 subfamily. p67phox- and p47phox-like genes are seen in the sea urchin Strongylocentrotus purpuratus and the limpet Lottia gigantea that also possess Nox2-like co-orthologs of vertebrate Nox1-3. Duplication of primordial p47phox and p67phox genes occurred in vertebrates, with the duplicated branches evolving into NOXO1 and NOXA1. Analysis of characteristic domains of regulatory subunits suggests a novel view of the evolution of Nox: in fish, p40phox participated in regulating both Nox1 and Nox2, but after the appearance of mammals, Nox1 (but not Nox2) became independent of p40phox. In the fish Oryzias latipes, a NOXO1 ortholog retains an autoinhibitory region that is characteristic of mammalian p47phox, and this was subsequently lost from NOXO1 in later vertebrates. Detailed amino acid sequence comparisons identified both putative key residues conserved in characteristic domains and previously unidentified conserved regions. Also, candidate organizer/activator proteins in fungi and amoeba are identified and hypothetical activation models are suggested. This is the first report to provide the comprehensive view of the molecular evolution of regulatory subunits for Nox enzymes. This approach provides clues for understanding the evolution of biochemical and physiological functions for regulatory-subunit-dependent Nox enzymes.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "c9411266b7014dedb3a042e1c5632fa7", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[128, 128], [288, 288], [349, 349], [338, 338], [255, 255]], "char_spans": [[700, 703], [1623, 1626], [1974, 1977], [1922, 1925], [1430, 1433]]}]}], "context_tokens": [["The", 0], ["reactive", 4], ["oxygen", 13], ["-", 19], ["generating", 20], ["NADPH", 31], ["oxidases", 37], ["(", 46], ["Noxes", 47], [")", 52], ["function", 54], ["in", 63], ["a", 66], ["variety", 68], ["of", 76], ["biological", 79], ["roles", 90], [",", 95], ["and", 97], ["can", 101], ["be", 105], ["broadly", 108], ["classified", 116], ["into", 127], ["those", 132], ["that", 138], ["are", 143], ["regulated", 147], ["by", 157], ["subunit", 160], ["interactions", 168], ["and", 181], ["those", 185], ["that", 191], ["are", 196], ["regulated", 200], ["by", 210], ["calcium", 213], [".", 220], ["The", 222], ["prototypical", 226], ["subunit", 239], ["-", 246], ["regulated", 247], ["Nox", 257], [",", 260], ["Nox2", 262], [",", 266], ["is", 268], ["the", 271], ["membrane", 275], ["-", 283], ["associated", 284], ["catalytic", 295], ["subunit", 305], ["of", 313], ["the", 316], ["phagocyte", 320], ["NADPH", 330], ["-", 335], ["oxidase", 336], [".", 343], ["Nox2", 345], ["forms", 350], ["a", 356], ["heterodimer", 358], ["with", 370], ["the", 375], ["integral", 379], ["membrane", 388], ["protein", 397], [",", 404], ["p22phox", 406], [",", 413], ["and", 415], ["this", 419], ["heterodimer", 424], ["binds", 436], ["to", 442], ["the", 445], ["regulatory", 449], ["subunits", 460], ["p47phox", 469], [",", 476], ["p67phox", 478], [",", 485], ["p40phox", 487], ["and", 495], ["the", 499], ["small", 503], ["GTPase", 509], ["Rac", 516], [",", 519], ["triggering", 521], ["superoxide", 532], ["generation", 543], [".", 553], ["Nox", 555], ["-", 558], ["organizer", 559], ["protein", 569], ["1", 577], ["(", 579], ["NOXO1", 580], [")", 585], ["and", 587], ["Nox", 591], ["-", 594], ["activator", 595], ["1", 605], ["(", 607], ["NOXA1", 608], [")", 613], [",", 614], ["respective", 616], ["homologs", 627], ["of", 636], ["p47phox", 639], ["and", 647], ["p67phox", 651], [",", 658], ["together", 660], ["with", 669], ["p22phox", 674], ["and", 682], ["Rac", 686], [",", 689], ["activate", 691], ["Nox1", 700], [",", 704], ["a", 706], ["non", 708], ["-", 711], ["phagocytic", 712], ["homolog", 723], ["of", 731], ["Nox2", 734], [".", 738], ["NOXO1", 740], ["and", 746], ["p22phox", 750], ["also", 758], ["regulate", 763], ["Nox3", 772], [",", 776], ["whereas", 778], ["Nox4", 786], ["requires", 791], ["only", 800], ["p22phox", 805], [".", 812], ["In", 814], ["this", 817], ["study", 822], [",", 827], ["we", 829], ["have", 832], ["assembled", 837], ["and", 847], ["analyzed", 851], ["amino", 860], ["acid", 866], ["sequences", 871], ["of", 881], ["Nox", 884], ["regulatory", 888], ["subunit", 899], ["orthologs", 907], ["from", 917], ["vertebrates", 922], [",", 933], ["a", 935], ["urochordate", 937], [",", 948], ["an", 950], ["echinoderm", 953], [",", 963], ["a", 965], ["mollusc", 967], [",", 974], ["a", 976], ["cnidarian", 978], [",", 987], ["a", 989], ["choanoflagellate", 991], [",", 1007], ["fungi", 1009], ["and", 1015], ["a", 1019], ["slime", 1021], ["mold", 1027], ["amoeba", 1032], ["to", 1039], ["investigate", 1042], ["the", 1054], ["evolutionary", 1058], ["history", 1071], ["of", 1079], ["these", 1082], ["subunits", 1088], [".", 1096], ["Ancestral", 1098], ["p47phox", 1108], [",", 1115], ["p67phox", 1117], [",", 1124], ["and", 1126], ["p22phox", 1130], ["genes", 1138], ["are", 1144], ["broadly", 1148], ["seen", 1156], ["in", 1161], ["the", 1164], ["metazoa", 1168], [",", 1175], ["except", 1177], ["for", 1184], ["the", 1188], ["ecdysozoans", 1192], [".", 1203], ["The", 1205], ["choanoflagellate", 1209], ["Monosiga", 1226], ["brevicollis", 1235], [",", 1246], ["the", 1248], ["unicellular", 1252], ["organism", 1264], ["that", 1273], ["is", 1278], ["the", 1281], ["closest", 1285], ["relatives", 1293], ["of", 1303], ["multicellular", 1306], ["animals", 1320], [",", 1327], ["encodes", 1329], ["early", 1337], ["prototypes", 1343], ["of", 1354], ["p22phox", 1357], [",", 1364], ["p47phox", 1366], ["as", 1374], ["well", 1377], ["as", 1382], ["the", 1385], ["earliest", 1389], ["known", 1398], ["Nox2-like", 1404], ["ancestor", 1414], ["of", 1423], ["the", 1426], ["Nox1", 1430], ["-", 1434], ["3", 1435], ["subfamily", 1437], [".", 1446], ["p67phox-", 1448], ["and", 1457], ["p47phox", 1461], ["-", 1468], ["like", 1469], ["genes", 1474], ["are", 1480], ["seen", 1484], ["in", 1489], ["the", 1492], ["sea", 1496], ["urchin", 1500], ["Strongylocentrotus", 1507], ["purpuratus", 1526], ["and", 1537], ["the", 1541], ["limpet", 1545], ["Lottia", 1552], ["gigantea", 1559], ["that", 1568], ["also", 1573], ["possess", 1578], ["Nox2-like", 1586], ["co", 1596], ["-", 1598], ["orthologs", 1599], ["of", 1609], ["vertebrate", 1612], ["Nox1", 1623], ["-", 1627], ["3", 1628], [".", 1629], ["Duplication", 1631], ["of", 1643], ["primordial", 1646], ["p47phox", 1657], ["and", 1665], ["p67phox", 1669], ["genes", 1677], ["occurred", 1683], ["in", 1692], ["vertebrates", 1695], [",", 1706], ["with", 1708], ["the", 1713], ["duplicated", 1717], ["branches", 1728], ["evolving", 1737], ["into", 1746], ["NOXO1", 1751], ["and", 1757], ["NOXA1", 1761], [".", 1766], ["Analysis", 1768], ["of", 1777], ["characteristic", 1780], ["domains", 1795], ["of", 1803], ["regulatory", 1806], ["subunits", 1817], ["suggests", 1826], ["a", 1835], ["novel", 1837], ["view", 1843], ["of", 1848], ["the", 1851], ["evolution", 1855], ["of", 1865], ["Nox", 1868], [":", 1871], ["in", 1873], ["fish", 1876], [",", 1880], ["p40phox", 1882], ["participated", 1890], ["in", 1903], ["regulating", 1906], ["both", 1917], ["Nox1", 1922], ["and", 1927], ["Nox2", 1931], [",", 1935], ["but", 1937], ["after", 1941], ["the", 1947], ["appearance", 1951], ["of", 1962], ["mammals", 1965], [",", 1972], ["Nox1", 1974], ["(", 1979], ["but", 1980], ["not", 1984], ["Nox2", 1988], [")", 1992], ["became", 1994], ["independent", 2001], ["of", 2013], ["p40phox", 2016], [".", 2023], ["In", 2025], ["the", 2028], ["fish", 2032], ["Oryzias", 2037], ["latipes", 2045], [",", 2052], ["a", 2054], ["NOXO1", 2056], ["ortholog", 2062], ["retains", 2071], ["an", 2079], ["autoinhibitory", 2082], ["region", 2097], ["that", 2104], ["is", 2109], ["characteristic", 2112], ["of", 2127], ["mammalian", 2130], ["p47phox", 2140], [",", 2147], ["and", 2149], ["this", 2153], ["was", 2158], ["subsequently", 2162], ["lost", 2175], ["from", 2180], ["NOXO1", 2185], ["in", 2191], ["later", 2194], ["vertebrates", 2200], [".", 2211], ["Detailed", 2213], ["amino", 2222], ["acid", 2228], ["sequence", 2233], ["comparisons", 2242], ["identified", 2254], ["both", 2265], ["putative", 2270], ["key", 2279], ["residues", 2283], ["conserved", 2292], ["in", 2302], ["characteristic", 2305], ["domains", 2320], ["and", 2328], ["previously", 2332], ["unidentified", 2343], ["conserved", 2356], ["regions", 2366], [".", 2373], ["Also", 2375], [",", 2379], ["candidate", 2381], ["organizer", 2391], ["/", 2400], ["activator", 2401], ["proteins", 2411], ["in", 2420], ["fungi", 2423], ["and", 2429], ["amoeba", 2433], ["are", 2440], ["identified", 2444], ["and", 2455], ["hypothetical", 2459], ["activation", 2472], ["models", 2483], ["are", 2490], ["suggested", 2494], [".", 2503], ["This", 2505], ["is", 2510], ["the", 2513], ["first", 2517], ["report", 2523], ["to", 2530], ["provide", 2533], ["the", 2541], ["comprehensive", 2545], ["view", 2559], ["of", 2564], ["the", 2567], ["molecular", 2571], ["evolution", 2581], ["of", 2591], ["regulatory", 2594], ["subunits", 2605], ["for", 2614], ["Nox", 2618], ["enzymes", 2622], [".", 2629], ["This", 2631], ["approach", 2636], ["provides", 2645], ["clues", 2654], ["for", 2660], ["understanding", 2664], ["the", 2678], ["evolution", 2682], ["of", 2692], ["biochemical", 2695], ["and", 2707], ["physiological", 2711], ["functions", 2725], ["for", 2735], ["regulatory", 2739], ["-", 2749], ["subunit", 2750], ["-", 2757], ["dependent", 2758], ["Nox", 2768], ["enzymes", 2772], [".", 2779]]}
{"context": "Selexipag is a first-in-class orally available selective non-prostanoid IP receptor agonist. This review was based on a PubMed search and focuses on the potential role of selexipag in the treatment of pulmonary arterial hypertension (PAH). Selexipag is rapidly hydrolyzed to an active metabolite, ACT-333679. Both selexipag and its metabolite are highly selective for the IP receptor compared with other prostanoid receptors. This selectivity for the IP receptor offers the potential for improved tolerability with selexipag, as side effects (e.g., nausea and vomiting) that might result from activation of the other prostanoid receptors may be minimized. In addition, the selexipag metabolite has a half-life of 7.9 h, thus permitting oral dosing twice daily. Selexipag showed effects on pharmacodynamic end points obtained with right heart catheterization in a Phase II trial in patients with PAH, and is being evaluated in the ongoing Phase III trial (GRIPHON trial, Clinicaltrials.gov NCT01106014). The signal of a beneficial effect of selexipag on disease progression may become more robust for long term under prolonged exposure. Pending the GRIPHON trial results, selexipag could provide a convenient first-line prostacyclin treatment option for patients with PAH.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "d69c9463ec08444a919447d7f33855f7", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[38, 40]], "char_spans": [[201, 231]]}]}], "context_tokens": [["Selexipag", 0], ["is", 10], ["a", 13], ["first", 15], ["-", 20], ["in", 21], ["-", 23], ["class", 24], ["orally", 30], ["available", 37], ["selective", 47], ["non", 57], ["-", 60], ["prostanoid", 61], ["IP", 72], ["receptor", 75], ["agonist", 84], [".", 91], ["This", 93], ["review", 98], ["was", 105], ["based", 109], ["on", 115], ["a", 118], ["PubMed", 120], ["search", 127], ["and", 134], ["focuses", 138], ["on", 146], ["the", 149], ["potential", 153], ["role", 163], ["of", 168], ["selexipag", 171], ["in", 181], ["the", 184], ["treatment", 188], ["of", 198], ["pulmonary", 201], ["arterial", 211], ["hypertension", 220], ["(", 233], ["PAH", 234], [")", 237], [".", 238], ["Selexipag", 240], ["is", 250], ["rapidly", 253], ["hydrolyzed", 261], ["to", 272], ["an", 275], ["active", 278], ["metabolite", 285], [",", 295], ["ACT-333679", 297], [".", 307], ["Both", 309], ["selexipag", 314], ["and", 324], ["its", 328], ["metabolite", 332], ["are", 343], ["highly", 347], ["selective", 354], ["for", 364], ["the", 368], ["IP", 372], ["receptor", 375], ["compared", 384], ["with", 393], ["other", 398], ["prostanoid", 404], ["receptors", 415], [".", 424], ["This", 426], ["selectivity", 431], ["for", 443], ["the", 447], ["IP", 451], ["receptor", 454], ["offers", 463], ["the", 470], ["potential", 474], ["for", 484], ["improved", 488], ["tolerability", 497], ["with", 510], ["selexipag", 515], [",", 524], ["as", 526], ["side", 529], ["effects", 534], ["(", 542], ["e.g.", 543], [",", 547], ["nausea", 549], ["and", 556], ["vomiting", 560], [")", 568], ["that", 570], ["might", 575], ["result", 581], ["from", 588], ["activation", 593], ["of", 604], ["the", 607], ["other", 611], ["prostanoid", 617], ["receptors", 628], ["may", 638], ["be", 642], ["minimized", 645], [".", 654], ["In", 656], ["addition", 659], [",", 667], ["the", 669], ["selexipag", 673], ["metabolite", 683], ["has", 694], ["a", 698], ["half", 700], ["-", 704], ["life", 705], ["of", 710], ["7.9", 713], ["h", 717], [",", 718], ["thus", 720], ["permitting", 725], ["oral", 736], ["dosing", 741], ["twice", 748], ["daily", 754], [".", 759], ["Selexipag", 761], ["showed", 771], ["effects", 778], ["on", 786], ["pharmacodynamic", 789], ["end", 805], ["points", 809], ["obtained", 816], ["with", 825], ["right", 830], ["heart", 836], ["catheterization", 842], ["in", 858], ["a", 861], ["Phase", 863], ["II", 869], ["trial", 872], ["in", 878], ["patients", 881], ["with", 890], ["PAH", 895], [",", 898], ["and", 900], ["is", 904], ["being", 907], ["evaluated", 913], ["in", 923], ["the", 926], ["ongoing", 930], ["Phase", 938], ["III", 944], ["trial", 948], ["(", 954], ["GRIPHON", 955], ["trial", 963], [",", 968], ["Clinicaltrials.gov", 970], ["NCT01106014", 989], [")", 1000], [".", 1001], ["The", 1003], ["signal", 1007], ["of", 1014], ["a", 1017], ["beneficial", 1019], ["effect", 1030], ["of", 1037], ["selexipag", 1040], ["on", 1050], ["disease", 1053], ["progression", 1061], ["may", 1073], ["become", 1077], ["more", 1084], ["robust", 1089], ["for", 1096], ["long", 1100], ["term", 1105], ["under", 1110], ["prolonged", 1116], ["exposure", 1126], [".", 1134], ["Pending", 1136], ["the", 1144], ["GRIPHON", 1148], ["trial", 1156], ["results", 1162], [",", 1169], ["selexipag", 1171], ["could", 1181], ["provide", 1187], ["a", 1195], ["convenient", 1197], ["first", 1208], ["-", 1213], ["line", 1214], ["prostacyclin", 1219], ["treatment", 1232], ["option", 1242], ["for", 1249], ["patients", 1253], ["with", 1262], ["PAH", 1267], [".", 1270]]}
{"context": "Several gene products are involved in co-translational insertion of selenocysteine by the tRNA(Sec). In addition, a stem-loop structure in the mRNAs coding for selenoproteins is essential to mediate the selection of the proper selenocysteine UGA codon. Interestingly, in eukaryotic selenoprotein mRNAs, this stem-loop structure, the selenocysteine insertion sequence (SECIS) element, resides in the 3'-untranslated region, far downstream of the UGA codon. In view of unravelling the underlying complex mechanism, we have attempted to detect RNA-binding proteins with specificity for the SECIS element. Using mobility shift assays, we could show that a protein, present in different types of mammalian cell extracts, possesses the capacity of binding the SECIS element of the selenoprotein glutathione peroxidase (GPx) mRNA. We have termed this protein SBP, for Secis Binding Protein. Competition experiments attested that the binding is highly specific and UV cross-linking indicated that the protein has an apparent molecular weight in the range of 60-65 kDa. Finally, some data suggest that the SECIS elements in the mRNAs of GPx and another selenoprotein, type I iodothyronine 5' deiodinase, recognize the same SBP protein. This constitutes the first report of the existence of a 3' UTR binding protein possibly involved in the eukaryotic selenocysteine insertion mechanism.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "22db25e825ff4bcfb783e89d2d7a8162", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[131, 131], [101, 101], [151, 151], [62, 62], [194, 194]], "char_spans": [[754, 758], [587, 591], [861, 865], [368, 372], [1097, 1101]]}]}], "context_tokens": [["Several", 0], ["gene", 8], ["products", 13], ["are", 22], ["involved", 26], ["in", 35], ["co", 38], ["-", 40], ["translational", 41], ["insertion", 55], ["of", 65], ["selenocysteine", 68], ["by", 83], ["the", 86], ["tRNA(Sec", 90], [")", 98], [".", 99], ["In", 101], ["addition", 104], [",", 112], ["a", 114], ["stem", 116], ["-", 120], ["loop", 121], ["structure", 126], ["in", 136], ["the", 139], ["mRNAs", 143], ["coding", 149], ["for", 156], ["selenoproteins", 160], ["is", 175], ["essential", 178], ["to", 188], ["mediate", 191], ["the", 199], ["selection", 203], ["of", 213], ["the", 216], ["proper", 220], ["selenocysteine", 227], ["UGA", 242], ["codon", 246], [".", 251], ["Interestingly", 253], [",", 266], ["in", 268], ["eukaryotic", 271], ["selenoprotein", 282], ["mRNAs", 296], [",", 301], ["this", 303], ["stem", 308], ["-", 312], ["loop", 313], ["structure", 318], [",", 327], ["the", 329], ["selenocysteine", 333], ["insertion", 348], ["sequence", 358], ["(", 367], ["SECIS", 368], [")", 373], ["element", 375], [",", 382], ["resides", 384], ["in", 392], ["the", 395], ["3'-untranslated", 399], ["region", 415], [",", 421], ["far", 423], ["downstream", 427], ["of", 438], ["the", 441], ["UGA", 445], ["codon", 449], [".", 454], ["In", 456], ["view", 459], ["of", 464], ["unravelling", 467], ["the", 479], ["underlying", 483], ["complex", 494], ["mechanism", 502], [",", 511], ["we", 513], ["have", 516], ["attempted", 521], ["to", 531], ["detect", 534], ["RNA", 541], ["-", 544], ["binding", 545], ["proteins", 553], ["with", 562], ["specificity", 567], ["for", 579], ["the", 583], ["SECIS", 587], ["element", 593], [".", 600], ["Using", 602], ["mobility", 608], ["shift", 617], ["assays", 623], [",", 629], ["we", 631], ["could", 634], ["show", 640], ["that", 645], ["a", 650], ["protein", 652], [",", 659], ["present", 661], ["in", 669], ["different", 672], ["types", 682], ["of", 688], ["mammalian", 691], ["cell", 701], ["extracts", 706], [",", 714], ["possesses", 716], ["the", 726], ["capacity", 730], ["of", 739], ["binding", 742], ["the", 750], ["SECIS", 754], ["element", 760], ["of", 768], ["the", 771], ["selenoprotein", 775], ["glutathione", 789], ["peroxidase", 801], ["(", 812], ["GPx", 813], [")", 816], ["mRNA", 818], [".", 822], ["We", 824], ["have", 827], ["termed", 832], ["this", 839], ["protein", 844], ["SBP", 852], [",", 855], ["for", 857], ["Secis", 861], ["Binding", 867], ["Protein", 875], [".", 882], ["Competition", 884], ["experiments", 896], ["attested", 908], ["that", 917], ["the", 922], ["binding", 926], ["is", 934], ["highly", 937], ["specific", 944], ["and", 953], ["UV", 957], ["cross", 960], ["-", 965], ["linking", 966], ["indicated", 974], ["that", 984], ["the", 989], ["protein", 993], ["has", 1001], ["an", 1005], ["apparent", 1008], ["molecular", 1017], ["weight", 1027], ["in", 1034], ["the", 1037], ["range", 1041], ["of", 1047], ["60", 1050], ["-", 1052], ["65", 1053], ["kDa", 1056], [".", 1059], ["Finally", 1061], [",", 1068], ["some", 1070], ["data", 1075], ["suggest", 1080], ["that", 1088], ["the", 1093], ["SECIS", 1097], ["elements", 1103], ["in", 1112], ["the", 1115], ["mRNAs", 1119], ["of", 1125], ["GPx", 1128], ["and", 1132], ["another", 1136], ["selenoprotein", 1144], [",", 1157], ["type", 1159], ["I", 1164], ["iodothyronine", 1166], ["5", 1180], ["'", 1181], ["deiodinase", 1183], [",", 1193], ["recognize", 1195], ["the", 1205], ["same", 1209], ["SBP", 1214], ["protein", 1218], [".", 1225], ["This", 1227], ["constitutes", 1232], ["the", 1244], ["first", 1248], ["report", 1254], ["of", 1261], ["the", 1264], ["existence", 1268], ["of", 1278], ["a", 1281], ["3", 1283], ["'", 1284], ["UTR", 1286], ["binding", 1290], ["protein", 1298], ["possibly", 1306], ["involved", 1315], ["in", 1324], ["the", 1327], ["eukaryotic", 1331], ["selenocysteine", 1342], ["insertion", 1357], ["mechanism", 1367], [".", 1376]]}
{"context": "Mowat-Wilson syndrome (MWS) is a rare genetic condition where variable and multiple congenital anomalies including Hirschsprung's disease, intellectual disability, and prominent facial features are present. At molecular level, MWS is characterized by many different described mutations in the zinc finger E-box protein 2 (ZEB2) gene, ultimately leading to loss of gene function. This report is the first to describe the association of MWS with two different asynchronous malignant brain tumors (medulloblastoma and glioblastoma) occurring in a child.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "1d067f852f5b46409f02c83de355022e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[55, 55]], "char_spans": [[322, 325]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["rare", 33], ["genetic", 38], ["condition", 46], ["where", 56], ["variable", 62], ["and", 71], ["multiple", 75], ["congenital", 84], ["anomalies", 95], ["including", 105], ["Hirschsprung", 115], ["'s", 127], ["disease", 130], [",", 137], ["intellectual", 139], ["disability", 152], [",", 162], ["and", 164], ["prominent", 168], ["facial", 178], ["features", 185], ["are", 194], ["present", 198], [".", 205], ["At", 207], ["molecular", 210], ["level", 220], [",", 225], ["MWS", 227], ["is", 231], ["characterized", 234], ["by", 248], ["many", 251], ["different", 256], ["described", 266], ["mutations", 276], ["in", 286], ["the", 289], ["zinc", 293], ["finger", 298], ["E", 305], ["-", 306], ["box", 307], ["protein", 311], ["2", 319], ["(", 321], ["ZEB2", 322], [")", 326], ["gene", 328], [",", 332], ["ultimately", 334], ["leading", 345], ["to", 353], ["loss", 356], ["of", 361], ["gene", 364], ["function", 369], [".", 377], ["This", 379], ["report", 384], ["is", 391], ["the", 394], ["first", 398], ["to", 404], ["describe", 407], ["the", 416], ["association", 420], ["of", 432], ["MWS", 435], ["with", 439], ["two", 444], ["different", 448], ["asynchronous", 458], ["malignant", 471], ["brain", 481], ["tumors", 487], ["(", 494], ["medulloblastoma", 495], ["and", 511], ["glioblastoma", 515], [")", 527], ["occurring", 529], ["in", 539], ["a", 542], ["child", 544], [".", 549]]}
{"context": "Heroin overdose is a major cause of death among heroin users, and often occurs in the company of other users. However, sudden death after injection is rare, giving ample opportunity for intervention. Naloxone hydrochloride, an injectable opioid antagonist which reverses the respiratory depression, sedation and hypotension associated with opioids, has long been used to treat opioid overdose. Experts have suggested that, as part of a comprehensive overdose prevention strategy, naloxone should be provided to heroin users for peer administration after an overdose. A trial could be conducted to determine whether this intervention improves the management of overdose or results in a net increase in harm (by undermining existing prevention strategies, precipitating naloxone-related complications, or resulting in riskier heroin use).", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "6e72346d9baf4bee8b690349f4e87241", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[80, 80], [37, 37], [125, 125]], "char_spans": [[480, 487], [200, 207], [768, 775]]}]}], "context_tokens": [["Heroin", 0], ["overdose", 7], ["is", 16], ["a", 19], ["major", 21], ["cause", 27], ["of", 33], ["death", 36], ["among", 42], ["heroin", 48], ["users", 55], [",", 60], ["and", 62], ["often", 66], ["occurs", 72], ["in", 79], ["the", 82], ["company", 86], ["of", 94], ["other", 97], ["users", 103], [".", 108], ["However", 110], [",", 117], ["sudden", 119], ["death", 126], ["after", 132], ["injection", 138], ["is", 148], ["rare", 151], [",", 155], ["giving", 157], ["ample", 164], ["opportunity", 170], ["for", 182], ["intervention", 186], [".", 198], ["Naloxone", 200], ["hydrochloride", 209], [",", 222], ["an", 224], ["injectable", 227], ["opioid", 238], ["antagonist", 245], ["which", 256], ["reverses", 262], ["the", 271], ["respiratory", 275], ["depression", 287], [",", 297], ["sedation", 299], ["and", 308], ["hypotension", 312], ["associated", 324], ["with", 335], ["opioids", 340], [",", 347], ["has", 349], ["long", 353], ["been", 358], ["used", 363], ["to", 368], ["treat", 371], ["opioid", 377], ["overdose", 384], [".", 392], ["Experts", 394], ["have", 402], ["suggested", 407], ["that", 417], [",", 421], ["as", 423], ["part", 426], ["of", 431], ["a", 434], ["comprehensive", 436], ["overdose", 450], ["prevention", 459], ["strategy", 470], [",", 478], ["naloxone", 480], ["should", 489], ["be", 496], ["provided", 499], ["to", 508], ["heroin", 511], ["users", 518], ["for", 524], ["peer", 528], ["administration", 533], ["after", 548], ["an", 554], ["overdose", 557], [".", 565], ["A", 567], ["trial", 569], ["could", 575], ["be", 581], ["conducted", 584], ["to", 594], ["determine", 597], ["whether", 607], ["this", 615], ["intervention", 620], ["improves", 633], ["the", 642], ["management", 646], ["of", 657], ["overdose", 660], ["or", 669], ["results", 672], ["in", 680], ["a", 683], ["net", 685], ["increase", 689], ["in", 698], ["harm", 701], ["(", 706], ["by", 707], ["undermining", 710], ["existing", 722], ["prevention", 731], ["strategies", 742], [",", 752], ["precipitating", 754], ["naloxone", 768], ["-", 776], ["related", 777], ["complications", 785], [",", 798], ["or", 800], ["resulting", 803], ["in", 813], ["riskier", 816], ["heroin", 824], ["use", 831], [")", 834], [".", 835]]}
{"context": "Accumulation and deposition of \u03b2-amyloid peptides (A\u03b2) in the brain is a central event in the pathogenesis of Alzheimer's disease (AD). Besides the parenchymal pathology, A\u03b2 is known to undergo active transport across the blood-brain barrier and cerebral amyloid angiopathy (CAA) is a prominent feature in the majority of AD. Although impaired cerebral blood flow (CBF) has been implicated in faulty A\u03b2 transport and clearance, and cerebral hypoperfusion can exist in the pre-clinical phase of Alzheimer's disease (AD), it is still unclear whether it is one of the causal factors for AD pathogenesis, or an early consequence of a multi-factor condition that would lead to AD at late stage. To study the potential interaction between faulty CBF and amyloid accumulation in clinical-relevant situation, we generated a new amyloid precursor protein (APP) knock-in allele that expresses humanized A\u03b2 and a Dutch mutation in addition to Swedish/London mutations and compared this line with an equivalent knock-in line but in the absence of the Dutch mutation, both crossed onto the PS1M146V knock-in background. Introduction of the Dutch mutation results in robust CAA and parenchymal A\u03b2 pathology, age-dependent reduction of spatial learning and memory deficits, and CBF reduction as detected by fMRI. Direct manipulation of CBF by transverse aortic constriction surgery on the left common carotid artery caused differential changes in CBF in the anterior and middle region of the cortex, where it is reduced on the left side and increased on the right side. However these perturbations in CBF resulted in the same effect: both significantly exacerbate CAA and amyloid pathology. Our study reveals a direct and positive link between vascular and parenchymal A\u03b2; both can be modulated by CBF. The new APP knock-in mouse model recapitulates many symptoms of AD including progressive vascular and parenchymal A\u03b2 pathology and behavioral deficits in the absence of APP overexpression.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "fd787f32d19848dbb65fe34c00222562", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[22, 24], [94, 96]], "char_spans": [[110, 128], [494, 512]]}, {"text": "AD", "token_spans": [[131, 131], [98, 98], [26, 26], [342, 342], [62, 62], [114, 114]], "char_spans": [[672, 673], [515, 516], [131, 132], [1852, 1853], [322, 323], [584, 585]]}]}], "context_tokens": [["Accumulation", 0], ["and", 13], ["deposition", 17], ["of", 28], ["\u03b2", 31], ["-", 32], ["amyloid", 33], ["peptides", 41], ["(", 50], ["A\u03b2", 51], [")", 53], ["in", 55], ["the", 58], ["brain", 62], ["is", 68], ["a", 71], ["central", 73], ["event", 81], ["in", 87], ["the", 90], ["pathogenesis", 94], ["of", 107], ["Alzheimer", 110], ["'s", 119], ["disease", 122], ["(", 130], ["AD", 131], [")", 133], [".", 134], ["Besides", 136], ["the", 144], ["parenchymal", 148], ["pathology", 160], [",", 169], ["A\u03b2", 171], ["is", 174], ["known", 177], ["to", 183], ["undergo", 186], ["active", 194], ["transport", 201], ["across", 211], ["the", 218], ["blood", 222], ["-", 227], ["brain", 228], ["barrier", 234], ["and", 242], ["cerebral", 246], ["amyloid", 255], ["angiopathy", 263], ["(", 274], ["CAA", 275], [")", 278], ["is", 280], ["a", 283], ["prominent", 285], ["feature", 295], ["in", 303], ["the", 306], ["majority", 310], ["of", 319], ["AD", 322], [".", 324], ["Although", 326], ["impaired", 335], ["cerebral", 344], ["blood", 353], ["flow", 359], ["(", 364], ["CBF", 365], [")", 368], ["has", 370], ["been", 374], ["implicated", 379], ["in", 390], ["faulty", 393], ["A\u03b2", 400], ["transport", 403], ["and", 413], ["clearance", 417], [",", 426], ["and", 428], ["cerebral", 432], ["hypoperfusion", 441], ["can", 455], ["exist", 459], ["in", 465], ["the", 468], ["pre", 472], ["-", 475], ["clinical", 476], ["phase", 485], ["of", 491], ["Alzheimer", 494], ["'s", 503], ["disease", 506], ["(", 514], ["AD", 515], [")", 517], [",", 518], ["it", 520], ["is", 523], ["still", 526], ["unclear", 532], ["whether", 540], ["it", 548], ["is", 551], ["one", 554], ["of", 558], ["the", 561], ["causal", 565], ["factors", 572], ["for", 580], ["AD", 584], ["pathogenesis", 587], [",", 599], ["or", 601], ["an", 604], ["early", 607], ["consequence", 613], ["of", 625], ["a", 628], ["multi", 630], ["-", 635], ["factor", 636], ["condition", 643], ["that", 653], ["would", 658], ["lead", 664], ["to", 669], ["AD", 672], ["at", 675], ["late", 678], ["stage", 683], [".", 688], ["To", 690], ["study", 693], ["the", 699], ["potential", 703], ["interaction", 713], ["between", 725], ["faulty", 733], ["CBF", 740], ["and", 744], ["amyloid", 748], ["accumulation", 756], ["in", 769], ["clinical", 772], ["-", 780], ["relevant", 781], ["situation", 790], [",", 799], ["we", 801], ["generated", 804], ["a", 814], ["new", 816], ["amyloid", 820], ["precursor", 828], ["protein", 838], ["(", 846], ["APP", 847], [")", 850], ["knock", 852], ["-", 857], ["in", 858], ["allele", 861], ["that", 868], ["expresses", 873], ["humanized", 883], ["A\u03b2", 893], ["and", 896], ["a", 900], ["Dutch", 902], ["mutation", 908], ["in", 917], ["addition", 920], ["to", 929], ["Swedish", 932], ["/", 939], ["London", 940], ["mutations", 947], ["and", 957], ["compared", 961], ["this", 970], ["line", 975], ["with", 980], ["an", 985], ["equivalent", 988], ["knock", 999], ["-", 1004], ["in", 1005], ["line", 1008], ["but", 1013], ["in", 1017], ["the", 1020], ["absence", 1024], ["of", 1032], ["the", 1035], ["Dutch", 1039], ["mutation", 1045], [",", 1053], ["both", 1055], ["crossed", 1060], ["onto", 1068], ["the", 1073], ["PS1M146V", 1077], ["knock", 1086], ["-", 1091], ["in", 1092], ["background", 1095], [".", 1105], ["Introduction", 1107], ["of", 1120], ["the", 1123], ["Dutch", 1127], ["mutation", 1133], ["results", 1142], ["in", 1150], ["robust", 1153], ["CAA", 1160], ["and", 1164], ["parenchymal", 1168], ["A\u03b2", 1180], ["pathology", 1183], [",", 1192], ["age", 1194], ["-", 1197], ["dependent", 1198], ["reduction", 1208], ["of", 1218], ["spatial", 1221], ["learning", 1229], ["and", 1238], ["memory", 1242], ["deficits", 1249], [",", 1257], ["and", 1259], ["CBF", 1263], ["reduction", 1267], ["as", 1277], ["detected", 1280], ["by", 1289], ["fMRI", 1292], [".", 1296], ["Direct", 1298], ["manipulation", 1305], ["of", 1318], ["CBF", 1321], ["by", 1325], ["transverse", 1328], ["aortic", 1339], ["constriction", 1346], ["surgery", 1359], ["on", 1367], ["the", 1370], ["left", 1374], ["common", 1379], ["carotid", 1386], ["artery", 1394], ["caused", 1401], ["differential", 1408], ["changes", 1421], ["in", 1429], ["CBF", 1432], ["in", 1436], ["the", 1439], ["anterior", 1443], ["and", 1452], ["middle", 1456], ["region", 1463], ["of", 1470], ["the", 1473], ["cortex", 1477], [",", 1483], ["where", 1485], ["it", 1491], ["is", 1494], ["reduced", 1497], ["on", 1505], ["the", 1508], ["left", 1512], ["side", 1517], ["and", 1522], ["increased", 1526], ["on", 1536], ["the", 1539], ["right", 1543], ["side", 1549], [".", 1553], ["However", 1555], ["these", 1563], ["perturbations", 1569], ["in", 1583], ["CBF", 1586], ["resulted", 1590], ["in", 1599], ["the", 1602], ["same", 1606], ["effect", 1611], [":", 1617], ["both", 1619], ["significantly", 1624], ["exacerbate", 1638], ["CAA", 1649], ["and", 1653], ["amyloid", 1657], ["pathology", 1665], [".", 1674], ["Our", 1676], ["study", 1680], ["reveals", 1686], ["a", 1694], ["direct", 1696], ["and", 1703], ["positive", 1707], ["link", 1716], ["between", 1721], ["vascular", 1729], ["and", 1738], ["parenchymal", 1742], ["A\u03b2", 1754], [";", 1756], ["both", 1758], ["can", 1763], ["be", 1767], ["modulated", 1770], ["by", 1780], ["CBF", 1783], [".", 1786], ["The", 1788], ["new", 1792], ["APP", 1796], ["knock", 1800], ["-", 1805], ["in", 1806], ["mouse", 1809], ["model", 1815], ["recapitulates", 1821], ["many", 1835], ["symptoms", 1840], ["of", 1849], ["AD", 1852], ["including", 1855], ["progressive", 1865], ["vascular", 1877], ["and", 1886], ["parenchymal", 1890], ["A\u03b2", 1902], ["pathology", 1905], ["and", 1915], ["behavioral", 1919], ["deficits", 1930], ["in", 1939], ["the", 1942], ["absence", 1946], ["of", 1954], ["APP", 1957], ["overexpression", 1961], [".", 1975]]}
{"context": "To investigate the clinicopathologic features of focal cortical dysplasia (FCD) in patients with refractory epilepsy. The clinical, radiologic and pathologic features of 38 cases of FCD receiving surgical treatment in 2005 were reviewed retrospectively. The mean age of disease onset was 9.2 years. The disease lasted for 11.9 years on average and often presented as complex partial seizure. Radiologic examination revealed hippocampal sclerosis, or abnormal signals in the grey matter in 21 cases. According to Palmini's classification system, the following pathologic subgroups were identified: FCD type IA (3/38), FCD type IB (20/38), FCD type IIA (5/38) and FCD type IIB (5/38). The remaining 5 cases were classified as mild cortical dysplasia. Topographically, FCD type II was often seen in the extratemporal region (8/10), predominantly in the frontal lobe (5/8). Dual pathology was identified only in cases with FCD type IB. Immunohistochemical study showed that the giant neurons, immature neurons and dysmorphic neurons were strongly positive for NeuN. A small number of balloon cells expressed nestin. FCD is a common cause of refractory epilepsy. FCD type IB is the predominant pathologic subtype. Associated hippocampal sclerosis is sometimes seen. Clinicopathologic differences between FCD type I and FCD type II are observed.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "c273e4acf5d244feb5d5fca095c0254f", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[6, 8]], "char_spans": [[49, 72]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["clinicopathologic", 19], ["features", 37], ["of", 46], ["focal", 49], ["cortical", 55], ["dysplasia", 64], ["(", 74], ["FCD", 75], [")", 78], ["in", 80], ["patients", 83], ["with", 92], ["refractory", 97], ["epilepsy", 108], [".", 116], ["The", 118], ["clinical", 122], [",", 130], ["radiologic", 132], ["and", 143], ["pathologic", 147], ["features", 158], ["of", 167], ["38", 170], ["cases", 173], ["of", 179], ["FCD", 182], ["receiving", 186], ["surgical", 196], ["treatment", 205], ["in", 215], ["2005", 218], ["were", 223], ["reviewed", 228], ["retrospectively", 237], [".", 252], ["The", 254], ["mean", 258], ["age", 263], ["of", 267], ["disease", 270], ["onset", 278], ["was", 284], ["9.2", 288], ["years", 292], [".", 297], ["The", 299], ["disease", 303], ["lasted", 311], ["for", 318], ["11.9", 322], ["years", 327], ["on", 333], ["average", 336], ["and", 344], ["often", 348], ["presented", 354], ["as", 364], ["complex", 367], ["partial", 375], ["seizure", 383], [".", 390], ["Radiologic", 392], ["examination", 403], ["revealed", 415], ["hippocampal", 424], ["sclerosis", 436], [",", 445], ["or", 447], ["abnormal", 450], ["signals", 459], ["in", 467], ["the", 470], ["grey", 474], ["matter", 479], ["in", 486], ["21", 489], ["cases", 492], [".", 497], ["According", 499], ["to", 509], ["Palmini", 512], ["'s", 519], ["classification", 522], ["system", 537], [",", 543], ["the", 545], ["following", 549], ["pathologic", 559], ["subgroups", 570], ["were", 580], ["identified", 585], [":", 595], ["FCD", 597], ["type", 601], ["IA", 606], ["(", 609], ["3/38", 610], [")", 614], [",", 615], ["FCD", 617], ["type", 621], ["IB", 626], ["(", 629], ["20/38", 630], [")", 635], [",", 636], ["FCD", 638], ["type", 642], ["IIA", 647], ["(", 651], ["5/38", 652], [")", 656], ["and", 658], ["FCD", 662], ["type", 666], ["IIB", 671], ["(", 675], ["5/38", 676], [")", 680], [".", 681], ["The", 683], ["remaining", 687], ["5", 697], ["cases", 699], ["were", 705], ["classified", 710], ["as", 721], ["mild", 724], ["cortical", 729], ["dysplasia", 738], [".", 747], ["Topographically", 749], [",", 764], ["FCD", 766], ["type", 770], ["II", 775], ["was", 778], ["often", 782], ["seen", 788], ["in", 793], ["the", 796], ["extratemporal", 800], ["region", 814], ["(", 821], ["8/10", 822], [")", 826], [",", 827], ["predominantly", 829], ["in", 843], ["the", 846], ["frontal", 850], ["lobe", 858], ["(", 863], ["5/8", 864], [")", 867], [".", 868], ["Dual", 870], ["pathology", 875], ["was", 885], ["identified", 889], ["only", 900], ["in", 905], ["cases", 908], ["with", 914], ["FCD", 919], ["type", 923], ["IB", 928], [".", 930], ["Immunohistochemical", 932], ["study", 952], ["showed", 958], ["that", 965], ["the", 970], ["giant", 974], ["neurons", 980], [",", 987], ["immature", 989], ["neurons", 998], ["and", 1006], ["dysmorphic", 1010], ["neurons", 1021], ["were", 1029], ["strongly", 1034], ["positive", 1043], ["for", 1052], ["NeuN.", 1056], ["A", 1062], ["small", 1064], ["number", 1070], ["of", 1077], ["balloon", 1080], ["cells", 1088], ["expressed", 1094], ["nestin", 1104], [".", 1110], ["FCD", 1112], ["is", 1116], ["a", 1119], ["common", 1121], ["cause", 1128], ["of", 1134], ["refractory", 1137], ["epilepsy", 1148], [".", 1156], ["FCD", 1158], ["type", 1162], ["IB", 1167], ["is", 1170], ["the", 1173], ["predominant", 1177], ["pathologic", 1189], ["subtype", 1200], [".", 1207], ["Associated", 1209], ["hippocampal", 1220], ["sclerosis", 1232], ["is", 1242], ["sometimes", 1245], ["seen", 1255], [".", 1259], ["Clinicopathologic", 1261], ["differences", 1279], ["between", 1291], ["FCD", 1299], ["type", 1303], ["I", 1308], ["and", 1310], ["FCD", 1314], ["type", 1318], ["II", 1323], ["are", 1326], ["observed", 1330], [".", 1338]]}
{"context": "Pulmonary hypertension (PH) is a progressive disease that is accompanied by a poor prognosis. Pulmonary vasoconstriction is facilitated through multiple pathways and results in increased pulmonary vascular pressure leading to cell proliferation, vascular remodeling, right ventricular hypertrophy/failure, and ultimately death. Until recently, just six medications were approved -all for one subclass of PH. On October 8, 2013, riociguat (Adempas\u00ae) became the first medication approved for multiple etiologies of PH. Preclinical studies have demonstrated safety and efficacy with significant clinical trials supporting its advancement into phase IV trials. Although long-term safety and efficacy and place in therapy remain to be established, riociguat presents as an exciting new option for the treatment of PH and potentially has additional indications in the near future.", "qas": [{"question": "What is generic name of drug Adempas?", "answers": ["riociguat"], "qid": "1a49f6b645ff49e59f4946d1e6242dc5", "question_tokens": [["What", 0], ["is", 5], ["generic", 8], ["name", 16], ["of", 21], ["drug", 24], ["Adempas", 29], ["?", 36]], "detected_answers": [{"text": "riociguat", "token_spans": [[121, 121], [70, 70]], "char_spans": [[743, 751], [428, 436]]}]}], "context_tokens": [["Pulmonary", 0], ["hypertension", 10], ["(", 23], ["PH", 24], [")", 26], ["is", 28], ["a", 31], ["progressive", 33], ["disease", 45], ["that", 53], ["is", 58], ["accompanied", 61], ["by", 73], ["a", 76], ["poor", 78], ["prognosis", 83], [".", 92], ["Pulmonary", 94], ["vasoconstriction", 104], ["is", 121], ["facilitated", 124], ["through", 136], ["multiple", 144], ["pathways", 153], ["and", 162], ["results", 166], ["in", 174], ["increased", 177], ["pulmonary", 187], ["vascular", 197], ["pressure", 206], ["leading", 215], ["to", 223], ["cell", 226], ["proliferation", 231], [",", 244], ["vascular", 246], ["remodeling", 255], [",", 265], ["right", 267], ["ventricular", 273], ["hypertrophy", 285], ["/", 296], ["failure", 297], [",", 304], ["and", 306], ["ultimately", 310], ["death", 321], [".", 326], ["Until", 328], ["recently", 334], [",", 342], ["just", 344], ["six", 349], ["medications", 353], ["were", 365], ["approved", 370], ["-all", 379], ["for", 384], ["one", 388], ["subclass", 392], ["of", 401], ["PH", 404], [".", 406], ["On", 408], ["October", 411], ["8", 419], [",", 420], ["2013", 422], [",", 426], ["riociguat", 428], ["(", 438], ["Adempas", 439], ["\u00ae", 446], [")", 447], ["became", 449], ["the", 456], ["first", 460], ["medication", 466], ["approved", 477], ["for", 486], ["multiple", 490], ["etiologies", 499], ["of", 510], ["PH", 513], [".", 515], ["Preclinical", 517], ["studies", 529], ["have", 537], ["demonstrated", 542], ["safety", 555], ["and", 562], ["efficacy", 566], ["with", 575], ["significant", 580], ["clinical", 592], ["trials", 601], ["supporting", 608], ["its", 619], ["advancement", 623], ["into", 635], ["phase", 640], ["IV", 646], ["trials", 649], [".", 655], ["Although", 657], ["long", 666], ["-", 670], ["term", 671], ["safety", 676], ["and", 683], ["efficacy", 687], ["and", 696], ["place", 700], ["in", 706], ["therapy", 709], ["remain", 717], ["to", 724], ["be", 727], ["established", 730], [",", 741], ["riociguat", 743], ["presents", 753], ["as", 762], ["an", 765], ["exciting", 768], ["new", 777], ["option", 781], ["for", 788], ["the", 792], ["treatment", 796], ["of", 806], ["PH", 809], ["and", 812], ["potentially", 816], ["has", 828], ["additional", 832], ["indications", 843], ["in", 855], ["the", 858], ["near", 862], ["future", 867], [".", 873]]}
{"context": "Susceptibility to autoimmune disorders results from the interaction of multiple genetic factors that regulate the threshold of autoreactivity. Genome-wide microsatellite screens and large-scale single nucleotide polymorphism (SNP) association studies have identified chromosomal loci that are associated with specific disorders including systemic lupus erythematosus, rheumatoid arthritis, juvenile arthritis, multiple sclerosis, and diabetes. Numerous candidate gene association studies have in turn investigated the association of specific genes within these chromosomal regions, with susceptibility to autoimmune diseases (e.g. FcgammaReceptors, TYK2 and systemic lupus). More recently, large-scale differential gene expression studies performed on selected tissues from patients with autoimmune disorders, have led to the identification of gene signatures associated with the activation of specific pathways in these diseases (e.g. interferon signature in lupus). In the future, integrated analyses of gene (and protein) expression together with SNP data will allow us to sketch an intelligible picture of the genesis of autoimmunity in humans. This review sets out to illustrate how the most recent advances in the field of systemic lupus erythematosus, rheumatoid arthritis and juvenile arthritis have led to a better understanding of these disorders.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "b57e6d932c6f403896f80cdbf5c54bf9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "Interferon signature", "token_spans": [[137, 138]], "char_spans": [[936, 955]]}]}], "context_tokens": [["Susceptibility", 0], ["to", 15], ["autoimmune", 18], ["disorders", 29], ["results", 39], ["from", 47], ["the", 52], ["interaction", 56], ["of", 68], ["multiple", 71], ["genetic", 80], ["factors", 88], ["that", 96], ["regulate", 101], ["the", 110], ["threshold", 114], ["of", 124], ["autoreactivity", 127], [".", 141], ["Genome", 143], ["-", 149], ["wide", 150], ["microsatellite", 155], ["screens", 170], ["and", 178], ["large", 182], ["-", 187], ["scale", 188], ["single", 194], ["nucleotide", 201], ["polymorphism", 212], ["(", 225], ["SNP", 226], [")", 229], ["association", 231], ["studies", 243], ["have", 251], ["identified", 256], ["chromosomal", 267], ["loci", 279], ["that", 284], ["are", 289], ["associated", 293], ["with", 304], ["specific", 309], ["disorders", 318], ["including", 328], ["systemic", 338], ["lupus", 347], ["erythematosus", 353], [",", 366], ["rheumatoid", 368], ["arthritis", 379], [",", 388], ["juvenile", 390], ["arthritis", 399], [",", 408], ["multiple", 410], ["sclerosis", 419], [",", 428], ["and", 430], ["diabetes", 434], [".", 442], ["Numerous", 444], ["candidate", 453], ["gene", 463], ["association", 468], ["studies", 480], ["have", 488], ["in", 493], ["turn", 496], ["investigated", 501], ["the", 514], ["association", 518], ["of", 530], ["specific", 533], ["genes", 542], ["within", 548], ["these", 555], ["chromosomal", 561], ["regions", 573], [",", 580], ["with", 582], ["susceptibility", 587], ["to", 602], ["autoimmune", 605], ["diseases", 616], ["(", 625], ["e.g.", 626], ["FcgammaReceptors", 631], [",", 647], ["TYK2", 649], ["and", 654], ["systemic", 658], ["lupus", 667], [")", 672], [".", 673], ["More", 675], ["recently", 680], [",", 688], ["large", 690], ["-", 695], ["scale", 696], ["differential", 702], ["gene", 715], ["expression", 720], ["studies", 731], ["performed", 739], ["on", 749], ["selected", 752], ["tissues", 761], ["from", 769], ["patients", 774], ["with", 783], ["autoimmune", 788], ["disorders", 799], [",", 808], ["have", 810], ["led", 815], ["to", 819], ["the", 822], ["identification", 826], ["of", 841], ["gene", 844], ["signatures", 849], ["associated", 860], ["with", 871], ["the", 876], ["activation", 880], ["of", 891], ["specific", 894], ["pathways", 903], ["in", 912], ["these", 915], ["diseases", 921], ["(", 930], ["e.g.", 931], ["interferon", 936], ["signature", 947], ["in", 957], ["lupus", 960], [")", 965], [".", 966], ["In", 968], ["the", 971], ["future", 975], [",", 981], ["integrated", 983], ["analyses", 994], ["of", 1003], ["gene", 1006], ["(", 1011], ["and", 1012], ["protein", 1016], [")", 1023], ["expression", 1025], ["together", 1036], ["with", 1045], ["SNP", 1050], ["data", 1054], ["will", 1059], ["allow", 1064], ["us", 1070], ["to", 1073], ["sketch", 1076], ["an", 1083], ["intelligible", 1086], ["picture", 1099], ["of", 1107], ["the", 1110], ["genesis", 1114], ["of", 1122], ["autoimmunity", 1125], ["in", 1138], ["humans", 1141], [".", 1147], ["This", 1149], ["review", 1154], ["sets", 1161], ["out", 1166], ["to", 1170], ["illustrate", 1173], ["how", 1184], ["the", 1188], ["most", 1192], ["recent", 1197], ["advances", 1204], ["in", 1213], ["the", 1216], ["field", 1220], ["of", 1226], ["systemic", 1229], ["lupus", 1238], ["erythematosus", 1244], [",", 1257], ["rheumatoid", 1259], ["arthritis", 1270], ["and", 1280], ["juvenile", 1284], ["arthritis", 1293], ["have", 1303], ["led", 1308], ["to", 1312], ["a", 1315], ["better", 1317], ["understanding", 1324], ["of", 1338], ["these", 1341], ["disorders", 1347], [".", 1356]]}
{"context": "An outbreak of Clostridium difficile infection (CDI) caused by ribotype 027 (B1/NAP1) began in our hospital in November 2014, and produced 141 episodes in the following months. The aim of this study is to describe this outbreak, assess risk factors for recurrence of CDI-027 and to analyze the implementation of a novel treatment strategy. This is a prospective study of all patients with CDI-027, from November 2014 to November 2015. The epidemiological data were collected daily for each patient. We compared clinical characteristics and treatment between patients with and without recurrence of CDI-027. Interestingly, liver cirrhosis was present in 22% of the patients, and most of them received prophylaxis for hepatic encephalopathy with rifaximin. Patients were also taking antimicrobial drugs (93.6%) and proton pump inhibitors (80.1%). Overall, 27 (23.5%) patients had a first recurrence of CDI-027. Liver cirrhosis increased the risk of recurrence (44.4% vs 14.8%). Patients treated with a prolonged oral vancomycin regimen vs the conventional regimen (oral metronidazole or 10\u00a0days of vancomycin) had fewer recurrences (8.6 versus 44.7% [p\u00a0\u2264\u00a00.01]; OR, 0.91; 95% CI, 0.028-0.294) and less attributable mortality (0% versus 7.1%; p\u00a0=\u00a00.058). We report an outbreak of CDI-027, mainly in patients with liver cirrhosis. Recurrence of CDI-027 was more common in those patients. A novel approach involving high-dose prolonged vancomycin taper as a first-line treatment, together with a bundle of outbreak measures, seemed to reduce the number of cases of CDI-027, recurrences, and attributable mortality. Nevertheless, this approach warrants further investigation.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "38addabed56946b49d470b639537d475", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[11, 12]], "char_spans": [[63, 74]]}]}], "context_tokens": [["An", 0], ["outbreak", 3], ["of", 12], ["Clostridium", 15], ["difficile", 27], ["infection", 37], ["(", 47], ["CDI", 48], [")", 51], ["caused", 53], ["by", 60], ["ribotype", 63], ["027", 72], ["(", 76], ["B1/NAP1", 77], [")", 84], ["began", 86], ["in", 92], ["our", 95], ["hospital", 99], ["in", 108], ["November", 111], ["2014", 120], [",", 124], ["and", 126], ["produced", 130], ["141", 139], ["episodes", 143], ["in", 152], ["the", 155], ["following", 159], ["months", 169], [".", 175], ["The", 177], ["aim", 181], ["of", 185], ["this", 188], ["study", 193], ["is", 199], ["to", 202], ["describe", 205], ["this", 214], ["outbreak", 219], [",", 227], ["assess", 229], ["risk", 236], ["factors", 241], ["for", 249], ["recurrence", 253], ["of", 264], ["CDI-027", 267], ["and", 275], ["to", 279], ["analyze", 282], ["the", 290], ["implementation", 294], ["of", 309], ["a", 312], ["novel", 314], ["treatment", 320], ["strategy", 330], [".", 338], ["This", 340], ["is", 345], ["a", 348], ["prospective", 350], ["study", 362], ["of", 368], ["all", 371], ["patients", 375], ["with", 384], ["CDI-027", 389], [",", 396], ["from", 398], ["November", 403], ["2014", 412], ["to", 417], ["November", 420], ["2015", 429], [".", 433], ["The", 435], ["epidemiological", 439], ["data", 455], ["were", 460], ["collected", 465], ["daily", 475], ["for", 481], ["each", 485], ["patient", 490], [".", 497], ["We", 499], ["compared", 502], ["clinical", 511], ["characteristics", 520], ["and", 536], ["treatment", 540], ["between", 550], ["patients", 558], ["with", 567], ["and", 572], ["without", 576], ["recurrence", 584], ["of", 595], ["CDI-027", 598], [".", 605], ["Interestingly", 607], [",", 620], ["liver", 622], ["cirrhosis", 628], ["was", 638], ["present", 642], ["in", 650], ["22", 653], ["%", 655], ["of", 657], ["the", 660], ["patients", 664], [",", 672], ["and", 674], ["most", 678], ["of", 683], ["them", 686], ["received", 691], ["prophylaxis", 700], ["for", 712], ["hepatic", 716], ["encephalopathy", 724], ["with", 739], ["rifaximin", 744], [".", 753], ["Patients", 755], ["were", 764], ["also", 769], ["taking", 774], ["antimicrobial", 781], ["drugs", 795], ["(", 801], ["93.6", 802], ["%", 806], [")", 807], ["and", 809], ["proton", 813], ["pump", 820], ["inhibitors", 825], ["(", 836], ["80.1", 837], ["%", 841], [")", 842], [".", 843], ["Overall", 845], [",", 852], ["27", 854], ["(", 857], ["23.5", 858], ["%", 862], [")", 863], ["patients", 865], ["had", 874], ["a", 878], ["first", 880], ["recurrence", 886], ["of", 897], ["CDI-027", 900], [".", 907], ["Liver", 909], ["cirrhosis", 915], ["increased", 925], ["the", 935], ["risk", 939], ["of", 944], ["recurrence", 947], ["(", 958], ["44.4", 959], ["%", 963], ["vs", 965], ["14.8", 968], ["%", 972], [")", 973], [".", 974], ["Patients", 976], ["treated", 985], ["with", 993], ["a", 998], ["prolonged", 1000], ["oral", 1010], ["vancomycin", 1015], ["regimen", 1026], ["vs", 1034], ["the", 1037], ["conventional", 1041], ["regimen", 1054], ["(", 1062], ["oral", 1063], ["metronidazole", 1068], ["or", 1082], ["10", 1085], ["days", 1088], ["of", 1093], ["vancomycin", 1096], [")", 1106], ["had", 1108], ["fewer", 1112], ["recurrences", 1118], ["(", 1130], ["8.6", 1131], ["versus", 1135], ["44.7", 1142], ["%", 1146], ["[", 1148], ["p", 1149], ["\u2264", 1151], ["0.01", 1153], ["]", 1157], [";", 1158], ["OR", 1160], [",", 1162], ["0.91", 1164], [";", 1168], ["95", 1170], ["%", 1172], ["CI", 1174], [",", 1176], ["0.028", 1178], ["-", 1183], ["0.294", 1184], [")", 1189], ["and", 1191], ["less", 1195], ["attributable", 1200], ["mortality", 1213], ["(", 1223], ["0", 1224], ["%", 1225], ["versus", 1227], ["7.1", 1234], ["%", 1237], [";", 1238], ["p", 1240], ["=", 1242], ["0.058", 1244], [")", 1249], [".", 1250], ["We", 1252], ["report", 1255], ["an", 1262], ["outbreak", 1265], ["of", 1274], ["CDI-027", 1277], [",", 1284], ["mainly", 1286], ["in", 1293], ["patients", 1296], ["with", 1305], ["liver", 1310], ["cirrhosis", 1316], [".", 1325], ["Recurrence", 1327], ["of", 1338], ["CDI-027", 1341], ["was", 1349], ["more", 1353], ["common", 1358], ["in", 1365], ["those", 1368], ["patients", 1374], [".", 1382], ["A", 1384], ["novel", 1386], ["approach", 1392], ["involving", 1401], ["high", 1411], ["-", 1415], ["dose", 1416], ["prolonged", 1421], ["vancomycin", 1431], ["taper", 1442], ["as", 1448], ["a", 1451], ["first", 1453], ["-", 1458], ["line", 1459], ["treatment", 1464], [",", 1473], ["together", 1475], ["with", 1484], ["a", 1489], ["bundle", 1491], ["of", 1498], ["outbreak", 1501], ["measures", 1510], [",", 1518], ["seemed", 1520], ["to", 1527], ["reduce", 1530], ["the", 1537], ["number", 1541], ["of", 1548], ["cases", 1551], ["of", 1557], ["CDI-027", 1560], [",", 1567], ["recurrences", 1569], [",", 1580], ["and", 1582], ["attributable", 1586], ["mortality", 1599], [".", 1608], ["Nevertheless", 1610], [",", 1622], ["this", 1624], ["approach", 1629], ["warrants", 1638], ["further", 1647], ["investigation", 1655], [".", 1668]]}
{"context": "Vascular Ehlers-Danlos Syndrome (VEDS), previously called Ehlers-Danlos syndrome type-IV, is a heterogeneous group of heritable connective tissue disorders characterized by thin, translucent skin, easy bruising, arterial, intestinal, and/or uterine fragility. There is large vessel involvement that leads to arterial rupture often preceded by aneurysm, arteriovenous fistulae, or dissection. Noninvasive imaging studies such as CT angiography and MR angiography are preferred as diagnostic studies for this condition. We are reporting a 4 years old girl who was presented with right sided unilateral convulsions and hypertension. CT angiogram showed stenosis with post-stenotic dilatation of coeliac and superior mesenteric arteries. There were extensive calcified plaques with atherosclerotic changes in the segment of right common iliac artery with aneurysmal dilatation of celiac, superior mesenteric and common iliac artery. Radiological findings were consistent with vascular Ehlers-Danlos syndrome. She was successfully managed with anti-hypertensive and anticonvulsants.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "c4aa033a18f745d98c38639082418fe4", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[25, 26]], "char_spans": [[128, 144]]}]}], "context_tokens": [["Vascular", 0], ["Ehlers", 9], ["-", 15], ["Danlos", 16], ["Syndrome", 23], ["(", 32], ["VEDS", 33], [")", 37], [",", 38], ["previously", 40], ["called", 51], ["Ehlers", 58], ["-", 64], ["Danlos", 65], ["syndrome", 72], ["type", 81], ["-", 85], ["IV", 86], [",", 88], ["is", 90], ["a", 93], ["heterogeneous", 95], ["group", 109], ["of", 115], ["heritable", 118], ["connective", 128], ["tissue", 139], ["disorders", 146], ["characterized", 156], ["by", 170], ["thin", 173], [",", 177], ["translucent", 179], ["skin", 191], [",", 195], ["easy", 197], ["bruising", 202], [",", 210], ["arterial", 212], [",", 220], ["intestinal", 222], [",", 232], ["and/or", 234], ["uterine", 241], ["fragility", 249], [".", 258], ["There", 260], ["is", 266], ["large", 269], ["vessel", 275], ["involvement", 282], ["that", 294], ["leads", 299], ["to", 305], ["arterial", 308], ["rupture", 317], ["often", 325], ["preceded", 331], ["by", 340], ["aneurysm", 343], [",", 351], ["arteriovenous", 353], ["fistulae", 367], [",", 375], ["or", 377], ["dissection", 380], [".", 390], ["Noninvasive", 392], ["imaging", 404], ["studies", 412], ["such", 420], ["as", 425], ["CT", 428], ["angiography", 431], ["and", 443], ["MR", 447], ["angiography", 450], ["are", 462], ["preferred", 466], ["as", 476], ["diagnostic", 479], ["studies", 490], ["for", 498], ["this", 502], ["condition", 507], [".", 516], ["We", 518], ["are", 521], ["reporting", 525], ["a", 535], ["4", 537], ["years", 539], ["old", 545], ["girl", 549], ["who", 554], ["was", 558], ["presented", 562], ["with", 572], ["right", 577], ["sided", 583], ["unilateral", 589], ["convulsions", 600], ["and", 612], ["hypertension", 616], [".", 628], ["CT", 630], ["angiogram", 633], ["showed", 643], ["stenosis", 650], ["with", 659], ["post", 664], ["-", 668], ["stenotic", 669], ["dilatation", 678], ["of", 689], ["coeliac", 692], ["and", 700], ["superior", 704], ["mesenteric", 713], ["arteries", 724], [".", 732], ["There", 734], ["were", 740], ["extensive", 745], ["calcified", 755], ["plaques", 765], ["with", 773], ["atherosclerotic", 778], ["changes", 794], ["in", 802], ["the", 805], ["segment", 809], ["of", 817], ["right", 820], ["common", 826], ["iliac", 833], ["artery", 839], ["with", 846], ["aneurysmal", 851], ["dilatation", 862], ["of", 873], ["celiac", 876], [",", 882], ["superior", 884], ["mesenteric", 893], ["and", 904], ["common", 908], ["iliac", 915], ["artery", 921], [".", 927], ["Radiological", 929], ["findings", 942], ["were", 951], ["consistent", 956], ["with", 967], ["vascular", 972], ["Ehlers", 981], ["-", 987], ["Danlos", 988], ["syndrome", 995], [".", 1003], ["She", 1005], ["was", 1009], ["successfully", 1013], ["managed", 1026], ["with", 1034], ["anti", 1039], ["-", 1043], ["hypertensive", 1044], ["and", 1057], ["anticonvulsants", 1061], [".", 1076]]}
{"context": "The identification of the Philadelphia chromosome in cells from individuals with chronic myelogenous leukemia (CML) led to the recognition that the BCR-ABL tyrosine kinase causes CML. This in turn led to the development of imatinib mesylate, a clinically successful inhibitor of the BCR-ABL kinase. Incorporating the use of markers of BCR-ABL kinase inhibition into clinical trials led to the realization that imatinib-resistant kinase domain mutations are the major cause of relapse during imatinib therapy and the subsequent development of new inhibitors to treat CML patients. The development of imatinib validates an emerging paradigm in cancer, in which a tumor is defined by genetic abnormalities and effective therapies are developed that target events critical to the growth and survival of a specific tumor.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "773d0b65b19340d59e18c9cf74fe8c94", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[48, 50], [59, 61], [23, 25]], "char_spans": [[283, 289], [335, 341], [148, 154]]}]}], "context_tokens": [["The", 0], ["identification", 4], ["of", 19], ["the", 22], ["Philadelphia", 26], ["chromosome", 39], ["in", 50], ["cells", 53], ["from", 59], ["individuals", 64], ["with", 76], ["chronic", 81], ["myelogenous", 89], ["leukemia", 101], ["(", 110], ["CML", 111], [")", 114], ["led", 116], ["to", 120], ["the", 123], ["recognition", 127], ["that", 139], ["the", 144], ["BCR", 148], ["-", 151], ["ABL", 152], ["tyrosine", 156], ["kinase", 165], ["causes", 172], ["CML", 179], [".", 182], ["This", 184], ["in", 189], ["turn", 192], ["led", 197], ["to", 201], ["the", 204], ["development", 208], ["of", 220], ["imatinib", 223], ["mesylate", 232], [",", 240], ["a", 242], ["clinically", 244], ["successful", 255], ["inhibitor", 266], ["of", 276], ["the", 279], ["BCR", 283], ["-", 286], ["ABL", 287], ["kinase", 291], [".", 297], ["Incorporating", 299], ["the", 313], ["use", 317], ["of", 321], ["markers", 324], ["of", 332], ["BCR", 335], ["-", 338], ["ABL", 339], ["kinase", 343], ["inhibition", 350], ["into", 361], ["clinical", 366], ["trials", 375], ["led", 382], ["to", 386], ["the", 389], ["realization", 393], ["that", 405], ["imatinib", 410], ["-", 418], ["resistant", 419], ["kinase", 429], ["domain", 436], ["mutations", 443], ["are", 453], ["the", 457], ["major", 461], ["cause", 467], ["of", 473], ["relapse", 476], ["during", 484], ["imatinib", 491], ["therapy", 500], ["and", 508], ["the", 512], ["subsequent", 516], ["development", 527], ["of", 539], ["new", 542], ["inhibitors", 546], ["to", 557], ["treat", 560], ["CML", 566], ["patients", 570], [".", 578], ["The", 580], ["development", 584], ["of", 596], ["imatinib", 599], ["validates", 608], ["an", 618], ["emerging", 621], ["paradigm", 630], ["in", 639], ["cancer", 642], [",", 648], ["in", 650], ["which", 653], ["a", 659], ["tumor", 661], ["is", 667], ["defined", 670], ["by", 678], ["genetic", 681], ["abnormalities", 689], ["and", 703], ["effective", 707], ["therapies", 717], ["are", 727], ["developed", 731], ["that", 741], ["target", 746], ["events", 753], ["critical", 760], ["to", 769], ["the", 772], ["growth", 776], ["and", 783], ["survival", 787], ["of", 796], ["a", 799], ["specific", 801], ["tumor", 810], [".", 815]]}
{"context": "The precursor of the non-Abeta component of Alzheimer's disease amyloid (NACP) (also known as alpha-synuclein) is a presynaptic terminal molecule that abnormally accumulates in the plaques of Alzheimer's disease (AD) and in the Lewy bodies (LBs) of Lewy body variant of AD, diffuse Lewy body disease, and Parkinson's disease. To better understand the distribution of NACP/alpha-synuclein and its fragments in the LB-bearing neurons and neurites, as well as to clarify the patterns of NACP/alpha-synuclein compartmentalization, we studied NACP/alpha-synuclein immunoreactivity using antibodies against the C-terminal, N-terminal, and NAC regions after Proteinase K and formic acid treatment in the cortex of patients with LBs. Furthermore, studies of the subcellular localization of NACP/alpha-synuclein within LB-bearing neurons were performed by immunogold electron microscopy. These studies showed that the N-terminal antibody immunolabeled the LBs and dystrophic neurites with great intensity and, to a lesser extent, the synapses. In contrast, the C-terminal antibody strongly labeled the synapses and, to a lesser extent, the LBs and dystrophic neurites. Whereas Proteinase K treatment enhanced NACP/alpha-synuclein immunoreactivity with the C-terminal antibody, it diminished the N-terminal NACP/alpha-synuclein immunoreactivity. Furthermore, formic acid enhanced LB and dystrophic neurite labeling with both the C- and N-terminal antibodies. In addition, whereas without pretreatment only slight anti-NAC immunoreactivity was found in the LBs, formic acid pretreatment revealed an extensive anti-NAC immunostaining of LBs, plaques, and glial cells. Ultrastructural analysis revealed that NACP/alpha-synuclein immunoreactivity was diffusely distributed within the amorphous electrodense material in the LBs and as small clusters in the filaments of LBs and neurites. These results support the view that aggregated NACP/alpha-synuclein might play an important role in the pathogenesis of disorders associated with LBs.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "d3600ecb55744469b54fde10d8d1c38e", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[247, 249], [100, 102], [20, 22], [228, 230], [109, 111], [153, 155], [351, 353], [315, 317], [75, 77]], "char_spans": [[1302, 1316], [489, 503], [94, 108], [1205, 1219], [543, 557], [787, 801], [1925, 1939], [1700, 1714], [372, 386]]}]}], "context_tokens": [["The", 0], ["precursor", 4], ["of", 14], ["the", 17], ["non", 21], ["-", 24], ["Abeta", 25], ["component", 31], ["of", 41], ["Alzheimer", 44], ["'s", 53], ["disease", 56], ["amyloid", 64], ["(", 72], ["NACP", 73], [")", 77], ["(", 79], ["also", 80], ["known", 85], ["as", 91], ["alpha", 94], ["-", 99], ["synuclein", 100], [")", 109], ["is", 111], ["a", 114], ["presynaptic", 116], ["terminal", 128], ["molecule", 137], ["that", 146], ["abnormally", 151], ["accumulates", 162], ["in", 174], ["the", 177], ["plaques", 181], ["of", 189], ["Alzheimer", 192], ["'s", 201], ["disease", 204], ["(", 212], ["AD", 213], [")", 215], ["and", 217], ["in", 221], ["the", 224], ["Lewy", 228], ["bodies", 233], ["(", 240], ["LBs", 241], [")", 244], ["of", 246], ["Lewy", 249], ["body", 254], ["variant", 259], ["of", 267], ["AD", 270], [",", 272], ["diffuse", 274], ["Lewy", 282], ["body", 287], ["disease", 292], [",", 299], ["and", 301], ["Parkinson", 305], ["'s", 314], ["disease", 317], [".", 324], ["To", 326], ["better", 329], ["understand", 336], ["the", 347], ["distribution", 351], ["of", 364], ["NACP", 367], ["/", 371], ["alpha", 372], ["-", 377], ["synuclein", 378], ["and", 388], ["its", 392], ["fragments", 396], ["in", 406], ["the", 409], ["LB", 413], ["-", 415], ["bearing", 416], ["neurons", 424], ["and", 432], ["neurites", 436], [",", 444], ["as", 446], ["well", 449], ["as", 454], ["to", 457], ["clarify", 460], ["the", 468], ["patterns", 472], ["of", 481], ["NACP", 484], ["/", 488], ["alpha", 489], ["-", 494], ["synuclein", 495], ["compartmentalization", 505], [",", 525], ["we", 527], ["studied", 530], ["NACP", 538], ["/", 542], ["alpha", 543], ["-", 548], ["synuclein", 549], ["immunoreactivity", 559], ["using", 576], ["antibodies", 582], ["against", 593], ["the", 601], ["C", 605], ["-", 606], ["terminal", 607], [",", 615], ["N", 617], ["-", 618], ["terminal", 619], [",", 627], ["and", 629], ["NAC", 633], ["regions", 637], ["after", 645], ["Proteinase", 651], ["K", 662], ["and", 664], ["formic", 668], ["acid", 675], ["treatment", 680], ["in", 690], ["the", 693], ["cortex", 697], ["of", 704], ["patients", 707], ["with", 716], ["LBs", 721], [".", 724], ["Furthermore", 726], [",", 737], ["studies", 739], ["of", 747], ["the", 750], ["subcellular", 754], ["localization", 766], ["of", 779], ["NACP", 782], ["/", 786], ["alpha", 787], ["-", 792], ["synuclein", 793], ["within", 803], ["LB", 810], ["-", 812], ["bearing", 813], ["neurons", 821], ["were", 829], ["performed", 834], ["by", 844], ["immunogold", 847], ["electron", 858], ["microscopy", 867], [".", 877], ["These", 879], ["studies", 885], ["showed", 893], ["that", 900], ["the", 905], ["N", 909], ["-", 910], ["terminal", 911], ["antibody", 920], ["immunolabeled", 929], ["the", 943], ["LBs", 947], ["and", 951], ["dystrophic", 955], ["neurites", 966], ["with", 975], ["great", 980], ["intensity", 986], ["and", 996], [",", 999], ["to", 1001], ["a", 1004], ["lesser", 1006], ["extent", 1013], [",", 1019], ["the", 1021], ["synapses", 1025], [".", 1033], ["In", 1035], ["contrast", 1038], [",", 1046], ["the", 1048], ["C", 1052], ["-", 1053], ["terminal", 1054], ["antibody", 1063], ["strongly", 1072], ["labeled", 1081], ["the", 1089], ["synapses", 1093], ["and", 1102], [",", 1105], ["to", 1107], ["a", 1110], ["lesser", 1112], ["extent", 1119], [",", 1125], ["the", 1127], ["LBs", 1131], ["and", 1135], ["dystrophic", 1139], ["neurites", 1150], [".", 1158], ["Whereas", 1160], ["Proteinase", 1168], ["K", 1179], ["treatment", 1181], ["enhanced", 1191], ["NACP", 1200], ["/", 1204], ["alpha", 1205], ["-", 1210], ["synuclein", 1211], ["immunoreactivity", 1221], ["with", 1238], ["the", 1243], ["C", 1247], ["-", 1248], ["terminal", 1249], ["antibody", 1258], [",", 1266], ["it", 1268], ["diminished", 1271], ["the", 1282], ["N", 1286], ["-", 1287], ["terminal", 1288], ["NACP", 1297], ["/", 1301], ["alpha", 1302], ["-", 1307], ["synuclein", 1308], ["immunoreactivity", 1318], [".", 1334], ["Furthermore", 1336], [",", 1347], ["formic", 1349], ["acid", 1356], ["enhanced", 1361], ["LB", 1370], ["and", 1373], ["dystrophic", 1377], ["neurite", 1388], ["labeling", 1396], ["with", 1405], ["both", 1410], ["the", 1415], ["C-", 1419], ["and", 1422], ["N", 1426], ["-", 1427], ["terminal", 1428], ["antibodies", 1437], [".", 1447], ["In", 1449], ["addition", 1452], [",", 1460], ["whereas", 1462], ["without", 1470], ["pretreatment", 1478], ["only", 1491], ["slight", 1496], ["anti", 1503], ["-", 1507], ["NAC", 1508], ["immunoreactivity", 1512], ["was", 1529], ["found", 1533], ["in", 1539], ["the", 1542], ["LBs", 1546], [",", 1549], ["formic", 1551], ["acid", 1558], ["pretreatment", 1563], ["revealed", 1576], ["an", 1585], ["extensive", 1588], ["anti", 1598], ["-", 1602], ["NAC", 1603], ["immunostaining", 1607], ["of", 1622], ["LBs", 1625], [",", 1628], ["plaques", 1630], [",", 1637], ["and", 1639], ["glial", 1643], ["cells", 1649], [".", 1654], ["Ultrastructural", 1656], ["analysis", 1672], ["revealed", 1681], ["that", 1690], ["NACP", 1695], ["/", 1699], ["alpha", 1700], ["-", 1705], ["synuclein", 1706], ["immunoreactivity", 1716], ["was", 1733], ["diffusely", 1737], ["distributed", 1747], ["within", 1759], ["the", 1766], ["amorphous", 1770], ["electrodense", 1780], ["material", 1793], ["in", 1802], ["the", 1805], ["LBs", 1809], ["and", 1813], ["as", 1817], ["small", 1820], ["clusters", 1826], ["in", 1835], ["the", 1838], ["filaments", 1842], ["of", 1852], ["LBs", 1855], ["and", 1859], ["neurites", 1863], [".", 1871], ["These", 1873], ["results", 1879], ["support", 1887], ["the", 1895], ["view", 1899], ["that", 1904], ["aggregated", 1909], ["NACP", 1920], ["/", 1924], ["alpha", 1925], ["-", 1930], ["synuclein", 1931], ["might", 1941], ["play", 1947], ["an", 1952], ["important", 1955], ["role", 1965], ["in", 1970], ["the", 1973], ["pathogenesis", 1977], ["of", 1990], ["disorders", 1993], ["associated", 2003], ["with", 2014], ["LBs", 2019], [".", 2022]]}
{"context": "1. Using SEA0400, a potent and selective inhibitor of the Na+-Ca2+ exchanger (NCX), we examined whether NCX is involved in nitric oxide (NO)-induced disturbance of endoplasmic reticulum (ER) Ca2+ homeostasis followed by apoptosis in cultured rat microglia. 2. Sodium nitroprusside (SNP), an NO donor, decreased cell viability in a dose- and time-dependent manner with apoptotic cell death in cultured microglia. 3. Treatment with SNP decreased the ER Ca2+ levels as evaluated by measuring the increase in cytosolic Ca2+ level induced by exposing cells to thapsigargin, an irreversible inhibitor of ER Ca2+-ATPase. 4. The treatment with SNP also increased mRNA expression of CHOP and GPR78, makers of ER stress. 5. SEA0400 at 0.3-1.0 microM protected microglia against SNP-induced apoptosis. 6. SEA0400 blocked not only the SNP-induced decrease in ER Ca2+ levels but also SNP-induced increase in CHOP and GRP78 mRNAs. 7. SEA0400 did not affect capacitative Ca2+ entry in the presence and absence of SNP. 8. SNP increased Na+-dependent 45Ca2+ uptake and this increase was blocked by SEA0400. 9. These results suggest that SNP induces apoptosis via the ER stress pathway and SEA0400 attenuates SNP-induced apoptosis via suppression of the ER stress in cultured microglia. Our findings imply that NCX plays a role in ER Ca2+ depletion under pathological conditions.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "0e4286e02a654fdcade9b809d5a16301", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[250, 250], [16, 16], [22, 22]], "char_spans": [[1293, 1295], [78, 80], [104, 106]]}]}], "context_tokens": [["1", 0], [".", 1], ["Using", 3], ["SEA0400", 9], [",", 16], ["a", 18], ["potent", 20], ["and", 27], ["selective", 31], ["inhibitor", 41], ["of", 51], ["the", 54], ["Na+-Ca2", 58], ["+", 65], ["exchanger", 67], ["(", 77], ["NCX", 78], [")", 81], [",", 82], ["we", 84], ["examined", 87], ["whether", 96], ["NCX", 104], ["is", 108], ["involved", 111], ["in", 120], ["nitric", 123], ["oxide", 130], ["(", 136], ["NO)-induced", 137], ["disturbance", 149], ["of", 161], ["endoplasmic", 164], ["reticulum", 176], ["(", 186], ["ER", 187], [")", 189], ["Ca2", 191], ["+", 194], ["homeostasis", 196], ["followed", 208], ["by", 217], ["apoptosis", 220], ["in", 230], ["cultured", 233], ["rat", 242], ["microglia", 246], [".", 255], ["2", 257], [".", 258], ["Sodium", 260], ["nitroprusside", 267], ["(", 281], ["SNP", 282], [")", 285], [",", 286], ["an", 288], ["NO", 291], ["donor", 294], [",", 299], ["decreased", 301], ["cell", 311], ["viability", 316], ["in", 326], ["a", 329], ["dose-", 331], ["and", 337], ["time", 341], ["-", 345], ["dependent", 346], ["manner", 356], ["with", 363], ["apoptotic", 368], ["cell", 378], ["death", 383], ["in", 389], ["cultured", 392], ["microglia", 401], [".", 410], ["3", 412], [".", 413], ["Treatment", 415], ["with", 425], ["SNP", 430], ["decreased", 434], ["the", 444], ["ER", 448], ["Ca2", 451], ["+", 454], ["levels", 456], ["as", 463], ["evaluated", 466], ["by", 476], ["measuring", 479], ["the", 489], ["increase", 493], ["in", 502], ["cytosolic", 505], ["Ca2", 515], ["+", 518], ["level", 520], ["induced", 526], ["by", 534], ["exposing", 537], ["cells", 546], ["to", 552], ["thapsigargin", 555], [",", 567], ["an", 569], ["irreversible", 572], ["inhibitor", 585], ["of", 595], ["ER", 598], ["Ca2", 601], ["+", 604], ["-ATPase", 605], [".", 612], ["4", 614], [".", 615], ["The", 617], ["treatment", 621], ["with", 631], ["SNP", 636], ["also", 640], ["increased", 645], ["mRNA", 655], ["expression", 660], ["of", 671], ["CHOP", 674], ["and", 679], ["GPR78", 683], [",", 688], ["makers", 690], ["of", 697], ["ER", 700], ["stress", 703], [".", 709], ["5", 711], [".", 712], ["SEA0400", 714], ["at", 722], ["0.3", 725], ["-", 728], ["1.0", 729], ["microM", 733], ["protected", 740], ["microglia", 750], ["against", 760], ["SNP", 768], ["-", 771], ["induced", 772], ["apoptosis", 780], [".", 789], ["6", 791], [".", 792], ["SEA0400", 794], ["blocked", 802], ["not", 810], ["only", 814], ["the", 819], ["SNP", 823], ["-", 826], ["induced", 827], ["decrease", 835], ["in", 844], ["ER", 847], ["Ca2", 850], ["+", 853], ["levels", 855], ["but", 862], ["also", 866], ["SNP", 871], ["-", 874], ["induced", 875], ["increase", 883], ["in", 892], ["CHOP", 895], ["and", 900], ["GRP78", 904], ["mRNAs", 910], [".", 915], ["7", 917], [".", 918], ["SEA0400", 920], ["did", 928], ["not", 932], ["affect", 936], ["capacitative", 943], ["Ca2", 956], ["+", 959], ["entry", 961], ["in", 967], ["the", 970], ["presence", 974], ["and", 983], ["absence", 987], ["of", 995], ["SNP", 998], [".", 1001], ["8", 1003], [".", 1004], ["SNP", 1006], ["increased", 1010], ["Na+-dependent", 1020], ["45Ca2", 1034], ["+", 1039], ["uptake", 1041], ["and", 1048], ["this", 1052], ["increase", 1057], ["was", 1066], ["blocked", 1070], ["by", 1078], ["SEA0400", 1081], [".", 1088], ["9", 1090], [".", 1091], ["These", 1093], ["results", 1099], ["suggest", 1107], ["that", 1115], ["SNP", 1120], ["induces", 1124], ["apoptosis", 1132], ["via", 1142], ["the", 1146], ["ER", 1150], ["stress", 1153], ["pathway", 1160], ["and", 1168], ["SEA0400", 1172], ["attenuates", 1180], ["SNP", 1191], ["-", 1194], ["induced", 1195], ["apoptosis", 1203], ["via", 1213], ["suppression", 1217], ["of", 1229], ["the", 1232], ["ER", 1236], ["stress", 1239], ["in", 1246], ["cultured", 1249], ["microglia", 1258], [".", 1267], ["Our", 1269], ["findings", 1273], ["imply", 1282], ["that", 1288], ["NCX", 1293], ["plays", 1297], ["a", 1303], ["role", 1305], ["in", 1310], ["ER", 1313], ["Ca2", 1316], ["+", 1319], ["depletion", 1321], ["under", 1331], ["pathological", 1337], ["conditions", 1350], [".", 1360]]}
{"context": "A mutation in the alpha-synuclein gene has recently been linked to some cases of familial Parkinson's disease (PD). We characterized the expression of this presynaptic protein in the midbrain, striatum, and temporal cortex of control, PD, and dementia with Lewy bodies (DLB) brain. Control brain showed punctate pericellular immunostaining. PD brain demonstrated alpha-synuclein immunoreactivity in nigral Lewy bodies, pale bodies and abnormal neurites. Rare neuronal soma in PD brain were immunoreactive for alpha-synuclein. DLB cases demonstrated these findings as well as alpha-synuclein immunoreactivity in cortical Lewy bodies and CA2-3 neurites. These results suggest that, even in sporadic cases, there is an early and direct role for alpha-synuclein in the pathogenesis of PD and the neuropathologically related disorder DLB.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "65a878a609f441afbfab92ba3203df80", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[134, 136], [102, 104], [4, 6], [90, 92], [66, 68]], "char_spans": [[742, 756], [575, 589], [18, 32], [509, 523], [363, 377]]}]}], "context_tokens": [["A", 0], ["mutation", 2], ["in", 11], ["the", 14], ["alpha", 18], ["-", 23], ["synuclein", 24], ["gene", 34], ["has", 39], ["recently", 43], ["been", 52], ["linked", 57], ["to", 64], ["some", 67], ["cases", 72], ["of", 78], ["familial", 81], ["Parkinson", 90], ["'s", 99], ["disease", 102], ["(", 110], ["PD", 111], [")", 113], [".", 114], ["We", 116], ["characterized", 119], ["the", 133], ["expression", 137], ["of", 148], ["this", 151], ["presynaptic", 156], ["protein", 168], ["in", 176], ["the", 179], ["midbrain", 183], [",", 191], ["striatum", 193], [",", 201], ["and", 203], ["temporal", 207], ["cortex", 216], ["of", 223], ["control", 226], [",", 233], ["PD", 235], [",", 237], ["and", 239], ["dementia", 243], ["with", 252], ["Lewy", 257], ["bodies", 262], ["(", 269], ["DLB", 270], [")", 273], ["brain", 275], [".", 280], ["Control", 282], ["brain", 290], ["showed", 296], ["punctate", 303], ["pericellular", 312], ["immunostaining", 325], [".", 339], ["PD", 341], ["brain", 344], ["demonstrated", 350], ["alpha", 363], ["-", 368], ["synuclein", 369], ["immunoreactivity", 379], ["in", 396], ["nigral", 399], ["Lewy", 406], ["bodies", 411], [",", 417], ["pale", 419], ["bodies", 424], ["and", 431], ["abnormal", 435], ["neurites", 444], [".", 452], ["Rare", 454], ["neuronal", 459], ["soma", 468], ["in", 473], ["PD", 476], ["brain", 479], ["were", 485], ["immunoreactive", 490], ["for", 505], ["alpha", 509], ["-", 514], ["synuclein", 515], [".", 524], ["DLB", 526], ["cases", 530], ["demonstrated", 536], ["these", 549], ["findings", 555], ["as", 564], ["well", 567], ["as", 572], ["alpha", 575], ["-", 580], ["synuclein", 581], ["immunoreactivity", 591], ["in", 608], ["cortical", 611], ["Lewy", 620], ["bodies", 625], ["and", 632], ["CA2", 636], ["-", 639], ["3", 640], ["neurites", 642], [".", 650], ["These", 652], ["results", 658], ["suggest", 666], ["that", 674], [",", 678], ["even", 680], ["in", 685], ["sporadic", 688], ["cases", 697], [",", 702], ["there", 704], ["is", 710], ["an", 713], ["early", 716], ["and", 722], ["direct", 726], ["role", 733], ["for", 738], ["alpha", 742], ["-", 747], ["synuclein", 748], ["in", 758], ["the", 761], ["pathogenesis", 765], ["of", 778], ["PD", 781], ["and", 784], ["the", 788], ["neuropathologically", 792], ["related", 812], ["disorder", 820], ["DLB", 829], [".", 832]]}
{"context": "Trimethylation of histone H3 Lys4 (H3K4) is associated with transcriptional activation. One of the chief effectors of H3K4 methylation is mixed-lineage leukemia 1 (MLL1), a gene that is disrupted by chromosomal translocation in acute leukemia and a master regulator of Hox and other genes. In a recent paper, core components of the human MLL histone methyltransferase (MT) complex were found to form a structural platform, with one component (WDR5) mediating association between the specific histone H3K4 substrate and the MT. This novel regulatory mechanism, which is conserved from yeast to human, is required for both methylation and downstream target gene transcription.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "f5a528ae5c1742e2a05b03ecd56fb554", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[20, 20], [90, 90], [6, 6]], "char_spans": [[118, 121], [500, 503], [35, 38]]}]}], "context_tokens": [["Trimethylation", 0], ["of", 15], ["histone", 18], ["H3", 26], ["Lys4", 29], ["(", 34], ["H3K4", 35], [")", 39], ["is", 41], ["associated", 44], ["with", 55], ["transcriptional", 60], ["activation", 76], [".", 86], ["One", 88], ["of", 92], ["the", 95], ["chief", 99], ["effectors", 105], ["of", 115], ["H3K4", 118], ["methylation", 123], ["is", 135], ["mixed", 138], ["-", 143], ["lineage", 144], ["leukemia", 152], ["1", 161], ["(", 163], ["MLL1", 164], [")", 168], [",", 169], ["a", 171], ["gene", 173], ["that", 178], ["is", 183], ["disrupted", 186], ["by", 196], ["chromosomal", 199], ["translocation", 211], ["in", 225], ["acute", 228], ["leukemia", 234], ["and", 243], ["a", 247], ["master", 249], ["regulator", 256], ["of", 266], ["Hox", 269], ["and", 273], ["other", 277], ["genes", 283], [".", 288], ["In", 290], ["a", 293], ["recent", 295], ["paper", 302], [",", 307], ["core", 309], ["components", 314], ["of", 325], ["the", 328], ["human", 332], ["MLL", 338], ["histone", 342], ["methyltransferase", 350], ["(", 368], ["MT", 369], [")", 371], ["complex", 373], ["were", 381], ["found", 386], ["to", 392], ["form", 395], ["a", 400], ["structural", 402], ["platform", 413], [",", 421], ["with", 423], ["one", 428], ["component", 432], ["(", 442], ["WDR5", 443], [")", 447], ["mediating", 449], ["association", 459], ["between", 471], ["the", 479], ["specific", 483], ["histone", 492], ["H3K4", 500], ["substrate", 505], ["and", 515], ["the", 519], ["MT", 523], [".", 525], ["This", 527], ["novel", 532], ["regulatory", 538], ["mechanism", 549], [",", 558], ["which", 560], ["is", 566], ["conserved", 569], ["from", 579], ["yeast", 584], ["to", 590], ["human", 593], [",", 598], ["is", 600], ["required", 603], ["for", 612], ["both", 616], ["methylation", 621], ["and", 633], ["downstream", 637], ["target", 648], ["gene", 655], ["transcription", 660], [".", 673]]}
{"context": "Research is ongoing to develop multipurpose vaginal rings to be used continuously for contraception and to prevent Human Immunodeficiency Virus (HIV) infection. Contraceptive vaginal rings (CVRs) are available in a number of countries and are most of the time used intermittently i.e. three weeks out of a 4-week cycle. Efficacy trials with a dapivirine-containing vaginal ring for HIV prevention are ongoing and plans to develop multi-purpose vaginal rings for prevention of both HIV and pregnancy have been elaborated. In contrast with the CVRs, multi-purpose vaginal rings will have to be used continuously. Women who continuously use a CVR will no longer have menses. Furthermore, some safety aspects of CVR use have never been studied in-depth in the past, such as the impact of the vaginal ring on the vaginal microbiota, biofilm formation and induction of inflammation. We studied acceptability and these novel aspects of safety in Rwandan women. Although significant progress has been made over the past decade, Rwanda still has a high unmet need for contraception (with 47% unplanned births) and a generalized HIV epidemic, and CVRs are not yet available. We will conduct an open label, single centre, randomized controlled trial. A total of 120 HIV-negative women will be randomized to intermittent CVR use (to allow menstruation) or continuous CVR use. Women will be followed for a maximum of 14 weeks. In parallel, we will conduct a qualitative study using in-depth interview and focus group discussion methodology. In addition to evaluating the safety and acceptability of intermittent and continuous CVR use in Rwandan women, we hope that our findings will inform the development of future multipurpose vaginal rings, will prepare Rwandan study populations for future clinical trials of multipurpose vaginal rings, and will pave the way for introduction of CVRs on African markets. Clinicaltrials.gov NCT01796613 . Registered 14 February 2013.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "bf0da804130241878073b33d36565f05", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[229, 229], [21, 21], [201, 201], [82, 82], [65, 65]], "char_spans": [[1255, 1257], [145, 147], [1119, 1121], [481, 483], [382, 384]]}]}], "context_tokens": [["Research", 0], ["is", 9], ["ongoing", 12], ["to", 20], ["develop", 23], ["multipurpose", 31], ["vaginal", 44], ["rings", 52], ["to", 58], ["be", 61], ["used", 64], ["continuously", 69], ["for", 82], ["contraception", 86], ["and", 100], ["to", 104], ["prevent", 107], ["Human", 115], ["Immunodeficiency", 121], ["Virus", 138], ["(", 144], ["HIV", 145], [")", 148], ["infection", 150], [".", 159], ["Contraceptive", 161], ["vaginal", 175], ["rings", 183], ["(", 189], ["CVRs", 190], [")", 194], ["are", 196], ["available", 200], ["in", 210], ["a", 213], ["number", 215], ["of", 222], ["countries", 225], ["and", 235], ["are", 239], ["most", 243], ["of", 248], ["the", 251], ["time", 255], ["used", 260], ["intermittently", 265], ["i.e.", 280], ["three", 285], ["weeks", 291], ["out", 297], ["of", 301], ["a", 304], ["4-week", 306], ["cycle", 313], [".", 318], ["Efficacy", 320], ["trials", 329], ["with", 336], ["a", 341], ["dapivirine", 343], ["-", 353], ["containing", 354], ["vaginal", 365], ["ring", 373], ["for", 378], ["HIV", 382], ["prevention", 386], ["are", 397], ["ongoing", 401], ["and", 409], ["plans", 413], ["to", 419], ["develop", 422], ["multi", 430], ["-", 435], ["purpose", 436], ["vaginal", 444], ["rings", 452], ["for", 458], ["prevention", 462], ["of", 473], ["both", 476], ["HIV", 481], ["and", 485], ["pregnancy", 489], ["have", 499], ["been", 504], ["elaborated", 509], [".", 519], ["In", 521], ["contrast", 524], ["with", 533], ["the", 538], ["CVRs", 542], [",", 546], ["multi", 548], ["-", 553], ["purpose", 554], ["vaginal", 562], ["rings", 570], ["will", 576], ["have", 581], ["to", 586], ["be", 589], ["used", 592], ["continuously", 597], [".", 609], ["Women", 611], ["who", 617], ["continuously", 621], ["use", 634], ["a", 638], ["CVR", 640], ["will", 644], ["no", 649], ["longer", 652], ["have", 659], ["menses", 664], [".", 670], ["Furthermore", 672], [",", 683], ["some", 685], ["safety", 690], ["aspects", 697], ["of", 705], ["CVR", 708], ["use", 712], ["have", 716], ["never", 721], ["been", 727], ["studied", 732], ["in", 740], ["-", 742], ["depth", 743], ["in", 749], ["the", 752], ["past", 756], [",", 760], ["such", 762], ["as", 767], ["the", 770], ["impact", 774], ["of", 781], ["the", 784], ["vaginal", 788], ["ring", 796], ["on", 801], ["the", 804], ["vaginal", 808], ["microbiota", 816], [",", 826], ["biofilm", 828], ["formation", 836], ["and", 846], ["induction", 850], ["of", 860], ["inflammation", 863], [".", 875], ["We", 877], ["studied", 880], ["acceptability", 888], ["and", 902], ["these", 906], ["novel", 912], ["aspects", 918], ["of", 926], ["safety", 929], ["in", 936], ["Rwandan", 939], ["women", 947], [".", 952], ["Although", 954], ["significant", 963], ["progress", 975], ["has", 984], ["been", 988], ["made", 993], ["over", 998], ["the", 1003], ["past", 1007], ["decade", 1012], [",", 1018], ["Rwanda", 1020], ["still", 1027], ["has", 1033], ["a", 1037], ["high", 1039], ["unmet", 1044], ["need", 1050], ["for", 1055], ["contraception", 1059], ["(", 1073], ["with", 1074], ["47", 1079], ["%", 1081], ["unplanned", 1083], ["births", 1093], [")", 1099], ["and", 1101], ["a", 1105], ["generalized", 1107], ["HIV", 1119], ["epidemic", 1123], [",", 1131], ["and", 1133], ["CVRs", 1137], ["are", 1142], ["not", 1146], ["yet", 1150], ["available", 1154], [".", 1163], ["We", 1165], ["will", 1168], ["conduct", 1173], ["an", 1181], ["open", 1184], ["label", 1189], [",", 1194], ["single", 1196], ["centre", 1203], [",", 1209], ["randomized", 1211], ["controlled", 1222], ["trial", 1233], [".", 1238], ["A", 1240], ["total", 1242], ["of", 1248], ["120", 1251], ["HIV", 1255], ["-", 1258], ["negative", 1259], ["women", 1268], ["will", 1274], ["be", 1279], ["randomized", 1282], ["to", 1293], ["intermittent", 1296], ["CVR", 1309], ["use", 1313], ["(", 1317], ["to", 1318], ["allow", 1321], ["menstruation", 1327], [")", 1339], ["or", 1341], ["continuous", 1344], ["CVR", 1355], ["use", 1359], [".", 1362], ["Women", 1364], ["will", 1370], ["be", 1375], ["followed", 1378], ["for", 1387], ["a", 1391], ["maximum", 1393], ["of", 1401], ["14", 1404], ["weeks", 1407], [".", 1412], ["In", 1414], ["parallel", 1417], [",", 1425], ["we", 1427], ["will", 1430], ["conduct", 1435], ["a", 1443], ["qualitative", 1445], ["study", 1457], ["using", 1463], ["in", 1469], ["-", 1471], ["depth", 1472], ["interview", 1478], ["and", 1488], ["focus", 1492], ["group", 1498], ["discussion", 1504], ["methodology", 1515], [".", 1526], ["In", 1528], ["addition", 1531], ["to", 1540], ["evaluating", 1543], ["the", 1554], ["safety", 1558], ["and", 1565], ["acceptability", 1569], ["of", 1583], ["intermittent", 1586], ["and", 1599], ["continuous", 1603], ["CVR", 1614], ["use", 1618], ["in", 1622], ["Rwandan", 1625], ["women", 1633], [",", 1638], ["we", 1640], ["hope", 1643], ["that", 1648], ["our", 1653], ["findings", 1657], ["will", 1666], ["inform", 1671], ["the", 1678], ["development", 1682], ["of", 1694], ["future", 1697], ["multipurpose", 1704], ["vaginal", 1717], ["rings", 1725], [",", 1730], ["will", 1732], ["prepare", 1737], ["Rwandan", 1745], ["study", 1753], ["populations", 1759], ["for", 1771], ["future", 1775], ["clinical", 1782], ["trials", 1791], ["of", 1798], ["multipurpose", 1801], ["vaginal", 1814], ["rings", 1822], [",", 1827], ["and", 1829], ["will", 1833], ["pave", 1838], ["the", 1843], ["way", 1847], ["for", 1851], ["introduction", 1855], ["of", 1868], ["CVRs", 1871], ["on", 1876], ["African", 1879], ["markets", 1887], [".", 1894], ["Clinicaltrials.gov", 1896], ["NCT01796613", 1915], [".", 1927], ["Registered", 1929], ["14", 1940], ["February", 1943], ["2013", 1952], [".", 1956]]}
{"context": "The development of novel oral anticoagulants (NOACs) has revolutionized oral anticoagulation. Rapid incorporation of NOACs into general practice has heightened the demand for directed reversal agents. Idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran. While it is a welcome addition to reversal strategies of dabigatran, a number of clinical questions exist regarding its place in therapy. We describe controversies regarding the use of idarucizumab therapy in patients with dabigatran-associated bleeding. Although existing clinical studies show a rapid reversal of coagulation assays, these studies did not describe a corresponding improvement in mortality or rapid cessation of hemorrhage. It is questionable how heavily clinicians can rely upon the use of the surrogate endpoints in clinical studies, such as ecarin clotting time and dilute thrombin time. Another issue is whether patients exhibiting re-elevation of coagulation assays would benefit from an additional dose of idarucizumab, because this has not been studied. It is currently unclear if blood products must be given in addition to idarucizumab can be used as monotherapy. The initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran. As more clinical practice experience is gained with the agent and the remaining data on its use are released, clinicians can better guide the clinical use of idarucizumab. At present, there is currently not enough evidence for idarucizumab to be used as monotherapy.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "dc40f38b59fd40f9bfc5fdd3040d8e0c", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[60, 60], [48, 48], [211, 211], [86, 86]], "char_spans": [[385, 394], [316, 325], [1317, 1326], [551, 560]]}]}], "context_tokens": [["The", 0], ["development", 4], ["of", 16], ["novel", 19], ["oral", 25], ["anticoagulants", 30], ["(", 45], ["NOACs", 46], [")", 51], ["has", 53], ["revolutionized", 57], ["oral", 72], ["anticoagulation", 77], [".", 92], ["Rapid", 94], ["incorporation", 100], ["of", 114], ["NOACs", 117], ["into", 123], ["general", 128], ["practice", 136], ["has", 145], ["heightened", 149], ["the", 160], ["demand", 164], ["for", 171], ["directed", 175], ["reversal", 184], ["agents", 193], [".", 199], ["Idarucizumab", 201], ["is", 214], ["a", 217], ["targeted", 219], ["reversal", 228], ["agent", 237], ["that", 243], ["is", 248], ["approved", 251], ["for", 260], ["the", 264], ["urgent", 268], ["reversal", 275], ["of", 284], ["the", 287], ["anticoagulant", 291], ["effects", 305], ["of", 313], ["dabigatran", 316], [".", 326], ["While", 328], ["it", 334], ["is", 337], ["a", 340], ["welcome", 342], ["addition", 350], ["to", 359], ["reversal", 362], ["strategies", 371], ["of", 382], ["dabigatran", 385], [",", 395], ["a", 397], ["number", 399], ["of", 406], ["clinical", 409], ["questions", 418], ["exist", 428], ["regarding", 434], ["its", 444], ["place", 448], ["in", 454], ["therapy", 457], [".", 464], ["We", 466], ["describe", 469], ["controversies", 478], ["regarding", 492], ["the", 502], ["use", 506], ["of", 510], ["idarucizumab", 513], ["therapy", 526], ["in", 534], ["patients", 537], ["with", 546], ["dabigatran", 551], ["-", 561], ["associated", 562], ["bleeding", 573], [".", 581], ["Although", 583], ["existing", 592], ["clinical", 601], ["studies", 610], ["show", 618], ["a", 623], ["rapid", 625], ["reversal", 631], ["of", 640], ["coagulation", 643], ["assays", 655], [",", 661], ["these", 663], ["studies", 669], ["did", 677], ["not", 681], ["describe", 685], ["a", 694], ["corresponding", 696], ["improvement", 710], ["in", 722], ["mortality", 725], ["or", 735], ["rapid", 738], ["cessation", 744], ["of", 754], ["hemorrhage", 757], [".", 767], ["It", 769], ["is", 772], ["questionable", 775], ["how", 788], ["heavily", 792], ["clinicians", 800], ["can", 811], ["rely", 815], ["upon", 820], ["the", 825], ["use", 829], ["of", 833], ["the", 836], ["surrogate", 840], ["endpoints", 850], ["in", 860], ["clinical", 863], ["studies", 872], [",", 879], ["such", 881], ["as", 886], ["ecarin", 889], ["clotting", 896], ["time", 905], ["and", 910], ["dilute", 914], ["thrombin", 921], ["time", 930], [".", 934], ["Another", 936], ["issue", 944], ["is", 950], ["whether", 953], ["patients", 961], ["exhibiting", 970], ["re", 981], ["-", 983], ["elevation", 984], ["of", 994], ["coagulation", 997], ["assays", 1009], ["would", 1016], ["benefit", 1022], ["from", 1030], ["an", 1035], ["additional", 1038], ["dose", 1049], ["of", 1054], ["idarucizumab", 1057], [",", 1069], ["because", 1071], ["this", 1079], ["has", 1084], ["not", 1088], ["been", 1092], ["studied", 1097], [".", 1104], ["It", 1106], ["is", 1109], ["currently", 1112], ["unclear", 1122], ["if", 1130], ["blood", 1133], ["products", 1139], ["must", 1148], ["be", 1153], ["given", 1156], ["in", 1162], ["addition", 1165], ["to", 1174], ["idarucizumab", 1177], ["can", 1190], ["be", 1194], ["used", 1197], ["as", 1202], ["monotherapy", 1205], [".", 1216], ["The", 1218], ["initial", 1222], ["data", 1230], ["suggest", 1235], ["a", 1243], ["definite", 1245], ["role", 1254], ["for", 1259], ["idarucizumab", 1263], ["in", 1276], ["treatment", 1279], ["of", 1289], ["bleeding", 1292], ["associated", 1301], ["with", 1312], ["dabigatran", 1317], [".", 1327], ["As", 1329], ["more", 1332], ["clinical", 1337], ["practice", 1346], ["experience", 1355], ["is", 1366], ["gained", 1369], ["with", 1376], ["the", 1381], ["agent", 1385], ["and", 1391], ["the", 1395], ["remaining", 1399], ["data", 1409], ["on", 1414], ["its", 1417], ["use", 1421], ["are", 1425], ["released", 1429], [",", 1437], ["clinicians", 1439], ["can", 1450], ["better", 1454], ["guide", 1461], ["the", 1467], ["clinical", 1471], ["use", 1480], ["of", 1484], ["idarucizumab", 1487], [".", 1499], ["At", 1501], ["present", 1504], [",", 1511], ["there", 1513], ["is", 1519], ["currently", 1522], ["not", 1532], ["enough", 1536], ["evidence", 1543], ["for", 1552], ["idarucizumab", 1556], ["to", 1569], ["be", 1572], ["used", 1575], ["as", 1580], ["monotherapy", 1583], [".", 1594]]}
{"context": "Our objective was to evaluate the diagnostic value of computed tomography angiography (CTA) and ventilation perfusion (V/Q) scan in the assessment of pulmonary embolism (PE) by means of a Bayesian statistical model. Wells criteria defined pretest probability. Sensitivity and specificity of CTA and V/Q scan for PE were derived from pooled meta-analysis data. Likelihood ratios calculated for CTA and V/Q were inserted in the nomogram. Absolute (ADG) and relative diagnostic gains (RDG) were analyzed comparing post- and pretest probability. Comparative gain difference was calculated for CTA ADG over V/Q scan integrating ANOVA p value set at 0.05. The sensitivity for CT was 86.0% (95% CI: 80.2%, 92.1%) and specificity of 93.7% (95% CI: 91.1%, 96.3%). The V/Q scan yielded a sensitivity of 96% (95% CI: 95%, 97%) and a specificity of 97% (95% CI: 96%, 98%). Bayes nomogram results for CTA were low risk and yielded a posttest probability of 71.1%, an ADG of 56.1%, and an RDG of 374%, moderate-risk posttest probability was 85.1%, an ADG of 56.1%, and an RDG of 193.4%, and high-risk posttest probability was 95.2%, an ADG of 36.2%, and an RDG of 61.35%. The comparative gain difference for low-risk population was 46.1%; in moderate-risk 41.6%; and in high-risk a 22.1% superiority. ANOVA analysis for LR+ and LR- showed no significant difference (p\u00a0=\u00a00.8745, p\u00a0=\u00a00.9841 respectively). This Bayesian model demonstrated a superiority of CTA when compared to V/Q scan for the diagnosis of pulmonary embolism. Low-risk patients are recognized to have a superior overall comparative gain favoring CTA.", "qas": [{"question": "What can be predicted with the Wells criteria?", "answers": ["pulmonary embolism"], "qid": "fc7a87328e5b4888b2a342e3a22a865e", "question_tokens": [["What", 0], ["can", 5], ["be", 9], ["predicted", 12], ["with", 22], ["the", 27], ["Wells", 31], ["criteria", 37], ["?", 45]], "detected_answers": [{"text": "pulmonary embolism", "token_spans": [[28, 29], [343, 344]], "char_spans": [[150, 167], [1491, 1508]]}]}], "context_tokens": [["Our", 0], ["objective", 4], ["was", 14], ["to", 18], ["evaluate", 21], ["the", 30], ["diagnostic", 34], ["value", 45], ["of", 51], ["computed", 54], ["tomography", 63], ["angiography", 74], ["(", 86], ["CTA", 87], [")", 90], ["and", 92], ["ventilation", 96], ["perfusion", 108], ["(", 118], ["V", 119], ["/", 120], ["Q", 121], [")", 122], ["scan", 124], ["in", 129], ["the", 132], ["assessment", 136], ["of", 147], ["pulmonary", 150], ["embolism", 160], ["(", 169], ["PE", 170], [")", 172], ["by", 174], ["means", 177], ["of", 183], ["a", 186], ["Bayesian", 188], ["statistical", 197], ["model", 209], [".", 214], ["Wells", 216], ["criteria", 222], ["defined", 231], ["pretest", 239], ["probability", 247], [".", 258], ["Sensitivity", 260], ["and", 272], ["specificity", 276], ["of", 288], ["CTA", 291], ["and", 295], ["V", 299], ["/", 300], ["Q", 301], ["scan", 303], ["for", 308], ["PE", 312], ["were", 315], ["derived", 320], ["from", 328], ["pooled", 333], ["meta", 340], ["-", 344], ["analysis", 345], ["data", 354], [".", 358], ["Likelihood", 360], ["ratios", 371], ["calculated", 378], ["for", 389], ["CTA", 393], ["and", 397], ["V", 401], ["/", 402], ["Q", 403], ["were", 405], ["inserted", 410], ["in", 419], ["the", 422], ["nomogram", 426], [".", 434], ["Absolute", 436], ["(", 445], ["ADG", 446], [")", 449], ["and", 451], ["relative", 455], ["diagnostic", 464], ["gains", 475], ["(", 481], ["RDG", 482], [")", 485], ["were", 487], ["analyzed", 492], ["comparing", 501], ["post-", 511], ["and", 517], ["pretest", 521], ["probability", 529], [".", 540], ["Comparative", 542], ["gain", 554], ["difference", 559], ["was", 570], ["calculated", 574], ["for", 585], ["CTA", 589], ["ADG", 593], ["over", 597], ["V", 602], ["/", 603], ["Q", 604], ["scan", 606], ["integrating", 611], ["ANOVA", 623], ["p", 629], ["value", 631], ["set", 637], ["at", 641], ["0.05", 644], [".", 648], ["The", 650], ["sensitivity", 654], ["for", 666], ["CT", 670], ["was", 673], ["86.0", 677], ["%", 681], ["(", 683], ["95", 684], ["%", 686], ["CI", 688], [":", 690], ["80.2", 692], ["%", 696], [",", 697], ["92.1", 699], ["%", 703], [")", 704], ["and", 706], ["specificity", 710], ["of", 722], ["93.7", 725], ["%", 729], ["(", 731], ["95", 732], ["%", 734], ["CI", 736], [":", 738], ["91.1", 740], ["%", 744], [",", 745], ["96.3", 747], ["%", 751], [")", 752], [".", 753], ["The", 755], ["V", 759], ["/", 760], ["Q", 761], ["scan", 763], ["yielded", 768], ["a", 776], ["sensitivity", 778], ["of", 790], ["96", 793], ["%", 795], ["(", 797], ["95", 798], ["%", 800], ["CI", 802], [":", 804], ["95", 806], ["%", 808], [",", 809], ["97", 811], ["%", 813], [")", 814], ["and", 816], ["a", 820], ["specificity", 822], ["of", 834], ["97", 837], ["%", 839], ["(", 841], ["95", 842], ["%", 844], ["CI", 846], [":", 848], ["96", 850], ["%", 852], [",", 853], ["98", 855], ["%", 857], [")", 858], [".", 859], ["Bayes", 861], ["nomogram", 867], ["results", 876], ["for", 884], ["CTA", 888], ["were", 892], ["low", 897], ["risk", 901], ["and", 906], ["yielded", 910], ["a", 918], ["posttest", 920], ["probability", 929], ["of", 941], ["71.1", 944], ["%", 948], [",", 949], ["an", 951], ["ADG", 954], ["of", 958], ["56.1", 961], ["%", 965], [",", 966], ["and", 968], ["an", 972], ["RDG", 975], ["of", 979], ["374", 982], ["%", 985], [",", 986], ["moderate", 988], ["-", 996], ["risk", 997], ["posttest", 1002], ["probability", 1011], ["was", 1023], ["85.1", 1027], ["%", 1031], [",", 1032], ["an", 1034], ["ADG", 1037], ["of", 1041], ["56.1", 1044], ["%", 1048], [",", 1049], ["and", 1051], ["an", 1055], ["RDG", 1058], ["of", 1062], ["193.4", 1065], ["%", 1070], [",", 1071], ["and", 1073], ["high", 1077], ["-", 1081], ["risk", 1082], ["posttest", 1087], ["probability", 1096], ["was", 1108], ["95.2", 1112], ["%", 1116], [",", 1117], ["an", 1119], ["ADG", 1122], ["of", 1126], ["36.2", 1129], ["%", 1133], [",", 1134], ["and", 1136], ["an", 1140], ["RDG", 1143], ["of", 1147], ["61.35", 1150], ["%", 1155], [".", 1156], ["The", 1158], ["comparative", 1162], ["gain", 1174], ["difference", 1179], ["for", 1190], ["low", 1194], ["-", 1197], ["risk", 1198], ["population", 1203], ["was", 1214], ["46.1", 1218], ["%", 1222], [";", 1223], ["in", 1225], ["moderate", 1228], ["-", 1236], ["risk", 1237], ["41.6", 1242], ["%", 1246], [";", 1247], ["and", 1249], ["in", 1253], ["high", 1256], ["-", 1260], ["risk", 1261], ["a", 1266], ["22.1", 1268], ["%", 1272], ["superiority", 1274], [".", 1285], ["ANOVA", 1287], ["analysis", 1293], ["for", 1302], ["LR+", 1306], ["and", 1310], ["LR-", 1314], ["showed", 1318], ["no", 1325], ["significant", 1328], ["difference", 1340], ["(", 1351], ["p", 1352], ["=", 1354], ["0.8745", 1356], [",", 1362], ["p", 1364], ["=", 1366], ["0.9841", 1368], ["respectively", 1375], [")", 1387], [".", 1388], ["This", 1390], ["Bayesian", 1395], ["model", 1404], ["demonstrated", 1410], ["a", 1423], ["superiority", 1425], ["of", 1437], ["CTA", 1440], ["when", 1444], ["compared", 1449], ["to", 1458], ["V", 1461], ["/", 1462], ["Q", 1463], ["scan", 1465], ["for", 1470], ["the", 1474], ["diagnosis", 1478], ["of", 1488], ["pulmonary", 1491], ["embolism", 1501], [".", 1509], ["Low", 1511], ["-", 1514], ["risk", 1515], ["patients", 1520], ["are", 1529], ["recognized", 1533], ["to", 1544], ["have", 1547], ["a", 1552], ["superior", 1554], ["overall", 1563], ["comparative", 1571], ["gain", 1583], ["favoring", 1588], ["CTA", 1597], [".", 1600]]}
{"context": "A specialized nucleotide excision repair pathway known as transcription-coupled repair (TCR) counteracts the toxic effects of DNA damage in transcriptionally active genes. The clustering of active genes into gene-rich chromosomal domains predicts that the sites of TCR are unevenly distributed through the genome. To elucidate the genomic organization and chromosomal localization of TCR, we isolated DNA fragments encompassing TCR-mediated repair sites from UV-C irradiated xeroderma pigmentosum group C cells, which can only repair the transcribed strand of active genes. This DNA was used as a molecular probe to visualize TCR in normal metaphase spreads by reverse fluorescence in situ hybridization. Whereas DNA repair sites in normal human cells are evenly distributed through the genome, TCR is highly localized at specific chromosomal domains. Particularly, clusters of TCR sites were identified at early-replicating gene-rich bands and telomeric regions of several chromosomes. High gene-density chromosomes such as chromosome 19 and the GC-rich domains of several chromosomes (T bands) are preferential locations of TCR. Our results demonstrate that the intragenomic localization of TCR resembles the uneven distribution of the human transcriptome, CpG islands, and hyperacetylated histones, enforcing the basic link between DNA repair, transcription, and nuclear organization in a complex genome.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "a279fbb04c944d8dbfb90dbe26a570cd", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[88, 89]], "char_spans": [[538, 555]]}]}], "context_tokens": [["A", 0], ["specialized", 2], ["nucleotide", 14], ["excision", 25], ["repair", 34], ["pathway", 41], ["known", 49], ["as", 55], ["transcription", 58], ["-", 71], ["coupled", 72], ["repair", 80], ["(", 87], ["TCR", 88], [")", 91], ["counteracts", 93], ["the", 105], ["toxic", 109], ["effects", 115], ["of", 123], ["DNA", 126], ["damage", 130], ["in", 137], ["transcriptionally", 140], ["active", 158], ["genes", 165], [".", 170], ["The", 172], ["clustering", 176], ["of", 187], ["active", 190], ["genes", 197], ["into", 203], ["gene", 208], ["-", 212], ["rich", 213], ["chromosomal", 218], ["domains", 230], ["predicts", 238], ["that", 247], ["the", 252], ["sites", 256], ["of", 262], ["TCR", 265], ["are", 269], ["unevenly", 273], ["distributed", 282], ["through", 294], ["the", 302], ["genome", 306], [".", 312], ["To", 314], ["elucidate", 317], ["the", 327], ["genomic", 331], ["organization", 339], ["and", 352], ["chromosomal", 356], ["localization", 368], ["of", 381], ["TCR", 384], [",", 387], ["we", 389], ["isolated", 392], ["DNA", 401], ["fragments", 405], ["encompassing", 415], ["TCR", 428], ["-", 431], ["mediated", 432], ["repair", 441], ["sites", 448], ["from", 454], ["UV", 459], ["-", 461], ["C", 462], ["irradiated", 464], ["xeroderma", 475], ["pigmentosum", 485], ["group", 497], ["C", 503], ["cells", 505], [",", 510], ["which", 512], ["can", 518], ["only", 522], ["repair", 527], ["the", 534], ["transcribed", 538], ["strand", 550], ["of", 557], ["active", 560], ["genes", 567], [".", 572], ["This", 574], ["DNA", 579], ["was", 583], ["used", 587], ["as", 592], ["a", 595], ["molecular", 597], ["probe", 607], ["to", 613], ["visualize", 616], ["TCR", 626], ["in", 630], ["normal", 633], ["metaphase", 640], ["spreads", 650], ["by", 658], ["reverse", 661], ["fluorescence", 669], ["in", 682], ["situ", 685], ["hybridization", 690], [".", 703], ["Whereas", 705], ["DNA", 713], ["repair", 717], ["sites", 724], ["in", 730], ["normal", 733], ["human", 740], ["cells", 746], ["are", 752], ["evenly", 756], ["distributed", 763], ["through", 775], ["the", 783], ["genome", 787], [",", 793], ["TCR", 795], ["is", 799], ["highly", 802], ["localized", 809], ["at", 819], ["specific", 822], ["chromosomal", 831], ["domains", 843], [".", 850], ["Particularly", 852], [",", 864], ["clusters", 866], ["of", 875], ["TCR", 878], ["sites", 882], ["were", 888], ["identified", 893], ["at", 904], ["early", 907], ["-", 912], ["replicating", 913], ["gene", 925], ["-", 929], ["rich", 930], ["bands", 935], ["and", 941], ["telomeric", 945], ["regions", 955], ["of", 963], ["several", 966], ["chromosomes", 974], [".", 985], ["High", 987], ["gene", 992], ["-", 996], ["density", 997], ["chromosomes", 1005], ["such", 1017], ["as", 1022], ["chromosome", 1025], ["19", 1036], ["and", 1039], ["the", 1043], ["GC", 1047], ["-", 1049], ["rich", 1050], ["domains", 1055], ["of", 1063], ["several", 1066], ["chromosomes", 1074], ["(", 1086], ["T", 1087], ["bands", 1089], [")", 1094], ["are", 1096], ["preferential", 1100], ["locations", 1113], ["of", 1123], ["TCR", 1126], [".", 1129], ["Our", 1131], ["results", 1135], ["demonstrate", 1143], ["that", 1155], ["the", 1160], ["intragenomic", 1164], ["localization", 1177], ["of", 1190], ["TCR", 1193], ["resembles", 1197], ["the", 1207], ["uneven", 1211], ["distribution", 1218], ["of", 1231], ["the", 1234], ["human", 1238], ["transcriptome", 1244], [",", 1257], ["CpG", 1259], ["islands", 1263], [",", 1270], ["and", 1272], ["hyperacetylated", 1276], ["histones", 1292], [",", 1300], ["enforcing", 1302], ["the", 1312], ["basic", 1316], ["link", 1322], ["between", 1327], ["DNA", 1335], ["repair", 1339], [",", 1345], ["transcription", 1347], [",", 1360], ["and", 1362], ["nuclear", 1366], ["organization", 1374], ["in", 1387], ["a", 1390], ["complex", 1392], ["genome", 1400], [".", 1406]]}
{"context": "H2A.Z is a highly conserved variant of histone H2A with well-characterized roles in transcriptional regulation. We previously reported that H2A.Z and Mcd1, a subunit of the cohesin complex, regulate the establishment of transcriptional silencing at telomeres in Saccharomyces cerevisiae and that H2A.Z broadly dissociated from chromatin during the anaphase-to-telophase transition, coincident with the dissociation of Mcd1 from chromosomes and dissolution of cohesion. In this study, we show that depletion of H2A.Z causes precocious loss of sister chromatid cohesion in yeast without loss of Mcd1 from chromosomes. H2A.Z is deposited into chromatin by the SWR1 complex and is subject to acetylation of its four N-terminal tail lysine residues by the NuA4 and SAGA histone acetyltransferase complexes. We found that cells compromised for function of the SWR1 complex were defective in cohesion, as were cells expressing a form of H2A.Z not subject to acetylation. Finally, inactivation of H2A.Z in metaphase-blocked cells led immediately to cohesion defects, suggesting a direct role for H2A.Z in the maintenance of sister chromatid cohesion.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "4ef05543761e4948b74e9fa078a5e4bc", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[140, 140], [106, 106]], "char_spans": [[854, 857], [657, 660]]}]}], "context_tokens": [["H2A.Z", 0], ["is", 6], ["a", 9], ["highly", 11], ["conserved", 18], ["variant", 28], ["of", 36], ["histone", 39], ["H2A", 47], ["with", 51], ["well", 56], ["-", 60], ["characterized", 61], ["roles", 75], ["in", 81], ["transcriptional", 84], ["regulation", 100], [".", 110], ["We", 112], ["previously", 115], ["reported", 126], ["that", 135], ["H2A.Z", 140], ["and", 146], ["Mcd1", 150], [",", 154], ["a", 156], ["subunit", 158], ["of", 166], ["the", 169], ["cohesin", 173], ["complex", 181], [",", 188], ["regulate", 190], ["the", 199], ["establishment", 203], ["of", 217], ["transcriptional", 220], ["silencing", 236], ["at", 246], ["telomeres", 249], ["in", 259], ["Saccharomyces", 262], ["cerevisiae", 276], ["and", 287], ["that", 291], ["H2A.Z", 296], ["broadly", 302], ["dissociated", 310], ["from", 322], ["chromatin", 327], ["during", 337], ["the", 344], ["anaphase", 348], ["-", 356], ["to", 357], ["-", 359], ["telophase", 360], ["transition", 370], [",", 380], ["coincident", 382], ["with", 393], ["the", 398], ["dissociation", 402], ["of", 415], ["Mcd1", 418], ["from", 423], ["chromosomes", 428], ["and", 440], ["dissolution", 444], ["of", 456], ["cohesion", 459], [".", 467], ["In", 469], ["this", 472], ["study", 477], [",", 482], ["we", 484], ["show", 487], ["that", 492], ["depletion", 497], ["of", 507], ["H2A.Z", 510], ["causes", 516], ["precocious", 523], ["loss", 534], ["of", 539], ["sister", 542], ["chromatid", 549], ["cohesion", 559], ["in", 568], ["yeast", 571], ["without", 577], ["loss", 585], ["of", 590], ["Mcd1", 593], ["from", 598], ["chromosomes", 603], [".", 614], ["H2A.Z", 616], ["is", 622], ["deposited", 625], ["into", 635], ["chromatin", 640], ["by", 650], ["the", 653], ["SWR1", 657], ["complex", 662], ["and", 670], ["is", 674], ["subject", 677], ["to", 685], ["acetylation", 688], ["of", 700], ["its", 703], ["four", 707], ["N", 712], ["-", 713], ["terminal", 714], ["tail", 723], ["lysine", 728], ["residues", 735], ["by", 744], ["the", 747], ["NuA4", 751], ["and", 756], ["SAGA", 760], ["histone", 765], ["acetyltransferase", 773], ["complexes", 791], [".", 800], ["We", 802], ["found", 805], ["that", 811], ["cells", 816], ["compromised", 822], ["for", 834], ["function", 838], ["of", 847], ["the", 850], ["SWR1", 854], ["complex", 859], ["were", 867], ["defective", 872], ["in", 882], ["cohesion", 885], [",", 893], ["as", 895], ["were", 898], ["cells", 903], ["expressing", 909], ["a", 920], ["form", 922], ["of", 927], ["H2A.Z", 930], ["not", 936], ["subject", 940], ["to", 948], ["acetylation", 951], [".", 962], ["Finally", 964], [",", 971], ["inactivation", 973], ["of", 986], ["H2A.Z", 989], ["in", 995], ["metaphase", 998], ["-", 1007], ["blocked", 1008], ["cells", 1016], ["led", 1022], ["immediately", 1026], ["to", 1038], ["cohesion", 1041], ["defects", 1050], [",", 1057], ["suggesting", 1059], ["a", 1070], ["direct", 1072], ["role", 1079], ["for", 1084], ["H2A.Z", 1088], ["in", 1094], ["the", 1097], ["maintenance", 1101], ["of", 1113], ["sister", 1116], ["chromatid", 1123], ["cohesion", 1133], [".", 1141]]}
{"context": "Stem cells, one of the progenitors of cancer, exist predominately in a quiescent state. Thus, understanding the mechanisms of DNA repair and mutagenesis in such arrested cells may help unravel the complex process of tumorigenesis. Two major nucleotide excision repair (NER) pathways are known to remove bulky physical or chemical lesions from DNA. Transcription-coupled repair (TCR) acts solely on the transcribed strand of expressed genes, while global genomic repair (GGR) is responsible for the ubiquitous repair of the genome. Indirectly, it has been shown that while TCR functions in quiescent cells GGR does not. To explicitly elucidate this phenomenon, we adapted a quantitative PCR (QPCR) assay to study UV-damage repair via TCR and GGR in quiescent and proliferating cells. We present evidence that repair of untranscribed silent regions of the genome and repair of the non-transcribed strand of active genes proceeds by two discrete mechanisms in quiescent cells; rather than by GGR, which was believed to encompass both. Thus, our findings suggest the existence of an alternate NER pathway in quiescent cells. The proposed subcategories of NER are as follows: (i) TCR, responsible for maintenance of transcribed strands; (ii) GGR, responsible for ubiquitous genome repair; and (iii) non-transcribed strand repair (NTSR), predominantly responsible for the repair of the NTS in arrested cells. In quiescent cells, it is evident that TCR and NTSR function and GGR are arrested. As a consequence, mutation accumulation at temporally silent genes and incomplete or imperfect repair of transcribed genes, in quiescent stem cells, may provide a source of cancer causing mutations.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "d4a589e25b7e41539ef282bbbf96e4a6", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[72, 73], [241, 242], [161, 162]], "char_spans": [[402, 419], [1298, 1315], [883, 900]]}]}], "context_tokens": [["Stem", 0], ["cells", 5], [",", 10], ["one", 12], ["of", 16], ["the", 19], ["progenitors", 23], ["of", 35], ["cancer", 38], [",", 44], ["exist", 46], ["predominately", 52], ["in", 66], ["a", 69], ["quiescent", 71], ["state", 81], [".", 86], ["Thus", 88], [",", 92], ["understanding", 94], ["the", 108], ["mechanisms", 112], ["of", 123], ["DNA", 126], ["repair", 130], ["and", 137], ["mutagenesis", 141], ["in", 153], ["such", 156], ["arrested", 161], ["cells", 170], ["may", 176], ["help", 180], ["unravel", 185], ["the", 193], ["complex", 197], ["process", 205], ["of", 213], ["tumorigenesis", 216], [".", 229], ["Two", 231], ["major", 235], ["nucleotide", 241], ["excision", 252], ["repair", 261], ["(", 268], ["NER", 269], [")", 272], ["pathways", 274], ["are", 283], ["known", 287], ["to", 293], ["remove", 296], ["bulky", 303], ["physical", 309], ["or", 318], ["chemical", 321], ["lesions", 330], ["from", 338], ["DNA", 343], [".", 346], ["Transcription", 348], ["-", 361], ["coupled", 362], ["repair", 370], ["(", 377], ["TCR", 378], [")", 381], ["acts", 383], ["solely", 388], ["on", 395], ["the", 398], ["transcribed", 402], ["strand", 414], ["of", 421], ["expressed", 424], ["genes", 434], [",", 439], ["while", 441], ["global", 447], ["genomic", 454], ["repair", 462], ["(", 469], ["GGR", 470], [")", 473], ["is", 475], ["responsible", 478], ["for", 490], ["the", 494], ["ubiquitous", 498], ["repair", 509], ["of", 516], ["the", 519], ["genome", 523], [".", 529], ["Indirectly", 531], [",", 541], ["it", 543], ["has", 546], ["been", 550], ["shown", 555], ["that", 561], ["while", 566], ["TCR", 572], ["functions", 576], ["in", 586], ["quiescent", 589], ["cells", 599], ["GGR", 605], ["does", 609], ["not", 614], [".", 617], ["To", 619], ["explicitly", 622], ["elucidate", 633], ["this", 643], ["phenomenon", 648], [",", 658], ["we", 660], ["adapted", 663], ["a", 671], ["quantitative", 673], ["PCR", 686], ["(", 690], ["QPCR", 691], [")", 695], ["assay", 697], ["to", 703], ["study", 706], ["UV", 712], ["-", 714], ["damage", 715], ["repair", 722], ["via", 729], ["TCR", 733], ["and", 737], ["GGR", 741], ["in", 745], ["quiescent", 748], ["and", 758], ["proliferating", 762], ["cells", 776], [".", 781], ["We", 783], ["present", 786], ["evidence", 794], ["that", 803], ["repair", 808], ["of", 815], ["untranscribed", 818], ["silent", 832], ["regions", 839], ["of", 847], ["the", 850], ["genome", 854], ["and", 861], ["repair", 865], ["of", 872], ["the", 875], ["non", 879], ["-", 882], ["transcribed", 883], ["strand", 895], ["of", 902], ["active", 905], ["genes", 912], ["proceeds", 918], ["by", 927], ["two", 930], ["discrete", 934], ["mechanisms", 943], ["in", 954], ["quiescent", 957], ["cells", 967], [";", 972], ["rather", 974], ["than", 981], ["by", 986], ["GGR", 989], [",", 992], ["which", 994], ["was", 1000], ["believed", 1004], ["to", 1013], ["encompass", 1016], ["both", 1026], [".", 1030], ["Thus", 1032], [",", 1036], ["our", 1038], ["findings", 1042], ["suggest", 1051], ["the", 1059], ["existence", 1063], ["of", 1073], ["an", 1076], ["alternate", 1079], ["NER", 1089], ["pathway", 1093], ["in", 1101], ["quiescent", 1104], ["cells", 1114], [".", 1119], ["The", 1121], ["proposed", 1125], ["subcategories", 1134], ["of", 1148], ["NER", 1151], ["are", 1155], ["as", 1159], ["follows", 1162], [":", 1169], ["(", 1171], ["i", 1172], [")", 1173], ["TCR", 1175], [",", 1178], ["responsible", 1180], ["for", 1192], ["maintenance", 1196], ["of", 1208], ["transcribed", 1211], ["strands", 1223], [";", 1230], ["(", 1232], ["ii", 1233], [")", 1235], ["GGR", 1237], [",", 1240], ["responsible", 1242], ["for", 1254], ["ubiquitous", 1258], ["genome", 1269], ["repair", 1276], [";", 1282], ["and", 1284], ["(", 1288], ["iii", 1289], [")", 1292], ["non", 1294], ["-", 1297], ["transcribed", 1298], ["strand", 1310], ["repair", 1317], ["(", 1324], ["NTSR", 1325], [")", 1329], [",", 1330], ["predominantly", 1332], ["responsible", 1346], ["for", 1358], ["the", 1362], ["repair", 1366], ["of", 1373], ["the", 1376], ["NTS", 1380], ["in", 1384], ["arrested", 1387], ["cells", 1396], [".", 1401], ["In", 1403], ["quiescent", 1406], ["cells", 1416], [",", 1421], ["it", 1423], ["is", 1426], ["evident", 1429], ["that", 1437], ["TCR", 1442], ["and", 1446], ["NTSR", 1450], ["function", 1455], ["and", 1464], ["GGR", 1468], ["are", 1472], ["arrested", 1476], [".", 1484], ["As", 1486], ["a", 1489], ["consequence", 1491], [",", 1502], ["mutation", 1504], ["accumulation", 1513], ["at", 1526], ["temporally", 1529], ["silent", 1540], ["genes", 1547], ["and", 1553], ["incomplete", 1557], ["or", 1568], ["imperfect", 1571], ["repair", 1581], ["of", 1588], ["transcribed", 1591], ["genes", 1603], [",", 1608], ["in", 1610], ["quiescent", 1613], ["stem", 1623], ["cells", 1628], [",", 1633], ["may", 1635], ["provide", 1639], ["a", 1647], ["source", 1649], ["of", 1656], ["cancer", 1659], ["causing", 1666], ["mutations", 1674], [".", 1683]]}
{"context": "Untreated sleep disorders may contribute to secondary causes of uncontrolled hypertension, cardiovascular disease (CVD), and stroke. Restless legs syndrome, or Willis-Ekbom Disease (RLS/WED), is a common sensorimotor disorder with a circadian rhythmicity defined by an uncontrollable urge to move the legs that worsens during periods of inactivity or at rest in the evening, often resulting in sleep disruptions. Sleep disorders such as insomnia and obstructive sleep apnea (OSA) are established risk factors for increased risk of hypertension and vascular diseases. This literature review outlines the lessons learned from studies demonstrating insomnia and OSA as risk factors for hypertension and vascular diseases to support the epidemiologic and physiologic evidence suggesting a similar increase in hypertension and vascular disease risk due to RLS. Understanding the relationships between RLS and hypertension, CVD, and stroke has important implications for reducing the risks associated with these diseases.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "3117044f9a5c499699d0b54e0b238a5a", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[21, 23]], "char_spans": [[133, 154]]}]}], "context_tokens": [["Untreated", 0], ["sleep", 10], ["disorders", 16], ["may", 26], ["contribute", 30], ["to", 41], ["secondary", 44], ["causes", 54], ["of", 61], ["uncontrolled", 64], ["hypertension", 77], [",", 89], ["cardiovascular", 91], ["disease", 106], ["(", 114], ["CVD", 115], [")", 118], [",", 119], ["and", 121], ["stroke", 125], [".", 131], ["Restless", 133], ["legs", 142], ["syndrome", 147], [",", 155], ["or", 157], ["Willis", 160], ["-", 166], ["Ekbom", 167], ["Disease", 173], ["(", 181], ["RLS", 182], ["/", 185], ["WED", 186], [")", 189], [",", 190], ["is", 192], ["a", 195], ["common", 197], ["sensorimotor", 204], ["disorder", 217], ["with", 226], ["a", 231], ["circadian", 233], ["rhythmicity", 243], ["defined", 255], ["by", 263], ["an", 266], ["uncontrollable", 269], ["urge", 284], ["to", 289], ["move", 292], ["the", 297], ["legs", 301], ["that", 306], ["worsens", 311], ["during", 319], ["periods", 326], ["of", 334], ["inactivity", 337], ["or", 348], ["at", 351], ["rest", 354], ["in", 359], ["the", 362], ["evening", 366], [",", 373], ["often", 375], ["resulting", 381], ["in", 391], ["sleep", 394], ["disruptions", 400], [".", 411], ["Sleep", 413], ["disorders", 419], ["such", 429], ["as", 434], ["insomnia", 437], ["and", 446], ["obstructive", 450], ["sleep", 462], ["apnea", 468], ["(", 474], ["OSA", 475], [")", 478], ["are", 480], ["established", 484], ["risk", 496], ["factors", 501], ["for", 509], ["increased", 513], ["risk", 523], ["of", 528], ["hypertension", 531], ["and", 544], ["vascular", 548], ["diseases", 557], [".", 565], ["This", 567], ["literature", 572], ["review", 583], ["outlines", 590], ["the", 599], ["lessons", 603], ["learned", 611], ["from", 619], ["studies", 624], ["demonstrating", 632], ["insomnia", 646], ["and", 655], ["OSA", 659], ["as", 663], ["risk", 666], ["factors", 671], ["for", 679], ["hypertension", 683], ["and", 696], ["vascular", 700], ["diseases", 709], ["to", 718], ["support", 721], ["the", 729], ["epidemiologic", 733], ["and", 747], ["physiologic", 751], ["evidence", 763], ["suggesting", 772], ["a", 783], ["similar", 785], ["increase", 793], ["in", 802], ["hypertension", 805], ["and", 818], ["vascular", 822], ["disease", 831], ["risk", 839], ["due", 844], ["to", 848], ["RLS", 851], [".", 854], ["Understanding", 856], ["the", 870], ["relationships", 874], ["between", 888], ["RLS", 896], ["and", 900], ["hypertension", 904], [",", 916], ["CVD", 918], [",", 921], ["and", 923], ["stroke", 927], ["has", 934], ["important", 938], ["implications", 948], ["for", 961], ["reducing", 965], ["the", 974], ["risks", 978], ["associated", 984], ["with", 995], ["these", 1000], ["diseases", 1006], [".", 1014]]}
{"context": "Turner's syndrome (TS) is a chromosomal disorder that results from the loss of the entire or a part of the X-chromosome and occurs in 1/2,500 female births. According to the majority of specific reports, intelligence in TS is generally found to be normal and the prevalence of mental retardation does not seem to be increased in TS except for those patients with a small ring X-chromosome. We evaluated 33 girls with TS with chronological age from 6-18 years. Intellectual assessment included the WISC III and the WAIS-R scales. Our results showed: 1) mean full scale intelligence quotient (FSIQ) was significantly lower than expected based on normative data (p < 0.0005); 2) no correlation was present between height and general intellectual ability; 3) mean performance intelligence quotient (PIQ) was significantly lower than both mean verbal intelligence quotient (VIQ) and FSIQ (p < 0.0025 and p < 0.01, respectively), and most patients had a VIQ-PIQ discrepancy; 4) the frequency of mental retardation in our study group was significantly higher than that observed in the general population (15.1% vs 2.3%, p < 0.025); 5) a significant association was found between karyotype and VIQ, and the best score was achieved in the subgroup of patients with structural abnormalities of the X-chromosome. In the light of these findings we conclude that the clinical picture in TS may encompass a slightly reduced FSIQ, VIQ and especially an inadequate PIQ, but this neurocognitive profile is not significantly affected by statural impairment. Since these neurocognitive defects can be responsible for misdiagnosed school difficulties, we suggest that girls with TS should receive specialized educational support and multidisciplinary care.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "12fa90a3c056479a92f47b23fd5275bf", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[252, 252], [72, 72], [23, 23]], "char_spans": [[1288, 1288], [376, 376], [107, 107]]}]}], "context_tokens": [["Turner", 0], ["'s", 6], ["syndrome", 9], ["(", 18], ["TS", 19], [")", 21], ["is", 23], ["a", 26], ["chromosomal", 28], ["disorder", 40], ["that", 49], ["results", 54], ["from", 62], ["the", 67], ["loss", 71], ["of", 76], ["the", 79], ["entire", 83], ["or", 90], ["a", 93], ["part", 95], ["of", 100], ["the", 103], ["X", 107], ["-", 108], ["chromosome", 109], ["and", 120], ["occurs", 124], ["in", 131], ["1/2,500", 134], ["female", 142], ["births", 149], [".", 155], ["According", 157], ["to", 167], ["the", 170], ["majority", 174], ["of", 183], ["specific", 186], ["reports", 195], [",", 202], ["intelligence", 204], ["in", 217], ["TS", 220], ["is", 223], ["generally", 226], ["found", 236], ["to", 242], ["be", 245], ["normal", 248], ["and", 255], ["the", 259], ["prevalence", 263], ["of", 274], ["mental", 277], ["retardation", 284], ["does", 296], ["not", 301], ["seem", 305], ["to", 310], ["be", 313], ["increased", 316], ["in", 326], ["TS", 329], ["except", 332], ["for", 339], ["those", 343], ["patients", 349], ["with", 358], ["a", 363], ["small", 365], ["ring", 371], ["X", 376], ["-", 377], ["chromosome", 378], [".", 388], ["We", 390], ["evaluated", 393], ["33", 403], ["girls", 406], ["with", 412], ["TS", 417], ["with", 420], ["chronological", 425], ["age", 439], ["from", 443], ["6", 448], ["-", 449], ["18", 450], ["years", 453], [".", 458], ["Intellectual", 460], ["assessment", 473], ["included", 484], ["the", 493], ["WISC", 497], ["III", 502], ["and", 506], ["the", 510], ["WAIS", 514], ["-", 518], ["R", 519], ["scales", 521], [".", 527], ["Our", 529], ["results", 533], ["showed", 541], [":", 547], ["1", 549], [")", 550], ["mean", 552], ["full", 557], ["scale", 562], ["intelligence", 568], ["quotient", 581], ["(", 590], ["FSIQ", 591], [")", 595], ["was", 597], ["significantly", 601], ["lower", 615], ["than", 621], ["expected", 626], ["based", 635], ["on", 641], ["normative", 644], ["data", 654], ["(", 659], ["p", 660], ["<", 662], ["0.0005", 664], [")", 670], [";", 671], ["2", 673], [")", 674], ["no", 676], ["correlation", 679], ["was", 691], ["present", 695], ["between", 703], ["height", 711], ["and", 718], ["general", 722], ["intellectual", 730], ["ability", 743], [";", 750], ["3", 752], [")", 753], ["mean", 755], ["performance", 760], ["intelligence", 772], ["quotient", 785], ["(", 794], ["PIQ", 795], [")", 798], ["was", 800], ["significantly", 804], ["lower", 818], ["than", 824], ["both", 829], ["mean", 834], ["verbal", 839], ["intelligence", 846], ["quotient", 859], ["(", 868], ["VIQ", 869], [")", 872], ["and", 874], ["FSIQ", 878], ["(", 883], ["p", 884], ["<", 886], ["0.0025", 888], ["and", 895], ["p", 899], ["<", 901], ["0.01", 903], [",", 907], ["respectively", 909], [")", 921], [",", 922], ["and", 924], ["most", 928], ["patients", 933], ["had", 942], ["a", 946], ["VIQ", 948], ["-", 951], ["PIQ", 952], ["discrepancy", 956], [";", 967], ["4", 969], [")", 970], ["the", 972], ["frequency", 976], ["of", 986], ["mental", 989], ["retardation", 996], ["in", 1008], ["our", 1011], ["study", 1015], ["group", 1021], ["was", 1027], ["significantly", 1031], ["higher", 1045], ["than", 1052], ["that", 1057], ["observed", 1062], ["in", 1071], ["the", 1074], ["general", 1078], ["population", 1086], ["(", 1097], ["15.1", 1098], ["%", 1102], ["vs", 1104], ["2.3", 1107], ["%", 1110], [",", 1111], ["p", 1113], ["<", 1115], ["0.025", 1117], [")", 1122], [";", 1123], ["5", 1125], [")", 1126], ["a", 1128], ["significant", 1130], ["association", 1142], ["was", 1154], ["found", 1158], ["between", 1164], ["karyotype", 1172], ["and", 1182], ["VIQ", 1186], [",", 1189], ["and", 1191], ["the", 1195], ["best", 1199], ["score", 1204], ["was", 1210], ["achieved", 1214], ["in", 1223], ["the", 1226], ["subgroup", 1230], ["of", 1239], ["patients", 1242], ["with", 1251], ["structural", 1256], ["abnormalities", 1267], ["of", 1281], ["the", 1284], ["X", 1288], ["-", 1289], ["chromosome", 1290], [".", 1300], ["In", 1302], ["the", 1305], ["light", 1309], ["of", 1315], ["these", 1318], ["findings", 1324], ["we", 1333], ["conclude", 1336], ["that", 1345], ["the", 1350], ["clinical", 1354], ["picture", 1363], ["in", 1371], ["TS", 1374], ["may", 1377], ["encompass", 1381], ["a", 1391], ["slightly", 1393], ["reduced", 1402], ["FSIQ", 1410], [",", 1414], ["VIQ", 1416], ["and", 1420], ["especially", 1424], ["an", 1435], ["inadequate", 1438], ["PIQ", 1449], [",", 1452], ["but", 1454], ["this", 1458], ["neurocognitive", 1463], ["profile", 1478], ["is", 1486], ["not", 1489], ["significantly", 1493], ["affected", 1507], ["by", 1516], ["statural", 1519], ["impairment", 1528], [".", 1538], ["Since", 1540], ["these", 1546], ["neurocognitive", 1552], ["defects", 1567], ["can", 1575], ["be", 1579], ["responsible", 1582], ["for", 1594], ["misdiagnosed", 1598], ["school", 1611], ["difficulties", 1618], [",", 1630], ["we", 1632], ["suggest", 1635], ["that", 1643], ["girls", 1648], ["with", 1654], ["TS", 1659], ["should", 1662], ["receive", 1669], ["specialized", 1677], ["educational", 1689], ["support", 1701], ["and", 1709], ["multidisciplinary", 1713], ["care", 1731], [".", 1735]]}
{"context": "Chronic myeloid leukaemia (CML) is a genetically associated malignancy of haematopoietic stem cells, characterized by a t(9;22) translocation that forms the Philadelphia chromosome and creates a novel fusion gene, BCR-ABL. Treatment with molecular-targeted therapy is usually initiated with imatinib, an inhibitor of BCR-ABL tyrosine kinase. Imatinib resistance is, however, observed in some CML patients, especially in those with advanced disease. Through computerized literature searches, a systematic analysis was conducted to examine the efficacy and benefits of dasatinib therapy for imatinib resistant or intolerant CML patients in the chronic phase (CP), accelerated phase (AP) and fatal blast crisis phase (BC). In terms of major haematological and cytogenetic responses, this meta-analysis showed no significant differences in dasatinib treatment between myeloid BC-CML and lymphoid BC-CML patients with imatinib resistance or intolerance. Dasatinib therapy was, however, significantly more effective in improving major haematological and cytogenetic responses for CP-CML patients than for AP-CML patients with imatinib resistance or intolerance.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "4039d749db1e402c81b273c51d21f59b", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[53, 55], [34, 36]], "char_spans": [[317, 323], [214, 220]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukaemia", 16], ["(", 26], ["CML", 27], [")", 30], ["is", 32], ["a", 35], ["genetically", 37], ["associated", 49], ["malignancy", 60], ["of", 71], ["haematopoietic", 74], ["stem", 89], ["cells", 94], [",", 99], ["characterized", 101], ["by", 115], ["a", 118], ["t(9;22", 120], [")", 126], ["translocation", 128], ["that", 142], ["forms", 147], ["the", 153], ["Philadelphia", 157], ["chromosome", 170], ["and", 181], ["creates", 185], ["a", 193], ["novel", 195], ["fusion", 201], ["gene", 208], [",", 212], ["BCR", 214], ["-", 217], ["ABL", 218], [".", 221], ["Treatment", 223], ["with", 233], ["molecular", 238], ["-", 247], ["targeted", 248], ["therapy", 257], ["is", 265], ["usually", 268], ["initiated", 276], ["with", 286], ["imatinib", 291], [",", 299], ["an", 301], ["inhibitor", 304], ["of", 314], ["BCR", 317], ["-", 320], ["ABL", 321], ["tyrosine", 325], ["kinase", 334], [".", 340], ["Imatinib", 342], ["resistance", 351], ["is", 362], [",", 364], ["however", 366], [",", 373], ["observed", 375], ["in", 384], ["some", 387], ["CML", 392], ["patients", 396], [",", 404], ["especially", 406], ["in", 417], ["those", 420], ["with", 426], ["advanced", 431], ["disease", 440], [".", 447], ["Through", 449], ["computerized", 457], ["literature", 470], ["searches", 481], [",", 489], ["a", 491], ["systematic", 493], ["analysis", 504], ["was", 513], ["conducted", 517], ["to", 527], ["examine", 530], ["the", 538], ["efficacy", 542], ["and", 551], ["benefits", 555], ["of", 564], ["dasatinib", 567], ["therapy", 577], ["for", 585], ["imatinib", 589], ["resistant", 598], ["or", 608], ["intolerant", 611], ["CML", 622], ["patients", 626], ["in", 635], ["the", 638], ["chronic", 642], ["phase", 650], ["(", 656], ["CP", 657], [")", 659], [",", 660], ["accelerated", 662], ["phase", 674], ["(", 680], ["AP", 681], [")", 683], ["and", 685], ["fatal", 689], ["blast", 695], ["crisis", 701], ["phase", 708], ["(", 714], ["BC", 715], [")", 717], [".", 718], ["In", 720], ["terms", 723], ["of", 729], ["major", 732], ["haematological", 738], ["and", 753], ["cytogenetic", 757], ["responses", 769], [",", 778], ["this", 780], ["meta", 785], ["-", 789], ["analysis", 790], ["showed", 799], ["no", 806], ["significant", 809], ["differences", 821], ["in", 833], ["dasatinib", 836], ["treatment", 846], ["between", 856], ["myeloid", 864], ["BC", 872], ["-", 874], ["CML", 875], ["and", 879], ["lymphoid", 883], ["BC", 892], ["-", 894], ["CML", 895], ["patients", 899], ["with", 908], ["imatinib", 913], ["resistance", 922], ["or", 933], ["intolerance", 936], [".", 947], ["Dasatinib", 949], ["therapy", 959], ["was", 967], [",", 970], ["however", 972], [",", 979], ["significantly", 981], ["more", 995], ["effective", 1000], ["in", 1010], ["improving", 1013], ["major", 1023], ["haematological", 1029], ["and", 1044], ["cytogenetic", 1048], ["responses", 1060], ["for", 1070], ["CP", 1074], ["-", 1076], ["CML", 1077], ["patients", 1081], ["than", 1090], ["for", 1095], ["AP", 1099], ["-", 1101], ["CML", 1102], ["patients", 1106], ["with", 1115], ["imatinib", 1120], ["resistance", 1129], ["or", 1140], ["intolerance", 1143], [".", 1154]]}
{"context": "The Muenke syndrome (MS) is characterized by unicoronal or bicoronal craniosynostosis, midfacial hypoplasia, ocular hypertelorism, and a variety of minor abnormalities associated with a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. The birth prevalence is approximately one in 10,000 live births, accounting for 8-10% of patients with coronal synostosis. Although MS is a relatively common diagnosis in patients with craniosynostosis syndromes, with autosomal dominant inheritance, there has been no report of MS, in an affected Korean family with typical cephalo-facial morphology that has been confirmed by molecular studies. Here, we report a familial case of MS in a female patient with a Pro250Arg mutation in exon 7 (IgII-IGIII linker domain) of the FGFR3 gene. This patient had mild midfacial hypoplasia, hypertelorism, downslanting palpebral fissures, a beak shaped nose, plagio-brachycephaly, and mild neurodevelopmental delay. The same mutation was confirmed in the patient's mother, two of the mother's sisters and the maternal grandfather. The severity of the cephalo-facial anomalies was variable among these family members.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "d053f9773d0649b8b2acea49e06af19f", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[32, 38]], "char_spans": [[202, 243]]}]}], "context_tokens": [["The", 0], ["Muenke", 4], ["syndrome", 11], ["(", 20], ["MS", 21], [")", 23], ["is", 25], ["characterized", 28], ["by", 42], ["unicoronal", 45], ["or", 56], ["bicoronal", 59], ["craniosynostosis", 69], [",", 85], ["midfacial", 87], ["hypoplasia", 97], [",", 107], ["ocular", 109], ["hypertelorism", 116], [",", 129], ["and", 131], ["a", 135], ["variety", 137], ["of", 145], ["minor", 148], ["abnormalities", 154], ["associated", 168], ["with", 179], ["a", 184], ["mutation", 186], ["in", 195], ["the", 198], ["fibroblast", 202], ["growth", 213], ["factor", 220], ["receptor", 227], ["3", 236], ["(", 238], ["FGFR3", 239], [")", 244], ["gene", 246], [".", 250], ["The", 252], ["birth", 256], ["prevalence", 262], ["is", 273], ["approximately", 276], ["one", 290], ["in", 294], ["10,000", 297], ["live", 304], ["births", 309], [",", 315], ["accounting", 317], ["for", 328], ["8", 332], ["-", 333], ["10", 334], ["%", 336], ["of", 338], ["patients", 341], ["with", 350], ["coronal", 355], ["synostosis", 363], [".", 373], ["Although", 375], ["MS", 384], ["is", 387], ["a", 390], ["relatively", 392], ["common", 403], ["diagnosis", 410], ["in", 420], ["patients", 423], ["with", 432], ["craniosynostosis", 437], ["syndromes", 454], [",", 463], ["with", 465], ["autosomal", 470], ["dominant", 480], ["inheritance", 489], [",", 500], ["there", 502], ["has", 508], ["been", 512], ["no", 517], ["report", 520], ["of", 527], ["MS", 530], [",", 532], ["in", 534], ["an", 537], ["affected", 540], ["Korean", 549], ["family", 556], ["with", 563], ["typical", 568], ["cephalo", 576], ["-", 583], ["facial", 584], ["morphology", 591], ["that", 602], ["has", 607], ["been", 611], ["confirmed", 616], ["by", 626], ["molecular", 629], ["studies", 639], [".", 646], ["Here", 648], [",", 652], ["we", 654], ["report", 657], ["a", 664], ["familial", 666], ["case", 675], ["of", 680], ["MS", 683], ["in", 686], ["a", 689], ["female", 691], ["patient", 698], ["with", 706], ["a", 711], ["Pro250Arg", 713], ["mutation", 723], ["in", 732], ["exon", 735], ["7", 740], ["(", 742], ["IgII", 743], ["-", 747], ["IGIII", 748], ["linker", 754], ["domain", 761], [")", 767], ["of", 769], ["the", 772], ["FGFR3", 776], ["gene", 782], [".", 786], ["This", 788], ["patient", 793], ["had", 801], ["mild", 805], ["midfacial", 810], ["hypoplasia", 820], [",", 830], ["hypertelorism", 832], [",", 845], ["downslanting", 847], ["palpebral", 860], ["fissures", 870], [",", 878], ["a", 880], ["beak", 882], ["shaped", 887], ["nose", 894], [",", 898], ["plagio", 900], ["-", 906], ["brachycephaly", 907], [",", 920], ["and", 922], ["mild", 926], ["neurodevelopmental", 931], ["delay", 950], [".", 955], ["The", 957], ["same", 961], ["mutation", 966], ["was", 975], ["confirmed", 979], ["in", 989], ["the", 992], ["patient", 996], ["'s", 1003], ["mother", 1006], [",", 1012], ["two", 1014], ["of", 1018], ["the", 1021], ["mother", 1025], ["'s", 1031], ["sisters", 1034], ["and", 1042], ["the", 1046], ["maternal", 1050], ["grandfather", 1059], [".", 1070], ["The", 1072], ["severity", 1076], ["of", 1085], ["the", 1088], ["cephalo", 1092], ["-", 1099], ["facial", 1100], ["anomalies", 1107], ["was", 1117], ["variable", 1121], ["among", 1130], ["these", 1136], ["family", 1142], ["members", 1149], [".", 1156]]}
{"context": "The purpose of this study is to determine the sensibility of each imaging tool in identifying focal cortical dysplasia (FCD) in children and adolescents with epilepsy and to define the prognostic factors of pediatric and adolescent epilepsy surgery. We identified 48 children with FCD who underwent resective surgery and analyzed their preoperative data. The results of various anatomic and functional neuroimaging studies were compared for accuracy in locating the lesion. We also investigated clinical factors that affected the outcome of surgical treatment. Brain magnetic resonance imaging (MRI) was able to localize FCD in 30 patients and fluorodeoxyglucose positron emission tomography (FDG-PET) and/or subtraction ictal single photon emission computed tomography (SPECT) coregistered with MRI provided additional information that helped to define the lesion in 13 patients. When comparing the pathologic results between a mild malformation of cortical development (MCD) and FCD type I and II, we noted a strong tendency for patients with FCD to have MRI abnormalities (p = 0.005). In addition, severe pathologic features (Palmini's classification, FCD type II) (p = 0.025) showed significant correlation with a better surgical outcome. To define the primary epileptogenic area, various interictal epileptiform discharges and the results of multimodal neuroimaging studies were helpful, and younger age at the time of operation could aid in more favorable surgical outcomes (p = 0.048). Our study showed a significant relationship between pathologic grade and the detectability of FCD by brain MRI. In addition, early surgery can be justified by showing that advanced neuroimaging studies in children with FCD and even with extensive epileptiform discharges have a higher rate of success.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "4e97ba94bae54666969f2d440b9221ff", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[16, 18]], "char_spans": [[94, 117]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["study", 20], ["is", 26], ["to", 29], ["determine", 32], ["the", 42], ["sensibility", 46], ["of", 58], ["each", 61], ["imaging", 66], ["tool", 74], ["in", 79], ["identifying", 82], ["focal", 94], ["cortical", 100], ["dysplasia", 109], ["(", 119], ["FCD", 120], [")", 123], ["in", 125], ["children", 128], ["and", 137], ["adolescents", 141], ["with", 153], ["epilepsy", 158], ["and", 167], ["to", 171], ["define", 174], ["the", 181], ["prognostic", 185], ["factors", 196], ["of", 204], ["pediatric", 207], ["and", 217], ["adolescent", 221], ["epilepsy", 232], ["surgery", 241], [".", 248], ["We", 250], ["identified", 253], ["48", 264], ["children", 267], ["with", 276], ["FCD", 281], ["who", 285], ["underwent", 289], ["resective", 299], ["surgery", 309], ["and", 317], ["analyzed", 321], ["their", 330], ["preoperative", 336], ["data", 349], [".", 353], ["The", 355], ["results", 359], ["of", 367], ["various", 370], ["anatomic", 378], ["and", 387], ["functional", 391], ["neuroimaging", 402], ["studies", 415], ["were", 423], ["compared", 428], ["for", 437], ["accuracy", 441], ["in", 450], ["locating", 453], ["the", 462], ["lesion", 466], [".", 472], ["We", 474], ["also", 477], ["investigated", 482], ["clinical", 495], ["factors", 504], ["that", 512], ["affected", 517], ["the", 526], ["outcome", 530], ["of", 538], ["surgical", 541], ["treatment", 550], [".", 559], ["Brain", 561], ["magnetic", 567], ["resonance", 576], ["imaging", 586], ["(", 594], ["MRI", 595], [")", 598], ["was", 600], ["able", 604], ["to", 609], ["localize", 612], ["FCD", 621], ["in", 625], ["30", 628], ["patients", 631], ["and", 640], ["fluorodeoxyglucose", 644], ["positron", 663], ["emission", 672], ["tomography", 681], ["(", 692], ["FDG", 693], ["-", 696], ["PET", 697], [")", 700], ["and/or", 702], ["subtraction", 709], ["ictal", 721], ["single", 727], ["photon", 734], ["emission", 741], ["computed", 750], ["tomography", 759], ["(", 770], ["SPECT", 771], [")", 776], ["coregistered", 778], ["with", 791], ["MRI", 796], ["provided", 800], ["additional", 809], ["information", 820], ["that", 832], ["helped", 837], ["to", 844], ["define", 847], ["the", 854], ["lesion", 858], ["in", 865], ["13", 868], ["patients", 871], [".", 879], ["When", 881], ["comparing", 886], ["the", 896], ["pathologic", 900], ["results", 911], ["between", 919], ["a", 927], ["mild", 929], ["malformation", 934], ["of", 947], ["cortical", 950], ["development", 959], ["(", 971], ["MCD", 972], [")", 975], ["and", 977], ["FCD", 981], ["type", 985], ["I", 990], ["and", 992], ["II", 996], [",", 998], ["we", 1000], ["noted", 1003], ["a", 1009], ["strong", 1011], ["tendency", 1018], ["for", 1027], ["patients", 1031], ["with", 1040], ["FCD", 1045], ["to", 1049], ["have", 1052], ["MRI", 1057], ["abnormalities", 1061], ["(", 1075], ["p", 1076], ["=", 1078], ["0.005", 1080], [")", 1085], [".", 1086], ["In", 1088], ["addition", 1091], [",", 1099], ["severe", 1101], ["pathologic", 1108], ["features", 1119], ["(", 1128], ["Palmini", 1129], ["'s", 1136], ["classification", 1139], [",", 1153], ["FCD", 1155], ["type", 1159], ["II", 1164], [")", 1166], ["(", 1168], ["p", 1169], ["=", 1171], ["0.025", 1173], [")", 1178], ["showed", 1180], ["significant", 1187], ["correlation", 1199], ["with", 1211], ["a", 1216], ["better", 1218], ["surgical", 1225], ["outcome", 1234], [".", 1241], ["To", 1243], ["define", 1246], ["the", 1253], ["primary", 1257], ["epileptogenic", 1265], ["area", 1279], [",", 1283], ["various", 1285], ["interictal", 1293], ["epileptiform", 1304], ["discharges", 1317], ["and", 1328], ["the", 1332], ["results", 1336], ["of", 1344], ["multimodal", 1347], ["neuroimaging", 1358], ["studies", 1371], ["were", 1379], ["helpful", 1384], [",", 1391], ["and", 1393], ["younger", 1397], ["age", 1405], ["at", 1409], ["the", 1412], ["time", 1416], ["of", 1421], ["operation", 1424], ["could", 1434], ["aid", 1440], ["in", 1444], ["more", 1447], ["favorable", 1452], ["surgical", 1462], ["outcomes", 1471], ["(", 1480], ["p", 1481], ["=", 1483], ["0.048", 1485], [")", 1490], [".", 1491], ["Our", 1493], ["study", 1497], ["showed", 1503], ["a", 1510], ["significant", 1512], ["relationship", 1524], ["between", 1537], ["pathologic", 1545], ["grade", 1556], ["and", 1562], ["the", 1566], ["detectability", 1570], ["of", 1584], ["FCD", 1587], ["by", 1591], ["brain", 1594], ["MRI", 1600], [".", 1603], ["In", 1605], ["addition", 1608], [",", 1616], ["early", 1618], ["surgery", 1624], ["can", 1632], ["be", 1636], ["justified", 1639], ["by", 1649], ["showing", 1652], ["that", 1660], ["advanced", 1665], ["neuroimaging", 1674], ["studies", 1687], ["in", 1695], ["children", 1698], ["with", 1707], ["FCD", 1712], ["and", 1716], ["even", 1720], ["with", 1725], ["extensive", 1730], ["epileptiform", 1740], ["discharges", 1753], ["have", 1764], ["a", 1769], ["higher", 1771], ["rate", 1778], ["of", 1783], ["success", 1786], [".", 1793]]}
{"context": "Angelman syndrome (AS) is caused by a lack of expression of the maternally inherited UBE3A gene in the brain. However, about 10% of individuals with a clinical diagnosis of AS do not have an identifiable molecular defect. It is likely that most of those individuals have an AS-like syndrome that is clinically and molecularly distinct from AS. These AS-like syndromes can be broadly classified into chromosomal microdeletion and microduplication syndromes, and single-gene disorders. The microdeletion/microduplication syndromes are now easily identified by chromosomal microarray analysis and include Phelan\u2013McDermid syndrome (chromosome 22q13.3 deletion), MBD5 haploinsufficiency syndrome (chromosome 2q23.1 deletion), and KANSL1 haploinsufficiency syndrome (chromosome 17q21.31 deletion). The single-gene disorders include Pitt\u2013Hopkins syndrome (TCF4), Christianson syndrome (SLC9A6), Mowat\u2013Wilson syndrome (ZEB2), Kleefstra syndrome (EHMT1), and Rett (MECP2) syndrome. They also include disorders due to mutations in HERC2, adenylosuccinase lyase (ADSL), CDKL5, FOXG1, MECP2 (duplications), MEF2C, and ATRX. Although many of these single-gene disorders can be caused by chromosomal microdeletions resulting in haploinsufficiency of the critical gene, the individual disorders are often caused by intragenic mutations that cannot be detected by chromosomal microarray analysis. We provide an overview of the clinical features of these syndromes, comparing and contrasting them with AS, in the hope that it will help guide clinicians in the diagnostic work-up of individuals with AS-like syndromes.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "ddf1ff17a2ea4e5088dd93222e4a7289", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[149, 149]], "char_spans": [[879, 884]]}]}], "context_tokens": [["Angelman", 0], ["syndrome", 9], ["(", 18], ["AS", 19], [")", 21], ["is", 23], ["caused", 26], ["by", 33], ["a", 36], ["lack", 38], ["of", 43], ["expression", 46], ["of", 57], ["the", 60], ["maternally", 64], ["inherited", 75], ["UBE3A", 85], ["gene", 91], ["in", 96], ["the", 99], ["brain", 103], [".", 108], ["However", 110], [",", 117], ["about", 119], ["10", 125], ["%", 127], ["of", 129], ["individuals", 132], ["with", 144], ["a", 149], ["clinical", 151], ["diagnosis", 160], ["of", 170], ["AS", 173], ["do", 176], ["not", 179], ["have", 183], ["an", 188], ["identifiable", 191], ["molecular", 204], ["defect", 214], [".", 220], ["It", 222], ["is", 225], ["likely", 228], ["that", 235], ["most", 240], ["of", 245], ["those", 248], ["individuals", 254], ["have", 266], ["an", 271], ["AS", 274], ["-", 276], ["like", 277], ["syndrome", 282], ["that", 291], ["is", 296], ["clinically", 299], ["and", 310], ["molecularly", 314], ["distinct", 326], ["from", 335], ["AS", 340], [".", 342], ["These", 344], ["AS", 350], ["-", 352], ["like", 353], ["syndromes", 358], ["can", 368], ["be", 372], ["broadly", 375], ["classified", 383], ["into", 394], ["chromosomal", 399], ["microdeletion", 411], ["and", 425], ["microduplication", 429], ["syndromes", 446], [",", 455], ["and", 457], ["single", 461], ["-", 467], ["gene", 468], ["disorders", 473], [".", 482], ["The", 484], ["microdeletion", 488], ["/", 501], ["microduplication", 502], ["syndromes", 519], ["are", 529], ["now", 533], ["easily", 537], ["identified", 544], ["by", 555], ["chromosomal", 558], ["microarray", 570], ["analysis", 581], ["and", 590], ["include", 594], ["Phelan", 602], ["\u2013", 608], ["McDermid", 609], ["syndrome", 618], ["(", 627], ["chromosome", 628], ["22q13.3", 639], ["deletion", 647], [")", 655], [",", 656], ["MBD5", 658], ["haploinsufficiency", 663], ["syndrome", 682], ["(", 691], ["chromosome", 692], ["2q23.1", 703], ["deletion", 710], [")", 718], [",", 719], ["and", 721], ["KANSL1", 725], ["haploinsufficiency", 732], ["syndrome", 751], ["(", 760], ["chromosome", 761], ["17q21.31", 772], ["deletion", 781], [")", 789], [".", 790], ["The", 792], ["single", 796], ["-", 802], ["gene", 803], ["disorders", 808], ["include", 818], ["Pitt", 826], ["\u2013", 830], ["Hopkins", 831], ["syndrome", 839], ["(", 848], ["TCF4", 849], [")", 853], [",", 854], ["Christianson", 856], ["syndrome", 869], ["(", 878], ["SLC9A6", 879], [")", 885], [",", 886], ["Mowat", 888], ["\u2013", 893], ["Wilson", 894], ["syndrome", 901], ["(", 910], ["ZEB2", 911], [")", 915], [",", 916], ["Kleefstra", 918], ["syndrome", 928], ["(", 937], ["EHMT1", 938], [")", 943], [",", 944], ["and", 946], ["Rett", 950], ["(", 955], ["MECP2", 956], [")", 961], ["syndrome", 963], [".", 971], ["They", 973], ["also", 978], ["include", 983], ["disorders", 991], ["due", 1001], ["to", 1005], ["mutations", 1008], ["in", 1018], ["HERC2", 1021], [",", 1026], ["adenylosuccinase", 1028], ["lyase", 1045], ["(", 1051], ["ADSL", 1052], [")", 1056], [",", 1057], ["CDKL5", 1059], [",", 1064], ["FOXG1", 1066], [",", 1071], ["MECP2", 1073], ["(", 1079], ["duplications", 1080], [")", 1092], [",", 1093], ["MEF2C", 1095], [",", 1100], ["and", 1102], ["ATRX", 1106], [".", 1110], ["Although", 1112], ["many", 1121], ["of", 1126], ["these", 1129], ["single", 1135], ["-", 1141], ["gene", 1142], ["disorders", 1147], ["can", 1157], ["be", 1161], ["caused", 1164], ["by", 1171], ["chromosomal", 1174], ["microdeletions", 1186], ["resulting", 1201], ["in", 1211], ["haploinsufficiency", 1214], ["of", 1233], ["the", 1236], ["critical", 1240], ["gene", 1249], [",", 1253], ["the", 1255], ["individual", 1259], ["disorders", 1270], ["are", 1280], ["often", 1284], ["caused", 1290], ["by", 1297], ["intragenic", 1300], ["mutations", 1311], ["that", 1321], ["can", 1326], ["not", 1329], ["be", 1333], ["detected", 1336], ["by", 1345], ["chromosomal", 1348], ["microarray", 1360], ["analysis", 1371], [".", 1379], ["We", 1381], ["provide", 1384], ["an", 1392], ["overview", 1395], ["of", 1404], ["the", 1407], ["clinical", 1411], ["features", 1420], ["of", 1429], ["these", 1432], ["syndromes", 1438], [",", 1447], ["comparing", 1449], ["and", 1459], ["contrasting", 1463], ["them", 1475], ["with", 1480], ["AS", 1485], [",", 1487], ["in", 1489], ["the", 1492], ["hope", 1496], ["that", 1501], ["it", 1506], ["will", 1509], ["help", 1514], ["guide", 1519], ["clinicians", 1525], ["in", 1536], ["the", 1539], ["diagnostic", 1543], ["work", 1554], ["-", 1558], ["up", 1559], ["of", 1562], ["individuals", 1565], ["with", 1577], ["AS", 1582], ["-", 1584], ["like", 1585], ["syndromes", 1590], [".", 1599]]}
{"context": "Neurofibromatosis type 1 (NF1) is a common familial tumour syndrome with multiple clinical features such as neurofibromas, caf\u00e9-au-lait spots (CLS), iris Lisch nodules, axillary freckling, optic glioma, specific bone lesions and an increased risk of malignant tumours. It is caused by a wide spectrum of mutations affecting the NF1 gene. Most mutations result in the loss of one allele at the DNA, mRNA or protein level and thus in the loss of any function of the gene product neurofibromin. The idea of the simultaneous loss of several different neurofibromin functions has been postulated to explain the pleiotropic effects of its loss. However, we have identified a novel missense mutation in a family with a classical multi-symptomatic NF1 phenotype, including a malignant schwannoma, that specifically abolishes the Ras-GTPase-activating function of neurofibromin. In this family, Arg1276 had mutated into proline. Based on complex biochemical studies as well as the analysis of the crystal structure of the GTPase-activating protein (GAP) domain of p120GAP in the presence of Ras, we unequivocally identified this amino acid as the arginine finger of the neurofibromin GAP-related domain (GRD)-the most essential catalytic element for RasGAP activity. Here, we present data demonstrating that the mutation R1276P, unlike previously reported missense mutations of the GRD region, does not impair the secondary and tertiary protein structure. It neither reduces the level of cellular neurofibromin nor influences its binding to Ras substantially, but it does completely disable GAP activity. Our findings provide direct evidence that failure of neurofibromin GAP activity is the critical element of NF1 pathogenesis. Thus, therapeutic approaches aimed at the reduction of Ras.GTP levels in neural crest-derived cells can be expected to relieve most of the NF1 symptoms.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "6f4df195db2e4569b74922aec8abb058", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[298, 298], [4, 4], [137, 137], [328, 328], [62, 62]], "char_spans": [[1703, 1705], [26, 28], [740, 742], [1860, 1862], [328, 330]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["common", 36], ["familial", 43], ["tumour", 52], ["syndrome", 59], ["with", 68], ["multiple", 73], ["clinical", 82], ["features", 91], ["such", 100], ["as", 105], ["neurofibromas", 108], [",", 121], ["caf\u00e9", 123], ["-", 127], ["au", 128], ["-", 130], ["lait", 131], ["spots", 136], ["(", 142], ["CLS", 143], [")", 146], [",", 147], ["iris", 149], ["Lisch", 154], ["nodules", 160], [",", 167], ["axillary", 169], ["freckling", 178], [",", 187], ["optic", 189], ["glioma", 195], [",", 201], ["specific", 203], ["bone", 212], ["lesions", 217], ["and", 225], ["an", 229], ["increased", 232], ["risk", 242], ["of", 247], ["malignant", 250], ["tumours", 260], [".", 267], ["It", 269], ["is", 272], ["caused", 275], ["by", 282], ["a", 285], ["wide", 287], ["spectrum", 292], ["of", 301], ["mutations", 304], ["affecting", 314], ["the", 324], ["NF1", 328], ["gene", 332], [".", 336], ["Most", 338], ["mutations", 343], ["result", 353], ["in", 360], ["the", 363], ["loss", 367], ["of", 372], ["one", 375], ["allele", 379], ["at", 386], ["the", 389], ["DNA", 393], [",", 396], ["mRNA", 398], ["or", 403], ["protein", 406], ["level", 414], ["and", 420], ["thus", 424], ["in", 429], ["the", 432], ["loss", 436], ["of", 441], ["any", 444], ["function", 448], ["of", 457], ["the", 460], ["gene", 464], ["product", 469], ["neurofibromin", 477], [".", 490], ["The", 492], ["idea", 496], ["of", 501], ["the", 504], ["simultaneous", 508], ["loss", 521], ["of", 526], ["several", 529], ["different", 537], ["neurofibromin", 547], ["functions", 561], ["has", 571], ["been", 575], ["postulated", 580], ["to", 591], ["explain", 594], ["the", 602], ["pleiotropic", 606], ["effects", 618], ["of", 626], ["its", 629], ["loss", 633], [".", 637], ["However", 639], [",", 646], ["we", 648], ["have", 651], ["identified", 656], ["a", 667], ["novel", 669], ["missense", 675], ["mutation", 684], ["in", 693], ["a", 696], ["family", 698], ["with", 705], ["a", 710], ["classical", 712], ["multi", 722], ["-", 727], ["symptomatic", 728], ["NF1", 740], ["phenotype", 744], [",", 753], ["including", 755], ["a", 765], ["malignant", 767], ["schwannoma", 777], [",", 787], ["that", 789], ["specifically", 794], ["abolishes", 807], ["the", 817], ["Ras", 821], ["-", 824], ["GTPase", 825], ["-", 831], ["activating", 832], ["function", 843], ["of", 852], ["neurofibromin", 855], [".", 868], ["In", 870], ["this", 873], ["family", 878], [",", 884], ["Arg1276", 886], ["had", 894], ["mutated", 898], ["into", 906], ["proline", 911], [".", 918], ["Based", 920], ["on", 926], ["complex", 929], ["biochemical", 937], ["studies", 949], ["as", 957], ["well", 960], ["as", 965], ["the", 968], ["analysis", 972], ["of", 981], ["the", 984], ["crystal", 988], ["structure", 996], ["of", 1006], ["the", 1009], ["GTPase", 1013], ["-", 1019], ["activating", 1020], ["protein", 1031], ["(", 1039], ["GAP", 1040], [")", 1043], ["domain", 1045], ["of", 1052], ["p120GAP", 1055], ["in", 1063], ["the", 1066], ["presence", 1070], ["of", 1079], ["Ras", 1082], [",", 1085], ["we", 1087], ["unequivocally", 1090], ["identified", 1104], ["this", 1115], ["amino", 1120], ["acid", 1126], ["as", 1131], ["the", 1134], ["arginine", 1138], ["finger", 1147], ["of", 1154], ["the", 1157], ["neurofibromin", 1161], ["GAP", 1175], ["-", 1178], ["related", 1179], ["domain", 1187], ["(", 1194], ["GRD)-the", 1195], ["most", 1204], ["essential", 1209], ["catalytic", 1219], ["element", 1229], ["for", 1237], ["RasGAP", 1241], ["activity", 1248], [".", 1256], ["Here", 1258], [",", 1262], ["we", 1264], ["present", 1267], ["data", 1275], ["demonstrating", 1280], ["that", 1294], ["the", 1299], ["mutation", 1303], ["R1276P", 1312], [",", 1318], ["unlike", 1320], ["previously", 1327], ["reported", 1338], ["missense", 1347], ["mutations", 1356], ["of", 1366], ["the", 1369], ["GRD", 1373], ["region", 1377], [",", 1383], ["does", 1385], ["not", 1390], ["impair", 1394], ["the", 1401], ["secondary", 1405], ["and", 1415], ["tertiary", 1419], ["protein", 1428], ["structure", 1436], [".", 1445], ["It", 1447], ["neither", 1450], ["reduces", 1458], ["the", 1466], ["level", 1470], ["of", 1476], ["cellular", 1479], ["neurofibromin", 1488], ["nor", 1502], ["influences", 1506], ["its", 1517], ["binding", 1521], ["to", 1529], ["Ras", 1532], ["substantially", 1536], [",", 1549], ["but", 1551], ["it", 1555], ["does", 1558], ["completely", 1563], ["disable", 1574], ["GAP", 1582], ["activity", 1586], [".", 1594], ["Our", 1596], ["findings", 1600], ["provide", 1609], ["direct", 1617], ["evidence", 1624], ["that", 1633], ["failure", 1638], ["of", 1646], ["neurofibromin", 1649], ["GAP", 1663], ["activity", 1667], ["is", 1676], ["the", 1679], ["critical", 1683], ["element", 1692], ["of", 1700], ["NF1", 1703], ["pathogenesis", 1707], [".", 1719], ["Thus", 1721], [",", 1725], ["therapeutic", 1727], ["approaches", 1739], ["aimed", 1750], ["at", 1756], ["the", 1759], ["reduction", 1763], ["of", 1773], ["Ras", 1776], [".", 1779], ["GTP", 1780], ["levels", 1784], ["in", 1791], ["neural", 1794], ["crest", 1801], ["-", 1806], ["derived", 1807], ["cells", 1815], ["can", 1821], ["be", 1825], ["expected", 1828], ["to", 1837], ["relieve", 1840], ["most", 1848], ["of", 1853], ["the", 1856], ["NF1", 1860], ["symptoms", 1864], [".", 1872]]}
{"context": "alpha-Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles in the pathogenesis of Lewy bodies. We examined the relationship between alpha-synuclein, ubiquitin, and lipids in Lewy bodies of fixed brain sections or isolated from cortical tissues of dementia with Lewy bodies. Lewy bodies exhibited a range of labeling patterns for alpha-synuclein and ubiquitin, from a homogeneous pattern in which alpha-synuclein and ubiquitin were evenly distributed and overlapped across the inclusion body to a concentric pattern in which alpha-synuclein and ubiquitin were partially segregated, with alpha-synuclein labeling concentrated in the peripheral domain and ubiquitin in the central domain of the Lewy body. Lipids represented a significant component in both homogeneous and concentric Lewy bodies. These results suggest that Lewy bodies are heterogeneous in their subregional composition. The segregation of alpha-synuclein to Lewy body peripheral domain is consistent with the hypothesis that alpha-synuclein is continually deposited onto Lewy bodies.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "84268ced61744024a40b6f8d2316d275", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[63, 65], [28, 30], [154, 156], [168, 170], [95, 97], [105, 107], [0, 2], [75, 77]], "char_spans": [[370, 384], [173, 187], [945, 959], [1031, 1045], [565, 579], [627, 641], [0, 14], [437, 451]]}]}], "context_tokens": [["alpha", 0], ["-", 5], ["Synuclein", 6], ["and", 16], ["ubiquitin", 20], ["are", 30], ["two", 34], ["Lewy", 38], ["body", 43], ["protein", 48], ["components", 56], ["that", 67], ["may", 72], ["play", 76], ["antagonistic", 81], ["roles", 94], ["in", 100], ["the", 103], ["pathogenesis", 107], ["of", 120], ["Lewy", 123], ["bodies", 128], [".", 134], ["We", 136], ["examined", 139], ["the", 148], ["relationship", 152], ["between", 165], ["alpha", 173], ["-", 178], ["synuclein", 179], [",", 188], ["ubiquitin", 190], [",", 199], ["and", 201], ["lipids", 205], ["in", 212], ["Lewy", 215], ["bodies", 220], ["of", 227], ["fixed", 230], ["brain", 236], ["sections", 242], ["or", 251], ["isolated", 254], ["from", 263], ["cortical", 268], ["tissues", 277], ["of", 285], ["dementia", 288], ["with", 297], ["Lewy", 302], ["bodies", 307], [".", 313], ["Lewy", 315], ["bodies", 320], ["exhibited", 327], ["a", 337], ["range", 339], ["of", 345], ["labeling", 348], ["patterns", 357], ["for", 366], ["alpha", 370], ["-", 375], ["synuclein", 376], ["and", 386], ["ubiquitin", 390], [",", 399], ["from", 401], ["a", 406], ["homogeneous", 408], ["pattern", 420], ["in", 428], ["which", 431], ["alpha", 437], ["-", 442], ["synuclein", 443], ["and", 453], ["ubiquitin", 457], ["were", 467], ["evenly", 472], ["distributed", 479], ["and", 491], ["overlapped", 495], ["across", 506], ["the", 513], ["inclusion", 517], ["body", 527], ["to", 532], ["a", 535], ["concentric", 537], ["pattern", 548], ["in", 556], ["which", 559], ["alpha", 565], ["-", 570], ["synuclein", 571], ["and", 581], ["ubiquitin", 585], ["were", 595], ["partially", 600], ["segregated", 610], [",", 620], ["with", 622], ["alpha", 627], ["-", 632], ["synuclein", 633], ["labeling", 643], ["concentrated", 652], ["in", 665], ["the", 668], ["peripheral", 672], ["domain", 683], ["and", 690], ["ubiquitin", 694], ["in", 704], ["the", 707], ["central", 711], ["domain", 719], ["of", 726], ["the", 729], ["Lewy", 733], ["body", 738], [".", 742], ["Lipids", 744], ["represented", 751], ["a", 763], ["significant", 765], ["component", 777], ["in", 787], ["both", 790], ["homogeneous", 795], ["and", 807], ["concentric", 811], ["Lewy", 822], ["bodies", 827], [".", 833], ["These", 835], ["results", 841], ["suggest", 849], ["that", 857], ["Lewy", 862], ["bodies", 867], ["are", 874], ["heterogeneous", 878], ["in", 892], ["their", 895], ["subregional", 901], ["composition", 913], [".", 924], ["The", 926], ["segregation", 930], ["of", 942], ["alpha", 945], ["-", 950], ["synuclein", 951], ["to", 961], ["Lewy", 964], ["body", 969], ["peripheral", 974], ["domain", 985], ["is", 992], ["consistent", 995], ["with", 1006], ["the", 1011], ["hypothesis", 1015], ["that", 1026], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], ["is", 1047], ["continually", 1050], ["deposited", 1062], ["onto", 1072], ["Lewy", 1077], ["bodies", 1082], [".", 1088]]}
{"context": "To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent. A literature search was conducted consisting of a PubMed database using the MeSH term idarucizumab and the key word dabigatran antidote. Studies evaluating the pharmacology, pharmacokinetics, safety, and efficacy of idarucizumab for the reversal of the anticoagulant activity of dabigatran were included. Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran. Studies evaluating reversal of dabigatran-induced anticoagulation have demonstrated immediate, complete, and sustained effects with idarucizumab. Idarucizumab did not overcorrect thrombin generation. Additionally, evaluations have shown that dabigatran can be safely reinitiated 24 hours after the administration of idarucizumab. The United States Food and Drug Administration granted priority review for the biologic license application and accelerated approval for idarucizumab. Idarucizumab represents an encouraging development in the reversal of dabigatran. Its novel mechanism of action, pharmacokinetics, tolerability, and lack of thrombotic events contribute positively to its use in patients who experience bleeding or for those who require emergent surgery or procedures.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "ef28a6cc8b5d472b98e489b35d514e0b", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[186, 186], [108, 108], [60, 60], [84, 84], [23, 23], [114, 114], [143, 143]], "char_spans": [[1252, 1261], [689, 698], [366, 375], [529, 538], [143, 152], [732, 741], [943, 952]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["role", 16], ["of", 21], ["idarucizumab", 24], [",", 36], ["a", 38], ["humanized", 40], ["monoclonal", 50], ["antibody", 61], ["fragment", 70], [",", 78], ["as", 80], ["a", 83], ["specific", 85], ["reversal", 94], ["agent", 103], ["for", 109], ["the", 113], ["anticoagulant", 117], ["activity", 131], ["of", 140], ["dabigatran", 143], ["and", 154], ["to", 158], ["review", 161], ["the", 168], ["pharmacology", 172], [",", 184], ["pharmacokinetic", 186], ["properties", 202], [",", 212], ["efficacy", 214], [",", 222], ["and", 224], ["safety", 228], ["of", 235], ["this", 238], ["agent", 243], [".", 248], ["A", 250], ["literature", 252], ["search", 263], ["was", 270], ["conducted", 274], ["consisting", 284], ["of", 295], ["a", 298], ["PubMed", 300], ["database", 307], ["using", 316], ["the", 322], ["MeSH", 326], ["term", 331], ["idarucizumab", 336], ["and", 349], ["the", 353], ["key", 357], ["word", 361], ["dabigatran", 366], ["antidote", 377], [".", 385], ["Studies", 387], ["evaluating", 395], ["the", 406], ["pharmacology", 410], [",", 422], ["pharmacokinetics", 424], [",", 440], ["safety", 442], [",", 448], ["and", 450], ["efficacy", 454], ["of", 463], ["idarucizumab", 466], ["for", 479], ["the", 483], ["reversal", 487], ["of", 496], ["the", 499], ["anticoagulant", 503], ["activity", 517], ["of", 526], ["dabigatran", 529], ["were", 540], ["included", 545], [".", 553], ["Idarucizumab", 555], ["represents", 568], ["a", 579], ["novel", 581], ["treatment", 587], ["option", 597], ["as", 604], ["it", 607], ["is", 610], ["the", 613], ["only", 617], ["humanized", 622], [",", 631], ["monoclonal", 633], ["antibody", 644], ["fragment", 653], ["that", 662], ["specifically", 667], ["binds", 680], ["to", 686], ["dabigatran", 689], [".", 699], ["Studies", 701], ["evaluating", 709], ["reversal", 720], ["of", 729], ["dabigatran", 732], ["-", 742], ["induced", 743], ["anticoagulation", 751], ["have", 767], ["demonstrated", 772], ["immediate", 785], [",", 794], ["complete", 796], [",", 804], ["and", 806], ["sustained", 810], ["effects", 820], ["with", 828], ["idarucizumab", 833], [".", 845], ["Idarucizumab", 847], ["did", 860], ["not", 864], ["overcorrect", 868], ["thrombin", 880], ["generation", 889], [".", 899], ["Additionally", 901], [",", 913], ["evaluations", 915], ["have", 927], ["shown", 932], ["that", 938], ["dabigatran", 943], ["can", 954], ["be", 958], ["safely", 961], ["reinitiated", 968], ["24", 980], ["hours", 983], ["after", 989], ["the", 995], ["administration", 999], ["of", 1014], ["idarucizumab", 1017], [".", 1029], ["The", 1031], ["United", 1035], ["States", 1042], ["Food", 1049], ["and", 1054], ["Drug", 1058], ["Administration", 1063], ["granted", 1078], ["priority", 1086], ["review", 1095], ["for", 1102], ["the", 1106], ["biologic", 1110], ["license", 1119], ["application", 1127], ["and", 1139], ["accelerated", 1143], ["approval", 1155], ["for", 1164], ["idarucizumab", 1168], [".", 1180], ["Idarucizumab", 1182], ["represents", 1195], ["an", 1206], ["encouraging", 1209], ["development", 1221], ["in", 1233], ["the", 1236], ["reversal", 1240], ["of", 1249], ["dabigatran", 1252], [".", 1262], ["Its", 1264], ["novel", 1268], ["mechanism", 1274], ["of", 1284], ["action", 1287], [",", 1293], ["pharmacokinetics", 1295], [",", 1311], ["tolerability", 1313], [",", 1325], ["and", 1327], ["lack", 1331], ["of", 1336], ["thrombotic", 1339], ["events", 1350], ["contribute", 1357], ["positively", 1368], ["to", 1379], ["its", 1382], ["use", 1386], ["in", 1390], ["patients", 1393], ["who", 1402], ["experience", 1406], ["bleeding", 1417], ["or", 1426], ["for", 1429], ["those", 1433], ["who", 1439], ["require", 1443], ["emergent", 1451], ["surgery", 1460], ["or", 1468], ["procedures", 1471], [".", 1481]]}
{"context": "Postoperative methicillin-resistant Staphylococcus aureus (MRSA) infections are occasionally fatal. We hypothesized that nasal MRSA screening might predict the risk of postoperative MRSA infections. The aim of the current study was to elucidate the relationship between the positivity of nasal MRSA screening and postoperative MRSA infections. Six hundred and fourteen surgical patients who were admitted to the intensive care unit and underwent nasal MRSA screening between April 2006 and March 2011 were divided into MRSA-positive and -negative groups. The incidence of postoperative MRSA infections in the MRSA-positive and MRSA-negative groups were compared, and various risk factors for MRSA infections were evaluated. The incidence of postoperative MRSA infections, such as pneumonia and enteritis, in the MRSA-positive group was significantly higher than that in the MRSA-negative group (41.9 vs. 3.1 %). The significant independent risk factors for postoperative MRSA infections were a positive MRSA screening, an operation lasting more than 300 min and an emergency operation. A positive MRSA screening was the most statistically significant risk factor for postoperative MRSA pneumonia and enteritis, but was not a risk factor for MRSA surgical site infections. Nasal MRSA screening can help to identify patients who have an increased risk of developing postoperative MRSA infections, and would enable physicians to take a prompt action if these complications occur.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "a9817a6931814cc1929eed39d878021d", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[80, 80], [160, 160], [45, 45], [205, 205], [211, 211], [7, 7], [111, 111], [120, 120], [69, 69], [131, 131], [142, 142], [226, 226], [193, 193], [49, 49], [26, 26], [91, 91], [99, 99], [165, 165], [182, 182], [18, 18], [95, 95]], "char_spans": [[519, 522], [971, 974], [294, 297], [1241, 1244], [1278, 1281], [59, 62], [692, 695], [755, 758], [452, 455], [812, 815], [874, 877], [1378, 1381], [1181, 1184], [327, 330], [182, 185], [586, 589], [627, 630], [1003, 1006], [1097, 1100], [127, 130], [609, 612]]}]}], "context_tokens": [["Postoperative", 0], ["methicillin", 14], ["-", 25], ["resistant", 26], ["Staphylococcus", 36], ["aureus", 51], ["(", 58], ["MRSA", 59], [")", 63], ["infections", 65], ["are", 76], ["occasionally", 80], ["fatal", 93], [".", 98], ["We", 100], ["hypothesized", 103], ["that", 116], ["nasal", 121], ["MRSA", 127], ["screening", 132], ["might", 142], ["predict", 148], ["the", 156], ["risk", 160], ["of", 165], ["postoperative", 168], ["MRSA", 182], ["infections", 187], [".", 197], ["The", 199], ["aim", 203], ["of", 207], ["the", 210], ["current", 214], ["study", 222], ["was", 228], ["to", 232], ["elucidate", 235], ["the", 245], ["relationship", 249], ["between", 262], ["the", 270], ["positivity", 274], ["of", 285], ["nasal", 288], ["MRSA", 294], ["screening", 299], ["and", 309], ["postoperative", 313], ["MRSA", 327], ["infections", 332], [".", 342], ["Six", 344], ["hundred", 348], ["and", 356], ["fourteen", 360], ["surgical", 369], ["patients", 378], ["who", 387], ["were", 391], ["admitted", 396], ["to", 405], ["the", 408], ["intensive", 412], ["care", 422], ["unit", 427], ["and", 432], ["underwent", 436], ["nasal", 446], ["MRSA", 452], ["screening", 457], ["between", 467], ["April", 475], ["2006", 481], ["and", 486], ["March", 490], ["2011", 496], ["were", 501], ["divided", 506], ["into", 514], ["MRSA", 519], ["-", 523], ["positive", 524], ["and", 533], ["-negative", 537], ["groups", 547], [".", 553], ["The", 555], ["incidence", 559], ["of", 569], ["postoperative", 572], ["MRSA", 586], ["infections", 591], ["in", 602], ["the", 605], ["MRSA", 609], ["-", 613], ["positive", 614], ["and", 623], ["MRSA", 627], ["-", 631], ["negative", 632], ["groups", 641], ["were", 648], ["compared", 653], [",", 661], ["and", 663], ["various", 667], ["risk", 675], ["factors", 680], ["for", 688], ["MRSA", 692], ["infections", 697], ["were", 708], ["evaluated", 713], [".", 722], ["The", 724], ["incidence", 728], ["of", 738], ["postoperative", 741], ["MRSA", 755], ["infections", 760], [",", 770], ["such", 772], ["as", 777], ["pneumonia", 780], ["and", 790], ["enteritis", 794], [",", 803], ["in", 805], ["the", 808], ["MRSA", 812], ["-", 816], ["positive", 817], ["group", 826], ["was", 832], ["significantly", 836], ["higher", 850], ["than", 857], ["that", 862], ["in", 867], ["the", 870], ["MRSA", 874], ["-", 878], ["negative", 879], ["group", 888], ["(", 894], ["41.9", 895], ["vs.", 900], ["3.1", 904], ["%", 908], [")", 909], [".", 910], ["The", 912], ["significant", 916], ["independent", 928], ["risk", 940], ["factors", 945], ["for", 953], ["postoperative", 957], ["MRSA", 971], ["infections", 976], ["were", 987], ["a", 992], ["positive", 994], ["MRSA", 1003], ["screening", 1008], [",", 1017], ["an", 1019], ["operation", 1022], ["lasting", 1032], ["more", 1040], ["than", 1045], ["300", 1050], ["min", 1054], ["and", 1058], ["an", 1062], ["emergency", 1065], ["operation", 1075], [".", 1084], ["A", 1086], ["positive", 1088], ["MRSA", 1097], ["screening", 1102], ["was", 1112], ["the", 1116], ["most", 1120], ["statistically", 1125], ["significant", 1139], ["risk", 1151], ["factor", 1156], ["for", 1163], ["postoperative", 1167], ["MRSA", 1181], ["pneumonia", 1186], ["and", 1196], ["enteritis", 1200], [",", 1209], ["but", 1211], ["was", 1215], ["not", 1219], ["a", 1223], ["risk", 1225], ["factor", 1230], ["for", 1237], ["MRSA", 1241], ["surgical", 1246], ["site", 1255], ["infections", 1260], [".", 1270], ["Nasal", 1272], ["MRSA", 1278], ["screening", 1283], ["can", 1293], ["help", 1297], ["to", 1302], ["identify", 1305], ["patients", 1314], ["who", 1323], ["have", 1327], ["an", 1332], ["increased", 1335], ["risk", 1345], ["of", 1350], ["developing", 1353], ["postoperative", 1364], ["MRSA", 1378], ["infections", 1383], [",", 1393], ["and", 1395], ["would", 1399], ["enable", 1405], ["physicians", 1412], ["to", 1423], ["take", 1426], ["a", 1431], ["prompt", 1433], ["action", 1440], ["if", 1447], ["these", 1450], ["complications", 1456], ["occur", 1470], [".", 1475]]}
{"context": "Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an autosomal dominant heart muscle disorder that causes arrhythmia, heart failure, and sudden death. Previously we mapped the genetic locus for the triad of autosomal recessive ARVC, palmoplantar keratoderma, and woolly hair (Naxos disease) to chromosome 17q21, in which the gene for plakoglobin is encoded. This protein is a key component of desmosomes and adherens junctions, and is important for the tight adhesion of many cell types, including those in the heart and skin. We studied 19 individuals with Naxos disease, as well as unaffected family members and unrelated individuals from the neighbouring Greek islands of Naxos and Milos. Gene sequence was determined by reverse transcriptase PCR from RNA isolated from the skin of an affected individual and mutations in other cases were confirmed by restriction-enzyme analysis. A homozygous 2 base pair deletion in the plakoglobin gene was identified only in the 19 affected individuals. This deletion caused a frameshift and premature termination of the protein, which was shown by western blot analysis. 29 clinically unaffected family members were heterozygous for the mutation; 20 unrelated individuals from Naxos and 43 autosomal dominant ARVC probands were homozygous for the normal allele. The finding of a deletion in plakoglobin in ARVC suggests that the proteins involved in cell-cell adhesion play an important part in maintaining myocyte integrity, and when junctions are disrupted, cell death, and fibrofatty replacement occur. Therefore, the discovery of a mutation in a protein with functions in maintaining cell junction integrity has important implications for other dominant forms of ARVC, related cardiomyopathies, and other cutaneous diseases.", "qas": [{"question": "Which gene is mutated in a subtype of arrhythmogenic right ventricular cardiomyopathy known as Naxos disease?", "answers": ["The Plakoglobin gene", "plakoglobin[jup]"], "qid": "204004adaf394da29332aa0a6d83a243", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["mutated", 14], ["in", 22], ["a", 25], ["subtype", 27], ["of", 35], ["arrhythmogenic", 38], ["right", 53], ["ventricular", 59], ["cardiomyopathy", 71], ["known", 86], ["as", 92], ["Naxos", 95], ["disease", 101], ["?", 108]], "detected_answers": [{"text": "The Plakoglobin gene", "token_spans": [[160, 161]], "char_spans": [[933, 948]]}]}], "context_tokens": [["Arrhythmogenic", 0], ["right", 15], ["ventricular", 21], ["cardiomyopathy", 33], ["(", 48], ["ARVC", 49], [")", 53], ["is", 55], ["an", 58], ["autosomal", 61], ["dominant", 71], ["heart", 80], ["muscle", 86], ["disorder", 93], ["that", 102], ["causes", 107], ["arrhythmia", 114], [",", 124], ["heart", 126], ["failure", 132], [",", 139], ["and", 141], ["sudden", 145], ["death", 152], [".", 157], ["Previously", 159], ["we", 170], ["mapped", 173], ["the", 180], ["genetic", 184], ["locus", 192], ["for", 198], ["the", 202], ["triad", 206], ["of", 212], ["autosomal", 215], ["recessive", 225], ["ARVC", 235], [",", 239], ["palmoplantar", 241], ["keratoderma", 254], [",", 265], ["and", 267], ["woolly", 271], ["hair", 278], ["(", 283], ["Naxos", 284], ["disease", 290], [")", 297], ["to", 299], ["chromosome", 302], ["17q21", 313], [",", 318], ["in", 320], ["which", 323], ["the", 329], ["gene", 333], ["for", 338], ["plakoglobin", 342], ["is", 354], ["encoded", 357], [".", 364], ["This", 366], ["protein", 371], ["is", 379], ["a", 382], ["key", 384], ["component", 388], ["of", 398], ["desmosomes", 401], ["and", 412], ["adherens", 416], ["junctions", 425], [",", 434], ["and", 436], ["is", 440], ["important", 443], ["for", 453], ["the", 457], ["tight", 461], ["adhesion", 467], ["of", 476], ["many", 479], ["cell", 484], ["types", 489], [",", 494], ["including", 496], ["those", 506], ["in", 512], ["the", 515], ["heart", 519], ["and", 525], ["skin", 529], [".", 533], ["We", 535], ["studied", 538], ["19", 546], ["individuals", 549], ["with", 561], ["Naxos", 566], ["disease", 572], [",", 579], ["as", 581], ["well", 584], ["as", 589], ["unaffected", 592], ["family", 603], ["members", 610], ["and", 618], ["unrelated", 622], ["individuals", 632], ["from", 644], ["the", 649], ["neighbouring", 653], ["Greek", 666], ["islands", 672], ["of", 680], ["Naxos", 683], ["and", 689], ["Milos", 693], [".", 698], ["Gene", 700], ["sequence", 705], ["was", 714], ["determined", 718], ["by", 729], ["reverse", 732], ["transcriptase", 740], ["PCR", 754], ["from", 758], ["RNA", 763], ["isolated", 767], ["from", 776], ["the", 781], ["skin", 785], ["of", 790], ["an", 793], ["affected", 796], ["individual", 805], ["and", 816], ["mutations", 820], ["in", 830], ["other", 833], ["cases", 839], ["were", 845], ["confirmed", 850], ["by", 860], ["restriction", 863], ["-", 874], ["enzyme", 875], ["analysis", 882], [".", 890], ["A", 892], ["homozygous", 894], ["2", 905], ["base", 907], ["pair", 912], ["deletion", 917], ["in", 926], ["the", 929], ["plakoglobin", 933], ["gene", 945], ["was", 950], ["identified", 954], ["only", 965], ["in", 970], ["the", 973], ["19", 977], ["affected", 980], ["individuals", 989], [".", 1000], ["This", 1002], ["deletion", 1007], ["caused", 1016], ["a", 1023], ["frameshift", 1025], ["and", 1036], ["premature", 1040], ["termination", 1050], ["of", 1062], ["the", 1065], ["protein", 1069], [",", 1076], ["which", 1078], ["was", 1084], ["shown", 1088], ["by", 1094], ["western", 1097], ["blot", 1105], ["analysis", 1110], [".", 1118], ["29", 1120], ["clinically", 1123], ["unaffected", 1134], ["family", 1145], ["members", 1152], ["were", 1160], ["heterozygous", 1165], ["for", 1178], ["the", 1182], ["mutation", 1186], [";", 1194], ["20", 1196], ["unrelated", 1199], ["individuals", 1209], ["from", 1221], ["Naxos", 1226], ["and", 1232], ["43", 1236], ["autosomal", 1239], ["dominant", 1249], ["ARVC", 1258], ["probands", 1263], ["were", 1272], ["homozygous", 1277], ["for", 1288], ["the", 1292], ["normal", 1296], ["allele", 1303], [".", 1309], ["The", 1311], ["finding", 1315], ["of", 1323], ["a", 1326], ["deletion", 1328], ["in", 1337], ["plakoglobin", 1340], ["in", 1352], ["ARVC", 1355], ["suggests", 1360], ["that", 1369], ["the", 1374], ["proteins", 1378], ["involved", 1387], ["in", 1396], ["cell", 1399], ["-", 1403], ["cell", 1404], ["adhesion", 1409], ["play", 1418], ["an", 1423], ["important", 1426], ["part", 1436], ["in", 1441], ["maintaining", 1444], ["myocyte", 1456], ["integrity", 1464], [",", 1473], ["and", 1475], ["when", 1479], ["junctions", 1484], ["are", 1494], ["disrupted", 1498], [",", 1507], ["cell", 1509], ["death", 1514], [",", 1519], ["and", 1521], ["fibrofatty", 1525], ["replacement", 1536], ["occur", 1548], [".", 1553], ["Therefore", 1555], [",", 1564], ["the", 1566], ["discovery", 1570], ["of", 1580], ["a", 1583], ["mutation", 1585], ["in", 1594], ["a", 1597], ["protein", 1599], ["with", 1607], ["functions", 1612], ["in", 1622], ["maintaining", 1625], ["cell", 1637], ["junction", 1642], ["integrity", 1651], ["has", 1661], ["important", 1665], ["implications", 1675], ["for", 1688], ["other", 1692], ["dominant", 1698], ["forms", 1707], ["of", 1713], ["ARVC", 1716], [",", 1720], ["related", 1722], ["cardiomyopathies", 1730], [",", 1746], ["and", 1748], ["other", 1752], ["cutaneous", 1758], ["diseases", 1768], [".", 1776]]}
{"context": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA) in the clinical laboratory. Under disk diffusion testing conditions designed to maximize detection of MRSA (incubation at 32 degrees C, pre-induction with methicillin, or plating on 4% NaCl-supplemented agar), BORSA strains also tend to appear resistant to semisynthetic penicillins. Under these conditions, ampicillin/sulbactam appears to be more accurate than amoxicillin/clavulanic acid for differentiating BORSA from MRSA.", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "a859d7dd48d14f7ba82f37892f524538", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[0, 5]], "char_spans": [[0, 51]]}]}], "context_tokens": [["Borderline", 0], ["oxacillin", 11], ["-", 20], ["resistant", 21], ["Staphylococcus", 31], ["aureus", 46], ["(", 53], ["BORSA", 54], [")", 59], ["may", 61], ["be", 65], ["misidentified", 68], ["as", 82], ["intrinsically", 85], ["methicillin", 99], ["-", 110], ["resistant", 111], ["Staphylococcus", 121], ["aureus", 136], ["(", 143], ["MRSA", 144], [")", 148], ["in", 150], ["the", 153], ["clinical", 157], ["laboratory", 166], [".", 176], ["Under", 178], ["disk", 184], ["diffusion", 189], ["testing", 199], ["conditions", 207], ["designed", 218], ["to", 227], ["maximize", 230], ["detection", 239], ["of", 249], ["MRSA", 252], ["(", 257], ["incubation", 258], ["at", 269], ["32", 272], ["degrees", 275], ["C", 283], [",", 284], ["pre", 286], ["-", 289], ["induction", 290], ["with", 300], ["methicillin", 305], [",", 316], ["or", 318], ["plating", 321], ["on", 329], ["4", 332], ["%", 333], ["NaCl", 335], ["-", 339], ["supplemented", 340], ["agar", 353], [")", 357], [",", 358], ["BORSA", 360], ["strains", 366], ["also", 374], ["tend", 379], ["to", 384], ["appear", 387], ["resistant", 394], ["to", 404], ["semisynthetic", 407], ["penicillins", 421], [".", 432], ["Under", 434], ["these", 440], ["conditions", 446], [",", 456], ["ampicillin", 458], ["/", 468], ["sulbactam", 469], ["appears", 479], ["to", 487], ["be", 490], ["more", 493], ["accurate", 498], ["than", 507], ["amoxicillin", 512], ["/", 523], ["clavulanic", 524], ["acid", 535], ["for", 540], ["differentiating", 544], ["BORSA", 560], ["from", 566], ["MRSA", 571], [".", 575]]}
{"context": "Epilepsy, a neurologic disorder characterized by the predisposition to recurrent unprovoked seizures, is reported in more than 300 genetic syndromes. Muenke syndrome is an autosomal-dominant craniosynostosis syndrome characterized by unilateral or bilateral coronal craniosynostosis, hearing loss, intellectual disability, and relatively subtle limb findings such as carpal bone fusion and tarsal bone fusion. Muenke syndrome is caused by a single defining point mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. Epilepsy rarely occurs in individuals with Muenke syndrome, and little detail is reported on types of epilepsy, patient characteristics, and long-term outcomes. We present seven patients with Muenke syndrome and seizures. A review of 789 published cases of Muenke syndrome, with a focus on epilepsy and intracranial anomalies in Muenke syndrome, revealed epilepsy in six patients, with intracranial anomalies in five. The occurrence of epilepsy in Muenke syndrome within our cohort of 58 patients, of whom seven manifested epilepsy, and the intracranial anomalies and epilepsy reported in the literature, suggest that patients with Muenke syndrome may be at risk for epilepsy and intracranial anomalies. Furthermore, the impact of Muenke syndrome on the central nervous system may be greater than previously thought.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "9e843dbf324d404f9ec7fd6b491f8693", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[73, 79]], "char_spans": [[479, 520]]}]}], "context_tokens": [["Epilepsy", 0], [",", 8], ["a", 10], ["neurologic", 12], ["disorder", 23], ["characterized", 32], ["by", 46], ["the", 49], ["predisposition", 53], ["to", 68], ["recurrent", 71], ["unprovoked", 81], ["seizures", 92], [",", 100], ["is", 102], ["reported", 105], ["in", 114], ["more", 117], ["than", 122], ["300", 127], ["genetic", 131], ["syndromes", 139], [".", 148], ["Muenke", 150], ["syndrome", 157], ["is", 166], ["an", 169], ["autosomal", 172], ["-", 181], ["dominant", 182], ["craniosynostosis", 191], ["syndrome", 208], ["characterized", 217], ["by", 231], ["unilateral", 234], ["or", 245], ["bilateral", 248], ["coronal", 258], ["craniosynostosis", 266], [",", 282], ["hearing", 284], ["loss", 292], [",", 296], ["intellectual", 298], ["disability", 311], [",", 321], ["and", 323], ["relatively", 327], ["subtle", 338], ["limb", 345], ["findings", 350], ["such", 359], ["as", 364], ["carpal", 367], ["bone", 374], ["fusion", 379], ["and", 386], ["tarsal", 390], ["bone", 397], ["fusion", 402], [".", 408], ["Muenke", 410], ["syndrome", 417], ["is", 426], ["caused", 429], ["by", 436], ["a", 439], ["single", 441], ["defining", 448], ["point", 457], ["mutation", 463], ["in", 472], ["the", 475], ["fibroblast", 479], ["growth", 490], ["factor", 497], ["receptor", 504], ["3", 513], ["(", 515], ["FGFR3", 516], [")", 521], ["gene", 523], [".", 527], ["Epilepsy", 529], ["rarely", 538], ["occurs", 545], ["in", 552], ["individuals", 555], ["with", 567], ["Muenke", 572], ["syndrome", 579], [",", 587], ["and", 589], ["little", 593], ["detail", 600], ["is", 607], ["reported", 610], ["on", 619], ["types", 622], ["of", 628], ["epilepsy", 631], [",", 639], ["patient", 641], ["characteristics", 649], [",", 664], ["and", 666], ["long", 670], ["-", 674], ["term", 675], ["outcomes", 680], [".", 688], ["We", 690], ["present", 693], ["seven", 701], ["patients", 707], ["with", 716], ["Muenke", 721], ["syndrome", 728], ["and", 737], ["seizures", 741], [".", 749], ["A", 751], ["review", 753], ["of", 760], ["789", 763], ["published", 767], ["cases", 777], ["of", 783], ["Muenke", 786], ["syndrome", 793], [",", 801], ["with", 803], ["a", 808], ["focus", 810], ["on", 816], ["epilepsy", 819], ["and", 828], ["intracranial", 832], ["anomalies", 845], ["in", 855], ["Muenke", 858], ["syndrome", 865], [",", 873], ["revealed", 875], ["epilepsy", 884], ["in", 893], ["six", 896], ["patients", 900], [",", 908], ["with", 910], ["intracranial", 915], ["anomalies", 928], ["in", 938], ["five", 941], [".", 945], ["The", 947], ["occurrence", 951], ["of", 962], ["epilepsy", 965], ["in", 974], ["Muenke", 977], ["syndrome", 984], ["within", 993], ["our", 1000], ["cohort", 1004], ["of", 1011], ["58", 1014], ["patients", 1017], [",", 1025], ["of", 1027], ["whom", 1030], ["seven", 1035], ["manifested", 1041], ["epilepsy", 1052], [",", 1060], ["and", 1062], ["the", 1066], ["intracranial", 1070], ["anomalies", 1083], ["and", 1093], ["epilepsy", 1097], ["reported", 1106], ["in", 1115], ["the", 1118], ["literature", 1122], [",", 1132], ["suggest", 1134], ["that", 1142], ["patients", 1147], ["with", 1156], ["Muenke", 1161], ["syndrome", 1168], ["may", 1177], ["be", 1181], ["at", 1184], ["risk", 1187], ["for", 1192], ["epilepsy", 1196], ["and", 1205], ["intracranial", 1209], ["anomalies", 1222], [".", 1231], ["Furthermore", 1233], [",", 1244], ["the", 1246], ["impact", 1250], ["of", 1257], ["Muenke", 1260], ["syndrome", 1267], ["on", 1276], ["the", 1279], ["central", 1283], ["nervous", 1291], ["system", 1299], ["may", 1306], ["be", 1310], ["greater", 1313], ["than", 1321], ["previously", 1326], ["thought", 1337], [".", 1344]]}
{"context": "The Philadelphia chromosome found in leukemia cells of chronic myelogenous leukemia (CML) patients is produced by translocation between chromosomes 9 and 22, resulting in expression of a chimera protein of Bcr and Abl kinase in the cytoplasm. Bcr-Abl kinase attracted oncology researchers as a molecular target for CML therapy, and a variety of small Abl kinase inhibitors were synthesized. STI571 (imatinib mesylate) was produced by modification of 2-phenylaminopyrimidine, a core structure of protein kinase C inhibitor, to improve selectivity, stability, solubility, and bioavailability. STI571 competitively binds to the ATP binding site of Bcr-Abl kinase and inhibits Abl tyrosine kinase activity. STI571 showed significant efficacy in the clinical study with CML patients at all stages: chronic phase, accelerated phase, and blast crisis. More than 90% of the patients showed good hematologic response to STI571. STI571 is also a potent inhibitor of a receptor-type c-Kit tyrosine kinase. Therefore, STI571 was examined for therapeutic efficacy against malignant Gastro-Intestinal Stromal Tumors (GIST), which are mainly caused by aberrant expression of a mutated c-Kit that is constitutively active without binding of a ligand, stem cell factor (SCF). More than a half of the metastatic GIST patients enrolled in the clinical study responded to STI571. Thus, STI571 is now used as a therapeutic drug for both CML and GIST in more than 80 countries worldwide. Certain point mutations in the ATP binding site were found to be a cause of resistance to STI571 in both Bcr-Abl and c-Kit kinases. Therefore, it would be better to make a precise therapeutic strategy with STI571 based on the gene analysis data. It is also expected that it will be possible to design an inhibitor to overcome such resistance by using the structural information on the mutants.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "8061c24a56e44d69a227a7f6c6c90a8f", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[41, 43], [108, 110], [284, 286]], "char_spans": [[243, 249], [645, 651], [1571, 1577]]}]}], "context_tokens": [["The", 0], ["Philadelphia", 4], ["chromosome", 17], ["found", 28], ["in", 34], ["leukemia", 37], ["cells", 46], ["of", 52], ["chronic", 55], ["myelogenous", 63], ["leukemia", 75], ["(", 84], ["CML", 85], [")", 88], ["patients", 90], ["is", 99], ["produced", 102], ["by", 111], ["translocation", 114], ["between", 128], ["chromosomes", 136], ["9", 148], ["and", 150], ["22", 154], [",", 156], ["resulting", 158], ["in", 168], ["expression", 171], ["of", 182], ["a", 185], ["chimera", 187], ["protein", 195], ["of", 203], ["Bcr", 206], ["and", 210], ["Abl", 214], ["kinase", 218], ["in", 225], ["the", 228], ["cytoplasm", 232], [".", 241], ["Bcr", 243], ["-", 246], ["Abl", 247], ["kinase", 251], ["attracted", 258], ["oncology", 268], ["researchers", 277], ["as", 289], ["a", 292], ["molecular", 294], ["target", 304], ["for", 311], ["CML", 315], ["therapy", 319], [",", 326], ["and", 328], ["a", 332], ["variety", 334], ["of", 342], ["small", 345], ["Abl", 351], ["kinase", 355], ["inhibitors", 362], ["were", 373], ["synthesized", 378], [".", 389], ["STI571", 391], ["(", 398], ["imatinib", 399], ["mesylate", 408], [")", 416], ["was", 418], ["produced", 422], ["by", 431], ["modification", 434], ["of", 447], ["2-phenylaminopyrimidine", 450], [",", 473], ["a", 475], ["core", 477], ["structure", 482], ["of", 492], ["protein", 495], ["kinase", 503], ["C", 510], ["inhibitor", 512], [",", 521], ["to", 523], ["improve", 526], ["selectivity", 534], [",", 545], ["stability", 547], [",", 556], ["solubility", 558], [",", 568], ["and", 570], ["bioavailability", 574], [".", 589], ["STI571", 591], ["competitively", 598], ["binds", 612], ["to", 618], ["the", 621], ["ATP", 625], ["binding", 629], ["site", 637], ["of", 642], ["Bcr", 645], ["-", 648], ["Abl", 649], ["kinase", 653], ["and", 660], ["inhibits", 664], ["Abl", 673], ["tyrosine", 677], ["kinase", 686], ["activity", 693], [".", 701], ["STI571", 703], ["showed", 710], ["significant", 717], ["efficacy", 729], ["in", 738], ["the", 741], ["clinical", 745], ["study", 754], ["with", 760], ["CML", 765], ["patients", 769], ["at", 778], ["all", 781], ["stages", 785], [":", 791], ["chronic", 793], ["phase", 801], [",", 806], ["accelerated", 808], ["phase", 820], [",", 825], ["and", 827], ["blast", 831], ["crisis", 837], [".", 843], ["More", 845], ["than", 850], ["90", 855], ["%", 857], ["of", 859], ["the", 862], ["patients", 866], ["showed", 875], ["good", 882], ["hematologic", 887], ["response", 899], ["to", 908], ["STI571", 911], [".", 917], ["STI571", 919], ["is", 926], ["also", 929], ["a", 934], ["potent", 936], ["inhibitor", 943], ["of", 953], ["a", 956], ["receptor", 958], ["-", 966], ["type", 967], ["c", 972], ["-", 973], ["Kit", 974], ["tyrosine", 978], ["kinase", 987], [".", 993], ["Therefore", 995], [",", 1004], ["STI571", 1006], ["was", 1013], ["examined", 1017], ["for", 1026], ["therapeutic", 1030], ["efficacy", 1042], ["against", 1051], ["malignant", 1059], ["Gastro", 1069], ["-", 1075], ["Intestinal", 1076], ["Stromal", 1087], ["Tumors", 1095], ["(", 1102], ["GIST", 1103], [")", 1107], [",", 1108], ["which", 1110], ["are", 1116], ["mainly", 1120], ["caused", 1127], ["by", 1134], ["aberrant", 1137], ["expression", 1146], ["of", 1157], ["a", 1160], ["mutated", 1162], ["c", 1170], ["-", 1171], ["Kit", 1172], ["that", 1176], ["is", 1181], ["constitutively", 1184], ["active", 1199], ["without", 1206], ["binding", 1214], ["of", 1222], ["a", 1225], ["ligand", 1227], [",", 1233], ["stem", 1235], ["cell", 1240], ["factor", 1245], ["(", 1252], ["SCF", 1253], [")", 1256], [".", 1257], ["More", 1259], ["than", 1264], ["a", 1269], ["half", 1271], ["of", 1276], ["the", 1279], ["metastatic", 1283], ["GIST", 1294], ["patients", 1299], ["enrolled", 1308], ["in", 1317], ["the", 1320], ["clinical", 1324], ["study", 1333], ["responded", 1339], ["to", 1349], ["STI571", 1352], [".", 1358], ["Thus", 1360], [",", 1364], ["STI571", 1366], ["is", 1373], ["now", 1376], ["used", 1380], ["as", 1385], ["a", 1388], ["therapeutic", 1390], ["drug", 1402], ["for", 1407], ["both", 1411], ["CML", 1416], ["and", 1420], ["GIST", 1424], ["in", 1429], ["more", 1432], ["than", 1437], ["80", 1442], ["countries", 1445], ["worldwide", 1455], [".", 1464], ["Certain", 1466], ["point", 1474], ["mutations", 1480], ["in", 1490], ["the", 1493], ["ATP", 1497], ["binding", 1501], ["site", 1509], ["were", 1514], ["found", 1519], ["to", 1525], ["be", 1528], ["a", 1531], ["cause", 1533], ["of", 1539], ["resistance", 1542], ["to", 1553], ["STI571", 1556], ["in", 1563], ["both", 1566], ["Bcr", 1571], ["-", 1574], ["Abl", 1575], ["and", 1579], ["c", 1583], ["-", 1584], ["Kit", 1585], ["kinases", 1589], [".", 1596], ["Therefore", 1598], [",", 1607], ["it", 1609], ["would", 1612], ["be", 1618], ["better", 1621], ["to", 1628], ["make", 1631], ["a", 1636], ["precise", 1638], ["therapeutic", 1646], ["strategy", 1658], ["with", 1667], ["STI571", 1672], ["based", 1679], ["on", 1685], ["the", 1688], ["gene", 1692], ["analysis", 1697], ["data", 1706], [".", 1710], ["It", 1712], ["is", 1715], ["also", 1718], ["expected", 1723], ["that", 1732], ["it", 1737], ["will", 1740], ["be", 1745], ["possible", 1748], ["to", 1757], ["design", 1760], ["an", 1767], ["inhibitor", 1770], ["to", 1780], ["overcome", 1783], ["such", 1792], ["resistance", 1797], ["by", 1808], ["using", 1811], ["the", 1817], ["structural", 1821], ["information", 1832], ["on", 1844], ["the", 1847], ["mutants", 1851], [".", 1858]]}
{"context": "Restless legs syndrome is a neurological disorder characterized by an urgency to move the legs during periods of rest. Data from a variety of sources provide a compelling argument that the amount of iron in the brain is lower in individuals with restless legs syndrome compared with neurologically normal individuals. Moreover, a significant percentage of patients with restless legs syndrome are responsive to intravenous iron therapy. The mechanism underlying the decreased iron concentrations in restless legs syndrome brains is unknown. We hypothesize that the source of the brain iron deficit is at the blood-brain interface. Thus we analysed the expression of iron management proteins in the epithelial cells of the choroid plexus and the brain microvasculature in post-mortem tissues. The choroid plexus, obtained at autopsy, from 18 neurologically normal controls and 14 individuals who had primary restless legs syndrome was subjected to histochemical staining for iron and immunostaining for iron management proteins. Iron and heavy chain ferritin staining was reduced in the epithelial cells of choroid plexus in restless legs syndrome. Divalent metal transporter, ferroportin, transferrin and its receptor were upregulated in the choroid plexus in restless legs syndrome. Microvessels were isolated from the motor cortex of 11 restless legs syndrome and 14 control brains obtained at autopsy and quantitative immunoblot analyses was performed. Expression of heavy chain ferritin, transferrin and its receptor in the microvessels from restless legs syndrome was significantly decreased compared with the controls but divalent metal protein 1, ferroportin, prohepcidin, mitochondrial ferritin and light-chain ferritin remained unchanged. The presence of an iron regulatory protein was demonstrated in the brain microvasculature and the activity of this protein is decreased in restless legs syndrome; a finding similar to our earlier report in neuromelanin cells from the substantia nigra of restless legs syndrome brains. This study reveals that there are alterations in the iron management protein profile in restless legs syndrome compared with controls at the site of blood-brain interface suggesting fundamental differences in brain iron acquisition in individuals with restless legs syndrome. Furthermore, the decrease in transferrin receptor expression in the microvasculature in the presence of relative brain iron deficiency reported in restless legs syndrome brains may underlie the problems associated with brain iron acquisition in restless legs syndrome. The consistent finding of loss of iron regulatory protein activity in restless legs syndrome brain tissue further implicates this protein as a factor in the underlying cause of the iron deficiency in the restless legs syndrome brain. The data herein provide evidence for regulation of iron uptake and storage within brain microvessels that challenge the existing paradigm that the blood-brain barrier is merely a transport system.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "240a062b131041ab863a237c0c0a8a73", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[158, 158], [93, 93], [75, 75], [109, 109], [67, 67], [166, 166], [397, 397], [332, 332], [356, 356], [281, 281], [410, 410], [450, 450], [34, 34], [382, 382], [433, 433], [162, 162]], "char_spans": [[974, 977], [585, 588], [476, 479], [666, 669], [423, 426], [1028, 1031], [2534, 2537], [2086, 2089], [2248, 2251], [1767, 1770], [2612, 2615], [2863, 2866], [199, 202], [2428, 2431], [2759, 2762], [1002, 1005]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["is", 23], ["a", 26], ["neurological", 28], ["disorder", 41], ["characterized", 50], ["by", 64], ["an", 67], ["urgency", 70], ["to", 78], ["move", 81], ["the", 86], ["legs", 90], ["during", 95], ["periods", 102], ["of", 110], ["rest", 113], [".", 117], ["Data", 119], ["from", 124], ["a", 129], ["variety", 131], ["of", 139], ["sources", 142], ["provide", 150], ["a", 158], ["compelling", 160], ["argument", 171], ["that", 180], ["the", 185], ["amount", 189], ["of", 196], ["iron", 199], ["in", 204], ["the", 207], ["brain", 211], ["is", 217], ["lower", 220], ["in", 226], ["individuals", 229], ["with", 241], ["restless", 246], ["legs", 255], ["syndrome", 260], ["compared", 269], ["with", 278], ["neurologically", 283], ["normal", 298], ["individuals", 305], [".", 316], ["Moreover", 318], [",", 326], ["a", 328], ["significant", 330], ["percentage", 342], ["of", 353], ["patients", 356], ["with", 365], ["restless", 370], ["legs", 379], ["syndrome", 384], ["are", 393], ["responsive", 397], ["to", 408], ["intravenous", 411], ["iron", 423], ["therapy", 428], [".", 435], ["The", 437], ["mechanism", 441], ["underlying", 451], ["the", 462], ["decreased", 466], ["iron", 476], ["concentrations", 481], ["in", 496], ["restless", 499], ["legs", 508], ["syndrome", 513], ["brains", 522], ["is", 529], ["unknown", 532], [".", 539], ["We", 541], ["hypothesize", 544], ["that", 556], ["the", 561], ["source", 565], ["of", 572], ["the", 575], ["brain", 579], ["iron", 585], ["deficit", 590], ["is", 598], ["at", 601], ["the", 604], ["blood", 608], ["-", 613], ["brain", 614], ["interface", 620], [".", 629], ["Thus", 631], ["we", 636], ["analysed", 639], ["the", 648], ["expression", 652], ["of", 663], ["iron", 666], ["management", 671], ["proteins", 682], ["in", 691], ["the", 694], ["epithelial", 698], ["cells", 709], ["of", 715], ["the", 718], ["choroid", 722], ["plexus", 730], ["and", 737], ["the", 741], ["brain", 745], ["microvasculature", 751], ["in", 768], ["post", 771], ["-", 775], ["mortem", 776], ["tissues", 783], [".", 790], ["The", 792], ["choroid", 796], ["plexus", 804], [",", 810], ["obtained", 812], ["at", 821], ["autopsy", 824], [",", 831], ["from", 833], ["18", 838], ["neurologically", 841], ["normal", 856], ["controls", 863], ["and", 872], ["14", 876], ["individuals", 879], ["who", 891], ["had", 895], ["primary", 899], ["restless", 907], ["legs", 916], ["syndrome", 921], ["was", 930], ["subjected", 934], ["to", 944], ["histochemical", 947], ["staining", 961], ["for", 970], ["iron", 974], ["and", 979], ["immunostaining", 983], ["for", 998], ["iron", 1002], ["management", 1007], ["proteins", 1018], [".", 1026], ["Iron", 1028], ["and", 1033], ["heavy", 1037], ["chain", 1043], ["ferritin", 1049], ["staining", 1058], ["was", 1067], ["reduced", 1071], ["in", 1079], ["the", 1082], ["epithelial", 1086], ["cells", 1097], ["of", 1103], ["choroid", 1106], ["plexus", 1114], ["in", 1121], ["restless", 1124], ["legs", 1133], ["syndrome", 1138], [".", 1146], ["Divalent", 1148], ["metal", 1157], ["transporter", 1163], [",", 1174], ["ferroportin", 1176], [",", 1187], ["transferrin", 1189], ["and", 1201], ["its", 1205], ["receptor", 1209], ["were", 1218], ["upregulated", 1223], ["in", 1235], ["the", 1238], ["choroid", 1242], ["plexus", 1250], ["in", 1257], ["restless", 1260], ["legs", 1269], ["syndrome", 1274], [".", 1282], ["Microvessels", 1284], ["were", 1297], ["isolated", 1302], ["from", 1311], ["the", 1316], ["motor", 1320], ["cortex", 1326], ["of", 1333], ["11", 1336], ["restless", 1339], ["legs", 1348], ["syndrome", 1353], ["and", 1362], ["14", 1366], ["control", 1369], ["brains", 1377], ["obtained", 1384], ["at", 1393], ["autopsy", 1396], ["and", 1404], ["quantitative", 1408], ["immunoblot", 1421], ["analyses", 1432], ["was", 1441], ["performed", 1445], [".", 1454], ["Expression", 1456], ["of", 1467], ["heavy", 1470], ["chain", 1476], ["ferritin", 1482], [",", 1490], ["transferrin", 1492], ["and", 1504], ["its", 1508], ["receptor", 1512], ["in", 1521], ["the", 1524], ["microvessels", 1528], ["from", 1541], ["restless", 1546], ["legs", 1555], ["syndrome", 1560], ["was", 1569], ["significantly", 1573], ["decreased", 1587], ["compared", 1597], ["with", 1606], ["the", 1611], ["controls", 1615], ["but", 1624], ["divalent", 1628], ["metal", 1637], ["protein", 1643], ["1", 1651], [",", 1652], ["ferroportin", 1654], [",", 1665], ["prohepcidin", 1667], [",", 1678], ["mitochondrial", 1680], ["ferritin", 1694], ["and", 1703], ["light", 1707], ["-", 1712], ["chain", 1713], ["ferritin", 1719], ["remained", 1728], ["unchanged", 1737], [".", 1746], ["The", 1748], ["presence", 1752], ["of", 1761], ["an", 1764], ["iron", 1767], ["regulatory", 1772], ["protein", 1783], ["was", 1791], ["demonstrated", 1795], ["in", 1808], ["the", 1811], ["brain", 1815], ["microvasculature", 1821], ["and", 1838], ["the", 1842], ["activity", 1846], ["of", 1855], ["this", 1858], ["protein", 1863], ["is", 1871], ["decreased", 1874], ["in", 1884], ["restless", 1887], ["legs", 1896], ["syndrome", 1901], [";", 1909], ["a", 1911], ["finding", 1913], ["similar", 1921], ["to", 1929], ["our", 1932], ["earlier", 1936], ["report", 1944], ["in", 1951], ["neuromelanin", 1954], ["cells", 1967], ["from", 1973], ["the", 1978], ["substantia", 1982], ["nigra", 1993], ["of", 1999], ["restless", 2002], ["legs", 2011], ["syndrome", 2016], ["brains", 2025], [".", 2031], ["This", 2033], ["study", 2038], ["reveals", 2044], ["that", 2052], ["there", 2057], ["are", 2063], ["alterations", 2067], ["in", 2079], ["the", 2082], ["iron", 2086], ["management", 2091], ["protein", 2102], ["profile", 2110], ["in", 2118], ["restless", 2121], ["legs", 2130], ["syndrome", 2135], ["compared", 2144], ["with", 2153], ["controls", 2158], ["at", 2167], ["the", 2170], ["site", 2174], ["of", 2179], ["blood", 2182], ["-", 2187], ["brain", 2188], ["interface", 2194], ["suggesting", 2204], ["fundamental", 2215], ["differences", 2227], ["in", 2239], ["brain", 2242], ["iron", 2248], ["acquisition", 2253], ["in", 2265], ["individuals", 2268], ["with", 2280], ["restless", 2285], ["legs", 2294], ["syndrome", 2299], [".", 2307], ["Furthermore", 2309], [",", 2320], ["the", 2322], ["decrease", 2326], ["in", 2335], ["transferrin", 2338], ["receptor", 2350], ["expression", 2359], ["in", 2370], ["the", 2373], ["microvasculature", 2377], ["in", 2394], ["the", 2397], ["presence", 2401], ["of", 2410], ["relative", 2413], ["brain", 2422], ["iron", 2428], ["deficiency", 2433], ["reported", 2444], ["in", 2453], ["restless", 2456], ["legs", 2465], ["syndrome", 2470], ["brains", 2479], ["may", 2486], ["underlie", 2490], ["the", 2499], ["problems", 2503], ["associated", 2512], ["with", 2523], ["brain", 2528], ["iron", 2534], ["acquisition", 2539], ["in", 2551], ["restless", 2554], ["legs", 2563], ["syndrome", 2568], [".", 2576], ["The", 2578], ["consistent", 2582], ["finding", 2593], ["of", 2601], ["loss", 2604], ["of", 2609], ["iron", 2612], ["regulatory", 2617], ["protein", 2628], ["activity", 2636], ["in", 2645], ["restless", 2648], ["legs", 2657], ["syndrome", 2662], ["brain", 2671], ["tissue", 2677], ["further", 2684], ["implicates", 2692], ["this", 2703], ["protein", 2708], ["as", 2716], ["a", 2719], ["factor", 2721], ["in", 2728], ["the", 2731], ["underlying", 2735], ["cause", 2746], ["of", 2752], ["the", 2755], ["iron", 2759], ["deficiency", 2764], ["in", 2775], ["the", 2778], ["restless", 2782], ["legs", 2791], ["syndrome", 2796], ["brain", 2805], [".", 2810], ["The", 2812], ["data", 2816], ["herein", 2821], ["provide", 2828], ["evidence", 2836], ["for", 2845], ["regulation", 2849], ["of", 2860], ["iron", 2863], ["uptake", 2868], ["and", 2875], ["storage", 2879], ["within", 2887], ["brain", 2894], ["microvessels", 2900], ["that", 2913], ["challenge", 2918], ["the", 2928], ["existing", 2932], ["paradigm", 2941], ["that", 2950], ["the", 2955], ["blood", 2959], ["-", 2964], ["brain", 2965], ["barrier", 2971], ["is", 2979], ["merely", 2982], ["a", 2989], ["transport", 2991], ["system", 3001], [".", 3007]]}
{"context": "Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) carrying pvl is an emerging problem worldwide. CA-MRSA tends to harbor staphylococcal cassette chromosome mec type IV (SCCmec IV), to be non-multiantibiotic resistant, and to have different genotypes from the local hospital-acquired MRSA (HA-MRSA). However, in Ireland, 80% of HA-MRSA isolates have the non-multiantibiotic-resistant genotype ST22-MRSA-IV. This study investigated MRSA isolates from Ireland (CA-MRSA, health care-associated MRSA, and HA-MRSA) for the carriage of pvl and determined the genotypic characteristics of all pvl-positive isolates identified. All 1,389 MRSA isolates were investigated by antibiogram-resistogram typing and SmaI DNA macrorestriction analysis. pvl-positive isolates were further characterized by multilocus sequence typing and SCCmec, agr, and toxin gene typing. Twenty-five (1.8%) MRSA isolates belonging to six genotypes (ST30, ST8, ST22, ST80, ST5, and ST154) harbored pvl. Nineteen of these (76%) were CA-MRSA isolates, but a prospective study of MRSA isolates from 401 patients showed that only 6.7% (2/30) of patients with CA-MRSA yielded pvl-positive isolates. Thus, pvl cannot be used as a sole marker for CA-MRSA. Fifty-two percent of pvl-positive MRSA isolates were recovered from patients with skin and soft tissue infections; thirty-six percent were from patients of non-Irish ethnic origin, reflecting the increasing heterogeneity of the Irish population due to immigration. All 25 pvl-positive isolates carried SCCmec IV; 14 (56%) harbored SCCmec IV.1 or IV.3, and the remaining 11 isolates could not be subtyped. This study demonstrates that pvl is not a reliable marker for CA-MRSA in Ireland and reveals the emergence and importation of diverse genotypes of pvl-positive MRSA in Ireland.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "f981f754748548ed8b74416b9b29aedd", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[362, 362], [11, 11], [173, 173], [90, 90], [214, 214], [253, 253], [346, 346], [60, 60], [108, 108], [73, 73], [23, 23], [103, 103], [263, 263], [56, 56], [232, 232], [206, 206], [130, 130], [97, 97]], "char_spans": [[1802, 1805], [67, 70], [896, 899], [453, 456], [1065, 1068], [1231, 1234], [1707, 1710], [315, 318], [526, 529], [353, 356], [123, 126], [513, 516], [1271, 1274], [306, 309], [1146, 1149], [1023, 1026], [652, 655], [484, 487]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["acquired", 10], ["methicillin", 19], ["-", 30], ["resistant", 31], ["Staphylococcus", 41], ["aureus", 56], ["(", 63], ["CA", 64], ["-", 66], ["MRSA", 67], [")", 71], ["carrying", 73], ["pvl", 82], ["is", 86], ["an", 89], ["emerging", 92], ["problem", 101], ["worldwide", 109], [".", 118], ["CA", 120], ["-", 122], ["MRSA", 123], ["tends", 128], ["to", 134], ["harbor", 137], ["staphylococcal", 144], ["cassette", 159], ["chromosome", 168], ["mec", 179], ["type", 183], ["IV", 188], ["(", 191], ["SCCmec", 192], ["IV", 199], [")", 201], [",", 202], ["to", 204], ["be", 207], ["non", 210], ["-", 213], ["multiantibiotic", 214], ["resistant", 230], [",", 239], ["and", 241], ["to", 245], ["have", 248], ["different", 253], ["genotypes", 263], ["from", 273], ["the", 278], ["local", 282], ["hospital", 288], ["-", 296], ["acquired", 297], ["MRSA", 306], ["(", 311], ["HA", 312], ["-", 314], ["MRSA", 315], [")", 319], [".", 320], ["However", 322], [",", 329], ["in", 331], ["Ireland", 334], [",", 341], ["80", 343], ["%", 345], ["of", 347], ["HA", 350], ["-", 352], ["MRSA", 353], ["isolates", 358], ["have", 367], ["the", 372], ["non", 376], ["-", 379], ["multiantibiotic", 380], ["-", 395], ["resistant", 396], ["genotype", 406], ["ST22-MRSA", 415], ["-", 424], ["IV", 425], [".", 427], ["This", 429], ["study", 434], ["investigated", 440], ["MRSA", 453], ["isolates", 458], ["from", 467], ["Ireland", 472], ["(", 480], ["CA", 481], ["-", 483], ["MRSA", 484], [",", 488], ["health", 490], ["care", 497], ["-", 501], ["associated", 502], ["MRSA", 513], [",", 517], ["and", 519], ["HA", 523], ["-", 525], ["MRSA", 526], [")", 530], ["for", 532], ["the", 536], ["carriage", 540], ["of", 549], ["pvl", 552], ["and", 556], ["determined", 560], ["the", 571], ["genotypic", 575], ["characteristics", 585], ["of", 601], ["all", 604], ["pvl", 608], ["-", 611], ["positive", 612], ["isolates", 621], ["identified", 630], [".", 640], ["All", 642], ["1,389", 646], ["MRSA", 652], ["isolates", 657], ["were", 666], ["investigated", 671], ["by", 684], ["antibiogram", 687], ["-", 698], ["resistogram", 699], ["typing", 711], ["and", 718], ["SmaI", 722], ["DNA", 727], ["macrorestriction", 731], ["analysis", 748], [".", 756], ["pvl", 758], ["-", 761], ["positive", 762], ["isolates", 771], ["were", 780], ["further", 785], ["characterized", 793], ["by", 807], ["multilocus", 810], ["sequence", 821], ["typing", 830], ["and", 837], ["SCCmec", 841], [",", 847], ["agr", 849], [",", 852], ["and", 854], ["toxin", 858], ["gene", 864], ["typing", 869], [".", 875], ["Twenty", 877], ["-", 883], ["five", 884], ["(", 889], ["1.8", 890], ["%", 893], [")", 894], ["MRSA", 896], ["isolates", 901], ["belonging", 910], ["to", 920], ["six", 923], ["genotypes", 927], ["(", 937], ["ST30", 938], [",", 942], ["ST8", 944], [",", 947], ["ST22", 949], [",", 953], ["ST80", 955], [",", 959], ["ST5", 961], [",", 964], ["and", 966], ["ST154", 970], [")", 975], ["harbored", 977], ["pvl", 986], [".", 989], ["Nineteen", 991], ["of", 1000], ["these", 1003], ["(", 1009], ["76", 1010], ["%", 1012], [")", 1013], ["were", 1015], ["CA", 1020], ["-", 1022], ["MRSA", 1023], ["isolates", 1028], [",", 1036], ["but", 1038], ["a", 1042], ["prospective", 1044], ["study", 1056], ["of", 1062], ["MRSA", 1065], ["isolates", 1070], ["from", 1079], ["401", 1084], ["patients", 1088], ["showed", 1097], ["that", 1104], ["only", 1109], ["6.7", 1114], ["%", 1117], ["(", 1119], ["2/30", 1120], [")", 1124], ["of", 1126], ["patients", 1129], ["with", 1138], ["CA", 1143], ["-", 1145], ["MRSA", 1146], ["yielded", 1151], ["pvl", 1159], ["-", 1162], ["positive", 1163], ["isolates", 1172], [".", 1180], ["Thus", 1182], [",", 1186], ["pvl", 1188], ["can", 1192], ["not", 1195], ["be", 1199], ["used", 1202], ["as", 1207], ["a", 1210], ["sole", 1212], ["marker", 1217], ["for", 1224], ["CA", 1228], ["-", 1230], ["MRSA", 1231], [".", 1235], ["Fifty", 1237], ["-", 1242], ["two", 1243], ["percent", 1247], ["of", 1255], ["pvl", 1258], ["-", 1261], ["positive", 1262], ["MRSA", 1271], ["isolates", 1276], ["were", 1285], ["recovered", 1290], ["from", 1300], ["patients", 1305], ["with", 1314], ["skin", 1319], ["and", 1324], ["soft", 1328], ["tissue", 1333], ["infections", 1340], [";", 1350], ["thirty", 1352], ["-", 1358], ["six", 1359], ["percent", 1363], ["were", 1371], ["from", 1376], ["patients", 1381], ["of", 1390], ["non", 1393], ["-", 1396], ["Irish", 1397], ["ethnic", 1403], ["origin", 1410], [",", 1416], ["reflecting", 1418], ["the", 1429], ["increasing", 1433], ["heterogeneity", 1444], ["of", 1458], ["the", 1461], ["Irish", 1465], ["population", 1471], ["due", 1482], ["to", 1486], ["immigration", 1489], [".", 1500], ["All", 1502], ["25", 1506], ["pvl", 1509], ["-", 1512], ["positive", 1513], ["isolates", 1522], ["carried", 1531], ["SCCmec", 1539], ["IV", 1546], [";", 1548], ["14", 1550], ["(", 1553], ["56", 1554], ["%", 1556], [")", 1557], ["harbored", 1559], ["SCCmec", 1568], ["IV.1", 1575], ["or", 1580], ["IV.3", 1583], [",", 1587], ["and", 1589], ["the", 1593], ["remaining", 1597], ["11", 1607], ["isolates", 1610], ["could", 1619], ["not", 1625], ["be", 1629], ["subtyped", 1632], [".", 1640], ["This", 1642], ["study", 1647], ["demonstrates", 1653], ["that", 1666], ["pvl", 1671], ["is", 1675], ["not", 1678], ["a", 1682], ["reliable", 1684], ["marker", 1693], ["for", 1700], ["CA", 1704], ["-", 1706], ["MRSA", 1707], ["in", 1712], ["Ireland", 1715], ["and", 1723], ["reveals", 1727], ["the", 1735], ["emergence", 1739], ["and", 1749], ["importation", 1753], ["of", 1765], ["diverse", 1768], ["genotypes", 1776], ["of", 1786], ["pvl", 1789], ["-", 1792], ["positive", 1793], ["MRSA", 1802], ["in", 1807], ["Ireland", 1810], [".", 1817]]}
{"context": "A 29-year-old man with a history of elevated creatine kinase and necrotizing myopathy was reviewed. Prominent red cell acanthocytosis in association with reduced Kell antigen expression was present, findings consistent with the McLeod syndrome. Investigation of the patient's XK gene revealed a novel TGG- to-TAG transition at position 1023 in exon 3. This point mutation creates an in-frame stop codon (W314X), and predicts a truncated XK protein of 313 amino acids, compared with 444 amino acids in the normal XK protein. The mutation was not identified in the patient's mother or sister indicating that this mutation was spontaneous.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "d82fcc5243f04463a79983358c686ff9", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[44, 44], [79, 79], [94, 94]], "char_spans": [[276, 277], [437, 438], [512, 513]]}]}], "context_tokens": [["A", 0], ["29-year", 2], ["-", 9], ["old", 10], ["man", 14], ["with", 18], ["a", 23], ["history", 25], ["of", 33], ["elevated", 36], ["creatine", 45], ["kinase", 54], ["and", 61], ["necrotizing", 65], ["myopathy", 77], ["was", 86], ["reviewed", 90], [".", 98], ["Prominent", 100], ["red", 110], ["cell", 114], ["acanthocytosis", 119], ["in", 134], ["association", 137], ["with", 149], ["reduced", 154], ["Kell", 162], ["antigen", 167], ["expression", 175], ["was", 186], ["present", 190], [",", 197], ["findings", 199], ["consistent", 208], ["with", 219], ["the", 224], ["McLeod", 228], ["syndrome", 235], [".", 243], ["Investigation", 245], ["of", 259], ["the", 262], ["patient", 266], ["'s", 273], ["XK", 276], ["gene", 279], ["revealed", 284], ["a", 293], ["novel", 295], ["TGG-", 301], ["to", 306], ["-", 308], ["TAG", 309], ["transition", 313], ["at", 324], ["position", 327], ["1023", 336], ["in", 341], ["exon", 344], ["3", 349], [".", 350], ["This", 352], ["point", 357], ["mutation", 363], ["creates", 372], ["an", 380], ["in", 383], ["-", 385], ["frame", 386], ["stop", 392], ["codon", 397], ["(", 403], ["W314X", 404], [")", 409], [",", 410], ["and", 412], ["predicts", 416], ["a", 425], ["truncated", 427], ["XK", 437], ["protein", 440], ["of", 448], ["313", 451], ["amino", 455], ["acids", 461], [",", 466], ["compared", 468], ["with", 477], ["444", 482], ["amino", 486], ["acids", 492], ["in", 498], ["the", 501], ["normal", 505], ["XK", 512], ["protein", 515], [".", 522], ["The", 524], ["mutation", 528], ["was", 537], ["not", 541], ["identified", 545], ["in", 556], ["the", 559], ["patient", 563], ["'s", 570], ["mother", 573], ["or", 580], ["sister", 583], ["indicating", 590], ["that", 601], ["this", 606], ["mutation", 611], ["was", 620], ["spontaneous", 624], [".", 635]]}
{"context": "Selenocysteine, a selenium-containing analog of cysteine, is found in the prokaryotic and eukaryotic kingdoms in active sites of enzymes involved in oxidation-reduction reactions. Its biosynthesis and cotranslational insertion into selenoproteins is performed by an outstanding mechanism, implying the participation of several gene products. The tRNA(Sec) is one of these. In eukaryotes, its transcription mode by RNA polymerase III differs from that of classical tRNA genes, both at the level of the promoter elements and transcription factors involved. In addition, enhanced transcription is afforded by a newly characterized zinc finger activator. Not only transcription of the gene, but also the tRNA(Sec) itself is atypical since its 2D and 3D structures exhibit features which set it apart from classical tRNAs. Decoding of eukaryotic selenocysteine UGA codons requires a stem-loop structure in the 3'UTR of mRNAs, the selenocysteine insertion sequence (SECIS) element. Structure probing and sequence comparisons led us to propose a 2D structure model for the SECIS element, containing a novel RNA motif composed of four consecutive non-Watson-Crick base-pairs. A 3D model, rationalizing the accessibility data, was elaborated by computer modeling. It yields indicative or suggestive evidence for the role that could play some conserved residues and/or structural features in SECIS function. These might act as signals for interaction with SBP, the SECIS binding protein that we have characterized.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "8588c6a6d2b34d4ba7cbf44f2320db4d", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[160, 160], [248, 248], [179, 179], [234, 234]], "char_spans": [[960, 964], [1455, 1459], [1066, 1070], [1382, 1386]]}]}], "context_tokens": [["Selenocysteine", 0], [",", 14], ["a", 16], ["selenium", 18], ["-", 26], ["containing", 27], ["analog", 38], ["of", 45], ["cysteine", 48], [",", 56], ["is", 58], ["found", 61], ["in", 67], ["the", 70], ["prokaryotic", 74], ["and", 86], ["eukaryotic", 90], ["kingdoms", 101], ["in", 110], ["active", 113], ["sites", 120], ["of", 126], ["enzymes", 129], ["involved", 137], ["in", 146], ["oxidation", 149], ["-", 158], ["reduction", 159], ["reactions", 169], [".", 178], ["Its", 180], ["biosynthesis", 184], ["and", 197], ["cotranslational", 201], ["insertion", 217], ["into", 227], ["selenoproteins", 232], ["is", 247], ["performed", 250], ["by", 260], ["an", 263], ["outstanding", 266], ["mechanism", 278], [",", 287], ["implying", 289], ["the", 298], ["participation", 302], ["of", 316], ["several", 319], ["gene", 327], ["products", 332], [".", 340], ["The", 342], ["tRNA(Sec", 346], [")", 354], ["is", 356], ["one", 359], ["of", 363], ["these", 366], [".", 371], ["In", 373], ["eukaryotes", 376], [",", 386], ["its", 388], ["transcription", 392], ["mode", 406], ["by", 411], ["RNA", 414], ["polymerase", 418], ["III", 429], ["differs", 433], ["from", 441], ["that", 446], ["of", 451], ["classical", 454], ["tRNA", 464], ["genes", 469], [",", 474], ["both", 476], ["at", 481], ["the", 484], ["level", 488], ["of", 494], ["the", 497], ["promoter", 501], ["elements", 510], ["and", 519], ["transcription", 523], ["factors", 537], ["involved", 545], [".", 553], ["In", 555], ["addition", 558], [",", 566], ["enhanced", 568], ["transcription", 577], ["is", 591], ["afforded", 594], ["by", 603], ["a", 606], ["newly", 608], ["characterized", 614], ["zinc", 628], ["finger", 633], ["activator", 640], [".", 649], ["Not", 651], ["only", 655], ["transcription", 660], ["of", 674], ["the", 677], ["gene", 681], [",", 685], ["but", 687], ["also", 691], ["the", 696], ["tRNA(Sec", 700], [")", 708], ["itself", 710], ["is", 717], ["atypical", 720], ["since", 729], ["its", 735], ["2D", 739], ["and", 742], ["3D", 746], ["structures", 749], ["exhibit", 760], ["features", 768], ["which", 777], ["set", 783], ["it", 787], ["apart", 790], ["from", 796], ["classical", 801], ["tRNAs", 811], [".", 816], ["Decoding", 818], ["of", 827], ["eukaryotic", 830], ["selenocysteine", 841], ["UGA", 856], ["codons", 860], ["requires", 867], ["a", 876], ["stem", 878], ["-", 882], ["loop", 883], ["structure", 888], ["in", 898], ["the", 901], ["3'UTR", 905], ["of", 911], ["mRNAs", 914], [",", 919], ["the", 921], ["selenocysteine", 925], ["insertion", 940], ["sequence", 950], ["(", 959], ["SECIS", 960], [")", 965], ["element", 967], [".", 974], ["Structure", 976], ["probing", 986], ["and", 994], ["sequence", 998], ["comparisons", 1007], ["led", 1019], ["us", 1023], ["to", 1026], ["propose", 1029], ["a", 1037], ["2D", 1039], ["structure", 1042], ["model", 1052], ["for", 1058], ["the", 1062], ["SECIS", 1066], ["element", 1072], [",", 1079], ["containing", 1081], ["a", 1092], ["novel", 1094], ["RNA", 1100], ["motif", 1104], ["composed", 1110], ["of", 1119], ["four", 1122], ["consecutive", 1127], ["non", 1139], ["-", 1142], ["Watson", 1143], ["-", 1149], ["Crick", 1150], ["base", 1156], ["-", 1160], ["pairs", 1161], [".", 1166], ["A", 1168], ["3D", 1170], ["model", 1173], [",", 1178], ["rationalizing", 1180], ["the", 1194], ["accessibility", 1198], ["data", 1212], [",", 1216], ["was", 1218], ["elaborated", 1222], ["by", 1233], ["computer", 1236], ["modeling", 1245], [".", 1253], ["It", 1255], ["yields", 1258], ["indicative", 1265], ["or", 1276], ["suggestive", 1279], ["evidence", 1290], ["for", 1299], ["the", 1303], ["role", 1307], ["that", 1312], ["could", 1317], ["play", 1323], ["some", 1328], ["conserved", 1333], ["residues", 1343], ["and/or", 1352], ["structural", 1359], ["features", 1370], ["in", 1379], ["SECIS", 1382], ["function", 1388], [".", 1396], ["These", 1398], ["might", 1404], ["act", 1410], ["as", 1414], ["signals", 1417], ["for", 1425], ["interaction", 1429], ["with", 1441], ["SBP", 1446], [",", 1449], ["the", 1451], ["SECIS", 1455], ["binding", 1461], ["protein", 1469], ["that", 1477], ["we", 1482], ["have", 1485], ["characterized", 1490], [".", 1503]]}
{"context": "Chronic myelogenous leukemia (CML) is a clonal hematopoietic disorder caused by the reciprocal translocation between chromosome 9 and 22. As a result of this translocation, a novel fusion gene, BCR-ABL, is created on Philadelphia (Ph) chromosome, and the constitutive activity of the BCR-ABL protein tyrosine kinase plays a critical role in the disease pathogenesis. Imatinib mesylate, a selective BCR-ABL tyrosine kinase inhibitor, was first given to a patient with CML in June 1998. Since then, it has continued to demonstrate remarkable efficacy in treating patients with CML. Based upon the results of early phase I and II studies, a phase III study (IRIS Study) that was randomized to first-line imatinib (400 mg/day) or to standard treatment with interferon+low-dose Ara-C, was conducted on 1,106 patients newly diagnosed (within 6 months) with chronic-phase CML. After median follow-up of 30 months, imatinib showed significantly superior tolerability, hematologic and cytogenetic responses (major cytogenetic response, 90%; complete cytogenetic response, 82%), and overall survival (95% without censoring allo-HSCT). Although imatinib is the first-line therapy and has changed the paradigm of CML treatment strategy, questions remain as to the meaning of cytogenetic and molecular response, curability, optimal dose, and relation with allo-HSCT.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "90bd5d6d1bbd4a51af5bf2328d5aebb7", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[73, 75], [53, 55], [34, 36]], "char_spans": [[398, 404], [284, 290], [194, 200]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["a", 38], ["clonal", 40], ["hematopoietic", 47], ["disorder", 61], ["caused", 70], ["by", 77], ["the", 80], ["reciprocal", 84], ["translocation", 95], ["between", 109], ["chromosome", 117], ["9", 128], ["and", 130], ["22", 134], [".", 136], ["As", 138], ["a", 141], ["result", 143], ["of", 150], ["this", 153], ["translocation", 158], [",", 171], ["a", 173], ["novel", 175], ["fusion", 181], ["gene", 188], [",", 192], ["BCR", 194], ["-", 197], ["ABL", 198], [",", 201], ["is", 203], ["created", 206], ["on", 214], ["Philadelphia", 217], ["(", 230], ["Ph", 231], [")", 233], ["chromosome", 235], [",", 245], ["and", 247], ["the", 251], ["constitutive", 255], ["activity", 268], ["of", 277], ["the", 280], ["BCR", 284], ["-", 287], ["ABL", 288], ["protein", 292], ["tyrosine", 300], ["kinase", 309], ["plays", 316], ["a", 322], ["critical", 324], ["role", 333], ["in", 338], ["the", 341], ["disease", 345], ["pathogenesis", 353], [".", 365], ["Imatinib", 367], ["mesylate", 376], [",", 384], ["a", 386], ["selective", 388], ["BCR", 398], ["-", 401], ["ABL", 402], ["tyrosine", 406], ["kinase", 415], ["inhibitor", 422], [",", 431], ["was", 433], ["first", 437], ["given", 443], ["to", 449], ["a", 452], ["patient", 454], ["with", 462], ["CML", 467], ["in", 471], ["June", 474], ["1998", 479], [".", 483], ["Since", 485], ["then", 491], [",", 495], ["it", 497], ["has", 500], ["continued", 504], ["to", 514], ["demonstrate", 517], ["remarkable", 529], ["efficacy", 540], ["in", 549], ["treating", 552], ["patients", 561], ["with", 570], ["CML", 575], [".", 578], ["Based", 580], ["upon", 586], ["the", 591], ["results", 595], ["of", 603], ["early", 606], ["phase", 612], ["I", 618], ["and", 620], ["II", 624], ["studies", 627], [",", 634], ["a", 636], ["phase", 638], ["III", 644], ["study", 648], ["(", 654], ["IRIS", 655], ["Study", 660], [")", 665], ["that", 667], ["was", 672], ["randomized", 676], ["to", 687], ["first", 690], ["-", 695], ["line", 696], ["imatinib", 701], ["(", 710], ["400", 711], ["mg", 715], ["/", 717], ["day", 718], [")", 721], ["or", 723], ["to", 726], ["standard", 729], ["treatment", 738], ["with", 748], ["interferon+low", 753], ["-", 767], ["dose", 768], ["Ara", 773], ["-", 776], ["C", 777], [",", 778], ["was", 780], ["conducted", 784], ["on", 794], ["1,106", 797], ["patients", 803], ["newly", 812], ["diagnosed", 818], ["(", 828], ["within", 829], ["6", 836], ["months", 838], [")", 844], ["with", 846], ["chronic", 851], ["-", 858], ["phase", 859], ["CML", 865], [".", 868], ["After", 870], ["median", 876], ["follow", 883], ["-", 889], ["up", 890], ["of", 893], ["30", 896], ["months", 899], [",", 905], ["imatinib", 907], ["showed", 916], ["significantly", 923], ["superior", 937], ["tolerability", 946], [",", 958], ["hematologic", 960], ["and", 972], ["cytogenetic", 976], ["responses", 988], ["(", 998], ["major", 999], ["cytogenetic", 1005], ["response", 1017], [",", 1025], ["90", 1027], ["%", 1029], [";", 1030], ["complete", 1032], ["cytogenetic", 1041], ["response", 1053], [",", 1061], ["82", 1063], ["%", 1065], [")", 1066], [",", 1067], ["and", 1069], ["overall", 1073], ["survival", 1081], ["(", 1090], ["95", 1091], ["%", 1093], ["without", 1095], ["censoring", 1103], ["allo", 1113], ["-", 1117], ["HSCT", 1118], [")", 1122], [".", 1123], ["Although", 1125], ["imatinib", 1134], ["is", 1143], ["the", 1146], ["first", 1150], ["-", 1155], ["line", 1156], ["therapy", 1161], ["and", 1169], ["has", 1173], ["changed", 1177], ["the", 1185], ["paradigm", 1189], ["of", 1198], ["CML", 1201], ["treatment", 1205], ["strategy", 1215], [",", 1223], ["questions", 1225], ["remain", 1235], ["as", 1242], ["to", 1245], ["the", 1248], ["meaning", 1252], ["of", 1260], ["cytogenetic", 1263], ["and", 1275], ["molecular", 1279], ["response", 1289], [",", 1297], ["curability", 1299], [",", 1309], ["optimal", 1311], ["dose", 1319], [",", 1323], ["and", 1325], ["relation", 1329], ["with", 1338], ["allo", 1343], ["-", 1347], ["HSCT", 1348], [".", 1352]]}
{"context": "Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED) is a common condition characterized by an irresistible urge to move the legs, concomitant with an unpleasant sensation in the lower limbs, which is typically relieved by movement. Symptoms occur predominantly at rest and prevail in the afternoon or evening. Treatment of patients with RLS/WED is indicated for those patients who suffer from clinically relevant symptoms. The management of mild forms of RLS/WED is mainly based on dopamine agonists (DA) therapy (including pramipexole and ropinirole) and \u03b1-2-\u03b4 calcium-channel ligand. Nevertheless, with passing of time, symptoms tend to become more severe and the patient can eventually develop pharmacoresistance. Furthermore, long-term treatment with dopaminergic agents may be complicated by the development of augmentation, which is defined by an increase in the severity and frequency of RLS/WED symptoms despite adequate treatment. Here, we discuss which are the best therapeutic options when RLS/WED becomes intractable, with a focus on advantages and side effects of the available medications. Prevention strategies include managing lifestyle changes and a good sleep hygiene. Different drug options are available. Switching to longer-acting dopaminergic agents may be a possibility if the patient is well-tolerating DA treatment. An association with \u03b1-2-\u03b4 calcium-channel ligand is another first-line approach. In refractory RLS/WED, opioids such as oxycodone-naloxone have demonstrated good efficacy. Other pharmacological approaches include IV iron, benzodiazepines such as clonazepam, and antiepileptic drugs, with different level of evidence of efficacy. Therefore, the final decision regarding the agent to use in treating severe RLS/WED symptoms should be tailored to the patient, taking into account the symptomatology, comorbidities, the availability of treatment and the history of the disease.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "57c7f4ca7dcc421f8be58691a3878467", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["Legs", 9], ["Syndrome", 14], ["/", 22], ["Willis", 23], ["-", 29], ["Ekbom", 30], ["Disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["is", 54], ["a", 57], ["common", 59], ["condition", 66], ["characterized", 76], ["by", 90], ["an", 93], ["irresistible", 96], ["urge", 109], ["to", 114], ["move", 117], ["the", 122], ["legs", 126], [",", 130], ["concomitant", 132], ["with", 144], ["an", 149], ["unpleasant", 152], ["sensation", 163], ["in", 173], ["the", 176], ["lower", 180], ["limbs", 186], [",", 191], ["which", 193], ["is", 199], ["typically", 202], ["relieved", 212], ["by", 221], ["movement", 224], [".", 232], ["Symptoms", 234], ["occur", 243], ["predominantly", 249], ["at", 263], ["rest", 266], ["and", 271], ["prevail", 275], ["in", 283], ["the", 286], ["afternoon", 290], ["or", 300], ["evening", 303], [".", 310], ["Treatment", 312], ["of", 322], ["patients", 325], ["with", 334], ["RLS", 339], ["/", 342], ["WED", 343], ["is", 347], ["indicated", 350], ["for", 360], ["those", 364], ["patients", 370], ["who", 379], ["suffer", 383], ["from", 390], ["clinically", 395], ["relevant", 406], ["symptoms", 415], [".", 423], ["The", 425], ["management", 429], ["of", 440], ["mild", 443], ["forms", 448], ["of", 454], ["RLS", 457], ["/", 460], ["WED", 461], ["is", 465], ["mainly", 468], ["based", 475], ["on", 481], ["dopamine", 484], ["agonists", 493], ["(", 502], ["DA", 503], [")", 505], ["therapy", 507], ["(", 515], ["including", 516], ["pramipexole", 526], ["and", 538], ["ropinirole", 542], [")", 552], ["and", 554], ["\u03b1-2-\u03b4", 558], ["calcium", 564], ["-", 571], ["channel", 572], ["ligand", 580], [".", 586], ["Nevertheless", 588], [",", 600], ["with", 602], ["passing", 607], ["of", 615], ["time", 618], [",", 622], ["symptoms", 624], ["tend", 633], ["to", 638], ["become", 641], ["more", 648], ["severe", 653], ["and", 660], ["the", 664], ["patient", 668], ["can", 676], ["eventually", 680], ["develop", 691], ["pharmacoresistance", 699], [".", 717], ["Furthermore", 719], [",", 730], ["long", 732], ["-", 736], ["term", 737], ["treatment", 742], ["with", 752], ["dopaminergic", 757], ["agents", 770], ["may", 777], ["be", 781], ["complicated", 784], ["by", 796], ["the", 799], ["development", 803], ["of", 815], ["augmentation", 818], [",", 830], ["which", 832], ["is", 838], ["defined", 841], ["by", 849], ["an", 852], ["increase", 855], ["in", 864], ["the", 867], ["severity", 871], ["and", 880], ["frequency", 884], ["of", 894], ["RLS", 897], ["/", 900], ["WED", 901], ["symptoms", 905], ["despite", 914], ["adequate", 922], ["treatment", 931], [".", 940], ["Here", 942], [",", 946], ["we", 948], ["discuss", 951], ["which", 959], ["are", 965], ["the", 969], ["best", 973], ["therapeutic", 978], ["options", 990], ["when", 998], ["RLS", 1003], ["/", 1006], ["WED", 1007], ["becomes", 1011], ["intractable", 1019], [",", 1030], ["with", 1032], ["a", 1037], ["focus", 1039], ["on", 1045], ["advantages", 1048], ["and", 1059], ["side", 1063], ["effects", 1068], ["of", 1076], ["the", 1079], ["available", 1083], ["medications", 1093], [".", 1104], ["Prevention", 1106], ["strategies", 1117], ["include", 1128], ["managing", 1136], ["lifestyle", 1145], ["changes", 1155], ["and", 1163], ["a", 1167], ["good", 1169], ["sleep", 1174], ["hygiene", 1180], [".", 1187], ["Different", 1189], ["drug", 1199], ["options", 1204], ["are", 1212], ["available", 1216], [".", 1225], ["Switching", 1227], ["to", 1237], ["longer", 1240], ["-", 1246], ["acting", 1247], ["dopaminergic", 1254], ["agents", 1267], ["may", 1274], ["be", 1278], ["a", 1281], ["possibility", 1283], ["if", 1295], ["the", 1298], ["patient", 1302], ["is", 1310], ["well", 1313], ["-", 1317], ["tolerating", 1318], ["DA", 1329], ["treatment", 1332], [".", 1341], ["An", 1343], ["association", 1346], ["with", 1358], ["\u03b1-2-\u03b4", 1363], ["calcium", 1369], ["-", 1376], ["channel", 1377], ["ligand", 1385], ["is", 1392], ["another", 1395], ["first", 1403], ["-", 1408], ["line", 1409], ["approach", 1414], [".", 1422], ["In", 1424], ["refractory", 1427], ["RLS", 1438], ["/", 1441], ["WED", 1442], [",", 1445], ["opioids", 1447], ["such", 1455], ["as", 1460], ["oxycodone", 1463], ["-", 1472], ["naloxone", 1473], ["have", 1482], ["demonstrated", 1487], ["good", 1500], ["efficacy", 1505], [".", 1513], ["Other", 1515], ["pharmacological", 1521], ["approaches", 1537], ["include", 1548], ["IV", 1556], ["iron", 1559], [",", 1563], ["benzodiazepines", 1565], ["such", 1581], ["as", 1586], ["clonazepam", 1589], [",", 1599], ["and", 1601], ["antiepileptic", 1605], ["drugs", 1619], [",", 1624], ["with", 1626], ["different", 1631], ["level", 1641], ["of", 1647], ["evidence", 1650], ["of", 1659], ["efficacy", 1662], [".", 1670], ["Therefore", 1672], [",", 1681], ["the", 1683], ["final", 1687], ["decision", 1693], ["regarding", 1702], ["the", 1712], ["agent", 1716], ["to", 1722], ["use", 1725], ["in", 1729], ["treating", 1732], ["severe", 1741], ["RLS", 1748], ["/", 1751], ["WED", 1752], ["symptoms", 1756], ["should", 1765], ["be", 1772], ["tailored", 1775], ["to", 1784], ["the", 1787], ["patient", 1791], [",", 1798], ["taking", 1800], ["into", 1807], ["account", 1812], ["the", 1820], ["symptomatology", 1824], [",", 1838], ["comorbidities", 1840], [",", 1853], ["the", 1855], ["availability", 1859], ["of", 1872], ["treatment", 1875], ["and", 1885], ["the", 1889], ["history", 1893], ["of", 1901], ["the", 1904], ["disease", 1908], [".", 1915]]}
{"context": "Aging research in vertebrates is hampered by the lack of short-lived models. Annual fishes of the genus Nothobranchius live in East African seasonal ponds. Their life expectancy in the wild is limited by the duration of the wet season and their lifespan in captivity is also short. Nothobranchius are popular aquarium fishes and many different species are kept as captive strains, providing rich material for comparative studies. The present paper aims at reviving the interest in these fishes by reporting that: (1) Nothobranchius can be cultured, and their eggs stored dry at room temperature for months or years, offering inexpensive methods of embryo storage; (2) Nothobranchius show accelerated growth and expression of aging biomarkers at the level of histology and behaviour; (3) the species Nothobranchius furzeri has a maximum lifespan of only 3 months and offers the possibility to perform investigations thus far unthinkable in a vertebrate, such as drug screening with life-long pharmacological treatments and experimental evolution; (4) when the lifespan of different species is compared, a general correlation is found between wet season duration in their natural habitat and longevity in captivity; and (5) vertebrate aging-related genes, such as p66Shc and MTP, can be easily isolated in Nothobranchius by homology cloning. These fishes can become excellent models for aging studies. They can be employed to test the effects of experimental manipulation on aging at a pace comparable with that of Drosophila and to probe the effects of natural selection on the evolution of aging-related genes.", "qas": [{"question": "What can Nothobranchius furzeri be used as a model system for?", "answers": ["aging research"], "qid": "ea59c7ee76424a47bdecc74c9987666f", "question_tokens": [["What", 0], ["can", 5], ["Nothobranchius", 9], ["furzeri", 24], ["be", 32], ["used", 35], ["as", 40], ["a", 43], ["model", 45], ["system", 51], ["for", 58], ["?", 61]], "detected_answers": [{"text": "aging research", "token_spans": [[0, 1]], "char_spans": [[0, 13]]}]}], "context_tokens": [["Aging", 0], ["research", 6], ["in", 15], ["vertebrates", 18], ["is", 30], ["hampered", 33], ["by", 42], ["the", 45], ["lack", 49], ["of", 54], ["short", 57], ["-", 62], ["lived", 63], ["models", 69], [".", 75], ["Annual", 77], ["fishes", 84], ["of", 91], ["the", 94], ["genus", 98], ["Nothobranchius", 104], ["live", 119], ["in", 124], ["East", 127], ["African", 132], ["seasonal", 140], ["ponds", 149], [".", 154], ["Their", 156], ["life", 162], ["expectancy", 167], ["in", 178], ["the", 181], ["wild", 185], ["is", 190], ["limited", 193], ["by", 201], ["the", 204], ["duration", 208], ["of", 217], ["the", 220], ["wet", 224], ["season", 228], ["and", 235], ["their", 239], ["lifespan", 245], ["in", 254], ["captivity", 257], ["is", 267], ["also", 270], ["short", 275], [".", 280], ["Nothobranchius", 282], ["are", 297], ["popular", 301], ["aquarium", 309], ["fishes", 318], ["and", 325], ["many", 329], ["different", 334], ["species", 344], ["are", 352], ["kept", 356], ["as", 361], ["captive", 364], ["strains", 372], [",", 379], ["providing", 381], ["rich", 391], ["material", 396], ["for", 405], ["comparative", 409], ["studies", 421], [".", 428], ["The", 430], ["present", 434], ["paper", 442], ["aims", 448], ["at", 453], ["reviving", 456], ["the", 465], ["interest", 469], ["in", 478], ["these", 481], ["fishes", 487], ["by", 494], ["reporting", 497], ["that", 507], [":", 511], ["(", 513], ["1", 514], [")", 515], ["Nothobranchius", 517], ["can", 532], ["be", 536], ["cultured", 539], [",", 547], ["and", 549], ["their", 553], ["eggs", 559], ["stored", 564], ["dry", 571], ["at", 575], ["room", 578], ["temperature", 583], ["for", 595], ["months", 599], ["or", 606], ["years", 609], [",", 614], ["offering", 616], ["inexpensive", 625], ["methods", 637], ["of", 645], ["embryo", 648], ["storage", 655], [";", 662], ["(", 664], ["2", 665], [")", 666], ["Nothobranchius", 668], ["show", 683], ["accelerated", 688], ["growth", 700], ["and", 707], ["expression", 711], ["of", 722], ["aging", 725], ["biomarkers", 731], ["at", 742], ["the", 745], ["level", 749], ["of", 755], ["histology", 758], ["and", 768], ["behaviour", 772], [";", 781], ["(", 783], ["3", 784], [")", 785], ["the", 787], ["species", 791], ["Nothobranchius", 799], ["furzeri", 814], ["has", 822], ["a", 826], ["maximum", 828], ["lifespan", 836], ["of", 845], ["only", 848], ["3", 853], ["months", 855], ["and", 862], ["offers", 866], ["the", 873], ["possibility", 877], ["to", 889], ["perform", 892], ["investigations", 900], ["thus", 915], ["far", 920], ["unthinkable", 924], ["in", 936], ["a", 939], ["vertebrate", 941], [",", 951], ["such", 953], ["as", 958], ["drug", 961], ["screening", 966], ["with", 976], ["life", 981], ["-", 985], ["long", 986], ["pharmacological", 991], ["treatments", 1007], ["and", 1018], ["experimental", 1022], ["evolution", 1035], [";", 1044], ["(", 1046], ["4", 1047], [")", 1048], ["when", 1050], ["the", 1055], ["lifespan", 1059], ["of", 1068], ["different", 1071], ["species", 1081], ["is", 1089], ["compared", 1092], [",", 1100], ["a", 1102], ["general", 1104], ["correlation", 1112], ["is", 1124], ["found", 1127], ["between", 1133], ["wet", 1141], ["season", 1145], ["duration", 1152], ["in", 1161], ["their", 1164], ["natural", 1170], ["habitat", 1178], ["and", 1186], ["longevity", 1190], ["in", 1200], ["captivity", 1203], [";", 1212], ["and", 1214], ["(", 1218], ["5", 1219], [")", 1220], ["vertebrate", 1222], ["aging", 1233], ["-", 1238], ["related", 1239], ["genes", 1247], [",", 1252], ["such", 1254], ["as", 1259], ["p66Shc", 1262], ["and", 1269], ["MTP", 1273], [",", 1276], ["can", 1278], ["be", 1282], ["easily", 1285], ["isolated", 1292], ["in", 1301], ["Nothobranchius", 1304], ["by", 1319], ["homology", 1322], ["cloning", 1331], [".", 1338], ["These", 1340], ["fishes", 1346], ["can", 1353], ["become", 1357], ["excellent", 1364], ["models", 1374], ["for", 1381], ["aging", 1385], ["studies", 1391], [".", 1398], ["They", 1400], ["can", 1405], ["be", 1409], ["employed", 1412], ["to", 1421], ["test", 1424], ["the", 1429], ["effects", 1433], ["of", 1441], ["experimental", 1444], ["manipulation", 1457], ["on", 1470], ["aging", 1473], ["at", 1479], ["a", 1482], ["pace", 1484], ["comparable", 1489], ["with", 1500], ["that", 1505], ["of", 1510], ["Drosophila", 1513], ["and", 1524], ["to", 1528], ["probe", 1531], ["the", 1537], ["effects", 1541], ["of", 1549], ["natural", 1552], ["selection", 1560], ["on", 1570], ["the", 1573], ["evolution", 1577], ["of", 1587], ["aging", 1590], ["-", 1595], ["related", 1596], ["genes", 1604], [".", 1609]]}
{"context": "Lung cancer is the leading cause of death worldwide. Adenocarcinomas, the most common histologic subtype of non-small cell lung cancer (NSCLC), are frequently associated with activating mutations in the epidermal growth factor receptor (EGFR) gene. Although these patients often respond clinically to the EGFR tyrosine kinase inhibitors erlotinib and gefitinib, relapse inevitably occurs, suggesting the development of escape mechanisms that promote cell survival. Using a loss-of-function, whole genome short hairpin RNA (shRNA) screen, we identified that the canonical Wnt pathway contributes to the maintenance of NSCLC cells during EGFR inhibition, particularly the poly-ADP-ribosylating enzymes tankyrase 1 and 2 that positively regulate canonical Wnt signaling. Inhibition of tankyrase and various other components of the Wnt pathway with shRNAs or small molecules significantly increased the efficacy of EGFR inhibitors both in vitro and in vivo. Our findings therefore reveal a critical role for tankyrase and the canonical Wnt pathway in maintaining lung cancer cells during EGFR inhibition. Targeting the Wnt-tankyrase-\u03b2-catenin pathway together with EGFR inhibition may improve clinical outcome in patients with NSCLC.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "5cfd33dc4aa142d6ae71e5954d750d83", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[36, 43]], "char_spans": [[203, 246]]}]}], "context_tokens": [["Lung", 0], ["cancer", 5], ["is", 12], ["the", 15], ["leading", 19], ["cause", 27], ["of", 33], ["death", 36], ["worldwide", 42], [".", 51], ["Adenocarcinomas", 53], [",", 68], ["the", 70], ["most", 74], ["common", 79], ["histologic", 86], ["subtype", 97], ["of", 105], ["non", 108], ["-", 111], ["small", 112], ["cell", 118], ["lung", 123], ["cancer", 128], ["(", 135], ["NSCLC", 136], [")", 141], [",", 142], ["are", 144], ["frequently", 148], ["associated", 159], ["with", 170], ["activating", 175], ["mutations", 186], ["in", 196], ["the", 199], ["epidermal", 203], ["growth", 213], ["factor", 220], ["receptor", 227], ["(", 236], ["EGFR", 237], [")", 241], ["gene", 243], [".", 247], ["Although", 249], ["these", 258], ["patients", 264], ["often", 273], ["respond", 279], ["clinically", 287], ["to", 298], ["the", 301], ["EGFR", 305], ["tyrosine", 310], ["kinase", 319], ["inhibitors", 326], ["erlotinib", 337], ["and", 347], ["gefitinib", 351], [",", 360], ["relapse", 362], ["inevitably", 370], ["occurs", 381], [",", 387], ["suggesting", 389], ["the", 400], ["development", 404], ["of", 416], ["escape", 419], ["mechanisms", 426], ["that", 437], ["promote", 442], ["cell", 450], ["survival", 455], [".", 463], ["Using", 465], ["a", 471], ["loss", 473], ["-", 477], ["of", 478], ["-", 480], ["function", 481], [",", 489], ["whole", 491], ["genome", 497], ["short", 504], ["hairpin", 510], ["RNA", 518], ["(", 522], ["shRNA", 523], [")", 528], ["screen", 530], [",", 536], ["we", 538], ["identified", 541], ["that", 552], ["the", 557], ["canonical", 561], ["Wnt", 571], ["pathway", 575], ["contributes", 583], ["to", 595], ["the", 598], ["maintenance", 602], ["of", 614], ["NSCLC", 617], ["cells", 623], ["during", 629], ["EGFR", 636], ["inhibition", 641], [",", 651], ["particularly", 653], ["the", 666], ["poly", 670], ["-", 674], ["ADP", 675], ["-", 678], ["ribosylating", 679], ["enzymes", 692], ["tankyrase", 700], ["1", 710], ["and", 712], ["2", 716], ["that", 718], ["positively", 723], ["regulate", 734], ["canonical", 743], ["Wnt", 753], ["signaling", 757], [".", 766], ["Inhibition", 768], ["of", 779], ["tankyrase", 782], ["and", 792], ["various", 796], ["other", 804], ["components", 810], ["of", 821], ["the", 824], ["Wnt", 828], ["pathway", 832], ["with", 840], ["shRNAs", 845], ["or", 852], ["small", 855], ["molecules", 861], ["significantly", 871], ["increased", 885], ["the", 895], ["efficacy", 899], ["of", 908], ["EGFR", 911], ["inhibitors", 916], ["both", 927], ["in", 932], ["vitro", 935], ["and", 941], ["in", 945], ["vivo", 948], [".", 952], ["Our", 954], ["findings", 958], ["therefore", 967], ["reveal", 977], ["a", 984], ["critical", 986], ["role", 995], ["for", 1000], ["tankyrase", 1004], ["and", 1014], ["the", 1018], ["canonical", 1022], ["Wnt", 1032], ["pathway", 1036], ["in", 1044], ["maintaining", 1047], ["lung", 1059], ["cancer", 1064], ["cells", 1071], ["during", 1077], ["EGFR", 1084], ["inhibition", 1089], [".", 1099], ["Targeting", 1101], ["the", 1111], ["Wnt", 1115], ["-", 1118], ["tankyrase", 1119], ["-", 1128], ["\u03b2", 1129], ["-", 1130], ["catenin", 1131], ["pathway", 1139], ["together", 1147], ["with", 1156], ["EGFR", 1161], ["inhibition", 1166], ["may", 1177], ["improve", 1181], ["clinical", 1189], ["outcome", 1198], ["in", 1206], ["patients", 1209], ["with", 1218], ["NSCLC", 1223], [".", 1228]]}
{"context": "The plasma membrane Na(+)/Ca(2+) exchanger (NCX) is a bidirectional ion transporter that couples the translocation of Na(+) in one direction with that of Ca(2+) in the opposite direction. This system contributes to the regulation of intracellular Ca(2+) concentration via the forward mode (Ca(2+) efflux) or the reverse mode (Ca(2+) influx). We have previously demonstrated that the Ca(2+) paradox, an in vitro reperfusion model, causes the sustained activation of the reverse mode of the NCX, the disruption of Ca(2+) homeostasis, and subsequent delayed apoptotic-like death in astrocytes. In addition, we found that the nitric oxide (NO)-cyclic GMP signaling pathway inhibits Ca(2+) paradox-mediated astrocyte apoptosis, while a high concentration of NO induces cytotoxicity. In this way, Ca(2+) and NO may work together in the pathogenesis of several cells in the central nervous system. Concerning the role of NCX in NO cytotoxicity, we have found, using the specific inhibitor of NCX 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400), that NCX is involved in NO-induced cytotoxicity in cultured microglia, astrocytes, and neuronal cells. This review summarizes the pathological roles of the NCX as a new target for NO-mediated cellular toxicity, based on our studies on NO-NCX-mediated glial toxicity.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "5658da3cc5b84d219d6f6991552febf0", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[3, 6]], "char_spans": [[20, 41]]}, {"text": "NCX", "token_spans": [[96, 96], [224, 224], [243, 243], [177, 177], [198, 198], [8, 8], [191, 191]], "char_spans": [[489, 491], [1215, 1217], [1297, 1299], [914, 916], [1064, 1066], [44, 46], [985, 987]]}]}], "context_tokens": [["The", 0], ["plasma", 4], ["membrane", 11], ["Na(+)/Ca(2", 20], ["+", 30], [")", 31], ["exchanger", 33], ["(", 43], ["NCX", 44], [")", 47], ["is", 49], ["a", 52], ["bidirectional", 54], ["ion", 68], ["transporter", 72], ["that", 84], ["couples", 89], ["the", 97], ["translocation", 101], ["of", 115], ["Na(+", 118], [")", 122], ["in", 124], ["one", 127], ["direction", 131], ["with", 141], ["that", 146], ["of", 151], ["Ca(2", 154], ["+", 158], [")", 159], ["in", 161], ["the", 164], ["opposite", 168], ["direction", 177], [".", 186], ["This", 188], ["system", 193], ["contributes", 200], ["to", 212], ["the", 215], ["regulation", 219], ["of", 230], ["intracellular", 233], ["Ca(2", 247], ["+", 251], [")", 252], ["concentration", 254], ["via", 268], ["the", 272], ["forward", 276], ["mode", 284], ["(", 289], ["Ca(2", 290], ["+", 294], [")", 295], ["efflux", 297], [")", 303], ["or", 305], ["the", 308], ["reverse", 312], ["mode", 320], ["(", 325], ["Ca(2", 326], ["+", 330], [")", 331], ["influx", 333], [")", 339], [".", 340], ["We", 342], ["have", 345], ["previously", 350], ["demonstrated", 361], ["that", 374], ["the", 379], ["Ca(2", 383], ["+", 387], [")", 388], ["paradox", 390], [",", 397], ["an", 399], ["in", 402], ["vitro", 405], ["reperfusion", 411], ["model", 423], [",", 428], ["causes", 430], ["the", 437], ["sustained", 441], ["activation", 451], ["of", 462], ["the", 465], ["reverse", 469], ["mode", 477], ["of", 482], ["the", 485], ["NCX", 489], [",", 492], ["the", 494], ["disruption", 498], ["of", 509], ["Ca(2", 512], ["+", 516], [")", 517], ["homeostasis", 519], [",", 530], ["and", 532], ["subsequent", 536], ["delayed", 547], ["apoptotic", 555], ["-", 564], ["like", 565], ["death", 570], ["in", 576], ["astrocytes", 579], [".", 589], ["In", 591], ["addition", 594], [",", 602], ["we", 604], ["found", 607], ["that", 613], ["the", 618], ["nitric", 622], ["oxide", 629], ["(", 635], ["NO)-cyclic", 636], ["GMP", 647], ["signaling", 651], ["pathway", 661], ["inhibits", 669], ["Ca(2", 678], ["+", 682], [")", 683], ["paradox", 685], ["-", 692], ["mediated", 693], ["astrocyte", 702], ["apoptosis", 712], [",", 721], ["while", 723], ["a", 729], ["high", 731], ["concentration", 736], ["of", 750], ["NO", 753], ["induces", 756], ["cytotoxicity", 764], [".", 776], ["In", 778], ["this", 781], ["way", 786], [",", 789], ["Ca(2", 791], ["+", 795], [")", 796], ["and", 798], ["NO", 802], ["may", 805], ["work", 809], ["together", 814], ["in", 823], ["the", 826], ["pathogenesis", 830], ["of", 843], ["several", 846], ["cells", 854], ["in", 860], ["the", 863], ["central", 867], ["nervous", 875], ["system", 883], [".", 889], ["Concerning", 891], ["the", 902], ["role", 906], ["of", 911], ["NCX", 914], ["in", 918], ["NO", 921], ["cytotoxicity", 924], [",", 936], ["we", 938], ["have", 941], ["found", 946], [",", 951], ["using", 953], ["the", 959], ["specific", 963], ["inhibitor", 972], ["of", 982], ["NCX", 985], ["2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline", 989], ["(", 1048], ["SEA0400", 1049], [")", 1056], [",", 1057], ["that", 1059], ["NCX", 1064], ["is", 1068], ["involved", 1071], ["in", 1080], ["NO", 1083], ["-", 1085], ["induced", 1086], ["cytotoxicity", 1094], ["in", 1107], ["cultured", 1110], ["microglia", 1119], [",", 1128], ["astrocytes", 1130], [",", 1140], ["and", 1142], ["neuronal", 1146], ["cells", 1155], [".", 1160], ["This", 1162], ["review", 1167], ["summarizes", 1174], ["the", 1185], ["pathological", 1189], ["roles", 1202], ["of", 1208], ["the", 1211], ["NCX", 1215], ["as", 1219], ["a", 1222], ["new", 1224], ["target", 1228], ["for", 1235], ["NO", 1239], ["-", 1241], ["mediated", 1242], ["cellular", 1251], ["toxicity", 1260], [",", 1268], ["based", 1270], ["on", 1276], ["our", 1279], ["studies", 1283], ["on", 1291], ["NO", 1294], ["-", 1296], ["NCX", 1297], ["-", 1300], ["mediated", 1301], ["glial", 1310], ["toxicity", 1316], [".", 1324]]}
{"context": "Secretory phospholipase A2 (sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2 inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. To determine the effects of sPLA2 inhibition with varespladib on cardiovascular outcomes. A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n\u2009=\u20092572) or placebo (n\u2009=\u20092573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. The primary efficacy measure was a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95% CI, 0.97-1.61; log-rank P\u2009=\u2009.08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95% CI, 1.16-2.39; log-rank P\u2009=\u2009.005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P\u2009=\u2009.04). In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2 inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. clinicaltrials.gov Identifier: NCT01130246.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "9b9bcd725a354906b933c55de76f23a8", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[0, 2]], "char_spans": [[0, 25]]}]}], "context_tokens": [["Secretory", 0], ["phospholipase", 10], ["A2", 24], ["(", 27], ["sPLA2", 28], [")", 33], ["generates", 35], ["bioactive", 45], ["phospholipid", 55], ["products", 68], ["implicated", 77], ["in", 88], ["atherosclerosis", 91], [".", 106], ["The", 108], ["sPLA2", 112], ["inhibitor", 118], ["varespladib", 128], ["has", 140], ["favorable", 144], ["effects", 154], ["on", 162], ["lipid", 165], ["and", 171], ["inflammatory", 175], ["markers", 188], [";", 195], ["however", 197], [",", 204], ["its", 206], ["effect", 210], ["on", 217], ["cardiovascular", 220], ["outcomes", 235], ["is", 244], ["unknown", 247], [".", 254], ["To", 256], ["determine", 259], ["the", 269], ["effects", 273], ["of", 281], ["sPLA2", 284], ["inhibition", 290], ["with", 301], ["varespladib", 306], ["on", 318], ["cardiovascular", 321], ["outcomes", 336], [".", 344], ["A", 346], ["double", 348], ["-", 354], ["blind", 355], [",", 360], ["randomized", 362], [",", 372], ["multicenter", 374], ["trial", 386], ["at", 392], ["362", 395], ["academic", 399], ["and", 408], ["community", 412], ["hospitals", 422], ["in", 432], ["Europe", 435], [",", 441], ["Australia", 443], [",", 452], ["New", 454], ["Zealand", 458], [",", 465], ["India", 467], [",", 472], ["and", 474], ["North", 478], ["America", 484], ["of", 492], ["5145", 495], ["patients", 500], ["randomized", 509], ["within", 520], ["96", 527], ["hours", 530], ["of", 536], ["presentation", 539], ["of", 552], ["an", 555], ["acute", 558], ["coronary", 564], ["syndrome", 573], ["(", 582], ["ACS", 583], [")", 586], ["to", 588], ["either", 591], ["varespladib", 598], ["(", 610], ["n", 611], ["=", 613], ["2572", 615], [")", 619], ["or", 621], ["placebo", 624], ["(", 632], ["n", 633], ["=", 635], ["2573", 637], [")", 641], ["with", 643], ["enrollment", 648], ["between", 659], ["June", 667], ["1", 672], [",", 673], ["2010", 675], [",", 679], ["and", 681], ["March", 685], ["7", 691], [",", 692], ["2012", 694], ["(", 699], ["study", 700], ["termination", 706], ["on", 718], ["March", 721], ["9", 727], [",", 728], ["2012", 730], [")", 734], [".", 735], ["Participants", 737], ["were", 750], ["randomized", 755], ["to", 766], ["receive", 769], ["varespladib", 777], ["(", 789], ["500", 790], ["mg", 794], [")", 796], ["or", 798], ["placebo", 801], ["daily", 809], ["for", 815], ["16", 819], ["weeks", 822], [",", 827], ["in", 829], ["addition", 832], ["to", 841], ["atorvastatin", 844], ["and", 857], ["other", 861], ["established", 867], ["therapies", 879], [".", 888], ["The", 890], ["primary", 894], ["efficacy", 902], ["measure", 911], ["was", 919], ["a", 923], ["composite", 925], ["of", 935], ["cardiovascular", 938], ["mortality", 953], [",", 962], ["nonfatal", 964], ["myocardial", 973], ["infarction", 984], ["(", 995], ["MI", 996], [")", 998], [",", 999], ["nonfatal", 1001], ["stroke", 1010], [",", 1016], ["or", 1018], ["unstable", 1021], ["angina", 1030], ["with", 1037], ["evidence", 1042], ["of", 1051], ["ischemia", 1054], ["requiring", 1063], ["hospitalization", 1073], ["at", 1089], ["16", 1092], ["weeks", 1095], [".", 1100], ["Six", 1102], ["-", 1105], ["month", 1106], ["survival", 1112], ["status", 1121], ["was", 1128], ["also", 1132], ["evaluated", 1137], [".", 1146], ["At", 1148], ["a", 1151], ["prespecified", 1153], ["interim", 1166], ["analysis", 1174], [",", 1182], ["including", 1184], ["212", 1194], ["primary", 1198], ["end", 1206], ["point", 1210], ["events", 1216], [",", 1222], ["the", 1224], ["independent", 1228], ["data", 1240], ["and", 1245], ["safety", 1249], ["monitoring", 1256], ["board", 1267], ["recommended", 1273], ["termination", 1285], ["of", 1297], ["the", 1300], ["trial", 1304], ["for", 1310], ["futility", 1314], ["and", 1323], ["possible", 1327], ["harm", 1336], [".", 1340], ["The", 1342], ["primary", 1346], ["end", 1354], ["point", 1358], ["occurred", 1364], ["in", 1373], ["136", 1376], ["patients", 1380], ["(", 1389], ["6.1", 1390], ["%", 1393], [")", 1394], ["treated", 1396], ["with", 1404], ["varespladib", 1409], ["compared", 1421], ["with", 1430], ["109", 1435], ["patients", 1439], ["(", 1448], ["5.1", 1449], ["%", 1452], [")", 1453], ["treated", 1455], ["with", 1463], ["placebo", 1468], ["(", 1476], ["hazard", 1477], ["ratio", 1484], ["[", 1490], ["HR", 1491], ["]", 1493], [",", 1494], ["1.25", 1496], [";", 1500], ["95", 1502], ["%", 1504], ["CI", 1506], [",", 1508], ["0.97", 1510], ["-", 1514], ["1.61", 1515], [";", 1519], ["log", 1521], ["-", 1524], ["rank", 1525], ["P", 1530], ["=", 1532], [".08", 1534], [")", 1537], [".", 1538], ["Varespladib", 1540], ["was", 1552], ["associated", 1556], ["with", 1567], ["a", 1572], ["greater", 1574], ["risk", 1582], ["of", 1587], ["MI", 1590], ["(", 1593], ["78", 1594], ["[", 1597], ["3.4", 1598], ["%", 1601], ["]", 1602], ["vs", 1604], ["47", 1607], ["[", 1610], ["2.2", 1611], ["%", 1614], ["]", 1615], [";", 1616], ["HR", 1618], [",", 1620], ["1.66", 1622], [";", 1626], ["95", 1628], ["%", 1630], ["CI", 1632], [",", 1634], ["1.16", 1636], ["-", 1640], ["2.39", 1641], [";", 1645], ["log", 1647], ["-", 1650], ["rank", 1651], ["P", 1656], ["=", 1658], [".005", 1660], [")", 1664], [".", 1665], ["The", 1667], ["composite", 1671], ["secondary", 1681], ["end", 1691], ["point", 1695], ["of", 1701], ["cardiovascular", 1704], ["mortality", 1719], [",", 1728], ["MI", 1730], [",", 1732], ["and", 1734], ["stroke", 1738], ["was", 1745], ["observed", 1749], ["in", 1758], ["107", 1761], ["patients", 1765], ["(", 1774], ["4.6", 1775], ["%", 1778], [")", 1779], ["in", 1781], ["the", 1784], ["varespladib", 1788], ["group", 1800], ["and", 1806], ["79", 1810], ["patients", 1813], ["(", 1822], ["3.8", 1823], ["%", 1826], [")", 1827], ["in", 1829], ["the", 1832], ["placebo", 1836], ["group", 1844], ["(", 1850], ["HR", 1851], [",", 1853], ["1.36", 1855], [";", 1859], ["95", 1861], ["%", 1863], ["CI", 1865], [",", 1867], ["1.02", 1869], ["-", 1873], ["1.82", 1874], [";", 1878], ["P", 1880], ["=", 1882], [".04", 1884], [")", 1887], [".", 1888], ["In", 1890], ["patients", 1893], ["with", 1902], ["recent", 1907], ["ACS", 1914], [",", 1917], ["varespladib", 1919], ["did", 1931], ["not", 1935], ["reduce", 1939], ["the", 1946], ["risk", 1950], ["of", 1955], ["recurrent", 1958], ["cardiovascular", 1968], ["events", 1983], ["and", 1990], ["significantly", 1994], ["increased", 2008], ["the", 2018], ["risk", 2022], ["of", 2027], ["MI", 2030], [".", 2032], ["The", 2034], ["sPLA2", 2038], ["inhibition", 2044], ["with", 2055], ["varespladib", 2060], ["may", 2072], ["be", 2076], ["harmful", 2079], ["and", 2087], ["is", 2091], ["not", 2094], ["a", 2098], ["useful", 2100], ["strategy", 2107], ["to", 2116], ["reduce", 2119], ["adverse", 2126], ["cardiovascular", 2134], ["outcomes", 2149], ["after", 2158], ["ACS", 2164], [".", 2167], ["clinicaltrials.gov", 2169], ["Identifier", 2188], [":", 2198], ["NCT01130246", 2200], [".", 2211]]}
{"context": "This report describes the reliability, validity, treatment sensitivity, diagnostic performance and normative values for the Short Post-Traumatic Stress Disorder (PTSD) Rating Interview (SPRINT), a brief, global assessment for PTSD. The SPRINT was administered to subjects participating in a clinical trial of PTSD and in a population survey assessing PTSD prevalence. The 8-item SPRINT includes questions assessing the core symptoms of PTSD, as well as related aspects of somatic malaise, stress vulnerability and functional impairment. Validity was assessed against the MINI structured interview, the Davidson Trauma Scale, Treatment Outcome for PTSD Scale, Connor-Davidson Resilience Scale, Sheehan Stress Vulnerability Scale, Sheehan Disability Scale and Clinical Global Impressions of Severity and Improvement Scales. Good test-retest reliability, internal consistency, convergent and divergent validity were obtained. The SPRINT was responsive to symptom change over time and correlated with comparable PTSD symptom measures. In victims of trauma, a score of 14-17 was associated with 96% diagnostic accuracy, whereas in those with PTSD, highest efficiency corresponded to a range of 11-13. The SPRINT demonstrates solid psychometric properties and can serve as a reliable, valid and homogeneous measure of PTSD illness severity and of global improvement.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "4426d2042a6d4887bdddfa6bb9150c20", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[19, 23]], "char_spans": [[130, 159]]}, {"text": "PTSD", "token_spans": [[53, 53], [107, 107], [163, 163], [221, 221], [60, 60], [39, 39], [25, 25], [73, 73], [190, 190]], "char_spans": [[309, 312], [647, 650], [1008, 1011], [1312, 1315], [351, 354], [226, 229], [162, 165], [436, 439], [1137, 1140]]}]}], "context_tokens": [["This", 0], ["report", 5], ["describes", 12], ["the", 22], ["reliability", 26], [",", 37], ["validity", 39], [",", 47], ["treatment", 49], ["sensitivity", 59], [",", 70], ["diagnostic", 72], ["performance", 83], ["and", 95], ["normative", 99], ["values", 109], ["for", 116], ["the", 120], ["Short", 124], ["Post", 130], ["-", 134], ["Traumatic", 135], ["Stress", 145], ["Disorder", 152], ["(", 161], ["PTSD", 162], [")", 166], ["Rating", 168], ["Interview", 175], ["(", 185], ["SPRINT", 186], [")", 192], [",", 193], ["a", 195], ["brief", 197], [",", 202], ["global", 204], ["assessment", 211], ["for", 222], ["PTSD", 226], [".", 230], ["The", 232], ["SPRINT", 236], ["was", 243], ["administered", 247], ["to", 260], ["subjects", 263], ["participating", 272], ["in", 286], ["a", 289], ["clinical", 291], ["trial", 300], ["of", 306], ["PTSD", 309], ["and", 314], ["in", 318], ["a", 321], ["population", 323], ["survey", 334], ["assessing", 341], ["PTSD", 351], ["prevalence", 356], [".", 366], ["The", 368], ["8-item", 372], ["SPRINT", 379], ["includes", 386], ["questions", 395], ["assessing", 405], ["the", 415], ["core", 419], ["symptoms", 424], ["of", 433], ["PTSD", 436], [",", 440], ["as", 442], ["well", 445], ["as", 450], ["related", 453], ["aspects", 461], ["of", 469], ["somatic", 472], ["malaise", 480], [",", 487], ["stress", 489], ["vulnerability", 496], ["and", 510], ["functional", 514], ["impairment", 525], [".", 535], ["Validity", 537], ["was", 546], ["assessed", 550], ["against", 559], ["the", 567], ["MINI", 571], ["structured", 576], ["interview", 587], [",", 596], ["the", 598], ["Davidson", 602], ["Trauma", 611], ["Scale", 618], [",", 623], ["Treatment", 625], ["Outcome", 635], ["for", 643], ["PTSD", 647], ["Scale", 652], [",", 657], ["Connor", 659], ["-", 665], ["Davidson", 666], ["Resilience", 675], ["Scale", 686], [",", 691], ["Sheehan", 693], ["Stress", 701], ["Vulnerability", 708], ["Scale", 722], [",", 727], ["Sheehan", 729], ["Disability", 737], ["Scale", 748], ["and", 754], ["Clinical", 758], ["Global", 767], ["Impressions", 774], ["of", 786], ["Severity", 789], ["and", 798], ["Improvement", 802], ["Scales", 814], [".", 820], ["Good", 822], ["test", 827], ["-", 831], ["retest", 832], ["reliability", 839], [",", 850], ["internal", 852], ["consistency", 861], [",", 872], ["convergent", 874], ["and", 885], ["divergent", 889], ["validity", 899], ["were", 908], ["obtained", 913], [".", 921], ["The", 923], ["SPRINT", 927], ["was", 934], ["responsive", 938], ["to", 949], ["symptom", 952], ["change", 960], ["over", 967], ["time", 972], ["and", 977], ["correlated", 981], ["with", 992], ["comparable", 997], ["PTSD", 1008], ["symptom", 1013], ["measures", 1021], [".", 1029], ["In", 1031], ["victims", 1034], ["of", 1042], ["trauma", 1045], [",", 1051], ["a", 1053], ["score", 1055], ["of", 1061], ["14", 1064], ["-", 1066], ["17", 1067], ["was", 1070], ["associated", 1074], ["with", 1085], ["96", 1090], ["%", 1092], ["diagnostic", 1094], ["accuracy", 1105], [",", 1113], ["whereas", 1115], ["in", 1123], ["those", 1126], ["with", 1132], ["PTSD", 1137], [",", 1141], ["highest", 1143], ["efficiency", 1151], ["corresponded", 1162], ["to", 1175], ["a", 1178], ["range", 1180], ["of", 1186], ["11", 1189], ["-", 1191], ["13", 1192], [".", 1194], ["The", 1196], ["SPRINT", 1200], ["demonstrates", 1207], ["solid", 1220], ["psychometric", 1226], ["properties", 1239], ["and", 1250], ["can", 1254], ["serve", 1258], ["as", 1264], ["a", 1267], ["reliable", 1269], [",", 1277], ["valid", 1279], ["and", 1285], ["homogeneous", 1289], ["measure", 1301], ["of", 1309], ["PTSD", 1312], ["illness", 1317], ["severity", 1325], ["and", 1334], ["of", 1338], ["global", 1341], ["improvement", 1348], [".", 1359]]}
{"context": "Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1. Pulmonary arterial hypertension (PAH) in patients with NF1 is hypothesized to be secondary to an underlying vasculopathy. We describe the entity we term NF1-associated PAH (NF1-PAH) in four new patients and update the data on four previously published reports of patients with PAH and NF1. We performed genetic testing of the bone morphogenic protein receptor 2 (BMPR2) gene, which mutated in 70% of patients with familial PAH and approximately 25% of patients with idiopathic PAH. We report, for the first time, pathologic findings in the autopsy-obtained lung of one patient with NF1-PAH. Patients with NF1-PAH have a generally poor long-term prognosis. In four patients, we observed the mosaic pattern of lung attenuation on a CT scan of the chest, a radiographic finding that can be consistent with an underlying vasculopathy. No mutations or rearrangements in the BMPR2 gene were found. We observed complex plexiform lesions in the one available autopsy specimen. Similar lesions are a hallmark of plexogenic pulmonary arteriopathy and are associated with several severe types of PAH. (Plexiform lesions should not be confused with plexiform neurofibromas, which are distinctive tumors seen in NF1.) Our findings suggest that NF1 should be considered as being \"associated with PAH as outlined in the Revised Clinical Classification of Pulmonary Hypertension. Understanding the mechanism of PAH in NF1 may inform the pathogenesis of PAH, NF1-PAH itself, and other NF1-associated vasculopathies. The pulmonary vasculature should now be included among the arterial beds affected by NF1 vasculopathy.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "d0289ed00e594970840413f51ee34e30", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[243, 243], [299, 299], [22, 22], [236, 236], [4, 4], [73, 73], [270, 270], [33, 33]], "char_spans": [[1370, 1372], [1723, 1725], [134, 136], [1338, 1340], [26, 28], [424, 426], [1541, 1543], [194, 196]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["common", 36], ["disorder", 43], ["of", 52], ["dysregulated", 55], ["tissue", 68], ["growth", 75], ["secondary", 82], ["to", 92], ["mutations", 95], ["in", 105], ["the", 108], ["tumor", 112], ["suppressor", 118], ["gene", 129], ["NF1", 134], [".", 137], ["Pulmonary", 139], ["arterial", 149], ["hypertension", 158], ["(", 171], ["PAH", 172], [")", 175], ["in", 177], ["patients", 180], ["with", 189], ["NF1", 194], ["is", 198], ["hypothesized", 201], ["to", 214], ["be", 217], ["secondary", 220], ["to", 230], ["an", 233], ["underlying", 236], ["vasculopathy", 247], [".", 259], ["We", 261], ["describe", 264], ["the", 273], ["entity", 277], ["we", 284], ["term", 287], ["NF1-associated", 292], ["PAH", 307], ["(", 311], ["NF1-PAH", 312], [")", 319], ["in", 321], ["four", 324], ["new", 329], ["patients", 333], ["and", 342], ["update", 346], ["the", 353], ["data", 357], ["on", 362], ["four", 365], ["previously", 370], ["published", 381], ["reports", 391], ["of", 399], ["patients", 402], ["with", 411], ["PAH", 416], ["and", 420], ["NF1", 424], [".", 427], ["We", 429], ["performed", 432], ["genetic", 442], ["testing", 450], ["of", 458], ["the", 461], ["bone", 465], ["morphogenic", 470], ["protein", 482], ["receptor", 490], ["2", 499], ["(", 501], ["BMPR2", 502], [")", 507], ["gene", 509], [",", 513], ["which", 515], ["mutated", 521], ["in", 529], ["70", 532], ["%", 534], ["of", 536], ["patients", 539], ["with", 548], ["familial", 553], ["PAH", 562], ["and", 566], ["approximately", 570], ["25", 584], ["%", 586], ["of", 588], ["patients", 591], ["with", 600], ["idiopathic", 605], ["PAH", 616], [".", 619], ["We", 621], ["report", 624], [",", 630], ["for", 632], ["the", 636], ["first", 640], ["time", 646], [",", 650], ["pathologic", 652], ["findings", 663], ["in", 672], ["the", 675], ["autopsy", 679], ["-", 686], ["obtained", 687], ["lung", 696], ["of", 701], ["one", 704], ["patient", 708], ["with", 716], ["NF1-PAH", 721], [".", 728], ["Patients", 730], ["with", 739], ["NF1-PAH", 744], ["have", 752], ["a", 757], ["generally", 759], ["poor", 769], ["long", 774], ["-", 778], ["term", 779], ["prognosis", 784], [".", 793], ["In", 795], ["four", 798], ["patients", 803], [",", 811], ["we", 813], ["observed", 816], ["the", 825], ["mosaic", 829], ["pattern", 836], ["of", 844], ["lung", 847], ["attenuation", 852], ["on", 864], ["a", 867], ["CT", 869], ["scan", 872], ["of", 877], ["the", 880], ["chest", 884], [",", 889], ["a", 891], ["radiographic", 893], ["finding", 906], ["that", 914], ["can", 919], ["be", 923], ["consistent", 926], ["with", 937], ["an", 942], ["underlying", 945], ["vasculopathy", 956], [".", 968], ["No", 970], ["mutations", 973], ["or", 983], ["rearrangements", 986], ["in", 1001], ["the", 1004], ["BMPR2", 1008], ["gene", 1014], ["were", 1019], ["found", 1024], [".", 1029], ["We", 1031], ["observed", 1034], ["complex", 1043], ["plexiform", 1051], ["lesions", 1061], ["in", 1069], ["the", 1072], ["one", 1076], ["available", 1080], ["autopsy", 1090], ["specimen", 1098], [".", 1106], ["Similar", 1108], ["lesions", 1116], ["are", 1124], ["a", 1128], ["hallmark", 1130], ["of", 1139], ["plexogenic", 1142], ["pulmonary", 1153], ["arteriopathy", 1163], ["and", 1176], ["are", 1180], ["associated", 1184], ["with", 1195], ["several", 1200], ["severe", 1208], ["types", 1215], ["of", 1221], ["PAH", 1224], [".", 1227], ["(", 1229], ["Plexiform", 1230], ["lesions", 1240], ["should", 1248], ["not", 1255], ["be", 1259], ["confused", 1262], ["with", 1271], ["plexiform", 1276], ["neurofibromas", 1286], [",", 1299], ["which", 1301], ["are", 1307], ["distinctive", 1311], ["tumors", 1323], ["seen", 1330], ["in", 1335], ["NF1", 1338], [".", 1341], [")", 1342], ["Our", 1344], ["findings", 1348], ["suggest", 1357], ["that", 1365], ["NF1", 1370], ["should", 1374], ["be", 1381], ["considered", 1384], ["as", 1395], ["being", 1398], ["\"", 1404], ["associated", 1405], ["with", 1416], ["PAH", 1421], ["as", 1425], ["outlined", 1428], ["in", 1437], ["the", 1440], ["Revised", 1444], ["Clinical", 1452], ["Classification", 1461], ["of", 1476], ["Pulmonary", 1479], ["Hypertension", 1489], [".", 1501], ["Understanding", 1503], ["the", 1517], ["mechanism", 1521], ["of", 1531], ["PAH", 1534], ["in", 1538], ["NF1", 1541], ["may", 1545], ["inform", 1549], ["the", 1556], ["pathogenesis", 1560], ["of", 1573], ["PAH", 1576], [",", 1579], ["NF1-PAH", 1581], ["itself", 1589], [",", 1595], ["and", 1597], ["other", 1601], ["NF1-associated", 1607], ["vasculopathies", 1622], [".", 1636], ["The", 1638], ["pulmonary", 1642], ["vasculature", 1652], ["should", 1664], ["now", 1671], ["be", 1675], ["included", 1678], ["among", 1687], ["the", 1693], ["arterial", 1697], ["beds", 1706], ["affected", 1711], ["by", 1720], ["NF1", 1723], ["vasculopathy", 1727], [".", 1739]]}
{"context": "Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder, caused by an expansion of a CTG triplet repeat in the DMPK gene. The aims of the present study were to classify a cohort of children with DM1, to describe their neuropsychiatric problems and cognitive level, to estimate the size of the CTG expansion, and to correlate the molecular findings with the neuropsychiatric problems. Fifty-seven children and adolescents (26 females; 31 males) with DM1 (CTG repeats > 40) were included in the study. The following instruments were used: Autism Diagnostic Interview-Revised (ADI-R), 5-15, Griffiths Mental Development Scales, and the Wechsler Scales. Based on age at onset and presenting symptoms, the children were divided into four DM1 groups; severe congenital (n = 19), mild congenital (n = 18), childhood (n = 18), and classical DM1 (n = 2). Forty-nine percent had an autism spectrum disorder (ASD) and autistic disorder was the most common diagnosis present in 35% of the subjects. Eighty-six percent of the individuals with DM1 had mental retardation (MR), most of them moderate or severe MR. ASD was significantly correlated with the DM1 form; the more severe the form of DM1, the higher the frequency of ASD. The frequency of ASD increased with increasing CTG repeat expansions. ASD and/or other neuropsychiatric disorders such as attention deficit hyperactivity disorder, and Tourette's disorder were found in 54% of the total DM1 group. In conclusion, awareness of ASD comorbidity in DM1 is essential. Further studies are warranted to elucidate the molecular etiology causing neurodevelopmental symptoms such as ASD and MR in DM1.", "qas": [{"question": "How is myotonic dystrophy inherited?", "answers": ["autosomal dominant"], "qid": "d33ad3bcc29749269c3aa087a59610af", "question_tokens": [["How", 0], ["is", 4], ["myotonic", 7], ["dystrophy", 16], ["inherited", 26], ["?", 35]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[9, 10]], "char_spans": [[38, 55]]}]}], "context_tokens": [["Myotonic", 0], ["dystrophy", 9], ["type", 19], ["1", 24], ["(", 26], ["DM1", 27], [")", 30], ["is", 32], ["an", 35], ["autosomal", 38], ["dominant", 48], ["disorder", 57], [",", 65], ["caused", 67], ["by", 74], ["an", 77], ["expansion", 80], ["of", 90], ["a", 93], ["CTG", 95], ["triplet", 99], ["repeat", 107], ["in", 114], ["the", 117], ["DMPK", 121], ["gene", 126], [".", 130], ["The", 132], ["aims", 136], ["of", 141], ["the", 144], ["present", 148], ["study", 156], ["were", 162], ["to", 167], ["classify", 170], ["a", 179], ["cohort", 181], ["of", 188], ["children", 191], ["with", 200], ["DM1", 205], [",", 208], ["to", 210], ["describe", 213], ["their", 222], ["neuropsychiatric", 228], ["problems", 245], ["and", 254], ["cognitive", 258], ["level", 268], [",", 273], ["to", 275], ["estimate", 278], ["the", 287], ["size", 291], ["of", 296], ["the", 299], ["CTG", 303], ["expansion", 307], [",", 316], ["and", 318], ["to", 322], ["correlate", 325], ["the", 335], ["molecular", 339], ["findings", 349], ["with", 358], ["the", 363], ["neuropsychiatric", 367], ["problems", 384], [".", 392], ["Fifty", 394], ["-", 399], ["seven", 400], ["children", 406], ["and", 415], ["adolescents", 419], ["(", 431], ["26", 432], ["females", 435], [";", 442], ["31", 444], ["males", 447], [")", 452], ["with", 454], ["DM1", 459], ["(", 463], ["CTG", 464], ["repeats", 468], [">", 476], ["40", 478], [")", 480], ["were", 482], ["included", 487], ["in", 496], ["the", 499], ["study", 503], [".", 508], ["The", 510], ["following", 514], ["instruments", 524], ["were", 536], ["used", 541], [":", 545], ["Autism", 547], ["Diagnostic", 554], ["Interview", 565], ["-", 574], ["Revised", 575], ["(", 583], ["ADI", 584], ["-", 587], ["R", 588], [")", 589], [",", 590], ["5", 592], ["-", 593], ["15", 594], [",", 596], ["Griffiths", 598], ["Mental", 608], ["Development", 615], ["Scales", 627], [",", 633], ["and", 635], ["the", 639], ["Wechsler", 643], ["Scales", 652], [".", 658], ["Based", 660], ["on", 666], ["age", 669], ["at", 673], ["onset", 676], ["and", 682], ["presenting", 686], ["symptoms", 697], [",", 705], ["the", 707], ["children", 711], ["were", 720], ["divided", 725], ["into", 733], ["four", 738], ["DM1", 743], ["groups", 747], [";", 753], ["severe", 755], ["congenital", 762], ["(", 773], ["n", 774], ["=", 776], ["19", 778], [")", 780], [",", 781], ["mild", 783], ["congenital", 788], ["(", 799], ["n", 800], ["=", 802], ["18", 804], [")", 806], [",", 807], ["childhood", 809], ["(", 819], ["n", 820], ["=", 822], ["18", 824], [")", 826], [",", 827], ["and", 829], ["classical", 833], ["DM1", 843], ["(", 847], ["n", 848], ["=", 850], ["2", 852], [")", 853], [".", 854], ["Forty", 856], ["-", 861], ["nine", 862], ["percent", 867], ["had", 875], ["an", 879], ["autism", 882], ["spectrum", 889], ["disorder", 898], ["(", 907], ["ASD", 908], [")", 911], ["and", 913], ["autistic", 917], ["disorder", 926], ["was", 935], ["the", 939], ["most", 943], ["common", 948], ["diagnosis", 955], ["present", 965], ["in", 973], ["35", 976], ["%", 978], ["of", 980], ["the", 983], ["subjects", 987], [".", 995], ["Eighty", 997], ["-", 1003], ["six", 1004], ["percent", 1008], ["of", 1016], ["the", 1019], ["individuals", 1023], ["with", 1035], ["DM1", 1040], ["had", 1044], ["mental", 1048], ["retardation", 1055], ["(", 1067], ["MR", 1068], [")", 1070], [",", 1071], ["most", 1073], ["of", 1078], ["them", 1081], ["moderate", 1086], ["or", 1095], ["severe", 1098], ["MR", 1105], [".", 1107], ["ASD", 1109], ["was", 1113], ["significantly", 1117], ["correlated", 1131], ["with", 1142], ["the", 1147], ["DM1", 1151], ["form", 1155], [";", 1159], ["the", 1161], ["more", 1165], ["severe", 1170], ["the", 1177], ["form", 1181], ["of", 1186], ["DM1", 1189], [",", 1192], ["the", 1194], ["higher", 1198], ["the", 1205], ["frequency", 1209], ["of", 1219], ["ASD", 1222], [".", 1225], ["The", 1227], ["frequency", 1231], ["of", 1241], ["ASD", 1244], ["increased", 1248], ["with", 1258], ["increasing", 1263], ["CTG", 1274], ["repeat", 1278], ["expansions", 1285], [".", 1295], ["ASD", 1297], ["and/or", 1301], ["other", 1308], ["neuropsychiatric", 1314], ["disorders", 1331], ["such", 1341], ["as", 1346], ["attention", 1349], ["deficit", 1359], ["hyperactivity", 1367], ["disorder", 1381], [",", 1389], ["and", 1391], ["Tourette", 1395], ["'s", 1403], ["disorder", 1406], ["were", 1415], ["found", 1420], ["in", 1426], ["54", 1429], ["%", 1431], ["of", 1433], ["the", 1436], ["total", 1440], ["DM1", 1446], ["group", 1450], [".", 1455], ["In", 1457], ["conclusion", 1460], [",", 1470], ["awareness", 1472], ["of", 1482], ["ASD", 1485], ["comorbidity", 1489], ["in", 1501], ["DM1", 1504], ["is", 1508], ["essential", 1511], [".", 1520], ["Further", 1522], ["studies", 1530], ["are", 1538], ["warranted", 1542], ["to", 1552], ["elucidate", 1555], ["the", 1565], ["molecular", 1569], ["etiology", 1579], ["causing", 1588], ["neurodevelopmental", 1596], ["symptoms", 1615], ["such", 1624], ["as", 1629], ["ASD", 1632], ["and", 1636], ["MR", 1640], ["in", 1643], ["DM1", 1646], [".", 1649]]}
{"context": "The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells. We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma. A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg. Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematologic toxic effects. The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an additional 20% and 15% of patients in the respective groups had a partial response with lymphocytosis. The response was independent of clinical and genomic risk factors present before treatment, including advanced-stage disease, the number of previous therapies, and the 17p13.1 deletion. At 26 months, the estimated progression-free survival rate was 75% and the rate of overall survival was 83%. Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01105247.).", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "d7642cf38cf1490688ccfa02b942b4ab", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[281, 281], [129, 129], [71, 71]], "char_spans": [[1510, 1518], [702, 710], [416, 424]]}]}], "context_tokens": [["The", 0], ["treatment", 4], ["of", 14], ["relapsed", 17], ["chronic", 26], ["lymphocytic", 34], ["leukemia", 46], ["(", 55], ["CLL", 56], [")", 59], ["has", 61], ["resulted", 65], ["in", 74], ["few", 77], ["durable", 81], ["remissions", 89], [".", 99], ["Bruton", 101], ["'s", 107], ["tyrosine", 110], ["kinase", 119], ["(", 126], ["BTK", 127], [")", 130], [",", 131], ["an", 133], ["essential", 136], ["component", 146], ["of", 156], ["B", 159], ["-", 160], ["cell", 161], ["-", 165], ["receptor", 166], ["signaling", 175], [",", 184], ["mediates", 186], ["interactions", 195], ["with", 208], ["the", 213], ["tumor", 217], ["microenvironment", 223], ["and", 240], ["promotes", 244], ["the", 253], ["survival", 257], ["and", 266], ["proliferation", 270], ["of", 284], ["CLL", 287], ["cells", 291], [".", 296], ["We", 298], ["conducted", 301], ["a", 311], ["phase", 313], ["1b-2", 319], ["multicenter", 324], ["study", 336], ["to", 342], ["assess", 345], ["the", 352], ["safety", 356], [",", 362], ["efficacy", 364], [",", 372], ["pharmacokinetics", 374], [",", 390], ["and", 392], ["pharmacodynamics", 396], ["of", 413], ["ibrutinib", 416], ["(", 426], ["PCI-32765", 427], [")", 436], [",", 437], ["a", 439], ["first", 441], ["-", 446], ["in", 447], ["-", 449], ["class", 450], [",", 455], ["oral", 457], ["covalent", 462], ["inhibitor", 471], ["of", 481], ["BTK", 484], ["designed", 488], ["for", 497], ["treatment", 501], ["of", 511], ["B", 514], ["-", 515], ["cell", 516], ["cancers", 521], [",", 528], ["in", 530], ["patients", 533], ["with", 542], ["relapsed", 547], ["or", 556], ["refractory", 559], ["CLL", 570], ["or", 574], ["small", 577], ["lymphocytic", 583], ["lymphoma", 595], [".", 603], ["A", 605], ["total", 607], ["of", 613], ["85", 616], ["patients", 619], [",", 627], ["the", 629], ["majority", 633], ["of", 642], ["whom", 645], ["were", 650], ["considered", 655], ["to", 666], ["have", 669], ["high", 674], ["-", 678], ["risk", 679], ["disease", 684], [",", 691], ["received", 693], ["ibrutinib", 702], ["orally", 712], ["once", 719], ["daily", 724], [";", 729], ["51", 731], ["received", 734], ["420", 743], ["mg", 747], [",", 749], ["and", 751], ["34", 755], ["received", 758], ["840", 767], ["mg", 771], [".", 773], ["Toxic", 775], ["effects", 781], ["were", 789], ["predominantly", 794], ["grade", 808], ["1", 814], ["or", 816], ["2", 819], ["and", 821], ["included", 825], ["transient", 834], ["diarrhea", 844], [",", 852], ["fatigue", 854], [",", 861], ["and", 863], ["upper", 867], ["respiratory", 873], ["tract", 885], ["infection", 891], [";", 900], ["thus", 902], [",", 906], ["patients", 908], ["could", 917], ["receive", 923], ["extended", 931], ["treatment", 940], ["with", 950], ["minimal", 955], ["hematologic", 963], ["toxic", 975], ["effects", 981], [".", 988], ["The", 990], ["overall", 994], ["response", 1002], ["rate", 1011], ["was", 1016], ["the", 1020], ["same", 1024], ["in", 1029], ["the", 1032], ["group", 1036], ["that", 1042], ["received", 1047], ["420", 1056], ["mg", 1060], ["and", 1063], ["the", 1067], ["group", 1071], ["that", 1077], ["received", 1082], ["840", 1091], ["mg", 1095], ["(", 1098], ["71", 1099], ["%", 1101], [")", 1102], [",", 1103], ["and", 1105], ["an", 1109], ["additional", 1112], ["20", 1123], ["%", 1125], ["and", 1127], ["15", 1131], ["%", 1133], ["of", 1135], ["patients", 1138], ["in", 1147], ["the", 1150], ["respective", 1154], ["groups", 1165], ["had", 1172], ["a", 1176], ["partial", 1178], ["response", 1186], ["with", 1195], ["lymphocytosis", 1200], [".", 1213], ["The", 1215], ["response", 1219], ["was", 1228], ["independent", 1232], ["of", 1244], ["clinical", 1247], ["and", 1256], ["genomic", 1260], ["risk", 1268], ["factors", 1273], ["present", 1281], ["before", 1289], ["treatment", 1296], [",", 1305], ["including", 1307], ["advanced", 1317], ["-", 1325], ["stage", 1326], ["disease", 1332], [",", 1339], ["the", 1341], ["number", 1345], ["of", 1352], ["previous", 1355], ["therapies", 1364], [",", 1373], ["and", 1375], ["the", 1379], ["17p13.1", 1383], ["deletion", 1391], [".", 1399], ["At", 1401], ["26", 1404], ["months", 1407], [",", 1413], ["the", 1415], ["estimated", 1419], ["progression", 1429], ["-", 1440], ["free", 1441], ["survival", 1446], ["rate", 1455], ["was", 1460], ["75", 1464], ["%", 1466], ["and", 1468], ["the", 1472], ["rate", 1476], ["of", 1481], ["overall", 1484], ["survival", 1492], ["was", 1501], ["83", 1505], ["%", 1507], [".", 1508], ["Ibrutinib", 1510], ["was", 1520], ["associated", 1524], ["with", 1535], ["a", 1540], ["high", 1542], ["frequency", 1547], ["of", 1557], ["durable", 1560], ["remissions", 1568], ["in", 1579], ["patients", 1582], ["with", 1591], ["relapsed", 1596], ["or", 1605], ["refractory", 1608], ["CLL", 1619], ["and", 1623], ["small", 1627], ["lymphocytic", 1633], ["lymphoma", 1645], [",", 1653], ["including", 1655], ["patients", 1665], ["with", 1674], ["high", 1679], ["-", 1683], ["risk", 1684], ["genetic", 1689], ["lesions", 1697], [".", 1704], ["(", 1706], ["Funded", 1707], ["by", 1714], ["Pharmacyclics", 1717], ["and", 1731], ["others", 1735], [";", 1741], ["ClinicalTrials.gov", 1743], ["number", 1762], [",", 1768], ["NCT01105247", 1770], [".", 1781], [")", 1782], [".", 1783]]}
{"context": "The histone variant H2AZ is incorporated preferentially at specific locations in chromatin to modulate chromosome functions. In Saccharomyces cerevisiae, deposition of histone H2AZ is mediated by the multiprotein SWR1 complex, which catalyzes ATP-dependent exchange of nucleosomal histone H2A for H2AZ. Here, we define interactions between SWR1 components and H2AZ, revealing a link between the ATPase domain of Swr1 and three subunits required for the binding of H2AZ. We discovered that Swc2 binds directly to and is essential for transfer of H2AZ. Swc6 and Arp6 are necessary for the association of Swc2 and for nucleosome binding, whereas other subunits, Swc5 and Yaf9, are required for H2AZ transfer but neither H2AZ nor nucleosome binding. Finally, the C-terminal alpha-helix of H2AZ is crucial for its recognition by SWR1. These findings provide insight on the initial events of histone exchange.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "62476e02ad284ed2b1d1125d42c416a2", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[143, 143], [52, 52], [65, 65], [30, 30]], "char_spans": [[824, 827], [340, 343], [412, 415], [213, 216]]}]}], "context_tokens": [["The", 0], ["histone", 4], ["variant", 12], ["H2AZ", 20], ["is", 25], ["incorporated", 28], ["preferentially", 41], ["at", 56], ["specific", 59], ["locations", 68], ["in", 78], ["chromatin", 81], ["to", 91], ["modulate", 94], ["chromosome", 103], ["functions", 114], [".", 123], ["In", 125], ["Saccharomyces", 128], ["cerevisiae", 142], [",", 152], ["deposition", 154], ["of", 165], ["histone", 168], ["H2AZ", 176], ["is", 181], ["mediated", 184], ["by", 193], ["the", 196], ["multiprotein", 200], ["SWR1", 213], ["complex", 218], [",", 225], ["which", 227], ["catalyzes", 233], ["ATP", 243], ["-", 246], ["dependent", 247], ["exchange", 257], ["of", 266], ["nucleosomal", 269], ["histone", 281], ["H2A", 289], ["for", 293], ["H2AZ", 297], [".", 301], ["Here", 303], [",", 307], ["we", 309], ["define", 312], ["interactions", 319], ["between", 332], ["SWR1", 340], ["components", 345], ["and", 356], ["H2AZ", 360], [",", 364], ["revealing", 366], ["a", 376], ["link", 378], ["between", 383], ["the", 391], ["ATPase", 395], ["domain", 402], ["of", 409], ["Swr1", 412], ["and", 417], ["three", 421], ["subunits", 427], ["required", 436], ["for", 445], ["the", 449], ["binding", 453], ["of", 461], ["H2AZ", 464], [".", 468], ["We", 470], ["discovered", 473], ["that", 484], ["Swc2", 489], ["binds", 494], ["directly", 500], ["to", 509], ["and", 512], ["is", 516], ["essential", 519], ["for", 529], ["transfer", 533], ["of", 542], ["H2AZ", 545], [".", 549], ["Swc6", 551], ["and", 556], ["Arp6", 560], ["are", 565], ["necessary", 569], ["for", 579], ["the", 583], ["association", 587], ["of", 599], ["Swc2", 602], ["and", 607], ["for", 611], ["nucleosome", 615], ["binding", 626], [",", 633], ["whereas", 635], ["other", 643], ["subunits", 649], [",", 657], ["Swc5", 659], ["and", 664], ["Yaf9", 668], [",", 672], ["are", 674], ["required", 678], ["for", 687], ["H2AZ", 691], ["transfer", 696], ["but", 705], ["neither", 709], ["H2AZ", 717], ["nor", 722], ["nucleosome", 726], ["binding", 737], [".", 744], ["Finally", 746], [",", 753], ["the", 755], ["C", 759], ["-", 760], ["terminal", 761], ["alpha", 770], ["-", 775], ["helix", 776], ["of", 782], ["H2AZ", 785], ["is", 790], ["crucial", 793], ["for", 801], ["its", 805], ["recognition", 809], ["by", 821], ["SWR1", 824], [".", 828], ["These", 830], ["findings", 836], ["provide", 845], ["insight", 853], ["on", 861], ["the", 864], ["initial", 868], ["events", 876], ["of", 883], ["histone", 886], ["exchange", 894], [".", 902]]}
{"context": "The overlap between symptoms of PTSD and MDD is substantial. PTSD symptoms arise after a traumatic experience and the trauma is present in all of the diagnostic clusters. In individuals who have experienced a trauma a long time before, it is difficult to establish the exact moment of onset of their symptoms in relation to the trauma suffered. We proposed to raise awareness among operators who may encounter this problem, with the aim of providing them with valuable help in order to achieve a correct differential diagnosis. A sample of subjects suffering from PTSD without comorbidity was assessed to confirm the diagnosis and the severity of post-traumatic symptoms. The Kruskal-Wallis test was used to compare any modifications in the parameters analyzed through the Davidson Trauma Scale with the presence and severity of depressive symptoms as evaluated by the Hamilton-D scale. Half of the PSTD patients recruited showed values of HAM-D > 18, although an active Major Depressive Episode was clinically excluded. Symptom of \"numbing\", despite being different from the apathy experienced in depression, is identified as a depressive symptom by the HAM-D. Giving prevalence to depressive symptoms may be misleading for diagnosis and may ultimately result in inappropriate treatment.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "dbf89c9e9b394c7eae08a4dc8b5b7ce5", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[99, 99], [11, 11], [5, 5]], "char_spans": [[564, 567], [61, 64], [32, 35]]}]}], "context_tokens": [["The", 0], ["overlap", 4], ["between", 12], ["symptoms", 20], ["of", 29], ["PTSD", 32], ["and", 37], ["MDD", 41], ["is", 45], ["substantial", 48], [".", 59], ["PTSD", 61], ["symptoms", 66], ["arise", 75], ["after", 81], ["a", 87], ["traumatic", 89], ["experience", 99], ["and", 110], ["the", 114], ["trauma", 118], ["is", 125], ["present", 128], ["in", 136], ["all", 139], ["of", 143], ["the", 146], ["diagnostic", 150], ["clusters", 161], [".", 169], ["In", 171], ["individuals", 174], ["who", 186], ["have", 190], ["experienced", 195], ["a", 207], ["trauma", 209], ["a", 216], ["long", 218], ["time", 223], ["before", 228], [",", 234], ["it", 236], ["is", 239], ["difficult", 242], ["to", 252], ["establish", 255], ["the", 265], ["exact", 269], ["moment", 275], ["of", 282], ["onset", 285], ["of", 291], ["their", 294], ["symptoms", 300], ["in", 309], ["relation", 312], ["to", 321], ["the", 324], ["trauma", 328], ["suffered", 335], [".", 343], ["We", 345], ["proposed", 348], ["to", 357], ["raise", 360], ["awareness", 366], ["among", 376], ["operators", 382], ["who", 392], ["may", 396], ["encounter", 400], ["this", 410], ["problem", 415], [",", 422], ["with", 424], ["the", 429], ["aim", 433], ["of", 437], ["providing", 440], ["them", 450], ["with", 455], ["valuable", 460], ["help", 469], ["in", 474], ["order", 477], ["to", 483], ["achieve", 486], ["a", 494], ["correct", 496], ["differential", 504], ["diagnosis", 517], [".", 526], ["A", 528], ["sample", 530], ["of", 537], ["subjects", 540], ["suffering", 549], ["from", 559], ["PTSD", 564], ["without", 569], ["comorbidity", 577], ["was", 589], ["assessed", 593], ["to", 602], ["confirm", 605], ["the", 613], ["diagnosis", 617], ["and", 627], ["the", 631], ["severity", 635], ["of", 644], ["post", 647], ["-", 651], ["traumatic", 652], ["symptoms", 662], [".", 670], ["The", 672], ["Kruskal", 676], ["-", 683], ["Wallis", 684], ["test", 691], ["was", 696], ["used", 700], ["to", 705], ["compare", 708], ["any", 716], ["modifications", 720], ["in", 734], ["the", 737], ["parameters", 741], ["analyzed", 752], ["through", 761], ["the", 769], ["Davidson", 773], ["Trauma", 782], ["Scale", 789], ["with", 795], ["the", 800], ["presence", 804], ["and", 813], ["severity", 817], ["of", 826], ["depressive", 829], ["symptoms", 840], ["as", 849], ["evaluated", 852], ["by", 862], ["the", 865], ["Hamilton", 869], ["-", 877], ["D", 878], ["scale", 880], [".", 885], ["Half", 887], ["of", 892], ["the", 895], ["PSTD", 899], ["patients", 904], ["recruited", 913], ["showed", 923], ["values", 930], ["of", 937], ["HAM", 940], ["-", 943], ["D", 944], [">", 946], ["18", 948], [",", 950], ["although", 952], ["an", 961], ["active", 964], ["Major", 971], ["Depressive", 977], ["Episode", 988], ["was", 996], ["clinically", 1000], ["excluded", 1011], [".", 1019], ["Symptom", 1021], ["of", 1029], ["\"", 1032], ["numbing", 1033], ["\"", 1040], [",", 1041], ["despite", 1043], ["being", 1051], ["different", 1057], ["from", 1067], ["the", 1072], ["apathy", 1076], ["experienced", 1083], ["in", 1095], ["depression", 1098], [",", 1108], ["is", 1110], ["identified", 1113], ["as", 1124], ["a", 1127], ["depressive", 1129], ["symptom", 1140], ["by", 1148], ["the", 1151], ["HAM", 1155], ["-", 1158], ["D.", 1159], ["Giving", 1162], ["prevalence", 1169], ["to", 1180], ["depressive", 1183], ["symptoms", 1194], ["may", 1203], ["be", 1207], ["misleading", 1210], ["for", 1221], ["diagnosis", 1225], ["and", 1235], ["may", 1239], ["ultimately", 1243], ["result", 1254], ["in", 1261], ["inappropriate", 1264], ["treatment", 1278], [".", 1287]]}
{"context": "Activity-dependent modifications of excitatory synapses contribute to synaptic maturation and plasticity, and are critical for learning and memory. Consequently, impairments in synapse formation or synaptic transmission are thought to be responsible for several types of mental disabilities. BRAG1 is a guanine nucleotide exchange factor for the small GTP-binding protein Arf6 that localizes to the postsynaptic density of excitatory synapses. Mutations in BRAG1 have been identified in families with X-linked intellectual disability (XLID). These mutations mapped to either the catalytic domain or an IQ-like motif; however, the pathophysiological basis of these mutations remains unknown. Here, we show that the BRAG1 IQ motif binds apo-calmodulin (CaM), and that calcium-induced CaM release triggers a reversible conformational change in human BRAG1. We demonstrate that BRAG1 activity, stimulated by activation of NMDA-sensitive glutamate receptors, depresses AMPA receptor (AMPA-R)-mediated transmission via JNK-mediated synaptic removal of GluA1-containing AMPA-Rs in rat hippocampal neurons. Importantly, a BRAG1 mutant that fails to activate Arf6 also fails to depress AMPA-R signaling, indicating that Arf6 activity is necessary for this process. Conversely, a mutation in the BRAG1 IQ-like motif that impairs CaM binding results in hyperactivation of Arf6 signaling and constitutive depression of AMPA transmission. Our findings reveal a role for BRAG1 in response to neuronal activity with possible clinical relevance to nonsyndromic XLID.", "qas": [{"question": "Which disease is linked to mutations within BRAG1?", "answers": ["X-linked intellectual disability"], "qid": "8c77296f28c84ecf8c27e74782380f94", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["linked", 17], ["to", 24], ["mutations", 27], ["within", 37], ["BRAG1", 44], ["?", 49]], "detected_answers": [{"text": "X-linked intellectual disability", "token_spans": [[77, 81]], "char_spans": [[501, 532]]}]}], "context_tokens": [["Activity", 0], ["-", 8], ["dependent", 9], ["modifications", 19], ["of", 33], ["excitatory", 36], ["synapses", 47], ["contribute", 56], ["to", 67], ["synaptic", 70], ["maturation", 79], ["and", 90], ["plasticity", 94], [",", 104], ["and", 106], ["are", 110], ["critical", 114], ["for", 123], ["learning", 127], ["and", 136], ["memory", 140], [".", 146], ["Consequently", 148], [",", 160], ["impairments", 162], ["in", 174], ["synapse", 177], ["formation", 185], ["or", 195], ["synaptic", 198], ["transmission", 207], ["are", 220], ["thought", 224], ["to", 232], ["be", 235], ["responsible", 238], ["for", 250], ["several", 254], ["types", 262], ["of", 268], ["mental", 271], ["disabilities", 278], [".", 290], ["BRAG1", 292], ["is", 298], ["a", 301], ["guanine", 303], ["nucleotide", 311], ["exchange", 322], ["factor", 331], ["for", 338], ["the", 342], ["small", 346], ["GTP", 352], ["-", 355], ["binding", 356], ["protein", 364], ["Arf6", 372], ["that", 377], ["localizes", 382], ["to", 392], ["the", 395], ["postsynaptic", 399], ["density", 412], ["of", 420], ["excitatory", 423], ["synapses", 434], [".", 442], ["Mutations", 444], ["in", 454], ["BRAG1", 457], ["have", 463], ["been", 468], ["identified", 473], ["in", 484], ["families", 487], ["with", 496], ["X", 501], ["-", 502], ["linked", 503], ["intellectual", 510], ["disability", 523], ["(", 534], ["XLID", 535], [")", 539], [".", 540], ["These", 542], ["mutations", 548], ["mapped", 558], ["to", 565], ["either", 568], ["the", 575], ["catalytic", 579], ["domain", 589], ["or", 596], ["an", 599], ["IQ", 602], ["-", 604], ["like", 605], ["motif", 610], [";", 615], ["however", 617], [",", 624], ["the", 626], ["pathophysiological", 630], ["basis", 649], ["of", 655], ["these", 658], ["mutations", 664], ["remains", 674], ["unknown", 682], [".", 689], ["Here", 691], [",", 695], ["we", 697], ["show", 700], ["that", 705], ["the", 710], ["BRAG1", 714], ["IQ", 720], ["motif", 723], ["binds", 729], ["apo", 735], ["-", 738], ["calmodulin", 739], ["(", 750], ["CaM", 751], [")", 754], [",", 755], ["and", 757], ["that", 761], ["calcium", 766], ["-", 773], ["induced", 774], ["CaM", 782], ["release", 786], ["triggers", 794], ["a", 803], ["reversible", 805], ["conformational", 816], ["change", 831], ["in", 838], ["human", 841], ["BRAG1", 847], [".", 852], ["We", 854], ["demonstrate", 857], ["that", 869], ["BRAG1", 874], ["activity", 880], [",", 888], ["stimulated", 890], ["by", 901], ["activation", 904], ["of", 915], ["NMDA", 918], ["-", 922], ["sensitive", 923], ["glutamate", 933], ["receptors", 943], [",", 952], ["depresses", 954], ["AMPA", 964], ["receptor", 969], ["(", 978], ["AMPA", 979], ["-", 983], ["R)-mediated", 984], ["transmission", 996], ["via", 1009], ["JNK", 1013], ["-", 1016], ["mediated", 1017], ["synaptic", 1026], ["removal", 1035], ["of", 1043], ["GluA1-containing", 1046], ["AMPA", 1063], ["-", 1067], ["Rs", 1068], ["in", 1071], ["rat", 1074], ["hippocampal", 1078], ["neurons", 1090], [".", 1097], ["Importantly", 1099], [",", 1110], ["a", 1112], ["BRAG1", 1114], ["mutant", 1120], ["that", 1127], ["fails", 1132], ["to", 1138], ["activate", 1141], ["Arf6", 1150], ["also", 1155], ["fails", 1160], ["to", 1166], ["depress", 1169], ["AMPA", 1177], ["-", 1181], ["R", 1182], ["signaling", 1184], [",", 1193], ["indicating", 1195], ["that", 1206], ["Arf6", 1211], ["activity", 1216], ["is", 1225], ["necessary", 1228], ["for", 1238], ["this", 1242], ["process", 1247], [".", 1254], ["Conversely", 1256], [",", 1266], ["a", 1268], ["mutation", 1270], ["in", 1279], ["the", 1282], ["BRAG1", 1286], ["IQ", 1292], ["-", 1294], ["like", 1295], ["motif", 1300], ["that", 1306], ["impairs", 1311], ["CaM", 1319], ["binding", 1323], ["results", 1331], ["in", 1339], ["hyperactivation", 1342], ["of", 1358], ["Arf6", 1361], ["signaling", 1366], ["and", 1376], ["constitutive", 1380], ["depression", 1393], ["of", 1404], ["AMPA", 1407], ["transmission", 1412], [".", 1424], ["Our", 1426], ["findings", 1430], ["reveal", 1439], ["a", 1446], ["role", 1448], ["for", 1453], ["BRAG1", 1457], ["in", 1463], ["response", 1466], ["to", 1475], ["neuronal", 1478], ["activity", 1487], ["with", 1496], ["possible", 1501], ["clinical", 1510], ["relevance", 1519], ["to", 1529], ["nonsyndromic", 1532], ["XLID", 1545], [".", 1549]]}
{"context": "Quantitative real-time PCR (QPCR) has emerged as an accurate and valuable tool in profiling gene expression levels. One of its many advantages is a lower detection limit compared to other methods of gene expression profiling while using smaller amounts of input for each assay. Automated qPCR setup has improved this field by allowing for greater reproducibility. Its convenient and rapid setup allows for high-throughput experiments, enabling the profiling of many different genes simultaneously in each experiment. This method along with internal plate controls also reduces experimental variables common to other techniques. We recently developed a qPCR assay for profiling of pre-microRNAs (pre-miRNAs) using a set of 186 primer pairs. MicroRNAs have emerged as a novel class of small, non-coding RNAs with the ability to regulate many mRNA targets at the post-transcriptional level. These small RNAs are first transcribed by RNA polymerase II as a primary miRNA (pri-miRNA) transcript, which is then cleaved into the precursor miRNA (pre-miRNA). Pre-miRNAs are exported to the cytoplasm where Dicer cleaves the hairpin loop to yield mature miRNAs. Increases in miRNA levels can be observed at both the precursor and mature miRNA levels and profiling of both of these forms can be useful. There are several commercially available assays for mature miRNAs; however, their high cost may deter researchers from this profiling technique. Here, we discuss a cost-effective, reliable, SYBR-based qPCR method of profiling pre-miRNAs. Changes in pre-miRNA levels often reflect mature miRNA changes and can be a useful indicator of mature miRNA expression. However, simultaneous profiling of both pre-miRNAs and mature miRNAs may be optimal as they can contribute nonredundant information and provide insight into microRNA processing. Furthermore, the technique described here can be expanded to encompass the profiling of other library sets for specific pathways or pathogens.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "d5012159612c4b0b9722b00581b7cf34", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[164, 166]], "char_spans": [[930, 946]]}]}], "context_tokens": [["Quantitative", 0], ["real", 13], ["-", 17], ["time", 18], ["PCR", 23], ["(", 27], ["QPCR", 28], [")", 32], ["has", 34], ["emerged", 38], ["as", 46], ["an", 49], ["accurate", 52], ["and", 61], ["valuable", 65], ["tool", 74], ["in", 79], ["profiling", 82], ["gene", 92], ["expression", 97], ["levels", 108], [".", 114], ["One", 116], ["of", 120], ["its", 123], ["many", 127], ["advantages", 132], ["is", 143], ["a", 146], ["lower", 148], ["detection", 154], ["limit", 164], ["compared", 170], ["to", 179], ["other", 182], ["methods", 188], ["of", 196], ["gene", 199], ["expression", 204], ["profiling", 215], ["while", 225], ["using", 231], ["smaller", 237], ["amounts", 245], ["of", 253], ["input", 256], ["for", 262], ["each", 266], ["assay", 271], [".", 276], ["Automated", 278], ["qPCR", 288], ["setup", 293], ["has", 299], ["improved", 303], ["this", 312], ["field", 317], ["by", 323], ["allowing", 326], ["for", 335], ["greater", 339], ["reproducibility", 347], [".", 362], ["Its", 364], ["convenient", 368], ["and", 379], ["rapid", 383], ["setup", 389], ["allows", 395], ["for", 402], ["high", 406], ["-", 410], ["throughput", 411], ["experiments", 422], [",", 433], ["enabling", 435], ["the", 444], ["profiling", 448], ["of", 458], ["many", 461], ["different", 466], ["genes", 476], ["simultaneously", 482], ["in", 497], ["each", 500], ["experiment", 505], [".", 515], ["This", 517], ["method", 522], ["along", 529], ["with", 535], ["internal", 540], ["plate", 549], ["controls", 555], ["also", 564], ["reduces", 569], ["experimental", 577], ["variables", 590], ["common", 600], ["to", 607], ["other", 610], ["techniques", 616], [".", 626], ["We", 628], ["recently", 631], ["developed", 640], ["a", 650], ["qPCR", 652], ["assay", 657], ["for", 663], ["profiling", 667], ["of", 677], ["pre", 680], ["-", 683], ["microRNAs", 684], ["(", 694], ["pre", 695], ["-", 698], ["miRNAs", 699], [")", 705], ["using", 707], ["a", 713], ["set", 715], ["of", 719], ["186", 722], ["primer", 726], ["pairs", 733], [".", 738], ["MicroRNAs", 740], ["have", 750], ["emerged", 755], ["as", 763], ["a", 766], ["novel", 768], ["class", 774], ["of", 780], ["small", 783], [",", 788], ["non", 790], ["-", 793], ["coding", 794], ["RNAs", 801], ["with", 806], ["the", 811], ["ability", 815], ["to", 823], ["regulate", 826], ["many", 835], ["mRNA", 840], ["targets", 845], ["at", 853], ["the", 856], ["post", 860], ["-", 864], ["transcriptional", 865], ["level", 881], [".", 886], ["These", 888], ["small", 894], ["RNAs", 900], ["are", 905], ["first", 909], ["transcribed", 915], ["by", 927], ["RNA", 930], ["polymerase", 934], ["II", 945], ["as", 948], ["a", 951], ["primary", 953], ["miRNA", 961], ["(", 967], ["pri", 968], ["-", 971], ["miRNA", 972], [")", 977], ["transcript", 979], [",", 989], ["which", 991], ["is", 997], ["then", 1000], ["cleaved", 1005], ["into", 1013], ["the", 1018], ["precursor", 1022], ["miRNA", 1032], ["(", 1038], ["pre", 1039], ["-", 1042], ["miRNA", 1043], [")", 1048], [".", 1049], ["Pre", 1051], ["-", 1054], ["miRNAs", 1055], ["are", 1062], ["exported", 1066], ["to", 1075], ["the", 1078], ["cytoplasm", 1082], ["where", 1092], ["Dicer", 1098], ["cleaves", 1104], ["the", 1112], ["hairpin", 1116], ["loop", 1124], ["to", 1129], ["yield", 1132], ["mature", 1138], ["miRNAs", 1145], [".", 1151], ["Increases", 1153], ["in", 1163], ["miRNA", 1166], ["levels", 1172], ["can", 1179], ["be", 1183], ["observed", 1186], ["at", 1195], ["both", 1198], ["the", 1203], ["precursor", 1207], ["and", 1217], ["mature", 1221], ["miRNA", 1228], ["levels", 1234], ["and", 1241], ["profiling", 1245], ["of", 1255], ["both", 1258], ["of", 1263], ["these", 1266], ["forms", 1272], ["can", 1278], ["be", 1282], ["useful", 1285], [".", 1291], ["There", 1293], ["are", 1299], ["several", 1303], ["commercially", 1311], ["available", 1324], ["assays", 1334], ["for", 1341], ["mature", 1345], ["miRNAs", 1352], [";", 1358], ["however", 1360], [",", 1367], ["their", 1369], ["high", 1375], ["cost", 1380], ["may", 1385], ["deter", 1389], ["researchers", 1395], ["from", 1407], ["this", 1412], ["profiling", 1417], ["technique", 1427], [".", 1436], ["Here", 1438], [",", 1442], ["we", 1444], ["discuss", 1447], ["a", 1455], ["cost", 1457], ["-", 1461], ["effective", 1462], [",", 1471], ["reliable", 1473], [",", 1481], ["SYBR", 1483], ["-", 1487], ["based", 1488], ["qPCR", 1494], ["method", 1499], ["of", 1506], ["profiling", 1509], ["pre", 1519], ["-", 1522], ["miRNAs", 1523], [".", 1529], ["Changes", 1531], ["in", 1539], ["pre", 1542], ["-", 1545], ["miRNA", 1546], ["levels", 1552], ["often", 1559], ["reflect", 1565], ["mature", 1573], ["miRNA", 1580], ["changes", 1586], ["and", 1594], ["can", 1598], ["be", 1602], ["a", 1605], ["useful", 1607], ["indicator", 1614], ["of", 1624], ["mature", 1627], ["miRNA", 1634], ["expression", 1640], [".", 1650], ["However", 1652], [",", 1659], ["simultaneous", 1661], ["profiling", 1674], ["of", 1684], ["both", 1687], ["pre", 1692], ["-", 1695], ["miRNAs", 1696], ["and", 1703], ["mature", 1707], ["miRNAs", 1714], ["may", 1721], ["be", 1725], ["optimal", 1728], ["as", 1736], ["they", 1739], ["can", 1744], ["contribute", 1748], ["nonredundant", 1759], ["information", 1772], ["and", 1784], ["provide", 1788], ["insight", 1796], ["into", 1804], ["microRNA", 1809], ["processing", 1818], [".", 1828], ["Furthermore", 1830], [",", 1841], ["the", 1843], ["technique", 1847], ["described", 1857], ["here", 1867], ["can", 1872], ["be", 1876], ["expanded", 1879], ["to", 1888], ["encompass", 1891], ["the", 1901], ["profiling", 1905], ["of", 1915], ["other", 1918], ["library", 1924], ["sets", 1932], ["for", 1937], ["specific", 1941], ["pathways", 1950], ["or", 1959], ["pathogens", 1962], [".", 1971]]}
{"context": "Loss-of-function mutations in the gene ced-8 lead to the late appearance of cell corpses during embryonic development in C. elegans. ced-8 functions downstream of or in parallel to-the regulatory cell death gene ced-9 and may function as a cell death effector downstream of the caspase encoded by the programmed cell death killer gene ced-3. In ced-8 mutants, embryonic programmed cell death probably initiates normally but proceeds slowly. ced-8 encodes a transmembrane protein that appears to be localized to the plasma membrane. The CED-8 protein is similar to human XK, a putative membrane transport protein implicated in McLeod Syndrome, a form of hereditary neuroacanthocytosis.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "0574b68d8a1845829336d0bb8c46aef6", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[99, 99]], "char_spans": [[570, 571]]}]}], "context_tokens": [["Loss", 0], ["-", 4], ["of", 5], ["-", 7], ["function", 8], ["mutations", 17], ["in", 27], ["the", 30], ["gene", 34], ["ced-8", 39], ["lead", 45], ["to", 50], ["the", 53], ["late", 57], ["appearance", 62], ["of", 73], ["cell", 76], ["corpses", 81], ["during", 89], ["embryonic", 96], ["development", 106], ["in", 118], ["C.", 121], ["elegans", 124], [".", 131], ["ced-8", 133], ["functions", 139], ["downstream", 149], ["of", 160], ["or", 163], ["in", 166], ["parallel", 169], ["to", 178], ["-", 180], ["the", 181], ["regulatory", 185], ["cell", 196], ["death", 201], ["gene", 207], ["ced-9", 212], ["and", 218], ["may", 222], ["function", 226], ["as", 235], ["a", 238], ["cell", 240], ["death", 245], ["effector", 251], ["downstream", 260], ["of", 271], ["the", 274], ["caspase", 278], ["encoded", 286], ["by", 294], ["the", 297], ["programmed", 301], ["cell", 312], ["death", 317], ["killer", 323], ["gene", 330], ["ced-3", 335], [".", 340], ["In", 342], ["ced-8", 345], ["mutants", 351], [",", 358], ["embryonic", 360], ["programmed", 370], ["cell", 381], ["death", 386], ["probably", 392], ["initiates", 401], ["normally", 411], ["but", 420], ["proceeds", 424], ["slowly", 433], [".", 439], ["ced-8", 441], ["encodes", 447], ["a", 455], ["transmembrane", 457], ["protein", 471], ["that", 479], ["appears", 484], ["to", 492], ["be", 495], ["localized", 498], ["to", 508], ["the", 511], ["plasma", 515], ["membrane", 522], [".", 530], ["The", 532], ["CED-8", 536], ["protein", 542], ["is", 550], ["similar", 553], ["to", 561], ["human", 564], ["XK", 570], [",", 572], ["a", 574], ["putative", 576], ["membrane", 585], ["transport", 594], ["protein", 604], ["implicated", 612], ["in", 623], ["McLeod", 626], ["Syndrome", 633], [",", 641], ["a", 643], ["form", 645], ["of", 650], ["hereditary", 653], ["neuroacanthocytosis", 664], [".", 683]]}
{"context": "Chronic myelogenous leukemia is characterized by the Philadelphia-chromosome, a shortened chromosome 22 which is the result of a reciprocal translocation between chromosome 9 and 22. The fusion gene is called BCR-ABL. After transcription and translation the constitutively activated p210 BCR-ABL oncoprotein is formed. This leads to uncontrolled activation of the ABL tyrosin kinase. Deregulated cellular proliferation and diminished apoptosis of BCR-ABL transformed cells is the result. Expression of the BCR-ABL oncoprotein is sufficient and necessary for the development of a CML phenotype. Imatinib mesylate (Glivec) is a small molecule that binds to the ATP pocket of ABL and blocks downstream signalling events. Imatinib is very effective in the treatment of CML in all stages of the disease. Patients with newly diagnosed chronic phase CML were randomized to imatinib or to interferon plus cytarabine in the IRIS trial. Imatinib showed significantly superior tolerability, hematologic and cytogenetic resposes and increased time to progression. In patients with advanced phase CML, imatinib is less effective and response duration is short. Median overall survival of blast crisis patients is 6.9 months only. Additional BCR-ABL independent chromosomal abnormalities are common in advanced phase CML and result in resistance to imatinib. BCR-ABL kinase-domaine mutations are frequently found in imatinib resistant patients and confer diminished sensitivity to imatinib. Second generation, more powerful ABL kinase inhibitors, which are effective against most of the known mutations are currently tested in clinical trials.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "d9cb4426446f4f91ae4e64614349182c", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[71, 73], [46, 48], [205, 207], [224, 226], [34, 36], [83, 85]], "char_spans": [[447, 453], [288, 294], [1228, 1234], [1345, 1351], [209, 215], [506, 512]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["is", 29], ["characterized", 32], ["by", 46], ["the", 49], ["Philadelphia", 53], ["-", 65], ["chromosome", 66], [",", 76], ["a", 78], ["shortened", 80], ["chromosome", 90], ["22", 101], ["which", 104], ["is", 110], ["the", 113], ["result", 117], ["of", 124], ["a", 127], ["reciprocal", 129], ["translocation", 140], ["between", 154], ["chromosome", 162], ["9", 173], ["and", 175], ["22", 179], [".", 181], ["The", 183], ["fusion", 187], ["gene", 194], ["is", 199], ["called", 202], ["BCR", 209], ["-", 212], ["ABL", 213], [".", 216], ["After", 218], ["transcription", 224], ["and", 238], ["translation", 242], ["the", 254], ["constitutively", 258], ["activated", 273], ["p210", 283], ["BCR", 288], ["-", 291], ["ABL", 292], ["oncoprotein", 296], ["is", 308], ["formed", 311], [".", 317], ["This", 319], ["leads", 324], ["to", 330], ["uncontrolled", 333], ["activation", 346], ["of", 357], ["the", 360], ["ABL", 364], ["tyrosin", 368], ["kinase", 376], [".", 382], ["Deregulated", 384], ["cellular", 396], ["proliferation", 405], ["and", 419], ["diminished", 423], ["apoptosis", 434], ["of", 444], ["BCR", 447], ["-", 450], ["ABL", 451], ["transformed", 455], ["cells", 467], ["is", 473], ["the", 476], ["result", 480], [".", 486], ["Expression", 488], ["of", 499], ["the", 502], ["BCR", 506], ["-", 509], ["ABL", 510], ["oncoprotein", 514], ["is", 526], ["sufficient", 529], ["and", 540], ["necessary", 544], ["for", 554], ["the", 558], ["development", 562], ["of", 574], ["a", 577], ["CML", 579], ["phenotype", 583], [".", 592], ["Imatinib", 594], ["mesylate", 603], ["(", 612], ["Glivec", 613], [")", 619], ["is", 621], ["a", 624], ["small", 626], ["molecule", 632], ["that", 641], ["binds", 646], ["to", 652], ["the", 655], ["ATP", 659], ["pocket", 663], ["of", 670], ["ABL", 673], ["and", 677], ["blocks", 681], ["downstream", 688], ["signalling", 699], ["events", 710], [".", 716], ["Imatinib", 718], ["is", 727], ["very", 730], ["effective", 735], ["in", 745], ["the", 748], ["treatment", 752], ["of", 762], ["CML", 765], ["in", 769], ["all", 772], ["stages", 776], ["of", 783], ["the", 786], ["disease", 790], [".", 797], ["Patients", 799], ["with", 808], ["newly", 813], ["diagnosed", 819], ["chronic", 829], ["phase", 837], ["CML", 843], ["were", 847], ["randomized", 852], ["to", 863], ["imatinib", 866], ["or", 875], ["to", 878], ["interferon", 881], ["plus", 892], ["cytarabine", 897], ["in", 908], ["the", 911], ["IRIS", 915], ["trial", 920], [".", 925], ["Imatinib", 927], ["showed", 936], ["significantly", 943], ["superior", 957], ["tolerability", 966], [",", 978], ["hematologic", 980], ["and", 992], ["cytogenetic", 996], ["resposes", 1008], ["and", 1017], ["increased", 1021], ["time", 1031], ["to", 1036], ["progression", 1039], [".", 1050], ["In", 1052], ["patients", 1055], ["with", 1064], ["advanced", 1069], ["phase", 1078], ["CML", 1084], [",", 1087], ["imatinib", 1089], ["is", 1098], ["less", 1101], ["effective", 1106], ["and", 1116], ["response", 1120], ["duration", 1129], ["is", 1138], ["short", 1141], [".", 1146], ["Median", 1148], ["overall", 1155], ["survival", 1163], ["of", 1172], ["blast", 1175], ["crisis", 1181], ["patients", 1188], ["is", 1197], ["6.9", 1200], ["months", 1204], ["only", 1211], [".", 1215], ["Additional", 1217], ["BCR", 1228], ["-", 1231], ["ABL", 1232], ["independent", 1236], ["chromosomal", 1248], ["abnormalities", 1260], ["are", 1274], ["common", 1278], ["in", 1285], ["advanced", 1288], ["phase", 1297], ["CML", 1303], ["and", 1307], ["result", 1311], ["in", 1318], ["resistance", 1321], ["to", 1332], ["imatinib", 1335], [".", 1343], ["BCR", 1345], ["-", 1348], ["ABL", 1349], ["kinase", 1353], ["-", 1359], ["domaine", 1360], ["mutations", 1368], ["are", 1378], ["frequently", 1382], ["found", 1393], ["in", 1399], ["imatinib", 1402], ["resistant", 1411], ["patients", 1421], ["and", 1430], ["confer", 1434], ["diminished", 1441], ["sensitivity", 1452], ["to", 1464], ["imatinib", 1467], [".", 1475], ["Second", 1477], ["generation", 1484], [",", 1494], ["more", 1496], ["powerful", 1501], ["ABL", 1510], ["kinase", 1514], ["inhibitors", 1521], [",", 1531], ["which", 1533], ["are", 1539], ["effective", 1543], ["against", 1553], ["most", 1561], ["of", 1566], ["the", 1569], ["known", 1573], ["mutations", 1579], ["are", 1589], ["currently", 1593], ["tested", 1603], ["in", 1610], ["clinical", 1613], ["trials", 1622], [".", 1628]]}
{"context": "The selective serotonin reuptake inhibitors have become a first line treatment for post-traumatic stress disorder (PTSD). In a recent double-blind study in civilians, fluoxetine produced clinically and statistically significant effects on all general measures of PTSD. We examined the specific effects of fluoxetine versus placebo in the above mentioned study of PTSD clusters and individual symptoms. Individuals were included if they met criteria for PTSD according to the Structured Clinical Interview for DSM-III-R (SCID). Symptoms were assessed at sequential time points by the Structured Interview for PTSD (SIP), a clinician interview based assessment, and a self-report scale, the Davidson Trauma Scale (DTS). A total of 53 patients were included in the analysis. On the SIP and DTS, fluoxetine was found to produce statistically significant changes on all clusters. Significant effects for fluoxetine were noted on 10 items of the DTS, and 8 items of the SIP. The SIP and DTS had 6 items in common that were significant. Fluoxetine exerts a broad spectrum effect in reducing all the symptom clusters of PTSD in this sample. The symptoms of being physically upset at reminders of the trauma, avoiding thoughts of the trauma, having difficulty enjoying things, feeling distant/estranged, having a sense of foreshortened future, and impaired concentration, were the symptoms most responsive to the effects of treatment with fluoxetine on both scales.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "8358e9aead9e4d0e8e8aa54a33b9eff9", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[12, 16]], "char_spans": [[83, 112]]}, {"text": "PTSD", "token_spans": [[43, 43], [74, 74], [60, 60], [204, 204], [103, 103], [18, 18]], "char_spans": [[263, 266], [453, 456], [363, 366], [1112, 1115], [608, 611], [115, 118]]}]}], "context_tokens": [["The", 0], ["selective", 4], ["serotonin", 14], ["reuptake", 24], ["inhibitors", 33], ["have", 44], ["become", 49], ["a", 56], ["first", 58], ["line", 64], ["treatment", 69], ["for", 79], ["post", 83], ["-", 87], ["traumatic", 88], ["stress", 98], ["disorder", 105], ["(", 114], ["PTSD", 115], [")", 119], [".", 120], ["In", 122], ["a", 125], ["recent", 127], ["double", 134], ["-", 140], ["blind", 141], ["study", 147], ["in", 153], ["civilians", 156], [",", 165], ["fluoxetine", 167], ["produced", 178], ["clinically", 187], ["and", 198], ["statistically", 202], ["significant", 216], ["effects", 228], ["on", 236], ["all", 239], ["general", 243], ["measures", 251], ["of", 260], ["PTSD", 263], [".", 267], ["We", 269], ["examined", 272], ["the", 281], ["specific", 285], ["effects", 294], ["of", 302], ["fluoxetine", 305], ["versus", 316], ["placebo", 323], ["in", 331], ["the", 334], ["above", 338], ["mentioned", 344], ["study", 354], ["of", 360], ["PTSD", 363], ["clusters", 368], ["and", 377], ["individual", 381], ["symptoms", 392], [".", 400], ["Individuals", 402], ["were", 414], ["included", 419], ["if", 428], ["they", 431], ["met", 436], ["criteria", 440], ["for", 449], ["PTSD", 453], ["according", 458], ["to", 468], ["the", 471], ["Structured", 475], ["Clinical", 486], ["Interview", 495], ["for", 505], ["DSM", 509], ["-", 512], ["III", 513], ["-", 516], ["R", 517], ["(", 519], ["SCID", 520], [")", 524], [".", 525], ["Symptoms", 527], ["were", 536], ["assessed", 541], ["at", 550], ["sequential", 553], ["time", 564], ["points", 569], ["by", 576], ["the", 579], ["Structured", 583], ["Interview", 594], ["for", 604], ["PTSD", 608], ["(", 613], ["SIP", 614], [")", 617], [",", 618], ["a", 620], ["clinician", 622], ["interview", 632], ["based", 642], ["assessment", 648], [",", 658], ["and", 660], ["a", 664], ["self", 666], ["-", 670], ["report", 671], ["scale", 678], [",", 683], ["the", 685], ["Davidson", 689], ["Trauma", 698], ["Scale", 705], ["(", 711], ["DTS", 712], [")", 715], [".", 716], ["A", 718], ["total", 720], ["of", 726], ["53", 729], ["patients", 732], ["were", 741], ["included", 746], ["in", 755], ["the", 758], ["analysis", 762], [".", 770], ["On", 772], ["the", 775], ["SIP", 779], ["and", 783], ["DTS", 787], [",", 790], ["fluoxetine", 792], ["was", 803], ["found", 807], ["to", 813], ["produce", 816], ["statistically", 824], ["significant", 838], ["changes", 850], ["on", 858], ["all", 861], ["clusters", 865], [".", 873], ["Significant", 875], ["effects", 887], ["for", 895], ["fluoxetine", 899], ["were", 910], ["noted", 915], ["on", 921], ["10", 924], ["items", 927], ["of", 933], ["the", 936], ["DTS", 940], [",", 943], ["and", 945], ["8", 949], ["items", 951], ["of", 957], ["the", 960], ["SIP", 964], [".", 967], ["The", 969], ["SIP", 973], ["and", 977], ["DTS", 981], ["had", 985], ["6", 989], ["items", 991], ["in", 997], ["common", 1000], ["that", 1007], ["were", 1012], ["significant", 1017], [".", 1028], ["Fluoxetine", 1030], ["exerts", 1041], ["a", 1048], ["broad", 1050], ["spectrum", 1056], ["effect", 1065], ["in", 1072], ["reducing", 1075], ["all", 1084], ["the", 1088], ["symptom", 1092], ["clusters", 1100], ["of", 1109], ["PTSD", 1112], ["in", 1117], ["this", 1120], ["sample", 1125], [".", 1131], ["The", 1133], ["symptoms", 1137], ["of", 1146], ["being", 1149], ["physically", 1155], ["upset", 1166], ["at", 1172], ["reminders", 1175], ["of", 1185], ["the", 1188], ["trauma", 1192], [",", 1198], ["avoiding", 1200], ["thoughts", 1209], ["of", 1218], ["the", 1221], ["trauma", 1225], [",", 1231], ["having", 1233], ["difficulty", 1240], ["enjoying", 1251], ["things", 1260], [",", 1266], ["feeling", 1268], ["distant", 1276], ["/", 1283], ["estranged", 1284], [",", 1293], ["having", 1295], ["a", 1302], ["sense", 1304], ["of", 1310], ["foreshortened", 1313], ["future", 1327], [",", 1333], ["and", 1335], ["impaired", 1339], ["concentration", 1348], [",", 1361], ["were", 1363], ["the", 1368], ["symptoms", 1372], ["most", 1381], ["responsive", 1386], ["to", 1397], ["the", 1400], ["effects", 1404], ["of", 1412], ["treatment", 1415], ["with", 1425], ["fluoxetine", 1430], ["on", 1441], ["both", 1444], ["scales", 1449], [".", 1455]]}
{"context": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. Imatinib induces complete haematological and cytogenetic response in high percentage of patients. The aim of this study was to identify potential prognostic factors before beginning treatment with imatinib associated with complete cytogenetic response. We analyzed 20 patients with newly diagnosed Philadelphia positive chronic myelogenous leukemia treated at our institution from June 2006 until May 2009. These patients were treated with imatinib mesylate in oral dose of 400 to 800 mg daily. Complete blood counts were performed every month, while serum chemistry evaluations and bone marrow evaluations including morphology and cytogenetics were performed every 6 months. Of the 20 patients analyzed in this study, 19 (95%) achieved complete haematologic response within three months. In all patients cytogenetic analyses were done and all have achieved absolute cytogenetic response. The best cytogenetic response rate at any time during study treatment among 20 patients was: complete cytogenetic response in 15, partial cytogenetic response in three and minor cytogenetic response in two patients. Among 11 observed base-line patients' characteristics five were independent predictors of a high rate of complete cytogenetic response; the absence of blasts and basophils in peripheral blood, the presence of less than 5 percent of bone marrow blasts, white blood cell count less than 10 x 10(9)/L and the absence of splenomegaly (p < 0.01). Our results showed that some pre-treatment characteristics of patients might be the cause of differences in treatment outcome. On the basis of this analysis, we identified several pre-treatment patients' characteristics to be independent prognostic factors for achievement of complete cytogenetic response.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "6a2e5c9b921c417c892010de2379c6d7", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[5, 7]], "char_spans": [[31, 37]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["a", 19], ["selective", 21], ["Bcr", 31], ["-", 34], ["Abl", 35], ["tyrosine", 39], ["kinase", 48], ["inhibitor", 55], [",", 64], ["has", 66], ["proved", 70], ["to", 77], ["be", 80], ["most", 83], ["effective", 88], ["therapy", 98], ["of", 106], ["Philadelphia", 109], ["chromosome", 122], ["-", 132], ["positive", 133], ["chronic", 142], ["myelogenous", 150], ["leukemia", 162], [".", 170], ["Imatinib", 172], ["induces", 181], ["complete", 189], ["haematological", 198], ["and", 213], ["cytogenetic", 217], ["response", 229], ["in", 238], ["high", 241], ["percentage", 246], ["of", 257], ["patients", 260], [".", 268], ["The", 270], ["aim", 274], ["of", 278], ["this", 281], ["study", 286], ["was", 292], ["to", 296], ["identify", 299], ["potential", 308], ["prognostic", 318], ["factors", 329], ["before", 337], ["beginning", 344], ["treatment", 354], ["with", 364], ["imatinib", 369], ["associated", 378], ["with", 389], ["complete", 394], ["cytogenetic", 403], ["response", 415], [".", 423], ["We", 425], ["analyzed", 428], ["20", 437], ["patients", 440], ["with", 449], ["newly", 454], ["diagnosed", 460], ["Philadelphia", 470], ["positive", 483], ["chronic", 492], ["myelogenous", 500], ["leukemia", 512], ["treated", 521], ["at", 529], ["our", 532], ["institution", 536], ["from", 548], ["June", 553], ["2006", 558], ["until", 563], ["May", 569], ["2009", 573], [".", 577], ["These", 579], ["patients", 585], ["were", 594], ["treated", 599], ["with", 607], ["imatinib", 612], ["mesylate", 621], ["in", 630], ["oral", 633], ["dose", 638], ["of", 643], ["400", 646], ["to", 650], ["800", 653], ["mg", 657], ["daily", 660], [".", 665], ["Complete", 667], ["blood", 676], ["counts", 682], ["were", 689], ["performed", 694], ["every", 704], ["month", 710], [",", 715], ["while", 717], ["serum", 723], ["chemistry", 729], ["evaluations", 739], ["and", 751], ["bone", 755], ["marrow", 760], ["evaluations", 767], ["including", 779], ["morphology", 789], ["and", 800], ["cytogenetics", 804], ["were", 817], ["performed", 822], ["every", 832], ["6", 838], ["months", 840], [".", 846], ["Of", 848], ["the", 851], ["20", 855], ["patients", 858], ["analyzed", 867], ["in", 876], ["this", 879], ["study", 884], [",", 889], ["19", 891], ["(", 894], ["95", 895], ["%", 897], [")", 898], ["achieved", 900], ["complete", 909], ["haematologic", 918], ["response", 931], ["within", 940], ["three", 947], ["months", 953], [".", 959], ["In", 961], ["all", 964], ["patients", 968], ["cytogenetic", 977], ["analyses", 989], ["were", 998], ["done", 1003], ["and", 1008], ["all", 1012], ["have", 1016], ["achieved", 1021], ["absolute", 1030], ["cytogenetic", 1039], ["response", 1051], [".", 1059], ["The", 1061], ["best", 1065], ["cytogenetic", 1070], ["response", 1082], ["rate", 1091], ["at", 1096], ["any", 1099], ["time", 1103], ["during", 1108], ["study", 1115], ["treatment", 1121], ["among", 1131], ["20", 1137], ["patients", 1140], ["was", 1149], [":", 1152], ["complete", 1154], ["cytogenetic", 1163], ["response", 1175], ["in", 1184], ["15", 1187], [",", 1189], ["partial", 1191], ["cytogenetic", 1199], ["response", 1211], ["in", 1220], ["three", 1223], ["and", 1229], ["minor", 1233], ["cytogenetic", 1239], ["response", 1251], ["in", 1260], ["two", 1263], ["patients", 1267], [".", 1275], ["Among", 1277], ["11", 1283], ["observed", 1286], ["base", 1295], ["-", 1299], ["line", 1300], ["patients", 1305], ["'", 1313], ["characteristics", 1315], ["five", 1331], ["were", 1336], ["independent", 1341], ["predictors", 1353], ["of", 1364], ["a", 1367], ["high", 1369], ["rate", 1374], ["of", 1379], ["complete", 1382], ["cytogenetic", 1391], ["response", 1403], [";", 1411], ["the", 1413], ["absence", 1417], ["of", 1425], ["blasts", 1428], ["and", 1435], ["basophils", 1439], ["in", 1449], ["peripheral", 1452], ["blood", 1463], [",", 1468], ["the", 1470], ["presence", 1474], ["of", 1483], ["less", 1486], ["than", 1491], ["5", 1496], ["percent", 1498], ["of", 1506], ["bone", 1509], ["marrow", 1514], ["blasts", 1521], [",", 1527], ["white", 1529], ["blood", 1535], ["cell", 1541], ["count", 1546], ["less", 1552], ["than", 1557], ["10", 1562], ["x", 1565], ["10(9)/L", 1567], ["and", 1575], ["the", 1579], ["absence", 1583], ["of", 1591], ["splenomegaly", 1594], ["(", 1607], ["p", 1608], ["<", 1610], ["0.01", 1612], [")", 1616], [".", 1617], ["Our", 1619], ["results", 1623], ["showed", 1631], ["that", 1638], ["some", 1643], ["pre", 1648], ["-", 1651], ["treatment", 1652], ["characteristics", 1662], ["of", 1678], ["patients", 1681], ["might", 1690], ["be", 1696], ["the", 1699], ["cause", 1703], ["of", 1709], ["differences", 1712], ["in", 1724], ["treatment", 1727], ["outcome", 1737], [".", 1744], ["On", 1746], ["the", 1749], ["basis", 1753], ["of", 1759], ["this", 1762], ["analysis", 1767], [",", 1775], ["we", 1777], ["identified", 1780], ["several", 1791], ["pre", 1799], ["-", 1802], ["treatment", 1803], ["patients", 1813], ["'", 1821], ["characteristics", 1823], ["to", 1839], ["be", 1842], ["independent", 1845], ["prognostic", 1857], ["factors", 1868], ["for", 1876], ["achievement", 1880], ["of", 1892], ["complete", 1895], ["cytogenetic", 1904], ["response", 1916], [".", 1924]]}
{"context": "Marfanoid phenotype with craniosynostosis (Shprintzen-Goldberg syndrome) is a rare disorder previously described in only 5 patients. We report on the sixth known patient with this condition. The findings which distinguish our patient from others reported previously are that she was ascertained prenatally as having a cloverleaf skull; this is the first female patient described with this condition. Postnatally, she presented with arachnodactyly, camptodactyly, and clover-leaf skull. Imaging studies of the brain documented microcephaly with malformed brain, hydrocephaly, and hypoplasia of the corpus callosum. She also had choanal atresia and stenosis, a clinical finding previously reported only once, in this disorder.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "78c142601b5048dd9ab83e39d4e8e15f", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[3, 3]], "char_spans": [[25, 40]]}]}], "context_tokens": [["Marfanoid", 0], ["phenotype", 10], ["with", 20], ["craniosynostosis", 25], ["(", 42], ["Shprintzen", 43], ["-", 53], ["Goldberg", 54], ["syndrome", 63], [")", 71], ["is", 73], ["a", 76], ["rare", 78], ["disorder", 83], ["previously", 92], ["described", 103], ["in", 113], ["only", 116], ["5", 121], ["patients", 123], [".", 131], ["We", 133], ["report", 136], ["on", 143], ["the", 146], ["sixth", 150], ["known", 156], ["patient", 162], ["with", 170], ["this", 175], ["condition", 180], [".", 189], ["The", 191], ["findings", 195], ["which", 204], ["distinguish", 210], ["our", 222], ["patient", 226], ["from", 234], ["others", 239], ["reported", 246], ["previously", 255], ["are", 266], ["that", 270], ["she", 275], ["was", 279], ["ascertained", 283], ["prenatally", 295], ["as", 306], ["having", 309], ["a", 316], ["cloverleaf", 318], ["skull", 329], [";", 334], ["this", 336], ["is", 341], ["the", 344], ["first", 348], ["female", 354], ["patient", 361], ["described", 369], ["with", 379], ["this", 384], ["condition", 389], [".", 398], ["Postnatally", 400], [",", 411], ["she", 413], ["presented", 417], ["with", 427], ["arachnodactyly", 432], [",", 446], ["camptodactyly", 448], [",", 461], ["and", 463], ["clover", 467], ["-", 473], ["leaf", 474], ["skull", 479], [".", 484], ["Imaging", 486], ["studies", 494], ["of", 502], ["the", 505], ["brain", 509], ["documented", 515], ["microcephaly", 526], ["with", 539], ["malformed", 544], ["brain", 554], [",", 559], ["hydrocephaly", 561], [",", 573], ["and", 575], ["hypoplasia", 579], ["of", 590], ["the", 593], ["corpus", 597], ["callosum", 604], [".", 612], ["She", 614], ["also", 618], ["had", 623], ["choanal", 627], ["atresia", 635], ["and", 643], ["stenosis", 647], [",", 655], ["a", 657], ["clinical", 659], ["finding", 668], ["previously", 676], ["reported", 687], ["only", 696], ["once", 701], [",", 705], ["in", 707], ["this", 710], ["disorder", 715], [".", 723]]}
{"context": "Bone pain is a common symptom in bone metastases. The therapies that are currently available include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, steroids and gabapentin which have been demonstrated to improve neuropathic pain. In addition, preclinical studies indicate that agents such as transient receptor potential vanilloid 1 antagonists and cannabinoid 2 receptor agonist could be considered as adjuncts in ameliorating opioid side effects. New drugs are in the clinical phase of development, among which the most promising molecules seem to be anti-nerve growth factor (NGF) antibodies. Anti-NGF antibody therapy may be particularly effective in blocking bone cancer pain because NGF appears to be integrally involved in the upregulation, sensitization and disinhibition of multiple neurotransmitters, ion channels and receptors in the primary afferent nerve. The best way to treat bone metastases pain is to improve the control of skeletal disease burden. Recently, denosumab, a noncytotoxic IgG2 monoclonal antibody with high affinity for human RANKL, has been demonstrated to significantly prevent clinically relevant increase in pain compared with zoledronic acid across the tumor types. Based on these data, it has been suggested that denosumab has the potential to become a new standard of treatment in bone metastases management.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "19f21e68fc4946c181d7758601dee5d5", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[175, 175]], "char_spans": [[1065, 1069]]}]}], "context_tokens": [["Bone", 0], ["pain", 5], ["is", 10], ["a", 13], ["common", 15], ["symptom", 22], ["in", 30], ["bone", 33], ["metastases", 38], [".", 48], ["The", 50], ["therapies", 54], ["that", 64], ["are", 69], ["currently", 73], ["available", 83], ["include", 93], ["nonsteroidal", 101], ["anti", 114], ["-", 118], ["inflammatory", 119], ["drugs", 132], ["(", 138], ["NSAIDs", 139], [")", 145], [",", 146], ["opioids", 148], [",", 155], ["steroids", 157], ["and", 166], ["gabapentin", 170], ["which", 181], ["have", 187], ["been", 192], ["demonstrated", 197], ["to", 210], ["improve", 213], ["neuropathic", 221], ["pain", 233], [".", 237], ["In", 239], ["addition", 242], [",", 250], ["preclinical", 252], ["studies", 264], ["indicate", 272], ["that", 281], ["agents", 286], ["such", 293], ["as", 298], ["transient", 301], ["receptor", 311], ["potential", 320], ["vanilloid", 330], ["1", 340], ["antagonists", 342], ["and", 354], ["cannabinoid", 358], ["2", 370], ["receptor", 372], ["agonist", 381], ["could", 389], ["be", 395], ["considered", 398], ["as", 409], ["adjuncts", 412], ["in", 421], ["ameliorating", 424], ["opioid", 437], ["side", 444], ["effects", 449], [".", 456], ["New", 458], ["drugs", 462], ["are", 468], ["in", 472], ["the", 475], ["clinical", 479], ["phase", 488], ["of", 494], ["development", 497], [",", 508], ["among", 510], ["which", 516], ["the", 522], ["most", 526], ["promising", 531], ["molecules", 541], ["seem", 551], ["to", 556], ["be", 559], ["anti", 562], ["-", 566], ["nerve", 567], ["growth", 573], ["factor", 580], ["(", 587], ["NGF", 588], [")", 591], ["antibodies", 593], [".", 603], ["Anti", 605], ["-", 609], ["NGF", 610], ["antibody", 614], ["therapy", 623], ["may", 631], ["be", 635], ["particularly", 638], ["effective", 651], ["in", 661], ["blocking", 664], ["bone", 673], ["cancer", 678], ["pain", 685], ["because", 690], ["NGF", 698], ["appears", 702], ["to", 710], ["be", 713], ["integrally", 716], ["involved", 727], ["in", 736], ["the", 739], ["upregulation", 743], [",", 755], ["sensitization", 757], ["and", 771], ["disinhibition", 775], ["of", 789], ["multiple", 792], ["neurotransmitters", 801], [",", 818], ["ion", 820], ["channels", 824], ["and", 833], ["receptors", 837], ["in", 847], ["the", 850], ["primary", 854], ["afferent", 862], ["nerve", 871], [".", 876], ["The", 878], ["best", 882], ["way", 887], ["to", 891], ["treat", 894], ["bone", 900], ["metastases", 905], ["pain", 916], ["is", 921], ["to", 924], ["improve", 927], ["the", 935], ["control", 939], ["of", 947], ["skeletal", 950], ["disease", 959], ["burden", 967], [".", 973], ["Recently", 975], [",", 983], ["denosumab", 985], [",", 994], ["a", 996], ["noncytotoxic", 998], ["IgG2", 1011], ["monoclonal", 1016], ["antibody", 1027], ["with", 1036], ["high", 1041], ["affinity", 1046], ["for", 1055], ["human", 1059], ["RANKL", 1065], [",", 1070], ["has", 1072], ["been", 1076], ["demonstrated", 1081], ["to", 1094], ["significantly", 1097], ["prevent", 1111], ["clinically", 1119], ["relevant", 1130], ["increase", 1139], ["in", 1148], ["pain", 1151], ["compared", 1156], ["with", 1165], ["zoledronic", 1170], ["acid", 1181], ["across", 1186], ["the", 1193], ["tumor", 1197], ["types", 1203], [".", 1208], ["Based", 1210], ["on", 1216], ["these", 1219], ["data", 1225], [",", 1229], ["it", 1231], ["has", 1234], ["been", 1238], ["suggested", 1243], ["that", 1253], ["denosumab", 1258], ["has", 1268], ["the", 1272], ["potential", 1276], ["to", 1286], ["become", 1289], ["a", 1296], ["new", 1298], ["standard", 1302], ["of", 1311], ["treatment", 1314], ["in", 1324], ["bone", 1327], ["metastases", 1332], ["management", 1343], [".", 1353]]}
{"context": "The major protein constituent of Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein, but other proteins, in particular the microtubule-associated protein tau, have been implicated in the pathogenesis of LBs. Tau is the major structural component of neurofibrillary tangles (NFTs). Both direct immunochemical studies of partially purified LBs and indirect immunohistochemical studies have suggested that LBs may contain tau, but most of these studies were based upon a single tau antibody, and immunologic cross-reactivity was not completely excluded. To gain insight into the relation between tau and alpha-synuclein in LBs, double immunostaining was performed in Lewy body cases with a rabbit polyclonal antibody to alpha-synuclein and a panel of monoclonal antibodies to phospho- and nonphospho-tau epitopes (Alz50, CP9, CP13, PG5, TG3, PHFI) that spanned the length of the tau molecule. Tau-immunoreactive LBs were present in the medulla in 80% of the cases, irrespective of Braak stage. All tau antibodies recognized at least some LBs, arguing against nonspecific antibody cross-reactivity. In most lesions the tau immunostaining was present at the periphery of the LB. The phospho-tau antibody, TG3, detected more LBs than any of the other tau antibodies. The proportion of LBs with tau immunoreactivity was greatest in neurons vulnerable to NETs, such as those in the locus ceruleus and basal nucleus of Meynert, and least in neurons resistant to NFTs, such as the dorsal motor nucleus of the vagus in the medulla. The present results suggest that tau may coaggregate with alpha-synuclein in LBs, especially in neuronal populations vulnerable to both NFTs and LBs.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "dd51992abbdc4acdbe0da902d5a6786a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[306, 308], [138, 140], [118, 120], [27, 29]], "char_spans": [[1661, 1675], [799, 813], [683, 697], [150, 164]]}]}], "context_tokens": [["The", 0], ["major", 4], ["protein", 10], ["constituent", 18], ["of", 30], ["Lewy", 33], ["bodies", 38], ["(", 45], ["LBs", 46], [")", 49], [",", 50], ["the", 52], ["pathological", 56], ["hallmark", 69], ["of", 78], ["Parkinson", 81], ["disease", 91], ["and", 99], ["dementia", 103], ["with", 112], ["Lewy", 117], ["bodies", 122], [",", 128], ["is", 130], ["considered", 133], ["to", 144], ["be", 147], ["alpha", 150], ["-", 155], ["synuclein", 156], [",", 165], ["but", 167], ["other", 171], ["proteins", 177], [",", 185], ["in", 187], ["particular", 190], ["the", 201], ["microtubule", 205], ["-", 216], ["associated", 217], ["protein", 228], ["tau", 236], [",", 239], ["have", 241], ["been", 246], ["implicated", 251], ["in", 262], ["the", 265], ["pathogenesis", 269], ["of", 282], ["LBs", 285], [".", 288], ["Tau", 290], ["is", 294], ["the", 297], ["major", 301], ["structural", 307], ["component", 318], ["of", 328], ["neurofibrillary", 331], ["tangles", 347], ["(", 355], ["NFTs", 356], [")", 360], [".", 361], ["Both", 363], ["direct", 368], ["immunochemical", 375], ["studies", 390], ["of", 398], ["partially", 401], ["purified", 411], ["LBs", 420], ["and", 424], ["indirect", 428], ["immunohistochemical", 437], ["studies", 457], ["have", 465], ["suggested", 470], ["that", 480], ["LBs", 485], ["may", 489], ["contain", 493], ["tau", 501], [",", 504], ["but", 506], ["most", 510], ["of", 515], ["these", 518], ["studies", 524], ["were", 532], ["based", 537], ["upon", 543], ["a", 548], ["single", 550], ["tau", 557], ["antibody", 561], [",", 569], ["and", 571], ["immunologic", 575], ["cross", 587], ["-", 592], ["reactivity", 593], ["was", 604], ["not", 608], ["completely", 612], ["excluded", 623], [".", 631], ["To", 633], ["gain", 636], ["insight", 641], ["into", 649], ["the", 654], ["relation", 658], ["between", 667], ["tau", 675], ["and", 679], ["alpha", 683], ["-", 688], ["synuclein", 689], ["in", 699], ["LBs", 702], [",", 705], ["double", 707], ["immunostaining", 714], ["was", 729], ["performed", 733], ["in", 743], ["Lewy", 746], ["body", 751], ["cases", 756], ["with", 762], ["a", 767], ["rabbit", 769], ["polyclonal", 776], ["antibody", 787], ["to", 796], ["alpha", 799], ["-", 804], ["synuclein", 805], ["and", 815], ["a", 819], ["panel", 821], ["of", 827], ["monoclonal", 830], ["antibodies", 841], ["to", 852], ["phospho-", 855], ["and", 864], ["nonphospho", 868], ["-", 878], ["tau", 879], ["epitopes", 883], ["(", 892], ["Alz50", 893], [",", 898], ["CP9", 900], [",", 903], ["CP13", 905], [",", 909], ["PG5", 911], [",", 914], ["TG3", 916], [",", 919], ["PHFI", 921], [")", 925], ["that", 927], ["spanned", 932], ["the", 940], ["length", 944], ["of", 951], ["the", 954], ["tau", 958], ["molecule", 962], [".", 970], ["Tau", 972], ["-", 975], ["immunoreactive", 976], ["LBs", 991], ["were", 995], ["present", 1000], ["in", 1008], ["the", 1011], ["medulla", 1015], ["in", 1023], ["80", 1026], ["%", 1028], ["of", 1030], ["the", 1033], ["cases", 1037], [",", 1042], ["irrespective", 1044], ["of", 1057], ["Braak", 1060], ["stage", 1066], [".", 1071], ["All", 1073], ["tau", 1077], ["antibodies", 1081], ["recognized", 1092], ["at", 1103], ["least", 1106], ["some", 1112], ["LBs", 1117], [",", 1120], ["arguing", 1122], ["against", 1130], ["nonspecific", 1138], ["antibody", 1150], ["cross", 1159], ["-", 1164], ["reactivity", 1165], [".", 1175], ["In", 1177], ["most", 1180], ["lesions", 1185], ["the", 1193], ["tau", 1197], ["immunostaining", 1201], ["was", 1216], ["present", 1220], ["at", 1228], ["the", 1231], ["periphery", 1235], ["of", 1245], ["the", 1248], ["LB", 1252], [".", 1254], ["The", 1256], ["phospho", 1260], ["-", 1267], ["tau", 1268], ["antibody", 1272], [",", 1280], ["TG3", 1282], [",", 1285], ["detected", 1287], ["more", 1296], ["LBs", 1301], ["than", 1305], ["any", 1310], ["of", 1314], ["the", 1317], ["other", 1321], ["tau", 1327], ["antibodies", 1331], [".", 1341], ["The", 1343], ["proportion", 1347], ["of", 1358], ["LBs", 1361], ["with", 1365], ["tau", 1370], ["immunoreactivity", 1374], ["was", 1391], ["greatest", 1395], ["in", 1404], ["neurons", 1407], ["vulnerable", 1415], ["to", 1426], ["NETs", 1429], [",", 1433], ["such", 1435], ["as", 1440], ["those", 1443], ["in", 1449], ["the", 1452], ["locus", 1456], ["ceruleus", 1462], ["and", 1471], ["basal", 1475], ["nucleus", 1481], ["of", 1489], ["Meynert", 1492], [",", 1499], ["and", 1501], ["least", 1505], ["in", 1511], ["neurons", 1514], ["resistant", 1522], ["to", 1532], ["NFTs", 1535], [",", 1539], ["such", 1541], ["as", 1546], ["the", 1549], ["dorsal", 1553], ["motor", 1560], ["nucleus", 1566], ["of", 1574], ["the", 1577], ["vagus", 1581], ["in", 1587], ["the", 1590], ["medulla", 1594], [".", 1601], ["The", 1603], ["present", 1607], ["results", 1615], ["suggest", 1623], ["that", 1631], ["tau", 1636], ["may", 1640], ["coaggregate", 1644], ["with", 1656], ["alpha", 1661], ["-", 1666], ["synuclein", 1667], ["in", 1677], ["LBs", 1680], [",", 1683], ["especially", 1685], ["in", 1696], ["neuronal", 1699], ["populations", 1708], ["vulnerable", 1720], ["to", 1731], ["both", 1734], ["NFTs", 1739], ["and", 1744], ["LBs", 1748], [".", 1751]]}
{"context": "Bacillus anthracis plasmid pXO1 carries the structural genes for the three anthrax toxin proteins, cya (edema factor), lef (lethal factor), and pag (protective antigen). Expression of the toxin genes by B. anthracis is enhanced during growth under elevated levels of CO2. This CO2 effect is observed only in the presence of another pXO1 gene, atxA, which encodes a transactivator of anthrax toxin synthesis. Here we show that transcription of atxA does not appear to differ in cells grown in 5% CO2 compared with cells grown in air. Using a new efficient method for gene replacement in B. anthracis, we constructed an atxA-null mutant in which the atxA-coding sequence on pXO1 is replaced with an omega km-2 cassette. Transcription of all three toxin genes is decreased in the absence of atxA. The pag gene possesses two apparent transcription start sites, P1 and P2; only transcripts with 5' ends mapping to P1 are decreased in the atxA-null mutant. Deletion analysis of the pag promoter region indicates that the 111 bp region upstream of the P1 site is sufficient for atxA-mediated activation of this transcript. The cya and lef genes each have one apparent start site for transcription. Transcripts with 5' ends mapping to these sites are not detected in the atxA-null mutant. The atxA-null mutant is avirulent in mice. Moreover, the antibody response to all three toxin proteins is decreased significantly in atxA-null mutant-infected mice. These data suggest that the atxA gene product also regulates toxin gene expression during infection.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "e37eef543acc42c0902146dfb8efe1c7", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "CO2", "token_spans": [[95, 95], [53, 53], [50, 50]], "char_spans": [[495, 497], [277, 279], [267, 269]]}]}], "context_tokens": [["Bacillus", 0], ["anthracis", 9], ["plasmid", 19], ["pXO1", 27], ["carries", 32], ["the", 40], ["structural", 44], ["genes", 55], ["for", 61], ["the", 65], ["three", 69], ["anthrax", 75], ["toxin", 83], ["proteins", 89], [",", 97], ["cya", 99], ["(", 103], ["edema", 104], ["factor", 110], [")", 116], [",", 117], ["lef", 119], ["(", 123], ["lethal", 124], ["factor", 131], [")", 137], [",", 138], ["and", 140], ["pag", 144], ["(", 148], ["protective", 149], ["antigen", 160], [")", 167], [".", 168], ["Expression", 170], ["of", 181], ["the", 184], ["toxin", 188], ["genes", 194], ["by", 200], ["B.", 203], ["anthracis", 206], ["is", 216], ["enhanced", 219], ["during", 228], ["growth", 235], ["under", 242], ["elevated", 248], ["levels", 257], ["of", 264], ["CO2", 267], [".", 270], ["This", 272], ["CO2", 277], ["effect", 281], ["is", 288], ["observed", 291], ["only", 300], ["in", 305], ["the", 308], ["presence", 312], ["of", 321], ["another", 324], ["pXO1", 332], ["gene", 337], [",", 341], ["atxA", 343], [",", 347], ["which", 349], ["encodes", 355], ["a", 363], ["transactivator", 365], ["of", 380], ["anthrax", 383], ["toxin", 391], ["synthesis", 397], [".", 406], ["Here", 408], ["we", 413], ["show", 416], ["that", 421], ["transcription", 426], ["of", 440], ["atxA", 443], ["does", 448], ["not", 453], ["appear", 457], ["to", 464], ["differ", 467], ["in", 474], ["cells", 477], ["grown", 483], ["in", 489], ["5", 492], ["%", 493], ["CO2", 495], ["compared", 499], ["with", 508], ["cells", 513], ["grown", 519], ["in", 525], ["air", 528], [".", 531], ["Using", 533], ["a", 539], ["new", 541], ["efficient", 545], ["method", 555], ["for", 562], ["gene", 566], ["replacement", 571], ["in", 583], ["B.", 586], ["anthracis", 589], [",", 598], ["we", 600], ["constructed", 603], ["an", 615], ["atxA", 618], ["-", 622], ["null", 623], ["mutant", 628], ["in", 635], ["which", 638], ["the", 644], ["atxA", 648], ["-", 652], ["coding", 653], ["sequence", 660], ["on", 669], ["pXO1", 672], ["is", 677], ["replaced", 680], ["with", 689], ["an", 694], ["omega", 697], ["km-2", 703], ["cassette", 708], [".", 716], ["Transcription", 718], ["of", 732], ["all", 735], ["three", 739], ["toxin", 745], ["genes", 751], ["is", 757], ["decreased", 760], ["in", 770], ["the", 773], ["absence", 777], ["of", 785], ["atxA.", 788], ["The", 794], ["pag", 798], ["gene", 802], ["possesses", 807], ["two", 817], ["apparent", 821], ["transcription", 830], ["start", 844], ["sites", 850], [",", 855], ["P1", 857], ["and", 860], ["P2", 864], [";", 866], ["only", 868], ["transcripts", 873], ["with", 885], ["5", 890], ["'", 891], ["ends", 893], ["mapping", 898], ["to", 906], ["P1", 909], ["are", 912], ["decreased", 916], ["in", 926], ["the", 929], ["atxA", 933], ["-", 937], ["null", 938], ["mutant", 943], [".", 949], ["Deletion", 951], ["analysis", 960], ["of", 969], ["the", 972], ["pag", 976], ["promoter", 980], ["region", 989], ["indicates", 996], ["that", 1006], ["the", 1011], ["111", 1015], ["bp", 1019], ["region", 1022], ["upstream", 1029], ["of", 1038], ["the", 1041], ["P1", 1045], ["site", 1048], ["is", 1053], ["sufficient", 1056], ["for", 1067], ["atxA", 1071], ["-", 1075], ["mediated", 1076], ["activation", 1085], ["of", 1096], ["this", 1099], ["transcript", 1104], [".", 1114], ["The", 1116], ["cya", 1120], ["and", 1124], ["lef", 1128], ["genes", 1132], ["each", 1138], ["have", 1143], ["one", 1148], ["apparent", 1152], ["start", 1161], ["site", 1167], ["for", 1172], ["transcription", 1176], [".", 1189], ["Transcripts", 1191], ["with", 1203], ["5", 1208], ["'", 1209], ["ends", 1211], ["mapping", 1216], ["to", 1224], ["these", 1227], ["sites", 1233], ["are", 1239], ["not", 1243], ["detected", 1247], ["in", 1256], ["the", 1259], ["atxA", 1263], ["-", 1267], ["null", 1268], ["mutant", 1273], [".", 1279], ["The", 1281], ["atxA", 1285], ["-", 1289], ["null", 1290], ["mutant", 1295], ["is", 1302], ["avirulent", 1305], ["in", 1315], ["mice", 1318], [".", 1322], ["Moreover", 1324], [",", 1332], ["the", 1334], ["antibody", 1338], ["response", 1347], ["to", 1356], ["all", 1359], ["three", 1363], ["toxin", 1369], ["proteins", 1375], ["is", 1384], ["decreased", 1387], ["significantly", 1397], ["in", 1411], ["atxA", 1414], ["-", 1418], ["null", 1419], ["mutant", 1424], ["-", 1430], ["infected", 1431], ["mice", 1440], [".", 1444], ["These", 1446], ["data", 1452], ["suggest", 1457], ["that", 1465], ["the", 1470], ["atxA", 1474], ["gene", 1479], ["product", 1484], ["also", 1492], ["regulates", 1497], ["toxin", 1507], ["gene", 1513], ["expression", 1518], ["during", 1529], ["infection", 1536], [".", 1545]]}
{"context": "Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), we randomly assigned 738 patients (in the ERASURE study) and 1306 patients (in the FIXTURE study) to subcutaneous secukinumab at a dose of 300 mg or 150 mg (administered once weekly for 5 weeks, then every 4 weeks), placebo, or (in the FIXTURE study only) etanercept at a dose of 50 mg (administered twice weekly for 12 weeks, then once weekly). The objective of each study was to show the superiority of secukinumab over placebo at week 12 with respect to the proportion of patients who had a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) and a score of 0 (clear) or 1 (almost clear) on a 5-point modified investigator's global assessment (coprimary end points). The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 81.6% with 300 mg of secukinumab, 71.6% with 150 mg of secukinumab, and 4.5% with placebo; in the FIXTURE study, the rates were 77.1% with 300 mg of secukinumab, 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo (P<0.001 for each secukinumab dose vs. comparators). The proportion of patients with a response of 0 or 1 on the modified investigator's global assessment at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 65.3% with 300 mg of secukinumab, 51.2% with 150 mg of secukinumab, and 2.4% with placebo; in the FIXTURE study, the rates were 62.5% with 300 mg of secukinumab, 51.1% with 150 mg of secukinumab, 27.2% with etanercept, and 2.8% with placebo (P<0.001 for each secukinumab dose vs. comparators). The rates of infection were higher with secukinumab than with placebo in both studies and were similar to those with etanercept. Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov numbers, NCT01365455 and NCT01358578, respectively.).", "qas": [{"question": "Which molecule is targeted by a monoclonal antibody Secukinumab?", "answers": ["interleukin-17A"], "qid": "d6448dc3be2e45b2be46a0805cc13200", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["a", 30], ["monoclonal", 32], ["antibody", 43], ["Secukinumab", 52], ["?", 63]], "detected_answers": [{"text": "interleukin-17A", "token_spans": [[0, 0], [21, 21], [478, 478]], "char_spans": [[0, 14], [123, 137], [2400, 2414]]}]}], "context_tokens": [["Interleukin-17A", 0], ["is", 16], ["considered", 19], ["to", 30], ["be", 33], ["central", 36], ["to", 44], ["the", 47], ["pathogenesis", 51], ["of", 64], ["psoriasis", 67], [".", 76], ["We", 78], ["evaluated", 81], ["secukinumab", 91], [",", 102], ["a", 104], ["fully", 106], ["human", 112], ["anti", 118], ["-", 122], ["interleukin-17A", 123], ["monoclonal", 139], ["antibody", 150], [",", 158], ["in", 160], ["patients", 163], ["with", 172], ["moderate", 177], ["-", 185], ["to", 186], ["-", 188], ["severe", 189], ["plaque", 196], ["psoriasis", 203], [".", 212], ["In", 214], ["two", 217], ["phase", 221], ["3", 227], [",", 228], ["double", 230], ["-", 236], ["blind", 237], [",", 242], ["52-week", 244], ["trials", 252], [",", 258], ["ERASURE", 260], ["(", 268], ["Efficacy", 269], ["of", 278], ["Response", 281], ["and", 290], ["Safety", 294], ["of", 301], ["Two", 304], ["Fixed", 308], ["Secukinumab", 314], ["Regimens", 326], ["in", 335], ["Psoriasis", 338], [")", 347], ["and", 349], ["FIXTURE", 353], ["(", 361], ["Full", 362], ["Year", 367], ["Investigative", 372], ["Examination", 386], ["of", 398], ["Secukinumab", 401], ["vs.", 413], ["Etanercept", 417], ["Using", 428], ["Two", 434], ["Dosing", 438], ["Regimens", 445], ["to", 454], ["Determine", 457], ["Efficacy", 467], ["in", 476], ["Psoriasis", 479], [")", 488], [",", 489], ["we", 491], ["randomly", 494], ["assigned", 503], ["738", 512], ["patients", 516], ["(", 525], ["in", 526], ["the", 529], ["ERASURE", 533], ["study", 541], [")", 546], ["and", 548], ["1306", 552], ["patients", 557], ["(", 566], ["in", 567], ["the", 570], ["FIXTURE", 574], ["study", 582], [")", 587], ["to", 589], ["subcutaneous", 592], ["secukinumab", 605], ["at", 617], ["a", 620], ["dose", 622], ["of", 627], ["300", 630], ["mg", 634], ["or", 637], ["150", 640], ["mg", 644], ["(", 647], ["administered", 648], ["once", 661], ["weekly", 666], ["for", 673], ["5", 677], ["weeks", 679], [",", 684], ["then", 686], ["every", 691], ["4", 697], ["weeks", 699], [")", 704], [",", 705], ["placebo", 707], [",", 714], ["or", 716], ["(", 719], ["in", 720], ["the", 723], ["FIXTURE", 727], ["study", 735], ["only", 741], [")", 745], ["etanercept", 747], ["at", 758], ["a", 761], ["dose", 763], ["of", 768], ["50", 771], ["mg", 774], ["(", 777], ["administered", 778], ["twice", 791], ["weekly", 797], ["for", 804], ["12", 808], ["weeks", 811], [",", 816], ["then", 818], ["once", 823], ["weekly", 828], [")", 834], [".", 835], ["The", 837], ["objective", 841], ["of", 851], ["each", 854], ["study", 859], ["was", 865], ["to", 869], ["show", 872], ["the", 877], ["superiority", 881], ["of", 893], ["secukinumab", 896], ["over", 908], ["placebo", 913], ["at", 921], ["week", 924], ["12", 929], ["with", 932], ["respect", 937], ["to", 945], ["the", 948], ["proportion", 952], ["of", 963], ["patients", 966], ["who", 975], ["had", 979], ["a", 983], ["reduction", 985], ["of", 995], ["75", 998], ["%", 1000], ["or", 1002], ["more", 1005], ["from", 1010], ["baseline", 1015], ["in", 1024], ["the", 1027], ["psoriasis", 1031], ["area", 1041], ["-", 1045], ["and", 1046], ["-", 1049], ["severity", 1050], ["index", 1059], ["score", 1065], ["(", 1071], ["PASI", 1072], ["75", 1077], [")", 1079], ["and", 1081], ["a", 1085], ["score", 1087], ["of", 1093], ["0", 1096], ["(", 1098], ["clear", 1099], [")", 1104], ["or", 1106], ["1", 1109], ["(", 1111], ["almost", 1112], ["clear", 1119], [")", 1124], ["on", 1126], ["a", 1129], ["5-point", 1131], ["modified", 1139], ["investigator", 1148], ["'s", 1160], ["global", 1163], ["assessment", 1170], ["(", 1181], ["coprimary", 1182], ["end", 1192], ["points", 1196], [")", 1202], [".", 1203], ["The", 1205], ["proportion", 1209], ["of", 1220], ["patients", 1223], ["who", 1232], ["met", 1236], ["the", 1240], ["criterion", 1244], ["for", 1254], ["PASI", 1258], ["75", 1263], ["at", 1266], ["week", 1269], ["12", 1274], ["was", 1277], ["higher", 1281], ["with", 1288], ["each", 1293], ["secukinumab", 1298], ["dose", 1310], ["than", 1315], ["with", 1320], ["placebo", 1325], ["or", 1333], ["etanercept", 1336], [":", 1346], ["in", 1348], ["the", 1351], ["ERASURE", 1355], ["study", 1363], [",", 1368], ["the", 1370], ["rates", 1374], ["were", 1380], ["81.6", 1385], ["%", 1389], ["with", 1391], ["300", 1396], ["mg", 1400], ["of", 1403], ["secukinumab", 1406], [",", 1417], ["71.6", 1419], ["%", 1423], ["with", 1425], ["150", 1430], ["mg", 1434], ["of", 1437], ["secukinumab", 1440], [",", 1451], ["and", 1453], ["4.5", 1457], ["%", 1460], ["with", 1462], ["placebo", 1467], [";", 1474], ["in", 1476], ["the", 1479], ["FIXTURE", 1483], ["study", 1491], [",", 1496], ["the", 1498], ["rates", 1502], ["were", 1508], ["77.1", 1513], ["%", 1517], ["with", 1519], ["300", 1524], ["mg", 1528], ["of", 1531], ["secukinumab", 1534], [",", 1545], ["67.0", 1547], ["%", 1551], ["with", 1553], ["150", 1558], ["mg", 1562], ["of", 1565], ["secukinumab", 1568], [",", 1579], ["44.0", 1581], ["%", 1585], ["with", 1587], ["etanercept", 1592], [",", 1602], ["and", 1604], ["4.9", 1608], ["%", 1611], ["with", 1613], ["placebo", 1618], ["(", 1626], ["P<0.001", 1627], ["for", 1635], ["each", 1639], ["secukinumab", 1644], ["dose", 1656], ["vs.", 1661], ["comparators", 1665], [")", 1676], [".", 1677], ["The", 1679], ["proportion", 1683], ["of", 1694], ["patients", 1697], ["with", 1706], ["a", 1711], ["response", 1713], ["of", 1722], ["0", 1725], ["or", 1727], ["1", 1730], ["on", 1732], ["the", 1735], ["modified", 1739], ["investigator", 1748], ["'s", 1760], ["global", 1763], ["assessment", 1770], ["at", 1781], ["week", 1784], ["12", 1789], ["was", 1792], ["higher", 1796], ["with", 1803], ["each", 1808], ["secukinumab", 1813], ["dose", 1825], ["than", 1830], ["with", 1835], ["placebo", 1840], ["or", 1848], ["etanercept", 1851], [":", 1861], ["in", 1863], ["the", 1866], ["ERASURE", 1870], ["study", 1878], [",", 1883], ["the", 1885], ["rates", 1889], ["were", 1895], ["65.3", 1900], ["%", 1904], ["with", 1906], ["300", 1911], ["mg", 1915], ["of", 1918], ["secukinumab", 1921], [",", 1932], ["51.2", 1934], ["%", 1938], ["with", 1940], ["150", 1945], ["mg", 1949], ["of", 1952], ["secukinumab", 1955], [",", 1966], ["and", 1968], ["2.4", 1972], ["%", 1975], ["with", 1977], ["placebo", 1982], [";", 1989], ["in", 1991], ["the", 1994], ["FIXTURE", 1998], ["study", 2006], [",", 2011], ["the", 2013], ["rates", 2017], ["were", 2023], ["62.5", 2028], ["%", 2032], ["with", 2034], ["300", 2039], ["mg", 2043], ["of", 2046], ["secukinumab", 2049], [",", 2060], ["51.1", 2062], ["%", 2066], ["with", 2068], ["150", 2073], ["mg", 2077], ["of", 2080], ["secukinumab", 2083], [",", 2094], ["27.2", 2096], ["%", 2100], ["with", 2102], ["etanercept", 2107], [",", 2117], ["and", 2119], ["2.8", 2123], ["%", 2126], ["with", 2128], ["placebo", 2133], ["(", 2141], ["P<0.001", 2142], ["for", 2150], ["each", 2154], ["secukinumab", 2159], ["dose", 2171], ["vs.", 2176], ["comparators", 2180], [")", 2191], [".", 2192], ["The", 2194], ["rates", 2198], ["of", 2204], ["infection", 2207], ["were", 2217], ["higher", 2222], ["with", 2229], ["secukinumab", 2234], ["than", 2246], ["with", 2251], ["placebo", 2256], ["in", 2264], ["both", 2267], ["studies", 2272], ["and", 2280], ["were", 2284], ["similar", 2289], ["to", 2297], ["those", 2300], ["with", 2306], ["etanercept", 2311], [".", 2321], ["Secukinumab", 2323], ["was", 2335], ["effective", 2339], ["for", 2349], ["psoriasis", 2353], ["in", 2363], ["two", 2366], ["randomized", 2370], ["trials", 2381], [",", 2387], ["validating", 2389], ["interleukin-17A", 2400], ["as", 2416], ["a", 2419], ["therapeutic", 2421], ["target", 2433], [".", 2439], ["(", 2441], ["Funded", 2442], ["by", 2449], ["Novartis", 2452], ["Pharmaceuticals", 2461], [";", 2476], ["ERASURE", 2478], ["and", 2486], ["FIXTURE", 2490], ["ClinicalTrials.gov", 2498], ["numbers", 2517], [",", 2524], ["NCT01365455", 2526], ["and", 2538], ["NCT01358578", 2542], [",", 2553], ["respectively", 2555], [".", 2567], [")", 2568], [".", 2569]]}
{"context": "Neurofibromatosis type 1 is one of the most common autosomal dominant disorders, affecting about 1:3,500 individuals. NF1 exon 7 displays weakly defined exon-intron boundaries, and is particularly prone to missplicing. In this study we investigated the expression of exon 7 transcripts using bioinformatic identification of splicing regulatory sequences, and functional minigene analysis of four sequence changes [c.910C>T (R304X), c.945G>A/c.946C>A (Q315Q/L316M), c.1005T>C (N335N)] identified in exon 7 of three different NF1 patients. Our results detected the presence of three exonic splicing enhancers (ESEs) and one putative exonic splicing silencer (ESS) element. The wild type minigene assay resulted in three alternative isoforms, including a transcript lacking NF1 exon 7 (NF1DeltaE7). Both the wild type and the mutated constructs shared NF1DeltaE7 in addition to the complete messenger, but displayed a different ratio between the two transcripts. In the presence of R304X and Q315Q/L316M mutations, the relative proportion between the different isoforms is shifted toward the expression of NF1DeltaE7, while in the presence of N335N variant, the NF1DeltaE7 expression is abolished. In conclusion, it appears mandatory to investigate the role of each nucleotide change within the NF1 coding sequence, since a significant proportion of NF1 exon 7 mutations affects pre-mRNA splicing, by disrupting exonic splicing motifs and modifying the delicate balance between aberrantly and correctly spliced transcripts.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "8264477aefe0438e81189bea1f1be19d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[99, 99], [141, 141], [232, 232], [18, 18], [241, 241]], "char_spans": [[524, 526], [771, 773], [1292, 1294], [118, 120], [1347, 1349]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["is", 25], ["one", 28], ["of", 32], ["the", 35], ["most", 39], ["common", 44], ["autosomal", 51], ["dominant", 61], ["disorders", 70], [",", 79], ["affecting", 81], ["about", 91], ["1:3,500", 97], ["individuals", 105], [".", 116], ["NF1", 118], ["exon", 122], ["7", 127], ["displays", 129], ["weakly", 138], ["defined", 145], ["exon", 153], ["-", 157], ["intron", 158], ["boundaries", 165], [",", 175], ["and", 177], ["is", 181], ["particularly", 184], ["prone", 197], ["to", 203], ["missplicing", 206], [".", 217], ["In", 219], ["this", 222], ["study", 227], ["we", 233], ["investigated", 236], ["the", 249], ["expression", 253], ["of", 264], ["exon", 267], ["7", 272], ["transcripts", 274], ["using", 286], ["bioinformatic", 292], ["identification", 306], ["of", 321], ["splicing", 324], ["regulatory", 333], ["sequences", 344], [",", 353], ["and", 355], ["functional", 359], ["minigene", 370], ["analysis", 379], ["of", 388], ["four", 391], ["sequence", 396], ["changes", 405], ["[", 413], ["c.910C", 414], [">", 420], ["T", 421], ["(", 423], ["R304X", 424], [")", 429], [",", 430], ["c.945G", 432], [">", 438], ["A", 439], ["/", 440], ["c.946C", 441], [">", 447], ["A", 448], ["(", 450], ["Q315Q", 451], ["/", 456], ["L316", 457], ["M", 461], [")", 462], [",", 463], ["c.1005T", 465], [">", 472], ["C", 473], ["(", 475], ["N335N", 476], [")", 481], ["]", 482], ["identified", 484], ["in", 495], ["exon", 498], ["7", 503], ["of", 505], ["three", 508], ["different", 514], ["NF1", 524], ["patients", 528], [".", 536], ["Our", 538], ["results", 542], ["detected", 550], ["the", 559], ["presence", 563], ["of", 572], ["three", 575], ["exonic", 581], ["splicing", 588], ["enhancers", 597], ["(", 607], ["ESEs", 608], [")", 612], ["and", 614], ["one", 618], ["putative", 622], ["exonic", 631], ["splicing", 638], ["silencer", 647], ["(", 656], ["ESS", 657], [")", 660], ["element", 662], [".", 669], ["The", 671], ["wild", 675], ["type", 680], ["minigene", 685], ["assay", 694], ["resulted", 700], ["in", 709], ["three", 712], ["alternative", 718], ["isoforms", 730], [",", 738], ["including", 740], ["a", 750], ["transcript", 752], ["lacking", 763], ["NF1", 771], ["exon", 775], ["7", 780], ["(", 782], ["NF1DeltaE7", 783], [")", 793], [".", 794], ["Both", 796], ["the", 801], ["wild", 805], ["type", 810], ["and", 815], ["the", 819], ["mutated", 823], ["constructs", 831], ["shared", 842], ["NF1DeltaE7", 849], ["in", 860], ["addition", 863], ["to", 872], ["the", 875], ["complete", 879], ["messenger", 888], [",", 897], ["but", 899], ["displayed", 903], ["a", 913], ["different", 915], ["ratio", 925], ["between", 931], ["the", 939], ["two", 943], ["transcripts", 947], [".", 958], ["In", 960], ["the", 963], ["presence", 967], ["of", 976], ["R304X", 979], ["and", 985], ["Q315Q", 989], ["/", 994], ["L316", 995], ["M", 999], ["mutations", 1001], [",", 1010], ["the", 1012], ["relative", 1016], ["proportion", 1025], ["between", 1036], ["the", 1044], ["different", 1048], ["isoforms", 1058], ["is", 1067], ["shifted", 1070], ["toward", 1078], ["the", 1085], ["expression", 1089], ["of", 1100], ["NF1DeltaE7", 1103], [",", 1113], ["while", 1115], ["in", 1121], ["the", 1124], ["presence", 1128], ["of", 1137], ["N335N", 1140], ["variant", 1146], [",", 1153], ["the", 1155], ["NF1DeltaE7", 1159], ["expression", 1170], ["is", 1181], ["abolished", 1184], [".", 1193], ["In", 1195], ["conclusion", 1198], [",", 1208], ["it", 1210], ["appears", 1213], ["mandatory", 1221], ["to", 1231], ["investigate", 1234], ["the", 1246], ["role", 1250], ["of", 1255], ["each", 1258], ["nucleotide", 1263], ["change", 1274], ["within", 1281], ["the", 1288], ["NF1", 1292], ["coding", 1296], ["sequence", 1303], [",", 1311], ["since", 1313], ["a", 1319], ["significant", 1321], ["proportion", 1333], ["of", 1344], ["NF1", 1347], ["exon", 1351], ["7", 1356], ["mutations", 1358], ["affects", 1368], ["pre", 1376], ["-", 1379], ["mRNA", 1380], ["splicing", 1385], [",", 1393], ["by", 1395], ["disrupting", 1398], ["exonic", 1409], ["splicing", 1416], ["motifs", 1425], ["and", 1432], ["modifying", 1436], ["the", 1446], ["delicate", 1450], ["balance", 1459], ["between", 1467], ["aberrantly", 1475], ["and", 1486], ["correctly", 1490], ["spliced", 1500], ["transcripts", 1508], [".", 1519]]}
{"context": "Mgm1 is a member of the dynamin family of GTP-binding proteins. Mgm1 was first identified in yeast, where it affects mitochondrial morphology. The human homologue of Mgm1 is called OPA1. Mutations in the OPA1 gene are the prevailing cause of dominant optic atrophy, a hereditary disease in which progressive degeneration of the optic nerve can lead to blindness. Here we investigate the properties of the Mgm1/OPA1 protein in mammalian cells. We find that Mgm1/OPA1 is localized to the mitochondrial intermembrane space, where it is tightly bound to the outer surface of the inner membrane. Overexpression of wild type or mutant forms of the Mgm1/OPA1 protein cause mitochondria to fragment and, in some cases, cluster near the nucleus, whereas the loss of protein caused by small interfering RNA (siRNA) leads to dispersal of mitochondrial fragments throughout the cytosol. The cristae of these fragmented mitochondria are disorganized. At early time points after transfection with Mgm1/OPA1 siRNA, the mitochondria are not yet fragmented. Instead, the mitochondria swell and stretch, after which they form localized constrictions similar to the mitochondrial abnormalities observed during the early stages of apoptosis. These abnormalities might be the earliest effects of losing Mgm1/OPA1 protein.", "qas": [{"question": "Which is the cellular localization of the protein Opa1?", "answers": ["mitochondrial intermembrane space"], "qid": "da99a2b47daf44bb94a87ccf477bf308", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["localization", 22], ["of", 35], ["the", 38], ["protein", 42], ["Opa1", 50], ["?", 54]], "detected_answers": [{"text": "mitochondrial intermembrane space", "token_spans": [[87, 89]], "char_spans": [[486, 518]]}]}], "context_tokens": [["Mgm1", 0], ["is", 5], ["a", 8], ["member", 10], ["of", 17], ["the", 20], ["dynamin", 24], ["family", 32], ["of", 39], ["GTP", 42], ["-", 45], ["binding", 46], ["proteins", 54], [".", 62], ["Mgm1", 64], ["was", 69], ["first", 73], ["identified", 79], ["in", 90], ["yeast", 93], [",", 98], ["where", 100], ["it", 106], ["affects", 109], ["mitochondrial", 117], ["morphology", 131], [".", 141], ["The", 143], ["human", 147], ["homologue", 153], ["of", 163], ["Mgm1", 166], ["is", 171], ["called", 174], ["OPA1", 181], [".", 185], ["Mutations", 187], ["in", 197], ["the", 200], ["OPA1", 204], ["gene", 209], ["are", 214], ["the", 218], ["prevailing", 222], ["cause", 233], ["of", 239], ["dominant", 242], ["optic", 251], ["atrophy", 257], [",", 264], ["a", 266], ["hereditary", 268], ["disease", 279], ["in", 287], ["which", 290], ["progressive", 296], ["degeneration", 308], ["of", 321], ["the", 324], ["optic", 328], ["nerve", 334], ["can", 340], ["lead", 344], ["to", 349], ["blindness", 352], [".", 361], ["Here", 363], ["we", 368], ["investigate", 371], ["the", 383], ["properties", 387], ["of", 398], ["the", 401], ["Mgm1/OPA1", 405], ["protein", 415], ["in", 423], ["mammalian", 426], ["cells", 436], [".", 441], ["We", 443], ["find", 446], ["that", 451], ["Mgm1/OPA1", 456], ["is", 466], ["localized", 469], ["to", 479], ["the", 482], ["mitochondrial", 486], ["intermembrane", 500], ["space", 514], [",", 519], ["where", 521], ["it", 527], ["is", 530], ["tightly", 533], ["bound", 541], ["to", 547], ["the", 550], ["outer", 554], ["surface", 560], ["of", 568], ["the", 571], ["inner", 575], ["membrane", 581], [".", 589], ["Overexpression", 591], ["of", 606], ["wild", 609], ["type", 614], ["or", 619], ["mutant", 622], ["forms", 629], ["of", 635], ["the", 638], ["Mgm1/OPA1", 642], ["protein", 652], ["cause", 660], ["mitochondria", 666], ["to", 679], ["fragment", 682], ["and", 691], [",", 694], ["in", 696], ["some", 699], ["cases", 704], [",", 709], ["cluster", 711], ["near", 719], ["the", 724], ["nucleus", 728], [",", 735], ["whereas", 737], ["the", 745], ["loss", 749], ["of", 754], ["protein", 757], ["caused", 765], ["by", 772], ["small", 775], ["interfering", 781], ["RNA", 793], ["(", 797], ["siRNA", 798], [")", 803], ["leads", 805], ["to", 811], ["dispersal", 814], ["of", 824], ["mitochondrial", 827], ["fragments", 841], ["throughout", 851], ["the", 862], ["cytosol", 866], [".", 873], ["The", 875], ["cristae", 879], ["of", 887], ["these", 890], ["fragmented", 896], ["mitochondria", 907], ["are", 920], ["disorganized", 924], [".", 936], ["At", 938], ["early", 941], ["time", 947], ["points", 952], ["after", 959], ["transfection", 965], ["with", 978], ["Mgm1/OPA1", 983], ["siRNA", 993], [",", 998], ["the", 1000], ["mitochondria", 1004], ["are", 1017], ["not", 1021], ["yet", 1025], ["fragmented", 1029], [".", 1039], ["Instead", 1041], [",", 1048], ["the", 1050], ["mitochondria", 1054], ["swell", 1067], ["and", 1073], ["stretch", 1077], [",", 1084], ["after", 1086], ["which", 1092], ["they", 1098], ["form", 1103], ["localized", 1108], ["constrictions", 1118], ["similar", 1132], ["to", 1140], ["the", 1143], ["mitochondrial", 1147], ["abnormalities", 1161], ["observed", 1175], ["during", 1184], ["the", 1191], ["early", 1195], ["stages", 1201], ["of", 1208], ["apoptosis", 1211], [".", 1220], ["These", 1222], ["abnormalities", 1228], ["might", 1242], ["be", 1248], ["the", 1251], ["earliest", 1255], ["effects", 1264], ["of", 1272], ["losing", 1275], ["Mgm1/OPA1", 1282], ["protein", 1292], [".", 1299]]}
{"context": "The mixed-lineage leukemia protein MLL1 is a transcriptional regulator with an essential role in early development and hematopoiesis. The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain. We have determined the crystal structure of the MLL1 SET domain in complex with cofactor product AdoHcy and a histone H3 peptide. This structure indicates that, in order to form a well-ordered active site, a highly variable but essential component of the SET domain must be repositioned. To test this idea, we compared the effect of the addition of MLL complex members on methyltransferase activity and show that both RbBP5 and Ash2L but not Wdr5 stimulate activity. Additionally, we have determined the effect of posttranslational modifications on histone H3 residues downstream and upstream from the target lysine and provide a structural explanation for why H3T3 phosphorylation and H3K9 acetylation regulate activity.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "76dece4105a44e9e9041be62fc48fbed", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[31, 31]], "char_spans": [[193, 196]]}]}], "context_tokens": [["The", 0], ["mixed", 4], ["-", 9], ["lineage", 10], ["leukemia", 18], ["protein", 27], ["MLL1", 35], ["is", 40], ["a", 43], ["transcriptional", 45], ["regulator", 61], ["with", 71], ["an", 76], ["essential", 79], ["role", 89], ["in", 94], ["early", 97], ["development", 103], ["and", 115], ["hematopoiesis", 119], [".", 132], ["The", 134], ["biological", 138], ["function", 149], ["of", 158], ["MLL1", 161], ["is", 166], ["mediated", 169], ["by", 178], ["the", 181], ["histone", 185], ["H3K4", 193], ["methyltransferase", 198], ["activity", 216], ["of", 225], ["the", 228], ["carboxyl", 232], ["-", 240], ["terminal", 241], ["SET", 250], ["domain", 254], [".", 260], ["We", 262], ["have", 265], ["determined", 270], ["the", 281], ["crystal", 285], ["structure", 293], ["of", 303], ["the", 306], ["MLL1", 310], ["SET", 315], ["domain", 319], ["in", 326], ["complex", 329], ["with", 337], ["cofactor", 342], ["product", 351], ["AdoHcy", 359], ["and", 366], ["a", 370], ["histone", 372], ["H3", 380], ["peptide", 383], [".", 390], ["This", 392], ["structure", 397], ["indicates", 407], ["that", 417], [",", 421], ["in", 423], ["order", 426], ["to", 432], ["form", 435], ["a", 440], ["well", 442], ["-", 446], ["ordered", 447], ["active", 455], ["site", 462], [",", 466], ["a", 468], ["highly", 470], ["variable", 477], ["but", 486], ["essential", 490], ["component", 500], ["of", 510], ["the", 513], ["SET", 517], ["domain", 521], ["must", 528], ["be", 533], ["repositioned", 536], [".", 548], ["To", 550], ["test", 553], ["this", 558], ["idea", 563], [",", 567], ["we", 569], ["compared", 572], ["the", 581], ["effect", 585], ["of", 592], ["the", 595], ["addition", 599], ["of", 608], ["MLL", 611], ["complex", 615], ["members", 623], ["on", 631], ["methyltransferase", 634], ["activity", 652], ["and", 661], ["show", 665], ["that", 670], ["both", 675], ["RbBP5", 680], ["and", 686], ["Ash2L", 690], ["but", 696], ["not", 700], ["Wdr5", 704], ["stimulate", 709], ["activity", 719], [".", 727], ["Additionally", 729], [",", 741], ["we", 743], ["have", 746], ["determined", 751], ["the", 762], ["effect", 766], ["of", 773], ["posttranslational", 776], ["modifications", 794], ["on", 808], ["histone", 811], ["H3", 819], ["residues", 822], ["downstream", 831], ["and", 842], ["upstream", 846], ["from", 855], ["the", 860], ["target", 864], ["lysine", 871], ["and", 878], ["provide", 882], ["a", 890], ["structural", 892], ["explanation", 903], ["for", 915], ["why", 919], ["H3T3", 923], ["phosphorylation", 928], ["and", 944], ["H3K9", 948], ["acetylation", 953], ["regulate", 965], ["activity", 974], [".", 982]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom Disease (WED), is a sensorimotor disorder for which the exact pathophysiology remains unclear. Brain iron insufficiency and altered dopaminergic function appear to play important roles in the etiology of the disorder. This concept is based partly on extensive research studies using cerebrospinal fluid (CSF), autopsy material, and brain imaging indicating reduced regional brain iron and on the clinical efficacy of dopamine receptor agonists for alleviating RLS symptoms. Finding causal relations, linking low brain iron to altered dopaminergic function in RLS, has required however the use of animal models. These models have provided insights into how alterations in brain iron homeostasis and dopaminergic system may be involved in RLS. The results of animal models of RLS and biochemical, postmortem, and imaging studies in patients with the disease suggest that disruptions in brain iron trafficking lead to disturbances in striatal dopamine neurotransmission for at least some patients with RLS. This review examines the data supporting an iron deficiency-dopamine metabolic theory of RLS by relating the results from animal model investigations of the influence of brain iron deficiency on dopaminergic systems to data from clinical studies in patients with RLS.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "363dd991aef248d6b70acffea567a64a", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["Disease", 57], ["(", 65], ["WED", 66], [")", 69], [",", 70], ["is", 72], ["a", 75], ["sensorimotor", 77], ["disorder", 90], ["for", 99], ["which", 103], ["the", 109], ["exact", 113], ["pathophysiology", 119], ["remains", 135], ["unclear", 143], [".", 150], ["Brain", 152], ["iron", 158], ["insufficiency", 163], ["and", 177], ["altered", 181], ["dopaminergic", 189], ["function", 202], ["appear", 211], ["to", 218], ["play", 221], ["important", 226], ["roles", 236], ["in", 242], ["the", 245], ["etiology", 249], ["of", 258], ["the", 261], ["disorder", 265], [".", 273], ["This", 275], ["concept", 280], ["is", 288], ["based", 291], ["partly", 297], ["on", 304], ["extensive", 307], ["research", 317], ["studies", 326], ["using", 334], ["cerebrospinal", 340], ["fluid", 354], ["(", 360], ["CSF", 361], [")", 364], [",", 365], ["autopsy", 367], ["material", 375], [",", 383], ["and", 385], ["brain", 389], ["imaging", 395], ["indicating", 403], ["reduced", 414], ["regional", 422], ["brain", 431], ["iron", 437], ["and", 442], ["on", 446], ["the", 449], ["clinical", 453], ["efficacy", 462], ["of", 471], ["dopamine", 474], ["receptor", 483], ["agonists", 492], ["for", 501], ["alleviating", 505], ["RLS", 517], ["symptoms", 521], [".", 529], ["Finding", 531], ["causal", 539], ["relations", 546], [",", 555], ["linking", 557], ["low", 565], ["brain", 569], ["iron", 575], ["to", 580], ["altered", 583], ["dopaminergic", 591], ["function", 604], ["in", 613], ["RLS", 616], [",", 619], ["has", 621], ["required", 625], ["however", 634], ["the", 642], ["use", 646], ["of", 650], ["animal", 653], ["models", 660], [".", 666], ["These", 668], ["models", 674], ["have", 681], ["provided", 686], ["insights", 695], ["into", 704], ["how", 709], ["alterations", 713], ["in", 725], ["brain", 728], ["iron", 734], ["homeostasis", 739], ["and", 751], ["dopaminergic", 755], ["system", 768], ["may", 775], ["be", 779], ["involved", 782], ["in", 791], ["RLS", 794], [".", 797], ["The", 799], ["results", 803], ["of", 811], ["animal", 814], ["models", 821], ["of", 828], ["RLS", 831], ["and", 835], ["biochemical", 839], [",", 850], ["postmortem", 852], [",", 862], ["and", 864], ["imaging", 868], ["studies", 876], ["in", 884], ["patients", 887], ["with", 896], ["the", 901], ["disease", 905], ["suggest", 913], ["that", 921], ["disruptions", 926], ["in", 938], ["brain", 941], ["iron", 947], ["trafficking", 952], ["lead", 964], ["to", 969], ["disturbances", 972], ["in", 985], ["striatal", 988], ["dopamine", 997], ["neurotransmission", 1006], ["for", 1024], ["at", 1028], ["least", 1031], ["some", 1037], ["patients", 1042], ["with", 1051], ["RLS", 1056], [".", 1059], ["This", 1061], ["review", 1066], ["examines", 1073], ["the", 1082], ["data", 1086], ["supporting", 1091], ["an", 1102], ["iron", 1105], ["deficiency", 1110], ["-", 1120], ["dopamine", 1121], ["metabolic", 1130], ["theory", 1140], ["of", 1147], ["RLS", 1150], ["by", 1154], ["relating", 1157], ["the", 1166], ["results", 1170], ["from", 1178], ["animal", 1183], ["model", 1190], ["investigations", 1196], ["of", 1211], ["the", 1214], ["influence", 1218], ["of", 1228], ["brain", 1231], ["iron", 1237], ["deficiency", 1242], ["on", 1253], ["dopaminergic", 1256], ["systems", 1269], ["to", 1277], ["data", 1280], ["from", 1285], ["clinical", 1290], ["studies", 1299], ["in", 1307], ["patients", 1310], ["with", 1319], ["RLS", 1324], [".", 1327]]}
{"context": "The BCR/ABL gene fusion, the hallmark of chronic myelogenous leukemia (CML) is generated in 2-10% of patients by a variant Ph translocation involving 9q34, 22q11.2, and one or more additional genomic regions. The objective of this study was the characterization by conventional and molecular cytogenetics of complex variant Ph translocations present at diagnosis. FISH studies were performed in 7 cases using the LSI BCR/ABL ES probe allowing the detection of the fusion BCR/ABL gene on the Ph chromosome in all of them and 9q34 deletions in 2 cases. Three cryptic complex rearrangements were detected by FISH studies. The third and the fourth chromosome regions involved in the 8 complex variant translocations were: 1q21, 1p36, 5q31, 11q13, 12q13, 12p13, and 20q12. In conclusion, FISH studies have been useful in the detection of the BCR/ABL rearrangements and 9q34 deletions, and to identify complex rearrangements that differ from the ones previously established by conventional cytogenetics.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "85a18e64fb2d47b0afeee4832c599891", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[1, 5]], "char_spans": [[4, 22]]}]}], "context_tokens": [["The", 0], ["BCR", 4], ["/", 7], ["ABL", 8], ["gene", 12], ["fusion", 17], [",", 23], ["the", 25], ["hallmark", 29], ["of", 38], ["chronic", 41], ["myelogenous", 49], ["leukemia", 61], ["(", 70], ["CML", 71], [")", 74], ["is", 76], ["generated", 79], ["in", 89], ["2", 92], ["-", 93], ["10", 94], ["%", 96], ["of", 98], ["patients", 101], ["by", 110], ["a", 113], ["variant", 115], ["Ph", 123], ["translocation", 126], ["involving", 140], ["9q34", 150], [",", 154], ["22q11.2", 156], [",", 163], ["and", 165], ["one", 169], ["or", 173], ["more", 176], ["additional", 181], ["genomic", 192], ["regions", 200], [".", 207], ["The", 209], ["objective", 213], ["of", 223], ["this", 226], ["study", 231], ["was", 237], ["the", 241], ["characterization", 245], ["by", 262], ["conventional", 265], ["and", 278], ["molecular", 282], ["cytogenetics", 292], ["of", 305], ["complex", 308], ["variant", 316], ["Ph", 324], ["translocations", 327], ["present", 342], ["at", 350], ["diagnosis", 353], [".", 362], ["FISH", 364], ["studies", 369], ["were", 377], ["performed", 382], ["in", 392], ["7", 395], ["cases", 397], ["using", 403], ["the", 409], ["LSI", 413], ["BCR", 417], ["/", 420], ["ABL", 421], ["ES", 425], ["probe", 428], ["allowing", 434], ["the", 443], ["detection", 447], ["of", 457], ["the", 460], ["fusion", 464], ["BCR", 471], ["/", 474], ["ABL", 475], ["gene", 479], ["on", 484], ["the", 487], ["Ph", 491], ["chromosome", 494], ["in", 505], ["all", 508], ["of", 512], ["them", 515], ["and", 520], ["9q34", 524], ["deletions", 529], ["in", 539], ["2", 542], ["cases", 544], [".", 549], ["Three", 551], ["cryptic", 557], ["complex", 565], ["rearrangements", 573], ["were", 588], ["detected", 593], ["by", 602], ["FISH", 605], ["studies", 610], [".", 617], ["The", 619], ["third", 623], ["and", 629], ["the", 633], ["fourth", 637], ["chromosome", 644], ["regions", 655], ["involved", 663], ["in", 672], ["the", 675], ["8", 679], ["complex", 681], ["variant", 689], ["translocations", 697], ["were", 712], [":", 716], ["1q21", 718], [",", 722], ["1p36", 724], [",", 728], ["5q31", 730], [",", 734], ["11q13", 736], [",", 741], ["12q13", 743], [",", 748], ["12p13", 750], [",", 755], ["and", 757], ["20q12", 761], [".", 766], ["In", 768], ["conclusion", 771], [",", 781], ["FISH", 783], ["studies", 788], ["have", 796], ["been", 801], ["useful", 806], ["in", 813], ["the", 816], ["detection", 820], ["of", 830], ["the", 833], ["BCR", 837], ["/", 840], ["ABL", 841], ["rearrangements", 845], ["and", 860], ["9q34", 864], ["deletions", 869], [",", 878], ["and", 880], ["to", 884], ["identify", 887], ["complex", 896], ["rearrangements", 904], ["that", 919], ["differ", 924], ["from", 931], ["the", 936], ["ones", 940], ["previously", 945], ["established", 956], ["by", 968], ["conventional", 971], ["cytogenetics", 984], [".", 996]]}
{"context": "Neurofibromatosis type 1 (NF1) is one of the most common human genetic disorders and is associated with significant morbidity and mortality. The gene responsible for this disorder, NF1, encodes neurofibromin, which can function to down-regulate ras activity. Mutations that inactivate NF7 result in elevated levels of ras signaling and increased cell proliferation in some tissues. NF7 functions as a tumor suppressor gene; patients inherit one mutated copy and are believed to acquire a \"second hit\" in tissues that go on to form benign or malignant tumors. NF7 is expressed widely, yet certain tissues are more susceptible to growth dysregulation in NF1 patients. Cardiovascular defects also contribute to NF1, though the cause remains unclear. In a recent study, we used tissue-specific gene inactivation in mice to study the role of neurofibromin in heart development. A further understanding of neurofibromin function will help to elucidate the pathophysiology of NF1 and will also lead to a better understanding of cell cycle regulation and ras pathways in specific cell types. Finally, we comment on how similar genetic strategies can be used in mice to study the role of additional signaling pathways involved in heart development.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "85c02eb57c7c40d099713e942323c658", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[123, 123], [115, 115], [4, 4], [168, 168], [31, 31]], "char_spans": [[708, 710], [652, 654], [26, 28], [969, 971], [181, 183]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["one", 34], ["of", 38], ["the", 41], ["most", 45], ["common", 50], ["human", 57], ["genetic", 63], ["disorders", 71], ["and", 81], ["is", 85], ["associated", 88], ["with", 99], ["significant", 104], ["morbidity", 116], ["and", 126], ["mortality", 130], [".", 139], ["The", 141], ["gene", 145], ["responsible", 150], ["for", 162], ["this", 166], ["disorder", 171], [",", 179], ["NF1", 181], [",", 184], ["encodes", 186], ["neurofibromin", 194], [",", 207], ["which", 209], ["can", 215], ["function", 219], ["to", 228], ["down", 231], ["-", 235], ["regulate", 236], ["ras", 245], ["activity", 249], [".", 257], ["Mutations", 259], ["that", 269], ["inactivate", 274], ["NF7", 285], ["result", 289], ["in", 296], ["elevated", 299], ["levels", 308], ["of", 315], ["ras", 318], ["signaling", 322], ["and", 332], ["increased", 336], ["cell", 346], ["proliferation", 351], ["in", 365], ["some", 368], ["tissues", 373], [".", 380], ["NF7", 382], ["functions", 386], ["as", 396], ["a", 399], ["tumor", 401], ["suppressor", 407], ["gene", 418], [";", 422], ["patients", 424], ["inherit", 433], ["one", 441], ["mutated", 445], ["copy", 453], ["and", 458], ["are", 462], ["believed", 466], ["to", 475], ["acquire", 478], ["a", 486], ["\"", 488], ["second", 489], ["hit", 496], ["\"", 499], ["in", 501], ["tissues", 504], ["that", 512], ["go", 517], ["on", 520], ["to", 523], ["form", 526], ["benign", 531], ["or", 538], ["malignant", 541], ["tumors", 551], [".", 557], ["NF7", 559], ["is", 563], ["expressed", 566], ["widely", 576], [",", 582], ["yet", 584], ["certain", 588], ["tissues", 596], ["are", 604], ["more", 608], ["susceptible", 613], ["to", 625], ["growth", 628], ["dysregulation", 635], ["in", 649], ["NF1", 652], ["patients", 656], [".", 664], ["Cardiovascular", 666], ["defects", 681], ["also", 689], ["contribute", 694], ["to", 705], ["NF1", 708], [",", 711], ["though", 713], ["the", 720], ["cause", 724], ["remains", 730], ["unclear", 738], [".", 745], ["In", 747], ["a", 750], ["recent", 752], ["study", 759], [",", 764], ["we", 766], ["used", 769], ["tissue", 774], ["-", 780], ["specific", 781], ["gene", 790], ["inactivation", 795], ["in", 808], ["mice", 811], ["to", 816], ["study", 819], ["the", 825], ["role", 829], ["of", 834], ["neurofibromin", 837], ["in", 851], ["heart", 854], ["development", 860], [".", 871], ["A", 873], ["further", 875], ["understanding", 883], ["of", 897], ["neurofibromin", 900], ["function", 914], ["will", 923], ["help", 928], ["to", 933], ["elucidate", 936], ["the", 946], ["pathophysiology", 950], ["of", 966], ["NF1", 969], ["and", 973], ["will", 977], ["also", 982], ["lead", 987], ["to", 992], ["a", 995], ["better", 997], ["understanding", 1004], ["of", 1018], ["cell", 1021], ["cycle", 1026], ["regulation", 1032], ["and", 1043], ["ras", 1047], ["pathways", 1051], ["in", 1060], ["specific", 1063], ["cell", 1072], ["types", 1077], [".", 1082], ["Finally", 1084], [",", 1091], ["we", 1093], ["comment", 1096], ["on", 1104], ["how", 1107], ["similar", 1111], ["genetic", 1119], ["strategies", 1127], ["can", 1138], ["be", 1142], ["used", 1145], ["in", 1150], ["mice", 1153], ["to", 1158], ["study", 1161], ["the", 1167], ["role", 1171], ["of", 1176], ["additional", 1179], ["signaling", 1190], ["pathways", 1200], ["involved", 1209], ["in", 1218], ["heart", 1221], ["development", 1227], [".", 1238]]}
{"context": "RNA editing by deamination of specific adenosine bases to inosines during pre-mRNA processing generates edited isoforms of proteins. Recoding RNA editing is more widespread in Drosophila than in vertebrates. Editing levels rise strongly at metamorphosis, and Adar(5G1) null mutant flies lack editing events in hundreds of CNS transcripts; mutant flies have reduced viability, severely defective locomotion and age-dependent neurodegeneration. On the other hand, overexpressing an adult dADAR isoform with high enzymatic activity ubiquitously during larval and pupal stages is lethal. Advantage was taken of this to screen for genetic modifiers; Adar overexpression lethality is rescued by reduced dosage of the Rdl (Resistant to dieldrin), gene encoding a subunit of inhibitory GABA receptors. Reduced dosage of the Gad1 gene encoding the GABA synthetase also rescues Adar overexpression lethality. Drosophila Adar(5G1) mutant phenotypes are ameliorated by feeding GABA modulators. We demonstrate that neuronal excitability is linked to dADAR expression levels in individual neurons; Adar-overexpressing larval motor neurons show reduced excitability whereas Adar(5G1) null mutant or targeted Adar knockdown motor neurons exhibit increased excitability. GABA inhibitory signalling is impaired in human epileptic and autistic conditions, and vertebrate ADARs may have a relevant evolutionarily conserved control over neuronal excitability.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "8c9513c5db4344709452efcb0a8fca01", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[104, 104], [189, 189], [173, 173], [142, 142]], "char_spans": [[645, 648], [1193, 1196], [1084, 1087], [868, 871]]}]}], "context_tokens": [["RNA", 0], ["editing", 4], ["by", 12], ["deamination", 15], ["of", 27], ["specific", 30], ["adenosine", 39], ["bases", 49], ["to", 55], ["inosines", 58], ["during", 67], ["pre", 74], ["-", 77], ["mRNA", 78], ["processing", 83], ["generates", 94], ["edited", 104], ["isoforms", 111], ["of", 120], ["proteins", 123], [".", 131], ["Recoding", 133], ["RNA", 142], ["editing", 146], ["is", 154], ["more", 157], ["widespread", 162], ["in", 173], ["Drosophila", 176], ["than", 187], ["in", 192], ["vertebrates", 195], [".", 206], ["Editing", 208], ["levels", 216], ["rise", 223], ["strongly", 228], ["at", 237], ["metamorphosis", 240], [",", 253], ["and", 255], ["Adar(5G1", 259], [")", 267], ["null", 269], ["mutant", 274], ["flies", 281], ["lack", 287], ["editing", 292], ["events", 300], ["in", 307], ["hundreds", 310], ["of", 319], ["CNS", 322], ["transcripts", 326], [";", 337], ["mutant", 339], ["flies", 346], ["have", 352], ["reduced", 357], ["viability", 365], [",", 374], ["severely", 376], ["defective", 385], ["locomotion", 395], ["and", 406], ["age", 410], ["-", 413], ["dependent", 414], ["neurodegeneration", 424], [".", 441], ["On", 443], ["the", 446], ["other", 450], ["hand", 456], [",", 460], ["overexpressing", 462], ["an", 477], ["adult", 480], ["dADAR", 486], ["isoform", 492], ["with", 500], ["high", 505], ["enzymatic", 510], ["activity", 520], ["ubiquitously", 529], ["during", 542], ["larval", 549], ["and", 556], ["pupal", 560], ["stages", 566], ["is", 573], ["lethal", 576], [".", 582], ["Advantage", 584], ["was", 594], ["taken", 598], ["of", 604], ["this", 607], ["to", 612], ["screen", 615], ["for", 622], ["genetic", 626], ["modifiers", 634], [";", 643], ["Adar", 645], ["overexpression", 650], ["lethality", 665], ["is", 675], ["rescued", 678], ["by", 686], ["reduced", 689], ["dosage", 697], ["of", 704], ["the", 707], ["Rdl", 711], ["(", 715], ["Resistant", 716], ["to", 726], ["dieldrin", 729], [")", 737], [",", 738], ["gene", 740], ["encoding", 745], ["a", 754], ["subunit", 756], ["of", 764], ["inhibitory", 767], ["GABA", 778], ["receptors", 783], [".", 792], ["Reduced", 794], ["dosage", 802], ["of", 809], ["the", 812], ["Gad1", 816], ["gene", 821], ["encoding", 826], ["the", 835], ["GABA", 839], ["synthetase", 844], ["also", 855], ["rescues", 860], ["Adar", 868], ["overexpression", 873], ["lethality", 888], [".", 897], ["Drosophila", 899], ["Adar(5G1", 910], [")", 918], ["mutant", 920], ["phenotypes", 927], ["are", 938], ["ameliorated", 942], ["by", 954], ["feeding", 957], ["GABA", 965], ["modulators", 970], [".", 980], ["We", 982], ["demonstrate", 985], ["that", 997], ["neuronal", 1002], ["excitability", 1011], ["is", 1024], ["linked", 1027], ["to", 1034], ["dADAR", 1037], ["expression", 1043], ["levels", 1054], ["in", 1061], ["individual", 1064], ["neurons", 1075], [";", 1082], ["Adar", 1084], ["-", 1088], ["overexpressing", 1089], ["larval", 1104], ["motor", 1111], ["neurons", 1117], ["show", 1125], ["reduced", 1130], ["excitability", 1138], ["whereas", 1151], ["Adar(5G1", 1159], [")", 1167], ["null", 1169], ["mutant", 1174], ["or", 1181], ["targeted", 1184], ["Adar", 1193], ["knockdown", 1198], ["motor", 1208], ["neurons", 1214], ["exhibit", 1222], ["increased", 1230], ["excitability", 1240], [".", 1252], ["GABA", 1254], ["inhibitory", 1259], ["signalling", 1270], ["is", 1281], ["impaired", 1284], ["in", 1293], ["human", 1296], ["epileptic", 1302], ["and", 1312], ["autistic", 1316], ["conditions", 1325], [",", 1335], ["and", 1337], ["vertebrate", 1341], ["ADARs", 1352], ["may", 1358], ["have", 1362], ["a", 1367], ["relevant", 1369], ["evolutionarily", 1378], ["conserved", 1393], ["control", 1403], ["over", 1411], ["neuronal", 1416], ["excitability", 1425], [".", 1437]]}
{"context": "Pannexin2 (Panx2) is the largest of three members of the pannexin proteins. Pannexins are topologically related to connexins and innexins, but serve different functional roles than forming gap junctions. We previously showed that pannexins form oligomeric channels but unlike connexins and innexins, they form only single membrane channels. High levels of Panx2 mRNA and protein in the Central Nervous System (CNS) have been documented. Whereas Pannexin1 (Panx1) is fairly ubiquitous and Pannexin3 (Panx3) is found in skin and connective tissue, both are fully glycosylated, traffic to the plasma membrane and have functions correlated with extracellular ATP release. Here, we describe trafficking and subcellular localizations of exogenous Panx2 and Panx1 protein expression in MDCK, HeLa, and HEK 293T cells as well as endogenous Panx1 and Panx2 patterns in the CNS. Panx2 was found in intracellular localizations, was partially N-glycosylated, and localizations were non-overlapping with Panx1. Confocal images of hippocampal sections immunolabeled for the astrocytic protein GFAP, Panx1 and Panx2 demonstrated that the two isoforms, Panx1 and Panx2, localized at different subcellular compartments in both astrocytes and neurons. Using recombinant fusions of Panx2 with appended genetic tags developed for correlated light and electron microscopy and then expressed in different cell lines, we determined that Panx2 is localized in the membrane of intracellular vesicles and not in the endoplasmic reticulum as initially indicated by calnexin colocalization experiments. Dual immunofluorescence imaging with protein markers for specific vesicle compartments showed that Panx2 vesicles are early endosomal in origin. In electron tomographic volumes, cross-sections of these vesicles displayed fine structural details and close proximity to actin filaments. Thus, pannexins expressed at different subcellular compartments likely exert distinct functional roles, particularly in the nervous system.", "qas": [{"question": "Where is the protein Pannexin1 located?", "answers": ["plasma membrane"], "qid": "08b59657cf0b4a05a3b821cb53bc7eeb", "question_tokens": [["Where", 0], ["is", 6], ["the", 9], ["protein", 13], ["Pannexin1", 21], ["located", 31], ["?", 38]], "detected_answers": [{"text": "plasma membrane", "token_spans": [[103, 104]], "char_spans": [[590, 604]]}]}], "context_tokens": [["Pannexin2", 0], ["(", 10], ["Panx2", 11], [")", 16], ["is", 18], ["the", 21], ["largest", 25], ["of", 33], ["three", 36], ["members", 42], ["of", 50], ["the", 53], ["pannexin", 57], ["proteins", 66], [".", 74], ["Pannexins", 76], ["are", 86], ["topologically", 90], ["related", 104], ["to", 112], ["connexins", 115], ["and", 125], ["innexins", 129], [",", 137], ["but", 139], ["serve", 143], ["different", 149], ["functional", 159], ["roles", 170], ["than", 176], ["forming", 181], ["gap", 189], ["junctions", 193], [".", 202], ["We", 204], ["previously", 207], ["showed", 218], ["that", 225], ["pannexins", 230], ["form", 240], ["oligomeric", 245], ["channels", 256], ["but", 265], ["unlike", 269], ["connexins", 276], ["and", 286], ["innexins", 290], [",", 298], ["they", 300], ["form", 305], ["only", 310], ["single", 315], ["membrane", 322], ["channels", 331], [".", 339], ["High", 341], ["levels", 346], ["of", 353], ["Panx2", 356], ["mRNA", 362], ["and", 367], ["protein", 371], ["in", 379], ["the", 382], ["Central", 386], ["Nervous", 394], ["System", 402], ["(", 409], ["CNS", 410], [")", 413], ["have", 415], ["been", 420], ["documented", 425], [".", 435], ["Whereas", 437], ["Pannexin1", 445], ["(", 455], ["Panx1", 456], [")", 461], ["is", 463], ["fairly", 466], ["ubiquitous", 473], ["and", 484], ["Pannexin3", 488], ["(", 498], ["Panx3", 499], [")", 504], ["is", 506], ["found", 509], ["in", 515], ["skin", 518], ["and", 523], ["connective", 527], ["tissue", 538], [",", 544], ["both", 546], ["are", 551], ["fully", 555], ["glycosylated", 561], [",", 573], ["traffic", 575], ["to", 583], ["the", 586], ["plasma", 590], ["membrane", 597], ["and", 606], ["have", 610], ["functions", 615], ["correlated", 625], ["with", 636], ["extracellular", 641], ["ATP", 655], ["release", 659], [".", 666], ["Here", 668], [",", 672], ["we", 674], ["describe", 677], ["trafficking", 686], ["and", 698], ["subcellular", 702], ["localizations", 714], ["of", 728], ["exogenous", 731], ["Panx2", 741], ["and", 747], ["Panx1", 751], ["protein", 757], ["expression", 765], ["in", 776], ["MDCK", 779], [",", 783], ["HeLa", 785], [",", 789], ["and", 791], ["HEK", 795], ["293", 799], ["T", 802], ["cells", 804], ["as", 810], ["well", 813], ["as", 818], ["endogenous", 821], ["Panx1", 832], ["and", 838], ["Panx2", 842], ["patterns", 848], ["in", 857], ["the", 860], ["CNS", 864], [".", 867], ["Panx2", 869], ["was", 875], ["found", 879], ["in", 885], ["intracellular", 888], ["localizations", 902], [",", 915], ["was", 917], ["partially", 921], ["N", 931], ["-", 932], ["glycosylated", 933], [",", 945], ["and", 947], ["localizations", 951], ["were", 965], ["non", 970], ["-", 973], ["overlapping", 974], ["with", 986], ["Panx1", 991], [".", 996], ["Confocal", 998], ["images", 1007], ["of", 1014], ["hippocampal", 1017], ["sections", 1029], ["immunolabeled", 1038], ["for", 1052], ["the", 1056], ["astrocytic", 1060], ["protein", 1071], ["GFAP", 1079], [",", 1083], ["Panx1", 1085], ["and", 1091], ["Panx2", 1095], ["demonstrated", 1101], ["that", 1114], ["the", 1119], ["two", 1123], ["isoforms", 1127], [",", 1135], ["Panx1", 1137], ["and", 1143], ["Panx2", 1147], [",", 1152], ["localized", 1154], ["at", 1164], ["different", 1167], ["subcellular", 1177], ["compartments", 1189], ["in", 1202], ["both", 1205], ["astrocytes", 1210], ["and", 1221], ["neurons", 1225], [".", 1232], ["Using", 1234], ["recombinant", 1240], ["fusions", 1252], ["of", 1260], ["Panx2", 1263], ["with", 1269], ["appended", 1274], ["genetic", 1283], ["tags", 1291], ["developed", 1296], ["for", 1306], ["correlated", 1310], ["light", 1321], ["and", 1327], ["electron", 1331], ["microscopy", 1340], ["and", 1351], ["then", 1355], ["expressed", 1360], ["in", 1370], ["different", 1373], ["cell", 1383], ["lines", 1388], [",", 1393], ["we", 1395], ["determined", 1398], ["that", 1409], ["Panx2", 1414], ["is", 1420], ["localized", 1423], ["in", 1433], ["the", 1436], ["membrane", 1440], ["of", 1449], ["intracellular", 1452], ["vesicles", 1466], ["and", 1475], ["not", 1479], ["in", 1483], ["the", 1486], ["endoplasmic", 1490], ["reticulum", 1502], ["as", 1512], ["initially", 1515], ["indicated", 1525], ["by", 1535], ["calnexin", 1538], ["colocalization", 1547], ["experiments", 1562], [".", 1573], ["Dual", 1575], ["immunofluorescence", 1580], ["imaging", 1599], ["with", 1607], ["protein", 1612], ["markers", 1620], ["for", 1628], ["specific", 1632], ["vesicle", 1641], ["compartments", 1649], ["showed", 1662], ["that", 1669], ["Panx2", 1674], ["vesicles", 1680], ["are", 1689], ["early", 1693], ["endosomal", 1699], ["in", 1709], ["origin", 1712], [".", 1718], ["In", 1720], ["electron", 1723], ["tomographic", 1732], ["volumes", 1744], [",", 1751], ["cross", 1753], ["-", 1758], ["sections", 1759], ["of", 1768], ["these", 1771], ["vesicles", 1777], ["displayed", 1786], ["fine", 1796], ["structural", 1801], ["details", 1812], ["and", 1820], ["close", 1824], ["proximity", 1830], ["to", 1840], ["actin", 1843], ["filaments", 1849], [".", 1858], ["Thus", 1860], [",", 1864], ["pannexins", 1866], ["expressed", 1876], ["at", 1886], ["different", 1889], ["subcellular", 1899], ["compartments", 1911], ["likely", 1924], ["exert", 1931], ["distinct", 1937], ["functional", 1946], ["roles", 1957], [",", 1962], ["particularly", 1964], ["in", 1977], ["the", 1980], ["nervous", 1984], ["system", 1992], [".", 1998]]}
{"context": "Calcineurin, a Ca(2+)/calmodulin-stimulated protein phosphatase, plays a key role in T-cell activation by regulating the activity of NFAT (nuclear factor of activated T cells), a family of transcription factors required for the synthesis of several cytokine genes. Calcineurin is the target of the immunosuppressive drugs cyclosporin A and FK506 complexed with their cytoplasmic receptors cyclophilin and FKBP12, respectively. In this study we report that calcineurin is also the target of a recently identified Ca(2+)-binding protein, CHP (for calcineurin homologous protein), which shares a high degree of homology with the regulatory B subunit of calcineurin and with calmodulin. In Jurkat and HeLa cells, overexpression of CHP specifically impaired the nuclear translocation and transcriptional activity of NFAT but had no effect on AP-1 transcriptional activity and only a small (<25%) inhibitory effect on the transcriptional activity of NFkappaB. Further study indicated that CHP inhibits calcineurin activity. In cells overexpressing CHP, the phosphatase activity of immunoprecipitated calcineurin was inhibited by approximately 50%; and in a reconstituted assay, the activity of purified calcineurin was inhibited up to 97% by the addition of purified recombinant CHP in a dose-dependent manner. Moreover, prolonged activation of Jurkat cells was associated with a decreased abundance of CHP, suggesting a possible regulatory mechanism allowing activation of calcineurin. CHP, therefore, is a previously unrecognized endogenous inhibitor of calcineurin activity.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "e689ed17e25f4a969ae75153c594f23b", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[0, 0], [240, 240], [91, 91], [109, 109], [177, 177], [195, 195], [253, 253], [76, 76], [164, 164], [47, 47]], "char_spans": [[0, 10], [1468, 1478], [545, 555], [650, 660], [1094, 1104], [1197, 1207], [1550, 1560], [456, 466], [996, 1006], [265, 275]]}]}], "context_tokens": [["Calcineurin", 0], [",", 11], ["a", 13], ["Ca(2+)/calmodulin", 15], ["-", 32], ["stimulated", 33], ["protein", 44], ["phosphatase", 52], [",", 63], ["plays", 65], ["a", 71], ["key", 73], ["role", 77], ["in", 82], ["T", 85], ["-", 86], ["cell", 87], ["activation", 92], ["by", 103], ["regulating", 106], ["the", 117], ["activity", 121], ["of", 130], ["NFAT", 133], ["(", 138], ["nuclear", 139], ["factor", 147], ["of", 154], ["activated", 157], ["T", 167], ["cells", 169], [")", 174], [",", 175], ["a", 177], ["family", 179], ["of", 186], ["transcription", 189], ["factors", 203], ["required", 211], ["for", 220], ["the", 224], ["synthesis", 228], ["of", 238], ["several", 241], ["cytokine", 249], ["genes", 258], [".", 263], ["Calcineurin", 265], ["is", 277], ["the", 280], ["target", 284], ["of", 291], ["the", 294], ["immunosuppressive", 298], ["drugs", 316], ["cyclosporin", 322], ["A", 334], ["and", 336], ["FK506", 340], ["complexed", 346], ["with", 356], ["their", 361], ["cytoplasmic", 367], ["receptors", 379], ["cyclophilin", 389], ["and", 401], ["FKBP12", 405], [",", 411], ["respectively", 413], [".", 425], ["In", 427], ["this", 430], ["study", 435], ["we", 441], ["report", 444], ["that", 451], ["calcineurin", 456], ["is", 468], ["also", 471], ["the", 476], ["target", 480], ["of", 487], ["a", 490], ["recently", 492], ["identified", 501], ["Ca(2+)-binding", 512], ["protein", 527], [",", 534], ["CHP", 536], ["(", 540], ["for", 541], ["calcineurin", 545], ["homologous", 557], ["protein", 568], [")", 575], [",", 576], ["which", 578], ["shares", 584], ["a", 591], ["high", 593], ["degree", 598], ["of", 605], ["homology", 608], ["with", 617], ["the", 622], ["regulatory", 626], ["B", 637], ["subunit", 639], ["of", 647], ["calcineurin", 650], ["and", 662], ["with", 666], ["calmodulin", 671], [".", 681], ["In", 683], ["Jurkat", 686], ["and", 693], ["HeLa", 697], ["cells", 702], [",", 707], ["overexpression", 709], ["of", 724], ["CHP", 727], ["specifically", 731], ["impaired", 744], ["the", 753], ["nuclear", 757], ["translocation", 765], ["and", 779], ["transcriptional", 783], ["activity", 799], ["of", 808], ["NFAT", 811], ["but", 816], ["had", 820], ["no", 824], ["effect", 827], ["on", 834], ["AP-1", 837], ["transcriptional", 842], ["activity", 858], ["and", 867], ["only", 871], ["a", 876], ["small", 878], ["(", 884], ["<", 885], ["25", 886], ["%", 888], [")", 889], ["inhibitory", 891], ["effect", 902], ["on", 909], ["the", 912], ["transcriptional", 916], ["activity", 932], ["of", 941], ["NFkappaB.", 944], ["Further", 954], ["study", 962], ["indicated", 968], ["that", 978], ["CHP", 983], ["inhibits", 987], ["calcineurin", 996], ["activity", 1008], [".", 1016], ["In", 1018], ["cells", 1021], ["overexpressing", 1027], ["CHP", 1042], [",", 1045], ["the", 1047], ["phosphatase", 1051], ["activity", 1063], ["of", 1072], ["immunoprecipitated", 1075], ["calcineurin", 1094], ["was", 1106], ["inhibited", 1110], ["by", 1120], ["approximately", 1123], ["50", 1137], ["%", 1139], [";", 1140], ["and", 1142], ["in", 1146], ["a", 1149], ["reconstituted", 1151], ["assay", 1165], [",", 1170], ["the", 1172], ["activity", 1176], ["of", 1185], ["purified", 1188], ["calcineurin", 1197], ["was", 1209], ["inhibited", 1213], ["up", 1223], ["to", 1226], ["97", 1229], ["%", 1231], ["by", 1233], ["the", 1236], ["addition", 1240], ["of", 1249], ["purified", 1252], ["recombinant", 1261], ["CHP", 1273], ["in", 1277], ["a", 1280], ["dose", 1282], ["-", 1286], ["dependent", 1287], ["manner", 1297], [".", 1303], ["Moreover", 1305], [",", 1313], ["prolonged", 1315], ["activation", 1325], ["of", 1336], ["Jurkat", 1339], ["cells", 1346], ["was", 1352], ["associated", 1356], ["with", 1367], ["a", 1372], ["decreased", 1374], ["abundance", 1384], ["of", 1394], ["CHP", 1397], [",", 1400], ["suggesting", 1402], ["a", 1413], ["possible", 1415], ["regulatory", 1424], ["mechanism", 1435], ["allowing", 1445], ["activation", 1454], ["of", 1465], ["calcineurin", 1468], [".", 1479], ["CHP", 1481], [",", 1484], ["therefore", 1486], [",", 1495], ["is", 1497], ["a", 1500], ["previously", 1502], ["unrecognized", 1513], ["endogenous", 1526], ["inhibitor", 1537], ["of", 1547], ["calcineurin", 1550], ["activity", 1562], [".", 1570]]}
{"context": "The direct thrombin inhibitor dabigatran and the anti-Xa agents rivaroxaban, edoxaban, and apixaban are a new generation of oral anticoagulants. Their advantage over the vitamin K antagonists is the lack of the need for monitoring and dose adjustment. Their main disadvantage is currently the absence of a specific reversal agent. Dabigatran's, unlike the anti-Xa agents, absorption can be reduced by activated charcoal if administered shortly after ingestion and it can be removed from the blood with hemodialysis. Prothrombin complex concentrate, activated prothrombin complex concentrate, and recombinant factor VIIa all show some activity in reversing the anticoagulant effect of these drugs but this is based on ex vivo, animal, and volunteer studies. It is unclear, which, if any, of these drugs is the most suitable for emergency reversal. Three novel molecules (idarucizumab, andexanet, and PER977) may provide the most effective and safest way of reversal. These agents are currently in premarketing studies.", "qas": [{"question": "Idarucizumab is an antidote of which drug?", "answers": ["dabigatran"], "qid": "8dfe7776209f42c6b08aeb043f1ac872", "question_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antidote", 19], ["of", 28], ["which", 31], ["drug", 37], ["?", 41]], "detected_answers": [{"text": "dabigatran", "token_spans": [[4, 4], [57, 57]], "char_spans": [[30, 39], [331, 340]]}]}], "context_tokens": [["The", 0], ["direct", 4], ["thrombin", 11], ["inhibitor", 20], ["dabigatran", 30], ["and", 41], ["the", 45], ["anti", 49], ["-", 53], ["Xa", 54], ["agents", 57], ["rivaroxaban", 64], [",", 75], ["edoxaban", 77], [",", 85], ["and", 87], ["apixaban", 91], ["are", 100], ["a", 104], ["new", 106], ["generation", 110], ["of", 121], ["oral", 124], ["anticoagulants", 129], [".", 143], ["Their", 145], ["advantage", 151], ["over", 161], ["the", 166], ["vitamin", 170], ["K", 178], ["antagonists", 180], ["is", 192], ["the", 195], ["lack", 199], ["of", 204], ["the", 207], ["need", 211], ["for", 216], ["monitoring", 220], ["and", 231], ["dose", 235], ["adjustment", 240], [".", 250], ["Their", 252], ["main", 258], ["disadvantage", 263], ["is", 276], ["currently", 279], ["the", 289], ["absence", 293], ["of", 301], ["a", 304], ["specific", 306], ["reversal", 315], ["agent", 324], [".", 329], ["Dabigatran", 331], ["'s", 341], [",", 343], ["unlike", 345], ["the", 352], ["anti", 356], ["-", 360], ["Xa", 361], ["agents", 364], [",", 370], ["absorption", 372], ["can", 383], ["be", 387], ["reduced", 390], ["by", 398], ["activated", 401], ["charcoal", 411], ["if", 420], ["administered", 423], ["shortly", 436], ["after", 444], ["ingestion", 450], ["and", 460], ["it", 464], ["can", 467], ["be", 471], ["removed", 474], ["from", 482], ["the", 487], ["blood", 491], ["with", 497], ["hemodialysis", 502], [".", 514], ["Prothrombin", 516], ["complex", 528], ["concentrate", 536], [",", 547], ["activated", 549], ["prothrombin", 559], ["complex", 571], ["concentrate", 579], [",", 590], ["and", 592], ["recombinant", 596], ["factor", 608], ["VIIa", 615], ["all", 620], ["show", 624], ["some", 629], ["activity", 634], ["in", 643], ["reversing", 646], ["the", 656], ["anticoagulant", 660], ["effect", 674], ["of", 681], ["these", 684], ["drugs", 690], ["but", 696], ["this", 700], ["is", 705], ["based", 708], ["on", 714], ["ex", 717], ["vivo", 720], [",", 724], ["animal", 726], [",", 732], ["and", 734], ["volunteer", 738], ["studies", 748], [".", 755], ["It", 757], ["is", 760], ["unclear", 763], [",", 770], ["which", 772], [",", 777], ["if", 779], ["any", 782], [",", 785], ["of", 787], ["these", 790], ["drugs", 796], ["is", 802], ["the", 805], ["most", 809], ["suitable", 814], ["for", 823], ["emergency", 827], ["reversal", 837], [".", 845], ["Three", 847], ["novel", 853], ["molecules", 859], ["(", 869], ["idarucizumab", 870], [",", 882], ["andexanet", 884], [",", 893], ["and", 895], ["PER977", 899], [")", 905], ["may", 907], ["provide", 911], ["the", 919], ["most", 923], ["effective", 928], ["and", 938], ["safest", 942], ["way", 949], ["of", 953], ["reversal", 956], [".", 964], ["These", 966], ["agents", 972], ["are", 979], ["currently", 983], ["in", 993], ["premarketing", 996], ["studies", 1009], [".", 1016]]}
{"context": "We investigated the expression of Na(+)/Ca(2+) exchanger (NCX) and the functional role of NCX in retinal damage by using NCX1-heterozygous deficient mice (NCX1(+/-)) and SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy] phenoxy]-5-ethoxyaniline), a selective NCX inhibitor in vivo. We also examined the role of NCX in oxygen-glucose deprivation (OGD) stress with a retinal ganglion cell line (RGC-5) cell culture in vitro. The expression of NCX1 was confirmed and entirely localized in retina by immunoblotting and immunohistochemistry, respectively. NCX1(+/-) mice possessed significant protection against retinal damage induced by intravitreal injection of N-methyl-D-aspartate (NMDA). SEA0400 at 3 and 10 mg/kg significantly reduced NMDA- or high intraocular pressure-induced retinal cell damage in mice. Furthermore, SEA0400 reduced the number of TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling)-positive cells and the expression of phosphorylated mitogen-activated protein kinases (ERK1/2, JNK, p38) induced by NMDA injection. In RGC-5, SEA0400 at 0.3 and 1 microM significantly inhibited OGD-induced cell damage. OGD-induced cell damage was aggravated by ouabain (a Na(+),K(+)-ATPase inhibitor) at 100 microM, and this increased damage was significantly reduced by SEA0400 at 1 microM. In conclusion, these results suggest that NCX1 may play a role in retinal cell death induced by NMDA and ischemia-reperfusion.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "251f6ff810384420b6df79a29f772ff0", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[5, 8]], "char_spans": [[34, 55]]}, {"text": "NCX", "token_spans": [[40, 40], [17, 17], [51, 51], [10, 10]], "char_spans": [[253, 255], [90, 92], [305, 307], [58, 60]]}]}], "context_tokens": [["We", 0], ["investigated", 3], ["the", 16], ["expression", 20], ["of", 31], ["Na(+)/Ca(2", 34], ["+", 44], [")", 45], ["exchanger", 47], ["(", 57], ["NCX", 58], [")", 61], ["and", 63], ["the", 67], ["functional", 71], ["role", 82], ["of", 87], ["NCX", 90], ["in", 94], ["retinal", 97], ["damage", 105], ["by", 112], ["using", 115], ["NCX1-heterozygous", 121], ["deficient", 139], ["mice", 149], ["(", 154], ["NCX1(+/-", 155], [")", 163], [")", 164], ["and", 166], ["SEA0400", 170], ["(", 178], ["2-[4-[(2,5-difluorophenyl)methoxy", 179], ["]", 212], ["phenoxy]-5-ethoxyaniline", 214], [")", 238], [",", 239], ["a", 241], ["selective", 243], ["NCX", 253], ["inhibitor", 257], ["in", 267], ["vivo", 270], [".", 274], ["We", 276], ["also", 279], ["examined", 284], ["the", 293], ["role", 297], ["of", 302], ["NCX", 305], ["in", 309], ["oxygen", 312], ["-", 318], ["glucose", 319], ["deprivation", 327], ["(", 339], ["OGD", 340], [")", 343], ["stress", 345], ["with", 352], ["a", 357], ["retinal", 359], ["ganglion", 367], ["cell", 376], ["line", 381], ["(", 386], ["RGC-5", 387], [")", 392], ["cell", 394], ["culture", 399], ["in", 407], ["vitro", 410], [".", 415], ["The", 417], ["expression", 421], ["of", 432], ["NCX1", 435], ["was", 440], ["confirmed", 444], ["and", 454], ["entirely", 458], ["localized", 467], ["in", 477], ["retina", 480], ["by", 487], ["immunoblotting", 490], ["and", 505], ["immunohistochemistry", 509], [",", 529], ["respectively", 531], [".", 543], ["NCX1(+/-", 545], [")", 553], ["mice", 555], ["possessed", 560], ["significant", 570], ["protection", 582], ["against", 593], ["retinal", 601], ["damage", 609], ["induced", 616], ["by", 624], ["intravitreal", 627], ["injection", 640], ["of", 650], ["N", 653], ["-", 654], ["methyl", 655], ["-", 661], ["D", 662], ["-", 663], ["aspartate", 664], ["(", 674], ["NMDA", 675], [")", 679], [".", 680], ["SEA0400", 682], ["at", 690], ["3", 693], ["and", 695], ["10", 699], ["mg", 702], ["/", 704], ["kg", 705], ["significantly", 708], ["reduced", 722], ["NMDA-", 730], ["or", 736], ["high", 739], ["intraocular", 744], ["pressure", 756], ["-", 764], ["induced", 765], ["retinal", 773], ["cell", 781], ["damage", 786], ["in", 793], ["mice", 796], [".", 800], ["Furthermore", 802], [",", 813], ["SEA0400", 815], ["reduced", 823], ["the", 831], ["number", 835], ["of", 842], ["TUNEL", 845], ["(", 851], ["terminal", 852], ["deoxynucleotidyl", 861], ["transferase", 878], ["dUTP", 890], ["nick", 895], ["-", 899], ["end", 900], ["labeling)-positive", 904], ["cells", 923], ["and", 929], ["the", 933], ["expression", 937], ["of", 948], ["phosphorylated", 951], ["mitogen", 966], ["-", 973], ["activated", 974], ["protein", 984], ["kinases", 992], ["(", 1000], ["ERK1/2", 1001], [",", 1007], ["JNK", 1009], [",", 1012], ["p38", 1014], [")", 1017], ["induced", 1019], ["by", 1027], ["NMDA", 1030], ["injection", 1035], [".", 1044], ["In", 1046], ["RGC-5", 1049], [",", 1054], ["SEA0400", 1056], ["at", 1064], ["0.3", 1067], ["and", 1071], ["1", 1075], ["microM", 1077], ["significantly", 1084], ["inhibited", 1098], ["OGD", 1108], ["-", 1111], ["induced", 1112], ["cell", 1120], ["damage", 1125], [".", 1131], ["OGD", 1133], ["-", 1136], ["induced", 1137], ["cell", 1145], ["damage", 1150], ["was", 1157], ["aggravated", 1161], ["by", 1172], ["ouabain", 1175], ["(", 1183], ["a", 1184], ["Na(+),K(+)-ATPase", 1186], ["inhibitor", 1204], [")", 1213], ["at", 1215], ["100", 1218], ["microM", 1222], [",", 1228], ["and", 1230], ["this", 1234], ["increased", 1239], ["damage", 1249], ["was", 1256], ["significantly", 1260], ["reduced", 1274], ["by", 1282], ["SEA0400", 1285], ["at", 1293], ["1", 1296], ["microM.", 1298], ["In", 1306], ["conclusion", 1309], [",", 1319], ["these", 1321], ["results", 1327], ["suggest", 1335], ["that", 1343], ["NCX1", 1348], ["may", 1353], ["play", 1357], ["a", 1362], ["role", 1364], ["in", 1369], ["retinal", 1372], ["cell", 1380], ["death", 1385], ["induced", 1391], ["by", 1399], ["NMDA", 1402], ["and", 1407], ["ischemia", 1411], ["-", 1419], ["reperfusion", 1420], [".", 1431]]}
{"context": "Turner syndrome is a genetic disorder caused by the complete or partial absence of an X chromosome in affected women. Individuals with TS show characteristic difficulties with executive functions, visual-spatial and mathematical cognition, with relatively intact verbal skills, and congruent abnormalities in structural development of the posterior parietal cortex (PPC). The functionally heterogeneous PPC has recently been investigated using connectivity-based clustering methods, which sub-divide a given region into clusters of voxels showing similar structural or functional connectivity to other brain regions. In the present study, we extended this method to compare connectivity-based clustering between groups and investigate whether functional networks differentially recruit the PPC in TS. To this end, we parcellated the PPC into sub-regions based on temporal correlations with other regions of the brain. fMRI data were collected from 15 girls with TS and 14 typically developing (TD) girls, aged 7-14, while they performed a visual-spatial task. Temporal correlations between voxels in the PPC and a set of seed regions were calculated, and the PPC divided into clusters of voxels showing similar connectivity. It was found that in general the PPC parcellates similarly in TS and TD girls, but that regions in bilateral inferior parietal lobules, and posterior right superior parietal lobule, were reliably recruited by different networks in TS relative to TD participants. These regions showed weaker correlation in TS with a set of regions involved in visual processing. These results suggest that abnormal development of visuospatial functional networks in TS may relate to the well documented cognitive difficulties in this disorder.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "9aae75f96acc4b5ba4f5bc32a39f1e8f", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[15, 15]], "char_spans": [[86, 86]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["is", 16], ["a", 19], ["genetic", 21], ["disorder", 29], ["caused", 38], ["by", 45], ["the", 48], ["complete", 52], ["or", 61], ["partial", 64], ["absence", 72], ["of", 80], ["an", 83], ["X", 86], ["chromosome", 88], ["in", 99], ["affected", 102], ["women", 111], [".", 116], ["Individuals", 118], ["with", 130], ["TS", 135], ["show", 138], ["characteristic", 143], ["difficulties", 158], ["with", 171], ["executive", 176], ["functions", 186], [",", 195], ["visual", 197], ["-", 203], ["spatial", 204], ["and", 212], ["mathematical", 216], ["cognition", 229], [",", 238], ["with", 240], ["relatively", 245], ["intact", 256], ["verbal", 263], ["skills", 270], [",", 276], ["and", 278], ["congruent", 282], ["abnormalities", 292], ["in", 306], ["structural", 309], ["development", 320], ["of", 332], ["the", 335], ["posterior", 339], ["parietal", 349], ["cortex", 358], ["(", 365], ["PPC", 366], [")", 369], [".", 370], ["The", 372], ["functionally", 376], ["heterogeneous", 389], ["PPC", 403], ["has", 407], ["recently", 411], ["been", 420], ["investigated", 425], ["using", 438], ["connectivity", 444], ["-", 456], ["based", 457], ["clustering", 463], ["methods", 474], [",", 481], ["which", 483], ["sub", 489], ["-", 492], ["divide", 493], ["a", 500], ["given", 502], ["region", 508], ["into", 515], ["clusters", 520], ["of", 529], ["voxels", 532], ["showing", 539], ["similar", 547], ["structural", 555], ["or", 566], ["functional", 569], ["connectivity", 580], ["to", 593], ["other", 596], ["brain", 602], ["regions", 608], [".", 615], ["In", 617], ["the", 620], ["present", 624], ["study", 632], [",", 637], ["we", 639], ["extended", 642], ["this", 651], ["method", 656], ["to", 663], ["compare", 666], ["connectivity", 674], ["-", 686], ["based", 687], ["clustering", 693], ["between", 704], ["groups", 712], ["and", 719], ["investigate", 723], ["whether", 735], ["functional", 743], ["networks", 754], ["differentially", 763], ["recruit", 778], ["the", 786], ["PPC", 790], ["in", 794], ["TS", 797], [".", 799], ["To", 801], ["this", 804], ["end", 809], [",", 812], ["we", 814], ["parcellated", 817], ["the", 829], ["PPC", 833], ["into", 837], ["sub", 842], ["-", 845], ["regions", 846], ["based", 854], ["on", 860], ["temporal", 863], ["correlations", 872], ["with", 885], ["other", 890], ["regions", 896], ["of", 904], ["the", 907], ["brain", 911], [".", 916], ["fMRI", 918], ["data", 923], ["were", 928], ["collected", 933], ["from", 943], ["15", 948], ["girls", 951], ["with", 957], ["TS", 962], ["and", 965], ["14", 969], ["typically", 972], ["developing", 982], ["(", 993], ["TD", 994], [")", 996], ["girls", 998], [",", 1003], ["aged", 1005], ["7", 1010], ["-", 1011], ["14", 1012], [",", 1014], ["while", 1016], ["they", 1022], ["performed", 1027], ["a", 1037], ["visual", 1039], ["-", 1045], ["spatial", 1046], ["task", 1054], [".", 1058], ["Temporal", 1060], ["correlations", 1069], ["between", 1082], ["voxels", 1090], ["in", 1097], ["the", 1100], ["PPC", 1104], ["and", 1108], ["a", 1112], ["set", 1114], ["of", 1118], ["seed", 1121], ["regions", 1126], ["were", 1134], ["calculated", 1139], [",", 1149], ["and", 1151], ["the", 1155], ["PPC", 1159], ["divided", 1163], ["into", 1171], ["clusters", 1176], ["of", 1185], ["voxels", 1188], ["showing", 1195], ["similar", 1203], ["connectivity", 1211], [".", 1223], ["It", 1225], ["was", 1228], ["found", 1232], ["that", 1238], ["in", 1243], ["general", 1246], ["the", 1254], ["PPC", 1258], ["parcellates", 1262], ["similarly", 1274], ["in", 1284], ["TS", 1287], ["and", 1290], ["TD", 1294], ["girls", 1297], [",", 1302], ["but", 1304], ["that", 1308], ["regions", 1313], ["in", 1321], ["bilateral", 1324], ["inferior", 1334], ["parietal", 1343], ["lobules", 1352], [",", 1359], ["and", 1361], ["posterior", 1365], ["right", 1375], ["superior", 1381], ["parietal", 1390], ["lobule", 1399], [",", 1405], ["were", 1407], ["reliably", 1412], ["recruited", 1421], ["by", 1431], ["different", 1434], ["networks", 1444], ["in", 1453], ["TS", 1456], ["relative", 1459], ["to", 1468], ["TD", 1471], ["participants", 1474], [".", 1486], ["These", 1488], ["regions", 1494], ["showed", 1502], ["weaker", 1509], ["correlation", 1516], ["in", 1528], ["TS", 1531], ["with", 1534], ["a", 1539], ["set", 1541], ["of", 1545], ["regions", 1548], ["involved", 1556], ["in", 1565], ["visual", 1568], ["processing", 1575], [".", 1585], ["These", 1587], ["results", 1593], ["suggest", 1601], ["that", 1609], ["abnormal", 1614], ["development", 1623], ["of", 1635], ["visuospatial", 1638], ["functional", 1651], ["networks", 1662], ["in", 1671], ["TS", 1674], ["may", 1677], ["relate", 1681], ["to", 1688], ["the", 1691], ["well", 1695], ["documented", 1700], ["cognitive", 1711], ["difficulties", 1721], ["in", 1734], ["this", 1737], ["disorder", 1742], [".", 1750]]}
{"context": "Ehlers-Danlos syndrome is a complex hereditary connective tissue disorder that is characterized by abnormalities of the skin and joints and visceral and neurological manifestations. At present, at least 11 forms are recognized on the basis of their clinical characteristics, methods of transmission, and biochemical defect. The neurologic manifestations include cerebrovascular disease, peripheral neuropathy, plexopathy, periventricular subependymal heterotopias, and epilepsy. Previously, 2 females were reported to be affected with subependimal periventricular heterotopias and Ehlers-Danlos syndrome type 1. The authors report a new case of a 12-year-old girl with similar clinical and neuroradiological features.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "10de1ab61b0a47219444a92bc141d960", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[8, 9]], "char_spans": [[47, 63]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["a", 26], ["complex", 28], ["hereditary", 36], ["connective", 47], ["tissue", 58], ["disorder", 65], ["that", 74], ["is", 79], ["characterized", 82], ["by", 96], ["abnormalities", 99], ["of", 113], ["the", 116], ["skin", 120], ["and", 125], ["joints", 129], ["and", 136], ["visceral", 140], ["and", 149], ["neurological", 153], ["manifestations", 166], [".", 180], ["At", 182], ["present", 185], [",", 192], ["at", 194], ["least", 197], ["11", 203], ["forms", 206], ["are", 212], ["recognized", 216], ["on", 227], ["the", 230], ["basis", 234], ["of", 240], ["their", 243], ["clinical", 249], ["characteristics", 258], [",", 273], ["methods", 275], ["of", 283], ["transmission", 286], [",", 298], ["and", 300], ["biochemical", 304], ["defect", 316], [".", 322], ["The", 324], ["neurologic", 328], ["manifestations", 339], ["include", 354], ["cerebrovascular", 362], ["disease", 378], [",", 385], ["peripheral", 387], ["neuropathy", 398], [",", 408], ["plexopathy", 410], [",", 420], ["periventricular", 422], ["subependymal", 438], ["heterotopias", 451], [",", 463], ["and", 465], ["epilepsy", 469], [".", 477], ["Previously", 479], [",", 489], ["2", 491], ["females", 493], ["were", 501], ["reported", 506], ["to", 515], ["be", 518], ["affected", 521], ["with", 530], ["subependimal", 535], ["periventricular", 548], ["heterotopias", 564], ["and", 577], ["Ehlers", 581], ["-", 587], ["Danlos", 588], ["syndrome", 595], ["type", 604], ["1", 609], [".", 610], ["The", 612], ["authors", 616], ["report", 624], ["a", 631], ["new", 633], ["case", 637], ["of", 642], ["a", 645], ["12-year", 647], ["-", 654], ["old", 655], ["girl", 659], ["with", 664], ["similar", 669], ["clinical", 677], ["and", 686], ["neuroradiological", 690], ["features", 708], [".", 716]]}
{"context": "Antisense therapy with both chemistries of phosphorodiamidate morpholino oligomers (PMOs) and 2'-O-methyl phosphorothioate has demonstrated the capability to induce dystrophin expression in Duchenne muscular dystrophy (DMD) patients in phase II-III clinical trials with benefit in muscle functions. However, potential of the therapy for DMD at different stages of the disease progression is not understood. In this study, we examined the effect of peptide-conjugated PMO (PPMO)-mediated exon skipping on disease progression of utrophin-dystrophin-deficient mice (dko) of four age groups (21-29, 30-39, 40-49 and 50+ days), representing diseases from early stage to advanced stage with severe kyphosis. Biweekly intravenous (i.v.) administration of the PPMO restored the dystrophin expression in nearly 100% skeletal muscle fibers in all age groups. This was associated with the restoration of dystrophin-associated proteins including functional glycosylated dystroglycan and neuronal nitric synthase. However, therapeutic outcomes clearly depended on severity of the disease at the time the treatment started. The PPMO treatment alleviated the disease pathology and significantly prolonged the life span of the mice receiving treatment at younger age with mild phenotype. However, restoration of high levels of dystrophin expression failed to prevent disease progression to the mice receiving treatment when disease was already at advanced stage. The results could be critical for design of clinical trials with antisense therapy to DMD.", "qas": [{"question": "In what percentage of skeletal muscle fibers is dystrophin expression restored after PPMO- mediated exon skipping?", "answers": ["100%"], "qid": "d6fb14e3be8245baaf66693d4b546e8f", "question_tokens": [["In", 0], ["what", 3], ["percentage", 8], ["of", 19], ["skeletal", 22], ["muscle", 31], ["fibers", 38], ["is", 45], ["dystrophin", 48], ["expression", 59], ["restored", 70], ["after", 79], ["PPMO-", 85], ["mediated", 91], ["exon", 100], ["skipping", 105], ["?", 113]], "detected_answers": [{"text": "100%", "token_spans": [[145, 145]], "char_spans": [[802, 804]]}]}], "context_tokens": [["Antisense", 0], ["therapy", 10], ["with", 18], ["both", 23], ["chemistries", 28], ["of", 40], ["phosphorodiamidate", 43], ["morpholino", 62], ["oligomers", 73], ["(", 83], ["PMOs", 84], [")", 88], ["and", 90], ["2'-O", 94], ["-", 98], ["methyl", 99], ["phosphorothioate", 106], ["has", 123], ["demonstrated", 127], ["the", 140], ["capability", 144], ["to", 155], ["induce", 158], ["dystrophin", 165], ["expression", 176], ["in", 187], ["Duchenne", 190], ["muscular", 199], ["dystrophy", 208], ["(", 218], ["DMD", 219], [")", 222], ["patients", 224], ["in", 233], ["phase", 236], ["II", 242], ["-", 244], ["III", 245], ["clinical", 249], ["trials", 258], ["with", 265], ["benefit", 270], ["in", 278], ["muscle", 281], ["functions", 288], [".", 297], ["However", 299], [",", 306], ["potential", 308], ["of", 318], ["the", 321], ["therapy", 325], ["for", 333], ["DMD", 337], ["at", 341], ["different", 344], ["stages", 354], ["of", 361], ["the", 364], ["disease", 368], ["progression", 376], ["is", 388], ["not", 391], ["understood", 395], [".", 405], ["In", 407], ["this", 410], ["study", 415], [",", 420], ["we", 422], ["examined", 425], ["the", 434], ["effect", 438], ["of", 445], ["peptide", 448], ["-", 455], ["conjugated", 456], ["PMO", 467], ["(", 471], ["PPMO)-mediated", 472], ["exon", 487], ["skipping", 492], ["on", 501], ["disease", 504], ["progression", 512], ["of", 524], ["utrophin", 527], ["-", 535], ["dystrophin", 536], ["-", 546], ["deficient", 547], ["mice", 557], ["(", 562], ["dko", 563], [")", 566], ["of", 568], ["four", 571], ["age", 576], ["groups", 580], ["(", 587], ["21", 588], ["-", 590], ["29", 591], [",", 593], ["30", 595], ["-", 597], ["39", 598], [",", 600], ["40", 602], ["-", 604], ["49", 605], ["and", 608], ["50", 612], ["+", 614], ["days", 616], [")", 620], [",", 621], ["representing", 623], ["diseases", 636], ["from", 645], ["early", 650], ["stage", 656], ["to", 662], ["advanced", 665], ["stage", 674], ["with", 680], ["severe", 685], ["kyphosis", 692], [".", 700], ["Biweekly", 702], ["intravenous", 711], ["(", 723], ["i.v", 724], [".", 727], [")", 728], ["administration", 730], ["of", 745], ["the", 748], ["PPMO", 752], ["restored", 757], ["the", 766], ["dystrophin", 770], ["expression", 781], ["in", 792], ["nearly", 795], ["100", 802], ["%", 805], ["skeletal", 807], ["muscle", 816], ["fibers", 823], ["in", 830], ["all", 833], ["age", 837], ["groups", 841], [".", 847], ["This", 849], ["was", 854], ["associated", 858], ["with", 869], ["the", 874], ["restoration", 878], ["of", 890], ["dystrophin", 893], ["-", 903], ["associated", 904], ["proteins", 915], ["including", 924], ["functional", 934], ["glycosylated", 945], ["dystroglycan", 958], ["and", 971], ["neuronal", 975], ["nitric", 984], ["synthase", 991], [".", 999], ["However", 1001], [",", 1008], ["therapeutic", 1010], ["outcomes", 1022], ["clearly", 1031], ["depended", 1039], ["on", 1048], ["severity", 1051], ["of", 1060], ["the", 1063], ["disease", 1067], ["at", 1075], ["the", 1078], ["time", 1082], ["the", 1087], ["treatment", 1091], ["started", 1101], [".", 1108], ["The", 1110], ["PPMO", 1114], ["treatment", 1119], ["alleviated", 1129], ["the", 1140], ["disease", 1144], ["pathology", 1152], ["and", 1162], ["significantly", 1166], ["prolonged", 1180], ["the", 1190], ["life", 1194], ["span", 1199], ["of", 1204], ["the", 1207], ["mice", 1211], ["receiving", 1216], ["treatment", 1226], ["at", 1236], ["younger", 1239], ["age", 1247], ["with", 1251], ["mild", 1256], ["phenotype", 1261], [".", 1270], ["However", 1272], [",", 1279], ["restoration", 1281], ["of", 1293], ["high", 1296], ["levels", 1301], ["of", 1308], ["dystrophin", 1311], ["expression", 1322], ["failed", 1333], ["to", 1340], ["prevent", 1343], ["disease", 1351], ["progression", 1359], ["to", 1371], ["the", 1374], ["mice", 1378], ["receiving", 1383], ["treatment", 1393], ["when", 1403], ["disease", 1408], ["was", 1416], ["already", 1420], ["at", 1428], ["advanced", 1431], ["stage", 1440], [".", 1445], ["The", 1447], ["results", 1451], ["could", 1459], ["be", 1465], ["critical", 1468], ["for", 1477], ["design", 1481], ["of", 1488], ["clinical", 1491], ["trials", 1500], ["with", 1507], ["antisense", 1512], ["therapy", 1522], ["to", 1530], ["DMD", 1533], [".", 1536]]}
{"context": "Chronic myeloid leukemia (CML) originates from the hematopoietic stem cell and is characterized by the reciprocal translocation t(9;22)(q34;q11), which results in the BCR-ABL fusion gene on chromosome 22q-, also known as the Philadelphia chromosome. This chimeric gene codes for a cytoplasmic protein with constitutive tyrosine-kinase activity, responsible for cellular transformation and leukemogenesis in CML. The aim of this observational cohort study was to discriminate and quantify BCR-ABL transcripts in the peripheral blood of patients with CML who were treated with imatinib mesylate (Glivec, Novartis). Twenty-two patients were followed for six months during treatment. Quantitative real time polymerase chain reaction was performed before treatment and after 3 and 6 months from treatment initiation. As compared with the third month, there was a significant decrease in BCR-ABL expression in the sixth month of treatment (P = 0.0002). At the sixth month, there was a significant difference in the levels of the two major transcripts of BCR-ABL, B2A2 and B3A2 (P = 0.0347), indicating that B2A2 may be more sensitive to imatinib. The results of our study indicate that imatinib is able to modify the natural history of CML, and raise the hypothesis that patients who express the B2A2 transcript may have a better prognosis.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "e19160c7bb354a72b145aeab75882fde", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[78, 80], [182, 184], [26, 28], [147, 149]], "char_spans": [[488, 494], [1048, 1054], [167, 173], [882, 888]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["originates", 31], ["from", 42], ["the", 47], ["hematopoietic", 51], ["stem", 65], ["cell", 70], ["and", 75], ["is", 79], ["characterized", 82], ["by", 96], ["the", 99], ["reciprocal", 103], ["translocation", 114], ["t(9;22)(q34;q11", 128], [")", 143], [",", 144], ["which", 146], ["results", 152], ["in", 160], ["the", 163], ["BCR", 167], ["-", 170], ["ABL", 171], ["fusion", 175], ["gene", 182], ["on", 187], ["chromosome", 190], ["22q-", 201], [",", 205], ["also", 207], ["known", 212], ["as", 218], ["the", 221], ["Philadelphia", 225], ["chromosome", 238], [".", 248], ["This", 250], ["chimeric", 255], ["gene", 264], ["codes", 269], ["for", 275], ["a", 279], ["cytoplasmic", 281], ["protein", 293], ["with", 301], ["constitutive", 306], ["tyrosine", 319], ["-", 327], ["kinase", 328], ["activity", 335], [",", 343], ["responsible", 345], ["for", 357], ["cellular", 361], ["transformation", 370], ["and", 385], ["leukemogenesis", 389], ["in", 404], ["CML", 407], [".", 410], ["The", 412], ["aim", 416], ["of", 420], ["this", 423], ["observational", 428], ["cohort", 442], ["study", 449], ["was", 455], ["to", 459], ["discriminate", 462], ["and", 475], ["quantify", 479], ["BCR", 488], ["-", 491], ["ABL", 492], ["transcripts", 496], ["in", 508], ["the", 511], ["peripheral", 515], ["blood", 526], ["of", 532], ["patients", 535], ["with", 544], ["CML", 549], ["who", 553], ["were", 557], ["treated", 562], ["with", 570], ["imatinib", 575], ["mesylate", 584], ["(", 593], ["Glivec", 594], [",", 600], ["Novartis", 602], [")", 610], [".", 611], ["Twenty", 613], ["-", 619], ["two", 620], ["patients", 624], ["were", 633], ["followed", 638], ["for", 647], ["six", 651], ["months", 655], ["during", 662], ["treatment", 669], [".", 678], ["Quantitative", 680], ["real", 693], ["time", 698], ["polymerase", 703], ["chain", 714], ["reaction", 720], ["was", 729], ["performed", 733], ["before", 743], ["treatment", 750], ["and", 760], ["after", 764], ["3", 770], ["and", 772], ["6", 776], ["months", 778], ["from", 785], ["treatment", 790], ["initiation", 800], [".", 810], ["As", 812], ["compared", 815], ["with", 824], ["the", 829], ["third", 833], ["month", 839], [",", 844], ["there", 846], ["was", 852], ["a", 856], ["significant", 858], ["decrease", 870], ["in", 879], ["BCR", 882], ["-", 885], ["ABL", 886], ["expression", 890], ["in", 901], ["the", 904], ["sixth", 908], ["month", 914], ["of", 920], ["treatment", 923], ["(", 933], ["P", 934], ["=", 936], ["0.0002", 938], [")", 944], [".", 945], ["At", 947], ["the", 950], ["sixth", 954], ["month", 960], [",", 965], ["there", 967], ["was", 973], ["a", 977], ["significant", 979], ["difference", 991], ["in", 1002], ["the", 1005], ["levels", 1009], ["of", 1016], ["the", 1019], ["two", 1023], ["major", 1027], ["transcripts", 1033], ["of", 1045], ["BCR", 1048], ["-", 1051], ["ABL", 1052], [",", 1055], ["B2A2", 1057], ["and", 1062], ["B3A2", 1066], ["(", 1071], ["P", 1072], ["=", 1074], ["0.0347", 1076], [")", 1082], [",", 1083], ["indicating", 1085], ["that", 1096], ["B2A2", 1101], ["may", 1106], ["be", 1110], ["more", 1113], ["sensitive", 1118], ["to", 1128], ["imatinib", 1131], [".", 1139], ["The", 1141], ["results", 1145], ["of", 1153], ["our", 1156], ["study", 1160], ["indicate", 1166], ["that", 1175], ["imatinib", 1180], ["is", 1189], ["able", 1192], ["to", 1197], ["modify", 1200], ["the", 1207], ["natural", 1211], ["history", 1219], ["of", 1227], ["CML", 1230], [",", 1233], ["and", 1235], ["raise", 1239], ["the", 1245], ["hypothesis", 1249], ["that", 1260], ["patients", 1265], ["who", 1274], ["express", 1278], ["the", 1286], ["B2A2", 1290], ["transcript", 1295], ["may", 1306], ["have", 1310], ["a", 1315], ["better", 1317], ["prognosis", 1324], [".", 1333]]}
{"context": "Stress-induced mutagenesis describes the accumulation of mutations that occur in nongrowing cells, in contrast to mutagenesis that occurs in actively dividing populations, and has been referred to as stationary-phase or adaptive mutagenesis. The most widely studied system for stress-induced mutagenesis involves monitoring the appearance of Lac(+) revertants of the strain FC40 under starvation conditions in Escherichia coli. The SOS-inducible translesion DNA polymerase DinB plays an important role in this phenomenon. Loss of DinB (DNA pol IV) function results in a severe reduction of Lac(+) revertants. We previously reported that NusA, an essential component of elongating RNA polymerases, interacts with DinB. Here we report our unexpected observation that wild-type NusA function is required for stress-induced mutagenesis. We present evidence that this effect is unlikely to be due to defects in transcription of lac genes but rather is due to an inability to adapt and mutate in response to environmental stress. Furthermore, we extended our analysis to the formation of stress-induced mutants in response to antibiotic treatment, observing the same striking abolition of mutagenesis under entirely different conditions. Our results are the first to implicate NusA as a crucial participant in the phenomenon of stress-induced mutagenesis.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase", "stationary-phase"], "qid": "1daf44d1e59d499da16d3746bd6277c2", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[32, 34]], "char_spans": [[200, 215]]}]}], "context_tokens": [["Stress", 0], ["-", 6], ["induced", 7], ["mutagenesis", 15], ["describes", 27], ["the", 37], ["accumulation", 41], ["of", 54], ["mutations", 57], ["that", 67], ["occur", 72], ["in", 78], ["nongrowing", 81], ["cells", 92], [",", 97], ["in", 99], ["contrast", 102], ["to", 111], ["mutagenesis", 114], ["that", 126], ["occurs", 131], ["in", 138], ["actively", 141], ["dividing", 150], ["populations", 159], [",", 170], ["and", 172], ["has", 176], ["been", 180], ["referred", 185], ["to", 194], ["as", 197], ["stationary", 200], ["-", 210], ["phase", 211], ["or", 217], ["adaptive", 220], ["mutagenesis", 229], [".", 240], ["The", 242], ["most", 246], ["widely", 251], ["studied", 258], ["system", 266], ["for", 273], ["stress", 277], ["-", 283], ["induced", 284], ["mutagenesis", 292], ["involves", 304], ["monitoring", 313], ["the", 324], ["appearance", 328], ["of", 339], ["Lac(+", 342], [")", 347], ["revertants", 349], ["of", 360], ["the", 363], ["strain", 367], ["FC40", 374], ["under", 379], ["starvation", 385], ["conditions", 396], ["in", 407], ["Escherichia", 410], ["coli", 422], [".", 426], ["The", 428], ["SOS", 432], ["-", 435], ["inducible", 436], ["translesion", 446], ["DNA", 458], ["polymerase", 462], ["DinB", 473], ["plays", 478], ["an", 484], ["important", 487], ["role", 497], ["in", 502], ["this", 505], ["phenomenon", 510], [".", 520], ["Loss", 522], ["of", 527], ["DinB", 530], ["(", 535], ["DNA", 536], ["pol", 540], ["IV", 544], [")", 546], ["function", 548], ["results", 557], ["in", 565], ["a", 568], ["severe", 570], ["reduction", 577], ["of", 587], ["Lac(+", 590], [")", 595], ["revertants", 597], [".", 607], ["We", 609], ["previously", 612], ["reported", 623], ["that", 632], ["NusA", 637], [",", 641], ["an", 643], ["essential", 646], ["component", 656], ["of", 666], ["elongating", 669], ["RNA", 680], ["polymerases", 684], [",", 695], ["interacts", 697], ["with", 707], ["DinB.", 712], ["Here", 718], ["we", 723], ["report", 726], ["our", 733], ["unexpected", 737], ["observation", 748], ["that", 760], ["wild", 765], ["-", 769], ["type", 770], ["NusA", 775], ["function", 780], ["is", 789], ["required", 792], ["for", 801], ["stress", 805], ["-", 811], ["induced", 812], ["mutagenesis", 820], [".", 831], ["We", 833], ["present", 836], ["evidence", 844], ["that", 853], ["this", 858], ["effect", 863], ["is", 870], ["unlikely", 873], ["to", 882], ["be", 885], ["due", 888], ["to", 892], ["defects", 895], ["in", 903], ["transcription", 906], ["of", 920], ["lac", 923], ["genes", 927], ["but", 933], ["rather", 937], ["is", 944], ["due", 947], ["to", 951], ["an", 954], ["inability", 957], ["to", 967], ["adapt", 970], ["and", 976], ["mutate", 980], ["in", 987], ["response", 990], ["to", 999], ["environmental", 1002], ["stress", 1016], [".", 1022], ["Furthermore", 1024], [",", 1035], ["we", 1037], ["extended", 1040], ["our", 1049], ["analysis", 1053], ["to", 1062], ["the", 1065], ["formation", 1069], ["of", 1079], ["stress", 1082], ["-", 1088], ["induced", 1089], ["mutants", 1097], ["in", 1105], ["response", 1108], ["to", 1117], ["antibiotic", 1120], ["treatment", 1131], [",", 1140], ["observing", 1142], ["the", 1152], ["same", 1156], ["striking", 1161], ["abolition", 1170], ["of", 1180], ["mutagenesis", 1183], ["under", 1195], ["entirely", 1201], ["different", 1210], ["conditions", 1220], [".", 1230], ["Our", 1232], ["results", 1236], ["are", 1244], ["the", 1248], ["first", 1252], ["to", 1258], ["implicate", 1261], ["NusA", 1271], ["as", 1276], ["a", 1279], ["crucial", 1281], ["participant", 1289], ["in", 1301], ["the", 1304], ["phenomenon", 1308], ["of", 1319], ["stress", 1322], ["-", 1328], ["induced", 1329], ["mutagenesis", 1337], [".", 1348]]}
{"context": "In Russia, an intradermal Diaskintest\u00ae drug has been designed, which is a recombinant tuberculosis allergen based on M. tuberculosis-- specific proteins: ESAT-6 and CFP-10 produced by a genetically modified Escherichia coli culture. Diaskintest\u00ae test and Mantoux test with 2TE PPD-L were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection. Diaskintest\u00ae showed a high sensitivity not only in active tuberculosis, but also in occult, the so-called latent, tuberculosis infection. This is suggested by the following evidence. The high percentage (83.8%) of positive responses to Diaskintest\u00ae is noted in children and adolescents with tuberculosis, receiving an intensive course of chemotherapy. Negative tests were observed only in minor forms at the resolution stage. In the children who had completed treatment, positive tests were seen in 78.3%, moreover in those with prior tuberculosis of intrathoracic lymph nodes; negative tests were observed not earlier than 18 months after start of treatment. The highest sensitivity of Diaskintest\u00ae was shown in children with early primary tuberculosis infection and through family contact with bacteria-excreting subjects (91.7%). These children may be judged with the highest assurance to have latent tuberculosis infection, the population of which is in an active state at the moment of the study. The children with early primary tuberculosis infection, but in no family contact with bacteria-excreting individuals, showed a lower percentage of positive responses to Diaskintest\u00ae both before (37.5%) and after (10%) treatment, which suggests that there must be a lower bacterial burden in the child. A high percentage of positive responses to Diaskintest\u00ae (76.2%) were found in subjects with hyperergic reactions to tuberculin. These were in only 16.7% in the group of patients receiving preventive therapy. In children and adolescents with a persistent positive Mantoux test (for more than 3 years), the response to Diaskintest\u00ae was negative in most cases since in early infection when mycobacteria propagated, the reaction to the drug was positive, but as 3 years pass the probability of the infection transition to the persistence stage is high--at that time the response to Diaskintest\u00ae becomes negative. Diaskintest\u00ae induces no delayed hypersensitivity associated with BCG vaccination, suggesting its high specificity. There were no positive reactions in patients with nonspecific lung diseases.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "bceaab52532745f2b18e2703008352a9", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[16, 16], [80, 80], [67, 67], [21, 21], [58, 58], [93, 93], [106, 106], [213, 213], [180, 180], [137, 137], [265, 265], [241, 241]], "char_spans": [[86, 97], [483, 494], [399, 410], [120, 133], [350, 361], [565, 576], [621, 632], [1248, 1259], [1042, 1053], [798, 809], [1541, 1552], [1411, 1422]]}]}], "context_tokens": [["In", 0], ["Russia", 3], [",", 9], ["an", 11], ["intradermal", 14], ["Diaskintest", 26], ["\u00ae", 37], ["drug", 39], ["has", 44], ["been", 48], ["designed", 53], [",", 61], ["which", 63], ["is", 69], ["a", 72], ["recombinant", 74], ["tuberculosis", 86], ["allergen", 99], ["based", 108], ["on", 114], ["M.", 117], ["tuberculosis--", 120], ["specific", 135], ["proteins", 144], [":", 152], ["ESAT-6", 154], ["and", 161], ["CFP-10", 165], ["produced", 172], ["by", 181], ["a", 184], ["genetically", 186], ["modified", 198], ["Escherichia", 207], ["coli", 219], ["culture", 224], [".", 231], ["Diaskintest", 233], ["\u00ae", 244], ["test", 246], ["and", 251], ["Mantoux", 255], ["test", 263], ["with", 268], ["2TE", 273], ["PPD", 277], ["-", 280], ["L", 281], ["were", 283], ["concurrently", 288], ["carried", 301], ["out", 309], ["in", 313], ["300", 316], ["children", 320], ["and", 329], ["adolescents", 333], ["with", 345], ["tuberculosis", 350], ["and", 363], ["followed", 367], ["up", 376], ["in", 379], ["risk", 382], ["groups", 387], ["at", 394], ["a", 397], ["tuberculosis", 399], ["dispensary", 412], ["to", 423], ["determine", 426], ["the", 436], ["sensitivity", 440], ["of", 452], ["the", 455], ["new", 459], ["skin", 463], ["test", 468], ["in", 473], ["active", 476], ["tuberculosis", 483], ["infection", 496], [".", 505], ["Diaskintest", 507], ["\u00ae", 518], ["showed", 520], ["a", 527], ["high", 529], ["sensitivity", 534], ["not", 546], ["only", 550], ["in", 555], ["active", 558], ["tuberculosis", 565], [",", 577], ["but", 579], ["also", 583], ["in", 588], ["occult", 591], [",", 597], ["the", 599], ["so", 603], ["-", 605], ["called", 606], ["latent", 613], [",", 619], ["tuberculosis", 621], ["infection", 634], [".", 643], ["This", 645], ["is", 650], ["suggested", 653], ["by", 663], ["the", 666], ["following", 670], ["evidence", 680], [".", 688], ["The", 690], ["high", 694], ["percentage", 699], ["(", 710], ["83.8", 711], ["%", 715], [")", 716], ["of", 718], ["positive", 721], ["responses", 730], ["to", 740], ["Diaskintest", 743], ["\u00ae", 754], ["is", 756], ["noted", 759], ["in", 765], ["children", 768], ["and", 777], ["adolescents", 781], ["with", 793], ["tuberculosis", 798], [",", 810], ["receiving", 812], ["an", 822], ["intensive", 825], ["course", 835], ["of", 842], ["chemotherapy", 845], [".", 857], ["Negative", 859], ["tests", 868], ["were", 874], ["observed", 879], ["only", 888], ["in", 893], ["minor", 896], ["forms", 902], ["at", 908], ["the", 911], ["resolution", 915], ["stage", 926], [".", 931], ["In", 933], ["the", 936], ["children", 940], ["who", 949], ["had", 953], ["completed", 957], ["treatment", 967], [",", 976], ["positive", 978], ["tests", 987], ["were", 993], ["seen", 998], ["in", 1003], ["78.3", 1006], ["%", 1010], [",", 1011], ["moreover", 1013], ["in", 1022], ["those", 1025], ["with", 1031], ["prior", 1036], ["tuberculosis", 1042], ["of", 1055], ["intrathoracic", 1058], ["lymph", 1072], ["nodes", 1078], [";", 1083], ["negative", 1085], ["tests", 1094], ["were", 1100], ["observed", 1105], ["not", 1114], ["earlier", 1118], ["than", 1126], ["18", 1131], ["months", 1134], ["after", 1141], ["start", 1147], ["of", 1153], ["treatment", 1156], [".", 1165], ["The", 1167], ["highest", 1171], ["sensitivity", 1179], ["of", 1191], ["Diaskintest", 1194], ["\u00ae", 1205], ["was", 1207], ["shown", 1211], ["in", 1217], ["children", 1220], ["with", 1229], ["early", 1234], ["primary", 1240], ["tuberculosis", 1248], ["infection", 1261], ["and", 1271], ["through", 1275], ["family", 1283], ["contact", 1290], ["with", 1298], ["bacteria", 1303], ["-", 1311], ["excreting", 1312], ["subjects", 1322], ["(", 1331], ["91.7", 1332], ["%", 1336], [")", 1337], [".", 1338], ["These", 1340], ["children", 1346], ["may", 1355], ["be", 1359], ["judged", 1362], ["with", 1369], ["the", 1374], ["highest", 1378], ["assurance", 1386], ["to", 1396], ["have", 1399], ["latent", 1404], ["tuberculosis", 1411], ["infection", 1424], [",", 1433], ["the", 1435], ["population", 1439], ["of", 1450], ["which", 1453], ["is", 1459], ["in", 1462], ["an", 1465], ["active", 1468], ["state", 1475], ["at", 1481], ["the", 1484], ["moment", 1488], ["of", 1495], ["the", 1498], ["study", 1502], [".", 1507], ["The", 1509], ["children", 1513], ["with", 1522], ["early", 1527], ["primary", 1533], ["tuberculosis", 1541], ["infection", 1554], [",", 1563], ["but", 1565], ["in", 1569], ["no", 1572], ["family", 1575], ["contact", 1582], ["with", 1590], ["bacteria", 1595], ["-", 1603], ["excreting", 1604], ["individuals", 1614], [",", 1625], ["showed", 1627], ["a", 1634], ["lower", 1636], ["percentage", 1642], ["of", 1653], ["positive", 1656], ["responses", 1665], ["to", 1675], ["Diaskintest", 1678], ["\u00ae", 1689], ["both", 1691], ["before", 1696], ["(", 1703], ["37.5", 1704], ["%", 1708], [")", 1709], ["and", 1711], ["after", 1715], ["(", 1721], ["10", 1722], ["%", 1724], [")", 1725], ["treatment", 1727], [",", 1736], ["which", 1738], ["suggests", 1744], ["that", 1753], ["there", 1758], ["must", 1764], ["be", 1769], ["a", 1772], ["lower", 1774], ["bacterial", 1780], ["burden", 1790], ["in", 1797], ["the", 1800], ["child", 1804], [".", 1809], ["A", 1811], ["high", 1813], ["percentage", 1818], ["of", 1829], ["positive", 1832], ["responses", 1841], ["to", 1851], ["Diaskintest", 1854], ["\u00ae", 1865], ["(", 1867], ["76.2", 1868], ["%", 1872], [")", 1873], ["were", 1875], ["found", 1880], ["in", 1886], ["subjects", 1889], ["with", 1898], ["hyperergic", 1903], ["reactions", 1914], ["to", 1924], ["tuberculin", 1927], [".", 1937], ["These", 1939], ["were", 1945], ["in", 1950], ["only", 1953], ["16.7", 1958], ["%", 1962], ["in", 1964], ["the", 1967], ["group", 1971], ["of", 1977], ["patients", 1980], ["receiving", 1989], ["preventive", 1999], ["therapy", 2010], [".", 2017], ["In", 2019], ["children", 2022], ["and", 2031], ["adolescents", 2035], ["with", 2047], ["a", 2052], ["persistent", 2054], ["positive", 2065], ["Mantoux", 2074], ["test", 2082], ["(", 2087], ["for", 2088], ["more", 2092], ["than", 2097], ["3", 2102], ["years", 2104], [")", 2109], [",", 2110], ["the", 2112], ["response", 2116], ["to", 2125], ["Diaskintest", 2128], ["\u00ae", 2139], ["was", 2141], ["negative", 2145], ["in", 2154], ["most", 2157], ["cases", 2162], ["since", 2168], ["in", 2174], ["early", 2177], ["infection", 2183], ["when", 2193], ["mycobacteria", 2198], ["propagated", 2211], [",", 2221], ["the", 2223], ["reaction", 2227], ["to", 2236], ["the", 2239], ["drug", 2243], ["was", 2248], ["positive", 2252], [",", 2260], ["but", 2262], ["as", 2266], ["3", 2269], ["years", 2271], ["pass", 2277], ["the", 2282], ["probability", 2286], ["of", 2298], ["the", 2301], ["infection", 2305], ["transition", 2315], ["to", 2326], ["the", 2329], ["persistence", 2333], ["stage", 2345], ["is", 2351], ["high", 2354], ["--", 2358], ["at", 2360], ["that", 2363], ["time", 2368], ["the", 2373], ["response", 2377], ["to", 2386], ["Diaskintest", 2389], ["\u00ae", 2400], ["becomes", 2402], ["negative", 2410], [".", 2418], ["Diaskintest", 2420], ["\u00ae", 2431], ["induces", 2433], ["no", 2441], ["delayed", 2444], ["hypersensitivity", 2452], ["associated", 2469], ["with", 2480], ["BCG", 2485], ["vaccination", 2489], [",", 2500], ["suggesting", 2502], ["its", 2513], ["high", 2517], ["specificity", 2522], [".", 2533], ["There", 2535], ["were", 2541], ["no", 2546], ["positive", 2549], ["reactions", 2558], ["in", 2568], ["patients", 2571], ["with", 2580], ["nonspecific", 2585], ["lung", 2597], ["diseases", 2602], [".", 2610]]}
{"context": "Type 2 diabetes mellitus (T2DM) is increasing worldwide. Treatment of T2DM continues to present challenges, with a significant proportion of patients failing to achieve and maintain glycemic targets. Despite the availability of many oral antidiabetic agents, therapeutic efficacy is also offset by side effects such as weight gain and hypoglycemia. Therefore, the search for novel therapeutic agents with an improved benefit-risk profile continues. In the following review we focus on a novel class of oral antidiabetic drugs, the sodium glucose transporter protein 2 (SGLT2) inhibitors, which have unique characteristics. SGLT2 inhibitors focus on the kidney as a therapeutic target, where they inhibit the reabsorption of glucose in the proximal tubule, causing an increase in urinary glucose excretion. Doing this, they reduce plasma glucose independently of the \u03b2-cell function of the pancreas. SGLT2 inhibitors are effective at lowering hemoglobin A1c, but also induce weight loss and reduce blood pressure, with a low risk of hypoglycemia. In general, the SGLT2 inhibitors are well tolerated, with the most frequent adverse events being mild urinal and genital infections. Since their primary site of effect is the kidney, these drugs are less effective in patients with impaired kidney function but evidence is emerging that these drugs may also have a protective effect against diabetic nephropathy. This review focuses on the most extensively studied SGLT2 inhibitors dapagliflozin, canagliflozin and empagliflozin. Dapagliflozin and canagliflozin have already been approved for marketing by the US Food and Drug Administration. The European Medicines Agency has accepted all three drugs for marketing.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "4978663209ad4e3098899ad04290262e", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[96, 96], [154, 154], [105, 105], [249, 249], [184, 184]], "char_spans": [[569, 573], [899, 903], [623, 627], [1460, 1464], [1062, 1066]]}]}], "context_tokens": [["Type", 0], ["2", 5], ["diabetes", 7], ["mellitus", 16], ["(", 25], ["T2DM", 26], [")", 30], ["is", 32], ["increasing", 35], ["worldwide", 46], [".", 55], ["Treatment", 57], ["of", 67], ["T2DM", 70], ["continues", 75], ["to", 85], ["present", 88], ["challenges", 96], [",", 106], ["with", 108], ["a", 113], ["significant", 115], ["proportion", 127], ["of", 138], ["patients", 141], ["failing", 150], ["to", 158], ["achieve", 161], ["and", 169], ["maintain", 173], ["glycemic", 182], ["targets", 191], [".", 198], ["Despite", 200], ["the", 208], ["availability", 212], ["of", 225], ["many", 228], ["oral", 233], ["antidiabetic", 238], ["agents", 251], [",", 257], ["therapeutic", 259], ["efficacy", 271], ["is", 280], ["also", 283], ["offset", 288], ["by", 295], ["side", 298], ["effects", 303], ["such", 311], ["as", 316], ["weight", 319], ["gain", 326], ["and", 331], ["hypoglycemia", 335], [".", 347], ["Therefore", 349], [",", 358], ["the", 360], ["search", 364], ["for", 371], ["novel", 375], ["therapeutic", 381], ["agents", 393], ["with", 400], ["an", 405], ["improved", 408], ["benefit", 417], ["-", 424], ["risk", 425], ["profile", 430], ["continues", 438], [".", 447], ["In", 449], ["the", 452], ["following", 456], ["review", 466], ["we", 473], ["focus", 476], ["on", 482], ["a", 485], ["novel", 487], ["class", 493], ["of", 499], ["oral", 502], ["antidiabetic", 507], ["drugs", 520], [",", 525], ["the", 527], ["sodium", 531], ["glucose", 538], ["transporter", 546], ["protein", 558], ["2", 566], ["(", 568], ["SGLT2", 569], [")", 574], ["inhibitors", 576], [",", 586], ["which", 588], ["have", 594], ["unique", 599], ["characteristics", 606], [".", 621], ["SGLT2", 623], ["inhibitors", 629], ["focus", 640], ["on", 646], ["the", 649], ["kidney", 653], ["as", 660], ["a", 663], ["therapeutic", 665], ["target", 677], [",", 683], ["where", 685], ["they", 691], ["inhibit", 696], ["the", 704], ["reabsorption", 708], ["of", 721], ["glucose", 724], ["in", 732], ["the", 735], ["proximal", 739], ["tubule", 748], [",", 754], ["causing", 756], ["an", 764], ["increase", 767], ["in", 776], ["urinary", 779], ["glucose", 787], ["excretion", 795], [".", 804], ["Doing", 806], ["this", 812], [",", 816], ["they", 818], ["reduce", 823], ["plasma", 830], ["glucose", 837], ["independently", 845], ["of", 859], ["the", 862], ["\u03b2", 866], ["-", 867], ["cell", 868], ["function", 873], ["of", 882], ["the", 885], ["pancreas", 889], [".", 897], ["SGLT2", 899], ["inhibitors", 905], ["are", 916], ["effective", 920], ["at", 930], ["lowering", 933], ["hemoglobin", 942], ["A1c", 953], [",", 956], ["but", 958], ["also", 962], ["induce", 967], ["weight", 974], ["loss", 981], ["and", 986], ["reduce", 990], ["blood", 997], ["pressure", 1003], [",", 1011], ["with", 1013], ["a", 1018], ["low", 1020], ["risk", 1024], ["of", 1029], ["hypoglycemia", 1032], [".", 1044], ["In", 1046], ["general", 1049], [",", 1056], ["the", 1058], ["SGLT2", 1062], ["inhibitors", 1068], ["are", 1079], ["well", 1083], ["tolerated", 1088], [",", 1097], ["with", 1099], ["the", 1104], ["most", 1108], ["frequent", 1113], ["adverse", 1122], ["events", 1130], ["being", 1137], ["mild", 1143], ["urinal", 1148], ["and", 1155], ["genital", 1159], ["infections", 1167], [".", 1177], ["Since", 1179], ["their", 1185], ["primary", 1191], ["site", 1199], ["of", 1204], ["effect", 1207], ["is", 1214], ["the", 1217], ["kidney", 1221], [",", 1227], ["these", 1229], ["drugs", 1235], ["are", 1241], ["less", 1245], ["effective", 1250], ["in", 1260], ["patients", 1263], ["with", 1272], ["impaired", 1277], ["kidney", 1286], ["function", 1293], ["but", 1302], ["evidence", 1306], ["is", 1315], ["emerging", 1318], ["that", 1327], ["these", 1332], ["drugs", 1338], ["may", 1344], ["also", 1348], ["have", 1353], ["a", 1358], ["protective", 1360], ["effect", 1371], ["against", 1378], ["diabetic", 1386], ["nephropathy", 1395], [".", 1406], ["This", 1408], ["review", 1413], ["focuses", 1420], ["on", 1428], ["the", 1431], ["most", 1435], ["extensively", 1440], ["studied", 1452], ["SGLT2", 1460], ["inhibitors", 1466], ["dapagliflozin", 1477], [",", 1490], ["canagliflozin", 1492], ["and", 1506], ["empagliflozin", 1510], [".", 1523], ["Dapagliflozin", 1525], ["and", 1539], ["canagliflozin", 1543], ["have", 1557], ["already", 1562], ["been", 1570], ["approved", 1575], ["for", 1584], ["marketing", 1588], ["by", 1598], ["the", 1601], ["US", 1605], ["Food", 1608], ["and", 1613], ["Drug", 1617], ["Administration", 1622], [".", 1636], ["The", 1638], ["European", 1642], ["Medicines", 1651], ["Agency", 1661], ["has", 1668], ["accepted", 1672], ["all", 1681], ["three", 1685], ["drugs", 1691], ["for", 1697], ["marketing", 1701], [".", 1710]]}
{"context": "To investigate whether the effects of nerve growth factor (NGF) inhibition with tanezumab on rats with medial meniscal tear (MMT) effectively model rapidly progressive osteoarthritis (RPOA) observed in clinical trials. Male Lewis rats underwent MMT surgery and were treated weekly with tanezumab (0.1, 1 or 10\u2005mg/kg), isotype control or vehicle for 7, 14 or 28\u2005days. Gait deficiency was measured to assess weight-bearing on the operated limb. Joint damage was assessed via histopathology. A second arm, delayed onset of treatment (starting 3-8\u2005weeks after MMT surgery) was used to control for analgesia early in the disease process. A third arm, mid-tibial amputation, evaluated the dependency of the model on weight-bearing. Gait deficiency in untreated rats was present 3-7\u2005days after MMT surgery, with a return to normal weight-bearing by days 14-28. Prophylactic treatment with tanezumab prevented gait deficiency and resulted in more severe cartilage damage. When onset of treatment with tanezumab was delayed to 3-8\u2005weeks after MMT surgery, there was no increase in cartilage damage. Mid-tibial amputation completely prevented cartilage damage in untreated MMT rats. These data suggest that analgesia due to NGF inhibition during the acute injury phase is responsible for increased voluntary weight-bearing and subsequent cartilage damage in the rat MMT model. This model failed to replicate the hypotrophic bone response observed in tanezumab-treated patients with RPOA.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "50ae8202b2234d05a6012bace0a32fa7", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[6, 8]], "char_spans": [[38, 56]]}, {"text": "NGF", "token_spans": [[232, 232], [10, 10]], "char_spans": [[1214, 1216], [59, 61]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["the", 23], ["effects", 27], ["of", 35], ["nerve", 38], ["growth", 44], ["factor", 51], ["(", 58], ["NGF", 59], [")", 62], ["inhibition", 64], ["with", 75], ["tanezumab", 80], ["on", 90], ["rats", 93], ["with", 98], ["medial", 103], ["meniscal", 110], ["tear", 119], ["(", 124], ["MMT", 125], [")", 128], ["effectively", 130], ["model", 142], ["rapidly", 148], ["progressive", 156], ["osteoarthritis", 168], ["(", 183], ["RPOA", 184], [")", 188], ["observed", 190], ["in", 199], ["clinical", 202], ["trials", 211], [".", 217], ["Male", 219], ["Lewis", 224], ["rats", 230], ["underwent", 235], ["MMT", 245], ["surgery", 249], ["and", 257], ["were", 261], ["treated", 266], ["weekly", 274], ["with", 281], ["tanezumab", 286], ["(", 296], ["0.1", 297], [",", 300], ["1", 302], ["or", 304], ["10", 307], ["mg", 310], ["/", 312], ["kg", 313], [")", 315], [",", 316], ["isotype", 318], ["control", 326], ["or", 334], ["vehicle", 337], ["for", 345], ["7", 349], [",", 350], ["14", 352], ["or", 355], ["28", 358], ["days", 361], [".", 365], ["Gait", 367], ["deficiency", 372], ["was", 383], ["measured", 387], ["to", 396], ["assess", 399], ["weight", 406], ["-", 412], ["bearing", 413], ["on", 421], ["the", 424], ["operated", 428], ["limb", 437], [".", 441], ["Joint", 443], ["damage", 449], ["was", 456], ["assessed", 460], ["via", 469], ["histopathology", 473], [".", 487], ["A", 489], ["second", 491], ["arm", 498], [",", 501], ["delayed", 503], ["onset", 511], ["of", 517], ["treatment", 520], ["(", 530], ["starting", 531], ["3", 540], ["-", 541], ["8", 542], ["weeks", 544], ["after", 550], ["MMT", 556], ["surgery", 560], [")", 567], ["was", 569], ["used", 573], ["to", 578], ["control", 581], ["for", 589], ["analgesia", 593], ["early", 603], ["in", 609], ["the", 612], ["disease", 616], ["process", 624], [".", 631], ["A", 633], ["third", 635], ["arm", 641], [",", 644], ["mid", 646], ["-", 649], ["tibial", 650], ["amputation", 657], [",", 667], ["evaluated", 669], ["the", 679], ["dependency", 683], ["of", 694], ["the", 697], ["model", 701], ["on", 707], ["weight", 710], ["-", 716], ["bearing", 717], [".", 724], ["Gait", 726], ["deficiency", 731], ["in", 742], ["untreated", 745], ["rats", 755], ["was", 760], ["present", 764], ["3", 772], ["-", 773], ["7", 774], ["days", 776], ["after", 781], ["MMT", 787], ["surgery", 791], [",", 798], ["with", 800], ["a", 805], ["return", 807], ["to", 814], ["normal", 817], ["weight", 824], ["-", 830], ["bearing", 831], ["by", 839], ["days", 842], ["14", 847], ["-", 849], ["28", 850], [".", 852], ["Prophylactic", 854], ["treatment", 867], ["with", 877], ["tanezumab", 882], ["prevented", 892], ["gait", 902], ["deficiency", 907], ["and", 918], ["resulted", 922], ["in", 931], ["more", 934], ["severe", 939], ["cartilage", 946], ["damage", 956], [".", 962], ["When", 964], ["onset", 969], ["of", 975], ["treatment", 978], ["with", 988], ["tanezumab", 993], ["was", 1003], ["delayed", 1007], ["to", 1015], ["3", 1018], ["-", 1019], ["8", 1020], ["weeks", 1022], ["after", 1028], ["MMT", 1034], ["surgery", 1038], [",", 1045], ["there", 1047], ["was", 1053], ["no", 1057], ["increase", 1060], ["in", 1069], ["cartilage", 1072], ["damage", 1082], [".", 1088], ["Mid", 1090], ["-", 1093], ["tibial", 1094], ["amputation", 1101], ["completely", 1112], ["prevented", 1123], ["cartilage", 1133], ["damage", 1143], ["in", 1150], ["untreated", 1153], ["MMT", 1163], ["rats", 1167], [".", 1171], ["These", 1173], ["data", 1179], ["suggest", 1184], ["that", 1192], ["analgesia", 1197], ["due", 1207], ["to", 1211], ["NGF", 1214], ["inhibition", 1218], ["during", 1229], ["the", 1236], ["acute", 1240], ["injury", 1246], ["phase", 1253], ["is", 1259], ["responsible", 1262], ["for", 1274], ["increased", 1278], ["voluntary", 1288], ["weight", 1298], ["-", 1304], ["bearing", 1305], ["and", 1313], ["subsequent", 1317], ["cartilage", 1328], ["damage", 1338], ["in", 1345], ["the", 1348], ["rat", 1352], ["MMT", 1356], ["model", 1360], [".", 1365], ["This", 1367], ["model", 1372], ["failed", 1378], ["to", 1385], ["replicate", 1388], ["the", 1398], ["hypotrophic", 1402], ["bone", 1414], ["response", 1419], ["observed", 1428], ["in", 1437], ["tanezumab", 1440], ["-", 1449], ["treated", 1450], ["patients", 1458], ["with", 1467], ["RPOA", 1472], [".", 1476]]}
{"context": "Mammalian selenium-containing proteins identified thus far contain selenium in the form of a selenocysteine residue encoded by UGA. These proteins lack common amino acid sequence motifs, but 3'-untranslated regions of selenoprotein genes contain a common stem-loop structure, selenocysteine insertion sequence (SECIS) element, that is necessary for decoding UGA as selenocysteine rather than a stop signal. We describe here a computer program, SECISearch, that identifies mammalian selenoprotein genes by recognizing SECIS elements on the basis of their primary and secondary structures and free energy requirements. When SECISearch was applied to search human dbEST, two new mammalian selenoproteins, designated SelT and SelR, were identified. We determined their cDNA sequences and expressed them in a monkey cell line as fusion proteins with a green fluorescent protein. Incorporation of selenium into new proteins was confirmed by metabolic labeling with (75)Se, and expression of SelT was additionally documented in immunoblot assays. SelT and SelR did not have homology to previously characterized proteins, but their putative homologs were detected in various organisms. SelR homologs were present in every organism characterized by complete genome sequencing. The data suggest applicability of SECISearch for identification of new selenoprotein genes in nucleotide data bases.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0d1597667c614526ba0ceede9a3ecc54", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[48, 48], [82, 82]], "char_spans": [[311, 315], [517, 521]]}]}], "context_tokens": [["Mammalian", 0], ["selenium", 10], ["-", 18], ["containing", 19], ["proteins", 30], ["identified", 39], ["thus", 50], ["far", 55], ["contain", 59], ["selenium", 67], ["in", 76], ["the", 79], ["form", 83], ["of", 88], ["a", 91], ["selenocysteine", 93], ["residue", 108], ["encoded", 116], ["by", 124], ["UGA", 127], [".", 130], ["These", 132], ["proteins", 138], ["lack", 147], ["common", 152], ["amino", 159], ["acid", 165], ["sequence", 170], ["motifs", 179], [",", 185], ["but", 187], ["3'-untranslated", 191], ["regions", 207], ["of", 215], ["selenoprotein", 218], ["genes", 232], ["contain", 238], ["a", 246], ["common", 248], ["stem", 255], ["-", 259], ["loop", 260], ["structure", 265], [",", 274], ["selenocysteine", 276], ["insertion", 291], ["sequence", 301], ["(", 310], ["SECIS", 311], [")", 316], ["element", 318], [",", 325], ["that", 327], ["is", 332], ["necessary", 335], ["for", 345], ["decoding", 349], ["UGA", 358], ["as", 362], ["selenocysteine", 365], ["rather", 380], ["than", 387], ["a", 392], ["stop", 394], ["signal", 399], [".", 405], ["We", 407], ["describe", 410], ["here", 419], ["a", 424], ["computer", 426], ["program", 435], [",", 442], ["SECISearch", 444], [",", 454], ["that", 456], ["identifies", 461], ["mammalian", 472], ["selenoprotein", 482], ["genes", 496], ["by", 502], ["recognizing", 505], ["SECIS", 517], ["elements", 523], ["on", 532], ["the", 535], ["basis", 539], ["of", 545], ["their", 548], ["primary", 554], ["and", 562], ["secondary", 566], ["structures", 576], ["and", 587], ["free", 591], ["energy", 596], ["requirements", 603], [".", 615], ["When", 617], ["SECISearch", 622], ["was", 633], ["applied", 637], ["to", 645], ["search", 648], ["human", 655], ["dbEST", 661], [",", 666], ["two", 668], ["new", 672], ["mammalian", 676], ["selenoproteins", 686], [",", 700], ["designated", 702], ["SelT", 713], ["and", 718], ["SelR", 722], [",", 726], ["were", 728], ["identified", 733], [".", 743], ["We", 745], ["determined", 748], ["their", 759], ["cDNA", 765], ["sequences", 770], ["and", 780], ["expressed", 784], ["them", 794], ["in", 799], ["a", 802], ["monkey", 804], ["cell", 811], ["line", 816], ["as", 821], ["fusion", 824], ["proteins", 831], ["with", 840], ["a", 845], ["green", 847], ["fluorescent", 853], ["protein", 865], [".", 872], ["Incorporation", 874], ["of", 888], ["selenium", 891], ["into", 900], ["new", 905], ["proteins", 909], ["was", 918], ["confirmed", 922], ["by", 932], ["metabolic", 935], ["labeling", 945], ["with", 954], ["(", 959], ["75)Se", 960], [",", 965], ["and", 967], ["expression", 971], ["of", 982], ["SelT", 985], ["was", 990], ["additionally", 994], ["documented", 1007], ["in", 1018], ["immunoblot", 1021], ["assays", 1032], [".", 1038], ["SelT", 1040], ["and", 1045], ["SelR", 1049], ["did", 1054], ["not", 1058], ["have", 1062], ["homology", 1067], ["to", 1076], ["previously", 1079], ["characterized", 1090], ["proteins", 1104], [",", 1112], ["but", 1114], ["their", 1118], ["putative", 1124], ["homologs", 1133], ["were", 1142], ["detected", 1147], ["in", 1156], ["various", 1159], ["organisms", 1167], [".", 1176], ["SelR", 1178], ["homologs", 1183], ["were", 1192], ["present", 1197], ["in", 1205], ["every", 1208], ["organism", 1214], ["characterized", 1223], ["by", 1237], ["complete", 1240], ["genome", 1249], ["sequencing", 1256], [".", 1266], ["The", 1268], ["data", 1272], ["suggest", 1277], ["applicability", 1285], ["of", 1299], ["SECISearch", 1302], ["for", 1313], ["identification", 1317], ["of", 1332], ["new", 1335], ["selenoprotein", 1339], ["genes", 1353], ["in", 1359], ["nucleotide", 1362], ["data", 1373], ["bases", 1378], [".", 1383]]}
{"context": "Health care workers (HCW) are particularly at risk of acquiring tuberculosis (TB), even in countries with low TB incidence. Therefore, TB screening in HCW is a useful prevention strategy in countries with both low and high TB incidence. Tuberculin skin test (TST) is widely used although it suffers of low specificity; on the contrary, the in vitro enzyme immunoassay tests (IGRA) show superior specificity and sensitivity but are more expensive. The present study reports the results of a three-year TB surveillance among HCW in a large teaching hospital in Rome, using TST (by standard Mantoux technique) and IGRA (by QuantiFERON-TB) as first- and second-level screening tests, respectively. Out of 2290 HCW enrolled, 141 (6.1%) had a positive TST; among them, 99 (70.2%) underwent the IGRA and 16 tested positive (16.1%). The frequency of HCW tested positive for TB seems not far from other experiences in low incidence countries. Our results confirm the higher specificity of IGRA, but, due to its higher cost, TST can be considered a good first level screening test, whose positive results should be further confirmed by IGRA before the patients undergo X-ray diagnosis and/or chemotherapy.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "62a1183be31d4c208669a471c24c419c", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[12, 12]], "char_spans": [[64, 75]]}]}], "context_tokens": [["Health", 0], ["care", 7], ["workers", 12], ["(", 20], ["HCW", 21], [")", 24], ["are", 26], ["particularly", 30], ["at", 43], ["risk", 46], ["of", 51], ["acquiring", 54], ["tuberculosis", 64], ["(", 77], ["TB", 78], [")", 80], [",", 81], ["even", 83], ["in", 88], ["countries", 91], ["with", 101], ["low", 106], ["TB", 110], ["incidence", 113], [".", 122], ["Therefore", 124], [",", 133], ["TB", 135], ["screening", 138], ["in", 148], ["HCW", 151], ["is", 155], ["a", 158], ["useful", 160], ["prevention", 167], ["strategy", 178], ["in", 187], ["countries", 190], ["with", 200], ["both", 205], ["low", 210], ["and", 214], ["high", 218], ["TB", 223], ["incidence", 226], [".", 235], ["Tuberculin", 237], ["skin", 248], ["test", 253], ["(", 258], ["TST", 259], [")", 262], ["is", 264], ["widely", 267], ["used", 274], ["although", 279], ["it", 288], ["suffers", 291], ["of", 299], ["low", 302], ["specificity", 306], [";", 317], ["on", 319], ["the", 322], ["contrary", 326], [",", 334], ["the", 336], ["in", 340], ["vitro", 343], ["enzyme", 349], ["immunoassay", 356], ["tests", 368], ["(", 374], ["IGRA", 375], [")", 379], ["show", 381], ["superior", 386], ["specificity", 395], ["and", 407], ["sensitivity", 411], ["but", 423], ["are", 427], ["more", 431], ["expensive", 436], [".", 445], ["The", 447], ["present", 451], ["study", 459], ["reports", 465], ["the", 473], ["results", 477], ["of", 485], ["a", 488], ["three", 490], ["-", 495], ["year", 496], ["TB", 501], ["surveillance", 504], ["among", 517], ["HCW", 523], ["in", 527], ["a", 530], ["large", 532], ["teaching", 538], ["hospital", 547], ["in", 556], ["Rome", 559], [",", 563], ["using", 565], ["TST", 571], ["(", 575], ["by", 576], ["standard", 579], ["Mantoux", 588], ["technique", 596], [")", 605], ["and", 607], ["IGRA", 611], ["(", 616], ["by", 617], ["QuantiFERON", 620], ["-", 631], ["TB", 632], [")", 634], ["as", 636], ["first-", 639], ["and", 646], ["second", 650], ["-", 656], ["level", 657], ["screening", 663], ["tests", 673], [",", 678], ["respectively", 680], [".", 692], ["Out", 694], ["of", 698], ["2290", 701], ["HCW", 706], ["enrolled", 710], [",", 718], ["141", 720], ["(", 724], ["6.1", 725], ["%", 728], [")", 729], ["had", 731], ["a", 735], ["positive", 737], ["TST", 746], [";", 749], ["among", 751], ["them", 757], [",", 761], ["99", 763], ["(", 766], ["70.2", 767], ["%", 771], [")", 772], ["underwent", 774], ["the", 784], ["IGRA", 788], ["and", 793], ["16", 797], ["tested", 800], ["positive", 807], ["(", 816], ["16.1", 817], ["%", 821], [")", 822], [".", 823], ["The", 825], ["frequency", 829], ["of", 839], ["HCW", 842], ["tested", 846], ["positive", 853], ["for", 862], ["TB", 866], ["seems", 869], ["not", 875], ["far", 879], ["from", 883], ["other", 888], ["experiences", 894], ["in", 906], ["low", 909], ["incidence", 913], ["countries", 923], [".", 932], ["Our", 934], ["results", 938], ["confirm", 946], ["the", 954], ["higher", 958], ["specificity", 965], ["of", 977], ["IGRA", 980], [",", 984], ["but", 986], [",", 989], ["due", 991], ["to", 995], ["its", 998], ["higher", 1002], ["cost", 1009], [",", 1013], ["TST", 1015], ["can", 1019], ["be", 1023], ["considered", 1026], ["a", 1037], ["good", 1039], ["first", 1044], ["level", 1050], ["screening", 1056], ["test", 1066], [",", 1070], ["whose", 1072], ["positive", 1078], ["results", 1087], ["should", 1095], ["be", 1102], ["further", 1105], ["confirmed", 1113], ["by", 1123], ["IGRA", 1126], ["before", 1131], ["the", 1138], ["patients", 1142], ["undergo", 1151], ["X", 1159], ["-", 1160], ["ray", 1161], ["diagnosis", 1165], ["and/or", 1175], ["chemotherapy", 1182], [".", 1194]]}
{"context": "Chronic myeloid leukemia (CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality. Identification of the Bcr-Abl kinase fusion protein and its pivotal role in the pathogenesis of CML provided new opportunities to develop molecular-targeted therapies. Imatinib mesylate (IM, Gleevec, Novartis Pharmaceuticals, Basel, Switzerland), which specifically inhibits the autophosphorylation of the Abl TK, has improved the treatment of CML. However, resistance is often reported in patients with advanced-stage disease. Several novel TK inhibitors have been developed that override IM resistance mechanisms caused by point mutations within the Abl kinase domain. Inhibitors of Abl TK are divided into two main groups, namely, ATP-competitive and ATP noncompetitive inhibitors. The ATP-competitive inhibitors fall into two subclasses, the Src/Abl inhibitors, and the 2-phenylaminopyrimidine-based compounds. Dasatinib (formerly BMS-354825), AP23464, SKI-606, and PD166326 are classified as Src/Abl inhibitors, while nilotinib (AMN107) and INNO-406 (NS-187) belong to the latter subclass of inhibitors. Of these agents, dasatinib and nilotinib underwent clinical trials earlier than the others and favorable results are now accumulating. Clinical studies of the other compounds, including SKI-606 and INNO-406, have been performed in rapid succession. Because of their strong affinities for the ATP-binding site compared to IM, most ATP-competitive inhibitors may be effective in IM-resistant patients. However, an ATP-competitive inhibitor that can inhibit the phosphorylation of T315I Bcr-Abl has not yet been developed. Instead, ATP noncompetitive inhibitors, such as ON012380, Aurora kinase inhibitor MK0457 (VX-680), and p38 MAP kinase inhibitor BIRB-796, have been developed to address this problem. This review provides an update on the underlying pathophysiologies of disease progression and IM resistance, and discusses the development of new targeted TK inhibitors for managing CML and the importance of future strategies targeting CML stem cells.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "96ef8f92eb7d4bfe9aab1036cd522d2e", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[26, 28], [284, 286]], "char_spans": [[147, 153], [1618, 1624]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["was", 31], ["the", 35], ["first", 39], ["human", 45], ["malignant", 51], ["disease", 61], ["to", 69], ["be", 72], ["linked", 75], ["to", 82], ["a", 85], ["single", 87], [",", 93], ["acquired", 95], ["genetic", 104], ["abnormality", 112], [".", 123], ["Identification", 125], ["of", 140], ["the", 143], ["Bcr", 147], ["-", 150], ["Abl", 151], ["kinase", 155], ["fusion", 162], ["protein", 169], ["and", 177], ["its", 181], ["pivotal", 185], ["role", 193], ["in", 198], ["the", 201], ["pathogenesis", 205], ["of", 218], ["CML", 221], ["provided", 225], ["new", 234], ["opportunities", 238], ["to", 252], ["develop", 255], ["molecular", 263], ["-", 272], ["targeted", 273], ["therapies", 282], [".", 291], ["Imatinib", 293], ["mesylate", 302], ["(", 311], ["IM", 312], [",", 314], ["Gleevec", 316], [",", 323], ["Novartis", 325], ["Pharmaceuticals", 334], [",", 349], ["Basel", 351], [",", 356], ["Switzerland", 358], [")", 369], [",", 370], ["which", 372], ["specifically", 378], ["inhibits", 391], ["the", 400], ["autophosphorylation", 404], ["of", 424], ["the", 427], ["Abl", 431], ["TK", 435], [",", 437], ["has", 439], ["improved", 443], ["the", 452], ["treatment", 456], ["of", 466], ["CML", 469], [".", 472], ["However", 474], [",", 481], ["resistance", 483], ["is", 494], ["often", 497], ["reported", 503], ["in", 512], ["patients", 515], ["with", 524], ["advanced", 529], ["-", 537], ["stage", 538], ["disease", 544], [".", 551], ["Several", 553], ["novel", 561], ["TK", 567], ["inhibitors", 570], ["have", 581], ["been", 586], ["developed", 591], ["that", 601], ["override", 606], ["IM", 615], ["resistance", 618], ["mechanisms", 629], ["caused", 640], ["by", 647], ["point", 650], ["mutations", 656], ["within", 666], ["the", 673], ["Abl", 677], ["kinase", 681], ["domain", 688], [".", 694], ["Inhibitors", 696], ["of", 707], ["Abl", 710], ["TK", 714], ["are", 717], ["divided", 721], ["into", 729], ["two", 734], ["main", 738], ["groups", 743], [",", 749], ["namely", 751], [",", 757], ["ATP", 759], ["-", 762], ["competitive", 763], ["and", 775], ["ATP", 779], ["noncompetitive", 783], ["inhibitors", 798], [".", 808], ["The", 810], ["ATP", 814], ["-", 817], ["competitive", 818], ["inhibitors", 830], ["fall", 841], ["into", 846], ["two", 851], ["subclasses", 855], [",", 865], ["the", 867], ["Src", 871], ["/", 874], ["Abl", 875], ["inhibitors", 879], [",", 889], ["and", 891], ["the", 895], ["2-phenylaminopyrimidine", 899], ["-", 922], ["based", 923], ["compounds", 929], [".", 938], ["Dasatinib", 940], ["(", 950], ["formerly", 951], ["BMS-354825", 960], [")", 970], [",", 971], ["AP23464", 973], [",", 980], ["SKI-606", 982], [",", 989], ["and", 991], ["PD166326", 995], ["are", 1004], ["classified", 1008], ["as", 1019], ["Src", 1022], ["/", 1025], ["Abl", 1026], ["inhibitors", 1030], [",", 1040], ["while", 1042], ["nilotinib", 1048], ["(", 1058], ["AMN107", 1059], [")", 1065], ["and", 1067], ["INNO-406", 1071], ["(", 1080], ["NS-187", 1081], [")", 1087], ["belong", 1089], ["to", 1096], ["the", 1099], ["latter", 1103], ["subclass", 1110], ["of", 1119], ["inhibitors", 1122], [".", 1132], ["Of", 1134], ["these", 1137], ["agents", 1143], [",", 1149], ["dasatinib", 1151], ["and", 1161], ["nilotinib", 1165], ["underwent", 1175], ["clinical", 1185], ["trials", 1194], ["earlier", 1201], ["than", 1209], ["the", 1214], ["others", 1218], ["and", 1225], ["favorable", 1229], ["results", 1239], ["are", 1247], ["now", 1251], ["accumulating", 1255], [".", 1267], ["Clinical", 1269], ["studies", 1278], ["of", 1286], ["the", 1289], ["other", 1293], ["compounds", 1299], [",", 1308], ["including", 1310], ["SKI-606", 1320], ["and", 1328], ["INNO-406", 1332], [",", 1340], ["have", 1342], ["been", 1347], ["performed", 1352], ["in", 1362], ["rapid", 1365], ["succession", 1371], [".", 1381], ["Because", 1383], ["of", 1391], ["their", 1394], ["strong", 1400], ["affinities", 1407], ["for", 1418], ["the", 1422], ["ATP", 1426], ["-", 1429], ["binding", 1430], ["site", 1438], ["compared", 1443], ["to", 1452], ["IM", 1455], [",", 1457], ["most", 1459], ["ATP", 1464], ["-", 1467], ["competitive", 1468], ["inhibitors", 1480], ["may", 1491], ["be", 1495], ["effective", 1498], ["in", 1508], ["IM", 1511], ["-", 1513], ["resistant", 1514], ["patients", 1524], [".", 1532], ["However", 1534], [",", 1541], ["an", 1543], ["ATP", 1546], ["-", 1549], ["competitive", 1550], ["inhibitor", 1562], ["that", 1572], ["can", 1577], ["inhibit", 1581], ["the", 1589], ["phosphorylation", 1593], ["of", 1609], ["T315I", 1612], ["Bcr", 1618], ["-", 1621], ["Abl", 1622], ["has", 1626], ["not", 1630], ["yet", 1634], ["been", 1638], ["developed", 1643], [".", 1652], ["Instead", 1654], [",", 1661], ["ATP", 1663], ["noncompetitive", 1667], ["inhibitors", 1682], [",", 1692], ["such", 1694], ["as", 1699], ["ON012380", 1702], [",", 1710], ["Aurora", 1712], ["kinase", 1719], ["inhibitor", 1726], ["MK0457", 1736], ["(", 1743], ["VX-680", 1744], [")", 1750], [",", 1751], ["and", 1753], ["p38", 1757], ["MAP", 1761], ["kinase", 1765], ["inhibitor", 1772], ["BIRB-796", 1782], [",", 1790], ["have", 1792], ["been", 1797], ["developed", 1802], ["to", 1812], ["address", 1815], ["this", 1823], ["problem", 1828], [".", 1835], ["This", 1837], ["review", 1842], ["provides", 1849], ["an", 1858], ["update", 1861], ["on", 1868], ["the", 1871], ["underlying", 1875], ["pathophysiologies", 1886], ["of", 1904], ["disease", 1907], ["progression", 1915], ["and", 1927], ["IM", 1931], ["resistance", 1934], [",", 1944], ["and", 1946], ["discusses", 1950], ["the", 1960], ["development", 1964], ["of", 1976], ["new", 1979], ["targeted", 1983], ["TK", 1992], ["inhibitors", 1995], ["for", 2006], ["managing", 2010], ["CML", 2019], ["and", 2023], ["the", 2027], ["importance", 2031], ["of", 2042], ["future", 2045], ["strategies", 2052], ["targeting", 2063], ["CML", 2073], ["stem", 2077], ["cells", 2082], [".", 2087]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disease, characterized by an autosomal dominant mode of inheritance, facial involvement, and selectivity and asymmetry of muscle involvement. In general, FSHD typically presents before age 20 years. Usually, FSHD muscle involvement starts in the face and then progresses to the shoulder girdle, the humeral muscles and the abdominal muscles, and then the anterolateral compartment of the leg. Disease severity is highly variable and progression is very slow. About 20% of FSHD patients become wheelchair-bound. Lifespan is not shortened. The diagnosis of FSHD is based on a genetic test by which a deletion of 3.3kb DNA repeats (named D4Z4 and mapping to the subtelomeric region of chromosome 4q35) is identified. The progressive pattern of FSHD requires that the severity of symptoms as well as their physical, social and psychological impact be evaluated on a regular basis. A yearly assessment is recommended. Multidisciplinary management of FSHD--consisting of a combination of genetic counselling, functional assessment, an assessment by a physical therapist, prescription of symptomatic therapies and prevention of known complications of this disease--is required. Prescription of physical therapy sessions and orthopedic appliances are to be adapted to the patient's deficiencies and contractures.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "9366db61286b41f79e9e069494d2c271", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[14, 15]], "char_spans": [[94, 111]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["neuromuscular", 51], ["disease", 65], [",", 72], ["characterized", 74], ["by", 88], ["an", 91], ["autosomal", 94], ["dominant", 104], ["mode", 113], ["of", 118], ["inheritance", 121], [",", 132], ["facial", 134], ["involvement", 141], [",", 152], ["and", 154], ["selectivity", 158], ["and", 170], ["asymmetry", 174], ["of", 184], ["muscle", 187], ["involvement", 194], [".", 205], ["In", 207], ["general", 210], [",", 217], ["FSHD", 219], ["typically", 224], ["presents", 234], ["before", 243], ["age", 250], ["20", 254], ["years", 257], [".", 262], ["Usually", 264], [",", 271], ["FSHD", 273], ["muscle", 278], ["involvement", 285], ["starts", 297], ["in", 304], ["the", 307], ["face", 311], ["and", 316], ["then", 320], ["progresses", 325], ["to", 336], ["the", 339], ["shoulder", 343], ["girdle", 352], [",", 358], ["the", 360], ["humeral", 364], ["muscles", 372], ["and", 380], ["the", 384], ["abdominal", 388], ["muscles", 398], [",", 405], ["and", 407], ["then", 411], ["the", 416], ["anterolateral", 420], ["compartment", 434], ["of", 446], ["the", 449], ["leg", 453], [".", 456], ["Disease", 458], ["severity", 466], ["is", 475], ["highly", 478], ["variable", 485], ["and", 494], ["progression", 498], ["is", 510], ["very", 513], ["slow", 518], [".", 522], ["About", 524], ["20", 530], ["%", 532], ["of", 534], ["FSHD", 537], ["patients", 542], ["become", 551], ["wheelchair", 558], ["-", 568], ["bound", 569], [".", 574], ["Lifespan", 576], ["is", 585], ["not", 588], ["shortened", 592], [".", 601], ["The", 603], ["diagnosis", 607], ["of", 617], ["FSHD", 620], ["is", 625], ["based", 628], ["on", 634], ["a", 637], ["genetic", 639], ["test", 647], ["by", 652], ["which", 655], ["a", 661], ["deletion", 663], ["of", 672], ["3.3", 675], ["kb", 678], ["DNA", 681], ["repeats", 685], ["(", 693], ["named", 694], ["D4Z4", 700], ["and", 705], ["mapping", 709], ["to", 717], ["the", 720], ["subtelomeric", 724], ["region", 737], ["of", 744], ["chromosome", 747], ["4q35", 758], [")", 762], ["is", 764], ["identified", 767], [".", 777], ["The", 779], ["progressive", 783], ["pattern", 795], ["of", 803], ["FSHD", 806], ["requires", 811], ["that", 820], ["the", 825], ["severity", 829], ["of", 838], ["symptoms", 841], ["as", 850], ["well", 853], ["as", 858], ["their", 861], ["physical", 867], [",", 875], ["social", 877], ["and", 884], ["psychological", 888], ["impact", 902], ["be", 909], ["evaluated", 912], ["on", 922], ["a", 925], ["regular", 927], ["basis", 935], [".", 940], ["A", 942], ["yearly", 944], ["assessment", 951], ["is", 962], ["recommended", 965], [".", 976], ["Multidisciplinary", 978], ["management", 996], ["of", 1007], ["FSHD", 1010], ["--", 1014], ["consisting", 1016], ["of", 1027], ["a", 1030], ["combination", 1032], ["of", 1044], ["genetic", 1047], ["counselling", 1055], [",", 1066], ["functional", 1068], ["assessment", 1079], [",", 1089], ["an", 1091], ["assessment", 1094], ["by", 1105], ["a", 1108], ["physical", 1110], ["therapist", 1119], [",", 1128], ["prescription", 1130], ["of", 1143], ["symptomatic", 1146], ["therapies", 1158], ["and", 1168], ["prevention", 1172], ["of", 1183], ["known", 1186], ["complications", 1192], ["of", 1206], ["this", 1209], ["disease", 1214], ["--", 1221], ["is", 1223], ["required", 1226], [".", 1234], ["Prescription", 1236], ["of", 1249], ["physical", 1252], ["therapy", 1261], ["sessions", 1269], ["and", 1278], ["orthopedic", 1282], ["appliances", 1293], ["are", 1304], ["to", 1308], ["be", 1311], ["adapted", 1314], ["to", 1322], ["the", 1325], ["patient", 1329], ["'s", 1336], ["deficiencies", 1339], ["and", 1352], ["contractures", 1356], [".", 1368]]}
{"context": "Idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation. Safety, pharmacokinetics and pharmacodynamics of idarucizumab were investigated in dabigatran-treated, middle-aged, elderly and renally impaired volunteers with characteristics similar to patients receiving anticoagulant therapy. In this randomized, double-blind, crossover study, 46 subjects (12 middle-aged, 45-64\u00a0years; 16 elderly, 65-80\u00a0years; and 18 with mild or moderate renal impairment) received dabigatran etexilate (DE; 220 or 150\u00a0mg twice daily) for 4\u00a0days. Idarucizumab doses of 1, 2.5 and 5\u00a0g or 2\u00a0\u00d7\u00a02.5\u00a0g 1\u00a0h apart, or placebo, were administered as a rapid (5\u00a0min) infusion ~2\u00a0h after DE at steady state. Dabigatran-prolonged diluted thrombin time, ecarin clotting time and activated partial thromboplastin time were reversed to baseline immediately after idarucizumab infusion in all groups. Reversal was sustained with doses \u22652.5\u00a0g. Idarucizumab was well tolerated under all conditions. No impact of age on idarucizumab pharmacokinetics was observed; however, subjects with mild or moderate renal impairment demonstrated increased exposure (up to 84\u00a0%), decreased clearance and prolonged (by up to 49\u00a0%) initial half-life of idarucizumab compared with healthy middle-aged subjects. Impaired renal function was associated with increased exposure and decreased clearance of idarucizumab. Idarucizumab resulted in immediate, complete and sustained reversal of dabigatran anticoagulant activity, and was safe and well tolerated in middle-aged, elderly and renally impaired volunteers. The results support the clinical use of a 5\u00a0g dose of idarucizumab. http://www.clinicaltrials.gov . Unique identifier: NCT01955720.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "1617e42426ba4b0483170d68366da72d", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[262, 262], [87, 87], [23, 23], [8, 8], [142, 142]], "char_spans": [[1474, 1483], [505, 514], [184, 193], [64, 73], [720, 729]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antibody", 19], ["fragment", 28], ["that", 37], ["specifically", 42], ["reverses", 55], ["dabigatran", 64], ["-", 74], ["mediated", 75], ["anticoagulation", 84], [".", 99], ["Safety", 101], [",", 107], ["pharmacokinetics", 109], ["and", 126], ["pharmacodynamics", 130], ["of", 147], ["idarucizumab", 150], ["were", 163], ["investigated", 168], ["in", 181], ["dabigatran", 184], ["-", 194], ["treated", 195], [",", 202], ["middle", 204], ["-", 210], ["aged", 211], [",", 215], ["elderly", 217], ["and", 225], ["renally", 229], ["impaired", 237], ["volunteers", 246], ["with", 257], ["characteristics", 262], ["similar", 278], ["to", 286], ["patients", 289], ["receiving", 298], ["anticoagulant", 308], ["therapy", 322], [".", 329], ["In", 331], ["this", 334], ["randomized", 339], [",", 349], ["double", 351], ["-", 357], ["blind", 358], [",", 363], ["crossover", 365], ["study", 375], [",", 380], ["46", 382], ["subjects", 385], ["(", 394], ["12", 395], ["middle", 398], ["-", 404], ["aged", 405], [",", 409], ["45", 411], ["-", 413], ["64", 414], ["years", 417], [";", 422], ["16", 424], ["elderly", 427], [",", 434], ["65", 436], ["-", 438], ["80", 439], ["years", 442], [";", 447], ["and", 449], ["18", 453], ["with", 456], ["mild", 461], ["or", 466], ["moderate", 469], ["renal", 478], ["impairment", 484], [")", 494], ["received", 496], ["dabigatran", 505], ["etexilate", 516], ["(", 526], ["DE", 527], [";", 529], ["220", 531], ["or", 535], ["150", 538], ["mg", 542], ["twice", 545], ["daily", 551], [")", 556], ["for", 558], ["4", 562], ["days", 564], [".", 568], ["Idarucizumab", 570], ["doses", 583], ["of", 589], ["1", 592], [",", 593], ["2.5", 595], ["and", 599], ["5", 603], ["g", 605], ["or", 607], ["2", 610], ["\u00d7", 612], ["2.5", 614], ["g", 618], ["1", 620], ["h", 622], ["apart", 624], [",", 629], ["or", 631], ["placebo", 634], [",", 641], ["were", 643], ["administered", 648], ["as", 661], ["a", 664], ["rapid", 666], ["(", 672], ["5", 673], ["min", 675], [")", 678], ["infusion", 680], ["~2", 689], ["h", 692], ["after", 694], ["DE", 700], ["at", 703], ["steady", 706], ["state", 713], [".", 718], ["Dabigatran", 720], ["-", 730], ["prolonged", 731], ["diluted", 741], ["thrombin", 749], ["time", 758], [",", 762], ["ecarin", 764], ["clotting", 771], ["time", 780], ["and", 785], ["activated", 789], ["partial", 799], ["thromboplastin", 807], ["time", 822], ["were", 827], ["reversed", 832], ["to", 841], ["baseline", 844], ["immediately", 853], ["after", 865], ["idarucizumab", 871], ["infusion", 884], ["in", 893], ["all", 896], ["groups", 900], [".", 906], ["Reversal", 908], ["was", 917], ["sustained", 921], ["with", 931], ["doses", 936], ["\u22652.5", 942], ["g.", 947], ["Idarucizumab", 950], ["was", 963], ["well", 967], ["tolerated", 972], ["under", 982], ["all", 988], ["conditions", 992], [".", 1002], ["No", 1004], ["impact", 1007], ["of", 1014], ["age", 1017], ["on", 1021], ["idarucizumab", 1024], ["pharmacokinetics", 1037], ["was", 1054], ["observed", 1058], [";", 1066], ["however", 1068], [",", 1075], ["subjects", 1077], ["with", 1086], ["mild", 1091], ["or", 1096], ["moderate", 1099], ["renal", 1108], ["impairment", 1114], ["demonstrated", 1125], ["increased", 1138], ["exposure", 1148], ["(", 1157], ["up", 1158], ["to", 1161], ["84", 1164], ["%", 1167], [")", 1168], [",", 1169], ["decreased", 1171], ["clearance", 1181], ["and", 1191], ["prolonged", 1195], ["(", 1205], ["by", 1206], ["up", 1209], ["to", 1212], ["49", 1215], ["%", 1218], [")", 1219], ["initial", 1221], ["half", 1229], ["-", 1233], ["life", 1234], ["of", 1239], ["idarucizumab", 1242], ["compared", 1255], ["with", 1264], ["healthy", 1269], ["middle", 1277], ["-", 1283], ["aged", 1284], ["subjects", 1289], [".", 1297], ["Impaired", 1299], ["renal", 1308], ["function", 1314], ["was", 1323], ["associated", 1327], ["with", 1338], ["increased", 1343], ["exposure", 1353], ["and", 1362], ["decreased", 1366], ["clearance", 1376], ["of", 1386], ["idarucizumab", 1389], [".", 1401], ["Idarucizumab", 1403], ["resulted", 1416], ["in", 1425], ["immediate", 1428], [",", 1437], ["complete", 1439], ["and", 1448], ["sustained", 1452], ["reversal", 1462], ["of", 1471], ["dabigatran", 1474], ["anticoagulant", 1485], ["activity", 1499], [",", 1507], ["and", 1509], ["was", 1513], ["safe", 1517], ["and", 1522], ["well", 1526], ["tolerated", 1531], ["in", 1541], ["middle", 1544], ["-", 1550], ["aged", 1551], [",", 1555], ["elderly", 1557], ["and", 1565], ["renally", 1569], ["impaired", 1577], ["volunteers", 1586], [".", 1596], ["The", 1598], ["results", 1602], ["support", 1610], ["the", 1618], ["clinical", 1622], ["use", 1631], ["of", 1635], ["a", 1638], ["5", 1640], ["g", 1642], ["dose", 1644], ["of", 1649], ["idarucizumab", 1652], [".", 1664], ["http://www.clinicaltrials.gov", 1666], [".", 1696], ["Unique", 1698], ["identifier", 1705], [":", 1715], ["NCT01955720", 1717], [".", 1728]]}
{"context": "Restless legs syndrome, now called Willis-Ekbom Disease (RLS/WED), is a sensorimotor-related sleep disorder. Little is known of the effect of RLS/WED on motor function. The current study investigated upper limb function in RLS/WED patients. We hypothesised that RLS/WED patients exhibit subtle changes in tremor amplitude but normal dexterity and movement speed and rhythmicity compared to healthy controls. RLS/WED patients (n=17, 59 \u00b1 7 years) with moderate disease and healthy controls (n=17, 58 \u00b1 6 years) completed screening tests and five tasks including object manipulation, maximal pinch grip, flexion and extension of the index finger (tremor assessment), maximal finger tapping (movement speed and rhythmicity assessment), and the grooved pegboard test. Force, acceleration, and/or first dorsal interosseus EMG were recorded during four of the tasks. Task performance did not differ between groups. Learning was evident on tasks with repeated trials and the magnitude of learning did not differ between groups. Hand function, tremor, and task learning were unaffected in RLS/WED patients. Patients manipulated objects in a normal manner and exhibited normal movement speed, rhythmicity, and tremor. Further research is needed to assess other types of movement in RLS/WED patients to gain insight into the motor circuitry affected and the underlying pathophysiology.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "3e5986f118e1472abdf00781a69c02a0", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], [",", 22], ["now", 24], ["called", 28], ["Willis", 35], ["-", 41], ["Ekbom", 42], ["Disease", 48], ["(", 56], ["RLS", 57], ["/", 60], ["WED", 61], [")", 64], [",", 65], ["is", 67], ["a", 70], ["sensorimotor", 72], ["-", 84], ["related", 85], ["sleep", 93], ["disorder", 99], [".", 107], ["Little", 109], ["is", 116], ["known", 119], ["of", 125], ["the", 128], ["effect", 132], ["of", 139], ["RLS", 142], ["/", 145], ["WED", 146], ["on", 150], ["motor", 153], ["function", 159], [".", 167], ["The", 169], ["current", 173], ["study", 181], ["investigated", 187], ["upper", 200], ["limb", 206], ["function", 211], ["in", 220], ["RLS", 223], ["/", 226], ["WED", 227], ["patients", 231], [".", 239], ["We", 241], ["hypothesised", 244], ["that", 257], ["RLS", 262], ["/", 265], ["WED", 266], ["patients", 270], ["exhibit", 279], ["subtle", 287], ["changes", 294], ["in", 302], ["tremor", 305], ["amplitude", 312], ["but", 322], ["normal", 326], ["dexterity", 333], ["and", 343], ["movement", 347], ["speed", 356], ["and", 362], ["rhythmicity", 366], ["compared", 378], ["to", 387], ["healthy", 390], ["controls", 398], [".", 406], ["RLS", 408], ["/", 411], ["WED", 412], ["patients", 416], ["(", 425], ["n=17", 426], [",", 430], ["59", 432], ["\u00b1", 435], ["7", 437], ["years", 439], [")", 444], ["with", 446], ["moderate", 451], ["disease", 460], ["and", 468], ["healthy", 472], ["controls", 480], ["(", 489], ["n=17", 490], [",", 494], ["58", 496], ["\u00b1", 499], ["6", 501], ["years", 503], [")", 508], ["completed", 510], ["screening", 520], ["tests", 530], ["and", 536], ["five", 540], ["tasks", 545], ["including", 551], ["object", 561], ["manipulation", 568], [",", 580], ["maximal", 582], ["pinch", 590], ["grip", 596], [",", 600], ["flexion", 602], ["and", 610], ["extension", 614], ["of", 624], ["the", 627], ["index", 631], ["finger", 637], ["(", 644], ["tremor", 645], ["assessment", 652], [")", 662], [",", 663], ["maximal", 665], ["finger", 673], ["tapping", 680], ["(", 688], ["movement", 689], ["speed", 698], ["and", 704], ["rhythmicity", 708], ["assessment", 720], [")", 730], [",", 731], ["and", 733], ["the", 737], ["grooved", 741], ["pegboard", 749], ["test", 758], [".", 762], ["Force", 764], [",", 769], ["acceleration", 771], [",", 783], ["and/or", 785], ["first", 792], ["dorsal", 798], ["interosseus", 805], ["EMG", 817], ["were", 821], ["recorded", 826], ["during", 835], ["four", 842], ["of", 847], ["the", 850], ["tasks", 854], [".", 859], ["Task", 861], ["performance", 866], ["did", 878], ["not", 882], ["differ", 886], ["between", 893], ["groups", 901], [".", 907], ["Learning", 909], ["was", 918], ["evident", 922], ["on", 930], ["tasks", 933], ["with", 939], ["repeated", 944], ["trials", 953], ["and", 960], ["the", 964], ["magnitude", 968], ["of", 978], ["learning", 981], ["did", 990], ["not", 994], ["differ", 998], ["between", 1005], ["groups", 1013], [".", 1019], ["Hand", 1021], ["function", 1026], [",", 1034], ["tremor", 1036], [",", 1042], ["and", 1044], ["task", 1048], ["learning", 1053], ["were", 1062], ["unaffected", 1067], ["in", 1078], ["RLS", 1081], ["/", 1084], ["WED", 1085], ["patients", 1089], [".", 1097], ["Patients", 1099], ["manipulated", 1108], ["objects", 1120], ["in", 1128], ["a", 1131], ["normal", 1133], ["manner", 1140], ["and", 1147], ["exhibited", 1151], ["normal", 1161], ["movement", 1168], ["speed", 1177], [",", 1182], ["rhythmicity", 1184], [",", 1195], ["and", 1197], ["tremor", 1201], [".", 1207], ["Further", 1209], ["research", 1217], ["is", 1226], ["needed", 1229], ["to", 1236], ["assess", 1239], ["other", 1246], ["types", 1252], ["of", 1258], ["movement", 1261], ["in", 1270], ["RLS", 1273], ["/", 1276], ["WED", 1277], ["patients", 1281], ["to", 1290], ["gain", 1293], ["insight", 1298], ["into", 1306], ["the", 1311], ["motor", 1315], ["circuitry", 1321], ["affected", 1331], ["and", 1340], ["the", 1344], ["underlying", 1348], ["pathophysiology", 1359], [".", 1374]]}
{"context": "The gangliosidoses comprise a family of lysosomal storage diseases characterized by the accumulation of complex glycosphingolipids in the nervous system and other tissues, secondary to the deficient activity of lysosomal hydrolases or their associated activator proteins. GM1 and GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase respectively. All gangliosidoses are characterized by progressive neurodegeneration, the severity of which is proportional to the residual enzyme activity. The GM1 gangliosidoses are characterized by dysostosis, organomegaly and coarsening in their most severe forms, whereas children with classic infantile GM2 gangliosidosis (Tay-Sachs disease) are usually spared systemic involvement, except in the case of the Sandhoff variant, in which organomegaly may occur. Cherry-red macular spots occur in the early onset forms of the gangliosidoses, but are less frequently seen in the less severe, later onset phenotypes. Macrocephaly, an exaggerated startle response, cognitive decline, seizures, ataxia, and progressive muscular atrophy may occur in different forms of gangliosidosis. The diagnosis is made by assay of enzyme activity, and can be confirmed by mutation analysis. Carrier screening for Tay-Sachs disease has been remarkably successful in reducing the incidence of this disease in the at-risk Ashkenazi population. There are no proven disease-modifying therapies for the gangliosidoses.", "qas": [{"question": "Which enzyme deficiency can cause GM1 gangliosidoses?", "answers": ["\u03b2-galactosidase"], "qid": "91ba5f0e9cdb420b8e49daf63935d388", "question_tokens": [["Which", 0], ["enzyme", 6], ["deficiency", 13], ["can", 24], ["cause", 28], ["GM1", 34], ["gangliosidoses", 38], ["?", 52]], "detected_answers": [{"text": "\u03b2-galactosidase", "token_spans": [[47, 49]], "char_spans": [[333, 347]]}]}], "context_tokens": [["The", 0], ["gangliosidoses", 4], ["comprise", 19], ["a", 28], ["family", 30], ["of", 37], ["lysosomal", 40], ["storage", 50], ["diseases", 58], ["characterized", 67], ["by", 81], ["the", 84], ["accumulation", 88], ["of", 101], ["complex", 104], ["glycosphingolipids", 112], ["in", 131], ["the", 134], ["nervous", 138], ["system", 146], ["and", 153], ["other", 157], ["tissues", 163], [",", 170], ["secondary", 172], ["to", 182], ["the", 185], ["deficient", 189], ["activity", 199], ["of", 208], ["lysosomal", 211], ["hydrolases", 221], ["or", 232], ["their", 235], ["associated", 241], ["activator", 252], ["proteins", 262], [".", 270], ["GM1", 272], ["and", 276], ["GM2", 280], ["gangliosidosis", 284], ["are", 299], ["associated", 303], ["with", 314], ["deficiency", 319], ["of", 330], ["\u03b2", 333], ["-", 334], ["galactosidase", 335], ["and", 349], ["\u03b2", 353], ["-", 354], ["hexosaminidase", 355], ["respectively", 370], [".", 382], ["All", 384], ["gangliosidoses", 388], ["are", 403], ["characterized", 407], ["by", 421], ["progressive", 424], ["neurodegeneration", 436], [",", 453], ["the", 455], ["severity", 459], ["of", 468], ["which", 471], ["is", 477], ["proportional", 480], ["to", 493], ["the", 496], ["residual", 500], ["enzyme", 509], ["activity", 516], [".", 524], ["The", 526], ["GM1", 530], ["gangliosidoses", 534], ["are", 549], ["characterized", 553], ["by", 567], ["dysostosis", 570], [",", 580], ["organomegaly", 582], ["and", 595], ["coarsening", 599], ["in", 610], ["their", 613], ["most", 619], ["severe", 624], ["forms", 631], [",", 636], ["whereas", 638], ["children", 646], ["with", 655], ["classic", 660], ["infantile", 668], ["GM2", 678], ["gangliosidosis", 682], ["(", 697], ["Tay", 698], ["-", 701], ["Sachs", 702], ["disease", 708], [")", 715], ["are", 717], ["usually", 721], ["spared", 729], ["systemic", 736], ["involvement", 745], [",", 756], ["except", 758], ["in", 765], ["the", 768], ["case", 772], ["of", 777], ["the", 780], ["Sandhoff", 784], ["variant", 793], [",", 800], ["in", 802], ["which", 805], ["organomegaly", 811], ["may", 824], ["occur", 828], [".", 833], ["Cherry", 835], ["-", 841], ["red", 842], ["macular", 846], ["spots", 854], ["occur", 860], ["in", 866], ["the", 869], ["early", 873], ["onset", 879], ["forms", 885], ["of", 891], ["the", 894], ["gangliosidoses", 898], [",", 912], ["but", 914], ["are", 918], ["less", 922], ["frequently", 927], ["seen", 938], ["in", 943], ["the", 946], ["less", 950], ["severe", 955], [",", 961], ["later", 963], ["onset", 969], ["phenotypes", 975], [".", 985], ["Macrocephaly", 987], [",", 999], ["an", 1001], ["exaggerated", 1004], ["startle", 1016], ["response", 1024], [",", 1032], ["cognitive", 1034], ["decline", 1044], [",", 1051], ["seizures", 1053], [",", 1061], ["ataxia", 1063], [",", 1069], ["and", 1071], ["progressive", 1075], ["muscular", 1087], ["atrophy", 1096], ["may", 1104], ["occur", 1108], ["in", 1114], ["different", 1117], ["forms", 1127], ["of", 1133], ["gangliosidosis", 1136], [".", 1150], ["The", 1152], ["diagnosis", 1156], ["is", 1166], ["made", 1169], ["by", 1174], ["assay", 1177], ["of", 1183], ["enzyme", 1186], ["activity", 1193], [",", 1201], ["and", 1203], ["can", 1207], ["be", 1211], ["confirmed", 1214], ["by", 1224], ["mutation", 1227], ["analysis", 1236], [".", 1244], ["Carrier", 1246], ["screening", 1254], ["for", 1264], ["Tay", 1268], ["-", 1271], ["Sachs", 1272], ["disease", 1278], ["has", 1286], ["been", 1290], ["remarkably", 1295], ["successful", 1306], ["in", 1317], ["reducing", 1320], ["the", 1329], ["incidence", 1333], ["of", 1343], ["this", 1346], ["disease", 1351], ["in", 1359], ["the", 1362], ["at", 1366], ["-", 1368], ["risk", 1369], ["Ashkenazi", 1374], ["population", 1384], [".", 1394], ["There", 1396], ["are", 1402], ["no", 1406], ["proven", 1409], ["disease", 1416], ["-", 1423], ["modifying", 1424], ["therapies", 1434], ["for", 1444], ["the", 1448], ["gangliosidoses", 1452], [".", 1466]]}
{"context": "S100A4 is a small calcium-binding protein that is commonly overexpressed in a range of different tumor types, and it is widely accepted that S100A4 has an important role in the process of cancer metastasis. In vitro binding assays has shown that S100A4 interacts with the tumor suppressor protein p53, indicating that S100A4 may have additional roles in tumor development. In the present study, we show that endogenous S100A4 and p53 interact in complex samples, and that the interaction increases after inhibition of MDM2-dependent p53 degradation using Nutlin-3A. Further, using proximity ligation assay, we show that the interaction takes place in the cell nucleus. S100A4 knockdown experiments in two p53 wild-type cell lines, A549 and HeLa, resulted in stabilization of p53 protein, indicating that S100A4 is promoting p53 degradation. Finally, we demonstrate that S100A4 knockdown leads to p53-dependent cell cycle arrest and increased cisplatin-induced apoptosis. Thus, our data add a new layer to the oncogenic properties of S100A4 through its inhibition of p53-dependent processes.", "qas": [{"question": "Where in the cell does the proteins S100A4 and p53 interact ?", "answers": ["nucleus"], "qid": "b2838cb187da4004873628ecd5e3851c", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["does", 18], ["the", 23], ["proteins", 27], ["S100A4", 36], ["and", 43], ["p53", 47], ["interact", 51], ["?", 60]], "detected_answers": [{"text": "nucleus", "token_spans": [[112, 112]], "char_spans": [[660, 666]]}]}], "context_tokens": [["S100A4", 0], ["is", 7], ["a", 10], ["small", 12], ["calcium", 18], ["-", 25], ["binding", 26], ["protein", 34], ["that", 42], ["is", 47], ["commonly", 50], ["overexpressed", 59], ["in", 73], ["a", 76], ["range", 78], ["of", 84], ["different", 87], ["tumor", 97], ["types", 103], [",", 108], ["and", 110], ["it", 114], ["is", 117], ["widely", 120], ["accepted", 127], ["that", 136], ["S100A4", 141], ["has", 148], ["an", 152], ["important", 155], ["role", 165], ["in", 170], ["the", 173], ["process", 177], ["of", 185], ["cancer", 188], ["metastasis", 195], [".", 205], ["In", 207], ["vitro", 210], ["binding", 216], ["assays", 224], ["has", 231], ["shown", 235], ["that", 241], ["S100A4", 246], ["interacts", 253], ["with", 263], ["the", 268], ["tumor", 272], ["suppressor", 278], ["protein", 289], ["p53", 297], [",", 300], ["indicating", 302], ["that", 313], ["S100A4", 318], ["may", 325], ["have", 329], ["additional", 334], ["roles", 345], ["in", 351], ["tumor", 354], ["development", 360], [".", 371], ["In", 373], ["the", 376], ["present", 380], ["study", 388], [",", 393], ["we", 395], ["show", 398], ["that", 403], ["endogenous", 408], ["S100A4", 419], ["and", 426], ["p53", 430], ["interact", 434], ["in", 443], ["complex", 446], ["samples", 454], [",", 461], ["and", 463], ["that", 467], ["the", 472], ["interaction", 476], ["increases", 488], ["after", 498], ["inhibition", 504], ["of", 515], ["MDM2-dependent", 518], ["p53", 533], ["degradation", 537], ["using", 549], ["Nutlin-3A.", 555], ["Further", 566], [",", 573], ["using", 575], ["proximity", 581], ["ligation", 591], ["assay", 600], [",", 605], ["we", 607], ["show", 610], ["that", 615], ["the", 620], ["interaction", 624], ["takes", 636], ["place", 642], ["in", 648], ["the", 651], ["cell", 655], ["nucleus", 660], [".", 667], ["S100A4", 669], ["knockdown", 676], ["experiments", 686], ["in", 698], ["two", 701], ["p53", 705], ["wild", 709], ["-", 713], ["type", 714], ["cell", 719], ["lines", 724], [",", 729], ["A549", 731], ["and", 736], ["HeLa", 740], [",", 744], ["resulted", 746], ["in", 755], ["stabilization", 758], ["of", 772], ["p53", 775], ["protein", 779], [",", 786], ["indicating", 788], ["that", 799], ["S100A4", 804], ["is", 811], ["promoting", 814], ["p53", 824], ["degradation", 828], [".", 839], ["Finally", 841], [",", 848], ["we", 850], ["demonstrate", 853], ["that", 865], ["S100A4", 870], ["knockdown", 877], ["leads", 887], ["to", 893], ["p53-dependent", 896], ["cell", 910], ["cycle", 915], ["arrest", 921], ["and", 928], ["increased", 932], ["cisplatin", 942], ["-", 951], ["induced", 952], ["apoptosis", 960], [".", 969], ["Thus", 971], [",", 975], ["our", 977], ["data", 981], ["add", 986], ["a", 990], ["new", 992], ["layer", 996], ["to", 1002], ["the", 1005], ["oncogenic", 1009], ["properties", 1019], ["of", 1030], ["S100A4", 1033], ["through", 1040], ["its", 1048], ["inhibition", 1052], ["of", 1063], ["p53-dependent", 1066], ["processes", 1080], [".", 1089]]}
{"context": "Restless legs syndrome (RLS)/Willis-Ekbom disease (WED) has a significant negative effect on quality of life. The decreased quality of life is similar to that of other chronic diseases, such as diabetes type 2, depression, and osteoarthritis. RLS/WED disrupts sleep length, sleep quality, and daytime alertness. Sleep disruption can contribute to depression. RLS/WED has been associated with cardiovascular disease and high blood pressure, possibly because of increased sympathetic tone caused by periodic limb movements of sleep. RLS/WED is underdiagnosed, leading to chronic sleep disruption and daytime consequences. Patients with RLS/WED have decreased productivity at work, which potentially has far-reaching economic consequences.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "f67084a71c774272be8ec7fc8baa5f52", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS)/Willis", 24], ["-", 35], ["Ekbom", 36], ["disease", 42], ["(", 50], ["WED", 51], [")", 54], ["has", 56], ["a", 60], ["significant", 62], ["negative", 74], ["effect", 83], ["on", 90], ["quality", 93], ["of", 101], ["life", 104], [".", 108], ["The", 110], ["decreased", 114], ["quality", 124], ["of", 132], ["life", 135], ["is", 140], ["similar", 143], ["to", 151], ["that", 154], ["of", 159], ["other", 162], ["chronic", 168], ["diseases", 176], [",", 184], ["such", 186], ["as", 191], ["diabetes", 194], ["type", 203], ["2", 208], [",", 209], ["depression", 211], [",", 221], ["and", 223], ["osteoarthritis", 227], [".", 241], ["RLS", 243], ["/", 246], ["WED", 247], ["disrupts", 251], ["sleep", 260], ["length", 266], [",", 272], ["sleep", 274], ["quality", 280], [",", 287], ["and", 289], ["daytime", 293], ["alertness", 301], [".", 310], ["Sleep", 312], ["disruption", 318], ["can", 329], ["contribute", 333], ["to", 344], ["depression", 347], [".", 357], ["RLS", 359], ["/", 362], ["WED", 363], ["has", 367], ["been", 371], ["associated", 376], ["with", 387], ["cardiovascular", 392], ["disease", 407], ["and", 415], ["high", 419], ["blood", 424], ["pressure", 430], [",", 438], ["possibly", 440], ["because", 449], ["of", 457], ["increased", 460], ["sympathetic", 470], ["tone", 482], ["caused", 487], ["by", 494], ["periodic", 497], ["limb", 506], ["movements", 511], ["of", 521], ["sleep", 524], [".", 529], ["RLS", 531], ["/", 534], ["WED", 535], ["is", 539], ["underdiagnosed", 542], [",", 556], ["leading", 558], ["to", 566], ["chronic", 569], ["sleep", 577], ["disruption", 583], ["and", 594], ["daytime", 598], ["consequences", 606], [".", 618], ["Patients", 620], ["with", 629], ["RLS", 634], ["/", 637], ["WED", 638], ["have", 642], ["decreased", 647], ["productivity", 657], ["at", 670], ["work", 673], [",", 677], ["which", 679], ["potentially", 685], ["has", 697], ["far", 701], ["-", 704], ["reaching", 705], ["economic", 714], ["consequences", 723], [".", 735]]}
{"context": "The performance of CURB65 in predicting mortality in community-acquired pneumonia (CAP) has been tested in two large observational studies. However, it has not been tested against generic sepsis and early warning scores, which are increasingly being advocated for identification of high-risk patients in acute medical wards. A retrospective analysis was performed of data prospectively collected for a CAP quality improvement study. The ability to stratify mortality and performance characteristics (sensitivity, specificity, positive predictive value, negative predictive value and area under the receiver operating curve) were calculated for stratifications of CURB65, CRB65, the systemic inflammatory response syndrome (SIRS) criteria and the standardised early warning score (SEWS). 419 patients were included in the main analysis with a median age of 74 years (men = 47%). CURB65 and CRB65 stratified mortality in a more clinically useful way and had more favourable operating characteristics than SIRS or SEWS; for example, mortality in low-risk patients was 2% when defined by CURB65, but 9% when defined by SEWS and 11-17% when defined by variations of the SIRS criteria. The sensitivity, specificity, positive predictive value and negative predictive value of CURB65 was 71%, 69%, 35% and 91%, respectively, compared with 62%, 73%, 35% and 89% for the best performing version of SIRS and 52%, 67%, 27% and 86% for SEWS. CURB65 had the greatest area under the receiver operating curve (0.78 v 0.73 for CRB65, 0.68 for SIRS and 0.64 for SEWS). CURB65 should not be supplanted by SIRS or SEWS for initial prognostic assessment in CAP. Further research to identify better generic prognostic tools is required.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "cc706a937ac44341a23ae0cae23e2bdd", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[11, 11]], "char_spans": [[72, 80]]}]}], "context_tokens": [["The", 0], ["performance", 4], ["of", 16], ["CURB65", 19], ["in", 26], ["predicting", 29], ["mortality", 40], ["in", 50], ["community", 53], ["-", 62], ["acquired", 63], ["pneumonia", 72], ["(", 82], ["CAP", 83], [")", 86], ["has", 88], ["been", 92], ["tested", 97], ["in", 104], ["two", 107], ["large", 111], ["observational", 117], ["studies", 131], [".", 138], ["However", 140], [",", 147], ["it", 149], ["has", 152], ["not", 156], ["been", 160], ["tested", 165], ["against", 172], ["generic", 180], ["sepsis", 188], ["and", 195], ["early", 199], ["warning", 205], ["scores", 213], [",", 219], ["which", 221], ["are", 227], ["increasingly", 231], ["being", 244], ["advocated", 250], ["for", 260], ["identification", 264], ["of", 279], ["high", 282], ["-", 286], ["risk", 287], ["patients", 292], ["in", 301], ["acute", 304], ["medical", 310], ["wards", 318], [".", 323], ["A", 325], ["retrospective", 327], ["analysis", 341], ["was", 350], ["performed", 354], ["of", 364], ["data", 367], ["prospectively", 372], ["collected", 386], ["for", 396], ["a", 400], ["CAP", 402], ["quality", 406], ["improvement", 414], ["study", 426], [".", 431], ["The", 433], ["ability", 437], ["to", 445], ["stratify", 448], ["mortality", 457], ["and", 467], ["performance", 471], ["characteristics", 483], ["(", 499], ["sensitivity", 500], [",", 511], ["specificity", 513], [",", 524], ["positive", 526], ["predictive", 535], ["value", 546], [",", 551], ["negative", 553], ["predictive", 562], ["value", 573], ["and", 579], ["area", 583], ["under", 588], ["the", 594], ["receiver", 598], ["operating", 607], ["curve", 617], [")", 622], ["were", 624], ["calculated", 629], ["for", 640], ["stratifications", 644], ["of", 660], ["CURB65", 663], [",", 669], ["CRB65", 671], [",", 676], ["the", 678], ["systemic", 682], ["inflammatory", 691], ["response", 704], ["syndrome", 713], ["(", 722], ["SIRS", 723], [")", 727], ["criteria", 729], ["and", 738], ["the", 742], ["standardised", 746], ["early", 759], ["warning", 765], ["score", 773], ["(", 779], ["SEWS", 780], [")", 784], [".", 785], ["419", 787], ["patients", 791], ["were", 800], ["included", 805], ["in", 814], ["the", 817], ["main", 821], ["analysis", 826], ["with", 835], ["a", 840], ["median", 842], ["age", 849], ["of", 853], ["74", 856], ["years", 859], ["(", 865], ["men", 866], ["=", 870], ["47", 872], ["%", 874], [")", 875], [".", 876], ["CURB65", 878], ["and", 885], ["CRB65", 889], ["stratified", 895], ["mortality", 906], ["in", 916], ["a", 919], ["more", 921], ["clinically", 926], ["useful", 937], ["way", 944], ["and", 948], ["had", 952], ["more", 956], ["favourable", 961], ["operating", 972], ["characteristics", 982], ["than", 998], ["SIRS", 1003], ["or", 1008], ["SEWS", 1011], [";", 1015], ["for", 1017], ["example", 1021], [",", 1028], ["mortality", 1030], ["in", 1040], ["low", 1043], ["-", 1046], ["risk", 1047], ["patients", 1052], ["was", 1061], ["2", 1065], ["%", 1066], ["when", 1068], ["defined", 1073], ["by", 1081], ["CURB65", 1084], [",", 1090], ["but", 1092], ["9", 1096], ["%", 1097], ["when", 1099], ["defined", 1104], ["by", 1112], ["SEWS", 1115], ["and", 1120], ["11", 1124], ["-", 1126], ["17", 1127], ["%", 1129], ["when", 1131], ["defined", 1136], ["by", 1144], ["variations", 1147], ["of", 1158], ["the", 1161], ["SIRS", 1165], ["criteria", 1170], [".", 1178], ["The", 1180], ["sensitivity", 1184], [",", 1195], ["specificity", 1197], [",", 1208], ["positive", 1210], ["predictive", 1219], ["value", 1230], ["and", 1236], ["negative", 1240], ["predictive", 1249], ["value", 1260], ["of", 1266], ["CURB65", 1269], ["was", 1276], ["71", 1280], ["%", 1282], [",", 1283], ["69", 1285], ["%", 1287], [",", 1288], ["35", 1290], ["%", 1292], ["and", 1294], ["91", 1298], ["%", 1300], [",", 1301], ["respectively", 1303], [",", 1315], ["compared", 1317], ["with", 1326], ["62", 1331], ["%", 1333], [",", 1334], ["73", 1336], ["%", 1338], [",", 1339], ["35", 1341], ["%", 1343], ["and", 1345], ["89", 1349], ["%", 1351], ["for", 1353], ["the", 1357], ["best", 1361], ["performing", 1366], ["version", 1377], ["of", 1385], ["SIRS", 1388], ["and", 1393], ["52", 1397], ["%", 1399], [",", 1400], ["67", 1402], ["%", 1404], [",", 1405], ["27", 1407], ["%", 1409], ["and", 1411], ["86", 1415], ["%", 1417], ["for", 1419], ["SEWS", 1423], [".", 1427], ["CURB65", 1429], ["had", 1436], ["the", 1440], ["greatest", 1444], ["area", 1453], ["under", 1458], ["the", 1464], ["receiver", 1468], ["operating", 1477], ["curve", 1487], ["(", 1493], ["0.78", 1494], ["v", 1499], ["0.73", 1501], ["for", 1506], ["CRB65", 1510], [",", 1515], ["0.68", 1517], ["for", 1522], ["SIRS", 1526], ["and", 1531], ["0.64", 1535], ["for", 1540], ["SEWS", 1544], [")", 1548], [".", 1549], ["CURB65", 1551], ["should", 1558], ["not", 1565], ["be", 1569], ["supplanted", 1572], ["by", 1583], ["SIRS", 1586], ["or", 1591], ["SEWS", 1594], ["for", 1599], ["initial", 1603], ["prognostic", 1611], ["assessment", 1622], ["in", 1633], ["CAP", 1636], [".", 1639], ["Further", 1641], ["research", 1649], ["to", 1658], ["identify", 1661], ["better", 1670], ["generic", 1677], ["prognostic", 1685], ["tools", 1696], ["is", 1702], ["required", 1705], [".", 1713]]}
{"context": "SECIS elements form stem-loop structures in the 3' untranslated regions (UTR) of eukaryotic mRNAs that encode selenoproteins. These elements direct incorporation of selenocysteine at UGA codons, provided the SECIS element lies a sufficient distance from the UGA. The cDNAs encoding skeletal muscle selenoprotein W from human, rhesus monkey, sheep, rat, and mouse contained highly similar SECIS elements that retained important features common to all known SECIS elements. Comparative analysis of these SECIS elements showed that in some regions both predicted secondary structure and nucleotide sequences were conserved, in other areas secondary structure was maintained using different primary sequence, and in still other portions, base pairing was not conserved. The rodent and sheep selenoprotein W mRNAs used UGA as a stop codon and as a selenocysteine codon. Thus, UGA specified both selenocysteine incorporation and termination in a single mRNA. The selenoprotein W SECIS elements contained an additional highly conserved base-paired stem that may prevent inappropriate selenocysteine incorporation at the UGA stop codons.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "22a6d5d4fcc740a0998d3d943187fa60", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[0, 0], [35, 35], [77, 77], [67, 67], [84, 84], [161, 161]], "char_spans": [[0, 4], [208, 212], [456, 460], [388, 392], [502, 506], [973, 977]]}]}], "context_tokens": [["SECIS", 0], ["elements", 6], ["form", 15], ["stem", 20], ["-", 24], ["loop", 25], ["structures", 30], ["in", 41], ["the", 44], ["3", 48], ["'", 49], ["untranslated", 51], ["regions", 64], ["(", 72], ["UTR", 73], [")", 76], ["of", 78], ["eukaryotic", 81], ["mRNAs", 92], ["that", 98], ["encode", 103], ["selenoproteins", 110], [".", 124], ["These", 126], ["elements", 132], ["direct", 141], ["incorporation", 148], ["of", 162], ["selenocysteine", 165], ["at", 180], ["UGA", 183], ["codons", 187], [",", 193], ["provided", 195], ["the", 204], ["SECIS", 208], ["element", 214], ["lies", 222], ["a", 227], ["sufficient", 229], ["distance", 240], ["from", 249], ["the", 254], ["UGA", 258], [".", 261], ["The", 263], ["cDNAs", 267], ["encoding", 273], ["skeletal", 282], ["muscle", 291], ["selenoprotein", 298], ["W", 312], ["from", 314], ["human", 319], [",", 324], ["rhesus", 326], ["monkey", 333], [",", 339], ["sheep", 341], [",", 346], ["rat", 348], [",", 351], ["and", 353], ["mouse", 357], ["contained", 363], ["highly", 373], ["similar", 380], ["SECIS", 388], ["elements", 394], ["that", 403], ["retained", 408], ["important", 417], ["features", 427], ["common", 436], ["to", 443], ["all", 446], ["known", 450], ["SECIS", 456], ["elements", 462], [".", 470], ["Comparative", 472], ["analysis", 484], ["of", 493], ["these", 496], ["SECIS", 502], ["elements", 508], ["showed", 517], ["that", 524], ["in", 529], ["some", 532], ["regions", 537], ["both", 545], ["predicted", 550], ["secondary", 560], ["structure", 570], ["and", 580], ["nucleotide", 584], ["sequences", 595], ["were", 605], ["conserved", 610], [",", 619], ["in", 621], ["other", 624], ["areas", 630], ["secondary", 636], ["structure", 646], ["was", 656], ["maintained", 660], ["using", 671], ["different", 677], ["primary", 687], ["sequence", 695], [",", 703], ["and", 705], ["in", 709], ["still", 712], ["other", 718], ["portions", 724], [",", 732], ["base", 734], ["pairing", 739], ["was", 747], ["not", 751], ["conserved", 755], [".", 764], ["The", 766], ["rodent", 770], ["and", 777], ["sheep", 781], ["selenoprotein", 787], ["W", 801], ["mRNAs", 803], ["used", 809], ["UGA", 814], ["as", 818], ["a", 821], ["stop", 823], ["codon", 828], ["and", 834], ["as", 838], ["a", 841], ["selenocysteine", 843], ["codon", 858], [".", 863], ["Thus", 865], [",", 869], ["UGA", 871], ["specified", 875], ["both", 885], ["selenocysteine", 890], ["incorporation", 905], ["and", 919], ["termination", 923], ["in", 935], ["a", 938], ["single", 940], ["mRNA", 947], [".", 951], ["The", 953], ["selenoprotein", 957], ["W", 971], ["SECIS", 973], ["elements", 979], ["contained", 988], ["an", 998], ["additional", 1001], ["highly", 1012], ["conserved", 1019], ["base", 1029], ["-", 1033], ["paired", 1034], ["stem", 1041], ["that", 1046], ["may", 1051], ["prevent", 1055], ["inappropriate", 1063], ["selenocysteine", 1077], ["incorporation", 1092], ["at", 1106], ["the", 1109], ["UGA", 1113], ["stop", 1117], ["codons", 1122], [".", 1128]]}
{"context": "Antibody-mediated glomerulonephritis, including that resulting from immune complexes, is an important cause of renal failure and is in need of more specific and effective treatment. Binding of antibody or immune complexes to Fc receptors activates intracellular signal transduction pathways, including spleen tyrosine kinase (Syk), leading to the production of inflammatory cytokines. We examined the effect of R788 (fostamatinib disodium), an oral prodrug of the selective Syk inhibitor R406, in nephrotoxic nephritis in Wistar-Kyoto rats. Treatment with R788 reduced proteinuria, tissue injury, glomerular macrophage and CD8+ cell numbers, and renal monocyte chemoattractant protein-1 (MCP-1) and IL-1beta, even when we started treatment after the onset of glomerulonephritis. When we administered R788 from days 4 to 10, glomerular crescents reduced by 100% (P < 0.01) compared with the vehicle group. When we administered R788 treatment from days 7 to 14, established glomerular crescents reversed (reduced by 21%, P < 0.001), and renal function was better than the vehicle group (P < 0.001). In vitro, R406 downregulated MCP-1 production from mesangial cells and macrophages stimulated with aggregated IgG. These results suggest that Syk is an important therapeutic target for the treatment of glomerulonephritis.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "5742d0bc42aa44c8a4614ab95fa1c3ff", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[46, 48]], "char_spans": [[302, 323]]}]}], "context_tokens": [["Antibody", 0], ["-", 8], ["mediated", 9], ["glomerulonephritis", 18], [",", 36], ["including", 38], ["that", 48], ["resulting", 53], ["from", 63], ["immune", 68], ["complexes", 75], [",", 84], ["is", 86], ["an", 89], ["important", 92], ["cause", 102], ["of", 108], ["renal", 111], ["failure", 117], ["and", 125], ["is", 129], ["in", 132], ["need", 135], ["of", 140], ["more", 143], ["specific", 148], ["and", 157], ["effective", 161], ["treatment", 171], [".", 180], ["Binding", 182], ["of", 190], ["antibody", 193], ["or", 202], ["immune", 205], ["complexes", 212], ["to", 222], ["Fc", 225], ["receptors", 228], ["activates", 238], ["intracellular", 248], ["signal", 262], ["transduction", 269], ["pathways", 282], [",", 290], ["including", 292], ["spleen", 302], ["tyrosine", 309], ["kinase", 318], ["(", 325], ["Syk", 326], [")", 329], [",", 330], ["leading", 332], ["to", 340], ["the", 343], ["production", 347], ["of", 358], ["inflammatory", 361], ["cytokines", 374], [".", 383], ["We", 385], ["examined", 388], ["the", 397], ["effect", 401], ["of", 408], ["R788", 411], ["(", 416], ["fostamatinib", 417], ["disodium", 430], [")", 438], [",", 439], ["an", 441], ["oral", 444], ["prodrug", 449], ["of", 457], ["the", 460], ["selective", 464], ["Syk", 474], ["inhibitor", 478], ["R406", 488], [",", 492], ["in", 494], ["nephrotoxic", 497], ["nephritis", 509], ["in", 519], ["Wistar", 522], ["-", 528], ["Kyoto", 529], ["rats", 535], [".", 539], ["Treatment", 541], ["with", 551], ["R788", 556], ["reduced", 561], ["proteinuria", 569], [",", 580], ["tissue", 582], ["injury", 589], [",", 595], ["glomerular", 597], ["macrophage", 608], ["and", 619], ["CD8", 623], ["+", 626], ["cell", 628], ["numbers", 633], [",", 640], ["and", 642], ["renal", 646], ["monocyte", 652], ["chemoattractant", 661], ["protein-1", 677], ["(", 687], ["MCP-1", 688], [")", 693], ["and", 695], ["IL-1beta", 699], [",", 707], ["even", 709], ["when", 714], ["we", 719], ["started", 722], ["treatment", 730], ["after", 740], ["the", 746], ["onset", 750], ["of", 756], ["glomerulonephritis", 759], [".", 777], ["When", 779], ["we", 784], ["administered", 787], ["R788", 800], ["from", 805], ["days", 810], ["4", 815], ["to", 817], ["10", 820], [",", 822], ["glomerular", 824], ["crescents", 835], ["reduced", 845], ["by", 853], ["100", 856], ["%", 859], ["(", 861], ["P", 862], ["<", 864], ["0.01", 866], [")", 870], ["compared", 872], ["with", 881], ["the", 886], ["vehicle", 890], ["group", 898], [".", 903], ["When", 905], ["we", 910], ["administered", 913], ["R788", 926], ["treatment", 931], ["from", 941], ["days", 946], ["7", 951], ["to", 953], ["14", 956], [",", 958], ["established", 960], ["glomerular", 972], ["crescents", 983], ["reversed", 993], ["(", 1002], ["reduced", 1003], ["by", 1011], ["21", 1014], ["%", 1016], [",", 1017], ["P", 1019], ["<", 1021], ["0.001", 1023], [")", 1028], [",", 1029], ["and", 1031], ["renal", 1035], ["function", 1041], ["was", 1050], ["better", 1054], ["than", 1061], ["the", 1066], ["vehicle", 1070], ["group", 1078], ["(", 1084], ["P", 1085], ["<", 1087], ["0.001", 1089], [")", 1094], [".", 1095], ["In", 1097], ["vitro", 1100], [",", 1105], ["R406", 1107], ["downregulated", 1112], ["MCP-1", 1126], ["production", 1132], ["from", 1143], ["mesangial", 1148], ["cells", 1158], ["and", 1164], ["macrophages", 1168], ["stimulated", 1180], ["with", 1191], ["aggregated", 1196], ["IgG.", 1207], ["These", 1212], ["results", 1218], ["suggest", 1226], ["that", 1234], ["Syk", 1239], ["is", 1243], ["an", 1246], ["important", 1249], ["therapeutic", 1259], ["target", 1271], ["for", 1278], ["the", 1282], ["treatment", 1286], ["of", 1296], ["glomerulonephritis", 1299], [".", 1317]]}
{"context": "Neurofibromatosis type 1 (NF1) is the most frequent neurocutaneous disorder with autosomal dominant inheritance. Phenotype variability is high ranging from merely several caf\u00e9-au-lait spots to malignant peripheral nerve sheath tumors or severe disfigurement through plexiform neurofibromas. Identification of genetic factors that modify the NF1 phenotype would contribute to the understanding of NF1 pathophysiology and improve patient counselling. As even monozygotic (MZ) twins with NF1 may differ phenotypically, we wondered whether these variations might be inherited in a non-Mendelian fashion. Mitochondrial DNA (mtDNA) is inherited extrachromosomally through the cytoplasm of the oocyte and often harbours heteroplasmic sequence variations. At the time of blastomere separation, these variants may be skewedly distributed and effect phenotypic differences. Because of their co-localization with the tumor suppressor protein neurofibromin, which is mutated in NF1, mitochondria were particular attractive candidates for investigation. MtDNA was extracted from nucleated blood cells of four pairs of discordant MZ twins with NF1 and from cutaneous neurofibromas of one twin pair. We sequenced the entire mitochondrial genome and determined the state of heteroplasmy by investigating a microsatellite region of the mitochondrial D-loop (D310-tract). The clinical diagnosis was confirmed in all patients by detection of pathogenic mutations in the NF1 gene. Monozygosity was verified by genotyping. However, we did not detect evidence for mtDNA sequence differences or for different degrees of heteroplasmy between individuals of the same twin pair. The phenotypic discordance of MZ twins with NF1 cannot be explained by skewed distribution of mtDNA mutations or polymorphisms.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "1c8a233817e24aaf970974c3d66dfce4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[59, 59], [51, 51], [150, 150], [74, 74], [227, 227], [4, 4], [268, 268], [175, 175]], "char_spans": [[396, 398], [341, 343], [966, 968], [485, 487], [1451, 1453], [26, 28], [1697, 1699], [1130, 1132]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["the", 34], ["most", 38], ["frequent", 43], ["neurocutaneous", 52], ["disorder", 67], ["with", 76], ["autosomal", 81], ["dominant", 91], ["inheritance", 100], [".", 111], ["Phenotype", 113], ["variability", 123], ["is", 135], ["high", 138], ["ranging", 143], ["from", 151], ["merely", 156], ["several", 163], ["caf\u00e9", 171], ["-", 175], ["au", 176], ["-", 178], ["lait", 179], ["spots", 184], ["to", 190], ["malignant", 193], ["peripheral", 203], ["nerve", 214], ["sheath", 220], ["tumors", 227], ["or", 234], ["severe", 237], ["disfigurement", 244], ["through", 258], ["plexiform", 266], ["neurofibromas", 276], [".", 289], ["Identification", 291], ["of", 306], ["genetic", 309], ["factors", 317], ["that", 325], ["modify", 330], ["the", 337], ["NF1", 341], ["phenotype", 345], ["would", 355], ["contribute", 361], ["to", 372], ["the", 375], ["understanding", 379], ["of", 393], ["NF1", 396], ["pathophysiology", 400], ["and", 416], ["improve", 420], ["patient", 428], ["counselling", 436], [".", 447], ["As", 449], ["even", 452], ["monozygotic", 457], ["(", 469], ["MZ", 470], [")", 472], ["twins", 474], ["with", 480], ["NF1", 485], ["may", 489], ["differ", 493], ["phenotypically", 500], [",", 514], ["we", 516], ["wondered", 519], ["whether", 528], ["these", 536], ["variations", 542], ["might", 553], ["be", 559], ["inherited", 562], ["in", 572], ["a", 575], ["non", 577], ["-", 580], ["Mendelian", 581], ["fashion", 591], [".", 598], ["Mitochondrial", 600], ["DNA", 614], ["(", 618], ["mtDNA", 619], [")", 624], ["is", 626], ["inherited", 629], ["extrachromosomally", 639], ["through", 658], ["the", 666], ["cytoplasm", 670], ["of", 680], ["the", 683], ["oocyte", 687], ["and", 694], ["often", 698], ["harbours", 704], ["heteroplasmic", 713], ["sequence", 727], ["variations", 736], [".", 746], ["At", 748], ["the", 751], ["time", 755], ["of", 760], ["blastomere", 763], ["separation", 774], [",", 784], ["these", 786], ["variants", 792], ["may", 801], ["be", 805], ["skewedly", 808], ["distributed", 817], ["and", 829], ["effect", 833], ["phenotypic", 840], ["differences", 851], [".", 862], ["Because", 864], ["of", 872], ["their", 875], ["co", 881], ["-", 883], ["localization", 884], ["with", 897], ["the", 902], ["tumor", 906], ["suppressor", 912], ["protein", 923], ["neurofibromin", 931], [",", 944], ["which", 946], ["is", 952], ["mutated", 955], ["in", 963], ["NF1", 966], [",", 969], ["mitochondria", 971], ["were", 984], ["particular", 989], ["attractive", 1000], ["candidates", 1011], ["for", 1022], ["investigation", 1026], [".", 1039], ["MtDNA", 1041], ["was", 1047], ["extracted", 1051], ["from", 1061], ["nucleated", 1066], ["blood", 1076], ["cells", 1082], ["of", 1088], ["four", 1091], ["pairs", 1096], ["of", 1102], ["discordant", 1105], ["MZ", 1116], ["twins", 1119], ["with", 1125], ["NF1", 1130], ["and", 1134], ["from", 1138], ["cutaneous", 1143], ["neurofibromas", 1153], ["of", 1167], ["one", 1170], ["twin", 1174], ["pair", 1179], [".", 1183], ["We", 1185], ["sequenced", 1188], ["the", 1198], ["entire", 1202], ["mitochondrial", 1209], ["genome", 1223], ["and", 1230], ["determined", 1234], ["the", 1245], ["state", 1249], ["of", 1255], ["heteroplasmy", 1258], ["by", 1271], ["investigating", 1274], ["a", 1288], ["microsatellite", 1290], ["region", 1305], ["of", 1312], ["the", 1315], ["mitochondrial", 1319], ["D", 1333], ["-", 1334], ["loop", 1335], ["(", 1340], ["D310-tract", 1341], [")", 1351], [".", 1352], ["The", 1354], ["clinical", 1358], ["diagnosis", 1367], ["was", 1377], ["confirmed", 1381], ["in", 1391], ["all", 1394], ["patients", 1398], ["by", 1407], ["detection", 1410], ["of", 1420], ["pathogenic", 1423], ["mutations", 1434], ["in", 1444], ["the", 1447], ["NF1", 1451], ["gene", 1455], [".", 1459], ["Monozygosity", 1461], ["was", 1474], ["verified", 1478], ["by", 1487], ["genotyping", 1490], [".", 1500], ["However", 1502], [",", 1509], ["we", 1511], ["did", 1514], ["not", 1518], ["detect", 1522], ["evidence", 1529], ["for", 1538], ["mtDNA", 1542], ["sequence", 1548], ["differences", 1557], ["or", 1569], ["for", 1572], ["different", 1576], ["degrees", 1586], ["of", 1594], ["heteroplasmy", 1597], ["between", 1610], ["individuals", 1618], ["of", 1630], ["the", 1633], ["same", 1637], ["twin", 1642], ["pair", 1647], [".", 1651], ["The", 1653], ["phenotypic", 1657], ["discordance", 1668], ["of", 1680], ["MZ", 1683], ["twins", 1686], ["with", 1692], ["NF1", 1697], ["can", 1701], ["not", 1704], ["be", 1708], ["explained", 1711], ["by", 1721], ["skewed", 1724], ["distribution", 1731], ["of", 1744], ["mtDNA", 1747], ["mutations", 1753], ["or", 1763], ["polymorphisms", 1766], [".", 1779]]}
{"context": "The ABL1 proto-oncogene encodes a cytoplasmic and nuclear protein tyrosine kinase (c-Abl) that has been implicated in processes of cell differentiation, cell division, cell adhesion and stress response. Alterations of ABL1 by chromosomal rearrangement or viral transduction can lead to malignant transformation. Activity of the c-Abl protein is negatively regulated by its SH3 domain through an unknown mechanism, and deletion of the SH3 domain turns ABL1 into an oncogene. We present evidence for an intramolecular inhibitory interaction of the SH3 domain with the catalytic domain and with the linker between the SH2 and catalytic domain (SH2-CD linker). Site-directed mutations in each of these three elements activate c-Abl. Mutations in the linker cause a conformational change of the molecule and increase binding of the SH3 domain to peptide ligands. Individual mutation of two charged residues in the SH3 and catalytic domain activates c-Abl, while inhibition is restored in the double reciprocal mutant. We propose that regulators of c-Abl will have opposite effects on its activity depending on their ability to favour or disrupt these intramolecular interactions.", "qas": [{"question": "What kind of enzyme is encoded by the proto-oncogene ABL1?", "answers": ["Nonreceptor tyrosine kinase", "Protein-Tyrosine Kinase", "protein tyrosine kinase"], "qid": "0e43309febce41e0bc84f3276562043b", "question_tokens": [["What", 0], ["kind", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["encoded", 23], ["by", 31], ["the", 34], ["proto", 38], ["-", 43], ["oncogene", 44], ["ABL1", 53], ["?", 57]], "detected_answers": [{"text": "Protein-Tyrosine Kinase", "token_spans": [[10, 12]], "char_spans": [[58, 80]]}]}], "context_tokens": [["The", 0], ["ABL1", 4], ["proto", 9], ["-", 14], ["oncogene", 15], ["encodes", 24], ["a", 32], ["cytoplasmic", 34], ["and", 46], ["nuclear", 50], ["protein", 58], ["tyrosine", 66], ["kinase", 75], ["(", 82], ["c", 83], ["-", 84], ["Abl", 85], [")", 88], ["that", 90], ["has", 95], ["been", 99], ["implicated", 104], ["in", 115], ["processes", 118], ["of", 128], ["cell", 131], ["differentiation", 136], [",", 151], ["cell", 153], ["division", 158], [",", 166], ["cell", 168], ["adhesion", 173], ["and", 182], ["stress", 186], ["response", 193], [".", 201], ["Alterations", 203], ["of", 215], ["ABL1", 218], ["by", 223], ["chromosomal", 226], ["rearrangement", 238], ["or", 252], ["viral", 255], ["transduction", 261], ["can", 274], ["lead", 278], ["to", 283], ["malignant", 286], ["transformation", 296], [".", 310], ["Activity", 312], ["of", 321], ["the", 324], ["c", 328], ["-", 329], ["Abl", 330], ["protein", 334], ["is", 342], ["negatively", 345], ["regulated", 356], ["by", 366], ["its", 369], ["SH3", 373], ["domain", 377], ["through", 384], ["an", 392], ["unknown", 395], ["mechanism", 403], [",", 412], ["and", 414], ["deletion", 418], ["of", 427], ["the", 430], ["SH3", 434], ["domain", 438], ["turns", 445], ["ABL1", 451], ["into", 456], ["an", 461], ["oncogene", 464], [".", 472], ["We", 474], ["present", 477], ["evidence", 485], ["for", 494], ["an", 498], ["intramolecular", 501], ["inhibitory", 516], ["interaction", 527], ["of", 539], ["the", 542], ["SH3", 546], ["domain", 550], ["with", 557], ["the", 562], ["catalytic", 566], ["domain", 576], ["and", 583], ["with", 587], ["the", 592], ["linker", 596], ["between", 603], ["the", 611], ["SH2", 615], ["and", 619], ["catalytic", 623], ["domain", 633], ["(", 640], ["SH2-CD", 641], ["linker", 648], [")", 654], [".", 655], ["Site", 657], ["-", 661], ["directed", 662], ["mutations", 671], ["in", 681], ["each", 684], ["of", 689], ["these", 692], ["three", 698], ["elements", 704], ["activate", 713], ["c", 722], ["-", 723], ["Abl", 724], [".", 727], ["Mutations", 729], ["in", 739], ["the", 742], ["linker", 746], ["cause", 753], ["a", 759], ["conformational", 761], ["change", 776], ["of", 783], ["the", 786], ["molecule", 790], ["and", 799], ["increase", 803], ["binding", 812], ["of", 820], ["the", 823], ["SH3", 827], ["domain", 831], ["to", 838], ["peptide", 841], ["ligands", 849], [".", 856], ["Individual", 858], ["mutation", 869], ["of", 878], ["two", 881], ["charged", 885], ["residues", 893], ["in", 902], ["the", 905], ["SH3", 909], ["and", 913], ["catalytic", 917], ["domain", 927], ["activates", 934], ["c", 944], ["-", 945], ["Abl", 946], [",", 949], ["while", 951], ["inhibition", 957], ["is", 968], ["restored", 971], ["in", 980], ["the", 983], ["double", 987], ["reciprocal", 994], ["mutant", 1005], [".", 1011], ["We", 1013], ["propose", 1016], ["that", 1024], ["regulators", 1029], ["of", 1040], ["c", 1043], ["-", 1044], ["Abl", 1045], ["will", 1049], ["have", 1054], ["opposite", 1059], ["effects", 1068], ["on", 1076], ["its", 1079], ["activity", 1083], ["depending", 1092], ["on", 1102], ["their", 1105], ["ability", 1111], ["to", 1119], ["favour", 1122], ["or", 1129], ["disrupt", 1132], ["these", 1140], ["intramolecular", 1146], ["interactions", 1161], [".", 1173]]}
{"context": "Dopamine (DA) replacement therapy with l-DOPA remains the standard pharmacotherapy for Parkinson's disease (PD). Unfortunately, chronic l-DOPA treatment is accompanied by development of motor fluctuations and l-DOPA-induced dyskinesia (LID). While serotonin (5-HT)(1A) agonists acutely reduce these complications, their prophylactic and long-term effects are not well-delineated. To test this, male Sprague-Dawley rats received unilateral 6-hydroxydopamine (6-OHDA) lesions. In experiment 1, l-DOPA-primed rats were pre-treated with Vehicle (0.9% NaCl), various doses of the partial 5-HT(1A) agonist, buspirone (0.25, 1.0 or 2.5 mg/kg, ip) or buspirone (2.5 mg/kg, ip)+the 5-HT(1A) antagonist, WAY100635 (0.5 mg/kg, ip) 5 min prior to l-DOPA (12 mg/kg+15 mg/kg benserazide, ip). Rats were tested for LID using the abnormal involuntary movements (AIMs) scale and motor performance using the forepaw adjusting steps test (FAS). In experiment 2, l-DOPA-na\u00efve rats received co-administration of l-DOPA+buspirone (1.0 or 2.5 mg/kg, ip) for 2 weeks. AIMs and FAS were measured throughout. In l-DOPA-primed rats, buspirone dose-dependently reduced LID and improved l-DOPA-related motor performance due to action at the 5-HT(1A) receptor. In l-DOPA-na\u00efve rats, buspirone delayed LID development while improving l-DOPA's anti-parkinsonian efficacy indicating the potential long-term benefits of 5-HT(1A) agonists for reduction of l-DOPA-related side effects.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "9109377696c0452b896a102d8836ded8", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[241, 243], [273, 275], [158, 160], [92, 94], [286, 288], [308, 310], [37, 39], [205, 207], [25, 27], [256, 258], [7, 9]], "char_spans": [[1086, 1091], [1234, 1239], [735, 740], [492, 497], [1303, 1308], [1421, 1426], [209, 214], [943, 948], [136, 141], [1158, 1163], [39, 44]]}]}], "context_tokens": [["Dopamine", 0], ["(", 9], ["DA", 10], [")", 12], ["replacement", 14], ["therapy", 26], ["with", 34], ["l", 39], ["-", 40], ["DOPA", 41], ["remains", 46], ["the", 54], ["standard", 58], ["pharmacotherapy", 67], ["for", 83], ["Parkinson", 87], ["'s", 96], ["disease", 99], ["(", 107], ["PD", 108], [")", 110], [".", 111], ["Unfortunately", 113], [",", 126], ["chronic", 128], ["l", 136], ["-", 137], ["DOPA", 138], ["treatment", 143], ["is", 153], ["accompanied", 156], ["by", 168], ["development", 171], ["of", 183], ["motor", 186], ["fluctuations", 192], ["and", 205], ["l", 209], ["-", 210], ["DOPA", 211], ["-", 215], ["induced", 216], ["dyskinesia", 224], ["(", 235], ["LID", 236], [")", 239], [".", 240], ["While", 242], ["serotonin", 248], ["(", 258], ["5-HT)(1A", 259], [")", 267], ["agonists", 269], ["acutely", 278], ["reduce", 286], ["these", 293], ["complications", 299], [",", 312], ["their", 314], ["prophylactic", 320], ["and", 333], ["long", 337], ["-", 341], ["term", 342], ["effects", 347], ["are", 355], ["not", 359], ["well", 363], ["-", 367], ["delineated", 368], [".", 378], ["To", 380], ["test", 383], ["this", 388], [",", 392], ["male", 394], ["Sprague", 399], ["-", 406], ["Dawley", 407], ["rats", 414], ["received", 419], ["unilateral", 428], ["6-hydroxydopamine", 439], ["(", 457], ["6-OHDA", 458], [")", 464], ["lesions", 466], [".", 473], ["In", 475], ["experiment", 478], ["1", 489], [",", 490], ["l", 492], ["-", 493], ["DOPA", 494], ["-", 498], ["primed", 499], ["rats", 506], ["were", 511], ["pre", 516], ["-", 519], ["treated", 520], ["with", 528], ["Vehicle", 533], ["(", 541], ["0.9", 542], ["%", 545], ["NaCl", 547], [")", 551], [",", 552], ["various", 554], ["doses", 562], ["of", 568], ["the", 571], ["partial", 575], ["5-HT(1A", 583], [")", 590], ["agonist", 592], [",", 599], ["buspirone", 601], ["(", 611], ["0.25", 612], [",", 616], ["1.0", 618], ["or", 622], ["2.5", 625], ["mg", 629], ["/", 631], ["kg", 632], [",", 634], ["ip", 636], [")", 638], ["or", 640], ["buspirone", 643], ["(", 653], ["2.5", 654], ["mg", 658], ["/", 660], ["kg", 661], [",", 663], ["ip)+the", 665], ["5-HT(1A", 673], [")", 680], ["antagonist", 682], [",", 692], ["WAY100635", 694], ["(", 704], ["0.5", 705], ["mg", 709], ["/", 711], ["kg", 712], [",", 714], ["ip", 716], [")", 718], ["5", 720], ["min", 722], ["prior", 726], ["to", 732], ["l", 735], ["-", 736], ["DOPA", 737], ["(", 742], ["12", 743], ["mg", 746], ["/", 748], ["kg+15", 749], ["mg", 755], ["/", 757], ["kg", 758], ["benserazide", 761], [",", 772], ["ip", 774], [")", 776], [".", 777], ["Rats", 779], ["were", 784], ["tested", 789], ["for", 796], ["LID", 800], ["using", 804], ["the", 810], ["abnormal", 814], ["involuntary", 823], ["movements", 835], ["(", 845], ["AIMs", 846], [")", 850], ["scale", 852], ["and", 858], ["motor", 862], ["performance", 868], ["using", 880], ["the", 886], ["forepaw", 890], ["adjusting", 898], ["steps", 908], ["test", 914], ["(", 919], ["FAS", 920], [")", 923], [".", 924], ["In", 926], ["experiment", 929], ["2", 940], [",", 941], ["l", 943], ["-", 944], ["DOPA", 945], ["-", 949], ["na\u00efve", 950], ["rats", 956], ["received", 961], ["co", 970], ["-", 972], ["administration", 973], ["of", 988], ["l", 991], ["-", 992], ["DOPA+buspirone", 993], ["(", 1008], ["1.0", 1009], ["or", 1013], ["2.5", 1016], ["mg", 1020], ["/", 1022], ["kg", 1023], [",", 1025], ["ip", 1027], [")", 1029], ["for", 1031], ["2", 1035], ["weeks", 1037], [".", 1042], ["AIMs", 1044], ["and", 1049], ["FAS", 1053], ["were", 1057], ["measured", 1062], ["throughout", 1071], [".", 1081], ["In", 1083], ["l", 1086], ["-", 1087], ["DOPA", 1088], ["-", 1092], ["primed", 1093], ["rats", 1100], [",", 1104], ["buspirone", 1106], ["dose", 1116], ["-", 1120], ["dependently", 1121], ["reduced", 1133], ["LID", 1141], ["and", 1145], ["improved", 1149], ["l", 1158], ["-", 1159], ["DOPA", 1160], ["-", 1164], ["related", 1165], ["motor", 1173], ["performance", 1179], ["due", 1191], ["to", 1195], ["action", 1198], ["at", 1205], ["the", 1208], ["5-HT(1A", 1212], [")", 1219], ["receptor", 1221], [".", 1229], ["In", 1231], ["l", 1234], ["-", 1235], ["DOPA", 1236], ["-", 1240], ["na\u00efve", 1241], ["rats", 1247], [",", 1251], ["buspirone", 1253], ["delayed", 1263], ["LID", 1271], ["development", 1275], ["while", 1287], ["improving", 1293], ["l", 1303], ["-", 1304], ["DOPA", 1305], ["'s", 1309], ["anti", 1312], ["-", 1316], ["parkinsonian", 1317], ["efficacy", 1330], ["indicating", 1339], ["the", 1350], ["potential", 1354], ["long", 1364], ["-", 1368], ["term", 1369], ["benefits", 1374], ["of", 1383], ["5-HT(1A", 1386], [")", 1393], ["agonists", 1395], ["for", 1404], ["reduction", 1408], ["of", 1418], ["l", 1421], ["-", 1422], ["DOPA", 1423], ["-", 1427], ["related", 1428], ["side", 1436], ["effects", 1441], [".", 1448]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disorder linked to contractions of the D4Z4 repeat array in the subtelomeric region of chromosome 4q. By comparing genome-wide gene expression data from muscle biopsies of patients with FSHD to those of 11 other neuromuscular disorders, paired-like homeodomain transcription factor 1 (PITX1) was found specifically up-regulated in patients with FSHD. In addition, we showed that the double homeobox 4 gene (DUX4) that maps within the D4Z4 repeat unit was up-regulated in patient myoblasts at both mRNA and protein level. We further showed that the DUX4 protein could activate transient expression of a luciferase reporter gene fused to the Pitx1 promoter as well as the endogenous Pitx1 gene in transfected C2C12 cells. In EMSAs, DUX4 specifically interacted with a 30-bp sequence 5'-CGGATGCTGTCTTCTAATTAGTTTGGACCC-3' in the Pitx1 promoter. Mutations of the TAAT core affected Pitx1-LUC activation in C2C12 cells and DUX4 binding in vitro. Our results suggest that up-regulation of both DUX4 and PITX1 in FSHD muscles may play critical roles in the molecular mechanisms of the disease.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "5d0d556d41284947986e2a22525e867b", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[4, 4], [69, 69], [41, 41], [186, 186]], "char_spans": [[40, 43], [416, 419], [257, 260], [1076, 1079]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["an", 49], ["autosomal", 52], ["dominant", 62], ["disorder", 71], ["linked", 80], ["to", 87], ["contractions", 90], ["of", 103], ["the", 106], ["D4Z4", 110], ["repeat", 115], ["array", 122], ["in", 128], ["the", 131], ["subtelomeric", 135], ["region", 148], ["of", 155], ["chromosome", 158], ["4q", 169], [".", 171], ["By", 173], ["comparing", 176], ["genome", 186], ["-", 192], ["wide", 193], ["gene", 198], ["expression", 203], ["data", 214], ["from", 219], ["muscle", 224], ["biopsies", 231], ["of", 240], ["patients", 243], ["with", 252], ["FSHD", 257], ["to", 262], ["those", 265], ["of", 271], ["11", 274], ["other", 277], ["neuromuscular", 283], ["disorders", 297], [",", 306], ["paired", 308], ["-", 314], ["like", 315], ["homeodomain", 320], ["transcription", 332], ["factor", 346], ["1", 353], ["(", 355], ["PITX1", 356], [")", 361], ["was", 363], ["found", 367], ["specifically", 373], ["up", 386], ["-", 388], ["regulated", 389], ["in", 399], ["patients", 402], ["with", 411], ["FSHD", 416], [".", 420], ["In", 422], ["addition", 425], [",", 433], ["we", 435], ["showed", 438], ["that", 445], ["the", 450], ["double", 454], ["homeobox", 461], ["4", 470], ["gene", 472], ["(", 477], ["DUX4", 478], [")", 482], ["that", 484], ["maps", 489], ["within", 494], ["the", 501], ["D4Z4", 505], ["repeat", 510], ["unit", 517], ["was", 522], ["up", 526], ["-", 528], ["regulated", 529], ["in", 539], ["patient", 542], ["myoblasts", 550], ["at", 560], ["both", 563], ["mRNA", 568], ["and", 573], ["protein", 577], ["level", 585], [".", 590], ["We", 592], ["further", 595], ["showed", 603], ["that", 610], ["the", 615], ["DUX4", 619], ["protein", 624], ["could", 632], ["activate", 638], ["transient", 647], ["expression", 657], ["of", 668], ["a", 671], ["luciferase", 673], ["reporter", 684], ["gene", 693], ["fused", 698], ["to", 704], ["the", 707], ["Pitx1", 711], ["promoter", 717], ["as", 726], ["well", 729], ["as", 734], ["the", 737], ["endogenous", 741], ["Pitx1", 752], ["gene", 758], ["in", 763], ["transfected", 766], ["C2C12", 778], ["cells", 784], [".", 789], ["In", 791], ["EMSAs", 794], [",", 799], ["DUX4", 801], ["specifically", 806], ["interacted", 819], ["with", 830], ["a", 835], ["30-bp", 837], ["sequence", 843], ["5'-CGGATGCTGTCTTCTAATTAGTTTGGACCC-3", 852], ["'", 887], ["in", 889], ["the", 892], ["Pitx1", 896], ["promoter", 902], [".", 910], ["Mutations", 912], ["of", 922], ["the", 925], ["TAAT", 929], ["core", 934], ["affected", 939], ["Pitx1-LUC", 948], ["activation", 958], ["in", 969], ["C2C12", 972], ["cells", 978], ["and", 984], ["DUX4", 988], ["binding", 993], ["in", 1001], ["vitro", 1004], [".", 1009], ["Our", 1011], ["results", 1015], ["suggest", 1023], ["that", 1031], ["up", 1036], ["-", 1038], ["regulation", 1039], ["of", 1050], ["both", 1053], ["DUX4", 1058], ["and", 1063], ["PITX1", 1067], ["in", 1073], ["FSHD", 1076], ["muscles", 1081], ["may", 1089], ["play", 1093], ["critical", 1098], ["roles", 1107], ["in", 1113], ["the", 1116], ["molecular", 1120], ["mechanisms", 1130], ["of", 1141], ["the", 1144], ["disease", 1148], [".", 1155]]}
{"context": "Fostamatinib (R788) is an orally dosed prodrug designed to deliver the active metabolite R940406 (R406), a spleen tyrosine kinase (SYK) inhibitor, for the treatment of rheumatoid arthritis. The objectives were to evaluate the human pharmacokinetic properties of fostamatinib and R406. Three clinical studies were conducted in healthy subjects: (A) A single ascending dose study for R406 with doses ranging from 80-600\u2009mg, (B) a single- and multiple-dose study of fostamatinib in aqueous suspension, with single doses ranging from 80-400\u2009mg and multiple doses at 160\u2009mg twice daily and (C) a study comparing suspension and tablet of fostamatinib, with the latter tested in both fed and fasted states. These studies demonstrated that when administered as a solution, R406 was rapidly absorbed. Increases in exposure were observed with doses up to 400\u2009mg. A terminal half-life of 12-21\u2009h was observed. Similar R406 exposure could be achieved with fostamatinib suspension and steady-state was achieved after 3-4 days following twice daily administration. Fostamatinib tablet and suspension exhibited similar R406 exposure. Upon co-administration with food, a delay in peak time and lower peak concentrations of R406 were observed but at the same time the overall exposure did not change. Fostamatinib demonstrates rapid and extensive conversion to R406, an inhibitor of SYK. Solid dosage forms of fostamatinib overcome the challenge of low aqueous solubility of R406. The PK profile of R406 could potentially allow once daily or twice daily oral administration of fostamatinib.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "68d14ce5231c4bba93f1b52c90dd2f8c", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[21, 23]], "char_spans": [[107, 128]]}]}], "context_tokens": [["Fostamatinib", 0], ["(", 13], ["R788", 14], [")", 18], ["is", 20], ["an", 23], ["orally", 26], ["dosed", 33], ["prodrug", 39], ["designed", 47], ["to", 56], ["deliver", 59], ["the", 67], ["active", 71], ["metabolite", 78], ["R940406", 89], ["(", 97], ["R406", 98], [")", 102], [",", 103], ["a", 105], ["spleen", 107], ["tyrosine", 114], ["kinase", 123], ["(", 130], ["SYK", 131], [")", 134], ["inhibitor", 136], [",", 145], ["for", 147], ["the", 151], ["treatment", 155], ["of", 165], ["rheumatoid", 168], ["arthritis", 179], [".", 188], ["The", 190], ["objectives", 194], ["were", 205], ["to", 210], ["evaluate", 213], ["the", 222], ["human", 226], ["pharmacokinetic", 232], ["properties", 248], ["of", 259], ["fostamatinib", 262], ["and", 275], ["R406", 279], [".", 283], ["Three", 285], ["clinical", 291], ["studies", 300], ["were", 308], ["conducted", 313], ["in", 323], ["healthy", 326], ["subjects", 334], [":", 342], ["(", 344], ["A", 345], [")", 346], ["A", 348], ["single", 350], ["ascending", 357], ["dose", 367], ["study", 372], ["for", 378], ["R406", 382], ["with", 387], ["doses", 392], ["ranging", 398], ["from", 406], ["80", 411], ["-", 413], ["600", 414], ["mg", 418], [",", 420], ["(", 422], ["B", 423], [")", 424], ["a", 426], ["single-", 428], ["and", 436], ["multiple", 440], ["-", 448], ["dose", 449], ["study", 454], ["of", 460], ["fostamatinib", 463], ["in", 476], ["aqueous", 479], ["suspension", 487], [",", 497], ["with", 499], ["single", 504], ["doses", 511], ["ranging", 517], ["from", 525], ["80", 530], ["-", 532], ["400", 533], ["mg", 537], ["and", 540], ["multiple", 544], ["doses", 553], ["at", 559], ["160", 562], ["mg", 566], ["twice", 569], ["daily", 575], ["and", 581], ["(", 585], ["C", 586], [")", 587], ["a", 589], ["study", 591], ["comparing", 597], ["suspension", 607], ["and", 618], ["tablet", 622], ["of", 629], ["fostamatinib", 632], [",", 644], ["with", 646], ["the", 651], ["latter", 655], ["tested", 662], ["in", 669], ["both", 672], ["fed", 677], ["and", 681], ["fasted", 685], ["states", 692], [".", 698], ["These", 700], ["studies", 706], ["demonstrated", 714], ["that", 727], ["when", 732], ["administered", 737], ["as", 750], ["a", 753], ["solution", 755], [",", 763], ["R406", 765], ["was", 770], ["rapidly", 774], ["absorbed", 782], [".", 790], ["Increases", 792], ["in", 802], ["exposure", 805], ["were", 814], ["observed", 819], ["with", 828], ["doses", 833], ["up", 839], ["to", 842], ["400", 845], ["mg", 849], [".", 851], ["A", 853], ["terminal", 855], ["half", 864], ["-", 868], ["life", 869], ["of", 874], ["12", 877], ["-", 879], ["21", 880], ["h", 883], ["was", 885], ["observed", 889], [".", 897], ["Similar", 899], ["R406", 907], ["exposure", 912], ["could", 921], ["be", 927], ["achieved", 930], ["with", 939], ["fostamatinib", 944], ["suspension", 957], ["and", 968], ["steady", 972], ["-", 978], ["state", 979], ["was", 985], ["achieved", 989], ["after", 998], ["3", 1004], ["-", 1005], ["4", 1006], ["days", 1008], ["following", 1013], ["twice", 1023], ["daily", 1029], ["administration", 1035], [".", 1049], ["Fostamatinib", 1051], ["tablet", 1064], ["and", 1071], ["suspension", 1075], ["exhibited", 1086], ["similar", 1096], ["R406", 1104], ["exposure", 1109], [".", 1117], ["Upon", 1119], ["co", 1124], ["-", 1126], ["administration", 1127], ["with", 1142], ["food", 1147], [",", 1151], ["a", 1153], ["delay", 1155], ["in", 1161], ["peak", 1164], ["time", 1169], ["and", 1174], ["lower", 1178], ["peak", 1184], ["concentrations", 1189], ["of", 1204], ["R406", 1207], ["were", 1212], ["observed", 1217], ["but", 1226], ["at", 1230], ["the", 1233], ["same", 1237], ["time", 1242], ["the", 1247], ["overall", 1251], ["exposure", 1259], ["did", 1268], ["not", 1272], ["change", 1276], [".", 1282], ["Fostamatinib", 1284], ["demonstrates", 1297], ["rapid", 1310], ["and", 1316], ["extensive", 1320], ["conversion", 1330], ["to", 1341], ["R406", 1344], [",", 1348], ["an", 1350], ["inhibitor", 1353], ["of", 1363], ["SYK", 1366], [".", 1369], ["Solid", 1371], ["dosage", 1377], ["forms", 1384], ["of", 1390], ["fostamatinib", 1393], ["overcome", 1406], ["the", 1415], ["challenge", 1419], ["of", 1429], ["low", 1432], ["aqueous", 1436], ["solubility", 1444], ["of", 1455], ["R406", 1458], [".", 1462], ["The", 1464], ["PK", 1468], ["profile", 1471], ["of", 1479], ["R406", 1482], ["could", 1487], ["potentially", 1493], ["allow", 1505], ["once", 1511], ["daily", 1516], ["or", 1522], ["twice", 1525], ["daily", 1531], ["oral", 1537], ["administration", 1542], ["of", 1557], ["fostamatinib", 1560], [".", 1572]]}
{"context": "The identification of the alpha-synuclein gene on chromosome 4q as a locus for familial Lewy-body parkinsonism and of alpha-synuclein as a component of Lewy bodies has heralded a new era in the study of Parkinson's disease. We have identified a large family with Lewy body parkinsonism linked to a novel locus on chromosome 4p15 that does not have a mutation in the alpha-synuclein gene. Here we report the clinical and neuropathological findings in an individual from this family and describe unusual high molecular weight alpha-synuclein-immunoreactive proteins in brain homogenates from brain regions with the most marked neuropathology. Distinctive histopathology was revealed with alpha-synuclein immunostaining, including pleomorphic Lewy bodies, synuclein-positive glial inclusions and widespread, severe neuritic dystrophy. We also discuss the relationship of this familial disorder to a Lewy body disease clinical spectrum, ranging from Parkinson's disease to dementia with psychosis.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "89d94b385eb34bc8ba92ccfb2605442f", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[22, 24], [70, 72], [118, 120], [4, 6], [95, 97]], "char_spans": [[118, 132], [366, 380], [686, 700], [26, 40], [524, 538]]}]}], "context_tokens": [["The", 0], ["identification", 4], ["of", 19], ["the", 22], ["alpha", 26], ["-", 31], ["synuclein", 32], ["gene", 42], ["on", 47], ["chromosome", 50], ["4q", 61], ["as", 64], ["a", 67], ["locus", 69], ["for", 75], ["familial", 79], ["Lewy", 88], ["-", 92], ["body", 93], ["parkinsonism", 98], ["and", 111], ["of", 115], ["alpha", 118], ["-", 123], ["synuclein", 124], ["as", 134], ["a", 137], ["component", 139], ["of", 149], ["Lewy", 152], ["bodies", 157], ["has", 164], ["heralded", 168], ["a", 177], ["new", 179], ["era", 183], ["in", 187], ["the", 190], ["study", 194], ["of", 200], ["Parkinson", 203], ["'s", 212], ["disease", 215], [".", 222], ["We", 224], ["have", 227], ["identified", 232], ["a", 243], ["large", 245], ["family", 251], ["with", 258], ["Lewy", 263], ["body", 268], ["parkinsonism", 273], ["linked", 286], ["to", 293], ["a", 296], ["novel", 298], ["locus", 304], ["on", 310], ["chromosome", 313], ["4p15", 324], ["that", 329], ["does", 334], ["not", 339], ["have", 343], ["a", 348], ["mutation", 350], ["in", 359], ["the", 362], ["alpha", 366], ["-", 371], ["synuclein", 372], ["gene", 382], [".", 386], ["Here", 388], ["we", 393], ["report", 396], ["the", 403], ["clinical", 407], ["and", 416], ["neuropathological", 420], ["findings", 438], ["in", 447], ["an", 450], ["individual", 453], ["from", 464], ["this", 469], ["family", 474], ["and", 481], ["describe", 485], ["unusual", 494], ["high", 502], ["molecular", 507], ["weight", 517], ["alpha", 524], ["-", 529], ["synuclein", 530], ["-", 539], ["immunoreactive", 540], ["proteins", 555], ["in", 564], ["brain", 567], ["homogenates", 573], ["from", 585], ["brain", 590], ["regions", 596], ["with", 604], ["the", 609], ["most", 613], ["marked", 618], ["neuropathology", 625], [".", 639], ["Distinctive", 641], ["histopathology", 653], ["was", 668], ["revealed", 672], ["with", 681], ["alpha", 686], ["-", 691], ["synuclein", 692], ["immunostaining", 702], [",", 716], ["including", 718], ["pleomorphic", 728], ["Lewy", 740], ["bodies", 745], [",", 751], ["synuclein", 753], ["-", 762], ["positive", 763], ["glial", 772], ["inclusions", 778], ["and", 789], ["widespread", 793], [",", 803], ["severe", 805], ["neuritic", 812], ["dystrophy", 821], [".", 830], ["We", 832], ["also", 835], ["discuss", 840], ["the", 848], ["relationship", 852], ["of", 865], ["this", 868], ["familial", 873], ["disorder", 882], ["to", 891], ["a", 894], ["Lewy", 896], ["body", 901], ["disease", 906], ["clinical", 914], ["spectrum", 923], [",", 931], ["ranging", 933], ["from", 941], ["Parkinson", 946], ["'s", 955], ["disease", 958], ["to", 966], ["dementia", 969], ["with", 978], ["psychosis", 983], [".", 992]]}
{"context": "Oral empagliflozin (Jardiance(\u00ae)), a sodium glucose cotransporter-2 (SGLT2) inhibitor, is a convenient once-daily treatment for adult patients with type 2 diabetes mellitus. By inhibiting reabsorption of glucose from the proximal tubules in the kidney via inhibition of SGLT2, empagliflozin provides a novel insulin-independent mechanism of lowering blood glucose. In several phase III trials (\u2264104\u00a0weeks' duration; typically 24\u00a0weeks' duration) and extension studies (typically\u00a0\u226576\u00a0weeks' treatment), empagliflozin monotherapy or add-on therapy to other antihyperglycaemics, including insulin, improved glycaemic control and reduced bodyweight and systolic blood pressure in adult patients with type 2 diabetes. In a large phase III trial, as add-on therapy to metformin, empagliflozin was shown to be noninferior to glimepiride at 52 and 104\u00a0weeks and superior to glimepiride at 104\u00a0weeks, in terms of reductions in glycated haemoglobin level (primary endpoint). Empagliflozin was well tolerated by participants in these clinical trials, with most adverse events being mild or moderate in intensity. Empagliflozin treatment appeared to have no intrinsic risk of hypoglycaemia, although hypoglycaemia occurred more frequently when empagliflozin was coadministered with insulin and/or a sulfonylurea. With its insulin-independent mechanism of action, empagliflozin monotherapy or combination therapy with other antidiabetic drugs, including insulin, provides a useful addition to the therapeutic options for the management of type 2 diabetes. This article reviews the pharmacological properties and clinical use of empagliflozin in patients with type 2 diabetes.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "95f5fe67a6334781a72627254072209a", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[49, 49], [14, 14]], "char_spans": [[270, 274], [69, 73]]}]}], "context_tokens": [["Oral", 0], ["empagliflozin", 5], ["(", 19], ["Jardiance", 20], ["(", 29], ["\u00ae", 30], [")", 31], [")", 32], [",", 33], ["a", 35], ["sodium", 37], ["glucose", 44], ["cotransporter-2", 52], ["(", 68], ["SGLT2", 69], [")", 74], ["inhibitor", 76], [",", 85], ["is", 87], ["a", 90], ["convenient", 92], ["once", 103], ["-", 107], ["daily", 108], ["treatment", 114], ["for", 124], ["adult", 128], ["patients", 134], ["with", 143], ["type", 148], ["2", 153], ["diabetes", 155], ["mellitus", 164], [".", 172], ["By", 174], ["inhibiting", 177], ["reabsorption", 188], ["of", 201], ["glucose", 204], ["from", 212], ["the", 217], ["proximal", 221], ["tubules", 230], ["in", 238], ["the", 241], ["kidney", 245], ["via", 252], ["inhibition", 256], ["of", 267], ["SGLT2", 270], [",", 275], ["empagliflozin", 277], ["provides", 291], ["a", 300], ["novel", 302], ["insulin", 308], ["-", 315], ["independent", 316], ["mechanism", 328], ["of", 338], ["lowering", 341], ["blood", 350], ["glucose", 356], [".", 363], ["In", 365], ["several", 368], ["phase", 376], ["III", 382], ["trials", 386], ["(", 393], ["\u2264104", 394], ["weeks", 399], ["'", 404], ["duration", 406], [";", 414], ["typically", 416], ["24", 426], ["weeks", 429], ["'", 434], ["duration", 436], [")", 444], ["and", 446], ["extension", 450], ["studies", 460], ["(", 468], ["typically", 469], ["\u226576", 479], ["weeks", 483], ["'", 488], ["treatment", 490], [")", 499], [",", 500], ["empagliflozin", 502], ["monotherapy", 516], ["or", 528], ["add", 531], ["-", 534], ["on", 535], ["therapy", 538], ["to", 546], ["other", 549], ["antihyperglycaemics", 555], [",", 574], ["including", 576], ["insulin", 586], [",", 593], ["improved", 595], ["glycaemic", 604], ["control", 614], ["and", 622], ["reduced", 626], ["bodyweight", 634], ["and", 645], ["systolic", 649], ["blood", 658], ["pressure", 664], ["in", 673], ["adult", 676], ["patients", 682], ["with", 691], ["type", 696], ["2", 701], ["diabetes", 703], [".", 711], ["In", 713], ["a", 716], ["large", 718], ["phase", 724], ["III", 730], ["trial", 734], [",", 739], ["as", 741], ["add", 744], ["-", 747], ["on", 748], ["therapy", 751], ["to", 759], ["metformin", 762], [",", 771], ["empagliflozin", 773], ["was", 787], ["shown", 791], ["to", 797], ["be", 800], ["noninferior", 803], ["to", 815], ["glimepiride", 818], ["at", 830], ["52", 833], ["and", 836], ["104", 840], ["weeks", 844], ["and", 850], ["superior", 854], ["to", 863], ["glimepiride", 866], ["at", 878], ["104", 881], ["weeks", 885], [",", 890], ["in", 892], ["terms", 895], ["of", 901], ["reductions", 904], ["in", 915], ["glycated", 918], ["haemoglobin", 927], ["level", 939], ["(", 945], ["primary", 946], ["endpoint", 954], [")", 962], [".", 963], ["Empagliflozin", 965], ["was", 979], ["well", 983], ["tolerated", 988], ["by", 998], ["participants", 1001], ["in", 1014], ["these", 1017], ["clinical", 1023], ["trials", 1032], [",", 1038], ["with", 1040], ["most", 1045], ["adverse", 1050], ["events", 1058], ["being", 1065], ["mild", 1071], ["or", 1076], ["moderate", 1079], ["in", 1088], ["intensity", 1091], [".", 1100], ["Empagliflozin", 1102], ["treatment", 1116], ["appeared", 1126], ["to", 1135], ["have", 1138], ["no", 1143], ["intrinsic", 1146], ["risk", 1156], ["of", 1161], ["hypoglycaemia", 1164], [",", 1177], ["although", 1179], ["hypoglycaemia", 1188], ["occurred", 1202], ["more", 1211], ["frequently", 1216], ["when", 1227], ["empagliflozin", 1232], ["was", 1246], ["coadministered", 1250], ["with", 1265], ["insulin", 1270], ["and/or", 1278], ["a", 1285], ["sulfonylurea", 1287], [".", 1299], ["With", 1301], ["its", 1306], ["insulin", 1310], ["-", 1317], ["independent", 1318], ["mechanism", 1330], ["of", 1340], ["action", 1343], [",", 1349], ["empagliflozin", 1351], ["monotherapy", 1365], ["or", 1377], ["combination", 1380], ["therapy", 1392], ["with", 1400], ["other", 1405], ["antidiabetic", 1411], ["drugs", 1424], [",", 1429], ["including", 1431], ["insulin", 1441], [",", 1448], ["provides", 1450], ["a", 1459], ["useful", 1461], ["addition", 1468], ["to", 1477], ["the", 1480], ["therapeutic", 1484], ["options", 1496], ["for", 1504], ["the", 1508], ["management", 1512], ["of", 1523], ["type", 1526], ["2", 1531], ["diabetes", 1533], [".", 1541], ["This", 1543], ["article", 1548], ["reviews", 1556], ["the", 1564], ["pharmacological", 1568], ["properties", 1584], ["and", 1595], ["clinical", 1599], ["use", 1608], ["of", 1612], ["empagliflozin", 1615], ["in", 1629], ["patients", 1632], ["with", 1641], ["type", 1646], ["2", 1651], ["diabetes", 1653], [".", 1661]]}
{"context": "It is unanimously accepted that there is an unmet need for pain medications that are both effective and safe. Unfortunately, no really novel analgesics have been approved over the past three decades. In view of both experimental and clinical evidence of a major role for nerve growth factor (NGF) in the generation and maintenance of a wide range of pain states, drug discovery efforts focusing on the development of anti-NGF agents have aroused particular interest. Several humanized anti-NGF monoclonal antibodies (mAbs) have entered clinical trials as potential analgesics. In this respect, tanezumab is at an advanced stage of clinical development while fulranumab, fasinumab and ABT-110, previously known as PG110, are in early phases of clinical development. This Current Opinion article aims at describing the rationale for targeting NGF for pain, reviewing the analgesic efficacy and safety of anti-NGF agents based on data from fully published studies, conference abstracts, and the US Food and Drug Administration (FDA) website, and discussing the possible future of these agents in managing chronic pain. Anti-NGF mAbs produced significant pain relief and functional improvement in patients with osteoarthritis of the knee and/or hip. Conversely, studies in non-specific lower back pain generated mixed results; overall, this condition appeared to be less responsive to anti-NGF agents than osteoarthritis. Finally, there was no conclusive evidence of the effectiveness of anti-NGF mAbs in some types of chronic visceral or neuropathic pain. Furthermore, these studies raised safety concerns about anti-NGF mAbs. As a class, these drugs may cause or worsen peripheral neuropathies. But the most problematic issue-which prompted the FDA to place studies of these compounds on clinical hold in 2010-was rapid joint destruction leading to joint replacement surgery. The aetiologies of these side effects have been much debated and their pathophysiology is poorly understood. After an Arthritis Advisory Committee meeting held in March 2012, pharmaceutical companies negotiated with the FDA on the conditions for restarting clinical studies. Although the FDA lifted its clinical hold, there remain many unresolved issues about the long-term efficacy and safety of anti-NGF mAbs. While acknowledging that the future of these drugs is unforeseeable, it appears that they may not be the safe and effective painkillers that have been awaited for decades.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "9345b19e2b08406092884e3a093f3bd3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[48, 50]], "char_spans": [[271, 289]]}, {"text": "NGF", "token_spans": [[77, 77], [262, 262], [52, 52], [244, 244], [199, 199], [284, 284], [396, 396], [88, 88], [146, 146], [159, 159]], "char_spans": [[422, 424], [1489, 1491], [292, 294], [1386, 1388], [1121, 1123], [1614, 1616], [2276, 2278], [490, 492], [841, 843], [907, 909]]}]}], "context_tokens": [["It", 0], ["is", 3], ["unanimously", 6], ["accepted", 18], ["that", 27], ["there", 32], ["is", 38], ["an", 41], ["unmet", 44], ["need", 50], ["for", 55], ["pain", 59], ["medications", 64], ["that", 76], ["are", 81], ["both", 85], ["effective", 90], ["and", 100], ["safe", 104], [".", 108], ["Unfortunately", 110], [",", 123], ["no", 125], ["really", 128], ["novel", 135], ["analgesics", 141], ["have", 152], ["been", 157], ["approved", 162], ["over", 171], ["the", 176], ["past", 180], ["three", 185], ["decades", 191], [".", 198], ["In", 200], ["view", 203], ["of", 208], ["both", 211], ["experimental", 216], ["and", 229], ["clinical", 233], ["evidence", 242], ["of", 251], ["a", 254], ["major", 256], ["role", 262], ["for", 267], ["nerve", 271], ["growth", 277], ["factor", 284], ["(", 291], ["NGF", 292], [")", 295], ["in", 297], ["the", 300], ["generation", 304], ["and", 315], ["maintenance", 319], ["of", 331], ["a", 334], ["wide", 336], ["range", 341], ["of", 347], ["pain", 350], ["states", 355], [",", 361], ["drug", 363], ["discovery", 368], ["efforts", 378], ["focusing", 386], ["on", 395], ["the", 398], ["development", 402], ["of", 414], ["anti", 417], ["-", 421], ["NGF", 422], ["agents", 426], ["have", 433], ["aroused", 438], ["particular", 446], ["interest", 457], [".", 465], ["Several", 467], ["humanized", 475], ["anti", 485], ["-", 489], ["NGF", 490], ["monoclonal", 494], ["antibodies", 505], ["(", 516], ["mAbs", 517], [")", 521], ["have", 523], ["entered", 528], ["clinical", 536], ["trials", 545], ["as", 552], ["potential", 555], ["analgesics", 565], [".", 575], ["In", 577], ["this", 580], ["respect", 585], [",", 592], ["tanezumab", 594], ["is", 604], ["at", 607], ["an", 610], ["advanced", 613], ["stage", 622], ["of", 628], ["clinical", 631], ["development", 640], ["while", 652], ["fulranumab", 658], [",", 668], ["fasinumab", 670], ["and", 680], ["ABT-110", 684], [",", 691], ["previously", 693], ["known", 704], ["as", 710], ["PG110", 713], [",", 718], ["are", 720], ["in", 724], ["early", 727], ["phases", 733], ["of", 740], ["clinical", 743], ["development", 752], [".", 763], ["This", 765], ["Current", 770], ["Opinion", 778], ["article", 786], ["aims", 794], ["at", 799], ["describing", 802], ["the", 813], ["rationale", 817], ["for", 827], ["targeting", 831], ["NGF", 841], ["for", 845], ["pain", 849], [",", 853], ["reviewing", 855], ["the", 865], ["analgesic", 869], ["efficacy", 879], ["and", 888], ["safety", 892], ["of", 899], ["anti", 902], ["-", 906], ["NGF", 907], ["agents", 911], ["based", 918], ["on", 924], ["data", 927], ["from", 932], ["fully", 937], ["published", 943], ["studies", 953], [",", 960], ["conference", 962], ["abstracts", 973], [",", 982], ["and", 984], ["the", 988], ["US", 992], ["Food", 995], ["and", 1000], ["Drug", 1004], ["Administration", 1009], ["(", 1024], ["FDA", 1025], [")", 1028], ["website", 1030], [",", 1037], ["and", 1039], ["discussing", 1043], ["the", 1054], ["possible", 1058], ["future", 1067], ["of", 1074], ["these", 1077], ["agents", 1083], ["in", 1090], ["managing", 1093], ["chronic", 1102], ["pain", 1110], [".", 1114], ["Anti", 1116], ["-", 1120], ["NGF", 1121], ["mAbs", 1125], ["produced", 1130], ["significant", 1139], ["pain", 1151], ["relief", 1156], ["and", 1163], ["functional", 1167], ["improvement", 1178], ["in", 1190], ["patients", 1193], ["with", 1202], ["osteoarthritis", 1207], ["of", 1222], ["the", 1225], ["knee", 1229], ["and/or", 1234], ["hip", 1241], [".", 1244], ["Conversely", 1246], [",", 1256], ["studies", 1258], ["in", 1266], ["non", 1269], ["-", 1272], ["specific", 1273], ["lower", 1282], ["back", 1288], ["pain", 1293], ["generated", 1298], ["mixed", 1308], ["results", 1314], [";", 1321], ["overall", 1323], [",", 1330], ["this", 1332], ["condition", 1337], ["appeared", 1347], ["to", 1356], ["be", 1359], ["less", 1362], ["responsive", 1367], ["to", 1378], ["anti", 1381], ["-", 1385], ["NGF", 1386], ["agents", 1390], ["than", 1397], ["osteoarthritis", 1402], [".", 1416], ["Finally", 1418], [",", 1425], ["there", 1427], ["was", 1433], ["no", 1437], ["conclusive", 1440], ["evidence", 1451], ["of", 1460], ["the", 1463], ["effectiveness", 1467], ["of", 1481], ["anti", 1484], ["-", 1488], ["NGF", 1489], ["mAbs", 1493], ["in", 1498], ["some", 1501], ["types", 1506], ["of", 1512], ["chronic", 1515], ["visceral", 1523], ["or", 1532], ["neuropathic", 1535], ["pain", 1547], [".", 1551], ["Furthermore", 1553], [",", 1564], ["these", 1566], ["studies", 1572], ["raised", 1580], ["safety", 1587], ["concerns", 1594], ["about", 1603], ["anti", 1609], ["-", 1613], ["NGF", 1614], ["mAbs", 1618], [".", 1622], ["As", 1624], ["a", 1627], ["class", 1629], [",", 1634], ["these", 1636], ["drugs", 1642], ["may", 1648], ["cause", 1652], ["or", 1658], ["worsen", 1661], ["peripheral", 1668], ["neuropathies", 1679], [".", 1691], ["But", 1693], ["the", 1697], ["most", 1701], ["problematic", 1706], ["issue", 1718], ["-", 1723], ["which", 1724], ["prompted", 1730], ["the", 1739], ["FDA", 1743], ["to", 1747], ["place", 1750], ["studies", 1756], ["of", 1764], ["these", 1767], ["compounds", 1773], ["on", 1783], ["clinical", 1786], ["hold", 1795], ["in", 1800], ["2010-was", 1803], ["rapid", 1812], ["joint", 1818], ["destruction", 1824], ["leading", 1836], ["to", 1844], ["joint", 1847], ["replacement", 1853], ["surgery", 1865], [".", 1872], ["The", 1874], ["aetiologies", 1878], ["of", 1890], ["these", 1893], ["side", 1899], ["effects", 1904], ["have", 1912], ["been", 1917], ["much", 1922], ["debated", 1927], ["and", 1935], ["their", 1939], ["pathophysiology", 1945], ["is", 1961], ["poorly", 1964], ["understood", 1971], [".", 1981], ["After", 1983], ["an", 1989], ["Arthritis", 1992], ["Advisory", 2002], ["Committee", 2011], ["meeting", 2021], ["held", 2029], ["in", 2034], ["March", 2037], ["2012", 2043], [",", 2047], ["pharmaceutical", 2049], ["companies", 2064], ["negotiated", 2074], ["with", 2085], ["the", 2090], ["FDA", 2094], ["on", 2098], ["the", 2101], ["conditions", 2105], ["for", 2116], ["restarting", 2120], ["clinical", 2131], ["studies", 2140], [".", 2147], ["Although", 2149], ["the", 2158], ["FDA", 2162], ["lifted", 2166], ["its", 2173], ["clinical", 2177], ["hold", 2186], [",", 2190], ["there", 2192], ["remain", 2198], ["many", 2205], ["unresolved", 2210], ["issues", 2221], ["about", 2228], ["the", 2234], ["long", 2238], ["-", 2242], ["term", 2243], ["efficacy", 2248], ["and", 2257], ["safety", 2261], ["of", 2268], ["anti", 2271], ["-", 2275], ["NGF", 2276], ["mAbs", 2280], [".", 2284], ["While", 2286], ["acknowledging", 2292], ["that", 2306], ["the", 2311], ["future", 2315], ["of", 2322], ["these", 2325], ["drugs", 2331], ["is", 2337], ["unforeseeable", 2340], [",", 2353], ["it", 2355], ["appears", 2358], ["that", 2366], ["they", 2371], ["may", 2376], ["not", 2380], ["be", 2384], ["the", 2387], ["safe", 2391], ["and", 2396], ["effective", 2400], ["painkillers", 2410], ["that", 2422], ["have", 2427], ["been", 2432], ["awaited", 2437], ["for", 2445], ["decades", 2449], [".", 2456]]}
{"context": "Interdigital foot infections are mostly caused initially by dermatophytes, yeasts and less frequently by bacteria. Erythrasma caused by Corynebacterium minutissimum can be confused with superficial mycoses. The aim of the study was to determine the prevalence of the etiologic agents of superficial mycoses and the frequency of Corynebacterium minutissimum in interdigital foot infections. All the samples obtained from the 121 patients with interdigital foot infections were examined directly with the use of 20% potassium hydroxide mounts and Gram stain under the microscope and cultured on Sabouraud's dextrose agar plates. In identification of superficial mycoses, the rate was found to be 14% with the cultural method and 14% with direct microscopic examination. Using a combination of direct microscopic examination and culture, a 33.8% ratio was achieved. In the culture of these samples, the most isolated factor was Trichophyton rubrum (33.7%). In 24 of the patients (19.8%) Corynebacterium minutissimum was detected by Gram staining, in 6 of these patients Trichophyton rubrum was found, Trichophyton mentagrophytes was found in 2 and Trichosporon spp. was found in 1. The examination of interdigital foot lesions in the laboratory, the coexistence of erythrasma with dermatophytes and yeast should be considered.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "f20fb69656624faba286b877bd7b0c35", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[20, 21], [50, 51], [167, 168]], "char_spans": [[136, 163], [328, 355], [984, 1011]]}]}], "context_tokens": [["Interdigital", 0], ["foot", 13], ["infections", 18], ["are", 29], ["mostly", 33], ["caused", 40], ["initially", 47], ["by", 57], ["dermatophytes", 60], [",", 73], ["yeasts", 75], ["and", 82], ["less", 86], ["frequently", 91], ["by", 102], ["bacteria", 105], [".", 113], ["Erythrasma", 115], ["caused", 126], ["by", 133], ["Corynebacterium", 136], ["minutissimum", 152], ["can", 165], ["be", 169], ["confused", 172], ["with", 181], ["superficial", 186], ["mycoses", 198], [".", 205], ["The", 207], ["aim", 211], ["of", 215], ["the", 218], ["study", 222], ["was", 228], ["to", 232], ["determine", 235], ["the", 245], ["prevalence", 249], ["of", 260], ["the", 263], ["etiologic", 267], ["agents", 277], ["of", 284], ["superficial", 287], ["mycoses", 299], ["and", 307], ["the", 311], ["frequency", 315], ["of", 325], ["Corynebacterium", 328], ["minutissimum", 344], ["in", 357], ["interdigital", 360], ["foot", 373], ["infections", 378], [".", 388], ["All", 390], ["the", 394], ["samples", 398], ["obtained", 406], ["from", 415], ["the", 420], ["121", 424], ["patients", 428], ["with", 437], ["interdigital", 442], ["foot", 455], ["infections", 460], ["were", 471], ["examined", 476], ["directly", 485], ["with", 494], ["the", 499], ["use", 503], ["of", 507], ["20", 510], ["%", 512], ["potassium", 514], ["hydroxide", 524], ["mounts", 534], ["and", 541], ["Gram", 545], ["stain", 550], ["under", 556], ["the", 562], ["microscope", 566], ["and", 577], ["cultured", 581], ["on", 590], ["Sabouraud", 593], ["'s", 602], ["dextrose", 605], ["agar", 614], ["plates", 619], [".", 625], ["In", 627], ["identification", 630], ["of", 645], ["superficial", 648], ["mycoses", 660], [",", 667], ["the", 669], ["rate", 673], ["was", 678], ["found", 682], ["to", 688], ["be", 691], ["14", 694], ["%", 696], ["with", 698], ["the", 703], ["cultural", 707], ["method", 716], ["and", 723], ["14", 727], ["%", 729], ["with", 731], ["direct", 736], ["microscopic", 743], ["examination", 755], [".", 766], ["Using", 768], ["a", 774], ["combination", 776], ["of", 788], ["direct", 791], ["microscopic", 798], ["examination", 810], ["and", 822], ["culture", 826], [",", 833], ["a", 835], ["33.8", 837], ["%", 841], ["ratio", 843], ["was", 849], ["achieved", 853], [".", 861], ["In", 863], ["the", 866], ["culture", 870], ["of", 878], ["these", 881], ["samples", 887], [",", 894], ["the", 896], ["most", 900], ["isolated", 905], ["factor", 914], ["was", 921], ["Trichophyton", 925], ["rubrum", 938], ["(", 945], ["33.7", 946], ["%", 950], [")", 951], [".", 952], ["In", 954], ["24", 957], ["of", 960], ["the", 963], ["patients", 967], ["(", 976], ["19.8", 977], ["%", 981], [")", 982], ["Corynebacterium", 984], ["minutissimum", 1000], ["was", 1013], ["detected", 1017], ["by", 1026], ["Gram", 1029], ["staining", 1034], [",", 1042], ["in", 1044], ["6", 1047], ["of", 1049], ["these", 1052], ["patients", 1058], ["Trichophyton", 1067], ["rubrum", 1080], ["was", 1087], ["found", 1091], [",", 1096], ["Trichophyton", 1098], ["mentagrophytes", 1111], ["was", 1126], ["found", 1130], ["in", 1136], ["2", 1139], ["and", 1141], ["Trichosporon", 1145], ["spp", 1158], [".", 1161], ["was", 1163], ["found", 1167], ["in", 1173], ["1", 1176], [".", 1177], ["The", 1179], ["examination", 1183], ["of", 1195], ["interdigital", 1198], ["foot", 1211], ["lesions", 1216], ["in", 1224], ["the", 1227], ["laboratory", 1231], [",", 1241], ["the", 1243], ["coexistence", 1247], ["of", 1259], ["erythrasma", 1262], ["with", 1273], ["dermatophytes", 1278], ["and", 1292], ["yeast", 1296], ["should", 1302], ["be", 1309], ["considered", 1312], [".", 1322]]}
{"context": "Epidermal growth factor receptor (EGFR) gene mutations have been found in a subset of non-small cell lung cancer (NSCLC) with good clinical response to gefitinib therapy. A quick and sensitive method with large throughput is required to utilize the information to determine whether the molecular targeted therapy should be applied for the particular NSCLC patients. Using probes for the 13 different mutations including 11 that have already been reported, we have genotyped the EGFR mutation status in 94 NSCLC patients using the TaqMan PCR assay. We have also genotyped the EGFR mutations status in additional 182 NSCLC patients, as well as 63 gastric, 95 esophagus and 70 colon carcinoma patients. In 94 NSCLC samples, the result of the TaqMan PCR assay perfectly matched with that of the sequencing excluding one patient. In one sample in which no EGFR mutation was detected by direct sequencing, the TaqMan PCR assay detected a mutation. This patient was a gefitinib responder. In a serial dilution study, the assay could detect a mutant sample diluted in 1/10 with a wild-type sample. Of 182 NSCLC samples, 46 mutations were detected. EGFR mutation was significantly correlated with gender, smoking status, pathological subtypes, and differentiation of lung cancers. There was no mutation detected by the TaqMan PCR assay in gastric, esophagus and colon carcinomas. TaqMan PCR assay is a rapid and sensitive method of detection of EGFR mutations with high throughput, and may be useful to determine whether gefitinib should be offered for the treatment of NSCLC patients. The TaqMan PCR assay can offer us a complementary and confirmative test.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "db82e6a831de4a5e9ce53368a088128a", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[0, 7]], "char_spans": [[0, 43]]}]}], "context_tokens": [["Epidermal", 0], ["growth", 10], ["factor", 17], ["receptor", 24], ["(", 33], ["EGFR", 34], [")", 38], ["gene", 40], ["mutations", 45], ["have", 55], ["been", 60], ["found", 65], ["in", 71], ["a", 74], ["subset", 76], ["of", 83], ["non", 86], ["-", 89], ["small", 90], ["cell", 96], ["lung", 101], ["cancer", 106], ["(", 113], ["NSCLC", 114], [")", 119], ["with", 121], ["good", 126], ["clinical", 131], ["response", 140], ["to", 149], ["gefitinib", 152], ["therapy", 162], [".", 169], ["A", 171], ["quick", 173], ["and", 179], ["sensitive", 183], ["method", 193], ["with", 200], ["large", 205], ["throughput", 211], ["is", 222], ["required", 225], ["to", 234], ["utilize", 237], ["the", 245], ["information", 249], ["to", 261], ["determine", 264], ["whether", 274], ["the", 282], ["molecular", 286], ["targeted", 296], ["therapy", 305], ["should", 313], ["be", 320], ["applied", 323], ["for", 331], ["the", 335], ["particular", 339], ["NSCLC", 350], ["patients", 356], [".", 364], ["Using", 366], ["probes", 372], ["for", 379], ["the", 383], ["13", 387], ["different", 390], ["mutations", 400], ["including", 410], ["11", 420], ["that", 423], ["have", 428], ["already", 433], ["been", 441], ["reported", 446], [",", 454], ["we", 456], ["have", 459], ["genotyped", 464], ["the", 474], ["EGFR", 478], ["mutation", 483], ["status", 492], ["in", 499], ["94", 502], ["NSCLC", 505], ["patients", 511], ["using", 520], ["the", 526], ["TaqMan", 530], ["PCR", 537], ["assay", 541], [".", 546], ["We", 548], ["have", 551], ["also", 556], ["genotyped", 561], ["the", 571], ["EGFR", 575], ["mutations", 580], ["status", 590], ["in", 597], ["additional", 600], ["182", 611], ["NSCLC", 615], ["patients", 621], [",", 629], ["as", 631], ["well", 634], ["as", 639], ["63", 642], ["gastric", 645], [",", 652], ["95", 654], ["esophagus", 657], ["and", 667], ["70", 671], ["colon", 674], ["carcinoma", 680], ["patients", 690], [".", 698], ["In", 700], ["94", 703], ["NSCLC", 706], ["samples", 712], [",", 719], ["the", 721], ["result", 725], ["of", 732], ["the", 735], ["TaqMan", 739], ["PCR", 746], ["assay", 750], ["perfectly", 756], ["matched", 766], ["with", 774], ["that", 779], ["of", 784], ["the", 787], ["sequencing", 791], ["excluding", 802], ["one", 812], ["patient", 816], [".", 823], ["In", 825], ["one", 828], ["sample", 832], ["in", 839], ["which", 842], ["no", 848], ["EGFR", 851], ["mutation", 856], ["was", 865], ["detected", 869], ["by", 878], ["direct", 881], ["sequencing", 888], [",", 898], ["the", 900], ["TaqMan", 904], ["PCR", 911], ["assay", 915], ["detected", 921], ["a", 930], ["mutation", 932], [".", 940], ["This", 942], ["patient", 947], ["was", 955], ["a", 959], ["gefitinib", 961], ["responder", 971], [".", 980], ["In", 982], ["a", 985], ["serial", 987], ["dilution", 994], ["study", 1003], [",", 1008], ["the", 1010], ["assay", 1014], ["could", 1020], ["detect", 1026], ["a", 1033], ["mutant", 1035], ["sample", 1042], ["diluted", 1049], ["in", 1057], ["1/10", 1060], ["with", 1065], ["a", 1070], ["wild", 1072], ["-", 1076], ["type", 1077], ["sample", 1082], [".", 1088], ["Of", 1090], ["182", 1093], ["NSCLC", 1097], ["samples", 1103], [",", 1110], ["46", 1112], ["mutations", 1115], ["were", 1125], ["detected", 1130], [".", 1138], ["EGFR", 1140], ["mutation", 1145], ["was", 1154], ["significantly", 1158], ["correlated", 1172], ["with", 1183], ["gender", 1188], [",", 1194], ["smoking", 1196], ["status", 1204], [",", 1210], ["pathological", 1212], ["subtypes", 1225], [",", 1233], ["and", 1235], ["differentiation", 1239], ["of", 1255], ["lung", 1258], ["cancers", 1263], [".", 1270], ["There", 1272], ["was", 1278], ["no", 1282], ["mutation", 1285], ["detected", 1294], ["by", 1303], ["the", 1306], ["TaqMan", 1310], ["PCR", 1317], ["assay", 1321], ["in", 1327], ["gastric", 1330], [",", 1337], ["esophagus", 1339], ["and", 1349], ["colon", 1353], ["carcinomas", 1359], [".", 1369], ["TaqMan", 1371], ["PCR", 1378], ["assay", 1382], ["is", 1388], ["a", 1391], ["rapid", 1393], ["and", 1399], ["sensitive", 1403], ["method", 1413], ["of", 1420], ["detection", 1423], ["of", 1433], ["EGFR", 1436], ["mutations", 1441], ["with", 1451], ["high", 1456], ["throughput", 1461], [",", 1471], ["and", 1473], ["may", 1477], ["be", 1481], ["useful", 1484], ["to", 1491], ["determine", 1494], ["whether", 1504], ["gefitinib", 1512], ["should", 1522], ["be", 1529], ["offered", 1532], ["for", 1540], ["the", 1544], ["treatment", 1548], ["of", 1558], ["NSCLC", 1561], ["patients", 1567], [".", 1575], ["The", 1577], ["TaqMan", 1581], ["PCR", 1588], ["assay", 1592], ["can", 1598], ["offer", 1602], ["us", 1608], ["a", 1611], ["complementary", 1613], ["and", 1627], ["confirmative", 1631], ["test", 1644], [".", 1648]]}
{"context": "Christianson syndrome (CS) is an X-linked neurodevelopmental disorder caused by deleterious mutations in SLC9A6. Affected families organized the inaugural Christianson Syndrome Association conference to advance CS knowledge and develop questions that may be prioritized in future research.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "7bc7d50257d34f87ab4fb5cf15488ef8", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[17, 17]], "char_spans": [[105, 110]]}]}], "context_tokens": [["Christianson", 0], ["syndrome", 13], ["(", 22], ["CS", 23], [")", 25], ["is", 27], ["an", 30], ["X", 33], ["-", 34], ["linked", 35], ["neurodevelopmental", 42], ["disorder", 61], ["caused", 70], ["by", 77], ["deleterious", 80], ["mutations", 92], ["in", 102], ["SLC9A6", 105], [".", 111], ["Affected", 113], ["families", 122], ["organized", 131], ["the", 141], ["inaugural", 145], ["Christianson", 155], ["Syndrome", 168], ["Association", 177], ["conference", 189], ["to", 200], ["advance", 203], ["CS", 211], ["knowledge", 214], ["and", 224], ["develop", 228], ["questions", 236], ["that", 246], ["may", 251], ["be", 255], ["prioritized", 258], ["in", 270], ["future", 273], ["research", 280], [".", 288]]}
{"context": "Rates of remission were examined in two controlled 12-week studies of sertraline and placebo for post-traumatic stress disorder (PTSD). The performance of three scales was evaluated: the self-rated Davidson Trauma Scale (DTS), and two interviewer scales: the Clinician Administered PTSD Scale (CAPS) and Clinical Global Impressions (CGI). Sertraline proved significantly superior to placebo with respect to remission on all three ratings. Rates of remission were very similar for all scales, ranging from 23.1-26.3% for sertraline and 13.9-14.9% for placebo. Traditional thresholds for the CAPS and DTS were tested relative to the CGI and to each other. The CAPS and DTS thresholds of < 20 and < 18 were found to be valid.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b086ca841a4040e58142b56004268573", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[15, 19]], "char_spans": [[97, 126]]}, {"text": "PTSD", "token_spans": [[21, 21], [51, 51]], "char_spans": [[129, 132], [282, 285]]}]}], "context_tokens": [["Rates", 0], ["of", 6], ["remission", 9], ["were", 19], ["examined", 24], ["in", 33], ["two", 36], ["controlled", 40], ["12-week", 51], ["studies", 59], ["of", 67], ["sertraline", 70], ["and", 81], ["placebo", 85], ["for", 93], ["post", 97], ["-", 101], ["traumatic", 102], ["stress", 112], ["disorder", 119], ["(", 128], ["PTSD", 129], [")", 133], [".", 134], ["The", 136], ["performance", 140], ["of", 152], ["three", 155], ["scales", 161], ["was", 168], ["evaluated", 172], [":", 181], ["the", 183], ["self", 187], ["-", 191], ["rated", 192], ["Davidson", 198], ["Trauma", 207], ["Scale", 214], ["(", 220], ["DTS", 221], [")", 224], [",", 225], ["and", 227], ["two", 231], ["interviewer", 235], ["scales", 247], [":", 253], ["the", 255], ["Clinician", 259], ["Administered", 269], ["PTSD", 282], ["Scale", 287], ["(", 293], ["CAPS", 294], [")", 298], ["and", 300], ["Clinical", 304], ["Global", 313], ["Impressions", 320], ["(", 332], ["CGI", 333], [")", 336], [".", 337], ["Sertraline", 339], ["proved", 350], ["significantly", 357], ["superior", 371], ["to", 380], ["placebo", 383], ["with", 391], ["respect", 396], ["to", 404], ["remission", 407], ["on", 417], ["all", 420], ["three", 424], ["ratings", 430], [".", 437], ["Rates", 439], ["of", 445], ["remission", 448], ["were", 458], ["very", 463], ["similar", 468], ["for", 476], ["all", 480], ["scales", 484], [",", 490], ["ranging", 492], ["from", 500], ["23.1", 505], ["-", 509], ["26.3", 510], ["%", 514], ["for", 516], ["sertraline", 520], ["and", 531], ["13.9", 535], ["-", 539], ["14.9", 540], ["%", 544], ["for", 546], ["placebo", 550], [".", 557], ["Traditional", 559], ["thresholds", 571], ["for", 582], ["the", 586], ["CAPS", 590], ["and", 595], ["DTS", 599], ["were", 603], ["tested", 608], ["relative", 615], ["to", 624], ["the", 627], ["CGI", 631], ["and", 635], ["to", 639], ["each", 642], ["other", 647], [".", 652], ["The", 654], ["CAPS", 658], ["and", 663], ["DTS", 667], ["thresholds", 671], ["of", 682], ["<", 685], ["20", 687], ["and", 690], ["<", 694], ["18", 696], ["were", 699], ["found", 704], ["to", 710], ["be", 713], ["valid", 716], [".", 721]]}
{"context": "Lewy bodies, neuropathological hallmarks of Parkinson's disease and dementia with Lewy bodies, comprise alpha-synuclein filaments and other less defined proteins. Characterization of Lewy body proteins that interact with alpha-synuclein may provide insight into the mechanism of Lewy body formation. Double immunofluorescence labeling and confocal microscopy revealed approximately 80% of cortical Lewy bodies contained microtubule-associated protein 1B (MAP-1B) that overlapped with alpha-synuclein. Lewy bodies were isolated using an immunomagnetic technique from brain tissue of patients dying with dementia with Lewy bodies. Lewy body proteins were resolved by polyacrylamide gel electrophoresis. Immunoblotting confirmed the presence of MAP-1B and alpha-synuclein in purified Lewy bodies. Direct binding studies revealed a high affinity interaction (IC(50) approximately 20 nm) between MAP-1B and alpha-synuclein. The MAP-1B-binding sites were mapped to the last 45 amino acids of the alpha-synuclein C terminus. MAP-1B also bound in vitro assembled alpha-synuclein fibrils. Thus, MAP-1B may be involved in the pathogenesis of Lewy bodies via its interaction with monomeric and fibrillar alpha-synuclein.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "61399ac72d9a4c4397aa7b80ee902d25", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[172, 174], [196, 198], [141, 143], [74, 76], [16, 18], [160, 162], [34, 36], [115, 117]], "char_spans": [[1055, 1069], [1193, 1207], [902, 916], [484, 498], [104, 118], [990, 1004], [221, 235], [753, 767]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], [",", 11], ["neuropathological", 13], ["hallmarks", 31], ["of", 41], ["Parkinson", 44], ["'s", 53], ["disease", 56], ["and", 64], ["dementia", 68], ["with", 77], ["Lewy", 82], ["bodies", 87], [",", 93], ["comprise", 95], ["alpha", 104], ["-", 109], ["synuclein", 110], ["filaments", 120], ["and", 130], ["other", 134], ["less", 140], ["defined", 145], ["proteins", 153], [".", 161], ["Characterization", 163], ["of", 180], ["Lewy", 183], ["body", 188], ["proteins", 193], ["that", 202], ["interact", 207], ["with", 216], ["alpha", 221], ["-", 226], ["synuclein", 227], ["may", 237], ["provide", 241], ["insight", 249], ["into", 257], ["the", 262], ["mechanism", 266], ["of", 276], ["Lewy", 279], ["body", 284], ["formation", 289], [".", 298], ["Double", 300], ["immunofluorescence", 307], ["labeling", 326], ["and", 335], ["confocal", 339], ["microscopy", 348], ["revealed", 359], ["approximately", 368], ["80", 382], ["%", 384], ["of", 386], ["cortical", 389], ["Lewy", 398], ["bodies", 403], ["contained", 410], ["microtubule", 420], ["-", 431], ["associated", 432], ["protein", 443], ["1B", 451], ["(", 454], ["MAP-1B", 455], [")", 461], ["that", 463], ["overlapped", 468], ["with", 479], ["alpha", 484], ["-", 489], ["synuclein", 490], [".", 499], ["Lewy", 501], ["bodies", 506], ["were", 513], ["isolated", 518], ["using", 527], ["an", 533], ["immunomagnetic", 536], ["technique", 551], ["from", 561], ["brain", 566], ["tissue", 572], ["of", 579], ["patients", 582], ["dying", 591], ["with", 597], ["dementia", 602], ["with", 611], ["Lewy", 616], ["bodies", 621], [".", 627], ["Lewy", 629], ["body", 634], ["proteins", 639], ["were", 648], ["resolved", 653], ["by", 662], ["polyacrylamide", 665], ["gel", 680], ["electrophoresis", 684], [".", 699], ["Immunoblotting", 701], ["confirmed", 716], ["the", 726], ["presence", 730], ["of", 739], ["MAP-1B", 742], ["and", 749], ["alpha", 753], ["-", 758], ["synuclein", 759], ["in", 769], ["purified", 772], ["Lewy", 781], ["bodies", 786], [".", 792], ["Direct", 794], ["binding", 801], ["studies", 809], ["revealed", 817], ["a", 826], ["high", 828], ["affinity", 833], ["interaction", 842], ["(", 854], ["IC(50", 855], [")", 860], ["approximately", 862], ["20", 876], ["nm", 879], [")", 881], ["between", 883], ["MAP-1B", 891], ["and", 898], ["alpha", 902], ["-", 907], ["synuclein", 908], [".", 917], ["The", 919], ["MAP-1B", 923], ["-", 929], ["binding", 930], ["sites", 938], ["were", 944], ["mapped", 949], ["to", 956], ["the", 959], ["last", 963], ["45", 968], ["amino", 971], ["acids", 977], ["of", 983], ["the", 986], ["alpha", 990], ["-", 995], ["synuclein", 996], ["C", 1006], ["terminus", 1008], [".", 1016], ["MAP-1B", 1018], ["also", 1025], ["bound", 1030], ["in", 1036], ["vitro", 1039], ["assembled", 1045], ["alpha", 1055], ["-", 1060], ["synuclein", 1061], ["fibrils", 1071], [".", 1078], ["Thus", 1080], [",", 1084], ["MAP-1B", 1086], ["may", 1093], ["be", 1097], ["involved", 1100], ["in", 1109], ["the", 1112], ["pathogenesis", 1116], ["of", 1129], ["Lewy", 1132], ["bodies", 1137], ["via", 1144], ["its", 1148], ["interaction", 1152], ["with", 1164], ["monomeric", 1169], ["and", 1179], ["fibrillar", 1183], ["alpha", 1193], ["-", 1198], ["synuclein", 1199], [".", 1208]]}
{"context": "Since reports that precursor cells in the adult subventricular zone (SVZ) contribute to regenerative neuro- and gliogenesis in CA1, we wondered whether a similar route of migration might also exist under physiological conditions. Permanent labeling of SVZ precursor cells with a lentiviral vector for green fluorescent protein did not reveal any migration from the SVZ into CA1 in the intact murine brain. However, in a nestin-GFP reporter mouse we found proliferating cells within the corpus callosum/alveus region expressing nestin and glial fibrillary acidic protein similar to precursor cells in the neighboring neurogenic region of the adult dentate gyrus. Within 3 weeks of BrdU administration, BrdU-positive nestin-GFP-expressing protoplasmic astrocytes emerged in CA1. Similar to precursor cells isolated from the dentate gyrus and the SVZ, nestin-GFP-expressing cells from corpus callosum/alveus were self-renewing and multipotent in vitro, whereas cells isolated from CA1 were not. Nestin-GFP-expressing cells in CA1 differentiated into postmitotic astrocytes characterized by S100beta expression. No new neurons were found in CA1. The number of nestin-GFP-expressing astrocytes in CA1 was increased by environmental enrichment. We conclude that astrogenesis in CA1 is influenced by environmental conditions. However, SVZ precursor cells do not contribute to physiological cellular plasticity in CA1.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "030fff89fcaf4f7a8d31056a6f48f949", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[171, 171], [119, 119], [71, 71], [199, 199], [88, 88], [143, 143]], "char_spans": [[992, 997], [715, 720], [420, 425], [1156, 1161], [527, 532], [849, 854]]}]}], "context_tokens": [["Since", 0], ["reports", 6], ["that", 14], ["precursor", 19], ["cells", 29], ["in", 35], ["the", 38], ["adult", 42], ["subventricular", 48], ["zone", 63], ["(", 68], ["SVZ", 69], [")", 72], ["contribute", 74], ["to", 85], ["regenerative", 88], ["neuro-", 101], ["and", 108], ["gliogenesis", 112], ["in", 124], ["CA1", 127], [",", 130], ["we", 132], ["wondered", 135], ["whether", 144], ["a", 152], ["similar", 154], ["route", 162], ["of", 168], ["migration", 171], ["might", 181], ["also", 187], ["exist", 192], ["under", 198], ["physiological", 204], ["conditions", 218], [".", 228], ["Permanent", 230], ["labeling", 240], ["of", 249], ["SVZ", 252], ["precursor", 256], ["cells", 266], ["with", 272], ["a", 277], ["lentiviral", 279], ["vector", 290], ["for", 297], ["green", 301], ["fluorescent", 307], ["protein", 319], ["did", 327], ["not", 331], ["reveal", 335], ["any", 342], ["migration", 346], ["from", 356], ["the", 361], ["SVZ", 365], ["into", 369], ["CA1", 374], ["in", 378], ["the", 381], ["intact", 385], ["murine", 392], ["brain", 399], [".", 404], ["However", 406], [",", 413], ["in", 415], ["a", 418], ["nestin", 420], ["-", 426], ["GFP", 427], ["reporter", 431], ["mouse", 440], ["we", 446], ["found", 449], ["proliferating", 455], ["cells", 469], ["within", 475], ["the", 482], ["corpus", 486], ["callosum", 493], ["/", 501], ["alveus", 502], ["region", 509], ["expressing", 516], ["nestin", 527], ["and", 534], ["glial", 538], ["fibrillary", 544], ["acidic", 555], ["protein", 562], ["similar", 570], ["to", 578], ["precursor", 581], ["cells", 591], ["in", 597], ["the", 600], ["neighboring", 604], ["neurogenic", 616], ["region", 627], ["of", 634], ["the", 637], ["adult", 641], ["dentate", 647], ["gyrus", 655], [".", 660], ["Within", 662], ["3", 669], ["weeks", 671], ["of", 677], ["BrdU", 680], ["administration", 685], [",", 699], ["BrdU", 701], ["-", 705], ["positive", 706], ["nestin", 715], ["-", 721], ["GFP", 722], ["-", 725], ["expressing", 726], ["protoplasmic", 737], ["astrocytes", 750], ["emerged", 761], ["in", 769], ["CA1", 772], [".", 775], ["Similar", 777], ["to", 785], ["precursor", 788], ["cells", 798], ["isolated", 804], ["from", 813], ["the", 818], ["dentate", 822], ["gyrus", 830], ["and", 836], ["the", 840], ["SVZ", 844], [",", 847], ["nestin", 849], ["-", 855], ["GFP", 856], ["-", 859], ["expressing", 860], ["cells", 871], ["from", 877], ["corpus", 882], ["callosum", 889], ["/", 897], ["alveus", 898], ["were", 905], ["self", 910], ["-", 914], ["renewing", 915], ["and", 924], ["multipotent", 928], ["in", 940], ["vitro", 943], [",", 948], ["whereas", 950], ["cells", 958], ["isolated", 964], ["from", 973], ["CA1", 978], ["were", 982], ["not", 987], [".", 990], ["Nestin", 992], ["-", 998], ["GFP", 999], ["-", 1002], ["expressing", 1003], ["cells", 1014], ["in", 1020], ["CA1", 1023], ["differentiated", 1027], ["into", 1042], ["postmitotic", 1047], ["astrocytes", 1059], ["characterized", 1070], ["by", 1084], ["S100beta", 1087], ["expression", 1096], [".", 1106], ["No", 1108], ["new", 1111], ["neurons", 1115], ["were", 1123], ["found", 1128], ["in", 1134], ["CA1", 1137], [".", 1140], ["The", 1142], ["number", 1146], ["of", 1153], ["nestin", 1156], ["-", 1162], ["GFP", 1163], ["-", 1166], ["expressing", 1167], ["astrocytes", 1178], ["in", 1189], ["CA1", 1192], ["was", 1196], ["increased", 1200], ["by", 1210], ["environmental", 1213], ["enrichment", 1227], [".", 1237], ["We", 1239], ["conclude", 1242], ["that", 1251], ["astrogenesis", 1256], ["in", 1269], ["CA1", 1272], ["is", 1276], ["influenced", 1279], ["by", 1290], ["environmental", 1293], ["conditions", 1307], [".", 1317], ["However", 1319], [",", 1326], ["SVZ", 1328], ["precursor", 1332], ["cells", 1342], ["do", 1348], ["not", 1351], ["contribute", 1355], ["to", 1366], ["physiological", 1369], ["cellular", 1383], ["plasticity", 1392], ["in", 1403], ["CA1", 1406], [".", 1409]]}
{"context": "Nucleotide excision repair (NER), which is arguably the most versatile DNA repair system, is strongly attenuated in human cells of the monocytic lineage when they differentiate into macrophages. Within active genes, however, both DNA strands continue to be proficiently repaired. The proficient repair of the nontranscribed strand cannot be explained by the dedicated subpathway of transcription-coupled repair (TCR), which is targeted to the transcribed strand in expressed genes. We now report that the previously termed differentiation-associated repair (DAR) depends upon transcription, but not simply upon RNA polymerase II (RNAPII) encountering a lesion: proficient repair of both DNA strands can occur in a part of a gene that the polymerase never reaches, and even if the translocation of RNAPII is blocked with transcription inhibitors. This suggests that DAR may be a subset of global NER, restricted to the subnuclear compartments or chromatin domains within which transcription occurs. Downregulation of selected NER genes with small interfering RNA has confirmed that DAR relies upon the same genes as global genome repair, rather than upon TCR-specific genes. Our findings support the general view that the genomic domains within which transcription is active are more accessible than the bulk of the genome to the recognition and repair of lesions through the global pathway and that TCR is superimposed upon that pathway of NER.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "84dfe31ea9704f369ff876aaf7937ab8", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[77, 78]], "char_spans": [[443, 460]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], [",", 32], ["which", 34], ["is", 40], ["arguably", 43], ["the", 52], ["most", 56], ["versatile", 61], ["DNA", 71], ["repair", 75], ["system", 82], [",", 88], ["is", 90], ["strongly", 93], ["attenuated", 102], ["in", 113], ["human", 116], ["cells", 122], ["of", 128], ["the", 131], ["monocytic", 135], ["lineage", 145], ["when", 153], ["they", 158], ["differentiate", 163], ["into", 177], ["macrophages", 182], [".", 193], ["Within", 195], ["active", 202], ["genes", 209], [",", 214], ["however", 216], [",", 223], ["both", 225], ["DNA", 230], ["strands", 234], ["continue", 242], ["to", 251], ["be", 254], ["proficiently", 257], ["repaired", 270], [".", 278], ["The", 280], ["proficient", 284], ["repair", 295], ["of", 302], ["the", 305], ["nontranscribed", 309], ["strand", 324], ["can", 331], ["not", 334], ["be", 338], ["explained", 341], ["by", 351], ["the", 354], ["dedicated", 358], ["subpathway", 368], ["of", 379], ["transcription", 382], ["-", 395], ["coupled", 396], ["repair", 404], ["(", 411], ["TCR", 412], [")", 415], [",", 416], ["which", 418], ["is", 424], ["targeted", 427], ["to", 436], ["the", 439], ["transcribed", 443], ["strand", 455], ["in", 462], ["expressed", 465], ["genes", 475], [".", 480], ["We", 482], ["now", 485], ["report", 489], ["that", 496], ["the", 501], ["previously", 505], ["termed", 516], ["differentiation", 523], ["-", 538], ["associated", 539], ["repair", 550], ["(", 557], ["DAR", 558], [")", 561], ["depends", 563], ["upon", 571], ["transcription", 576], [",", 589], ["but", 591], ["not", 595], ["simply", 599], ["upon", 606], ["RNA", 611], ["polymerase", 615], ["II", 626], ["(", 629], ["RNAPII", 630], [")", 636], ["encountering", 638], ["a", 651], ["lesion", 653], [":", 659], ["proficient", 661], ["repair", 672], ["of", 679], ["both", 682], ["DNA", 687], ["strands", 691], ["can", 699], ["occur", 703], ["in", 709], ["a", 712], ["part", 714], ["of", 719], ["a", 722], ["gene", 724], ["that", 729], ["the", 734], ["polymerase", 738], ["never", 749], ["reaches", 755], [",", 762], ["and", 764], ["even", 768], ["if", 773], ["the", 776], ["translocation", 780], ["of", 794], ["RNAPII", 797], ["is", 804], ["blocked", 807], ["with", 815], ["transcription", 820], ["inhibitors", 834], [".", 844], ["This", 846], ["suggests", 851], ["that", 860], ["DAR", 865], ["may", 869], ["be", 873], ["a", 876], ["subset", 878], ["of", 885], ["global", 888], ["NER", 895], [",", 898], ["restricted", 900], ["to", 911], ["the", 914], ["subnuclear", 918], ["compartments", 929], ["or", 942], ["chromatin", 945], ["domains", 955], ["within", 963], ["which", 970], ["transcription", 976], ["occurs", 990], [".", 996], ["Downregulation", 998], ["of", 1013], ["selected", 1016], ["NER", 1025], ["genes", 1029], ["with", 1035], ["small", 1040], ["interfering", 1046], ["RNA", 1058], ["has", 1062], ["confirmed", 1066], ["that", 1076], ["DAR", 1081], ["relies", 1085], ["upon", 1092], ["the", 1097], ["same", 1101], ["genes", 1106], ["as", 1112], ["global", 1115], ["genome", 1122], ["repair", 1129], [",", 1135], ["rather", 1137], ["than", 1144], ["upon", 1149], ["TCR", 1154], ["-", 1157], ["specific", 1158], ["genes", 1167], [".", 1172], ["Our", 1174], ["findings", 1178], ["support", 1187], ["the", 1195], ["general", 1199], ["view", 1207], ["that", 1212], ["the", 1217], ["genomic", 1221], ["domains", 1229], ["within", 1237], ["which", 1244], ["transcription", 1250], ["is", 1264], ["active", 1267], ["are", 1274], ["more", 1278], ["accessible", 1283], ["than", 1294], ["the", 1299], ["bulk", 1303], ["of", 1308], ["the", 1311], ["genome", 1315], ["to", 1322], ["the", 1325], ["recognition", 1329], ["and", 1341], ["repair", 1345], ["of", 1352], ["lesions", 1355], ["through", 1363], ["the", 1371], ["global", 1375], ["pathway", 1382], ["and", 1390], ["that", 1394], ["TCR", 1399], ["is", 1403], ["superimposed", 1406], ["upon", 1419], ["that", 1424], ["pathway", 1429], ["of", 1437], ["NER", 1440], [".", 1443]]}
{"context": "The McLeod syndrome is an X-linked disorder caused by mutations of the XK gene encoding the XK protein. The syndrome is characterized by absent Kx erythrocyte antigen, weak expression of Kell blood group system antigens, and acanthocytosis. In some allelic variants, elevated creatine kinase, myopathy, neurogenic muscle atrophy, and progressive chorea are found. We describe a family with a novel point mutation in the XK gene consisting of a C to T base transition at nucleotide position 977, introducing a stop codon. Among seven affected males, five manifested with psychiatric disorders such as depression, bipolar disorder, or personality disorder, but only two presented with chorea Positron emission tomography and magnetic resonance volumetry revealed reduced striatal 2-fluoro-2-deoxy-glucose (FDG) uptake and diminished volumes of the caudate nucleus and putamen that correlated with disease duration. In contrast, none of 12 female mutation carriers showed psychiatric or movement disorders. However, a semidominant effect of the mutation was suggested by erythrocyte and blood group mosaicism and reduced striatal FDG uptake without structural abnormalities. Therefore, patients with psychiatric signs or symptoms segregating in an X-linked trait should be examined for acanthocytosis and Kell/Kx blood group serology.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "2f7b7e71153e42089cfb1ba8aff9bd9e", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[18, 18], [75, 75], [14, 14]], "char_spans": [[92, 93], [420, 421], [71, 72]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["an", 23], ["X", 26], ["-", 27], ["linked", 28], ["disorder", 35], ["caused", 44], ["by", 51], ["mutations", 54], ["of", 64], ["the", 67], ["XK", 71], ["gene", 74], ["encoding", 79], ["the", 88], ["XK", 92], ["protein", 95], [".", 102], ["The", 104], ["syndrome", 108], ["is", 117], ["characterized", 120], ["by", 134], ["absent", 137], ["Kx", 144], ["erythrocyte", 147], ["antigen", 159], [",", 166], ["weak", 168], ["expression", 173], ["of", 184], ["Kell", 187], ["blood", 192], ["group", 198], ["system", 204], ["antigens", 211], [",", 219], ["and", 221], ["acanthocytosis", 225], [".", 239], ["In", 241], ["some", 244], ["allelic", 249], ["variants", 257], [",", 265], ["elevated", 267], ["creatine", 276], ["kinase", 285], [",", 291], ["myopathy", 293], [",", 301], ["neurogenic", 303], ["muscle", 314], ["atrophy", 321], [",", 328], ["and", 330], ["progressive", 334], ["chorea", 346], ["are", 353], ["found", 357], [".", 362], ["We", 364], ["describe", 367], ["a", 376], ["family", 378], ["with", 385], ["a", 390], ["novel", 392], ["point", 398], ["mutation", 404], ["in", 413], ["the", 416], ["XK", 420], ["gene", 423], ["consisting", 428], ["of", 439], ["a", 442], ["C", 444], ["to", 446], ["T", 449], ["base", 451], ["transition", 456], ["at", 467], ["nucleotide", 470], ["position", 481], ["977", 490], [",", 493], ["introducing", 495], ["a", 507], ["stop", 509], ["codon", 514], [".", 519], ["Among", 521], ["seven", 527], ["affected", 533], ["males", 542], [",", 547], ["five", 549], ["manifested", 554], ["with", 565], ["psychiatric", 570], ["disorders", 582], ["such", 592], ["as", 597], ["depression", 600], [",", 610], ["bipolar", 612], ["disorder", 620], [",", 628], ["or", 630], ["personality", 633], ["disorder", 645], [",", 653], ["but", 655], ["only", 659], ["two", 664], ["presented", 668], ["with", 678], ["chorea", 683], ["Positron", 690], ["emission", 699], ["tomography", 708], ["and", 719], ["magnetic", 723], ["resonance", 732], ["volumetry", 742], ["revealed", 752], ["reduced", 761], ["striatal", 769], ["2-fluoro-2-deoxy", 778], ["-", 794], ["glucose", 795], ["(", 803], ["FDG", 804], [")", 807], ["uptake", 809], ["and", 816], ["diminished", 820], ["volumes", 831], ["of", 839], ["the", 842], ["caudate", 846], ["nucleus", 854], ["and", 862], ["putamen", 866], ["that", 874], ["correlated", 879], ["with", 890], ["disease", 895], ["duration", 903], [".", 911], ["In", 913], ["contrast", 916], [",", 924], ["none", 926], ["of", 931], ["12", 934], ["female", 937], ["mutation", 944], ["carriers", 953], ["showed", 962], ["psychiatric", 969], ["or", 981], ["movement", 984], ["disorders", 993], [".", 1002], ["However", 1004], [",", 1011], ["a", 1013], ["semidominant", 1015], ["effect", 1028], ["of", 1035], ["the", 1038], ["mutation", 1042], ["was", 1051], ["suggested", 1055], ["by", 1065], ["erythrocyte", 1068], ["and", 1080], ["blood", 1084], ["group", 1090], ["mosaicism", 1096], ["and", 1106], ["reduced", 1110], ["striatal", 1118], ["FDG", 1127], ["uptake", 1131], ["without", 1138], ["structural", 1146], ["abnormalities", 1157], [".", 1170], ["Therefore", 1172], [",", 1181], ["patients", 1183], ["with", 1192], ["psychiatric", 1197], ["signs", 1209], ["or", 1215], ["symptoms", 1218], ["segregating", 1227], ["in", 1239], ["an", 1242], ["X", 1245], ["-", 1246], ["linked", 1247], ["trait", 1254], ["should", 1260], ["be", 1267], ["examined", 1270], ["for", 1279], ["acanthocytosis", 1283], ["and", 1298], ["Kell", 1302], ["/", 1306], ["Kx", 1307], ["blood", 1310], ["group", 1316], ["serology", 1322], [".", 1330]]}
{"context": "Plasmids are ubiquitous mobile elements that serve as a pool of many host beneficial traits such as antibiotic resistance in bacterial communities. To understand the importance of plasmids in horizontal gene transfer, we need to gain insight into the 'evolutionary history' of these plasmids, i.e. the range of hosts in which they have evolved. Since extensive data support the proposal that foreign DNA acquires the host's nucleotide composition during long-term residence, comparison of nucleotide composition of plasmids and chromosomes could shed light on a plasmid's evolutionary history. The average absolute dinucleotide relative abundance difference, termed delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and plasmids. Here, we introduce the Mahalanobis distance, which takes into account the variance-covariance structure of the chromosome signatures. We demonstrate that the Mahalanobis distance is better than the delta-distance at measuring genomic signature differences between plasmids and chromosomes of potential hosts. We illustrate the usefulness of this metric for proposing candidate long-term hosts for plasmids, focusing on the virulence plasmids pXO1 from Bacillus anthracis, and pO157 from Escherichia coli O157:H7, as well as the broad host range multi-drug resistance plasmid pB10 from an unknown host.", "qas": [{"question": "Which is the most common measure of differences between dinucleotide relative abundance \"genomic signatures\"", "answers": ["delta-distance"], "qid": "082b7ea2976047d8b572fd00bfddec04", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["measure", 25], ["of", 33], ["differences", 36], ["between", 48], ["dinucleotide", 56], ["relative", 69], ["abundance", 78], ["\"", 88], ["genomic", 89], ["signatures", 97], ["\"", 107]], "detected_answers": [{"text": "delta-distance", "token_spans": [[108, 110], [167, 169]], "char_spans": [[666, 679], [1023, 1036]]}]}], "context_tokens": [["Plasmids", 0], ["are", 9], ["ubiquitous", 13], ["mobile", 24], ["elements", 31], ["that", 40], ["serve", 45], ["as", 51], ["a", 54], ["pool", 56], ["of", 61], ["many", 64], ["host", 69], ["beneficial", 74], ["traits", 85], ["such", 92], ["as", 97], ["antibiotic", 100], ["resistance", 111], ["in", 122], ["bacterial", 125], ["communities", 135], [".", 146], ["To", 148], ["understand", 151], ["the", 162], ["importance", 166], ["of", 177], ["plasmids", 180], ["in", 189], ["horizontal", 192], ["gene", 203], ["transfer", 208], [",", 216], ["we", 218], ["need", 221], ["to", 226], ["gain", 229], ["insight", 234], ["into", 242], ["the", 247], ["'", 251], ["evolutionary", 252], ["history", 265], ["'", 272], ["of", 274], ["these", 277], ["plasmids", 283], [",", 291], ["i.e.", 293], ["the", 298], ["range", 302], ["of", 308], ["hosts", 311], ["in", 317], ["which", 320], ["they", 326], ["have", 331], ["evolved", 336], [".", 343], ["Since", 345], ["extensive", 351], ["data", 361], ["support", 366], ["the", 374], ["proposal", 378], ["that", 387], ["foreign", 392], ["DNA", 400], ["acquires", 404], ["the", 413], ["host", 417], ["'s", 421], ["nucleotide", 424], ["composition", 435], ["during", 447], ["long", 454], ["-", 458], ["term", 459], ["residence", 464], [",", 473], ["comparison", 475], ["of", 486], ["nucleotide", 489], ["composition", 500], ["of", 512], ["plasmids", 515], ["and", 524], ["chromosomes", 528], ["could", 540], ["shed", 546], ["light", 551], ["on", 557], ["a", 560], ["plasmid", 562], ["'s", 569], ["evolutionary", 572], ["history", 585], [".", 592], ["The", 594], ["average", 598], ["absolute", 606], ["dinucleotide", 615], ["relative", 628], ["abundance", 637], ["difference", 647], [",", 657], ["termed", 659], ["delta", 666], ["-", 671], ["distance", 672], [",", 680], ["has", 682], ["been", 686], ["commonly", 691], ["used", 700], ["to", 705], ["measure", 708], ["differences", 716], ["in", 728], ["dinucleotide", 731], ["composition", 744], [",", 755], ["or", 757], ["'", 760], ["genomic", 761], ["signature", 769], ["'", 778], [",", 779], ["between", 781], ["bacterial", 789], ["chromosomes", 799], ["and", 811], ["plasmids", 815], [".", 823], ["Here", 825], [",", 829], ["we", 831], ["introduce", 834], ["the", 844], ["Mahalanobis", 848], ["distance", 860], [",", 868], ["which", 870], ["takes", 876], ["into", 882], ["account", 887], ["the", 895], ["variance", 899], ["-", 907], ["covariance", 908], ["structure", 919], ["of", 929], ["the", 932], ["chromosome", 936], ["signatures", 947], [".", 957], ["We", 959], ["demonstrate", 962], ["that", 974], ["the", 979], ["Mahalanobis", 983], ["distance", 995], ["is", 1004], ["better", 1007], ["than", 1014], ["the", 1019], ["delta", 1023], ["-", 1028], ["distance", 1029], ["at", 1038], ["measuring", 1041], ["genomic", 1051], ["signature", 1059], ["differences", 1069], ["between", 1081], ["plasmids", 1089], ["and", 1098], ["chromosomes", 1102], ["of", 1114], ["potential", 1117], ["hosts", 1127], [".", 1132], ["We", 1134], ["illustrate", 1137], ["the", 1148], ["usefulness", 1152], ["of", 1163], ["this", 1166], ["metric", 1171], ["for", 1178], ["proposing", 1182], ["candidate", 1192], ["long", 1202], ["-", 1206], ["term", 1207], ["hosts", 1212], ["for", 1218], ["plasmids", 1222], [",", 1230], ["focusing", 1232], ["on", 1241], ["the", 1244], ["virulence", 1248], ["plasmids", 1258], ["pXO1", 1267], ["from", 1272], ["Bacillus", 1277], ["anthracis", 1286], [",", 1295], ["and", 1297], ["pO157", 1301], ["from", 1307], ["Escherichia", 1312], ["coli", 1324], ["O157:H7", 1329], [",", 1336], ["as", 1338], ["well", 1341], ["as", 1346], ["the", 1349], ["broad", 1353], ["host", 1359], ["range", 1364], ["multi", 1370], ["-", 1375], ["drug", 1376], ["resistance", 1381], ["plasmid", 1392], ["pB10", 1400], ["from", 1405], ["an", 1410], ["unknown", 1413], ["host", 1421], [".", 1425]]}
{"context": "Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium. But there is no consensus as to what constitutes an alpha-proteobacterial gene. Is it a gene found in all or several alpha-proteobacteria, or in only one? Here, we examine the proportion of alpha-proteobacterial genes in alpha-proteobacterial genomes by means of sequence comparisons. We find that each alpha-proteobacterium harbours a particular collection of genes and that, depending upon the lineage examined, between 97 and 33% are alpha-proteobacterial by the nearest-neighbour criterion. Our findings bear upon attempts to reconstruct the mitochondrial ancestor and upon inferences concerning the collection of genes that the mitochondrial ancestor possessed at the time that it became an endosymbiont.", "qas": [{"question": "Which species of bacteria did the mitochondria originate from?", "answers": ["Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium."], "qid": "1bcd341d9896445e8554027ad01ed066", "question_tokens": [["Which", 0], ["species", 6], ["of", 14], ["bacteria", 17], ["did", 26], ["the", 30], ["mitochondria", 34], ["originate", 47], ["from", 57], ["?", 61]], "detected_answers": [{"text": "Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium.", "token_spans": [[0, 11]], "char_spans": [[0, 78]]}]}], "context_tokens": [["Biologists", 0], ["agree", 11], ["that", 17], ["the", 22], ["ancestor", 26], ["of", 35], ["mitochondria", 38], ["was", 51], ["an", 55], ["alpha", 58], ["-", 63], ["proteobacterium", 64], [".", 79], ["But", 81], ["there", 85], ["is", 91], ["no", 94], ["consensus", 97], ["as", 107], ["to", 110], ["what", 113], ["constitutes", 118], ["an", 130], ["alpha", 133], ["-", 138], ["proteobacterial", 139], ["gene", 155], [".", 159], ["Is", 161], ["it", 164], ["a", 167], ["gene", 169], ["found", 174], ["in", 180], ["all", 183], ["or", 187], ["several", 190], ["alpha", 198], ["-", 203], ["proteobacteria", 204], [",", 218], ["or", 220], ["in", 223], ["only", 226], ["one", 231], ["?", 234], ["Here", 236], [",", 240], ["we", 242], ["examine", 245], ["the", 253], ["proportion", 257], ["of", 268], ["alpha", 271], ["-", 276], ["proteobacterial", 277], ["genes", 293], ["in", 299], ["alpha", 302], ["-", 307], ["proteobacterial", 308], ["genomes", 324], ["by", 332], ["means", 335], ["of", 341], ["sequence", 344], ["comparisons", 353], [".", 364], ["We", 366], ["find", 369], ["that", 374], ["each", 379], ["alpha", 384], ["-", 389], ["proteobacterium", 390], ["harbours", 406], ["a", 415], ["particular", 417], ["collection", 428], ["of", 439], ["genes", 442], ["and", 448], ["that", 452], [",", 456], ["depending", 458], ["upon", 468], ["the", 473], ["lineage", 477], ["examined", 485], [",", 493], ["between", 495], ["97", 503], ["and", 506], ["33", 510], ["%", 512], ["are", 514], ["alpha", 518], ["-", 523], ["proteobacterial", 524], ["by", 540], ["the", 543], ["nearest", 547], ["-", 554], ["neighbour", 555], ["criterion", 565], [".", 574], ["Our", 576], ["findings", 580], ["bear", 589], ["upon", 594], ["attempts", 599], ["to", 608], ["reconstruct", 611], ["the", 623], ["mitochondrial", 627], ["ancestor", 641], ["and", 650], ["upon", 654], ["inferences", 659], ["concerning", 670], ["the", 681], ["collection", 685], ["of", 696], ["genes", 699], ["that", 705], ["the", 710], ["mitochondrial", 714], ["ancestor", 728], ["possessed", 737], ["at", 747], ["the", 750], ["time", 754], ["that", 759], ["it", 764], ["became", 767], ["an", 774], ["endosymbiont", 777], [".", 789]]}
{"context": "Women in sub-Saharan Africa are a priority population for evaluation of new biomedical HIV-1 prevention strategies. Antiretroviral pre-exposure prophylaxis is a promising prevention approach; however, clinical trials among young women using daily or coitally-dependent products have found low adherence. Antiretroviral-containing vaginal microbicide rings, which release medication over a month or longer, may reduce these adherence challenges. ASPIRE (A Study to Prevent Infection with a Ring for Extended Use) is a phase III, randomized, double-blind, placebo-controlled trial testing the safety and effectiveness of a vaginal ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine for prevention of HIV-1 infection. We describe the baseline characteristics of African women enrolled in the ASPIRE trial. Between August 2012 and June 2014, 5516 women were screened and 2629 HIV-1 seronegative women between 18-45 years of age were enrolled from 15 research sites in Malawi, South Africa, Uganda, and Zimbabwe. The median age was 26 years (IQR 22-31) and the majority (59%) were unmarried. Nearly 100% of participants reported having a primary sex partner in the prior three months but 43% did not know the HIV-1 status of their primary partner; 17% reported additional concurrent partners. Nearly two-thirds (64%) reported having disclosed to primary partners about planned vaginal ring use in the trial. Sexually transmitted infections were prevalent: 12% had Chlamydia trachomatis, 7% Trichomonas vaginalis, 4% Neisseria gonorrhoeae, and 1% syphilis. African HIV-1 seronegative women at risk of HIV -1 infection were successfully enrolled into a phase III trial of dapivirine vaginal ring for HIV-1 prevention.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "5c077ce1a2b84aa199040b93309cc5b6", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[294, 294]], "char_spans": [[1622, 1624]]}]}], "context_tokens": [["Women", 0], ["in", 6], ["sub", 9], ["-", 12], ["Saharan", 13], ["Africa", 21], ["are", 28], ["a", 32], ["priority", 34], ["population", 43], ["for", 54], ["evaluation", 58], ["of", 69], ["new", 72], ["biomedical", 76], ["HIV-1", 87], ["prevention", 93], ["strategies", 104], [".", 114], ["Antiretroviral", 116], ["pre", 131], ["-", 134], ["exposure", 135], ["prophylaxis", 144], ["is", 156], ["a", 159], ["promising", 161], ["prevention", 171], ["approach", 182], [";", 190], ["however", 192], [",", 199], ["clinical", 201], ["trials", 210], ["among", 217], ["young", 223], ["women", 229], ["using", 235], ["daily", 241], ["or", 247], ["coitally", 250], ["-", 258], ["dependent", 259], ["products", 269], ["have", 278], ["found", 283], ["low", 289], ["adherence", 293], [".", 302], ["Antiretroviral", 304], ["-", 318], ["containing", 319], ["vaginal", 330], ["microbicide", 338], ["rings", 350], [",", 355], ["which", 357], ["release", 363], ["medication", 371], ["over", 382], ["a", 387], ["month", 389], ["or", 395], ["longer", 398], [",", 404], ["may", 406], ["reduce", 410], ["these", 417], ["adherence", 423], ["challenges", 433], [".", 443], ["ASPIRE", 445], ["(", 452], ["A", 453], ["Study", 455], ["to", 461], ["Prevent", 464], ["Infection", 472], ["with", 482], ["a", 487], ["Ring", 489], ["for", 494], ["Extended", 498], ["Use", 507], [")", 510], ["is", 512], ["a", 515], ["phase", 517], ["III", 523], [",", 526], ["randomized", 528], [",", 538], ["double", 540], ["-", 546], ["blind", 547], [",", 552], ["placebo", 554], ["-", 561], ["controlled", 562], ["trial", 573], ["testing", 579], ["the", 587], ["safety", 591], ["and", 598], ["effectiveness", 602], ["of", 616], ["a", 619], ["vaginal", 621], ["ring", 629], ["containing", 634], ["the", 645], ["non", 649], ["-", 652], ["nucleoside", 653], ["reverse", 664], ["transcriptase", 672], ["inhibitor", 686], ["dapivirine", 696], ["for", 707], ["prevention", 711], ["of", 722], ["HIV-1", 725], ["infection", 731], [".", 740], ["We", 742], ["describe", 745], ["the", 754], ["baseline", 758], ["characteristics", 767], ["of", 783], ["African", 786], ["women", 794], ["enrolled", 800], ["in", 809], ["the", 812], ["ASPIRE", 816], ["trial", 823], [".", 828], ["Between", 830], ["August", 838], ["2012", 845], ["and", 850], ["June", 854], ["2014", 859], [",", 863], ["5516", 865], ["women", 870], ["were", 876], ["screened", 881], ["and", 890], ["2629", 894], ["HIV-1", 899], ["seronegative", 905], ["women", 918], ["between", 924], ["18", 932], ["-", 934], ["45", 935], ["years", 938], ["of", 944], ["age", 947], ["were", 951], ["enrolled", 956], ["from", 965], ["15", 970], ["research", 973], ["sites", 982], ["in", 988], ["Malawi", 991], [",", 997], ["South", 999], ["Africa", 1005], [",", 1011], ["Uganda", 1013], [",", 1019], ["and", 1021], ["Zimbabwe", 1025], [".", 1033], ["The", 1035], ["median", 1039], ["age", 1046], ["was", 1050], ["26", 1054], ["years", 1057], ["(", 1063], ["IQR", 1064], ["22", 1068], ["-", 1070], ["31", 1071], [")", 1073], ["and", 1075], ["the", 1079], ["majority", 1083], ["(", 1092], ["59", 1093], ["%", 1095], [")", 1096], ["were", 1098], ["unmarried", 1103], [".", 1112], ["Nearly", 1114], ["100", 1121], ["%", 1124], ["of", 1126], ["participants", 1129], ["reported", 1142], ["having", 1151], ["a", 1158], ["primary", 1160], ["sex", 1168], ["partner", 1172], ["in", 1180], ["the", 1183], ["prior", 1187], ["three", 1193], ["months", 1199], ["but", 1206], ["43", 1210], ["%", 1212], ["did", 1214], ["not", 1218], ["know", 1222], ["the", 1227], ["HIV-1", 1231], ["status", 1237], ["of", 1244], ["their", 1247], ["primary", 1253], ["partner", 1261], [";", 1268], ["17", 1270], ["%", 1272], ["reported", 1274], ["additional", 1283], ["concurrent", 1294], ["partners", 1305], [".", 1313], ["Nearly", 1315], ["two", 1322], ["-", 1325], ["thirds", 1326], ["(", 1333], ["64", 1334], ["%", 1336], [")", 1337], ["reported", 1339], ["having", 1348], ["disclosed", 1355], ["to", 1365], ["primary", 1368], ["partners", 1376], ["about", 1385], ["planned", 1391], ["vaginal", 1399], ["ring", 1407], ["use", 1412], ["in", 1416], ["the", 1419], ["trial", 1423], [".", 1428], ["Sexually", 1430], ["transmitted", 1439], ["infections", 1451], ["were", 1462], ["prevalent", 1467], [":", 1476], ["12", 1478], ["%", 1480], ["had", 1482], ["Chlamydia", 1486], ["trachomatis", 1496], [",", 1507], ["7", 1509], ["%", 1510], ["Trichomonas", 1512], ["vaginalis", 1524], [",", 1533], ["4", 1535], ["%", 1536], ["Neisseria", 1538], ["gonorrhoeae", 1548], [",", 1559], ["and", 1561], ["1", 1565], ["%", 1566], ["syphilis", 1568], [".", 1576], ["African", 1578], ["HIV-1", 1586], ["seronegative", 1592], ["women", 1605], ["at", 1611], ["risk", 1614], ["of", 1619], ["HIV", 1622], ["-1", 1626], ["infection", 1629], ["were", 1639], ["successfully", 1644], ["enrolled", 1657], ["into", 1666], ["a", 1671], ["phase", 1673], ["III", 1679], ["trial", 1683], ["of", 1689], ["dapivirine", 1692], ["vaginal", 1703], ["ring", 1711], ["for", 1716], ["HIV-1", 1720], ["prevention", 1726], [".", 1736]]}
{"context": "The new International League Against Epilepsy (ILAE) classification for focal cortical dysplasia (FCD) differentiates between patients with isolated FCD (type 1) and FCD with an associated hippocampal sclerosis (HS) (type 3a). In contrast to the former FCD classification by Palmini, which considered only histologic features, the novel ILAE classification also relies on magnetic resonance imaging (MRI) findings and presumed pathogenesis. We investigated in a cohort of 100 patients with exclusively temporal FCD if the new subdivision of FCD is reflected in clinical characteristics. Thirty-one patients with FCD type 1 and 50 patients with FCD type 3a in the temporal lobe were included. In all patients MRI and histology of the FCD were available. Both patient groups were compared to 19 patients with temporal FCD type 2 with clearly different histologic appearance. Patients with FCD type 1 and type 3a presented with similar clinical features in many respects. In univariate analyses, no statistically significant differences were found as to age at epilepsy onset (p = 0.07) and epilepsy surgery (p = 0.14), a normal appearing neocortical temporal lobe (p = 0.08) or diagnosis of FCD by visual inspection of MRI (p = 0.08), preoperative seizure frequency (p = 0.06), and the predominance of an epigastric aura (p = 0.08). The postoperative outcome was nearly identical 1 year (p = 0.8) and 2 (p = 0.8), 3 (p = 0.8), 5 (p = 0.7), and 8 (p = 1.0) years postoperatively. Only febrile seizures (p = 0.025) and an aura (p = 0.03) were significantly more frequently reported in patients with FCD type 3a. Similar results were obtained from a multivariate logistic regression analysis. Patients with FCD type 2 were more different: Compared to FCD type 3a, age at epilepsy surgery was significantly lower (p = 0.004) and auras (p = 0.005) were significantly less frequently reported. Epigastric auras (p = 0.04) and febrile seizures (p = 0.025) occurred significantly less frequently in patients with FCD type 2 without HS compared to FCD type 3a. The diagnosis of an FCD was significantly more frequently made (p = 0.03) by visual inspection of the MRI compared to FCD type 1. Clinical features did not allow to clear separation of temporal FCD types 1 and 3a. Statistically significant differences were seen in a history of febrile seizures and the occurrence of auras more common in FCD type 3a. However, FCD type 2 in the same localization but with different histology presented with further differences such as more frequent FCD diagnosis by visual inspection of MRI, earlier operation, and less frequent epigastric auras.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "b9e939ba9f2c4fa89af0a12d34b058f2", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[11, 13]], "char_spans": [[72, 95]]}]}], "context_tokens": [["The", 0], ["new", 4], ["International", 8], ["League", 22], ["Against", 29], ["Epilepsy", 37], ["(", 46], ["ILAE", 47], [")", 51], ["classification", 53], ["for", 68], ["focal", 72], ["cortical", 78], ["dysplasia", 87], ["(", 97], ["FCD", 98], [")", 101], ["differentiates", 103], ["between", 118], ["patients", 126], ["with", 135], ["isolated", 140], ["FCD", 149], ["(", 153], ["type", 154], ["1", 159], [")", 160], ["and", 162], ["FCD", 166], ["with", 170], ["an", 175], ["associated", 178], ["hippocampal", 189], ["sclerosis", 201], ["(", 211], ["HS", 212], [")", 214], ["(", 216], ["type", 217], ["3a", 222], [")", 224], [".", 225], ["In", 227], ["contrast", 230], ["to", 239], ["the", 242], ["former", 246], ["FCD", 253], ["classification", 257], ["by", 272], ["Palmini", 275], [",", 282], ["which", 284], ["considered", 290], ["only", 301], ["histologic", 306], ["features", 317], [",", 325], ["the", 327], ["novel", 331], ["ILAE", 337], ["classification", 342], ["also", 357], ["relies", 362], ["on", 369], ["magnetic", 372], ["resonance", 381], ["imaging", 391], ["(", 399], ["MRI", 400], [")", 403], ["findings", 405], ["and", 414], ["presumed", 418], ["pathogenesis", 427], [".", 439], ["We", 441], ["investigated", 444], ["in", 457], ["a", 460], ["cohort", 462], ["of", 469], ["100", 472], ["patients", 476], ["with", 485], ["exclusively", 490], ["temporal", 502], ["FCD", 511], ["if", 515], ["the", 518], ["new", 522], ["subdivision", 526], ["of", 538], ["FCD", 541], ["is", 545], ["reflected", 548], ["in", 558], ["clinical", 561], ["characteristics", 570], [".", 585], ["Thirty", 587], ["-", 593], ["one", 594], ["patients", 598], ["with", 607], ["FCD", 612], ["type", 616], ["1", 621], ["and", 623], ["50", 627], ["patients", 630], ["with", 639], ["FCD", 644], ["type", 648], ["3a", 653], ["in", 656], ["the", 659], ["temporal", 663], ["lobe", 672], ["were", 677], ["included", 682], [".", 690], ["In", 692], ["all", 695], ["patients", 699], ["MRI", 708], ["and", 712], ["histology", 716], ["of", 726], ["the", 729], ["FCD", 733], ["were", 737], ["available", 742], [".", 751], ["Both", 753], ["patient", 758], ["groups", 766], ["were", 773], ["compared", 778], ["to", 787], ["19", 790], ["patients", 793], ["with", 802], ["temporal", 807], ["FCD", 816], ["type", 820], ["2", 825], ["with", 827], ["clearly", 832], ["different", 840], ["histologic", 850], ["appearance", 861], [".", 871], ["Patients", 873], ["with", 882], ["FCD", 887], ["type", 891], ["1", 896], ["and", 898], ["type", 902], ["3a", 907], ["presented", 910], ["with", 920], ["similar", 925], ["clinical", 933], ["features", 942], ["in", 951], ["many", 954], ["respects", 959], [".", 967], ["In", 969], ["univariate", 972], ["analyses", 983], [",", 991], ["no", 993], ["statistically", 996], ["significant", 1010], ["differences", 1022], ["were", 1034], ["found", 1039], ["as", 1045], ["to", 1048], ["age", 1051], ["at", 1055], ["epilepsy", 1058], ["onset", 1067], ["(", 1073], ["p", 1074], ["=", 1076], ["0.07", 1078], [")", 1082], ["and", 1084], ["epilepsy", 1088], ["surgery", 1097], ["(", 1105], ["p", 1106], ["=", 1108], ["0.14", 1110], [")", 1114], [",", 1115], ["a", 1117], ["normal", 1119], ["appearing", 1126], ["neocortical", 1136], ["temporal", 1148], ["lobe", 1157], ["(", 1162], ["p", 1163], ["=", 1165], ["0.08", 1167], [")", 1171], ["or", 1173], ["diagnosis", 1176], ["of", 1186], ["FCD", 1189], ["by", 1193], ["visual", 1196], ["inspection", 1203], ["of", 1214], ["MRI", 1217], ["(", 1221], ["p", 1222], ["=", 1224], ["0.08", 1226], [")", 1230], [",", 1231], ["preoperative", 1233], ["seizure", 1246], ["frequency", 1254], ["(", 1264], ["p", 1265], ["=", 1267], ["0.06", 1269], [")", 1273], [",", 1274], ["and", 1276], ["the", 1280], ["predominance", 1284], ["of", 1297], ["an", 1300], ["epigastric", 1303], ["aura", 1314], ["(", 1319], ["p", 1320], ["=", 1322], ["0.08", 1324], [")", 1328], [".", 1329], ["The", 1331], ["postoperative", 1335], ["outcome", 1349], ["was", 1357], ["nearly", 1361], ["identical", 1368], ["1", 1378], ["year", 1380], ["(", 1385], ["p", 1386], ["=", 1388], ["0.8", 1390], [")", 1393], ["and", 1395], ["2", 1399], ["(", 1401], ["p", 1402], ["=", 1404], ["0.8", 1406], [")", 1409], [",", 1410], ["3", 1412], ["(", 1414], ["p", 1415], ["=", 1417], ["0.8", 1419], [")", 1422], [",", 1423], ["5", 1425], ["(", 1427], ["p", 1428], ["=", 1430], ["0.7", 1432], [")", 1435], [",", 1436], ["and", 1438], ["8", 1442], ["(", 1444], ["p", 1445], ["=", 1447], ["1.0", 1449], [")", 1452], ["years", 1454], ["postoperatively", 1460], [".", 1475], ["Only", 1477], ["febrile", 1482], ["seizures", 1490], ["(", 1499], ["p", 1500], ["=", 1502], ["0.025", 1504], [")", 1509], ["and", 1511], ["an", 1515], ["aura", 1518], ["(", 1523], ["p", 1524], ["=", 1526], ["0.03", 1528], [")", 1532], ["were", 1534], ["significantly", 1539], ["more", 1553], ["frequently", 1558], ["reported", 1569], ["in", 1578], ["patients", 1581], ["with", 1590], ["FCD", 1595], ["type", 1599], ["3a", 1604], [".", 1606], ["Similar", 1608], ["results", 1616], ["were", 1624], ["obtained", 1629], ["from", 1638], ["a", 1643], ["multivariate", 1645], ["logistic", 1658], ["regression", 1667], ["analysis", 1678], [".", 1686], ["Patients", 1688], ["with", 1697], ["FCD", 1702], ["type", 1706], ["2", 1711], ["were", 1713], ["more", 1718], ["different", 1723], [":", 1732], ["Compared", 1734], ["to", 1743], ["FCD", 1746], ["type", 1750], ["3a", 1755], [",", 1757], ["age", 1759], ["at", 1763], ["epilepsy", 1766], ["surgery", 1775], ["was", 1783], ["significantly", 1787], ["lower", 1801], ["(", 1807], ["p", 1808], ["=", 1810], ["0.004", 1812], [")", 1817], ["and", 1819], ["auras", 1823], ["(", 1829], ["p", 1830], ["=", 1832], ["0.005", 1834], [")", 1839], ["were", 1841], ["significantly", 1846], ["less", 1860], ["frequently", 1865], ["reported", 1876], [".", 1884], ["Epigastric", 1886], ["auras", 1897], ["(", 1903], ["p", 1904], ["=", 1906], ["0.04", 1908], [")", 1912], ["and", 1914], ["febrile", 1918], ["seizures", 1926], ["(", 1935], ["p", 1936], ["=", 1938], ["0.025", 1940], [")", 1945], ["occurred", 1947], ["significantly", 1956], ["less", 1970], ["frequently", 1975], ["in", 1986], ["patients", 1989], ["with", 1998], ["FCD", 2003], ["type", 2007], ["2", 2012], ["without", 2014], ["HS", 2022], ["compared", 2025], ["to", 2034], ["FCD", 2037], ["type", 2041], ["3a", 2046], [".", 2048], ["The", 2050], ["diagnosis", 2054], ["of", 2064], ["an", 2067], ["FCD", 2070], ["was", 2074], ["significantly", 2078], ["more", 2092], ["frequently", 2097], ["made", 2108], ["(", 2113], ["p", 2114], ["=", 2116], ["0.03", 2118], [")", 2122], ["by", 2124], ["visual", 2127], ["inspection", 2134], ["of", 2145], ["the", 2148], ["MRI", 2152], ["compared", 2156], ["to", 2165], ["FCD", 2168], ["type", 2172], ["1", 2177], [".", 2178], ["Clinical", 2180], ["features", 2189], ["did", 2198], ["not", 2202], ["allow", 2206], ["to", 2212], ["clear", 2215], ["separation", 2221], ["of", 2232], ["temporal", 2235], ["FCD", 2244], ["types", 2248], ["1", 2254], ["and", 2256], ["3a", 2260], [".", 2262], ["Statistically", 2264], ["significant", 2278], ["differences", 2290], ["were", 2302], ["seen", 2307], ["in", 2312], ["a", 2315], ["history", 2317], ["of", 2325], ["febrile", 2328], ["seizures", 2336], ["and", 2345], ["the", 2349], ["occurrence", 2353], ["of", 2364], ["auras", 2367], ["more", 2373], ["common", 2378], ["in", 2385], ["FCD", 2388], ["type", 2392], ["3a", 2397], [".", 2399], ["However", 2401], [",", 2408], ["FCD", 2410], ["type", 2414], ["2", 2419], ["in", 2421], ["the", 2424], ["same", 2428], ["localization", 2433], ["but", 2446], ["with", 2450], ["different", 2455], ["histology", 2465], ["presented", 2475], ["with", 2485], ["further", 2490], ["differences", 2498], ["such", 2510], ["as", 2515], ["more", 2518], ["frequent", 2523], ["FCD", 2532], ["diagnosis", 2536], ["by", 2546], ["visual", 2549], ["inspection", 2556], ["of", 2567], ["MRI", 2570], [",", 2573], ["earlier", 2575], ["operation", 2583], [",", 2592], ["and", 2594], ["less", 2598], ["frequent", 2603], ["epigastric", 2612], ["auras", 2623], [".", 2628]]}
{"context": "To evaluate the impact of a more limited paraurethral dissection, avoidance of perforating the obturator membrane with scissors or guide, and a more medial trajectory of the trocar in positioning the TVT-O device on stress urinary incontinence cure rates. One hundred and ten patients were recruited for this randomized, single blind, multicenter, non-inferiority study, with a 1:1 ratio to undergo the traditional (n=55) or the modified (n=55) technique. Preoperatively, patients underwent POP-Q staging, Q-tip test, challenge stress test and urodynamics, and completed the I-QoL, PISQ-12, and PGI-S questionnaires. During the post-operative period, patients attributed a pain VAS score 1, 3, 6, 12 and 24h after the procedure and were followed up at 12 months, undergoing the same baseline evaluations. The primary outcome was the cure rate (absence of urine leaks at the challenge stress test or urodynamic testing) one year after the procedure. The primary outcome was evaluated using a non-inferiority test. No differences were observed in cure rates (traditional technique 92.3% vs. modified technique 88.8% and non-inferiority P<0.05) and in questionnaire scores between the two groups. Post-operative pain was significantly lower in the modified technique group at each time point assessed, with the exception of 12h post-operatively. No differences between the two groups were observed in the number of analgesic vials administered. The modified technique does not seem to reduce the efficacy of TVT-O, but induces a reduction of post-operative pain.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "aee1887f35d54a65b4bb576170e07197", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[38, 40]], "char_spans": [[216, 242]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["impact", 16], ["of", 23], ["a", 26], ["more", 28], ["limited", 33], ["paraurethral", 41], ["dissection", 54], [",", 64], ["avoidance", 66], ["of", 76], ["perforating", 79], ["the", 91], ["obturator", 95], ["membrane", 105], ["with", 114], ["scissors", 119], ["or", 128], ["guide", 131], [",", 136], ["and", 138], ["a", 142], ["more", 144], ["medial", 149], ["trajectory", 156], ["of", 167], ["the", 170], ["trocar", 174], ["in", 181], ["positioning", 184], ["the", 196], ["TVT", 200], ["-", 203], ["O", 204], ["device", 206], ["on", 213], ["stress", 216], ["urinary", 223], ["incontinence", 231], ["cure", 244], ["rates", 249], [".", 254], ["One", 256], ["hundred", 260], ["and", 268], ["ten", 272], ["patients", 276], ["were", 285], ["recruited", 290], ["for", 300], ["this", 304], ["randomized", 309], [",", 319], ["single", 321], ["blind", 328], [",", 333], ["multicenter", 335], [",", 346], ["non", 348], ["-", 351], ["inferiority", 352], ["study", 364], [",", 369], ["with", 371], ["a", 376], ["1:1", 378], ["ratio", 382], ["to", 388], ["undergo", 391], ["the", 399], ["traditional", 403], ["(", 415], ["n=55", 416], [")", 420], ["or", 422], ["the", 425], ["modified", 429], ["(", 438], ["n=55", 439], [")", 443], ["technique", 445], [".", 454], ["Preoperatively", 456], [",", 470], ["patients", 472], ["underwent", 481], ["POP", 491], ["-", 494], ["Q", 495], ["staging", 497], [",", 504], ["Q", 506], ["-", 507], ["tip", 508], ["test", 512], [",", 516], ["challenge", 518], ["stress", 528], ["test", 535], ["and", 540], ["urodynamics", 544], [",", 555], ["and", 557], ["completed", 561], ["the", 571], ["I", 575], ["-", 576], ["QoL", 577], [",", 580], ["PISQ-12", 582], [",", 589], ["and", 591], ["PGI", 595], ["-", 598], ["S", 599], ["questionnaires", 601], [".", 615], ["During", 617], ["the", 624], ["post", 628], ["-", 632], ["operative", 633], ["period", 643], [",", 649], ["patients", 651], ["attributed", 660], ["a", 671], ["pain", 673], ["VAS", 678], ["score", 682], ["1", 688], [",", 689], ["3", 691], [",", 692], ["6", 694], [",", 695], ["12", 697], ["and", 700], ["24h", 704], ["after", 708], ["the", 714], ["procedure", 718], ["and", 728], ["were", 732], ["followed", 737], ["up", 746], ["at", 749], ["12", 752], ["months", 755], [",", 761], ["undergoing", 763], ["the", 774], ["same", 778], ["baseline", 783], ["evaluations", 792], [".", 803], ["The", 805], ["primary", 809], ["outcome", 817], ["was", 825], ["the", 829], ["cure", 833], ["rate", 838], ["(", 843], ["absence", 844], ["of", 852], ["urine", 855], ["leaks", 861], ["at", 867], ["the", 870], ["challenge", 874], ["stress", 884], ["test", 891], ["or", 896], ["urodynamic", 899], ["testing", 910], [")", 917], ["one", 919], ["year", 923], ["after", 928], ["the", 934], ["procedure", 938], [".", 947], ["The", 949], ["primary", 953], ["outcome", 961], ["was", 969], ["evaluated", 973], ["using", 983], ["a", 989], ["non", 991], ["-", 994], ["inferiority", 995], ["test", 1007], [".", 1011], ["No", 1013], ["differences", 1016], ["were", 1028], ["observed", 1033], ["in", 1042], ["cure", 1045], ["rates", 1050], ["(", 1056], ["traditional", 1057], ["technique", 1069], ["92.3", 1079], ["%", 1083], ["vs.", 1085], ["modified", 1089], ["technique", 1098], ["88.8", 1108], ["%", 1112], ["and", 1114], ["non", 1118], ["-", 1121], ["inferiority", 1122], ["P<0.05", 1134], [")", 1140], ["and", 1142], ["in", 1146], ["questionnaire", 1149], ["scores", 1163], ["between", 1170], ["the", 1178], ["two", 1182], ["groups", 1186], [".", 1192], ["Post", 1194], ["-", 1198], ["operative", 1199], ["pain", 1209], ["was", 1214], ["significantly", 1218], ["lower", 1232], ["in", 1238], ["the", 1241], ["modified", 1245], ["technique", 1254], ["group", 1264], ["at", 1270], ["each", 1273], ["time", 1278], ["point", 1283], ["assessed", 1289], [",", 1297], ["with", 1299], ["the", 1304], ["exception", 1308], ["of", 1318], ["12h", 1321], ["post", 1325], ["-", 1329], ["operatively", 1330], [".", 1341], ["No", 1343], ["differences", 1346], ["between", 1358], ["the", 1366], ["two", 1370], ["groups", 1374], ["were", 1381], ["observed", 1386], ["in", 1395], ["the", 1398], ["number", 1402], ["of", 1409], ["analgesic", 1412], ["vials", 1422], ["administered", 1428], [".", 1440], ["The", 1442], ["modified", 1446], ["technique", 1455], ["does", 1465], ["not", 1470], ["seem", 1474], ["to", 1479], ["reduce", 1482], ["the", 1489], ["efficacy", 1493], ["of", 1502], ["TVT", 1505], ["-", 1508], ["O", 1509], [",", 1510], ["but", 1512], ["induces", 1516], ["a", 1524], ["reduction", 1526], ["of", 1536], ["post", 1539], ["-", 1543], ["operative", 1544], ["pain", 1554], [".", 1558]]}
{"context": "Empagliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that inhibits renal glucose reabsorption and is being investigated for the treatment of type 2 diabetes mellitus (T2DM). In this open-label study, the effect of renal impairment on the pharmacokinetics, pharmacodynamics and safety of a 50\u2009mg dose of empagliflozin was investigated in 40 subjects, grouped according to estimated glomerular filtration rate (eGFR). Maximum empagliflozin plasma concentrations were similar in subjects with normal renal function and renal impairment. Area under the empagliflozin concentration-time curve (AUC0 -\u221e ) values increased by approximately 18, 20, 66 and 48% in subjects with mild, moderate, severe renal impairment and renal failure/end stage renal disease (ESRD), respectively, in comparison to healthy subjects. This was attributed to decreased renal clearance (CLR ). Urinary glucose excretion (UGE) decreased with increasing renal impairment and correlated with decreased eGFR and CLR . Empagliflozin was well tolerated, with no increase in adverse events associated with renal impairment. Renal insufficiency resulted in decreased CLR of empagliflozin, moderately increased systemic exposure and decreased UGE. A single 50\u2009mg dose of empagliflozin was well tolerated in subjects with normal renal function and any degree of renal impairment. The pharmacokinetic results of this study indicate that no dose adjustment of empagliflozin is required in patients with renal impairment.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "d298832c62de4e73ad3b013ea2443d51", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[9, 9]], "char_spans": [[61, 65]]}]}], "context_tokens": [["Empagliflozin", 0], ["is", 14], ["a", 17], ["selective", 19], ["sodium", 29], ["glucose", 36], ["cotransporter", 44], ["2", 58], ["(", 60], ["SGLT2", 61], [")", 66], ["inhibitor", 68], ["that", 78], ["inhibits", 83], ["renal", 92], ["glucose", 98], ["reabsorption", 106], ["and", 119], ["is", 123], ["being", 126], ["investigated", 132], ["for", 145], ["the", 149], ["treatment", 153], ["of", 163], ["type", 166], ["2", 171], ["diabetes", 173], ["mellitus", 182], ["(", 191], ["T2DM", 192], [")", 196], [".", 197], ["In", 199], ["this", 202], ["open", 207], ["-", 211], ["label", 212], ["study", 218], [",", 223], ["the", 225], ["effect", 229], ["of", 236], ["renal", 239], ["impairment", 245], ["on", 256], ["the", 259], ["pharmacokinetics", 263], [",", 279], ["pharmacodynamics", 281], ["and", 298], ["safety", 302], ["of", 309], ["a", 312], ["50", 314], ["mg", 317], ["dose", 320], ["of", 325], ["empagliflozin", 328], ["was", 342], ["investigated", 346], ["in", 359], ["40", 362], ["subjects", 365], [",", 373], ["grouped", 375], ["according", 383], ["to", 393], ["estimated", 396], ["glomerular", 406], ["filtration", 417], ["rate", 428], ["(", 433], ["eGFR", 434], [")", 438], [".", 439], ["Maximum", 441], ["empagliflozin", 449], ["plasma", 463], ["concentrations", 470], ["were", 485], ["similar", 490], ["in", 498], ["subjects", 501], ["with", 510], ["normal", 515], ["renal", 522], ["function", 528], ["and", 537], ["renal", 541], ["impairment", 547], [".", 557], ["Area", 559], ["under", 564], ["the", 570], ["empagliflozin", 574], ["concentration", 588], ["-", 601], ["time", 602], ["curve", 607], ["(", 613], ["AUC0", 614], ["-\u221e", 619], [")", 622], ["values", 624], ["increased", 631], ["by", 641], ["approximately", 644], ["18", 658], [",", 660], ["20", 662], [",", 664], ["66", 666], ["and", 669], ["48", 673], ["%", 675], ["in", 677], ["subjects", 680], ["with", 689], ["mild", 694], [",", 698], ["moderate", 700], [",", 708], ["severe", 710], ["renal", 717], ["impairment", 723], ["and", 734], ["renal", 738], ["failure", 744], ["/", 751], ["end", 752], ["stage", 756], ["renal", 762], ["disease", 768], ["(", 776], ["ESRD", 777], [")", 781], [",", 782], ["respectively", 784], [",", 796], ["in", 798], ["comparison", 801], ["to", 812], ["healthy", 815], ["subjects", 823], [".", 831], ["This", 833], ["was", 838], ["attributed", 842], ["to", 853], ["decreased", 856], ["renal", 866], ["clearance", 872], ["(", 882], ["CLR", 883], [")", 887], [".", 888], ["Urinary", 890], ["glucose", 898], ["excretion", 906], ["(", 916], ["UGE", 917], [")", 920], ["decreased", 922], ["with", 932], ["increasing", 937], ["renal", 948], ["impairment", 954], ["and", 965], ["correlated", 969], ["with", 980], ["decreased", 985], ["eGFR", 995], ["and", 1000], ["CLR", 1004], [".", 1008], ["Empagliflozin", 1010], ["was", 1024], ["well", 1028], ["tolerated", 1033], [",", 1042], ["with", 1044], ["no", 1049], ["increase", 1052], ["in", 1061], ["adverse", 1064], ["events", 1072], ["associated", 1079], ["with", 1090], ["renal", 1095], ["impairment", 1101], [".", 1111], ["Renal", 1113], ["insufficiency", 1119], ["resulted", 1133], ["in", 1142], ["decreased", 1145], ["CLR", 1155], ["of", 1159], ["empagliflozin", 1162], [",", 1175], ["moderately", 1177], ["increased", 1188], ["systemic", 1198], ["exposure", 1207], ["and", 1216], ["decreased", 1220], ["UGE", 1230], [".", 1233], ["A", 1235], ["single", 1237], ["50", 1244], ["mg", 1247], ["dose", 1250], ["of", 1255], ["empagliflozin", 1258], ["was", 1272], ["well", 1276], ["tolerated", 1281], ["in", 1291], ["subjects", 1294], ["with", 1303], ["normal", 1308], ["renal", 1315], ["function", 1321], ["and", 1330], ["any", 1334], ["degree", 1338], ["of", 1345], ["renal", 1348], ["impairment", 1354], [".", 1364], ["The", 1366], ["pharmacokinetic", 1370], ["results", 1386], ["of", 1394], ["this", 1397], ["study", 1402], ["indicate", 1408], ["that", 1417], ["no", 1422], ["dose", 1425], ["adjustment", 1430], ["of", 1441], ["empagliflozin", 1444], ["is", 1458], ["required", 1461], ["in", 1470], ["patients", 1473], ["with", 1482], ["renal", 1487], ["impairment", 1493], [".", 1503]]}
{"context": "Patients with multiple myeloma (MM) experience pathologic fractures, bone pain, hypercalcemia, neurologic symptoms, and renal insufficiency with substantial morbidity and mortality. Bisphosphonates have been used successfully for the management of MM-related bone disease. Increased incidence of osteonecrosis of the jaw has been observed in patients with cancer receiving bisphosphonate therapy. Recent advances in the pathobiology of MM-related bone disease and other cancer-related bone metastases have led to the identification of novel therapeutic targets, such as receptor activator of nuclear factor-kappaB (RANK); its ligand (RANKL); and a decoy receptor, osteoprotegerin, for the development of potential targeted agents. Initials studies have demonstrated that targeting RANK/ RANKL signaling with the fully human monoclonal antibody denosumab prevented skeletal complications in patients with MM and other cancers with bone metastases. Ongoing studies evaluating the clinical utility of denosumab in cancer- related bone destruction have been discussed. In addition, several potential targets, such as macrophage inflammatory protein-1alpha, chemokine receptors 1 and 5, interleukin-3, and Wnt signaling, are b riefly described.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "3e9485482dda405c9488b643f9e2b125", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[105, 105], [130, 130]], "char_spans": [[634, 638], [787, 791]]}]}], "context_tokens": [["Patients", 0], ["with", 9], ["multiple", 14], ["myeloma", 23], ["(", 31], ["MM", 32], [")", 34], ["experience", 36], ["pathologic", 47], ["fractures", 58], [",", 67], ["bone", 69], ["pain", 74], [",", 78], ["hypercalcemia", 80], [",", 93], ["neurologic", 95], ["symptoms", 106], [",", 114], ["and", 116], ["renal", 120], ["insufficiency", 126], ["with", 140], ["substantial", 145], ["morbidity", 157], ["and", 167], ["mortality", 171], [".", 180], ["Bisphosphonates", 182], ["have", 198], ["been", 203], ["used", 208], ["successfully", 213], ["for", 226], ["the", 230], ["management", 234], ["of", 245], ["MM", 248], ["-", 250], ["related", 251], ["bone", 259], ["disease", 264], [".", 271], ["Increased", 273], ["incidence", 283], ["of", 293], ["osteonecrosis", 296], ["of", 310], ["the", 313], ["jaw", 317], ["has", 321], ["been", 325], ["observed", 330], ["in", 339], ["patients", 342], ["with", 351], ["cancer", 356], ["receiving", 363], ["bisphosphonate", 373], ["therapy", 388], [".", 395], ["Recent", 397], ["advances", 404], ["in", 413], ["the", 416], ["pathobiology", 420], ["of", 433], ["MM", 436], ["-", 438], ["related", 439], ["bone", 447], ["disease", 452], ["and", 460], ["other", 464], ["cancer", 470], ["-", 476], ["related", 477], ["bone", 485], ["metastases", 490], ["have", 501], ["led", 506], ["to", 510], ["the", 513], ["identification", 517], ["of", 532], ["novel", 535], ["therapeutic", 541], ["targets", 553], [",", 560], ["such", 562], ["as", 567], ["receptor", 570], ["activator", 579], ["of", 589], ["nuclear", 592], ["factor", 600], ["-", 606], ["kappaB", 607], ["(", 614], ["RANK", 615], [")", 619], [";", 620], ["its", 622], ["ligand", 626], ["(", 633], ["RANKL", 634], [")", 639], [";", 640], ["and", 642], ["a", 646], ["decoy", 648], ["receptor", 654], [",", 662], ["osteoprotegerin", 664], [",", 679], ["for", 681], ["the", 685], ["development", 689], ["of", 701], ["potential", 704], ["targeted", 714], ["agents", 723], [".", 729], ["Initials", 731], ["studies", 740], ["have", 748], ["demonstrated", 753], ["that", 766], ["targeting", 771], ["RANK/", 781], ["RANKL", 787], ["signaling", 793], ["with", 803], ["the", 808], ["fully", 812], ["human", 818], ["monoclonal", 824], ["antibody", 835], ["denosumab", 844], ["prevented", 854], ["skeletal", 864], ["complications", 873], ["in", 887], ["patients", 890], ["with", 899], ["MM", 904], ["and", 907], ["other", 911], ["cancers", 917], ["with", 925], ["bone", 930], ["metastases", 935], [".", 945], ["Ongoing", 947], ["studies", 955], ["evaluating", 963], ["the", 974], ["clinical", 978], ["utility", 987], ["of", 995], ["denosumab", 998], ["in", 1008], ["cancer-", 1011], ["related", 1019], ["bone", 1027], ["destruction", 1032], ["have", 1044], ["been", 1049], ["discussed", 1054], [".", 1063], ["In", 1065], ["addition", 1068], [",", 1076], ["several", 1078], ["potential", 1086], ["targets", 1096], [",", 1103], ["such", 1105], ["as", 1110], ["macrophage", 1113], ["inflammatory", 1124], ["protein-1alpha", 1137], [",", 1151], ["chemokine", 1153], ["receptors", 1163], ["1", 1173], ["and", 1175], ["5", 1179], [",", 1180], ["interleukin-3", 1182], [",", 1195], ["and", 1197], ["Wnt", 1201], ["signaling", 1205], [",", 1214], ["are", 1216], ["b", 1220], ["riefly", 1222], ["described", 1229], [".", 1238]]}
{"context": "Mowat-Wilson syndrome is a genetic condition characterized by a recognizable facial phenotype in addition to moderate to severe cognitive disability with severe speech impairment and variable multiple congenital anomalies. The anomalies may include Hirschsprung disease, heart defects, structural eye anomalies including microphthalmia, agenesis of the corpus callosum, and urogenital anomalies. Microcephaly, seizure disorder and constipation are common. All typical cases result from haploinsufficiency of the ZEB2 (also known as ZFHX1B or SIP-1) gene, with over 100 distinct mutations now described. Approximately 80% of patients have a nonsense or frameshift mutation detectable by sequencing, with the rest having gross deletions necessitating a dosage sensitive assay. Here we report on the results of comprehensive molecular testing for 27 patients testing positive for MWS. Twenty-one patients had a nonsense, frameshift, or splice site mutation identified by sequencing; 14 of which localized to exon 8 and 17 of which are novel. Six patients had deletions in the ZEB2 gene, including two novel partial gene deletions. This report, the first such analysis in North American patients, adds to the growing list of both novel pathogenic mutations associated with MWS, as well as other variants in the ZEB2 gene. In addition, we suggest an economical testing strategy.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "6aab95b5bc40449b812caabddc308265", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[80, 80]], "char_spans": [[532, 537]]}, {"text": "ZEB2", "token_spans": [[220, 220], [75, 75], [177, 177]], "char_spans": [[1307, 1310], [512, 515], [1073, 1076]]}, {"text": "SIP-1", "token_spans": [[82, 82]], "char_spans": [[542, 546]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["genetic", 27], ["condition", 35], ["characterized", 45], ["by", 59], ["a", 62], ["recognizable", 64], ["facial", 77], ["phenotype", 84], ["in", 94], ["addition", 97], ["to", 106], ["moderate", 109], ["to", 118], ["severe", 121], ["cognitive", 128], ["disability", 138], ["with", 149], ["severe", 154], ["speech", 161], ["impairment", 168], ["and", 179], ["variable", 183], ["multiple", 192], ["congenital", 201], ["anomalies", 212], [".", 221], ["The", 223], ["anomalies", 227], ["may", 237], ["include", 241], ["Hirschsprung", 249], ["disease", 262], [",", 269], ["heart", 271], ["defects", 277], [",", 284], ["structural", 286], ["eye", 297], ["anomalies", 301], ["including", 311], ["microphthalmia", 321], [",", 335], ["agenesis", 337], ["of", 346], ["the", 349], ["corpus", 353], ["callosum", 360], [",", 368], ["and", 370], ["urogenital", 374], ["anomalies", 385], [".", 394], ["Microcephaly", 396], [",", 408], ["seizure", 410], ["disorder", 418], ["and", 427], ["constipation", 431], ["are", 444], ["common", 448], [".", 454], ["All", 456], ["typical", 460], ["cases", 468], ["result", 474], ["from", 481], ["haploinsufficiency", 486], ["of", 505], ["the", 508], ["ZEB2", 512], ["(", 517], ["also", 518], ["known", 523], ["as", 529], ["ZFHX1B", 532], ["or", 539], ["SIP-1", 542], [")", 547], ["gene", 549], [",", 553], ["with", 555], ["over", 560], ["100", 565], ["distinct", 569], ["mutations", 578], ["now", 588], ["described", 592], [".", 601], ["Approximately", 603], ["80", 617], ["%", 619], ["of", 621], ["patients", 624], ["have", 633], ["a", 638], ["nonsense", 640], ["or", 649], ["frameshift", 652], ["mutation", 663], ["detectable", 672], ["by", 683], ["sequencing", 686], [",", 696], ["with", 698], ["the", 703], ["rest", 707], ["having", 712], ["gross", 719], ["deletions", 725], ["necessitating", 735], ["a", 749], ["dosage", 751], ["sensitive", 758], ["assay", 768], [".", 773], ["Here", 775], ["we", 780], ["report", 783], ["on", 790], ["the", 793], ["results", 797], ["of", 805], ["comprehensive", 808], ["molecular", 822], ["testing", 832], ["for", 840], ["27", 844], ["patients", 847], ["testing", 856], ["positive", 864], ["for", 873], ["MWS", 877], [".", 880], ["Twenty", 882], ["-", 888], ["one", 889], ["patients", 893], ["had", 902], ["a", 906], ["nonsense", 908], [",", 916], ["frameshift", 918], [",", 928], ["or", 930], ["splice", 933], ["site", 940], ["mutation", 945], ["identified", 954], ["by", 965], ["sequencing", 968], [";", 978], ["14", 980], ["of", 983], ["which", 986], ["localized", 992], ["to", 1002], ["exon", 1005], ["8", 1010], ["and", 1012], ["17", 1016], ["of", 1019], ["which", 1022], ["are", 1028], ["novel", 1032], [".", 1037], ["Six", 1039], ["patients", 1043], ["had", 1052], ["deletions", 1056], ["in", 1066], ["the", 1069], ["ZEB2", 1073], ["gene", 1078], [",", 1082], ["including", 1084], ["two", 1094], ["novel", 1098], ["partial", 1104], ["gene", 1112], ["deletions", 1117], [".", 1126], ["This", 1128], ["report", 1133], [",", 1139], ["the", 1141], ["first", 1145], ["such", 1151], ["analysis", 1156], ["in", 1165], ["North", 1168], ["American", 1174], ["patients", 1183], [",", 1191], ["adds", 1193], ["to", 1198], ["the", 1201], ["growing", 1205], ["list", 1213], ["of", 1218], ["both", 1221], ["novel", 1226], ["pathogenic", 1232], ["mutations", 1243], ["associated", 1253], ["with", 1264], ["MWS", 1269], [",", 1272], ["as", 1274], ["well", 1277], ["as", 1282], ["other", 1285], ["variants", 1291], ["in", 1300], ["the", 1303], ["ZEB2", 1307], ["gene", 1312], [".", 1316], ["In", 1318], ["addition", 1321], [",", 1329], ["we", 1331], ["suggest", 1334], ["an", 1342], ["economical", 1345], ["testing", 1356], ["strategy", 1364], [".", 1372]]}
{"context": "Mutations in NOTCH3 are the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a hereditary angiopathy causing stroke and vascular dementia. All CADASIL mutations identified so far result in the loss or gain of one cysteine residue within epidermal growth factor (EGF)-like repeat domains. Here an in-frame deletion causing a loss of three cysteine residues within EGF repeat 6 is reported. These data are consistent with the hypothesis that the change toward an odd number of cysteine residues within a given EGF repeat and therefore an unpaired, reactive cysteine residue is the common and critical molecular event in CADASIL.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "04da2c70e07e4c2581afe158af0e1759", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[65, 65], [89, 89], [43, 43], [102, 102]], "char_spans": [[400, 407], [537, 544], [275, 282], [617, 624]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["NOTCH3", 13], ["are", 20], ["the", 24], ["cause", 28], ["of", 34], ["cerebral", 37], ["autosomal", 46], ["dominant", 56], ["arteriopathy", 65], ["with", 78], ["subcortical", 83], ["infarcts", 95], ["and", 104], ["leukoencephalopathy", 108], ["(", 128], ["CADASIL", 129], [")", 136], [",", 137], ["a", 139], ["hereditary", 141], ["angiopathy", 152], ["causing", 163], ["stroke", 171], ["and", 178], ["vascular", 182], ["dementia", 191], [".", 199], ["All", 201], ["CADASIL", 205], ["mutations", 213], ["identified", 223], ["so", 234], ["far", 237], ["result", 241], ["in", 248], ["the", 251], ["loss", 255], ["or", 260], ["gain", 263], ["of", 268], ["one", 271], ["cysteine", 275], ["residue", 284], ["within", 292], ["epidermal", 299], ["growth", 309], ["factor", 316], ["(", 323], ["EGF)-like", 324], ["repeat", 334], ["domains", 341], [".", 348], ["Here", 350], ["an", 355], ["in", 358], ["-", 360], ["frame", 361], ["deletion", 367], ["causing", 376], ["a", 384], ["loss", 386], ["of", 391], ["three", 394], ["cysteine", 400], ["residues", 409], ["within", 418], ["EGF", 425], ["repeat", 429], ["6", 436], ["is", 438], ["reported", 441], [".", 449], ["These", 451], ["data", 457], ["are", 462], ["consistent", 466], ["with", 477], ["the", 482], ["hypothesis", 486], ["that", 497], ["the", 502], ["change", 506], ["toward", 513], ["an", 520], ["odd", 523], ["number", 527], ["of", 534], ["cysteine", 537], ["residues", 546], ["within", 555], ["a", 562], ["given", 564], ["EGF", 570], ["repeat", 574], ["and", 581], ["therefore", 585], ["an", 595], ["unpaired", 598], [",", 606], ["reactive", 608], ["cysteine", 617], ["residue", 626], ["is", 634], ["the", 637], ["common", 641], ["and", 648], ["critical", 652], ["molecular", 661], ["event", 671], ["in", 677], ["CADASIL", 680], [".", 687]]}
{"context": "Nerve growth factor (NGF) is indispensable during normal embryonic development and critical for the amplification of pain signals in adults. Intervention in NGF signaling holds promise for the alleviation of pain resulting from human diseases such as osteoarthritis, cancer and chronic lower back disorders. We developed a fast, high-fidelity method to convert a hybridoma-derived NGF-targeted mouse antibody into a clinical candidate. This method, termed Library Scanning Mutagenesis (LSM), resulted in the ultra-high affinity antibody tanezumab, a first-in-class anti-hyperalgesic specific for an NGF epitope. Functional and structural comparisons between tanezumab and the mouse 911 precursor antibody using neurotrophin-specific cell survival assays and X-ray crystal structures of both Fab-antigen complexes illustrated high fidelity retention of the NGF epitope. These results suggest the potential for wide applicability of the LSM method for optimization of well-characterized antibodies during humanization.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "702ca078e3664e4f8f2e876395b0f7d4", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "NGF", "token_spans": [[64, 64], [107, 107], [147, 147], [4, 4], [25, 25]], "char_spans": [[381, 383], [599, 601], [856, 858], [21, 23], [157, 159]]}]}], "context_tokens": [["Nerve", 0], ["growth", 6], ["factor", 13], ["(", 20], ["NGF", 21], [")", 24], ["is", 26], ["indispensable", 29], ["during", 43], ["normal", 50], ["embryonic", 57], ["development", 67], ["and", 79], ["critical", 83], ["for", 92], ["the", 96], ["amplification", 100], ["of", 114], ["pain", 117], ["signals", 122], ["in", 130], ["adults", 133], [".", 139], ["Intervention", 141], ["in", 154], ["NGF", 157], ["signaling", 161], ["holds", 171], ["promise", 177], ["for", 185], ["the", 189], ["alleviation", 193], ["of", 205], ["pain", 208], ["resulting", 213], ["from", 223], ["human", 228], ["diseases", 234], ["such", 243], ["as", 248], ["osteoarthritis", 251], [",", 265], ["cancer", 267], ["and", 274], ["chronic", 278], ["lower", 286], ["back", 292], ["disorders", 297], [".", 306], ["We", 308], ["developed", 311], ["a", 321], ["fast", 323], [",", 327], ["high", 329], ["-", 333], ["fidelity", 334], ["method", 343], ["to", 350], ["convert", 353], ["a", 361], ["hybridoma", 363], ["-", 372], ["derived", 373], ["NGF", 381], ["-", 384], ["targeted", 385], ["mouse", 394], ["antibody", 400], ["into", 409], ["a", 414], ["clinical", 416], ["candidate", 425], [".", 434], ["This", 436], ["method", 441], [",", 447], ["termed", 449], ["Library", 456], ["Scanning", 464], ["Mutagenesis", 473], ["(", 485], ["LSM", 486], [")", 489], [",", 490], ["resulted", 492], ["in", 501], ["the", 504], ["ultra", 508], ["-", 513], ["high", 514], ["affinity", 519], ["antibody", 528], ["tanezumab", 537], [",", 546], ["a", 548], ["first", 550], ["-", 555], ["in", 556], ["-", 558], ["class", 559], ["anti", 565], ["-", 569], ["hyperalgesic", 570], ["specific", 583], ["for", 592], ["an", 596], ["NGF", 599], ["epitope", 603], [".", 610], ["Functional", 612], ["and", 623], ["structural", 627], ["comparisons", 638], ["between", 650], ["tanezumab", 658], ["and", 668], ["the", 672], ["mouse", 676], ["911", 682], ["precursor", 686], ["antibody", 696], ["using", 705], ["neurotrophin", 711], ["-", 723], ["specific", 724], ["cell", 733], ["survival", 738], ["assays", 747], ["and", 754], ["X", 758], ["-", 759], ["ray", 760], ["crystal", 764], ["structures", 772], ["of", 783], ["both", 786], ["Fab", 791], ["-", 794], ["antigen", 795], ["complexes", 803], ["illustrated", 813], ["high", 825], ["fidelity", 830], ["retention", 839], ["of", 849], ["the", 852], ["NGF", 856], ["epitope", 860], [".", 867], ["These", 869], ["results", 875], ["suggest", 883], ["the", 891], ["potential", 895], ["for", 905], ["wide", 909], ["applicability", 914], ["of", 928], ["the", 931], ["LSM", 935], ["method", 939], ["for", 946], ["optimization", 950], ["of", 963], ["well", 966], ["-", 970], ["characterized", 971], ["antibodies", 985], ["during", 996], ["humanization", 1003], [".", 1015]]}
{"context": "A study was carried out on 200 patients of ages 20-40 years suffering from acute viral hepatitis. Sera were tested for markers of hepatitis B (HBsAg, and IgM anti-HBc) and hepatitis A (IgM-anti-HAV) by the ELISA technique. Sera negative for the markers of both viruses: Hepatitis A (HAV) and Hepatitis B (HBV) were subsequently tested for IGM Heterophil antibodies against Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV (IgM) by ELISA technique for the diagnosis of acute Cytomegalovirus (CMV) infection. Non-A, non-B hepatitis (NANB) was diagnosed by exclusion. The results of the study showed that 133 (66.5%) patients had evidence of HBV infection, while only 9(4.5%) were diagnosed as HAV infection. EBV and CMV were the possible etiological agents of acute viral hepatitis in (3.5%) and 1%) respectively. Accordingly the Non-A, non-B hepatitis in this study amounts to (24.5%) of the acute viral hepatitis.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "c5f3d85f9a094b98b72b423fbde816d2", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[80, 83]], "char_spans": [[373, 390]]}]}], "context_tokens": [["A", 0], ["study", 2], ["was", 8], ["carried", 12], ["out", 20], ["on", 24], ["200", 27], ["patients", 31], ["of", 40], ["ages", 43], ["20", 48], ["-", 50], ["40", 51], ["years", 54], ["suffering", 60], ["from", 70], ["acute", 75], ["viral", 81], ["hepatitis", 87], [".", 96], ["Sera", 98], ["were", 103], ["tested", 108], ["for", 115], ["markers", 119], ["of", 127], ["hepatitis", 130], ["B", 140], ["(", 142], ["HBsAg", 143], [",", 148], ["and", 150], ["IgM", 154], ["anti", 158], ["-", 162], ["HBc", 163], [")", 166], ["and", 168], ["hepatitis", 172], ["A", 182], ["(", 184], ["IgM", 185], ["-", 188], ["anti", 189], ["-", 193], ["HAV", 194], [")", 197], ["by", 199], ["the", 202], ["ELISA", 206], ["technique", 212], [".", 221], ["Sera", 223], ["negative", 228], ["for", 237], ["the", 241], ["markers", 245], ["of", 253], ["both", 256], ["viruses", 261], [":", 268], ["Hepatitis", 270], ["A", 280], ["(", 282], ["HAV", 283], [")", 286], ["and", 288], ["Hepatitis", 292], ["B", 302], ["(", 304], ["HBV", 305], [")", 308], ["were", 310], ["subsequently", 315], ["tested", 328], ["for", 335], ["IGM", 339], ["Heterophil", 343], ["antibodies", 354], ["against", 365], ["Epstein", 373], ["-", 380], ["Barr", 381], ["virus", 386], ["(", 392], ["EBV", 393], [")", 396], ["by", 398], ["the", 401], ["Monospot", 405], ["slide", 414], ["test", 420], ["to", 425], ["diagnose", 428], ["acute", 437], ["infectious", 443], ["mononucleosis", 454], ["and", 468], ["tested", 472], ["for", 479], ["anti", 483], ["-", 487], ["CMV", 488], ["(", 492], ["IgM", 493], [")", 496], ["by", 498], ["ELISA", 501], ["technique", 507], ["for", 517], ["the", 521], ["diagnosis", 525], ["of", 535], ["acute", 538], ["Cytomegalovirus", 544], ["(", 560], ["CMV", 561], [")", 564], ["infection", 566], [".", 575], ["Non", 577], ["-", 580], ["A", 581], [",", 582], ["non", 584], ["-", 587], ["B", 588], ["hepatitis", 590], ["(", 600], ["NANB", 601], [")", 605], ["was", 607], ["diagnosed", 611], ["by", 621], ["exclusion", 624], [".", 633], ["The", 635], ["results", 639], ["of", 647], ["the", 650], ["study", 654], ["showed", 660], ["that", 667], ["133", 672], ["(", 676], ["66.5", 677], ["%", 681], [")", 682], ["patients", 684], ["had", 693], ["evidence", 697], ["of", 706], ["HBV", 709], ["infection", 713], [",", 722], ["while", 724], ["only", 730], ["9(4.5", 735], ["%", 740], [")", 741], ["were", 743], ["diagnosed", 748], ["as", 758], ["HAV", 761], ["infection", 765], [".", 774], ["EBV", 776], ["and", 780], ["CMV", 784], ["were", 788], ["the", 793], ["possible", 797], ["etiological", 806], ["agents", 818], ["of", 825], ["acute", 828], ["viral", 834], ["hepatitis", 840], ["in", 850], ["(", 853], ["3.5", 854], ["%", 857], [")", 858], ["and", 860], ["1", 864], ["%", 865], [")", 866], ["respectively", 868], [".", 880], ["Accordingly", 882], ["the", 894], ["Non", 898], ["-", 901], ["A", 902], [",", 903], ["non", 905], ["-", 908], ["B", 909], ["hepatitis", 911], ["in", 921], ["this", 924], ["study", 929], ["amounts", 935], ["to", 943], ["(", 946], ["24.5", 947], ["%", 951], [")", 952], ["of", 954], ["the", 957], ["acute", 961], ["viral", 967], ["hepatitis", 973], [".", 982]]}
{"context": "It was found in the present study that combined use of fusidic acid (FA) and berberine chloride (BBR) offered an in vitro synergistic action against 7 of the 30 clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, with a fractional inhibitory concentration (FIC) index ranging from 0.5 to 0.19. This synergistic effect was most pronounced on MRSA 4806, an FA-resistant isolate, with a minimum inhibitory concentration (MIC) value of 1,024 \u03bcg/ml. The time-kill curve experiment showed that FA plus BBR yielded a 4.2 log10 c.f.u./ml reduction in the number of MRSA 4806 bacteria after 24-h incubation as compared with BBR alone. Viable count analysis showed that FA plus BBR produced a 3.0 log10 c.f.u./ml decrease in biofilm formation and a 1.5 log10 c.f.u./ml decrease in mature biofilm in viable cell density as compared with BBR alone. In addition, phase contrast micrographs confirmed that biofilm formation was significantly inhibited and mature biofilm was obviously destructed when FA was used in combination with BBR. These results provide evidence that combined use of FA and BBR may prove to be a promising clinical therapeutic strategy against MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "4cf67c0ee39c479999455e6a1bb0566a", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[40, 40], [208, 208], [111, 111], [66, 66]], "char_spans": [[215, 218], [1170, 1173], [574, 577], [358, 361]]}]}], "context_tokens": [["It", 0], ["was", 3], ["found", 7], ["in", 13], ["the", 16], ["present", 20], ["study", 28], ["that", 34], ["combined", 39], ["use", 48], ["of", 52], ["fusidic", 55], ["acid", 63], ["(", 68], ["FA", 69], [")", 71], ["and", 73], ["berberine", 77], ["chloride", 87], ["(", 96], ["BBR", 97], [")", 100], ["offered", 102], ["an", 110], ["in", 113], ["vitro", 116], ["synergistic", 122], ["action", 134], ["against", 141], ["7", 149], ["of", 151], ["the", 154], ["30", 158], ["clinical", 161], ["methicillin", 170], ["-", 181], ["resistant", 182], ["Staphylococcus", 192], ["aureus", 207], ["(", 214], ["MRSA", 215], [")", 219], ["strains", 221], [",", 228], ["with", 230], ["a", 235], ["fractional", 237], ["inhibitory", 248], ["concentration", 259], ["(", 273], ["FIC", 274], [")", 277], ["index", 279], ["ranging", 285], ["from", 293], ["0.5", 298], ["to", 302], ["0.19", 305], [".", 309], ["This", 311], ["synergistic", 316], ["effect", 328], ["was", 335], ["most", 339], ["pronounced", 344], ["on", 355], ["MRSA", 358], ["4806", 363], [",", 367], ["an", 369], ["FA", 372], ["-", 374], ["resistant", 375], ["isolate", 385], [",", 392], ["with", 394], ["a", 399], ["minimum", 401], ["inhibitory", 409], ["concentration", 420], ["(", 434], ["MIC", 435], [")", 438], ["value", 440], ["of", 446], ["1,024", 449], ["\u03bcg", 455], ["/", 457], ["ml", 458], [".", 460], ["The", 462], ["time", 466], ["-", 470], ["kill", 471], ["curve", 476], ["experiment", 482], ["showed", 493], ["that", 500], ["FA", 505], ["plus", 508], ["BBR", 513], ["yielded", 517], ["a", 525], ["4.2", 527], ["log10", 531], ["c.f.u./ml", 537], ["reduction", 547], ["in", 557], ["the", 560], ["number", 564], ["of", 571], ["MRSA", 574], ["4806", 579], ["bacteria", 584], ["after", 593], ["24-h", 599], ["incubation", 604], ["as", 615], ["compared", 618], ["with", 627], ["BBR", 632], ["alone", 636], [".", 641], ["Viable", 643], ["count", 650], ["analysis", 656], ["showed", 665], ["that", 672], ["FA", 677], ["plus", 680], ["BBR", 685], ["produced", 689], ["a", 698], ["3.0", 700], ["log10", 704], ["c.f.u./ml", 710], ["decrease", 720], ["in", 729], ["biofilm", 732], ["formation", 740], ["and", 750], ["a", 754], ["1.5", 756], ["log10", 760], ["c.f.u./ml", 766], ["decrease", 776], ["in", 785], ["mature", 788], ["biofilm", 795], ["in", 803], ["viable", 806], ["cell", 813], ["density", 818], ["as", 826], ["compared", 829], ["with", 838], ["BBR", 843], ["alone", 847], [".", 852], ["In", 854], ["addition", 857], [",", 865], ["phase", 867], ["contrast", 873], ["micrographs", 882], ["confirmed", 894], ["that", 904], ["biofilm", 909], ["formation", 917], ["was", 927], ["significantly", 931], ["inhibited", 945], ["and", 955], ["mature", 959], ["biofilm", 966], ["was", 974], ["obviously", 978], ["destructed", 988], ["when", 999], ["FA", 1004], ["was", 1007], ["used", 1011], ["in", 1016], ["combination", 1019], ["with", 1031], ["BBR", 1036], [".", 1039], ["These", 1041], ["results", 1047], ["provide", 1055], ["evidence", 1063], ["that", 1072], ["combined", 1077], ["use", 1086], ["of", 1090], ["FA", 1093], ["and", 1096], ["BBR", 1100], ["may", 1104], ["prove", 1108], ["to", 1114], ["be", 1117], ["a", 1120], ["promising", 1122], ["clinical", 1132], ["therapeutic", 1141], ["strategy", 1153], ["against", 1162], ["MRSA", 1170], [".", 1174]]}
{"context": "Allele-specific gene silencing by RNA interference (RNAi) is therapeutically useful for specifically suppressing the expression of alleles associated with disease. To realize such allele-specific RNAi (ASPRNAi), the design and assessment of small interfering RNA (siRNA) duplexes conferring ASP-RNAi is vital, but is also difficult. Here, we show ASP-RNAi against the Swedish- and London-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease using two reporter alleles encoding the Photinus and Renilla luciferase genes and carrying mutant and wild-type allelic sequences in their 3'-untranslated regions. We examined the effects of siRNA duplexes against the mutant alleles in allele-specific gene silencing and off-target silencing against the wild-type allele under heterozygous conditions, which were generated by cotransfecting the reporter alleles and siRNA duplexes into cultured human cells. Consistently, the siRNA duplexes determined to confer ASP-RNAi also inhibited the expression of the bona fide mutant APP and the production of either amyloid beta 40- or 42-peptide in Cos-7 cells expressing both the full-length Swedish- and wild-type APP alleles. The present data suggest that the system with reporter alleles may permit the preclinical assessment of siRNA duplexes conferring ASP-RNAi, and thus contribute to the design and selection of the most suitable of such siRNA duplexes.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "32973e8f67554664bd82736f4b992923", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[84, 86]], "char_spans": [[454, 472]]}]}], "context_tokens": [["Allele", 0], ["-", 6], ["specific", 7], ["gene", 16], ["silencing", 21], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["is", 58], ["therapeutically", 61], ["useful", 77], ["for", 84], ["specifically", 88], ["suppressing", 101], ["the", 113], ["expression", 117], ["of", 128], ["alleles", 131], ["associated", 139], ["with", 150], ["disease", 155], [".", 162], ["To", 164], ["realize", 167], ["such", 175], ["allele", 180], ["-", 186], ["specific", 187], ["RNAi", 196], ["(", 201], ["ASPRNAi", 202], [")", 209], [",", 210], ["the", 212], ["design", 216], ["and", 223], ["assessment", 227], ["of", 238], ["small", 241], ["interfering", 247], ["RNA", 259], ["(", 263], ["siRNA", 264], [")", 269], ["duplexes", 271], ["conferring", 280], ["ASP", 291], ["-", 294], ["RNAi", 295], ["is", 300], ["vital", 303], [",", 308], ["but", 310], ["is", 314], ["also", 317], ["difficult", 322], [".", 331], ["Here", 333], [",", 337], ["we", 339], ["show", 342], ["ASP", 347], ["-", 350], ["RNAi", 351], ["against", 356], ["the", 364], ["Swedish-", 368], ["and", 377], ["London", 381], ["-", 387], ["type", 388], ["amyloid", 393], ["precursor", 401], ["protein", 411], ["(", 419], ["APP", 420], [")", 423], ["variants", 425], ["related", 434], ["to", 442], ["familial", 445], ["Alzheimer", 454], ["'s", 463], ["disease", 466], ["using", 474], ["two", 480], ["reporter", 484], ["alleles", 493], ["encoding", 501], ["the", 510], ["Photinus", 514], ["and", 523], ["Renilla", 527], ["luciferase", 535], ["genes", 546], ["and", 552], ["carrying", 556], ["mutant", 565], ["and", 572], ["wild", 576], ["-", 580], ["type", 581], ["allelic", 586], ["sequences", 594], ["in", 604], ["their", 607], ["3'-untranslated", 613], ["regions", 629], [".", 636], ["We", 638], ["examined", 641], ["the", 650], ["effects", 654], ["of", 662], ["siRNA", 665], ["duplexes", 671], ["against", 680], ["the", 688], ["mutant", 692], ["alleles", 699], ["in", 707], ["allele", 710], ["-", 716], ["specific", 717], ["gene", 726], ["silencing", 731], ["and", 741], ["off", 745], ["-", 748], ["target", 749], ["silencing", 756], ["against", 766], ["the", 774], ["wild", 778], ["-", 782], ["type", 783], ["allele", 788], ["under", 795], ["heterozygous", 801], ["conditions", 814], [",", 824], ["which", 826], ["were", 832], ["generated", 837], ["by", 847], ["cotransfecting", 850], ["the", 865], ["reporter", 869], ["alleles", 878], ["and", 886], ["siRNA", 890], ["duplexes", 896], ["into", 905], ["cultured", 910], ["human", 919], ["cells", 925], [".", 930], ["Consistently", 932], [",", 944], ["the", 946], ["siRNA", 950], ["duplexes", 956], ["determined", 965], ["to", 976], ["confer", 979], ["ASP", 986], ["-", 989], ["RNAi", 990], ["also", 995], ["inhibited", 1000], ["the", 1010], ["expression", 1014], ["of", 1025], ["the", 1028], ["bona", 1032], ["fide", 1037], ["mutant", 1042], ["APP", 1049], ["and", 1053], ["the", 1057], ["production", 1061], ["of", 1072], ["either", 1075], ["amyloid", 1082], ["beta", 1090], ["40-", 1095], ["or", 1099], ["42-peptide", 1102], ["in", 1113], ["Cos-7", 1116], ["cells", 1122], ["expressing", 1128], ["both", 1139], ["the", 1144], ["full", 1148], ["-", 1152], ["length", 1153], ["Swedish-", 1160], ["and", 1169], ["wild", 1173], ["-", 1177], ["type", 1178], ["APP", 1183], ["alleles", 1187], [".", 1194], ["The", 1196], ["present", 1200], ["data", 1208], ["suggest", 1213], ["that", 1221], ["the", 1226], ["system", 1230], ["with", 1237], ["reporter", 1242], ["alleles", 1251], ["may", 1259], ["permit", 1263], ["the", 1270], ["preclinical", 1274], ["assessment", 1286], ["of", 1297], ["siRNA", 1300], ["duplexes", 1306], ["conferring", 1315], ["ASP", 1326], ["-", 1329], ["RNAi", 1330], [",", 1334], ["and", 1336], ["thus", 1340], ["contribute", 1345], ["to", 1356], ["the", 1359], ["design", 1363], ["and", 1370], ["selection", 1374], ["of", 1384], ["the", 1387], ["most", 1391], ["suitable", 1396], ["of", 1405], ["such", 1408], ["siRNA", 1413], ["duplexes", 1419], [".", 1427]]}
{"context": "Prior studies, all using SPECT techniques, failed to find any differences for dopamine transporter (DAT) in restless legs syndrome (RLS) subjects. The distinct pharmacokinetic properties associated with SPECT-determined DAT along with rapid biodynamic changes in DAT may, however, have missed membrane-bound DAT differences. The current studies assessed real-time DAT binding potentials (BP) in striatum of RLS patients using (11)C-methylphenidate and PET techniques. RLS medications were stopped at least 11 days prior to the PET study. Clinical severity of RLS was also assessed. PET scans were performed at 2 different times of day (starting at 08:30 and 19:30) in separate groups of subjects. The primary outcome measure was total striatal DAT BP. Thirty-six patients with primary RLS and 34 age- and gender-matched controls. RLS subjects had significantly lower DAT binding in the striatum compared to controls on both the Day and the Night scans. DAT was decreased in putamen and caudate but not the ventral striatum of RLS subjects. There were no diurnal differences in DAT for the total group or for control and RLS separately. DAT BP did not correlate with any clinical measures of RLS. The current study found a significant decrease in DAT BP in two independent studies. These results when viewed along with prior RLS SPECT and autopsy studies of DAT, and cell culture studies with iron deficiency and DAT, suggest that membrane-bound striatal DAT, but not total cellular DAT, may be decreased in RLS.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "b2a12b8918344a65a2cc5f9b028e8d2b", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[258, 258]], "char_spans": [[1392, 1395]]}]}], "context_tokens": [["Prior", 0], ["studies", 6], [",", 13], ["all", 15], ["using", 19], ["SPECT", 25], ["techniques", 31], [",", 41], ["failed", 43], ["to", 50], ["find", 53], ["any", 58], ["differences", 62], ["for", 74], ["dopamine", 78], ["transporter", 87], ["(", 99], ["DAT", 100], [")", 103], ["in", 105], ["restless", 108], ["legs", 117], ["syndrome", 122], ["(", 131], ["RLS", 132], [")", 135], ["subjects", 137], [".", 145], ["The", 147], ["distinct", 151], ["pharmacokinetic", 160], ["properties", 176], ["associated", 187], ["with", 198], ["SPECT", 203], ["-", 208], ["determined", 209], ["DAT", 220], ["along", 224], ["with", 230], ["rapid", 235], ["biodynamic", 241], ["changes", 252], ["in", 260], ["DAT", 263], ["may", 267], [",", 270], ["however", 272], [",", 279], ["have", 281], ["missed", 286], ["membrane", 293], ["-", 301], ["bound", 302], ["DAT", 308], ["differences", 312], [".", 323], ["The", 325], ["current", 329], ["studies", 337], ["assessed", 345], ["real", 354], ["-", 358], ["time", 359], ["DAT", 364], ["binding", 368], ["potentials", 376], ["(", 387], ["BP", 388], [")", 390], ["in", 392], ["striatum", 395], ["of", 404], ["RLS", 407], ["patients", 411], ["using", 420], ["(", 426], ["11)C", 427], ["-", 431], ["methylphenidate", 432], ["and", 448], ["PET", 452], ["techniques", 456], [".", 466], ["RLS", 468], ["medications", 472], ["were", 484], ["stopped", 489], ["at", 497], ["least", 500], ["11", 506], ["days", 509], ["prior", 514], ["to", 520], ["the", 523], ["PET", 527], ["study", 531], [".", 536], ["Clinical", 538], ["severity", 547], ["of", 556], ["RLS", 559], ["was", 563], ["also", 567], ["assessed", 572], [".", 580], ["PET", 582], ["scans", 586], ["were", 592], ["performed", 597], ["at", 607], ["2", 610], ["different", 612], ["times", 622], ["of", 628], ["day", 631], ["(", 635], ["starting", 636], ["at", 645], ["08:30", 648], ["and", 654], ["19:30", 658], [")", 663], ["in", 665], ["separate", 668], ["groups", 677], ["of", 684], ["subjects", 687], [".", 695], ["The", 697], ["primary", 701], ["outcome", 709], ["measure", 717], ["was", 725], ["total", 729], ["striatal", 735], ["DAT", 744], ["BP", 748], [".", 750], ["Thirty", 752], ["-", 758], ["six", 759], ["patients", 763], ["with", 772], ["primary", 777], ["RLS", 785], ["and", 789], ["34", 793], ["age-", 796], ["and", 801], ["gender", 805], ["-", 811], ["matched", 812], ["controls", 820], [".", 828], ["RLS", 830], ["subjects", 834], ["had", 843], ["significantly", 847], ["lower", 861], ["DAT", 867], ["binding", 871], ["in", 879], ["the", 882], ["striatum", 886], ["compared", 895], ["to", 904], ["controls", 907], ["on", 916], ["both", 919], ["the", 924], ["Day", 928], ["and", 932], ["the", 936], ["Night", 940], ["scans", 946], [".", 951], ["DAT", 953], ["was", 957], ["decreased", 961], ["in", 971], ["putamen", 974], ["and", 982], ["caudate", 986], ["but", 994], ["not", 998], ["the", 1002], ["ventral", 1006], ["striatum", 1014], ["of", 1023], ["RLS", 1026], ["subjects", 1030], [".", 1038], ["There", 1040], ["were", 1046], ["no", 1051], ["diurnal", 1054], ["differences", 1062], ["in", 1074], ["DAT", 1077], ["for", 1081], ["the", 1085], ["total", 1089], ["group", 1095], ["or", 1101], ["for", 1104], ["control", 1108], ["and", 1116], ["RLS", 1120], ["separately", 1124], [".", 1134], ["DAT", 1136], ["BP", 1140], ["did", 1143], ["not", 1147], ["correlate", 1151], ["with", 1161], ["any", 1166], ["clinical", 1170], ["measures", 1179], ["of", 1188], ["RLS", 1191], [".", 1194], ["The", 1196], ["current", 1200], ["study", 1208], ["found", 1214], ["a", 1220], ["significant", 1222], ["decrease", 1234], ["in", 1243], ["DAT", 1246], ["BP", 1250], ["in", 1253], ["two", 1256], ["independent", 1260], ["studies", 1272], [".", 1279], ["These", 1281], ["results", 1287], ["when", 1295], ["viewed", 1300], ["along", 1307], ["with", 1313], ["prior", 1318], ["RLS", 1324], ["SPECT", 1328], ["and", 1334], ["autopsy", 1338], ["studies", 1346], ["of", 1354], ["DAT", 1357], [",", 1360], ["and", 1362], ["cell", 1366], ["culture", 1371], ["studies", 1379], ["with", 1387], ["iron", 1392], ["deficiency", 1397], ["and", 1408], ["DAT", 1412], [",", 1415], ["suggest", 1417], ["that", 1425], ["membrane", 1430], ["-", 1438], ["bound", 1439], ["striatal", 1445], ["DAT", 1454], [",", 1457], ["but", 1459], ["not", 1463], ["total", 1467], ["cellular", 1473], ["DAT", 1482], [",", 1485], ["may", 1487], ["be", 1491], ["decreased", 1494], ["in", 1504], ["RLS", 1507], [".", 1510]]}
{"context": "Persistent pain represents a major health problem, and most current therapeutic approaches are associated with unwanted effects and unsatisfactory pain relief. Therefore, an urgent need exists to develop more effective drugs that are directed toward new molecular targets. Nerve growth factor (NGF) is involved in pain transduction mechanisms, playing a key role as a master switch in many chronic and inflammatory pain states; the NGF ligand and its receptor TrkA constitute well-validated targets for pain therapy. Tanezumab (RN-624), a first-in-class recombinant humanized mAb targeting NGF, is being developed by Pfizer Inc for the potential treatment of pain associated with several conditions. In preclinical studies, tanezumab, and its murine precursor muMab-911, effectively targeted the NGF pathway in various chronic and inflammatory pain models. Phase I and II clinical trials in osteoarthritic pain and chronic lower back pain demonstrated good efficacy for the compound, as well as a good safety and tolerability profile. Given that tanezumab is an antibody, the drug demonstrates the general advantages of this class of products (including good specificity and favorable pharmacokinetics), and also appears to be particularly well suited for targeting the chronic and inflammatory-mediating pain actions of NGF and its receptor system.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "5e08c43eb8b64887bf868e17d62cc5c8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[42, 44]], "char_spans": [[273, 291]]}, {"text": "NGF", "token_spans": [[102, 102], [136, 136], [72, 72], [46, 46], [223, 223]], "char_spans": [[590, 592], [796, 798], [432, 434], [294, 296], [1321, 1323]]}]}], "context_tokens": [["Persistent", 0], ["pain", 11], ["represents", 16], ["a", 27], ["major", 29], ["health", 35], ["problem", 42], [",", 49], ["and", 51], ["most", 55], ["current", 60], ["therapeutic", 68], ["approaches", 80], ["are", 91], ["associated", 95], ["with", 106], ["unwanted", 111], ["effects", 120], ["and", 128], ["unsatisfactory", 132], ["pain", 147], ["relief", 152], [".", 158], ["Therefore", 160], [",", 169], ["an", 171], ["urgent", 174], ["need", 181], ["exists", 186], ["to", 193], ["develop", 196], ["more", 204], ["effective", 209], ["drugs", 219], ["that", 225], ["are", 230], ["directed", 234], ["toward", 243], ["new", 250], ["molecular", 254], ["targets", 264], [".", 271], ["Nerve", 273], ["growth", 279], ["factor", 286], ["(", 293], ["NGF", 294], [")", 297], ["is", 299], ["involved", 302], ["in", 311], ["pain", 314], ["transduction", 319], ["mechanisms", 332], [",", 342], ["playing", 344], ["a", 352], ["key", 354], ["role", 358], ["as", 363], ["a", 366], ["master", 368], ["switch", 375], ["in", 382], ["many", 385], ["chronic", 390], ["and", 398], ["inflammatory", 402], ["pain", 415], ["states", 420], [";", 426], ["the", 428], ["NGF", 432], ["ligand", 436], ["and", 443], ["its", 447], ["receptor", 451], ["TrkA", 460], ["constitute", 465], ["well", 476], ["-", 480], ["validated", 481], ["targets", 491], ["for", 499], ["pain", 503], ["therapy", 508], [".", 515], ["Tanezumab", 517], ["(", 527], ["RN-624", 528], [")", 534], [",", 535], ["a", 537], ["first", 539], ["-", 544], ["in", 545], ["-", 547], ["class", 548], ["recombinant", 554], ["humanized", 566], ["mAb", 576], ["targeting", 580], ["NGF", 590], [",", 593], ["is", 595], ["being", 598], ["developed", 604], ["by", 614], ["Pfizer", 617], ["Inc", 624], ["for", 628], ["the", 632], ["potential", 636], ["treatment", 646], ["of", 656], ["pain", 659], ["associated", 664], ["with", 675], ["several", 680], ["conditions", 688], [".", 698], ["In", 700], ["preclinical", 703], ["studies", 715], [",", 722], ["tanezumab", 724], [",", 733], ["and", 735], ["its", 739], ["murine", 743], ["precursor", 750], ["muMab-911", 760], [",", 769], ["effectively", 771], ["targeted", 783], ["the", 792], ["NGF", 796], ["pathway", 800], ["in", 808], ["various", 811], ["chronic", 819], ["and", 827], ["inflammatory", 831], ["pain", 844], ["models", 849], [".", 855], ["Phase", 857], ["I", 863], ["and", 865], ["II", 869], ["clinical", 872], ["trials", 881], ["in", 888], ["osteoarthritic", 891], ["pain", 906], ["and", 911], ["chronic", 915], ["lower", 923], ["back", 929], ["pain", 934], ["demonstrated", 939], ["good", 952], ["efficacy", 957], ["for", 966], ["the", 970], ["compound", 974], [",", 982], ["as", 984], ["well", 987], ["as", 992], ["a", 995], ["good", 997], ["safety", 1002], ["and", 1009], ["tolerability", 1013], ["profile", 1026], [".", 1033], ["Given", 1035], ["that", 1041], ["tanezumab", 1046], ["is", 1056], ["an", 1059], ["antibody", 1062], [",", 1070], ["the", 1072], ["drug", 1076], ["demonstrates", 1081], ["the", 1094], ["general", 1098], ["advantages", 1106], ["of", 1117], ["this", 1120], ["class", 1125], ["of", 1131], ["products", 1134], ["(", 1143], ["including", 1144], ["good", 1154], ["specificity", 1159], ["and", 1171], ["favorable", 1175], ["pharmacokinetics", 1185], [")", 1201], [",", 1202], ["and", 1204], ["also", 1208], ["appears", 1213], ["to", 1221], ["be", 1224], ["particularly", 1227], ["well", 1240], ["suited", 1245], ["for", 1252], ["targeting", 1256], ["the", 1266], ["chronic", 1270], ["and", 1278], ["inflammatory", 1282], ["-", 1294], ["mediating", 1295], ["pain", 1305], ["actions", 1310], ["of", 1318], ["NGF", 1321], ["and", 1325], ["its", 1329], ["receptor", 1333], ["system", 1342], [".", 1348]]}
{"context": "Turner syndrome is a chromosomal disorder in which all or part of one X chromosome is missing. The meiotic or mitotic origin of most cases remains unknown due to the difficulty in detecting hidden mosaicism and to the lack of meiotic segregation studies. We analyzed 15 Turner patients, 10 with a 45,X whereas the rest had a second cell line with abnormal X-chromosomes: a pseudodicentric, an isochromosome, one large and one small ring, and the last with a long arm deletion. Our aims were: to detect X cryptic mosaicism in patients with a 45,X constitution; to determine the parental origin of the abnormality; to infer the zygotic origin of the karyotype and to suggest the timing and mechanism of the error(s) leading to the formation of abnormal X chromosomes from maternal origin. Molecular investigation did not revealed heterozygosity for any microsatellite, excluding X mosaicism in the 45,X cases. Parental origin of the single X chromosome was maternal in 90% of these patients. Three of the structurally abnormal Xs were maternally derived whereas the other two were paternal. These results allowed us to corroborate breakpoints in these abnormal X chromosomes and suggest that the pseudodicentric chromosome originated from post-zygotic sister chromatid exchange, whereas the Xq deleted chromosome probably arose after a recombination event during maternal meiosis.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "fb9765068c0047e8994ba18eabf79e88", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[13, 13], [97, 97], [141, 141], [170, 170], [158, 158], [65, 65], [207, 207]], "char_spans": [[70, 70], [502, 502], [751, 751], [938, 938], [877, 877], [356, 356], [1159, 1159]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["is", 16], ["a", 19], ["chromosomal", 21], ["disorder", 33], ["in", 42], ["which", 45], ["all", 51], ["or", 55], ["part", 58], ["of", 63], ["one", 66], ["X", 70], ["chromosome", 72], ["is", 83], ["missing", 86], [".", 93], ["The", 95], ["meiotic", 99], ["or", 107], ["mitotic", 110], ["origin", 118], ["of", 125], ["most", 128], ["cases", 133], ["remains", 139], ["unknown", 147], ["due", 155], ["to", 159], ["the", 162], ["difficulty", 166], ["in", 177], ["detecting", 180], ["hidden", 190], ["mosaicism", 197], ["and", 207], ["to", 211], ["the", 214], ["lack", 218], ["of", 223], ["meiotic", 226], ["segregation", 234], ["studies", 246], [".", 253], ["We", 255], ["analyzed", 258], ["15", 267], ["Turner", 270], ["patients", 277], [",", 285], ["10", 287], ["with", 290], ["a", 295], ["45,X", 297], ["whereas", 302], ["the", 310], ["rest", 314], ["had", 319], ["a", 323], ["second", 325], ["cell", 332], ["line", 337], ["with", 342], ["abnormal", 347], ["X", 356], ["-", 357], ["chromosomes", 358], [":", 369], ["a", 371], ["pseudodicentric", 373], [",", 388], ["an", 390], ["isochromosome", 393], [",", 406], ["one", 408], ["large", 412], ["and", 418], ["one", 422], ["small", 426], ["ring", 432], [",", 436], ["and", 438], ["the", 442], ["last", 446], ["with", 451], ["a", 456], ["long", 458], ["arm", 463], ["deletion", 467], [".", 475], ["Our", 477], ["aims", 481], ["were", 486], [":", 490], ["to", 492], ["detect", 495], ["X", 502], ["cryptic", 504], ["mosaicism", 512], ["in", 522], ["patients", 525], ["with", 534], ["a", 539], ["45,X", 541], ["constitution", 546], [";", 558], ["to", 560], ["determine", 563], ["the", 573], ["parental", 577], ["origin", 586], ["of", 593], ["the", 596], ["abnormality", 600], [";", 611], ["to", 613], ["infer", 616], ["the", 622], ["zygotic", 626], ["origin", 634], ["of", 641], ["the", 644], ["karyotype", 648], ["and", 658], ["to", 662], ["suggest", 665], ["the", 673], ["timing", 677], ["and", 684], ["mechanism", 688], ["of", 698], ["the", 701], ["error(s", 705], [")", 712], ["leading", 714], ["to", 722], ["the", 725], ["formation", 729], ["of", 739], ["abnormal", 742], ["X", 751], ["chromosomes", 753], ["from", 765], ["maternal", 770], ["origin", 779], [".", 785], ["Molecular", 787], ["investigation", 797], ["did", 811], ["not", 815], ["revealed", 819], ["heterozygosity", 828], ["for", 843], ["any", 847], ["microsatellite", 851], [",", 865], ["excluding", 867], ["X", 877], ["mosaicism", 879], ["in", 889], ["the", 892], ["45,X", 896], ["cases", 901], [".", 906], ["Parental", 908], ["origin", 917], ["of", 924], ["the", 927], ["single", 931], ["X", 938], ["chromosome", 940], ["was", 951], ["maternal", 955], ["in", 964], ["90", 967], ["%", 969], ["of", 971], ["these", 974], ["patients", 980], [".", 988], ["Three", 990], ["of", 996], ["the", 999], ["structurally", 1003], ["abnormal", 1016], ["Xs", 1025], ["were", 1028], ["maternally", 1033], ["derived", 1044], ["whereas", 1052], ["the", 1060], ["other", 1064], ["two", 1070], ["were", 1074], ["paternal", 1079], [".", 1087], ["These", 1089], ["results", 1095], ["allowed", 1103], ["us", 1111], ["to", 1114], ["corroborate", 1117], ["breakpoints", 1129], ["in", 1141], ["these", 1144], ["abnormal", 1150], ["X", 1159], ["chromosomes", 1161], ["and", 1173], ["suggest", 1177], ["that", 1185], ["the", 1190], ["pseudodicentric", 1194], ["chromosome", 1210], ["originated", 1221], ["from", 1232], ["post", 1237], ["-", 1241], ["zygotic", 1242], ["sister", 1250], ["chromatid", 1257], ["exchange", 1267], [",", 1275], ["whereas", 1277], ["the", 1285], ["Xq", 1289], ["deleted", 1292], ["chromosome", 1300], ["probably", 1311], ["arose", 1320], ["after", 1326], ["a", 1332], ["recombination", 1334], ["event", 1348], ["during", 1354], ["maternal", 1361], ["meiosis", 1370], [".", 1377]]}
{"context": "Neurofibromatosis type 1 (NF1) is characterized primarily by tumor formation in the nervous system, but patients report other neurological complications including pain and itch. Individuals with NF1 harbor 1 mutated NF1 allele causing heterozygous expression in all of their cells. In mice, Nf1 heterozygosity leads to hyperexcitability of sensory neurons and hyperproliferation of mast cells, both of which could lead to increased hypersensitivity and scratching in response to noxious and pruritic stimuli. To determine whether Nf1 heterozygosity may increase pain and itch behaviors independent of secondary effects of tumor formation, we used mice with a targeted, heterozygous Nf1 gene deletion (Nf1\u00b1) that lack tumors. Nf1\u00b1 mice exhibited normal baseline responses to thermal and mechanical stimuli. Moreover, similar to wild-type littermates, Nf1\u00b1 mice developed inflammation-induced heat\u00a0and mechanical hypersensitivity, capsaicin-induced nocifensive behavior, histamine-dependent or -independent scratching, and chronic constriction injury-induced cold allodynia. However, Nf1\u00b1\u00a0mice exhibited an attenuated first phase of formalin-induced spontaneous behavior and expedited resolution of formalin-induced heat hypersensitivity. These results are not consistent with the hypothesis that Nf1 heterozygosity alone is sufficient to increase pain and itch sensation in mice, and they suggest that additional mechanisms may underlie reports of increased pain and itch in NF1 patients. This study assessed whether Nf1 heterozygosity in mice increased hypersensitivity and scratching following noxious and pruritic stimuli. Using Nf1\u00b1 mice lacking tumors, this study finds no increases in pain or itch behavior, suggesting that there is no predisposition for either clinical symptom solely due to Nf1 heterozygosity.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "40227f76b00344a78411177630545e7b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[48, 48], [83, 83], [107, 107], [30, 30], [205, 205], [234, 234], [285, 285], [4, 4], [34, 34], [241, 241]], "char_spans": [[291, 293], [530, 532], [682, 684], [195, 197], [1295, 1297], [1474, 1476], [1798, 1800], [26, 28], [216, 218], [1516, 1518]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["characterized", 34], ["primarily", 48], ["by", 58], ["tumor", 61], ["formation", 67], ["in", 77], ["the", 80], ["nervous", 84], ["system", 92], [",", 98], ["but", 100], ["patients", 104], ["report", 113], ["other", 120], ["neurological", 126], ["complications", 139], ["including", 153], ["pain", 163], ["and", 168], ["itch", 172], [".", 176], ["Individuals", 178], ["with", 190], ["NF1", 195], ["harbor", 199], ["1", 206], ["mutated", 208], ["NF1", 216], ["allele", 220], ["causing", 227], ["heterozygous", 235], ["expression", 248], ["in", 259], ["all", 262], ["of", 266], ["their", 269], ["cells", 275], [".", 280], ["In", 282], ["mice", 285], [",", 289], ["Nf1", 291], ["heterozygosity", 295], ["leads", 310], ["to", 316], ["hyperexcitability", 319], ["of", 337], ["sensory", 340], ["neurons", 348], ["and", 356], ["hyperproliferation", 360], ["of", 379], ["mast", 382], ["cells", 387], [",", 392], ["both", 394], ["of", 399], ["which", 402], ["could", 408], ["lead", 414], ["to", 419], ["increased", 422], ["hypersensitivity", 432], ["and", 449], ["scratching", 453], ["in", 464], ["response", 467], ["to", 476], ["noxious", 479], ["and", 487], ["pruritic", 491], ["stimuli", 500], [".", 507], ["To", 509], ["determine", 512], ["whether", 522], ["Nf1", 530], ["heterozygosity", 534], ["may", 549], ["increase", 553], ["pain", 562], ["and", 567], ["itch", 571], ["behaviors", 576], ["independent", 586], ["of", 598], ["secondary", 601], ["effects", 611], ["of", 619], ["tumor", 622], ["formation", 628], [",", 637], ["we", 639], ["used", 642], ["mice", 647], ["with", 652], ["a", 657], ["targeted", 659], [",", 667], ["heterozygous", 669], ["Nf1", 682], ["gene", 686], ["deletion", 691], ["(", 700], ["Nf1\u00b1", 701], [")", 705], ["that", 707], ["lack", 712], ["tumors", 717], [".", 723], ["Nf1\u00b1", 725], ["mice", 730], ["exhibited", 735], ["normal", 745], ["baseline", 752], ["responses", 761], ["to", 771], ["thermal", 774], ["and", 782], ["mechanical", 786], ["stimuli", 797], [".", 804], ["Moreover", 806], [",", 814], ["similar", 816], ["to", 824], ["wild", 827], ["-", 831], ["type", 832], ["littermates", 837], [",", 848], ["Nf1\u00b1", 850], ["mice", 855], ["developed", 860], ["inflammation", 870], ["-", 882], ["induced", 883], ["heat", 891], ["and", 896], ["mechanical", 900], ["hypersensitivity", 911], [",", 927], ["capsaicin", 929], ["-", 938], ["induced", 939], ["nocifensive", 947], ["behavior", 959], [",", 967], ["histamine", 969], ["-", 978], ["dependent", 979], ["or", 989], ["-independent", 992], ["scratching", 1005], [",", 1015], ["and", 1017], ["chronic", 1021], ["constriction", 1029], ["injury", 1042], ["-", 1048], ["induced", 1049], ["cold", 1057], ["allodynia", 1062], [".", 1071], ["However", 1073], [",", 1080], ["Nf1\u00b1", 1082], ["mice", 1087], ["exhibited", 1092], ["an", 1102], ["attenuated", 1105], ["first", 1116], ["phase", 1122], ["of", 1128], ["formalin", 1131], ["-", 1139], ["induced", 1140], ["spontaneous", 1148], ["behavior", 1160], ["and", 1169], ["expedited", 1173], ["resolution", 1183], ["of", 1194], ["formalin", 1197], ["-", 1205], ["induced", 1206], ["heat", 1214], ["hypersensitivity", 1219], [".", 1235], ["These", 1237], ["results", 1243], ["are", 1251], ["not", 1255], ["consistent", 1259], ["with", 1270], ["the", 1275], ["hypothesis", 1279], ["that", 1290], ["Nf1", 1295], ["heterozygosity", 1299], ["alone", 1314], ["is", 1320], ["sufficient", 1323], ["to", 1334], ["increase", 1337], ["pain", 1346], ["and", 1351], ["itch", 1355], ["sensation", 1360], ["in", 1370], ["mice", 1373], [",", 1377], ["and", 1379], ["they", 1383], ["suggest", 1388], ["that", 1396], ["additional", 1401], ["mechanisms", 1412], ["may", 1423], ["underlie", 1427], ["reports", 1436], ["of", 1444], ["increased", 1447], ["pain", 1457], ["and", 1462], ["itch", 1466], ["in", 1471], ["NF1", 1474], ["patients", 1478], [".", 1486], ["This", 1488], ["study", 1493], ["assessed", 1499], ["whether", 1508], ["Nf1", 1516], ["heterozygosity", 1520], ["in", 1535], ["mice", 1538], ["increased", 1543], ["hypersensitivity", 1553], ["and", 1570], ["scratching", 1574], ["following", 1585], ["noxious", 1595], ["and", 1603], ["pruritic", 1607], ["stimuli", 1616], [".", 1623], ["Using", 1625], ["Nf1\u00b1", 1631], ["mice", 1636], ["lacking", 1641], ["tumors", 1649], [",", 1655], ["this", 1657], ["study", 1662], ["finds", 1668], ["no", 1674], ["increases", 1677], ["in", 1687], ["pain", 1690], ["or", 1695], ["itch", 1698], ["behavior", 1703], [",", 1711], ["suggesting", 1713], ["that", 1724], ["there", 1729], ["is", 1735], ["no", 1738], ["predisposition", 1741], ["for", 1756], ["either", 1760], ["clinical", 1767], ["symptom", 1776], ["solely", 1784], ["due", 1791], ["to", 1795], ["Nf1", 1798], ["heterozygosity", 1802], [".", 1816]]}
{"context": "Inflammation plays an important role in the pathophysiology of atherosclerosis and endothelial dysfunction, and occurs after percutaneous coronary intervention (PCI). We evaluated whether endothelial function is attenuated after PCI and if inhibition of secretory phospholipase A2 (sPLA2) activity augments endothelial function and coronary flow reserve (CFR) in these patients. In the sPLA2 Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) study, patients undergoing elective PCI were randomized to receive Varespladib (Anthera Pharmaceuticals Inc, San Mateo, CA), an inhibitor of sPLA2, or placebo 3-5 days prior to PCI and for 5 days after PCI. In this substudy, endothelial function was assessed in 31 patients by flow-mediated dilation (FMD) before treatment and on the day after PCI, while taking study medication. During the PCI procedure, CFR was assessed using a Doppler guide wire. Baseline and procedural characteristics were comparable in both groups and sPLA2 activity was similar at baseline. After PCI, sPLA2 activity decreased only in the Varespladib group (2.9 \u00b1 0.9 to 0.5 \u00b1 0.4 ng/mL), and high-sensitivity C-reactive protein (hsCRP) increased by more than 100% in both groups. FMD at baseline was 3.66 \u00b1 2.45% (Varespladib) and 3.37 \u00b1 1.73% (placebo) with nonsignificant increase in both groups after PCI. The effect of Varespladib on FMD, adjusted for pre-PCI FMD by linear regression, was -1.16 \u00b1 1.68%; P = 0.5. CFR was 2.45 \u00b1 0.66 and 2.77 \u00b1 0.85 in the Varespladib and placebo groups, respectively (P = 0.36). Systemic endothelial function is not reduced after elective PCI despite eliciting acute inflammatory response. Acute inhibition of sPLA2 activity with Varespladib does not affect endothelial or microvascular function after PCI.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "5326d703c9324e3ea9439b9de254c05a", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[37, 39]], "char_spans": [[254, 279]]}]}], "context_tokens": [["Inflammation", 0], ["plays", 13], ["an", 19], ["important", 22], ["role", 32], ["in", 37], ["the", 40], ["pathophysiology", 44], ["of", 60], ["atherosclerosis", 63], ["and", 79], ["endothelial", 83], ["dysfunction", 95], [",", 106], ["and", 108], ["occurs", 112], ["after", 119], ["percutaneous", 125], ["coronary", 138], ["intervention", 147], ["(", 160], ["PCI", 161], [")", 164], [".", 165], ["We", 167], ["evaluated", 170], ["whether", 180], ["endothelial", 188], ["function", 200], ["is", 209], ["attenuated", 212], ["after", 223], ["PCI", 229], ["and", 233], ["if", 237], ["inhibition", 240], ["of", 251], ["secretory", 254], ["phospholipase", 264], ["A2", 278], ["(", 281], ["sPLA2", 282], [")", 287], ["activity", 289], ["augments", 298], ["endothelial", 307], ["function", 319], ["and", 328], ["coronary", 332], ["flow", 341], ["reserve", 346], ["(", 354], ["CFR", 355], [")", 358], ["in", 360], ["these", 363], ["patients", 369], [".", 377], ["In", 379], ["the", 382], ["sPLA2", 386], ["Inhibition", 392], ["to", 403], ["Decrease", 406], ["Enzyme", 415], ["Release", 422], ["After", 430], ["Percutaneous", 436], ["Coronary", 449], ["Intervention", 458], ["(", 471], ["SPIDER", 472], ["-", 478], ["PCI", 479], [")", 482], ["study", 484], [",", 489], ["patients", 491], ["undergoing", 500], ["elective", 511], ["PCI", 520], ["were", 524], ["randomized", 529], ["to", 540], ["receive", 543], ["Varespladib", 551], ["(", 563], ["Anthera", 564], ["Pharmaceuticals", 572], ["Inc", 588], [",", 591], ["San", 593], ["Mateo", 597], [",", 602], ["CA", 604], [")", 606], [",", 607], ["an", 609], ["inhibitor", 612], ["of", 622], ["sPLA2", 625], [",", 630], ["or", 632], ["placebo", 635], ["3", 643], ["-", 644], ["5", 645], ["days", 647], ["prior", 652], ["to", 658], ["PCI", 661], ["and", 665], ["for", 669], ["5", 673], ["days", 675], ["after", 680], ["PCI", 686], [".", 689], ["In", 691], ["this", 694], ["substudy", 699], [",", 707], ["endothelial", 709], ["function", 721], ["was", 730], ["assessed", 734], ["in", 743], ["31", 746], ["patients", 749], ["by", 758], ["flow", 761], ["-", 765], ["mediated", 766], ["dilation", 775], ["(", 784], ["FMD", 785], [")", 788], ["before", 790], ["treatment", 797], ["and", 807], ["on", 811], ["the", 814], ["day", 818], ["after", 822], ["PCI", 828], [",", 831], ["while", 833], ["taking", 839], ["study", 846], ["medication", 852], [".", 862], ["During", 864], ["the", 871], ["PCI", 875], ["procedure", 879], [",", 888], ["CFR", 890], ["was", 894], ["assessed", 898], ["using", 907], ["a", 913], ["Doppler", 915], ["guide", 923], ["wire", 929], [".", 933], ["Baseline", 935], ["and", 944], ["procedural", 948], ["characteristics", 959], ["were", 975], ["comparable", 980], ["in", 991], ["both", 994], ["groups", 999], ["and", 1006], ["sPLA2", 1010], ["activity", 1016], ["was", 1025], ["similar", 1029], ["at", 1037], ["baseline", 1040], [".", 1048], ["After", 1050], ["PCI", 1056], [",", 1059], ["sPLA2", 1061], ["activity", 1067], ["decreased", 1076], ["only", 1086], ["in", 1091], ["the", 1094], ["Varespladib", 1098], ["group", 1110], ["(", 1116], ["2.9", 1117], ["\u00b1", 1121], ["0.9", 1123], ["to", 1127], ["0.5", 1130], ["\u00b1", 1134], ["0.4", 1136], ["ng", 1140], ["/", 1142], ["mL", 1143], [")", 1145], [",", 1146], ["and", 1148], ["high", 1152], ["-", 1156], ["sensitivity", 1157], ["C", 1169], ["-", 1170], ["reactive", 1171], ["protein", 1180], ["(", 1188], ["hsCRP", 1189], [")", 1194], ["increased", 1196], ["by", 1206], ["more", 1209], ["than", 1214], ["100", 1219], ["%", 1222], ["in", 1224], ["both", 1227], ["groups", 1232], [".", 1238], ["FMD", 1240], ["at", 1244], ["baseline", 1247], ["was", 1256], ["3.66", 1260], ["\u00b1", 1265], ["2.45", 1267], ["%", 1271], ["(", 1273], ["Varespladib", 1274], [")", 1285], ["and", 1287], ["3.37", 1291], ["\u00b1", 1296], ["1.73", 1298], ["%", 1302], ["(", 1304], ["placebo", 1305], [")", 1312], ["with", 1314], ["nonsignificant", 1319], ["increase", 1334], ["in", 1343], ["both", 1346], ["groups", 1351], ["after", 1358], ["PCI", 1364], [".", 1367], ["The", 1369], ["effect", 1373], ["of", 1380], ["Varespladib", 1383], ["on", 1395], ["FMD", 1398], [",", 1401], ["adjusted", 1403], ["for", 1412], ["pre", 1416], ["-", 1419], ["PCI", 1420], ["FMD", 1424], ["by", 1428], ["linear", 1431], ["regression", 1438], [",", 1448], ["was", 1450], ["-1.16", 1454], ["\u00b1", 1460], ["1.68", 1462], ["%", 1466], [";", 1467], ["P", 1469], ["=", 1471], ["0.5", 1473], [".", 1476], ["CFR", 1478], ["was", 1482], ["2.45", 1486], ["\u00b1", 1491], ["0.66", 1493], ["and", 1498], ["2.77", 1502], ["\u00b1", 1507], ["0.85", 1509], ["in", 1514], ["the", 1517], ["Varespladib", 1521], ["and", 1533], ["placebo", 1537], ["groups", 1545], [",", 1551], ["respectively", 1553], ["(", 1566], ["P", 1567], ["=", 1569], ["0.36", 1571], [")", 1575], [".", 1576], ["Systemic", 1578], ["endothelial", 1587], ["function", 1599], ["is", 1608], ["not", 1611], ["reduced", 1615], ["after", 1623], ["elective", 1629], ["PCI", 1638], ["despite", 1642], ["eliciting", 1650], ["acute", 1660], ["inflammatory", 1666], ["response", 1679], [".", 1687], ["Acute", 1689], ["inhibition", 1695], ["of", 1706], ["sPLA2", 1709], ["activity", 1715], ["with", 1724], ["Varespladib", 1729], ["does", 1741], ["not", 1746], ["affect", 1750], ["endothelial", 1757], ["or", 1769], ["microvascular", 1772], ["function", 1786], ["after", 1795], ["PCI", 1801], [".", 1804]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem. Rapid detection of MRSA-colonized patients has the potential to limit spread of the organism. We evaluated the sensitivities and specificities of MRSA detection by two molecular methods (IDI-MRSA PCR assay and GenoType MRSA Direct PCR assay) and three selective MRSA agars (MRSA ID, MRSASelect, and CHROMagar MRSA), using 205 (101 nasal, 52 groin, and 52 axillary samples) samples from consecutive known MRSA-infected and/or -colonized patients. All detection methods had higher MRSA detection rates for nasal swabs than for axillary and groin swabs. Detection of MRSA by IDI-MRSA was the most sensitive method, independent of the site (94% for nasal samples, 80% for nonnasal samples, and 90% overall). The sensitivities of the GenoType MRSA Direct assay and the MRSA ID, MRSASelect, and CHROMagar MRSA agars with nasal swabs were 70%, 72%, 68%, and 75%, respectively. All detection methods had high specificities (95 to 99%), independent of the swab site. Extended incubation for a further 24 h with selective MRSA agars increased the detection of MRSA, with a corresponding decline in specificity secondary to a significant increase in false-positive results. There was a noticeable difference in test performance of the GenoType MRSA Direct assay in detection of MRSA (28/38 samples [74%]) compared with detection of nonmultiresistant MRSA (17/31 samples [55%]) (susceptible to two or more non-beta-lactam antibiotics). This was not observed with selective MRSA agar plates or IDI-MRSA. Although it is more expensive, in addition to rapid turnaround times of 2 to 4 h, IDI-MRSA offers greater detection of MRSA colonization, independent of the swab site, than do conventional selective agars and GenoType MRSA Direct.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "b942fc23c0bf4ebe9bf8e76ac4b3a998", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[161, 161], [351, 351], [16, 16], [51, 51], [117, 117], [6, 6], [308, 308], [121, 121], [259, 259], [59, 59], [69, 69], [253, 253], [302, 302], [62, 62], [335, 335], [90, 90], [102, 102], [217, 217], [273, 273], [37, 37], [330, 330], [156, 156], [168, 168], [46, 46], [223, 223]], "char_spans": [[841, 844], [1786, 1789], [96, 99], [296, 299], [641, 644], [45, 48], [1562, 1565], [653, 656], [1344, 1347], [339, 342], [386, 389], [1310, 1313], [1538, 1541], [351, 354], [1687, 1690], [481, 484], [556, 559], [1089, 1092], [1416, 1419], [223, 226], [1654, 1657], [815, 818], [876, 879], [268, 271], [1127, 1130]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["is", 51], ["an", 54], ["increasing", 57], ["problem", 68], [".", 75], ["Rapid", 77], ["detection", 83], ["of", 93], ["MRSA", 96], ["-", 100], ["colonized", 101], ["patients", 111], ["has", 120], ["the", 124], ["potential", 128], ["to", 138], ["limit", 141], ["spread", 147], ["of", 154], ["the", 157], ["organism", 161], [".", 169], ["We", 171], ["evaluated", 174], ["the", 184], ["sensitivities", 188], ["and", 202], ["specificities", 206], ["of", 220], ["MRSA", 223], ["detection", 228], ["by", 238], ["two", 241], ["molecular", 245], ["methods", 255], ["(", 263], ["IDI", 264], ["-", 267], ["MRSA", 268], ["PCR", 273], ["assay", 277], ["and", 283], ["GenoType", 287], ["MRSA", 296], ["Direct", 301], ["PCR", 308], ["assay", 312], [")", 317], ["and", 319], ["three", 323], ["selective", 329], ["MRSA", 339], ["agars", 344], ["(", 350], ["MRSA", 351], ["ID", 356], [",", 358], ["MRSASelect", 360], [",", 370], ["and", 372], ["CHROMagar", 376], ["MRSA", 386], [")", 390], [",", 391], ["using", 393], ["205", 399], ["(", 403], ["101", 404], ["nasal", 408], [",", 413], ["52", 415], ["groin", 418], [",", 423], ["and", 425], ["52", 429], ["axillary", 432], ["samples", 441], [")", 448], ["samples", 450], ["from", 458], ["consecutive", 463], ["known", 475], ["MRSA", 481], ["-", 485], ["infected", 486], ["and/or", 495], ["-colonized", 502], ["patients", 513], [".", 521], ["All", 523], ["detection", 527], ["methods", 537], ["had", 545], ["higher", 549], ["MRSA", 556], ["detection", 561], ["rates", 571], ["for", 577], ["nasal", 581], ["swabs", 587], ["than", 593], ["for", 598], ["axillary", 602], ["and", 611], ["groin", 615], ["swabs", 621], [".", 626], ["Detection", 628], ["of", 638], ["MRSA", 641], ["by", 646], ["IDI", 649], ["-", 652], ["MRSA", 653], ["was", 658], ["the", 662], ["most", 666], ["sensitive", 671], ["method", 681], [",", 687], ["independent", 689], ["of", 701], ["the", 704], ["site", 708], ["(", 713], ["94", 714], ["%", 716], ["for", 718], ["nasal", 722], ["samples", 728], [",", 735], ["80", 737], ["%", 739], ["for", 741], ["nonnasal", 745], ["samples", 754], [",", 761], ["and", 763], ["90", 767], ["%", 769], ["overall", 771], [")", 778], [".", 779], ["The", 781], ["sensitivities", 785], ["of", 799], ["the", 802], ["GenoType", 806], ["MRSA", 815], ["Direct", 820], ["assay", 827], ["and", 833], ["the", 837], ["MRSA", 841], ["ID", 846], [",", 848], ["MRSASelect", 850], [",", 860], ["and", 862], ["CHROMagar", 866], ["MRSA", 876], ["agars", 881], ["with", 887], ["nasal", 892], ["swabs", 898], ["were", 904], ["70", 909], ["%", 911], [",", 912], ["72", 914], ["%", 916], [",", 917], ["68", 919], ["%", 921], [",", 922], ["and", 924], ["75", 928], ["%", 930], [",", 931], ["respectively", 933], [".", 945], ["All", 947], ["detection", 951], ["methods", 961], ["had", 969], ["high", 973], ["specificities", 978], ["(", 992], ["95", 993], ["to", 996], ["99", 999], ["%", 1001], [")", 1002], [",", 1003], ["independent", 1005], ["of", 1017], ["the", 1020], ["swab", 1024], ["site", 1029], [".", 1033], ["Extended", 1035], ["incubation", 1044], ["for", 1055], ["a", 1059], ["further", 1061], ["24", 1069], ["h", 1072], ["with", 1074], ["selective", 1079], ["MRSA", 1089], ["agars", 1094], ["increased", 1100], ["the", 1110], ["detection", 1114], ["of", 1124], ["MRSA", 1127], [",", 1131], ["with", 1133], ["a", 1138], ["corresponding", 1140], ["decline", 1154], ["in", 1162], ["specificity", 1165], ["secondary", 1177], ["to", 1187], ["a", 1190], ["significant", 1192], ["increase", 1204], ["in", 1213], ["false", 1216], ["-", 1221], ["positive", 1222], ["results", 1231], [".", 1238], ["There", 1240], ["was", 1246], ["a", 1250], ["noticeable", 1252], ["difference", 1263], ["in", 1274], ["test", 1277], ["performance", 1282], ["of", 1294], ["the", 1297], ["GenoType", 1301], ["MRSA", 1310], ["Direct", 1315], ["assay", 1322], ["in", 1328], ["detection", 1331], ["of", 1341], ["MRSA", 1344], ["(", 1349], ["28/38", 1350], ["samples", 1356], ["[", 1364], ["74", 1365], ["%", 1367], ["]", 1368], [")", 1369], ["compared", 1371], ["with", 1380], ["detection", 1385], ["of", 1395], ["nonmultiresistant", 1398], ["MRSA", 1416], ["(", 1421], ["17/31", 1422], ["samples", 1428], ["[", 1436], ["55", 1437], ["%", 1439], ["]", 1440], [")", 1441], ["(", 1443], ["susceptible", 1444], ["to", 1456], ["two", 1459], ["or", 1463], ["more", 1466], ["non", 1471], ["-", 1474], ["beta", 1475], ["-", 1479], ["lactam", 1480], ["antibiotics", 1487], [")", 1498], [".", 1499], ["This", 1501], ["was", 1506], ["not", 1510], ["observed", 1514], ["with", 1523], ["selective", 1528], ["MRSA", 1538], ["agar", 1543], ["plates", 1548], ["or", 1555], ["IDI", 1558], ["-", 1561], ["MRSA", 1562], [".", 1566], ["Although", 1568], ["it", 1577], ["is", 1580], ["more", 1583], ["expensive", 1588], [",", 1597], ["in", 1599], ["addition", 1602], ["to", 1611], ["rapid", 1614], ["turnaround", 1620], ["times", 1631], ["of", 1637], ["2", 1640], ["to", 1642], ["4", 1645], ["h", 1647], [",", 1648], ["IDI", 1650], ["-", 1653], ["MRSA", 1654], ["offers", 1659], ["greater", 1666], ["detection", 1674], ["of", 1684], ["MRSA", 1687], ["colonization", 1692], [",", 1704], ["independent", 1706], ["of", 1718], ["the", 1721], ["swab", 1725], ["site", 1730], [",", 1734], ["than", 1736], ["do", 1741], ["conventional", 1744], ["selective", 1757], ["agars", 1767], ["and", 1773], ["GenoType", 1777], ["MRSA", 1786], ["Direct", 1791], [".", 1797]]}
{"context": "Flumazenil, a specific benzodiazepine antagonist, is useful in reversing the sedation and respiratory depression that often occur when benzodiazepines are administered to patients undergoing anesthesia or when patients have taken an intentional benzodiazepine overdose. Judicious use of flumazenil may provide useful diagnostic information and may obviate the need for mechanical ventilation and other invasive supportive measures. Although some controversy exists regarding the possible precipitation of seizure activity in the setting of mixed tricyclic antidepressant-benzodiazepine overdose, worldwide experience with flumazenil has validated its safety and efficacy.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "b4b16d825b304cf98373a45e742826da", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [85, 85], [40, 40]], "char_spans": [[0, 9], [622, 631], [287, 296]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["specific", 14], ["benzodiazepine", 23], ["antagonist", 38], [",", 48], ["is", 50], ["useful", 53], ["in", 60], ["reversing", 63], ["the", 73], ["sedation", 77], ["and", 86], ["respiratory", 90], ["depression", 102], ["that", 113], ["often", 118], ["occur", 124], ["when", 130], ["benzodiazepines", 135], ["are", 151], ["administered", 155], ["to", 168], ["patients", 171], ["undergoing", 180], ["anesthesia", 191], ["or", 202], ["when", 205], ["patients", 210], ["have", 219], ["taken", 224], ["an", 230], ["intentional", 233], ["benzodiazepine", 245], ["overdose", 260], [".", 268], ["Judicious", 270], ["use", 280], ["of", 284], ["flumazenil", 287], ["may", 298], ["provide", 302], ["useful", 310], ["diagnostic", 317], ["information", 328], ["and", 340], ["may", 344], ["obviate", 348], ["the", 356], ["need", 360], ["for", 365], ["mechanical", 369], ["ventilation", 380], ["and", 392], ["other", 396], ["invasive", 402], ["supportive", 411], ["measures", 422], [".", 430], ["Although", 432], ["some", 441], ["controversy", 446], ["exists", 458], ["regarding", 465], ["the", 475], ["possible", 479], ["precipitation", 488], ["of", 502], ["seizure", 505], ["activity", 513], ["in", 522], ["the", 525], ["setting", 529], ["of", 537], ["mixed", 540], ["tricyclic", 546], ["antidepressant", 556], ["-", 570], ["benzodiazepine", 571], ["overdose", 586], [",", 594], ["worldwide", 596], ["experience", 606], ["with", 617], ["flumazenil", 622], ["has", 633], ["validated", 637], ["its", 647], ["safety", 651], ["and", 658], ["efficacy", 662], [".", 670]]}
{"context": "Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited. We report two cases of patients on dabigatran with acute intracerebral hemorrhage who received idarucizumab. In both cases, idarucizumab promptly reversed the anticoagulant effect of dabigatran and there was no hematoma expansion in follow-up imaging. In addition to clinical and preclinical studies, our cases add to the experience regarding the safety and efficacy of idarucizumab. They show that idarucizumab may be an important safety option for patients on dabigatran in emergency situations.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "0f0142c6d85345b6ad31f47e1f7b98d4", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[144, 144], [96, 96], [10, 10], [76, 76], [47, 47]], "char_spans": [[856, 865], [577, 586], [44, 53], [429, 438], [286, 295]]}]}], "context_tokens": [["Non", 0], ["-", 3], ["vitamin", 4], ["K", 12], ["anticoagulants", 14], ["(", 29], ["NOAC", 30], [")", 34], ["such", 36], ["as", 41], ["dabigatran", 44], ["have", 55], ["become", 60], ["important", 67], ["therapeutic", 77], ["options", 89], ["for", 97], ["the", 101], ["prevention", 105], ["of", 116], ["stroke", 119], [".", 125], ["Until", 127], ["recently", 133], [",", 141], ["there", 143], ["were", 149], ["only", 154], ["nonspecific", 159], ["agents", 171], ["to", 178], ["reverse", 181], ["their", 189], ["anticoagulant", 195], ["effects", 209], ["in", 217], ["a", 220], ["case", 222], ["of", 227], ["emergency", 230], [".", 239], ["Idarucizumab", 241], [",", 253], ["an", 255], ["antibody", 258], ["fragment", 267], ["targeting", 276], ["dabigatran", 286], [",", 296], ["is", 298], ["the", 301], ["first", 305], ["specific", 311], ["antidote", 320], ["for", 329], ["a", 333], ["NOAC", 335], ["to", 340], ["be", 343], ["approved", 346], [",", 354], ["but", 356], ["real", 360], ["-", 364], ["world", 365], ["experience", 371], ["is", 382], ["limited", 385], [".", 392], ["We", 394], ["report", 397], ["two", 404], ["cases", 408], ["of", 414], ["patients", 417], ["on", 426], ["dabigatran", 429], ["with", 440], ["acute", 445], ["intracerebral", 451], ["hemorrhage", 465], ["who", 476], ["received", 480], ["idarucizumab", 489], [".", 501], ["In", 503], ["both", 506], ["cases", 511], [",", 516], ["idarucizumab", 518], ["promptly", 531], ["reversed", 540], ["the", 549], ["anticoagulant", 553], ["effect", 567], ["of", 574], ["dabigatran", 577], ["and", 588], ["there", 592], ["was", 598], ["no", 602], ["hematoma", 605], ["expansion", 614], ["in", 624], ["follow", 627], ["-", 633], ["up", 634], ["imaging", 637], [".", 644], ["In", 646], ["addition", 649], ["to", 658], ["clinical", 661], ["and", 670], ["preclinical", 674], ["studies", 686], [",", 693], ["our", 695], ["cases", 699], ["add", 705], ["to", 709], ["the", 712], ["experience", 716], ["regarding", 727], ["the", 737], ["safety", 741], ["and", 748], ["efficacy", 752], ["of", 761], ["idarucizumab", 764], [".", 776], ["They", 778], ["show", 783], ["that", 788], ["idarucizumab", 793], ["may", 806], ["be", 810], ["an", 813], ["important", 816], ["safety", 826], ["option", 833], ["for", 840], ["patients", 844], ["on", 853], ["dabigatran", 856], ["in", 867], ["emergency", 870], ["situations", 880], [".", 890]]}
{"context": "With the avalanche of biological sequences generated in the post-genomic age, one of the most challenging problems in computational biology is how to effectively formulate the sequence of a biological sample (such as DNA, RNA or protein) with a discrete model or a vector that can effectively reflect its sequence pattern information or capture its key features concerned. Although several web servers and stand-alone tools were developed to address this problem, all these tools, however, can only handle one type of samples. Furthermore, the number of their built-in properties is limited, and hence it is often difficult for users to formulate the biological sequences according to their desired features or properties. In this article, with a much larger number of built-in properties, we are to propose a much more flexible web server called Pse-in-One (http://bioinformatics.hitsz.edu.cn/Pse-in-One/), which can, through its 28 different modes, generate nearly all the possible feature vectors for DNA, RNA and protein sequences. Particularly, it can also generate those feature vectors with the properties defined by users themselves. These feature vectors can be easily combined with machine-learning algorithms to develop computational predictors and analysis methods for various tasks in bioinformatics and system biology. It is anticipated that the Pse-in-One web server will become a very useful tool in computational proteomics, genomics, as well as biological sequence analysis. Moreover, to maximize users' convenience, its stand-alone version can also be downloaded from http://bioinformatics.hitsz.edu.cn/Pse-in-One/download/, and directly run on Windows, Linux, Unix and Mac OS.", "qas": [{"question": "Which server is used for generating modes of pseudo components of DNA, RNA and protein sequences?", "answers": ["Pse-in-One"], "qid": "6f46d726a7c249e68c5a8726f672c870", "question_tokens": [["Which", 0], ["server", 6], ["is", 13], ["used", 16], ["for", 21], ["generating", 25], ["modes", 36], ["of", 42], ["pseudo", 45], ["components", 52], ["of", 63], ["DNA", 66], [",", 69], ["RNA", 71], ["and", 75], ["protein", 79], ["sequences", 87], ["?", 96]], "detected_answers": [{"text": "Pse-in-One", "token_spans": [[155, 159], [238, 242]], "char_spans": [[847, 856], [1360, 1369]]}]}], "context_tokens": [["With", 0], ["the", 5], ["avalanche", 9], ["of", 19], ["biological", 22], ["sequences", 33], ["generated", 43], ["in", 53], ["the", 56], ["post", 60], ["-", 64], ["genomic", 65], ["age", 73], [",", 76], ["one", 78], ["of", 82], ["the", 85], ["most", 89], ["challenging", 94], ["problems", 106], ["in", 115], ["computational", 118], ["biology", 132], ["is", 140], ["how", 143], ["to", 147], ["effectively", 150], ["formulate", 162], ["the", 172], ["sequence", 176], ["of", 185], ["a", 188], ["biological", 190], ["sample", 201], ["(", 208], ["such", 209], ["as", 214], ["DNA", 217], [",", 220], ["RNA", 222], ["or", 226], ["protein", 229], [")", 236], ["with", 238], ["a", 243], ["discrete", 245], ["model", 254], ["or", 260], ["a", 263], ["vector", 265], ["that", 272], ["can", 277], ["effectively", 281], ["reflect", 293], ["its", 301], ["sequence", 305], ["pattern", 314], ["information", 322], ["or", 334], ["capture", 337], ["its", 345], ["key", 349], ["features", 353], ["concerned", 362], [".", 371], ["Although", 373], ["several", 382], ["web", 390], ["servers", 394], ["and", 402], ["stand", 406], ["-", 411], ["alone", 412], ["tools", 418], ["were", 424], ["developed", 429], ["to", 439], ["address", 442], ["this", 450], ["problem", 455], [",", 462], ["all", 464], ["these", 468], ["tools", 474], [",", 479], ["however", 481], [",", 488], ["can", 490], ["only", 494], ["handle", 499], ["one", 506], ["type", 510], ["of", 515], ["samples", 518], [".", 525], ["Furthermore", 527], [",", 538], ["the", 540], ["number", 544], ["of", 551], ["their", 554], ["built", 560], ["-", 565], ["in", 566], ["properties", 569], ["is", 580], ["limited", 583], [",", 590], ["and", 592], ["hence", 596], ["it", 602], ["is", 605], ["often", 608], ["difficult", 614], ["for", 624], ["users", 628], ["to", 634], ["formulate", 637], ["the", 647], ["biological", 651], ["sequences", 662], ["according", 672], ["to", 682], ["their", 685], ["desired", 691], ["features", 699], ["or", 708], ["properties", 711], [".", 721], ["In", 723], ["this", 726], ["article", 731], [",", 738], ["with", 740], ["a", 745], ["much", 747], ["larger", 752], ["number", 759], ["of", 766], ["built", 769], ["-", 774], ["in", 775], ["properties", 778], [",", 788], ["we", 790], ["are", 793], ["to", 797], ["propose", 800], ["a", 808], ["much", 810], ["more", 815], ["flexible", 820], ["web", 829], ["server", 833], ["called", 840], ["Pse", 847], ["-", 850], ["in", 851], ["-", 853], ["One", 854], ["(", 858], ["http://bioinformatics.hitsz.edu.cn/Pse-in-One/", 859], [")", 905], [",", 906], ["which", 908], ["can", 914], [",", 917], ["through", 919], ["its", 927], ["28", 931], ["different", 934], ["modes", 944], [",", 949], ["generate", 951], ["nearly", 960], ["all", 967], ["the", 971], ["possible", 975], ["feature", 984], ["vectors", 992], ["for", 1000], ["DNA", 1004], [",", 1007], ["RNA", 1009], ["and", 1013], ["protein", 1017], ["sequences", 1025], [".", 1034], ["Particularly", 1036], [",", 1048], ["it", 1050], ["can", 1053], ["also", 1057], ["generate", 1062], ["those", 1071], ["feature", 1077], ["vectors", 1085], ["with", 1093], ["the", 1098], ["properties", 1102], ["defined", 1113], ["by", 1121], ["users", 1124], ["themselves", 1130], [".", 1140], ["These", 1142], ["feature", 1148], ["vectors", 1156], ["can", 1164], ["be", 1168], ["easily", 1171], ["combined", 1178], ["with", 1187], ["machine", 1192], ["-", 1199], ["learning", 1200], ["algorithms", 1209], ["to", 1220], ["develop", 1223], ["computational", 1231], ["predictors", 1245], ["and", 1256], ["analysis", 1260], ["methods", 1269], ["for", 1277], ["various", 1281], ["tasks", 1289], ["in", 1295], ["bioinformatics", 1298], ["and", 1313], ["system", 1317], ["biology", 1324], [".", 1331], ["It", 1333], ["is", 1336], ["anticipated", 1339], ["that", 1351], ["the", 1356], ["Pse", 1360], ["-", 1363], ["in", 1364], ["-", 1366], ["One", 1367], ["web", 1371], ["server", 1375], ["will", 1382], ["become", 1387], ["a", 1394], ["very", 1396], ["useful", 1401], ["tool", 1408], ["in", 1413], ["computational", 1416], ["proteomics", 1430], [",", 1440], ["genomics", 1442], [",", 1450], ["as", 1452], ["well", 1455], ["as", 1460], ["biological", 1463], ["sequence", 1474], ["analysis", 1483], [".", 1491], ["Moreover", 1493], [",", 1501], ["to", 1503], ["maximize", 1506], ["users", 1515], ["'", 1520], ["convenience", 1522], [",", 1533], ["its", 1535], ["stand", 1539], ["-", 1544], ["alone", 1545], ["version", 1551], ["can", 1559], ["also", 1563], ["be", 1568], ["downloaded", 1571], ["from", 1582], ["http://bioinformatics.hitsz.edu.cn/Pse-in-One/download/", 1587], [",", 1642], ["and", 1644], ["directly", 1648], ["run", 1657], ["on", 1661], ["Windows", 1664], [",", 1671], ["Linux", 1673], [",", 1678], ["Unix", 1680], ["and", 1685], ["Mac", 1689], ["OS", 1693], [".", 1695]]}
{"context": "Transcription-coupled repair (TCR) is the major pathway involved in the removal of UV-induced photolesions from the transcribed strand of active genes. Two Cockayne syndrome (CS) complementation group proteins, CSA and CSB, are important for TCR repair. The molecular mechanisms by which CS proteins regulate TCR remain elusive. Here, we report the characterization of KIAA1530, an evolutionarily conserved protein that participates in this pathway through its interaction with CSA and the TFIIH complex. We found that UV irradiation led to the recruitment of KIAA1530 onto chromatin in a CSA-dependent manner. Cells lacking KIAA1530 were highly sensitive to UV irradiation and displayed deficiency in TCR. In addition, KIAA1530 depletion abrogated stability of the CSB protein following UV irradiation. More excitingly, we found that a unique CSA mutant (W361C), which was previously identified in a patient with UV(s)S syndrome, showed defective KIAA1530 binding and resulted in a failure of recruiting KIAA1530 and stabilizing CSB after UV treatment. Together, our data not only reveal that KIAA1530 is an important player in TCR but also lead to a better understanding of the molecular mechanism underlying UV(s)S syndrome.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "0ee48960a85e4cb08d71437204c23131", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[22, 23]], "char_spans": [[116, 133]]}]}], "context_tokens": [["Transcription", 0], ["-", 13], ["coupled", 14], ["repair", 22], ["(", 29], ["TCR", 30], [")", 33], ["is", 35], ["the", 38], ["major", 42], ["pathway", 48], ["involved", 56], ["in", 65], ["the", 68], ["removal", 72], ["of", 80], ["UV", 83], ["-", 85], ["induced", 86], ["photolesions", 94], ["from", 107], ["the", 112], ["transcribed", 116], ["strand", 128], ["of", 135], ["active", 138], ["genes", 145], [".", 150], ["Two", 152], ["Cockayne", 156], ["syndrome", 165], ["(", 174], ["CS", 175], [")", 177], ["complementation", 179], ["group", 195], ["proteins", 201], [",", 209], ["CSA", 211], ["and", 215], ["CSB", 219], [",", 222], ["are", 224], ["important", 228], ["for", 238], ["TCR", 242], ["repair", 246], [".", 252], ["The", 254], ["molecular", 258], ["mechanisms", 268], ["by", 279], ["which", 282], ["CS", 288], ["proteins", 291], ["regulate", 300], ["TCR", 309], ["remain", 313], ["elusive", 320], [".", 327], ["Here", 329], [",", 333], ["we", 335], ["report", 338], ["the", 345], ["characterization", 349], ["of", 366], ["KIAA1530", 369], [",", 377], ["an", 379], ["evolutionarily", 382], ["conserved", 397], ["protein", 407], ["that", 415], ["participates", 420], ["in", 433], ["this", 436], ["pathway", 441], ["through", 449], ["its", 457], ["interaction", 461], ["with", 473], ["CSA", 478], ["and", 482], ["the", 486], ["TFIIH", 490], ["complex", 496], [".", 503], ["We", 505], ["found", 508], ["that", 514], ["UV", 519], ["irradiation", 522], ["led", 534], ["to", 538], ["the", 541], ["recruitment", 545], ["of", 557], ["KIAA1530", 560], ["onto", 569], ["chromatin", 574], ["in", 584], ["a", 587], ["CSA", 589], ["-", 592], ["dependent", 593], ["manner", 603], [".", 609], ["Cells", 611], ["lacking", 617], ["KIAA1530", 625], ["were", 634], ["highly", 639], ["sensitive", 646], ["to", 656], ["UV", 659], ["irradiation", 662], ["and", 674], ["displayed", 678], ["deficiency", 688], ["in", 699], ["TCR", 702], [".", 705], ["In", 707], ["addition", 710], [",", 718], ["KIAA1530", 720], ["depletion", 729], ["abrogated", 739], ["stability", 749], ["of", 759], ["the", 762], ["CSB", 766], ["protein", 770], ["following", 778], ["UV", 788], ["irradiation", 791], [".", 802], ["More", 804], ["excitingly", 809], [",", 819], ["we", 821], ["found", 824], ["that", 830], ["a", 835], ["unique", 837], ["CSA", 844], ["mutant", 848], ["(", 855], ["W361C", 856], [")", 861], [",", 862], ["which", 864], ["was", 870], ["previously", 874], ["identified", 885], ["in", 896], ["a", 899], ["patient", 901], ["with", 909], ["UV(s)S", 914], ["syndrome", 921], [",", 929], ["showed", 931], ["defective", 938], ["KIAA1530", 948], ["binding", 957], ["and", 965], ["resulted", 969], ["in", 978], ["a", 981], ["failure", 983], ["of", 991], ["recruiting", 994], ["KIAA1530", 1005], ["and", 1014], ["stabilizing", 1018], ["CSB", 1030], ["after", 1034], ["UV", 1040], ["treatment", 1043], [".", 1052], ["Together", 1054], [",", 1062], ["our", 1064], ["data", 1068], ["not", 1073], ["only", 1077], ["reveal", 1082], ["that", 1089], ["KIAA1530", 1094], ["is", 1103], ["an", 1106], ["important", 1109], ["player", 1119], ["in", 1126], ["TCR", 1129], ["but", 1133], ["also", 1137], ["lead", 1142], ["to", 1147], ["a", 1150], ["better", 1152], ["understanding", 1159], ["of", 1173], ["the", 1176], ["molecular", 1180], ["mechanism", 1190], ["underlying", 1200], ["UV(s)S", 1211], ["syndrome", 1218], [".", 1226]]}
{"context": "Interleukin-1\u03b2 (IL-1\u03b2) is a key orchestrator in inflammatory and several immune responses. IL-1\u03b2 exerts its effects through interleukin-1 receptor type I (IL-1RI) and interleukin-1 receptor accessory protein (IL-1RAcP), which together form a heterotrimeric signaling-competent complex. Canakinumab and gevokizumab are highly specific IL-1\u03b2 monoclonal antibodies. Canakinumab is known to neutralize IL-1\u03b2 by competing for binding to IL-1R and therefore blocking signaling by the antigen:antibody complex. Gevokizumab is claimed to be a regulatory therapeutic antibody that modulates IL-1\u03b2 bioactivity by reducing the affinity for its IL-1RI:IL-1RAcP signaling complex. How IL-1\u03b2 signaling is affected by both canakinumab and gevokizumab was not yet experimentally determined. We have analyzed the crystal structures of canakinumab and gevokizumab antibody binding fragment (Fab) as well as of their binary complexes with IL-1\u03b2. Furthermore, we characterized the epitopes on IL-1\u03b2 employed by the antibodies by NMR epitope mapping studies. The direct comparison of NMR and X-ray data shows that the epitope defined by the crystal structure encompasses predominantly those residues whose NMR resonances are severely perturbed upon complex formation. The antigen:Fab co-structures confirm the previously identified key contact residues on IL-1\u03b2 and provide insight into the mechanisms leading to their distinct modulation of IL-1\u03b2 signaling. A significant steric overlap of the binding interfaces of IL-1R and canakinumab on IL-1\u03b2 causes competitive inhibition of the association of IL-1\u03b2 and its receptor. In contrast, gevokizumab occupies an allosteric site on IL-1\u03b2 and complex formation results in a minor reduction of binding affinity to IL-1RI. This suggests two different mechanisms of IL-1\u03b2 pathway attenuation.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "2f0cee196ddb4065924495ca24e444df", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[144, 144], [61, 61], [90, 90], [52, 52], [212, 212], [105, 105], [153, 153], [249, 249], [263, 263], [284, 284], [225, 225], [2, 2], [15, 15], [241, 241]], "char_spans": [[920, 924], [398, 402], [582, 586], [334, 338], [1335, 1339], [672, 676], [973, 977], [1579, 1583], [1659, 1663], [1789, 1793], [1421, 1425], [16, 20], [91, 95], [1521, 1525]]}]}], "context_tokens": [["Interleukin-1\u03b2", 0], ["(", 15], ["IL-1\u03b2", 16], [")", 21], ["is", 23], ["a", 26], ["key", 28], ["orchestrator", 32], ["in", 45], ["inflammatory", 48], ["and", 61], ["several", 65], ["immune", 73], ["responses", 80], [".", 89], ["IL-1\u03b2", 91], ["exerts", 97], ["its", 104], ["effects", 108], ["through", 116], ["interleukin-1", 124], ["receptor", 138], ["type", 147], ["I", 152], ["(", 154], ["IL-1RI", 155], [")", 161], ["and", 163], ["interleukin-1", 167], ["receptor", 181], ["accessory", 190], ["protein", 200], ["(", 208], ["IL-1RAcP", 209], [")", 217], [",", 218], ["which", 220], ["together", 226], ["form", 235], ["a", 240], ["heterotrimeric", 242], ["signaling", 257], ["-", 266], ["competent", 267], ["complex", 277], [".", 284], ["Canakinumab", 286], ["and", 298], ["gevokizumab", 302], ["are", 314], ["highly", 318], ["specific", 325], ["IL-1\u03b2", 334], ["monoclonal", 340], ["antibodies", 351], [".", 361], ["Canakinumab", 363], ["is", 375], ["known", 378], ["to", 384], ["neutralize", 387], ["IL-1\u03b2", 398], ["by", 404], ["competing", 407], ["for", 417], ["binding", 421], ["to", 429], ["IL-1R", 432], ["and", 438], ["therefore", 442], ["blocking", 452], ["signaling", 461], ["by", 471], ["the", 474], ["antigen", 478], [":", 485], ["antibody", 486], ["complex", 495], [".", 502], ["Gevokizumab", 504], ["is", 516], ["claimed", 519], ["to", 527], ["be", 530], ["a", 533], ["regulatory", 535], ["therapeutic", 546], ["antibody", 558], ["that", 567], ["modulates", 572], ["IL-1\u03b2", 582], ["bioactivity", 588], ["by", 600], ["reducing", 603], ["the", 612], ["affinity", 616], ["for", 625], ["its", 629], ["IL-1RI", 633], [":", 639], ["IL-1RAcP", 640], ["signaling", 649], ["complex", 659], [".", 666], ["How", 668], ["IL-1\u03b2", 672], ["signaling", 678], ["is", 688], ["affected", 691], ["by", 700], ["both", 703], ["canakinumab", 708], ["and", 720], ["gevokizumab", 724], ["was", 736], ["not", 740], ["yet", 744], ["experimentally", 748], ["determined", 763], [".", 773], ["We", 775], ["have", 778], ["analyzed", 783], ["the", 792], ["crystal", 796], ["structures", 804], ["of", 815], ["canakinumab", 818], ["and", 830], ["gevokizumab", 834], ["antibody", 846], ["binding", 855], ["fragment", 863], ["(", 872], ["Fab", 873], [")", 876], ["as", 878], ["well", 881], ["as", 886], ["of", 889], ["their", 892], ["binary", 898], ["complexes", 905], ["with", 915], ["IL-1\u03b2", 920], [".", 925], ["Furthermore", 927], [",", 938], ["we", 940], ["characterized", 943], ["the", 957], ["epitopes", 961], ["on", 970], ["IL-1\u03b2", 973], ["employed", 979], ["by", 988], ["the", 991], ["antibodies", 995], ["by", 1006], ["NMR", 1009], ["epitope", 1013], ["mapping", 1021], ["studies", 1029], [".", 1036], ["The", 1038], ["direct", 1042], ["comparison", 1049], ["of", 1060], ["NMR", 1063], ["and", 1067], ["X", 1071], ["-", 1072], ["ray", 1073], ["data", 1077], ["shows", 1082], ["that", 1088], ["the", 1093], ["epitope", 1097], ["defined", 1105], ["by", 1113], ["the", 1116], ["crystal", 1120], ["structure", 1128], ["encompasses", 1138], ["predominantly", 1150], ["those", 1164], ["residues", 1170], ["whose", 1179], ["NMR", 1185], ["resonances", 1189], ["are", 1200], ["severely", 1204], ["perturbed", 1213], ["upon", 1223], ["complex", 1228], ["formation", 1236], [".", 1245], ["The", 1247], ["antigen", 1251], [":", 1258], ["Fab", 1259], ["co", 1263], ["-", 1265], ["structures", 1266], ["confirm", 1277], ["the", 1285], ["previously", 1289], ["identified", 1300], ["key", 1311], ["contact", 1315], ["residues", 1323], ["on", 1332], ["IL-1\u03b2", 1335], ["and", 1341], ["provide", 1345], ["insight", 1353], ["into", 1361], ["the", 1366], ["mechanisms", 1370], ["leading", 1381], ["to", 1389], ["their", 1392], ["distinct", 1398], ["modulation", 1407], ["of", 1418], ["IL-1\u03b2", 1421], ["signaling", 1427], [".", 1436], ["A", 1438], ["significant", 1440], ["steric", 1452], ["overlap", 1459], ["of", 1467], ["the", 1470], ["binding", 1474], ["interfaces", 1482], ["of", 1493], ["IL-1R", 1496], ["and", 1502], ["canakinumab", 1506], ["on", 1518], ["IL-1\u03b2", 1521], ["causes", 1527], ["competitive", 1534], ["inhibition", 1546], ["of", 1557], ["the", 1560], ["association", 1564], ["of", 1576], ["IL-1\u03b2", 1579], ["and", 1585], ["its", 1589], ["receptor", 1593], [".", 1601], ["In", 1603], ["contrast", 1606], [",", 1614], ["gevokizumab", 1616], ["occupies", 1628], ["an", 1637], ["allosteric", 1640], ["site", 1651], ["on", 1656], ["IL-1\u03b2", 1659], ["and", 1665], ["complex", 1669], ["formation", 1677], ["results", 1687], ["in", 1695], ["a", 1698], ["minor", 1700], ["reduction", 1706], ["of", 1716], ["binding", 1719], ["affinity", 1727], ["to", 1736], ["IL-1RI", 1739], [".", 1745], ["This", 1747], ["suggests", 1752], ["two", 1761], ["different", 1765], ["mechanisms", 1775], ["of", 1786], ["IL-1\u03b2", 1789], ["pathway", 1795], ["attenuation", 1803], [".", 1814]]}
{"context": "Cep135 is a 135-kDa, coiled-coil centrosome protein important for microtubule organization in mammalian cells [Ohta et al., 2002: J. Cell Biol. 156:87-99]. To identify Cep135-interacting molecules, we screened yeast two-hybrid libraries. One clone encoded dynamitin, a p50 dynactin subunit, which localized at the centrosome and has been shown to be involved in anchoring microtubules to centrosomes. The central domain of p50 binds to the C-terminal sequence of Cep135; this was further confirmed by immunoprecipitation and immunostaining of CHO cells co-expressing the binding domains for Cep135 and p50. Exogenous p50 lacking the Cep 135-binding domain failed to locate at the centrosome, suggesting that Cep135 is required for initial targeting of the centrosome. Altered levels of Cep135 and p50 by RNAi and protein overexpression caused the release of endogenous partner molecules from centrosomes. This also resulted in dislocation of other centrosomal molecules, such as gamma-tubulin and pericentrin, ultimately leading to disorganization of microtubule patterns. These results suggest that Cep135 and p50 play an important role in assembly and maintenance of functional microtubule-organizing centers.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "08c3aa54125445ca90f9fe4a6632bcf7", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[134, 134], [8, 8], [59, 59], [122, 122]], "char_spans": [[756, 765], [33, 42], [314, 323], [680, 689]]}]}], "context_tokens": [["Cep135", 0], ["is", 7], ["a", 10], ["135-kDa", 12], [",", 19], ["coiled", 21], ["-", 27], ["coil", 28], ["centrosome", 33], ["protein", 44], ["important", 52], ["for", 62], ["microtubule", 66], ["organization", 78], ["in", 91], ["mammalian", 94], ["cells", 104], ["[", 110], ["Ohta", 111], ["et", 116], ["al", 119], [".", 121], [",", 122], ["2002", 124], [":", 128], ["J.", 130], ["Cell", 133], ["Biol", 138], [".", 142], ["156:87", 144], ["-", 150], ["99].", 151], ["To", 156], ["identify", 159], ["Cep135-interacting", 168], ["molecules", 187], [",", 196], ["we", 198], ["screened", 201], ["yeast", 210], ["two", 216], ["-", 219], ["hybrid", 220], ["libraries", 227], [".", 236], ["One", 238], ["clone", 242], ["encoded", 248], ["dynamitin", 256], [",", 265], ["a", 267], ["p50", 269], ["dynactin", 273], ["subunit", 282], [",", 289], ["which", 291], ["localized", 297], ["at", 307], ["the", 310], ["centrosome", 314], ["and", 325], ["has", 329], ["been", 333], ["shown", 338], ["to", 344], ["be", 347], ["involved", 350], ["in", 359], ["anchoring", 362], ["microtubules", 372], ["to", 385], ["centrosomes", 388], [".", 399], ["The", 401], ["central", 405], ["domain", 413], ["of", 420], ["p50", 423], ["binds", 427], ["to", 433], ["the", 436], ["C", 440], ["-", 441], ["terminal", 442], ["sequence", 451], ["of", 460], ["Cep135", 463], [";", 469], ["this", 471], ["was", 476], ["further", 480], ["confirmed", 488], ["by", 498], ["immunoprecipitation", 501], ["and", 521], ["immunostaining", 525], ["of", 540], ["CHO", 543], ["cells", 547], ["co", 553], ["-", 555], ["expressing", 556], ["the", 567], ["binding", 571], ["domains", 579], ["for", 587], ["Cep135", 591], ["and", 598], ["p50", 602], [".", 605], ["Exogenous", 607], ["p50", 617], ["lacking", 621], ["the", 629], ["Cep", 633], ["135-binding", 637], ["domain", 649], ["failed", 656], ["to", 663], ["locate", 666], ["at", 673], ["the", 676], ["centrosome", 680], [",", 690], ["suggesting", 692], ["that", 703], ["Cep135", 708], ["is", 715], ["required", 718], ["for", 727], ["initial", 731], ["targeting", 739], ["of", 749], ["the", 752], ["centrosome", 756], [".", 766], ["Altered", 768], ["levels", 776], ["of", 783], ["Cep135", 786], ["and", 793], ["p50", 797], ["by", 801], ["RNAi", 804], ["and", 809], ["protein", 813], ["overexpression", 821], ["caused", 836], ["the", 843], ["release", 847], ["of", 855], ["endogenous", 858], ["partner", 869], ["molecules", 877], ["from", 887], ["centrosomes", 892], [".", 903], ["This", 905], ["also", 910], ["resulted", 915], ["in", 924], ["dislocation", 927], ["of", 939], ["other", 942], ["centrosomal", 948], ["molecules", 960], [",", 969], ["such", 971], ["as", 976], ["gamma", 979], ["-", 984], ["tubulin", 985], ["and", 993], ["pericentrin", 997], [",", 1008], ["ultimately", 1010], ["leading", 1021], ["to", 1029], ["disorganization", 1032], ["of", 1048], ["microtubule", 1051], ["patterns", 1063], [".", 1071], ["These", 1073], ["results", 1079], ["suggest", 1087], ["that", 1095], ["Cep135", 1100], ["and", 1107], ["p50", 1111], ["play", 1115], ["an", 1120], ["important", 1123], ["role", 1133], ["in", 1138], ["assembly", 1141], ["and", 1150], ["maintenance", 1154], ["of", 1166], ["functional", 1169], ["microtubule", 1180], ["-", 1191], ["organizing", 1192], ["centers", 1203], [".", 1210]]}
{"context": "CML (chronic myeloid leukaemia) is a myeloproliferative disease that originates in an HSC (haemopoietic stem cell) as a result of the t(9;22) translocation, giving rise to the Ph (Philadelphia chromosome) and bcr-abl oncoprotein. The disease starts in CP (chronic phase), but as a result of genomic instability, it progresses over time to accelerated phase and then to BC (blast crisis), becoming increasingly resistant to therapy. bcr-abl is a constitutively active tyrosine kinase that has been targeted by TKIs (tyrosine kinase inhibitors), including IM (imatinib mesylate), nilotinib and dasatinib. We have developed various flow cytometry techniques to enable us to isolate candidate CML stem cells from CP patients at diagnosis that efflux Hoechst dye, express CD34, lack CD38 and are cytokine-non-responsive in culture over periods of up to 12 days in growth factors. These stem cells have been shown to regenerate bcr-abl-positive haemopoiesis in immunocompromised mice upon transplantation. We previously demonstrated that IM was antiproliferative for CML stem cells but did not induce apoptosis. Clinical experience now confirms that IM may not target CML stem cells in vivo with few patients achieving complete molecular remission and relapse occurring rapidly upon drug withdrawal. Our recent efforts have focused on understanding why CML stem cells are resistant to IM and on trying to find novel ways to induce apoptosis of this population. We have shown that CML stem cells express very high levels of functional wild-type bcr-abl; no kinase domain mutations have been detected in the stem cell population. Dasatinib, a more potent multitargeted TKI than IM, inhibits bcr-abl activity more efficiently than IM but still does not induce apoptosis of the stem cell population. Most recently, we have tested a number of novel drug combinations and found that FTIs (farnesyl transferase inhibitors) have activity against CML. BMS-214662 is the most effective of these and induces apoptosis of phenotypically and functionally defined CML stem cells in vitro, as a single agent and in combination with IM or dasatinib. The effect against CML stem cells is selective with little effect on normal stem cells. The drug is also effective against BC CML stem cells and equally effective against wild-type and mutant bcr-abl, including the most resistant mutant T315I. In association with apoptosis, there is activation of caspase 8 and caspase 3, inhibition of the MAPK pathway, IAP-1 (inhibitor of apoptosis protein-1), NF-kappaB (nuclear factor kappaB) and iNOS (inducible nitric oxide synthase). Furthermore, BMS-214662 synergizes with MEK1/2 [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase 1/2] inhibitors, suggesting a second mechanism other that RAS inhibition for induction of apoptosis. Our intentions are now to explore the activity of BMS-214662 in other cancer stem cell disorders and to move this preclinical work to a clinical trial combining dasatinib with BMS-214662 in CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "88390fb06cb44b229884042b868e9663", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[84, 86], [278, 280], [420, 422], [39, 41], [306, 308], [175, 177]], "char_spans": [[432, 438], [1538, 1544], [2320, 2326], [209, 215], [1683, 1689], [922, 928]]}]}], "context_tokens": [["CML", 0], ["(", 4], ["chronic", 5], ["myeloid", 13], ["leukaemia", 21], [")", 30], ["is", 32], ["a", 35], ["myeloproliferative", 37], ["disease", 56], ["that", 64], ["originates", 69], ["in", 80], ["an", 83], ["HSC", 86], ["(", 90], ["haemopoietic", 91], ["stem", 104], ["cell", 109], [")", 113], ["as", 115], ["a", 118], ["result", 120], ["of", 127], ["the", 130], ["t(9;22", 134], [")", 140], ["translocation", 142], [",", 155], ["giving", 157], ["rise", 164], ["to", 169], ["the", 172], ["Ph", 176], ["(", 179], ["Philadelphia", 180], ["chromosome", 193], [")", 203], ["and", 205], ["bcr", 209], ["-", 212], ["abl", 213], ["oncoprotein", 217], [".", 228], ["The", 230], ["disease", 234], ["starts", 242], ["in", 249], ["CP", 252], ["(", 255], ["chronic", 256], ["phase", 264], [")", 269], [",", 270], ["but", 272], ["as", 276], ["a", 279], ["result", 281], ["of", 288], ["genomic", 291], ["instability", 299], [",", 310], ["it", 312], ["progresses", 315], ["over", 326], ["time", 331], ["to", 336], ["accelerated", 339], ["phase", 351], ["and", 357], ["then", 361], ["to", 366], ["BC", 369], ["(", 372], ["blast", 373], ["crisis", 379], [")", 385], [",", 386], ["becoming", 388], ["increasingly", 397], ["resistant", 410], ["to", 420], ["therapy", 423], [".", 430], ["bcr", 432], ["-", 435], ["abl", 436], ["is", 440], ["a", 443], ["constitutively", 445], ["active", 460], ["tyrosine", 467], ["kinase", 476], ["that", 483], ["has", 488], ["been", 492], ["targeted", 497], ["by", 506], ["TKIs", 509], ["(", 514], ["tyrosine", 515], ["kinase", 524], ["inhibitors", 531], [")", 541], [",", 542], ["including", 544], ["IM", 554], ["(", 557], ["imatinib", 558], ["mesylate", 567], [")", 575], [",", 576], ["nilotinib", 578], ["and", 588], ["dasatinib", 592], [".", 601], ["We", 603], ["have", 606], ["developed", 611], ["various", 621], ["flow", 629], ["cytometry", 634], ["techniques", 644], ["to", 655], ["enable", 658], ["us", 665], ["to", 668], ["isolate", 671], ["candidate", 679], ["CML", 689], ["stem", 693], ["cells", 698], ["from", 704], ["CP", 709], ["patients", 712], ["at", 721], ["diagnosis", 724], ["that", 734], ["efflux", 739], ["Hoechst", 746], ["dye", 754], [",", 757], ["express", 759], ["CD34", 767], [",", 771], ["lack", 773], ["CD38", 778], ["and", 783], ["are", 787], ["cytokine", 791], ["-", 799], ["non", 800], ["-", 803], ["responsive", 804], ["in", 815], ["culture", 818], ["over", 826], ["periods", 831], ["of", 839], ["up", 842], ["to", 845], ["12", 848], ["days", 851], ["in", 856], ["growth", 859], ["factors", 866], [".", 873], ["These", 875], ["stem", 881], ["cells", 886], ["have", 892], ["been", 897], ["shown", 902], ["to", 908], ["regenerate", 911], ["bcr", 922], ["-", 925], ["abl", 926], ["-", 929], ["positive", 930], ["haemopoiesis", 939], ["in", 952], ["immunocompromised", 955], ["mice", 973], ["upon", 978], ["transplantation", 983], [".", 998], ["We", 1000], ["previously", 1003], ["demonstrated", 1014], ["that", 1027], ["IM", 1032], ["was", 1035], ["antiproliferative", 1039], ["for", 1057], ["CML", 1061], ["stem", 1065], ["cells", 1070], ["but", 1076], ["did", 1080], ["not", 1084], ["induce", 1088], ["apoptosis", 1095], [".", 1104], ["Clinical", 1106], ["experience", 1115], ["now", 1126], ["confirms", 1130], ["that", 1139], ["IM", 1144], ["may", 1147], ["not", 1151], ["target", 1155], ["CML", 1162], ["stem", 1166], ["cells", 1171], ["in", 1177], ["vivo", 1180], ["with", 1185], ["few", 1190], ["patients", 1194], ["achieving", 1203], ["complete", 1213], ["molecular", 1222], ["remission", 1232], ["and", 1242], ["relapse", 1246], ["occurring", 1254], ["rapidly", 1264], ["upon", 1272], ["drug", 1277], ["withdrawal", 1282], [".", 1292], ["Our", 1294], ["recent", 1298], ["efforts", 1305], ["have", 1313], ["focused", 1318], ["on", 1326], ["understanding", 1329], ["why", 1343], ["CML", 1347], ["stem", 1351], ["cells", 1356], ["are", 1362], ["resistant", 1366], ["to", 1376], ["IM", 1379], ["and", 1382], ["on", 1386], ["trying", 1389], ["to", 1396], ["find", 1399], ["novel", 1404], ["ways", 1410], ["to", 1415], ["induce", 1418], ["apoptosis", 1425], ["of", 1435], ["this", 1438], ["population", 1443], [".", 1453], ["We", 1455], ["have", 1458], ["shown", 1463], ["that", 1469], ["CML", 1474], ["stem", 1478], ["cells", 1483], ["express", 1489], ["very", 1497], ["high", 1502], ["levels", 1507], ["of", 1514], ["functional", 1517], ["wild", 1528], ["-", 1532], ["type", 1533], ["bcr", 1538], ["-", 1541], ["abl", 1542], [";", 1545], ["no", 1547], ["kinase", 1550], ["domain", 1557], ["mutations", 1564], ["have", 1574], ["been", 1579], ["detected", 1584], ["in", 1593], ["the", 1596], ["stem", 1600], ["cell", 1605], ["population", 1610], [".", 1620], ["Dasatinib", 1622], [",", 1631], ["a", 1633], ["more", 1635], ["potent", 1640], ["multitargeted", 1647], ["TKI", 1661], ["than", 1665], ["IM", 1670], [",", 1672], ["inhibits", 1674], ["bcr", 1683], ["-", 1686], ["abl", 1687], ["activity", 1691], ["more", 1700], ["efficiently", 1705], ["than", 1717], ["IM", 1722], ["but", 1725], ["still", 1729], ["does", 1735], ["not", 1740], ["induce", 1744], ["apoptosis", 1751], ["of", 1761], ["the", 1764], ["stem", 1768], ["cell", 1773], ["population", 1778], [".", 1788], ["Most", 1790], ["recently", 1795], [",", 1803], ["we", 1805], ["have", 1808], ["tested", 1813], ["a", 1820], ["number", 1822], ["of", 1829], ["novel", 1832], ["drug", 1838], ["combinations", 1843], ["and", 1856], ["found", 1860], ["that", 1866], ["FTIs", 1871], ["(", 1876], ["farnesyl", 1877], ["transferase", 1886], ["inhibitors", 1898], [")", 1908], ["have", 1910], ["activity", 1915], ["against", 1924], ["CML", 1932], [".", 1935], ["BMS-214662", 1937], ["is", 1948], ["the", 1951], ["most", 1955], ["effective", 1960], ["of", 1970], ["these", 1973], ["and", 1979], ["induces", 1983], ["apoptosis", 1991], ["of", 2001], ["phenotypically", 2004], ["and", 2019], ["functionally", 2023], ["defined", 2036], ["CML", 2044], ["stem", 2048], ["cells", 2053], ["in", 2059], ["vitro", 2062], [",", 2067], ["as", 2069], ["a", 2072], ["single", 2074], ["agent", 2081], ["and", 2087], ["in", 2091], ["combination", 2094], ["with", 2106], ["IM", 2111], ["or", 2114], ["dasatinib", 2117], [".", 2126], ["The", 2128], ["effect", 2132], ["against", 2139], ["CML", 2147], ["stem", 2151], ["cells", 2156], ["is", 2162], ["selective", 2165], ["with", 2175], ["little", 2180], ["effect", 2187], ["on", 2194], ["normal", 2197], ["stem", 2204], ["cells", 2209], [".", 2214], ["The", 2216], ["drug", 2220], ["is", 2225], ["also", 2228], ["effective", 2233], ["against", 2243], ["BC", 2251], ["CML", 2254], ["stem", 2258], ["cells", 2263], ["and", 2269], ["equally", 2273], ["effective", 2281], ["against", 2291], ["wild", 2299], ["-", 2303], ["type", 2304], ["and", 2309], ["mutant", 2313], ["bcr", 2320], ["-", 2323], ["abl", 2324], [",", 2327], ["including", 2329], ["the", 2339], ["most", 2343], ["resistant", 2348], ["mutant", 2358], ["T315I.", 2365], ["In", 2372], ["association", 2375], ["with", 2387], ["apoptosis", 2392], [",", 2401], ["there", 2403], ["is", 2409], ["activation", 2412], ["of", 2423], ["caspase", 2426], ["8", 2434], ["and", 2436], ["caspase", 2440], ["3", 2448], [",", 2449], ["inhibition", 2451], ["of", 2462], ["the", 2465], ["MAPK", 2469], ["pathway", 2474], [",", 2481], ["IAP-1", 2483], ["(", 2489], ["inhibitor", 2490], ["of", 2500], ["apoptosis", 2503], ["protein-1", 2513], [")", 2522], [",", 2523], ["NF", 2525], ["-", 2527], ["kappaB", 2528], ["(", 2535], ["nuclear", 2536], ["factor", 2544], ["kappaB", 2551], [")", 2557], ["and", 2559], ["iNOS", 2563], ["(", 2568], ["inducible", 2569], ["nitric", 2579], ["oxide", 2586], ["synthase", 2592], [")", 2600], [".", 2601], ["Furthermore", 2603], [",", 2614], ["BMS-214662", 2616], ["synergizes", 2627], ["with", 2638], ["MEK1/2", 2643], ["[", 2650], ["MAPK", 2651], ["(", 2656], ["mitogen", 2657], ["-", 2664], ["activated", 2665], ["protein", 2675], ["kinase)/ERK", 2683], ["(", 2695], ["extracellular", 2696], ["-", 2709], ["signal", 2710], ["-", 2716], ["regulated", 2717], ["kinase", 2727], [")", 2733], ["kinase", 2735], ["1/2", 2742], ["]", 2745], ["inhibitors", 2747], [",", 2757], ["suggesting", 2759], ["a", 2770], ["second", 2772], ["mechanism", 2779], ["other", 2789], ["that", 2795], ["RAS", 2800], ["inhibition", 2804], ["for", 2815], ["induction", 2819], ["of", 2829], ["apoptosis", 2832], [".", 2841], ["Our", 2843], ["intentions", 2847], ["are", 2858], ["now", 2862], ["to", 2866], ["explore", 2869], ["the", 2877], ["activity", 2881], ["of", 2890], ["BMS-214662", 2893], ["in", 2904], ["other", 2907], ["cancer", 2913], ["stem", 2920], ["cell", 2925], ["disorders", 2930], ["and", 2940], ["to", 2944], ["move", 2947], ["this", 2952], ["preclinical", 2957], ["work", 2969], ["to", 2974], ["a", 2977], ["clinical", 2979], ["trial", 2988], ["combining", 2994], ["dasatinib", 3004], ["with", 3014], ["BMS-214662", 3019], ["in", 3030], ["CML", 3033], [".", 3036]]}
{"context": "Although methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to vancomycin (RVS-MRSA; including vancomycin-intermediate S. aureus [VISA] and heterogeneous VISA [hVISA]) have been linked with vancomycin treatment failure, it is unclear whether they are more pathogenic than vancomycin-susceptible MRSA (VS-MRSA). We prospectively assessed patients with clinical MRSA isolates during a 10-month period to determine clinical status (infection versus colonization) and therapeutic outcome before correlating these findings with the results of detailed in vitro assessment of vancomycin susceptibility, including population analysis profile (PAP) testing. hVISA and VISA were defined by standard PAP criteria (area-under-the-curve ratio compared to that of the reference hVISA strain Mu3 [>or=0.9]) and routine CLSI criteria (vancomycin MIC, 4 to 8 microg/ml), respectively. Among the 117 patients assessed, 58 had RVS-MRSA isolates (56 hVISA and 2 VISA) and 59 had VS-MRSA isolates; the patient demographics and comorbidities were similar. RVS-MRSA was associated with a lower rate of infection than VS-MRSA (29/58 versus 46/59; P = 0.003), including a lower rate of bacteremia (3/58 versus 20/59, respectively; P < 0.001). The cure rates in RVS-MRSA and VS-MRSA groups were not statistically different (16/26 versus 31/42; P = 0.43), but the post hoc assessment of treatment regimes and study size made detailed conclusions difficult. The results of the macro method Etest correlated well with the PAP results (sensitivity, 98.3%, and specificity, 91.5%), but broth microdilution and our preliminary RVS-MRSA detection method correlated poorly. All isolates were susceptible to linezolid and daptomycin. These data suggest that detailed prospective laboratory identification of RVS-MRSA isolates may be of limited value and that, instead, such in vitro investigation should be reserved for isolates from patients who are failing appropriate anti-MRSA therapy.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "ceea58daf75a47a2a1f4006fe10ba779", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[69, 69], [211, 211], [186, 186], [246, 246], [250, 250], [342, 342], [60, 60], [172, 172], [7, 7], [199, 199], [316, 316], [371, 371], [56, 56], [18, 18]], "char_spans": [[409, 412], [1147, 1150], [1012, 1015], [1290, 1293], [1302, 1305], [1827, 1830], [353, 356], [962, 965], [67, 70], [1088, 1091], [1649, 1652], [1991, 1994], [344, 347], [128, 131]]}]}], "context_tokens": [["Although", 0], ["methicillin", 9], ["(", 21], ["meticillin)-resistant", 22], ["Staphylococcus", 44], ["aureus", 59], ["(", 66], ["MRSA", 67], [")", 71], ["strains", 73], ["with", 81], ["reduced", 86], ["susceptibility", 94], ["to", 109], ["vancomycin", 112], ["(", 123], ["RVS", 124], ["-", 127], ["MRSA", 128], [";", 132], ["including", 134], ["vancomycin", 144], ["-", 154], ["intermediate", 155], ["S.", 168], ["aureus", 171], ["[", 178], ["VISA", 179], ["]", 183], ["and", 185], ["heterogeneous", 189], ["VISA", 203], ["[", 208], ["hVISA", 209], ["]", 214], [")", 215], ["have", 217], ["been", 222], ["linked", 227], ["with", 234], ["vancomycin", 239], ["treatment", 250], ["failure", 260], [",", 267], ["it", 269], ["is", 272], ["unclear", 275], ["whether", 283], ["they", 291], ["are", 296], ["more", 300], ["pathogenic", 305], ["than", 316], ["vancomycin", 321], ["-", 331], ["susceptible", 332], ["MRSA", 344], ["(", 349], ["VS", 350], ["-", 352], ["MRSA", 353], [")", 357], [".", 358], ["We", 360], ["prospectively", 363], ["assessed", 377], ["patients", 386], ["with", 395], ["clinical", 400], ["MRSA", 409], ["isolates", 414], ["during", 423], ["a", 430], ["10-month", 432], ["period", 441], ["to", 448], ["determine", 451], ["clinical", 461], ["status", 470], ["(", 477], ["infection", 478], ["versus", 488], ["colonization", 495], [")", 507], ["and", 509], ["therapeutic", 513], ["outcome", 525], ["before", 533], ["correlating", 540], ["these", 552], ["findings", 558], ["with", 567], ["the", 572], ["results", 576], ["of", 584], ["detailed", 587], ["in", 596], ["vitro", 599], ["assessment", 605], ["of", 616], ["vancomycin", 619], ["susceptibility", 630], [",", 644], ["including", 646], ["population", 656], ["analysis", 667], ["profile", 676], ["(", 684], ["PAP", 685], [")", 688], ["testing", 690], [".", 697], ["hVISA", 699], ["and", 705], ["VISA", 709], ["were", 714], ["defined", 719], ["by", 727], ["standard", 730], ["PAP", 739], ["criteria", 743], ["(", 752], ["area", 753], ["-", 757], ["under", 758], ["-", 763], ["the", 764], ["-", 767], ["curve", 768], ["ratio", 774], ["compared", 780], ["to", 789], ["that", 792], ["of", 797], ["the", 800], ["reference", 804], ["hVISA", 814], ["strain", 820], ["Mu3", 827], ["[", 831], [">", 832], ["or=0.9", 833], ["]", 839], [")", 840], ["and", 842], ["routine", 846], ["CLSI", 854], ["criteria", 859], ["(", 868], ["vancomycin", 869], ["MIC", 880], [",", 883], ["4", 885], ["to", 887], ["8", 890], ["microg", 892], ["/", 898], ["ml", 899], [")", 901], [",", 902], ["respectively", 904], [".", 916], ["Among", 918], ["the", 924], ["117", 928], ["patients", 932], ["assessed", 941], [",", 949], ["58", 951], ["had", 954], ["RVS", 958], ["-", 961], ["MRSA", 962], ["isolates", 967], ["(", 976], ["56", 977], ["hVISA", 980], ["and", 986], ["2", 990], ["VISA", 992], [")", 996], ["and", 998], ["59", 1002], ["had", 1005], ["VS", 1009], ["-", 1011], ["MRSA", 1012], ["isolates", 1017], [";", 1025], ["the", 1027], ["patient", 1031], ["demographics", 1039], ["and", 1052], ["comorbidities", 1056], ["were", 1070], ["similar", 1075], [".", 1082], ["RVS", 1084], ["-", 1087], ["MRSA", 1088], ["was", 1093], ["associated", 1097], ["with", 1108], ["a", 1113], ["lower", 1115], ["rate", 1121], ["of", 1126], ["infection", 1129], ["than", 1139], ["VS", 1144], ["-", 1146], ["MRSA", 1147], ["(", 1152], ["29/58", 1153], ["versus", 1159], ["46/59", 1166], [";", 1171], ["P", 1173], ["=", 1175], ["0.003", 1177], [")", 1182], [",", 1183], ["including", 1185], ["a", 1195], ["lower", 1197], ["rate", 1203], ["of", 1208], ["bacteremia", 1211], ["(", 1222], ["3/58", 1223], ["versus", 1228], ["20/59", 1235], [",", 1240], ["respectively", 1242], [";", 1254], ["P", 1256], ["<", 1258], ["0.001", 1260], [")", 1265], [".", 1266], ["The", 1268], ["cure", 1272], ["rates", 1277], ["in", 1283], ["RVS", 1286], ["-", 1289], ["MRSA", 1290], ["and", 1295], ["VS", 1299], ["-", 1301], ["MRSA", 1302], ["groups", 1307], ["were", 1314], ["not", 1319], ["statistically", 1323], ["different", 1337], ["(", 1347], ["16/26", 1348], ["versus", 1354], ["31/42", 1361], [";", 1366], ["P", 1368], ["=", 1370], ["0.43", 1372], [")", 1376], [",", 1377], ["but", 1379], ["the", 1383], ["post", 1387], ["hoc", 1392], ["assessment", 1396], ["of", 1407], ["treatment", 1410], ["regimes", 1420], ["and", 1428], ["study", 1432], ["size", 1438], ["made", 1443], ["detailed", 1448], ["conclusions", 1457], ["difficult", 1469], [".", 1478], ["The", 1480], ["results", 1484], ["of", 1492], ["the", 1495], ["macro", 1499], ["method", 1505], ["Etest", 1512], ["correlated", 1518], ["well", 1529], ["with", 1534], ["the", 1539], ["PAP", 1543], ["results", 1547], ["(", 1555], ["sensitivity", 1556], [",", 1567], ["98.3", 1569], ["%", 1573], [",", 1574], ["and", 1576], ["specificity", 1580], [",", 1591], ["91.5", 1593], ["%", 1597], [")", 1598], [",", 1599], ["but", 1601], ["broth", 1605], ["microdilution", 1611], ["and", 1625], ["our", 1629], ["preliminary", 1633], ["RVS", 1645], ["-", 1648], ["MRSA", 1649], ["detection", 1654], ["method", 1664], ["correlated", 1671], ["poorly", 1682], [".", 1688], ["All", 1690], ["isolates", 1694], ["were", 1703], ["susceptible", 1708], ["to", 1720], ["linezolid", 1723], ["and", 1733], ["daptomycin", 1737], [".", 1747], ["These", 1749], ["data", 1755], ["suggest", 1760], ["that", 1768], ["detailed", 1773], ["prospective", 1782], ["laboratory", 1794], ["identification", 1805], ["of", 1820], ["RVS", 1823], ["-", 1826], ["MRSA", 1827], ["isolates", 1832], ["may", 1841], ["be", 1845], ["of", 1848], ["limited", 1851], ["value", 1859], ["and", 1865], ["that", 1869], [",", 1873], ["instead", 1875], [",", 1882], ["such", 1884], ["in", 1889], ["vitro", 1892], ["investigation", 1898], ["should", 1912], ["be", 1919], ["reserved", 1922], ["for", 1931], ["isolates", 1935], ["from", 1944], ["patients", 1949], ["who", 1958], ["are", 1962], ["failing", 1966], ["appropriate", 1974], ["anti", 1986], ["-", 1990], ["MRSA", 1991], ["therapy", 1996], [".", 2003]]}
{"context": "One of the primary criticismes of vestibular schwannoma (VS) radiosurgery is that the risk of surgical morbidity is increased for patients whose tumor progresses after the procedures. We reviewed the French experience of operated patients after failed Gamma Knife radiosurgery. From July 1992 to January 2002, 25 out of the 1000 treated patients underwent another treatment procedure for a gamma knife failure. Excluding the NF2 patients, 21 patients have been operated and the present study shows the data collected for 20 of them. In order to analyze the difficulties observed during the surgery, a questionnaire was filled by the surgeons. The mean interval between radiosurgery and removal was 36 Months, from 10 to 83 Months. The mean increase in Volume was 559% (37 to 3036%, median 160%). Evolution of the Koos grading was found from 8 grade II, 10 grade III et 2 grade IV to 10 grade III and 10 grade IV. Patients have been operated for radiological tumor growth in 7 cases and for clinico-radiological evolution in 13 cases. In 9 cases, the surgeon considered that he had to face unusual difficulties mainly because of adhesion of the tumor to neurovascular structures. Tumor removal was total in 14 cases, near total in 4 cases and subtotal in 2 cases. One case of venous infarction was noticed at the second day following surgery responsible of hemiparesis and aphasia that gradually recovered. At last follow-up examination, facial nerve was normal (House and Brackmann grade I and II) in 10 cases while it was a grade III in 7 cases and grade IV and V in 3 cases. We recommend that the decision for surgical removal of growing vestibular schwannoma after Gamma Knife treatment should be done after a sufficiently long follow-up period. Our results show that the quality of removal and of facial nerve preservation might be impaired by radiosurgery in half of cases. However these results do not support a change in our policy of radiosurgical treatment of small to medium size vestibular schwannoma.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "82b7ad0ac3da45f8850154988038abc3", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[312, 313], [6, 7], [372, 373]], "char_spans": [[1640, 1660], [34, 54], [1990, 2010]]}]}], "context_tokens": [["One", 0], ["of", 4], ["the", 7], ["primary", 11], ["criticismes", 19], ["of", 31], ["vestibular", 34], ["schwannoma", 45], ["(", 56], ["VS", 57], [")", 59], ["radiosurgery", 61], ["is", 74], ["that", 77], ["the", 82], ["risk", 86], ["of", 91], ["surgical", 94], ["morbidity", 103], ["is", 113], ["increased", 116], ["for", 126], ["patients", 130], ["whose", 139], ["tumor", 145], ["progresses", 151], ["after", 162], ["the", 168], ["procedures", 172], [".", 182], ["We", 184], ["reviewed", 187], ["the", 196], ["French", 200], ["experience", 207], ["of", 218], ["operated", 221], ["patients", 230], ["after", 239], ["failed", 245], ["Gamma", 252], ["Knife", 258], ["radiosurgery", 264], [".", 276], ["From", 278], ["July", 283], ["1992", 288], ["to", 293], ["January", 296], ["2002", 304], [",", 308], ["25", 310], ["out", 313], ["of", 317], ["the", 320], ["1000", 324], ["treated", 329], ["patients", 337], ["underwent", 346], ["another", 356], ["treatment", 364], ["procedure", 374], ["for", 384], ["a", 388], ["gamma", 390], ["knife", 396], ["failure", 402], [".", 409], ["Excluding", 411], ["the", 421], ["NF2", 425], ["patients", 429], [",", 437], ["21", 439], ["patients", 442], ["have", 451], ["been", 456], ["operated", 461], ["and", 470], ["the", 474], ["present", 478], ["study", 486], ["shows", 492], ["the", 498], ["data", 502], ["collected", 507], ["for", 517], ["20", 521], ["of", 524], ["them", 527], [".", 531], ["In", 533], ["order", 536], ["to", 542], ["analyze", 545], ["the", 553], ["difficulties", 557], ["observed", 570], ["during", 579], ["the", 586], ["surgery", 590], [",", 597], ["a", 599], ["questionnaire", 601], ["was", 615], ["filled", 619], ["by", 626], ["the", 629], ["surgeons", 633], [".", 641], ["The", 643], ["mean", 647], ["interval", 652], ["between", 661], ["radiosurgery", 669], ["and", 682], ["removal", 686], ["was", 694], ["36", 698], ["Months", 701], [",", 707], ["from", 709], ["10", 714], ["to", 717], ["83", 720], ["Months", 723], [".", 729], ["The", 731], ["mean", 735], ["increase", 740], ["in", 749], ["Volume", 752], ["was", 759], ["559", 763], ["%", 766], ["(", 768], ["37", 769], ["to", 772], ["3036", 775], ["%", 779], [",", 780], ["median", 782], ["160", 789], ["%", 792], [")", 793], [".", 794], ["Evolution", 796], ["of", 806], ["the", 809], ["Koos", 813], ["grading", 818], ["was", 826], ["found", 830], ["from", 836], ["8", 841], ["grade", 843], ["II", 849], [",", 851], ["10", 853], ["grade", 856], ["III", 862], ["et", 866], ["2", 869], ["grade", 871], ["IV", 877], ["to", 880], ["10", 883], ["grade", 886], ["III", 892], ["and", 896], ["10", 900], ["grade", 903], ["IV", 909], [".", 911], ["Patients", 913], ["have", 922], ["been", 927], ["operated", 932], ["for", 941], ["radiological", 945], ["tumor", 958], ["growth", 964], ["in", 971], ["7", 974], ["cases", 976], ["and", 982], ["for", 986], ["clinico", 990], ["-", 997], ["radiological", 998], ["evolution", 1011], ["in", 1021], ["13", 1024], ["cases", 1027], [".", 1032], ["In", 1034], ["9", 1037], ["cases", 1039], [",", 1044], ["the", 1046], ["surgeon", 1050], ["considered", 1058], ["that", 1069], ["he", 1074], ["had", 1077], ["to", 1081], ["face", 1084], ["unusual", 1089], ["difficulties", 1097], ["mainly", 1110], ["because", 1117], ["of", 1125], ["adhesion", 1128], ["of", 1137], ["the", 1140], ["tumor", 1144], ["to", 1150], ["neurovascular", 1153], ["structures", 1167], [".", 1177], ["Tumor", 1179], ["removal", 1185], ["was", 1193], ["total", 1197], ["in", 1203], ["14", 1206], ["cases", 1209], [",", 1214], ["near", 1216], ["total", 1221], ["in", 1227], ["4", 1230], ["cases", 1232], ["and", 1238], ["subtotal", 1242], ["in", 1251], ["2", 1254], ["cases", 1256], [".", 1261], ["One", 1263], ["case", 1267], ["of", 1272], ["venous", 1275], ["infarction", 1282], ["was", 1293], ["noticed", 1297], ["at", 1305], ["the", 1308], ["second", 1312], ["day", 1319], ["following", 1323], ["surgery", 1333], ["responsible", 1341], ["of", 1353], ["hemiparesis", 1356], ["and", 1368], ["aphasia", 1372], ["that", 1380], ["gradually", 1385], ["recovered", 1395], [".", 1404], ["At", 1406], ["last", 1409], ["follow", 1414], ["-", 1420], ["up", 1421], ["examination", 1424], [",", 1435], ["facial", 1437], ["nerve", 1444], ["was", 1450], ["normal", 1454], ["(", 1461], ["House", 1462], ["and", 1468], ["Brackmann", 1472], ["grade", 1482], ["I", 1488], ["and", 1490], ["II", 1494], [")", 1496], ["in", 1498], ["10", 1501], ["cases", 1504], ["while", 1510], ["it", 1516], ["was", 1519], ["a", 1523], ["grade", 1525], ["III", 1531], ["in", 1535], ["7", 1538], ["cases", 1540], ["and", 1546], ["grade", 1550], ["IV", 1556], ["and", 1559], ["V", 1563], ["in", 1565], ["3", 1568], ["cases", 1570], [".", 1575], ["We", 1577], ["recommend", 1580], ["that", 1590], ["the", 1595], ["decision", 1599], ["for", 1608], ["surgical", 1612], ["removal", 1621], ["of", 1629], ["growing", 1632], ["vestibular", 1640], ["schwannoma", 1651], ["after", 1662], ["Gamma", 1668], ["Knife", 1674], ["treatment", 1680], ["should", 1690], ["be", 1697], ["done", 1700], ["after", 1705], ["a", 1711], ["sufficiently", 1713], ["long", 1726], ["follow", 1731], ["-", 1737], ["up", 1738], ["period", 1741], [".", 1747], ["Our", 1749], ["results", 1753], ["show", 1761], ["that", 1766], ["the", 1771], ["quality", 1775], ["of", 1783], ["removal", 1786], ["and", 1794], ["of", 1798], ["facial", 1801], ["nerve", 1808], ["preservation", 1814], ["might", 1827], ["be", 1833], ["impaired", 1836], ["by", 1845], ["radiosurgery", 1848], ["in", 1861], ["half", 1864], ["of", 1869], ["cases", 1872], [".", 1877], ["However", 1879], ["these", 1887], ["results", 1893], ["do", 1901], ["not", 1904], ["support", 1908], ["a", 1916], ["change", 1918], ["in", 1925], ["our", 1928], ["policy", 1932], ["of", 1939], ["radiosurgical", 1942], ["treatment", 1956], ["of", 1966], ["small", 1969], ["to", 1975], ["medium", 1978], ["size", 1985], ["vestibular", 1990], ["schwannoma", 2001], [".", 2011]]}
{"context": "Hallervorden-Spatz syndrome (HSS) is a rare autosomal recessive disorder clinically characterized by extrapyramidal signs and progressive dementia. In a typical case, the clinical symptoms become apparent during late childhood, and usually the course is protracted over a decade or more. We recently had an opportunity to study the brains of two cases of HSS with a clinical course of over 30 years. Case 1 was a 44-year-old female and case 2 was a 37-year-old male. Grossly, the brains showed severe fronto-temporal lobar atrophy with abundant spheroids and mild iron deposits in the globus pallidus, associated with features of motor neuron disease. In addition, there was diffuse sponginess in the atrophic cortex as well as widespread Alzheimer's neurofibrillary tangles (NFTs) and Lewy bodies (LBs) in the cortical and subcortical regions, including the spinal cord. Ultrastructurally, NFTs were composed of paired helical filaments, and LBs of central dense cores with radiating fibrils. Discrete immunostaining was demonstrated in NFTs and neuropil threads with various antibodies against phosphorylated tau, and in LBs with antibody against alpha-synuclein. In addition, diffuse, overlapping immunoreactivity of alpha-synuclein and phosphorylated tau was seen within the cytoplasm of many neurons. However, when LBs and NFTs coexisted within the same neurons, they were clearly segregated. The findings of our present cases as well as those reported in the literature may indicate that simultaneous and extensive occurrence of abnormal phosphorylation of tau and accumulation of alpha-synuclein may constitute cardinal pathological features of HSS with protracted clinical course.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "4a2d924caf4d464aa5a7837b4e6e320d", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[214, 216], [202, 204], [275, 277]], "char_spans": [[1220, 1234], [1149, 1163], [1587, 1601]]}]}], "context_tokens": [["Hallervorden", 0], ["-", 12], ["Spatz", 13], ["syndrome", 19], ["(", 28], ["HSS", 29], [")", 32], ["is", 34], ["a", 37], ["rare", 39], ["autosomal", 44], ["recessive", 54], ["disorder", 64], ["clinically", 73], ["characterized", 84], ["by", 98], ["extrapyramidal", 101], ["signs", 116], ["and", 122], ["progressive", 126], ["dementia", 138], [".", 146], ["In", 148], ["a", 151], ["typical", 153], ["case", 161], [",", 165], ["the", 167], ["clinical", 171], ["symptoms", 180], ["become", 189], ["apparent", 196], ["during", 205], ["late", 212], ["childhood", 217], [",", 226], ["and", 228], ["usually", 232], ["the", 240], ["course", 244], ["is", 251], ["protracted", 254], ["over", 265], ["a", 270], ["decade", 272], ["or", 279], ["more", 282], [".", 286], ["We", 288], ["recently", 291], ["had", 300], ["an", 304], ["opportunity", 307], ["to", 319], ["study", 322], ["the", 328], ["brains", 332], ["of", 339], ["two", 342], ["cases", 346], ["of", 352], ["HSS", 355], ["with", 359], ["a", 364], ["clinical", 366], ["course", 375], ["of", 382], ["over", 385], ["30", 390], ["years", 393], [".", 398], ["Case", 400], ["1", 405], ["was", 407], ["a", 411], ["44-year", 413], ["-", 420], ["old", 421], ["female", 425], ["and", 432], ["case", 436], ["2", 441], ["was", 443], ["a", 447], ["37-year", 449], ["-", 456], ["old", 457], ["male", 461], [".", 465], ["Grossly", 467], [",", 474], ["the", 476], ["brains", 480], ["showed", 487], ["severe", 494], ["fronto", 501], ["-", 507], ["temporal", 508], ["lobar", 517], ["atrophy", 523], ["with", 531], ["abundant", 536], ["spheroids", 545], ["and", 555], ["mild", 559], ["iron", 564], ["deposits", 569], ["in", 578], ["the", 581], ["globus", 585], ["pallidus", 592], [",", 600], ["associated", 602], ["with", 613], ["features", 618], ["of", 627], ["motor", 630], ["neuron", 636], ["disease", 643], [".", 650], ["In", 652], ["addition", 655], [",", 663], ["there", 665], ["was", 671], ["diffuse", 675], ["sponginess", 683], ["in", 694], ["the", 697], ["atrophic", 701], ["cortex", 710], ["as", 717], ["well", 720], ["as", 725], ["widespread", 728], ["Alzheimer", 739], ["'s", 748], ["neurofibrillary", 751], ["tangles", 767], ["(", 775], ["NFTs", 776], [")", 780], ["and", 782], ["Lewy", 786], ["bodies", 791], ["(", 798], ["LBs", 799], [")", 802], ["in", 804], ["the", 807], ["cortical", 811], ["and", 820], ["subcortical", 824], ["regions", 836], [",", 843], ["including", 845], ["the", 855], ["spinal", 859], ["cord", 866], [".", 870], ["Ultrastructurally", 872], [",", 889], ["NFTs", 891], ["were", 896], ["composed", 901], ["of", 910], ["paired", 913], ["helical", 920], ["filaments", 928], [",", 937], ["and", 939], ["LBs", 943], ["of", 947], ["central", 950], ["dense", 958], ["cores", 964], ["with", 970], ["radiating", 975], ["fibrils", 985], [".", 992], ["Discrete", 994], ["immunostaining", 1003], ["was", 1018], ["demonstrated", 1022], ["in", 1035], ["NFTs", 1038], ["and", 1043], ["neuropil", 1047], ["threads", 1056], ["with", 1064], ["various", 1069], ["antibodies", 1077], ["against", 1088], ["phosphorylated", 1096], ["tau", 1111], [",", 1114], ["and", 1116], ["in", 1120], ["LBs", 1123], ["with", 1127], ["antibody", 1132], ["against", 1141], ["alpha", 1149], ["-", 1154], ["synuclein", 1155], [".", 1164], ["In", 1166], ["addition", 1169], [",", 1177], ["diffuse", 1179], [",", 1186], ["overlapping", 1188], ["immunoreactivity", 1200], ["of", 1217], ["alpha", 1220], ["-", 1225], ["synuclein", 1226], ["and", 1236], ["phosphorylated", 1240], ["tau", 1255], ["was", 1259], ["seen", 1263], ["within", 1268], ["the", 1275], ["cytoplasm", 1279], ["of", 1289], ["many", 1292], ["neurons", 1297], [".", 1304], ["However", 1306], [",", 1313], ["when", 1315], ["LBs", 1320], ["and", 1324], ["NFTs", 1328], ["coexisted", 1333], ["within", 1343], ["the", 1350], ["same", 1354], ["neurons", 1359], [",", 1366], ["they", 1368], ["were", 1373], ["clearly", 1378], ["segregated", 1386], [".", 1396], ["The", 1398], ["findings", 1402], ["of", 1411], ["our", 1414], ["present", 1418], ["cases", 1426], ["as", 1432], ["well", 1435], ["as", 1440], ["those", 1443], ["reported", 1449], ["in", 1458], ["the", 1461], ["literature", 1465], ["may", 1476], ["indicate", 1480], ["that", 1489], ["simultaneous", 1494], ["and", 1507], ["extensive", 1511], ["occurrence", 1521], ["of", 1532], ["abnormal", 1535], ["phosphorylation", 1544], ["of", 1560], ["tau", 1563], ["and", 1567], ["accumulation", 1571], ["of", 1584], ["alpha", 1587], ["-", 1592], ["synuclein", 1593], ["may", 1603], ["constitute", 1607], ["cardinal", 1618], ["pathological", 1627], ["features", 1640], ["of", 1649], ["HSS", 1652], ["with", 1656], ["protracted", 1661], ["clinical", 1672], ["course", 1681], [".", 1687]]}
{"context": "In eukaryotic cells, there are two sub-pathways of nucleotide excision repair (NER), the global genome (gg) NER and the transcription-coupled repair (TCR). TCR can preferentially remove the bulky DNA lesions located at the transcribed strand of a transcriptional active gene more rapidly than those at the untranscribed strand or overall genomic DNA. This strand-specific repair in a suitable restriction fragment is usually determined by alkaline gel electrophoresis followed by Southern blotting transfer and hybridization with an indirect end-labeled single-stranded probe. Here we describe a new method of TCR assay based on strand-specific-PCR (SS-PCR). Using this method, we have investigated the role of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a member of the phosphatidylinositol 3-kinase-related protein kinases (PIKK) family, in the TCR pathway of UV-induced DNA damage. Although depletion of DNA-PKcs sensitized HeLa cells to UV radiation, it did not affect the ggNER efficiency of UV-induced cyclobutane pyrimidine dimers (CPD) damage. We postulated that DNA-PKcs may involve in the TCR process. To test this hypothesis, we have firstly developed a novel method of TCR assay based on the strand-specific PCR technology with a set of smart primers, which allows the strand-specific amplification of a restricted gene fragment of UV radiation-damaged genomic DNA in mammalian cells. Using this new method, we confirmed that siRNA-mediated downregulation of Cockayne syndrome B resulted in a deficiency of TCR of the UV-damaged dihydrofolate reductase (DHFR) gene. In addition, DMSO-induced silencing of the c-myc gene led to a decreased TCR efficiency of UV radiation-damaged c-myc gene in HL60 cells. On the basis of the above methodology verification, we found that the depletion of DNA-PKcs mediated by siRNA significantly decreased the TCR capacity of repairing the UV-induced CPDs damage in DHFR gene in HeLa cells, indicating that DNA-PKcs may also be involved in the TCR pathway of DNA damage repair. By means of immunoprecipitation and MALDI-TOF-Mass spectrometric analysis, we have revealed the interaction of DNA-PKcs and cyclin T2, which is a subunit of the human transcription elongation factor (P-TEFb). While the P-TEFb complex can phosphorylate the serine 2 of the carboxyl-terminal domain (CTD) of RNA polymerase II and promote transcription elongation. A new method of TCR assay was developed based the strand-specific-PCR (SS-PCR). Our data suggest that DNA-PKcs plays a role in the TCR pathway of UV-damaged DNA. One possible mechanistic hypothesis is that DNA-PKcs may function through associating with CyclinT2/CDK9 (P-TEFb) to modulate the activity of RNA Pol II, which has already been identified as a key molecule recognizing and initializing TCR.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "bdc9cd8b282d4eb29e42242885c5b466", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[46, 47]], "char_spans": [[223, 240]]}]}], "context_tokens": [["In", 0], ["eukaryotic", 3], ["cells", 14], [",", 19], ["there", 21], ["are", 27], ["two", 31], ["sub", 35], ["-", 38], ["pathways", 39], ["of", 48], ["nucleotide", 51], ["excision", 62], ["repair", 71], ["(", 78], ["NER", 79], [")", 82], [",", 83], ["the", 85], ["global", 89], ["genome", 96], ["(", 103], ["gg", 104], [")", 106], ["NER", 108], ["and", 112], ["the", 116], ["transcription", 120], ["-", 133], ["coupled", 134], ["repair", 142], ["(", 149], ["TCR", 150], [")", 153], [".", 154], ["TCR", 156], ["can", 160], ["preferentially", 164], ["remove", 179], ["the", 186], ["bulky", 190], ["DNA", 196], ["lesions", 200], ["located", 208], ["at", 216], ["the", 219], ["transcribed", 223], ["strand", 235], ["of", 242], ["a", 245], ["transcriptional", 247], ["active", 263], ["gene", 270], ["more", 275], ["rapidly", 280], ["than", 288], ["those", 293], ["at", 299], ["the", 302], ["untranscribed", 306], ["strand", 320], ["or", 327], ["overall", 330], ["genomic", 338], ["DNA", 346], [".", 349], ["This", 351], ["strand", 356], ["-", 362], ["specific", 363], ["repair", 372], ["in", 379], ["a", 382], ["suitable", 384], ["restriction", 393], ["fragment", 405], ["is", 414], ["usually", 417], ["determined", 425], ["by", 436], ["alkaline", 439], ["gel", 448], ["electrophoresis", 452], ["followed", 468], ["by", 477], ["Southern", 480], ["blotting", 489], ["transfer", 498], ["and", 507], ["hybridization", 511], ["with", 525], ["an", 530], ["indirect", 533], ["end", 542], ["-", 545], ["labeled", 546], ["single", 554], ["-", 560], ["stranded", 561], ["probe", 570], [".", 575], ["Here", 577], ["we", 582], ["describe", 585], ["a", 594], ["new", 596], ["method", 600], ["of", 607], ["TCR", 610], ["assay", 614], ["based", 620], ["on", 626], ["strand", 629], ["-", 635], ["specific", 636], ["-", 644], ["PCR", 645], ["(", 649], ["SS", 650], ["-", 652], ["PCR", 653], [")", 656], [".", 657], ["Using", 659], ["this", 665], ["method", 670], [",", 676], ["we", 678], ["have", 681], ["investigated", 686], ["the", 699], ["role", 703], ["of", 708], ["DNA", 711], ["-", 714], ["dependent", 715], ["protein", 725], ["kinase", 733], ["catalytic", 740], ["subunit", 750], ["(", 758], ["DNA", 759], ["-", 762], ["PKcs", 763], [")", 767], [",", 768], ["a", 770], ["member", 772], ["of", 779], ["the", 782], ["phosphatidylinositol", 786], ["3-kinase", 807], ["-", 815], ["related", 816], ["protein", 824], ["kinases", 832], ["(", 840], ["PIKK", 841], [")", 845], ["family", 847], [",", 853], ["in", 855], ["the", 858], ["TCR", 862], ["pathway", 866], ["of", 874], ["UV", 877], ["-", 879], ["induced", 880], ["DNA", 888], ["damage", 892], [".", 898], ["Although", 900], ["depletion", 909], ["of", 919], ["DNA", 922], ["-", 925], ["PKcs", 926], ["sensitized", 931], ["HeLa", 942], ["cells", 947], ["to", 953], ["UV", 956], ["radiation", 959], [",", 968], ["it", 970], ["did", 973], ["not", 977], ["affect", 981], ["the", 988], ["ggNER", 992], ["efficiency", 998], ["of", 1009], ["UV", 1012], ["-", 1014], ["induced", 1015], ["cyclobutane", 1023], ["pyrimidine", 1035], ["dimers", 1046], ["(", 1053], ["CPD", 1054], [")", 1057], ["damage", 1059], [".", 1065], ["We", 1067], ["postulated", 1070], ["that", 1081], ["DNA", 1086], ["-", 1089], ["PKcs", 1090], ["may", 1095], ["involve", 1099], ["in", 1107], ["the", 1110], ["TCR", 1114], ["process", 1118], [".", 1125], ["To", 1127], ["test", 1130], ["this", 1135], ["hypothesis", 1140], [",", 1150], ["we", 1152], ["have", 1155], ["firstly", 1160], ["developed", 1168], ["a", 1178], ["novel", 1180], ["method", 1186], ["of", 1193], ["TCR", 1196], ["assay", 1200], ["based", 1206], ["on", 1212], ["the", 1215], ["strand", 1219], ["-", 1225], ["specific", 1226], ["PCR", 1235], ["technology", 1239], ["with", 1250], ["a", 1255], ["set", 1257], ["of", 1261], ["smart", 1264], ["primers", 1270], [",", 1277], ["which", 1279], ["allows", 1285], ["the", 1292], ["strand", 1296], ["-", 1302], ["specific", 1303], ["amplification", 1312], ["of", 1326], ["a", 1329], ["restricted", 1331], ["gene", 1342], ["fragment", 1347], ["of", 1356], ["UV", 1359], ["radiation", 1362], ["-", 1371], ["damaged", 1372], ["genomic", 1380], ["DNA", 1388], ["in", 1392], ["mammalian", 1395], ["cells", 1405], [".", 1410], ["Using", 1412], ["this", 1418], ["new", 1423], ["method", 1427], [",", 1433], ["we", 1435], ["confirmed", 1438], ["that", 1448], ["siRNA", 1453], ["-", 1458], ["mediated", 1459], ["downregulation", 1468], ["of", 1483], ["Cockayne", 1486], ["syndrome", 1495], ["B", 1504], ["resulted", 1506], ["in", 1515], ["a", 1518], ["deficiency", 1520], ["of", 1531], ["TCR", 1534], ["of", 1538], ["the", 1541], ["UV", 1545], ["-", 1547], ["damaged", 1548], ["dihydrofolate", 1556], ["reductase", 1570], ["(", 1580], ["DHFR", 1581], [")", 1585], ["gene", 1587], [".", 1591], ["In", 1593], ["addition", 1596], [",", 1604], ["DMSO", 1606], ["-", 1610], ["induced", 1611], ["silencing", 1619], ["of", 1629], ["the", 1632], ["c", 1636], ["-", 1637], ["myc", 1638], ["gene", 1642], ["led", 1647], ["to", 1651], ["a", 1654], ["decreased", 1656], ["TCR", 1666], ["efficiency", 1670], ["of", 1681], ["UV", 1684], ["radiation", 1687], ["-", 1696], ["damaged", 1697], ["c", 1705], ["-", 1706], ["myc", 1707], ["gene", 1711], ["in", 1716], ["HL60", 1719], ["cells", 1724], [".", 1729], ["On", 1731], ["the", 1734], ["basis", 1738], ["of", 1744], ["the", 1747], ["above", 1751], ["methodology", 1757], ["verification", 1769], [",", 1781], ["we", 1783], ["found", 1786], ["that", 1792], ["the", 1797], ["depletion", 1801], ["of", 1811], ["DNA", 1814], ["-", 1817], ["PKcs", 1818], ["mediated", 1823], ["by", 1832], ["siRNA", 1835], ["significantly", 1841], ["decreased", 1855], ["the", 1865], ["TCR", 1869], ["capacity", 1873], ["of", 1882], ["repairing", 1885], ["the", 1895], ["UV", 1899], ["-", 1901], ["induced", 1902], ["CPDs", 1910], ["damage", 1915], ["in", 1922], ["DHFR", 1925], ["gene", 1930], ["in", 1935], ["HeLa", 1938], ["cells", 1943], [",", 1948], ["indicating", 1950], ["that", 1961], ["DNA", 1966], ["-", 1969], ["PKcs", 1970], ["may", 1975], ["also", 1979], ["be", 1984], ["involved", 1987], ["in", 1996], ["the", 1999], ["TCR", 2003], ["pathway", 2007], ["of", 2015], ["DNA", 2018], ["damage", 2022], ["repair", 2029], [".", 2035], ["By", 2037], ["means", 2040], ["of", 2046], ["immunoprecipitation", 2049], ["and", 2069], ["MALDI", 2073], ["-", 2078], ["TOF", 2079], ["-", 2082], ["Mass", 2083], ["spectrometric", 2088], ["analysis", 2102], [",", 2110], ["we", 2112], ["have", 2115], ["revealed", 2120], ["the", 2129], ["interaction", 2133], ["of", 2145], ["DNA", 2148], ["-", 2151], ["PKcs", 2152], ["and", 2157], ["cyclin", 2161], ["T2", 2168], [",", 2170], ["which", 2172], ["is", 2178], ["a", 2181], ["subunit", 2183], ["of", 2191], ["the", 2194], ["human", 2198], ["transcription", 2204], ["elongation", 2218], ["factor", 2229], ["(", 2236], ["P", 2237], ["-", 2238], ["TEFb", 2239], [")", 2243], [".", 2244], ["While", 2246], ["the", 2252], ["P", 2256], ["-", 2257], ["TEFb", 2258], ["complex", 2263], ["can", 2271], ["phosphorylate", 2275], ["the", 2289], ["serine", 2293], ["2", 2300], ["of", 2302], ["the", 2305], ["carboxyl", 2309], ["-", 2317], ["terminal", 2318], ["domain", 2327], ["(", 2334], ["CTD", 2335], [")", 2338], ["of", 2340], ["RNA", 2343], ["polymerase", 2347], ["II", 2358], ["and", 2361], ["promote", 2365], ["transcription", 2373], ["elongation", 2387], [".", 2397], ["A", 2399], ["new", 2401], ["method", 2405], ["of", 2412], ["TCR", 2415], ["assay", 2419], ["was", 2425], ["developed", 2429], ["based", 2439], ["the", 2445], ["strand", 2449], ["-", 2455], ["specific", 2456], ["-", 2464], ["PCR", 2465], ["(", 2469], ["SS", 2470], ["-", 2472], ["PCR", 2473], [")", 2476], [".", 2477], ["Our", 2479], ["data", 2483], ["suggest", 2488], ["that", 2496], ["DNA", 2501], ["-", 2504], ["PKcs", 2505], ["plays", 2510], ["a", 2516], ["role", 2518], ["in", 2523], ["the", 2526], ["TCR", 2530], ["pathway", 2534], ["of", 2542], ["UV", 2545], ["-", 2547], ["damaged", 2548], ["DNA", 2556], [".", 2559], ["One", 2561], ["possible", 2565], ["mechanistic", 2574], ["hypothesis", 2586], ["is", 2597], ["that", 2600], ["DNA", 2605], ["-", 2608], ["PKcs", 2609], ["may", 2614], ["function", 2618], ["through", 2627], ["associating", 2635], ["with", 2647], ["CyclinT2/CDK9", 2652], ["(", 2666], ["P", 2667], ["-", 2668], ["TEFb", 2669], [")", 2673], ["to", 2675], ["modulate", 2678], ["the", 2687], ["activity", 2691], ["of", 2700], ["RNA", 2703], ["Pol", 2707], ["II", 2711], [",", 2713], ["which", 2715], ["has", 2721], ["already", 2725], ["been", 2733], ["identified", 2738], ["as", 2749], ["a", 2752], ["key", 2754], ["molecule", 2758], ["recognizing", 2767], ["and", 2779], ["initializing", 2783], ["TCR", 2796], [".", 2799]]}
{"context": "The clear connection between ribosome biogenesis dysfunction and specific hematopoiesis-related disorders prompted us to examine the role of critical lineage-specific transcription factors in the transcriptional regulation of ribosomal protein (RP) genes during terminal erythroid differentiation. By applying EMSA and ChIP methodologies in mouse erythroleukemia cells we show that GATA1 and PU.1 bind in vitro and in vivo the proximal promoter region of the RPS19 gene which is frequently mutated in Diamond-Blackfan Anemia. Moreover, ChIPseq data analysis also demonstrates that several RP genes are enriched as potential GATA1 and PU.1 gene targets in mouse and human erythroid cells, with GATA1 binding showing an association with higher ribosomal protein gene expression levels during terminal erythroid differentiation in human and mouse. Our results suggest that RP gene expression and hence balanced ribosome biosynthesis may be specifically and selectively regulated by lineage specific transcription factors during hematopoiesis, a finding which may be clinically relevant to ribosomopathies.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "35f2d4aeaa304a9d9c6fb6f5340d5589", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[77, 80]], "char_spans": [[501, 523]]}]}], "context_tokens": [["The", 0], ["clear", 4], ["connection", 10], ["between", 21], ["ribosome", 29], ["biogenesis", 38], ["dysfunction", 49], ["and", 61], ["specific", 65], ["hematopoiesis", 74], ["-", 87], ["related", 88], ["disorders", 96], ["prompted", 106], ["us", 115], ["to", 118], ["examine", 121], ["the", 129], ["role", 133], ["of", 138], ["critical", 141], ["lineage", 150], ["-", 157], ["specific", 158], ["transcription", 167], ["factors", 181], ["in", 189], ["the", 192], ["transcriptional", 196], ["regulation", 212], ["of", 223], ["ribosomal", 226], ["protein", 236], ["(", 244], ["RP", 245], [")", 247], ["genes", 249], ["during", 255], ["terminal", 262], ["erythroid", 271], ["differentiation", 281], [".", 296], ["By", 298], ["applying", 301], ["EMSA", 310], ["and", 315], ["ChIP", 319], ["methodologies", 324], ["in", 338], ["mouse", 341], ["erythroleukemia", 347], ["cells", 363], ["we", 369], ["show", 372], ["that", 377], ["GATA1", 382], ["and", 388], ["PU.1", 392], ["bind", 397], ["in", 402], ["vitro", 405], ["and", 411], ["in", 415], ["vivo", 418], ["the", 423], ["proximal", 427], ["promoter", 436], ["region", 445], ["of", 452], ["the", 455], ["RPS19", 459], ["gene", 465], ["which", 470], ["is", 476], ["frequently", 479], ["mutated", 490], ["in", 498], ["Diamond", 501], ["-", 508], ["Blackfan", 509], ["Anemia", 518], [".", 524], ["Moreover", 526], [",", 534], ["ChIPseq", 536], ["data", 544], ["analysis", 549], ["also", 558], ["demonstrates", 563], ["that", 576], ["several", 581], ["RP", 589], ["genes", 592], ["are", 598], ["enriched", 602], ["as", 611], ["potential", 614], ["GATA1", 624], ["and", 630], ["PU.1", 634], ["gene", 639], ["targets", 644], ["in", 652], ["mouse", 655], ["and", 661], ["human", 665], ["erythroid", 671], ["cells", 681], [",", 686], ["with", 688], ["GATA1", 693], ["binding", 699], ["showing", 707], ["an", 715], ["association", 718], ["with", 730], ["higher", 735], ["ribosomal", 742], ["protein", 752], ["gene", 760], ["expression", 765], ["levels", 776], ["during", 783], ["terminal", 790], ["erythroid", 799], ["differentiation", 809], ["in", 825], ["human", 828], ["and", 834], ["mouse", 838], [".", 843], ["Our", 845], ["results", 849], ["suggest", 857], ["that", 865], ["RP", 870], ["gene", 873], ["expression", 878], ["and", 889], ["hence", 893], ["balanced", 899], ["ribosome", 908], ["biosynthesis", 917], ["may", 930], ["be", 934], ["specifically", 937], ["and", 950], ["selectively", 954], ["regulated", 966], ["by", 976], ["lineage", 979], ["specific", 987], ["transcription", 996], ["factors", 1010], ["during", 1018], ["hematopoiesis", 1025], [",", 1038], ["a", 1040], ["finding", 1042], ["which", 1050], ["may", 1056], ["be", 1060], ["clinically", 1063], ["relevant", 1074], ["to", 1083], ["ribosomopathies", 1086], [".", 1101]]}
{"context": "Gefitinib is a specific inhibitor of the epidermal growth factor receptor (EGFR) that causes growth delay in cancer cell lines and human tumor xenografts expressing high levels of EGFR. An understanding of the downstream cellular targets of gefitinib will allow the discovery of biomarkers for predicting outcomes and monitoring anti-EGFR therapies and provide information for key targets for therapeutic intervention. In this study, we investigated the role of FOXO3a in gefitinib action and resistance. Using two gefitinib-sensitive (i.e., BT474 and SKBR3) as well as three other resistant breast carcinoma cell lines (i.e., MCF-7, MDA-MB-231, and MDA-MB-453), we showed that gefitinib targets the transcription factor FOXO3a to mediate cell cycle arrest and cell death in sensitive breast cancer cells. In the sensitive cells, gefitinib treatment causes cell cycle arrest predominantly at the G(0)-G(1) phase and apoptosis, which is associated with FOXO3a dephosphorylation at Akt sites and nuclear translocation, whereas in the resistant cells, FOXO3a stays phosphorylated and remains in the cytoplasm. The nuclear accumulation of FOXO3a in response to gefitinib was confirmed in tumor tissue sections from breast cancer patients presurgically treated with gefitinib as monotherapy. We also showed that knockdown of FOXO3a expression using small interfering RNA (siRNA) can rescue sensitive BT474 cells from gefitinib-induced cell-proliferative arrest, whereas reintroduction of active FOXO3a in resistant MDA-MB-231 cells can at least partially restore cell-proliferative arrest and sensitivity to gefitinib. These results suggest that the FOXO3a dephosphorylation and nuclear localization have a direct role in mediating the gefitinib-induced proliferative arrest and in determining sensitivity to gefitinib.", "qas": [{"question": "Which is the cellular target of gefitinib?", "answers": ["Epidermal growth factor receptor (EGFR)"], "qid": "5ad5edb13de04cb2b3191b68d0eab76d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["target", 22], ["of", 29], ["gefitinib", 32], ["?", 41]], "detected_answers": [{"text": "Epidermal growth factor receptor (EGFR)", "token_spans": [[7, 12]], "char_spans": [[41, 78]]}]}], "context_tokens": [["Gefitinib", 0], ["is", 10], ["a", 13], ["specific", 15], ["inhibitor", 24], ["of", 34], ["the", 37], ["epidermal", 41], ["growth", 51], ["factor", 58], ["receptor", 65], ["(", 74], ["EGFR", 75], [")", 79], ["that", 81], ["causes", 86], ["growth", 93], ["delay", 100], ["in", 106], ["cancer", 109], ["cell", 116], ["lines", 121], ["and", 127], ["human", 131], ["tumor", 137], ["xenografts", 143], ["expressing", 154], ["high", 165], ["levels", 170], ["of", 177], ["EGFR", 180], [".", 184], ["An", 186], ["understanding", 189], ["of", 203], ["the", 206], ["downstream", 210], ["cellular", 221], ["targets", 230], ["of", 238], ["gefitinib", 241], ["will", 251], ["allow", 256], ["the", 262], ["discovery", 266], ["of", 276], ["biomarkers", 279], ["for", 290], ["predicting", 294], ["outcomes", 305], ["and", 314], ["monitoring", 318], ["anti", 329], ["-", 333], ["EGFR", 334], ["therapies", 339], ["and", 349], ["provide", 353], ["information", 361], ["for", 373], ["key", 377], ["targets", 381], ["for", 389], ["therapeutic", 393], ["intervention", 405], [".", 417], ["In", 419], ["this", 422], ["study", 427], [",", 432], ["we", 434], ["investigated", 437], ["the", 450], ["role", 454], ["of", 459], ["FOXO3a", 462], ["in", 469], ["gefitinib", 472], ["action", 482], ["and", 489], ["resistance", 493], [".", 503], ["Using", 505], ["two", 511], ["gefitinib", 515], ["-", 524], ["sensitive", 525], ["(", 535], ["i.e.", 536], [",", 540], ["BT474", 542], ["and", 548], ["SKBR3", 552], [")", 557], ["as", 559], ["well", 562], ["as", 567], ["three", 570], ["other", 576], ["resistant", 582], ["breast", 592], ["carcinoma", 599], ["cell", 609], ["lines", 614], ["(", 620], ["i.e.", 621], [",", 625], ["MCF-7", 627], [",", 632], ["MDA", 634], ["-", 637], ["MB-231", 638], [",", 644], ["and", 646], ["MDA", 650], ["-", 653], ["MB-453", 654], [")", 660], [",", 661], ["we", 663], ["showed", 666], ["that", 673], ["gefitinib", 678], ["targets", 688], ["the", 696], ["transcription", 700], ["factor", 714], ["FOXO3a", 721], ["to", 728], ["mediate", 731], ["cell", 739], ["cycle", 744], ["arrest", 750], ["and", 757], ["cell", 761], ["death", 766], ["in", 772], ["sensitive", 775], ["breast", 785], ["cancer", 792], ["cells", 799], [".", 804], ["In", 806], ["the", 809], ["sensitive", 813], ["cells", 823], [",", 828], ["gefitinib", 830], ["treatment", 840], ["causes", 850], ["cell", 857], ["cycle", 862], ["arrest", 868], ["predominantly", 875], ["at", 889], ["the", 892], ["G(0)-G(1", 896], [")", 904], ["phase", 906], ["and", 912], ["apoptosis", 916], [",", 925], ["which", 927], ["is", 933], ["associated", 936], ["with", 947], ["FOXO3a", 952], ["dephosphorylation", 959], ["at", 977], ["Akt", 980], ["sites", 984], ["and", 990], ["nuclear", 994], ["translocation", 1002], [",", 1015], ["whereas", 1017], ["in", 1025], ["the", 1028], ["resistant", 1032], ["cells", 1042], [",", 1047], ["FOXO3a", 1049], ["stays", 1056], ["phosphorylated", 1062], ["and", 1077], ["remains", 1081], ["in", 1089], ["the", 1092], ["cytoplasm", 1096], [".", 1105], ["The", 1107], ["nuclear", 1111], ["accumulation", 1119], ["of", 1132], ["FOXO3a", 1135], ["in", 1142], ["response", 1145], ["to", 1154], ["gefitinib", 1157], ["was", 1167], ["confirmed", 1171], ["in", 1181], ["tumor", 1184], ["tissue", 1190], ["sections", 1197], ["from", 1206], ["breast", 1211], ["cancer", 1218], ["patients", 1225], ["presurgically", 1234], ["treated", 1248], ["with", 1256], ["gefitinib", 1261], ["as", 1271], ["monotherapy", 1274], [".", 1285], ["We", 1287], ["also", 1290], ["showed", 1295], ["that", 1302], ["knockdown", 1307], ["of", 1317], ["FOXO3a", 1320], ["expression", 1327], ["using", 1338], ["small", 1344], ["interfering", 1350], ["RNA", 1362], ["(", 1366], ["siRNA", 1367], [")", 1372], ["can", 1374], ["rescue", 1378], ["sensitive", 1385], ["BT474", 1395], ["cells", 1401], ["from", 1407], ["gefitinib", 1412], ["-", 1421], ["induced", 1422], ["cell", 1430], ["-", 1434], ["proliferative", 1435], ["arrest", 1449], [",", 1455], ["whereas", 1457], ["reintroduction", 1465], ["of", 1480], ["active", 1483], ["FOXO3a", 1490], ["in", 1497], ["resistant", 1500], ["MDA", 1510], ["-", 1513], ["MB-231", 1514], ["cells", 1521], ["can", 1527], ["at", 1531], ["least", 1534], ["partially", 1540], ["restore", 1550], ["cell", 1558], ["-", 1562], ["proliferative", 1563], ["arrest", 1577], ["and", 1584], ["sensitivity", 1588], ["to", 1600], ["gefitinib", 1603], [".", 1612], ["These", 1614], ["results", 1620], ["suggest", 1628], ["that", 1636], ["the", 1641], ["FOXO3a", 1645], ["dephosphorylation", 1652], ["and", 1670], ["nuclear", 1674], ["localization", 1682], ["have", 1695], ["a", 1700], ["direct", 1702], ["role", 1709], ["in", 1714], ["mediating", 1717], ["the", 1727], ["gefitinib", 1731], ["-", 1740], ["induced", 1741], ["proliferative", 1749], ["arrest", 1763], ["and", 1770], ["in", 1774], ["determining", 1777], ["sensitivity", 1789], ["to", 1801], ["gefitinib", 1804], [".", 1813]]}
{"context": "Chronic myeloid leukemia (CML) is arguably the best understood of all human malignancies. Its origins in the hematopoietic stem cell can be traced to a reciprocal translocation involving chromosomes 9 and 22, dubbed the Philadelphia chromosome, which is observed in essentially all patients. The resulting fusion gene, BCR/ABL, encodes an activated tyrosine kinase that can act alone to induce a CML-like syndrome in mouse models. These animal models have validated BCR/ABL as a target for the development of specific pharmaceutical inhibitors. The kinase inhibitor imatinib mesylate (Gleevec) is highly specific, effective, and minimally toxic, but may not effect cures as a single agent, particularly in patients with accelerated and blast-phase disease. Resistance to imatinib can confound therapy. Surprisingly, a high percentage of resistant cases manifest intact or augmented BCR/ABL signaling, suggesting that this oncoprotein, or signaling pathways emanating from it, remain viable targets. Combination chemotherapy is under active investigation, and among the most compelling strategies is dual treatment with agents that both target BCR/ABL signal transduction. BCR/ABL activates Ras, and compounds designed to antagonize Ras function called farnesyl transferase inhibitors (FTIs) have shown potent activity in vitro and in animal models of BCR/ABL-induced leukemia. Initial clinical trials in patients with refractory acute myeloid leukemia and CML in blast crisis have shown significant activity, suggesting that trials combining imatinib and FTIs are warranted.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7ab997001a3a4c77a2cb4d78612ac48f", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[54, 56], [197, 199], [234, 236], [203, 205], [83, 85], [155, 157]], "char_spans": [[319, 325], [1143, 1149], [1351, 1357], [1172, 1178], [466, 472], [882, 888]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["arguably", 34], ["the", 43], ["best", 47], ["understood", 52], ["of", 63], ["all", 66], ["human", 70], ["malignancies", 76], [".", 88], ["Its", 90], ["origins", 94], ["in", 102], ["the", 105], ["hematopoietic", 109], ["stem", 123], ["cell", 128], ["can", 133], ["be", 137], ["traced", 140], ["to", 147], ["a", 150], ["reciprocal", 152], ["translocation", 163], ["involving", 177], ["chromosomes", 187], ["9", 199], ["and", 201], ["22", 205], [",", 207], ["dubbed", 209], ["the", 216], ["Philadelphia", 220], ["chromosome", 233], [",", 243], ["which", 245], ["is", 251], ["observed", 254], ["in", 263], ["essentially", 266], ["all", 278], ["patients", 282], [".", 290], ["The", 292], ["resulting", 296], ["fusion", 306], ["gene", 313], [",", 317], ["BCR", 319], ["/", 322], ["ABL", 323], [",", 326], ["encodes", 328], ["an", 336], ["activated", 339], ["tyrosine", 349], ["kinase", 358], ["that", 365], ["can", 370], ["act", 374], ["alone", 378], ["to", 384], ["induce", 387], ["a", 394], ["CML", 396], ["-", 399], ["like", 400], ["syndrome", 405], ["in", 414], ["mouse", 417], ["models", 423], [".", 429], ["These", 431], ["animal", 437], ["models", 444], ["have", 451], ["validated", 456], ["BCR", 466], ["/", 469], ["ABL", 470], ["as", 474], ["a", 477], ["target", 479], ["for", 486], ["the", 490], ["development", 494], ["of", 506], ["specific", 509], ["pharmaceutical", 518], ["inhibitors", 533], [".", 543], ["The", 545], ["kinase", 549], ["inhibitor", 556], ["imatinib", 566], ["mesylate", 575], ["(", 584], ["Gleevec", 585], [")", 592], ["is", 594], ["highly", 597], ["specific", 604], [",", 612], ["effective", 614], [",", 623], ["and", 625], ["minimally", 629], ["toxic", 639], [",", 644], ["but", 646], ["may", 650], ["not", 654], ["effect", 658], ["cures", 665], ["as", 671], ["a", 674], ["single", 676], ["agent", 683], [",", 688], ["particularly", 690], ["in", 703], ["patients", 706], ["with", 715], ["accelerated", 720], ["and", 732], ["blast", 736], ["-", 741], ["phase", 742], ["disease", 748], [".", 755], ["Resistance", 757], ["to", 768], ["imatinib", 771], ["can", 780], ["confound", 784], ["therapy", 793], [".", 800], ["Surprisingly", 802], [",", 814], ["a", 816], ["high", 818], ["percentage", 823], ["of", 834], ["resistant", 837], ["cases", 847], ["manifest", 853], ["intact", 862], ["or", 869], ["augmented", 872], ["BCR", 882], ["/", 885], ["ABL", 886], ["signaling", 890], [",", 899], ["suggesting", 901], ["that", 912], ["this", 917], ["oncoprotein", 922], [",", 933], ["or", 935], ["signaling", 938], ["pathways", 948], ["emanating", 957], ["from", 967], ["it", 972], [",", 974], ["remain", 976], ["viable", 983], ["targets", 990], [".", 997], ["Combination", 999], ["chemotherapy", 1011], ["is", 1024], ["under", 1027], ["active", 1033], ["investigation", 1040], [",", 1053], ["and", 1055], ["among", 1059], ["the", 1065], ["most", 1069], ["compelling", 1074], ["strategies", 1085], ["is", 1096], ["dual", 1099], ["treatment", 1104], ["with", 1114], ["agents", 1119], ["that", 1126], ["both", 1131], ["target", 1136], ["BCR", 1143], ["/", 1146], ["ABL", 1147], ["signal", 1151], ["transduction", 1158], [".", 1170], ["BCR", 1172], ["/", 1175], ["ABL", 1176], ["activates", 1180], ["Ras", 1190], [",", 1193], ["and", 1195], ["compounds", 1199], ["designed", 1209], ["to", 1218], ["antagonize", 1221], ["Ras", 1232], ["function", 1236], ["called", 1245], ["farnesyl", 1252], ["transferase", 1261], ["inhibitors", 1273], ["(", 1284], ["FTIs", 1285], [")", 1289], ["have", 1291], ["shown", 1296], ["potent", 1302], ["activity", 1309], ["in", 1318], ["vitro", 1321], ["and", 1327], ["in", 1331], ["animal", 1334], ["models", 1341], ["of", 1348], ["BCR", 1351], ["/", 1354], ["ABL", 1355], ["-", 1358], ["induced", 1359], ["leukemia", 1367], [".", 1375], ["Initial", 1377], ["clinical", 1385], ["trials", 1394], ["in", 1401], ["patients", 1404], ["with", 1413], ["refractory", 1418], ["acute", 1429], ["myeloid", 1435], ["leukemia", 1443], ["and", 1452], ["CML", 1456], ["in", 1460], ["blast", 1463], ["crisis", 1469], ["have", 1476], ["shown", 1481], ["significant", 1487], ["activity", 1499], [",", 1507], ["suggesting", 1509], ["that", 1520], ["trials", 1525], ["combining", 1532], ["imatinib", 1542], ["and", 1551], ["FTIs", 1555], ["are", 1560], ["warranted", 1564], [".", 1573]]}
{"context": "The mammalian radiation has corresponded with rapid changes in noncoding regions of the genome, but we lack a comprehensive understanding of regulatory evolution in mammals. Here, we track the evolution of promoters and enhancers active in liver across 20 mammalian species from six diverse orders by profiling genomic enrichment of H3K27 acetylation and H3K4 trimethylation. We report that rapid evolution of enhancers is a universal feature of mammalian genomes. Most of the recently evolved enhancers arise from ancestral DNA exaptation, rather than lineage-specific expansions of repeat elements. In contrast, almost all liver promoters are partially or fully conserved across these species. Our data further reveal that recently evolved enhancers can be associated with genes under positive selection, demonstrating the power of this approach for annotating regulatory adaptations in genomic sequences. These results provide important insight into the functional genetics underpinning mammalian regulatory evolution.", "qas": [{"question": "Are human enhancers or promoters evolving faster?", "answers": ["enhancers"], "qid": "ce06b70fdbb149389828f705b0d6faaf", "question_tokens": [["Are", 0], ["human", 4], ["enhancers", 10], ["or", 20], ["promoters", 23], ["evolving", 33], ["faster", 42], ["?", 48]], "detected_answers": [{"text": "enhancers", "token_spans": [[119, 119], [36, 36], [65, 65], [79, 79]], "char_spans": [[742, 750], [220, 228], [410, 418], [494, 502]]}]}], "context_tokens": [["The", 0], ["mammalian", 4], ["radiation", 14], ["has", 24], ["corresponded", 28], ["with", 41], ["rapid", 46], ["changes", 52], ["in", 60], ["noncoding", 63], ["regions", 73], ["of", 81], ["the", 84], ["genome", 88], [",", 94], ["but", 96], ["we", 100], ["lack", 103], ["a", 108], ["comprehensive", 110], ["understanding", 124], ["of", 138], ["regulatory", 141], ["evolution", 152], ["in", 162], ["mammals", 165], [".", 172], ["Here", 174], [",", 178], ["we", 180], ["track", 183], ["the", 189], ["evolution", 193], ["of", 203], ["promoters", 206], ["and", 216], ["enhancers", 220], ["active", 230], ["in", 237], ["liver", 240], ["across", 246], ["20", 253], ["mammalian", 256], ["species", 266], ["from", 274], ["six", 279], ["diverse", 283], ["orders", 291], ["by", 298], ["profiling", 301], ["genomic", 311], ["enrichment", 319], ["of", 330], ["H3K27", 333], ["acetylation", 339], ["and", 351], ["H3K4", 355], ["trimethylation", 360], [".", 374], ["We", 376], ["report", 379], ["that", 386], ["rapid", 391], ["evolution", 397], ["of", 407], ["enhancers", 410], ["is", 420], ["a", 423], ["universal", 425], ["feature", 435], ["of", 443], ["mammalian", 446], ["genomes", 456], [".", 463], ["Most", 465], ["of", 470], ["the", 473], ["recently", 477], ["evolved", 486], ["enhancers", 494], ["arise", 504], ["from", 510], ["ancestral", 515], ["DNA", 525], ["exaptation", 529], [",", 539], ["rather", 541], ["than", 548], ["lineage", 553], ["-", 560], ["specific", 561], ["expansions", 570], ["of", 581], ["repeat", 584], ["elements", 591], [".", 599], ["In", 601], ["contrast", 604], [",", 612], ["almost", 614], ["all", 621], ["liver", 625], ["promoters", 631], ["are", 641], ["partially", 645], ["or", 655], ["fully", 658], ["conserved", 664], ["across", 674], ["these", 681], ["species", 687], [".", 694], ["Our", 696], ["data", 700], ["further", 705], ["reveal", 713], ["that", 720], ["recently", 725], ["evolved", 734], ["enhancers", 742], ["can", 752], ["be", 756], ["associated", 759], ["with", 770], ["genes", 775], ["under", 781], ["positive", 787], ["selection", 796], [",", 805], ["demonstrating", 807], ["the", 821], ["power", 825], ["of", 831], ["this", 834], ["approach", 839], ["for", 848], ["annotating", 852], ["regulatory", 863], ["adaptations", 874], ["in", 886], ["genomic", 889], ["sequences", 897], [".", 906], ["These", 908], ["results", 914], ["provide", 922], ["important", 930], ["insight", 940], ["into", 948], ["the", 953], ["functional", 957], ["genetics", 968], ["underpinning", 977], ["mammalian", 990], ["regulatory", 1000], ["evolution", 1011], [".", 1020]]}
{"context": "To study the effects of siltuximab on the interleukin-6 (IL-6)/signal transducer and activator of transcription 3 (Stat3) signaling pathway in ovarian epithelial carcinoma. (1) Expressions of IL-6 in ovarian cancer patient specimens were assessed by immunohistochemistry. (2) Expression of phosphorylation Stat3 (pStat3) protein in siltuximab and IL-6 treated SKOV3 cell lines was determined by western blot, and expression levels of Stat3-induced bcl-XL, MCL-1, survivin, in siltuximab treated SKOV3/TR and CAOV3/TR cells lines were also determined by western blot. (3) Real-time image analysis was used to study the nuclear translocation of pEGFP-Stat3 fusion protein in ovarian cancer cell line SKOV3-pEGFP-Stat3 treated with siltuximab and IL-6. (4) Paclitaxel sensitivity in siltuximab treated SKOV3/TR and CAOV3/TR cell lines were assessed using the methyl thiazolyl tetrazolium (MTT). The 50% inhibiting concentration (IC(50)) was defined as the paclitaxel concentration required to decrease the A(490) value to 50%. (1) There were significantly difference in IL-6 staining density and the positive rate of IL-6 protein stained among the metastatic, and drug-resistant recurrent tumors, and matched primary tumors [69% (18/26)] vs. 77% (20/26) vs. 23% (6/26), P < 0.05]. (2)A clear increase in Stat3 phosphorylation levels was observed in the IL-6-treated SKOV3 cell lines as compared to the SKOV3 cell lines. When the IL-6-treated SKOV3 cells were incubated with siltuximab with a range of concentrations of 0.001, 0.01, 0.1, 1.0 and 10 \u00b5g/ml, there were trends toward reduced pStat3 expression in the treated cell lines. Compared without treatment with siltuximab, the expression of the anti-apoptotic proteins MCL-1, bcl-XL and survivin in SKOV3/TR and CAOV3/TR cell lines were significantly decreased after treated with siltuximab. (3) In resting cells, the majority of pEGFP-Stat3 was cytoplasmic until the addition of human IL-6, which promptly induced the translocation of fluorescent Stat3 molecules to the nucleus. Exposure of cells to siltuximab with a range of concentrations of 0.001, 0.01, 0.1, 1.0 and 10 \u00b5g/ml, followed by an incubation in IL-6 significantly reduced pEGFP-Stat3 nucleocytoplasmic translocation. (4) MTT cytotoxicity assay demonstrated that siltuximab increased paclitaxel-induced cell death and partially overcame paclitaxel resistance. Treated with siltuximab (1 and 10 \u00b5g/ml), the paclitaxel IC(50) value of siltuximab in SKOV3/TR (0.49, 0.19 \u00b5g/ml) and CAOV3/TR (0.0010, 0.0008 \u00b5g/ml) cells were significantly lower than those in untreated cells (0.71, 0.0021 \u00b5g/ml; all P < 0.05). These results demonstrated that siltuximab effectively block the IL-6 signaling pathways, which. Blockage of IL-6 signaling may provide benefits for the treatment of ovarian cancer.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "0913b9c795bf4b8b9f202745a57d8d03", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[8, 8]], "char_spans": [[42, 54]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["effects", 13], ["of", 21], ["siltuximab", 24], ["on", 35], ["the", 38], ["interleukin-6", 42], ["(", 56], ["IL-6)/signal", 57], ["transducer", 70], ["and", 81], ["activator", 85], ["of", 95], ["transcription", 98], ["3", 112], ["(", 114], ["Stat3", 115], [")", 120], ["signaling", 122], ["pathway", 132], ["in", 140], ["ovarian", 143], ["epithelial", 151], ["carcinoma", 162], [".", 171], ["(", 173], ["1", 174], [")", 175], ["Expressions", 177], ["of", 189], ["IL-6", 192], ["in", 197], ["ovarian", 200], ["cancer", 208], ["patient", 215], ["specimens", 223], ["were", 233], ["assessed", 238], ["by", 247], ["immunohistochemistry", 250], [".", 270], ["(", 272], ["2", 273], [")", 274], ["Expression", 276], ["of", 287], ["phosphorylation", 290], ["Stat3", 306], ["(", 312], ["pStat3", 313], [")", 319], ["protein", 321], ["in", 329], ["siltuximab", 332], ["and", 343], ["IL-6", 347], ["treated", 352], ["SKOV3", 360], ["cell", 366], ["lines", 371], ["was", 377], ["determined", 381], ["by", 392], ["western", 395], ["blot", 403], [",", 407], ["and", 409], ["expression", 413], ["levels", 424], ["of", 431], ["Stat3-induced", 434], ["bcl", 448], ["-", 451], ["XL", 452], [",", 454], ["MCL-1", 456], [",", 461], ["survivin", 463], [",", 471], ["in", 473], ["siltuximab", 476], ["treated", 487], ["SKOV3/TR", 495], ["and", 504], ["CAOV3/TR", 508], ["cells", 517], ["lines", 523], ["were", 529], ["also", 534], ["determined", 539], ["by", 550], ["western", 553], ["blot", 561], [".", 565], ["(", 567], ["3", 568], [")", 569], ["Real", 571], ["-", 575], ["time", 576], ["image", 581], ["analysis", 587], ["was", 596], ["used", 600], ["to", 605], ["study", 608], ["the", 614], ["nuclear", 618], ["translocation", 626], ["of", 640], ["pEGFP", 643], ["-", 648], ["Stat3", 649], ["fusion", 655], ["protein", 662], ["in", 670], ["ovarian", 673], ["cancer", 681], ["cell", 688], ["line", 693], ["SKOV3-pEGFP", 698], ["-", 709], ["Stat3", 710], ["treated", 716], ["with", 724], ["siltuximab", 729], ["and", 740], ["IL-6", 744], [".", 748], ["(", 750], ["4", 751], [")", 752], ["Paclitaxel", 754], ["sensitivity", 765], ["in", 777], ["siltuximab", 780], ["treated", 791], ["SKOV3/TR", 799], ["and", 808], ["CAOV3/TR", 812], ["cell", 821], ["lines", 826], ["were", 832], ["assessed", 837], ["using", 846], ["the", 852], ["methyl", 856], ["thiazolyl", 863], ["tetrazolium", 873], ["(", 885], ["MTT", 886], [")", 889], [".", 890], ["The", 892], ["50", 896], ["%", 898], ["inhibiting", 900], ["concentration", 911], ["(", 925], ["IC(50", 926], [")", 931], [")", 932], ["was", 934], ["defined", 938], ["as", 946], ["the", 949], ["paclitaxel", 953], ["concentration", 964], ["required", 978], ["to", 987], ["decrease", 990], ["the", 999], ["A(490", 1003], [")", 1008], ["value", 1010], ["to", 1016], ["50", 1019], ["%", 1021], [".", 1022], ["(", 1024], ["1", 1025], [")", 1026], ["There", 1028], ["were", 1034], ["significantly", 1039], ["difference", 1053], ["in", 1064], ["IL-6", 1067], ["staining", 1072], ["density", 1081], ["and", 1089], ["the", 1093], ["positive", 1097], ["rate", 1106], ["of", 1111], ["IL-6", 1114], ["protein", 1119], ["stained", 1127], ["among", 1135], ["the", 1141], ["metastatic", 1145], [",", 1155], ["and", 1157], ["drug", 1161], ["-", 1165], ["resistant", 1166], ["recurrent", 1176], ["tumors", 1186], [",", 1192], ["and", 1194], ["matched", 1198], ["primary", 1206], ["tumors", 1214], ["[", 1221], ["69", 1222], ["%", 1224], ["(", 1226], ["18/26", 1227], [")", 1232], ["]", 1233], ["vs.", 1235], ["77", 1239], ["%", 1241], ["(", 1243], ["20/26", 1244], [")", 1249], ["vs.", 1251], ["23", 1255], ["%", 1257], ["(", 1259], ["6/26", 1260], [")", 1264], [",", 1265], ["P", 1267], ["<", 1269], ["0.05].", 1271], ["(", 1278], ["2)A", 1279], ["clear", 1283], ["increase", 1289], ["in", 1298], ["Stat3", 1301], ["phosphorylation", 1307], ["levels", 1323], ["was", 1330], ["observed", 1334], ["in", 1343], ["the", 1346], ["IL-6-treated", 1350], ["SKOV3", 1363], ["cell", 1369], ["lines", 1374], ["as", 1380], ["compared", 1383], ["to", 1392], ["the", 1395], ["SKOV3", 1399], ["cell", 1405], ["lines", 1410], [".", 1415], ["When", 1417], ["the", 1422], ["IL-6-treated", 1426], ["SKOV3", 1439], ["cells", 1445], ["were", 1451], ["incubated", 1456], ["with", 1466], ["siltuximab", 1471], ["with", 1482], ["a", 1487], ["range", 1489], ["of", 1495], ["concentrations", 1498], ["of", 1513], ["0.001", 1516], [",", 1521], ["0.01", 1523], [",", 1527], ["0.1", 1529], [",", 1532], ["1.0", 1534], ["and", 1538], ["10", 1542], ["\u00b5g", 1545], ["/", 1547], ["ml", 1548], [",", 1550], ["there", 1552], ["were", 1558], ["trends", 1563], ["toward", 1570], ["reduced", 1577], ["pStat3", 1585], ["expression", 1592], ["in", 1603], ["the", 1606], ["treated", 1610], ["cell", 1618], ["lines", 1623], [".", 1628], ["Compared", 1630], ["without", 1639], ["treatment", 1647], ["with", 1657], ["siltuximab", 1662], [",", 1672], ["the", 1674], ["expression", 1678], ["of", 1689], ["the", 1692], ["anti", 1696], ["-", 1700], ["apoptotic", 1701], ["proteins", 1711], ["MCL-1", 1720], [",", 1725], ["bcl", 1727], ["-", 1730], ["XL", 1731], ["and", 1734], ["survivin", 1738], ["in", 1747], ["SKOV3/TR", 1750], ["and", 1759], ["CAOV3/TR", 1763], ["cell", 1772], ["lines", 1777], ["were", 1783], ["significantly", 1788], ["decreased", 1802], ["after", 1812], ["treated", 1818], ["with", 1826], ["siltuximab", 1831], [".", 1841], ["(", 1843], ["3", 1844], [")", 1845], ["In", 1847], ["resting", 1850], ["cells", 1858], [",", 1863], ["the", 1865], ["majority", 1869], ["of", 1878], ["pEGFP", 1881], ["-", 1886], ["Stat3", 1887], ["was", 1893], ["cytoplasmic", 1897], ["until", 1909], ["the", 1915], ["addition", 1919], ["of", 1928], ["human", 1931], ["IL-6", 1937], [",", 1941], ["which", 1943], ["promptly", 1949], ["induced", 1958], ["the", 1966], ["translocation", 1970], ["of", 1984], ["fluorescent", 1987], ["Stat3", 1999], ["molecules", 2005], ["to", 2015], ["the", 2018], ["nucleus", 2022], [".", 2029], ["Exposure", 2031], ["of", 2040], ["cells", 2043], ["to", 2049], ["siltuximab", 2052], ["with", 2063], ["a", 2068], ["range", 2070], ["of", 2076], ["concentrations", 2079], ["of", 2094], ["0.001", 2097], [",", 2102], ["0.01", 2104], [",", 2108], ["0.1", 2110], [",", 2113], ["1.0", 2115], ["and", 2119], ["10", 2123], ["\u00b5g", 2126], ["/", 2128], ["ml", 2129], [",", 2131], ["followed", 2133], ["by", 2142], ["an", 2145], ["incubation", 2148], ["in", 2159], ["IL-6", 2162], ["significantly", 2167], ["reduced", 2181], ["pEGFP", 2189], ["-", 2194], ["Stat3", 2195], ["nucleocytoplasmic", 2201], ["translocation", 2219], [".", 2232], ["(", 2234], ["4", 2235], [")", 2236], ["MTT", 2238], ["cytotoxicity", 2242], ["assay", 2255], ["demonstrated", 2261], ["that", 2274], ["siltuximab", 2279], ["increased", 2290], ["paclitaxel", 2300], ["-", 2310], ["induced", 2311], ["cell", 2319], ["death", 2324], ["and", 2330], ["partially", 2334], ["overcame", 2344], ["paclitaxel", 2353], ["resistance", 2364], [".", 2374], ["Treated", 2376], ["with", 2384], ["siltuximab", 2389], ["(", 2400], ["1", 2401], ["and", 2403], ["10", 2407], ["\u00b5g", 2410], ["/", 2412], ["ml", 2413], [")", 2415], [",", 2416], ["the", 2418], ["paclitaxel", 2422], ["IC(50", 2433], [")", 2438], ["value", 2440], ["of", 2446], ["siltuximab", 2449], ["in", 2460], ["SKOV3/TR", 2463], ["(", 2472], ["0.49", 2473], [",", 2477], ["0.19", 2479], ["\u00b5g", 2484], ["/", 2486], ["ml", 2487], [")", 2489], ["and", 2491], ["CAOV3/TR", 2495], ["(", 2504], ["0.0010", 2505], [",", 2511], ["0.0008", 2513], ["\u00b5g", 2520], ["/", 2522], ["ml", 2523], [")", 2525], ["cells", 2527], ["were", 2533], ["significantly", 2538], ["lower", 2552], ["than", 2558], ["those", 2563], ["in", 2569], ["untreated", 2572], ["cells", 2582], ["(", 2588], ["0.71", 2589], [",", 2593], ["0.0021", 2595], ["\u00b5g", 2602], ["/", 2604], ["ml", 2605], [";", 2607], ["all", 2609], ["P", 2613], ["<", 2615], ["0.05", 2617], [")", 2621], [".", 2622], ["These", 2624], ["results", 2630], ["demonstrated", 2638], ["that", 2651], ["siltuximab", 2656], ["effectively", 2667], ["block", 2679], ["the", 2685], ["IL-6", 2689], ["signaling", 2694], ["pathways", 2704], [",", 2712], ["which", 2714], [".", 2719], ["Blockage", 2721], ["of", 2730], ["IL-6", 2733], ["signaling", 2738], ["may", 2748], ["provide", 2752], ["benefits", 2760], ["for", 2769], ["the", 2773], ["treatment", 2777], ["of", 2787], ["ovarian", 2790], ["cancer", 2798], [".", 2804]]}
{"context": "Heat shock proteins (Hsp) are known to enhance cell survival under various stress conditions. In the heart, the small Hsp20 has emerged as a key mediator of protection against apoptosis, remodeling, and ischemia/reperfusion injury. Moreover, Hsp20 has been implicated in modulation of cardiac contractility ex vivo. The objective of this study was to determine the in vivo role of Hsp20 in the heart and the mechanisms underlying its regulatory effects in calcium (Ca) cycling. Hsp20 overexpression in intact animals resulted in significant enhancement of cardiac function, coupled with augmented Ca cycling and sarcoplasmic reticulum Ca load in isolated cardiomyocytes. This was associated with specific increases in phosphorylation of phospholamban (PLN) at both Ser16 and Thr17, relieving its inhibition of the apparent Ca affinity of SERCA2a. Accordingly, the inotropic effects of Hsp20 were abrogated in cardiomyocytes expressing nonphosphorylatable PLN (S16A/T17A). Interestingly, the activity of type 1 protein phosphatase (PP1), a known regulator of PLN signaling, was significantly reduced by Hsp20 overexpression, suggesting that the Hsp20 stimulatory effects are partially mediated through the PP1-PLN axis. This hypothesis was supported by cell fractionation, coimmunoprecipitation, and coimmunolocalization studies, which revealed an association between Hsp20, PP1, and PLN. Furthermore, recombinant protein studies confirmed a physical interaction between AA 73 to 160 in Hsp20 and AA 163 to 330 in PP1. Hsp20 is a novel regulator of sarcoplasmic reticulum Ca cycling by targeting the PP1-PLN axis. These findings, coupled with the well-recognized cardioprotective role of Hsp20, suggest a dual benefit of targeting Hsp20 in heart disease.", "qas": [{"question": "Which protein phosphatase has been found to interact with the heat shock protein, HSP20?", "answers": ["Protein phosphatase 1", "PP1"], "qid": "04c9df99ae544e2a96f40f77fd2378b2", "question_tokens": [["Which", 0], ["protein", 6], ["phosphatase", 14], ["has", 26], ["been", 30], ["found", 35], ["to", 41], ["interact", 44], ["with", 53], ["the", 58], ["heat", 62], ["shock", 67], ["protein", 73], [",", 80], ["HSP20", 82], ["?", 87]], "detected_answers": [{"text": "PP1", "token_spans": [[227, 227], [175, 175], [254, 254]], "char_spans": [[1374, 1376], [1031, 1033], [1513, 1515]]}]}], "context_tokens": [["Heat", 0], ["shock", 5], ["proteins", 11], ["(", 20], ["Hsp", 21], [")", 24], ["are", 26], ["known", 30], ["to", 36], ["enhance", 39], ["cell", 47], ["survival", 52], ["under", 61], ["various", 67], ["stress", 75], ["conditions", 82], [".", 92], ["In", 94], ["the", 97], ["heart", 101], [",", 106], ["the", 108], ["small", 112], ["Hsp20", 118], ["has", 124], ["emerged", 128], ["as", 136], ["a", 139], ["key", 141], ["mediator", 145], ["of", 154], ["protection", 157], ["against", 168], ["apoptosis", 176], [",", 185], ["remodeling", 187], [",", 197], ["and", 199], ["ischemia", 203], ["/", 211], ["reperfusion", 212], ["injury", 224], [".", 230], ["Moreover", 232], [",", 240], ["Hsp20", 242], ["has", 248], ["been", 252], ["implicated", 257], ["in", 268], ["modulation", 271], ["of", 282], ["cardiac", 285], ["contractility", 293], ["ex", 307], ["vivo", 310], [".", 314], ["The", 316], ["objective", 320], ["of", 330], ["this", 333], ["study", 338], ["was", 344], ["to", 348], ["determine", 351], ["the", 361], ["in", 365], ["vivo", 368], ["role", 373], ["of", 378], ["Hsp20", 381], ["in", 387], ["the", 390], ["heart", 394], ["and", 400], ["the", 404], ["mechanisms", 408], ["underlying", 419], ["its", 430], ["regulatory", 434], ["effects", 445], ["in", 453], ["calcium", 456], ["(", 464], ["Ca", 465], [")", 467], ["cycling", 469], [".", 476], ["Hsp20", 478], ["overexpression", 484], ["in", 499], ["intact", 502], ["animals", 509], ["resulted", 517], ["in", 526], ["significant", 529], ["enhancement", 541], ["of", 553], ["cardiac", 556], ["function", 564], [",", 572], ["coupled", 574], ["with", 582], ["augmented", 587], ["Ca", 597], ["cycling", 600], ["and", 608], ["sarcoplasmic", 612], ["reticulum", 625], ["Ca", 635], ["load", 638], ["in", 643], ["isolated", 646], ["cardiomyocytes", 655], [".", 669], ["This", 671], ["was", 676], ["associated", 680], ["with", 691], ["specific", 696], ["increases", 705], ["in", 715], ["phosphorylation", 718], ["of", 734], ["phospholamban", 737], ["(", 751], ["PLN", 752], [")", 755], ["at", 757], ["both", 760], ["Ser16", 765], ["and", 771], ["Thr17", 775], [",", 780], ["relieving", 782], ["its", 792], ["inhibition", 796], ["of", 807], ["the", 810], ["apparent", 814], ["Ca", 823], ["affinity", 826], ["of", 835], ["SERCA2a", 838], [".", 845], ["Accordingly", 847], [",", 858], ["the", 860], ["inotropic", 864], ["effects", 874], ["of", 882], ["Hsp20", 885], ["were", 891], ["abrogated", 896], ["in", 906], ["cardiomyocytes", 909], ["expressing", 924], ["nonphosphorylatable", 935], ["PLN", 955], ["(", 959], ["S16A", 960], ["/", 964], ["T17A", 965], [")", 969], [".", 970], ["Interestingly", 972], [",", 985], ["the", 987], ["activity", 991], ["of", 1000], ["type", 1003], ["1", 1008], ["protein", 1010], ["phosphatase", 1018], ["(", 1030], ["PP1", 1031], [")", 1034], [",", 1035], ["a", 1037], ["known", 1039], ["regulator", 1045], ["of", 1055], ["PLN", 1058], ["signaling", 1062], [",", 1071], ["was", 1073], ["significantly", 1077], ["reduced", 1091], ["by", 1099], ["Hsp20", 1102], ["overexpression", 1108], [",", 1122], ["suggesting", 1124], ["that", 1135], ["the", 1140], ["Hsp20", 1144], ["stimulatory", 1150], ["effects", 1162], ["are", 1170], ["partially", 1174], ["mediated", 1184], ["through", 1193], ["the", 1201], ["PP1-PLN", 1205], ["axis", 1213], [".", 1217], ["This", 1219], ["hypothesis", 1224], ["was", 1235], ["supported", 1239], ["by", 1249], ["cell", 1252], ["fractionation", 1257], [",", 1270], ["coimmunoprecipitation", 1272], [",", 1293], ["and", 1295], ["coimmunolocalization", 1299], ["studies", 1320], [",", 1327], ["which", 1329], ["revealed", 1335], ["an", 1344], ["association", 1347], ["between", 1359], ["Hsp20", 1367], [",", 1372], ["PP1", 1374], [",", 1377], ["and", 1379], ["PLN", 1383], [".", 1386], ["Furthermore", 1388], [",", 1399], ["recombinant", 1401], ["protein", 1413], ["studies", 1421], ["confirmed", 1429], ["a", 1439], ["physical", 1441], ["interaction", 1450], ["between", 1462], ["AA", 1470], ["73", 1473], ["to", 1476], ["160", 1479], ["in", 1483], ["Hsp20", 1486], ["and", 1492], ["AA", 1496], ["163", 1499], ["to", 1503], ["330", 1506], ["in", 1510], ["PP1", 1513], [".", 1516], ["Hsp20", 1518], ["is", 1524], ["a", 1527], ["novel", 1529], ["regulator", 1535], ["of", 1545], ["sarcoplasmic", 1548], ["reticulum", 1561], ["Ca", 1571], ["cycling", 1574], ["by", 1582], ["targeting", 1585], ["the", 1595], ["PP1-PLN", 1599], ["axis", 1607], [".", 1611], ["These", 1613], ["findings", 1619], [",", 1627], ["coupled", 1629], ["with", 1637], ["the", 1642], ["well", 1646], ["-", 1650], ["recognized", 1651], ["cardioprotective", 1662], ["role", 1679], ["of", 1684], ["Hsp20", 1687], [",", 1692], ["suggest", 1694], ["a", 1702], ["dual", 1704], ["benefit", 1709], ["of", 1717], ["targeting", 1720], ["Hsp20", 1730], ["in", 1736], ["heart", 1739], ["disease", 1745], [".", 1752]]}
{"context": "\u03b1-Synuclein is the major protein component of Lewy bodies--the pathological hallmark of Parkinson's disease (PD) and Dementia with Lewy bodies (DLB). Its accumulation into intracellular aggregates is implicated in the process of Lewy body formation. However, its roles in both normal function, and disease, remain controversial. Using a novel model of chronic oxidative stress in cultured dopaminergic and cortical neurons, we report that endogenous \u03b1-synuclein is upregulated in response to low dose toxicity. This response is conserved between subpopulations of cortical and dopaminergic neurons, and confers relative resistance to apoptosis following secondary insult. Additional acute oxidative stress leads to intracellular accumulation of \u03b1-synuclein. These punctate deposits colocalize with ubiquitin, which is central to proteosome-mediated protein degeneration, and is the second major component of Lewy bodies. The current results imply that differential levels of \u03b1-synuclein expression may influence neuronal vulnerability in chronic neurodegenerative diseases. They further support a 'two hit' hypothesis for Lewy body formation, whereby mild stress causes a protective upregulation of \u03b1-synuclein. However, such increased levels of \u03b1-synuclein may drive its accumulation, following additional toxic insult. Finally, these results support a common mechanism for degeneration of dopaminergic and cortical neurons, affected in PD, and DLB, respectively.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4504ae5e0d41435984b259c276b8cf7f", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[80, 82], [0, 2], [197, 199], [207, 209], [162, 164], [123, 125]], "char_spans": [[450, 460], [0, 10], [1199, 1209], [1246, 1256], [975, 985], [745, 755]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["is", 12], ["the", 15], ["major", 19], ["protein", 25], ["component", 33], ["of", 43], ["Lewy", 46], ["bodies", 51], ["--", 57], ["the", 59], ["pathological", 63], ["hallmark", 76], ["of", 85], ["Parkinson", 88], ["'s", 97], ["disease", 100], ["(", 108], ["PD", 109], [")", 111], ["and", 113], ["Dementia", 117], ["with", 126], ["Lewy", 131], ["bodies", 136], ["(", 143], ["DLB", 144], [")", 147], [".", 148], ["Its", 150], ["accumulation", 154], ["into", 167], ["intracellular", 172], ["aggregates", 186], ["is", 197], ["implicated", 200], ["in", 211], ["the", 214], ["process", 218], ["of", 226], ["Lewy", 229], ["body", 234], ["formation", 239], [".", 248], ["However", 250], [",", 257], ["its", 259], ["roles", 263], ["in", 269], ["both", 272], ["normal", 277], ["function", 284], [",", 292], ["and", 294], ["disease", 298], [",", 305], ["remain", 307], ["controversial", 314], [".", 327], ["Using", 329], ["a", 335], ["novel", 337], ["model", 343], ["of", 349], ["chronic", 352], ["oxidative", 360], ["stress", 370], ["in", 377], ["cultured", 380], ["dopaminergic", 389], ["and", 402], ["cortical", 406], ["neurons", 415], [",", 422], ["we", 424], ["report", 427], ["that", 434], ["endogenous", 439], ["\u03b1", 450], ["-", 451], ["synuclein", 452], ["is", 462], ["upregulated", 465], ["in", 477], ["response", 480], ["to", 489], ["low", 492], ["dose", 496], ["toxicity", 501], [".", 509], ["This", 511], ["response", 516], ["is", 525], ["conserved", 528], ["between", 538], ["subpopulations", 546], ["of", 561], ["cortical", 564], ["and", 573], ["dopaminergic", 577], ["neurons", 590], [",", 597], ["and", 599], ["confers", 603], ["relative", 611], ["resistance", 620], ["to", 631], ["apoptosis", 634], ["following", 644], ["secondary", 654], ["insult", 664], [".", 670], ["Additional", 672], ["acute", 683], ["oxidative", 689], ["stress", 699], ["leads", 706], ["to", 712], ["intracellular", 715], ["accumulation", 729], ["of", 742], ["\u03b1", 745], ["-", 746], ["synuclein", 747], [".", 756], ["These", 758], ["punctate", 764], ["deposits", 773], ["colocalize", 782], ["with", 793], ["ubiquitin", 798], [",", 807], ["which", 809], ["is", 815], ["central", 818], ["to", 826], ["proteosome", 829], ["-", 839], ["mediated", 840], ["protein", 849], ["degeneration", 857], [",", 869], ["and", 871], ["is", 875], ["the", 878], ["second", 882], ["major", 889], ["component", 895], ["of", 905], ["Lewy", 908], ["bodies", 913], [".", 919], ["The", 921], ["current", 925], ["results", 933], ["imply", 941], ["that", 947], ["differential", 952], ["levels", 965], ["of", 972], ["\u03b1", 975], ["-", 976], ["synuclein", 977], ["expression", 987], ["may", 998], ["influence", 1002], ["neuronal", 1012], ["vulnerability", 1021], ["in", 1035], ["chronic", 1038], ["neurodegenerative", 1046], ["diseases", 1064], [".", 1072], ["They", 1074], ["further", 1079], ["support", 1087], ["a", 1095], ["'", 1097], ["two", 1098], ["hit", 1102], ["'", 1105], ["hypothesis", 1107], ["for", 1118], ["Lewy", 1122], ["body", 1127], ["formation", 1132], [",", 1141], ["whereby", 1143], ["mild", 1151], ["stress", 1156], ["causes", 1163], ["a", 1170], ["protective", 1172], ["upregulation", 1183], ["of", 1196], ["\u03b1", 1199], ["-", 1200], ["synuclein", 1201], [".", 1210], ["However", 1212], [",", 1219], ["such", 1221], ["increased", 1226], ["levels", 1236], ["of", 1243], ["\u03b1", 1246], ["-", 1247], ["synuclein", 1248], ["may", 1258], ["drive", 1262], ["its", 1268], ["accumulation", 1272], [",", 1284], ["following", 1286], ["additional", 1296], ["toxic", 1307], ["insult", 1313], [".", 1319], ["Finally", 1321], [",", 1328], ["these", 1330], ["results", 1336], ["support", 1344], ["a", 1352], ["common", 1354], ["mechanism", 1361], ["for", 1371], ["degeneration", 1375], ["of", 1388], ["dopaminergic", 1391], ["and", 1404], ["cortical", 1408], ["neurons", 1417], [",", 1424], ["affected", 1426], ["in", 1435], ["PD", 1438], [",", 1440], ["and", 1442], ["DLB", 1446], [",", 1449], ["respectively", 1451], [".", 1463]]}
{"context": "An inheritable bleeding disorder with light coat color caused by an autosomal recessive gene has been reported in a population of Japanese black cattle. The disease has been diagnosed as Chediak-Higashi Syndrome (CHS) of cattle which correspond to a human inheritable disorder caused by mutation in LYST gene. To characterize the molecular lesion causing CHS in cattle, cDNAs encoding bovine LYST were isolated from a bovine brain cDNA library. The nucleotide and deduced amino acid sequences of bovine LYST had 89.6 and 90.2% identity with those of the human LYST gene, respectively. In order to identify the mutation within the LYST gene causing CHS in cattle, cDNA fragments of the LYST gene were amplified from an affected animal by RT-PCR and their nucleotide sequences were completely determined. Notably, a nucleotide substitution of A to G transition, resulting in an amino acid substitution of histidine to arginine (H2015R) was identified in the affected animal. The presence of the substitution was completely corresponding with the occurrence of the CHS phenotype among 105 members of pedigrees of the Japanese black cattle and no cattle of other populations had this substitution. These findings strongly suggested that H2015R is the causative mutation in CHS of Japanese black cattle.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "3ca8e7b15fbb4a1fac7c75a96d9043d5", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[31, 34]], "char_spans": [[187, 210]]}]}], "context_tokens": [["An", 0], ["inheritable", 3], ["bleeding", 15], ["disorder", 24], ["with", 33], ["light", 38], ["coat", 44], ["color", 49], ["caused", 55], ["by", 62], ["an", 65], ["autosomal", 68], ["recessive", 78], ["gene", 88], ["has", 93], ["been", 97], ["reported", 102], ["in", 111], ["a", 114], ["population", 116], ["of", 127], ["Japanese", 130], ["black", 139], ["cattle", 145], [".", 151], ["The", 153], ["disease", 157], ["has", 165], ["been", 169], ["diagnosed", 174], ["as", 184], ["Chediak", 187], ["-", 194], ["Higashi", 195], ["Syndrome", 203], ["(", 212], ["CHS", 213], [")", 216], ["of", 218], ["cattle", 221], ["which", 228], ["correspond", 234], ["to", 245], ["a", 248], ["human", 250], ["inheritable", 256], ["disorder", 268], ["caused", 277], ["by", 284], ["mutation", 287], ["in", 296], ["LYST", 299], ["gene", 304], [".", 308], ["To", 310], ["characterize", 313], ["the", 326], ["molecular", 330], ["lesion", 340], ["causing", 347], ["CHS", 355], ["in", 359], ["cattle", 362], [",", 368], ["cDNAs", 370], ["encoding", 376], ["bovine", 385], ["LYST", 392], ["were", 397], ["isolated", 402], ["from", 411], ["a", 416], ["bovine", 418], ["brain", 425], ["cDNA", 431], ["library", 436], [".", 443], ["The", 445], ["nucleotide", 449], ["and", 460], ["deduced", 464], ["amino", 472], ["acid", 478], ["sequences", 483], ["of", 493], ["bovine", 496], ["LYST", 503], ["had", 508], ["89.6", 512], ["and", 517], ["90.2", 521], ["%", 525], ["identity", 527], ["with", 536], ["those", 541], ["of", 547], ["the", 550], ["human", 554], ["LYST", 560], ["gene", 565], [",", 569], ["respectively", 571], [".", 583], ["In", 585], ["order", 588], ["to", 594], ["identify", 597], ["the", 606], ["mutation", 610], ["within", 619], ["the", 626], ["LYST", 630], ["gene", 635], ["causing", 640], ["CHS", 648], ["in", 652], ["cattle", 655], [",", 661], ["cDNA", 663], ["fragments", 668], ["of", 678], ["the", 681], ["LYST", 685], ["gene", 690], ["were", 695], ["amplified", 700], ["from", 710], ["an", 715], ["affected", 718], ["animal", 727], ["by", 734], ["RT", 737], ["-", 739], ["PCR", 740], ["and", 744], ["their", 748], ["nucleotide", 754], ["sequences", 765], ["were", 775], ["completely", 780], ["determined", 791], [".", 801], ["Notably", 803], [",", 810], ["a", 812], ["nucleotide", 814], ["substitution", 825], ["of", 838], ["A", 841], ["to", 843], ["G", 846], ["transition", 848], [",", 858], ["resulting", 860], ["in", 870], ["an", 873], ["amino", 876], ["acid", 882], ["substitution", 887], ["of", 900], ["histidine", 903], ["to", 913], ["arginine", 916], ["(", 925], ["H2015R", 926], [")", 932], ["was", 934], ["identified", 938], ["in", 949], ["the", 952], ["affected", 956], ["animal", 965], [".", 971], ["The", 973], ["presence", 977], ["of", 986], ["the", 989], ["substitution", 993], ["was", 1006], ["completely", 1010], ["corresponding", 1021], ["with", 1035], ["the", 1040], ["occurrence", 1044], ["of", 1055], ["the", 1058], ["CHS", 1062], ["phenotype", 1066], ["among", 1076], ["105", 1082], ["members", 1086], ["of", 1094], ["pedigrees", 1097], ["of", 1107], ["the", 1110], ["Japanese", 1114], ["black", 1123], ["cattle", 1129], ["and", 1136], ["no", 1140], ["cattle", 1143], ["of", 1150], ["other", 1153], ["populations", 1159], ["had", 1171], ["this", 1175], ["substitution", 1180], [".", 1192], ["These", 1194], ["findings", 1200], ["strongly", 1209], ["suggested", 1218], ["that", 1228], ["H2015R", 1233], ["is", 1240], ["the", 1243], ["causative", 1247], ["mutation", 1257], ["in", 1266], ["CHS", 1269], ["of", 1273], ["Japanese", 1276], ["black", 1285], ["cattle", 1291], [".", 1297]]}
{"context": "Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by Philadelphia chromosome and resultant production of the constitutively activated BCR-ABL tyrosine kinase. Imatinib (STI571), selective inhibitor of the ABL-tyrosine kinase, inhibits the activity of BCR-ABL tyrosine kinase. A phase I and II study of STI571 showed remarkable cytogenetic effect in patients with interferon-refractory CML, offering new hope for therapy for CML. It will, however, require long-term follow-up data from phase II and III clinical studies to validate the effect of STI571 on survival. As therapy for CML improves, monitoring minimal residual disease will be important.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "0bb3119e6d6d48ffa24785cf272e280e", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[48, 50], [24, 26]], "char_spans": [[291, 297], [174, 180]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["clonal", 36], ["hematopoietic", 43], ["stem", 57], ["cell", 62], ["disorder", 67], ["characterized", 76], ["by", 90], ["Philadelphia", 93], ["chromosome", 106], ["and", 117], ["resultant", 121], ["production", 131], ["of", 142], ["the", 145], ["constitutively", 149], ["activated", 164], ["BCR", 174], ["-", 177], ["ABL", 178], ["tyrosine", 182], ["kinase", 191], [".", 197], ["Imatinib", 199], ["(", 208], ["STI571", 209], [")", 215], [",", 216], ["selective", 218], ["inhibitor", 228], ["of", 238], ["the", 241], ["ABL", 245], ["-", 248], ["tyrosine", 249], ["kinase", 258], [",", 264], ["inhibits", 266], ["the", 275], ["activity", 279], ["of", 288], ["BCR", 291], ["-", 294], ["ABL", 295], ["tyrosine", 299], ["kinase", 308], [".", 314], ["A", 316], ["phase", 318], ["I", 324], ["and", 326], ["II", 330], ["study", 333], ["of", 339], ["STI571", 342], ["showed", 349], ["remarkable", 356], ["cytogenetic", 367], ["effect", 379], ["in", 386], ["patients", 389], ["with", 398], ["interferon", 403], ["-", 413], ["refractory", 414], ["CML", 425], [",", 428], ["offering", 430], ["new", 439], ["hope", 443], ["for", 448], ["therapy", 452], ["for", 460], ["CML", 464], [".", 467], ["It", 469], ["will", 472], [",", 476], ["however", 478], [",", 485], ["require", 487], ["long", 495], ["-", 499], ["term", 500], ["follow", 505], ["-", 511], ["up", 512], ["data", 515], ["from", 520], ["phase", 525], ["II", 531], ["and", 534], ["III", 538], ["clinical", 542], ["studies", 551], ["to", 559], ["validate", 562], ["the", 571], ["effect", 575], ["of", 582], ["STI571", 585], ["on", 592], ["survival", 595], [".", 603], ["As", 605], ["therapy", 608], ["for", 616], ["CML", 620], ["improves", 624], [",", 632], ["monitoring", 634], ["minimal", 645], ["residual", 653], ["disease", 662], ["will", 670], ["be", 675], ["important", 678], [".", 687]]}
{"context": "The conserved histone variant H2A.Z functions in euchromatin to antagonize the spread of heterochromatin. The mechanism by which histone H2A is replaced by H2A.Z in the nucleosome is unknown. We identified a complex containing 13 different polypeptides associated with a soluble pool of H2A.Z in Saccharomyces cerevisiae. This complex was designated SWR1-Com in reference to the Swr1p subunit, a Swi2/Snf2-paralog. Swr1p and six other subunits were found only in SWR1-Com, whereas six other subunits were also found in the NuA4 histone acetyltransferase and/or the Ino80 chromatin remodeling complex. H2A.Z and SWR1 were essential for viability of cells lacking the EAF1 component of NuA4, pointing to a close functional connection between these two complexes. Strikingly, chromatin immunoprecipitation analysis of cells lacking Swr1p, the presumed ATPase of the complex, revealed a profound defect in the deposition of H2A.Z at euchromatic regions that flank the silent mating type cassette HMR and at 12 other chromosomal sites tested. Consistent with a specialized role for Swr1p in H2A.Z deposition, the majority of the genome-wide transcriptional defects seen in swr1Delta cells were also found in htz1Delta cells. These studies revealed a novel role for a member of the ATP-dependent chromatin remodeling enzyme family in determining the region-specific histone subunit composition of chromatin in vivo and controlling the epigenetic state of chromatin. Metazoan orthologs of Swr1p (Drosophila Domino; human SRCAP and p400) may have analogous functions.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "30f3fe33aa974d54aa12ad555cb22644", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[97, 97]], "char_spans": [[611, 614]]}]}], "context_tokens": [["The", 0], ["conserved", 4], ["histone", 14], ["variant", 22], ["H2A.Z", 30], ["functions", 36], ["in", 46], ["euchromatin", 49], ["to", 61], ["antagonize", 64], ["the", 75], ["spread", 79], ["of", 86], ["heterochromatin", 89], [".", 104], ["The", 106], ["mechanism", 110], ["by", 120], ["which", 123], ["histone", 129], ["H2A", 137], ["is", 141], ["replaced", 144], ["by", 153], ["H2A.Z", 156], ["in", 162], ["the", 165], ["nucleosome", 169], ["is", 180], ["unknown", 183], [".", 190], ["We", 192], ["identified", 195], ["a", 206], ["complex", 208], ["containing", 216], ["13", 227], ["different", 230], ["polypeptides", 240], ["associated", 253], ["with", 264], ["a", 269], ["soluble", 271], ["pool", 279], ["of", 284], ["H2A.Z", 287], ["in", 293], ["Saccharomyces", 296], ["cerevisiae", 310], [".", 320], ["This", 322], ["complex", 327], ["was", 335], ["designated", 339], ["SWR1-Com", 350], ["in", 359], ["reference", 362], ["to", 372], ["the", 375], ["Swr1p", 379], ["subunit", 385], [",", 392], ["a", 394], ["Swi2/Snf2-paralog", 396], [".", 413], ["Swr1p", 415], ["and", 421], ["six", 425], ["other", 429], ["subunits", 435], ["were", 444], ["found", 449], ["only", 455], ["in", 460], ["SWR1-Com", 463], [",", 471], ["whereas", 473], ["six", 481], ["other", 485], ["subunits", 491], ["were", 500], ["also", 505], ["found", 510], ["in", 516], ["the", 519], ["NuA4", 523], ["histone", 528], ["acetyltransferase", 536], ["and/or", 554], ["the", 561], ["Ino80", 565], ["chromatin", 571], ["remodeling", 581], ["complex", 592], [".", 599], ["H2A.Z", 601], ["and", 607], ["SWR1", 611], ["were", 616], ["essential", 621], ["for", 631], ["viability", 635], ["of", 645], ["cells", 648], ["lacking", 654], ["the", 662], ["EAF1", 666], ["component", 671], ["of", 681], ["NuA4", 684], [",", 688], ["pointing", 690], ["to", 699], ["a", 702], ["close", 704], ["functional", 710], ["connection", 721], ["between", 732], ["these", 740], ["two", 746], ["complexes", 750], [".", 759], ["Strikingly", 761], [",", 771], ["chromatin", 773], ["immunoprecipitation", 783], ["analysis", 803], ["of", 812], ["cells", 815], ["lacking", 821], ["Swr1p", 829], [",", 834], ["the", 836], ["presumed", 840], ["ATPase", 849], ["of", 856], ["the", 859], ["complex", 863], [",", 870], ["revealed", 872], ["a", 881], ["profound", 883], ["defect", 892], ["in", 899], ["the", 902], ["deposition", 906], ["of", 917], ["H2A.Z", 920], ["at", 926], ["euchromatic", 929], ["regions", 941], ["that", 949], ["flank", 954], ["the", 960], ["silent", 964], ["mating", 971], ["type", 978], ["cassette", 983], ["HMR", 992], ["and", 996], ["at", 1000], ["12", 1003], ["other", 1006], ["chromosomal", 1012], ["sites", 1024], ["tested", 1030], [".", 1036], ["Consistent", 1038], ["with", 1049], ["a", 1054], ["specialized", 1056], ["role", 1068], ["for", 1073], ["Swr1p", 1077], ["in", 1083], ["H2A.Z", 1086], ["deposition", 1092], [",", 1102], ["the", 1104], ["majority", 1108], ["of", 1117], ["the", 1120], ["genome", 1124], ["-", 1130], ["wide", 1131], ["transcriptional", 1136], ["defects", 1152], ["seen", 1160], ["in", 1165], ["swr1Delta", 1168], ["cells", 1178], ["were", 1184], ["also", 1189], ["found", 1194], ["in", 1200], ["htz1Delta", 1203], ["cells", 1213], [".", 1218], ["These", 1220], ["studies", 1226], ["revealed", 1234], ["a", 1243], ["novel", 1245], ["role", 1251], ["for", 1256], ["a", 1260], ["member", 1262], ["of", 1269], ["the", 1272], ["ATP", 1276], ["-", 1279], ["dependent", 1280], ["chromatin", 1290], ["remodeling", 1300], ["enzyme", 1311], ["family", 1318], ["in", 1325], ["determining", 1328], ["the", 1340], ["region", 1344], ["-", 1350], ["specific", 1351], ["histone", 1360], ["subunit", 1368], ["composition", 1376], ["of", 1388], ["chromatin", 1391], ["in", 1401], ["vivo", 1404], ["and", 1409], ["controlling", 1413], ["the", 1425], ["epigenetic", 1429], ["state", 1440], ["of", 1446], ["chromatin", 1449], [".", 1458], ["Metazoan", 1460], ["orthologs", 1469], ["of", 1479], ["Swr1p", 1482], ["(", 1488], ["Drosophila", 1489], ["Domino", 1500], [";", 1506], ["human", 1508], ["SRCAP", 1514], ["and", 1520], ["p400", 1524], [")", 1528], ["may", 1530], ["have", 1534], ["analogous", 1539], ["functions", 1549], [".", 1558]]}
{"context": "It is increasingly clear that the normal protein alpha-synuclein is in some manner closely associated with presynaptic components of select neuronal types within the adult human central nervous system (CNS) and, in addition, that in its pathologically altered state alpha-synuclein aggregates selectively in the form of filamentous inclusion bodies during certain progressive neurodegenerative disorders, such as familial and sporadic Parkinson's disease. By having the antibody AFshp raised specifically to alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered protein, an initial attempt is made to map the overall distribution pattern and describe the staining behavior of the immunoreactive punctae in select regions of the prosencephalon. Neocortical immunolabeling is most prominent in the prodigious, but incompletely myelinated, association fields and faintest in the heavily myelinated primary motor and primary sensory fields, with the premotor and first order sensory association areas occupying an intermediate position. Of the thalamic grays evaluated, those containing powerfully myelinated fiber tracts (e.g. centrum medianum, habenular complex) show the weakest immunolabeling, whereas, less sturdily myelinated structures are highly immunoreactive. The fact that the immunostaining spectrum for normal alpha-synuclein is so broad, together with the fact that some thalamic sites actually are immunonegative leads to the following conclusions (1) alpha-synuclein, although present in the synaptic boutons of many nerve cells in the adult human CNS, is by no means ubiquitous there, and (2) neuronal types lacking the normal protein cannot generate the Parkinson's disease-specific filamentous pathology.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "56f2ae49145640039f519cc53fd849b2", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[80, 82], [45, 47], [8, 10], [216, 218], [242, 244]], "char_spans": [[508, 522], [266, 280], [49, 63], [1400, 1414], [1544, 1558]]}]}], "context_tokens": [["It", 0], ["is", 3], ["increasingly", 6], ["clear", 19], ["that", 25], ["the", 30], ["normal", 34], ["protein", 41], ["alpha", 49], ["-", 54], ["synuclein", 55], ["is", 65], ["in", 68], ["some", 71], ["manner", 76], ["closely", 83], ["associated", 91], ["with", 102], ["presynaptic", 107], ["components", 119], ["of", 130], ["select", 133], ["neuronal", 140], ["types", 149], ["within", 155], ["the", 162], ["adult", 166], ["human", 172], ["central", 178], ["nervous", 186], ["system", 194], ["(", 201], ["CNS", 202], [")", 205], ["and", 207], [",", 210], ["in", 212], ["addition", 215], [",", 223], ["that", 225], ["in", 230], ["its", 233], ["pathologically", 237], ["altered", 252], ["state", 260], ["alpha", 266], ["-", 271], ["synuclein", 272], ["aggregates", 282], ["selectively", 293], ["in", 305], ["the", 308], ["form", 312], ["of", 317], ["filamentous", 320], ["inclusion", 332], ["bodies", 342], ["during", 349], ["certain", 356], ["progressive", 364], ["neurodegenerative", 376], ["disorders", 394], [",", 403], ["such", 405], ["as", 410], ["familial", 413], ["and", 422], ["sporadic", 426], ["Parkinson", 435], ["'s", 444], ["disease", 447], [".", 454], ["By", 456], ["having", 459], ["the", 466], ["antibody", 470], ["AFshp", 479], ["raised", 485], ["specifically", 492], ["to", 505], ["alpha", 508], ["-", 513], ["synuclein", 514], ["to", 524], ["label", 527], ["Parkinson", 533], ["disease", 543], ["-", 550], ["specific", 551], ["Lewy", 560], ["bodies", 565], ["and", 572], ["Lewy", 576], ["neurites", 581], ["as", 590], ["well", 593], ["as", 598], ["synaptic", 601], ["boutons", 610], ["containing", 618], ["the", 629], ["unaltered", 633], ["protein", 643], [",", 650], ["an", 652], ["initial", 655], ["attempt", 663], ["is", 671], ["made", 674], ["to", 679], ["map", 682], ["the", 686], ["overall", 690], ["distribution", 698], ["pattern", 711], ["and", 719], ["describe", 723], ["the", 732], ["staining", 736], ["behavior", 745], ["of", 754], ["the", 757], ["immunoreactive", 761], ["punctae", 776], ["in", 784], ["select", 787], ["regions", 794], ["of", 802], ["the", 805], ["prosencephalon", 809], [".", 823], ["Neocortical", 825], ["immunolabeling", 837], ["is", 852], ["most", 855], ["prominent", 860], ["in", 870], ["the", 873], ["prodigious", 877], [",", 887], ["but", 889], ["incompletely", 893], ["myelinated", 906], [",", 916], ["association", 918], ["fields", 930], ["and", 937], ["faintest", 941], ["in", 950], ["the", 953], ["heavily", 957], ["myelinated", 965], ["primary", 976], ["motor", 984], ["and", 990], ["primary", 994], ["sensory", 1002], ["fields", 1010], [",", 1016], ["with", 1018], ["the", 1023], ["premotor", 1027], ["and", 1036], ["first", 1040], ["order", 1046], ["sensory", 1052], ["association", 1060], ["areas", 1072], ["occupying", 1078], ["an", 1088], ["intermediate", 1091], ["position", 1104], [".", 1112], ["Of", 1114], ["the", 1117], ["thalamic", 1121], ["grays", 1130], ["evaluated", 1136], [",", 1145], ["those", 1147], ["containing", 1153], ["powerfully", 1164], ["myelinated", 1175], ["fiber", 1186], ["tracts", 1192], ["(", 1199], ["e.g.", 1200], ["centrum", 1205], ["medianum", 1213], [",", 1221], ["habenular", 1223], ["complex", 1233], [")", 1240], ["show", 1242], ["the", 1247], ["weakest", 1251], ["immunolabeling", 1259], [",", 1273], ["whereas", 1275], [",", 1282], ["less", 1284], ["sturdily", 1289], ["myelinated", 1298], ["structures", 1309], ["are", 1320], ["highly", 1324], ["immunoreactive", 1331], [".", 1345], ["The", 1347], ["fact", 1351], ["that", 1356], ["the", 1361], ["immunostaining", 1365], ["spectrum", 1380], ["for", 1389], ["normal", 1393], ["alpha", 1400], ["-", 1405], ["synuclein", 1406], ["is", 1416], ["so", 1419], ["broad", 1422], [",", 1427], ["together", 1429], ["with", 1438], ["the", 1443], ["fact", 1447], ["that", 1452], ["some", 1457], ["thalamic", 1462], ["sites", 1471], ["actually", 1477], ["are", 1486], ["immunonegative", 1490], ["leads", 1505], ["to", 1511], ["the", 1514], ["following", 1518], ["conclusions", 1528], ["(", 1540], ["1", 1541], [")", 1542], ["alpha", 1544], ["-", 1549], ["synuclein", 1550], [",", 1559], ["although", 1561], ["present", 1570], ["in", 1578], ["the", 1581], ["synaptic", 1585], ["boutons", 1594], ["of", 1602], ["many", 1605], ["nerve", 1610], ["cells", 1616], ["in", 1622], ["the", 1625], ["adult", 1629], ["human", 1635], ["CNS", 1641], [",", 1644], ["is", 1646], ["by", 1649], ["no", 1652], ["means", 1655], ["ubiquitous", 1661], ["there", 1672], [",", 1677], ["and", 1679], ["(", 1683], ["2", 1684], [")", 1685], ["neuronal", 1687], ["types", 1696], ["lacking", 1702], ["the", 1710], ["normal", 1714], ["protein", 1721], ["can", 1729], ["not", 1732], ["generate", 1736], ["the", 1745], ["Parkinson", 1749], ["'s", 1758], ["disease", 1761], ["-", 1768], ["specific", 1769], ["filamentous", 1778], ["pathology", 1790], [".", 1799]]}
{"context": "We report on maternal first cousins with bilateral microtia, micrognathia, cleft palate and hematologic findings of Diamond-Blackfan anemia (DBA). The similarity of findings shared between our cases and a female reported by Hasan and Inoue [1993] suggests that this is a distinctive syndrome, rather than a chance association. DBA is a heterogeneous disorder, caused in about 25% of cases by heterozygous mutations in the RPS19 gene (DBA1). Mutation analysis in our cases did not show an RPS19 mutation, and 2 alleles were present in each. Segregation analysis for DBA1 on chromosome 19 and DBA2 on 8p23 was not consistent with linkage. We conclude that this syndrome of microtia, cleft palate and DBA is not allelic to known DBA loci.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "18ad572dfb52412caadfcb13edb5accd", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[18, 21]], "char_spans": [[116, 138]]}, {"text": "DBA", "token_spans": [[137, 137], [59, 59], [23, 23], [131, 131]], "char_spans": [[726, 728], [327, 329], [141, 143], [698, 700]]}]}], "context_tokens": [["We", 0], ["report", 3], ["on", 10], ["maternal", 13], ["first", 22], ["cousins", 28], ["with", 36], ["bilateral", 41], ["microtia", 51], [",", 59], ["micrognathia", 61], [",", 73], ["cleft", 75], ["palate", 81], ["and", 88], ["hematologic", 92], ["findings", 104], ["of", 113], ["Diamond", 116], ["-", 123], ["Blackfan", 124], ["anemia", 133], ["(", 140], ["DBA", 141], [")", 144], [".", 145], ["The", 147], ["similarity", 151], ["of", 162], ["findings", 165], ["shared", 174], ["between", 181], ["our", 189], ["cases", 193], ["and", 199], ["a", 203], ["female", 205], ["reported", 212], ["by", 221], ["Hasan", 224], ["and", 230], ["Inoue", 234], ["[", 240], ["1993", 241], ["]", 245], ["suggests", 247], ["that", 256], ["this", 261], ["is", 266], ["a", 269], ["distinctive", 271], ["syndrome", 283], [",", 291], ["rather", 293], ["than", 300], ["a", 305], ["chance", 307], ["association", 314], [".", 325], ["DBA", 327], ["is", 331], ["a", 334], ["heterogeneous", 336], ["disorder", 350], [",", 358], ["caused", 360], ["in", 367], ["about", 370], ["25", 376], ["%", 378], ["of", 380], ["cases", 383], ["by", 389], ["heterozygous", 392], ["mutations", 405], ["in", 415], ["the", 418], ["RPS19", 422], ["gene", 428], ["(", 433], ["DBA1", 434], [")", 438], [".", 439], ["Mutation", 441], ["analysis", 450], ["in", 459], ["our", 462], ["cases", 466], ["did", 472], ["not", 476], ["show", 480], ["an", 485], ["RPS19", 488], ["mutation", 494], [",", 502], ["and", 504], ["2", 508], ["alleles", 510], ["were", 518], ["present", 523], ["in", 531], ["each", 534], [".", 538], ["Segregation", 540], ["analysis", 552], ["for", 561], ["DBA1", 565], ["on", 570], ["chromosome", 573], ["19", 584], ["and", 587], ["DBA2", 591], ["on", 596], ["8p23", 599], ["was", 604], ["not", 608], ["consistent", 612], ["with", 623], ["linkage", 628], [".", 635], ["We", 637], ["conclude", 640], ["that", 649], ["this", 654], ["syndrome", 659], ["of", 668], ["microtia", 671], [",", 679], ["cleft", 681], ["palate", 687], ["and", 694], ["DBA", 698], ["is", 702], ["not", 705], ["allelic", 709], ["to", 717], ["known", 720], ["DBA", 726], ["loci", 730], [".", 734]]}
{"context": "To characterise activation of the type I interferon (IFN) pathway in patients with systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid arthritis (RA) and systemic scleroderma (SSc) and to evaluate the potential to develop a molecular diagnostic tool from the peripheral blood that reflects this activation in disease-affected tissues. Overexpressed transcripts were identified in the whole blood (WB) of 262 patients with SLE, 44 with DM, 33 with PM, 28 with SSc and 89 with RA and compared with 24 healthy subjects using Affymetrix microarrays. A five gene type I IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this pathway in the WB with clinical measurements. A common set of 36 type I IFN inducible transcripts were identified among the most overexpressed in the WB of all subjects. Significant activation of the type I IFN pathway in subgroups of each of the five diseases studied was observed. Baseline disease activity measurements correlated with a type I IFN gene signature in the WB of subjects with SLE, PM and SSc, as did various serum autoantibody levels in subjects with SLE and DM. This signature was also well correlated between disease-affected tissue and WB in subjects with SLE, DM, PM and SSc. The results indicate that the type I IFN pathway is activated in patient subsets of five rheumatic diseases and suggest that these subsets may benefit from anti-IFN therapy.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "3d4407ef652d4c23ba87702480b6b50a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[115, 116]], "char_spans": [[601, 613]]}]}], "context_tokens": [["To", 0], ["characterise", 3], ["activation", 16], ["of", 27], ["the", 30], ["type", 34], ["I", 39], ["interferon", 41], ["(", 52], ["IFN", 53], [")", 56], ["pathway", 58], ["in", 66], ["patients", 69], ["with", 78], ["systemic", 83], ["lupus", 92], ["erythematosus", 98], ["(", 112], ["SLE", 113], [")", 116], [",", 117], ["dermatomyositis", 119], ["(", 135], ["DM", 136], [")", 138], [",", 139], ["polymyositis", 141], ["(", 154], ["PM", 155], [")", 157], [",", 158], ["rheumatoid", 160], ["arthritis", 171], ["(", 181], ["RA", 182], [")", 184], ["and", 186], ["systemic", 190], ["scleroderma", 199], ["(", 211], ["SSc", 212], [")", 215], ["and", 217], ["to", 221], ["evaluate", 224], ["the", 233], ["potential", 237], ["to", 247], ["develop", 250], ["a", 258], ["molecular", 260], ["diagnostic", 270], ["tool", 281], ["from", 286], ["the", 291], ["peripheral", 295], ["blood", 306], ["that", 312], ["reflects", 317], ["this", 326], ["activation", 331], ["in", 342], ["disease", 345], ["-", 352], ["affected", 353], ["tissues", 362], [".", 369], ["Overexpressed", 371], ["transcripts", 385], ["were", 397], ["identified", 402], ["in", 413], ["the", 416], ["whole", 420], ["blood", 426], ["(", 432], ["WB", 433], [")", 435], ["of", 437], ["262", 440], ["patients", 444], ["with", 453], ["SLE", 458], [",", 461], ["44", 463], ["with", 466], ["DM", 471], [",", 473], ["33", 475], ["with", 478], ["PM", 483], [",", 485], ["28", 487], ["with", 490], ["SSc", 495], ["and", 499], ["89", 503], ["with", 506], ["RA", 511], ["and", 514], ["compared", 518], ["with", 527], ["24", 532], ["healthy", 535], ["subjects", 543], ["using", 552], ["Affymetrix", 558], ["microarrays", 569], [".", 580], ["A", 582], ["five", 584], ["gene", 589], ["type", 594], ["I", 599], ["IFN", 601], ["signature", 605], ["was", 615], ["assessed", 619], ["in", 628], ["these", 631], ["subjects", 637], ["to", 646], ["identify", 649], ["subpopulations", 658], ["showing", 673], ["both", 681], ["activation", 686], ["and", 697], ["concordance", 701], ["of", 713], ["the", 716], ["type", 720], ["I", 725], ["IFN", 727], ["pathway", 731], ["in", 739], ["the", 742], ["peripheral", 746], ["blood", 757], ["and", 763], ["disease", 767], ["-", 774], ["affected", 775], ["tissues", 784], ["of", 792], ["each", 795], ["disease", 800], ["and", 808], ["to", 812], ["correlate", 815], ["activation", 825], ["of", 836], ["this", 839], ["pathway", 844], ["in", 852], ["the", 855], ["WB", 859], ["with", 862], ["clinical", 867], ["measurements", 876], [".", 888], ["A", 890], ["common", 892], ["set", 899], ["of", 903], ["36", 906], ["type", 909], ["I", 914], ["IFN", 916], ["inducible", 920], ["transcripts", 930], ["were", 942], ["identified", 947], ["among", 958], ["the", 964], ["most", 968], ["overexpressed", 973], ["in", 987], ["the", 990], ["WB", 994], ["of", 997], ["all", 1000], ["subjects", 1004], [".", 1012], ["Significant", 1014], ["activation", 1026], ["of", 1037], ["the", 1040], ["type", 1044], ["I", 1049], ["IFN", 1051], ["pathway", 1055], ["in", 1063], ["subgroups", 1066], ["of", 1076], ["each", 1079], ["of", 1084], ["the", 1087], ["five", 1091], ["diseases", 1096], ["studied", 1105], ["was", 1113], ["observed", 1117], [".", 1125], ["Baseline", 1127], ["disease", 1136], ["activity", 1144], ["measurements", 1153], ["correlated", 1166], ["with", 1177], ["a", 1182], ["type", 1184], ["I", 1189], ["IFN", 1191], ["gene", 1195], ["signature", 1200], ["in", 1210], ["the", 1213], ["WB", 1217], ["of", 1220], ["subjects", 1223], ["with", 1232], ["SLE", 1237], [",", 1240], ["PM", 1242], ["and", 1245], ["SSc", 1249], [",", 1252], ["as", 1254], ["did", 1257], ["various", 1261], ["serum", 1269], ["autoantibody", 1275], ["levels", 1288], ["in", 1295], ["subjects", 1298], ["with", 1307], ["SLE", 1312], ["and", 1316], ["DM", 1320], [".", 1322], ["This", 1324], ["signature", 1329], ["was", 1339], ["also", 1343], ["well", 1348], ["correlated", 1353], ["between", 1364], ["disease", 1372], ["-", 1379], ["affected", 1380], ["tissue", 1389], ["and", 1396], ["WB", 1400], ["in", 1403], ["subjects", 1406], ["with", 1415], ["SLE", 1420], [",", 1423], ["DM", 1425], [",", 1427], ["PM", 1429], ["and", 1432], ["SSc", 1436], [".", 1439], ["The", 1441], ["results", 1445], ["indicate", 1453], ["that", 1462], ["the", 1467], ["type", 1471], ["I", 1476], ["IFN", 1478], ["pathway", 1482], ["is", 1490], ["activated", 1493], ["in", 1503], ["patient", 1506], ["subsets", 1514], ["of", 1522], ["five", 1525], ["rheumatic", 1530], ["diseases", 1540], ["and", 1549], ["suggest", 1553], ["that", 1561], ["these", 1566], ["subsets", 1572], ["may", 1580], ["benefit", 1584], ["from", 1592], ["anti", 1597], ["-", 1601], ["IFN", 1602], ["therapy", 1606], [".", 1613]]}
{"context": "Recently the relevance of Simpson resection grade as a prognostic factor for recurrence of WHO Grade I meningiomas was challenged, contradicting many previous scientific reports and traditional neurosurgical teaching. The objective of this study was to determine whether the predictive value of Simpson resection grade is outdated or remains valid with respect to meningioma recurrence and overall survival. All patients at least 16 years old who underwent primary craniotomies for convexity meningiomas at Oslo University-affiliated hospitals (Rikshospitalet and Ullev\u00e5l University Hospitals) in the period between January 1, 1990, and January 27, 2011, were included. Overall survival and retreatment-free survival rates were correlated with patient- and surgery-specific factors. Three hundred ninety-one consecutive patients were included in the study. The median patient age was 60.1 years (range 19-92 years). The female-to-male ratio was 2.1:1. The WHO grades were Grade I in 353 (90.3%), Grade II in 22 (5.6%), and Grade III in 16 (4.1%). The follow-up rate was 100%. Median follow-up time was 7.1 years (range 0.0-20.9 years) and total observation time was 3147 patient-years. The 1-, 5-, and 10-year overall survival rates were 96%, 89%, and 78%, respectively. Age, sex, WHO grade, and Simpson grade were significantly associated with overall survival. The 1-, 5-, and 10-year retreatment-free survival rates were 99%, 94%, and 90%, respectively. Simpson resection grade and WHO grade were significantly associated with retreatment-free survival. The hazard ratios for retreatment after combined Simpson resection Grades II+III and IV+V were 4.9- and 13.2-times higher than after Simpson Grade I resection, respectively. Simpson Grade I resection should continue to be the goal for convexity meningiomas.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "e876f360fb1c426aaf2c11c8f1ff0327", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[55, 55]], "char_spans": [[364, 373]]}]}], "context_tokens": [["Recently", 0], ["the", 9], ["relevance", 13], ["of", 23], ["Simpson", 26], ["resection", 34], ["grade", 44], ["as", 50], ["a", 53], ["prognostic", 55], ["factor", 66], ["for", 73], ["recurrence", 77], ["of", 88], ["WHO", 91], ["Grade", 95], ["I", 101], ["meningiomas", 103], ["was", 115], ["challenged", 119], [",", 129], ["contradicting", 131], ["many", 145], ["previous", 150], ["scientific", 159], ["reports", 170], ["and", 178], ["traditional", 182], ["neurosurgical", 194], ["teaching", 208], [".", 216], ["The", 218], ["objective", 222], ["of", 232], ["this", 235], ["study", 240], ["was", 246], ["to", 250], ["determine", 253], ["whether", 263], ["the", 271], ["predictive", 275], ["value", 286], ["of", 292], ["Simpson", 295], ["resection", 303], ["grade", 313], ["is", 319], ["outdated", 322], ["or", 331], ["remains", 334], ["valid", 342], ["with", 348], ["respect", 353], ["to", 361], ["meningioma", 364], ["recurrence", 375], ["and", 386], ["overall", 390], ["survival", 398], [".", 406], ["All", 408], ["patients", 412], ["at", 421], ["least", 424], ["16", 430], ["years", 433], ["old", 439], ["who", 443], ["underwent", 447], ["primary", 457], ["craniotomies", 465], ["for", 478], ["convexity", 482], ["meningiomas", 492], ["at", 504], ["Oslo", 507], ["University", 512], ["-", 522], ["affiliated", 523], ["hospitals", 534], ["(", 544], ["Rikshospitalet", 545], ["and", 560], ["Ullev\u00e5l", 564], ["University", 572], ["Hospitals", 583], [")", 592], ["in", 594], ["the", 597], ["period", 601], ["between", 608], ["January", 616], ["1", 624], [",", 625], ["1990", 627], [",", 631], ["and", 633], ["January", 637], ["27", 645], [",", 647], ["2011", 649], [",", 653], ["were", 655], ["included", 660], [".", 668], ["Overall", 670], ["survival", 678], ["and", 687], ["retreatment", 691], ["-", 702], ["free", 703], ["survival", 708], ["rates", 717], ["were", 723], ["correlated", 728], ["with", 739], ["patient-", 744], ["and", 753], ["surgery", 757], ["-", 764], ["specific", 765], ["factors", 774], [".", 781], ["Three", 783], ["hundred", 789], ["ninety", 797], ["-", 803], ["one", 804], ["consecutive", 808], ["patients", 820], ["were", 829], ["included", 834], ["in", 843], ["the", 846], ["study", 850], [".", 855], ["The", 857], ["median", 861], ["patient", 868], ["age", 876], ["was", 880], ["60.1", 884], ["years", 889], ["(", 895], ["range", 896], ["19", 902], ["-", 904], ["92", 905], ["years", 908], [")", 913], [".", 914], ["The", 916], ["female", 920], ["-", 926], ["to", 927], ["-", 929], ["male", 930], ["ratio", 935], ["was", 941], ["2.1:1", 945], [".", 950], ["The", 952], ["WHO", 956], ["grades", 960], ["were", 967], ["Grade", 972], ["I", 978], ["in", 980], ["353", 983], ["(", 987], ["90.3", 988], ["%", 992], [")", 993], [",", 994], ["Grade", 996], ["II", 1002], ["in", 1005], ["22", 1008], ["(", 1011], ["5.6", 1012], ["%", 1015], [")", 1016], [",", 1017], ["and", 1019], ["Grade", 1023], ["III", 1029], ["in", 1033], ["16", 1036], ["(", 1039], ["4.1", 1040], ["%", 1043], [")", 1044], [".", 1045], ["The", 1047], ["follow", 1051], ["-", 1057], ["up", 1058], ["rate", 1061], ["was", 1066], ["100", 1070], ["%", 1073], [".", 1074], ["Median", 1076], ["follow", 1083], ["-", 1089], ["up", 1090], ["time", 1093], ["was", 1098], ["7.1", 1102], ["years", 1106], ["(", 1112], ["range", 1113], ["0.0", 1119], ["-", 1122], ["20.9", 1123], ["years", 1128], [")", 1133], ["and", 1135], ["total", 1139], ["observation", 1145], ["time", 1157], ["was", 1162], ["3147", 1166], ["patient", 1171], ["-", 1178], ["years", 1179], [".", 1184], ["The", 1186], ["1-", 1190], [",", 1192], ["5-", 1194], [",", 1196], ["and", 1198], ["10-year", 1202], ["overall", 1210], ["survival", 1218], ["rates", 1227], ["were", 1233], ["96", 1238], ["%", 1240], [",", 1241], ["89", 1243], ["%", 1245], [",", 1246], ["and", 1248], ["78", 1252], ["%", 1254], [",", 1255], ["respectively", 1257], [".", 1269], ["Age", 1271], [",", 1274], ["sex", 1276], [",", 1279], ["WHO", 1281], ["grade", 1285], [",", 1290], ["and", 1292], ["Simpson", 1296], ["grade", 1304], ["were", 1310], ["significantly", 1315], ["associated", 1329], ["with", 1340], ["overall", 1345], ["survival", 1353], [".", 1361], ["The", 1363], ["1-", 1367], [",", 1369], ["5-", 1371], [",", 1373], ["and", 1375], ["10-year", 1379], ["retreatment", 1387], ["-", 1398], ["free", 1399], ["survival", 1404], ["rates", 1413], ["were", 1419], ["99", 1424], ["%", 1426], [",", 1427], ["94", 1429], ["%", 1431], [",", 1432], ["and", 1434], ["90", 1438], ["%", 1440], [",", 1441], ["respectively", 1443], [".", 1455], ["Simpson", 1457], ["resection", 1465], ["grade", 1475], ["and", 1481], ["WHO", 1485], ["grade", 1489], ["were", 1495], ["significantly", 1500], ["associated", 1514], ["with", 1525], ["retreatment", 1530], ["-", 1541], ["free", 1542], ["survival", 1547], [".", 1555], ["The", 1557], ["hazard", 1561], ["ratios", 1568], ["for", 1575], ["retreatment", 1579], ["after", 1591], ["combined", 1597], ["Simpson", 1606], ["resection", 1614], ["Grades", 1624], ["II+III", 1631], ["and", 1638], ["IV+V", 1642], ["were", 1647], ["4.9-", 1652], ["and", 1657], ["13.2-times", 1661], ["higher", 1672], ["than", 1679], ["after", 1684], ["Simpson", 1690], ["Grade", 1698], ["I", 1704], ["resection", 1706], [",", 1715], ["respectively", 1717], [".", 1729], ["Simpson", 1731], ["Grade", 1739], ["I", 1745], ["resection", 1747], ["should", 1757], ["continue", 1764], ["to", 1773], ["be", 1776], ["the", 1779], ["goal", 1783], ["for", 1788], ["convexity", 1792], ["meningiomas", 1802], [".", 1813]]}
{"context": "High circulating levels of group IIA secretory phospholipase A2 (sPLA2-IIA) activity and mass are independent cardiovascular risk factors. Therefore, inhibition of sPLA2-IIA may be a target for the treatment of atherosclerotic cardiovascular disease. The present study evaluated the effects of sPLA2-IIA inhibition with varespladib acid in a novel mouse model, human apolipoprotein B (apoB)/human cholesteryl ester transfer protein (CETP)/human sPLA2-IIA triple transgenic mice (TTT) fed a Western-type diet. sPLA2-IIA expression increased atherosclerotic lesion formation in TTT compared with human apoB/human CETP double transgenic mice (P<0.01). Varespladib acid effectively inhibited plasma sPLA2-IIA activity. Surprisingly, however, administration of varespladib acid to TTT had no impact on atherosclerosis, which could be attributed to a proatherogenic plasma lipoprotein profile that appears in response to sPLA2-IIA inhibition because of increased plasma CETP activity. In the TTT model, sPLA2-IIA decreased CETP activity by reducing the acceptor properties of sPLA2-IIA-modified very low-density lipoproteins specifically because of a significantly lower apoE content. Increasing very low-density lipoprotein-apoE content by means of adenovirus-mediated gene transfer in sPLA2-IIA transgenic mice restored the acceptor properties for CETP. These data show that in a humanized triple transgenic mouse model with hypercholesterolemia, sPLA2-IIA inhibition increases CETP activity via increasing the very low-density lipoprotein-apoE content, resulting in a proatherogenic lipoprotein profile.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "9f57803776af4b0bbe0deae68fbd40b0", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[6, 8]], "char_spans": [[37, 62]]}]}], "context_tokens": [["High", 0], ["circulating", 5], ["levels", 17], ["of", 24], ["group", 27], ["IIA", 33], ["secretory", 37], ["phospholipase", 47], ["A2", 61], ["(", 64], ["sPLA2-IIA", 65], [")", 74], ["activity", 76], ["and", 85], ["mass", 89], ["are", 94], ["independent", 98], ["cardiovascular", 110], ["risk", 125], ["factors", 130], [".", 137], ["Therefore", 139], [",", 148], ["inhibition", 150], ["of", 161], ["sPLA2-IIA", 164], ["may", 174], ["be", 178], ["a", 181], ["target", 183], ["for", 190], ["the", 194], ["treatment", 198], ["of", 208], ["atherosclerotic", 211], ["cardiovascular", 227], ["disease", 242], [".", 249], ["The", 251], ["present", 255], ["study", 263], ["evaluated", 269], ["the", 279], ["effects", 283], ["of", 291], ["sPLA2-IIA", 294], ["inhibition", 304], ["with", 315], ["varespladib", 320], ["acid", 332], ["in", 337], ["a", 340], ["novel", 342], ["mouse", 348], ["model", 354], [",", 359], ["human", 361], ["apolipoprotein", 367], ["B", 382], ["(", 384], ["apoB)/human", 385], ["cholesteryl", 397], ["ester", 409], ["transfer", 415], ["protein", 424], ["(", 432], ["CETP)/human", 433], ["sPLA2-IIA", 445], ["triple", 455], ["transgenic", 462], ["mice", 473], ["(", 478], ["TTT", 479], [")", 482], ["fed", 484], ["a", 488], ["Western", 490], ["-", 497], ["type", 498], ["diet", 503], [".", 507], ["sPLA2-IIA", 509], ["expression", 519], ["increased", 530], ["atherosclerotic", 540], ["lesion", 556], ["formation", 563], ["in", 573], ["TTT", 576], ["compared", 580], ["with", 589], ["human", 594], ["apoB", 600], ["/", 604], ["human", 605], ["CETP", 611], ["double", 616], ["transgenic", 623], ["mice", 634], ["(", 639], ["P<0.01", 640], [")", 646], [".", 647], ["Varespladib", 649], ["acid", 661], ["effectively", 666], ["inhibited", 678], ["plasma", 688], ["sPLA2-IIA", 695], ["activity", 705], [".", 713], ["Surprisingly", 715], [",", 727], ["however", 729], [",", 736], ["administration", 738], ["of", 753], ["varespladib", 756], ["acid", 768], ["to", 773], ["TTT", 776], ["had", 780], ["no", 784], ["impact", 787], ["on", 794], ["atherosclerosis", 797], [",", 812], ["which", 814], ["could", 820], ["be", 826], ["attributed", 829], ["to", 840], ["a", 843], ["proatherogenic", 845], ["plasma", 860], ["lipoprotein", 867], ["profile", 879], ["that", 887], ["appears", 892], ["in", 900], ["response", 903], ["to", 912], ["sPLA2-IIA", 915], ["inhibition", 925], ["because", 936], ["of", 944], ["increased", 947], ["plasma", 957], ["CETP", 964], ["activity", 969], [".", 977], ["In", 979], ["the", 982], ["TTT", 986], ["model", 990], [",", 995], ["sPLA2-IIA", 997], ["decreased", 1007], ["CETP", 1017], ["activity", 1022], ["by", 1031], ["reducing", 1034], ["the", 1043], ["acceptor", 1047], ["properties", 1056], ["of", 1067], ["sPLA2-IIA", 1070], ["-", 1079], ["modified", 1080], ["very", 1089], ["low", 1094], ["-", 1097], ["density", 1098], ["lipoproteins", 1106], ["specifically", 1119], ["because", 1132], ["of", 1140], ["a", 1143], ["significantly", 1145], ["lower", 1159], ["apoE", 1165], ["content", 1170], [".", 1177], ["Increasing", 1179], ["very", 1190], ["low", 1195], ["-", 1198], ["density", 1199], ["lipoprotein", 1207], ["-", 1218], ["apoE", 1219], ["content", 1224], ["by", 1232], ["means", 1235], ["of", 1241], ["adenovirus", 1244], ["-", 1254], ["mediated", 1255], ["gene", 1264], ["transfer", 1269], ["in", 1278], ["sPLA2-IIA", 1281], ["transgenic", 1291], ["mice", 1302], ["restored", 1307], ["the", 1316], ["acceptor", 1320], ["properties", 1329], ["for", 1340], ["CETP", 1344], [".", 1348], ["These", 1350], ["data", 1356], ["show", 1361], ["that", 1366], ["in", 1371], ["a", 1374], ["humanized", 1376], ["triple", 1386], ["transgenic", 1393], ["mouse", 1404], ["model", 1410], ["with", 1416], ["hypercholesterolemia", 1421], [",", 1441], ["sPLA2-IIA", 1443], ["inhibition", 1453], ["increases", 1464], ["CETP", 1474], ["activity", 1479], ["via", 1488], ["increasing", 1492], ["the", 1503], ["very", 1507], ["low", 1512], ["-", 1515], ["density", 1516], ["lipoprotein", 1524], ["-", 1535], ["apoE", 1536], ["content", 1541], [",", 1548], ["resulting", 1550], ["in", 1560], ["a", 1563], ["proatherogenic", 1565], ["lipoprotein", 1580], ["profile", 1592], [".", 1599]]}
{"context": "The Shprintzen-Goldberg syndrome is an extremely rare syndrome with a characteristic face. This is one of a group of disorders characterized by craniosynostosis and marfanoid features. The aim of this study was to present a new sporadic case of the syndrome and describe in detail the findings at the maxillofacial region.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "0e334455b93e49ba8dc2280657d82443", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[25, 25]], "char_spans": [[144, 159]]}]}], "context_tokens": [["The", 0], ["Shprintzen", 4], ["-", 14], ["Goldberg", 15], ["syndrome", 24], ["is", 33], ["an", 36], ["extremely", 39], ["rare", 49], ["syndrome", 54], ["with", 63], ["a", 68], ["characteristic", 70], ["face", 85], [".", 89], ["This", 91], ["is", 96], ["one", 99], ["of", 103], ["a", 106], ["group", 108], ["of", 114], ["disorders", 117], ["characterized", 127], ["by", 141], ["craniosynostosis", 144], ["and", 161], ["marfanoid", 165], ["features", 175], [".", 183], ["The", 185], ["aim", 189], ["of", 193], ["this", 196], ["study", 201], ["was", 207], ["to", 211], ["present", 214], ["a", 222], ["new", 224], ["sporadic", 228], ["case", 237], ["of", 242], ["the", 245], ["syndrome", 249], ["and", 258], ["describe", 262], ["in", 271], ["detail", 274], ["the", 281], ["findings", 285], ["at", 294], ["the", 297], ["maxillofacial", 301], ["region", 315], [".", 321]]}
{"context": "The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia. The BCR-ABL inhibitor imatinib is also known to inhibit the tyrosine kinase of the stem cell factor receptor, c-Kit. Nilotinib is 30 times more potent than imatinib towards BCR-ABL in vitro. Studies in healthy volunteers and patients with chronic myelogenous leukemia or gastrointestinal stromal tumors have shown that therapeutic doses of nilotinib deliver drug levels similar to those of imatinib. The aim of this study was to compare the inhibitory effects of imatinib and nilotinib on proliferation, differentiation, adhesion, migration and engraftment capacities of human cord blood CD34(+) cells. After a 48-hour cell culture with or without TKIs, CFC, LTC-IC, migration, adhesion and cell cycle analysis were performed. In a second time, the impact of these TKIs on engraftment was assessed in a xenotransplantation model using NOD/SCID/IL-2R\u03b3 (null) mice. TKIs did not affect LTC-IC frequencies despite in vitro inhibition of CFC formation due to inhibition of CD34(+) cell cycle entry. Adhesion of CD34(+) cells to retronectin was reduced in the presence of either imatinib or nilotinib but only at high concentrations. Migration through a SDF-1\u03b1 gradient was not changed by cell culture in the presence of TKIs. Finally, bone marrow cellularity and human chimerism were not affected by daily doses of imatinib and nilotinib in a xenogenic transplantation model. No significant difference was seen between TKIs given the equivalent affinity of imatinib and nilotinib for KIT. These data suggest that combining non-myeloablative conditioning regimen with TKIs starting the day of the transplantation could be safe.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "345ca0bfb3974062abd3ec10a6cbc84a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[21, 23], [54, 56]], "char_spans": [[144, 150], [313, 319]]}]}], "context_tokens": [["The", 0], ["availability", 4], ["of", 17], ["tyrosine", 20], ["kinase", 29], ["inhibitors", 36], ["(", 47], ["TKIs", 48], [")", 52], ["has", 54], ["considerably", 58], ["changed", 71], ["the", 79], ["management", 83], ["of", 94], ["Philadelphia", 97], ["chromosome", 110], ["positive", 121], ["leukemia", 130], [".", 138], ["The", 140], ["BCR", 144], ["-", 147], ["ABL", 148], ["inhibitor", 152], ["imatinib", 162], ["is", 171], ["also", 174], ["known", 179], ["to", 185], ["inhibit", 188], ["the", 196], ["tyrosine", 200], ["kinase", 209], ["of", 216], ["the", 219], ["stem", 223], ["cell", 228], ["factor", 233], ["receptor", 240], [",", 248], ["c", 250], ["-", 251], ["Kit", 252], [".", 255], ["Nilotinib", 257], ["is", 267], ["30", 270], ["times", 273], ["more", 279], ["potent", 284], ["than", 291], ["imatinib", 296], ["towards", 305], ["BCR", 313], ["-", 316], ["ABL", 317], ["in", 321], ["vitro", 324], [".", 329], ["Studies", 331], ["in", 339], ["healthy", 342], ["volunteers", 350], ["and", 361], ["patients", 365], ["with", 374], ["chronic", 379], ["myelogenous", 387], ["leukemia", 399], ["or", 408], ["gastrointestinal", 411], ["stromal", 428], ["tumors", 436], ["have", 443], ["shown", 448], ["that", 454], ["therapeutic", 459], ["doses", 471], ["of", 477], ["nilotinib", 480], ["deliver", 490], ["drug", 498], ["levels", 503], ["similar", 510], ["to", 518], ["those", 521], ["of", 527], ["imatinib", 530], [".", 538], ["The", 540], ["aim", 544], ["of", 548], ["this", 551], ["study", 556], ["was", 562], ["to", 566], ["compare", 569], ["the", 577], ["inhibitory", 581], ["effects", 592], ["of", 600], ["imatinib", 603], ["and", 612], ["nilotinib", 616], ["on", 626], ["proliferation", 629], [",", 642], ["differentiation", 644], [",", 659], ["adhesion", 661], [",", 669], ["migration", 671], ["and", 681], ["engraftment", 685], ["capacities", 697], ["of", 708], ["human", 711], ["cord", 717], ["blood", 722], ["CD34(+", 728], [")", 734], ["cells", 736], [".", 741], ["After", 743], ["a", 749], ["48-hour", 751], ["cell", 759], ["culture", 764], ["with", 772], ["or", 777], ["without", 780], ["TKIs", 788], [",", 792], ["CFC", 794], [",", 797], ["LTC", 799], ["-", 802], ["IC", 803], [",", 805], ["migration", 807], [",", 816], ["adhesion", 818], ["and", 827], ["cell", 831], ["cycle", 836], ["analysis", 842], ["were", 851], ["performed", 856], [".", 865], ["In", 867], ["a", 870], ["second", 872], ["time", 879], [",", 883], ["the", 885], ["impact", 889], ["of", 896], ["these", 899], ["TKIs", 905], ["on", 910], ["engraftment", 913], ["was", 925], ["assessed", 929], ["in", 938], ["a", 941], ["xenotransplantation", 943], ["model", 963], ["using", 969], ["NOD", 975], ["/", 978], ["SCID", 979], ["/", 983], ["IL-2R\u03b3", 984], ["(", 991], ["null", 992], [")", 996], ["mice", 998], [".", 1002], ["TKIs", 1004], ["did", 1009], ["not", 1013], ["affect", 1017], ["LTC", 1024], ["-", 1027], ["IC", 1028], ["frequencies", 1031], ["despite", 1043], ["in", 1051], ["vitro", 1054], ["inhibition", 1060], ["of", 1071], ["CFC", 1074], ["formation", 1078], ["due", 1088], ["to", 1092], ["inhibition", 1095], ["of", 1106], ["CD34(+", 1109], [")", 1115], ["cell", 1117], ["cycle", 1122], ["entry", 1128], [".", 1133], ["Adhesion", 1135], ["of", 1144], ["CD34(+", 1147], [")", 1153], ["cells", 1155], ["to", 1161], ["retronectin", 1164], ["was", 1176], ["reduced", 1180], ["in", 1188], ["the", 1191], ["presence", 1195], ["of", 1204], ["either", 1207], ["imatinib", 1214], ["or", 1223], ["nilotinib", 1226], ["but", 1236], ["only", 1240], ["at", 1245], ["high", 1248], ["concentrations", 1253], [".", 1267], ["Migration", 1269], ["through", 1279], ["a", 1287], ["SDF-1\u03b1", 1289], ["gradient", 1296], ["was", 1305], ["not", 1309], ["changed", 1313], ["by", 1321], ["cell", 1324], ["culture", 1329], ["in", 1337], ["the", 1340], ["presence", 1344], ["of", 1353], ["TKIs", 1356], [".", 1360], ["Finally", 1362], [",", 1369], ["bone", 1371], ["marrow", 1376], ["cellularity", 1383], ["and", 1395], ["human", 1399], ["chimerism", 1405], ["were", 1415], ["not", 1420], ["affected", 1424], ["by", 1433], ["daily", 1436], ["doses", 1442], ["of", 1448], ["imatinib", 1451], ["and", 1460], ["nilotinib", 1464], ["in", 1474], ["a", 1477], ["xenogenic", 1479], ["transplantation", 1489], ["model", 1505], [".", 1510], ["No", 1512], ["significant", 1515], ["difference", 1527], ["was", 1538], ["seen", 1542], ["between", 1547], ["TKIs", 1555], ["given", 1560], ["the", 1566], ["equivalent", 1570], ["affinity", 1581], ["of", 1590], ["imatinib", 1593], ["and", 1602], ["nilotinib", 1606], ["for", 1616], ["KIT", 1620], [".", 1623], ["These", 1625], ["data", 1631], ["suggest", 1636], ["that", 1644], ["combining", 1649], ["non", 1659], ["-", 1662], ["myeloablative", 1663], ["conditioning", 1677], ["regimen", 1690], ["with", 1698], ["TKIs", 1703], ["starting", 1708], ["the", 1717], ["day", 1721], ["of", 1725], ["the", 1728], ["transplantation", 1732], ["could", 1748], ["be", 1754], ["safe", 1757], [".", 1761]]}
{"context": "To determine long-term efficacy and safety of epilepsy surgery in children and adolescents with malformations of cortical development (MCD) and to identify differences in seizure outcome of the various MCD subgroups. Special focus was set on the newly introduced International League Against Epilepsy (ILAE) classification of focal cortical dysplasia (FCD). This is a single center retrospective cross-sectional analysis of prospectively collected data. age at surgery <18 years, pre-surgical evaluation and epilepsy surgery performed at the Vienna pediatric epilepsy center, histologically proven MCD, complete follow-up data for at least 12 months. Clinical variables evaluated: type and localization of MCD, type of surgery and a variety of clinical characteristics reported to be associated with (un-)favorable outcomes. MCD were classified following the existing classification schemes (Barkovich et al., 2012. Brain. 135, 1348-1369; Palmini et al., 2004. Neurology. 62, S2-S8) and the ILAE classification for FCD recently proposed by Bl\u00fcmcke in 2011. Seizure outcome was classified using the ILAE classification proposed by Wieser in 2001. 60 Patients (51.7% male) were included. Follow up was up to 14 (mean 4.4 \u00b1 3.2) years. Mean age at surgery was 8.0 \u00b1 6.0 (median 6.0) years; mean age at epilepsy onset was 2.9 \u00b1 3.2 (median 2.0) years; duration of epilepsy before surgery was 4.8 \u00b1 4.4 (median 3.0) years. 80% of the patients were seizure free at last follow-up. AEDs were successfully withdrawn in 56.7% of all patients. Extended surgery, lesion localization in the temporal lobes and absence of inter-ictal spikes in postsurgical EEG recordings were predictive of favorable seizure outcomes after surgery. However, no association was found between outcome and MCD sub-types. Epilepsy surgery is highly effective in carefully selected drug-resistant children with MCD. Surrogate markers for complete resection of the epileptogenic zone remain the only significant predictors for seizure freedom after surgery.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "1ca976e520c446edbad5c210775e0dc5", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[53, 55]], "char_spans": [[326, 349]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["long", 13], ["-", 17], ["term", 18], ["efficacy", 23], ["and", 32], ["safety", 36], ["of", 43], ["epilepsy", 46], ["surgery", 55], ["in", 63], ["children", 66], ["and", 75], ["adolescents", 79], ["with", 91], ["malformations", 96], ["of", 110], ["cortical", 113], ["development", 122], ["(", 134], ["MCD", 135], [")", 138], ["and", 140], ["to", 144], ["identify", 147], ["differences", 156], ["in", 168], ["seizure", 171], ["outcome", 179], ["of", 187], ["the", 190], ["various", 194], ["MCD", 202], ["subgroups", 206], [".", 215], ["Special", 217], ["focus", 225], ["was", 231], ["set", 235], ["on", 239], ["the", 242], ["newly", 246], ["introduced", 252], ["International", 263], ["League", 277], ["Against", 284], ["Epilepsy", 292], ["(", 301], ["ILAE", 302], [")", 306], ["classification", 308], ["of", 323], ["focal", 326], ["cortical", 332], ["dysplasia", 341], ["(", 351], ["FCD", 352], [")", 355], [".", 356], ["This", 358], ["is", 363], ["a", 366], ["single", 368], ["center", 375], ["retrospective", 382], ["cross", 396], ["-", 401], ["sectional", 402], ["analysis", 412], ["of", 421], ["prospectively", 424], ["collected", 438], ["data", 448], [".", 452], ["age", 454], ["at", 458], ["surgery", 461], ["<", 469], ["18", 470], ["years", 473], [",", 478], ["pre", 480], ["-", 483], ["surgical", 484], ["evaluation", 493], ["and", 504], ["epilepsy", 508], ["surgery", 517], ["performed", 525], ["at", 535], ["the", 538], ["Vienna", 542], ["pediatric", 549], ["epilepsy", 559], ["center", 568], [",", 574], ["histologically", 576], ["proven", 591], ["MCD", 598], [",", 601], ["complete", 603], ["follow", 612], ["-", 618], ["up", 619], ["data", 622], ["for", 627], ["at", 631], ["least", 634], ["12", 640], ["months", 643], [".", 649], ["Clinical", 651], ["variables", 660], ["evaluated", 670], [":", 679], ["type", 681], ["and", 686], ["localization", 690], ["of", 703], ["MCD", 706], [",", 709], ["type", 711], ["of", 716], ["surgery", 719], ["and", 727], ["a", 731], ["variety", 733], ["of", 741], ["clinical", 744], ["characteristics", 753], ["reported", 769], ["to", 778], ["be", 781], ["associated", 784], ["with", 795], ["(", 800], ["un-)favorable", 801], ["outcomes", 815], [".", 823], ["MCD", 825], ["were", 829], ["classified", 834], ["following", 845], ["the", 855], ["existing", 859], ["classification", 868], ["schemes", 883], ["(", 891], ["Barkovich", 892], ["et", 902], ["al", 905], [".", 907], [",", 908], ["2012", 910], [".", 914], ["Brain", 916], [".", 921], ["135", 923], [",", 926], ["1348", 928], ["-", 932], ["1369", 933], [";", 937], ["Palmini", 939], ["et", 947], ["al", 950], [".", 952], [",", 953], ["2004", 955], [".", 959], ["Neurology", 961], [".", 970], ["62", 972], [",", 974], ["S2-S8", 976], [")", 981], ["and", 983], ["the", 987], ["ILAE", 991], ["classification", 996], ["for", 1011], ["FCD", 1015], ["recently", 1019], ["proposed", 1028], ["by", 1037], ["Bl\u00fcmcke", 1040], ["in", 1048], ["2011", 1051], [".", 1055], ["Seizure", 1057], ["outcome", 1065], ["was", 1073], ["classified", 1077], ["using", 1088], ["the", 1094], ["ILAE", 1098], ["classification", 1103], ["proposed", 1118], ["by", 1127], ["Wieser", 1130], ["in", 1137], ["2001", 1140], [".", 1144], ["60", 1146], ["Patients", 1149], ["(", 1158], ["51.7", 1159], ["%", 1163], ["male", 1165], [")", 1169], ["were", 1171], ["included", 1176], [".", 1184], ["Follow", 1186], ["up", 1193], ["was", 1196], ["up", 1200], ["to", 1203], ["14", 1206], ["(", 1209], ["mean", 1210], ["4.4", 1215], ["\u00b1", 1219], ["3.2", 1221], [")", 1224], ["years", 1226], [".", 1231], ["Mean", 1233], ["age", 1238], ["at", 1242], ["surgery", 1245], ["was", 1253], ["8.0", 1257], ["\u00b1", 1261], ["6.0", 1263], ["(", 1267], ["median", 1268], ["6.0", 1275], [")", 1278], ["years", 1280], [";", 1285], ["mean", 1287], ["age", 1292], ["at", 1296], ["epilepsy", 1299], ["onset", 1308], ["was", 1314], ["2.9", 1318], ["\u00b1", 1322], ["3.2", 1324], ["(", 1328], ["median", 1329], ["2.0", 1336], [")", 1339], ["years", 1341], [";", 1346], ["duration", 1348], ["of", 1357], ["epilepsy", 1360], ["before", 1369], ["surgery", 1376], ["was", 1384], ["4.8", 1388], ["\u00b1", 1392], ["4.4", 1394], ["(", 1398], ["median", 1399], ["3.0", 1406], [")", 1409], ["years", 1411], [".", 1416], ["80", 1418], ["%", 1420], ["of", 1422], ["the", 1425], ["patients", 1429], ["were", 1438], ["seizure", 1443], ["free", 1451], ["at", 1456], ["last", 1459], ["follow", 1464], ["-", 1470], ["up", 1471], [".", 1473], ["AEDs", 1475], ["were", 1480], ["successfully", 1485], ["withdrawn", 1498], ["in", 1508], ["56.7", 1511], ["%", 1515], ["of", 1517], ["all", 1520], ["patients", 1524], [".", 1532], ["Extended", 1534], ["surgery", 1543], [",", 1550], ["lesion", 1552], ["localization", 1559], ["in", 1572], ["the", 1575], ["temporal", 1579], ["lobes", 1588], ["and", 1594], ["absence", 1598], ["of", 1606], ["inter", 1609], ["-", 1614], ["ictal", 1615], ["spikes", 1621], ["in", 1628], ["postsurgical", 1631], ["EEG", 1644], ["recordings", 1648], ["were", 1659], ["predictive", 1664], ["of", 1675], ["favorable", 1678], ["seizure", 1688], ["outcomes", 1696], ["after", 1705], ["surgery", 1711], [".", 1718], ["However", 1720], [",", 1727], ["no", 1729], ["association", 1732], ["was", 1744], ["found", 1748], ["between", 1754], ["outcome", 1762], ["and", 1770], ["MCD", 1774], ["sub", 1778], ["-", 1781], ["types", 1782], [".", 1787], ["Epilepsy", 1789], ["surgery", 1798], ["is", 1806], ["highly", 1809], ["effective", 1816], ["in", 1826], ["carefully", 1829], ["selected", 1839], ["drug", 1848], ["-", 1852], ["resistant", 1853], ["children", 1863], ["with", 1872], ["MCD", 1877], [".", 1880], ["Surrogate", 1882], ["markers", 1892], ["for", 1900], ["complete", 1904], ["resection", 1913], ["of", 1923], ["the", 1926], ["epileptogenic", 1930], ["zone", 1944], ["remain", 1949], ["the", 1956], ["only", 1960], ["significant", 1965], ["predictors", 1977], ["for", 1988], ["seizure", 1992], ["freedom", 2000], ["after", 2008], ["surgery", 2014], [".", 2021]]}
{"context": "The vitamin K antagonists (VKAs) have been the standard (and only) oral anticoagulants used for the long-term treatment or prevention of venous thromboembolism or stroke in patients with atrial fibrillation. The coagulopathy induced by VKAs can be reversed with vitamin K, and in urgent situations, the vitamin K-dependent coagulation factors can be replaced by transfusion. In the last decade, a new class of oral anticoagulants has been developed, direct oral anticoagulants that bind to a specific coagulation factor and neutralize it. These compounds were shown to be effective and safe compared with the VKAs and were licensed for specific indications, but without a specific reversal agent. The absence of a reversal agent is a barrier to more widespread use of these agents. Currently, for the management of major life-threatening bleeding with the direct oral anticoagulants, most authorities recommend the use of four factor prothrombin complex concentrates. There are now three reversal agents in development and poised to enter the market. Idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the USA. Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin. Ciraparantag is an antidote targeted to reverse the direct thrombin and factor Xa inhibitors as well as the indirect inhibitor enoxaparin.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "708d81adb4e44a03ab3e302e8165cec5", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[197, 197]], "char_spans": [[1138, 1147]]}]}], "context_tokens": [["The", 0], ["vitamin", 4], ["K", 12], ["antagonists", 14], ["(", 26], ["VKAs", 27], [")", 31], ["have", 33], ["been", 38], ["the", 43], ["standard", 47], ["(", 56], ["and", 57], ["only", 61], [")", 65], ["oral", 67], ["anticoagulants", 72], ["used", 87], ["for", 92], ["the", 96], ["long", 100], ["-", 104], ["term", 105], ["treatment", 110], ["or", 120], ["prevention", 123], ["of", 134], ["venous", 137], ["thromboembolism", 144], ["or", 160], ["stroke", 163], ["in", 170], ["patients", 173], ["with", 182], ["atrial", 187], ["fibrillation", 194], [".", 206], ["The", 208], ["coagulopathy", 212], ["induced", 225], ["by", 233], ["VKAs", 236], ["can", 241], ["be", 245], ["reversed", 248], ["with", 257], ["vitamin", 262], ["K", 270], [",", 271], ["and", 273], ["in", 277], ["urgent", 280], ["situations", 287], [",", 297], ["the", 299], ["vitamin", 303], ["K", 311], ["-", 312], ["dependent", 313], ["coagulation", 323], ["factors", 335], ["can", 343], ["be", 347], ["replaced", 350], ["by", 359], ["transfusion", 362], [".", 373], ["In", 375], ["the", 378], ["last", 382], ["decade", 387], [",", 393], ["a", 395], ["new", 397], ["class", 401], ["of", 407], ["oral", 410], ["anticoagulants", 415], ["has", 430], ["been", 434], ["developed", 439], [",", 448], ["direct", 450], ["oral", 457], ["anticoagulants", 462], ["that", 477], ["bind", 482], ["to", 487], ["a", 490], ["specific", 492], ["coagulation", 501], ["factor", 513], ["and", 520], ["neutralize", 524], ["it", 535], [".", 537], ["These", 539], ["compounds", 545], ["were", 555], ["shown", 560], ["to", 566], ["be", 569], ["effective", 572], ["and", 582], ["safe", 586], ["compared", 591], ["with", 600], ["the", 605], ["VKAs", 609], ["and", 614], ["were", 618], ["licensed", 623], ["for", 632], ["specific", 636], ["indications", 645], [",", 656], ["but", 658], ["without", 662], ["a", 670], ["specific", 672], ["reversal", 681], ["agent", 690], [".", 695], ["The", 697], ["absence", 701], ["of", 709], ["a", 712], ["reversal", 714], ["agent", 723], ["is", 729], ["a", 732], ["barrier", 734], ["to", 742], ["more", 745], ["widespread", 750], ["use", 761], ["of", 765], ["these", 768], ["agents", 774], [".", 780], ["Currently", 782], [",", 791], ["for", 793], ["the", 797], ["management", 801], ["of", 812], ["major", 815], ["life", 821], ["-", 825], ["threatening", 826], ["bleeding", 838], ["with", 847], ["the", 852], ["direct", 856], ["oral", 863], ["anticoagulants", 868], [",", 882], ["most", 884], ["authorities", 889], ["recommend", 901], ["the", 911], ["use", 915], ["of", 919], ["four", 922], ["factor", 927], ["prothrombin", 934], ["complex", 946], ["concentrates", 954], [".", 966], ["There", 968], ["are", 974], ["now", 978], ["three", 982], ["reversal", 988], ["agents", 997], ["in", 1004], ["development", 1007], ["and", 1019], ["poised", 1023], ["to", 1030], ["enter", 1033], ["the", 1039], ["market", 1043], [".", 1049], ["Idarucizumab", 1051], ["is", 1064], ["a", 1067], ["specific", 1069], ["antidote", 1078], ["targeted", 1087], ["to", 1096], ["reverse", 1099], ["the", 1107], ["direct", 1111], ["thrombin", 1118], ["inhibitor", 1127], [",", 1136], ["dabigatran", 1138], [",", 1148], ["which", 1150], ["was", 1156], ["recently", 1160], ["approved", 1169], ["for", 1178], ["use", 1182], ["in", 1186], ["the", 1189], ["USA", 1193], [".", 1196], ["Andexanet", 1198], ["alfa", 1208], ["is", 1213], ["an", 1216], ["antidote", 1219], ["targeted", 1228], ["to", 1237], ["reverse", 1240], ["the", 1248], ["oral", 1252], ["direct", 1257], ["factor", 1264], ["Xa", 1271], ["inhibitors", 1274], ["as", 1285], ["well", 1288], ["as", 1293], ["the", 1296], ["indirect", 1300], ["inhibitor", 1309], ["enoxaparin", 1319], [".", 1329], ["Ciraparantag", 1331], ["is", 1344], ["an", 1347], ["antidote", 1350], ["targeted", 1359], ["to", 1368], ["reverse", 1371], ["the", 1379], ["direct", 1383], ["thrombin", 1390], ["and", 1399], ["factor", 1403], ["Xa", 1410], ["inhibitors", 1413], ["as", 1424], ["well", 1427], ["as", 1432], ["the", 1435], ["indirect", 1439], ["inhibitor", 1448], ["enoxaparin", 1458], [".", 1468]]}
{"context": "Clinical features variability between familial and sporadic restless legs syndrome/Willis-Ekbom disease (RLS/WED) has been previously reported. With this retrospective cohort study, we aimed to determine the clinical and polysomnographic characteristics of 400 RLS/WED patients. Patients with familial RLS/WED were significantly younger than sporadic RLS/WED, while clinical and polysomnographic characteristics were similar in both groups. No difference was found for the age-at-onset between idiopathic and secondary RLS/WED. Periodic limb movements (PLM) index and REM sleep time were higher in idiopathic RLS/WED. Time of onset of symptoms was in the evening or at bedtime in 28.04 and 37.80% of patients, respectively, while in 21.34% of patients onset was more than 1 h after sleep onset. Impulse control and compulsive behaviours (ICBs) were found in 13.29% patients on dopamine agonist therapy. Our analyses support the hypothesis that patients with a familial history of RLS/WED may have a genetic component. Nevertheless, the dichotomy between early and late onset disease seems to be less sharp than previously reported. A large proportion of RLS/WED patients can have atypical features, therefore making the diagnosis challenging. Some cases can be missed even when the patient refers to a sleep specialist, as revealed by the partial absence of daytime symptoms, the high comorbidity with insomnia and other sleep complaints and the high percentage of symptoms beginning after sleep onset. This draws attention on the importance of a careful evaluation of the patient, to recognize potentially treatable secondary forms of RLS/WED.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "c287836b570a4d18b1c683334df92f91", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[7, 9]], "char_spans": [[60, 81]]}]}], "context_tokens": [["Clinical", 0], ["features", 9], ["variability", 18], ["between", 30], ["familial", 38], ["and", 47], ["sporadic", 51], ["restless", 60], ["legs", 69], ["syndrome", 74], ["/", 82], ["Willis", 83], ["-", 89], ["Ekbom", 90], ["disease", 96], ["(", 104], ["RLS", 105], ["/", 108], ["WED", 109], [")", 112], ["has", 114], ["been", 118], ["previously", 123], ["reported", 134], [".", 142], ["With", 144], ["this", 149], ["retrospective", 154], ["cohort", 168], ["study", 175], [",", 180], ["we", 182], ["aimed", 185], ["to", 191], ["determine", 194], ["the", 204], ["clinical", 208], ["and", 217], ["polysomnographic", 221], ["characteristics", 238], ["of", 254], ["400", 257], ["RLS", 261], ["/", 264], ["WED", 265], ["patients", 269], [".", 277], ["Patients", 279], ["with", 288], ["familial", 293], ["RLS", 302], ["/", 305], ["WED", 306], ["were", 310], ["significantly", 315], ["younger", 329], ["than", 337], ["sporadic", 342], ["RLS", 351], ["/", 354], ["WED", 355], [",", 358], ["while", 360], ["clinical", 366], ["and", 375], ["polysomnographic", 379], ["characteristics", 396], ["were", 412], ["similar", 417], ["in", 425], ["both", 428], ["groups", 433], [".", 439], ["No", 441], ["difference", 444], ["was", 455], ["found", 459], ["for", 465], ["the", 469], ["age", 473], ["-", 476], ["at", 477], ["-", 479], ["onset", 480], ["between", 486], ["idiopathic", 494], ["and", 505], ["secondary", 509], ["RLS", 519], ["/", 522], ["WED", 523], [".", 526], ["Periodic", 528], ["limb", 537], ["movements", 542], ["(", 552], ["PLM", 553], [")", 556], ["index", 558], ["and", 564], ["REM", 568], ["sleep", 572], ["time", 578], ["were", 583], ["higher", 588], ["in", 595], ["idiopathic", 598], ["RLS", 609], ["/", 612], ["WED", 613], [".", 616], ["Time", 618], ["of", 623], ["onset", 626], ["of", 632], ["symptoms", 635], ["was", 644], ["in", 648], ["the", 651], ["evening", 655], ["or", 663], ["at", 666], ["bedtime", 669], ["in", 677], ["28.04", 680], ["and", 686], ["37.80", 690], ["%", 695], ["of", 697], ["patients", 700], [",", 708], ["respectively", 710], [",", 722], ["while", 724], ["in", 730], ["21.34", 733], ["%", 738], ["of", 740], ["patients", 743], ["onset", 752], ["was", 758], ["more", 762], ["than", 767], ["1", 772], ["h", 774], ["after", 776], ["sleep", 782], ["onset", 788], [".", 793], ["Impulse", 795], ["control", 803], ["and", 811], ["compulsive", 815], ["behaviours", 826], ["(", 837], ["ICBs", 838], [")", 842], ["were", 844], ["found", 849], ["in", 855], ["13.29", 858], ["%", 863], ["patients", 865], ["on", 874], ["dopamine", 877], ["agonist", 886], ["therapy", 894], [".", 901], ["Our", 903], ["analyses", 907], ["support", 916], ["the", 924], ["hypothesis", 928], ["that", 939], ["patients", 944], ["with", 953], ["a", 958], ["familial", 960], ["history", 969], ["of", 977], ["RLS", 980], ["/", 983], ["WED", 984], ["may", 988], ["have", 992], ["a", 997], ["genetic", 999], ["component", 1007], [".", 1016], ["Nevertheless", 1018], [",", 1030], ["the", 1032], ["dichotomy", 1036], ["between", 1046], ["early", 1054], ["and", 1060], ["late", 1064], ["onset", 1069], ["disease", 1075], ["seems", 1083], ["to", 1089], ["be", 1092], ["less", 1095], ["sharp", 1100], ["than", 1106], ["previously", 1111], ["reported", 1122], [".", 1130], ["A", 1132], ["large", 1134], ["proportion", 1140], ["of", 1151], ["RLS", 1154], ["/", 1157], ["WED", 1158], ["patients", 1162], ["can", 1171], ["have", 1175], ["atypical", 1180], ["features", 1189], [",", 1197], ["therefore", 1199], ["making", 1209], ["the", 1216], ["diagnosis", 1220], ["challenging", 1230], [".", 1241], ["Some", 1243], ["cases", 1248], ["can", 1254], ["be", 1258], ["missed", 1261], ["even", 1268], ["when", 1273], ["the", 1278], ["patient", 1282], ["refers", 1290], ["to", 1297], ["a", 1300], ["sleep", 1302], ["specialist", 1308], [",", 1318], ["as", 1320], ["revealed", 1323], ["by", 1332], ["the", 1335], ["partial", 1339], ["absence", 1347], ["of", 1355], ["daytime", 1358], ["symptoms", 1366], [",", 1374], ["the", 1376], ["high", 1380], ["comorbidity", 1385], ["with", 1397], ["insomnia", 1402], ["and", 1411], ["other", 1415], ["sleep", 1421], ["complaints", 1427], ["and", 1438], ["the", 1442], ["high", 1446], ["percentage", 1451], ["of", 1462], ["symptoms", 1465], ["beginning", 1474], ["after", 1484], ["sleep", 1490], ["onset", 1496], [".", 1501], ["This", 1503], ["draws", 1508], ["attention", 1514], ["on", 1524], ["the", 1527], ["importance", 1531], ["of", 1542], ["a", 1545], ["careful", 1547], ["evaluation", 1555], ["of", 1566], ["the", 1569], ["patient", 1573], [",", 1580], ["to", 1582], ["recognize", 1585], ["potentially", 1595], ["treatable", 1607], ["secondary", 1617], ["forms", 1627], ["of", 1633], ["RLS", 1636], ["/", 1639], ["WED", 1640], [".", 1643]]}
{"context": "Background Inappropriate use of antibiotic treatment for pharyngitis by community pharmacists is prevalent in developing countries. Little is known about how the pharmacists identify patients with bacterial pharyngitis. Objective To ascertain the appropriateness of diagnosis of streptococcal pharyngitis among Thai community pharmacists according to the Centor criteria and to identify factors related to antibiotic dispensing. Setting 1040 Thai community pharmacists. Method A cross-sectional survey of community pharmacists was conducted in November 2012 to March 2013. The self-administered questionnaires were mailed to 57\u00a0% of community pharmacists in the south of Thailand (n\u00a0=\u00a01040). The survey included questions on diagnosis of streptococcal pharyngitis, knowledge on pharyngitis, and attitudes and control beliefs regarding antibiotic dispensing. Main outcome measure The appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified Centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing. Results Approximately 68\u00a0% completed the questionnaires (n\u00a0=\u00a0703). Compared to the pharmacists who reported not dispensing antibiotics in the hypothetical case with common cold, those reported dispensing antibiotics were more likely to consider the following conditions-presence of cough, mild sore throat and patients with age >60\u00a0years as cues for diagnosis of streptococcal pharyngitis (p\u00a0<\u00a00.05). The use of fewer scores of the clinical prediction rules for diagnosis was observed in antibiotic dispensers, compared to who did not do so (p\u00a0<\u00a00.005). Antibiotic dispensing was positively associated with period of dispensing experience (>5\u00a0years) [odds ratio (OR) 1.52; 95\u00a0% confidence interval (CI) 1.03-2.23], belief that antibiotics could shorten duration of pharyngitis (OR 1.48; 95\u00a0% CI 1.11-1.99), belief that antibiotics could prevent the complications (OR 1.44; 95\u00a0% CI 1.09-1.91) and belief that dispensing antibiotics could satisfy the patients (OR 1.31; 95\u00a0% CI 1.01-1.71). Nonetheless, antibiotic dispensing was negatively associated with knowledge about pharyngitis (OR 0.83; 95\u00a0% CI 0.75-0.93). Conclusion Pharmacists who are knowledgeable on the Centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "fd56ae32cdb74808971cdd1f6e9b58ae", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[113, 114], [38, 39], [404, 405], [233, 234], [137, 138]], "char_spans": [[738, 762], [279, 303], [2400, 2424], [1541, 1565], [915, 939]]}]}], "context_tokens": [["Background", 0], ["Inappropriate", 11], ["use", 25], ["of", 29], ["antibiotic", 32], ["treatment", 43], ["for", 53], ["pharyngitis", 57], ["by", 69], ["community", 72], ["pharmacists", 82], ["is", 94], ["prevalent", 97], ["in", 107], ["developing", 110], ["countries", 121], [".", 130], ["Little", 132], ["is", 139], ["known", 142], ["about", 148], ["how", 154], ["the", 158], ["pharmacists", 162], ["identify", 174], ["patients", 183], ["with", 192], ["bacterial", 197], ["pharyngitis", 207], [".", 218], ["Objective", 220], ["To", 230], ["ascertain", 233], ["the", 243], ["appropriateness", 247], ["of", 263], ["diagnosis", 266], ["of", 276], ["streptococcal", 279], ["pharyngitis", 293], ["among", 305], ["Thai", 311], ["community", 316], ["pharmacists", 326], ["according", 338], ["to", 348], ["the", 351], ["Centor", 355], ["criteria", 362], ["and", 371], ["to", 375], ["identify", 378], ["factors", 387], ["related", 395], ["to", 403], ["antibiotic", 406], ["dispensing", 417], [".", 427], ["Setting", 429], ["1040", 437], ["Thai", 442], ["community", 447], ["pharmacists", 457], [".", 468], ["Method", 470], ["A", 477], ["cross", 479], ["-", 484], ["sectional", 485], ["survey", 495], ["of", 502], ["community", 505], ["pharmacists", 515], ["was", 527], ["conducted", 531], ["in", 541], ["November", 544], ["2012", 553], ["to", 558], ["March", 561], ["2013", 567], [".", 571], ["The", 573], ["self", 577], ["-", 581], ["administered", 582], ["questionnaires", 595], ["were", 610], ["mailed", 615], ["to", 622], ["57", 625], ["%", 628], ["of", 630], ["community", 633], ["pharmacists", 643], ["in", 655], ["the", 658], ["south", 662], ["of", 668], ["Thailand", 671], ["(", 680], ["n", 681], ["=", 683], ["1040", 685], [")", 689], [".", 690], ["The", 692], ["survey", 696], ["included", 703], ["questions", 712], ["on", 722], ["diagnosis", 725], ["of", 735], ["streptococcal", 738], ["pharyngitis", 752], [",", 763], ["knowledge", 765], ["on", 775], ["pharyngitis", 778], [",", 789], ["and", 791], ["attitudes", 795], ["and", 805], ["control", 809], ["beliefs", 817], ["regarding", 825], ["antibiotic", 835], ["dispensing", 846], [".", 856], ["Main", 858], ["outcome", 863], ["measure", 871], ["The", 879], ["appropriateness", 883], ["of", 899], ["diagnosis", 902], ["of", 912], ["streptococcal", 915], ["pharyngitis", 929], ["according", 941], ["to", 951], ["the", 954], ["original", 958], ["and", 967], ["modified", 971], ["Centor", 980], ["criteria", 987], ["and", 996], ["determinants", 1000], ["of", 1013], ["antibiotic", 1016], ["dispensing", 1027], ["including", 1038], ["demographic", 1048], ["characteristics", 1060], ["of", 1076], ["pharmacists", 1079], [",", 1090], ["knowledge", 1092], ["on", 1102], ["pharyngitis", 1105], [",", 1116], ["and", 1118], ["attitudes", 1122], ["and", 1132], ["control", 1136], ["beliefs", 1144], ["on", 1152], ["antibiotic", 1155], ["dispensing", 1166], [".", 1176], ["Results", 1178], ["Approximately", 1186], ["68", 1200], ["%", 1203], ["completed", 1205], ["the", 1215], ["questionnaires", 1219], ["(", 1234], ["n", 1235], ["=", 1237], ["703", 1239], [")", 1242], [".", 1243], ["Compared", 1245], ["to", 1254], ["the", 1257], ["pharmacists", 1261], ["who", 1273], ["reported", 1277], ["not", 1286], ["dispensing", 1290], ["antibiotics", 1301], ["in", 1313], ["the", 1316], ["hypothetical", 1320], ["case", 1333], ["with", 1338], ["common", 1343], ["cold", 1350], [",", 1354], ["those", 1356], ["reported", 1362], ["dispensing", 1371], ["antibiotics", 1382], ["were", 1394], ["more", 1399], ["likely", 1404], ["to", 1411], ["consider", 1414], ["the", 1423], ["following", 1427], ["conditions", 1437], ["-", 1447], ["presence", 1448], ["of", 1457], ["cough", 1460], [",", 1465], ["mild", 1467], ["sore", 1472], ["throat", 1477], ["and", 1484], ["patients", 1488], ["with", 1497], ["age", 1502], [">", 1506], ["60", 1507], ["years", 1510], ["as", 1516], ["cues", 1519], ["for", 1524], ["diagnosis", 1528], ["of", 1538], ["streptococcal", 1541], ["pharyngitis", 1555], ["(", 1567], ["p", 1568], ["<", 1570], ["0.05", 1572], [")", 1576], [".", 1577], ["The", 1579], ["use", 1583], ["of", 1587], ["fewer", 1590], ["scores", 1596], ["of", 1603], ["the", 1606], ["clinical", 1610], ["prediction", 1619], ["rules", 1630], ["for", 1636], ["diagnosis", 1640], ["was", 1650], ["observed", 1654], ["in", 1663], ["antibiotic", 1666], ["dispensers", 1677], [",", 1687], ["compared", 1689], ["to", 1698], ["who", 1701], ["did", 1705], ["not", 1709], ["do", 1713], ["so", 1716], ["(", 1719], ["p", 1720], ["<", 1722], ["0.005", 1724], [")", 1729], [".", 1730], ["Antibiotic", 1732], ["dispensing", 1743], ["was", 1754], ["positively", 1758], ["associated", 1769], ["with", 1780], ["period", 1785], ["of", 1792], ["dispensing", 1795], ["experience", 1806], ["(", 1817], [">", 1818], ["5", 1819], ["years", 1821], [")", 1826], ["[", 1828], ["odds", 1829], ["ratio", 1834], ["(", 1840], ["OR", 1841], [")", 1843], ["1.52", 1845], [";", 1849], ["95", 1851], ["%", 1854], ["confidence", 1856], ["interval", 1867], ["(", 1876], ["CI", 1877], [")", 1879], ["1.03", 1881], ["-", 1885], ["2.23", 1886], ["]", 1890], [",", 1891], ["belief", 1893], ["that", 1900], ["antibiotics", 1905], ["could", 1917], ["shorten", 1923], ["duration", 1931], ["of", 1940], ["pharyngitis", 1943], ["(", 1955], ["OR", 1956], ["1.48", 1959], [";", 1963], ["95", 1965], ["%", 1968], ["CI", 1970], ["1.11", 1973], ["-", 1977], ["1.99", 1978], [")", 1982], [",", 1983], ["belief", 1985], ["that", 1992], ["antibiotics", 1997], ["could", 2009], ["prevent", 2015], ["the", 2023], ["complications", 2027], ["(", 2041], ["OR", 2042], ["1.44", 2045], [";", 2049], ["95", 2051], ["%", 2054], ["CI", 2056], ["1.09", 2059], ["-", 2063], ["1.91", 2064], [")", 2068], ["and", 2070], ["belief", 2074], ["that", 2081], ["dispensing", 2086], ["antibiotics", 2097], ["could", 2109], ["satisfy", 2115], ["the", 2123], ["patients", 2127], ["(", 2136], ["OR", 2137], ["1.31", 2140], [";", 2144], ["95", 2146], ["%", 2149], ["CI", 2151], ["1.01", 2154], ["-", 2158], ["1.71", 2159], [")", 2163], [".", 2164], ["Nonetheless", 2166], [",", 2177], ["antibiotic", 2179], ["dispensing", 2190], ["was", 2201], ["negatively", 2205], ["associated", 2216], ["with", 2227], ["knowledge", 2232], ["about", 2242], ["pharyngitis", 2248], ["(", 2260], ["OR", 2261], ["0.83", 2264], [";", 2268], ["95", 2270], ["%", 2273], ["CI", 2275], ["0.75", 2278], ["-", 2282], ["0.93", 2283], [")", 2287], [".", 2288], ["Conclusion", 2290], ["Pharmacists", 2301], ["who", 2313], ["are", 2317], ["knowledgeable", 2321], ["on", 2335], ["the", 2338], ["Centor", 2342], ["criteria", 2349], ["are", 2358], ["more", 2362], ["likely", 2367], ["to", 2374], ["appropriately", 2377], ["diagnose", 2391], ["streptococcal", 2400], ["pharyngitis", 2414], ["and", 2426], ["less", 2430], ["likely", 2435], ["to", 2442], ["dispense", 2445], ["antibiotics", 2454], ["in", 2466], ["such", 2469], ["case", 2474], [".", 2478]]}
{"context": "Double homeobox 4 (DUX4) is a candidate disease gene for facioscapulohumeral dystrophy (FSHD), one of the most common muscular dystrophies characterized by progressive skeletal muscle degeneration. Despite great strides in understanding precise genetics of FSHD, the molecular pathophysiology of the disease remains unclear. One of the major limitations has been the availability of appropriate molecular tools to study DUX4 protein. In the present study, we report the development of five new monoclonal antibodies targeted against the N- and C-termini of human DUX4, and characterize their reactivity using Western blot and immunofluorescence staining. Additionally, we show that expression of the canonical full coding DUX4 induces cell death in human primary muscle cells, whereas the expression of a shorter splice form of DUX4 results in no such toxicity. Immunostaining with these new antibodies reveals a differential effect of two DUX4 isoforms on human muscle cells. These antibodies will provide an excellent tool for investigating the role of DUX4 in FSHD pathogenesis.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "7247ffe169f140339020744b6f54923c", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "Facioscapulohumeral dystrophy", "token_spans": [[12, 13]], "char_spans": [[57, 85]]}, {"text": "FSHD", "token_spans": [[175, 175], [40, 40], [15, 15]], "char_spans": [[1063, 1066], [257, 260], [88, 91]]}]}], "context_tokens": [["Double", 0], ["homeobox", 7], ["4", 16], ["(", 18], ["DUX4", 19], [")", 23], ["is", 25], ["a", 28], ["candidate", 30], ["disease", 40], ["gene", 48], ["for", 53], ["facioscapulohumeral", 57], ["dystrophy", 77], ["(", 87], ["FSHD", 88], [")", 92], [",", 93], ["one", 95], ["of", 99], ["the", 102], ["most", 106], ["common", 111], ["muscular", 118], ["dystrophies", 127], ["characterized", 139], ["by", 153], ["progressive", 156], ["skeletal", 168], ["muscle", 177], ["degeneration", 184], [".", 196], ["Despite", 198], ["great", 206], ["strides", 212], ["in", 220], ["understanding", 223], ["precise", 237], ["genetics", 245], ["of", 254], ["FSHD", 257], [",", 261], ["the", 263], ["molecular", 267], ["pathophysiology", 277], ["of", 293], ["the", 296], ["disease", 300], ["remains", 308], ["unclear", 316], [".", 323], ["One", 325], ["of", 329], ["the", 332], ["major", 336], ["limitations", 342], ["has", 354], ["been", 358], ["the", 363], ["availability", 367], ["of", 380], ["appropriate", 383], ["molecular", 395], ["tools", 405], ["to", 411], ["study", 414], ["DUX4", 420], ["protein", 425], [".", 432], ["In", 434], ["the", 437], ["present", 441], ["study", 449], [",", 454], ["we", 456], ["report", 459], ["the", 466], ["development", 470], ["of", 482], ["five", 485], ["new", 490], ["monoclonal", 494], ["antibodies", 505], ["targeted", 516], ["against", 525], ["the", 533], ["N-", 537], ["and", 540], ["C", 544], ["-", 545], ["termini", 546], ["of", 554], ["human", 557], ["DUX4", 563], [",", 567], ["and", 569], ["characterize", 573], ["their", 586], ["reactivity", 592], ["using", 603], ["Western", 609], ["blot", 617], ["and", 622], ["immunofluorescence", 626], ["staining", 645], [".", 653], ["Additionally", 655], [",", 667], ["we", 669], ["show", 672], ["that", 677], ["expression", 682], ["of", 693], ["the", 696], ["canonical", 700], ["full", 710], ["coding", 715], ["DUX4", 722], ["induces", 727], ["cell", 735], ["death", 740], ["in", 746], ["human", 749], ["primary", 755], ["muscle", 763], ["cells", 770], [",", 775], ["whereas", 777], ["the", 785], ["expression", 789], ["of", 800], ["a", 803], ["shorter", 805], ["splice", 813], ["form", 820], ["of", 825], ["DUX4", 828], ["results", 833], ["in", 841], ["no", 844], ["such", 847], ["toxicity", 852], [".", 860], ["Immunostaining", 862], ["with", 877], ["these", 882], ["new", 888], ["antibodies", 892], ["reveals", 903], ["a", 911], ["differential", 913], ["effect", 926], ["of", 933], ["two", 936], ["DUX4", 940], ["isoforms", 945], ["on", 954], ["human", 957], ["muscle", 963], ["cells", 970], [".", 975], ["These", 977], ["antibodies", 983], ["will", 994], ["provide", 999], ["an", 1007], ["excellent", 1010], ["tool", 1020], ["for", 1025], ["investigating", 1029], ["the", 1043], ["role", 1047], ["of", 1052], ["DUX4", 1055], ["in", 1060], ["FSHD", 1063], ["pathogenesis", 1068], [".", 1080]]}
{"context": "Spleen tyrosine kinase (Syk) is an important modulator of immune signaling. The objective of this phase 2 study was to evaluate the efficacy and safety of R788, an oral inhibitor of Syk, in patients with active rheumatoid arthritis despite methotrexate therapy. We enrolled 457 patients who had active rheumatoid arthritis despite long-term methotrexate therapy in a 6-month, double-blind, placebo-controlled trial. The primary outcome was the American College of Rheumatology (ACR) 20 response (which indicates at least a 20% reduction in the number of both tender and swollen joints and improvement in at least three of five other criteria) at month 6. R788, at a dose of 100 mg twice daily and at a dose of 150 mg once daily, was significantly superior to placebo at month 6 (ACR 20 response rates of 67% and 57%, respectively, vs. 35%; P<0.001 for the comparison of both doses with placebo). It was also significantly superior with respect to ACR 50, which indicates at least a 50% improvement (43% and 32% vs. 19%; P<0.001 for the comparison of the 100-mg dose with placebo, P=0.007 for the comparison of the 150-mg dose with placebo) and ACR 70 (28% and 14% vs. 10%; P<0.001 for the comparison of the 100-mg dose with placebo, P=0.34 for the comparison of the 150-mg dose with placebo). A clinically significant effect was noted by the end of the first week of treatment. Adverse effects included diarrhea (in 19% of subjects taking the 100-mg dose of R788 vs. 3% of those taking placebo), upper respiratory infections (14% vs. 7%), and neutropenia (6% vs. 1%). R788 was associated with an increase in systolic blood pressure of approximately 3 mm Hg between baseline and month 1, as compared with a decrease of 2 mm Hg with placebo; 23% of the patients taking R788 vs. 7% of the patients receiving placebo required the initiation of or a change in antihypertensive therapy. In this phase 2 study, a Syk inhibitor reduced disease activity in patients with rheumatoid arthritis; adverse events included diarrhea, hypertension, and neutropenia. Additional studies will be needed to further assess the safety and efficacy of Syk-inhibition therapy in patients with rheumatoid arthritis. (Funded by Rigel; ClinicalTrials.gov number, NCT00665925.)", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "f793e627a2a246e4bdb80b8e39f246c4", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["Syk", 24], [")", 27], ["is", 29], ["an", 32], ["important", 35], ["modulator", 45], ["of", 55], ["immune", 58], ["signaling", 65], [".", 74], ["The", 76], ["objective", 80], ["of", 90], ["this", 93], ["phase", 98], ["2", 104], ["study", 106], ["was", 112], ["to", 116], ["evaluate", 119], ["the", 128], ["efficacy", 132], ["and", 141], ["safety", 145], ["of", 152], ["R788", 155], [",", 159], ["an", 161], ["oral", 164], ["inhibitor", 169], ["of", 179], ["Syk", 182], [",", 185], ["in", 187], ["patients", 190], ["with", 199], ["active", 204], ["rheumatoid", 211], ["arthritis", 222], ["despite", 232], ["methotrexate", 240], ["therapy", 253], [".", 260], ["We", 262], ["enrolled", 265], ["457", 274], ["patients", 278], ["who", 287], ["had", 291], ["active", 295], ["rheumatoid", 302], ["arthritis", 313], ["despite", 323], ["long", 331], ["-", 335], ["term", 336], ["methotrexate", 341], ["therapy", 354], ["in", 362], ["a", 365], ["6-month", 367], [",", 374], ["double", 376], ["-", 382], ["blind", 383], [",", 388], ["placebo", 390], ["-", 397], ["controlled", 398], ["trial", 409], [".", 414], ["The", 416], ["primary", 420], ["outcome", 428], ["was", 436], ["the", 440], ["American", 444], ["College", 453], ["of", 461], ["Rheumatology", 464], ["(", 477], ["ACR", 478], [")", 481], ["20", 483], ["response", 486], ["(", 495], ["which", 496], ["indicates", 502], ["at", 512], ["least", 515], ["a", 521], ["20", 523], ["%", 525], ["reduction", 527], ["in", 537], ["the", 540], ["number", 544], ["of", 551], ["both", 554], ["tender", 559], ["and", 566], ["swollen", 570], ["joints", 578], ["and", 585], ["improvement", 589], ["in", 601], ["at", 604], ["least", 607], ["three", 613], ["of", 619], ["five", 622], ["other", 627], ["criteria", 633], [")", 641], ["at", 643], ["month", 646], ["6", 652], [".", 653], ["R788", 655], [",", 659], ["at", 661], ["a", 664], ["dose", 666], ["of", 671], ["100", 674], ["mg", 678], ["twice", 681], ["daily", 687], ["and", 693], ["at", 697], ["a", 700], ["dose", 702], ["of", 707], ["150", 710], ["mg", 714], ["once", 717], ["daily", 722], [",", 727], ["was", 729], ["significantly", 733], ["superior", 747], ["to", 756], ["placebo", 759], ["at", 767], ["month", 770], ["6", 776], ["(", 778], ["ACR", 779], ["20", 783], ["response", 786], ["rates", 795], ["of", 801], ["67", 804], ["%", 806], ["and", 808], ["57", 812], ["%", 814], [",", 815], ["respectively", 817], [",", 829], ["vs.", 831], ["35", 835], ["%", 837], [";", 838], ["P<0.001", 840], ["for", 848], ["the", 852], ["comparison", 856], ["of", 867], ["both", 870], ["doses", 875], ["with", 881], ["placebo", 886], [")", 893], [".", 894], ["It", 896], ["was", 899], ["also", 903], ["significantly", 908], ["superior", 922], ["with", 931], ["respect", 936], ["to", 944], ["ACR", 947], ["50", 951], [",", 953], ["which", 955], ["indicates", 961], ["at", 971], ["least", 974], ["a", 980], ["50", 982], ["%", 984], ["improvement", 986], ["(", 998], ["43", 999], ["%", 1001], ["and", 1003], ["32", 1007], ["%", 1009], ["vs.", 1011], ["19", 1015], ["%", 1017], [";", 1018], ["P<0.001", 1020], ["for", 1028], ["the", 1032], ["comparison", 1036], ["of", 1047], ["the", 1050], ["100-mg", 1054], ["dose", 1061], ["with", 1066], ["placebo", 1071], [",", 1078], ["P=0.007", 1080], ["for", 1088], ["the", 1092], ["comparison", 1096], ["of", 1107], ["the", 1110], ["150-mg", 1114], ["dose", 1121], ["with", 1126], ["placebo", 1131], [")", 1138], ["and", 1140], ["ACR", 1144], ["70", 1148], ["(", 1151], ["28", 1152], ["%", 1154], ["and", 1156], ["14", 1160], ["%", 1162], ["vs.", 1164], ["10", 1168], ["%", 1170], [";", 1171], ["P<0.001", 1173], ["for", 1181], ["the", 1185], ["comparison", 1189], ["of", 1200], ["the", 1203], ["100-mg", 1207], ["dose", 1214], ["with", 1219], ["placebo", 1224], [",", 1231], ["P=0.34", 1233], ["for", 1240], ["the", 1244], ["comparison", 1248], ["of", 1259], ["the", 1262], ["150-mg", 1266], ["dose", 1273], ["with", 1278], ["placebo", 1283], [")", 1290], [".", 1291], ["A", 1293], ["clinically", 1295], ["significant", 1306], ["effect", 1318], ["was", 1325], ["noted", 1329], ["by", 1335], ["the", 1338], ["end", 1342], ["of", 1346], ["the", 1349], ["first", 1353], ["week", 1359], ["of", 1364], ["treatment", 1367], [".", 1376], ["Adverse", 1378], ["effects", 1386], ["included", 1394], ["diarrhea", 1403], ["(", 1412], ["in", 1413], ["19", 1416], ["%", 1418], ["of", 1420], ["subjects", 1423], ["taking", 1432], ["the", 1439], ["100-mg", 1443], ["dose", 1450], ["of", 1455], ["R788", 1458], ["vs.", 1463], ["3", 1467], ["%", 1468], ["of", 1470], ["those", 1473], ["taking", 1479], ["placebo", 1486], [")", 1493], [",", 1494], ["upper", 1496], ["respiratory", 1502], ["infections", 1514], ["(", 1525], ["14", 1526], ["%", 1528], ["vs.", 1530], ["7", 1534], ["%", 1535], [")", 1536], [",", 1537], ["and", 1539], ["neutropenia", 1543], ["(", 1555], ["6", 1556], ["%", 1557], ["vs.", 1559], ["1", 1563], ["%", 1564], [")", 1565], [".", 1566], ["R788", 1568], ["was", 1573], ["associated", 1577], ["with", 1588], ["an", 1593], ["increase", 1596], ["in", 1605], ["systolic", 1608], ["blood", 1617], ["pressure", 1623], ["of", 1632], ["approximately", 1635], ["3", 1649], ["mm", 1651], ["Hg", 1654], ["between", 1657], ["baseline", 1665], ["and", 1674], ["month", 1678], ["1", 1684], [",", 1685], ["as", 1687], ["compared", 1690], ["with", 1699], ["a", 1704], ["decrease", 1706], ["of", 1715], ["2", 1718], ["mm", 1720], ["Hg", 1723], ["with", 1726], ["placebo", 1731], [";", 1738], ["23", 1740], ["%", 1742], ["of", 1744], ["the", 1747], ["patients", 1751], ["taking", 1760], ["R788", 1767], ["vs.", 1772], ["7", 1776], ["%", 1777], ["of", 1779], ["the", 1782], ["patients", 1786], ["receiving", 1795], ["placebo", 1805], ["required", 1813], ["the", 1822], ["initiation", 1826], ["of", 1837], ["or", 1840], ["a", 1843], ["change", 1845], ["in", 1852], ["antihypertensive", 1855], ["therapy", 1872], [".", 1879], ["In", 1881], ["this", 1884], ["phase", 1889], ["2", 1895], ["study", 1897], [",", 1902], ["a", 1904], ["Syk", 1906], ["inhibitor", 1910], ["reduced", 1920], ["disease", 1928], ["activity", 1936], ["in", 1945], ["patients", 1948], ["with", 1957], ["rheumatoid", 1962], ["arthritis", 1973], [";", 1982], ["adverse", 1984], ["events", 1992], ["included", 1999], ["diarrhea", 2008], [",", 2016], ["hypertension", 2018], [",", 2030], ["and", 2032], ["neutropenia", 2036], [".", 2047], ["Additional", 2049], ["studies", 2060], ["will", 2068], ["be", 2073], ["needed", 2076], ["to", 2083], ["further", 2086], ["assess", 2094], ["the", 2101], ["safety", 2105], ["and", 2112], ["efficacy", 2116], ["of", 2125], ["Syk", 2128], ["-", 2131], ["inhibition", 2132], ["therapy", 2143], ["in", 2151], ["patients", 2154], ["with", 2163], ["rheumatoid", 2168], ["arthritis", 2179], [".", 2188], ["(", 2190], ["Funded", 2191], ["by", 2198], ["Rigel", 2201], [";", 2206], ["ClinicalTrials.gov", 2208], ["number", 2227], [",", 2233], ["NCT00665925", 2235], [".", 2246], [")", 2247]]}
{"context": "Prostate cancer is the most common cancer in men in Europe and the United             States, and the third leading cause of death from cancer in Europe. Survival of             prostate cancer cells is dependent on the activation of androgen receptors (AR),             that are overexpressed in this tumor. Furthermore, ~90% of prostate cancer patients             that respond to first-line androgen deprivation therapy (ADT) undergo rapid progression.             This condition is defined as castration-resistant prostate cancer (CRPC). Docetaxel-based             regimens significantly improve overall survival (OS) in patients with CRPC and             represent the only treatment strategy approved by the Food and Drug Administration             (FDA). Recently, abiraterone (second hormonal therapy) and cabazitaxel (new taxane)             have been shown to improve survival in patients with CRPC who progressed following             docetaxel-based chemotherapy. Vaccine therapy has also been demonstrated to improve             OS in patients with asymptomatic or minimally symptomatic metastatic CRPC. Additional             therapeutic targets have been analyzed in prostate cancer, including apoptosis,             angiogenic receptors, vitamin D and Src pathways. Several phase II studies are             ongoing. The high frequency of prostate cancer-related metastatic bone disease             has led to consider this pathway as a therapeutic target. To this end, several             bone-targeted agents have been investigated, most notably zoledronic acid, which             is highly effective at stabilizing the bone and preventing skeletal complications.             More recently, a nuclear factor-\u03b2 ligand (RANKL) inhibitor, denosumab, has been             developed for the treatment of bone metastases.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "db3d5700fb404c9d9b22de58652e441b", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[265, 265]], "char_spans": [[1736, 1740]]}]}], "context_tokens": [["Prostate", 0], ["cancer", 9], ["is", 16], ["the", 19], ["most", 23], ["common", 28], ["cancer", 35], ["in", 42], ["men", 45], ["in", 49], ["Europe", 52], ["and", 59], ["the", 63], ["United", 67], ["States", 86], [",", 92], ["and", 94], ["the", 98], ["third", 102], ["leading", 108], ["cause", 116], ["of", 122], ["death", 125], ["from", 131], ["cancer", 136], ["in", 143], ["Europe", 146], [".", 152], ["Survival", 154], ["of", 163], ["prostate", 178], ["cancer", 187], ["cells", 194], ["is", 200], ["dependent", 203], ["on", 213], ["the", 216], ["activation", 220], ["of", 231], ["androgen", 234], ["receptors", 243], ["(", 253], ["AR", 254], [")", 256], [",", 257], ["that", 271], ["are", 276], ["overexpressed", 280], ["in", 294], ["this", 297], ["tumor", 302], [".", 307], ["Furthermore", 309], [",", 320], ["~90", 322], ["%", 325], ["of", 327], ["prostate", 330], ["cancer", 339], ["patients", 346], ["that", 367], ["respond", 372], ["to", 380], ["first", 383], ["-", 388], ["line", 389], ["androgen", 394], ["deprivation", 403], ["therapy", 415], ["(", 423], ["ADT", 424], [")", 427], ["undergo", 429], ["rapid", 437], ["progression", 443], [".", 454], ["This", 468], ["condition", 473], ["is", 483], ["defined", 486], ["as", 494], ["castration", 497], ["-", 507], ["resistant", 508], ["prostate", 518], ["cancer", 527], ["(", 534], ["CRPC", 535], [")", 539], [".", 540], ["Docetaxel", 542], ["-", 551], ["based", 552], ["regimens", 570], ["significantly", 579], ["improve", 593], ["overall", 601], ["survival", 609], ["(", 618], ["OS", 619], [")", 621], ["in", 623], ["patients", 626], ["with", 635], ["CRPC", 640], ["and", 645], ["represent", 661], ["the", 671], ["only", 675], ["treatment", 680], ["strategy", 690], ["approved", 699], ["by", 708], ["the", 711], ["Food", 715], ["and", 720], ["Drug", 724], ["Administration", 729], ["(", 756], ["FDA", 757], [")", 760], [".", 761], ["Recently", 763], [",", 771], ["abiraterone", 773], ["(", 785], ["second", 786], ["hormonal", 793], ["therapy", 802], [")", 809], ["and", 811], ["cabazitaxel", 815], ["(", 827], ["new", 828], ["taxane", 832], [")", 838], ["have", 852], ["been", 857], ["shown", 862], ["to", 868], ["improve", 871], ["survival", 879], ["in", 888], ["patients", 891], ["with", 900], ["CRPC", 905], ["who", 910], ["progressed", 914], ["following", 925], ["docetaxel", 947], ["-", 956], ["based", 957], ["chemotherapy", 963], [".", 975], ["Vaccine", 977], ["therapy", 985], ["has", 993], ["also", 997], ["been", 1002], ["demonstrated", 1007], ["to", 1020], ["improve", 1023], ["OS", 1043], ["in", 1046], ["patients", 1049], ["with", 1058], ["asymptomatic", 1063], ["or", 1076], ["minimally", 1079], ["symptomatic", 1089], ["metastatic", 1101], ["CRPC", 1112], [".", 1116], ["Additional", 1118], ["therapeutic", 1141], ["targets", 1153], ["have", 1161], ["been", 1166], ["analyzed", 1171], ["in", 1180], ["prostate", 1183], ["cancer", 1192], [",", 1198], ["including", 1200], ["apoptosis", 1210], [",", 1219], ["angiogenic", 1233], ["receptors", 1244], [",", 1253], ["vitamin", 1255], ["D", 1263], ["and", 1265], ["Src", 1269], ["pathways", 1273], [".", 1281], ["Several", 1283], ["phase", 1291], ["II", 1297], ["studies", 1300], ["are", 1308], ["ongoing", 1324], [".", 1331], ["The", 1333], ["high", 1337], ["frequency", 1342], ["of", 1352], ["prostate", 1355], ["cancer", 1364], ["-", 1370], ["related", 1371], ["metastatic", 1379], ["bone", 1390], ["disease", 1395], ["has", 1415], ["led", 1419], ["to", 1423], ["consider", 1426], ["this", 1435], ["pathway", 1440], ["as", 1448], ["a", 1451], ["therapeutic", 1453], ["target", 1465], [".", 1471], ["To", 1473], ["this", 1476], ["end", 1481], [",", 1484], ["several", 1486], ["bone", 1506], ["-", 1510], ["targeted", 1511], ["agents", 1520], ["have", 1527], ["been", 1532], ["investigated", 1537], [",", 1549], ["most", 1551], ["notably", 1556], ["zoledronic", 1564], ["acid", 1575], [",", 1579], ["which", 1581], ["is", 1599], ["highly", 1602], ["effective", 1609], ["at", 1619], ["stabilizing", 1622], ["the", 1634], ["bone", 1638], ["and", 1643], ["preventing", 1647], ["skeletal", 1658], ["complications", 1667], [".", 1680], ["More", 1694], ["recently", 1699], [",", 1707], ["a", 1709], ["nuclear", 1711], ["factor", 1719], ["-", 1725], ["\u03b2", 1726], ["ligand", 1728], ["(", 1735], ["RANKL", 1736], [")", 1741], ["inhibitor", 1743], [",", 1752], ["denosumab", 1754], [",", 1763], ["has", 1765], ["been", 1769], ["developed", 1786], ["for", 1796], ["the", 1800], ["treatment", 1804], ["of", 1814], ["bone", 1817], ["metastases", 1822], [".", 1832]]}
{"context": "Selexipag is a novel, oral, selective prostacyclin (PGI2) receptor agonist in clinical development for the treatment of pulmonary arterial hypertension. Film-coated tablets with strength between 200 and 1,600 \u03bcg were used. Bioequivalence between 8 x 200 \u03bcg and a new 1,600 \u03bcg tablet was evaluated at steady state in healthy male subjects. This was an open-label, 2-treatment, 2-period, crossover, up-titration, phase 1 study. The treatments were selexipag at 1,600 \u03bcg b.i.d. for 4.5 days either as 8 x 200 \u03bcg tablets (reference: A) or 1 x 1,600 \u03bcg tablet (test: B), both preceded by an up-titration phase starting from 400 \u03bcg b.i.d. doses, in 200-\u03bcg steps every 4th day. Subjects were randomized 1 : 1 to the A-B or B-A sequence. The pharmacokinetics and tolerability of selexipag and its active metabolite, ACT-333679, were investigated. 80 subjects were enrolled in the study: 65 subjects completed the study according to protocol, and 15 subjects withdrew from the study. The most frequent adverse events (AEs) were headache (86%), myalgia (73%), and jaw pain (73%). There was no difference in nature and overall frequency of AEs between the two treatments. Steady state was attained within 3 days of the selexipag 1,600 \u00ce\u00bcg b.i.d. The 90% confidence intervals (CIs) of the geometric mean ratio (B/A) at steady state for AUC\u00cf\u0084 and Cmax,ss were within (0.80, 1.25) bioequivalence interval: (0.92, 1.06) and (0.95, 1.14), respectively, for selexipag and (0.95, 1.06) and (0.94, 1.07), respectively, for the active metabolite, ACT-333679. Bioequivalence was demonstrated between 8 x 200 \u03bcg and 1 x 1,600 \u03bcg selexipag at steady state.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "990c3fbed6b34ba08dd9a7685e257613", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[21, 23]], "char_spans": [[120, 150]]}]}], "context_tokens": [["Selexipag", 0], ["is", 10], ["a", 13], ["novel", 15], [",", 20], ["oral", 22], [",", 26], ["selective", 28], ["prostacyclin", 38], ["(", 51], ["PGI2", 52], [")", 56], ["receptor", 58], ["agonist", 67], ["in", 75], ["clinical", 78], ["development", 87], ["for", 99], ["the", 103], ["treatment", 107], ["of", 117], ["pulmonary", 120], ["arterial", 130], ["hypertension", 139], [".", 151], ["Film", 153], ["-", 157], ["coated", 158], ["tablets", 165], ["with", 173], ["strength", 178], ["between", 187], ["200", 195], ["and", 199], ["1,600", 203], ["\u03bcg", 209], ["were", 212], ["used", 217], [".", 221], ["Bioequivalence", 223], ["between", 238], ["8", 246], ["x", 248], ["200", 250], ["\u03bcg", 254], ["and", 257], ["a", 261], ["new", 263], ["1,600", 267], ["\u03bcg", 273], ["tablet", 276], ["was", 283], ["evaluated", 287], ["at", 297], ["steady", 300], ["state", 307], ["in", 313], ["healthy", 316], ["male", 324], ["subjects", 329], [".", 337], ["This", 339], ["was", 344], ["an", 348], ["open", 351], ["-", 355], ["label", 356], [",", 361], ["2-treatment", 363], [",", 374], ["2-period", 376], [",", 384], ["crossover", 386], [",", 395], ["up", 397], ["-", 399], ["titration", 400], [",", 409], ["phase", 411], ["1", 417], ["study", 419], [".", 424], ["The", 426], ["treatments", 430], ["were", 441], ["selexipag", 446], ["at", 456], ["1,600", 459], ["\u03bcg", 465], ["b.i.d", 468], [".", 473], ["for", 475], ["4.5", 479], ["days", 483], ["either", 488], ["as", 495], ["8", 498], ["x", 500], ["200", 502], ["\u03bcg", 506], ["tablets", 509], ["(", 517], ["reference", 518], [":", 527], ["A", 529], [")", 530], ["or", 532], ["1", 535], ["x", 537], ["1,600", 539], ["\u03bcg", 545], ["tablet", 548], ["(", 555], ["test", 556], [":", 560], ["B", 562], [")", 563], [",", 564], ["both", 566], ["preceded", 571], ["by", 580], ["an", 583], ["up", 586], ["-", 588], ["titration", 589], ["phase", 599], ["starting", 605], ["from", 614], ["400", 619], ["\u03bcg", 623], ["b.i.d", 626], [".", 631], ["doses", 633], [",", 638], ["in", 640], ["200-\u03bcg", 643], ["steps", 650], ["every", 656], ["4th", 662], ["day", 666], [".", 669], ["Subjects", 671], ["were", 680], ["randomized", 685], ["1", 696], [":", 698], ["1", 700], ["to", 702], ["the", 705], ["A", 709], ["-", 710], ["B", 711], ["or", 713], ["B", 716], ["-", 717], ["A", 718], ["sequence", 720], [".", 728], ["The", 730], ["pharmacokinetics", 734], ["and", 751], ["tolerability", 755], ["of", 768], ["selexipag", 771], ["and", 781], ["its", 785], ["active", 789], ["metabolite", 796], [",", 806], ["ACT-333679", 808], [",", 818], ["were", 820], ["investigated", 825], [".", 837], ["80", 839], ["subjects", 842], ["were", 851], ["enrolled", 856], ["in", 865], ["the", 868], ["study", 872], [":", 877], ["65", 879], ["subjects", 882], ["completed", 891], ["the", 901], ["study", 905], ["according", 911], ["to", 921], ["protocol", 924], [",", 932], ["and", 934], ["15", 938], ["subjects", 941], ["withdrew", 950], ["from", 959], ["the", 964], ["study", 968], [".", 973], ["The", 975], ["most", 979], ["frequent", 984], ["adverse", 993], ["events", 1001], ["(", 1008], ["AEs", 1009], [")", 1012], ["were", 1014], ["headache", 1019], ["(", 1028], ["86", 1029], ["%", 1031], [")", 1032], [",", 1033], ["myalgia", 1035], ["(", 1043], ["73", 1044], ["%", 1046], [")", 1047], [",", 1048], ["and", 1050], ["jaw", 1054], ["pain", 1058], ["(", 1063], ["73", 1064], ["%", 1066], [")", 1067], [".", 1068], ["There", 1070], ["was", 1076], ["no", 1080], ["difference", 1083], ["in", 1094], ["nature", 1097], ["and", 1104], ["overall", 1108], ["frequency", 1116], ["of", 1126], ["AEs", 1129], ["between", 1133], ["the", 1141], ["two", 1145], ["treatments", 1149], [".", 1159], ["Steady", 1161], ["state", 1168], ["was", 1174], ["attained", 1178], ["within", 1187], ["3", 1194], ["days", 1196], ["of", 1201], ["the", 1204], ["selexipag", 1208], ["1,600", 1218], ["\u00ce\u00bcg", 1224], ["b.i.d", 1228], [".", 1233], ["The", 1235], ["90", 1239], ["%", 1241], ["confidence", 1243], ["intervals", 1254], ["(", 1264], ["CIs", 1265], [")", 1268], ["of", 1270], ["the", 1273], ["geometric", 1277], ["mean", 1287], ["ratio", 1292], ["(", 1298], ["B", 1299], ["/", 1300], ["A", 1301], [")", 1302], ["at", 1304], ["steady", 1307], ["state", 1314], ["for", 1320], ["AUC\u00cf\u0084", 1324], ["and", 1330], ["Cmax", 1334], [",", 1338], ["ss", 1339], ["were", 1342], ["within", 1347], ["(", 1354], ["0.80", 1355], [",", 1359], ["1.25", 1361], [")", 1365], ["bioequivalence", 1367], ["interval", 1382], [":", 1390], ["(", 1392], ["0.92", 1393], [",", 1397], ["1.06", 1399], [")", 1403], ["and", 1405], ["(", 1409], ["0.95", 1410], [",", 1414], ["1.14", 1416], [")", 1420], [",", 1421], ["respectively", 1423], [",", 1435], ["for", 1437], ["selexipag", 1441], ["and", 1451], ["(", 1455], ["0.95", 1456], [",", 1460], ["1.06", 1462], [")", 1466], ["and", 1468], ["(", 1472], ["0.94", 1473], [",", 1477], ["1.07", 1479], [")", 1483], [",", 1484], ["respectively", 1486], [",", 1498], ["for", 1500], ["the", 1504], ["active", 1508], ["metabolite", 1515], [",", 1525], ["ACT-333679", 1527], [".", 1537], ["Bioequivalence", 1539], ["was", 1554], ["demonstrated", 1558], ["between", 1571], ["8", 1579], ["x", 1581], ["200", 1583], ["\u03bcg", 1587], ["and", 1590], ["1", 1594], ["x", 1596], ["1,600", 1598], ["\u03bcg", 1604], ["selexipag", 1607], ["at", 1617], ["steady", 1620], ["state", 1627], [".", 1632]]}
{"context": "Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality. Here we describe the rationale and design of the Phase 3 APOLLO study, a randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of patisiran in patients with hATTR amyloidosis with polyneuropathy. Eligible patients are 18-85\u00a0years old with hATTR amyloidosis, investigator-estimated survival of \u22652\u00a0years, Neuropathy Impairment Score (NIS) of 5-130, and polyneuropathy disability score\u00a0\u2264IIIb. Patients are randomized 2:1 to receive either intravenous patisiran 0.3\u00a0mg/kg or placebo once every 3\u00a0weeks. The primary objective is to determine the efficacy of patisiran at 18\u00a0months based on the difference in the change in modified NIS+7 (a composite measure of motor strength, sensation, reflexes, nerve conduction, and autonomic function) between the patisiran and placebo groups. Secondary objectives are to evaluate the effect of patisiran on Norfolk-Diabetic Neuropathy quality of life questionnaire score, nutritional status (as evaluated by modified body mass index), motor function (as measured by NIS-weakness and timed 10-m walk test), and autonomic symptoms (as measured by the Composite Autonomic Symptom Score-31 questionnaire). Exploratory objectives include assessment of cardiac function and pathologic evaluation to assess nerve fiber innervation and amyloid burden. Safety of patisiran will be assessed throughout the study. APOLLO represents the largest randomized, Phase 3 study to date in patients with hATTR amyloidosis, with endpoints that capture the multisystemic nature of this disease. This trial is registered at clinicaltrials.gov ( NCT01960348 ); October 9, 2013.", "qas": [{"question": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?", "answers": ["Patisiran"], "qid": "f6d7e1841db1466093bc4a2667512ecc", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["RNAi", 24], ["investigational", 29], ["drug", 45], ["being", 50], ["developed", 56], ["against", 66], ["hereditary", 74], ["amyloidosis", 85], ["?", 96]], "detected_answers": [{"text": "Patisiran", "token_spans": [[0, 0], [269, 269], [70, 70], [180, 180], [124, 124], [193, 193], [145, 145]], "char_spans": [[0, 8], [1558, 1566], [400, 408], [1017, 1025], [718, 726], [1098, 1106], [823, 831]]}]}], "context_tokens": [["Patisiran", 0], ["is", 10], ["an", 13], ["investigational", 16], ["RNA", 32], ["interference", 36], ["(", 49], ["RNAi", 50], [")", 54], ["therapeutic", 56], ["in", 68], ["development", 71], ["for", 83], ["the", 87], ["treatment", 91], ["of", 101], ["hereditary", 104], ["ATTR", 115], ["(", 120], ["hATTR", 121], [")", 126], ["amyloidosis", 128], [",", 139], ["a", 141], ["progressive", 143], ["disease", 155], ["associated", 163], ["with", 174], ["significant", 179], ["disability", 191], [",", 201], ["morbidity", 203], [",", 212], ["and", 214], ["mortality", 218], [".", 227], ["Here", 229], ["we", 234], ["describe", 237], ["the", 246], ["rationale", 250], ["and", 260], ["design", 264], ["of", 271], ["the", 274], ["Phase", 278], ["3", 284], ["APOLLO", 286], ["study", 293], [",", 298], ["a", 300], ["randomized", 302], [",", 312], ["double", 314], ["-", 320], ["blind", 321], [",", 326], ["placebo", 328], ["-", 335], ["controlled", 336], [",", 346], ["global", 348], ["study", 355], ["to", 361], ["evaluate", 364], ["the", 373], ["efficacy", 377], ["and", 386], ["safety", 390], ["of", 397], ["patisiran", 400], ["in", 410], ["patients", 413], ["with", 422], ["hATTR", 427], ["amyloidosis", 433], ["with", 445], ["polyneuropathy", 450], [".", 464], ["Eligible", 466], ["patients", 475], ["are", 484], ["18", 488], ["-", 490], ["85", 491], ["years", 494], ["old", 500], ["with", 504], ["hATTR", 509], ["amyloidosis", 515], [",", 526], ["investigator", 528], ["-", 540], ["estimated", 541], ["survival", 551], ["of", 560], ["\u22652", 563], ["years", 566], [",", 571], ["Neuropathy", 573], ["Impairment", 584], ["Score", 595], ["(", 601], ["NIS", 602], [")", 605], ["of", 607], ["5", 610], ["-", 611], ["130", 612], [",", 615], ["and", 617], ["polyneuropathy", 621], ["disability", 636], ["score", 647], ["\u2264IIIb", 653], [".", 658], ["Patients", 660], ["are", 669], ["randomized", 673], ["2:1", 684], ["to", 688], ["receive", 691], ["either", 699], ["intravenous", 706], ["patisiran", 718], ["0.3", 728], ["mg", 732], ["/", 734], ["kg", 735], ["or", 738], ["placebo", 741], ["once", 749], ["every", 754], ["3", 760], ["weeks", 762], [".", 767], ["The", 769], ["primary", 773], ["objective", 781], ["is", 791], ["to", 794], ["determine", 797], ["the", 807], ["efficacy", 811], ["of", 820], ["patisiran", 823], ["at", 833], ["18", 836], ["months", 839], ["based", 846], ["on", 852], ["the", 855], ["difference", 859], ["in", 870], ["the", 873], ["change", 877], ["in", 884], ["modified", 887], ["NIS+7", 896], ["(", 902], ["a", 903], ["composite", 905], ["measure", 915], ["of", 923], ["motor", 926], ["strength", 932], [",", 940], ["sensation", 942], [",", 951], ["reflexes", 953], [",", 961], ["nerve", 963], ["conduction", 969], [",", 979], ["and", 981], ["autonomic", 985], ["function", 995], [")", 1003], ["between", 1005], ["the", 1013], ["patisiran", 1017], ["and", 1027], ["placebo", 1031], ["groups", 1039], [".", 1045], ["Secondary", 1047], ["objectives", 1057], ["are", 1068], ["to", 1072], ["evaluate", 1075], ["the", 1084], ["effect", 1088], ["of", 1095], ["patisiran", 1098], ["on", 1108], ["Norfolk", 1111], ["-", 1118], ["Diabetic", 1119], ["Neuropathy", 1128], ["quality", 1139], ["of", 1147], ["life", 1150], ["questionnaire", 1155], ["score", 1169], [",", 1174], ["nutritional", 1176], ["status", 1188], ["(", 1195], ["as", 1196], ["evaluated", 1199], ["by", 1209], ["modified", 1212], ["body", 1221], ["mass", 1226], ["index", 1231], [")", 1236], [",", 1237], ["motor", 1239], ["function", 1245], ["(", 1254], ["as", 1255], ["measured", 1258], ["by", 1267], ["NIS", 1270], ["-", 1273], ["weakness", 1274], ["and", 1283], ["timed", 1287], ["10-m", 1293], ["walk", 1298], ["test", 1303], [")", 1307], [",", 1308], ["and", 1310], ["autonomic", 1314], ["symptoms", 1324], ["(", 1333], ["as", 1334], ["measured", 1337], ["by", 1346], ["the", 1349], ["Composite", 1353], ["Autonomic", 1363], ["Symptom", 1373], ["Score-31", 1381], ["questionnaire", 1390], [")", 1403], [".", 1404], ["Exploratory", 1406], ["objectives", 1418], ["include", 1429], ["assessment", 1437], ["of", 1448], ["cardiac", 1451], ["function", 1459], ["and", 1468], ["pathologic", 1472], ["evaluation", 1483], ["to", 1494], ["assess", 1497], ["nerve", 1504], ["fiber", 1510], ["innervation", 1516], ["and", 1528], ["amyloid", 1532], ["burden", 1540], [".", 1546], ["Safety", 1548], ["of", 1555], ["patisiran", 1558], ["will", 1568], ["be", 1573], ["assessed", 1576], ["throughout", 1585], ["the", 1596], ["study", 1600], [".", 1605], ["APOLLO", 1607], ["represents", 1614], ["the", 1625], ["largest", 1629], ["randomized", 1637], [",", 1647], ["Phase", 1649], ["3", 1655], ["study", 1657], ["to", 1663], ["date", 1666], ["in", 1671], ["patients", 1674], ["with", 1683], ["hATTR", 1688], ["amyloidosis", 1694], [",", 1705], ["with", 1707], ["endpoints", 1712], ["that", 1722], ["capture", 1727], ["the", 1735], ["multisystemic", 1739], ["nature", 1753], ["of", 1760], ["this", 1763], ["disease", 1768], [".", 1775], ["This", 1777], ["trial", 1782], ["is", 1788], ["registered", 1791], ["at", 1802], ["clinicaltrials.gov", 1805], ["(", 1824], ["NCT01960348", 1826], [")", 1838], [";", 1839], ["October", 1841], ["9", 1849], [",", 1850], ["2013", 1852], [".", 1856]]}
{"context": "Eighty-eight Staphylococcus aureus clinical isolates meeting criteria for borderline oxacillin resistance (intermediate susceptibility or resistance to oxacillin but susceptibility to amoxicillin/clavulanic acid upon disk diffusion testing) were studied to determine optimal test techniques and conditions for differentiating borderline oxacillin-resistant Staphylococcus aureus (BORSA) from methicillin-resistant Staphylococcus aureus (MRSA). Further testing revealed three distinct resistance patterns: 61 strains (69%) consistently met BORSA criteria and had average beta-lactamase levels five- to six-fold higher than oxacillin-susceptible controls; 11 strains (13%) were markedly heteroresistant MRSA with delayed appearance of resistant colonies leading to spurious susceptibility to amoxicillin/clavulanic acid; 16 strains (18%) appeared to be oxacillin-susceptible on repetitive testing. Under conditions used to elicit intrinsic methicillin resistance in Staphylococcus aureus, a large percentage of BORSA appeared resistant to amoxicillin/clavulanic acid. This clearly shows that BORSA may be misidentified as MRSA while heteroresistant MRSA may appear to be BORSA. It is concluded that amoxicillin/clavulanic acid zone sizes should be measured after a full 24 hours of incubation, that susceptibility testing of Staphylococcus aureus under certain environmental conditions should be interpreted with caution, and that MIC testing is the most reliable technique for differentiating these two resistance patterns in Staphylococcus aureus.", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "3d2f68914f0e4658990df1920e00cd94", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[43, 48]], "char_spans": [[326, 377]]}]}], "context_tokens": [["Eighty", 0], ["-", 6], ["eight", 7], ["Staphylococcus", 13], ["aureus", 28], ["clinical", 35], ["isolates", 44], ["meeting", 53], ["criteria", 61], ["for", 70], ["borderline", 74], ["oxacillin", 85], ["resistance", 95], ["(", 106], ["intermediate", 107], ["susceptibility", 120], ["or", 135], ["resistance", 138], ["to", 149], ["oxacillin", 152], ["but", 162], ["susceptibility", 166], ["to", 181], ["amoxicillin", 184], ["/", 195], ["clavulanic", 196], ["acid", 207], ["upon", 212], ["disk", 217], ["diffusion", 222], ["testing", 232], [")", 239], ["were", 241], ["studied", 246], ["to", 254], ["determine", 257], ["optimal", 267], ["test", 275], ["techniques", 280], ["and", 291], ["conditions", 295], ["for", 306], ["differentiating", 310], ["borderline", 326], ["oxacillin", 337], ["-", 346], ["resistant", 347], ["Staphylococcus", 357], ["aureus", 372], ["(", 379], ["BORSA", 380], [")", 385], ["from", 387], ["methicillin", 392], ["-", 403], ["resistant", 404], ["Staphylococcus", 414], ["aureus", 429], ["(", 436], ["MRSA", 437], [")", 441], [".", 442], ["Further", 444], ["testing", 452], ["revealed", 460], ["three", 469], ["distinct", 475], ["resistance", 484], ["patterns", 495], [":", 503], ["61", 505], ["strains", 508], ["(", 516], ["69", 517], ["%", 519], [")", 520], ["consistently", 522], ["met", 535], ["BORSA", 539], ["criteria", 545], ["and", 554], ["had", 558], ["average", 562], ["beta", 570], ["-", 574], ["lactamase", 575], ["levels", 585], ["five-", 592], ["to", 598], ["six", 601], ["-", 604], ["fold", 605], ["higher", 610], ["than", 617], ["oxacillin", 622], ["-", 631], ["susceptible", 632], ["controls", 644], [";", 652], ["11", 654], ["strains", 657], ["(", 665], ["13", 666], ["%", 668], [")", 669], ["were", 671], ["markedly", 676], ["heteroresistant", 685], ["MRSA", 701], ["with", 706], ["delayed", 711], ["appearance", 719], ["of", 730], ["resistant", 733], ["colonies", 743], ["leading", 752], ["to", 760], ["spurious", 763], ["susceptibility", 772], ["to", 787], ["amoxicillin", 790], ["/", 801], ["clavulanic", 802], ["acid", 813], [";", 817], ["16", 819], ["strains", 822], ["(", 830], ["18", 831], ["%", 833], [")", 834], ["appeared", 836], ["to", 845], ["be", 848], ["oxacillin", 851], ["-", 860], ["susceptible", 861], ["on", 873], ["repetitive", 876], ["testing", 887], [".", 894], ["Under", 896], ["conditions", 902], ["used", 913], ["to", 918], ["elicit", 921], ["intrinsic", 928], ["methicillin", 938], ["resistance", 950], ["in", 961], ["Staphylococcus", 964], ["aureus", 979], [",", 985], ["a", 987], ["large", 989], ["percentage", 995], ["of", 1006], ["BORSA", 1009], ["appeared", 1015], ["resistant", 1024], ["to", 1034], ["amoxicillin", 1037], ["/", 1048], ["clavulanic", 1049], ["acid", 1060], [".", 1064], ["This", 1066], ["clearly", 1071], ["shows", 1079], ["that", 1085], ["BORSA", 1090], ["may", 1096], ["be", 1100], ["misidentified", 1103], ["as", 1117], ["MRSA", 1120], ["while", 1125], ["heteroresistant", 1131], ["MRSA", 1147], ["may", 1152], ["appear", 1156], ["to", 1163], ["be", 1166], ["BORSA", 1169], [".", 1174], ["It", 1176], ["is", 1179], ["concluded", 1182], ["that", 1192], ["amoxicillin", 1197], ["/", 1208], ["clavulanic", 1209], ["acid", 1220], ["zone", 1225], ["sizes", 1230], ["should", 1236], ["be", 1243], ["measured", 1246], ["after", 1255], ["a", 1261], ["full", 1263], ["24", 1268], ["hours", 1271], ["of", 1277], ["incubation", 1280], [",", 1290], ["that", 1292], ["susceptibility", 1297], ["testing", 1312], ["of", 1320], ["Staphylococcus", 1323], ["aureus", 1338], ["under", 1345], ["certain", 1351], ["environmental", 1359], ["conditions", 1373], ["should", 1384], ["be", 1391], ["interpreted", 1394], ["with", 1406], ["caution", 1411], [",", 1418], ["and", 1420], ["that", 1424], ["MIC", 1429], ["testing", 1433], ["is", 1441], ["the", 1444], ["most", 1448], ["reliable", 1453], ["technique", 1462], ["for", 1472], ["differentiating", 1476], ["these", 1492], ["two", 1498], ["resistance", 1502], ["patterns", 1513], ["in", 1522], ["Staphylococcus", 1525], ["aureus", 1540], [".", 1546]]}
{"context": "Interstitial deletions of chromosome band Xq26.3 are rare. We report on a 2-year-old boy in whom array comparative genomic hybridization analysis revealed an interstitial 314 kb deletion in Xq26.3 affecting SLC9A6 and FHL1. Mutations in SLC9A6 are associated with Christianson syndrome (OMIM 300243), a syndromic form of X-linked mental retardation (XLMR) characterized by microcephaly, severe global developmental delay, ataxia and seizures. FHL1 mutations cause Emery-Dreifuss muscular dystrophy (OMIM 310300), X-linked myopathy with postural muscle atrophy (XMPMA, OMIM 300696), scapuloperoneal myopathy (OMIM 300695), or reducing body myopathy (OMIM 300717, 300718). The clinical problems of the patient reported here comprised severe intellectual disability, absent speech, ataxia, epilepsy, and gastroesophageal reflux, and could mostly be attributed to SLC9A6 insufficiency. In contrast to the majority of reported Christianson syndrome patients who were microcephalic, this patient was normocephalic, but his head circumference had decelerated from the 50th centile at birth to the 25th centile at the age of 2 \u00b2/\u00b9\u00b2 years. Muscle problems due to the FHL1 deletion are not to be expected before late childhood, which is the earliest age of onset for FHL1 associated Emery-Dreifuss muscular dystrophy. This patient broadens the spectrum of SLC9A6 mutations and contributes to the clinical delineation of Christianson syndrome. This is also the first patient with a deletion affecting both SLC9A6 and the complete FHL1 gene.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "66ed19703ab9429588260046aacc2ac1", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[235, 235], [151, 151], [39, 39], [258, 258], [33, 33]], "char_spans": [[1346, 1351], [860, 865], [237, 242], [1495, 1500], [207, 212]]}]}], "context_tokens": [["Interstitial", 0], ["deletions", 13], ["of", 23], ["chromosome", 26], ["band", 37], ["Xq26.3", 42], ["are", 49], ["rare", 53], [".", 57], ["We", 59], ["report", 62], ["on", 69], ["a", 72], ["2-year", 74], ["-", 80], ["old", 81], ["boy", 85], ["in", 89], ["whom", 92], ["array", 97], ["comparative", 103], ["genomic", 115], ["hybridization", 123], ["analysis", 137], ["revealed", 146], ["an", 155], ["interstitial", 158], ["314", 171], ["kb", 175], ["deletion", 178], ["in", 187], ["Xq26.3", 190], ["affecting", 197], ["SLC9A6", 207], ["and", 214], ["FHL1", 218], [".", 222], ["Mutations", 224], ["in", 234], ["SLC9A6", 237], ["are", 244], ["associated", 248], ["with", 259], ["Christianson", 264], ["syndrome", 277], ["(", 286], ["OMIM", 287], ["300243", 292], [")", 298], [",", 299], ["a", 301], ["syndromic", 303], ["form", 313], ["of", 318], ["X", 321], ["-", 322], ["linked", 323], ["mental", 330], ["retardation", 337], ["(", 349], ["XLMR", 350], [")", 354], ["characterized", 356], ["by", 370], ["microcephaly", 373], [",", 385], ["severe", 387], ["global", 394], ["developmental", 401], ["delay", 415], [",", 420], ["ataxia", 422], ["and", 429], ["seizures", 433], [".", 441], ["FHL1", 443], ["mutations", 448], ["cause", 458], ["Emery", 464], ["-", 469], ["Dreifuss", 470], ["muscular", 479], ["dystrophy", 488], ["(", 498], ["OMIM", 499], ["310300", 504], [")", 510], [",", 511], ["X", 513], ["-", 514], ["linked", 515], ["myopathy", 522], ["with", 531], ["postural", 536], ["muscle", 545], ["atrophy", 552], ["(", 560], ["XMPMA", 561], [",", 566], ["OMIM", 568], ["300696", 573], [")", 579], [",", 580], ["scapuloperoneal", 582], ["myopathy", 598], ["(", 607], ["OMIM", 608], ["300695", 613], [")", 619], [",", 620], ["or", 622], ["reducing", 625], ["body", 634], ["myopathy", 639], ["(", 648], ["OMIM", 649], ["300717", 654], [",", 660], ["300718", 662], [")", 668], [".", 669], ["The", 671], ["clinical", 675], ["problems", 684], ["of", 693], ["the", 696], ["patient", 700], ["reported", 708], ["here", 717], ["comprised", 722], ["severe", 732], ["intellectual", 739], ["disability", 752], [",", 762], ["absent", 764], ["speech", 771], [",", 777], ["ataxia", 779], [",", 785], ["epilepsy", 787], [",", 795], ["and", 797], ["gastroesophageal", 801], ["reflux", 818], [",", 824], ["and", 826], ["could", 830], ["mostly", 836], ["be", 843], ["attributed", 846], ["to", 857], ["SLC9A6", 860], ["insufficiency", 867], [".", 880], ["In", 882], ["contrast", 885], ["to", 894], ["the", 897], ["majority", 901], ["of", 910], ["reported", 913], ["Christianson", 922], ["syndrome", 935], ["patients", 944], ["who", 953], ["were", 957], ["microcephalic", 962], [",", 975], ["this", 977], ["patient", 982], ["was", 990], ["normocephalic", 994], [",", 1007], ["but", 1009], ["his", 1013], ["head", 1017], ["circumference", 1022], ["had", 1036], ["decelerated", 1040], ["from", 1052], ["the", 1057], ["50th", 1061], ["centile", 1066], ["at", 1074], ["birth", 1077], ["to", 1083], ["the", 1086], ["25th", 1090], ["centile", 1095], ["at", 1103], ["the", 1106], ["age", 1110], ["of", 1114], ["2", 1117], ["\u00b2/\u00b9\u00b2", 1119], ["years", 1124], [".", 1129], ["Muscle", 1131], ["problems", 1138], ["due", 1147], ["to", 1151], ["the", 1154], ["FHL1", 1158], ["deletion", 1163], ["are", 1172], ["not", 1176], ["to", 1180], ["be", 1183], ["expected", 1186], ["before", 1195], ["late", 1202], ["childhood", 1207], [",", 1216], ["which", 1218], ["is", 1224], ["the", 1227], ["earliest", 1231], ["age", 1240], ["of", 1244], ["onset", 1247], ["for", 1253], ["FHL1", 1257], ["associated", 1262], ["Emery", 1273], ["-", 1278], ["Dreifuss", 1279], ["muscular", 1288], ["dystrophy", 1297], [".", 1306], ["This", 1308], ["patient", 1313], ["broadens", 1321], ["the", 1330], ["spectrum", 1334], ["of", 1343], ["SLC9A6", 1346], ["mutations", 1353], ["and", 1363], ["contributes", 1367], ["to", 1379], ["the", 1382], ["clinical", 1386], ["delineation", 1395], ["of", 1407], ["Christianson", 1410], ["syndrome", 1423], [".", 1431], ["This", 1433], ["is", 1438], ["also", 1441], ["the", 1446], ["first", 1450], ["patient", 1456], ["with", 1464], ["a", 1469], ["deletion", 1471], ["affecting", 1480], ["both", 1490], ["SLC9A6", 1495], ["and", 1502], ["the", 1506], ["complete", 1510], ["FHL1", 1519], ["gene", 1524], [".", 1528]]}
{"context": "A monoclonal antibody (mAb) has been produced which reacts with human mitofilin, a mitochondrial inner membrane protein. This mAb immunocaptures its target protein in association with six other proteins, metaxins 1 and 2, SAM50, CHCHD3, CHCHD6 and DnaJC11, respectively. The first three are outer membrane proteins, CHCHD3 has been assigned to the matrix space, and the other two proteins have not been described in mitochondria previously. The functional role of this new complex is uncertain. However, a role in protein import related to maintenance of mitochondrial structure is suggested as mitofilin helps regulate mitochondrial morphology and at least four of the associated proteins (metaxins 1 and 2, SAM50 and CHCHD3) have been implicated in protein import, while DnaJC11 is a chaperone-like protein that may have a similar role.", "qas": [{"question": "What is the localization of the protein encoded by the gene DNAJC11?", "answers": ["mitochondrial inner membrane"], "qid": "8c2a0605602f461d93cb146b331734aa", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["localization", 12], ["of", 25], ["the", 28], ["protein", 32], ["encoded", 40], ["by", 48], ["the", 51], ["gene", 55], ["DNAJC11", 60], ["?", 67]], "detected_answers": [{"text": "mitochondrial inner membrane", "token_spans": [[16, 18]], "char_spans": [[83, 110]]}]}], "context_tokens": [["A", 0], ["monoclonal", 2], ["antibody", 13], ["(", 22], ["mAb", 23], [")", 26], ["has", 28], ["been", 32], ["produced", 37], ["which", 46], ["reacts", 52], ["with", 59], ["human", 64], ["mitofilin", 70], [",", 79], ["a", 81], ["mitochondrial", 83], ["inner", 97], ["membrane", 103], ["protein", 112], [".", 119], ["This", 121], ["mAb", 126], ["immunocaptures", 130], ["its", 145], ["target", 149], ["protein", 156], ["in", 164], ["association", 167], ["with", 179], ["six", 184], ["other", 188], ["proteins", 194], [",", 202], ["metaxins", 204], ["1", 213], ["and", 215], ["2", 219], [",", 220], ["SAM50", 222], [",", 227], ["CHCHD3", 229], [",", 235], ["CHCHD6", 237], ["and", 244], ["DnaJC11", 248], [",", 255], ["respectively", 257], [".", 269], ["The", 271], ["first", 275], ["three", 281], ["are", 287], ["outer", 291], ["membrane", 297], ["proteins", 306], [",", 314], ["CHCHD3", 316], ["has", 323], ["been", 327], ["assigned", 332], ["to", 341], ["the", 344], ["matrix", 348], ["space", 355], [",", 360], ["and", 362], ["the", 366], ["other", 370], ["two", 376], ["proteins", 380], ["have", 389], ["not", 394], ["been", 398], ["described", 403], ["in", 413], ["mitochondria", 416], ["previously", 429], [".", 439], ["The", 441], ["functional", 445], ["role", 456], ["of", 461], ["this", 464], ["new", 469], ["complex", 473], ["is", 481], ["uncertain", 484], [".", 493], ["However", 495], [",", 502], ["a", 504], ["role", 506], ["in", 511], ["protein", 514], ["import", 522], ["related", 529], ["to", 537], ["maintenance", 540], ["of", 552], ["mitochondrial", 555], ["structure", 569], ["is", 579], ["suggested", 582], ["as", 592], ["mitofilin", 595], ["helps", 605], ["regulate", 611], ["mitochondrial", 620], ["morphology", 634], ["and", 645], ["at", 649], ["least", 652], ["four", 658], ["of", 663], ["the", 666], ["associated", 670], ["proteins", 681], ["(", 690], ["metaxins", 691], ["1", 700], ["and", 702], ["2", 706], [",", 707], ["SAM50", 709], ["and", 715], ["CHCHD3", 719], [")", 725], ["have", 727], ["been", 732], ["implicated", 737], ["in", 748], ["protein", 751], ["import", 759], [",", 765], ["while", 767], ["DnaJC11", 773], ["is", 781], ["a", 784], ["chaperone", 786], ["-", 795], ["like", 796], ["protein", 801], ["that", 809], ["may", 814], ["have", 818], ["a", 823], ["similar", 825], ["role", 833], [".", 837]]}
{"context": "Alzheimer's disease (AD) is the most common cause of dementia in humans. A pathological hallmark in the brain of an AD patient is extracellular amyloid plaques formed by accumulated beta-amyloid protein (Abeta), a metabolic product of amyloid precursor protein (APP). Studies have revealed a strong genetic linkage in the early-onset familial form (<60 years old) of AD. For example, some mutant APPs are transmitted dominantly and are segregated with inheritance of early onset AD. These mutants facilitate Abeta production. The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON)) are examples of these mutants. Selective silencing of these mutant alleles holds therapeutic promise for AD. Here we show that the expression of the mutant APPs was selectively inhibited by RNA interference. The best selectivity was obtained when the mismatches were centrally placed in the antisense strand of small interfering RNAs. Introducing an additional mismatch in the antisense strand may improve the selectivity. The addition of a G at 5' end of the antisense strand may enhance the efficacy of gene silencing by RNA interference. Our results illustrate the guiding principles for selection of targeted sequences to achieve allele-specific silencing. The sequences that are effective to silence APP(SW) and APP(LON) as identified in this study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD development.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "7f2e06512c64492fae5b7778eda5946f", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "AD", "token_spans": [[269, 269], [92, 92], [4, 4], [73, 73], [135, 135], [24, 24]], "char_spans": [[1472, 1473], [479, 480], [21, 22], [367, 368], [702, 703], [116, 117]]}]}], "context_tokens": [["Alzheimer", 0], ["'s", 9], ["disease", 12], ["(", 20], ["AD", 21], [")", 23], ["is", 25], ["the", 28], ["most", 32], ["common", 37], ["cause", 44], ["of", 50], ["dementia", 53], ["in", 62], ["humans", 65], [".", 71], ["A", 73], ["pathological", 75], ["hallmark", 88], ["in", 97], ["the", 100], ["brain", 104], ["of", 110], ["an", 113], ["AD", 116], ["patient", 119], ["is", 127], ["extracellular", 130], ["amyloid", 144], ["plaques", 152], ["formed", 160], ["by", 167], ["accumulated", 170], ["beta", 182], ["-", 186], ["amyloid", 187], ["protein", 195], ["(", 203], ["Abeta", 204], [")", 209], [",", 210], ["a", 212], ["metabolic", 214], ["product", 224], ["of", 232], ["amyloid", 235], ["precursor", 243], ["protein", 253], ["(", 261], ["APP", 262], [")", 265], [".", 266], ["Studies", 268], ["have", 276], ["revealed", 281], ["a", 290], ["strong", 292], ["genetic", 299], ["linkage", 307], ["in", 315], ["the", 318], ["early", 322], ["-", 327], ["onset", 328], ["familial", 334], ["form", 343], ["(", 348], ["<", 349], ["60", 350], ["years", 353], ["old", 359], [")", 362], ["of", 364], ["AD", 367], [".", 369], ["For", 371], ["example", 375], [",", 382], ["some", 384], ["mutant", 389], ["APPs", 396], ["are", 401], ["transmitted", 405], ["dominantly", 417], ["and", 428], ["are", 432], ["segregated", 436], ["with", 447], ["inheritance", 452], ["of", 464], ["early", 467], ["onset", 473], ["AD", 479], [".", 481], ["These", 483], ["mutants", 489], ["facilitate", 497], ["Abeta", 508], ["production", 514], [".", 524], ["The", 526], ["\"", 530], ["Swedish", 531], ["\"", 538], ["mutations", 540], ["(", 550], ["APP(SW", 551], [")", 557], [")", 558], ["and", 560], ["the", 564], ["\"", 568], ["London", 569], ["\"", 575], ["mutation", 577], ["(", 586], ["APP(LON", 587], [")", 594], [")", 595], ["are", 597], ["examples", 601], ["of", 610], ["these", 613], ["mutants", 619], [".", 626], ["Selective", 628], ["silencing", 638], ["of", 648], ["these", 651], ["mutant", 657], ["alleles", 664], ["holds", 672], ["therapeutic", 678], ["promise", 690], ["for", 698], ["AD", 702], [".", 704], ["Here", 706], ["we", 711], ["show", 714], ["that", 719], ["the", 724], ["expression", 728], ["of", 739], ["the", 742], ["mutant", 746], ["APPs", 753], ["was", 758], ["selectively", 762], ["inhibited", 774], ["by", 784], ["RNA", 787], ["interference", 791], [".", 803], ["The", 805], ["best", 809], ["selectivity", 814], ["was", 826], ["obtained", 830], ["when", 839], ["the", 844], ["mismatches", 848], ["were", 859], ["centrally", 864], ["placed", 874], ["in", 881], ["the", 884], ["antisense", 888], ["strand", 898], ["of", 905], ["small", 908], ["interfering", 914], ["RNAs", 926], [".", 930], ["Introducing", 932], ["an", 944], ["additional", 947], ["mismatch", 958], ["in", 967], ["the", 970], ["antisense", 974], ["strand", 984], ["may", 991], ["improve", 995], ["the", 1003], ["selectivity", 1007], [".", 1018], ["The", 1020], ["addition", 1024], ["of", 1033], ["a", 1036], ["G", 1038], ["at", 1040], ["5", 1043], ["'", 1044], ["end", 1046], ["of", 1050], ["the", 1053], ["antisense", 1057], ["strand", 1067], ["may", 1074], ["enhance", 1078], ["the", 1086], ["efficacy", 1090], ["of", 1099], ["gene", 1102], ["silencing", 1107], ["by", 1117], ["RNA", 1120], ["interference", 1124], [".", 1136], ["Our", 1138], ["results", 1142], ["illustrate", 1150], ["the", 1161], ["guiding", 1165], ["principles", 1173], ["for", 1184], ["selection", 1188], ["of", 1198], ["targeted", 1201], ["sequences", 1210], ["to", 1220], ["achieve", 1223], ["allele", 1231], ["-", 1237], ["specific", 1238], ["silencing", 1247], [".", 1256], ["The", 1258], ["sequences", 1262], ["that", 1272], ["are", 1277], ["effective", 1281], ["to", 1291], ["silence", 1294], ["APP(SW", 1302], [")", 1308], ["and", 1310], ["APP(LON", 1314], [")", 1321], ["as", 1323], ["identified", 1326], ["in", 1337], ["this", 1340], ["study", 1345], ["may", 1351], ["be", 1355], ["useful", 1358], ["in", 1365], ["both", 1368], ["in", 1373], ["vivo", 1376], ["and", 1381], ["in", 1385], ["vitro", 1388], ["studies", 1394], ["to", 1402], ["investigate", 1405], ["the", 1417], ["pathophysiological", 1421], ["role", 1440], ["of", 1445], ["APP(SW", 1448], [")", 1454], ["and", 1456], ["APP(LON", 1460], [")", 1467], ["in", 1469], ["AD", 1472], ["development", 1475], [".", 1486]]}
{"context": "Secretory phospholipase A2 (sPLA2), which links surfactant catabolism and lung inflammation, is associated with lung stiffness, surfactant dysfunction, and degree of respiratory support in acute respiratory distress syndrome and in some forms of neonatal lung injury. Varespladib potently inhibits sPLA2 in animal models. The authors investigate varespladib ex vivo efficacy in different forms of neonatal lung injury. Bronchoalveolar lavage fluid was obtained from 40 neonates affected by hyaline membrane disease, infections, or meconium aspiration and divided in 4 aliquots added with increasing varespladib or saline. sPLA2 activity, proteins, and albumin were measured. Dilution was corrected with the urea ratio. Varespladib was also tested in vitro against pancreatic sPLA2 mixed with different albumin concentration. Varespladib was able to inhibit sPLA2 in the types of neonatal lung injury investigated. sPLA2 activity was reduced in hyaline membrane disease (P < .0001), infections (P = .003), and meconium aspiration (P = .04) using 40 \u00b5M varespladib; 10 \u00b5M was able to lower enzyme activity (P = .001), with an IC(50) of 87 \u00b5M. An inverse relationship existed between protein level and activity reduction (r = 0.5; P = .029). The activity reduction/protein ratio tended to be higher in hyaline membrane disease. Varespladib efficacy was higher in vitro than in lavage fluids obtained from neonates (P < .001).", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "1aedf35d15b449439a4efb13c4c5ebd0", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[0, 2]], "char_spans": [[0, 25]]}]}], "context_tokens": [["Secretory", 0], ["phospholipase", 10], ["A2", 24], ["(", 27], ["sPLA2", 28], [")", 33], [",", 34], ["which", 36], ["links", 42], ["surfactant", 48], ["catabolism", 59], ["and", 70], ["lung", 74], ["inflammation", 79], [",", 91], ["is", 93], ["associated", 96], ["with", 107], ["lung", 112], ["stiffness", 117], [",", 126], ["surfactant", 128], ["dysfunction", 139], [",", 150], ["and", 152], ["degree", 156], ["of", 163], ["respiratory", 166], ["support", 178], ["in", 186], ["acute", 189], ["respiratory", 195], ["distress", 207], ["syndrome", 216], ["and", 225], ["in", 229], ["some", 232], ["forms", 237], ["of", 243], ["neonatal", 246], ["lung", 255], ["injury", 260], [".", 266], ["Varespladib", 268], ["potently", 280], ["inhibits", 289], ["sPLA2", 298], ["in", 304], ["animal", 307], ["models", 314], [".", 320], ["The", 322], ["authors", 326], ["investigate", 334], ["varespladib", 346], ["ex", 358], ["vivo", 361], ["efficacy", 366], ["in", 375], ["different", 378], ["forms", 388], ["of", 394], ["neonatal", 397], ["lung", 406], ["injury", 411], [".", 417], ["Bronchoalveolar", 419], ["lavage", 435], ["fluid", 442], ["was", 448], ["obtained", 452], ["from", 461], ["40", 466], ["neonates", 469], ["affected", 478], ["by", 487], ["hyaline", 490], ["membrane", 498], ["disease", 507], [",", 514], ["infections", 516], [",", 526], ["or", 528], ["meconium", 531], ["aspiration", 540], ["and", 551], ["divided", 555], ["in", 563], ["4", 566], ["aliquots", 568], ["added", 577], ["with", 583], ["increasing", 588], ["varespladib", 599], ["or", 611], ["saline", 614], [".", 620], ["sPLA2", 622], ["activity", 628], [",", 636], ["proteins", 638], [",", 646], ["and", 648], ["albumin", 652], ["were", 660], ["measured", 665], [".", 673], ["Dilution", 675], ["was", 684], ["corrected", 688], ["with", 698], ["the", 703], ["urea", 707], ["ratio", 712], [".", 717], ["Varespladib", 719], ["was", 731], ["also", 735], ["tested", 740], ["in", 747], ["vitro", 750], ["against", 756], ["pancreatic", 764], ["sPLA2", 775], ["mixed", 781], ["with", 787], ["different", 792], ["albumin", 802], ["concentration", 810], [".", 823], ["Varespladib", 825], ["was", 837], ["able", 841], ["to", 846], ["inhibit", 849], ["sPLA2", 857], ["in", 863], ["the", 866], ["types", 870], ["of", 876], ["neonatal", 879], ["lung", 888], ["injury", 893], ["investigated", 900], [".", 912], ["sPLA2", 914], ["activity", 920], ["was", 929], ["reduced", 933], ["in", 941], ["hyaline", 944], ["membrane", 952], ["disease", 961], ["(", 969], ["P", 970], ["<", 972], [".0001", 974], [")", 979], [",", 980], ["infections", 982], ["(", 993], ["P", 994], ["=", 996], [".003", 998], [")", 1002], [",", 1003], ["and", 1005], ["meconium", 1009], ["aspiration", 1018], ["(", 1029], ["P", 1030], ["=", 1032], [".04", 1034], [")", 1037], ["using", 1039], ["40", 1045], ["\u00b5M", 1048], ["varespladib", 1051], [";", 1062], ["10", 1064], ["\u00b5M", 1067], ["was", 1070], ["able", 1074], ["to", 1079], ["lower", 1082], ["enzyme", 1088], ["activity", 1095], ["(", 1104], ["P", 1105], ["=", 1107], [".001", 1109], [")", 1113], [",", 1114], ["with", 1116], ["an", 1121], ["IC(50", 1124], [")", 1129], ["of", 1131], ["87", 1134], ["\u00b5M.", 1137], ["An", 1141], ["inverse", 1144], ["relationship", 1152], ["existed", 1165], ["between", 1173], ["protein", 1181], ["level", 1189], ["and", 1195], ["activity", 1199], ["reduction", 1208], ["(", 1218], ["r", 1219], ["=", 1221], ["0.5", 1223], [";", 1226], ["P", 1228], ["=", 1230], [".029", 1232], [")", 1236], [".", 1237], ["The", 1239], ["activity", 1243], ["reduction", 1252], ["/", 1261], ["protein", 1262], ["ratio", 1270], ["tended", 1276], ["to", 1283], ["be", 1286], ["higher", 1289], ["in", 1296], ["hyaline", 1299], ["membrane", 1307], ["disease", 1316], [".", 1323], ["Varespladib", 1325], ["efficacy", 1337], ["was", 1346], ["higher", 1350], ["in", 1357], ["vitro", 1360], ["than", 1366], ["in", 1371], ["lavage", 1374], ["fluids", 1381], ["obtained", 1388], ["from", 1397], ["neonates", 1402], ["(", 1411], ["P", 1412], ["<", 1414], [".001", 1416], [")", 1420], [".", 1421]]}
{"context": "Parkinson's disease (PD) is one of many neurodegenerative diseases that are characterized by amyloid fibril formation. Alpha-synuclein is a primary component of the fibrillar neuronal inclusions, known as Lewy bodies, that are diagnostic of PD. In addition, the alpha-synuclein gene is linked to familial PD. Fibril formation by alpha-synuclein proceeds via discrete beta-sheet-rich oligomers, or protofibrils, that are consumed as fibrils grow. Both FPD mutations accelerate formation of protofibrils, suggesting that these intermediates, rather than the fibril product, trigger neuronal loss. In idiopathic PD, other factors may be responsible for accelerating protofibril formation by wild-type alpha-synuclein. One possible factor could be molecular crowding in the neuronal cytoplasm. We demonstrate here that crowding using inert polymers significantly reduced the lag time for protofibril formation and the conversion of the protofibril to the fibril, but did not affect the morphology of either species. Physiologically realistic changes in the degree of in vitro crowding have significant kinetic consequences. Thus, nonspecific changes in the total cytoplasmic protein concentration, induced by cell volume changes and/or altered protein degradation, could promote formation of and stabilize the alpha-synuclein protofibril.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "7206b07769574e8793fa79da4f2aab29", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[124, 126], [20, 22], [61, 63], [48, 50], [219, 221]], "char_spans": [[698, 712], [119, 133], [329, 343], [262, 276], [1306, 1320]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["one", 28], ["of", 32], ["many", 35], ["neurodegenerative", 40], ["diseases", 58], ["that", 67], ["are", 72], ["characterized", 76], ["by", 90], ["amyloid", 93], ["fibril", 101], ["formation", 108], [".", 117], ["Alpha", 119], ["-", 124], ["synuclein", 125], ["is", 135], ["a", 138], ["primary", 140], ["component", 148], ["of", 158], ["the", 161], ["fibrillar", 165], ["neuronal", 175], ["inclusions", 184], [",", 194], ["known", 196], ["as", 202], ["Lewy", 205], ["bodies", 210], [",", 216], ["that", 218], ["are", 223], ["diagnostic", 227], ["of", 238], ["PD", 241], [".", 243], ["In", 245], ["addition", 248], [",", 256], ["the", 258], ["alpha", 262], ["-", 267], ["synuclein", 268], ["gene", 278], ["is", 283], ["linked", 286], ["to", 293], ["familial", 296], ["PD", 305], [".", 307], ["Fibril", 309], ["formation", 316], ["by", 326], ["alpha", 329], ["-", 334], ["synuclein", 335], ["proceeds", 345], ["via", 354], ["discrete", 358], ["beta", 367], ["-", 371], ["sheet", 372], ["-", 377], ["rich", 378], ["oligomers", 383], [",", 392], ["or", 394], ["protofibrils", 397], [",", 409], ["that", 411], ["are", 416], ["consumed", 420], ["as", 429], ["fibrils", 432], ["grow", 440], [".", 444], ["Both", 446], ["FPD", 451], ["mutations", 455], ["accelerate", 465], ["formation", 476], ["of", 486], ["protofibrils", 489], [",", 501], ["suggesting", 503], ["that", 514], ["these", 519], ["intermediates", 525], [",", 538], ["rather", 540], ["than", 547], ["the", 552], ["fibril", 556], ["product", 563], [",", 570], ["trigger", 572], ["neuronal", 580], ["loss", 589], [".", 593], ["In", 595], ["idiopathic", 598], ["PD", 609], [",", 611], ["other", 613], ["factors", 619], ["may", 627], ["be", 631], ["responsible", 634], ["for", 646], ["accelerating", 650], ["protofibril", 663], ["formation", 675], ["by", 685], ["wild", 688], ["-", 692], ["type", 693], ["alpha", 698], ["-", 703], ["synuclein", 704], [".", 713], ["One", 715], ["possible", 719], ["factor", 728], ["could", 735], ["be", 741], ["molecular", 744], ["crowding", 754], ["in", 763], ["the", 766], ["neuronal", 770], ["cytoplasm", 779], [".", 788], ["We", 790], ["demonstrate", 793], ["here", 805], ["that", 810], ["crowding", 815], ["using", 824], ["inert", 830], ["polymers", 836], ["significantly", 845], ["reduced", 859], ["the", 867], ["lag", 871], ["time", 875], ["for", 880], ["protofibril", 884], ["formation", 896], ["and", 906], ["the", 910], ["conversion", 914], ["of", 925], ["the", 928], ["protofibril", 932], ["to", 944], ["the", 947], ["fibril", 951], [",", 957], ["but", 959], ["did", 963], ["not", 967], ["affect", 971], ["the", 978], ["morphology", 982], ["of", 993], ["either", 996], ["species", 1003], [".", 1010], ["Physiologically", 1012], ["realistic", 1028], ["changes", 1038], ["in", 1046], ["the", 1049], ["degree", 1053], ["of", 1060], ["in", 1063], ["vitro", 1066], ["crowding", 1072], ["have", 1081], ["significant", 1086], ["kinetic", 1098], ["consequences", 1106], [".", 1118], ["Thus", 1120], [",", 1124], ["nonspecific", 1126], ["changes", 1138], ["in", 1146], ["the", 1149], ["total", 1153], ["cytoplasmic", 1159], ["protein", 1171], ["concentration", 1179], [",", 1192], ["induced", 1194], ["by", 1202], ["cell", 1205], ["volume", 1210], ["changes", 1217], ["and/or", 1225], ["altered", 1232], ["protein", 1240], ["degradation", 1248], [",", 1259], ["could", 1261], ["promote", 1267], ["formation", 1275], ["of", 1285], ["and", 1288], ["stabilize", 1292], ["the", 1302], ["alpha", 1306], ["-", 1311], ["synuclein", 1312], ["protofibril", 1322], [".", 1333]]}
{"context": "The purpose of this study was to describe the technique and usefulness of ultrasound-guided intrasheath injection of triamcinolone in the treatment of de Quervain's disease (dQD). Our study was retrospective in design. Seventy-one wrists of 62 patients who were treated with an ultrasound-guided triamcinolone injection for dQD were included. A literature search was performed to compare our results. In the literature we found supportive evidence that accurate injection of triamcinolone in the first dorsal compartment of the wrist is important for a good outcome. In this retrospective study we found that treatment with ultrasound-guided injections of triamcinolone is both safe and effective. After two injections, 91% of the patients had good long-term results, which is a higher cure rate than found in most other studies. Furthermore, we found that Finkelstein's test can give a false positive result. Therefore, ultrasound should not only be considered to improve the treatment outcome, but can also be useful as a diagnostic tool in the management of de Quervain's disease.", "qas": [{"question": "Which disease is diagnosed using the Finkelstein's test?", "answers": ["de Quervain's disease"], "qid": "28c063ee9b8f48c0a4043216a47ce037", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["diagnosed", 17], ["using", 27], ["the", 33], ["Finkelstein", 37], ["'s", 48], ["test", 51], ["?", 55]], "detected_answers": [{"text": "de Quervain's disease", "token_spans": [[190, 193], [24, 27]], "char_spans": [[1061, 1081], [151, 171]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["study", 20], ["was", 26], ["to", 30], ["describe", 33], ["the", 42], ["technique", 46], ["and", 56], ["usefulness", 60], ["of", 71], ["ultrasound", 74], ["-", 84], ["guided", 85], ["intrasheath", 92], ["injection", 104], ["of", 114], ["triamcinolone", 117], ["in", 131], ["the", 134], ["treatment", 138], ["of", 148], ["de", 151], ["Quervain", 154], ["'s", 162], ["disease", 165], ["(", 173], ["dQD", 174], [")", 177], [".", 178], ["Our", 180], ["study", 184], ["was", 190], ["retrospective", 194], ["in", 208], ["design", 211], [".", 217], ["Seventy", 219], ["-", 226], ["one", 227], ["wrists", 231], ["of", 238], ["62", 241], ["patients", 244], ["who", 253], ["were", 257], ["treated", 262], ["with", 270], ["an", 275], ["ultrasound", 278], ["-", 288], ["guided", 289], ["triamcinolone", 296], ["injection", 310], ["for", 320], ["dQD", 324], ["were", 328], ["included", 333], [".", 341], ["A", 343], ["literature", 345], ["search", 356], ["was", 363], ["performed", 367], ["to", 377], ["compare", 380], ["our", 388], ["results", 392], [".", 399], ["In", 401], ["the", 404], ["literature", 408], ["we", 419], ["found", 422], ["supportive", 428], ["evidence", 439], ["that", 448], ["accurate", 453], ["injection", 462], ["of", 472], ["triamcinolone", 475], ["in", 489], ["the", 492], ["first", 496], ["dorsal", 502], ["compartment", 509], ["of", 521], ["the", 524], ["wrist", 528], ["is", 534], ["important", 537], ["for", 547], ["a", 551], ["good", 553], ["outcome", 558], [".", 565], ["In", 567], ["this", 570], ["retrospective", 575], ["study", 589], ["we", 595], ["found", 598], ["that", 604], ["treatment", 609], ["with", 619], ["ultrasound", 624], ["-", 634], ["guided", 635], ["injections", 642], ["of", 653], ["triamcinolone", 656], ["is", 670], ["both", 673], ["safe", 678], ["and", 683], ["effective", 687], [".", 696], ["After", 698], ["two", 704], ["injections", 708], [",", 718], ["91", 720], ["%", 722], ["of", 724], ["the", 727], ["patients", 731], ["had", 740], ["good", 744], ["long", 749], ["-", 753], ["term", 754], ["results", 759], [",", 766], ["which", 768], ["is", 774], ["a", 777], ["higher", 779], ["cure", 786], ["rate", 791], ["than", 796], ["found", 801], ["in", 807], ["most", 810], ["other", 815], ["studies", 821], [".", 828], ["Furthermore", 830], [",", 841], ["we", 843], ["found", 846], ["that", 852], ["Finkelstein", 857], ["'s", 868], ["test", 871], ["can", 876], ["give", 880], ["a", 885], ["false", 887], ["positive", 893], ["result", 902], [".", 908], ["Therefore", 910], [",", 919], ["ultrasound", 921], ["should", 932], ["not", 939], ["only", 943], ["be", 948], ["considered", 951], ["to", 962], ["improve", 965], ["the", 973], ["treatment", 977], ["outcome", 987], [",", 994], ["but", 996], ["can", 1000], ["also", 1004], ["be", 1009], ["useful", 1012], ["as", 1019], ["a", 1022], ["diagnostic", 1024], ["tool", 1035], ["in", 1040], ["the", 1043], ["management", 1047], ["of", 1058], ["de", 1061], ["Quervain", 1064], ["'s", 1072], ["disease", 1075], [".", 1082]]}
{"context": "In this randomized, double-blind, placebo controlled phase 2 study we investigated tanezumab, a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for interstitial cystitis pain. Patients with interstitial cystitis received a single intravenous dose of 200 \u03bcg/kg tanezumab or placebo. Patients recorded daily pain scores (on an 11-point numerical rating scale) 7 days before attending study visits and completed a urinary symptom diary for 3 of those days. Patients also completed the Interstitial Cystitis Symptom Index questionnaire and a global response assessment. The primary end point was change in average daily numerical rating scale pain score from baseline to week 6. Secondary end points included global response assessment, Interstitial Cystitis Symptom Index score, micturition and urgency episode frequency per 24 hours, and mean voided volume per micturition. The incidence of adverse events was also assessed. A total of 34 patients received tanezumab and 30 received placebo. At week 6 tanezumab produced a significant reduction from baseline in average daily pain score vs placebo (treatment difference [LS mean, 90% CI] was -1.4 [-2.2, -0.5]). A significantly higher proportion of patients on tanezumab responded as improved in the global response assessment and tanezumab also significantly reduced urgency episode frequency vs placebo. Tanezumab had no significant effect on Interstitial Cystitis Symptom Index score, micturition frequency or mean voided volume per micturition. The most common adverse events were headache (tanezumab 20.6%, placebo 16.7%) and paresthesia (tanezumab 17.6%, placebo 3.3%). Tanezumab has shown preliminary efficacy in the treatment of pain associated with interstitial cystitis.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "e516230f0c0040adab7360b90e76c7e0", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[24, 26]], "char_spans": [[153, 171]]}]}], "context_tokens": [["In", 0], ["this", 3], ["randomized", 8], [",", 18], ["double", 20], ["-", 26], ["blind", 27], [",", 32], ["placebo", 34], ["controlled", 42], ["phase", 53], ["2", 59], ["study", 61], ["we", 67], ["investigated", 70], ["tanezumab", 83], [",", 92], ["a", 94], ["humanized", 96], ["monoclonal", 106], ["antibody", 117], ["that", 126], ["specifically", 131], ["inhibits", 144], ["nerve", 153], ["growth", 159], ["factor", 166], ["as", 173], ["a", 176], ["treatment", 178], ["for", 188], ["interstitial", 192], ["cystitis", 205], ["pain", 214], [".", 218], ["Patients", 220], ["with", 229], ["interstitial", 234], ["cystitis", 247], ["received", 256], ["a", 265], ["single", 267], ["intravenous", 274], ["dose", 286], ["of", 291], ["200", 294], ["\u03bcg", 298], ["/", 300], ["kg", 301], ["tanezumab", 304], ["or", 314], ["placebo", 317], [".", 324], ["Patients", 326], ["recorded", 335], ["daily", 344], ["pain", 350], ["scores", 355], ["(", 362], ["on", 363], ["an", 366], ["11-point", 369], ["numerical", 378], ["rating", 388], ["scale", 395], [")", 400], ["7", 402], ["days", 404], ["before", 409], ["attending", 416], ["study", 426], ["visits", 432], ["and", 439], ["completed", 443], ["a", 453], ["urinary", 455], ["symptom", 463], ["diary", 471], ["for", 477], ["3", 481], ["of", 483], ["those", 486], ["days", 492], [".", 496], ["Patients", 498], ["also", 507], ["completed", 512], ["the", 522], ["Interstitial", 526], ["Cystitis", 539], ["Symptom", 548], ["Index", 556], ["questionnaire", 562], ["and", 576], ["a", 580], ["global", 582], ["response", 589], ["assessment", 598], [".", 608], ["The", 610], ["primary", 614], ["end", 622], ["point", 626], ["was", 632], ["change", 636], ["in", 643], ["average", 646], ["daily", 654], ["numerical", 660], ["rating", 670], ["scale", 677], ["pain", 683], ["score", 688], ["from", 694], ["baseline", 699], ["to", 708], ["week", 711], ["6", 716], [".", 717], ["Secondary", 719], ["end", 729], ["points", 733], ["included", 740], ["global", 749], ["response", 756], ["assessment", 765], [",", 775], ["Interstitial", 777], ["Cystitis", 790], ["Symptom", 799], ["Index", 807], ["score", 813], [",", 818], ["micturition", 820], ["and", 832], ["urgency", 836], ["episode", 844], ["frequency", 852], ["per", 862], ["24", 866], ["hours", 869], [",", 874], ["and", 876], ["mean", 880], ["voided", 885], ["volume", 892], ["per", 899], ["micturition", 903], [".", 914], ["The", 916], ["incidence", 920], ["of", 930], ["adverse", 933], ["events", 941], ["was", 948], ["also", 952], ["assessed", 957], [".", 965], ["A", 967], ["total", 969], ["of", 975], ["34", 978], ["patients", 981], ["received", 990], ["tanezumab", 999], ["and", 1009], ["30", 1013], ["received", 1016], ["placebo", 1025], [".", 1032], ["At", 1034], ["week", 1037], ["6", 1042], ["tanezumab", 1044], ["produced", 1054], ["a", 1063], ["significant", 1065], ["reduction", 1077], ["from", 1087], ["baseline", 1092], ["in", 1101], ["average", 1104], ["daily", 1112], ["pain", 1118], ["score", 1123], ["vs", 1129], ["placebo", 1132], ["(", 1140], ["treatment", 1141], ["difference", 1151], ["[", 1162], ["LS", 1163], ["mean", 1166], [",", 1170], ["90", 1172], ["%", 1174], ["CI", 1176], ["]", 1178], ["was", 1180], ["-1.4", 1184], ["[", 1189], ["-2.2", 1190], [",", 1194], ["-0.5", 1196], ["]", 1200], [")", 1201], [".", 1202], ["A", 1204], ["significantly", 1206], ["higher", 1220], ["proportion", 1227], ["of", 1238], ["patients", 1241], ["on", 1250], ["tanezumab", 1253], ["responded", 1263], ["as", 1273], ["improved", 1276], ["in", 1285], ["the", 1288], ["global", 1292], ["response", 1299], ["assessment", 1308], ["and", 1319], ["tanezumab", 1323], ["also", 1333], ["significantly", 1338], ["reduced", 1352], ["urgency", 1360], ["episode", 1368], ["frequency", 1376], ["vs", 1386], ["placebo", 1389], [".", 1396], ["Tanezumab", 1398], ["had", 1408], ["no", 1412], ["significant", 1415], ["effect", 1427], ["on", 1434], ["Interstitial", 1437], ["Cystitis", 1450], ["Symptom", 1459], ["Index", 1467], ["score", 1473], [",", 1478], ["micturition", 1480], ["frequency", 1492], ["or", 1502], ["mean", 1505], ["voided", 1510], ["volume", 1517], ["per", 1524], ["micturition", 1528], [".", 1539], ["The", 1541], ["most", 1545], ["common", 1550], ["adverse", 1557], ["events", 1565], ["were", 1572], ["headache", 1577], ["(", 1586], ["tanezumab", 1587], ["20.6", 1597], ["%", 1601], [",", 1602], ["placebo", 1604], ["16.7", 1612], ["%", 1616], [")", 1617], ["and", 1619], ["paresthesia", 1623], ["(", 1635], ["tanezumab", 1636], ["17.6", 1646], ["%", 1650], [",", 1651], ["placebo", 1653], ["3.3", 1661], ["%", 1664], [")", 1665], [".", 1666], ["Tanezumab", 1668], ["has", 1678], ["shown", 1682], ["preliminary", 1688], ["efficacy", 1700], ["in", 1709], ["the", 1712], ["treatment", 1716], ["of", 1726], ["pain", 1729], ["associated", 1734], ["with", 1745], ["interstitial", 1750], ["cystitis", 1763], [".", 1771]]}
{"context": "A case of mosaic Turner's syndrome with a 45,X/46,XX/47,XXX karyotype, who was also a fragile X obligate carrier as the mother of an affected boy, was identified by molecular diagnosis. Complete haplotyping and direct DNA analysis showed that the X chromosome in all metaphases was the normal X. At the age of 57, she is mentally normal. Her external appearance was typical of Turner's syndrome. This report shows that molecular studies in conjunction with cytogenetic analysis can help in the clinical diagnosis of a rare case and can show the uniqueness of a case such as the one here described.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "1fea59437aaa4c8d9584b01338bcf0c7", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[51, 51], [17, 17], [43, 43]], "char_spans": [[293, 294], [94, 94], [247, 247]]}]}], "context_tokens": [["A", 0], ["case", 2], ["of", 7], ["mosaic", 10], ["Turner", 17], ["'s", 23], ["syndrome", 26], ["with", 35], ["a", 40], ["45,X/46,XX/47,XXX", 42], ["karyotype", 60], [",", 69], ["who", 71], ["was", 75], ["also", 79], ["a", 84], ["fragile", 86], ["X", 94], ["obligate", 96], ["carrier", 105], ["as", 113], ["the", 116], ["mother", 120], ["of", 127], ["an", 130], ["affected", 133], ["boy", 142], [",", 145], ["was", 147], ["identified", 151], ["by", 162], ["molecular", 165], ["diagnosis", 175], [".", 184], ["Complete", 186], ["haplotyping", 195], ["and", 207], ["direct", 211], ["DNA", 218], ["analysis", 222], ["showed", 231], ["that", 238], ["the", 243], ["X", 247], ["chromosome", 249], ["in", 260], ["all", 263], ["metaphases", 267], ["was", 278], ["the", 282], ["normal", 286], ["X.", 293], ["At", 296], ["the", 299], ["age", 303], ["of", 307], ["57", 310], [",", 312], ["she", 314], ["is", 318], ["mentally", 321], ["normal", 330], [".", 336], ["Her", 338], ["external", 342], ["appearance", 351], ["was", 362], ["typical", 366], ["of", 374], ["Turner", 377], ["'s", 383], ["syndrome", 386], [".", 394], ["This", 396], ["report", 401], ["shows", 408], ["that", 414], ["molecular", 419], ["studies", 429], ["in", 437], ["conjunction", 440], ["with", 452], ["cytogenetic", 457], ["analysis", 469], ["can", 478], ["help", 482], ["in", 487], ["the", 490], ["clinical", 494], ["diagnosis", 503], ["of", 513], ["a", 516], ["rare", 518], ["case", 523], ["and", 528], ["can", 532], ["show", 536], ["the", 541], ["uniqueness", 545], ["of", 556], ["a", 559], ["case", 561], ["such", 566], ["as", 571], ["the", 574], ["one", 578], ["here", 582], ["described", 587], [".", 596]]}
{"context": "Dopa decarboxylase (DDC), a pyridoxal 5'-phosphate (PLP) enzyme responsible for the biosynthesis of dopamine and serotonin, is involved in Parkinson's disease (PD). PD is a neurodegenerative disease mainly due to a progressive loss of dopamine-producing cells in the midbrain. Co-administration of L-Dopa with peripheral DDC inhibitors (carbidopa or benserazide) is the most effective symptomatic treatment for PD. Although carbidopa and trihydroxybenzylhydrazine (the in vivo hydrolysis product of benserazide) are both powerful irreversible DDC inhibitors, they are not selective because they irreversibly bind to free PLP and PLP-enzymes, thus inducing diverse side effects. Therefore, the main goals of this study were (a) to use virtual screening to identify potential human DDC inhibitors and (b) to evaluate the reliability of our virtual-screening (VS) protocol by experimentally testing the \"in vitro\" activity of selected molecules. Starting from the crystal structure of the DDC-carbidopa complex, a new VS protocol, integrating pharmacophore searches and molecular docking, was developed. Analysis of 15 selected compounds, obtained by filtering the public ZINC database, yielded two molecules that bind to the active site of human DDC and behave as competitive inhibitors with K(i) values \u226510 \u00b5M. By performing in silico similarity search on the latter compounds followed by a substructure search using the core of the most active compound we identified several competitive inhibitors of human DDC with K(i) values in the low micromolar range, unable to bind free PLP, and predicted to not cross the blood-brain barrier. The most potent inhibitor with a K(i) value of 500 nM represents a new lead compound, targeting human DDC, that may be the basis for lead optimization in the development of new DDC inhibitors. To our knowledge, a similar approach has not been reported yet in the field of DDC inhibitors discovery.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "d11256fd28f844698bd688152f464ae5", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[56, 58]], "char_spans": [[298, 303]]}]}], "context_tokens": [["Dopa", 0], ["decarboxylase", 5], ["(", 19], ["DDC", 20], [")", 23], [",", 24], ["a", 26], ["pyridoxal", 28], ["5'-phosphate", 38], ["(", 51], ["PLP", 52], [")", 55], ["enzyme", 57], ["responsible", 64], ["for", 76], ["the", 80], ["biosynthesis", 84], ["of", 97], ["dopamine", 100], ["and", 109], ["serotonin", 113], [",", 122], ["is", 124], ["involved", 127], ["in", 136], ["Parkinson", 139], ["'s", 148], ["disease", 151], ["(", 159], ["PD", 160], [")", 162], [".", 163], ["PD", 165], ["is", 168], ["a", 171], ["neurodegenerative", 173], ["disease", 191], ["mainly", 199], ["due", 206], ["to", 210], ["a", 213], ["progressive", 215], ["loss", 227], ["of", 232], ["dopamine", 235], ["-", 243], ["producing", 244], ["cells", 254], ["in", 260], ["the", 263], ["midbrain", 267], [".", 275], ["Co", 277], ["-", 279], ["administration", 280], ["of", 295], ["L", 298], ["-", 299], ["Dopa", 300], ["with", 305], ["peripheral", 310], ["DDC", 321], ["inhibitors", 325], ["(", 336], ["carbidopa", 337], ["or", 347], ["benserazide", 350], [")", 361], ["is", 363], ["the", 366], ["most", 370], ["effective", 375], ["symptomatic", 385], ["treatment", 397], ["for", 407], ["PD", 411], [".", 413], ["Although", 415], ["carbidopa", 424], ["and", 434], ["trihydroxybenzylhydrazine", 438], ["(", 464], ["the", 465], ["in", 469], ["vivo", 472], ["hydrolysis", 477], ["product", 488], ["of", 496], ["benserazide", 499], [")", 510], ["are", 512], ["both", 516], ["powerful", 521], ["irreversible", 530], ["DDC", 543], ["inhibitors", 547], [",", 557], ["they", 559], ["are", 564], ["not", 568], ["selective", 572], ["because", 582], ["they", 590], ["irreversibly", 595], ["bind", 608], ["to", 613], ["free", 616], ["PLP", 621], ["and", 625], ["PLP", 629], ["-", 632], ["enzymes", 633], [",", 640], ["thus", 642], ["inducing", 647], ["diverse", 656], ["side", 664], ["effects", 669], [".", 676], ["Therefore", 678], [",", 687], ["the", 689], ["main", 693], ["goals", 698], ["of", 704], ["this", 707], ["study", 712], ["were", 718], ["(", 723], ["a", 724], [")", 725], ["to", 727], ["use", 730], ["virtual", 734], ["screening", 742], ["to", 752], ["identify", 755], ["potential", 764], ["human", 774], ["DDC", 780], ["inhibitors", 784], ["and", 795], ["(", 799], ["b", 800], [")", 801], ["to", 803], ["evaluate", 806], ["the", 815], ["reliability", 819], ["of", 831], ["our", 834], ["virtual", 838], ["-", 845], ["screening", 846], ["(", 856], ["VS", 857], [")", 859], ["protocol", 861], ["by", 870], ["experimentally", 873], ["testing", 888], ["the", 896], ["\"", 900], ["in", 901], ["vitro", 904], ["\"", 909], ["activity", 911], ["of", 920], ["selected", 923], ["molecules", 932], [".", 941], ["Starting", 943], ["from", 952], ["the", 957], ["crystal", 961], ["structure", 969], ["of", 979], ["the", 982], ["DDC", 986], ["-", 989], ["carbidopa", 990], ["complex", 1000], [",", 1007], ["a", 1009], ["new", 1011], ["VS", 1015], ["protocol", 1018], [",", 1026], ["integrating", 1028], ["pharmacophore", 1040], ["searches", 1054], ["and", 1063], ["molecular", 1067], ["docking", 1077], [",", 1084], ["was", 1086], ["developed", 1090], [".", 1099], ["Analysis", 1101], ["of", 1110], ["15", 1113], ["selected", 1116], ["compounds", 1125], [",", 1134], ["obtained", 1136], ["by", 1145], ["filtering", 1148], ["the", 1158], ["public", 1162], ["ZINC", 1169], ["database", 1174], [",", 1182], ["yielded", 1184], ["two", 1192], ["molecules", 1196], ["that", 1206], ["bind", 1211], ["to", 1216], ["the", 1219], ["active", 1223], ["site", 1230], ["of", 1235], ["human", 1238], ["DDC", 1244], ["and", 1248], ["behave", 1252], ["as", 1259], ["competitive", 1262], ["inhibitors", 1274], ["with", 1285], ["K(i", 1290], [")", 1293], ["values", 1295], ["\u226510", 1302], ["\u00b5M.", 1306], ["By", 1310], ["performing", 1313], ["in", 1324], ["silico", 1327], ["similarity", 1334], ["search", 1345], ["on", 1352], ["the", 1355], ["latter", 1359], ["compounds", 1366], ["followed", 1376], ["by", 1385], ["a", 1388], ["substructure", 1390], ["search", 1403], ["using", 1410], ["the", 1416], ["core", 1420], ["of", 1425], ["the", 1428], ["most", 1432], ["active", 1437], ["compound", 1444], ["we", 1453], ["identified", 1456], ["several", 1467], ["competitive", 1475], ["inhibitors", 1487], ["of", 1498], ["human", 1501], ["DDC", 1507], ["with", 1511], ["K(i", 1516], [")", 1519], ["values", 1521], ["in", 1528], ["the", 1531], ["low", 1535], ["micromolar", 1539], ["range", 1550], [",", 1555], ["unable", 1557], ["to", 1564], ["bind", 1567], ["free", 1572], ["PLP", 1577], [",", 1580], ["and", 1582], ["predicted", 1586], ["to", 1596], ["not", 1599], ["cross", 1603], ["the", 1609], ["blood", 1613], ["-", 1618], ["brain", 1619], ["barrier", 1625], [".", 1632], ["The", 1634], ["most", 1638], ["potent", 1643], ["inhibitor", 1650], ["with", 1660], ["a", 1665], ["K(i", 1667], [")", 1670], ["value", 1672], ["of", 1678], ["500", 1681], ["nM", 1685], ["represents", 1688], ["a", 1699], ["new", 1701], ["lead", 1705], ["compound", 1710], [",", 1718], ["targeting", 1720], ["human", 1730], ["DDC", 1736], [",", 1739], ["that", 1741], ["may", 1746], ["be", 1750], ["the", 1753], ["basis", 1757], ["for", 1763], ["lead", 1767], ["optimization", 1772], ["in", 1785], ["the", 1788], ["development", 1792], ["of", 1804], ["new", 1807], ["DDC", 1811], ["inhibitors", 1815], [".", 1825], ["To", 1827], ["our", 1830], ["knowledge", 1834], [",", 1843], ["a", 1845], ["similar", 1847], ["approach", 1855], ["has", 1864], ["not", 1868], ["been", 1872], ["reported", 1877], ["yet", 1886], ["in", 1890], ["the", 1893], ["field", 1897], ["of", 1903], ["DDC", 1906], ["inhibitors", 1910], ["discovery", 1921], [".", 1930]]}
{"context": "Nestin is an intermediate filament protein expressed in neuroepithelial stem cells during development and it is later replaced by cell specific neuronal or glial filaments. Nevertheless, nestin\u207a cells remain within adult tissues and they can be regarded as potential neural stem cell (NSC). Nestin\u207a cells have been detected in Schwann cells related with sensory corpuscles of rodent and they have been demonstrated to be NSC. We have investigated the existence of nestin\u207a in human cutaneous cells Meissner and Pacinian corpuscles through the use of immunohistochemistry techniques and in situ hybridization. S100 protein (also regarded as a marker for NSC) and vimentin (the intermediate filament of mature Schwann cells in sensory corpuscles) were also investigated. The results show that the adult human cutaneous sensory Meissner and Pacinian corpuscles contains a small population of Schwann-related cells (vimentin\u207a) which on the basis of their basic immunohistochemical characteristics (S100 protein\u207a, nestin\u207a) can be potential NSCs. Cells sharing identical immunohistochemical profile were also found in the close vicinity of Meissner corpuscles. Because their localization they are easily accessible and may represent a peripheral niche of NSC to be used for therapeutic goals.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "5545d0766eda451eb3ef4f3e3ac2706e", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[0, 0]], "char_spans": [[0, 5]]}]}], "context_tokens": [["Nestin", 0], ["is", 7], ["an", 10], ["intermediate", 13], ["filament", 26], ["protein", 35], ["expressed", 43], ["in", 53], ["neuroepithelial", 56], ["stem", 72], ["cells", 77], ["during", 83], ["development", 90], ["and", 102], ["it", 106], ["is", 109], ["later", 112], ["replaced", 118], ["by", 127], ["cell", 130], ["specific", 135], ["neuronal", 144], ["or", 153], ["glial", 156], ["filaments", 162], [".", 171], ["Nevertheless", 173], [",", 185], ["nestin\u207a", 187], ["cells", 195], ["remain", 201], ["within", 208], ["adult", 215], ["tissues", 221], ["and", 229], ["they", 233], ["can", 238], ["be", 242], ["regarded", 245], ["as", 254], ["potential", 257], ["neural", 267], ["stem", 274], ["cell", 279], ["(", 284], ["NSC", 285], [")", 288], [".", 289], ["Nestin\u207a", 291], ["cells", 299], ["have", 305], ["been", 310], ["detected", 315], ["in", 324], ["Schwann", 327], ["cells", 335], ["related", 341], ["with", 349], ["sensory", 354], ["corpuscles", 362], ["of", 373], ["rodent", 376], ["and", 383], ["they", 387], ["have", 392], ["been", 397], ["demonstrated", 402], ["to", 415], ["be", 418], ["NSC", 421], [".", 424], ["We", 426], ["have", 429], ["investigated", 434], ["the", 447], ["existence", 451], ["of", 461], ["nestin\u207a", 464], ["in", 472], ["human", 475], ["cutaneous", 481], ["cells", 491], ["Meissner", 497], ["and", 506], ["Pacinian", 510], ["corpuscles", 519], ["through", 530], ["the", 538], ["use", 542], ["of", 546], ["immunohistochemistry", 549], ["techniques", 570], ["and", 581], ["in", 585], ["situ", 588], ["hybridization", 593], [".", 606], ["S100", 608], ["protein", 613], ["(", 621], ["also", 622], ["regarded", 627], ["as", 636], ["a", 639], ["marker", 641], ["for", 648], ["NSC", 652], [")", 655], ["and", 657], ["vimentin", 661], ["(", 670], ["the", 671], ["intermediate", 675], ["filament", 688], ["of", 697], ["mature", 700], ["Schwann", 707], ["cells", 715], ["in", 721], ["sensory", 724], ["corpuscles", 732], [")", 742], ["were", 744], ["also", 749], ["investigated", 754], [".", 766], ["The", 768], ["results", 772], ["show", 780], ["that", 785], ["the", 790], ["adult", 794], ["human", 800], ["cutaneous", 806], ["sensory", 816], ["Meissner", 824], ["and", 833], ["Pacinian", 837], ["corpuscles", 846], ["contains", 857], ["a", 866], ["small", 868], ["population", 874], ["of", 885], ["Schwann", 888], ["-", 895], ["related", 896], ["cells", 904], ["(", 910], ["vimentin\u207a", 911], [")", 920], ["which", 922], ["on", 928], ["the", 931], ["basis", 935], ["of", 941], ["their", 944], ["basic", 950], ["immunohistochemical", 956], ["characteristics", 976], ["(", 992], ["S100", 993], ["protein\u207a", 998], [",", 1006], ["nestin\u207a", 1008], [")", 1015], ["can", 1017], ["be", 1021], ["potential", 1024], ["NSCs", 1034], [".", 1038], ["Cells", 1040], ["sharing", 1046], ["identical", 1054], ["immunohistochemical", 1064], ["profile", 1084], ["were", 1092], ["also", 1097], ["found", 1102], ["in", 1108], ["the", 1111], ["close", 1115], ["vicinity", 1121], ["of", 1130], ["Meissner", 1133], ["corpuscles", 1142], [".", 1152], ["Because", 1154], ["their", 1162], ["localization", 1168], ["they", 1181], ["are", 1186], ["easily", 1190], ["accessible", 1197], ["and", 1208], ["may", 1212], ["represent", 1216], ["a", 1226], ["peripheral", 1228], ["niche", 1239], ["of", 1245], ["NSC", 1248], ["to", 1252], ["be", 1255], ["used", 1258], ["for", 1263], ["therapeutic", 1267], ["goals", 1279], [".", 1284]]}
{"context": "Since it is unknown whether \u03b2-lactam antimicrobial agents can be used effectively against borderline oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MICs \u22654 mg/L, the in vitro bactericidal activity and pharmacodynamic effect of oxacillin against clinical BORSA isolates was evaluated. Time-kill experiments with oxacillin were performed and the results compared with those obtained with vancomycin, daptomycin and linezolid against BORSA with oxacillin MICs \u22654 mg/L and BORSA with oxacillin MICs \u22642 mg/L. Furthermore, the effect of \u03b2-lactamase production and plasmid profile analysis were taken into account to clarify responses to oxacillin. Oxacillin killing activity was attenuated against BORSA compared with ATCC 29213 since the pharmacodynamic parameters revealed that the potency of oxacillin was markedly reduced (c. ten-fold) against BORSA with oxacillin MICs \u22654 mg/L. pBORa53-like plasmid-containing BORSA with oxacillin MICs \u22642 mg/L showed markedly more regrowth. In conclusion, oxacillin was non-effective in the eradication of either (i) BORSA with oxacillin MICs \u22654 mg/L or (ii) \u03b2-lactamase-hyperproducing BORSA (MICs \u22642 mg/L). Further investigation into \u03b2-lactam dosing strategies against different BORSA strains is warranted in order to avoid possible therapy failure.", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "4da97c18b61b4722ba0a7e536831f947", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[15, 20]], "char_spans": [[90, 141]]}]}], "context_tokens": [["Since", 0], ["it", 6], ["is", 9], ["unknown", 12], ["whether", 20], ["\u03b2", 28], ["-", 29], ["lactam", 30], ["antimicrobial", 37], ["agents", 51], ["can", 58], ["be", 62], ["used", 65], ["effectively", 70], ["against", 82], ["borderline", 90], ["oxacillin", 101], ["-", 110], ["resistant", 111], ["Staphylococcus", 121], ["aureus", 136], ["(", 143], ["BORSA", 144], [")", 149], ["with", 151], ["oxacillin", 156], ["MICs", 166], ["\u22654", 171], ["mg", 174], ["/", 176], ["L", 177], [",", 178], ["the", 180], ["in", 184], ["vitro", 187], ["bactericidal", 193], ["activity", 206], ["and", 215], ["pharmacodynamic", 219], ["effect", 235], ["of", 242], ["oxacillin", 245], ["against", 255], ["clinical", 263], ["BORSA", 272], ["isolates", 278], ["was", 287], ["evaluated", 291], [".", 300], ["Time", 302], ["-", 306], ["kill", 307], ["experiments", 312], ["with", 324], ["oxacillin", 329], ["were", 339], ["performed", 344], ["and", 354], ["the", 358], ["results", 362], ["compared", 370], ["with", 379], ["those", 384], ["obtained", 390], ["with", 399], ["vancomycin", 404], [",", 414], ["daptomycin", 416], ["and", 427], ["linezolid", 431], ["against", 441], ["BORSA", 449], ["with", 455], ["oxacillin", 460], ["MICs", 470], ["\u22654", 475], ["mg", 478], ["/", 480], ["L", 481], ["and", 483], ["BORSA", 487], ["with", 493], ["oxacillin", 498], ["MICs", 508], ["\u22642", 513], ["mg", 516], ["/", 518], ["L.", 519], ["Furthermore", 522], [",", 533], ["the", 535], ["effect", 539], ["of", 546], ["\u03b2", 549], ["-", 550], ["lactamase", 551], ["production", 561], ["and", 572], ["plasmid", 576], ["profile", 584], ["analysis", 592], ["were", 601], ["taken", 606], ["into", 612], ["account", 617], ["to", 625], ["clarify", 628], ["responses", 636], ["to", 646], ["oxacillin", 649], [".", 658], ["Oxacillin", 660], ["killing", 670], ["activity", 678], ["was", 687], ["attenuated", 691], ["against", 702], ["BORSA", 710], ["compared", 716], ["with", 725], ["ATCC", 730], ["29213", 735], ["since", 741], ["the", 747], ["pharmacodynamic", 751], ["parameters", 767], ["revealed", 778], ["that", 787], ["the", 792], ["potency", 796], ["of", 804], ["oxacillin", 807], ["was", 817], ["markedly", 821], ["reduced", 830], ["(", 838], ["c.", 839], ["ten", 842], ["-", 845], ["fold", 846], [")", 850], ["against", 852], ["BORSA", 860], ["with", 866], ["oxacillin", 871], ["MICs", 881], ["\u22654", 886], ["mg", 889], ["/", 891], ["L.", 892], ["pBORa53-like", 895], ["plasmid", 908], ["-", 915], ["containing", 916], ["BORSA", 927], ["with", 933], ["oxacillin", 938], ["MICs", 948], ["\u22642", 953], ["mg", 956], ["/", 958], ["L", 959], ["showed", 961], ["markedly", 968], ["more", 977], ["regrowth", 982], [".", 990], ["In", 992], ["conclusion", 995], [",", 1005], ["oxacillin", 1007], ["was", 1017], ["non", 1021], ["-", 1024], ["effective", 1025], ["in", 1035], ["the", 1038], ["eradication", 1042], ["of", 1054], ["either", 1057], ["(", 1064], ["i", 1065], [")", 1066], ["BORSA", 1068], ["with", 1074], ["oxacillin", 1079], ["MICs", 1089], ["\u22654", 1094], ["mg", 1097], ["/", 1099], ["L", 1100], ["or", 1102], ["(", 1105], ["ii", 1106], [")", 1108], ["\u03b2", 1110], ["-", 1111], ["lactamase", 1112], ["-", 1121], ["hyperproducing", 1122], ["BORSA", 1137], ["(", 1143], ["MICs", 1144], ["\u22642", 1149], ["mg", 1152], ["/", 1154], ["L", 1155], [")", 1156], [".", 1157], ["Further", 1159], ["investigation", 1167], ["into", 1181], ["\u03b2", 1186], ["-", 1187], ["lactam", 1188], ["dosing", 1195], ["strategies", 1202], ["against", 1213], ["different", 1221], ["BORSA", 1231], ["strains", 1237], ["is", 1245], ["warranted", 1248], ["in", 1258], ["order", 1261], ["to", 1267], ["avoid", 1270], ["possible", 1276], ["therapy", 1285], ["failure", 1293], [".", 1300]]}
{"context": "Molecular remodeling in heart failure includes slowing of repolarization, leading to proarrhythmia. To evaluate the effects of Na(+)/Ca(2+) exchanger (NCX) inhibition on repolarization as a novel antiarrhythmic concept in chronic heart failure (CHF). CHF was induced by rapid ventricular pacing in rabbits. Left ventricular function was assessed by echocardiography. Monophasic action potentials (MAPs) showed a prolongation of repolarization in CHF after atrioventricular block and stimulation at different cycle lengths. Sotalol (100 \u03bcM, n = 13) or veratridine (0.5 \u03bcM; n = 15) resulted in a further significant increase in the MAP duration. CHF was associated with an increased dispersion of repolarization, as compared with sotalol-treated (+22 \u00b1 7 ms; P < .05) and veratridine-treated (+20 \u00b1 6 ms; P < .05) sham hearts. In the presence of a low potassium concentration, sotalol and veratridine reproducibly induced early afterdepolarizations (EADs) and polymorphic ventricular tachyarrhythmias (VTs). SEA0400 (1 \u03bcM), a pharmacological inhibitor of NCX, significantly shortened the MAP duration (P < .01) and reduced dispersion (P < .05). It suppressed EAD in 6 of 13 sotalol-treated failing hearts and in 9 of 10 veratridine-treated failing hearts, leading to a reduction in VT (60% in sotalol-treated failing hearts and 83% in veratridine-treated failing hearts). Simulations using a mathematical model showed a reduction in the action potential duration and the number of EADs by the NCX block in all subgroups. In an experimental model of CHF, the acute inhibition of NCX (1) reduces the MAP duration, (2) decreases dispersion of repolarization, and (3) suppresses EAD and VT. Our observations indicate for the first time that pharmacological NCX inhibition increases repolarization reserve and protects against VTs in heart failure.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "71fee14086b941aea68a85c15ba9b987", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[19, 22]], "char_spans": [[127, 148]]}, {"text": "NCX", "token_spans": [[283, 283], [335, 335], [300, 300], [24, 24], [193, 193]], "char_spans": [[1491, 1493], [1751, 1753], [1576, 1578], [151, 153], [1053, 1055]]}]}], "context_tokens": [["Molecular", 0], ["remodeling", 10], ["in", 21], ["heart", 24], ["failure", 30], ["includes", 38], ["slowing", 47], ["of", 55], ["repolarization", 58], [",", 72], ["leading", 74], ["to", 82], ["proarrhythmia", 85], [".", 98], ["To", 100], ["evaluate", 103], ["the", 112], ["effects", 116], ["of", 124], ["Na(+)/Ca(2", 127], ["+", 137], [")", 138], ["exchanger", 140], ["(", 150], ["NCX", 151], [")", 154], ["inhibition", 156], ["on", 167], ["repolarization", 170], ["as", 185], ["a", 188], ["novel", 190], ["antiarrhythmic", 196], ["concept", 211], ["in", 219], ["chronic", 222], ["heart", 230], ["failure", 236], ["(", 244], ["CHF", 245], [")", 248], [".", 249], ["CHF", 251], ["was", 255], ["induced", 259], ["by", 267], ["rapid", 270], ["ventricular", 276], ["pacing", 288], ["in", 295], ["rabbits", 298], [".", 305], ["Left", 307], ["ventricular", 312], ["function", 324], ["was", 333], ["assessed", 337], ["by", 346], ["echocardiography", 349], [".", 365], ["Monophasic", 367], ["action", 378], ["potentials", 385], ["(", 396], ["MAPs", 397], [")", 401], ["showed", 403], ["a", 410], ["prolongation", 412], ["of", 425], ["repolarization", 428], ["in", 443], ["CHF", 446], ["after", 450], ["atrioventricular", 456], ["block", 473], ["and", 479], ["stimulation", 483], ["at", 495], ["different", 498], ["cycle", 508], ["lengths", 514], [".", 521], ["Sotalol", 523], ["(", 531], ["100", 532], ["\u03bcM", 536], [",", 538], ["n", 540], ["=", 542], ["13", 544], [")", 546], ["or", 548], ["veratridine", 551], ["(", 563], ["0.5", 564], ["\u03bcM", 568], [";", 570], ["n", 572], ["=", 574], ["15", 576], [")", 578], ["resulted", 580], ["in", 589], ["a", 592], ["further", 594], ["significant", 602], ["increase", 614], ["in", 623], ["the", 626], ["MAP", 630], ["duration", 634], [".", 642], ["CHF", 644], ["was", 648], ["associated", 652], ["with", 663], ["an", 668], ["increased", 671], ["dispersion", 681], ["of", 692], ["repolarization", 695], [",", 709], ["as", 711], ["compared", 714], ["with", 723], ["sotalol", 728], ["-", 735], ["treated", 736], ["(", 744], ["+22", 745], ["\u00b1", 749], ["7", 751], ["ms", 753], [";", 755], ["P", 757], ["<", 759], [".05", 761], [")", 764], ["and", 766], ["veratridine", 770], ["-", 781], ["treated", 782], ["(", 790], ["+20", 791], ["\u00b1", 795], ["6", 797], ["ms", 799], [";", 801], ["P", 803], ["<", 805], [".05", 807], [")", 810], ["sham", 812], ["hearts", 817], [".", 823], ["In", 825], ["the", 828], ["presence", 832], ["of", 841], ["a", 844], ["low", 846], ["potassium", 850], ["concentration", 860], [",", 873], ["sotalol", 875], ["and", 883], ["veratridine", 887], ["reproducibly", 899], ["induced", 912], ["early", 920], ["afterdepolarizations", 926], ["(", 947], ["EADs", 948], [")", 952], ["and", 954], ["polymorphic", 958], ["ventricular", 970], ["tachyarrhythmias", 982], ["(", 999], ["VTs", 1000], [")", 1003], [".", 1004], ["SEA0400", 1006], ["(", 1014], ["1", 1015], ["\u03bcM", 1017], [")", 1019], [",", 1020], ["a", 1022], ["pharmacological", 1024], ["inhibitor", 1040], ["of", 1050], ["NCX", 1053], [",", 1056], ["significantly", 1058], ["shortened", 1072], ["the", 1082], ["MAP", 1086], ["duration", 1090], ["(", 1099], ["P", 1100], ["<", 1102], [".01", 1104], [")", 1107], ["and", 1109], ["reduced", 1113], ["dispersion", 1121], ["(", 1132], ["P", 1133], ["<", 1135], [".05", 1137], [")", 1140], [".", 1141], ["It", 1143], ["suppressed", 1146], ["EAD", 1157], ["in", 1161], ["6", 1164], ["of", 1166], ["13", 1169], ["sotalol", 1172], ["-", 1179], ["treated", 1180], ["failing", 1188], ["hearts", 1196], ["and", 1203], ["in", 1207], ["9", 1210], ["of", 1212], ["10", 1215], ["veratridine", 1218], ["-", 1229], ["treated", 1230], ["failing", 1238], ["hearts", 1246], [",", 1252], ["leading", 1254], ["to", 1262], ["a", 1265], ["reduction", 1267], ["in", 1277], ["VT", 1280], ["(", 1283], ["60", 1284], ["%", 1286], ["in", 1288], ["sotalol", 1291], ["-", 1298], ["treated", 1299], ["failing", 1307], ["hearts", 1315], ["and", 1322], ["83", 1326], ["%", 1328], ["in", 1330], ["veratridine", 1333], ["-", 1344], ["treated", 1345], ["failing", 1353], ["hearts", 1361], [")", 1367], [".", 1368], ["Simulations", 1370], ["using", 1382], ["a", 1388], ["mathematical", 1390], ["model", 1403], ["showed", 1409], ["a", 1416], ["reduction", 1418], ["in", 1428], ["the", 1431], ["action", 1435], ["potential", 1442], ["duration", 1452], ["and", 1461], ["the", 1465], ["number", 1469], ["of", 1476], ["EADs", 1479], ["by", 1484], ["the", 1487], ["NCX", 1491], ["block", 1495], ["in", 1501], ["all", 1504], ["subgroups", 1508], [".", 1517], ["In", 1519], ["an", 1522], ["experimental", 1525], ["model", 1538], ["of", 1544], ["CHF", 1547], [",", 1550], ["the", 1552], ["acute", 1556], ["inhibition", 1562], ["of", 1573], ["NCX", 1576], ["(", 1580], ["1", 1581], [")", 1582], ["reduces", 1584], ["the", 1592], ["MAP", 1596], ["duration", 1600], [",", 1608], ["(", 1610], ["2", 1611], [")", 1612], ["decreases", 1614], ["dispersion", 1624], ["of", 1635], ["repolarization", 1638], [",", 1652], ["and", 1654], ["(", 1658], ["3", 1659], [")", 1660], ["suppresses", 1662], ["EAD", 1673], ["and", 1677], ["VT", 1681], [".", 1683], ["Our", 1685], ["observations", 1689], ["indicate", 1702], ["for", 1711], ["the", 1715], ["first", 1719], ["time", 1725], ["that", 1730], ["pharmacological", 1735], ["NCX", 1751], ["inhibition", 1755], ["increases", 1766], ["repolarization", 1776], ["reserve", 1791], ["and", 1799], ["protects", 1803], ["against", 1812], ["VTs", 1820], ["in", 1824], ["heart", 1827], ["failure", 1833], [".", 1840]]}
{"context": "The spectrin heterodimer is formed by the antiparallel lateral association of an alpha and a beta subunit, each of which comprises largely a series of homologous triple-helical motifs. Initiation of dimer assembly involves strong binding between complementary motifs near the actin-binding end of the dimer. In this study, the mechanism of lateral spectrin association at this dimer nucleation site was investigated using the analytical ultracentrifuge to analyze heterodimers formed from recombinant peptides containing two or four homologous motifs from each subunit (alpha20-21/beta1-2; alpha18-21/beta1-4). Both the two-motif and four-motif dimer associations were weakened substantially with increasing salt concentration, indicating that electrostatic interactions are important for the dimer initiation process. Modeling of the electrostatic potential on the surface of the alpha20 and beta2 motifs showed that the side of the motifs comprising the A and B helices is the most favorable for association, with an area of positive electrostatic potential on the AB face of the beta2 motif opposite negative potential on the AB face of the alpha20 motif and vise versa. Protease protection analysis of the alpha20-21/beta1-2 dimer showed that multiple trypsin and proteinase K sites in the A helices of the beta2 and alpha21 motifs become buried upon dimer formation. Together, these data support a model where complementary long range electrostatic interactions on the AB faces of the triple-helical motifs in the dimer nucleation site initiate the correct pairing of motifs, i.e. alpha21-beta1 and alpha20-beta2. After initial docking of these complementary triple-helical motifs, this association is probably stabilized by subsequent formation of stronger hydrophobic interactions in a complex involving the A helices of both subunits and possibly most of the AB faces. The beta subunit A helix in particular appears to be buried in the dimer interface.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "341b721c73f64225b0bb8a8e9b4fdbef", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[7, 7]], "char_spans": [[42, 53]]}]}], "context_tokens": [["The", 0], ["spectrin", 4], ["heterodimer", 13], ["is", 25], ["formed", 28], ["by", 35], ["the", 38], ["antiparallel", 42], ["lateral", 55], ["association", 63], ["of", 75], ["an", 78], ["alpha", 81], ["and", 87], ["a", 91], ["beta", 93], ["subunit", 98], [",", 105], ["each", 107], ["of", 112], ["which", 115], ["comprises", 121], ["largely", 131], ["a", 139], ["series", 141], ["of", 148], ["homologous", 151], ["triple", 162], ["-", 168], ["helical", 169], ["motifs", 177], [".", 183], ["Initiation", 185], ["of", 196], ["dimer", 199], ["assembly", 205], ["involves", 214], ["strong", 223], ["binding", 230], ["between", 238], ["complementary", 246], ["motifs", 260], ["near", 267], ["the", 272], ["actin", 276], ["-", 281], ["binding", 282], ["end", 290], ["of", 294], ["the", 297], ["dimer", 301], [".", 306], ["In", 308], ["this", 311], ["study", 316], [",", 321], ["the", 323], ["mechanism", 327], ["of", 337], ["lateral", 340], ["spectrin", 348], ["association", 357], ["at", 369], ["this", 372], ["dimer", 377], ["nucleation", 383], ["site", 394], ["was", 399], ["investigated", 403], ["using", 416], ["the", 422], ["analytical", 426], ["ultracentrifuge", 437], ["to", 453], ["analyze", 456], ["heterodimers", 464], ["formed", 477], ["from", 484], ["recombinant", 489], ["peptides", 501], ["containing", 510], ["two", 521], ["or", 525], ["four", 528], ["homologous", 533], ["motifs", 544], ["from", 551], ["each", 556], ["subunit", 561], ["(", 569], ["alpha20", 570], ["-", 577], ["21/beta1", 578], ["-", 586], ["2", 587], [";", 588], ["alpha18", 590], ["-", 597], ["21/beta1", 598], ["-", 606], ["4", 607], [")", 608], [".", 609], ["Both", 611], ["the", 616], ["two", 620], ["-", 623], ["motif", 624], ["and", 630], ["four", 634], ["-", 638], ["motif", 639], ["dimer", 645], ["associations", 651], ["were", 664], ["weakened", 669], ["substantially", 678], ["with", 692], ["increasing", 697], ["salt", 708], ["concentration", 713], [",", 726], ["indicating", 728], ["that", 739], ["electrostatic", 744], ["interactions", 758], ["are", 771], ["important", 775], ["for", 785], ["the", 789], ["dimer", 793], ["initiation", 799], ["process", 810], [".", 817], ["Modeling", 819], ["of", 828], ["the", 831], ["electrostatic", 835], ["potential", 849], ["on", 859], ["the", 862], ["surface", 866], ["of", 874], ["the", 877], ["alpha20", 881], ["and", 889], ["beta2", 893], ["motifs", 899], ["showed", 906], ["that", 913], ["the", 918], ["side", 922], ["of", 927], ["the", 930], ["motifs", 934], ["comprising", 941], ["the", 952], ["A", 956], ["and", 958], ["B", 962], ["helices", 964], ["is", 972], ["the", 975], ["most", 979], ["favorable", 984], ["for", 994], ["association", 998], [",", 1009], ["with", 1011], ["an", 1016], ["area", 1019], ["of", 1024], ["positive", 1027], ["electrostatic", 1036], ["potential", 1050], ["on", 1060], ["the", 1063], ["AB", 1067], ["face", 1070], ["of", 1075], ["the", 1078], ["beta2", 1082], ["motif", 1088], ["opposite", 1094], ["negative", 1103], ["potential", 1112], ["on", 1122], ["the", 1125], ["AB", 1129], ["face", 1132], ["of", 1137], ["the", 1140], ["alpha20", 1144], ["motif", 1152], ["and", 1158], ["vise", 1162], ["versa", 1167], [".", 1172], ["Protease", 1174], ["protection", 1183], ["analysis", 1194], ["of", 1203], ["the", 1206], ["alpha20", 1210], ["-", 1217], ["21/beta1", 1218], ["-", 1226], ["2", 1227], ["dimer", 1229], ["showed", 1235], ["that", 1242], ["multiple", 1247], ["trypsin", 1256], ["and", 1264], ["proteinase", 1268], ["K", 1279], ["sites", 1281], ["in", 1287], ["the", 1290], ["A", 1294], ["helices", 1296], ["of", 1304], ["the", 1307], ["beta2", 1311], ["and", 1317], ["alpha21", 1321], ["motifs", 1329], ["become", 1336], ["buried", 1343], ["upon", 1350], ["dimer", 1355], ["formation", 1361], [".", 1370], ["Together", 1372], [",", 1380], ["these", 1382], ["data", 1388], ["support", 1393], ["a", 1401], ["model", 1403], ["where", 1409], ["complementary", 1415], ["long", 1429], ["range", 1434], ["electrostatic", 1440], ["interactions", 1454], ["on", 1467], ["the", 1470], ["AB", 1474], ["faces", 1477], ["of", 1483], ["the", 1486], ["triple", 1490], ["-", 1496], ["helical", 1497], ["motifs", 1505], ["in", 1512], ["the", 1515], ["dimer", 1519], ["nucleation", 1525], ["site", 1536], ["initiate", 1541], ["the", 1550], ["correct", 1554], ["pairing", 1562], ["of", 1570], ["motifs", 1573], [",", 1579], ["i.e.", 1581], ["alpha21-beta1", 1586], ["and", 1600], ["alpha20-beta2", 1604], [".", 1617], ["After", 1619], ["initial", 1625], ["docking", 1633], ["of", 1641], ["these", 1644], ["complementary", 1650], ["triple", 1664], ["-", 1670], ["helical", 1671], ["motifs", 1679], [",", 1685], ["this", 1687], ["association", 1692], ["is", 1704], ["probably", 1707], ["stabilized", 1716], ["by", 1727], ["subsequent", 1730], ["formation", 1741], ["of", 1751], ["stronger", 1754], ["hydrophobic", 1763], ["interactions", 1775], ["in", 1788], ["a", 1791], ["complex", 1793], ["involving", 1801], ["the", 1811], ["A", 1815], ["helices", 1817], ["of", 1825], ["both", 1828], ["subunits", 1833], ["and", 1842], ["possibly", 1846], ["most", 1855], ["of", 1860], ["the", 1863], ["AB", 1867], ["faces", 1870], [".", 1875], ["The", 1877], ["beta", 1881], ["subunit", 1886], ["A", 1894], ["helix", 1896], ["in", 1902], ["particular", 1905], ["appears", 1916], ["to", 1924], ["be", 1927], ["buried", 1930], ["in", 1937], ["the", 1940], ["dimer", 1944], ["interface", 1950], [".", 1959]]}
{"context": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1 activator 1, and Rac1. Interleukin-1beta, flagellin, interferon-gamma, and tumor necrosis factor alpha (TNF-alpha) similarly induced Nox1 in a colon cancer cell line (T84), whereas only TNF-alpha fully induced NOXO1 and upregulated superoxide-producing activity by ninefold. This upregulation was canceled by knockdown of NOXO1 with small interfering RNAs. TNF-alpha rapidly phosphorylated p38 mitogen-activated protein kinase and c-Jun N-terminal kinase 1/2, followed by phosphorylation of c-Jun and c-Fos and appearance of an AP-1 binding activity within 30 min. We cloned the 5' flank of the human NOXO1 gene (-3888 to +263 bp), and found that the region between -585 and -452 bp, which contains consensus elements of YY-1, AP-1, and Ets, and the GC-rich region encoding three putative binding sites for SP-1, was crucial for TNF-alpha-dependent promoter activity. Serial mutation analysis of the elements identified an AP-1 binding site (from -561 to -551 bp, agtAAGtcatg) as a crucial element for TNF-alpha-stimulated transcription of the human NOXO1 gene, which was also confirmed by the AP-1 decoy experiments. Thus, TNF-alpha acts as a potent activator of Nox1-based oxidase in colon epithelial cells, suggesting a potential role of this oxidase in inflammation of the colon.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "6779bef390824d269a423840772240f6", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}, {"text": "NOX1", "token_spans": [[4, 4], [49, 49], [22, 22]], "char_spans": [[17, 20], [238, 241], [100, 103]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["1", 14], ["(", 16], ["Nox1", 17], [")", 21], ["is", 23], ["a", 26], ["multicomponent", 28], ["enzyme", 43], ["consisting", 50], ["of", 61], ["p22(phox", 64], [")", 72], [",", 73], ["Nox", 75], ["organizer", 79], ["1", 89], ["(", 91], ["NOXO1", 92], [")", 97], [",", 98], ["Nox1", 100], ["activator", 105], ["1", 115], [",", 116], ["and", 118], ["Rac1", 122], [".", 126], ["Interleukin-1beta", 128], [",", 145], ["flagellin", 147], [",", 156], ["interferon", 158], ["-", 168], ["gamma", 169], [",", 174], ["and", 176], ["tumor", 180], ["necrosis", 186], ["factor", 195], ["alpha", 202], ["(", 208], ["TNF", 209], ["-", 212], ["alpha", 213], [")", 218], ["similarly", 220], ["induced", 230], ["Nox1", 238], ["in", 243], ["a", 246], ["colon", 248], ["cancer", 254], ["cell", 261], ["line", 266], ["(", 271], ["T84", 272], [")", 275], [",", 276], ["whereas", 278], ["only", 286], ["TNF", 291], ["-", 294], ["alpha", 295], ["fully", 301], ["induced", 307], ["NOXO1", 315], ["and", 321], ["upregulated", 325], ["superoxide", 337], ["-", 347], ["producing", 348], ["activity", 358], ["by", 367], ["ninefold", 370], [".", 378], ["This", 380], ["upregulation", 385], ["was", 398], ["canceled", 402], ["by", 411], ["knockdown", 414], ["of", 424], ["NOXO1", 427], ["with", 433], ["small", 438], ["interfering", 444], ["RNAs", 456], [".", 460], ["TNF", 462], ["-", 465], ["alpha", 466], ["rapidly", 472], ["phosphorylated", 480], ["p38", 495], ["mitogen", 499], ["-", 506], ["activated", 507], ["protein", 517], ["kinase", 525], ["and", 532], ["c", 536], ["-", 537], ["Jun", 538], ["N", 542], ["-", 543], ["terminal", 544], ["kinase", 553], ["1/2", 560], [",", 563], ["followed", 565], ["by", 574], ["phosphorylation", 577], ["of", 593], ["c", 596], ["-", 597], ["Jun", 598], ["and", 602], ["c", 606], ["-", 607], ["Fos", 608], ["and", 612], ["appearance", 616], ["of", 627], ["an", 630], ["AP-1", 633], ["binding", 638], ["activity", 646], ["within", 655], ["30", 662], ["min", 665], [".", 668], ["We", 670], ["cloned", 673], ["the", 680], ["5", 684], ["'", 685], ["flank", 687], ["of", 693], ["the", 696], ["human", 700], ["NOXO1", 706], ["gene", 712], ["(", 717], ["-3888", 718], ["to", 724], ["+263", 727], ["bp", 732], [")", 734], [",", 735], ["and", 737], ["found", 741], ["that", 747], ["the", 752], ["region", 756], ["between", 763], ["-585", 771], ["and", 776], ["-452", 780], ["bp", 785], [",", 787], ["which", 789], ["contains", 795], ["consensus", 804], ["elements", 814], ["of", 823], ["YY-1", 826], [",", 830], ["AP-1", 832], [",", 836], ["and", 838], ["Ets", 842], [",", 845], ["and", 847], ["the", 851], ["GC", 855], ["-", 857], ["rich", 858], ["region", 863], ["encoding", 870], ["three", 879], ["putative", 885], ["binding", 894], ["sites", 902], ["for", 908], ["SP-1", 912], [",", 916], ["was", 918], ["crucial", 922], ["for", 930], ["TNF", 934], ["-", 937], ["alpha", 938], ["-", 943], ["dependent", 944], ["promoter", 954], ["activity", 963], [".", 971], ["Serial", 973], ["mutation", 980], ["analysis", 989], ["of", 998], ["the", 1001], ["elements", 1005], ["identified", 1014], ["an", 1025], ["AP-1", 1028], ["binding", 1033], ["site", 1041], ["(", 1046], ["from", 1047], ["-561", 1052], ["to", 1057], ["-551", 1060], ["bp", 1065], [",", 1067], ["agtAAGtcatg", 1069], [")", 1080], ["as", 1082], ["a", 1085], ["crucial", 1087], ["element", 1095], ["for", 1103], ["TNF", 1107], ["-", 1110], ["alpha", 1111], ["-", 1116], ["stimulated", 1117], ["transcription", 1128], ["of", 1142], ["the", 1145], ["human", 1149], ["NOXO1", 1155], ["gene", 1161], [",", 1165], ["which", 1167], ["was", 1173], ["also", 1177], ["confirmed", 1182], ["by", 1192], ["the", 1195], ["AP-1", 1199], ["decoy", 1204], ["experiments", 1210], [".", 1221], ["Thus", 1223], [",", 1227], ["TNF", 1229], ["-", 1232], ["alpha", 1233], ["acts", 1239], ["as", 1244], ["a", 1247], ["potent", 1249], ["activator", 1256], ["of", 1266], ["Nox1-based", 1269], ["oxidase", 1280], ["in", 1288], ["colon", 1291], ["epithelial", 1297], ["cells", 1308], [",", 1313], ["suggesting", 1315], ["a", 1326], ["potential", 1328], ["role", 1338], ["of", 1343], ["this", 1346], ["oxidase", 1351], ["in", 1359], ["inflammation", 1362], ["of", 1375], ["the", 1378], ["colon", 1382], [".", 1387]]}
{"context": "It is increasingly clear that the normal protein alpha-synuclein is in some manner closely associated with presynaptic components of select neuronal types within the adult human central nervous system (CNS) and, in addition, that in its pathologically altered state alpha-synuclein aggregates selectively in the form of filamentous inclusion bodies during certain progressive neurodegenerative disorders, such as familial and sporadic Parkinson's disease. By having the antibody AFshp raised specifically to alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered protein, an initial attempt is made to map the overall distribution pattern and describe the staining behavior of the immunoreactive punctae in select regions of the prosencephalon. Neocortical immunolabeling is most prominent in the prodigious, but incompletely myelinated, association fields and faintest in the heavily myelinated primary motor and primary sensory fields, with the premotor and first order sensory association areas occupying an intermediate position. Of the thalamic grays evaluated, those containing powerfully myelinated fiber tracts (e.g. centrum medianum, habenular complex) show the weakest immunolabeling, whereas, less sturdily myelinated structures are highly immunoreactive. The fact that the immunostaining spectrum for normal alpha-synuclein is so broad, together with the fact that some thalamic sites actually are immunonegative leads to the following conclusions (1) alpha-synuclein, although present in the synaptic boutons of many nerve cells in the adult human CNS, is by no means ubiquitous there, and (2) neuronal types lacking the normal protein cannot generate the Parkinson's disease-specific filamentous pathology.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "2c9a3ae9437648e1834a87d46d29cd29", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[80, 82], [45, 47], [8, 10], [216, 218], [242, 244]], "char_spans": [[508, 522], [266, 280], [49, 63], [1400, 1414], [1544, 1558]]}]}], "context_tokens": [["It", 0], ["is", 3], ["increasingly", 6], ["clear", 19], ["that", 25], ["the", 30], ["normal", 34], ["protein", 41], ["alpha", 49], ["-", 54], ["synuclein", 55], ["is", 65], ["in", 68], ["some", 71], ["manner", 76], ["closely", 83], ["associated", 91], ["with", 102], ["presynaptic", 107], ["components", 119], ["of", 130], ["select", 133], ["neuronal", 140], ["types", 149], ["within", 155], ["the", 162], ["adult", 166], ["human", 172], ["central", 178], ["nervous", 186], ["system", 194], ["(", 201], ["CNS", 202], [")", 205], ["and", 207], [",", 210], ["in", 212], ["addition", 215], [",", 223], ["that", 225], ["in", 230], ["its", 233], ["pathologically", 237], ["altered", 252], ["state", 260], ["alpha", 266], ["-", 271], ["synuclein", 272], ["aggregates", 282], ["selectively", 293], ["in", 305], ["the", 308], ["form", 312], ["of", 317], ["filamentous", 320], ["inclusion", 332], ["bodies", 342], ["during", 349], ["certain", 356], ["progressive", 364], ["neurodegenerative", 376], ["disorders", 394], [",", 403], ["such", 405], ["as", 410], ["familial", 413], ["and", 422], ["sporadic", 426], ["Parkinson", 435], ["'s", 444], ["disease", 447], [".", 454], ["By", 456], ["having", 459], ["the", 466], ["antibody", 470], ["AFshp", 479], ["raised", 485], ["specifically", 492], ["to", 505], ["alpha", 508], ["-", 513], ["synuclein", 514], ["to", 524], ["label", 527], ["Parkinson", 533], ["disease", 543], ["-", 550], ["specific", 551], ["Lewy", 560], ["bodies", 565], ["and", 572], ["Lewy", 576], ["neurites", 581], ["as", 590], ["well", 593], ["as", 598], ["synaptic", 601], ["boutons", 610], ["containing", 618], ["the", 629], ["unaltered", 633], ["protein", 643], [",", 650], ["an", 652], ["initial", 655], ["attempt", 663], ["is", 671], ["made", 674], ["to", 679], ["map", 682], ["the", 686], ["overall", 690], ["distribution", 698], ["pattern", 711], ["and", 719], ["describe", 723], ["the", 732], ["staining", 736], ["behavior", 745], ["of", 754], ["the", 757], ["immunoreactive", 761], ["punctae", 776], ["in", 784], ["select", 787], ["regions", 794], ["of", 802], ["the", 805], ["prosencephalon", 809], [".", 823], ["Neocortical", 825], ["immunolabeling", 837], ["is", 852], ["most", 855], ["prominent", 860], ["in", 870], ["the", 873], ["prodigious", 877], [",", 887], ["but", 889], ["incompletely", 893], ["myelinated", 906], [",", 916], ["association", 918], ["fields", 930], ["and", 937], ["faintest", 941], ["in", 950], ["the", 953], ["heavily", 957], ["myelinated", 965], ["primary", 976], ["motor", 984], ["and", 990], ["primary", 994], ["sensory", 1002], ["fields", 1010], [",", 1016], ["with", 1018], ["the", 1023], ["premotor", 1027], ["and", 1036], ["first", 1040], ["order", 1046], ["sensory", 1052], ["association", 1060], ["areas", 1072], ["occupying", 1078], ["an", 1088], ["intermediate", 1091], ["position", 1104], [".", 1112], ["Of", 1114], ["the", 1117], ["thalamic", 1121], ["grays", 1130], ["evaluated", 1136], [",", 1145], ["those", 1147], ["containing", 1153], ["powerfully", 1164], ["myelinated", 1175], ["fiber", 1186], ["tracts", 1192], ["(", 1199], ["e.g.", 1200], ["centrum", 1205], ["medianum", 1213], [",", 1221], ["habenular", 1223], ["complex", 1233], [")", 1240], ["show", 1242], ["the", 1247], ["weakest", 1251], ["immunolabeling", 1259], [",", 1273], ["whereas", 1275], [",", 1282], ["less", 1284], ["sturdily", 1289], ["myelinated", 1298], ["structures", 1309], ["are", 1320], ["highly", 1324], ["immunoreactive", 1331], [".", 1345], ["The", 1347], ["fact", 1351], ["that", 1356], ["the", 1361], ["immunostaining", 1365], ["spectrum", 1380], ["for", 1389], ["normal", 1393], ["alpha", 1400], ["-", 1405], ["synuclein", 1406], ["is", 1416], ["so", 1419], ["broad", 1422], [",", 1427], ["together", 1429], ["with", 1438], ["the", 1443], ["fact", 1447], ["that", 1452], ["some", 1457], ["thalamic", 1462], ["sites", 1471], ["actually", 1477], ["are", 1486], ["immunonegative", 1490], ["leads", 1505], ["to", 1511], ["the", 1514], ["following", 1518], ["conclusions", 1528], ["(", 1540], ["1", 1541], [")", 1542], ["alpha", 1544], ["-", 1549], ["synuclein", 1550], [",", 1559], ["although", 1561], ["present", 1570], ["in", 1578], ["the", 1581], ["synaptic", 1585], ["boutons", 1594], ["of", 1602], ["many", 1605], ["nerve", 1610], ["cells", 1616], ["in", 1622], ["the", 1625], ["adult", 1629], ["human", 1635], ["CNS", 1641], [",", 1644], ["is", 1646], ["by", 1649], ["no", 1652], ["means", 1655], ["ubiquitous", 1661], ["there", 1672], [",", 1677], ["and", 1679], ["(", 1683], ["2", 1684], [")", 1685], ["neuronal", 1687], ["types", 1696], ["lacking", 1702], ["the", 1710], ["normal", 1714], ["protein", 1721], ["can", 1729], ["not", 1732], ["generate", 1736], ["the", 1745], ["Parkinson", 1749], ["'s", 1758], ["disease", 1761], ["-", 1768], ["specific", 1769], ["filamentous", 1778], ["pathology", 1790], [".", 1799]]}
{"context": "to determine the rate of MRSA-carrier among patients, family members and health care providers, and the association between MRSA-carrier family members and health care providers on MRSA infection patient after orthopaedic surgery. this is a cross-sectional analytical study. Samples were taken consecutively during December 2010 to December 2011, consisting of postoperative patients infected with MRSA, attending family members, and the medical officers with history of contact with the patient. Swab culture were taken from nasal and axilla of all subjects. The incidence of MRSA infection, and MRSA-carrier on the patient, family members and medical officers were presented descriptively, while their association with MRSA infection was statistically tested using Fischer exact test. during the study period, there were 759 surgeries, with 4 (0.5%) patients were identified to have MRSA infection. Of these four cases, 48 subjects were enrolled. The rate of MRSA-carrier among patients, family and health care providers were 50%, 25% and 0% respectively. There were no significant association between MRSA and the rates of MRSA-carrier on the family member or health care providers. the incidence of MRSA infection, MRSA-carrier patient, MRSA-carrier health care providers, and family member carrier were 0.5%, 50%, 0%, and 25% respectively. No significant association found between MRSA-carrier on the family member or health care providers and MRSA infection patient. There were no MRSA infection found on the health care provider.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "5b64caa5cdd9442cbac616d39d8d3854", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[32, 32], [256, 256], [5, 5], [197, 197], [22, 22], [102, 102], [122, 122], [202, 202], [220, 220], [268, 268], [153, 153], [169, 169], [217, 217], [275, 275], [225, 225], [98, 98], [65, 65]], "char_spans": [[181, 184], [1386, 1389], [25, 28], [1104, 1107], [124, 127], [597, 600], [721, 724], [1126, 1129], [1219, 1222], [1449, 1452], [885, 888], [961, 964], [1203, 1206], [1487, 1490], [1241, 1244], [577, 580], [398, 401]]}]}], "context_tokens": [["to", 0], ["determine", 3], ["the", 13], ["rate", 17], ["of", 22], ["MRSA", 25], ["-", 29], ["carrier", 30], ["among", 38], ["patients", 44], [",", 52], ["family", 54], ["members", 61], ["and", 69], ["health", 73], ["care", 80], ["providers", 85], [",", 94], ["and", 96], ["the", 100], ["association", 104], ["between", 116], ["MRSA", 124], ["-", 128], ["carrier", 129], ["family", 137], ["members", 144], ["and", 152], ["health", 156], ["care", 163], ["providers", 168], ["on", 178], ["MRSA", 181], ["infection", 186], ["patient", 196], ["after", 204], ["orthopaedic", 210], ["surgery", 222], [".", 229], ["this", 231], ["is", 236], ["a", 239], ["cross", 241], ["-", 246], ["sectional", 247], ["analytical", 257], ["study", 268], [".", 273], ["Samples", 275], ["were", 283], ["taken", 288], ["consecutively", 294], ["during", 308], ["December", 315], ["2010", 324], ["to", 329], ["December", 332], ["2011", 341], [",", 345], ["consisting", 347], ["of", 358], ["postoperative", 361], ["patients", 375], ["infected", 384], ["with", 393], ["MRSA", 398], [",", 402], ["attending", 404], ["family", 414], ["members", 421], [",", 428], ["and", 430], ["the", 434], ["medical", 438], ["officers", 446], ["with", 455], ["history", 460], ["of", 468], ["contact", 471], ["with", 479], ["the", 484], ["patient", 488], [".", 495], ["Swab", 497], ["culture", 502], ["were", 510], ["taken", 515], ["from", 521], ["nasal", 526], ["and", 532], ["axilla", 536], ["of", 543], ["all", 546], ["subjects", 550], [".", 558], ["The", 560], ["incidence", 564], ["of", 574], ["MRSA", 577], ["infection", 582], [",", 591], ["and", 593], ["MRSA", 597], ["-", 601], ["carrier", 602], ["on", 610], ["the", 613], ["patient", 617], [",", 624], ["family", 626], ["members", 633], ["and", 641], ["medical", 645], ["officers", 653], ["were", 662], ["presented", 667], ["descriptively", 677], [",", 690], ["while", 692], ["their", 698], ["association", 704], ["with", 716], ["MRSA", 721], ["infection", 726], ["was", 736], ["statistically", 740], ["tested", 754], ["using", 761], ["Fischer", 767], ["exact", 775], ["test", 781], [".", 785], ["during", 787], ["the", 794], ["study", 798], ["period", 804], [",", 810], ["there", 812], ["were", 818], ["759", 823], ["surgeries", 827], [",", 836], ["with", 838], ["4", 843], ["(", 845], ["0.5", 846], ["%", 849], [")", 850], ["patients", 852], ["were", 861], ["identified", 866], ["to", 877], ["have", 880], ["MRSA", 885], ["infection", 890], [".", 899], ["Of", 901], ["these", 904], ["four", 910], ["cases", 915], [",", 920], ["48", 922], ["subjects", 925], ["were", 934], ["enrolled", 939], [".", 947], ["The", 949], ["rate", 953], ["of", 958], ["MRSA", 961], ["-", 965], ["carrier", 966], ["among", 974], ["patients", 980], [",", 988], ["family", 990], ["and", 997], ["health", 1001], ["care", 1008], ["providers", 1013], ["were", 1023], ["50", 1028], ["%", 1030], [",", 1031], ["25", 1033], ["%", 1035], ["and", 1037], ["0", 1041], ["%", 1042], ["respectively", 1044], [".", 1056], ["There", 1058], ["were", 1064], ["no", 1069], ["significant", 1072], ["association", 1084], ["between", 1096], ["MRSA", 1104], ["and", 1109], ["the", 1113], ["rates", 1117], ["of", 1123], ["MRSA", 1126], ["-", 1130], ["carrier", 1131], ["on", 1139], ["the", 1142], ["family", 1146], ["member", 1153], ["or", 1160], ["health", 1163], ["care", 1170], ["providers", 1175], [".", 1184], ["the", 1186], ["incidence", 1190], ["of", 1200], ["MRSA", 1203], ["infection", 1208], [",", 1217], ["MRSA", 1219], ["-", 1223], ["carrier", 1224], ["patient", 1232], [",", 1239], ["MRSA", 1241], ["-", 1245], ["carrier", 1246], ["health", 1254], ["care", 1261], ["providers", 1266], [",", 1275], ["and", 1277], ["family", 1281], ["member", 1288], ["carrier", 1295], ["were", 1303], ["0.5", 1308], ["%", 1311], [",", 1312], ["50", 1314], ["%", 1316], [",", 1317], ["0", 1319], ["%", 1320], [",", 1321], ["and", 1323], ["25", 1327], ["%", 1329], ["respectively", 1331], [".", 1343], ["No", 1345], ["significant", 1348], ["association", 1360], ["found", 1372], ["between", 1378], ["MRSA", 1386], ["-", 1390], ["carrier", 1391], ["on", 1399], ["the", 1402], ["family", 1406], ["member", 1413], ["or", 1420], ["health", 1423], ["care", 1430], ["providers", 1435], ["and", 1445], ["MRSA", 1449], ["infection", 1454], ["patient", 1464], [".", 1471], ["There", 1473], ["were", 1479], ["no", 1484], ["MRSA", 1487], ["infection", 1492], ["found", 1502], ["on", 1508], ["the", 1511], ["health", 1515], ["care", 1522], ["provider", 1527], [".", 1535]]}
{"context": "Magnetic resonance imaging (MRI) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. MRI performs somewhat better than any of several common tests--probe to bone (PTB), erythrocyte sedimentation rate (ESR) >70 mm/hr, C-reactive protein (CRP) >14 mg/L, procalcitonin >0.3 ng/mL, and ulcer size >2 cm\u00b2--although PTB has the highest specificity of any test and is commonly used together with MRI. No studies have directly compared MRI with a combination of these tests, which may assist in diagnosis.", "qas": [{"question": "Which disease can be diagnosed with the \"probe to bone\" test?", "answers": ["diabetic foot osteomyelitis"], "qid": "63e453c58aac4f2abda1af843d1f2c50", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["diagnosed", 21], ["with", 31], ["the", 36], ["\"", 40], ["probe", 41], ["to", 47], ["bone", 50], ["\"", 54], ["test", 56], ["?", 60]], "detected_answers": [{"text": "diabetic foot osteomyelitis", "token_spans": [[31, 33]], "char_spans": [[140, 166]]}]}], "context_tokens": [["Magnetic", 0], ["resonance", 9], ["imaging", 19], ["(", 27], ["MRI", 28], [")", 31], ["has", 33], ["a", 37], ["higher", 39], ["sensitivity", 46], ["and", 58], ["specificity", 62], ["(", 74], ["90", 75], ["%", 77], ["and", 79], ["79", 83], ["%", 85], [")", 86], ["than", 88], ["plain", 93], ["radiography", 99], ["(", 111], ["54", 112], ["%", 114], ["and", 116], ["68", 120], ["%", 122], [")", 123], ["for", 125], ["diagnosing", 129], ["diabetic", 140], ["foot", 149], ["osteomyelitis", 154], [".", 167], ["MRI", 169], ["performs", 173], ["somewhat", 182], ["better", 191], ["than", 198], ["any", 203], ["of", 207], ["several", 210], ["common", 218], ["tests", 225], ["--", 230], ["probe", 232], ["to", 238], ["bone", 241], ["(", 246], ["PTB", 247], [")", 250], [",", 251], ["erythrocyte", 253], ["sedimentation", 265], ["rate", 279], ["(", 284], ["ESR", 285], [")", 288], [">", 290], ["70", 291], ["mm", 294], ["/", 296], ["hr", 297], [",", 299], ["C", 301], ["-", 302], ["reactive", 303], ["protein", 312], ["(", 320], ["CRP", 321], [")", 324], [">", 326], ["14", 327], ["mg", 330], ["/", 332], ["L", 333], [",", 334], ["procalcitonin", 336], [">", 350], ["0.3", 351], ["ng", 355], ["/", 357], ["mL", 358], [",", 360], ["and", 362], ["ulcer", 366], ["size", 372], [">", 377], ["2", 378], ["cm\u00b2--although", 380], ["PTB", 394], ["has", 398], ["the", 402], ["highest", 406], ["specificity", 414], ["of", 426], ["any", 429], ["test", 433], ["and", 438], ["is", 442], ["commonly", 445], ["used", 454], ["together", 459], ["with", 468], ["MRI", 473], [".", 476], ["No", 478], ["studies", 481], ["have", 489], ["directly", 494], ["compared", 503], ["MRI", 512], ["with", 516], ["a", 521], ["combination", 523], ["of", 535], ["these", 538], ["tests", 544], [",", 549], ["which", 551], ["may", 557], ["assist", 561], ["in", 568], ["diagnosis", 571], [".", 580]]}
{"context": "Long QT and short QT syndromes (LQTS and SQTS) are cardiac repolarization abnormalities that are characterized by length perturbations of the QT interval as measured on electrocardiogram (ECG). Prolonged QT interval and a propensity for ventricular tachycardia of the torsades de pointes (TdP) type are characteristic of LQTS, while SQTS is characterized by shortened QT interval with tall peaked T-waves and a propensity for atrial fibrillation. Both syndromes represent a high risk for syncope and sudden death. LQTS exists as a congenital genetic disease (cLQTS) with more than 700 mutations described in 12 genes (LQT1-12), but can also be acquired (aLQTS). The genetic forms of LQTS include Romano-Ward syndrome (RWS), which is characterized by isolated LQTS and an autosomal dominant pattern of inheritance, and syndromes with LQTS in association with other conditions. The latter includes Jervell and Lange-Nielsen syndrome (JLNS), Andersen syndrome (AS), and Timothy syndrome (TS). The genetics are further complicated by the occurrence of double and triple heterozygotes in LQTS and a considerable number of nonpathogenic rare polymorphisms in the involved genes. SQTS is a very rare condition, caused by mutations in five genes (SQTS1-5). The present mutation update is a comprehensive description of all known LQTS- and SQTS-associated mutations.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "857f5bd2ba3140ffa45bbf468805dfa3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[145, 146]], "char_spans": [[771, 788]]}]}], "context_tokens": [["Long", 0], ["QT", 5], ["and", 8], ["short", 12], ["QT", 18], ["syndromes", 21], ["(", 31], ["LQTS", 32], ["and", 37], ["SQTS", 41], [")", 45], ["are", 47], ["cardiac", 51], ["repolarization", 59], ["abnormalities", 74], ["that", 88], ["are", 93], ["characterized", 97], ["by", 111], ["length", 114], ["perturbations", 121], ["of", 135], ["the", 138], ["QT", 142], ["interval", 145], ["as", 154], ["measured", 157], ["on", 166], ["electrocardiogram", 169], ["(", 187], ["ECG", 188], [")", 191], [".", 192], ["Prolonged", 194], ["QT", 204], ["interval", 207], ["and", 216], ["a", 220], ["propensity", 222], ["for", 233], ["ventricular", 237], ["tachycardia", 249], ["of", 261], ["the", 264], ["torsades", 268], ["de", 277], ["pointes", 280], ["(", 288], ["TdP", 289], [")", 292], ["type", 294], ["are", 299], ["characteristic", 303], ["of", 318], ["LQTS", 321], [",", 325], ["while", 327], ["SQTS", 333], ["is", 338], ["characterized", 341], ["by", 355], ["shortened", 358], ["QT", 368], ["interval", 371], ["with", 380], ["tall", 385], ["peaked", 390], ["T", 397], ["-", 398], ["waves", 399], ["and", 405], ["a", 409], ["propensity", 411], ["for", 422], ["atrial", 426], ["fibrillation", 433], [".", 445], ["Both", 447], ["syndromes", 452], ["represent", 462], ["a", 472], ["high", 474], ["risk", 479], ["for", 484], ["syncope", 488], ["and", 496], ["sudden", 500], ["death", 507], [".", 512], ["LQTS", 514], ["exists", 519], ["as", 526], ["a", 529], ["congenital", 531], ["genetic", 542], ["disease", 550], ["(", 558], ["cLQTS", 559], [")", 564], ["with", 566], ["more", 571], ["than", 576], ["700", 581], ["mutations", 585], ["described", 595], ["in", 605], ["12", 608], ["genes", 611], ["(", 617], ["LQT1", 618], ["-", 622], ["12", 623], [")", 625], [",", 626], ["but", 628], ["can", 632], ["also", 636], ["be", 641], ["acquired", 644], ["(", 653], ["aLQTS", 654], [")", 659], [".", 660], ["The", 662], ["genetic", 666], ["forms", 674], ["of", 680], ["LQTS", 683], ["include", 688], ["Romano", 696], ["-", 702], ["Ward", 703], ["syndrome", 708], ["(", 717], ["RWS", 718], [")", 721], [",", 722], ["which", 724], ["is", 730], ["characterized", 733], ["by", 747], ["isolated", 750], ["LQTS", 759], ["and", 764], ["an", 768], ["autosomal", 771], ["dominant", 781], ["pattern", 790], ["of", 798], ["inheritance", 801], [",", 812], ["and", 814], ["syndromes", 818], ["with", 828], ["LQTS", 833], ["in", 838], ["association", 841], ["with", 853], ["other", 858], ["conditions", 864], [".", 874], ["The", 876], ["latter", 880], ["includes", 887], ["Jervell", 896], ["and", 904], ["Lange", 908], ["-", 913], ["Nielsen", 914], ["syndrome", 922], ["(", 931], ["JLNS", 932], [")", 936], [",", 937], ["Andersen", 939], ["syndrome", 948], ["(", 957], ["AS", 958], [")", 960], [",", 961], ["and", 963], ["Timothy", 967], ["syndrome", 975], ["(", 984], ["TS", 985], [")", 987], [".", 988], ["The", 990], ["genetics", 994], ["are", 1003], ["further", 1007], ["complicated", 1015], ["by", 1027], ["the", 1030], ["occurrence", 1034], ["of", 1045], ["double", 1048], ["and", 1055], ["triple", 1059], ["heterozygotes", 1066], ["in", 1080], ["LQTS", 1083], ["and", 1088], ["a", 1092], ["considerable", 1094], ["number", 1107], ["of", 1114], ["nonpathogenic", 1117], ["rare", 1131], ["polymorphisms", 1136], ["in", 1150], ["the", 1153], ["involved", 1157], ["genes", 1166], [".", 1171], ["SQTS", 1173], ["is", 1178], ["a", 1181], ["very", 1183], ["rare", 1188], ["condition", 1193], [",", 1202], ["caused", 1204], ["by", 1211], ["mutations", 1214], ["in", 1224], ["five", 1227], ["genes", 1232], ["(", 1238], ["SQTS1", 1239], ["-", 1244], ["5", 1245], [")", 1246], [".", 1247], ["The", 1249], ["present", 1253], ["mutation", 1261], ["update", 1270], ["is", 1277], ["a", 1280], ["comprehensive", 1282], ["description", 1296], ["of", 1308], ["all", 1311], ["known", 1315], ["LQTS-", 1321], ["and", 1327], ["SQTS", 1331], ["-", 1335], ["associated", 1336], ["mutations", 1347], [".", 1356]]}
{"context": "The effect of the newly synthesized compound 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400) on the Na+-Ca2+ exchanger (NCX) was investigated and compared against that of 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea (KB-R7943). In addition, the effects of SEA0400 on reperfusion injury in vitro and in vivo were examined. SEA0400 was extremely more potent than KB-R7943 in inhibiting Na+-dependent Ca2+ uptake in cultured neurons, astrocytes, and microglia: IC50s of SEA0400 and KB-R7943 were 5 to 33 nM and 2 to 4 microM, respectively. SEA0400 at the concentration range that inhibited NCX exhibited negligible affinities for the Ca2+ channels, Na+ channels, K+ channels, norepinephrine transporter, and 14 receptors, and did not affect the activities of the Na+/H+ exchanger, Na+,K+-ATPase, Ca2+-ATPase, and five enzymes. SEA0400, unlike KB-R7943, did not inhibit the store-operated Ca2+ entry in cultured astrocytes. SEA0400 attenuated dose- dependently paradoxical Ca2+ challenge-induced production of reactive oxygen species, DNA ladder formation, and nuclear condensation in cultured astrocytes, whereas it did not affect thapsigargin-induced cell injury. Furthermore, administration of SEA0400 reduced infarct volumes after a transient middle cerebral artery occlusion in rat cerebral cortex and striatum. These results indicate that SEA0400 is the most potent and selective inhibitor of NCX, and suggest that the compound may exert protective effects on postischemic brain damage.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "e77f03a3c71044b98123b465164c6cc7", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[240, 240], [17, 17], [102, 102]], "char_spans": [[1422, 1424], [141, 143], [614, 616]]}]}], "context_tokens": [["The", 0], ["effect", 4], ["of", 11], ["the", 14], ["newly", 18], ["synthesized", 24], ["compound", 36], ["2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline", 45], ["(", 104], ["SEA0400", 105], [")", 112], ["on", 114], ["the", 117], ["Na+-Ca2", 121], ["+", 128], ["exchanger", 130], ["(", 140], ["NCX", 141], [")", 144], ["was", 146], ["investigated", 150], ["and", 163], ["compared", 167], ["against", 176], ["that", 184], ["of", 189], ["2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea", 192], ["(", 243], ["KB", 244], ["-", 246], ["R7943", 247], [")", 252], [".", 253], ["In", 255], ["addition", 258], [",", 266], ["the", 268], ["effects", 272], ["of", 280], ["SEA0400", 283], ["on", 291], ["reperfusion", 294], ["injury", 306], ["in", 313], ["vitro", 316], ["and", 322], ["in", 326], ["vivo", 329], ["were", 334], ["examined", 339], [".", 347], ["SEA0400", 349], ["was", 357], ["extremely", 361], ["more", 371], ["potent", 376], ["than", 383], ["KB", 388], ["-", 390], ["R7943", 391], ["in", 397], ["inhibiting", 400], ["Na+-dependent", 411], ["Ca2", 425], ["+", 428], ["uptake", 430], ["in", 437], ["cultured", 440], ["neurons", 449], [",", 456], ["astrocytes", 458], [",", 468], ["and", 470], ["microglia", 474], [":", 483], ["IC50s", 485], ["of", 491], ["SEA0400", 494], ["and", 502], ["KB", 506], ["-", 508], ["R7943", 509], ["were", 515], ["5", 520], ["to", 522], ["33", 525], ["nM", 528], ["and", 531], ["2", 535], ["to", 537], ["4", 540], ["microM", 542], [",", 548], ["respectively", 550], [".", 562], ["SEA0400", 564], ["at", 572], ["the", 575], ["concentration", 579], ["range", 593], ["that", 599], ["inhibited", 604], ["NCX", 614], ["exhibited", 618], ["negligible", 628], ["affinities", 639], ["for", 650], ["the", 654], ["Ca2", 658], ["+", 661], ["channels", 663], [",", 671], ["Na+", 673], ["channels", 677], [",", 685], ["K+", 687], ["channels", 690], [",", 698], ["norepinephrine", 700], ["transporter", 715], [",", 726], ["and", 728], ["14", 732], ["receptors", 735], [",", 744], ["and", 746], ["did", 750], ["not", 754], ["affect", 758], ["the", 765], ["activities", 769], ["of", 780], ["the", 783], ["Na+/H+", 787], ["exchanger", 794], [",", 803], ["Na+,K+-ATPase", 805], [",", 818], ["Ca2", 820], ["+", 823], ["-ATPase", 824], [",", 831], ["and", 833], ["five", 837], ["enzymes", 842], [".", 849], ["SEA0400", 851], [",", 858], ["unlike", 860], ["KB", 867], ["-", 869], ["R7943", 870], [",", 875], ["did", 877], ["not", 881], ["inhibit", 885], ["the", 893], ["store", 897], ["-", 902], ["operated", 903], ["Ca2", 912], ["+", 915], ["entry", 917], ["in", 923], ["cultured", 926], ["astrocytes", 935], [".", 945], ["SEA0400", 947], ["attenuated", 955], ["dose-", 966], ["dependently", 972], ["paradoxical", 984], ["Ca2", 996], ["+", 999], ["challenge", 1001], ["-", 1010], ["induced", 1011], ["production", 1019], ["of", 1030], ["reactive", 1033], ["oxygen", 1042], ["species", 1049], [",", 1056], ["DNA", 1058], ["ladder", 1062], ["formation", 1069], [",", 1078], ["and", 1080], ["nuclear", 1084], ["condensation", 1092], ["in", 1105], ["cultured", 1108], ["astrocytes", 1117], [",", 1127], ["whereas", 1129], ["it", 1137], ["did", 1140], ["not", 1144], ["affect", 1148], ["thapsigargin", 1155], ["-", 1167], ["induced", 1168], ["cell", 1176], ["injury", 1181], [".", 1187], ["Furthermore", 1189], [",", 1200], ["administration", 1202], ["of", 1217], ["SEA0400", 1220], ["reduced", 1228], ["infarct", 1236], ["volumes", 1244], ["after", 1252], ["a", 1258], ["transient", 1260], ["middle", 1270], ["cerebral", 1277], ["artery", 1286], ["occlusion", 1293], ["in", 1303], ["rat", 1306], ["cerebral", 1310], ["cortex", 1319], ["and", 1326], ["striatum", 1330], [".", 1338], ["These", 1340], ["results", 1346], ["indicate", 1354], ["that", 1363], ["SEA0400", 1368], ["is", 1376], ["the", 1379], ["most", 1383], ["potent", 1388], ["and", 1395], ["selective", 1399], ["inhibitor", 1409], ["of", 1419], ["NCX", 1422], [",", 1425], ["and", 1427], ["suggest", 1431], ["that", 1439], ["the", 1444], ["compound", 1448], ["may", 1457], ["exert", 1461], ["protective", 1467], ["effects", 1478], ["on", 1486], ["postischemic", 1489], ["brain", 1502], ["damage", 1508], [".", 1514]]}
{"context": "The study of cancer predisposition syndromes presents unique opportunities to gain insights into the genetic events associated with tumor pathogenesis. Individuals with two inherited cancer syndromes, neurofibromatosis 1 (NF1) and neurofibromatosis 2 (NF2), develop both benign and malignant tumors. The corresponding genes mutated in these two disorders encode tumor suppressor proteins, termed neurofibromin (NF1) and merlin (NF2), which function in novel ways to regulate cell growth and differentiation. Neurofibromin inhibits cell proliferation, at least in part, by modulating mitogenic pathway signaling through inactivation of p21-ras. In contrast, merlin may act as a membrane-associated molecular switch that regulates cell-cell and cell-matrix signals transduced by cell surface receptors. Significant progress in our understanding of the genetics and biology of NF1 and NF2 has elucidated the roles of these genes in tumor initiation and progression.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "15f2966fce5a4fd499e583236823391a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[63, 63], [31, 31], [143, 143]], "char_spans": [[411, 413], [222, 224], [874, 876]]}]}], "context_tokens": [["The", 0], ["study", 4], ["of", 10], ["cancer", 13], ["predisposition", 20], ["syndromes", 35], ["presents", 45], ["unique", 54], ["opportunities", 61], ["to", 75], ["gain", 78], ["insights", 83], ["into", 92], ["the", 97], ["genetic", 101], ["events", 109], ["associated", 116], ["with", 127], ["tumor", 132], ["pathogenesis", 138], [".", 150], ["Individuals", 152], ["with", 164], ["two", 169], ["inherited", 173], ["cancer", 183], ["syndromes", 190], [",", 199], ["neurofibromatosis", 201], ["1", 219], ["(", 221], ["NF1", 222], [")", 225], ["and", 227], ["neurofibromatosis", 231], ["2", 249], ["(", 251], ["NF2", 252], [")", 255], [",", 256], ["develop", 258], ["both", 266], ["benign", 271], ["and", 278], ["malignant", 282], ["tumors", 292], [".", 298], ["The", 300], ["corresponding", 304], ["genes", 318], ["mutated", 324], ["in", 332], ["these", 335], ["two", 341], ["disorders", 345], ["encode", 355], ["tumor", 362], ["suppressor", 368], ["proteins", 379], [",", 387], ["termed", 389], ["neurofibromin", 396], ["(", 410], ["NF1", 411], [")", 414], ["and", 416], ["merlin", 420], ["(", 427], ["NF2", 428], [")", 431], [",", 432], ["which", 434], ["function", 440], ["in", 449], ["novel", 452], ["ways", 458], ["to", 463], ["regulate", 466], ["cell", 475], ["growth", 480], ["and", 487], ["differentiation", 491], [".", 506], ["Neurofibromin", 508], ["inhibits", 522], ["cell", 531], ["proliferation", 536], [",", 549], ["at", 551], ["least", 554], ["in", 560], ["part", 563], [",", 567], ["by", 569], ["modulating", 572], ["mitogenic", 583], ["pathway", 593], ["signaling", 601], ["through", 611], ["inactivation", 619], ["of", 632], ["p21-ras", 635], [".", 642], ["In", 644], ["contrast", 647], [",", 655], ["merlin", 657], ["may", 664], ["act", 668], ["as", 672], ["a", 675], ["membrane", 677], ["-", 685], ["associated", 686], ["molecular", 697], ["switch", 707], ["that", 714], ["regulates", 719], ["cell", 729], ["-", 733], ["cell", 734], ["and", 739], ["cell", 743], ["-", 747], ["matrix", 748], ["signals", 755], ["transduced", 763], ["by", 774], ["cell", 777], ["surface", 782], ["receptors", 790], [".", 799], ["Significant", 801], ["progress", 813], ["in", 822], ["our", 825], ["understanding", 829], ["of", 843], ["the", 846], ["genetics", 850], ["and", 859], ["biology", 863], ["of", 871], ["NF1", 874], ["and", 878], ["NF2", 882], ["has", 886], ["elucidated", 890], ["the", 901], ["roles", 905], ["of", 911], ["these", 914], ["genes", 920], ["in", 926], ["tumor", 929], ["initiation", 935], ["and", 946], ["progression", 950], [".", 961]]}
{"context": "Chronic myeloid leukemia cells contain a BCR-ABL oncoprotein with an enhanced tyrosine kinase activity, which is considered to be the principal 'cause' of the leukemia. Though the precise mechanisms underlying the leukemogenesis remains enigmatic, the use of imatinib to inhibit the dysregulated kinase activity has proved remarkably successful in clinical practice. Imatinib was the first small molecule developed to inhibit BCR-ABL tyrosine kinase activity and its success introduced the current era of molecularly targeted therapies for a number of other malignancies. In patients with chronic myeloid leukaemia who develop resistance to imatinib, the Bcr-Abl signaling pathway is often re-established. This has led to the emergence of a number of alternative treatment strategies designed to target the leukemic cell which are resistant to imatinib.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "34f1609a5e28421ea7ca56e3a8591062", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[104, 106], [6, 8], [67, 69]], "char_spans": [[655, 661], [41, 47], [426, 432]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["cells", 25], ["contain", 31], ["a", 39], ["BCR", 41], ["-", 44], ["ABL", 45], ["oncoprotein", 49], ["with", 61], ["an", 66], ["enhanced", 69], ["tyrosine", 78], ["kinase", 87], ["activity", 94], [",", 102], ["which", 104], ["is", 110], ["considered", 113], ["to", 124], ["be", 127], ["the", 130], ["principal", 134], ["'cause", 144], ["'", 150], ["of", 152], ["the", 155], ["leukemia", 159], [".", 167], ["Though", 169], ["the", 176], ["precise", 180], ["mechanisms", 188], ["underlying", 199], ["the", 210], ["leukemogenesis", 214], ["remains", 229], ["enigmatic", 237], [",", 246], ["the", 248], ["use", 252], ["of", 256], ["imatinib", 259], ["to", 268], ["inhibit", 271], ["the", 279], ["dysregulated", 283], ["kinase", 296], ["activity", 303], ["has", 312], ["proved", 316], ["remarkably", 323], ["successful", 334], ["in", 345], ["clinical", 348], ["practice", 357], [".", 365], ["Imatinib", 367], ["was", 376], ["the", 380], ["first", 384], ["small", 390], ["molecule", 396], ["developed", 405], ["to", 415], ["inhibit", 418], ["BCR", 426], ["-", 429], ["ABL", 430], ["tyrosine", 434], ["kinase", 443], ["activity", 450], ["and", 459], ["its", 463], ["success", 467], ["introduced", 475], ["the", 486], ["current", 490], ["era", 498], ["of", 502], ["molecularly", 505], ["targeted", 517], ["therapies", 526], ["for", 536], ["a", 540], ["number", 542], ["of", 549], ["other", 552], ["malignancies", 558], [".", 570], ["In", 572], ["patients", 575], ["with", 584], ["chronic", 589], ["myeloid", 597], ["leukaemia", 605], ["who", 615], ["develop", 619], ["resistance", 627], ["to", 638], ["imatinib", 641], [",", 649], ["the", 651], ["Bcr", 655], ["-", 658], ["Abl", 659], ["signaling", 663], ["pathway", 673], ["is", 681], ["often", 684], ["re", 690], ["-", 692], ["established", 693], [".", 704], ["This", 706], ["has", 711], ["led", 715], ["to", 719], ["the", 722], ["emergence", 726], ["of", 736], ["a", 739], ["number", 741], ["of", 748], ["alternative", 751], ["treatment", 763], ["strategies", 773], ["designed", 784], ["to", 793], ["target", 796], ["the", 803], ["leukemic", 807], ["cell", 816], ["which", 821], ["are", 827], ["resistant", 831], ["to", 841], ["imatinib", 844], [".", 852]]}
{"context": "The transcriptional networks that regulate embryonic stem (ES) cell pluripotency and lineage specification are the subject of considerable attention. To date such studies have focused almost exclusively on protein-coding transcripts. However, recent transcriptome analyses show that the mammalian genome contains thousands of long noncoding RNAs (ncRNAs), many of which appear to be expressed in a developmentally regulated manner. The functions of these remain untested. To identify ncRNAs involved in ES cell biology, we used a custom-designed microarray to examine the expression profiles of mouse ES cells differentiating as embryoid bodies (EBs) over a 16-d time course. We identified 945 ncRNAs expressed during EB differentiation, of which 174 were differentially expressed, many correlating with pluripotency or specific differentiation events. Candidate ncRNAs were identified for further characterization by an integrated examination of expression profiles, genomic context, chromatin state, and promoter analysis. Many ncRNAs showed coordinated expression with genomically associated developmental genes, such as Dlx1, Dlx4, Gata6, and Ecsit. We examined two novel developmentally regulated ncRNAs, Evx1as and Hoxb5/6as, which are derived from homeotic loci and share similar expression patterns and localization in mouse embryos with their associated protein-coding genes. Using chromatin immunoprecipitation, we provide evidence that both ncRNAs are associated with trimethylated H3K4 histones and histone methyltransferase MLL1, suggesting a role in epigenetic regulation of homeotic loci during ES cell differentiation. Taken together, our data indicate that long ncRNAs are likely to be important in processes directing pluripotency and alternative differentiation programs, in some cases through engagement of the epigenetic machinery.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "7f852a929e6a4b24adcfac462afb1477", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[236, 236]], "char_spans": [[1493, 1496]]}]}], "context_tokens": [["The", 0], ["transcriptional", 4], ["networks", 20], ["that", 29], ["regulate", 34], ["embryonic", 43], ["stem", 53], ["(", 58], ["ES", 59], [")", 61], ["cell", 63], ["pluripotency", 68], ["and", 81], ["lineage", 85], ["specification", 93], ["are", 107], ["the", 111], ["subject", 115], ["of", 123], ["considerable", 126], ["attention", 139], [".", 148], ["To", 150], ["date", 153], ["such", 158], ["studies", 163], ["have", 171], ["focused", 176], ["almost", 184], ["exclusively", 191], ["on", 203], ["protein", 206], ["-", 213], ["coding", 214], ["transcripts", 221], [".", 232], ["However", 234], [",", 241], ["recent", 243], ["transcriptome", 250], ["analyses", 264], ["show", 273], ["that", 278], ["the", 283], ["mammalian", 287], ["genome", 297], ["contains", 304], ["thousands", 313], ["of", 323], ["long", 326], ["noncoding", 331], ["RNAs", 341], ["(", 346], ["ncRNAs", 347], [")", 353], [",", 354], ["many", 356], ["of", 361], ["which", 364], ["appear", 370], ["to", 377], ["be", 380], ["expressed", 383], ["in", 393], ["a", 396], ["developmentally", 398], ["regulated", 414], ["manner", 424], [".", 430], ["The", 432], ["functions", 436], ["of", 446], ["these", 449], ["remain", 455], ["untested", 462], [".", 470], ["To", 472], ["identify", 475], ["ncRNAs", 484], ["involved", 491], ["in", 500], ["ES", 503], ["cell", 506], ["biology", 511], [",", 518], ["we", 520], ["used", 523], ["a", 528], ["custom", 530], ["-", 536], ["designed", 537], ["microarray", 546], ["to", 557], ["examine", 560], ["the", 568], ["expression", 572], ["profiles", 583], ["of", 592], ["mouse", 595], ["ES", 601], ["cells", 604], ["differentiating", 610], ["as", 626], ["embryoid", 629], ["bodies", 638], ["(", 645], ["EBs", 646], [")", 649], ["over", 651], ["a", 656], ["16-d", 658], ["time", 663], ["course", 668], [".", 674], ["We", 676], ["identified", 679], ["945", 690], ["ncRNAs", 694], ["expressed", 701], ["during", 711], ["EB", 718], ["differentiation", 721], [",", 736], ["of", 738], ["which", 741], ["174", 747], ["were", 751], ["differentially", 756], ["expressed", 771], [",", 780], ["many", 782], ["correlating", 787], ["with", 799], ["pluripotency", 804], ["or", 817], ["specific", 820], ["differentiation", 829], ["events", 845], [".", 851], ["Candidate", 853], ["ncRNAs", 863], ["were", 870], ["identified", 875], ["for", 886], ["further", 890], ["characterization", 898], ["by", 915], ["an", 918], ["integrated", 921], ["examination", 932], ["of", 944], ["expression", 947], ["profiles", 958], [",", 966], ["genomic", 968], ["context", 976], [",", 983], ["chromatin", 985], ["state", 995], [",", 1000], ["and", 1002], ["promoter", 1006], ["analysis", 1015], [".", 1023], ["Many", 1025], ["ncRNAs", 1030], ["showed", 1037], ["coordinated", 1044], ["expression", 1056], ["with", 1067], ["genomically", 1072], ["associated", 1084], ["developmental", 1095], ["genes", 1109], [",", 1114], ["such", 1116], ["as", 1121], ["Dlx1", 1124], [",", 1128], ["Dlx4", 1130], [",", 1134], ["Gata6", 1136], [",", 1141], ["and", 1143], ["Ecsit", 1147], [".", 1152], ["We", 1154], ["examined", 1157], ["two", 1166], ["novel", 1170], ["developmentally", 1176], ["regulated", 1192], ["ncRNAs", 1202], [",", 1208], ["Evx1as", 1210], ["and", 1217], ["Hoxb5/6as", 1221], [",", 1230], ["which", 1232], ["are", 1238], ["derived", 1242], ["from", 1250], ["homeotic", 1255], ["loci", 1264], ["and", 1269], ["share", 1273], ["similar", 1279], ["expression", 1287], ["patterns", 1298], ["and", 1307], ["localization", 1311], ["in", 1324], ["mouse", 1327], ["embryos", 1333], ["with", 1341], ["their", 1346], ["associated", 1352], ["protein", 1363], ["-", 1370], ["coding", 1371], ["genes", 1378], [".", 1383], ["Using", 1385], ["chromatin", 1391], ["immunoprecipitation", 1401], [",", 1420], ["we", 1422], ["provide", 1425], ["evidence", 1433], ["that", 1442], ["both", 1447], ["ncRNAs", 1452], ["are", 1459], ["associated", 1463], ["with", 1474], ["trimethylated", 1479], ["H3K4", 1493], ["histones", 1498], ["and", 1507], ["histone", 1511], ["methyltransferase", 1519], ["MLL1", 1537], [",", 1541], ["suggesting", 1543], ["a", 1554], ["role", 1556], ["in", 1561], ["epigenetic", 1564], ["regulation", 1575], ["of", 1586], ["homeotic", 1589], ["loci", 1598], ["during", 1603], ["ES", 1610], ["cell", 1613], ["differentiation", 1618], [".", 1633], ["Taken", 1635], ["together", 1641], [",", 1649], ["our", 1651], ["data", 1655], ["indicate", 1660], ["that", 1669], ["long", 1674], ["ncRNAs", 1679], ["are", 1686], ["likely", 1690], ["to", 1697], ["be", 1700], ["important", 1703], ["in", 1713], ["processes", 1716], ["directing", 1726], ["pluripotency", 1736], ["and", 1749], ["alternative", 1753], ["differentiation", 1765], ["programs", 1781], [",", 1789], ["in", 1791], ["some", 1794], ["cases", 1799], ["through", 1805], ["engagement", 1813], ["of", 1824], ["the", 1827], ["epigenetic", 1831], ["machinery", 1842], [".", 1851]]}
{"context": "The FOXP2 gene is important for the development of proper speech motor control in humans. However, the role of the gene in general vocal behavior in other mammals, including mice, is unclear. Here, we track the vocal development of Foxp2 heterozygous knockout (Foxp2+/-) mice and their wildtype (WT) littermates from juvenile to adult ages, and observe severe abnormalities in the courtship song of Foxp2+/- mice. In comparison to their WT littermates, Foxp2+/- mice vocalized less, produced shorter syllable sequences, and possessed an abnormal syllable inventory. In addition, Foxp2+/- song also exhibited irregular rhythmic structure, and its development did not follow the consistent trajectories observed in WT vocalizations. These results demonstrate that the Foxp2 gene is critical for normal vocal behavior in juvenile and adult mice, and that Foxp2 mutant mice may provide a tractable model system for the study of the gene's role in general vocal motor control.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "9d3f3ba44ee44d29bc6fd1b262200ffb", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[45, 45], [131, 131], [74, 74], [147, 147], [84, 84], [104, 104], [1, 1], [49, 49]], "char_spans": [[232, 236], [766, 770], [399, 406], [852, 856], [453, 460], [579, 586], [4, 8], [261, 268]]}]}], "context_tokens": [["The", 0], ["FOXP2", 4], ["gene", 10], ["is", 15], ["important", 18], ["for", 28], ["the", 32], ["development", 36], ["of", 48], ["proper", 51], ["speech", 58], ["motor", 65], ["control", 71], ["in", 79], ["humans", 82], [".", 88], ["However", 90], [",", 97], ["the", 99], ["role", 103], ["of", 108], ["the", 111], ["gene", 115], ["in", 120], ["general", 123], ["vocal", 131], ["behavior", 137], ["in", 146], ["other", 149], ["mammals", 155], [",", 162], ["including", 164], ["mice", 174], [",", 178], ["is", 180], ["unclear", 183], [".", 190], ["Here", 192], [",", 196], ["we", 198], ["track", 201], ["the", 207], ["vocal", 211], ["development", 217], ["of", 229], ["Foxp2", 232], ["heterozygous", 238], ["knockout", 251], ["(", 260], ["Foxp2+/-", 261], [")", 269], ["mice", 271], ["and", 276], ["their", 280], ["wildtype", 286], ["(", 295], ["WT", 296], [")", 298], ["littermates", 300], ["from", 312], ["juvenile", 317], ["to", 326], ["adult", 329], ["ages", 335], [",", 339], ["and", 341], ["observe", 345], ["severe", 353], ["abnormalities", 360], ["in", 374], ["the", 377], ["courtship", 381], ["song", 391], ["of", 396], ["Foxp2+/-", 399], ["mice", 408], [".", 412], ["In", 414], ["comparison", 417], ["to", 428], ["their", 431], ["WT", 437], ["littermates", 440], [",", 451], ["Foxp2+/-", 453], ["mice", 462], ["vocalized", 467], ["less", 477], [",", 481], ["produced", 483], ["shorter", 492], ["syllable", 500], ["sequences", 509], [",", 518], ["and", 520], ["possessed", 524], ["an", 534], ["abnormal", 537], ["syllable", 546], ["inventory", 555], [".", 564], ["In", 566], ["addition", 569], [",", 577], ["Foxp2+/-", 579], ["song", 588], ["also", 593], ["exhibited", 598], ["irregular", 608], ["rhythmic", 618], ["structure", 627], [",", 636], ["and", 638], ["its", 642], ["development", 646], ["did", 658], ["not", 662], ["follow", 666], ["the", 673], ["consistent", 677], ["trajectories", 688], ["observed", 701], ["in", 710], ["WT", 713], ["vocalizations", 716], [".", 729], ["These", 731], ["results", 737], ["demonstrate", 745], ["that", 757], ["the", 762], ["Foxp2", 766], ["gene", 772], ["is", 777], ["critical", 780], ["for", 789], ["normal", 793], ["vocal", 800], ["behavior", 806], ["in", 815], ["juvenile", 818], ["and", 827], ["adult", 831], ["mice", 837], [",", 841], ["and", 843], ["that", 847], ["Foxp2", 852], ["mutant", 858], ["mice", 865], ["may", 870], ["provide", 874], ["a", 882], ["tractable", 884], ["model", 894], ["system", 900], ["for", 907], ["the", 911], ["study", 915], ["of", 921], ["the", 924], ["gene", 928], ["'s", 932], ["role", 935], ["in", 940], ["general", 943], ["vocal", 951], ["motor", 957], ["control", 963], [".", 970]]}
{"context": "Peripheral neuropathy (PN) has been reported in idiopathic and hereditary forms of parkinsonism, but the pathogenic mechanisms are unclear and likely heterogeneous. Levodopa-induced vitamin B12 deficiency has been discussed as a causal factor of PN in idiopathic Parkinson's disease, but peripheral nervous system involvement might also be a consequence of the underlying neurodegenerative process. Occurrence of PN with parkinsonism has been associated with a panel of mitochondrial cytopathies, more frequently related to a nuclear gene defect and mainly polymerase gamma (POLG1) gene. Parkin (PARK2) gene mutations are responsible for juvenile parkinsonism, and possible peripheral nervous system involvement has been reported. Rarely, an association of parkinsonism with PN may be encountered in other neurodegenerative diseases such as fragile X-associated tremor and ataxia syndrome related to premutation CGG repeat expansion in the fragile X mental retardation (FMR1) gene, Machado-Joseph disease related to an abnormal CAG repeat expansion in ataxin-3 (ATXN3) gene, Kufor-Rakeb syndrome caused by mutations in ATP13A2 gene, or in hereditary systemic disorders such as Gaucher disease due to mutations in the \u03b2-glucocerebrosidase (GBA) gene and Chediak-Higashi syndrome due to LYST gene mutations. This article reviews conditions in which PN may coexist with parkinsonism.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "ccaf40e8947045dbb86dafd325b2f626", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[216, 217]], "char_spans": [[1285, 1293]]}]}], "context_tokens": [["Peripheral", 0], ["neuropathy", 11], ["(", 22], ["PN", 23], [")", 25], ["has", 27], ["been", 31], ["reported", 36], ["in", 45], ["idiopathic", 48], ["and", 59], ["hereditary", 63], ["forms", 74], ["of", 80], ["parkinsonism", 83], [",", 95], ["but", 97], ["the", 101], ["pathogenic", 105], ["mechanisms", 116], ["are", 127], ["unclear", 131], ["and", 139], ["likely", 143], ["heterogeneous", 150], [".", 163], ["Levodopa", 165], ["-", 173], ["induced", 174], ["vitamin", 182], ["B12", 190], ["deficiency", 194], ["has", 205], ["been", 209], ["discussed", 214], ["as", 224], ["a", 227], ["causal", 229], ["factor", 236], ["of", 243], ["PN", 246], ["in", 249], ["idiopathic", 252], ["Parkinson", 263], ["'s", 272], ["disease", 275], [",", 282], ["but", 284], ["peripheral", 288], ["nervous", 299], ["system", 307], ["involvement", 314], ["might", 326], ["also", 332], ["be", 337], ["a", 340], ["consequence", 342], ["of", 354], ["the", 357], ["underlying", 361], ["neurodegenerative", 372], ["process", 390], [".", 397], ["Occurrence", 399], ["of", 410], ["PN", 413], ["with", 416], ["parkinsonism", 421], ["has", 434], ["been", 438], ["associated", 443], ["with", 454], ["a", 459], ["panel", 461], ["of", 467], ["mitochondrial", 470], ["cytopathies", 484], [",", 495], ["more", 497], ["frequently", 502], ["related", 513], ["to", 521], ["a", 524], ["nuclear", 526], ["gene", 534], ["defect", 539], ["and", 546], ["mainly", 550], ["polymerase", 557], ["gamma", 568], ["(", 574], ["POLG1", 575], [")", 580], ["gene", 582], [".", 586], ["Parkin", 588], ["(", 595], ["PARK2", 596], [")", 601], ["gene", 603], ["mutations", 608], ["are", 618], ["responsible", 622], ["for", 634], ["juvenile", 638], ["parkinsonism", 647], [",", 659], ["and", 661], ["possible", 665], ["peripheral", 674], ["nervous", 685], ["system", 693], ["involvement", 700], ["has", 712], ["been", 716], ["reported", 721], [".", 729], ["Rarely", 731], [",", 737], ["an", 739], ["association", 742], ["of", 754], ["parkinsonism", 757], ["with", 770], ["PN", 775], ["may", 778], ["be", 782], ["encountered", 785], ["in", 797], ["other", 800], ["neurodegenerative", 806], ["diseases", 824], ["such", 833], ["as", 838], ["fragile", 841], ["X", 849], ["-", 850], ["associated", 851], ["tremor", 862], ["and", 869], ["ataxia", 873], ["syndrome", 880], ["related", 889], ["to", 897], ["premutation", 900], ["CGG", 912], ["repeat", 916], ["expansion", 923], ["in", 933], ["the", 936], ["fragile", 940], ["X", 948], ["mental", 950], ["retardation", 957], ["(", 969], ["FMR1", 970], [")", 974], ["gene", 976], [",", 980], ["Machado", 982], ["-", 989], ["Joseph", 990], ["disease", 997], ["related", 1005], ["to", 1013], ["an", 1016], ["abnormal", 1019], ["CAG", 1028], ["repeat", 1032], ["expansion", 1039], ["in", 1049], ["ataxin-3", 1052], ["(", 1061], ["ATXN3", 1062], [")", 1067], ["gene", 1069], [",", 1073], ["Kufor", 1075], ["-", 1080], ["Rakeb", 1081], ["syndrome", 1087], ["caused", 1096], ["by", 1103], ["mutations", 1106], ["in", 1116], ["ATP13A2", 1119], ["gene", 1127], [",", 1131], ["or", 1133], ["in", 1136], ["hereditary", 1139], ["systemic", 1150], ["disorders", 1159], ["such", 1169], ["as", 1174], ["Gaucher", 1177], ["disease", 1185], ["due", 1193], ["to", 1197], ["mutations", 1200], ["in", 1210], ["the", 1213], ["\u03b2", 1217], ["-", 1218], ["glucocerebrosidase", 1219], ["(", 1238], ["GBA", 1239], [")", 1242], ["gene", 1244], ["and", 1249], ["Chediak", 1253], ["-", 1260], ["Higashi", 1261], ["syndrome", 1269], ["due", 1278], ["to", 1282], ["LYST", 1285], ["gene", 1290], ["mutations", 1295], [".", 1304], ["This", 1306], ["article", 1311], ["reviews", 1319], ["conditions", 1327], ["in", 1338], ["which", 1341], ["PN", 1347], ["may", 1350], ["coexist", 1354], ["with", 1362], ["parkinsonism", 1367], [".", 1379]]}
{"context": "Methylation of lysine residues of histones is an important epigenetic mark that correlates with functionally distinct regions of chromatin. We present here the crystal structure of a ternary complex of the enzyme Pr-Set7 (also known as Set8) that methylates Lys 20 of histone H4 (H4-K20). We show that the enzyme is exclusively a mono-methylase and is therefore responsible for a signaling role quite distinct from that established by other enzymes that target this histone residue. We provide evidence from NMR for the C-flanking domains of SET proteins becoming ordered upon addition of AdoMet cofactor and develop a model for the catalytic cycle of these enzymes. The crystal structure reveals the basis of the specificity of the enzyme for H4-K20 because a histidine residue within the substrate, close to the target lysine, is required for completion of the active site. We also show how a highly variable component of the SET domain is responsible for many of the enzymes' interactions with its target histone peptide and probably also how this part of the structure ensures that Pr-Set7 is nucleosome specific.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "f424eb5bb7c24c5185b12545eb402821", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[166, 167]], "char_spans": [[928, 937]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["lysine", 15], ["residues", 22], ["of", 31], ["histones", 34], ["is", 43], ["an", 46], ["important", 49], ["epigenetic", 59], ["mark", 70], ["that", 75], ["correlates", 80], ["with", 91], ["functionally", 96], ["distinct", 109], ["regions", 118], ["of", 126], ["chromatin", 129], [".", 138], ["We", 140], ["present", 143], ["here", 151], ["the", 156], ["crystal", 160], ["structure", 168], ["of", 178], ["a", 181], ["ternary", 183], ["complex", 191], ["of", 199], ["the", 202], ["enzyme", 206], ["Pr", 213], ["-", 215], ["Set7", 216], ["(", 221], ["also", 222], ["known", 227], ["as", 233], ["Set8", 236], [")", 240], ["that", 242], ["methylates", 247], ["Lys", 258], ["20", 262], ["of", 265], ["histone", 268], ["H4", 276], ["(", 279], ["H4-K20", 280], [")", 286], [".", 287], ["We", 289], ["show", 292], ["that", 297], ["the", 302], ["enzyme", 306], ["is", 313], ["exclusively", 316], ["a", 328], ["mono", 330], ["-", 334], ["methylase", 335], ["and", 345], ["is", 349], ["therefore", 352], ["responsible", 362], ["for", 374], ["a", 378], ["signaling", 380], ["role", 390], ["quite", 395], ["distinct", 401], ["from", 410], ["that", 415], ["established", 420], ["by", 432], ["other", 435], ["enzymes", 441], ["that", 449], ["target", 454], ["this", 461], ["histone", 466], ["residue", 474], [".", 481], ["We", 483], ["provide", 486], ["evidence", 494], ["from", 503], ["NMR", 508], ["for", 512], ["the", 516], ["C", 520], ["-", 521], ["flanking", 522], ["domains", 531], ["of", 539], ["SET", 542], ["proteins", 546], ["becoming", 555], ["ordered", 564], ["upon", 572], ["addition", 577], ["of", 586], ["AdoMet", 589], ["cofactor", 596], ["and", 605], ["develop", 609], ["a", 617], ["model", 619], ["for", 625], ["the", 629], ["catalytic", 633], ["cycle", 643], ["of", 649], ["these", 652], ["enzymes", 658], [".", 665], ["The", 667], ["crystal", 671], ["structure", 679], ["reveals", 689], ["the", 697], ["basis", 701], ["of", 707], ["the", 710], ["specificity", 714], ["of", 726], ["the", 729], ["enzyme", 733], ["for", 740], ["H4-K20", 744], ["because", 751], ["a", 759], ["histidine", 761], ["residue", 771], ["within", 779], ["the", 786], ["substrate", 790], [",", 799], ["close", 801], ["to", 807], ["the", 810], ["target", 814], ["lysine", 821], [",", 827], ["is", 829], ["required", 832], ["for", 841], ["completion", 845], ["of", 856], ["the", 859], ["active", 863], ["site", 870], [".", 874], ["We", 876], ["also", 879], ["show", 884], ["how", 889], ["a", 893], ["highly", 895], ["variable", 902], ["component", 911], ["of", 921], ["the", 924], ["SET", 928], ["domain", 932], ["is", 939], ["responsible", 942], ["for", 954], ["many", 958], ["of", 963], ["the", 966], ["enzymes", 970], ["'", 977], ["interactions", 979], ["with", 992], ["its", 997], ["target", 1001], ["histone", 1008], ["peptide", 1016], ["and", 1024], ["probably", 1028], ["also", 1037], ["how", 1042], ["this", 1046], ["part", 1051], ["of", 1056], ["the", 1059], ["structure", 1063], ["ensures", 1073], ["that", 1081], ["Pr", 1086], ["-", 1088], ["Set7", 1089], ["is", 1094], ["nucleosome", 1097], ["specific", 1108], [".", 1116]]}
{"context": "To identify the origin and study the morphology of small supernumerary marker chromosome (sSMC) in Turner syndrome with 45, X/46, X, + mar karyotype. Using the conventional chromosome G-banding technique, 10 cases of Turner syndrome with 45, X/46, X, + mar chromosome karyotype were obtained, dual-color fluorescence in situ hybridization was applied to study the origin and morphology of the sSMC. In the 10 cases of Turner syndrome with 45, X/46, X, + mar karyotype, the sSMC of 7 cases was derived from X chromosome [sSMC(X)], the sSMC of 2 cases was derived from Y chromosome [sSMC(Y)] and the remaining 1 case was derived from the autosome. There were 4 cases of ring(r) chromosomes and 3 of centric minutes (min) in the 7 sSMC (X) cases. In the 2 sSMC(Y), one case was dicentric (dic) and the other was centric minute (min). The sSMC originated from the autosome was a centric minute (min). The origin of sSMC of Turner syndrome with 45, X/46, X, + mar karyotype was almost all from sex chromosomes, and rarely from autosomes. sSMC can exist as isodicentric, ring, or centric minute. The molecular cytogenetic features of the sSMC can provide useful information for genetic counseling, prenatal diagnosis and treatment of the Turner syndrome patients with a 45, X/46, X, + mar karyotype.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "00f4c5c0e5df41acb2f90c62057cceb8", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[156, 156], [268, 268], [103, 103], [89, 89], [24, 24], [209, 209], [49, 49]], "char_spans": [[734, 734], [1274, 1274], [506, 506], [449, 449], [130, 130], [950, 950], [248, 248]]}]}], "context_tokens": [["To", 0], ["identify", 3], ["the", 12], ["origin", 16], ["and", 23], ["study", 27], ["the", 33], ["morphology", 37], ["of", 48], ["small", 51], ["supernumerary", 57], ["marker", 71], ["chromosome", 78], ["(", 89], ["sSMC", 90], [")", 94], ["in", 96], ["Turner", 99], ["syndrome", 106], ["with", 115], ["45", 120], [",", 122], ["X/46", 124], [",", 128], ["X", 130], [",", 131], ["+", 133], ["mar", 135], ["karyotype", 139], [".", 148], ["Using", 150], ["the", 156], ["conventional", 160], ["chromosome", 173], ["G", 184], ["-", 185], ["banding", 186], ["technique", 194], [",", 203], ["10", 205], ["cases", 208], ["of", 214], ["Turner", 217], ["syndrome", 224], ["with", 233], ["45", 238], [",", 240], ["X/46", 242], [",", 246], ["X", 248], [",", 249], ["+", 251], ["mar", 253], ["chromosome", 257], ["karyotype", 268], ["were", 278], ["obtained", 283], [",", 291], ["dual", 293], ["-", 297], ["color", 298], ["fluorescence", 304], ["in", 317], ["situ", 320], ["hybridization", 325], ["was", 339], ["applied", 343], ["to", 351], ["study", 354], ["the", 360], ["origin", 364], ["and", 371], ["morphology", 375], ["of", 386], ["the", 389], ["sSMC", 393], [".", 397], ["In", 399], ["the", 402], ["10", 406], ["cases", 409], ["of", 415], ["Turner", 418], ["syndrome", 425], ["with", 434], ["45", 439], [",", 441], ["X/46", 443], [",", 447], ["X", 449], [",", 450], ["+", 452], ["mar", 454], ["karyotype", 458], [",", 467], ["the", 469], ["sSMC", 473], ["of", 478], ["7", 481], ["cases", 483], ["was", 489], ["derived", 493], ["from", 501], ["X", 506], ["chromosome", 508], ["[", 519], ["sSMC(X", 520], [")", 526], ["]", 527], [",", 528], ["the", 530], ["sSMC", 534], ["of", 539], ["2", 542], ["cases", 544], ["was", 550], ["derived", 554], ["from", 562], ["Y", 567], ["chromosome", 569], ["[", 580], ["sSMC(Y", 581], [")", 587], ["]", 588], ["and", 590], ["the", 594], ["remaining", 598], ["1", 608], ["case", 610], ["was", 615], ["derived", 619], ["from", 627], ["the", 632], ["autosome", 636], [".", 644], ["There", 646], ["were", 652], ["4", 657], ["cases", 659], ["of", 665], ["ring(r", 668], [")", 674], ["chromosomes", 676], ["and", 688], ["3", 692], ["of", 694], ["centric", 697], ["minutes", 705], ["(", 713], ["min", 714], [")", 717], ["in", 719], ["the", 722], ["7", 726], ["sSMC", 728], ["(", 733], ["X", 734], [")", 735], ["cases", 737], [".", 742], ["In", 744], ["the", 747], ["2", 751], ["sSMC(Y", 753], [")", 759], [",", 760], ["one", 762], ["case", 766], ["was", 771], ["dicentric", 775], ["(", 785], ["dic", 786], [")", 789], ["and", 791], ["the", 795], ["other", 799], ["was", 805], ["centric", 809], ["minute", 817], ["(", 824], ["min", 825], [")", 828], [".", 829], ["The", 831], ["sSMC", 835], ["originated", 840], ["from", 851], ["the", 856], ["autosome", 860], ["was", 869], ["a", 873], ["centric", 875], ["minute", 883], ["(", 890], ["min", 891], [")", 894], [".", 895], ["The", 897], ["origin", 901], ["of", 908], ["sSMC", 911], ["of", 916], ["Turner", 919], ["syndrome", 926], ["with", 935], ["45", 940], [",", 942], ["X/46", 944], [",", 948], ["X", 950], [",", 951], ["+", 953], ["mar", 955], ["karyotype", 959], ["was", 969], ["almost", 973], ["all", 980], ["from", 984], ["sex", 989], ["chromosomes", 993], [",", 1004], ["and", 1006], ["rarely", 1010], ["from", 1017], ["autosomes", 1022], [".", 1031], ["sSMC", 1033], ["can", 1038], ["exist", 1042], ["as", 1048], ["isodicentric", 1051], [",", 1063], ["ring", 1065], [",", 1069], ["or", 1071], ["centric", 1074], ["minute", 1082], [".", 1088], ["The", 1090], ["molecular", 1094], ["cytogenetic", 1104], ["features", 1116], ["of", 1125], ["the", 1128], ["sSMC", 1132], ["can", 1137], ["provide", 1141], ["useful", 1149], ["information", 1156], ["for", 1168], ["genetic", 1172], ["counseling", 1180], [",", 1190], ["prenatal", 1192], ["diagnosis", 1201], ["and", 1211], ["treatment", 1215], ["of", 1225], ["the", 1228], ["Turner", 1232], ["syndrome", 1239], ["patients", 1248], ["with", 1257], ["a", 1262], ["45", 1264], [",", 1266], ["X/46", 1268], [",", 1272], ["X", 1274], [",", 1275], ["+", 1277], ["mar", 1279], ["karyotype", 1283], [".", 1292]]}
{"context": "Forces deployed to the first Gulf War report more ill health than veterans who did not serve there. Many studies of post-Gulf morbidity are based on relatively small sample sizes and selection bias is often a concern. In a setting where selection bias relating to the ill health of veterans may be reduced, we: i) examined self-reported adult ill health in a large sample of male UK Gulf War veterans and a demographically similar non-deployed comparison group; and ii) explored self-reported ill health among veterans who believed that they had Gulf War syndrome. This study uses data from a retrospective cohort study of reproduction and child health in which a validated postal questionnaire was sent to all UK Gulf War veterans (GWV) and a comparison cohort of Armed Service personnel who were not deployed to the Gulf (NGWV). The cohort for analysis comprises 42,818 males who responded to the questionnaire. We confirmed that GWV report higher rates of general ill health. GWV were significantly more likely to have reported at least one new medical symptom or disease since 1990 than NGWV (61% versus 37%, OR 2.7, 95% CI 2.5-2.8). They were also more likely to report higher numbers of symptoms. The strongest associations were for mood swings (OR 20.9, 95%CI 16.2-27.0), memory loss/lack of concentration (OR 19.6, 95% CI 15.5-24.8), night sweats (OR 9.9, 95% CI 6.5-15.2), general fatigue (OR 9.6, 95% CI 8.3-11.1) and sexual dysfunction (OR 4.6, 95%CI 3.2-6.6). 6% of GWV believed they had Gulf War syndrome (GWS), and this was associated with the highest symptom reporting. Increased levels of reported ill health among GWV were confirmed. This study was the first to use a questionnaire which did not focus specifically on the veterans' symptoms themselves. Nevertheless, the results are consistent with those of other studies of post-Gulf war illness and thus strengthen overall findings in this area of research. Further examination of the mechanisms underlying the reporting of ill health is required.", "qas": [{"question": "What memory problems are reported in the \" Gulf war syndrome\"", "answers": ["memory loss"], "qid": "b59f8200d7c241df95bf00fcbea3ba21", "question_tokens": [["What", 0], ["memory", 5], ["problems", 12], ["are", 21], ["reported", 25], ["in", 34], ["the", 37], ["\"", 41], ["Gulf", 43], ["war", 48], ["syndrome", 52], ["\"", 60]], "detected_answers": [{"text": "memory loss", "token_spans": [[251, 252]], "char_spans": [[1279, 1289]]}]}], "context_tokens": [["Forces", 0], ["deployed", 7], ["to", 16], ["the", 19], ["first", 23], ["Gulf", 29], ["War", 34], ["report", 38], ["more", 45], ["ill", 50], ["health", 54], ["than", 61], ["veterans", 66], ["who", 75], ["did", 79], ["not", 83], ["serve", 87], ["there", 93], [".", 98], ["Many", 100], ["studies", 105], ["of", 113], ["post", 116], ["-", 120], ["Gulf", 121], ["morbidity", 126], ["are", 136], ["based", 140], ["on", 146], ["relatively", 149], ["small", 160], ["sample", 166], ["sizes", 173], ["and", 179], ["selection", 183], ["bias", 193], ["is", 198], ["often", 201], ["a", 207], ["concern", 209], [".", 216], ["In", 218], ["a", 221], ["setting", 223], ["where", 231], ["selection", 237], ["bias", 247], ["relating", 252], ["to", 261], ["the", 264], ["ill", 268], ["health", 272], ["of", 279], ["veterans", 282], ["may", 291], ["be", 295], ["reduced", 298], [",", 305], ["we", 307], [":", 309], ["i", 311], [")", 312], ["examined", 314], ["self", 323], ["-", 327], ["reported", 328], ["adult", 337], ["ill", 343], ["health", 347], ["in", 354], ["a", 357], ["large", 359], ["sample", 365], ["of", 372], ["male", 375], ["UK", 380], ["Gulf", 383], ["War", 388], ["veterans", 392], ["and", 401], ["a", 405], ["demographically", 407], ["similar", 423], ["non", 431], ["-", 434], ["deployed", 435], ["comparison", 444], ["group", 455], [";", 460], ["and", 462], ["ii", 466], [")", 468], ["explored", 470], ["self", 479], ["-", 483], ["reported", 484], ["ill", 493], ["health", 497], ["among", 504], ["veterans", 510], ["who", 519], ["believed", 523], ["that", 532], ["they", 537], ["had", 542], ["Gulf", 546], ["War", 551], ["syndrome", 555], [".", 563], ["This", 565], ["study", 570], ["uses", 576], ["data", 581], ["from", 586], ["a", 591], ["retrospective", 593], ["cohort", 607], ["study", 614], ["of", 620], ["reproduction", 623], ["and", 636], ["child", 640], ["health", 646], ["in", 653], ["which", 656], ["a", 662], ["validated", 664], ["postal", 674], ["questionnaire", 681], ["was", 695], ["sent", 699], ["to", 704], ["all", 707], ["UK", 711], ["Gulf", 714], ["War", 719], ["veterans", 723], ["(", 732], ["GWV", 733], [")", 736], ["and", 738], ["a", 742], ["comparison", 744], ["cohort", 755], ["of", 762], ["Armed", 765], ["Service", 771], ["personnel", 779], ["who", 789], ["were", 793], ["not", 798], ["deployed", 802], ["to", 811], ["the", 814], ["Gulf", 818], ["(", 823], ["NGWV", 824], [")", 828], [".", 829], ["The", 831], ["cohort", 835], ["for", 842], ["analysis", 846], ["comprises", 855], ["42,818", 865], ["males", 872], ["who", 878], ["responded", 882], ["to", 892], ["the", 895], ["questionnaire", 899], [".", 912], ["We", 914], ["confirmed", 917], ["that", 927], ["GWV", 932], ["report", 936], ["higher", 943], ["rates", 950], ["of", 956], ["general", 959], ["ill", 967], ["health", 971], [".", 977], ["GWV", 979], ["were", 983], ["significantly", 988], ["more", 1002], ["likely", 1007], ["to", 1014], ["have", 1017], ["reported", 1022], ["at", 1031], ["least", 1034], ["one", 1040], ["new", 1044], ["medical", 1048], ["symptom", 1056], ["or", 1064], ["disease", 1067], ["since", 1075], ["1990", 1081], ["than", 1086], ["NGWV", 1091], ["(", 1096], ["61", 1097], ["%", 1099], ["versus", 1101], ["37", 1108], ["%", 1110], [",", 1111], ["OR", 1113], ["2.7", 1116], [",", 1119], ["95", 1121], ["%", 1123], ["CI", 1125], ["2.5", 1128], ["-", 1131], ["2.8", 1132], [")", 1135], [".", 1136], ["They", 1138], ["were", 1143], ["also", 1148], ["more", 1153], ["likely", 1158], ["to", 1165], ["report", 1168], ["higher", 1175], ["numbers", 1182], ["of", 1190], ["symptoms", 1193], [".", 1201], ["The", 1203], ["strongest", 1207], ["associations", 1217], ["were", 1230], ["for", 1235], ["mood", 1239], ["swings", 1244], ["(", 1251], ["OR", 1252], ["20.9", 1255], [",", 1259], ["95%CI", 1261], ["16.2", 1267], ["-", 1271], ["27.0", 1272], [")", 1276], [",", 1277], ["memory", 1279], ["loss", 1286], ["/", 1290], ["lack", 1291], ["of", 1296], ["concentration", 1299], ["(", 1313], ["OR", 1314], ["19.6", 1317], [",", 1321], ["95", 1323], ["%", 1325], ["CI", 1327], ["15.5", 1330], ["-", 1334], ["24.8", 1335], [")", 1339], [",", 1340], ["night", 1342], ["sweats", 1348], ["(", 1355], ["OR", 1356], ["9.9", 1359], [",", 1362], ["95", 1364], ["%", 1366], ["CI", 1368], ["6.5", 1371], ["-", 1374], ["15.2", 1375], [")", 1379], [",", 1380], ["general", 1382], ["fatigue", 1390], ["(", 1398], ["OR", 1399], ["9.6", 1402], [",", 1405], ["95", 1407], ["%", 1409], ["CI", 1411], ["8.3", 1414], ["-", 1417], ["11.1", 1418], [")", 1422], ["and", 1424], ["sexual", 1428], ["dysfunction", 1435], ["(", 1447], ["OR", 1448], ["4.6", 1451], [",", 1454], ["95%CI", 1456], ["3.2", 1462], ["-", 1465], ["6.6", 1466], [")", 1469], [".", 1470], ["6", 1472], ["%", 1473], ["of", 1475], ["GWV", 1478], ["believed", 1482], ["they", 1491], ["had", 1496], ["Gulf", 1500], ["War", 1505], ["syndrome", 1509], ["(", 1518], ["GWS", 1519], [")", 1522], [",", 1523], ["and", 1525], ["this", 1529], ["was", 1534], ["associated", 1538], ["with", 1549], ["the", 1554], ["highest", 1558], ["symptom", 1566], ["reporting", 1574], [".", 1583], ["Increased", 1585], ["levels", 1595], ["of", 1602], ["reported", 1605], ["ill", 1614], ["health", 1618], ["among", 1625], ["GWV", 1631], ["were", 1635], ["confirmed", 1640], [".", 1649], ["This", 1651], ["study", 1656], ["was", 1662], ["the", 1666], ["first", 1670], ["to", 1676], ["use", 1679], ["a", 1683], ["questionnaire", 1685], ["which", 1699], ["did", 1705], ["not", 1709], ["focus", 1713], ["specifically", 1719], ["on", 1732], ["the", 1735], ["veterans", 1739], ["'", 1747], ["symptoms", 1749], ["themselves", 1758], [".", 1768], ["Nevertheless", 1770], [",", 1782], ["the", 1784], ["results", 1788], ["are", 1796], ["consistent", 1800], ["with", 1811], ["those", 1816], ["of", 1822], ["other", 1825], ["studies", 1831], ["of", 1839], ["post", 1842], ["-", 1846], ["Gulf", 1847], ["war", 1852], ["illness", 1856], ["and", 1864], ["thus", 1868], ["strengthen", 1873], ["overall", 1884], ["findings", 1892], ["in", 1901], ["this", 1904], ["area", 1909], ["of", 1914], ["research", 1917], [".", 1925], ["Further", 1927], ["examination", 1935], ["of", 1947], ["the", 1950], ["mechanisms", 1954], ["underlying", 1965], ["the", 1976], ["reporting", 1980], ["of", 1990], ["ill", 1993], ["health", 1997], ["is", 2004], ["required", 2007], [".", 2015]]}
{"context": "We generated a genome-wide replication profile in the genome of Lachancea kluyveri and assessed the relationship between replication and base composition. This species diverged from Saccharomyces cerevisiae before the ancestral whole genome duplication. The genome comprises eight chromosomes among which a chromosomal arm of 1 Mb has a G + C-content much higher than the rest of the genome. We identified 252 active replication origins in L. kluyveri and found considerable divergence in origin location with S. cerevisiae and with Lachancea waltii. Although some global features of S. cerevisiae replication are conserved: Centromeres replicate early, whereas telomeres replicate late, we found that replication origins both in L. kluyveri and L. waltii do not behave as evolutionary fragile sites. In L. kluyveri, replication timing along chromosomes alternates between regions of early and late activating origins, except for the 1 Mb GC-rich chromosomal arm. This chromosomal arm contains an origin consensus motif different from other chromosomes and is replicated early during S-phase. We showed that precocious replication results from the specific absence of late firing origins in this chromosomal arm. In addition, we found a correlation between GC-content and distance from replication origins as well as a lack of replication-associated compositional skew between leading and lagging strands specifically in this GC-rich chromosomal arm. These findings suggest that the unusual base composition in the genome of L. kluyveri could be linked to replication.", "qas": [{"question": "Do origins of replication close to yeast centromeres fire early or late?", "answers": ["Early"], "qid": "d8b6714eca6845d68ff4a83b405e4a77", "question_tokens": [["Do", 0], ["origins", 3], ["of", 11], ["replication", 14], ["close", 26], ["to", 32], ["yeast", 35], ["centromeres", 41], ["fire", 53], ["early", 58], ["or", 64], ["late", 67], ["?", 71]], "detected_answers": [{"text": "Early", "token_spans": [[174, 174], [103, 103], [142, 142]], "char_spans": [[1071, 1075], [647, 651], [884, 888]]}]}], "context_tokens": [["We", 0], ["generated", 3], ["a", 13], ["genome", 15], ["-", 21], ["wide", 22], ["replication", 27], ["profile", 39], ["in", 47], ["the", 50], ["genome", 54], ["of", 61], ["Lachancea", 64], ["kluyveri", 74], ["and", 83], ["assessed", 87], ["the", 96], ["relationship", 100], ["between", 113], ["replication", 121], ["and", 133], ["base", 137], ["composition", 142], [".", 153], ["This", 155], ["species", 160], ["diverged", 168], ["from", 177], ["Saccharomyces", 182], ["cerevisiae", 196], ["before", 207], ["the", 214], ["ancestral", 218], ["whole", 228], ["genome", 234], ["duplication", 241], [".", 252], ["The", 254], ["genome", 258], ["comprises", 265], ["eight", 275], ["chromosomes", 281], ["among", 293], ["which", 299], ["a", 305], ["chromosomal", 307], ["arm", 319], ["of", 323], ["1", 326], ["Mb", 328], ["has", 331], ["a", 335], ["G", 337], ["+", 339], ["C", 341], ["-", 342], ["content", 343], ["much", 351], ["higher", 356], ["than", 363], ["the", 368], ["rest", 372], ["of", 377], ["the", 380], ["genome", 384], [".", 390], ["We", 392], ["identified", 395], ["252", 406], ["active", 410], ["replication", 417], ["origins", 429], ["in", 437], ["L.", 440], ["kluyveri", 443], ["and", 452], ["found", 456], ["considerable", 462], ["divergence", 475], ["in", 486], ["origin", 489], ["location", 496], ["with", 505], ["S.", 510], ["cerevisiae", 513], ["and", 524], ["with", 528], ["Lachancea", 533], ["waltii", 543], [".", 549], ["Although", 551], ["some", 560], ["global", 565], ["features", 572], ["of", 581], ["S.", 584], ["cerevisiae", 587], ["replication", 598], ["are", 610], ["conserved", 614], [":", 623], ["Centromeres", 625], ["replicate", 637], ["early", 647], [",", 652], ["whereas", 654], ["telomeres", 662], ["replicate", 672], ["late", 682], [",", 686], ["we", 688], ["found", 691], ["that", 697], ["replication", 702], ["origins", 714], ["both", 722], ["in", 727], ["L.", 730], ["kluyveri", 733], ["and", 742], ["L.", 746], ["waltii", 749], ["do", 756], ["not", 759], ["behave", 763], ["as", 770], ["evolutionary", 773], ["fragile", 786], ["sites", 794], [".", 799], ["In", 801], ["L.", 804], ["kluyveri", 807], [",", 815], ["replication", 817], ["timing", 829], ["along", 836], ["chromosomes", 842], ["alternates", 854], ["between", 865], ["regions", 873], ["of", 881], ["early", 884], ["and", 890], ["late", 894], ["activating", 899], ["origins", 910], [",", 917], ["except", 919], ["for", 926], ["the", 930], ["1", 934], ["Mb", 936], ["GC", 939], ["-", 941], ["rich", 942], ["chromosomal", 947], ["arm", 959], [".", 962], ["This", 964], ["chromosomal", 969], ["arm", 981], ["contains", 985], ["an", 994], ["origin", 997], ["consensus", 1004], ["motif", 1014], ["different", 1020], ["from", 1030], ["other", 1035], ["chromosomes", 1041], ["and", 1053], ["is", 1057], ["replicated", 1060], ["early", 1071], ["during", 1077], ["S", 1084], ["-", 1085], ["phase", 1086], [".", 1091], ["We", 1093], ["showed", 1096], ["that", 1103], ["precocious", 1108], ["replication", 1119], ["results", 1131], ["from", 1139], ["the", 1144], ["specific", 1148], ["absence", 1157], ["of", 1165], ["late", 1168], ["firing", 1173], ["origins", 1180], ["in", 1188], ["this", 1191], ["chromosomal", 1196], ["arm", 1208], [".", 1211], ["In", 1213], ["addition", 1216], [",", 1224], ["we", 1226], ["found", 1229], ["a", 1235], ["correlation", 1237], ["between", 1249], ["GC", 1257], ["-", 1259], ["content", 1260], ["and", 1268], ["distance", 1272], ["from", 1281], ["replication", 1286], ["origins", 1298], ["as", 1306], ["well", 1309], ["as", 1314], ["a", 1317], ["lack", 1319], ["of", 1324], ["replication", 1327], ["-", 1338], ["associated", 1339], ["compositional", 1350], ["skew", 1364], ["between", 1369], ["leading", 1377], ["and", 1385], ["lagging", 1389], ["strands", 1397], ["specifically", 1405], ["in", 1418], ["this", 1421], ["GC", 1426], ["-", 1428], ["rich", 1429], ["chromosomal", 1434], ["arm", 1446], [".", 1449], ["These", 1451], ["findings", 1457], ["suggest", 1466], ["that", 1474], ["the", 1479], ["unusual", 1483], ["base", 1491], ["composition", 1496], ["in", 1508], ["the", 1511], ["genome", 1515], ["of", 1522], ["L.", 1525], ["kluyveri", 1528], ["could", 1537], ["be", 1543], ["linked", 1546], ["to", 1553], ["replication", 1556], [".", 1567]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a vascular dementing disease caused by mutations in the NOTCH3 gene, most which are missense mutations leading to an uneven number of cysteine residues in epidermal growth factor-like repeats in the extracellular domain of Notch3 receptor (N3ECD). CADASIL is characterized by degeneration of vascular smooth muscle cells (VSMC) and accumulation of N3ECD on the VSMCs of small and middle-sized arteries. Recent studies have demonstrated that impairment of Notch3 signaling is not the primary cause of the disease. In the present study we used proteomic analysis to characterize the protein expression pattern of a unique material of genetically genuine cultured human CADASIL VSMCs. We identified 11 differentially expressed proteins, which are involved in protein degradation and folding, contraction of VSMCs, and cellular stress. Our findings indicate that misfolding of Notch3 may cause endoplasmic reticulum stress and activation of unfolded protein response, leading to increased reactive oxygen species and inhibition of cell proliferation. In addition, upregulation of contractile proteins suggests an alteration in the signaling system of VSMC contraction. The accumulation of N3ECD on the cell surface possibly upregulates the angiotensin II regulatory feedback loop and thereby enhances the readiness of the cells to respond to angiotensin II stimulation.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "23e49b37f14a466999405fd5b5603a3b", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[22, 23]], "char_spans": [[160, 170]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["a", 104], ["vascular", 106], ["dementing", 115], ["disease", 125], ["caused", 133], ["by", 140], ["mutations", 143], ["in", 153], ["the", 156], ["NOTCH3", 160], ["gene", 167], [",", 171], ["most", 173], ["which", 178], ["are", 184], ["missense", 188], ["mutations", 197], ["leading", 207], ["to", 215], ["an", 218], ["uneven", 221], ["number", 228], ["of", 235], ["cysteine", 238], ["residues", 247], ["in", 256], ["epidermal", 259], ["growth", 269], ["factor", 276], ["-", 282], ["like", 283], ["repeats", 288], ["in", 296], ["the", 299], ["extracellular", 303], ["domain", 317], ["of", 324], ["Notch3", 327], ["receptor", 334], ["(", 343], ["N3ECD", 344], [")", 349], [".", 350], ["CADASIL", 352], ["is", 360], ["characterized", 363], ["by", 377], ["degeneration", 380], ["of", 393], ["vascular", 396], ["smooth", 405], ["muscle", 412], ["cells", 419], ["(", 425], ["VSMC", 426], [")", 430], ["and", 432], ["accumulation", 436], ["of", 449], ["N3ECD", 452], ["on", 458], ["the", 461], ["VSMCs", 465], ["of", 471], ["small", 474], ["and", 480], ["middle", 484], ["-", 490], ["sized", 491], ["arteries", 497], [".", 505], ["Recent", 507], ["studies", 514], ["have", 522], ["demonstrated", 527], ["that", 540], ["impairment", 545], ["of", 556], ["Notch3", 559], ["signaling", 566], ["is", 576], ["not", 579], ["the", 583], ["primary", 587], ["cause", 595], ["of", 601], ["the", 604], ["disease", 608], [".", 615], ["In", 617], ["the", 620], ["present", 624], ["study", 632], ["we", 638], ["used", 641], ["proteomic", 646], ["analysis", 656], ["to", 665], ["characterize", 668], ["the", 681], ["protein", 685], ["expression", 693], ["pattern", 704], ["of", 712], ["a", 715], ["unique", 717], ["material", 724], ["of", 733], ["genetically", 736], ["genuine", 748], ["cultured", 756], ["human", 765], ["CADASIL", 771], ["VSMCs", 779], [".", 784], ["We", 786], ["identified", 789], ["11", 800], ["differentially", 803], ["expressed", 818], ["proteins", 828], [",", 836], ["which", 838], ["are", 844], ["involved", 848], ["in", 857], ["protein", 860], ["degradation", 868], ["and", 880], ["folding", 884], [",", 891], ["contraction", 893], ["of", 905], ["VSMCs", 908], [",", 913], ["and", 915], ["cellular", 919], ["stress", 928], [".", 934], ["Our", 936], ["findings", 940], ["indicate", 949], ["that", 958], ["misfolding", 963], ["of", 974], ["Notch3", 977], ["may", 984], ["cause", 988], ["endoplasmic", 994], ["reticulum", 1006], ["stress", 1016], ["and", 1023], ["activation", 1027], ["of", 1038], ["unfolded", 1041], ["protein", 1050], ["response", 1058], [",", 1066], ["leading", 1068], ["to", 1076], ["increased", 1079], ["reactive", 1089], ["oxygen", 1098], ["species", 1105], ["and", 1113], ["inhibition", 1117], ["of", 1128], ["cell", 1131], ["proliferation", 1136], [".", 1149], ["In", 1151], ["addition", 1154], [",", 1162], ["upregulation", 1164], ["of", 1177], ["contractile", 1180], ["proteins", 1192], ["suggests", 1201], ["an", 1210], ["alteration", 1213], ["in", 1224], ["the", 1227], ["signaling", 1231], ["system", 1241], ["of", 1248], ["VSMC", 1251], ["contraction", 1256], [".", 1267], ["The", 1269], ["accumulation", 1273], ["of", 1286], ["N3ECD", 1289], ["on", 1295], ["the", 1298], ["cell", 1302], ["surface", 1307], ["possibly", 1315], ["upregulates", 1324], ["the", 1336], ["angiotensin", 1340], ["II", 1352], ["regulatory", 1355], ["feedback", 1366], ["loop", 1375], ["and", 1380], ["thereby", 1384], ["enhances", 1392], ["the", 1401], ["readiness", 1405], ["of", 1415], ["the", 1418], ["cells", 1422], ["to", 1428], ["respond", 1431], ["to", 1439], ["angiotensin", 1442], ["II", 1454], ["stimulation", 1457], [".", 1468]]}
{"context": "Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm characterized by the presence of the Philadelphia chromosome. This arises from a balanced translocation between chromosomes 9 and 22, creating the bcr-abl fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation, which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy. After imatinib treatment, > 90% of patients had a complete hematologic response, and 70%-80% had a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging and exhibit a major change in the natural history of the disease. The understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance. The outlook today for patients with CML is much brighter than that of a few years ago.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "daeaeaba2d634317b4b23a5d6051f0e1", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[37, 39], [71, 73]], "char_spans": [[238, 244], [418, 424]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["a", 38], ["progressive", 40], ["and", 52], ["often", 56], ["fatal", 62], ["hematopoietic", 68], ["neoplasm", 82], ["characterized", 91], ["by", 105], ["the", 108], ["presence", 112], ["of", 121], ["the", 124], ["Philadelphia", 128], ["chromosome", 141], [".", 151], ["This", 153], ["arises", 158], ["from", 165], ["a", 170], ["balanced", 172], ["translocation", 181], ["between", 195], ["chromosomes", 203], ["9", 215], ["and", 217], ["22", 221], [",", 223], ["creating", 225], ["the", 234], ["bcr", 238], ["-", 241], ["abl", 242], ["fusion", 246], ["gene", 253], [".", 257], ["It", 259], ["is", 262], ["often", 265], ["stated", 271], ["that", 278], ["the", 283], ["only", 287], ["proven", 292], ["curative", 299], ["option", 308], ["is", 315], ["allogeneic", 318], ["stem", 329], ["cell", 334], ["transplantation", 339], [",", 354], ["which", 356], ["is", 362], ["indicated", 365], ["for", 375], ["only", 379], ["a", 384], ["limited", 386], ["subset", 394], ["of", 401], ["patients", 404], [".", 412], ["The", 414], ["Bcr", 418], ["-", 421], ["Abl", 422], ["tyrosine", 426], ["kinase", 435], ["inhibitor", 442], ["imatinib", 452], ["represented", 461], ["a", 473], ["major", 475], ["advance", 481], ["over", 489], ["conventional", 494], ["CML", 507], ["therapy", 511], [".", 518], ["After", 520], ["imatinib", 526], ["treatment", 535], [",", 544], [">", 546], ["90", 548], ["%", 550], ["of", 552], ["patients", 555], ["had", 564], ["a", 568], ["complete", 570], ["hematologic", 579], ["response", 591], [",", 599], ["and", 601], ["70%-80", 605], ["%", 611], ["had", 613], ["a", 617], ["complete", 619], ["cytogenetic", 628], ["response", 640], [".", 648], ["With", 650], ["5", 655], ["years", 657], ["of", 663], ["follow", 666], ["-", 672], ["up", 673], [",", 675], ["the", 677], ["data", 681], ["are", 686], ["very", 690], ["encouraging", 695], ["and", 707], ["exhibit", 711], ["a", 719], ["major", 721], ["change", 727], ["in", 734], ["the", 737], ["natural", 741], ["history", 749], ["of", 757], ["the", 760], ["disease", 764], [".", 771], ["The", 773], ["understanding", 777], ["of", 791], ["some", 794], ["of", 799], ["the", 802], ["mechanisms", 806], ["of", 817], ["resistance", 820], ["to", 831], ["imatinib", 834], ["has", 843], ["led", 847], ["to", 851], ["a", 854], ["rapid", 856], ["development", 862], ["of", 874], ["new", 877], ["agents", 881], ["that", 888], ["might", 893], ["overcome", 899], ["this", 908], ["resistance", 913], [".", 923], ["The", 925], ["outlook", 929], ["today", 937], ["for", 943], ["patients", 947], ["with", 956], ["CML", 961], ["is", 965], ["much", 968], ["brighter", 973], ["than", 982], ["that", 987], ["of", 992], ["a", 995], ["few", 997], ["years", 1001], ["ago", 1007], [".", 1010]]}
{"context": "Understanding the pathogenesis of CLL has uncovered a plethora of novel targets for human application of monoclonal antibodies, engineered T cells, or inhibitors of signal transduction pathways. The B-cell receptor signaling pathway is being actively explored as a therapeutic target in CLL. Ibrutinib, an inhibitor of Bruton's tyrosine kinase is showing impressive responses in heavily pre-treated high-risk CLL, whether alone or in combination with MoAbs or chemotherapy. Other key components of the BCR pathway, namely PI3K-\u03b4, are also being targeted with novel therapies with promising results as well. Future trials would likely evaluate ibrutinib in the front-line setting. Moreover, improvements in allogeneic HCT mostly by continuing to reduce associated toxicity as well as incorporating cellular therapies such as autologous CLL tumor vaccines, among others, will continue to expand. This is also the case for the next generation of chimeric antigen receptor therapy for CLL once genetically modified T cells are available at broad scale and with improved efficacy. As our ability to further refine and integrate these therapies continues to improve, and we gain further knowledge from gene sequencing, we anticipate that treatment algorithms will continue to be revised to a more personalized approach to treat this disease with improved efficacy and devoid of unnecessary toxicity.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "e34cd287534b4fd788442be110013bba", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[48, 48], [112, 112]], "char_spans": [[292, 300], [643, 651]]}]}], "context_tokens": [["Understanding", 0], ["the", 14], ["pathogenesis", 18], ["of", 31], ["CLL", 34], ["has", 38], ["uncovered", 42], ["a", 52], ["plethora", 54], ["of", 63], ["novel", 66], ["targets", 72], ["for", 80], ["human", 84], ["application", 90], ["of", 102], ["monoclonal", 105], ["antibodies", 116], [",", 126], ["engineered", 128], ["T", 139], ["cells", 141], [",", 146], ["or", 148], ["inhibitors", 151], ["of", 162], ["signal", 165], ["transduction", 172], ["pathways", 185], [".", 193], ["The", 195], ["B", 199], ["-", 200], ["cell", 201], ["receptor", 206], ["signaling", 215], ["pathway", 225], ["is", 233], ["being", 236], ["actively", 242], ["explored", 251], ["as", 260], ["a", 263], ["therapeutic", 265], ["target", 277], ["in", 284], ["CLL", 287], [".", 290], ["Ibrutinib", 292], [",", 301], ["an", 303], ["inhibitor", 306], ["of", 316], ["Bruton", 319], ["'s", 325], ["tyrosine", 328], ["kinase", 337], ["is", 344], ["showing", 347], ["impressive", 355], ["responses", 366], ["in", 376], ["heavily", 379], ["pre", 387], ["-", 390], ["treated", 391], ["high", 399], ["-", 403], ["risk", 404], ["CLL", 409], [",", 412], ["whether", 414], ["alone", 422], ["or", 428], ["in", 431], ["combination", 434], ["with", 446], ["MoAbs", 451], ["or", 457], ["chemotherapy", 460], [".", 472], ["Other", 474], ["key", 480], ["components", 484], ["of", 495], ["the", 498], ["BCR", 502], ["pathway", 506], [",", 513], ["namely", 515], ["PI3K", 522], ["-", 526], ["\u03b4", 527], [",", 528], ["are", 530], ["also", 534], ["being", 539], ["targeted", 545], ["with", 554], ["novel", 559], ["therapies", 565], ["with", 575], ["promising", 580], ["results", 590], ["as", 598], ["well", 601], [".", 605], ["Future", 607], ["trials", 614], ["would", 621], ["likely", 627], ["evaluate", 634], ["ibrutinib", 643], ["in", 653], ["the", 656], ["front", 660], ["-", 665], ["line", 666], ["setting", 671], [".", 678], ["Moreover", 680], [",", 688], ["improvements", 690], ["in", 703], ["allogeneic", 706], ["HCT", 717], ["mostly", 721], ["by", 728], ["continuing", 731], ["to", 742], ["reduce", 745], ["associated", 752], ["toxicity", 763], ["as", 772], ["well", 775], ["as", 780], ["incorporating", 783], ["cellular", 797], ["therapies", 806], ["such", 816], ["as", 821], ["autologous", 824], ["CLL", 835], ["tumor", 839], ["vaccines", 845], [",", 853], ["among", 855], ["others", 861], [",", 867], ["will", 869], ["continue", 874], ["to", 883], ["expand", 886], [".", 892], ["This", 894], ["is", 899], ["also", 902], ["the", 907], ["case", 911], ["for", 916], ["the", 920], ["next", 924], ["generation", 929], ["of", 940], ["chimeric", 943], ["antigen", 952], ["receptor", 960], ["therapy", 969], ["for", 977], ["CLL", 981], ["once", 985], ["genetically", 990], ["modified", 1002], ["T", 1011], ["cells", 1013], ["are", 1019], ["available", 1023], ["at", 1033], ["broad", 1036], ["scale", 1042], ["and", 1048], ["with", 1052], ["improved", 1057], ["efficacy", 1066], [".", 1074], ["As", 1076], ["our", 1079], ["ability", 1083], ["to", 1091], ["further", 1094], ["refine", 1102], ["and", 1109], ["integrate", 1113], ["these", 1123], ["therapies", 1129], ["continues", 1139], ["to", 1149], ["improve", 1152], [",", 1159], ["and", 1161], ["we", 1165], ["gain", 1168], ["further", 1173], ["knowledge", 1181], ["from", 1191], ["gene", 1196], ["sequencing", 1201], [",", 1211], ["we", 1213], ["anticipate", 1216], ["that", 1227], ["treatment", 1232], ["algorithms", 1242], ["will", 1253], ["continue", 1258], ["to", 1267], ["be", 1270], ["revised", 1273], ["to", 1281], ["a", 1284], ["more", 1286], ["personalized", 1291], ["approach", 1304], ["to", 1313], ["treat", 1316], ["this", 1322], ["disease", 1327], ["with", 1335], ["improved", 1340], ["efficacy", 1349], ["and", 1358], ["devoid", 1362], ["of", 1369], ["unnecessary", 1372], ["toxicity", 1384], [".", 1392]]}
{"context": "Gaucher's disease is an uncommon inborn recessive autosomal disease, due to a deficient activity of the lysosomal enzyme beta glucocerebrosidase. This disease is usually diagnosed in the first or second decade of life with the arising of bone pains, splenomegaly and hemorragic manifestations due to thrombocytopenia. When the enlarged spleen is not evident, or after splenectomy, patients may be mis-identified as having Gaucher's disease. We present here two cases of elderly patients aged 70 and 46 years respectively, in whom the disease was a surprising finding of bone marrow examination, during check up for pancytopenia.", "qas": [{"question": "Which enzyme is deficient in Gaucher's disease?", "answers": ["Beta glucocerebrosidase"], "qid": "c4ce6c58dde54eb782917fdb75d3caf0", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["deficient", 16], ["in", 26], ["Gaucher", 29], ["'s", 36], ["disease", 39], ["?", 46]], "detected_answers": [{"text": "Beta glucocerebrosidase", "token_spans": [[20, 21]], "char_spans": [[121, 143]]}]}], "context_tokens": [["Gaucher", 0], ["'s", 7], ["disease", 10], ["is", 18], ["an", 21], ["uncommon", 24], ["inborn", 33], ["recessive", 40], ["autosomal", 50], ["disease", 60], [",", 67], ["due", 69], ["to", 73], ["a", 76], ["deficient", 78], ["activity", 88], ["of", 97], ["the", 100], ["lysosomal", 104], ["enzyme", 114], ["beta", 121], ["glucocerebrosidase", 126], [".", 144], ["This", 146], ["disease", 151], ["is", 159], ["usually", 162], ["diagnosed", 170], ["in", 180], ["the", 183], ["first", 187], ["or", 193], ["second", 196], ["decade", 203], ["of", 210], ["life", 213], ["with", 218], ["the", 223], ["arising", 227], ["of", 235], ["bone", 238], ["pains", 243], [",", 248], ["splenomegaly", 250], ["and", 263], ["hemorragic", 267], ["manifestations", 278], ["due", 293], ["to", 297], ["thrombocytopenia", 300], [".", 316], ["When", 318], ["the", 323], ["enlarged", 327], ["spleen", 336], ["is", 343], ["not", 346], ["evident", 350], [",", 357], ["or", 359], ["after", 362], ["splenectomy", 368], [",", 379], ["patients", 381], ["may", 390], ["be", 394], ["mis", 397], ["-", 400], ["identified", 401], ["as", 412], ["having", 415], ["Gaucher", 422], ["'s", 429], ["disease", 432], [".", 439], ["We", 441], ["present", 444], ["here", 452], ["two", 457], ["cases", 461], ["of", 467], ["elderly", 470], ["patients", 478], ["aged", 487], ["70", 492], ["and", 495], ["46", 499], ["years", 502], ["respectively", 508], [",", 520], ["in", 522], ["whom", 525], ["the", 530], ["disease", 534], ["was", 542], ["a", 546], ["surprising", 548], ["finding", 559], ["of", 567], ["bone", 570], ["marrow", 575], ["examination", 582], [",", 593], ["during", 595], ["check", 602], ["up", 608], ["for", 611], ["pancytopenia", 615], [".", 627]]}
{"context": "A 50-year-old man presented with worsening, virtually lifelong, chorea and progressive behavioural disturbance, involving disinhibition and hoarding, over 10 years. Clinical assessment revealed chorea, dysarthria, areflexia, an inappropriately jovial, impulsive manner and neuropsychological evidence of frontosubcortical dysfunction. Investigation results included an elevated creatine kinase, caudate atrophy and hypoperfusion, acanthocytes in the peripheral blood and the McLeod phenotype. DNA studies demonstrated a single-base deletion at position 172 in exon 1 of the XK gene, giving rise to a premature stop codon at position 129 in exon 2.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c44de3a52803425c8e515bdb5fb039ac", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[88, 88]], "char_spans": [[574, 575]]}]}], "context_tokens": [["A", 0], ["50-year", 2], ["-", 9], ["old", 10], ["man", 14], ["presented", 18], ["with", 28], ["worsening", 33], [",", 42], ["virtually", 44], ["lifelong", 54], [",", 62], ["chorea", 64], ["and", 71], ["progressive", 75], ["behavioural", 87], ["disturbance", 99], [",", 110], ["involving", 112], ["disinhibition", 122], ["and", 136], ["hoarding", 140], [",", 148], ["over", 150], ["10", 155], ["years", 158], [".", 163], ["Clinical", 165], ["assessment", 174], ["revealed", 185], ["chorea", 194], [",", 200], ["dysarthria", 202], [",", 212], ["areflexia", 214], [",", 223], ["an", 225], ["inappropriately", 228], ["jovial", 244], [",", 250], ["impulsive", 252], ["manner", 262], ["and", 269], ["neuropsychological", 273], ["evidence", 292], ["of", 301], ["frontosubcortical", 304], ["dysfunction", 322], [".", 333], ["Investigation", 335], ["results", 349], ["included", 357], ["an", 366], ["elevated", 369], ["creatine", 378], ["kinase", 387], [",", 393], ["caudate", 395], ["atrophy", 403], ["and", 411], ["hypoperfusion", 415], [",", 428], ["acanthocytes", 430], ["in", 443], ["the", 446], ["peripheral", 450], ["blood", 461], ["and", 467], ["the", 471], ["McLeod", 475], ["phenotype", 482], [".", 491], ["DNA", 493], ["studies", 497], ["demonstrated", 505], ["a", 518], ["single", 520], ["-", 526], ["base", 527], ["deletion", 532], ["at", 541], ["position", 544], ["172", 553], ["in", 557], ["exon", 560], ["1", 565], ["of", 567], ["the", 570], ["XK", 574], ["gene", 577], [",", 581], ["giving", 583], ["rise", 590], ["to", 595], ["a", 598], ["premature", 600], ["stop", 610], ["codon", 615], ["at", 621], ["position", 624], ["129", 633], ["in", 637], ["exon", 640], ["2", 645], [".", 646]]}
{"context": "The acromelic dysplasia group includes three rare disorders: Weill-Marchesani syndrome (WMS), Geleophysic dysplasia (GD) and Acromicric dysplasia (AD) all characterized by short stature, short hands and stiff joints. The clinical overlap between the three disorders is striking. Indeed, in addition to the diagnostic criteria, they all share common features including delayed bone age, cone shaped epiphyses, thick skin and heart disease. In contrast, a microspherophakic lens seems to be a characteristic feature of WMS whereas hepatomegaly and a severe outcome are encountered only in the most severe forms of GD. Finally, WMS is transmitted either by an autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD by an autosomal dominant mode of inheritance. Using genetic approaches, we have identified the molecular basis of WMS and GD which both involved the same superfamily of proteins, the ADAMTS [A Disintegrin-like And Metalloproteinase domain (reprolysin type) with ThromboSpondin type 1 repeats (TSR)]. We have found ADAMTS10 mutations in the recessive form of WMS and Fibrillin 1 mutations in the dominant form of WMS. More recently, we have identified ADAMTSL2 mutations in GD. The function of ADAMTS1 0 and AD AMTSL 2 are unknown. But the findings of FBN1 and ADAMTS10 mutations in WMS suggest a direct link between the two proteins. Using a yeast double hybrid screen, we have identified LTBP1 (Latent TGFbeta Binding protein 1) as a partner of ADAMTSL2. The combination of these findings suggests that ADAMTS10 and ADAMTSL2 are both involved in the microfibrillar network.", "qas": [{"question": "What is the mode of inheritance of Acromicric dysplasia?", "answers": ["autosomal dominant"], "qid": "30fd38ce62fe459b88937446ee06bcbb", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Acromicric", 35], ["dysplasia", 46], ["?", 55]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[143, 144], [118, 119]], "char_spans": [[790, 807], [657, 674]]}]}], "context_tokens": [["The", 0], ["acromelic", 4], ["dysplasia", 14], ["group", 24], ["includes", 30], ["three", 39], ["rare", 45], ["disorders", 50], [":", 59], ["Weill", 61], ["-", 66], ["Marchesani", 67], ["syndrome", 78], ["(", 87], ["WMS", 88], [")", 91], [",", 92], ["Geleophysic", 94], ["dysplasia", 106], ["(", 116], ["GD", 117], [")", 119], ["and", 121], ["Acromicric", 125], ["dysplasia", 136], ["(", 146], ["AD", 147], [")", 149], ["all", 151], ["characterized", 155], ["by", 169], ["short", 172], ["stature", 178], [",", 185], ["short", 187], ["hands", 193], ["and", 199], ["stiff", 203], ["joints", 209], [".", 215], ["The", 217], ["clinical", 221], ["overlap", 230], ["between", 238], ["the", 246], ["three", 250], ["disorders", 256], ["is", 266], ["striking", 269], [".", 277], ["Indeed", 279], [",", 285], ["in", 287], ["addition", 290], ["to", 299], ["the", 302], ["diagnostic", 306], ["criteria", 317], [",", 325], ["they", 327], ["all", 332], ["share", 336], ["common", 342], ["features", 349], ["including", 358], ["delayed", 368], ["bone", 376], ["age", 381], [",", 384], ["cone", 386], ["shaped", 391], ["epiphyses", 398], [",", 407], ["thick", 409], ["skin", 415], ["and", 420], ["heart", 424], ["disease", 430], [".", 437], ["In", 439], ["contrast", 442], [",", 450], ["a", 452], ["microspherophakic", 454], ["lens", 472], ["seems", 477], ["to", 483], ["be", 486], ["a", 489], ["characteristic", 491], ["feature", 506], ["of", 514], ["WMS", 517], ["whereas", 521], ["hepatomegaly", 529], ["and", 542], ["a", 546], ["severe", 548], ["outcome", 555], ["are", 563], ["encountered", 567], ["only", 579], ["in", 584], ["the", 587], ["most", 591], ["severe", 596], ["forms", 603], ["of", 609], ["GD", 612], [".", 614], ["Finally", 616], [",", 623], ["WMS", 625], ["is", 629], ["transmitted", 632], ["either", 644], ["by", 651], ["an", 654], ["autosomal", 657], ["dominant", 667], ["or", 676], ["an", 679], ["autosomal", 682], ["recessive", 692], ["(", 702], ["AR", 703], [")", 705], ["mode", 707], ["of", 712], ["inheritance", 715], [",", 726], ["GD", 728], ["by", 731], ["an", 734], ["autosomal", 737], ["recessive", 747], ["mode", 757], ["of", 762], ["inheritance", 765], ["and", 777], ["AD", 781], ["by", 784], ["an", 787], ["autosomal", 790], ["dominant", 800], ["mode", 809], ["of", 814], ["inheritance", 817], [".", 828], ["Using", 830], ["genetic", 836], ["approaches", 844], [",", 854], ["we", 856], ["have", 859], ["identified", 864], ["the", 875], ["molecular", 879], ["basis", 889], ["of", 895], ["WMS", 898], ["and", 902], ["GD", 906], ["which", 909], ["both", 915], ["involved", 920], ["the", 929], ["same", 933], ["superfamily", 938], ["of", 950], ["proteins", 953], [",", 961], ["the", 963], ["ADAMTS", 967], ["[", 974], ["A", 975], ["Disintegrin", 977], ["-", 988], ["like", 989], ["And", 994], ["Metalloproteinase", 998], ["domain", 1016], ["(", 1023], ["reprolysin", 1024], ["type", 1035], [")", 1039], ["with", 1041], ["ThromboSpondin", 1046], ["type", 1061], ["1", 1066], ["repeats", 1068], ["(", 1076], ["TSR)].", 1077], ["We", 1084], ["have", 1087], ["found", 1092], ["ADAMTS10", 1098], ["mutations", 1107], ["in", 1117], ["the", 1120], ["recessive", 1124], ["form", 1134], ["of", 1139], ["WMS", 1142], ["and", 1146], ["Fibrillin", 1150], ["1", 1160], ["mutations", 1162], ["in", 1172], ["the", 1175], ["dominant", 1179], ["form", 1188], ["of", 1193], ["WMS", 1196], [".", 1199], ["More", 1201], ["recently", 1206], [",", 1214], ["we", 1216], ["have", 1219], ["identified", 1224], ["ADAMTSL2", 1235], ["mutations", 1244], ["in", 1254], ["GD", 1257], [".", 1259], ["The", 1261], ["function", 1265], ["of", 1274], ["ADAMTS1", 1277], ["0", 1285], ["and", 1287], ["AD", 1291], ["AMTSL", 1294], ["2", 1300], ["are", 1302], ["unknown", 1306], [".", 1313], ["But", 1315], ["the", 1319], ["findings", 1323], ["of", 1332], ["FBN1", 1335], ["and", 1340], ["ADAMTS10", 1344], ["mutations", 1353], ["in", 1363], ["WMS", 1366], ["suggest", 1370], ["a", 1378], ["direct", 1380], ["link", 1387], ["between", 1392], ["the", 1400], ["two", 1404], ["proteins", 1408], [".", 1416], ["Using", 1418], ["a", 1424], ["yeast", 1426], ["double", 1432], ["hybrid", 1439], ["screen", 1446], [",", 1452], ["we", 1454], ["have", 1457], ["identified", 1462], ["LTBP1", 1473], ["(", 1479], ["Latent", 1480], ["TGFbeta", 1487], ["Binding", 1495], ["protein", 1503], ["1", 1511], [")", 1512], ["as", 1514], ["a", 1517], ["partner", 1519], ["of", 1527], ["ADAMTSL2", 1530], [".", 1538], ["The", 1540], ["combination", 1544], ["of", 1556], ["these", 1559], ["findings", 1565], ["suggests", 1574], ["that", 1583], ["ADAMTS10", 1588], ["and", 1597], ["ADAMTSL2", 1601], ["are", 1610], ["both", 1614], ["involved", 1619], ["in", 1628], ["the", 1631], ["microfibrillar", 1635], ["network", 1650], [".", 1657]]}
{"context": "Bladder pain syndrome (BPS)/interstitial cystitis (IC) is associated with sensory lower urinary tract symptoms. Unfortunately, many of the existing oral treatments are ineffective in most patients of BPS/IC, which is the motivation for developing new drugs and therapeutic approaches. This review covers the latest drugs that have been investigated in BPS/IC patients. Intravesical treatments offer the opportunity to directly target the painful bladder with less systemic side effects. In this review, the authors analyze the existing literature supporting the treatment of BPS/IC with conventional drugs including heparin, hyaluronic acid, chondroitin sulfate, and dimethylsulfoxide (DMSO). Furthermore, investigational drugs such as tanezumab and adalimumab, capable of sequestering nerve growth factor (NGF), and Tumor necrosis factor-\u03b1 (TNF- \u03b1) are discussed. Investigational treatments such as liposomes, botulinum toxin (BTX), liposomal BTX, PD-0299685 (a Ca(2+) channel \u02512\u03b4 ligand), continuous intravesical lidocaine, and AQX-1125 (a novel SHIP1 activating compound) are also covered. New investigational drugs offer promising improvements in clinical outcomes for BPS/IC patients; however, BPS/IC is a chronic pain disorder that is very vulnerable to a strong placebo effect. In addition, BPS/IC is a heterogeneous disorder that can be classified into several phenotypes. Since different phenotypes of BPS/IC respond differently to systemic and intravesical treatments, the authors believe that new drugs developed for BPS/IC are more likely to meet their predetermined clinical endpoints if the inclusion/exclusion criterion is tailored to specific phenotype of BPS/IC patients.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "8d8314284e3742b58233aac35847fb78", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[129, 131]], "char_spans": [[786, 804]]}, {"text": "NGF", "token_spans": [[133, 133]], "char_spans": [[807, 809]]}]}], "context_tokens": [["Bladder", 0], ["pain", 8], ["syndrome", 13], ["(", 22], ["BPS)/interstitial", 23], ["cystitis", 41], ["(", 50], ["IC", 51], [")", 53], ["is", 55], ["associated", 58], ["with", 69], ["sensory", 74], ["lower", 82], ["urinary", 88], ["tract", 96], ["symptoms", 102], [".", 110], ["Unfortunately", 112], [",", 125], ["many", 127], ["of", 132], ["the", 135], ["existing", 139], ["oral", 148], ["treatments", 153], ["are", 164], ["ineffective", 168], ["in", 180], ["most", 183], ["patients", 188], ["of", 197], ["BPS", 200], ["/", 203], ["IC", 204], [",", 206], ["which", 208], ["is", 214], ["the", 217], ["motivation", 221], ["for", 232], ["developing", 236], ["new", 247], ["drugs", 251], ["and", 257], ["therapeutic", 261], ["approaches", 273], [".", 283], ["This", 285], ["review", 290], ["covers", 297], ["the", 304], ["latest", 308], ["drugs", 315], ["that", 321], ["have", 326], ["been", 331], ["investigated", 336], ["in", 349], ["BPS", 352], ["/", 355], ["IC", 356], ["patients", 359], [".", 367], ["Intravesical", 369], ["treatments", 382], ["offer", 393], ["the", 399], ["opportunity", 403], ["to", 415], ["directly", 418], ["target", 427], ["the", 434], ["painful", 438], ["bladder", 446], ["with", 454], ["less", 459], ["systemic", 464], ["side", 473], ["effects", 478], [".", 485], ["In", 487], ["this", 490], ["review", 495], [",", 501], ["the", 503], ["authors", 507], ["analyze", 515], ["the", 523], ["existing", 527], ["literature", 536], ["supporting", 547], ["the", 558], ["treatment", 562], ["of", 572], ["BPS", 575], ["/", 578], ["IC", 579], ["with", 582], ["conventional", 587], ["drugs", 600], ["including", 606], ["heparin", 616], [",", 623], ["hyaluronic", 625], ["acid", 636], [",", 640], ["chondroitin", 642], ["sulfate", 654], [",", 661], ["and", 663], ["dimethylsulfoxide", 667], ["(", 685], ["DMSO", 686], [")", 690], [".", 691], ["Furthermore", 693], [",", 704], ["investigational", 706], ["drugs", 722], ["such", 728], ["as", 733], ["tanezumab", 736], ["and", 746], ["adalimumab", 750], [",", 760], ["capable", 762], ["of", 770], ["sequestering", 773], ["nerve", 786], ["growth", 792], ["factor", 799], ["(", 806], ["NGF", 807], [")", 810], [",", 811], ["and", 813], ["Tumor", 817], ["necrosis", 823], ["factor", 832], ["-", 838], ["\u03b1", 839], ["(", 841], ["TNF-", 842], ["\u03b1", 847], [")", 848], ["are", 850], ["discussed", 854], [".", 863], ["Investigational", 865], ["treatments", 881], ["such", 892], ["as", 897], ["liposomes", 900], [",", 909], ["botulinum", 911], ["toxin", 921], ["(", 927], ["BTX", 928], [")", 931], [",", 932], ["liposomal", 934], ["BTX", 944], [",", 947], ["PD-0299685", 949], ["(", 960], ["a", 961], ["Ca(2", 963], ["+", 967], [")", 968], ["channel", 970], ["\u02512\u03b4", 978], ["ligand", 982], [")", 988], [",", 989], ["continuous", 991], ["intravesical", 1002], ["lidocaine", 1015], [",", 1024], ["and", 1026], ["AQX-1125", 1030], ["(", 1039], ["a", 1040], ["novel", 1042], ["SHIP1", 1048], ["activating", 1054], ["compound", 1065], [")", 1073], ["are", 1075], ["also", 1079], ["covered", 1084], [".", 1091], ["New", 1093], ["investigational", 1097], ["drugs", 1113], ["offer", 1119], ["promising", 1125], ["improvements", 1135], ["in", 1148], ["clinical", 1151], ["outcomes", 1160], ["for", 1169], ["BPS", 1173], ["/", 1176], ["IC", 1177], ["patients", 1180], [";", 1188], ["however", 1190], [",", 1197], ["BPS", 1199], ["/", 1202], ["IC", 1203], ["is", 1206], ["a", 1209], ["chronic", 1211], ["pain", 1219], ["disorder", 1224], ["that", 1233], ["is", 1238], ["very", 1241], ["vulnerable", 1246], ["to", 1257], ["a", 1260], ["strong", 1262], ["placebo", 1269], ["effect", 1277], [".", 1283], ["In", 1285], ["addition", 1288], [",", 1296], ["BPS", 1298], ["/", 1301], ["IC", 1302], ["is", 1305], ["a", 1308], ["heterogeneous", 1310], ["disorder", 1324], ["that", 1333], ["can", 1338], ["be", 1342], ["classified", 1345], ["into", 1356], ["several", 1361], ["phenotypes", 1369], [".", 1379], ["Since", 1381], ["different", 1387], ["phenotypes", 1397], ["of", 1408], ["BPS", 1411], ["/", 1414], ["IC", 1415], ["respond", 1418], ["differently", 1426], ["to", 1438], ["systemic", 1441], ["and", 1450], ["intravesical", 1454], ["treatments", 1467], [",", 1477], ["the", 1479], ["authors", 1483], ["believe", 1491], ["that", 1499], ["new", 1504], ["drugs", 1508], ["developed", 1514], ["for", 1524], ["BPS", 1528], ["/", 1531], ["IC", 1532], ["are", 1535], ["more", 1539], ["likely", 1544], ["to", 1551], ["meet", 1554], ["their", 1559], ["predetermined", 1565], ["clinical", 1579], ["endpoints", 1588], ["if", 1598], ["the", 1601], ["inclusion", 1605], ["/", 1614], ["exclusion", 1615], ["criterion", 1625], ["is", 1635], ["tailored", 1638], ["to", 1647], ["specific", 1650], ["phenotype", 1659], ["of", 1669], ["BPS", 1672], ["/", 1675], ["IC", 1676], ["patients", 1679], [".", 1687]]}
{"context": "Mutant ataxin-3 is aberrantly folded and proteolytically cleaved in spinocerebellar ataxia type 3. The C-terminal region of the protein includes a polyglutamine stretch that is expanded in spinocerebellar ataxia type 3. Here, we report on the analysis of an ataxin-3 mutant mouse that has been obtained by gene trap integration. The ataxin-3 fusion protein encompasses 259\u2009N-terminal amino acids including the Josephin domain and an ubiquitin-interacting motif but lacks the C-terminus with the polyglutamine stretch, the valosin-containing protein binding region and part of the ubiquitin-interacting motif 2. Homozygous ataxin-3 mutant mice were viable and showed no apparent anatomical defects at birth. However, at the age of 9 months, homozygous and heterozygous mutant mice revealed significantly altered behaviour and progressing deficits of motor coordination followed by premature death at \u223c12 months. At this time, prominent extranuclear protein aggregates and neuronal cell death was found in mutant mice. This was associated with disturbances of the endoplasmic reticulum-mediated unfolded protein response, consistent with the normal role of ataxin-3 in endoplasmic reticulum homeostasis. Thus, the ataxin-3 gene trap model provides evidence for a contribution of the non-polyglutamine containing ataxin-3\u2009N-terminus, which mimics a calpain fragment that has been observed in spinocerebellar ataxia type 3. Consistent with the disease in humans, gene trap mice develop cytoplasmic inclusion bodies and implicate impaired unfolded protein response in the pathogenesis of spinocerebellar ataxia type 3.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "b4fcd51ad7b44e5b973a0b67bc523ce8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[106, 106], [44, 44], [57, 57], [215, 215], [1, 1], [200, 200], [191, 191]], "char_spans": [[622, 629], [258, 265], [333, 340], [1310, 1317], [7, 14], [1212, 1219], [1155, 1162]]}]}], "context_tokens": [["Mutant", 0], ["ataxin-3", 7], ["is", 16], ["aberrantly", 19], ["folded", 30], ["and", 37], ["proteolytically", 41], ["cleaved", 57], ["in", 65], ["spinocerebellar", 68], ["ataxia", 84], ["type", 91], ["3", 96], [".", 97], ["The", 99], ["C", 103], ["-", 104], ["terminal", 105], ["region", 114], ["of", 121], ["the", 124], ["protein", 128], ["includes", 136], ["a", 145], ["polyglutamine", 147], ["stretch", 161], ["that", 169], ["is", 174], ["expanded", 177], ["in", 186], ["spinocerebellar", 189], ["ataxia", 205], ["type", 212], ["3", 217], [".", 218], ["Here", 220], [",", 224], ["we", 226], ["report", 229], ["on", 236], ["the", 239], ["analysis", 243], ["of", 252], ["an", 255], ["ataxin-3", 258], ["mutant", 267], ["mouse", 274], ["that", 280], ["has", 285], ["been", 289], ["obtained", 294], ["by", 303], ["gene", 306], ["trap", 311], ["integration", 316], [".", 327], ["The", 329], ["ataxin-3", 333], ["fusion", 342], ["protein", 349], ["encompasses", 357], ["259", 369], ["N", 373], ["-", 374], ["terminal", 375], ["amino", 384], ["acids", 390], ["including", 396], ["the", 406], ["Josephin", 410], ["domain", 419], ["and", 426], ["an", 430], ["ubiquitin", 433], ["-", 442], ["interacting", 443], ["motif", 455], ["but", 461], ["lacks", 465], ["the", 471], ["C", 475], ["-", 476], ["terminus", 477], ["with", 486], ["the", 491], ["polyglutamine", 495], ["stretch", 509], [",", 516], ["the", 518], ["valosin", 522], ["-", 529], ["containing", 530], ["protein", 541], ["binding", 549], ["region", 557], ["and", 564], ["part", 568], ["of", 573], ["the", 576], ["ubiquitin", 580], ["-", 589], ["interacting", 590], ["motif", 602], ["2", 608], [".", 609], ["Homozygous", 611], ["ataxin-3", 622], ["mutant", 631], ["mice", 638], ["were", 643], ["viable", 648], ["and", 655], ["showed", 659], ["no", 666], ["apparent", 669], ["anatomical", 678], ["defects", 689], ["at", 697], ["birth", 700], [".", 705], ["However", 707], [",", 714], ["at", 716], ["the", 719], ["age", 723], ["of", 727], ["9", 730], ["months", 732], [",", 738], ["homozygous", 740], ["and", 751], ["heterozygous", 755], ["mutant", 768], ["mice", 775], ["revealed", 780], ["significantly", 789], ["altered", 803], ["behaviour", 811], ["and", 821], ["progressing", 825], ["deficits", 837], ["of", 846], ["motor", 849], ["coordination", 855], ["followed", 868], ["by", 877], ["premature", 880], ["death", 890], ["at", 896], ["\u223c12", 899], ["months", 903], [".", 909], ["At", 911], ["this", 914], ["time", 919], [",", 923], ["prominent", 925], ["extranuclear", 935], ["protein", 948], ["aggregates", 956], ["and", 967], ["neuronal", 971], ["cell", 980], ["death", 985], ["was", 991], ["found", 995], ["in", 1001], ["mutant", 1004], ["mice", 1011], [".", 1015], ["This", 1017], ["was", 1022], ["associated", 1026], ["with", 1037], ["disturbances", 1042], ["of", 1055], ["the", 1058], ["endoplasmic", 1062], ["reticulum", 1074], ["-", 1083], ["mediated", 1084], ["unfolded", 1093], ["protein", 1102], ["response", 1110], [",", 1118], ["consistent", 1120], ["with", 1131], ["the", 1136], ["normal", 1140], ["role", 1147], ["of", 1152], ["ataxin-3", 1155], ["in", 1164], ["endoplasmic", 1167], ["reticulum", 1179], ["homeostasis", 1189], [".", 1200], ["Thus", 1202], [",", 1206], ["the", 1208], ["ataxin-3", 1212], ["gene", 1221], ["trap", 1226], ["model", 1231], ["provides", 1237], ["evidence", 1246], ["for", 1255], ["a", 1259], ["contribution", 1261], ["of", 1274], ["the", 1277], ["non", 1281], ["-", 1284], ["polyglutamine", 1285], ["containing", 1299], ["ataxin-3", 1310], ["N", 1319], ["-", 1320], ["terminus", 1321], [",", 1329], ["which", 1331], ["mimics", 1337], ["a", 1344], ["calpain", 1346], ["fragment", 1354], ["that", 1363], ["has", 1368], ["been", 1372], ["observed", 1377], ["in", 1386], ["spinocerebellar", 1389], ["ataxia", 1405], ["type", 1412], ["3", 1417], [".", 1418], ["Consistent", 1420], ["with", 1431], ["the", 1436], ["disease", 1440], ["in", 1448], ["humans", 1451], [",", 1457], ["gene", 1459], ["trap", 1464], ["mice", 1469], ["develop", 1474], ["cytoplasmic", 1482], ["inclusion", 1494], ["bodies", 1504], ["and", 1511], ["implicate", 1515], ["impaired", 1525], ["unfolded", 1534], ["protein", 1543], ["response", 1551], ["in", 1560], ["the", 1563], ["pathogenesis", 1567], ["of", 1580], ["spinocerebellar", 1583], ["ataxia", 1599], ["type", 1606], ["3", 1611], [".", 1612]]}
{"context": "Cis-regulatory modules are non-protein-coding regions of DNA essential for the control of gene expression. One class of regulatory modules is embryonic enhancers, which drive gene expression during development as a result of transcription factor protein binding at the enhancer sequences. Recent comparative studies have begun to investigate the evolution of the sequence architecture within enhancers. These analyses are illuminating the way that developmental biologists think about enhancers by revealing their molecular mechanism of function.", "qas": [{"question": "Are human enhancers or promoters evolving faster?", "answers": ["enhancers"], "qid": "c5f738e45b874642afbdf22cb1b0c970", "question_tokens": [["Are", 0], ["human", 4], ["enhancers", 10], ["or", 20], ["promoters", 23], ["evolving", 33], ["faster", 42], ["?", 48]], "detected_answers": [{"text": "enhancers", "token_spans": [[28, 28], [76, 76], [63, 63]], "char_spans": [[152, 160], [485, 493], [392, 400]]}]}], "context_tokens": [["Cis", 0], ["-", 3], ["regulatory", 4], ["modules", 15], ["are", 23], ["non", 27], ["-", 30], ["protein", 31], ["-", 38], ["coding", 39], ["regions", 46], ["of", 54], ["DNA", 57], ["essential", 61], ["for", 71], ["the", 75], ["control", 79], ["of", 87], ["gene", 90], ["expression", 95], [".", 105], ["One", 107], ["class", 111], ["of", 117], ["regulatory", 120], ["modules", 131], ["is", 139], ["embryonic", 142], ["enhancers", 152], [",", 161], ["which", 163], ["drive", 169], ["gene", 175], ["expression", 180], ["during", 191], ["development", 198], ["as", 210], ["a", 213], ["result", 215], ["of", 222], ["transcription", 225], ["factor", 239], ["protein", 246], ["binding", 254], ["at", 262], ["the", 265], ["enhancer", 269], ["sequences", 278], [".", 287], ["Recent", 289], ["comparative", 296], ["studies", 308], ["have", 316], ["begun", 321], ["to", 327], ["investigate", 330], ["the", 342], ["evolution", 346], ["of", 356], ["the", 359], ["sequence", 363], ["architecture", 372], ["within", 385], ["enhancers", 392], [".", 401], ["These", 403], ["analyses", 409], ["are", 418], ["illuminating", 422], ["the", 435], ["way", 439], ["that", 443], ["developmental", 448], ["biologists", 462], ["think", 473], ["about", 479], ["enhancers", 485], ["by", 495], ["revealing", 498], ["their", 508], ["molecular", 514], ["mechanism", 524], ["of", 534], ["function", 537], [".", 545]]}
{"context": "Clinical evidence for failure with beta-lactam therapy has been lacking for patients with borderline oxacillin-resistant Staphylococcus aureus (BORSA) infections. We describe a failure of cloxacillin for a patient with endocarditis due to BORSA. The isolate also had false-negative thermonuclease and coagulase test results.", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "6b5bba7ac78e49bf91eca71131576311", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[15, 20]], "char_spans": [[90, 141]]}]}], "context_tokens": [["Clinical", 0], ["evidence", 9], ["for", 18], ["failure", 22], ["with", 30], ["beta", 35], ["-", 39], ["lactam", 40], ["therapy", 47], ["has", 55], ["been", 59], ["lacking", 64], ["for", 72], ["patients", 76], ["with", 85], ["borderline", 90], ["oxacillin", 101], ["-", 110], ["resistant", 111], ["Staphylococcus", 121], ["aureus", 136], ["(", 143], ["BORSA", 144], [")", 149], ["infections", 151], [".", 161], ["We", 163], ["describe", 166], ["a", 175], ["failure", 177], ["of", 185], ["cloxacillin", 188], ["for", 200], ["a", 204], ["patient", 206], ["with", 214], ["endocarditis", 219], ["due", 232], ["to", 236], ["BORSA", 239], [".", 244], ["The", 246], ["isolate", 250], ["also", 258], ["had", 263], ["false", 267], ["-", 272], ["negative", 273], ["thermonuclease", 282], ["and", 297], ["coagulase", 301], ["test", 311], ["results", 316], [".", 323]]}
{"context": "Iron depletion is common in regular blood donors. The objective of the study was to investigate the frequency and severity of iron depletion in regular blood donors and whether IV iron is more effective than oral to avoid iron depletion and symptoms thereof, especially restless legs syndrome (RLS). One hundred and twenty blood donors with at least five previous whole blood donations were randomized to receive either IV iron sucrose (Venofer(\u00ae), RenaPharma/Vifor, Uppsala, Sweden), 200 mg, or to 20\u00d7100 mg of oral iron sulphate (Duroferon(\u00ae), GlaxoSmithKline, Stockholm, Sweden), after each blood donation during 1 year. Iron status and RLS incidence and severity were investigated. Iron status was generally poor among regular blood donors, especially in women, with a high incidence of iron depletion (>20%) and RLS (18%). The IV iron group increased storage iron to a greater extent than the oral iron group after 12 months (P=0\u00b70043). Female donors were more responsive to IV iron sucrose compared to oral iron sulphate, particularly female donors below 50 years of age. RLS severity scores were significantly lower in the IV iron group. The two treatments were safe. Iron status is poor in regular blood donors, restless legs syndrome is common, and the routine iron supplementation is insufficient. IV iron sucrose substitutes iron loss in blood donors more efficiently compared with oral iron sulphate, especially in women. Iron substitution to blood donors should be individualized and based on P-ferritin monitoring.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "a118373d91094ae6aca3047edf9b0bac", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[171, 171], [179, 179], [122, 122], [267, 267], [248, 248], [195, 195], [132, 132], [254, 254], [257, 257], [0, 0], [230, 230], [39, 39], [167, 167], [99, 99], [221, 221], [22, 22], [73, 73], [151, 151], [200, 200], [274, 274], [31, 31]], "char_spans": [[864, 867], [903, 906], [624, 627], [1398, 1401], [1270, 1273], [983, 986], [686, 689], [1311, 1314], [1336, 1339], [0, 3], [1175, 1178], [222, 225], [835, 838], [517, 520], [1133, 1136], [126, 129], [423, 426], [791, 794], [1013, 1016], [1434, 1437], [180, 183]]}]}], "context_tokens": [["Iron", 0], ["depletion", 5], ["is", 15], ["common", 18], ["in", 25], ["regular", 28], ["blood", 36], ["donors", 42], [".", 48], ["The", 50], ["objective", 54], ["of", 64], ["the", 67], ["study", 71], ["was", 77], ["to", 81], ["investigate", 84], ["the", 96], ["frequency", 100], ["and", 110], ["severity", 114], ["of", 123], ["iron", 126], ["depletion", 131], ["in", 141], ["regular", 144], ["blood", 152], ["donors", 158], ["and", 165], ["whether", 169], ["IV", 177], ["iron", 180], ["is", 185], ["more", 188], ["effective", 193], ["than", 203], ["oral", 208], ["to", 213], ["avoid", 216], ["iron", 222], ["depletion", 227], ["and", 237], ["symptoms", 241], ["thereof", 250], [",", 257], ["especially", 259], ["restless", 270], ["legs", 279], ["syndrome", 284], ["(", 293], ["RLS", 294], [")", 297], [".", 298], ["One", 300], ["hundred", 304], ["and", 312], ["twenty", 316], ["blood", 323], ["donors", 329], ["with", 336], ["at", 341], ["least", 344], ["five", 350], ["previous", 355], ["whole", 364], ["blood", 370], ["donations", 376], ["were", 386], ["randomized", 391], ["to", 402], ["receive", 405], ["either", 413], ["IV", 420], ["iron", 423], ["sucrose", 428], ["(", 436], ["Venofer", 437], ["(", 444], ["\u00ae", 445], [")", 446], [",", 447], ["RenaPharma", 449], ["/", 459], ["Vifor", 460], [",", 465], ["Uppsala", 467], [",", 474], ["Sweden", 476], [")", 482], [",", 483], ["200", 485], ["mg", 489], [",", 491], ["or", 493], ["to", 496], ["20\u00d7100", 499], ["mg", 506], ["of", 509], ["oral", 512], ["iron", 517], ["sulphate", 522], ["(", 531], ["Duroferon", 532], ["(", 541], ["\u00ae", 542], [")", 543], [",", 544], ["GlaxoSmithKline", 546], [",", 561], ["Stockholm", 563], [",", 572], ["Sweden", 574], [")", 580], [",", 581], ["after", 583], ["each", 589], ["blood", 594], ["donation", 600], ["during", 609], ["1", 616], ["year", 618], [".", 622], ["Iron", 624], ["status", 629], ["and", 636], ["RLS", 640], ["incidence", 644], ["and", 654], ["severity", 658], ["were", 667], ["investigated", 672], [".", 684], ["Iron", 686], ["status", 691], ["was", 698], ["generally", 702], ["poor", 712], ["among", 717], ["regular", 723], ["blood", 731], ["donors", 737], [",", 743], ["especially", 745], ["in", 756], ["women", 759], [",", 764], ["with", 766], ["a", 771], ["high", 773], ["incidence", 778], ["of", 788], ["iron", 791], ["depletion", 796], ["(", 806], [">", 807], ["20", 808], ["%", 810], [")", 811], ["and", 813], ["RLS", 817], ["(", 821], ["18", 822], ["%", 824], [")", 825], [".", 826], ["The", 828], ["IV", 832], ["iron", 835], ["group", 840], ["increased", 846], ["storage", 856], ["iron", 864], ["to", 869], ["a", 872], ["greater", 874], ["extent", 882], ["than", 889], ["the", 894], ["oral", 898], ["iron", 903], ["group", 908], ["after", 914], ["12", 920], ["months", 923], ["(", 930], ["P=0\u00b70043", 931], [")", 939], [".", 940], ["Female", 942], ["donors", 949], ["were", 956], ["more", 961], ["responsive", 966], ["to", 977], ["IV", 980], ["iron", 983], ["sucrose", 988], ["compared", 996], ["to", 1005], ["oral", 1008], ["iron", 1013], ["sulphate", 1018], [",", 1026], ["particularly", 1028], ["female", 1041], ["donors", 1048], ["below", 1055], ["50", 1061], ["years", 1064], ["of", 1070], ["age", 1073], [".", 1076], ["RLS", 1078], ["severity", 1082], ["scores", 1091], ["were", 1098], ["significantly", 1103], ["lower", 1117], ["in", 1123], ["the", 1126], ["IV", 1130], ["iron", 1133], ["group", 1138], [".", 1143], ["The", 1145], ["two", 1149], ["treatments", 1153], ["were", 1164], ["safe", 1169], [".", 1173], ["Iron", 1175], ["status", 1180], ["is", 1187], ["poor", 1190], ["in", 1195], ["regular", 1198], ["blood", 1206], ["donors", 1212], [",", 1218], ["restless", 1220], ["legs", 1229], ["syndrome", 1234], ["is", 1243], ["common", 1246], [",", 1252], ["and", 1254], ["the", 1258], ["routine", 1262], ["iron", 1270], ["supplementation", 1275], ["is", 1291], ["insufficient", 1294], [".", 1306], ["IV", 1308], ["iron", 1311], ["sucrose", 1316], ["substitutes", 1324], ["iron", 1336], ["loss", 1341], ["in", 1346], ["blood", 1349], ["donors", 1355], ["more", 1362], ["efficiently", 1367], ["compared", 1379], ["with", 1388], ["oral", 1393], ["iron", 1398], ["sulphate", 1403], [",", 1411], ["especially", 1413], ["in", 1424], ["women", 1427], [".", 1432], ["Iron", 1434], ["substitution", 1439], ["to", 1452], ["blood", 1455], ["donors", 1461], ["should", 1468], ["be", 1475], ["individualized", 1478], ["and", 1493], ["based", 1497], ["on", 1503], ["P", 1506], ["-", 1507], ["ferritin", 1508], ["monitoring", 1517], [".", 1527]]}
{"context": "To compare the outcome of outside-in biological and synthetic transobturator tape (TOT) operation, including subjective and objective success rates, urodynamics, and quality of life. One hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (SUI) were randomized into biological material TOT (PELVILACE\u00ae TO) or synthetic material TOT (ALIGN\u00aeTO Urethral Support System) groups. Preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, Q-tip test, and urodynamics were performed. For the evaluation of quality of life, the King's Health Questionnaire, Urogenital Distress Inventory-6, Incontinence Impact Questionnaire-7, and Prolapse Quality of Life were used. There was no significant difference between the two groups regarding objective and subjective cure rates and quality of life. At 1-year follow-up, the subjective cure rate was 68 % in the biological material TOT and 70 % in the synthetic material TOT group. No perioperative complications developed. Groin pain developed in 2 patients in the biological TOT group and 1 patient had dehiscence in the periurethral incision, which healed with local estrogen. Two patients had transient urinary retention in the synthetic TOT group, 1 patient developed groin pain, and 1 patient had mesh erosion observed at the 1-year follow-up. Transobturator tape with biological material in the management of SUI has a rate of success and patient satisfaction similar to those of synthetic material at 1-year follow-up. Studies with longer follow-up and larger cohorts are necessary to evaluate possible autolysis and degradation of biological slings and a possible reduction in efficacy over time.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "bc7735fd4a4446a7a5c1378082daf71f", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[40, 42]], "char_spans": [[246, 272]]}]}], "context_tokens": [["To", 0], ["compare", 3], ["the", 11], ["outcome", 15], ["of", 23], ["outside", 26], ["-", 33], ["in", 34], ["biological", 37], ["and", 48], ["synthetic", 52], ["transobturator", 62], ["tape", 77], ["(", 82], ["TOT", 83], [")", 86], ["operation", 88], [",", 97], ["including", 99], ["subjective", 109], ["and", 120], ["objective", 124], ["success", 134], ["rates", 142], [",", 147], ["urodynamics", 149], [",", 160], ["and", 162], ["quality", 166], ["of", 174], ["life", 177], [".", 181], ["One", 183], ["hundred", 187], ["patients", 195], ["suffering", 204], ["from", 214], ["clinical", 219], ["and/or", 228], ["urodynamic", 235], ["stress", 246], ["urinary", 253], ["incontinence", 261], ["(", 274], ["SUI", 275], [")", 278], ["were", 280], ["randomized", 285], ["into", 296], ["biological", 301], ["material", 312], ["TOT", 321], ["(", 325], ["PELVILACE", 326], ["\u00ae", 335], ["TO", 337], [")", 339], ["or", 341], ["synthetic", 344], ["material", 354], ["TOT", 363], ["(", 367], ["ALIGN", 368], ["\u00ae", 373], ["TO", 374], ["Urethral", 377], ["Support", 386], ["System", 394], [")", 400], ["groups", 402], [".", 408], ["Preoperative", 410], ["and", 423], ["at", 427], ["1", 430], ["year", 432], ["postoperative", 437], ["urogynecological", 451], ["symptom", 468], ["assessment", 476], [",", 486], ["1-h", 488], ["pad", 492], ["test", 496], [",", 500], ["4-day", 502], ["bladder", 508], ["diary", 516], [",", 521], ["stress", 523], ["test", 530], [",", 534], ["Q", 536], ["-", 537], ["tip", 538], ["test", 542], [",", 546], ["and", 548], ["urodynamics", 552], ["were", 564], ["performed", 569], [".", 578], ["For", 580], ["the", 584], ["evaluation", 588], ["of", 599], ["quality", 602], ["of", 610], ["life", 613], [",", 617], ["the", 619], ["King", 623], ["'s", 627], ["Health", 630], ["Questionnaire", 637], [",", 650], ["Urogenital", 652], ["Distress", 663], ["Inventory-6", 672], [",", 683], ["Incontinence", 685], ["Impact", 698], ["Questionnaire-7", 705], [",", 720], ["and", 722], ["Prolapse", 726], ["Quality", 735], ["of", 743], ["Life", 746], ["were", 751], ["used", 756], [".", 760], ["There", 762], ["was", 768], ["no", 772], ["significant", 775], ["difference", 787], ["between", 798], ["the", 806], ["two", 810], ["groups", 814], ["regarding", 821], ["objective", 831], ["and", 841], ["subjective", 845], ["cure", 856], ["rates", 861], ["and", 867], ["quality", 871], ["of", 879], ["life", 882], [".", 886], ["At", 888], ["1-year", 891], ["follow", 898], ["-", 904], ["up", 905], [",", 907], ["the", 909], ["subjective", 913], ["cure", 924], ["rate", 929], ["was", 934], ["68", 938], ["%", 941], ["in", 943], ["the", 946], ["biological", 950], ["material", 961], ["TOT", 970], ["and", 974], ["70", 978], ["%", 981], ["in", 983], ["the", 986], ["synthetic", 990], ["material", 1000], ["TOT", 1009], ["group", 1013], [".", 1018], ["No", 1020], ["perioperative", 1023], ["complications", 1037], ["developed", 1051], [".", 1060], ["Groin", 1062], ["pain", 1068], ["developed", 1073], ["in", 1083], ["2", 1086], ["patients", 1088], ["in", 1097], ["the", 1100], ["biological", 1104], ["TOT", 1115], ["group", 1119], ["and", 1125], ["1", 1129], ["patient", 1131], ["had", 1139], ["dehiscence", 1143], ["in", 1154], ["the", 1157], ["periurethral", 1161], ["incision", 1174], [",", 1182], ["which", 1184], ["healed", 1190], ["with", 1197], ["local", 1202], ["estrogen", 1208], [".", 1216], ["Two", 1218], ["patients", 1222], ["had", 1231], ["transient", 1235], ["urinary", 1245], ["retention", 1253], ["in", 1263], ["the", 1266], ["synthetic", 1270], ["TOT", 1280], ["group", 1284], [",", 1289], ["1", 1291], ["patient", 1293], ["developed", 1301], ["groin", 1311], ["pain", 1317], [",", 1321], ["and", 1323], ["1", 1327], ["patient", 1329], ["had", 1337], ["mesh", 1341], ["erosion", 1346], ["observed", 1354], ["at", 1363], ["the", 1366], ["1-year", 1370], ["follow", 1377], ["-", 1383], ["up", 1384], [".", 1386], ["Transobturator", 1388], ["tape", 1403], ["with", 1408], ["biological", 1413], ["material", 1424], ["in", 1433], ["the", 1436], ["management", 1440], ["of", 1451], ["SUI", 1454], ["has", 1458], ["a", 1462], ["rate", 1464], ["of", 1469], ["success", 1472], ["and", 1480], ["patient", 1484], ["satisfaction", 1492], ["similar", 1505], ["to", 1513], ["those", 1516], ["of", 1522], ["synthetic", 1525], ["material", 1535], ["at", 1544], ["1-year", 1547], ["follow", 1554], ["-", 1560], ["up", 1561], [".", 1563], ["Studies", 1565], ["with", 1573], ["longer", 1578], ["follow", 1585], ["-", 1591], ["up", 1592], ["and", 1595], ["larger", 1599], ["cohorts", 1606], ["are", 1614], ["necessary", 1618], ["to", 1628], ["evaluate", 1631], ["possible", 1640], ["autolysis", 1649], ["and", 1659], ["degradation", 1663], ["of", 1675], ["biological", 1678], ["slings", 1689], ["and", 1696], ["a", 1700], ["possible", 1702], ["reduction", 1711], ["in", 1721], ["efficacy", 1724], ["over", 1733], ["time", 1738], [".", 1742]]}
{"context": "Sleep disorders are frequent comorbidities in neurologic patients. This review focuses on clinical aspects and prognosis of 3 neurologic sleep disorders: narcolepsy, restless legs syndrome/Willis-Ekbom disease (RLS/WED), and REM sleep behavior disorder (RBD). Narcolepsy causes pervasive, enduring excessive daytime sleepiness, adversely affecting patients' daily functioning. RLS/WED is characterized by an uncomfortable urge to move the legs before sleep, often evolving toward augmentation and resulting in daylong bothersome symptoms. RBD causes potentially injurious dream enactment behaviors that often signify future evolution of overt synucleinopathy neurodegeneration in as many as 81% of patients. Timely recognition, referral for polysomnography, and longitudinal follow-up of narcolepsy, RLS/WED, and RBD patients are imperatives for neurologists in providing quality comprehensive patient care.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "2e85dc045cba4859af5eff8296aecc96", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[25, 27]], "char_spans": [[166, 187]]}]}], "context_tokens": [["Sleep", 0], ["disorders", 6], ["are", 16], ["frequent", 20], ["comorbidities", 29], ["in", 43], ["neurologic", 46], ["patients", 57], [".", 65], ["This", 67], ["review", 72], ["focuses", 79], ["on", 87], ["clinical", 90], ["aspects", 99], ["and", 107], ["prognosis", 111], ["of", 121], ["3", 124], ["neurologic", 126], ["sleep", 137], ["disorders", 143], [":", 152], ["narcolepsy", 154], [",", 164], ["restless", 166], ["legs", 175], ["syndrome", 180], ["/", 188], ["Willis", 189], ["-", 195], ["Ekbom", 196], ["disease", 202], ["(", 210], ["RLS", 211], ["/", 214], ["WED", 215], [")", 218], [",", 219], ["and", 221], ["REM", 225], ["sleep", 229], ["behavior", 235], ["disorder", 244], ["(", 253], ["RBD", 254], [")", 257], [".", 258], ["Narcolepsy", 260], ["causes", 271], ["pervasive", 278], [",", 287], ["enduring", 289], ["excessive", 298], ["daytime", 308], ["sleepiness", 316], [",", 326], ["adversely", 328], ["affecting", 338], ["patients", 348], ["'", 356], ["daily", 358], ["functioning", 364], [".", 375], ["RLS", 377], ["/", 380], ["WED", 381], ["is", 385], ["characterized", 388], ["by", 402], ["an", 405], ["uncomfortable", 408], ["urge", 422], ["to", 427], ["move", 430], ["the", 435], ["legs", 439], ["before", 444], ["sleep", 451], [",", 456], ["often", 458], ["evolving", 464], ["toward", 473], ["augmentation", 480], ["and", 493], ["resulting", 497], ["in", 507], ["daylong", 510], ["bothersome", 518], ["symptoms", 529], [".", 537], ["RBD", 539], ["causes", 543], ["potentially", 550], ["injurious", 562], ["dream", 572], ["enactment", 578], ["behaviors", 588], ["that", 598], ["often", 603], ["signify", 609], ["future", 617], ["evolution", 624], ["of", 634], ["overt", 637], ["synucleinopathy", 643], ["neurodegeneration", 659], ["in", 677], ["as", 680], ["many", 683], ["as", 688], ["81", 691], ["%", 693], ["of", 695], ["patients", 698], [".", 706], ["Timely", 708], ["recognition", 715], [",", 726], ["referral", 728], ["for", 737], ["polysomnography", 741], [",", 756], ["and", 758], ["longitudinal", 762], ["follow", 775], ["-", 781], ["up", 782], ["of", 785], ["narcolepsy", 788], [",", 798], ["RLS", 800], ["/", 803], ["WED", 804], [",", 807], ["and", 809], ["RBD", 813], ["patients", 817], ["are", 826], ["imperatives", 830], ["for", 842], ["neurologists", 846], ["in", 859], ["providing", 862], ["quality", 872], ["comprehensive", 880], ["patient", 894], ["care", 902], [".", 906]]}
{"context": "The current methods available to detect chromosomal abnormalities from DNA microarray expression data are cumbersome and inflexible. CAFE has been developed to alleviate these issues. It is implemented as an R package that analyzes Affymetrix *.CEL files and comes with flexible plotting functions, easing visualization of chromosomal abnormalities. CAFE is available from https://bitbucket.org/cob87icW6z/cafe/ as both source and compiled packages for Linux and Windows. It is released under the GPL version 3 license. CAFE will also be freely available from Bioconductor. sander.h.bollen@gmail.com or nancy.mah@mdc-berlin.de Supplementary data are available at Bioinformatics online.", "qas": [{"question": "Which R package is used for the detection of chromosomal abnormalities from microarray data?", "answers": ["CAFE"], "qid": "ab902c462f7c4599b28d61cef6b38d84", "question_tokens": [["Which", 0], ["R", 6], ["package", 8], ["is", 16], ["used", 19], ["for", 24], ["the", 28], ["detection", 32], ["of", 42], ["chromosomal", 45], ["abnormalities", 57], ["from", 71], ["microarray", 76], ["data", 87], ["?", 91]], "detected_answers": [{"text": "CAFE", "token_spans": [[79, 79], [53, 53], [18, 18]], "char_spans": [[520, 523], [350, 353], [133, 136]]}]}], "context_tokens": [["The", 0], ["current", 4], ["methods", 12], ["available", 20], ["to", 30], ["detect", 33], ["chromosomal", 40], ["abnormalities", 52], ["from", 66], ["DNA", 71], ["microarray", 75], ["expression", 86], ["data", 97], ["are", 102], ["cumbersome", 106], ["and", 117], ["inflexible", 121], [".", 131], ["CAFE", 133], ["has", 138], ["been", 142], ["developed", 147], ["to", 157], ["alleviate", 160], ["these", 170], ["issues", 176], [".", 182], ["It", 184], ["is", 187], ["implemented", 190], ["as", 202], ["an", 205], ["R", 208], ["package", 210], ["that", 218], ["analyzes", 223], ["Affymetrix", 232], ["*", 243], [".CEL", 244], ["files", 249], ["and", 255], ["comes", 259], ["with", 265], ["flexible", 270], ["plotting", 279], ["functions", 288], [",", 297], ["easing", 299], ["visualization", 306], ["of", 320], ["chromosomal", 323], ["abnormalities", 335], [".", 348], ["CAFE", 350], ["is", 355], ["available", 358], ["from", 368], ["https://bitbucket.org/cob87icW6z/cafe/", 373], ["as", 412], ["both", 415], ["source", 420], ["and", 427], ["compiled", 431], ["packages", 440], ["for", 449], ["Linux", 453], ["and", 459], ["Windows", 463], [".", 470], ["It", 472], ["is", 475], ["released", 478], ["under", 487], ["the", 493], ["GPL", 497], ["version", 501], ["3", 509], ["license", 511], [".", 518], ["CAFE", 520], ["will", 525], ["also", 530], ["be", 535], ["freely", 538], ["available", 545], ["from", 555], ["Bioconductor", 560], [".", 572], ["sander.h.bollen@gmail.com", 574], ["or", 600], ["nancy.mah@mdc-berlin.de", 603], ["Supplementary", 627], ["data", 641], ["are", 646], ["available", 650], ["at", 660], ["Bioinformatics", 663], ["online", 678], [".", 684]]}
{"context": "Flumazenil is a competitive benzodiazepine antagonist that acts to reverse their sedative and hypnotic effects. It is indicated in the management of benzodiazepine overdose, but its role in the routine reversal of endoscopic conscious sedation has not been defined. Patients undergoing diagnostic upper endoscopy who received sedation with either diazepam or midazolam alone were given flumazenil 0.2 mg incrementally immediately following the procedure until awake. They were then asked to repeat three psychomotor tests measuring cognitive and motor skills, with their baseline scores compared with postprocedure scores over a 3-hour period. Full psychomotor function was restored to baseline values within 30 minutes after flumazenil in 79% of patients, with no differences in the reversal of psychomotor skill impairment observed between diazepam and midazolam sedation. There was no evidence of rebound sedation seen for up to 3 hours. No significant anterograde amnesia was evident in 78% of individuals. These results demonstrate that flumazenil's effects on reversing psychomotor impairment are similar when midazolam or diazepam are used for conscious sedation. However, the potential usefulness of routine flumazenil reversal of conscious sedation will require further evaluation of specific psychomotor performance skills (such as driving a car) before we lift the admonition against leaving the endoscopic suite unattended, driving a vehicle, or operating complicated machinery for several hours.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "8c08be9367e44a248f7e98941e6d911d", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [163, 163], [189, 189], [109, 109], [58, 58]], "char_spans": [[0, 9], [1042, 1051], [1216, 1225], [726, 735], [386, 395]]}]}], "context_tokens": [["Flumazenil", 0], ["is", 11], ["a", 14], ["competitive", 16], ["benzodiazepine", 28], ["antagonist", 43], ["that", 54], ["acts", 59], ["to", 64], ["reverse", 67], ["their", 75], ["sedative", 81], ["and", 90], ["hypnotic", 94], ["effects", 103], [".", 110], ["It", 112], ["is", 115], ["indicated", 118], ["in", 128], ["the", 131], ["management", 135], ["of", 146], ["benzodiazepine", 149], ["overdose", 164], [",", 172], ["but", 174], ["its", 178], ["role", 182], ["in", 187], ["the", 190], ["routine", 194], ["reversal", 202], ["of", 211], ["endoscopic", 214], ["conscious", 225], ["sedation", 235], ["has", 244], ["not", 248], ["been", 252], ["defined", 257], [".", 264], ["Patients", 266], ["undergoing", 275], ["diagnostic", 286], ["upper", 297], ["endoscopy", 303], ["who", 313], ["received", 317], ["sedation", 326], ["with", 335], ["either", 340], ["diazepam", 347], ["or", 356], ["midazolam", 359], ["alone", 369], ["were", 375], ["given", 380], ["flumazenil", 386], ["0.2", 397], ["mg", 401], ["incrementally", 404], ["immediately", 418], ["following", 430], ["the", 440], ["procedure", 444], ["until", 454], ["awake", 460], [".", 465], ["They", 467], ["were", 472], ["then", 477], ["asked", 482], ["to", 488], ["repeat", 491], ["three", 498], ["psychomotor", 504], ["tests", 516], ["measuring", 522], ["cognitive", 532], ["and", 542], ["motor", 546], ["skills", 552], [",", 558], ["with", 560], ["their", 565], ["baseline", 571], ["scores", 580], ["compared", 587], ["with", 596], ["postprocedure", 601], ["scores", 615], ["over", 622], ["a", 627], ["3-hour", 629], ["period", 636], [".", 642], ["Full", 644], ["psychomotor", 649], ["function", 661], ["was", 670], ["restored", 674], ["to", 683], ["baseline", 686], ["values", 695], ["within", 702], ["30", 709], ["minutes", 712], ["after", 720], ["flumazenil", 726], ["in", 737], ["79", 740], ["%", 742], ["of", 744], ["patients", 747], [",", 755], ["with", 757], ["no", 762], ["differences", 765], ["in", 777], ["the", 780], ["reversal", 784], ["of", 793], ["psychomotor", 796], ["skill", 808], ["impairment", 814], ["observed", 825], ["between", 834], ["diazepam", 842], ["and", 851], ["midazolam", 855], ["sedation", 865], [".", 873], ["There", 875], ["was", 881], ["no", 885], ["evidence", 888], ["of", 897], ["rebound", 900], ["sedation", 908], ["seen", 917], ["for", 922], ["up", 926], ["to", 929], ["3", 932], ["hours", 934], [".", 939], ["No", 941], ["significant", 944], ["anterograde", 956], ["amnesia", 968], ["was", 976], ["evident", 980], ["in", 988], ["78", 991], ["%", 993], ["of", 995], ["individuals", 998], [".", 1009], ["These", 1011], ["results", 1017], ["demonstrate", 1025], ["that", 1037], ["flumazenil", 1042], ["'s", 1052], ["effects", 1055], ["on", 1063], ["reversing", 1066], ["psychomotor", 1076], ["impairment", 1088], ["are", 1099], ["similar", 1103], ["when", 1111], ["midazolam", 1116], ["or", 1126], ["diazepam", 1129], ["are", 1138], ["used", 1142], ["for", 1147], ["conscious", 1151], ["sedation", 1161], [".", 1169], ["However", 1171], [",", 1178], ["the", 1180], ["potential", 1184], ["usefulness", 1194], ["of", 1205], ["routine", 1208], ["flumazenil", 1216], ["reversal", 1227], ["of", 1236], ["conscious", 1239], ["sedation", 1249], ["will", 1258], ["require", 1263], ["further", 1271], ["evaluation", 1279], ["of", 1290], ["specific", 1293], ["psychomotor", 1302], ["performance", 1314], ["skills", 1326], ["(", 1333], ["such", 1334], ["as", 1339], ["driving", 1342], ["a", 1350], ["car", 1352], [")", 1355], ["before", 1357], ["we", 1364], ["lift", 1367], ["the", 1372], ["admonition", 1376], ["against", 1387], ["leaving", 1395], ["the", 1403], ["endoscopic", 1407], ["suite", 1418], ["unattended", 1424], [",", 1434], ["driving", 1436], ["a", 1444], ["vehicle", 1446], [",", 1453], ["or", 1455], ["operating", 1458], ["complicated", 1468], ["machinery", 1480], ["for", 1490], ["several", 1494], ["hours", 1502], [".", 1507]]}
{"context": "Schimke immuno-osseous dysplasia (OMIM 242900) is an uncommon autosomal-recessive multisystem disease caused by mutations in SMARCAL1 (swi/snf-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1), a gene encoding a putative chromatin remodeling protein. Neurologic manifestations identified to date relate to enhanced atherosclerosis and cerebrovascular disease. Based on a clinical survey, we determined that half of Schimke immuno-osseous dysplasia patients have a small head circumference, and 15% have social, language, motor, or cognitive abnormalities. Postmortem examination of 2 Schimke immuno-osseous dysplasia patients showed low brain weights and subtle brain histologic abnormalities suggestive of perturbed neuron-glial migration such as heterotopia, irregular cortical thickness, incomplete gyral formation, and poor definition of cortical layers. We found that SMARCAL1 is highly expressed in the developing and adult mouse and human brain, including neural precursors and neuronal lineage cells. These observations suggest that SMARCAL1 deficiency may influence brain development and function in addition to its previously recognized effect on cerebral circulation.", "qas": [{"question": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "answers": ["HARP", "SMARCAL1 (swi/snf-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1", "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)"], "qid": "86b60944892d4aba80de48bd155dcdcb", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["cause", 24], ["Schimke", 30], ["immune", 38], ["-", 44], ["osseous", 45], ["dysplasia", 53], ["?", 62]], "detected_answers": [{"text": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "token_spans": [[21, 44]], "char_spans": [[125, 228]]}]}], "context_tokens": [["Schimke", 0], ["immuno", 8], ["-", 14], ["osseous", 15], ["dysplasia", 23], ["(", 33], ["OMIM", 34], ["242900", 39], [")", 45], ["is", 47], ["an", 50], ["uncommon", 53], ["autosomal", 62], ["-", 71], ["recessive", 72], ["multisystem", 82], ["disease", 94], ["caused", 102], ["by", 109], ["mutations", 112], ["in", 122], ["SMARCAL1", 125], ["(", 134], ["swi", 135], ["/", 138], ["snf", 139], ["-", 142], ["related", 143], [",", 150], ["matrix", 152], ["-", 158], ["associated", 159], [",", 169], ["actin", 171], ["-", 176], ["dependent", 177], ["regulator", 187], ["of", 197], ["chromatin", 200], [",", 209], ["subfamily", 211], ["a", 221], ["-", 222], ["like", 223], ["1", 228], [")", 229], [",", 230], ["a", 232], ["gene", 234], ["encoding", 239], ["a", 248], ["putative", 250], ["chromatin", 259], ["remodeling", 269], ["protein", 280], [".", 287], ["Neurologic", 289], ["manifestations", 300], ["identified", 315], ["to", 326], ["date", 329], ["relate", 334], ["to", 341], ["enhanced", 344], ["atherosclerosis", 353], ["and", 369], ["cerebrovascular", 373], ["disease", 389], [".", 396], ["Based", 398], ["on", 404], ["a", 407], ["clinical", 409], ["survey", 418], [",", 424], ["we", 426], ["determined", 429], ["that", 440], ["half", 445], ["of", 450], ["Schimke", 453], ["immuno", 461], ["-", 467], ["osseous", 468], ["dysplasia", 476], ["patients", 486], ["have", 495], ["a", 500], ["small", 502], ["head", 508], ["circumference", 513], [",", 526], ["and", 528], ["15", 532], ["%", 534], ["have", 536], ["social", 541], [",", 547], ["language", 549], [",", 557], ["motor", 559], [",", 564], ["or", 566], ["cognitive", 569], ["abnormalities", 579], [".", 592], ["Postmortem", 594], ["examination", 605], ["of", 617], ["2", 620], ["Schimke", 622], ["immuno", 630], ["-", 636], ["osseous", 637], ["dysplasia", 645], ["patients", 655], ["showed", 664], ["low", 671], ["brain", 675], ["weights", 681], ["and", 689], ["subtle", 693], ["brain", 700], ["histologic", 706], ["abnormalities", 717], ["suggestive", 731], ["of", 742], ["perturbed", 745], ["neuron", 755], ["-", 761], ["glial", 762], ["migration", 768], ["such", 778], ["as", 783], ["heterotopia", 786], [",", 797], ["irregular", 799], ["cortical", 809], ["thickness", 818], [",", 827], ["incomplete", 829], ["gyral", 840], ["formation", 846], [",", 855], ["and", 857], ["poor", 861], ["definition", 866], ["of", 877], ["cortical", 880], ["layers", 889], [".", 895], ["We", 897], ["found", 900], ["that", 906], ["SMARCAL1", 911], ["is", 920], ["highly", 923], ["expressed", 930], ["in", 940], ["the", 943], ["developing", 947], ["and", 958], ["adult", 962], ["mouse", 968], ["and", 974], ["human", 978], ["brain", 984], [",", 989], ["including", 991], ["neural", 1001], ["precursors", 1008], ["and", 1019], ["neuronal", 1023], ["lineage", 1032], ["cells", 1040], [".", 1045], ["These", 1047], ["observations", 1053], ["suggest", 1066], ["that", 1074], ["SMARCAL1", 1079], ["deficiency", 1088], ["may", 1099], ["influence", 1103], ["brain", 1113], ["development", 1119], ["and", 1131], ["function", 1135], ["in", 1144], ["addition", 1147], ["to", 1156], ["its", 1159], ["previously", 1163], ["recognized", 1174], ["effect", 1185], ["on", 1192], ["cerebral", 1195], ["circulation", 1204], [".", 1215]]}
{"context": "The present study aimed at evaluating the effect of opicapone, a third generation nitrocatechol catechol-O-methyltransferase (COMT) inhibitor, on the systemic and central bioavailability of 3,4-dihydroxy-l-phenylalanine (levodopa) and related metabolites in the cynomolgus monkey. Four monkeys, implanted with guiding cannulas for microdialysis probes, in the substantia nigra, dorsal striatum and prefrontal cortex, were randomized in two groups that received, in a crossover design, vehicle or 100 mg/kg opicapone for 14 days. Twenty-three hours after last administration of vehicle or opicapone, animals were challenged with levodopa/benserazide (12/3 mg/kg). Extracellular dialysate and blood samples were collected over 360 min (at 30 min intervals) for the assays of catecholamine and COMT activity. Opicapone increased levodopa systemic exposure by 2-fold not changing Cmax values and reduced both 3-O-methyldopa (3-OMD) exposure and Cmax values by 5-fold. These changes were accompanied by \u223c76-84% reduction in erythrocyte COMT activity. In dorsal striatum and substantia nigra, opicapone increased levodopa exposure by 1.7- and 1.4-fold, respectively, reducing 3-OMD exposure by 5- and 7-fold respectively. DOPAC exposure was increased by 4-fold in the substantia nigra. In the prefrontal cortex, opicapone increased levodopa exposure and reduced 3-OMD levels by 2.3- and 2.4-fold, respectively. Opicapone behaved as long-acting COMT inhibitor that markedly increased systemic and central levodopa bioavailability. Opicapone is a strong candidate to fill the unmet need for COMT inhibitors that lead to more sustained levodopa levels in Parkinson's disease patients.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "ca9ef69c3b7343959201d7a68ea4835c", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[15, 19]], "char_spans": [[96, 123]]}]}], "context_tokens": [["The", 0], ["present", 4], ["study", 12], ["aimed", 18], ["at", 24], ["evaluating", 27], ["the", 38], ["effect", 42], ["of", 49], ["opicapone", 52], [",", 61], ["a", 63], ["third", 65], ["generation", 71], ["nitrocatechol", 82], ["catechol", 96], ["-", 104], ["O", 105], ["-", 106], ["methyltransferase", 107], ["(", 125], ["COMT", 126], [")", 130], ["inhibitor", 132], [",", 141], ["on", 143], ["the", 146], ["systemic", 150], ["and", 159], ["central", 163], ["bioavailability", 171], ["of", 187], ["3,4-dihydroxy", 190], ["-", 203], ["l", 204], ["-", 205], ["phenylalanine", 206], ["(", 220], ["levodopa", 221], [")", 229], ["and", 231], ["related", 235], ["metabolites", 243], ["in", 255], ["the", 258], ["cynomolgus", 262], ["monkey", 273], [".", 279], ["Four", 281], ["monkeys", 286], [",", 293], ["implanted", 295], ["with", 305], ["guiding", 310], ["cannulas", 318], ["for", 327], ["microdialysis", 331], ["probes", 345], [",", 351], ["in", 353], ["the", 356], ["substantia", 360], ["nigra", 371], [",", 376], ["dorsal", 378], ["striatum", 385], ["and", 394], ["prefrontal", 398], ["cortex", 409], [",", 415], ["were", 417], ["randomized", 422], ["in", 433], ["two", 436], ["groups", 440], ["that", 447], ["received", 452], [",", 460], ["in", 462], ["a", 465], ["crossover", 467], ["design", 477], [",", 483], ["vehicle", 485], ["or", 493], ["100", 496], ["mg", 500], ["/", 502], ["kg", 503], ["opicapone", 506], ["for", 516], ["14", 520], ["days", 523], [".", 527], ["Twenty", 529], ["-", 535], ["three", 536], ["hours", 542], ["after", 548], ["last", 554], ["administration", 559], ["of", 574], ["vehicle", 577], ["or", 585], ["opicapone", 588], [",", 597], ["animals", 599], ["were", 607], ["challenged", 612], ["with", 623], ["levodopa", 628], ["/", 636], ["benserazide", 637], ["(", 649], ["12/3", 650], ["mg", 655], ["/", 657], ["kg", 658], [")", 660], [".", 661], ["Extracellular", 663], ["dialysate", 677], ["and", 687], ["blood", 691], ["samples", 697], ["were", 705], ["collected", 710], ["over", 720], ["360", 725], ["min", 729], ["(", 733], ["at", 734], ["30", 737], ["min", 740], ["intervals", 744], [")", 753], ["for", 755], ["the", 759], ["assays", 763], ["of", 770], ["catecholamine", 773], ["and", 787], ["COMT", 791], ["activity", 796], [".", 804], ["Opicapone", 806], ["increased", 816], ["levodopa", 826], ["systemic", 835], ["exposure", 844], ["by", 853], ["2-fold", 856], ["not", 863], ["changing", 867], ["Cmax", 876], ["values", 881], ["and", 888], ["reduced", 892], ["both", 900], ["3-O", 905], ["-", 908], ["methyldopa", 909], ["(", 920], ["3-OMD", 921], [")", 926], ["exposure", 928], ["and", 937], ["Cmax", 941], ["values", 946], ["by", 953], ["5-fold", 956], [".", 962], ["These", 964], ["changes", 970], ["were", 978], ["accompanied", 983], ["by", 995], ["\u223c76", 998], ["-", 1001], ["84", 1002], ["%", 1004], ["reduction", 1006], ["in", 1016], ["erythrocyte", 1019], ["COMT", 1031], ["activity", 1036], [".", 1044], ["In", 1046], ["dorsal", 1049], ["striatum", 1056], ["and", 1065], ["substantia", 1069], ["nigra", 1080], [",", 1085], ["opicapone", 1087], ["increased", 1097], ["levodopa", 1107], ["exposure", 1116], ["by", 1125], ["1.7-", 1128], ["and", 1133], ["1.4-fold", 1137], [",", 1145], ["respectively", 1147], [",", 1159], ["reducing", 1161], ["3-OMD", 1170], ["exposure", 1176], ["by", 1185], ["5-", 1188], ["and", 1191], ["7-fold", 1195], ["respectively", 1202], [".", 1214], ["DOPAC", 1216], ["exposure", 1222], ["was", 1231], ["increased", 1235], ["by", 1245], ["4-fold", 1248], ["in", 1255], ["the", 1258], ["substantia", 1262], ["nigra", 1273], [".", 1278], ["In", 1280], ["the", 1283], ["prefrontal", 1287], ["cortex", 1298], [",", 1304], ["opicapone", 1306], ["increased", 1316], ["levodopa", 1326], ["exposure", 1335], ["and", 1344], ["reduced", 1348], ["3-OMD", 1356], ["levels", 1362], ["by", 1369], ["2.3-", 1372], ["and", 1377], ["2.4-fold", 1381], [",", 1389], ["respectively", 1391], [".", 1403], ["Opicapone", 1405], ["behaved", 1415], ["as", 1423], ["long", 1426], ["-", 1430], ["acting", 1431], ["COMT", 1438], ["inhibitor", 1443], ["that", 1453], ["markedly", 1458], ["increased", 1467], ["systemic", 1477], ["and", 1486], ["central", 1490], ["levodopa", 1498], ["bioavailability", 1507], [".", 1522], ["Opicapone", 1524], ["is", 1534], ["a", 1537], ["strong", 1539], ["candidate", 1546], ["to", 1556], ["fill", 1559], ["the", 1564], ["unmet", 1568], ["need", 1574], ["for", 1579], ["COMT", 1583], ["inhibitors", 1588], ["that", 1599], ["lead", 1604], ["to", 1609], ["more", 1612], ["sustained", 1617], ["levodopa", 1627], ["levels", 1636], ["in", 1643], ["Parkinson", 1646], ["'s", 1655], ["disease", 1658], ["patients", 1666], [".", 1674]]}
{"context": "De Quervain's disease has different clinical features. Different tests have been described in the past, the most popular test being the Eichhoff's test, often wrongly named as the Finkelstein's test. Over the years, a misinterpretation has occurred between these two tests, the latter being confused with the first. To compare the Eichhoff's test with a new test, the wrist hyperflexion and abduction of the thumb test, we set up a prospective study over a period of three years for a cohort of 100 patients (88 women, 12 men) presenting spontaneous pain over the radial side of the styloid of the radius (de Quervain tendinopathy). The purpose of the study was to compare the accuracy of the Eichhoff's test and wrist hyperflexion and abduction of the thumb test to diagnose correctly de Quervain's disease by comparing clinical findings using those tests with the results on ultrasound. The wrist hyperflexion and abduction of the thumb test revealed greater sensitivity (0.99) and an improved specificity (0.29) together with a slightly better positive predictive value (0.95) and an improved negative predictive value (0.67). Moreover, the study showed us that the wrist hyperflexion and abduction of the thumb test is very valuable in diagnosing dynamic instability after successful decompression of the first extensor compartment. Our results support that the wrist hyperflexion and abduction of the thumb test is a more precise tool for the diagnosis of de Quervain's disease than the Eichhoff's test and thus could be adopted to guide clinical diagnosis in the early stages of de Quervain's tendinopathy.", "qas": [{"question": "Which disease is diagnosed using the Finkelstein's test?", "answers": ["de Quervain's disease"], "qid": "8e529191f1b142e8bc214514c56ad188", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["diagnosed", 17], ["using", 27], ["the", 33], ["Finkelstein", 37], ["'s", 48], ["test", 51], ["?", 55]], "detected_answers": [{"text": "de Quervain's disease", "token_spans": [[264, 267], [0, 3], [150, 153]], "char_spans": [[1461, 1481], [0, 20], [786, 806]]}]}], "context_tokens": [["De", 0], ["Quervain", 3], ["'s", 11], ["disease", 14], ["has", 22], ["different", 26], ["clinical", 36], ["features", 45], [".", 53], ["Different", 55], ["tests", 65], ["have", 71], ["been", 76], ["described", 81], ["in", 91], ["the", 94], ["past", 98], [",", 102], ["the", 104], ["most", 108], ["popular", 113], ["test", 121], ["being", 126], ["the", 132], ["Eichhoff", 136], ["'s", 144], ["test", 147], [",", 151], ["often", 153], ["wrongly", 159], ["named", 167], ["as", 173], ["the", 176], ["Finkelstein", 180], ["'s", 191], ["test", 194], [".", 198], ["Over", 200], ["the", 205], ["years", 209], [",", 214], ["a", 216], ["misinterpretation", 218], ["has", 236], ["occurred", 240], ["between", 249], ["these", 257], ["two", 263], ["tests", 267], [",", 272], ["the", 274], ["latter", 278], ["being", 285], ["confused", 291], ["with", 300], ["the", 305], ["first", 309], [".", 314], ["To", 316], ["compare", 319], ["the", 327], ["Eichhoff", 331], ["'s", 339], ["test", 342], ["with", 347], ["a", 352], ["new", 354], ["test", 358], [",", 362], ["the", 364], ["wrist", 368], ["hyperflexion", 374], ["and", 387], ["abduction", 391], ["of", 401], ["the", 404], ["thumb", 408], ["test", 414], [",", 418], ["we", 420], ["set", 423], ["up", 427], ["a", 430], ["prospective", 432], ["study", 444], ["over", 450], ["a", 455], ["period", 457], ["of", 464], ["three", 467], ["years", 473], ["for", 479], ["a", 483], ["cohort", 485], ["of", 492], ["100", 495], ["patients", 499], ["(", 508], ["88", 509], ["women", 512], [",", 517], ["12", 519], ["men", 522], [")", 525], ["presenting", 527], ["spontaneous", 538], ["pain", 550], ["over", 555], ["the", 560], ["radial", 564], ["side", 571], ["of", 576], ["the", 579], ["styloid", 583], ["of", 591], ["the", 594], ["radius", 598], ["(", 605], ["de", 606], ["Quervain", 609], ["tendinopathy", 618], [")", 630], [".", 631], ["The", 633], ["purpose", 637], ["of", 645], ["the", 648], ["study", 652], ["was", 658], ["to", 662], ["compare", 665], ["the", 673], ["accuracy", 677], ["of", 686], ["the", 689], ["Eichhoff", 693], ["'s", 701], ["test", 704], ["and", 709], ["wrist", 713], ["hyperflexion", 719], ["and", 732], ["abduction", 736], ["of", 746], ["the", 749], ["thumb", 753], ["test", 759], ["to", 764], ["diagnose", 767], ["correctly", 776], ["de", 786], ["Quervain", 789], ["'s", 797], ["disease", 800], ["by", 808], ["comparing", 811], ["clinical", 821], ["findings", 830], ["using", 839], ["those", 845], ["tests", 851], ["with", 857], ["the", 862], ["results", 866], ["on", 874], ["ultrasound", 877], [".", 887], ["The", 889], ["wrist", 893], ["hyperflexion", 899], ["and", 912], ["abduction", 916], ["of", 926], ["the", 929], ["thumb", 933], ["test", 939], ["revealed", 944], ["greater", 953], ["sensitivity", 961], ["(", 973], ["0.99", 974], [")", 978], ["and", 980], ["an", 984], ["improved", 987], ["specificity", 996], ["(", 1008], ["0.29", 1009], [")", 1013], ["together", 1015], ["with", 1024], ["a", 1029], ["slightly", 1031], ["better", 1040], ["positive", 1047], ["predictive", 1056], ["value", 1067], ["(", 1073], ["0.95", 1074], [")", 1078], ["and", 1080], ["an", 1084], ["improved", 1087], ["negative", 1096], ["predictive", 1105], ["value", 1116], ["(", 1122], ["0.67", 1123], [")", 1127], [".", 1128], ["Moreover", 1130], [",", 1138], ["the", 1140], ["study", 1144], ["showed", 1150], ["us", 1157], ["that", 1160], ["the", 1165], ["wrist", 1169], ["hyperflexion", 1175], ["and", 1188], ["abduction", 1192], ["of", 1202], ["the", 1205], ["thumb", 1209], ["test", 1215], ["is", 1220], ["very", 1223], ["valuable", 1228], ["in", 1237], ["diagnosing", 1240], ["dynamic", 1251], ["instability", 1259], ["after", 1271], ["successful", 1277], ["decompression", 1288], ["of", 1302], ["the", 1305], ["first", 1309], ["extensor", 1315], ["compartment", 1324], [".", 1335], ["Our", 1337], ["results", 1341], ["support", 1349], ["that", 1357], ["the", 1362], ["wrist", 1366], ["hyperflexion", 1372], ["and", 1385], ["abduction", 1389], ["of", 1399], ["the", 1402], ["thumb", 1406], ["test", 1412], ["is", 1417], ["a", 1420], ["more", 1422], ["precise", 1427], ["tool", 1435], ["for", 1440], ["the", 1444], ["diagnosis", 1448], ["of", 1458], ["de", 1461], ["Quervain", 1464], ["'s", 1472], ["disease", 1475], ["than", 1483], ["the", 1488], ["Eichhoff", 1492], ["'s", 1500], ["test", 1503], ["and", 1508], ["thus", 1512], ["could", 1517], ["be", 1523], ["adopted", 1526], ["to", 1534], ["guide", 1537], ["clinical", 1543], ["diagnosis", 1552], ["in", 1562], ["the", 1565], ["early", 1569], ["stages", 1575], ["of", 1582], ["de", 1585], ["Quervain", 1588], ["'s", 1596], ["tendinopathy", 1599], [".", 1611]]}
{"context": "Carpal tunnel syndrome is a complex of symptoms as a result of compression of the median nerve in the carpal tunnel. As nerve entrapment induces impairment of somatic fibres followed by clinical symptoms and signs of the syndrome, one can assume that sympathetic fibres are involved too. Results of studies focused on this problem show presence of sympathetic symptoms in about half of patients, including Raynaud phenomenon, blanching of hands, painful swelling of fingers, dry or excessive sweating of palms. Activity of sympathetic system can be investigated by means of sympathetic skin response and vasomotor response. Eight papers presenting the results of sympathetic skin response from median nerve in carpal tunnel syndrome were analysed. Results of 4 studies showed decreased sympathetic activity, in 2 findings were equivocal and 2 studies failed to reveal any abnormalities. The following variables were considered in the interpretation of sympathetic skin response curve: amplitude, latency and area under the chart, each of them having limited diagnostic value due to inter-and intrasubject variation of these parameters. Vasomotor response was investigated in 2 studies by means of Doppler ultrasound flow examination in digital arteries. Results of both studies showed decreased vasomotor response in carpal tunnel syndrome. The review of current knowledge on sympathetic impairment in carpal tunnel syndrome fails to provide a definitive determination of its range and clinical consequences. It confirms, however, that routine examination of sympathetic disturbances is unnecessary due to their minor clinical significance.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "3da4e2bccf984afb8212d78a6eab3d6f", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[15, 15], [115, 115]], "char_spans": [[82, 87], [694, 699]]}]}], "context_tokens": [["Carpal", 0], ["tunnel", 7], ["syndrome", 14], ["is", 23], ["a", 26], ["complex", 28], ["of", 36], ["symptoms", 39], ["as", 48], ["a", 51], ["result", 53], ["of", 60], ["compression", 63], ["of", 75], ["the", 78], ["median", 82], ["nerve", 89], ["in", 95], ["the", 98], ["carpal", 102], ["tunnel", 109], [".", 115], ["As", 117], ["nerve", 120], ["entrapment", 126], ["induces", 137], ["impairment", 145], ["of", 156], ["somatic", 159], ["fibres", 167], ["followed", 174], ["by", 183], ["clinical", 186], ["symptoms", 195], ["and", 204], ["signs", 208], ["of", 214], ["the", 217], ["syndrome", 221], [",", 229], ["one", 231], ["can", 235], ["assume", 239], ["that", 246], ["sympathetic", 251], ["fibres", 263], ["are", 270], ["involved", 274], ["too", 283], [".", 286], ["Results", 288], ["of", 296], ["studies", 299], ["focused", 307], ["on", 315], ["this", 318], ["problem", 323], ["show", 331], ["presence", 336], ["of", 345], ["sympathetic", 348], ["symptoms", 360], ["in", 369], ["about", 372], ["half", 378], ["of", 383], ["patients", 386], [",", 394], ["including", 396], ["Raynaud", 406], ["phenomenon", 414], [",", 424], ["blanching", 426], ["of", 436], ["hands", 439], [",", 444], ["painful", 446], ["swelling", 454], ["of", 463], ["fingers", 466], [",", 473], ["dry", 475], ["or", 479], ["excessive", 482], ["sweating", 492], ["of", 501], ["palms", 504], [".", 509], ["Activity", 511], ["of", 520], ["sympathetic", 523], ["system", 535], ["can", 542], ["be", 546], ["investigated", 549], ["by", 562], ["means", 565], ["of", 571], ["sympathetic", 574], ["skin", 586], ["response", 591], ["and", 600], ["vasomotor", 604], ["response", 614], [".", 622], ["Eight", 624], ["papers", 630], ["presenting", 637], ["the", 648], ["results", 652], ["of", 660], ["sympathetic", 663], ["skin", 675], ["response", 680], ["from", 689], ["median", 694], ["nerve", 701], ["in", 707], ["carpal", 710], ["tunnel", 717], ["syndrome", 724], ["were", 733], ["analysed", 738], [".", 746], ["Results", 748], ["of", 756], ["4", 759], ["studies", 761], ["showed", 769], ["decreased", 776], ["sympathetic", 786], ["activity", 798], [",", 806], ["in", 808], ["2", 811], ["findings", 813], ["were", 822], ["equivocal", 827], ["and", 837], ["2", 841], ["studies", 843], ["failed", 851], ["to", 858], ["reveal", 861], ["any", 868], ["abnormalities", 872], [".", 885], ["The", 887], ["following", 891], ["variables", 901], ["were", 911], ["considered", 916], ["in", 927], ["the", 930], ["interpretation", 934], ["of", 949], ["sympathetic", 952], ["skin", 964], ["response", 969], ["curve", 978], [":", 983], ["amplitude", 985], [",", 994], ["latency", 996], ["and", 1004], ["area", 1008], ["under", 1013], ["the", 1019], ["chart", 1023], [",", 1028], ["each", 1030], ["of", 1035], ["them", 1038], ["having", 1043], ["limited", 1050], ["diagnostic", 1058], ["value", 1069], ["due", 1075], ["to", 1079], ["inter", 1082], ["-", 1087], ["and", 1088], ["intrasubject", 1092], ["variation", 1105], ["of", 1115], ["these", 1118], ["parameters", 1124], [".", 1134], ["Vasomotor", 1136], ["response", 1146], ["was", 1155], ["investigated", 1159], ["in", 1172], ["2", 1175], ["studies", 1177], ["by", 1185], ["means", 1188], ["of", 1194], ["Doppler", 1197], ["ultrasound", 1205], ["flow", 1216], ["examination", 1221], ["in", 1233], ["digital", 1236], ["arteries", 1244], [".", 1252], ["Results", 1254], ["of", 1262], ["both", 1265], ["studies", 1270], ["showed", 1278], ["decreased", 1285], ["vasomotor", 1295], ["response", 1305], ["in", 1314], ["carpal", 1317], ["tunnel", 1324], ["syndrome", 1331], [".", 1339], ["The", 1341], ["review", 1345], ["of", 1352], ["current", 1355], ["knowledge", 1363], ["on", 1373], ["sympathetic", 1376], ["impairment", 1388], ["in", 1399], ["carpal", 1402], ["tunnel", 1409], ["syndrome", 1416], ["fails", 1425], ["to", 1431], ["provide", 1434], ["a", 1442], ["definitive", 1444], ["determination", 1455], ["of", 1469], ["its", 1472], ["range", 1476], ["and", 1482], ["clinical", 1486], ["consequences", 1495], [".", 1507], ["It", 1509], ["confirms", 1512], [",", 1520], ["however", 1522], [",", 1529], ["that", 1531], ["routine", 1536], ["examination", 1544], ["of", 1556], ["sympathetic", 1559], ["disturbances", 1571], ["is", 1584], ["unnecessary", 1587], ["due", 1599], ["to", 1603], ["their", 1606], ["minor", 1612], ["clinical", 1618], ["significance", 1627], [".", 1639]]}
{"context": "The Long QT syndrome (LQTS) is a relatively rare disorder. It has a major clinical impact as affected individuals are prone to syncope and sudden arrhythmogenic cardiac death. The LQTS comprises three groups of patients. The Jervell-Lange-Nielsen syndrome is characterized by an autosomal recessive pattern of inheritance and congenital neural deafness. The Romano-Ward syndrome shows an autosomal dominant pattern of inheritance and normal hearing. Patients with the sporadic form of LQTS have no evidence of familial transmission and have normal hearing. Imbalance of sympathetic cardiac innervation with predominance of the left stellate ganglion and an intrinsic myocardial defect leading to early afterdepolarization are the two pathogenetic mechanisms of LQTS discussed today. More recently a genetic basis for the Romano-Ward LQTS has been reported. The genetic linkage to the Harvey ras-1 gene provides the basis for a new hypothesis that an impairment of guanine nucleotide binding proteins is responsible for symptoms observed in LQTS. This paper discusses the genetic basis, pathology and pathophysiology of LQTS and tries to unify the different theories.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "26694e93ebbc4962895a9d5377a2e4e8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[68, 69]], "char_spans": [[388, 405]]}]}], "context_tokens": [["The", 0], ["Long", 4], ["QT", 9], ["syndrome", 12], ["(", 21], ["LQTS", 22], [")", 26], ["is", 28], ["a", 31], ["relatively", 33], ["rare", 44], ["disorder", 49], [".", 57], ["It", 59], ["has", 62], ["a", 66], ["major", 68], ["clinical", 74], ["impact", 83], ["as", 90], ["affected", 93], ["individuals", 102], ["are", 114], ["prone", 118], ["to", 124], ["syncope", 127], ["and", 135], ["sudden", 139], ["arrhythmogenic", 146], ["cardiac", 161], ["death", 169], [".", 174], ["The", 176], ["LQTS", 180], ["comprises", 185], ["three", 195], ["groups", 201], ["of", 208], ["patients", 211], [".", 219], ["The", 221], ["Jervell", 225], ["-", 232], ["Lange", 233], ["-", 238], ["Nielsen", 239], ["syndrome", 247], ["is", 256], ["characterized", 259], ["by", 273], ["an", 276], ["autosomal", 279], ["recessive", 289], ["pattern", 299], ["of", 307], ["inheritance", 310], ["and", 322], ["congenital", 326], ["neural", 337], ["deafness", 344], [".", 352], ["The", 354], ["Romano", 358], ["-", 364], ["Ward", 365], ["syndrome", 370], ["shows", 379], ["an", 385], ["autosomal", 388], ["dominant", 398], ["pattern", 407], ["of", 415], ["inheritance", 418], ["and", 430], ["normal", 434], ["hearing", 441], [".", 448], ["Patients", 450], ["with", 459], ["the", 464], ["sporadic", 468], ["form", 477], ["of", 482], ["LQTS", 485], ["have", 490], ["no", 495], ["evidence", 498], ["of", 507], ["familial", 510], ["transmission", 519], ["and", 532], ["have", 536], ["normal", 541], ["hearing", 548], [".", 555], ["Imbalance", 557], ["of", 567], ["sympathetic", 570], ["cardiac", 582], ["innervation", 590], ["with", 602], ["predominance", 607], ["of", 620], ["the", 623], ["left", 627], ["stellate", 632], ["ganglion", 641], ["and", 650], ["an", 654], ["intrinsic", 657], ["myocardial", 667], ["defect", 678], ["leading", 685], ["to", 693], ["early", 696], ["afterdepolarization", 702], ["are", 722], ["the", 726], ["two", 730], ["pathogenetic", 734], ["mechanisms", 747], ["of", 758], ["LQTS", 761], ["discussed", 766], ["today", 776], [".", 781], ["More", 783], ["recently", 788], ["a", 797], ["genetic", 799], ["basis", 807], ["for", 813], ["the", 817], ["Romano", 821], ["-", 827], ["Ward", 828], ["LQTS", 833], ["has", 838], ["been", 842], ["reported", 847], [".", 855], ["The", 857], ["genetic", 861], ["linkage", 869], ["to", 877], ["the", 880], ["Harvey", 884], ["ras-1", 891], ["gene", 897], ["provides", 902], ["the", 911], ["basis", 915], ["for", 921], ["a", 925], ["new", 927], ["hypothesis", 931], ["that", 942], ["an", 947], ["impairment", 950], ["of", 961], ["guanine", 964], ["nucleotide", 972], ["binding", 983], ["proteins", 991], ["is", 1000], ["responsible", 1003], ["for", 1015], ["symptoms", 1019], ["observed", 1028], ["in", 1037], ["LQTS", 1040], [".", 1044], ["This", 1046], ["paper", 1051], ["discusses", 1057], ["the", 1067], ["genetic", 1071], ["basis", 1079], [",", 1084], ["pathology", 1086], ["and", 1096], ["pathophysiology", 1100], ["of", 1116], ["LQTS", 1119], ["and", 1124], ["tries", 1128], ["to", 1134], ["unify", 1137], ["the", 1143], ["different", 1147], ["theories", 1157], [".", 1165]]}
{"context": "Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran. It has demonstrated prompt and durable reversal of the anticoagulant effects of dabigatran in animal studies and phase 1 studies of young, elderly, and renally impaired volunteers. Although elective invasive procedures and most bleeding complications in dabigatran-treated patients can be managed by temporarily stopping dabigatran therapy and using supportive measures, there are rare clinical situations that require urgent reversal of the anticoagulant effect of dabigatran. The effectiveness and safety of 5 g of intravenous idarucizumab is being investigated in a prospective, open-label, single-cohort study in patients with serious bleeding or in those requiring an urgent procedure. In an interim analysis of the first 90 participants, idarucizumab rapidly and completely reversed the anticoagulant activity of dabigatran in 88%-98% of participants, and there were no safety concerns, with no deaths or serious adverse events being attributable to idarucizumab. Supported by these interim results, idarucizumab has been approved in the United States and the European Union for use when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in patients with life-threatening or uncontrolled bleeding. Clinical use of idarucizumab should follow the same processes as patient enrollment in this study, which is projected to be completed in 2016. The outcomes achieved with this specific reversal agent are likely to be of continued interest to treating physicians.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "8031bea26fff4e0ca71ad6c3b3448396", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[60, 60], [140, 140], [23, 23], [9, 9], [50, 50], [193, 193], [81, 81]], "char_spans": [[405, 414], [903, 912], [164, 173], [72, 81], [338, 347], [1219, 1228], [550, 559]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["monoclonal", 18], ["antibody", 29], ["fragment", 38], ["specifically", 47], ["targeted", 60], ["to", 69], ["dabigatran", 72], [".", 82], ["It", 84], ["has", 87], ["demonstrated", 91], ["prompt", 104], ["and", 111], ["durable", 115], ["reversal", 123], ["of", 132], ["the", 135], ["anticoagulant", 139], ["effects", 153], ["of", 161], ["dabigatran", 164], ["in", 175], ["animal", 178], ["studies", 185], ["and", 193], ["phase", 197], ["1", 203], ["studies", 205], ["of", 213], ["young", 216], [",", 221], ["elderly", 223], [",", 230], ["and", 232], ["renally", 236], ["impaired", 244], ["volunteers", 253], [".", 263], ["Although", 265], ["elective", 274], ["invasive", 283], ["procedures", 292], ["and", 303], ["most", 307], ["bleeding", 312], ["complications", 321], ["in", 335], ["dabigatran", 338], ["-", 348], ["treated", 349], ["patients", 357], ["can", 366], ["be", 370], ["managed", 373], ["by", 381], ["temporarily", 384], ["stopping", 396], ["dabigatran", 405], ["therapy", 416], ["and", 424], ["using", 428], ["supportive", 434], ["measures", 445], [",", 453], ["there", 455], ["are", 461], ["rare", 465], ["clinical", 470], ["situations", 479], ["that", 490], ["require", 495], ["urgent", 503], ["reversal", 510], ["of", 519], ["the", 522], ["anticoagulant", 526], ["effect", 540], ["of", 547], ["dabigatran", 550], [".", 560], ["The", 562], ["effectiveness", 566], ["and", 580], ["safety", 584], ["of", 591], ["5", 594], ["g", 596], ["of", 598], ["intravenous", 601], ["idarucizumab", 613], ["is", 626], ["being", 629], ["investigated", 635], ["in", 648], ["a", 651], ["prospective", 653], [",", 664], ["open", 666], ["-", 670], ["label", 671], [",", 676], ["single", 678], ["-", 684], ["cohort", 685], ["study", 692], ["in", 698], ["patients", 701], ["with", 710], ["serious", 715], ["bleeding", 723], ["or", 732], ["in", 735], ["those", 738], ["requiring", 744], ["an", 754], ["urgent", 757], ["procedure", 764], [".", 773], ["In", 775], ["an", 778], ["interim", 781], ["analysis", 789], ["of", 798], ["the", 801], ["first", 805], ["90", 811], ["participants", 814], [",", 826], ["idarucizumab", 828], ["rapidly", 841], ["and", 849], ["completely", 853], ["reversed", 864], ["the", 873], ["anticoagulant", 877], ["activity", 891], ["of", 900], ["dabigatran", 903], ["in", 914], ["88%-98", 917], ["%", 923], ["of", 925], ["participants", 928], [",", 940], ["and", 942], ["there", 946], ["were", 952], ["no", 957], ["safety", 960], ["concerns", 967], [",", 975], ["with", 977], ["no", 982], ["deaths", 985], ["or", 992], ["serious", 995], ["adverse", 1003], ["events", 1011], ["being", 1018], ["attributable", 1024], ["to", 1037], ["idarucizumab", 1040], [".", 1052], ["Supported", 1054], ["by", 1064], ["these", 1067], ["interim", 1073], ["results", 1081], [",", 1088], ["idarucizumab", 1090], ["has", 1103], ["been", 1107], ["approved", 1112], ["in", 1121], ["the", 1124], ["United", 1128], ["States", 1135], ["and", 1142], ["the", 1146], ["European", 1150], ["Union", 1159], ["for", 1165], ["use", 1169], ["when", 1173], ["reversal", 1178], ["of", 1187], ["the", 1190], ["anticoagulant", 1194], ["effects", 1208], ["of", 1216], ["dabigatran", 1219], ["is", 1230], ["needed", 1233], ["for", 1240], ["emergency", 1244], ["surgery", 1254], ["/", 1261], ["urgent", 1262], ["procedures", 1269], ["or", 1280], ["in", 1283], ["patients", 1286], ["with", 1295], ["life", 1300], ["-", 1304], ["threatening", 1305], ["or", 1317], ["uncontrolled", 1320], ["bleeding", 1333], [".", 1341], ["Clinical", 1343], ["use", 1352], ["of", 1356], ["idarucizumab", 1359], ["should", 1372], ["follow", 1379], ["the", 1386], ["same", 1390], ["processes", 1395], ["as", 1405], ["patient", 1408], ["enrollment", 1416], ["in", 1427], ["this", 1430], ["study", 1435], [",", 1440], ["which", 1442], ["is", 1448], ["projected", 1451], ["to", 1461], ["be", 1464], ["completed", 1467], ["in", 1477], ["2016", 1480], [".", 1484], ["The", 1486], ["outcomes", 1490], ["achieved", 1499], ["with", 1508], ["this", 1513], ["specific", 1518], ["reversal", 1527], ["agent", 1536], ["are", 1542], ["likely", 1546], ["to", 1553], ["be", 1556], ["of", 1559], ["continued", 1562], ["interest", 1572], ["to", 1581], ["treating", 1584], ["physicians", 1593], [".", 1603]]}
{"context": "It is well known that autonomic failure is severer in patients with dementia with Lewy bodies (DLB) compared with patients with Parkinson's disease (PD). According to the Braak's hypothesis, Lewy bodies first appear in the olfactory bulb or peripheral autonomic nervous system. Lewy bodies in the peripheral autonomic nervous system ascend to dorsal motor nuclei of vagus nerve, while those in the olfactory bulb expand to the limbic system. Lewy bodies later attain the substantia nigra. However, it seems that Braak staging can not explain difference in severity of autonomic failure between DLB and PD. As a possibility, in DLB patients with significant autonomic failure, Lewy bodies may have been localized to the peripheral autonomic nervous system in a long time before onset of dementia or parkinsonism, and propagation of Lewy bodies into the central nervous system may be initiated by apparition of certain promotion factor, such as ageing and amyloid-\u03b2.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "db39b179aff4498e87b78355b6034f5b", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[23, 27]], "char_spans": [[128, 150]]}]}], "context_tokens": [["It", 0], ["is", 3], ["well", 6], ["known", 11], ["that", 17], ["autonomic", 22], ["failure", 32], ["is", 40], ["severer", 43], ["in", 51], ["patients", 54], ["with", 63], ["dementia", 68], ["with", 77], ["Lewy", 82], ["bodies", 87], ["(", 94], ["DLB", 95], [")", 98], ["compared", 100], ["with", 109], ["patients", 114], ["with", 123], ["Parkinson", 128], ["'s", 137], ["disease", 140], ["(", 148], ["PD", 149], [")", 151], [".", 152], ["According", 154], ["to", 164], ["the", 167], ["Braak", 171], ["'s", 176], ["hypothesis", 179], [",", 189], ["Lewy", 191], ["bodies", 196], ["first", 203], ["appear", 209], ["in", 216], ["the", 219], ["olfactory", 223], ["bulb", 233], ["or", 238], ["peripheral", 241], ["autonomic", 252], ["nervous", 262], ["system", 270], [".", 276], ["Lewy", 278], ["bodies", 283], ["in", 290], ["the", 293], ["peripheral", 297], ["autonomic", 308], ["nervous", 318], ["system", 326], ["ascend", 333], ["to", 340], ["dorsal", 343], ["motor", 350], ["nuclei", 356], ["of", 363], ["vagus", 366], ["nerve", 372], [",", 377], ["while", 379], ["those", 385], ["in", 391], ["the", 394], ["olfactory", 398], ["bulb", 408], ["expand", 413], ["to", 420], ["the", 423], ["limbic", 427], ["system", 434], [".", 440], ["Lewy", 442], ["bodies", 447], ["later", 454], ["attain", 460], ["the", 467], ["substantia", 471], ["nigra", 482], [".", 487], ["However", 489], [",", 496], ["it", 498], ["seems", 501], ["that", 507], ["Braak", 512], ["staging", 518], ["can", 526], ["not", 530], ["explain", 534], ["difference", 542], ["in", 553], ["severity", 556], ["of", 565], ["autonomic", 568], ["failure", 578], ["between", 586], ["DLB", 594], ["and", 598], ["PD", 602], [".", 604], ["As", 606], ["a", 609], ["possibility", 611], [",", 622], ["in", 624], ["DLB", 627], ["patients", 631], ["with", 640], ["significant", 645], ["autonomic", 657], ["failure", 667], [",", 674], ["Lewy", 676], ["bodies", 681], ["may", 688], ["have", 692], ["been", 697], ["localized", 702], ["to", 712], ["the", 715], ["peripheral", 719], ["autonomic", 730], ["nervous", 740], ["system", 748], ["in", 755], ["a", 758], ["long", 760], ["time", 765], ["before", 770], ["onset", 777], ["of", 783], ["dementia", 786], ["or", 795], ["parkinsonism", 798], [",", 810], ["and", 812], ["propagation", 816], ["of", 828], ["Lewy", 831], ["bodies", 836], ["into", 843], ["the", 848], ["central", 852], ["nervous", 860], ["system", 868], ["may", 875], ["be", 879], ["initiated", 882], ["by", 892], ["apparition", 895], ["of", 906], ["certain", 909], ["promotion", 917], ["factor", 927], [",", 933], ["such", 935], ["as", 940], ["ageing", 943], ["and", 950], ["amyloid", 954], ["-", 961], ["\u03b2", 962], [".", 963]]}
{"context": "Canonical primary microRNA (pri-miRNA) precursors are transcribed by RNA polymerase II and then processed by the Drosha endonuclease to generate approximately 60 nt pre-miRNA hairpins. Pre-miRNAs in turn are cleaved by Dicer to generate mature miRNAs. Previously, some short introns, called miRtrons, were reported to fold into pre-miRNA hairpins after splicing and debranching, and miRNAs can also be excised by Dicer cleavage of rare endogenous short hairpin RNAs. Here we report that the miRNAs encoded by murine gamma-herpesvirus 68 (MHV68) are also generated via atypical mechanisms. Specifically, MHV68 miRNAs are transcribed from RNA polymerase III promoters located within adjacent viral tRNA-like sequences. The resultant pri-miRNAs, which bear a 5' tRNA moiety, are not processed by Drosha but instead by cellular tRNase Z, which cleaves 3' to the tRNA to liberate pre-miRNA hairpins that are then processed by Dicer to yield the mature viral miRNAs.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "354a06365eb5430db7d04eb6bea5af55", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[12, 14]], "char_spans": [[69, 85]]}]}], "context_tokens": [["Canonical", 0], ["primary", 10], ["microRNA", 18], ["(", 27], ["pri", 28], ["-", 31], ["miRNA", 32], [")", 37], ["precursors", 39], ["are", 50], ["transcribed", 54], ["by", 66], ["RNA", 69], ["polymerase", 73], ["II", 84], ["and", 87], ["then", 91], ["processed", 96], ["by", 106], ["the", 109], ["Drosha", 113], ["endonuclease", 120], ["to", 133], ["generate", 136], ["approximately", 145], ["60", 159], ["nt", 162], ["pre", 165], ["-", 168], ["miRNA", 169], ["hairpins", 175], [".", 183], ["Pre", 185], ["-", 188], ["miRNAs", 189], ["in", 196], ["turn", 199], ["are", 204], ["cleaved", 208], ["by", 216], ["Dicer", 219], ["to", 225], ["generate", 228], ["mature", 237], ["miRNAs", 244], [".", 250], ["Previously", 252], [",", 262], ["some", 264], ["short", 269], ["introns", 275], [",", 282], ["called", 284], ["miRtrons", 291], [",", 299], ["were", 301], ["reported", 306], ["to", 315], ["fold", 318], ["into", 323], ["pre", 328], ["-", 331], ["miRNA", 332], ["hairpins", 338], ["after", 347], ["splicing", 353], ["and", 362], ["debranching", 366], [",", 377], ["and", 379], ["miRNAs", 383], ["can", 390], ["also", 394], ["be", 399], ["excised", 402], ["by", 410], ["Dicer", 413], ["cleavage", 419], ["of", 428], ["rare", 431], ["endogenous", 436], ["short", 447], ["hairpin", 453], ["RNAs", 461], [".", 465], ["Here", 467], ["we", 472], ["report", 475], ["that", 482], ["the", 487], ["miRNAs", 491], ["encoded", 498], ["by", 506], ["murine", 509], ["gamma", 516], ["-", 521], ["herpesvirus", 522], ["68", 534], ["(", 537], ["MHV68", 538], [")", 543], ["are", 545], ["also", 549], ["generated", 554], ["via", 564], ["atypical", 568], ["mechanisms", 577], [".", 587], ["Specifically", 589], [",", 601], ["MHV68", 603], ["miRNAs", 609], ["are", 616], ["transcribed", 620], ["from", 632], ["RNA", 637], ["polymerase", 641], ["III", 652], ["promoters", 656], ["located", 666], ["within", 674], ["adjacent", 681], ["viral", 690], ["tRNA", 696], ["-", 700], ["like", 701], ["sequences", 706], [".", 715], ["The", 717], ["resultant", 721], ["pri", 731], ["-", 734], ["miRNAs", 735], [",", 741], ["which", 743], ["bear", 749], ["a", 754], ["5", 756], ["'", 757], ["tRNA", 759], ["moiety", 764], [",", 770], ["are", 772], ["not", 776], ["processed", 780], ["by", 790], ["Drosha", 793], ["but", 800], ["instead", 804], ["by", 812], ["cellular", 815], ["tRNase", 824], ["Z", 831], [",", 832], ["which", 834], ["cleaves", 840], ["3", 848], ["'", 849], ["to", 851], ["the", 854], ["tRNA", 858], ["to", 863], ["liberate", 866], ["pre", 875], ["-", 878], ["miRNA", 879], ["hairpins", 885], ["that", 894], ["are", 899], ["then", 903], ["processed", 908], ["by", 918], ["Dicer", 921], ["to", 927], ["yield", 930], ["the", 936], ["mature", 940], ["viral", 947], ["miRNAs", 953], [".", 959]]}
{"context": "To investigate the migraine locus around the C19p13 region through analysis of the NOTCH3 gene (C19p13.2-p13.1), previously shown to be a gene involved in CADASIL and the TNFSF7 gene (C19p13), homologous to the ligands of TNF-alpha and TNF-beta, genes that have previously been associated with migraine. The NOTCH3 gene was analysed by sequencing all exons with known CADASIL mutations in a typical (non-familial hemiplegic) migraine family (MF1) that has previously been shown to be linked to C19p13. The TNFSF7 gene was investigated through SNP association analysis using a matched case-control migraine population. NOTCH3 gene sequencing results for affected members of MF1 proved to be negative for all known sequence variants giving rise to mutations for CADASIL. TNFSF7 gene chi-square results showed non-significant P values across all populations tested against controls, except for the MO subgroup which displayed a possible association with the TNFSF7 SNP (genotype, allele analysis P = 0.036, P = 0.017 respectively). Our results suggest that common migraine is not caused by any known CADASIL mutations in the NOTCH3 gene of interest. However, the TNFSF7 gene displayed signs of involvement in a MO affected population and indicates that further independent studies of this marker are warranted.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "fc24f2392a694a878abd703ed179be42", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[13, 14], [203, 204], [59, 60], [114, 115]], "char_spans": [[83, 93], [1122, 1132], [308, 318], [618, 628]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["migraine", 19], ["locus", 28], ["around", 34], ["the", 41], ["C19p13", 45], ["region", 52], ["through", 59], ["analysis", 67], ["of", 76], ["the", 79], ["NOTCH3", 83], ["gene", 90], ["(", 95], ["C19p13.2-p13.1", 96], [")", 110], [",", 111], ["previously", 113], ["shown", 124], ["to", 130], ["be", 133], ["a", 136], ["gene", 138], ["involved", 143], ["in", 152], ["CADASIL", 155], ["and", 163], ["the", 167], ["TNFSF7", 171], ["gene", 178], ["(", 183], ["C19p13", 184], [")", 190], [",", 191], ["homologous", 193], ["to", 204], ["the", 207], ["ligands", 211], ["of", 219], ["TNF", 222], ["-", 225], ["alpha", 226], ["and", 232], ["TNF", 236], ["-", 239], ["beta", 240], [",", 244], ["genes", 246], ["that", 252], ["have", 257], ["previously", 262], ["been", 273], ["associated", 278], ["with", 289], ["migraine", 294], [".", 302], ["The", 304], ["NOTCH3", 308], ["gene", 315], ["was", 320], ["analysed", 324], ["by", 333], ["sequencing", 336], ["all", 347], ["exons", 351], ["with", 357], ["known", 362], ["CADASIL", 368], ["mutations", 376], ["in", 386], ["a", 389], ["typical", 391], ["(", 399], ["non", 400], ["-", 403], ["familial", 404], ["hemiplegic", 413], [")", 423], ["migraine", 425], ["family", 434], ["(", 441], ["MF1", 442], [")", 445], ["that", 447], ["has", 452], ["previously", 456], ["been", 467], ["shown", 472], ["to", 478], ["be", 481], ["linked", 484], ["to", 491], ["C19p13", 494], [".", 500], ["The", 502], ["TNFSF7", 506], ["gene", 513], ["was", 518], ["investigated", 522], ["through", 535], ["SNP", 543], ["association", 547], ["analysis", 559], ["using", 568], ["a", 574], ["matched", 576], ["case", 584], ["-", 588], ["control", 589], ["migraine", 597], ["population", 606], [".", 616], ["NOTCH3", 618], ["gene", 625], ["sequencing", 630], ["results", 641], ["for", 649], ["affected", 653], ["members", 662], ["of", 670], ["MF1", 673], ["proved", 677], ["to", 684], ["be", 687], ["negative", 690], ["for", 699], ["all", 703], ["known", 707], ["sequence", 713], ["variants", 722], ["giving", 731], ["rise", 738], ["to", 743], ["mutations", 746], ["for", 756], ["CADASIL", 760], [".", 767], ["TNFSF7", 769], ["gene", 776], ["chi", 781], ["-", 784], ["square", 785], ["results", 792], ["showed", 800], ["non", 807], ["-", 810], ["significant", 811], ["P", 823], ["values", 825], ["across", 832], ["all", 839], ["populations", 843], ["tested", 855], ["against", 862], ["controls", 870], [",", 878], ["except", 880], ["for", 887], ["the", 891], ["MO", 895], ["subgroup", 898], ["which", 907], ["displayed", 913], ["a", 923], ["possible", 925], ["association", 934], ["with", 946], ["the", 951], ["TNFSF7", 955], ["SNP", 962], ["(", 966], ["genotype", 967], [",", 975], ["allele", 977], ["analysis", 984], ["P", 993], ["=", 995], ["0.036", 997], [",", 1002], ["P", 1004], ["=", 1006], ["0.017", 1008], ["respectively", 1014], [")", 1026], [".", 1027], ["Our", 1029], ["results", 1033], ["suggest", 1041], ["that", 1049], ["common", 1054], ["migraine", 1061], ["is", 1070], ["not", 1073], ["caused", 1077], ["by", 1084], ["any", 1087], ["known", 1091], ["CADASIL", 1097], ["mutations", 1105], ["in", 1115], ["the", 1118], ["NOTCH3", 1122], ["gene", 1129], ["of", 1134], ["interest", 1137], [".", 1145], ["However", 1147], [",", 1154], ["the", 1156], ["TNFSF7", 1160], ["gene", 1167], ["displayed", 1172], ["signs", 1182], ["of", 1188], ["involvement", 1191], ["in", 1203], ["a", 1206], ["MO", 1208], ["affected", 1211], ["population", 1220], ["and", 1231], ["indicates", 1235], ["that", 1245], ["further", 1250], ["independent", 1258], ["studies", 1270], ["of", 1278], ["this", 1281], ["marker", 1286], ["are", 1293], ["warranted", 1297], [".", 1306]]}
{"context": "The Web site for the Anxiety Disorders Association of America (ADAA) receives more than 5 million visits per month and thus represents a unique medium for the study of anxiety disorders. ADAA Web site users from October 2002 to January 2003 were invited to complete a survey oriented toward trauma history and psychiatric sequelae. A diagnostic approximation of posttraumatic stress disorder (PTSD) was based on responses to the Trauma Questionnaire, the Davidson Trauma Scale, and questions about impairment. The Connor-Davidson Resilience Scale was also used. Variables were tested for their association with PTSD. Among 1558 participants, 87% had a history of trauma, and 38% had current PTSD. The population was comprised predominantly of white middle-class women, half of whom were married. More than 90% were first-time users of the site. Factors associated with PTSD included death of, or harm to, a loved one; personal history of incest, rape, or physical abuse; lower age; lower income; unemployment; missed work; increased medical care; dissatisfaction with psychotropic medication; depressive symptoms; and lower resilience. In this selective convenience sample, there were high rates of traumatization and PTSD. The demographics of this group are similar to those seen in previously studied populations that had contacted the ADAA. Furthermore, the factors associated with PTSD were like those in many community surveys. The ADAA Web site has the opportunity to benefit large numbers of highly distressed individuals.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "7b813fb8fbe444c2b8ed096bcfc51ca6", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[123, 123], [251, 251], [104, 104], [159, 159], [66, 66], [223, 223]], "char_spans": [[691, 694], [1385, 1388], [611, 614], [869, 872], [393, 396], [1218, 1221]]}]}], "context_tokens": [["The", 0], ["Web", 4], ["site", 8], ["for", 13], ["the", 17], ["Anxiety", 21], ["Disorders", 29], ["Association", 39], ["of", 51], ["America", 54], ["(", 62], ["ADAA", 63], [")", 67], ["receives", 69], ["more", 78], ["than", 83], ["5", 88], ["million", 90], ["visits", 98], ["per", 105], ["month", 109], ["and", 115], ["thus", 119], ["represents", 124], ["a", 135], ["unique", 137], ["medium", 144], ["for", 151], ["the", 155], ["study", 159], ["of", 165], ["anxiety", 168], ["disorders", 176], [".", 185], ["ADAA", 187], ["Web", 192], ["site", 196], ["users", 201], ["from", 207], ["October", 212], ["2002", 220], ["to", 225], ["January", 228], ["2003", 236], ["were", 241], ["invited", 246], ["to", 254], ["complete", 257], ["a", 266], ["survey", 268], ["oriented", 275], ["toward", 284], ["trauma", 291], ["history", 298], ["and", 306], ["psychiatric", 310], ["sequelae", 322], [".", 330], ["A", 332], ["diagnostic", 334], ["approximation", 345], ["of", 359], ["posttraumatic", 362], ["stress", 376], ["disorder", 383], ["(", 392], ["PTSD", 393], [")", 397], ["was", 399], ["based", 403], ["on", 409], ["responses", 412], ["to", 422], ["the", 425], ["Trauma", 429], ["Questionnaire", 436], [",", 449], ["the", 451], ["Davidson", 455], ["Trauma", 464], ["Scale", 471], [",", 476], ["and", 478], ["questions", 482], ["about", 492], ["impairment", 498], [".", 508], ["The", 510], ["Connor", 514], ["-", 520], ["Davidson", 521], ["Resilience", 530], ["Scale", 541], ["was", 547], ["also", 551], ["used", 556], [".", 560], ["Variables", 562], ["were", 572], ["tested", 577], ["for", 584], ["their", 588], ["association", 594], ["with", 606], ["PTSD", 611], [".", 615], ["Among", 617], ["1558", 623], ["participants", 628], [",", 640], ["87", 642], ["%", 644], ["had", 646], ["a", 650], ["history", 652], ["of", 660], ["trauma", 663], [",", 669], ["and", 671], ["38", 675], ["%", 677], ["had", 679], ["current", 683], ["PTSD", 691], [".", 695], ["The", 697], ["population", 701], ["was", 712], ["comprised", 716], ["predominantly", 726], ["of", 740], ["white", 743], ["middle", 749], ["-", 755], ["class", 756], ["women", 762], [",", 767], ["half", 769], ["of", 774], ["whom", 777], ["were", 782], ["married", 787], [".", 794], ["More", 796], ["than", 801], ["90", 806], ["%", 808], ["were", 810], ["first", 815], ["-", 820], ["time", 821], ["users", 826], ["of", 832], ["the", 835], ["site", 839], [".", 843], ["Factors", 845], ["associated", 853], ["with", 864], ["PTSD", 869], ["included", 874], ["death", 883], ["of", 889], [",", 891], ["or", 893], ["harm", 896], ["to", 901], [",", 903], ["a", 905], ["loved", 907], ["one", 913], [";", 916], ["personal", 918], ["history", 927], ["of", 935], ["incest", 938], [",", 944], ["rape", 946], [",", 950], ["or", 952], ["physical", 955], ["abuse", 964], [";", 969], ["lower", 971], ["age", 977], [";", 980], ["lower", 982], ["income", 988], [";", 994], ["unemployment", 996], [";", 1008], ["missed", 1010], ["work", 1017], [";", 1021], ["increased", 1023], ["medical", 1033], ["care", 1041], [";", 1045], ["dissatisfaction", 1047], ["with", 1063], ["psychotropic", 1068], ["medication", 1081], [";", 1091], ["depressive", 1093], ["symptoms", 1104], [";", 1112], ["and", 1114], ["lower", 1118], ["resilience", 1124], [".", 1134], ["In", 1136], ["this", 1139], ["selective", 1144], ["convenience", 1154], ["sample", 1166], [",", 1172], ["there", 1174], ["were", 1180], ["high", 1185], ["rates", 1190], ["of", 1196], ["traumatization", 1199], ["and", 1214], ["PTSD", 1218], [".", 1222], ["The", 1224], ["demographics", 1228], ["of", 1241], ["this", 1244], ["group", 1249], ["are", 1255], ["similar", 1259], ["to", 1267], ["those", 1270], ["seen", 1276], ["in", 1281], ["previously", 1284], ["studied", 1295], ["populations", 1303], ["that", 1315], ["had", 1320], ["contacted", 1324], ["the", 1334], ["ADAA", 1338], [".", 1342], ["Furthermore", 1344], [",", 1355], ["the", 1357], ["factors", 1361], ["associated", 1369], ["with", 1380], ["PTSD", 1385], ["were", 1390], ["like", 1395], ["those", 1400], ["in", 1406], ["many", 1409], ["community", 1414], ["surveys", 1424], [".", 1431], ["The", 1433], ["ADAA", 1437], ["Web", 1442], ["site", 1446], ["has", 1451], ["the", 1455], ["opportunity", 1459], ["to", 1471], ["benefit", 1474], ["large", 1482], ["numbers", 1488], ["of", 1496], ["highly", 1499], ["distressed", 1506], ["individuals", 1517], [".", 1528]]}
{"context": "Ehlers-Danlos syndromes (EDS) are a heterogeneous group of heritable connective tissue disorders. Gastrointestinal manifestations in EDS have been described but their frequency, nature and impact are poorly known. We aimed to assess digestive features in a national cohort of EDS patients. A questionnaire has been sent to 212 EDS patients through the French patient support group, all of which had been formally diagnosed according to the Villefranche criteria. The questionnaire included questions about digestive functional symptoms, the GIQLI (Gastrointestinal Quality of Life Index), KESS scoring system and the Rome III criteria. Overall, 135 patients (64% response rate) completed the questionnaire and 134 were analyzable (123 women; 91%). Mean age and Body Mass Index were respectively 35\u00b114.7 years and 24.3\u00b16.1 kg/m(2). The most common EDS subtype was hypermobility form (n=108; 80.6%). GIQLI and KESS median values were respectively 63.5 (27-117) and 19 [13.5-22]. Eighty four percent of patients had functional bowel disorders (FBD) according to the Rome III criteria. An irritable bowel syndrome according to the same criteria was observed in 64 patients (48%) and 48 patients (36%) reported functional constipation. A gastro-esophageal reflux disease (GERD) was reported in 90 patients (68.7%), significantly associated with a poorer GIQLI (60.5\u00b116.8 versus 75.9\u00b120.3; p<0.0001). GIQLI was also negatively impacted by the presence of an irritable bowel syndrome or functional constipation (p=0.007). There was a significant correlation between FBD and GERD. Natural frequency of gastrointestinal manifestations in EDS seems higher than previously assessed. FBD and GERD are very common in our study population, the largest ever published until now. Their impact is herein shown to be important. A systematic clinical assessment of digestive features should be recommended in EDS.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "922ae9318d264f8ea1e929e98b4bbe0b", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14]], "char_spans": [[69, 85]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndromes", 14], ["(", 24], ["EDS", 25], [")", 28], ["are", 30], ["a", 34], ["heterogeneous", 36], ["group", 50], ["of", 56], ["heritable", 59], ["connective", 69], ["tissue", 80], ["disorders", 87], [".", 96], ["Gastrointestinal", 98], ["manifestations", 115], ["in", 130], ["EDS", 133], ["have", 137], ["been", 142], ["described", 147], ["but", 157], ["their", 161], ["frequency", 167], [",", 176], ["nature", 178], ["and", 185], ["impact", 189], ["are", 196], ["poorly", 200], ["known", 207], [".", 212], ["We", 214], ["aimed", 217], ["to", 223], ["assess", 226], ["digestive", 233], ["features", 243], ["in", 252], ["a", 255], ["national", 257], ["cohort", 266], ["of", 273], ["EDS", 276], ["patients", 280], [".", 288], ["A", 290], ["questionnaire", 292], ["has", 306], ["been", 310], ["sent", 315], ["to", 320], ["212", 323], ["EDS", 327], ["patients", 331], ["through", 340], ["the", 348], ["French", 352], ["patient", 359], ["support", 367], ["group", 375], [",", 380], ["all", 382], ["of", 386], ["which", 389], ["had", 395], ["been", 399], ["formally", 404], ["diagnosed", 413], ["according", 423], ["to", 433], ["the", 436], ["Villefranche", 440], ["criteria", 453], [".", 461], ["The", 463], ["questionnaire", 467], ["included", 481], ["questions", 490], ["about", 500], ["digestive", 506], ["functional", 516], ["symptoms", 527], [",", 535], ["the", 537], ["GIQLI", 541], ["(", 547], ["Gastrointestinal", 548], ["Quality", 565], ["of", 573], ["Life", 576], ["Index", 581], [")", 586], [",", 587], ["KESS", 589], ["scoring", 594], ["system", 602], ["and", 609], ["the", 613], ["Rome", 617], ["III", 622], ["criteria", 626], [".", 634], ["Overall", 636], [",", 643], ["135", 645], ["patients", 649], ["(", 658], ["64", 659], ["%", 661], ["response", 663], ["rate", 672], [")", 676], ["completed", 678], ["the", 688], ["questionnaire", 692], ["and", 706], ["134", 710], ["were", 714], ["analyzable", 719], ["(", 730], ["123", 731], ["women", 735], [";", 740], ["91", 742], ["%", 744], [")", 745], [".", 746], ["Mean", 748], ["age", 753], ["and", 757], ["Body", 761], ["Mass", 766], ["Index", 771], ["were", 777], ["respectively", 782], ["35\u00b114.7", 795], ["years", 803], ["and", 809], ["24.3\u00b16.1", 813], ["kg", 822], ["/", 824], ["m(2", 825], [")", 828], [".", 829], ["The", 831], ["most", 835], ["common", 840], ["EDS", 847], ["subtype", 851], ["was", 859], ["hypermobility", 863], ["form", 877], ["(", 882], ["n=108", 883], [";", 888], ["80.6", 890], ["%", 894], [")", 895], [".", 896], ["GIQLI", 898], ["and", 904], ["KESS", 908], ["median", 913], ["values", 920], ["were", 927], ["respectively", 932], ["63.5", 945], ["(", 950], ["27", 951], ["-", 953], ["117", 954], [")", 957], ["and", 959], ["19", 963], ["[", 966], ["13.5", 967], ["-", 971], ["22].", 972], ["Eighty", 977], ["four", 984], ["percent", 989], ["of", 997], ["patients", 1000], ["had", 1009], ["functional", 1013], ["bowel", 1024], ["disorders", 1030], ["(", 1040], ["FBD", 1041], [")", 1044], ["according", 1046], ["to", 1056], ["the", 1059], ["Rome", 1063], ["III", 1068], ["criteria", 1072], [".", 1080], ["An", 1082], ["irritable", 1085], ["bowel", 1095], ["syndrome", 1101], ["according", 1110], ["to", 1120], ["the", 1123], ["same", 1127], ["criteria", 1132], ["was", 1141], ["observed", 1145], ["in", 1154], ["64", 1157], ["patients", 1160], ["(", 1169], ["48", 1170], ["%", 1172], [")", 1173], ["and", 1175], ["48", 1179], ["patients", 1182], ["(", 1191], ["36", 1192], ["%", 1194], [")", 1195], ["reported", 1197], ["functional", 1206], ["constipation", 1217], [".", 1229], ["A", 1231], ["gastro", 1233], ["-", 1239], ["esophageal", 1240], ["reflux", 1251], ["disease", 1258], ["(", 1266], ["GERD", 1267], [")", 1271], ["was", 1273], ["reported", 1277], ["in", 1286], ["90", 1289], ["patients", 1292], ["(", 1301], ["68.7", 1302], ["%", 1306], [")", 1307], [",", 1308], ["significantly", 1310], ["associated", 1324], ["with", 1335], ["a", 1340], ["poorer", 1342], ["GIQLI", 1349], ["(", 1355], ["60.5\u00b116.8", 1356], ["versus", 1366], ["75.9\u00b120.3", 1373], [";", 1382], ["p<0.0001", 1384], [")", 1392], [".", 1393], ["GIQLI", 1395], ["was", 1401], ["also", 1405], ["negatively", 1410], ["impacted", 1421], ["by", 1430], ["the", 1433], ["presence", 1437], ["of", 1446], ["an", 1449], ["irritable", 1452], ["bowel", 1462], ["syndrome", 1468], ["or", 1477], ["functional", 1480], ["constipation", 1491], ["(", 1504], ["p=0.007", 1505], [")", 1512], [".", 1513], ["There", 1515], ["was", 1521], ["a", 1525], ["significant", 1527], ["correlation", 1539], ["between", 1551], ["FBD", 1559], ["and", 1563], ["GERD", 1567], [".", 1571], ["Natural", 1573], ["frequency", 1581], ["of", 1591], ["gastrointestinal", 1594], ["manifestations", 1611], ["in", 1626], ["EDS", 1629], ["seems", 1633], ["higher", 1639], ["than", 1646], ["previously", 1651], ["assessed", 1662], [".", 1670], ["FBD", 1672], ["and", 1676], ["GERD", 1680], ["are", 1685], ["very", 1689], ["common", 1694], ["in", 1701], ["our", 1704], ["study", 1708], ["population", 1714], [",", 1724], ["the", 1726], ["largest", 1730], ["ever", 1738], ["published", 1743], ["until", 1753], ["now", 1759], [".", 1762], ["Their", 1764], ["impact", 1770], ["is", 1777], ["herein", 1780], ["shown", 1787], ["to", 1793], ["be", 1796], ["important", 1799], [".", 1808], ["A", 1810], ["systematic", 1812], ["clinical", 1823], ["assessment", 1832], ["of", 1843], ["digestive", 1846], ["features", 1856], ["should", 1865], ["be", 1872], ["recommended", 1875], ["in", 1887], ["EDS", 1890], [".", 1893]]}
{"context": "Hospitalization for exacerbation of COPD is associated with a high risk of mortality. A risk-prediction model using information easily obtained on admission could help to identify high-risk individuals. The CURB65 score was developed to predict mortality risk in community acquired pneumonia. A retrospective study found that this score was also associated with mortality in COPD exacerbations. We conducted a prospective study to assess the utility of the CURB65 score in acute COPD exacerbations. Consecutive patients with physician diagnosed COPD exacerbations admitted to a public hospital during a 1-year period were studied prospectively. The CURB65 scores were calculated from information obtained at initial hospital presentation. CURB65\u2003=\u2003one point each for Confusion, Urea\u2003>\u20037 mmol/L, Respiratory rate\u2003\u2265\u200330/min, low Blood pressure, age\u2003\u2265\u200365 years. 30-day mortality data were available for 249 of 252 patients. CURB65 scores on admission significantly predicted risk of death during the hospital admission and at 30\u2003days. The 30-day mortality by score groups were: low risk (scores 0-1) 2.0% (2/98), moderate risk (score 2) 6.7% (6/90) and high risk (scores 3-5) 21.3% (13/61). CURB65 scores were not predictive of 1-year mortality. A simple 6-point score based on confusion, blood urea, respiratory rate, blood pressure and age can be used to stratify patients with COPD exacerbation into different management groups. The CURB65 score was as effective in predicting early mortality in our cohort of acute COPD exacerbations as it was in previous cohorts with community acquired pneumonia. Our findings suggest that CURB65 scores can help clinicians to assess patients with exacerbation of COPD.", "qas": [{"question": "CURB65 score is used for stratification of which disease?", "answers": ["pneumonia"], "qid": "930ebd41e49942059fff966207ce5c03", "question_tokens": [["CURB65", 0], ["score", 7], ["is", 13], ["used", 16], ["for", 21], ["stratification", 25], ["of", 40], ["which", 43], ["disease", 49], ["?", 56]], "detected_answers": [{"text": "pneumonia", "token_spans": [[288, 288], [46, 46]], "char_spans": [[1588, 1596], [282, 290]]}]}], "context_tokens": [["Hospitalization", 0], ["for", 16], ["exacerbation", 20], ["of", 33], ["COPD", 36], ["is", 41], ["associated", 44], ["with", 55], ["a", 60], ["high", 62], ["risk", 67], ["of", 72], ["mortality", 75], [".", 84], ["A", 86], ["risk", 88], ["-", 92], ["prediction", 93], ["model", 104], ["using", 110], ["information", 116], ["easily", 128], ["obtained", 135], ["on", 144], ["admission", 147], ["could", 157], ["help", 163], ["to", 168], ["identify", 171], ["high", 180], ["-", 184], ["risk", 185], ["individuals", 190], [".", 201], ["The", 203], ["CURB65", 207], ["score", 214], ["was", 220], ["developed", 224], ["to", 234], ["predict", 237], ["mortality", 245], ["risk", 255], ["in", 260], ["community", 263], ["acquired", 273], ["pneumonia", 282], [".", 291], ["A", 293], ["retrospective", 295], ["study", 309], ["found", 315], ["that", 321], ["this", 326], ["score", 331], ["was", 337], ["also", 341], ["associated", 346], ["with", 357], ["mortality", 362], ["in", 372], ["COPD", 375], ["exacerbations", 380], [".", 393], ["We", 395], ["conducted", 398], ["a", 408], ["prospective", 410], ["study", 422], ["to", 428], ["assess", 431], ["the", 438], ["utility", 442], ["of", 450], ["the", 453], ["CURB65", 457], ["score", 464], ["in", 470], ["acute", 473], ["COPD", 479], ["exacerbations", 484], [".", 497], ["Consecutive", 499], ["patients", 511], ["with", 520], ["physician", 525], ["diagnosed", 535], ["COPD", 545], ["exacerbations", 550], ["admitted", 564], ["to", 573], ["a", 576], ["public", 578], ["hospital", 585], ["during", 594], ["a", 601], ["1-year", 603], ["period", 610], ["were", 617], ["studied", 622], ["prospectively", 630], [".", 643], ["The", 645], ["CURB65", 649], ["scores", 656], ["were", 663], ["calculated", 668], ["from", 679], ["information", 684], ["obtained", 696], ["at", 705], ["initial", 708], ["hospital", 716], ["presentation", 725], [".", 737], ["CURB65", 739], ["=", 746], ["one", 748], ["point", 752], ["each", 758], ["for", 763], ["Confusion", 767], [",", 776], ["Urea", 778], [">", 783], ["7", 785], ["mmol", 787], ["/", 791], ["L", 792], [",", 793], ["Respiratory", 795], ["rate", 807], ["\u2265", 812], ["30/min", 814], [",", 820], ["low", 822], ["Blood", 826], ["pressure", 832], [",", 840], ["age", 842], ["\u2265", 846], ["65", 848], ["years", 851], [".", 856], ["30-day", 858], ["mortality", 865], ["data", 875], ["were", 880], ["available", 885], ["for", 895], ["249", 899], ["of", 903], ["252", 906], ["patients", 910], [".", 918], ["CURB65", 920], ["scores", 927], ["on", 934], ["admission", 937], ["significantly", 947], ["predicted", 961], ["risk", 971], ["of", 976], ["death", 979], ["during", 985], ["the", 992], ["hospital", 996], ["admission", 1005], ["and", 1015], ["at", 1019], ["30", 1022], ["days", 1025], [".", 1029], ["The", 1031], ["30-day", 1035], ["mortality", 1042], ["by", 1052], ["score", 1055], ["groups", 1061], ["were", 1068], [":", 1072], ["low", 1074], ["risk", 1078], ["(", 1083], ["scores", 1084], ["0", 1091], ["-", 1092], ["1", 1093], [")", 1094], ["2.0", 1096], ["%", 1099], ["(", 1101], ["2/98", 1102], [")", 1106], [",", 1107], ["moderate", 1109], ["risk", 1118], ["(", 1123], ["score", 1124], ["2", 1130], [")", 1131], ["6.7", 1133], ["%", 1136], ["(", 1138], ["6/90", 1139], [")", 1143], ["and", 1145], ["high", 1149], ["risk", 1154], ["(", 1159], ["scores", 1160], ["3", 1167], ["-", 1168], ["5", 1169], [")", 1170], ["21.3", 1172], ["%", 1176], ["(", 1178], ["13/61", 1179], [")", 1184], [".", 1185], ["CURB65", 1187], ["scores", 1194], ["were", 1201], ["not", 1206], ["predictive", 1210], ["of", 1221], ["1-year", 1224], ["mortality", 1231], [".", 1240], ["A", 1242], ["simple", 1244], ["6-point", 1251], ["score", 1259], ["based", 1265], ["on", 1271], ["confusion", 1274], [",", 1283], ["blood", 1285], ["urea", 1291], [",", 1295], ["respiratory", 1297], ["rate", 1309], [",", 1313], ["blood", 1315], ["pressure", 1321], ["and", 1330], ["age", 1334], ["can", 1338], ["be", 1342], ["used", 1345], ["to", 1350], ["stratify", 1353], ["patients", 1362], ["with", 1371], ["COPD", 1376], ["exacerbation", 1381], ["into", 1394], ["different", 1399], ["management", 1409], ["groups", 1420], [".", 1426], ["The", 1428], ["CURB65", 1432], ["score", 1439], ["was", 1445], ["as", 1449], ["effective", 1452], ["in", 1462], ["predicting", 1465], ["early", 1476], ["mortality", 1482], ["in", 1492], ["our", 1495], ["cohort", 1499], ["of", 1506], ["acute", 1509], ["COPD", 1515], ["exacerbations", 1520], ["as", 1534], ["it", 1537], ["was", 1540], ["in", 1544], ["previous", 1547], ["cohorts", 1556], ["with", 1564], ["community", 1569], ["acquired", 1579], ["pneumonia", 1588], [".", 1597], ["Our", 1599], ["findings", 1603], ["suggest", 1612], ["that", 1620], ["CURB65", 1625], ["scores", 1632], ["can", 1639], ["help", 1643], ["clinicians", 1648], ["to", 1659], ["assess", 1662], ["patients", 1669], ["with", 1678], ["exacerbation", 1683], ["of", 1696], ["COPD", 1699], [".", 1703]]}
{"context": "Lamp2a acts as a receptor in the lysosomal membrane for substrate proteins of chaperone-mediated autophagy. Using antibodies specific for the cytosolic tail of lamp2a and others recognizing all lamp2 isoforms, we found that in rat liver lamp2a represents 25% of lamp2s in the lysosome. We show that lamp2a levels in the lysosomal membrane in rat liver and fibroblasts in culture directly correlate with rates of chaperone-mediated autophagy in a variety of physiological and pathological conditions. The concentration of other lamp2s in the lysosomal membrane show no correlation under the same conditions. Furthermore, substrate proteins bind to lamp2a but not to other lamp2s. Four positively-charged amino acids uniquely present in the cytosolic tail of lamp2a are required for the binding of substrate proteins. Lamp2a also distributes to an unique subpopulation of perinuclear lysosomes in cultured fibroblasts in response to serum withdrawal, and lamp2a, more than other lamp2s, tends to multimerize. These characteristics may be important for lamp2a to act as a receptor for chaperone-mediated autophagy.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "4688b81a249a4edd87b46d5ce300cfcf", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[0, 0], [107, 107], [53, 53], [26, 26], [157, 157], [137, 137], [40, 40], [174, 174], [127, 127]], "char_spans": [[0, 5], [647, 652], [299, 304], [160, 165], [953, 958], [816, 821], [237, 242], [1050, 1055], [757, 762]]}]}], "context_tokens": [["Lamp2a", 0], ["acts", 7], ["as", 12], ["a", 15], ["receptor", 17], ["in", 26], ["the", 29], ["lysosomal", 33], ["membrane", 43], ["for", 52], ["substrate", 56], ["proteins", 66], ["of", 75], ["chaperone", 78], ["-", 87], ["mediated", 88], ["autophagy", 97], [".", 106], ["Using", 108], ["antibodies", 114], ["specific", 125], ["for", 134], ["the", 138], ["cytosolic", 142], ["tail", 152], ["of", 157], ["lamp2a", 160], ["and", 167], ["others", 171], ["recognizing", 178], ["all", 190], ["lamp2", 194], ["isoforms", 200], [",", 208], ["we", 210], ["found", 213], ["that", 219], ["in", 224], ["rat", 227], ["liver", 231], ["lamp2a", 237], ["represents", 244], ["25", 255], ["%", 257], ["of", 259], ["lamp2s", 262], ["in", 269], ["the", 272], ["lysosome", 276], [".", 284], ["We", 286], ["show", 289], ["that", 294], ["lamp2a", 299], ["levels", 306], ["in", 313], ["the", 316], ["lysosomal", 320], ["membrane", 330], ["in", 339], ["rat", 342], ["liver", 346], ["and", 352], ["fibroblasts", 356], ["in", 368], ["culture", 371], ["directly", 379], ["correlate", 388], ["with", 398], ["rates", 403], ["of", 409], ["chaperone", 412], ["-", 421], ["mediated", 422], ["autophagy", 431], ["in", 441], ["a", 444], ["variety", 446], ["of", 454], ["physiological", 457], ["and", 471], ["pathological", 475], ["conditions", 488], [".", 498], ["The", 500], ["concentration", 504], ["of", 518], ["other", 521], ["lamp2s", 527], ["in", 534], ["the", 537], ["lysosomal", 541], ["membrane", 551], ["show", 560], ["no", 565], ["correlation", 568], ["under", 580], ["the", 586], ["same", 590], ["conditions", 595], [".", 605], ["Furthermore", 607], [",", 618], ["substrate", 620], ["proteins", 630], ["bind", 639], ["to", 644], ["lamp2a", 647], ["but", 654], ["not", 658], ["to", 662], ["other", 665], ["lamp2s", 671], [".", 677], ["Four", 679], ["positively", 684], ["-", 694], ["charged", 695], ["amino", 703], ["acids", 709], ["uniquely", 715], ["present", 724], ["in", 732], ["the", 735], ["cytosolic", 739], ["tail", 749], ["of", 754], ["lamp2a", 757], ["are", 764], ["required", 768], ["for", 777], ["the", 781], ["binding", 785], ["of", 793], ["substrate", 796], ["proteins", 806], [".", 814], ["Lamp2a", 816], ["also", 823], ["distributes", 828], ["to", 840], ["an", 843], ["unique", 846], ["subpopulation", 853], ["of", 867], ["perinuclear", 870], ["lysosomes", 882], ["in", 892], ["cultured", 895], ["fibroblasts", 904], ["in", 916], ["response", 919], ["to", 928], ["serum", 931], ["withdrawal", 937], [",", 947], ["and", 949], ["lamp2a", 953], [",", 959], ["more", 961], ["than", 966], ["other", 971], ["lamp2s", 977], [",", 983], ["tends", 985], ["to", 991], ["multimerize", 994], [".", 1005], ["These", 1007], ["characteristics", 1013], ["may", 1029], ["be", 1033], ["important", 1036], ["for", 1046], ["lamp2a", 1050], ["to", 1057], ["act", 1060], ["as", 1064], ["a", 1067], ["receptor", 1069], ["for", 1078], ["chaperone", 1082], ["-", 1091], ["mediated", 1092], ["autophagy", 1101], [".", 1110]]}
{"context": "Restless legs syndrome (RLS), recently renamed Willis-Ekbom disease (WED), is a common movement disorder. It is characterised by the need to move mainly the legs due to uncomfortable, sometimes painful sensations in the legs, which have a diurnal variation and a release with movement. Management is complex. First, centres should establish the severity of RLS using a simple 10-item RLS severity rating scale (IRLS). They should also exclude secondary causes, in particular ensuring normal iron levels. Mild cases can be managed by lifestyle changes, but patients with a IRLS score above 15 usually require pharmacological treatment. Dopaminergic therapies remain the mainstay of medical therapies, with recent evidence suggesting opioids may be particularly effective. This article focuses on the different treatment strategies in RLS, their associated complications and ways to manage them.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "9cce10bf0b6546509cf2de1aba61138e", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["recently", 30], ["renamed", 39], ["Willis", 47], ["-", 53], ["Ekbom", 54], ["disease", 60], ["(", 68], ["WED", 69], [")", 72], [",", 73], ["is", 75], ["a", 78], ["common", 80], ["movement", 87], ["disorder", 96], [".", 104], ["It", 106], ["is", 109], ["characterised", 112], ["by", 126], ["the", 129], ["need", 133], ["to", 138], ["move", 141], ["mainly", 146], ["the", 153], ["legs", 157], ["due", 162], ["to", 166], ["uncomfortable", 169], [",", 182], ["sometimes", 184], ["painful", 194], ["sensations", 202], ["in", 213], ["the", 216], ["legs", 220], [",", 224], ["which", 226], ["have", 232], ["a", 237], ["diurnal", 239], ["variation", 247], ["and", 257], ["a", 261], ["release", 263], ["with", 271], ["movement", 276], [".", 284], ["Management", 286], ["is", 297], ["complex", 300], [".", 307], ["First", 309], [",", 314], ["centres", 316], ["should", 324], ["establish", 331], ["the", 341], ["severity", 345], ["of", 354], ["RLS", 357], ["using", 361], ["a", 367], ["simple", 369], ["10-item", 376], ["RLS", 384], ["severity", 388], ["rating", 397], ["scale", 404], ["(", 410], ["IRLS", 411], [")", 415], [".", 416], ["They", 418], ["should", 423], ["also", 430], ["exclude", 435], ["secondary", 443], ["causes", 453], [",", 459], ["in", 461], ["particular", 464], ["ensuring", 475], ["normal", 484], ["iron", 491], ["levels", 496], [".", 502], ["Mild", 504], ["cases", 509], ["can", 515], ["be", 519], ["managed", 522], ["by", 530], ["lifestyle", 533], ["changes", 543], [",", 550], ["but", 552], ["patients", 556], ["with", 565], ["a", 570], ["IRLS", 572], ["score", 577], ["above", 583], ["15", 589], ["usually", 592], ["require", 600], ["pharmacological", 608], ["treatment", 624], [".", 633], ["Dopaminergic", 635], ["therapies", 648], ["remain", 658], ["the", 665], ["mainstay", 669], ["of", 678], ["medical", 681], ["therapies", 689], [",", 698], ["with", 700], ["recent", 705], ["evidence", 712], ["suggesting", 721], ["opioids", 732], ["may", 740], ["be", 744], ["particularly", 747], ["effective", 760], [".", 769], ["This", 771], ["article", 776], ["focuses", 784], ["on", 792], ["the", 795], ["different", 799], ["treatment", 809], ["strategies", 819], ["in", 830], ["RLS", 833], [",", 836], ["their", 838], ["associated", 844], ["complications", 855], ["and", 869], ["ways", 873], ["to", 878], ["manage", 881], ["them", 888], [".", 892]]}
{"context": "Metastasis is the major factor affecting patient survival in ovarian cancer. However, its molecular mechanisms remain unclear. Our study used isogenic pairs of low- and high-invasive ovarian cancer cell lines to demonstrate the downregulation of miRNA-138 in the highly invasive cells, and its functioning as an inhibitor of cell migration and invasion. An orthotopic xenograft mouse model further demonstrated that the expression of miRNA-138 inhibited ovarian cancer metastasis to other organs. Results indicated that miR-138 directly targeted SRY-related high mobility group box 4 (SOX4) and hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), and overexpression of SOX4 and HIF-1\u03b1 effectively reversed the miR-138-mediated suppression of cell invasion. Epidermal growth factor receptor acted as the downstream molecule of SOX4 by way of direct transcriptional control, whereas Slug was the downstream molecule of HIF-1\u03b1 by way of proteasome-mediated degradation. Analysis of human ovarian tumors further revealed downregulation of miR-138 and upregulation of SOX4 in late-stage tumors. Patients with miR-138(low)/SOX(high) signature are predominant in late stage and tend to have malignant phenotypes including lymph nodes metastasis, larger ascites volume and higher tumor grade. Our study demonstrates the role and clinical relevance of miR-138 in ovarian cancer cell invasion and metastasis, providing a potential therapeutic strategy for suppression of ovarian cancer metastasis by targeting SOX4 and HIF-1\u03b1 pathways.", "qas": [{"question": "Which miRNA is targeted by SRY/Sox9?", "answers": ["mir-138"], "qid": "8975f12eced24dab8b0c41383c7ba4d8", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["targeted", 15], ["by", 24], ["SRY", 27], ["/", 30], ["Sox9", 31], ["?", 35]], "detected_answers": [{"text": "mir-138", "token_spans": [[212, 212], [163, 163], [82, 82]], "char_spans": [[1329, 1335], [1021, 1027], [520, 526]]}]}], "context_tokens": [["Metastasis", 0], ["is", 11], ["the", 14], ["major", 18], ["factor", 24], ["affecting", 31], ["patient", 41], ["survival", 49], ["in", 58], ["ovarian", 61], ["cancer", 69], [".", 75], ["However", 77], [",", 84], ["its", 86], ["molecular", 90], ["mechanisms", 100], ["remain", 111], ["unclear", 118], [".", 125], ["Our", 127], ["study", 131], ["used", 137], ["isogenic", 142], ["pairs", 151], ["of", 157], ["low-", 160], ["and", 165], ["high", 169], ["-", 173], ["invasive", 174], ["ovarian", 183], ["cancer", 191], ["cell", 198], ["lines", 203], ["to", 209], ["demonstrate", 212], ["the", 224], ["downregulation", 228], ["of", 243], ["miRNA-138", 246], ["in", 256], ["the", 259], ["highly", 263], ["invasive", 270], ["cells", 279], [",", 284], ["and", 286], ["its", 290], ["functioning", 294], ["as", 306], ["an", 309], ["inhibitor", 312], ["of", 322], ["cell", 325], ["migration", 330], ["and", 340], ["invasion", 344], [".", 352], ["An", 354], ["orthotopic", 357], ["xenograft", 368], ["mouse", 378], ["model", 384], ["further", 390], ["demonstrated", 398], ["that", 411], ["the", 416], ["expression", 420], ["of", 431], ["miRNA-138", 434], ["inhibited", 444], ["ovarian", 454], ["cancer", 462], ["metastasis", 469], ["to", 480], ["other", 483], ["organs", 489], [".", 495], ["Results", 497], ["indicated", 505], ["that", 515], ["miR-138", 520], ["directly", 528], ["targeted", 537], ["SRY", 546], ["-", 549], ["related", 550], ["high", 558], ["mobility", 563], ["group", 572], ["box", 578], ["4", 582], ["(", 584], ["SOX4", 585], [")", 589], ["and", 591], ["hypoxia", 595], ["-", 602], ["inducible", 603], ["factor-1\u03b1", 613], ["(", 623], ["HIF-1\u03b1", 624], [")", 630], [",", 631], ["and", 633], ["overexpression", 637], ["of", 652], ["SOX4", 655], ["and", 660], ["HIF-1\u03b1", 664], ["effectively", 671], ["reversed", 683], ["the", 692], ["miR-138-mediated", 696], ["suppression", 713], ["of", 725], ["cell", 728], ["invasion", 733], [".", 741], ["Epidermal", 743], ["growth", 753], ["factor", 760], ["receptor", 767], ["acted", 776], ["as", 782], ["the", 785], ["downstream", 789], ["molecule", 800], ["of", 809], ["SOX4", 812], ["by", 817], ["way", 820], ["of", 824], ["direct", 827], ["transcriptional", 834], ["control", 850], [",", 857], ["whereas", 859], ["Slug", 867], ["was", 872], ["the", 876], ["downstream", 880], ["molecule", 891], ["of", 900], ["HIF-1\u03b1", 903], ["by", 910], ["way", 913], ["of", 917], ["proteasome", 920], ["-", 930], ["mediated", 931], ["degradation", 940], [".", 951], ["Analysis", 953], ["of", 962], ["human", 965], ["ovarian", 971], ["tumors", 979], ["further", 986], ["revealed", 994], ["downregulation", 1003], ["of", 1018], ["miR-138", 1021], ["and", 1029], ["upregulation", 1033], ["of", 1046], ["SOX4", 1049], ["in", 1054], ["late", 1057], ["-", 1061], ["stage", 1062], ["tumors", 1068], [".", 1074], ["Patients", 1076], ["with", 1085], ["miR-138(low)/SOX(high", 1090], [")", 1111], ["signature", 1113], ["are", 1123], ["predominant", 1127], ["in", 1139], ["late", 1142], ["stage", 1147], ["and", 1153], ["tend", 1157], ["to", 1162], ["have", 1165], ["malignant", 1170], ["phenotypes", 1180], ["including", 1191], ["lymph", 1201], ["nodes", 1207], ["metastasis", 1213], [",", 1223], ["larger", 1225], ["ascites", 1232], ["volume", 1240], ["and", 1247], ["higher", 1251], ["tumor", 1258], ["grade", 1264], [".", 1269], ["Our", 1271], ["study", 1275], ["demonstrates", 1281], ["the", 1294], ["role", 1298], ["and", 1303], ["clinical", 1307], ["relevance", 1316], ["of", 1326], ["miR-138", 1329], ["in", 1337], ["ovarian", 1340], ["cancer", 1348], ["cell", 1355], ["invasion", 1360], ["and", 1369], ["metastasis", 1373], [",", 1383], ["providing", 1385], ["a", 1395], ["potential", 1397], ["therapeutic", 1407], ["strategy", 1419], ["for", 1428], ["suppression", 1432], ["of", 1444], ["ovarian", 1447], ["cancer", 1455], ["metastasis", 1462], ["by", 1473], ["targeting", 1476], ["SOX4", 1486], ["and", 1491], ["HIF-1\u03b1", 1495], ["pathways", 1502], [".", 1510]]}
{"context": "To assess the potential of polymeric nanoparticles (NPs) to affect the genital distribution and local and systemic pharmacokinetics (PK) of the anti-HIV microbicide drug candidate dapivirine after vaginal delivery. Dapivirine-loaded, poly(ethylene oxide)-coated poly(epsilon-caprolactone) (PEO-PCL) NPs were prepared by a nanoprecipitation method. Genital distribution of NPs and their ability to modify the PK of dapivirine up to 24 h was assessed after vaginal instillation in a female mouse model. Also, the safety of NPs upon daily administration for 14 days was assessed by histological analysis and chemokine/cytokine content in vaginal lavages. PEO-PCL NPs (180-200 nm) were rapidly eliminated after administration but able to distribute throughout the vagina and lower uterus, and capable of tackling mucus and penetrate the epithelial lining. Nanocarriers modified the PK of dapivirine, with higher drug levels being recovered from vaginal lavages and vaginal/lower uterine tissues as compared to a drug suspension. Systemic drug exposure was reduced when NPs were used. Also, NPs were shown safe upon administration for 14 days. Dapivirine-loaded PEO-PCL NPs were able to provide likely favorable genital drug levels, thus attesting the potential value of using this vaginal drug delivery nanosystem in the context of HIV prophylaxis.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "1e55c4f1758248f58dd8977c35ab8ead", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[27, 27], [234, 234]], "char_spans": [[149, 151], [1328, 1330]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["potential", 14], ["of", 24], ["polymeric", 27], ["nanoparticles", 37], ["(", 51], ["NPs", 52], [")", 55], ["to", 57], ["affect", 60], ["the", 67], ["genital", 71], ["distribution", 79], ["and", 92], ["local", 96], ["and", 102], ["systemic", 106], ["pharmacokinetics", 115], ["(", 132], ["PK", 133], [")", 135], ["of", 137], ["the", 140], ["anti", 144], ["-", 148], ["HIV", 149], ["microbicide", 153], ["drug", 165], ["candidate", 170], ["dapivirine", 180], ["after", 191], ["vaginal", 197], ["delivery", 205], [".", 213], ["Dapivirine", 215], ["-", 225], ["loaded", 226], [",", 232], ["poly(ethylene", 234], ["oxide)-coated", 248], ["poly(epsilon", 262], ["-", 274], ["caprolactone", 275], [")", 287], ["(", 289], ["PEO", 290], ["-", 293], ["PCL", 294], [")", 297], ["NPs", 299], ["were", 303], ["prepared", 308], ["by", 317], ["a", 320], ["nanoprecipitation", 322], ["method", 340], [".", 346], ["Genital", 348], ["distribution", 356], ["of", 369], ["NPs", 372], ["and", 376], ["their", 380], ["ability", 386], ["to", 394], ["modify", 397], ["the", 404], ["PK", 408], ["of", 411], ["dapivirine", 414], ["up", 425], ["to", 428], ["24", 431], ["h", 434], ["was", 436], ["assessed", 440], ["after", 449], ["vaginal", 455], ["instillation", 463], ["in", 476], ["a", 479], ["female", 481], ["mouse", 488], ["model", 494], [".", 499], ["Also", 501], [",", 505], ["the", 507], ["safety", 511], ["of", 518], ["NPs", 521], ["upon", 525], ["daily", 530], ["administration", 536], ["for", 551], ["14", 555], ["days", 558], ["was", 563], ["assessed", 567], ["by", 576], ["histological", 579], ["analysis", 592], ["and", 601], ["chemokine", 605], ["/", 614], ["cytokine", 615], ["content", 624], ["in", 632], ["vaginal", 635], ["lavages", 643], [".", 650], ["PEO", 652], ["-", 655], ["PCL", 656], ["NPs", 660], ["(", 664], ["180", 665], ["-", 668], ["200", 669], ["nm", 673], [")", 675], ["were", 677], ["rapidly", 682], ["eliminated", 690], ["after", 701], ["administration", 707], ["but", 722], ["able", 726], ["to", 731], ["distribute", 734], ["throughout", 745], ["the", 756], ["vagina", 760], ["and", 767], ["lower", 771], ["uterus", 777], [",", 783], ["and", 785], ["capable", 789], ["of", 797], ["tackling", 800], ["mucus", 809], ["and", 815], ["penetrate", 819], ["the", 829], ["epithelial", 833], ["lining", 844], [".", 850], ["Nanocarriers", 852], ["modified", 865], ["the", 874], ["PK", 878], ["of", 881], ["dapivirine", 884], [",", 894], ["with", 896], ["higher", 901], ["drug", 908], ["levels", 913], ["being", 920], ["recovered", 926], ["from", 936], ["vaginal", 941], ["lavages", 949], ["and", 957], ["vaginal", 961], ["/", 968], ["lower", 969], ["uterine", 975], ["tissues", 983], ["as", 991], ["compared", 994], ["to", 1003], ["a", 1006], ["drug", 1008], ["suspension", 1013], [".", 1023], ["Systemic", 1025], ["drug", 1034], ["exposure", 1039], ["was", 1048], ["reduced", 1052], ["when", 1060], ["NPs", 1065], ["were", 1069], ["used", 1074], [".", 1078], ["Also", 1080], [",", 1084], ["NPs", 1086], ["were", 1090], ["shown", 1095], ["safe", 1101], ["upon", 1106], ["administration", 1111], ["for", 1126], ["14", 1130], ["days", 1133], [".", 1137], ["Dapivirine", 1139], ["-", 1149], ["loaded", 1150], ["PEO", 1157], ["-", 1160], ["PCL", 1161], ["NPs", 1165], ["were", 1169], ["able", 1174], ["to", 1179], ["provide", 1182], ["likely", 1190], ["favorable", 1197], ["genital", 1207], ["drug", 1215], ["levels", 1220], [",", 1226], ["thus", 1228], ["attesting", 1233], ["the", 1243], ["potential", 1247], ["value", 1257], ["of", 1263], ["using", 1266], ["this", 1272], ["vaginal", 1277], ["drug", 1285], ["delivery", 1290], ["nanosystem", 1299], ["in", 1310], ["the", 1313], ["context", 1317], ["of", 1325], ["HIV", 1328], ["prophylaxis", 1332], [".", 1343]]}
{"context": "Sotos syndrome is a genetic disorder characterized by a typical facial appearance, macrocephaly, accelerated growth, developmental delay, and a variable range of associated abnormalities. The NSD1 gene was recently found to be responsible for Sotos syndrome, and more than 150 patients with NSD1 alterations have been identified. A significant ethnic difference is found in the prevalence of different types of mutation, with a high percentage of microdeletions identified in Japanese Sotos syndrome patients and with intragenic mutations in most non-Japanese patients. NSD1 aberrations are rather specific for Sotos syndrome, but have also been detected in patients lacking one or more major criteria of the disorder, namely overgrowth, macrocephaly, and advanced bone age. Thus, new diagnostic criteria should be considered. Studies have reported different frequencies of mutations versus non-mutations in Sotos syndrome, thus indicating allelic or locus hetereogeneity. Although some authors have suggested genotype/phenotype correlations, further studies are needed.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "e3fcd872a2a34c279d4633b77cd0d266", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[30, 31]], "char_spans": [[192, 200]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["is", 15], ["a", 18], ["genetic", 20], ["disorder", 28], ["characterized", 37], ["by", 51], ["a", 54], ["typical", 56], ["facial", 64], ["appearance", 71], [",", 81], ["macrocephaly", 83], [",", 95], ["accelerated", 97], ["growth", 109], [",", 115], ["developmental", 117], ["delay", 131], [",", 136], ["and", 138], ["a", 142], ["variable", 144], ["range", 153], ["of", 159], ["associated", 162], ["abnormalities", 173], [".", 186], ["The", 188], ["NSD1", 192], ["gene", 197], ["was", 202], ["recently", 206], ["found", 215], ["to", 221], ["be", 224], ["responsible", 227], ["for", 239], ["Sotos", 243], ["syndrome", 249], [",", 257], ["and", 259], ["more", 263], ["than", 268], ["150", 273], ["patients", 277], ["with", 286], ["NSD1", 291], ["alterations", 296], ["have", 308], ["been", 313], ["identified", 318], [".", 328], ["A", 330], ["significant", 332], ["ethnic", 344], ["difference", 351], ["is", 362], ["found", 365], ["in", 371], ["the", 374], ["prevalence", 378], ["of", 389], ["different", 392], ["types", 402], ["of", 408], ["mutation", 411], [",", 419], ["with", 421], ["a", 426], ["high", 428], ["percentage", 433], ["of", 444], ["microdeletions", 447], ["identified", 462], ["in", 473], ["Japanese", 476], ["Sotos", 485], ["syndrome", 491], ["patients", 500], ["and", 509], ["with", 513], ["intragenic", 518], ["mutations", 529], ["in", 539], ["most", 542], ["non", 547], ["-", 550], ["Japanese", 551], ["patients", 560], [".", 568], ["NSD1", 570], ["aberrations", 575], ["are", 587], ["rather", 591], ["specific", 598], ["for", 607], ["Sotos", 611], ["syndrome", 617], [",", 625], ["but", 627], ["have", 631], ["also", 636], ["been", 641], ["detected", 646], ["in", 655], ["patients", 658], ["lacking", 667], ["one", 675], ["or", 679], ["more", 682], ["major", 687], ["criteria", 693], ["of", 702], ["the", 705], ["disorder", 709], [",", 717], ["namely", 719], ["overgrowth", 726], [",", 736], ["macrocephaly", 738], [",", 750], ["and", 752], ["advanced", 756], ["bone", 765], ["age", 770], [".", 773], ["Thus", 775], [",", 779], ["new", 781], ["diagnostic", 785], ["criteria", 796], ["should", 805], ["be", 812], ["considered", 815], [".", 825], ["Studies", 827], ["have", 835], ["reported", 840], ["different", 849], ["frequencies", 859], ["of", 871], ["mutations", 874], ["versus", 884], ["non", 891], ["-", 894], ["mutations", 895], ["in", 905], ["Sotos", 908], ["syndrome", 914], [",", 922], ["thus", 924], ["indicating", 929], ["allelic", 940], ["or", 948], ["locus", 951], ["hetereogeneity", 957], [".", 971], ["Although", 973], ["some", 982], ["authors", 987], ["have", 995], ["suggested", 1000], ["genotype", 1010], ["/", 1018], ["phenotype", 1019], ["correlations", 1029], [",", 1041], ["further", 1043], ["studies", 1051], ["are", 1059], ["needed", 1063], [".", 1069]]}
{"context": "Inherited ventricular arrhythmias such as the long QT syndrome (LQTS), Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), idiopathic ventricular fibrillation (VF), and arrhythmogenic right ventricular cardiomyopathy (ARVC) account for a relevant proportion of sudden cardiac death cases in young patients cohorts. The detailed pathogenetic mechanisms of inherited ventricular arrhythmias are still poorly understood because systematic investigations are difficult to perform due to low patient numbers and the lack of appropriate experimental models. However, recent advances in research and science have identified a genetic background for many of these diseases. In LQTS, various mutations in different genes encoding for cardiac potassium and sodium channel proteins have been identified (\"channelopathy\"), and initial progress in genotype-phenotype correlation is made. Mutations in the cardiac sodium channel gene have also been identified in a subset of patients with Brugada syndrome, whereas a genetic background has not yet been demonstrated in idiopathic VF and right ventricular outflow-tract tachycardia (RVO-VT). Very recently, mutations in the cardiac ryanodine receptor gene have been identified in CPVT and in a subgroup of patients with ARVC. Although several chromosomal loci were suggested, no other responsible genes or mutations have been found in autosomal dominant forms of ARVC. However, in Naxos disease, a recessive form of ARVC with coexpression of palmoplantar keratoderma and woolly hair, a mutation in the plakoglobin gene has recently been discovered, thus underscoring the potential role of genetic alterations in cytoskeletal proteins in ARVC. In the next years, significant progress in the genetic diagnosis pathophysiologic understanding of disease mechanisms, genotype-phenotype correlation, and the development of gene- or target-directed treatment strategies can be expected in the field of inherited ventricular arrhythmias. This review summarizes the current knowledge of the molecular mechanisms, including aspects of pathoanatomy, autonomic innervation, genetics, and genotype-phenotype correlations with their potential implications for diagnosis and treatment of inherited ventricular arrhythmias.", "qas": [{"question": "Which gene is mutated in a subtype of arrhythmogenic right ventricular cardiomyopathy known as Naxos disease?", "answers": ["The Plakoglobin gene", "plakoglobin[jup]"], "qid": "82cb45ef0dce4731bfd7549461b332ab", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["mutated", 14], ["in", 22], ["a", 25], ["subtype", 27], ["of", 35], ["arrhythmogenic", 38], ["right", 53], ["ventricular", 59], ["cardiomyopathy", 71], ["known", 86], ["as", 92], ["Naxos", 95], ["disease", 101], ["?", 108]], "detected_answers": [{"text": "The Plakoglobin gene", "token_spans": [[257, 258]], "char_spans": [[1565, 1580]]}]}], "context_tokens": [["Inherited", 0], ["ventricular", 10], ["arrhythmias", 22], ["such", 34], ["as", 39], ["the", 42], ["long", 46], ["QT", 51], ["syndrome", 54], ["(", 63], ["LQTS", 64], [")", 68], [",", 69], ["Brugada", 71], ["syndrome", 79], [",", 87], ["catecholaminergic", 89], ["polymorphic", 107], ["ventricular", 119], ["tachycardia", 131], ["(", 143], ["CPVT", 144], [")", 148], [",", 149], ["idiopathic", 151], ["ventricular", 162], ["fibrillation", 174], ["(", 187], ["VF", 188], [")", 190], [",", 191], ["and", 193], ["arrhythmogenic", 197], ["right", 212], ["ventricular", 218], ["cardiomyopathy", 230], ["(", 245], ["ARVC", 246], [")", 250], ["account", 252], ["for", 260], ["a", 264], ["relevant", 266], ["proportion", 275], ["of", 286], ["sudden", 289], ["cardiac", 296], ["death", 304], ["cases", 310], ["in", 316], ["young", 319], ["patients", 325], ["cohorts", 334], [".", 341], ["The", 343], ["detailed", 347], ["pathogenetic", 356], ["mechanisms", 369], ["of", 380], ["inherited", 383], ["ventricular", 393], ["arrhythmias", 405], ["are", 417], ["still", 421], ["poorly", 427], ["understood", 434], ["because", 445], ["systematic", 453], ["investigations", 464], ["are", 479], ["difficult", 483], ["to", 493], ["perform", 496], ["due", 504], ["to", 508], ["low", 511], ["patient", 515], ["numbers", 523], ["and", 531], ["the", 535], ["lack", 539], ["of", 544], ["appropriate", 547], ["experimental", 559], ["models", 572], [".", 578], ["However", 580], [",", 587], ["recent", 589], ["advances", 596], ["in", 605], ["research", 608], ["and", 617], ["science", 621], ["have", 629], ["identified", 634], ["a", 645], ["genetic", 647], ["background", 655], ["for", 666], ["many", 670], ["of", 675], ["these", 678], ["diseases", 684], [".", 692], ["In", 694], ["LQTS", 697], [",", 701], ["various", 703], ["mutations", 711], ["in", 721], ["different", 724], ["genes", 734], ["encoding", 740], ["for", 749], ["cardiac", 753], ["potassium", 761], ["and", 771], ["sodium", 775], ["channel", 782], ["proteins", 790], ["have", 799], ["been", 804], ["identified", 809], ["(", 820], ["\"", 821], ["channelopathy", 822], ["\"", 835], [")", 836], [",", 837], ["and", 839], ["initial", 843], ["progress", 851], ["in", 860], ["genotype", 863], ["-", 871], ["phenotype", 872], ["correlation", 882], ["is", 894], ["made", 897], [".", 901], ["Mutations", 903], ["in", 913], ["the", 916], ["cardiac", 920], ["sodium", 928], ["channel", 935], ["gene", 943], ["have", 948], ["also", 953], ["been", 958], ["identified", 963], ["in", 974], ["a", 977], ["subset", 979], ["of", 986], ["patients", 989], ["with", 998], ["Brugada", 1003], ["syndrome", 1011], [",", 1019], ["whereas", 1021], ["a", 1029], ["genetic", 1031], ["background", 1039], ["has", 1050], ["not", 1054], ["yet", 1058], ["been", 1062], ["demonstrated", 1067], ["in", 1080], ["idiopathic", 1083], ["VF", 1094], ["and", 1097], ["right", 1101], ["ventricular", 1107], ["outflow", 1119], ["-", 1126], ["tract", 1127], ["tachycardia", 1133], ["(", 1145], ["RVO", 1146], ["-", 1149], ["VT", 1150], [")", 1152], [".", 1153], ["Very", 1155], ["recently", 1160], [",", 1168], ["mutations", 1170], ["in", 1180], ["the", 1183], ["cardiac", 1187], ["ryanodine", 1195], ["receptor", 1205], ["gene", 1214], ["have", 1219], ["been", 1224], ["identified", 1229], ["in", 1240], ["CPVT", 1243], ["and", 1248], ["in", 1252], ["a", 1255], ["subgroup", 1257], ["of", 1266], ["patients", 1269], ["with", 1278], ["ARVC", 1283], [".", 1287], ["Although", 1289], ["several", 1298], ["chromosomal", 1306], ["loci", 1318], ["were", 1323], ["suggested", 1328], [",", 1337], ["no", 1339], ["other", 1342], ["responsible", 1348], ["genes", 1360], ["or", 1366], ["mutations", 1369], ["have", 1379], ["been", 1384], ["found", 1389], ["in", 1395], ["autosomal", 1398], ["dominant", 1408], ["forms", 1417], ["of", 1423], ["ARVC", 1426], [".", 1430], ["However", 1432], [",", 1439], ["in", 1441], ["Naxos", 1444], ["disease", 1450], [",", 1457], ["a", 1459], ["recessive", 1461], ["form", 1471], ["of", 1476], ["ARVC", 1479], ["with", 1484], ["coexpression", 1489], ["of", 1502], ["palmoplantar", 1505], ["keratoderma", 1518], ["and", 1530], ["woolly", 1534], ["hair", 1541], [",", 1545], ["a", 1547], ["mutation", 1549], ["in", 1558], ["the", 1561], ["plakoglobin", 1565], ["gene", 1577], ["has", 1582], ["recently", 1586], ["been", 1595], ["discovered", 1600], [",", 1610], ["thus", 1612], ["underscoring", 1617], ["the", 1630], ["potential", 1634], ["role", 1644], ["of", 1649], ["genetic", 1652], ["alterations", 1660], ["in", 1672], ["cytoskeletal", 1675], ["proteins", 1688], ["in", 1697], ["ARVC", 1700], [".", 1704], ["In", 1706], ["the", 1709], ["next", 1713], ["years", 1718], [",", 1723], ["significant", 1725], ["progress", 1737], ["in", 1746], ["the", 1749], ["genetic", 1753], ["diagnosis", 1761], ["pathophysiologic", 1771], ["understanding", 1788], ["of", 1802], ["disease", 1805], ["mechanisms", 1813], [",", 1823], ["genotype", 1825], ["-", 1833], ["phenotype", 1834], ["correlation", 1844], [",", 1855], ["and", 1857], ["the", 1861], ["development", 1865], ["of", 1877], ["gene-", 1880], ["or", 1886], ["target", 1889], ["-", 1895], ["directed", 1896], ["treatment", 1905], ["strategies", 1915], ["can", 1926], ["be", 1930], ["expected", 1933], ["in", 1942], ["the", 1945], ["field", 1949], ["of", 1955], ["inherited", 1958], ["ventricular", 1968], ["arrhythmias", 1980], [".", 1991], ["This", 1993], ["review", 1998], ["summarizes", 2005], ["the", 2016], ["current", 2020], ["knowledge", 2028], ["of", 2038], ["the", 2041], ["molecular", 2045], ["mechanisms", 2055], [",", 2065], ["including", 2067], ["aspects", 2077], ["of", 2085], ["pathoanatomy", 2088], [",", 2100], ["autonomic", 2102], ["innervation", 2112], [",", 2123], ["genetics", 2125], [",", 2133], ["and", 2135], ["genotype", 2139], ["-", 2147], ["phenotype", 2148], ["correlations", 2158], ["with", 2171], ["their", 2176], ["potential", 2182], ["implications", 2192], ["for", 2205], ["diagnosis", 2209], ["and", 2219], ["treatment", 2223], ["of", 2233], ["inherited", 2236], ["ventricular", 2246], ["arrhythmias", 2258], [".", 2269]]}
{"context": "Focusing on three Anglo-American outbreaks of industrial anthrax, this essay engages the question of how local circumstances influenced the transmission of scientific knowledge in the late nineteenth century. Walpole (Massachusetts), Glasgow, and Bradford (Yorkshire) served as important nodes of transnational investigation into anthrax. Knowledge about the morphology and behavior of Bacillus anthracis changed little while in transit between these nodes, even during complex debates about the nature of bacterial morphology, disease causation, and spontaneous generation. Working independently of their more famous counterparts (Robert Koch and Louis Pasteur), Anglo-American anthrax investigators used visual representations of anthrax bacilli to persuade their peers that a specific, identifiable cause produced all forms of anthrax-malignant pustule (cutaneous anthrax), intestinal anthrax, and woolsorter's disease (pneumonic anthrax). By the late 1870s, this point of view also supported what we would today call an ecological notion of the disease's origins in the interactions of people, animals, and microorganisms in the context of global commerce.", "qas": [{"question": "What organism causes woolsorter's disease", "answers": ["Bacillus Anthracis"], "qid": "7cb5e988b4514ab3944739cfd8b67239", "question_tokens": [["What", 0], ["organism", 5], ["causes", 14], ["woolsorter", 21], ["'s", 31], ["disease", 34]], "detected_answers": [{"text": "Bacillus Anthracis", "token_spans": [[61, 62]], "char_spans": [[386, 403]]}]}], "context_tokens": [["Focusing", 0], ["on", 9], ["three", 12], ["Anglo", 18], ["-", 23], ["American", 24], ["outbreaks", 33], ["of", 43], ["industrial", 46], ["anthrax", 57], [",", 64], ["this", 66], ["essay", 71], ["engages", 77], ["the", 85], ["question", 89], ["of", 98], ["how", 101], ["local", 105], ["circumstances", 111], ["influenced", 125], ["the", 136], ["transmission", 140], ["of", 153], ["scientific", 156], ["knowledge", 167], ["in", 177], ["the", 180], ["late", 184], ["nineteenth", 189], ["century", 200], [".", 207], ["Walpole", 209], ["(", 217], ["Massachusetts", 218], [")", 231], [",", 232], ["Glasgow", 234], [",", 241], ["and", 243], ["Bradford", 247], ["(", 256], ["Yorkshire", 257], [")", 266], ["served", 268], ["as", 275], ["important", 278], ["nodes", 288], ["of", 294], ["transnational", 297], ["investigation", 311], ["into", 325], ["anthrax", 330], [".", 337], ["Knowledge", 339], ["about", 349], ["the", 355], ["morphology", 359], ["and", 370], ["behavior", 374], ["of", 383], ["Bacillus", 386], ["anthracis", 395], ["changed", 405], ["little", 413], ["while", 420], ["in", 426], ["transit", 429], ["between", 437], ["these", 445], ["nodes", 451], [",", 456], ["even", 458], ["during", 463], ["complex", 470], ["debates", 478], ["about", 486], ["the", 492], ["nature", 496], ["of", 503], ["bacterial", 506], ["morphology", 516], [",", 526], ["disease", 528], ["causation", 536], [",", 545], ["and", 547], ["spontaneous", 551], ["generation", 563], [".", 573], ["Working", 575], ["independently", 583], ["of", 597], ["their", 600], ["more", 606], ["famous", 611], ["counterparts", 618], ["(", 631], ["Robert", 632], ["Koch", 639], ["and", 644], ["Louis", 648], ["Pasteur", 654], [")", 661], [",", 662], ["Anglo", 664], ["-", 669], ["American", 670], ["anthrax", 679], ["investigators", 687], ["used", 701], ["visual", 706], ["representations", 713], ["of", 729], ["anthrax", 732], ["bacilli", 740], ["to", 748], ["persuade", 751], ["their", 760], ["peers", 766], ["that", 772], ["a", 777], ["specific", 779], [",", 787], ["identifiable", 789], ["cause", 802], ["produced", 808], ["all", 817], ["forms", 821], ["of", 827], ["anthrax", 830], ["-", 837], ["malignant", 838], ["pustule", 848], ["(", 856], ["cutaneous", 857], ["anthrax", 867], [")", 874], [",", 875], ["intestinal", 877], ["anthrax", 888], [",", 895], ["and", 897], ["woolsorter", 901], ["'s", 911], ["disease", 914], ["(", 922], ["pneumonic", 923], ["anthrax", 933], [")", 940], [".", 941], ["By", 943], ["the", 946], ["late", 950], ["1870s", 955], [",", 960], ["this", 962], ["point", 967], ["of", 973], ["view", 976], ["also", 981], ["supported", 986], ["what", 996], ["we", 1001], ["would", 1004], ["today", 1010], ["call", 1016], ["an", 1021], ["ecological", 1024], ["notion", 1035], ["of", 1042], ["the", 1045], ["disease", 1049], ["'s", 1056], ["origins", 1059], ["in", 1067], ["the", 1070], ["interactions", 1074], ["of", 1087], ["people", 1090], [",", 1096], ["animals", 1098], [",", 1105], ["and", 1107], ["microorganisms", 1111], ["in", 1126], ["the", 1129], ["context", 1133], ["of", 1141], ["global", 1144], ["commerce", 1151], [".", 1159]]}
{"context": "The SWR1 complex replaces the canonical histone H2A with the variant H2A.Z (Htz1 in yeast) at specific chromatin regions. This dynamic alteration in nucleosome structure provides a molecular mechanism to regulate transcription, gene silencing, chromosome segregation and DNA repair. Here we show that genetic instability, sensitivity to drugs impairing different cellular processes and genome-wide transcriptional misregulation in htz1Delta can be partially or totally suppressed if SWR1 is not formed (swr1Delta), if it forms but cannot bind to chromatin (swc2Delta) or if it binds to chromatin but lacks histone replacement activity (swc5Delta and the ATPase-dead swr1-K727G). These results suggest that in htz1Delta the nucleosome remodelling activity of SWR1 affects chromatin integrity because of an attempt to replace H2A with Htz1 in the absence of the latter. This would impair transcription and, either directly or indirectly, other cellular processes. Specifically, we show that in htz1Delta, the SWR1 complex causes an accumulation of recombinogenic DNA damage by a mechanism dependent on phosphorylation of H2A at Ser129, a modification that occurs in response to DNA damage, suggesting that the SWR1 complex impairs the repair of spontaneous DNA damage in htz1Delta. In addition, SWR1 causes DSBs sensitivity in htz1Delta; consistently, in the absence of Htz1 the SWR1 complex bound near an endonuclease HO-induced DSB at the mating-type (MAT) locus impairs DSB-induced checkpoint activation. Our results support a stepwise mechanism for the replacement of H2A with Htz1 and demonstrate that a tight control of this mechanism is essential to regulate chromatin dynamics but also to prevent the deleterious consequences of an incomplete nucleosome remodelling.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "d2627627aba84f99995af53314a00a58", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[171, 171], [219, 219], [74, 74], [234, 234], [204, 204], [1, 1], [127, 127]], "char_spans": [[1007, 1010], [1293, 1296], [483, 486], [1377, 1380], [1208, 1211], [4, 7], [758, 761]]}]}], "context_tokens": [["The", 0], ["SWR1", 4], ["complex", 9], ["replaces", 17], ["the", 26], ["canonical", 30], ["histone", 40], ["H2A", 48], ["with", 52], ["the", 57], ["variant", 61], ["H2A.Z", 69], ["(", 75], ["Htz1", 76], ["in", 81], ["yeast", 84], [")", 89], ["at", 91], ["specific", 94], ["chromatin", 103], ["regions", 113], [".", 120], ["This", 122], ["dynamic", 127], ["alteration", 135], ["in", 146], ["nucleosome", 149], ["structure", 160], ["provides", 170], ["a", 179], ["molecular", 181], ["mechanism", 191], ["to", 201], ["regulate", 204], ["transcription", 213], [",", 226], ["gene", 228], ["silencing", 233], [",", 242], ["chromosome", 244], ["segregation", 255], ["and", 267], ["DNA", 271], ["repair", 275], [".", 281], ["Here", 283], ["we", 288], ["show", 291], ["that", 296], ["genetic", 301], ["instability", 309], [",", 320], ["sensitivity", 322], ["to", 334], ["drugs", 337], ["impairing", 343], ["different", 353], ["cellular", 363], ["processes", 372], ["and", 382], ["genome", 386], ["-", 392], ["wide", 393], ["transcriptional", 398], ["misregulation", 414], ["in", 428], ["htz1Delta", 431], ["can", 441], ["be", 445], ["partially", 448], ["or", 458], ["totally", 461], ["suppressed", 469], ["if", 480], ["SWR1", 483], ["is", 488], ["not", 491], ["formed", 495], ["(", 502], ["swr1Delta", 503], [")", 512], [",", 513], ["if", 515], ["it", 518], ["forms", 521], ["but", 527], ["can", 531], ["not", 534], ["bind", 538], ["to", 543], ["chromatin", 546], ["(", 556], ["swc2Delta", 557], [")", 566], ["or", 568], ["if", 571], ["it", 574], ["binds", 577], ["to", 583], ["chromatin", 586], ["but", 596], ["lacks", 600], ["histone", 606], ["replacement", 614], ["activity", 626], ["(", 635], ["swc5Delta", 636], ["and", 646], ["the", 650], ["ATPase", 654], ["-", 660], ["dead", 661], ["swr1-K727", 666], ["G", 675], [")", 676], [".", 677], ["These", 679], ["results", 685], ["suggest", 693], ["that", 701], ["in", 706], ["htz1Delta", 709], ["the", 719], ["nucleosome", 723], ["remodelling", 734], ["activity", 746], ["of", 755], ["SWR1", 758], ["affects", 763], ["chromatin", 771], ["integrity", 781], ["because", 791], ["of", 799], ["an", 802], ["attempt", 805], ["to", 813], ["replace", 816], ["H2A", 824], ["with", 828], ["Htz1", 833], ["in", 838], ["the", 841], ["absence", 845], ["of", 853], ["the", 856], ["latter", 860], [".", 866], ["This", 868], ["would", 873], ["impair", 879], ["transcription", 886], ["and", 900], [",", 903], ["either", 905], ["directly", 912], ["or", 921], ["indirectly", 924], [",", 934], ["other", 936], ["cellular", 942], ["processes", 951], [".", 960], ["Specifically", 962], [",", 974], ["we", 976], ["show", 979], ["that", 984], ["in", 989], ["htz1Delta", 992], [",", 1001], ["the", 1003], ["SWR1", 1007], ["complex", 1012], ["causes", 1020], ["an", 1027], ["accumulation", 1030], ["of", 1043], ["recombinogenic", 1046], ["DNA", 1061], ["damage", 1065], ["by", 1072], ["a", 1075], ["mechanism", 1077], ["dependent", 1087], ["on", 1097], ["phosphorylation", 1100], ["of", 1116], ["H2A", 1119], ["at", 1123], ["Ser129", 1126], [",", 1132], ["a", 1134], ["modification", 1136], ["that", 1149], ["occurs", 1154], ["in", 1161], ["response", 1164], ["to", 1173], ["DNA", 1176], ["damage", 1180], [",", 1186], ["suggesting", 1188], ["that", 1199], ["the", 1204], ["SWR1", 1208], ["complex", 1213], ["impairs", 1221], ["the", 1229], ["repair", 1233], ["of", 1240], ["spontaneous", 1243], ["DNA", 1255], ["damage", 1259], ["in", 1266], ["htz1Delta", 1269], [".", 1278], ["In", 1280], ["addition", 1283], [",", 1291], ["SWR1", 1293], ["causes", 1298], ["DSBs", 1305], ["sensitivity", 1310], ["in", 1322], ["htz1Delta", 1325], [";", 1334], ["consistently", 1336], [",", 1348], ["in", 1350], ["the", 1353], ["absence", 1357], ["of", 1365], ["Htz1", 1368], ["the", 1373], ["SWR1", 1377], ["complex", 1382], ["bound", 1390], ["near", 1396], ["an", 1401], ["endonuclease", 1404], ["HO", 1417], ["-", 1419], ["induced", 1420], ["DSB", 1428], ["at", 1432], ["the", 1435], ["mating", 1439], ["-", 1445], ["type", 1446], ["(", 1451], ["MAT", 1452], [")", 1455], ["locus", 1457], ["impairs", 1463], ["DSB", 1471], ["-", 1474], ["induced", 1475], ["checkpoint", 1483], ["activation", 1494], [".", 1504], ["Our", 1506], ["results", 1510], ["support", 1518], ["a", 1526], ["stepwise", 1528], ["mechanism", 1537], ["for", 1547], ["the", 1551], ["replacement", 1555], ["of", 1567], ["H2A", 1570], ["with", 1574], ["Htz1", 1579], ["and", 1584], ["demonstrate", 1588], ["that", 1600], ["a", 1605], ["tight", 1607], ["control", 1613], ["of", 1621], ["this", 1624], ["mechanism", 1629], ["is", 1639], ["essential", 1642], ["to", 1652], ["regulate", 1655], ["chromatin", 1664], ["dynamics", 1674], ["but", 1683], ["also", 1687], ["to", 1692], ["prevent", 1695], ["the", 1703], ["deleterious", 1707], ["consequences", 1719], ["of", 1732], ["an", 1735], ["incomplete", 1738], ["nucleosome", 1749], ["remodelling", 1760], [".", 1771]]}
{"context": "The genetic disorders xeroderma pigmentosum (XP) and Cockayne syndrome (CS) exhibit deficiencies in the repair of UV-induced DNA damage. CS fibroblasts retain proficient nucleotide excision repair (NER) of inactive (or bulk) DNA, but are deficient in the transcription-coupled repair (TCR) of active genes. In contrast, XP complementation group C (XP-C) fibroblasts retain proficient TCR, but are deficient in bulk DNA repair. The remaining NER-deficient XP groups exhibit deficiencies in both repair pathways. Ad5HCMVsp1lacZ is a recombinant adenovirus vector that is unable to replicate in human fibroblasts, but can efficiently infect and express the beta-galactosidase reporter gene in these cells. We have examined the host cell reactivation (HCR) of beta-galactosidase activity for UV-irradiated Ad5HCMVsp1lacZ in non-irradiated and UV-irradiated normal, XP-B, XP-C, XP-D, XP-F, XP-G, CS-A and CS-B fibroblasts. HCR of beta-galactosidase activity for UV-irradiated Ad5HCMVsp1lacZ was reduced in non-irradiated cells from each of the repair-deficient groups examined (including XP-C) relative to that in non-irradiated normal cells. Prior irradiation of cells with low UV fluences resulted in an enhancement of HCR for normal and XP-C strains, but not for the remaining XP and CS strains. HCR of the UV-damaged reporter gene in UV-irradiated XP and CS strains was similar to measurements of TCR reported previously for these cells. These results suggest that UV treatment results in an induced repair of UV-damaged DNA in the transcribed strand of an active gene in XP-C and normal cells through an enhancement of TCR or a mechanism which involves the TCR pathway.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "9ee2e86c5d1a4a1a9251990f2f2d84c6", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[310, 311]], "char_spans": [[1531, 1548]]}]}], "context_tokens": [["The", 0], ["genetic", 4], ["disorders", 12], ["xeroderma", 22], ["pigmentosum", 32], ["(", 44], ["XP", 45], [")", 47], ["and", 49], ["Cockayne", 53], ["syndrome", 62], ["(", 71], ["CS", 72], [")", 74], ["exhibit", 76], ["deficiencies", 84], ["in", 97], ["the", 100], ["repair", 104], ["of", 111], ["UV", 114], ["-", 116], ["induced", 117], ["DNA", 125], ["damage", 129], [".", 135], ["CS", 137], ["fibroblasts", 140], ["retain", 152], ["proficient", 159], ["nucleotide", 170], ["excision", 181], ["repair", 190], ["(", 197], ["NER", 198], [")", 201], ["of", 203], ["inactive", 206], ["(", 215], ["or", 216], ["bulk", 219], [")", 223], ["DNA", 225], [",", 228], ["but", 230], ["are", 234], ["deficient", 238], ["in", 248], ["the", 251], ["transcription", 255], ["-", 268], ["coupled", 269], ["repair", 277], ["(", 284], ["TCR", 285], [")", 288], ["of", 290], ["active", 293], ["genes", 300], [".", 305], ["In", 307], ["contrast", 310], [",", 318], ["XP", 320], ["complementation", 323], ["group", 339], ["C", 345], ["(", 347], ["XP", 348], ["-", 350], ["C", 351], [")", 352], ["fibroblasts", 354], ["retain", 366], ["proficient", 373], ["TCR", 384], [",", 387], ["but", 389], ["are", 393], ["deficient", 397], ["in", 407], ["bulk", 410], ["DNA", 415], ["repair", 419], [".", 425], ["The", 427], ["remaining", 431], ["NER", 441], ["-", 444], ["deficient", 445], ["XP", 455], ["groups", 458], ["exhibit", 465], ["deficiencies", 473], ["in", 486], ["both", 489], ["repair", 494], ["pathways", 501], [".", 509], ["Ad5HCMVsp1lacZ", 511], ["is", 526], ["a", 529], ["recombinant", 531], ["adenovirus", 543], ["vector", 554], ["that", 561], ["is", 566], ["unable", 569], ["to", 576], ["replicate", 579], ["in", 589], ["human", 592], ["fibroblasts", 598], [",", 609], ["but", 611], ["can", 615], ["efficiently", 619], ["infect", 631], ["and", 638], ["express", 642], ["the", 650], ["beta", 654], ["-", 658], ["galactosidase", 659], ["reporter", 673], ["gene", 682], ["in", 687], ["these", 690], ["cells", 696], [".", 701], ["We", 703], ["have", 706], ["examined", 711], ["the", 720], ["host", 724], ["cell", 729], ["reactivation", 734], ["(", 747], ["HCR", 748], [")", 751], ["of", 753], ["beta", 756], ["-", 760], ["galactosidase", 761], ["activity", 775], ["for", 784], ["UV", 788], ["-", 790], ["irradiated", 791], ["Ad5HCMVsp1lacZ", 802], ["in", 817], ["non", 820], ["-", 823], ["irradiated", 824], ["and", 835], ["UV", 839], ["-", 841], ["irradiated", 842], ["normal", 853], [",", 859], ["XP", 861], ["-", 863], ["B", 864], [",", 865], ["XP", 867], ["-", 869], ["C", 870], [",", 871], ["XP", 873], ["-", 875], ["D", 876], [",", 877], ["XP", 879], ["-", 881], ["F", 882], [",", 883], ["XP", 885], ["-", 887], ["G", 888], [",", 889], ["CS", 891], ["-", 893], ["A", 894], ["and", 896], ["CS", 900], ["-", 902], ["B", 903], ["fibroblasts", 905], [".", 916], ["HCR", 918], ["of", 922], ["beta", 925], ["-", 929], ["galactosidase", 930], ["activity", 944], ["for", 953], ["UV", 957], ["-", 959], ["irradiated", 960], ["Ad5HCMVsp1lacZ", 971], ["was", 986], ["reduced", 990], ["in", 998], ["non", 1001], ["-", 1004], ["irradiated", 1005], ["cells", 1016], ["from", 1022], ["each", 1027], ["of", 1032], ["the", 1035], ["repair", 1039], ["-", 1045], ["deficient", 1046], ["groups", 1056], ["examined", 1063], ["(", 1072], ["including", 1073], ["XP", 1083], ["-", 1085], ["C", 1086], [")", 1087], ["relative", 1089], ["to", 1098], ["that", 1101], ["in", 1106], ["non", 1109], ["-", 1112], ["irradiated", 1113], ["normal", 1124], ["cells", 1131], [".", 1136], ["Prior", 1138], ["irradiation", 1144], ["of", 1156], ["cells", 1159], ["with", 1165], ["low", 1170], ["UV", 1174], ["fluences", 1177], ["resulted", 1186], ["in", 1195], ["an", 1198], ["enhancement", 1201], ["of", 1213], ["HCR", 1216], ["for", 1220], ["normal", 1224], ["and", 1231], ["XP", 1235], ["-", 1237], ["C", 1238], ["strains", 1240], [",", 1247], ["but", 1249], ["not", 1253], ["for", 1257], ["the", 1261], ["remaining", 1265], ["XP", 1275], ["and", 1278], ["CS", 1282], ["strains", 1285], [".", 1292], ["HCR", 1294], ["of", 1298], ["the", 1301], ["UV", 1305], ["-", 1307], ["damaged", 1308], ["reporter", 1316], ["gene", 1325], ["in", 1330], ["UV", 1333], ["-", 1335], ["irradiated", 1336], ["XP", 1347], ["and", 1350], ["CS", 1354], ["strains", 1357], ["was", 1365], ["similar", 1369], ["to", 1377], ["measurements", 1380], ["of", 1393], ["TCR", 1396], ["reported", 1400], ["previously", 1409], ["for", 1420], ["these", 1424], ["cells", 1430], [".", 1435], ["These", 1437], ["results", 1443], ["suggest", 1451], ["that", 1459], ["UV", 1464], ["treatment", 1467], ["results", 1477], ["in", 1485], ["an", 1488], ["induced", 1491], ["repair", 1499], ["of", 1506], ["UV", 1509], ["-", 1511], ["damaged", 1512], ["DNA", 1520], ["in", 1524], ["the", 1527], ["transcribed", 1531], ["strand", 1543], ["of", 1550], ["an", 1553], ["active", 1556], ["gene", 1563], ["in", 1568], ["XP", 1571], ["-", 1573], ["C", 1574], ["and", 1576], ["normal", 1580], ["cells", 1587], ["through", 1593], ["an", 1601], ["enhancement", 1604], ["of", 1616], ["TCR", 1619], ["or", 1623], ["a", 1626], ["mechanism", 1628], ["which", 1638], ["involves", 1644], ["the", 1653], ["TCR", 1657], ["pathway", 1661], [".", 1668]]}
{"context": "The Ehlers-Danlos syndromes (EDS) are a group of connective tissue disorders characterized by triad of joint hypermobility, skin extensibility, and tissue fragility. Ehlers-Danlos syndrome type IV places patients at risk for life-threatening, spontaneous, vascular or visceral rupture due to reduced or abnormal secretion of type III collagen. We present an adolescent male who was found to have a perisigmoid abscess with a fistula connecting to adjacent sigmoid colon secondary to undiagnosed EDS type IV. Conservative management with antibiotics and bowel rest was pursued to allow for elective resection for his acute complicated diverticulitis at a safer time.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "4e62eca3bf0e4c1ebc9b576649a1ebc5", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[12, 13]], "char_spans": [[49, 65]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndromes", 18], ["(", 28], ["EDS", 29], [")", 32], ["are", 34], ["a", 38], ["group", 40], ["of", 46], ["connective", 49], ["tissue", 60], ["disorders", 67], ["characterized", 77], ["by", 91], ["triad", 94], ["of", 100], ["joint", 103], ["hypermobility", 109], [",", 122], ["skin", 124], ["extensibility", 129], [",", 142], ["and", 144], ["tissue", 148], ["fragility", 155], [".", 164], ["Ehlers", 166], ["-", 172], ["Danlos", 173], ["syndrome", 180], ["type", 189], ["IV", 194], ["places", 197], ["patients", 204], ["at", 213], ["risk", 216], ["for", 221], ["life", 225], ["-", 229], ["threatening", 230], [",", 241], ["spontaneous", 243], [",", 254], ["vascular", 256], ["or", 265], ["visceral", 268], ["rupture", 277], ["due", 285], ["to", 289], ["reduced", 292], ["or", 300], ["abnormal", 303], ["secretion", 312], ["of", 322], ["type", 325], ["III", 330], ["collagen", 334], [".", 342], ["We", 344], ["present", 347], ["an", 355], ["adolescent", 358], ["male", 369], ["who", 374], ["was", 378], ["found", 382], ["to", 388], ["have", 391], ["a", 396], ["perisigmoid", 398], ["abscess", 410], ["with", 418], ["a", 423], ["fistula", 425], ["connecting", 433], ["to", 444], ["adjacent", 447], ["sigmoid", 456], ["colon", 464], ["secondary", 470], ["to", 480], ["undiagnosed", 483], ["EDS", 495], ["type", 499], ["IV", 504], [".", 506], ["Conservative", 508], ["management", 521], ["with", 532], ["antibiotics", 537], ["and", 549], ["bowel", 553], ["rest", 559], ["was", 564], ["pursued", 568], ["to", 576], ["allow", 579], ["for", 585], ["elective", 589], ["resection", 598], ["for", 608], ["his", 612], ["acute", 616], ["complicated", 622], ["diverticulitis", 634], ["at", 649], ["a", 652], ["safer", 654], ["time", 660], [".", 664]]}
{"context": "Dasatinib is an oral small molecule inhibitor of Abl and Src family tyrosine kinases (SFK), including p56(Lck) (Lck). Given the central importance of Lck in transmitting signals from the T-cell receptor (TCR) signaling complex and the potent ability of dasatinib to inhibit Lck activity, we hypothesized this agent could provide a novel route of immunomodulation via targeted inhibition of antigen-induced signaling. Herein, we show that dasatinib inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-cell responses. However, dasatinib-mediated inhibition does not induce apoptosis because the effect is reversible or may be overcome by signals bypassing the TCR, such as phorbol ester. Signal transduction and proliferative responses via IL-2 remain essentially unperturbed, suggesting that dasatinib displays specificity for TCR signaling. In addition, dasatinib combined with cyclosporine A or rapamycin led to a much more potent inhibition of T-cell activation, suggesting that targeted inhibition of Lck could be a useful adjunct for enhanced immunomodulation. In combination with currently available immunomodulatory agents, SFK inhibition could potentially increase immunomodulatory efficacy while minimizing toxicity of individual agents.", "qas": [{"question": "Does dasatinib promote or inhibit T-cell proliferation?", "answers": ["inhibits"], "qid": "61ec5684d44c4296809c466509051021", "question_tokens": [["Does", 0], ["dasatinib", 5], ["promote", 15], ["or", 23], ["inhibit", 26], ["T", 34], ["-", 35], ["cell", 36], ["proliferation", 41], ["?", 54]], "detected_answers": [{"text": "inhibits", "token_spans": [[82, 82]], "char_spans": [[448, 455]]}]}], "context_tokens": [["Dasatinib", 0], ["is", 10], ["an", 13], ["oral", 16], ["small", 21], ["molecule", 27], ["inhibitor", 36], ["of", 46], ["Abl", 49], ["and", 53], ["Src", 57], ["family", 61], ["tyrosine", 68], ["kinases", 77], ["(", 85], ["SFK", 86], [")", 89], [",", 90], ["including", 92], ["p56(Lck", 102], [")", 109], ["(", 111], ["Lck", 112], [")", 115], [".", 116], ["Given", 118], ["the", 124], ["central", 128], ["importance", 136], ["of", 147], ["Lck", 150], ["in", 154], ["transmitting", 157], ["signals", 170], ["from", 178], ["the", 183], ["T", 187], ["-", 188], ["cell", 189], ["receptor", 194], ["(", 203], ["TCR", 204], [")", 207], ["signaling", 209], ["complex", 219], ["and", 227], ["the", 231], ["potent", 235], ["ability", 242], ["of", 250], ["dasatinib", 253], ["to", 263], ["inhibit", 266], ["Lck", 274], ["activity", 278], [",", 286], ["we", 288], ["hypothesized", 291], ["this", 304], ["agent", 309], ["could", 315], ["provide", 321], ["a", 329], ["novel", 331], ["route", 337], ["of", 343], ["immunomodulation", 346], ["via", 363], ["targeted", 367], ["inhibition", 376], ["of", 387], ["antigen", 390], ["-", 397], ["induced", 398], ["signaling", 406], [".", 415], ["Herein", 417], [",", 423], ["we", 425], ["show", 428], ["that", 433], ["dasatinib", 438], ["inhibits", 448], ["TCR", 457], ["-", 460], ["mediated", 461], ["signal", 470], ["transduction", 477], [",", 489], ["cellular", 491], ["proliferation", 500], [",", 513], ["cytokine", 515], ["production", 524], [",", 534], ["and", 536], ["in", 540], ["vivo", 543], ["T", 548], ["-", 549], ["cell", 550], ["responses", 555], [".", 564], ["However", 566], [",", 573], ["dasatinib", 575], ["-", 584], ["mediated", 585], ["inhibition", 594], ["does", 605], ["not", 610], ["induce", 614], ["apoptosis", 621], ["because", 631], ["the", 639], ["effect", 643], ["is", 650], ["reversible", 653], ["or", 664], ["may", 667], ["be", 671], ["overcome", 674], ["by", 683], ["signals", 686], ["bypassing", 694], ["the", 704], ["TCR", 708], [",", 711], ["such", 713], ["as", 718], ["phorbol", 721], ["ester", 729], [".", 734], ["Signal", 736], ["transduction", 743], ["and", 756], ["proliferative", 760], ["responses", 774], ["via", 784], ["IL-2", 788], ["remain", 793], ["essentially", 800], ["unperturbed", 812], [",", 823], ["suggesting", 825], ["that", 836], ["dasatinib", 841], ["displays", 851], ["specificity", 860], ["for", 872], ["TCR", 876], ["signaling", 880], [".", 889], ["In", 891], ["addition", 894], [",", 902], ["dasatinib", 904], ["combined", 914], ["with", 923], ["cyclosporine", 928], ["A", 941], ["or", 943], ["rapamycin", 946], ["led", 956], ["to", 960], ["a", 963], ["much", 965], ["more", 970], ["potent", 975], ["inhibition", 982], ["of", 993], ["T", 996], ["-", 997], ["cell", 998], ["activation", 1003], [",", 1013], ["suggesting", 1015], ["that", 1026], ["targeted", 1031], ["inhibition", 1040], ["of", 1051], ["Lck", 1054], ["could", 1058], ["be", 1064], ["a", 1067], ["useful", 1069], ["adjunct", 1076], ["for", 1084], ["enhanced", 1088], ["immunomodulation", 1097], [".", 1113], ["In", 1115], ["combination", 1118], ["with", 1130], ["currently", 1135], ["available", 1145], ["immunomodulatory", 1155], ["agents", 1172], [",", 1178], ["SFK", 1180], ["inhibition", 1184], ["could", 1195], ["potentially", 1201], ["increase", 1213], ["immunomodulatory", 1222], ["efficacy", 1239], ["while", 1248], ["minimizing", 1254], ["toxicity", 1265], ["of", 1274], ["individual", 1277], ["agents", 1288], [".", 1294]]}
{"context": "Atrial fibrillation (AF), a common cardiac arrhythmia associated with increased risk of heart failure, thromboembolic phenomena and death, is a leading cause of hospitalization of adults. A major complication of AF is an increased risk of ischemic stroke leading to long-term disability and in severe cases, death. Historically, Coumadin has been the drug of choice for chronic anticoagulation and stroke prevention in AF patients however, given the need for constant monitoring and multiple drug interactions, newer anticoagulants have been developed. One such drug is dabigatran, with the promise of less frequent monitoring and decreased bleeding tendencies as compared to Coumadin. The main disadvantage of dabigatran has been the lack of a reversal agent in case of severe bleeding or emergent surgical intervention. This was until the recent The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran. In this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "d6e9cee2def349948db2eae4577d1aaa", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[158, 158], [120, 120], [180, 180], [98, 98]], "char_spans": [[938, 947], [711, 720], [1077, 1086], [570, 579]]}]}], "context_tokens": [["Atrial", 0], ["fibrillation", 7], ["(", 20], ["AF", 21], [")", 23], [",", 24], ["a", 26], ["common", 28], ["cardiac", 35], ["arrhythmia", 43], ["associated", 54], ["with", 65], ["increased", 70], ["risk", 80], ["of", 85], ["heart", 88], ["failure", 94], [",", 101], ["thromboembolic", 103], ["phenomena", 118], ["and", 128], ["death", 132], [",", 137], ["is", 139], ["a", 142], ["leading", 144], ["cause", 152], ["of", 158], ["hospitalization", 161], ["of", 177], ["adults", 180], [".", 186], ["A", 188], ["major", 190], ["complication", 196], ["of", 209], ["AF", 212], ["is", 215], ["an", 218], ["increased", 221], ["risk", 231], ["of", 236], ["ischemic", 239], ["stroke", 248], ["leading", 255], ["to", 263], ["long", 266], ["-", 270], ["term", 271], ["disability", 276], ["and", 287], ["in", 291], ["severe", 294], ["cases", 301], [",", 306], ["death", 308], [".", 313], ["Historically", 315], [",", 327], ["Coumadin", 329], ["has", 338], ["been", 342], ["the", 347], ["drug", 351], ["of", 356], ["choice", 359], ["for", 366], ["chronic", 370], ["anticoagulation", 378], ["and", 394], ["stroke", 398], ["prevention", 405], ["in", 416], ["AF", 419], ["patients", 422], ["however", 431], [",", 438], ["given", 440], ["the", 446], ["need", 450], ["for", 455], ["constant", 459], ["monitoring", 468], ["and", 479], ["multiple", 483], ["drug", 492], ["interactions", 497], [",", 509], ["newer", 511], ["anticoagulants", 517], ["have", 532], ["been", 537], ["developed", 542], [".", 551], ["One", 553], ["such", 557], ["drug", 562], ["is", 567], ["dabigatran", 570], [",", 580], ["with", 582], ["the", 587], ["promise", 591], ["of", 599], ["less", 602], ["frequent", 607], ["monitoring", 616], ["and", 627], ["decreased", 631], ["bleeding", 641], ["tendencies", 650], ["as", 661], ["compared", 664], ["to", 673], ["Coumadin", 676], [".", 684], ["The", 686], ["main", 690], ["disadvantage", 695], ["of", 708], ["dabigatran", 711], ["has", 722], ["been", 726], ["the", 731], ["lack", 735], ["of", 740], ["a", 743], ["reversal", 745], ["agent", 754], ["in", 760], ["case", 763], ["of", 768], ["severe", 771], ["bleeding", 778], ["or", 787], ["emergent", 790], ["surgical", 799], ["intervention", 808], [".", 820], ["This", 822], ["was", 827], ["until", 831], ["the", 837], ["recent", 841], ["The", 848], ["Food", 852], ["and", 857], ["Drug", 861], ["Administration", 866], ["approval", 881], ["of", 890], ["idarucizumab", 893], [",", 905], ["a", 907], ["potential", 909], ["reversal", 919], ["agent", 928], ["for", 934], ["dabigatran", 938], [".", 948], ["In", 950], ["this", 953], ["article", 958], [",", 965], ["we", 967], ["discuss", 970], ["the", 978], ["evidence", 982], ["addressing", 991], ["idarucizumab", 1002], ["safety", 1015], [",", 1021], ["tolerability", 1023], ["and", 1036], ["its", 1040], ["efficacy", 1044], ["for", 1053], ["reversing", 1057], ["effect", 1067], ["of", 1074], ["dabigatran", 1077], [".", 1087]]}
{"context": "Willis-Ekbom disease/restless legs syndrome (WED/RLS) is the most common sleep-related movement disorder in pregnancy. We designed a prospective longitudinal study to investigate the correlates of WED/RLS during and after pregnancy. A total of 138 pregnant women with WED/RLS and a control group of 251 age-matched pregnant women were enrolled prospectively. A questionnaire was administered during a face-to-face interview at first evaluation during pregnancy and three months after delivery. Among all women in the first trimester, 15.6% were diagnosed with WED/RLS, whereas 32.8% of those in the second trimester and 38.8% of those in the third trimester were diagnosed with WED/RLS (p\u2009=\u20090.032). In regression analysis, later gestational age [p\u2009<\u20090.001; odds ratio (OR) 1.054] and previous history of WED/RLS (p\u2009=\u20090.001; OR 2.795) were positively correlated with the presence of WED/RLS, while ferritin levels (p\u2009=\u20090.001; OR 0.956) were negatively correlated with the presence of WED/RLS. Ferritin levels were also negatively correlated with the International RLS Study Group severity index (p\u2009=\u20090.041). Forty-eight patients (34.8%) experienced WED/RLS symptomatology after delivery. The ferritin levels were lower, and the mean number of pregnancies was higher, in women with residual WED/RLS (p\u2009=\u20090.008). Our survey showed that WED/RLS was more common in the second and third trimesters. Emergence of WED/RLS during the second trimester was strongly associated with residual WED/RLS. Lower ferritin levels were associated with both WED/RLS in pregnancy and residual WED/RLS after delivery. A higher number of pregnancies were also associated with a greater likelihood of having residual WED/RLS after delivery.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "c13bddb9e37b47c69428caa895cea7ae", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[5, 7]], "char_spans": [[21, 42]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["/", 20], ["restless", 21], ["legs", 30], ["syndrome", 35], ["(", 44], ["WED", 45], ["/", 48], ["RLS", 49], [")", 52], ["is", 54], ["the", 57], ["most", 61], ["common", 66], ["sleep", 73], ["-", 78], ["related", 79], ["movement", 87], ["disorder", 96], ["in", 105], ["pregnancy", 108], [".", 117], ["We", 119], ["designed", 122], ["a", 131], ["prospective", 133], ["longitudinal", 145], ["study", 158], ["to", 164], ["investigate", 167], ["the", 179], ["correlates", 183], ["of", 194], ["WED", 197], ["/", 200], ["RLS", 201], ["during", 205], ["and", 212], ["after", 216], ["pregnancy", 222], [".", 231], ["A", 233], ["total", 235], ["of", 241], ["138", 244], ["pregnant", 248], ["women", 257], ["with", 263], ["WED", 268], ["/", 271], ["RLS", 272], ["and", 276], ["a", 280], ["control", 282], ["group", 290], ["of", 296], ["251", 299], ["age", 303], ["-", 306], ["matched", 307], ["pregnant", 315], ["women", 324], ["were", 330], ["enrolled", 335], ["prospectively", 344], [".", 357], ["A", 359], ["questionnaire", 361], ["was", 375], ["administered", 379], ["during", 392], ["a", 399], ["face", 401], ["-", 405], ["to", 406], ["-", 408], ["face", 409], ["interview", 414], ["at", 424], ["first", 427], ["evaluation", 433], ["during", 444], ["pregnancy", 451], ["and", 461], ["three", 465], ["months", 471], ["after", 478], ["delivery", 484], [".", 492], ["Among", 494], ["all", 500], ["women", 504], ["in", 510], ["the", 513], ["first", 517], ["trimester", 523], [",", 532], ["15.6", 534], ["%", 538], ["were", 540], ["diagnosed", 545], ["with", 555], ["WED", 560], ["/", 563], ["RLS", 564], [",", 567], ["whereas", 569], ["32.8", 577], ["%", 581], ["of", 583], ["those", 586], ["in", 592], ["the", 595], ["second", 599], ["trimester", 606], ["and", 616], ["38.8", 620], ["%", 624], ["of", 626], ["those", 629], ["in", 635], ["the", 638], ["third", 642], ["trimester", 648], ["were", 658], ["diagnosed", 663], ["with", 673], ["WED", 678], ["/", 681], ["RLS", 682], ["(", 686], ["p", 687], ["=", 689], ["0.032", 691], [")", 696], [".", 697], ["In", 699], ["regression", 702], ["analysis", 713], [",", 721], ["later", 723], ["gestational", 729], ["age", 741], ["[", 745], ["p", 746], ["<", 748], ["0.001", 750], [";", 755], ["odds", 757], ["ratio", 762], ["(", 768], ["OR", 769], [")", 771], ["1.054", 773], ["]", 778], ["and", 780], ["previous", 784], ["history", 793], ["of", 801], ["WED", 804], ["/", 807], ["RLS", 808], ["(", 812], ["p", 813], ["=", 815], ["0.001", 817], [";", 822], ["OR", 824], ["2.795", 827], [")", 832], ["were", 834], ["positively", 839], ["correlated", 850], ["with", 861], ["the", 866], ["presence", 870], ["of", 879], ["WED", 882], ["/", 885], ["RLS", 886], [",", 889], ["while", 891], ["ferritin", 897], ["levels", 906], ["(", 913], ["p", 914], ["=", 916], ["0.001", 918], [";", 923], ["OR", 925], ["0.956", 928], [")", 933], ["were", 935], ["negatively", 940], ["correlated", 951], ["with", 962], ["the", 967], ["presence", 971], ["of", 980], ["WED", 983], ["/", 986], ["RLS", 987], [".", 990], ["Ferritin", 992], ["levels", 1001], ["were", 1008], ["also", 1013], ["negatively", 1018], ["correlated", 1029], ["with", 1040], ["the", 1045], ["International", 1049], ["RLS", 1063], ["Study", 1067], ["Group", 1073], ["severity", 1079], ["index", 1088], ["(", 1094], ["p", 1095], ["=", 1097], ["0.041", 1099], [")", 1104], [".", 1105], ["Forty", 1107], ["-", 1112], ["eight", 1113], ["patients", 1119], ["(", 1128], ["34.8", 1129], ["%", 1133], [")", 1134], ["experienced", 1136], ["WED", 1148], ["/", 1151], ["RLS", 1152], ["symptomatology", 1156], ["after", 1171], ["delivery", 1177], [".", 1185], ["The", 1187], ["ferritin", 1191], ["levels", 1200], ["were", 1207], ["lower", 1212], [",", 1217], ["and", 1219], ["the", 1223], ["mean", 1227], ["number", 1232], ["of", 1239], ["pregnancies", 1242], ["was", 1254], ["higher", 1258], [",", 1264], ["in", 1266], ["women", 1269], ["with", 1275], ["residual", 1280], ["WED", 1289], ["/", 1292], ["RLS", 1293], ["(", 1297], ["p", 1298], ["=", 1300], ["0.008", 1302], [")", 1307], [".", 1308], ["Our", 1310], ["survey", 1314], ["showed", 1321], ["that", 1328], ["WED", 1333], ["/", 1336], ["RLS", 1337], ["was", 1341], ["more", 1345], ["common", 1350], ["in", 1357], ["the", 1360], ["second", 1364], ["and", 1371], ["third", 1375], ["trimesters", 1381], [".", 1391], ["Emergence", 1393], ["of", 1403], ["WED", 1406], ["/", 1409], ["RLS", 1410], ["during", 1414], ["the", 1421], ["second", 1425], ["trimester", 1432], ["was", 1442], ["strongly", 1446], ["associated", 1455], ["with", 1466], ["residual", 1471], ["WED", 1480], ["/", 1483], ["RLS", 1484], [".", 1487], ["Lower", 1489], ["ferritin", 1495], ["levels", 1504], ["were", 1511], ["associated", 1516], ["with", 1527], ["both", 1532], ["WED", 1537], ["/", 1540], ["RLS", 1541], ["in", 1545], ["pregnancy", 1548], ["and", 1558], ["residual", 1562], ["WED", 1571], ["/", 1574], ["RLS", 1575], ["after", 1579], ["delivery", 1585], [".", 1593], ["A", 1595], ["higher", 1597], ["number", 1604], ["of", 1611], ["pregnancies", 1614], ["were", 1626], ["also", 1631], ["associated", 1636], ["with", 1647], ["a", 1652], ["greater", 1654], ["likelihood", 1662], ["of", 1673], ["having", 1676], ["residual", 1683], ["WED", 1692], ["/", 1695], ["RLS", 1696], ["after", 1700], ["delivery", 1706], [".", 1714]]}
{"context": "Ten years after Fire and Melo's Nobel Prize for discovery of gene silencing by double-stranded RNA, a remarkable progress was achieved in RNA interference (RNAi). Changes in the chemical structure of synthetic oligonucleotides make them more stable and specific, and new delivery strategies became progressively available. The attention of pharmaceutical industry rapidly turned to RNAi, as an opportunity to explore new drug targets. This review addresses nine small-interfering RNAs (siRNAs) and one unique microRNA (miRNA) inhibitor, which entered the phase 2-3 clinical trials. The siRNAs in focus are PF-04523655, TKM-080301, Atu027, SYL040012, SYL1001, siG12D-LODER (phase 2), QPI-1002, QPI-1007, and patisiran (phase 3). Regarding miRNAs, their content can be down- or up-regulated, by using miRNA inhibitors (AntimiRs) or miRNA mimics. Miravirsen is an AntimiR-122 for hepatitis C virus infection. The flexibility of RNAi technology is easily understood taking into account: (i) the different drug targets (i.e. p53, caspase 2, PKN3, \u03b22-adrenergic receptor, mutated KRAS, microRNAs); (ii) therapeutic conditions, including ophthalmic diseases, kidney injury, amyloidosis, pancreatic cancer, viral hepatitis; and (iii) routes of administration (ocular, intravenous, subcutaneous, intratumoral). Although some issues are still matters of concern (delivery, toxicity, cost, and biological barriers), RNAi definitively opens a wide avenue for drug development.", "qas": [{"question": "In November 2017,  in what phase  was  the clinical trial for the drug SYL040012?", "answers": ["Phase 3"], "qid": "d2fdd08c60094d70a63f61dde1ded606", "question_tokens": [["In", 0], ["November", 3], ["2017", 12], [",", 16], [" ", 18], ["in", 19], ["what", 22], ["phase", 27], [" ", 33], ["was", 34], [" ", 38], ["the", 39], ["clinical", 43], ["trial", 52], ["for", 58], ["the", 62], ["drug", 66], ["SYL040012", 71], ["?", 80]], "detected_answers": [{"text": "Phase 3", "token_spans": [[134, 135]], "char_spans": [[718, 724]]}]}], "context_tokens": [["Ten", 0], ["years", 4], ["after", 10], ["Fire", 16], ["and", 21], ["Melo", 25], ["'s", 29], ["Nobel", 32], ["Prize", 38], ["for", 44], ["discovery", 48], ["of", 58], ["gene", 61], ["silencing", 66], ["by", 76], ["double", 79], ["-", 85], ["stranded", 86], ["RNA", 95], [",", 98], ["a", 100], ["remarkable", 102], ["progress", 113], ["was", 122], ["achieved", 126], ["in", 135], ["RNA", 138], ["interference", 142], ["(", 155], ["RNAi", 156], [")", 160], [".", 161], ["Changes", 163], ["in", 171], ["the", 174], ["chemical", 178], ["structure", 187], ["of", 197], ["synthetic", 200], ["oligonucleotides", 210], ["make", 227], ["them", 232], ["more", 237], ["stable", 242], ["and", 249], ["specific", 253], [",", 261], ["and", 263], ["new", 267], ["delivery", 271], ["strategies", 280], ["became", 291], ["progressively", 298], ["available", 312], [".", 321], ["The", 323], ["attention", 327], ["of", 337], ["pharmaceutical", 340], ["industry", 355], ["rapidly", 364], ["turned", 372], ["to", 379], ["RNAi", 382], [",", 386], ["as", 388], ["an", 391], ["opportunity", 394], ["to", 406], ["explore", 409], ["new", 417], ["drug", 421], ["targets", 426], [".", 433], ["This", 435], ["review", 440], ["addresses", 447], ["nine", 457], ["small", 462], ["-", 467], ["interfering", 468], ["RNAs", 480], ["(", 485], ["siRNAs", 486], [")", 492], ["and", 494], ["one", 498], ["unique", 502], ["microRNA", 509], ["(", 518], ["miRNA", 519], [")", 524], ["inhibitor", 526], [",", 535], ["which", 537], ["entered", 543], ["the", 551], ["phase", 555], ["2", 561], ["-", 562], ["3", 563], ["clinical", 565], ["trials", 574], [".", 580], ["The", 582], ["siRNAs", 586], ["in", 593], ["focus", 596], ["are", 602], ["PF-04523655", 606], [",", 617], ["TKM-080301", 619], [",", 629], ["Atu027", 631], [",", 637], ["SYL040012", 639], [",", 648], ["SYL1001", 650], [",", 657], ["siG12D", 659], ["-", 665], ["LODER", 666], ["(", 672], ["phase", 673], ["2", 679], [")", 680], [",", 681], ["QPI-1002", 683], [",", 691], ["QPI-1007", 693], [",", 701], ["and", 703], ["patisiran", 707], ["(", 717], ["phase", 718], ["3", 724], [")", 725], [".", 726], ["Regarding", 728], ["miRNAs", 738], [",", 744], ["their", 746], ["content", 752], ["can", 760], ["be", 764], ["down-", 767], ["or", 773], ["up", 776], ["-", 778], ["regulated", 779], [",", 788], ["by", 790], ["using", 793], ["miRNA", 799], ["inhibitors", 805], ["(", 816], ["AntimiRs", 817], [")", 825], ["or", 827], ["miRNA", 830], ["mimics", 836], [".", 842], ["Miravirsen", 844], ["is", 855], ["an", 858], ["AntimiR-122", 861], ["for", 873], ["hepatitis", 877], ["C", 887], ["virus", 889], ["infection", 895], [".", 904], ["The", 906], ["flexibility", 910], ["of", 922], ["RNAi", 925], ["technology", 930], ["is", 941], ["easily", 944], ["understood", 951], ["taking", 962], ["into", 969], ["account", 974], [":", 981], ["(", 983], ["i", 984], [")", 985], ["the", 987], ["different", 991], ["drug", 1001], ["targets", 1006], ["(", 1014], ["i.e.", 1015], ["p53", 1020], [",", 1023], ["caspase", 1025], ["2", 1033], [",", 1034], ["PKN3", 1036], [",", 1040], ["\u03b22-adrenergic", 1042], ["receptor", 1056], [",", 1064], ["mutated", 1066], ["KRAS", 1074], [",", 1078], ["microRNAs", 1080], [")", 1089], [";", 1090], ["(", 1092], ["ii", 1093], [")", 1095], ["therapeutic", 1097], ["conditions", 1109], [",", 1119], ["including", 1121], ["ophthalmic", 1131], ["diseases", 1142], [",", 1150], ["kidney", 1152], ["injury", 1159], [",", 1165], ["amyloidosis", 1167], [",", 1178], ["pancreatic", 1180], ["cancer", 1191], [",", 1197], ["viral", 1199], ["hepatitis", 1205], [";", 1214], ["and", 1216], ["(", 1220], ["iii", 1221], [")", 1224], ["routes", 1226], ["of", 1233], ["administration", 1236], ["(", 1251], ["ocular", 1252], [",", 1258], ["intravenous", 1260], [",", 1271], ["subcutaneous", 1273], [",", 1285], ["intratumoral", 1287], [")", 1299], [".", 1300], ["Although", 1302], ["some", 1311], ["issues", 1316], ["are", 1323], ["still", 1327], ["matters", 1333], ["of", 1341], ["concern", 1344], ["(", 1352], ["delivery", 1353], [",", 1361], ["toxicity", 1363], [",", 1371], ["cost", 1373], [",", 1377], ["and", 1379], ["biological", 1383], ["barriers", 1394], [")", 1402], [",", 1403], ["RNAi", 1405], ["definitively", 1410], ["opens", 1423], ["a", 1429], ["wide", 1431], ["avenue", 1436], ["for", 1443], ["drug", 1447], ["development", 1452], [".", 1463]]}
{"context": "Spinocerebellar ataxia type 3 (SCA3) is an inherited spinocerebellar ataxia caused by the expansion of trinucleotide CAG repeats in the gene encoding ataxin-3. The clinical manifestations of SCA3 include peripheral neuropathy, which is an important cause of disability in a subset of patients. Although the loss of neurones in the dorsal root ganglion (DRG) has been postulated to be the cause of this neuropathy, the precise mechanism remains to be elucidated. To clarify the clinicopathological characteristics of SCA3-associated peripheral neuropathy, we performed nerve conduction studies and histopathological analyses. Nerve conduction studies were carried out in 18 SCA3 patients. Immunohistochemical analyses of the anterior and posterior roots of the spinal cord and peripheral nerves were performed in five SCA3 patients. We also employed immunohistochemistry and immunoelectron microscopy analyses with an anti-polyglutamine antibody. The mean sensory nerve action potentials of the SCA3 patients were half of the normal values. The motor conduction velocities were decreased, and the distal latencies were also significantly prolonged in the nerves studied relative to the those in normal controls. Histopathological analyses detected axonal sprouting and myelin thinning in all cases. Ataxin-3 aggregates were found in the cytoplasm of Schwann cells in all of the SCA3 patients examined but not in control subjects. In addition to the previously reported neuronopathy, the results of the present study indicate that Schwann cells are involved in the formation of the pathogenic intracytoplasmic ataxin-3 protein aggregates in patients with SCA3-associated neuropathy.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "d3819cb8ec4f4b7ca419852b254520d5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[24, 24], [203, 203], [253, 253]], "char_spans": [[150, 157], [1298, 1305], [1608, 1615]]}]}], "context_tokens": [["Spinocerebellar", 0], ["ataxia", 16], ["type", 23], ["3", 28], ["(", 30], ["SCA3", 31], [")", 35], ["is", 37], ["an", 40], ["inherited", 43], ["spinocerebellar", 53], ["ataxia", 69], ["caused", 76], ["by", 83], ["the", 86], ["expansion", 90], ["of", 100], ["trinucleotide", 103], ["CAG", 117], ["repeats", 121], ["in", 129], ["the", 132], ["gene", 136], ["encoding", 141], ["ataxin-3", 150], [".", 158], ["The", 160], ["clinical", 164], ["manifestations", 173], ["of", 188], ["SCA3", 191], ["include", 196], ["peripheral", 204], ["neuropathy", 215], [",", 225], ["which", 227], ["is", 233], ["an", 236], ["important", 239], ["cause", 249], ["of", 255], ["disability", 258], ["in", 269], ["a", 272], ["subset", 274], ["of", 281], ["patients", 284], [".", 292], ["Although", 294], ["the", 303], ["loss", 307], ["of", 312], ["neurones", 315], ["in", 324], ["the", 327], ["dorsal", 331], ["root", 338], ["ganglion", 343], ["(", 352], ["DRG", 353], [")", 356], ["has", 358], ["been", 362], ["postulated", 367], ["to", 378], ["be", 381], ["the", 384], ["cause", 388], ["of", 394], ["this", 397], ["neuropathy", 402], [",", 412], ["the", 414], ["precise", 418], ["mechanism", 426], ["remains", 436], ["to", 444], ["be", 447], ["elucidated", 450], [".", 460], ["To", 462], ["clarify", 465], ["the", 473], ["clinicopathological", 477], ["characteristics", 497], ["of", 513], ["SCA3-associated", 516], ["peripheral", 532], ["neuropathy", 543], [",", 553], ["we", 555], ["performed", 558], ["nerve", 568], ["conduction", 574], ["studies", 585], ["and", 593], ["histopathological", 597], ["analyses", 615], [".", 623], ["Nerve", 625], ["conduction", 631], ["studies", 642], ["were", 650], ["carried", 655], ["out", 663], ["in", 667], ["18", 670], ["SCA3", 673], ["patients", 678], [".", 686], ["Immunohistochemical", 688], ["analyses", 708], ["of", 717], ["the", 720], ["anterior", 724], ["and", 733], ["posterior", 737], ["roots", 747], ["of", 753], ["the", 756], ["spinal", 760], ["cord", 767], ["and", 772], ["peripheral", 776], ["nerves", 787], ["were", 794], ["performed", 799], ["in", 809], ["five", 812], ["SCA3", 817], ["patients", 822], [".", 830], ["We", 832], ["also", 835], ["employed", 840], ["immunohistochemistry", 849], ["and", 870], ["immunoelectron", 874], ["microscopy", 889], ["analyses", 900], ["with", 909], ["an", 914], ["anti", 917], ["-", 921], ["polyglutamine", 922], ["antibody", 936], [".", 944], ["The", 946], ["mean", 950], ["sensory", 955], ["nerve", 963], ["action", 969], ["potentials", 976], ["of", 987], ["the", 990], ["SCA3", 994], ["patients", 999], ["were", 1008], ["half", 1013], ["of", 1018], ["the", 1021], ["normal", 1025], ["values", 1032], [".", 1038], ["The", 1040], ["motor", 1044], ["conduction", 1050], ["velocities", 1061], ["were", 1072], ["decreased", 1077], [",", 1086], ["and", 1088], ["the", 1092], ["distal", 1096], ["latencies", 1103], ["were", 1113], ["also", 1118], ["significantly", 1123], ["prolonged", 1137], ["in", 1147], ["the", 1150], ["nerves", 1154], ["studied", 1161], ["relative", 1169], ["to", 1178], ["the", 1181], ["those", 1185], ["in", 1191], ["normal", 1194], ["controls", 1201], [".", 1209], ["Histopathological", 1211], ["analyses", 1229], ["detected", 1238], ["axonal", 1247], ["sprouting", 1254], ["and", 1264], ["myelin", 1268], ["thinning", 1275], ["in", 1284], ["all", 1287], ["cases", 1291], [".", 1296], ["Ataxin-3", 1298], ["aggregates", 1307], ["were", 1318], ["found", 1323], ["in", 1329], ["the", 1332], ["cytoplasm", 1336], ["of", 1346], ["Schwann", 1349], ["cells", 1357], ["in", 1363], ["all", 1366], ["of", 1370], ["the", 1373], ["SCA3", 1377], ["patients", 1382], ["examined", 1391], ["but", 1400], ["not", 1404], ["in", 1408], ["control", 1411], ["subjects", 1419], [".", 1427], ["In", 1429], ["addition", 1432], ["to", 1441], ["the", 1444], ["previously", 1448], ["reported", 1459], ["neuronopathy", 1468], [",", 1480], ["the", 1482], ["results", 1486], ["of", 1494], ["the", 1497], ["present", 1501], ["study", 1509], ["indicate", 1515], ["that", 1524], ["Schwann", 1529], ["cells", 1537], ["are", 1543], ["involved", 1547], ["in", 1556], ["the", 1559], ["formation", 1563], ["of", 1573], ["the", 1576], ["pathogenic", 1580], ["intracytoplasmic", 1591], ["ataxin-3", 1608], ["protein", 1617], ["aggregates", 1625], ["in", 1636], ["patients", 1639], ["with", 1648], ["SCA3-associated", 1653], ["neuropathy", 1669], [".", 1679]]}
{"context": "Dendritic cells (DCs), professional antigen-presenting cells with the unique ability to initiate primary T-cell responses, are present in atherosclerotic lesions where they are exposed to oxidative stress that generates cytotoxic reactive oxygen species (ROS). A large body of evidence indicates that cell death is a major modulating factor of atherogenesis. We examined antioxidant defence systems of human monocyte-derived (mo)DCs and monocytes in response to oxidative stress. Oxidative stress was induced by addition of tertiary-butylhydroperoxide (tert-BHP, 30 min). Cellular responses were evaluated using flow cytometry and confocal live cell imaging (both using 5-(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein diacetate, CM-H(2)DCFDA). Viability was assessed by the neutral red assay. Total RNA was extracted for a PCR profiler array. Five genes were selected for confirmation by Taqman gene expression assays, and by immunoblotting or immunohistochemistry for protein levels. Tert-BHP increased CM-H(2)DCFDA fluorescence and caused cell death. Interestingly, all processes occurred more slowly in moDCs than in monocytes. The mRNA profiler array showed more than 2-fold differential expression of 32 oxidative stress-related genes in unstimulated moDCs, including peroxiredoxin-2 (PRDX2), an enzyme reducing hydrogen peroxide and lipid peroxides. PRDX2 upregulation was confirmed by Taqman assays, immunoblotting and immunohistochemistry. Silencing PRDX2 in moDCs by means of siRNA significantly increased CM-DCF fluorescence and cell death upon tert-BHP-stimulation. Our results indicate that moDCs exhibit higher intracellular antioxidant capacities, making them better equipped to resist oxidative stress than monocytes. Upregulation of PRDX2 is involved in the neutralization of ROS in moDCs. Taken together, this points to better survival skills of DCs in oxidative stress environments, such as atherosclerotic plaques.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "e0afb40c95bf43ecb23eaab63790e3b4", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[64, 64], [270, 270]], "char_spans": [[371, 381], [1644, 1654]]}]}], "context_tokens": [["Dendritic", 0], ["cells", 10], ["(", 16], ["DCs", 17], [")", 20], [",", 21], ["professional", 23], ["antigen", 36], ["-", 43], ["presenting", 44], ["cells", 55], ["with", 61], ["the", 66], ["unique", 70], ["ability", 77], ["to", 85], ["initiate", 88], ["primary", 97], ["T", 105], ["-", 106], ["cell", 107], ["responses", 112], [",", 121], ["are", 123], ["present", 127], ["in", 135], ["atherosclerotic", 138], ["lesions", 154], ["where", 162], ["they", 168], ["are", 173], ["exposed", 177], ["to", 185], ["oxidative", 188], ["stress", 198], ["that", 205], ["generates", 210], ["cytotoxic", 220], ["reactive", 230], ["oxygen", 239], ["species", 246], ["(", 254], ["ROS", 255], [")", 258], [".", 259], ["A", 261], ["large", 263], ["body", 269], ["of", 274], ["evidence", 277], ["indicates", 286], ["that", 296], ["cell", 301], ["death", 306], ["is", 312], ["a", 315], ["major", 317], ["modulating", 323], ["factor", 334], ["of", 341], ["atherogenesis", 344], [".", 357], ["We", 359], ["examined", 362], ["antioxidant", 371], ["defence", 383], ["systems", 391], ["of", 399], ["human", 402], ["monocyte", 408], ["-", 416], ["derived", 417], ["(", 425], ["mo)DCs", 426], ["and", 433], ["monocytes", 437], ["in", 447], ["response", 450], ["to", 459], ["oxidative", 462], ["stress", 472], [".", 478], ["Oxidative", 480], ["stress", 490], ["was", 497], ["induced", 501], ["by", 509], ["addition", 512], ["of", 521], ["tertiary", 524], ["-", 532], ["butylhydroperoxide", 533], ["(", 552], ["tert", 553], ["-", 557], ["BHP", 558], [",", 561], ["30", 563], ["min", 566], [")", 569], [".", 570], ["Cellular", 572], ["responses", 581], ["were", 591], ["evaluated", 596], ["using", 606], ["flow", 612], ["cytometry", 617], ["and", 627], ["confocal", 631], ["live", 640], ["cell", 645], ["imaging", 650], ["(", 658], ["both", 659], ["using", 664], ["5-(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein", 670], ["diacetate", 724], [",", 733], ["CM", 735], ["-", 737], ["H(2)DCFDA", 738], [")", 747], [".", 748], ["Viability", 750], ["was", 760], ["assessed", 764], ["by", 773], ["the", 776], ["neutral", 780], ["red", 788], ["assay", 792], [".", 797], ["Total", 799], ["RNA", 805], ["was", 809], ["extracted", 813], ["for", 823], ["a", 827], ["PCR", 829], ["profiler", 833], ["array", 842], [".", 847], ["Five", 849], ["genes", 854], ["were", 860], ["selected", 865], ["for", 874], ["confirmation", 878], ["by", 891], ["Taqman", 894], ["gene", 901], ["expression", 906], ["assays", 917], [",", 923], ["and", 925], ["by", 929], ["immunoblotting", 932], ["or", 947], ["immunohistochemistry", 950], ["for", 971], ["protein", 975], ["levels", 983], [".", 989], ["Tert", 991], ["-", 995], ["BHP", 996], ["increased", 1000], ["CM", 1010], ["-", 1012], ["H(2)DCFDA", 1013], ["fluorescence", 1023], ["and", 1036], ["caused", 1040], ["cell", 1047], ["death", 1052], [".", 1057], ["Interestingly", 1059], [",", 1072], ["all", 1074], ["processes", 1078], ["occurred", 1088], ["more", 1097], ["slowly", 1102], ["in", 1109], ["moDCs", 1112], ["than", 1118], ["in", 1123], ["monocytes", 1126], [".", 1135], ["The", 1137], ["mRNA", 1141], ["profiler", 1146], ["array", 1155], ["showed", 1161], ["more", 1168], ["than", 1173], ["2-fold", 1178], ["differential", 1185], ["expression", 1198], ["of", 1209], ["32", 1212], ["oxidative", 1215], ["stress", 1225], ["-", 1231], ["related", 1232], ["genes", 1240], ["in", 1246], ["unstimulated", 1249], ["moDCs", 1262], [",", 1267], ["including", 1269], ["peroxiredoxin-2", 1279], ["(", 1295], ["PRDX2", 1296], [")", 1301], [",", 1302], ["an", 1304], ["enzyme", 1307], ["reducing", 1314], ["hydrogen", 1323], ["peroxide", 1332], ["and", 1341], ["lipid", 1345], ["peroxides", 1351], [".", 1360], ["PRDX2", 1362], ["upregulation", 1368], ["was", 1381], ["confirmed", 1385], ["by", 1395], ["Taqman", 1398], ["assays", 1405], [",", 1411], ["immunoblotting", 1413], ["and", 1428], ["immunohistochemistry", 1432], [".", 1452], ["Silencing", 1454], ["PRDX2", 1464], ["in", 1470], ["moDCs", 1473], ["by", 1479], ["means", 1482], ["of", 1488], ["siRNA", 1491], ["significantly", 1497], ["increased", 1511], ["CM", 1521], ["-", 1523], ["DCF", 1524], ["fluorescence", 1528], ["and", 1541], ["cell", 1545], ["death", 1550], ["upon", 1556], ["tert", 1561], ["-", 1565], ["BHP", 1566], ["-", 1569], ["stimulation", 1570], [".", 1581], ["Our", 1583], ["results", 1587], ["indicate", 1595], ["that", 1604], ["moDCs", 1609], ["exhibit", 1615], ["higher", 1623], ["intracellular", 1630], ["antioxidant", 1644], ["capacities", 1656], [",", 1666], ["making", 1668], ["them", 1675], ["better", 1680], ["equipped", 1687], ["to", 1696], ["resist", 1699], ["oxidative", 1706], ["stress", 1716], ["than", 1723], ["monocytes", 1728], [".", 1737], ["Upregulation", 1739], ["of", 1752], ["PRDX2", 1755], ["is", 1761], ["involved", 1764], ["in", 1773], ["the", 1776], ["neutralization", 1780], ["of", 1795], ["ROS", 1798], ["in", 1802], ["moDCs", 1805], [".", 1810], ["Taken", 1812], ["together", 1818], [",", 1826], ["this", 1828], ["points", 1833], ["to", 1840], ["better", 1843], ["survival", 1850], ["skills", 1859], ["of", 1866], ["DCs", 1869], ["in", 1873], ["oxidative", 1876], ["stress", 1886], ["environments", 1893], [",", 1905], ["such", 1907], ["as", 1912], ["atherosclerotic", 1915], ["plaques", 1931], [".", 1938]]}
{"context": "To evaluate the results of facial nerve (FN) grafting using great auricular cable graft and fibrin glue without suturing to palliate FN disruption after removal of large cerebellopontine angle (CPA) vestibular schwannoma (VS) or facial nerve schwannoma (FNS). To assess whether tumor size and origin influenced the results. Retrospective review of all patients having undergone removal of FNS/VS and needing intraoperative FN repair between 2001 and 2011. FN was rehabilitated using great auricular nerve cable graft and fibrin glue (Tisseal) without stitching suture. All data recorded were reviewed to access age, sex, tumor type, and tumor size according to the Koos classification and presenting symptoms. FN function was evaluated preoperatively and at 18 months using the House-Brackmann (HB) grading system. Among the 595 patients operated for CPA schwannomas in this period, 15 patients (2.5%) underwent FN repair, including 7 cases of FNS and 8 cases of VS. Tumor removal was total in all cases. FN recovery was HB3 in 13 cases (86.7%) and HB4 in 2. The mean time to the first clinical signs of facial reinnervation was 10 months (6-12 mo). No significant relation was found between postoperative facial function and tumor size or type, even if all cases of preoperative FP were noted in FNS. Immediate FN reconstruction with fibrin glue-aided greater auricular nerve graft can effectively restore FN function with excellent outcomes. The results seem better than those observed by other authors using sutured grafts or delayed hypoglossal-facial nerve anastomosis.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "daa709616eec470dae4a7428b85cf00d", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[34, 35]], "char_spans": [[199, 219]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["results", 16], ["of", 24], ["facial", 27], ["nerve", 34], ["(", 40], ["FN", 41], [")", 43], ["grafting", 45], ["using", 54], ["great", 60], ["auricular", 66], ["cable", 76], ["graft", 82], ["and", 88], ["fibrin", 92], ["glue", 99], ["without", 104], ["suturing", 112], ["to", 121], ["palliate", 124], ["FN", 133], ["disruption", 136], ["after", 147], ["removal", 153], ["of", 161], ["large", 164], ["cerebellopontine", 170], ["angle", 187], ["(", 193], ["CPA", 194], [")", 197], ["vestibular", 199], ["schwannoma", 210], ["(", 221], ["VS", 222], [")", 224], ["or", 226], ["facial", 229], ["nerve", 236], ["schwannoma", 242], ["(", 253], ["FNS", 254], [")", 257], [".", 258], ["To", 260], ["assess", 263], ["whether", 270], ["tumor", 278], ["size", 284], ["and", 289], ["origin", 293], ["influenced", 300], ["the", 311], ["results", 315], [".", 322], ["Retrospective", 324], ["review", 338], ["of", 345], ["all", 348], ["patients", 352], ["having", 361], ["undergone", 368], ["removal", 378], ["of", 386], ["FNS", 389], ["/", 392], ["VS", 393], ["and", 396], ["needing", 400], ["intraoperative", 408], ["FN", 423], ["repair", 426], ["between", 433], ["2001", 441], ["and", 446], ["2011", 450], [".", 454], ["FN", 456], ["was", 459], ["rehabilitated", 463], ["using", 477], ["great", 483], ["auricular", 489], ["nerve", 499], ["cable", 505], ["graft", 511], ["and", 517], ["fibrin", 521], ["glue", 528], ["(", 533], ["Tisseal", 534], [")", 541], ["without", 543], ["stitching", 551], ["suture", 561], [".", 567], ["All", 569], ["data", 573], ["recorded", 578], ["were", 587], ["reviewed", 592], ["to", 601], ["access", 604], ["age", 611], [",", 614], ["sex", 616], [",", 619], ["tumor", 621], ["type", 627], [",", 631], ["and", 633], ["tumor", 637], ["size", 643], ["according", 648], ["to", 658], ["the", 661], ["Koos", 665], ["classification", 670], ["and", 685], ["presenting", 689], ["symptoms", 700], [".", 708], ["FN", 710], ["function", 713], ["was", 722], ["evaluated", 726], ["preoperatively", 736], ["and", 751], ["at", 755], ["18", 758], ["months", 761], ["using", 768], ["the", 774], ["House", 778], ["-", 783], ["Brackmann", 784], ["(", 794], ["HB", 795], [")", 797], ["grading", 799], ["system", 807], [".", 813], ["Among", 815], ["the", 821], ["595", 825], ["patients", 829], ["operated", 838], ["for", 847], ["CPA", 851], ["schwannomas", 855], ["in", 867], ["this", 870], ["period", 875], [",", 881], ["15", 883], ["patients", 886], ["(", 895], ["2.5", 896], ["%", 899], [")", 900], ["underwent", 902], ["FN", 912], ["repair", 915], [",", 921], ["including", 923], ["7", 933], ["cases", 935], ["of", 941], ["FNS", 944], ["and", 948], ["8", 952], ["cases", 954], ["of", 960], ["VS", 963], [".", 965], ["Tumor", 967], ["removal", 973], ["was", 981], ["total", 985], ["in", 991], ["all", 994], ["cases", 998], [".", 1003], ["FN", 1005], ["recovery", 1008], ["was", 1017], ["HB3", 1021], ["in", 1025], ["13", 1028], ["cases", 1031], ["(", 1037], ["86.7", 1038], ["%", 1042], [")", 1043], ["and", 1045], ["HB4", 1049], ["in", 1053], ["2", 1056], [".", 1057], ["The", 1059], ["mean", 1063], ["time", 1068], ["to", 1073], ["the", 1076], ["first", 1080], ["clinical", 1086], ["signs", 1095], ["of", 1101], ["facial", 1104], ["reinnervation", 1111], ["was", 1125], ["10", 1129], ["months", 1132], ["(", 1139], ["6", 1140], ["-", 1141], ["12", 1142], ["mo", 1145], [")", 1147], [".", 1148], ["No", 1150], ["significant", 1153], ["relation", 1165], ["was", 1174], ["found", 1178], ["between", 1184], ["postoperative", 1192], ["facial", 1206], ["function", 1213], ["and", 1222], ["tumor", 1226], ["size", 1232], ["or", 1237], ["type", 1240], [",", 1244], ["even", 1246], ["if", 1251], ["all", 1254], ["cases", 1258], ["of", 1264], ["preoperative", 1267], ["FP", 1280], ["were", 1283], ["noted", 1288], ["in", 1294], ["FNS", 1297], [".", 1300], ["Immediate", 1302], ["FN", 1312], ["reconstruction", 1315], ["with", 1330], ["fibrin", 1335], ["glue", 1342], ["-", 1346], ["aided", 1347], ["greater", 1353], ["auricular", 1361], ["nerve", 1371], ["graft", 1377], ["can", 1383], ["effectively", 1387], ["restore", 1399], ["FN", 1407], ["function", 1410], ["with", 1419], ["excellent", 1424], ["outcomes", 1434], [".", 1442], ["The", 1444], ["results", 1448], ["seem", 1456], ["better", 1461], ["than", 1468], ["those", 1473], ["observed", 1479], ["by", 1488], ["other", 1491], ["authors", 1497], ["using", 1505], ["sutured", 1511], ["grafts", 1519], ["or", 1526], ["delayed", 1529], ["hypoglossal", 1537], ["-", 1548], ["facial", 1549], ["nerve", 1556], ["anastomosis", 1562], [".", 1573]]}
{"context": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to decompose peroxides. Prx2 is the third most abundant protein in erythrocytes, and competes effectively with catalase and glutathione peroxidase to scavenge low levels of hydrogen peroxide, including that derived from hemoglobin autoxidation. Low thioredoxin reductase activity in the erythrocyte is able to keep up with this basal oxidation and maintain the Prx2 in its reduced form, but exposure to exogenous hydrogen peroxide causes accumulation of the disulfide-linked dimer. The high cellular concentration means that although turnover is slow, erythrocyte Prx2 can act as a noncatalytic scavenger of hydrogen peroxide and a sink for hydrogen peroxide before turnover becomes limiting. The consequences of Prx2 oxidation for the erythrocyte are not well characterized, but mice deficient in this protein develop severe hemolytic anemia associated with Heinz body formation. Prx2, also known as calpromotin, regulates ion transport by associating with the membrane and activating the G\u00e1rdos channel. How Prx2 redox transformations are linked to membrane association and channel activation is yet to be established. In this review, we discuss the functional properties of Prx2 and its role as a major component of the erythrocyte antioxidant system.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "26a83e722adc4516a5e0f6a8f7c8caaa", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[212, 212], [7, 7]], "char_spans": [[1311, 1321], [29, 39]]}]}], "context_tokens": [["Peroxiredoxin", 0], ["2", 14], ["(", 16], ["Prx2", 17], [")", 21], ["is", 23], ["an", 26], ["antioxidant", 29], ["enzyme", 41], ["that", 48], ["uses", 53], ["cysteine", 58], ["residues", 67], ["to", 76], ["decompose", 79], ["peroxides", 89], [".", 98], ["Prx2", 100], ["is", 105], ["the", 108], ["third", 112], ["most", 118], ["abundant", 123], ["protein", 132], ["in", 140], ["erythrocytes", 143], [",", 155], ["and", 157], ["competes", 161], ["effectively", 170], ["with", 182], ["catalase", 187], ["and", 196], ["glutathione", 200], ["peroxidase", 212], ["to", 223], ["scavenge", 226], ["low", 235], ["levels", 239], ["of", 246], ["hydrogen", 249], ["peroxide", 258], [",", 266], ["including", 268], ["that", 278], ["derived", 283], ["from", 291], ["hemoglobin", 296], ["autoxidation", 307], [".", 319], ["Low", 321], ["thioredoxin", 325], ["reductase", 337], ["activity", 347], ["in", 356], ["the", 359], ["erythrocyte", 363], ["is", 375], ["able", 378], ["to", 383], ["keep", 386], ["up", 391], ["with", 394], ["this", 399], ["basal", 404], ["oxidation", 410], ["and", 420], ["maintain", 424], ["the", 433], ["Prx2", 437], ["in", 442], ["its", 445], ["reduced", 449], ["form", 457], [",", 461], ["but", 463], ["exposure", 467], ["to", 476], ["exogenous", 479], ["hydrogen", 489], ["peroxide", 498], ["causes", 507], ["accumulation", 514], ["of", 527], ["the", 530], ["disulfide", 534], ["-", 543], ["linked", 544], ["dimer", 551], [".", 556], ["The", 558], ["high", 562], ["cellular", 567], ["concentration", 576], ["means", 590], ["that", 596], ["although", 601], ["turnover", 610], ["is", 619], ["slow", 622], [",", 626], ["erythrocyte", 628], ["Prx2", 640], ["can", 645], ["act", 649], ["as", 653], ["a", 656], ["noncatalytic", 658], ["scavenger", 671], ["of", 681], ["hydrogen", 684], ["peroxide", 693], ["and", 702], ["a", 706], ["sink", 708], ["for", 713], ["hydrogen", 717], ["peroxide", 726], ["before", 735], ["turnover", 742], ["becomes", 751], ["limiting", 759], [".", 767], ["The", 769], ["consequences", 773], ["of", 786], ["Prx2", 789], ["oxidation", 794], ["for", 804], ["the", 808], ["erythrocyte", 812], ["are", 824], ["not", 828], ["well", 832], ["characterized", 837], [",", 850], ["but", 852], ["mice", 856], ["deficient", 861], ["in", 871], ["this", 874], ["protein", 879], ["develop", 887], ["severe", 895], ["hemolytic", 902], ["anemia", 912], ["associated", 919], ["with", 930], ["Heinz", 935], ["body", 941], ["formation", 946], [".", 955], ["Prx2", 957], [",", 961], ["also", 963], ["known", 968], ["as", 974], ["calpromotin", 977], [",", 988], ["regulates", 990], ["ion", 1000], ["transport", 1004], ["by", 1014], ["associating", 1017], ["with", 1029], ["the", 1034], ["membrane", 1038], ["and", 1047], ["activating", 1051], ["the", 1062], ["G\u00e1rdos", 1066], ["channel", 1073], [".", 1080], ["How", 1082], ["Prx2", 1086], ["redox", 1091], ["transformations", 1097], ["are", 1113], ["linked", 1117], ["to", 1124], ["membrane", 1127], ["association", 1136], ["and", 1148], ["channel", 1152], ["activation", 1160], ["is", 1171], ["yet", 1174], ["to", 1178], ["be", 1181], ["established", 1184], [".", 1195], ["In", 1197], ["this", 1200], ["review", 1205], [",", 1211], ["we", 1213], ["discuss", 1216], ["the", 1224], ["functional", 1228], ["properties", 1239], ["of", 1250], ["Prx2", 1253], ["and", 1258], ["its", 1262], ["role", 1266], ["as", 1271], ["a", 1274], ["major", 1276], ["component", 1282], ["of", 1292], ["the", 1295], ["erythrocyte", 1299], ["antioxidant", 1311], ["system", 1323], [".", 1329]]}
{"context": "Shprintzen-Goldberg syndrome (SGS) is characterized by craniosynostosis and marfanoid habitus. The clinical findings of SGS include neurological, cardiovascular, connective tissue, and skeletal abnormalities. Among these skeletal findings, developmental scoliosis is recognized in half of all patients with SGS. However, no earlier reports have described the surgical treatment of scoliosis associated with SGS. Four patients (2 boys and 2 girls; mean age at the time of surgery, 7.3\u00b14.4 y) with SGS who underwent surgical treatment for progressive scoliosis were reviewed. The radiologic findings, operative findings, and perioperative complications were evaluated. The mean preoperative Cobb angle was 102.8\u00b116.9 degrees. The curve patterns were a double curve in 2 cases and a triple curve in 2 cases. Local kyphosis at the thoracolumbar area was recognized in all the cases with a mean kyphosis angle of 49\u00b116 degrees. Growing rod procedures were performed in 2 patients, and posterior correction and fusion were performed in 2 patients. The mean correction rate was 45% in the patients who underwent the growing rod procedures at the time of growing rod placement and 51% in the patients who underwent posterior correction and fusion. Dislodgement of the proximal anchors occurred in 3 of the 4 patients. One patient developed pseudoarthrosis. Two patients developed deep wound infections, and implant removal was necessary in 1 patient. Surgical treatment for scoliosis in patients with SGS was associated with a high incidence of perioperative and postoperative complications including implant dislodgements and deep wound infections attributable to poor bone quality and a thin body habitus, which are characteristic clinical features of this syndrome. Careful preoperative surgical planning and postoperative care are critical for the surgical treatment of scoliosis associated with SGS, especially in infants requiring multiple surgeries. Level IV.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "07d30350f8434b48815eaa39fc6cedd9", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[10, 10]], "char_spans": [[55, 70]]}]}], "context_tokens": [["Shprintzen", 0], ["-", 10], ["Goldberg", 11], ["syndrome", 20], ["(", 29], ["SGS", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["craniosynostosis", 55], ["and", 72], ["marfanoid", 76], ["habitus", 86], [".", 93], ["The", 95], ["clinical", 99], ["findings", 108], ["of", 117], ["SGS", 120], ["include", 124], ["neurological", 132], [",", 144], ["cardiovascular", 146], [",", 160], ["connective", 162], ["tissue", 173], [",", 179], ["and", 181], ["skeletal", 185], ["abnormalities", 194], [".", 207], ["Among", 209], ["these", 215], ["skeletal", 221], ["findings", 230], [",", 238], ["developmental", 240], ["scoliosis", 254], ["is", 264], ["recognized", 267], ["in", 278], ["half", 281], ["of", 286], ["all", 289], ["patients", 293], ["with", 302], ["SGS", 307], [".", 310], ["However", 312], [",", 319], ["no", 321], ["earlier", 324], ["reports", 332], ["have", 340], ["described", 345], ["the", 355], ["surgical", 359], ["treatment", 368], ["of", 378], ["scoliosis", 381], ["associated", 391], ["with", 402], ["SGS", 407], [".", 410], ["Four", 412], ["patients", 417], ["(", 426], ["2", 427], ["boys", 429], ["and", 434], ["2", 438], ["girls", 440], [";", 445], ["mean", 447], ["age", 452], ["at", 456], ["the", 459], ["time", 463], ["of", 468], ["surgery", 471], [",", 478], ["7.3\u00b14.4", 480], ["y", 488], [")", 489], ["with", 491], ["SGS", 496], ["who", 500], ["underwent", 504], ["surgical", 514], ["treatment", 523], ["for", 533], ["progressive", 537], ["scoliosis", 549], ["were", 559], ["reviewed", 564], [".", 572], ["The", 574], ["radiologic", 578], ["findings", 589], [",", 597], ["operative", 599], ["findings", 609], [",", 617], ["and", 619], ["perioperative", 623], ["complications", 637], ["were", 651], ["evaluated", 656], [".", 665], ["The", 667], ["mean", 671], ["preoperative", 676], ["Cobb", 689], ["angle", 694], ["was", 700], ["102.8\u00b116.9", 704], ["degrees", 715], [".", 722], ["The", 724], ["curve", 728], ["patterns", 734], ["were", 743], ["a", 748], ["double", 750], ["curve", 757], ["in", 763], ["2", 766], ["cases", 768], ["and", 774], ["a", 778], ["triple", 780], ["curve", 787], ["in", 793], ["2", 796], ["cases", 798], [".", 803], ["Local", 805], ["kyphosis", 811], ["at", 820], ["the", 823], ["thoracolumbar", 827], ["area", 841], ["was", 846], ["recognized", 850], ["in", 861], ["all", 864], ["the", 868], ["cases", 872], ["with", 878], ["a", 883], ["mean", 885], ["kyphosis", 890], ["angle", 899], ["of", 905], ["49\u00b116", 908], ["degrees", 914], [".", 921], ["Growing", 923], ["rod", 931], ["procedures", 935], ["were", 946], ["performed", 951], ["in", 961], ["2", 964], ["patients", 966], [",", 974], ["and", 976], ["posterior", 980], ["correction", 990], ["and", 1001], ["fusion", 1005], ["were", 1012], ["performed", 1017], ["in", 1027], ["2", 1030], ["patients", 1032], [".", 1040], ["The", 1042], ["mean", 1046], ["correction", 1051], ["rate", 1062], ["was", 1067], ["45", 1071], ["%", 1073], ["in", 1075], ["the", 1078], ["patients", 1082], ["who", 1091], ["underwent", 1095], ["the", 1105], ["growing", 1109], ["rod", 1117], ["procedures", 1121], ["at", 1132], ["the", 1135], ["time", 1139], ["of", 1144], ["growing", 1147], ["rod", 1155], ["placement", 1159], ["and", 1169], ["51", 1173], ["%", 1175], ["in", 1177], ["the", 1180], ["patients", 1184], ["who", 1193], ["underwent", 1197], ["posterior", 1207], ["correction", 1217], ["and", 1228], ["fusion", 1232], [".", 1238], ["Dislodgement", 1240], ["of", 1253], ["the", 1256], ["proximal", 1260], ["anchors", 1269], ["occurred", 1277], ["in", 1286], ["3", 1289], ["of", 1291], ["the", 1294], ["4", 1298], ["patients", 1300], [".", 1308], ["One", 1310], ["patient", 1314], ["developed", 1322], ["pseudoarthrosis", 1332], [".", 1347], ["Two", 1349], ["patients", 1353], ["developed", 1362], ["deep", 1372], ["wound", 1377], ["infections", 1383], [",", 1393], ["and", 1395], ["implant", 1399], ["removal", 1407], ["was", 1415], ["necessary", 1419], ["in", 1429], ["1", 1432], ["patient", 1434], [".", 1441], ["Surgical", 1443], ["treatment", 1452], ["for", 1462], ["scoliosis", 1466], ["in", 1476], ["patients", 1479], ["with", 1488], ["SGS", 1493], ["was", 1497], ["associated", 1501], ["with", 1512], ["a", 1517], ["high", 1519], ["incidence", 1524], ["of", 1534], ["perioperative", 1537], ["and", 1551], ["postoperative", 1555], ["complications", 1569], ["including", 1583], ["implant", 1593], ["dislodgements", 1601], ["and", 1615], ["deep", 1619], ["wound", 1624], ["infections", 1630], ["attributable", 1641], ["to", 1654], ["poor", 1657], ["bone", 1662], ["quality", 1667], ["and", 1675], ["a", 1679], ["thin", 1681], ["body", 1686], ["habitus", 1691], [",", 1698], ["which", 1700], ["are", 1706], ["characteristic", 1710], ["clinical", 1725], ["features", 1734], ["of", 1743], ["this", 1746], ["syndrome", 1751], [".", 1759], ["Careful", 1761], ["preoperative", 1769], ["surgical", 1782], ["planning", 1791], ["and", 1800], ["postoperative", 1804], ["care", 1818], ["are", 1823], ["critical", 1827], ["for", 1836], ["the", 1840], ["surgical", 1844], ["treatment", 1853], ["of", 1863], ["scoliosis", 1866], ["associated", 1876], ["with", 1887], ["SGS", 1892], [",", 1895], ["especially", 1897], ["in", 1908], ["infants", 1911], ["requiring", 1919], ["multiple", 1929], ["surgeries", 1938], [".", 1947], ["Level", 1949], ["IV", 1955], [".", 1957]]}
{"context": "Dasatinib (BMS-354825) is a Src/ABL tyrosine kinase inhibitor currently approved for the treatment of chronic myeloid leukemia. Dasatinib has increased potency against ABL compared to the current therapy imatinib, and is effective in many cases where disease is resistant to imatinib. Dasatinib also inhibits many Src-family tyrosine kinases. We have demonstrated in this study that dasatinib is able to block the function of normal human T-lymphocytes in vitro at clinically relevant concentrations. T-cell functions including proliferation, activation and cytokine production were all uniformly inhibited in the presence of dasatinib. We also demonstrated inhibition of TCR signalling through Src-family kinase LCK, and predicted that inhibition of LCK and other kinases involved in T-cell signalling by dasatinib is responsible for the suppression of T-cell function. These findings raise the concern about potential T-cell inhibition in patients taking dasatinib, and suggest a possible application for the treatment of T-cell mediated immune disorders.", "qas": [{"question": "Does dasatinib promote or inhibit T-cell proliferation?", "answers": ["inhibits"], "qid": "5b937d99df5342ca8ffb9a12ec8714ce", "question_tokens": [["Does", 0], ["dasatinib", 5], ["promote", 15], ["or", 23], ["inhibit", 26], ["T", 34], ["-", 35], ["cell", 36], ["proliferation", 41], ["?", 54]], "detected_answers": [{"text": "inhibits", "token_spans": [[50, 50]], "char_spans": [[300, 307]]}]}], "context_tokens": [["Dasatinib", 0], ["(", 10], ["BMS-354825", 11], [")", 21], ["is", 23], ["a", 26], ["Src", 28], ["/", 31], ["ABL", 32], ["tyrosine", 36], ["kinase", 45], ["inhibitor", 52], ["currently", 62], ["approved", 72], ["for", 81], ["the", 85], ["treatment", 89], ["of", 99], ["chronic", 102], ["myeloid", 110], ["leukemia", 118], [".", 126], ["Dasatinib", 128], ["has", 138], ["increased", 142], ["potency", 152], ["against", 160], ["ABL", 168], ["compared", 172], ["to", 181], ["the", 184], ["current", 188], ["therapy", 196], ["imatinib", 204], [",", 212], ["and", 214], ["is", 218], ["effective", 221], ["in", 231], ["many", 234], ["cases", 239], ["where", 245], ["disease", 251], ["is", 259], ["resistant", 262], ["to", 272], ["imatinib", 275], [".", 283], ["Dasatinib", 285], ["also", 295], ["inhibits", 300], ["many", 309], ["Src", 314], ["-", 317], ["family", 318], ["tyrosine", 325], ["kinases", 334], [".", 341], ["We", 343], ["have", 346], ["demonstrated", 351], ["in", 364], ["this", 367], ["study", 372], ["that", 378], ["dasatinib", 383], ["is", 393], ["able", 396], ["to", 401], ["block", 404], ["the", 410], ["function", 414], ["of", 423], ["normal", 426], ["human", 433], ["T", 439], ["-", 440], ["lymphocytes", 441], ["in", 453], ["vitro", 456], ["at", 462], ["clinically", 465], ["relevant", 476], ["concentrations", 485], [".", 499], ["T", 501], ["-", 502], ["cell", 503], ["functions", 508], ["including", 518], ["proliferation", 528], [",", 541], ["activation", 543], ["and", 554], ["cytokine", 558], ["production", 567], ["were", 578], ["all", 583], ["uniformly", 587], ["inhibited", 597], ["in", 607], ["the", 610], ["presence", 614], ["of", 623], ["dasatinib", 626], [".", 635], ["We", 637], ["also", 640], ["demonstrated", 645], ["inhibition", 658], ["of", 669], ["TCR", 672], ["signalling", 676], ["through", 687], ["Src", 695], ["-", 698], ["family", 699], ["kinase", 706], ["LCK", 713], [",", 716], ["and", 718], ["predicted", 722], ["that", 732], ["inhibition", 737], ["of", 748], ["LCK", 751], ["and", 755], ["other", 759], ["kinases", 765], ["involved", 773], ["in", 782], ["T", 785], ["-", 786], ["cell", 787], ["signalling", 792], ["by", 803], ["dasatinib", 806], ["is", 816], ["responsible", 819], ["for", 831], ["the", 835], ["suppression", 839], ["of", 851], ["T", 854], ["-", 855], ["cell", 856], ["function", 861], [".", 869], ["These", 871], ["findings", 877], ["raise", 886], ["the", 892], ["concern", 896], ["about", 904], ["potential", 910], ["T", 920], ["-", 921], ["cell", 922], ["inhibition", 927], ["in", 938], ["patients", 941], ["taking", 950], ["dasatinib", 957], [",", 966], ["and", 968], ["suggest", 972], ["a", 980], ["possible", 982], ["application", 991], ["for", 1003], ["the", 1007], ["treatment", 1011], ["of", 1021], ["T", 1024], ["-", 1025], ["cell", 1026], ["mediated", 1031], ["immune", 1040], ["disorders", 1047], [".", 1056]]}
{"context": "Tuberculosis (Tb) continues to be a dreadful infection worldwide with nearly 1.5 million deaths in 2013. Furthermore multi/extensively drug-resistant Tb (MDR/XDR-Tb) worsens the condition. Recently approved anti-Tb drugs (bedaquiline and delamanid) have the potential to induce arrhythmia and are recommended in patients with MDR-Tb when other alternatives fail. The goal of elimination of Tb by 2050 will not be achieved without an effective new vaccine. The recent advancement in the development of Tb vaccines is the keen focus of this review. To date, Bacille Calmette Guerin (BCG) is the only licensed Tb vaccine in use, however its efficacy in pulmonary Tb is variable in adolescents and adults. There are nearly 15 vaccine candidates in various phases of clinical trials, includes five protein or adjuvant vaccines, four viral-vectored vaccines, three mycobacterial whole cell or extract vaccines, and one each of the recombinant live and the attenuated Mycobacterium tuberculosis (Mtb) vaccine.", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "70def1204d7c4c8eacdf2cc36356ec55", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[0, 0], [180, 180]], "char_spans": [[0, 11], [975, 986]]}]}], "context_tokens": [["Tuberculosis", 0], ["(", 13], ["Tb", 14], [")", 16], ["continues", 18], ["to", 28], ["be", 31], ["a", 34], ["dreadful", 36], ["infection", 45], ["worldwide", 55], ["with", 65], ["nearly", 70], ["1.5", 77], ["million", 81], ["deaths", 89], ["in", 96], ["2013", 99], [".", 103], ["Furthermore", 105], ["multi", 117], ["/", 122], ["extensively", 123], ["drug", 135], ["-", 139], ["resistant", 140], ["Tb", 150], ["(", 153], ["MDR", 154], ["/", 157], ["XDR", 158], ["-", 161], ["Tb", 162], [")", 164], ["worsens", 166], ["the", 174], ["condition", 178], [".", 187], ["Recently", 189], ["approved", 198], ["anti", 207], ["-", 211], ["Tb", 212], ["drugs", 215], ["(", 221], ["bedaquiline", 222], ["and", 234], ["delamanid", 238], [")", 247], ["have", 249], ["the", 254], ["potential", 258], ["to", 268], ["induce", 271], ["arrhythmia", 278], ["and", 289], ["are", 293], ["recommended", 297], ["in", 309], ["patients", 312], ["with", 321], ["MDR", 326], ["-", 329], ["Tb", 330], ["when", 333], ["other", 338], ["alternatives", 344], ["fail", 357], [".", 361], ["The", 363], ["goal", 367], ["of", 372], ["elimination", 375], ["of", 387], ["Tb", 390], ["by", 393], ["2050", 396], ["will", 401], ["not", 406], ["be", 410], ["achieved", 413], ["without", 422], ["an", 430], ["effective", 433], ["new", 443], ["vaccine", 447], [".", 454], ["The", 456], ["recent", 460], ["advancement", 467], ["in", 479], ["the", 482], ["development", 486], ["of", 498], ["Tb", 501], ["vaccines", 504], ["is", 513], ["the", 516], ["keen", 520], ["focus", 525], ["of", 531], ["this", 534], ["review", 539], [".", 545], ["To", 547], ["date", 550], [",", 554], ["Bacille", 556], ["Calmette", 564], ["Guerin", 573], ["(", 580], ["BCG", 581], [")", 584], ["is", 586], ["the", 589], ["only", 593], ["licensed", 598], ["Tb", 607], ["vaccine", 610], ["in", 618], ["use", 621], [",", 624], ["however", 626], ["its", 634], ["efficacy", 638], ["in", 647], ["pulmonary", 650], ["Tb", 660], ["is", 663], ["variable", 666], ["in", 675], ["adolescents", 678], ["and", 690], ["adults", 694], [".", 700], ["There", 702], ["are", 708], ["nearly", 712], ["15", 719], ["vaccine", 722], ["candidates", 730], ["in", 741], ["various", 744], ["phases", 752], ["of", 759], ["clinical", 762], ["trials", 771], [",", 777], ["includes", 779], ["five", 788], ["protein", 793], ["or", 801], ["adjuvant", 804], ["vaccines", 813], [",", 821], ["four", 823], ["viral", 828], ["-", 833], ["vectored", 834], ["vaccines", 843], [",", 851], ["three", 853], ["mycobacterial", 859], ["whole", 873], ["cell", 879], ["or", 884], ["extract", 887], ["vaccines", 895], [",", 903], ["and", 905], ["one", 909], ["each", 913], ["of", 918], ["the", 921], ["recombinant", 925], ["live", 937], ["and", 942], ["the", 946], ["attenuated", 950], ["Mycobacterium", 961], ["tuberculosis", 975], ["(", 988], ["Mtb", 989], [")", 992], ["vaccine", 994], [".", 1001]]}
{"context": "Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is triggered by constitutively activated BCR-ABL and SRC family tyrosine kinases.They account for the activations of multiple growth-signaling pathways, including Raf/MEK/ERK, Akt/mTOR and STAT5 pathways. The BCR-ABL tyrosine kinase inhibitor imatinib is the standard treatment for Ph+ leukemia and plays efficacious role in CML. However, imatinib has few inhibitory effects on SRC tyrosine kinase with response rate of Ph+ ALL lower and relapse more frequent and quicker compared with CML. Previous studies showed that oridonin inhibits proliferation and induces apoptosis in many tumor cells. However, the anticancer activity and mechanism of oridonin in Ph+ ALL is unknown. To investigate the anticancer activity of oridonin, we examined its role in constitutively activated Akt/mTOR, Raf/MEK/ERK, STAT5 and SRC pathway, mRNA level of bcr/abl gene, cell viability and apoptosis in Ph+ ALL SUP-B15 cells. Furthermore, we detected synergetic effect of oridonin plus imatinib. Our results showed that oridonin inhibiting activations of LYN (one of SRC family kinases) and ABL and their downstream Akt/mTOR, Raf/MEK/ERK and STAT5 pathways, downregulated Bcl-2 but upregulated Bax protein and then induced apoptosis in Ph+ ALL cells. Oridonin plus imatinib exerted synergetic effects by overcoming imatinib defect of upregulating Akt/mTOR and LYN signaling. Additionally, we examined the effect of oridonin on the signaling pathways in the primary specimens from Ph+ ALL patients. Our data showed that oridonin remarkably suppressed activations of Akt/mTOR, Raf/MEK and STAT5 pathway in these primary specimens and oridonin with imatinib exerted synergetic suppressive effects on mTOR, STAT5 and LYN signaling in one imatinib resistant patient specimen. Additional evaluation of oridonin as a potential therapeutic agent for Ph+ ALL seems warranted.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "86cf7cabdc464986812d7f76361ff136", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[52, 54], [16, 18], [164, 166]], "char_spans": [[281, 287], [113, 119], [910, 916]]}]}], "context_tokens": [["Philadelphia", 0], ["chromosome", 13], ["-", 23], ["positive", 24], ["acute", 33], ["lymphoblastic", 39], ["leukemia", 53], ["(", 62], ["Ph+", 63], ["ALL", 67], [")", 70], ["is", 72], ["triggered", 75], ["by", 85], ["constitutively", 88], ["activated", 103], ["BCR", 113], ["-", 116], ["ABL", 117], ["and", 121], ["SRC", 125], ["family", 129], ["tyrosine", 136], ["kinases", 145], [".", 152], ["They", 153], ["account", 158], ["for", 166], ["the", 170], ["activations", 174], ["of", 186], ["multiple", 189], ["growth", 198], ["-", 204], ["signaling", 205], ["pathways", 215], [",", 223], ["including", 225], ["Raf", 235], ["/", 238], ["MEK", 239], ["/", 242], ["ERK", 243], [",", 246], ["Akt", 248], ["/", 251], ["mTOR", 252], ["and", 257], ["STAT5", 261], ["pathways", 267], [".", 275], ["The", 277], ["BCR", 281], ["-", 284], ["ABL", 285], ["tyrosine", 289], ["kinase", 298], ["inhibitor", 305], ["imatinib", 315], ["is", 324], ["the", 327], ["standard", 331], ["treatment", 340], ["for", 350], ["Ph+", 354], ["leukemia", 358], ["and", 367], ["plays", 371], ["efficacious", 377], ["role", 389], ["in", 394], ["CML", 397], [".", 400], ["However", 402], [",", 409], ["imatinib", 411], ["has", 420], ["few", 424], ["inhibitory", 428], ["effects", 439], ["on", 447], ["SRC", 450], ["tyrosine", 454], ["kinase", 463], ["with", 470], ["response", 475], ["rate", 484], ["of", 489], ["Ph+", 492], ["ALL", 496], ["lower", 500], ["and", 506], ["relapse", 510], ["more", 518], ["frequent", 523], ["and", 532], ["quicker", 536], ["compared", 544], ["with", 553], ["CML", 558], [".", 561], ["Previous", 563], ["studies", 572], ["showed", 580], ["that", 587], ["oridonin", 592], ["inhibits", 601], ["proliferation", 610], ["and", 624], ["induces", 628], ["apoptosis", 636], ["in", 646], ["many", 649], ["tumor", 654], ["cells", 660], [".", 665], ["However", 667], [",", 674], ["the", 676], ["anticancer", 680], ["activity", 691], ["and", 700], ["mechanism", 704], ["of", 714], ["oridonin", 717], ["in", 726], ["Ph+", 729], ["ALL", 733], ["is", 737], ["unknown", 740], [".", 747], ["To", 749], ["investigate", 752], ["the", 764], ["anticancer", 768], ["activity", 779], ["of", 788], ["oridonin", 791], [",", 799], ["we", 801], ["examined", 804], ["its", 813], ["role", 817], ["in", 822], ["constitutively", 825], ["activated", 840], ["Akt", 850], ["/", 853], ["mTOR", 854], [",", 858], ["Raf", 860], ["/", 863], ["MEK", 864], ["/", 867], ["ERK", 868], [",", 871], ["STAT5", 873], ["and", 879], ["SRC", 883], ["pathway", 887], [",", 894], ["mRNA", 896], ["level", 901], ["of", 907], ["bcr", 910], ["/", 913], ["abl", 914], ["gene", 918], [",", 922], ["cell", 924], ["viability", 929], ["and", 939], ["apoptosis", 943], ["in", 953], ["Ph+", 956], ["ALL", 960], ["SUP", 964], ["-", 967], ["B15", 968], ["cells", 972], [".", 977], ["Furthermore", 979], [",", 990], ["we", 992], ["detected", 995], ["synergetic", 1004], ["effect", 1015], ["of", 1022], ["oridonin", 1025], ["plus", 1034], ["imatinib", 1039], [".", 1047], ["Our", 1049], ["results", 1053], ["showed", 1061], ["that", 1068], ["oridonin", 1073], ["inhibiting", 1082], ["activations", 1093], ["of", 1105], ["LYN", 1108], ["(", 1112], ["one", 1113], ["of", 1117], ["SRC", 1120], ["family", 1124], ["kinases", 1131], [")", 1138], ["and", 1140], ["ABL", 1144], ["and", 1148], ["their", 1152], ["downstream", 1158], ["Akt", 1169], ["/", 1172], ["mTOR", 1173], [",", 1177], ["Raf", 1179], ["/", 1182], ["MEK", 1183], ["/", 1186], ["ERK", 1187], ["and", 1191], ["STAT5", 1195], ["pathways", 1201], [",", 1209], ["downregulated", 1211], ["Bcl-2", 1225], ["but", 1231], ["upregulated", 1235], ["Bax", 1247], ["protein", 1251], ["and", 1259], ["then", 1263], ["induced", 1268], ["apoptosis", 1276], ["in", 1286], ["Ph+", 1289], ["ALL", 1293], ["cells", 1297], [".", 1302], ["Oridonin", 1304], ["plus", 1313], ["imatinib", 1318], ["exerted", 1327], ["synergetic", 1335], ["effects", 1346], ["by", 1354], ["overcoming", 1357], ["imatinib", 1368], ["defect", 1377], ["of", 1384], ["upregulating", 1387], ["Akt", 1400], ["/", 1403], ["mTOR", 1404], ["and", 1409], ["LYN", 1413], ["signaling", 1417], [".", 1426], ["Additionally", 1428], [",", 1440], ["we", 1442], ["examined", 1445], ["the", 1454], ["effect", 1458], ["of", 1465], ["oridonin", 1468], ["on", 1477], ["the", 1480], ["signaling", 1484], ["pathways", 1494], ["in", 1503], ["the", 1506], ["primary", 1510], ["specimens", 1518], ["from", 1528], ["Ph+", 1533], ["ALL", 1537], ["patients", 1541], [".", 1549], ["Our", 1551], ["data", 1555], ["showed", 1560], ["that", 1567], ["oridonin", 1572], ["remarkably", 1581], ["suppressed", 1592], ["activations", 1603], ["of", 1615], ["Akt", 1618], ["/", 1621], ["mTOR", 1622], [",", 1626], ["Raf", 1628], ["/", 1631], ["MEK", 1632], ["and", 1636], ["STAT5", 1640], ["pathway", 1646], ["in", 1654], ["these", 1657], ["primary", 1663], ["specimens", 1671], ["and", 1681], ["oridonin", 1685], ["with", 1694], ["imatinib", 1699], ["exerted", 1708], ["synergetic", 1716], ["suppressive", 1727], ["effects", 1739], ["on", 1747], ["mTOR", 1750], [",", 1754], ["STAT5", 1756], ["and", 1762], ["LYN", 1766], ["signaling", 1770], ["in", 1780], ["one", 1783], ["imatinib", 1787], ["resistant", 1796], ["patient", 1806], ["specimen", 1814], [".", 1822], ["Additional", 1824], ["evaluation", 1835], ["of", 1846], ["oridonin", 1849], ["as", 1858], ["a", 1861], ["potential", 1863], ["therapeutic", 1873], ["agent", 1885], ["for", 1891], ["Ph+", 1895], ["ALL", 1899], ["seems", 1903], ["warranted", 1909], [".", 1918]]}
{"context": "The classical view of the molecular clock is based on interlocked transcriptional-translational feedback loops. Because a substantial fraction of the mammalian genome is expressed in a circadian manner, chromatin remodeling has been proposed to be crucial in clock function. Here we show that Lys4 (K4) trimethylation of histone H3 is rhythmic and follows the same profile as previously described H3 acetylation on circadian promoters. MLL1, a mammalian homolog of Drosophila trithorax, is an H3K4-specific methyltransferase implicated in transcriptional control. We demonstrate that MLL1 is essential for circadian transcription and cyclic H3K4 trimethylation. MLL1 is in a complex with CLOCK-BMAL1 and contributes to its rhythmic recruitment to circadian promoters and to H3 acetylation. Yet MLL1 fails to interact with CLOCK\u039419, providing an explanation for this mutation's dominant negative phenotype. Our results favor a scenario in which H3K4 trimethylation by MLL1 is required to establish a permissive chromatin state for circadian transcription.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "795cf9fac2ef407ba53defde51145ed3", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[153, 153], [101, 101]], "char_spans": [[944, 947], [641, 644]]}]}], "context_tokens": [["The", 0], ["classical", 4], ["view", 14], ["of", 19], ["the", 22], ["molecular", 26], ["clock", 36], ["is", 42], ["based", 45], ["on", 51], ["interlocked", 54], ["transcriptional", 66], ["-", 81], ["translational", 82], ["feedback", 96], ["loops", 105], [".", 110], ["Because", 112], ["a", 120], ["substantial", 122], ["fraction", 134], ["of", 143], ["the", 146], ["mammalian", 150], ["genome", 160], ["is", 167], ["expressed", 170], ["in", 180], ["a", 183], ["circadian", 185], ["manner", 195], [",", 201], ["chromatin", 203], ["remodeling", 213], ["has", 224], ["been", 228], ["proposed", 233], ["to", 242], ["be", 245], ["crucial", 248], ["in", 256], ["clock", 259], ["function", 265], [".", 273], ["Here", 275], ["we", 280], ["show", 283], ["that", 288], ["Lys4", 293], ["(", 298], ["K4", 299], [")", 301], ["trimethylation", 303], ["of", 318], ["histone", 321], ["H3", 329], ["is", 332], ["rhythmic", 335], ["and", 344], ["follows", 348], ["the", 356], ["same", 360], ["profile", 365], ["as", 373], ["previously", 376], ["described", 387], ["H3", 397], ["acetylation", 400], ["on", 412], ["circadian", 415], ["promoters", 425], [".", 434], ["MLL1", 436], [",", 440], ["a", 442], ["mammalian", 444], ["homolog", 454], ["of", 462], ["Drosophila", 465], ["trithorax", 476], [",", 485], ["is", 487], ["an", 490], ["H3K4-specific", 493], ["methyltransferase", 507], ["implicated", 525], ["in", 536], ["transcriptional", 539], ["control", 555], [".", 562], ["We", 564], ["demonstrate", 567], ["that", 579], ["MLL1", 584], ["is", 589], ["essential", 592], ["for", 602], ["circadian", 606], ["transcription", 616], ["and", 630], ["cyclic", 634], ["H3K4", 641], ["trimethylation", 646], [".", 660], ["MLL1", 662], ["is", 667], ["in", 670], ["a", 673], ["complex", 675], ["with", 683], ["CLOCK", 688], ["-", 693], ["BMAL1", 694], ["and", 700], ["contributes", 704], ["to", 716], ["its", 719], ["rhythmic", 723], ["recruitment", 732], ["to", 744], ["circadian", 747], ["promoters", 757], ["and", 767], ["to", 771], ["H3", 774], ["acetylation", 777], [".", 788], ["Yet", 790], ["MLL1", 794], ["fails", 799], ["to", 805], ["interact", 808], ["with", 817], ["CLOCK\u039419", 822], [",", 830], ["providing", 832], ["an", 842], ["explanation", 845], ["for", 857], ["this", 861], ["mutation", 866], ["'s", 874], ["dominant", 877], ["negative", 886], ["phenotype", 895], [".", 904], ["Our", 906], ["results", 910], ["favor", 918], ["a", 924], ["scenario", 926], ["in", 935], ["which", 938], ["H3K4", 944], ["trimethylation", 949], ["by", 964], ["MLL1", 967], ["is", 972], ["required", 975], ["to", 984], ["establish", 987], ["a", 997], ["permissive", 999], ["chromatin", 1010], ["state", 1020], ["for", 1026], ["circadian", 1030], ["transcription", 1040], [".", 1053]]}
{"context": "Restless leg syndrome (RLS) and periodic limb movement disorder (PLMD) are considered to be a continuum of a neurological sleep disorder associated with abnormal iron metabolism or deficiency. I describe a case of RLS and PLMD in a cystic fibrosis patient with iron deficiency from chronic hemoptysis. This is the first case that reports RLS and PLMD manifesting from iron deficiency caused by chronic hemoptysis in advanced cystic fibrosis lung disease.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "cecd920cbb724d98aaf99c70c2dcc371", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[65, 65], [28, 28], [47, 47]], "char_spans": [[368, 371], [162, 165], [261, 264]]}]}], "context_tokens": [["Restless", 0], ["leg", 9], ["syndrome", 13], ["(", 22], ["RLS", 23], [")", 26], ["and", 28], ["periodic", 32], ["limb", 41], ["movement", 46], ["disorder", 55], ["(", 64], ["PLMD", 65], [")", 69], ["are", 71], ["considered", 75], ["to", 86], ["be", 89], ["a", 92], ["continuum", 94], ["of", 104], ["a", 107], ["neurological", 109], ["sleep", 122], ["disorder", 128], ["associated", 137], ["with", 148], ["abnormal", 153], ["iron", 162], ["metabolism", 167], ["or", 178], ["deficiency", 181], [".", 191], ["I", 193], ["describe", 195], ["a", 204], ["case", 206], ["of", 211], ["RLS", 214], ["and", 218], ["PLMD", 222], ["in", 227], ["a", 230], ["cystic", 232], ["fibrosis", 239], ["patient", 248], ["with", 256], ["iron", 261], ["deficiency", 266], ["from", 277], ["chronic", 282], ["hemoptysis", 290], [".", 300], ["This", 302], ["is", 307], ["the", 310], ["first", 314], ["case", 320], ["that", 325], ["reports", 330], ["RLS", 338], ["and", 342], ["PLMD", 346], ["manifesting", 351], ["from", 363], ["iron", 368], ["deficiency", 373], ["caused", 384], ["by", 391], ["chronic", 394], ["hemoptysis", 402], ["in", 413], ["advanced", 416], ["cystic", 425], ["fibrosis", 432], ["lung", 441], ["disease", 446], [".", 453]]}
{"context": "Ehlers-Danlos syndromes (EDS) are a heterogeneous group of hereditary connective tissue disorders characterized by joint hypermobility, widespread musculoskeletal pain and tissue fragility. Psychiatric disorders and psychosocial impairment are common, yet poorly characterized, findings in EDS patients. We investigated the frequency and types of psychiatric disorders and their relationship to systemic manifestations in a cohort of 106 classic and hypermobility type EDS patients. In this retrospective study, extensive medical chart review was performed for patients referred at two genetics clinics who were diagnosed with EDS. Statistical analysis was undertaken to determine the frequency of psychiatric disorders and association with systemic findings. Psychiatric disorders were found in 42.5% of the EDS cohort, with 22.7% of patients affected with 2 or more psychiatric diagnoses. Anxiety and depression were most commonly reported, with frequencies of 23.6 and 25.5%, respectively. A variety of other psychiatric diagnoses were also identified. Abdominal pain [odds ratio (OR) 7.38], neuropathic pain (OR 4.07), migraines (OR 5.21), joint pain (OR 2.85) and fatigue (OR 5.55) were significantly associated with the presence of a psychiatric disorder. The presence of any pain symptom was significantly associated with having a psychiatric disorder (OR 9.68). Muscle pain (OR 2.79), abdominal pain (OR 5.78), neuropathic pain (OR 3.91), migraines (OR 2.63) and fatigue (OR 3.78) were significantly associated with having an anxiety or mood disorder. Joint hypermobility and the classic dermatological features of EDS showed no significant association with having a psychiatric disorder. Our findings demonstrate a high frequency of psychiatric disorders and an association with pain symptoms in EDS.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "09a953250a1f4db4816c782183c4fa89", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14]], "char_spans": [[70, 86]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndromes", 14], ["(", 24], ["EDS", 25], [")", 28], ["are", 30], ["a", 34], ["heterogeneous", 36], ["group", 50], ["of", 56], ["hereditary", 59], ["connective", 70], ["tissue", 81], ["disorders", 88], ["characterized", 98], ["by", 112], ["joint", 115], ["hypermobility", 121], [",", 134], ["widespread", 136], ["musculoskeletal", 147], ["pain", 163], ["and", 168], ["tissue", 172], ["fragility", 179], [".", 188], ["Psychiatric", 190], ["disorders", 202], ["and", 212], ["psychosocial", 216], ["impairment", 229], ["are", 240], ["common", 244], [",", 250], ["yet", 252], ["poorly", 256], ["characterized", 263], [",", 276], ["findings", 278], ["in", 287], ["EDS", 290], ["patients", 294], [".", 302], ["We", 304], ["investigated", 307], ["the", 320], ["frequency", 324], ["and", 334], ["types", 338], ["of", 344], ["psychiatric", 347], ["disorders", 359], ["and", 369], ["their", 373], ["relationship", 379], ["to", 392], ["systemic", 395], ["manifestations", 404], ["in", 419], ["a", 422], ["cohort", 424], ["of", 431], ["106", 434], ["classic", 438], ["and", 446], ["hypermobility", 450], ["type", 464], ["EDS", 469], ["patients", 473], [".", 481], ["In", 483], ["this", 486], ["retrospective", 491], ["study", 505], [",", 510], ["extensive", 512], ["medical", 522], ["chart", 530], ["review", 536], ["was", 543], ["performed", 547], ["for", 557], ["patients", 561], ["referred", 570], ["at", 579], ["two", 582], ["genetics", 586], ["clinics", 595], ["who", 603], ["were", 607], ["diagnosed", 612], ["with", 622], ["EDS", 627], [".", 630], ["Statistical", 632], ["analysis", 644], ["was", 653], ["undertaken", 657], ["to", 668], ["determine", 671], ["the", 681], ["frequency", 685], ["of", 695], ["psychiatric", 698], ["disorders", 710], ["and", 720], ["association", 724], ["with", 736], ["systemic", 741], ["findings", 750], [".", 758], ["Psychiatric", 760], ["disorders", 772], ["were", 782], ["found", 787], ["in", 793], ["42.5", 796], ["%", 800], ["of", 802], ["the", 805], ["EDS", 809], ["cohort", 813], [",", 819], ["with", 821], ["22.7", 826], ["%", 830], ["of", 832], ["patients", 835], ["affected", 844], ["with", 853], ["2", 858], ["or", 860], ["more", 863], ["psychiatric", 868], ["diagnoses", 880], [".", 889], ["Anxiety", 891], ["and", 899], ["depression", 903], ["were", 914], ["most", 919], ["commonly", 924], ["reported", 933], [",", 941], ["with", 943], ["frequencies", 948], ["of", 960], ["23.6", 963], ["and", 968], ["25.5", 972], ["%", 976], [",", 977], ["respectively", 979], [".", 991], ["A", 993], ["variety", 995], ["of", 1003], ["other", 1006], ["psychiatric", 1012], ["diagnoses", 1024], ["were", 1034], ["also", 1039], ["identified", 1044], [".", 1054], ["Abdominal", 1056], ["pain", 1066], ["[", 1071], ["odds", 1072], ["ratio", 1077], ["(", 1083], ["OR", 1084], [")", 1086], ["7.38", 1088], ["]", 1092], [",", 1093], ["neuropathic", 1095], ["pain", 1107], ["(", 1112], ["OR", 1113], ["4.07", 1116], [")", 1120], [",", 1121], ["migraines", 1123], ["(", 1133], ["OR", 1134], ["5.21", 1137], [")", 1141], [",", 1142], ["joint", 1144], ["pain", 1150], ["(", 1155], ["OR", 1156], ["2.85", 1159], [")", 1163], ["and", 1165], ["fatigue", 1169], ["(", 1177], ["OR", 1178], ["5.55", 1181], [")", 1185], ["were", 1187], ["significantly", 1192], ["associated", 1206], ["with", 1217], ["the", 1222], ["presence", 1226], ["of", 1235], ["a", 1238], ["psychiatric", 1240], ["disorder", 1252], [".", 1260], ["The", 1262], ["presence", 1266], ["of", 1275], ["any", 1278], ["pain", 1282], ["symptom", 1287], ["was", 1295], ["significantly", 1299], ["associated", 1313], ["with", 1324], ["having", 1329], ["a", 1336], ["psychiatric", 1338], ["disorder", 1350], ["(", 1359], ["OR", 1360], ["9.68", 1363], [")", 1367], [".", 1368], ["Muscle", 1370], ["pain", 1377], ["(", 1382], ["OR", 1383], ["2.79", 1386], [")", 1390], [",", 1391], ["abdominal", 1393], ["pain", 1403], ["(", 1408], ["OR", 1409], ["5.78", 1412], [")", 1416], [",", 1417], ["neuropathic", 1419], ["pain", 1431], ["(", 1436], ["OR", 1437], ["3.91", 1440], [")", 1444], [",", 1445], ["migraines", 1447], ["(", 1457], ["OR", 1458], ["2.63", 1461], [")", 1465], ["and", 1467], ["fatigue", 1471], ["(", 1479], ["OR", 1480], ["3.78", 1483], [")", 1487], ["were", 1489], ["significantly", 1494], ["associated", 1508], ["with", 1519], ["having", 1524], ["an", 1531], ["anxiety", 1534], ["or", 1542], ["mood", 1545], ["disorder", 1550], [".", 1558], ["Joint", 1560], ["hypermobility", 1566], ["and", 1580], ["the", 1584], ["classic", 1588], ["dermatological", 1596], ["features", 1611], ["of", 1620], ["EDS", 1623], ["showed", 1627], ["no", 1634], ["significant", 1637], ["association", 1649], ["with", 1661], ["having", 1666], ["a", 1673], ["psychiatric", 1675], ["disorder", 1687], [".", 1695], ["Our", 1697], ["findings", 1701], ["demonstrate", 1710], ["a", 1722], ["high", 1724], ["frequency", 1729], ["of", 1739], ["psychiatric", 1742], ["disorders", 1754], ["and", 1764], ["an", 1768], ["association", 1771], ["with", 1783], ["pain", 1788], ["symptoms", 1793], ["in", 1802], ["EDS", 1805], [".", 1808]]}
{"context": "Treslin/TICRR (TopBP1-interacting, replication stimulating protein/TopBP1-interacting, checkpoint, and replication regulator), the human ortholog of the yeast Sld3 protein, is an essential DNA replication factor that is regulated by cyclin-dependent kinases and the DNA damage checkpoint. We identified MDM two binding protein (MTBP) as a factor that interacts with Treslin/TICRR throughout the cell cycle. We show that MTBP depletion by means of small interfering RNA inhibits DNA replication by preventing assembly of the CMG (Cdc45-MCM-GINS) holohelicase during origin firing. Although MTBP has been implicated in the function of the p53 tumor suppressor, we found MTBP is required for DNA replication irrespective of a cell's p53 status. We propose that MTBP acts with Treslin/TICRR to integrate signals from cell cycle and DNA damage response pathways to control the initiation of DNA replication in human cells.", "qas": [{"question": "Which factor interacts with Treslin/TICRR throughout the cell cycle of human cells?", "answers": ["MDM two binding protein (MTBP)"], "qid": "470f42e7c572482a84dd8e9d4a279059", "question_tokens": [["Which", 0], ["factor", 6], ["interacts", 13], ["with", 23], ["Treslin", 28], ["/", 35], ["TICRR", 36], ["throughout", 42], ["the", 53], ["cell", 57], ["cycle", 62], ["of", 68], ["human", 71], ["cells", 77], ["?", 82]], "detected_answers": [{"text": "MDM two binding protein (MTBP)", "token_spans": [[50, 55]], "char_spans": [[303, 331]]}]}], "context_tokens": [["Treslin", 0], ["/", 7], ["TICRR", 8], ["(", 14], ["TopBP1-interacting", 15], [",", 33], ["replication", 35], ["stimulating", 47], ["protein", 59], ["/", 66], ["TopBP1-interacting", 67], [",", 85], ["checkpoint", 87], [",", 97], ["and", 99], ["replication", 103], ["regulator", 115], [")", 124], [",", 125], ["the", 127], ["human", 131], ["ortholog", 137], ["of", 146], ["the", 149], ["yeast", 153], ["Sld3", 159], ["protein", 164], [",", 171], ["is", 173], ["an", 176], ["essential", 179], ["DNA", 189], ["replication", 193], ["factor", 205], ["that", 212], ["is", 217], ["regulated", 220], ["by", 230], ["cyclin", 233], ["-", 239], ["dependent", 240], ["kinases", 250], ["and", 258], ["the", 262], ["DNA", 266], ["damage", 270], ["checkpoint", 277], [".", 287], ["We", 289], ["identified", 292], ["MDM", 303], ["two", 307], ["binding", 311], ["protein", 319], ["(", 327], ["MTBP", 328], [")", 332], ["as", 334], ["a", 337], ["factor", 339], ["that", 346], ["interacts", 351], ["with", 361], ["Treslin", 366], ["/", 373], ["TICRR", 374], ["throughout", 380], ["the", 391], ["cell", 395], ["cycle", 400], [".", 405], ["We", 407], ["show", 410], ["that", 415], ["MTBP", 420], ["depletion", 425], ["by", 435], ["means", 438], ["of", 444], ["small", 447], ["interfering", 453], ["RNA", 465], ["inhibits", 469], ["DNA", 478], ["replication", 482], ["by", 494], ["preventing", 497], ["assembly", 508], ["of", 517], ["the", 520], ["CMG", 524], ["(", 528], ["Cdc45-MCM", 529], ["-", 538], ["GINS", 539], [")", 543], ["holohelicase", 545], ["during", 558], ["origin", 565], ["firing", 572], [".", 578], ["Although", 580], ["MTBP", 589], ["has", 594], ["been", 598], ["implicated", 603], ["in", 614], ["the", 617], ["function", 621], ["of", 630], ["the", 633], ["p53", 637], ["tumor", 641], ["suppressor", 647], [",", 657], ["we", 659], ["found", 662], ["MTBP", 668], ["is", 673], ["required", 676], ["for", 685], ["DNA", 689], ["replication", 693], ["irrespective", 705], ["of", 718], ["a", 721], ["cell", 723], ["'s", 727], ["p53", 730], ["status", 734], [".", 740], ["We", 742], ["propose", 745], ["that", 753], ["MTBP", 758], ["acts", 763], ["with", 768], ["Treslin", 773], ["/", 780], ["TICRR", 781], ["to", 787], ["integrate", 790], ["signals", 800], ["from", 808], ["cell", 813], ["cycle", 818], ["and", 824], ["DNA", 828], ["damage", 832], ["response", 839], ["pathways", 848], ["to", 857], ["control", 860], ["the", 868], ["initiation", 872], ["of", 883], ["DNA", 886], ["replication", 890], ["in", 902], ["human", 905], ["cells", 911], [".", 916]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited cerebrovascular disease due to mutations involving loss or gain of a cysteine residue in the NOTCH3 gene. A cluster of mutations around exons 3 and 4 was originally reported. Identification of pathogenic mutation is important for diagnostic confirmation of the disease, however genetic counselling and testing of relatives at risk is critical in mutation carriers. Mutation analysis of the NOTCH3 gene was performed through direct sequencing in 140 patients with clinical suspicion of CADASIL. Patients underwent genetic counselling pre and post testing. The 2-23 exons containing all EGF-like domains were screened. 14 familial forms of the disease have been identified with 14 different causative mutations in exons 2, 3, 4, 5, 7, 10, 14, 19, 20 and 22 of the NOTCH3 gene; no pathogenetic mutations have been identified in exons 6 and 8; several genetic variations both in coding as well as in intronic regions were identified too. Our data confirm the importance of screening the whole EGF-like domains region of NOTCH3 gene for the molecular diagnosis of CADASIL among the Italian population too. Moreover genetic variants different from loss or gain of a cysteine residue are identified and presented.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "18b6217da1e544f0816a04e6db73ff7d", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[224, 224], [26, 26]], "char_spans": [[1277, 1284], [186, 193]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["an", 104], ["inherited", 107], ["cerebrovascular", 117], ["disease", 133], ["due", 141], ["to", 145], ["mutations", 148], ["involving", 158], ["loss", 168], ["or", 173], ["gain", 176], ["of", 181], ["a", 184], ["cysteine", 186], ["residue", 195], ["in", 203], ["the", 206], ["NOTCH3", 210], ["gene", 217], [".", 221], ["A", 223], ["cluster", 225], ["of", 233], ["mutations", 236], ["around", 246], ["exons", 253], ["3", 259], ["and", 261], ["4", 265], ["was", 267], ["originally", 271], ["reported", 282], [".", 290], ["Identification", 292], ["of", 307], ["pathogenic", 310], ["mutation", 321], ["is", 330], ["important", 333], ["for", 343], ["diagnostic", 347], ["confirmation", 358], ["of", 371], ["the", 374], ["disease", 378], [",", 385], ["however", 387], ["genetic", 395], ["counselling", 403], ["and", 415], ["testing", 419], ["of", 427], ["relatives", 430], ["at", 440], ["risk", 443], ["is", 448], ["critical", 451], ["in", 460], ["mutation", 463], ["carriers", 472], [".", 480], ["Mutation", 482], ["analysis", 491], ["of", 500], ["the", 503], ["NOTCH3", 507], ["gene", 514], ["was", 519], ["performed", 523], ["through", 533], ["direct", 541], ["sequencing", 548], ["in", 559], ["140", 562], ["patients", 566], ["with", 575], ["clinical", 580], ["suspicion", 589], ["of", 599], ["CADASIL", 602], [".", 609], ["Patients", 611], ["underwent", 620], ["genetic", 630], ["counselling", 638], ["pre", 650], ["and", 654], ["post", 658], ["testing", 663], [".", 670], ["The", 672], ["2", 676], ["-", 677], ["23", 678], ["exons", 681], ["containing", 687], ["all", 698], ["EGF", 702], ["-", 705], ["like", 706], ["domains", 711], ["were", 719], ["screened", 724], [".", 732], ["14", 734], ["familial", 737], ["forms", 746], ["of", 752], ["the", 755], ["disease", 759], ["have", 767], ["been", 772], ["identified", 777], ["with", 788], ["14", 793], ["different", 796], ["causative", 806], ["mutations", 816], ["in", 826], ["exons", 829], ["2", 835], [",", 836], ["3", 838], [",", 839], ["4", 841], [",", 842], ["5", 844], [",", 845], ["7", 847], [",", 848], ["10", 850], [",", 852], ["14", 854], [",", 856], ["19", 858], [",", 860], ["20", 862], ["and", 865], ["22", 869], ["of", 872], ["the", 875], ["NOTCH3", 879], ["gene", 886], [";", 890], ["no", 892], ["pathogenetic", 895], ["mutations", 908], ["have", 918], ["been", 923], ["identified", 928], ["in", 939], ["exons", 942], ["6", 948], ["and", 950], ["8", 954], [";", 955], ["several", 957], ["genetic", 965], ["variations", 973], ["both", 984], ["in", 989], ["coding", 992], ["as", 999], ["well", 1002], ["as", 1007], ["in", 1010], ["intronic", 1013], ["regions", 1022], ["were", 1030], ["identified", 1035], ["too", 1046], [".", 1049], ["Our", 1051], ["data", 1055], ["confirm", 1060], ["the", 1068], ["importance", 1072], ["of", 1083], ["screening", 1086], ["the", 1096], ["whole", 1100], ["EGF", 1106], ["-", 1109], ["like", 1110], ["domains", 1115], ["region", 1123], ["of", 1130], ["NOTCH3", 1133], ["gene", 1140], ["for", 1145], ["the", 1149], ["molecular", 1153], ["diagnosis", 1163], ["of", 1173], ["CADASIL", 1176], ["among", 1184], ["the", 1190], ["Italian", 1194], ["population", 1202], ["too", 1213], [".", 1216], ["Moreover", 1218], ["genetic", 1227], ["variants", 1235], ["different", 1244], ["from", 1254], ["loss", 1259], ["or", 1264], ["gain", 1267], ["of", 1272], ["a", 1275], ["cysteine", 1277], ["residue", 1286], ["are", 1294], ["identified", 1298], ["and", 1309], ["presented", 1313], [".", 1322]]}
{"context": "A 54-y-old man ingested 2 g of bulk laboratory diazepam and was treated with activated charcoal, enhanced diuresis and flumazenil infusion. The treatment resulted in awakening, but the patient had drowsiness, dysarthria, diplopia, and dizziness for 9 d. Blood levels of diazepam and its main metabolite, nordiazepam, were obtained for 1 mo. The half-lives in this benzodiazepine overdose were longer than those seen with therapeutic doses. Benzodiazepines should not be readministrated when patients awake after suicide attempts.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "f11fbd28f9c1426ebef6f55f607da505", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[22, 22]], "char_spans": [[119, 128]]}]}], "context_tokens": [["A", 0], ["54-y", 2], ["-", 6], ["old", 7], ["man", 11], ["ingested", 15], ["2", 24], ["g", 26], ["of", 28], ["bulk", 31], ["laboratory", 36], ["diazepam", 47], ["and", 56], ["was", 60], ["treated", 64], ["with", 72], ["activated", 77], ["charcoal", 87], [",", 95], ["enhanced", 97], ["diuresis", 106], ["and", 115], ["flumazenil", 119], ["infusion", 130], [".", 138], ["The", 140], ["treatment", 144], ["resulted", 154], ["in", 163], ["awakening", 166], [",", 175], ["but", 177], ["the", 181], ["patient", 185], ["had", 193], ["drowsiness", 197], [",", 207], ["dysarthria", 209], [",", 219], ["diplopia", 221], [",", 229], ["and", 231], ["dizziness", 235], ["for", 245], ["9", 249], ["d.", 251], ["Blood", 254], ["levels", 260], ["of", 267], ["diazepam", 270], ["and", 279], ["its", 283], ["main", 287], ["metabolite", 292], [",", 302], ["nordiazepam", 304], [",", 315], ["were", 317], ["obtained", 322], ["for", 331], ["1", 335], ["mo", 337], [".", 339], ["The", 341], ["half", 345], ["-", 349], ["lives", 350], ["in", 356], ["this", 359], ["benzodiazepine", 364], ["overdose", 379], ["were", 388], ["longer", 393], ["than", 400], ["those", 405], ["seen", 411], ["with", 416], ["therapeutic", 421], ["doses", 433], [".", 438], ["Benzodiazepines", 440], ["should", 456], ["not", 463], ["be", 467], ["readministrated", 470], ["when", 486], ["patients", 491], ["awake", 500], ["after", 506], ["suicide", 512], ["attempts", 520], [".", 528]]}
{"context": "The complex expression patterns observed for many genes are often regulated by distal transcription enhancers. Changes in the nucleotide sequences of enhancers may therefore lead to changes in gene expression, representing a central mechanism by which organisms evolve. With the development of the experimental technique of chromatin immunoprecipitation (ChIP), in which discrete regions of the genome bound by specific proteins can be identified, it is now possible to identify transcription factor binding events (putative cis-regulatory elements) in entire genomes. Comparing protein-DNA binding maps allows us, for the first time, to attempt to identify regulatory differences and infer global patterns of change in gene expression across species. Here, we review studies that used genome-wide ChIP to study the evolution of enhancers. The trend is one of high divergence of cis-regulatory elements between species, possibly compensated by extensive creation and loss of regulatory elements and rewiring of their target genes. We speculate on the meaning of the differences observed and discuss that although ChIP experiments identify the biochemical event of protein-DNA interaction, it cannot determine whether the event results in a biological function, and therefore more studies are required to establish the effect of divergence of binding events on species-specific gene expression.", "qas": [{"question": "Are human enhancers or promoters evolving faster?", "answers": ["enhancers"], "qid": "2127733422e64157bc1703f3baf19fbd", "question_tokens": [["Are", 0], ["human", 4], ["enhancers", 10], ["or", 20], ["promoters", 23], ["evolving", 33], ["faster", 42], ["?", 48]], "detected_answers": [{"text": "enhancers", "token_spans": [[22, 22], [139, 139], [14, 14]], "char_spans": [[150, 158], [829, 837], [100, 108]]}]}], "context_tokens": [["The", 0], ["complex", 4], ["expression", 12], ["patterns", 23], ["observed", 32], ["for", 41], ["many", 45], ["genes", 50], ["are", 56], ["often", 60], ["regulated", 66], ["by", 76], ["distal", 79], ["transcription", 86], ["enhancers", 100], [".", 109], ["Changes", 111], ["in", 119], ["the", 122], ["nucleotide", 126], ["sequences", 137], ["of", 147], ["enhancers", 150], ["may", 160], ["therefore", 164], ["lead", 174], ["to", 179], ["changes", 182], ["in", 190], ["gene", 193], ["expression", 198], [",", 208], ["representing", 210], ["a", 223], ["central", 225], ["mechanism", 233], ["by", 243], ["which", 246], ["organisms", 252], ["evolve", 262], [".", 268], ["With", 270], ["the", 275], ["development", 279], ["of", 291], ["the", 294], ["experimental", 298], ["technique", 311], ["of", 321], ["chromatin", 324], ["immunoprecipitation", 334], ["(", 354], ["ChIP", 355], [")", 359], [",", 360], ["in", 362], ["which", 365], ["discrete", 371], ["regions", 380], ["of", 388], ["the", 391], ["genome", 395], ["bound", 402], ["by", 408], ["specific", 411], ["proteins", 420], ["can", 429], ["be", 433], ["identified", 436], [",", 446], ["it", 448], ["is", 451], ["now", 454], ["possible", 458], ["to", 467], ["identify", 470], ["transcription", 479], ["factor", 493], ["binding", 500], ["events", 508], ["(", 515], ["putative", 516], ["cis", 525], ["-", 528], ["regulatory", 529], ["elements", 540], [")", 548], ["in", 550], ["entire", 553], ["genomes", 560], [".", 567], ["Comparing", 569], ["protein", 579], ["-", 586], ["DNA", 587], ["binding", 591], ["maps", 599], ["allows", 604], ["us", 611], [",", 613], ["for", 615], ["the", 619], ["first", 623], ["time", 629], [",", 633], ["to", 635], ["attempt", 638], ["to", 646], ["identify", 649], ["regulatory", 658], ["differences", 669], ["and", 681], ["infer", 685], ["global", 691], ["patterns", 698], ["of", 707], ["change", 710], ["in", 717], ["gene", 720], ["expression", 725], ["across", 736], ["species", 743], [".", 750], ["Here", 752], [",", 756], ["we", 758], ["review", 761], ["studies", 768], ["that", 776], ["used", 781], ["genome", 786], ["-", 792], ["wide", 793], ["ChIP", 798], ["to", 803], ["study", 806], ["the", 812], ["evolution", 816], ["of", 826], ["enhancers", 829], [".", 838], ["The", 840], ["trend", 844], ["is", 850], ["one", 853], ["of", 857], ["high", 860], ["divergence", 865], ["of", 876], ["cis", 879], ["-", 882], ["regulatory", 883], ["elements", 894], ["between", 903], ["species", 911], [",", 918], ["possibly", 920], ["compensated", 929], ["by", 941], ["extensive", 944], ["creation", 954], ["and", 963], ["loss", 967], ["of", 972], ["regulatory", 975], ["elements", 986], ["and", 995], ["rewiring", 999], ["of", 1008], ["their", 1011], ["target", 1017], ["genes", 1024], [".", 1029], ["We", 1031], ["speculate", 1034], ["on", 1044], ["the", 1047], ["meaning", 1051], ["of", 1059], ["the", 1062], ["differences", 1066], ["observed", 1078], ["and", 1087], ["discuss", 1091], ["that", 1099], ["although", 1104], ["ChIP", 1113], ["experiments", 1118], ["identify", 1130], ["the", 1139], ["biochemical", 1143], ["event", 1155], ["of", 1161], ["protein", 1164], ["-", 1171], ["DNA", 1172], ["interaction", 1176], [",", 1187], ["it", 1189], ["can", 1192], ["not", 1195], ["determine", 1199], ["whether", 1209], ["the", 1217], ["event", 1221], ["results", 1227], ["in", 1235], ["a", 1238], ["biological", 1240], ["function", 1251], [",", 1259], ["and", 1261], ["therefore", 1265], ["more", 1275], ["studies", 1280], ["are", 1288], ["required", 1292], ["to", 1301], ["establish", 1304], ["the", 1314], ["effect", 1318], ["of", 1325], ["divergence", 1328], ["of", 1339], ["binding", 1342], ["events", 1350], ["on", 1357], ["species", 1360], ["-", 1367], ["specific", 1368], ["gene", 1377], ["expression", 1382], [".", 1392]]}
{"context": "Autonomic failure with Lewy bodies (AF-LB) was first described by Fichefet et al. in 1965, and more than ten cases have been reported to date. AF-LB and Parkinson's disease (PD) share the neuropathological findings characterized by widely distributed Lewy bodies in the central nervous system including the substantia nigra and locus coeruleus. However, clinical manifestations of AF-LB are far different from PD in which autonomic dysfunction, if present, is not a predominant feature. In the present study, clinical features were comparatively analysed in AF-LB and PD to investigate the nosological relation between PD and AF-LB. The subjects were 94 patients with PD and 11 reported cases of AF-LB in the literature. A test of 70 degrees passive head-up tilt was performed upon the patients with PD in our laboratory. Based on the results in tilting test, the patients with PD were divided into two groups; PD-I (69 cases) with an orthostatic fall of systolic blood pressure less than 30 mmHg, and PD-II (25 cases) with a fall of 30 mmHg or more. Autonomic dysfunctions were more extent in PD-II than in PD-I, because the incidences of anhidrosis, impotence, neurogenic bladder and constipation were higher in PD-II. All of the cases of AF-LB were contained in the previous literatures with reasonably full clinical descriptions. Mean age at onset of the disease was 62.1 +/- 8.7 (mean +/- SD) years old in PD-I, 64.5 +/- 7.5 years old in PD-II and 63.9 +/- 9.0 years old in AF-LB, and no significant differences were found among the three groups.(ABSTRACT TRUNCATED AT 250 WORDS)", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "fe5cca28fd2c430ca12e90e27e78ad75", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[36, 40]], "char_spans": [[153, 175]]}]}], "context_tokens": [["Autonomic", 0], ["failure", 10], ["with", 18], ["Lewy", 23], ["bodies", 28], ["(", 35], ["AF", 36], ["-", 38], ["LB", 39], [")", 41], ["was", 43], ["first", 47], ["described", 53], ["by", 63], ["Fichefet", 66], ["et", 75], ["al", 78], [".", 80], ["in", 82], ["1965", 85], [",", 89], ["and", 91], ["more", 95], ["than", 100], ["ten", 105], ["cases", 109], ["have", 115], ["been", 120], ["reported", 125], ["to", 134], ["date", 137], [".", 141], ["AF", 143], ["-", 145], ["LB", 146], ["and", 149], ["Parkinson", 153], ["'s", 162], ["disease", 165], ["(", 173], ["PD", 174], [")", 176], ["share", 178], ["the", 184], ["neuropathological", 188], ["findings", 206], ["characterized", 215], ["by", 229], ["widely", 232], ["distributed", 239], ["Lewy", 251], ["bodies", 256], ["in", 263], ["the", 266], ["central", 270], ["nervous", 278], ["system", 286], ["including", 293], ["the", 303], ["substantia", 307], ["nigra", 318], ["and", 324], ["locus", 328], ["coeruleus", 334], [".", 343], ["However", 345], [",", 352], ["clinical", 354], ["manifestations", 363], ["of", 378], ["AF", 381], ["-", 383], ["LB", 384], ["are", 387], ["far", 391], ["different", 395], ["from", 405], ["PD", 410], ["in", 413], ["which", 416], ["autonomic", 422], ["dysfunction", 432], [",", 443], ["if", 445], ["present", 448], [",", 455], ["is", 457], ["not", 460], ["a", 464], ["predominant", 466], ["feature", 478], [".", 485], ["In", 487], ["the", 490], ["present", 494], ["study", 502], [",", 507], ["clinical", 509], ["features", 518], ["were", 527], ["comparatively", 532], ["analysed", 546], ["in", 555], ["AF", 558], ["-", 560], ["LB", 561], ["and", 564], ["PD", 568], ["to", 571], ["investigate", 574], ["the", 586], ["nosological", 590], ["relation", 602], ["between", 611], ["PD", 619], ["and", 622], ["AF", 626], ["-", 628], ["LB", 629], [".", 631], ["The", 633], ["subjects", 637], ["were", 646], ["94", 651], ["patients", 654], ["with", 663], ["PD", 668], ["and", 671], ["11", 675], ["reported", 678], ["cases", 687], ["of", 693], ["AF", 696], ["-", 698], ["LB", 699], ["in", 702], ["the", 705], ["literature", 709], [".", 719], ["A", 721], ["test", 723], ["of", 728], ["70", 731], ["degrees", 734], ["passive", 742], ["head", 750], ["-", 754], ["up", 755], ["tilt", 758], ["was", 763], ["performed", 767], ["upon", 777], ["the", 782], ["patients", 786], ["with", 795], ["PD", 800], ["in", 803], ["our", 806], ["laboratory", 810], [".", 820], ["Based", 822], ["on", 828], ["the", 831], ["results", 835], ["in", 843], ["tilting", 846], ["test", 854], [",", 858], ["the", 860], ["patients", 864], ["with", 873], ["PD", 878], ["were", 881], ["divided", 886], ["into", 894], ["two", 899], ["groups", 903], [";", 909], ["PD", 911], ["-", 913], ["I", 914], ["(", 916], ["69", 917], ["cases", 920], [")", 925], ["with", 927], ["an", 932], ["orthostatic", 935], ["fall", 947], ["of", 952], ["systolic", 955], ["blood", 964], ["pressure", 970], ["less", 979], ["than", 984], ["30", 989], ["mmHg", 992], [",", 996], ["and", 998], ["PD", 1002], ["-", 1004], ["II", 1005], ["(", 1008], ["25", 1009], ["cases", 1012], [")", 1017], ["with", 1019], ["a", 1024], ["fall", 1026], ["of", 1031], ["30", 1034], ["mmHg", 1037], ["or", 1042], ["more", 1045], [".", 1049], ["Autonomic", 1051], ["dysfunctions", 1061], ["were", 1074], ["more", 1079], ["extent", 1084], ["in", 1091], ["PD", 1094], ["-", 1096], ["II", 1097], ["than", 1100], ["in", 1105], ["PD", 1108], ["-", 1110], ["I", 1111], [",", 1112], ["because", 1114], ["the", 1122], ["incidences", 1126], ["of", 1137], ["anhidrosis", 1140], [",", 1150], ["impotence", 1152], [",", 1161], ["neurogenic", 1163], ["bladder", 1174], ["and", 1182], ["constipation", 1186], ["were", 1199], ["higher", 1204], ["in", 1211], ["PD", 1214], ["-", 1216], ["II", 1217], [".", 1219], ["All", 1221], ["of", 1225], ["the", 1228], ["cases", 1232], ["of", 1238], ["AF", 1241], ["-", 1243], ["LB", 1244], ["were", 1247], ["contained", 1252], ["in", 1262], ["the", 1265], ["previous", 1269], ["literatures", 1278], ["with", 1290], ["reasonably", 1295], ["full", 1306], ["clinical", 1311], ["descriptions", 1320], [".", 1332], ["Mean", 1334], ["age", 1339], ["at", 1343], ["onset", 1346], ["of", 1352], ["the", 1355], ["disease", 1359], ["was", 1367], ["62.1", 1371], ["+", 1376], ["/-", 1377], ["8.7", 1380], ["(", 1384], ["mean", 1385], ["+", 1390], ["/-", 1391], ["SD", 1394], [")", 1396], ["years", 1398], ["old", 1404], ["in", 1408], ["PD", 1411], ["-", 1413], ["I", 1414], [",", 1415], ["64.5", 1417], ["+", 1422], ["/-", 1423], ["7.5", 1426], ["years", 1430], ["old", 1436], ["in", 1440], ["PD", 1443], ["-", 1445], ["II", 1446], ["and", 1449], ["63.9", 1453], ["+", 1458], ["/-", 1459], ["9.0", 1462], ["years", 1466], ["old", 1472], ["in", 1476], ["AF", 1479], ["-", 1481], ["LB", 1482], [",", 1484], ["and", 1486], ["no", 1490], ["significant", 1493], ["differences", 1505], ["were", 1517], ["found", 1522], ["among", 1528], ["the", 1534], ["three", 1538], ["groups.(ABSTRACT", 1544], ["TRUNCATED", 1561], ["AT", 1571], ["250", 1574], ["WORDS", 1578], [")", 1583]]}
{"context": "The light-harvesting chlorophyll a/b-protein complex of photosystem II (LHCII) is the most abundant membrane protein in green plants, and its degradation is a crucial process for the acclimation to high light conditions and for the recovery of nitrogen (N) and carbon (C) during senescence. However, the molecular mechanism of LHCII degradation is largely unknown. Here, we report that chlorophyll b reductase, which catalyzes the first step of chlorophyll b degradation, plays a central role in LHCII degradation. When the genes for chlorophyll b reductases NOL and NYC1 were disrupted in Arabidopsis thaliana, chlorophyll b and LHCII were not degraded during senescence, whereas other pigment complexes completely disappeared. When purified trimeric LHCII was incubated with recombinant chlorophyll b reductase (NOL), expressed in Escherichia coli, the chlorophyll b in LHCII was converted to 7-hydroxymethyl chlorophyll a. Accompanying this conversion, chlorophylls were released from LHCII apoproteins until all the chlorophyll molecules in LHCII dissociated from the complexes. Chlorophyll-depleted LHCII apoproteins did not dissociate into monomeric forms but remained in the trimeric form. Based on these results, we propose the novel hypothesis that chlorophyll b reductase catalyzes the initial step of LHCII degradation, and that trimeric LHCII is a substrate of LHCII degradation.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "e65867b72b4e4b6cab1e8ae033a60312", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[64, 64], [226, 226], [133, 133], [154, 154], [177, 177], [186, 186], [116, 116], [220, 220], [169, 169], [231, 231], [94, 94], [15, 15]], "char_spans": [[327, 331], [1349, 1353], [752, 756], [872, 876], [1045, 1049], [1104, 1108], [630, 634], [1312, 1316], [988, 992], [1373, 1377], [496, 500], [72, 76]]}]}], "context_tokens": [["The", 0], ["light", 4], ["-", 9], ["harvesting", 10], ["chlorophyll", 21], ["a", 33], ["/", 34], ["b", 35], ["-", 36], ["protein", 37], ["complex", 45], ["of", 53], ["photosystem", 56], ["II", 68], ["(", 71], ["LHCII", 72], [")", 77], ["is", 79], ["the", 82], ["most", 86], ["abundant", 91], ["membrane", 100], ["protein", 109], ["in", 117], ["green", 120], ["plants", 126], [",", 132], ["and", 134], ["its", 138], ["degradation", 142], ["is", 154], ["a", 157], ["crucial", 159], ["process", 167], ["for", 175], ["the", 179], ["acclimation", 183], ["to", 195], ["high", 198], ["light", 203], ["conditions", 209], ["and", 220], ["for", 224], ["the", 228], ["recovery", 232], ["of", 241], ["nitrogen", 244], ["(", 253], ["N", 254], [")", 255], ["and", 257], ["carbon", 261], ["(", 268], ["C", 269], [")", 270], ["during", 272], ["senescence", 279], [".", 289], ["However", 291], [",", 298], ["the", 300], ["molecular", 304], ["mechanism", 314], ["of", 324], ["LHCII", 327], ["degradation", 333], ["is", 345], ["largely", 348], ["unknown", 356], [".", 363], ["Here", 365], [",", 369], ["we", 371], ["report", 374], ["that", 381], ["chlorophyll", 386], ["b", 398], ["reductase", 400], [",", 409], ["which", 411], ["catalyzes", 417], ["the", 427], ["first", 431], ["step", 437], ["of", 442], ["chlorophyll", 445], ["b", 457], ["degradation", 459], [",", 470], ["plays", 472], ["a", 478], ["central", 480], ["role", 488], ["in", 493], ["LHCII", 496], ["degradation", 502], [".", 513], ["When", 515], ["the", 520], ["genes", 524], ["for", 530], ["chlorophyll", 534], ["b", 546], ["reductases", 548], ["NOL", 559], ["and", 563], ["NYC1", 567], ["were", 572], ["disrupted", 577], ["in", 587], ["Arabidopsis", 590], ["thaliana", 602], [",", 610], ["chlorophyll", 612], ["b", 624], ["and", 626], ["LHCII", 630], ["were", 636], ["not", 641], ["degraded", 645], ["during", 654], ["senescence", 661], [",", 671], ["whereas", 673], ["other", 681], ["pigment", 687], ["complexes", 695], ["completely", 705], ["disappeared", 716], [".", 727], ["When", 729], ["purified", 734], ["trimeric", 743], ["LHCII", 752], ["was", 758], ["incubated", 762], ["with", 772], ["recombinant", 777], ["chlorophyll", 789], ["b", 801], ["reductase", 803], ["(", 813], ["NOL", 814], [")", 817], [",", 818], ["expressed", 820], ["in", 830], ["Escherichia", 833], ["coli", 845], [",", 849], ["the", 851], ["chlorophyll", 855], ["b", 867], ["in", 869], ["LHCII", 872], ["was", 878], ["converted", 882], ["to", 892], ["7-hydroxymethyl", 895], ["chlorophyll", 911], ["a.", 923], ["Accompanying", 926], ["this", 939], ["conversion", 944], [",", 954], ["chlorophylls", 956], ["were", 969], ["released", 974], ["from", 983], ["LHCII", 988], ["apoproteins", 994], ["until", 1006], ["all", 1012], ["the", 1016], ["chlorophyll", 1020], ["molecules", 1032], ["in", 1042], ["LHCII", 1045], ["dissociated", 1051], ["from", 1063], ["the", 1068], ["complexes", 1072], [".", 1081], ["Chlorophyll", 1083], ["-", 1094], ["depleted", 1095], ["LHCII", 1104], ["apoproteins", 1110], ["did", 1122], ["not", 1126], ["dissociate", 1130], ["into", 1141], ["monomeric", 1146], ["forms", 1156], ["but", 1162], ["remained", 1166], ["in", 1175], ["the", 1178], ["trimeric", 1182], ["form", 1191], [".", 1195], ["Based", 1197], ["on", 1203], ["these", 1206], ["results", 1212], [",", 1219], ["we", 1221], ["propose", 1224], ["the", 1232], ["novel", 1236], ["hypothesis", 1242], ["that", 1253], ["chlorophyll", 1258], ["b", 1270], ["reductase", 1272], ["catalyzes", 1282], ["the", 1292], ["initial", 1296], ["step", 1304], ["of", 1309], ["LHCII", 1312], ["degradation", 1318], [",", 1329], ["and", 1331], ["that", 1335], ["trimeric", 1340], ["LHCII", 1349], ["is", 1355], ["a", 1358], ["substrate", 1360], ["of", 1370], ["LHCII", 1373], ["degradation", 1379], [".", 1390]]}
{"context": "Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are characterized by abnormal deposition of \u03b1-synuclein aggregates in many regions of the central and peripheral nervous systems. Accumulating evidence suggests that the \u03b1-synuclein pathology initiates in a few discrete regions and spreads to larger areas in the nervous system. Recent pathological studies of PD patients have raised the possibility that the enteric nervous system is one of the initial sites of \u03b1-synuclein aggregation and propagation. Here, we evaluated the induction and propagation of \u03b1-synuclein aggregates in the enteric nervous system of the A53T \u03b1-synuclein transgenic mice after injection of human brain tissue extracts into the gastric walls of the mice. Western analysis of the brain extracts showed that the DLB extract contained detergent-stable \u03b1-synuclein aggregates, but the normal brain extract did not. Injection of the DLB extract resulted in an increased deposition of \u03b1-synuclein in the myenteric neurons, in which \u03b1-synuclein formed punctate aggregates over time up to 4 months. In these mice, inflammatory responses were increased transiently at early time points. None of these changes were observed in the A53T mice injected with saline or the normal brain extract, nor were these found in the wild type mice injected with the DLB extract. These results demonstrate that pathological \u03b1-synuclein aggregates present in the brain of DLB patient can induce the aggregation of endogenous \u03b1-synuclein in the myenteric neurons in A53T mice, suggesting the transmission of synucleinopathy lesions in the enteric nervous system.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "9a225d6aa2034d27a58fc2dea42dbe40", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["and", 25], ["dementia", 29], ["with", 38], ["Lewy", 43], ["bodies", 48], ["(", 55], ["DLB", 56], [")", 59], ["are", 61], ["characterized", 65], ["by", 79], ["abnormal", 82], ["deposition", 91], ["of", 102], ["\u03b1", 105], ["-", 106], ["synuclein", 107], ["aggregates", 117], ["in", 128], ["many", 131], ["regions", 136], ["of", 144], ["the", 147], ["central", 151], ["and", 159], ["peripheral", 163], ["nervous", 174], ["systems", 182], [".", 189], ["Accumulating", 191], ["evidence", 204], ["suggests", 213], ["that", 222], ["the", 227], ["\u03b1", 231], ["-", 232], ["synuclein", 233], ["pathology", 243], ["initiates", 253], ["in", 263], ["a", 266], ["few", 268], ["discrete", 272], ["regions", 281], ["and", 289], ["spreads", 293], ["to", 301], ["larger", 304], ["areas", 311], ["in", 317], ["the", 320], ["nervous", 324], ["system", 332], [".", 338], ["Recent", 340], ["pathological", 347], ["studies", 360], ["of", 368], ["PD", 371], ["patients", 374], ["have", 383], ["raised", 388], ["the", 395], ["possibility", 399], ["that", 411], ["the", 416], ["enteric", 420], ["nervous", 428], ["system", 436], ["is", 443], ["one", 446], ["of", 450], ["the", 453], ["initial", 457], ["sites", 465], ["of", 471], ["\u03b1", 474], ["-", 475], ["synuclein", 476], ["aggregation", 486], ["and", 498], ["propagation", 502], [".", 513], ["Here", 515], [",", 519], ["we", 521], ["evaluated", 524], ["the", 534], ["induction", 538], ["and", 548], ["propagation", 552], ["of", 564], ["\u03b1", 567], ["-", 568], ["synuclein", 569], ["aggregates", 579], ["in", 590], ["the", 593], ["enteric", 597], ["nervous", 605], ["system", 613], ["of", 620], ["the", 623], ["A53", 627], ["T", 630], ["\u03b1", 632], ["-", 633], ["synuclein", 634], ["transgenic", 644], ["mice", 655], ["after", 660], ["injection", 666], ["of", 676], ["human", 679], ["brain", 685], ["tissue", 691], ["extracts", 698], ["into", 707], ["the", 712], ["gastric", 716], ["walls", 724], ["of", 730], ["the", 733], ["mice", 737], [".", 741], ["Western", 743], ["analysis", 751], ["of", 760], ["the", 763], ["brain", 767], ["extracts", 773], ["showed", 782], ["that", 789], ["the", 794], ["DLB", 798], ["extract", 802], ["contained", 810], ["detergent", 820], ["-", 829], ["stable", 830], ["\u03b1", 837], ["-", 838], ["synuclein", 839], ["aggregates", 849], [",", 859], ["but", 861], ["the", 865], ["normal", 869], ["brain", 876], ["extract", 882], ["did", 890], ["not", 894], [".", 897], ["Injection", 899], ["of", 909], ["the", 912], ["DLB", 916], ["extract", 920], ["resulted", 928], ["in", 937], ["an", 940], ["increased", 943], ["deposition", 953], ["of", 964], ["\u03b1", 967], ["-", 968], ["synuclein", 969], ["in", 979], ["the", 982], ["myenteric", 986], ["neurons", 996], [",", 1003], ["in", 1005], ["which", 1008], ["\u03b1", 1014], ["-", 1015], ["synuclein", 1016], ["formed", 1026], ["punctate", 1033], ["aggregates", 1042], ["over", 1053], ["time", 1058], ["up", 1063], ["to", 1066], ["4", 1069], ["months", 1071], [".", 1077], ["In", 1079], ["these", 1082], ["mice", 1088], [",", 1092], ["inflammatory", 1094], ["responses", 1107], ["were", 1117], ["increased", 1122], ["transiently", 1132], ["at", 1144], ["early", 1147], ["time", 1153], ["points", 1158], [".", 1164], ["None", 1166], ["of", 1171], ["these", 1174], ["changes", 1180], ["were", 1188], ["observed", 1193], ["in", 1202], ["the", 1205], ["A53", 1209], ["T", 1212], ["mice", 1214], ["injected", 1219], ["with", 1228], ["saline", 1233], ["or", 1240], ["the", 1243], ["normal", 1247], ["brain", 1254], ["extract", 1260], [",", 1267], ["nor", 1269], ["were", 1273], ["these", 1278], ["found", 1284], ["in", 1290], ["the", 1293], ["wild", 1297], ["type", 1302], ["mice", 1307], ["injected", 1312], ["with", 1321], ["the", 1326], ["DLB", 1330], ["extract", 1334], [".", 1341], ["These", 1343], ["results", 1349], ["demonstrate", 1357], ["that", 1369], ["pathological", 1374], ["\u03b1", 1387], ["-", 1388], ["synuclein", 1389], ["aggregates", 1399], ["present", 1410], ["in", 1418], ["the", 1421], ["brain", 1425], ["of", 1431], ["DLB", 1434], ["patient", 1438], ["can", 1446], ["induce", 1450], ["the", 1457], ["aggregation", 1461], ["of", 1473], ["endogenous", 1476], ["\u03b1", 1487], ["-", 1488], ["synuclein", 1489], ["in", 1499], ["the", 1502], ["myenteric", 1506], ["neurons", 1516], ["in", 1524], ["A53", 1527], ["T", 1530], ["mice", 1532], [",", 1536], ["suggesting", 1538], ["the", 1549], ["transmission", 1553], ["of", 1566], ["synucleinopathy", 1569], ["lesions", 1585], ["in", 1593], ["the", 1596], ["enteric", 1600], ["nervous", 1608], ["system", 1616], [".", 1622]]}
{"context": "The Malaria Policy Advisory Committee to the World Health Organization met in Geneva, Switzerland from 13 to 15 March, 2013. This article provides a summary of the discussions, conclusions and recommendations from that meeting.Meeting sessions included: a review of the efficacy of artemisinin-based combination therapy in Guyana and Suriname; the outcomes from a consultation on non-malaria febrile illness; the outcomes from the second meeting of the Evidence Review Group on malaria burden estimation; an update on the review of the WHO Guidelines for the Treatment of Malaria; an update regarding progress on the constitution of the vector control Technical Expert Group; updates on the RTS, S/AS01 vaccine and the malaria vaccine technology roadmap; financing and resource allocation for malaria control; malaria surveillance and the need for a surveillance, monitoring and evaluation Technical Expert Group; criteria and classification related to malaria elimination; the next meeting of the Evidence Review Group on Intermittent Preventive Treatment in pregnancy; an update on the soon-to-be launched Elimination Scenario Planning Tool; and an update on the process for the Global Technical Strategy for Malaria Control and Elimination (2016-2025).Policy statements, position statements, and guidelines that arise from the MPAC meeting conclusions and recommendations will be formally issued and disseminated to World Health Organization Member States by the World Health Organization Global Malaria Programme.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "08c2300228d848599dbb36a771fdc904", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[128, 128], [83, 83], [67, 67], [138, 138], [141, 141], [100, 100], [249, 249], [162, 162], [1, 1], [207, 207]], "char_spans": [[719, 725], [478, 484], [384, 390], [793, 799], [810, 816], [572, 578], [1499, 1505], [953, 959], [4, 10], [1211, 1217]]}]}], "context_tokens": [["The", 0], ["Malaria", 4], ["Policy", 12], ["Advisory", 19], ["Committee", 28], ["to", 38], ["the", 41], ["World", 45], ["Health", 51], ["Organization", 58], ["met", 71], ["in", 75], ["Geneva", 78], [",", 84], ["Switzerland", 86], ["from", 98], ["13", 103], ["to", 106], ["15", 109], ["March", 112], [",", 117], ["2013", 119], [".", 123], ["This", 125], ["article", 130], ["provides", 138], ["a", 147], ["summary", 149], ["of", 157], ["the", 160], ["discussions", 164], [",", 175], ["conclusions", 177], ["and", 189], ["recommendations", 193], ["from", 209], ["that", 214], ["meeting", 219], [".", 226], ["Meeting", 227], ["sessions", 235], ["included", 244], [":", 252], ["a", 254], ["review", 256], ["of", 263], ["the", 266], ["efficacy", 270], ["of", 279], ["artemisinin", 282], ["-", 293], ["based", 294], ["combination", 300], ["therapy", 312], ["in", 320], ["Guyana", 323], ["and", 330], ["Suriname", 334], [";", 342], ["the", 344], ["outcomes", 348], ["from", 357], ["a", 362], ["consultation", 364], ["on", 377], ["non", 380], ["-", 383], ["malaria", 384], ["febrile", 392], ["illness", 400], [";", 407], ["the", 409], ["outcomes", 413], ["from", 422], ["the", 427], ["second", 431], ["meeting", 438], ["of", 446], ["the", 449], ["Evidence", 453], ["Review", 462], ["Group", 469], ["on", 475], ["malaria", 478], ["burden", 486], ["estimation", 493], [";", 503], ["an", 505], ["update", 508], ["on", 515], ["the", 518], ["review", 522], ["of", 529], ["the", 532], ["WHO", 536], ["Guidelines", 540], ["for", 551], ["the", 555], ["Treatment", 559], ["of", 569], ["Malaria", 572], [";", 579], ["an", 581], ["update", 584], ["regarding", 591], ["progress", 601], ["on", 610], ["the", 613], ["constitution", 617], ["of", 630], ["the", 633], ["vector", 637], ["control", 644], ["Technical", 652], ["Expert", 662], ["Group", 669], [";", 674], ["updates", 676], ["on", 684], ["the", 687], ["RTS", 691], [",", 694], ["S", 696], ["/", 697], ["AS01", 698], ["vaccine", 703], ["and", 711], ["the", 715], ["malaria", 719], ["vaccine", 727], ["technology", 735], ["roadmap", 746], [";", 753], ["financing", 755], ["and", 765], ["resource", 769], ["allocation", 778], ["for", 789], ["malaria", 793], ["control", 801], [";", 808], ["malaria", 810], ["surveillance", 818], ["and", 831], ["the", 835], ["need", 839], ["for", 844], ["a", 848], ["surveillance", 850], [",", 862], ["monitoring", 864], ["and", 875], ["evaluation", 879], ["Technical", 890], ["Expert", 900], ["Group", 907], [";", 912], ["criteria", 914], ["and", 923], ["classification", 927], ["related", 942], ["to", 950], ["malaria", 953], ["elimination", 961], [";", 972], ["the", 974], ["next", 978], ["meeting", 983], ["of", 991], ["the", 994], ["Evidence", 998], ["Review", 1007], ["Group", 1014], ["on", 1020], ["Intermittent", 1023], ["Preventive", 1036], ["Treatment", 1047], ["in", 1057], ["pregnancy", 1060], [";", 1069], ["an", 1071], ["update", 1074], ["on", 1081], ["the", 1084], ["soon", 1088], ["-", 1092], ["to", 1093], ["-", 1095], ["be", 1096], ["launched", 1099], ["Elimination", 1108], ["Scenario", 1120], ["Planning", 1129], ["Tool", 1138], [";", 1142], ["and", 1144], ["an", 1148], ["update", 1151], ["on", 1158], ["the", 1161], ["process", 1165], ["for", 1173], ["the", 1177], ["Global", 1181], ["Technical", 1188], ["Strategy", 1198], ["for", 1207], ["Malaria", 1211], ["Control", 1219], ["and", 1227], ["Elimination", 1231], ["(", 1243], ["2016", 1244], ["-", 1248], ["2025).Policy", 1249], ["statements", 1262], [",", 1272], ["position", 1274], ["statements", 1283], [",", 1293], ["and", 1295], ["guidelines", 1299], ["that", 1310], ["arise", 1315], ["from", 1321], ["the", 1326], ["MPAC", 1330], ["meeting", 1335], ["conclusions", 1343], ["and", 1355], ["recommendations", 1359], ["will", 1375], ["be", 1380], ["formally", 1383], ["issued", 1392], ["and", 1399], ["disseminated", 1403], ["to", 1416], ["World", 1419], ["Health", 1425], ["Organization", 1432], ["Member", 1445], ["States", 1452], ["by", 1459], ["the", 1462], ["World", 1466], ["Health", 1472], ["Organization", 1479], ["Global", 1492], ["Malaria", 1499], ["Programme", 1507], [".", 1516]]}
{"context": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM). PubMed was searched using the search terms empagliflozin, BI 10773, and BI10773, for entries between January 1, 2000, and December 1, 2014. Reference lists from retrieved articles were searched manually for additional peer-reviewed publications. All publications reporting clinical trials of empagliflozin were eligible for inclusion. Empagliflozin is a new once-daily oral SGLT2 inhibitor with a mechanism of action that is independent of \u03b2-cell function and the insulin pathway. Data from a comprehensive phase III clinical trial program have demonstrated its efficacy as monotherapy, as add-on to other glucose-lowering agents, and in different patient populations. In these studies, empagliflozin resulted in improvements in blood glucose levels as well as reductions in body weight and blood pressure. Empagliflozin was well tolerated and was not associated with an increased risk of hypoglycemia versus placebo. The oral antidiabetes agent, empagliflozin, can be used as monotherapy or alongside other glucose-lowering treatments, including insulin, to treat T2DM.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "8e4362d962304849af0e9a9cf344f780", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[108, 108], [14, 14]], "char_spans": [[621, 625], [81, 85]]}]}], "context_tokens": [["To", 0], ["review", 3], ["available", 10], ["studies", 20], ["of", 28], ["empagliflozin", 31], [",", 44], ["a", 46], ["sodium", 48], ["glucose", 55], ["co", 63], ["-", 65], ["transporter-2", 66], ["(", 80], ["SGLT2", 81], [")", 86], ["inhibitor", 88], ["approved", 98], ["in", 107], ["2014", 110], ["by", 115], ["the", 118], ["European", 122], ["Commission", 131], ["and", 142], ["the", 146], ["United", 150], ["States", 157], ["Food", 164], ["and", 169], ["Drug", 173], ["Administration", 178], ["for", 193], ["the", 197], ["treatment", 201], ["of", 211], ["type", 214], ["2", 219], ["diabetes", 221], ["mellitus", 230], ["(", 239], ["T2DM", 240], [")", 244], [".", 245], ["PubMed", 247], ["was", 254], ["searched", 258], ["using", 267], ["the", 273], ["search", 277], ["terms", 284], ["empagliflozin", 290], [",", 303], ["BI", 305], ["10773", 308], [",", 313], ["and", 315], ["BI10773", 319], [",", 326], ["for", 328], ["entries", 332], ["between", 340], ["January", 348], ["1", 356], [",", 357], ["2000", 359], [",", 363], ["and", 365], ["December", 369], ["1", 378], [",", 379], ["2014", 381], [".", 385], ["Reference", 387], ["lists", 397], ["from", 403], ["retrieved", 408], ["articles", 418], ["were", 427], ["searched", 432], ["manually", 441], ["for", 450], ["additional", 454], ["peer", 465], ["-", 469], ["reviewed", 470], ["publications", 479], [".", 491], ["All", 493], ["publications", 497], ["reporting", 510], ["clinical", 520], ["trials", 529], ["of", 536], ["empagliflozin", 539], ["were", 553], ["eligible", 558], ["for", 567], ["inclusion", 571], [".", 580], ["Empagliflozin", 582], ["is", 596], ["a", 599], ["new", 601], ["once", 605], ["-", 609], ["daily", 610], ["oral", 616], ["SGLT2", 621], ["inhibitor", 627], ["with", 637], ["a", 642], ["mechanism", 644], ["of", 654], ["action", 657], ["that", 664], ["is", 669], ["independent", 672], ["of", 684], ["\u03b2", 687], ["-", 688], ["cell", 689], ["function", 694], ["and", 703], ["the", 707], ["insulin", 711], ["pathway", 719], [".", 726], ["Data", 728], ["from", 733], ["a", 738], ["comprehensive", 740], ["phase", 754], ["III", 760], ["clinical", 764], ["trial", 773], ["program", 779], ["have", 787], ["demonstrated", 792], ["its", 805], ["efficacy", 809], ["as", 818], ["monotherapy", 821], [",", 832], ["as", 834], ["add", 837], ["-", 840], ["on", 841], ["to", 844], ["other", 847], ["glucose", 853], ["-", 860], ["lowering", 861], ["agents", 870], [",", 876], ["and", 878], ["in", 882], ["different", 885], ["patient", 895], ["populations", 903], [".", 914], ["In", 916], ["these", 919], ["studies", 925], [",", 932], ["empagliflozin", 934], ["resulted", 948], ["in", 957], ["improvements", 960], ["in", 973], ["blood", 976], ["glucose", 982], ["levels", 990], ["as", 997], ["well", 1000], ["as", 1005], ["reductions", 1008], ["in", 1019], ["body", 1022], ["weight", 1027], ["and", 1034], ["blood", 1038], ["pressure", 1044], [".", 1052], ["Empagliflozin", 1054], ["was", 1068], ["well", 1072], ["tolerated", 1077], ["and", 1087], ["was", 1091], ["not", 1095], ["associated", 1099], ["with", 1110], ["an", 1115], ["increased", 1118], ["risk", 1128], ["of", 1133], ["hypoglycemia", 1136], ["versus", 1149], ["placebo", 1156], [".", 1163], ["The", 1165], ["oral", 1169], ["antidiabetes", 1174], ["agent", 1187], [",", 1192], ["empagliflozin", 1194], [",", 1207], ["can", 1209], ["be", 1213], ["used", 1216], ["as", 1221], ["monotherapy", 1224], ["or", 1236], ["alongside", 1239], ["other", 1249], ["glucose", 1255], ["-", 1262], ["lowering", 1263], ["treatments", 1272], [",", 1282], ["including", 1284], ["insulin", 1294], [",", 1301], ["to", 1303], ["treat", 1306], ["T2DM", 1312], [".", 1316]]}
{"context": "To evaluate the role of apoptosis in the pathogenesis of brain lesions in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a hereditary microangiopathy leading to cognitive decline and dementia, caused by mutations in the NOTCH3 gene. Detection of apoptotic nuclei in temporal lobe, brain stem, medulla oblongata, hippocampus and basal ganglia from one young CADASIL patient was performed by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL). Our results showed a great involvement of glial cells in apoptotic cell death in the majority of the brain regions examined; neuronal apoptosis was significantly present only in the brain stem region. We hypothesized that in the early stages of the disease neuronal involvement of apoptosis is limited to the cells of the brain stem, sparing the cortical area which is involved in neuronal apoptosis and cognitive decline later.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "63bd935131b94b97a6120e16b7ff3249", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[41, 42]], "char_spans": [[275, 285]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["role", 16], ["of", 21], ["apoptosis", 24], ["in", 34], ["the", 37], ["pathogenesis", 41], ["of", 54], ["brain", 57], ["lesions", 63], ["in", 71], ["cerebral", 74], ["autosomal", 83], ["dominant", 93], ["arteriopathy", 102], ["with", 115], ["subcortical", 120], ["infarcts", 132], ["and", 141], ["leukoencephalopathy", 145], ["(", 165], ["CADASIL", 166], [")", 173], [",", 174], ["a", 176], ["hereditary", 178], ["microangiopathy", 189], ["leading", 205], ["to", 213], ["cognitive", 216], ["decline", 226], ["and", 234], ["dementia", 238], [",", 246], ["caused", 248], ["by", 255], ["mutations", 258], ["in", 268], ["the", 271], ["NOTCH3", 275], ["gene", 282], [".", 286], ["Detection", 288], ["of", 298], ["apoptotic", 301], ["nuclei", 311], ["in", 318], ["temporal", 321], ["lobe", 330], [",", 334], ["brain", 336], ["stem", 342], [",", 346], ["medulla", 348], ["oblongata", 356], [",", 365], ["hippocampus", 367], ["and", 379], ["basal", 383], ["ganglia", 389], ["from", 397], ["one", 402], ["young", 406], ["CADASIL", 412], ["patient", 420], ["was", 428], ["performed", 432], ["by", 442], ["terminal", 445], ["deoxynucleotidyl", 454], ["transferase", 471], ["(", 483], ["TdT)-mediated", 484], ["dUTP", 498], ["nick", 503], ["end", 508], ["-", 511], ["labeling", 512], ["(", 521], ["TUNEL", 522], [")", 527], [".", 528], ["Our", 530], ["results", 534], ["showed", 542], ["a", 549], ["great", 551], ["involvement", 557], ["of", 569], ["glial", 572], ["cells", 578], ["in", 584], ["apoptotic", 587], ["cell", 597], ["death", 602], ["in", 608], ["the", 611], ["majority", 615], ["of", 624], ["the", 627], ["brain", 631], ["regions", 637], ["examined", 645], [";", 653], ["neuronal", 655], ["apoptosis", 664], ["was", 674], ["significantly", 678], ["present", 692], ["only", 700], ["in", 705], ["the", 708], ["brain", 712], ["stem", 718], ["region", 723], [".", 729], ["We", 731], ["hypothesized", 734], ["that", 747], ["in", 752], ["the", 755], ["early", 759], ["stages", 765], ["of", 772], ["the", 775], ["disease", 779], ["neuronal", 787], ["involvement", 796], ["of", 808], ["apoptosis", 811], ["is", 821], ["limited", 824], ["to", 832], ["the", 835], ["cells", 839], ["of", 845], ["the", 848], ["brain", 852], ["stem", 858], [",", 862], ["sparing", 864], ["the", 872], ["cortical", 876], ["area", 885], ["which", 890], ["is", 896], ["involved", 899], ["in", 908], ["neuronal", 911], ["apoptosis", 920], ["and", 930], ["cognitive", 934], ["decline", 944], ["later", 952], [".", 957]]}
{"context": "In eukaryotes, co-translational insertion of selenocysteine into selenoproteins necessitates the participation of the selenocysteine insertion sequence (SECIS), an element lying in the 3'-untranslated region of selenoprotein mRNAs. We report a detailed experimental study of the secondary structures of the SECIS elements of three selenoprotein mRNAs, the rat and human type I iodothyronine deiodinase (5'DI) and rat glutathione peroxidase (GPx). Based on RNase and chemical probing, a new secondary structure model is established. It is characterized by a stem-loop structure, comprising two helices (I and II) separated by an internal loop, with an apical loop surmounting helix II. Sequence comparisons of 20 SECIS elements, arising from 2 5'DI, 13 GPx, 2 selenoprotein P, and 1 selenoprotein W mRNAs, confirm the secondary structure model. The most striking finding of the experimental study concerns a set of conserved sequences in helix II that interact to form a novel RNA structural motif consisting of a quartet composed of non-Watson-Crick base pairs 5'UGAY3': 5'UGAU3'. The potential for forming the quartet is preserved in 15 SECIS elements, but three consecutive non-Watson-Crick base pairs can nevertheless form in the other five SECIS, the central G.A tandem being invariant in all cases. A 3D model, derived by computer modeling with the use of the solution data, suggests that the base pairing interactions in the G.A tandem are of the type found in GNRA loops. The 3D model displays the quartet lying in an accessible position at the foot of helix II, which is bent at the internal loop, suggesting that the non-Watson-Crick base pair arrangement provides an unusual pattern of chemical groups for putative ligand interaction.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "3fe09fafae1c4200bf36faea155c3c62", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[123, 123], [205, 205], [20, 20], [46, 46], [225, 225]], "char_spans": [[712, 716], [1138, 1142], [153, 157], [307, 311], [1244, 1248]]}]}], "context_tokens": [["In", 0], ["eukaryotes", 3], [",", 13], ["co", 15], ["-", 17], ["translational", 18], ["insertion", 32], ["of", 42], ["selenocysteine", 45], ["into", 60], ["selenoproteins", 65], ["necessitates", 80], ["the", 93], ["participation", 97], ["of", 111], ["the", 114], ["selenocysteine", 118], ["insertion", 133], ["sequence", 143], ["(", 152], ["SECIS", 153], [")", 158], [",", 159], ["an", 161], ["element", 164], ["lying", 172], ["in", 178], ["the", 181], ["3'-untranslated", 185], ["region", 201], ["of", 208], ["selenoprotein", 211], ["mRNAs", 225], [".", 230], ["We", 232], ["report", 235], ["a", 242], ["detailed", 244], ["experimental", 253], ["study", 266], ["of", 272], ["the", 275], ["secondary", 279], ["structures", 289], ["of", 300], ["the", 303], ["SECIS", 307], ["elements", 313], ["of", 322], ["three", 325], ["selenoprotein", 331], ["mRNAs", 345], [",", 350], ["the", 352], ["rat", 356], ["and", 360], ["human", 364], ["type", 370], ["I", 375], ["iodothyronine", 377], ["deiodinase", 391], ["(", 402], ["5'DI", 403], [")", 407], ["and", 409], ["rat", 413], ["glutathione", 417], ["peroxidase", 429], ["(", 440], ["GPx", 441], [")", 444], [".", 445], ["Based", 447], ["on", 453], ["RNase", 456], ["and", 462], ["chemical", 466], ["probing", 475], [",", 482], ["a", 484], ["new", 486], ["secondary", 490], ["structure", 500], ["model", 510], ["is", 516], ["established", 519], [".", 530], ["It", 532], ["is", 535], ["characterized", 538], ["by", 552], ["a", 555], ["stem", 557], ["-", 561], ["loop", 562], ["structure", 567], [",", 576], ["comprising", 578], ["two", 589], ["helices", 593], ["(", 601], ["I", 602], ["and", 604], ["II", 608], [")", 610], ["separated", 612], ["by", 622], ["an", 625], ["internal", 628], ["loop", 637], [",", 641], ["with", 643], ["an", 648], ["apical", 651], ["loop", 658], ["surmounting", 663], ["helix", 675], ["II", 681], [".", 683], ["Sequence", 685], ["comparisons", 694], ["of", 706], ["20", 709], ["SECIS", 712], ["elements", 718], [",", 726], ["arising", 728], ["from", 736], ["2", 741], ["5'DI", 743], [",", 747], ["13", 749], ["GPx", 752], [",", 755], ["2", 757], ["selenoprotein", 759], ["P", 773], [",", 774], ["and", 776], ["1", 780], ["selenoprotein", 782], ["W", 796], ["mRNAs", 798], [",", 803], ["confirm", 805], ["the", 813], ["secondary", 817], ["structure", 827], ["model", 837], [".", 842], ["The", 844], ["most", 848], ["striking", 853], ["finding", 862], ["of", 870], ["the", 873], ["experimental", 877], ["study", 890], ["concerns", 896], ["a", 905], ["set", 907], ["of", 911], ["conserved", 914], ["sequences", 924], ["in", 934], ["helix", 937], ["II", 943], ["that", 946], ["interact", 951], ["to", 960], ["form", 963], ["a", 968], ["novel", 970], ["RNA", 976], ["structural", 980], ["motif", 991], ["consisting", 997], ["of", 1008], ["a", 1011], ["quartet", 1013], ["composed", 1021], ["of", 1030], ["non", 1033], ["-", 1036], ["Watson", 1037], ["-", 1043], ["Crick", 1044], ["base", 1050], ["pairs", 1055], ["5'UGAY3", 1061], ["'", 1068], [":", 1069], ["5'UGAU3", 1071], ["'", 1078], [".", 1079], ["The", 1081], ["potential", 1085], ["for", 1095], ["forming", 1099], ["the", 1107], ["quartet", 1111], ["is", 1119], ["preserved", 1122], ["in", 1132], ["15", 1135], ["SECIS", 1138], ["elements", 1144], [",", 1152], ["but", 1154], ["three", 1158], ["consecutive", 1164], ["non", 1176], ["-", 1179], ["Watson", 1180], ["-", 1186], ["Crick", 1187], ["base", 1193], ["pairs", 1198], ["can", 1204], ["nevertheless", 1208], ["form", 1221], ["in", 1226], ["the", 1229], ["other", 1233], ["five", 1239], ["SECIS", 1244], [",", 1249], ["the", 1251], ["central", 1255], ["G.A", 1263], ["tandem", 1267], ["being", 1274], ["invariant", 1280], ["in", 1290], ["all", 1293], ["cases", 1297], [".", 1302], ["A", 1304], ["3D", 1306], ["model", 1309], [",", 1314], ["derived", 1316], ["by", 1324], ["computer", 1327], ["modeling", 1336], ["with", 1345], ["the", 1350], ["use", 1354], ["of", 1358], ["the", 1361], ["solution", 1365], ["data", 1374], [",", 1378], ["suggests", 1380], ["that", 1389], ["the", 1394], ["base", 1398], ["pairing", 1403], ["interactions", 1411], ["in", 1424], ["the", 1427], ["G.A", 1431], ["tandem", 1435], ["are", 1442], ["of", 1446], ["the", 1449], ["type", 1453], ["found", 1458], ["in", 1464], ["GNRA", 1467], ["loops", 1472], [".", 1477], ["The", 1479], ["3D", 1483], ["model", 1486], ["displays", 1492], ["the", 1501], ["quartet", 1505], ["lying", 1513], ["in", 1519], ["an", 1522], ["accessible", 1525], ["position", 1536], ["at", 1545], ["the", 1548], ["foot", 1552], ["of", 1557], ["helix", 1560], ["II", 1566], [",", 1568], ["which", 1570], ["is", 1576], ["bent", 1579], ["at", 1584], ["the", 1587], ["internal", 1591], ["loop", 1600], [",", 1604], ["suggesting", 1606], ["that", 1617], ["the", 1622], ["non", 1626], ["-", 1629], ["Watson", 1630], ["-", 1636], ["Crick", 1637], ["base", 1643], ["pair", 1648], ["arrangement", 1653], ["provides", 1665], ["an", 1674], ["unusual", 1677], ["pattern", 1685], ["of", 1693], ["chemical", 1696], ["groups", 1705], ["for", 1712], ["putative", 1716], ["ligand", 1725], ["interaction", 1732], [".", 1743]]}
{"context": "Dapivirine, formerly known as TMC 120, is a poorly-water soluble anti-HIV drug, currently being developed as a vaginal microbicide. The clinical use of this drug has been limited due to its poor solubility. The aim of this study was to design solid dispersion systems of Dapivirine to improve its solubility. Solid dispersions were prepared by solvent and fusion methods. Dapivirine release from the solid dispersion system was determined by conducting in-vitro dissolution studies. The physicochemical characteristics of the drug and its formulation were studied using Differential Scanning Calorimetry (DSC), powder X-ray Diffraction (XRD), Fourier-transform Infrared Spectroscopy (FTIR) and Scanning Electron Microscopy (SEM). A significant improvement in drug dissolution rate was observed with the solid dispersion systems. XRD, SEM and DSC results indicated the transformation of pure Dapivirine which exists in crystalline form into an amorphous form in selected solid dispersion formulations. FTIR and HPLC analysis confirmed the absence of drug-excipient interactions. Solid dispersion systems can be used to improve the dissolution rate of Dapivirine. This improvement could be attributed to the reduction or absence of drug crystallinity, existence of drug particles in an amorphous form and improved wettability of the drug.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "ac9d766d13164566b8388415dae6d5db", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[16, 16]], "char_spans": [[70, 72]]}]}], "context_tokens": [["Dapivirine", 0], [",", 10], ["formerly", 12], ["known", 21], ["as", 27], ["TMC", 30], ["120", 34], [",", 37], ["is", 39], ["a", 42], ["poorly", 44], ["-", 50], ["water", 51], ["soluble", 57], ["anti", 65], ["-", 69], ["HIV", 70], ["drug", 74], [",", 78], ["currently", 80], ["being", 90], ["developed", 96], ["as", 106], ["a", 109], ["vaginal", 111], ["microbicide", 119], [".", 130], ["The", 132], ["clinical", 136], ["use", 145], ["of", 149], ["this", 152], ["drug", 157], ["has", 162], ["been", 166], ["limited", 171], ["due", 179], ["to", 183], ["its", 186], ["poor", 190], ["solubility", 195], [".", 205], ["The", 207], ["aim", 211], ["of", 215], ["this", 218], ["study", 223], ["was", 229], ["to", 233], ["design", 236], ["solid", 243], ["dispersion", 249], ["systems", 260], ["of", 268], ["Dapivirine", 271], ["to", 282], ["improve", 285], ["its", 293], ["solubility", 297], [".", 307], ["Solid", 309], ["dispersions", 315], ["were", 327], ["prepared", 332], ["by", 341], ["solvent", 344], ["and", 352], ["fusion", 356], ["methods", 363], [".", 370], ["Dapivirine", 372], ["release", 383], ["from", 391], ["the", 396], ["solid", 400], ["dispersion", 406], ["system", 417], ["was", 424], ["determined", 428], ["by", 439], ["conducting", 442], ["in", 453], ["-", 455], ["vitro", 456], ["dissolution", 462], ["studies", 474], [".", 481], ["The", 483], ["physicochemical", 487], ["characteristics", 503], ["of", 519], ["the", 522], ["drug", 526], ["and", 531], ["its", 535], ["formulation", 539], ["were", 551], ["studied", 556], ["using", 564], ["Differential", 570], ["Scanning", 583], ["Calorimetry", 592], ["(", 604], ["DSC", 605], [")", 608], [",", 609], ["powder", 611], ["X", 618], ["-", 619], ["ray", 620], ["Diffraction", 624], ["(", 636], ["XRD", 637], [")", 640], [",", 641], ["Fourier", 643], ["-", 650], ["transform", 651], ["Infrared", 661], ["Spectroscopy", 670], ["(", 683], ["FTIR", 684], [")", 688], ["and", 690], ["Scanning", 694], ["Electron", 703], ["Microscopy", 712], ["(", 723], ["SEM", 724], [")", 727], [".", 728], ["A", 730], ["significant", 732], ["improvement", 744], ["in", 756], ["drug", 759], ["dissolution", 764], ["rate", 776], ["was", 781], ["observed", 785], ["with", 794], ["the", 799], ["solid", 803], ["dispersion", 809], ["systems", 820], [".", 827], ["XRD", 829], [",", 832], ["SEM", 834], ["and", 838], ["DSC", 842], ["results", 846], ["indicated", 854], ["the", 864], ["transformation", 868], ["of", 883], ["pure", 886], ["Dapivirine", 891], ["which", 902], ["exists", 908], ["in", 915], ["crystalline", 918], ["form", 930], ["into", 935], ["an", 940], ["amorphous", 943], ["form", 953], ["in", 958], ["selected", 961], ["solid", 970], ["dispersion", 976], ["formulations", 987], [".", 999], ["FTIR", 1001], ["and", 1006], ["HPLC", 1010], ["analysis", 1015], ["confirmed", 1024], ["the", 1034], ["absence", 1038], ["of", 1046], ["drug", 1049], ["-", 1053], ["excipient", 1054], ["interactions", 1064], [".", 1076], ["Solid", 1078], ["dispersion", 1084], ["systems", 1095], ["can", 1103], ["be", 1107], ["used", 1110], ["to", 1115], ["improve", 1118], ["the", 1126], ["dissolution", 1130], ["rate", 1142], ["of", 1147], ["Dapivirine", 1150], [".", 1160], ["This", 1162], ["improvement", 1167], ["could", 1179], ["be", 1185], ["attributed", 1188], ["to", 1199], ["the", 1202], ["reduction", 1206], ["or", 1216], ["absence", 1219], ["of", 1227], ["drug", 1230], ["crystallinity", 1235], [",", 1248], ["existence", 1250], ["of", 1260], ["drug", 1263], ["particles", 1268], ["in", 1278], ["an", 1281], ["amorphous", 1284], ["form", 1294], ["and", 1299], ["improved", 1303], ["wettability", 1312], ["of", 1324], ["the", 1327], ["drug", 1331], [".", 1335]]}
{"context": "Bazex syndrome, or acrokeratosis paraneoplastica, is a cutaneous paraneoplastic syndrome characterized by psoriasiform lesions associated with, usually, a squamous cell carcinoma of the upper aerodigestive tract. We present a case of Bazex syndrome associated with metastatic cervical squamous cell carcinoma with an unknown primary. The features of the condition are discussed in the light of current knowledge.", "qas": [{"question": "Name synonym of Acrokeratosis paraneoplastica.", "answers": ["Bazex syndrome"], "qid": "13712b1db9094ec2bd023d0036495b5d", "question_tokens": [["Name", 0], ["synonym", 5], ["of", 13], ["Acrokeratosis", 16], ["paraneoplastica", 30], [".", 45]], "detected_answers": [{"text": "Bazex syndrome", "token_spans": [[0, 1], [36, 37]], "char_spans": [[0, 13], [234, 247]]}]}], "context_tokens": [["Bazex", 0], ["syndrome", 6], [",", 14], ["or", 16], ["acrokeratosis", 19], ["paraneoplastica", 33], [",", 48], ["is", 50], ["a", 53], ["cutaneous", 55], ["paraneoplastic", 65], ["syndrome", 80], ["characterized", 89], ["by", 103], ["psoriasiform", 106], ["lesions", 119], ["associated", 127], ["with", 138], [",", 142], ["usually", 144], [",", 151], ["a", 153], ["squamous", 155], ["cell", 164], ["carcinoma", 169], ["of", 179], ["the", 182], ["upper", 186], ["aerodigestive", 192], ["tract", 206], [".", 211], ["We", 213], ["present", 216], ["a", 224], ["case", 226], ["of", 231], ["Bazex", 234], ["syndrome", 240], ["associated", 249], ["with", 260], ["metastatic", 265], ["cervical", 276], ["squamous", 285], ["cell", 294], ["carcinoma", 299], ["with", 309], ["an", 314], ["unknown", 317], ["primary", 325], [".", 332], ["The", 334], ["features", 338], ["of", 347], ["the", 350], ["condition", 354], ["are", 364], ["discussed", 368], ["in", 378], ["the", 381], ["light", 385], ["of", 391], ["current", 394], ["knowledge", 402], [".", 411]]}
{"context": "Chronic myelogenous leukemia (CML) is characterized by Philadelphia (Ph) chromosome with a chimeric gene BCR-ABL created by reciprocal t(9:22) (q34;q11) translocation. Variant Ph chromosome translocations involving chromosomes other than 9 and 22 are found in 5-10% of CML cases. We here report a CML patient who carries a four-way Ph chromosome translocation, t(9;22;15;19) (q34;q11;q15;q13). The patient was diagnosed in 1997 and initially treated with hydroxyurea. In 2002, treatment with imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was started but Ph-positive chromosomes remained at the levels of 42-65%, indicating imatinib failure. In 2006, the point mutations of F359I and L387M were detected in BCR/ABL gene, which may be related to imatinib failure. Treatment with nilotinib, a TKI with high target specificity, was then started which resulted in durable major molecular response. Administration of nilotinib offered an effective treatment in a CML patient with variant Ph chromosome translocations and BCR-ABL point mutations after imatinib failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "fdeaba7b6cb142ef8d135fd8ca5d8c0a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[193, 195], [141, 143], [18, 20], [96, 98]], "char_spans": [[1032, 1038], [723, 729], [105, 111], [514, 520]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["Philadelphia", 55], ["(", 68], ["Ph", 69], [")", 71], ["chromosome", 73], ["with", 84], ["a", 89], ["chimeric", 91], ["gene", 100], ["BCR", 105], ["-", 108], ["ABL", 109], ["created", 113], ["by", 121], ["reciprocal", 124], ["t(9:22", 135], [")", 141], ["(", 143], ["q34;q11", 144], [")", 151], ["translocation", 153], [".", 166], ["Variant", 168], ["Ph", 176], ["chromosome", 179], ["translocations", 190], ["involving", 205], ["chromosomes", 215], ["other", 227], ["than", 233], ["9", 238], ["and", 240], ["22", 244], ["are", 247], ["found", 251], ["in", 257], ["5", 260], ["-", 261], ["10", 262], ["%", 264], ["of", 266], ["CML", 269], ["cases", 273], [".", 278], ["We", 280], ["here", 283], ["report", 288], ["a", 295], ["CML", 297], ["patient", 301], ["who", 309], ["carries", 313], ["a", 321], ["four", 323], ["-", 327], ["way", 328], ["Ph", 332], ["chromosome", 335], ["translocation", 346], [",", 359], ["t(9;22;15;19", 361], [")", 373], ["(", 375], ["q34;q11;q15;q13", 376], [")", 391], [".", 392], ["The", 394], ["patient", 398], ["was", 406], ["diagnosed", 410], ["in", 420], ["1997", 423], ["and", 428], ["initially", 432], ["treated", 442], ["with", 450], ["hydroxyurea", 455], [".", 466], ["In", 468], ["2002", 471], [",", 475], ["treatment", 477], ["with", 487], ["imatinib", 492], [",", 500], ["a", 502], ["selective", 504], ["BCR", 514], ["-", 517], ["ABL", 518], ["tyrosine", 522], ["kinase", 531], ["inhibitor", 538], ["(", 548], ["TKI", 549], [")", 552], [",", 553], ["was", 555], ["started", 559], ["but", 567], ["Ph", 571], ["-", 573], ["positive", 574], ["chromosomes", 583], ["remained", 595], ["at", 604], ["the", 607], ["levels", 611], ["of", 618], ["42", 621], ["-", 623], ["65", 624], ["%", 626], [",", 627], ["indicating", 629], ["imatinib", 640], ["failure", 649], [".", 656], ["In", 658], ["2006", 661], [",", 665], ["the", 667], ["point", 671], ["mutations", 677], ["of", 687], ["F359I", 690], ["and", 696], ["L387", 700], ["M", 704], ["were", 706], ["detected", 711], ["in", 720], ["BCR", 723], ["/", 726], ["ABL", 727], ["gene", 731], [",", 735], ["which", 737], ["may", 743], ["be", 747], ["related", 750], ["to", 758], ["imatinib", 761], ["failure", 770], [".", 777], ["Treatment", 779], ["with", 789], ["nilotinib", 794], [",", 803], ["a", 805], ["TKI", 807], ["with", 811], ["high", 816], ["target", 821], ["specificity", 828], [",", 839], ["was", 841], ["then", 845], ["started", 850], ["which", 858], ["resulted", 864], ["in", 873], ["durable", 876], ["major", 884], ["molecular", 890], ["response", 900], [".", 908], ["Administration", 910], ["of", 925], ["nilotinib", 928], ["offered", 938], ["an", 946], ["effective", 949], ["treatment", 959], ["in", 969], ["a", 972], ["CML", 974], ["patient", 978], ["with", 986], ["variant", 991], ["Ph", 999], ["chromosome", 1002], ["translocations", 1013], ["and", 1028], ["BCR", 1032], ["-", 1035], ["ABL", 1036], ["point", 1040], ["mutations", 1046], ["after", 1056], ["imatinib", 1062], ["failure", 1071], [".", 1078]]}
{"context": "In melanoma, transition to the vertical growth phase is the critical step in conversion to a deadly malignant disease. Here, we offer the first evidence that an antioxidant enzyme has a key role in this transition. We found that the antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells. Silencing Prx2 expression stimulated proliferation and migration, whereas ectopic expression of Prx2 produced the opposite effect. Mechanistic investigations indicated that Prx2 negatively regulated Src/ERK activation status, which in turn fortified adherens junctions function by increasing E-cadherin expression and phospho-Y654-dependent retention of \u03b2-catenin in the plasma membrane. In murine melanoma cells, Prx2 silencing enhanced lung metastasis in vivo. Interestingly, the natural compound gliotoxin, which is known to exert a Prx-like activity, inhibited proliferation and migration as well as lung metastasis of Prx2-deficient melanoma cells. Overall, our findings reveal that Prx2 is a key regulator of invasion and metastasis in melanoma, and also suggest a pharmacologic strategy to effectively decrease deadly malignant forms of this disease.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "4725ab4959074b2b82db8e9b8383de5d", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[44, 44], [30, 30]], "char_spans": [[233, 243], [161, 171]]}]}], "context_tokens": [["In", 0], ["melanoma", 3], [",", 11], ["transition", 13], ["to", 24], ["the", 27], ["vertical", 31], ["growth", 40], ["phase", 47], ["is", 53], ["the", 56], ["critical", 60], ["step", 69], ["in", 74], ["conversion", 77], ["to", 88], ["a", 91], ["deadly", 93], ["malignant", 100], ["disease", 110], [".", 117], ["Here", 119], [",", 123], ["we", 125], ["offer", 128], ["the", 134], ["first", 138], ["evidence", 144], ["that", 153], ["an", 158], ["antioxidant", 161], ["enzyme", 173], ["has", 180], ["a", 184], ["key", 186], ["role", 190], ["in", 195], ["this", 198], ["transition", 203], [".", 213], ["We", 215], ["found", 218], ["that", 224], ["the", 229], ["antioxidant", 233], ["enzyme", 245], ["peroxiredoxin-2", 252], ["(", 268], ["Prx2", 269], [")", 273], ["inversely", 275], ["correlated", 285], ["with", 296], ["the", 301], ["metastatic", 305], ["capacity", 316], ["of", 325], ["human", 328], ["melanoma", 334], ["cells", 343], [".", 348], ["Silencing", 350], ["Prx2", 360], ["expression", 365], ["stimulated", 376], ["proliferation", 387], ["and", 401], ["migration", 405], [",", 414], ["whereas", 416], ["ectopic", 424], ["expression", 432], ["of", 443], ["Prx2", 446], ["produced", 451], ["the", 460], ["opposite", 464], ["effect", 473], [".", 479], ["Mechanistic", 481], ["investigations", 493], ["indicated", 508], ["that", 518], ["Prx2", 523], ["negatively", 528], ["regulated", 539], ["Src", 549], ["/", 552], ["ERK", 553], ["activation", 557], ["status", 568], [",", 574], ["which", 576], ["in", 582], ["turn", 585], ["fortified", 590], ["adherens", 600], ["junctions", 609], ["function", 619], ["by", 628], ["increasing", 631], ["E", 642], ["-", 643], ["cadherin", 644], ["expression", 653], ["and", 664], ["phospho", 668], ["-", 675], ["Y654-dependent", 676], ["retention", 691], ["of", 701], ["\u03b2", 704], ["-", 705], ["catenin", 706], ["in", 714], ["the", 717], ["plasma", 721], ["membrane", 728], [".", 736], ["In", 738], ["murine", 741], ["melanoma", 748], ["cells", 757], [",", 762], ["Prx2", 764], ["silencing", 769], ["enhanced", 779], ["lung", 788], ["metastasis", 793], ["in", 804], ["vivo", 807], [".", 811], ["Interestingly", 813], [",", 826], ["the", 828], ["natural", 832], ["compound", 840], ["gliotoxin", 849], [",", 858], ["which", 860], ["is", 866], ["known", 869], ["to", 875], ["exert", 878], ["a", 884], ["Prx", 886], ["-", 889], ["like", 890], ["activity", 895], [",", 903], ["inhibited", 905], ["proliferation", 915], ["and", 929], ["migration", 933], ["as", 943], ["well", 946], ["as", 951], ["lung", 954], ["metastasis", 959], ["of", 970], ["Prx2-deficient", 973], ["melanoma", 988], ["cells", 997], [".", 1002], ["Overall", 1004], [",", 1011], ["our", 1013], ["findings", 1017], ["reveal", 1026], ["that", 1033], ["Prx2", 1038], ["is", 1043], ["a", 1046], ["key", 1048], ["regulator", 1052], ["of", 1062], ["invasion", 1065], ["and", 1074], ["metastasis", 1078], ["in", 1089], ["melanoma", 1092], [",", 1100], ["and", 1102], ["also", 1106], ["suggest", 1111], ["a", 1119], ["pharmacologic", 1121], ["strategy", 1135], ["to", 1144], ["effectively", 1147], ["decrease", 1159], ["deadly", 1168], ["malignant", 1175], ["forms", 1185], ["of", 1191], ["this", 1194], ["disease", 1199], [".", 1206]]}
{"context": "A blinded, retrospective study was performed to determine the value of supine abdominal radiographs in diagnosing pneumoperitoneum. Supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including Rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-V sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant). One or more of these signs were present in 26 cases (59%) of pneumoperitoneum, including the right-upper-quadrant gas sign in 18 cases (41%), Rigler's sign in 14 cases (32%), and the falciform ligament and football signs in one case each (2%). Unfortunately, there were frequent errors in the interpretation of the right-upper-quadrant gas sign and Rigler's sign, with a total of 11 false-positive cases (13%). Further analysis of the true-positive right-upper-quadrant gas signs showed that these gas collections were always triangular or linear with an inferolateral to superomedial orientation and, if triangular, a concave superolateral border. In the true-positive Rigler's signs, the bowel wall thickness ranged from 1 to 8 mm, whereas the false positives all had a bowel wall thickness of 1 mm or less. Proper interpretation of the various signs of pneumoperitoneum on supine films should lead to more accurate diagnosis of this condition.", "qas": [{"question": "Falciform ligament sign is characteristic to which disease?", "answers": ["pneumoperitoneum"], "qid": "9305f4338a854725ab83e9b81c3c35b4", "question_tokens": [["Falciform", 0], ["ligament", 10], ["sign", 19], ["is", 24], ["characteristic", 27], ["to", 42], ["which", 45], ["disease", 51], ["?", 58]], "detected_answers": [{"text": "pneumoperitoneum", "token_spans": [[309, 309], [54, 54], [25, 25], [17, 17], [143, 143]], "char_spans": [[1553, 1568], [344, 359], [162, 177], [114, 129], [758, 773]]}]}], "context_tokens": [["A", 0], ["blinded", 2], [",", 9], ["retrospective", 11], ["study", 25], ["was", 31], ["performed", 35], ["to", 45], ["determine", 48], ["the", 58], ["value", 62], ["of", 68], ["supine", 71], ["abdominal", 78], ["radiographs", 88], ["in", 100], ["diagnosing", 103], ["pneumoperitoneum", 114], [".", 130], ["Supine", 132], ["films", 139], ["from", 145], ["44", 150], ["cases", 153], ["of", 159], ["pneumoperitoneum", 162], ["were", 179], ["randomly", 184], ["interspersed", 193], ["among", 206], ["supine", 212], ["films", 219], ["from", 225], ["87", 230], ["control", 233], ["subjects", 241], ["without", 250], ["free", 258], ["air", 263], [",", 266], ["and", 268], ["the", 272], ["films", 276], ["were", 282], ["reviewed", 287], ["for", 296], ["the", 300], ["presence", 304], ["or", 313], ["absence", 316], ["of", 324], ["various", 327], ["signs", 335], ["of", 341], ["pneumoperitoneum", 344], [",", 360], ["including", 362], ["Rigler", 372], ["'s", 378], ["sign", 381], ["(", 386], ["gas", 387], ["on", 391], ["both", 394], ["sides", 399], ["of", 405], ["the", 408], ["bowel", 412], ["wall", 418], [")", 422], [",", 423], ["the", 425], ["falciform", 429], ["ligament", 439], ["sign", 448], ["(", 453], ["gas", 454], ["outlining", 458], ["the", 468], ["falciform", 472], ["ligament", 482], [")", 490], [",", 491], ["the", 493], ["football", 497], ["sign", 506], ["(", 511], ["gas", 512], ["outlining", 516], ["the", 526], ["peritoneal", 530], ["cavity", 541], [")", 547], [",", 548], ["the", 550], ["inverted", 554], ["-", 562], ["V", 563], ["sign", 565], ["(", 570], ["gas", 571], ["outlining", 575], ["the", 585], ["medial", 589], ["umbilical", 596], ["folds", 606], [")", 611], [",", 612], ["and", 614], ["the", 618], ["right", 622], ["-", 627], ["upper", 628], ["-", 633], ["quadrant", 634], ["gas", 643], ["sign", 647], ["(", 652], ["localized", 653], ["gas", 663], ["in", 667], ["the", 670], ["right", 674], ["upper", 680], ["quadrant", 686], [")", 694], [".", 695], ["One", 697], ["or", 701], ["more", 704], ["of", 709], ["these", 712], ["signs", 718], ["were", 724], ["present", 729], ["in", 737], ["26", 740], ["cases", 743], ["(", 749], ["59", 750], ["%", 752], [")", 753], ["of", 755], ["pneumoperitoneum", 758], [",", 774], ["including", 776], ["the", 786], ["right", 790], ["-", 795], ["upper", 796], ["-", 801], ["quadrant", 802], ["gas", 811], ["sign", 815], ["in", 820], ["18", 823], ["cases", 826], ["(", 832], ["41", 833], ["%", 835], [")", 836], [",", 837], ["Rigler", 839], ["'s", 845], ["sign", 848], ["in", 853], ["14", 856], ["cases", 859], ["(", 865], ["32", 866], ["%", 868], [")", 869], [",", 870], ["and", 872], ["the", 876], ["falciform", 880], ["ligament", 890], ["and", 899], ["football", 903], ["signs", 912], ["in", 918], ["one", 921], ["case", 925], ["each", 930], ["(", 935], ["2", 936], ["%", 937], [")", 938], [".", 939], ["Unfortunately", 941], [",", 954], ["there", 956], ["were", 962], ["frequent", 967], ["errors", 976], ["in", 983], ["the", 986], ["interpretation", 990], ["of", 1005], ["the", 1008], ["right", 1012], ["-", 1017], ["upper", 1018], ["-", 1023], ["quadrant", 1024], ["gas", 1033], ["sign", 1037], ["and", 1042], ["Rigler", 1046], ["'s", 1052], ["sign", 1055], [",", 1059], ["with", 1061], ["a", 1066], ["total", 1068], ["of", 1074], ["11", 1077], ["false", 1080], ["-", 1085], ["positive", 1086], ["cases", 1095], ["(", 1101], ["13", 1102], ["%", 1104], [")", 1105], [".", 1106], ["Further", 1108], ["analysis", 1116], ["of", 1125], ["the", 1128], ["true", 1132], ["-", 1136], ["positive", 1137], ["right", 1146], ["-", 1151], ["upper", 1152], ["-", 1157], ["quadrant", 1158], ["gas", 1167], ["signs", 1171], ["showed", 1177], ["that", 1184], ["these", 1189], ["gas", 1195], ["collections", 1199], ["were", 1211], ["always", 1216], ["triangular", 1223], ["or", 1234], ["linear", 1237], ["with", 1244], ["an", 1249], ["inferolateral", 1252], ["to", 1266], ["superomedial", 1269], ["orientation", 1282], ["and", 1294], [",", 1297], ["if", 1299], ["triangular", 1302], [",", 1312], ["a", 1314], ["concave", 1316], ["superolateral", 1324], ["border", 1338], [".", 1344], ["In", 1346], ["the", 1349], ["true", 1353], ["-", 1357], ["positive", 1358], ["Rigler", 1367], ["'s", 1373], ["signs", 1376], [",", 1381], ["the", 1383], ["bowel", 1387], ["wall", 1393], ["thickness", 1398], ["ranged", 1408], ["from", 1415], ["1", 1420], ["to", 1422], ["8", 1425], ["mm", 1427], [",", 1429], ["whereas", 1431], ["the", 1439], ["false", 1443], ["positives", 1449], ["all", 1459], ["had", 1463], ["a", 1467], ["bowel", 1469], ["wall", 1475], ["thickness", 1480], ["of", 1490], ["1", 1493], ["mm", 1495], ["or", 1498], ["less", 1501], [".", 1505], ["Proper", 1507], ["interpretation", 1514], ["of", 1529], ["the", 1532], ["various", 1536], ["signs", 1544], ["of", 1550], ["pneumoperitoneum", 1553], ["on", 1570], ["supine", 1573], ["films", 1580], ["should", 1586], ["lead", 1593], ["to", 1598], ["more", 1601], ["accurate", 1606], ["diagnosis", 1615], ["of", 1625], ["this", 1628], ["condition", 1633], [".", 1642]]}
{"context": "Using post-embedding immunogold electron microscopy, TAR DNA-binding protein of 43 kDa (TDP-43) was localized to neuronal cytoplasmic (NCI) and intranuclear (NII) inclusions, as well as unmyelinated neurites, in frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U), amyotrophic lateral sclerosis (ALS), Alzheimer's (AD), Pick's disease (PiD) and Lewy body disease (LBD). The TDP-43 immunoreactive structures were morphologically heterogeneous. The most common was characterized by bundles of 10-20 nm diameter straight filaments with electron dense granular material within NCI, NII and neurites. This type of pathology was found in FTLD-U, ALS and some cases of AD. Less often, inclusions in neuritic processes of FTLD-U and some cases of AD contained 10-17 nm diameter straight filaments without granular material. A final type of TDP-43 immunoreactivity was labeling of filaments and granular material associated with tau filaments in neurofibrillary tangles of AD and Pick bodies of PiD or alpha-synuclein filaments in Lewy bodies of LBD. The results suggest that TDP-43 is the primary component of the granulofilamentous inclusions in FTLD-U and ALS. Similar inclusions sometimes accompany filamentous aggregates composed of other abnormal proteins in AD, PiD and LBD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "2f91c196e1e14427999116eb471acf92", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[189, 191]], "char_spans": [[1014, 1028]]}]}], "context_tokens": [["Using", 0], ["post", 6], ["-", 10], ["embedding", 11], ["immunogold", 21], ["electron", 32], ["microscopy", 41], [",", 51], ["TAR", 53], ["DNA", 57], ["-", 60], ["binding", 61], ["protein", 69], ["of", 77], ["43", 80], ["kDa", 83], ["(", 87], ["TDP-43", 88], [")", 94], ["was", 96], ["localized", 100], ["to", 110], ["neuronal", 113], ["cytoplasmic", 122], ["(", 134], ["NCI", 135], [")", 138], ["and", 140], ["intranuclear", 144], ["(", 157], ["NII", 158], [")", 161], ["inclusions", 163], [",", 173], ["as", 175], ["well", 178], ["as", 183], ["unmyelinated", 186], ["neurites", 199], [",", 207], ["in", 209], ["frontotemporal", 212], ["lobar", 227], ["degeneration", 233], ["with", 246], ["ubiquitinated", 251], ["inclusions", 265], ["(", 276], ["FTLD", 277], ["-", 281], ["U", 282], [")", 283], [",", 284], ["amyotrophic", 286], ["lateral", 298], ["sclerosis", 306], ["(", 316], ["ALS", 317], [")", 320], [",", 321], ["Alzheimer", 323], ["'s", 332], ["(", 335], ["AD", 336], [")", 338], [",", 339], ["Pick", 341], ["'s", 345], ["disease", 348], ["(", 356], ["PiD", 357], [")", 360], ["and", 362], ["Lewy", 366], ["body", 371], ["disease", 376], ["(", 384], ["LBD", 385], [")", 388], [".", 389], ["The", 391], ["TDP-43", 395], ["immunoreactive", 402], ["structures", 417], ["were", 428], ["morphologically", 433], ["heterogeneous", 449], [".", 462], ["The", 464], ["most", 468], ["common", 473], ["was", 480], ["characterized", 484], ["by", 498], ["bundles", 501], ["of", 509], ["10", 512], ["-", 514], ["20", 515], ["nm", 518], ["diameter", 521], ["straight", 530], ["filaments", 539], ["with", 549], ["electron", 554], ["dense", 563], ["granular", 569], ["material", 578], ["within", 587], ["NCI", 594], [",", 597], ["NII", 599], ["and", 603], ["neurites", 607], [".", 615], ["This", 617], ["type", 622], ["of", 627], ["pathology", 630], ["was", 640], ["found", 644], ["in", 650], ["FTLD", 653], ["-", 657], ["U", 658], [",", 659], ["ALS", 661], ["and", 665], ["some", 669], ["cases", 674], ["of", 680], ["AD", 683], [".", 685], ["Less", 687], ["often", 692], [",", 697], ["inclusions", 699], ["in", 710], ["neuritic", 713], ["processes", 722], ["of", 732], ["FTLD", 735], ["-", 739], ["U", 740], ["and", 742], ["some", 746], ["cases", 751], ["of", 757], ["AD", 760], ["contained", 763], ["10", 773], ["-", 775], ["17", 776], ["nm", 779], ["diameter", 782], ["straight", 791], ["filaments", 800], ["without", 810], ["granular", 818], ["material", 827], [".", 835], ["A", 837], ["final", 839], ["type", 845], ["of", 850], ["TDP-43", 853], ["immunoreactivity", 860], ["was", 877], ["labeling", 881], ["of", 890], ["filaments", 893], ["and", 903], ["granular", 907], ["material", 916], ["associated", 925], ["with", 936], ["tau", 941], ["filaments", 945], ["in", 955], ["neurofibrillary", 958], ["tangles", 974], ["of", 982], ["AD", 985], ["and", 988], ["Pick", 992], ["bodies", 997], ["of", 1004], ["PiD", 1007], ["or", 1011], ["alpha", 1014], ["-", 1019], ["synuclein", 1020], ["filaments", 1030], ["in", 1040], ["Lewy", 1043], ["bodies", 1048], ["of", 1055], ["LBD", 1058], [".", 1061], ["The", 1063], ["results", 1067], ["suggest", 1075], ["that", 1083], ["TDP-43", 1088], ["is", 1095], ["the", 1098], ["primary", 1102], ["component", 1110], ["of", 1120], ["the", 1123], ["granulofilamentous", 1127], ["inclusions", 1146], ["in", 1157], ["FTLD", 1160], ["-", 1164], ["U", 1165], ["and", 1167], ["ALS", 1171], [".", 1174], ["Similar", 1176], ["inclusions", 1184], ["sometimes", 1195], ["accompany", 1205], ["filamentous", 1215], ["aggregates", 1227], ["composed", 1238], ["of", 1247], ["other", 1250], ["abnormal", 1256], ["proteins", 1265], ["in", 1274], ["AD", 1277], [",", 1279], ["PiD", 1281], ["and", 1285], ["LBD", 1289], [".", 1292]]}
{"context": "Nerve growth factor (NGF) antagonism has long been proposed as a chronic pain treatment. In 2010, the FDA suspended clinical trials using tanezumab, a humanized monoclonal anti-NGF antibody, to treat osteoarthritis due to worsening joint damage in 16 patients. Increased physical activity in the absence of acute pain which normally prevents self-harm was purported as a potential cause. Such an adverse effect is consistent with an extension of tanezumab's primary mechanism of action by decreasing pain sensitivity below baseline levels. In animal inflammatory pain models, NGF antagonism decreases intraepidermal nerve fiber (IENF) density and attenuates increases in expression of nociception-related proteins, such as calcitonin gene-related peptide (CGRP) and substance P (SP). Little is known of the effects of NGF antagonism in noninflamed animals and the hypoalgesia that ensues. In the current study, we immunized rats with NGF or cytochrome C (cytC) and examined (1) nocifensive behaviors with thermal latencies, mechanical thresholds, the hot plate test, and the tail flick test, (2) IENF density, and (3) expression of CGRP, SP, voltage-gated sodium channel 1.8 (Nav1.8), and glutaminase in subpopulations of dorsal root ganglion (DRG) neurons separated by size and isolectin B4 (IB4) labeling. Rats with high anti-NGF titers had delayed responses on the hot plate test but no other behavioral abnormalities. Delayed hot plate responses correlated with lower IENF density. CGRP and SP expression was decreased principally in medium (400-800 \u03bcm(2)) and small neurons (<400 \u03bcm(2)), respectively, regardless of IB4 labeling. Expression of Nav1.8 was only decreased in small and medium IB4 negative neurons. NGF immunization appears to result in a more profound antagonism of NGF than tanezumab therapy, but we hypothesize that decreases in IENF density and nociception-related protein expression are potential mechanisms for tanezumab-induced hypoalgesia.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "589de266ea4f4f239030a2ea5f61bf8b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "NGF", "token_spans": [[165, 165], [251, 251], [335, 335], [100, 100], [4, 4], [324, 324], [33, 33], [145, 145]], "char_spans": [[934, 936], [1328, 1330], [1785, 1787], [576, 578], [21, 23], [1717, 1719], [177, 179], [818, 820]]}]}], "context_tokens": [["Nerve", 0], ["growth", 6], ["factor", 13], ["(", 20], ["NGF", 21], [")", 24], ["antagonism", 26], ["has", 37], ["long", 41], ["been", 46], ["proposed", 51], ["as", 60], ["a", 63], ["chronic", 65], ["pain", 73], ["treatment", 78], [".", 87], ["In", 89], ["2010", 92], [",", 96], ["the", 98], ["FDA", 102], ["suspended", 106], ["clinical", 116], ["trials", 125], ["using", 132], ["tanezumab", 138], [",", 147], ["a", 149], ["humanized", 151], ["monoclonal", 161], ["anti", 172], ["-", 176], ["NGF", 177], ["antibody", 181], [",", 189], ["to", 191], ["treat", 194], ["osteoarthritis", 200], ["due", 215], ["to", 219], ["worsening", 222], ["joint", 232], ["damage", 238], ["in", 245], ["16", 248], ["patients", 251], [".", 259], ["Increased", 261], ["physical", 271], ["activity", 280], ["in", 289], ["the", 292], ["absence", 296], ["of", 304], ["acute", 307], ["pain", 313], ["which", 318], ["normally", 324], ["prevents", 333], ["self", 342], ["-", 346], ["harm", 347], ["was", 352], ["purported", 356], ["as", 366], ["a", 369], ["potential", 371], ["cause", 381], [".", 386], ["Such", 388], ["an", 393], ["adverse", 396], ["effect", 404], ["is", 411], ["consistent", 414], ["with", 425], ["an", 430], ["extension", 433], ["of", 443], ["tanezumab", 446], ["'s", 455], ["primary", 458], ["mechanism", 466], ["of", 476], ["action", 479], ["by", 486], ["decreasing", 489], ["pain", 500], ["sensitivity", 505], ["below", 517], ["baseline", 523], ["levels", 532], [".", 538], ["In", 540], ["animal", 543], ["inflammatory", 550], ["pain", 563], ["models", 568], [",", 574], ["NGF", 576], ["antagonism", 580], ["decreases", 591], ["intraepidermal", 601], ["nerve", 616], ["fiber", 622], ["(", 628], ["IENF", 629], [")", 633], ["density", 635], ["and", 643], ["attenuates", 647], ["increases", 658], ["in", 668], ["expression", 671], ["of", 682], ["nociception", 685], ["-", 696], ["related", 697], ["proteins", 705], [",", 713], ["such", 715], ["as", 720], ["calcitonin", 723], ["gene", 734], ["-", 738], ["related", 739], ["peptide", 747], ["(", 755], ["CGRP", 756], [")", 760], ["and", 762], ["substance", 766], ["P", 776], ["(", 778], ["SP", 779], [")", 781], [".", 782], ["Little", 784], ["is", 791], ["known", 794], ["of", 800], ["the", 803], ["effects", 807], ["of", 815], ["NGF", 818], ["antagonism", 822], ["in", 833], ["noninflamed", 836], ["animals", 848], ["and", 856], ["the", 860], ["hypoalgesia", 864], ["that", 876], ["ensues", 881], [".", 887], ["In", 889], ["the", 892], ["current", 896], ["study", 904], [",", 909], ["we", 911], ["immunized", 914], ["rats", 924], ["with", 929], ["NGF", 934], ["or", 938], ["cytochrome", 941], ["C", 952], ["(", 954], ["cytC", 955], [")", 959], ["and", 961], ["examined", 965], ["(", 974], ["1", 975], [")", 976], ["nocifensive", 978], ["behaviors", 990], ["with", 1000], ["thermal", 1005], ["latencies", 1013], [",", 1022], ["mechanical", 1024], ["thresholds", 1035], [",", 1045], ["the", 1047], ["hot", 1051], ["plate", 1055], ["test", 1061], [",", 1065], ["and", 1067], ["the", 1071], ["tail", 1075], ["flick", 1080], ["test", 1086], [",", 1090], ["(", 1092], ["2", 1093], [")", 1094], ["IENF", 1096], ["density", 1101], [",", 1108], ["and", 1110], ["(", 1114], ["3", 1115], [")", 1116], ["expression", 1118], ["of", 1129], ["CGRP", 1132], [",", 1136], ["SP", 1138], [",", 1140], ["voltage", 1142], ["-", 1149], ["gated", 1150], ["sodium", 1156], ["channel", 1163], ["1.8", 1171], ["(", 1175], ["Nav1.8", 1176], [")", 1182], [",", 1183], ["and", 1185], ["glutaminase", 1189], ["in", 1201], ["subpopulations", 1204], ["of", 1219], ["dorsal", 1222], ["root", 1229], ["ganglion", 1234], ["(", 1243], ["DRG", 1244], [")", 1247], ["neurons", 1249], ["separated", 1257], ["by", 1267], ["size", 1270], ["and", 1275], ["isolectin", 1279], ["B4", 1289], ["(", 1292], ["IB4", 1293], [")", 1296], ["labeling", 1298], [".", 1306], ["Rats", 1308], ["with", 1313], ["high", 1318], ["anti", 1323], ["-", 1327], ["NGF", 1328], ["titers", 1332], ["had", 1339], ["delayed", 1343], ["responses", 1351], ["on", 1361], ["the", 1364], ["hot", 1368], ["plate", 1372], ["test", 1378], ["but", 1383], ["no", 1387], ["other", 1390], ["behavioral", 1396], ["abnormalities", 1407], [".", 1420], ["Delayed", 1422], ["hot", 1430], ["plate", 1434], ["responses", 1440], ["correlated", 1450], ["with", 1461], ["lower", 1466], ["IENF", 1472], ["density", 1477], [".", 1484], ["CGRP", 1486], ["and", 1491], ["SP", 1495], ["expression", 1498], ["was", 1509], ["decreased", 1513], ["principally", 1523], ["in", 1535], ["medium", 1538], ["(", 1545], ["400", 1546], ["-", 1549], ["800", 1550], ["\u03bcm(2", 1554], [")", 1558], [")", 1559], ["and", 1561], ["small", 1565], ["neurons", 1571], ["(", 1579], ["<", 1580], ["400", 1581], ["\u03bcm(2", 1585], [")", 1589], [")", 1590], [",", 1591], ["respectively", 1593], [",", 1605], ["regardless", 1607], ["of", 1618], ["IB4", 1621], ["labeling", 1625], [".", 1633], ["Expression", 1635], ["of", 1646], ["Nav1.8", 1649], ["was", 1656], ["only", 1660], ["decreased", 1665], ["in", 1675], ["small", 1678], ["and", 1684], ["medium", 1688], ["IB4", 1695], ["negative", 1699], ["neurons", 1708], [".", 1715], ["NGF", 1717], ["immunization", 1721], ["appears", 1734], ["to", 1742], ["result", 1745], ["in", 1752], ["a", 1755], ["more", 1757], ["profound", 1762], ["antagonism", 1771], ["of", 1782], ["NGF", 1785], ["than", 1789], ["tanezumab", 1794], ["therapy", 1804], [",", 1811], ["but", 1813], ["we", 1817], ["hypothesize", 1820], ["that", 1832], ["decreases", 1837], ["in", 1847], ["IENF", 1850], ["density", 1855], ["and", 1863], ["nociception", 1867], ["-", 1878], ["related", 1879], ["protein", 1887], ["expression", 1895], ["are", 1906], ["potential", 1910], ["mechanisms", 1920], ["for", 1931], ["tanezumab", 1935], ["-", 1944], ["induced", 1945], ["hypoalgesia", 1953], [".", 1964]]}
{"context": "Tumors of the central nervous system are the most frequent solid tumors in childhood. With 30-40% of this heterogenous group, low-grade astrocytomas represent the most common subtype. Neurofibromatosis type 1 (NF1) is strongly associated with the development of pilocytic astrocytoma (PA), frequently appearing as optic glioma. Neurofibromatosis 1 gene (NF1 ) fulfills the criteria of a tumor suppressor gene and is deleted or mutated heterozygously in patients with NF1. This suggests an involvement in the development of PA. To clarify whether silencing of NF1 by promoter methylation plays a role in PA and especially in optic glioma, the authors investigated the methylation status in 30 PA, 6 of which had optic glioma. However, no methylation was found at the NF1 promoter region in PA. To rule out that silencing of NF1 by promoter methylation is restricted to higher-grade astrocytomas, 15 pediatric WHO II degree and IV degree astrocytomas were analyzed: 12 astrocytomas II and 3 glioblastomas displayed no NF1 promoter methylation. The authors conclude that NF1 silencing by methylation plays no role in low-grade astrocytoma.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "50efbe779a774f9abfa654638c3497ac", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[64, 64], [192, 192], [83, 83], [100, 100], [140, 140], [39, 39], [152, 152], [184, 184]], "char_spans": [[354, 356], [1068, 1070], [467, 469], [559, 561], [766, 768], [210, 212], [823, 825], [1016, 1018]]}]}], "context_tokens": [["Tumors", 0], ["of", 7], ["the", 10], ["central", 14], ["nervous", 22], ["system", 30], ["are", 37], ["the", 41], ["most", 45], ["frequent", 50], ["solid", 59], ["tumors", 65], ["in", 72], ["childhood", 75], [".", 84], ["With", 86], ["30", 91], ["-", 93], ["40", 94], ["%", 96], ["of", 98], ["this", 101], ["heterogenous", 106], ["group", 119], [",", 124], ["low", 126], ["-", 129], ["grade", 130], ["astrocytomas", 136], ["represent", 149], ["the", 159], ["most", 163], ["common", 168], ["subtype", 175], [".", 182], ["Neurofibromatosis", 184], ["type", 202], ["1", 207], ["(", 209], ["NF1", 210], [")", 213], ["is", 215], ["strongly", 218], ["associated", 227], ["with", 238], ["the", 243], ["development", 247], ["of", 259], ["pilocytic", 262], ["astrocytoma", 272], ["(", 284], ["PA", 285], [")", 287], [",", 288], ["frequently", 290], ["appearing", 301], ["as", 311], ["optic", 314], ["glioma", 320], [".", 326], ["Neurofibromatosis", 328], ["1", 346], ["gene", 348], ["(", 353], ["NF1", 354], [")", 358], ["fulfills", 360], ["the", 369], ["criteria", 373], ["of", 382], ["a", 385], ["tumor", 387], ["suppressor", 393], ["gene", 404], ["and", 409], ["is", 413], ["deleted", 416], ["or", 424], ["mutated", 427], ["heterozygously", 435], ["in", 450], ["patients", 453], ["with", 462], ["NF1", 467], [".", 470], ["This", 472], ["suggests", 477], ["an", 486], ["involvement", 489], ["in", 501], ["the", 504], ["development", 508], ["of", 520], ["PA", 523], [".", 525], ["To", 527], ["clarify", 530], ["whether", 538], ["silencing", 546], ["of", 556], ["NF1", 559], ["by", 563], ["promoter", 566], ["methylation", 575], ["plays", 587], ["a", 593], ["role", 595], ["in", 600], ["PA", 603], ["and", 606], ["especially", 610], ["in", 621], ["optic", 624], ["glioma", 630], [",", 636], ["the", 638], ["authors", 642], ["investigated", 650], ["the", 663], ["methylation", 667], ["status", 679], ["in", 686], ["30", 689], ["PA", 692], [",", 694], ["6", 696], ["of", 698], ["which", 701], ["had", 707], ["optic", 711], ["glioma", 717], [".", 723], ["However", 725], [",", 732], ["no", 734], ["methylation", 737], ["was", 749], ["found", 753], ["at", 759], ["the", 762], ["NF1", 766], ["promoter", 770], ["region", 779], ["in", 786], ["PA", 789], [".", 791], ["To", 793], ["rule", 796], ["out", 801], ["that", 805], ["silencing", 810], ["of", 820], ["NF1", 823], ["by", 827], ["promoter", 830], ["methylation", 839], ["is", 851], ["restricted", 854], ["to", 865], ["higher", 868], ["-", 874], ["grade", 875], ["astrocytomas", 881], [",", 893], ["15", 895], ["pediatric", 898], ["WHO", 908], ["II", 912], ["degree", 915], ["and", 922], ["IV", 926], ["degree", 929], ["astrocytomas", 936], ["were", 949], ["analyzed", 954], [":", 962], ["12", 964], ["astrocytomas", 967], ["II", 980], ["and", 983], ["3", 987], ["glioblastomas", 989], ["displayed", 1003], ["no", 1013], ["NF1", 1016], ["promoter", 1020], ["methylation", 1029], [".", 1040], ["The", 1042], ["authors", 1046], ["conclude", 1054], ["that", 1063], ["NF1", 1068], ["silencing", 1072], ["by", 1082], ["methylation", 1085], ["plays", 1097], ["no", 1103], ["role", 1106], ["in", 1111], ["low", 1114], ["-", 1117], ["grade", 1118], ["astrocytoma", 1124], [".", 1135]]}
{"context": "Combination microbicide vaginal rings may be more effective than single microbicide rings at reducing/preventing sexual transmission of HIV. Here, we report the pre-clinical development and macaque pharmacokinetics of matrix-type silicone elastomer vaginal rings containing dapivirine and darunavir. Macaque rings containing 25 mg dapivirine, 100 mg dapivirine, 300 mg darunavir or 100 mg dapivirine+300 mg darunavir were manufactured and characterized by differential scanning calorimetry. In vitro release was assessed into isopropanol/water and simulated vaginal fluid. Macaque vaginal fluid and blood serum concentrations for both antiretrovirals were measured during 28 day ring use. Tissue levels were measured on day 28. Ex vivo challenge studies were performed on vaginal fluid samples and IC50 values were calculated. Darunavir caused a concentration-dependent reduction in the dapivirine melting temperature in both solid drug mixes and in the combination ring. In vitro release from rings was dependent on drug loading, the number of drugs present and the release medium. In macaques, serum concentrations of both microbicides were maintained between 10(1) and 10(2) pg/mL. Vaginal fluid levels ranged between 10(3) and 10(4) ng/g and between 10(4) and 10(5) ng/g for dapivirine and darunavir, respectively. Both dapivirine and darunavir showed very similar concentrations in each tissue type; the range of drug tissue concentrations followed the general rank order: vagina (1.8\u200a\u00d7\u200a10(3)-3.8\u200a\u00d7\u200a10(3) ng/g) \u200a>\u200acervix (9.4\u200a\u00d7\u200a10(1)-3.9\u200a\u00d7\u200a10(2) ng/g) \u200a>\u200auterus (0-108 ng/g) \u200a>\u200arectum (0-40 ng/g). Measured IC50 values were >2 ng/mL for both compounds. Based on these results, and in light of recent clinical progress of the 25 mg dapivirine ring, a combination vaginal ring containing dapivirine and darunavir is a viable second-generation HIV microbicide candidate.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "dc9bceb110f546b884dbdd371fc5a5b9", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[19, 19], [341, 341]], "char_spans": [[136, 138], [1846, 1848]]}]}], "context_tokens": [["Combination", 0], ["microbicide", 12], ["vaginal", 24], ["rings", 32], ["may", 38], ["be", 42], ["more", 45], ["effective", 50], ["than", 60], ["single", 65], ["microbicide", 72], ["rings", 84], ["at", 90], ["reducing", 93], ["/", 101], ["preventing", 102], ["sexual", 113], ["transmission", 120], ["of", 133], ["HIV", 136], [".", 139], ["Here", 141], [",", 145], ["we", 147], ["report", 150], ["the", 157], ["pre", 161], ["-", 164], ["clinical", 165], ["development", 174], ["and", 186], ["macaque", 190], ["pharmacokinetics", 198], ["of", 215], ["matrix", 218], ["-", 224], ["type", 225], ["silicone", 230], ["elastomer", 239], ["vaginal", 249], ["rings", 257], ["containing", 263], ["dapivirine", 274], ["and", 285], ["darunavir", 289], [".", 298], ["Macaque", 300], ["rings", 308], ["containing", 314], ["25", 325], ["mg", 328], ["dapivirine", 331], [",", 341], ["100", 343], ["mg", 347], ["dapivirine", 350], [",", 360], ["300", 362], ["mg", 366], ["darunavir", 369], ["or", 379], ["100", 382], ["mg", 386], ["dapivirine+300", 389], ["mg", 404], ["darunavir", 407], ["were", 417], ["manufactured", 422], ["and", 435], ["characterized", 439], ["by", 453], ["differential", 456], ["scanning", 469], ["calorimetry", 478], [".", 489], ["In", 491], ["vitro", 494], ["release", 500], ["was", 508], ["assessed", 512], ["into", 521], ["isopropanol", 526], ["/", 537], ["water", 538], ["and", 544], ["simulated", 548], ["vaginal", 558], ["fluid", 566], [".", 571], ["Macaque", 573], ["vaginal", 581], ["fluid", 589], ["and", 595], ["blood", 599], ["serum", 605], ["concentrations", 611], ["for", 626], ["both", 630], ["antiretrovirals", 635], ["were", 651], ["measured", 656], ["during", 665], ["28", 672], ["day", 675], ["ring", 679], ["use", 684], [".", 687], ["Tissue", 689], ["levels", 696], ["were", 703], ["measured", 708], ["on", 717], ["day", 720], ["28", 724], [".", 726], ["Ex", 728], ["vivo", 731], ["challenge", 736], ["studies", 746], ["were", 754], ["performed", 759], ["on", 769], ["vaginal", 772], ["fluid", 780], ["samples", 786], ["and", 794], ["IC50", 798], ["values", 803], ["were", 810], ["calculated", 815], [".", 825], ["Darunavir", 827], ["caused", 837], ["a", 844], ["concentration", 846], ["-", 859], ["dependent", 860], ["reduction", 870], ["in", 880], ["the", 883], ["dapivirine", 887], ["melting", 898], ["temperature", 906], ["in", 918], ["both", 921], ["solid", 926], ["drug", 932], ["mixes", 937], ["and", 943], ["in", 947], ["the", 950], ["combination", 954], ["ring", 966], [".", 970], ["In", 972], ["vitro", 975], ["release", 981], ["from", 989], ["rings", 994], ["was", 1000], ["dependent", 1004], ["on", 1014], ["drug", 1017], ["loading", 1022], [",", 1029], ["the", 1031], ["number", 1035], ["of", 1042], ["drugs", 1045], ["present", 1051], ["and", 1059], ["the", 1063], ["release", 1067], ["medium", 1075], [".", 1081], ["In", 1083], ["macaques", 1086], [",", 1094], ["serum", 1096], ["concentrations", 1102], ["of", 1117], ["both", 1120], ["microbicides", 1125], ["were", 1138], ["maintained", 1143], ["between", 1154], ["10(1", 1162], [")", 1166], ["and", 1168], ["10(2", 1172], [")", 1176], ["pg", 1178], ["/", 1180], ["mL.", 1181], ["Vaginal", 1185], ["fluid", 1193], ["levels", 1199], ["ranged", 1206], ["between", 1213], ["10(3", 1221], [")", 1225], ["and", 1227], ["10(4", 1231], [")", 1235], ["ng", 1237], ["/", 1239], ["g", 1240], ["and", 1242], ["between", 1246], ["10(4", 1254], [")", 1258], ["and", 1260], ["10(5", 1264], [")", 1268], ["ng", 1270], ["/", 1272], ["g", 1273], ["for", 1275], ["dapivirine", 1279], ["and", 1290], ["darunavir", 1294], [",", 1303], ["respectively", 1305], [".", 1317], ["Both", 1319], ["dapivirine", 1324], ["and", 1335], ["darunavir", 1339], ["showed", 1349], ["very", 1356], ["similar", 1361], ["concentrations", 1369], ["in", 1384], ["each", 1387], ["tissue", 1392], ["type", 1399], [";", 1403], ["the", 1405], ["range", 1409], ["of", 1415], ["drug", 1418], ["tissue", 1423], ["concentrations", 1430], ["followed", 1445], ["the", 1454], ["general", 1458], ["rank", 1466], ["order", 1471], [":", 1476], ["vagina", 1478], ["(", 1485], ["1.8", 1486], ["\u00d7", 1490], ["10(3)-3.8", 1492], ["\u00d7", 1502], ["10(3", 1504], [")", 1508], ["ng", 1510], ["/", 1512], ["g", 1513], [")", 1514], [">", 1517], ["cervix", 1519], ["(", 1526], ["9.4", 1527], ["\u00d7", 1531], ["10(1)-3.9", 1533], ["\u00d7", 1543], ["10(2", 1545], [")", 1549], ["ng", 1551], ["/", 1553], ["g", 1554], [")", 1555], [">", 1558], ["uterus", 1560], ["(", 1567], ["0", 1568], ["-", 1569], ["108", 1570], ["ng", 1574], ["/", 1576], ["g", 1577], [")", 1578], [">", 1581], ["rectum", 1583], ["(", 1590], ["0", 1591], ["-", 1592], ["40", 1593], ["ng", 1596], ["/", 1598], ["g", 1599], [")", 1600], [".", 1601], ["Measured", 1603], ["IC50", 1612], ["values", 1617], ["were", 1624], [">", 1629], ["2", 1630], ["ng", 1632], ["/", 1634], ["mL", 1635], ["for", 1638], ["both", 1642], ["compounds", 1647], [".", 1656], ["Based", 1658], ["on", 1664], ["these", 1667], ["results", 1673], [",", 1680], ["and", 1682], ["in", 1686], ["light", 1689], ["of", 1695], ["recent", 1698], ["clinical", 1705], ["progress", 1714], ["of", 1723], ["the", 1726], ["25", 1730], ["mg", 1733], ["dapivirine", 1736], ["ring", 1747], [",", 1751], ["a", 1753], ["combination", 1755], ["vaginal", 1767], ["ring", 1775], ["containing", 1780], ["dapivirine", 1791], ["and", 1802], ["darunavir", 1806], ["is", 1816], ["a", 1819], ["viable", 1821], ["second", 1828], ["-", 1834], ["generation", 1835], ["HIV", 1846], ["microbicide", 1850], ["candidate", 1862], [".", 1871]]}
{"context": "Mutations in FOXP2 cause developmental verbal dyspraxia (DVD), but only a few cases have been described. We characterize 13 patients with DVD--5 with hemizygous paternal deletions spanning the FOXP2 gene, 1 with a translocation interrupting FOXP2, and the remaining 7 with maternal uniparental disomy of chromosome 7 (UPD7), who were also given a diagnosis of Silver-Russell Syndrome (SRS). Of these individuals with DVD, all 12 for whom parental DNA was available showed absence of a paternal copy of FOXP2. Five other individuals with deletions of paternally inherited FOXP2 but with incomplete clinical information or phenotypes too complex to properly assess are also described. Four of the patients with DVD also meet criteria for autism spectrum disorder. Individuals with paternal UPD7 or with partial maternal UPD7 or deletion starting downstream of FOXP2 do not have DVD. Using quantitative real-time polymerase chain reaction, we show the maternally inherited FOXP2 to be comparatively underexpressed. Our results indicate that absence of paternal FOXP2 is the cause of DVD in patients with SRS with maternal UPD7. The data also point to a role for differential parent-of-origin expression of FOXP2 in human speech development.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "a5597097671740739398b8d4cab19549", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[32, 32], [93, 93], [181, 181], [211, 211], [148, 148], [103, 103], [40, 40], [168, 168], [2, 2]], "char_spans": [[193, 197], [502, 506], [1058, 1062], [1203, 1207], [858, 862], [571, 575], [241, 245], [970, 974], [13, 17]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["FOXP2", 13], ["cause", 19], ["developmental", 25], ["verbal", 39], ["dyspraxia", 46], ["(", 56], ["DVD", 57], [")", 60], [",", 61], ["but", 63], ["only", 67], ["a", 72], ["few", 74], ["cases", 78], ["have", 84], ["been", 89], ["described", 94], [".", 103], ["We", 105], ["characterize", 108], ["13", 121], ["patients", 124], ["with", 133], ["DVD--5", 138], ["with", 145], ["hemizygous", 150], ["paternal", 161], ["deletions", 170], ["spanning", 180], ["the", 189], ["FOXP2", 193], ["gene", 199], [",", 203], ["1", 205], ["with", 207], ["a", 212], ["translocation", 214], ["interrupting", 228], ["FOXP2", 241], [",", 246], ["and", 248], ["the", 252], ["remaining", 256], ["7", 266], ["with", 268], ["maternal", 273], ["uniparental", 282], ["disomy", 294], ["of", 301], ["chromosome", 304], ["7", 315], ["(", 317], ["UPD7", 318], [")", 322], [",", 323], ["who", 325], ["were", 329], ["also", 334], ["given", 339], ["a", 345], ["diagnosis", 347], ["of", 357], ["Silver", 360], ["-", 366], ["Russell", 367], ["Syndrome", 375], ["(", 384], ["SRS", 385], [")", 388], [".", 389], ["Of", 391], ["these", 394], ["individuals", 400], ["with", 412], ["DVD", 417], [",", 420], ["all", 422], ["12", 426], ["for", 429], ["whom", 433], ["parental", 438], ["DNA", 447], ["was", 451], ["available", 455], ["showed", 465], ["absence", 472], ["of", 480], ["a", 483], ["paternal", 485], ["copy", 494], ["of", 499], ["FOXP2", 502], [".", 507], ["Five", 509], ["other", 514], ["individuals", 520], ["with", 532], ["deletions", 537], ["of", 547], ["paternally", 550], ["inherited", 561], ["FOXP2", 571], ["but", 577], ["with", 581], ["incomplete", 586], ["clinical", 597], ["information", 606], ["or", 618], ["phenotypes", 621], ["too", 632], ["complex", 636], ["to", 644], ["properly", 647], ["assess", 656], ["are", 663], ["also", 667], ["described", 672], [".", 681], ["Four", 683], ["of", 688], ["the", 691], ["patients", 695], ["with", 704], ["DVD", 709], ["also", 713], ["meet", 718], ["criteria", 723], ["for", 732], ["autism", 736], ["spectrum", 743], ["disorder", 752], [".", 760], ["Individuals", 762], ["with", 774], ["paternal", 779], ["UPD7", 788], ["or", 793], ["with", 796], ["partial", 801], ["maternal", 809], ["UPD7", 818], ["or", 823], ["deletion", 826], ["starting", 835], ["downstream", 844], ["of", 855], ["FOXP2", 858], ["do", 864], ["not", 867], ["have", 871], ["DVD", 876], [".", 879], ["Using", 881], ["quantitative", 887], ["real", 900], ["-", 904], ["time", 905], ["polymerase", 910], ["chain", 921], ["reaction", 927], [",", 935], ["we", 937], ["show", 940], ["the", 945], ["maternally", 949], ["inherited", 960], ["FOXP2", 970], ["to", 976], ["be", 979], ["comparatively", 982], ["underexpressed", 996], [".", 1010], ["Our", 1012], ["results", 1016], ["indicate", 1024], ["that", 1033], ["absence", 1038], ["of", 1046], ["paternal", 1049], ["FOXP2", 1058], ["is", 1064], ["the", 1067], ["cause", 1071], ["of", 1077], ["DVD", 1080], ["in", 1084], ["patients", 1087], ["with", 1096], ["SRS", 1101], ["with", 1105], ["maternal", 1110], ["UPD7", 1119], [".", 1123], ["The", 1125], ["data", 1129], ["also", 1134], ["point", 1139], ["to", 1145], ["a", 1148], ["role", 1150], ["for", 1155], ["differential", 1159], ["parent", 1172], ["-", 1178], ["of", 1179], ["-", 1181], ["origin", 1182], ["expression", 1189], ["of", 1200], ["FOXP2", 1203], ["in", 1209], ["human", 1212], ["speech", 1218], ["development", 1225], [".", 1236]]}
{"context": "Our previous work has shown that gene knockout of the sodium-glucose cotransporter SGLT2 modestly lowered blood glucose in streptozotocin-diabetic mice (BG; from 470 to 300 mg/dl) and prevented glomerular hyperfiltration but did not attenuate albuminuria or renal growth and inflammation. Here we determined effects of the SGLT2 inhibitor empagliflozin (300 mg/kg of diet for 15 wk; corresponding to 60-80 mg\u00b7kg(-1)\u00b7day(-1)) in type 1 diabetic Akita mice that, opposite to streptozotocin-diabetes, upregulate renal SGLT2 expression. Akita diabetes, empagliflozin, and Akita + empagliflozin similarly increased renal membrane SGLT2 expression (by 38-56%) and reduced the expression of SGLT1 (by 33-37%) vs. vehicle-treated wild-type controls (WT). The diabetes-induced changes in SGLT2/SGLT1 protein expression are expected to enhance the BG-lowering potential of SGLT2 inhibition, and empagliflozin strongly lowered BG in Akita (means of 187-237 vs. 517-535 mg/dl in vehicle group; 100-140 mg/dl in WT). Empagliflozin modestly reduced GFR in WT (250 vs. 306 \u03bcl/min) and completely prevented the diabetes-induced increase in glomerular filtration rate (GFR) (255 vs. 397 \u03bcl/min). Empagliflozin attenuated increases in kidney weight and urinary albumin/creatinine ratio in Akita in proportion to hyperglycemia. Empagliflozin did not increase urinary glucose/creatinine ratios in Akita, indicating the reduction in filtered glucose balanced the inhibition of glucose reabsorption. Empagliflozin attenuated/prevented the increase in systolic blood pressure, glomerular size, and molecular markers of kidney growth, inflammation, and gluconeogenesis in Akita. We propose that SGLT2 inhibition can lower GFR independent of reducing BG (consistent with the tubular hypothesis of diabetic glomerular hyperfiltration), while attenuation of albuminuria, kidney growth, and inflammation in the early diabetic kidney may mostly be secondary to lower BG.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "9be314d9fc724bababf59b5df8079c8c", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[14, 14], [163, 163], [313, 313], [56, 56], [94, 94], [110, 110]], "char_spans": [[83, 87], [863, 867], [1671, 1675], [323, 327], [515, 519], [625, 629]]}]}], "context_tokens": [["Our", 0], ["previous", 4], ["work", 13], ["has", 18], ["shown", 22], ["that", 28], ["gene", 33], ["knockout", 38], ["of", 47], ["the", 50], ["sodium", 54], ["-", 60], ["glucose", 61], ["cotransporter", 69], ["SGLT2", 83], ["modestly", 89], ["lowered", 98], ["blood", 106], ["glucose", 112], ["in", 120], ["streptozotocin", 123], ["-", 137], ["diabetic", 138], ["mice", 147], ["(", 152], ["BG", 153], [";", 155], ["from", 157], ["470", 162], ["to", 166], ["300", 169], ["mg", 173], ["/", 175], ["dl", 176], [")", 178], ["and", 180], ["prevented", 184], ["glomerular", 194], ["hyperfiltration", 205], ["but", 221], ["did", 225], ["not", 229], ["attenuate", 233], ["albuminuria", 243], ["or", 255], ["renal", 258], ["growth", 264], ["and", 271], ["inflammation", 275], [".", 287], ["Here", 289], ["we", 294], ["determined", 297], ["effects", 308], ["of", 316], ["the", 319], ["SGLT2", 323], ["inhibitor", 329], ["empagliflozin", 339], ["(", 353], ["300", 354], ["mg", 358], ["/", 360], ["kg", 361], ["of", 364], ["diet", 367], ["for", 372], ["15", 376], ["wk", 379], [";", 381], ["corresponding", 383], ["to", 397], ["60", 400], ["-", 402], ["80", 403], ["mg\u00b7kg(-1)\u00b7day(-1", 406], [")", 422], [")", 423], ["in", 425], ["type", 428], ["1", 433], ["diabetic", 435], ["Akita", 444], ["mice", 450], ["that", 455], [",", 459], ["opposite", 461], ["to", 470], ["streptozotocin", 473], ["-", 487], ["diabetes", 488], [",", 496], ["upregulate", 498], ["renal", 509], ["SGLT2", 515], ["expression", 521], [".", 531], ["Akita", 533], ["diabetes", 539], [",", 547], ["empagliflozin", 549], [",", 562], ["and", 564], ["Akita", 568], ["+", 574], ["empagliflozin", 576], ["similarly", 590], ["increased", 600], ["renal", 610], ["membrane", 616], ["SGLT2", 625], ["expression", 631], ["(", 642], ["by", 643], ["38", 646], ["-", 648], ["56", 649], ["%", 651], [")", 652], ["and", 654], ["reduced", 658], ["the", 666], ["expression", 670], ["of", 681], ["SGLT1", 684], ["(", 690], ["by", 691], ["33", 694], ["-", 696], ["37", 697], ["%", 699], [")", 700], ["vs.", 702], ["vehicle", 706], ["-", 713], ["treated", 714], ["wild", 722], ["-", 726], ["type", 727], ["controls", 732], ["(", 741], ["WT", 742], [")", 744], [".", 745], ["The", 747], ["diabetes", 751], ["-", 759], ["induced", 760], ["changes", 768], ["in", 776], ["SGLT2/SGLT1", 779], ["protein", 791], ["expression", 799], ["are", 810], ["expected", 814], ["to", 823], ["enhance", 826], ["the", 834], ["BG", 838], ["-", 840], ["lowering", 841], ["potential", 850], ["of", 860], ["SGLT2", 863], ["inhibition", 869], [",", 879], ["and", 881], ["empagliflozin", 885], ["strongly", 899], ["lowered", 908], ["BG", 916], ["in", 919], ["Akita", 922], ["(", 928], ["means", 929], ["of", 935], ["187", 938], ["-", 941], ["237", 942], ["vs.", 946], ["517", 950], ["-", 953], ["535", 954], ["mg", 958], ["/", 960], ["dl", 961], ["in", 964], ["vehicle", 967], ["group", 975], [";", 980], ["100", 982], ["-", 985], ["140", 986], ["mg", 990], ["/", 992], ["dl", 993], ["in", 996], ["WT", 999], [")", 1001], [".", 1002], ["Empagliflozin", 1004], ["modestly", 1018], ["reduced", 1027], ["GFR", 1035], ["in", 1039], ["WT", 1042], ["(", 1045], ["250", 1046], ["vs.", 1050], ["306", 1054], ["\u03bcl", 1058], ["/", 1060], ["min", 1061], [")", 1064], ["and", 1066], ["completely", 1070], ["prevented", 1081], ["the", 1091], ["diabetes", 1095], ["-", 1103], ["induced", 1104], ["increase", 1112], ["in", 1121], ["glomerular", 1124], ["filtration", 1135], ["rate", 1146], ["(", 1151], ["GFR", 1152], [")", 1155], ["(", 1157], ["255", 1158], ["vs.", 1162], ["397", 1166], ["\u03bcl", 1170], ["/", 1172], ["min", 1173], [")", 1176], [".", 1177], ["Empagliflozin", 1179], ["attenuated", 1193], ["increases", 1204], ["in", 1214], ["kidney", 1217], ["weight", 1224], ["and", 1231], ["urinary", 1235], ["albumin", 1243], ["/", 1250], ["creatinine", 1251], ["ratio", 1262], ["in", 1268], ["Akita", 1271], ["in", 1277], ["proportion", 1280], ["to", 1291], ["hyperglycemia", 1294], [".", 1307], ["Empagliflozin", 1309], ["did", 1323], ["not", 1327], ["increase", 1331], ["urinary", 1340], ["glucose", 1348], ["/", 1355], ["creatinine", 1356], ["ratios", 1367], ["in", 1374], ["Akita", 1377], [",", 1382], ["indicating", 1384], ["the", 1395], ["reduction", 1399], ["in", 1409], ["filtered", 1412], ["glucose", 1421], ["balanced", 1429], ["the", 1438], ["inhibition", 1442], ["of", 1453], ["glucose", 1456], ["reabsorption", 1464], [".", 1476], ["Empagliflozin", 1478], ["attenuated", 1492], ["/", 1502], ["prevented", 1503], ["the", 1513], ["increase", 1517], ["in", 1526], ["systolic", 1529], ["blood", 1538], ["pressure", 1544], [",", 1552], ["glomerular", 1554], ["size", 1565], [",", 1569], ["and", 1571], ["molecular", 1575], ["markers", 1585], ["of", 1593], ["kidney", 1596], ["growth", 1603], [",", 1609], ["inflammation", 1611], [",", 1623], ["and", 1625], ["gluconeogenesis", 1629], ["in", 1645], ["Akita", 1648], [".", 1653], ["We", 1655], ["propose", 1658], ["that", 1666], ["SGLT2", 1671], ["inhibition", 1677], ["can", 1688], ["lower", 1692], ["GFR", 1698], ["independent", 1702], ["of", 1714], ["reducing", 1717], ["BG", 1726], ["(", 1729], ["consistent", 1730], ["with", 1741], ["the", 1746], ["tubular", 1750], ["hypothesis", 1758], ["of", 1769], ["diabetic", 1772], ["glomerular", 1781], ["hyperfiltration", 1792], [")", 1807], [",", 1808], ["while", 1810], ["attenuation", 1816], ["of", 1828], ["albuminuria", 1831], [",", 1842], ["kidney", 1844], ["growth", 1851], [",", 1857], ["and", 1859], ["inflammation", 1863], ["in", 1876], ["the", 1879], ["early", 1883], ["diabetic", 1889], ["kidney", 1898], ["may", 1905], ["mostly", 1909], ["be", 1916], ["secondary", 1919], ["to", 1929], ["lower", 1932], ["BG", 1938], [".", 1940]]}
{"context": "Batten disease [juvenile-onset neuronal ceroid lipofuscinosis (JNCL)], the most common progressive encephalopathy of childhood, is caused by mutations in a novel lysosomal membrane protein (CLN3) with unknown function. In this study, we have confirmed the lysosomal localization of the CLN3 protein by immunoelectron microscopy by co-localizing it with soluble and membrane-associated lysosomal proteins. We have analysed the intracellular processing and localization of two mutants, 461-677del, which is present in 85% of CLN3 alleles and causes the classical JNCL, and E295K [corrected], which is a rare missense mutation associated with an atypical form of JNCL. Pulse-chase labelling and immunoprecipitation of the two mutant proteins in COS-1-cells indicated that 461-677del is synthesized as an approximately 24 kDa truncated polypeptide, whereas the maturation of E295K [corrected] resembles that of the wild-type CLN3 polypeptide. Transient expression of the two mutants in BHK cells showed that 461-677del is retained in the endoplasmic reticulum, whereas E295K [corrected] was capable of reaching the lysosomal compartment. The CLN3 polypeptides were expressed further in mouse primary neurons where the wild-type CLN3 protein was localized both in the cell soma and in neuronal extensions, whereas the 461-677del mutant was arrested in the cell soma. Interestingly, co-localization of the wild-type CLN3 and E295K [corrected] proteins with a synaptic vesicle marker indicates that the CLN3 protein might participate in synaptic vesicle transport/transmission. The data presented here provide clear evidence for a cellular distinction between classical and atypical forms of Batten disease both in neural and non-neural cells.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "6d7b3c37d90b4259923fc6b4defc1056", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[0, 1], [300, 301]], "char_spans": [[0, 13], [1685, 1698]]}, {"text": "juvenile-onset neuronal ceroid lipofuscinosis", "token_spans": [[3, 8]], "char_spans": [[16, 60]]}, {"text": "JNCL", "token_spans": [[120, 120], [99, 99], [10, 10]], "char_spans": [[660, 663], [561, 564], [63, 66]]}]}], "context_tokens": [["Batten", 0], ["disease", 7], ["[", 15], ["juvenile", 16], ["-", 24], ["onset", 25], ["neuronal", 31], ["ceroid", 40], ["lipofuscinosis", 47], ["(", 62], ["JNCL", 63], [")", 67], ["]", 68], [",", 69], ["the", 71], ["most", 75], ["common", 80], ["progressive", 87], ["encephalopathy", 99], ["of", 114], ["childhood", 117], [",", 126], ["is", 128], ["caused", 131], ["by", 138], ["mutations", 141], ["in", 151], ["a", 154], ["novel", 156], ["lysosomal", 162], ["membrane", 172], ["protein", 181], ["(", 189], ["CLN3", 190], [")", 194], ["with", 196], ["unknown", 201], ["function", 209], [".", 217], ["In", 219], ["this", 222], ["study", 227], [",", 232], ["we", 234], ["have", 237], ["confirmed", 242], ["the", 252], ["lysosomal", 256], ["localization", 266], ["of", 279], ["the", 282], ["CLN3", 286], ["protein", 291], ["by", 299], ["immunoelectron", 302], ["microscopy", 317], ["by", 328], ["co", 331], ["-", 333], ["localizing", 334], ["it", 345], ["with", 348], ["soluble", 353], ["and", 361], ["membrane", 365], ["-", 373], ["associated", 374], ["lysosomal", 385], ["proteins", 395], [".", 403], ["We", 405], ["have", 408], ["analysed", 413], ["the", 422], ["intracellular", 426], ["processing", 440], ["and", 451], ["localization", 455], ["of", 468], ["two", 471], ["mutants", 475], [",", 482], ["461", 484], ["-", 487], ["677del", 488], [",", 494], ["which", 496], ["is", 502], ["present", 505], ["in", 513], ["85", 516], ["%", 518], ["of", 520], ["CLN3", 523], ["alleles", 528], ["and", 536], ["causes", 540], ["the", 547], ["classical", 551], ["JNCL", 561], [",", 565], ["and", 567], ["E295", 571], ["K", 575], ["[", 577], ["corrected", 578], ["]", 587], [",", 588], ["which", 590], ["is", 596], ["a", 599], ["rare", 601], ["missense", 606], ["mutation", 615], ["associated", 624], ["with", 635], ["an", 640], ["atypical", 643], ["form", 652], ["of", 657], ["JNCL", 660], [".", 664], ["Pulse", 666], ["-", 671], ["chase", 672], ["labelling", 678], ["and", 688], ["immunoprecipitation", 692], ["of", 712], ["the", 715], ["two", 719], ["mutant", 723], ["proteins", 730], ["in", 739], ["COS-1-cells", 742], ["indicated", 754], ["that", 764], ["461", 769], ["-", 772], ["677del", 773], ["is", 780], ["synthesized", 783], ["as", 795], ["an", 798], ["approximately", 801], ["24", 815], ["kDa", 818], ["truncated", 822], ["polypeptide", 832], [",", 843], ["whereas", 845], ["the", 853], ["maturation", 857], ["of", 868], ["E295", 871], ["K", 875], ["[", 877], ["corrected", 878], ["]", 887], ["resembles", 889], ["that", 899], ["of", 904], ["the", 907], ["wild", 911], ["-", 915], ["type", 916], ["CLN3", 921], ["polypeptide", 926], [".", 937], ["Transient", 939], ["expression", 949], ["of", 960], ["the", 963], ["two", 967], ["mutants", 971], ["in", 979], ["BHK", 982], ["cells", 986], ["showed", 992], ["that", 999], ["461", 1004], ["-", 1007], ["677del", 1008], ["is", 1015], ["retained", 1018], ["in", 1027], ["the", 1030], ["endoplasmic", 1034], ["reticulum", 1046], [",", 1055], ["whereas", 1057], ["E295", 1065], ["K", 1069], ["[", 1071], ["corrected", 1072], ["]", 1081], ["was", 1083], ["capable", 1087], ["of", 1095], ["reaching", 1098], ["the", 1107], ["lysosomal", 1111], ["compartment", 1121], [".", 1132], ["The", 1134], ["CLN3", 1138], ["polypeptides", 1143], ["were", 1156], ["expressed", 1161], ["further", 1171], ["in", 1179], ["mouse", 1182], ["primary", 1188], ["neurons", 1196], ["where", 1204], ["the", 1210], ["wild", 1214], ["-", 1218], ["type", 1219], ["CLN3", 1224], ["protein", 1229], ["was", 1237], ["localized", 1241], ["both", 1251], ["in", 1256], ["the", 1259], ["cell", 1263], ["soma", 1268], ["and", 1273], ["in", 1277], ["neuronal", 1280], ["extensions", 1289], [",", 1299], ["whereas", 1301], ["the", 1309], ["461", 1313], ["-", 1316], ["677del", 1317], ["mutant", 1324], ["was", 1331], ["arrested", 1335], ["in", 1344], ["the", 1347], ["cell", 1351], ["soma", 1356], [".", 1360], ["Interestingly", 1362], [",", 1375], ["co", 1377], ["-", 1379], ["localization", 1380], ["of", 1393], ["the", 1396], ["wild", 1400], ["-", 1404], ["type", 1405], ["CLN3", 1410], ["and", 1415], ["E295", 1419], ["K", 1423], ["[", 1425], ["corrected", 1426], ["]", 1435], ["proteins", 1437], ["with", 1446], ["a", 1451], ["synaptic", 1453], ["vesicle", 1462], ["marker", 1470], ["indicates", 1477], ["that", 1487], ["the", 1492], ["CLN3", 1496], ["protein", 1501], ["might", 1509], ["participate", 1515], ["in", 1527], ["synaptic", 1530], ["vesicle", 1539], ["transport", 1547], ["/", 1556], ["transmission", 1557], [".", 1569], ["The", 1571], ["data", 1575], ["presented", 1580], ["here", 1590], ["provide", 1595], ["clear", 1603], ["evidence", 1609], ["for", 1618], ["a", 1622], ["cellular", 1624], ["distinction", 1633], ["between", 1645], ["classical", 1653], ["and", 1663], ["atypical", 1667], ["forms", 1676], ["of", 1682], ["Batten", 1685], ["disease", 1692], ["both", 1700], ["in", 1705], ["neural", 1708], ["and", 1715], ["non", 1719], ["-", 1722], ["neural", 1723], ["cells", 1730], [".", 1735]]}
{"context": "A novel Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II) inhibitor, KN-93 potently inhibits gastric acid secretion from parietal cells. As previously reported (1), treatment of parietal cells with a selective inhibitor of CaM kinase II, KN-62 resulted in the inhibition of cholinergic-stimulated rabbit parietal cell secretion, whereas it failed to inhibit the histamine and forskolin response. In contrast effects of carbachol, histamine and forskolin were significantly inhibited by KN-93 with an IC50 of 0.15, 0.3 and 1 microM, respectively; these effects occurred without any changes in intracellular cyclic AMP and Ca2+ levels. In the present study we investigated the mechanism by which KN-93 acts upon the acid-secreting machinery of gastric parietal cells. Neither redistribution of the proton pump activity nor the morphological transformation were affected by KN-93. The drug only weakly inhibited the H+, K(+)-ATPase activity but strongly dissipated the proton gradient formed in the gastric membrane vesicles and reduced the volume of luminal space. Thus KN-93 acts at pH gradient formation whereas KN-62 acts only at CaM Kinase II.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II", "CAMK2"], "qid": "b747f9b082a644009fdd2023df633b19", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "CaM kinase II", "token_spans": [[193, 195], [9, 11], [41, 43]], "char_spans": [[1141, 1153], [53, 65], [233, 245]]}]}], "context_tokens": [["A", 0], ["novel", 2], ["Ca2+/calmodulin", 8], ["-", 23], ["dependent", 24], ["protein", 34], ["kinase", 42], ["II", 49], ["(", 52], ["CaM", 53], ["Kinase", 57], ["II", 64], [")", 66], ["inhibitor", 68], [",", 77], ["KN-93", 79], ["potently", 85], ["inhibits", 94], ["gastric", 103], ["acid", 111], ["secretion", 116], ["from", 126], ["parietal", 131], ["cells", 140], [".", 145], ["As", 147], ["previously", 150], ["reported", 161], ["(", 170], ["1", 171], [")", 172], [",", 173], ["treatment", 175], ["of", 185], ["parietal", 188], ["cells", 197], ["with", 203], ["a", 208], ["selective", 210], ["inhibitor", 220], ["of", 230], ["CaM", 233], ["kinase", 237], ["II", 244], [",", 246], ["KN-62", 248], ["resulted", 254], ["in", 263], ["the", 266], ["inhibition", 270], ["of", 281], ["cholinergic", 284], ["-", 295], ["stimulated", 296], ["rabbit", 307], ["parietal", 314], ["cell", 323], ["secretion", 328], [",", 337], ["whereas", 339], ["it", 347], ["failed", 350], ["to", 357], ["inhibit", 360], ["the", 368], ["histamine", 372], ["and", 382], ["forskolin", 386], ["response", 396], [".", 404], ["In", 406], ["contrast", 409], ["effects", 418], ["of", 426], ["carbachol", 429], [",", 438], ["histamine", 440], ["and", 450], ["forskolin", 454], ["were", 464], ["significantly", 469], ["inhibited", 483], ["by", 493], ["KN-93", 496], ["with", 502], ["an", 507], ["IC50", 510], ["of", 515], ["0.15", 518], [",", 522], ["0.3", 524], ["and", 528], ["1", 532], ["microM", 534], [",", 540], ["respectively", 542], [";", 554], ["these", 556], ["effects", 562], ["occurred", 570], ["without", 579], ["any", 587], ["changes", 591], ["in", 599], ["intracellular", 602], ["cyclic", 616], ["AMP", 623], ["and", 627], ["Ca2", 631], ["+", 634], ["levels", 636], [".", 642], ["In", 644], ["the", 647], ["present", 651], ["study", 659], ["we", 665], ["investigated", 668], ["the", 681], ["mechanism", 685], ["by", 695], ["which", 698], ["KN-93", 704], ["acts", 710], ["upon", 715], ["the", 720], ["acid", 724], ["-", 728], ["secreting", 729], ["machinery", 739], ["of", 749], ["gastric", 752], ["parietal", 760], ["cells", 769], [".", 774], ["Neither", 776], ["redistribution", 784], ["of", 799], ["the", 802], ["proton", 806], ["pump", 813], ["activity", 818], ["nor", 827], ["the", 831], ["morphological", 835], ["transformation", 849], ["were", 864], ["affected", 869], ["by", 878], ["KN-93", 881], [".", 886], ["The", 888], ["drug", 892], ["only", 897], ["weakly", 902], ["inhibited", 909], ["the", 919], ["H+", 923], [",", 925], ["K(+)-ATPase", 927], ["activity", 939], ["but", 948], ["strongly", 952], ["dissipated", 961], ["the", 972], ["proton", 976], ["gradient", 983], ["formed", 992], ["in", 999], ["the", 1002], ["gastric", 1006], ["membrane", 1014], ["vesicles", 1023], ["and", 1032], ["reduced", 1036], ["the", 1044], ["volume", 1048], ["of", 1055], ["luminal", 1058], ["space", 1066], [".", 1071], ["Thus", 1073], ["KN-93", 1078], ["acts", 1084], ["at", 1089], ["pH", 1092], ["gradient", 1095], ["formation", 1104], ["whereas", 1114], ["KN-62", 1122], ["acts", 1128], ["only", 1133], ["at", 1138], ["CaM", 1141], ["Kinase", 1145], ["II", 1152], [".", 1154]]}
{"context": "The performance of two proteomic sample preparation methods, \"pseudoshotgun\" (PSG) and filter-aided sample preparation (FASP) were compared in terms of the number of identified proteins, representation of cellular component GO (gene ontology) categories in the obtained list of proteins, and the efficiency of both methods in the proteomic analysis of a very low number of cells. Both methods were combined to obtain a proteomic profile of a short-term culture (passage 3) of melanoma cells, established in our laboratory from a human metastatic melanoma lesion. The data revealed that with FASP, usually more proteins are identified than with PSG when analyzing a higher number of cells (\u2265 5000/injection), whereas PSG is favorable when analyzing only a very small amount of cells (250-500/injection). PSG and FASP, however, are complementary techniques, as combining both methods further increases the number of identified proteins. Moreover, we show that it is feasible to identify a substantial number of proteins from only 250 cells/injection that is equivalent to 60 ng of protein.", "qas": [{"question": "What is the method FASP used for?", "answers": ["proteomic sample preparation"], "qid": "302b827bb3634be7b8c958d4d56fa6da", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["method", 12], ["FASP", 19], ["used", 24], ["for", 29], ["?", 32]], "detected_answers": [{"text": "proteomic sample preparation", "token_spans": [[4, 6]], "char_spans": [[23, 50]]}]}], "context_tokens": [["The", 0], ["performance", 4], ["of", 16], ["two", 19], ["proteomic", 23], ["sample", 33], ["preparation", 40], ["methods", 52], [",", 59], ["\"", 61], ["pseudoshotgun", 62], ["\"", 75], ["(", 77], ["PSG", 78], [")", 81], ["and", 83], ["filter", 87], ["-", 93], ["aided", 94], ["sample", 100], ["preparation", 107], ["(", 119], ["FASP", 120], [")", 124], ["were", 126], ["compared", 131], ["in", 140], ["terms", 143], ["of", 149], ["the", 152], ["number", 156], ["of", 163], ["identified", 166], ["proteins", 177], [",", 185], ["representation", 187], ["of", 202], ["cellular", 205], ["component", 214], ["GO", 224], ["(", 227], ["gene", 228], ["ontology", 233], [")", 241], ["categories", 243], ["in", 254], ["the", 257], ["obtained", 261], ["list", 270], ["of", 275], ["proteins", 278], [",", 286], ["and", 288], ["the", 292], ["efficiency", 296], ["of", 307], ["both", 310], ["methods", 315], ["in", 323], ["the", 326], ["proteomic", 330], ["analysis", 340], ["of", 349], ["a", 352], ["very", 354], ["low", 359], ["number", 363], ["of", 370], ["cells", 373], [".", 378], ["Both", 380], ["methods", 385], ["were", 393], ["combined", 398], ["to", 407], ["obtain", 410], ["a", 417], ["proteomic", 419], ["profile", 429], ["of", 437], ["a", 440], ["short", 442], ["-", 447], ["term", 448], ["culture", 453], ["(", 461], ["passage", 462], ["3", 470], [")", 471], ["of", 473], ["melanoma", 476], ["cells", 485], [",", 490], ["established", 492], ["in", 504], ["our", 507], ["laboratory", 511], ["from", 522], ["a", 527], ["human", 529], ["metastatic", 535], ["melanoma", 546], ["lesion", 555], [".", 561], ["The", 563], ["data", 567], ["revealed", 572], ["that", 581], ["with", 586], ["FASP", 591], [",", 595], ["usually", 597], ["more", 605], ["proteins", 610], ["are", 619], ["identified", 623], ["than", 634], ["with", 639], ["PSG", 644], ["when", 648], ["analyzing", 653], ["a", 663], ["higher", 665], ["number", 672], ["of", 679], ["cells", 682], ["(", 688], ["\u2265", 689], ["5000/injection", 691], [")", 705], [",", 706], ["whereas", 708], ["PSG", 716], ["is", 720], ["favorable", 723], ["when", 733], ["analyzing", 738], ["only", 748], ["a", 753], ["very", 755], ["small", 760], ["amount", 766], ["of", 773], ["cells", 776], ["(", 782], ["250", 783], ["-", 786], ["500/injection", 787], [")", 800], [".", 801], ["PSG", 803], ["and", 807], ["FASP", 811], [",", 815], ["however", 817], [",", 824], ["are", 826], ["complementary", 830], ["techniques", 844], [",", 854], ["as", 856], ["combining", 859], ["both", 869], ["methods", 874], ["further", 882], ["increases", 890], ["the", 900], ["number", 904], ["of", 911], ["identified", 914], ["proteins", 925], [".", 933], ["Moreover", 935], [",", 943], ["we", 945], ["show", 948], ["that", 953], ["it", 958], ["is", 961], ["feasible", 964], ["to", 973], ["identify", 976], ["a", 985], ["substantial", 987], ["number", 999], ["of", 1006], ["proteins", 1009], ["from", 1018], ["only", 1023], ["250", 1028], ["cells", 1032], ["/", 1037], ["injection", 1038], ["that", 1048], ["is", 1053], ["equivalent", 1056], ["to", 1067], ["60", 1070], ["ng", 1073], ["of", 1076], ["protein", 1079], [".", 1086]]}
{"context": "Mutations in the solute carrier family 9, subfamily A member 6 (SLC9A6) gene, encoding the endosomal Na+/H+ exchanger 6 (NHE6) are associated with Christianson syndrome, a syndromic form of X-linked intellectual disability characterized by microcephaly, severe global developmental delay, autistic behavior, early onset seizures and ataxia. In a 7-year-old boy with characteristic clinical and neuroimaging features of Christianson syndrome and epileptic encephalopathy with continuous spikes and waves during sleep, we identified a novel splice site mutation (IVS10-1G>A) in SLC9A6. These findings expand the clinical spectrum of the syndrome and indicate NHE6 dysfunction as a new cause of electrical status epilepticus during slow-wave sleep (ESES).", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "9051b478ee6f41f98b58e2be06353573", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[100, 100], [13, 13]], "char_spans": [[576, 581], [64, 69]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["solute", 17], ["carrier", 24], ["family", 32], ["9", 39], [",", 40], ["subfamily", 42], ["A", 52], ["member", 54], ["6", 61], ["(", 63], ["SLC9A6", 64], [")", 70], ["gene", 72], [",", 76], ["encoding", 78], ["the", 87], ["endosomal", 91], ["Na+/H+", 101], ["exchanger", 108], ["6", 118], ["(", 120], ["NHE6", 121], [")", 125], ["are", 127], ["associated", 131], ["with", 142], ["Christianson", 147], ["syndrome", 160], [",", 168], ["a", 170], ["syndromic", 172], ["form", 182], ["of", 187], ["X", 190], ["-", 191], ["linked", 192], ["intellectual", 199], ["disability", 212], ["characterized", 223], ["by", 237], ["microcephaly", 240], [",", 252], ["severe", 254], ["global", 261], ["developmental", 268], ["delay", 282], [",", 287], ["autistic", 289], ["behavior", 298], [",", 306], ["early", 308], ["onset", 314], ["seizures", 320], ["and", 329], ["ataxia", 333], [".", 339], ["In", 341], ["a", 344], ["7-year", 346], ["-", 352], ["old", 353], ["boy", 357], ["with", 361], ["characteristic", 366], ["clinical", 381], ["and", 390], ["neuroimaging", 394], ["features", 407], ["of", 416], ["Christianson", 419], ["syndrome", 432], ["and", 441], ["epileptic", 445], ["encephalopathy", 455], ["with", 470], ["continuous", 475], ["spikes", 486], ["and", 493], ["waves", 497], ["during", 503], ["sleep", 510], [",", 515], ["we", 517], ["identified", 520], ["a", 531], ["novel", 533], ["splice", 539], ["site", 546], ["mutation", 551], ["(", 560], ["IVS10", 561], ["-", 566], ["1G", 567], [">", 569], ["A", 570], [")", 571], ["in", 573], ["SLC9A6", 576], [".", 582], ["These", 584], ["findings", 590], ["expand", 599], ["the", 606], ["clinical", 610], ["spectrum", 619], ["of", 628], ["the", 631], ["syndrome", 635], ["and", 644], ["indicate", 648], ["NHE6", 657], ["dysfunction", 662], ["as", 674], ["a", 677], ["new", 679], ["cause", 683], ["of", 689], ["electrical", 692], ["status", 703], ["epilepticus", 710], ["during", 722], ["slow", 729], ["-", 733], ["wave", 734], ["sleep", 739], ["(", 745], ["ESES", 746], [")", 750], [".", 751]]}
{"context": "Vaginal microbicides for the prevention of HIV transmission may be an important option for protecting women from infection. Incorporation of dapivirine, a lead candidate nonnucleoside reverse transcriptase inhibitor, into intravaginal rings (IVRs) for sustained mucosal delivery may increase microbicide product adherence and efficacy compared with conventional vaginal formulations. Twenty-four healthy HIV-negative women 18-35 years of age were randomly assigned (1:1:1) to dapivirine matrix IVR, dapivirine reservoir IVR, or placebo IVR. Dapivirine concentrations were measured in plasma and vaginal fluid samples collected at sequential time points over the 33-day study period (28 days of IVR use, 5 days of follow-up). Safety was assessed by pelvic/colposcopic examinations, clinical laboratory tests, and adverse events. Both IVR types were safe and well tolerated with similar adverse events observed in the placebo and dapivirine groups. Dapivirine from both IVR types was successfully distributed throughout the lower genital tract at concentrations over 4 logs greater than the EC50 against wild-type HIV-1 (LAI) in MT4 cells. Maximum concentration (Cmax) and area under the concentration-time curve (AUC) values were significantly higher with the matrix than reservoir IVR. Mean plasma concentrations of dapivirine were <2 ng/mL. These findings suggest that IVR delivery of microbicides is a viable option meriting further study.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "34061c30316348ec982b81f03c74200e", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[58, 58], [6, 6]], "char_spans": [[404, 406], [43, 45]]}]}], "context_tokens": [["Vaginal", 0], ["microbicides", 8], ["for", 21], ["the", 25], ["prevention", 29], ["of", 40], ["HIV", 43], ["transmission", 47], ["may", 60], ["be", 64], ["an", 67], ["important", 70], ["option", 80], ["for", 87], ["protecting", 91], ["women", 102], ["from", 108], ["infection", 113], [".", 122], ["Incorporation", 124], ["of", 138], ["dapivirine", 141], [",", 151], ["a", 153], ["lead", 155], ["candidate", 160], ["nonnucleoside", 170], ["reverse", 184], ["transcriptase", 192], ["inhibitor", 206], [",", 215], ["into", 217], ["intravaginal", 222], ["rings", 235], ["(", 241], ["IVRs", 242], [")", 246], ["for", 248], ["sustained", 252], ["mucosal", 262], ["delivery", 270], ["may", 279], ["increase", 283], ["microbicide", 292], ["product", 304], ["adherence", 312], ["and", 322], ["efficacy", 326], ["compared", 335], ["with", 344], ["conventional", 349], ["vaginal", 362], ["formulations", 370], [".", 382], ["Twenty", 384], ["-", 390], ["four", 391], ["healthy", 396], ["HIV", 404], ["-", 407], ["negative", 408], ["women", 417], ["18", 423], ["-", 425], ["35", 426], ["years", 429], ["of", 435], ["age", 438], ["were", 442], ["randomly", 447], ["assigned", 456], ["(", 465], ["1:1:1", 466], [")", 471], ["to", 473], ["dapivirine", 476], ["matrix", 487], ["IVR", 494], [",", 497], ["dapivirine", 499], ["reservoir", 510], ["IVR", 520], [",", 523], ["or", 525], ["placebo", 528], ["IVR", 536], [".", 539], ["Dapivirine", 541], ["concentrations", 552], ["were", 567], ["measured", 572], ["in", 581], ["plasma", 584], ["and", 591], ["vaginal", 595], ["fluid", 603], ["samples", 609], ["collected", 617], ["at", 627], ["sequential", 630], ["time", 641], ["points", 646], ["over", 653], ["the", 658], ["33-day", 662], ["study", 669], ["period", 675], ["(", 682], ["28", 683], ["days", 686], ["of", 691], ["IVR", 694], ["use", 698], [",", 701], ["5", 703], ["days", 705], ["of", 710], ["follow", 713], ["-", 719], ["up", 720], [")", 722], [".", 723], ["Safety", 725], ["was", 732], ["assessed", 736], ["by", 745], ["pelvic", 748], ["/", 754], ["colposcopic", 755], ["examinations", 767], [",", 779], ["clinical", 781], ["laboratory", 790], ["tests", 801], [",", 806], ["and", 808], ["adverse", 812], ["events", 820], [".", 826], ["Both", 828], ["IVR", 833], ["types", 837], ["were", 843], ["safe", 848], ["and", 853], ["well", 857], ["tolerated", 862], ["with", 872], ["similar", 877], ["adverse", 885], ["events", 893], ["observed", 900], ["in", 909], ["the", 912], ["placebo", 916], ["and", 924], ["dapivirine", 928], ["groups", 939], [".", 945], ["Dapivirine", 947], ["from", 958], ["both", 963], ["IVR", 968], ["types", 972], ["was", 978], ["successfully", 982], ["distributed", 995], ["throughout", 1007], ["the", 1018], ["lower", 1022], ["genital", 1028], ["tract", 1036], ["at", 1042], ["concentrations", 1045], ["over", 1060], ["4", 1065], ["logs", 1067], ["greater", 1072], ["than", 1080], ["the", 1085], ["EC50", 1089], ["against", 1094], ["wild", 1102], ["-", 1106], ["type", 1107], ["HIV-1", 1112], ["(", 1118], ["LAI", 1119], [")", 1122], ["in", 1124], ["MT4", 1127], ["cells", 1131], [".", 1136], ["Maximum", 1138], ["concentration", 1146], ["(", 1160], ["Cmax", 1161], [")", 1165], ["and", 1167], ["area", 1171], ["under", 1176], ["the", 1182], ["concentration", 1186], ["-", 1199], ["time", 1200], ["curve", 1205], ["(", 1211], ["AUC", 1212], [")", 1215], ["values", 1217], ["were", 1224], ["significantly", 1229], ["higher", 1243], ["with", 1250], ["the", 1255], ["matrix", 1259], ["than", 1266], ["reservoir", 1271], ["IVR", 1281], [".", 1284], ["Mean", 1286], ["plasma", 1291], ["concentrations", 1298], ["of", 1313], ["dapivirine", 1316], ["were", 1327], ["<", 1332], ["2", 1333], ["ng", 1335], ["/", 1337], ["mL.", 1338], ["These", 1342], ["findings", 1348], ["suggest", 1357], ["that", 1365], ["IVR", 1370], ["delivery", 1374], ["of", 1383], ["microbicides", 1386], ["is", 1399], ["a", 1402], ["viable", 1404], ["option", 1411], ["meriting", 1418], ["further", 1427], ["study", 1435], [".", 1440]]}
{"context": "Ribosomal protein S19 (RPS19) is frequently mutated in Diamond-Blackfan anemia (DBA), a rare congenital hypoplastic anemia. Recent studies have shown that RPS19 expression decreases during terminal erythroid differentiation. Currently no information is available on the subcellular localization of normal RPS19 and the potential effects of various RPS19 mutations on cellular localization. In the present study, using wild-type and mutant RPS19 cDNA, we explored the subcellular distribution of normal and mutant proteins in a fibroblast cell line (Cos-7 cells). RPS19 was detected primarily in the nucleus, and more specifically in the nucleoli, where RPS19 colocalized with the nucleolar protein nucleolin. Using various N-terminal and C-terminal deletion constructs, we identified 2 nucleolar localization signals (NoSs) in RPS19: the first comprising amino acids Met1 to Arg16 in the NH2-terminus and the second comprising Gly120 to Asn142 in the COOH-terminus. Importantly, 2 mutations identified in DBA patients, Val15Phe and Gly127Gln, each of which localized to 1 of the 2 NoS, failed to localize RPS19 to the nucleolus. In addition to their mislocalization, there was a dramatic decrease in the expression of the 2 mutant proteins compared to the wild type. This decrease in protein expression was specific for the mutant RPS19, since expression of other proteins was normal. The present findings enable us to document the nucleolar localization signals in RPS19 and help define the phenotypic consequences of some mutations in RPS19 in DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "457215d830bf41e89e644ec8a579e6a3", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[10, 13]], "char_spans": [[55, 77]]}, {"text": "DBA", "token_spans": [[173, 173], [15, 15], [269, 269]], "char_spans": [[1005, 1007], [80, 82], [1546, 1548]]}]}], "context_tokens": [["Ribosomal", 0], ["protein", 10], ["S19", 18], ["(", 22], ["RPS19", 23], [")", 28], ["is", 30], ["frequently", 33], ["mutated", 44], ["in", 52], ["Diamond", 55], ["-", 62], ["Blackfan", 63], ["anemia", 72], ["(", 79], ["DBA", 80], [")", 83], [",", 84], ["a", 86], ["rare", 88], ["congenital", 93], ["hypoplastic", 104], ["anemia", 116], [".", 122], ["Recent", 124], ["studies", 131], ["have", 139], ["shown", 144], ["that", 150], ["RPS19", 155], ["expression", 161], ["decreases", 172], ["during", 182], ["terminal", 189], ["erythroid", 198], ["differentiation", 208], [".", 223], ["Currently", 225], ["no", 235], ["information", 238], ["is", 250], ["available", 253], ["on", 263], ["the", 266], ["subcellular", 270], ["localization", 282], ["of", 295], ["normal", 298], ["RPS19", 305], ["and", 311], ["the", 315], ["potential", 319], ["effects", 329], ["of", 337], ["various", 340], ["RPS19", 348], ["mutations", 354], ["on", 364], ["cellular", 367], ["localization", 376], [".", 388], ["In", 390], ["the", 393], ["present", 397], ["study", 405], [",", 410], ["using", 412], ["wild", 418], ["-", 422], ["type", 423], ["and", 428], ["mutant", 432], ["RPS19", 439], ["cDNA", 445], [",", 449], ["we", 451], ["explored", 454], ["the", 463], ["subcellular", 467], ["distribution", 479], ["of", 492], ["normal", 495], ["and", 502], ["mutant", 506], ["proteins", 513], ["in", 522], ["a", 525], ["fibroblast", 527], ["cell", 538], ["line", 543], ["(", 548], ["Cos-7", 549], ["cells", 555], [")", 560], [".", 561], ["RPS19", 563], ["was", 569], ["detected", 573], ["primarily", 582], ["in", 592], ["the", 595], ["nucleus", 599], [",", 606], ["and", 608], ["more", 612], ["specifically", 617], ["in", 630], ["the", 633], ["nucleoli", 637], [",", 645], ["where", 647], ["RPS19", 653], ["colocalized", 659], ["with", 671], ["the", 676], ["nucleolar", 680], ["protein", 690], ["nucleolin", 698], [".", 707], ["Using", 709], ["various", 715], ["N", 723], ["-", 724], ["terminal", 725], ["and", 734], ["C", 738], ["-", 739], ["terminal", 740], ["deletion", 749], ["constructs", 758], [",", 768], ["we", 770], ["identified", 773], ["2", 784], ["nucleolar", 786], ["localization", 796], ["signals", 809], ["(", 817], ["NoSs", 818], [")", 822], ["in", 824], ["RPS19", 827], [":", 832], ["the", 834], ["first", 838], ["comprising", 844], ["amino", 855], ["acids", 861], ["Met1", 867], ["to", 872], ["Arg16", 875], ["in", 881], ["the", 884], ["NH2-terminus", 888], ["and", 901], ["the", 905], ["second", 909], ["comprising", 916], ["Gly120", 927], ["to", 934], ["Asn142", 937], ["in", 944], ["the", 947], ["COOH", 951], ["-", 955], ["terminus", 956], [".", 964], ["Importantly", 966], [",", 977], ["2", 979], ["mutations", 981], ["identified", 991], ["in", 1002], ["DBA", 1005], ["patients", 1009], [",", 1017], ["Val15Phe", 1019], ["and", 1028], ["Gly127Gln", 1032], [",", 1041], ["each", 1043], ["of", 1048], ["which", 1051], ["localized", 1057], ["to", 1067], ["1", 1070], ["of", 1072], ["the", 1075], ["2", 1079], ["NoS", 1081], [",", 1084], ["failed", 1086], ["to", 1093], ["localize", 1096], ["RPS19", 1105], ["to", 1111], ["the", 1114], ["nucleolus", 1118], [".", 1127], ["In", 1129], ["addition", 1132], ["to", 1141], ["their", 1144], ["mislocalization", 1150], [",", 1165], ["there", 1167], ["was", 1173], ["a", 1177], ["dramatic", 1179], ["decrease", 1188], ["in", 1197], ["the", 1200], ["expression", 1204], ["of", 1215], ["the", 1218], ["2", 1222], ["mutant", 1224], ["proteins", 1231], ["compared", 1240], ["to", 1249], ["the", 1252], ["wild", 1256], ["type", 1261], [".", 1265], ["This", 1267], ["decrease", 1272], ["in", 1281], ["protein", 1284], ["expression", 1292], ["was", 1303], ["specific", 1307], ["for", 1316], ["the", 1320], ["mutant", 1324], ["RPS19", 1331], [",", 1336], ["since", 1338], ["expression", 1344], ["of", 1355], ["other", 1358], ["proteins", 1364], ["was", 1373], ["normal", 1377], [".", 1383], ["The", 1385], ["present", 1389], ["findings", 1397], ["enable", 1406], ["us", 1413], ["to", 1416], ["document", 1419], ["the", 1428], ["nucleolar", 1432], ["localization", 1442], ["signals", 1455], ["in", 1463], ["RPS19", 1466], ["and", 1472], ["help", 1476], ["define", 1481], ["the", 1488], ["phenotypic", 1492], ["consequences", 1503], ["of", 1516], ["some", 1519], ["mutations", 1524], ["in", 1534], ["RPS19", 1537], ["in", 1543], ["DBA", 1546], [".", 1549]]}
{"context": "Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis. In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (nearly all of whom were negative for the human immunodeficiency virus) with pulmonary multidrug-resistant tuberculosis to receive delamanid, at a dose of 100 mg twice daily (161 patients) or 200 mg twice daily (160 patients), or placebo (160 patients) for 2 months in combination with a background drug regimen developed according to World Health Organization guidelines. Sputum cultures were assessed weekly with the use of both liquid broth and solid medium; sputum-culture conversion was defined as a series of five or more consecutive cultures that were negative for growth of M. tuberculosis. The primary efficacy end point was the proportion of patients with sputum-culture conversion in liquid broth medium at 2 months. Among patients who received a background drug regimen plus 100 mg of delamanid twice daily, 45.4% had sputum-culture conversion in liquid broth at 2 months, as compared with 29.6% of patients who received a background drug regimen plus placebo (P=0.008). Likewise, as compared with the placebo group, the group that received the background drug regimen plus 200 mg of delamanid twice daily had a higher proportion of patients with sputum-culture conversion (41.9%, P=0.04). The findings were similar with assessment of sputum-culture conversion in solid medium. Most adverse events were mild to moderate in severity and were evenly distributed across groups. Although no clinical events due to QT prolongation on electrocardiography were observed, QT prolongation was reported significantly more frequently in the groups that received delamanid. Delamanid was associated with an increase in sputum-culture conversion at 2 months among patients with multidrug-resistant tuberculosis. This finding suggests that delamanid could enhance treatment options for multidrug-resistant tuberculosis. (Funded by Otsuka Pharmaceutical Development and Commercialization; ClinicalTrials.gov number, NCT00685360.).", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "9dd06b2102304cdc8188c97c503ffb35", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[165, 165], [374, 374], [76, 76], [359, 359], [40, 40]], "char_spans": [[933, 944], [2152, 2163], [455, 466], [2045, 2056], [239, 250]]}]}], "context_tokens": [["Delamanid", 0], ["(", 10], ["OPC-67683", 11], [")", 20], [",", 21], ["a", 23], ["nitro", 25], ["-", 30], ["dihydro", 31], ["-", 38], ["imidazooxazole", 39], ["derivative", 54], [",", 64], ["is", 66], ["a", 69], ["new", 71], ["antituberculosis", 75], ["medication", 92], ["that", 103], ["inhibits", 108], ["mycolic", 117], ["acid", 125], ["synthesis", 130], ["and", 140], ["has", 144], ["shown", 148], ["potent", 154], ["in", 161], ["vitro", 164], ["and", 170], ["in", 174], ["vivo", 177], ["activity", 182], ["against", 191], ["drug", 199], ["-", 203], ["resistant", 204], ["strains", 214], ["of", 222], ["Mycobacterium", 225], ["tuberculosis", 239], [".", 251], ["In", 253], ["this", 256], ["randomized", 261], [",", 271], ["placebo", 273], ["-", 280], ["controlled", 281], [",", 291], ["multinational", 293], ["clinical", 307], ["trial", 316], [",", 321], ["we", 323], ["assigned", 326], ["481", 335], ["patients", 339], ["(", 348], ["nearly", 349], ["all", 356], ["of", 360], ["whom", 363], ["were", 368], ["negative", 373], ["for", 382], ["the", 386], ["human", 390], ["immunodeficiency", 396], ["virus", 413], [")", 418], ["with", 420], ["pulmonary", 425], ["multidrug", 435], ["-", 444], ["resistant", 445], ["tuberculosis", 455], ["to", 468], ["receive", 471], ["delamanid", 479], [",", 488], ["at", 490], ["a", 493], ["dose", 495], ["of", 500], ["100", 503], ["mg", 507], ["twice", 510], ["daily", 516], ["(", 522], ["161", 523], ["patients", 527], [")", 535], ["or", 537], ["200", 540], ["mg", 544], ["twice", 547], ["daily", 553], ["(", 559], ["160", 560], ["patients", 564], [")", 572], [",", 573], ["or", 575], ["placebo", 578], ["(", 586], ["160", 587], ["patients", 591], [")", 599], ["for", 601], ["2", 605], ["months", 607], ["in", 614], ["combination", 617], ["with", 629], ["a", 634], ["background", 636], ["drug", 647], ["regimen", 652], ["developed", 660], ["according", 670], ["to", 680], ["World", 683], ["Health", 689], ["Organization", 696], ["guidelines", 709], [".", 719], ["Sputum", 721], ["cultures", 728], ["were", 737], ["assessed", 742], ["weekly", 751], ["with", 758], ["the", 763], ["use", 767], ["of", 771], ["both", 774], ["liquid", 779], ["broth", 786], ["and", 792], ["solid", 796], ["medium", 802], [";", 808], ["sputum", 810], ["-", 816], ["culture", 817], ["conversion", 825], ["was", 836], ["defined", 840], ["as", 848], ["a", 851], ["series", 853], ["of", 860], ["five", 863], ["or", 868], ["more", 871], ["consecutive", 876], ["cultures", 888], ["that", 897], ["were", 902], ["negative", 907], ["for", 916], ["growth", 920], ["of", 927], ["M.", 930], ["tuberculosis", 933], [".", 945], ["The", 947], ["primary", 951], ["efficacy", 959], ["end", 968], ["point", 972], ["was", 978], ["the", 982], ["proportion", 986], ["of", 997], ["patients", 1000], ["with", 1009], ["sputum", 1014], ["-", 1020], ["culture", 1021], ["conversion", 1029], ["in", 1040], ["liquid", 1043], ["broth", 1050], ["medium", 1056], ["at", 1063], ["2", 1066], ["months", 1068], [".", 1074], ["Among", 1076], ["patients", 1082], ["who", 1091], ["received", 1095], ["a", 1104], ["background", 1106], ["drug", 1117], ["regimen", 1122], ["plus", 1130], ["100", 1135], ["mg", 1139], ["of", 1142], ["delamanid", 1145], ["twice", 1155], ["daily", 1161], [",", 1166], ["45.4", 1168], ["%", 1172], ["had", 1174], ["sputum", 1178], ["-", 1184], ["culture", 1185], ["conversion", 1193], ["in", 1204], ["liquid", 1207], ["broth", 1214], ["at", 1220], ["2", 1223], ["months", 1225], [",", 1231], ["as", 1233], ["compared", 1236], ["with", 1245], ["29.6", 1250], ["%", 1254], ["of", 1256], ["patients", 1259], ["who", 1268], ["received", 1272], ["a", 1281], ["background", 1283], ["drug", 1294], ["regimen", 1299], ["plus", 1307], ["placebo", 1312], ["(", 1320], ["P=0.008", 1321], [")", 1328], [".", 1329], ["Likewise", 1331], [",", 1339], ["as", 1341], ["compared", 1344], ["with", 1353], ["the", 1358], ["placebo", 1362], ["group", 1370], [",", 1375], ["the", 1377], ["group", 1381], ["that", 1387], ["received", 1392], ["the", 1401], ["background", 1405], ["drug", 1416], ["regimen", 1421], ["plus", 1429], ["200", 1434], ["mg", 1438], ["of", 1441], ["delamanid", 1444], ["twice", 1454], ["daily", 1460], ["had", 1466], ["a", 1470], ["higher", 1472], ["proportion", 1479], ["of", 1490], ["patients", 1493], ["with", 1502], ["sputum", 1507], ["-", 1513], ["culture", 1514], ["conversion", 1522], ["(", 1533], ["41.9", 1534], ["%", 1538], [",", 1539], ["P=0.04", 1541], [")", 1547], [".", 1548], ["The", 1550], ["findings", 1554], ["were", 1563], ["similar", 1568], ["with", 1576], ["assessment", 1581], ["of", 1592], ["sputum", 1595], ["-", 1601], ["culture", 1602], ["conversion", 1610], ["in", 1621], ["solid", 1624], ["medium", 1630], [".", 1636], ["Most", 1638], ["adverse", 1643], ["events", 1651], ["were", 1658], ["mild", 1663], ["to", 1668], ["moderate", 1671], ["in", 1680], ["severity", 1683], ["and", 1692], ["were", 1696], ["evenly", 1701], ["distributed", 1708], ["across", 1720], ["groups", 1727], [".", 1733], ["Although", 1735], ["no", 1744], ["clinical", 1747], ["events", 1756], ["due", 1763], ["to", 1767], ["QT", 1770], ["prolongation", 1773], ["on", 1786], ["electrocardiography", 1789], ["were", 1809], ["observed", 1814], [",", 1822], ["QT", 1824], ["prolongation", 1827], ["was", 1840], ["reported", 1844], ["significantly", 1853], ["more", 1867], ["frequently", 1872], ["in", 1883], ["the", 1886], ["groups", 1890], ["that", 1897], ["received", 1902], ["delamanid", 1911], [".", 1920], ["Delamanid", 1922], ["was", 1932], ["associated", 1936], ["with", 1947], ["an", 1952], ["increase", 1955], ["in", 1964], ["sputum", 1967], ["-", 1973], ["culture", 1974], ["conversion", 1982], ["at", 1993], ["2", 1996], ["months", 1998], ["among", 2005], ["patients", 2011], ["with", 2020], ["multidrug", 2025], ["-", 2034], ["resistant", 2035], ["tuberculosis", 2045], [".", 2057], ["This", 2059], ["finding", 2064], ["suggests", 2072], ["that", 2081], ["delamanid", 2086], ["could", 2096], ["enhance", 2102], ["treatment", 2110], ["options", 2120], ["for", 2128], ["multidrug", 2132], ["-", 2141], ["resistant", 2142], ["tuberculosis", 2152], [".", 2164], ["(", 2166], ["Funded", 2167], ["by", 2174], ["Otsuka", 2177], ["Pharmaceutical", 2184], ["Development", 2199], ["and", 2211], ["Commercialization", 2215], [";", 2232], ["ClinicalTrials.gov", 2234], ["number", 2253], [",", 2259], ["NCT00685360", 2261], [".", 2272], [")", 2273], [".", 2274]]}
{"context": "Osteoporosis is characterised by a progressive loss of bone mass and microarchitecture which leads to increased fracture risk. Some of the drugs available to date have shown reductions in vertebral and non-vertebral fracture risk. However, in the ageing population of industrialised countries, still more fractures happen today than are avoided, which highlights the large medical need for new treatment options, models, and strategies. Recent insights into bone biology, have led to a better understanding of bone cell functions and crosstalk between osteoblasts, osteoclasts, and osteocytes at the molecular level. In the future, the armamentarium against osteoporotic fractures will likely be enriched by (1.) new bone anabolic substances such as antibodies directed against the endogenous inhibitors of bone formation sclerostin and dickkopf-1, PTH and PTHrp analogues, and possibly calcilytics; (2.) new inhibitors of bone resorption such as cathepsin K inhibitors which may suppress osteoclast function without impairing osteoclast viability and thus maintain bone formation by preserving the osteoclast-osteoblast crosstalk, and denosumab, an already widely available antibody against RANKL which inhibits osteoclast formation, function, and survival; and (3.) new therapeutic strategies based on an extended understanding of the pathophysiology of osteoporosis which may include sequential therapies with two or more bone active substances aimed at optimising the management of bone capital acquired during adolescence and maintained during adulthood in terms of both quantity and quality. Finally, one of the future challenges will be to identify those patients and patient populations expected to benefit the most from a given drug therapy or regimen. The WHO fracture risk assessment tool FRAX\u00ae and improved access to bone mineral density measurements by DXA will play a key role in this regard.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "66863c5ce37e431c8b6c293c8776da2d", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[194, 194]], "char_spans": [[1192, 1196]]}]}], "context_tokens": [["Osteoporosis", 0], ["is", 13], ["characterised", 16], ["by", 30], ["a", 33], ["progressive", 35], ["loss", 47], ["of", 52], ["bone", 55], ["mass", 60], ["and", 65], ["microarchitecture", 69], ["which", 87], ["leads", 93], ["to", 99], ["increased", 102], ["fracture", 112], ["risk", 121], [".", 125], ["Some", 127], ["of", 132], ["the", 135], ["drugs", 139], ["available", 145], ["to", 155], ["date", 158], ["have", 163], ["shown", 168], ["reductions", 174], ["in", 185], ["vertebral", 188], ["and", 198], ["non", 202], ["-", 205], ["vertebral", 206], ["fracture", 216], ["risk", 225], [".", 229], ["However", 231], [",", 238], ["in", 240], ["the", 243], ["ageing", 247], ["population", 254], ["of", 265], ["industrialised", 268], ["countries", 283], [",", 292], ["still", 294], ["more", 300], ["fractures", 305], ["happen", 315], ["today", 322], ["than", 328], ["are", 333], ["avoided", 337], [",", 344], ["which", 346], ["highlights", 352], ["the", 363], ["large", 367], ["medical", 373], ["need", 381], ["for", 386], ["new", 390], ["treatment", 394], ["options", 404], [",", 411], ["models", 413], [",", 419], ["and", 421], ["strategies", 425], [".", 435], ["Recent", 437], ["insights", 444], ["into", 453], ["bone", 458], ["biology", 463], [",", 470], ["have", 472], ["led", 477], ["to", 481], ["a", 484], ["better", 486], ["understanding", 493], ["of", 507], ["bone", 510], ["cell", 515], ["functions", 520], ["and", 530], ["crosstalk", 534], ["between", 544], ["osteoblasts", 552], [",", 563], ["osteoclasts", 565], [",", 576], ["and", 578], ["osteocytes", 582], ["at", 593], ["the", 596], ["molecular", 600], ["level", 610], [".", 615], ["In", 617], ["the", 620], ["future", 624], [",", 630], ["the", 632], ["armamentarium", 636], ["against", 650], ["osteoporotic", 658], ["fractures", 671], ["will", 681], ["likely", 686], ["be", 693], ["enriched", 696], ["by", 705], ["(", 708], ["1", 709], [".", 710], [")", 711], ["new", 713], ["bone", 717], ["anabolic", 722], ["substances", 731], ["such", 742], ["as", 747], ["antibodies", 750], ["directed", 761], ["against", 770], ["the", 778], ["endogenous", 782], ["inhibitors", 793], ["of", 804], ["bone", 807], ["formation", 812], ["sclerostin", 822], ["and", 833], ["dickkopf-1", 837], [",", 847], ["PTH", 849], ["and", 853], ["PTHrp", 857], ["analogues", 863], [",", 872], ["and", 874], ["possibly", 878], ["calcilytics", 887], [";", 898], ["(", 900], ["2", 901], [".", 902], [")", 903], ["new", 905], ["inhibitors", 909], ["of", 920], ["bone", 923], ["resorption", 928], ["such", 939], ["as", 944], ["cathepsin", 947], ["K", 957], ["inhibitors", 959], ["which", 970], ["may", 976], ["suppress", 980], ["osteoclast", 989], ["function", 1000], ["without", 1009], ["impairing", 1017], ["osteoclast", 1027], ["viability", 1038], ["and", 1048], ["thus", 1052], ["maintain", 1057], ["bone", 1066], ["formation", 1071], ["by", 1081], ["preserving", 1084], ["the", 1095], ["osteoclast", 1099], ["-", 1109], ["osteoblast", 1110], ["crosstalk", 1121], [",", 1130], ["and", 1132], ["denosumab", 1136], [",", 1145], ["an", 1147], ["already", 1150], ["widely", 1158], ["available", 1165], ["antibody", 1175], ["against", 1184], ["RANKL", 1192], ["which", 1198], ["inhibits", 1204], ["osteoclast", 1213], ["formation", 1224], [",", 1233], ["function", 1235], [",", 1243], ["and", 1245], ["survival", 1249], [";", 1257], ["and", 1259], ["(", 1263], ["3", 1264], [".", 1265], [")", 1266], ["new", 1268], ["therapeutic", 1272], ["strategies", 1284], ["based", 1295], ["on", 1301], ["an", 1304], ["extended", 1307], ["understanding", 1316], ["of", 1330], ["the", 1333], ["pathophysiology", 1337], ["of", 1353], ["osteoporosis", 1356], ["which", 1369], ["may", 1375], ["include", 1379], ["sequential", 1387], ["therapies", 1398], ["with", 1408], ["two", 1413], ["or", 1417], ["more", 1420], ["bone", 1425], ["active", 1430], ["substances", 1437], ["aimed", 1448], ["at", 1454], ["optimising", 1457], ["the", 1468], ["management", 1472], ["of", 1483], ["bone", 1486], ["capital", 1491], ["acquired", 1499], ["during", 1508], ["adolescence", 1515], ["and", 1527], ["maintained", 1531], ["during", 1542], ["adulthood", 1549], ["in", 1559], ["terms", 1562], ["of", 1568], ["both", 1571], ["quantity", 1576], ["and", 1585], ["quality", 1589], [".", 1596], ["Finally", 1598], [",", 1605], ["one", 1607], ["of", 1611], ["the", 1614], ["future", 1618], ["challenges", 1625], ["will", 1636], ["be", 1641], ["to", 1644], ["identify", 1647], ["those", 1656], ["patients", 1662], ["and", 1671], ["patient", 1675], ["populations", 1683], ["expected", 1695], ["to", 1704], ["benefit", 1707], ["the", 1715], ["most", 1719], ["from", 1724], ["a", 1729], ["given", 1731], ["drug", 1737], ["therapy", 1742], ["or", 1750], ["regimen", 1753], [".", 1760], ["The", 1762], ["WHO", 1766], ["fracture", 1770], ["risk", 1779], ["assessment", 1784], ["tool", 1795], ["FRAX", 1800], ["\u00ae", 1804], ["and", 1806], ["improved", 1810], ["access", 1819], ["to", 1826], ["bone", 1829], ["mineral", 1834], ["density", 1842], ["measurements", 1850], ["by", 1863], ["DXA", 1866], ["will", 1870], ["play", 1875], ["a", 1880], ["key", 1882], ["role", 1886], ["in", 1891], ["this", 1894], ["regard", 1899], [".", 1905]]}
{"context": "Amyloid precursor protein (AbetaPP), a precursor of amyloid beta (Abeta) peptide, is one of the molecules involved in the pathogenesis of Alzheimer's disease (AD). Specific mutations in AbetaPP have been found in patients inheriting familial AD (FAD). These mutant AbetaPP proteins cause cell death in neuronal cell lines in vitro, but the molecular mechanism of cytotoxicity has not yet been clarified completely. We analyzed the cytotoxic mechanisms of the London-type AbetaPP mutant, V642I-AbetaPP, in primary cortical neurons utilizing an adenovirus-mediated gene transfer system. Expression of V642I-AbetaPP protein induced degeneration of the primary neurons. This cytotoxicity was blocked by pertussis toxin, a specific inhibitor for heterotrimeric G proteins, Go/i, and was suppressed by an inhibitor of caspase-3/7 and an antioxidant, glutathione ethyl ester. A specific inhibitor for NADPH oxidase, apocynin, but not a xanthine oxidase inhibitor or a nitric oxide inhibitor, blocked V642I-AbetaPP-induced cytotoxicity. Among mitogen-activated protein kinase (MAPK) family proteins, c-Jun N-terminal kinase (JNK) and p38MAPK, but not extracellular regulated kinase (ERK), were involved in this cytotoxic pathway. The V642I-AbetaPP-induced cytotoxicity was not suppressed by two secretase inhibitors, suggesting that Abeta does not play a major role in this cytotoxicity. Two neuroprotective factors, insulin-like growth factor I (IGF-I) and Humanin, protected these primary neurons from V642I-AbetaPP-induced cytotoxicity. Furthermore, interleukin-6 and -11 also attenuated this cytotoxicity. This study demonstrated that the signaling pathway activated by mutated AbetaPP in the primary neurons is the same as that by the other artificial insults such as antibody binding to AbetaPP and the artificial dimerization of cytoplasmic domain of AbetaPP. The potential of neurotrophic factors and cytokines in AD therapy is also indicated.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "67266c29b6f5450a9294e9b1d43aa376", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[27, 29]], "char_spans": [[138, 156]]}, {"text": "AD", "token_spans": [[343, 343], [45, 45], [31, 31]], "char_spans": [[1914, 1915], [242, 243], [159, 160]]}]}], "context_tokens": [["Amyloid", 0], ["precursor", 8], ["protein", 18], ["(", 26], ["AbetaPP", 27], [")", 34], [",", 35], ["a", 37], ["precursor", 39], ["of", 49], ["amyloid", 52], ["beta", 60], ["(", 65], ["Abeta", 66], [")", 71], ["peptide", 73], [",", 80], ["is", 82], ["one", 85], ["of", 89], ["the", 92], ["molecules", 96], ["involved", 106], ["in", 115], ["the", 118], ["pathogenesis", 122], ["of", 135], ["Alzheimer", 138], ["'s", 147], ["disease", 150], ["(", 158], ["AD", 159], [")", 161], [".", 162], ["Specific", 164], ["mutations", 173], ["in", 183], ["AbetaPP", 186], ["have", 194], ["been", 199], ["found", 204], ["in", 210], ["patients", 213], ["inheriting", 222], ["familial", 233], ["AD", 242], ["(", 245], ["FAD", 246], [")", 249], [".", 250], ["These", 252], ["mutant", 258], ["AbetaPP", 265], ["proteins", 273], ["cause", 282], ["cell", 288], ["death", 293], ["in", 299], ["neuronal", 302], ["cell", 311], ["lines", 316], ["in", 322], ["vitro", 325], [",", 330], ["but", 332], ["the", 336], ["molecular", 340], ["mechanism", 350], ["of", 360], ["cytotoxicity", 363], ["has", 376], ["not", 380], ["yet", 384], ["been", 388], ["clarified", 393], ["completely", 403], [".", 413], ["We", 415], ["analyzed", 418], ["the", 427], ["cytotoxic", 431], ["mechanisms", 441], ["of", 452], ["the", 455], ["London", 459], ["-", 465], ["type", 466], ["AbetaPP", 471], ["mutant", 479], [",", 485], ["V642I", 487], ["-", 492], ["AbetaPP", 493], [",", 500], ["in", 502], ["primary", 505], ["cortical", 513], ["neurons", 522], ["utilizing", 530], ["an", 540], ["adenovirus", 543], ["-", 553], ["mediated", 554], ["gene", 563], ["transfer", 568], ["system", 577], [".", 583], ["Expression", 585], ["of", 596], ["V642I", 599], ["-", 604], ["AbetaPP", 605], ["protein", 613], ["induced", 621], ["degeneration", 629], ["of", 642], ["the", 645], ["primary", 649], ["neurons", 657], [".", 664], ["This", 666], ["cytotoxicity", 671], ["was", 684], ["blocked", 688], ["by", 696], ["pertussis", 699], ["toxin", 709], [",", 714], ["a", 716], ["specific", 718], ["inhibitor", 727], ["for", 737], ["heterotrimeric", 741], ["G", 756], ["proteins", 758], [",", 766], ["Go", 768], ["/", 770], ["i", 771], [",", 772], ["and", 774], ["was", 778], ["suppressed", 782], ["by", 793], ["an", 796], ["inhibitor", 799], ["of", 809], ["caspase-3/7", 812], ["and", 824], ["an", 828], ["antioxidant", 831], [",", 842], ["glutathione", 844], ["ethyl", 856], ["ester", 862], [".", 867], ["A", 869], ["specific", 871], ["inhibitor", 880], ["for", 890], ["NADPH", 894], ["oxidase", 900], [",", 907], ["apocynin", 909], [",", 917], ["but", 919], ["not", 923], ["a", 927], ["xanthine", 929], ["oxidase", 938], ["inhibitor", 946], ["or", 956], ["a", 959], ["nitric", 961], ["oxide", 968], ["inhibitor", 974], [",", 983], ["blocked", 985], ["V642I", 993], ["-", 998], ["AbetaPP", 999], ["-", 1006], ["induced", 1007], ["cytotoxicity", 1015], [".", 1027], ["Among", 1029], ["mitogen", 1035], ["-", 1042], ["activated", 1043], ["protein", 1053], ["kinase", 1061], ["(", 1068], ["MAPK", 1069], [")", 1073], ["family", 1075], ["proteins", 1082], [",", 1090], ["c", 1092], ["-", 1093], ["Jun", 1094], ["N", 1098], ["-", 1099], ["terminal", 1100], ["kinase", 1109], ["(", 1116], ["JNK", 1117], [")", 1120], ["and", 1122], ["p38MAPK", 1126], [",", 1133], ["but", 1135], ["not", 1139], ["extracellular", 1143], ["regulated", 1157], ["kinase", 1167], ["(", 1174], ["ERK", 1175], [")", 1178], [",", 1179], ["were", 1181], ["involved", 1186], ["in", 1195], ["this", 1198], ["cytotoxic", 1203], ["pathway", 1213], [".", 1220], ["The", 1222], ["V642I", 1226], ["-", 1231], ["AbetaPP", 1232], ["-", 1239], ["induced", 1240], ["cytotoxicity", 1248], ["was", 1261], ["not", 1265], ["suppressed", 1269], ["by", 1280], ["two", 1283], ["secretase", 1287], ["inhibitors", 1297], [",", 1307], ["suggesting", 1309], ["that", 1320], ["Abeta", 1325], ["does", 1331], ["not", 1336], ["play", 1340], ["a", 1345], ["major", 1347], ["role", 1353], ["in", 1358], ["this", 1361], ["cytotoxicity", 1366], [".", 1378], ["Two", 1380], ["neuroprotective", 1384], ["factors", 1400], [",", 1407], ["insulin", 1409], ["-", 1416], ["like", 1417], ["growth", 1422], ["factor", 1429], ["I", 1436], ["(", 1438], ["IGF", 1439], ["-", 1442], ["I", 1443], [")", 1444], ["and", 1446], ["Humanin", 1450], [",", 1457], ["protected", 1459], ["these", 1469], ["primary", 1475], ["neurons", 1483], ["from", 1491], ["V642I", 1496], ["-", 1501], ["AbetaPP", 1502], ["-", 1509], ["induced", 1510], ["cytotoxicity", 1518], [".", 1530], ["Furthermore", 1532], [",", 1543], ["interleukin-6", 1545], ["and", 1559], ["-11", 1563], ["also", 1567], ["attenuated", 1572], ["this", 1583], ["cytotoxicity", 1588], [".", 1600], ["This", 1602], ["study", 1607], ["demonstrated", 1613], ["that", 1626], ["the", 1631], ["signaling", 1635], ["pathway", 1645], ["activated", 1653], ["by", 1663], ["mutated", 1666], ["AbetaPP", 1674], ["in", 1682], ["the", 1685], ["primary", 1689], ["neurons", 1697], ["is", 1705], ["the", 1708], ["same", 1712], ["as", 1717], ["that", 1720], ["by", 1725], ["the", 1728], ["other", 1732], ["artificial", 1738], ["insults", 1749], ["such", 1757], ["as", 1762], ["antibody", 1765], ["binding", 1774], ["to", 1782], ["AbetaPP", 1785], ["and", 1793], ["the", 1797], ["artificial", 1801], ["dimerization", 1812], ["of", 1825], ["cytoplasmic", 1828], ["domain", 1840], ["of", 1847], ["AbetaPP", 1850], [".", 1857], ["The", 1859], ["potential", 1863], ["of", 1873], ["neurotrophic", 1876], ["factors", 1889], ["and", 1897], ["cytokines", 1901], ["in", 1911], ["AD", 1914], ["therapy", 1917], ["is", 1925], ["also", 1928], ["indicated", 1933], [".", 1942]]}
{"context": "The restless legs syndrome is characterized by an unpleasant sensation in the legs which causes an imperative need to move the legs and is therefore considered to be a disorder of movement. When it appears before going to sleep, it may interfere with falling asleep and lead to a sleep-deficit. It is a clinical condition with a satisfactory treatment, and improvement of the associated sleep disorder. The etiology is unknown, sometimes it is familial. The syndrome is increasingly often diagnosed, particularly in association with iron deficiency, during pregnancy, in chronic renal failure and in patients with peripheral neuropathy. Polysomnography is not necessary, unless one suspects an associated disorder of periodic leg movements. Treatment is by dopaminergic, opiate, benzodiazepine, anticonvulsant drugs or clonidine.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "d4042c8ae89c41c5b5b34e283593ecf2", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[94, 94]], "char_spans": [[533, 536]]}]}], "context_tokens": [["The", 0], ["restless", 4], ["legs", 13], ["syndrome", 18], ["is", 27], ["characterized", 30], ["by", 44], ["an", 47], ["unpleasant", 50], ["sensation", 61], ["in", 71], ["the", 74], ["legs", 78], ["which", 83], ["causes", 89], ["an", 96], ["imperative", 99], ["need", 110], ["to", 115], ["move", 118], ["the", 123], ["legs", 127], ["and", 132], ["is", 136], ["therefore", 139], ["considered", 149], ["to", 160], ["be", 163], ["a", 166], ["disorder", 168], ["of", 177], ["movement", 180], [".", 188], ["When", 190], ["it", 195], ["appears", 198], ["before", 206], ["going", 213], ["to", 219], ["sleep", 222], [",", 227], ["it", 229], ["may", 232], ["interfere", 236], ["with", 246], ["falling", 251], ["asleep", 259], ["and", 266], ["lead", 270], ["to", 275], ["a", 278], ["sleep", 280], ["-", 285], ["deficit", 286], [".", 293], ["It", 295], ["is", 298], ["a", 301], ["clinical", 303], ["condition", 312], ["with", 322], ["a", 327], ["satisfactory", 329], ["treatment", 342], [",", 351], ["and", 353], ["improvement", 357], ["of", 369], ["the", 372], ["associated", 376], ["sleep", 387], ["disorder", 393], [".", 401], ["The", 403], ["etiology", 407], ["is", 416], ["unknown", 419], [",", 426], ["sometimes", 428], ["it", 438], ["is", 441], ["familial", 444], [".", 452], ["The", 454], ["syndrome", 458], ["is", 467], ["increasingly", 470], ["often", 483], ["diagnosed", 489], [",", 498], ["particularly", 500], ["in", 513], ["association", 516], ["with", 528], ["iron", 533], ["deficiency", 538], [",", 548], ["during", 550], ["pregnancy", 557], [",", 566], ["in", 568], ["chronic", 571], ["renal", 579], ["failure", 585], ["and", 593], ["in", 597], ["patients", 600], ["with", 609], ["peripheral", 614], ["neuropathy", 625], [".", 635], ["Polysomnography", 637], ["is", 653], ["not", 656], ["necessary", 660], [",", 669], ["unless", 671], ["one", 678], ["suspects", 682], ["an", 691], ["associated", 694], ["disorder", 705], ["of", 714], ["periodic", 717], ["leg", 726], ["movements", 730], [".", 739], ["Treatment", 741], ["is", 751], ["by", 754], ["dopaminergic", 757], [",", 769], ["opiate", 771], [",", 777], ["benzodiazepine", 779], [",", 793], ["anticonvulsant", 795], ["drugs", 810], ["or", 816], ["clonidine", 819], [".", 828]]}
{"context": "The antennal lobe (primary olfactory center of insects) is completely reorganized during metamorphosis. This reorganization is accompanied by changing patterns of calcium signaling in neurons and glial cells. In the present study, we investigated the developmental distribution of a major calcium-dependent protein, viz., calcium/calmodulin-dependent protein kinase II (CaM kinase II), in the antennal lobe of the sphinx moth Manduca sexta by using a monoclonal antibody. During synaptogenesis (developmental stages 6-10), we found a redistribution of CaM kinase II immunoreactivity, from a homogeneous distribution in the immature neuropil to an accumulation in the neuropil of the glomeruli. CaM kinase II immunoreactivity was less intense in olfactory receptor axons of the antennal nerve and antennal lobe glial cells. Western blot analysis revealed a growing content of CaM kinase II in antennal lobe tissue throughout metamorphosis. Injection of the CaM kinase inhibitor KN-93 into pupae resulted in a reduced number of antennal lobe glial cells migrating into the neuropil to form borders around glomeruli. The results suggest that CaM kinase II is involved in glial cell migration.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["CAMK2", "calcium/calmodulin-dependent protein kinase II", "The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II"], "qid": "f06d0fa0fbbc473f94d4d0b3591a5676", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "The calcium/calmodulin-dependent protein kinase-II", "token_spans": [[53, 60]], "char_spans": [[322, 367]]}, {"text": "CaM kinase II", "token_spans": [[193, 195], [150, 152], [62, 64], [121, 123], [98, 100]], "char_spans": [[1139, 1151], [875, 887], [370, 382], [694, 706], [552, 564]]}]}], "context_tokens": [["The", 0], ["antennal", 4], ["lobe", 13], ["(", 18], ["primary", 19], ["olfactory", 27], ["center", 37], ["of", 44], ["insects", 47], [")", 54], ["is", 56], ["completely", 59], ["reorganized", 70], ["during", 82], ["metamorphosis", 89], [".", 102], ["This", 104], ["reorganization", 109], ["is", 124], ["accompanied", 127], ["by", 139], ["changing", 142], ["patterns", 151], ["of", 160], ["calcium", 163], ["signaling", 171], ["in", 181], ["neurons", 184], ["and", 192], ["glial", 196], ["cells", 202], [".", 207], ["In", 209], ["the", 212], ["present", 216], ["study", 224], [",", 229], ["we", 231], ["investigated", 234], ["the", 247], ["developmental", 251], ["distribution", 265], ["of", 278], ["a", 281], ["major", 283], ["calcium", 289], ["-", 296], ["dependent", 297], ["protein", 307], [",", 314], ["viz", 316], [".", 319], [",", 320], ["calcium", 322], ["/", 329], ["calmodulin", 330], ["-", 340], ["dependent", 341], ["protein", 351], ["kinase", 359], ["II", 366], ["(", 369], ["CaM", 370], ["kinase", 374], ["II", 381], [")", 383], [",", 384], ["in", 386], ["the", 389], ["antennal", 393], ["lobe", 402], ["of", 407], ["the", 410], ["sphinx", 414], ["moth", 421], ["Manduca", 426], ["sexta", 434], ["by", 440], ["using", 443], ["a", 449], ["monoclonal", 451], ["antibody", 462], [".", 470], ["During", 472], ["synaptogenesis", 479], ["(", 494], ["developmental", 495], ["stages", 509], ["6", 516], ["-", 517], ["10", 518], [")", 520], [",", 521], ["we", 523], ["found", 526], ["a", 532], ["redistribution", 534], ["of", 549], ["CaM", 552], ["kinase", 556], ["II", 563], ["immunoreactivity", 566], [",", 582], ["from", 584], ["a", 589], ["homogeneous", 591], ["distribution", 603], ["in", 616], ["the", 619], ["immature", 623], ["neuropil", 632], ["to", 641], ["an", 644], ["accumulation", 647], ["in", 660], ["the", 663], ["neuropil", 667], ["of", 676], ["the", 679], ["glomeruli", 683], [".", 692], ["CaM", 694], ["kinase", 698], ["II", 705], ["immunoreactivity", 708], ["was", 725], ["less", 729], ["intense", 734], ["in", 742], ["olfactory", 745], ["receptor", 755], ["axons", 764], ["of", 770], ["the", 773], ["antennal", 777], ["nerve", 786], ["and", 792], ["antennal", 796], ["lobe", 805], ["glial", 810], ["cells", 816], [".", 821], ["Western", 823], ["blot", 831], ["analysis", 836], ["revealed", 845], ["a", 854], ["growing", 856], ["content", 864], ["of", 872], ["CaM", 875], ["kinase", 879], ["II", 886], ["in", 889], ["antennal", 892], ["lobe", 901], ["tissue", 906], ["throughout", 913], ["metamorphosis", 924], [".", 937], ["Injection", 939], ["of", 949], ["the", 952], ["CaM", 956], ["kinase", 960], ["inhibitor", 967], ["KN-93", 977], ["into", 983], ["pupae", 988], ["resulted", 994], ["in", 1003], ["a", 1006], ["reduced", 1008], ["number", 1016], ["of", 1023], ["antennal", 1026], ["lobe", 1035], ["glial", 1040], ["cells", 1046], ["migrating", 1052], ["into", 1062], ["the", 1067], ["neuropil", 1071], ["to", 1080], ["form", 1083], ["borders", 1088], ["around", 1096], ["glomeruli", 1103], [".", 1112], ["The", 1114], ["results", 1118], ["suggest", 1126], ["that", 1134], ["CaM", 1139], ["kinase", 1143], ["II", 1150], ["is", 1153], ["involved", 1156], ["in", 1165], ["glial", 1168], ["cell", 1174], ["migration", 1179], [".", 1188]]}
{"context": "Transcription of the major Bacillus anthracis virulence genes is triggered by CO2, a signal mimicking the host environment. A 182-kb plasmid, pXO1, carries the anthrax toxin genes and the genes responsible for their regulation of transcription, namely atxA and, pagR, the second gene of the pag operon. AtxA has major effects on the physiology of B. anthracis. It coordinates the transcription activation of the toxin genes with that of the capsule biosynthetic enzyme operon, located on the second virulence plasmid, pXO2. In rich medium, B. anthracis synthesises alternatively two S-layer proteins (Sap and EA1). An exponential phase \"Sap-layer\" is subsequently replaced by a stationary phase \"EA1-layer\". S-layer gene transcription is controlled by alternative sigma factors and by Sap acting as a transcriptional repressor of eag. Furthermore, in vitro in presence of CO2 and in vivo, AtxA is part of the sap and eag regulatory network. Only eag is significantly expressed in these conditions and this is due to AtxA activating eag and repressing sap transcription. PagR, and not AtxA itself, is the direct effector of this regulation by binding to sap and eag promoter regions. Therefore, PagR mediates the effect of AtxA on eag and sap and is the most downstream element of a signalling cascade initiated by AtxA. Taken together, these results indicate that the B. anthracis transcriptional regulator AtxA is controlling the synthesis of the three toxin components and of the surface elements (capsule and S-layer). Thus, AtxA is a master regulator that coordinates the response to host signals by orchestrating positive and negative controls over genes located on all genetic elements.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "877eabc12fb54287bc30ec4db7f37e8a", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "CO2", "token_spans": [[160, 160], [11, 11]], "char_spans": [[872, 874], [78, 80]]}]}], "context_tokens": [["Transcription", 0], ["of", 14], ["the", 17], ["major", 21], ["Bacillus", 27], ["anthracis", 36], ["virulence", 46], ["genes", 56], ["is", 62], ["triggered", 65], ["by", 75], ["CO2", 78], [",", 81], ["a", 83], ["signal", 85], ["mimicking", 92], ["the", 102], ["host", 106], ["environment", 111], [".", 122], ["A", 124], ["182-kb", 126], ["plasmid", 133], [",", 140], ["pXO1", 142], [",", 146], ["carries", 148], ["the", 156], ["anthrax", 160], ["toxin", 168], ["genes", 174], ["and", 180], ["the", 184], ["genes", 188], ["responsible", 194], ["for", 206], ["their", 210], ["regulation", 216], ["of", 227], ["transcription", 230], [",", 243], ["namely", 245], ["atxA", 252], ["and", 257], [",", 260], ["pagR", 262], [",", 266], ["the", 268], ["second", 272], ["gene", 279], ["of", 284], ["the", 287], ["pag", 291], ["operon", 295], [".", 301], ["AtxA", 303], ["has", 308], ["major", 312], ["effects", 318], ["on", 326], ["the", 329], ["physiology", 333], ["of", 344], ["B.", 347], ["anthracis", 350], [".", 359], ["It", 361], ["coordinates", 364], ["the", 376], ["transcription", 380], ["activation", 394], ["of", 405], ["the", 408], ["toxin", 412], ["genes", 418], ["with", 424], ["that", 429], ["of", 434], ["the", 437], ["capsule", 441], ["biosynthetic", 449], ["enzyme", 462], ["operon", 469], [",", 475], ["located", 477], ["on", 485], ["the", 488], ["second", 492], ["virulence", 499], ["plasmid", 509], [",", 516], ["pXO2", 518], [".", 522], ["In", 524], ["rich", 527], ["medium", 532], [",", 538], ["B.", 540], ["anthracis", 543], ["synthesises", 553], ["alternatively", 565], ["two", 579], ["S", 583], ["-", 584], ["layer", 585], ["proteins", 591], ["(", 600], ["Sap", 601], ["and", 605], ["EA1", 609], [")", 612], [".", 613], ["An", 615], ["exponential", 618], ["phase", 630], ["\"", 636], ["Sap", 637], ["-", 640], ["layer", 641], ["\"", 646], ["is", 648], ["subsequently", 651], ["replaced", 664], ["by", 673], ["a", 676], ["stationary", 678], ["phase", 689], ["\"", 695], ["EA1-layer", 696], ["\"", 705], [".", 706], ["S", 708], ["-", 709], ["layer", 710], ["gene", 716], ["transcription", 721], ["is", 735], ["controlled", 738], ["by", 749], ["alternative", 752], ["sigma", 764], ["factors", 770], ["and", 778], ["by", 782], ["Sap", 785], ["acting", 789], ["as", 796], ["a", 799], ["transcriptional", 801], ["repressor", 817], ["of", 827], ["eag", 830], [".", 833], ["Furthermore", 835], [",", 846], ["in", 848], ["vitro", 851], ["in", 857], ["presence", 860], ["of", 869], ["CO2", 872], ["and", 876], ["in", 880], ["vivo", 883], [",", 887], ["AtxA", 889], ["is", 894], ["part", 897], ["of", 902], ["the", 905], ["sap", 909], ["and", 913], ["eag", 917], ["regulatory", 921], ["network", 932], [".", 939], ["Only", 941], ["eag", 946], ["is", 950], ["significantly", 953], ["expressed", 967], ["in", 977], ["these", 980], ["conditions", 986], ["and", 997], ["this", 1001], ["is", 1006], ["due", 1009], ["to", 1013], ["AtxA", 1016], ["activating", 1021], ["eag", 1032], ["and", 1036], ["repressing", 1040], ["sap", 1051], ["transcription", 1055], [".", 1068], ["PagR", 1070], [",", 1074], ["and", 1076], ["not", 1080], ["AtxA", 1084], ["itself", 1089], [",", 1095], ["is", 1097], ["the", 1100], ["direct", 1104], ["effector", 1111], ["of", 1120], ["this", 1123], ["regulation", 1128], ["by", 1139], ["binding", 1142], ["to", 1150], ["sap", 1153], ["and", 1157], ["eag", 1161], ["promoter", 1165], ["regions", 1174], [".", 1181], ["Therefore", 1183], [",", 1192], ["PagR", 1194], ["mediates", 1199], ["the", 1208], ["effect", 1212], ["of", 1219], ["AtxA", 1222], ["on", 1227], ["eag", 1230], ["and", 1234], ["sap", 1238], ["and", 1242], ["is", 1246], ["the", 1249], ["most", 1253], ["downstream", 1258], ["element", 1269], ["of", 1277], ["a", 1280], ["signalling", 1282], ["cascade", 1293], ["initiated", 1301], ["by", 1311], ["AtxA.", 1314], ["Taken", 1320], ["together", 1326], [",", 1334], ["these", 1336], ["results", 1342], ["indicate", 1350], ["that", 1359], ["the", 1364], ["B.", 1368], ["anthracis", 1371], ["transcriptional", 1381], ["regulator", 1397], ["AtxA", 1407], ["is", 1412], ["controlling", 1415], ["the", 1427], ["synthesis", 1431], ["of", 1441], ["the", 1444], ["three", 1448], ["toxin", 1454], ["components", 1460], ["and", 1471], ["of", 1475], ["the", 1478], ["surface", 1482], ["elements", 1490], ["(", 1499], ["capsule", 1500], ["and", 1508], ["S", 1512], ["-", 1513], ["layer", 1514], [")", 1519], [".", 1520], ["Thus", 1522], [",", 1526], ["AtxA", 1528], ["is", 1533], ["a", 1536], ["master", 1538], ["regulator", 1545], ["that", 1555], ["coordinates", 1560], ["the", 1572], ["response", 1576], ["to", 1585], ["host", 1588], ["signals", 1593], ["by", 1601], ["orchestrating", 1604], ["positive", 1618], ["and", 1627], ["negative", 1631], ["controls", 1640], ["over", 1649], ["genes", 1654], ["located", 1660], ["on", 1668], ["all", 1671], ["genetic", 1675], ["elements", 1683], [".", 1691]]}
{"context": "Many different cellular pathways have evolved to protect the genome from the deleterious effects of DNA damage that result from exposure to chemical and physical agents. Among these is a process called transcription-coupled repair (TCR) that catalyzes the removal of DNA lesions from the transcribed strand of expressed genes, often resulting in a preferential bias of damage clearance from this strand relative to its non-transcribed counterpart. Lesions subject to this type of repair include cyclobutane pyrimidine dimers that are normally repaired by nucleotide excision repair (NER) and thymine glycols (TGs) that are removed primarily by base excision repair (BER). While the mechanism underlying TCR is not completely clear, it is known that its facilitation requires proteins used by other repair pathways like NER. It is also believed that the signal for TCR is the stalled RNA polymerase that results when DNA damage prevents its translocation during transcription elongation. While there is a clear role for some NER proteins in TCR, the involvement of BER proteins is less clear. To explore this further, we studied the removal of 7-methylguanine (7MeG) and 3-methyladenine (3MeA) from the dihydrofolate reductase (dhfr) gene of murine cell lines that vary in their repair phenotypes. 7MeG and 3MeA constitute the two principal N-methylpurines formed in DNA following exposure to methylating agents. In mammalian cells, alkyladenine DNA alkyladenine glycosylase (Aag) is the major enzyme required for the repair of these lesions via BER, and their removal from the total genome is quite rapid. There is no observable TCR of these lesions in specific genes in DNA repair proficient cells; however, it is possible that the rapid repair of these adducts by BER masks any TCR. The repair of 3MeA and 7MeG was examined in cells lacking Aag, NER, or both Aag and NER to determine if rapid overall repair masks TCR. The results show that both 3MeA and 7MeG are removed without strand bias from the dhfr gene of BER deficient (Aag deficient) and NER deficient murine cell lines. Furthermore, repair of 3MeA in this region is highly dependent on Aag, but repair of 7MeG is equally efficient in the repair proficient, BER deficient, and NER deficient cell lines. Strikingly, in the absence of both BER and NER, neither 7MeG nor 3MeA is repaired. These results demonstrate that NER, but not TCR, contributes to the repair of 7MeG, and to a lesser extent 3MeA.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "1cde295a27944b1b94e1e91a3f0c2a84", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[49, 50]], "char_spans": [[288, 305]]}]}], "context_tokens": [["Many", 0], ["different", 5], ["cellular", 15], ["pathways", 24], ["have", 33], ["evolved", 38], ["to", 46], ["protect", 49], ["the", 57], ["genome", 61], ["from", 68], ["the", 73], ["deleterious", 77], ["effects", 89], ["of", 97], ["DNA", 100], ["damage", 104], ["that", 111], ["result", 116], ["from", 123], ["exposure", 128], ["to", 137], ["chemical", 140], ["and", 149], ["physical", 153], ["agents", 162], [".", 168], ["Among", 170], ["these", 176], ["is", 182], ["a", 185], ["process", 187], ["called", 195], ["transcription", 202], ["-", 215], ["coupled", 216], ["repair", 224], ["(", 231], ["TCR", 232], [")", 235], ["that", 237], ["catalyzes", 242], ["the", 252], ["removal", 256], ["of", 264], ["DNA", 267], ["lesions", 271], ["from", 279], ["the", 284], ["transcribed", 288], ["strand", 300], ["of", 307], ["expressed", 310], ["genes", 320], [",", 325], ["often", 327], ["resulting", 333], ["in", 343], ["a", 346], ["preferential", 348], ["bias", 361], ["of", 366], ["damage", 369], ["clearance", 376], ["from", 386], ["this", 391], ["strand", 396], ["relative", 403], ["to", 412], ["its", 415], ["non", 419], ["-", 422], ["transcribed", 423], ["counterpart", 435], [".", 446], ["Lesions", 448], ["subject", 456], ["to", 464], ["this", 467], ["type", 472], ["of", 477], ["repair", 480], ["include", 487], ["cyclobutane", 495], ["pyrimidine", 507], ["dimers", 518], ["that", 525], ["are", 530], ["normally", 534], ["repaired", 543], ["by", 552], ["nucleotide", 555], ["excision", 566], ["repair", 575], ["(", 582], ["NER", 583], [")", 586], ["and", 588], ["thymine", 592], ["glycols", 600], ["(", 608], ["TGs", 609], [")", 612], ["that", 614], ["are", 619], ["removed", 623], ["primarily", 631], ["by", 641], ["base", 644], ["excision", 649], ["repair", 658], ["(", 665], ["BER", 666], [")", 669], [".", 670], ["While", 672], ["the", 678], ["mechanism", 682], ["underlying", 692], ["TCR", 703], ["is", 707], ["not", 710], ["completely", 714], ["clear", 725], [",", 730], ["it", 732], ["is", 735], ["known", 738], ["that", 744], ["its", 749], ["facilitation", 753], ["requires", 766], ["proteins", 775], ["used", 784], ["by", 789], ["other", 792], ["repair", 798], ["pathways", 805], ["like", 814], ["NER", 819], [".", 822], ["It", 824], ["is", 827], ["also", 830], ["believed", 835], ["that", 844], ["the", 849], ["signal", 853], ["for", 860], ["TCR", 864], ["is", 868], ["the", 871], ["stalled", 875], ["RNA", 883], ["polymerase", 887], ["that", 898], ["results", 903], ["when", 911], ["DNA", 916], ["damage", 920], ["prevents", 927], ["its", 936], ["translocation", 940], ["during", 954], ["transcription", 961], ["elongation", 975], [".", 985], ["While", 987], ["there", 993], ["is", 999], ["a", 1002], ["clear", 1004], ["role", 1010], ["for", 1015], ["some", 1019], ["NER", 1024], ["proteins", 1028], ["in", 1037], ["TCR", 1040], [",", 1043], ["the", 1045], ["involvement", 1049], ["of", 1061], ["BER", 1064], ["proteins", 1068], ["is", 1077], ["less", 1080], ["clear", 1085], [".", 1090], ["To", 1092], ["explore", 1095], ["this", 1103], ["further", 1108], [",", 1115], ["we", 1117], ["studied", 1120], ["the", 1128], ["removal", 1132], ["of", 1140], ["7-methylguanine", 1143], ["(", 1159], ["7MeG", 1160], [")", 1164], ["and", 1166], ["3-methyladenine", 1170], ["(", 1186], ["3MeA", 1187], [")", 1191], ["from", 1193], ["the", 1198], ["dihydrofolate", 1202], ["reductase", 1216], ["(", 1226], ["dhfr", 1227], [")", 1231], ["gene", 1233], ["of", 1238], ["murine", 1241], ["cell", 1248], ["lines", 1253], ["that", 1259], ["vary", 1264], ["in", 1269], ["their", 1272], ["repair", 1278], ["phenotypes", 1285], [".", 1295], ["7MeG", 1297], ["and", 1302], ["3MeA", 1306], ["constitute", 1311], ["the", 1322], ["two", 1326], ["principal", 1330], ["N", 1340], ["-", 1341], ["methylpurines", 1342], ["formed", 1356], ["in", 1363], ["DNA", 1366], ["following", 1370], ["exposure", 1380], ["to", 1389], ["methylating", 1392], ["agents", 1404], [".", 1410], ["In", 1412], ["mammalian", 1415], ["cells", 1425], [",", 1430], ["alkyladenine", 1432], ["DNA", 1445], ["alkyladenine", 1449], ["glycosylase", 1462], ["(", 1474], ["Aag", 1475], [")", 1478], ["is", 1480], ["the", 1483], ["major", 1487], ["enzyme", 1493], ["required", 1500], ["for", 1509], ["the", 1513], ["repair", 1517], ["of", 1524], ["these", 1527], ["lesions", 1533], ["via", 1541], ["BER", 1545], [",", 1548], ["and", 1550], ["their", 1554], ["removal", 1560], ["from", 1568], ["the", 1573], ["total", 1577], ["genome", 1583], ["is", 1590], ["quite", 1593], ["rapid", 1599], [".", 1604], ["There", 1606], ["is", 1612], ["no", 1615], ["observable", 1618], ["TCR", 1629], ["of", 1633], ["these", 1636], ["lesions", 1642], ["in", 1650], ["specific", 1653], ["genes", 1662], ["in", 1668], ["DNA", 1671], ["repair", 1675], ["proficient", 1682], ["cells", 1693], [";", 1698], ["however", 1700], [",", 1707], ["it", 1709], ["is", 1712], ["possible", 1715], ["that", 1724], ["the", 1729], ["rapid", 1733], ["repair", 1739], ["of", 1746], ["these", 1749], ["adducts", 1755], ["by", 1763], ["BER", 1766], ["masks", 1770], ["any", 1776], ["TCR", 1780], [".", 1783], ["The", 1785], ["repair", 1789], ["of", 1796], ["3MeA", 1799], ["and", 1804], ["7MeG", 1808], ["was", 1813], ["examined", 1817], ["in", 1826], ["cells", 1829], ["lacking", 1835], ["Aag", 1843], [",", 1846], ["NER", 1848], [",", 1851], ["or", 1853], ["both", 1856], ["Aag", 1861], ["and", 1865], ["NER", 1869], ["to", 1873], ["determine", 1876], ["if", 1886], ["rapid", 1889], ["overall", 1895], ["repair", 1903], ["masks", 1910], ["TCR", 1916], [".", 1919], ["The", 1921], ["results", 1925], ["show", 1933], ["that", 1938], ["both", 1943], ["3MeA", 1948], ["and", 1953], ["7MeG", 1957], ["are", 1962], ["removed", 1966], ["without", 1974], ["strand", 1982], ["bias", 1989], ["from", 1994], ["the", 1999], ["dhfr", 2003], ["gene", 2008], ["of", 2013], ["BER", 2016], ["deficient", 2020], ["(", 2030], ["Aag", 2031], ["deficient", 2035], [")", 2044], ["and", 2046], ["NER", 2050], ["deficient", 2054], ["murine", 2064], ["cell", 2071], ["lines", 2076], [".", 2081], ["Furthermore", 2083], [",", 2094], ["repair", 2096], ["of", 2103], ["3MeA", 2106], ["in", 2111], ["this", 2114], ["region", 2119], ["is", 2126], ["highly", 2129], ["dependent", 2136], ["on", 2146], ["Aag", 2149], [",", 2152], ["but", 2154], ["repair", 2158], ["of", 2165], ["7MeG", 2168], ["is", 2173], ["equally", 2176], ["efficient", 2184], ["in", 2194], ["the", 2197], ["repair", 2201], ["proficient", 2208], [",", 2218], ["BER", 2220], ["deficient", 2224], [",", 2233], ["and", 2235], ["NER", 2239], ["deficient", 2243], ["cell", 2253], ["lines", 2258], [".", 2263], ["Strikingly", 2265], [",", 2275], ["in", 2277], ["the", 2280], ["absence", 2284], ["of", 2292], ["both", 2295], ["BER", 2300], ["and", 2304], ["NER", 2308], [",", 2311], ["neither", 2313], ["7MeG", 2321], ["nor", 2326], ["3MeA", 2330], ["is", 2335], ["repaired", 2338], [".", 2346], ["These", 2348], ["results", 2354], ["demonstrate", 2362], ["that", 2374], ["NER", 2379], [",", 2382], ["but", 2384], ["not", 2388], ["TCR", 2392], [",", 2395], ["contributes", 2397], ["to", 2409], ["the", 2412], ["repair", 2416], ["of", 2423], ["7MeG", 2426], [",", 2430], ["and", 2432], ["to", 2436], ["a", 2439], ["lesser", 2441], ["extent", 2448], ["3MeA.", 2455]]}
{"context": "Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI) designed as a prototypic short-acting BCR-ABL-targeted TKI that inhibits BCR-ABL with greater potency compared with imatinib, nilotinib, bosutinib, and ponatinib and has been shown to have potential immunomodulatory effects. Dasatinib is approved for the treatment of all phases of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to prior imatinib treatment and first-line treatment for CML in chronic phase. In this article, the development of dasatinib as a treatment for patients with CML is reviewed. This is a review of the relevant literature regarding dasatinib development in CML (2003-2013). Dasatinib demonstrates efficacy against most BCR-ABL mutations arising during imatinib therapy and is effective in treating patients with imatinib resistance due to other mechanisms. Randomized trial data show that first-line dasatinib provides superior responses compared with imatinib and enables patients to achieve early, deep responses correlated with improved longer-term outcomes. Dasatinib has a generally acceptable safety profile, with most adverse events (AEs) proving manageable and reversible. Cytopenias are commonly observed with dasatinib, and some nonhematologic AEs including pleural effusion have been consistently reported. Dasatinib is an effective treatment option for patients with CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "5c2cbb8eaf4742919bc8a56682ea0e5a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[138, 140], [20, 22], [28, 30]], "char_spans": [[779, 785], [98, 104], [133, 139]]}]}], "context_tokens": [["Dasatinib", 0], ["is", 10], ["a", 13], ["dual", 15], ["Abl", 20], ["/", 23], ["Src", 24], ["tyrosine", 28], ["kinase", 37], ["inhibitor", 44], ["(", 54], ["TKI", 55], [")", 58], ["designed", 60], ["as", 69], ["a", 72], ["prototypic", 74], ["short", 85], ["-", 90], ["acting", 91], ["BCR", 98], ["-", 101], ["ABL", 102], ["-", 105], ["targeted", 106], ["TKI", 115], ["that", 119], ["inhibits", 124], ["BCR", 133], ["-", 136], ["ABL", 137], ["with", 141], ["greater", 146], ["potency", 154], ["compared", 162], ["with", 171], ["imatinib", 176], [",", 184], ["nilotinib", 186], [",", 195], ["bosutinib", 197], [",", 206], ["and", 208], ["ponatinib", 212], ["and", 222], ["has", 226], ["been", 230], ["shown", 235], ["to", 241], ["have", 244], ["potential", 249], ["immunomodulatory", 259], ["effects", 276], [".", 283], ["Dasatinib", 285], ["is", 295], ["approved", 298], ["for", 307], ["the", 311], ["treatment", 315], ["of", 325], ["all", 328], ["phases", 332], ["of", 339], ["chronic", 342], ["myeloid", 350], ["leukemia", 358], ["(", 367], ["CML", 368], [")", 371], ["and", 373], ["Philadelphia", 377], ["chromosome", 390], ["-", 400], ["positive", 401], ["acute", 410], ["lymphoblastic", 416], ["leukemia", 430], ["resistant", 439], ["or", 449], ["intolerant", 452], ["to", 463], ["prior", 466], ["imatinib", 472], ["treatment", 481], ["and", 491], ["first", 495], ["-", 500], ["line", 501], ["treatment", 506], ["for", 516], ["CML", 520], ["in", 524], ["chronic", 527], ["phase", 535], [".", 540], ["In", 542], ["this", 545], ["article", 550], [",", 557], ["the", 559], ["development", 563], ["of", 575], ["dasatinib", 578], ["as", 588], ["a", 591], ["treatment", 593], ["for", 603], ["patients", 607], ["with", 616], ["CML", 621], ["is", 625], ["reviewed", 628], [".", 636], ["This", 638], ["is", 643], ["a", 646], ["review", 648], ["of", 655], ["the", 658], ["relevant", 662], ["literature", 671], ["regarding", 682], ["dasatinib", 692], ["development", 702], ["in", 714], ["CML", 717], ["(", 721], ["2003", 722], ["-", 726], ["2013", 727], [")", 731], [".", 732], ["Dasatinib", 734], ["demonstrates", 744], ["efficacy", 757], ["against", 766], ["most", 774], ["BCR", 779], ["-", 782], ["ABL", 783], ["mutations", 787], ["arising", 797], ["during", 805], ["imatinib", 812], ["therapy", 821], ["and", 829], ["is", 833], ["effective", 836], ["in", 846], ["treating", 849], ["patients", 858], ["with", 867], ["imatinib", 872], ["resistance", 881], ["due", 892], ["to", 896], ["other", 899], ["mechanisms", 905], [".", 915], ["Randomized", 917], ["trial", 928], ["data", 934], ["show", 939], ["that", 944], ["first", 949], ["-", 954], ["line", 955], ["dasatinib", 960], ["provides", 970], ["superior", 979], ["responses", 988], ["compared", 998], ["with", 1007], ["imatinib", 1012], ["and", 1021], ["enables", 1025], ["patients", 1033], ["to", 1042], ["achieve", 1045], ["early", 1053], [",", 1058], ["deep", 1060], ["responses", 1065], ["correlated", 1075], ["with", 1086], ["improved", 1091], ["longer", 1100], ["-", 1106], ["term", 1107], ["outcomes", 1112], [".", 1120], ["Dasatinib", 1122], ["has", 1132], ["a", 1136], ["generally", 1138], ["acceptable", 1148], ["safety", 1159], ["profile", 1166], [",", 1173], ["with", 1175], ["most", 1180], ["adverse", 1185], ["events", 1193], ["(", 1200], ["AEs", 1201], [")", 1204], ["proving", 1206], ["manageable", 1214], ["and", 1225], ["reversible", 1229], [".", 1239], ["Cytopenias", 1241], ["are", 1252], ["commonly", 1256], ["observed", 1265], ["with", 1274], ["dasatinib", 1279], [",", 1288], ["and", 1290], ["some", 1294], ["nonhematologic", 1299], ["AEs", 1314], ["including", 1318], ["pleural", 1328], ["effusion", 1336], ["have", 1345], ["been", 1350], ["consistently", 1355], ["reported", 1368], [".", 1376], ["Dasatinib", 1378], ["is", 1388], ["an", 1391], ["effective", 1394], ["treatment", 1404], ["option", 1414], ["for", 1421], ["patients", 1425], ["with", 1434], ["CML", 1439], [".", 1442]]}
{"context": "Recurrent syncope, malignant ventricular arrhythmias, and sudden death are complications of the long QT syndrome (LQTS). Two well-known syndromes with long QT intervals are known. The Jervell and Lange-Nielsen syndrome (JLNS) is characterized by prolongation of the QT interval, deafness, and autosomal-recessive inheritance, and the Romano-Ward syndrome is characterized by a prolonged QT interval, autosomal-dominant inheritance, and no deafness. In the present study assessment was performed of the diagnostic importance of the ventricular derepolarization parameters, clinical features, and prevalence of JLNS among 132 children with congenital hearing loss (CHL). In the CHL group the mean QT, QTc, JT, and JTc intervals and the dispersion values (QT-d, JT-d, QTc-d, and JTc-d) were significantly longer than those of control subjects (n = 96) (P < 0.05). Patients with CHL and JLNS (n = 5) had significantly longer mean values of QT, QTc, JT, and JTc intervals and dispersion values than those of CHL without JLNS (n = 127) and control subjects (P < 0.05). The results suggest that assessment of ventricular derepolarization parameters in children with CHL will be helpful in the early detection of JLNS because infants with CHL cannot accurately describe the symptoms of syncope.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "e5d58ee5c70045e09f9863cc375814b3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[74, 76]], "char_spans": [[400, 417]]}]}], "context_tokens": [["Recurrent", 0], ["syncope", 10], [",", 17], ["malignant", 19], ["ventricular", 29], ["arrhythmias", 41], [",", 52], ["and", 54], ["sudden", 58], ["death", 65], ["are", 71], ["complications", 75], ["of", 89], ["the", 92], ["long", 96], ["QT", 101], ["syndrome", 104], ["(", 113], ["LQTS", 114], [")", 118], [".", 119], ["Two", 121], ["well", 125], ["-", 129], ["known", 130], ["syndromes", 136], ["with", 146], ["long", 151], ["QT", 156], ["intervals", 159], ["are", 169], ["known", 173], [".", 178], ["The", 180], ["Jervell", 184], ["and", 192], ["Lange", 196], ["-", 201], ["Nielsen", 202], ["syndrome", 210], ["(", 219], ["JLNS", 220], [")", 224], ["is", 226], ["characterized", 229], ["by", 243], ["prolongation", 246], ["of", 259], ["the", 262], ["QT", 266], ["interval", 269], [",", 277], ["deafness", 279], [",", 287], ["and", 289], ["autosomal", 293], ["-", 302], ["recessive", 303], ["inheritance", 313], [",", 324], ["and", 326], ["the", 330], ["Romano", 334], ["-", 340], ["Ward", 341], ["syndrome", 346], ["is", 355], ["characterized", 358], ["by", 372], ["a", 375], ["prolonged", 377], ["QT", 387], ["interval", 390], [",", 398], ["autosomal", 400], ["-", 409], ["dominant", 410], ["inheritance", 419], [",", 430], ["and", 432], ["no", 436], ["deafness", 439], [".", 447], ["In", 449], ["the", 452], ["present", 456], ["study", 464], ["assessment", 470], ["was", 481], ["performed", 485], ["of", 495], ["the", 498], ["diagnostic", 502], ["importance", 513], ["of", 524], ["the", 527], ["ventricular", 531], ["derepolarization", 543], ["parameters", 560], [",", 570], ["clinical", 572], ["features", 581], [",", 589], ["and", 591], ["prevalence", 595], ["of", 606], ["JLNS", 609], ["among", 614], ["132", 620], ["children", 624], ["with", 633], ["congenital", 638], ["hearing", 649], ["loss", 657], ["(", 662], ["CHL", 663], [")", 666], [".", 667], ["In", 669], ["the", 672], ["CHL", 676], ["group", 680], ["the", 686], ["mean", 690], ["QT", 695], [",", 697], ["QTc", 699], [",", 702], ["JT", 704], [",", 706], ["and", 708], ["JTc", 712], ["intervals", 716], ["and", 726], ["the", 730], ["dispersion", 734], ["values", 745], ["(", 752], ["QT", 753], ["-", 755], ["d", 756], [",", 757], ["JT", 759], ["-", 761], ["d", 762], [",", 763], ["QTc", 765], ["-", 768], ["d", 769], [",", 770], ["and", 772], ["JTc", 776], ["-", 779], ["d", 780], [")", 781], ["were", 783], ["significantly", 788], ["longer", 802], ["than", 809], ["those", 814], ["of", 820], ["control", 823], ["subjects", 831], ["(", 840], ["n", 841], ["=", 843], ["96", 845], [")", 847], ["(", 849], ["P", 850], ["<", 852], ["0.05", 854], [")", 858], [".", 859], ["Patients", 861], ["with", 870], ["CHL", 875], ["and", 879], ["JLNS", 883], ["(", 888], ["n", 889], ["=", 891], ["5", 893], [")", 894], ["had", 896], ["significantly", 900], ["longer", 914], ["mean", 921], ["values", 926], ["of", 933], ["QT", 936], [",", 938], ["QTc", 940], [",", 943], ["JT", 945], [",", 947], ["and", 949], ["JTc", 953], ["intervals", 957], ["and", 967], ["dispersion", 971], ["values", 982], ["than", 989], ["those", 994], ["of", 1000], ["CHL", 1003], ["without", 1007], ["JLNS", 1015], ["(", 1020], ["n", 1021], ["=", 1023], ["127", 1025], [")", 1028], ["and", 1030], ["control", 1034], ["subjects", 1042], ["(", 1051], ["P", 1052], ["<", 1054], ["0.05", 1056], [")", 1060], [".", 1061], ["The", 1063], ["results", 1067], ["suggest", 1075], ["that", 1083], ["assessment", 1088], ["of", 1099], ["ventricular", 1102], ["derepolarization", 1114], ["parameters", 1131], ["in", 1142], ["children", 1145], ["with", 1154], ["CHL", 1159], ["will", 1163], ["be", 1168], ["helpful", 1171], ["in", 1179], ["the", 1182], ["early", 1186], ["detection", 1192], ["of", 1202], ["JLNS", 1205], ["because", 1210], ["infants", 1218], ["with", 1226], ["CHL", 1231], ["can", 1235], ["not", 1238], ["accurately", 1242], ["describe", 1253], ["the", 1262], ["symptoms", 1266], ["of", 1275], ["syncope", 1278], [".", 1285]]}
{"context": "The health benefits of leisure-time physical activity are well known, however the effects of engaging in competitive sports on health are uncertain. This literature review examines mortality and longevity of elite athletes and attempts to understand the association between long-term vigorous exercise training and survival rates. Fourteen articles of epidemiological studies were identified and classified by type of sport. Life expectancy, standardised mortality ratio, standardised proportionate mortality ratio, mortality rate, and mortality odds ratio for all causes of death were used to analyse mortality and longevity of elite athletes. It appears that elite endurance (aerobic) athletes and mixed-sports (aerobic and anaerobic) athletes survive longer than the general population, as indicated by lower mortality and higher longevity. Lower cardiovascular disease mortality is likely the primary reason for their better survival rates. On the other hand, there are inconsistent results among studies of power (anaerobic) athletes. When elite athletes engaging in various sports are analysed together, their mortality is lower than that of the general population. In conclusion, long-term vigorous exercise training is associated with increased survival rates of specific groups of athletes.", "qas": [{"question": "What is the life expectancy of professional athletes in respect to the general population?", "answers": ["longer than the general population", "No clear results indicating improved life expectancy in professional athletes"], "qid": "5a537555a5e843839c53a7739cd95f64", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["life", 12], ["expectancy", 17], ["of", 28], ["professional", 31], ["athletes", 44], ["in", 53], ["respect", 56], ["to", 64], ["the", 67], ["general", 71], ["population", 79], ["?", 89]], "detected_answers": [{"text": "longer than the general population", "token_spans": [[122, 126]], "char_spans": [[754, 787]]}]}], "context_tokens": [["The", 0], ["health", 4], ["benefits", 11], ["of", 20], ["leisure", 23], ["-", 30], ["time", 31], ["physical", 36], ["activity", 45], ["are", 54], ["well", 58], ["known", 63], [",", 68], ["however", 70], ["the", 78], ["effects", 82], ["of", 90], ["engaging", 93], ["in", 102], ["competitive", 105], ["sports", 117], ["on", 124], ["health", 127], ["are", 134], ["uncertain", 138], [".", 147], ["This", 149], ["literature", 154], ["review", 165], ["examines", 172], ["mortality", 181], ["and", 191], ["longevity", 195], ["of", 205], ["elite", 208], ["athletes", 214], ["and", 223], ["attempts", 227], ["to", 236], ["understand", 239], ["the", 250], ["association", 254], ["between", 266], ["long", 274], ["-", 278], ["term", 279], ["vigorous", 284], ["exercise", 293], ["training", 302], ["and", 311], ["survival", 315], ["rates", 324], [".", 329], ["Fourteen", 331], ["articles", 340], ["of", 349], ["epidemiological", 352], ["studies", 368], ["were", 376], ["identified", 381], ["and", 392], ["classified", 396], ["by", 407], ["type", 410], ["of", 415], ["sport", 418], [".", 423], ["Life", 425], ["expectancy", 430], [",", 440], ["standardised", 442], ["mortality", 455], ["ratio", 465], [",", 470], ["standardised", 472], ["proportionate", 485], ["mortality", 499], ["ratio", 509], [",", 514], ["mortality", 516], ["rate", 526], [",", 530], ["and", 532], ["mortality", 536], ["odds", 546], ["ratio", 551], ["for", 557], ["all", 561], ["causes", 565], ["of", 572], ["death", 575], ["were", 581], ["used", 586], ["to", 591], ["analyse", 594], ["mortality", 602], ["and", 612], ["longevity", 616], ["of", 626], ["elite", 629], ["athletes", 635], [".", 643], ["It", 645], ["appears", 648], ["that", 656], ["elite", 661], ["endurance", 667], ["(", 677], ["aerobic", 678], [")", 685], ["athletes", 687], ["and", 696], ["mixed", 700], ["-", 705], ["sports", 706], ["(", 713], ["aerobic", 714], ["and", 722], ["anaerobic", 726], [")", 735], ["athletes", 737], ["survive", 746], ["longer", 754], ["than", 761], ["the", 766], ["general", 770], ["population", 778], [",", 788], ["as", 790], ["indicated", 793], ["by", 803], ["lower", 806], ["mortality", 812], ["and", 822], ["higher", 826], ["longevity", 833], [".", 842], ["Lower", 844], ["cardiovascular", 850], ["disease", 865], ["mortality", 873], ["is", 883], ["likely", 886], ["the", 893], ["primary", 897], ["reason", 905], ["for", 912], ["their", 916], ["better", 922], ["survival", 929], ["rates", 938], [".", 943], ["On", 945], ["the", 948], ["other", 952], ["hand", 958], [",", 962], ["there", 964], ["are", 970], ["inconsistent", 974], ["results", 987], ["among", 995], ["studies", 1001], ["of", 1009], ["power", 1012], ["(", 1018], ["anaerobic", 1019], [")", 1028], ["athletes", 1030], [".", 1038], ["When", 1040], ["elite", 1045], ["athletes", 1051], ["engaging", 1060], ["in", 1069], ["various", 1072], ["sports", 1080], ["are", 1087], ["analysed", 1091], ["together", 1100], [",", 1108], ["their", 1110], ["mortality", 1116], ["is", 1126], ["lower", 1129], ["than", 1135], ["that", 1140], ["of", 1145], ["the", 1148], ["general", 1152], ["population", 1160], [".", 1170], ["In", 1172], ["conclusion", 1175], [",", 1185], ["long", 1187], ["-", 1191], ["term", 1192], ["vigorous", 1197], ["exercise", 1206], ["training", 1215], ["is", 1224], ["associated", 1227], ["with", 1238], ["increased", 1243], ["survival", 1253], ["rates", 1262], ["of", 1268], ["specific", 1271], ["groups", 1280], ["of", 1287], ["athletes", 1290], [".", 1298]]}
{"context": "Emerging data suggest that second-generation antipsychotics such as aripiprazole may be effective in the treatment of post-traumatic stress disorder (PTSD). However, few clinical trials have used aripiprazole in PTSD, and data are limited on its use in Veterans with PTSD. The objective of this pilot trial was to investigate the safety and efficacy of aripiprazole in Veterans with PTSD. Ten individuals (five men and five women) meeting the Diagnostic and statistical manual of mental disorders, 4th ed., PTSD criteria participated in this 12-week, open-label, flexibly dosed monotherapy trial. The dose range of aripiprazole was 5-30 mg/day, titrated to tolerability and clinical response. The primary outcome measure was the Clinician-Administered PTSD Scale. Additional outcomes included the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale (Top-8), the Davidson Trauma Scale, the Positive and Negative Syndrome Scale, the Beck Depression Inventory-Fast Screen, and Clinical Global Impressions-Improvement. Eight participants completed the study, and aripiprazole was generally well tolerated and associated with a significant improvement in PTSD symptoms, as measured by the Clinician-Administered PTSD Scale (primary outcome measure) and by the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale, and the Davidson Trauma Scale. An improvement was also observed on all three Positive and Negative Syndrome Scale subscales and the Beck Depression Inventory-Fast Screen, and the average Clinical Global Impressions-Improvement ratings indicated that patients were 'much improved'. These promising initial results merit further investigation in a larger, randomized-controlled trial.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "0b4eb5fc8d864052918d6cffa3730c7d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[18, 22]], "char_spans": [[118, 147]]}, {"text": "PTSD", "token_spans": [[48, 48], [226, 226], [93, 93], [205, 205], [138, 138], [36, 36], [68, 68], [153, 153], [215, 215], [233, 233], [24, 24], [146, 146]], "char_spans": [[267, 270], [1271, 1274], [507, 510], [1160, 1163], [752, 755], [212, 215], [383, 386], [848, 851], [1217, 1220], [1316, 1319], [150, 153], [803, 806]]}]}], "context_tokens": [["Emerging", 0], ["data", 9], ["suggest", 14], ["that", 22], ["second", 27], ["-", 33], ["generation", 34], ["antipsychotics", 45], ["such", 60], ["as", 65], ["aripiprazole", 68], ["may", 81], ["be", 85], ["effective", 88], ["in", 98], ["the", 101], ["treatment", 105], ["of", 115], ["post", 118], ["-", 122], ["traumatic", 123], ["stress", 133], ["disorder", 140], ["(", 149], ["PTSD", 150], [")", 154], [".", 155], ["However", 157], [",", 164], ["few", 166], ["clinical", 170], ["trials", 179], ["have", 186], ["used", 191], ["aripiprazole", 196], ["in", 209], ["PTSD", 212], [",", 216], ["and", 218], ["data", 222], ["are", 227], ["limited", 231], ["on", 239], ["its", 242], ["use", 246], ["in", 250], ["Veterans", 253], ["with", 262], ["PTSD", 267], [".", 271], ["The", 273], ["objective", 277], ["of", 287], ["this", 290], ["pilot", 295], ["trial", 301], ["was", 307], ["to", 311], ["investigate", 314], ["the", 326], ["safety", 330], ["and", 337], ["efficacy", 341], ["of", 350], ["aripiprazole", 353], ["in", 366], ["Veterans", 369], ["with", 378], ["PTSD", 383], [".", 387], ["Ten", 389], ["individuals", 393], ["(", 405], ["five", 406], ["men", 411], ["and", 415], ["five", 419], ["women", 424], [")", 429], ["meeting", 431], ["the", 439], ["Diagnostic", 443], ["and", 454], ["statistical", 458], ["manual", 470], ["of", 477], ["mental", 480], ["disorders", 487], [",", 496], ["4th", 498], ["ed", 502], [".", 504], [",", 505], ["PTSD", 507], ["criteria", 512], ["participated", 521], ["in", 534], ["this", 537], ["12-week", 542], [",", 549], ["open", 551], ["-", 555], ["label", 556], [",", 561], ["flexibly", 563], ["dosed", 572], ["monotherapy", 578], ["trial", 590], [".", 595], ["The", 597], ["dose", 601], ["range", 606], ["of", 612], ["aripiprazole", 615], ["was", 628], ["5", 632], ["-", 633], ["30", 634], ["mg", 637], ["/", 639], ["day", 640], [",", 643], ["titrated", 645], ["to", 654], ["tolerability", 657], ["and", 670], ["clinical", 674], ["response", 683], [".", 691], ["The", 693], ["primary", 697], ["outcome", 705], ["measure", 713], ["was", 721], ["the", 725], ["Clinician", 729], ["-", 738], ["Administered", 739], ["PTSD", 752], ["Scale", 757], [".", 762], ["Additional", 764], ["outcomes", 775], ["included", 784], ["the", 793], ["Short", 797], ["PTSD", 803], ["Rating", 808], ["Interview", 815], [",", 824], ["the", 826], ["Treatment", 830], ["Outcome", 840], ["PTSD", 848], ["Scale", 853], ["(", 859], ["Top-8", 860], [")", 865], [",", 866], ["the", 868], ["Davidson", 872], ["Trauma", 881], ["Scale", 888], [",", 893], ["the", 895], ["Positive", 899], ["and", 908], ["Negative", 912], ["Syndrome", 921], ["Scale", 930], [",", 935], ["the", 937], ["Beck", 941], ["Depression", 946], ["Inventory", 957], ["-", 966], ["Fast", 967], ["Screen", 972], [",", 978], ["and", 980], ["Clinical", 984], ["Global", 993], ["Impressions", 1000], ["-", 1011], ["Improvement", 1012], [".", 1023], ["Eight", 1025], ["participants", 1031], ["completed", 1044], ["the", 1054], ["study", 1058], [",", 1063], ["and", 1065], ["aripiprazole", 1069], ["was", 1082], ["generally", 1086], ["well", 1096], ["tolerated", 1101], ["and", 1111], ["associated", 1115], ["with", 1126], ["a", 1131], ["significant", 1133], ["improvement", 1145], ["in", 1157], ["PTSD", 1160], ["symptoms", 1165], [",", 1173], ["as", 1175], ["measured", 1178], ["by", 1187], ["the", 1190], ["Clinician", 1194], ["-", 1203], ["Administered", 1204], ["PTSD", 1217], ["Scale", 1222], ["(", 1228], ["primary", 1229], ["outcome", 1237], ["measure", 1245], [")", 1252], ["and", 1254], ["by", 1258], ["the", 1261], ["Short", 1265], ["PTSD", 1271], ["Rating", 1276], ["Interview", 1283], [",", 1292], ["the", 1294], ["Treatment", 1298], ["Outcome", 1308], ["PTSD", 1316], ["Scale", 1321], [",", 1326], ["and", 1328], ["the", 1332], ["Davidson", 1336], ["Trauma", 1345], ["Scale", 1352], [".", 1357], ["An", 1359], ["improvement", 1362], ["was", 1374], ["also", 1378], ["observed", 1383], ["on", 1392], ["all", 1395], ["three", 1399], ["Positive", 1405], ["and", 1414], ["Negative", 1418], ["Syndrome", 1427], ["Scale", 1436], ["subscales", 1442], ["and", 1452], ["the", 1456], ["Beck", 1460], ["Depression", 1465], ["Inventory", 1476], ["-", 1485], ["Fast", 1486], ["Screen", 1491], [",", 1497], ["and", 1499], ["the", 1503], ["average", 1507], ["Clinical", 1515], ["Global", 1524], ["Impressions", 1531], ["-", 1542], ["Improvement", 1543], ["ratings", 1555], ["indicated", 1563], ["that", 1573], ["patients", 1578], ["were", 1587], ["'", 1592], ["much", 1593], ["improved", 1598], ["'", 1606], [".", 1607], ["These", 1609], ["promising", 1615], ["initial", 1625], ["results", 1633], ["merit", 1641], ["further", 1647], ["investigation", 1655], ["in", 1669], ["a", 1672], ["larger", 1674], [",", 1680], ["randomized", 1682], ["-", 1692], ["controlled", 1693], ["trial", 1704], [".", 1709]]}
{"context": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse. This painless syndrome appears during or after a long period of drug addiction. It involves the hands and sometimes the forearms, and may cause functional, aesthetic and social disturbances when the hand volume is important. Physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies, infectious complications and direct toxicity of injected drugs and their adulterants. Low-stretch bandage and elastic garment, usually used in lymphedema treatment, are proposed to treat the puffy hand syndrome.", "qas": [{"question": "What causes \"Puffy hand syndrome\"?", "answers": ["intravenous drug abuse"], "qid": "da08626bddab419dbddfc38db2657996", "question_tokens": [["What", 0], ["causes", 5], ["\"", 12], ["Puffy", 13], ["hand", 19], ["syndrome", 24], ["\"", 32], ["?", 33]], "detected_answers": [{"text": "intravenous drug abuse", "token_spans": [[8, 10]], "char_spans": [[55, 76]]}]}], "context_tokens": [["Puffy", 0], ["hand", 6], ["syndrome", 11], ["is", 20], ["an", 23], ["unrecognized", 26], ["complication", 39], ["of", 52], ["intravenous", 55], ["drug", 67], ["abuse", 72], [".", 77], ["This", 79], ["painless", 84], ["syndrome", 93], ["appears", 102], ["during", 110], ["or", 117], ["after", 120], ["a", 126], ["long", 128], ["period", 133], ["of", 140], ["drug", 143], ["addiction", 148], [".", 157], ["It", 159], ["involves", 162], ["the", 171], ["hands", 175], ["and", 181], ["sometimes", 185], ["the", 195], ["forearms", 199], [",", 207], ["and", 209], ["may", 213], ["cause", 217], ["functional", 223], [",", 233], ["aesthetic", 235], ["and", 245], ["social", 249], ["disturbances", 256], ["when", 269], ["the", 274], ["hand", 278], ["volume", 283], ["is", 290], ["important", 293], [".", 302], ["Physiopathological", 304], ["mechanisms", 323], ["of", 334], ["the", 337], ["puffy", 341], ["hand", 347], ["syndrome", 352], ["are", 361], ["unclear", 365], ["and", 373], ["include", 377], ["venous", 385], ["and", 392], ["lymphatic", 396], ["insufficiencies", 406], [",", 421], ["infectious", 423], ["complications", 434], ["and", 448], ["direct", 452], ["toxicity", 459], ["of", 468], ["injected", 471], ["drugs", 480], ["and", 486], ["their", 490], ["adulterants", 496], [".", 507], ["Low", 509], ["-", 512], ["stretch", 513], ["bandage", 521], ["and", 529], ["elastic", 533], ["garment", 541], [",", 548], ["usually", 550], ["used", 558], ["in", 563], ["lymphedema", 566], ["treatment", 577], [",", 586], ["are", 588], ["proposed", 592], ["to", 601], ["treat", 604], ["the", 610], ["puffy", 614], ["hand", 620], ["syndrome", 625], [".", 633]]}
{"context": "The Sotos syndrome gene product, NSD1, is a SET domain histone methyltransferase that primarily dimethylates nucleosomal histone H3 lysine 36 (H3K36). To date, the intrinsic properties of NSD1 that determine its nucleosomal substrate selectivity and dimethyl H3K36 product specificity remain unknown. The 1.7 \u00c5 structure of the catalytic domain of NSD1 presented here shows that a regulatory loop adopts a conformation that prevents free access of H3K36 to the bound S-adenosyl-L-methionine. Molecular dynamics simulation and computational docking revealed that this normally inhibitory loop can adopt an active conformation, allowing H3K36 access to the active site, and that the nucleosome may stabilize the active conformation of the regulatory loop. Hence, our study reveals an autoregulatory mechanism of NSD1 and provides insight into the molecular mechanism of the nucleosomal substrate selectivity of this disease-related H3K36 methyltransferase.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "d8dc6dcb02604df98e1a216e74a229fa", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[10, 11]], "char_spans": [[44, 53]]}]}], "context_tokens": [["The", 0], ["Sotos", 4], ["syndrome", 10], ["gene", 19], ["product", 24], [",", 31], ["NSD1", 33], [",", 37], ["is", 39], ["a", 42], ["SET", 44], ["domain", 48], ["histone", 55], ["methyltransferase", 63], ["that", 81], ["primarily", 86], ["dimethylates", 96], ["nucleosomal", 109], ["histone", 121], ["H3", 129], ["lysine", 132], ["36", 139], ["(", 142], ["H3K36", 143], [")", 148], [".", 149], ["To", 151], ["date", 154], [",", 158], ["the", 160], ["intrinsic", 164], ["properties", 174], ["of", 185], ["NSD1", 188], ["that", 193], ["determine", 198], ["its", 208], ["nucleosomal", 212], ["substrate", 224], ["selectivity", 234], ["and", 246], ["dimethyl", 250], ["H3K36", 259], ["product", 265], ["specificity", 273], ["remain", 285], ["unknown", 292], [".", 299], ["The", 301], ["1.7", 305], ["\u00c5", 309], ["structure", 311], ["of", 321], ["the", 324], ["catalytic", 328], ["domain", 338], ["of", 345], ["NSD1", 348], ["presented", 353], ["here", 363], ["shows", 368], ["that", 374], ["a", 379], ["regulatory", 381], ["loop", 392], ["adopts", 397], ["a", 404], ["conformation", 406], ["that", 419], ["prevents", 424], ["free", 433], ["access", 438], ["of", 445], ["H3K36", 448], ["to", 454], ["the", 457], ["bound", 461], ["S", 467], ["-", 468], ["adenosyl", 469], ["-", 477], ["L", 478], ["-", 479], ["methionine", 480], [".", 490], ["Molecular", 492], ["dynamics", 502], ["simulation", 511], ["and", 522], ["computational", 526], ["docking", 540], ["revealed", 548], ["that", 557], ["this", 562], ["normally", 567], ["inhibitory", 576], ["loop", 587], ["can", 592], ["adopt", 596], ["an", 602], ["active", 605], ["conformation", 612], [",", 624], ["allowing", 626], ["H3K36", 635], ["access", 641], ["to", 648], ["the", 651], ["active", 655], ["site", 662], [",", 666], ["and", 668], ["that", 672], ["the", 677], ["nucleosome", 681], ["may", 692], ["stabilize", 696], ["the", 706], ["active", 710], ["conformation", 717], ["of", 730], ["the", 733], ["regulatory", 737], ["loop", 748], [".", 752], ["Hence", 754], [",", 759], ["our", 761], ["study", 765], ["reveals", 771], ["an", 779], ["autoregulatory", 782], ["mechanism", 797], ["of", 807], ["NSD1", 810], ["and", 815], ["provides", 819], ["insight", 828], ["into", 836], ["the", 841], ["molecular", 845], ["mechanism", 855], ["of", 865], ["the", 868], ["nucleosomal", 872], ["substrate", 884], ["selectivity", 894], ["of", 906], ["this", 909], ["disease", 914], ["-", 921], ["related", 922], ["H3K36", 930], ["methyltransferase", 936], [".", 953]]}
{"context": "Transgenic mice expressing a human mutant alpha-galactosidase with an R301Q substitution, which was found in a patient with a variant form of Fabry disease, were established. The mice transcribed a sufficient amount of alpha-galactosidase mRNA, but the steady-state levels of the enzyme protein were decreased in liver, kidney and heart, only residual activity being detected in these tissues. The mice will be useful for the clarification of the defective regulation of the structurally altered enzyme protein expressed by the mutant gene at the organ or individual level as well as for the evaluation of drugs that stabilize and/or activate the mutant alpha-galactosidase.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "0b96af4f05454584acfec3b094cb01bf", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[114, 116], [38, 40], [6, 8]], "char_spans": [[654, 672], [219, 237], [42, 60]]}]}], "context_tokens": [["Transgenic", 0], ["mice", 11], ["expressing", 16], ["a", 27], ["human", 29], ["mutant", 35], ["alpha", 42], ["-", 47], ["galactosidase", 48], ["with", 62], ["an", 67], ["R301Q", 70], ["substitution", 76], [",", 88], ["which", 90], ["was", 96], ["found", 100], ["in", 106], ["a", 109], ["patient", 111], ["with", 119], ["a", 124], ["variant", 126], ["form", 134], ["of", 139], ["Fabry", 142], ["disease", 148], [",", 155], ["were", 157], ["established", 162], [".", 173], ["The", 175], ["mice", 179], ["transcribed", 184], ["a", 196], ["sufficient", 198], ["amount", 209], ["of", 216], ["alpha", 219], ["-", 224], ["galactosidase", 225], ["mRNA", 239], [",", 243], ["but", 245], ["the", 249], ["steady", 253], ["-", 259], ["state", 260], ["levels", 266], ["of", 273], ["the", 276], ["enzyme", 280], ["protein", 287], ["were", 295], ["decreased", 300], ["in", 310], ["liver", 313], [",", 318], ["kidney", 320], ["and", 327], ["heart", 331], [",", 336], ["only", 338], ["residual", 343], ["activity", 352], ["being", 361], ["detected", 367], ["in", 376], ["these", 379], ["tissues", 385], [".", 392], ["The", 394], ["mice", 398], ["will", 403], ["be", 408], ["useful", 411], ["for", 418], ["the", 422], ["clarification", 426], ["of", 440], ["the", 443], ["defective", 447], ["regulation", 457], ["of", 468], ["the", 471], ["structurally", 475], ["altered", 488], ["enzyme", 496], ["protein", 503], ["expressed", 511], ["by", 521], ["the", 524], ["mutant", 528], ["gene", 535], ["at", 540], ["the", 543], ["organ", 547], ["or", 553], ["individual", 556], ["level", 567], ["as", 573], ["well", 576], ["as", 581], ["for", 584], ["the", 588], ["evaluation", 592], ["of", 603], ["drugs", 606], ["that", 612], ["stabilize", 617], ["and/or", 627], ["activate", 634], ["the", 643], ["mutant", 647], ["alpha", 654], ["-", 659], ["galactosidase", 660], [".", 673]]}
{"context": "With an ageing population and improving cancer therapies, the two most common benign and malignant bone diseases, osteoporosis and bone metastases, will continue to affect an increasing number of patients. Our expanding knowledge of the molecular processes underlying these conditions has resulted in novel bone targets that are currently being explored in clinical trials. Clearly, the approval of denosumab, a monoclonal antibody directed against RANKL, has just marked the beginning of a new era for bone therapy with several additional new therapies lining up for clinical approval in the coming years. Potential agents targeting the osteoclast include cathepsin K, currently in phase 3 trials, and src inhibitors. Amongst anabolic agents, inhibitors of the Wnt-inhibitor sclerostin and dickkopf-1 are promising in clinical trials. Here, we will provide a comprehensive overview of the most promising agents currently explored for the treatment of bone diseases.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "ba391f992ee74328aaba8df43265479c", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[71, 71]], "char_spans": [[449, 453]]}]}], "context_tokens": [["With", 0], ["an", 5], ["ageing", 8], ["population", 15], ["and", 26], ["improving", 30], ["cancer", 40], ["therapies", 47], [",", 56], ["the", 58], ["two", 62], ["most", 66], ["common", 71], ["benign", 78], ["and", 85], ["malignant", 89], ["bone", 99], ["diseases", 104], [",", 112], ["osteoporosis", 114], ["and", 127], ["bone", 131], ["metastases", 136], [",", 146], ["will", 148], ["continue", 153], ["to", 162], ["affect", 165], ["an", 172], ["increasing", 175], ["number", 186], ["of", 193], ["patients", 196], [".", 204], ["Our", 206], ["expanding", 210], ["knowledge", 220], ["of", 230], ["the", 233], ["molecular", 237], ["processes", 247], ["underlying", 257], ["these", 268], ["conditions", 274], ["has", 285], ["resulted", 289], ["in", 298], ["novel", 301], ["bone", 307], ["targets", 312], ["that", 320], ["are", 325], ["currently", 329], ["being", 339], ["explored", 345], ["in", 354], ["clinical", 357], ["trials", 366], [".", 372], ["Clearly", 374], [",", 381], ["the", 383], ["approval", 387], ["of", 396], ["denosumab", 399], [",", 408], ["a", 410], ["monoclonal", 412], ["antibody", 423], ["directed", 432], ["against", 441], ["RANKL", 449], [",", 454], ["has", 456], ["just", 460], ["marked", 465], ["the", 472], ["beginning", 476], ["of", 486], ["a", 489], ["new", 491], ["era", 495], ["for", 499], ["bone", 503], ["therapy", 508], ["with", 516], ["several", 521], ["additional", 529], ["new", 540], ["therapies", 544], ["lining", 554], ["up", 561], ["for", 564], ["clinical", 568], ["approval", 577], ["in", 586], ["the", 589], ["coming", 593], ["years", 600], [".", 605], ["Potential", 607], ["agents", 617], ["targeting", 624], ["the", 634], ["osteoclast", 638], ["include", 649], ["cathepsin", 657], ["K", 667], [",", 668], ["currently", 670], ["in", 680], ["phase", 683], ["3", 689], ["trials", 691], [",", 697], ["and", 699], ["src", 703], ["inhibitors", 707], [".", 717], ["Amongst", 719], ["anabolic", 727], ["agents", 736], [",", 742], ["inhibitors", 744], ["of", 755], ["the", 758], ["Wnt", 762], ["-", 765], ["inhibitor", 766], ["sclerostin", 776], ["and", 787], ["dickkopf-1", 791], ["are", 802], ["promising", 806], ["in", 816], ["clinical", 819], ["trials", 828], [".", 834], ["Here", 836], [",", 840], ["we", 842], ["will", 845], ["provide", 850], ["a", 858], ["comprehensive", 860], ["overview", 874], ["of", 883], ["the", 886], ["most", 890], ["promising", 895], ["agents", 905], ["currently", 912], ["explored", 922], ["for", 931], ["the", 935], ["treatment", 939], ["of", 949], ["bone", 952], ["diseases", 957], [".", 965]]}
{"context": "Patients with splenomegaly and abnormally high leukocyte counts were first recognized in France, Germany, and Scotland in the 1840s. The only well-documented therapy in the 19th century was use of arsenic in one or other form, which did undoubtedly reduce the leukocyte count but probably did little or nothing to prolong life. These early cases were probably examples of chronic myeloid leukemia (CML) (then called chronic granulocytic leukemia). In the 20th century important steps in unraveling the pathogenesis of CML were the discovery of the Philadelphia chromosome in 1960, and of the (9;22) translocation in 1973. There followed definition of the breakpoint cluster region on chromosome 22 in 1984 and the demonstration of the BCR-ABL transcript in CML in 1985. In the first half of the 20th century patients were treated predominantly with radiotherapy, and later on with busulfan, hydroxycarbamide, or interferon-alfa (IFN-\u03b1). From 1980 onwards allogeneic stem cell transplantation (SCT) became the treatment of choice for eligible patients. The era of tyrosine kinase inhibitors (TKI) began in 1998 and today the use of the original TKI, imatinib, has replaced SCT as initial therapy for patients who present with CML in chronic phase.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7a34cd7025714d5fa78883088d8a1b82", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[130, 132]], "char_spans": [[735, 741]]}]}], "context_tokens": [["Patients", 0], ["with", 9], ["splenomegaly", 14], ["and", 27], ["abnormally", 31], ["high", 42], ["leukocyte", 47], ["counts", 57], ["were", 64], ["first", 69], ["recognized", 75], ["in", 86], ["France", 89], [",", 95], ["Germany", 97], [",", 104], ["and", 106], ["Scotland", 110], ["in", 119], ["the", 122], ["1840s", 126], [".", 131], ["The", 133], ["only", 137], ["well", 142], ["-", 146], ["documented", 147], ["therapy", 158], ["in", 166], ["the", 169], ["19th", 173], ["century", 178], ["was", 186], ["use", 190], ["of", 194], ["arsenic", 197], ["in", 205], ["one", 208], ["or", 212], ["other", 215], ["form", 221], [",", 225], ["which", 227], ["did", 233], ["undoubtedly", 237], ["reduce", 249], ["the", 256], ["leukocyte", 260], ["count", 270], ["but", 276], ["probably", 280], ["did", 289], ["little", 293], ["or", 300], ["nothing", 303], ["to", 311], ["prolong", 314], ["life", 322], [".", 326], ["These", 328], ["early", 334], ["cases", 340], ["were", 346], ["probably", 351], ["examples", 360], ["of", 369], ["chronic", 372], ["myeloid", 380], ["leukemia", 388], ["(", 397], ["CML", 398], [")", 401], ["(", 403], ["then", 404], ["called", 409], ["chronic", 416], ["granulocytic", 424], ["leukemia", 437], [")", 445], [".", 446], ["In", 448], ["the", 451], ["20th", 455], ["century", 460], ["important", 468], ["steps", 478], ["in", 484], ["unraveling", 487], ["the", 498], ["pathogenesis", 502], ["of", 515], ["CML", 518], ["were", 522], ["the", 527], ["discovery", 531], ["of", 541], ["the", 544], ["Philadelphia", 548], ["chromosome", 561], ["in", 572], ["1960", 575], [",", 579], ["and", 581], ["of", 585], ["the", 588], ["(", 592], ["9;22", 593], [")", 597], ["translocation", 599], ["in", 613], ["1973", 616], [".", 620], ["There", 622], ["followed", 628], ["definition", 637], ["of", 648], ["the", 651], ["breakpoint", 655], ["cluster", 666], ["region", 674], ["on", 681], ["chromosome", 684], ["22", 695], ["in", 698], ["1984", 701], ["and", 706], ["the", 710], ["demonstration", 714], ["of", 728], ["the", 731], ["BCR", 735], ["-", 738], ["ABL", 739], ["transcript", 743], ["in", 754], ["CML", 757], ["in", 761], ["1985", 764], [".", 768], ["In", 770], ["the", 773], ["first", 777], ["half", 783], ["of", 788], ["the", 791], ["20th", 795], ["century", 800], ["patients", 808], ["were", 817], ["treated", 822], ["predominantly", 830], ["with", 844], ["radiotherapy", 849], [",", 861], ["and", 863], ["later", 867], ["on", 873], ["with", 876], ["busulfan", 881], [",", 889], ["hydroxycarbamide", 891], [",", 907], ["or", 909], ["interferon", 912], ["-", 922], ["alfa", 923], ["(", 928], ["IFN", 929], ["-", 932], ["\u03b1", 933], [")", 934], [".", 935], ["From", 937], ["1980", 942], ["onwards", 947], ["allogeneic", 955], ["stem", 966], ["cell", 971], ["transplantation", 976], ["(", 992], ["SCT", 993], [")", 996], ["became", 998], ["the", 1005], ["treatment", 1009], ["of", 1019], ["choice", 1022], ["for", 1029], ["eligible", 1033], ["patients", 1042], [".", 1050], ["The", 1052], ["era", 1056], ["of", 1060], ["tyrosine", 1063], ["kinase", 1072], ["inhibitors", 1079], ["(", 1090], ["TKI", 1091], [")", 1094], ["began", 1096], ["in", 1102], ["1998", 1105], ["and", 1110], ["today", 1114], ["the", 1120], ["use", 1124], ["of", 1128], ["the", 1131], ["original", 1135], ["TKI", 1144], [",", 1147], ["imatinib", 1149], [",", 1157], ["has", 1159], ["replaced", 1163], ["SCT", 1172], ["as", 1176], ["initial", 1179], ["therapy", 1187], ["for", 1195], ["patients", 1199], ["who", 1208], ["present", 1212], ["with", 1220], ["CML", 1225], ["in", 1229], ["chronic", 1232], ["phase", 1240], [".", 1245]]}
{"context": "Parkinson's disease (PD) is characterized by the progressive loss of substantia nigra dopaminergic neurons and the presence of cytoplasmic inclusions named Lewy bodies. Two missense mutations of the alpha-synuclein (alpha-syn; A30P and A53T) have been described in several families with an autosomal dominant form of PD. alpha-Syn also constitutes one of the main components of Lewy bodies in sporadic cases of PD. To develop an animal model of PD, lentiviral vectors expressing different human or rat forms of alpha-syn were injected into the substantia nigra of rats. In contrast to transgenic mice models, a selective loss of nigral dopaminergic neurons associated with a dopaminergic denervation of the striatum was observed in animals expressing either wild-type or mutant forms of human alpha-syn. This neuronal degeneration correlates with the appearance of abundant alpha-syn-positive inclusions and extensive neuritic pathology detected with both alpha-syn and silver staining. Lentiviral-mediated expression of wild-type or mutated forms of human alpha-syn recapitulates the essential neuropathological features of PD. Rat alpha-syn similarly leads to protein aggregation but without cell loss, suggesting that inclusions are not the primary cause of cell degeneration in PD. Viral-mediated genetic models may contribute to elucidate the mechanism of alpha-syn-induced cell death and allow the screening of candidate therapeutic molecules.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "d8e3b9a07469427db951cf2a0ae90c0f", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[32, 34]], "char_spans": [[199, 213]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["characterized", 28], ["by", 42], ["the", 45], ["progressive", 49], ["loss", 61], ["of", 66], ["substantia", 69], ["nigra", 80], ["dopaminergic", 86], ["neurons", 99], ["and", 107], ["the", 111], ["presence", 115], ["of", 124], ["cytoplasmic", 127], ["inclusions", 139], ["named", 150], ["Lewy", 156], ["bodies", 161], [".", 167], ["Two", 169], ["missense", 173], ["mutations", 182], ["of", 192], ["the", 195], ["alpha", 199], ["-", 204], ["synuclein", 205], ["(", 215], ["alpha", 216], ["-", 221], ["syn", 222], [";", 225], ["A30P", 227], ["and", 232], ["A53", 236], ["T", 239], [")", 240], ["have", 242], ["been", 247], ["described", 252], ["in", 262], ["several", 265], ["families", 273], ["with", 282], ["an", 287], ["autosomal", 290], ["dominant", 300], ["form", 309], ["of", 314], ["PD", 317], [".", 319], ["alpha", 321], ["-", 326], ["Syn", 327], ["also", 331], ["constitutes", 336], ["one", 348], ["of", 352], ["the", 355], ["main", 359], ["components", 364], ["of", 375], ["Lewy", 378], ["bodies", 383], ["in", 390], ["sporadic", 393], ["cases", 402], ["of", 408], ["PD", 411], [".", 413], ["To", 415], ["develop", 418], ["an", 426], ["animal", 429], ["model", 436], ["of", 442], ["PD", 445], [",", 447], ["lentiviral", 449], ["vectors", 460], ["expressing", 468], ["different", 479], ["human", 489], ["or", 495], ["rat", 498], ["forms", 502], ["of", 508], ["alpha", 511], ["-", 516], ["syn", 517], ["were", 521], ["injected", 526], ["into", 535], ["the", 540], ["substantia", 544], ["nigra", 555], ["of", 561], ["rats", 564], [".", 568], ["In", 570], ["contrast", 573], ["to", 582], ["transgenic", 585], ["mice", 596], ["models", 601], [",", 607], ["a", 609], ["selective", 611], ["loss", 621], ["of", 626], ["nigral", 629], ["dopaminergic", 636], ["neurons", 649], ["associated", 657], ["with", 668], ["a", 673], ["dopaminergic", 675], ["denervation", 688], ["of", 700], ["the", 703], ["striatum", 707], ["was", 716], ["observed", 720], ["in", 729], ["animals", 732], ["expressing", 740], ["either", 751], ["wild", 758], ["-", 762], ["type", 763], ["or", 768], ["mutant", 771], ["forms", 778], ["of", 784], ["human", 787], ["alpha", 793], ["-", 798], ["syn", 799], [".", 802], ["This", 804], ["neuronal", 809], ["degeneration", 818], ["correlates", 831], ["with", 842], ["the", 847], ["appearance", 851], ["of", 862], ["abundant", 865], ["alpha", 874], ["-", 879], ["syn", 880], ["-", 883], ["positive", 884], ["inclusions", 893], ["and", 904], ["extensive", 908], ["neuritic", 918], ["pathology", 927], ["detected", 937], ["with", 946], ["both", 951], ["alpha", 956], ["-", 961], ["syn", 962], ["and", 966], ["silver", 970], ["staining", 977], [".", 985], ["Lentiviral", 987], ["-", 997], ["mediated", 998], ["expression", 1007], ["of", 1018], ["wild", 1021], ["-", 1025], ["type", 1026], ["or", 1031], ["mutated", 1034], ["forms", 1042], ["of", 1048], ["human", 1051], ["alpha", 1057], ["-", 1062], ["syn", 1063], ["recapitulates", 1067], ["the", 1081], ["essential", 1085], ["neuropathological", 1095], ["features", 1113], ["of", 1122], ["PD", 1125], [".", 1127], ["Rat", 1129], ["alpha", 1133], ["-", 1138], ["syn", 1139], ["similarly", 1143], ["leads", 1153], ["to", 1159], ["protein", 1162], ["aggregation", 1170], ["but", 1182], ["without", 1186], ["cell", 1194], ["loss", 1199], [",", 1203], ["suggesting", 1205], ["that", 1216], ["inclusions", 1221], ["are", 1232], ["not", 1236], ["the", 1240], ["primary", 1244], ["cause", 1252], ["of", 1258], ["cell", 1261], ["degeneration", 1266], ["in", 1279], ["PD", 1282], [".", 1284], ["Viral", 1286], ["-", 1291], ["mediated", 1292], ["genetic", 1301], ["models", 1309], ["may", 1316], ["contribute", 1320], ["to", 1331], ["elucidate", 1334], ["the", 1344], ["mechanism", 1348], ["of", 1358], ["alpha", 1361], ["-", 1366], ["syn", 1367], ["-", 1370], ["induced", 1371], ["cell", 1379], ["death", 1384], ["and", 1390], ["allow", 1394], ["the", 1400], ["screening", 1404], ["of", 1414], ["candidate", 1417], ["therapeutic", 1427], ["molecules", 1439], [".", 1448]]}
{"context": "In this study psychometric properties of seven self-report measures of posttraumatic stress disorder (PTSD) were compared. The seven scales evaluated were the Davidson Trauma Scale (DTS), the PTSD Checklist (PCL), the Posttraumatic Stress Diagnostic Scale (PDS), the Civilian Mississippi Scale (CMS), the Impact of Event Scale-Revised (IES-R), the Penn Inventory for Posttraumatic Stress Disorder (Penn), and the PK scale of the MMPI-2 (PK). Participants were 239 (79 male and 160 female) trauma-exposed undergraduates. All seven measures exhibited good test-retest reliability and internal consistency. The PDS, PCL and DTS demonstrated the best convergent validity; the IES-R, PDS, and PCL demonstrated the best discriminant validity; and the PDS, PCL, and IES-R demonstrated the best diagnostic utility. Overall, results most strongly support the use of the PDS and the PCL for the assessment of PTSD in this population.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "c59a1bea5cff48498990324b541702a8", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[16, 16], [35, 35], [182, 182]], "char_spans": [[102, 105], [192, 195], [899, 902]]}]}], "context_tokens": [["In", 0], ["this", 3], ["study", 8], ["psychometric", 14], ["properties", 27], ["of", 38], ["seven", 41], ["self", 47], ["-", 51], ["report", 52], ["measures", 59], ["of", 68], ["posttraumatic", 71], ["stress", 85], ["disorder", 92], ["(", 101], ["PTSD", 102], [")", 106], ["were", 108], ["compared", 113], [".", 121], ["The", 123], ["seven", 127], ["scales", 133], ["evaluated", 140], ["were", 150], ["the", 155], ["Davidson", 159], ["Trauma", 168], ["Scale", 175], ["(", 181], ["DTS", 182], [")", 185], [",", 186], ["the", 188], ["PTSD", 192], ["Checklist", 197], ["(", 207], ["PCL", 208], [")", 211], [",", 212], ["the", 214], ["Posttraumatic", 218], ["Stress", 232], ["Diagnostic", 239], ["Scale", 250], ["(", 256], ["PDS", 257], [")", 260], [",", 261], ["the", 263], ["Civilian", 267], ["Mississippi", 276], ["Scale", 288], ["(", 294], ["CMS", 295], [")", 298], [",", 299], ["the", 301], ["Impact", 305], ["of", 312], ["Event", 315], ["Scale", 321], ["-", 326], ["Revised", 327], ["(", 335], ["IES", 336], ["-", 339], ["R", 340], [")", 341], [",", 342], ["the", 344], ["Penn", 348], ["Inventory", 353], ["for", 363], ["Posttraumatic", 367], ["Stress", 381], ["Disorder", 388], ["(", 397], ["Penn", 398], [")", 402], [",", 403], ["and", 405], ["the", 409], ["PK", 413], ["scale", 416], ["of", 422], ["the", 425], ["MMPI-2", 429], ["(", 436], ["PK", 437], [")", 439], [".", 440], ["Participants", 442], ["were", 455], ["239", 460], ["(", 464], ["79", 465], ["male", 468], ["and", 473], ["160", 477], ["female", 481], [")", 487], ["trauma", 489], ["-", 495], ["exposed", 496], ["undergraduates", 504], [".", 518], ["All", 520], ["seven", 524], ["measures", 530], ["exhibited", 539], ["good", 549], ["test", 554], ["-", 558], ["retest", 559], ["reliability", 566], ["and", 578], ["internal", 582], ["consistency", 591], [".", 602], ["The", 604], ["PDS", 608], [",", 611], ["PCL", 613], ["and", 617], ["DTS", 621], ["demonstrated", 625], ["the", 638], ["best", 642], ["convergent", 647], ["validity", 658], [";", 666], ["the", 668], ["IES", 672], ["-", 675], ["R", 676], [",", 677], ["PDS", 679], [",", 682], ["and", 684], ["PCL", 688], ["demonstrated", 692], ["the", 705], ["best", 709], ["discriminant", 714], ["validity", 727], [";", 735], ["and", 737], ["the", 741], ["PDS", 745], [",", 748], ["PCL", 750], [",", 753], ["and", 755], ["IES", 759], ["-", 762], ["R", 763], ["demonstrated", 765], ["the", 778], ["best", 782], ["diagnostic", 787], ["utility", 798], [".", 805], ["Overall", 807], [",", 814], ["results", 816], ["most", 824], ["strongly", 829], ["support", 838], ["the", 846], ["use", 850], ["of", 854], ["the", 857], ["PDS", 861], ["and", 865], ["the", 869], ["PCL", 873], ["for", 877], ["the", 881], ["assessment", 885], ["of", 896], ["PTSD", 899], ["in", 904], ["this", 907], ["population", 912], [".", 922]]}
{"context": "We have determined sequences of PCR-amplified B1 elements from hamster and rat (Myomorpha), chipmunk (Sciuromorpha), and guinea pig (Caviomorpha). Between three and six B1 subfamilies were found in these species. In the phylogenetic analysis B1 sequences of hamster, mouse, and rat clustered separately from those of chipmunk and those of guinea pig. This is consistent with an independent evolution of B1 elements in separate rodent lineages. We exclude the possibility of convergent mutations to explain certain diagnostic characters within the modern B1 quasi-dimers and view these elements as mosaic structures assembling preexisting mutations. Furthermore, the presence of Alu-like structural motifs supports the hypothesis of the monophyletic origin of Alu and B1 repeats, i.e., from a common 7SL RNA-derived retroposing monomeric element.", "qas": [{"question": "From which sequence does the Alu repeat originate from?", "answers": ["7SL RNA"], "qid": "e4f9aab09e074c42b56d239bd1ea6bf9", "question_tokens": [["From", 0], ["which", 5], ["sequence", 11], ["does", 20], ["the", 25], ["Alu", 29], ["repeat", 33], ["originate", 40], ["from", 50], ["?", 54]], "detected_answers": [{"text": "7SL RNA", "token_spans": [[140, 141]], "char_spans": [[799, 805]]}]}], "context_tokens": [["We", 0], ["have", 3], ["determined", 8], ["sequences", 19], ["of", 29], ["PCR", 32], ["-", 35], ["amplified", 36], ["B1", 46], ["elements", 49], ["from", 58], ["hamster", 63], ["and", 71], ["rat", 75], ["(", 79], ["Myomorpha", 80], [")", 89], [",", 90], ["chipmunk", 92], ["(", 101], ["Sciuromorpha", 102], [")", 114], [",", 115], ["and", 117], ["guinea", 121], ["pig", 128], ["(", 132], ["Caviomorpha", 133], [")", 144], [".", 145], ["Between", 147], ["three", 155], ["and", 161], ["six", 165], ["B1", 169], ["subfamilies", 172], ["were", 184], ["found", 189], ["in", 195], ["these", 198], ["species", 204], [".", 211], ["In", 213], ["the", 216], ["phylogenetic", 220], ["analysis", 233], ["B1", 242], ["sequences", 245], ["of", 255], ["hamster", 258], [",", 265], ["mouse", 267], [",", 272], ["and", 274], ["rat", 278], ["clustered", 282], ["separately", 292], ["from", 303], ["those", 308], ["of", 314], ["chipmunk", 317], ["and", 326], ["those", 330], ["of", 336], ["guinea", 339], ["pig", 346], [".", 349], ["This", 351], ["is", 356], ["consistent", 359], ["with", 370], ["an", 375], ["independent", 378], ["evolution", 390], ["of", 400], ["B1", 403], ["elements", 406], ["in", 415], ["separate", 418], ["rodent", 427], ["lineages", 434], [".", 442], ["We", 444], ["exclude", 447], ["the", 455], ["possibility", 459], ["of", 471], ["convergent", 474], ["mutations", 485], ["to", 495], ["explain", 498], ["certain", 506], ["diagnostic", 514], ["characters", 525], ["within", 536], ["the", 543], ["modern", 547], ["B1", 554], ["quasi", 557], ["-", 562], ["dimers", 563], ["and", 570], ["view", 574], ["these", 579], ["elements", 585], ["as", 594], ["mosaic", 597], ["structures", 604], ["assembling", 615], ["preexisting", 626], ["mutations", 638], [".", 647], ["Furthermore", 649], [",", 660], ["the", 662], ["presence", 666], ["of", 675], ["Alu", 678], ["-", 681], ["like", 682], ["structural", 687], ["motifs", 698], ["supports", 705], ["the", 714], ["hypothesis", 718], ["of", 729], ["the", 732], ["monophyletic", 736], ["origin", 749], ["of", 756], ["Alu", 759], ["and", 763], ["B1", 767], ["repeats", 770], [",", 777], ["i.e.", 779], [",", 783], ["from", 785], ["a", 790], ["common", 792], ["7SL", 799], ["RNA", 803], ["-", 806], ["derived", 807], ["retroposing", 815], ["monomeric", 827], ["element", 837], [".", 844]]}
{"context": "Two spontaneous mutant beige rats, with phenotypes resembling human Chediak- Higashi syndrome (CHS), were found independently in two inbred strains. Both beige mutations were identified to be recessive alleles in the Lyst locus on rat chromosome 17 and the alleles were denoted Lyst(bg) and Lyst(bg-Kyo). As it is almost impossible to discriminate these mutations phenotypically, we developed an allele-specific genotyping method for the Lyst gene. The nested PCR amplification was followed by restriction fragment length polymorphism (RFLP) analysis. By this method, we could discriminate the mutant Lyst(bg), Lyst(bg-Kyo) alleles, and the normal Lyst allele, easily and accurately.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome", "Chediak- Higashi syndrome"], "qid": "23bd86de677a400e8ee3c4a56c6f39e1", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[10, 12]], "char_spans": [[68, 92]]}]}], "context_tokens": [["Two", 0], ["spontaneous", 4], ["mutant", 16], ["beige", 23], ["rats", 29], [",", 33], ["with", 35], ["phenotypes", 40], ["resembling", 51], ["human", 62], ["Chediak-", 68], ["Higashi", 77], ["syndrome", 85], ["(", 94], ["CHS", 95], [")", 98], [",", 99], ["were", 101], ["found", 106], ["independently", 112], ["in", 126], ["two", 129], ["inbred", 133], ["strains", 140], [".", 147], ["Both", 149], ["beige", 154], ["mutations", 160], ["were", 170], ["identified", 175], ["to", 186], ["be", 189], ["recessive", 192], ["alleles", 202], ["in", 210], ["the", 213], ["Lyst", 217], ["locus", 222], ["on", 228], ["rat", 231], ["chromosome", 235], ["17", 246], ["and", 249], ["the", 253], ["alleles", 257], ["were", 265], ["denoted", 270], ["Lyst(bg", 278], [")", 285], ["and", 287], ["Lyst(bg", 291], ["-", 298], ["Kyo", 299], [")", 302], [".", 303], ["As", 305], ["it", 308], ["is", 311], ["almost", 314], ["impossible", 321], ["to", 332], ["discriminate", 335], ["these", 348], ["mutations", 354], ["phenotypically", 364], [",", 378], ["we", 380], ["developed", 383], ["an", 393], ["allele", 396], ["-", 402], ["specific", 403], ["genotyping", 412], ["method", 423], ["for", 430], ["the", 434], ["Lyst", 438], ["gene", 443], [".", 447], ["The", 449], ["nested", 453], ["PCR", 460], ["amplification", 464], ["was", 478], ["followed", 482], ["by", 491], ["restriction", 494], ["fragment", 506], ["length", 515], ["polymorphism", 522], ["(", 535], ["RFLP", 536], [")", 540], ["analysis", 542], [".", 550], ["By", 552], ["this", 555], ["method", 560], [",", 566], ["we", 568], ["could", 571], ["discriminate", 577], ["the", 590], ["mutant", 594], ["Lyst(bg", 601], [")", 608], [",", 609], ["Lyst(bg", 611], ["-", 618], ["Kyo", 619], [")", 622], ["alleles", 624], [",", 631], ["and", 633], ["the", 637], ["normal", 641], ["Lyst", 648], ["allele", 653], [",", 659], ["easily", 661], ["and", 668], ["accurately", 672], [".", 682]]}
{"context": "Batten disease (juvenile-onset neuronal ceroid lipofuscinosis, JNCL), the most common neurodegenerative disorder of childhood, is caused by mutations in a recently identified gene ( CLN3 ) localized to chromosome 16p11.2-12.1. To elucidate the biosynthesis and localization of the CLN3 protein, we expressed CLN3 cDNA in COS-1 and HeLa cell lines. In vitro translation, immunoprecipitation and Western blotting analyses detected an approximately 43 kDa polypeptide. Pulse-chase experiments indicated that the CLN3 protein is synthesized as an N -glycosylated single-chain polypeptide, which was not detected in growth medium. Confocal immunofluorescence microscopy revealed that the CLN3 protein is localized to the lysosomal compartment. These results provide evidence that Batten disease can be classified as a member of lysosomal diseases.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "4a70e96cd685482787d78a9a40f450ca", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[0, 1], [126, 127]], "char_spans": [[0, 13], [775, 788]]}, {"text": "juvenile-onset neuronal ceroid lipofuscinosis", "token_spans": [[3, 8]], "char_spans": [[16, 60]]}, {"text": "JNCL", "token_spans": [[10, 10]], "char_spans": [[63, 66]]}]}], "context_tokens": [["Batten", 0], ["disease", 7], ["(", 15], ["juvenile", 16], ["-", 24], ["onset", 25], ["neuronal", 31], ["ceroid", 40], ["lipofuscinosis", 47], [",", 61], ["JNCL", 63], [")", 67], [",", 68], ["the", 70], ["most", 74], ["common", 79], ["neurodegenerative", 86], ["disorder", 104], ["of", 113], ["childhood", 116], [",", 125], ["is", 127], ["caused", 130], ["by", 137], ["mutations", 140], ["in", 150], ["a", 153], ["recently", 155], ["identified", 164], ["gene", 175], ["(", 180], ["CLN3", 182], [")", 187], ["localized", 189], ["to", 199], ["chromosome", 202], ["16p11.2", 213], ["-", 220], ["12.1", 221], [".", 225], ["To", 227], ["elucidate", 230], ["the", 240], ["biosynthesis", 244], ["and", 257], ["localization", 261], ["of", 274], ["the", 277], ["CLN3", 281], ["protein", 286], [",", 293], ["we", 295], ["expressed", 298], ["CLN3", 308], ["cDNA", 313], ["in", 318], ["COS-1", 321], ["and", 327], ["HeLa", 331], ["cell", 336], ["lines", 341], [".", 346], ["In", 348], ["vitro", 351], ["translation", 357], [",", 368], ["immunoprecipitation", 370], ["and", 390], ["Western", 394], ["blotting", 402], ["analyses", 411], ["detected", 420], ["an", 429], ["approximately", 432], ["43", 446], ["kDa", 449], ["polypeptide", 453], [".", 464], ["Pulse", 466], ["-", 471], ["chase", 472], ["experiments", 478], ["indicated", 490], ["that", 500], ["the", 505], ["CLN3", 509], ["protein", 514], ["is", 522], ["synthesized", 525], ["as", 537], ["an", 540], ["N", 543], ["-glycosylated", 545], ["single", 559], ["-", 565], ["chain", 566], ["polypeptide", 572], [",", 583], ["which", 585], ["was", 591], ["not", 595], ["detected", 599], ["in", 608], ["growth", 611], ["medium", 618], [".", 624], ["Confocal", 626], ["immunofluorescence", 635], ["microscopy", 654], ["revealed", 665], ["that", 674], ["the", 679], ["CLN3", 683], ["protein", 688], ["is", 696], ["localized", 699], ["to", 709], ["the", 712], ["lysosomal", 716], ["compartment", 726], [".", 737], ["These", 739], ["results", 745], ["provide", 753], ["evidence", 761], ["that", 770], ["Batten", 775], ["disease", 782], ["can", 790], ["be", 794], ["classified", 797], ["as", 808], ["a", 811], ["member", 813], ["of", 820], ["lysosomal", 823], ["diseases", 833], [".", 841]]}
{"context": "This study aimed to explore retrospective childhood ADHD symptomatology, psychiatric comorbidity, rates of substance-use disorders (SUD), as well as their association with high-risk health behaviors in prison and adverse health outcomes. A randomly selected representative sample of inmates in the Puerto Rico correctional system (N = 1,179) was assessed with the Spanish-language Wender Utah Rating Scale (WURS); the Composite International Diagnostic Interview (CIDI) modules for lifetime/current major depression disorder (MDD), generalized anxiety disorder (GAD), and SUD; the Davidson Trauma Scale (DTS; posttraumatic stress disorder [PTSD]); and self-reports of in-site high-risk behaviors. Wald \u03c7(2) tests revealed significant associations of ADHD with MDD and PTSD, as well as increased risk for overdosing and intravenous drug use in prison. A logistic regression model adjusted for mood and anxiety comorbidity predicted lifetime SUD diagnosis (odds ratio = 2.38; 95% confidence interval = [1.15, 4.94]). Our results provide further evidence on the association of drug dependence and ADHD symptoms, and their overrepresentation among prison inmates.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "cb4d005ff43d41c896f0469ab1363b38", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[144, 144], [115, 115]], "char_spans": [[768, 771], [640, 643]]}]}], "context_tokens": [["This", 0], ["study", 5], ["aimed", 11], ["to", 17], ["explore", 20], ["retrospective", 28], ["childhood", 42], ["ADHD", 52], ["symptomatology", 57], [",", 71], ["psychiatric", 73], ["comorbidity", 85], [",", 96], ["rates", 98], ["of", 104], ["substance", 107], ["-", 116], ["use", 117], ["disorders", 121], ["(", 131], ["SUD", 132], [")", 135], [",", 136], ["as", 138], ["well", 141], ["as", 146], ["their", 149], ["association", 155], ["with", 167], ["high", 172], ["-", 176], ["risk", 177], ["health", 182], ["behaviors", 189], ["in", 199], ["prison", 202], ["and", 209], ["adverse", 213], ["health", 221], ["outcomes", 228], [".", 236], ["A", 238], ["randomly", 240], ["selected", 249], ["representative", 258], ["sample", 273], ["of", 280], ["inmates", 283], ["in", 291], ["the", 294], ["Puerto", 298], ["Rico", 305], ["correctional", 310], ["system", 323], ["(", 330], ["N", 331], ["=", 333], ["1,179", 335], [")", 340], ["was", 342], ["assessed", 346], ["with", 355], ["the", 360], ["Spanish", 364], ["-", 371], ["language", 372], ["Wender", 381], ["Utah", 388], ["Rating", 393], ["Scale", 400], ["(", 406], ["WURS", 407], [")", 411], [";", 412], ["the", 414], ["Composite", 418], ["International", 428], ["Diagnostic", 442], ["Interview", 453], ["(", 463], ["CIDI", 464], [")", 468], ["modules", 470], ["for", 478], ["lifetime", 482], ["/", 490], ["current", 491], ["major", 499], ["depression", 505], ["disorder", 516], ["(", 525], ["MDD", 526], [")", 529], [",", 530], ["generalized", 532], ["anxiety", 544], ["disorder", 552], ["(", 561], ["GAD", 562], [")", 565], [",", 566], ["and", 568], ["SUD", 572], [";", 575], ["the", 577], ["Davidson", 581], ["Trauma", 590], ["Scale", 597], ["(", 603], ["DTS", 604], [";", 607], ["posttraumatic", 609], ["stress", 623], ["disorder", 630], ["[", 639], ["PTSD", 640], ["]", 644], [")", 645], [";", 646], ["and", 648], ["self", 652], ["-", 656], ["reports", 657], ["of", 665], ["in", 668], ["-", 670], ["site", 671], ["high", 676], ["-", 680], ["risk", 681], ["behaviors", 686], [".", 695], ["Wald", 697], ["\u03c7(2", 702], [")", 705], ["tests", 707], ["revealed", 713], ["significant", 722], ["associations", 734], ["of", 747], ["ADHD", 750], ["with", 755], ["MDD", 760], ["and", 764], ["PTSD", 768], [",", 772], ["as", 774], ["well", 777], ["as", 782], ["increased", 785], ["risk", 795], ["for", 800], ["overdosing", 804], ["and", 815], ["intravenous", 819], ["drug", 831], ["use", 836], ["in", 840], ["prison", 843], [".", 849], ["A", 851], ["logistic", 853], ["regression", 862], ["model", 873], ["adjusted", 879], ["for", 888], ["mood", 892], ["and", 897], ["anxiety", 901], ["comorbidity", 909], ["predicted", 921], ["lifetime", 931], ["SUD", 940], ["diagnosis", 944], ["(", 954], ["odds", 955], ["ratio", 960], ["=", 966], ["2.38", 968], [";", 972], ["95", 974], ["%", 976], ["confidence", 978], ["interval", 989], ["=", 998], ["[", 1000], ["1.15", 1001], [",", 1005], ["4.94", 1007], ["]", 1011], [")", 1012], [".", 1013], ["Our", 1015], ["results", 1019], ["provide", 1027], ["further", 1035], ["evidence", 1043], ["on", 1052], ["the", 1055], ["association", 1059], ["of", 1071], ["drug", 1074], ["dependence", 1079], ["and", 1090], ["ADHD", 1094], ["symptoms", 1099], [",", 1107], ["and", 1109], ["their", 1113], ["overrepresentation", 1119], ["among", 1138], ["prison", 1144], ["inmates", 1151], [".", 1158]]}
{"context": "Denosumab is a human monoclonal antibody which specifically blocks receptor activator of nuclear factor \u03baB ligand and is a very potent antiresorptive drug. Its efficacy in reducing the risk of vertebral, hip and nonskeletal fracture has been proven in a large prospective, randomized multicenter study of 7808 postmenopausal women with osteoporosis [Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial]. Denosumab causes somewhat greater increases in bone mineral density (BMD) than the class of bisphosphonate antiresorptives. Denosumab also causes an increase in bone mass and bone strength in the spine, ultradistal and diaphysis of the radius, proximal tibia and the hip. Recently long-term treatment with denosumab has been shown to cause a continued almost linear increase in total hip and femoral neck BMD beyond 3 years up to 8 years. In this respect, denosumab seems to differ from the bisphosphonate group in which the rate of improvement of BMD diminishes and for some drugs becomes negative after 3-4 years when the process of secondary mineralization flattens out. This unique property of an antiresorptive drug points towards mechanisms of action which differ from the bisphosphonate group. Both types of antiresorptives decrease cortical porosity but contrary to bisphosphonates the reduction in cortical porosity continues with denosumab which, in addition, also seems to cause a slight continuous modeling-based formation of new bone despite suppression of bone remodeling. The net effect is an increase in cortical thickening and bone mass, and increased strength of cortical bone. This may contribute substantially to the significant further reduction of the nonvertebral fracture risk which was found in the long-term denosumab arm of the FREEDOM extension trial during years 4-7.", "qas": [{"question": "Which is the target of the drug Denosumab?", "answers": ["receptor activator of nuclear factor \u03baB ligand", "RANKL", "receptor activator of nuclear factor-\u03baB ligand"], "qid": "d38d490c5d9f45a0818bec552463879b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["the", 23], ["drug", 27], ["Denosumab", 32], ["?", 41]], "detected_answers": [{"text": "receptor activator of nuclear factor-\u03baB ligand", "token_spans": [[9, 15]], "char_spans": [[67, 112]]}]}], "context_tokens": [["Denosumab", 0], ["is", 10], ["a", 13], ["human", 15], ["monoclonal", 21], ["antibody", 32], ["which", 41], ["specifically", 47], ["blocks", 60], ["receptor", 67], ["activator", 76], ["of", 86], ["nuclear", 89], ["factor", 97], ["\u03baB", 104], ["ligand", 107], ["and", 114], ["is", 118], ["a", 121], ["very", 123], ["potent", 128], ["antiresorptive", 135], ["drug", 150], [".", 154], ["Its", 156], ["efficacy", 160], ["in", 169], ["reducing", 172], ["the", 181], ["risk", 185], ["of", 190], ["vertebral", 193], [",", 202], ["hip", 204], ["and", 208], ["nonskeletal", 212], ["fracture", 224], ["has", 233], ["been", 237], ["proven", 242], ["in", 249], ["a", 252], ["large", 254], ["prospective", 260], [",", 271], ["randomized", 273], ["multicenter", 284], ["study", 296], ["of", 302], ["7808", 305], ["postmenopausal", 310], ["women", 325], ["with", 331], ["osteoporosis", 336], ["[", 349], ["Fracture", 350], ["Reduction", 359], ["Evaluation", 369], ["of", 380], ["Denosumab", 383], ["in", 393], ["Osteoporosis", 396], ["Every", 409], ["6", 415], ["Months", 417], ["(", 424], ["FREEDOM", 425], [")", 432], ["trial].", 434], ["Denosumab", 442], ["causes", 452], ["somewhat", 459], ["greater", 468], ["increases", 476], ["in", 486], ["bone", 489], ["mineral", 494], ["density", 502], ["(", 510], ["BMD", 511], [")", 514], ["than", 516], ["the", 521], ["class", 525], ["of", 531], ["bisphosphonate", 534], ["antiresorptives", 549], [".", 564], ["Denosumab", 566], ["also", 576], ["causes", 581], ["an", 588], ["increase", 591], ["in", 600], ["bone", 603], ["mass", 608], ["and", 613], ["bone", 617], ["strength", 622], ["in", 631], ["the", 634], ["spine", 638], [",", 643], ["ultradistal", 645], ["and", 657], ["diaphysis", 661], ["of", 671], ["the", 674], ["radius", 678], [",", 684], ["proximal", 686], ["tibia", 695], ["and", 701], ["the", 705], ["hip", 709], [".", 712], ["Recently", 714], ["long", 723], ["-", 727], ["term", 728], ["treatment", 733], ["with", 743], ["denosumab", 748], ["has", 758], ["been", 762], ["shown", 767], ["to", 773], ["cause", 776], ["a", 782], ["continued", 784], ["almost", 794], ["linear", 801], ["increase", 808], ["in", 817], ["total", 820], ["hip", 826], ["and", 830], ["femoral", 834], ["neck", 842], ["BMD", 847], ["beyond", 851], ["3", 858], ["years", 860], ["up", 866], ["to", 869], ["8", 872], ["years", 874], [".", 879], ["In", 881], ["this", 884], ["respect", 889], [",", 896], ["denosumab", 898], ["seems", 908], ["to", 914], ["differ", 917], ["from", 924], ["the", 929], ["bisphosphonate", 933], ["group", 948], ["in", 954], ["which", 957], ["the", 963], ["rate", 967], ["of", 972], ["improvement", 975], ["of", 987], ["BMD", 990], ["diminishes", 994], ["and", 1005], ["for", 1009], ["some", 1013], ["drugs", 1018], ["becomes", 1024], ["negative", 1032], ["after", 1041], ["3", 1047], ["-", 1048], ["4", 1049], ["years", 1051], ["when", 1057], ["the", 1062], ["process", 1066], ["of", 1074], ["secondary", 1077], ["mineralization", 1087], ["flattens", 1102], ["out", 1111], [".", 1114], ["This", 1116], ["unique", 1121], ["property", 1128], ["of", 1137], ["an", 1140], ["antiresorptive", 1143], ["drug", 1158], ["points", 1163], ["towards", 1170], ["mechanisms", 1178], ["of", 1189], ["action", 1192], ["which", 1199], ["differ", 1205], ["from", 1212], ["the", 1217], ["bisphosphonate", 1221], ["group", 1236], [".", 1241], ["Both", 1243], ["types", 1248], ["of", 1254], ["antiresorptives", 1257], ["decrease", 1273], ["cortical", 1282], ["porosity", 1291], ["but", 1300], ["contrary", 1304], ["to", 1313], ["bisphosphonates", 1316], ["the", 1332], ["reduction", 1336], ["in", 1346], ["cortical", 1349], ["porosity", 1358], ["continues", 1367], ["with", 1377], ["denosumab", 1382], ["which", 1392], [",", 1397], ["in", 1399], ["addition", 1402], [",", 1410], ["also", 1412], ["seems", 1417], ["to", 1423], ["cause", 1426], ["a", 1432], ["slight", 1434], ["continuous", 1441], ["modeling", 1452], ["-", 1460], ["based", 1461], ["formation", 1467], ["of", 1477], ["new", 1480], ["bone", 1484], ["despite", 1489], ["suppression", 1497], ["of", 1509], ["bone", 1512], ["remodeling", 1517], [".", 1527], ["The", 1529], ["net", 1533], ["effect", 1537], ["is", 1544], ["an", 1547], ["increase", 1550], ["in", 1559], ["cortical", 1562], ["thickening", 1571], ["and", 1582], ["bone", 1586], ["mass", 1591], [",", 1595], ["and", 1597], ["increased", 1601], ["strength", 1611], ["of", 1620], ["cortical", 1623], ["bone", 1632], [".", 1636], ["This", 1638], ["may", 1643], ["contribute", 1647], ["substantially", 1658], ["to", 1672], ["the", 1675], ["significant", 1679], ["further", 1691], ["reduction", 1699], ["of", 1709], ["the", 1712], ["nonvertebral", 1716], ["fracture", 1729], ["risk", 1738], ["which", 1743], ["was", 1749], ["found", 1753], ["in", 1759], ["the", 1762], ["long", 1766], ["-", 1770], ["term", 1771], ["denosumab", 1776], ["arm", 1786], ["of", 1790], ["the", 1793], ["FREEDOM", 1797], ["extension", 1805], ["trial", 1815], ["during", 1821], ["years", 1828], ["4", 1834], ["-", 1835], ["7", 1836], [".", 1837]]}
{"context": "\u03b1-Synuclein is the major pathological component of synucleinopathies including Parkinson's disease and dementia with Lewy bodies. Recent studies have demonstrated that \u03b1-synuclein also plays important roles in the release of synaptic vesicles and synaptic membrane recycling in healthy neurons. However, the precise relationship between the pathogenicity and physiological functions of \u03b1-synuclein remains to be elucidated. To address this issue, we investigated the subcellular localization of \u03b1-synuclein in normal and pathological conditions using primary mouse hippocampal neuronal cultures. While some neurons expressed high levels of \u03b1-synuclein in presynaptic boutons and cell bodies, other neurons either did not or only very weakly expressed the protein. These \u03b1-synuclein-negative cells were identified as inhibitory neurons by immunostaining with specific antibodies against glutamic acid decarboxylase (GAD), parvalbumin, and somatostatin. In contrast, \u03b1-synuclein-positive synapses were colocalized with the excitatory synapse marker vesicular glutamate transporter-1. This expression profile of \u03b1-synuclein was conserved in the hippocampus in vivo. In addition, we found that while presynaptic \u03b1-synuclein colocalizes with synapsin, a marker of presynaptic vesicles, it is not essential for activity-dependent membrane recycling induced by high potassium treatment. Exogenous supply of preformed fibrils generated by recombinant \u03b1-synuclein was shown to promote the formation of Lewy body (LB) -like intracellular aggregates involving endogenous \u03b1-synuclein. GAD-positive neurons did not form LB-like aggregates following treatment with preformed fibrils, however, exogenous expression of human \u03b1-synuclein allowed intracellular aggregate formation in these cells. These results suggest the presence of a different mechanism for regulation of the expression of \u03b1-synuclein between excitatory and inhibitory neurons. Furthermore, \u03b1-synuclein expression levels may determine the efficiency of intracellular aggregate formation in different neuronal subtypes.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "02aedd384e0844e18fd9364151f02926", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[195, 197], [305, 307], [176, 178], [252, 254], [316, 318], [155, 157], [77, 79], [58, 60], [232, 234], [279, 281], [25, 27], [123, 125], [0, 2], [99, 101]], "char_spans": [[1208, 1218], [1875, 1885], [1109, 1119], [1560, 1570], [1943, 1953], [965, 975], [495, 505], [386, 396], [1443, 1453], [1709, 1719], [168, 178], [770, 780], [0, 10], [640, 650]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["is", 12], ["the", 15], ["major", 19], ["pathological", 25], ["component", 38], ["of", 48], ["synucleinopathies", 51], ["including", 69], ["Parkinson", 79], ["'s", 88], ["disease", 91], ["and", 99], ["dementia", 103], ["with", 112], ["Lewy", 117], ["bodies", 122], [".", 128], ["Recent", 130], ["studies", 137], ["have", 145], ["demonstrated", 150], ["that", 163], ["\u03b1", 168], ["-", 169], ["synuclein", 170], ["also", 180], ["plays", 185], ["important", 191], ["roles", 201], ["in", 207], ["the", 210], ["release", 214], ["of", 222], ["synaptic", 225], ["vesicles", 234], ["and", 243], ["synaptic", 247], ["membrane", 256], ["recycling", 265], ["in", 275], ["healthy", 278], ["neurons", 286], [".", 293], ["However", 295], [",", 302], ["the", 304], ["precise", 308], ["relationship", 316], ["between", 329], ["the", 337], ["pathogenicity", 341], ["and", 355], ["physiological", 359], ["functions", 373], ["of", 383], ["\u03b1", 386], ["-", 387], ["synuclein", 388], ["remains", 398], ["to", 406], ["be", 409], ["elucidated", 412], [".", 422], ["To", 424], ["address", 427], ["this", 435], ["issue", 440], [",", 445], ["we", 447], ["investigated", 450], ["the", 463], ["subcellular", 467], ["localization", 479], ["of", 492], ["\u03b1", 495], ["-", 496], ["synuclein", 497], ["in", 507], ["normal", 510], ["and", 517], ["pathological", 521], ["conditions", 534], ["using", 545], ["primary", 551], ["mouse", 559], ["hippocampal", 565], ["neuronal", 577], ["cultures", 586], [".", 594], ["While", 596], ["some", 602], ["neurons", 607], ["expressed", 615], ["high", 625], ["levels", 630], ["of", 637], ["\u03b1", 640], ["-", 641], ["synuclein", 642], ["in", 652], ["presynaptic", 655], ["boutons", 667], ["and", 675], ["cell", 679], ["bodies", 684], [",", 690], ["other", 692], ["neurons", 698], ["either", 706], ["did", 713], ["not", 717], ["or", 721], ["only", 724], ["very", 729], ["weakly", 734], ["expressed", 741], ["the", 751], ["protein", 755], [".", 762], ["These", 764], ["\u03b1", 770], ["-", 771], ["synuclein", 772], ["-", 781], ["negative", 782], ["cells", 791], ["were", 797], ["identified", 802], ["as", 813], ["inhibitory", 816], ["neurons", 827], ["by", 835], ["immunostaining", 838], ["with", 853], ["specific", 858], ["antibodies", 867], ["against", 878], ["glutamic", 886], ["acid", 895], ["decarboxylase", 900], ["(", 914], ["GAD", 915], [")", 918], [",", 919], ["parvalbumin", 921], [",", 932], ["and", 934], ["somatostatin", 938], [".", 950], ["In", 952], ["contrast", 955], [",", 963], ["\u03b1", 965], ["-", 966], ["synuclein", 967], ["-", 976], ["positive", 977], ["synapses", 986], ["were", 995], ["colocalized", 1000], ["with", 1012], ["the", 1017], ["excitatory", 1021], ["synapse", 1032], ["marker", 1040], ["vesicular", 1047], ["glutamate", 1057], ["transporter-1", 1067], [".", 1080], ["This", 1082], ["expression", 1087], ["profile", 1098], ["of", 1106], ["\u03b1", 1109], ["-", 1110], ["synuclein", 1111], ["was", 1121], ["conserved", 1125], ["in", 1135], ["the", 1138], ["hippocampus", 1142], ["in", 1154], ["vivo", 1157], [".", 1161], ["In", 1163], ["addition", 1166], [",", 1174], ["we", 1176], ["found", 1179], ["that", 1185], ["while", 1190], ["presynaptic", 1196], ["\u03b1", 1208], ["-", 1209], ["synuclein", 1210], ["colocalizes", 1220], ["with", 1232], ["synapsin", 1237], [",", 1245], ["a", 1247], ["marker", 1249], ["of", 1256], ["presynaptic", 1259], ["vesicles", 1271], [",", 1279], ["it", 1281], ["is", 1284], ["not", 1287], ["essential", 1291], ["for", 1301], ["activity", 1305], ["-", 1313], ["dependent", 1314], ["membrane", 1324], ["recycling", 1333], ["induced", 1343], ["by", 1351], ["high", 1354], ["potassium", 1359], ["treatment", 1369], [".", 1378], ["Exogenous", 1380], ["supply", 1390], ["of", 1397], ["preformed", 1400], ["fibrils", 1410], ["generated", 1418], ["by", 1428], ["recombinant", 1431], ["\u03b1", 1443], ["-", 1444], ["synuclein", 1445], ["was", 1455], ["shown", 1459], ["to", 1465], ["promote", 1468], ["the", 1476], ["formation", 1480], ["of", 1490], ["Lewy", 1493], ["body", 1498], ["(", 1503], ["LB", 1504], [")", 1506], ["-like", 1508], ["intracellular", 1514], ["aggregates", 1528], ["involving", 1539], ["endogenous", 1549], ["\u03b1", 1560], ["-", 1561], ["synuclein", 1562], [".", 1571], ["GAD", 1573], ["-", 1576], ["positive", 1577], ["neurons", 1586], ["did", 1594], ["not", 1598], ["form", 1602], ["LB", 1607], ["-", 1609], ["like", 1610], ["aggregates", 1615], ["following", 1626], ["treatment", 1636], ["with", 1646], ["preformed", 1651], ["fibrils", 1661], [",", 1668], ["however", 1670], [",", 1677], ["exogenous", 1679], ["expression", 1689], ["of", 1700], ["human", 1703], ["\u03b1", 1709], ["-", 1710], ["synuclein", 1711], ["allowed", 1721], ["intracellular", 1729], ["aggregate", 1743], ["formation", 1753], ["in", 1763], ["these", 1766], ["cells", 1772], [".", 1777], ["These", 1779], ["results", 1785], ["suggest", 1793], ["the", 1801], ["presence", 1805], ["of", 1814], ["a", 1817], ["different", 1819], ["mechanism", 1829], ["for", 1839], ["regulation", 1843], ["of", 1854], ["the", 1857], ["expression", 1861], ["of", 1872], ["\u03b1", 1875], ["-", 1876], ["synuclein", 1877], ["between", 1887], ["excitatory", 1895], ["and", 1906], ["inhibitory", 1910], ["neurons", 1921], [".", 1928], ["Furthermore", 1930], [",", 1941], ["\u03b1", 1943], ["-", 1944], ["synuclein", 1945], ["expression", 1955], ["levels", 1966], ["may", 1973], ["determine", 1977], ["the", 1987], ["efficiency", 1991], ["of", 2002], ["intracellular", 2005], ["aggregate", 2019], ["formation", 2029], ["in", 2039], ["different", 2042], ["neuronal", 2052], ["subtypes", 2061], [".", 2069]]}
{"context": "Spinocerebellar ataxia type 3 (SCA3) is the most frequent inherited cerebellar ataxia in Europe, the US and Japan, leading to disability and death through motor complications. Although the affected protein ataxin-3 is found ubiquitously in the brain, grey matter atrophy is predominant in the cerebellum and the brainstem. White matter pathology is generally less severe and thought to occur in the brainstem, spinal cord, and cerebellar white matter. Here, we investigated both grey and white matter pathology in a group of 12 SCA3 patients and matched controls. We used voxel-based morphometry for analysis of tissue loss, and tract-based spatial statistics (TBSS) on diffusion magnetic resonance imaging to investigate microstructural pathology. We analysed correlations between microstructural properties of the brain and ataxia severity, as measured by the Scale for the Assessment and Rating of Ataxia (SARA) score. SCA3 patients exhibited significant loss of both grey and white matter in the cerebellar hemispheres, brainstem including pons and in lateral thalamus. On between-group analysis, TBSS detected widespread microstructural white matter pathology in the cerebellum, brainstem, and bilaterally in thalamus and the cerebral hemispheres. Furthermore, fractional anisotropy in a white matter network comprising frontal, thalamic, brainstem and left cerebellar white matter strongly and negatively correlated with SARA ataxia scores. Tractography identified the thalamic white matter thus implicated as belonging to ventrolateral thalamus. Disruption of white matter integrity in patients suffering from SCA3 is more widespread than previously thought. Moreover, our data provide evidence that microstructural white matter changes in SCA3 are strongly related to the clinical severity of ataxia symptoms.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "3b79b6f68f774f36a9a24a3a0960be22", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[35, 35]], "char_spans": [[206, 213]]}]}], "context_tokens": [["Spinocerebellar", 0], ["ataxia", 16], ["type", 23], ["3", 28], ["(", 30], ["SCA3", 31], [")", 35], ["is", 37], ["the", 40], ["most", 44], ["frequent", 49], ["inherited", 58], ["cerebellar", 68], ["ataxia", 79], ["in", 86], ["Europe", 89], [",", 95], ["the", 97], ["US", 101], ["and", 104], ["Japan", 108], [",", 113], ["leading", 115], ["to", 123], ["disability", 126], ["and", 137], ["death", 141], ["through", 147], ["motor", 155], ["complications", 161], [".", 174], ["Although", 176], ["the", 185], ["affected", 189], ["protein", 198], ["ataxin-3", 206], ["is", 215], ["found", 218], ["ubiquitously", 224], ["in", 237], ["the", 240], ["brain", 244], [",", 249], ["grey", 251], ["matter", 256], ["atrophy", 263], ["is", 271], ["predominant", 274], ["in", 286], ["the", 289], ["cerebellum", 293], ["and", 304], ["the", 308], ["brainstem", 312], [".", 321], ["White", 323], ["matter", 329], ["pathology", 336], ["is", 346], ["generally", 349], ["less", 359], ["severe", 364], ["and", 371], ["thought", 375], ["to", 383], ["occur", 386], ["in", 392], ["the", 395], ["brainstem", 399], [",", 408], ["spinal", 410], ["cord", 417], [",", 421], ["and", 423], ["cerebellar", 427], ["white", 438], ["matter", 444], [".", 450], ["Here", 452], [",", 456], ["we", 458], ["investigated", 461], ["both", 474], ["grey", 479], ["and", 484], ["white", 488], ["matter", 494], ["pathology", 501], ["in", 511], ["a", 514], ["group", 516], ["of", 522], ["12", 525], ["SCA3", 528], ["patients", 533], ["and", 542], ["matched", 546], ["controls", 554], [".", 562], ["We", 564], ["used", 567], ["voxel", 572], ["-", 577], ["based", 578], ["morphometry", 584], ["for", 596], ["analysis", 600], ["of", 609], ["tissue", 612], ["loss", 619], [",", 623], ["and", 625], ["tract", 629], ["-", 634], ["based", 635], ["spatial", 641], ["statistics", 649], ["(", 660], ["TBSS", 661], [")", 665], ["on", 667], ["diffusion", 670], ["magnetic", 680], ["resonance", 689], ["imaging", 699], ["to", 707], ["investigate", 710], ["microstructural", 722], ["pathology", 738], [".", 747], ["We", 749], ["analysed", 752], ["correlations", 761], ["between", 774], ["microstructural", 782], ["properties", 798], ["of", 809], ["the", 812], ["brain", 816], ["and", 822], ["ataxia", 826], ["severity", 833], [",", 841], ["as", 843], ["measured", 846], ["by", 855], ["the", 858], ["Scale", 862], ["for", 868], ["the", 872], ["Assessment", 876], ["and", 887], ["Rating", 891], ["of", 898], ["Ataxia", 901], ["(", 908], ["SARA", 909], [")", 913], ["score", 915], [".", 920], ["SCA3", 922], ["patients", 927], ["exhibited", 936], ["significant", 946], ["loss", 958], ["of", 963], ["both", 966], ["grey", 971], ["and", 976], ["white", 980], ["matter", 986], ["in", 993], ["the", 996], ["cerebellar", 1000], ["hemispheres", 1011], [",", 1022], ["brainstem", 1024], ["including", 1034], ["pons", 1044], ["and", 1049], ["in", 1053], ["lateral", 1056], ["thalamus", 1064], [".", 1072], ["On", 1074], ["between", 1077], ["-", 1084], ["group", 1085], ["analysis", 1091], [",", 1099], ["TBSS", 1101], ["detected", 1106], ["widespread", 1115], ["microstructural", 1126], ["white", 1142], ["matter", 1148], ["pathology", 1155], ["in", 1165], ["the", 1168], ["cerebellum", 1172], [",", 1182], ["brainstem", 1184], [",", 1193], ["and", 1195], ["bilaterally", 1199], ["in", 1211], ["thalamus", 1214], ["and", 1223], ["the", 1227], ["cerebral", 1231], ["hemispheres", 1240], [".", 1251], ["Furthermore", 1253], [",", 1264], ["fractional", 1266], ["anisotropy", 1277], ["in", 1288], ["a", 1291], ["white", 1293], ["matter", 1299], ["network", 1306], ["comprising", 1314], ["frontal", 1325], [",", 1332], ["thalamic", 1334], [",", 1342], ["brainstem", 1344], ["and", 1354], ["left", 1358], ["cerebellar", 1363], ["white", 1374], ["matter", 1380], ["strongly", 1387], ["and", 1396], ["negatively", 1400], ["correlated", 1411], ["with", 1422], ["SARA", 1427], ["ataxia", 1432], ["scores", 1439], [".", 1445], ["Tractography", 1447], ["identified", 1460], ["the", 1471], ["thalamic", 1475], ["white", 1484], ["matter", 1490], ["thus", 1497], ["implicated", 1502], ["as", 1513], ["belonging", 1516], ["to", 1526], ["ventrolateral", 1529], ["thalamus", 1543], [".", 1551], ["Disruption", 1553], ["of", 1564], ["white", 1567], ["matter", 1573], ["integrity", 1580], ["in", 1590], ["patients", 1593], ["suffering", 1602], ["from", 1612], ["SCA3", 1617], ["is", 1622], ["more", 1625], ["widespread", 1630], ["than", 1641], ["previously", 1646], ["thought", 1657], [".", 1664], ["Moreover", 1666], [",", 1674], ["our", 1676], ["data", 1680], ["provide", 1685], ["evidence", 1693], ["that", 1702], ["microstructural", 1707], ["white", 1723], ["matter", 1729], ["changes", 1736], ["in", 1744], ["SCA3", 1747], ["are", 1752], ["strongly", 1756], ["related", 1765], ["to", 1773], ["the", 1776], ["clinical", 1780], ["severity", 1789], ["of", 1798], ["ataxia", 1801], ["symptoms", 1808], [".", 1816]]}
{"context": "Tropomyosin receptor kinases (Trks) are a family of three similar tyrosine kinases activated by peptide hormones of the neurotrophin family. The nerve growth factor antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA pathway in pain. As an alternative modality, small-molecule inhibitors of the Trks have been pursued in recent years to probe the role of these neurotrophin pathways in pain, cancer and other indications. This paper reviews the patent literature between mid-2009 and 2013, claiming inhibitors of Trk family members as the primary biological targets. Additional patents have been reviewed where Trk is not the main kinase of interest but in which high Trk potency is observed and the chemical matter is particularly noteworthy. Patents pre-dating this period have been reviewed previously. Scifinder and Google were used to find relevant patents and clinical information using Trk or Tropomyosin as the search term. Considerable recent progress has been made in the identification of selective pan Trk inhibitors with pharmacodynamic and pharmacokinetic properties appropriate for clinical evaluation. Inhibitors of both active and inactive conformations of the Trks as well as peripherally restricted molecules have been identified. Furthermore, TrkA-selective allosteric inhibitors have recently been disclosed, which enables the biology of this isoform to be probed. The recent identification of a TrkA gene fusion in a subset of lung cancer patients will increase further the attraction of Trk inhibition to the pharmaceutical industry.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "6f76097048934cc28e54c79c8ca57345", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[24, 26]], "char_spans": [[145, 163]]}]}], "context_tokens": [["Tropomyosin", 0], ["receptor", 12], ["kinases", 21], ["(", 29], ["Trks", 30], [")", 34], ["are", 36], ["a", 40], ["family", 42], ["of", 49], ["three", 52], ["similar", 58], ["tyrosine", 66], ["kinases", 75], ["activated", 83], ["by", 93], ["peptide", 96], ["hormones", 104], ["of", 113], ["the", 116], ["neurotrophin", 120], ["family", 133], [".", 139], ["The", 141], ["nerve", 145], ["growth", 151], ["factor", 158], ["antibody", 165], ["tanezumab", 174], ["has", 184], ["provided", 188], ["clinical", 197], ["proof", 206], ["of", 212], ["concept", 215], ["for", 223], ["inhibition", 227], ["of", 238], ["the", 241], ["TrkA", 245], ["pathway", 250], ["in", 258], ["pain", 261], [".", 265], ["As", 267], ["an", 270], ["alternative", 273], ["modality", 285], [",", 293], ["small", 295], ["-", 300], ["molecule", 301], ["inhibitors", 310], ["of", 321], ["the", 324], ["Trks", 328], ["have", 333], ["been", 338], ["pursued", 343], ["in", 351], ["recent", 354], ["years", 361], ["to", 367], ["probe", 370], ["the", 376], ["role", 380], ["of", 385], ["these", 388], ["neurotrophin", 394], ["pathways", 407], ["in", 416], ["pain", 419], [",", 423], ["cancer", 425], ["and", 432], ["other", 436], ["indications", 442], [".", 453], ["This", 455], ["paper", 460], ["reviews", 466], ["the", 474], ["patent", 478], ["literature", 485], ["between", 496], ["mid-2009", 504], ["and", 513], ["2013", 517], [",", 521], ["claiming", 523], ["inhibitors", 532], ["of", 543], ["Trk", 546], ["family", 550], ["members", 557], ["as", 565], ["the", 568], ["primary", 572], ["biological", 580], ["targets", 591], [".", 598], ["Additional", 600], ["patents", 611], ["have", 619], ["been", 624], ["reviewed", 629], ["where", 638], ["Trk", 644], ["is", 648], ["not", 651], ["the", 655], ["main", 659], ["kinase", 664], ["of", 671], ["interest", 674], ["but", 683], ["in", 687], ["which", 690], ["high", 696], ["Trk", 701], ["potency", 705], ["is", 713], ["observed", 716], ["and", 725], ["the", 729], ["chemical", 733], ["matter", 742], ["is", 749], ["particularly", 752], ["noteworthy", 765], [".", 775], ["Patents", 777], ["pre", 785], ["-", 788], ["dating", 789], ["this", 796], ["period", 801], ["have", 808], ["been", 813], ["reviewed", 818], ["previously", 827], [".", 837], ["Scifinder", 839], ["and", 849], ["Google", 853], ["were", 860], ["used", 865], ["to", 870], ["find", 873], ["relevant", 878], ["patents", 887], ["and", 895], ["clinical", 899], ["information", 908], ["using", 920], ["Trk", 926], ["or", 930], ["Tropomyosin", 933], ["as", 945], ["the", 948], ["search", 952], ["term", 959], [".", 963], ["Considerable", 965], ["recent", 978], ["progress", 985], ["has", 994], ["been", 998], ["made", 1003], ["in", 1008], ["the", 1011], ["identification", 1015], ["of", 1030], ["selective", 1033], ["pan", 1043], ["Trk", 1047], ["inhibitors", 1051], ["with", 1062], ["pharmacodynamic", 1067], ["and", 1083], ["pharmacokinetic", 1087], ["properties", 1103], ["appropriate", 1114], ["for", 1126], ["clinical", 1130], ["evaluation", 1139], [".", 1149], ["Inhibitors", 1151], ["of", 1162], ["both", 1165], ["active", 1170], ["and", 1177], ["inactive", 1181], ["conformations", 1190], ["of", 1204], ["the", 1207], ["Trks", 1211], ["as", 1216], ["well", 1219], ["as", 1224], ["peripherally", 1227], ["restricted", 1240], ["molecules", 1251], ["have", 1261], ["been", 1266], ["identified", 1271], [".", 1281], ["Furthermore", 1283], [",", 1294], ["TrkA", 1296], ["-", 1300], ["selective", 1301], ["allosteric", 1311], ["inhibitors", 1322], ["have", 1333], ["recently", 1338], ["been", 1347], ["disclosed", 1352], [",", 1361], ["which", 1363], ["enables", 1369], ["the", 1377], ["biology", 1381], ["of", 1389], ["this", 1392], ["isoform", 1397], ["to", 1405], ["be", 1408], ["probed", 1411], [".", 1417], ["The", 1419], ["recent", 1423], ["identification", 1430], ["of", 1445], ["a", 1448], ["TrkA", 1450], ["gene", 1455], ["fusion", 1460], ["in", 1467], ["a", 1470], ["subset", 1472], ["of", 1479], ["lung", 1482], ["cancer", 1487], ["patients", 1494], ["will", 1503], ["increase", 1508], ["further", 1517], ["the", 1525], ["attraction", 1529], ["of", 1540], ["Trk", 1543], ["inhibition", 1547], ["to", 1558], ["the", 1561], ["pharmaceutical", 1565], ["industry", 1580], [".", 1588]]}
{"context": "Restless Legs Syndrome (RLS) or Willis-Ekbom Disease (WED) is highly prevalent, but patients and healthcare providers alike know little about it. Furthermore, controversy persists as to the best way of diagnosing this nosological entity. To verify whether the term used to refer to this disease entity (Restless Legs Syndrome or Willis-Ekbom Disease) affects the prevalence of self-diagnosed RLS/WED in a sample of newly graduated physicians. Newly graduated physicians were asked to self-evaluate for the presence of RLS/WED. Briefly, participants were allocated randomly across two groups. One was asked to self-assess for RLS, while the other was asked to self-assess for WED. The evaluation form given to one group asked 'Do you have Restless Legs Syndrome?' whereas the form given to participants in the other group asked 'Do you have Willis-Ekbom Disease?'. Both forms also contained the four criteria for diagnosing RLS proposed by the International Restless Legs Syndrome Study Group (IRLSSG) and instructions for self-diagnosis according to these criteria. The study sample comprised 1413 newly graduated physicians. Of the 708 participants who were given the form that used the term RLS, 87 (12.28%) diagnosed themselves with the condition. Conversely, of 705 physicians given the form with the term WED, 13 (1.84%) diagnosed themselves with the condition (p\u2009<0.0001). A greater proportion of newly graduated physicians diagnosed themselves with RLS/WED when presented with the term Restless Legs Syndrome than when presented with the term Willis-Ekbom Disease. This suggests that the term Restless Legs Syndrome may not be the most appropriate term to denote this nosological entity.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "16a25da84839436a89074d9ddedd979f", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[145, 147], [306, 308], [186, 188], [57, 59], [0, 2], [287, 289]], "char_spans": [[738, 759], [1600, 1621], [957, 978], [303, 324], [0, 21], [1493, 1514]]}]}], "context_tokens": [["Restless", 0], ["Legs", 9], ["Syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["or", 29], ["Willis", 32], ["-", 38], ["Ekbom", 39], ["Disease", 45], ["(", 53], ["WED", 54], [")", 57], ["is", 59], ["highly", 62], ["prevalent", 69], [",", 78], ["but", 80], ["patients", 84], ["and", 93], ["healthcare", 97], ["providers", 108], ["alike", 118], ["know", 124], ["little", 129], ["about", 136], ["it", 142], [".", 144], ["Furthermore", 146], [",", 157], ["controversy", 159], ["persists", 171], ["as", 180], ["to", 183], ["the", 186], ["best", 190], ["way", 195], ["of", 199], ["diagnosing", 202], ["this", 213], ["nosological", 218], ["entity", 230], [".", 236], ["To", 238], ["verify", 241], ["whether", 248], ["the", 256], ["term", 260], ["used", 265], ["to", 270], ["refer", 273], ["to", 279], ["this", 282], ["disease", 287], ["entity", 295], ["(", 302], ["Restless", 303], ["Legs", 312], ["Syndrome", 317], ["or", 326], ["Willis", 329], ["-", 335], ["Ekbom", 336], ["Disease", 342], [")", 349], ["affects", 351], ["the", 359], ["prevalence", 363], ["of", 374], ["self", 377], ["-", 381], ["diagnosed", 382], ["RLS", 392], ["/", 395], ["WED", 396], ["in", 400], ["a", 403], ["sample", 405], ["of", 412], ["newly", 415], ["graduated", 421], ["physicians", 431], [".", 441], ["Newly", 443], ["graduated", 449], ["physicians", 459], ["were", 470], ["asked", 475], ["to", 481], ["self", 484], ["-", 488], ["evaluate", 489], ["for", 498], ["the", 502], ["presence", 506], ["of", 515], ["RLS", 518], ["/", 521], ["WED", 522], [".", 525], ["Briefly", 527], [",", 534], ["participants", 536], ["were", 549], ["allocated", 554], ["randomly", 564], ["across", 573], ["two", 580], ["groups", 584], [".", 590], ["One", 592], ["was", 596], ["asked", 600], ["to", 606], ["self", 609], ["-", 613], ["assess", 614], ["for", 621], ["RLS", 625], [",", 628], ["while", 630], ["the", 636], ["other", 640], ["was", 646], ["asked", 650], ["to", 656], ["self", 659], ["-", 663], ["assess", 664], ["for", 671], ["WED", 675], [".", 678], ["The", 680], ["evaluation", 684], ["form", 695], ["given", 700], ["to", 706], ["one", 709], ["group", 713], ["asked", 719], ["'", 725], ["Do", 726], ["you", 729], ["have", 733], ["Restless", 738], ["Legs", 747], ["Syndrome", 752], ["?", 760], ["'", 761], ["whereas", 763], ["the", 771], ["form", 775], ["given", 780], ["to", 786], ["participants", 789], ["in", 802], ["the", 805], ["other", 809], ["group", 815], ["asked", 821], ["'", 827], ["Do", 828], ["you", 831], ["have", 835], ["Willis", 840], ["-", 846], ["Ekbom", 847], ["Disease", 853], ["?", 860], ["'", 861], [".", 862], ["Both", 864], ["forms", 869], ["also", 875], ["contained", 880], ["the", 890], ["four", 894], ["criteria", 899], ["for", 908], ["diagnosing", 912], ["RLS", 923], ["proposed", 927], ["by", 936], ["the", 939], ["International", 943], ["Restless", 957], ["Legs", 966], ["Syndrome", 971], ["Study", 980], ["Group", 986], ["(", 992], ["IRLSSG", 993], [")", 999], ["and", 1001], ["instructions", 1005], ["for", 1018], ["self", 1022], ["-", 1026], ["diagnosis", 1027], ["according", 1037], ["to", 1047], ["these", 1050], ["criteria", 1056], [".", 1064], ["The", 1066], ["study", 1070], ["sample", 1076], ["comprised", 1083], ["1413", 1093], ["newly", 1098], ["graduated", 1104], ["physicians", 1114], [".", 1124], ["Of", 1126], ["the", 1129], ["708", 1133], ["participants", 1137], ["who", 1150], ["were", 1154], ["given", 1159], ["the", 1165], ["form", 1169], ["that", 1174], ["used", 1179], ["the", 1184], ["term", 1188], ["RLS", 1193], [",", 1196], ["87", 1198], ["(", 1201], ["12.28", 1202], ["%", 1207], [")", 1208], ["diagnosed", 1210], ["themselves", 1220], ["with", 1231], ["the", 1236], ["condition", 1240], [".", 1249], ["Conversely", 1251], [",", 1261], ["of", 1263], ["705", 1266], ["physicians", 1270], ["given", 1281], ["the", 1287], ["form", 1291], ["with", 1296], ["the", 1301], ["term", 1305], ["WED", 1310], [",", 1313], ["13", 1315], ["(", 1318], ["1.84", 1319], ["%", 1323], [")", 1324], ["diagnosed", 1326], ["themselves", 1336], ["with", 1347], ["the", 1352], ["condition", 1356], ["(", 1366], ["p", 1367], ["<", 1369], ["0.0001", 1370], [")", 1376], [".", 1377], ["A", 1379], ["greater", 1381], ["proportion", 1389], ["of", 1400], ["newly", 1403], ["graduated", 1409], ["physicians", 1419], ["diagnosed", 1430], ["themselves", 1440], ["with", 1451], ["RLS", 1456], ["/", 1459], ["WED", 1460], ["when", 1464], ["presented", 1469], ["with", 1479], ["the", 1484], ["term", 1488], ["Restless", 1493], ["Legs", 1502], ["Syndrome", 1507], ["than", 1516], ["when", 1521], ["presented", 1526], ["with", 1536], ["the", 1541], ["term", 1545], ["Willis", 1550], ["-", 1556], ["Ekbom", 1557], ["Disease", 1563], [".", 1570], ["This", 1572], ["suggests", 1577], ["that", 1586], ["the", 1591], ["term", 1595], ["Restless", 1600], ["Legs", 1609], ["Syndrome", 1614], ["may", 1623], ["not", 1627], ["be", 1631], ["the", 1634], ["most", 1638], ["appropriate", 1643], ["term", 1655], ["to", 1660], ["denote", 1663], ["this", 1670], ["nosological", 1675], ["entity", 1687], [".", 1693]]}
{"context": "Heme is critical for a variety of cellular processes, but excess intracellular heme may result in oxidative stress and membrane injury. Feline leukemia virus subgroup C receptor (FLVCR1), a member of the SLC49 family of four paralogous genes, is a cell surface heme exporter, essential for erythropoiesis and systemic iron homeostasis. Disruption of FLVCR1 function blocks development of erythroid progenitors, likely due to heme toxicity. Mutations of SLC49A1 encoding FLVCR1 are noted in patients with a rare neurodegenerative disorder: posterior column ataxia with retinitis pigmentosa. FLVCR2 is highly homologous to FLVCR1 and may function as a cellular heme importer. Mutations of SLC49A2 encoding FLVCR2 are observed in Fowler syndrome, a rare proliferative vascular disorder of the brain. The functions of the remaining members of the SLC49 family, MFSD7 and DIRC2 (encoded by the SLC49A3 and SLC49A4 genes), are unknown, although the latter is implicated in hereditary renal carcinomas. SLC48A1 (heme responsive gene-1, HRG-1), the sole member of the SLC48 family, is associated with the endosome and appears to transport heme from the endosome into the cytosol.", "qas": [{"question": "Which SLC family is FLVCR1 a member of?", "answers": ["SLC49"], "qid": "a338247c1f654179887259220bfbd8d6", "question_tokens": [["Which", 0], ["SLC", 6], ["family", 10], ["is", 17], ["FLVCR1", 20], ["a", 27], ["member", 29], ["of", 36], ["?", 38]], "detected_answers": [{"text": "SLC49", "token_spans": [[140, 140], [37, 37]], "char_spans": [[843, 847], [204, 208]]}]}], "context_tokens": [["Heme", 0], ["is", 5], ["critical", 8], ["for", 17], ["a", 21], ["variety", 23], ["of", 31], ["cellular", 34], ["processes", 43], [",", 52], ["but", 54], ["excess", 58], ["intracellular", 65], ["heme", 79], ["may", 84], ["result", 88], ["in", 95], ["oxidative", 98], ["stress", 108], ["and", 115], ["membrane", 119], ["injury", 128], [".", 134], ["Feline", 136], ["leukemia", 143], ["virus", 152], ["subgroup", 158], ["C", 167], ["receptor", 169], ["(", 178], ["FLVCR1", 179], [")", 185], [",", 186], ["a", 188], ["member", 190], ["of", 197], ["the", 200], ["SLC49", 204], ["family", 210], ["of", 217], ["four", 220], ["paralogous", 225], ["genes", 236], [",", 241], ["is", 243], ["a", 246], ["cell", 248], ["surface", 253], ["heme", 261], ["exporter", 266], [",", 274], ["essential", 276], ["for", 286], ["erythropoiesis", 290], ["and", 305], ["systemic", 309], ["iron", 318], ["homeostasis", 323], [".", 334], ["Disruption", 336], ["of", 347], ["FLVCR1", 350], ["function", 357], ["blocks", 366], ["development", 373], ["of", 385], ["erythroid", 388], ["progenitors", 398], [",", 409], ["likely", 411], ["due", 418], ["to", 422], ["heme", 425], ["toxicity", 430], [".", 438], ["Mutations", 440], ["of", 450], ["SLC49A1", 453], ["encoding", 461], ["FLVCR1", 470], ["are", 477], ["noted", 481], ["in", 487], ["patients", 490], ["with", 499], ["a", 504], ["rare", 506], ["neurodegenerative", 511], ["disorder", 529], [":", 537], ["posterior", 539], ["column", 549], ["ataxia", 556], ["with", 563], ["retinitis", 568], ["pigmentosa", 578], [".", 588], ["FLVCR2", 590], ["is", 597], ["highly", 600], ["homologous", 607], ["to", 618], ["FLVCR1", 621], ["and", 628], ["may", 632], ["function", 636], ["as", 645], ["a", 648], ["cellular", 650], ["heme", 659], ["importer", 664], [".", 672], ["Mutations", 674], ["of", 684], ["SLC49A2", 687], ["encoding", 695], ["FLVCR2", 704], ["are", 711], ["observed", 715], ["in", 724], ["Fowler", 727], ["syndrome", 734], [",", 742], ["a", 744], ["rare", 746], ["proliferative", 751], ["vascular", 765], ["disorder", 774], ["of", 783], ["the", 786], ["brain", 790], [".", 795], ["The", 797], ["functions", 801], ["of", 811], ["the", 814], ["remaining", 818], ["members", 828], ["of", 836], ["the", 839], ["SLC49", 843], ["family", 849], [",", 855], ["MFSD7", 857], ["and", 863], ["DIRC2", 867], ["(", 873], ["encoded", 874], ["by", 882], ["the", 885], ["SLC49A3", 889], ["and", 897], ["SLC49A4", 901], ["genes", 909], [")", 914], [",", 915], ["are", 917], ["unknown", 921], [",", 928], ["although", 930], ["the", 939], ["latter", 943], ["is", 950], ["implicated", 953], ["in", 964], ["hereditary", 967], ["renal", 978], ["carcinomas", 984], [".", 994], ["SLC48A1", 996], ["(", 1004], ["heme", 1005], ["responsive", 1010], ["gene-1", 1021], [",", 1027], ["HRG-1", 1029], [")", 1034], [",", 1035], ["the", 1037], ["sole", 1041], ["member", 1046], ["of", 1053], ["the", 1056], ["SLC48", 1060], ["family", 1066], [",", 1072], ["is", 1074], ["associated", 1077], ["with", 1088], ["the", 1093], ["endosome", 1097], ["and", 1106], ["appears", 1110], ["to", 1118], ["transport", 1121], ["heme", 1131], ["from", 1136], ["the", 1141], ["endosome", 1145], ["into", 1154], ["the", 1159], ["cytosol", 1163], [".", 1170]]}
{"context": "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare arrythmogenic disease characterized by exercise--or stress--induced ventricular tachyarrythmias, syncope, or sudden death, usually in the pediatric age group. Familial occurrence has been noted in about 30% of cases. Inheritance may be autosomal dominant or recessive, usually with high penetrance. The causative genes have been mapped to chromosome 1. Mutations of the cardiac ryanodine receptor gene (RyR2) have been identified in autosomal dominant pedigrees, while calsequestrin gene (CASQ2) mutations are seen in recessive cases. Due to its potential lethal outcome, exclusion or confirmation of catecholaminergic polymorphic ventricular tachycardia in children with physical and emotional syncope is mandatory. We report a case of catecholaminergic polymorphic ventricular tachycardia in a three-year-old child only diagnosed by genetic mapping.", "qas": [{"question": "What is the inheritance pattern of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) caused by RYR2 mutations?", "answers": ["autosomal dominant"], "qid": "023fcc86e5c846d2b6220e8e9e90de4c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["inheritance", 12], ["pattern", 24], ["of", 32], ["Catecholaminergic", 35], ["Polymorphic", 53], ["Ventricular", 65], ["Tachycardia", 77], ["(", 89], ["CPVT", 90], [")", 94], ["caused", 96], ["by", 103], ["RYR2", 106], ["mutations", 111], ["?", 120]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[85, 86], [51, 52]], "char_spans": [[504, 521], [307, 324]]}]}], "context_tokens": [["Catecholaminergic", 0], ["polymorphic", 18], ["ventricular", 30], ["tachycardia", 42], ["(", 54], ["CPVT", 55], [")", 59], ["is", 61], ["a", 64], ["rare", 66], ["arrythmogenic", 71], ["disease", 85], ["characterized", 93], ["by", 107], ["exercise", 110], ["--", 118], ["or", 120], ["stress", 123], ["--", 129], ["induced", 131], ["ventricular", 139], ["tachyarrythmias", 151], [",", 166], ["syncope", 168], [",", 175], ["or", 177], ["sudden", 180], ["death", 187], [",", 192], ["usually", 194], ["in", 202], ["the", 205], ["pediatric", 209], ["age", 219], ["group", 223], [".", 228], ["Familial", 230], ["occurrence", 239], ["has", 250], ["been", 254], ["noted", 259], ["in", 265], ["about", 268], ["30", 274], ["%", 276], ["of", 278], ["cases", 281], [".", 286], ["Inheritance", 288], ["may", 300], ["be", 304], ["autosomal", 307], ["dominant", 317], ["or", 326], ["recessive", 329], [",", 338], ["usually", 340], ["with", 348], ["high", 353], ["penetrance", 358], [".", 368], ["The", 370], ["causative", 374], ["genes", 384], ["have", 390], ["been", 395], ["mapped", 400], ["to", 407], ["chromosome", 410], ["1", 421], [".", 422], ["Mutations", 424], ["of", 434], ["the", 437], ["cardiac", 441], ["ryanodine", 449], ["receptor", 459], ["gene", 468], ["(", 473], ["RyR2", 474], [")", 478], ["have", 480], ["been", 485], ["identified", 490], ["in", 501], ["autosomal", 504], ["dominant", 514], ["pedigrees", 523], [",", 532], ["while", 534], ["calsequestrin", 540], ["gene", 554], ["(", 559], ["CASQ2", 560], [")", 565], ["mutations", 567], ["are", 577], ["seen", 581], ["in", 586], ["recessive", 589], ["cases", 599], [".", 604], ["Due", 606], ["to", 610], ["its", 613], ["potential", 617], ["lethal", 627], ["outcome", 634], [",", 641], ["exclusion", 643], ["or", 653], ["confirmation", 656], ["of", 669], ["catecholaminergic", 672], ["polymorphic", 690], ["ventricular", 702], ["tachycardia", 714], ["in", 726], ["children", 729], ["with", 738], ["physical", 743], ["and", 752], ["emotional", 756], ["syncope", 766], ["is", 774], ["mandatory", 777], [".", 786], ["We", 788], ["report", 791], ["a", 798], ["case", 800], ["of", 805], ["catecholaminergic", 808], ["polymorphic", 826], ["ventricular", 838], ["tachycardia", 850], ["in", 862], ["a", 865], ["three", 867], ["-", 872], ["year", 873], ["-", 877], ["old", 878], ["child", 882], ["only", 888], ["diagnosed", 893], ["by", 903], ["genetic", 906], ["mapping", 914], [".", 921]]}
{"context": "Proteins of the Notch family are cell surface receptors that transduce signals between neighbouring cells. The Notch signalling pathway is highly evolutionarily conserved and critical for cell fate determination during embryonic development, including many aspects of vascular development. The interaction of Notch receptors with ligands leads to cleavage of the Notch intracellular domain (NICD) which then translocates to the nucleus and activates the transcription factor CBF1/JBP-Jkappa, regulating downstream gene expression. To date four Notch receptors have been found in mammals. Of these, Notch3 is predominantly expressed in adult arterial smooth muscle cells in human. NOTCH3 gene mutations cause the autosomal dominant condition, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoecephelopathy (CADASIL), an inherited early stroke syndrome leading to dementia due to systemic vascular degeneration. This suggests that Notch3 plays a critical role in maintaining the phenotypic stability of vascular smooth muscle cells (VSMCs). Recent publications indicate that Notch3 is involved in vascular injury and is a determinant of VSMC survival, but its exact function is unknown. The molecular mechanisms underlying CADASIL pathology are therefore intriguing. Investigation of CADASIL mutant Notch3 shows that the majority of mutations do not change CBF1/JBP-Jkappa mediated classic Notch activation, so the pathological consequences of NOTCH3 mutations in CADASIL patients can not be simply explained by loss- or gain-of-function in the classic Notch signalling pathway. This suggests that a novel Notch3-mediated signalling pathway may be present in VSMCs, or cross-regulation of Notch3 to other signalling pathway(s) may play a critical role on VSMCs survival. Alternatively, the mutant Notch3 may gain a novel or toxic function in VSMCs. This review will focus on recent findings of Notch3 in vascular development and in regulating the VSMC behaviour and phenotype, and will use findings on investigating the molecular pathology of the single gene disorder CADASIL to understand the function of Notch3 in VSMCs.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "2c9f414f7a3a499893e29b02c1e7994e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[106, 107]], "char_spans": [[680, 690]]}]}], "context_tokens": [["Proteins", 0], ["of", 9], ["the", 12], ["Notch", 16], ["family", 22], ["are", 29], ["cell", 33], ["surface", 38], ["receptors", 46], ["that", 56], ["transduce", 61], ["signals", 71], ["between", 79], ["neighbouring", 87], ["cells", 100], [".", 105], ["The", 107], ["Notch", 111], ["signalling", 117], ["pathway", 128], ["is", 136], ["highly", 139], ["evolutionarily", 146], ["conserved", 161], ["and", 171], ["critical", 175], ["for", 184], ["cell", 188], ["fate", 193], ["determination", 198], ["during", 212], ["embryonic", 219], ["development", 229], [",", 240], ["including", 242], ["many", 252], ["aspects", 257], ["of", 265], ["vascular", 268], ["development", 277], [".", 288], ["The", 290], ["interaction", 294], ["of", 306], ["Notch", 309], ["receptors", 315], ["with", 325], ["ligands", 330], ["leads", 338], ["to", 344], ["cleavage", 347], ["of", 356], ["the", 359], ["Notch", 363], ["intracellular", 369], ["domain", 383], ["(", 390], ["NICD", 391], [")", 395], ["which", 397], ["then", 403], ["translocates", 408], ["to", 421], ["the", 424], ["nucleus", 428], ["and", 436], ["activates", 440], ["the", 450], ["transcription", 454], ["factor", 468], ["CBF1/JBP", 475], ["-", 483], ["Jkappa", 484], [",", 490], ["regulating", 492], ["downstream", 503], ["gene", 514], ["expression", 519], [".", 529], ["To", 531], ["date", 534], ["four", 539], ["Notch", 544], ["receptors", 550], ["have", 560], ["been", 565], ["found", 570], ["in", 576], ["mammals", 579], [".", 586], ["Of", 588], ["these", 591], [",", 596], ["Notch3", 598], ["is", 605], ["predominantly", 608], ["expressed", 622], ["in", 632], ["adult", 635], ["arterial", 641], ["smooth", 650], ["muscle", 657], ["cells", 664], ["in", 670], ["human", 673], [".", 678], ["NOTCH3", 680], ["gene", 687], ["mutations", 692], ["cause", 702], ["the", 708], ["autosomal", 712], ["dominant", 722], ["condition", 731], [",", 740], ["cerebral", 742], ["autosomal", 751], ["dominant", 761], ["arteriopathy", 770], ["with", 783], ["subcortical", 788], ["infarcts", 800], ["and", 809], ["leukoecephelopathy", 813], ["(", 832], ["CADASIL", 833], [")", 840], [",", 841], ["an", 843], ["inherited", 846], ["early", 856], ["stroke", 862], ["syndrome", 869], ["leading", 878], ["to", 886], ["dementia", 889], ["due", 898], ["to", 902], ["systemic", 905], ["vascular", 914], ["degeneration", 923], [".", 935], ["This", 937], ["suggests", 942], ["that", 951], ["Notch3", 956], ["plays", 963], ["a", 969], ["critical", 971], ["role", 980], ["in", 985], ["maintaining", 988], ["the", 1000], ["phenotypic", 1004], ["stability", 1015], ["of", 1025], ["vascular", 1028], ["smooth", 1037], ["muscle", 1044], ["cells", 1051], ["(", 1057], ["VSMCs", 1058], [")", 1063], [".", 1064], ["Recent", 1066], ["publications", 1073], ["indicate", 1086], ["that", 1095], ["Notch3", 1100], ["is", 1107], ["involved", 1110], ["in", 1119], ["vascular", 1122], ["injury", 1131], ["and", 1138], ["is", 1142], ["a", 1145], ["determinant", 1147], ["of", 1159], ["VSMC", 1162], ["survival", 1167], [",", 1175], ["but", 1177], ["its", 1181], ["exact", 1185], ["function", 1191], ["is", 1200], ["unknown", 1203], [".", 1210], ["The", 1212], ["molecular", 1216], ["mechanisms", 1226], ["underlying", 1237], ["CADASIL", 1248], ["pathology", 1256], ["are", 1266], ["therefore", 1270], ["intriguing", 1280], [".", 1290], ["Investigation", 1292], ["of", 1306], ["CADASIL", 1309], ["mutant", 1317], ["Notch3", 1324], ["shows", 1331], ["that", 1337], ["the", 1342], ["majority", 1346], ["of", 1355], ["mutations", 1358], ["do", 1368], ["not", 1371], ["change", 1375], ["CBF1/JBP", 1382], ["-", 1390], ["Jkappa", 1391], ["mediated", 1398], ["classic", 1407], ["Notch", 1415], ["activation", 1421], [",", 1431], ["so", 1433], ["the", 1436], ["pathological", 1440], ["consequences", 1453], ["of", 1466], ["NOTCH3", 1469], ["mutations", 1476], ["in", 1486], ["CADASIL", 1489], ["patients", 1497], ["can", 1506], ["not", 1510], ["be", 1514], ["simply", 1517], ["explained", 1524], ["by", 1534], ["loss-", 1537], ["or", 1543], ["gain", 1546], ["-", 1550], ["of", 1551], ["-", 1553], ["function", 1554], ["in", 1563], ["the", 1566], ["classic", 1570], ["Notch", 1578], ["signalling", 1584], ["pathway", 1595], [".", 1602], ["This", 1604], ["suggests", 1609], ["that", 1618], ["a", 1623], ["novel", 1625], ["Notch3-mediated", 1631], ["signalling", 1647], ["pathway", 1658], ["may", 1666], ["be", 1670], ["present", 1673], ["in", 1681], ["VSMCs", 1684], [",", 1689], ["or", 1691], ["cross", 1694], ["-", 1699], ["regulation", 1700], ["of", 1711], ["Notch3", 1714], ["to", 1721], ["other", 1724], ["signalling", 1730], ["pathway(s", 1741], [")", 1750], ["may", 1752], ["play", 1756], ["a", 1761], ["critical", 1763], ["role", 1772], ["on", 1777], ["VSMCs", 1780], ["survival", 1786], [".", 1794], ["Alternatively", 1796], [",", 1809], ["the", 1811], ["mutant", 1815], ["Notch3", 1822], ["may", 1829], ["gain", 1833], ["a", 1838], ["novel", 1840], ["or", 1846], ["toxic", 1849], ["function", 1855], ["in", 1864], ["VSMCs", 1867], [".", 1872], ["This", 1874], ["review", 1879], ["will", 1886], ["focus", 1891], ["on", 1897], ["recent", 1900], ["findings", 1907], ["of", 1916], ["Notch3", 1919], ["in", 1926], ["vascular", 1929], ["development", 1938], ["and", 1950], ["in", 1954], ["regulating", 1957], ["the", 1968], ["VSMC", 1972], ["behaviour", 1977], ["and", 1987], ["phenotype", 1991], [",", 2000], ["and", 2002], ["will", 2006], ["use", 2011], ["findings", 2015], ["on", 2024], ["investigating", 2027], ["the", 2041], ["molecular", 2045], ["pathology", 2055], ["of", 2065], ["the", 2068], ["single", 2072], ["gene", 2079], ["disorder", 2084], ["CADASIL", 2093], ["to", 2101], ["understand", 2104], ["the", 2115], ["function", 2119], ["of", 2128], ["Notch3", 2131], ["in", 2138], ["VSMCs", 2141], [".", 2146]]}
{"context": "To compare tumor control rates after surgical resection or stereotactic radiosurgery for patients with small- to medium-size intracranial meningiomas. Between 1990 and 1997, 198 adult meningioma patients treated at our center underwent either surgical resection (n = 136) or radiosurgery (n = 62) as primary management for benign meningiomas <35 mm in average diameter. Tumor recurrence or progression rates were calculated by the Kaplan-Meier method according to an independent radiographic review. The mean follow-up was 64 months. The tumor resections were Simpson Grade 1 in 57 (42%), Grade 2 in 57 (42%), and Grade 3-4 in 22 (16%). The mean margin and maximal radiation dose at radiosurgery was 17.7 Gy and 34.9 Gy, respectively. Tumor recurrence/progression was more frequent in the surgical resection group (12%) than in the radiosurgical group (2%; p = 0.04). No statistically significant difference was detected in the 3- and 7-year actuarial progression-free survival (PFS) rate between patients with Simpson Grade 1 resections (100% and 96%, respectively) and patients who underwent radiosurgery (100% and 95%, respectively; p = 0.94). Radiosurgery provided a higher PFS rate compared with patients with Simpson Grade 2 (3- and 7-year PFS rate, 91% and 82%, respectively; p <0.05) and Grade 3-4 (3- and 7-year PFS rate, 68% and 34%, respectively; p <0.001) resections. Subsequent tumor treatments were more common after surgical resection (15% vs. 3%, p = 0.02). Complications occurred in 10% of patients after radiosurgery compared with 22% of patients after surgical resection (p = 0.06). The PFS rate after radiosurgery was equivalent to that after resection of a Simpson Grade 1 tumor and was superior to Grade 2 and 3-4 resections in our study. If long-term follow-up confirms the high tumor control rate and low morbidity of radiosurgery, this technique will likely become the preferred treatment for most patients with small- to moderate-size meningiomas without symptomatic mass effect.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "df74d144994648f89a2af1ac7f36e432", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[29, 29]], "char_spans": [[184, 193]]}]}], "context_tokens": [["To", 0], ["compare", 3], ["tumor", 11], ["control", 17], ["rates", 25], ["after", 31], ["surgical", 37], ["resection", 46], ["or", 56], ["stereotactic", 59], ["radiosurgery", 72], ["for", 85], ["patients", 89], ["with", 98], ["small-", 103], ["to", 110], ["medium", 113], ["-", 119], ["size", 120], ["intracranial", 125], ["meningiomas", 138], [".", 149], ["Between", 151], ["1990", 159], ["and", 164], ["1997", 168], [",", 172], ["198", 174], ["adult", 178], ["meningioma", 184], ["patients", 195], ["treated", 204], ["at", 212], ["our", 215], ["center", 219], ["underwent", 226], ["either", 236], ["surgical", 243], ["resection", 252], ["(", 262], ["n", 263], ["=", 265], ["136", 267], [")", 270], ["or", 272], ["radiosurgery", 275], ["(", 288], ["n", 289], ["=", 291], ["62", 293], [")", 295], ["as", 297], ["primary", 300], ["management", 308], ["for", 319], ["benign", 323], ["meningiomas", 330], ["<", 342], ["35", 343], ["mm", 346], ["in", 349], ["average", 352], ["diameter", 360], [".", 368], ["Tumor", 370], ["recurrence", 376], ["or", 387], ["progression", 390], ["rates", 402], ["were", 408], ["calculated", 413], ["by", 424], ["the", 427], ["Kaplan", 431], ["-", 437], ["Meier", 438], ["method", 444], ["according", 451], ["to", 461], ["an", 464], ["independent", 467], ["radiographic", 479], ["review", 492], [".", 498], ["The", 500], ["mean", 504], ["follow", 509], ["-", 515], ["up", 516], ["was", 519], ["64", 523], ["months", 526], [".", 532], ["The", 534], ["tumor", 538], ["resections", 544], ["were", 555], ["Simpson", 560], ["Grade", 568], ["1", 574], ["in", 576], ["57", 579], ["(", 582], ["42", 583], ["%", 585], [")", 586], [",", 587], ["Grade", 589], ["2", 595], ["in", 597], ["57", 600], ["(", 603], ["42", 604], ["%", 606], [")", 607], [",", 608], ["and", 610], ["Grade", 614], ["3", 620], ["-", 621], ["4", 622], ["in", 624], ["22", 627], ["(", 630], ["16", 631], ["%", 633], [")", 634], [".", 635], ["The", 637], ["mean", 641], ["margin", 646], ["and", 653], ["maximal", 657], ["radiation", 665], ["dose", 675], ["at", 680], ["radiosurgery", 683], ["was", 696], ["17.7", 700], ["Gy", 705], ["and", 708], ["34.9", 712], ["Gy", 717], [",", 719], ["respectively", 721], [".", 733], ["Tumor", 735], ["recurrence", 741], ["/", 751], ["progression", 752], ["was", 764], ["more", 768], ["frequent", 773], ["in", 782], ["the", 785], ["surgical", 789], ["resection", 798], ["group", 808], ["(", 814], ["12", 815], ["%", 817], [")", 818], ["than", 820], ["in", 825], ["the", 828], ["radiosurgical", 832], ["group", 846], ["(", 852], ["2", 853], ["%", 854], [";", 855], ["p", 857], ["=", 859], ["0.04", 861], [")", 865], [".", 866], ["No", 868], ["statistically", 871], ["significant", 885], ["difference", 897], ["was", 908], ["detected", 912], ["in", 921], ["the", 924], ["3-", 928], ["and", 931], ["7-year", 935], ["actuarial", 942], ["progression", 952], ["-", 963], ["free", 964], ["survival", 969], ["(", 978], ["PFS", 979], [")", 982], ["rate", 984], ["between", 989], ["patients", 997], ["with", 1006], ["Simpson", 1011], ["Grade", 1019], ["1", 1025], ["resections", 1027], ["(", 1038], ["100", 1039], ["%", 1042], ["and", 1044], ["96", 1048], ["%", 1050], [",", 1051], ["respectively", 1053], [")", 1065], ["and", 1067], ["patients", 1071], ["who", 1080], ["underwent", 1084], ["radiosurgery", 1094], ["(", 1107], ["100", 1108], ["%", 1111], ["and", 1113], ["95", 1117], ["%", 1119], [",", 1120], ["respectively", 1122], [";", 1134], ["p", 1136], ["=", 1138], ["0.94", 1140], [")", 1144], [".", 1145], ["Radiosurgery", 1147], ["provided", 1160], ["a", 1169], ["higher", 1171], ["PFS", 1178], ["rate", 1182], ["compared", 1187], ["with", 1196], ["patients", 1201], ["with", 1210], ["Simpson", 1215], ["Grade", 1223], ["2", 1229], ["(", 1231], ["3-", 1232], ["and", 1235], ["7-year", 1239], ["PFS", 1246], ["rate", 1250], [",", 1254], ["91", 1256], ["%", 1258], ["and", 1260], ["82", 1264], ["%", 1266], [",", 1267], ["respectively", 1269], [";", 1281], ["p", 1283], ["<", 1285], ["0.05", 1286], [")", 1290], ["and", 1292], ["Grade", 1296], ["3", 1302], ["-", 1303], ["4", 1304], ["(", 1306], ["3-", 1307], ["and", 1310], ["7-year", 1314], ["PFS", 1321], ["rate", 1325], [",", 1329], ["68", 1331], ["%", 1333], ["and", 1335], ["34", 1339], ["%", 1341], [",", 1342], ["respectively", 1344], [";", 1356], ["p", 1358], ["<", 1360], ["0.001", 1361], [")", 1366], ["resections", 1368], [".", 1378], ["Subsequent", 1380], ["tumor", 1391], ["treatments", 1397], ["were", 1408], ["more", 1413], ["common", 1418], ["after", 1425], ["surgical", 1431], ["resection", 1440], ["(", 1450], ["15", 1451], ["%", 1453], ["vs.", 1455], ["3", 1459], ["%", 1460], [",", 1461], ["p", 1463], ["=", 1465], ["0.02", 1467], [")", 1471], [".", 1472], ["Complications", 1474], ["occurred", 1488], ["in", 1497], ["10", 1500], ["%", 1502], ["of", 1504], ["patients", 1507], ["after", 1516], ["radiosurgery", 1522], ["compared", 1535], ["with", 1544], ["22", 1549], ["%", 1551], ["of", 1553], ["patients", 1556], ["after", 1565], ["surgical", 1571], ["resection", 1580], ["(", 1590], ["p", 1591], ["=", 1593], ["0.06", 1595], [")", 1599], [".", 1600], ["The", 1602], ["PFS", 1606], ["rate", 1610], ["after", 1615], ["radiosurgery", 1621], ["was", 1634], ["equivalent", 1638], ["to", 1649], ["that", 1652], ["after", 1657], ["resection", 1663], ["of", 1673], ["a", 1676], ["Simpson", 1678], ["Grade", 1686], ["1", 1692], ["tumor", 1694], ["and", 1700], ["was", 1704], ["superior", 1708], ["to", 1717], ["Grade", 1720], ["2", 1726], ["and", 1728], ["3", 1732], ["-", 1733], ["4", 1734], ["resections", 1736], ["in", 1747], ["our", 1750], ["study", 1754], [".", 1759], ["If", 1761], ["long", 1764], ["-", 1768], ["term", 1769], ["follow", 1774], ["-", 1780], ["up", 1781], ["confirms", 1784], ["the", 1793], ["high", 1797], ["tumor", 1802], ["control", 1808], ["rate", 1816], ["and", 1821], ["low", 1825], ["morbidity", 1829], ["of", 1839], ["radiosurgery", 1842], [",", 1854], ["this", 1856], ["technique", 1861], ["will", 1871], ["likely", 1876], ["become", 1883], ["the", 1890], ["preferred", 1894], ["treatment", 1904], ["for", 1914], ["most", 1918], ["patients", 1923], ["with", 1932], ["small-", 1937], ["to", 1944], ["moderate", 1947], ["-", 1955], ["size", 1956], ["meningiomas", 1961], ["without", 1973], ["symptomatic", 1981], ["mass", 1993], ["effect", 1998], [".", 2004]]}
{"context": "Community-associated methicillin-resistant Staphylococcus aureus-(CA-MRSA) strains have emerged in Argentina. We investigated the clinical and molecular evolution of community-onset MRSA infections (CO-MRSA) in children of C\u00f3rdoba, Argentina, 2005-2008. Additionally, data from 2007 were compared with the epidemiology of these infections in other regions of the country. Two datasets were used: i) lab-based prospective surveillance of CA-MRSA isolates from 3 C\u00f3rdoba pediatric hospitals-(CBAH1-H3) in 2007-2008 (compared to previously published data of 2005) and ii) a sampling of CO-MRSA from a study involving both, healthcare-associated community-onset-(HACO) infections in children with risk-factors for healthcare-associated infections-(HRFs), and CA-MRSA infections in patients without HRFs detected in multiple centers of Argentina in 2007. Molecular typing was performed on the CA-MRSA-(n: 99) isolates from the CBAH1-H3-dataset and on the HACO-MRSA-(n: 51) and CA-MRSA-(n: 213) isolates from other regions. Between 2005-2008, the annual proportion of CA-MRSA/CA-S. aureus in C\u00f3rdoba hospitals increased from 25% to 49%, P<0.01. Total CA-MRSA infections increased 3.6 fold-(5.1 to 18.6 cases/100,000 annual-visits, P<0.0001), associated with an important increase of invasive CA-MRSA infections-(8.5 fold). In all regions analyzed, a single genotype prevailed in both CA-MRSA (82%) and HACO-MRSA(57%), which showed pulsed-field-gel electrophoresis-(PFGE)-type-\"I\", sequence-type-5-(ST5), SCCmec-type-IVa, spa-t311, and was positive for PVL. The second clone, pulsotype-N/ST30/CC30/SCCmecIVc/t019/PVL(+), accounted for 11.5% of total CA-MRSA infections. Importantly, the first 4 isolates of Argentina belonging to South American-USA300 clone-(USA300/ST8/CC8/SCCmecIVc/t008/PVL(+)/ACME(-)) were detected. We also demonstrated that a HA-MRSA clone-(pulsotype-C/ST100/CC5) caused 2% and 10% of CA-MRSA and HACO-MRSA infections respectively and was associated with a SCCmec type closely related to SCCmecIV(2B&5). The dissemination of epidemic MRSA clone, ST5-IV-PVL(+) was the main cause of increasing staphylococcal community-onset infections in Argentinean children (2003-2008), conversely to other countries. The predominance of this clone, which has capacity to express the h-VISA phenotype, in healthcare-associated community-onset cases suggests that it has infiltrated into hospital-settings.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "e471eaad8b7f456298a4d3d189d07e9f", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[226, 226], [384, 384], [141, 141], [250, 250], [28, 28], [204, 204], [9, 9], [268, 268], [332, 332], [364, 364], [380, 380], [404, 404], [110, 110], [33, 33], [81, 81]], "char_spans": [[1148, 1151], [1917, 1920], [758, 761], [1289, 1292], [182, 185], [1065, 1068], [69, 72], [1381, 1384], [1646, 1649], [1844, 1847], [1903, 1906], [2049, 2052], [586, 589], [202, 205], [440, 443]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["associated", 10], ["methicillin", 21], ["-", 32], ["resistant", 33], ["Staphylococcus", 43], ["aureus-(CA", 58], ["-", 68], ["MRSA", 69], [")", 73], ["strains", 75], ["have", 83], ["emerged", 88], ["in", 96], ["Argentina", 99], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["clinical", 130], ["and", 139], ["molecular", 143], ["evolution", 153], ["of", 163], ["community", 166], ["-", 175], ["onset", 176], ["MRSA", 182], ["infections", 187], ["(", 198], ["CO", 199], ["-", 201], ["MRSA", 202], [")", 206], ["in", 208], ["children", 211], ["of", 220], ["C\u00f3rdoba", 223], [",", 230], ["Argentina", 232], [",", 241], ["2005", 243], ["-", 247], ["2008", 248], [".", 252], ["Additionally", 254], [",", 266], ["data", 268], ["from", 273], ["2007", 278], ["were", 283], ["compared", 288], ["with", 297], ["the", 302], ["epidemiology", 306], ["of", 319], ["these", 322], ["infections", 328], ["in", 339], ["other", 342], ["regions", 348], ["of", 356], ["the", 359], ["country", 363], [".", 370], ["Two", 372], ["datasets", 376], ["were", 385], ["used", 390], [":", 394], ["i", 396], [")", 397], ["lab", 399], ["-", 402], ["based", 403], ["prospective", 409], ["surveillance", 421], ["of", 434], ["CA", 437], ["-", 439], ["MRSA", 440], ["isolates", 445], ["from", 454], ["3", 459], ["C\u00f3rdoba", 461], ["pediatric", 469], ["hospitals-(CBAH1-H3", 479], [")", 498], ["in", 500], ["2007", 503], ["-", 507], ["2008", 508], ["(", 513], ["compared", 514], ["to", 523], ["previously", 526], ["published", 537], ["data", 547], ["of", 552], ["2005", 555], [")", 559], ["and", 561], ["ii", 565], [")", 567], ["a", 569], ["sampling", 571], ["of", 580], ["CO", 583], ["-", 585], ["MRSA", 586], ["from", 591], ["a", 596], ["study", 598], ["involving", 604], ["both", 614], [",", 618], ["healthcare", 620], ["-", 630], ["associated", 631], ["community", 642], ["-", 651], ["onset-(HACO", 652], [")", 663], ["infections", 665], ["in", 676], ["children", 679], ["with", 688], ["risk", 693], ["-", 697], ["factors", 698], ["for", 706], ["healthcare", 710], ["-", 720], ["associated", 721], ["infections-(HRFs", 732], [")", 748], [",", 749], ["and", 751], ["CA", 755], ["-", 757], ["MRSA", 758], ["infections", 763], ["in", 774], ["patients", 777], ["without", 786], ["HRFs", 794], ["detected", 799], ["in", 808], ["multiple", 811], ["centers", 820], ["of", 828], ["Argentina", 831], ["in", 841], ["2007", 844], [".", 848], ["Molecular", 850], ["typing", 860], ["was", 867], ["performed", 871], ["on", 881], ["the", 884], ["CA", 888], ["-", 890], ["MRSA-(n", 891], [":", 898], ["99", 900], [")", 902], ["isolates", 904], ["from", 913], ["the", 918], ["CBAH1-H3-dataset", 922], ["and", 939], ["on", 943], ["the", 946], ["HACO", 950], ["-", 954], ["MRSA-(n", 955], [":", 962], ["51", 964], [")", 966], ["and", 968], ["CA", 972], ["-", 974], ["MRSA-(n", 975], [":", 982], ["213", 984], [")", 987], ["isolates", 989], ["from", 998], ["other", 1003], ["regions", 1009], [".", 1016], ["Between", 1018], ["2005", 1026], ["-", 1030], ["2008", 1031], [",", 1035], ["the", 1037], ["annual", 1041], ["proportion", 1048], ["of", 1059], ["CA", 1062], ["-", 1064], ["MRSA", 1065], ["/", 1069], ["CA", 1070], ["-", 1072], ["S.", 1073], ["aureus", 1076], ["in", 1083], ["C\u00f3rdoba", 1086], ["hospitals", 1094], ["increased", 1104], ["from", 1114], ["25", 1119], ["%", 1121], ["to", 1123], ["49", 1126], ["%", 1128], [",", 1129], ["P<0.01", 1131], [".", 1137], ["Total", 1139], ["CA", 1145], ["-", 1147], ["MRSA", 1148], ["infections", 1153], ["increased", 1164], ["3.6", 1174], ["fold-(5.1", 1178], ["to", 1188], ["18.6", 1191], ["cases/100,000", 1196], ["annual", 1210], ["-", 1216], ["visits", 1217], [",", 1223], ["P<0.0001", 1225], [")", 1233], [",", 1234], ["associated", 1236], ["with", 1247], ["an", 1252], ["important", 1255], ["increase", 1265], ["of", 1274], ["invasive", 1277], ["CA", 1286], ["-", 1288], ["MRSA", 1289], ["infections-(8.5", 1294], ["fold", 1310], [")", 1314], [".", 1315], ["In", 1317], ["all", 1320], ["regions", 1324], ["analyzed", 1332], [",", 1340], ["a", 1342], ["single", 1344], ["genotype", 1351], ["prevailed", 1360], ["in", 1370], ["both", 1373], ["CA", 1378], ["-", 1380], ["MRSA", 1381], ["(", 1386], ["82", 1387], ["%", 1389], [")", 1390], ["and", 1392], ["HACO", 1396], ["-", 1400], ["MRSA(57", 1401], ["%", 1408], [")", 1409], [",", 1410], ["which", 1412], ["showed", 1418], ["pulsed", 1425], ["-", 1431], ["field", 1432], ["-", 1437], ["gel", 1438], ["electrophoresis-(PFGE)-type-\"I", 1442], ["\"", 1472], [",", 1473], ["sequence", 1475], ["-", 1483], ["type-5-(ST5", 1484], [")", 1495], [",", 1496], ["SCCmec", 1498], ["-", 1504], ["type", 1505], ["-", 1509], ["IVa", 1510], [",", 1513], ["spa", 1515], ["-", 1518], ["t311", 1519], [",", 1523], ["and", 1525], ["was", 1529], ["positive", 1533], ["for", 1542], ["PVL", 1546], [".", 1549], ["The", 1551], ["second", 1555], ["clone", 1562], [",", 1567], ["pulsotype", 1569], ["-", 1578], ["N", 1579], ["/", 1580], ["ST30/CC30/SCCmecIVc", 1581], ["/", 1600], ["t019/PVL(+", 1601], [")", 1611], [",", 1612], ["accounted", 1614], ["for", 1624], ["11.5", 1628], ["%", 1632], ["of", 1634], ["total", 1637], ["CA", 1643], ["-", 1645], ["MRSA", 1646], ["infections", 1651], [".", 1661], ["Importantly", 1663], [",", 1674], ["the", 1676], ["first", 1680], ["4", 1686], ["isolates", 1688], ["of", 1697], ["Argentina", 1700], ["belonging", 1710], ["to", 1720], ["South", 1723], ["American", 1729], ["-", 1737], ["USA300", 1738], ["clone-(USA300/ST8/CC8/SCCmecIVc", 1745], ["/", 1776], ["t008/PVL(+)/ACME(-", 1777], [")", 1795], [")", 1796], ["were", 1798], ["detected", 1803], [".", 1811], ["We", 1813], ["also", 1816], ["demonstrated", 1821], ["that", 1834], ["a", 1839], ["HA", 1841], ["-", 1843], ["MRSA", 1844], ["clone-(pulsotype", 1849], ["-", 1865], ["C", 1866], ["/", 1867], ["ST100/CC5", 1868], [")", 1877], ["caused", 1879], ["2", 1886], ["%", 1887], ["and", 1889], ["10", 1893], ["%", 1895], ["of", 1897], ["CA", 1900], ["-", 1902], ["MRSA", 1903], ["and", 1908], ["HACO", 1912], ["-", 1916], ["MRSA", 1917], ["infections", 1922], ["respectively", 1933], ["and", 1946], ["was", 1950], ["associated", 1954], ["with", 1965], ["a", 1970], ["SCCmec", 1972], ["type", 1979], ["closely", 1984], ["related", 1992], ["to", 2000], ["SCCmecIV(2B&5", 2003], [")", 2016], [".", 2017], ["The", 2019], ["dissemination", 2023], ["of", 2037], ["epidemic", 2040], ["MRSA", 2049], ["clone", 2054], [",", 2059], ["ST5-IV", 2061], ["-", 2067], ["PVL(+", 2068], [")", 2073], ["was", 2075], ["the", 2079], ["main", 2083], ["cause", 2088], ["of", 2094], ["increasing", 2097], ["staphylococcal", 2108], ["community", 2123], ["-", 2132], ["onset", 2133], ["infections", 2139], ["in", 2150], ["Argentinean", 2153], ["children", 2165], ["(", 2174], ["2003", 2175], ["-", 2179], ["2008", 2180], [")", 2184], [",", 2185], ["conversely", 2187], ["to", 2198], ["other", 2201], ["countries", 2207], [".", 2216], ["The", 2218], ["predominance", 2222], ["of", 2235], ["this", 2238], ["clone", 2243], [",", 2248], ["which", 2250], ["has", 2256], ["capacity", 2260], ["to", 2269], ["express", 2272], ["the", 2280], ["h", 2284], ["-", 2285], ["VISA", 2286], ["phenotype", 2291], [",", 2300], ["in", 2302], ["healthcare", 2305], ["-", 2315], ["associated", 2316], ["community", 2327], ["-", 2336], ["onset", 2337], ["cases", 2343], ["suggests", 2349], ["that", 2358], ["it", 2363], ["has", 2366], ["infiltrated", 2370], ["into", 2382], ["hospital", 2387], ["-", 2395], ["settings", 2396], [".", 2404]]}
{"context": "TIA-1 is an RNA binding protein that promotes the assembly of stress granules (SGs), discrete cytoplasmic inclusions into which stalled translation initiation complexes are dynamically recruited in cells subjected to environmental stress. The RNA recognition motifs of TIA-1 are linked to a glutamine-rich prion-related domain (PRD). Truncation mutants lacking the PRD domain do not induce spontaneous SGs and are not recruited to arsenite-induced SGs, whereas the PRD forms aggregates that are recruited to SGs in low-level-expressing cells but prevent SG assembly in high-level-expressing cells. The PRD of TIA-1 exhibits many characteristics of prions: concentration-dependent aggregation that is inhibited by the molecular chaperone heat shock protein (HSP)70; resistance to protease digestion; sequestration of HSP27, HSP40, and HSP70; and induction of HSP70, a feedback regulator of PRD disaggregation. Substitution of the PRD with the aggregation domain of a yeast prion, SUP35-NM, reconstitutes SG assembly, confirming that a prion domain can mediate the assembly of SGs. Mouse embryomic fibroblasts (MEFs) lacking TIA-1 exhibit impaired ability to form SGs, although they exhibit normal phosphorylation of eukaryotic initiation factor (eIF)2alpha in response to arsenite. Our results reveal that prion-like aggregation of TIA-1 regulates SG formation downstream of eIF2alpha phosphorylation in response to stress.", "qas": [{"question": "Which domain of TIA-1 is necessary for stress granule assembly?", "answers": ["The glutamine-rich prion-related domain (PRD)"], "qid": "b0c5cb7e458c48f9a369b023a6f154ef", "question_tokens": [["Which", 0], ["domain", 6], ["of", 13], ["TIA-1", 16], ["is", 22], ["necessary", 25], ["for", 35], ["stress", 39], ["granule", 46], ["assembly", 54], ["?", 62]], "detected_answers": [{"text": "The glutamine-rich prion-related domain (PRD)", "token_spans": [[46, 54]], "char_spans": [[291, 330]]}]}], "context_tokens": [["TIA-1", 0], ["is", 6], ["an", 9], ["RNA", 12], ["binding", 16], ["protein", 24], ["that", 32], ["promotes", 37], ["the", 46], ["assembly", 50], ["of", 59], ["stress", 62], ["granules", 69], ["(", 78], ["SGs", 79], [")", 82], [",", 83], ["discrete", 85], ["cytoplasmic", 94], ["inclusions", 106], ["into", 117], ["which", 122], ["stalled", 128], ["translation", 136], ["initiation", 148], ["complexes", 159], ["are", 169], ["dynamically", 173], ["recruited", 185], ["in", 195], ["cells", 198], ["subjected", 204], ["to", 214], ["environmental", 217], ["stress", 231], [".", 237], ["The", 239], ["RNA", 243], ["recognition", 247], ["motifs", 259], ["of", 266], ["TIA-1", 269], ["are", 275], ["linked", 279], ["to", 286], ["a", 289], ["glutamine", 291], ["-", 300], ["rich", 301], ["prion", 306], ["-", 311], ["related", 312], ["domain", 320], ["(", 327], ["PRD", 328], [")", 331], [".", 332], ["Truncation", 334], ["mutants", 345], ["lacking", 353], ["the", 361], ["PRD", 365], ["domain", 369], ["do", 376], ["not", 379], ["induce", 383], ["spontaneous", 390], ["SGs", 402], ["and", 406], ["are", 410], ["not", 414], ["recruited", 418], ["to", 428], ["arsenite", 431], ["-", 439], ["induced", 440], ["SGs", 448], [",", 451], ["whereas", 453], ["the", 461], ["PRD", 465], ["forms", 469], ["aggregates", 475], ["that", 486], ["are", 491], ["recruited", 495], ["to", 505], ["SGs", 508], ["in", 512], ["low", 515], ["-", 518], ["level", 519], ["-", 524], ["expressing", 525], ["cells", 536], ["but", 542], ["prevent", 546], ["SG", 554], ["assembly", 557], ["in", 566], ["high", 569], ["-", 573], ["level", 574], ["-", 579], ["expressing", 580], ["cells", 591], [".", 596], ["The", 598], ["PRD", 602], ["of", 606], ["TIA-1", 609], ["exhibits", 615], ["many", 624], ["characteristics", 629], ["of", 645], ["prions", 648], [":", 654], ["concentration", 656], ["-", 669], ["dependent", 670], ["aggregation", 680], ["that", 692], ["is", 697], ["inhibited", 700], ["by", 710], ["the", 713], ["molecular", 717], ["chaperone", 727], ["heat", 737], ["shock", 742], ["protein", 748], ["(", 756], ["HSP)70", 757], [";", 763], ["resistance", 765], ["to", 776], ["protease", 779], ["digestion", 788], [";", 797], ["sequestration", 799], ["of", 813], ["HSP27", 816], [",", 821], ["HSP40", 823], [",", 828], ["and", 830], ["HSP70", 834], [";", 839], ["and", 841], ["induction", 845], ["of", 855], ["HSP70", 858], [",", 863], ["a", 865], ["feedback", 867], ["regulator", 876], ["of", 886], ["PRD", 889], ["disaggregation", 893], [".", 907], ["Substitution", 909], ["of", 922], ["the", 925], ["PRD", 929], ["with", 933], ["the", 938], ["aggregation", 942], ["domain", 954], ["of", 961], ["a", 964], ["yeast", 966], ["prion", 972], [",", 977], ["SUP35-NM", 979], [",", 987], ["reconstitutes", 989], ["SG", 1003], ["assembly", 1006], [",", 1014], ["confirming", 1016], ["that", 1027], ["a", 1032], ["prion", 1034], ["domain", 1040], ["can", 1047], ["mediate", 1051], ["the", 1059], ["assembly", 1063], ["of", 1072], ["SGs", 1075], [".", 1078], ["Mouse", 1080], ["embryomic", 1086], ["fibroblasts", 1096], ["(", 1108], ["MEFs", 1109], [")", 1113], ["lacking", 1115], ["TIA-1", 1123], ["exhibit", 1129], ["impaired", 1137], ["ability", 1146], ["to", 1154], ["form", 1157], ["SGs", 1162], [",", 1165], ["although", 1167], ["they", 1176], ["exhibit", 1181], ["normal", 1189], ["phosphorylation", 1196], ["of", 1212], ["eukaryotic", 1215], ["initiation", 1226], ["factor", 1237], ["(", 1244], ["eIF)2alpha", 1245], ["in", 1256], ["response", 1259], ["to", 1268], ["arsenite", 1271], [".", 1279], ["Our", 1281], ["results", 1285], ["reveal", 1293], ["that", 1300], ["prion", 1305], ["-", 1310], ["like", 1311], ["aggregation", 1316], ["of", 1328], ["TIA-1", 1331], ["regulates", 1337], ["SG", 1347], ["formation", 1350], ["downstream", 1360], ["of", 1371], ["eIF2alpha", 1374], ["phosphorylation", 1384], ["in", 1400], ["response", 1403], ["to", 1412], ["stress", 1415], [".", 1421]]}
{"context": "Self-report questionnaires are frequently used to identify PTSD among U.S. military personnel and Veterans. Two common scoring methods used to classify PTSD include: (1) a cut score threshold and (2) endorsement of PTSD symptoms meeting DSM-IV-TR symptom cluster criteria (SCM). A third method requiring a cut score in addition to SCM has been proposed, but has received little study. The current study examined the diagnostic accuracy of three scoring methods for the Davidson Trauma Scale (DTS) among 804 Afghanistan and Iraq war-era military Service Members and Veterans. Data were weighted to approximate the prevalence of PTSD and other Axis I disorders in VA primary care. As expected, adding a cut score criterion to SCM improved specificity and positive predictive power. However, a cut score of 68-72 provided optimal diagnostic accuracy. The utility of the DTS, the role of baseline prevalence, and recommendations for future research are discussed.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "30101ccbda904d208ed2525e9f6e992c", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[117, 117], [24, 24], [9, 9], [40, 40]], "char_spans": [[627, 630], [152, 155], [59, 62], [215, 218]]}]}], "context_tokens": [["Self", 0], ["-", 4], ["report", 5], ["questionnaires", 12], ["are", 27], ["frequently", 31], ["used", 42], ["to", 47], ["identify", 50], ["PTSD", 59], ["among", 64], ["U.S.", 70], ["military", 75], ["personnel", 84], ["and", 94], ["Veterans", 98], [".", 106], ["Two", 108], ["common", 112], ["scoring", 119], ["methods", 127], ["used", 135], ["to", 140], ["classify", 143], ["PTSD", 152], ["include", 157], [":", 164], ["(", 166], ["1", 167], [")", 168], ["a", 170], ["cut", 172], ["score", 176], ["threshold", 182], ["and", 192], ["(", 196], ["2", 197], [")", 198], ["endorsement", 200], ["of", 212], ["PTSD", 215], ["symptoms", 220], ["meeting", 229], ["DSM", 237], ["-", 240], ["IV", 241], ["-", 243], ["TR", 244], ["symptom", 247], ["cluster", 255], ["criteria", 263], ["(", 272], ["SCM", 273], [")", 276], [".", 277], ["A", 279], ["third", 281], ["method", 287], ["requiring", 294], ["a", 304], ["cut", 306], ["score", 310], ["in", 316], ["addition", 319], ["to", 328], ["SCM", 331], ["has", 335], ["been", 339], ["proposed", 344], [",", 352], ["but", 354], ["has", 358], ["received", 362], ["little", 371], ["study", 378], [".", 383], ["The", 385], ["current", 389], ["study", 397], ["examined", 403], ["the", 412], ["diagnostic", 416], ["accuracy", 427], ["of", 436], ["three", 439], ["scoring", 445], ["methods", 453], ["for", 461], ["the", 465], ["Davidson", 469], ["Trauma", 478], ["Scale", 485], ["(", 491], ["DTS", 492], [")", 495], ["among", 497], ["804", 503], ["Afghanistan", 507], ["and", 519], ["Iraq", 523], ["war", 528], ["-", 531], ["era", 532], ["military", 536], ["Service", 545], ["Members", 553], ["and", 561], ["Veterans", 565], [".", 573], ["Data", 575], ["were", 580], ["weighted", 585], ["to", 594], ["approximate", 597], ["the", 609], ["prevalence", 613], ["of", 624], ["PTSD", 627], ["and", 632], ["other", 636], ["Axis", 642], ["I", 647], ["disorders", 649], ["in", 659], ["VA", 662], ["primary", 665], ["care", 673], [".", 677], ["As", 679], ["expected", 682], [",", 690], ["adding", 692], ["a", 699], ["cut", 701], ["score", 705], ["criterion", 711], ["to", 721], ["SCM", 724], ["improved", 728], ["specificity", 737], ["and", 749], ["positive", 753], ["predictive", 762], ["power", 773], [".", 778], ["However", 780], [",", 787], ["a", 789], ["cut", 791], ["score", 795], ["of", 801], ["68", 804], ["-", 806], ["72", 807], ["provided", 810], ["optimal", 819], ["diagnostic", 827], ["accuracy", 838], [".", 846], ["The", 848], ["utility", 852], ["of", 860], ["the", 863], ["DTS", 867], [",", 870], ["the", 872], ["role", 876], ["of", 881], ["baseline", 884], ["prevalence", 893], [",", 903], ["and", 905], ["recommendations", 909], ["for", 925], ["future", 929], ["research", 936], ["are", 945], ["discussed", 949], [".", 958]]}
{"context": "Imatinib mesylate was designed as an inhibitor targeting the BCR-ABL tyrosine kinase, the molecular counterpart of the Philadelphia translocation t(9;22)(q34;q11). We report on a patient with chronic myeloid leukemia (CML) undergoing acceleration during imatinib treatment. Cytogenetic analysis revealed four different cell populations: 46,XX,t(9;22)(q34;q11),der(18)t(2;18)(p11;p11)[1]/47,idem,i(17)(q10),-der(18)t(2;18),+der(22)t(9;22)[1]/46,idem,-t(9;22),der(9)t(9;22),ider(22)t(9;22)[12]/ 47,idem,-t(9;22),der(9)t(9;22),+22,ider(22)t(9;22)x2[1]. FISH analysis confirmed the presence of these four clones. Moreover, 49% of the interphase nuclei contained either one or two clustered fusion signals, indicating a low-level amplification of the BCR-ABL fusion gene. With quantitative real-time RT-PCR, a BCR-ABL/G6PDH ratio of 0.8 was determined, which is comparable to that measured in the K562 cell line with a known BCR-ABL amplification and which is increased by more than about 60-fold compared to a CML at diagnosis with >80% Philadelphia-positive cells. We give further evidence that the genomic BCR-ABL amplification results in an increased level of BCR-ABL transcript linking two potent mechanisms of resistance against imatinib treatment.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "513d7255d5544f56ac4e2cdea3c6e3c5", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[108, 110], [92, 94], [133, 135], [168, 170], [9, 11], [178, 180]], "char_spans": [[805, 811], [746, 752], [920, 926], [1104, 1110], [61, 67], [1159, 1165]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["was", 18], ["designed", 22], ["as", 31], ["an", 34], ["inhibitor", 37], ["targeting", 47], ["the", 57], ["BCR", 61], ["-", 64], ["ABL", 65], ["tyrosine", 69], ["kinase", 78], [",", 84], ["the", 86], ["molecular", 90], ["counterpart", 100], ["of", 112], ["the", 115], ["Philadelphia", 119], ["translocation", 132], ["t(9;22)(q34;q11", 146], [")", 161], [".", 162], ["We", 164], ["report", 167], ["on", 174], ["a", 177], ["patient", 179], ["with", 187], ["chronic", 192], ["myeloid", 200], ["leukemia", 208], ["(", 217], ["CML", 218], [")", 221], ["undergoing", 223], ["acceleration", 234], ["during", 247], ["imatinib", 254], ["treatment", 263], [".", 272], ["Cytogenetic", 274], ["analysis", 286], ["revealed", 295], ["four", 304], ["different", 309], ["cell", 319], ["populations", 324], [":", 335], ["46,XX", 337], [",", 342], ["t(9;22)(q34;q11),der(18)t(2;18)(p11;p11)[1]/47,idem", 343], [",", 394], ["i(17)(q10),-der(18)t(2;18),+der(22)t(9;22)[1]/46,idem,-t(9;22),der(9)t(9;22),ider(22)t(9;22)[12]/", 395], ["47,idem,-t(9;22),der(9)t(9;22),+22,ider(22)t(9;22)x2[1].", 493], ["FISH", 550], ["analysis", 555], ["confirmed", 564], ["the", 574], ["presence", 578], ["of", 587], ["these", 590], ["four", 596], ["clones", 601], [".", 607], ["Moreover", 609], [",", 617], ["49", 619], ["%", 621], ["of", 623], ["the", 626], ["interphase", 630], ["nuclei", 641], ["contained", 648], ["either", 658], ["one", 665], ["or", 669], ["two", 672], ["clustered", 676], ["fusion", 686], ["signals", 693], [",", 700], ["indicating", 702], ["a", 713], ["low", 715], ["-", 718], ["level", 719], ["amplification", 725], ["of", 739], ["the", 742], ["BCR", 746], ["-", 749], ["ABL", 750], ["fusion", 754], ["gene", 761], [".", 765], ["With", 767], ["quantitative", 772], ["real", 785], ["-", 789], ["time", 790], ["RT", 795], ["-", 797], ["PCR", 798], [",", 801], ["a", 803], ["BCR", 805], ["-", 808], ["ABL", 809], ["/", 812], ["G6PDH", 813], ["ratio", 819], ["of", 825], ["0.8", 828], ["was", 832], ["determined", 836], [",", 846], ["which", 848], ["is", 854], ["comparable", 857], ["to", 868], ["that", 871], ["measured", 876], ["in", 885], ["the", 888], ["K562", 892], ["cell", 897], ["line", 902], ["with", 907], ["a", 912], ["known", 914], ["BCR", 920], ["-", 923], ["ABL", 924], ["amplification", 928], ["and", 942], ["which", 946], ["is", 952], ["increased", 955], ["by", 965], ["more", 968], ["than", 973], ["about", 978], ["60-fold", 984], ["compared", 992], ["to", 1001], ["a", 1004], ["CML", 1006], ["at", 1010], ["diagnosis", 1013], ["with", 1023], [">", 1028], ["80", 1029], ["%", 1031], ["Philadelphia", 1033], ["-", 1045], ["positive", 1046], ["cells", 1055], [".", 1060], ["We", 1062], ["give", 1065], ["further", 1070], ["evidence", 1078], ["that", 1087], ["the", 1092], ["genomic", 1096], ["BCR", 1104], ["-", 1107], ["ABL", 1108], ["amplification", 1112], ["results", 1126], ["in", 1134], ["an", 1137], ["increased", 1140], ["level", 1150], ["of", 1156], ["BCR", 1159], ["-", 1162], ["ABL", 1163], ["transcript", 1167], ["linking", 1178], ["two", 1186], ["potent", 1190], ["mechanisms", 1197], ["of", 1208], ["resistance", 1211], ["against", 1222], ["imatinib", 1230], ["treatment", 1239], [".", 1248]]}
{"context": "MicroRNAs (miRNAs) regulate many biological processes such as development, metabolism, and others. They are processed from their primary transcripts called primary miRNA transcripts (pri-miRNAs) by the processor complex containing the RNAse III enzyme, DICER-LIKE1 (DCL1), in plants. Consequently, miRNA biogenesis is controlled through altering pri-miRNA accumulation and processing, which is crucial for plant development and adaptation to environmental changes. Plant pri-miRNAs are transcribed by DNA-dependent RNA polymerase II (Pol II) and their levels are determined through transcription and degradation, whereas pri-miRNA processing is affected by its structure, splicing, alternative splicing, loading to the processor and the processor activity, which involve in many accessory proteins. Here, we summarize recent progresses related to pri-miRNA transcription, stability, and processing in plants.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "900bfac64b0f4a6b8c03e872ceb0fbf1", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[90, 92]], "char_spans": [[515, 531]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["regulate", 19], ["many", 28], ["biological", 33], ["processes", 44], ["such", 54], ["as", 59], ["development", 62], [",", 73], ["metabolism", 75], [",", 85], ["and", 87], ["others", 91], [".", 97], ["They", 99], ["are", 104], ["processed", 108], ["from", 118], ["their", 123], ["primary", 129], ["transcripts", 137], ["called", 149], ["primary", 156], ["miRNA", 164], ["transcripts", 170], ["(", 182], ["pri", 183], ["-", 186], ["miRNAs", 187], [")", 193], ["by", 195], ["the", 198], ["processor", 202], ["complex", 212], ["containing", 220], ["the", 231], ["RNAse", 235], ["III", 241], ["enzyme", 245], [",", 251], ["DICER", 253], ["-", 258], ["LIKE1", 259], ["(", 265], ["DCL1", 266], [")", 270], [",", 271], ["in", 273], ["plants", 276], [".", 282], ["Consequently", 284], [",", 296], ["miRNA", 298], ["biogenesis", 304], ["is", 315], ["controlled", 318], ["through", 329], ["altering", 337], ["pri", 346], ["-", 349], ["miRNA", 350], ["accumulation", 356], ["and", 369], ["processing", 373], [",", 383], ["which", 385], ["is", 391], ["crucial", 394], ["for", 402], ["plant", 406], ["development", 412], ["and", 424], ["adaptation", 428], ["to", 439], ["environmental", 442], ["changes", 456], [".", 463], ["Plant", 465], ["pri", 471], ["-", 474], ["miRNAs", 475], ["are", 482], ["transcribed", 486], ["by", 498], ["DNA", 501], ["-", 504], ["dependent", 505], ["RNA", 515], ["polymerase", 519], ["II", 530], ["(", 533], ["Pol", 534], ["II", 538], [")", 540], ["and", 542], ["their", 546], ["levels", 552], ["are", 559], ["determined", 563], ["through", 574], ["transcription", 582], ["and", 596], ["degradation", 600], [",", 611], ["whereas", 613], ["pri", 621], ["-", 624], ["miRNA", 625], ["processing", 631], ["is", 642], ["affected", 645], ["by", 654], ["its", 657], ["structure", 661], [",", 670], ["splicing", 672], [",", 680], ["alternative", 682], ["splicing", 694], [",", 702], ["loading", 704], ["to", 712], ["the", 715], ["processor", 719], ["and", 729], ["the", 733], ["processor", 737], ["activity", 747], [",", 755], ["which", 757], ["involve", 763], ["in", 771], ["many", 774], ["accessory", 779], ["proteins", 789], [".", 797], ["Here", 799], [",", 803], ["we", 805], ["summarize", 808], ["recent", 818], ["progresses", 825], ["related", 836], ["to", 844], ["pri", 847], ["-", 850], ["miRNA", 851], ["transcription", 857], [",", 870], ["stability", 872], [",", 881], ["and", 883], ["processing", 887], ["in", 898], ["plants", 901], [".", 907]]}
{"context": "Lewy bodies and coarse Lewy neurites are the pathological hallmarks of degenerating neurons in the brains of patients suffering from Parkinson's disease (PD). Recently, the presynaptic protein alpha-synuclein was shown to be a major component of Lewy bodies and Lewy neurites. This study demonstrates for the first time that extensive and thin alpha-synuclein-immunoreactive inclusions are present in the axonal processes of neurons.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "62d0c93b45ca401ca522395ff2d09c8b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[60, 62], [32, 34]], "char_spans": [[344, 358], [193, 207]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], ["and", 12], ["coarse", 16], ["Lewy", 23], ["neurites", 28], ["are", 37], ["the", 41], ["pathological", 45], ["hallmarks", 58], ["of", 68], ["degenerating", 71], ["neurons", 84], ["in", 92], ["the", 95], ["brains", 99], ["of", 106], ["patients", 109], ["suffering", 118], ["from", 128], ["Parkinson", 133], ["'s", 142], ["disease", 145], ["(", 153], ["PD", 154], [")", 156], [".", 157], ["Recently", 159], [",", 167], ["the", 169], ["presynaptic", 173], ["protein", 185], ["alpha", 193], ["-", 198], ["synuclein", 199], ["was", 209], ["shown", 213], ["to", 219], ["be", 222], ["a", 225], ["major", 227], ["component", 233], ["of", 243], ["Lewy", 246], ["bodies", 251], ["and", 258], ["Lewy", 262], ["neurites", 267], [".", 275], ["This", 277], ["study", 282], ["demonstrates", 288], ["for", 301], ["the", 305], ["first", 309], ["time", 315], ["that", 320], ["extensive", 325], ["and", 335], ["thin", 339], ["alpha", 344], ["-", 349], ["synuclein", 350], ["-", 359], ["immunoreactive", 360], ["inclusions", 375], ["are", 386], ["present", 390], ["in", 398], ["the", 401], ["axonal", 405], ["processes", 412], ["of", 422], ["neurons", 425], [".", 432]]}
{"context": "Chronic myeloid leukemia (CML) is the first human malignancy for which the promise of targeted therapy has come true. CML is invariably associated with a specific genetic lesion--the t(9;22) chromosomal translocation. As a consequence of this translocation, a BCR-ABL fusion gene is formed on the 22q- derivative (traditionally known as the Philadelphia chromosome) and the deregulated tyrosine kinase activity of the protein encoded by this gene has been shown to be both necessary and sufficient for initiation and maintenance of the disease. Imatinib mesylate, an orally available tyrosine kinase inhibitor that targets Bcr-Abl, entered clinical evaluation in 1998. Its efficacy surpassed almost everyone's predictions, and the observation of high response rates and favorable toxicity profile associated with imatinib therapy led to its approval as first-line treatment for all newly diagnosed CML patients over an exceptionally short period of time. The 6-year results of the Phase III trial have recently been reported and confirm durability of responses and declining incidence of adverse events over time, although, at present, occurrence of unexpected side effects in the long term cannot be excluded. Although imatinib does not 'cure' CML and has to be administered chronically to patients, it has revolutionized both outcome and quality of life of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "b84adc8ad62e42e3b5cd84477d1d0750", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[46, 48], [106, 108]], "char_spans": [[260, 266], [623, 629]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["the", 34], ["first", 38], ["human", 44], ["malignancy", 50], ["for", 61], ["which", 65], ["the", 71], ["promise", 75], ["of", 83], ["targeted", 86], ["therapy", 95], ["has", 103], ["come", 107], ["true", 112], [".", 116], ["CML", 118], ["is", 122], ["invariably", 125], ["associated", 136], ["with", 147], ["a", 152], ["specific", 154], ["genetic", 163], ["lesion", 171], ["--", 177], ["the", 179], ["t(9;22", 183], [")", 189], ["chromosomal", 191], ["translocation", 203], [".", 216], ["As", 218], ["a", 221], ["consequence", 223], ["of", 235], ["this", 238], ["translocation", 243], [",", 256], ["a", 258], ["BCR", 260], ["-", 263], ["ABL", 264], ["fusion", 268], ["gene", 275], ["is", 280], ["formed", 283], ["on", 290], ["the", 293], ["22q-", 297], ["derivative", 302], ["(", 313], ["traditionally", 314], ["known", 328], ["as", 334], ["the", 337], ["Philadelphia", 341], ["chromosome", 354], [")", 364], ["and", 366], ["the", 370], ["deregulated", 374], ["tyrosine", 386], ["kinase", 395], ["activity", 402], ["of", 411], ["the", 414], ["protein", 418], ["encoded", 426], ["by", 434], ["this", 437], ["gene", 442], ["has", 447], ["been", 451], ["shown", 456], ["to", 462], ["be", 465], ["both", 468], ["necessary", 473], ["and", 483], ["sufficient", 487], ["for", 498], ["initiation", 502], ["and", 513], ["maintenance", 517], ["of", 529], ["the", 532], ["disease", 536], [".", 543], ["Imatinib", 545], ["mesylate", 554], [",", 562], ["an", 564], ["orally", 567], ["available", 574], ["tyrosine", 584], ["kinase", 593], ["inhibitor", 600], ["that", 610], ["targets", 615], ["Bcr", 623], ["-", 626], ["Abl", 627], [",", 630], ["entered", 632], ["clinical", 640], ["evaluation", 649], ["in", 660], ["1998", 663], [".", 667], ["Its", 669], ["efficacy", 673], ["surpassed", 682], ["almost", 692], ["everyone", 699], ["'s", 707], ["predictions", 710], [",", 721], ["and", 723], ["the", 727], ["observation", 731], ["of", 743], ["high", 746], ["response", 751], ["rates", 760], ["and", 766], ["favorable", 770], ["toxicity", 780], ["profile", 789], ["associated", 797], ["with", 808], ["imatinib", 813], ["therapy", 822], ["led", 830], ["to", 834], ["its", 837], ["approval", 841], ["as", 850], ["first", 853], ["-", 858], ["line", 859], ["treatment", 864], ["for", 874], ["all", 878], ["newly", 882], ["diagnosed", 888], ["CML", 898], ["patients", 902], ["over", 911], ["an", 916], ["exceptionally", 919], ["short", 933], ["period", 939], ["of", 946], ["time", 949], [".", 953], ["The", 955], ["6-year", 959], ["results", 966], ["of", 974], ["the", 977], ["Phase", 981], ["III", 987], ["trial", 991], ["have", 997], ["recently", 1002], ["been", 1011], ["reported", 1016], ["and", 1025], ["confirm", 1029], ["durability", 1037], ["of", 1048], ["responses", 1051], ["and", 1061], ["declining", 1065], ["incidence", 1075], ["of", 1085], ["adverse", 1088], ["events", 1096], ["over", 1103], ["time", 1108], [",", 1112], ["although", 1114], [",", 1122], ["at", 1124], ["present", 1127], [",", 1134], ["occurrence", 1136], ["of", 1147], ["unexpected", 1150], ["side", 1161], ["effects", 1166], ["in", 1174], ["the", 1177], ["long", 1181], ["term", 1186], ["can", 1191], ["not", 1194], ["be", 1198], ["excluded", 1201], [".", 1209], ["Although", 1211], ["imatinib", 1220], ["does", 1229], ["not", 1234], ["'", 1238], ["cure", 1239], ["'", 1243], ["CML", 1245], ["and", 1249], ["has", 1253], ["to", 1257], ["be", 1260], ["administered", 1263], ["chronically", 1276], ["to", 1288], ["patients", 1291], [",", 1299], ["it", 1301], ["has", 1304], ["revolutionized", 1308], ["both", 1323], ["outcome", 1328], ["and", 1336], ["quality", 1340], ["of", 1348], ["life", 1351], ["of", 1356], ["CML", 1359], ["patients", 1363], [".", 1371]]}
{"context": "Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disease characterized by variable degrees of oculocutaneous albinism, recurrent infections, and a mild bleeding tendency, with late neurologic dysfunction. Most patients also undergo an accelerated phase of lymphohistiocytosis and die at an early age unless they receive an allogeneic hematopoietic stem cell transplant (SCT). Mutations in the CHS1 (LYST) gene result in CHS. Here, we describe an adopted infant who is compound heterozygous for two novel CHS1 gene mutations, both of which are predicted to result in truncated proteins. The two mutations are a nonsense mutation (c.1540 C>T, CGA>TGA, R514X) in exon 5 and a one base pair deletion (del c.9893T, F3298fsX3304) in exon 43, coding for part of the CHS1 protein's BEACH domain. These two newly described mutations are expected to give rise to a severe phenotype and, indeed, the patient had absolutely no cytotoxicity by natural killer cells or cytotoxic lymphocytes prior to his allogeneic SCT.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "08de58bba59d48acbc705a1f43e25d57", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], ["autosomal", 41], ["recessive", 51], ["disease", 61], ["characterized", 69], ["by", 83], ["variable", 86], ["degrees", 95], ["of", 103], ["oculocutaneous", 106], ["albinism", 121], [",", 129], ["recurrent", 131], ["infections", 141], [",", 151], ["and", 153], ["a", 157], ["mild", 159], ["bleeding", 164], ["tendency", 173], [",", 181], ["with", 183], ["late", 188], ["neurologic", 193], ["dysfunction", 204], [".", 215], ["Most", 217], ["patients", 222], ["also", 231], ["undergo", 236], ["an", 244], ["accelerated", 247], ["phase", 259], ["of", 265], ["lymphohistiocytosis", 268], ["and", 288], ["die", 292], ["at", 296], ["an", 299], ["early", 302], ["age", 308], ["unless", 312], ["they", 319], ["receive", 324], ["an", 332], ["allogeneic", 335], ["hematopoietic", 346], ["stem", 360], ["cell", 365], ["transplant", 370], ["(", 381], ["SCT", 382], [")", 385], [".", 386], ["Mutations", 388], ["in", 398], ["the", 401], ["CHS1", 405], ["(", 410], ["LYST", 411], [")", 415], ["gene", 417], ["result", 422], ["in", 429], ["CHS", 432], [".", 435], ["Here", 437], [",", 441], ["we", 443], ["describe", 446], ["an", 455], ["adopted", 458], ["infant", 466], ["who", 473], ["is", 477], ["compound", 480], ["heterozygous", 489], ["for", 502], ["two", 506], ["novel", 510], ["CHS1", 516], ["gene", 521], ["mutations", 526], [",", 535], ["both", 537], ["of", 542], ["which", 545], ["are", 551], ["predicted", 555], ["to", 565], ["result", 568], ["in", 575], ["truncated", 578], ["proteins", 588], [".", 596], ["The", 598], ["two", 602], ["mutations", 606], ["are", 616], ["a", 620], ["nonsense", 622], ["mutation", 631], ["(", 640], ["c.1540", 641], ["C", 648], [">", 649], ["T", 650], [",", 651], ["CGA", 653], [">", 656], ["TGA", 657], [",", 660], ["R514X", 662], [")", 667], ["in", 669], ["exon", 672], ["5", 677], ["and", 679], ["a", 683], ["one", 685], ["base", 689], ["pair", 694], ["deletion", 699], ["(", 708], ["del", 709], ["c.9893", 713], ["T", 719], [",", 720], ["F3298fsX3304", 722], [")", 734], ["in", 736], ["exon", 739], ["43", 744], [",", 746], ["coding", 748], ["for", 755], ["part", 759], ["of", 764], ["the", 767], ["CHS1", 771], ["protein", 776], ["'s", 783], ["BEACH", 786], ["domain", 792], [".", 798], ["These", 800], ["two", 806], ["newly", 810], ["described", 816], ["mutations", 826], ["are", 836], ["expected", 840], ["to", 849], ["give", 852], ["rise", 857], ["to", 862], ["a", 865], ["severe", 867], ["phenotype", 874], ["and", 884], [",", 887], ["indeed", 889], [",", 895], ["the", 897], ["patient", 901], ["had", 909], ["absolutely", 913], ["no", 924], ["cytotoxicity", 927], ["by", 940], ["natural", 943], ["killer", 951], ["cells", 958], ["or", 964], ["cytotoxic", 967], ["lymphocytes", 977], ["prior", 989], ["to", 995], ["his", 998], ["allogeneic", 1002], ["SCT", 1013], [".", 1016]]}
{"context": "Lack of specific antidotes is a major concern in intracerebral hemorrhage (ICH) related to direct anticoagulants including dabigatran (OAC-ICH). We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab. Pretreatment with DE increased intracerebral hematoma volume and cerebral hemoglobin content. Idarucizumab in equimolar dose prevented excess hematoma expansion for both DE doses. In more extensive ICH, idarucizumab significantly reduced mortality. Thus, idarucizumab prevents excess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.", "qas": [{"question": "Idarucizumab is an antidote of which drug?", "answers": ["dabigatran"], "qid": "37ea67d513cc47e680a8cad150662beb", "question_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antidote", 19], ["of", 28], ["which", 31], ["drug", 37], ["?", 41]], "detected_answers": [{"text": "dabigatran", "token_spans": [[121, 121], [19, 19], [49, 49], [38, 38]], "char_spans": [[746, 755], [123, 132], [260, 269], [219, 228]]}]}], "context_tokens": [["Lack", 0], ["of", 5], ["specific", 8], ["antidotes", 17], ["is", 27], ["a", 30], ["major", 32], ["concern", 38], ["in", 46], ["intracerebral", 49], ["hemorrhage", 63], ["(", 74], ["ICH", 75], [")", 78], ["related", 80], ["to", 88], ["direct", 91], ["anticoagulants", 98], ["including", 113], ["dabigatran", 123], ["(", 134], ["OAC", 135], ["-", 138], ["ICH", 139], [")", 142], [".", 143], ["We", 145], ["examined", 148], ["the", 157], ["efficacy", 161], ["of", 170], ["idarucizumab", 173], [",", 185], ["an", 187], ["antibody", 190], ["fragment", 199], ["binding", 208], ["to", 216], ["dabigatran", 219], [",", 229], ["in", 231], ["a", 234], ["mouse", 236], ["model", 242], ["of", 248], ["OAC", 251], ["-", 254], ["ICH", 255], [".", 258], ["Dabigatran", 260], ["etexilate", 271], ["(", 281], ["DE", 282], [")", 284], ["dose", 286], ["-", 290], ["dependently", 291], ["prolonged", 303], ["diluted", 313], ["thrombin", 321], ["time", 330], ["and", 335], ["tail", 339], ["-", 343], ["vein", 344], ["bleeding", 349], ["time", 358], [",", 362], ["which", 364], ["were", 370], ["reversed", 375], ["by", 384], ["idarucizumab", 387], [".", 399], ["Pretreatment", 401], ["with", 414], ["DE", 419], ["increased", 422], ["intracerebral", 432], ["hematoma", 446], ["volume", 455], ["and", 462], ["cerebral", 466], ["hemoglobin", 475], ["content", 486], [".", 493], ["Idarucizumab", 495], ["in", 508], ["equimolar", 511], ["dose", 521], ["prevented", 526], ["excess", 536], ["hematoma", 543], ["expansion", 552], ["for", 562], ["both", 566], ["DE", 571], ["doses", 574], [".", 579], ["In", 581], ["more", 584], ["extensive", 589], ["ICH", 599], [",", 602], ["idarucizumab", 604], ["significantly", 617], ["reduced", 631], ["mortality", 639], [".", 648], ["Thus", 650], [",", 654], ["idarucizumab", 656], ["prevents", 669], ["excess", 678], ["intracerebral", 685], ["hematoma", 699], ["formation", 708], ["in", 718], ["mice", 721], ["anticoagulated", 726], ["with", 741], ["dabigatran", 746], ["and", 757], ["reduces", 761], ["mortality", 769], [".", 778]]}
{"context": "To assess the efficacy and safety of R788 (fostamatinib disodium), an inhibitor of spleen tyrosine kinase (Syk), in patients with active rheumatoid arthritis (RA) that did not respond to biologic therapies. A total of 219 patients with active RA in whom treatment with biologic agents had failed were enrolled in a 3-month multicenter, randomized, double-blind, placebo-controlled trial of R788. The primary end point was the percentage of patients who met the American College of Rheumatology 20% improvement criteria (achieved an ACR20 response) at month 3. Secondary end points included changes in inflammation and damage, as assessed by magnetic resonance imaging (MRI), and changes in the Disease Activity Score. The ACR20 response in the R788 100 mg twice daily group was 38%, versus 37% in the placebo group, at month 3. No significant differences were achieved in the ACR20, ACR50, or ACR70 response levels at 3 months. There were differences between the groups from baseline to month 3 in the secondary end points C-reactive protein (CRP) level and synovitis score on MRI. There were baseline differences in steroid use, prior biologic use, and synovitis score on MRI between the R788 group and the placebo group that may have affected the outcomes. A high placebo response rate was seen in this trial, and exploratory analysis suggested that this may in part have been driven by patients who entered the trial with an elevated erythrocyte sedimentation rate but normal CRP level. Our findings indicate that there were no differences in the primary end point between the R788 and placebo groups. Differences were observed between the R788 and placebo groups in secondary end points, particularly in those patients who entered the study with an elevated CRP level.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "da2a8dc6772a49fb956f810030d12b53", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[16, 18]], "char_spans": [[83, 104]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["efficacy", 14], ["and", 23], ["safety", 27], ["of", 34], ["R788", 37], ["(", 42], ["fostamatinib", 43], ["disodium", 56], [")", 64], [",", 65], ["an", 67], ["inhibitor", 70], ["of", 80], ["spleen", 83], ["tyrosine", 90], ["kinase", 99], ["(", 106], ["Syk", 107], [")", 110], [",", 111], ["in", 113], ["patients", 116], ["with", 125], ["active", 130], ["rheumatoid", 137], ["arthritis", 148], ["(", 158], ["RA", 159], [")", 161], ["that", 163], ["did", 168], ["not", 172], ["respond", 176], ["to", 184], ["biologic", 187], ["therapies", 196], [".", 205], ["A", 207], ["total", 209], ["of", 215], ["219", 218], ["patients", 222], ["with", 231], ["active", 236], ["RA", 243], ["in", 246], ["whom", 249], ["treatment", 254], ["with", 264], ["biologic", 269], ["agents", 278], ["had", 285], ["failed", 289], ["were", 296], ["enrolled", 301], ["in", 310], ["a", 313], ["3-month", 315], ["multicenter", 323], [",", 334], ["randomized", 336], [",", 346], ["double", 348], ["-", 354], ["blind", 355], [",", 360], ["placebo", 362], ["-", 369], ["controlled", 370], ["trial", 381], ["of", 387], ["R788", 390], [".", 394], ["The", 396], ["primary", 400], ["end", 408], ["point", 412], ["was", 418], ["the", 422], ["percentage", 426], ["of", 437], ["patients", 440], ["who", 449], ["met", 453], ["the", 457], ["American", 461], ["College", 470], ["of", 478], ["Rheumatology", 481], ["20", 494], ["%", 496], ["improvement", 498], ["criteria", 510], ["(", 519], ["achieved", 520], ["an", 529], ["ACR20", 532], ["response", 538], [")", 546], ["at", 548], ["month", 551], ["3", 557], [".", 558], ["Secondary", 560], ["end", 570], ["points", 574], ["included", 581], ["changes", 590], ["in", 598], ["inflammation", 601], ["and", 614], ["damage", 618], [",", 624], ["as", 626], ["assessed", 629], ["by", 638], ["magnetic", 641], ["resonance", 650], ["imaging", 660], ["(", 668], ["MRI", 669], [")", 672], [",", 673], ["and", 675], ["changes", 679], ["in", 687], ["the", 690], ["Disease", 694], ["Activity", 702], ["Score", 711], [".", 716], ["The", 718], ["ACR20", 722], ["response", 728], ["in", 737], ["the", 740], ["R788", 744], ["100", 749], ["mg", 753], ["twice", 756], ["daily", 762], ["group", 768], ["was", 774], ["38", 778], ["%", 780], [",", 781], ["versus", 783], ["37", 790], ["%", 792], ["in", 794], ["the", 797], ["placebo", 801], ["group", 809], [",", 814], ["at", 816], ["month", 819], ["3", 825], [".", 826], ["No", 828], ["significant", 831], ["differences", 843], ["were", 855], ["achieved", 860], ["in", 869], ["the", 872], ["ACR20", 876], [",", 881], ["ACR50", 883], [",", 888], ["or", 890], ["ACR70", 893], ["response", 899], ["levels", 908], ["at", 915], ["3", 918], ["months", 920], [".", 926], ["There", 928], ["were", 934], ["differences", 939], ["between", 951], ["the", 959], ["groups", 963], ["from", 970], ["baseline", 975], ["to", 984], ["month", 987], ["3", 993], ["in", 995], ["the", 998], ["secondary", 1002], ["end", 1012], ["points", 1016], ["C", 1023], ["-", 1024], ["reactive", 1025], ["protein", 1034], ["(", 1042], ["CRP", 1043], [")", 1046], ["level", 1048], ["and", 1054], ["synovitis", 1058], ["score", 1068], ["on", 1074], ["MRI", 1077], [".", 1080], ["There", 1082], ["were", 1088], ["baseline", 1093], ["differences", 1102], ["in", 1114], ["steroid", 1117], ["use", 1125], [",", 1128], ["prior", 1130], ["biologic", 1136], ["use", 1145], [",", 1148], ["and", 1150], ["synovitis", 1154], ["score", 1164], ["on", 1170], ["MRI", 1173], ["between", 1177], ["the", 1185], ["R788", 1189], ["group", 1194], ["and", 1200], ["the", 1204], ["placebo", 1208], ["group", 1216], ["that", 1222], ["may", 1227], ["have", 1231], ["affected", 1236], ["the", 1245], ["outcomes", 1249], [".", 1257], ["A", 1259], ["high", 1261], ["placebo", 1266], ["response", 1274], ["rate", 1283], ["was", 1288], ["seen", 1292], ["in", 1297], ["this", 1300], ["trial", 1305], [",", 1310], ["and", 1312], ["exploratory", 1316], ["analysis", 1328], ["suggested", 1337], ["that", 1347], ["this", 1352], ["may", 1357], ["in", 1361], ["part", 1364], ["have", 1369], ["been", 1374], ["driven", 1379], ["by", 1386], ["patients", 1389], ["who", 1398], ["entered", 1402], ["the", 1410], ["trial", 1414], ["with", 1420], ["an", 1425], ["elevated", 1428], ["erythrocyte", 1437], ["sedimentation", 1449], ["rate", 1463], ["but", 1468], ["normal", 1472], ["CRP", 1479], ["level", 1483], [".", 1488], ["Our", 1490], ["findings", 1494], ["indicate", 1503], ["that", 1512], ["there", 1517], ["were", 1523], ["no", 1528], ["differences", 1531], ["in", 1543], ["the", 1546], ["primary", 1550], ["end", 1558], ["point", 1562], ["between", 1568], ["the", 1576], ["R788", 1580], ["and", 1585], ["placebo", 1589], ["groups", 1597], [".", 1603], ["Differences", 1605], ["were", 1617], ["observed", 1622], ["between", 1631], ["the", 1639], ["R788", 1643], ["and", 1648], ["placebo", 1652], ["groups", 1660], ["in", 1667], ["secondary", 1670], ["end", 1680], ["points", 1684], [",", 1690], ["particularly", 1692], ["in", 1705], ["those", 1708], ["patients", 1714], ["who", 1723], ["entered", 1727], ["the", 1735], ["study", 1739], ["with", 1745], ["an", 1750], ["elevated", 1753], ["CRP", 1762], ["level", 1766], [".", 1771]]}
{"context": "ATP13A2 (PARK9) loss of function mutations are a genetic cause of an early-onset form of Parkinson's disease (PD), with in vitro studies showing that ATP13A2 deficits lead to lysosomal and mitochondrial dysfunction and \u03b1-synuclein accumulation, while elevated ATP13A2 expression reduces \u03b1-synuclein toxicity. The three human brain tissue studies assessing changes in ATP13A2 expression in PD produced divergent results; mRNA is increased while protein levels were observed to be either increased or decreased. This apparent conflict in protein levels might have arisen from examining Lewy body disease cases with coexisting Alzheimer-type pathologies.To assess whether ATP13A2 levels in Lewy body disease are modified by Alzheimer-type \u03b2-amyloid deposition, we evaluated cases of pure PD and pure dementia with Lewy bodies (DLB) for changes in ATP13A2, \u03b1-synuclein and \u03b2-amyloid protein levels in cortical regions with and without Lewy bodies. In all Lewy body disease cases, we identified decreased ATP13A2 protein levels that correlated with increases in both \u03b1-synuclein and \u03b2-amyloid. Partial colocalization was observed between ATP13A2 and \u03b1-synuclein in Lewy bodies, whereas ATP13A2 did not colocalize with pathological \u03b2-amyloid deposition. Our data show that patients with Lewy body diseases have an overall deficit in ATP13A2 protein levels, with the remaining protein being more insoluble and partially redistributing towards Lewy bodies. This supports the concept that increasing ATP13A2 levels may offer potential therapeutic benefits to patients with Lewy body diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "5c8a8c9ddaa24aa699e91a1ac4502ebb", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[150, 152], [202, 204], [51, 53], [41, 43], [187, 189]], "char_spans": [[853, 863], [1145, 1155], [287, 297], [219, 229], [1062, 1072]]}]}], "context_tokens": [["ATP13A2", 0], ["(", 8], ["PARK9", 9], [")", 14], ["loss", 16], ["of", 21], ["function", 24], ["mutations", 33], ["are", 43], ["a", 47], ["genetic", 49], ["cause", 57], ["of", 63], ["an", 66], ["early", 69], ["-", 74], ["onset", 75], ["form", 81], ["of", 86], ["Parkinson", 89], ["'s", 98], ["disease", 101], ["(", 109], ["PD", 110], [")", 112], [",", 113], ["with", 115], ["in", 120], ["vitro", 123], ["studies", 129], ["showing", 137], ["that", 145], ["ATP13A2", 150], ["deficits", 158], ["lead", 167], ["to", 172], ["lysosomal", 175], ["and", 185], ["mitochondrial", 189], ["dysfunction", 203], ["and", 215], ["\u03b1", 219], ["-", 220], ["synuclein", 221], ["accumulation", 231], [",", 243], ["while", 245], ["elevated", 251], ["ATP13A2", 260], ["expression", 268], ["reduces", 279], ["\u03b1", 287], ["-", 288], ["synuclein", 289], ["toxicity", 299], [".", 307], ["The", 309], ["three", 313], ["human", 319], ["brain", 325], ["tissue", 331], ["studies", 338], ["assessing", 346], ["changes", 356], ["in", 364], ["ATP13A2", 367], ["expression", 375], ["in", 386], ["PD", 389], ["produced", 392], ["divergent", 401], ["results", 411], [";", 418], ["mRNA", 420], ["is", 425], ["increased", 428], ["while", 438], ["protein", 444], ["levels", 452], ["were", 459], ["observed", 464], ["to", 473], ["be", 476], ["either", 479], ["increased", 486], ["or", 496], ["decreased", 499], [".", 508], ["This", 510], ["apparent", 515], ["conflict", 524], ["in", 533], ["protein", 536], ["levels", 544], ["might", 551], ["have", 557], ["arisen", 562], ["from", 569], ["examining", 574], ["Lewy", 584], ["body", 589], ["disease", 594], ["cases", 602], ["with", 608], ["coexisting", 613], ["Alzheimer", 624], ["-", 633], ["type", 634], ["pathologies", 639], [".", 650], ["To", 651], ["assess", 654], ["whether", 661], ["ATP13A2", 669], ["levels", 677], ["in", 684], ["Lewy", 687], ["body", 692], ["disease", 697], ["are", 705], ["modified", 709], ["by", 718], ["Alzheimer", 721], ["-", 730], ["type", 731], ["\u03b2", 736], ["-", 737], ["amyloid", 738], ["deposition", 746], [",", 756], ["we", 758], ["evaluated", 761], ["cases", 771], ["of", 777], ["pure", 780], ["PD", 785], ["and", 788], ["pure", 792], ["dementia", 797], ["with", 806], ["Lewy", 811], ["bodies", 816], ["(", 823], ["DLB", 824], [")", 827], ["for", 829], ["changes", 833], ["in", 841], ["ATP13A2", 844], [",", 851], ["\u03b1", 853], ["-", 854], ["synuclein", 855], ["and", 865], ["\u03b2", 869], ["-", 870], ["amyloid", 871], ["protein", 879], ["levels", 887], ["in", 894], ["cortical", 897], ["regions", 906], ["with", 914], ["and", 919], ["without", 923], ["Lewy", 931], ["bodies", 936], [".", 942], ["In", 944], ["all", 947], ["Lewy", 951], ["body", 956], ["disease", 961], ["cases", 969], [",", 974], ["we", 976], ["identified", 979], ["decreased", 990], ["ATP13A2", 1000], ["protein", 1008], ["levels", 1016], ["that", 1023], ["correlated", 1028], ["with", 1039], ["increases", 1044], ["in", 1054], ["both", 1057], ["\u03b1", 1062], ["-", 1063], ["synuclein", 1064], ["and", 1074], ["\u03b2", 1078], ["-", 1079], ["amyloid", 1080], [".", 1087], ["Partial", 1089], ["colocalization", 1097], ["was", 1112], ["observed", 1116], ["between", 1125], ["ATP13A2", 1133], ["and", 1141], ["\u03b1", 1145], ["-", 1146], ["synuclein", 1147], ["in", 1157], ["Lewy", 1160], ["bodies", 1165], [",", 1171], ["whereas", 1173], ["ATP13A2", 1181], ["did", 1189], ["not", 1193], ["colocalize", 1197], ["with", 1208], ["pathological", 1213], ["\u03b2", 1226], ["-", 1227], ["amyloid", 1228], ["deposition", 1236], [".", 1246], ["Our", 1248], ["data", 1252], ["show", 1257], ["that", 1262], ["patients", 1267], ["with", 1276], ["Lewy", 1281], ["body", 1286], ["diseases", 1291], ["have", 1300], ["an", 1305], ["overall", 1308], ["deficit", 1316], ["in", 1324], ["ATP13A2", 1327], ["protein", 1335], ["levels", 1343], [",", 1349], ["with", 1351], ["the", 1356], ["remaining", 1360], ["protein", 1370], ["being", 1378], ["more", 1384], ["insoluble", 1389], ["and", 1399], ["partially", 1403], ["redistributing", 1413], ["towards", 1428], ["Lewy", 1436], ["bodies", 1441], [".", 1447], ["This", 1449], ["supports", 1454], ["the", 1463], ["concept", 1467], ["that", 1475], ["increasing", 1480], ["ATP13A2", 1491], ["levels", 1499], ["may", 1506], ["offer", 1510], ["potential", 1516], ["therapeutic", 1526], ["benefits", 1538], ["to", 1547], ["patients", 1550], ["with", 1559], ["Lewy", 1564], ["body", 1569], ["diseases", 1574], [".", 1582]]}
{"context": "There has been no previous side-by-side comparison of the diagnostic criteria for restless legs syndrome (RLS) (Willis-Ekbom disease) and growing pains. In our review, we explore this comparison emphasizing overlaps and disconnects, summarize recent literature exploring the relationship between the 2 entities, and make suggestions for future research. There is considerable overlap in the diagnostic criteria for childhood RLS and growing pains. The literature also indicates that RLS and growing pains more commonly occur together than one would expect based on chance alone, and the family histories of RLS and growing pains often are overlapping. Leg rubbing to obtain relief from leg discomfort is common to both disorders, though walking to obtain relief seems unique to RLS. Childhood RLS also has been reported to be painful in up to 45% of cases. The development of standard diagnostic criteria is necessary to move forward in the field of growing pains research. A quantitative and validated rating scale for growing pains severity already exists. Because of the clinical and genetic similarity between RLS and growing pains, studies that parallel those previously performed in RLS patients are recommended for growing pains patients. For example, a genome wide association study in growing pains patients of all possible genes with particular attention to those identified as related to RLS and a therapeutic trial of medications known to be effective in RLS would be welcome. Abnormalities in vitamin D metabolism also may be common to both disorders.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "3dc26f38ab6044c4a7bf30e5bd9852c6", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[16, 18]], "char_spans": [[82, 103]]}]}], "context_tokens": [["There", 0], ["has", 6], ["been", 10], ["no", 15], ["previous", 18], ["side", 27], ["-", 31], ["by", 32], ["-", 34], ["side", 35], ["comparison", 40], ["of", 51], ["the", 54], ["diagnostic", 58], ["criteria", 69], ["for", 78], ["restless", 82], ["legs", 91], ["syndrome", 96], ["(", 105], ["RLS", 106], [")", 109], ["(", 111], ["Willis", 112], ["-", 118], ["Ekbom", 119], ["disease", 125], [")", 132], ["and", 134], ["growing", 138], ["pains", 146], [".", 151], ["In", 153], ["our", 156], ["review", 160], [",", 166], ["we", 168], ["explore", 171], ["this", 179], ["comparison", 184], ["emphasizing", 195], ["overlaps", 207], ["and", 216], ["disconnects", 220], [",", 231], ["summarize", 233], ["recent", 243], ["literature", 250], ["exploring", 261], ["the", 271], ["relationship", 275], ["between", 288], ["the", 296], ["2", 300], ["entities", 302], [",", 310], ["and", 312], ["make", 316], ["suggestions", 321], ["for", 333], ["future", 337], ["research", 344], [".", 352], ["There", 354], ["is", 360], ["considerable", 363], ["overlap", 376], ["in", 384], ["the", 387], ["diagnostic", 391], ["criteria", 402], ["for", 411], ["childhood", 415], ["RLS", 425], ["and", 429], ["growing", 433], ["pains", 441], [".", 446], ["The", 448], ["literature", 452], ["also", 463], ["indicates", 468], ["that", 478], ["RLS", 483], ["and", 487], ["growing", 491], ["pains", 499], ["more", 505], ["commonly", 510], ["occur", 519], ["together", 525], ["than", 534], ["one", 539], ["would", 543], ["expect", 549], ["based", 556], ["on", 562], ["chance", 565], ["alone", 572], [",", 577], ["and", 579], ["the", 583], ["family", 587], ["histories", 594], ["of", 604], ["RLS", 607], ["and", 611], ["growing", 615], ["pains", 623], ["often", 629], ["are", 635], ["overlapping", 639], [".", 650], ["Leg", 652], ["rubbing", 656], ["to", 664], ["obtain", 667], ["relief", 674], ["from", 681], ["leg", 686], ["discomfort", 690], ["is", 701], ["common", 704], ["to", 711], ["both", 714], ["disorders", 719], [",", 728], ["though", 730], ["walking", 737], ["to", 745], ["obtain", 748], ["relief", 755], ["seems", 762], ["unique", 768], ["to", 775], ["RLS", 778], [".", 781], ["Childhood", 783], ["RLS", 793], ["also", 797], ["has", 802], ["been", 806], ["reported", 811], ["to", 820], ["be", 823], ["painful", 826], ["in", 834], ["up", 837], ["to", 840], ["45", 843], ["%", 845], ["of", 847], ["cases", 850], [".", 855], ["The", 857], ["development", 861], ["of", 873], ["standard", 876], ["diagnostic", 885], ["criteria", 896], ["is", 905], ["necessary", 908], ["to", 918], ["move", 921], ["forward", 926], ["in", 934], ["the", 937], ["field", 941], ["of", 947], ["growing", 950], ["pains", 958], ["research", 964], [".", 972], ["A", 974], ["quantitative", 976], ["and", 989], ["validated", 993], ["rating", 1003], ["scale", 1010], ["for", 1016], ["growing", 1020], ["pains", 1028], ["severity", 1034], ["already", 1043], ["exists", 1051], [".", 1057], ["Because", 1059], ["of", 1067], ["the", 1070], ["clinical", 1074], ["and", 1083], ["genetic", 1087], ["similarity", 1095], ["between", 1106], ["RLS", 1114], ["and", 1118], ["growing", 1122], ["pains", 1130], [",", 1135], ["studies", 1137], ["that", 1145], ["parallel", 1150], ["those", 1159], ["previously", 1165], ["performed", 1176], ["in", 1186], ["RLS", 1189], ["patients", 1193], ["are", 1202], ["recommended", 1206], ["for", 1218], ["growing", 1222], ["pains", 1230], ["patients", 1236], [".", 1244], ["For", 1246], ["example", 1250], [",", 1257], ["a", 1259], ["genome", 1261], ["wide", 1268], ["association", 1273], ["study", 1285], ["in", 1291], ["growing", 1294], ["pains", 1302], ["patients", 1308], ["of", 1317], ["all", 1320], ["possible", 1324], ["genes", 1333], ["with", 1339], ["particular", 1344], ["attention", 1355], ["to", 1365], ["those", 1368], ["identified", 1374], ["as", 1385], ["related", 1388], ["to", 1396], ["RLS", 1399], ["and", 1403], ["a", 1407], ["therapeutic", 1409], ["trial", 1421], ["of", 1427], ["medications", 1430], ["known", 1442], ["to", 1448], ["be", 1451], ["effective", 1454], ["in", 1464], ["RLS", 1467], ["would", 1471], ["be", 1477], ["welcome", 1480], [".", 1487], ["Abnormalities", 1489], ["in", 1503], ["vitamin", 1506], ["D", 1514], ["metabolism", 1516], ["also", 1527], ["may", 1532], ["be", 1536], ["common", 1539], ["to", 1546], ["both", 1549], ["disorders", 1554], [".", 1563]]}
{"context": "It has been previously shown that disruption of RAD26 in yeast strain W303-1B results in a strain that is deficient in transcription-coupled repair (TCR), the preferential repair of the transcribed strand of an expressed gene over the non-transcribed strand and the rest of the genome. RAD26 encodes a protein that is homologous to Cockayne syndrome group B protein (CSB) and is a member of the SWI2/SNF2 family of DNA-dependent ATPases involved in chromatin remodeling. Like the rad26 mutant, cells from Cockayne syndrome patients are defective in TCR. We examined the role of Rad26 in TCR by disrupting RAD26 in two repair-proficient laboratory strains and, remarkably, observed no effect upon TCR. Our results indicate that disruption of RAD26 alone is insufficient to impair TCR. Thus, W303-1B must already possess a mutation that, together with disruption of RAD26, causes a deficiency in TCR. We suggest that other genes are mutated in Cockayne syndrome cells that contribute to the deficiency in TCR. Surprisingly, deletion of RAD26 results in expression of genes that are repressed by flanking transposon delta elements, an Spt(-) phenotype. The delta elements appear to perturb local chromatin structure. Expression of genes flanked by delta elements in rad26Delta mutants is consistent with a role for Rad26 in chromatin remodeling.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "d013353ea4e742219ed6b636f0489445", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[36, 37], [46, 47]], "char_spans": [[186, 203], [239, 256]]}]}], "context_tokens": [["It", 0], ["has", 3], ["been", 7], ["previously", 12], ["shown", 23], ["that", 29], ["disruption", 34], ["of", 45], ["RAD26", 48], ["in", 54], ["yeast", 57], ["strain", 63], ["W303", 70], ["-", 74], ["1B", 75], ["results", 78], ["in", 86], ["a", 89], ["strain", 91], ["that", 98], ["is", 103], ["deficient", 106], ["in", 116], ["transcription", 119], ["-", 132], ["coupled", 133], ["repair", 141], ["(", 148], ["TCR", 149], [")", 152], [",", 153], ["the", 155], ["preferential", 159], ["repair", 172], ["of", 179], ["the", 182], ["transcribed", 186], ["strand", 198], ["of", 205], ["an", 208], ["expressed", 211], ["gene", 221], ["over", 226], ["the", 231], ["non", 235], ["-", 238], ["transcribed", 239], ["strand", 251], ["and", 258], ["the", 262], ["rest", 266], ["of", 271], ["the", 274], ["genome", 278], [".", 284], ["RAD26", 286], ["encodes", 292], ["a", 300], ["protein", 302], ["that", 310], ["is", 315], ["homologous", 318], ["to", 329], ["Cockayne", 332], ["syndrome", 341], ["group", 350], ["B", 356], ["protein", 358], ["(", 366], ["CSB", 367], [")", 370], ["and", 372], ["is", 376], ["a", 379], ["member", 381], ["of", 388], ["the", 391], ["SWI2/SNF2", 395], ["family", 405], ["of", 412], ["DNA", 415], ["-", 418], ["dependent", 419], ["ATPases", 429], ["involved", 437], ["in", 446], ["chromatin", 449], ["remodeling", 459], [".", 469], ["Like", 471], ["the", 476], ["rad26", 480], ["mutant", 486], [",", 492], ["cells", 494], ["from", 500], ["Cockayne", 505], ["syndrome", 514], ["patients", 523], ["are", 532], ["defective", 536], ["in", 546], ["TCR", 549], [".", 552], ["We", 554], ["examined", 557], ["the", 566], ["role", 570], ["of", 575], ["Rad26", 578], ["in", 584], ["TCR", 587], ["by", 591], ["disrupting", 594], ["RAD26", 605], ["in", 611], ["two", 614], ["repair", 618], ["-", 624], ["proficient", 625], ["laboratory", 636], ["strains", 647], ["and", 655], [",", 658], ["remarkably", 660], [",", 670], ["observed", 672], ["no", 681], ["effect", 684], ["upon", 691], ["TCR", 696], [".", 699], ["Our", 701], ["results", 705], ["indicate", 713], ["that", 722], ["disruption", 727], ["of", 738], ["RAD26", 741], ["alone", 747], ["is", 753], ["insufficient", 756], ["to", 769], ["impair", 772], ["TCR", 779], [".", 782], ["Thus", 784], [",", 788], ["W303", 790], ["-", 794], ["1B", 795], ["must", 798], ["already", 803], ["possess", 811], ["a", 819], ["mutation", 821], ["that", 830], [",", 834], ["together", 836], ["with", 845], ["disruption", 850], ["of", 861], ["RAD26", 864], [",", 869], ["causes", 871], ["a", 878], ["deficiency", 880], ["in", 891], ["TCR", 894], [".", 897], ["We", 899], ["suggest", 902], ["that", 910], ["other", 915], ["genes", 921], ["are", 927], ["mutated", 931], ["in", 939], ["Cockayne", 942], ["syndrome", 951], ["cells", 960], ["that", 966], ["contribute", 971], ["to", 982], ["the", 985], ["deficiency", 989], ["in", 1000], ["TCR", 1003], [".", 1006], ["Surprisingly", 1008], [",", 1020], ["deletion", 1022], ["of", 1031], ["RAD26", 1034], ["results", 1040], ["in", 1048], ["expression", 1051], ["of", 1062], ["genes", 1065], ["that", 1071], ["are", 1076], ["repressed", 1080], ["by", 1090], ["flanking", 1093], ["transposon", 1102], ["delta", 1113], ["elements", 1119], [",", 1127], ["an", 1129], ["Spt(-", 1132], [")", 1137], ["phenotype", 1139], [".", 1148], ["The", 1150], ["delta", 1154], ["elements", 1160], ["appear", 1169], ["to", 1176], ["perturb", 1179], ["local", 1187], ["chromatin", 1193], ["structure", 1203], [".", 1212], ["Expression", 1214], ["of", 1225], ["genes", 1228], ["flanked", 1234], ["by", 1242], ["delta", 1245], ["elements", 1251], ["in", 1260], ["rad26Delta", 1263], ["mutants", 1274], ["is", 1282], ["consistent", 1285], ["with", 1296], ["a", 1301], ["role", 1303], ["for", 1308], ["Rad26", 1312], ["in", 1318], ["chromatin", 1321], ["remodeling", 1331], [".", 1341]]}
{"context": "The ESET (also called SETDB1) protein contains an N-terminal tudor domain that mediates protein-protein interactions and a C-terminal SET domain that catalyzes methylation of histone H3 at lysine 9. We report here that ESET protein is transiently upregulated in prehypertrophic chondrocytes in newborn mice. To investigate the in vivo effects of ESET on chondrocyte differentiation, we generated conditional knockout mice to specifically eliminate the catalytic SET domain of ESET protein only in mesenchymal cells. Such deletion of the ESET gene caused acceleration of chondrocyte hypertrophy in both embryos and young animals, depleting chondrocytes that are otherwise available to form epiphyseal plates for endochondral bone growth. ESET-deficient mice are thus characterized by defective long bone growth and trabecular bone formation. To understand the underlying mechanism for ESET regulation of chondrocytes, we carried out co-expression experiments and found that ESET associates with histone deacetylase 4 to bind and inhibit the activity of Runx2, a hypertrophy-promoting transcription factor. Repression of Runx2-mediated gene transactivation by ESET is dependent on its H3-K9 methyltransferase activity as well as its associated histone deacetylase activity. In addition, knockout of ESET is associated with repression of Indian hedgehog gene in pre- and early hypertrophic chondrocytes. Together, these results provide clear evidence that ESET controls hypertrophic differentiation of growth plate chondrocytes and endochondral ossification during embryogenesis and postnatal development.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "d0135b10802e48faa90f81f7c49257ad", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[76, 77], [26, 27]], "char_spans": [[462, 471], [134, 143]]}]}], "context_tokens": [["The", 0], ["ESET", 4], ["(", 9], ["also", 10], ["called", 15], ["SETDB1", 22], [")", 28], ["protein", 30], ["contains", 38], ["an", 47], ["N", 50], ["-", 51], ["terminal", 52], ["tudor", 61], ["domain", 67], ["that", 74], ["mediates", 79], ["protein", 88], ["-", 95], ["protein", 96], ["interactions", 104], ["and", 117], ["a", 121], ["C", 123], ["-", 124], ["terminal", 125], ["SET", 134], ["domain", 138], ["that", 145], ["catalyzes", 150], ["methylation", 160], ["of", 172], ["histone", 175], ["H3", 183], ["at", 186], ["lysine", 189], ["9", 196], [".", 197], ["We", 199], ["report", 202], ["here", 209], ["that", 214], ["ESET", 219], ["protein", 224], ["is", 232], ["transiently", 235], ["upregulated", 247], ["in", 259], ["prehypertrophic", 262], ["chondrocytes", 278], ["in", 291], ["newborn", 294], ["mice", 302], [".", 306], ["To", 308], ["investigate", 311], ["the", 323], ["in", 327], ["vivo", 330], ["effects", 335], ["of", 343], ["ESET", 346], ["on", 351], ["chondrocyte", 354], ["differentiation", 366], [",", 381], ["we", 383], ["generated", 386], ["conditional", 396], ["knockout", 408], ["mice", 417], ["to", 422], ["specifically", 425], ["eliminate", 438], ["the", 448], ["catalytic", 452], ["SET", 462], ["domain", 466], ["of", 473], ["ESET", 476], ["protein", 481], ["only", 489], ["in", 494], ["mesenchymal", 497], ["cells", 509], [".", 514], ["Such", 516], ["deletion", 521], ["of", 530], ["the", 533], ["ESET", 537], ["gene", 542], ["caused", 547], ["acceleration", 554], ["of", 567], ["chondrocyte", 570], ["hypertrophy", 582], ["in", 594], ["both", 597], ["embryos", 602], ["and", 610], ["young", 614], ["animals", 620], [",", 627], ["depleting", 629], ["chondrocytes", 639], ["that", 652], ["are", 657], ["otherwise", 661], ["available", 671], ["to", 681], ["form", 684], ["epiphyseal", 689], ["plates", 700], ["for", 707], ["endochondral", 711], ["bone", 724], ["growth", 729], [".", 735], ["ESET", 737], ["-", 741], ["deficient", 742], ["mice", 752], ["are", 757], ["thus", 761], ["characterized", 766], ["by", 780], ["defective", 783], ["long", 793], ["bone", 798], ["growth", 803], ["and", 810], ["trabecular", 814], ["bone", 825], ["formation", 830], [".", 839], ["To", 841], ["understand", 844], ["the", 855], ["underlying", 859], ["mechanism", 870], ["for", 880], ["ESET", 884], ["regulation", 889], ["of", 900], ["chondrocytes", 903], [",", 915], ["we", 917], ["carried", 920], ["out", 928], ["co", 932], ["-", 934], ["expression", 935], ["experiments", 946], ["and", 958], ["found", 962], ["that", 968], ["ESET", 973], ["associates", 978], ["with", 989], ["histone", 994], ["deacetylase", 1002], ["4", 1014], ["to", 1016], ["bind", 1019], ["and", 1024], ["inhibit", 1028], ["the", 1036], ["activity", 1040], ["of", 1049], ["Runx2", 1052], [",", 1057], ["a", 1059], ["hypertrophy", 1061], ["-", 1072], ["promoting", 1073], ["transcription", 1083], ["factor", 1097], [".", 1103], ["Repression", 1105], ["of", 1116], ["Runx2-mediated", 1119], ["gene", 1134], ["transactivation", 1139], ["by", 1155], ["ESET", 1158], ["is", 1163], ["dependent", 1166], ["on", 1176], ["its", 1179], ["H3-K9", 1183], ["methyltransferase", 1189], ["activity", 1207], ["as", 1216], ["well", 1219], ["as", 1224], ["its", 1227], ["associated", 1231], ["histone", 1242], ["deacetylase", 1250], ["activity", 1262], [".", 1270], ["In", 1272], ["addition", 1275], [",", 1283], ["knockout", 1285], ["of", 1294], ["ESET", 1297], ["is", 1302], ["associated", 1305], ["with", 1316], ["repression", 1321], ["of", 1332], ["Indian", 1335], ["hedgehog", 1342], ["gene", 1351], ["in", 1356], ["pre-", 1359], ["and", 1364], ["early", 1368], ["hypertrophic", 1374], ["chondrocytes", 1387], [".", 1399], ["Together", 1401], [",", 1409], ["these", 1411], ["results", 1417], ["provide", 1425], ["clear", 1433], ["evidence", 1439], ["that", 1448], ["ESET", 1453], ["controls", 1458], ["hypertrophic", 1467], ["differentiation", 1480], ["of", 1496], ["growth", 1499], ["plate", 1506], ["chondrocytes", 1512], ["and", 1525], ["endochondral", 1529], ["ossification", 1542], ["during", 1555], ["embryogenesis", 1562], ["and", 1576], ["postnatal", 1580], ["development", 1590], [".", 1601]]}
{"context": "To define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography. Body indices (height, weight, and body mass index) were analyzed in 60 healthy adults, and electromyography and sonography were also performed. The cross-sectional areas of the proximal and distal median nerve and carpal tunnel were obtained by sonography. The proximal and distal nerve/tunnel indices were obtained by calculating the ratio between the proximal and distal cross-sectional areas of the median nerve to those of the carpal tunnel and multiplying the value by 100. Although the proximal cross-sectional areas of the median nerve and body indices showed statistically significant relationships with weak positive correlations, the proximal and distal areas of the carpal tunnel showed relatively stronger correlations with body indices. Between sexes, there were significant differences in the proximal median nerve cross-sectional area (mean \u00b1 SD: male, 10.48 \u00b1 3.21 mm(2); female, 8.81 \u00b1 3.21 mm(2); P < .05) and proximal carpal tunnel area (male, 182.50 \u00b1 21.15 mm(2); female, 151.23 \u00b1 21.14 mm(2); P < .05). There was no difference in the proximal nerve/tunnel index (male, 5.80% \u00b1 1.72%; female, 5.91% \u00b1 1.63%). There was a statistically significant difference in the distal carpal tunnel cross-sectional area (male, 138.90 \u00b1 20.95 mm(2); female, 121.50 \u00b1 18.99 mm(2); P < .05) between sexes, but the distal median area (male, 9.99 \u00b1 3.42 mm(2); female, 8.46 \u00b1 1.84 mm(2)) and distal nerve/tunnel index (male, 7.15% \u00b1 2.00%; female, 7.01% \u00b1 1.38%) showed no significant differences. The proximal index was significantly higher than the distal index (proximal, 5.85% \u00b1 1.66%; distal, 7.08% \u00b1 1.71%). The nerve/tunnel index is unaffected by body indices or sex and thus may be a useful and objective standard for diagnosing carpal tunnel syndrome.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "75f0878c248e4bbab73420d14772e958", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[181, 181], [310, 310], [116, 116], [140, 140], [20, 20], [81, 81]], "char_spans": [[1072, 1077], [1582, 1587], [658, 663], [786, 791], [117, 122], [453, 458]]}]}], "context_tokens": [["To", 0], ["define", 3], ["the", 10], ["relationship", 14], ["between", 27], ["body", 35], ["indices", 40], ["of", 48], ["healthy", 51], ["adults", 59], ["and", 66], ["cross", 70], ["-", 75], ["sectional", 76], ["areas", 86], ["of", 92], ["the", 95], ["carpal", 99], ["tunnel", 106], ["and", 113], ["median", 117], ["nerve", 124], ["and", 130], ["to", 134], ["obtain", 137], ["the", 144], ["nerve", 148], ["/", 153], ["tunnel", 154], ["index", 161], [",", 166], ["which", 168], ["represents", 174], ["a", 185], ["new", 187], ["standard", 191], ["for", 200], ["diagnosing", 204], ["carpal", 215], ["tunnel", 222], ["syndrome", 229], ["using", 238], ["sonography", 244], [".", 254], ["Body", 256], ["indices", 261], ["(", 269], ["height", 270], [",", 276], ["weight", 278], [",", 284], ["and", 286], ["body", 290], ["mass", 295], ["index", 300], [")", 305], ["were", 307], ["analyzed", 312], ["in", 321], ["60", 324], ["healthy", 327], ["adults", 335], [",", 341], ["and", 343], ["electromyography", 347], ["and", 364], ["sonography", 368], ["were", 379], ["also", 384], ["performed", 389], [".", 398], ["The", 400], ["cross", 404], ["-", 409], ["sectional", 410], ["areas", 420], ["of", 426], ["the", 429], ["proximal", 433], ["and", 442], ["distal", 446], ["median", 453], ["nerve", 460], ["and", 466], ["carpal", 470], ["tunnel", 477], ["were", 484], ["obtained", 489], ["by", 498], ["sonography", 501], [".", 511], ["The", 513], ["proximal", 517], ["and", 526], ["distal", 530], ["nerve", 537], ["/", 542], ["tunnel", 543], ["indices", 550], ["were", 558], ["obtained", 563], ["by", 572], ["calculating", 575], ["the", 587], ["ratio", 591], ["between", 597], ["the", 605], ["proximal", 609], ["and", 618], ["distal", 622], ["cross", 629], ["-", 634], ["sectional", 635], ["areas", 645], ["of", 651], ["the", 654], ["median", 658], ["nerve", 665], ["to", 671], ["those", 674], ["of", 680], ["the", 683], ["carpal", 687], ["tunnel", 694], ["and", 701], ["multiplying", 705], ["the", 717], ["value", 721], ["by", 727], ["100", 730], [".", 733], ["Although", 735], ["the", 744], ["proximal", 748], ["cross", 757], ["-", 762], ["sectional", 763], ["areas", 773], ["of", 779], ["the", 782], ["median", 786], ["nerve", 793], ["and", 799], ["body", 803], ["indices", 808], ["showed", 816], ["statistically", 823], ["significant", 837], ["relationships", 849], ["with", 863], ["weak", 868], ["positive", 873], ["correlations", 882], [",", 894], ["the", 896], ["proximal", 900], ["and", 909], ["distal", 913], ["areas", 920], ["of", 926], ["the", 929], ["carpal", 933], ["tunnel", 940], ["showed", 947], ["relatively", 954], ["stronger", 965], ["correlations", 974], ["with", 987], ["body", 992], ["indices", 997], [".", 1004], ["Between", 1006], ["sexes", 1014], [",", 1019], ["there", 1021], ["were", 1027], ["significant", 1032], ["differences", 1044], ["in", 1056], ["the", 1059], ["proximal", 1063], ["median", 1072], ["nerve", 1079], ["cross", 1085], ["-", 1090], ["sectional", 1091], ["area", 1101], ["(", 1106], ["mean", 1107], ["\u00b1", 1112], ["SD", 1114], [":", 1116], ["male", 1118], [",", 1122], ["10.48", 1124], ["\u00b1", 1130], ["3.21", 1132], ["mm(2", 1137], [")", 1141], [";", 1142], ["female", 1144], [",", 1150], ["8.81", 1152], ["\u00b1", 1157], ["3.21", 1159], ["mm(2", 1164], [")", 1168], [";", 1169], ["P", 1171], ["<", 1173], [".05", 1175], [")", 1178], ["and", 1180], ["proximal", 1184], ["carpal", 1193], ["tunnel", 1200], ["area", 1207], ["(", 1212], ["male", 1213], [",", 1217], ["182.50", 1219], ["\u00b1", 1226], ["21.15", 1228], ["mm(2", 1234], [")", 1238], [";", 1239], ["female", 1241], [",", 1247], ["151.23", 1249], ["\u00b1", 1256], ["21.14", 1258], ["mm(2", 1264], [")", 1268], [";", 1269], ["P", 1271], ["<", 1273], [".05", 1275], [")", 1278], [".", 1279], ["There", 1281], ["was", 1287], ["no", 1291], ["difference", 1294], ["in", 1305], ["the", 1308], ["proximal", 1312], ["nerve", 1321], ["/", 1326], ["tunnel", 1327], ["index", 1334], ["(", 1340], ["male", 1341], [",", 1345], ["5.80", 1347], ["%", 1351], ["\u00b1", 1353], ["1.72", 1355], ["%", 1359], [";", 1360], ["female", 1362], [",", 1368], ["5.91", 1370], ["%", 1374], ["\u00b1", 1376], ["1.63", 1378], ["%", 1382], [")", 1383], [".", 1384], ["There", 1386], ["was", 1392], ["a", 1396], ["statistically", 1398], ["significant", 1412], ["difference", 1424], ["in", 1435], ["the", 1438], ["distal", 1442], ["carpal", 1449], ["tunnel", 1456], ["cross", 1463], ["-", 1468], ["sectional", 1469], ["area", 1479], ["(", 1484], ["male", 1485], [",", 1489], ["138.90", 1491], ["\u00b1", 1498], ["20.95", 1500], ["mm(2", 1506], [")", 1510], [";", 1511], ["female", 1513], [",", 1519], ["121.50", 1521], ["\u00b1", 1528], ["18.99", 1530], ["mm(2", 1536], [")", 1540], [";", 1541], ["P", 1543], ["<", 1545], [".05", 1547], [")", 1550], ["between", 1552], ["sexes", 1560], [",", 1565], ["but", 1567], ["the", 1571], ["distal", 1575], ["median", 1582], ["area", 1589], ["(", 1594], ["male", 1595], [",", 1599], ["9.99", 1601], ["\u00b1", 1606], ["3.42", 1608], ["mm(2", 1613], [")", 1617], [";", 1618], ["female", 1620], [",", 1626], ["8.46", 1628], ["\u00b1", 1633], ["1.84", 1635], ["mm(2", 1640], [")", 1644], [")", 1645], ["and", 1647], ["distal", 1651], ["nerve", 1658], ["/", 1663], ["tunnel", 1664], ["index", 1671], ["(", 1677], ["male", 1678], [",", 1682], ["7.15", 1684], ["%", 1688], ["\u00b1", 1690], ["2.00", 1692], ["%", 1696], [";", 1697], ["female", 1699], [",", 1705], ["7.01", 1707], ["%", 1711], ["\u00b1", 1713], ["1.38", 1715], ["%", 1719], [")", 1720], ["showed", 1722], ["no", 1729], ["significant", 1732], ["differences", 1744], [".", 1755], ["The", 1757], ["proximal", 1761], ["index", 1770], ["was", 1776], ["significantly", 1780], ["higher", 1794], ["than", 1801], ["the", 1806], ["distal", 1810], ["index", 1817], ["(", 1823], ["proximal", 1824], [",", 1832], ["5.85", 1834], ["%", 1838], ["\u00b1", 1840], ["1.66", 1842], ["%", 1846], [";", 1847], ["distal", 1849], [",", 1855], ["7.08", 1857], ["%", 1861], ["\u00b1", 1863], ["1.71", 1865], ["%", 1869], [")", 1870], [".", 1871], ["The", 1873], ["nerve", 1877], ["/", 1882], ["tunnel", 1883], ["index", 1890], ["is", 1896], ["unaffected", 1899], ["by", 1910], ["body", 1913], ["indices", 1918], ["or", 1926], ["sex", 1929], ["and", 1933], ["thus", 1937], ["may", 1942], ["be", 1946], ["a", 1949], ["useful", 1951], ["and", 1958], ["objective", 1962], ["standard", 1972], ["for", 1981], ["diagnosing", 1985], ["carpal", 1996], ["tunnel", 2003], ["syndrome", 2010], [".", 2018]]}
{"context": "The CRISPR/Cas system in prokaryotes provides resistance against invading viruses and plasmids. Three distinct stages in the mechanism can be recognized. Initially, fragments of invader DNA are integrated as new spacers into the repetitive CRISPR locus. Subsequently, the CRISPR is transcribed and the transcript is cleaved by a Cas protein within the repeats, generating short RNAs (crRNAs) that contain the spacer sequence. Finally, crRNAs guide the Cas protein machinery to a complementary invader target, either DNA or RNA, resulting in inhibition of virus or plasmid proliferation. In this article, we discuss our current understanding of this fascinating adaptive and heritable defense system, and describe functional similarities and differences with RNAi in eukaryotes.", "qas": [{"question": "Gene silencing can be achieved by RNA interference (RNAi) in eukaryotic organisms. What is the name of the analogous process in prokaryotic organisms?", "answers": ["CRISPR-Cas"], "qid": "3b60bd7ce68145749fb65cfe5ee7d2cf", "question_tokens": [["Gene", 0], ["silencing", 5], ["can", 15], ["be", 19], ["achieved", 22], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["in", 58], ["eukaryotic", 61], ["organisms", 72], [".", 81], ["What", 83], ["is", 88], ["the", 91], ["name", 95], ["of", 100], ["the", 103], ["analogous", 107], ["process", 117], ["in", 125], ["prokaryotic", 128], ["organisms", 140], ["?", 149]], "detected_answers": [{"text": "CRISPR-Cas", "token_spans": [[1, 3]], "char_spans": [[4, 13]]}]}], "context_tokens": [["The", 0], ["CRISPR", 4], ["/", 10], ["Cas", 11], ["system", 15], ["in", 22], ["prokaryotes", 25], ["provides", 37], ["resistance", 46], ["against", 57], ["invading", 65], ["viruses", 74], ["and", 82], ["plasmids", 86], [".", 94], ["Three", 96], ["distinct", 102], ["stages", 111], ["in", 118], ["the", 121], ["mechanism", 125], ["can", 135], ["be", 139], ["recognized", 142], [".", 152], ["Initially", 154], [",", 163], ["fragments", 165], ["of", 175], ["invader", 178], ["DNA", 186], ["are", 190], ["integrated", 194], ["as", 205], ["new", 208], ["spacers", 212], ["into", 220], ["the", 225], ["repetitive", 229], ["CRISPR", 240], ["locus", 247], [".", 252], ["Subsequently", 254], [",", 266], ["the", 268], ["CRISPR", 272], ["is", 279], ["transcribed", 282], ["and", 294], ["the", 298], ["transcript", 302], ["is", 313], ["cleaved", 316], ["by", 324], ["a", 327], ["Cas", 329], ["protein", 333], ["within", 341], ["the", 348], ["repeats", 352], [",", 359], ["generating", 361], ["short", 372], ["RNAs", 378], ["(", 383], ["crRNAs", 384], [")", 390], ["that", 392], ["contain", 397], ["the", 405], ["spacer", 409], ["sequence", 416], [".", 424], ["Finally", 426], [",", 433], ["crRNAs", 435], ["guide", 442], ["the", 448], ["Cas", 452], ["protein", 456], ["machinery", 464], ["to", 474], ["a", 477], ["complementary", 479], ["invader", 493], ["target", 501], [",", 507], ["either", 509], ["DNA", 516], ["or", 520], ["RNA", 523], [",", 526], ["resulting", 528], ["in", 538], ["inhibition", 541], ["of", 552], ["virus", 555], ["or", 561], ["plasmid", 564], ["proliferation", 572], [".", 585], ["In", 587], ["this", 590], ["article", 595], [",", 602], ["we", 604], ["discuss", 607], ["our", 615], ["current", 619], ["understanding", 627], ["of", 641], ["this", 644], ["fascinating", 649], ["adaptive", 661], ["and", 670], ["heritable", 674], ["defense", 684], ["system", 692], [",", 698], ["and", 700], ["describe", 704], ["functional", 713], ["similarities", 724], ["and", 737], ["differences", 741], ["with", 753], ["RNAi", 758], ["in", 763], ["eukaryotes", 766], [".", 776]]}
{"context": "Chediak-Higashi syndrome, a rare autosomal recessive disorder, was described over 50 years ago. Patients show hypopigmentation, recurrent infections, mild coagulation defects and varying neurologic problems. Treatment is bone marrow transplant, which is effective in treating the hematologic and immune defects, however the neurologic problems persist. The CHS1/LYST gene was identified over 10 years ago and homologous CHS1/LYST genes are present in all eukaryotes. This review will discuss the advances made in understanding the clinical aspects of the syndrome and the function of CHS1/LYST/Beige. Clinical reports of Chediak-Higashi syndrome have identified mutations throughout the CHS1/LYST gene. The nature of the mutation can be a predictor of the severity of the disease. Over the past decade the CHS1/LYST family of proteins has been analyzed using model organisms, two-hybrid analysis, overexpression phenotypes and dominant negatives. These studies suggest that the CHS1/LYST protein is involved in either vesicle fusion or fission. Although CHS is a rare disease, the Chediak-like family of proteins is providing insight into the regulation of vesicle trafficking. Understanding the basic mechanisms that govern vesicle trafficking will provide essential information regarding how loss of CHS1/LYST affects hematologic, immunologic and neurologic processes.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "8283a8628bfe440b908b5fe0ef0625ea", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3], [101, 104]], "char_spans": [[0, 23], [621, 644]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], [",", 24], ["a", 26], ["rare", 28], ["autosomal", 33], ["recessive", 43], ["disorder", 53], [",", 61], ["was", 63], ["described", 67], ["over", 77], ["50", 82], ["years", 85], ["ago", 91], [".", 94], ["Patients", 96], ["show", 105], ["hypopigmentation", 110], [",", 126], ["recurrent", 128], ["infections", 138], [",", 148], ["mild", 150], ["coagulation", 155], ["defects", 167], ["and", 175], ["varying", 179], ["neurologic", 187], ["problems", 198], [".", 206], ["Treatment", 208], ["is", 218], ["bone", 221], ["marrow", 226], ["transplant", 233], [",", 243], ["which", 245], ["is", 251], ["effective", 254], ["in", 264], ["treating", 267], ["the", 276], ["hematologic", 280], ["and", 292], ["immune", 296], ["defects", 303], [",", 310], ["however", 312], ["the", 320], ["neurologic", 324], ["problems", 335], ["persist", 344], [".", 351], ["The", 353], ["CHS1/LYST", 357], ["gene", 367], ["was", 372], ["identified", 376], ["over", 387], ["10", 392], ["years", 395], ["ago", 401], ["and", 405], ["homologous", 409], ["CHS1/LYST", 420], ["genes", 430], ["are", 436], ["present", 440], ["in", 448], ["all", 451], ["eukaryotes", 455], [".", 465], ["This", 467], ["review", 472], ["will", 479], ["discuss", 484], ["the", 492], ["advances", 496], ["made", 505], ["in", 510], ["understanding", 513], ["the", 527], ["clinical", 531], ["aspects", 540], ["of", 548], ["the", 551], ["syndrome", 555], ["and", 564], ["the", 568], ["function", 572], ["of", 581], ["CHS1/LYST", 584], ["/", 593], ["Beige", 594], [".", 599], ["Clinical", 601], ["reports", 610], ["of", 618], ["Chediak", 621], ["-", 628], ["Higashi", 629], ["syndrome", 637], ["have", 646], ["identified", 651], ["mutations", 662], ["throughout", 672], ["the", 683], ["CHS1/LYST", 687], ["gene", 697], [".", 701], ["The", 703], ["nature", 707], ["of", 714], ["the", 717], ["mutation", 721], ["can", 730], ["be", 734], ["a", 737], ["predictor", 739], ["of", 749], ["the", 752], ["severity", 756], ["of", 765], ["the", 768], ["disease", 772], [".", 779], ["Over", 781], ["the", 786], ["past", 790], ["decade", 795], ["the", 802], ["CHS1/LYST", 806], ["family", 816], ["of", 823], ["proteins", 826], ["has", 835], ["been", 839], ["analyzed", 844], ["using", 853], ["model", 859], ["organisms", 865], [",", 874], ["two", 876], ["-", 879], ["hybrid", 880], ["analysis", 887], [",", 895], ["overexpression", 897], ["phenotypes", 912], ["and", 923], ["dominant", 927], ["negatives", 936], [".", 945], ["These", 947], ["studies", 953], ["suggest", 961], ["that", 969], ["the", 974], ["CHS1/LYST", 978], ["protein", 988], ["is", 996], ["involved", 999], ["in", 1008], ["either", 1011], ["vesicle", 1018], ["fusion", 1026], ["or", 1033], ["fission", 1036], [".", 1043], ["Although", 1045], ["CHS", 1054], ["is", 1058], ["a", 1061], ["rare", 1063], ["disease", 1068], [",", 1075], ["the", 1077], ["Chediak", 1081], ["-", 1088], ["like", 1089], ["family", 1094], ["of", 1101], ["proteins", 1104], ["is", 1113], ["providing", 1116], ["insight", 1126], ["into", 1134], ["the", 1139], ["regulation", 1143], ["of", 1154], ["vesicle", 1157], ["trafficking", 1165], [".", 1176], ["Understanding", 1178], ["the", 1192], ["basic", 1196], ["mechanisms", 1202], ["that", 1213], ["govern", 1218], ["vesicle", 1225], ["trafficking", 1233], ["will", 1245], ["provide", 1250], ["essential", 1258], ["information", 1268], ["regarding", 1280], ["how", 1290], ["loss", 1294], ["of", 1299], ["CHS1/LYST", 1302], ["affects", 1312], ["hematologic", 1320], [",", 1331], ["immunologic", 1333], ["and", 1345], ["neurologic", 1349], ["processes", 1360], [".", 1369]]}
{"context": "The malaria vaccine candidate antigen RTS,S includes parts of the pre-erythrocytic stage circumsporozoite protein fused to the Hepatitis B surface antigen. Two Adjuvant Systems are in development for this vaccine, an oil-in water emulsion--based formulation (AS02) and a formulation based on liposomes (AS01). In this Phase II, double-blind study (NCT00307021), 180 healthy Gabonese children aged 18 months to 4 years were randomized to receive either RTS,S/AS01(E) or RTS,S/AS02(D), on a 0-1-2 month vaccination schedule. The children were followed-up daily for six days after each vaccination and monthly for 14 months. Blood samples were collected at 4 time-points. Both vaccines were well tolerated. Safety parameters were distributed similarly between the two groups. Both vaccines elicited a strong specific immune response after Doses 2 and 3 with a ratio of anti-CS GMT titers (AS02(D)/AS01(E)) of 0.88 (95% CI: 0.68-1.15) post-Dose 3. After Doses 2 and 3 of experimental vaccines, anti-CS and anti-HBs antibody GMTs were higher in children who had been previously vaccinated with at least one dose of hepatitis B vaccine compared to those not previously vaccinated. RTS,S/AS01(E) proved similarly as well tolerated and immunogenic as RTS,S/AS02(D), completing an essential step in the age de-escalation process within the RTS,S clinical development plan. ClinicalTrials.gov. NCT00307021.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "b3cdf347d3884750ab5f93ca7c8f1257", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[1, 1]], "char_spans": [[4, 10]]}]}], "context_tokens": [["The", 0], ["malaria", 4], ["vaccine", 12], ["candidate", 20], ["antigen", 30], ["RTS", 38], [",", 41], ["S", 42], ["includes", 44], ["parts", 53], ["of", 59], ["the", 62], ["pre", 66], ["-", 69], ["erythrocytic", 70], ["stage", 83], ["circumsporozoite", 89], ["protein", 106], ["fused", 114], ["to", 120], ["the", 123], ["Hepatitis", 127], ["B", 137], ["surface", 139], ["antigen", 147], [".", 154], ["Two", 156], ["Adjuvant", 160], ["Systems", 169], ["are", 177], ["in", 181], ["development", 184], ["for", 196], ["this", 200], ["vaccine", 205], [",", 212], ["an", 214], ["oil", 217], ["-", 220], ["in", 221], ["water", 224], ["emulsion", 230], ["--", 238], ["based", 240], ["formulation", 246], ["(", 258], ["AS02", 259], [")", 263], ["and", 265], ["a", 269], ["formulation", 271], ["based", 283], ["on", 289], ["liposomes", 292], ["(", 302], ["AS01", 303], [")", 307], [".", 308], ["In", 310], ["this", 313], ["Phase", 318], ["II", 324], [",", 326], ["double", 328], ["-", 334], ["blind", 335], ["study", 341], ["(", 347], ["NCT00307021", 348], [")", 359], [",", 360], ["180", 362], ["healthy", 366], ["Gabonese", 374], ["children", 383], ["aged", 392], ["18", 397], ["months", 400], ["to", 407], ["4", 410], ["years", 412], ["were", 418], ["randomized", 423], ["to", 434], ["receive", 437], ["either", 445], ["RTS", 452], [",", 455], ["S", 456], ["/", 457], ["AS01(E", 458], [")", 464], ["or", 466], ["RTS", 469], [",", 472], ["S", 473], ["/", 474], ["AS02(D", 475], [")", 481], [",", 482], ["on", 484], ["a", 487], ["0", 489], ["-", 490], ["1", 491], ["-", 492], ["2", 493], ["month", 495], ["vaccination", 501], ["schedule", 513], [".", 521], ["The", 523], ["children", 527], ["were", 536], ["followed", 541], ["-", 549], ["up", 550], ["daily", 553], ["for", 559], ["six", 563], ["days", 567], ["after", 572], ["each", 578], ["vaccination", 583], ["and", 595], ["monthly", 599], ["for", 607], ["14", 611], ["months", 614], [".", 620], ["Blood", 622], ["samples", 628], ["were", 636], ["collected", 641], ["at", 651], ["4", 654], ["time", 656], ["-", 660], ["points", 661], [".", 667], ["Both", 669], ["vaccines", 674], ["were", 683], ["well", 688], ["tolerated", 693], [".", 702], ["Safety", 704], ["parameters", 711], ["were", 722], ["distributed", 727], ["similarly", 739], ["between", 749], ["the", 757], ["two", 761], ["groups", 765], [".", 771], ["Both", 773], ["vaccines", 778], ["elicited", 787], ["a", 796], ["strong", 798], ["specific", 805], ["immune", 814], ["response", 821], ["after", 830], ["Doses", 836], ["2", 842], ["and", 844], ["3", 848], ["with", 850], ["a", 855], ["ratio", 857], ["of", 863], ["anti", 866], ["-", 870], ["CS", 871], ["GMT", 874], ["titers", 878], ["(", 885], ["AS02(D)/AS01(E", 886], [")", 900], [")", 901], ["of", 903], ["0.88", 906], ["(", 911], ["95", 912], ["%", 914], ["CI", 916], [":", 918], ["0.68", 920], ["-", 924], ["1.15", 925], [")", 929], ["post", 931], ["-", 935], ["Dose", 936], ["3", 941], [".", 942], ["After", 944], ["Doses", 950], ["2", 956], ["and", 958], ["3", 962], ["of", 964], ["experimental", 967], ["vaccines", 980], [",", 988], ["anti", 990], ["-", 994], ["CS", 995], ["and", 998], ["anti", 1002], ["-", 1006], ["HBs", 1007], ["antibody", 1011], ["GMTs", 1020], ["were", 1025], ["higher", 1030], ["in", 1037], ["children", 1040], ["who", 1049], ["had", 1053], ["been", 1057], ["previously", 1062], ["vaccinated", 1073], ["with", 1084], ["at", 1089], ["least", 1092], ["one", 1098], ["dose", 1102], ["of", 1107], ["hepatitis", 1110], ["B", 1120], ["vaccine", 1122], ["compared", 1130], ["to", 1139], ["those", 1142], ["not", 1148], ["previously", 1152], ["vaccinated", 1163], [".", 1173], ["RTS", 1175], [",", 1178], ["S", 1179], ["/", 1180], ["AS01(E", 1181], [")", 1187], ["proved", 1189], ["similarly", 1196], ["as", 1206], ["well", 1209], ["tolerated", 1214], ["and", 1224], ["immunogenic", 1228], ["as", 1240], ["RTS", 1243], [",", 1246], ["S", 1247], ["/", 1248], ["AS02(D", 1249], [")", 1255], [",", 1256], ["completing", 1258], ["an", 1269], ["essential", 1272], ["step", 1282], ["in", 1287], ["the", 1290], ["age", 1294], ["de", 1298], ["-", 1300], ["escalation", 1301], ["process", 1312], ["within", 1320], ["the", 1327], ["RTS", 1331], [",", 1334], ["S", 1335], ["clinical", 1337], ["development", 1346], ["plan", 1358], [".", 1362], ["ClinicalTrials.gov", 1364], [".", 1382], ["NCT00307021", 1384], [".", 1395]]}
{"context": "Fibrillar \u03b1-synuclein (AS) is the major component of Lewy bodies, the pathological hallmark of Parkinson's disease. Mouse AS (mAS) aggregates much faster than human AS (hAS), although mAS differs from hAS at only seven positions in its primary sequence. Currently, little is known about the site-specific structural differences between mAS and hAS fibrils. Here, we applied state-of-the-art solid-state nuclear magnetic resonance (ssNMR) methods to structurally characterize mAS fibrils. The assignment strategy employed a set of high-resolution 2D and 3D ssNMR spectra recorded on uniformly [(13)C, (15)N], [1-(13)C]glucose, and [2-(13)C]glucose labeled mAS fibrils. An almost complete resonance assignment (96% of backbone amide (15)N and 93% of all (13)C nuclei) was obtained for residues from Gly41 to Val95, which form the core of mAS fibrils. Six \u03b2-strands were identified to be within the fibril core of mAS based on a secondary chemical shift and NHHC analysis. Intermolecular (13)C:(15)N labeled restraints obtained from mixed 1:1 (13)C/(15)N-labeled mAS fibrils reveal a parallel, in-register supramolecular \u03b2-sheet arrangement. The results were compared in detail to recent structural studies on hAS fibrils and indicate the presence of a structurally conserved motif comprising residues Glu61-Lys80.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "0a1c02809201488c903f97ee1cd9280f", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[1, 3]], "char_spans": [[10, 20]]}]}], "context_tokens": [["Fibrillar", 0], ["\u03b1", 10], ["-", 11], ["synuclein", 12], ["(", 22], ["AS", 23], [")", 25], ["is", 27], ["the", 30], ["major", 34], ["component", 40], ["of", 50], ["Lewy", 53], ["bodies", 58], [",", 64], ["the", 66], ["pathological", 70], ["hallmark", 83], ["of", 92], ["Parkinson", 95], ["'s", 104], ["disease", 107], [".", 114], ["Mouse", 116], ["AS", 122], ["(", 125], ["mAS", 126], [")", 129], ["aggregates", 131], ["much", 142], ["faster", 147], ["than", 154], ["human", 159], ["AS", 165], ["(", 168], ["hAS", 169], [")", 172], [",", 173], ["although", 175], ["mAS", 184], ["differs", 188], ["from", 196], ["hAS", 201], ["at", 205], ["only", 208], ["seven", 213], ["positions", 219], ["in", 229], ["its", 232], ["primary", 236], ["sequence", 244], [".", 252], ["Currently", 254], [",", 263], ["little", 265], ["is", 272], ["known", 275], ["about", 281], ["the", 287], ["site", 291], ["-", 295], ["specific", 296], ["structural", 305], ["differences", 316], ["between", 328], ["mAS", 336], ["and", 340], ["hAS", 344], ["fibrils", 348], [".", 355], ["Here", 357], [",", 361], ["we", 363], ["applied", 366], ["state", 374], ["-", 379], ["of", 380], ["-", 382], ["the", 383], ["-", 386], ["art", 387], ["solid", 391], ["-", 396], ["state", 397], ["nuclear", 403], ["magnetic", 411], ["resonance", 420], ["(", 430], ["ssNMR", 431], [")", 436], ["methods", 438], ["to", 446], ["structurally", 449], ["characterize", 462], ["mAS", 475], ["fibrils", 479], [".", 486], ["The", 488], ["assignment", 492], ["strategy", 503], ["employed", 512], ["a", 521], ["set", 523], ["of", 527], ["high", 530], ["-", 534], ["resolution", 535], ["2D", 546], ["and", 549], ["3D", 553], ["ssNMR", 556], ["spectra", 562], ["recorded", 570], ["on", 579], ["uniformly", 582], ["[", 592], ["(", 593], ["13)C", 594], [",", 598], ["(", 600], ["15)N", 601], ["]", 605], [",", 606], ["[", 608], ["1-(13)C]glucose", 609], [",", 624], ["and", 626], ["[", 630], ["2-(13)C]glucose", 631], ["labeled", 647], ["mAS", 655], ["fibrils", 659], [".", 666], ["An", 668], ["almost", 671], ["complete", 678], ["resonance", 687], ["assignment", 697], ["(", 708], ["96", 709], ["%", 711], ["of", 713], ["backbone", 716], ["amide", 725], ["(", 731], ["15)N", 732], ["and", 737], ["93", 741], ["%", 743], ["of", 745], ["all", 748], ["(", 752], ["13)C", 753], ["nuclei", 758], [")", 764], ["was", 766], ["obtained", 770], ["for", 779], ["residues", 783], ["from", 792], ["Gly41", 797], ["to", 803], ["Val95", 806], [",", 811], ["which", 813], ["form", 819], ["the", 824], ["core", 828], ["of", 833], ["mAS", 836], ["fibrils", 840], [".", 847], ["Six", 849], ["\u03b2", 853], ["-", 854], ["strands", 855], ["were", 863], ["identified", 868], ["to", 879], ["be", 882], ["within", 885], ["the", 892], ["fibril", 896], ["core", 903], ["of", 908], ["mAS", 911], ["based", 915], ["on", 921], ["a", 924], ["secondary", 926], ["chemical", 936], ["shift", 945], ["and", 951], ["NHHC", 955], ["analysis", 960], [".", 968], ["Intermolecular", 970], ["(", 985], ["13)C:(15)N", 986], ["labeled", 997], ["restraints", 1005], ["obtained", 1016], ["from", 1025], ["mixed", 1030], ["1:1", 1036], ["(", 1040], ["13)C/(15)N", 1041], ["-", 1051], ["labeled", 1052], ["mAS", 1060], ["fibrils", 1064], ["reveal", 1072], ["a", 1079], ["parallel", 1081], [",", 1089], ["in", 1091], ["-", 1093], ["register", 1094], ["supramolecular", 1103], ["\u03b2", 1118], ["-", 1119], ["sheet", 1120], ["arrangement", 1126], [".", 1137], ["The", 1139], ["results", 1143], ["were", 1151], ["compared", 1156], ["in", 1165], ["detail", 1168], ["to", 1175], ["recent", 1178], ["structural", 1185], ["studies", 1196], ["on", 1204], ["hAS", 1207], ["fibrils", 1211], ["and", 1219], ["indicate", 1223], ["the", 1232], ["presence", 1236], ["of", 1245], ["a", 1248], ["structurally", 1250], ["conserved", 1263], ["motif", 1273], ["comprising", 1279], ["residues", 1290], ["Glu61-Lys80", 1299], [".", 1310]]}
{"context": "A proteomic study predicted that about one hundred kinds of proteins constitute a basic structure of the centrosome. Most of the core centrosomal proteins contain extensive coiled-coil domains, suggesting that the protein-protein interaction is a critical force for the core centrosome configuration. In the present study, we investigated a novel interaction between CEP135 and C-NAP1, two core centriolar proteins. Depletion of CEP135 caused a premature centrosome splitting. Reduction of the centrosomal C-NAP1 level was accompanied in a specific manner. Ectopic expression of the CEP135 mutant proteins also caused centrosome splitting in association with the reduction of the centrosomal C-NAP1 levels. Based on these results, we propose that CEP135 acts as a platform protein for C-NAP1 at the centriole.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "ed3f5c3a0167499384a5f2031c714e92", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[104, 104], [17, 17], [77, 77], [46, 46]], "char_spans": [[618, 627], [105, 114], [455, 464], [275, 284]]}]}], "context_tokens": [["A", 0], ["proteomic", 2], ["study", 12], ["predicted", 18], ["that", 28], ["about", 33], ["one", 39], ["hundred", 43], ["kinds", 51], ["of", 57], ["proteins", 60], ["constitute", 69], ["a", 80], ["basic", 82], ["structure", 88], ["of", 98], ["the", 101], ["centrosome", 105], [".", 115], ["Most", 117], ["of", 122], ["the", 125], ["core", 129], ["centrosomal", 134], ["proteins", 146], ["contain", 155], ["extensive", 163], ["coiled", 173], ["-", 179], ["coil", 180], ["domains", 185], [",", 192], ["suggesting", 194], ["that", 205], ["the", 210], ["protein", 214], ["-", 221], ["protein", 222], ["interaction", 230], ["is", 242], ["a", 245], ["critical", 247], ["force", 256], ["for", 262], ["the", 266], ["core", 270], ["centrosome", 275], ["configuration", 286], [".", 299], ["In", 301], ["the", 304], ["present", 308], ["study", 316], [",", 321], ["we", 323], ["investigated", 326], ["a", 339], ["novel", 341], ["interaction", 347], ["between", 359], ["CEP135", 367], ["and", 374], ["C", 378], ["-", 379], ["NAP1", 380], [",", 384], ["two", 386], ["core", 390], ["centriolar", 395], ["proteins", 406], [".", 414], ["Depletion", 416], ["of", 426], ["CEP135", 429], ["caused", 436], ["a", 443], ["premature", 445], ["centrosome", 455], ["splitting", 466], [".", 475], ["Reduction", 477], ["of", 487], ["the", 490], ["centrosomal", 494], ["C", 506], ["-", 507], ["NAP1", 508], ["level", 513], ["was", 519], ["accompanied", 523], ["in", 535], ["a", 538], ["specific", 540], ["manner", 549], [".", 555], ["Ectopic", 557], ["expression", 565], ["of", 576], ["the", 579], ["CEP135", 583], ["mutant", 590], ["proteins", 597], ["also", 606], ["caused", 611], ["centrosome", 618], ["splitting", 629], ["in", 639], ["association", 642], ["with", 654], ["the", 659], ["reduction", 663], ["of", 673], ["the", 676], ["centrosomal", 680], ["C", 692], ["-", 693], ["NAP1", 694], ["levels", 699], [".", 705], ["Based", 707], ["on", 713], ["these", 716], ["results", 722], [",", 729], ["we", 731], ["propose", 734], ["that", 742], ["CEP135", 747], ["acts", 754], ["as", 759], ["a", 762], ["platform", 764], ["protein", 773], ["for", 781], ["C", 785], ["-", 786], ["NAP1", 787], ["at", 792], ["the", 795], ["centriole", 799], [".", 808]]}
{"context": "The relevance of the Simpson grading system as a predictor of meningioma progression or recurrence in modern neurosurgical practice has recently been called into question. The aim of our study was to compare the risk of progression/recurrence of tumours that had been treated with different Simpson grade resections in a contemporary population of benign (WHO grade I) meningioma patients. One hundred eighty-three patients with histologically confirmed WHO grade I meningioma were retrospectively analysed. All patients underwent first-time craniotomy as their initial therapy between 2004 and 2012. Univariate analysis was performed using log-rank testing and Kaplan-Meier analysis for progression/recurrence-free survival. Multivariate analysis was performed using Cox proportional hazards regression modelling. The three-year progression/recurrence-free survival rates for patients receiving Simpson grade 1, 2 or 4 resections were 95 %, 87 % and 67 %, respectively. Simpson grade 4 resections progressed/recurred at a significantly greater rate than Simpson grade 1 resections (hazard ratio [HR]\u2009=\u20093.26, P\u2009=\u20090.04), whereas Simpson grade 2 resections did not progress/recur at a significantly greater rate than Simpson grade 1 resections (HR\u2009=\u20091.78, P\u2009=\u20090.29). Subtotal resections progressed/recurred at a significantly greater rate than gross-total resections (HR\u2009=\u20092.47, P\u2009=\u20090.03). Tumours that undergo subtotal resection are at a significantly greater risk of progression/recurrence than tumours that undergo gross-total resection. Gross-total resection should therefore be the aim of surgery. However, given modern access to follow-up imaging and stereotactic radiosurgery, these results should not be used to justify overly 'heroic' tumour resection.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "44e178e35d844cdd95994960d939d4dd", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[11, 11], [77, 77], [62, 62]], "char_spans": [[62, 71], [466, 475], [369, 378]]}]}], "context_tokens": [["The", 0], ["relevance", 4], ["of", 14], ["the", 17], ["Simpson", 21], ["grading", 29], ["system", 37], ["as", 44], ["a", 47], ["predictor", 49], ["of", 59], ["meningioma", 62], ["progression", 73], ["or", 85], ["recurrence", 88], ["in", 99], ["modern", 102], ["neurosurgical", 109], ["practice", 123], ["has", 132], ["recently", 136], ["been", 145], ["called", 150], ["into", 157], ["question", 162], [".", 170], ["The", 172], ["aim", 176], ["of", 180], ["our", 183], ["study", 187], ["was", 193], ["to", 197], ["compare", 200], ["the", 208], ["risk", 212], ["of", 217], ["progression", 220], ["/", 231], ["recurrence", 232], ["of", 243], ["tumours", 246], ["that", 254], ["had", 259], ["been", 263], ["treated", 268], ["with", 276], ["different", 281], ["Simpson", 291], ["grade", 299], ["resections", 305], ["in", 316], ["a", 319], ["contemporary", 321], ["population", 334], ["of", 345], ["benign", 348], ["(", 355], ["WHO", 356], ["grade", 360], ["I", 366], [")", 367], ["meningioma", 369], ["patients", 380], [".", 388], ["One", 390], ["hundred", 394], ["eighty", 402], ["-", 408], ["three", 409], ["patients", 415], ["with", 424], ["histologically", 429], ["confirmed", 444], ["WHO", 454], ["grade", 458], ["I", 464], ["meningioma", 466], ["were", 477], ["retrospectively", 482], ["analysed", 498], [".", 506], ["All", 508], ["patients", 512], ["underwent", 521], ["first", 531], ["-", 536], ["time", 537], ["craniotomy", 542], ["as", 553], ["their", 556], ["initial", 562], ["therapy", 570], ["between", 578], ["2004", 586], ["and", 591], ["2012", 595], [".", 599], ["Univariate", 601], ["analysis", 612], ["was", 621], ["performed", 625], ["using", 635], ["log", 641], ["-", 644], ["rank", 645], ["testing", 650], ["and", 658], ["Kaplan", 662], ["-", 668], ["Meier", 669], ["analysis", 675], ["for", 684], ["progression", 688], ["/", 699], ["recurrence", 700], ["-", 710], ["free", 711], ["survival", 716], [".", 724], ["Multivariate", 726], ["analysis", 739], ["was", 748], ["performed", 752], ["using", 762], ["Cox", 768], ["proportional", 772], ["hazards", 785], ["regression", 793], ["modelling", 804], [".", 813], ["The", 815], ["three", 819], ["-", 824], ["year", 825], ["progression", 830], ["/", 841], ["recurrence", 842], ["-", 852], ["free", 853], ["survival", 858], ["rates", 867], ["for", 873], ["patients", 877], ["receiving", 886], ["Simpson", 896], ["grade", 904], ["1", 910], [",", 911], ["2", 913], ["or", 915], ["4", 918], ["resections", 920], ["were", 931], ["95", 936], ["%", 939], [",", 940], ["87", 942], ["%", 945], ["and", 947], ["67", 951], ["%", 954], [",", 955], ["respectively", 957], [".", 969], ["Simpson", 971], ["grade", 979], ["4", 985], ["resections", 987], ["progressed", 998], ["/", 1008], ["recurred", 1009], ["at", 1018], ["a", 1021], ["significantly", 1023], ["greater", 1037], ["rate", 1045], ["than", 1050], ["Simpson", 1055], ["grade", 1063], ["1", 1069], ["resections", 1071], ["(", 1082], ["hazard", 1083], ["ratio", 1090], ["[", 1096], ["HR", 1097], ["]", 1099], ["=", 1101], ["3.26", 1103], [",", 1107], ["P", 1109], ["=", 1111], ["0.04", 1113], [")", 1117], [",", 1118], ["whereas", 1120], ["Simpson", 1128], ["grade", 1136], ["2", 1142], ["resections", 1144], ["did", 1155], ["not", 1159], ["progress", 1163], ["/", 1171], ["recur", 1172], ["at", 1178], ["a", 1181], ["significantly", 1183], ["greater", 1197], ["rate", 1205], ["than", 1210], ["Simpson", 1215], ["grade", 1223], ["1", 1229], ["resections", 1231], ["(", 1242], ["HR", 1243], ["=", 1246], ["1.78", 1248], [",", 1252], ["P", 1254], ["=", 1256], ["0.29", 1258], [")", 1262], [".", 1263], ["Subtotal", 1265], ["resections", 1274], ["progressed", 1285], ["/", 1295], ["recurred", 1296], ["at", 1305], ["a", 1308], ["significantly", 1310], ["greater", 1324], ["rate", 1332], ["than", 1337], ["gross", 1342], ["-", 1347], ["total", 1348], ["resections", 1354], ["(", 1365], ["HR", 1366], ["=", 1369], ["2.47", 1371], [",", 1375], ["P", 1377], ["=", 1379], ["0.03", 1381], [")", 1385], [".", 1386], ["Tumours", 1388], ["that", 1396], ["undergo", 1401], ["subtotal", 1409], ["resection", 1418], ["are", 1428], ["at", 1432], ["a", 1435], ["significantly", 1437], ["greater", 1451], ["risk", 1459], ["of", 1464], ["progression", 1467], ["/", 1478], ["recurrence", 1479], ["than", 1490], ["tumours", 1495], ["that", 1503], ["undergo", 1508], ["gross", 1516], ["-", 1521], ["total", 1522], ["resection", 1528], [".", 1537], ["Gross", 1539], ["-", 1544], ["total", 1545], ["resection", 1551], ["should", 1561], ["therefore", 1568], ["be", 1578], ["the", 1581], ["aim", 1585], ["of", 1589], ["surgery", 1592], [".", 1599], ["However", 1601], [",", 1608], ["given", 1610], ["modern", 1616], ["access", 1623], ["to", 1630], ["follow", 1633], ["-", 1639], ["up", 1640], ["imaging", 1643], ["and", 1651], ["stereotactic", 1655], ["radiosurgery", 1668], [",", 1680], ["these", 1682], ["results", 1688], ["should", 1696], ["not", 1703], ["be", 1707], ["used", 1710], ["to", 1715], ["justify", 1718], ["overly", 1726], ["'", 1733], ["heroic", 1734], ["'", 1740], ["tumour", 1742], ["resection", 1749], [".", 1758]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by the Philadelphia translocation that fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9. The chimerical Bcr-Abl protein expressed by CML cells has constitutive tyrosine kinase activity, which is essential for the pathogenesis of the disease. Imatinib, an ATP-competitive selective inhibitor of Bcr-Abl, has unprecedented efficacy for the treatment of CML. Most patients with early stage disease achieve durable complete hematological and complete cytogenetic remissions, with minimal toxicity. In contrast, responses are less stable in patients with advanced CML. This review highlights the pathogenesis of CML, its clinical features, and the development of imatinib as a specific molecularly targeted therapy. Aspects of disease monitoring and side effects are covered as well as resistance to imatinib and strategies to overcome resistance, such as alternative signal transduction inhibitors and drug combinations. Perspectives for further development are also discussed.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "d31cc811c4ed4d9a840643c3c97ec8b6", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[30, 32], [63, 65]], "char_spans": [[183, 189], [373, 379]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["the", 51], ["Philadelphia", 55], ["translocation", 68], ["that", 82], ["fuses", 87], ["BCR", 93], ["sequences", 97], ["from", 107], ["chromosome", 112], ["22", 123], ["upstream", 126], ["of", 135], ["the", 138], ["ABL", 142], ["gene", 146], ["on", 151], ["chromosome", 154], ["9", 165], [".", 166], ["The", 168], ["chimerical", 172], ["Bcr", 183], ["-", 186], ["Abl", 187], ["protein", 191], ["expressed", 199], ["by", 209], ["CML", 212], ["cells", 216], ["has", 222], ["constitutive", 226], ["tyrosine", 239], ["kinase", 248], ["activity", 255], [",", 263], ["which", 265], ["is", 271], ["essential", 274], ["for", 284], ["the", 288], ["pathogenesis", 292], ["of", 305], ["the", 308], ["disease", 312], [".", 319], ["Imatinib", 321], [",", 329], ["an", 331], ["ATP", 334], ["-", 337], ["competitive", 338], ["selective", 350], ["inhibitor", 360], ["of", 370], ["Bcr", 373], ["-", 376], ["Abl", 377], [",", 380], ["has", 382], ["unprecedented", 386], ["efficacy", 400], ["for", 409], ["the", 413], ["treatment", 417], ["of", 427], ["CML", 430], [".", 433], ["Most", 435], ["patients", 440], ["with", 449], ["early", 454], ["stage", 460], ["disease", 466], ["achieve", 474], ["durable", 482], ["complete", 490], ["hematological", 499], ["and", 513], ["complete", 517], ["cytogenetic", 526], ["remissions", 538], [",", 548], ["with", 550], ["minimal", 555], ["toxicity", 563], [".", 571], ["In", 573], ["contrast", 576], [",", 584], ["responses", 586], ["are", 596], ["less", 600], ["stable", 605], ["in", 612], ["patients", 615], ["with", 624], ["advanced", 629], ["CML", 638], [".", 641], ["This", 643], ["review", 648], ["highlights", 655], ["the", 666], ["pathogenesis", 670], ["of", 683], ["CML", 686], [",", 689], ["its", 691], ["clinical", 695], ["features", 704], [",", 712], ["and", 714], ["the", 718], ["development", 722], ["of", 734], ["imatinib", 737], ["as", 746], ["a", 749], ["specific", 751], ["molecularly", 760], ["targeted", 772], ["therapy", 781], [".", 788], ["Aspects", 790], ["of", 798], ["disease", 801], ["monitoring", 809], ["and", 820], ["side", 824], ["effects", 829], ["are", 837], ["covered", 841], ["as", 849], ["well", 852], ["as", 857], ["resistance", 860], ["to", 871], ["imatinib", 874], ["and", 883], ["strategies", 887], ["to", 898], ["overcome", 901], ["resistance", 910], [",", 920], ["such", 922], ["as", 927], ["alternative", 930], ["signal", 942], ["transduction", 949], ["inhibitors", 962], ["and", 973], ["drug", 977], ["combinations", 982], [".", 994], ["Perspectives", 996], ["for", 1009], ["further", 1013], ["development", 1021], ["are", 1033], ["also", 1037], ["discussed", 1042], [".", 1051]]}
{"context": "Rapid laboratory methods provide optimal support for active surveillance efforts to screen for methicillin-resistant Staphylococcus aureus (MRSA). Most laboratories struggle to determine the optimal use of resources, considering options to balance cost, speed, and diagnostic accuracy. To assess the performance of common methods, the first comparison of MRSASelect agar (MS) and CHROMagar MRSA (CA), with and without broth enrichment followed by a 24-h subculture to MS, was performed. Results were compared to those of the Xpert MRSA assay. For direct culture methods, the agreement between MS and CA was 98.8%. At 18 h, direct MS identified 93% of all positive samples from direct culture and 84% of those identified by the Xpert MRSA. For Trypticase soy broth-enriched MS culture, incubated overnight and then subcultured for an additional 24 h, the agreement with Xpert MRSA was 96%. The agreement between direct MS and Xpert MRSA was 100% when semiquantitative culture revealed a bacterial density of 2+ or greater; however, discrepancies between culture and Xpert MRSA arose for MRSA bacterial densities of 1+ or less, indicating low density as a common cause of false-negative culture results. Since 1+ or less was established as the most common MRSA carrier state, broth enrichment or PCR may be critical for the identification of all MRSA carriers who may be reservoirs for transmission. In this active-surveillance convenience sample, the use of broth enrichment followed by subculture to MS offered a low-cost but sensitive method for MRSA screening, with performance similar to that of Xpert MRSA PCR.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "3bb7162086024ef8ac8c5df12b9b21a0", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[64, 64], [93, 93], [19, 19], [198, 198], [235, 235], [251, 251], [201, 201], [297, 297], [136, 136], [287, 287], [162, 162], [174, 174]], "char_spans": [[390, 393], [531, 534], [140, 143], [1071, 1074], [1254, 1257], [1344, 1347], [1086, 1089], [1605, 1608], [733, 736], [1547, 1550], [875, 878], [931, 934]]}]}], "context_tokens": [["Rapid", 0], ["laboratory", 6], ["methods", 17], ["provide", 25], ["optimal", 33], ["support", 41], ["for", 49], ["active", 53], ["surveillance", 60], ["efforts", 73], ["to", 81], ["screen", 84], ["for", 91], ["methicillin", 95], ["-", 106], ["resistant", 107], ["Staphylococcus", 117], ["aureus", 132], ["(", 139], ["MRSA", 140], [")", 144], [".", 145], ["Most", 147], ["laboratories", 152], ["struggle", 165], ["to", 174], ["determine", 177], ["the", 187], ["optimal", 191], ["use", 199], ["of", 203], ["resources", 206], [",", 215], ["considering", 217], ["options", 229], ["to", 237], ["balance", 240], ["cost", 248], [",", 252], ["speed", 254], [",", 259], ["and", 261], ["diagnostic", 265], ["accuracy", 276], [".", 284], ["To", 286], ["assess", 289], ["the", 296], ["performance", 300], ["of", 312], ["common", 315], ["methods", 322], [",", 329], ["the", 331], ["first", 335], ["comparison", 341], ["of", 352], ["MRSASelect", 355], ["agar", 366], ["(", 371], ["MS", 372], [")", 374], ["and", 376], ["CHROMagar", 380], ["MRSA", 390], ["(", 395], ["CA", 396], [")", 398], [",", 399], ["with", 401], ["and", 406], ["without", 410], ["broth", 418], ["enrichment", 424], ["followed", 435], ["by", 444], ["a", 447], ["24-h", 449], ["subculture", 454], ["to", 465], ["MS", 468], [",", 470], ["was", 472], ["performed", 476], [".", 485], ["Results", 487], ["were", 495], ["compared", 500], ["to", 509], ["those", 512], ["of", 518], ["the", 521], ["Xpert", 525], ["MRSA", 531], ["assay", 536], [".", 541], ["For", 543], ["direct", 547], ["culture", 554], ["methods", 562], [",", 569], ["the", 571], ["agreement", 575], ["between", 585], ["MS", 593], ["and", 596], ["CA", 600], ["was", 603], ["98.8", 607], ["%", 611], [".", 612], ["At", 614], ["18", 617], ["h", 620], [",", 621], ["direct", 623], ["MS", 630], ["identified", 633], ["93", 644], ["%", 646], ["of", 648], ["all", 651], ["positive", 655], ["samples", 664], ["from", 672], ["direct", 677], ["culture", 684], ["and", 692], ["84", 696], ["%", 698], ["of", 700], ["those", 703], ["identified", 709], ["by", 720], ["the", 723], ["Xpert", 727], ["MRSA", 733], [".", 737], ["For", 739], ["Trypticase", 743], ["soy", 754], ["broth", 758], ["-", 763], ["enriched", 764], ["MS", 773], ["culture", 776], [",", 783], ["incubated", 785], ["overnight", 795], ["and", 805], ["then", 809], ["subcultured", 814], ["for", 826], ["an", 830], ["additional", 833], ["24", 844], ["h", 847], [",", 848], ["the", 850], ["agreement", 854], ["with", 864], ["Xpert", 869], ["MRSA", 875], ["was", 880], ["96", 884], ["%", 886], [".", 887], ["The", 889], ["agreement", 893], ["between", 903], ["direct", 911], ["MS", 918], ["and", 921], ["Xpert", 925], ["MRSA", 931], ["was", 936], ["100", 940], ["%", 943], ["when", 945], ["semiquantitative", 950], ["culture", 967], ["revealed", 975], ["a", 984], ["bacterial", 986], ["density", 996], ["of", 1004], ["2", 1007], ["+", 1008], ["or", 1010], ["greater", 1013], [";", 1020], ["however", 1022], [",", 1029], ["discrepancies", 1031], ["between", 1045], ["culture", 1053], ["and", 1061], ["Xpert", 1065], ["MRSA", 1071], ["arose", 1076], ["for", 1082], ["MRSA", 1086], ["bacterial", 1091], ["densities", 1101], ["of", 1111], ["1", 1114], ["+", 1115], ["or", 1117], ["less", 1120], [",", 1124], ["indicating", 1126], ["low", 1137], ["density", 1141], ["as", 1149], ["a", 1152], ["common", 1154], ["cause", 1161], ["of", 1167], ["false", 1170], ["-", 1175], ["negative", 1176], ["culture", 1185], ["results", 1193], [".", 1200], ["Since", 1202], ["1", 1208], ["+", 1209], ["or", 1211], ["less", 1214], ["was", 1219], ["established", 1223], ["as", 1235], ["the", 1238], ["most", 1242], ["common", 1247], ["MRSA", 1254], ["carrier", 1259], ["state", 1267], [",", 1272], ["broth", 1274], ["enrichment", 1280], ["or", 1291], ["PCR", 1294], ["may", 1298], ["be", 1302], ["critical", 1305], ["for", 1314], ["the", 1318], ["identification", 1322], ["of", 1337], ["all", 1340], ["MRSA", 1344], ["carriers", 1349], ["who", 1358], ["may", 1362], ["be", 1366], ["reservoirs", 1369], ["for", 1380], ["transmission", 1384], [".", 1396], ["In", 1398], ["this", 1401], ["active", 1406], ["-", 1412], ["surveillance", 1413], ["convenience", 1426], ["sample", 1438], [",", 1444], ["the", 1446], ["use", 1450], ["of", 1454], ["broth", 1457], ["enrichment", 1463], ["followed", 1474], ["by", 1483], ["subculture", 1486], ["to", 1497], ["MS", 1500], ["offered", 1503], ["a", 1511], ["low", 1513], ["-", 1516], ["cost", 1517], ["but", 1522], ["sensitive", 1526], ["method", 1536], ["for", 1543], ["MRSA", 1547], ["screening", 1552], [",", 1561], ["with", 1563], ["performance", 1568], ["similar", 1580], ["to", 1588], ["that", 1591], ["of", 1596], ["Xpert", 1599], ["MRSA", 1605], ["PCR", 1610], [".", 1613]]}
{"context": "In yeast, the macromolecular complex Set1/COMPASS is capable of methylating H3K4, a posttranslational modification associated with actively transcribed genes. There is only one Set1 in yeast; yet in mammalian cells there are multiple H3K4 methylases, including Set1A/B, forming human COMPASS complexes, and MLL1-4, forming human COMPASS-like complexes. We have shown that Wdr82, which associates with chromatin in a histone H2B ubiquitination-dependent manner, is a specific component of Set1 complexes but not that of MLL1-4 complexes. RNA interference-mediated knockdown of Wdr82 results in a reduction in the H3K4 trimethylation levels, although these cells still possess active MLL complexes. Comprehensive in vitro enzymatic studies with Set1 and MLL complexes demonstrated that the Set1 complex is a more robust H3K4 trimethylase in vitro than the MLL complexes. Given our in vivo and in vitro observations, it appears that the human Set1 complex plays a more widespread role in H3K4 trimethylation than do the MLL complexes in mammalian cells.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "66e99ba7d17c47c9b3445238952287b4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[37, 37], [173, 173], [11, 11], [142, 142], [110, 110]], "char_spans": [[234, 237], [985, 988], [76, 79], [818, 821], [612, 615]]}]}], "context_tokens": [["In", 0], ["yeast", 3], [",", 8], ["the", 10], ["macromolecular", 14], ["complex", 29], ["Set1/COMPASS", 37], ["is", 50], ["capable", 53], ["of", 61], ["methylating", 64], ["H3K4", 76], [",", 80], ["a", 82], ["posttranslational", 84], ["modification", 102], ["associated", 115], ["with", 126], ["actively", 131], ["transcribed", 140], ["genes", 152], [".", 157], ["There", 159], ["is", 165], ["only", 168], ["one", 173], ["Set1", 177], ["in", 182], ["yeast", 185], [";", 190], ["yet", 192], ["in", 196], ["mammalian", 199], ["cells", 209], ["there", 215], ["are", 221], ["multiple", 225], ["H3K4", 234], ["methylases", 239], [",", 249], ["including", 251], ["Set1A", 261], ["/", 266], ["B", 267], [",", 268], ["forming", 270], ["human", 278], ["COMPASS", 284], ["complexes", 292], [",", 301], ["and", 303], ["MLL1", 307], ["-", 311], ["4", 312], [",", 313], ["forming", 315], ["human", 323], ["COMPASS", 329], ["-", 336], ["like", 337], ["complexes", 342], [".", 351], ["We", 353], ["have", 356], ["shown", 361], ["that", 367], ["Wdr82", 372], [",", 377], ["which", 379], ["associates", 385], ["with", 396], ["chromatin", 401], ["in", 411], ["a", 414], ["histone", 416], ["H2B", 424], ["ubiquitination", 428], ["-", 442], ["dependent", 443], ["manner", 453], [",", 459], ["is", 461], ["a", 464], ["specific", 466], ["component", 475], ["of", 485], ["Set1", 488], ["complexes", 493], ["but", 503], ["not", 507], ["that", 511], ["of", 516], ["MLL1", 519], ["-", 523], ["4", 524], ["complexes", 526], [".", 535], ["RNA", 537], ["interference", 541], ["-", 553], ["mediated", 554], ["knockdown", 563], ["of", 573], ["Wdr82", 576], ["results", 582], ["in", 590], ["a", 593], ["reduction", 595], ["in", 605], ["the", 608], ["H3K4", 612], ["trimethylation", 617], ["levels", 632], [",", 638], ["although", 640], ["these", 649], ["cells", 655], ["still", 661], ["possess", 667], ["active", 675], ["MLL", 682], ["complexes", 686], [".", 695], ["Comprehensive", 697], ["in", 711], ["vitro", 714], ["enzymatic", 720], ["studies", 730], ["with", 738], ["Set1", 743], ["and", 748], ["MLL", 752], ["complexes", 756], ["demonstrated", 766], ["that", 779], ["the", 784], ["Set1", 788], ["complex", 793], ["is", 801], ["a", 804], ["more", 806], ["robust", 811], ["H3K4", 818], ["trimethylase", 823], ["in", 836], ["vitro", 839], ["than", 845], ["the", 850], ["MLL", 854], ["complexes", 858], [".", 867], ["Given", 869], ["our", 875], ["in", 879], ["vivo", 882], ["and", 887], ["in", 891], ["vitro", 894], ["observations", 900], [",", 912], ["it", 914], ["appears", 917], ["that", 925], ["the", 930], ["human", 934], ["Set1", 940], ["complex", 945], ["plays", 953], ["a", 959], ["more", 961], ["widespread", 966], ["role", 977], ["in", 982], ["H3K4", 985], ["trimethylation", 990], ["than", 1005], ["do", 1010], ["the", 1013], ["MLL", 1017], ["complexes", 1021], ["in", 1031], ["mammalian", 1034], ["cells", 1044], [".", 1049]]}
{"context": "Adenosine-to-inosine RNA editing is a highly conserved process that post-transcriptionally modifies mRNA, generating proteomic diversity, particularly within the nervous system of metazoans. Transcripts encoding proteins involved in neurotransmission predominate as targets of such modifications. Previous reports suggest that RNA editing is responsive to environmental inputs in the form of temperature alterations. However, the molecular determinants underlying temperature-dependent RNA editing responses are not well understood. Using the poikilotherm Drosophila, we show that acute temperature alterations within a normal physiological range result in substantial changes in RNA editing levels. Our examination of particular sites reveals diversity in the patterns with which editing responds to temperature, and these patterns are conserved across five species of Drosophilidae representing over 10 million years of divergence. In addition, we show that expression of the editing enzyme, ADAR (adenosine deaminase acting on RNA), is dramatically decreased at elevated temperatures, partially, but not fully, explaining some target responses to temperature. Interestingly, this reduction in editing enzyme levels at elevated temperature is only partially reversed by a return to lower temperatures. Lastly, we show that engineered structural variants of the most temperature-sensitive editing site, in a sodium channel transcript, perturb thermal responsiveness in RNA editing profile for a particular RNA structure. Our results suggest that the RNA editing process responds to temperature alterations via two distinct molecular mechanisms: through intrinsic thermo-sensitivity of the RNA structures that direct editing, and due to temperature sensitive expression or stability of the RNA editing enzyme. Environmental cues, in this case temperature, rapidly reprogram the Drosophila transcriptome through RNA editing, presumably resulting in altered proteomic ratios of edited and unedited proteins.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "9ec37c93f75941a1a648eced56f60b4f", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[151, 151]], "char_spans": [[994, 997]]}]}], "context_tokens": [["Adenosine", 0], ["-", 9], ["to", 10], ["-", 12], ["inosine", 13], ["RNA", 21], ["editing", 25], ["is", 33], ["a", 36], ["highly", 38], ["conserved", 45], ["process", 55], ["that", 63], ["post", 68], ["-", 72], ["transcriptionally", 73], ["modifies", 91], ["mRNA", 100], [",", 104], ["generating", 106], ["proteomic", 117], ["diversity", 127], [",", 136], ["particularly", 138], ["within", 151], ["the", 158], ["nervous", 162], ["system", 170], ["of", 177], ["metazoans", 180], [".", 189], ["Transcripts", 191], ["encoding", 203], ["proteins", 212], ["involved", 221], ["in", 230], ["neurotransmission", 233], ["predominate", 251], ["as", 263], ["targets", 266], ["of", 274], ["such", 277], ["modifications", 282], [".", 295], ["Previous", 297], ["reports", 306], ["suggest", 314], ["that", 322], ["RNA", 327], ["editing", 331], ["is", 339], ["responsive", 342], ["to", 353], ["environmental", 356], ["inputs", 370], ["in", 377], ["the", 380], ["form", 384], ["of", 389], ["temperature", 392], ["alterations", 404], [".", 415], ["However", 417], [",", 424], ["the", 426], ["molecular", 430], ["determinants", 440], ["underlying", 453], ["temperature", 464], ["-", 475], ["dependent", 476], ["RNA", 486], ["editing", 490], ["responses", 498], ["are", 508], ["not", 512], ["well", 516], ["understood", 521], [".", 531], ["Using", 533], ["the", 539], ["poikilotherm", 543], ["Drosophila", 556], [",", 566], ["we", 568], ["show", 571], ["that", 576], ["acute", 581], ["temperature", 587], ["alterations", 599], ["within", 611], ["a", 618], ["normal", 620], ["physiological", 627], ["range", 641], ["result", 647], ["in", 654], ["substantial", 657], ["changes", 669], ["in", 677], ["RNA", 680], ["editing", 684], ["levels", 692], [".", 698], ["Our", 700], ["examination", 704], ["of", 716], ["particular", 719], ["sites", 730], ["reveals", 736], ["diversity", 744], ["in", 754], ["the", 757], ["patterns", 761], ["with", 770], ["which", 775], ["editing", 781], ["responds", 789], ["to", 798], ["temperature", 801], [",", 812], ["and", 814], ["these", 818], ["patterns", 824], ["are", 833], ["conserved", 837], ["across", 847], ["five", 854], ["species", 859], ["of", 867], ["Drosophilidae", 870], ["representing", 884], ["over", 897], ["10", 902], ["million", 905], ["years", 913], ["of", 919], ["divergence", 922], [".", 932], ["In", 934], ["addition", 937], [",", 945], ["we", 947], ["show", 950], ["that", 955], ["expression", 960], ["of", 971], ["the", 974], ["editing", 978], ["enzyme", 986], [",", 992], ["ADAR", 994], ["(", 999], ["adenosine", 1000], ["deaminase", 1010], ["acting", 1020], ["on", 1027], ["RNA", 1030], [")", 1033], [",", 1034], ["is", 1036], ["dramatically", 1039], ["decreased", 1052], ["at", 1062], ["elevated", 1065], ["temperatures", 1074], [",", 1086], ["partially", 1088], [",", 1097], ["but", 1099], ["not", 1103], ["fully", 1107], [",", 1112], ["explaining", 1114], ["some", 1125], ["target", 1130], ["responses", 1137], ["to", 1147], ["temperature", 1150], [".", 1161], ["Interestingly", 1163], [",", 1176], ["this", 1178], ["reduction", 1183], ["in", 1193], ["editing", 1196], ["enzyme", 1204], ["levels", 1211], ["at", 1218], ["elevated", 1221], ["temperature", 1230], ["is", 1242], ["only", 1245], ["partially", 1250], ["reversed", 1260], ["by", 1269], ["a", 1272], ["return", 1274], ["to", 1281], ["lower", 1284], ["temperatures", 1290], [".", 1302], ["Lastly", 1304], [",", 1310], ["we", 1312], ["show", 1315], ["that", 1320], ["engineered", 1325], ["structural", 1336], ["variants", 1347], ["of", 1356], ["the", 1359], ["most", 1363], ["temperature", 1368], ["-", 1379], ["sensitive", 1380], ["editing", 1390], ["site", 1398], [",", 1402], ["in", 1404], ["a", 1407], ["sodium", 1409], ["channel", 1416], ["transcript", 1424], [",", 1434], ["perturb", 1436], ["thermal", 1444], ["responsiveness", 1452], ["in", 1467], ["RNA", 1470], ["editing", 1474], ["profile", 1482], ["for", 1490], ["a", 1494], ["particular", 1496], ["RNA", 1507], ["structure", 1511], [".", 1520], ["Our", 1522], ["results", 1526], ["suggest", 1534], ["that", 1542], ["the", 1547], ["RNA", 1551], ["editing", 1555], ["process", 1563], ["responds", 1571], ["to", 1580], ["temperature", 1583], ["alterations", 1595], ["via", 1607], ["two", 1611], ["distinct", 1615], ["molecular", 1624], ["mechanisms", 1634], [":", 1644], ["through", 1646], ["intrinsic", 1654], ["thermo", 1664], ["-", 1670], ["sensitivity", 1671], ["of", 1683], ["the", 1686], ["RNA", 1690], ["structures", 1694], ["that", 1705], ["direct", 1710], ["editing", 1717], [",", 1724], ["and", 1726], ["due", 1730], ["to", 1734], ["temperature", 1737], ["sensitive", 1749], ["expression", 1759], ["or", 1770], ["stability", 1773], ["of", 1783], ["the", 1786], ["RNA", 1790], ["editing", 1794], ["enzyme", 1802], [".", 1808], ["Environmental", 1810], ["cues", 1824], [",", 1828], ["in", 1830], ["this", 1833], ["case", 1838], ["temperature", 1843], [",", 1854], ["rapidly", 1856], ["reprogram", 1864], ["the", 1874], ["Drosophila", 1878], ["transcriptome", 1889], ["through", 1903], ["RNA", 1911], ["editing", 1915], [",", 1922], ["presumably", 1924], ["resulting", 1935], ["in", 1945], ["altered", 1948], ["proteomic", 1956], ["ratios", 1966], ["of", 1973], ["edited", 1976], ["and", 1983], ["unedited", 1987], ["proteins", 1996], [".", 2004]]}
{"context": "Reactive oxygen species (ROS) production by NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOXA1), and Rac1. Contrary to that of its phagocyte counterpart NOX2, the molecular basis of NOX1 regulation is not clear. Because NOXO1 lacks the phosphorylated region found in its homolog p47(PHOX), the current view is that NOX1 activation occurs without NOXO1 phosphorylation. Here, however, we demonstrate that phorbol myristate acetate (PMA) stimulates NOXO1 phosphorylation in a transfected human embryonic kidney (HEK) 293 epithelial cell model via protein kinase C and identify Ser-154 as the major phosphorylated site. Endogenous NOXO1 from T84 colon epithelial cells was also phosphorylated, suggesting that NOXO1 phosphorylation is physiologically relevant. In transfected HEK-293 cells, PMA-induced phosphorylation on Ser-154 enhanced NOXO1 binding to NOXA1 (+97%) and to the p22(PHOX) C-terminal region (+384%), increased NOXO1 colocalization with p22(PHOX), and allowed optimal ROS production by NOX1 as demonstrated by the use of S154A and S154D mutants compared with that by wild-type NOXO1 (P<0.05). Pulldown experiments revealed that phos-phorylation on Ser-154 was sufficient to markedly enhance NOXO1 binding to NOXA1, which in turn acts as a molecular switch, allowing optimal interaction of NOXO1 with p22(PHOX). This study unexpectedly revealed that full assembly and activation of NOX1 is a tightly regulated process in which NOXO1 phosphorylation on Ser-154 is the initial trigger.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "ce8e78ef06ed459386b6f776879b5c3c", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[8, 10]], "char_spans": [[44, 58]]}, {"text": "NOX1", "token_spans": [[275, 275], [205, 205], [90, 90], [12, 12], [66, 66]], "char_spans": [[1543, 1546], [1148, 1151], [464, 467], [61, 64], [331, 334]]}]}], "context_tokens": [["Reactive", 0], ["oxygen", 9], ["species", 16], ["(", 24], ["ROS", 25], [")", 28], ["production", 30], ["by", 41], ["NADPH", 44], ["oxidase", 50], ["1", 58], ["(", 60], ["NOX1", 61], [")", 65], [",", 66], ["which", 68], ["is", 74], ["mainly", 77], ["expressed", 84], ["in", 94], ["colon", 97], ["epithelial", 103], ["cells", 114], [",", 119], ["requires", 121], ["the", 130], ["membrane", 134], ["-", 142], ["bound", 143], ["component", 149], ["p22(PHOX", 159], [")", 167], ["and", 169], ["the", 173], ["cytosolic", 177], ["partners", 187], ["NOX", 196], ["organizer", 200], ["1", 210], ["(", 212], ["NOXO1", 213], [")", 218], [",", 219], ["NOX", 221], ["activator", 225], ["1", 235], ["(", 237], ["NOXA1", 238], [")", 243], [",", 244], ["and", 246], ["Rac1", 250], [".", 254], ["Contrary", 256], ["to", 265], ["that", 268], ["of", 273], ["its", 276], ["phagocyte", 280], ["counterpart", 290], ["NOX2", 302], [",", 306], ["the", 308], ["molecular", 312], ["basis", 322], ["of", 328], ["NOX1", 331], ["regulation", 336], ["is", 347], ["not", 350], ["clear", 354], [".", 359], ["Because", 361], ["NOXO1", 369], ["lacks", 375], ["the", 381], ["phosphorylated", 385], ["region", 400], ["found", 407], ["in", 413], ["its", 416], ["homolog", 420], ["p47(PHOX", 428], [")", 436], [",", 437], ["the", 439], ["current", 443], ["view", 451], ["is", 456], ["that", 459], ["NOX1", 464], ["activation", 469], ["occurs", 480], ["without", 487], ["NOXO1", 495], ["phosphorylation", 501], [".", 516], ["Here", 518], [",", 522], ["however", 524], [",", 531], ["we", 533], ["demonstrate", 536], ["that", 548], ["phorbol", 553], ["myristate", 561], ["acetate", 571], ["(", 579], ["PMA", 580], [")", 583], ["stimulates", 585], ["NOXO1", 596], ["phosphorylation", 602], ["in", 618], ["a", 621], ["transfected", 623], ["human", 635], ["embryonic", 641], ["kidney", 651], ["(", 658], ["HEK", 659], [")", 662], ["293", 664], ["epithelial", 668], ["cell", 679], ["model", 684], ["via", 690], ["protein", 694], ["kinase", 702], ["C", 709], ["and", 711], ["identify", 715], ["Ser-154", 724], ["as", 732], ["the", 735], ["major", 739], ["phosphorylated", 745], ["site", 760], [".", 764], ["Endogenous", 766], ["NOXO1", 777], ["from", 783], ["T84", 788], ["colon", 792], ["epithelial", 798], ["cells", 809], ["was", 815], ["also", 819], ["phosphorylated", 824], [",", 838], ["suggesting", 840], ["that", 851], ["NOXO1", 856], ["phosphorylation", 862], ["is", 878], ["physiologically", 881], ["relevant", 897], [".", 905], ["In", 907], ["transfected", 910], ["HEK-293", 922], ["cells", 930], [",", 935], ["PMA", 937], ["-", 940], ["induced", 941], ["phosphorylation", 949], ["on", 965], ["Ser-154", 968], ["enhanced", 976], ["NOXO1", 985], ["binding", 991], ["to", 999], ["NOXA1", 1002], ["(", 1008], ["+97", 1009], ["%", 1012], [")", 1013], ["and", 1015], ["to", 1019], ["the", 1022], ["p22(PHOX", 1026], [")", 1034], ["C", 1036], ["-", 1037], ["terminal", 1038], ["region", 1047], ["(", 1054], ["+384", 1055], ["%", 1059], [")", 1060], [",", 1061], ["increased", 1063], ["NOXO1", 1073], ["colocalization", 1079], ["with", 1094], ["p22(PHOX", 1099], [")", 1107], [",", 1108], ["and", 1110], ["allowed", 1114], ["optimal", 1122], ["ROS", 1130], ["production", 1134], ["by", 1145], ["NOX1", 1148], ["as", 1153], ["demonstrated", 1156], ["by", 1169], ["the", 1172], ["use", 1176], ["of", 1180], ["S154A", 1183], ["and", 1189], ["S154D", 1193], ["mutants", 1199], ["compared", 1207], ["with", 1216], ["that", 1221], ["by", 1226], ["wild", 1229], ["-", 1233], ["type", 1234], ["NOXO1", 1239], ["(", 1245], ["P<0.05", 1246], [")", 1252], [".", 1253], ["Pulldown", 1255], ["experiments", 1264], ["revealed", 1276], ["that", 1285], ["phos", 1290], ["-", 1294], ["phorylation", 1295], ["on", 1307], ["Ser-154", 1310], ["was", 1318], ["sufficient", 1322], ["to", 1333], ["markedly", 1336], ["enhance", 1345], ["NOXO1", 1353], ["binding", 1359], ["to", 1367], ["NOXA1", 1370], [",", 1375], ["which", 1377], ["in", 1383], ["turn", 1386], ["acts", 1391], ["as", 1396], ["a", 1399], ["molecular", 1401], ["switch", 1411], [",", 1417], ["allowing", 1419], ["optimal", 1428], ["interaction", 1436], ["of", 1448], ["NOXO1", 1451], ["with", 1457], ["p22(PHOX", 1462], [")", 1470], [".", 1471], ["This", 1473], ["study", 1478], ["unexpectedly", 1484], ["revealed", 1497], ["that", 1506], ["full", 1511], ["assembly", 1516], ["and", 1525], ["activation", 1529], ["of", 1540], ["NOX1", 1543], ["is", 1548], ["a", 1551], ["tightly", 1553], ["regulated", 1561], ["process", 1571], ["in", 1579], ["which", 1582], ["NOXO1", 1588], ["phosphorylation", 1594], ["on", 1610], ["Ser-154", 1613], ["is", 1621], ["the", 1624], ["initial", 1628], ["trigger", 1636], [".", 1643]]}
{"context": "Atg8-family proteins are the best-studied proteins of the core autophagic machinery. They are essential for the elongation and closure of the phagophore into a proper autophagosome. Moreover, Atg8-family proteins are associated with the phagophore from the initiation of the autophagic process to, or just prior to, the fusion between autophagosomes with lysosomes. In addition to their implication in autophagosome biogenesis, they are crucial for selective autophagy through their ability to interact with selective autophagy receptor proteins necessary for the specific targeting of substrates for autophagic degradation. In the past few years it has been revealed that Atg8-interacting proteins include not only receptors but also components of the core autophagic machinery, proteins associated with vesicles and their transport, and specific proteins that are selectively degraded by autophagy. Atg8-interacting proteins contain a short linear LC3-interacting region/LC3 recognition sequence/Atg8-interacting motif (LIR/LRS/AIM) motif which is responsible for their interaction with Atg8-family proteins. These proteins are referred to as LIR-containing proteins (LIRCPs). So far, many experimental efforts have been carried out to identify new LIRCPs, leading to the characterization of some of them in the past 10\u00a0years. Given the need for the identification of LIRCPs in various organisms, we developed the iLIR database ( https://ilir.warwick.ac.uk ) as a freely available web resource, listing all the putative canonical LIRCPs identified in silico in the proteomes of 8 model organisms using the iLIR server, combined with a Gene Ontology (GO) term analysis. Additionally, a curated text-mining analysis of the literature permitted us to identify novel putative LICRPs in mammals that have not previously been associated with autophagy.", "qas": [{"question": "Which web resource for LIR motif-containing proteins in eukaryotes has been developed?", "answers": ["The iLIR database"], "qid": "16c89e69edec4f89b7e12d57432d4b48", "question_tokens": [["Which", 0], ["web", 6], ["resource", 10], ["for", 19], ["LIR", 23], ["motif", 27], ["-", 32], ["containing", 33], ["proteins", 44], ["in", 53], ["eukaryotes", 56], ["has", 67], ["been", 71], ["developed", 76], ["?", 85]], "detected_answers": [{"text": "The iLIR database", "token_spans": [[230, 231]], "char_spans": [[1416, 1428]]}]}], "context_tokens": [["Atg8-family", 0], ["proteins", 12], ["are", 21], ["the", 25], ["best", 29], ["-", 33], ["studied", 34], ["proteins", 42], ["of", 51], ["the", 54], ["core", 58], ["autophagic", 63], ["machinery", 74], [".", 83], ["They", 85], ["are", 90], ["essential", 94], ["for", 104], ["the", 108], ["elongation", 112], ["and", 123], ["closure", 127], ["of", 135], ["the", 138], ["phagophore", 142], ["into", 153], ["a", 158], ["proper", 160], ["autophagosome", 167], [".", 180], ["Moreover", 182], [",", 190], ["Atg8-family", 192], ["proteins", 204], ["are", 213], ["associated", 217], ["with", 228], ["the", 233], ["phagophore", 237], ["from", 248], ["the", 253], ["initiation", 257], ["of", 268], ["the", 271], ["autophagic", 275], ["process", 286], ["to", 294], [",", 296], ["or", 298], ["just", 301], ["prior", 306], ["to", 312], [",", 314], ["the", 316], ["fusion", 320], ["between", 327], ["autophagosomes", 335], ["with", 350], ["lysosomes", 355], [".", 364], ["In", 366], ["addition", 369], ["to", 378], ["their", 381], ["implication", 387], ["in", 399], ["autophagosome", 402], ["biogenesis", 416], [",", 426], ["they", 428], ["are", 433], ["crucial", 437], ["for", 445], ["selective", 449], ["autophagy", 459], ["through", 469], ["their", 477], ["ability", 483], ["to", 491], ["interact", 494], ["with", 503], ["selective", 508], ["autophagy", 518], ["receptor", 528], ["proteins", 537], ["necessary", 546], ["for", 556], ["the", 560], ["specific", 564], ["targeting", 573], ["of", 583], ["substrates", 586], ["for", 597], ["autophagic", 601], ["degradation", 612], [".", 623], ["In", 625], ["the", 628], ["past", 632], ["few", 637], ["years", 641], ["it", 647], ["has", 650], ["been", 654], ["revealed", 659], ["that", 668], ["Atg8-interacting", 673], ["proteins", 690], ["include", 699], ["not", 707], ["only", 711], ["receptors", 716], ["but", 726], ["also", 730], ["components", 735], ["of", 746], ["the", 749], ["core", 753], ["autophagic", 758], ["machinery", 769], [",", 778], ["proteins", 780], ["associated", 789], ["with", 800], ["vesicles", 805], ["and", 814], ["their", 818], ["transport", 824], [",", 833], ["and", 835], ["specific", 839], ["proteins", 848], ["that", 857], ["are", 862], ["selectively", 866], ["degraded", 878], ["by", 887], ["autophagy", 890], [".", 899], ["Atg8-interacting", 901], ["proteins", 918], ["contain", 927], ["a", 935], ["short", 937], ["linear", 943], ["LC3-interacting", 950], ["region", 966], ["/", 972], ["LC3", 973], ["recognition", 977], ["sequence", 989], ["/", 997], ["Atg8-interacting", 998], ["motif", 1015], ["(", 1021], ["LIR", 1022], ["/", 1025], ["LRS", 1026], ["/", 1029], ["AIM", 1030], [")", 1033], ["motif", 1035], ["which", 1041], ["is", 1047], ["responsible", 1050], ["for", 1062], ["their", 1066], ["interaction", 1072], ["with", 1084], ["Atg8-family", 1089], ["proteins", 1101], [".", 1109], ["These", 1111], ["proteins", 1117], ["are", 1126], ["referred", 1130], ["to", 1139], ["as", 1142], ["LIR", 1145], ["-", 1148], ["containing", 1149], ["proteins", 1160], ["(", 1169], ["LIRCPs", 1170], [")", 1176], [".", 1177], ["So", 1179], ["far", 1182], [",", 1185], ["many", 1187], ["experimental", 1192], ["efforts", 1205], ["have", 1213], ["been", 1218], ["carried", 1223], ["out", 1231], ["to", 1235], ["identify", 1238], ["new", 1247], ["LIRCPs", 1251], [",", 1257], ["leading", 1259], ["to", 1267], ["the", 1270], ["characterization", 1274], ["of", 1291], ["some", 1294], ["of", 1299], ["them", 1302], ["in", 1307], ["the", 1310], ["past", 1314], ["10", 1319], ["years", 1322], [".", 1327], ["Given", 1329], ["the", 1335], ["need", 1339], ["for", 1344], ["the", 1348], ["identification", 1352], ["of", 1367], ["LIRCPs", 1370], ["in", 1377], ["various", 1380], ["organisms", 1388], [",", 1397], ["we", 1399], ["developed", 1402], ["the", 1412], ["iLIR", 1416], ["database", 1421], ["(", 1430], ["https://ilir.warwick.ac.uk", 1432], [")", 1459], ["as", 1461], ["a", 1464], ["freely", 1466], ["available", 1473], ["web", 1483], ["resource", 1487], [",", 1495], ["listing", 1497], ["all", 1505], ["the", 1509], ["putative", 1513], ["canonical", 1522], ["LIRCPs", 1532], ["identified", 1539], ["in", 1550], ["silico", 1553], ["in", 1560], ["the", 1563], ["proteomes", 1567], ["of", 1577], ["8", 1580], ["model", 1582], ["organisms", 1588], ["using", 1598], ["the", 1604], ["iLIR", 1608], ["server", 1613], [",", 1619], ["combined", 1621], ["with", 1630], ["a", 1635], ["Gene", 1637], ["Ontology", 1642], ["(", 1651], ["GO", 1652], [")", 1654], ["term", 1656], ["analysis", 1661], [".", 1669], ["Additionally", 1671], [",", 1683], ["a", 1685], ["curated", 1687], ["text", 1695], ["-", 1699], ["mining", 1700], ["analysis", 1707], ["of", 1716], ["the", 1719], ["literature", 1723], ["permitted", 1734], ["us", 1744], ["to", 1747], ["identify", 1750], ["novel", 1759], ["putative", 1765], ["LICRPs", 1774], ["in", 1781], ["mammals", 1784], ["that", 1792], ["have", 1797], ["not", 1802], ["previously", 1806], ["been", 1817], ["associated", 1822], ["with", 1833], ["autophagy", 1838], [".", 1847]]}
{"context": "Two forms of neurofibromatosis, type 1 (NF1) and type 2 (NF2) are connected with genes localized on chromosomes 17 and 22, respectively. The genes that are inactivated in neurofibromatosis code for the proteins neurofibromine and merline, respectively. Since inactivation leads to neoplasia, they are called tumour suppressor genes. Neurofibromine shows resemblances to proteins that serve to inactivate oncogenes. Merline has a relationship with proteins that connect the cytoskeleton and the cell membrane. The precise function of the proteins is still unknown. The NF1 gene is characterized by extraordinarily high sensitivity to mutation; half the NF1 patients have not inherited the disease. In the familial form of neurofibromatosis, a mutated gene is inherited and the normal allele in the tumour is inactivated, making tumour growth possible. In the sporadic form of neurofibromatosis, both normal alleles are inactivated locally in the tissue so that a tumour develops in that place.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "02a0b88b776d4b2d90874b4cebd2bc40", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[8, 8], [96, 96], [109, 109]], "char_spans": [[40, 42], [568, 570], [652, 654]]}]}], "context_tokens": [["Two", 0], ["forms", 4], ["of", 10], ["neurofibromatosis", 13], [",", 30], ["type", 32], ["1", 37], ["(", 39], ["NF1", 40], [")", 43], ["and", 45], ["type", 49], ["2", 54], ["(", 56], ["NF2", 57], [")", 60], ["are", 62], ["connected", 66], ["with", 76], ["genes", 81], ["localized", 87], ["on", 97], ["chromosomes", 100], ["17", 112], ["and", 115], ["22", 119], [",", 121], ["respectively", 123], [".", 135], ["The", 137], ["genes", 141], ["that", 147], ["are", 152], ["inactivated", 156], ["in", 168], ["neurofibromatosis", 171], ["code", 189], ["for", 194], ["the", 198], ["proteins", 202], ["neurofibromine", 211], ["and", 226], ["merline", 230], [",", 237], ["respectively", 239], [".", 251], ["Since", 253], ["inactivation", 259], ["leads", 272], ["to", 278], ["neoplasia", 281], [",", 290], ["they", 292], ["are", 297], ["called", 301], ["tumour", 308], ["suppressor", 315], ["genes", 326], [".", 331], ["Neurofibromine", 333], ["shows", 348], ["resemblances", 354], ["to", 367], ["proteins", 370], ["that", 379], ["serve", 384], ["to", 390], ["inactivate", 393], ["oncogenes", 404], [".", 413], ["Merline", 415], ["has", 423], ["a", 427], ["relationship", 429], ["with", 442], ["proteins", 447], ["that", 456], ["connect", 461], ["the", 469], ["cytoskeleton", 473], ["and", 486], ["the", 490], ["cell", 494], ["membrane", 499], [".", 507], ["The", 509], ["precise", 513], ["function", 521], ["of", 530], ["the", 533], ["proteins", 537], ["is", 546], ["still", 549], ["unknown", 555], [".", 562], ["The", 564], ["NF1", 568], ["gene", 572], ["is", 577], ["characterized", 580], ["by", 594], ["extraordinarily", 597], ["high", 613], ["sensitivity", 618], ["to", 630], ["mutation", 633], [";", 641], ["half", 643], ["the", 648], ["NF1", 652], ["patients", 656], ["have", 665], ["not", 670], ["inherited", 674], ["the", 684], ["disease", 688], [".", 695], ["In", 697], ["the", 700], ["familial", 704], ["form", 713], ["of", 718], ["neurofibromatosis", 721], [",", 738], ["a", 740], ["mutated", 742], ["gene", 750], ["is", 755], ["inherited", 758], ["and", 768], ["the", 772], ["normal", 776], ["allele", 783], ["in", 790], ["the", 793], ["tumour", 797], ["is", 804], ["inactivated", 807], [",", 818], ["making", 820], ["tumour", 827], ["growth", 834], ["possible", 841], [".", 849], ["In", 851], ["the", 854], ["sporadic", 858], ["form", 867], ["of", 872], ["neurofibromatosis", 875], [",", 892], ["both", 894], ["normal", 899], ["alleles", 906], ["are", 914], ["inactivated", 918], ["locally", 930], ["in", 938], ["the", 941], ["tissue", 945], ["so", 952], ["that", 955], ["a", 960], ["tumour", 962], ["develops", 969], ["in", 978], ["that", 981], ["place", 986], [".", 991]]}
{"context": "The murine beige mutant phenotype and the human Chediak-Higashi syndrome are caused by mutations in the murine Lyst (lysosomal trafficking regulator) gene and the human CHS gene, respectively. In this report we have analyzed a novel murine mutant Lyst allele, called Lyst(bg-grey), that had been found in an ENU mutation screen and named grey because of the grey coat color of affected mice. The phenotype caused by the Lyst(bg-grey) mutation was inherited in a recessive fashion. Melanosomes of melanocytes associated with hair follicles and the choroid layer of the eye, as well as melanosomes in the neural tube-derived pigment epithelium of the retina, were larger and irregularly shaped in homozygous mutants compared with those of wild-type controls. Secretory vesicles in dermal mast cells of the mutant skin were enlarged as well. Test crosses with beige homozygous mutant mice (Lyst(bg)) showed that double heterozygotes (Lyst(bg)/Lyst(bg-grey)) were phenotypically indistinguishable from either homozygous parent, demonstrating that the ENU mutation was an allele of the murine Lyst gene. RT-PCR analyses revealed the skipping of exon 25 in Lyst(bg-grey) mutants, which is predicted to cause a missense D2399E mutation and the loss of the following 77 amino acids encoded by exon 25 but leave the C-terminal end of the protein intact. Analysis of the genomic Lyst locus around exon 25 showed that the splice donor at the end of exon 25 showed a T-to-C transition point mutation. Western blot analysis suggests that the Lyst(bg-grey) mutation causes instability of the LYST protein. Because the phenotype of Lyst(bg) and Lyst(bg-grey) mutants is indistinguishable, at least with respect to melanosomes and secretory granules in mast cells, the Lyst(bg-grey) mutation defines a critical region for the stability of the murine LYST protein.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "5f58316e6f574ba2a0272fb6ad55acac", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[8, 11]], "char_spans": [[48, 71]]}]}], "context_tokens": [["The", 0], ["murine", 4], ["beige", 11], ["mutant", 17], ["phenotype", 24], ["and", 34], ["the", 38], ["human", 42], ["Chediak", 48], ["-", 55], ["Higashi", 56], ["syndrome", 64], ["are", 73], ["caused", 77], ["by", 84], ["mutations", 87], ["in", 97], ["the", 100], ["murine", 104], ["Lyst", 111], ["(", 116], ["lysosomal", 117], ["trafficking", 127], ["regulator", 139], [")", 148], ["gene", 150], ["and", 155], ["the", 159], ["human", 163], ["CHS", 169], ["gene", 173], [",", 177], ["respectively", 179], [".", 191], ["In", 193], ["this", 196], ["report", 201], ["we", 208], ["have", 211], ["analyzed", 216], ["a", 225], ["novel", 227], ["murine", 233], ["mutant", 240], ["Lyst", 247], ["allele", 252], [",", 258], ["called", 260], ["Lyst(bg", 267], ["-", 274], ["grey", 275], [")", 279], [",", 280], ["that", 282], ["had", 287], ["been", 291], ["found", 296], ["in", 302], ["an", 305], ["ENU", 308], ["mutation", 312], ["screen", 321], ["and", 328], ["named", 332], ["grey", 338], ["because", 343], ["of", 351], ["the", 354], ["grey", 358], ["coat", 363], ["color", 368], ["of", 374], ["affected", 377], ["mice", 386], [".", 390], ["The", 392], ["phenotype", 396], ["caused", 406], ["by", 413], ["the", 416], ["Lyst(bg", 420], ["-", 427], ["grey", 428], [")", 432], ["mutation", 434], ["was", 443], ["inherited", 447], ["in", 457], ["a", 460], ["recessive", 462], ["fashion", 472], [".", 479], ["Melanosomes", 481], ["of", 493], ["melanocytes", 496], ["associated", 508], ["with", 519], ["hair", 524], ["follicles", 529], ["and", 539], ["the", 543], ["choroid", 547], ["layer", 555], ["of", 561], ["the", 564], ["eye", 568], [",", 571], ["as", 573], ["well", 576], ["as", 581], ["melanosomes", 584], ["in", 596], ["the", 599], ["neural", 603], ["tube", 610], ["-", 614], ["derived", 615], ["pigment", 623], ["epithelium", 631], ["of", 642], ["the", 645], ["retina", 649], [",", 655], ["were", 657], ["larger", 662], ["and", 669], ["irregularly", 673], ["shaped", 685], ["in", 692], ["homozygous", 695], ["mutants", 706], ["compared", 714], ["with", 723], ["those", 728], ["of", 734], ["wild", 737], ["-", 741], ["type", 742], ["controls", 747], [".", 755], ["Secretory", 757], ["vesicles", 767], ["in", 776], ["dermal", 779], ["mast", 786], ["cells", 791], ["of", 797], ["the", 800], ["mutant", 804], ["skin", 811], ["were", 816], ["enlarged", 821], ["as", 830], ["well", 833], [".", 837], ["Test", 839], ["crosses", 844], ["with", 852], ["beige", 857], ["homozygous", 863], ["mutant", 874], ["mice", 881], ["(", 886], ["Lyst(bg", 887], [")", 894], [")", 895], ["showed", 897], ["that", 904], ["double", 909], ["heterozygotes", 916], ["(", 930], ["Lyst(bg)/Lyst(bg", 931], ["-", 947], ["grey", 948], [")", 952], [")", 953], ["were", 955], ["phenotypically", 960], ["indistinguishable", 975], ["from", 993], ["either", 998], ["homozygous", 1005], ["parent", 1016], [",", 1022], ["demonstrating", 1024], ["that", 1038], ["the", 1043], ["ENU", 1047], ["mutation", 1051], ["was", 1060], ["an", 1064], ["allele", 1067], ["of", 1074], ["the", 1077], ["murine", 1081], ["Lyst", 1088], ["gene", 1093], [".", 1097], ["RT", 1099], ["-", 1101], ["PCR", 1102], ["analyses", 1106], ["revealed", 1115], ["the", 1124], ["skipping", 1128], ["of", 1137], ["exon", 1140], ["25", 1145], ["in", 1148], ["Lyst(bg", 1151], ["-", 1158], ["grey", 1159], [")", 1163], ["mutants", 1165], [",", 1172], ["which", 1174], ["is", 1180], ["predicted", 1183], ["to", 1193], ["cause", 1196], ["a", 1202], ["missense", 1204], ["D2399E", 1213], ["mutation", 1220], ["and", 1229], ["the", 1233], ["loss", 1237], ["of", 1242], ["the", 1245], ["following", 1249], ["77", 1259], ["amino", 1262], ["acids", 1268], ["encoded", 1274], ["by", 1282], ["exon", 1285], ["25", 1290], ["but", 1293], ["leave", 1297], ["the", 1303], ["C", 1307], ["-", 1308], ["terminal", 1309], ["end", 1318], ["of", 1322], ["the", 1325], ["protein", 1329], ["intact", 1337], [".", 1343], ["Analysis", 1345], ["of", 1354], ["the", 1357], ["genomic", 1361], ["Lyst", 1369], ["locus", 1374], ["around", 1380], ["exon", 1387], ["25", 1392], ["showed", 1395], ["that", 1402], ["the", 1407], ["splice", 1411], ["donor", 1418], ["at", 1424], ["the", 1427], ["end", 1431], ["of", 1435], ["exon", 1438], ["25", 1443], ["showed", 1446], ["a", 1453], ["T", 1455], ["-", 1456], ["to", 1457], ["-", 1459], ["C", 1460], ["transition", 1462], ["point", 1473], ["mutation", 1479], [".", 1487], ["Western", 1489], ["blot", 1497], ["analysis", 1502], ["suggests", 1511], ["that", 1520], ["the", 1525], ["Lyst(bg", 1529], ["-", 1536], ["grey", 1537], [")", 1541], ["mutation", 1543], ["causes", 1552], ["instability", 1559], ["of", 1571], ["the", 1574], ["LYST", 1578], ["protein", 1583], [".", 1590], ["Because", 1592], ["the", 1600], ["phenotype", 1604], ["of", 1614], ["Lyst(bg", 1617], [")", 1624], ["and", 1626], ["Lyst(bg", 1630], ["-", 1637], ["grey", 1638], [")", 1642], ["mutants", 1644], ["is", 1652], ["indistinguishable", 1655], [",", 1672], ["at", 1674], ["least", 1677], ["with", 1683], ["respect", 1688], ["to", 1696], ["melanosomes", 1699], ["and", 1711], ["secretory", 1715], ["granules", 1725], ["in", 1734], ["mast", 1737], ["cells", 1742], [",", 1747], ["the", 1749], ["Lyst(bg", 1753], ["-", 1760], ["grey", 1761], [")", 1765], ["mutation", 1767], ["defines", 1776], ["a", 1784], ["critical", 1786], ["region", 1795], ["for", 1802], ["the", 1806], ["stability", 1810], ["of", 1820], ["the", 1823], ["murine", 1827], ["LYST", 1834], ["protein", 1839], [".", 1846]]}
{"context": "Ehlers-Danlos syndrome is a heterogeneous group of heritable connective tissue disorders characterized by increased fragility of various non-ossified tissues. It is usually ascertained due to abnormal skin texture, scarring complications, vascular fragility, or chronic symptoms, such as fatigue and musculoskeletal pain. Sometimes, Ehlers-Danlos syndrome remains undetected until the patient, usually in the pediatric age, shows extensive or severe mucocutaneous injuries after only minor traumas. In this scenario, the misdiagnosis of Ehlers-Danlos syndrome with child abuse is a possibility, as occasionally reported in the literature. Recently, more attention was posed by lay people between the possible association of Ehlers-Danlos syndrome and bone fragility. Literature and personal experience show a strong association between Ehlers-Danlos syndrome, generalized joint hypermobility and reduced bone mass density in older children and adults, especially fertile women. The existence of a true increased risk of fracture in Ehlers-Danlos syndrome is still a matter of debate in children and adults with little and conflicting evidence. In case of suspected child abuse, Ehlers-Danlos syndrome is certainly on the differential for bruising, especially in EDS types with marked cutaneous and capillary involvement. In suspected child abuse cases, careful examination of the index case and her/his extended family is routine, as well as exclusion of other disorders such as osteogenesis imperfecta. The hypothesis of Ehlers-Danlos syndrome as an alternative explanation for infantile fractures remains speculative.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "ea17a6333c81457d803d594917b8f0b9", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[10, 11]], "char_spans": [[61, 77]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["a", 26], ["heterogeneous", 28], ["group", 42], ["of", 48], ["heritable", 51], ["connective", 61], ["tissue", 72], ["disorders", 79], ["characterized", 89], ["by", 103], ["increased", 106], ["fragility", 116], ["of", 126], ["various", 129], ["non", 137], ["-", 140], ["ossified", 141], ["tissues", 150], [".", 157], ["It", 159], ["is", 162], ["usually", 165], ["ascertained", 173], ["due", 185], ["to", 189], ["abnormal", 192], ["skin", 201], ["texture", 206], [",", 213], ["scarring", 215], ["complications", 224], [",", 237], ["vascular", 239], ["fragility", 248], [",", 257], ["or", 259], ["chronic", 262], ["symptoms", 270], [",", 278], ["such", 280], ["as", 285], ["fatigue", 288], ["and", 296], ["musculoskeletal", 300], ["pain", 316], [".", 320], ["Sometimes", 322], [",", 331], ["Ehlers", 333], ["-", 339], ["Danlos", 340], ["syndrome", 347], ["remains", 356], ["undetected", 364], ["until", 375], ["the", 381], ["patient", 385], [",", 392], ["usually", 394], ["in", 402], ["the", 405], ["pediatric", 409], ["age", 419], [",", 422], ["shows", 424], ["extensive", 430], ["or", 440], ["severe", 443], ["mucocutaneous", 450], ["injuries", 464], ["after", 473], ["only", 479], ["minor", 484], ["traumas", 490], [".", 497], ["In", 499], ["this", 502], ["scenario", 507], [",", 515], ["the", 517], ["misdiagnosis", 521], ["of", 534], ["Ehlers", 537], ["-", 543], ["Danlos", 544], ["syndrome", 551], ["with", 560], ["child", 565], ["abuse", 571], ["is", 577], ["a", 580], ["possibility", 582], [",", 593], ["as", 595], ["occasionally", 598], ["reported", 611], ["in", 620], ["the", 623], ["literature", 627], [".", 637], ["Recently", 639], [",", 647], ["more", 649], ["attention", 654], ["was", 664], ["posed", 668], ["by", 674], ["lay", 677], ["people", 681], ["between", 688], ["the", 696], ["possible", 700], ["association", 709], ["of", 721], ["Ehlers", 724], ["-", 730], ["Danlos", 731], ["syndrome", 738], ["and", 747], ["bone", 751], ["fragility", 756], [".", 765], ["Literature", 767], ["and", 778], ["personal", 782], ["experience", 791], ["show", 802], ["a", 807], ["strong", 809], ["association", 816], ["between", 828], ["Ehlers", 836], ["-", 842], ["Danlos", 843], ["syndrome", 850], [",", 858], ["generalized", 860], ["joint", 872], ["hypermobility", 878], ["and", 892], ["reduced", 896], ["bone", 904], ["mass", 909], ["density", 914], ["in", 922], ["older", 925], ["children", 931], ["and", 940], ["adults", 944], [",", 950], ["especially", 952], ["fertile", 963], ["women", 971], [".", 976], ["The", 978], ["existence", 982], ["of", 992], ["a", 995], ["true", 997], ["increased", 1002], ["risk", 1012], ["of", 1017], ["fracture", 1020], ["in", 1029], ["Ehlers", 1032], ["-", 1038], ["Danlos", 1039], ["syndrome", 1046], ["is", 1055], ["still", 1058], ["a", 1064], ["matter", 1066], ["of", 1073], ["debate", 1076], ["in", 1083], ["children", 1086], ["and", 1095], ["adults", 1099], ["with", 1106], ["little", 1111], ["and", 1118], ["conflicting", 1122], ["evidence", 1134], [".", 1142], ["In", 1144], ["case", 1147], ["of", 1152], ["suspected", 1155], ["child", 1165], ["abuse", 1171], [",", 1176], ["Ehlers", 1178], ["-", 1184], ["Danlos", 1185], ["syndrome", 1192], ["is", 1201], ["certainly", 1204], ["on", 1214], ["the", 1217], ["differential", 1221], ["for", 1234], ["bruising", 1238], [",", 1246], ["especially", 1248], ["in", 1259], ["EDS", 1262], ["types", 1266], ["with", 1272], ["marked", 1277], ["cutaneous", 1284], ["and", 1294], ["capillary", 1298], ["involvement", 1308], [".", 1319], ["In", 1321], ["suspected", 1324], ["child", 1334], ["abuse", 1340], ["cases", 1346], [",", 1351], ["careful", 1353], ["examination", 1361], ["of", 1373], ["the", 1376], ["index", 1380], ["case", 1386], ["and", 1391], ["her", 1395], ["/", 1398], ["his", 1399], ["extended", 1403], ["family", 1412], ["is", 1419], ["routine", 1422], [",", 1429], ["as", 1431], ["well", 1434], ["as", 1439], ["exclusion", 1442], ["of", 1452], ["other", 1455], ["disorders", 1461], ["such", 1471], ["as", 1476], ["osteogenesis", 1479], ["imperfecta", 1492], [".", 1502], ["The", 1504], ["hypothesis", 1508], ["of", 1519], ["Ehlers", 1522], ["-", 1528], ["Danlos", 1529], ["syndrome", 1536], ["as", 1545], ["an", 1548], ["alternative", 1551], ["explanation", 1563], ["for", 1575], ["infantile", 1579], ["fractures", 1589], ["remains", 1599], ["speculative", 1607], [".", 1618]]}
{"context": "Fostamatinib (R788) is a prodrug rapidly converted to its active metabolite on oral administration. This (known as R406) is a potent inhibitor of spleen tyrosine kinase, required for the expression of a number of proinflammatory cytokines. Fostamatinib has shown significantly superior efficacy (when compared with placebo) in the control of patients with rheumatoid arthritis not responding to methotrexate in Phase II clinical trials. Treatment emergent adverse events with a higher frequency than in those on placebo included diarrhea, hypertension, urinary tract infections, neutropenia and elevated transaminases. The studied doses have shown a linear pharmacokinetic pattern and the administration of methotrexate does not affect it. Fostamatinib may have a role in the therapy of patients with rheumatoid arthritis with poor response to conventional therapy. If these results are confirmed once Phase III studies are completed, it may find a place in the evolving treatment algorithm for rheumatoid arthritis.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "7c88f7862dc74ae8bded750a958b2e65", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[28, 30]], "char_spans": [[146, 167]]}]}], "context_tokens": [["Fostamatinib", 0], ["(", 13], ["R788", 14], [")", 18], ["is", 20], ["a", 23], ["prodrug", 25], ["rapidly", 33], ["converted", 41], ["to", 51], ["its", 54], ["active", 58], ["metabolite", 65], ["on", 76], ["oral", 79], ["administration", 84], [".", 98], ["This", 100], ["(", 105], ["known", 106], ["as", 112], ["R406", 115], [")", 119], ["is", 121], ["a", 124], ["potent", 126], ["inhibitor", 133], ["of", 143], ["spleen", 146], ["tyrosine", 153], ["kinase", 162], [",", 168], ["required", 170], ["for", 179], ["the", 183], ["expression", 187], ["of", 198], ["a", 201], ["number", 203], ["of", 210], ["proinflammatory", 213], ["cytokines", 229], [".", 238], ["Fostamatinib", 240], ["has", 253], ["shown", 257], ["significantly", 263], ["superior", 277], ["efficacy", 286], ["(", 295], ["when", 296], ["compared", 301], ["with", 310], ["placebo", 315], [")", 322], ["in", 324], ["the", 327], ["control", 331], ["of", 339], ["patients", 342], ["with", 351], ["rheumatoid", 356], ["arthritis", 367], ["not", 377], ["responding", 381], ["to", 392], ["methotrexate", 395], ["in", 408], ["Phase", 411], ["II", 417], ["clinical", 420], ["trials", 429], [".", 435], ["Treatment", 437], ["emergent", 447], ["adverse", 456], ["events", 464], ["with", 471], ["a", 476], ["higher", 478], ["frequency", 485], ["than", 495], ["in", 500], ["those", 503], ["on", 509], ["placebo", 512], ["included", 520], ["diarrhea", 529], [",", 537], ["hypertension", 539], [",", 551], ["urinary", 553], ["tract", 561], ["infections", 567], [",", 577], ["neutropenia", 579], ["and", 591], ["elevated", 595], ["transaminases", 604], [".", 617], ["The", 619], ["studied", 623], ["doses", 631], ["have", 637], ["shown", 642], ["a", 648], ["linear", 650], ["pharmacokinetic", 657], ["pattern", 673], ["and", 681], ["the", 685], ["administration", 689], ["of", 704], ["methotrexate", 707], ["does", 720], ["not", 725], ["affect", 729], ["it", 736], [".", 738], ["Fostamatinib", 740], ["may", 753], ["have", 757], ["a", 762], ["role", 764], ["in", 769], ["the", 772], ["therapy", 776], ["of", 784], ["patients", 787], ["with", 796], ["rheumatoid", 801], ["arthritis", 812], ["with", 822], ["poor", 827], ["response", 832], ["to", 841], ["conventional", 844], ["therapy", 857], [".", 864], ["If", 866], ["these", 869], ["results", 875], ["are", 883], ["confirmed", 887], ["once", 897], ["Phase", 902], ["III", 908], ["studies", 912], ["are", 920], ["completed", 924], [",", 933], ["it", 935], ["may", 938], ["find", 942], ["a", 947], ["place", 949], ["in", 955], ["the", 958], ["evolving", 962], ["treatment", 971], ["algorithm", 981], ["for", 991], ["rheumatoid", 995], ["arthritis", 1006], [".", 1015]]}
{"context": "The origin of brain tumors has attracted much controversy. Recent advances in neural stem cell biology coupled with the new concepts of central nervous system development have raised interesting possibilities regarding the oncogenic properties of neural stem/progenitor cells. To elucidate these putative properties further, the clinical materials from an infant brain tumor were analyzed, focusing on the relation with the neural stem/progenitor cells. The expression of neural stem/progenitor cell markers in the tumor cells and the cellular components of the infant brain tumor were examined using immunohistochemistry. The tumor cell biology was analyzed both in culture and in the grafted brain environment. Three main bodies of evidence were demonstrated indicating that the tumor was of possible subventricular zone postnatal or adult normal neural stem cell origin. First, in the tumor specimen we demonstrated the strong positive expression of the neural stem/progenitor cell markers, nestin and Musashi-1. Second, immunohistochemistry revealed the presence of neuronal, astrocytic, and immature precursor cells in the tumor tissue, similar to the cellular components of the subventricular zone, thereby pointing to the subventricular zone as the possible origin of the tumor. The subventricular zone also is one of the strong candidates for the location of postnatal/adult neural stem cells. This cellular evidence was strengthened further by the clinicoradiological findings that demonstrated the involvement of the subventricular zone of the lateral ventricle by the tumor. Third, in the in vitro and in vivo experiments, a dynamic shift in expression patterns between neural stem cells (nestin, Musashi-1) and differentiated cells (glial fibrillary acidic protein, neuron-specific Class III beta-tubulin) markers was seen, similar to the proposed behavior of postnatal/adult neural stem cells in situ. These findings suggest that this brain tumor originated from neural stem cells located in the subventricular zone, and the further possibility of the general oncogenic potential of neural stem cells.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "71a8f4bdfee54f928c7a8b69ef3ca448", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[161, 161], [278, 278]], "char_spans": [[994, 999], [1700, 1705]]}]}], "context_tokens": [["The", 0], ["origin", 4], ["of", 11], ["brain", 14], ["tumors", 20], ["has", 27], ["attracted", 31], ["much", 41], ["controversy", 46], [".", 57], ["Recent", 59], ["advances", 66], ["in", 75], ["neural", 78], ["stem", 85], ["cell", 90], ["biology", 95], ["coupled", 103], ["with", 111], ["the", 116], ["new", 120], ["concepts", 124], ["of", 133], ["central", 136], ["nervous", 144], ["system", 152], ["development", 159], ["have", 171], ["raised", 176], ["interesting", 183], ["possibilities", 195], ["regarding", 209], ["the", 219], ["oncogenic", 223], ["properties", 233], ["of", 244], ["neural", 247], ["stem", 254], ["/", 258], ["progenitor", 259], ["cells", 270], [".", 275], ["To", 277], ["elucidate", 280], ["these", 290], ["putative", 296], ["properties", 305], ["further", 316], [",", 323], ["the", 325], ["clinical", 329], ["materials", 338], ["from", 348], ["an", 353], ["infant", 356], ["brain", 363], ["tumor", 369], ["were", 375], ["analyzed", 380], [",", 388], ["focusing", 390], ["on", 399], ["the", 402], ["relation", 406], ["with", 415], ["the", 420], ["neural", 424], ["stem", 431], ["/", 435], ["progenitor", 436], ["cells", 447], [".", 452], ["The", 454], ["expression", 458], ["of", 469], ["neural", 472], ["stem", 479], ["/", 483], ["progenitor", 484], ["cell", 495], ["markers", 500], ["in", 508], ["the", 511], ["tumor", 515], ["cells", 521], ["and", 527], ["the", 531], ["cellular", 535], ["components", 544], ["of", 555], ["the", 558], ["infant", 562], ["brain", 569], ["tumor", 575], ["were", 581], ["examined", 586], ["using", 595], ["immunohistochemistry", 601], [".", 621], ["The", 623], ["tumor", 627], ["cell", 633], ["biology", 638], ["was", 646], ["analyzed", 650], ["both", 659], ["in", 664], ["culture", 667], ["and", 675], ["in", 679], ["the", 682], ["grafted", 686], ["brain", 694], ["environment", 700], [".", 711], ["Three", 713], ["main", 719], ["bodies", 724], ["of", 731], ["evidence", 734], ["were", 743], ["demonstrated", 748], ["indicating", 761], ["that", 772], ["the", 777], ["tumor", 781], ["was", 787], ["of", 791], ["possible", 794], ["subventricular", 803], ["zone", 818], ["postnatal", 823], ["or", 833], ["adult", 836], ["normal", 842], ["neural", 849], ["stem", 856], ["cell", 861], ["origin", 866], [".", 872], ["First", 874], [",", 879], ["in", 881], ["the", 884], ["tumor", 888], ["specimen", 894], ["we", 903], ["demonstrated", 906], ["the", 919], ["strong", 923], ["positive", 930], ["expression", 939], ["of", 950], ["the", 953], ["neural", 957], ["stem", 964], ["/", 968], ["progenitor", 969], ["cell", 980], ["markers", 985], [",", 992], ["nestin", 994], ["and", 1001], ["Musashi-1", 1005], [".", 1014], ["Second", 1016], [",", 1022], ["immunohistochemistry", 1024], ["revealed", 1045], ["the", 1054], ["presence", 1058], ["of", 1067], ["neuronal", 1070], [",", 1078], ["astrocytic", 1080], [",", 1090], ["and", 1092], ["immature", 1096], ["precursor", 1105], ["cells", 1115], ["in", 1121], ["the", 1124], ["tumor", 1128], ["tissue", 1134], [",", 1140], ["similar", 1142], ["to", 1150], ["the", 1153], ["cellular", 1157], ["components", 1166], ["of", 1177], ["the", 1180], ["subventricular", 1184], ["zone", 1199], [",", 1203], ["thereby", 1205], ["pointing", 1213], ["to", 1222], ["the", 1225], ["subventricular", 1229], ["zone", 1244], ["as", 1249], ["the", 1252], ["possible", 1256], ["origin", 1265], ["of", 1272], ["the", 1275], ["tumor", 1279], [".", 1284], ["The", 1286], ["subventricular", 1290], ["zone", 1305], ["also", 1310], ["is", 1315], ["one", 1318], ["of", 1322], ["the", 1325], ["strong", 1329], ["candidates", 1336], ["for", 1347], ["the", 1351], ["location", 1355], ["of", 1364], ["postnatal", 1367], ["/", 1376], ["adult", 1377], ["neural", 1383], ["stem", 1390], ["cells", 1395], [".", 1400], ["This", 1402], ["cellular", 1407], ["evidence", 1416], ["was", 1425], ["strengthened", 1429], ["further", 1442], ["by", 1450], ["the", 1453], ["clinicoradiological", 1457], ["findings", 1477], ["that", 1486], ["demonstrated", 1491], ["the", 1504], ["involvement", 1508], ["of", 1520], ["the", 1523], ["subventricular", 1527], ["zone", 1542], ["of", 1547], ["the", 1550], ["lateral", 1554], ["ventricle", 1562], ["by", 1572], ["the", 1575], ["tumor", 1579], [".", 1584], ["Third", 1586], [",", 1591], ["in", 1593], ["the", 1596], ["in", 1600], ["vitro", 1603], ["and", 1609], ["in", 1613], ["vivo", 1616], ["experiments", 1621], [",", 1632], ["a", 1634], ["dynamic", 1636], ["shift", 1644], ["in", 1650], ["expression", 1653], ["patterns", 1664], ["between", 1673], ["neural", 1681], ["stem", 1688], ["cells", 1693], ["(", 1699], ["nestin", 1700], [",", 1706], ["Musashi-1", 1708], [")", 1717], ["and", 1719], ["differentiated", 1723], ["cells", 1738], ["(", 1744], ["glial", 1745], ["fibrillary", 1751], ["acidic", 1762], ["protein", 1769], [",", 1776], ["neuron", 1778], ["-", 1784], ["specific", 1785], ["Class", 1794], ["III", 1800], ["beta", 1804], ["-", 1808], ["tubulin", 1809], [")", 1816], ["markers", 1818], ["was", 1826], ["seen", 1830], [",", 1834], ["similar", 1836], ["to", 1844], ["the", 1847], ["proposed", 1851], ["behavior", 1860], ["of", 1869], ["postnatal", 1872], ["/", 1881], ["adult", 1882], ["neural", 1888], ["stem", 1895], ["cells", 1900], ["in", 1906], ["situ", 1909], [".", 1913], ["These", 1915], ["findings", 1921], ["suggest", 1930], ["that", 1938], ["this", 1943], ["brain", 1948], ["tumor", 1954], ["originated", 1960], ["from", 1971], ["neural", 1976], ["stem", 1983], ["cells", 1988], ["located", 1994], ["in", 2002], ["the", 2005], ["subventricular", 2009], ["zone", 2024], [",", 2028], ["and", 2030], ["the", 2034], ["further", 2038], ["possibility", 2046], ["of", 2058], ["the", 2061], ["general", 2065], ["oncogenic", 2073], ["potential", 2083], ["of", 2093], ["neural", 2096], ["stem", 2103], ["cells", 2108], [".", 2113]]}
{"context": "Mutations in the human FOXP2 gene cause speech and language impairments. The FOXP2 protein is a transcription factor that regulates the expression of many downstream genes, which may have important roles in nervous system development and function. An adequate amount of functional FOXP2 protein is thought to be critical for the proper development of the neural circuitry underlying speech and language. However, how FOXP2 gene expression is regulated is not clearly understood. The FOXP2 mRNA has an approximately 4-kb-long 3' untranslated region (3' UTR), twice as long as its protein coding region, indicating that FOXP2 can be regulated by microRNAs (miRNAs). We identified multiple miRNAs that regulate the expression of the human FOXP2 gene using sequence analysis and in vitro cell systems. Focusing on let-7a, miR-9, and miR-129-5p, three brain-enriched miRNAs, we show that these miRNAs regulate human FOXP2 expression in a dosage-dependent manner and target specific sequences in the FOXP2 3' UTR. We further show that these three miRNAs are expressed in the cerebellum of the human fetal brain, where FOXP2 is known to be expressed. Our results reveal novel regulatory functions of the human FOXP2 3' UTR sequence and regulatory interactions between multiple miRNAs and the human FOXP2 gene. The expression of let-7a, miR-9, and miR-129-5p in the human fetal cerebellum is consistent with their roles in regulating FOXP2 expression during early cerebellum development. These results suggest that various genetic and environmental factors may contribute to speech and language development and related neural developmental disorders via the miRNA-FOXP2 regulatory network.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "e6f7d1e34eb24319b5b80ce914ab3c03", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[129, 129], [45, 45], [13, 13], [202, 202], [218, 218], [258, 258], [68, 68], [4, 4], [108, 108], [164, 164], [290, 290], [232, 232], [178, 178], [79, 79]], "char_spans": [[736, 740], [281, 285], [77, 81], [1112, 1116], [1203, 1207], [1426, 1430], [417, 421], [23, 27], [618, 622], [911, 915], [1656, 1660], [1291, 1295], [994, 998], [483, 487]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["human", 17], ["FOXP2", 23], ["gene", 29], ["cause", 34], ["speech", 40], ["and", 47], ["language", 51], ["impairments", 60], [".", 71], ["The", 73], ["FOXP2", 77], ["protein", 83], ["is", 91], ["a", 94], ["transcription", 96], ["factor", 110], ["that", 117], ["regulates", 122], ["the", 132], ["expression", 136], ["of", 147], ["many", 150], ["downstream", 155], ["genes", 166], [",", 171], ["which", 173], ["may", 179], ["have", 183], ["important", 188], ["roles", 198], ["in", 204], ["nervous", 207], ["system", 215], ["development", 222], ["and", 234], ["function", 238], [".", 246], ["An", 248], ["adequate", 251], ["amount", 260], ["of", 267], ["functional", 270], ["FOXP2", 281], ["protein", 287], ["is", 295], ["thought", 298], ["to", 306], ["be", 309], ["critical", 312], ["for", 321], ["the", 325], ["proper", 329], ["development", 336], ["of", 348], ["the", 351], ["neural", 355], ["circuitry", 362], ["underlying", 372], ["speech", 383], ["and", 390], ["language", 394], [".", 402], ["However", 404], [",", 411], ["how", 413], ["FOXP2", 417], ["gene", 423], ["expression", 428], ["is", 439], ["regulated", 442], ["is", 452], ["not", 455], ["clearly", 459], ["understood", 467], [".", 477], ["The", 479], ["FOXP2", 483], ["mRNA", 489], ["has", 494], ["an", 498], ["approximately", 501], ["4-kb", 515], ["-", 519], ["long", 520], ["3", 525], ["'", 526], ["untranslated", 528], ["region", 541], ["(", 548], ["3", 549], ["'", 550], ["UTR", 552], [")", 555], [",", 556], ["twice", 558], ["as", 564], ["long", 567], ["as", 572], ["its", 575], ["protein", 579], ["coding", 587], ["region", 594], [",", 600], ["indicating", 602], ["that", 613], ["FOXP2", 618], ["can", 624], ["be", 628], ["regulated", 631], ["by", 641], ["microRNAs", 644], ["(", 654], ["miRNAs", 655], [")", 661], [".", 662], ["We", 664], ["identified", 667], ["multiple", 678], ["miRNAs", 687], ["that", 694], ["regulate", 699], ["the", 708], ["expression", 712], ["of", 723], ["the", 726], ["human", 730], ["FOXP2", 736], ["gene", 742], ["using", 747], ["sequence", 753], ["analysis", 762], ["and", 771], ["in", 775], ["vitro", 778], ["cell", 784], ["systems", 789], [".", 796], ["Focusing", 798], ["on", 807], ["let-7a", 810], [",", 816], ["miR-9", 818], [",", 823], ["and", 825], ["miR-129", 829], ["-", 836], ["5p", 837], [",", 839], ["three", 841], ["brain", 847], ["-", 852], ["enriched", 853], ["miRNAs", 862], [",", 868], ["we", 870], ["show", 873], ["that", 878], ["these", 883], ["miRNAs", 889], ["regulate", 896], ["human", 905], ["FOXP2", 911], ["expression", 917], ["in", 928], ["a", 931], ["dosage", 933], ["-", 939], ["dependent", 940], ["manner", 950], ["and", 957], ["target", 961], ["specific", 968], ["sequences", 977], ["in", 987], ["the", 990], ["FOXP2", 994], ["3", 1000], ["'", 1001], ["UTR", 1003], [".", 1006], ["We", 1008], ["further", 1011], ["show", 1019], ["that", 1024], ["these", 1029], ["three", 1035], ["miRNAs", 1041], ["are", 1048], ["expressed", 1052], ["in", 1062], ["the", 1065], ["cerebellum", 1069], ["of", 1080], ["the", 1083], ["human", 1087], ["fetal", 1093], ["brain", 1099], [",", 1104], ["where", 1106], ["FOXP2", 1112], ["is", 1118], ["known", 1121], ["to", 1127], ["be", 1130], ["expressed", 1133], [".", 1142], ["Our", 1144], ["results", 1148], ["reveal", 1156], ["novel", 1163], ["regulatory", 1169], ["functions", 1180], ["of", 1190], ["the", 1193], ["human", 1197], ["FOXP2", 1203], ["3", 1209], ["'", 1210], ["UTR", 1212], ["sequence", 1216], ["and", 1225], ["regulatory", 1229], ["interactions", 1240], ["between", 1253], ["multiple", 1261], ["miRNAs", 1270], ["and", 1277], ["the", 1281], ["human", 1285], ["FOXP2", 1291], ["gene", 1297], [".", 1301], ["The", 1303], ["expression", 1307], ["of", 1318], ["let-7a", 1321], [",", 1327], ["miR-9", 1329], [",", 1334], ["and", 1336], ["miR-129", 1340], ["-", 1347], ["5p", 1348], ["in", 1351], ["the", 1354], ["human", 1358], ["fetal", 1364], ["cerebellum", 1370], ["is", 1381], ["consistent", 1384], ["with", 1395], ["their", 1400], ["roles", 1406], ["in", 1412], ["regulating", 1415], ["FOXP2", 1426], ["expression", 1432], ["during", 1443], ["early", 1450], ["cerebellum", 1456], ["development", 1467], [".", 1478], ["These", 1480], ["results", 1486], ["suggest", 1494], ["that", 1502], ["various", 1507], ["genetic", 1515], ["and", 1523], ["environmental", 1527], ["factors", 1541], ["may", 1549], ["contribute", 1553], ["to", 1564], ["speech", 1567], ["and", 1574], ["language", 1578], ["development", 1587], ["and", 1599], ["related", 1603], ["neural", 1611], ["developmental", 1618], ["disorders", 1632], ["via", 1642], ["the", 1646], ["miRNA", 1650], ["-", 1655], ["FOXP2", 1656], ["regulatory", 1662], ["network", 1673], [".", 1680]]}
{"context": "Alpha-synuclein forms the major component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies. Here we show that alpha-synuclein is also the major component of the filamentous inclusions of multiple system atrophy which comprises several neurodegenerative diseases with a shared filamentous pathology in nerve cells and glial cells. These findings provide an unexpected link between multiple system atrophy and Lewy body disorders and establish that alpha-synucleinopathies constitute a major class of human neurodegenerative disorder.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a4da3f3b9ad440b69aaf79b7d6f6f893", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2], [32, 34]], "char_spans": [[0, 14], [195, 209]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["forms", 16], ["the", 22], ["major", 26], ["component", 32], ["of", 42], ["Lewy", 45], ["bodies", 50], ["and", 57], ["Lewy", 61], ["neurites", 66], [",", 74], ["the", 76], ["defining", 80], ["neuropathological", 89], ["characteristics", 107], ["of", 123], ["Parkinson", 126], ["'s", 135], ["disease", 138], ["and", 146], ["dementia", 150], ["with", 159], ["Lewy", 164], ["bodies", 169], [".", 175], ["Here", 177], ["we", 182], ["show", 185], ["that", 190], ["alpha", 195], ["-", 200], ["synuclein", 201], ["is", 211], ["also", 214], ["the", 219], ["major", 223], ["component", 229], ["of", 239], ["the", 242], ["filamentous", 246], ["inclusions", 258], ["of", 269], ["multiple", 272], ["system", 281], ["atrophy", 288], ["which", 296], ["comprises", 302], ["several", 312], ["neurodegenerative", 320], ["diseases", 338], ["with", 347], ["a", 352], ["shared", 354], ["filamentous", 361], ["pathology", 373], ["in", 383], ["nerve", 386], ["cells", 392], ["and", 398], ["glial", 402], ["cells", 408], [".", 413], ["These", 415], ["findings", 421], ["provide", 430], ["an", 438], ["unexpected", 441], ["link", 452], ["between", 457], ["multiple", 465], ["system", 474], ["atrophy", 481], ["and", 489], ["Lewy", 493], ["body", 498], ["disorders", 503], ["and", 513], ["establish", 517], ["that", 527], ["alpha", 532], ["-", 537], ["synucleinopathies", 538], ["constitute", 556], ["a", 567], ["major", 569], ["class", 575], ["of", 581], ["human", 584], ["neurodegenerative", 590], ["disorder", 608], [".", 616]]}
{"context": "Little is known about the management of methicillin-resistant Staphylococcus aureus (MRSA) carriers in the German outpatient sector and about the impact of MRSA on their daily life. Reimbursement for MRSA related costs in the German outpatient sector is available since 2012, but its impact has not been studied yet. The aim of the study was to analyze the outpatient management of MRSA carriers from both, physicians' and MRSA carriers' perspective. Paper-based questionnaires were mailed to physicians providing outpatient care and to MRSA carriers in 2013. MRSA carriers were recruited among patients tested positive for MRSA during a hospital stay in 2012. General practitioners, specialists for internal medicine, urologists, and dermatologists working in the outpatient catchment areas of the hospitals were contacted. Out of 910 MRSA carriers 16.5\u00a0% completed the questionnaires; among 851 physicians 9.5\u00a0% participated. 27.3\u00a0% of the responding MRSA carriers stated that no healthcare professional had ever talked to them about MRSA. 17.4\u00a0% reported self-stigmatization in terms of restricting social contacts; 47.3\u00a0% remembered decolonization and 33.3\u00a0% reported that their MRSA status was checked after discharge. Physicians displayed heterogeneous attitude and activity towards MRSA (number of applied decolonization and MRSA screenings). A minority (15.2\u00a0%) were satisfied with the reimbursement of costs, 35.9\u00a0% reported full agreement with the general recommendations for the handling of MRSA carriers. MRSA carriers appear not well informed; (self-) stigmatization is occurring and should be tackled. Greater awareness of MRSA as a problem in the outpatient sector could lead to a better handling of MRSA carriers.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "78d3a470a5fc433fb380a0e051deb39c", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[176, 176], [256, 256], [13, 13], [99, 99], [26, 26], [163, 163], [253, 253], [277, 277], [68, 68], [76, 76], [108, 108], [201, 201], [215, 215], [222, 222], [292, 292], [34, 34], [143, 143], [94, 94]], "char_spans": [[1036, 1039], [1517, 1520], [85, 88], [560, 563], [156, 159], [953, 956], [1502, 1505], [1637, 1640], [382, 385], [423, 426], [624, 627], [1183, 1186], [1289, 1292], [1332, 1335], [1715, 1718], [200, 203], [836, 839], [537, 540]]}]}], "context_tokens": [["Little", 0], ["is", 7], ["known", 10], ["about", 16], ["the", 22], ["management", 26], ["of", 37], ["methicillin", 40], ["-", 51], ["resistant", 52], ["Staphylococcus", 62], ["aureus", 77], ["(", 84], ["MRSA", 85], [")", 89], ["carriers", 91], ["in", 100], ["the", 103], ["German", 107], ["outpatient", 114], ["sector", 125], ["and", 132], ["about", 136], ["the", 142], ["impact", 146], ["of", 153], ["MRSA", 156], ["on", 161], ["their", 164], ["daily", 170], ["life", 176], [".", 180], ["Reimbursement", 182], ["for", 196], ["MRSA", 200], ["related", 205], ["costs", 213], ["in", 219], ["the", 222], ["German", 226], ["outpatient", 233], ["sector", 244], ["is", 251], ["available", 254], ["since", 264], ["2012", 270], [",", 274], ["but", 276], ["its", 280], ["impact", 284], ["has", 291], ["not", 295], ["been", 299], ["studied", 304], ["yet", 312], [".", 315], ["The", 317], ["aim", 321], ["of", 325], ["the", 328], ["study", 332], ["was", 338], ["to", 342], ["analyze", 345], ["the", 353], ["outpatient", 357], ["management", 368], ["of", 379], ["MRSA", 382], ["carriers", 387], ["from", 396], ["both", 401], [",", 405], ["physicians", 407], ["'", 417], ["and", 419], ["MRSA", 423], ["carriers", 428], ["'", 436], ["perspective", 438], [".", 449], ["Paper", 451], ["-", 456], ["based", 457], ["questionnaires", 463], ["were", 478], ["mailed", 483], ["to", 490], ["physicians", 493], ["providing", 504], ["outpatient", 514], ["care", 525], ["and", 530], ["to", 534], ["MRSA", 537], ["carriers", 542], ["in", 551], ["2013", 554], [".", 558], ["MRSA", 560], ["carriers", 565], ["were", 574], ["recruited", 579], ["among", 589], ["patients", 595], ["tested", 604], ["positive", 611], ["for", 620], ["MRSA", 624], ["during", 629], ["a", 636], ["hospital", 638], ["stay", 647], ["in", 652], ["2012", 655], [".", 659], ["General", 661], ["practitioners", 669], [",", 682], ["specialists", 684], ["for", 696], ["internal", 700], ["medicine", 709], [",", 717], ["urologists", 719], [",", 729], ["and", 731], ["dermatologists", 735], ["working", 750], ["in", 758], ["the", 761], ["outpatient", 765], ["catchment", 776], ["areas", 786], ["of", 792], ["the", 795], ["hospitals", 799], ["were", 809], ["contacted", 814], [".", 823], ["Out", 825], ["of", 829], ["910", 832], ["MRSA", 836], ["carriers", 841], ["16.5", 850], ["%", 855], ["completed", 857], ["the", 867], ["questionnaires", 871], [";", 885], ["among", 887], ["851", 893], ["physicians", 897], ["9.5", 908], ["%", 912], ["participated", 914], [".", 926], ["27.3", 928], ["%", 933], ["of", 935], ["the", 938], ["responding", 942], ["MRSA", 953], ["carriers", 958], ["stated", 967], ["that", 974], ["no", 979], ["healthcare", 982], ["professional", 993], ["had", 1006], ["ever", 1010], ["talked", 1015], ["to", 1022], ["them", 1025], ["about", 1030], ["MRSA", 1036], [".", 1040], ["17.4", 1042], ["%", 1047], ["reported", 1049], ["self", 1058], ["-", 1062], ["stigmatization", 1063], ["in", 1078], ["terms", 1081], ["of", 1087], ["restricting", 1090], ["social", 1102], ["contacts", 1109], [";", 1117], ["47.3", 1119], ["%", 1124], ["remembered", 1126], ["decolonization", 1137], ["and", 1152], ["33.3", 1156], ["%", 1161], ["reported", 1163], ["that", 1172], ["their", 1177], ["MRSA", 1183], ["status", 1188], ["was", 1195], ["checked", 1199], ["after", 1207], ["discharge", 1213], [".", 1222], ["Physicians", 1224], ["displayed", 1235], ["heterogeneous", 1245], ["attitude", 1259], ["and", 1268], ["activity", 1272], ["towards", 1281], ["MRSA", 1289], ["(", 1294], ["number", 1295], ["of", 1302], ["applied", 1305], ["decolonization", 1313], ["and", 1328], ["MRSA", 1332], ["screenings", 1337], [")", 1347], [".", 1348], ["A", 1350], ["minority", 1352], ["(", 1361], ["15.2", 1362], ["%", 1367], [")", 1368], ["were", 1370], ["satisfied", 1375], ["with", 1385], ["the", 1390], ["reimbursement", 1394], ["of", 1408], ["costs", 1411], [",", 1416], ["35.9", 1418], ["%", 1423], ["reported", 1425], ["full", 1434], ["agreement", 1439], ["with", 1449], ["the", 1454], ["general", 1458], ["recommendations", 1466], ["for", 1482], ["the", 1486], ["handling", 1490], ["of", 1499], ["MRSA", 1502], ["carriers", 1507], [".", 1515], ["MRSA", 1517], ["carriers", 1522], ["appear", 1531], ["not", 1538], ["well", 1542], ["informed", 1547], [";", 1555], ["(", 1557], ["self-", 1558], [")", 1563], ["stigmatization", 1565], ["is", 1580], ["occurring", 1583], ["and", 1593], ["should", 1597], ["be", 1604], ["tackled", 1607], [".", 1614], ["Greater", 1616], ["awareness", 1624], ["of", 1634], ["MRSA", 1637], ["as", 1642], ["a", 1645], ["problem", 1647], ["in", 1655], ["the", 1658], ["outpatient", 1662], ["sector", 1673], ["could", 1680], ["lead", 1686], ["to", 1691], ["a", 1694], ["better", 1696], ["handling", 1703], ["of", 1712], ["MRSA", 1715], ["carriers", 1720], [".", 1728]]}
{"context": "Gefitinib, the specific inhibitor of the epidermal growth factor receptor (EGFR), may cause growth delay in cancer cell lines. Thorough understanding of the downstream cellular signaling of gefitinib will facilitate the discovery of biomarkers for predicting outcomes and monitoring anti-EGFR therapies, and provide information for key targets for therapeutic intervention. In this study, we investigated the role of transducer of erbB2.1 (TOB1) in gefitinib therapy. Using the lung carcinoma cell lines A549 and NCI-H1975, the results suggested that gefitinib might mediate cell cycle arrest in lung cancer cells at least by targeting TOB1 expression. Gefitinib treatment caused cell cycle arrest predominantly at the G1 phase, which is associated with TOB1 nuclear translocation and its interaction with cyclin D1. We also showed that knockdown of TOB1 expression by RNAi rescued lung cancer cells from gefitinib-induced cell-proliferative arrest. These results suggest that TOB1 interaction with cyclin D1 and nuclear translocation is directly involved in the gefitinib-induced anti-proliferative cell cycle arrest.", "qas": [{"question": "Which is the cellular target of gefitinib?", "answers": ["Epidermal growth factor receptor (EGFR)"], "qid": "69bb73c08e1848e080576cacd9b2c307", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["target", 22], ["of", 29], ["gefitinib", 32], ["?", 41]], "detected_answers": [{"text": "Epidermal growth factor receptor (EGFR)", "token_spans": [[7, 12]], "char_spans": [[41, 78]]}]}], "context_tokens": [["Gefitinib", 0], [",", 9], ["the", 11], ["specific", 15], ["inhibitor", 24], ["of", 34], ["the", 37], ["epidermal", 41], ["growth", 51], ["factor", 58], ["receptor", 65], ["(", 74], ["EGFR", 75], [")", 79], [",", 80], ["may", 82], ["cause", 86], ["growth", 92], ["delay", 99], ["in", 105], ["cancer", 108], ["cell", 115], ["lines", 120], [".", 125], ["Thorough", 127], ["understanding", 136], ["of", 150], ["the", 153], ["downstream", 157], ["cellular", 168], ["signaling", 177], ["of", 187], ["gefitinib", 190], ["will", 200], ["facilitate", 205], ["the", 216], ["discovery", 220], ["of", 230], ["biomarkers", 233], ["for", 244], ["predicting", 248], ["outcomes", 259], ["and", 268], ["monitoring", 272], ["anti", 283], ["-", 287], ["EGFR", 288], ["therapies", 293], [",", 302], ["and", 304], ["provide", 308], ["information", 316], ["for", 328], ["key", 332], ["targets", 336], ["for", 344], ["therapeutic", 348], ["intervention", 360], [".", 372], ["In", 374], ["this", 377], ["study", 382], [",", 387], ["we", 389], ["investigated", 392], ["the", 405], ["role", 409], ["of", 414], ["transducer", 417], ["of", 428], ["erbB2.1", 431], ["(", 439], ["TOB1", 440], [")", 444], ["in", 446], ["gefitinib", 449], ["therapy", 459], [".", 466], ["Using", 468], ["the", 474], ["lung", 478], ["carcinoma", 483], ["cell", 493], ["lines", 498], ["A549", 504], ["and", 509], ["NCI", 513], ["-", 516], ["H1975", 517], [",", 522], ["the", 524], ["results", 528], ["suggested", 536], ["that", 546], ["gefitinib", 551], ["might", 561], ["mediate", 567], ["cell", 575], ["cycle", 580], ["arrest", 586], ["in", 593], ["lung", 596], ["cancer", 601], ["cells", 608], ["at", 614], ["least", 617], ["by", 623], ["targeting", 626], ["TOB1", 636], ["expression", 641], [".", 651], ["Gefitinib", 653], ["treatment", 663], ["caused", 673], ["cell", 680], ["cycle", 685], ["arrest", 691], ["predominantly", 698], ["at", 712], ["the", 715], ["G1", 719], ["phase", 722], [",", 727], ["which", 729], ["is", 735], ["associated", 738], ["with", 749], ["TOB1", 754], ["nuclear", 759], ["translocation", 767], ["and", 781], ["its", 785], ["interaction", 789], ["with", 801], ["cyclin", 806], ["D1", 813], [".", 815], ["We", 817], ["also", 820], ["showed", 825], ["that", 832], ["knockdown", 837], ["of", 847], ["TOB1", 850], ["expression", 855], ["by", 866], ["RNAi", 869], ["rescued", 874], ["lung", 882], ["cancer", 887], ["cells", 894], ["from", 900], ["gefitinib", 905], ["-", 914], ["induced", 915], ["cell", 923], ["-", 927], ["proliferative", 928], ["arrest", 942], [".", 948], ["These", 950], ["results", 956], ["suggest", 964], ["that", 972], ["TOB1", 977], ["interaction", 982], ["with", 994], ["cyclin", 999], ["D1", 1006], ["and", 1009], ["nuclear", 1013], ["translocation", 1021], ["is", 1035], ["directly", 1038], ["involved", 1047], ["in", 1056], ["the", 1059], ["gefitinib", 1063], ["-", 1072], ["induced", 1073], ["anti", 1081], ["-", 1085], ["proliferative", 1086], ["cell", 1100], ["cycle", 1105], ["arrest", 1111], [".", 1117]]}
{"context": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications. Currently, there is no satisfactory pharmacotherapy for TD, which represents a major limitation to therapy with classical antipsychotics. In order to develop or optimize therapies for TD, and to develop new APDs with lower indices of motor side effects, the pathology underlying TD must first be understood. The use of animal models has been used to further this objective. Here, we review different preparations that have been used to model TD and discuss the contribution of neuroimaging studies conducted in these models. Studies in animal models have lead to several hypotheses of TD pathology, although none has yet emerged as the ultimate underlying cause of this syndrome. We discuss alterations in functional indices, neuron and synapse morphology and changes in specific neurotransmitter systems that have been described in animal models of TD, and outline how these findings have contributed to our understanding of antipsychotic-induced dyskinesias. We conclude that several non-mutually exclusive theories of TD are supported by animal studies, including increases in oxidative stress leading to structural and functional changes in specific neurotransmitter systems. Elucidating the mechanisms underlying TD neuropathology partly through the use of animal models will lead to the development of APDs with superior side effect profiles or more effective therapies for TD.", "qas": [{"question": "What is the cause of Tardive dyskinesia?", "answers": ["Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications."], "qid": "b0f3562cb2574620ba46ae33c88d65b3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["cause", 12], ["of", 18], ["Tardive", 21], ["dyskinesia", 29], ["?", 39]], "detected_answers": [{"text": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications.", "token_spans": [[0, 22]], "char_spans": [[0, 168]]}]}], "context_tokens": [["Tardive", 0], ["dyskinesia", 8], ["(", 19], ["TD", 20], [")", 22], ["is", 24], ["a", 27], ["movement", 29], ["disorder", 38], ["characterized", 47], ["by", 61], ["abnormal", 64], ["involuntary", 73], ["facial", 85], ["movements", 92], ["induced", 102], ["by", 110], ["chronic", 113], ["therapy", 121], ["with", 129], ["classical", 134], ["antipsychotic", 144], ["medications", 158], [".", 169], ["Currently", 171], [",", 180], ["there", 182], ["is", 188], ["no", 191], ["satisfactory", 194], ["pharmacotherapy", 207], ["for", 223], ["TD", 227], [",", 229], ["which", 231], ["represents", 237], ["a", 248], ["major", 250], ["limitation", 256], ["to", 267], ["therapy", 270], ["with", 278], ["classical", 283], ["antipsychotics", 293], [".", 307], ["In", 309], ["order", 312], ["to", 318], ["develop", 321], ["or", 329], ["optimize", 332], ["therapies", 341], ["for", 351], ["TD", 355], [",", 357], ["and", 359], ["to", 363], ["develop", 366], ["new", 374], ["APDs", 378], ["with", 383], ["lower", 388], ["indices", 394], ["of", 402], ["motor", 405], ["side", 411], ["effects", 416], [",", 423], ["the", 425], ["pathology", 429], ["underlying", 439], ["TD", 450], ["must", 453], ["first", 458], ["be", 464], ["understood", 467], [".", 477], ["The", 479], ["use", 483], ["of", 487], ["animal", 490], ["models", 497], ["has", 504], ["been", 508], ["used", 513], ["to", 518], ["further", 521], ["this", 529], ["objective", 534], [".", 543], ["Here", 545], [",", 549], ["we", 551], ["review", 554], ["different", 561], ["preparations", 571], ["that", 584], ["have", 589], ["been", 594], ["used", 599], ["to", 604], ["model", 607], ["TD", 613], ["and", 616], ["discuss", 620], ["the", 628], ["contribution", 632], ["of", 645], ["neuroimaging", 648], ["studies", 661], ["conducted", 669], ["in", 679], ["these", 682], ["models", 688], [".", 694], ["Studies", 696], ["in", 704], ["animal", 707], ["models", 714], ["have", 721], ["lead", 726], ["to", 731], ["several", 734], ["hypotheses", 742], ["of", 753], ["TD", 756], ["pathology", 759], [",", 768], ["although", 770], ["none", 779], ["has", 784], ["yet", 788], ["emerged", 792], ["as", 800], ["the", 803], ["ultimate", 807], ["underlying", 816], ["cause", 827], ["of", 833], ["this", 836], ["syndrome", 841], [".", 849], ["We", 851], ["discuss", 854], ["alterations", 862], ["in", 874], ["functional", 877], ["indices", 888], [",", 895], ["neuron", 897], ["and", 904], ["synapse", 908], ["morphology", 916], ["and", 927], ["changes", 931], ["in", 939], ["specific", 942], ["neurotransmitter", 951], ["systems", 968], ["that", 976], ["have", 981], ["been", 986], ["described", 991], ["in", 1001], ["animal", 1004], ["models", 1011], ["of", 1018], ["TD", 1021], [",", 1023], ["and", 1025], ["outline", 1029], ["how", 1037], ["these", 1041], ["findings", 1047], ["have", 1056], ["contributed", 1061], ["to", 1073], ["our", 1076], ["understanding", 1080], ["of", 1094], ["antipsychotic", 1097], ["-", 1110], ["induced", 1111], ["dyskinesias", 1119], [".", 1130], ["We", 1132], ["conclude", 1135], ["that", 1144], ["several", 1149], ["non", 1157], ["-", 1160], ["mutually", 1161], ["exclusive", 1170], ["theories", 1180], ["of", 1189], ["TD", 1192], ["are", 1195], ["supported", 1199], ["by", 1209], ["animal", 1212], ["studies", 1219], [",", 1226], ["including", 1228], ["increases", 1238], ["in", 1248], ["oxidative", 1251], ["stress", 1261], ["leading", 1268], ["to", 1276], ["structural", 1279], ["and", 1290], ["functional", 1294], ["changes", 1305], ["in", 1313], ["specific", 1316], ["neurotransmitter", 1325], ["systems", 1342], [".", 1349], ["Elucidating", 1351], ["the", 1363], ["mechanisms", 1367], ["underlying", 1378], ["TD", 1389], ["neuropathology", 1392], ["partly", 1407], ["through", 1414], ["the", 1422], ["use", 1426], ["of", 1430], ["animal", 1433], ["models", 1440], ["will", 1447], ["lead", 1452], ["to", 1457], ["the", 1460], ["development", 1464], ["of", 1476], ["APDs", 1479], ["with", 1484], ["superior", 1489], ["side", 1498], ["effect", 1503], ["profiles", 1510], ["or", 1519], ["more", 1522], ["effective", 1527], ["therapies", 1537], ["for", 1547], ["TD", 1551], [".", 1553]]}
{"context": "Although malaria has become a serious public health problem in Mauritania since the late 1990s, few documented data on its epidemiology exist. The objective of this study was to assess the morbidity of clinical malaria among children in Nouakchott. Three hundred and one febrile children, consulting at three health facilities of Nouakchott, were screened for malaria in 2009 (n=216) and 2010 (n=85). Plasmodium species identification and parasite density were determined by microscopic examination of Giemsa-stained thin and thick films and confirmed by rapid diagnostic test and nested PCR. Of 301 febrile children, 105 (34.9%) were malaria-positive by nested PCR and 87 (28.9%) by microscopy. Plasmodium vivax represented 97.1% (102/105) and P. falciparum accounted for 2.9% (3/105) of positive cases. All positive children under five years old were infected with P. vivax. The highest numbers of malaria positives were found during or shortly after the rainy season and the lowest during the dry season. Fifty-four of 105 (51.4%) malaria cases, all with P. vivax, had never travelled outside Nouakchott. Individuals belonging to the Moors ethnic group represented 97.0% of P. vivax cases. Results of the present study indicate that malaria is endemic in Nouakchott and that P. vivax is the principal causative agent. Regular surveillance is required to monitor malaria prevalence and incidence, and further measures are needed to counter the possible spread of malaria in the country.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "03a16d0eb3134070ad262ad943d2c738", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium species", "token_spans": [[72, 73]], "char_spans": [[401, 418]]}]}], "context_tokens": [["Although", 0], ["malaria", 9], ["has", 17], ["become", 21], ["a", 28], ["serious", 30], ["public", 38], ["health", 45], ["problem", 52], ["in", 60], ["Mauritania", 63], ["since", 74], ["the", 80], ["late", 84], ["1990s", 89], [",", 94], ["few", 96], ["documented", 100], ["data", 111], ["on", 116], ["its", 119], ["epidemiology", 123], ["exist", 136], [".", 141], ["The", 143], ["objective", 147], ["of", 157], ["this", 160], ["study", 165], ["was", 171], ["to", 175], ["assess", 178], ["the", 185], ["morbidity", 189], ["of", 199], ["clinical", 202], ["malaria", 211], ["among", 219], ["children", 225], ["in", 234], ["Nouakchott", 237], [".", 247], ["Three", 249], ["hundred", 255], ["and", 263], ["one", 267], ["febrile", 271], ["children", 279], [",", 287], ["consulting", 289], ["at", 300], ["three", 303], ["health", 309], ["facilities", 316], ["of", 327], ["Nouakchott", 330], [",", 340], ["were", 342], ["screened", 347], ["for", 356], ["malaria", 360], ["in", 368], ["2009", 371], ["(", 376], ["n=216", 377], [")", 382], ["and", 384], ["2010", 388], ["(", 393], ["n=85", 394], [")", 398], [".", 399], ["Plasmodium", 401], ["species", 412], ["identification", 420], ["and", 435], ["parasite", 439], ["density", 448], ["were", 456], ["determined", 461], ["by", 472], ["microscopic", 475], ["examination", 487], ["of", 499], ["Giemsa", 502], ["-", 508], ["stained", 509], ["thin", 517], ["and", 522], ["thick", 526], ["films", 532], ["and", 538], ["confirmed", 542], ["by", 552], ["rapid", 555], ["diagnostic", 561], ["test", 572], ["and", 577], ["nested", 581], ["PCR", 588], [".", 591], ["Of", 593], ["301", 596], ["febrile", 600], ["children", 608], [",", 616], ["105", 618], ["(", 622], ["34.9", 623], ["%", 627], [")", 628], ["were", 630], ["malaria", 635], ["-", 642], ["positive", 643], ["by", 652], ["nested", 655], ["PCR", 662], ["and", 666], ["87", 670], ["(", 673], ["28.9", 674], ["%", 678], [")", 679], ["by", 681], ["microscopy", 684], [".", 694], ["Plasmodium", 696], ["vivax", 707], ["represented", 713], ["97.1", 725], ["%", 729], ["(", 731], ["102/105", 732], [")", 739], ["and", 741], ["P.", 745], ["falciparum", 748], ["accounted", 759], ["for", 769], ["2.9", 773], ["%", 776], ["(", 778], ["3/105", 779], [")", 784], ["of", 786], ["positive", 789], ["cases", 798], [".", 803], ["All", 805], ["positive", 809], ["children", 818], ["under", 827], ["five", 833], ["years", 838], ["old", 844], ["were", 848], ["infected", 853], ["with", 862], ["P.", 867], ["vivax", 870], [".", 875], ["The", 877], ["highest", 881], ["numbers", 889], ["of", 897], ["malaria", 900], ["positives", 908], ["were", 918], ["found", 923], ["during", 929], ["or", 936], ["shortly", 939], ["after", 947], ["the", 953], ["rainy", 957], ["season", 963], ["and", 970], ["the", 974], ["lowest", 978], ["during", 985], ["the", 992], ["dry", 996], ["season", 1000], [".", 1006], ["Fifty", 1008], ["-", 1013], ["four", 1014], ["of", 1019], ["105", 1022], ["(", 1026], ["51.4", 1027], ["%", 1031], [")", 1032], ["malaria", 1034], ["cases", 1042], [",", 1047], ["all", 1049], ["with", 1053], ["P.", 1058], ["vivax", 1061], [",", 1066], ["had", 1068], ["never", 1072], ["travelled", 1078], ["outside", 1088], ["Nouakchott", 1096], [".", 1106], ["Individuals", 1108], ["belonging", 1120], ["to", 1130], ["the", 1133], ["Moors", 1137], ["ethnic", 1143], ["group", 1150], ["represented", 1156], ["97.0", 1168], ["%", 1172], ["of", 1174], ["P.", 1177], ["vivax", 1180], ["cases", 1186], [".", 1191], ["Results", 1193], ["of", 1201], ["the", 1204], ["present", 1208], ["study", 1216], ["indicate", 1222], ["that", 1231], ["malaria", 1236], ["is", 1244], ["endemic", 1247], ["in", 1255], ["Nouakchott", 1258], ["and", 1269], ["that", 1273], ["P.", 1278], ["vivax", 1281], ["is", 1287], ["the", 1290], ["principal", 1294], ["causative", 1304], ["agent", 1314], [".", 1319], ["Regular", 1321], ["surveillance", 1329], ["is", 1342], ["required", 1345], ["to", 1354], ["monitor", 1357], ["malaria", 1365], ["prevalence", 1373], ["and", 1384], ["incidence", 1388], [",", 1397], ["and", 1399], ["further", 1403], ["measures", 1411], ["are", 1420], ["needed", 1424], ["to", 1431], ["counter", 1434], ["the", 1442], ["possible", 1446], ["spread", 1455], ["of", 1462], ["malaria", 1465], ["in", 1473], ["the", 1476], ["country", 1480], [".", 1487]]}
{"context": "Imatinib was the first BCR-ABL tyrosine kinase inhibitor to become clinically available. In this study, we retrospectively evaluated the long-term efficacy of low-dose imatinib (final maintenance dose <300\u00a0mg per day) due to intolerance, in comparison to optimal-dose imatinib (\u2265300\u00a0mg per day) in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The Kaplan-Meier estimates of the median time to complete cytogenetic response, major molecular response, and complete molecular response were longer for 31 patients receiving low-dose imatinib (360, 1360, and 1420\u00a0days, respectively) than 74 patients receiving optimal-dose imatinib (170, 420, and 720\u00a0days, respectively). However, the differences in response shrank over time and progression-free survival were comparable between the two groups. These findings suggest that long-term treatment with low-dose imatinib is an acceptable alternative for patients with intolerance to the optimal dose.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "169d1ca25e78425dbd60b6192286d3dd", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[4, 6]], "char_spans": [[23, 29]]}]}], "context_tokens": [["Imatinib", 0], ["was", 9], ["the", 13], ["first", 17], ["BCR", 23], ["-", 26], ["ABL", 27], ["tyrosine", 31], ["kinase", 40], ["inhibitor", 47], ["to", 57], ["become", 60], ["clinically", 67], ["available", 78], [".", 87], ["In", 89], ["this", 92], ["study", 97], [",", 102], ["we", 104], ["retrospectively", 107], ["evaluated", 123], ["the", 133], ["long", 137], ["-", 141], ["term", 142], ["efficacy", 147], ["of", 156], ["low", 159], ["-", 162], ["dose", 163], ["imatinib", 168], ["(", 177], ["final", 178], ["maintenance", 184], ["dose", 196], ["<", 201], ["300", 202], ["mg", 206], ["per", 209], ["day", 213], [")", 216], ["due", 218], ["to", 222], ["intolerance", 225], [",", 236], ["in", 238], ["comparison", 241], ["to", 252], ["optimal", 255], ["-", 262], ["dose", 263], ["imatinib", 268], ["(", 277], ["\u2265300", 278], ["mg", 283], ["per", 286], ["day", 290], [")", 293], ["in", 295], ["patients", 298], ["with", 307], ["Philadelphia", 312], ["chromosome", 325], ["-", 335], ["positive", 336], ["chronic", 345], ["myeloid", 353], ["leukemia", 361], ["in", 370], ["the", 373], ["chronic", 377], ["phase", 385], [".", 390], ["The", 392], ["Kaplan", 396], ["-", 402], ["Meier", 403], ["estimates", 409], ["of", 419], ["the", 422], ["median", 426], ["time", 433], ["to", 438], ["complete", 441], ["cytogenetic", 450], ["response", 462], [",", 470], ["major", 472], ["molecular", 478], ["response", 488], [",", 496], ["and", 498], ["complete", 502], ["molecular", 511], ["response", 521], ["were", 530], ["longer", 535], ["for", 542], ["31", 546], ["patients", 549], ["receiving", 558], ["low", 568], ["-", 571], ["dose", 572], ["imatinib", 577], ["(", 586], ["360", 587], [",", 590], ["1360", 592], [",", 596], ["and", 598], ["1420", 602], ["days", 607], [",", 611], ["respectively", 613], [")", 625], ["than", 627], ["74", 632], ["patients", 635], ["receiving", 644], ["optimal", 654], ["-", 661], ["dose", 662], ["imatinib", 667], ["(", 676], ["170", 677], [",", 680], ["420", 682], [",", 685], ["and", 687], ["720", 691], ["days", 695], [",", 699], ["respectively", 701], [")", 713], [".", 714], ["However", 716], [",", 723], ["the", 725], ["differences", 729], ["in", 741], ["response", 744], ["shrank", 753], ["over", 760], ["time", 765], ["and", 770], ["progression", 774], ["-", 785], ["free", 786], ["survival", 791], ["were", 800], ["comparable", 805], ["between", 816], ["the", 824], ["two", 828], ["groups", 832], [".", 838], ["These", 840], ["findings", 846], ["suggest", 855], ["that", 863], ["long", 868], ["-", 872], ["term", 873], ["treatment", 878], ["with", 888], ["low", 893], ["-", 896], ["dose", 897], ["imatinib", 902], ["is", 911], ["an", 914], ["acceptable", 917], ["alternative", 928], ["for", 940], ["patients", 944], ["with", 953], ["intolerance", 958], ["to", 970], ["the", 973], ["optimal", 977], ["dose", 985], [".", 989]]}
{"context": "Desmosomes are cell-cell adhesion structures that integrate cytoskeletal networks. In addition to binding intermediate filaments, the desmosomal protein desmoplakin (DP) regulates microtubule reorganization in the epidermis. In this paper, we identify a specific subset of centrosomal proteins that are recruited to the cell cortex by DP upon epidermal differentiation. These include Lis1 and Ndel1, which are centrosomal proteins that regulate microtubule organization and anchoring in other cell types. This recruitment was mediated by a region of DP specific to a single isoform, DPI. Furthermore, we demonstrate that the epidermal-specific loss of Lis1 results in dramatic defects in microtubule reorganization. Lis1 ablation also causes desmosomal defects, characterized by decreased levels of desmosomal components, decreased attachment of keratin filaments, and increased turnover of desmosomal proteins at the cell cortex. This contributes to loss of epidermal barrier activity, resulting in completely penetrant perinatal lethality. This work reveals essential desmosome-associated components that control cortical microtubule organization and unexpected roles for centrosomal proteins in epidermal function.", "qas": [{"question": "What are the structures formed when keratin molecules come together?", "answers": ["Intermediate filaments"], "qid": "d4ee2e1fb7364cd6bb5931d72186c5bb", "question_tokens": [["What", 0], ["are", 5], ["the", 9], ["structures", 13], ["formed", 24], ["when", 31], ["keratin", 36], ["molecules", 44], ["come", 54], ["together", 59], ["?", 67]], "detected_answers": [{"text": "Intermediate filaments", "token_spans": [[16, 17]], "char_spans": [[106, 127]]}]}], "context_tokens": [["Desmosomes", 0], ["are", 11], ["cell", 15], ["-", 19], ["cell", 20], ["adhesion", 25], ["structures", 34], ["that", 45], ["integrate", 50], ["cytoskeletal", 60], ["networks", 73], [".", 81], ["In", 83], ["addition", 86], ["to", 95], ["binding", 98], ["intermediate", 106], ["filaments", 119], [",", 128], ["the", 130], ["desmosomal", 134], ["protein", 145], ["desmoplakin", 153], ["(", 165], ["DP", 166], [")", 168], ["regulates", 170], ["microtubule", 180], ["reorganization", 192], ["in", 207], ["the", 210], ["epidermis", 214], [".", 223], ["In", 225], ["this", 228], ["paper", 233], [",", 238], ["we", 240], ["identify", 243], ["a", 252], ["specific", 254], ["subset", 263], ["of", 270], ["centrosomal", 273], ["proteins", 285], ["that", 294], ["are", 299], ["recruited", 303], ["to", 313], ["the", 316], ["cell", 320], ["cortex", 325], ["by", 332], ["DP", 335], ["upon", 338], ["epidermal", 343], ["differentiation", 353], [".", 368], ["These", 370], ["include", 376], ["Lis1", 384], ["and", 389], ["Ndel1", 393], [",", 398], ["which", 400], ["are", 406], ["centrosomal", 410], ["proteins", 422], ["that", 431], ["regulate", 436], ["microtubule", 445], ["organization", 457], ["and", 470], ["anchoring", 474], ["in", 484], ["other", 487], ["cell", 493], ["types", 498], [".", 503], ["This", 505], ["recruitment", 510], ["was", 522], ["mediated", 526], ["by", 535], ["a", 538], ["region", 540], ["of", 547], ["DP", 550], ["specific", 553], ["to", 562], ["a", 565], ["single", 567], ["isoform", 574], [",", 581], ["DPI", 583], [".", 586], ["Furthermore", 588], [",", 599], ["we", 601], ["demonstrate", 604], ["that", 616], ["the", 621], ["epidermal", 625], ["-", 634], ["specific", 635], ["loss", 644], ["of", 649], ["Lis1", 652], ["results", 657], ["in", 665], ["dramatic", 668], ["defects", 677], ["in", 685], ["microtubule", 688], ["reorganization", 700], [".", 714], ["Lis1", 716], ["ablation", 721], ["also", 730], ["causes", 735], ["desmosomal", 742], ["defects", 753], [",", 760], ["characterized", 762], ["by", 776], ["decreased", 779], ["levels", 789], ["of", 796], ["desmosomal", 799], ["components", 810], [",", 820], ["decreased", 822], ["attachment", 832], ["of", 843], ["keratin", 846], ["filaments", 854], [",", 863], ["and", 865], ["increased", 869], ["turnover", 879], ["of", 888], ["desmosomal", 891], ["proteins", 902], ["at", 911], ["the", 914], ["cell", 918], ["cortex", 923], [".", 929], ["This", 931], ["contributes", 936], ["to", 948], ["loss", 951], ["of", 956], ["epidermal", 959], ["barrier", 969], ["activity", 977], [",", 985], ["resulting", 987], ["in", 997], ["completely", 1000], ["penetrant", 1011], ["perinatal", 1021], ["lethality", 1031], [".", 1040], ["This", 1042], ["work", 1047], ["reveals", 1052], ["essential", 1060], ["desmosome", 1070], ["-", 1079], ["associated", 1080], ["components", 1091], ["that", 1102], ["control", 1107], ["cortical", 1115], ["microtubule", 1124], ["organization", 1136], ["and", 1149], ["unexpected", 1153], ["roles", 1164], ["for", 1170], ["centrosomal", 1174], ["proteins", 1186], ["in", 1195], ["epidermal", 1198], ["function", 1208], [".", 1216]]}
{"context": "\u03b1-Synuclein (\u03b1Syn), which forms amyloid fibrils, is linked to the neuronal pathology of Parkinson's disease, as it is the major fibrillar component of Lewy bodies, the inclusions that are characteristic of the disease. Oligomeric structures, common to many neurodegenerative disease-related proteins, may in fact be the primary toxic species, while the amyloid fibrils exist either as a less toxic dead-end species or even as a beneficial mechanism for clearing damaged proteins. To alter the progression of the aggregation and gain insights into the prefibrillar structures, we determined the effect of heme on \u03b1Syn oligomerization by several different techniques, including native (nondenaturing) polyacrylamide gel electrophoresis, thioflavin T fluorescence, transmission electron microscopy, atomic force microscopy, circular dichroism, and membrane permeation using a calcein release assay. During aggregation, heme is able to bind the \u03b1Syn in a specific fashion, stabilizing distinct oligomeric conformations and promoting the formation of \u03b1Syn into annular structures, thereby delaying and/or inhibiting the fibrillation process. These results indicate that heme may play a regulatory role in the progression of Parkinson's disease; in addition, they provide insights into how the aggregation process may be altered, which may be applicable to the understanding of many neurodegenerative diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "bbcdadd974b7443eae14570e28207e80", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 10]]}, {"text": "\u03b1Syn", "token_spans": [[175, 175], [4, 4], [160, 160], [111, 111]], "char_spans": [[1046, 1049], [13, 16], [941, 944], [612, 615]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["(", 12], ["\u03b1Syn", 13], [")", 17], [",", 18], ["which", 20], ["forms", 26], ["amyloid", 32], ["fibrils", 40], [",", 47], ["is", 49], ["linked", 52], ["to", 59], ["the", 62], ["neuronal", 66], ["pathology", 75], ["of", 85], ["Parkinson", 88], ["'s", 97], ["disease", 100], [",", 107], ["as", 109], ["it", 112], ["is", 115], ["the", 118], ["major", 122], ["fibrillar", 128], ["component", 138], ["of", 148], ["Lewy", 151], ["bodies", 156], [",", 162], ["the", 164], ["inclusions", 168], ["that", 179], ["are", 184], ["characteristic", 188], ["of", 203], ["the", 206], ["disease", 210], [".", 217], ["Oligomeric", 219], ["structures", 230], [",", 240], ["common", 242], ["to", 249], ["many", 252], ["neurodegenerative", 257], ["disease", 275], ["-", 282], ["related", 283], ["proteins", 291], [",", 299], ["may", 301], ["in", 305], ["fact", 308], ["be", 313], ["the", 316], ["primary", 320], ["toxic", 328], ["species", 334], [",", 341], ["while", 343], ["the", 349], ["amyloid", 353], ["fibrils", 361], ["exist", 369], ["either", 375], ["as", 382], ["a", 385], ["less", 387], ["toxic", 392], ["dead", 398], ["-", 402], ["end", 403], ["species", 407], ["or", 415], ["even", 418], ["as", 423], ["a", 426], ["beneficial", 428], ["mechanism", 439], ["for", 449], ["clearing", 453], ["damaged", 462], ["proteins", 470], [".", 478], ["To", 480], ["alter", 483], ["the", 489], ["progression", 493], ["of", 505], ["the", 508], ["aggregation", 512], ["and", 524], ["gain", 528], ["insights", 533], ["into", 542], ["the", 547], ["prefibrillar", 551], ["structures", 564], [",", 574], ["we", 576], ["determined", 579], ["the", 590], ["effect", 594], ["of", 601], ["heme", 604], ["on", 609], ["\u03b1Syn", 612], ["oligomerization", 617], ["by", 633], ["several", 636], ["different", 644], ["techniques", 654], [",", 664], ["including", 666], ["native", 676], ["(", 683], ["nondenaturing", 684], [")", 697], ["polyacrylamide", 699], ["gel", 714], ["electrophoresis", 718], [",", 733], ["thioflavin", 735], ["T", 746], ["fluorescence", 748], [",", 760], ["transmission", 762], ["electron", 775], ["microscopy", 784], [",", 794], ["atomic", 796], ["force", 803], ["microscopy", 809], [",", 819], ["circular", 821], ["dichroism", 830], [",", 839], ["and", 841], ["membrane", 845], ["permeation", 854], ["using", 865], ["a", 871], ["calcein", 873], ["release", 881], ["assay", 889], [".", 894], ["During", 896], ["aggregation", 903], [",", 914], ["heme", 916], ["is", 921], ["able", 924], ["to", 929], ["bind", 932], ["the", 937], ["\u03b1Syn", 941], ["in", 946], ["a", 949], ["specific", 951], ["fashion", 960], [",", 967], ["stabilizing", 969], ["distinct", 981], ["oligomeric", 990], ["conformations", 1001], ["and", 1015], ["promoting", 1019], ["the", 1029], ["formation", 1033], ["of", 1043], ["\u03b1Syn", 1046], ["into", 1051], ["annular", 1056], ["structures", 1064], [",", 1074], ["thereby", 1076], ["delaying", 1084], ["and/or", 1093], ["inhibiting", 1100], ["the", 1111], ["fibrillation", 1115], ["process", 1128], [".", 1135], ["These", 1137], ["results", 1143], ["indicate", 1151], ["that", 1160], ["heme", 1165], ["may", 1170], ["play", 1174], ["a", 1179], ["regulatory", 1181], ["role", 1192], ["in", 1197], ["the", 1200], ["progression", 1204], ["of", 1216], ["Parkinson", 1219], ["'s", 1228], ["disease", 1231], [";", 1238], ["in", 1240], ["addition", 1243], [",", 1251], ["they", 1253], ["provide", 1258], ["insights", 1266], ["into", 1275], ["how", 1280], ["the", 1284], ["aggregation", 1288], ["process", 1300], ["may", 1308], ["be", 1312], ["altered", 1315], [",", 1322], ["which", 1324], ["may", 1330], ["be", 1334], ["applicable", 1337], ["to", 1348], ["the", 1351], ["understanding", 1355], ["of", 1369], ["many", 1372], ["neurodegenerative", 1377], ["diseases", 1395], [".", 1403]]}
{"context": "The mature central nervous system contains precursor cells in the subventricular zone of the lateral ventricle. In this study we examined the possibility to affect fate of precursor cells through exogenous manipulations. The results indicate that administration of thyroid hormone and retinoic acid increases the expression of Ki67, a nuclear antigen associated with cell proliferation, and of nestin, a marker protein for precursor cells in the subventricular zone of adult male rats. Moreover, retinoic acid increases polysialated-neural cell adhesion molecules (PSA-NCAM)-immunoreactivity. These data suggest that nuclear receptor ligands are potential candidates for fate determination of precursor cells in the subventricular zone also in the adult brain.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "2a963d7335cb4cfa9452f4ded58a357f", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[61, 61]], "char_spans": [[394, 399]]}]}], "context_tokens": [["The", 0], ["mature", 4], ["central", 11], ["nervous", 19], ["system", 27], ["contains", 34], ["precursor", 43], ["cells", 53], ["in", 59], ["the", 62], ["subventricular", 66], ["zone", 81], ["of", 86], ["the", 89], ["lateral", 93], ["ventricle", 101], [".", 110], ["In", 112], ["this", 115], ["study", 120], ["we", 126], ["examined", 129], ["the", 138], ["possibility", 142], ["to", 154], ["affect", 157], ["fate", 164], ["of", 169], ["precursor", 172], ["cells", 182], ["through", 188], ["exogenous", 196], ["manipulations", 206], [".", 219], ["The", 221], ["results", 225], ["indicate", 233], ["that", 242], ["administration", 247], ["of", 262], ["thyroid", 265], ["hormone", 273], ["and", 281], ["retinoic", 285], ["acid", 294], ["increases", 299], ["the", 309], ["expression", 313], ["of", 324], ["Ki67", 327], [",", 331], ["a", 333], ["nuclear", 335], ["antigen", 343], ["associated", 351], ["with", 362], ["cell", 367], ["proliferation", 372], [",", 385], ["and", 387], ["of", 391], ["nestin", 394], [",", 400], ["a", 402], ["marker", 404], ["protein", 411], ["for", 419], ["precursor", 423], ["cells", 433], ["in", 439], ["the", 442], ["subventricular", 446], ["zone", 461], ["of", 466], ["adult", 469], ["male", 475], ["rats", 480], [".", 484], ["Moreover", 486], [",", 494], ["retinoic", 496], ["acid", 505], ["increases", 510], ["polysialated", 520], ["-", 532], ["neural", 533], ["cell", 540], ["adhesion", 545], ["molecules", 554], ["(", 564], ["PSA", 565], ["-", 568], ["NCAM)-immunoreactivity", 569], [".", 591], ["These", 593], ["data", 599], ["suggest", 604], ["that", 612], ["nuclear", 617], ["receptor", 625], ["ligands", 634], ["are", 642], ["potential", 646], ["candidates", 656], ["for", 667], ["fate", 671], ["determination", 676], ["of", 690], ["precursor", 693], ["cells", 703], ["in", 709], ["the", 712], ["subventricular", 716], ["zone", 731], ["also", 736], ["in", 741], ["the", 744], ["adult", 748], ["brain", 754], [".", 759]]}
{"context": "Transgenic mice over-expressing a mutated form of the human amyloid precursor protein (APP, 695 isoform) bearing a mutation associated with Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and wild-type controls were studied at age periods (3 and 10 months) prior to the overt development of neuritic amyloid plaques. Both 3- and 10-month-old APPLd2 mice had reflex eyelid responses like those of controls, but only younger mice were able to acquire a classical conditioning of eyelid responses in a trace paradigm. In vitro studies on hippocampal slices showed that 10-month-old APPLd2 mice also presented deficits in paired-pulse facilitation and long-term potentiation, but presented a normal synaptic activation of CA1 pyramidal cells by the stimulation of Schaffer collaterals. It is proposed that definite functional changes may appear well in advance of noticeable structural alterations in this animal model of Alzheimer's disease, and that specific learning tasks could have a relevant diagnostic value.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "b8293e4bcc944de3949762790d040d05", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[25, 27], [167, 169]], "char_spans": [[140, 158], [943, 961]]}]}], "context_tokens": [["Transgenic", 0], ["mice", 11], ["over", 16], ["-", 20], ["expressing", 21], ["a", 32], ["mutated", 34], ["form", 42], ["of", 47], ["the", 50], ["human", 54], ["amyloid", 60], ["precursor", 68], ["protein", 78], ["(", 86], ["APP", 87], [",", 90], ["695", 92], ["isoform", 96], [")", 103], ["bearing", 105], ["a", 113], ["mutation", 115], ["associated", 124], ["with", 135], ["Alzheimer", 140], ["'s", 149], ["disease", 152], ["(", 160], ["V642I", 161], [",", 166], ["so", 168], ["-", 170], ["called", 171], ["London", 178], ["mutation", 185], [",", 193], ["hereafter", 195], ["APPLd2", 205], [")", 211], ["and", 213], ["wild", 217], ["-", 221], ["type", 222], ["controls", 227], ["were", 236], ["studied", 241], ["at", 249], ["age", 252], ["periods", 256], ["(", 264], ["3", 265], ["and", 267], ["10", 271], ["months", 274], [")", 280], ["prior", 282], ["to", 288], ["the", 291], ["overt", 295], ["development", 301], ["of", 313], ["neuritic", 316], ["amyloid", 325], ["plaques", 333], [".", 340], ["Both", 342], ["3-", 347], ["and", 350], ["10-month", 354], ["-", 362], ["old", 363], ["APPLd2", 367], ["mice", 374], ["had", 379], ["reflex", 383], ["eyelid", 390], ["responses", 397], ["like", 407], ["those", 412], ["of", 418], ["controls", 421], [",", 429], ["but", 431], ["only", 435], ["younger", 440], ["mice", 448], ["were", 453], ["able", 458], ["to", 463], ["acquire", 466], ["a", 474], ["classical", 476], ["conditioning", 486], ["of", 499], ["eyelid", 502], ["responses", 509], ["in", 519], ["a", 522], ["trace", 524], ["paradigm", 530], [".", 538], ["In", 540], ["vitro", 543], ["studies", 549], ["on", 557], ["hippocampal", 560], ["slices", 572], ["showed", 579], ["that", 586], ["10-month", 591], ["-", 599], ["old", 600], ["APPLd2", 604], ["mice", 611], ["also", 616], ["presented", 621], ["deficits", 631], ["in", 640], ["paired", 643], ["-", 649], ["pulse", 650], ["facilitation", 656], ["and", 669], ["long", 673], ["-", 677], ["term", 678], ["potentiation", 683], [",", 695], ["but", 697], ["presented", 701], ["a", 711], ["normal", 713], ["synaptic", 720], ["activation", 729], ["of", 740], ["CA1", 743], ["pyramidal", 747], ["cells", 757], ["by", 763], ["the", 766], ["stimulation", 770], ["of", 782], ["Schaffer", 785], ["collaterals", 794], [".", 805], ["It", 807], ["is", 810], ["proposed", 813], ["that", 822], ["definite", 827], ["functional", 836], ["changes", 847], ["may", 855], ["appear", 859], ["well", 866], ["in", 871], ["advance", 874], ["of", 882], ["noticeable", 885], ["structural", 896], ["alterations", 907], ["in", 919], ["this", 922], ["animal", 927], ["model", 934], ["of", 940], ["Alzheimer", 943], ["'s", 952], ["disease", 955], [",", 962], ["and", 964], ["that", 968], ["specific", 973], ["learning", 982], ["tasks", 991], ["could", 997], ["have", 1003], ["a", 1008], ["relevant", 1010], ["diagnostic", 1019], ["value", 1030], [".", 1035]]}
{"context": "Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder affecting one in 3,500 individuals. The mutation rate in the NF1 gene is one of the highest known for human genes. Compared to other methods, the protein truncation test (PTT) provides improved efficiency in detecting NF1 mutations which are dispersed throughout the gene which spans 350 kilobases of genomic DNA. We have applied the PTT and subsequent sequence analysis of cloned cDNA to identify mutations in NF1 patients. We report here the identification of two novel (W336X and Q315X), and one recurrent (R304X) mutation located in exon 7 and show that all three premature termination codons lead to skipping of exon 7 in a proportion of the transcripts derived from the mutated allele. Possible mutation-induced alterations of the RNA secondary structure and their impact on skipping of exon 7 of the NF1 gene are explored and discussed.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "b4e786bd8b8a4087859d3959d3641b2a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[84, 84], [4, 4], [52, 52], [23, 23], [158, 158]], "char_spans": [[484, 486], [26, 28], [291, 293], [134, 136], [880, 882]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["an", 34], ["autosomal", 37], ["dominant", 47], ["genetic", 56], ["disorder", 64], ["affecting", 73], ["one", 83], ["in", 87], ["3,500", 90], ["individuals", 96], [".", 107], ["The", 109], ["mutation", 113], ["rate", 122], ["in", 127], ["the", 130], ["NF1", 134], ["gene", 138], ["is", 143], ["one", 146], ["of", 150], ["the", 153], ["highest", 157], ["known", 165], ["for", 171], ["human", 175], ["genes", 181], [".", 186], ["Compared", 188], ["to", 197], ["other", 200], ["methods", 206], [",", 213], ["the", 215], ["protein", 219], ["truncation", 227], ["test", 238], ["(", 243], ["PTT", 244], [")", 247], ["provides", 249], ["improved", 258], ["efficiency", 267], ["in", 278], ["detecting", 281], ["NF1", 291], ["mutations", 295], ["which", 305], ["are", 311], ["dispersed", 315], ["throughout", 325], ["the", 336], ["gene", 340], ["which", 345], ["spans", 351], ["350", 357], ["kilobases", 361], ["of", 371], ["genomic", 374], ["DNA", 382], [".", 385], ["We", 387], ["have", 390], ["applied", 395], ["the", 403], ["PTT", 407], ["and", 411], ["subsequent", 415], ["sequence", 426], ["analysis", 435], ["of", 444], ["cloned", 447], ["cDNA", 454], ["to", 459], ["identify", 462], ["mutations", 471], ["in", 481], ["NF1", 484], ["patients", 488], [".", 496], ["We", 498], ["report", 501], ["here", 508], ["the", 513], ["identification", 517], ["of", 532], ["two", 535], ["novel", 539], ["(", 545], ["W336X", 546], ["and", 552], ["Q315X", 556], [")", 561], [",", 562], ["and", 564], ["one", 568], ["recurrent", 572], ["(", 582], ["R304X", 583], [")", 588], ["mutation", 590], ["located", 599], ["in", 607], ["exon", 610], ["7", 615], ["and", 617], ["show", 621], ["that", 626], ["all", 631], ["three", 635], ["premature", 641], ["termination", 651], ["codons", 663], ["lead", 670], ["to", 675], ["skipping", 678], ["of", 687], ["exon", 690], ["7", 695], ["in", 697], ["a", 700], ["proportion", 702], ["of", 713], ["the", 716], ["transcripts", 720], ["derived", 732], ["from", 740], ["the", 745], ["mutated", 749], ["allele", 757], [".", 763], ["Possible", 765], ["mutation", 774], ["-", 782], ["induced", 783], ["alterations", 791], ["of", 803], ["the", 806], ["RNA", 810], ["secondary", 814], ["structure", 824], ["and", 834], ["their", 838], ["impact", 844], ["on", 851], ["skipping", 854], ["of", 863], ["exon", 866], ["7", 871], ["of", 873], ["the", 876], ["NF1", 880], ["gene", 884], ["are", 889], ["explored", 893], ["and", 902], ["discussed", 906], [".", 915]]}
{"context": "Deubiquitinating enzymes (DUbs) play important roles in many ubiquitin-dependent pathways, yet how DUbs themselves are regulated is not well understood. Here, we provide insight into the mechanism by which ubiquitination directly enhances the activity of ataxin-3, a DUb implicated in protein quality control and the disease protein in the polyglutamine neurodegenerative disorder, Spinocerebellar Ataxia Type 3. We identify Lys-117, which resides near the catalytic triad, as the primary site of ubiquitination in wild type and pathogenic ataxin-3. Further studies indicate that ubiquitin-dependent activation of ataxin-3 at Lys-117 is important for its ability to reduce high molecular weight ubiquitinated species in cells. Ubiquitination at Lys-117 also facilitates the ability of ataxin-3 to induce aggresome formation in cells. Finally, structure-function studies support a model of activation whereby ubiquitination at Lys-117 enhances ataxin-3 activity independent of the known ubiquitin-binding sites in ataxin-3, most likely through a direct conformational change in or near the catalytic domain.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "76df6ea078eb43ef838474f8a30b5d15", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[160, 160], [149, 149], [99, 99], [125, 125], [42, 42], [88, 88]], "char_spans": [[1013, 1020], [943, 950], [614, 621], [785, 792], [255, 262], [540, 547]]}]}], "context_tokens": [["Deubiquitinating", 0], ["enzymes", 17], ["(", 25], ["DUbs", 26], [")", 30], ["play", 32], ["important", 37], ["roles", 47], ["in", 53], ["many", 56], ["ubiquitin", 61], ["-", 70], ["dependent", 71], ["pathways", 81], [",", 89], ["yet", 91], ["how", 95], ["DUbs", 99], ["themselves", 104], ["are", 115], ["regulated", 119], ["is", 129], ["not", 132], ["well", 136], ["understood", 141], [".", 151], ["Here", 153], [",", 157], ["we", 159], ["provide", 162], ["insight", 170], ["into", 178], ["the", 183], ["mechanism", 187], ["by", 197], ["which", 200], ["ubiquitination", 206], ["directly", 221], ["enhances", 230], ["the", 239], ["activity", 243], ["of", 252], ["ataxin-3", 255], [",", 263], ["a", 265], ["DUb", 267], ["implicated", 271], ["in", 282], ["protein", 285], ["quality", 293], ["control", 301], ["and", 309], ["the", 313], ["disease", 317], ["protein", 325], ["in", 333], ["the", 336], ["polyglutamine", 340], ["neurodegenerative", 354], ["disorder", 372], [",", 380], ["Spinocerebellar", 382], ["Ataxia", 398], ["Type", 405], ["3", 410], [".", 411], ["We", 413], ["identify", 416], ["Lys-117", 425], [",", 432], ["which", 434], ["resides", 440], ["near", 448], ["the", 453], ["catalytic", 457], ["triad", 467], [",", 472], ["as", 474], ["the", 477], ["primary", 481], ["site", 489], ["of", 494], ["ubiquitination", 497], ["in", 512], ["wild", 515], ["type", 520], ["and", 525], ["pathogenic", 529], ["ataxin-3", 540], [".", 548], ["Further", 550], ["studies", 558], ["indicate", 566], ["that", 575], ["ubiquitin", 580], ["-", 589], ["dependent", 590], ["activation", 600], ["of", 611], ["ataxin-3", 614], ["at", 623], ["Lys-117", 626], ["is", 634], ["important", 637], ["for", 647], ["its", 651], ["ability", 655], ["to", 663], ["reduce", 666], ["high", 673], ["molecular", 678], ["weight", 688], ["ubiquitinated", 695], ["species", 709], ["in", 717], ["cells", 720], [".", 725], ["Ubiquitination", 727], ["at", 742], ["Lys-117", 745], ["also", 753], ["facilitates", 758], ["the", 770], ["ability", 774], ["of", 782], ["ataxin-3", 785], ["to", 794], ["induce", 797], ["aggresome", 804], ["formation", 814], ["in", 824], ["cells", 827], [".", 832], ["Finally", 834], [",", 841], ["structure", 843], ["-", 852], ["function", 853], ["studies", 862], ["support", 870], ["a", 878], ["model", 880], ["of", 886], ["activation", 889], ["whereby", 900], ["ubiquitination", 908], ["at", 923], ["Lys-117", 926], ["enhances", 934], ["ataxin-3", 943], ["activity", 952], ["independent", 961], ["of", 973], ["the", 976], ["known", 980], ["ubiquitin", 986], ["-", 995], ["binding", 996], ["sites", 1004], ["in", 1010], ["ataxin-3", 1013], [",", 1021], ["most", 1023], ["likely", 1028], ["through", 1035], ["a", 1043], ["direct", 1045], ["conformational", 1052], ["change", 1067], ["in", 1074], ["or", 1077], ["near", 1080], ["the", 1085], ["catalytic", 1089], ["domain", 1099], [".", 1105]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited small-artery disease of mid-adulthood caused by mutations of the NOTCH3 gene. The disease is responsible for widespread white-matter lesions associated with lacunar infarctions in various subcortical areas. The disease is responsible for migraine with aura and ischemic strokes, and is associated with various degrees of cognitive impairment and with mood disturbances. CADASIL is considered as a unique model to investigate what is known as \"subcortical ischemic vascular dementia.\" Recent data suggest that the number of lacunar infarctions and severity of cerebral atrophy are the main magnetic resonance imaging markers associated with cognitive and motor disabilities in this disorder. Mood disturbances are reported in 10% to 20% of patients, most often in association with cognitive alterations. Their exact origin remains unknown; the presence of ischemic lesions within the basal ganglia or the frontal white matter may promote the occurrence of these symptoms. Further studies are needed to better understand the relationships between cerebral lesions and both cognitive and psychiatric symptoms in this small-vessel disease of the brain.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "b2f73e6827624d46a50622245bc0bc8c", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[28, 29]], "char_spans": [[182, 192]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["an", 104], ["inherited", 107], ["small", 117], ["-", 122], ["artery", 123], ["disease", 130], ["of", 138], ["mid", 141], ["-", 144], ["adulthood", 145], ["caused", 155], ["by", 162], ["mutations", 165], ["of", 175], ["the", 178], ["NOTCH3", 182], ["gene", 189], [".", 193], ["The", 195], ["disease", 199], ["is", 207], ["responsible", 210], ["for", 222], ["widespread", 226], ["white", 237], ["-", 242], ["matter", 243], ["lesions", 250], ["associated", 258], ["with", 269], ["lacunar", 274], ["infarctions", 282], ["in", 294], ["various", 297], ["subcortical", 305], ["areas", 317], [".", 322], ["The", 324], ["disease", 328], ["is", 336], ["responsible", 339], ["for", 351], ["migraine", 355], ["with", 364], ["aura", 369], ["and", 374], ["ischemic", 378], ["strokes", 387], [",", 394], ["and", 396], ["is", 400], ["associated", 403], ["with", 414], ["various", 419], ["degrees", 427], ["of", 435], ["cognitive", 438], ["impairment", 448], ["and", 459], ["with", 463], ["mood", 468], ["disturbances", 473], [".", 485], ["CADASIL", 487], ["is", 495], ["considered", 498], ["as", 509], ["a", 512], ["unique", 514], ["model", 521], ["to", 527], ["investigate", 530], ["what", 542], ["is", 547], ["known", 550], ["as", 556], ["\"", 559], ["subcortical", 560], ["ischemic", 572], ["vascular", 581], ["dementia", 590], [".", 598], ["\"", 599], ["Recent", 601], ["data", 608], ["suggest", 613], ["that", 621], ["the", 626], ["number", 630], ["of", 637], ["lacunar", 640], ["infarctions", 648], ["and", 660], ["severity", 664], ["of", 673], ["cerebral", 676], ["atrophy", 685], ["are", 693], ["the", 697], ["main", 701], ["magnetic", 706], ["resonance", 715], ["imaging", 725], ["markers", 733], ["associated", 741], ["with", 752], ["cognitive", 757], ["and", 767], ["motor", 771], ["disabilities", 777], ["in", 790], ["this", 793], ["disorder", 798], [".", 806], ["Mood", 808], ["disturbances", 813], ["are", 826], ["reported", 830], ["in", 839], ["10", 842], ["%", 844], ["to", 846], ["20", 849], ["%", 851], ["of", 853], ["patients", 856], [",", 864], ["most", 866], ["often", 871], ["in", 877], ["association", 880], ["with", 892], ["cognitive", 897], ["alterations", 907], [".", 918], ["Their", 920], ["exact", 926], ["origin", 932], ["remains", 939], ["unknown", 947], [";", 954], ["the", 956], ["presence", 960], ["of", 969], ["ischemic", 972], ["lesions", 981], ["within", 989], ["the", 996], ["basal", 1000], ["ganglia", 1006], ["or", 1014], ["the", 1017], ["frontal", 1021], ["white", 1029], ["matter", 1035], ["may", 1042], ["promote", 1046], ["the", 1054], ["occurrence", 1058], ["of", 1069], ["these", 1072], ["symptoms", 1078], [".", 1086], ["Further", 1088], ["studies", 1096], ["are", 1104], ["needed", 1108], ["to", 1115], ["better", 1118], ["understand", 1125], ["the", 1136], ["relationships", 1140], ["between", 1154], ["cerebral", 1162], ["lesions", 1171], ["and", 1179], ["both", 1183], ["cognitive", 1188], ["and", 1198], ["psychiatric", 1202], ["symptoms", 1214], ["in", 1223], ["this", 1226], ["small", 1231], ["-", 1236], ["vessel", 1237], ["disease", 1244], ["of", 1252], ["the", 1255], ["brain", 1259], [".", 1264]]}
{"context": "Turner's syndrome (TS) is a chromosomal defect with partial or total absence of the X chromosome. Our objective is to report our experience in Greece with patients suffering from TS and trying to conceive; therefore, we present four patients with TS, who underwent In vitro fertilization (ICSI) with donor oocytes in order to get pregnant. Three out of four patients managed to conceive and bring pregnancy to completion. It was shown that patients diagnosed in childhood or adolescence with TS have the possibility to undergo hormone replacement therapy (HRT) and thus, secondary sexual characteristics as well as uterus of almost normal size can develop. Assisted reproduction techniques (ART), predominantly with donated oocytes, could give these patients the possibility to have children.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "80b1b799ab8b4a54ad19e73ff5640506", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[17, 17]], "char_spans": [[84, 84]]}]}], "context_tokens": [["Turner", 0], ["'s", 6], ["syndrome", 9], ["(", 18], ["TS", 19], [")", 21], ["is", 23], ["a", 26], ["chromosomal", 28], ["defect", 40], ["with", 47], ["partial", 52], ["or", 60], ["total", 63], ["absence", 69], ["of", 77], ["the", 80], ["X", 84], ["chromosome", 86], [".", 96], ["Our", 98], ["objective", 102], ["is", 112], ["to", 115], ["report", 118], ["our", 125], ["experience", 129], ["in", 140], ["Greece", 143], ["with", 150], ["patients", 155], ["suffering", 164], ["from", 174], ["TS", 179], ["and", 182], ["trying", 186], ["to", 193], ["conceive", 196], [";", 204], ["therefore", 206], [",", 215], ["we", 217], ["present", 220], ["four", 228], ["patients", 233], ["with", 242], ["TS", 247], [",", 249], ["who", 251], ["underwent", 255], ["In", 265], ["vitro", 268], ["fertilization", 274], ["(", 288], ["ICSI", 289], [")", 293], ["with", 295], ["donor", 300], ["oocytes", 306], ["in", 314], ["order", 317], ["to", 323], ["get", 326], ["pregnant", 330], [".", 338], ["Three", 340], ["out", 346], ["of", 350], ["four", 353], ["patients", 358], ["managed", 367], ["to", 375], ["conceive", 378], ["and", 387], ["bring", 391], ["pregnancy", 397], ["to", 407], ["completion", 410], [".", 420], ["It", 422], ["was", 425], ["shown", 429], ["that", 435], ["patients", 440], ["diagnosed", 449], ["in", 459], ["childhood", 462], ["or", 472], ["adolescence", 475], ["with", 487], ["TS", 492], ["have", 495], ["the", 500], ["possibility", 504], ["to", 516], ["undergo", 519], ["hormone", 527], ["replacement", 535], ["therapy", 547], ["(", 555], ["HRT", 556], [")", 559], ["and", 561], ["thus", 565], [",", 569], ["secondary", 571], ["sexual", 581], ["characteristics", 588], ["as", 604], ["well", 607], ["as", 612], ["uterus", 615], ["of", 622], ["almost", 625], ["normal", 632], ["size", 639], ["can", 644], ["develop", 648], [".", 655], ["Assisted", 657], ["reproduction", 666], ["techniques", 679], ["(", 690], ["ART", 691], [")", 694], [",", 695], ["predominantly", 697], ["with", 711], ["donated", 716], ["oocytes", 724], [",", 731], ["could", 733], ["give", 739], ["these", 744], ["patients", 750], ["the", 759], ["possibility", 763], ["to", 775], ["have", 778], ["children", 783], [".", 791]]}
{"context": "In 1957, Simpson published a seminal paper defining the risk factors for recurrence following surgical treatment of intracranial meningiomas. Given that Simpson's study was published more than 50 years ago, preceding image guidance technology and MR imaging, the authors reviewed their own experience with surgical treatment of Grade I meningiomas to determine if Simpson's grading scale is still relevant to modern neurosurgical practice. From this cohort, the authors evaluated all patients undergoing craniotomy for resection of a histologically proven WHO Grade I meningioma as their initial therapy. Clinical information was retrospectively reconstructed using patient medical records and radiological data. Recurrence analysis was performed using the Kaplan-Meier method. The 5-year recurrence/progression-free survival for all patients receiving a Simpson Grade I, II, III, or IV resection was 95, 85, 88, and 81%, respectively (p = not significant, log-rank test). Kaplan-Meier analysis revealed no significant difference in recurrence-free survival between patients receiving a Simpson Grade I, II, III, or IV resection. Analysis limited to meningiomas arising from the skull base (excluding the cavernous sinus) similarly found no significant benefit to Simpson Grade I or II resection, and the survival curves were nearly superimposed. In this study of a cohort of patients undergoing surgery for WHO Grade I meningiomas, the authors demonstrate that the benefit of more aggressive attempts to resect the tumor with dura and underlying bone was negligible compared with simply removing the entire tumor, or even leaving small amounts of tumor attached to critical structures. The authors believe that these data reflect an evolution in the nature of meningioma surgery over the past 2 decades, and bring into question the relevance of using Simpson's grading system as the sole predictor of recurrence.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "2ae2864e473745f697faa29712bfb28c", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[303, 303], [90, 90]], "char_spans": [[1761, 1770], [568, 577]]}]}], "context_tokens": [["In", 0], ["1957", 3], [",", 7], ["Simpson", 9], ["published", 17], ["a", 27], ["seminal", 29], ["paper", 37], ["defining", 43], ["the", 52], ["risk", 56], ["factors", 61], ["for", 69], ["recurrence", 73], ["following", 84], ["surgical", 94], ["treatment", 103], ["of", 113], ["intracranial", 116], ["meningiomas", 129], [".", 140], ["Given", 142], ["that", 148], ["Simpson", 153], ["'s", 160], ["study", 163], ["was", 169], ["published", 173], ["more", 183], ["than", 188], ["50", 193], ["years", 196], ["ago", 202], [",", 205], ["preceding", 207], ["image", 217], ["guidance", 223], ["technology", 232], ["and", 243], ["MR", 247], ["imaging", 250], [",", 257], ["the", 259], ["authors", 263], ["reviewed", 271], ["their", 280], ["own", 286], ["experience", 290], ["with", 301], ["surgical", 306], ["treatment", 315], ["of", 325], ["Grade", 328], ["I", 334], ["meningiomas", 336], ["to", 348], ["determine", 351], ["if", 361], ["Simpson", 364], ["'s", 371], ["grading", 374], ["scale", 382], ["is", 388], ["still", 391], ["relevant", 397], ["to", 406], ["modern", 409], ["neurosurgical", 416], ["practice", 430], [".", 438], ["From", 440], ["this", 445], ["cohort", 450], [",", 456], ["the", 458], ["authors", 462], ["evaluated", 470], ["all", 480], ["patients", 484], ["undergoing", 493], ["craniotomy", 504], ["for", 515], ["resection", 519], ["of", 529], ["a", 532], ["histologically", 534], ["proven", 549], ["WHO", 556], ["Grade", 560], ["I", 566], ["meningioma", 568], ["as", 579], ["their", 582], ["initial", 588], ["therapy", 596], [".", 603], ["Clinical", 605], ["information", 614], ["was", 626], ["retrospectively", 630], ["reconstructed", 646], ["using", 660], ["patient", 666], ["medical", 674], ["records", 682], ["and", 690], ["radiological", 694], ["data", 707], [".", 711], ["Recurrence", 713], ["analysis", 724], ["was", 733], ["performed", 737], ["using", 747], ["the", 753], ["Kaplan", 757], ["-", 763], ["Meier", 764], ["method", 770], [".", 776], ["The", 778], ["5-year", 782], ["recurrence", 789], ["/", 799], ["progression", 800], ["-", 811], ["free", 812], ["survival", 817], ["for", 826], ["all", 830], ["patients", 834], ["receiving", 843], ["a", 853], ["Simpson", 855], ["Grade", 863], ["I", 869], [",", 870], ["II", 872], [",", 874], ["III", 876], [",", 879], ["or", 881], ["IV", 884], ["resection", 887], ["was", 897], ["95", 901], [",", 903], ["85", 905], [",", 907], ["88", 909], [",", 911], ["and", 913], ["81", 917], ["%", 919], [",", 920], ["respectively", 922], ["(", 935], ["p", 936], ["=", 938], ["not", 940], ["significant", 944], [",", 955], ["log", 957], ["-", 960], ["rank", 961], ["test", 966], [")", 970], [".", 971], ["Kaplan", 973], ["-", 979], ["Meier", 980], ["analysis", 986], ["revealed", 995], ["no", 1004], ["significant", 1007], ["difference", 1019], ["in", 1030], ["recurrence", 1033], ["-", 1043], ["free", 1044], ["survival", 1049], ["between", 1058], ["patients", 1066], ["receiving", 1075], ["a", 1085], ["Simpson", 1087], ["Grade", 1095], ["I", 1101], [",", 1102], ["II", 1104], [",", 1106], ["III", 1108], [",", 1111], ["or", 1113], ["IV", 1116], ["resection", 1119], [".", 1128], ["Analysis", 1130], ["limited", 1139], ["to", 1147], ["meningiomas", 1150], ["arising", 1162], ["from", 1170], ["the", 1175], ["skull", 1179], ["base", 1185], ["(", 1190], ["excluding", 1191], ["the", 1201], ["cavernous", 1205], ["sinus", 1215], [")", 1220], ["similarly", 1222], ["found", 1232], ["no", 1238], ["significant", 1241], ["benefit", 1253], ["to", 1261], ["Simpson", 1264], ["Grade", 1272], ["I", 1278], ["or", 1280], ["II", 1283], ["resection", 1286], [",", 1295], ["and", 1297], ["the", 1301], ["survival", 1305], ["curves", 1314], ["were", 1321], ["nearly", 1326], ["superimposed", 1333], [".", 1345], ["In", 1347], ["this", 1350], ["study", 1355], ["of", 1361], ["a", 1364], ["cohort", 1366], ["of", 1373], ["patients", 1376], ["undergoing", 1385], ["surgery", 1396], ["for", 1404], ["WHO", 1408], ["Grade", 1412], ["I", 1418], ["meningiomas", 1420], [",", 1431], ["the", 1433], ["authors", 1437], ["demonstrate", 1445], ["that", 1457], ["the", 1462], ["benefit", 1466], ["of", 1474], ["more", 1477], ["aggressive", 1482], ["attempts", 1493], ["to", 1502], ["resect", 1505], ["the", 1512], ["tumor", 1516], ["with", 1522], ["dura", 1527], ["and", 1532], ["underlying", 1536], ["bone", 1547], ["was", 1552], ["negligible", 1556], ["compared", 1567], ["with", 1576], ["simply", 1581], ["removing", 1588], ["the", 1597], ["entire", 1601], ["tumor", 1608], [",", 1613], ["or", 1615], ["even", 1618], ["leaving", 1623], ["small", 1631], ["amounts", 1637], ["of", 1645], ["tumor", 1648], ["attached", 1654], ["to", 1663], ["critical", 1666], ["structures", 1675], [".", 1685], ["The", 1687], ["authors", 1691], ["believe", 1699], ["that", 1707], ["these", 1712], ["data", 1718], ["reflect", 1723], ["an", 1731], ["evolution", 1734], ["in", 1744], ["the", 1747], ["nature", 1751], ["of", 1758], ["meningioma", 1761], ["surgery", 1772], ["over", 1780], ["the", 1785], ["past", 1789], ["2", 1794], ["decades", 1796], [",", 1803], ["and", 1805], ["bring", 1809], ["into", 1815], ["question", 1820], ["the", 1829], ["relevance", 1833], ["of", 1843], ["using", 1846], ["Simpson", 1852], ["'s", 1859], ["grading", 1862], ["system", 1870], ["as", 1877], ["the", 1880], ["sole", 1884], ["predictor", 1889], ["of", 1899], ["recurrence", 1902], [".", 1912]]}
{"context": "To determine the validity of the rapid antigen test (RAT) OSOM StrepA Genzyme for the diagnosis of acute pharyngitis caused by group A beta-haemolytic strep (GABHS). Diagnostic techniques survey. Urban primary care centre, Spain. All patients over 14 years old seen in 6 surgeries with sore throat and 2 or more Centor criteria: pharyngotonsillar exudate, tender laterocervical nodes, absence of coughing, and/or history or presence of fever. Pharyngeal swabs were taken from all the patients, one for RAT and another to send for culture in the microbiology department. A total of 182 patients were evaluable, with a mean age of 30.6 (12.1) years of which 116 were women (63.7%); 63 patients had 2 Centor criteria; 83 had 3 and 36, the 4 criteria. The culture was positive in 102 patients (56%), with GABHS showing infection in forty (22%; 95% confidence interval [CI], 21.2-22.8). Group C Streptococcus was isolated in 26 patients (14.3%). GABHS was higher among patients with four Centor criteria (38.9% vs 25.3% observed among those with 3 criteria and 7.9% with 2 criteria; P<.001). Sensitivity of RAT was 95%, with a specificity of 93%, a positive predictive value of 79.2% and a negative predictive value of 98.5%. These results show the usefulness of RAT for diagnosing streptococcal pharyngitis. Its use should be spread to all primary care practices.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "e8f16ae3e5874a4181985bd826ce59f8", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[268, 269]], "char_spans": [[1277, 1301]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["validity", 17], ["of", 26], ["the", 29], ["rapid", 33], ["antigen", 39], ["test", 47], ["(", 52], ["RAT", 53], [")", 56], ["OSOM", 58], ["StrepA", 63], ["Genzyme", 70], ["for", 78], ["the", 82], ["diagnosis", 86], ["of", 96], ["acute", 99], ["pharyngitis", 105], ["caused", 117], ["by", 124], ["group", 127], ["A", 133], ["beta", 135], ["-", 139], ["haemolytic", 140], ["strep", 151], ["(", 157], ["GABHS", 158], [")", 163], [".", 164], ["Diagnostic", 166], ["techniques", 177], ["survey", 188], [".", 194], ["Urban", 196], ["primary", 202], ["care", 210], ["centre", 215], [",", 221], ["Spain", 223], [".", 228], ["All", 230], ["patients", 234], ["over", 243], ["14", 248], ["years", 251], ["old", 257], ["seen", 261], ["in", 266], ["6", 269], ["surgeries", 271], ["with", 281], ["sore", 286], ["throat", 291], ["and", 298], ["2", 302], ["or", 304], ["more", 307], ["Centor", 312], ["criteria", 319], [":", 327], ["pharyngotonsillar", 329], ["exudate", 347], [",", 354], ["tender", 356], ["laterocervical", 363], ["nodes", 378], [",", 383], ["absence", 385], ["of", 393], ["coughing", 396], [",", 404], ["and/or", 406], ["history", 413], ["or", 421], ["presence", 424], ["of", 433], ["fever", 436], [".", 441], ["Pharyngeal", 443], ["swabs", 454], ["were", 460], ["taken", 465], ["from", 471], ["all", 476], ["the", 480], ["patients", 484], [",", 492], ["one", 494], ["for", 498], ["RAT", 502], ["and", 506], ["another", 510], ["to", 518], ["send", 521], ["for", 526], ["culture", 530], ["in", 538], ["the", 541], ["microbiology", 545], ["department", 558], [".", 568], ["A", 570], ["total", 572], ["of", 578], ["182", 581], ["patients", 585], ["were", 594], ["evaluable", 599], [",", 608], ["with", 610], ["a", 615], ["mean", 617], ["age", 622], ["of", 626], ["30.6", 629], ["(", 634], ["12.1", 635], [")", 639], ["years", 641], ["of", 647], ["which", 650], ["116", 656], ["were", 660], ["women", 665], ["(", 671], ["63.7", 672], ["%", 676], [")", 677], [";", 678], ["63", 680], ["patients", 683], ["had", 692], ["2", 696], ["Centor", 698], ["criteria", 705], [";", 713], ["83", 715], ["had", 718], ["3", 722], ["and", 724], ["36", 728], [",", 730], ["the", 732], ["4", 736], ["criteria", 738], [".", 746], ["The", 748], ["culture", 752], ["was", 760], ["positive", 764], ["in", 773], ["102", 776], ["patients", 780], ["(", 789], ["56", 790], ["%", 792], [")", 793], [",", 794], ["with", 796], ["GABHS", 801], ["showing", 807], ["infection", 815], ["in", 825], ["forty", 828], ["(", 834], ["22", 835], ["%", 837], [";", 838], ["95", 840], ["%", 842], ["confidence", 844], ["interval", 855], ["[", 864], ["CI", 865], ["]", 867], [",", 868], ["21.2", 870], ["-", 874], ["22.8", 875], [")", 879], [".", 880], ["Group", 882], ["C", 888], ["Streptococcus", 890], ["was", 904], ["isolated", 908], ["in", 917], ["26", 920], ["patients", 923], ["(", 932], ["14.3", 933], ["%", 937], [")", 938], [".", 939], ["GABHS", 941], ["was", 947], ["higher", 951], ["among", 958], ["patients", 964], ["with", 973], ["four", 978], ["Centor", 983], ["criteria", 990], ["(", 999], ["38.9", 1000], ["%", 1004], ["vs", 1006], ["25.3", 1009], ["%", 1013], ["observed", 1015], ["among", 1024], ["those", 1030], ["with", 1036], ["3", 1041], ["criteria", 1043], ["and", 1052], ["7.9", 1056], ["%", 1059], ["with", 1061], ["2", 1066], ["criteria", 1068], [";", 1076], ["P<.001", 1078], [")", 1084], [".", 1085], ["Sensitivity", 1087], ["of", 1099], ["RAT", 1102], ["was", 1106], ["95", 1110], ["%", 1112], [",", 1113], ["with", 1115], ["a", 1120], ["specificity", 1122], ["of", 1134], ["93", 1137], ["%", 1139], [",", 1140], ["a", 1142], ["positive", 1144], ["predictive", 1153], ["value", 1164], ["of", 1170], ["79.2", 1173], ["%", 1177], ["and", 1179], ["a", 1183], ["negative", 1185], ["predictive", 1194], ["value", 1205], ["of", 1211], ["98.5", 1214], ["%", 1218], [".", 1219], ["These", 1221], ["results", 1227], ["show", 1235], ["the", 1240], ["usefulness", 1244], ["of", 1255], ["RAT", 1258], ["for", 1262], ["diagnosing", 1266], ["streptococcal", 1277], ["pharyngitis", 1291], [".", 1302], ["Its", 1304], ["use", 1308], ["should", 1312], ["be", 1319], ["spread", 1322], ["to", 1329], ["all", 1332], ["primary", 1336], ["care", 1344], ["practices", 1349], [".", 1358]]}
{"context": "The natively disordered protein alpha-synuclein is the primary component of Lewy bodies, the cellular hallmark of Parkinson's disease. Most studies of this protein are performed in dilute solution, but its biologically relevant role is performed in the crowded environment inside cells. We addressed the effects of macromolecular crowding on alpha-synuclein by combining NMR data acquired in living Escherichia coli with in vitro NMR data. The crowded environment in the E.coli periplasm prevents a conformational change that is detected at 35 degrees C in dilute solution. This change is associated with an increase in hydrodynamic radius and the formation of secondary structure in the N-terminal 100 amino acid residues. By preventing this temperature-induced conformational change, crowding in the E.coli periplasm stabilizes the disordered monomer. We obtain the same stabilization in vitro upon crowding alpha-synuclein with 300 g/l of bovine serum albumin, indicating that crowding alone is sufficient to stabilize the disordered, monomeric protein. Two disease-associated variants (A30P and A53T) behave in the same way in both dilute solution and in the E.coli periplasm. These data reveal the importance of approaching the effects of macromolecular crowding on a case-by-case basis. Additionally, our work shows that discrete structured protein conformations may not be achieved by alpha-synuclein inside cells, implicating the commonly overlooked aspect of macromolecular crowding as a possible factor in the etiology of Parkinson's disease.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "ef3220cd0654492584edc7a94fda2c33", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[150, 152], [56, 58], [4, 6], [239, 241]], "char_spans": [[910, 924], [342, 356], [32, 46], [1392, 1406]]}]}], "context_tokens": [["The", 0], ["natively", 4], ["disordered", 13], ["protein", 24], ["alpha", 32], ["-", 37], ["synuclein", 38], ["is", 48], ["the", 51], ["primary", 55], ["component", 63], ["of", 73], ["Lewy", 76], ["bodies", 81], [",", 87], ["the", 89], ["cellular", 93], ["hallmark", 102], ["of", 111], ["Parkinson", 114], ["'s", 123], ["disease", 126], [".", 133], ["Most", 135], ["studies", 140], ["of", 148], ["this", 151], ["protein", 156], ["are", 164], ["performed", 168], ["in", 178], ["dilute", 181], ["solution", 188], [",", 196], ["but", 198], ["its", 202], ["biologically", 206], ["relevant", 219], ["role", 228], ["is", 233], ["performed", 236], ["in", 246], ["the", 249], ["crowded", 253], ["environment", 261], ["inside", 273], ["cells", 280], [".", 285], ["We", 287], ["addressed", 290], ["the", 300], ["effects", 304], ["of", 312], ["macromolecular", 315], ["crowding", 330], ["on", 339], ["alpha", 342], ["-", 347], ["synuclein", 348], ["by", 358], ["combining", 361], ["NMR", 371], ["data", 375], ["acquired", 380], ["in", 389], ["living", 392], ["Escherichia", 399], ["coli", 411], ["with", 416], ["in", 421], ["vitro", 424], ["NMR", 430], ["data", 434], [".", 438], ["The", 440], ["crowded", 444], ["environment", 452], ["in", 464], ["the", 467], ["E.coli", 471], ["periplasm", 478], ["prevents", 488], ["a", 497], ["conformational", 499], ["change", 514], ["that", 521], ["is", 526], ["detected", 529], ["at", 538], ["35", 541], ["degrees", 544], ["C", 552], ["in", 554], ["dilute", 557], ["solution", 564], [".", 572], ["This", 574], ["change", 579], ["is", 586], ["associated", 589], ["with", 600], ["an", 605], ["increase", 608], ["in", 617], ["hydrodynamic", 620], ["radius", 633], ["and", 640], ["the", 644], ["formation", 648], ["of", 658], ["secondary", 661], ["structure", 671], ["in", 681], ["the", 684], ["N", 688], ["-", 689], ["terminal", 690], ["100", 699], ["amino", 703], ["acid", 709], ["residues", 714], [".", 722], ["By", 724], ["preventing", 727], ["this", 738], ["temperature", 743], ["-", 754], ["induced", 755], ["conformational", 763], ["change", 778], [",", 784], ["crowding", 786], ["in", 795], ["the", 798], ["E.coli", 802], ["periplasm", 809], ["stabilizes", 819], ["the", 830], ["disordered", 834], ["monomer", 845], [".", 852], ["We", 854], ["obtain", 857], ["the", 864], ["same", 868], ["stabilization", 873], ["in", 887], ["vitro", 890], ["upon", 896], ["crowding", 901], ["alpha", 910], ["-", 915], ["synuclein", 916], ["with", 926], ["300", 931], ["g", 935], ["/", 936], ["l", 937], ["of", 939], ["bovine", 942], ["serum", 949], ["albumin", 955], [",", 962], ["indicating", 964], ["that", 975], ["crowding", 980], ["alone", 989], ["is", 995], ["sufficient", 998], ["to", 1009], ["stabilize", 1012], ["the", 1022], ["disordered", 1026], [",", 1036], ["monomeric", 1038], ["protein", 1048], [".", 1055], ["Two", 1057], ["disease", 1061], ["-", 1068], ["associated", 1069], ["variants", 1080], ["(", 1089], ["A30P", 1090], ["and", 1095], ["A53", 1099], ["T", 1102], [")", 1103], ["behave", 1105], ["in", 1112], ["the", 1115], ["same", 1119], ["way", 1124], ["in", 1128], ["both", 1131], ["dilute", 1136], ["solution", 1143], ["and", 1152], ["in", 1156], ["the", 1159], ["E.coli", 1163], ["periplasm", 1170], [".", 1179], ["These", 1181], ["data", 1187], ["reveal", 1192], ["the", 1199], ["importance", 1203], ["of", 1214], ["approaching", 1217], ["the", 1229], ["effects", 1233], ["of", 1241], ["macromolecular", 1244], ["crowding", 1259], ["on", 1268], ["a", 1271], ["case", 1273], ["-", 1277], ["by", 1278], ["-", 1280], ["case", 1281], ["basis", 1286], [".", 1291], ["Additionally", 1293], [",", 1305], ["our", 1307], ["work", 1311], ["shows", 1316], ["that", 1322], ["discrete", 1327], ["structured", 1336], ["protein", 1347], ["conformations", 1355], ["may", 1369], ["not", 1373], ["be", 1377], ["achieved", 1380], ["by", 1389], ["alpha", 1392], ["-", 1397], ["synuclein", 1398], ["inside", 1408], ["cells", 1415], [",", 1420], ["implicating", 1422], ["the", 1434], ["commonly", 1438], ["overlooked", 1447], ["aspect", 1458], ["of", 1465], ["macromolecular", 1468], ["crowding", 1483], ["as", 1492], ["a", 1495], ["possible", 1497], ["factor", 1506], ["in", 1513], ["the", 1516], ["etiology", 1520], ["of", 1529], ["Parkinson", 1532], ["'s", 1541], ["disease", 1544], [".", 1551]]}
{"context": "Contrary to earlier beliefs, viruses are not the smallest causative agents of infectious diseases. Single-stranded RNAs as small as 246 nucleotides exist in certain higher plants and cause more than a dozen crop diseases. These RNAs have been termed viroids. Despite their extremely limited information content, viroids replicate autonomously in susceptible cells--that is, they do not require helper functions from simultaneously replicating conventional viruses. Viroids are covalently closed circular molecules with a characteristic rodlike secondary structure in which short helical regions are interrupted by internal and bulge loops. Viroids are not translated; they are replicated by a host enzyme (or enzymes) (probably RNA polymerase II) via oligomeric RNA intermediates by a rolling circle mechanism. Viroidlike satellite RNAs resemble viroids in size and molecular structure, but are found within the capsids of specific helper viruses on which they depend for their own replication. These RNAs are of great interest to molecular biology for at least two reasons: 1) they are the smallest and simplest replicating molecules known, and 2) they may represent living fossils of precellular evolution in a hypothetical RNA world.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "2f0016f1f1004c60afce22d6816d93e1", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[75, 75], [53, 53], [100, 100], [44, 44], [136, 136]], "char_spans": [[465, 471], [312, 318], [640, 646], [250, 256], [846, 852]]}]}], "context_tokens": [["Contrary", 0], ["to", 9], ["earlier", 12], ["beliefs", 20], [",", 27], ["viruses", 29], ["are", 37], ["not", 41], ["the", 45], ["smallest", 49], ["causative", 58], ["agents", 68], ["of", 75], ["infectious", 78], ["diseases", 89], [".", 97], ["Single", 99], ["-", 105], ["stranded", 106], ["RNAs", 115], ["as", 120], ["small", 123], ["as", 129], ["246", 132], ["nucleotides", 136], ["exist", 148], ["in", 154], ["certain", 157], ["higher", 165], ["plants", 172], ["and", 179], ["cause", 183], ["more", 189], ["than", 194], ["a", 199], ["dozen", 201], ["crop", 207], ["diseases", 212], [".", 220], ["These", 222], ["RNAs", 228], ["have", 233], ["been", 238], ["termed", 243], ["viroids", 250], [".", 257], ["Despite", 259], ["their", 267], ["extremely", 273], ["limited", 283], ["information", 291], ["content", 303], [",", 310], ["viroids", 312], ["replicate", 320], ["autonomously", 330], ["in", 343], ["susceptible", 346], ["cells", 358], ["--", 363], ["that", 365], ["is", 370], [",", 372], ["they", 374], ["do", 379], ["not", 382], ["require", 386], ["helper", 394], ["functions", 401], ["from", 411], ["simultaneously", 416], ["replicating", 431], ["conventional", 443], ["viruses", 456], [".", 463], ["Viroids", 465], ["are", 473], ["covalently", 477], ["closed", 488], ["circular", 495], ["molecules", 504], ["with", 514], ["a", 519], ["characteristic", 521], ["rodlike", 536], ["secondary", 544], ["structure", 554], ["in", 564], ["which", 567], ["short", 573], ["helical", 579], ["regions", 587], ["are", 595], ["interrupted", 599], ["by", 611], ["internal", 614], ["and", 623], ["bulge", 627], ["loops", 633], [".", 638], ["Viroids", 640], ["are", 648], ["not", 652], ["translated", 656], [";", 666], ["they", 668], ["are", 673], ["replicated", 677], ["by", 688], ["a", 691], ["host", 693], ["enzyme", 698], ["(", 705], ["or", 706], ["enzymes", 709], [")", 716], ["(", 718], ["probably", 719], ["RNA", 728], ["polymerase", 732], ["II", 743], [")", 745], ["via", 747], ["oligomeric", 751], ["RNA", 762], ["intermediates", 766], ["by", 780], ["a", 783], ["rolling", 785], ["circle", 793], ["mechanism", 800], [".", 809], ["Viroidlike", 811], ["satellite", 822], ["RNAs", 832], ["resemble", 837], ["viroids", 846], ["in", 854], ["size", 857], ["and", 862], ["molecular", 866], ["structure", 876], [",", 885], ["but", 887], ["are", 891], ["found", 895], ["within", 901], ["the", 908], ["capsids", 912], ["of", 920], ["specific", 923], ["helper", 932], ["viruses", 939], ["on", 947], ["which", 950], ["they", 956], ["depend", 961], ["for", 968], ["their", 972], ["own", 978], ["replication", 982], [".", 993], ["These", 995], ["RNAs", 1001], ["are", 1006], ["of", 1010], ["great", 1013], ["interest", 1019], ["to", 1028], ["molecular", 1031], ["biology", 1041], ["for", 1049], ["at", 1053], ["least", 1056], ["two", 1062], ["reasons", 1066], [":", 1073], ["1", 1075], [")", 1076], ["they", 1078], ["are", 1083], ["the", 1087], ["smallest", 1091], ["and", 1100], ["simplest", 1104], ["replicating", 1113], ["molecules", 1125], ["known", 1135], [",", 1140], ["and", 1142], ["2", 1146], [")", 1147], ["they", 1149], ["may", 1154], ["represent", 1158], ["living", 1168], ["fossils", 1175], ["of", 1183], ["precellular", 1186], ["evolution", 1198], ["in", 1208], ["a", 1211], ["hypothetical", 1213], ["RNA", 1226], ["world", 1230], [".", 1235]]}
{"context": "Neural stem/progenitor cell (NSP) biology and neurogenesis in adult central nervous system (CNS) are important both towards potential future therapeutic applications for CNS repair, and for the fundamental function of the CNS. In the present study, we report the characterization of NSP population from subventricular zone (SVZ) of neonatal piglet brain using in vivo and in vitro systems. We show that the nestin and vimentin-positive neural progenitor cells are present in the SVZ of the lateral ventricles of neonatal piglet brain. In vitro, piglet NSPs proliferated as neurospheres, expressed the typical protein of neural progenitors, nestin and a range of well-established neurodevelopmental markers. Upon dissociation and subculture, piglet NSPs differentiated into neurons and glial cells. Clonal analysis demonstrates that piglet NSPs are multipotent and retain the capacity to generate both glia and neurons. These cells expressed VEGF, VEGFR1, VEGFR2 and Neuropilin-1 and -2 mRNAs. Real time PCR revealed that SVZ NSPs from newborn piglet expressed total VEGF and all VEGF splice variants. These findings show that piglet NSPs may be helpful to more effectively design growth factor based strategies to enhance endogenous precursor cells for cell transplantation studies potentially leading to the application of this strategy in the nervous system disease and injury.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "93550bd7ff2742e5be0946f9e56d9da7", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[113, 113], [74, 74]], "char_spans": [[640, 645], [407, 412]]}]}], "context_tokens": [["Neural", 0], ["stem", 7], ["/", 11], ["progenitor", 12], ["cell", 23], ["(", 28], ["NSP", 29], [")", 32], ["biology", 34], ["and", 42], ["neurogenesis", 46], ["in", 59], ["adult", 62], ["central", 68], ["nervous", 76], ["system", 84], ["(", 91], ["CNS", 92], [")", 95], ["are", 97], ["important", 101], ["both", 111], ["towards", 116], ["potential", 124], ["future", 134], ["therapeutic", 141], ["applications", 153], ["for", 166], ["CNS", 170], ["repair", 174], [",", 180], ["and", 182], ["for", 186], ["the", 190], ["fundamental", 194], ["function", 206], ["of", 215], ["the", 218], ["CNS", 222], [".", 225], ["In", 227], ["the", 230], ["present", 234], ["study", 242], [",", 247], ["we", 249], ["report", 252], ["the", 259], ["characterization", 263], ["of", 280], ["NSP", 283], ["population", 287], ["from", 298], ["subventricular", 303], ["zone", 318], ["(", 323], ["SVZ", 324], [")", 327], ["of", 329], ["neonatal", 332], ["piglet", 341], ["brain", 348], ["using", 354], ["in", 360], ["vivo", 363], ["and", 368], ["in", 372], ["vitro", 375], ["systems", 381], [".", 388], ["We", 390], ["show", 393], ["that", 398], ["the", 403], ["nestin", 407], ["and", 414], ["vimentin", 418], ["-", 426], ["positive", 427], ["neural", 436], ["progenitor", 443], ["cells", 454], ["are", 460], ["present", 464], ["in", 472], ["the", 475], ["SVZ", 479], ["of", 483], ["the", 486], ["lateral", 490], ["ventricles", 498], ["of", 509], ["neonatal", 512], ["piglet", 521], ["brain", 528], [".", 533], ["In", 535], ["vitro", 538], [",", 543], ["piglet", 545], ["NSPs", 552], ["proliferated", 557], ["as", 570], ["neurospheres", 573], [",", 585], ["expressed", 587], ["the", 597], ["typical", 601], ["protein", 609], ["of", 617], ["neural", 620], ["progenitors", 627], [",", 638], ["nestin", 640], ["and", 647], ["a", 651], ["range", 653], ["of", 659], ["well", 662], ["-", 666], ["established", 667], ["neurodevelopmental", 679], ["markers", 698], [".", 705], ["Upon", 707], ["dissociation", 712], ["and", 725], ["subculture", 729], [",", 739], ["piglet", 741], ["NSPs", 748], ["differentiated", 753], ["into", 768], ["neurons", 773], ["and", 781], ["glial", 785], ["cells", 791], [".", 796], ["Clonal", 798], ["analysis", 805], ["demonstrates", 814], ["that", 827], ["piglet", 832], ["NSPs", 839], ["are", 844], ["multipotent", 848], ["and", 860], ["retain", 864], ["the", 871], ["capacity", 875], ["to", 884], ["generate", 887], ["both", 896], ["glia", 901], ["and", 906], ["neurons", 910], [".", 917], ["These", 919], ["cells", 925], ["expressed", 931], ["VEGF", 941], [",", 945], ["VEGFR1", 947], [",", 953], ["VEGFR2", 955], ["and", 962], ["Neuropilin-1", 966], ["and", 979], ["-2", 983], ["mRNAs", 986], [".", 991], ["Real", 993], ["time", 998], ["PCR", 1003], ["revealed", 1007], ["that", 1016], ["SVZ", 1021], ["NSPs", 1025], ["from", 1030], ["newborn", 1035], ["piglet", 1043], ["expressed", 1050], ["total", 1060], ["VEGF", 1066], ["and", 1071], ["all", 1075], ["VEGF", 1079], ["splice", 1084], ["variants", 1091], [".", 1099], ["These", 1101], ["findings", 1107], ["show", 1116], ["that", 1121], ["piglet", 1126], ["NSPs", 1133], ["may", 1138], ["be", 1142], ["helpful", 1145], ["to", 1153], ["more", 1156], ["effectively", 1161], ["design", 1173], ["growth", 1180], ["factor", 1187], ["based", 1194], ["strategies", 1200], ["to", 1211], ["enhance", 1214], ["endogenous", 1222], ["precursor", 1233], ["cells", 1243], ["for", 1249], ["cell", 1253], ["transplantation", 1258], ["studies", 1274], ["potentially", 1282], ["leading", 1294], ["to", 1302], ["the", 1305], ["application", 1309], ["of", 1321], ["this", 1324], ["strategy", 1329], ["in", 1338], ["the", 1341], ["nervous", 1345], ["system", 1353], ["disease", 1360], ["and", 1368], ["injury", 1372], [".", 1378]]}
{"context": "Monosomy for the X chromosome is the most frequent cause of Turner's syndrome, a common clinical syndrome associated with particular physical and neurobehavioral features. The results from comprehensive assessment of prepubertal monozygotic female twins discordant for X monosomy are presented. Zygosity was established with DNA Fingerprinting and no evidence of chromosomal mosaicism was seen in either child. Physical features in the affected twin were relatively mild with respect to the full spectrum of physical malformations and disabilities associated with Turner's syndrome. The neurobehavioral phenotypes of the twins were compared. Although both sisters scored in the superior range of intelligence, the affected twin's Performance IQ was 18 points less than her sister, whereas Verbal IQ showed only a 3-point difference between the sisters. Other relative differences were noted within the executive, visuospatial, and visuomotor domains of function. Behavioral evaluation indicated greater problems with attention, hyperactivity, and anxiety in the affected twin. Quantitative analysis of brain anatomy revealed evidence of both general and regional effects of X monosomy on neurodevelopment. Cerebrospinal fluid volume was increased by 25% in the affected twin compared with her sister with a corresponding decrease in gray matter volume. The right frontal, right parietal-occipital, and left parietal-perisylvian regions showed the greatest discrepancy between the sisters with respect to increased cerebrospinal fluid and decreased gray matter volumes in twin with X monosomy. Differences in the posterior fossa were also noted with a 50% relative increase in the volumes of the fourth ventricle and cisterna magna and a 10 to 15% relative reduction in size of the cerebellar vermis, pons, and medulla in the affected twin. The association between the neurobehavioral and neuroanatomical findings in the affected twin is discussed. The unique nature of the naturally occurring genetic phenomenon seen in this twin pair provides an opportunity to more fully elucidate the neurobehavioral phenotype associated with X monosomy and Turner's syndrome.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "7e00d62adabb4717889af97b4ed46c4c", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[3, 3], [182, 182], [340, 340], [39, 39], [248, 248]], "char_spans": [[17, 17], [1174, 1174], [2129, 2129], [269, 269], [1581, 1581]]}]}], "context_tokens": [["Monosomy", 0], ["for", 9], ["the", 13], ["X", 17], ["chromosome", 19], ["is", 30], ["the", 33], ["most", 37], ["frequent", 42], ["cause", 51], ["of", 57], ["Turner", 60], ["'s", 66], ["syndrome", 69], [",", 77], ["a", 79], ["common", 81], ["clinical", 88], ["syndrome", 97], ["associated", 106], ["with", 117], ["particular", 122], ["physical", 133], ["and", 142], ["neurobehavioral", 146], ["features", 162], [".", 170], ["The", 172], ["results", 176], ["from", 184], ["comprehensive", 189], ["assessment", 203], ["of", 214], ["prepubertal", 217], ["monozygotic", 229], ["female", 241], ["twins", 248], ["discordant", 254], ["for", 265], ["X", 269], ["monosomy", 271], ["are", 280], ["presented", 284], [".", 293], ["Zygosity", 295], ["was", 304], ["established", 308], ["with", 320], ["DNA", 325], ["Fingerprinting", 329], ["and", 344], ["no", 348], ["evidence", 351], ["of", 360], ["chromosomal", 363], ["mosaicism", 375], ["was", 385], ["seen", 389], ["in", 394], ["either", 397], ["child", 404], [".", 409], ["Physical", 411], ["features", 420], ["in", 429], ["the", 432], ["affected", 436], ["twin", 445], ["were", 450], ["relatively", 455], ["mild", 466], ["with", 471], ["respect", 476], ["to", 484], ["the", 487], ["full", 491], ["spectrum", 496], ["of", 505], ["physical", 508], ["malformations", 517], ["and", 531], ["disabilities", 535], ["associated", 548], ["with", 559], ["Turner", 564], ["'s", 570], ["syndrome", 573], [".", 581], ["The", 583], ["neurobehavioral", 587], ["phenotypes", 603], ["of", 614], ["the", 617], ["twins", 621], ["were", 627], ["compared", 632], [".", 640], ["Although", 642], ["both", 651], ["sisters", 656], ["scored", 664], ["in", 671], ["the", 674], ["superior", 678], ["range", 687], ["of", 693], ["intelligence", 696], [",", 708], ["the", 710], ["affected", 714], ["twin", 723], ["'s", 727], ["Performance", 730], ["IQ", 742], ["was", 745], ["18", 749], ["points", 752], ["less", 759], ["than", 764], ["her", 769], ["sister", 773], [",", 779], ["whereas", 781], ["Verbal", 789], ["IQ", 796], ["showed", 799], ["only", 806], ["a", 811], ["3-point", 813], ["difference", 821], ["between", 832], ["the", 840], ["sisters", 844], [".", 851], ["Other", 853], ["relative", 859], ["differences", 868], ["were", 880], ["noted", 885], ["within", 891], ["the", 898], ["executive", 902], [",", 911], ["visuospatial", 913], [",", 925], ["and", 927], ["visuomotor", 931], ["domains", 942], ["of", 950], ["function", 953], [".", 961], ["Behavioral", 963], ["evaluation", 974], ["indicated", 985], ["greater", 995], ["problems", 1003], ["with", 1012], ["attention", 1017], [",", 1026], ["hyperactivity", 1028], [",", 1041], ["and", 1043], ["anxiety", 1047], ["in", 1055], ["the", 1058], ["affected", 1062], ["twin", 1071], [".", 1075], ["Quantitative", 1077], ["analysis", 1090], ["of", 1099], ["brain", 1102], ["anatomy", 1108], ["revealed", 1116], ["evidence", 1125], ["of", 1134], ["both", 1137], ["general", 1142], ["and", 1150], ["regional", 1154], ["effects", 1163], ["of", 1171], ["X", 1174], ["monosomy", 1176], ["on", 1185], ["neurodevelopment", 1188], [".", 1204], ["Cerebrospinal", 1206], ["fluid", 1220], ["volume", 1226], ["was", 1233], ["increased", 1237], ["by", 1247], ["25", 1250], ["%", 1252], ["in", 1254], ["the", 1257], ["affected", 1261], ["twin", 1270], ["compared", 1275], ["with", 1284], ["her", 1289], ["sister", 1293], ["with", 1300], ["a", 1305], ["corresponding", 1307], ["decrease", 1321], ["in", 1330], ["gray", 1333], ["matter", 1338], ["volume", 1345], [".", 1351], ["The", 1353], ["right", 1357], ["frontal", 1363], [",", 1370], ["right", 1372], ["parietal", 1378], ["-", 1386], ["occipital", 1387], [",", 1396], ["and", 1398], ["left", 1402], ["parietal", 1407], ["-", 1415], ["perisylvian", 1416], ["regions", 1428], ["showed", 1436], ["the", 1443], ["greatest", 1447], ["discrepancy", 1456], ["between", 1468], ["the", 1476], ["sisters", 1480], ["with", 1488], ["respect", 1493], ["to", 1501], ["increased", 1504], ["cerebrospinal", 1514], ["fluid", 1528], ["and", 1534], ["decreased", 1538], ["gray", 1548], ["matter", 1553], ["volumes", 1560], ["in", 1568], ["twin", 1571], ["with", 1576], ["X", 1581], ["monosomy", 1583], [".", 1591], ["Differences", 1593], ["in", 1605], ["the", 1608], ["posterior", 1612], ["fossa", 1622], ["were", 1628], ["also", 1633], ["noted", 1638], ["with", 1644], ["a", 1649], ["50", 1651], ["%", 1653], ["relative", 1655], ["increase", 1664], ["in", 1673], ["the", 1676], ["volumes", 1680], ["of", 1688], ["the", 1691], ["fourth", 1695], ["ventricle", 1702], ["and", 1712], ["cisterna", 1716], ["magna", 1725], ["and", 1731], ["a", 1735], ["10", 1737], ["to", 1740], ["15", 1743], ["%", 1745], ["relative", 1747], ["reduction", 1756], ["in", 1766], ["size", 1769], ["of", 1774], ["the", 1777], ["cerebellar", 1781], ["vermis", 1792], [",", 1798], ["pons", 1800], [",", 1804], ["and", 1806], ["medulla", 1810], ["in", 1818], ["the", 1821], ["affected", 1825], ["twin", 1834], [".", 1838], ["The", 1840], ["association", 1844], ["between", 1856], ["the", 1864], ["neurobehavioral", 1868], ["and", 1884], ["neuroanatomical", 1888], ["findings", 1904], ["in", 1913], ["the", 1916], ["affected", 1920], ["twin", 1929], ["is", 1934], ["discussed", 1937], [".", 1946], ["The", 1948], ["unique", 1952], ["nature", 1959], ["of", 1966], ["the", 1969], ["naturally", 1973], ["occurring", 1983], ["genetic", 1993], ["phenomenon", 2001], ["seen", 2012], ["in", 2017], ["this", 2020], ["twin", 2025], ["pair", 2030], ["provides", 2035], ["an", 2044], ["opportunity", 2047], ["to", 2059], ["more", 2062], ["fully", 2067], ["elucidate", 2073], ["the", 2083], ["neurobehavioral", 2087], ["phenotype", 2103], ["associated", 2113], ["with", 2124], ["X", 2129], ["monosomy", 2131], ["and", 2140], ["Turner", 2144], ["'s", 2150], ["syndrome", 2153], [".", 2161]]}
{"context": "Selective degradation of proteins by the ubiquitin-proteasome pathway is a critical determinant for maintaining cellular homeostasis. Most intracellular proteins are degraded by the proteasome, a multicatalytic enzyme complex containing a 20S catalytic core and two 19S regulatory complexes. Many proteasome target proteins are involved in the regulation of important processes of carcinogenesis and cancer cell survival, such as cell cycle progression, cell proliferation, differentiation and apoptosis. Indeed, the ubiquitin-proteasome-dependent degradation pathway plays an essential role in both the up-regulation of cell proliferation and down-regulation of cell death in human cancer cells. Both in vitro and in vivo experimental and clinical results have demonstrated the potential use of proteasome inhibitors as novel anticancer drugs. Proteasome inhibition in cancer cells leads to accumulation of pro-apoptotic target proteins followed by induction of cell death. The clinical efficacy of the proteasome inhibitor bortezomib toward multiple myeloma and other hematologic malignancies provides the \"proof of concept\" that targeting the proteasome is a promising strategy for cancer treatment. Several other proteasome inhibitors have also been identified from natural resources, such as marine microbial metabolites, green tea polyphenols, flavonoids, and medicinal compounds. Additionally, the use of metal complexes as proteasome inhibitors has also been investigated as a potential anticancer strategy. The clinical significance of targeting the tumor survival-associated proteasome pathway for cancer treatment, intervention and prevention will be discussed.", "qas": [{"question": "Which is the target of bortezomib used in cancer therapy?", "answers": ["The ubiquitin/proteasome pathway"], "qid": "db311c7e2115419da83e01e6c5610862", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["bortezomib", 23], ["used", 34], ["in", 39], ["cancer", 42], ["therapy", 49], ["?", 56]], "detected_answers": [{"text": "The ubiquitin/proteasome pathway", "token_spans": [[6, 9]], "char_spans": [[41, 68]]}]}], "context_tokens": [["Selective", 0], ["degradation", 10], ["of", 22], ["proteins", 25], ["by", 34], ["the", 37], ["ubiquitin", 41], ["-", 50], ["proteasome", 51], ["pathway", 62], ["is", 70], ["a", 73], ["critical", 75], ["determinant", 84], ["for", 96], ["maintaining", 100], ["cellular", 112], ["homeostasis", 121], [".", 132], ["Most", 134], ["intracellular", 139], ["proteins", 153], ["are", 162], ["degraded", 166], ["by", 175], ["the", 178], ["proteasome", 182], [",", 192], ["a", 194], ["multicatalytic", 196], ["enzyme", 211], ["complex", 218], ["containing", 226], ["a", 237], ["20S", 239], ["catalytic", 243], ["core", 253], ["and", 258], ["two", 262], ["19S", 266], ["regulatory", 270], ["complexes", 281], [".", 290], ["Many", 292], ["proteasome", 297], ["target", 308], ["proteins", 315], ["are", 324], ["involved", 328], ["in", 337], ["the", 340], ["regulation", 344], ["of", 355], ["important", 358], ["processes", 368], ["of", 378], ["carcinogenesis", 381], ["and", 396], ["cancer", 400], ["cell", 407], ["survival", 412], [",", 420], ["such", 422], ["as", 427], ["cell", 430], ["cycle", 435], ["progression", 441], [",", 452], ["cell", 454], ["proliferation", 459], [",", 472], ["differentiation", 474], ["and", 490], ["apoptosis", 494], [".", 503], ["Indeed", 505], [",", 511], ["the", 513], ["ubiquitin", 517], ["-", 526], ["proteasome", 527], ["-", 537], ["dependent", 538], ["degradation", 548], ["pathway", 560], ["plays", 568], ["an", 574], ["essential", 577], ["role", 587], ["in", 592], ["both", 595], ["the", 600], ["up", 604], ["-", 606], ["regulation", 607], ["of", 618], ["cell", 621], ["proliferation", 626], ["and", 640], ["down", 644], ["-", 648], ["regulation", 649], ["of", 660], ["cell", 663], ["death", 668], ["in", 674], ["human", 677], ["cancer", 683], ["cells", 690], [".", 695], ["Both", 697], ["in", 702], ["vitro", 705], ["and", 711], ["in", 715], ["vivo", 718], ["experimental", 723], ["and", 736], ["clinical", 740], ["results", 749], ["have", 757], ["demonstrated", 762], ["the", 775], ["potential", 779], ["use", 789], ["of", 793], ["proteasome", 796], ["inhibitors", 807], ["as", 818], ["novel", 821], ["anticancer", 827], ["drugs", 838], [".", 843], ["Proteasome", 845], ["inhibition", 856], ["in", 867], ["cancer", 870], ["cells", 877], ["leads", 883], ["to", 889], ["accumulation", 892], ["of", 905], ["pro", 908], ["-", 911], ["apoptotic", 912], ["target", 922], ["proteins", 929], ["followed", 938], ["by", 947], ["induction", 950], ["of", 960], ["cell", 963], ["death", 968], [".", 973], ["The", 975], ["clinical", 979], ["efficacy", 988], ["of", 997], ["the", 1000], ["proteasome", 1004], ["inhibitor", 1015], ["bortezomib", 1025], ["toward", 1036], ["multiple", 1043], ["myeloma", 1052], ["and", 1060], ["other", 1064], ["hematologic", 1070], ["malignancies", 1082], ["provides", 1095], ["the", 1104], ["\"", 1108], ["proof", 1109], ["of", 1115], ["concept", 1118], ["\"", 1125], ["that", 1127], ["targeting", 1132], ["the", 1142], ["proteasome", 1146], ["is", 1157], ["a", 1160], ["promising", 1162], ["strategy", 1172], ["for", 1181], ["cancer", 1185], ["treatment", 1192], [".", 1201], ["Several", 1203], ["other", 1211], ["proteasome", 1217], ["inhibitors", 1228], ["have", 1239], ["also", 1244], ["been", 1249], ["identified", 1254], ["from", 1265], ["natural", 1270], ["resources", 1278], [",", 1287], ["such", 1289], ["as", 1294], ["marine", 1297], ["microbial", 1304], ["metabolites", 1314], [",", 1325], ["green", 1327], ["tea", 1333], ["polyphenols", 1337], [",", 1348], ["flavonoids", 1350], [",", 1360], ["and", 1362], ["medicinal", 1366], ["compounds", 1376], [".", 1385], ["Additionally", 1387], [",", 1399], ["the", 1401], ["use", 1405], ["of", 1409], ["metal", 1412], ["complexes", 1418], ["as", 1428], ["proteasome", 1431], ["inhibitors", 1442], ["has", 1453], ["also", 1457], ["been", 1462], ["investigated", 1467], ["as", 1480], ["a", 1483], ["potential", 1485], ["anticancer", 1495], ["strategy", 1506], [".", 1514], ["The", 1516], ["clinical", 1520], ["significance", 1529], ["of", 1542], ["targeting", 1545], ["the", 1555], ["tumor", 1559], ["survival", 1565], ["-", 1573], ["associated", 1574], ["proteasome", 1585], ["pathway", 1596], ["for", 1604], ["cancer", 1608], ["treatment", 1615], [",", 1624], ["intervention", 1626], ["and", 1639], ["prevention", 1643], ["will", 1654], ["be", 1659], ["discussed", 1662], [".", 1671]]}
{"context": "Previously, using a chromosomal reversion assay system, we established that an adaptive mutagenic process occurs in nongrowing Bacillus subtilis cells under stress, and we demonstrated that multiple mechanisms are involved in generating these mutations (41, 43). In an attempt to delineate how these mutations are generated, we began an investigation into whether or not transcription and transcription-associated proteins influence adaptive mutagenesis. In B. subtilis, the Mfd protein (transcription repair coupling factor) facilitates removal of RNA polymerase stalled at transcriptional blockages and recruitment of repair proteins to DNA lesions on the transcribed strand. Here we demonstrate that the loss of Mfd has a depressive effect on stationary-phase mutagenesis. An association between Mfd mutagenesis and aspects of transcription is discussed.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase", "stationary-phase"], "qid": "91db4f5a6e754a4889b60c8eb22bc009", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[120, 122]], "char_spans": [[746, 761]]}]}], "context_tokens": [["Previously", 0], [",", 10], ["using", 12], ["a", 18], ["chromosomal", 20], ["reversion", 32], ["assay", 42], ["system", 48], [",", 54], ["we", 56], ["established", 59], ["that", 71], ["an", 76], ["adaptive", 79], ["mutagenic", 88], ["process", 98], ["occurs", 106], ["in", 113], ["nongrowing", 116], ["Bacillus", 127], ["subtilis", 136], ["cells", 145], ["under", 151], ["stress", 157], [",", 163], ["and", 165], ["we", 169], ["demonstrated", 172], ["that", 185], ["multiple", 190], ["mechanisms", 199], ["are", 210], ["involved", 214], ["in", 223], ["generating", 226], ["these", 237], ["mutations", 243], ["(", 253], ["41", 254], [",", 256], ["43", 258], [")", 260], [".", 261], ["In", 263], ["an", 266], ["attempt", 269], ["to", 277], ["delineate", 280], ["how", 290], ["these", 294], ["mutations", 300], ["are", 310], ["generated", 314], [",", 323], ["we", 325], ["began", 328], ["an", 334], ["investigation", 337], ["into", 351], ["whether", 356], ["or", 364], ["not", 367], ["transcription", 371], ["and", 385], ["transcription", 389], ["-", 402], ["associated", 403], ["proteins", 414], ["influence", 423], ["adaptive", 433], ["mutagenesis", 442], [".", 453], ["In", 455], ["B.", 458], ["subtilis", 461], [",", 469], ["the", 471], ["Mfd", 475], ["protein", 479], ["(", 487], ["transcription", 488], ["repair", 502], ["coupling", 509], ["factor", 518], [")", 524], ["facilitates", 526], ["removal", 538], ["of", 546], ["RNA", 549], ["polymerase", 553], ["stalled", 564], ["at", 572], ["transcriptional", 575], ["blockages", 591], ["and", 601], ["recruitment", 605], ["of", 617], ["repair", 620], ["proteins", 627], ["to", 636], ["DNA", 639], ["lesions", 643], ["on", 651], ["the", 654], ["transcribed", 658], ["strand", 670], [".", 676], ["Here", 678], ["we", 683], ["demonstrate", 686], ["that", 698], ["the", 703], ["loss", 707], ["of", 712], ["Mfd", 715], ["has", 719], ["a", 723], ["depressive", 725], ["effect", 736], ["on", 743], ["stationary", 746], ["-", 756], ["phase", 757], ["mutagenesis", 763], [".", 774], ["An", 776], ["association", 779], ["between", 791], ["Mfd", 799], ["mutagenesis", 803], ["and", 815], ["aspects", 819], ["of", 827], ["transcription", 830], ["is", 844], ["discussed", 847], [".", 856]]}
{"context": "The management of de Quervain's disease (DD) is nonoperative in the first instance, but surgery should be considered if conservative measures fail. We present the long-term results of operative treatment of DD. From July 1988 to July 1998, 94 consecutive patients with DD were treated operatively by a single surgeon. There were 80 women and 14 men. Average age at the time of operation was 47.4 years (range 22-76). The right wrist was involved in 43 cases, the left in 51 cases. All operations were done under tourniquet control with local infiltration anaesthesia using a longitudinal incision and partial resection of the extensor ligament. There were six perioperative complications, including one superficial wound infection, one delayed wound healing, and four transient lesions of the radial nerve. A successful outcome was achieved in all cases with negative Finkelstein's test. Simple decompression of both tendons and partial resection of the extensor ligament with a maximum of 3 mm can be recommended in operative treatment of DD with excellent long-term results.", "qas": [{"question": "Which disease is diagnosed using the Finkelstein's test?", "answers": ["de Quervain's disease"], "qid": "94956aa6f46c40d6942aab9ac607436f", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["diagnosed", 17], ["using", 27], ["the", 33], ["Finkelstein", 37], ["'s", 48], ["test", 51], ["?", 55]], "detected_answers": [{"text": "de Quervain's disease", "token_spans": [[3, 6]], "char_spans": [[18, 38]]}]}], "context_tokens": [["The", 0], ["management", 4], ["of", 15], ["de", 18], ["Quervain", 21], ["'s", 29], ["disease", 32], ["(", 40], ["DD", 41], [")", 43], ["is", 45], ["nonoperative", 48], ["in", 61], ["the", 64], ["first", 68], ["instance", 74], [",", 82], ["but", 84], ["surgery", 88], ["should", 96], ["be", 103], ["considered", 106], ["if", 117], ["conservative", 120], ["measures", 133], ["fail", 142], [".", 146], ["We", 148], ["present", 151], ["the", 159], ["long", 163], ["-", 167], ["term", 168], ["results", 173], ["of", 181], ["operative", 184], ["treatment", 194], ["of", 204], ["DD", 207], [".", 209], ["From", 211], ["July", 216], ["1988", 221], ["to", 226], ["July", 229], ["1998", 234], [",", 238], ["94", 240], ["consecutive", 243], ["patients", 255], ["with", 264], ["DD", 269], ["were", 272], ["treated", 277], ["operatively", 285], ["by", 297], ["a", 300], ["single", 302], ["surgeon", 309], [".", 316], ["There", 318], ["were", 324], ["80", 329], ["women", 332], ["and", 338], ["14", 342], ["men", 345], [".", 348], ["Average", 350], ["age", 358], ["at", 362], ["the", 365], ["time", 369], ["of", 374], ["operation", 377], ["was", 387], ["47.4", 391], ["years", 396], ["(", 402], ["range", 403], ["22", 409], ["-", 411], ["76", 412], [")", 414], [".", 415], ["The", 417], ["right", 421], ["wrist", 427], ["was", 433], ["involved", 437], ["in", 446], ["43", 449], ["cases", 452], [",", 457], ["the", 459], ["left", 463], ["in", 468], ["51", 471], ["cases", 474], [".", 479], ["All", 481], ["operations", 485], ["were", 496], ["done", 501], ["under", 506], ["tourniquet", 512], ["control", 523], ["with", 531], ["local", 536], ["infiltration", 542], ["anaesthesia", 555], ["using", 567], ["a", 573], ["longitudinal", 575], ["incision", 588], ["and", 597], ["partial", 601], ["resection", 609], ["of", 619], ["the", 622], ["extensor", 626], ["ligament", 635], [".", 643], ["There", 645], ["were", 651], ["six", 656], ["perioperative", 660], ["complications", 674], [",", 687], ["including", 689], ["one", 699], ["superficial", 703], ["wound", 715], ["infection", 721], [",", 730], ["one", 732], ["delayed", 736], ["wound", 744], ["healing", 750], [",", 757], ["and", 759], ["four", 763], ["transient", 768], ["lesions", 778], ["of", 786], ["the", 789], ["radial", 793], ["nerve", 800], [".", 805], ["A", 807], ["successful", 809], ["outcome", 820], ["was", 828], ["achieved", 832], ["in", 841], ["all", 844], ["cases", 848], ["with", 854], ["negative", 859], ["Finkelstein", 868], ["'s", 879], ["test", 882], [".", 886], ["Simple", 888], ["decompression", 895], ["of", 909], ["both", 912], ["tendons", 917], ["and", 925], ["partial", 929], ["resection", 937], ["of", 947], ["the", 950], ["extensor", 954], ["ligament", 963], ["with", 972], ["a", 977], ["maximum", 979], ["of", 987], ["3", 990], ["mm", 992], ["can", 995], ["be", 999], ["recommended", 1002], ["in", 1014], ["operative", 1017], ["treatment", 1027], ["of", 1037], ["DD", 1040], ["with", 1043], ["excellent", 1048], ["long", 1058], ["-", 1062], ["term", 1063], ["results", 1068], [".", 1075]]}
{"context": "AtxA, a unique regulatory protein of unknown molecular function, positively controls expression of the major virulence genes of Bacillus anthracis. The 475 amino acid sequence of AtxA reveals DNA binding motifs and regions similar to proteins associated with the phosphoenolpyruvate: carbohydrate phosphotransferase system (PTS). We used strains producing native and functional epitope-tagged AtxA proteins to examine protein-protein interactions in cell lysates and in solutions of purified protein. Co-affinity purification, non-denaturing polyacrylamide gel electrophoresis and bis(maleimido)hexane (BMH) cross-linking experiments revealed AtxA homo-multimers. Dimers were the most abundant species. BMH cross-links available cysteines within 13 \u00c5. To localize interaction sites, six AtxA mutants containing distinct Cys\u2192Ser substitutions were tested for multimerization and cross-linking. All mutants multimerized, but one mutation, C402S, prevented cross-linking. Thus, BMH uses C402 to make the inter-molecular bond between AtxA proteins, but C402 is not required for protein-protein interaction. C402 is in a region bearing amino acid similarity to Enzyme IIB proteins of the PTS. The AtxA EIIB motif may function in protein oligomerization. Finally, cultures grown with elevated CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function by shifting the dimer/monomer equilibrium towards the dimeric state.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "47491f59f6b14de09b72e1a703284430", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "bicarbonate", "token_spans": [[240, 240], [219, 219]], "char_spans": [[1428, 1439], [1293, 1304]]}]}], "context_tokens": [["AtxA", 0], [",", 4], ["a", 6], ["unique", 8], ["regulatory", 15], ["protein", 26], ["of", 34], ["unknown", 37], ["molecular", 45], ["function", 55], [",", 63], ["positively", 65], ["controls", 76], ["expression", 85], ["of", 96], ["the", 99], ["major", 103], ["virulence", 109], ["genes", 119], ["of", 125], ["Bacillus", 128], ["anthracis", 137], [".", 146], ["The", 148], ["475", 152], ["amino", 156], ["acid", 162], ["sequence", 167], ["of", 176], ["AtxA", 179], ["reveals", 184], ["DNA", 192], ["binding", 196], ["motifs", 204], ["and", 211], ["regions", 215], ["similar", 223], ["to", 231], ["proteins", 234], ["associated", 243], ["with", 254], ["the", 259], ["phosphoenolpyruvate", 263], [":", 282], ["carbohydrate", 284], ["phosphotransferase", 297], ["system", 316], ["(", 323], ["PTS", 324], [")", 327], [".", 328], ["We", 330], ["used", 333], ["strains", 338], ["producing", 346], ["native", 356], ["and", 363], ["functional", 367], ["epitope", 378], ["-", 385], ["tagged", 386], ["AtxA", 393], ["proteins", 398], ["to", 407], ["examine", 410], ["protein", 418], ["-", 425], ["protein", 426], ["interactions", 434], ["in", 447], ["cell", 450], ["lysates", 455], ["and", 463], ["in", 467], ["solutions", 470], ["of", 480], ["purified", 483], ["protein", 492], [".", 499], ["Co", 501], ["-", 503], ["affinity", 504], ["purification", 513], [",", 525], ["non", 527], ["-", 530], ["denaturing", 531], ["polyacrylamide", 542], ["gel", 557], ["electrophoresis", 561], ["and", 577], ["bis(maleimido)hexane", 581], ["(", 602], ["BMH", 603], [")", 606], ["cross", 608], ["-", 613], ["linking", 614], ["experiments", 622], ["revealed", 634], ["AtxA", 643], ["homo", 648], ["-", 652], ["multimers", 653], [".", 662], ["Dimers", 664], ["were", 671], ["the", 676], ["most", 680], ["abundant", 685], ["species", 694], [".", 701], ["BMH", 703], ["cross", 707], ["-", 712], ["links", 713], ["available", 719], ["cysteines", 729], ["within", 739], ["13", 746], ["\u00c5.", 749], ["To", 752], ["localize", 755], ["interaction", 764], ["sites", 776], [",", 781], ["six", 783], ["AtxA", 787], ["mutants", 792], ["containing", 800], ["distinct", 811], ["Cys\u2192Ser", 820], ["substitutions", 828], ["were", 842], ["tested", 847], ["for", 854], ["multimerization", 858], ["and", 874], ["cross", 878], ["-", 883], ["linking", 884], [".", 891], ["All", 893], ["mutants", 897], ["multimerized", 905], [",", 917], ["but", 919], ["one", 923], ["mutation", 927], [",", 935], ["C402S", 937], [",", 942], ["prevented", 944], ["cross", 954], ["-", 959], ["linking", 960], [".", 967], ["Thus", 969], [",", 973], ["BMH", 975], ["uses", 979], ["C402", 984], ["to", 989], ["make", 992], ["the", 997], ["inter", 1001], ["-", 1006], ["molecular", 1007], ["bond", 1017], ["between", 1022], ["AtxA", 1030], ["proteins", 1035], [",", 1043], ["but", 1045], ["C402", 1049], ["is", 1054], ["not", 1057], ["required", 1061], ["for", 1070], ["protein", 1074], ["-", 1081], ["protein", 1082], ["interaction", 1090], [".", 1101], ["C402", 1103], ["is", 1108], ["in", 1111], ["a", 1114], ["region", 1116], ["bearing", 1123], ["amino", 1131], ["acid", 1137], ["similarity", 1142], ["to", 1153], ["Enzyme", 1156], ["IIB", 1163], ["proteins", 1167], ["of", 1176], ["the", 1179], ["PTS", 1183], [".", 1186], ["The", 1188], ["AtxA", 1192], ["EIIB", 1197], ["motif", 1202], ["may", 1208], ["function", 1212], ["in", 1221], ["protein", 1224], ["oligomerization", 1232], [".", 1247], ["Finally", 1249], [",", 1256], ["cultures", 1258], ["grown", 1267], ["with", 1273], ["elevated", 1278], ["CO(2", 1287], [")", 1291], ["/bicarbonate", 1293], ["exhibited", 1306], ["increased", 1316], ["AtxA", 1326], ["dimer", 1331], ["/", 1336], ["monomer", 1337], ["ratios", 1345], ["and", 1352], ["increased", 1356], ["AtxA", 1366], ["activity", 1371], [",", 1379], ["relative", 1381], ["to", 1390], ["cultures", 1393], ["grown", 1402], ["without", 1408], ["added", 1416], ["CO(2", 1422], [")", 1426], ["/bicarbonate", 1428], [",", 1440], ["suggesting", 1442], ["that", 1453], ["this", 1458], ["host", 1463], ["-", 1467], ["associated", 1468], ["signal", 1479], ["enhances", 1486], ["AtxA", 1495], ["function", 1500], ["by", 1509], ["shifting", 1512], ["the", 1521], ["dimer", 1525], ["/", 1530], ["monomer", 1531], ["equilibrium", 1539], ["towards", 1551], ["the", 1559], ["dimeric", 1563], ["state", 1571], [".", 1576]]}
{"context": "McLeod syndrome is caused by mutations of XK, an X-chromosomal gene of unknown function. Originally defined as a peculiar Kell blood group variant, the disease affects multiple organs, including the nervous system, but is certainly underdiagnosed. We analyzed the mutations and clinical findings of 22 affected men, aged 27 to 72 years. Fifteen different XK mutations were found, nine of which were novel, including the one of the eponymous case McLeod. Their common result is predicted absence or truncation of the XK protein. All patients showed elevated levels of muscle creatine phosphokinase, but clinical myopathy was less common. A peripheral neuropathy with areflexia was found in all but 2 patients. The central nervous system was affected in 15 patients, as obvious from the occurrence of seizures, cognitive impairment, psychopathology, and choreatic movements. Neuroimaging emphasized the particular involvement of the basal ganglia, which was also detected in 1 asymptomatic young patient. Most features develop with age, mainly after the fourth decade. The resemblance of McLeod syndrome with Huntington's disease and with autosomal recessive chorea-acanthocytosis suggests that the corresponding proteins--XK, huntingtin, and chorein--might belong to a common pathway, the dysfunction of which causes degeneration of the basal ganglia.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "8f600aec47fb4b109b628824fc85d81f", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[64, 64], [208, 208], [7, 7], [94, 94]], "char_spans": [[355, 356], [1221, 1222], [42, 43], [516, 517]]}]}], "context_tokens": [["McLeod", 0], ["syndrome", 7], ["is", 16], ["caused", 19], ["by", 26], ["mutations", 29], ["of", 39], ["XK", 42], [",", 44], ["an", 46], ["X", 49], ["-", 50], ["chromosomal", 51], ["gene", 63], ["of", 68], ["unknown", 71], ["function", 79], [".", 87], ["Originally", 89], ["defined", 100], ["as", 108], ["a", 111], ["peculiar", 113], ["Kell", 122], ["blood", 127], ["group", 133], ["variant", 139], [",", 146], ["the", 148], ["disease", 152], ["affects", 160], ["multiple", 168], ["organs", 177], [",", 183], ["including", 185], ["the", 195], ["nervous", 199], ["system", 207], [",", 213], ["but", 215], ["is", 219], ["certainly", 222], ["underdiagnosed", 232], [".", 246], ["We", 248], ["analyzed", 251], ["the", 260], ["mutations", 264], ["and", 274], ["clinical", 278], ["findings", 287], ["of", 296], ["22", 299], ["affected", 302], ["men", 311], [",", 314], ["aged", 316], ["27", 321], ["to", 324], ["72", 327], ["years", 330], [".", 335], ["Fifteen", 337], ["different", 345], ["XK", 355], ["mutations", 358], ["were", 368], ["found", 373], [",", 378], ["nine", 380], ["of", 385], ["which", 388], ["were", 394], ["novel", 399], [",", 404], ["including", 406], ["the", 416], ["one", 420], ["of", 424], ["the", 427], ["eponymous", 431], ["case", 441], ["McLeod", 446], [".", 452], ["Their", 454], ["common", 460], ["result", 467], ["is", 474], ["predicted", 477], ["absence", 487], ["or", 495], ["truncation", 498], ["of", 509], ["the", 512], ["XK", 516], ["protein", 519], [".", 526], ["All", 528], ["patients", 532], ["showed", 541], ["elevated", 548], ["levels", 557], ["of", 564], ["muscle", 567], ["creatine", 574], ["phosphokinase", 583], [",", 596], ["but", 598], ["clinical", 602], ["myopathy", 611], ["was", 620], ["less", 624], ["common", 629], [".", 635], ["A", 637], ["peripheral", 639], ["neuropathy", 650], ["with", 661], ["areflexia", 666], ["was", 676], ["found", 680], ["in", 686], ["all", 689], ["but", 693], ["2", 697], ["patients", 699], [".", 707], ["The", 709], ["central", 713], ["nervous", 721], ["system", 729], ["was", 736], ["affected", 740], ["in", 749], ["15", 752], ["patients", 755], [",", 763], ["as", 765], ["obvious", 768], ["from", 776], ["the", 781], ["occurrence", 785], ["of", 796], ["seizures", 799], [",", 807], ["cognitive", 809], ["impairment", 819], [",", 829], ["psychopathology", 831], [",", 846], ["and", 848], ["choreatic", 852], ["movements", 862], [".", 871], ["Neuroimaging", 873], ["emphasized", 886], ["the", 897], ["particular", 901], ["involvement", 912], ["of", 924], ["the", 927], ["basal", 931], ["ganglia", 937], [",", 944], ["which", 946], ["was", 952], ["also", 956], ["detected", 961], ["in", 970], ["1", 973], ["asymptomatic", 975], ["young", 988], ["patient", 994], [".", 1001], ["Most", 1003], ["features", 1008], ["develop", 1017], ["with", 1025], ["age", 1030], [",", 1033], ["mainly", 1035], ["after", 1042], ["the", 1048], ["fourth", 1052], ["decade", 1059], [".", 1065], ["The", 1067], ["resemblance", 1071], ["of", 1083], ["McLeod", 1086], ["syndrome", 1093], ["with", 1102], ["Huntington", 1107], ["'s", 1117], ["disease", 1120], ["and", 1128], ["with", 1132], ["autosomal", 1137], ["recessive", 1147], ["chorea", 1157], ["-", 1163], ["acanthocytosis", 1164], ["suggests", 1179], ["that", 1188], ["the", 1193], ["corresponding", 1197], ["proteins", 1211], ["--", 1219], ["XK", 1221], [",", 1223], ["huntingtin", 1225], [",", 1235], ["and", 1237], ["chorein", 1241], ["--", 1248], ["might", 1250], ["belong", 1256], ["to", 1263], ["a", 1266], ["common", 1268], ["pathway", 1275], [",", 1282], ["the", 1284], ["dysfunction", 1288], ["of", 1300], ["which", 1303], ["causes", 1309], ["degeneration", 1316], ["of", 1329], ["the", 1332], ["basal", 1336], ["ganglia", 1342], [".", 1349]]}
{"context": "Lack of specific antidotes is a major concern in intracerebral hemorrhage (ICH) related to direct anticoagulants including dabigatran (OAC-ICH). We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab. Pretreatment with DE increased intracerebral hematoma volume and cerebral hemoglobin content. Idarucizumab in equimolar dose prevented excess hematoma expansion for both DE doses. In more extensive ICH, idarucizumab significantly reduced mortality. Thus, idarucizumab prevents excess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "6aac3d7c2f5e40e09f41b4cb9a267ef5", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[121, 121], [19, 19], [49, 49], [38, 38]], "char_spans": [[746, 755], [123, 132], [260, 269], [219, 228]]}]}], "context_tokens": [["Lack", 0], ["of", 5], ["specific", 8], ["antidotes", 17], ["is", 27], ["a", 30], ["major", 32], ["concern", 38], ["in", 46], ["intracerebral", 49], ["hemorrhage", 63], ["(", 74], ["ICH", 75], [")", 78], ["related", 80], ["to", 88], ["direct", 91], ["anticoagulants", 98], ["including", 113], ["dabigatran", 123], ["(", 134], ["OAC", 135], ["-", 138], ["ICH", 139], [")", 142], [".", 143], ["We", 145], ["examined", 148], ["the", 157], ["efficacy", 161], ["of", 170], ["idarucizumab", 173], [",", 185], ["an", 187], ["antibody", 190], ["fragment", 199], ["binding", 208], ["to", 216], ["dabigatran", 219], [",", 229], ["in", 231], ["a", 234], ["mouse", 236], ["model", 242], ["of", 248], ["OAC", 251], ["-", 254], ["ICH", 255], [".", 258], ["Dabigatran", 260], ["etexilate", 271], ["(", 281], ["DE", 282], [")", 284], ["dose", 286], ["-", 290], ["dependently", 291], ["prolonged", 303], ["diluted", 313], ["thrombin", 321], ["time", 330], ["and", 335], ["tail", 339], ["-", 343], ["vein", 344], ["bleeding", 349], ["time", 358], [",", 362], ["which", 364], ["were", 370], ["reversed", 375], ["by", 384], ["idarucizumab", 387], [".", 399], ["Pretreatment", 401], ["with", 414], ["DE", 419], ["increased", 422], ["intracerebral", 432], ["hematoma", 446], ["volume", 455], ["and", 462], ["cerebral", 466], ["hemoglobin", 475], ["content", 486], [".", 493], ["Idarucizumab", 495], ["in", 508], ["equimolar", 511], ["dose", 521], ["prevented", 526], ["excess", 536], ["hematoma", 543], ["expansion", 552], ["for", 562], ["both", 566], ["DE", 571], ["doses", 574], [".", 579], ["In", 581], ["more", 584], ["extensive", 589], ["ICH", 599], [",", 602], ["idarucizumab", 604], ["significantly", 617], ["reduced", 631], ["mortality", 639], [".", 648], ["Thus", 650], [",", 654], ["idarucizumab", 656], ["prevents", 669], ["excess", 678], ["intracerebral", 685], ["hematoma", 699], ["formation", 708], ["in", 718], ["mice", 721], ["anticoagulated", 726], ["with", 741], ["dabigatran", 746], ["and", 757], ["reduces", 761], ["mortality", 769], [".", 778]]}
{"context": "Since the early 2000s, the incidence of methicillin-resistant Staphylococcus aureus (MRSA) infections among the community of people lacking known healthcare risk factors has increased. This MRSA infection is referred to as community-associated MRSA (CA-MRSA) infection and is distinct from hospital-associated MRSA (HA-MRSA) infection, which occurs among people with known healthcare risk factors. Understanding the epidemiology of CA-MRSA infections is critical; however, this has not been investigated in detail in Japan. Our objective was to investigate the incidence of CA-MRSA infections in a regional hospital. We investigated CA-MRSA isolates and infections in a rural regional hospital by reviewing medical records of one year. Infections were classified as CA-MRSA if no established risk factors were identified. During 2008, 31 Staphylococcus aureus (S. aureus) isolates were detected in 29 unique patients, with 1 methicillin-sensitive S. aureus (MSSA) isolates obtained from 19 patients (66%) and MRSA obtained from 10 patients (34%). In the 10 patients with MRSA, the number of HA-MRSA and CA-MRSA cases were nine (32% of patients with S. aureus isolates) and one (3%), respectively. The patient with CA-MRSA was diagnosed with cellulitis due to CA-MRSA. All nine patients with HA-MRSA exhibited colonization. We observed a CA-MRSA case in a regional hospital in Japan, suggesting that incidence trends of CA-MRSA should be considered in future research and treatment.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "0d5291094d50485392d99b2aa3d5c380", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[208, 208], [139, 139], [58, 58], [186, 186], [44, 44], [116, 116], [212, 212], [249, 249], [78, 78], [14, 14], [257, 257], [240, 240], [282, 282], [54, 54], [266, 266], [105, 105], [201, 201], [40, 40], [31, 31]], "char_spans": [[1094, 1097], [769, 772], [319, 322], [1009, 1012], [253, 256], [636, 639], [1106, 1109], [1262, 1265], [435, 438], [85, 88], [1294, 1297], [1217, 1220], [1422, 1425], [310, 313], [1340, 1343], [577, 580], [1071, 1074], [244, 247], [190, 193]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["early", 10], ["2000s", 16], [",", 21], ["the", 23], ["incidence", 27], ["of", 37], ["methicillin", 40], ["-", 51], ["resistant", 52], ["Staphylococcus", 62], ["aureus", 77], ["(", 84], ["MRSA", 85], [")", 89], ["infections", 91], ["among", 102], ["the", 108], ["community", 112], ["of", 122], ["people", 125], ["lacking", 132], ["known", 140], ["healthcare", 146], ["risk", 157], ["factors", 162], ["has", 170], ["increased", 174], [".", 183], ["This", 185], ["MRSA", 190], ["infection", 195], ["is", 205], ["referred", 208], ["to", 217], ["as", 220], ["community", 223], ["-", 232], ["associated", 233], ["MRSA", 244], ["(", 249], ["CA", 250], ["-", 252], ["MRSA", 253], [")", 257], ["infection", 259], ["and", 269], ["is", 273], ["distinct", 276], ["from", 285], ["hospital", 290], ["-", 298], ["associated", 299], ["MRSA", 310], ["(", 315], ["HA", 316], ["-", 318], ["MRSA", 319], [")", 323], ["infection", 325], [",", 334], ["which", 336], ["occurs", 342], ["among", 349], ["people", 355], ["with", 362], ["known", 367], ["healthcare", 373], ["risk", 384], ["factors", 389], [".", 396], ["Understanding", 398], ["the", 412], ["epidemiology", 416], ["of", 429], ["CA", 432], ["-", 434], ["MRSA", 435], ["infections", 440], ["is", 451], ["critical", 454], [";", 462], ["however", 464], [",", 471], ["this", 473], ["has", 478], ["not", 482], ["been", 486], ["investigated", 491], ["in", 504], ["detail", 507], ["in", 514], ["Japan", 517], [".", 522], ["Our", 524], ["objective", 528], ["was", 538], ["to", 542], ["investigate", 545], ["the", 557], ["incidence", 561], ["of", 571], ["CA", 574], ["-", 576], ["MRSA", 577], ["infections", 582], ["in", 593], ["a", 596], ["regional", 598], ["hospital", 607], [".", 615], ["We", 617], ["investigated", 620], ["CA", 633], ["-", 635], ["MRSA", 636], ["isolates", 641], ["and", 650], ["infections", 654], ["in", 665], ["a", 668], ["rural", 670], ["regional", 676], ["hospital", 685], ["by", 694], ["reviewing", 697], ["medical", 707], ["records", 715], ["of", 723], ["one", 726], ["year", 730], [".", 734], ["Infections", 736], ["were", 747], ["classified", 752], ["as", 763], ["CA", 766], ["-", 768], ["MRSA", 769], ["if", 774], ["no", 777], ["established", 780], ["risk", 792], ["factors", 797], ["were", 805], ["identified", 810], [".", 820], ["During", 822], ["2008", 829], [",", 833], ["31", 835], ["Staphylococcus", 838], ["aureus", 853], ["(", 860], ["S.", 861], ["aureus", 864], [")", 870], ["isolates", 872], ["were", 881], ["detected", 886], ["in", 895], ["29", 898], ["unique", 901], ["patients", 908], [",", 916], ["with", 918], ["1", 923], ["methicillin", 925], ["-", 936], ["sensitive", 937], ["S.", 947], ["aureus", 950], ["(", 957], ["MSSA", 958], [")", 962], ["isolates", 964], ["obtained", 973], ["from", 982], ["19", 987], ["patients", 990], ["(", 999], ["66", 1000], ["%", 1002], [")", 1003], ["and", 1005], ["MRSA", 1009], ["obtained", 1014], ["from", 1023], ["10", 1028], ["patients", 1031], ["(", 1040], ["34", 1041], ["%", 1043], [")", 1044], [".", 1045], ["In", 1047], ["the", 1050], ["10", 1054], ["patients", 1057], ["with", 1066], ["MRSA", 1071], [",", 1075], ["the", 1077], ["number", 1081], ["of", 1088], ["HA", 1091], ["-", 1093], ["MRSA", 1094], ["and", 1099], ["CA", 1103], ["-", 1105], ["MRSA", 1106], ["cases", 1111], ["were", 1117], ["nine", 1122], ["(", 1127], ["32", 1128], ["%", 1130], ["of", 1132], ["patients", 1135], ["with", 1144], ["S.", 1149], ["aureus", 1152], ["isolates", 1159], [")", 1167], ["and", 1169], ["one", 1173], ["(", 1177], ["3", 1178], ["%", 1179], [")", 1180], [",", 1181], ["respectively", 1183], [".", 1195], ["The", 1197], ["patient", 1201], ["with", 1209], ["CA", 1214], ["-", 1216], ["MRSA", 1217], ["was", 1222], ["diagnosed", 1226], ["with", 1236], ["cellulitis", 1241], ["due", 1252], ["to", 1256], ["CA", 1259], ["-", 1261], ["MRSA", 1262], [".", 1266], ["All", 1268], ["nine", 1272], ["patients", 1277], ["with", 1286], ["HA", 1291], ["-", 1293], ["MRSA", 1294], ["exhibited", 1299], ["colonization", 1309], [".", 1321], ["We", 1323], ["observed", 1326], ["a", 1335], ["CA", 1337], ["-", 1339], ["MRSA", 1340], ["case", 1345], ["in", 1350], ["a", 1353], ["regional", 1355], ["hospital", 1364], ["in", 1373], ["Japan", 1376], [",", 1381], ["suggesting", 1383], ["that", 1394], ["incidence", 1399], ["trends", 1409], ["of", 1416], ["CA", 1419], ["-", 1421], ["MRSA", 1422], ["should", 1427], ["be", 1434], ["considered", 1437], ["in", 1448], ["future", 1451], ["research", 1458], ["and", 1467], ["treatment", 1471], [".", 1480]]}
{"context": "CLIP-Seq protocols such as PAR-CLIP, HITS-CLIP or iCLIP allow a genome-wide analysis of protein-RNA interactions. For the processing of the resulting short read data, various tools are utilized. Some of these tools were specifically developed for CLIP-Seq data, whereas others were designed for the analysis of RNA-Seq data. To this date, however, it has not been assessed which of the available tools are most appropriate for the analysis of CLIP-Seq data. This is because an experimental gold standard dataset on which methods can be accessed and compared, is still not available. To address this lack of a gold-standard dataset, we here present Cseq-Simulator, a simulator for PAR-CLIP, HITS-CLIP and iCLIP-data. This simulator can be applied to generate realistic datasets that can serve as surrogates for experimental gold standard dataset. In this work, we also show how Cseq-Simulator can be used to perform a comparison of steps of typical CLIP-Seq analysis pipelines, such as the read alignment or the peak calling. These comparisons show which tools are useful in different settings and also allow identifying pitfalls in the data analysis.", "qas": [{"question": "Which data simulator is available for CLIP-SEQ experiments?", "answers": ["Cseq-Simulator"], "qid": "eb43bbf0c4bb484dba710614100c1204", "question_tokens": [["Which", 0], ["data", 6], ["simulator", 11], ["is", 21], ["available", 24], ["for", 34], ["CLIP", 38], ["-", 42], ["SEQ", 43], ["experiments", 47], ["?", 58]], "detected_answers": [{"text": "Cseq-Simulator", "token_spans": [[132, 134], [179, 181]], "char_spans": [[648, 661], [877, 890]]}]}], "context_tokens": [["CLIP", 0], ["-", 4], ["Seq", 5], ["protocols", 9], ["such", 19], ["as", 24], ["PAR", 27], ["-", 30], ["CLIP", 31], [",", 35], ["HITS", 37], ["-", 41], ["CLIP", 42], ["or", 47], ["iCLIP", 50], ["allow", 56], ["a", 62], ["genome", 64], ["-", 70], ["wide", 71], ["analysis", 76], ["of", 85], ["protein", 88], ["-", 95], ["RNA", 96], ["interactions", 100], [".", 112], ["For", 114], ["the", 118], ["processing", 122], ["of", 133], ["the", 136], ["resulting", 140], ["short", 150], ["read", 156], ["data", 161], [",", 165], ["various", 167], ["tools", 175], ["are", 181], ["utilized", 185], [".", 193], ["Some", 195], ["of", 200], ["these", 203], ["tools", 209], ["were", 215], ["specifically", 220], ["developed", 233], ["for", 243], ["CLIP", 247], ["-", 251], ["Seq", 252], ["data", 256], [",", 260], ["whereas", 262], ["others", 270], ["were", 277], ["designed", 282], ["for", 291], ["the", 295], ["analysis", 299], ["of", 308], ["RNA", 311], ["-", 314], ["Seq", 315], ["data", 319], [".", 323], ["To", 325], ["this", 328], ["date", 333], [",", 337], ["however", 339], [",", 346], ["it", 348], ["has", 351], ["not", 355], ["been", 359], ["assessed", 364], ["which", 373], ["of", 379], ["the", 382], ["available", 386], ["tools", 396], ["are", 402], ["most", 406], ["appropriate", 411], ["for", 423], ["the", 427], ["analysis", 431], ["of", 440], ["CLIP", 443], ["-", 447], ["Seq", 448], ["data", 452], [".", 456], ["This", 458], ["is", 463], ["because", 466], ["an", 474], ["experimental", 477], ["gold", 490], ["standard", 495], ["dataset", 504], ["on", 512], ["which", 515], ["methods", 521], ["can", 529], ["be", 533], ["accessed", 536], ["and", 545], ["compared", 549], [",", 557], ["is", 559], ["still", 562], ["not", 568], ["available", 572], [".", 581], ["To", 583], ["address", 586], ["this", 594], ["lack", 599], ["of", 604], ["a", 607], ["gold", 609], ["-", 613], ["standard", 614], ["dataset", 623], [",", 630], ["we", 632], ["here", 635], ["present", 640], ["Cseq", 648], ["-", 652], ["Simulator", 653], [",", 662], ["a", 664], ["simulator", 666], ["for", 676], ["PAR", 680], ["-", 683], ["CLIP", 684], [",", 688], ["HITS", 690], ["-", 694], ["CLIP", 695], ["and", 700], ["iCLIP", 704], ["-", 709], ["data", 710], [".", 714], ["This", 716], ["simulator", 721], ["can", 731], ["be", 735], ["applied", 738], ["to", 746], ["generate", 749], ["realistic", 758], ["datasets", 768], ["that", 777], ["can", 782], ["serve", 786], ["as", 792], ["surrogates", 795], ["for", 806], ["experimental", 810], ["gold", 823], ["standard", 828], ["dataset", 837], [".", 844], ["In", 846], ["this", 849], ["work", 854], [",", 858], ["we", 860], ["also", 863], ["show", 868], ["how", 873], ["Cseq", 877], ["-", 881], ["Simulator", 882], ["can", 892], ["be", 896], ["used", 899], ["to", 904], ["perform", 907], ["a", 915], ["comparison", 917], ["of", 928], ["steps", 931], ["of", 937], ["typical", 940], ["CLIP", 948], ["-", 952], ["Seq", 953], ["analysis", 957], ["pipelines", 966], [",", 975], ["such", 977], ["as", 982], ["the", 985], ["read", 989], ["alignment", 994], ["or", 1004], ["the", 1007], ["peak", 1011], ["calling", 1016], [".", 1023], ["These", 1025], ["comparisons", 1031], ["show", 1043], ["which", 1048], ["tools", 1054], ["are", 1060], ["useful", 1064], ["in", 1071], ["different", 1074], ["settings", 1084], ["and", 1093], ["also", 1097], ["allow", 1102], ["identifying", 1108], ["pitfalls", 1120], ["in", 1129], ["the", 1132], ["data", 1136], ["analysis", 1141], [".", 1149]]}
{"context": "The completeness of meningioma resection depends on the resection of dura mater invaded by the tumor. The pathological changes of the dura around the tumor can be interpreted by evaluating the dural tail sign (DTS) on MRI studies. The goal of this study was to clarify the pathological characteristics of the DTSs, propose a classification based on the histopathological and radiological correlation, and identify the invasive range of tumor cells in different types of DTS. The authors retrospectively reviewed 179 patients with convexity meningiomas who underwent Simpson Grade I resection. All patients underwent an enhanced MRI examination preoperatively. The convexity meningiomas were dichotomized into various subtypes in accordance with the 2007 WHO classification of tumors of the CNS, and the DTS was identified based on the Goldsher criteria. The range of resection of the involved dura was 3 cm from the base of the tumor, which corresponded with the length of DTS on MRI studies. Histopathological examination of dura at 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 cm from the base of the tumor was conducted, and the findings were correlated with the preoperative MRI appearance of the DTS. A total of 154 (86%) of 179 convexity meningiomas were classified into WHO Grade I subtype, including transitional (44 [28.6%] of 154), meningothelial (36 [23.4%] of 154), fibrous (23 [14.9%] of 154), psammomatous (22 [14.3%] of 154), secretory (10 [6.5%] of 154), and angiomatous (19 [12.3%] of 154). The other 25 (14%) were non-Grade I (WHO) tumors, including atypical (12 [48%] of 25), anaplastic (5 [20%] of 25), and papillary (8 [32%] of 25). The DTS was classified into 5 types: smooth (16 [8.9%] of 179), nodular (36 [20.1%] of 179), mixed (57 [31.8%] of 179), symmetrical multipolar (15 [8.4%] of 179), and asymmetrical multipolar (55 [30.7%] of 179). There was a significant difference in distribution of DTS type between Grade I and non-Grade I tumors (p = 0.004), whereas the difference was not significant among Grade I tumors (0.841) or among non-Grade I tumors (p = 0.818). All smooth-type DTSs were encountered in Grade I tumors, and the mixed DTS (52 [33.8%] of 154) was the most common type in these tumors. Nodular-type DTS was more commonly seen in non-Grade I tumors (12 [48%] of 25). Tumor invasion was found in 88.3% (158 of 179) of convexity meningiomas, of which the range of invasion in 82.3% (130 of 158) was within 2 cm and that in 94.9% (150 of 158) was within 2.5 cm. The incidence of invasion and the range invaded by tumor cells varied in different types of DTS, and differences were statistically significant (p < 0.001). Nodular-type DTS on MRI studies might be associated with non-Grade I tumors. The range of dural resection for convexity meningiomas should be 2.5 cm from the tumor base, and if this extent of resection is not feasible, the type of DTS should be considered. However, for skull base meningiomas, in which mostly Simpson Grade II resection is achieved, the use of this classification should be further validated. The classification of DTS enables the surgeon to predict preoperatively and then to achieve the optimal range of dural resection that might significantly reduce the recurrence rate of meningiomas.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "dfc371178f7740ec80686c0baf2ecc3a", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[3, 3]], "char_spans": [[20, 29]]}]}], "context_tokens": [["The", 0], ["completeness", 4], ["of", 17], ["meningioma", 20], ["resection", 31], ["depends", 41], ["on", 49], ["the", 52], ["resection", 56], ["of", 66], ["dura", 69], ["mater", 74], ["invaded", 80], ["by", 88], ["the", 91], ["tumor", 95], [".", 100], ["The", 102], ["pathological", 106], ["changes", 119], ["of", 127], ["the", 130], ["dura", 134], ["around", 139], ["the", 146], ["tumor", 150], ["can", 156], ["be", 160], ["interpreted", 163], ["by", 175], ["evaluating", 178], ["the", 189], ["dural", 193], ["tail", 199], ["sign", 204], ["(", 209], ["DTS", 210], [")", 213], ["on", 215], ["MRI", 218], ["studies", 222], [".", 229], ["The", 231], ["goal", 235], ["of", 240], ["this", 243], ["study", 248], ["was", 254], ["to", 258], ["clarify", 261], ["the", 269], ["pathological", 273], ["characteristics", 286], ["of", 302], ["the", 305], ["DTSs", 309], [",", 313], ["propose", 315], ["a", 323], ["classification", 325], ["based", 340], ["on", 346], ["the", 349], ["histopathological", 353], ["and", 371], ["radiological", 375], ["correlation", 388], [",", 399], ["and", 401], ["identify", 405], ["the", 414], ["invasive", 418], ["range", 427], ["of", 433], ["tumor", 436], ["cells", 442], ["in", 448], ["different", 451], ["types", 461], ["of", 467], ["DTS", 470], [".", 473], ["The", 475], ["authors", 479], ["retrospectively", 487], ["reviewed", 503], ["179", 512], ["patients", 516], ["with", 525], ["convexity", 530], ["meningiomas", 540], ["who", 552], ["underwent", 556], ["Simpson", 566], ["Grade", 574], ["I", 580], ["resection", 582], [".", 591], ["All", 593], ["patients", 597], ["underwent", 606], ["an", 616], ["enhanced", 619], ["MRI", 628], ["examination", 632], ["preoperatively", 644], [".", 658], ["The", 660], ["convexity", 664], ["meningiomas", 674], ["were", 686], ["dichotomized", 691], ["into", 704], ["various", 709], ["subtypes", 717], ["in", 726], ["accordance", 729], ["with", 740], ["the", 745], ["2007", 749], ["WHO", 754], ["classification", 758], ["of", 773], ["tumors", 776], ["of", 783], ["the", 786], ["CNS", 790], [",", 793], ["and", 795], ["the", 799], ["DTS", 803], ["was", 807], ["identified", 811], ["based", 822], ["on", 828], ["the", 831], ["Goldsher", 835], ["criteria", 844], [".", 852], ["The", 854], ["range", 858], ["of", 864], ["resection", 867], ["of", 877], ["the", 880], ["involved", 884], ["dura", 893], ["was", 898], ["3", 902], ["cm", 904], ["from", 907], ["the", 912], ["base", 916], ["of", 921], ["the", 924], ["tumor", 928], [",", 933], ["which", 935], ["corresponded", 941], ["with", 954], ["the", 959], ["length", 963], ["of", 970], ["DTS", 973], ["on", 977], ["MRI", 980], ["studies", 984], [".", 991], ["Histopathological", 993], ["examination", 1011], ["of", 1023], ["dura", 1026], ["at", 1031], ["0.5", 1034], [",", 1037], ["1.0", 1039], [",", 1042], ["1.5", 1044], [",", 1047], ["2.0", 1049], [",", 1052], ["2.5", 1054], [",", 1057], ["and", 1059], ["3.0", 1063], ["cm", 1067], ["from", 1070], ["the", 1075], ["base", 1079], ["of", 1084], ["the", 1087], ["tumor", 1091], ["was", 1097], ["conducted", 1101], [",", 1110], ["and", 1112], ["the", 1116], ["findings", 1120], ["were", 1129], ["correlated", 1134], ["with", 1145], ["the", 1150], ["preoperative", 1154], ["MRI", 1167], ["appearance", 1171], ["of", 1182], ["the", 1185], ["DTS", 1189], [".", 1192], ["A", 1194], ["total", 1196], ["of", 1202], ["154", 1205], ["(", 1209], ["86", 1210], ["%", 1212], [")", 1213], ["of", 1215], ["179", 1218], ["convexity", 1222], ["meningiomas", 1232], ["were", 1244], ["classified", 1249], ["into", 1260], ["WHO", 1265], ["Grade", 1269], ["I", 1275], ["subtype", 1277], [",", 1284], ["including", 1286], ["transitional", 1296], ["(", 1309], ["44", 1310], ["[", 1313], ["28.6", 1314], ["%", 1318], ["]", 1319], ["of", 1321], ["154", 1324], [")", 1327], [",", 1328], ["meningothelial", 1330], ["(", 1345], ["36", 1346], ["[", 1349], ["23.4", 1350], ["%", 1354], ["]", 1355], ["of", 1357], ["154", 1360], [")", 1363], [",", 1364], ["fibrous", 1366], ["(", 1374], ["23", 1375], ["[", 1378], ["14.9", 1379], ["%", 1383], ["]", 1384], ["of", 1386], ["154", 1389], [")", 1392], [",", 1393], ["psammomatous", 1395], ["(", 1408], ["22", 1409], ["[", 1412], ["14.3", 1413], ["%", 1417], ["]", 1418], ["of", 1420], ["154", 1423], [")", 1426], [",", 1427], ["secretory", 1429], ["(", 1439], ["10", 1440], ["[", 1443], ["6.5", 1444], ["%", 1447], ["]", 1448], ["of", 1450], ["154", 1453], [")", 1456], [",", 1457], ["and", 1459], ["angiomatous", 1463], ["(", 1475], ["19", 1476], ["[", 1479], ["12.3", 1480], ["%", 1484], ["]", 1485], ["of", 1487], ["154", 1490], [")", 1493], [".", 1494], ["The", 1496], ["other", 1500], ["25", 1506], ["(", 1509], ["14", 1510], ["%", 1512], [")", 1513], ["were", 1515], ["non", 1520], ["-", 1523], ["Grade", 1524], ["I", 1530], ["(", 1532], ["WHO", 1533], [")", 1536], ["tumors", 1538], [",", 1544], ["including", 1546], ["atypical", 1556], ["(", 1565], ["12", 1566], ["[", 1569], ["48", 1570], ["%", 1572], ["]", 1573], ["of", 1575], ["25", 1578], [")", 1580], [",", 1581], ["anaplastic", 1583], ["(", 1594], ["5", 1595], ["[", 1597], ["20", 1598], ["%", 1600], ["]", 1601], ["of", 1603], ["25", 1606], [")", 1608], [",", 1609], ["and", 1611], ["papillary", 1615], ["(", 1625], ["8", 1626], ["[", 1628], ["32", 1629], ["%", 1631], ["]", 1632], ["of", 1634], ["25", 1637], [")", 1639], [".", 1640], ["The", 1642], ["DTS", 1646], ["was", 1650], ["classified", 1654], ["into", 1665], ["5", 1670], ["types", 1672], [":", 1677], ["smooth", 1679], ["(", 1686], ["16", 1687], ["[", 1690], ["8.9", 1691], ["%", 1694], ["]", 1695], ["of", 1697], ["179", 1700], [")", 1703], [",", 1704], ["nodular", 1706], ["(", 1714], ["36", 1715], ["[", 1718], ["20.1", 1719], ["%", 1723], ["]", 1724], ["of", 1726], ["179", 1729], [")", 1732], [",", 1733], ["mixed", 1735], ["(", 1741], ["57", 1742], ["[", 1745], ["31.8", 1746], ["%", 1750], ["]", 1751], ["of", 1753], ["179", 1756], [")", 1759], [",", 1760], ["symmetrical", 1762], ["multipolar", 1774], ["(", 1785], ["15", 1786], ["[", 1789], ["8.4", 1790], ["%", 1793], ["]", 1794], ["of", 1796], ["179", 1799], [")", 1802], [",", 1803], ["and", 1805], ["asymmetrical", 1809], ["multipolar", 1822], ["(", 1833], ["55", 1834], ["[", 1837], ["30.7", 1838], ["%", 1842], ["]", 1843], ["of", 1845], ["179", 1848], [")", 1851], [".", 1852], ["There", 1854], ["was", 1860], ["a", 1864], ["significant", 1866], ["difference", 1878], ["in", 1889], ["distribution", 1892], ["of", 1905], ["DTS", 1908], ["type", 1912], ["between", 1917], ["Grade", 1925], ["I", 1931], ["and", 1933], ["non", 1937], ["-", 1940], ["Grade", 1941], ["I", 1947], ["tumors", 1949], ["(", 1956], ["p", 1957], ["=", 1959], ["0.004", 1961], [")", 1966], [",", 1967], ["whereas", 1969], ["the", 1977], ["difference", 1981], ["was", 1992], ["not", 1996], ["significant", 2000], ["among", 2012], ["Grade", 2018], ["I", 2024], ["tumors", 2026], ["(", 2033], ["0.841", 2034], [")", 2039], ["or", 2041], ["among", 2044], ["non", 2050], ["-", 2053], ["Grade", 2054], ["I", 2060], ["tumors", 2062], ["(", 2069], ["p", 2070], ["=", 2072], ["0.818", 2074], [")", 2079], [".", 2080], ["All", 2082], ["smooth", 2086], ["-", 2092], ["type", 2093], ["DTSs", 2098], ["were", 2103], ["encountered", 2108], ["in", 2120], ["Grade", 2123], ["I", 2129], ["tumors", 2131], [",", 2137], ["and", 2139], ["the", 2143], ["mixed", 2147], ["DTS", 2153], ["(", 2157], ["52", 2158], ["[", 2161], ["33.8", 2162], ["%", 2166], ["]", 2167], ["of", 2169], ["154", 2172], [")", 2175], ["was", 2177], ["the", 2181], ["most", 2185], ["common", 2190], ["type", 2197], ["in", 2202], ["these", 2205], ["tumors", 2211], [".", 2217], ["Nodular", 2219], ["-", 2226], ["type", 2227], ["DTS", 2232], ["was", 2236], ["more", 2240], ["commonly", 2245], ["seen", 2254], ["in", 2259], ["non", 2262], ["-", 2265], ["Grade", 2266], ["I", 2272], ["tumors", 2274], ["(", 2281], ["12", 2282], ["[", 2285], ["48", 2286], ["%", 2288], ["]", 2289], ["of", 2291], ["25", 2294], [")", 2296], [".", 2297], ["Tumor", 2299], ["invasion", 2305], ["was", 2314], ["found", 2318], ["in", 2324], ["88.3", 2327], ["%", 2331], ["(", 2333], ["158", 2334], ["of", 2338], ["179", 2341], [")", 2344], ["of", 2346], ["convexity", 2349], ["meningiomas", 2359], [",", 2370], ["of", 2372], ["which", 2375], ["the", 2381], ["range", 2385], ["of", 2391], ["invasion", 2394], ["in", 2403], ["82.3", 2406], ["%", 2410], ["(", 2412], ["130", 2413], ["of", 2417], ["158", 2420], [")", 2423], ["was", 2425], ["within", 2429], ["2", 2436], ["cm", 2438], ["and", 2441], ["that", 2445], ["in", 2450], ["94.9", 2453], ["%", 2457], ["(", 2459], ["150", 2460], ["of", 2464], ["158", 2467], [")", 2470], ["was", 2472], ["within", 2476], ["2.5", 2483], ["cm", 2487], [".", 2489], ["The", 2491], ["incidence", 2495], ["of", 2505], ["invasion", 2508], ["and", 2517], ["the", 2521], ["range", 2525], ["invaded", 2531], ["by", 2539], ["tumor", 2542], ["cells", 2548], ["varied", 2554], ["in", 2561], ["different", 2564], ["types", 2574], ["of", 2580], ["DTS", 2583], [",", 2586], ["and", 2588], ["differences", 2592], ["were", 2604], ["statistically", 2609], ["significant", 2623], ["(", 2635], ["p", 2636], ["<", 2638], ["0.001", 2640], [")", 2645], [".", 2646], ["Nodular", 2648], ["-", 2655], ["type", 2656], ["DTS", 2661], ["on", 2665], ["MRI", 2668], ["studies", 2672], ["might", 2680], ["be", 2686], ["associated", 2689], ["with", 2700], ["non", 2705], ["-", 2708], ["Grade", 2709], ["I", 2715], ["tumors", 2717], [".", 2723], ["The", 2725], ["range", 2729], ["of", 2735], ["dural", 2738], ["resection", 2744], ["for", 2754], ["convexity", 2758], ["meningiomas", 2768], ["should", 2780], ["be", 2787], ["2.5", 2790], ["cm", 2794], ["from", 2797], ["the", 2802], ["tumor", 2806], ["base", 2812], [",", 2816], ["and", 2818], ["if", 2822], ["this", 2825], ["extent", 2830], ["of", 2837], ["resection", 2840], ["is", 2850], ["not", 2853], ["feasible", 2857], [",", 2865], ["the", 2867], ["type", 2871], ["of", 2876], ["DTS", 2879], ["should", 2883], ["be", 2890], ["considered", 2893], [".", 2903], ["However", 2905], [",", 2912], ["for", 2914], ["skull", 2918], ["base", 2924], ["meningiomas", 2929], [",", 2940], ["in", 2942], ["which", 2945], ["mostly", 2951], ["Simpson", 2958], ["Grade", 2966], ["II", 2972], ["resection", 2975], ["is", 2985], ["achieved", 2988], [",", 2996], ["the", 2998], ["use", 3002], ["of", 3006], ["this", 3009], ["classification", 3014], ["should", 3029], ["be", 3036], ["further", 3039], ["validated", 3047], [".", 3056], ["The", 3058], ["classification", 3062], ["of", 3077], ["DTS", 3080], ["enables", 3084], ["the", 3092], ["surgeon", 3096], ["to", 3104], ["predict", 3107], ["preoperatively", 3115], ["and", 3130], ["then", 3134], ["to", 3139], ["achieve", 3142], ["the", 3150], ["optimal", 3154], ["range", 3162], ["of", 3168], ["dural", 3171], ["resection", 3177], ["that", 3187], ["might", 3192], ["significantly", 3198], ["reduce", 3212], ["the", 3219], ["recurrence", 3223], ["rate", 3234], ["of", 3239], ["meningiomas", 3242], [".", 3253]]}
{"context": "The precise regulation of microRNA (miRNA) transcription and processing is important for eukaryotic development. Plant miRNAs are first transcribed as stem-loop primary miRNAs (pri-miRNAs) by RNA polymerase II,then cleaved in the nucleus into mature miRNAs by Dicer-like 1 (DCL1). We identified a cycling DOF transcription factor, CDF2, which interacts with DCL1 and regulates the accumulation of a population of miRNAs. CDF2 binds directly to the promoters of some miRNAs and works as a transcription activator or repressor for these miRNA genes. CDF2 binds preferentially to the pri-miRNAs regulated by itself and affects DCL1-mediated processing of these pri-miRNAs. Genetically, CDF2 works in the same pathway as miR156 or miR172 to control flowering. We conclude that CDF2 regulates a group of pri-miRNAs at both the transcriptional and posttranscriptional levels to maintain proper levels of their mature miRNAs to control plant development.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "0d62867611e34119b3f038886614e0ab", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[34, 36]], "char_spans": [[192, 208]]}]}], "context_tokens": [["The", 0], ["precise", 4], ["regulation", 12], ["of", 23], ["microRNA", 26], ["(", 35], ["miRNA", 36], [")", 41], ["transcription", 43], ["and", 57], ["processing", 61], ["is", 72], ["important", 75], ["for", 85], ["eukaryotic", 89], ["development", 100], [".", 111], ["Plant", 113], ["miRNAs", 119], ["are", 126], ["first", 130], ["transcribed", 136], ["as", 148], ["stem", 151], ["-", 155], ["loop", 156], ["primary", 161], ["miRNAs", 169], ["(", 176], ["pri", 177], ["-", 180], ["miRNAs", 181], [")", 187], ["by", 189], ["RNA", 192], ["polymerase", 196], ["II", 207], [",", 209], ["then", 210], ["cleaved", 215], ["in", 223], ["the", 226], ["nucleus", 230], ["into", 238], ["mature", 243], ["miRNAs", 250], ["by", 257], ["Dicer", 260], ["-", 265], ["like", 266], ["1", 271], ["(", 273], ["DCL1", 274], [")", 278], [".", 279], ["We", 281], ["identified", 284], ["a", 295], ["cycling", 297], ["DOF", 305], ["transcription", 309], ["factor", 323], [",", 329], ["CDF2", 331], [",", 335], ["which", 337], ["interacts", 343], ["with", 353], ["DCL1", 358], ["and", 363], ["regulates", 367], ["the", 377], ["accumulation", 381], ["of", 394], ["a", 397], ["population", 399], ["of", 410], ["miRNAs", 413], [".", 419], ["CDF2", 421], ["binds", 426], ["directly", 432], ["to", 441], ["the", 444], ["promoters", 448], ["of", 458], ["some", 461], ["miRNAs", 466], ["and", 473], ["works", 477], ["as", 483], ["a", 486], ["transcription", 488], ["activator", 502], ["or", 512], ["repressor", 515], ["for", 525], ["these", 529], ["miRNA", 535], ["genes", 541], [".", 546], ["CDF2", 548], ["binds", 553], ["preferentially", 559], ["to", 574], ["the", 577], ["pri", 581], ["-", 584], ["miRNAs", 585], ["regulated", 592], ["by", 602], ["itself", 605], ["and", 612], ["affects", 616], ["DCL1-mediated", 624], ["processing", 638], ["of", 649], ["these", 652], ["pri", 658], ["-", 661], ["miRNAs", 662], [".", 668], ["Genetically", 670], [",", 681], ["CDF2", 683], ["works", 688], ["in", 694], ["the", 697], ["same", 701], ["pathway", 706], ["as", 714], ["miR156", 717], ["or", 724], ["miR172", 727], ["to", 734], ["control", 737], ["flowering", 745], [".", 754], ["We", 756], ["conclude", 759], ["that", 768], ["CDF2", 773], ["regulates", 778], ["a", 788], ["group", 790], ["of", 796], ["pri", 799], ["-", 802], ["miRNAs", 803], ["at", 810], ["both", 813], ["the", 818], ["transcriptional", 822], ["and", 838], ["posttranscriptional", 842], ["levels", 862], ["to", 869], ["maintain", 872], ["proper", 881], ["levels", 888], ["of", 895], ["their", 898], ["mature", 904], ["miRNAs", 911], ["to", 918], ["control", 921], ["plant", 929], ["development", 935], [".", 946]]}
{"context": "RNA editing usually affects only a fraction of expressed transcripts and there is a vast amount of variation in editing levels of ADAR (adenosine deaminase, RNA-specific) targets. Here we explore natural genetic variation affecting editing levels of particular sites in 81 natural strains of Drosophila melanogaster. The analysis of associations between editing levels and single-nucleotide polymorphisms allows us to map putative cis-regulatory regions affecting editing of 16 A-to-I editing sites (cis-RNA editing quantitative trait loci or cis-edQTLs, P\u00a0<\u00a010(-8)). The observed changes in editing levels are validated by independent molecular technique. All identified regulatory variants are located in close proximity of modulated editing sites. Moreover, colocalized editing sites are often regulated by same loci. Similar to expression and splicing QTL studies, the characterization of edQTLs will greatly expand our understanding of cis-regulatory evolution of gene expression.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "d56d38b84b684192b16ecad81b0152c7", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[22, 22]], "char_spans": [[130, 133]]}, {"text": "adenosine deaminase, RNA-specific", "token_spans": [[24, 29]], "char_spans": [[136, 168]]}]}], "context_tokens": [["RNA", 0], ["editing", 4], ["usually", 12], ["affects", 20], ["only", 28], ["a", 33], ["fraction", 35], ["of", 44], ["expressed", 47], ["transcripts", 57], ["and", 69], ["there", 73], ["is", 79], ["a", 82], ["vast", 84], ["amount", 89], ["of", 96], ["variation", 99], ["in", 109], ["editing", 112], ["levels", 120], ["of", 127], ["ADAR", 130], ["(", 135], ["adenosine", 136], ["deaminase", 146], [",", 155], ["RNA", 157], ["-", 160], ["specific", 161], [")", 169], ["targets", 171], [".", 178], ["Here", 180], ["we", 185], ["explore", 188], ["natural", 196], ["genetic", 204], ["variation", 212], ["affecting", 222], ["editing", 232], ["levels", 240], ["of", 247], ["particular", 250], ["sites", 261], ["in", 267], ["81", 270], ["natural", 273], ["strains", 281], ["of", 289], ["Drosophila", 292], ["melanogaster", 303], [".", 315], ["The", 317], ["analysis", 321], ["of", 330], ["associations", 333], ["between", 346], ["editing", 354], ["levels", 362], ["and", 369], ["single", 373], ["-", 379], ["nucleotide", 380], ["polymorphisms", 391], ["allows", 405], ["us", 412], ["to", 415], ["map", 418], ["putative", 422], ["cis", 431], ["-", 434], ["regulatory", 435], ["regions", 446], ["affecting", 454], ["editing", 464], ["of", 472], ["16", 475], ["A", 478], ["-", 479], ["to", 480], ["-", 482], ["I", 483], ["editing", 485], ["sites", 493], ["(", 499], ["cis", 500], ["-", 503], ["RNA", 504], ["editing", 508], ["quantitative", 516], ["trait", 529], ["loci", 535], ["or", 540], ["cis", 543], ["-", 546], ["edQTLs", 547], [",", 553], ["P", 555], ["<", 557], ["10(-8", 559], [")", 564], [")", 565], [".", 566], ["The", 568], ["observed", 572], ["changes", 581], ["in", 589], ["editing", 592], ["levels", 600], ["are", 607], ["validated", 611], ["by", 621], ["independent", 624], ["molecular", 636], ["technique", 646], [".", 655], ["All", 657], ["identified", 661], ["regulatory", 672], ["variants", 683], ["are", 692], ["located", 696], ["in", 704], ["close", 707], ["proximity", 713], ["of", 723], ["modulated", 726], ["editing", 736], ["sites", 744], [".", 749], ["Moreover", 751], [",", 759], ["colocalized", 761], ["editing", 773], ["sites", 781], ["are", 787], ["often", 791], ["regulated", 797], ["by", 807], ["same", 810], ["loci", 815], [".", 819], ["Similar", 821], ["to", 829], ["expression", 832], ["and", 843], ["splicing", 847], ["QTL", 856], ["studies", 860], [",", 867], ["the", 869], ["characterization", 873], ["of", 890], ["edQTLs", 893], ["will", 900], ["greatly", 905], ["expand", 913], ["our", 920], ["understanding", 924], ["of", 938], ["cis", 941], ["-", 944], ["regulatory", 945], ["evolution", 956], ["of", 966], ["gene", 969], ["expression", 974], [".", 984]]}
{"context": "Flumazenil, a potent benzodiazepine antagonist, is a newly synthetic imidazo-benzodiazepine, which blocks the neurological effects of benzodiazepines. The purpose of this study was to evaluate the effects of this agent in reversal of benzodiazepine overdose and differentiation of comatous patients with drug overdose. Fifteen comatous patients with suspected sedatives/hypnotics overdose were included in this study and flumazenil 0.25 mg per dose was administrated intravenously. The average score of Glasgow Coma Scale increased from 7.13 +/- 2.92 to 10.93 +/- 3.67 after one dose of flumazenil. Clear consciousness was restored after multiple doses of flumazenil administration. Three cases with different drug history and variant response after flumazenil treatment were also illustrated and discussed. The dosage of flumazenil used in this study ranged from 0.25 mg to 3 mg (average 0.87 +/- 0.74 mg). We concluded that flumazenil is an excellent antidote for benzodiazepine overdose and valuable for differentiating the patients in comatose.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "ebb1ae34a73c4a5d839b1240da0af1a4", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [96, 96], [106, 106], [154, 154], [119, 119], [130, 130], [65, 65]], "char_spans": [[0, 9], [587, 596], [656, 665], [926, 935], [750, 759], [822, 831], [421, 430]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["potent", 14], ["benzodiazepine", 21], ["antagonist", 36], [",", 46], ["is", 48], ["a", 51], ["newly", 53], ["synthetic", 59], ["imidazo", 69], ["-", 76], ["benzodiazepine", 77], [",", 91], ["which", 93], ["blocks", 99], ["the", 106], ["neurological", 110], ["effects", 123], ["of", 131], ["benzodiazepines", 134], [".", 149], ["The", 151], ["purpose", 155], ["of", 163], ["this", 166], ["study", 171], ["was", 177], ["to", 181], ["evaluate", 184], ["the", 193], ["effects", 197], ["of", 205], ["this", 208], ["agent", 213], ["in", 219], ["reversal", 222], ["of", 231], ["benzodiazepine", 234], ["overdose", 249], ["and", 258], ["differentiation", 262], ["of", 278], ["comatous", 281], ["patients", 290], ["with", 299], ["drug", 304], ["overdose", 309], [".", 317], ["Fifteen", 319], ["comatous", 327], ["patients", 336], ["with", 345], ["suspected", 350], ["sedatives", 360], ["/", 369], ["hypnotics", 370], ["overdose", 380], ["were", 389], ["included", 394], ["in", 403], ["this", 406], ["study", 411], ["and", 417], ["flumazenil", 421], ["0.25", 432], ["mg", 437], ["per", 440], ["dose", 444], ["was", 449], ["administrated", 453], ["intravenously", 467], [".", 480], ["The", 482], ["average", 486], ["score", 494], ["of", 500], ["Glasgow", 503], ["Coma", 511], ["Scale", 516], ["increased", 522], ["from", 532], ["7.13", 537], ["+", 542], ["/-", 543], ["2.92", 546], ["to", 551], ["10.93", 554], ["+", 560], ["/-", 561], ["3.67", 564], ["after", 569], ["one", 575], ["dose", 579], ["of", 584], ["flumazenil", 587], [".", 597], ["Clear", 599], ["consciousness", 605], ["was", 619], ["restored", 623], ["after", 632], ["multiple", 638], ["doses", 647], ["of", 653], ["flumazenil", 656], ["administration", 667], [".", 681], ["Three", 683], ["cases", 689], ["with", 695], ["different", 700], ["drug", 710], ["history", 715], ["and", 723], ["variant", 727], ["response", 735], ["after", 744], ["flumazenil", 750], ["treatment", 761], ["were", 771], ["also", 776], ["illustrated", 781], ["and", 793], ["discussed", 797], [".", 806], ["The", 808], ["dosage", 812], ["of", 819], ["flumazenil", 822], ["used", 833], ["in", 838], ["this", 841], ["study", 846], ["ranged", 852], ["from", 859], ["0.25", 864], ["mg", 869], ["to", 872], ["3", 875], ["mg", 877], ["(", 880], ["average", 881], ["0.87", 889], ["+", 894], ["/-", 895], ["0.74", 898], ["mg", 903], [")", 905], [".", 906], ["We", 908], ["concluded", 911], ["that", 921], ["flumazenil", 926], ["is", 937], ["an", 940], ["excellent", 943], ["antidote", 953], ["for", 962], ["benzodiazepine", 966], ["overdose", 981], ["and", 990], ["valuable", 994], ["for", 1003], ["differentiating", 1007], ["the", 1023], ["patients", 1027], ["in", 1036], ["comatose", 1039], [".", 1047]]}
{"context": "Malaria is a widespread and infectious disease that is a leading cause of death in many parts of the world. Eradication of malaria has been a major world health goal for decades, but one that still remains elusive. Other diseases have been eradicated using vaccination, but traditional vaccination methods have thus far been unsuccessful for malaria. Infection by Plasmodium species, the causative agent of malaria, is currently treated with drug-based therapies, but an increase in drug resistance has led to the need for new methods of treatment. A promising strategy for malaria treatment is to combine transmission blocking vaccines (TBVs) that prevent spread of disease with drug-based therapies to treat infected individuals. TBVs can be developed against surface protein antigens that are expressed during parasite reproduction in the mosquito. When the mosquito ingests blood from a vaccinated individual harboring the Plasmodium parasite, the antibodies generated by vaccination prevent completion of the parasites life-cycle. Animal studies have shown that immunization with Pfs48/45 results in the production of malaria transmission blocking antibodies; however, the development of this vaccine candidate has been hindered by poor expression in both prokaryotic and eukaryotic hosts. Recently, the chloroplast of Chlamydomonas reinhardtii has been used to express complex recombinant proteins. In this study, we show that the C-terminal antigenic region of the Pfs48/45 antigen can be expressed in the chloroplast of the green algae C. reinhardtii and that this recombinant protein has a conformation recognized by known transmission blocking antibodies. Production of this protein in algae has the potential to scale to the very large volumes required to meet the needs of millions at risk for contracting malaria.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "4b472a6cb9d048dd9901e39d6b2bb9d0", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium species", "token_spans": [[63, 64]], "char_spans": [[364, 381]]}]}], "context_tokens": [["Malaria", 0], ["is", 8], ["a", 11], ["widespread", 13], ["and", 24], ["infectious", 28], ["disease", 39], ["that", 47], ["is", 52], ["a", 55], ["leading", 57], ["cause", 65], ["of", 71], ["death", 74], ["in", 80], ["many", 83], ["parts", 88], ["of", 94], ["the", 97], ["world", 101], [".", 106], ["Eradication", 108], ["of", 120], ["malaria", 123], ["has", 131], ["been", 135], ["a", 140], ["major", 142], ["world", 148], ["health", 154], ["goal", 161], ["for", 166], ["decades", 170], [",", 177], ["but", 179], ["one", 183], ["that", 187], ["still", 192], ["remains", 198], ["elusive", 206], [".", 213], ["Other", 215], ["diseases", 221], ["have", 230], ["been", 235], ["eradicated", 240], ["using", 251], ["vaccination", 257], [",", 268], ["but", 270], ["traditional", 274], ["vaccination", 286], ["methods", 298], ["have", 306], ["thus", 311], ["far", 316], ["been", 320], ["unsuccessful", 325], ["for", 338], ["malaria", 342], [".", 349], ["Infection", 351], ["by", 361], ["Plasmodium", 364], ["species", 375], [",", 382], ["the", 384], ["causative", 388], ["agent", 398], ["of", 404], ["malaria", 407], [",", 414], ["is", 416], ["currently", 419], ["treated", 429], ["with", 437], ["drug", 442], ["-", 446], ["based", 447], ["therapies", 453], [",", 462], ["but", 464], ["an", 468], ["increase", 471], ["in", 480], ["drug", 483], ["resistance", 488], ["has", 499], ["led", 503], ["to", 507], ["the", 510], ["need", 514], ["for", 519], ["new", 523], ["methods", 527], ["of", 535], ["treatment", 538], [".", 547], ["A", 549], ["promising", 551], ["strategy", 561], ["for", 570], ["malaria", 574], ["treatment", 582], ["is", 592], ["to", 595], ["combine", 598], ["transmission", 606], ["blocking", 619], ["vaccines", 628], ["(", 637], ["TBVs", 638], [")", 642], ["that", 644], ["prevent", 649], ["spread", 657], ["of", 664], ["disease", 667], ["with", 675], ["drug", 680], ["-", 684], ["based", 685], ["therapies", 691], ["to", 701], ["treat", 704], ["infected", 710], ["individuals", 719], [".", 730], ["TBVs", 732], ["can", 737], ["be", 741], ["developed", 744], ["against", 754], ["surface", 762], ["protein", 770], ["antigens", 778], ["that", 787], ["are", 792], ["expressed", 796], ["during", 806], ["parasite", 813], ["reproduction", 822], ["in", 835], ["the", 838], ["mosquito", 842], [".", 850], ["When", 852], ["the", 857], ["mosquito", 861], ["ingests", 870], ["blood", 878], ["from", 884], ["a", 889], ["vaccinated", 891], ["individual", 902], ["harboring", 913], ["the", 923], ["Plasmodium", 927], ["parasite", 938], [",", 946], ["the", 948], ["antibodies", 952], ["generated", 963], ["by", 973], ["vaccination", 976], ["prevent", 988], ["completion", 996], ["of", 1007], ["the", 1010], ["parasites", 1014], ["life", 1024], ["-", 1028], ["cycle", 1029], [".", 1034], ["Animal", 1036], ["studies", 1043], ["have", 1051], ["shown", 1056], ["that", 1062], ["immunization", 1067], ["with", 1080], ["Pfs48/45", 1085], ["results", 1094], ["in", 1102], ["the", 1105], ["production", 1109], ["of", 1120], ["malaria", 1123], ["transmission", 1131], ["blocking", 1144], ["antibodies", 1153], [";", 1163], ["however", 1165], [",", 1172], ["the", 1174], ["development", 1178], ["of", 1190], ["this", 1193], ["vaccine", 1198], ["candidate", 1206], ["has", 1216], ["been", 1220], ["hindered", 1225], ["by", 1234], ["poor", 1237], ["expression", 1242], ["in", 1253], ["both", 1256], ["prokaryotic", 1261], ["and", 1273], ["eukaryotic", 1277], ["hosts", 1288], [".", 1293], ["Recently", 1295], [",", 1303], ["the", 1305], ["chloroplast", 1309], ["of", 1321], ["Chlamydomonas", 1324], ["reinhardtii", 1338], ["has", 1350], ["been", 1354], ["used", 1359], ["to", 1364], ["express", 1367], ["complex", 1375], ["recombinant", 1383], ["proteins", 1395], [".", 1403], ["In", 1405], ["this", 1408], ["study", 1413], [",", 1418], ["we", 1420], ["show", 1423], ["that", 1428], ["the", 1433], ["C", 1437], ["-", 1438], ["terminal", 1439], ["antigenic", 1448], ["region", 1458], ["of", 1465], ["the", 1468], ["Pfs48/45", 1472], ["antigen", 1481], ["can", 1489], ["be", 1493], ["expressed", 1496], ["in", 1506], ["the", 1509], ["chloroplast", 1513], ["of", 1525], ["the", 1528], ["green", 1532], ["algae", 1538], ["C.", 1544], ["reinhardtii", 1547], ["and", 1559], ["that", 1563], ["this", 1568], ["recombinant", 1573], ["protein", 1585], ["has", 1593], ["a", 1597], ["conformation", 1599], ["recognized", 1612], ["by", 1623], ["known", 1626], ["transmission", 1632], ["blocking", 1645], ["antibodies", 1654], [".", 1664], ["Production", 1666], ["of", 1677], ["this", 1680], ["protein", 1685], ["in", 1693], ["algae", 1696], ["has", 1702], ["the", 1706], ["potential", 1710], ["to", 1720], ["scale", 1723], ["to", 1729], ["the", 1732], ["very", 1736], ["large", 1741], ["volumes", 1747], ["required", 1755], ["to", 1764], ["meet", 1767], ["the", 1772], ["needs", 1776], ["of", 1782], ["millions", 1785], ["at", 1794], ["risk", 1797], ["for", 1802], ["contracting", 1806], ["malaria", 1818], [".", 1825]]}
{"context": "CADASIL is the most prominent inherited form of vascular dementia. The main clinical features include migraine with aura, stroke, mood disturbances, and cognitive decline, with a mid-life (30s-60s) adult onset. Genetic testing is the gold standard for the diagnosis. CADASIL is caused mostly by missense mutations in the NOTCH3 gene, invariably involving a cysteine residue. Only a couple of splice site mutations have been reported. In a few pathologically defined patients, genetic mutations remain unidentified. We report a family with late-onset CADASIL phenotype carrying a novel intronic deletion in the NOTCH3 gene (c.341-26_24delAAC). Transcript analysis revealed a splicing alteration, with the complete intron 3 retention. The insertion was in-frame and encoded an extra 25 amino acids, including 1 cysteine. This is the first report of an aberrant splicing event of the NOTCH3 gene associated with a mutation far away from the canonical splice site. Our finding suggests that the assays used to evaluate splicing should be mandatory in the diagnostic setting of genetically undefined CADASIL cases.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "dabfffc898254535a9a607a6650d2562", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[65, 65], [146, 146]], "char_spans": [[357, 364], [809, 816]]}]}], "context_tokens": [["CADASIL", 0], ["is", 8], ["the", 11], ["most", 15], ["prominent", 20], ["inherited", 30], ["form", 40], ["of", 45], ["vascular", 48], ["dementia", 57], [".", 65], ["The", 67], ["main", 71], ["clinical", 76], ["features", 85], ["include", 94], ["migraine", 102], ["with", 111], ["aura", 116], [",", 120], ["stroke", 122], [",", 128], ["mood", 130], ["disturbances", 135], [",", 147], ["and", 149], ["cognitive", 153], ["decline", 163], [",", 170], ["with", 172], ["a", 177], ["mid", 179], ["-", 182], ["life", 183], ["(", 188], ["30s-60s", 189], [")", 196], ["adult", 198], ["onset", 204], [".", 209], ["Genetic", 211], ["testing", 219], ["is", 227], ["the", 230], ["gold", 234], ["standard", 239], ["for", 248], ["the", 252], ["diagnosis", 256], [".", 265], ["CADASIL", 267], ["is", 275], ["caused", 278], ["mostly", 285], ["by", 292], ["missense", 295], ["mutations", 304], ["in", 314], ["the", 317], ["NOTCH3", 321], ["gene", 328], [",", 332], ["invariably", 334], ["involving", 345], ["a", 355], ["cysteine", 357], ["residue", 366], [".", 373], ["Only", 375], ["a", 380], ["couple", 382], ["of", 389], ["splice", 392], ["site", 399], ["mutations", 404], ["have", 414], ["been", 419], ["reported", 424], [".", 432], ["In", 434], ["a", 437], ["few", 439], ["pathologically", 443], ["defined", 458], ["patients", 466], [",", 474], ["genetic", 476], ["mutations", 484], ["remain", 494], ["unidentified", 501], [".", 513], ["We", 515], ["report", 518], ["a", 525], ["family", 527], ["with", 534], ["late", 539], ["-", 543], ["onset", 544], ["CADASIL", 550], ["phenotype", 558], ["carrying", 568], ["a", 577], ["novel", 579], ["intronic", 585], ["deletion", 594], ["in", 603], ["the", 606], ["NOTCH3", 610], ["gene", 617], ["(", 622], ["c.341", 623], ["-", 628], ["26_24delAAC", 629], [")", 640], [".", 641], ["Transcript", 643], ["analysis", 654], ["revealed", 663], ["a", 672], ["splicing", 674], ["alteration", 683], [",", 693], ["with", 695], ["the", 700], ["complete", 704], ["intron", 713], ["3", 720], ["retention", 722], [".", 731], ["The", 733], ["insertion", 737], ["was", 747], ["in", 751], ["-", 753], ["frame", 754], ["and", 760], ["encoded", 764], ["an", 772], ["extra", 775], ["25", 781], ["amino", 784], ["acids", 790], [",", 795], ["including", 797], ["1", 807], ["cysteine", 809], [".", 817], ["This", 819], ["is", 824], ["the", 827], ["first", 831], ["report", 837], ["of", 844], ["an", 847], ["aberrant", 850], ["splicing", 859], ["event", 868], ["of", 874], ["the", 877], ["NOTCH3", 881], ["gene", 888], ["associated", 893], ["with", 904], ["a", 909], ["mutation", 911], ["far", 920], ["away", 924], ["from", 929], ["the", 934], ["canonical", 938], ["splice", 948], ["site", 955], [".", 959], ["Our", 961], ["finding", 965], ["suggests", 973], ["that", 982], ["the", 987], ["assays", 991], ["used", 998], ["to", 1003], ["evaluate", 1006], ["splicing", 1015], ["should", 1024], ["be", 1031], ["mandatory", 1034], ["in", 1044], ["the", 1047], ["diagnostic", 1051], ["setting", 1062], ["of", 1070], ["genetically", 1073], ["undefined", 1085], ["CADASIL", 1095], ["cases", 1103], [".", 1108]]}
{"context": "To assess the pharmacokinetics of dapivirine in plasma and dapivirine concentrations in cervicovaginal fluids (CVF) and cervicovaginal tissues following vaginal administration of dapivirine microbicide gel in healthy, HIV-negative women for 10 days. A randomized, double-blind, phase I study was conducted at a single research center in South Africa. A total of 18 women used dapivirine gel (0.001%, 0.005%, or 0.02%) once daily on Days 1 and 10 and twice daily on Days 2-9. Pharmacokinetics of dapivirine were assessed in plasma on Days 1 and 10. Dapivirine concentrations were measured in CVF on Days 1 and 10 and in cervicovaginal tissues on Day 10. Safety was evaluated through laboratory tests (hematology, clinical chemistry, and urinalysis), physical examinations, and assessment of adverse events. Plasma concentrations of dapivirine increased over time with gel dose and were greater on Day 10 (C(max) 31 to 471\u2009pg/ml) than Day 1 (C(max) 23 to 80\u2009pg/ml). T(max) was 10-12\u2009h on Day 1, and 9\u2009h on Day 10. Concentrations in CVF generally increased with dose but were highly variable among participants. Mean peak values ranged from 4.6-8.3\u2009\u00d7\u200910(6) pg/ml on Day 1 and from 2.3-20.7\u2009\u00d7\u200910(6) pg/ml on Day 10 across dose groups. Dapivirine was detectable in all tissue biopsies on Day 10 at concentrations of 1.0-356\u2009\u00d7\u200910(3) pg/mg. Dapivirine was widely distributed throughout the lower genital tract with low systemic absorption when administered in a vaginal gel formulation for 10 consecutive days. The gel was safe and well tolerated.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "8e635a9039f64438813f3959150c7590", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[30, 30]], "char_spans": [[218, 220]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["pharmacokinetics", 14], ["of", 31], ["dapivirine", 34], ["in", 45], ["plasma", 48], ["and", 55], ["dapivirine", 59], ["concentrations", 70], ["in", 85], ["cervicovaginal", 88], ["fluids", 103], ["(", 110], ["CVF", 111], [")", 114], ["and", 116], ["cervicovaginal", 120], ["tissues", 135], ["following", 143], ["vaginal", 153], ["administration", 161], ["of", 176], ["dapivirine", 179], ["microbicide", 190], ["gel", 202], ["in", 206], ["healthy", 209], [",", 216], ["HIV", 218], ["-", 221], ["negative", 222], ["women", 231], ["for", 237], ["10", 241], ["days", 244], [".", 248], ["A", 250], ["randomized", 252], [",", 262], ["double", 264], ["-", 270], ["blind", 271], [",", 276], ["phase", 278], ["I", 284], ["study", 286], ["was", 292], ["conducted", 296], ["at", 306], ["a", 309], ["single", 311], ["research", 318], ["center", 327], ["in", 334], ["South", 337], ["Africa", 343], [".", 349], ["A", 351], ["total", 353], ["of", 359], ["18", 362], ["women", 365], ["used", 371], ["dapivirine", 376], ["gel", 387], ["(", 391], ["0.001", 392], ["%", 397], [",", 398], ["0.005", 400], ["%", 405], [",", 406], ["or", 408], ["0.02", 411], ["%", 415], [")", 416], ["once", 418], ["daily", 423], ["on", 429], ["Days", 432], ["1", 437], ["and", 439], ["10", 443], ["and", 446], ["twice", 450], ["daily", 456], ["on", 462], ["Days", 465], ["2", 470], ["-", 471], ["9", 472], [".", 473], ["Pharmacokinetics", 475], ["of", 492], ["dapivirine", 495], ["were", 506], ["assessed", 511], ["in", 520], ["plasma", 523], ["on", 530], ["Days", 533], ["1", 538], ["and", 540], ["10", 544], [".", 546], ["Dapivirine", 548], ["concentrations", 559], ["were", 574], ["measured", 579], ["in", 588], ["CVF", 591], ["on", 595], ["Days", 598], ["1", 603], ["and", 605], ["10", 609], ["and", 612], ["in", 616], ["cervicovaginal", 619], ["tissues", 634], ["on", 642], ["Day", 645], ["10", 649], [".", 651], ["Safety", 653], ["was", 660], ["evaluated", 664], ["through", 674], ["laboratory", 682], ["tests", 693], ["(", 699], ["hematology", 700], [",", 710], ["clinical", 712], ["chemistry", 721], [",", 730], ["and", 732], ["urinalysis", 736], [")", 746], [",", 747], ["physical", 749], ["examinations", 758], [",", 770], ["and", 772], ["assessment", 776], ["of", 787], ["adverse", 790], ["events", 798], [".", 804], ["Plasma", 806], ["concentrations", 813], ["of", 828], ["dapivirine", 831], ["increased", 842], ["over", 852], ["time", 857], ["with", 862], ["gel", 867], ["dose", 871], ["and", 876], ["were", 880], ["greater", 885], ["on", 893], ["Day", 896], ["10", 900], ["(", 903], ["C(max", 904], [")", 909], ["31", 911], ["to", 914], ["471", 917], ["pg", 921], ["/", 923], ["ml", 924], [")", 926], ["than", 928], ["Day", 933], ["1", 937], ["(", 939], ["C(max", 940], [")", 945], ["23", 947], ["to", 950], ["80", 953], ["pg", 956], ["/", 958], ["ml", 959], [")", 961], [".", 962], ["T(max", 964], [")", 969], ["was", 971], ["10", 975], ["-", 977], ["12", 978], ["h", 981], ["on", 983], ["Day", 986], ["1", 990], [",", 991], ["and", 993], ["9", 997], ["h", 999], ["on", 1001], ["Day", 1004], ["10", 1008], [".", 1010], ["Concentrations", 1012], ["in", 1027], ["CVF", 1030], ["generally", 1034], ["increased", 1044], ["with", 1054], ["dose", 1059], ["but", 1064], ["were", 1068], ["highly", 1073], ["variable", 1080], ["among", 1089], ["participants", 1095], [".", 1107], ["Mean", 1109], ["peak", 1114], ["values", 1119], ["ranged", 1126], ["from", 1133], ["4.6", 1138], ["-", 1141], ["8.3", 1142], ["\u00d7", 1146], ["10(6", 1148], [")", 1152], ["pg", 1154], ["/", 1156], ["ml", 1157], ["on", 1160], ["Day", 1163], ["1", 1167], ["and", 1169], ["from", 1173], ["2.3", 1178], ["-", 1181], ["20.7", 1182], ["\u00d7", 1187], ["10(6", 1189], [")", 1193], ["pg", 1195], ["/", 1197], ["ml", 1198], ["on", 1201], ["Day", 1204], ["10", 1208], ["across", 1211], ["dose", 1218], ["groups", 1223], [".", 1229], ["Dapivirine", 1231], ["was", 1242], ["detectable", 1246], ["in", 1257], ["all", 1260], ["tissue", 1264], ["biopsies", 1271], ["on", 1280], ["Day", 1283], ["10", 1287], ["at", 1290], ["concentrations", 1293], ["of", 1308], ["1.0", 1311], ["-", 1314], ["356", 1315], ["\u00d7", 1319], ["10(3", 1321], [")", 1325], ["pg", 1327], ["/", 1329], ["mg", 1330], [".", 1332], ["Dapivirine", 1334], ["was", 1345], ["widely", 1349], ["distributed", 1356], ["throughout", 1368], ["the", 1379], ["lower", 1383], ["genital", 1389], ["tract", 1397], ["with", 1403], ["low", 1408], ["systemic", 1412], ["absorption", 1421], ["when", 1432], ["administered", 1437], ["in", 1450], ["a", 1453], ["vaginal", 1455], ["gel", 1463], ["formulation", 1467], ["for", 1479], ["10", 1483], ["consecutive", 1486], ["days", 1498], [".", 1502], ["The", 1504], ["gel", 1508], ["was", 1512], ["safe", 1516], ["and", 1521], ["well", 1525], ["tolerated", 1530], [".", 1539]]}
{"context": "X-monosomy is a form of Turner syndrome (TS) in which an entire X chromosome is missing. It is usually assumed that neuropsychological deficits in females with TS result from insufficient dosage of gene products from alleles on the sex chromosomes. If so, then parental origin of the single X chromosome should be immaterial. However, if there are imprinted genes on the X chromosome affecting brain development, neuropsychological development will depend on the parental origin of the single X chromosome. We contrasted verbal and visuospatial memory in females with a single paternal X chromosome (45,X(p)) and those with a single maternal X (45,X(m)). Neither group showed any impairment on immediate story recall; if anything, performance was above control levels. Groups did not differ on a measure of delayed recall. However, when delayed recall was considered after adjusting for level of immediate recall, 45,X(m) females showed enhanced verbal forgetting relative to controls over a delay. On the Rey figure, both groups were poor at copying the figure, but, after adjusting scores for initial copy score and strategy, only the 45,X(p) females showed disproportionate forgetting relative to controls. We propose there may be one or more imprinted genes on the X chromosome that affect the development of lateralised brain regions important for memory function.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "0c3d11aaf8cc41e7937743b05820136c", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[0, 0], [16, 16], [229, 229], [70, 70], [102, 102], [87, 87], [55, 55], [114, 114]], "char_spans": [[0, 0], [64, 64], [1269, 1269], [371, 371], [586, 586], [493, 493], [291, 291], [642, 642]]}]}], "context_tokens": [["X", 0], ["-", 1], ["monosomy", 2], ["is", 11], ["a", 14], ["form", 16], ["of", 21], ["Turner", 24], ["syndrome", 31], ["(", 40], ["TS", 41], [")", 43], ["in", 45], ["which", 48], ["an", 54], ["entire", 57], ["X", 64], ["chromosome", 66], ["is", 77], ["missing", 80], [".", 87], ["It", 89], ["is", 92], ["usually", 95], ["assumed", 103], ["that", 111], ["neuropsychological", 116], ["deficits", 135], ["in", 144], ["females", 147], ["with", 155], ["TS", 160], ["result", 163], ["from", 170], ["insufficient", 175], ["dosage", 188], ["of", 195], ["gene", 198], ["products", 203], ["from", 212], ["alleles", 217], ["on", 225], ["the", 228], ["sex", 232], ["chromosomes", 236], [".", 247], ["If", 249], ["so", 252], [",", 254], ["then", 256], ["parental", 261], ["origin", 270], ["of", 277], ["the", 280], ["single", 284], ["X", 291], ["chromosome", 293], ["should", 304], ["be", 311], ["immaterial", 314], [".", 324], ["However", 326], [",", 333], ["if", 335], ["there", 338], ["are", 344], ["imprinted", 348], ["genes", 358], ["on", 364], ["the", 367], ["X", 371], ["chromosome", 373], ["affecting", 384], ["brain", 394], ["development", 400], [",", 411], ["neuropsychological", 413], ["development", 432], ["will", 444], ["depend", 449], ["on", 456], ["the", 459], ["parental", 463], ["origin", 472], ["of", 479], ["the", 482], ["single", 486], ["X", 493], ["chromosome", 495], [".", 505], ["We", 507], ["contrasted", 510], ["verbal", 521], ["and", 528], ["visuospatial", 532], ["memory", 545], ["in", 552], ["females", 555], ["with", 563], ["a", 568], ["single", 570], ["paternal", 577], ["X", 586], ["chromosome", 588], ["(", 599], ["45,X(p", 600], [")", 606], [")", 607], ["and", 609], ["those", 613], ["with", 619], ["a", 624], ["single", 626], ["maternal", 633], ["X", 642], ["(", 644], ["45,X(m", 645], [")", 651], [")", 652], [".", 653], ["Neither", 655], ["group", 663], ["showed", 669], ["any", 676], ["impairment", 680], ["on", 691], ["immediate", 694], ["story", 704], ["recall", 710], [";", 716], ["if", 718], ["anything", 721], [",", 729], ["performance", 731], ["was", 743], ["above", 747], ["control", 753], ["levels", 761], [".", 767], ["Groups", 769], ["did", 776], ["not", 780], ["differ", 784], ["on", 791], ["a", 794], ["measure", 796], ["of", 804], ["delayed", 807], ["recall", 815], [".", 821], ["However", 823], [",", 830], ["when", 832], ["delayed", 837], ["recall", 845], ["was", 852], ["considered", 856], ["after", 867], ["adjusting", 873], ["for", 883], ["level", 887], ["of", 893], ["immediate", 896], ["recall", 906], [",", 912], ["45,X(m", 914], [")", 920], ["females", 922], ["showed", 930], ["enhanced", 937], ["verbal", 946], ["forgetting", 953], ["relative", 964], ["to", 973], ["controls", 976], ["over", 985], ["a", 990], ["delay", 992], [".", 997], ["On", 999], ["the", 1002], ["Rey", 1006], ["figure", 1010], [",", 1016], ["both", 1018], ["groups", 1023], ["were", 1030], ["poor", 1035], ["at", 1040], ["copying", 1043], ["the", 1051], ["figure", 1055], [",", 1061], ["but", 1063], [",", 1066], ["after", 1068], ["adjusting", 1074], ["scores", 1084], ["for", 1091], ["initial", 1095], ["copy", 1103], ["score", 1108], ["and", 1114], ["strategy", 1118], [",", 1126], ["only", 1128], ["the", 1133], ["45,X(p", 1137], [")", 1143], ["females", 1145], ["showed", 1153], ["disproportionate", 1160], ["forgetting", 1177], ["relative", 1188], ["to", 1197], ["controls", 1200], [".", 1208], ["We", 1210], ["propose", 1213], ["there", 1221], ["may", 1227], ["be", 1231], ["one", 1234], ["or", 1238], ["more", 1241], ["imprinted", 1246], ["genes", 1256], ["on", 1262], ["the", 1265], ["X", 1269], ["chromosome", 1271], ["that", 1282], ["affect", 1287], ["the", 1294], ["development", 1298], ["of", 1310], ["lateralised", 1313], ["brain", 1325], ["regions", 1331], ["important", 1339], ["for", 1349], ["memory", 1353], ["function", 1360], [".", 1368]]}
{"context": "The natural phytoalexin resveratrol, found in grapes and red wine, recently rose to public fame for its positive effects on longevity in yeasts, worms and flies. Resveratrol anti-cancer and anti-inflammatory in vitro action on mammalian cell cultures also suggest a possible positive effect on human health and life-expectancy. To study the effects of resveratrol on vertebrate aging is obviously a particularly relevant question. We have studied resveratrol effects in a very short-lived vertebrate: the annual fish Nothobranchius furzeri. Resveratrol treatment prolonged lifespan and delayed the onset of age-related dysfunctions in this fish. This result identifies resveratrol as the first molecule which consistently retards aging in organisms as diverse as yeast, worm, fly and fish, but it also reveals the potential of this short-lived fish as an animal model for pharmacological research. Moreover, being related to stickleback (Gasterosteus aculeatus) the \"pufferfishes\" Takifugu and Tetraodon, and even more closely related to medaka (Oryzias latipes), it can greatly beneficiate from the recent development of genomic resources for these fish models and in the future become a complete model system for the aging research community.", "qas": [{"question": "What can Nothobranchius furzeri be used as a model system for?", "answers": ["aging research"], "qid": "28273676388a4bd8b10c28cc78703649", "question_tokens": [["What", 0], ["can", 5], ["Nothobranchius", 9], ["furzeri", 24], ["be", 32], ["used", 35], ["as", 40], ["a", 43], ["model", 45], ["system", 51], ["for", 58], ["?", 61]], "detected_answers": [{"text": "aging research", "token_spans": [[212, 213]], "char_spans": [[1219, 1232]]}]}], "context_tokens": [["The", 0], ["natural", 4], ["phytoalexin", 12], ["resveratrol", 24], [",", 35], ["found", 37], ["in", 43], ["grapes", 46], ["and", 53], ["red", 57], ["wine", 61], [",", 65], ["recently", 67], ["rose", 76], ["to", 81], ["public", 84], ["fame", 91], ["for", 96], ["its", 100], ["positive", 104], ["effects", 113], ["on", 121], ["longevity", 124], ["in", 134], ["yeasts", 137], [",", 143], ["worms", 145], ["and", 151], ["flies", 155], [".", 160], ["Resveratrol", 162], ["anti", 174], ["-", 178], ["cancer", 179], ["and", 186], ["anti", 190], ["-", 194], ["inflammatory", 195], ["in", 208], ["vitro", 211], ["action", 217], ["on", 224], ["mammalian", 227], ["cell", 237], ["cultures", 242], ["also", 251], ["suggest", 256], ["a", 264], ["possible", 266], ["positive", 275], ["effect", 284], ["on", 291], ["human", 294], ["health", 300], ["and", 307], ["life", 311], ["-", 315], ["expectancy", 316], [".", 326], ["To", 328], ["study", 331], ["the", 337], ["effects", 341], ["of", 349], ["resveratrol", 352], ["on", 364], ["vertebrate", 367], ["aging", 378], ["is", 384], ["obviously", 387], ["a", 397], ["particularly", 399], ["relevant", 412], ["question", 421], [".", 429], ["We", 431], ["have", 434], ["studied", 439], ["resveratrol", 447], ["effects", 459], ["in", 467], ["a", 470], ["very", 472], ["short", 477], ["-", 482], ["lived", 483], ["vertebrate", 489], [":", 499], ["the", 501], ["annual", 505], ["fish", 512], ["Nothobranchius", 517], ["furzeri", 532], [".", 539], ["Resveratrol", 541], ["treatment", 553], ["prolonged", 563], ["lifespan", 573], ["and", 582], ["delayed", 586], ["the", 594], ["onset", 598], ["of", 604], ["age", 607], ["-", 610], ["related", 611], ["dysfunctions", 619], ["in", 632], ["this", 635], ["fish", 640], [".", 644], ["This", 646], ["result", 651], ["identifies", 658], ["resveratrol", 669], ["as", 681], ["the", 684], ["first", 688], ["molecule", 694], ["which", 703], ["consistently", 709], ["retards", 722], ["aging", 730], ["in", 736], ["organisms", 739], ["as", 749], ["diverse", 752], ["as", 760], ["yeast", 763], [",", 768], ["worm", 770], [",", 774], ["fly", 776], ["and", 780], ["fish", 784], [",", 788], ["but", 790], ["it", 794], ["also", 797], ["reveals", 802], ["the", 810], ["potential", 814], ["of", 824], ["this", 827], ["short", 832], ["-", 837], ["lived", 838], ["fish", 844], ["as", 849], ["an", 852], ["animal", 855], ["model", 862], ["for", 868], ["pharmacological", 872], ["research", 888], [".", 896], ["Moreover", 898], [",", 906], ["being", 908], ["related", 914], ["to", 922], ["stickleback", 925], ["(", 937], ["Gasterosteus", 938], ["aculeatus", 951], [")", 960], ["the", 962], ["\"", 966], ["pufferfishes", 967], ["\"", 979], ["Takifugu", 981], ["and", 990], ["Tetraodon", 994], [",", 1003], ["and", 1005], ["even", 1009], ["more", 1014], ["closely", 1019], ["related", 1027], ["to", 1035], ["medaka", 1038], ["(", 1045], ["Oryzias", 1046], ["latipes", 1054], [")", 1061], [",", 1062], ["it", 1064], ["can", 1067], ["greatly", 1071], ["beneficiate", 1079], ["from", 1091], ["the", 1096], ["recent", 1100], ["development", 1107], ["of", 1119], ["genomic", 1122], ["resources", 1130], ["for", 1140], ["these", 1144], ["fish", 1150], ["models", 1155], ["and", 1162], ["in", 1166], ["the", 1169], ["future", 1173], ["become", 1180], ["a", 1187], ["complete", 1189], ["model", 1198], ["system", 1204], ["for", 1211], ["the", 1215], ["aging", 1219], ["research", 1225], ["community", 1234], [".", 1243]]}
{"context": "Selenoproteins are an elite group of proteins containing a rare amino acid, selenocysteine (Sec), encoded by the codon, UGA. In eukaryotes, incorporation of Sec requires a Sec insertion sequence (SECIS) element, a stem-loop structure located in the 3'-untranslated regions of selenoprotein mRNAs. Here we report identification of a noncanonical form of SECIS element in Toxoplasma gondii and Neospora canine, single-celled apicomplexan parasites of humans and domestic animals. This SECIS has a GGGA sequence in the SBP2-binding site in place of AUGA previously considered invariant. Using a combination of computational and molecular techniques, we show that Toxoplasma and Neospora possess both canonical and noncanonical SECIS elements. The GGGA-type SECIS element supported Sec insertion in mammalian HEK 293 and NIH 3T3 cells and did so more efficiently than the natural mammalian SECIS elements tested. In addition, mammalian type I and type II SECIS elements mutated into the GGGA forms were functional but manifested decreased Sec insertion efficiency. We carried out computational searches for both AUGA and GGGA forms of SECIS elements in Toxoplasma and detected five selenoprotein genes, including one coding for a previously undescribed selenoprotein, designated SelQ, and two containing the GGGA form of the SECIS element. In contrast, the GGGA-type SECIS elements were not detected in mammals and nematodes. As a practical outcome of the study, we developed pSelExpress1, a vector for convenient expression of selenoproteins in mammalian cells. It contains an SBP2 gene and the most efficient tested SECIS element: an AUGA mutant of the GGGA-type Toxoplasma SelT structure.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "60845a786b424b11bfedd9ec58170947", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[64, 64], [192, 192], [37, 37], [85, 85], [122, 122], [275, 275], [164, 164], [151, 151], [232, 232], [222, 222], [129, 129]], "char_spans": [[353, 357], [1131, 1135], [196, 200], [483, 487], [724, 728], [1614, 1618], [951, 955], [886, 890], [1363, 1367], [1321, 1325], [754, 758]]}]}], "context_tokens": [["Selenoproteins", 0], ["are", 15], ["an", 19], ["elite", 22], ["group", 28], ["of", 34], ["proteins", 37], ["containing", 46], ["a", 57], ["rare", 59], ["amino", 64], ["acid", 70], [",", 74], ["selenocysteine", 76], ["(", 91], ["Sec", 92], [")", 95], [",", 96], ["encoded", 98], ["by", 106], ["the", 109], ["codon", 113], [",", 118], ["UGA", 120], [".", 123], ["In", 125], ["eukaryotes", 128], [",", 138], ["incorporation", 140], ["of", 154], ["Sec", 157], ["requires", 161], ["a", 170], ["Sec", 172], ["insertion", 176], ["sequence", 186], ["(", 195], ["SECIS", 196], [")", 201], ["element", 203], [",", 210], ["a", 212], ["stem", 214], ["-", 218], ["loop", 219], ["structure", 224], ["located", 234], ["in", 242], ["the", 245], ["3'-untranslated", 249], ["regions", 265], ["of", 273], ["selenoprotein", 276], ["mRNAs", 290], [".", 295], ["Here", 297], ["we", 302], ["report", 305], ["identification", 312], ["of", 327], ["a", 330], ["noncanonical", 332], ["form", 345], ["of", 350], ["SECIS", 353], ["element", 359], ["in", 367], ["Toxoplasma", 370], ["gondii", 381], ["and", 388], ["Neospora", 392], ["canine", 401], [",", 407], ["single", 409], ["-", 415], ["celled", 416], ["apicomplexan", 423], ["parasites", 436], ["of", 446], ["humans", 449], ["and", 456], ["domestic", 460], ["animals", 469], [".", 476], ["This", 478], ["SECIS", 483], ["has", 489], ["a", 493], ["GGGA", 495], ["sequence", 500], ["in", 509], ["the", 512], ["SBP2-binding", 516], ["site", 529], ["in", 534], ["place", 537], ["of", 543], ["AUGA", 546], ["previously", 551], ["considered", 562], ["invariant", 573], [".", 582], ["Using", 584], ["a", 590], ["combination", 592], ["of", 604], ["computational", 607], ["and", 621], ["molecular", 625], ["techniques", 635], [",", 645], ["we", 647], ["show", 650], ["that", 655], ["Toxoplasma", 660], ["and", 671], ["Neospora", 675], ["possess", 684], ["both", 692], ["canonical", 697], ["and", 707], ["noncanonical", 711], ["SECIS", 724], ["elements", 730], [".", 738], ["The", 740], ["GGGA", 744], ["-", 748], ["type", 749], ["SECIS", 754], ["element", 760], ["supported", 768], ["Sec", 778], ["insertion", 782], ["in", 792], ["mammalian", 795], ["HEK", 805], ["293", 809], ["and", 813], ["NIH", 817], ["3T3", 821], ["cells", 825], ["and", 831], ["did", 835], ["so", 839], ["more", 842], ["efficiently", 847], ["than", 859], ["the", 864], ["natural", 868], ["mammalian", 876], ["SECIS", 886], ["elements", 892], ["tested", 901], [".", 907], ["In", 909], ["addition", 912], [",", 920], ["mammalian", 922], ["type", 932], ["I", 937], ["and", 939], ["type", 943], ["II", 948], ["SECIS", 951], ["elements", 957], ["mutated", 966], ["into", 974], ["the", 979], ["GGGA", 983], ["forms", 988], ["were", 994], ["functional", 999], ["but", 1010], ["manifested", 1014], ["decreased", 1025], ["Sec", 1035], ["insertion", 1039], ["efficiency", 1049], [".", 1059], ["We", 1061], ["carried", 1064], ["out", 1072], ["computational", 1076], ["searches", 1090], ["for", 1099], ["both", 1103], ["AUGA", 1108], ["and", 1113], ["GGGA", 1117], ["forms", 1122], ["of", 1128], ["SECIS", 1131], ["elements", 1137], ["in", 1146], ["Toxoplasma", 1149], ["and", 1160], ["detected", 1164], ["five", 1173], ["selenoprotein", 1178], ["genes", 1192], [",", 1197], ["including", 1199], ["one", 1209], ["coding", 1213], ["for", 1220], ["a", 1224], ["previously", 1226], ["undescribed", 1237], ["selenoprotein", 1249], [",", 1262], ["designated", 1264], ["SelQ", 1275], [",", 1279], ["and", 1281], ["two", 1285], ["containing", 1289], ["the", 1300], ["GGGA", 1304], ["form", 1309], ["of", 1314], ["the", 1317], ["SECIS", 1321], ["element", 1327], [".", 1334], ["In", 1336], ["contrast", 1339], [",", 1347], ["the", 1349], ["GGGA", 1353], ["-", 1357], ["type", 1358], ["SECIS", 1363], ["elements", 1369], ["were", 1378], ["not", 1383], ["detected", 1387], ["in", 1396], ["mammals", 1399], ["and", 1407], ["nematodes", 1411], [".", 1420], ["As", 1422], ["a", 1425], ["practical", 1427], ["outcome", 1437], ["of", 1445], ["the", 1448], ["study", 1452], [",", 1457], ["we", 1459], ["developed", 1462], ["pSelExpress1", 1472], [",", 1484], ["a", 1486], ["vector", 1488], ["for", 1495], ["convenient", 1499], ["expression", 1510], ["of", 1521], ["selenoproteins", 1524], ["in", 1539], ["mammalian", 1542], ["cells", 1552], [".", 1557], ["It", 1559], ["contains", 1562], ["an", 1571], ["SBP2", 1574], ["gene", 1579], ["and", 1584], ["the", 1588], ["most", 1592], ["efficient", 1597], ["tested", 1607], ["SECIS", 1614], ["element", 1620], [":", 1627], ["an", 1629], ["AUGA", 1632], ["mutant", 1637], ["of", 1644], ["the", 1647], ["GGGA", 1651], ["-", 1655], ["type", 1656], ["Toxoplasma", 1661], ["SelT", 1672], ["structure", 1677], [".", 1686]]}
{"context": "Mutations in the SLC9A6 gene cause Christianson syndrome in boys. This X-linked syndrome is characterized by profound mental retardation with autistic behavior, microcephaly, epilepsy, ophthalmoplegia, and ataxia. Progressive cerebellar atrophy with motor regression is a remarkable feature in some patients. We report on a 22year-old male patient with Christianson syndrome carrying the novel p.Gln306X mutation. The infantile phenotype suggested pervasive developmental disorder, then profound mental retardation ensued. In later childhood, progressive cerebellar atrophy was diagnosed on serial brain MRIs and motor regression occurred. Furthermore, ophthalmological evaluations showed a retinitis pigmentosum previously unreported in this condition. We conclude that the natural history of the disease in this patient tends to confirm the degenerative nature of Christianson syndrome, and that retinal degeneration may be part of the condition. Before the onset of degeneration, the syndromic association of severe mental retardation, autistic behavior, external ophthalmoplegia, and facial dysmorphism in male patients is a clue to the diagnosis.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "1c8d376fd6a5424aa7f69d6d2222e256", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[3, 3]], "char_spans": [[17, 22]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["SLC9A6", 17], ["gene", 24], ["cause", 29], ["Christianson", 35], ["syndrome", 48], ["in", 57], ["boys", 60], [".", 64], ["This", 66], ["X", 71], ["-", 72], ["linked", 73], ["syndrome", 80], ["is", 89], ["characterized", 92], ["by", 106], ["profound", 109], ["mental", 118], ["retardation", 125], ["with", 137], ["autistic", 142], ["behavior", 151], [",", 159], ["microcephaly", 161], [",", 173], ["epilepsy", 175], [",", 183], ["ophthalmoplegia", 185], [",", 200], ["and", 202], ["ataxia", 206], [".", 212], ["Progressive", 214], ["cerebellar", 226], ["atrophy", 237], ["with", 245], ["motor", 250], ["regression", 256], ["is", 267], ["a", 270], ["remarkable", 272], ["feature", 283], ["in", 291], ["some", 294], ["patients", 299], [".", 307], ["We", 309], ["report", 312], ["on", 319], ["a", 322], ["22year", 324], ["-", 330], ["old", 331], ["male", 335], ["patient", 340], ["with", 348], ["Christianson", 353], ["syndrome", 366], ["carrying", 375], ["the", 384], ["novel", 388], ["p", 394], [".", 395], ["Gln306X", 396], ["mutation", 404], [".", 412], ["The", 414], ["infantile", 418], ["phenotype", 428], ["suggested", 438], ["pervasive", 448], ["developmental", 458], ["disorder", 472], [",", 480], ["then", 482], ["profound", 487], ["mental", 496], ["retardation", 503], ["ensued", 515], [".", 521], ["In", 523], ["later", 526], ["childhood", 532], [",", 541], ["progressive", 543], ["cerebellar", 555], ["atrophy", 566], ["was", 574], ["diagnosed", 578], ["on", 588], ["serial", 591], ["brain", 598], ["MRIs", 604], ["and", 609], ["motor", 613], ["regression", 619], ["occurred", 630], [".", 638], ["Furthermore", 640], [",", 651], ["ophthalmological", 653], ["evaluations", 670], ["showed", 682], ["a", 689], ["retinitis", 691], ["pigmentosum", 701], ["previously", 713], ["unreported", 724], ["in", 735], ["this", 738], ["condition", 743], [".", 752], ["We", 754], ["conclude", 757], ["that", 766], ["the", 771], ["natural", 775], ["history", 783], ["of", 791], ["the", 794], ["disease", 798], ["in", 806], ["this", 809], ["patient", 814], ["tends", 822], ["to", 828], ["confirm", 831], ["the", 839], ["degenerative", 843], ["nature", 856], ["of", 863], ["Christianson", 866], ["syndrome", 879], [",", 887], ["and", 889], ["that", 893], ["retinal", 898], ["degeneration", 906], ["may", 919], ["be", 923], ["part", 926], ["of", 931], ["the", 934], ["condition", 938], [".", 947], ["Before", 949], ["the", 956], ["onset", 960], ["of", 966], ["degeneration", 969], [",", 981], ["the", 983], ["syndromic", 987], ["association", 997], ["of", 1009], ["severe", 1012], ["mental", 1019], ["retardation", 1026], [",", 1037], ["autistic", 1039], ["behavior", 1048], [",", 1056], ["external", 1058], ["ophthalmoplegia", 1067], [",", 1082], ["and", 1084], ["facial", 1088], ["dysmorphism", 1095], ["in", 1107], ["male", 1110], ["patients", 1115], ["is", 1124], ["a", 1127], ["clue", 1129], ["to", 1134], ["the", 1137], ["diagnosis", 1141], [".", 1150]]}
{"context": "Nucleotide excision repair (NER) is a remarkably versatile DNA repair system, essential for maintenance of genomic stability. Hereditary alterations in NER enzymes can result in increased cancer propensity, but also in developmental, neurodegenerative, and progeroid syndromes. NER can be operationally divided in three subtypes, which share many common steps: global genomic repair (GGR) operates on the whole genome level, transcription domain-associated repair (DAR) is a concentration of NER activity within transcription factories, and transcription-coupled repair (TCR) provides faster repair of the transcribed strand of active genes. Interestingly, ubiquitination plays an important role in all three classes of NER, as well as in associated phenomena, such as damage signalling by histone ubiquitination, and degradation of stalled RNA polymerase II when repair does not occur in a timely manner.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "eac37c9c5ffd4618bcc7270e473097f6", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[103, 104]], "char_spans": [[606, 623]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], ["is", 33], ["a", 36], ["remarkably", 38], ["versatile", 49], ["DNA", 59], ["repair", 63], ["system", 70], [",", 76], ["essential", 78], ["for", 88], ["maintenance", 92], ["of", 104], ["genomic", 107], ["stability", 115], [".", 124], ["Hereditary", 126], ["alterations", 137], ["in", 149], ["NER", 152], ["enzymes", 156], ["can", 164], ["result", 168], ["in", 175], ["increased", 178], ["cancer", 188], ["propensity", 195], [",", 205], ["but", 207], ["also", 211], ["in", 216], ["developmental", 219], [",", 232], ["neurodegenerative", 234], [",", 251], ["and", 253], ["progeroid", 257], ["syndromes", 267], [".", 276], ["NER", 278], ["can", 282], ["be", 286], ["operationally", 289], ["divided", 303], ["in", 311], ["three", 314], ["subtypes", 320], [",", 328], ["which", 330], ["share", 336], ["many", 342], ["common", 347], ["steps", 354], [":", 359], ["global", 361], ["genomic", 368], ["repair", 376], ["(", 383], ["GGR", 384], [")", 387], ["operates", 389], ["on", 398], ["the", 401], ["whole", 405], ["genome", 411], ["level", 418], [",", 423], ["transcription", 425], ["domain", 439], ["-", 445], ["associated", 446], ["repair", 457], ["(", 464], ["DAR", 465], [")", 468], ["is", 470], ["a", 473], ["concentration", 475], ["of", 489], ["NER", 492], ["activity", 496], ["within", 505], ["transcription", 512], ["factories", 526], [",", 535], ["and", 537], ["transcription", 541], ["-", 554], ["coupled", 555], ["repair", 563], ["(", 570], ["TCR", 571], [")", 574], ["provides", 576], ["faster", 585], ["repair", 592], ["of", 599], ["the", 602], ["transcribed", 606], ["strand", 618], ["of", 625], ["active", 628], ["genes", 635], [".", 640], ["Interestingly", 642], [",", 655], ["ubiquitination", 657], ["plays", 672], ["an", 678], ["important", 681], ["role", 691], ["in", 696], ["all", 699], ["three", 703], ["classes", 709], ["of", 717], ["NER", 720], [",", 723], ["as", 725], ["well", 728], ["as", 733], ["in", 736], ["associated", 739], ["phenomena", 750], [",", 759], ["such", 761], ["as", 766], ["damage", 769], ["signalling", 776], ["by", 787], ["histone", 790], ["ubiquitination", 798], [",", 812], ["and", 814], ["degradation", 818], ["of", 830], ["stalled", 833], ["RNA", 841], ["polymerase", 845], ["II", 856], ["when", 859], ["repair", 864], ["does", 871], ["not", 876], ["occur", 880], ["in", 886], ["a", 889], ["timely", 891], ["manner", 898], [".", 904]]}
{"context": "Chronic myeloid leukaemia (CML) is characterized cytogenetically by a t(9;22)(q34;ql1) reciprocal translocation which gives origin to a hybrid BCR-ABL gene, encoding a p2lO(BCR-ABL) fusion protein with elevated tyrosine kinase activity and transforming abilities. The t(9;22) was suggested to be associated with genomic imprinting of centromeric regions of chromosomes 9 and 22, but the genes directly affected by the translocation, ABL and BCR, were shown not to be imprinted. For most diagnostic and research purposes the BCR-ABL gene can be efficiently identified by reverse-transcription and polymerase chain reaction (RT/PCR) amplification of its fusion transcripts, which can be quantified by competitive PCR and similar assays for assessment of residual disease in the follow-up of therapy. In the great majority of CML patients the BCR-ABL transcripts exhibit a b2a2 and/or a b3a2 junction; in rare cases, the only detectable BCR-ABL transcripts have unusual junctions, such as b2a3, b3a3, e1a2 or e6a2. There is a recent suggestion that the BCR-ABL gene may not be always 'functional', since extremely low levels of BCR-ABL transcripts can be found in leucocytes from normal individuals and, conversely, it appears that no BCR-ABL transcription can be detected in a proportion of Ph-positive haematopoietic progenitors from some CML patients. The role, if any, of the reciprocal ABL-BCR hybrid gene in CML is unknown. Although its mRNA message is in frame, no ABL-BCR fusion protein has yet been identified in CML patients. The blast crisis of CML has been variably associated with abnormalities of proto-oncogenes, such as RAS and MYC, or of tumour suppressor genes, in particular RB, p53 and p16, or with the generation of chimeric transcription factors, as in the AML1-EVI1 gene fusion. It is likely, therefore, that multiple and alternative molecular defects, as opposed to a single universal mechanism, underlie the acute transformation of the disease.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "bab3517808284dd78fb78dee6116e087", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "ABL/BCR fusion", "token_spans": [[278, 281]], "char_spans": [[1469, 1482]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukaemia", 16], ["(", 26], ["CML", 27], [")", 30], ["is", 32], ["characterized", 35], ["cytogenetically", 49], ["by", 65], ["a", 68], ["t(9;22)(q34;ql1", 70], [")", 85], ["reciprocal", 87], ["translocation", 98], ["which", 112], ["gives", 118], ["origin", 124], ["to", 131], ["a", 134], ["hybrid", 136], ["BCR", 143], ["-", 146], ["ABL", 147], ["gene", 151], [",", 155], ["encoding", 157], ["a", 166], ["p2lO(BCR", 168], ["-", 176], ["ABL", 177], [")", 180], ["fusion", 182], ["protein", 189], ["with", 197], ["elevated", 202], ["tyrosine", 211], ["kinase", 220], ["activity", 227], ["and", 236], ["transforming", 240], ["abilities", 253], [".", 262], ["The", 264], ["t(9;22", 268], [")", 274], ["was", 276], ["suggested", 280], ["to", 290], ["be", 293], ["associated", 296], ["with", 307], ["genomic", 312], ["imprinting", 320], ["of", 331], ["centromeric", 334], ["regions", 346], ["of", 354], ["chromosomes", 357], ["9", 369], ["and", 371], ["22", 375], [",", 377], ["but", 379], ["the", 383], ["genes", 387], ["directly", 393], ["affected", 402], ["by", 411], ["the", 414], ["translocation", 418], [",", 431], ["ABL", 433], ["and", 437], ["BCR", 441], [",", 444], ["were", 446], ["shown", 451], ["not", 457], ["to", 461], ["be", 464], ["imprinted", 467], [".", 476], ["For", 478], ["most", 482], ["diagnostic", 487], ["and", 498], ["research", 502], ["purposes", 511], ["the", 520], ["BCR", 524], ["-", 527], ["ABL", 528], ["gene", 532], ["can", 537], ["be", 541], ["efficiently", 544], ["identified", 556], ["by", 567], ["reverse", 570], ["-", 577], ["transcription", 578], ["and", 592], ["polymerase", 596], ["chain", 607], ["reaction", 613], ["(", 622], ["RT", 623], ["/", 625], ["PCR", 626], [")", 629], ["amplification", 631], ["of", 645], ["its", 648], ["fusion", 652], ["transcripts", 659], [",", 670], ["which", 672], ["can", 678], ["be", 682], ["quantified", 685], ["by", 696], ["competitive", 699], ["PCR", 711], ["and", 715], ["similar", 719], ["assays", 727], ["for", 734], ["assessment", 738], ["of", 749], ["residual", 752], ["disease", 761], ["in", 769], ["the", 772], ["follow", 776], ["-", 782], ["up", 783], ["of", 786], ["therapy", 789], [".", 796], ["In", 798], ["the", 801], ["great", 805], ["majority", 811], ["of", 820], ["CML", 823], ["patients", 827], ["the", 836], ["BCR", 840], ["-", 843], ["ABL", 844], ["transcripts", 848], ["exhibit", 860], ["a", 868], ["b2a2", 870], ["and/or", 875], ["a", 882], ["b3a2", 884], ["junction", 889], [";", 897], ["in", 899], ["rare", 902], ["cases", 907], [",", 912], ["the", 914], ["only", 918], ["detectable", 923], ["BCR", 934], ["-", 937], ["ABL", 938], ["transcripts", 942], ["have", 954], ["unusual", 959], ["junctions", 967], [",", 976], ["such", 978], ["as", 983], ["b2a3", 986], [",", 990], ["b3a3", 992], [",", 996], ["e1a2", 998], ["or", 1003], ["e6a2", 1006], [".", 1010], ["There", 1012], ["is", 1018], ["a", 1021], ["recent", 1023], ["suggestion", 1030], ["that", 1041], ["the", 1046], ["BCR", 1050], ["-", 1053], ["ABL", 1054], ["gene", 1058], ["may", 1063], ["not", 1067], ["be", 1071], ["always", 1074], ["'", 1081], ["functional", 1082], ["'", 1092], [",", 1093], ["since", 1095], ["extremely", 1101], ["low", 1111], ["levels", 1115], ["of", 1122], ["BCR", 1125], ["-", 1128], ["ABL", 1129], ["transcripts", 1133], ["can", 1145], ["be", 1149], ["found", 1152], ["in", 1158], ["leucocytes", 1161], ["from", 1172], ["normal", 1177], ["individuals", 1184], ["and", 1196], [",", 1199], ["conversely", 1201], [",", 1211], ["it", 1213], ["appears", 1216], ["that", 1224], ["no", 1229], ["BCR", 1232], ["-", 1235], ["ABL", 1236], ["transcription", 1240], ["can", 1254], ["be", 1258], ["detected", 1261], ["in", 1270], ["a", 1273], ["proportion", 1275], ["of", 1286], ["Ph", 1289], ["-", 1291], ["positive", 1292], ["haematopoietic", 1301], ["progenitors", 1316], ["from", 1328], ["some", 1333], ["CML", 1338], ["patients", 1342], [".", 1350], ["The", 1352], ["role", 1356], [",", 1360], ["if", 1362], ["any", 1365], [",", 1368], ["of", 1370], ["the", 1373], ["reciprocal", 1377], ["ABL", 1388], ["-", 1391], ["BCR", 1392], ["hybrid", 1396], ["gene", 1403], ["in", 1408], ["CML", 1411], ["is", 1415], ["unknown", 1418], [".", 1425], ["Although", 1427], ["its", 1436], ["mRNA", 1440], ["message", 1445], ["is", 1453], ["in", 1456], ["frame", 1459], [",", 1464], ["no", 1466], ["ABL", 1469], ["-", 1472], ["BCR", 1473], ["fusion", 1477], ["protein", 1484], ["has", 1492], ["yet", 1496], ["been", 1500], ["identified", 1505], ["in", 1516], ["CML", 1519], ["patients", 1523], [".", 1531], ["The", 1533], ["blast", 1537], ["crisis", 1543], ["of", 1550], ["CML", 1553], ["has", 1557], ["been", 1561], ["variably", 1566], ["associated", 1575], ["with", 1586], ["abnormalities", 1591], ["of", 1605], ["proto", 1608], ["-", 1613], ["oncogenes", 1614], [",", 1623], ["such", 1625], ["as", 1630], ["RAS", 1633], ["and", 1637], ["MYC", 1641], [",", 1644], ["or", 1646], ["of", 1649], ["tumour", 1652], ["suppressor", 1659], ["genes", 1670], [",", 1675], ["in", 1677], ["particular", 1680], ["RB", 1691], [",", 1693], ["p53", 1695], ["and", 1699], ["p16", 1703], [",", 1706], ["or", 1708], ["with", 1711], ["the", 1716], ["generation", 1720], ["of", 1731], ["chimeric", 1734], ["transcription", 1743], ["factors", 1757], [",", 1764], ["as", 1766], ["in", 1769], ["the", 1772], ["AML1-EVI1", 1776], ["gene", 1786], ["fusion", 1791], [".", 1797], ["It", 1799], ["is", 1802], ["likely", 1805], [",", 1811], ["therefore", 1813], [",", 1822], ["that", 1824], ["multiple", 1829], ["and", 1838], ["alternative", 1842], ["molecular", 1854], ["defects", 1864], [",", 1871], ["as", 1873], ["opposed", 1876], ["to", 1884], ["a", 1887], ["single", 1889], ["universal", 1896], ["mechanism", 1906], [",", 1915], ["underlie", 1917], ["the", 1926], ["acute", 1930], ["transformation", 1936], ["of", 1951], ["the", 1954], ["disease", 1958], [".", 1965]]}
{"context": "Adenosine deaminases that act on RNA [adenosine deaminase, RNA specific (ADAR)] catalyze the site-specific conversion of adenosine to inosine in primary mRNA transcripts. These re-coding events affect coding potential, splice sites, and stability of mature mRNAs. ADAR is an essential gene, and studies in mouse, Caenorhabditis elegans, and Drosophila suggest that its primary function is to modify adult behavior by altering signaling components in the nervous system. By comparing the sequence of isogenic cDNAs to genomic DNA, we have identified and experimentally verified 27 new targets of Drosophila ADAR. Our analyses led us to identify new classes of genes whose transcripts are targets of ADAR, including components of the actin cytoskeleton and genes involved in ion homeostasis and signal transduction. Our results indicate that editing in Drosophila increases the diversity of the proteome, and does so in a manner that has direct functional consequences on protein function.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["adenosine deaminase, RNA-specific", "ADAR", "adenosine deaminase, RNA specific"], "qid": "39ab6d3436864e6ea8cc1a577a441db5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[106, 106], [13, 13], [123, 123], [49, 49]], "char_spans": [[606, 609], [73, 76], [698, 701], [264, 267]]}, {"text": "adenosine deaminase, RNA-specific", "token_spans": [[7, 11]], "char_spans": [[38, 70]]}]}], "context_tokens": [["Adenosine", 0], ["deaminases", 10], ["that", 21], ["act", 26], ["on", 30], ["RNA", 33], ["[", 37], ["adenosine", 38], ["deaminase", 48], [",", 57], ["RNA", 59], ["specific", 63], ["(", 72], ["ADAR", 73], [")", 77], ["]", 78], ["catalyze", 80], ["the", 89], ["site", 93], ["-", 97], ["specific", 98], ["conversion", 107], ["of", 118], ["adenosine", 121], ["to", 131], ["inosine", 134], ["in", 142], ["primary", 145], ["mRNA", 153], ["transcripts", 158], [".", 169], ["These", 171], ["re", 177], ["-", 179], ["coding", 180], ["events", 187], ["affect", 194], ["coding", 201], ["potential", 208], [",", 217], ["splice", 219], ["sites", 226], [",", 231], ["and", 233], ["stability", 237], ["of", 247], ["mature", 250], ["mRNAs", 257], [".", 262], ["ADAR", 264], ["is", 269], ["an", 272], ["essential", 275], ["gene", 285], [",", 289], ["and", 291], ["studies", 295], ["in", 303], ["mouse", 306], [",", 311], ["Caenorhabditis", 313], ["elegans", 328], [",", 335], ["and", 337], ["Drosophila", 341], ["suggest", 352], ["that", 360], ["its", 365], ["primary", 369], ["function", 377], ["is", 386], ["to", 389], ["modify", 392], ["adult", 399], ["behavior", 405], ["by", 414], ["altering", 417], ["signaling", 426], ["components", 436], ["in", 447], ["the", 450], ["nervous", 454], ["system", 462], [".", 468], ["By", 470], ["comparing", 473], ["the", 483], ["sequence", 487], ["of", 496], ["isogenic", 499], ["cDNAs", 508], ["to", 514], ["genomic", 517], ["DNA", 525], [",", 528], ["we", 530], ["have", 533], ["identified", 538], ["and", 549], ["experimentally", 553], ["verified", 568], ["27", 577], ["new", 580], ["targets", 584], ["of", 592], ["Drosophila", 595], ["ADAR", 606], [".", 610], ["Our", 612], ["analyses", 616], ["led", 625], ["us", 629], ["to", 632], ["identify", 635], ["new", 644], ["classes", 648], ["of", 656], ["genes", 659], ["whose", 665], ["transcripts", 671], ["are", 683], ["targets", 687], ["of", 695], ["ADAR", 698], [",", 702], ["including", 704], ["components", 714], ["of", 725], ["the", 728], ["actin", 732], ["cytoskeleton", 738], ["and", 751], ["genes", 755], ["involved", 761], ["in", 770], ["ion", 773], ["homeostasis", 777], ["and", 789], ["signal", 793], ["transduction", 800], [".", 812], ["Our", 814], ["results", 818], ["indicate", 826], ["that", 835], ["editing", 840], ["in", 848], ["Drosophila", 851], ["increases", 862], ["the", 872], ["diversity", 876], ["of", 886], ["the", 889], ["proteome", 893], [",", 901], ["and", 903], ["does", 907], ["so", 912], ["in", 915], ["a", 918], ["manner", 920], ["that", 927], ["has", 932], ["direct", 936], ["functional", 943], ["consequences", 954], ["on", 967], ["protein", 970], ["function", 978], [".", 986]]}
{"context": "The purpose of this paper is to assess the reliability and validity of the Spanish version of the Davidson trauma scale (DTS-S) and to determine the prevalence and correlates of post-traumatic stress disorder (PTSD) symptoms in a non-clinical random sample of prison inmates. Probabilistic samples of 1,179 inmates from 26 penal institutions in Puerto Rico were selected using a multistage sampling design. Population estimates and correlations were obtained for PTSD, generalized anxiety and depression. The reliability, factor structure, and convergent validity of the DTS-S were assessed. Cross-validation was employed to confirm the results of the factor analyses. Using the cut-offs adopted by the scale's author, 136 (13.4 percent) of the inmates are likely to have current PTSD and 117 (11.6 percent) reach the cut-off for sub-threshold PTSD. Confirmatory factor analysis generated two factors explaining 53 percent of the variance. High reliabilities were obtained for the total scale (\u03b1=0.95) and for the frequency and severity scales (\u03b1=0.90 and 0.91). Significantly higher DTS-S scores were found for females (t=2.26, p<0.025), for inmates diagnosed with depression or anxiety (t=2.02, p<0.05), and those reporting suicide attempts (t=4.47, p<0.0001). Findings support that the DTS-S is a reliable and valid measure to assess PTSD symptoms in Latino inmate populations and to identify individuals at risk for the disorder that require confirmatory diagnosis and clinical interventions.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b6a2b5c8312645a99ca848d823503319", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[34, 38]], "char_spans": [[178, 207]]}, {"text": "PTSD", "token_spans": [[160, 160], [144, 144], [40, 40], [254, 254], [81, 81]], "char_spans": [[844, 847], [780, 783], [210, 213], [1337, 1340], [463, 466]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["paper", 20], ["is", 26], ["to", 29], ["assess", 32], ["the", 39], ["reliability", 43], ["and", 55], ["validity", 59], ["of", 68], ["the", 71], ["Spanish", 75], ["version", 83], ["of", 91], ["the", 94], ["Davidson", 98], ["trauma", 107], ["scale", 114], ["(", 120], ["DTS", 121], ["-", 124], ["S", 125], [")", 126], ["and", 128], ["to", 132], ["determine", 135], ["the", 145], ["prevalence", 149], ["and", 160], ["correlates", 164], ["of", 175], ["post", 178], ["-", 182], ["traumatic", 183], ["stress", 193], ["disorder", 200], ["(", 209], ["PTSD", 210], [")", 214], ["symptoms", 216], ["in", 225], ["a", 228], ["non", 230], ["-", 233], ["clinical", 234], ["random", 243], ["sample", 250], ["of", 257], ["prison", 260], ["inmates", 267], [".", 274], ["Probabilistic", 276], ["samples", 290], ["of", 298], ["1,179", 301], ["inmates", 307], ["from", 315], ["26", 320], ["penal", 323], ["institutions", 329], ["in", 342], ["Puerto", 345], ["Rico", 352], ["were", 357], ["selected", 362], ["using", 371], ["a", 377], ["multistage", 379], ["sampling", 390], ["design", 399], [".", 405], ["Population", 407], ["estimates", 418], ["and", 428], ["correlations", 432], ["were", 445], ["obtained", 450], ["for", 459], ["PTSD", 463], [",", 467], ["generalized", 469], ["anxiety", 481], ["and", 489], ["depression", 493], [".", 503], ["The", 505], ["reliability", 509], [",", 520], ["factor", 522], ["structure", 529], [",", 538], ["and", 540], ["convergent", 544], ["validity", 555], ["of", 564], ["the", 567], ["DTS", 571], ["-", 574], ["S", 575], ["were", 577], ["assessed", 582], [".", 590], ["Cross", 592], ["-", 597], ["validation", 598], ["was", 609], ["employed", 613], ["to", 622], ["confirm", 625], ["the", 633], ["results", 637], ["of", 645], ["the", 648], ["factor", 652], ["analyses", 659], [".", 667], ["Using", 669], ["the", 675], ["cut", 679], ["-", 682], ["offs", 683], ["adopted", 688], ["by", 696], ["the", 699], ["scale", 703], ["'s", 708], ["author", 711], [",", 717], ["136", 719], ["(", 723], ["13.4", 724], ["percent", 729], [")", 736], ["of", 738], ["the", 741], ["inmates", 745], ["are", 753], ["likely", 757], ["to", 764], ["have", 767], ["current", 772], ["PTSD", 780], ["and", 785], ["117", 789], ["(", 793], ["11.6", 794], ["percent", 799], [")", 806], ["reach", 808], ["the", 814], ["cut", 818], ["-", 821], ["off", 822], ["for", 826], ["sub", 830], ["-", 833], ["threshold", 834], ["PTSD", 844], [".", 848], ["Confirmatory", 850], ["factor", 863], ["analysis", 870], ["generated", 879], ["two", 889], ["factors", 893], ["explaining", 901], ["53", 912], ["percent", 915], ["of", 923], ["the", 926], ["variance", 930], [".", 938], ["High", 940], ["reliabilities", 945], ["were", 959], ["obtained", 964], ["for", 973], ["the", 977], ["total", 981], ["scale", 987], ["(", 993], ["\u03b1=0.95", 994], [")", 1000], ["and", 1002], ["for", 1006], ["the", 1010], ["frequency", 1014], ["and", 1024], ["severity", 1028], ["scales", 1037], ["(", 1044], ["\u03b1=0.90", 1045], ["and", 1052], ["0.91", 1056], [")", 1060], [".", 1061], ["Significantly", 1063], ["higher", 1077], ["DTS", 1084], ["-", 1087], ["S", 1088], ["scores", 1090], ["were", 1097], ["found", 1102], ["for", 1108], ["females", 1112], ["(", 1120], ["t=2.26", 1121], [",", 1127], ["p<0.025", 1129], [")", 1136], [",", 1137], ["for", 1139], ["inmates", 1143], ["diagnosed", 1151], ["with", 1161], ["depression", 1166], ["or", 1177], ["anxiety", 1180], ["(", 1188], ["t=2.02", 1189], [",", 1195], ["p<0.05", 1197], [")", 1203], [",", 1204], ["and", 1206], ["those", 1210], ["reporting", 1216], ["suicide", 1226], ["attempts", 1234], ["(", 1243], ["t=4.47", 1244], [",", 1250], ["p<0.0001", 1252], [")", 1260], [".", 1261], ["Findings", 1263], ["support", 1272], ["that", 1280], ["the", 1285], ["DTS", 1289], ["-", 1292], ["S", 1293], ["is", 1295], ["a", 1298], ["reliable", 1300], ["and", 1309], ["valid", 1313], ["measure", 1319], ["to", 1327], ["assess", 1330], ["PTSD", 1337], ["symptoms", 1342], ["in", 1351], ["Latino", 1354], ["inmate", 1361], ["populations", 1368], ["and", 1380], ["to", 1384], ["identify", 1387], ["individuals", 1396], ["at", 1408], ["risk", 1411], ["for", 1416], ["the", 1420], ["disorder", 1424], ["that", 1433], ["require", 1438], ["confirmatory", 1446], ["diagnosis", 1459], ["and", 1469], ["clinical", 1473], ["interventions", 1482], [".", 1495]]}
{"context": "SECIS elements are stem-loop structures located in the 3' untranslated regions (UTRs) of eukaryotic selenoprotein mRNAs that are required for directing cotranslational selenocysteine incorporation at UGA codons. In prokaryotes, stem-loops mediating selenocysteine incorporation are located immediately downstream of the UGA selenocysteine codon, in the coding region. Previous characterization studies of the mammalian SECIS elements of type 1 deiodinase, glutathione peroxidase, and selenoprotein P showed that conserved nucleotides in the loops and unpaired bulges, and base pairing in the stems are required for SECIS function. These initial studies utilized approximately 175-230-nt segments of the 3'UTRs of the selenoprotein mRNAs. Here we define the minimal functional rat type 1 deiodinase SECIS element, a 45-nt segment, the 5' boundary of which corresponds precisely to the 5'-most critical conserved nucleotide identified previously. We also define base pairing requirements in the stem of this element. In view of the presence of SECIS elements in the open reading frames (ORFs) of bacterial selenoproteins, we examine the effects in the type 1 deiodinase of extending the ORF into the SECIS element, and find that this dramatically inhibits SECIS function. Finally, we define a minimal spacing requirement of 51-111 nt between a eukaryotic UGA selenocysteine codon and SECIS element.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "5798e357ab44416ea1ecd5323e3e7ae4", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[0, 0], [96, 96], [198, 198], [230, 230], [169, 169], [126, 126], [63, 63], [207, 207]], "char_spans": [[0, 4], [615, 619], [1198, 1202], [1382, 1386], [1042, 1046], [798, 802], [419, 423], [1254, 1258]]}]}], "context_tokens": [["SECIS", 0], ["elements", 6], ["are", 15], ["stem", 19], ["-", 23], ["loop", 24], ["structures", 29], ["located", 40], ["in", 48], ["the", 51], ["3", 55], ["'", 56], ["untranslated", 58], ["regions", 71], ["(", 79], ["UTRs", 80], [")", 84], ["of", 86], ["eukaryotic", 89], ["selenoprotein", 100], ["mRNAs", 114], ["that", 120], ["are", 125], ["required", 129], ["for", 138], ["directing", 142], ["cotranslational", 152], ["selenocysteine", 168], ["incorporation", 183], ["at", 197], ["UGA", 200], ["codons", 204], [".", 210], ["In", 212], ["prokaryotes", 215], [",", 226], ["stem", 228], ["-", 232], ["loops", 233], ["mediating", 239], ["selenocysteine", 249], ["incorporation", 264], ["are", 278], ["located", 282], ["immediately", 290], ["downstream", 302], ["of", 313], ["the", 316], ["UGA", 320], ["selenocysteine", 324], ["codon", 339], [",", 344], ["in", 346], ["the", 349], ["coding", 353], ["region", 360], [".", 366], ["Previous", 368], ["characterization", 377], ["studies", 394], ["of", 402], ["the", 405], ["mammalian", 409], ["SECIS", 419], ["elements", 425], ["of", 434], ["type", 437], ["1", 442], ["deiodinase", 444], [",", 454], ["glutathione", 456], ["peroxidase", 468], [",", 478], ["and", 480], ["selenoprotein", 484], ["P", 498], ["showed", 500], ["that", 507], ["conserved", 512], ["nucleotides", 522], ["in", 534], ["the", 537], ["loops", 541], ["and", 547], ["unpaired", 551], ["bulges", 560], [",", 566], ["and", 568], ["base", 572], ["pairing", 577], ["in", 585], ["the", 588], ["stems", 592], ["are", 598], ["required", 602], ["for", 611], ["SECIS", 615], ["function", 621], [".", 629], ["These", 631], ["initial", 637], ["studies", 645], ["utilized", 653], ["approximately", 662], ["175", 676], ["-", 679], ["230-nt", 680], ["segments", 687], ["of", 696], ["the", 699], ["3'UTRs", 703], ["of", 710], ["the", 713], ["selenoprotein", 717], ["mRNAs", 731], [".", 736], ["Here", 738], ["we", 743], ["define", 746], ["the", 753], ["minimal", 757], ["functional", 765], ["rat", 776], ["type", 780], ["1", 785], ["deiodinase", 787], ["SECIS", 798], ["element", 804], [",", 811], ["a", 813], ["45-nt", 815], ["segment", 821], [",", 828], ["the", 830], ["5", 834], ["'", 835], ["boundary", 837], ["of", 846], ["which", 849], ["corresponds", 855], ["precisely", 867], ["to", 877], ["the", 880], ["5'-most", 884], ["critical", 892], ["conserved", 901], ["nucleotide", 911], ["identified", 922], ["previously", 933], [".", 943], ["We", 945], ["also", 948], ["define", 953], ["base", 960], ["pairing", 965], ["requirements", 973], ["in", 986], ["the", 989], ["stem", 993], ["of", 998], ["this", 1001], ["element", 1006], [".", 1013], ["In", 1015], ["view", 1018], ["of", 1023], ["the", 1026], ["presence", 1030], ["of", 1039], ["SECIS", 1042], ["elements", 1048], ["in", 1057], ["the", 1060], ["open", 1064], ["reading", 1069], ["frames", 1077], ["(", 1084], ["ORFs", 1085], [")", 1089], ["of", 1091], ["bacterial", 1094], ["selenoproteins", 1104], [",", 1118], ["we", 1120], ["examine", 1123], ["the", 1131], ["effects", 1135], ["in", 1143], ["the", 1146], ["type", 1150], ["1", 1155], ["deiodinase", 1157], ["of", 1168], ["extending", 1171], ["the", 1181], ["ORF", 1185], ["into", 1189], ["the", 1194], ["SECIS", 1198], ["element", 1204], [",", 1211], ["and", 1213], ["find", 1217], ["that", 1222], ["this", 1227], ["dramatically", 1232], ["inhibits", 1245], ["SECIS", 1254], ["function", 1260], [".", 1268], ["Finally", 1270], [",", 1277], ["we", 1279], ["define", 1282], ["a", 1289], ["minimal", 1291], ["spacing", 1299], ["requirement", 1307], ["of", 1319], ["51", 1322], ["-", 1324], ["111", 1325], ["nt", 1329], ["between", 1332], ["a", 1340], ["eukaryotic", 1342], ["UGA", 1353], ["selenocysteine", 1357], ["codon", 1372], ["and", 1378], ["SECIS", 1382], ["element", 1388], [".", 1395]]}
{"context": "By using monoclonal antibodies raised against isolated clam centrosomes, we have identified a novel 135-kD centrosomal protein (Cep135), present in a wide range of organisms. Cep135 is located at the centrosome throughout the cell cycle, and localization is independent of the microtubule network. It distributes throughout the centrosomal area in association with the electron-dense material surrounding centrioles. Sequence analysis of cDNA isolated from CHO cells predicted a protein of 1,145-amino acid residues with extensive alpha-helical domains. Expression of a series of deletion constructs revealed the presence of three independent centrosome-targeting domains. Overexpression of Cep135 resulted in the accumulation of unique whorl-like particles in both the centrosome and the cytoplasm. Although their size, shape, and number varied according to the level of protein expression, these whorls were composed of parallel dense lines arranged in a 6-nm space. Altered levels of Cep135 by protein overexpression and/or suppression of endogenous Cep135 by RNA interference caused disorganization of interphase and mitotic spindle microtubules. Thus, Cep135 may play an important role in the centrosomal function of organizing microtubules in mammalian cells.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "531659cef16e4f2d9ad354129f13c0c8", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[123, 123], [35, 35], [102, 102]], "char_spans": [[770, 779], [200, 209], [643, 652]]}]}], "context_tokens": [["By", 0], ["using", 3], ["monoclonal", 9], ["antibodies", 20], ["raised", 31], ["against", 38], ["isolated", 46], ["clam", 55], ["centrosomes", 60], [",", 71], ["we", 73], ["have", 76], ["identified", 81], ["a", 92], ["novel", 94], ["135-kD", 100], ["centrosomal", 107], ["protein", 119], ["(", 127], ["Cep135", 128], [")", 134], [",", 135], ["present", 137], ["in", 145], ["a", 148], ["wide", 150], ["range", 155], ["of", 161], ["organisms", 164], [".", 173], ["Cep135", 175], ["is", 182], ["located", 185], ["at", 193], ["the", 196], ["centrosome", 200], ["throughout", 211], ["the", 222], ["cell", 226], ["cycle", 231], [",", 236], ["and", 238], ["localization", 242], ["is", 255], ["independent", 258], ["of", 270], ["the", 273], ["microtubule", 277], ["network", 289], [".", 296], ["It", 298], ["distributes", 301], ["throughout", 313], ["the", 324], ["centrosomal", 328], ["area", 340], ["in", 345], ["association", 348], ["with", 360], ["the", 365], ["electron", 369], ["-", 377], ["dense", 378], ["material", 384], ["surrounding", 393], ["centrioles", 405], [".", 415], ["Sequence", 417], ["analysis", 426], ["of", 435], ["cDNA", 438], ["isolated", 443], ["from", 452], ["CHO", 457], ["cells", 461], ["predicted", 467], ["a", 477], ["protein", 479], ["of", 487], ["1,145-amino", 490], ["acid", 502], ["residues", 507], ["with", 516], ["extensive", 521], ["alpha", 531], ["-", 536], ["helical", 537], ["domains", 545], [".", 552], ["Expression", 554], ["of", 565], ["a", 568], ["series", 570], ["of", 577], ["deletion", 580], ["constructs", 589], ["revealed", 600], ["the", 609], ["presence", 613], ["of", 622], ["three", 625], ["independent", 631], ["centrosome", 643], ["-", 653], ["targeting", 654], ["domains", 664], [".", 671], ["Overexpression", 673], ["of", 688], ["Cep135", 691], ["resulted", 698], ["in", 707], ["the", 710], ["accumulation", 714], ["of", 727], ["unique", 730], ["whorl", 737], ["-", 742], ["like", 743], ["particles", 748], ["in", 758], ["both", 761], ["the", 766], ["centrosome", 770], ["and", 781], ["the", 785], ["cytoplasm", 789], [".", 798], ["Although", 800], ["their", 809], ["size", 815], [",", 819], ["shape", 821], [",", 826], ["and", 828], ["number", 832], ["varied", 839], ["according", 846], ["to", 856], ["the", 859], ["level", 863], ["of", 869], ["protein", 872], ["expression", 880], [",", 890], ["these", 892], ["whorls", 898], ["were", 905], ["composed", 910], ["of", 919], ["parallel", 922], ["dense", 931], ["lines", 937], ["arranged", 943], ["in", 952], ["a", 955], ["6-nm", 957], ["space", 962], [".", 967], ["Altered", 969], ["levels", 977], ["of", 984], ["Cep135", 987], ["by", 994], ["protein", 997], ["overexpression", 1005], ["and/or", 1020], ["suppression", 1027], ["of", 1039], ["endogenous", 1042], ["Cep135", 1053], ["by", 1060], ["RNA", 1063], ["interference", 1067], ["caused", 1080], ["disorganization", 1087], ["of", 1103], ["interphase", 1106], ["and", 1117], ["mitotic", 1121], ["spindle", 1129], ["microtubules", 1137], [".", 1149], ["Thus", 1151], [",", 1155], ["Cep135", 1157], ["may", 1164], ["play", 1168], ["an", 1173], ["important", 1176], ["role", 1186], ["in", 1191], ["the", 1194], ["centrosomal", 1198], ["function", 1210], ["of", 1219], ["organizing", 1222], ["microtubules", 1233], ["in", 1246], ["mammalian", 1249], ["cells", 1259], [".", 1264]]}
{"context": "For dozens of years, a variety of pathological findings have been revealed through previous observations on surgically resected lesions from patients with intractable epilepsy, including excessive number of neurons in the molecular layer of cortices, unexpected existence of white matter neurons, and persistent columnar structure. These findings have sometimes been referred to as microdysgenesis (MD) or mild malformation of cortical development (mMCD), which is defined as microscopic abnormalities of brain formations with no macroscopical and neuroradiological findings. Taylor et al. (1971) described surgical cases with giant neurons and bizarre, grotesque cells as \"focal dysplasia of the cerebral cortices with epilepsy.\" Since 1997, such malformations have subsequently been referred to as focal cortical dysplasia (FCD), in Greenfield's Neuropathology. Since early 2000, the definition of FCD has gradually been given a broader interpretation than the case described by Taylor et al., as shown in Palmini's classification (2004) or the newest classification (2011) proposed by the Neuropathology Task Force of the International League Against Epilepsy (ILAE). The ILAE classification describes 3 types of disease: Type I, Type II, and Type III. Type I is equivalent to some, but not all, pathological phenotypes of MD or mMCD. Type II is Taylor's FCD alone. Type III, which was not included in Palmini's classification, merges brain malformation and other pathological findings. However, the reproducibility of pathological diagnosis by using the ILAE classification was low, except for Type IIb. Hence, future studies are necessary to provide further reliable criteria for the pathological diagnosis of epilepsy patients.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "71df3d8251d84f0f8c452651b470a6ec", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[129, 131]], "char_spans": [[800, 823]]}]}], "context_tokens": [["For", 0], ["dozens", 4], ["of", 11], ["years", 14], [",", 19], ["a", 21], ["variety", 23], ["of", 31], ["pathological", 34], ["findings", 47], ["have", 56], ["been", 61], ["revealed", 66], ["through", 75], ["previous", 83], ["observations", 92], ["on", 105], ["surgically", 108], ["resected", 119], ["lesions", 128], ["from", 136], ["patients", 141], ["with", 150], ["intractable", 155], ["epilepsy", 167], [",", 175], ["including", 177], ["excessive", 187], ["number", 197], ["of", 204], ["neurons", 207], ["in", 215], ["the", 218], ["molecular", 222], ["layer", 232], ["of", 238], ["cortices", 241], [",", 249], ["unexpected", 251], ["existence", 262], ["of", 272], ["white", 275], ["matter", 281], ["neurons", 288], [",", 295], ["and", 297], ["persistent", 301], ["columnar", 312], ["structure", 321], [".", 330], ["These", 332], ["findings", 338], ["have", 347], ["sometimes", 352], ["been", 362], ["referred", 367], ["to", 376], ["as", 379], ["microdysgenesis", 382], ["(", 398], ["MD", 399], [")", 401], ["or", 403], ["mild", 406], ["malformation", 411], ["of", 424], ["cortical", 427], ["development", 436], ["(", 448], ["mMCD", 449], [")", 453], [",", 454], ["which", 456], ["is", 462], ["defined", 465], ["as", 473], ["microscopic", 476], ["abnormalities", 488], ["of", 502], ["brain", 505], ["formations", 511], ["with", 522], ["no", 527], ["macroscopical", 530], ["and", 544], ["neuroradiological", 548], ["findings", 566], [".", 574], ["Taylor", 576], ["et", 583], ["al", 586], [".", 588], ["(", 590], ["1971", 591], [")", 595], ["described", 597], ["surgical", 607], ["cases", 616], ["with", 622], ["giant", 627], ["neurons", 633], ["and", 641], ["bizarre", 645], [",", 652], ["grotesque", 654], ["cells", 664], ["as", 670], ["\"", 673], ["focal", 674], ["dysplasia", 680], ["of", 690], ["the", 693], ["cerebral", 697], ["cortices", 706], ["with", 715], ["epilepsy", 720], [".", 728], ["\"", 729], ["Since", 731], ["1997", 737], [",", 741], ["such", 743], ["malformations", 748], ["have", 762], ["subsequently", 767], ["been", 780], ["referred", 785], ["to", 794], ["as", 797], ["focal", 800], ["cortical", 806], ["dysplasia", 815], ["(", 825], ["FCD", 826], [")", 829], [",", 830], ["in", 832], ["Greenfield", 835], ["'s", 845], ["Neuropathology", 848], [".", 862], ["Since", 864], ["early", 870], ["2000", 876], [",", 880], ["the", 882], ["definition", 886], ["of", 897], ["FCD", 900], ["has", 904], ["gradually", 908], ["been", 918], ["given", 923], ["a", 929], ["broader", 931], ["interpretation", 939], ["than", 954], ["the", 959], ["case", 963], ["described", 968], ["by", 978], ["Taylor", 981], ["et", 988], ["al", 991], [".", 993], [",", 994], ["as", 996], ["shown", 999], ["in", 1005], ["Palmini", 1008], ["'s", 1015], ["classification", 1018], ["(", 1033], ["2004", 1034], [")", 1038], ["or", 1040], ["the", 1043], ["newest", 1047], ["classification", 1054], ["(", 1069], ["2011", 1070], [")", 1074], ["proposed", 1076], ["by", 1085], ["the", 1088], ["Neuropathology", 1092], ["Task", 1107], ["Force", 1112], ["of", 1118], ["the", 1121], ["International", 1125], ["League", 1139], ["Against", 1146], ["Epilepsy", 1154], ["(", 1163], ["ILAE", 1164], [")", 1168], [".", 1169], ["The", 1171], ["ILAE", 1175], ["classification", 1180], ["describes", 1195], ["3", 1205], ["types", 1207], ["of", 1213], ["disease", 1216], [":", 1223], ["Type", 1225], ["I", 1230], [",", 1231], ["Type", 1233], ["II", 1238], [",", 1240], ["and", 1242], ["Type", 1246], ["III", 1251], [".", 1254], ["Type", 1256], ["I", 1261], ["is", 1263], ["equivalent", 1266], ["to", 1277], ["some", 1280], [",", 1284], ["but", 1286], ["not", 1290], ["all", 1294], [",", 1297], ["pathological", 1299], ["phenotypes", 1312], ["of", 1323], ["MD", 1326], ["or", 1329], ["mMCD", 1332], [".", 1336], ["Type", 1338], ["II", 1343], ["is", 1346], ["Taylor", 1349], ["'s", 1355], ["FCD", 1358], ["alone", 1362], [".", 1367], ["Type", 1369], ["III", 1374], [",", 1377], ["which", 1379], ["was", 1385], ["not", 1389], ["included", 1393], ["in", 1402], ["Palmini", 1405], ["'s", 1412], ["classification", 1415], [",", 1429], ["merges", 1431], ["brain", 1438], ["malformation", 1444], ["and", 1457], ["other", 1461], ["pathological", 1467], ["findings", 1480], [".", 1488], ["However", 1490], [",", 1497], ["the", 1499], ["reproducibility", 1503], ["of", 1519], ["pathological", 1522], ["diagnosis", 1535], ["by", 1545], ["using", 1548], ["the", 1554], ["ILAE", 1558], ["classification", 1563], ["was", 1578], ["low", 1582], [",", 1585], ["except", 1587], ["for", 1594], ["Type", 1598], ["IIb", 1603], [".", 1606], ["Hence", 1608], [",", 1613], ["future", 1615], ["studies", 1622], ["are", 1630], ["necessary", 1634], ["to", 1644], ["provide", 1647], ["further", 1655], ["reliable", 1663], ["criteria", 1672], ["for", 1681], ["the", 1685], ["pathological", 1689], ["diagnosis", 1702], ["of", 1712], ["epilepsy", 1715], ["patients", 1724], [".", 1732]]}
{"context": "To study the mechanism of centrosome duplication in cycling cells, we established a novel system of multiple centrosome formation in two types of cells: CHO cells treated with RO3306, a Cyclin-dependent kinase 1 (Cdk1) inhibitor and DT40 cells, in which Cdks were knocked out by chemical genetics. Cdk1-inactivated cells initiated DNA replication and centrosome duplication at the onset of S phase. They became arrested at the end of G2, but the centrosome cycle continued to produce supernumerary centrioles/centrosomes without DNA endoreplication in those cells. Centrosomes were amplified in a highly synchronous and reproducible manner: all of them were located next to the nucleus and spread widely apart from each other with several \u03bcm in distance. Double knockout of Cdk1 and Cdk2 caused cell cycle arrest at G1/S and centrosomes were no longer duplicated. However, cells continued to grow and increased their volume over 10-fold during 48 hr of culture. Centrosome components, including \u03b3-tubulin and Cep135, were synthesized and accumulated during the arrest, allowing rapid centrosome multiplication upon recovery from the cell cycle arrest or expression of exogenous Plk4 in G1/S cells. Thus centrosome amplification results from the discoordination of the centrosome cycle from the progression of other cell cycle events, which is controlled by different levels of Cdk activities.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "0c06ab7dd90c4dad83de126afa2b4101", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[5, 5], [82, 82], [188, 188], [215, 215], [18, 18], [168, 168], [62, 62], [207, 207]], "char_spans": [[26, 35], [446, 455], [1084, 1093], [1268, 1277], [109, 118], [962, 971], [351, 360], [1203, 1212]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["mechanism", 13], ["of", 23], ["centrosome", 26], ["duplication", 37], ["in", 49], ["cycling", 52], ["cells", 60], [",", 65], ["we", 67], ["established", 70], ["a", 82], ["novel", 84], ["system", 90], ["of", 97], ["multiple", 100], ["centrosome", 109], ["formation", 120], ["in", 130], ["two", 133], ["types", 137], ["of", 143], ["cells", 146], [":", 151], ["CHO", 153], ["cells", 157], ["treated", 163], ["with", 171], ["RO3306", 176], [",", 182], ["a", 184], ["Cyclin", 186], ["-", 192], ["dependent", 193], ["kinase", 203], ["1", 210], ["(", 212], ["Cdk1", 213], [")", 217], ["inhibitor", 219], ["and", 229], ["DT40", 233], ["cells", 238], [",", 243], ["in", 245], ["which", 248], ["Cdks", 254], ["were", 259], ["knocked", 264], ["out", 272], ["by", 276], ["chemical", 279], ["genetics", 288], [".", 296], ["Cdk1-inactivated", 298], ["cells", 315], ["initiated", 321], ["DNA", 331], ["replication", 335], ["and", 347], ["centrosome", 351], ["duplication", 362], ["at", 374], ["the", 377], ["onset", 381], ["of", 387], ["S", 390], ["phase", 392], [".", 397], ["They", 399], ["became", 404], ["arrested", 411], ["at", 420], ["the", 423], ["end", 427], ["of", 431], ["G2", 434], [",", 436], ["but", 438], ["the", 442], ["centrosome", 446], ["cycle", 457], ["continued", 463], ["to", 473], ["produce", 476], ["supernumerary", 484], ["centrioles", 498], ["/", 508], ["centrosomes", 509], ["without", 521], ["DNA", 529], ["endoreplication", 533], ["in", 549], ["those", 552], ["cells", 558], [".", 563], ["Centrosomes", 565], ["were", 577], ["amplified", 582], ["in", 592], ["a", 595], ["highly", 597], ["synchronous", 604], ["and", 616], ["reproducible", 620], ["manner", 633], [":", 639], ["all", 641], ["of", 645], ["them", 648], ["were", 653], ["located", 658], ["next", 666], ["to", 671], ["the", 674], ["nucleus", 678], ["and", 686], ["spread", 690], ["widely", 697], ["apart", 704], ["from", 710], ["each", 715], ["other", 720], ["with", 726], ["several", 731], ["\u03bcm", 739], ["in", 742], ["distance", 745], [".", 753], ["Double", 755], ["knockout", 762], ["of", 771], ["Cdk1", 774], ["and", 779], ["Cdk2", 783], ["caused", 788], ["cell", 795], ["cycle", 800], ["arrest", 806], ["at", 813], ["G1/S", 816], ["and", 821], ["centrosomes", 825], ["were", 837], ["no", 842], ["longer", 845], ["duplicated", 852], [".", 862], ["However", 864], [",", 871], ["cells", 873], ["continued", 879], ["to", 889], ["grow", 892], ["and", 897], ["increased", 901], ["their", 911], ["volume", 917], ["over", 924], ["10-fold", 929], ["during", 937], ["48", 944], ["hr", 947], ["of", 950], ["culture", 953], [".", 960], ["Centrosome", 962], ["components", 973], [",", 983], ["including", 985], ["\u03b3", 995], ["-", 996], ["tubulin", 997], ["and", 1005], ["Cep135", 1009], [",", 1015], ["were", 1017], ["synthesized", 1022], ["and", 1034], ["accumulated", 1038], ["during", 1050], ["the", 1057], ["arrest", 1061], [",", 1067], ["allowing", 1069], ["rapid", 1078], ["centrosome", 1084], ["multiplication", 1095], ["upon", 1110], ["recovery", 1115], ["from", 1124], ["the", 1129], ["cell", 1133], ["cycle", 1138], ["arrest", 1144], ["or", 1151], ["expression", 1154], ["of", 1165], ["exogenous", 1168], ["Plk4", 1178], ["in", 1183], ["G1/S", 1186], ["cells", 1191], [".", 1196], ["Thus", 1198], ["centrosome", 1203], ["amplification", 1214], ["results", 1228], ["from", 1236], ["the", 1241], ["discoordination", 1245], ["of", 1261], ["the", 1264], ["centrosome", 1268], ["cycle", 1279], ["from", 1285], ["the", 1290], ["progression", 1294], ["of", 1306], ["other", 1309], ["cell", 1315], ["cycle", 1320], ["events", 1326], [",", 1332], ["which", 1334], ["is", 1340], ["controlled", 1343], ["by", 1354], ["different", 1357], ["levels", 1367], ["of", 1374], ["Cdk", 1377], ["activities", 1381], [".", 1391]]}
{"context": "To evaluate short- and mid-term level of imbalance after vestibular schwannoma (VS) microsurgery by the transpetrosal approach, to search for factors predictive of vestibular compensation, and to determine which patient categories need a postoperative vestibular rehabilitation program. Prospective cohort study at a tertiary referral center. Between 2010 and 2011, patients aged 18 to 75 operated on for VS by transpetrosal approaches were included. VS was characterized by its size (Koos classification) and the presence or not of a cystic component. Hearing was classified according to the Gardner Robertson grading. The preoperative workup included an audiogram, computerized video nystagmography (VNG) with caloric testing, gaze study, rotatory tests, click-evoked cervical vestibular evoked myogenic potential measurements (cVEMPs), and subjective visual vertical test. Patients were asked to complete a Dizziness Handicap Inventory (DHI). Postoperatively, patients were reevaluated on D7 (clinical status), D90 (VNG and DHI), and D180 (DHI). Timing and duration of vestibular rehabilitation were also recorded. Forty-eight patients were included. Preoperatively, 77% experienced mild instability problems with a mean DHI score of 14.1 (range 4-32). Postoperatively, 71% reported stable or even improved perceived stability. Mean DHI scores were 28.1 on D90 and 19.8 on D180. Serviceable hearing, cystic transformation, normal cVEMPs, diplopia, and vestibular syndrome on D7 were found to be predictive of worse equilibrium outcome than when absent. A preoperative caloric deficit greater than 75% seemed to be a good prognostic factor. Vestibular rehabilitation was conducted in 56% of patients. Starting it early (<1 mo) seemed to be beneficial for final equilibrium outcome. VS microsurgery provides good stability results. Some preoperative parameters may be predictive of worse or improved balance recovery, as is clinical status on D7.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "44cd890f1a1b4d6a9b055e363d1c3221", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[11, 12]], "char_spans": [[57, 77]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["short-", 12], ["and", 19], ["mid", 23], ["-", 26], ["term", 27], ["level", 32], ["of", 38], ["imbalance", 41], ["after", 51], ["vestibular", 57], ["schwannoma", 68], ["(", 79], ["VS", 80], [")", 82], ["microsurgery", 84], ["by", 97], ["the", 100], ["transpetrosal", 104], ["approach", 118], [",", 126], ["to", 128], ["search", 131], ["for", 138], ["factors", 142], ["predictive", 150], ["of", 161], ["vestibular", 164], ["compensation", 175], [",", 187], ["and", 189], ["to", 193], ["determine", 196], ["which", 206], ["patient", 212], ["categories", 220], ["need", 231], ["a", 236], ["postoperative", 238], ["vestibular", 252], ["rehabilitation", 263], ["program", 278], [".", 285], ["Prospective", 287], ["cohort", 299], ["study", 306], ["at", 312], ["a", 315], ["tertiary", 317], ["referral", 326], ["center", 335], [".", 341], ["Between", 343], ["2010", 351], ["and", 356], ["2011", 360], [",", 364], ["patients", 366], ["aged", 375], ["18", 380], ["to", 383], ["75", 386], ["operated", 389], ["on", 398], ["for", 401], ["VS", 405], ["by", 408], ["transpetrosal", 411], ["approaches", 425], ["were", 436], ["included", 441], [".", 449], ["VS", 451], ["was", 454], ["characterized", 458], ["by", 472], ["its", 475], ["size", 479], ["(", 484], ["Koos", 485], ["classification", 490], [")", 504], ["and", 506], ["the", 510], ["presence", 514], ["or", 523], ["not", 526], ["of", 530], ["a", 533], ["cystic", 535], ["component", 542], [".", 551], ["Hearing", 553], ["was", 561], ["classified", 565], ["according", 576], ["to", 586], ["the", 589], ["Gardner", 593], ["Robertson", 601], ["grading", 611], [".", 618], ["The", 620], ["preoperative", 624], ["workup", 637], ["included", 644], ["an", 653], ["audiogram", 656], [",", 665], ["computerized", 667], ["video", 680], ["nystagmography", 686], ["(", 701], ["VNG", 702], [")", 705], ["with", 707], ["caloric", 712], ["testing", 720], [",", 727], ["gaze", 729], ["study", 734], [",", 739], ["rotatory", 741], ["tests", 750], [",", 755], ["click", 757], ["-", 762], ["evoked", 763], ["cervical", 770], ["vestibular", 779], ["evoked", 790], ["myogenic", 797], ["potential", 806], ["measurements", 816], ["(", 829], ["cVEMPs", 830], [")", 836], [",", 837], ["and", 839], ["subjective", 843], ["visual", 854], ["vertical", 861], ["test", 870], [".", 874], ["Patients", 876], ["were", 885], ["asked", 890], ["to", 896], ["complete", 899], ["a", 908], ["Dizziness", 910], ["Handicap", 920], ["Inventory", 929], ["(", 939], ["DHI", 940], [")", 943], [".", 944], ["Postoperatively", 946], [",", 961], ["patients", 963], ["were", 972], ["reevaluated", 977], ["on", 989], ["D7", 992], ["(", 995], ["clinical", 996], ["status", 1005], [")", 1011], [",", 1012], ["D90", 1014], ["(", 1018], ["VNG", 1019], ["and", 1023], ["DHI", 1027], [")", 1030], [",", 1031], ["and", 1033], ["D180", 1037], ["(", 1042], ["DHI", 1043], [")", 1046], [".", 1047], ["Timing", 1049], ["and", 1056], ["duration", 1060], ["of", 1069], ["vestibular", 1072], ["rehabilitation", 1083], ["were", 1098], ["also", 1103], ["recorded", 1108], [".", 1116], ["Forty", 1118], ["-", 1123], ["eight", 1124], ["patients", 1130], ["were", 1139], ["included", 1144], [".", 1152], ["Preoperatively", 1154], [",", 1168], ["77", 1170], ["%", 1172], ["experienced", 1174], ["mild", 1186], ["instability", 1191], ["problems", 1203], ["with", 1212], ["a", 1217], ["mean", 1219], ["DHI", 1224], ["score", 1228], ["of", 1234], ["14.1", 1237], ["(", 1242], ["range", 1243], ["4", 1249], ["-", 1250], ["32", 1251], [")", 1253], [".", 1254], ["Postoperatively", 1256], [",", 1271], ["71", 1273], ["%", 1275], ["reported", 1277], ["stable", 1286], ["or", 1293], ["even", 1296], ["improved", 1301], ["perceived", 1310], ["stability", 1320], [".", 1329], ["Mean", 1331], ["DHI", 1336], ["scores", 1340], ["were", 1347], ["28.1", 1352], ["on", 1357], ["D90", 1360], ["and", 1364], ["19.8", 1368], ["on", 1373], ["D180", 1376], [".", 1380], ["Serviceable", 1382], ["hearing", 1394], [",", 1401], ["cystic", 1403], ["transformation", 1410], [",", 1424], ["normal", 1426], ["cVEMPs", 1433], [",", 1439], ["diplopia", 1441], [",", 1449], ["and", 1451], ["vestibular", 1455], ["syndrome", 1466], ["on", 1475], ["D7", 1478], ["were", 1481], ["found", 1486], ["to", 1492], ["be", 1495], ["predictive", 1498], ["of", 1509], ["worse", 1512], ["equilibrium", 1518], ["outcome", 1530], ["than", 1538], ["when", 1543], ["absent", 1548], [".", 1554], ["A", 1556], ["preoperative", 1558], ["caloric", 1571], ["deficit", 1579], ["greater", 1587], ["than", 1595], ["75", 1600], ["%", 1602], ["seemed", 1604], ["to", 1611], ["be", 1614], ["a", 1617], ["good", 1619], ["prognostic", 1624], ["factor", 1635], [".", 1641], ["Vestibular", 1643], ["rehabilitation", 1654], ["was", 1669], ["conducted", 1673], ["in", 1683], ["56", 1686], ["%", 1688], ["of", 1690], ["patients", 1693], [".", 1701], ["Starting", 1703], ["it", 1712], ["early", 1715], ["(", 1721], ["<", 1722], ["1", 1723], ["mo", 1725], [")", 1727], ["seemed", 1729], ["to", 1736], ["be", 1739], ["beneficial", 1742], ["for", 1753], ["final", 1757], ["equilibrium", 1763], ["outcome", 1775], [".", 1782], ["VS", 1784], ["microsurgery", 1787], ["provides", 1800], ["good", 1809], ["stability", 1814], ["results", 1824], [".", 1831], ["Some", 1833], ["preoperative", 1838], ["parameters", 1851], ["may", 1862], ["be", 1866], ["predictive", 1869], ["of", 1880], ["worse", 1883], ["or", 1889], ["improved", 1892], ["balance", 1901], ["recovery", 1909], [",", 1917], ["as", 1919], ["is", 1922], ["clinical", 1925], ["status", 1934], ["on", 1941], ["D7", 1944], [".", 1946]]}
{"context": "The literature suggests that the d -dimer is useful in patients suspected of having pulmonary embolism and who have a low pretest probability of disease. A previously defined clinical decision rule, the Wells Criteria, may provide a reliable and reproducible means of determining this pretest probability. We evaluate the interrater agreement and external validity of Wells Criteria in determining pretest probability in patients suspected of having pulmonary embolism. This was a prospective observational study. Trained research assistants enrolled patients during 120 random 8-hour shifts. Patients who underwent imaging for pulmonary embolism after a medical history, physical examination, and chest radiograph were enrolled. Treating providers and research assistants determined pretest probability according to Wells Criteria in a blinded fashion. Two d -dimer assays were run. Three-month follow-up for the diagnosis of pulmonary embolism was performed. Interrater agreement tables were created. kappa Values, sensitivities, and specificities were determined. Of the 153 eligible patients, 3 patients were missed, 16 patients declined, and 134 (88%) patients were enrolled. Sixteen (12%) patients were diagnosed with pulmonary embolism. The kappa values for Wells Criteria were 0.54 and 0.72 for the trichotomized and dichotomized scorings, respectively. When Wells Criteria were trichotomized into low pretest probability (n=59, 44%), moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism prevalence was 2%, 15%, and 43%, respectively. When Wells Criteria were dichotomized into pulmonary embolism-unlikely (n=88, 66%) or pulmonary embolism-likely (n=46, 34%), the prevalence was 3% and 28%, respectively. The immunoturbidimetric and rapid enzyme-linked immunosorbent assay d -dimer assays had similar sensitivities (94%) and specificities (45% versus 46%). Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism.", "qas": [{"question": "What can be predicted with the Wells criteria?", "answers": ["pulmonary embolism"], "qid": "28e8fe6709904ff19ee941b716a6183e", "question_tokens": [["What", 0], ["can", 5], ["be", 9], ["predicted", 12], ["with", 22], ["the", 27], ["Wells", 31], ["criteria", 37], ["?", 45]], "detected_answers": [{"text": "pulmonary embolism", "token_spans": [[96, 97], [70, 71], [294, 295], [261, 262], [364, 365], [201, 202], [14, 15], [146, 147], [283, 284]], "char_spans": [[628, 645], [450, 467], [1682, 1699], [1530, 1547], [2059, 2076], [1224, 1241], [84, 101], [927, 944], [1639, 1656]]}]}], "context_tokens": [["The", 0], ["literature", 4], ["suggests", 15], ["that", 24], ["the", 29], ["d", 33], ["-dimer", 35], ["is", 42], ["useful", 45], ["in", 52], ["patients", 55], ["suspected", 64], ["of", 74], ["having", 77], ["pulmonary", 84], ["embolism", 94], ["and", 103], ["who", 107], ["have", 111], ["a", 116], ["low", 118], ["pretest", 122], ["probability", 130], ["of", 142], ["disease", 145], [".", 152], ["A", 154], ["previously", 156], ["defined", 167], ["clinical", 175], ["decision", 184], ["rule", 193], [",", 197], ["the", 199], ["Wells", 203], ["Criteria", 209], [",", 217], ["may", 219], ["provide", 223], ["a", 231], ["reliable", 233], ["and", 242], ["reproducible", 246], ["means", 259], ["of", 265], ["determining", 268], ["this", 280], ["pretest", 285], ["probability", 293], [".", 304], ["We", 306], ["evaluate", 309], ["the", 318], ["interrater", 322], ["agreement", 333], ["and", 343], ["external", 347], ["validity", 356], ["of", 365], ["Wells", 368], ["Criteria", 374], ["in", 383], ["determining", 386], ["pretest", 398], ["probability", 406], ["in", 418], ["patients", 421], ["suspected", 430], ["of", 440], ["having", 443], ["pulmonary", 450], ["embolism", 460], [".", 468], ["This", 470], ["was", 475], ["a", 479], ["prospective", 481], ["observational", 493], ["study", 507], [".", 512], ["Trained", 514], ["research", 522], ["assistants", 531], ["enrolled", 542], ["patients", 551], ["during", 560], ["120", 567], ["random", 571], ["8-hour", 578], ["shifts", 585], [".", 591], ["Patients", 593], ["who", 602], ["underwent", 606], ["imaging", 616], ["for", 624], ["pulmonary", 628], ["embolism", 638], ["after", 647], ["a", 653], ["medical", 655], ["history", 663], [",", 670], ["physical", 672], ["examination", 681], [",", 692], ["and", 694], ["chest", 698], ["radiograph", 704], ["were", 715], ["enrolled", 720], [".", 728], ["Treating", 730], ["providers", 739], ["and", 749], ["research", 753], ["assistants", 762], ["determined", 773], ["pretest", 784], ["probability", 792], ["according", 804], ["to", 814], ["Wells", 817], ["Criteria", 823], ["in", 832], ["a", 835], ["blinded", 837], ["fashion", 845], [".", 852], ["Two", 854], ["d", 858], ["-dimer", 860], ["assays", 867], ["were", 874], ["run", 879], [".", 882], ["Three", 884], ["-", 889], ["month", 890], ["follow", 896], ["-", 902], ["up", 903], ["for", 906], ["the", 910], ["diagnosis", 914], ["of", 924], ["pulmonary", 927], ["embolism", 937], ["was", 946], ["performed", 950], [".", 959], ["Interrater", 961], ["agreement", 972], ["tables", 982], ["were", 989], ["created", 994], [".", 1001], ["kappa", 1003], ["Values", 1009], [",", 1015], ["sensitivities", 1017], [",", 1030], ["and", 1032], ["specificities", 1036], ["were", 1050], ["determined", 1055], [".", 1065], ["Of", 1067], ["the", 1070], ["153", 1074], ["eligible", 1078], ["patients", 1087], [",", 1095], ["3", 1097], ["patients", 1099], ["were", 1108], ["missed", 1113], [",", 1119], ["16", 1121], ["patients", 1124], ["declined", 1133], [",", 1141], ["and", 1143], ["134", 1147], ["(", 1151], ["88", 1152], ["%", 1154], [")", 1155], ["patients", 1157], ["were", 1166], ["enrolled", 1171], [".", 1179], ["Sixteen", 1181], ["(", 1189], ["12", 1190], ["%", 1192], [")", 1193], ["patients", 1195], ["were", 1204], ["diagnosed", 1209], ["with", 1219], ["pulmonary", 1224], ["embolism", 1234], [".", 1242], ["The", 1244], ["kappa", 1248], ["values", 1254], ["for", 1261], ["Wells", 1265], ["Criteria", 1271], ["were", 1280], ["0.54", 1285], ["and", 1290], ["0.72", 1294], ["for", 1299], ["the", 1303], ["trichotomized", 1307], ["and", 1321], ["dichotomized", 1325], ["scorings", 1338], [",", 1346], ["respectively", 1348], [".", 1360], ["When", 1362], ["Wells", 1367], ["Criteria", 1373], ["were", 1382], ["trichotomized", 1387], ["into", 1401], ["low", 1406], ["pretest", 1410], ["probability", 1418], ["(", 1430], ["n=59", 1431], [",", 1435], ["44", 1437], ["%", 1439], [")", 1440], [",", 1441], ["moderate", 1443], ["pretest", 1452], ["probability", 1460], ["(", 1472], ["n=61", 1473], [",", 1477], ["46", 1479], ["%", 1481], [")", 1482], [",", 1483], ["or", 1485], ["high", 1488], ["pretest", 1493], ["probability", 1501], ["(", 1513], ["n=14", 1514], [",", 1518], ["10", 1520], ["%", 1522], [")", 1523], [",", 1524], ["the", 1526], ["pulmonary", 1530], ["embolism", 1540], ["prevalence", 1549], ["was", 1560], ["2", 1564], ["%", 1565], [",", 1566], ["15", 1568], ["%", 1570], [",", 1571], ["and", 1573], ["43", 1577], ["%", 1579], [",", 1580], ["respectively", 1582], [".", 1594], ["When", 1596], ["Wells", 1601], ["Criteria", 1607], ["were", 1616], ["dichotomized", 1621], ["into", 1634], ["pulmonary", 1639], ["embolism", 1649], ["-", 1657], ["unlikely", 1658], ["(", 1667], ["n=88", 1668], [",", 1672], ["66", 1674], ["%", 1676], [")", 1677], ["or", 1679], ["pulmonary", 1682], ["embolism", 1692], ["-", 1700], ["likely", 1701], ["(", 1708], ["n=46", 1709], [",", 1713], ["34", 1715], ["%", 1717], [")", 1718], [",", 1719], ["the", 1721], ["prevalence", 1725], ["was", 1736], ["3", 1740], ["%", 1741], ["and", 1743], ["28", 1747], ["%", 1749], [",", 1750], ["respectively", 1752], [".", 1764], ["The", 1766], ["immunoturbidimetric", 1770], ["and", 1790], ["rapid", 1794], ["enzyme", 1800], ["-", 1806], ["linked", 1807], ["immunosorbent", 1814], ["assay", 1828], ["d", 1834], ["-dimer", 1836], ["assays", 1843], ["had", 1850], ["similar", 1854], ["sensitivities", 1862], ["(", 1876], ["94", 1877], ["%", 1879], [")", 1880], ["and", 1882], ["specificities", 1886], ["(", 1900], ["45", 1901], ["%", 1903], ["versus", 1905], ["46", 1912], ["%", 1914], [")", 1915], [".", 1916], ["Wells", 1918], ["Criteria", 1924], ["have", 1933], ["a", 1938], ["moderate", 1940], ["to", 1949], ["substantial", 1952], ["interrater", 1964], ["agreement", 1975], ["and", 1985], ["reliably", 1989], ["risk", 1998], ["stratify", 2003], ["pretest", 2012], ["probability", 2020], ["in", 2032], ["patients", 2035], ["with", 2044], ["suspected", 2049], ["pulmonary", 2059], ["embolism", 2069], [".", 2077]]}
{"context": "We have recently shown that the Na(+)/Ca(2+) exchanger (NCX) is involved in nitric oxide (NO)-induced cytotoxicity in cultured astrocytes and neurons. However, there is no in vivo evidence suggesting the role of NCX in neurodegenerative disorders associated with NO. NO is implicated in the pathogenesis of neurodegenerative disorders such as Parkinson's disease. This study examined the effect of SEA0400, the specific NCX inhibitor, on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity, a model of Parkinson's disease, in C57BL/6J mice. MPTP treatment (10 mg/kg, four times at 2-h intervals) decreased dopamine levels in the midbrain and impaired motor coordination, and these effects were counteracted by S-methylthiocitrulline, a selective neuronal NO synthase inhibitor. SEA0400 protected against the dopaminergic neurotoxicity (determined by dopamine levels in the midbrain and striatum, tyrosine hydroxylase immunoreactivity in the substantia nigra and striatum, striatal dopamine release, and motor deficits) in MPTP-treated mice. SEA0400 had no radical-scavenging activity. SEA0400 did not affect MPTP metabolism and MPTP-induced NO production and microglial activation, while it attenuated MPTP-induced increases in extracellular signal-regulated kinase (ERK) phosphorylation and lipid peroxidation product, thiobarbituric acid reactive substance. These findings suggest that SEA0400 protects against MPTP-induced neurotoxicity probably by blocking ERK phosphorylation and lipid peroxidation which are downstream of NCX-mediated Ca(2+) influx.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "da32f12980d845719c03c2c03494afe1", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[6, 9]], "char_spans": [[32, 53]]}, {"text": "NCX", "token_spans": [[72, 72], [39, 39], [11, 11], [250, 250]], "char_spans": [[420, 422], [212, 214], [56, 58], [1563, 1565]]}]}], "context_tokens": [["We", 0], ["have", 3], ["recently", 8], ["shown", 17], ["that", 23], ["the", 28], ["Na(+)/Ca(2", 32], ["+", 42], [")", 43], ["exchanger", 45], ["(", 55], ["NCX", 56], [")", 59], ["is", 61], ["involved", 64], ["in", 73], ["nitric", 76], ["oxide", 83], ["(", 89], ["NO)-induced", 90], ["cytotoxicity", 102], ["in", 115], ["cultured", 118], ["astrocytes", 127], ["and", 138], ["neurons", 142], [".", 149], ["However", 151], [",", 158], ["there", 160], ["is", 166], ["no", 169], ["in", 172], ["vivo", 175], ["evidence", 180], ["suggesting", 189], ["the", 200], ["role", 204], ["of", 209], ["NCX", 212], ["in", 216], ["neurodegenerative", 219], ["disorders", 237], ["associated", 247], ["with", 258], ["NO", 263], [".", 265], ["NO", 267], ["is", 270], ["implicated", 273], ["in", 284], ["the", 287], ["pathogenesis", 291], ["of", 304], ["neurodegenerative", 307], ["disorders", 325], ["such", 335], ["as", 340], ["Parkinson", 343], ["'s", 352], ["disease", 355], [".", 362], ["This", 364], ["study", 369], ["examined", 375], ["the", 384], ["effect", 388], ["of", 395], ["SEA0400", 398], [",", 405], ["the", 407], ["specific", 411], ["NCX", 420], ["inhibitor", 424], [",", 433], ["on", 435], ["1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", 438], ["(", 483], ["MPTP)-induced", 484], ["dopaminergic", 498], ["neurotoxicity", 511], [",", 524], ["a", 526], ["model", 528], ["of", 534], ["Parkinson", 537], ["'s", 546], ["disease", 549], [",", 556], ["in", 558], ["C57BL/6J", 561], ["mice", 570], [".", 574], ["MPTP", 576], ["treatment", 581], ["(", 591], ["10", 592], ["mg", 595], ["/", 597], ["kg", 598], [",", 600], ["four", 602], ["times", 607], ["at", 613], ["2-h", 616], ["intervals", 620], [")", 629], ["decreased", 631], ["dopamine", 641], ["levels", 650], ["in", 657], ["the", 660], ["midbrain", 664], ["and", 673], ["impaired", 677], ["motor", 686], ["coordination", 692], [",", 704], ["and", 706], ["these", 710], ["effects", 716], ["were", 724], ["counteracted", 729], ["by", 742], ["S", 745], ["-", 746], ["methylthiocitrulline", 747], [",", 767], ["a", 769], ["selective", 771], ["neuronal", 781], ["NO", 790], ["synthase", 793], ["inhibitor", 802], [".", 811], ["SEA0400", 813], ["protected", 821], ["against", 831], ["the", 839], ["dopaminergic", 843], ["neurotoxicity", 856], ["(", 870], ["determined", 871], ["by", 882], ["dopamine", 885], ["levels", 894], ["in", 901], ["the", 904], ["midbrain", 908], ["and", 917], ["striatum", 921], [",", 929], ["tyrosine", 931], ["hydroxylase", 940], ["immunoreactivity", 952], ["in", 969], ["the", 972], ["substantia", 976], ["nigra", 987], ["and", 993], ["striatum", 997], [",", 1005], ["striatal", 1007], ["dopamine", 1016], ["release", 1025], [",", 1032], ["and", 1034], ["motor", 1038], ["deficits", 1044], [")", 1052], ["in", 1054], ["MPTP", 1057], ["-", 1061], ["treated", 1062], ["mice", 1070], [".", 1074], ["SEA0400", 1076], ["had", 1084], ["no", 1088], ["radical", 1091], ["-", 1098], ["scavenging", 1099], ["activity", 1110], [".", 1118], ["SEA0400", 1120], ["did", 1128], ["not", 1132], ["affect", 1136], ["MPTP", 1143], ["metabolism", 1148], ["and", 1159], ["MPTP", 1163], ["-", 1167], ["induced", 1168], ["NO", 1176], ["production", 1179], ["and", 1190], ["microglial", 1194], ["activation", 1205], [",", 1215], ["while", 1217], ["it", 1223], ["attenuated", 1226], ["MPTP", 1237], ["-", 1241], ["induced", 1242], ["increases", 1250], ["in", 1260], ["extracellular", 1263], ["signal", 1277], ["-", 1283], ["regulated", 1284], ["kinase", 1294], ["(", 1301], ["ERK", 1302], [")", 1305], ["phosphorylation", 1307], ["and", 1323], ["lipid", 1327], ["peroxidation", 1333], ["product", 1346], [",", 1353], ["thiobarbituric", 1355], ["acid", 1370], ["reactive", 1375], ["substance", 1384], [".", 1393], ["These", 1395], ["findings", 1401], ["suggest", 1410], ["that", 1418], ["SEA0400", 1423], ["protects", 1431], ["against", 1440], ["MPTP", 1448], ["-", 1452], ["induced", 1453], ["neurotoxicity", 1461], ["probably", 1475], ["by", 1484], ["blocking", 1487], ["ERK", 1496], ["phosphorylation", 1500], ["and", 1516], ["lipid", 1520], ["peroxidation", 1526], ["which", 1539], ["are", 1545], ["downstream", 1549], ["of", 1560], ["NCX", 1563], ["-", 1566], ["mediated", 1567], ["Ca(2", 1576], ["+", 1580], [")", 1581], ["influx", 1583], [".", 1589]]}
{"context": "A significant role for IFN\u03b1 in the pathogenesis of systemic lupus erythematosus is well supported, and clinical trials of anti-IFN\u03b1 monoclonal antibodies are in progress in this disease. In other autoimmune diseases characterized by substantial inflammation and tissue destruction, the role of type I interferons is less clear. Gene expression analysis of peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature similar to but less intense than that seen in patients with lupus. In both of those diseases, presence of the interferon signature has been associated with more significant clinical manifestations. At the same time, evidence supports an anti-inflammatory and beneficial role of IFN\u03b2 locally in the joints of patients with rheumatoid arthritis and in murine arthritis models, and many patients with multiple sclerosis show a clinical response to recombinant IFN\u03b2. As can also be proposed for type I diabetes mellitus, type I interferon appears to contribute to the development of autoimmunity and disease progression in multiple autoimmune diseases, while maintaining some capacity to control established disease - particularly at local sites of inflammation. Recent studies in both rheumatoid arthritis and multiple sclerosis suggest that quantification of type I interferon activity or target gene expression might be informative in predicting responses to distinct classes of therapeutic agents.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "ee9066e593e54642861b2b0705b2a15a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "Interferon signature", "token_spans": [[71, 72], [95, 96]], "char_spans": [[457, 476], [588, 607]]}]}], "context_tokens": [["A", 0], ["significant", 2], ["role", 14], ["for", 19], ["IFN\u03b1", 23], ["in", 28], ["the", 31], ["pathogenesis", 35], ["of", 48], ["systemic", 51], ["lupus", 60], ["erythematosus", 66], ["is", 80], ["well", 83], ["supported", 88], [",", 97], ["and", 99], ["clinical", 103], ["trials", 112], ["of", 119], ["anti", 122], ["-", 126], ["IFN\u03b1", 127], ["monoclonal", 132], ["antibodies", 143], ["are", 154], ["in", 158], ["progress", 161], ["in", 170], ["this", 173], ["disease", 178], [".", 185], ["In", 187], ["other", 190], ["autoimmune", 196], ["diseases", 207], ["characterized", 216], ["by", 230], ["substantial", 233], ["inflammation", 245], ["and", 258], ["tissue", 262], ["destruction", 269], [",", 280], ["the", 282], ["role", 286], ["of", 291], ["type", 294], ["I", 299], ["interferons", 301], ["is", 313], ["less", 316], ["clear", 321], [".", 326], ["Gene", 328], ["expression", 333], ["analysis", 344], ["of", 353], ["peripheral", 356], ["blood", 367], ["cells", 373], ["from", 379], ["patients", 384], ["with", 393], ["rheumatoid", 398], ["arthritis", 409], ["and", 419], ["multiple", 423], ["sclerosis", 432], ["demonstrate", 442], ["an", 454], ["interferon", 457], ["signature", 468], ["similar", 478], ["to", 486], ["but", 489], ["less", 493], ["intense", 498], ["than", 506], ["that", 511], ["seen", 516], ["in", 521], ["patients", 524], ["with", 533], ["lupus", 538], [".", 543], ["In", 545], ["both", 548], ["of", 553], ["those", 556], ["diseases", 562], [",", 570], ["presence", 572], ["of", 581], ["the", 584], ["interferon", 588], ["signature", 599], ["has", 609], ["been", 613], ["associated", 618], ["with", 629], ["more", 634], ["significant", 639], ["clinical", 651], ["manifestations", 660], [".", 674], ["At", 676], ["the", 679], ["same", 683], ["time", 688], [",", 692], ["evidence", 694], ["supports", 703], ["an", 712], ["anti", 715], ["-", 719], ["inflammatory", 720], ["and", 733], ["beneficial", 737], ["role", 748], ["of", 753], ["IFN\u03b2", 756], ["locally", 761], ["in", 769], ["the", 772], ["joints", 776], ["of", 783], ["patients", 786], ["with", 795], ["rheumatoid", 800], ["arthritis", 811], ["and", 821], ["in", 825], ["murine", 828], ["arthritis", 835], ["models", 845], [",", 851], ["and", 853], ["many", 857], ["patients", 862], ["with", 871], ["multiple", 876], ["sclerosis", 885], ["show", 895], ["a", 900], ["clinical", 902], ["response", 911], ["to", 920], ["recombinant", 923], ["IFN\u03b2", 935], [".", 939], ["As", 941], ["can", 944], ["also", 948], ["be", 953], ["proposed", 956], ["for", 965], ["type", 969], ["I", 974], ["diabetes", 976], ["mellitus", 985], [",", 993], ["type", 995], ["I", 1000], ["interferon", 1002], ["appears", 1013], ["to", 1021], ["contribute", 1024], ["to", 1035], ["the", 1038], ["development", 1042], ["of", 1054], ["autoimmunity", 1057], ["and", 1070], ["disease", 1074], ["progression", 1082], ["in", 1094], ["multiple", 1097], ["autoimmune", 1106], ["diseases", 1117], [",", 1125], ["while", 1127], ["maintaining", 1133], ["some", 1145], ["capacity", 1150], ["to", 1159], ["control", 1162], ["established", 1170], ["disease", 1182], ["-", 1190], ["particularly", 1192], ["at", 1205], ["local", 1208], ["sites", 1214], ["of", 1220], ["inflammation", 1223], [".", 1235], ["Recent", 1237], ["studies", 1244], ["in", 1252], ["both", 1255], ["rheumatoid", 1260], ["arthritis", 1271], ["and", 1281], ["multiple", 1285], ["sclerosis", 1294], ["suggest", 1304], ["that", 1312], ["quantification", 1317], ["of", 1332], ["type", 1335], ["I", 1340], ["interferon", 1342], ["activity", 1353], ["or", 1362], ["target", 1365], ["gene", 1372], ["expression", 1377], ["might", 1388], ["be", 1394], ["informative", 1397], ["in", 1409], ["predicting", 1412], ["responses", 1423], ["to", 1433], ["distinct", 1436], ["classes", 1445], ["of", 1453], ["therapeutic", 1456], ["agents", 1468], [".", 1474]]}
{"context": "The worldwide expansion in the use of benzodiazepines has led to their frequent, and often inappropriate, use and to increase in their involvement in self-induced poisoning and iatrogenic overdosing. Flumazenil is a specific and competitive antagonist at the central benzodiazepine receptor, reversing all effects of benzodiazepine agonists without tranquillising or anticonvulsant actions. Incremental intravenous bolus injections of flumazenil 0.1 to 0.3 mg are the most effective and well tolerated in the diagnosis and treatment of pure benzodiazepine overdose; additional boluses or an infusion (0.3 to 0.5 mg/h) can be given to prevent patients from relapsing into coma. Intravenous flumazenil 10 to 20 micrograms/kg is effective in neonates and small children. Intramuscular, oral (20 to 25 mg 3 times daily or as required) and rectal administration may be used as alternatives in long term regimens. Patients with mixed-drug overdose require higher doses (up to 2 mg bolus, approximately equal to 1 mg/h infusion) to regain consciousness. Children and the elderly, chronically ill patients, and pregnant women and their fetuses all respond satisfactorily to flumazenil, but the usefulness of the drug in patients with hepatic encephalopathy and alcohol overdose is debatable. The use of flumazenil results in complete awakening with restoration of upper airway protective reflexes, thus enabling gastric lavage to be performed and transfer of the patient from the emergency room to another hospital department. Resumption of effective spontaneous respiration allows for expeditious extubation, weaning off mechanical ventilation or the avoidance of endotracheal intubation. While flumazenil is not associated with haemodynamic adverse effects, caution should be exercised when using this agent in patients who have co-ingested chloral hydrate to carbamazepine or whose ECG shows abnormalities typical to those seen after overdose with tricyclic antidepressants (TCAs); the use of flumazenil in the presence of these drugs can sometimes induce treatable cardiac dysrrhythmia. Flumazenil per se does not induce adverse effects. Coma reversal by flumazenil may cause mild, short-lived reactions caused by sudden awakening. Withdrawal symptoms in long term benzodiazepine users and seizures in patients who have taken an overdose of TCA or carbamazepine and a benzodiazepine can occur with flumazenil; these symptoms are avoidable by utilising slow flumazenil dose titration.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "369cc5a5643045aebe426287af31c52b", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[64, 64], [224, 224], [355, 355], [395, 395], [202, 202], [404, 404], [329, 329], [343, 343], [280, 280], [34, 34], [111, 111]], "char_spans": [[435, 444], [1295, 1304], [2151, 2160], [2394, 2403], [1166, 1175], [2453, 2462], [1988, 1997], [2083, 2092], [1688, 1697], [200, 209], [689, 698]]}]}], "context_tokens": [["The", 0], ["worldwide", 4], ["expansion", 14], ["in", 24], ["the", 27], ["use", 31], ["of", 35], ["benzodiazepines", 38], ["has", 54], ["led", 58], ["to", 62], ["their", 65], ["frequent", 71], [",", 79], ["and", 81], ["often", 85], ["inappropriate", 91], [",", 104], ["use", 106], ["and", 110], ["to", 114], ["increase", 117], ["in", 126], ["their", 129], ["involvement", 135], ["in", 147], ["self", 150], ["-", 154], ["induced", 155], ["poisoning", 163], ["and", 173], ["iatrogenic", 177], ["overdosing", 188], [".", 198], ["Flumazenil", 200], ["is", 211], ["a", 214], ["specific", 216], ["and", 225], ["competitive", 229], ["antagonist", 241], ["at", 252], ["the", 255], ["central", 259], ["benzodiazepine", 267], ["receptor", 282], [",", 290], ["reversing", 292], ["all", 302], ["effects", 306], ["of", 314], ["benzodiazepine", 317], ["agonists", 332], ["without", 341], ["tranquillising", 349], ["or", 364], ["anticonvulsant", 367], ["actions", 382], [".", 389], ["Incremental", 391], ["intravenous", 403], ["bolus", 415], ["injections", 421], ["of", 432], ["flumazenil", 435], ["0.1", 446], ["to", 450], ["0.3", 453], ["mg", 457], ["are", 460], ["the", 464], ["most", 468], ["effective", 473], ["and", 483], ["well", 487], ["tolerated", 492], ["in", 502], ["the", 505], ["diagnosis", 509], ["and", 519], ["treatment", 523], ["of", 533], ["pure", 536], ["benzodiazepine", 541], ["overdose", 556], [";", 564], ["additional", 566], ["boluses", 577], ["or", 585], ["an", 588], ["infusion", 591], ["(", 600], ["0.3", 601], ["to", 605], ["0.5", 608], ["mg", 612], ["/", 614], ["h", 615], [")", 616], ["can", 618], ["be", 622], ["given", 625], ["to", 631], ["prevent", 634], ["patients", 642], ["from", 651], ["relapsing", 656], ["into", 666], ["coma", 671], [".", 675], ["Intravenous", 677], ["flumazenil", 689], ["10", 700], ["to", 703], ["20", 706], ["micrograms", 709], ["/", 719], ["kg", 720], ["is", 723], ["effective", 726], ["in", 736], ["neonates", 739], ["and", 748], ["small", 752], ["children", 758], [".", 766], ["Intramuscular", 768], [",", 781], ["oral", 783], ["(", 788], ["20", 789], ["to", 792], ["25", 795], ["mg", 798], ["3", 801], ["times", 803], ["daily", 809], ["or", 815], ["as", 818], ["required", 821], [")", 829], ["and", 831], ["rectal", 835], ["administration", 842], ["may", 857], ["be", 861], ["used", 864], ["as", 869], ["alternatives", 872], ["in", 885], ["long", 888], ["term", 893], ["regimens", 898], [".", 906], ["Patients", 908], ["with", 917], ["mixed", 922], ["-", 927], ["drug", 928], ["overdose", 933], ["require", 942], ["higher", 950], ["doses", 957], ["(", 963], ["up", 964], ["to", 967], ["2", 970], ["mg", 972], ["bolus", 975], [",", 980], ["approximately", 982], ["equal", 996], ["to", 1002], ["1", 1005], ["mg", 1007], ["/", 1009], ["h", 1010], ["infusion", 1012], [")", 1020], ["to", 1022], ["regain", 1025], ["consciousness", 1032], [".", 1045], ["Children", 1047], ["and", 1056], ["the", 1060], ["elderly", 1064], [",", 1071], ["chronically", 1073], ["ill", 1085], ["patients", 1089], [",", 1097], ["and", 1099], ["pregnant", 1103], ["women", 1112], ["and", 1118], ["their", 1122], ["fetuses", 1128], ["all", 1136], ["respond", 1140], ["satisfactorily", 1148], ["to", 1163], ["flumazenil", 1166], [",", 1176], ["but", 1178], ["the", 1182], ["usefulness", 1186], ["of", 1197], ["the", 1200], ["drug", 1204], ["in", 1209], ["patients", 1212], ["with", 1221], ["hepatic", 1226], ["encephalopathy", 1234], ["and", 1249], ["alcohol", 1253], ["overdose", 1261], ["is", 1270], ["debatable", 1273], [".", 1282], ["The", 1284], ["use", 1288], ["of", 1292], ["flumazenil", 1295], ["results", 1306], ["in", 1314], ["complete", 1317], ["awakening", 1326], ["with", 1336], ["restoration", 1341], ["of", 1353], ["upper", 1356], ["airway", 1362], ["protective", 1369], ["reflexes", 1380], [",", 1388], ["thus", 1390], ["enabling", 1395], ["gastric", 1404], ["lavage", 1412], ["to", 1419], ["be", 1422], ["performed", 1425], ["and", 1435], ["transfer", 1439], ["of", 1448], ["the", 1451], ["patient", 1455], ["from", 1463], ["the", 1468], ["emergency", 1472], ["room", 1482], ["to", 1487], ["another", 1490], ["hospital", 1498], ["department", 1507], [".", 1517], ["Resumption", 1519], ["of", 1530], ["effective", 1533], ["spontaneous", 1543], ["respiration", 1555], ["allows", 1567], ["for", 1574], ["expeditious", 1578], ["extubation", 1590], [",", 1600], ["weaning", 1602], ["off", 1610], ["mechanical", 1614], ["ventilation", 1625], ["or", 1637], ["the", 1640], ["avoidance", 1644], ["of", 1654], ["endotracheal", 1657], ["intubation", 1670], [".", 1680], ["While", 1682], ["flumazenil", 1688], ["is", 1699], ["not", 1702], ["associated", 1706], ["with", 1717], ["haemodynamic", 1722], ["adverse", 1735], ["effects", 1743], [",", 1750], ["caution", 1752], ["should", 1760], ["be", 1767], ["exercised", 1770], ["when", 1780], ["using", 1785], ["this", 1791], ["agent", 1796], ["in", 1802], ["patients", 1805], ["who", 1814], ["have", 1818], ["co", 1823], ["-", 1825], ["ingested", 1826], ["chloral", 1835], ["hydrate", 1843], ["to", 1851], ["carbamazepine", 1854], ["or", 1868], ["whose", 1871], ["ECG", 1877], ["shows", 1881], ["abnormalities", 1887], ["typical", 1901], ["to", 1909], ["those", 1912], ["seen", 1918], ["after", 1923], ["overdose", 1929], ["with", 1938], ["tricyclic", 1943], ["antidepressants", 1953], ["(", 1969], ["TCAs", 1970], [")", 1974], [";", 1975], ["the", 1977], ["use", 1981], ["of", 1985], ["flumazenil", 1988], ["in", 1999], ["the", 2002], ["presence", 2006], ["of", 2015], ["these", 2018], ["drugs", 2024], ["can", 2030], ["sometimes", 2034], ["induce", 2044], ["treatable", 2051], ["cardiac", 2061], ["dysrrhythmia", 2069], [".", 2081], ["Flumazenil", 2083], ["per", 2094], ["se", 2098], ["does", 2101], ["not", 2106], ["induce", 2110], ["adverse", 2117], ["effects", 2125], [".", 2132], ["Coma", 2134], ["reversal", 2139], ["by", 2148], ["flumazenil", 2151], ["may", 2162], ["cause", 2166], ["mild", 2172], [",", 2176], ["short", 2178], ["-", 2183], ["lived", 2184], ["reactions", 2190], ["caused", 2200], ["by", 2207], ["sudden", 2210], ["awakening", 2217], [".", 2226], ["Withdrawal", 2228], ["symptoms", 2239], ["in", 2248], ["long", 2251], ["term", 2256], ["benzodiazepine", 2261], ["users", 2276], ["and", 2282], ["seizures", 2286], ["in", 2295], ["patients", 2298], ["who", 2307], ["have", 2311], ["taken", 2316], ["an", 2322], ["overdose", 2325], ["of", 2334], ["TCA", 2337], ["or", 2341], ["carbamazepine", 2344], ["and", 2358], ["a", 2362], ["benzodiazepine", 2364], ["can", 2379], ["occur", 2383], ["with", 2389], ["flumazenil", 2394], [";", 2404], ["these", 2406], ["symptoms", 2412], ["are", 2421], ["avoidable", 2425], ["by", 2435], ["utilising", 2438], ["slow", 2448], ["flumazenil", 2453], ["dose", 2464], ["titration", 2469], [".", 2478]]}
{"context": "Purpose To determine the frequency of, and yield after, provider overrides of evidence-based clinical decision support (CDS) for ordering computed tomographic (CT) pulmonary angiography in the emergency department (ED). Materials and Methods This HIPAA-compliant, institutional review board-approved study was performed at a tertiary care, academic medical center ED with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism (PE) and who underwent CT pulmonary angiography between January 1, 2011, and August 31, 2013. The requirement to obtain informed consent was waived. Each CT order for pulmonary angiography was exposed to CDS on the basis of the Wells criteria. For patients with a Wells score of 4 or less, CDS alerts suggested d-dimer testing because acute PE is highly unlikely in these patients if d-dimer levels are normal. The yield of CT pulmonary angiography (number of positive PE diagnoses/total number of CT pulmonary angiographic examinations) was compared in patients in whom providers overrode CDS alerts (by performing CT pulmonary angiography in patients with a Wells score \u22644 and a normal d-dimer level or no d-dimer testing) (override group) and those in whom providers followed Wells criteria (CT pulmonary angiography only in patients with Wells score >4 or \u22644 with elevated d-dimer level) (adherent group). A validated natural language processing tool identified positive PE diagnoses, with subsegmental and/or indeterminate diagnoses removed by means of chart review. Statistical analysis was performed with the \u03c7", "qas": [{"question": "What can be predicted with the Wells criteria?", "answers": ["pulmonary embolism"], "qid": "0e98ec9fa2fc434f89b5688800607a86", "question_tokens": [["What", 0], ["can", 5], ["be", 9], ["predicted", 12], ["with", 22], ["the", 27], ["Wells", 31], ["criteria", 37], ["?", 45]], "detected_answers": [{"text": "pulmonary embolism", "token_spans": [[80, 81]], "char_spans": [[462, 479]]}]}], "context_tokens": [["Purpose", 0], ["To", 8], ["determine", 11], ["the", 21], ["frequency", 25], ["of", 35], [",", 37], ["and", 39], ["yield", 43], ["after", 49], [",", 54], ["provider", 56], ["overrides", 65], ["of", 75], ["evidence", 78], ["-", 86], ["based", 87], ["clinical", 93], ["decision", 102], ["support", 111], ["(", 119], ["CDS", 120], [")", 123], ["for", 125], ["ordering", 129], ["computed", 138], ["tomographic", 147], ["(", 159], ["CT", 160], [")", 162], ["pulmonary", 164], ["angiography", 174], ["in", 186], ["the", 189], ["emergency", 193], ["department", 203], ["(", 214], ["ED", 215], [")", 217], [".", 218], ["Materials", 220], ["and", 230], ["Methods", 234], ["This", 242], ["HIPAA", 247], ["-", 252], ["compliant", 253], [",", 262], ["institutional", 264], ["review", 278], ["board", 285], ["-", 290], ["approved", 291], ["study", 300], ["was", 306], ["performed", 310], ["at", 320], ["a", 323], ["tertiary", 325], ["care", 334], [",", 338], ["academic", 340], ["medical", 349], ["center", 357], ["ED", 364], ["with", 367], ["approximately", 372], ["60", 386], ["000", 389], ["annual", 393], ["visits", 400], ["and", 407], ["included", 411], ["all", 420], ["patients", 424], ["who", 433], ["were", 437], ["suspected", 442], ["of", 452], ["having", 455], ["pulmonary", 462], ["embolism", 472], ["(", 481], ["PE", 482], [")", 484], ["and", 486], ["who", 490], ["underwent", 494], ["CT", 504], ["pulmonary", 507], ["angiography", 517], ["between", 529], ["January", 537], ["1", 545], [",", 546], ["2011", 548], [",", 552], ["and", 554], ["August", 558], ["31", 565], [",", 567], ["2013", 569], [".", 573], ["The", 575], ["requirement", 579], ["to", 591], ["obtain", 594], ["informed", 601], ["consent", 610], ["was", 618], ["waived", 622], [".", 628], ["Each", 630], ["CT", 635], ["order", 638], ["for", 644], ["pulmonary", 648], ["angiography", 658], ["was", 670], ["exposed", 674], ["to", 682], ["CDS", 685], ["on", 689], ["the", 692], ["basis", 696], ["of", 702], ["the", 705], ["Wells", 709], ["criteria", 715], [".", 723], ["For", 725], ["patients", 729], ["with", 738], ["a", 743], ["Wells", 745], ["score", 751], ["of", 757], ["4", 760], ["or", 762], ["less", 765], [",", 769], ["CDS", 771], ["alerts", 775], ["suggested", 782], ["d", 792], ["-", 793], ["dimer", 794], ["testing", 800], ["because", 808], ["acute", 816], ["PE", 822], ["is", 825], ["highly", 828], ["unlikely", 835], ["in", 844], ["these", 847], ["patients", 853], ["if", 862], ["d", 865], ["-", 866], ["dimer", 867], ["levels", 873], ["are", 880], ["normal", 884], [".", 890], ["The", 892], ["yield", 896], ["of", 902], ["CT", 905], ["pulmonary", 908], ["angiography", 918], ["(", 930], ["number", 931], ["of", 938], ["positive", 941], ["PE", 950], ["diagnoses", 953], ["/", 962], ["total", 963], ["number", 969], ["of", 976], ["CT", 979], ["pulmonary", 982], ["angiographic", 992], ["examinations", 1005], [")", 1017], ["was", 1019], ["compared", 1023], ["in", 1032], ["patients", 1035], ["in", 1044], ["whom", 1047], ["providers", 1052], ["overrode", 1062], ["CDS", 1071], ["alerts", 1075], ["(", 1082], ["by", 1083], ["performing", 1086], ["CT", 1097], ["pulmonary", 1100], ["angiography", 1110], ["in", 1122], ["patients", 1125], ["with", 1134], ["a", 1139], ["Wells", 1141], ["score", 1147], ["\u22644", 1153], ["and", 1156], ["a", 1160], ["normal", 1162], ["d", 1169], ["-", 1170], ["dimer", 1171], ["level", 1177], ["or", 1183], ["no", 1186], ["d", 1189], ["-", 1190], ["dimer", 1191], ["testing", 1197], [")", 1204], ["(", 1206], ["override", 1207], ["group", 1216], [")", 1221], ["and", 1223], ["those", 1227], ["in", 1233], ["whom", 1236], ["providers", 1241], ["followed", 1251], ["Wells", 1260], ["criteria", 1266], ["(", 1275], ["CT", 1276], ["pulmonary", 1279], ["angiography", 1289], ["only", 1301], ["in", 1306], ["patients", 1309], ["with", 1318], ["Wells", 1323], ["score", 1329], [">", 1335], ["4", 1336], ["or", 1338], ["\u22644", 1341], ["with", 1344], ["elevated", 1349], ["d", 1358], ["-", 1359], ["dimer", 1360], ["level", 1366], [")", 1371], ["(", 1373], ["adherent", 1374], ["group", 1383], [")", 1388], [".", 1389], ["A", 1391], ["validated", 1393], ["natural", 1403], ["language", 1411], ["processing", 1420], ["tool", 1431], ["identified", 1436], ["positive", 1447], ["PE", 1456], ["diagnoses", 1459], [",", 1468], ["with", 1470], ["subsegmental", 1475], ["and/or", 1488], ["indeterminate", 1495], ["diagnoses", 1509], ["removed", 1519], ["by", 1527], ["means", 1530], ["of", 1536], ["chart", 1539], ["review", 1545], [".", 1551], ["Statistical", 1553], ["analysis", 1565], ["was", 1574], ["performed", 1578], ["with", 1588], ["the", 1593], ["\u03c7", 1597]]}
{"context": "Chronic myeloid leukemia (CML) is a pluripotent hematopoietic disorder that is currently considered incurable. The tyrosine kinase product of the Philadelphia chromosome, P210 BCR-ABL, provided a pathogenetic explanation for the initiation of the CML chronic phase and is the molecular therapeutic target for the disease. Imatinib mesylate, an orally available BCR-ABL kinase inhibitor, can induce haematologic and cytogenetic remission of CML. However, imatinib resistance occurs frequently, resulting in relapse. New treatment strategies are focusing on resistant CML stem cells and the bone marrow stroma. The identification of novel pathways and mechanisms in the bone marrow microenvironment could significantly contribute to the development of such strategies. In this work, we used a high-resolution label-free MS(E)  proteomic approach to identify differential protein expression in the CML bone marrow plasma of responsive and resistant patients. Oxidative lipid metabolism and regulation of the switch from canonical to noncanonical WNT signaling may contribute to CML resistance in the bone marrow compartment.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "c3ce02b73a0e40788ece57c69b7aafc1", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[59, 61], [27, 29]], "char_spans": [[361, 367], [176, 182]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["pluripotent", 36], ["hematopoietic", 48], ["disorder", 62], ["that", 71], ["is", 76], ["currently", 79], ["considered", 89], ["incurable", 100], [".", 109], ["The", 111], ["tyrosine", 115], ["kinase", 124], ["product", 131], ["of", 139], ["the", 142], ["Philadelphia", 146], ["chromosome", 159], [",", 169], ["P210", 171], ["BCR", 176], ["-", 179], ["ABL", 180], [",", 183], ["provided", 185], ["a", 194], ["pathogenetic", 196], ["explanation", 209], ["for", 221], ["the", 225], ["initiation", 229], ["of", 240], ["the", 243], ["CML", 247], ["chronic", 251], ["phase", 259], ["and", 265], ["is", 269], ["the", 272], ["molecular", 276], ["therapeutic", 286], ["target", 298], ["for", 305], ["the", 309], ["disease", 313], [".", 320], ["Imatinib", 322], ["mesylate", 331], [",", 339], ["an", 341], ["orally", 344], ["available", 351], ["BCR", 361], ["-", 364], ["ABL", 365], ["kinase", 369], ["inhibitor", 376], [",", 385], ["can", 387], ["induce", 391], ["haematologic", 398], ["and", 411], ["cytogenetic", 415], ["remission", 427], ["of", 437], ["CML", 440], [".", 443], ["However", 445], [",", 452], ["imatinib", 454], ["resistance", 463], ["occurs", 474], ["frequently", 481], [",", 491], ["resulting", 493], ["in", 503], ["relapse", 506], [".", 513], ["New", 515], ["treatment", 519], ["strategies", 529], ["are", 540], ["focusing", 544], ["on", 553], ["resistant", 556], ["CML", 566], ["stem", 570], ["cells", 575], ["and", 581], ["the", 585], ["bone", 589], ["marrow", 594], ["stroma", 601], [".", 607], ["The", 609], ["identification", 613], ["of", 628], ["novel", 631], ["pathways", 637], ["and", 646], ["mechanisms", 650], ["in", 661], ["the", 664], ["bone", 668], ["marrow", 673], ["microenvironment", 680], ["could", 697], ["significantly", 703], ["contribute", 717], ["to", 728], ["the", 731], ["development", 735], ["of", 747], ["such", 750], ["strategies", 755], [".", 765], ["In", 767], ["this", 770], ["work", 775], [",", 779], ["we", 781], ["used", 784], ["a", 789], ["high", 791], ["-", 795], ["resolution", 796], ["label", 807], ["-", 812], ["free", 813], ["MS(E", 818], [")", 822], ["proteomic", 825], ["approach", 835], ["to", 844], ["identify", 847], ["differential", 856], ["protein", 869], ["expression", 877], ["in", 888], ["the", 891], ["CML", 895], ["bone", 899], ["marrow", 904], ["plasma", 911], ["of", 918], ["responsive", 921], ["and", 932], ["resistant", 936], ["patients", 946], [".", 954], ["Oxidative", 956], ["lipid", 966], ["metabolism", 972], ["and", 983], ["regulation", 987], ["of", 998], ["the", 1001], ["switch", 1005], ["from", 1012], ["canonical", 1017], ["to", 1027], ["noncanonical", 1030], ["WNT", 1043], ["signaling", 1047], ["may", 1057], ["contribute", 1061], ["to", 1072], ["CML", 1075], ["resistance", 1079], ["in", 1090], ["the", 1093], ["bone", 1097], ["marrow", 1102], ["compartment", 1109], [".", 1120]]}
{"context": "The product of the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor gene, menin, is an integral component of MLL1/MLL2 histone methyltransferase complexes specific for Lys4 of histone H3 (H3K4). We show that menin is a transcriptional coactivator of the nuclear receptors for estrogen and vitamin D. Activation of the endogenous estrogen-responsive TFF1 (pS2) gene results in promoter recruitment of menin and in elevated trimethylation of H3K4. Knockdown of menin reduces both activated TFF1 (pS2) transcription and H3K4 trimethylation. In addition, menin can directly interact with the estrogen receptor-alpha (ERalpha) in a hormone-dependent manner. The majority of disease-related MEN1 mutations prevent menin-ERalpha interaction. Importantly, ERalpha-interacting mutants are also defective in coactivator function. Our results indicate that menin is a critical link between recruitment of histone methyltransferase complexes and nuclear receptor-mediated transcription.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "70cf419b833d4e9abc7eac1c6be3673c", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[91, 91], [77, 77], [34, 34]], "char_spans": [[528, 531], [451, 454], [199, 202]]}]}], "context_tokens": [["The", 0], ["product", 4], ["of", 12], ["the", 15], ["multiple", 19], ["endocrine", 28], ["neoplasia", 38], ["type", 48], ["1", 53], ["(", 55], ["MEN1", 56], [")", 60], ["tumor", 62], ["suppressor", 68], ["gene", 79], [",", 83], ["menin", 85], [",", 90], ["is", 92], ["an", 95], ["integral", 98], ["component", 107], ["of", 117], ["MLL1/MLL2", 120], ["histone", 130], ["methyltransferase", 138], ["complexes", 156], ["specific", 166], ["for", 175], ["Lys4", 179], ["of", 184], ["histone", 187], ["H3", 195], ["(", 198], ["H3K4", 199], [")", 203], [".", 204], ["We", 206], ["show", 209], ["that", 214], ["menin", 219], ["is", 225], ["a", 228], ["transcriptional", 230], ["coactivator", 246], ["of", 258], ["the", 261], ["nuclear", 265], ["receptors", 273], ["for", 283], ["estrogen", 287], ["and", 296], ["vitamin", 300], ["D.", 308], ["Activation", 311], ["of", 322], ["the", 325], ["endogenous", 329], ["estrogen", 340], ["-", 348], ["responsive", 349], ["TFF1", 360], ["(", 365], ["pS2", 366], [")", 369], ["gene", 371], ["results", 376], ["in", 384], ["promoter", 387], ["recruitment", 396], ["of", 408], ["menin", 411], ["and", 417], ["in", 421], ["elevated", 424], ["trimethylation", 433], ["of", 448], ["H3K4", 451], [".", 455], ["Knockdown", 457], ["of", 467], ["menin", 470], ["reduces", 476], ["both", 484], ["activated", 489], ["TFF1", 499], ["(", 504], ["pS2", 505], [")", 508], ["transcription", 510], ["and", 524], ["H3K4", 528], ["trimethylation", 533], [".", 547], ["In", 549], ["addition", 552], [",", 560], ["menin", 562], ["can", 568], ["directly", 572], ["interact", 581], ["with", 590], ["the", 595], ["estrogen", 599], ["receptor", 608], ["-", 616], ["alpha", 617], ["(", 623], ["ERalpha", 624], [")", 631], ["in", 633], ["a", 636], ["hormone", 638], ["-", 645], ["dependent", 646], ["manner", 656], [".", 662], ["The", 664], ["majority", 668], ["of", 677], ["disease", 680], ["-", 687], ["related", 688], ["MEN1", 696], ["mutations", 701], ["prevent", 711], ["menin", 719], ["-", 724], ["ERalpha", 725], ["interaction", 733], [".", 744], ["Importantly", 746], [",", 757], ["ERalpha", 759], ["-", 766], ["interacting", 767], ["mutants", 779], ["are", 787], ["also", 791], ["defective", 796], ["in", 806], ["coactivator", 809], ["function", 821], [".", 829], ["Our", 831], ["results", 835], ["indicate", 843], ["that", 852], ["menin", 857], ["is", 863], ["a", 866], ["critical", 868], ["link", 877], ["between", 882], ["recruitment", 890], ["of", 902], ["histone", 905], ["methyltransferase", 913], ["complexes", 931], ["and", 941], ["nuclear", 945], ["receptor", 953], ["-", 961], ["mediated", 962], ["transcription", 971], [".", 984]]}
{"context": "To determine the appropriate method to calculate the rate of methicillin-resistant Staphylococcus aureus (MRSA) infection and colonization (hereafter, MRSA rates) for interhospital comparisons, such that the large number of patients who are already MRSA positive on admission is taken into account. A prospective, multicenter, hospital-based surveillance of MRSA-positive case patients from January through December 2004. Data from 31 hospitals participating in the German national nosocomial infections surveillance system (KISS) were recorded during routine surveillance by the infection control team at each hospital. Data for 4,215 MRSA-positive case patients were evaluated. From this data, the following values were calculated. The median incidence density was 0.71 MRSA-positive case patients per 1,000 patient-days, and the median nosocomial incidence density was 0.27 patients with nosocomial MRSA infection or colonization per 1,000 patient-days (95% CI, 0.18-0.34). The median average daily MRSA burden was 1.13 MRSA patient-days per 100 patient-days (95% CI, 0.86-1.51), with the average daily MRSA burden defined as the total number of MRSA patient-days divided by the total number of patient-days times 100. The median MRSA-days-associated nosocomial MRSA infection and colonization rate, which describes the MRSA infection risk for other patients in hospitals housing large numbers of MRSA-positive patients and/or many patients who were MRSA positive on admission, was 23.1 cases of nosocomial MRSA infection and colonization per 1,000 MRSA patient-days (95% CI, 17.4-28.6). The values were also calculated for various MRSA screening levels. The MRSA-days-associated nosocomial MRSA rate allows investigators to assess the extent of MRSA colonization and infection at each hospital, taking into account cases that have been imported from other hospitals, as well as from the community. This information provides an appropriate incentive for hospitals to introduce further infection control measures.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "678ea6e0e70c41d294ee49eb162b3e9a", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[16, 16], [208, 208], [173, 173], [272, 272], [262, 262], [299, 299], [253, 253], [60, 60], [177, 177], [241, 241], [319, 319], [128, 128], [304, 304], [24, 24], [150, 150], [278, 278], [310, 310], [41, 41], [104, 104], [200, 200], [232, 232], [226, 226]], "char_spans": [[106, 109], [1149, 1152], [1002, 1005], [1510, 1513], [1453, 1456], [1635, 1638], [1400, 1403], [358, 361], [1023, 1026], [1323, 1326], [1749, 1752], [772, 775], [1662, 1665], [151, 154], [902, 905], [1552, 1555], [1694, 1697], [249, 252], [636, 639], [1106, 1109], [1265, 1268], [1233, 1236]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["appropriate", 17], ["method", 29], ["to", 36], ["calculate", 39], ["the", 49], ["rate", 53], ["of", 58], ["methicillin", 61], ["-", 72], ["resistant", 73], ["Staphylococcus", 83], ["aureus", 98], ["(", 105], ["MRSA", 106], [")", 110], ["infection", 112], ["and", 122], ["colonization", 126], ["(", 139], ["hereafter", 140], [",", 149], ["MRSA", 151], ["rates", 156], [")", 161], ["for", 163], ["interhospital", 167], ["comparisons", 181], [",", 192], ["such", 194], ["that", 199], ["the", 204], ["large", 208], ["number", 214], ["of", 221], ["patients", 224], ["who", 233], ["are", 237], ["already", 241], ["MRSA", 249], ["positive", 254], ["on", 263], ["admission", 266], ["is", 276], ["taken", 279], ["into", 285], ["account", 290], [".", 297], ["A", 299], ["prospective", 301], [",", 312], ["multicenter", 314], [",", 325], ["hospital", 327], ["-", 335], ["based", 336], ["surveillance", 342], ["of", 355], ["MRSA", 358], ["-", 362], ["positive", 363], ["case", 372], ["patients", 377], ["from", 386], ["January", 391], ["through", 399], ["December", 407], ["2004", 416], [".", 420], ["Data", 422], ["from", 427], ["31", 432], ["hospitals", 435], ["participating", 445], ["in", 459], ["the", 462], ["German", 466], ["national", 473], ["nosocomial", 482], ["infections", 493], ["surveillance", 504], ["system", 517], ["(", 524], ["KISS", 525], [")", 529], ["were", 531], ["recorded", 536], ["during", 545], ["routine", 552], ["surveillance", 560], ["by", 573], ["the", 576], ["infection", 580], ["control", 590], ["team", 598], ["at", 603], ["each", 606], ["hospital", 611], [".", 619], ["Data", 621], ["for", 626], ["4,215", 630], ["MRSA", 636], ["-", 640], ["positive", 641], ["case", 650], ["patients", 655], ["were", 664], ["evaluated", 669], [".", 678], ["From", 680], ["this", 685], ["data", 690], [",", 694], ["the", 696], ["following", 700], ["values", 710], ["were", 717], ["calculated", 722], [".", 732], ["The", 734], ["median", 738], ["incidence", 745], ["density", 755], ["was", 763], ["0.71", 767], ["MRSA", 772], ["-", 776], ["positive", 777], ["case", 786], ["patients", 791], ["per", 800], ["1,000", 804], ["patient", 810], ["-", 817], ["days", 818], [",", 822], ["and", 824], ["the", 828], ["median", 832], ["nosocomial", 839], ["incidence", 850], ["density", 860], ["was", 868], ["0.27", 872], ["patients", 877], ["with", 886], ["nosocomial", 891], ["MRSA", 902], ["infection", 907], ["or", 917], ["colonization", 920], ["per", 933], ["1,000", 937], ["patient", 943], ["-", 950], ["days", 951], ["(", 956], ["95", 957], ["%", 959], ["CI", 961], [",", 963], ["0.18", 965], ["-", 969], ["0.34", 970], [")", 974], [".", 975], ["The", 977], ["median", 981], ["average", 988], ["daily", 996], ["MRSA", 1002], ["burden", 1007], ["was", 1014], ["1.13", 1018], ["MRSA", 1023], ["patient", 1028], ["-", 1035], ["days", 1036], ["per", 1041], ["100", 1045], ["patient", 1049], ["-", 1056], ["days", 1057], ["(", 1062], ["95", 1063], ["%", 1065], ["CI", 1067], [",", 1069], ["0.86", 1071], ["-", 1075], ["1.51", 1076], [")", 1080], [",", 1081], ["with", 1083], ["the", 1088], ["average", 1092], ["daily", 1100], ["MRSA", 1106], ["burden", 1111], ["defined", 1118], ["as", 1126], ["the", 1129], ["total", 1133], ["number", 1139], ["of", 1146], ["MRSA", 1149], ["patient", 1154], ["-", 1161], ["days", 1162], ["divided", 1167], ["by", 1175], ["the", 1178], ["total", 1182], ["number", 1188], ["of", 1195], ["patient", 1198], ["-", 1205], ["days", 1206], ["times", 1211], ["100", 1217], [".", 1220], ["The", 1222], ["median", 1226], ["MRSA", 1233], ["-", 1237], ["days", 1238], ["-", 1242], ["associated", 1243], ["nosocomial", 1254], ["MRSA", 1265], ["infection", 1270], ["and", 1280], ["colonization", 1284], ["rate", 1297], [",", 1301], ["which", 1303], ["describes", 1309], ["the", 1319], ["MRSA", 1323], ["infection", 1328], ["risk", 1338], ["for", 1343], ["other", 1347], ["patients", 1353], ["in", 1362], ["hospitals", 1365], ["housing", 1375], ["large", 1383], ["numbers", 1389], ["of", 1397], ["MRSA", 1400], ["-", 1404], ["positive", 1405], ["patients", 1414], ["and/or", 1423], ["many", 1430], ["patients", 1435], ["who", 1444], ["were", 1448], ["MRSA", 1453], ["positive", 1458], ["on", 1467], ["admission", 1470], [",", 1479], ["was", 1481], ["23.1", 1485], ["cases", 1490], ["of", 1496], ["nosocomial", 1499], ["MRSA", 1510], ["infection", 1515], ["and", 1525], ["colonization", 1529], ["per", 1542], ["1,000", 1546], ["MRSA", 1552], ["patient", 1557], ["-", 1564], ["days", 1565], ["(", 1570], ["95", 1571], ["%", 1573], ["CI", 1575], [",", 1577], ["17.4", 1579], ["-", 1583], ["28.6", 1584], [")", 1588], [".", 1589], ["The", 1591], ["values", 1595], ["were", 1602], ["also", 1607], ["calculated", 1612], ["for", 1623], ["various", 1627], ["MRSA", 1635], ["screening", 1640], ["levels", 1650], [".", 1656], ["The", 1658], ["MRSA", 1662], ["-", 1666], ["days", 1667], ["-", 1671], ["associated", 1672], ["nosocomial", 1683], ["MRSA", 1694], ["rate", 1699], ["allows", 1704], ["investigators", 1711], ["to", 1725], ["assess", 1728], ["the", 1735], ["extent", 1739], ["of", 1746], ["MRSA", 1749], ["colonization", 1754], ["and", 1767], ["infection", 1771], ["at", 1781], ["each", 1784], ["hospital", 1789], [",", 1797], ["taking", 1799], ["into", 1806], ["account", 1811], ["cases", 1819], ["that", 1825], ["have", 1830], ["been", 1835], ["imported", 1840], ["from", 1849], ["other", 1854], ["hospitals", 1860], [",", 1869], ["as", 1871], ["well", 1874], ["as", 1879], ["from", 1882], ["the", 1887], ["community", 1891], [".", 1900], ["This", 1902], ["information", 1907], ["provides", 1919], ["an", 1928], ["appropriate", 1931], ["incentive", 1943], ["for", 1953], ["hospitals", 1957], ["to", 1967], ["introduce", 1970], ["further", 1980], ["infection", 1988], ["control", 1998], ["measures", 2006], [".", 2014]]}
{"context": "Kx is lacking in the RBCs of patients with the McLeod syndrome. This condition is sometimes associated with chronic granulomatous disease (CGD). If given allogeneic RBCs, CGD patients with the McLeod phenotype may produce anti-Kx and anti-Km, and only phenotypically matched McLeod blood would be compatible. McLeod phenotype persons without CGD have made anti-Km but not anti-Kx (2 examples), and thus both McLeod and K(O) blood would be compatible. RBCs from a transfused patient with the McLeod phenotype but not with CGD (non-CGD McLeod) were typed for the Kell blood group antigens, and the plasma was analyzed for the presence of antibody by agglutination. The molecular basis was determined by analyzing for XK protein on RBC membranes by Western immunoblotting, by sequencing the XK gene, and by RFLP. The RBCs did not react with anti-Kx + anti-Km and showed weakening of Kell system antigens. The patient's plasma reacted moderately (2+) with RBCs of common Kell type and strongly (4+) with K(O) RBCs and RBCs of common Kell type treated with dithiothreitol, and did not react with McLeod RBCs. XK protein was absent from the RBC membranes. The XK gene had a point mutation in the donor splice site of intron 1 (G>C). This is the first report describing the molecular alteration in a non-CGD McLeod patient who has made anti-Kx. The immune response of people with the McLeod phenotype can vary, and K(O) blood may not always be compatible.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "ae5bb34ab378486298ab61b3973ece7b", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[232, 232], [150, 150], [222, 222], [138, 138]], "char_spans": [[1154, 1155], [788, 789], [1104, 1105], [715, 716]]}]}], "context_tokens": [["Kx", 0], ["is", 3], ["lacking", 6], ["in", 14], ["the", 17], ["RBCs", 21], ["of", 26], ["patients", 29], ["with", 38], ["the", 43], ["McLeod", 47], ["syndrome", 54], [".", 62], ["This", 64], ["condition", 69], ["is", 79], ["sometimes", 82], ["associated", 92], ["with", 103], ["chronic", 108], ["granulomatous", 116], ["disease", 130], ["(", 138], ["CGD", 139], [")", 142], [".", 143], ["If", 145], ["given", 148], ["allogeneic", 154], ["RBCs", 165], [",", 169], ["CGD", 171], ["patients", 175], ["with", 184], ["the", 189], ["McLeod", 193], ["phenotype", 200], ["may", 210], ["produce", 214], ["anti", 222], ["-", 226], ["Kx", 227], ["and", 230], ["anti", 234], ["-", 238], ["Km", 239], [",", 241], ["and", 243], ["only", 247], ["phenotypically", 252], ["matched", 267], ["McLeod", 275], ["blood", 282], ["would", 288], ["be", 294], ["compatible", 297], [".", 307], ["McLeod", 309], ["phenotype", 316], ["persons", 326], ["without", 334], ["CGD", 342], ["have", 346], ["made", 351], ["anti", 356], ["-", 360], ["Km", 361], ["but", 364], ["not", 368], ["anti", 372], ["-", 376], ["Kx", 377], ["(", 380], ["2", 381], ["examples", 383], [")", 391], [",", 392], ["and", 394], ["thus", 398], ["both", 403], ["McLeod", 408], ["and", 415], ["K(O", 419], [")", 422], ["blood", 424], ["would", 430], ["be", 436], ["compatible", 439], [".", 449], ["RBCs", 451], ["from", 456], ["a", 461], ["transfused", 463], ["patient", 474], ["with", 482], ["the", 487], ["McLeod", 491], ["phenotype", 498], ["but", 508], ["not", 512], ["with", 516], ["CGD", 521], ["(", 525], ["non", 526], ["-", 529], ["CGD", 530], ["McLeod", 534], [")", 540], ["were", 542], ["typed", 547], ["for", 553], ["the", 557], ["Kell", 561], ["blood", 566], ["group", 572], ["antigens", 578], [",", 586], ["and", 588], ["the", 592], ["plasma", 596], ["was", 603], ["analyzed", 607], ["for", 616], ["the", 620], ["presence", 624], ["of", 633], ["antibody", 636], ["by", 645], ["agglutination", 648], [".", 661], ["The", 663], ["molecular", 667], ["basis", 677], ["was", 683], ["determined", 687], ["by", 698], ["analyzing", 701], ["for", 711], ["XK", 715], ["protein", 718], ["on", 726], ["RBC", 729], ["membranes", 733], ["by", 743], ["Western", 746], ["immunoblotting", 754], [",", 768], ["by", 770], ["sequencing", 773], ["the", 784], ["XK", 788], ["gene", 791], [",", 795], ["and", 797], ["by", 801], ["RFLP", 804], [".", 808], ["The", 810], ["RBCs", 814], ["did", 819], ["not", 823], ["react", 827], ["with", 833], ["anti", 838], ["-", 842], ["Kx", 843], ["+", 846], ["anti", 848], ["-", 852], ["Km", 853], ["and", 856], ["showed", 860], ["weakening", 867], ["of", 877], ["Kell", 880], ["system", 885], ["antigens", 892], [".", 900], ["The", 902], ["patient", 906], ["'s", 913], ["plasma", 916], ["reacted", 923], ["moderately", 931], ["(", 942], ["2", 943], ["+", 944], [")", 945], ["with", 947], ["RBCs", 952], ["of", 957], ["common", 960], ["Kell", 967], ["type", 972], ["and", 977], ["strongly", 981], ["(", 990], ["4", 991], ["+", 992], [")", 993], ["with", 995], ["K(O", 1000], [")", 1003], ["RBCs", 1005], ["and", 1010], ["RBCs", 1014], ["of", 1019], ["common", 1022], ["Kell", 1029], ["type", 1034], ["treated", 1039], ["with", 1047], ["dithiothreitol", 1052], [",", 1066], ["and", 1068], ["did", 1072], ["not", 1076], ["react", 1080], ["with", 1086], ["McLeod", 1091], ["RBCs", 1098], [".", 1102], ["XK", 1104], ["protein", 1107], ["was", 1115], ["absent", 1119], ["from", 1126], ["the", 1131], ["RBC", 1135], ["membranes", 1139], [".", 1148], ["The", 1150], ["XK", 1154], ["gene", 1157], ["had", 1162], ["a", 1166], ["point", 1168], ["mutation", 1174], ["in", 1183], ["the", 1186], ["donor", 1190], ["splice", 1196], ["site", 1203], ["of", 1208], ["intron", 1211], ["1", 1218], ["(", 1220], ["G", 1221], [">", 1222], ["C", 1223], [")", 1224], [".", 1225], ["This", 1227], ["is", 1232], ["the", 1235], ["first", 1239], ["report", 1245], ["describing", 1252], ["the", 1263], ["molecular", 1267], ["alteration", 1277], ["in", 1288], ["a", 1291], ["non", 1293], ["-", 1296], ["CGD", 1297], ["McLeod", 1301], ["patient", 1308], ["who", 1316], ["has", 1320], ["made", 1324], ["anti", 1329], ["-", 1333], ["Kx", 1334], [".", 1336], ["The", 1338], ["immune", 1342], ["response", 1349], ["of", 1358], ["people", 1361], ["with", 1368], ["the", 1373], ["McLeod", 1377], ["phenotype", 1384], ["can", 1394], ["vary", 1398], [",", 1402], ["and", 1404], ["K(O", 1408], [")", 1411], ["blood", 1413], ["may", 1419], ["not", 1423], ["always", 1427], ["be", 1434], ["compatible", 1437], [".", 1447]]}
{"context": "Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, which causes progressive and eventually fatal loss of motor function. Here, we describe genetic and pathologic characterization of brain tissue banked from 19 ALS patients over nearly 20\u00a0years at the Department of Anatomy and the Centre for Brain Research, University of Auckland, New Zealand. We screened for mutations in SOD1, TARDBP, FUS, and C9ORF72 genes and for neuropathology caused by phosphorylated TDP-43, dipeptide repeats (DPRs), and ubiquilin. We identified 2 cases with C9ORF72 repeat expansions. Both harbored phosphorylated TDP-43 and DPR inclusions. We show that DPR inclusions can incorporate or occur independently of ubiquilin. We also identified 1 case with a UBQLN2 mutation, which showed phosphorylated TDP-43 and characteristic ubiquilin protein inclusions. This is the first study of ALS genetics in New Zealand, adding New Zealand to the growing list of countries in which C9ORF72 repeat expansion and UBQLN2 mutations are detected in ALS cases.", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "56561ee2c5e6437da905d1d0cb1db046", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[175, 175], [4, 4], [37, 37], [149, 149]], "char_spans": [[1041, 1043], [31, 33], [239, 241], [889, 891]]}, {"text": "amyotrophic lateral sclerosis", "token_spans": [[0, 2]], "char_spans": [[0, 28]]}]}], "context_tokens": [["Amyotrophic", 0], ["lateral", 12], ["sclerosis", 20], ["(", 30], ["ALS", 31], [")", 34], ["is", 36], ["a", 39], ["devastating", 41], ["neurodegenerative", 53], ["disease", 71], [",", 78], ["which", 80], ["causes", 86], ["progressive", 93], ["and", 105], ["eventually", 109], ["fatal", 120], ["loss", 126], ["of", 131], ["motor", 134], ["function", 140], [".", 148], ["Here", 150], [",", 154], ["we", 156], ["describe", 159], ["genetic", 168], ["and", 176], ["pathologic", 180], ["characterization", 191], ["of", 208], ["brain", 211], ["tissue", 217], ["banked", 224], ["from", 231], ["19", 236], ["ALS", 239], ["patients", 243], ["over", 252], ["nearly", 257], ["20", 264], ["years", 267], ["at", 273], ["the", 276], ["Department", 280], ["of", 291], ["Anatomy", 294], ["and", 302], ["the", 306], ["Centre", 310], ["for", 317], ["Brain", 321], ["Research", 327], [",", 335], ["University", 337], ["of", 348], ["Auckland", 351], [",", 359], ["New", 361], ["Zealand", 365], [".", 372], ["We", 374], ["screened", 377], ["for", 386], ["mutations", 390], ["in", 400], ["SOD1", 403], [",", 407], ["TARDBP", 409], [",", 415], ["FUS", 417], [",", 420], ["and", 422], ["C9ORF72", 426], ["genes", 434], ["and", 440], ["for", 444], ["neuropathology", 448], ["caused", 463], ["by", 470], ["phosphorylated", 473], ["TDP-43", 488], [",", 494], ["dipeptide", 496], ["repeats", 506], ["(", 514], ["DPRs", 515], [")", 519], [",", 520], ["and", 522], ["ubiquilin", 526], [".", 535], ["We", 537], ["identified", 540], ["2", 551], ["cases", 553], ["with", 559], ["C9ORF72", 564], ["repeat", 572], ["expansions", 579], [".", 589], ["Both", 591], ["harbored", 596], ["phosphorylated", 605], ["TDP-43", 620], ["and", 627], ["DPR", 631], ["inclusions", 635], [".", 645], ["We", 647], ["show", 650], ["that", 655], ["DPR", 660], ["inclusions", 664], ["can", 675], ["incorporate", 679], ["or", 691], ["occur", 694], ["independently", 700], ["of", 714], ["ubiquilin", 717], [".", 726], ["We", 728], ["also", 731], ["identified", 736], ["1", 747], ["case", 749], ["with", 754], ["a", 759], ["UBQLN2", 761], ["mutation", 768], [",", 776], ["which", 778], ["showed", 784], ["phosphorylated", 791], ["TDP-43", 806], ["and", 813], ["characteristic", 817], ["ubiquilin", 832], ["protein", 842], ["inclusions", 850], [".", 860], ["This", 862], ["is", 867], ["the", 870], ["first", 874], ["study", 880], ["of", 886], ["ALS", 889], ["genetics", 893], ["in", 902], ["New", 905], ["Zealand", 909], [",", 916], ["adding", 918], ["New", 925], ["Zealand", 929], ["to", 937], ["the", 940], ["growing", 944], ["list", 952], ["of", 957], ["countries", 960], ["in", 970], ["which", 973], ["C9ORF72", 979], ["repeat", 987], ["expansion", 994], ["and", 1004], ["UBQLN2", 1008], ["mutations", 1015], ["are", 1025], ["detected", 1029], ["in", 1038], ["ALS", 1041], ["cases", 1045], [".", 1050]]}
{"context": "Infectious mononucleosis is a common, usually self-limited disease. However, infectious mononucleosis may present with severe manifestations. Complications may also occur. Consequently, diagnostic and treatment issues regarding infectious mononucleosis are of major importance. In this review, we focus on the evaluation of articles providing diagnosis and treatment data for infectious mononucleosis, published during the past 2 years. Twelve studies, deriving from extended search in PubMed, were included. Nine studies provided diagnosis data. The evaluated diagnostic methods were real-time PCR (RT-PCR), IgM/IgG antibodies measured with different assays [measurement of Epstein-Barr virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/monocyte counts, C-reactive protein values, and monospot test]. The sensitivities reported for RT-PCR were high. The available treatment data were scarce (three studies). Two of them suggested that antivirals (mainly acyclovir and valacyclovir) may have a role in the treatment of infectious mononucleosis with complications, whereas the remaining study presented novel potential therapeutic patents including 5-substituted uracyle, azacytosine derivatives, and peptides inhibiting EBV-mediated membrane fusion. RT-PCR and measurement of EBV-VL may provide useful tools for the early diagnosis of infectious mononucleosis in cases with inconclusive serological results. Antiviral agents may provide a useful treatment option in patients with severe infectious mononucleosis.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "fba1c150697a4864bbf8aedacd2d8a94", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[113, 116]], "char_spans": [[675, 692]]}]}], "context_tokens": [["Infectious", 0], ["mononucleosis", 11], ["is", 25], ["a", 28], ["common", 30], [",", 36], ["usually", 38], ["self", 46], ["-", 50], ["limited", 51], ["disease", 59], [".", 66], ["However", 68], [",", 75], ["infectious", 77], ["mononucleosis", 88], ["may", 102], ["present", 106], ["with", 114], ["severe", 119], ["manifestations", 126], [".", 140], ["Complications", 142], ["may", 156], ["also", 160], ["occur", 165], [".", 170], ["Consequently", 172], [",", 184], ["diagnostic", 186], ["and", 197], ["treatment", 201], ["issues", 211], ["regarding", 218], ["infectious", 228], ["mononucleosis", 239], ["are", 253], ["of", 257], ["major", 260], ["importance", 266], [".", 276], ["In", 278], ["this", 281], ["review", 286], [",", 292], ["we", 294], ["focus", 297], ["on", 303], ["the", 306], ["evaluation", 310], ["of", 321], ["articles", 324], ["providing", 333], ["diagnosis", 343], ["and", 353], ["treatment", 357], ["data", 367], ["for", 372], ["infectious", 376], ["mononucleosis", 387], [",", 400], ["published", 402], ["during", 412], ["the", 419], ["past", 423], ["2", 428], ["years", 430], [".", 435], ["Twelve", 437], ["studies", 444], [",", 451], ["deriving", 453], ["from", 462], ["extended", 467], ["search", 476], ["in", 483], ["PubMed", 486], [",", 492], ["were", 494], ["included", 499], [".", 507], ["Nine", 509], ["studies", 514], ["provided", 522], ["diagnosis", 531], ["data", 541], [".", 545], ["The", 547], ["evaluated", 551], ["diagnostic", 561], ["methods", 572], ["were", 580], ["real", 585], ["-", 589], ["time", 590], ["PCR", 595], ["(", 599], ["RT", 600], ["-", 602], ["PCR", 603], [")", 606], [",", 607], ["IgM", 609], ["/", 612], ["IgG", 613], ["antibodies", 617], ["measured", 628], ["with", 637], ["different", 642], ["assays", 652], ["[", 659], ["measurement", 660], ["of", 672], ["Epstein", 675], ["-", 682], ["Barr", 683], ["virus", 688], ["viral", 694], ["load", 700], ["(", 705], ["EBV", 706], ["-", 709], ["VL", 710], [")", 712], ["in", 714], ["peripheral", 717], ["blood", 728], [",", 733], ["neutrophil", 735], ["/", 745], ["lymphocyte", 746], ["/", 756], ["monocyte", 757], ["counts", 766], [",", 772], ["C", 774], ["-", 775], ["reactive", 776], ["protein", 785], ["values", 793], [",", 799], ["and", 801], ["monospot", 805], ["test].", 814], ["The", 821], ["sensitivities", 825], ["reported", 839], ["for", 848], ["RT", 852], ["-", 854], ["PCR", 855], ["were", 859], ["high", 864], [".", 868], ["The", 870], ["available", 874], ["treatment", 884], ["data", 894], ["were", 899], ["scarce", 904], ["(", 911], ["three", 912], ["studies", 918], [")", 925], [".", 926], ["Two", 928], ["of", 932], ["them", 935], ["suggested", 940], ["that", 950], ["antivirals", 955], ["(", 966], ["mainly", 967], ["acyclovir", 974], ["and", 984], ["valacyclovir", 988], [")", 1000], ["may", 1002], ["have", 1006], ["a", 1011], ["role", 1013], ["in", 1018], ["the", 1021], ["treatment", 1025], ["of", 1035], ["infectious", 1038], ["mononucleosis", 1049], ["with", 1063], ["complications", 1068], [",", 1081], ["whereas", 1083], ["the", 1091], ["remaining", 1095], ["study", 1105], ["presented", 1111], ["novel", 1121], ["potential", 1127], ["therapeutic", 1137], ["patents", 1149], ["including", 1157], ["5-substituted", 1167], ["uracyle", 1181], [",", 1188], ["azacytosine", 1190], ["derivatives", 1202], [",", 1213], ["and", 1215], ["peptides", 1219], ["inhibiting", 1228], ["EBV", 1239], ["-", 1242], ["mediated", 1243], ["membrane", 1252], ["fusion", 1261], [".", 1267], ["RT", 1269], ["-", 1271], ["PCR", 1272], ["and", 1276], ["measurement", 1280], ["of", 1292], ["EBV", 1295], ["-", 1298], ["VL", 1299], ["may", 1302], ["provide", 1306], ["useful", 1314], ["tools", 1321], ["for", 1327], ["the", 1331], ["early", 1335], ["diagnosis", 1341], ["of", 1351], ["infectious", 1354], ["mononucleosis", 1365], ["in", 1379], ["cases", 1382], ["with", 1388], ["inconclusive", 1393], ["serological", 1406], ["results", 1418], [".", 1425], ["Antiviral", 1427], ["agents", 1437], ["may", 1444], ["provide", 1448], ["a", 1456], ["useful", 1458], ["treatment", 1465], ["option", 1475], ["in", 1482], ["patients", 1485], ["with", 1494], ["severe", 1499], ["infectious", 1506], ["mononucleosis", 1517], [".", 1530]]}
{"context": "The objective of this study was to determine the performance of the Recognition Of Stroke In the Emergency Room (ROSIER) scale in risk-stratifying Chinese patients with suspected stroke in Hong Kong. This was a prospective cohort study in an urban academic emergency department (ED) over a 7-month period. Patients over 18 years of age with suspected stroke were recruited between June 2011 and December 2011. ROSIER scale assessment was performed in the ED triage area. Logistic regression analysis was used to estimate the impacts of diagnostic variables, including ROSIER scale, past history and ED characteristics. 715 suspected stroke patients were recruited for assessment, of whom 371 (52%) had acute cerebrovascular disease (302 ischaemic strokes, 24 transient ischaemic attacks (TIA), 45 intracerebral haemorrhages), and 344 (48%) had other illnesses i.e. stroke mimics. Common stroke mimics were spinal neuropathy, dementia, labyrinthitis and sepsis. The suggested cut-off score of>0 for the ROSIER scale for stroke diagnosis gave a sensitivity of 87% (95%CI 83-90), a specificity of 41% (95%CI 36-47), a positive predictive value of 62% (95%CI 57-66), and a negative predictive value of 75% (95%CI 68-81), and the AUC was 0.723. The overall accuracy at cut off>0 was 65% i.e. (323+141)/715. The ROSIER scale was not as effective at differentiating acute stroke from stroke mimics in Chinese patients in Hong Kong as it was in the original studies, primarily due to a much lower specificity. If the ROSIER scale is to be clinically useful in Chinese suspected stroke patients, it requires further refinement.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "382bb11c7a004d7c8c8db92c09fbed6f", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[14, 14], [64, 64], [160, 160], [309, 309], [156, 156], [184, 184], [110, 110], [273, 273], [31, 31], [271, 271]], "char_spans": [[83, 88], [351, 356], [887, 892], [1570, 1575], [865, 870], [1019, 1024], [633, 638], [1377, 1382], [179, 184], [1365, 1370]]}]}], "context_tokens": [["The", 0], ["objective", 4], ["of", 14], ["this", 17], ["study", 22], ["was", 28], ["to", 32], ["determine", 35], ["the", 45], ["performance", 49], ["of", 61], ["the", 64], ["Recognition", 68], ["Of", 80], ["Stroke", 83], ["In", 90], ["the", 93], ["Emergency", 97], ["Room", 107], ["(", 112], ["ROSIER", 113], [")", 119], ["scale", 121], ["in", 127], ["risk", 130], ["-", 134], ["stratifying", 135], ["Chinese", 147], ["patients", 155], ["with", 164], ["suspected", 169], ["stroke", 179], ["in", 186], ["Hong", 189], ["Kong", 194], [".", 198], ["This", 200], ["was", 205], ["a", 209], ["prospective", 211], ["cohort", 223], ["study", 230], ["in", 236], ["an", 239], ["urban", 242], ["academic", 248], ["emergency", 257], ["department", 267], ["(", 278], ["ED", 279], [")", 281], ["over", 283], ["a", 288], ["7-month", 290], ["period", 298], [".", 304], ["Patients", 306], ["over", 315], ["18", 320], ["years", 323], ["of", 329], ["age", 332], ["with", 336], ["suspected", 341], ["stroke", 351], ["were", 358], ["recruited", 363], ["between", 373], ["June", 381], ["2011", 386], ["and", 391], ["December", 395], ["2011", 404], [".", 408], ["ROSIER", 410], ["scale", 417], ["assessment", 423], ["was", 434], ["performed", 438], ["in", 448], ["the", 451], ["ED", 455], ["triage", 458], ["area", 465], [".", 469], ["Logistic", 471], ["regression", 480], ["analysis", 491], ["was", 500], ["used", 504], ["to", 509], ["estimate", 512], ["the", 521], ["impacts", 525], ["of", 533], ["diagnostic", 536], ["variables", 547], [",", 556], ["including", 558], ["ROSIER", 568], ["scale", 575], [",", 580], ["past", 582], ["history", 587], ["and", 595], ["ED", 599], ["characteristics", 602], [".", 617], ["715", 619], ["suspected", 623], ["stroke", 633], ["patients", 640], ["were", 649], ["recruited", 654], ["for", 664], ["assessment", 668], [",", 678], ["of", 680], ["whom", 683], ["371", 688], ["(", 692], ["52", 693], ["%", 695], [")", 696], ["had", 698], ["acute", 702], ["cerebrovascular", 708], ["disease", 724], ["(", 732], ["302", 733], ["ischaemic", 737], ["strokes", 747], [",", 754], ["24", 756], ["transient", 759], ["ischaemic", 769], ["attacks", 779], ["(", 787], ["TIA", 788], [")", 791], [",", 792], ["45", 794], ["intracerebral", 797], ["haemorrhages", 811], [")", 823], [",", 824], ["and", 826], ["344", 830], ["(", 834], ["48", 835], ["%", 837], [")", 838], ["had", 840], ["other", 844], ["illnesses", 850], ["i.e.", 860], ["stroke", 865], ["mimics", 872], [".", 878], ["Common", 880], ["stroke", 887], ["mimics", 894], ["were", 901], ["spinal", 906], ["neuropathy", 913], [",", 923], ["dementia", 925], [",", 933], ["labyrinthitis", 935], ["and", 949], ["sepsis", 953], [".", 959], ["The", 961], ["suggested", 965], ["cut", 975], ["-", 978], ["off", 979], ["score", 983], ["of>0", 989], ["for", 994], ["the", 998], ["ROSIER", 1002], ["scale", 1009], ["for", 1015], ["stroke", 1019], ["diagnosis", 1026], ["gave", 1036], ["a", 1041], ["sensitivity", 1043], ["of", 1055], ["87", 1058], ["%", 1060], ["(", 1062], ["95%CI", 1063], ["83", 1069], ["-", 1071], ["90", 1072], [")", 1074], [",", 1075], ["a", 1077], ["specificity", 1079], ["of", 1091], ["41", 1094], ["%", 1096], ["(", 1098], ["95%CI", 1099], ["36", 1105], ["-", 1107], ["47", 1108], [")", 1110], [",", 1111], ["a", 1113], ["positive", 1115], ["predictive", 1124], ["value", 1135], ["of", 1141], ["62", 1144], ["%", 1146], ["(", 1148], ["95%CI", 1149], ["57", 1155], ["-", 1157], ["66", 1158], [")", 1160], [",", 1161], ["and", 1163], ["a", 1167], ["negative", 1169], ["predictive", 1178], ["value", 1189], ["of", 1195], ["75", 1198], ["%", 1200], ["(", 1202], ["95%CI", 1203], ["68", 1209], ["-", 1211], ["81", 1212], [")", 1214], [",", 1215], ["and", 1217], ["the", 1221], ["AUC", 1225], ["was", 1229], ["0.723", 1233], [".", 1238], ["The", 1240], ["overall", 1244], ["accuracy", 1252], ["at", 1261], ["cut", 1264], ["off>0", 1268], ["was", 1274], ["65", 1278], ["%", 1280], ["i.e.", 1282], ["(", 1287], ["323", 1288], ["+", 1291], ["141)/715", 1292], [".", 1300], ["The", 1302], ["ROSIER", 1306], ["scale", 1313], ["was", 1319], ["not", 1323], ["as", 1327], ["effective", 1330], ["at", 1340], ["differentiating", 1343], ["acute", 1359], ["stroke", 1365], ["from", 1372], ["stroke", 1377], ["mimics", 1384], ["in", 1391], ["Chinese", 1394], ["patients", 1402], ["in", 1411], ["Hong", 1414], ["Kong", 1419], ["as", 1424], ["it", 1427], ["was", 1430], ["in", 1434], ["the", 1437], ["original", 1441], ["studies", 1450], [",", 1457], ["primarily", 1459], ["due", 1469], ["to", 1473], ["a", 1476], ["much", 1478], ["lower", 1483], ["specificity", 1489], [".", 1500], ["If", 1502], ["the", 1505], ["ROSIER", 1509], ["scale", 1516], ["is", 1522], ["to", 1525], ["be", 1528], ["clinically", 1531], ["useful", 1542], ["in", 1549], ["Chinese", 1552], ["suspected", 1560], ["stroke", 1570], ["patients", 1577], [",", 1585], ["it", 1587], ["requires", 1590], ["further", 1599], ["refinement", 1607], [".", 1617]]}
